PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Zhao, L; Yang, X				Zhao, Lei; Yang, Xi			Cross Talk Between Natural Killer T and Dendritic Cells and Its Impact on T Cell Responses in Infections	FRONTIERS IN IMMUNOLOGY			English	Review						dendritic cell; NKT cell; infection; cross-talk; innate immunity; T cell immunity; Chlamydiae; NK cell	NKT CELLS; ALPHA-GALACTOSYLCERAMIDE; IN-VIVO; ADAPTIVE IMMUNITY; CD8-ALPHA(+); SUBSETS; ANTIGEN; RECOGNITION; DISTINCT; ACTIVATION	Both innate and adaptive immunity is vital for host defense against infections. Dendritic cells (DCs) are critical for initiating and modulating adaptive immunity, especially for T-cell responses. Natural killer T (NKT) cells are a small population of innate-like T cells distributed in multiple organs. Many studies have suggested that the cross-talk between these two immune cells is critical for immunobiology and host defense mechanisms. Not only can DCs influence the activation/function of NKT cells, but NKT cells can feedback on DCs also, thus modulating the phenotype and function of DCs and DC subsets. This functional feedback of NKT cells on DCs, especially the preferential promoting effect on CD8 alpha+ and CD103+ DC subsets in lymphoid and non-lymphoid tissues, significantly impacts the systemic and local adaptive CD4 and CD8 T cell responses in infections. This review focuses on the two-way interaction between NKT cells and DCs, emphasizing the importance of NKT cell feedback on DCs in bridging innate and adaptive immune responses for host defense purposes.	[Zhao, Lei; Yang, Xi] Univ Manitoba, Max Rady Coll Med, Dept Immunol & Med Microbiol, Winnipeg, MB, Canada; [Zhao, Lei; Yang, Xi] Univ Manitoba, Max Rady Coll Med, Dept Infect Dis, Winnipeg, MB, Canada; [Zhao, Lei] Shandong Univ, Lab Basic Med Sci, Qilu Hosp, Jinan, Peoples R China	University of Manitoba; University of Manitoba; Shandong University	Yang, X (corresponding author), Univ Manitoba, Max Rady Coll Med, Dept Immunol & Med Microbiol, Winnipeg, MB, Canada.; Yang, X (corresponding author), Univ Manitoba, Max Rady Coll Med, Dept Infect Dis, Winnipeg, MB, Canada.	x.yang@umanitoba.ca			Canadian Institutes of Health Research (CIHR) [CCI 92213, MOP-130423]; National Natural Science Foundation of China [81501761, ZR2020MH303]; Natural Science Foundation of Shandong Province; Canada Research Chair in Infection and Immunity	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Shandong Province(Natural Science Foundation of Shandong Province); Canada Research Chair in Infection and Immunity(Canada Research Chairs)	Funding This work was supported by grants from the Canadian Institutes of Health Research (CIHR) to XY (CCI 92213, MOP-130423), National Natural Science Foundation of China to LZ (nos. 81501761) and Project ZR2020MH303 supported by Natural Science Foundation of Shandong Province to LZ. XY was the Canada Research Chair in Infection and Immunity.	Amsen D, 2004, CELL, V117, P515, DOI 10.1016/S0092-8674(04)00451-9; Barthelemy A, 2017, MUCOSAL IMMUNOL, V10, P460, DOI 10.1038/mi.2016.49; Behar SM, 2007, CURR TOP MICROBIOL, V314, P215; Berzins SP, 2005, CURR OPIN IMMUNOL, V17, P448, DOI 10.1016/j.coi.2005.05.012; Berzins SP, 2011, NAT REV IMMUNOL, V11, P131, DOI 10.1038/nri2904; Bilenki L, 2005, J IMMUNOL, V175, P3197, DOI 10.4049/jimmunol.175.5.3197; Bilenki L, 2006, J IMMUNOL, V177, P7067, DOI 10.4049/jimmunol.177.10.7067; Bochtler P, 2008, J IMMUNOL, V181, P1633, DOI 10.4049/jimmunol.181.3.1633; Brigl M, 2010, SEMIN IMMUNOL, V22, P79, DOI 10.1016/j.smim.2009.10.006; Brossay L, 1998, J EXP MED, V188, P1521, DOI 10.1084/jem.188.8.1521; Burugupalli S, 2020, CHEM SCI, V11, P2161, DOI 10.1039/c9sc05248h; Caielli S, 2010, J IMMUNOL, V185, P7317, DOI 10.4049/jimmunol.1000400; Cortesi F, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02375; Crosby CM, 2018, NAT REV IMMUNOL, V18, P559, DOI 10.1038/s41577-018-0034-2; Crowe NY, 2005, J EXP MED, V202, P1279, DOI 10.1084/jem.20050953; Crozat K, 2011, J IMMUNOL, V187, P4411, DOI 10.4049/jimmunol.1101717; Crozat K, 2010, J EXP MED, V207, P1283, DOI 10.1084/jem.20100223; de Guinoa JS, 2018, EMBO J, V37, DOI 10.15252/embj.201797537; De Santo C, 2008, J CLIN INVEST, V118, P4036, DOI 10.1172/JCI36264; del Rio ML, 2007, J IMMUNOL, V178, P6861, DOI 10.4049/jimmunol.178.11.6861; Edelson BT, 2010, J EXP MED, V207, P823, DOI 10.1084/jem.20091627; Fujii S, 2003, J EXP MED, V198, P267, DOI 10.1084/jem.20030324; Fujii SI, 2004, J EXP MED, V199, P1607, DOI 10.1084/jem.20040317; Godfrey DI, 2010, NAT IMMUNOL, V11, P197, DOI 10.1038/ni.1841; Godfrey DI, 2004, NAT REV IMMUNOL, V4, P231, DOI 10.1038/nri1309; Gonzalez-Aseguinolaza G, 2000, P NATL ACAD SCI USA, V97, P8461, DOI 10.1073/pnas.97.15.8461; Grabbe S, 2000, IMMUNOL TODAY, V21, P431, DOI 10.1016/S0167-5699(00)01694-7; Hermans IF, 2007, J IMMUNOL, V178, P2721, DOI 10.4049/jimmunol.178.5.2721; Hermans IF, 2003, J IMMUNOL, V171, P5140, DOI 10.4049/jimmunol.171.10.5140; Hongo D, 2017, BLOOD, V129, P1718, DOI 10.1182/blood-2016-07-723015; Huang YM, 2001, CYTOKINE, V13, P264, DOI 10.1006/cyto.2000.0835; Jahng A, 2004, J EXP MED, V199, P947, DOI 10.1084/jem.20031389; Jiao L, 2011, J IMMUNOL, V187, P401, DOI 10.4049/jimmunol.1002519; Joyee AG, 2008, AM J RESP CRIT CARE, V178, P745, DOI 10.1164/rccm.200804-517OC; Joyee AG, 2007, J IMMUNOL, V178, P1048, DOI 10.4049/jimmunol.178.2.1048; Joyee AG, 2010, J IMMUNOL, V184, P2095, DOI 10.4049/jimmunol.0901348; Keller CW, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00570; Li J, 2016, J CELL MOL MED, V20, P1339, DOI 10.1111/jcmm.12821; Lynch L, 2015, NAT IMMUNOL, V16, P85, DOI 10.1038/ni.3047; Macho-Fernandez E, 2015, FRONT IMMUNOL, V6, P1, DOI 10.3389/fimmu.2015.00362; Makowska A, 2000, SCAND J IMMUNOL, V52, P71; Maldonado-Lopez R, 1999, J LEUKOCYTE BIOL, V66, P242, DOI 10.1002/jlb.66.2.242; Maricic I, 2014, J IMMUNOL, V193, P1035, DOI 10.4049/jimmunol.1302898; Murray MP, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21574-w; Nieda M, 1999, HUM IMMUNOL, V60, P10, DOI 10.1016/S0198-8859(98)00100-1; Oki S, 2004, J CLIN INVEST, V113, P1631, DOI 10.1172/JCI200420862; Peng Y, 2012, CELL MOL IMMUNOL, V9, P361, DOI 10.1038/cmi.2012.19; Pulendran B, 1999, P NATL ACAD SCI USA, V96, P1036, DOI 10.1073/pnas.96.3.1036; Quan XQ, 2020, MICROB PATHOGENESIS, V149, DOI 10.1016/j.micpath.2020.104541; Reilly EC, 2010, CYTOKINE, V51, P227, DOI 10.1016/j.cyto.2010.04.016; Shekhar S, 2018, CELL MOL IMMUNOL, V15, P377, DOI 10.1038/cmi.2016.68; Shekhar S, 2015, EUR J IMMUNOL, V45, P2810, DOI 10.1002/eji.201445390; Shekhar S, 2015, FRONT IMMUNOL, V6, P1, DOI 10.3389/fimmu.2015.00233; Shekhar S, 2015, J INNATE IMMUN, V7, P260, DOI 10.1159/000368779; Singh AK, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01969; Steinbrink K, 1997, J IMMUNOL, V159, P4772; Stober D, 2003, J IMMUNOL, V170, P2540, DOI 10.4049/jimmunol.170.5.2540; Subleski JJ, 2009, J AUTOIMMUN, V33, P275, DOI 10.1016/j.jaut.2009.07.010; Sung SSJ, 2006, J IMMUNOL, V176, P2161, DOI 10.4049/jimmunol.176.4.2161; Tatituri RVV, 2013, P NATL ACAD SCI USA, V110, P1827, DOI 10.1073/pnas.1220601110; Thomas R, 2021, J IMMUNOL, V206, P1251, DOI 10.4049/jimmunol.2001013; Tripathi P, 2019, EUR J IMMUNOL, V49, P443, DOI 10.1002/eji.201847647; Trobonjaca Z, 2002, J IMMUNOL, V168, P3763, DOI 10.4049/jimmunol.168.8.3763; Tupin E, 2007, NAT REV MICROBIOL, V5, P405, DOI 10.1038/nrmicro1657; Vogt S, 2021, FRONT CELL INFECT MI, V11, DOI 10.3389/fcimb.2021.718350; Wang H, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.00296; Wang XT, 2021, PLOS PATHOG, V17, DOI 10.1371/journal.ppat.1009295; Wiethe C, 2008, J IMMUNOL, V180, P4371, DOI 10.4049/jimmunol.180.7.4371; Wikstrom ME, 2007, IMMUNOL CELL BIOL, V85, P182, DOI 10.1038/sj.icb.7100039; Wilson MT, 2003, P NATL ACAD SCI USA, V100, P10913, DOI 10.1073/pnas.1833166100; Wolf BJ, 2015, J IMMUNOL, V195, P2540, DOI 10.4049/jimmunol.1501019; Yang X, 2007, ADV EXP MED BIOL, V601, P243; Zajonc DM, 2008, J MOL BIOL, V377, P1104, DOI 10.1016/j.jmb.2008.01.061; Zajonc DM, 2009, IMMUNOL REV, V230, P188, DOI 10.1111/j.1600-065X.2009.00802.x; Zhao L, 2022, FRONT CELL INFECT MI, V11, DOI 10.3389/fcimb.2021.775663; Zhao L, 2020, CELL IMMUNOL, V353, DOI 10.1016/j.cellimm.2020.104132; Zhao L, 2019, MEDIAT INFLAMM, V2019, DOI 10.1155/2019/4742634	77	0	0	4	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 3	2022	13								837767	10.3389/fimmu.2022.837767	http://dx.doi.org/10.3389/fimmu.2022.837767			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZF9BE	35185930	Green Published, gold			2022-12-18	WOS:000759862300001
J	Zhong, YF; Cao, JH; Ma, YF; Zhang, Y; Liu, JX; Wang, HF				Zhong, Yifan; Cao, Jiahong; Ma, Yanfei; Zhang, Yu; Liu, Jianxin; Wang, Haifeng			Fecal Microbiota Transplantation Donor and Dietary Fiber Intervention Collectively Contribute to Gut Health in a Mouse Model	FRONTIERS IN IMMUNOLOGY			English	Article						fecal microbiota transplantation; dietary fiber; gut microbiota; metabolomics; gut barrier	CHAIN FATTY-ACIDS; AKKERMANSIA-MUCINIPHILA; METABOLIC BENEFITS; GLUCOSE-TOLERANCE; MUCUS BARRIER; OBESITY; PROTECTS; HOMEOSTASIS; EXPRESSION; IMPACT	Transforming the gut microbiota has turned into the most intriguing target for interventions in multiple gastrointestinal and non-gastrointestinal disorders. Fecal microbiota transplantation (FMT) is a therapeutic tool that administers feces collected from healthy donors into patients to help replenish the gut microbial balance. Considering the random donor selection, to maintain the optimal microbial ecosystem, post-FMT is critical for therapy outcomes but challenging. Aiming to study the interventions of different diets on recipients' gut microbiota post-FMT that originated from donors with different diets, we performed FMT from domestic vs. wild pigs that are living on low-fiber vs. high-fiber diets into the pseudo-GF mouse, followed with fiber-free (FF) or fiber-rich (FR) diets post-FMT. Different patterns of gut microbiota and metabolites were observed when mice FMT from different donors were paired with different dietary fiber contents. Enrichment of bacteria, including Akkermansia and Parabacteroides, together with alteration of metabolites, including palmitic acid, stearic acid, and nicotinic acid, was noted to improve crypt length and mucus layer in the gut in mice FMT from wild pigs fed an FR diet. The results provide novel insight into the different responses of reconstructed gut microbiota by FMT to dietary fiber. Our study highlighted the importance of post-FMT precise dietary interventions.	[Zhong, Yifan; Cao, Jiahong; Ma, Yanfei; Zhang, Yu; Liu, Jianxin; Wang, Haifeng] Zhejiang Univ, Key Lab Mol Anim Nutr, Minist Educ, Coll Anim Sci, Hangzhou, Peoples R China	Zhejiang University	Wang, HF (corresponding author), Zhejiang Univ, Key Lab Mol Anim Nutr, Minist Educ, Coll Anim Sci, Hangzhou, Peoples R China.	haifengwang@zju.edu.cn						Allegretti JR, 2018, CLIN GASTROENTEROL H, V16, P1832, DOI 10.1016/j.cgh.2017.10.031; Barker N, 2014, NAT REV MOL CELL BIO, V15, P19, DOI 10.1038/nrm3721; Bibbo S, 2020, J CLIN MED, V9, DOI 10.3390/jcm9061757; Bishehsari F, 2018, GENES-BASEL, V9, DOI 10.3390/genes9020102; Brown L, 1999, AM J CLIN NUTR, V69, P30; Burger-van Paassen N, 2009, BIOCHEM J, V420, P211, DOI 10.1042/BJ20082222; Chong J, 2018, NUCLEIC ACIDS RES, V46, pW486, DOI 10.1093/nar/gky310; CHU SY, 1995, P NATL ACAD SCI USA, V92, P3303, DOI 10.1073/pnas.92.8.3303; Chung HK, 2015, NUTR RES, V35, P1001, DOI 10.1016/j.nutres.2015.09.007; Clancy AK, 2021, FRONT NUTR, V8, DOI 10.3389/fnut.2021.653653; Cornick S, 2015, TISSUE BARRIERS, V3, DOI 10.4161/21688370.2014.982426; Correa-Fiz F, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-49897-1; Cuervo A, 2013, NUTR RES, V33, P811, DOI 10.1016/j.nutres.2013.05.016; CUMMINGS JH, 1987, GUT, V28, P1221, DOI 10.1136/gut.28.10.1221; Dao MC, 2016, GUT, V65, P426, DOI 10.1136/gutjnl-2014-308778; De Filippo C, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01979; De Filippo C, 2010, P NATL ACAD SCI USA, V107, P14691, DOI 10.1073/pnas.1005963107; De Vadder F, 2014, CELL, V156, P84, DOI 10.1016/j.cell.2013.12.016; Deehan EC, 2016, TRENDS ENDOCRIN MET, V27, P239, DOI 10.1016/j.tem.2016.03.001; Desai MS, 2016, CELL, V167, P1339, DOI 10.1016/j.cell.2016.10.043; Dunn WB, 2011, NAT PROTOC, V6, P1060, DOI 10.1038/nprot.2011.335; Escoula Q, 2019, NUTRIENTS, V11, DOI 10.3390/nu11092179; Etienne-Mesmin L, 2019, FEMS MICROBIOL REV, V43, P457, DOI 10.1093/femsre/fuz013; Everard A, 2013, P NATL ACAD SCI USA, V110, P9066, DOI 10.1073/pnas.1219451110; Fan Y, 2021, NAT REV MICROBIOL, V19, P55, DOI 10.1038/s41579-020-0433-9; Feng YH, 2018, CELL PHYSIOL BIOCHEM, V49, P190, DOI 10.1159/000492853; Freitag TL, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.02685; Gao K, 2016, SCI REP-UK, V6, DOI 10.1038/srep28332; Garrett WS, 2010, CELL, V140, P859, DOI 10.1016/j.cell.2010.01.023; Guess ND, 2015, NUTR METAB, V12, DOI 10.1186/s12986-015-0033-2; Hansson GC, 2019, J INTERN MED, V285, P479, DOI 10.1111/joim.12910; Hiippala K, 2020, NUTRIENTS, V12, DOI 10.3390/nu12040935; Hiippala K, 2018, NUTRIENTS, V10, DOI 10.3390/nu10080988; Huang JQ, 2020, ARCH MICROBIOL, V202, P843, DOI 10.1007/s00203-019-01787-w; Iyayi EA, 2015, J ANIM SCI, V93, P4781, DOI 10.2527/jas.2015-9081; Jang YO, 2020, EXP MOL MED, V52, P1128, DOI 10.1038/s12276-020-0469-y; Kaiko GE, 2016, CELL, V165, P1708, DOI 10.1016/j.cell.2016.05.018; Kazemian N, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-75162-x; Kelly CR, 2014, AM J GASTROENTEROL, V109, P1065, DOI 10.1038/ajg.2014.133; Kind T, 2009, ANAL CHEM, V81, P10038, DOI 10.1021/ac9019522; Koopen AM, 2021, FRONT MICROBIOL, V12, DOI 10.3389/fmicb.2021.662159; Larson G, 2005, SCIENCE, V307, P1618, DOI 10.1126/science.1106927; Li J, 2003, METABOLISM, V52, P1206, DOI 10.1016/S0026-0495(03)00159-8; Lin HP, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0031286, 10.1371/journal.pone.0035240]; Makki K, 2018, CELL HOST MICROBE, V23, P705, DOI 10.1016/j.chom.2018.05.012; Mardinoglu A, 2018, CELL METAB, V27, P559, DOI 10.1016/j.cmet.2018.01.005; Martens EC, 2018, NAT REV MICROBIOL, V16, P457, DOI 10.1038/s41579-018-0036-x; Masella AP, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-31; Moayyedi P, 2015, GASTROENTEROLOGY, V149, P102, DOI 10.1053/j.gastro.2015.04.001; Mocanu V, 2021, NAT MED, V27, P1272, DOI 10.1038/s41591-021-01399-2; Paone P, 2020, GUT, V69, P2232, DOI 10.1136/gutjnl-2020-322260; Reunanen J, 2015, APPL ENVIRON MICROB, V81, P3655, DOI 10.1128/AEM.04050-14; Riva A, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12413-0; Russell WR, 2011, AM J CLIN NUTR, V93, P1062, DOI 10.3945/ajcn.110.002188; Salem HA, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07280-y; Schneeberger M, 2015, SCI REP-UK, V5, DOI 10.1038/srep16643; Schroeder BO, 2018, CELL HOST MICROBE, V23, P27, DOI 10.1016/j.chom.2017.11.004; Smits SA, 2017, SCIENCE, V357, P802, DOI 10.1126/science.aan4834; Sonnenburg ED, 2016, NATURE, V529, P212, DOI 10.1038/nature16504; Sonnenburg ED, 2014, CELL METAB, V20, P779, DOI 10.1016/j.cmet.2014.07.003; Sood A., 2020, CROHNS COLITIS, V2, P1, DOI [10.1093/crocol/otaa067, DOI 10.1093/CROCOL/OTAA067]; Takahashi S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105592; Moreira DKT, 2017, FOOD RES INT, V95, P52, DOI 10.1016/j.foodres.2017.03.005; Tuohy KM, 2012, J AGR FOOD CHEM, V60, P8776, DOI 10.1021/jf2053959; Vigne JD, 2011, CR BIOL, V334, P171, DOI 10.1016/j.crvi.2010.12.009; Wang K, 2019, CELL REP, V26, P222, DOI 10.1016/j.celrep.2018.12.028; Wells JM, 2017, AM J PHYSIOL-GASTR L, V312, pG171, DOI 10.1152/ajpgi.00048.2015; Willemsen LEM, 2003, GUT, V52, P1442, DOI 10.1136/gut.52.10.1442; Wilson BC, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00002; Wu TR, 2019, GUT, V68, P248, DOI 10.1136/gutjnl-2017-315458; Xiao L, 2016, NAT MICROBIOL, V1, DOI [10.1038/NMICROBIOL.2016.161, 10.1038/nmicrobiol.2016.161]; Yamashita H, 2007, BIOSCI BIOTECH BIOCH, V71, P1236, DOI 10.1271/bbb.60668; Zhao L, 2018, MICROBIOME, V6, DOI 10.1186/s40168-018-0492-6; Zou J, 2018, CELL HOST MICROBE, V23, P41, DOI 10.1016/j.chom.2017.11.003	74	0	0	18	27	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 3	2022	13								842669	10.3389/fimmu.2022.842669	http://dx.doi.org/10.3389/fimmu.2022.842669			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZF9WI	35185934	Green Published, gold			2022-12-18	WOS:000759917600001
J	Cheok, YY; Tan, GMY; Fernandez, KC; Chan, YT; Lee, CYQ; Cheong, HC; Looi, CY; Vadivelu, J; Abdullah, S; Wong, WF				Cheok, Yi Ying; Tan, Grace Min Yi; Fernandez, Keith Conrad; Chan, Yee Teng; Lee, Chalystha Yie Qin; Cheong, Heng Choon; Looi, Chung Yeng; Vadivelu, Jamuna; Abdullah, Suhailah; Wong, Won Fen			Podoplanin Drives Motility of Active Macrophage via Regulating Filamin C During Helicobacter pylori Infection (vol 12, 702156, 2021)	FRONTIERS IN IMMUNOLOGY			English	Correction						podoplanin; macrophage; Helicobacter pylori; cell migration; Filamin C; interleukin-1 beta			[Cheok, Yi Ying; Tan, Grace Min Yi; Fernandez, Keith Conrad; Chan, Yee Teng; Lee, Chalystha Yie Qin; Cheong, Heng Choon; Vadivelu, Jamuna; Wong, Won Fen] Univ Malaya, Fac Med, Dept Med Microbiol, Kuala Lumpur, Malaysia; [Looi, Chung Yeng] Taylors Univ, Sch Biosci, Subang Jaya, Selangor, Malaysia; [Abdullah, Suhailah] Univ Malaya, Fac Med, Dept Med, Kuala Lumpur, Malaysia; [Tan, Grace Min Yi] Univ Otago, Dept Microbiol & Immunol, Dunedin, New Zealand; [Fernandez, Keith Conrad] Cornell Univ, Weill Cornell Grad Sch Med Sci, Immunol & Microbial Pathogenesis Program, New York, NY 10021 USA; [Lee, Chalystha Yie Qin] Royal Melbourne Inst Technol RMIT Univ, Sch Hlth & Biomed Sci, Bundoora, Vic, Australia	Universiti Malaya; Taylor's University; Universiti Malaya; University of Otago; Cornell University; Qatar Foundation (QF); Weill Cornell Medical College Qatar; Royal Melbourne Institute of Technology (RMIT)	Wong, WF (corresponding author), Univ Malaya, Fac Med, Dept Med Microbiol, Kuala Lumpur, Malaysia.	wonfen@um.edu.my	Wong, Won Fen/D-3087-2012; Cheok, Yi Ying/GLR-7091-2022; VADIVELU, JAMUNARANI S/B-8696-2010	Wong, Won Fen/0000-0003-1082-1956; VADIVELU, JAMUNARANI S/0000-0001-7322-3676				Cheok YY, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.702156	1	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 2	2022	13								857795	10.3389/fimmu.2022.857795	http://dx.doi.org/10.3389/fimmu.2022.857795			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZH4IT	35185941	gold, Green Published			2022-12-18	WOS:000760904700001
J	de Brito, AA; Santos, TG; Herculano, KZ; Estefano-Alves, C; Nascimento, CRD; Rigonato-Oliveira, NC; Chavantes, MC; Aimbire, F; da Palma, RK; de Oliveira, APL				de Brito, Aurileia Aparecida; Goncalves Santos, Tawany; Herculano, Karine Zanella; Estefano-Alves, Cintia; de Alvarenga Nascimento, Cristiano Rodrigo; Rigonato-Oliveira, Nicole Cristine; Chavantes, Maria Cristina; Aimbire, Flavio; da Palma, Renata Kelly; Ligeiro de Oliveira, Ana Paula			Photobiomodulation Therapy Restores IL-10 Secretion in a Murine Model of Chronic Asthma: Relevance to the Population of CD4(+)CD25(+)Foxp3(+) Cells in Lung	FRONTIERS IN IMMUNOLOGY			English	Article						bronchial asthma; airway inflammation; lung mechanics; Treg cells; IL-10; mice	LEVEL LASER THERAPY; REGULATORY T-CELLS; AIRWAY INFLAMMATION; PATHOGENESIS; PULMONARY; RESPONSES	It is largely known that photobiomodulation (PBM) has beneficial effects on allergic pulmonary inflammation. Our previous study showed an anti-inflammatory effect of the PBM in an acute experimental model of asthma, and we see that this mechanism is partly dependent on IL-10. However, it remains unclear whether the activation of regulatory T cells is mediated by PBM in a chronic experimental model of asthma. In this sense, the objective of this study was to verify the anti-inflammatory role of the PBM in the pulmonary inflammatory response in a chronic experimental asthma model. The protocol used for asthma induction was the administration of OVA subcutaneously (days 0 and 14) and intranasally (3 times/week, for 5 weeks). On day 50, the animals were sacrificed for the evaluation of the different parameters. The PBM used was the diode, with a wavelength of 660 nm, a power of 100 mW, and 5 J for 50 s/point, in three different application points. Our results showed that PBM decreases macrophages, neutrophils, and lymphocytes in the bronchoalveolar lavage fluid (BALF). Moreover, PBM decreased the release of cytokines by the lung, mucus, and collagen in the airways and pulmonary mechanics. When we analyzed the percentage of Treg cells in the group irradiated with laser, we verified an increase in these cells, as well as the release of IL-10 in the BALF. Therefore, we conclude that the use of PBM therapy in chronic airway inflammation attenuated the inflammatory process, as well as the pulmonary functional and structural parameters, probably due to an increase in Treg cells.	[de Brito, Aurileia Aparecida; de Alvarenga Nascimento, Cristiano Rodrigo] Innovat Hlth Syst Hlth Management IHS Med & Techn, Dept Res Dev & Innovat, Sao Paulo, Brazil; [Goncalves Santos, Tawany; Herculano, Karine Zanella; Estefano-Alves, Cintia; Rigonato-Oliveira, Nicole Cristine; Ligeiro de Oliveira, Ana Paula] Univ Nove Julho UNINOVE, Postgrad Program Biophoton Appl Hlth Sci, Sao Paulo, Brazil; [Chavantes, Maria Cristina] Univ Nove de Julho UNINOVE, Postgrad Program Med, Sao Paulo, Brazil; [Aimbire, Flavio] Fed Univ Sao Paulo UNIFESP, Translat Med, Sao Jose Dos Campos, Brazil; [da Palma, Renata Kelly] Univ Sao Paulo, Sch Vet Med & Anim Sci, Dept Surg, Sao Paulo, Brazil; [da Palma, Renata Kelly] Univ Francisco Vitoria, Fac Ciencias Expt, Madrid, Spain; [da Palma, Renata Kelly] Evanglic Univ Anapolis UniEVANGELICA, Postgrad Program Med Sch, Human Movement & Rehabil, Anapolis, Go, Brazil	Universidade Nove de Julho; Universidade Nove de Julho; Universidade Federal de Sao Paulo (UNIFESP); Universidade de Sao Paulo; Universidad Francisco de Vitoria	da Palma, RK (corresponding author), Univ Sao Paulo, Sch Vet Med & Anim Sci, Dept Surg, Sao Paulo, Brazil.; da Palma, RK (corresponding author), Univ Francisco Vitoria, Fac Ciencias Expt, Madrid, Spain.; da Palma, RK (corresponding author), Evanglic Univ Anapolis UniEVANGELICA, Postgrad Program Med Sch, Human Movement & Rehabil, Anapolis, Go, Brazil.	rekellyp@hotmail.com	Palma, Renata/N-5259-2015	Palma, Renata/0000-0002-4799-0385	Fundac<comma>ao de Amparo a Pesquisa do Estado de Sao Paulo -FAPESP [2012/16498-5]	Fundac<comma>ao de Amparo a Pesquisa do Estado de Sao Paulo -FAPESP	The authors were awarded with a grant supported by Fundacao de Amparo a Pesquisa do Estado de Sao Paulo -FAPESP (grant: 2012/16498-5).	Aimbire F, 2008, INFLAMMATION, V31, P189, DOI 10.1007/s10753-008-9064-4; Al-Muhsen S, 2011, J ALLERGY CLIN IMMUN, V128, P451, DOI 10.1016/j.jaci.2011.04.047; Alqualo-Costa R, 2018, PAIN MANAG, V8, P157, DOI 10.2217/pmt-2017-0057; Anatriello E, 2019, CELL IMMUNOL, V341, DOI 10.1016/j.cellimm.2019.103928; Barnes PJ, 2008, NAT REV IMMUNOL, V8, P183, DOI 10.1038/nri2254; Bax HJ, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00229; Blake KV, 2001, PHARMACOTHERAPY, V21, p3S, DOI 10.1592/phco.21.4.3S.34265; Blatt A, 2016, PHOTOMED LASER SURG, V34, P516, DOI 10.1089/pho.2015.3988; Cao Y, 2018, PROSTAG OTH LIPID M, V138, P23, DOI 10.1016/j.prostaglandins.2018.08.001; Carvalho JL, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0225560; Carvalho JL, 2017, LASER MED SCI, V32, P305, DOI 10.1007/s10103-016-2115-4; Carvalho JLC, 2016, J BIOPHOTONICS, V9, P1208, DOI 10.1002/jbio.201600061; da Silva CM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142816; de Brito AA, 2020, J PHOTOCH PHOTOBIO B, V203, DOI 10.1016/j.jphotobiol.2019.111731; de Lima FM, 2009, LASER SURG MED, V41, P68, DOI 10.1002/lsm.20735; Elmehy DA, 2021, ACTA TROP, V220, DOI 10.1016/j.actatropica.2021.105934; Fritzsching B, 2017, J ALLERGY CLIN IMMUN, V140, P190, DOI 10.1016/j.jaci.2016.09.045; Gao XL, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/9962922; Hawkshaw C, 2014, ALLERGY, V69, P924, DOI 10.1111/all.12422; Holgate ST, 1999, NATURE, V402, pB2, DOI 10.1038/35037000; Holgate ST, 2012, NAT MED, V18, P673, DOI 10.1038/nm.2731; Huang Z, 2015, OSTEOARTHR CARTILAGE, V23, P1437, DOI 10.1016/j.joca.2015.04.005; Li P, 2019, IRAN J ALLERGY ASTHM, V18, P369, DOI 10.18502/ijaai.v18i4.1415; de Souza GHM, 2020, LASER MED SCI, V35, P1055, DOI 10.1007/s10103-019-02885-3; Maslan J, 2014, OTOLARYNG CLIN N AM, V47, P13, DOI 10.1016/j.otc.2013.09.010; Mcgee HS, 2006, IMMUNOL RES, V35, P219, DOI 10.1385/IR:35:3:219; Moraes GD, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/6798238; Oliveira MC, 2014, J PHOTOCH PHOTOBIO B, V134, P57, DOI 10.1016/j.jphotobiol.2014.03.021; Potter PC, 2015, ANN ALLERG ASTHMA IM, V114, P327, DOI 10.1016/j.anai.2014.12.015; Rigonato-Oliveira NC, 2019, INT J INFLAMM, V2019, DOI 10.1155/2019/3945496; Rigonato-Oliveira Nicole Cristine, 2018, Exerc Immunol Rev, V24, P36; Rosa EP, 2020, LIFE SCI, V261, DOI 10.1016/j.lfs.2020.118257; Peron JPS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136942; Silva VR, 2014, RESP PHYSIOL NEUROBI, V194, P37, DOI 10.1016/j.resp.2014.01.008; Urquhart EL, 2020, BIOMED OPT EXPRESS, V11, P5783, DOI 10.1364/BOE.402047; Vieira RP, 2011, RESP PHYSIOL NEUROBI, V175, P383, DOI 10.1016/j.resp.2011.01.002; Walsh GM, 2008, EXPERT OPIN EMERG DR, V13, P643, DOI 10.1517/14728210802591378 ; Xu YQ, 2010, J ASTHMA, V47, P367, DOI 10.3109/02770903.2010.481340; Zhao ST, 2018, J ZHEJIANG UNIV-SC B, V19, P663, DOI 10.1631/jzus.B1700346; Zhou-Suckow Z, 2017, CELL TISSUE RES, V367, P537, DOI 10.1007/s00441-016-2562-z; Zoltowska AM, 2016, CLIN EXP ALLERGY, V46, P479, DOI 10.1111/cea.12683	41	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 2	2022	12								789426	10.3389/fimmu.2021.789426	http://dx.doi.org/10.3389/fimmu.2021.789426			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZE8QJ	35185864	Green Published, gold			2022-12-18	WOS:000759142500001
J	Lin, TH; Yang, CW; Chang, WK				Lin, Tai-Han; Yang, Chih-Wei; Chang, Wei-Kuo			Evaluation of Oropharyngeal Dysphagia in Older Patients for Risk Stratification of Pneumonia	FRONTIERS IN IMMUNOLOGY			English	Article						older patients; oropharyngeal dysphagia; aspiration pneumonia; percutaneous endoscopic gastrostomy; nasogastric tube; tube feeding; enteral feeding	PERCUTANEOUS ENDOSCOPIC GASTROSTOMY; ENTERAL NUTRITION; ASPIRATION; TUBE; COLONIZATION; MALNUTRITION; MANAGEMENT; DEMENTIA; DISEASE; AGE	ObjectiveNasogastric tube (NGT) and percutaneous endoscopic gastrostomy (PEG) are widely used techniques to feed older patients with oropharyngeal dysphagia. Aspiration pneumonia is the most common cause of death in these patients. This study aimed to evaluate the role of oropharyngeal dysphagia in older patients on long-term enteral feeding for risk stratification of pneumonia requiring hospitalization. MethodsWe performed modified flexible endoscopic evaluation of swallowing to evaluate oropharyngeal dysphagia in older patients and conducted prospective follow-up for pneumonia requiring hospitalization. A total of 664 oral-feeding patients and 155 tube-feeding patients were enrolled. Multivariate Cox analysis was performed to identify risk factors of pneumonia requiring hospitalization. ResultsMultivariate analyses showed that the risk of pneumonia requiring hospitalization significantly increased in older patients and in patients with neurological disorders, tube feeding, and oropharyngeal dysphagia. Subgroup analysis revealed that the risk of pneumonia requiring hospitalization was significantly lower in patients with PEG than in those with NGT among the patients with oropharyngeal dysphagia (adjusted hazard ratio 0.26, 95% confidence interval: 0.11-0.63, P = 0.003). ConclusionsFor older patients with oropharyngeal dysphagia requiring long-term enteral tube feeding, PEG is a better choice than NGT. Further research is needed to elucidate the role of oropharyngeal dysphagia in enteral feeding in older patients.	[Lin, Tai-Han] Natl Def Med Ctr, Triserv Gen Hosp, Dept Pathol, Taipei, Taiwan; [Lin, Tai-Han] Natl Def Med Ctr, Triserv Gen Hosp, Grad Inst Pathol & Parasitol, Taipei, Taiwan; [Yang, Chih-Wei; Chang, Wei-Kuo] Natl Def Med Ctr, Triserv Gen Hosp, Div Gastroenterol, Dept Internal Med, Taipei, Taiwan	National Defense Medical Center; Tri-Service General Hospital; National Defense Medical Center; Tri-Service General Hospital; National Defense Medical Center; Tri-Service General Hospital	Chang, WK (corresponding author), Natl Def Med Ctr, Triserv Gen Hosp, Div Gastroenterol, Dept Internal Med, Taipei, Taiwan.	weikuohome@hotmail.com						Alagiakrishnan K, 2013, ARCH GERONTOL GERIAT, V56, P1, DOI 10.1016/j.archger.2012.04.011; Almirall J, 2013, EUR RESPIR J, V41, P923, DOI 10.1183/09031936.00019012; Baijens LWJ, 2016, CLIN INTERV AGING, V11, P1403, DOI 10.2147/CIA.S107750; Berner YN, 2009, MEDITERR J NUTR META, V1, P141, DOI 10.1007/s12349-008-0021-4; Burgos R, 2018, CLIN NUTR, V37, P354, DOI 10.1016/j.clnu.2017.09.003; Carrion S, 2015, CLIN NUTR, V34, P436, DOI 10.1016/j.clnu.2014.04.014; Carucci LR, 2015, RADIOGRAPHICS, V35, P105, DOI 10.1148/rg.351130150; Chang WK, 2020, JPEN-PARENTER ENTER, V44, P239, DOI 10.1002/jpen.1592; Cheng XJ, 2020, PLOS MED, V17, DOI 10.1371/journal.pmed.1003138; Cintra MTG, 2014, J NUTR HEALTH AGING, V18, P894, DOI 10.1007/s12603-014-0487-3; Cook IJ, 2008, NAT CLIN PRACT GASTR, V5, P393, DOI 10.1038/ncpgasthep1153; Dziewas R, 2008, BMC NEUROL, V8, DOI 10.1186/1471-2377-8-28; Forster A, 2011, EUR GERIATR MED, V2, P356, DOI 10.1016/j.eurger.2011.08.007; Gomes CAR, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008096.pub4; Gomes GF, 2003, CURR OPIN CLIN NUTR, V6, P327, DOI 10.1097/01.mco.0000068970.34812.8b; Granell Jose, 2012, Int J Otolaryngol, V2012, P157630, DOI 10.1155/2012/157630; Hayashi Tetsuro, 2020, BMC Nutr, V6, P2, DOI 10.1186/s40795-019-0318-3; Hollaar VRY, 2017, BMC GERIATR, V17, DOI 10.1186/s12877-017-0519-z; Hong CHL, 2018, INT J DENT HYG, V16, pE96, DOI 10.1111/idh.12321; Jaafar MH, 2015, J NUTR HEALTH AGING, V19, P190, DOI 10.1007/s12603-014-0527-z; Kamarunas EE, 2014, DYSPHAGIA, V29, P33, DOI 10.1007/s00455-013-9473-x; Kano S, 2021, INT J CLIN ONCOL, V26, P1179, DOI 10.1007/s10147-021-01889-w; Kozeniecki M, 2015, NUTR CLIN PRACT, V30, P634, DOI 10.1177/0884533615594012; Kumagai R, 2012, PSYCHIAT CLIN NEUROS, V66, P418, DOI 10.1111/j.1440-1819.2012.02378.x; Langmore SE, 2017, DYSPHAGIA, V32, P27, DOI 10.1007/s00455-016-9775-x; Lee JS, 2010, AM J MED, V123, P304, DOI 10.1016/j.amjmed.2009.07.033; Lin LC, 2011, J CLIN NURS, V20, P802, DOI 10.1111/j.1365-2702.2010.03541.x; Mahmoodpoor A, 2017, J CRIT CARE, V38, P152, DOI 10.1016/j.jcrc.2016.11.007; Mamun K., 2005, SMJ Singapore Medical Journal, V46, P627; Mandell LA, 2019, NEW ENGL J MED, V380, P651, DOI 10.1056/NEJMra1714562; Marik PE, 2001, NEW ENGL J MED, V344, P665, DOI 10.1056/NEJM200103013440908; Metheny NA, 2008, AM J CRIT CARE, V17, P512; Neubauer PD, 2015, DYSPHAGIA, V30, P521, DOI 10.1007/s00455-015-9631-4; Nordin Nordiana, 2015, Journal of Nutrition in Gerontology and Geriatrics, V34, P34, DOI 10.1080/21551197.2014.998326; Nyabanga C., 2020, GERIATRIC GASTROENTE, DOI [10.1007/978-3-319-90761-1_40-1, DOI 10.1007/978-3-319-90761-1_40-1]; Pace CC, 2010, DYSPHAGIA, V25, P307, DOI 10.1007/s00455-010-9298-9; Palmer LB, 2001, AM J RESP CRIT CARE, V164, P464, DOI 10.1164/ajrccm.164.3.2008149; Pedersen AML, 2018, ORAL DIS, V24, P1399, DOI 10.1111/odi.12867; Roden DF, 2013, OTOLARYNG CLIN N AM, V46, P965, DOI 10.1016/j.otc.2013.08.008; Rofes L, 2011, GASTROENT RES PRACT, V2011, DOI 10.1155/2011/818979; Rosenbek JC, 1996, DYSPHAGIA, V11, P93, DOI 10.1007/BF00417897; Rowat Anne, 2015, Br J Nurs, V24, P142, DOI 10.12968/bjon.2015.24.3.138; Sakashita R., 2015, INTERFACE ORAL HLTH; Satou Y, 2013, J STROKE CEREBROVASC, V22, P185, DOI 10.1016/j.jstrokecerebrovasdis.2011.07.008; Serra-Prat M, 2012, AGE AGEING, V41, P376, DOI 10.1093/ageing/afs006; Shim YK, 2017, J NEUROGASTROENTEROL, V23, P229, DOI 10.5056/jnm16104; Srivanitchapoom P, 2014, PARKINSONISM RELAT D, V20, P1109, DOI [10.1016/S1353-8020(13)70029-4, 10.1016/j.parkreldis.2014.08.013]; Teasell RW, 1996, ARCH PHYS MED REHAB, V77, P707, DOI 10.1016/S0003-9993(96)90012-X; Tokunaga T, 2008, GERIATR GERONTOL INT, V8, P19, DOI 10.1111/j.1447-0594.2008.00442.x; van der Flier WM, 2005, J NEUROL NEUROSUR PS, V76, pV2, DOI 10.1136/jnnp.2005.082867; van der Maarel-Wierink CD, 2011, J DENT RES, V90, P1398, DOI 10.1177/0022034511422909; Virani SS, 2020, CIRCULATION, V141, pE139, DOI 10.1161/CIR.0000000000000757; Volkert D, 2019, CLIN NUTR, V38, P10, DOI 10.1016/j.clnu.2018.05.024; Wang ZY, 2019, BMC NEUROL, V19, DOI 10.1186/s12883-019-1314-6; Weir KA, 2011, CHEST, V140, P589, DOI 10.1378/chest.10-1618; Wilkinson JM, 2021, AM FAM PHYSICIAN, V103, P97; Wu CC, 2020, ASIA PAC J CLIN NUTR, V29, P266, DOI 10.6133/apjcn.202007_29(2).0009	57	0	0	2	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 2	2022	12								800029	10.3389/fimmu.2021.800029	http://dx.doi.org/10.3389/fimmu.2021.800029			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZE8PT	35185865	Green Published, gold			2022-12-18	WOS:000759140800001
J	Link-Rachner, CS; Sockel, K; Schuetz, C				Link-Rachner, Cornelia S.; Sockel, Katja; Schuetz, Catharina			Established and Emerging Treatments of Skin GvHD	FRONTIERS IN IMMUNOLOGY			English	Review						Graft-versus-host disease; cutaneous GvHD; acute skin GvHD; chronic skin GvHD; cell-based therapy; targeted therapy; GvHD treatment; GvHD therapies	VERSUS-HOST-DISEASE; STEROID-REFRACTORY ACUTE; CONSENSUS DEVELOPMENT PROJECT; STEM-CELL TRANSPLANTATION; BONE-MARROW-TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; EXTRACORPOREAL PHOTOPHERESIS; CLINICAL-TRIALS; DIAGNOSIS; PHASE-3	Graft-versus-host disease (GvHD) of the skin is a severe allo-immune reaction and complication following allogeneic stem cell transplantation. Over the past years, intensive pre-clinical research has led to an improved understanding of the pathophysiology of acute and to a lesser extend chronic GvHD. This has translated into the approval of several new agents for the treatment of both forms of GvHD. This review summarizes the most recent advances in underlying pathomechanisms, clinical trials and newly approved agents for GvHD, with a special focus on skin involvement.	[Link-Rachner, Cornelia S.; Sockel, Katja] Tech Univ Dresden, Med Klin & Poliklin 1, Med Fak Carl Gustav Carus, Dresden, Germany; [Link-Rachner, Cornelia S.] Tech Univ Dresden, Ctr Regenerat Therapies Dresden, Dresden, Germany; [Schuetz, Catharina] Tech Univ Dresden, Med Fak Carl Gustav Carus, Klin & Poliklin Kinder & Jugendmed, Dresden, Germany	Technische Universitat Dresden; Carl Gustav Carus University Hospital; Technische Universitat Dresden; Technische Universitat Dresden; Carl Gustav Carus University Hospital	Schuetz, C (corresponding author), Tech Univ Dresden, Med Fak Carl Gustav Carus, Klin & Poliklin Kinder & Jugendmed, Dresden, Germany.	catharina.schuetz@ukdd.de						Abu-Dalle I, 2014, BIOL BLOOD MARROW TR, V20, P1677, DOI 10.1016/j.bbmt.2014.05.017; Aggarwal S, 2005, BLOOD, V105, P1815, DOI 10.1182/blood-2004-04-1559; Alfred A, 2017, BRIT J HAEMATOL, V177, P287, DOI 10.1111/bjh.14537; Bader P, 2018, BONE MARROW TRANSPL, V53, P852, DOI 10.1038/s41409-018-0102-z; Baker KS, 2008, BEST PRACT RES CL HA, V21, P333, DOI 10.1016/j.beha.2008.03.002; Chen S, 2015, BLOOD, V126, P103, DOI 10.1182/blood-2014-12-617258; Cooke KR, 2017, BIOL BLOOD MARROW TR, V23, P211, DOI 10.1016/j.bbmt.2016.09.023; Cutler C, 2006, BLOOD, V108, P756, DOI 10.1182/blood-2006-01-0233; Cutler C, 2021, BLOOD, V138, P2278, DOI 10.1182/blood.2021012021; De Jong CN, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0187184; Dignan FL, 2012, BRIT J HAEMATOL, V158, P62, DOI 10.1111/j.1365-2141.2012.09131.x; Duggleby R, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00252; Feldstein JV, 2011, J AM ACAD DERMATOL, V65, P733, DOI 10.1016/j.jaad.2010.08.006; Filipovich AH, 2005, BIOL BLOOD MARROW TR, V11, P945, DOI 10.1016/j.bbmt.2005.09.004; Flowers MED, 2008, BLOOD, V112, P2667, DOI 10.1182/blood-2008-03-141481; GLUCKSBERG H, 1974, TRANSPLANTATION, V18, P295, DOI 10.1097/00007890-197410000-00001; Gooptu M, 2020, HAEMATOLOGICA, V105, P2550, DOI 10.3324/haematol.2019.240309; Greinix HT, 2006, HAEMATOLOGICA, V91, P405; Guo WW, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.697854; Harris AC, 2016, BIOL BLOOD MARROW TR, V22, P4, DOI 10.1016/j.bbmt.2015.09.001; Holler E, 2019, EBMT HANDBOOK: HEMATOPOIETIC STEM CELL TRANSPLANTATION AND CELLULAR THERAPIES, P323, DOI 10.1007/978-3-030-02278-5_43; Jagasia M, 2020, BLOOD, V135, P1739, DOI 10.1182/blood.2020004823; Jagasia M, 2019, BLOOD ADV, V3, P2218, DOI 10.1182/bloodadvances.2019000145; Jagasia MH, 2015, BIOL BLOOD MARROW TR, V21, P389, DOI 10.1016/j.bbmt.2014.12.001; Kelly K, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.761616; Kurtzberg J, 2020, BIOL BLOOD MARROW TR, V26, P845, DOI 10.1016/j.bbmt.2020.01.018; Luznik L, 2008, BIOL BLOOD MARROW TR, V14, P641, DOI 10.1016/j.bbmt.2008.03.005; Malard F, 2020, LEUKEMIA, V34, P1229, DOI 10.1038/s41375-020-0804-2; Mankarious M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00081; Martin PJ, 2017, BLOOD, V130, P360, DOI 10.1182/blood-2017-03-775767; Massenkeil G, 2002, BONE MARROW TRANSPL, V30, P899, DOI 10.1038/sj.bmt.1703737; Miklos D, 2017, BLOOD, V130, P2243, DOI 10.1182/blood-2017-07-793786; Moles-Poveda P, 2021, ARCH PHYS MED REHAB, V102, P776, DOI 10.1016/j.apmr.2020.10.141; Nash RA, 2000, BLOOD, V96, P2062; Nishimoto M, 2015, EXP HEMATOL, V43, P177, DOI 10.1016/j.exphem.2014.11.008; Nygaard M, 2018, BONE MARROW TRANSPL, V53, P844, DOI 10.1038/s41409-018-0099-3; Olivieri A, 2009, BLOOD, V114, P709, DOI 10.1182/blood-2009-02-204156; Park JH, 2014, KOREAN J INTERN MED, V29, P630, DOI 10.3904/kjim.2014.29.5.630; Penack O, 2020, LANCET HAEMATOL, V7, pE157, DOI 10.1016/S2352-3026(19)30256-X; Perfetti P, 2008, BONE MARROW TRANSPL, V42, P609, DOI 10.1038/bmt.2008.221; Pierelli L, 2013, TRANSFUSION, V53, P2340, DOI 10.1111/trf.12059; Przepiorka D, 2000, BLOOD, V95, P83, DOI 10.1182/blood.V95.1.83.001k18_83_89; Rachner TD, 2022, BONE, V158, DOI 10.1016/j.bone.2020.115684; Rodrigues KS, 2018, AM J CLIN DERMATOL, V19, P33, DOI 10.1007/s40257-017-0306-9; Ruutu T, 2014, BONE MARROW TRANSPL, V49, P168, DOI 10.1038/bmt.2013.107; Schroeder MA, 2020, BLOOD ADV, V4, P1656, DOI 10.1182/bloodadvances.2019001043; Schroeder MA, 2018, BIOL BLOOD MARROW TR, V24, P1125, DOI 10.1016/j.bbmt.2017.12.797; Sestili S, 2020, CYTOTHERAPY, V22, P445, DOI 10.1016/j.jcyt.2020.03.003; Socie G, 2019, BLOOD ADV, V3, P184, DOI 10.1182/bloodadvances.2018028282; Socie G, 2017, BLOOD, V129, P643, DOI 10.1182/blood-2016-09-738625; Takahashi S, 2018, BLOOD, V131, P2074, DOI 10.1182/blood-2017-06-792614; Tan YM, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2016.1277307; Teshima T, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.715424; Theil A, 2015, CYTOTHERAPY, V17, P473, DOI 10.1016/j.jcyt.2014.11.005; Trzonkowski P, 2009, CLIN IMMUNOL, V133, P22, DOI 10.1016/j.clim.2009.06.001; Velickovic VM, 2020, THER ADV HEMATOL, V11, DOI 10.1177/2040620720977039; von Dalowski F, 2016, STEM CELLS, V34, P357, DOI 10.1002/stem.2224; Wolff D, 2013, BIOL BLOOD MARROW TR, V19, P767, DOI 10.1016/j.bbmt.2013.01.018; Wolff D, 2010, BIOL BLOOD MARROW TR, V16, P1611, DOI 10.1016/j.bbmt.2010.06.015; Yalniz FE, 2017, BIOL BLOOD MARROW TR, V23, P1478, DOI 10.1016/j.bbmt.2017.05.001; Zeiser R, 2015, LEUKEMIA, V29, P2062, DOI 10.1038/leu.2015.212; Zeiser R, 2021, NEW ENGL J MED, V385, P228, DOI 10.1056/NEJMoa2033122; Zeiser R, 2020, NEW ENGL J MED, V382, P1800, DOI 10.1056/NEJMoa1917635; Zeiser R, 2019, BRIT J HAEMATOL, V187, P563, DOI 10.1111/bjh.16190; Zeiser R, 2017, NEW ENGL J MED, V377, P2167, DOI 10.1056/NEJMra1609337; Ziemer M, 2014, J EUR ACAD DERMATOL, V28, P915, DOI 10.1111/jdv.12215	67	0	0	9	13	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 2	2022	13								838494	10.3389/fimmu.2022.838494	http://dx.doi.org/10.3389/fimmu.2022.838494			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZF4GZ	35185931	Green Published, gold			2022-12-18	WOS:000759529500001
J	Ramani, K; Cormack, T; Cartwright, ANR; Alami, A; Parameswaran, P; Abdou, M; Wang, IR; Hilliard-Barth, K; Argueta, S; Raghunathan, D; Caffry, W; Davitt, CJH; Romano, FB; Ng, A; Kravitz, V; Rommel, T; Sizova, M; Kiran, EU; Pradeep, P; Ponichtera, HE; Ganguly, T; Bodmer, M; Itano, A				Ramani, Kritika; Cormack, Taylor; Cartwright, Adam N. R.; Alami, Aula; Parameswaran, Pooja; Abdou, Marynawal; Wang, Iris; Hilliard-Barth, Kristie; Argueta, Shannon; Raghunathan, Divya; Caffry, Will; Davitt, Christopher J. H.; Romano, Fabian B.; Ng, Aylwin; Kravitz, Valeria; Rommel, Tyler; Sizova, Maria; Kiran, Esra Uckun; Pradeep, Pallavi; Ponichtera, Holly E.; Ganguly, Tanmoy; Bodmer, Mark; Itano, Andrea			Regulation of Peripheral Inflammation by a Non-Viable, Non-Colonizing Strain of Commensal Bacteria	FRONTIERS IN IMMUNOLOGY			English	Article						Th1; Th17; Th2; inflammation; CNS; bacteria; gastrointestinal tract	T-CELLS; MICROBIOTA; IMMUNITY	The gastrointestinal tract represents one of the largest body surfaces that is exposed to the outside world. It is the only mucosal surface that is required to simultaneously recognize and defend against pathogens, while allowing nutrients containing foreign antigens to be tolerated and absorbed. It differentiates between these foreign substances through a complex system of pattern recognition receptors expressed on the surface of the intestinal epithelial cells as well as the underlying immune cells. These immune cells actively sample and evaluate microbes and other particles that pass through the lumen of the gut. This local sensing system is part of a broader distributed signaling system that is connected to the rest of the body through the enteric nervous system, the immune system, and the metabolic system. While local tissue homeostasis is maintained by commensal bacteria that colonize the gut, colonization itself may not be required for the activation of distributed signaling networks that can result in modulation of peripheral inflammation. Herein, we describe the ability of a gut-restricted strain of commensal bacteria to drive systemic anti-inflammatory effects in a manner that does not rely upon its ability to colonize the gastrointestinal tract or alter the mucosal microbiome. Orally administered EDP1867, a gamma-irradiated strain of Veillonella parvula, rapidly transits through the murine gut without colonization or alteration of the background microbiome flora. In murine models of inflammatory disease including delayed-type hypersensitivity (DTH), atopic dermatitis, psoriasis, and experimental autoimmune encephalomyelitis (EAE), treatment with EDP1867 resulted in significant reduction in inflammation and immunopathology. Ex vivo cytokine analyses revealed that EDP1867 treatment diminished production of pro-inflammatory cytokines involved in inflammatory cascades. Furthermore, blockade of lymphocyte migration to the gut-associated lymphoid tissues impaired the ability of EDP1867 to resolve peripheral inflammation, supporting the hypothesis that circulating immune cells are responsible for promulgating the signals from the gut to peripheral tissues. Finally, we show that adoptively transferred T cells from EDP1867-treated mice inhibit inflammation induced in recipient mice. These results demonstrate that an orally-delivered, non-viable strain of commensal bacteria can mediate potent anti-inflammatory effects in peripheral tissues through transient occupancy of the gastrointestinal tract, and support the development of non-living bacterial strains for therapeutic applications.	[Ramani, Kritika; Cormack, Taylor; Cartwright, Adam N. R.; Alami, Aula; Parameswaran, Pooja; Abdou, Marynawal; Wang, Iris; Hilliard-Barth, Kristie; Argueta, Shannon; Raghunathan, Divya; Caffry, Will; Davitt, Christopher J. H.; Romano, Fabian B.; Ng, Aylwin; Kravitz, Valeria; Rommel, Tyler; Sizova, Maria; Kiran, Esra Uckun; Pradeep, Pallavi; Ponichtera, Holly E.; Ganguly, Tanmoy; Bodmer, Mark; Itano, Andrea] Evelo Biosci, Cambridge, MA 02139 USA; [Parameswaran, Pooja] Univ Massachusetts, Worcester, MA 01605 USA; [Abdou, Marynawal] Beam Therapeut, Cambridge, MA USA; [Davitt, Christopher J. H.] Deepcure, Boston, MA USA	University of Massachusetts System; University of Massachusetts Worcester	Itano, A (corresponding author), Evelo Biosci, Cambridge, MA 02139 USA.	andrea@evelobio.com		Itano, Andrea/0000-0002-4766-6876; Davitt, Christopher/0000-0002-1081-5284				Aas JA, 2005, J CLIN MICROBIOL, V43, P5721, DOI 10.1128/JCM.43.11.5721-5732.2005; Akeson EC, 2006, GENOMICS, V87, P311, DOI 10.1016/j.ygeno.2005.09.022; Arrieta MC, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab2271; Atarashi K, 2013, NATURE, V500, P232, DOI 10.1038/nature12331; Boehme SA, 2009, INT IMMUNOL, V21, P81, DOI 10.1093/intimm/dxn127; Chen J, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0299-7; Dutt S, 2005, BLOOD, V106, P4009, DOI 10.1182/blood-2005-06-2339; Geva-Zatorsky N, 2017, CELL, V168, P928, DOI 10.1016/j.cell.2017.01.022; Hardman C, 2016, CURR OPIN IMMUNOL, V42, P16, DOI 10.1016/j.coi.2016.05.004; Hasegawa K, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2016-0218; Honda K, 2016, NATURE, V535, P75, DOI 10.1038/nature18848; Kollmann TR, 2012, IMMUNITY, V37, P771, DOI 10.1016/j.immuni.2012.10.014; Levy M, 2017, NAT REV IMMUNOL, V17, P219, DOI 10.1038/nri.2017.7; Mangalam A, 2017, CELL REP, V20, P1269, DOI 10.1016/j.celrep.2017.07.031; Marietta EV, 2016, ARTHRITIS RHEUMATOL, V68, P2878, DOI 10.1002/art.39785; Mowat AM, 2003, NAT REV IMMUNOL, V3, P331, DOI 10.1038/nri1057; Price AE, 2018, IMMUNITY, V49, P560, DOI 10.1016/j.immuni.2018.07.016; Scheiman J, 2019, NAT MED, V25, P1104, DOI 10.1038/s41591-019-0485-4; Sefik E, 2015, SCIENCE, V349, P993, DOI 10.1126/science.aaa9420; Sivan A, 2015, SCIENCE, V350, P1084, DOI 10.1126/science.aac4255; Sonkoly E, 2006, J ALLERGY CLIN IMMUN, V117, P411, DOI 10.1016/j.jaci.2005.10.033; Takeshita K, 2004, INT IMMUNOL, V16, P685, DOI 10.1093/intimm/dxh073; van den Bogert B, 2013, FEMS MICROBIOL ECOL, V85, P376, DOI 10.1111/1574-6941.12127; van der Fits L, 2009, J IMMUNOL, V182, P5836, DOI 10.4049/jimmunol.0802999; Whibley N, 2019, NAT IMMUNOL, V20, P386, DOI 10.1038/s41590-019-0351-z; Ziegler SF, 2012, J ALLERGY CLIN IMMUN, V130, P845, DOI 10.1016/j.jaci.2012.07.010	26	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 2	2022	13								768076	10.3389/fimmu.2022.768076	http://dx.doi.org/10.3389/fimmu.2022.768076			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZE8YI	35185874	Green Published, gold			2022-12-18	WOS:000759163600001
J	Tang, YT; Zhou, ZY; Yan, H; You, Y				Tang, Yutong; Zhou, Zhenyang; Yan, Han; You, Yong			Case Report: Preemptive Treatment With Low-Dose PD-1 Blockade and Azacitidine for Molecular Relapsed Acute Myeloid Leukemia With RUNX1-RUNX1T1 After Allogeneic Hematopoietic Stem Cell Transplantation	FRONTIERS IN IMMUNOLOGY			English	Article						acute myeloid leukemia; allogeneic hematopoietic stem cell transplantation; immune checkpoint inhibitors; preemptive treatment; hypomethylating agents; graft-versus-host disease; graft-versus-leukemia	IMMUNE CHECKPOINT BLOCKADE; INTERNATIONAL WORKSHOP; PREVENTION; BLOOD; MALIGNANCIES; EXPRESSION; NIVOLUMAB; RESPONSES; INFUSION; BIOLOGY	Acute myeloid leukemia (AML) patients who develop hematological relapse (HR) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) generally have dismal clinical outcomes. Measurable residual disease (MRD)-directed preemptive interventions are effective approaches to prevent disease progression and improve prognosis for molecular relapsed patients with warning signs of impending HR. In this situation, boosting the graft-vs-leukemia (GVL) effect with immune checkpoint inhibitors (ICIs) might be a promising prevention strategy, despite the potential for causing severe graft-vs-host disease (GVHD). In the present study, we reported for the first time an AML patient with RUNX1-RUNX1T1 who underwent preemptive treatment with the combined application of tislelizumab (an anti-PD-1 antibody) and azacitidine to avoid HR following allo-HSCT. On day +81, molecular relapse with MRD depicted by RUNX1-RUN1T1-positivity as well as mixed donor chimerism occurred in the patient. On day +95, with no signs of GVHD and an excellent eastern cooperative oncology group performance status (ECOG PS), the patient thus was administered with 100 mg of tislelizumab on day 1 and 100 mg of azacitidine on days 1-7. After the combination therapy, complete remission was successfully achieved with significant improvement in hematologic response, and the MRD marker RUNX1-RUNX1T1 turned negative, along with a complete donor chimerism in bone marrow. Meanwhile, the patient experienced moderate GVHD and immune-related adverse events (irAEs), successively involving the lung, liver, lower digestive tract and urinary system, which were well controlled by immunosuppressive therapies. As far as we know, this case is the first one to report the use of tislelizumab in combination with azacitidine to prevent post-transplant relapse in AML. In summary, the application of ICIs in MRD positive patients might be an attractive strategy for immune modulation in the future to reduce the incidence of HR in the post-transplant setting, but safer clinical application schedules need to be explored.	[Tang, Yutong; Yan, Han; You, Yong] Huazhong Univ Sci & Technol, Union Hosp, Inst Hematol, Tongji Med Coll, Wuhan, Peoples R China; [Zhou, Zhenyang] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Radiol, Wuhan, Peoples R China; [Zhou, Zhenyang] Hubei Prov Key Lab Mol Imaging, Wuhan, Peoples R China	Huazhong University of Science & Technology; Huazhong University of Science & Technology	Yan, H; You, Y (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Inst Hematol, Tongji Med Coll, Wuhan, Peoples R China.	picachu122@163.com; youunion@126.com			National Natural Science Foundation of China [81500168]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	Funding This work was supported by the National Natural Science Foundation of China (grant number 81500168).	ANTIN JH, 1993, BLOOD, V82, P2273; Armand P, 2015, BLOOD, V125, P3393, DOI 10.1182/blood-2015-02-567453; Bejanyan N, 2015, BIOL BLOOD MARROW TR, V21, P454, DOI 10.1016/j.bbmt.2014.11.007; Chan TSY, 2017, ANN HEMATOL, V96, P1569, DOI 10.1007/s00277-017-3033-7; Claiborne J, 2019, LEUKEMIA LYMPHOMA, V60, P2733, DOI 10.1080/10428194.2019.1605066; Cooper ML, 2017, J IMMUNOL, V198, P3746, DOI 10.4049/jimmunol.1502399; Craddock C, 2019, J CLIN ONCOL, V37, P580, DOI 10.1200/JCO.18.00889; Daver N, 2019, CANCER DISCOV, V9, P370, DOI 10.1158/2159-8290.CD-18-0774; Daver N, 2018, LEUKEMIA, V32, P1094, DOI 10.1038/s41375-018-0070-8; Davids MS, 2020, BLOOD, V135, P2182, DOI 10.1182/blood.2019004710; Davids MS, 2016, NEW ENGL J MED, V375, P143, DOI 10.1056/NEJMoa1601202; de Lima M, 2014, BIOL BLOOD MARROW TR, V20, P4, DOI 10.1016/j.bbmt.2013.08.012; Devillier R, 2013, LEUKEMIA LYMPHOMA, V54, P1228, DOI 10.3109/10428194.2012.741230; Dohner H, 2017, BLOOD, V129, P424, DOI 10.1182/blood-2016-08-733196; Dohner H, 2015, NEW ENGL J MED, V373, P1136, DOI 10.1056/NEJMra1406184; Dulos J, 2012, J IMMUNOTHER, V35, P169, DOI 10.1097/CJI.0b013e318247a4e7; Godfrey J, 2017, J IMMUNOTHER CANCER, V5, DOI 10.1186/s40425-017-0211-z; Haverkos BM, 2017, BLOOD, V130, P221, DOI 10.1182/blood-2017-01-761346; Herbaux C, 2018, BLOOD, V132, P9, DOI 10.1182/blood-2018-02-811174; Herbaux C, 2017, BLOOD, V129, P2471, DOI 10.1182/blood-2016-11-749556; Hirahara K, 2016, INT IMMUNOL, V28, P163, DOI 10.1093/intimm/dxw006; Hollein A, 2018, LEUKEMIA, V32, P2270, DOI 10.1038/s41375-018-0086-0; Holderried TAW, 2019, BONE MARROW TRANSPL, V54, P1662, DOI 10.1038/s41409-019-0498-0; Kohler N, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.634435; Kong Y, 2015, BLOOD CANCER J, V5, DOI 10.1038/bcj.2015.58; Kumar AJ, 2013, BIOL BLOOD MARROW TR, V19, P1094, DOI 10.1016/j.bbmt.2013.04.021; Liga M, 2013, BIOL BLOOD MARROW TR, V19, P75, DOI 10.1016/j.bbmt.2012.07.021; Loke J, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.659595; Loke J, 2020, BRIT J HAEMATOL, V188, P129, DOI 10.1111/bjh.16355; Minson A, 2019, BRIT J HAEMATOL, V184, P840, DOI 10.1111/bjh.15186; Nie J, 2019, J CLIN ONCOL, V37, P1479, DOI 10.1200/JCO.18.02151; Noviello M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08871-1; Porter DL, 2010, BIOL BLOOD MARROW TR, V16, P1467, DOI 10.1016/j.bbmt.2010.08.001; Rautenberg C, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20010228; Saberian C, 2021, J IMMUNOTHER CANCER, V9, DOI 10.1136/jitc-2020-001818; Schade H, 2016, BIOL BLOOD MARROW TR, V22, P2172, DOI 10.1016/j.bbmt.2016.08.007; Schmid C, 2018, HAEMATOLOGICA, V103, P237, DOI 10.3324/haematol.2017.168716; Schuler E, 2019, ANN HEMATOL, V98, P1225, DOI 10.1007/s00277-019-03670-6; Shi W, 2020, ACTA PHARMACOL SIN B, V10, P2125, DOI 10.1016/j.apsb.2020.06.012; Simonetta F, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01034; Soiffer RJ, 2018, BLOOD, V131, P1073, DOI 10.1182/blood-2017-10-752154; Sommer S, 2018, LEUKEMIA RES, V72, P20, DOI 10.1016/j.leukres.2018.07.005; Spyridonidis A, 2020, BLOOD, V135, P1639, DOI 10.1182/blood.2019003566; Sterling C, 2020, AM J HEMATOL, V95, P529, DOI 10.1002/ajh.25750; Vago L, 2019, HEMATOL-AM SOC HEMAT, P610, DOI 10.1182/hematology.2019000005; Wang Y, 2018, CANCER LETT, V438, P63, DOI 10.1016/j.canlet.2018.08.030; Wang Y, 2014, BLOOD, V124, P1880, DOI 10.1182/blood-2014-03-563403; Williams P, 2019, CANCER-AM CANCER SOC, V125, P1470, DOI 10.1002/cncr.31896; Wrangle J, 2013, ONCOTARGET, V4, P2067, DOI 10.18632/oncotarget.1542; Yang H, 2014, LEUKEMIA, V28, P1280, DOI 10.1038/leu.2013.355; Zhang XH, 2021, J HEMATOL ONCOL, V14, DOI 10.1186/s13045-021-01159-2	51	0	0	3	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 2	2022	13								810284	10.3389/fimmu.2022.810284	http://dx.doi.org/10.3389/fimmu.2022.810284			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZE8VC	35185899	gold, Green Published			2022-12-18	WOS:000759154900001
J	Zhang, D; Yang, J; Zhao, YH; Shan, JJ; Wang, LL; Yang, G; He, SS; Li, ER				Zhang, Dan; Yang, Jie; Zhao, Yuanhui; Shan, Jinjun; Wang, Lingling; Yang, Guang; He, Susu; Li, Erguang			RSV Infection in Neonatal Mice Induces Pulmonary Eosinophilia Responsible for Asthmatic Reaction	FRONTIERS IN IMMUNOLOGY			English	Article						RSV; asthma; adoptive transfer; eosinophilic inflammation; eosinophilia	RESPIRATORY SYNCYTIAL VIRUS; AIRWAY HYPERRESPONSIVENESS; ANTIGEN PRESENTATION; MOUSE MODEL; PATHOGENESIS; EXPRESSION; ACTIVATION; BRONCHIOLITIS; INFLAMMATION; TRAFFICKING	Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections in infants and young children. Severe respiratory viral infection in early life is intimately associated with childhood recurrent wheezing and is a risk factor for asthma later in life. Although eosinophilic airway inflammation is an important trait in asthma of children, the roles of pulmonary eosinophils in the disease have been inadequately understood. Here, we show that RSV infection in neonatal mice causes eosinophilia after allergen stimulation. We showed that RSV infection in neonatal mice exacerbated allergic asthma to allergen stimulation that was accompanied with increased detection of eosinophils in the lungs. In addition, we also detected accumulation of ILC2, CD4(+) T cells, and macrophages. Importantly, adoptive transfer of eosinophils from asthmatic mice with early-life RSV infection exacerbated pulmonary pathologies associated with allergic respiratory inflammation in naive mice in response to foreign antigen. The induction of asthmatic symptoms including AHR, tracheal wall thickening, and mucus production became more severe after further stimulation in those mice. The expression of antigen presentation-related molecules like CD80, CD86, and especially MHC II was markedly induced in eosinophils from OVA-stimulated asthmatic mice. The accumulation of CD4(+) T cells in the lungs was also significantly increased as a result of adoptive transfer of eosinophils. Importantly, the deterioration of lung pathology caused by adoptive transfer could be effectively attenuated by treatment with indomethacin, a nonsteroidal anti-inflammatory drug. Our findings highlight the significance of eosinophil-mediated proinflammatory response in allergic disease associated with early-life infection of the respiratory tract.	[Zhang, Dan; Wang, Lingling; He, Susu; Li, Erguang] Nanjing Univ, Med Sch, State Key Lab Pharmaceut Biotechnol, Nanjing, Peoples R China; [Zhang, Dan; Yang, Jie; Zhao, Yuanhui; Wang, Lingling; He, Susu; Li, Erguang] Nanjing Univ, Med Sch, Jiangsu Key Lab Mol Med, Nanjing, Peoples R China; [Zhang, Dan; He, Susu] Nanjing Univ, Med Sch, Yancheng Med Res Ctr, Yancheng, Peoples R China; [Zhao, Yuanhui; Li, Erguang] Nanjing Univ, Inst Med Virol, Med Sch, Drum Tower Hosp, Nanjing, Peoples R China; [Shan, Jinjun] Nanjing Univ Chinese Med, Coll Clin Med, Ctr Pediat Dis, Nanjing, Peoples R China; [Yang, Guang] Nanjing Med Univ, Nanjing Childrens Hosp, Nanjing, Peoples R China	Nanjing University; Nanjing University; Nanjing University; Nanjing University; Nanjing University of Chinese Medicine; Nanjing Medical University	He, SS; Li, ER (corresponding author), Nanjing Univ, Med Sch, State Key Lab Pharmaceut Biotechnol, Nanjing, Peoples R China.; He, SS; Li, ER (corresponding author), Nanjing Univ, Med Sch, Jiangsu Key Lab Mol Med, Nanjing, Peoples R China.; He, SS (corresponding author), Nanjing Univ, Med Sch, Yancheng Med Res Ctr, Yancheng, Peoples R China.; Li, ER (corresponding author), Nanjing Univ, Inst Med Virol, Med Sch, Drum Tower Hosp, Nanjing, Peoples R China.	erguang@nju.edu.cn; susuhetian@nju.edu.cn	ZHAO, YUAN/HCI-5831-2022	Li, Erguang/0000-0002-3065-1336	NSFC [81871636]; Jiangsu Natural Science Foundation [BK20200316]; Central Universities Fundamental Research Funds [14380470]; Science, Technology and Innovation Commission of Shenzhen Municipality [JSGG20200519160755008]	NSFC(National Natural Science Foundation of China (NSFC)); Jiangsu Natural Science Foundation(Natural Science Foundation of Jiangsu Province); Central Universities Fundamental Research Funds; Science, Technology and Innovation Commission of Shenzhen Municipality	The work was supported by grants from the NSFC (81871636 to EL), from Jiangsu Natural Science Foundation (BK20200316 to SH), from Central Universities Fundamental Research Funds (14380470 to SH), and from Science, Technology and Innovation Commission of Shenzhen Municipality (JSGG20200519160755008 to EL).	Abbafati C, 2020, LANCET, V396, P1204, DOI 10.1016/S0140-6736(20)30925-9; AIKAWA T, 1992, CHEST, V101, P916, DOI 10.1378/chest.101.4.916; Brasier AR, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12040472; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Busse WW, 2001, NEW ENGL J MED, V344, P350, DOI 10.1056/NEJM200102013440507; Cagnoni EF, 2015, J ALLERGY CLIN IMMUN, V135, P1352, DOI 10.1016/j.jaci.2014.08.021; Castillo JR, 2017, J ALLER CL IMM-PRACT, V5, P918, DOI 10.1016/j.jaip.2017.05.001; Castro M, 2008, J ALLERGY CLIN IMMUN, V122, P726, DOI 10.1016/j.jaci.2008.07.010; Chen C, 2013, FOOD CHEM TOXICOL, V62, P41, DOI 10.1016/j.fct.2013.08.004; Chen JC, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9060688; Chen SL, 2020, RESP RES, V21, DOI 10.1186/s12931-020-01453-6; Dakhama A, 2005, J IMMUNOL, V175, P1876, DOI 10.4049/jimmunol.175.3.1876; Dunican EM, 2018, J CLIN INVEST, V128, P997, DOI 10.1172/JCI95693; Fahy JV, 2015, NAT REV IMMUNOL, V15, P57, DOI 10.1038/nri3786; Farhan RK, 2016, IMMUNOLOGY, V149, P413, DOI 10.1111/imm.12658; GLEZEN WP, 1986, AM J DIS CHILD, V140, P543, DOI 10.1001/archpedi.1986.02140200053026; Guo XC, 2015, J VIROL, V89, P7636, DOI 10.1128/JVI.00349-15; Hamelmann E, 1997, AM J RESP CRIT CARE, V156, P766, DOI 10.1164/ajrccm.156.3.9606031; HANSEL TT, 1992, J IMMUNOL, V149, P2130; Hogan SP, 2008, CLIN EXP ALLERGY, V38, P709, DOI 10.1111/j.1365-2222.2008.02958.x; Holgate ST, 2012, NAT MED, V18, P673, DOI 10.1038/nm.2731; Holt PG, 2002, J EXP MED, V196, P1271, DOI 10.1084/jem.20021572; Humbles AA, 2004, SCIENCE, V305, P1776, DOI 10.1126/science.1100283; Jacobsen EA, 2021, ANNU REV IMMUNOL, V39, P719, DOI 10.1146/annurev-immunol-093019-125918; Jang MK, 2005, MOL CELL, V19, P523, DOI 10.1016/j.molcel.2005.06.027; Jartti T, 2017, J ALLERGY CLIN IMMUN, V140, P895, DOI 10.1016/j.jaci.2017.08.003; Johansson MW, 2017, FRONT MED-LAUSANNE, V4, DOI 10.3389/fmed.2017.00075; Kanda A, 2009, J ALLERGY CLIN IMMUN, V124, P573, DOI 10.1016/j.jaci.2009.04.031; Kandikattu HK, 2021, IMMUNOLOGY, V163, P220, DOI 10.1111/imm.13314; Kitcharoensakkul M, 2021, PEDIAT ALLERG IMM-UK, V32, P457, DOI 10.1111/pai.13399; Krishnamoorthy N, 2012, NAT MED, V18, P1525, DOI 10.1038/nm.2896; Kvarnhammar AM, 2011, IMMUNOLOGY, V134, P314, DOI 10.1111/j.1365-2567.2011.03492.x; Larche M, 2003, J ALLERGY CLIN IMMUN, V111, P450, DOI 10.1067/mai.2003.169; Lee JJ, 2004, SCIENCE, V305, P1773, DOI 10.1126/science.1099472; Lindsley AW, 2020, J ALLERGY CLIN IMMUN, V146, P1, DOI 10.1016/j.jaci.2020.04.021; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Luecke E, 2021, J ALLERGY CLIN IMMUN, V147, P112, DOI 10.1016/j.jaci.2020.09.026; Malinczak CA, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12050505; Malinczak CA, 2019, MUCOSAL IMMUNOL, V12, P969, DOI 10.1038/s41385-019-0171-3; Malmstrom K, 2020, CLIN EXP ALLERGY, V50, P558, DOI 10.1111/cea.13598; Mansson A, 2010, INT ARCH ALLERGY IMM, V151, P118, DOI 10.1159/000236001; McAdam AJ, 1998, IMMUNOL REV, V165, P231; Meissner HC, 2016, NEW ENGL J MED, V374, P62, DOI 10.1056/NEJMra1413456; Myou S, 2001, NAT IMMUNOL, V2, P145, DOI 10.1038/84244; Oh Jae-Won, 2006, Allergol Int, V55, P369; Padigel UM, 2007, J INFECT DIS, V196, P1844, DOI 10.1086/522968; Palaniyandi S, 2020, LAB INVEST, V100, P265, DOI 10.1038/s41374-019-0305-y; Peebles RS, 2019, CLIN CHEST MED, V40, P29, DOI 10.1016/j.ccm.2018.10.014; Perales-Linares R, 2013, IMMUNOLOGY, V140, P153, DOI 10.1111/imm.12143; Percopo CM, 2014, BLOOD, V123, P743, DOI 10.1182/blood-2013-05-502443; Pijnenburg MW, 2020, LANCET RESP MED, V8, P1032, DOI 10.1016/S2213-2600(20)30399-4; Pineros YSS, 2019, ALLERGY, V74, P1898, DOI 10.1111/all.13802; Possa SS, 2013, FRONT PHARMACOL, V4, DOI 10.3389/fphar.2013.00046; Ramsahai JM, 2019, AM J RESP CRIT CARE, V199, P423, DOI 10.1164/rccm.201810-1931CI; Reddy AT, 2013, J IMMUNOL, V191, P2053, DOI 10.4049/jimmunol.1300730; Restori KH, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01249; Rosenberg HF, 2013, NAT REV IMMUNOL, V13, P9, DOI 10.1038/nri3341; Rosenberg HF, 2001, J LEUKOCYTE BIOL, V70, P691; Shi HZ, 2000, J CLIN INVEST, V105, P945, DOI 10.1172/JCI8945; Shi T, 2017, LANCET, V390, P946, DOI [10.1016/s0140-6736(17)30938-8, 10.1016/S0140-6736(17)30938-8]; Su YC, 2015, J VIROL, V89, P1564, DOI 10.1128/JVI.01536-14; Szabo Shelagh M, 2013, Paediatr Respir Rev, V13 Suppl 2, pS1, DOI 10.1016/S1526-0542(12)00095-4; Tiwary Meenakshi, 2021, Methods Mol Biol, V2241, P99, DOI 10.1007/978-1-0716-1095-4_9; Tsuchiya K, 2012, AM J PHYSIOL-LUNG C, V303, pL54, DOI 10.1152/ajplung.00208.2011; Tumes DJ, 2007, J LEUKOCYTE BIOL, V81, P1362, DOI 10.1189/jlb.0106046; van Diepen A, 2015, J VIROL, V89, P5022, DOI 10.1128/JVI.03630-14; Van Hulst G, 2020, BIOCHEM PHARMACOL, V179, DOI 10.1016/j.bcp.2020.113963; Verwey C, 2020, PEDIATR PULM, V55, P1567, DOI 10.1002/ppul.24804; Wang HB, 2007, J IMMUNOL, V179, P7585, DOI 10.4049/jimmunol.179.11.7585; Wedi B, 2020, ALLERGY, V75, P2229, DOI 10.1111/all.14213; Woerly G, 1999, J EXP MED, V190, P487, DOI 10.1084/jem.190.4.487; Wong CK, 2007, AM J RESP CELL MOL, V37, P85, DOI 10.1165/rcmb.2006-0457OC; Yu CN, 2002, J EXP MED, V195, P1387, DOI 10.1084/jem.20020656; Zahran HS, 2018, MMWR-MORBID MORTAL W, V67, P149, DOI 10.15585/mmwr.mm6705e1	74	0	0	5	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 2	2022	13								817113	10.3389/fimmu.2022.817113	http://dx.doi.org/10.3389/fimmu.2022.817113			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZF4RF	35185908	gold, Green Published			2022-12-18	WOS:000759556300001
J	Ionov, S; Lee, JW				Ionov, Steven; Lee, Jiwon			An Immunoproteomic Survey of the Antibody Landscape: Insights and Opportunities Revealed by Serological Repertoire Profiling	FRONTIERS IN IMMUNOLOGY			English	Review						Ig-Seq; serological antibody repertoire; proteomics; infectious disease; cancer; autoimmunity	MOLECULAR-LEVEL ANALYSIS; HUMORAL IMMUNE-RESPONSE; MONOCLONAL-ANTIBODIES; INFLUENZA; PROTEOMICS; INFECTION; MECHANISMS; SARS-COV-2; PROTECTION; CLONING	Immunoproteomics has emerged as a versatile tool for analyzing the antibody repertoire in various disease contexts. Until recently, characterization of antibody molecules in biological fluids was limited to bulk serology, which identifies clinically relevant features of polyclonal antibody responses. The past decade, however, has seen the rise of mass-spectrometry-enabled proteomics methods that have allowed profiling of the antibody response at the molecular level, with the disease-specific serological repertoire elucidated in unprecedented detail. In this review, we present an up-to-date survey of insights into the disease-specific immunological repertoire by examining how quantitative proteomics-based approaches have shed light on the humoral immune response to infection and vaccination in pathogenic illnesses, the molecular basis of autoimmune disease, and the tumor-specific repertoire in cancer. We address limitations of this technology with a focus on emerging potential solutions and discuss the promise of high-resolution immunoproteomics in therapeutic discovery and novel vaccine design.	[Ionov, Steven; Lee, Jiwon] Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03755 USA	Dartmouth College	Lee, JW (corresponding author), Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03755 USA.	jiwon.lee@dartmouth.edu						Aebersold R, 2003, NATURE, V422, P198, DOI 10.1038/nature01511; Algaissi A, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-73491-5; Anderson EM, 2021, CELL, V184, P1858, DOI 10.1016/j.cell.2021.02.010; Bajic G, 2019, CELL HOST MICROBE, V25, P827, DOI 10.1016/j.chom.2019.04.003; Bangaru S, 2019, CELL, V177, P1136, DOI 10.1016/j.cell.2019.04.011; Barnidge DR, 2014, J PROTEOME RES, V13, P1905, DOI 10.1021/pr5000544; Behring EKS., 1890, DEUT MED WOCHENSCHR, V16, P1113, DOI [10.1055/s-0029-1207589, DOI 10.1055/S-0029-1207589]; Bodewes R, 2011, CLIN VACCINE IMMUNOL, V18, P469, DOI 10.1128/CVI.00396-10; Bondt A, 2021, CELL SYST, V12, P1131, DOI 10.1016/j.cels.2021.08.008; Briney BS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100839; Brochet X, 2008, NUCLEIC ACIDS RES, V36, pW503, DOI 10.1093/nar/gkn316; Broodman I, 2017, J PROTEOME RES, V16, P3, DOI 10.1021/acs.jproteome.6b00559; Butler SE, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.618685; Chen J, 2017, CELL REP, V18, P237, DOI 10.1016/j.celrep.2016.12.013; Cheung WC, 2012, NAT BIOTECHNOL, V30, P447, DOI 10.1038/nbt.2167; Cho MJ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5167; Coelho CH, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.143471; COX RJ, 1994, VACCINE, V12, P993, DOI 10.1016/0264-410X(94)90334-4; Curtis NC, 2020, CURR OPIN SYST BIOL, V24, P93, DOI 10.1016/j.coisb.2020.10.008; de Costa D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096029; DeKosky BJ, 2015, NAT MED, V21, P86, DOI 10.1038/nm.3743; Dugan HL, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abd3601; Ehrlich P., 1891, DEUT MED WOCHENSCHR, V17, P1218, DOI DOI 10.1055/S-0029-1206825; Feng S, 2021, NAT MED, V27, P2032, DOI 10.1038/s41591-021-01540-1; Fonville JM, 2014, SCIENCE, V346, P996, DOI 10.1126/science.1256427; FRANCIS T, 1947, AM J PUBLIC HEALTH, V37, P1013, DOI 10.2105/AJPH.37.8.1013; Francis T., 1960, P AM PHILOS SOC, V104, P572, DOI DOI 10.1371/JOURNAL.PPAT.1005806; Frasca D, 2010, VACCINE, V28, P8077, DOI 10.1016/j.vaccine.2010.10.023; Friedensohn S, 2017, TRENDS BIOTECHNOL, V35, P203, DOI 10.1016/j.tibtech.2016.09.010; Gillet LC, 2016, ANNU REV ANAL CHEM, V9, P449, DOI 10.1146/annurev-anchem-071015-041535; Gostic KM, 2016, SCIENCE, V354, P722, DOI 10.1126/science.aag1322; Guthals A, 2017, J PROTEOME RES, V16, P45, DOI 10.1021/acs.jproteome.6b00608; Haen SP, 2020, NAT REV CLIN ONCOL, V17, P595, DOI 10.1038/s41571-020-0387-x; Hammers CM, 2016, ANNU REV PATHOL-MECH, V11, P175, DOI 10.1146/annurev-pathol-012615-044313; Hansen CH, 2021, LANCET, V397, P1204, DOI 10.1016/S0140-6736(21)00575-4; HOBSON D, 1972, J HYG-CAMBRIDGE, V70, P767, DOI 10.1017/S0022172400022610; Holmgren J, 2005, NAT MED, V11, pS45, DOI 10.1038/nm1213; Iacob SA, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.02323; Iversen R, 2019, P NATL ACAD SCI USA, V116, P15134, DOI 10.1073/pnas.1901561116; Jung JW, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI148763; Kim SI, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abd6990; Kitteringham NR, 2009, J CHROMATOGR B, V877, P1229, DOI 10.1016/j.jchromb.2008.11.013; Krammer F, 2019, NAT REV IMMUNOL, V19, P383, DOI 10.1038/s41577-019-0143-6; Landsteiner K, 1940, J EXP MED, V71, P445, DOI 10.1084/jem.71.4.445; Lavinder JJ, 2014, P NATL ACAD SCI USA, V111, P2259, DOI 10.1073/pnas.1317793111; Lee J, 2019, CELL HOST MICROBE, V25, P367, DOI 10.1016/j.chom.2019.01.010; Lee J, 2016, NAT MED, V22, P1456, DOI 10.1038/nm.4224; Lindesmith LC, 2019, IMMUNITY, V50, P1530, DOI 10.1016/j.immuni.2019.05.007; Lindop R, 2011, ARTHRITIS RHEUM-US, V63, P3477, DOI 10.1002/art.30566; Liu LH, 2020, NATURE, V584, P450, DOI 10.1038/s41586-020-2571-7; Mason DM, 2021, NAT BIOMED ENG, V5, P600, DOI 10.1038/s41551-021-00699-9; Matsuda K, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI140794; Mauch RM, 2018, J CYST FIBROS, V17, P143, DOI 10.1016/j.jcf.2017.08.012; McCarthy KR, 2021, MBIO, V12, DOI 10.1128/mBio.01144-21; McCarthy KR, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2026752118; McDaniel JR, 2018, CANCER IMMUNOL IMMUN, V67, P729, DOI 10.1007/s00262-018-2123-2; McDaniel JR, 2016, NAT PROTOC, V11, P429, DOI 10.1038/nprot.2016.024; Miller MS, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006637; Morgenlander WR, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI146927; Nesvizhskii AI, 2014, NAT METHODS, V11, P1114, DOI [10.1038/NMETH.3144, 10.1038/nmeth.3144]; Tran NH, 2016, SCI REP-UK, V6, DOI 10.1038/srep31730; Obermeier B, 2008, NAT MED, V14, P688, DOI 10.1038/nm1714; Ogishi M, 2016, SCI REP-UK, V6, DOI 10.1038/srep29532; Peng WW, 2021, J PROTEOME RES, V20, P3559, DOI 10.1021/acs.jproteome.1c00169; Plotkin SA, 2010, CLIN VACCINE IMMUNOL, V17, P1055, DOI 10.1128/CVI.00131-10; Radbruch A, 2006, NAT REV IMMUNOL, V6, P741, DOI 10.1038/nri1886; Rajkumar SV, 2016, AM J HEMATOL, V91, P720, DOI 10.1002/ajh.24402; Rappazzo CG, 2021, SCIENCE, V371, P823, DOI 10.1126/science.abf4830; Robbiani DF, 2020, NATURE, V584, P437, DOI 10.1038/s41586-020-2456-9; Robinson WH, 2015, NAT REV RHEUMATOL, V11, P171, DOI 10.1038/nrrheum.2014.220; Sato S, 2012, NAT BIOTECHNOL, V30, P1039, DOI 10.1038/nbt.2406; Seow J, 2020, NAT MICROBIOL, V5, P1598, DOI 10.1038/s41564-020-00813-8; Simek MD, 2009, J VIROL, V83, P7337, DOI 10.1128/JVI.00110-09; Singh M, 2020, CELL, V180, P878, DOI 10.1016/j.cell.2020.01.029; Snapkov I, 2022, TRENDS BIOTECHNOL, V40, P463, DOI 10.1016/j.tibtech.2021.08.006; Spencer J, 2016, MUCOSAL IMMUNOL, V9, P1113, DOI 10.1038/mi.2016.59; ter Meulen J, 2006, PLOS MED, V3, P1071, DOI 10.1371/journal.pmed.0030237; Theprungsirikul J, 2020, J CYST FIBROS, V19, P196, DOI 10.1016/j.jcf.2019.06.006; Tipton CM, 2018, IMMUNOL REV, V284, P120, DOI 10.1111/imr.12660; Tipton CM, 2015, NAT IMMUNOL, V16, P755, DOI 10.1038/ni.3175; VanDuijn MM, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01286; Villar LM, 2005, J CLIN INVEST, V115, P187, DOI 10.1172/JCI200522833; Voss WN, 2021, SCIENCE, V372, P1108, DOI 10.1126/science.abg5268; Wagner Angelika, 2021, Commun Med (Lond), V1, P13, DOI 10.1038/s43856-021-00012-4; Walensky RP, 2021, JAMA-J AM MED ASSOC, V325, P1037, DOI 10.1001/jama.2021.2294; Wang JJ, 2018, CLIN EXP IMMUNOL, V194, P273, DOI 10.1111/cei.13197; Watanabe A, 2019, CELL, V177, P1124, DOI 10.1016/j.cell.2019.03.048; Wec AZ, 2020, SCIENCE, V369, P731, DOI 10.1126/science.abc7424; Wheatley AK, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21444-5; Williams LD, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aal2200; Wine Y, 2015, CURR OPIN IMMUNOL, V35, P89, DOI 10.1016/j.coi.2015.06.009; Wine Y, 2013, P NATL ACAD SCI USA, V110, P2993, DOI 10.1073/pnas.1213737110; Wrammert J, 2008, NATURE, V453, P667, DOI 10.1038/nature06890; Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]; Yadav R, 2019, J CYST FIBROS, V18, P636, DOI 10.1016/j.jcf.2018.12.010; Zhang J, 2012, MOL CELL PROTEOMICS, V11, DOI [10.1074/mcp.M111.010587, 10.1074/mcp.M111.015032]	99	0	0	0	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 1	2022	13								832533	10.3389/fimmu.2022.832533	http://dx.doi.org/10.3389/fimmu.2022.832533			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZA3QV	35178051	Green Published, gold			2022-12-18	WOS:000756083300001
J	Luo, YX; Zhu, ZL; Li, B; Bai, XC; Fang, H; Qiao, P; Chen, JL; Zhang, C; Zhi, DL; Dang, EL; Wang, G				Luo, Yixin; Zhu, Zhenlai; Li, Bing; Bai, Xiaocui; Fang, Hui; Qiao, Pei; Chen, Jiaoling; Zhang, Chen; Zhi, Dalong; Dang, Erle; Wang, Gang			Keratin 17 Promotes T Cell Response in Allergic Contact Dermatitis by Upregulating C-C Motif Chemokine Ligand 20	FRONTIERS IN IMMUNOLOGY			English	Article						allergic contact dermatitis; contact hypersensitivity; keratinocytes; keratin 17; CCL20; T cell infiltration	GENE-EXPRESSION; IMMUNE EVENTS; HYPERSENSITIVITY; PROLIFERATION; INFLAMMATION; INDUCTION; GROWTH	Allergic contact dermatitis (ACD) is a delayed-type hypersensitivity response to skin contact allergens in which keratinocytes are critical in the initiation of early responses. Keratin 17 (K17) is a cytoskeletal protein inducible under stressful conditions and regulates multiple cellular processes, especially in skin inflammatory diseases; however, knowledge regarding its contribution to ACD pathogenesis remains ill defined. In the present study, we clarified the proinflammatory role of K17 in an oxazolone (OXA)-induced contact hypersensitivity (CHS) murine model and identified the underlying molecular mechanisms. Our results showed that K17 was highly expressed in the lesional skin of ACD patients and OXA-induced CHS mice. Mice lacking K17 exhibited alleviated OXA-induced skin inflammation, including milder ear swelling, a reduced frequency of T cell infiltration, and decreased inflammatory cytokine levels. In vitro, K17 stimulated and activated human keratinocytes to produce plenty of proinflammatory mediators, especially the chemokine CCL20, and promoted keratinocyte-mediated T cell trafficking. The neutralization of CCL20 with a CCL20-neutralizing monoclonal antibody significantly alleviated OXA-induced skin inflammation in vivo. Moreover, K17 could translocate into the nucleus of activated keratinocytes through a process dependent on the nuclear-localization signal (NLS) and nuclear-export signal (NES) sequences, thus facilitating the activation and nuclear translocation of signal transducer and activator of transcription 3 (STAT3), further promoting the production of CCL20 and T cell trafficking to the lesional skin. Taken together, these results highlight the novel roles of K17 in driving allergen-induced skin inflammation and suggest targeting K17 as a potential strategy for ACD.	[Luo, Yixin; Zhu, Zhenlai; Li, Bing; Bai, Xiaocui; Fang, Hui; Qiao, Pei; Chen, Jiaoling; Zhang, Chen; Zhi, Dalong; Dang, Erle; Wang, Gang] Fourth Mil Med Univ, Xijing Hosp, Dept Dermatol, Xian, Peoples R China	Air Force Military Medical University	Wang, G (corresponding author), Fourth Mil Med Univ, Xijing Hosp, Dept Dermatol, Xian, Peoples R China.	wanggangxjyy@163.com						Ahlstrom MG, 2019, CONTACT DERMATITIS, V81, P227, DOI 10.1111/cod.13327; Akiba H, 2002, J IMMUNOL, V168, P3079, DOI 10.4049/jimmunol.168.6.3079; Babu S, 2019, MODERN PATHOL, V32, P717, DOI 10.1038/s41379-018-0177-5; Balmert SC, 2017, J CONTROL RELEASE, V261, P223, DOI 10.1016/j.jconrel.2017.07.006; Brys AK, 2020, J INVEST DERMATOL, V140, P21, DOI 10.1016/j.jid.2019.03.1133; Chung BM, 2015, J CELL BIOL, V208, P613, DOI 10.1083/jcb.201408026; DePianto D, 2010, NAT GENET, V42, P910, DOI 10.1038/ng.665; Ehrlich F, 2020, MOL BIOL EVOL, V37, P982, DOI 10.1093/molbev/msz279; Ehrlich F, 2019, MOL BIOL EVOL, V36, P328, DOI 10.1093/molbev/msy214; Frick VO, 2016, WORLD J GASTROENTERO, V22, P833, DOI 10.3748/wjg.v22.i2.833; Fu M, 2012, J DERMATOL SCI, V67, P161, DOI 10.1016/j.jdermsci.2012.06.008; Fullel L, 2018, MOL THER, V26, P95, DOI 10.1016/j.ymthe.2017.10.005; Furue K, 2020, SCAND J IMMUNOL, V91, DOI 10.1111/sji.12846; Getschman AE, 2017, P NATL ACAD SCI USA, V114, P12460, DOI 10.1073/pnas.1704958114; Hobbs RP, 2016, ONCOGENE, V35, P5653, DOI 10.1038/onc.2016.102; Hobbs RP, 2017, J INVEST DERMATOL, V137, P1410, DOI 10.1016/j.jid.2017.01.023; Hobbs RP, 2016, DEV CELL, V38, P227, DOI 10.1016/j.devcel.2016.07.022; Hobbs RP, 2015, NAT GENET, V47, P933, DOI 10.1038/ng.3355; Hobbs RP, 2012, J CELL SCI, V125, P5257, DOI 10.1242/jcs.122929; Honda T, 2013, J INVEST DERMATOL, V133, P303, DOI 10.1038/jid.2012.284; Jin L, 2014, MED RES REV, V34, P438, DOI 10.1002/med.21291; Kaplan DH, 2012, NAT REV IMMUNOL, V12, P114, DOI 10.1038/nri3150; Kennedy-Crispin M, 2012, J INVEST DERMATOL, V132, P105, DOI 10.1038/jid.2011.262; Merkin RD, 2017, HUM PATHOL, V62, P23, DOI 10.1016/j.humpath.2016.10.006; Mockler D, 2017, AM J CLIN PATHOL, V148, P264, DOI [10.1093/AJCP/AQX077, 10.1093/ajcp/aqx077]; Murata A, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00775; Saika A, 2021, FASEB J, V35, DOI 10.1096/fj.202001687R; Sakai H, 2019, INFLAMMATION, V42, P2226, DOI 10.1007/s10753-019-01086-y; Shen Z, 2005, J DERMATOL SCI, V38, P25, DOI 10.1016/j.jdermsci.2005.01.001; Shen Z, 2006, J AM ACAD DERMATOL, V54, P992, DOI 10.1016/j.jaad.2006.02.033; Toivola DM, 2015, CURR OPIN CELL BIOL, V32, P73, DOI 10.1016/j.ceb.2014.12.008; Vocanson M, 2009, ALLERGY, V64, P1699, DOI 10.1111/j.1398-9995.2009.02082.x; Vocanson Marc, 2005, Expert Rev Clin Immunol, V1, P75, DOI 10.1586/1744666X.1.1.75; Wang B, 2020, APOPTOSIS, V25, P663, DOI 10.1007/s10495-020-01623-3; Wang FR, 2016, METHOD ENZYMOL, V568, P303, DOI 10.1016/bs.mie.2015.09.032; Yang LT, 2019, J PATHOL, V247, P158, DOI 10.1002/path.5178; Yang LT, 2018, J INVEST DERMATOL, V138, P2568, DOI 10.1016/j.jid.2018.05.016; Yang LT, 2017, J INVEST DERMATOL, V137, P2168, DOI 10.1016/j.jid.2017.05.015; Zhang JY, 2017, MED SCI MONITOR, V23, P6049, DOI 10.12659/MSM.904850; Zhang W, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040797	40	0	0	2	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 1	2022	13								764793	10.3389/fimmu.2022.764793	http://dx.doi.org/10.3389/fimmu.2022.764793			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZH0RK	35178048	gold, Green Published			2022-12-18	WOS:000760655800001
J	Somers, V; Dunn-Walters, DK; van der Burg, M; Fraussen, J				Somers, Veerle; Dunn-Walters, Deborah K.; van der Burg, Mirjam; Fraussen, Judith			Editorial: New Insights Into B Cell Subsets in Health and Disease	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						B cell subsets; B cell function; B cell metabolism; B cell vaccination response; B cell biology; B cell pathology			[Somers, Veerle; Fraussen, Judith] Univ MS Ctr UMSC, Hasselt Pelt, Belgium; [Somers, Veerle; Fraussen, Judith] Hasselt Univ, Biomed Res Inst, Dept Immunol & Infect, Hasselt, Belgium; [Dunn-Walters, Deborah K.] Univ Surrey, Sch Biosci & Med, Guildford, Surrey, England; [van der Burg, Mirjam] Leiden Univ, Willem Alexander Childrens Hosp, Med Ctr, Lab Pediat Immunol,Dept Pediat, Leiden, Netherlands	Hasselt University; University of Surrey; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Fraussen, J (corresponding author), Univ MS Ctr UMSC, Hasselt Pelt, Belgium.; Fraussen, J (corresponding author), Hasselt Univ, Biomed Res Inst, Dept Immunol & Infect, Hasselt, Belgium.	judith.fraussen@uhasselt.be	Fraternali, Franca/C-8912-2009	Fraternali, Franca/0000-0002-3143-6574					0	0	0	3	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 1	2022	13								854889	10.3389/fimmu.2022.854889	http://dx.doi.org/10.3389/fimmu.2022.854889			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZC5IL	35178054	Green Published, gold			2022-12-18	WOS:000757553600001
J	Cai, MT; Qiao, S; Lai, QL; Zheng, Y; Yang, F; Fang, GL; Shen, CH; Zhang, YX; Ding, MP				Cai, Meng-Ting; Qiao, Song; Lai, Qi-Lun; Zheng, Yang; Yang, Fan; Fang, Gao-Li; Shen, Chun-Hong; Zhang, Yin-Xi; Ding, Mei-Ping			Evaluation of the Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes in China	FRONTIERS IN IMMUNOLOGY			English	Article						paraneoplastic neurologic syndrome; updated diagnostic criteria; clinical phenotype; antibody; cancer	EATON MYASTHENIC SYNDROME; CEREBELLAR DEGENERATION; ENCEPHALITIS; SPECTRUM; PATIENT	BackgroundRecently, the paraneoplastic neurologic syndrome (PNS) diagnostic criteria have received a major update with a new score system over the past 16 years. We aimed to evaluate the diagnostic performance and clinical utility in China. MethodsAn eligible cohort of 113 Chinese patients diagnosed with PNSs from the Second Affiliated Hospital School of Medicine Zhejiang University and published data were enrolled retrospectively. Data including clinical phenotype, antibody type, the presence of cancer, and duration of follow-up were reviewed and re-evaluated to classify the diagnostic levels for the 2004 and 2021 PNS criteria. The performances of these 2 criteria were compared. The critical parameters of antibody and cancer for the updated criteria were further explored. ResultsThe cohort consisted of 69 males and 44 females with a median age of 60 years. Limbic encephalitis (23, 20.4%), anti-Hu antibody (32, 28.3%), and small-cell lung cancer (32, 28.3%) were the most common clinical phenotype, detected antibody, and concomitant cancer, respectively. A total of 97 (85.8%) patients were diagnosed with definite PNS according to the 2004 criteria: only 42.3% (41/97) fulfilled the 2021 criteria, while the remaining 40, 14, and 2 re-diagnosed with probable PNS, possible PNS, and non-PNS. The requirement of cancers consistent with antibody and phenotype increased the specificity and thus greatly enhanced the accuracy of the 2021 criteria. ConclusionThe updated criteria for PNS emphasized the consistency between cancer phenotype and antibody and showed a better diagnostic value. A better diagnostic yield could benefit disease management.	[Cai, Meng-Ting; Qiao, Song; Shen, Chun-Hong; Zhang, Yin-Xi; Ding, Mei-Ping] Zhejiang Univ, Affiliated Hosp 2, Sch Med, Dept Neurol, Hangzhou, Peoples R China; [Lai, Qi-Lun] Zhejiang Hosp, Dept Neurol, Hangzhou, Peoples R China; [Zheng, Yang] Zhejiang Chinese Med Univ, Dept Neurol, Affiliated Hosp 1, Hangzhou, Peoples R China; [Yang, Fan] Peoples Hosp Anyang City, Dept Neurol, Anyang, Peoples R China; [Fang, Gao-Li] Zhejiang Chinese Med & Western Med Integrated Hos, Dept Neurol, Hangzhou, Peoples R China	Zhejiang University; Zhejiang Chinese Medical University	Zhang, YX; Ding, MP (corresponding author), Zhejiang Univ, Affiliated Hosp 2, Sch Med, Dept Neurol, Hangzhou, Peoples R China.	zyx-neurology@zju.edu.cn; dmp-neurology@zju.edu.cn	Zheng, Yang/AHE-7292-2022	Vogrig, Alberto/0000-0002-3652-7061	National Natural Science Foundation of China [82071443]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	Funding This study was supported by the National Natural Science Foundation of China (grant number 82071443).	Abbatemarco JR, 2021, NEUROL-NEUROIMMUNOL, V8, DOI 10.1212/NXI.0000000000001015; Abdulaziz ATA, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000010717; Blaes F, 2021, EXPERT REV NEUROTHER, V21, P675, DOI 10.1080/14737175.2021.1927713; Cai GX, 2020, NEUROL SCI, V41, P1277, DOI 10.1007/s10072-019-04139-0; Cao X, 2020, CHINESE MED J-PEKING, V133, P1005, DOI 10.1097/CM9.0000000000000736; Chan AM, 2019, J NEURO-ONCOL, V141, P431, DOI 10.1007/s11060-018-03053-3; Chan KY, 2016, ANN PALLIAT MED, V5, P311, DOI 10.21037/apm.2016.06.01; Cui D, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000007362; Dai YR, 2016, CLIN RESPIR J, V10, P495, DOI 10.1111/crj.12229; Darnell RB, 2003, NEW ENGL J MED, V349, P1543, DOI 10.1056/NEJMra023009; Devine MF, 2021, THER ADV NEUROL DISO, V14, DOI 10.1177/1756286420985323; Graus F, 2005, J NEUROIMMUNOL, V165, P166, DOI 10.1016/j.jneuroim.2005.03.020; Graus F, 2004, J NEUROL NEUROSUR PS, V75, P1135, DOI 10.1136/jnnp.2003.034447; Graus F, 2021, NEUROL-NEUROIMMUNOL, V8, DOI 10.1212/NXI.0000000000001014; Graus F, 2016, LANCET NEUROL, V15, P391, DOI 10.1016/S1474-4422(15)00401-9; Guan HZ, 2015, CHINESE MED J-PEKING, V128, P3023, DOI 10.4103/0366-6999.168989; Guan HZ, 2015, CHINESE MED J-PEKING, V128, P1836, DOI 10.4103/0366-6999.159365; Hebert J, 2020, NEUROL-NEUROIMMUNOL, V7, DOI 10.1212/NXI.0000000000000883; Honnorat J, 2007, ORPHANET J RARE DIS, V2, DOI 10.1186/1750-1172-2-22; Ju WN, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000008228; Kanikannan MA, 2015, J NEURO-ONCOL, V125, P197, DOI 10.1007/s11060-015-1898-7; Li CY, 2020, THORAC CANCER, V11, P465, DOI 10.1111/1759-7714.13290; Li J, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000010649; Li WH, 2015, CHINESE MED J-PEKING, V128, P2685, DOI 10.4103/0366-6999.166028; Liao SH, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00584; Liu H S, 2017, Zhonghua Yi Xue Za Zhi, V97, P2770, DOI 10.3760/cma.j.issn.0376-2491.2017.35.013; Liu Z, 2019, J NEUROIMMUNOL, V330, P136, DOI 10.1016/j.jneuroim.2019.03.001; Luo QY, 2019, BMC NEUROL, V19, DOI 10.1186/s12883-019-1358-7; Miao S, 2018, INT J NEUROSCI, V128, P821, DOI 10.1080/00207454.2018.1430693; Ni JJ, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000002291; Ren HT, 2021, J NEUROIMMUNOL, V350, DOI 10.1016/j.jneuroim.2020.577408; Shen KN, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25294-y; Shu YQ, 2021, ANN CLIN TRANSL NEUR, V8, P498, DOI 10.1002/acn3.51283; Sun XL, 2021, GLAND SURG, V10, P1154, DOI 10.21037/gs-20-780; Tian HQ, 2013, HEAD NECK-J SCI SPEC, V35, pE304, DOI 10.1002/hed.23164; Vogrig A, 2020, J NEUROL, V267, P26, DOI 10.1007/s00415-019-09544-1; Wang KY, 2021, J INT MED RES, V49, DOI 10.1177/0300060521992231; Wu X, 2019, FRONT NEUROL, V10, DOI 10.3389/fneur.2019.01064; Xu L, 2015, EXP THER MED, V9, P335, DOI 10.3892/etm.2014.2142; Yan JH, 2020, J INT MED RES, V48, DOI 10.1177/0300060520974466; Yan LY, 2018, MOL CLIN ONCOL, V9, P163, DOI 10.3892/mco.2018.1638; Yang J, 2021, MEDICINE, V100, DOI 10.1097/MD.0000000000025694; Yuan JL, 2019, CLIN INTERV AGING, V14, P1039, DOI 10.2147/CIA.S202102; Zhang KJ, 2015, EXP THER MED, V10, P117, DOI 10.3892/etm.2015.2454; Zhang RR, 2015, ONCOL LETT, V10, P1339, DOI 10.3892/ol.2015.3473; Zhu LF, 2019, J INT MED RES, V47, P5318, DOI 10.1177/0300060519863524; Zhu YF, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2349-3	47	0	0	2	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 31	2022	13								790400	10.3389/fimmu.2022.790400	http://dx.doi.org/10.3389/fimmu.2022.790400			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZA3CQ	35173717	gold, Green Published			2022-12-18	WOS:000756046400001
J	Chacon-Salinas, R; Di Nardo, A; Abraham, SN				Chacon-Salinas, Rommel; Di Nardo, Anna; Abraham, Soman N.			Editorial: Mast Cells: Bridging Host-Microorganism Interactions	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						mast cell (MC); bacteria; virus; fungi; microbiota			[Chacon-Salinas, Rommel] Inst Politecn Nacl ENCB IPN, Escuela Nacl Ciencias Biol, Dept Inmunol, Mexico City, DF, Mexico; [Di Nardo, Anna] Univ Calif San Diego, Dept Dermatol, San Diego, CA 92103 USA; [Abraham, Soman N.] Duke Univ, Sch Med, Dept Pathol, Durham, NC 27706 USA; [Abraham, Soman N.] Duke Univ, Sch Med, Dept Immunol, Durham, NC 27706 USA; [Abraham, Soman N.] Duke Univ, Dept Mol Genet & Microbiol, Durham, NC 27706 USA	University of California System; University of California San Diego; Duke University; Duke University; Duke University	Chacon-Salinas, R (corresponding author), Inst Politecn Nacl ENCB IPN, Escuela Nacl Ciencias Biol, Dept Inmunol, Mexico City, DF, Mexico.; Di Nardo, A (corresponding author), Univ Calif San Diego, Dept Dermatol, San Diego, CA 92103 USA.; Abraham, SN (corresponding author), Duke Univ, Sch Med, Dept Pathol, Durham, NC 27706 USA.; Abraham, SN (corresponding author), Duke Univ, Sch Med, Dept Immunol, Durham, NC 27706 USA.; Abraham, SN (corresponding author), Duke Univ, Dept Mol Genet & Microbiol, Durham, NC 27706 USA.	rommelchacons@yahoo.com.mx; adinardo@ucsd.edu; soman.abraham@duke.edu	CHACON-SALINAS, ROMMEL/L-4905-2017	CHACON-SALINAS, ROMMEL/0000-0002-4500-0253; Perez Rodriguez, Marian Jesabel/0000-0002-0383-0320	Secretaria de Investigacion y Posgrado I.P.N, (SIP-IPN)	Secretaria de Investigacion y Posgrado I.P.N, (SIP-IPN)	RC-S was supported by Secretaria de Investigacion y Posgrado I.P.N, (SIP-IPN).		0	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 31	2022	13								827375	10.3389/fimmu.2022.827375	http://dx.doi.org/10.3389/fimmu.2022.827375			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZC5JP	35173737	Green Published, gold			2022-12-18	WOS:000757556600001
J	Cristiani, CM; Capone, M; Garofalo, C; Madonna, G; Mallardo, D; Tuffanelli, M; Vanella, V; Greco, M; Foti, DP; Viglietto, G; Ascierto, PA; Spits, H; Carbone, E				Cristiani, Costanza Maria; Capone, Mariaelena; Garofalo, Cinzia; Madonna, Gabriele; Mallardo, Domenico; Tuffanelli, Marilena; Vanella, Vito; Greco, Marta; Foti, Daniela Patrizia; Viglietto, Giuseppe; Ascierto, Paolo Antonio; Spits, Hergen; Carbone, Ennio			Altered Frequencies and Functions of Innate Lymphoid Cells in Melanoma Patients Are Modulated by Immune Checkpoints Inhibitors	FRONTIERS IN IMMUNOLOGY			English	Article						innate lymphoid cells; cytokines; melanoma; immune checkpoints inhibitors; nivolumab	TUMOR-NECROSIS-FACTOR; SERUM INTERLEUKIN-8; NK CELLS; PD-1; BIOCHEMOTHERAPY; CYTOTOXICITY; PROGRESSION; CONVERSION; SURVIVAL; IL-4	Monoclonal antibodies targeting immune checkpoints improved clinical outcome of patients with malignant melanoma. However, the mechanisms are not fully elucidated. Since immune check-point receptors are also expressed by helper innate lymphoid cells (ILCs), we investigated the capability of immune checkpoints inhibitors to modulate ILCs in metastatic melanoma patients as well as melanoma cells effects on ILC functions. Here, we demonstrated that, compared to healthy donors, patients showed a higher frequency of total peripheral ILCs, lower percentages of CD117(+) ILC2s and CD117(+) ILCs as well as higher frequencies of CD117(-) ILCs. Functionally, melanoma patients also displayed an impaired TNF alpha secretion by CD117(-) ILCs and CD117(+) ILCs. Nivolumab therapy reduced the frequency of total peripheral ILCs but increased the percentage of CD117(-) ILC2s and enhanced the capability of ILC2s and CD117(+) ILCs to secrete IL-13 and TNF alpha, respectively. Before Nivolumab therapy, high CCL2 serum levels were associated with longer Overall Survival and Progression Free Survival. After two months of treatment, CD117(-) ILC2s frequency as well as serum concentrations of IL-6, CXCL8 and VEGF negatively correlated with both the parameters. Moreover, melanoma cells boosted TNF alpha production in all ILC subsets and increased the number of IL-13 producing ILC2s in vitro. Our work shows for the first time that PD-1 blockade is able to affect ILCs proportions and functions in melanoma patients and that a specific subpopulation is associated with the therapy response.	[Cristiani, Costanza Maria; Garofalo, Cinzia; Foti, Daniela Patrizia; Viglietto, Giuseppe; Carbone, Ennio] Magna Graecia Univ Catanzaro, Dept Expt & Clin Med, Catanzaro, Italy; [Capone, Mariaelena; Madonna, Gabriele; Mallardo, Domenico; Tuffanelli, Marilena; Vanella, Vito; Ascierto, Paolo Antonio] IRCCS, Ist Nazl Tumori, Fdn G Pascale, Naples, Italy; [Greco, Marta] Magna Graecia Univ Catanzaro, Dept Hlth Sci, Catanzaro, Italy; [Spits, Hergen] Univ Amsterdam, Univ Med Ctr UMC, Dept Expt Immunol, Amsterdam, Netherlands; [Carbone, Ennio] Karolinska Inst, Dept Microbiol Tumor & Cell Biol MTC, Biomed, Stockholm, Sweden	Magna Graecia University of Catanzaro; Fondazione IRCCS Istituto Nazionale Tumori Milan; IRCCS Fondazione Pascale; Magna Graecia University of Catanzaro; University of Amsterdam; Karolinska Institutet	Cristiani, CM (corresponding author), Magna Graecia Univ Catanzaro, Dept Expt & Clin Med, Catanzaro, Italy.; Ascierto, PA (corresponding author), IRCCS, Ist Nazl Tumori, Fdn G Pascale, Naples, Italy.	costanza.cristiani@unicz.it; p.ascierto@istitutotumori.na.it	Greco, Marta/K-8227-2016; Madonna, Gabriele/AAA-6456-2019; Mallardo, Domenico/I-8649-2018; Capone, Mariaelena/J-8670-2016	Greco, Marta/0000-0003-4192-3891; Madonna, Gabriele/0000-0001-9395-3190; Mallardo, Domenico/0000-0002-1081-5313; Capone, Mariaelena/0000-0002-1352-2532				Accattato F, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178900; Altan-Bonnet G, 2019, NAT REV IMMUNOL, V19, P205, DOI 10.1038/s41577-019-0131-x; Antonangeli F, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.584626; Artis D, 2015, NATURE, V517, P293, DOI 10.1038/nature14189; Bal SM, 2016, NAT IMMUNOL, V17, P636, DOI 10.1038/ni.3444; Balkwill F, 2009, NAT REV CANCER, V9, P361, DOI 10.1038/nrc2628; Beuraud C, 2019, ALLERGY, V74, P933, DOI 10.1111/all.13679; Cao YJ, 2019, IMMUNOLOGY, V156, P402, DOI 10.1111/imm.13040; Carrega P, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9280; Cortez VS, 2017, NAT IMMUNOL, V18, P995, DOI 10.1038/ni.3809; Cristiani CM, 2020, SCAND J IMMUNOL, V91, DOI 10.1111/sji.12861; Cristiani CM, 2019, CANCER IMMUNOL RES, V7, P841, DOI 10.1158/2326-6066.CIR-18-0651; Cristiani CM, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00656; de Weerdt I, 2016, HAEMATOLOGICA, V101, pE461, DOI 10.3324/haematol.2016.144725; Deroose JP, 2011, BRIT J SURG, V98, P1573, DOI 10.1002/bjs.7621; Eisenring M, 2010, NAT IMMUNOL, V11, P1030, DOI 10.1038/ni.1947; Ellyard JI, 2010, J IMMUNOTHER, V33, P443, DOI 10.1097/CJI.0b013e3181cd8746; Ercolano G, 2020, CANCER IMMUNOL RES, V8, P556, DOI 10.1158/2326-6066.CIR-19-0504; Gao YL, 2017, NAT IMMUNOL, V18, P1004, DOI 10.1038/ni.3800; Garofalo C, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.754541; Golebski K, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09883-7; Guia S, 2018, SEMIN IMMUNOPATHOL, V40, P331, DOI 10.1007/s00281-018-0685-x; Hardman CS, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abe5084; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Ikutani M, 2012, J IMMUNOL, V188, P703, DOI 10.4049/jimmunol.1101270; Jacquelot N, 2021, NAT IMMUNOL, V22, P851, DOI 10.1038/s41590-021-00943-z; Johansson J, 2020, ONCOIMMUNOLOGY, V9, DOI 10.1080/2162402X.2019.1684126; Khattak MA, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01041; Krabbendam L, 2021, CURR OPIN IMMUNOL, V68, P28, DOI 10.1016/j.coi.2020.08.007; Krabbendam Lisette, 2018, Curr Protoc Immunol, V122, pe55, DOI 10.1002/cpim.55; Lacal PM, 2005, INT J ONCOL, V27, P1625; Laino AS, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-000842; Larkin J, 2019, NEW ENGL J MED, V381, P1535, DOI 10.1056/NEJMoa1910836; Lim AI, 2017, CURR OPIN IMMUNOL, V44, P61, DOI 10.1016/j.coi.2017.03.010; Liu WL, 2021, ANN ALLERG ASTHMA IM, V126, P152, DOI 10.1016/j.anai.2020.08.005; Loyon R, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02121; Ma HL, 2004, INT IMMUNOL, V16, P1009, DOI 10.1093/intimm/dxh105; Maggi L, 2017, J ALLERGY CLIN IMMUN, V139, P964, DOI 10.1016/j.jaci.2016.06.032; Mohapatra P, 2019, MOL ONCOL, V13, P480, DOI 10.1002/1878-0261.12433; Moral JA, 2020, NATURE, V579, P130, DOI 10.1038/s41586-020-2015-4; Mouawad R, 2002, CYTOKINES CELL MOL T, V7, P151, DOI 10.1080/13684730210002328; Nagasawa M, 2019, J EXP MED, V216, P1762, DOI 10.1084/jem.20190490; Nakasone Y, 2012, AM J PATHOL, V180, P365, DOI 10.1016/j.ajpath.2011.09.005; Nussbaum K, 2017, J EXP MED, V214, P2331, DOI 10.1084/jem.20162031; Oldenhove G, 2018, CELL REP, V25, P2053, DOI 10.1016/j.celrep.2018.10.091; Rethacker L, 2021, CANCERS, V13, DOI 10.3390/cancers13061446; Rigas D, 2017, J ALLERGY CLIN IMMUN, V139, P1468, DOI 10.1016/j.jaci.2016.08.034; Robert C, 2015, NEW ENGL J MED, V372, P320, DOI 10.1056/NEJMoa1412082; Salimi M, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4262-4; Salome B, 2019, BLOOD ADV, V3, P3674, DOI 10.1182/bloodadvances.2018030478; Sanmamed MF, 2014, CLIN CANCER RES, V20, P5697, DOI 10.1158/1078-0432.CCR-13-3203; Schalper KA, 2020, NAT MED, V26, P688, DOI 10.1038/s41591-020-0856-x; Seillet C, 2016, CELL REP, V17, P436, DOI 10.1016/j.celrep.2016.09.025; Shen XF, 2018, J ALLERGY CLIN IMMUN, V141, P1929, DOI 10.1016/j.jaci.2018.01.005; Sottile R, 2019, INT J CANCER, V145, P2238, DOI 10.1002/ijc.32363; Soubrane C, 2005, MELANOMA RES, V15, P199, DOI 10.1097/00008390-200506000-00009; Taylor S, 2017, J EXP MED, V214, P1663, DOI 10.1084/jem.20161653; Trabanelli S, 2015, HAEMATOLOGICA, V100, pE257, DOI 10.3324/haematol.2014.119602; Tumino N, 2019, INT J CANCER, V145, P1660, DOI 10.1002/ijc.32262; Uen WC, 2015, MELANOMA RES, V25, P35, DOI 10.1097/CMR.0000000000000134; Ugurel S, 2001, J CLIN ONCOL, V19, P577, DOI 10.1200/JCO.2001.19.2.577; Vacca P, 2019, MUCOSAL IMMUNOL, V12, P624, DOI 10.1038/s41385-019-0141-9; Verheijden RJ, 2020, CLIN CANCER RES, V26, P2268, DOI 10.1158/1078-0432.CCR-19-3322; Vivier E, 2018, CELL, V174, P1054, DOI 10.1016/j.cell.2018.07.017; Vredevoogd DW, 2020, CELL, V180, P404, DOI 10.1016/j.cell.2020.01.005; Wang X, 2021, J ONCOL, V2021, DOI 10.1155/2021/6610769; Weston CA, 2019, J ALLERGY CLIN IMMUN, V143, P410, DOI 10.1016/j.jaci.2018.08.030; Xue LZ, 2014, J ALLERGY CLIN IMMUN, V133, P1184, DOI 10.1016/j.jaci.2013.10.056; Yu Y, 2016, NATURE, V539, P102, DOI 10.1038/nature20105	69	0	0	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 31	2022	13								811131	10.3389/fimmu.2022.811131	http://dx.doi.org/10.3389/fimmu.2022.811131			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZA2WN	35173725	Green Published, gold			2022-12-18	WOS:000756030300001
J	Cui, TCYX; Brady, AE; Zhang, YJ; Fulton, CT; Popova, AP				Cui, Tracy X.; Brady, Alexander E.; Zhang, Ying-Jian; Fulton, Christina T.; Popova, Antonia P.			Gelsolin Attenuates Neonatal Hyperoxia-Induced Inflammatory Responses to Rhinovirus Infection and Preserves Alveolarization	FRONTIERS IN IMMUNOLOGY			English	Article						gelsolin; prematurity; BPD; rhinovirus; dendritic cells; f-actin; lung inflammation	LOWER RESPIRATORY ILLNESS; CD103(+) DENDRITIC CELLS; HEALTH-CARE UTILIZATION; PLASMA GELSOLIN; BRONCHOPULMONARY DYSPLASIA; LUNG-FUNCTION; CROSS-PRESENTATION; EXTREMELY PRETERM; OXYGEN-TOXICITY; CHILDREN BORN	Prematurity and bronchopulmonary dysplasia (BPD) increase the risk of asthma later in life. Supplemental oxygen therapy is a risk factor for chronic respiratory symptoms in infants with BPD. Hyperoxia induces cell injury and release of damage-associated molecular patterns (DAMPs). Cytoskeletal filamentous actin (F-actin) is a DAMP which binds Clec9a, a C-type lectin selectively expressed on CD103+ dendritic cells (DCs). Co-stimulation of Clec9a and TLR3 induces maximal proinflammatory responses. We have shown that neonatal hyperoxia (a model of BPD) increases lung IL-12+Clec9a+CD103+ DCs, pro-inflammatory responses and airway hyperreactivity following rhinovirus (RV) infection. CD103+ DCs and Clec9a are required for these responses. Hyperoxia increases F-actin levels in bronchoalveolar lavage fluid (BALF). We hypothesized that the F-actin severing protein gelsolin attenuates neonatal hyperoxia-induced Clec9a+CD103+ DC-dependent pro-inflammatory responses to RV and preserves alveolarization. We exposed neonatal mice to hyperoxia and treated them with gelsolin intranasally. Subsequently we inoculated the mice with RV intranasally. Alternatively, we inoculated normoxic neonatal mice with BALF from hyperoxia-exposed mice (hyperoxic BALF), RV and gelsolin. We analyzed lung gene expression two days after RV infection. For in vitro studies, lung CD11c+ cells were isolated from C57BL/6J or Clec9a(gfp-/-) mice and incubated with hyperoxic BALF and RV. Cells were analyzed by flow cytometry. In neonatal mice, gelsolin blocked hyperoxia-induced Il12p40, TNF-alpha and IFN-gamma mRNA and protein expression in response to RV infection. Similar effects were observed when gelsolin was co-administered with hyperoxic BALF and RV. Gelsolin decreased F-actin levels in hyperoxic BALF in vitro and inhibited hyperoxia-induced D103lo DC expansion and inflammation in vivo. Gelsolin also attenuated hyperoxia-induced hypoalveolarization. Further, incubation of lung CD11c+ cells from WT and Clec9a(gfp-/-) mice with hyperoxic BALF and RV, showed Clec9a is required for maximal hyperoxic BALF and RV induced IL-12 expression in CD103+ DCs. Finally, in tracheal aspirates from mechanically ventilated human preterm infants the F-actin to gelsolin ratio positively correlates with FiO2, and gelsolin levels decrease during the first two weeks of mechanical ventilation. Collectively, our findings demonstrate a promising role for gelsolin, administered by inhalation into the airway to treat RV-induced exacerbations of BPD and prevent chronic lung disease.	[Cui, Tracy X.; Brady, Alexander E.; Zhang, Ying-Jian; Fulton, Christina T.; Popova, Antonia P.] Univ Michigan, Dept Pediat, Med Sch, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Popova, AP (corresponding author), Univ Michigan, Dept Pediat, Med Sch, Ann Arbor, MI 48109 USA.	antoniap@umich.edu		Brady, Alexander/0000-0002-4177-5203	NIH [R01 HL140572]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Funding This work was supported by NIH grant R01 HL140572.	Ahrens S, 2012, IMMUNITY, V36, P635, DOI 10.1016/j.immuni.2012.03.008; Ambalavanan N, 2009, PEDIATRICS, V123, P1132, DOI 10.1542/peds.2008-0526; Ashley SL, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aau9959; Ballard AR, 2016, J PERINATOL, V36, P1045, DOI 10.1038/jp.2016.138; Ballesteros-Tato A, 2010, NAT IMMUNOL, V11, P216, DOI 10.1038/ni.1838; Barazzone C, 1998, AM J RESP CELL MOL, V19, P573, DOI 10.1165/ajrcmb.19.4.3173; Been JV, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001596; Beeton ML, 2011, EUR RESPIR J, V37, P1424, DOI 10.1183/09031936.00037810; Bjorke-Monsen AL, 2017, AM J RESP CELL MOL, V56, P83, DOI 10.1165/rcmb.2016-0210OC; Bozyk PD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031336; Brostrom EB, 2010, RESP MED, V104, P362, DOI 10.1016/j.rmed.2009.10.008; Bucki R, 2005, BIOCHEMISTRY-US, V44, P9590, DOI 10.1021/bi0503504; Chidekel AS, 1997, PEDIATR INFECT DIS J, V16, P43, DOI 10.1097/00006454-199701000-00010; Christofidou-Solomidou M, 2002, LUNG, V180, P91, DOI 10.1007/s004080000084; Christofidou-Solomidou M, 2002, J INVEST MED, V50, P54, DOI 10.2310/6650.2002.33518; Coalson JJ, 2006, SEMIN PERINATOL, V30, P179, DOI 10.1053/j.semperi.2006.05.004; Cohen TS, 2011, CYTOKINE, V54, P235, DOI 10.1016/j.cyto.2011.02.006; Costa LF, 2014, PEDIATRICS, V133, pE312, DOI 10.1542/peds.2013-2216; Cui TX, 2021, AM J PHYSIOL-LUNG C, V320, pL193, DOI 10.1152/ajplung.00334.2019; Cui TX, 2016, J IMMUNOL, V196, P4692, DOI 10.4049/jimmunol.1501116; Dahl B, 2003, CRIT CARE MED, V31, P152, DOI 10.1097/00003246-200301000-00024; DEKLEINE MJK, 1990, THORAX, V45, P941, DOI 10.1136/thx.45.12.941; Desch AN, 2011, J EXP MED, V208, P1789, DOI 10.1084/jem.20110538; DiNubile MJ, 2012, AM J RESP CRIT CARE, V186, P1195, DOI 10.1164/ajrccm.186.11.1195; Dishop MK, 2010, PEDIAT ALLER IMM PUL, V23, P69, DOI 10.1089/ped.2010.0007; Dominguez R, 2011, ANNU REV BIOPHYS, V40, P169, DOI 10.1146/annurev-biophys-042910-155359; Drysdale SB, 2013, EUR RESPIR J, V42, P1029, DOI 10.1183/09031936.00109012; Durant LR, 2014, EUR J IMMUNOL, V44, P2340, DOI 10.1002/eji.201444454; Ehrenkranz RA, 2005, PEDIATRICS, V116, P1353, DOI 10.1542/peds.2005-0249; Fawke J, 2010, AM J RESP CRIT CARE, V182, P237, DOI 10.1164/rccm.200912-1806OC; FOX RB, 1981, AM REV RESPIR DIS, V123, P521; FREEMAN BA, 1982, ARCH BIOCHEM BIOPHYS, V216, P477, DOI 10.1016/0003-9861(82)90236-3; Gallucci S, 1999, NAT MED, V5, P1249, DOI 10.1038/15200; GeurtsvanKessel CH, 2008, J EXP MED, V205, P1621, DOI 10.1084/jem.20071365; Giampazolias E, 2021, CELL, V184, P4016, DOI 10.1016/j.cell.2021.05.021; Greenough A, 2006, ARCH DIS CHILD-FETAL, V91, P337, DOI 10.1136/adc.2005.088823; Greenough A, 2011, EUR J PEDIATR, V170, P969, DOI 10.1007/s00431-010-1381-6; Guntert A, 2010, J ALZHEIMERS DIS, V21, P585, DOI 10.3233/JAD-2010-100279; Gupta AK, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135558; Han MY, 2019, MUCOSAL IMMUNOL, V12, P958, DOI 10.1038/s41385-019-0172-2; Han MY, 2016, J ALLERGY CLIN IMMUN, V138, P1619, DOI 10.1016/j.jaci.2016.01.037; Hanc P, 2015, IMMUNITY, V42, P839, DOI 10.1016/j.immuni.2015.04.009; Hartling L, 2012, ARCH DIS CHILD-FETAL, V97, pF8, DOI 10.1136/adc.2010.210187; Hennrick KT, 2007, AM J RESP CRIT CARE, V175, P1158, DOI 10.1164/rccm.200607-941OC; Hong JY, 2014, J ALLERGY CLIN IMMUN, V134, P429, DOI 10.1016/j.jaci.2014.04.020; Hsia CCW, 2010, AM J RESP CRIT CARE, V181, P394, DOI 10.1164/rccm.200809-1522ST; Huang LF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025748; Huysamen C, 2008, J BIOL CHEM, V283, P16693, DOI 10.1074/jbc.M709923200; Jaakkola JJK, 2006, J ALLERGY CLIN IMMUN, V118, P823, DOI 10.1016/j.jaci.2006.06.043; Joffre OP, 2010, EUR J IMMUNOL, V40, P1255, DOI 10.1002/eji.201040419; Kallet RH, 2013, RESP CARE, V58, P123, DOI 10.4187/respcare.01963; Kulakowska A, 2010, BMC NEUROL, V10, DOI 10.1186/1471-2377-10-107; Lal CV, 2016, SCI REP-UK, V6, DOI 10.1038/srep31023; Lapcharoensap W, 2015, JAMA PEDIATR, V169, DOI 10.1001/jamapediatrics.2014.3676; LEE WM, 1992, NEW ENGL J MED, V326, P1335; Leroy S, 2018, J PEDIATR-US, V192, P60, DOI 10.1016/j.jpeds.2017.09.011; Li MJ, 2015, CELL BIOCHEM BIOPHYS, V71, P389, DOI 10.1007/s12013-014-0210-3; LIND SE, 1988, AM REV RESPIR DIS, V138, P429, DOI 10.1164/ajrccm/138.2.429; Linder JE, 2013, J ALLERGY CLIN IMMUN, V131, P69, DOI 10.1016/j.jaci.2012.09.033; Lum S, 2011, EUR RESPIR J, V37, P1199, DOI 10.1183/09031936.00071110; MARTIN S, 1993, J VIROL, V67, P3561, DOI 10.1128/JVI.67.6.3561-3568.1993; Mere J, 2005, BIOCHEM J, V386, P47, DOI 10.1042/BJ20041054; Miller EK, 2012, PEDIATRICS, V129, pE60, DOI 10.1542/peds.2011-0583; Mourani PM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025959; Nag S, 2009, P NATL ACAD SCI USA, V106, P13713, DOI 10.1073/pnas.0812374106; Nakano H, 2012, MUCOSAL IMMUNOL, V5, P53, DOI 10.1038/mi.2011.47; Newcomb DC, 2005, J BIOL CHEM, V280, P36952, DOI 10.1074/jbc.M502449200; Parks BW, 2013, J LIPID RES, V54, P1114, DOI 10.1194/jlr.M035352; Popova AP, 2012, AM J PHYSIOL-LUNG C, V303, pL439, DOI 10.1152/ajplung.00408.2011; Ruckwardt TJ, 2018, MUCOSAL IMMUNOL, V11, P186, DOI 10.1038/mi.2017.28; Ruckwardt TJ, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003934; Sancho D, 2009, NATURE, V458, P899, DOI 10.1038/nature07750; Schreibelt G, 2012, BLOOD, V119, P2284, DOI 10.1182/blood-2011-08-373944; Shi Y, 2002, EUR J IMMUNOL, V32, P155, DOI 10.1002/1521-4141(200201)32:1<155::AID-IMMU155>3.0.CO;2-P; Siltanen M, 2011, J ALLERGY CLIN IMMUN, V127, P935, DOI 10.1016/j.jaci.2010.12.1107; Tannetta DS, 2014, EUR J OBSTET GYN R B, V172, P32, DOI 10.1016/j.ejogrb.2013.10.022; Teig N, 2012, J PEDIATR-US, V161, P1085, DOI 10.1016/j.jpeds.2012.06.007; Wai KC, 2016, J PEDIATR-US, V177, P97, DOI 10.1016/j.jpeds.2016.06.079; Yang ZP, 2015, AM J PHYSIOL-LUNG C, V309, pL11, DOI 10.1152/ajplung.00094.2015; Zhang JG, 2012, IMMUNITY, V36, P646, DOI 10.1016/j.immuni.2012.03.009; Zhang QH, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-118	81	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 31	2022	13								792716	10.3389/fimmu.2022.792716	http://dx.doi.org/10.3389/fimmu.2022.792716			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZA3UT	35173718	gold, Green Published			2022-12-18	WOS:000756093500001
J	Fehr, T; Hubel, K; de Rougemont, O; Abela, I; Gaspert, A; Gungor, T; Hauri, M; Helmchen, B; Linsenmeier, C; Muller, T; Nilsson, J; Riesterer, O; Scandling, JD; Schanz, U; Cippa, PE				Fehr, Thomas; Huebel, Kerstin; de Rougemont, Olivier; Abela, Irene; Gaspert, Ariana; Guengoer, Tayfun; Hauri, Mathias; Helmchen, Birgit; Linsenmeier, Claudia; Mueller, Thomas; Nilsson, Jakob; Riesterer, Oliver; Scandling, John D.; Schanz, Urs; Cippa, Pietro E.			Successful Induction of Specific Immunological Tolerance by Combined Kidney and Hematopoietic Stem Cell Transplantation in HLA-Identical Siblings	FRONTIERS IN IMMUNOLOGY			English	Article						chimerism; hematopoietic stem cell transplantation (HSCT); tolerance; kidney transplantation; immunocompetence; COVID; 19	BONE-MARROW-TRANSPLANTATION; RENAL-TRANSPLANTATION; MIXED CHIMERISM; SURVIVAL	Induction of immunological tolerance has been the holy grail of transplantation immunology for decades. The only successful approach to achieve it in patients has been a combined kidney and hematopoietic stem cell transplantation from an HLA-matched or -mismatched living donor. Here, we report the first three patients in Europe included in a clinical trial aiming at the induction of tolerance by mixed lymphohematopoietic chimerism after kidney transplantation. Two female and one male patient were transplanted with a kidney and peripherally mobilized hematopoietic stem cells from their HLA-identical sibling donor. The protocol followed previous studies at Stanford University: kidney transplantation was performed on day 0 including induction with anti-thymocyte globulin followed by conditioning with 10x 1.2 Gy total lymphoid irradiation and the transfusion of CD34+ cells together with a body weight-adjusted dose of donor T cells on day 11. Immunosuppression consisted of cyclosporine A and steroids for 10 days, cyclosporine A and mycophenolate mofetil for 1 month, and then cyclosporine A monotherapy with tapering over 9-20 months. The 3 patients have been off immunosuppression for 4 years, 19 months and 8 months, respectively. No rejection or graft-versus-host disease occurred. Hematological donor chimerism was stable in the first, but slowly declining in the other two patients. A molecular microscope analysis in patient 2 revealed the genetic profile of a normal kidney. No relevant infections were observed, and the quality of life in all three patients is excellent. During the SARS-CoV-2 pandemic, all three patients were vaccinated with the mRNA vaccine BNT162b2 (Comirnaty(R)), and they showed excellent humoral and in 2 out 3 patients also cellular SARS-CoV-2-specific immunity. Thus, combined kidney and hematopoietic stem cell transplantation is a feasible and successful approach to induce specific immunological tolerance in the setting of HLA-matched sibling living kidney donation while maintaining immune responsiveness to an mRNA vaccine (ClinicalTrials.gov: NCT00365846).	[Fehr, Thomas; Huebel, Kerstin; Mueller, Thomas; Cippa, Pietro E.] Univ Hosp Zurich, Div Nephrol, Zurich, Switzerland; [Fehr, Thomas] Cantonal Hosp Graubuenden, Dept Internal Med, Chur, Switzerland; [Huebel, Kerstin; de Rougemont, Olivier] Univ Hosp Zurich, Dept Surg & Transplantat, Zurich, Switzerland; [Abela, Irene] Univ Zurich, Inst Med Virol, Zurich, Switzerland; [Gaspert, Ariana; Helmchen, Birgit] Univ Hosp Zurich, Dept Pathol, Zurich, Switzerland; [Guengoer, Tayfun; Hauri, Mathias] Univ Childrens Hosp Zurich, Eleonore Fdn, Div Stem Cell Transplantat, Zurich, Switzerland; [Guengoer, Tayfun; Hauri, Mathias] Childrens Res Ctr CRC, Zurich, Switzerland; [Linsenmeier, Claudia; Riesterer, Oliver] Univ Hosp Zurich, Dept Radiat Oncol, Zurich, Switzerland; [Nilsson, Jakob] Univ Hosp Zurich, Lab Transplantat Immunol, Zurich, Switzerland; [Scandling, John D.] Stanford Univ, Sch Med, Div Nephrol, Stanford, CA 94305 USA; [Schanz, Urs] Univ Hosp Zurich, Dept Med Oncol & Hematol, Zurich, Switzerland; [Cippa, Pietro E.] Ente Osped Cantonale, Div Nephrol, Lugano, Switzerland	University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital; University of Zurich; University of Zurich; University Zurich Hospital; University Children's Hospital Zurich; University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital; Stanford University; University of Zurich; University Zurich Hospital	Fehr, T (corresponding author), Univ Hosp Zurich, Div Nephrol, Zurich, Switzerland.; Fehr, T (corresponding author), Cantonal Hosp Graubuenden, Dept Internal Med, Chur, Switzerland.	thomas.fehr@uzh.ch	Fehr, Thomas/AFQ-9308-2022; Hauri-Hohl, Mathias M/X-5691-2018	Fehr, Thomas/0000-0003-1668-1800; Hauri-Hohl, Mathias M/0000-0003-4618-3319; Abela, Irene/0000-0002-5566-8628	Horton Foundation Switzerland	Horton Foundation Switzerland	The Horton Foundation Switzerland (a non-commercial private foundation supporting clinical and basic research) supports this trial.	Bigenzahn S, 2005, AM J TRANSPLANT, V5, P1237, DOI 10.1111/j.1600-6143.2005.00862.x; BILLINGHAM RE, 1953, NATURE, V172, P603, DOI 10.1038/172603a0; Boyarsky BJ, 2021, JAMA-J AM MED ASSOC, V325, P2204, DOI 10.1001/jama.2021.7489; Busque S, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aax8863; Cippa PE, 2013, BLOOD, V122, P1669, DOI 10.1182/blood-2012-09-453944; Cosimi AB, 2021, TRANSPLANTATION, V105, P935, DOI 10.1097/TP.0000000000003532; Crespo M, 2022, AM J TRANSPLANT, V22, P786, DOI 10.1111/ajt.16854; Fehr T, 2005, EUR J IMMUNOL, V35, P2679, DOI 10.1002/eji.200526190; Fehr T, 2010, BLOOD, V115, P1280, DOI 10.1182/blood-2009-07-230680; Halloran PF, 2017, AM J TRANSPLANT, V17, P2851, DOI 10.1111/ajt.14329; Hariharan S, 2021, NEW ENGL J MED, V385, P729, DOI 10.1056/NEJMra2014530; Hoshino A, 2014, J CLIN IMMUNOL, V34, P53, DOI 10.1007/s10875-013-9964-4; Kamar N, 2021, NEW ENGL J MED, V385, P661, DOI 10.1056/NEJMc2108861; Kawai T, 2008, NEW ENGL J MED, V358, P353, DOI 10.1056/NEJMoa071074; Kawai T, 2019, AM J TRANSPLANT, V19, P324, DOI 10.1111/ajt.15086; Lee KW, 2020, TRANSPLANTATION, V104, P1472, DOI 10.1097/TP.0000000000003006; Leventhal J, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003509; Leventhal JR, 2018, HUM IMMUNOL, V79, P272, DOI 10.1016/j.humimm.2018.01.007; Mathew JM, 2018, HUM IMMUNOL, V79, P322, DOI 10.1016/j.humimm.2018.01.009; Murakami Toru, 2009, Transplant Rev (Orlando), V23, P19, DOI 10.1016/j.trre.2008.08.006; Nakano D, 2018, KIDNEY INT, V94, P650, DOI 10.1016/j.kint.2018.05.025; Pilat N, 2010, AM J TRANSPLANT, V10, P751, DOI 10.1111/j.1600-6143.2010.03018.x; Rickert CG, 2019, CURR OPIN ORGAN TRAN, V24, P441, DOI 10.1097/MOT.0000000000000670; Scandling JD, 2015, AM J TRANSPLANT, V15, P695, DOI 10.1111/ajt.13091; Scandling JD, 2008, NEW ENGL J MED, V358, P362, DOI 10.1056/NEJMoa074191; Spitzer TR, 1999, TRANSPLANTATION, V68, P480, DOI 10.1097/00007890-199908270-00006; Werkele T, 2000, NAT MED, V6, P464, DOI 10.1038/74731; Zhang HD, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01392	28	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 31	2022	13								796456	10.3389/fimmu.2022.796456	http://dx.doi.org/10.3389/fimmu.2022.796456			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZF0HK	35173720	Green Published, gold			2022-12-18	WOS:000759256600001
J	Li, W; Shou, XY; Xiang, WQ; He, L; Li, L; Fu, HD; Mao, JH				Li, Wei; Shou, Xinyi; Xiang, Wenqing; He, Lin; Li, Lin; Fu, Haidong; Mao, Jianhua			Urinary Sediment mRNA Level of CREBBP and CYBA in Children With Steroid-Resistant Nephrotic Syndrome	FRONTIERS IN IMMUNOLOGY			English	Article						mRNA; idiopathic nephrotic syndrome; steroid resistance; urinary sediment; CREBBP; CYBA	INSULIN-RESISTANCE; EXPRESSION; NEPHROPATHY; DIAGNOSIS; PODOCYTE; PROTEIN; TARGET; GROWTH; ALPHA; SERUM	BackgroundThis study aimed to evaluate gene expression patterns in urinary sediment samples of children with steroid-resistant nephrotic syndrome (SRNS). MethodsThe messenger RNA (mRNA) levels of 770 immune-related genes were detected using a NanoString nCounter platform. To verify the NanoString results, quantitative analysis of nine gene mRNAs was performed using real-time RT-PCR in more samples. ResultsFirstly, compared with the steroid-sensitive nephrotic syndrome (SSNS) group (n=3), significant changes were observed in the mRNA level of 70 genes, including MAP3K14, CYBA, SLC3A2, CREB-binding protein (CREBBP), CD68, forkhead box P1 (FOXP1), CD74, ITGB2, IFI30, and so forth, in the SRNS group (n=3). A total of 129 children with idiopathic nephrotic syndrome (INS), 15 with acute glomerulonephritis, and 6 with immunoglobulin A nephropathy (IgAN) were enrolled to verify the NanoString results. Compared with patients with IgAN, those with INS had significantly lower levels of FOXP1 (P=0.047) and higher levels of CREBBP (P=0.023). Among SSNS, the mRNA level of ITGB2 was significantly lower in the non-relapse group than in the non-frequent relapse and frequent-relapse groups (P=0.006). Compared with the SSNS group, CREBBP was significantly elevated in the SRNS group (P=0.02). Further, CYBA significantly decreased in the SRNS group (P=0.01). The area under the curve (AUC) for CREBBP and CYBA was 0.655 and 0.669, respectively. CREBBP had a sensitivity of 83.3% and a specificity of 49.4% and CYBA had a sensitivity of 58.3% and a specificity of 83.1% to rule out SSNS and SRNS. The diagnosis value was better for CREBBP+CYBA than for CREBBP or CYBA alone, indicating that the combination of CREBBP and CYBA was a more effective biomarker in predicting steroid resistance (AUC=0.666; sensitivity=63.9%; specificity=76.4%). ConclusionsThis study was novel in investigating the urinary sediment mRNA level in children with INS using high-throughput NanoString nCounter technology, and 70 genes that may relate to SRNS were found. The results revealed that the urinary sediment mRNA level of ITGB2 was significantly lower in the non-relapse group than in the non-frequent relapse and frequent-relapse groups. Meanwhile, CREBBP was significantly elevated and CYBA was significantly lowered in the SRNS group compared with the SSNS group.	[Li, Wei; Xiang, Wenqing; He, Lin; Li, Lin] Zhejiang Univ, Childrens Hosp, Sch Med, Natl Clin Res Ctr Child Hlth,Dept Clin Lab, Hangzhou, Peoples R China; [Shou, Xinyi; Mao, Jianhua] Zhejiang Univ, Childrens Hosp, Sch Med, Natl Clin Res Ctr Child Hlth,Dept Nephrol, Hangzhou, Peoples R China	Zhejiang University; Zhejiang University	Mao, JH (corresponding author), Zhejiang Univ, Childrens Hosp, Sch Med, Natl Clin Res Ctr Child Hlth,Dept Nephrol, Hangzhou, Peoples R China.	jhmao88@zju.edu.cn	Mao, Jianhua/GOK-2713-2022		science and technology projects in Zhejiang Province [LGC21H200004]; Key Research and Development Plan of Zhejiang Province [2019C03028]; Medical Scientifc Projects from Health Department of Zhejiang Province [2018KY455]	science and technology projects in Zhejiang Province; Key Research and Development Plan of Zhejiang Province; Medical Scientifc Projects from Health Department of Zhejiang Province	Funding This study was funded by the science and technology projects in Zhejiang Province (LGC21H200004), Key Research and Development Plan of Zhejiang Province (2019C03028) and the Medical Scientifc Projects from Health Department of Zhejiang Province (2018KY455).	Agrawal S, 2020, KIDNEY INT REP, V5, P66, DOI 10.1016/j.ekir.2019.09.009; Ayers M, 2017, J CLIN INVEST, V127, P2930, DOI 10.1172/JCI91190; Bekheirnia MR, 2017, GENET MED, V19, P412, DOI 10.1038/gim.2016.131; Bot PT, 2011, ATHEROSCLEROSIS, V218, P33, DOI 10.1016/j.atherosclerosis.2011.05.017; Cavanaugh C, 2019, AM J KIDNEY DIS, V73, P258, DOI 10.1053/j.ajkd.2018.07.012; Chien JW, 2006, PEDIATR NEPHROL, V21, P490, DOI 10.1007/s00467-006-0016-7; Downie ML, 2017, PAEDIATR INT CHILD H, V37, P248, DOI 10.1080/20469047.2017.1374003; Dutto I, 2018, CELL MOL LIFE SCI, V75, P1325, DOI 10.1007/s00018-017-2717-4; Eddy AA, 2003, LANCET, V362, P629, DOI 10.1016/S0140-6736(03)14184-0; Gang W, 2013, CLIN CHIM ACTA, V418, P5, DOI 10.1016/j.cca.2012.12.011; Geiss GK, 2008, NAT BIOTECHNOL, V26, P317, DOI 10.1038/nbt1385; Goodman RH, 2000, GENE DEV, V14, P1553; Hung CC, 2020, MOLECULES, V25, DOI 10.3390/molecules25173815; Hutterer E, 2015, BRIT J HAEMATOL, V169, P286, DOI 10.1111/bjh.13188; KIMATA H, 1995, EUR J IMMUNOL, V25, P1497, DOI 10.1002/eji.1830250604; Koon HB, 2007, EXPERT OPIN THER TAR, V11, P955, DOI 10.1517/14728222.11.7.955; Li BS, 2020, BLOOD, V135, P41, DOI 10.1182/blood.2019002220; Lombel RM, 2013, PEDIATR NEPHROL, V28, P415, DOI 10.1007/s00467-012-2310-x; Luo Y, 2013, CLIN CHEM, V59, P658, DOI 10.1373/clinchem.2012.195297; Maas RJ, 2016, NAT REV NEPHROL, V12, P768, DOI 10.1038/nrneph.2016.147; Mekahli D, 2009, PEDIATR NEPHROL, V24, P1525, DOI 10.1007/s00467-009-1138-5; Mullighan CG, 2011, NATURE, V471, P235, DOI 10.1038/nature09727; Nakamura T, 2000, AM J NEPHROL, V20, P175, DOI 10.1159/000013580; Rabelo F, 2018, HEPATOB PANCREAT DIS, V17, P330, DOI 10.1016/j.hbpd.2018.06.005; Sardina JL, 2010, CELL DEATH DIFFER, V17, P1842, DOI 10.1038/cdd.2010.67; Stasia MJ, 2016, GENE, V586, P27, DOI 10.1016/j.gene.2016.03.050; Subspecialty Group of Renal Diseases the Society of Pediatrics Chinese Medical Association, 2017, Zhonghua Er Ke Za Zhi, V55, P729, DOI 10.3760/cma.j.issn.0578-1310.2017.10.003; Sueta D, 2012, AM J HYPERTENS, V25, P704, DOI 10.1038/ajh.2012.26; SURANYI MG, 1993, AM J KIDNEY DIS, V21, P251, DOI 10.1016/S0272-6386(12)80742-6; Szeto CC, 2015, CLIN NEPHROL, V84, P198, DOI 10.5414/CN108607; Szeto CC, 2014, CLIN CHIM ACTA, V436, P308, DOI 10.1016/j.cca.2014.06.016; Trautmann A, 2017, J AM SOC NEPHROL, V28, P3055, DOI 10.1681/ASN.2016101121; Tsuchida A, 2005, J PHARMACOL SCI, V97, P164, DOI 10.1254/jphs.FMJ04008X2; Tsuji K, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22010088; Van den Berg JG, 2000, J AM SOC NEPHROL, V11, P413, DOI 10.1681/ASN.V113413; Vivarelli M, 2017, CLIN J AM SOC NEPHRO, V12, P332, DOI 10.2215/CJN.05000516; Wang G, 2016, CLIN CHIM ACTA, V456, P157, DOI 10.1016/j.cca.2016.03.006; Wang P, 2015, EXP BIOL MED, V240, P169, DOI 10.1177/1535370214548995; Wang XW, 2013, CONTRIB NEPHROL, V181, P119, DOI 10.1159/000348470; Wasilewska A, 2005, PEDIATR NEPHROL, V20, P597, DOI 10.1007/s00467-004-1772-x; Xiang HL, 2019, CHEM-BIOL INTERACT, V313, DOI 10.1016/j.cbi.2019.108818; Yuki K, 2020, INFECT IMMUN, V88, DOI 10.1128/IAI.00031-20; Zhang SY, 2011, CONTRIB NEPHROL, V169, P94, DOI 10.1159/000313947	43	0	0	2	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 31	2022	12								801313	10.3389/fimmu.2021.801313	http://dx.doi.org/10.3389/fimmu.2021.801313			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZA3JG	35173708	gold, Green Published			2022-12-18	WOS:000756063600001
J	Liu, Y; Lei, J; San, D; Yang, Y; Paek, C; Xia, ZX; Chen, YS; Yin, L				Liu, Yang; Lei, Jun; San, Dan; Yang, Yi; Paek, Chonil; Xia, Zixiong; Chen, Yongshun; Yin, Lei			Structural Basis for Unusual TCR CDR3 beta Usage Against an Immunodominant HIV-1 Gag Protein Peptide Restricted to an HLA-B*81:01 Molecule	FRONTIERS IN IMMUNOLOGY			English	Article						HIV; T cell receptor; CD8(+) T cells; HLA; antigen presentation	T-CELL-RECEPTOR; CLASS-I; LATENT RESERVOIR; MHC; IMGT/3DSTRUCTURE-DB; REPLICATION; DISTINGUISH; CLONOTYPES; STABILITY; INFECTION	In HIV infection, some closely associated human leukocyte antigen (HLA) alleles are correlated with distinct clinical outcomes although presenting the same HIV epitopes. The mechanism that underpins this observation is still unknown, but may be due to the essential features of HLA alleles or T cell receptors (TCR). In this study, we investigate how T18A TCR, which is beneficial for a long-term control of HIV in clinic, recognizes immunodominant Gag epitope TL9 (TPQDLTML180-188) from HIV in the context of the antigen presenting molecule HLA-B*81:01. We found that T18A TCR exhibits differential recognition for TL9 restricted by HLA-B*81:01. Furthermore, via structural and biophysical approaches, we observed that TL9 complexes with HLA-B*81:01 undergoes no conformational change after TCR engagement. Remarkably, the CDR3 beta in T18A complexes does not contact with TL9 at all but with intensive contacts to HLA-B*81:01. The binding kinetic data of T18A TCR revealed that this TCR can recognize TL9 epitope and several mutant versions, which might explain the correlation of T18A TCR with better clinic outcomes despite the relative high mutation rate of HIV. Collectively, we provided a portrait of how CD8(+) T cells engage in HIV-mediated T cell response.	[Liu, Yang; San, Dan; Yang, Yi; Paek, Chonil; Xia, Zixiong; Yin, Lei] Wuhan Univ, Coll Life Sci, State Key Lab Virol, Wuhan, Peoples R China; [Lei, Jun; Chen, Yongshun] Wuhan Univ, Renmin Hosp, Dept Clin Oncol, Wuhan, Peoples R China	Wuhan University; Wuhan University	Yin, L (corresponding author), Wuhan Univ, Coll Life Sci, State Key Lab Virol, Wuhan, Peoples R China.; Chen, YS (corresponding author), Wuhan Univ, Renmin Hosp, Dept Clin Oncol, Wuhan, Peoples R China.	yongshun2007@163.com; yinlei@whu.edu.cn		chonil, paek/0000-0002-0708-2104; yin, lei/0000-0001-5203-2766	National Natural Science Foundation of China [32171210, 31870728]; Central Leading Local Science and Technology Development Special Foundation [ZYYD2020000169]; Science Foundation of Wuhan University [2042020kfxg02, 2042016kf0169]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Central Leading Local Science and Technology Development Special Foundation; Science Foundation of Wuhan University	This work was supported by the National Natural Science Foundation of China (32171210 and 31870728), Central Leading Local Science and Technology Development Special Foundation (ZYYD2020000169), and the Science Foundation of Wuhan University (2042020kfxg02, 2042016kf0169).	Blevins SJ, 2017, FRONT MOL BIOSCI, V4, DOI 10.3389/fmolb.2017.00002; BORROW P, 1994, J VIROL, V68, P6103, DOI 10.1128/JVI.68.9.6103-6110.1994; Bullen CK, 2014, NAT MED, V20, P425, DOI 10.1038/nm.3489; Burley SK, 2021, NUCLEIC ACIDS RES, V49, pD437, DOI 10.1093/nar/gkaa1038; Chen HB, 2012, NAT IMMUNOL, V13, P691, DOI 10.1038/ni.2342; Chen H, 2009, J VIROL, V83, P3138, DOI 10.1128/JVI.02073-08; CHOTHIA C, 1987, J MOL BIOL, V196, P901, DOI 10.1016/0022-2836(87)90412-8; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; Colby DJ, 2018, NAT MED, V24, P923, DOI 10.1038/s41591-018-0026-6; Cole DK, 2008, MOL IMMUNOL, V45, P2700, DOI 10.1016/j.molimm.2007.12.009; Cole DK, 2006, EUR J IMMUNOL, V36, P170, DOI 10.1002/eji.200535424; Collins DR, 2020, NAT REV IMMUNOL, V20, P471, DOI 10.1038/s41577-020-0274-9; Currier JR, 2006, BMC IMMUNOL, V7, DOI 10.1186/1471-2172-7-8; Dorrell L, 2001, EUR J IMMUNOL, V31, P1747, DOI 10.1002/1521-4141(200106)31:6<1747::AID-IMMU1747>3.3.CO;2-C; Ehrenmann Francois, 2011, Cold Spring Harb Protoc, V2011, P750, DOI 10.1101/pdb.prot5637; Ehrenmann F, 2010, NUCLEIC ACIDS RES, V38, pD301, DOI 10.1093/nar/gkp946; Feinberg MB, 2012, NAT IMMUNOL, V13, P632, DOI 10.1038/ni.2351; Finzi D, 1999, NAT MED, V5, P512, DOI 10.1038/8394; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; Frater AJ, 2007, J VIROL, V81, P6742, DOI 10.1128/JVI.00022-07; GARBOCZI DN, 1992, P NATL ACAD SCI USA, V89, P3429, DOI 10.1073/pnas.89.8.3429; Goonetilleke N, 2009, J EXP MED, V206, P1253, DOI 10.1084/jem.20090365; Hellman LM, 2016, J IMMUNOL METHODS, V432, P95, DOI 10.1016/j.jim.2016.02.016; Iglesias MC, 2011, BLOOD, V118, P2138, DOI 10.1182/blood-2011-01-328781; JAMESON SC, 1995, ANNU REV IMMUNOL, V13, P93, DOI 10.1146/annurev.iy.13.040195.000521; Kaas Q, 2004, NUCLEIC ACIDS RES, V32, pD208, DOI 10.1093/nar/gkh042; Kloverpris HN, 2015, J IMMUNOL, V194, P5329, DOI 10.4049/jimmunol.1400854; Kloverpris HN, 2015, RETROVIROLOGY, V12, DOI 10.1186/s12977-015-0149-5; Kloverpris HN, 2012, J VIROL, V86, P11493, DOI 10.1128/JVI.01020-12; Koofhethile CK, 2016, J VIROL, V90, P6818, DOI 10.1128/JVI.00276-16; Ladell K, 2013, IMMUNITY, V38, P425, DOI 10.1016/j.immuni.2012.11.021; Laird GM, 2015, J CLIN INVEST, V125, P1901, DOI 10.1172/JCI80142; Lefranc MP, 2009, NUCLEIC ACIDS RES, V37, pD1006, DOI 10.1093/nar/gkn838; Margolis David M, 2007, Curr HIV/AIDS Rep, V4, P60, DOI 10.1007/s11904-007-0009-6; Ntale RS, 2012, J VIROL, V86, P12013, DOI 10.1128/JVI.00539-12; Ogunshola F, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07209-7; Payne R, 2014, P NATL ACAD SCI USA, V111, pE5393, DOI 10.1073/pnas.1413339111; Pereyra FP, 2010, SCIENCE, V330, P1551, DOI 10.1126/science.1195271; Piepenbrink KH, 2009, METHOD ENZYMOL, V466, P359, DOI 10.1016/S0076-6879(09)66015-8; Pierce BG, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003478; Pipkin ME, 2007, CURR OPIN IMMUNOL, V19, P301, DOI 10.1016/j.coi.2007.04.011; Prentice HA, 2013, J VIROL, V87, P4043, DOI 10.1128/JVI.03302-12; Prins JM, 1999, AIDS, V13, P2405, DOI 10.1097/00002030-199912030-00012; Riley TP, 2018, NAT CHEM BIOL, V14, P934, DOI 10.1038/s41589-018-0130-4; Rossjohn J, 2015, ANNU REV IMMUNOL, V33, P169, DOI 10.1146/annurev-immunol-032414-112334; Rudolph MG, 2006, ANNU REV IMMUNOL, V24, P419, DOI 10.1146/annurev.immunol.23.021704.115658; Schmidt ME, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00678; Siliciano JD, 2003, NAT MED, V9, P727, DOI 10.1038/nm880; Stinchcombe JC, 2003, SEMIN IMMUNOL, V15, P301, DOI 10.1016/j.smim.2003.09.003; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291; ZINKERNA.RM, 1974, NATURE, V248, P701, DOI 10.1038/248701a0	51	0	0	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 31	2022	13								822210	10.3389/fimmu.2022.822210	http://dx.doi.org/10.3389/fimmu.2022.822210			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZB3DM	35173732	gold, Green Published			2022-12-18	WOS:000756726900001
J	Magda, M; Bettoni, S; Laabei, M; Fairley, D; Russo, TA; Riesbeck, K; Blom, AM				Magda, Michal; Bettoni, Serena; Laabei, Maisem; Fairley, Derek; Russo, Thomas A.; Riesbeck, Kristian; Blom, Anna M.			Clinical Isolates of Acinetobacter spp. Are Highly Serum Resistant Despite Efficient Recognition by the Complement System	FRONTIERS IN IMMUNOLOGY			English	Article						Acinetobacter baumannii; capsule; complement; membrane attack complex; phagocytosis	K1 CAPSULAR POLYSACCHARIDE; ANTIMICROBIAL RESISTANCE; BAUMANNII; PROTEINS; STRAIN; THREAT; BLOOD	Gram-negative bacteria from the genus Acinetobacter are responsible for life-threating hospital-related infections such as pneumonia, septicemia, and meningitis, especially in immunocompromised patients. Worryingly, Acinetobacter have become multi- and extensively drug resistant (MDR/XDR) over the last few decades. The complement system is the first line of defense against microbes, thus it is highly important to increase our understanding of evasion mechanisms used by Acinetobacter spp. Here, we studied clinical isolates of Acinetobacter spp. (n=50), aiming to characterize their recognition by the complement system. Most isolates tested survived 1 h incubation in 30% serum, and only 8 isolates had a lower survival rate, yet none of those isolates were fully killed. Intriguingly, four isolates survived in human whole blood containing all cell component. Their survival was, however, significantly reduced. Flow cytometry analyses revealed that most of the isolates were detected by human IgG and IgM. Interestingly, we could not detect any significant concentration of deposited C1q, despite observing C4b deposition that was abolished in C1q-deficient serum, indicating transient binding of C1q to bacteria. Moreover, several isolates were recognized by MBL, with C4b deposition abolished in MBL-deficient serum. C3b was deposited on most isolates, but this was not, however, seen with respect to C5b and formation of the membrane attack complex (MAC), indicating that many isolates could avoid complement-mediated lysis. India ink staining showed that isolates were capsulated, and capsule thickness varied significantly between isolates. Studies performed on a wild-type strain and capsule mutant strains, demonstrated that the production of a capsular polysaccharide is one mechanism that mediates resistance to complement-mediated bactericidal activity by preventing MAC deposition and lysis. Our data showed that most clinical Acinetobacter spp. isolates are highly serum resistant despite being efficiently recognized by the complement system.	[Magda, Michal; Bettoni, Serena; Blom, Anna M.] Lund Univ, Dept Translat Med, Prot Chem, Malmo, Sweden; [Laabei, Maisem] Univ Bath, Dept Biol & Biochem, Bath, Avon, England; [Fairley, Derek] Belfast Hlth & Social Care Trust, Dept Microbiol, Belfast, Antrim, North Ireland; [Russo, Thomas A.] Univ Buffalo, Jacobs Sch Med & Biomed Sci, Dept Med, Vet Adm New York Healthcare Syst, Buffalo, NY USA; [Riesbeck, Kristian] Lund Univ, Dept Translat Med, Clin Microbiol, Malmo, Sweden	Lund University; University of Bath; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Lund University	Blom, AM (corresponding author), Lund Univ, Dept Translat Med, Prot Chem, Malmo, Sweden.	anna.blom@med.lu.se	Laabei, Maisem/AAH-6383-2021; Blom, Anna/B-9607-2009; Blom, Anna/AFS-7369-2022; Blom, Anna/AFS-7343-2022	Laabei, Maisem/0000-0002-8425-3704; Blom, Anna/0000-0002-1348-1734; Riesbeck, Kristian/0000-0001-6274-6965				Bettoni S, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.726801; Bettoni S, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.131886; Blom AM, 2014, CLIN EXP IMMUNOL, V178, P142, DOI 10.1111/cei.12388; Blom AM, 2001, J BIOL CHEM, V276, P27136, DOI 10.1074/jbc.M102445200; Blom AM, 2017, J IMMUNOL, V199, P3828, DOI 10.4049/jimmunol.1700426; Blom AM, 2015, MOL IMMUNOL, V66, P164, DOI 10.1016/j.molimm.2015.02.029; Blom AM, 2009, MOL IMMUNOL, V46, P2808, DOI 10.1016/j.molimm.2009.04.025; BOUVET PJM, 1986, INT J SYST BACTERIOL, V36, P228, DOI 10.1099/00207713-36-2-228; Brinkac L, 2017, MICROB ECOL, V74, P1001, DOI 10.1007/s00248-017-0985-z; Carvalheira A, 2021, FOOD MICROBIOL, V95, DOI 10.1016/j.fm.2020.103675; Christaki E, 2020, J MOL EVOL, V88, P26, DOI 10.1007/s00239-019-09914-3; Clark NM, 2016, CURR OPIN CRIT CARE, V22, P491, DOI 10.1097/MCC.0000000000000337; Collins RF, 2007, P NATL ACAD SCI USA, V104, P2390, DOI 10.1073/pnas.0607763104; Dijkshoorn L, 2007, NAT REV MICROBIOL, V5, P939, DOI 10.1038/nrmicro1789; Alcantar-Curiel MD, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.02116; DUGUID JP, 1951, J PATHOL BACTERIOL, V63, P673, DOI 10.1002/path.1700630413; Duval RE, 2019, MOLECULES, V24, DOI 10.3390/molecules24173152; Ermert D, 2016, IMMUNOL LETT, V169, P82, DOI 10.1016/j.imlet.2015.11.014; Ferri M, 2017, CRIT REV FOOD SCI, V57, P2857, DOI 10.1080/10408398.2015.1077192; Gandhi JA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095707; Geisinger E, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004691; Gellings PS, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9121066; Grguric-Smith LM, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.01134; Hamidian M, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8121851; HUGH RUDOLPH, 1967, INT J SYST BACTERIOL, V17, P245; Junker F, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01393; Kamoshida G, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00178; Kamoshida G, 2015, J INFECT CHEMOTHER, V21, P43, DOI 10.1016/j.jiac.2014.08.032; Kim SW, 2009, FEMS MICROBIOL LETT, V301, P224, DOI 10.1111/j.1574-6968.2009.01820.x; King LB, 2013, J INFECT DIS, V207, P1128, DOI 10.1093/infdis/jis939; King LB, 2009, FEMS IMMUNOL MED MIC, V55, P414, DOI 10.1111/j.1574-695X.2009.00538.x; Koenigs A, 2016, J INFECT DIS, V213, P1388, DOI 10.1093/infdis/jiv601; Kon H, 2020, BMC MICROBIOL, V20, DOI 10.1186/s12866-020-01971-9; Lai CC, 2020, J MICROBIOL IMMUNOL, V53, P505, DOI 10.1016/j.jmii.2020.05.013; Li J, 2020, ANTIMICROB RESIST IN, V9, DOI 10.1186/s13756-020-00819-1; Lin MF, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141107; Ma CY, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060570; Maragakis LL, 2008, CLIN INFECT DIS, V46, P1254, DOI 10.1086/529198; Mastellos DC, 2015, EUR J CLIN INVEST, V45, P423, DOI 10.1111/eci.12419; Merle NS, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00262; Monem S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21155498; Moore SR, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.602277; Okroj M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047245; Pantophlet R, 2000, CLIN DIAGN LAB IMMUN, V7, P293, DOI 10.1128/CDLI.7.2.293-295.2000; Perez S, 2020, MMWR-MORBID MORTAL W, V69, P1827, DOI 10.15585/mmwr.mm6948e1; Qiu HY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040019; Rangel K, 2021, PATHOGENS, V10, DOI 10.3390/pathogens10081006; Rooijakkers SHM, 2007, MOL IMMUNOL, V44, P23, DOI 10.1016/j.molimm.2006.06.011; Russo TA, 2013, INFECT IMMUN, V81, P915, DOI 10.1128/IAI.01184-12; Russo TA, 2010, INFECT IMMUN, V78, P3993, DOI 10.1128/IAI.00366-10; Sanchez-Larrayoz AF, 2017, J IMMUNOL, V199, P2803, DOI 10.4049/jimmunol.1700877; Singh JK, 2019, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.03301; Tacconelli E, 2018, LANCET INFECT DIS, V18, P318, DOI [10.1016/S1473-3099(17)30753-3, 10.1016/s1473-3099(17)30753-3]; Talyansky Y, 2021, PLOS PATHOG, V17, DOI 10.1371/journal.ppat.1009291; TENNER AJ, 1981, J IMMUNOL, V126, P1174; Thofte O, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02910; Vidarsson G, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00520; Wisplinghoff H, 2012, J INFECTION, V64, P282, DOI 10.1016/j.jinf.2011.12.008; World Med Assoc, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI 10.1001/jama.2013.281053; Wyres KL, 2020, MICROB GENOMICS, V6, DOI 10.1099/mgen.0.000339; Yang FL, 2017, VACCINE, V35, P1440, DOI 10.1016/j.vaccine.2017.01.060; Yu KH, 2021, ANTIMICROB RESIST IN, V10, DOI 10.1186/s13756-020-00876-6; Zhang QY, 2021, MILITARY MED RES, V8, DOI 10.1186/s40779-021-00343-2; Zwarthoff SA, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2102787118	64	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 31	2022	13								814193	10.3389/fimmu.2022.814193	http://dx.doi.org/10.3389/fimmu.2022.814193			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZA3BV	35173727	gold, Green Published			2022-12-18	WOS:000756044300001
J	Parisi, S; Ruggeri, L; Dan, ELS; Rizzi, S; Sinigaglia, B; Ocadlikova, D; Bontadini, A; Giudice, V; Urbani, E; Ciardelli, S; Sartor, C; Cristiano, G; Nanni, J; Zannoni, L; Chirumbolo, G; Arpinati, M; Lewis, RE; Bonifazi, F; Marconi, G; Martinelli, G; Papayannidis, C; Paolini, S; Velardi, A; Cavo, M; Lemoli, RM; Curti, A				Parisi, Sarah; Ruggeri, Loredana; Dan, Elisa; Rizzi, Simonetta; Sinigaglia, Barbara; Ocadlikova, Darina; Bontadini, Andrea; Giudice, Valeria; Urbani, Elena; Ciardelli, Sara; Sartor, Chiara; Cristiano, Gianluca; Nanni, Jacopo; Zannoni, Letizia; Chirumbolo, Gabriella; Arpinati, Mario; Lewis, Russell E.; Bonifazi, Francesca; Marconi, Giovanni; Martinelli, Giovanni; Papayannidis, Cristina; Paolini, Stefania; Velardi, Andrea; Cavo, Michele; Lemoli, Roberto M.; Curti, Antonio			Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters	FRONTIERS IN IMMUNOLOGY			English	Article						acute myeloid leukemia; natural killer cells; adoptive immune therapies; alloreactivity; cell dose	ACUTE MYELOID-LEUKEMIA; MISSING SELF; TRANSPLANTATION	Recently, many reports were published supporting the clinical use of adoptively transferred natural killer (NK) cells as a therapeutic tool against cancer, including acute myeloid leukemia (AML). Our group demonstrated promising clinical response using adoptive immunotherapy with donor-derived alloreactive KIR-ligand-mismatched NK cells in AML patients. Moreover, the antileukemic effect was correlated with the dose of infused alloreactive NK cells ("functional NK cell dose"). Herein, we update the results of our previous study on a cohort of adult AML patients (median age at enrollment 64) in first morphological complete remission (CR), not eligible for allogeneic stem cell transplantation. After an extended median follow-up of 55.5 months, 8/16 evaluable patients (50%) are still off-therapy and alive disease-free. Overall survival (OS) and disease-free survival (DFS) are related with the dose of infused alloreactive NK cells (>= 2 x 10(5)/kg).	[Parisi, Sarah; Rizzi, Simonetta; Arpinati, Mario; Bonifazi, Francesca; Papayannidis, Cristina; Paolini, Stefania; Cavo, Michele; Curti, Antonio] IRCCS Azienda Osped Univ Bologna, Ist Ematol Seragnoli, Bologna, Italy; [Ruggeri, Loredana; Urbani, Elena; Ciardelli, Sara; Velardi, Andrea] Univ Perugia, Osped Santa Maria Misericordia, Dept Med, Div Hematol & Clin Immunol, Perugia, Italy; [Dan, Elisa; Sinigaglia, Barbara; Ocadlikova, Darina; Sartor, Chiara; Cristiano, Gianluca; Nanni, Jacopo; Zannoni, Letizia; Chirumbolo, Gabriella; Cavo, Michele] Univ Bologna, Dept Expt Diagnost & Specialty Med, Bologna, Italy; [Bontadini, Andrea] Santa Maria Angeli Hosp, Blood Transfus Dept, Pordenone, Italy; [Giudice, Valeria] Univ Hosp S Orsola Malpighi, Immunohematol Serv & Blood Bank, Bologna, Italy; [Lewis, Russell E.] Univ Bologna, Dept Med & Surg Sci, Bologna, Italy; [Marconi, Giovanni; Martinelli, Giovanni] IRCCS, Ist Sci Romagnolo Studio & Cura Tumori IRST, Meldola, Italy; [Lemoli, Roberto M.] Univ Genoa, Dept Internal Med DiMI, Clin Hematol, Genoa, Italy; [Lemoli, Roberto M.] IRCCS Policlin S Martino, Genoa, Italy	IRCCS Azienda Ospedaliero-Universitaria di Bologna; Hospital Santa Maria della Misericordia; University of Perugia; University of Bologna; IRCCS Azienda Ospedaliero-Universitaria di Bologna; University of Bologna; IRCCS Meldola (IRST); University of Genoa	Parisi, S (corresponding author), IRCCS Azienda Osped Univ Bologna, Ist Ematol Seragnoli, Bologna, Italy.	sarah.parisi2@unibo.it	marconi, giovanni/AAX-7449-2020; bonifazi, francesca/J-5643-2018; LEMOLI, ROBERTO/AAC-2370-2022; Papayannidis, Cristina/F-2141-2018	marconi, giovanni/0000-0001-6309-0515; bonifazi, francesca/0000-0003-1544-9911; LEMOLI, ROBERTO/0000-0001-9000-562X; Papayannidis, Cristina/0000-0001-8705-8333; CAVO, MICHELE/0000-0003-4514-3227; Curti, Antonio/0000-0002-7752-6049				Bachanova V, 2014, BLOOD, V123, P3855, DOI 10.1182/blood-2013-10-532531; Cooley S, 2010, BLOOD, V116, P2411, DOI 10.1182/blood-2010-05-283051; Curti A, 2016, CLIN CANCER RES, V22, P1914, DOI 10.1158/1078-0432.CCR-15-1604; Curti A, 2011, BLOOD, V118, P3273, DOI 10.1182/blood-2011-01-329508; Lemoli RM, 2017, EXP HEMATOL, V45, P10, DOI 10.1016/j.exphem.2016.10.007; LJUNGGREN HG, 1990, IMMUNOL TODAY, V11, P237, DOI 10.1016/0167-5699(90)90097-S; Miller JS, 2005, BLOOD, V105, P3051, DOI 10.1182/blood-2004-07-2974; Moretta L, 2014, INT ARCH ALLERGY IMM, V164, P253, DOI 10.1159/000365632; Parisi S, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01330; Ruggeri L, 2002, SCIENCE, V295, P2097, DOI 10.1126/science.1068440; Ruggeri L, 2007, BLOOD, V110, P433, DOI 10.1182/blood-2006-07-038687	11	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 31	2022	12								804988	10.3389/fimmu.2021.804988	http://dx.doi.org/10.3389/fimmu.2021.804988			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZB6HC	35173709	Green Published, gold			2022-12-18	WOS:000756939900001
J	Traylor-Knowles, N; Browne, WE; Mydlarz, LD; Palmer, CV; Rosental, B				Traylor-Knowles, Nikki; Browne, William E.; Mydlarz, Laura D.; Palmer, Caroline V.; Rosental, Benyamin			Editorial: Innate Immunity in Early Diverging Metazoans	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						invertebrate; innate immunity; metazoa; Cnidaria; Porifera	INTERFERENCE; POTENT; RNAS		[Traylor-Knowles, Nikki] Univ Miami, Rosenstiel Sch Marine & Atmospher Sci, Dept Marine Biol & Ecol, Miami, FL 33146 USA; [Browne, William E.] Univ Miami, Dept Biol, Cox Sci Bldg, Miami, FL USA; [Mydlarz, Laura D.] Univ Texas Arlington, Dept Biol, Arlington, TX 76019 USA; [Palmer, Caroline V.] Flourish Editing, London, Devon, England; [Rosental, Benyamin] Ben Gurion Univ Negev, Fac Hlth Sci, Regenerat Med & Stem Cell Res Ctr, Shraga Segal Dept Microbiol Immunol & Genet, Beer Sheva, Israel	University of Miami; University of Miami; University of Texas System; University of Texas Arlington; Ben Gurion University	Traylor-Knowles, N (corresponding author), Univ Miami, Rosenstiel Sch Marine & Atmospher Sci, Dept Marine Biol & Ecol, Miami, FL 33146 USA.	ntk1717@gmail.com	Browne, William E/D-4267-2013; Browne, William E./AAV-4035-2021; Rosental, Benyamin/X-5400-2019	Browne, William E/0000-0001-8200-6489; Browne, William E./0000-0001-8200-6489; Rosental, Benyamin/0000-0002-3974-3296	NSF-BSF [BSF-2019647, NSF-1951826]; NSF [OCE-1928771, OCE2109622]; Alex and Ann Lauterbach; Israel Science Foundation (ISF) [1416/19, 2841/19]; European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program [948476]; HFSP [RGY0085/2019];  [NSF-2013692]	NSF-BSF; NSF(National Science Foundation (NSF)); Alex and Ann Lauterbach; Israel Science Foundation (ISF)(Israel Science Foundation); European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program(European Research Council (ERC)); HFSP(Human Frontier Science Program); 	NT-K and BR were supported by NSF-BSF Grant: BSF-2019647, NSF-1951826. NT-K and WEB were supported by NSF-2013692. LDM: was supported by NSF OCE-1928771 and NSF OCE2109622. BR would like to thank Alex and Ann Lauterbach for funding the Comparative and Evolutionary Immunology Laboratory. The work of BR was supported by Israel Science Foundation (ISF) numbers: 1416/19 and 2841/19. BR has received funding from European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program under grant agreement No. 948476. BR has received funding from a HFSP grant (RGY0085/2019).	Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; JANEWAY CA, 1989, COLD SPRING HARB SYM, V54, P1; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; Metschnikoff E., 1884, J CELL SCI, V24, P112, DOI [10.1242/jcs.s2-24.93.112, DOI 10.1242/JCS.S2-24.93.112]; RIZKI MOHAMMED TAHIR MIRZA, 1957, J MORPH, V100, P437, DOI 10.1002/jmor.1051000303	7	0	0	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 31	2022	13								816550	10.3389/fimmu.2022.816550	http://dx.doi.org/10.3389/fimmu.2022.816550			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZC3VF	35173730	Green Published, gold			2022-12-18	WOS:000757451000001
J	Xu, JW; Wu, YF; Xu, YD; Qiu, Y; Li, XB; Song, YM; Zhang, L				Xu, Jiawei; Wu, Yongfeng; Xu, Yuedan; Qiu, Yuan; Li, Xiaobo; Song, Yumeng; Zhang, Ling			Safety of Neoadjuvant Immunotherapy in Resectable Cancers: A Meta-Analysis	FRONTIERS IN IMMUNOLOGY			English	Review						neoadjuvant immunotherapy; immune checkpoint inhibitors; safety; treatment-related adverse events; immune-related adverse events; meta-analysis	CELL LUNG-CANCER; OPEN-LABEL; SINGLE-ARM; CHEMOTHERAPY; MULTICENTER; EFFICACY	Background: Neoadjuvant immunotherapy has preliminarily been effective in multiple resectable cancers. However, its safety is still largely unknown.& nbsp;Methods: A systematic literature search was conducted in PubMed, Embase, Web of Science, and Cochrane Library up to February 28th, 2021. Pooled incidence and risk ratio (RR) of adverse events were calculated using the R software.& nbsp;Results: Twenty-eight studies involving 2863 patients were included. First, the incidence for all-grade treatment-related adverse events (trAEs) was 94% (95% CI, 81%-98%), with 43% (95% CI, 24%-64%) for high-grade trAEs. For different treatment groups, neoadjuvant immune checkpoint inhibitors (ICIs) plus chemotherapy was associated with a higher incidence of all-grade [99% (95% CI, 98%-99%) vs. 76% (95% CI 47%-92%); P < 0.001] and high-grade [80% (58%-92%) vs. 15% (9%-24%); P < 0.001] trAEs compared with neoadjuvant ICIs alone. The most common high-grade trAEs were lipase increased (5%; 95% CI, 2%-10%), colitis (3%; 95% CI, 0-7%) and transaminitis (3%; 95% CI, 0-7%) for neoadjuvant ICIs, and neutropenia (53%; 95% CI, 31%-74%), anemia (8%; 95% CI, 3%-15%) and AST increased (4%; 95% CI, 2%-7%) for neoadjuvant ICIs plus chemotherapy. Furthermore, the incidence rates of progressive disease while on treatment, treatment-related surgical delays and deaths were 6% (95% CI, 4%-10%), 3.2% (12 of 377 patients) and 0.47% (5 of 1075 patients), respectively.& nbsp;Conclusion: Compared with neoadjuvant ICIs alone, neoadjuvant ICIs plus chemotherapy had a higher incidence of trAEs. In addition, neoadjuvant immunotherapy had a low rate of progressive diseases, surgical delays and deaths.	[Xu, Jiawei; Xu, Yuedan; Qiu, Yuan; Li, Xiaobo; Song, Yumeng; Zhang, Ling] Zhejiang Univ, Zhejiang Prov Clin Res Ctr Oral Dis, Key Lab Oral Biomed Res Zhejiang Prov, Stomatol Hosp,Sch Stomatol,Sch Med,Canc Ctr, Hangzhou, Peoples R China; [Wu, Yongfeng] Zhejiang Univ, Affiliated Hosp 1, Sch Med, Dept Thorac Surg, Hangzhou, Peoples R China	Zhejiang University; Zhejiang University	Zhang, L (corresponding author), Zhejiang Univ, Zhejiang Prov Clin Res Ctr Oral Dis, Key Lab Oral Biomed Res Zhejiang Prov, Stomatol Hosp,Sch Stomatol,Sch Med,Canc Ctr, Hangzhou, Peoples R China.	jorlinzhang@zju.edu.cn	xu, jiawei/GWM-9710-2022					Amaria RN, 2018, NAT MED, V24, P1649, DOI 10.1038/s41591-018-0197-1; Blank CU, 2018, NAT MED, V24, P1655, DOI 10.1038/s41591-018-0198-0; Blidner AG, 2020, SUPPORT CARE CANCER, V28, P6111, DOI 10.1007/s00520-020-05705-5; Carthon BC, 2010, CLIN CANCER RES, V16, P2861, DOI 10.1158/1078-0432.CCR-10-0569; Chalabi M, 2020, NAT MED, V26, P566, DOI 10.1038/s41591-020-0805-8; Cloughesy TF, 2019, NAT MED, V25, P477, DOI 10.1038/s41591-018-0337-7; Ferrarotto R, 2020, CLIN CANCER RES, V26, P3211, DOI 10.1158/1078-0432.CCR-19-3977; Gao JJ, 2020, NAT MED, V26, DOI 10.1038/s41591-020-1086-y; Gao SG, 2020, J THORAC ONCOL, V15, P816, DOI 10.1016/j.jtho.2020.01.017; Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928; Huang AC, 2019, NAT MED, V25, P454, DOI 10.1038/s41591-019-0357-y; Jia XH, 2020, LUNG CANCER, V147, P143, DOI 10.1016/j.lungcan.2020.07.001; Kennedy LB, 2020, CA-CANCER J CLIN, V70, P86, DOI 10.3322/caac.21596; Levine LS, 2020, ANN SURG ONCOL, V27, P4122, DOI 10.1245/s10434-020-08648-7; Loibl S, 2019, ANN ONCOL, V30, P1279, DOI 10.1093/annonc/mdz158; Maher VE, 2019, J CLIN ONCOL, V37, P2730, DOI 10.1200/JCO.19.00318; Mittendorf EA, 2020, LANCET, V396, P1090, DOI 10.1016/S0140-6736(20)31953-X; Moher D, 2010, INT J SURG, V8, P658, DOI 10.1016/j.ijsu.2010.07.299; Nanda R, 2020, JAMA ONCOL, V6, P676, DOI 10.1001/jamaoncol.2019.6650; Necchi A, 2020, EUR UROL, V77, P439, DOI 10.1016/j.eururo.2019.10.026; O'Donnell JS, 2019, CLIN CANCER RES, V25, P5743, DOI 10.1158/1078-0432.CCR-18-2641; Powles T, 2019, NAT MED, V25, P1706, DOI 10.1038/s41591-019-0628-7; Provencio M, 2020, LANCET ONCOL, V21, P1413, DOI 10.1016/S1470-2045(20)30453-8; Reuss JE, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-001282; Ribas A, 2018, SCIENCE, V359, P1350, DOI 10.1126/science.aar4060; Rozeman EA, 2019, LANCET ONCOL, V20, P948, DOI 10.1016/S1470-2045(19)30151-2; Schalper KA, 2019, NAT MED, V25, P470, DOI 10.1038/s41591-018-0339-5; Schmid P, 2020, ANN ONCOL, V31, P569, DOI 10.1016/j.annonc.2020.01.072; Schmid P, 2020, NEW ENGL J MED, V382, P810, DOI 10.1056/NEJMoa1910549; Schoenfeld JD, 2020, JAMA ONCOL, V6, P1563, DOI 10.1001/jamaoncol.2020.2955; Shu CA, 2020, LANCET ONCOL, V21, P786, DOI 10.1016/S1470-2045(20)30140-6; Tarhini AA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087705; Topalian SL, 2020, J CLIN ONCOL, V38, P2476, DOI 10.1200/JCO.20.00201; Topalian SL, 2020, SCIENCE, V367, P525, DOI 10.1126/science.aax0182; Uppaluri R, 2020, CLIN CANCER RES, V26, P5140, DOI 10.1158/1078-0432.CCR-20-1695; Wang DY, 2018, JAMA ONCOL, V4, P1721, DOI 10.1001/jamaoncol.2018.3923; Wang QH, 2018, INT IMMUNOPHARMACOL, V58, P125, DOI 10.1016/j.intimp.2018.03.018; Wang YC, 2019, JAMA ONCOL, V5, P1008, DOI 10.1001/jamaoncol.2019.0393; Yang X, 2018, NEW ENGL J MED, V379, DOI 10.1056/NEJMc1808251; Yi JS, 2017, CLIN CANCER RES, V23, P7474, DOI 10.1158/1078-0432.CCR-17-2005; Zhou XX, 2021, LANCET ONCOL, V22, P1265, DOI 10.1016/S1470-2045(21)00333-8	41	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 31	2022	13								802672	10.3389/fimmu.2022.802672	http://dx.doi.org/10.3389/fimmu.2022.802672			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZC3RV	35173721	gold, Green Published			2022-12-18	WOS:000757442200001
J	Zhao, XL; Yue, DS; Qian, JJ; Zhang, L; Song, J; Zhang, B; Zhang, CM; Sun, LA; Ma, YC; Zhang, HH; Wang, CL				Zhao, Xiaoliang; Yue, Dongsheng; Qian, Juanjuan; Zhang, Lei; Song, Jin; Zhang, Bin; Zhang, Chunmei; Sun, Leina; Ma, Yuchen; Zhang, Henghui; Wang, Changli			Case Report: Sarcoid-Like Reactions and Tertiary Lymphoid Structures Following Dual Checkpoint Inhibition in a Patient with Early-Stage Lung Adenocarcinoma	FRONTIERS IN IMMUNOLOGY			English	Article						sarcoid-like reaction; tertiary lymphoid structure; immune checkpoint inhibitor; tumor immune microenvironment; non-small cell lung cancer	B-CELLS; PD-1 BLOCKADE; IMMUNOTHERAPY; CANCER; SURVIVAL; IMMUNITY	Immune checkpoint inhibitor-induced sarcoid-like reactions and tertiary lymphoid structures (TLSs) are increasingly recognized but rarely reported in the same patient. We report a patient with lung adenocarcinoma who displayed sarcoid-like reactions in intrathoracic lymph nodes and tertiary lymphoid structures in surgical tumor after neoadjuvant therapy with nivolumab plus ipilimumab. Pathological examination revealed 50% residual tumor cells after treatment, and the CT evaluation of the primary tumor showed a stable disease. The patient experienced a recurrence eight months after surgery. To identify immune correlates of the limited response to immunotherapy, we conducted genomic and transcriptional assays, multiplex immunoassay, and multiplex immunohistochemistry on the pre- and post-immunotherapy tumor, lymph node, and plasma samples. TP53 R181C, KRAS G12C and SMAD4 R361H were identified as driver mutations of the tumor. In addition to abundant infiltrated lymphocytes, immunotherapy induced high levels of inhibitory components in post-treatment tissue samples, especially the FOXP3(+) regulatory T cells in tumor and PD-L1 expression in the lymph node. Despite abundant TLSs in the post-treatment tumor, most TLSs were immature. Moreover, increasing levels of circulating checkpoint proteins BTLA, TIM-3, LAG-3, PD-1, PD-L1, and CTLA4 were observed during immunotherapy. Collectively, our observations revealed that high levels of immunosuppressive molecules in tumor, lymph nodes and/or in peripheral blood might indicate poor outcomes after immunotherapy, even in the setting of a patient with concurrent sarcoid-like reactions and tertiary lymphoid structures.	[Zhao, Xiaoliang; Yue, Dongsheng; Zhang, Bin; Sun, Leina; Ma, Yuchen; Wang, Changli] Tianjin Med Univ Canc Inst & Hosp, Tianjin Key Lab Canc Prevent & Therapy, Natl Clin Res Ctr Canc, Tianjin, Peoples R China; [Qian, Juanjuan; Zhang, Lei; Song, Jin; Zhang, Chunmei] Dept Med Genecast Biotechnol Co Ltd, Wuxi, Jiangsu, Peoples R China; [Zhang, Henghui] Capital Med Univ, Beijing Shijitan Hosp, Beijing, Peoples R China; [Zhang, Henghui] Capital Med Univ, Sch Oncol, Beijing, Peoples R China	Tianjin Medical University; Capital Medical University; Capital Medical University	Wang, CL (corresponding author), Tianjin Med Univ Canc Inst & Hosp, Tianjin Key Lab Canc Prevent & Therapy, Natl Clin Res Ctr Canc, Tianjin, Peoples R China.; Zhang, HH (corresponding author), Capital Med Univ, Beijing Shijitan Hosp, Beijing, Peoples R China.; Zhang, HH (corresponding author), Capital Med Univ, Sch Oncol, Beijing, Peoples R China.	zhhbao@ccmu.edu.cn; wangchangli@tjmuch.com	Zhang, Chun/GRE-8915-2022		National Key Sci-Tech Special Project of China [2018ZX10302207]	National Key Sci-Tech Special Project of China	Funding This study was supported by the National Key Sci-Tech Special Project of China (2018ZX10302207).	Bian B, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2018.1561120; Birnbaum Mathew R, 2017, JAAD Case Rep, V3, P208, DOI 10.1016/j.jdcr.2017.02.015; Cabanie C, 2021, EUR J CANCER, V156, P46, DOI 10.1016/j.ejca.2021.07.015; Cabrita R, 2020, NATURE, V577, P561, DOI 10.1038/s41586-019-1914-8; Cascone T, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-25188-0; Chanson Noemie, 2021, Eur J Cancer, V158, P208, DOI 10.1016/j.ejca.2021.05.041; Chorti E, 2020, EUR J CANCER, V131, P18, DOI 10.1016/j.ejca.2020.02.024; Cottrell TR, 2018, ANN ONCOL, V29, P1853, DOI 10.1093/annonc/mdy218; Cousin N, 2021, CANCER RES, V81, P4133, DOI 10.1158/0008-5472.CAN-21-0633; Dieu-Nosjean MC, 2008, J CLIN ONCOL, V26, P4410, DOI 10.1200/JCO.2007.15.0284; Eichhorn F, 2021, LUNG CANCER, V153, P150, DOI 10.1016/j.lungcan.2021.01.018; Eschweiler S, 2021, NAT IMMUNOL, V22, P1052, DOI 10.1038/s41590-021-00958-6; Finkin S, 2015, NAT IMMUNOL, V16, P1235, DOI 10.1038/ni.3290; Fukuhara M, 2022, CANCER IMMUNOL IMMUN, V71, P1129, DOI 10.1007/s00262-021-03067-3; Germain C, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.626776; Germain C, 2014, AM J RESP CRIT CARE, V189, P832, DOI 10.1164/rccm.201309-1611OC; Gkiozos I, 2018, J THORAC ONCOL, V13, P1076, DOI 10.1016/j.jtho.2018.04.031; Hassel JC, 2020, ANN ONCOL, V31, pS756, DOI 10.1016/j.annonc.2020.08.1249; Helmink BA, 2020, NATURE, V577, P549, DOI 10.1038/s41586-019-1922-8; Kinker GS, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.678127; Koyama S, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10501; Nishino M, 2018, CANCER IMMUNOL RES, V6, P630, DOI 10.1158/2326-6066.CIR-17-0715; Noguchi S, 2018, CASE REP ONCOL, V11, P562, DOI 10.1159/000492383; Paolini L, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0372-4; Petitprez F, 2020, NATURE, V577, P556, DOI 10.1038/s41586-019-1906-8; Rakaee M, 2021, BRIT J CANCER, V124, P1680, DOI 10.1038/s41416-021-01307-y; Rodriguez AB, 2020, CANCER IMMUNOL RES, V8, P1338, DOI 10.1158/2326-6066.CIR-20-0432; Sanderson E, 2020, RESPIROL CASE REP, V8, DOI 10.1002/rcr2.542; Sautes-Fridman C, 2019, NAT REV CANCER, V19, P307, DOI 10.1038/s41568-019-0144-6; Shen RL, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abf5107; Shinomiya S, 2021, JPN J CLIN ONCOL, V51, P1179, DOI 10.1093/jjco/hyab043; Silina K, 2018, CANCER RES, V78, P1308, DOI 10.1158/0008-5472.CAN-17-1987; Suozzi Kathleen C, 2016, JAAD Case Rep, V2, P264, DOI 10.1016/j.jdcr.2016.05.002; Takamori S, 2021, THORAC CANCER, V12, P2122, DOI 10.1111/1759-7714.14011; Tanaka A, 2017, CELL RES, V27, P109, DOI 10.1038/cr.2016.151; Tetzlaff MT, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0323-0; Vanhersecke L, 2021, NAT CANCER, V2, P794, DOI 10.1038/s43018-021-00232-6; Wang QC, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0810-y; Yousuf H, 2020, CUREUS, V12, DOI 10.7759/cureus.12395	39	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 31	2022	13								794217	10.3389/fimmu.2022.794217	http://dx.doi.org/10.3389/fimmu.2022.794217			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZA3FN	35173719	Green Published, gold			2022-12-18	WOS:000756053900001
J	Blanchard-Rohner, G; Peirolo, A; Coulon, L; Korff, C; Horvath, J; Burkhard, PR; Gumy-Pause, F; Ranza, E; Jandus, P; Dibra, H; Taylor, AMR; Fluss, J				Blanchard-Rohner, Geraldine; Peirolo, Anna; Coulon, Ludivine; Korff, Christian; Horvath, Judit; Burkhard, Pierre R.; Gumy-Pause, Fabienne; Ranza, Emmanuelle; Jandus, Peter; Dibra, Harpreet; Taylor, Alexander Malcolm R.; Fluss, Joel			Childhood-Onset Movement Disorders Can Mask a Primary Immunodeficiency: 6 Cases of Classical Ataxia-Telangiectasia and Variant Forms	FRONTIERS IN IMMUNOLOGY			English	Article						ATM kinase activity; immunodeficiency; ataxia telangiectasia; movement disorder; cerebellar ataxia	ATM; DEFICIENCY; GENOTYPE	Ataxia-telangiectasia (A-T) is a neurodegenerative and primary immunodeficiency disorder (PID) characterized by cerebellar ataxia, oculocutaneous telangiectasia, immunodeficiency, progressive respiratory failure, and an increased risk of malignancies. It demands specialized care tailored to the individual patient's needs. Besides the classical ataxia-telangiectasia (classical A-T) phenotype, a variant phenotype (variant A-T) exists with partly overlapping but some distinctive disease characteristics. Here we present a case series of 6 patients with classical A-T and variant A-T, which illustrates the phenotypic variability of A-T that can present in childhood with prominent extrapyramidal features, with or without cerebellar ataxia. We report the clinical data, together with a detailed genotype description, immunological analyses, and related expression of the ATM protein. We show that the presence of some residual ATM kinase activity leads to the clinical phenotype variant A-T that differs from the classical A-T. Our data illustrate that the diagnosis of the variant form of A-T can be delayed and difficult, while early recognition of the variant form as well as the classical A-T is a prerequisite for providing a correct prognosis and appropriate rehabilitation and support, including the avoidance of diagnostic X-ray procedures, given the increased risk of malignancies and the higher risk for side effects of subsequent cancer treatment.	[Blanchard-Rohner, Geraldine] Univ Geneva, Geneva Univ Hosp, Dept Pediat Gynecol & Obstet, Paediat Immunol & Vaccinol Unit,Div Gen Pediat, Geneva, Switzerland; [Peirolo, Anna] Univ Brescia, ASST Spedali Civili, Dept Clin & Expt Sci, Brescia, Italy; [Coulon, Ludivine] Univ Geneva, Geneva Univ Hosp, Dept Pediat Gynecol & Obstet, Div Gen Pediat, Geneva, Switzerland; [Korff, Christian; Fluss, Joel] Univ Geneva, Geneva Univ Hosp, Dept Pediat Gynecol & Obstet, Pediat Neurol Unit, Geneva, Switzerland; [Horvath, Judit; Burkhard, Pierre R.] Univ Hosp Geneva, Dept Neurol, Geneva, Switzerland; [Gumy-Pause, Fabienne] Geneva Univ Hosp, Dept Women Child & Adolescent Med, Div Pediat Oncol & Hematol, Geneva, Switzerland; [Gumy-Pause, Fabienne] Univ Geneva, Fac Med, Dept Pediat Gynaecol & Obstet, CANSEARCH Res Platform Pediat Oncol & Hematol, Geneva, Switzerland; [Ranza, Emmanuelle] Swiss Inst Genom Med, Medigenome, Geneva, Switzerland; [Jandus, Peter] Univ Hosp, Div Immunol & Allergol, Geneva, Switzerland; [Jandus, Peter] Med Fac Geneva, Geneva, Switzerland; [Dibra, Harpreet; Taylor, Alexander Malcolm R.] Univ Birmingham, Inst Canc & Genom Sci, Birmingham, W Midlands, England	University of Geneva; Hospital Spedali Civili Brescia; University of Brescia; University of Geneva; University of Geneva; University of Geneva; University of Geneva; University of Geneva; University of Geneva; University of Geneva; University of Birmingham	Blanchard-Rohner, G (corresponding author), Univ Geneva, Geneva Univ Hosp, Dept Pediat Gynecol & Obstet, Paediat Immunol & Vaccinol Unit,Div Gen Pediat, Geneva, Switzerland.	Geraldine.BlanchardRohner@hcuge.ch	Blanchard-Rohner, Geraldine/AAX-7643-2020	Blanchard-Rohner, Geraldine/0000-0002-9974-2172				Amirifar P, 2019, PEDIAT ALLERG IMM-UK, V30, P277, DOI 10.1111/pai.13020; Chopra C, 2014, CLIN EXP IMMUNOL, V176, P275, DOI 10.1111/cei.12262; ComansBitter WM, 1997, J PEDIATR-US, V130, P388, DOI 10.1016/S0022-3476(97)70200-2; Driessen GJ, 2013, J ALLERGY CLIN IMMUN, V131, P1367, DOI 10.1016/j.jaci.2013.01.053; Farr AK, 2002, AM J OPHTHALMOL, V134, P891, DOI 10.1016/S0002-9394(02)01796-8; Herrup K, 2013, DNA REPAIR, V12, P600, DOI 10.1016/j.dnarep.2013.04.012; Levy A, 2018, MOVEMENT DISORD, V33, P1238, DOI 10.1002/mds.27319; McGrath-Morrow SA, 2021, J MULTIDISCIP HEALTH, V14, P1637, DOI 10.2147/JMDH.S295486; Micol R, 2011, J ALLERGY CLIN IMMUN, V128, P382, DOI 10.1016/j.jaci.2011.03.052; Nissenkorn Andreea, 2015, Handb Clin Neurol, V132, P199, DOI 10.1016/B978-0-444-62702-5.00014-7; Nissenkorn A, 2011, J PEDIATR-US, V159, P466, DOI 10.1016/j.jpeds.2011.02.005; Nowak-Wegrzyn A, 2004, J PEDIATR-US, V144, P505, DOI 10.1016/j.jpeds.2003.12.046; Perez-Lloret S, 2021, MOVEMENT DISORD, V36, P283, DOI 10.1002/mds.28313; Rothblum-Oviatt C, 2016, ORPHANET J RARE DIS, V11, DOI 10.1186/s13023-016-0543-7; Schon K, 2019, ANN NEUROL, V85, P170, DOI 10.1002/ana.25394; Schroder S, 2020, AM J MED GENET A, V182, P2971, DOI 10.1002/ajmg.a.61870; Staples ER, 2008, CLIN EXP IMMUNOL, V153, P214, DOI 10.1111/j.1365-2249.2008.03684.x; Taylor AMR, 2019, NAT REV DIS PRIMERS, V5, DOI 10.1038/s41572-019-0113-0; Tiet MY, 2020, PRACT NEUROL, V20, P404, DOI 10.1136/practneurol-2019-002253; van Os NJH, 2017, DEV MED CHILD NEUROL, V59, P680, DOI 10.1111/dmcn.13424; Verhagen MMM, 2009, NEUROLOGY, V73, P430, DOI 10.1212/WNL.0b013e3181af33bd; Verhagen MMM, 2012, HUM MUTAT, V33, P561, DOI 10.1002/humu.22016	22	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 28	2022	13								791522	10.3389/fimmu.2022.791522	http://dx.doi.org/10.3389/fimmu.2022.791522			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZG4WV	35154108	Green Published, gold			2022-12-18	WOS:000760261000001
J	Cardozo, T; Cardozo, L; Boutjdir, M				Cardozo, Timothy; Cardozo, Lila; Boutjdir, Mohamed			Autoantibody:Autoantigen Competitor Decoys: Application to Cardiac Phenotypes	FRONTIERS IN IMMUNOLOGY			English	Review						autoantigen; autoantibody; therapeutics; decoy; autoimmune; long QT	CRYSTAL-STRUCTURE; RNA; AUTOANTIGEN; PEPTIDE; AUTOANTIBODIES; EPITOPE; INHIBITION; ANTIBODIES; SELECTION	Autoimmune diseases are often associated with autoantibodies that abnormally target self-antigens (autoantigens). An intuitive therapeutic strategy for diseases caused by aAbs is to design decoys, or soluble molecules that target the antigen combining site of these aAbs, thereby blocking binding of aAb to self-antigen and subsequent tissue damage. Here, we review the known decoy molecules of these types, discuss newer technological opportunities afforded by monoclonal antibody and structural biology advances, and discuss the challenges to this approach. Recent opportunities relevant to this approach for cardiac phenotypes, specifically Ro-associated long QT syndrome, are discussed.	[Cardozo, Timothy; Cardozo, Lila] NYU, Dept Biochem & Mol Pharmacol, Grossman Sch Med, New York, NY 10016 USA; [Boutjdir, Mohamed] NYU, Dept Med, Grossman Sch Med, 550 1St Ave, New York, NY 10016 USA; [Boutjdir, Mohamed] Suny Downstate Med Ctr, Dept Med Cell Biol & Pharmacol, New York, NY 10016 USA; [Boutjdir, Mohamed] VA New York Harbor Healthcare Syst, Cardiovasc Res Program, New York, NY 10016 USA	New York University; New York University; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center	Cardozo, T (corresponding author), NYU, Dept Biochem & Mol Pharmacol, Grossman Sch Med, New York, NY 10016 USA.; Boutjdir, M (corresponding author), NYU, Dept Med, Grossman Sch Med, 550 1St Ave, New York, NY 10016 USA.; Boutjdir, M (corresponding author), Suny Downstate Med Ctr, Dept Med Cell Biol & Pharmacol, New York, NY 10016 USA.; Boutjdir, M (corresponding author), VA New York Harbor Healthcare Syst, Cardiovasc Res Program, New York, NY 10016 USA.	cardot01@nyumc.org; mohamed.boutjdir@va.gov						Ahlin E, 2012, LUPUS, V21, P586, DOI 10.1177/0961203311434938; Boutjdir M, 2000, TRENDS CARDIOVAS MED, V10, P114, DOI 10.1016/S1050-1738(00)00059-1; Boutjdir M, 2020, J AM COLL CARDIOL, V75, P2153, DOI 10.1016/j.jacc.2020.03.027; Boutjdir Mohamed, 2016, Card Electrophysiol Clin, V8, P373, DOI 10.1016/j.ccep.2016.02.002; Corper AL, 1997, NAT STRUCT BIOL, V4, P374, DOI 10.1038/nsb0597-374; Dobritzsch D, 2011, ARTHRITIS RHEUM-US, V63, P3740, DOI 10.1002/art.30611; DOUDNA JA, 1995, P NATL ACAD SCI USA, V92, P2355, DOI 10.1073/pnas.92.6.2355; Drew BJ, 2010, J AM COLL CARDIOL, V55, P934, DOI [10.1016/j.jacc.2010.01.001, 10.1161/CIRCULATIONAHA.109.192704]; Dzhambazov B, 2006, J IMMUNOL, V176, P1525, DOI 10.4049/jimmunol.176.3.1525; Edo N, 2019, THYROID, V29, P1012, DOI 10.1089/thy.2018.0772; El-Sherif N, 2003, CURR OPIN CARDIOL, V18, P6, DOI 10.1097/00001573-200301000-00002; Fabris F, 2016, J PHYSIOL-LONDON, V594, P6175, DOI 10.1113/JP272151; Gaynor B, 1997, P NATL ACAD SCI USA, V94, P1955, DOI 10.1073/pnas.94.5.1955; Hwang B, 2002, BIOCHEM BIOPH RES CO, V290, P656, DOI 10.1006/bbrc.2001.6252; Ioannou Y, 2009, J THROMB HAEMOST, V7, P833, DOI 10.1111/j.1538-7836.2009.03316.x; Jumper J, 2021, NATURE, V596, P583, DOI 10.1038/s41586-021-03819-2; Jung HH, 2007, BIOCHEMISTRY-US, V46, P14987, DOI 10.1021/bi701298b; Karnabi E, 2010, SCAND J IMMUNOL, V72, P226, DOI 10.1111/j.1365-3083.2010.02439.x; Karnabi E, 2010, J AUTOIMMUN, V34, P80, DOI 10.1016/j.jaut.2009.06.005; Kavanaugh A, 2000, ARCH PATHOL LAB MED, V124, P71; Lazzerini PE, 2021, J AM HEART ASSOC, V10, DOI 10.1161/JAHA.120.018735; Lazzerini PE, 2019, FRONT CARDIOVASC MED, V6, DOI 10.3389/fcvm.2019.00181; Lazzerini PE, 2019, NAT REV IMMUNOL, V19, P63, DOI 10.1038/s41577-018-0098-z; Lazzerini PE, 2016, CIRC-ARRHYTHMIA ELEC, V9, DOI 10.1161/CIRCEP.115.003419; Lee SW, 1997, NAT BIOTECHNOL, V15, P41, DOI 10.1038/nbt0197-41; Li HL, 2015, HYPERTENSION, V65, P793, DOI 10.1161/HYPERTENSIONAHA.114.05037; Li YP, 2020, ARTHRITIS RES THER, V22, DOI 10.1186/s13075-020-02169-0; Lindop R, 2013, CLIN IMMUNOL, V148, P27, DOI 10.1016/j.clim.2013.03.015; Moss AJ, 2003, JAMA-J AM MED ASSOC, V289, P2041, DOI 10.1001/jama.289.16.2041; Nakamura K, 2007, J AM COLL CARDIOL, V50, P1808, DOI 10.1016/j.jacc.2007.07.037; Natsuga K, 2012, J IMMUNOL, V188, P5792, DOI 10.4049/jimmunol.1003402; Raposo B, 2014, J EXP MED, V211, P405, DOI 10.1084/jem.20130968; Reed JH, 2010, ARTHRITIS RHEUM-US, V62, P1448, DOI 10.1002/art.27370; Sanders P, 2011, J MOL ENDOCRINOL, V46, P81, DOI 10.1530/JME-10-0127; Seo HS, 2000, J MICROBIOL BIOTECHN, V10, P707; Shiroishi M, 2018, J BIOL CHEM, V293, P7008, DOI 10.1074/jbc.M117.814475; Sisirak V, 2016, CELL, V166, P88, DOI 10.1016/j.cell.2016.05.034; Stein AJ, 2005, CELL, V121, P529, DOI 10.1016/j.cell.2005.03.009; Tunyasuvunakool K, 2021, NATURE, V596, P590, DOI 10.1038/s41586-021-03828-1; VanPatten S, 2016, J MED CHEM, V59, P8859, DOI 10.1021/acs.jmedchem.6b00694; Vazquez-Lombardi R, 2015, DRUG DISCOV TODAY, V20, P1271, DOI 10.1016/j.drudis.2015.09.004; Wang D, 2017, NUCLEIC ACIDS RES, V45, pD769, DOI 10.1093/nar/gkw946; Wei XL, 2016, BIOMATERIALS, V111, P116, DOI 10.1016/j.biomaterials.2016.10.003; Wolin SL, 2006, AUTOIMMUN REV, V5, P367, DOI 10.1016/j.autrev.2005.10.004; Yue YK, 2015, CIRCULATION, V132, P230, DOI 10.1161/CIRCULATIONAHA.115.009800	45	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 28	2022	13								812649	10.3389/fimmu.2022.812649	http://dx.doi.org/10.3389/fimmu.2022.812649			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZG8YW	35154130	Green Published, gold			2022-12-18	WOS:000760539300001
J	Colden, MA; Kumar, S; Munkhbileg, B; Babushok, DV				Colden, Melissa A.; Kumar, Sushant; Munkhbileg, Bolormaa; Babushok, Daria V.			Insights Into the Emergence of Paroxysmal Nocturnal Hemoglobinuria	FRONTIERS IN IMMUNOLOGY			English	Review						paroxysmal nocturnal hemoglobinuria; PIGA; GPI-anchored; aplastic anemia (AA); bone marrow failure (BMF); autoimmunity; complement; clonal hematopoeisis	PIG-A GENE; GLYCOSYLPHOSPHATIDYLINOSITOL-ANCHORED PROTEINS; DECAY-ACCELERATING FACTOR; COMPLEMENT INHIBITOR ECULIZUMAB; NATURAL-KILLER-CELLS; APLASTIC-ANEMIA; SOMATIC MUTATIONS; STEM-CELLS; HEMATOPOIETIC-CELLS; BLOOD-CELLS	Paroxysmal Nocturnal Hemoglobinuria (PNH) is a disease as simple as it is complex. PNH patients develop somatic loss-of-function mutations in phosphatidylinositol N-acetylglucosaminyltransferase subunit A gene (PIGA), required for the biosynthesis of glycosylphosphatidylinositol (GPI) anchors. Ubiquitous in eukaryotes, GPI anchors are a group of conserved glycolipid molecules responsible for attaching nearly 150 distinct proteins to the surface of cell membranes. The loss of two GPI-anchored surface proteins, CD55 and CD59, from red blood cells causes unregulated complement activation and hemolysis in classical PNH disease. In PNH patients, PIGA-mutant, GPI (-) hematopoietic cells clonally expand to make up a large portion of patients' blood production, yet mechanisms leading to clonal expansion of GPI (-) cells remain enigmatic. Historical models of PNH in mice and the more recent PNH model in rhesus macaques showed that GPI (-) cells reconstitute near-normal hematopoiesis but have no intrinsic growth advantage and do not clonally expand over time. Landmark studies identified several potential mechanisms which can promote PNH clonal expansion. However, to what extent these contribute to PNH cell selection in patients continues to be a matter of active debate. Recent advancements in disease models and immunologic technologies, together with the growing understanding of autoimmune marrow failure, offer new opportunities to evaluate the mechanisms of clonal expansion in PNH. Here, we critically review published data on PNH cell biology and clonal expansion and highlight limitations and opportunities to further our understanding of the emergence of PNH clones.	[Colden, Melissa A.; Kumar, Sushant; Munkhbileg, Bolormaa; Babushok, Daria V.] Univ Penn, Div Hematol Oncol, Dept Med, Philadelphia, PA 19104 USA; [Colden, Melissa A.; Kumar, Sushant; Munkhbileg, Bolormaa; Babushok, Daria V.] Childrens Hosp Philadelphia, Dept Pediat, Comprehens Bone Marrow Failure Ctr, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Babushok, DV (corresponding author), Univ Penn, Div Hematol Oncol, Dept Med, Philadelphia, PA 19104 USA.; Babushok, DV (corresponding author), Childrens Hosp Philadelphia, Dept Pediat, Comprehens Bone Marrow Failure Ctr, Philadelphia, PA 19104 USA.	daria.babushok@pennmedicine.upenn.edu		Kumar, Sushant/0000-0002-7983-6761				Apweiler R, 2004, NUCLEIC ACIDS RES, V32, pD115, DOI 10.1093/nar/gkh131; Araten DJ, 1999, P NATL ACAD SCI USA, V96, P5209, DOI 10.1073/pnas.96.9.5209; Babushok DV, 2015, CANCER GENET-NY, V208, P115, DOI 10.1016/j.cancergen.2015.01.007; Babushok DV, 2017, BLOOD ADV, V1, P1900, DOI 10.1182/bloodadvances.2017010918; Barcellini W, 2004, HAEMATOLOGICA, V89, P651; Belet S, 2014, HUM MUTAT, V35, P350, DOI 10.1002/humu.22498; BESSLER M, 1994, EMBO J, V13, P110, DOI 10.1002/j.1460-2075.1994.tb06240.x; Blazar BR, 1998, BLOOD, V92, P4453, DOI 10.1182/blood.V92.11.4453.423k10_4453_4463; Boegel S, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/21624011.2014.954893; Bolden JE, 2018, J LEUKOCYTE BIOL, V104, P123, DOI 10.1002/JLB.1MA1217-475R; Britten CM, 2002, J IMMUNOL METHODS, V259, P95, DOI 10.1016/S0022-1759(01)00499-9; Brodsky RA, 1997, P NATL ACAD SCI USA, V94, P8756, DOI 10.1073/pnas.94.16.8756; Brodsky RA, 2008, BLOOD, V111, P1840, DOI 10.1182/blood-2007-06-094136; Brodsky RA, 2014, BLOOD, V124, P2804, DOI 10.1182/blood-2014-02-522128; Cannizzo E, 2019, ANN HEMATOL, V98, P1083, DOI 10.1007/s00277-019-03644-8; Chen G, 2005, LEUKEMIA, V19, P862, DOI 10.1038/sj.leu.2403678; Chen GB, 2002, EXP HEMATOL, V30, P774, DOI 10.1016/S0301-472X(02)00811-1; Chen R, 2000, J CLIN INVEST, V106, P689, DOI 10.1172/JCI8328; Chen YY, 2021, HEMATOLOGY, V26, P491, DOI 10.1080/16078454.2021.1945244; Choi J, 2019, NUCLEIC ACIDS RES, V47, pD780, DOI 10.1093/nar/gky1020; DAMESHEK W, 1967, BLOOD-J HEMATOL, V30, P251; De Graaf CA, 2016, STEM CELL REP, V7, P571, DOI 10.1016/j.stemcr.2016.07.007; DeZern AE, 2014, EUR J HAEMATOL, V92, P467, DOI 10.1111/ejh.12299; Dingli D, 2008, P NATL ACAD SCI USA, V105, P18496, DOI 10.1073/pnas.0802749105; Dunn DE, 1996, P NATL ACAD SCI USA, V93, P7938, DOI 10.1073/pnas.93.15.7938; ERUSALIMSKY JD, 1989, P NATL ACAD SCI USA, V86, P1973, DOI 10.1073/pnas.86.6.1973; Fattizzo B, 2021, LEUKEMIA, V35, P3223, DOI 10.1038/s41375-021-01190-9; Fauth C, 2016, AM J MED GENET A, V170, P392, DOI 10.1002/ajmg.a.37452; Gargiulo L, 2007, BLOOD, V109, P5036, DOI 10.1182/blood-2006-10-052381; Gargiulo L, 2017, BLOOD, V129, P388, DOI 10.1182/blood-2016-09-740845; Gargiulo L, 2013, BLOOD, V121, P2753, DOI 10.1182/blood-2012-11-469353; Gavriilaki Eleni, 2022, Blood, V139, P3571, DOI 10.1182/blood.2021012860; Godfrey DI, 2010, SEMIN IMMUNOL, V22, P61, DOI 10.1016/j.smim.2009.10.004; Hanaoka N, 2006, BLOOD, V107, P1184, DOI 10.1182/blood-2005-03-1337; Hanaoka N, 2013, BRIT J HAEMATOL, V160, P114, DOI 10.1111/bjh.12093; Hanaoka N, 2009, BRIT J HAEMATOL, V146, P538, DOI 10.1111/j.1365-2141.2009.07795.x; Hazenbos WLW, 2004, J IMMUNOL, V173, P3810, DOI 10.4049/jimmunol.173.6.3810; Hazenbos WLW, 2011, BLOOD, V118, P4377, DOI 10.1182/blood-2011-02-338053; Hill A, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.28; HILLMEN P, 1993, P NATL ACAD SCI USA, V90, P5272, DOI 10.1073/pnas.90.11.5272; Hillmen P, 2021, NEW ENGL J MED, V384, P1028, DOI 10.1056/NEJMoa2029073; Hillmen P, 2006, NEW ENGL J MED, V355, P1233, DOI 10.1056/NEJMoa061648; Holt DS, 2001, BLOOD, V98, P442, DOI 10.1182/blood.V98.2.442; Horikawa K, 1997, BLOOD, V90, P2716, DOI 10.1182/blood.V90.7.2716.2716_2716_2722; Hu R, 2005, BLOOD, V105, P3848, DOI 10.1182/blood-2004-04-1472; IIDA Y, 1994, BLOOD, V83, P3126, DOI 10.1182/blood.V83.11.3126.bloodjournal83113126; Ismail MM, 2003, BRIT J HAEMATOL, V123, P545, DOI 10.1046/j.1365-2141.2003.04643.x; Jahng A, 2004, J EXP MED, V199, P947, DOI 10.1084/jem.20031389; Jang JH., 2021, EHA 2021 HEM VIRT C, P42, DOI [10.1097/HS9.0000000000000566, DOI 10.1097/HS9.0000000000000566]; Jasinski M, 2001, BLOOD, V98, P2248, DOI 10.1182/blood.V98.7.2248; Johnston JJ, 2012, AM J HUM GENET, V90, P295, DOI 10.1016/j.ajhg.2011.11.031; Joyce S, 1998, SCIENCE, V279, P1541, DOI 10.1126/science.279.5356.1541; Kato M, 2014, NEUROLOGY, V82, P1587, DOI 10.1212/WNL.0000000000000389; KAWAGOE K, 1994, GENOMICS, V23, P566, DOI 10.1006/geno.1994.1544; Kawagoe K, 1996, BLOOD, V87, P3600, DOI 10.1182/blood.V87.9.3600.bloodjournal8793600; Keller P, 1999, P NATL ACAD SCI USA, V96, P7479, DOI 10.1073/pnas.96.13.7479; Keller P, 2001, J EXP MED, V194, P581, DOI 10.1084/jem.194.5.581; Kulasekararaj AG, 2021, BLOOD, V138, P1928, DOI 10.1182/blood.2021011388; Kulasekararaj AG, 2019, BLOOD, V133, P540, DOI 10.1182/blood-2018-09-876805; Kulasekararaj AG, 2014, BLOOD, V124, P2698, DOI 10.1182/blood-2014-05-574889; Kulkarni S, 2003, EXP HEMATOL, V31, P770, DOI 10.1016/S0301-472X(03)00189-9; Kulkarni S, 2002, J LEUKOCYTE BIOL, V72, P1228; Kumar Sushant, 2021, Blood Cells Mol Dis, V92, P102622, DOI 10.1016/j.bcmd.2021.102622; Kunyaboon Rajita, 2012, Hematol Oncol Stem Cell Ther, V5, P138, DOI 10.5144/1658-3876.2012.138; Lee JW, 2019, BLOOD, V133, P530, DOI 10.1182/blood-2018-09-876136; Lin F, 2001, IMMUNOLOGY, V104, P215, DOI 10.1046/j.1365-2567.2001.01287.x; Luzzatto L, 1997, CELL, V88, P1, DOI 10.1016/S0092-8674(00)81850-4; Luzzatto L, 2019, BRIT J HAEMATOL, V184, P465, DOI 10.1111/bjh.15111; Luzzatto Lucio, 2016, F1000Res, V5, DOI 10.12688/f1000research.7288.1; Macho-Fernandez E, 2015, FRONT IMMUNOL, V6, P1, DOI 10.3389/fimmu.2015.00362; Maciejewski JP, 2001, BLOOD, V98, P3513, DOI 10.1182/blood.V98.13.3513; Mannik LA, 2011, IMMUNOLOGY, V132, P361, DOI 10.1111/j.1365-2567.2010.03369.x; Marsman C, 2018, IMMUNOL CELL BIOL, V96, P1083, DOI 10.1111/imcb.12173; Masuishi Y, 2016, J PROTEOMICS, V139, P77, DOI 10.1016/j.jprot.2016.03.008; McArdel SL, 2016, CLIN IMMUNOL, V164, P10, DOI 10.1016/j.clim.2016.01.008; Miwa T, 2002, BLOOD, V99, P3707, DOI 10.1182/blood.V99.10.3707; MIYATA T, 1993, SCIENCE, V259, P1318, DOI 10.1126/science.7680492; MOLINA H, 1992, J EXP MED, V175, P121, DOI 10.1084/jem.175.1.121; Monaco G, 2019, CELL REP, V26, P1627, DOI 10.1016/j.celrep.2019.01.041; Murakami Y, 2002, BLOOD, V100, P4116, DOI 10.1182/blood-2002-06-1669; Murakami Y, 1999, BLOOD, V94, P2963, DOI 10.1182/blood.V94.9.2963.421k18_2963_2970; Murakami Y, 2012, BRIT J HAEMATOL, V156, P383, DOI 10.1111/j.1365-2141.2011.08914.x; Nagakura S, 2002, BLOOD, V100, P1031, DOI 10.1182/blood.V100.3.1031; Nakao S, 1997, BLOOD, V89, P3691, DOI 10.1182/blood.V89.10.3691.3691_3691_3699; NAKAO S, 1995, EXP HEMATOL, V23, P433; Negoro E, 2017, BLOOD, V130, P1953, DOI 10.1182/blood-2017-02-767731; Nishimura JI, 2004, MEDICINE, V83, P193, DOI 10.1097/01.md.0000126763.68170.46; Nozaki M, 1999, LAB INVEST, V79, P293; Paulick MG, 2008, BIOCHEMISTRY-US, V47, P6991, DOI 10.1021/bi8006324; Procopio DO, 2002, J IMMUNOL, V169, P3926, DOI 10.4049/jimmunol.169.7.3926; Qin XB, 2003, IMMUNITY, V18, P217, DOI 10.1016/S1074-7613(03)00022-0; Richards SJ, 2009, CYTOM PART B-CLIN CY, V76B, P47, DOI 10.1002/cyto.b.20438; Risitano AM., 2021, EHA HEM VIRT C, P704; Risitano AM, 2021, HAEMATOLOGICA, V106, P3188, DOI 10.3324/haematol.2020.261826; ROSSE WF, 1974, BRIT J HAEMATOL, V28, P181; Rosti V, 1997, J CLIN INVEST, V100, P1028, DOI 10.1172/JCI119613; Saunthararajah Y, 2002, BLOOD, V100, P1570, DOI 10.1182/blood.V100.5.1570.h81702001570_1570_1574; Savage WJ, 2007, HEMATOLOGY, V12, P371, DOI 10.1080/10245330701562634; Savage WJ, 2009, EXP HEMATOL, V37, P42, DOI 10.1016/j.exphem.2008.09.002; Schofield L, 1999, SCIENCE, V283, P225, DOI 10.1126/science.283.5399.225; Shah YB, 2021, BLOOD ADV, V5, P3216, DOI 10.1182/bloodadvances.2021004201; Shen WY, 2014, J CLIN INVEST, V124, P4529, DOI 10.1172/JCI74747; Shi W, 2015, NAT IMMUNOL, V16, P663, DOI 10.1038/ni.3154; Shichishima T, 2001, Rinsho Byori, V49, P986; Shin TH, 2019, BLOOD, V133, P2542, DOI 10.1182/blood.2019000800; Smrz D, 2007, J BIOL CHEM, V282, P10487, DOI 10.1074/jbc.M611090200; Socie G, 1996, LANCET, V348, P573, DOI 10.1016/S0140-6736(95)12360-1; SPICER AP, 1995, J IMMUNOL, V155, P3079; Sugimori C, 2009, BRIT J HAEMATOL, V147, P102, DOI 10.1111/j.1365-2141.2009.07822.x; Suny XJ, 1999, P NATL ACAD SCI USA, V96, P628, DOI 10.1073/pnas.96.2.628; TAKEDA J, 1993, CELL, V73, P703, DOI 10.1016/0092-8674(93)90250-T; Tarutani M, 1997, P NATL ACAD SCI USA, V94, P7400, DOI 10.1073/pnas.94.14.7400; Tominaga R, 2016, LEUKEMIA, V30, P1208, DOI 10.1038/leu.2015.268; Tremml G, 1999, BLOOD, V94, P2945, DOI 10.1182/blood.V94.9.2945.421k35_2945_2954; Ueda Y, 2016, IMMUNOBIOLOGY, V221, P1080, DOI 10.1016/j.imbio.2016.06.007; Uhlen M, 2015, SCIENCE, V347, DOI 10.1126/science.1260419; Um JW, 2017, TRENDS CELL BIOL, V27, P931, DOI 10.1016/j.tcb.2017.06.007; Visconte V, 2010, HAEMATOL-HEMATOL J, V95, P214, DOI 10.3324/haematol.2009.011650; Ware RE, 1998, BLOOD, V92, P2541, DOI 10.1182/blood.V92.7.2541.2541_2541_2550; Yamamoto T, 2002, EXP HEMATOL, V30, P187, DOI 10.1016/S0301-472X(01)00783-4; Yoshizato T, 2015, NEW ENGL J MED, V373, P35, DOI 10.1056/NEJMoa1414799; Zaimoku Y, 2017, BLOOD, V129, P2908, DOI 10.1182/blood-2016-11-752378; Zhang YL, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.705260	123	0	0	4	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 28	2022	12								830172	10.3389/fimmu.2021.830172	http://dx.doi.org/10.3389/fimmu.2021.830172			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZG9YT	35154088	gold, Green Published			2022-12-18	WOS:000760607300001
J	Gao, H; Ju, FR; Ti, RJ; Zhang, Y; Zhang, SX				Gao, Hao; Ju, Furong; Ti, Rujuan; Zhang, Yue; Zhang, Shengxiang			Differential Regulation of Microglial Activation in Response to Different Degree of Ischemia	FRONTIERS IN IMMUNOLOGY			English	Article						transcriptome; microglia; activation; proliferation; ischemia; inflammation	GLOBAL CEREBRAL-ISCHEMIA; GENE-EXPRESSION; STROKE; CELL; PROLIFERATION; MECHANISMS; MICROGLIA/MACROPHAGES; NEUROINFLAMMATION; TRANSFORMATION; NEUROGENESIS	Microglia are primary immune cells within the brain and are rapidly activated after cerebral ischemia. The degree of microglial activation is closely associated with the severity of ischemia. However, it remains largely unclear how microglial activation is differentially regulated in response to a different degree of ischemia. In this study, we used a bilateral common carotid artery ligation (BCAL) model and induced different degrees of ischemia by varying the duration of ligation to investigate the microglial response in CX3CR1(GFP/+) mice. Confocal microscopy, immunofluorescence staining, RNA sequencing, and qRT-PCR were used to evaluate the de-ramification, proliferation, and differential gene expression associated with microglial activation. Our results showed that 30 min of ischemia induced rapid de-ramification of microglia but did not have significant influence on the microglial density. In contrast, 60 min of ischemia led to a significant decrease in microglial density and more pronounced de-ramification of microglial processes. Importantly, 30 min of ischemia did not induce proliferation of microglia, but 60 min of ischemia led to a marked increase in the density of proliferative microglia. Further analysis utilized transcriptome sequencing showed that microglial activation is differentially regulated in response to different degrees of ischemia. A total of 1,097 genes were differentially regulated after 60 min of ischemia, but only 68 genes were differentially regulated after 30 min of ischemia. Pathway enrichment analysis showed that apoptosis, cell mitosis, immune receptor activity and inflammatory-related pathways were highly regulated after 60 min of ischemia compared to 30 min of ischemia. Multiple microglia-related genes such as Cxcl10, Tlr7, Cd86, Tnfrsf1a, Nfkbia, Tgfb1, Ccl2 and Il-6, were upregulated with prolonged ischemia. Pharmacological inhibition of CSF1 receptor demonstrated that CSF1R signaling pathway contributed to microglial proliferation. Together, these results suggest that the proliferation of microglia is gated by the duration of ischemia and microglia were differentially activated in responding to different degrees of ischemia.	[Gao, Hao; Ju, Furong; Ti, Rujuan; Zhang, Yue; Zhang, Shengxiang] Lanzhou Univ, Sch Life Sci, Gansu Key Lab Biomonitoring & Bioremediat Environ, Lanzhou, Peoples R China	Lanzhou University	Zhang, SX (corresponding author), Lanzhou Univ, Sch Life Sci, Gansu Key Lab Biomonitoring & Bioremediat Environ, Lanzhou, Peoples R China.	sxzhang@lzu.edu.cn						Akins PT, 1996, STROKE, V27, P1682, DOI 10.1161/01.STR.27.9.1682; Andreev DE, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0651-z; Asano S, 2016, CURR OPIN PHARMACOL, V26, P80, DOI 10.1016/j.coph.2015.10.004; Askew K, 2017, CELL REP, V18, P391, DOI 10.1016/j.celrep.2016.12.041; Bangsow T, 2008, J CEREBR BLOOD F MET, V28, P1249, DOI 10.1038/jcbfm.2008.19; Barr TL, 2010, NEUROLOGY, V75, P1009, DOI 10.1212/WNL.0b013e3181f2b37f; Biber K, 2007, TRENDS NEUROSCI, V30, P596, DOI 10.1016/j.tins.2007.08.007; Bruttger J, 2015, IMMUNITY, V43, P92, DOI 10.1016/j.immuni.2015.06.012; Chang F, 2003, LEUKEMIA, V17, P590, DOI 10.1038/sj.leu.2402824; Deckert M, 2006, ACTA NEUROPATHOL, V111, P548, DOI 10.1007/s00401-006-0062-z; Denes A, 2007, J CEREBR BLOOD F MET, V27, P1941, DOI 10.1038/sj.jcbfm.9600495; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; dos Santos IRC, 2021, NEURAL REGEN RES, V16, P456, DOI 10.4103/1673-5374.291383; Elmore MRP, 2014, NEURON, V82, P380, DOI 10.1016/j.neuron.2014.02.040; Gao G, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00161; Halleskog C., 2011, GLIA, V23, P1, DOI [10.1002/glia.21081.WNT, DOI 10.1002/GLIA.21081.WNT]; Hawkins PT, 2015, BBA-MOL CELL BIOL L, V1851, P882, DOI 10.1016/j.bbalip.2014.12.006; Hu X, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/6801587; Hu XM, 2012, STROKE, V43, P3063, DOI 10.1161/STROKEAHA.112.659656; Huang YB, 2018, NAT NEUROSCI, V21, P530, DOI 10.1038/s41593-018-0090-8; Imai F, 2007, J CEREBR BLOOD F MET, V27, P488, DOI 10.1038/sj.jcbfm.9600362; Intervention FOR., 1996, INJURY, V106, P1563, DOI [10.1161/01.CIR.0000030406.47365.26, DOI 10.1161/01.CIR.0000030406.47365.26]; Jayaraj RL, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974-019-1516-2; Ji J, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01241; Jin R, 2010, J LEUKOCYTE BIOL, V87, P779, DOI 10.1189/jlb.1109766; Ju FR, 2018, FRONT CELL NEUROSCI, V12, DOI 10.3389/fncel.2018.00236; Kanazawa M, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18102135; Kettenmann H, 2013, NEURON, V77, P10, DOI 10.1016/j.neuron.2012.12.023; Kettenmann H, 2011, PHYSIOL REV, V91, P461, DOI 10.1152/physrev.00011.2010; Khan A, 2017, NEUROSCIENCE, V348, P212, DOI 10.1016/j.neuroscience.2017.02.019; Khoshnam SE, 2017, NEUROL SCI, V38, P1167, DOI 10.1007/s10072-017-2938-1; Kierdorf K, 2017, J CLIN INVEST, V127, P3201, DOI [10.1172/JCI90602, 10.1172/jci90602]; Lau SF, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107530; Li T, 2021, J NEUROINFLAMM, V18, DOI 10.1186/s12974-021-02127-w; Li T, 2013, BRAIN, V136, P3578, DOI 10.1093/brain/awt287; Liao B, 2012, EXP NEUROL, V237, P147, DOI 10.1016/j.expneurol.2012.06.011; Liddelow SA, 2017, NATURE, V541, P481, DOI 10.1038/nature21029; Liu JL, 2001, J CEREBR BLOOD F MET, V21, P361, DOI 10.1097/00004647-200104000-00005; Liu L, 2021, STROKE, V52, P274, DOI 10.1161/STROKEAHA.120.032766; Lively S, 2018, FRONT CELL NEUROSCI, V12, DOI 10.3389/fncel.2018.00215; Lively S, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-75; Lodge PA, 1996, J LEUKOCYTE BIOL, V60, P502, DOI 10.1002/jlb.60.4.502; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Ma YY, 2017, PROG NEUROBIOL, V157, P247, DOI 10.1016/j.pneurobio.2016.01.005; Miyamoto A, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12540; Morrison HW, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-4; Neal ML, 2020, FASEB J, V34, P1679, DOI 10.1096/fj.201900567RR; Ofengeim D, 2017, P NATL ACAD SCI USA, V114, pE8788, DOI 10.1073/pnas.1714175114; Olmos G, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/861231; Orihuela R, 2016, BRIT J PHARMACOL, V173, P649, DOI 10.1111/bph.13139; Otxoa-de-Amezaga A, 2019, ACTA NEUROPATHOL, V137, P321, DOI 10.1007/s00401-018-1954-4; Pan HC, 2013, EUR J IMMUNOL, V43, P2854, DOI 10.1002/eji.201343301; Patel Anita R, 2013, Int J Physiol Pathophysiol Pharmacol, V5, P73; Peferoen L, 2014, IMMUNOLOGY, V141, P302, DOI 10.1111/imm.12163; Remington LT, 2007, AM J PATHOL, V170, P1713, DOI 10.2353/ajpath.2007.060783; Rogove AD, 2002, CELL DEATH DIFFER, V9, P801, DOI 10.1038/sj.cdd.4401041; Schroeter M, 1997, STROKE, V28, P382, DOI 10.1161/01.STR.28.2.382; Stanley ER, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a021857; Szalay G, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11499; Tan YL, 2020, MOL PSYCHIATR, V25, P351, DOI 10.1038/s41380-019-0609-8; Thion MS, 2018, SCIENCE, V362, P185, DOI 10.1126/science.aat0474; Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621; Tubbs Justin D, 2020, Brain Behav Immun Health, V7, P100108, DOI 10.1016/j.bbih.2020.100108; Unger MS, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1304-4; Wang J, 2018, BIOMED PHARMACOTHER, V105, P518, DOI 10.1016/j.biopha.2018.05.143; Weinhard L, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03566-5; Weinstein JR, 2010, FUTUR NEUROL, V5, P227, DOI 10.2217/FNL.10.1; Widera D, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-64; Wright GJ, 2001, IMMUNOLOGY, V102, P173, DOI 10.1046/j.1365-2567.2001.01163.x; Wu TZ, 2021, INNOVATION-AMSTERDAM, V2, DOI 10.1016/j.xinn.2021.100141; Xing F, 2018, CANCER RES, V78, P4316, DOI 10.1158/0008-5472.CAN-18-1102; Xiong XY, 2016, PROG NEUROBIOL, V142, P23, DOI 10.1016/j.pneurobio.2016.05.001; Xu DK, 2021, CNS NEUROSCI THER, V27, P674, DOI 10.1111/cns.13626; Yan ZQ, 2018, CLIN IMMUNOL, V189, P4, DOI 10.1016/j.clim.2016.09.014; Yu GC, 2010, BIOINFORMATICS, V26, P976, DOI 10.1093/bioinformatics/btq064; Zhang B, 2017, NEUROSCI LETT, V645, P113, DOI 10.1016/j.neulet.2017.03.001; Zhang SX, 2019, STROKE VASC NEUROL, V4, P71, DOI 10.1136/svn-2018-000196; Zhang Y, 2016, NEURON, V89, P37, DOI 10.1016/j.neuron.2015.11.013; Zhang Y, 2014, J NEUROSCI, V34, P11929, DOI [10.1523/JNEUROSCI.1860-14.2014, 10.11772/j.issn.1001-9081.2014.07.1929]; Zhao SC, 2017, ACTA PHARMACOL SIN, V38, P445, DOI 10.1038/aps.2016.162; Zhu LR, 2017, J CEREBR BLOOD F MET, V37, P2756, DOI 10.1177/0271678X16674736; Zhu LR, 2017, EXP NEUROL, V289, P1, DOI 10.1016/j.expneurol.2016.12.002	82	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 28	2022	13								792638	10.3389/fimmu.2022.792638	http://dx.doi.org/10.3389/fimmu.2022.792638			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZG9YL	35154109	Green Published, gold			2022-12-18	WOS:000760606500001
J	Gong, NY; Shi, L; Bing, X; Li, H; Hu, HY; Zhang, P; Yang, HM; Guo, N; Du, HJ; Xia, M; Liu, CC				Gong, Ningyue; Shi, Lei; Bing, Xin; Li, Hui; Hu, Houyang; Zhang, Pan; Yang, Huiming; Guo, Na; Du, Hongjie; Xia, Ming; Liu, Chengcheng			S100A4/TCF Complex Transcription Regulation Drives Epithelial-Mesenchymal Transition in Chronic Sinusitis Through Wnt/GSK-3 beta/beta-Catenin Signaling	FRONTIERS IN IMMUNOLOGY			English	Article						CRS; epigenetic regulation; EMT; inflammation	WNT/BETA-CATENIN PATHWAY; CALCIUM-BINDING PROTEIN; CHRONIC RHINOSINUSITIS; METASTATIC PHENOTYPE; BREAST-CANCER; S100 PROTEINS; CELL MOTILITY; MATRIX; AIRWAY; MTS1	Epithelial-mesenchymal transition (EMT) is thought to be involved in the tissue remodeling and long-term inflammatory process of chronic sinusitis (CRS), but the driving mechanism is still unclear. Using high-resolution mass spectrometry, we performed a proteomic screen of CRS nasal mucosal tissue to identify differentially expressed proteins. Data are available via ProteomeXchange with identifier PXD030884. Specifically, we identified S100 calcium binding protein A4 (S100A4), an effective factor in inflammation-related diseases, and its downstream protein closely related to tissue fibrosis collagen type I alpha 1 chain (COL1A1), which suggested its involvement in nasal mucosal tissue remodeling. In addition, stimulation of human nasal epithelial cells (HNEpCs) with lipopolysaccharide (LPS) mimicked the inflammatory environment of CRS and showed that S100A4 is involved in regulating EMT and thus accelerating tissue remodeling in the nasal mucosa, both in terms of increased cell motility and overexpression of mesenchymal-type proteins. Additionally, we further investigated the regulation mechanism of S100A4 involved in EMT in CRS. Our research results show that in the inflammatory environment of CRS nasal mucosal epithelial cells, TCF-4 will target to bind to S100A4 and regulate its transcription. The transcription of S100A4 in turn affects the execution of the important signaling pathway in EMT, the Wnt/GSK-3 beta/beta-catenin pathway, through the TCF-4/beta-catenin complex. In conclusion, this study confirmed that the expression of S100A4 was significantly increased during the progressive EMT process of CRS mucosal epithelial cells, and revealed that the transcriptional regulation of S100A4 plays an important role in the occurrence and development of EMT. This finding will help us to better understand the pathogenesis behind the remodeling in CRS patients, and identify target molecules for the treatment of CRS.	[Gong, Ningyue; Shi, Lei; Bing, Xin; Li, Hui; Hu, Houyang; Zhang, Pan; Yang, Huiming; Guo, Na; Xia, Ming] Shandong First Med Univ, Shandong Prov Hosp, Dept Otolaryngol, Jinan, Peoples R China; [Gong, Ningyue; Bing, Xin; Xia, Ming] Shandong Univ, Shandong Prov Hosp, Cheeloo Coll Med, Dept Otolaryngol, Jinan, Peoples R China; [Du, Hongjie] Qilu Pharmaceut CoLtd, Dept Biotechnol Res & Dev, Jinan, Peoples R China; [Liu, Chengcheng] Shandong First Med Univ, Shandong Prov Hosp, Cent Lab, Jinan, Peoples R China	Shandong First Medical University & Shandong Academy of Medical Sciences; Shandong First Medical University & Shandong Academy of Medical Sciences; Shandong University; Shandong First Medical University & Shandong Academy of Medical Sciences	Xia, M (corresponding author), Shandong First Med Univ, Shandong Prov Hosp, Dept Otolaryngol, Jinan, Peoples R China.; Xia, M (corresponding author), Shandong Univ, Shandong Prov Hosp, Cheeloo Coll Med, Dept Otolaryngol, Jinan, Peoples R China.; Liu, CC (corresponding author), Shandong First Med Univ, Shandong Prov Hosp, Cent Lab, Jinan, Peoples R China.	xiamingsdu@sohu.com; LCcheng211314@126.com			Medical Science and Technology Innovation Center, Shandong First Medical University & Shandong Academy of Medical Sciences; National Natural Science Foundation of China [81770979, 82071013, 81900922]; Natural Science Foundation of Shandong Province [ZR2019BH019]; Taishan Scholar Foundation of Shandong Province [tsqn201812134]	Medical Science and Technology Innovation Center, Shandong First Medical University & Shandong Academy of Medical Sciences; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Shandong Province(Natural Science Foundation of Shandong Province); Taishan Scholar Foundation of Shandong Province	This work was supported by the grants from the Medical Science and Technology Innovation Center, Shandong First Medical University & Shandong Academy of Medical Sciences, the National Natural Science Foundation of China (#81770979, #82071013, #81900922), Natural Science Foundation of Shandong Province (#ZR2019BH019) and Taishan Scholar Foundation of Shandong Province (#tsqn201812134).	Nieto MA, 2016, CELL, V166, P21, DOI 10.1016/j.cell.2016.06.028; Austermann J, 2017, EXPERT OPIN THER TAR, V21, P739, DOI 10.1080/14728222.2017.1330411; Bachert C, 2020, NAT REV DIS PRIMERS, V6, DOI 10.1038/s41572-020-00218-1; Barmeyer C, 2015, SEMIN CELL DEV BIOL, V42, P30, DOI 10.1016/j.semcdb.2015.05.006; Bertheloot D, 2017, CELL MOL IMMUNOL, V14, P43, DOI 10.1038/cmi.2016.34; Boteanu RM, 2017, J PROTEOMICS, V153, P21, DOI 10.1016/j.jprot.2016.11.006; Bowers RR, 2012, BIOCHEMISTRY-US, V51, P7740, DOI 10.1021/bi301006w; Bresnick AR, 2015, NAT REV CANCER, V15, P96, DOI 10.1038/nrc3893; Burock S, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4197-9; Carroll WW, 2016, INT FORUM ALLERGY RH, V6, P162, DOI 10.1002/alr.21636; Chow KH, 2017, CANCER RES, V77, P5360, DOI 10.1158/0008-5472.CAN-17-1294; Christensen MHE, 2015, EUR J ENDOCRINOL, V173, P9, DOI 10.1530/EJE-14-1038; Dahlmann M, 2016, CANCERS, V8, DOI 10.3390/cancers8060059; DAVIES BR, 1993, ONCOGENE, V8, P999; Deutsch EW, 2020, NUCLEIC ACIDS RES, V48, pD1145, DOI 10.1093/nar/gkz984; Donato R, 2013, CURR MOL MED, V13, P24, DOI 10.2174/156652413804486214; Fei F, 2017, CELL BIOSCI, V7, DOI 10.1186/s13578-017-0191-1; Fei F, 2017, ONCOTARGET, V8, P73219, DOI 10.18632/oncotarget.18016; Fokkens WJ, 2012, RHINOLOGY, V50, P1, DOI 10.4193/Rhin20.600; Forte E, 2017, CANCERS, V9, DOI 10.3390/cancers9080098; Gao C, 2010, CELL SIGNAL, V22, P717, DOI 10.1016/j.cellsig.2009.11.021; Garcia de Herreros A, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8101148; Gong T, 2020, NAT REV IMMUNOL, V20, P95, DOI 10.1038/s41577-019-0215-7; Gong XJ, 2015, EUR REV MED PHARMACO, V19, P2221; Grigorian M, 1996, INT J CANCER, V67, P831, DOI 10.1002/(SICI)1097-0215(19960917)67:6<831::AID-IJC13>3.0.CO;2-4; Grossman J, 1997, CHEST, V111, pS11, DOI 10.1378/chest.111.2_Supplement.11S; Grum-Schwensen B, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1034-2; Hammad H, 2015, IMMUNITY, V43, P29, DOI 10.1016/j.immuni.2015.07.007; Hansen MT, 2015, ONCOGENE, V34, P424, DOI 10.1038/onc.2013.568; Harada K, 2017, PEDIATR SURG INT, V33, P1243, DOI 10.1007/s00383-017-4154-8; Hoggard M, 2021, IMMUN INFLAMM DIS, V9, P90, DOI 10.1002/iid3.349; Holgate ST, 2011, IMMUNOL REV, V242, P205, DOI 10.1111/j.1600-065X.2011.01030.x; Homsi MT., 2020, STATPEARLS; Jiao J, 2019, EXPERT REV CLIN IMMU, V15, P679, DOI 10.1080/1744666X.2019.1601556; Jolly MK, 2017, MOL ONCOL, V11, P755, DOI 10.1002/1878-0261.12083; Kao SST, 2020, RHINOLOGY, V58, P418, DOI 10.4193/Rhin20.034; Kao SST, 2021, J ALLERGY CLIN IMMUN, V147, P168, DOI 10.1016/j.jaci.2020.06.037; Khalmuratova R, 2017, IMMUNE NETW, V17, P60, DOI 10.4110/in.2017.17.1.60; Kim WK, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-54890-9; Kriajevska M, 2002, J BIOL CHEM, V277, P5229, DOI 10.1074/jbc.M110976200; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Le Hir M, 2005, HISTOCHEM CELL BIOL, V123, P335, DOI 10.1007/s00418-005-0788-z; Liu J, 2018, DISCOV MED, V25, P211; Liu PY, 2020, GASTROENTEROLOGY, V158, P1029, DOI 10.1053/j.gastro.2019.11.302; Maelandsmo GM, 1996, CANCER RES, V56, P5490; Nasser MW, 2015, CANCER LETT, V365, P11, DOI 10.1016/j.canlet.2015.05.002; Niessen CM, 2007, J INVEST DERMATOL, V127, P2525, DOI 10.1038/sj.jid.5700865; Ning Q, 2018, J INVEST MED, V66, P334, DOI 10.1136/jim-2017-000542; Nissinen L, 2014, BBA-GEN SUBJECTS, V1840, P2571, DOI 10.1016/j.bbagen.2014.03.007; Niu J, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0883-1; Pierce JD, 2007, NURS HEALTH SCI, V9, P52, DOI 10.1111/j.1442-2018.2007.00295.x; Qian LJ, 2018, CELL PHYSIOL BIOCHEM, V46, P2551, DOI 10.1159/000489683; Raposo TP, 2015, VET J, V205, P161, DOI 10.1016/j.tvjl.2015.04.015; Sack U, 2011, MOL BIOL CELL, V22, P3344, DOI 10.1091/mbc.E10-09-0739; Schmidt-Hansen B, 2004, ONCOGENE, V23, P5487, DOI 10.1038/sj.onc.1207720; Schmidt-Hansen B, 2004, J BIOL CHEM, V279, P24498, DOI 10.1074/jbc.M400441200; Semov A, 2005, J BIOL CHEM, V280, P20833, DOI 10.1074/jbc.M412653200; Shi JB, 2015, ALLERGY, V70, P533, DOI 10.1111/all.12577; Shigetomi K, 2018, J BIOCHEM, V163, P265, DOI 10.1093/jb/mvx077; Stein U, 2006, GASTROENTEROLOGY, V131, P1486, DOI 10.1053/j.gastro.2006.08.041; Stewart RL, 2016, ONCOTARGET, V7, P34630, DOI 10.18632/oncotarget.8969; Sumsion JS, 2020, CURR OPIN ALLERGY CL, V20, P14, DOI 10.1097/ACI.0000000000000595; TAKENAGA K, 1994, JPN J CANCER RES, V85, P831, DOI 10.1111/j.1349-7006.1994.tb02955.x; Tomcik M, 2015, ANN RHEUM DIS, V74, P1748, DOI 10.1136/annrheumdis-2013-204516; Van Crombruggen K, 2016, EUR RESPIR J, V47, P264, DOI 10.1183/13993003.00159-2015; Wang ZH, 2020, PHARM BIOL, V58, P828, DOI 10.1080/13880209.2020.1809462; Wight TN, 2017, CELL IMMUNOL, V312, P1, DOI 10.1016/j.cellimm.2016.12.003; Wong SHM, 2018, CRIT REV ONCOL HEMAT, V121, P11, DOI 10.1016/j.critrevonc.2017.11.010; Xiao K, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-03034-3; Yammani RR, 2006, ARTHRITIS RHEUM-US, V54, P2901, DOI 10.1002/art.22042; Yammani RR, 2009, ARTHRITIS RHEUM, V60, P792, DOI 10.1002/art.24295; Yang F, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09289-5; Yeh Y, 2019, ADV EXP MED BIOL, V1210, P351, DOI 10.1007/978-3-030-32656-2_16; Zhang JH, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1461301; Zhang LN, 2019, ARCH BIOCHEM BIOPHYS, V676, DOI 10.1016/j.abb.2019.108137; Zhang L, 2020, RHINOLOGY, V58, P126, DOI 10.4193/Rhin19.184; Zhao YX, 2019, MOL CANCER RES, V17, P655, DOI 10.1158/1541-7786.MCR-18-0637; Zhou M, 2020, RESP MED, V162, DOI 10.1016/j.rmed.2020.105871; Zhu YP, 2019, CLIN PROTEOM, V16, DOI 10.1186/s12014-019-9232-6	79	0	0	7	9	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 28	2022	13								835888	10.3389/fimmu.2022.835888	http://dx.doi.org/10.3389/fimmu.2022.835888			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZG9AL	35154161	Green Published, gold			2022-12-18	WOS:000760543400001
J	Meier, HCS; Sandler, DP; Wilkerson, J; Miller, FW; Dinse, GE; Parks, CG				Meier, Helen C. S.; Sandler, Dale P.; Wilkerson, Jesse; Miller, Frederick W.; Dinse, Gregg E.; Parks, Christine G.			Hygiene Hypothesis Indicators and Prevalence of Antinuclear Antibodies in US Adolescents	FRONTIERS IN IMMUNOLOGY			English	Article						antinuclear antibodies (ANA); hygiene hypothesis; adolescents; asthma; allergy; autoimmunity	HAY-FEVER; DISEASE; AUTOIMMUNE; INFECTION; ASTHMA; MECHANISMS; EXPOSURES; ALLERGY; TYPE-2	Autoimmunity prevalence, as measured by antinuclear antibodies (ANA), is increasing in U.S. adolescents. Improved hygiene and cleaner environments in childhood may reduce exposure to infections and other immune challenges, resulting in improper immune responses to later-life exposures. We examined associations of hygiene hypothesis indicators, including asthma, allergies, and antibodies to infectious agents, with ANA prevalence, measured by HEp-2 immunofluorescence, in adolescents (aged 12-19 years) over a 25-year time span in the National Health and Nutrition Examination Survey (NHANES) (N=2,709), adjusting for age, sex, race/ethnicity, body mass index, education and survey cycle, overall and within individual time periods, using logistic regression. Prevalence of ANA in adolescents increased from 5.0% in 1988-1991 to 12.8% in 2011-2012. ANA were positively associated with diagnosis of asthma in early childhood (OR: 2.07, CI: 1.09-3.99) and the effect estimate for current hay fever was elevated but not statistically significant (OR: 1.55, CI: 0.85-2.84). Fewer than 2% of those with ANA in 1988-1991 had been diagnosed with asthma, compared with 18% in 1999-2000, and 27% in 2003-2004 and 2011-2012. ANA trended negatively with Helicobacter pylori antibodies (OR: 0.49, CI: 0.24-0.99). ANA may be useful as an additional indicator of inadequate immune education in adolescence, a critical period of growth and development.	[Meier, Helen C. S.] Univ Michigan, Inst Social Res, Neurodevelopment & Genet Program, Populat,Survey Res Ctr, Ann Arbor, MI 48109 USA; [Sandler, Dale P.; Parks, Christine G.] Natl Inst Environm Hlth Sci NIEHS, Epidmiol Branch, Durham, NC USA; [Wilkerson, Jesse; Dinse, Gregg E.] Publ Hlth & Sci Res Social & Sci Syst, Durham, NC USA; [Miller, Frederick W.] Natl Inst Environm Hlth Sci NIEHS, Environm Autoimmun Grp, Durham, NC USA	University of Michigan System; University of Michigan	Meier, HCS (corresponding author), Univ Michigan, Inst Social Res, Neurodevelopment & Genet Program, Populat,Survey Res Ctr, Ann Arbor, MI 48109 USA.	hspink@umich.edu			Intramural Research Program of NIH, National Institute of Environmental Health Sciences [Z01-ES049028, HHSN273201600011C]; Shaw Scientist Award from the Greater Milwaukee Foundation	Intramural Research Program of NIH, National Institute of Environmental Health Sciences; Shaw Scientist Award from the Greater Milwaukee Foundation	This work was supported in part by the Intramural Research Program of the NIH, National Institute of Environmental Health Sciences (Z01-ES049028) and contract HHSN273201600011C to Social & Scientific Systems, and in part by the Shaw Scientist Award from the Greater Milwaukee Foundation.	Aiello AE, 2008, J GERONTOL A-BIOL, V63, P610, DOI 10.1093/gerona/63.6.610; Alexandre-Silva GM, 2018, ACTA TROP, V188, P16, DOI 10.1016/j.actatropica.2018.08.032; Altobelli A, 2019, MBIO, V10, DOI 10.1128/mBio.00261-19; Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100; Barnes LL, 2015, J INFECT DIS, V211, P230, DOI 10.1093/infdis/jiu437; Centers for Disease Control and Prevention, 2013, NATL HLTH NUTR EXAMI; Chen Y, 2008, J INFECT DIS, V198, P553, DOI 10.1086/590158; Daley D, 2014, CURR OPIN ALLERGY CL, V14, P390, DOI 10.1097/ACI.0000000000000101; Dinse GE, 2020, ARTHRITIS RHEUMATOL, V72, P1026, DOI 10.1002/art.41214; Dinse GE, 2018, J AUTOIMMUN, V92, P93, DOI 10.1016/j.jaut.2018.05.006; Fanfair RN, 2013, SEX TRANSM DIS, V40, P860, DOI 10.1097/OLQ.0000000000000043; Georgountzou A, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00957; Im JH, 2020, INFECT DIS-NOR, V52, P177, DOI 10.1080/23744235.2019.1690676; Jatzlauk G, 2017, ALLERGY, V72, P1859, DOI 10.1111/all.13220; Johnson Clifford L, 2013, Vital Health Stat 2, P1; Kloes M, 2019, ALLERGY, V74, P2002, DOI 10.1111/all.13837; Kokkonen J, 2004, J AUTOIMMUN, V22, P341, DOI 10.1016/j.jaut.2004.03.006; Kyburz A, 2019, J ALLERGY CLIN IMMUN, V143, P1496, DOI 10.1016/j.jaci.2018.07.046; Lambrecht BN, 2017, NAT IMMUNOL, V18, P1076, DOI 10.1038/ni.3829; Lehours P, 2019, HELICOBACTER, V24, DOI 10.1111/hel.12644; Lindelof B, 2009, CLIN EXP ALLERGY, V39, P110, DOI 10.1111/j.1365-2222.2008.03115.x; Matricardi PM, 2002, J ALLERGY CLIN IMMUN, V110, P381, DOI 10.1067/mai.2002.126658; Meier HCS, 2020, EPIDEMIOL INFECT, V148, DOI 10.1017/S0950268820000126; Meier HCS, 2016, CANCER EPIDEM BIOMAR, V25, P1559, DOI 10.1158/1055-9965.EPI-16-0339; Pisetsky DS, 2020, J ALLERGY CLIN IMMUN, V146, P1346, DOI 10.1016/j.jaci.2020.09.006; Rabin RL, 2008, CLIN EXP IMMUNOL, V153, P19, DOI 10.1111/j.1365-2249.2008.03679.x; Rivera-Correa J, 2018, TRENDS IMMUNOL, V39, P515, DOI 10.1016/j.it.2018.04.003; Rook GAW, 2014, CLIN EXP IMMUNOL, V177, P1, DOI 10.1111/cei.12269; Saier MH, 2007, WATER AIR SOIL POLL, V181, P1, DOI 10.1007/s11270-007-9372-6; Satoh M, 2012, ARTHRITIS RHEUM-US, V64, P2319, DOI 10.1002/art.34380; Simanek AM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016103; Strachan David P., 2000, Thorax, V55, pS2, DOI 10.1136/thorax.55.suppl_1.S2; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Trivedi M, 2019, FRONT PEDIATR, V7, DOI 10.3389/fped.2019.00256; West LJ, 2002, HUM EXP TOXICOL, V21, P499, DOI 10.1191/0960327102ht288oa; Wynn TA, 2015, NAT REV IMMUNOL, V15, P271, DOI 10.1038/nri3831	36	0	0	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 28	2022	13								789379	10.3389/fimmu.2022.789379	http://dx.doi.org/10.3389/fimmu.2022.789379			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZF1LN	35154106	Green Published, gold			2022-12-18	WOS:000759335500001
J	Osero, BO; Cele, Z; Aruleba, RT; Maine, RA; Ozturk, M; Lutz, MB; Brombacher, F; Hurdayal, R				Osero, Bernard Ong'ondo; Cele, Zama; Aruleba, Raphael Taiwo; Maine, Rebeng A.; Ozturk, Mumin; Lutz, Manfred B.; Brombacher, Frank; Hurdayal, Ramona			Interleukin-4 Responsive Dendritic Cells Are Dispensable to Host Resistance Against Leishmania mexicana Infection	FRONTIERS IN IMMUNOLOGY			English	Article						Dendritic cells; IL-4R alpha; IL-4; Leishmania mexicana; mice	T-CELLS; CUTANEOUS LEISHMANIASIS; B-CELLS; MAJOR INFECTION; IMMUNE-SYSTEM; RECEPTOR; CD8(+); IL-13; SUSCEPTIBILITY; IGG1	IL-4 and IL-13 cytokines have been associated with a non-healing phenotype in murine leishmaniasis in L. mexicana -infected BALB/c mice as demonstrated in IL-4(-/-), IL-13(-/-) and IL-4R alpha(-/-) global knockout mouse studies. However, it is unclear from the studies which cell-type-specific IL-4/IL-13 signaling mediates protection to L. mexicana. Previous studies have ruled out a role for IL-4-mediated protection on CD4(+) T cells during L. mexicana infections. A candidate for this role may be non-lymphocyte cells, particularly DCs, as was previously shown in L. major infections, where IL-4 production drives dendritic cell-IL-12 production thereby mediating a type 1 immune response. However, it is unclear if this IL-4-instruction of type 1 immunity also occurs in CL caused by L. mexicana, since the outcome of cutaneous leishmaniasis often depends on the infecting Leishmania species. Thus, BALB/c mice with cell-specific deletion of the IL-4R alpha on CD11c(+) DCs (CD11c(cre)IL-4R alpha(-/lox)) were infected with L. mexicana promastigotes in the footpad and the clinical phenotype, humoral and cellular immune responses were investigated, compared to the littermate control. Our results show that CL disease progression in BALB/c mice is independent of IL-4R alpha signaling on DCs as CD11c(cre)IL-4R alpha(-/lox) mice had similar footpad lesion progression, parasite loads, humoral responses (IgE, IgG1, IgG 2a/b), and IFN-gamma cytokine secretion in comparison to littermate controls. Despite this comparable phenotype, surprisingly, IL-4 production in CD11c(cre)IL-4R alpha(-/lox) mice was significantly increased with an increasing trend of IL-13 when compared to littermate controls. Moreover, the absence of IL-4R alpha signaling did not significantly alter the frequency of CD4 and CD8 lymphocytes nor their activation, or memory phenotype compared to littermate controls. However, these populations were significantly increased in CD11c(cre)IL-4R alpha(-/lox) mice due to greater total cell infiltration into the lymph node. A similar trend was observed for B cells whereas the recruitment of myeloid populations (macrophages, DCs, neutrophils, and Mo-DCs) into LN was comparable to littermate IL-4R alpha(-/lox) mice. Interestingly, IL-4R alpha-deficient bone marrow-derived dendritic cells (BMDCs), stimulated with LPS or L. mexicana promastigotes in presence of IL-4, showed similar levels of IL-12p70 and IL-10 to littermate controls highlighting that IL-4-mediated DC instruction was not impaired in response to L. mexicana. Similarly, IL-4 stimulation did not affect the maturation or activation of IL-4R alpha-deficient BMDCs during L. mexicana infection nor their effector functions in production of nitrite and arginine-derived metabolite (urea). Together, this study suggests that IL-4 R alpha signaling on DCs is not key in the regulation of immune-mediated protection in mice against L. mexicana infection.	[Osero, Bernard Ong'ondo; Ozturk, Mumin; Brombacher, Frank; Hurdayal, Ramona] Univ Cape Town, Div Immunol, Dept Pathol, Fac Hlth Sci,Inst Infect Dis & Mol Med IDM,South, Cape Town, South Africa; [Osero, Bernard Ong'ondo; Ozturk, Mumin; Brombacher, Frank; Hurdayal, Ramona] Cape Town Component, Int Ctr Genet Engn & Biotechnol, Cape Town, South Africa; [Osero, Bernard Ong'ondo; Ozturk, Mumin; Brombacher, Frank; Hurdayal, Ramona] Univ Cape Town, Fac Hlth Sci, Wellcome Ctr Infect Dis Res Africa CIDRI, Inst Infect Dis & Mol Med IDM, Cape Town, South Africa; [Osero, Bernard Ong'ondo] Kenya Govt Med Res Ctr, Ctr Biotechnol Res & Dev, Nairobi, Kenya; [Cele, Zama; Aruleba, Raphael Taiwo; Maine, Rebeng A.; Hurdayal, Ramona] Univ Cape Town, Dept Mol & Cell Biol, Cape Town, South Africa; [Lutz, Manfred B.] Univ Wurzburg, Inst Virol & Immunobiol, Wurzburg, Germany	University of Cape Town; International Center for Genetic Engineering & Biotechnology (ICGEB); ICGEB Cape Town; University of Cape Town; Kenya Medical Research Institute; University of Cape Town; University of Wurzburg	Brombacher, F; Hurdayal, R (corresponding author), Univ Cape Town, Div Immunol, Dept Pathol, Fac Hlth Sci,Inst Infect Dis & Mol Med IDM,South, Cape Town, South Africa.; Brombacher, F; Hurdayal, R (corresponding author), Cape Town Component, Int Ctr Genet Engn & Biotechnol, Cape Town, South Africa.; Brombacher, F; Hurdayal, R (corresponding author), Univ Cape Town, Fac Hlth Sci, Wellcome Ctr Infect Dis Res Africa CIDRI, Inst Infect Dis & Mol Med IDM, Cape Town, South Africa.; Hurdayal, R (corresponding author), Univ Cape Town, Dept Mol & Cell Biol, Cape Town, South Africa.	brombacherfrank@gmail.com; ramona.hurdayal@uct.ac.za	Ozturk, Mumin/G-9739-2016	Ozturk, Mumin/0000-0001-9152-7614; Lutz, Manfred B./0000-0001-9193-1772; Aruleba, Raphael/0000-0003-0879-344X	National Research Foundation [113446, 120407]; University of Cape Town, Research, and Innovation: 2019 Enabling Grant Seeker Excellence Award and Poliomyelitis Research Foundation [19/12]; National Research Foundation (NRF) of South Africa; Department of Science and Technology (DST); South African Research Chair Initiative; International Center for Genetic Engineering and Biotechnology; Wellcome CIDRI-Africa [203135/Z/16/Z]	National Research Foundation; University of Cape Town, Research, and Innovation: 2019 Enabling Grant Seeker Excellence Award and Poliomyelitis Research Foundation; National Research Foundation (NRF) of South Africa(National Research Foundation - South Africa); Department of Science and Technology (DST)(Department of Science & Technology (India)); South African Research Chair Initiative; International Center for Genetic Engineering and Biotechnology; Wellcome CIDRI-Africa	This research was supported by funds from the National Research Foundation (grant numbers: 113446 and 120407), University of Cape Town, Research, and Innovation: 2019 Enabling Grant Seeker Excellence Award and Poliomyelitis Research Foundation (grant number: 19/12), under RH. Also, financial support from the National Research Foundation (NRF) of South Africa, Department of Science and Technology (DST), South African Research Chair Initiative, International Center for Genetic Engineering and Biotechnology, and Wellcome CIDRI-Africa (grant number: 203135/Z/16/Z) under FB.	Al-Qadhi Ban Noori, 2015, J Parasit Dis, V39, P361, DOI 10.1007/s12639-013-0368-4; Alexander J, 2002, EUR J IMMUNOL, V32, P2923, DOI 10.1002/1521-4141(2002010)32:10&lt;2923::AID-IMMU2923&gt;3.0.CO;2-E; Aruleba RT, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8071069; Baldwin TM, 2003, INFECT IMMUN, V71, P6830, DOI 10.1128/IAI.71.12.6830-6834.2003; Biedermann T, 2001, NAT IMMUNOL, V2, P1054, DOI 10.1038/ni725; Bogdan Christian, 2020, Cytokine X, V2, P100041, DOI 10.1016/j.cytox.2020.100041; Bosurgi L, 2017, SCIENCE, V356, P1072, DOI 10.1126/science.aai8132; Bryson KJ, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0000930; Burza S, 2018, LANCET, V392, P951, DOI 10.1016/S0140-6736(18)31204-2; Campos TM, 2020, J INFECT DIS, V221, P973, DOI 10.1093/infdis/jiz538; Cao Q, 2015, J AM SOC NEPHROL, V26, P349, DOI 10.1681/ASN.2013121336; Chu NS, 2010, J IMMUNOL, V185, P6939, DOI 10.4049/jimmunol.1002484; Contreras I, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003202; Crosby EJ, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003970; de Lima CMF, 2021, FRONT CELL INFECT MI, V11, DOI 10.3389/fcimb.2021.652956; De Trez C, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000494; den Haan JMM, 2000, J EXP MED, V192, P1685, DOI 10.1084/jem.192.12.1685; Didwania N, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01779; Fagundes-Silva GA, 2012, PARASITE IMMUNOL, V34, P486, DOI 10.1111/j.1365-3024.2012.01379.x; Fathi A, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.601170; Feijo D, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/3967436; Ghorbani M, 2018, DRUG DES DEV THER, V12, P25, DOI 10.2147/DDDT.S146521; Ghotloo S, 2015, IRAN J PARASITOL, V10, P571; Gibson-Corley KN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106426; Graber P, 1998, EUR J IMMUNOL, V28, P4286, DOI 10.1002/(SICI)1521-4141(199812)28:12<4286::AID-IMMU4286>3.0.CO;2-H; Hartley MA, 2014, TRENDS PARASITOL, V30, P412, DOI 10.1016/j.pt.2014.05.006; Heeb LEM, 2020, GENES IMMUN, V21, P143, DOI 10.1038/s41435-020-0095-7; Hefnawy A, 2017, TRENDS PARASITOL, V33, P162, DOI 10.1016/j.pt.2016.11.003; Henri S, 2002, INFECT IMMUN, V70, P3874, DOI 10.1128/IAI.70.7.3874-3880.2002; Herath S, 2003, PARASITE IMMUNOL, V25, P559, DOI 10.1111/j.0141-9838.2004.00668.x; Herbert DR, 2004, IMMUNITY, V20, P623, DOI 10.1016/S1074-7613(04)00107-4; Hurdayal R, 2020, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00479; Hurdayal R, 2017, P NATL ACAD SCI USA, V114, pE8430, DOI 10.1073/pnas.1708125114; Hurdayal R, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003699; James SL, 2018, LANCET, V392, P1789, DOI [10.1016/S0140-6736(18)32279-7, 10.1016/s0140-6736(18)32279-7]; Junttila IS, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00888; Kono H, 2008, NAT REV IMMUNOL, V8, P279, DOI 10.1038/nri2215; Kronenberg K, 2010, J INVEST DERMATOL, V130, P2602, DOI 10.1038/jid.2010.171; Kumar R, 2014, CLIN TRANSL IMMUNOL, V3, DOI 10.1038/cti.2014.4; Laskay T, 2008, IMMUNOBIOLOGY, V213, P183, DOI 10.1016/j.imbio.2007.11.010; Lutz MB, 1999, J IMMUNOL METHODS, V223, P77, DOI 10.1016/S0022-1759(98)00204-X; Mahmoudzadeh-Niknam H, 2013, KOREAN J PARASITOL, V51, P69, DOI 10.3347/kjp.2013.51.1.69; Martinez-Lopez M, 2015, EUR J IMMUNOL, V45, P119, DOI 10.1002/eji.201444651; McGwire BS, 2014, QJM-INT J MED, V107, P7, DOI 10.1093/qjmed/hct116; Miles SA, 2005, J EXP MED, V201, P747, DOI 10.1084/jem.20041470; Mohrs M, 1999, J IMMUNOL, V162, P7302; Molyneux DH, 2017, LANCET, V389, P312, DOI 10.1016/S0140-6736(16)30171-4; Nieuwenhuizen NE, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-19060-9; Nothelfer K, 2015, NAT REV MICROBIOL, V13, P173, DOI 10.1038/nrmicro3415; Novais FO, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006196; Novais FO, 2015, J INVEST DERMATOL, V135, P94, DOI 10.1038/jid.2014.305; Novais FO, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003504; O'Shea JJ, 2010, SCIENCE, V327, P1098, DOI 10.1126/science.1178334; Osero Bernard Ong'ondo, 2020, Cytokine X, V2, P100043, DOI 10.1016/j.cytox.2020.100043; Oualha R, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00153; Pigott DM, 2014, ELIFE, V3, DOI [10.7554/eLife.04395, 10.7554/eLife.02851]; Prina E, 2004, J CELL SCI, V117, P315, DOI 10.1242/jcs.00860; Radwanska M, 2007, PLOS PATHOG, V3, P619, DOI 10.1371/journal.ppat.0030068; Rahaman SO, 2002, CANCER RES, V62, P1103; Rivera-Fernandez I, 2019, J PARASITOL, V105, P359, DOI 10.1645/17-158; Rossi M, 2018, INT IMMUNOL, V30, P103, DOI 10.1093/intimm/dxx075; Sacks D, 2002, NAT REV IMMUNOL, V2, P845, DOI 10.1038/nri933; Santos CDS, 2013, J INVEST DERMATOL, V133, P1533, DOI 10.1038/jid.2013.4; SATOSKAR A, 1995, INFECT IMMUN, V63, P4894, DOI 10.1128/IAI.63.12.4894-4899.1995; Schleicher U, 2016, CELL REP, V15, P1062, DOI 10.1016/j.celrep.2016.04.001; Seyed N, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01227; Sheng JP, 2017, CELL REP, V21, P1203, DOI 10.1016/j.celrep.2017.10.024; Shin KS, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01887; Smulski CR, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02285; Snider H, 2009, NEUROIMMUNOMODULAT, V16, P106, DOI 10.1159/000180265; Sousa-Atta MLB, 2002, CLIN DIAGN LAB IMMUN, V9, P101, DOI 10.1128/CDLI.9.1.101-104.2002; Spotin A, 2016, PARASITOL RES, V115, P1221, DOI 10.1007/s00436-015-4858-4; Thomas BN, 2008, INFECT IMMUN, V76, P623, DOI 10.1128/IAI.00316-07; van der Poel CE, 2019, CELL REP, V29, P2745, DOI 10.1016/j.celrep.2019.10.086; vom Steeg LG, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005374; Wang XM, 2011, J EXP MED, V208, P2497, DOI 10.1084/jem.20111449; WHO, 2021, LEISHMANIASIS INTERN; Woytschak J, 2016, IMMUNITY, V45, P172, DOI 10.1016/j.immuni.2016.06.025; Yao YX, 2005, J EXP MED, V201, P1899, DOI 10.1084/jem.20050324; Zaph C, 2004, NAT MED, V10, P1104, DOI 10.1038/nm1108	80	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 28	2022	12								759021	10.3389/fimmu.2021.759021	http://dx.doi.org/10.3389/fimmu.2021.759021			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZH5ZI	35154068	Green Published, gold			2022-12-18	WOS:000761016300001
J	Silva, ACO; Bonfim, M; Fontes, JLM; dos-Santos, WLC; Mengel, J; Cardillo, F				Silva, Amanda C. O.; Bonfim, Maiara; Fontes, Jonathan L. M.; dos-Santos, Washington L. C.; Mengel, Jose; Cardillo, Fabiola			C57BL/6 Mice Pretreated With Alpha-Tocopherol Show a Better Outcome of Trypanosoma cruzi Infection With Less Tissue Inflammation and Fibrosis	FRONTIERS IN IMMUNOLOGY			English	Article						Chagas' disease; Trypanosoma cruzi; fibrosis; immunomodulation; adjuvants; interleukin-10; interferon-gamma; inflammation	T-CELLS; CHAGAS-DISEASE; ACQUIRED-IMMUNITY; GAMMA-INTERFERON; MOUSE MODEL; IL-10; INTERLEUKIN-10; PARASITE; INNATE; HYPERACTIVITY	Chagas disease is accompanied by a multisystem inflammatory disorder that follows Trypanosoma cruzi infection. Alpha-tocopherol has been described as an antioxidant and a potential adjuvant to enhance immune responses to vaccines. Therefore, we have evaluated the immune response to T. cruzi infection upon alpha-tocopherol pre-administration. The results show that administration of alpha-tocopherol before the infection results in lower parasitemia and lower mortality of C57BL/6 mice infected with the Tulahuen T. cruzi strain. Alpha-tocopherol administration in normal C57BL/6 mice resulted in higher levels of IFN-gamma production by T and NK cells before and after the infection with T. cruzi. More importantly, previous administration of alpha-tocopherol increased the production of IL-10 by T and myeloid suppressor cells and the formation of effector memory T cells while decreasing the expression of PD-1 on T cells. These results suggest that alpha-tocopherol may limit the appearance of dysfunctional T cells during the acute and early chronic phases of T. cruzi infection, contributing to control infection. In addition, alpha-tocopherol could diminish tissue inflammation and fibrosis in late acute disease. These results strongly suggest that alpha-tocopherol may be a helpful agent to be considered in Chagas disease.	[Silva, Amanda C. O.; Bonfim, Maiara; Fontes, Jonathan L. M.; dos-Santos, Washington L. C.; Cardillo, Fabiola] Fiocruz MS, Lab Mol & Struct Pathol, Goncalo Moniz Inst, Salvador, BA, Brazil; [dos-Santos, Washington L. C.] Univ Fed Bahia, Dept Pathol, Fac Med, Fed Univ Bahia, Salvador, BA, Brazil; [Mengel, Jose] Fiocruz MS, Inst Oswaldo Cruz, Rio De Janeiro, Brazil; [Mengel, Jose] UNIFASE, Petropolis Med Sch, Petropolis, RJ, Brazil	Fundacao Oswaldo Cruz; Universidade Federal da Bahia; Fundacao Oswaldo Cruz	Cardillo, F (corresponding author), Fiocruz MS, Lab Mol & Struct Pathol, Goncalo Moniz Inst, Salvador, BA, Brazil.; Mengel, J (corresponding author), Fiocruz MS, Inst Oswaldo Cruz, Rio De Janeiro, Brazil.; Mengel, J (corresponding author), UNIFASE, Petropolis Med Sch, Petropolis, RJ, Brazil.	jomengel@ioc.fiocruz.br; fabiola.cardillo@fiocruz.br			CNPq; FAPESB; FAPERJ; FIOCRUZ; FOG (Fundacao Octacilio Gualberto)	CNPq(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); FAPESB(Fundacao de Amparo a Pesquisa do Estado da Bahia (FAPESB)); FAPERJ(Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio De Janeiro (FAPERJ)); FIOCRUZ; FOG (Fundacao Octacilio Gualberto)	This work was supported by CNPq, FAPESB, FAPERJ, FIOCRUZ and FOG (Fundacao Octa ' cilio Gualberto).	Abrahamsohn IA, 1996, EXP PARASITOL, V84, P231, DOI 10.1006/expr.1996.0109; Adolfsson O, 2001, J IMMUNOL, V167, P3809, DOI 10.4049/jimmunol.167.7.3809; Natale MA, 2021, PLOS NEGLECT TROP D, V15, DOI 10.1371/journal.pntd.0009473; Andrade ZA, 1999, MEM I OSWALDO CRUZ, V94, P71, DOI 10.1590/S0074-02761999000700007; Angulo-Molina A, 2014, NUTR CANCER, V66, P167, DOI 10.1080/01635581.2014.863367; Antunez ML, 2004, EXP PARASITOL, V106, P85, DOI 10.1016/j.exppara.2004.03.008; Cardillo F, 2004, MED SCI MONITOR, V10, pBR259; Cardillo F, 1996, INFECT IMMUN, V64, P128, DOI 10.1128/IAI.64.1.128-134.1996; Cardillo F, 2002, SCAND J IMMUNOL, V55, P96, DOI 10.1046/j.1365-3083.2002.01034.x; Cardillo F, 2015, PATHOG DIS, V73, DOI 10.1093/femspd/ftv082; Carvalho LSC, 2006, T ROY SOC TROP MED H, V100, P1025, DOI 10.1016/j.trstmh.2005.12.009; Chagas C, 2008, INT J EPIDEMIOL, V37, P694, DOI 10.1093/ije/dyn149; Clayton J, 2010, NATURE, V465, pS4, DOI 10.1038/nature09220; Couper KN, 2008, J IMMUNOL, V180, P5771, DOI 10.4049/jimmunol.180.9.5771; Dang HX, 2021, FRONT NUTR, V8, DOI 10.3389/fnut.2021.648442; dos Santos GAS, 2012, LEUKEMIA, V26, P451, DOI 10.1038/leu.2011.216; Echavarria NG, 2021, CURR PROB CARDIOLOGY, V46, DOI 10.1016/j.cpcardiol.2019.100507; Flores-Garcia Y, 2011, INT J BIOL SCI, V7, P1093, DOI 10.7150/ijbs.7.1093; Fonseca R, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00997; Lidani KCF, 2019, FRONT PUBLIC HEALTH, V7, DOI 10.3389/fpubh.2019.00166; Freitas RA, 2009, LEUKEMIA RES, V33, P958, DOI 10.1016/j.leukres.2008.09.035; GAZZINELLI RT, 1992, EUR J IMMUNOL, V22, P2501, DOI 10.1002/eji.1830221006; GAZZINELLI RT, 1993, P NATL ACAD SCI USA, V90, P6115, DOI 10.1073/pnas.90.13.6115; Golgher D, 2004, AUTOIMMUNITY, V37, P399, DOI 10.1080/08916930410001713115; Gutierrez FRS, 2011, INFECT IMMUN, V79, P1873, DOI 10.1128/IAI.01047-10; Hoffman KA, 2021, FRONT CELL INFECT MI, V11, DOI 10.3389/fcimb.2021.708325; Holscher C, 2000, INFECT IMMUN, V68, P4075, DOI 10.1128/IAI.68.7.4075-4083.2000; Hunter CA, 1997, J IMMUNOL, V158, P3311; Karlsson I, 2017, HUM VACC IMMUNOTHER, V13, P1823, DOI 10.1080/21645515.2017.1321183; Keir ME, 2008, ANNU REV IMMUNOL, V26, P677, DOI 10.1146/annurev.immunol.26.021607.090331; Keir ME, 2007, CURR OPIN IMMUNOL, V19, P309, DOI 10.1016/j.coi.2007.04.012; Lee GY, 2018, NUTRIENTS, V10, DOI 10.3390/nu10111614; Manosso LM, 2013, PROG NEURO-PSYCHOPH, V46, P48, DOI 10.1016/j.pnpbp.2013.06.012; MELO RC, 1978, J PARASITOL, V64, P475, DOI 10.2307/3279787; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; Morillo CA, 2015, NEW ENGL J MED, V373, P1295, DOI 10.1056/NEJMoa1507574; Perez-Anton E, 2020, ACTA TROP, V202, DOI 10.1016/j.actatropica.2019.105242; Radhakrishnan AK, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/782067; Rassi A, 2010, LANCET, V375, P1388, DOI 10.1016/S0140-6736(10)60061-X; Roffe E, 2012, J IMMUNOL, V188, P649, DOI 10.4049/jimmunol.1003845; Roggero E, 2002, CLIN EXP IMMUNOL, V128, P421, DOI 10.1046/j.1365-2249.2002.01874.x; Roy S, 2019, J CELL SCI, V132, DOI 10.1242/jcs.226274; Santi-Rocca J, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08086-8; Sardinha LR, 2006, INFECT IMMUN, V74, P2031, DOI 10.1128/IAI.74.4.2031-2042.2006; Sathler-Avelar R, 2009, MEM I OSWALDO CRUZ, V104, P246, DOI 10.1590/S0074-02762009000900031; Stanaway JD, 2015, GLOB HEART, V10, P139, DOI 10.1016/j.gheart.2015.06.001; Tarleton RL, 2015, SEMIN IMMUNOPATHOL, V37, P233, DOI 10.1007/s00281-015-0481-9; Tzelepis F, 2006, INFECT IMMUN, V74, P2477, DOI 10.1128/IAI.74.4.2477-2481.2006	48	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 28	2022	13								833560	10.3389/fimmu.2022.833560	http://dx.doi.org/10.3389/fimmu.2022.833560			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZF8NW	35154155	Green Published, gold			2022-12-18	WOS:000759827600001
J	Yiu, G; Rasmussen, TK; Tsai, BDL; Diep, VK; Haddon, DJ; Tsoi, J; Miller, GD; Comin-Anduix, B; Deleuran, B; Crooks, GM; Utz, PJ				Yiu, Gloria; Rasmussen, Tue Kruse; Tsai, Brandon L.; Diep, Vivian K.; Haddon, David J.; Tsoi, Jennifer; Miller, Gopika D.; Comin-Anduix, Begona; Deleuran, Bent; Crooks, Gay M.; Utz, Paul J.			High Interferon Signature Leads to Increased STAT1/3/5 Phosphorylation in PBMCs From SLE Patients by Single Cell Mass Cytometry	FRONTIERS IN IMMUNOLOGY			English	Article						interferon; lupus (SLE); CyTOF mass cytometry; STAT3 (signal transducer and activator of transcription 3); STAT1; autoantibodies; interferon signature	SYSTEMIC-LUPUS-ERYTHEMATOSUS; REGULATORY T-CELLS; DISEASE-ACTIVITY; MONOCLONAL-ANTIBODY; PERIPHERAL-BLOOD; GAMMA; MECHANISMS; RESPONSES; STAT3; AUTOANTIBODIES	The establishment of an "interferon (IFN) signature" to subset SLE patients on disease severity has led to therapeutics targeting IFN alpha. Here, we investigate IFN signaling in SLE using multiplexed protein arrays and single cell cytometry by time of flight (CyTOF). First, the IFN signature for SLE patients (n=81) from the Stanford Lupus Registry is determined using fluidigm qPCR measuring 44 previously determined IFN-inducible transcripts. IFN-high (IFN-H) patients have increased SLE criteria and renal/CNS/immunologic involvement, and increased autoantibody reactivity against spliceosome-associated antigens. CyTOF analysis is performed on non-stimulated and stimulated (IFN alpha, IFN gamma, IL-21) PBMCs from SLE patients (n=25) and HCs (n=9) in a panel identifying changes in phosphorylation of intracellular signaling proteins (pTOF). Another panel is utilized to detect changes in intracellular cytokine (ICTOF) production in non-stimulated and stimulated (PMA/ionomycin) PBMCs from SLE patients (n=31) and HCs (n=17). Bioinformatic analysis by MetaCyto and OMIQ reveal phenotypic changes in immune cell subsets between IFN-H and IFN-low (IFN-L) patients. Most notably, IFN-H patients exhibit increased STAT1/3/5 phosphorylation downstream of cytokine stimulation and increased phosphorylation of non-canonical STAT proteins. These results suggest that IFN signaling in SLE modulates STAT phosphorylation, potentially uncovering possible targets for future therapeutic approaches.	[Yiu, Gloria; Rasmussen, Tue Kruse; Diep, Vivian K.; Haddon, David J.; Miller, Gopika D.; Utz, Paul J.] Stanford Sch Med, Div Rheumatol & Immunol, Dept Med, Stanford, CA 94305 USA; [Yiu, Gloria] Univ Calif Los Angeles, Dept Rheumatol, Los Angeles, CA USA; [Rasmussen, Tue Kruse; Deleuran, Bent] Aarhus Univ, Dept Biomed, Aarhus, Denmark; [Rasmussen, Tue Kruse; Deleuran, Bent] Aarhus Univ Hosp, Dept Rheumatol, Aarhus, Denmark; [Tsai, Brandon L.] Univ Calif Los Angeles, Dept Human Genet, Los Angeles, CA USA; [Tsoi, Jennifer; Comin-Anduix, Begona] Univ Calif Los Angeles, David Geffen Sch Med, Johnson Comprehens Canc Ctr, Dept Surg, Los Angeles, CA USA; [Comin-Anduix, Begona; Crooks, Gay M.] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA; [Comin-Anduix, Begona] Parker Inst Canc Immunotherapy, San Francisco, CA USA; [Crooks, Gay M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA USA; [Crooks, Gay M.] Univ Calif Los Angeles, Eli & Edythe Ctr Regenerat Med & Stem Cell Res, Los Angeles, CA USA; [Crooks, Gay M.] Univ Calif Los Angeles, David Geffen Sch Med, Div Pediat Hematol Oncol, Dept Pediat, Los Angeles, CA 90095 USA; [Utz, Paul J.] Stanford Univ, Inst Immun Transplantat & Infect, Sch Med, Stanford, CA 94305 USA	Stanford University; University of California System; University of California Los Angeles; Aarhus University; Aarhus University; University of California System; University of California Los Angeles; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Stanford University	Utz, PJ (corresponding author), Stanford Sch Med, Div Rheumatol & Immunol, Dept Med, Stanford, CA 94305 USA.; Utz, PJ (corresponding author), Stanford Univ, Inst Immun Transplantat & Infect, Sch Med, Stanford, CA 94305 USA.	pjutz@stanford.edu		Tsai, Brandon/0000-0002-7372-3504; Deleuran, Bent/0000-0002-7079-1587	NIH [U19-AI110491, AI125197-01]; Baxter Foundation; Henry Gustav Floren Trust; University of California, Los Angeles, Caltech Medical Scientist Training Program.; Stanford Immunology Graduate Program and Stanford Medical Scientist Training Program	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Baxter Foundation; Henry Gustav Floren Trust; University of California, Los Angeles, Caltech Medical Scientist Training Program.; Stanford Immunology Graduate Program and Stanford Medical Scientist Training Program	PU was supported by NIH U19-AI110491 and R01 AI125197-01; the Donald E. and Delia B. Baxter Foundation; and the Henry Gustav Floren Trust. The contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH or one of its institutes. BT acknowledges the support of the University of California, Los Angeles, Caltech Medical Scientist Training Program. GY acknowledges the support of the Stanford Immunology Graduate Program and Stanford Medical Scientist Training Program.	Arazi A, 2019, NAT IMMUNOL, V20, P902, DOI 10.1038/s41590-019-0398-x; Ayoub S, 2008, NAT CLIN PRACT RHEUM, V4, P98, DOI 10.1038/ncprheum0701; Baechler EC, 2003, P NATL ACAD SCI USA, V100, P2610, DOI 10.1073/pnas.0337679100; Balomenos D, 1998, J CLIN INVEST, V101, P364, DOI 10.1172/JCI750; Bauer JW, 2009, ARTHRITIS RHEUM-US, V60, P3098, DOI 10.1002/art.24803; Becker AM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067003; Belkina AC, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13055-y; Bendall SC, 2011, SCIENCE, V332, P687, DOI 10.1126/science.1198704; Bennett L, 2003, J EXP MED, V197, P711, DOI 10.1084/jem.20021553; Bocharnikov AV, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.130062; Bruce IN, 2015, ANN RHEUM DIS, V74, P1706, DOI 10.1136/annrheumdis-2013-205171; Crispin JC, 2003, J AUTOIMMUN, V21, P273, DOI 10.1016/S0896-8411(03)00121-5; Der E, 2019, NAT IMMUNOL, V20, P915, DOI 10.1038/s41590-019-0386-1; Dorner T, 2019, LANCET, V393, P2344, DOI 10.1016/S0140-6736(19)30546-X; Du HQ, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0200385; Fava A, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.138345; Fish EN, 1999, J BIOL CHEM, V274, P571, DOI 10.1074/jbc.274.2.571; Furie R, 2011, ARTHRITIS RHEUM-US, V63, P3918, DOI 10.1002/art.30613; Goropevsek A, 2017, CLIN REV ALLERG IMMU, V52, P164, DOI 10.1007/s12016-016-8550-y; Hall JC, 2012, P NATL ACAD SCI USA, V109, P17609, DOI 10.1073/pnas.1209724109; Ho HH, 2006, J BIOL CHEM, V281, P14111, DOI 10.1074/jbc.M511797200; Hostmann A, 2008, LUPUS, V17, P1064, DOI 10.1177/0961203308095138; Hu ZC, 2018, CELL REP, V24, P1377, DOI 10.1016/j.celrep.2018.07.003; Huang Z, 2011, J IMMUNOL, V186, P3421, DOI 10.4049/jimmunol.1000569; JACOB CO, 1987, J EXP MED, V166, P798, DOI 10.1084/jem.166.3.798; James Melville, 2020, Arxiv, DOI arXiv:1802.03426; Jiang SA, 2010, CANCER RES, V70, P3119, DOI 10.1158/0008-5472.CAN-09-4250; Kim HS, 2015, SCI REP-UK, V5, DOI 10.1038/srep13414; Lanata CM, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11845-y; Langefeld CD., 2016, LUPUS SCI MED, V3, pA31, DOI [10.1136/LUPUS-2016-000179.60, DOI 10.1136/LUPUS-2016-000179.60]; Liu CL, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3707; Liu MM, 2021, CLIN RHEUMATOL, V40, P1103, DOI 10.1007/s10067-020-05306-x; Liu MF, 2004, SCAND J IMMUNOL, V59, P198, DOI 10.1111/j.0300-9475.2004.01370.x; Lyons PA, 2010, ANN RHEUM DIS, V69, P1208, DOI 10.1136/ard.2009.108043; Morimoto AM, 2011, ARTHRITIS RHEUM-US, V63, P2407, DOI 10.1002/art.30399; Murimi-Worstell IB, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2019-031850; Nurieva RI, 2008, IMMUNITY, V29, P138, DOI 10.1016/j.immuni.2008.05.009; Odendahl M, 2000, J IMMUNOL, V165, P5970, DOI 10.4049/jimmunol.165.10.5970; Platanias LC, 2005, NAT REV IMMUNOL, V5, P375, DOI 10.1038/nri1604; Price JV, 2012, NAT MED, V18, P1434, DOI 10.1038/nm.2913; Rasmussen TK, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075-015-0660-z; Robinson WH, 2002, NAT MED, V8, P295, DOI 10.1038/nm0302-295; Rovin BH, 2019, KIDNEY INT, V95, P219, DOI 10.1016/j.kint.2018.08.025; Sadzak I., 2008, RECRUITMENT STAT1 CH; Seery JP, 1997, J EXP MED, V186, P1451, DOI 10.1084/jem.186.9.1451; Shin MS, 2019, ARTHRITIS RHEUMATOL, V71, P109, DOI 10.1002/art.40672; Simpson N, 2010, ARTHRITIS RHEUM-US, V62, P234, DOI 10.1002/art.25032; Slight-Webb S, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.124575; Soni C, 2020, IMMUNITY, V52, P1022, DOI 10.1016/j.immuni.2020.04.015; TAKEDA K, 1993, J EXP MED, V177, P155, DOI 10.1084/jem.177.1.155; Talaat RM, 2015, CYTOKINE, V72, P146, DOI 10.1016/j.cyto.2014.12.027; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101; Theofilopoulos AN, 2001, ARTHRITIS RES, V3, P136, DOI 10.1186/ar290; Thibault DL, 2008, J CLIN INVEST, V118, P1417, DOI 10.1172/JCI30065; Thibault DL, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2771; Tsokos GC, 2020, NAT IMMUNOL, V21, P605, DOI 10.1038/s41590-020-0677-6; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Van Gassen S, 2015, CYTOM PART A, V87A, P636, DOI 10.1002/cyto.a.22625; Vargas-Rojas MI, 2008, LUPUS, V17, P289, DOI 10.1177/0961203307088307; Vinuesa CG, 2009, NAT REV IMMUNOL, V9, P845, DOI 10.1038/nri2637; Wahren-Herlenius M, 2013, LANCET, V382, P819, DOI 10.1016/S0140-6736(13)60954-X; Wallace DJ, 2018, LANCET, V392, P222, DOI 10.1016/S0140-6736(18)31363-1; Wan CK, 2015, P NATL ACAD SCI USA, V112, P9394, DOI 10.1073/pnas.1511711112; Wang L, 2014, J RHEUMATOL, V41, P1781, DOI 10.3899/jrheum.131025; Wang WB, 2011, J IMMUNOL, V187, P2578, DOI 10.4049/jimmunol.1004128; Yiu G, 2016, ARTHRITIS RHEUMATOL, V68, P1233, DOI 10.1002/art.39535; Zeng R, 2007, BLOOD, V109, P4135, DOI 10.1182/blood-2006-10-054973	67	0	0	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 28	2022	13								833636	10.3389/fimmu.2022.833636	http://dx.doi.org/10.3389/fimmu.2022.833636			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZG0BC	35185925	gold, Green Published			2022-12-18	WOS:000759930100001
J	Zhou, XD; Zhao, RP; Yanamandra, AK; Hoth, M; Qu, B				Zhou, Xiangda; Zhao, Renping; Yanamandra, Archana K.; Hoth, Markus; Qu, Bin			Light-Sheet Scattering Microscopy to Visualize Long-Term Interactions Between Cells and Extracellular Matrix	FRONTIERS IN IMMUNOLOGY			English	Article						light-sheet; scattering microscopy; label-free; ECM-cell interaction; long-term	CONFOCAL REFLECTION MICROSCOPY; MIGRATION; DEFORMATION	Visualizing interactions between cells and the extracellular matrix (ECM) mesh is important to understand cell behavior and regulatory mechanisms by the extracellular environment. However, long term visualization of three-dimensional (3D) matrix structures remains challenging mainly due to photobleaching or blind spots perpendicular to the imaging plane. Here, we combine label-free light-sheet scattering microcopy (LSSM) and fluorescence microscopy to solve these problems. We verified that LSSM can reliably visualize structures of collagen matrices from different origin including bovine, human and rat tail. The quality and intensity of collagen structure images acquired by LSSM did not decline with time. LSSM offers abundant wavelength choice to visualize matrix structures, maximizing combination possibilities with fluorescently-labelled cells, allowing visualizing of long-term ECM-cell interactions in 3D. Interestingly, we observed ultrathin thread-like structures between cells and matrix using LSSM, which were not observed by normal fluorescence microscopy. Transient local alignment of matrix by cell-applied forces can be observed. In summary, LSSM provides a powerful and robust approach to investigate the complex interplay between cells and ECM.	[Zhou, Xiangda; Zhao, Renping; Yanamandra, Archana K.; Hoth, Markus; Qu, Bin] Saarland Univ, Sch Med, Ctr Integrat Physiol & Mol Med CIPMM, Biophys, Homburg, Germany; [Yanamandra, Archana K.; Qu, Bin] INM Leibniz Inst New Mat, Saarbrucken, Germany	Universitatsklinikum des Saarlandes; Leibniz Institut fur Neue Materialien (INM)	Qu, B (corresponding author), Saarland Univ, Sch Med, Ctr Integrat Physiol & Mol Med CIPMM, Biophys, Homburg, Germany.; Qu, B (corresponding author), INM Leibniz Inst New Mat, Saarbrucken, Germany.	bin.qu@uks.eu	Qu, Bin/AAK-2260-2021	Qu, Bin/0000-0002-9382-3203	Deutsche Forschungsgemeinschaft [SFB 1027, GZ: INST 256/419-1 FUGG]; Bundesministerium fuer Bildung und Forschung [031L0133]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Bundesministerium fuer Bildung und Forschung	Funding This project was funded by the Deutsche Forschungsgemeinschaft (SFB 1027 Project A2 to BQ, A11 to MH, and GZ: INST 256/419-1 FUGG to MH), and by Bundesministerium fuer Bildung und Forschung (031L0133 to MH).	Backes CS, 2018, J BIOL CHEM, V293, P16348, DOI 10.1074/jbc.RA118.004549; Barnett FH, 2016, SCI REP-UK, V6, DOI 10.1038/srep36659; Bolte S, 2006, J MICROSC-OXFORD, V224, P213, DOI 10.1111/j.1365-2818.2006.01706.x; Brightman AO, 2000, BIOPOLYMERS, V54, P222; Campagnola PJ, 2001, J BIOMED OPT, V6, P277, DOI 10.1117/1.1383294; Chen XY, 2012, NAT PROTOC, V7, P654, DOI 10.1038/nprot.2012.009; Davidson CD, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-37044-1; Doyle AD, 2018, BIO-PROTOCOL, V8, DOI 10.21769/BioProtoc.2919; Franck C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017833; Francois J, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abf3882; Friedl Peter, 2007, Curr Protoc Cell Biol, VChapter 4, DOI 10.1002/0471143030.cb0415s34; Han SB, 2020, ADV BIOSYST, V4, DOI 10.1002/adbi.202000247; Hazlett L, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-72931-6; Jawerth LM, 2010, BIOPHYS J, V98, pL1, DOI 10.1016/j.bpj.2009.09.065; Jones RR, 2019, NANOSCALE RES LETT, V14, DOI 10.1186/s11671-019-3039-2; Killilea AN, 2017, EXP CELL RES, V357, P291, DOI 10.1016/j.yexcr.2017.05.024; Kummerow C, 2014, EUR J IMMUNOL, V44, P1870, DOI 10.1002/eji.201444518; Lau D, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01514; McKay GN, 2021, BIOMED OPT EXPRESS, V12, P2575, DOI 10.1364/BOE.422993; Meijering E, 2012, METHOD ENZYMOL, V504, P183, DOI 10.1016/B978-0-12-391857-4.00009-4; Murphy DA, 2011, NAT REV MOL CELL BIO, V12, P413, DOI 10.1038/nrm3141; Nguyen CD, 2021, LASER SURG MED, V53, P872, DOI 10.1002/lsm.23361; Ostertag E, 2017, ANAL BIOANAL CHEM, V409, P6613, DOI 10.1007/s00216-017-0614-1; Renkawitz J, 2019, NATURE, V568, P546, DOI 10.1038/s41586-019-1087-5; Sadjadi Z, 2020, BIOPHYS J, V119, P2141, DOI 10.1016/j.bpj.2020.10.020; Salvermoser M, 2018, BLOOD, V131, P1887, DOI 10.1182/blood-2017-10-811851; Schoppmeyer R, 2018, JOVE-J VIS EXP, DOI 10.3791/57651; Starborg T, 2013, NAT PROTOC, V8, P1433, DOI 10.1038/nprot.2013.086; Underwood CJ, 2014, AM J PHYSIOL-HEART C, V307, pH152, DOI 10.1152/ajpheart.00995.2013; Wagenblast E, 2015, NATURE, V520, P358, DOI 10.1038/nature14403; Wang WY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09121-0; Welf ES, 2016, DEV CELL, V36, P462, DOI 10.1016/j.devcel.2016.01.022; Winkler J, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18794-x; Wolf K, 2013, J CELL BIOL, V201, P1069, DOI 10.1083/jcb.201210152; Wolf K, 2009, SEMIN CELL DEV BIOL, V20, P931, DOI 10.1016/j.semcdb.2009.08.005; Yang ZY, 2013, OPT EXPRESS, V21, P16239, DOI 10.1364/OE.21.016239; Zanotelli MR, 2018, MOL BIOL CELL, V29, P1, DOI 10.1091/mbc.E17-01-0041	37	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 28	2022	13								828634	10.3389/fimmu.2022.828634	http://dx.doi.org/10.3389/fimmu.2022.828634			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZH5KI	35154150	Green Published, gold			2022-12-18	WOS:000760977300001
J	Ataguenduez, P; Keser, G; Soy, M				Ataguenduez, Pamir; Keser, Goekhan; Soy, Mehmet			Interleukin-1 Inhibitors and Vaccination Including COVID-19 in Inflammatory Rheumatic Diseases: A Nonsystematic Review	FRONTIERS IN IMMUNOLOGY			English	Review						IL-1; interleukin-1 inhibitors; autoimmune; autoinflammatory rheumatic diseases; COVID-19; vaccination	MODIFYING ANTIRHEUMATIC DRUGS; JUVENILE IDIOPATHIC ARTHRITIS; OPEN-LABEL; RECOMMENDATIONS; ANAKINRA; INFLUENZA	Newly emerging variants of coronavirus 2 (SARS-CoV-2) raise concerns about the spread of the disease, and with the rising case numbers, the Coronavirus disease 2019 (COVID-19) remains a challenging medical emergency towards the end of the year 2021. Swiftly developed novel vaccines aid in the prevention of the spread, and it seems that a specific cure will not be at hand soon. The prognosis of COVID-19 in patients with autoimmune/autoinflammatory rheumatic diseases (AIIRD) is more severe when compared to the otherwise healthy population, and vaccination is essential. Evidence for both the efficacy and safety of COVID-19 vaccination in AIIRD under immunosuppression is accumulating, but the effect of Interleukin-1 on vaccination in general and in AIIRD patients is rarely addressed in the current literature. In light of the current literature, it seems that the level of agreement on the timing of COVID-19 vaccination is moderate in patients using IL-1 blockers, and expert opinions may vary. Generally, it may be recommended that patients under IL-1 blockade can be vaccinated without interrupting the anti-cytokine therapy, especially in patients with ongoing high disease activity to avoid disease relapses. However, in selected cases, after balancing for disease activity and risk of relapses, vaccination may be given seven days after the drug levels have returned to baseline, especially for IL-1 blocking agents with long half-lives such as canakinumab and rilonacept. This may help to ensure an ideal vaccine response in the face of the possibility that AIIRD patients may develop a more pronounced and severe COVID-19 disease course.	[Ataguenduez, Pamir] Marmara Univ, Sch Med, Dept Rheumatol, Istanbul, Turkey; [Keser, Goekhan] Ege Univ, Fac Med, Dept Rheumatol, Izmir, Turkey; [Soy, Mehmet] Altinbas Univ, Fac Med, Dept Internal Med & Rheumatol, Istanbul, Turkey	Marmara University; Ege University; Altinbas University	Ataguenduez, P (corresponding author), Marmara Univ, Sch Med, Dept Rheumatol, Istanbul, Turkey.	pamir.atagunduz@gmail.com		ATAGUNDUZ, MEHMET PAMIR/0000-0002-6393-7461				AminJafari A, 2020, INT IMMUNOPHARMACOL, V83, DOI 10.1016/j.intimp.2020.106455; ANTTILA HSI, 1990, J INVEST DERMATOL, V95, P31, DOI 10.1111/1523-1747.ep12873278; Bernal JL, 2021, BMJ-BRIT MED J, V373, DOI 10.1136/bmj.n1088; Bijlsma JWJ, 2021, ANN RHEUM DIS, V80, P411, DOI 10.1136/annrheumdis-2020-219773; Birhane M, 2021, MMWR-MORBID MORTAL W, V70, P792, DOI 10.15585/mmwr.mm7021e3; Brogan P., 2015, PEDIATR RHEUMATOL, V13, pP1, DOI [10.1186/1546-0096-13-s1-p1, DOI 10.1186/1546-0096-13-S1-P1]; Camacho-Lovillo MS, 2017, PEDIATR RHEUMATOL, V15, DOI 10.1186/s12969-017-0190-0; Chioato A, 2010, CLIN VACCINE IMMUNOL, V17, P1952, DOI 10.1128/CVI.00175-10; Cohen I, 2010, P NATL ACAD SCI USA, V107, P2574, DOI 10.1073/pnas.0915018107; Curtis JR, 2021, ARTHRITIS RHEUMATOL, V73, pE30, DOI 10.1002/art.41877; Curtis JR, 2021, ARTHRITIS RHEUMATOL, V73, P1093, DOI 10.1002/art.41734; D'Silva KM, 2021, ARTHRITIS RHEUMATOL, V73, P914, DOI 10.1002/art.41619; Dan JM, 2021, SCIENCE, V371, P587, DOI 10.1126/science.abf4063; Di Paolo NC, 2016, NAT IMMUNOL, V17, P906, DOI 10.1038/ni.3503; Dinarello CA, 2018, IMMUNOL REV, V281, P8, DOI 10.1111/imr.12621; European Medicines Agency, SUMMARY PRODUCT CHAR; Feldstein LR, 2020, NEW ENGL J MED, V383, P334, DOI 10.1056/NEJMoa2021680; Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4; Furer V, 2020, ANN RHEUM DIS, V79, P39, DOI 10.1136/annrheumdis-2019-215882; Gabay C, 2011, ARTHRITIS RHEUM-US, V63, P1486, DOI 10.1002/art.30325; Gabay C, 2010, NAT REV RHEUMATOL, V6, P232, DOI 10.1038/nrrheum.2010.4; Garlanda C, 2016, ENCYCLOPEDIA OF IMMUNOBIOLOGY, VOL 2: MOLECULAR IMMUNOLOGY, P438, DOI 10.1016/B978-0-12-374279-7.10001-3; Geisen UM, 2021, ANN RHEUM DIS, V80, P1306, DOI 10.1136/annrheumdis-2021-220272; Hacisuleyman E, 2021, NEW ENGL J MED, V384, P2212, DOI [10.1056/NEJMoa2105000, 10.1056/NEJMc2107808]; Heijstek MW, 2011, ANN RHEUM DIS, V70, P1704, DOI 10.1136/ard.2011.150193; Heijstek MW, 2013, JAMA-J AM MED ASSOC, V309, P2449, DOI 10.1001/jama.2013.6768; Hsu TYT, 2021, LANCET RHEUMATOL, V3, pE638, DOI 10.1016/S2665-9913(21)00140-5; Jaeger VK, 2017, RHEUMATOLOGY, V56, P1484, DOI 10.1093/rheumatology/kex185; Jeyaratnam J, 2018, PEDIATR RHEUMATOL, V16, DOI 10.1186/s12969-018-0235-z; Kooistra EJ, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03364-w; Lee K, 2009, GLOB INST, P1; Logunov DY, 2020, LANCET, V396, P887, DOI 10.1016/S0140-6736(20)31866-3; Monteagudo LA, 2020, ACR OPEN RHEUMATOL, V2, P276, DOI 10.1002/acr2.11135; Moutsopoulos HM, 2021, J AUTOIMMUN, V121, DOI 10.1016/j.jaut.2021.102649; Nigrovic PA O'Dell JR., UPTODATE INTERLEUKIN; Organization W.H, 2021, INT REC US PFIZ BION; Pasin L, 2021, EUR J INTERN MED, V86, P34, DOI 10.1016/j.ejim.2021.01.016; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Pyrillou K, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.613170; Quartier P, 2011, ANN RHEUM DIS, V70, P747, DOI 10.1136/ard.2010.134254; Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x; Shakoory B, 2016, CRIT CARE MED, V44, P275, DOI 10.1097/CCM.0000000000001402; Singh JA, 2012, ARTHRIT CARE RES, V64, P625, DOI 10.1002/acr.21641; Soy M, 2021, CLIN RHEUMATOL, V40, P3533, DOI 10.1007/s10067-021-05700-z; Soy M, 2020, CLIN RHEUMATOL, V39, P2085, DOI 10.1007/s10067-020-05190-5; Tan L, 2018, NANO RES, V11, P5338, DOI 10.1007/s12274-018-2091-z; ter Haar NM, 2015, ANN RHEUM DIS, V74, P1636, DOI 10.1136/annrheumdis-2015-207546; Thiagarajan K, 2021, BMJ-BRIT MED J, V373, DOI 10.1136/bmj.n997; van Assen S, 2011, ANN RHEUM DIS, V70, P414, DOI 10.1136/ard.2010.137216; Weber A, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.3105cm1; WHO, 2021, INTERIM RECOMMENDATI; Widge AT, 2021, NEW ENGL J MED, V384, P80, DOI 10.1056/NEJMc2032195	52	0	0	2	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 27	2022	12								734279	10.3389/fimmu.2021.734279	http://dx.doi.org/10.3389/fimmu.2021.734279			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YW7ZS	35154066	Green Published, gold			2022-12-18	WOS:000753633500001
J	Cespedes, N; Donnelly, EL; Lowder, C; Hansten, G; Wagers, D; Briggs, AM; Schauer, J; Haapanen, L; Abrink, M; van de Water, J; Luckhart, S				Cespedes, Nora; Donnelly, Erinn L.; Lowder, Casey; Hansten, Gretchen; Wagers, Delaney; Briggs, Anna M.; Schauer, Joseph; Haapanen, Lori; Abrink, Magnus; Van de Water, Judy; Luckhart, Shirley			Mast Cell Chymase/Mcpt4 Suppresses the Host Immune Response to Plasmodium yoelii, Limits Malaria-Associated Disruption of Intestinal Barrier Integrity and Reduces Parasite Transmission to Anopheles stephensi	FRONTIERS IN IMMUNOLOGY			English	Article						malaria; bacteremia; mast cells; Mcpt4; chymase; Plasmodium yoelii; Anopheles stephensi; intestinal permeability	ANTIINFLAMMATORY CYTOKINES; NEUTROPHIL ELASTASE; FALCIPARUM; INFLAMMATION; SALMONELLA; BLOCKING; DEGRADES; SERUM; IL-33; MICE	An increase in mast cells (MCs) and MCs mediators has been observed in malaria-associated bacteremia, however, the role of these granulocytes in malarial immunity is poorly understood. Herein, we studied the role of mouse MC protease (Mcpt) 4, an ortholog of human MC chymase, in malaria-induced bacteremia using Mcpt4 knockout (Mcpt4(-/-)) mice and Mcpt4(+/+) C57BL/6J controls, and the non-lethal mouse parasite Plasmodium yoelii yoelii 17XNL. Significantly lower parasitemia was observed in Mcpt4(-/-) mice compared with Mcpt4(+/+) controls by day 10 post infection (PI). Although bacterial 16S DNA levels in blood were not different between groups, increased intestinal permeability to FITC-dextran and altered ileal adherens junction E-cadherin were observed in Mcpt4(-/-) mice. Relative to infected Mcpt4(+/+) mice, ileal MC accumulation in Mcpt4(-/-) mice occurred two days earlier and IgE levels were higher by days 8-10 PI. Increased levels of circulating myeloperoxidase were observed at 6 and 10 days PI in Mcpt4(+/+) but not Mcpt4(-/-) mice, affirming a role for neutrophil activation that was not predictive of parasitemia or bacterial 16S copies in blood. In contrast, early increased plasma levels of TNF-alpha, IL-12p40 and IL-3 were observed in Mcpt4(-/-) mice, while levels of IL-2, IL-10 and MIP1 beta (CCL4) were increased over the same period in Mcpt4(+/+) mice, suggesting that the host response to infection was skewed toward a type-1 immune response in Mcpt4(-/-) mice and type-2 response in Mcpt4(+/+) mice. Spearman analysis revealed an early (day 4 PI) correlation of Mcpt4(-/-) parasitemia with TNF-alpha and IFN-gamma, inflammatory cytokines known for their roles in pathogen clearance, a pattern that was observed in Mcpt4(+/+) mice much later (day 10 PI). Transmission success of P. y. yoelii 17XNL to Anopheles stephensi was significantly higher from infected Mcpt4(-/-) mice compared with infected Mcpt4(+/+) mice, suggesting that Mcpt4 also impacts transmissibility of sexual stage parasites. Together, these results suggest that early MCs activation and release of Mcpt4 suppresses the host immune response to P. y. yoelii 17XNL, perhaps via degradation of TNF-alpha and promotion of a type-2 immune response that concordantly protects epithelial barrier integrity, while limiting the systemic response to bacteremia and parasite transmissibility.	[Cespedes, Nora; Lowder, Casey; Hansten, Gretchen; Wagers, Delaney; Briggs, Anna M.; Luckhart, Shirley] Univ Idaho, Dept Entomol Plant Pathol & Nematol, Moscow, ID 83843 USA; [Donnelly, Erinn L.; Luckhart, Shirley] Univ Idaho, Dept Biol Sci, Moscow, ID 83843 USA; [Schauer, Joseph; Haapanen, Lori; Van de Water, Judy] Univ Calif Davis, Div Rheumatol Allergy & Clin Immunol, Davis, CA 95616 USA; [Abrink, Magnus] Swedish Univ Agr Sci, Dept Biomed Sci & Vet Publ Hlth, Sect Immunol, Uppsala, Sweden	Idaho; University of Idaho; Idaho; University of Idaho; University of California System; University of California Davis; Swedish University of Agricultural Sciences	Luckhart, S (corresponding author), Univ Idaho, Dept Entomol Plant Pathol & Nematol, Moscow, ID 83843 USA.; Luckhart, S (corresponding author), Univ Idaho, Dept Biol Sci, Moscow, ID 83843 USA.	sluckhart@uidaho.edu		Abrink, Magnus/0000-0002-1335-3927				Aitken EH, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03005; Albert-Bayo M, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8020135; Aung NM, 2018, AM J TROP MED HYG, V99, P688, DOI 10.4269/ajtmh.18-0378; Bischoff SC, 2007, IMMUNOL REV, V217, P329, DOI 10.1111/j.1600-065X.2007.00523.x; Boettcher M, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-74370-9; Bradley J, 2018, ELIFE, V7, DOI [10.7554/eLife.34463, 10.7554/elife.34463]; CARTER R, 1991, Parassitologia (Rome), V33, P67; Castanheira FVS, 2019, BLOOD, V133, P2178, DOI 10.1182/blood-2018-11-844530; Cespedes N, 2020, INFECT IMMUN, V88, DOI 10.1128/IAI.00427-20; Chau JY, 2013, INFECT IMMUN, V81, P3515, DOI 10.1128/IAI.00380-13; Church J, 2014, BMC MED, V12, DOI 10.1186/1741-7015-12-31; de Jong RM, 2020, IMMUNOL REV, V293, P190, DOI 10.1111/imr.12828; Deshmane SL, 2009, J INTERF CYTOK RES, V29, P313, DOI 10.1089/jir.2008.0027; Donnelly Erinn, 2021, Curr Res Microb Sci, V2, P100036, DOI 10.1016/j.crmicr.2021.100036; Dowell AC, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184841; Fu ZR, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20205147; Fu ZR, 2017, J IMMUNOL, V198, P1474, DOI 10.4049/jimmunol.1601223; Goodier MR, 1997, INT IMMUNOL, V9, P1857, DOI 10.1093/intimm/9.12.1857; Groschwitz KR, 2009, P NATL ACAD SCI USA, V106, P22381, DOI 10.1073/pnas.0906372106; Hallett RL, 2006, PLOS CLIN TRIALS, V1, DOI 10.1371/journal.pctr.0010015; Healer J, 1999, INFECT IMMUN, V67, P2334, DOI 10.1128/IAI.67.5.2334-2339.1999; Helegbe GK, 2018, MALARIA J, V17, DOI 10.1186/s12936-018-2257-x; Herbert F, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0731-6; Hirche TO, 2005, J IMMUNOL, V174, P1557, DOI 10.4049/jimmunol.174.3.1557; Imwong M, 2016, J INFECT DIS, V213, P1322, DOI 10.1093/infdis/jiv596; Kenny EF, 2017, ELIFE, V6, DOI [10.7554/elife.24437, 10.7554/eLife.24437]; Krystel-Whittemore M, 2016, FRONT IMMUNOL, V6, P1, DOI 10.3389/fimmu.2015.00620; Li ZQ, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9040925; Lin AM, 2011, J IMMUNOL, V187, P490, DOI 10.4049/jimmunol.1100123; Luckhart S, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.593159; Luckhart S, 2015, CURR OPIN IMMUNOL, V36, P73, DOI 10.1016/j.coi.2015.07.002; Madjene LC, 2020, KIDNEY INT, V97, P516, DOI 10.1016/j.kint.2019.08.037; Matelski L, 2020, CURR RES TOXICOL, V1, P85, DOI 10.1016/j.crtox.2020.09.001; Mohanan V, 2018, SCIENCE, V359, P1161, DOI 10.1126/science.aan0814; Mooney JP, 2019, J LEUKOCYTE BIOL, V105, P645, DOI 10.1002/JLB.3RI1018-400R; Mooney JP, 2015, SCI REP-UK, V5, DOI 10.1038/srep14603; NAOTUNNE TD, 1990, EXP PARASITOL, V71, P305, DOI 10.1016/0014-4894(90)90035-B; Nelissen S, 2014, NEUROBIOL DIS, V62, P260, DOI 10.1016/j.nbd.2013.09.012; Phu NH, 2020, CLIN INFECT DIS, V71, pE465, DOI 10.1093/cid/ciaa191; Otterdal K, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-3593-8; Oyegue-Liabagui SL, 2017, AM J CLIN EXP IMMUNO, V6, P9; Pakpour N, 2014, CURR OPIN INSECT SCI, V3, P1, DOI 10.1016/j.cois.2014.07.001; Pakpour N, 2013, MICROBES INFECT, V15, P243, DOI 10.1016/j.micinf.2013.01.003; Papayannopoulos V, 2010, J CELL BIOL, V191, P677, DOI 10.1083/jcb.201006052; Paul REL, 2002, TRENDS PARASITOL, V18, P32, DOI 10.1016/S1471-4922(01)02122-5; Pejler G, 2007, ADV IMMUNOL, V95, P167, DOI 10.1016/S0065-2776(07)95006-3; Pejler G, 2020, J INNATE IMMUN, V12, P357, DOI 10.1159/000506985; Piliponsky AM, 2012, AM J PATHOL, V181, P875, DOI 10.1016/j.ajpath.2012.05.013; Potts RA, 2016, IMMUNOBIOLOGY, V221, P468, DOI 10.1016/j.imbio.2015.11.003; RILEY EM, 1990, J IMMUNOL, V144, P4810; Rodriguez AM, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11050719; Roy A, 2014, J BIOL CHEM, V289, P237, DOI 10.1074/jbc.M112.435156; Succar J, 2019, ADV WOUND CARE, V8, P469, DOI 10.1089/wound.2018.0898; Tam IYS, 2018, INT ARCH ALLERGY IMM, V177, P199, DOI 10.1159/000490533; Tchougounova E, 2003, J EXP MED, V198, P423, DOI 10.1084/jem.20030671; Torre D, 2002, LANCET INFECT DIS, V2, P719, DOI 10.1016/S1473-3099(02)00449-8; Tu JF, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003220; Vangansewinkel T, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39551-1; Waern I, 2013, MUCOSAL IMMUNOL, V6, P911, DOI 10.1038/mi.2012.129; WHO, 2010, WORLD MALARIA REPORT 2010, P1	60	0	0	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 27	2022	13								801120	10.3389/fimmu.2022.801120	http://dx.doi.org/10.3389/fimmu.2022.801120			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YW9CC	35154114	Green Submitted, gold, Green Published			2022-12-18	WOS:000753708000001
J	Donlon, NE; Davern, M; Sheppard, AD; O'Connell, F; Dunne, MR; Hayes, C; Mylod, E; Ramjit, S; Temperley, H; Mac Lean, M; Cotter, G; Bhardwaj, A; Butler, C; Conroy, MJ; O'Sullivan, J; Ravi, N; Donohoe, CL; Reynolds, JV; Lysaght, J				Donlon, Noel E.; Davern, Maria; Sheppard, Andrew D.; O'Connell, Fiona; Dunne, Margaret R.; Hayes, Conall; Mylod, Eimear; Ramjit, Sinead; Temperley, Hugo; Mac Lean, Michael; Cotter, Gillian; Bhardwaj, Anshul; Butler, Christine; Conroy, Melissa J.; O'Sullivan, Jacintha; Ravi, Narayanasamy; Donohoe, Claire L.; Reynolds, John V.; Lysaght, Joanne			The Impact of Esophageal Oncological Surgery on Perioperative Immune Function; Implications for Adjuvant Immune Checkpoint Inhibition	FRONTIERS IN IMMUNOLOGY			English	Article						perioperative immunosuppression; immunotherapy; surgery; neoadjuvant; esophageal cancer; adjuvant	CANCER; CELLS; SURVIVAL; ADENOCARCINOMA; METASTASIS; CARCINOMA; THERAPY; SYSTEM; MEMORY; CTLA-4	BackgroundImmune checkpoint inhibitors (ICIs) are being investigated for their role as an adjunct in the multimodal treatment of esophageal adenocarcinoma (EAC). The most effective time to incorporate ICIs remains unknown. Our study profiles systemic anti-tumor immunity perioperatively to help inform the optimal timing of ICIs into current standards of care for EAC patients. MethodsSystemic immunity in 11 EAC patients was phenotyped immediately prior to esophagectomy (POD-0) and post-operatively (POD)-1, 3, 7 and week 6. Longitudinal serological profiling was conducted by ELISA. The frequency of circulating lymphocytes, activation status, immune checkpoint expression and damage-associated molecular patterns was assessed by flow cytometry. ResultsThe frequency of naive T-cells significantly increased in circulation post-esophagectomy from POD-0 to POD-7 (p<0.01) with a significant decrease in effector memory T-cells by POD7 followed by a subsequent increase by week 6 (p<0.05). A significant increase in activated circulating CD27(+) T-cells was observed from POD-0 to POD-7 (p<0.05). The percentage of PD-1(+) and CTLA-4(+) T-cells peaked on POD-1 and was significantly decreased by week 6 (p<0.01). There was a significant increase in soluble PD-1, PD-L2, TIGIT and LAG-3 from POD-3 to week 6 (p<0.01). Increased checkpoint expression correlated with those who developed metastatic disease early in their postoperative course. Th1 cytokines and co-stimulatory factors decreased significantly in the immediate post-operative setting, with a reduction in IFN-gamma, IL-12p40, IL-1RA, CD28, CD40L and TNF-alpha. A simultaneous increase was observed in Th2 cytokines in the immediate post-operative setting, with a significant increase in IL-4, IL-10, IL-16 and MCP-1 before returning to preoperative levels at week 6. ConclusionOur study highlights the prevailing Th2-like immunophenotype post-surgery. Therefore, shifting the balance in favour of a Th1-like phenotype would offer a potent therapeutic approach to promote cancer regression and prevent recurrence in the adjuvant setting and could potentially propagate anti-tumour immune responses perioperatively if administered in the immediate neoadjuvant setting. Consequently, this body of work paves the way for further studies and appropriate trial design is needed to further interrogate and validate the use of ICI in the multimodal treatment of locally advanced disease in the neoadjuvant and adjuvant setting.	[Donlon, Noel E.; Davern, Maria; Sheppard, Andrew D.; Mylod, Eimear; Conroy, Melissa J.; Lysaght, Joanne] St James Hosp, Trinity St Jamess Canc Inst, Trinity Translat Med Inst, Canc Immunol & Immunotherapy Grp,Dept Surg, Dublin, Ireland; [Donlon, Noel E.; Davern, Maria; Sheppard, Andrew D.; O'Connell, Fiona; Dunne, Margaret R.; Hayes, Conall; Mylod, Eimear; Ramjit, Sinead; Temperley, Hugo; Mac Lean, Michael; Cotter, Gillian; Bhardwaj, Anshul; Butler, Christine; Conroy, Melissa J.; O'Sullivan, Jacintha; Ravi, Narayanasamy; Donohoe, Claire L.; Reynolds, John V.; Lysaght, Joanne] Trinity Coll Dublin, St Jamess Hosp, Trinity St Jamess Canc Inst, Trinity Translat Med Inst,Dept Surg, Dublin, Ireland	Trinity College Dublin; Trinity College Dublin	Donlon, NE (corresponding author), St James Hosp, Trinity St Jamess Canc Inst, Trinity Translat Med Inst, Canc Immunol & Immunotherapy Grp,Dept Surg, Dublin, Ireland.; Donlon, NE (corresponding author), Trinity Coll Dublin, St Jamess Hosp, Trinity St Jamess Canc Inst, Trinity Translat Med Inst,Dept Surg, Dublin, Ireland.	donlonn@tcd.ie	Dunne, Margaret/AAE-9152-2020; Lysaght, Joanne/AAC-2399-2022	Dunne, Margaret/0000-0002-2816-5064; Lysaght, Joanne/0000-0003-3363-3763	CROSS Cancer Charity [RCN: 15364]	CROSS Cancer Charity	Funding This work was supported by the CROSS Cancer Charity (RCN: 15364).	Al-Batran SE, 2019, LANCET, V393, P1948, DOI 10.1016/S0140-6736(18)32557-1; Aliru ML, 2018, IMMUNOTHERAPY-UK, V10, P299, DOI 10.2217/imt-2017-0082; Ando Makoto, 2020, Immunol Med, V43, P1, DOI 10.1080/25785826.2019.1698261; Bakos O, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0398-7; Benish Marganit, 2010, Cancers (Basel), V2, P1929, DOI 10.3390/cancers2041929; Berger C, 2008, J CLIN INVEST, V118, P294, DOI 10.1172/JCI32103; Dong PX, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00264; Donlon NE, 2021, CANCERS, V13, DOI 10.3390/cancers13164005; Donlon NE, 2021, ANN SURG, V274, P814, DOI 10.1097/SLA.0000000000005097; Donlon NE, 2020, CANCERS, V12, DOI 10.3390/cancers12113356; Donlon NE, 2020, ANN SURG, V272, P814, DOI 10.1097/SLA.0000000000004184; Fougeray S, 2006, VACCINE, V24, P5426, DOI 10.1016/j.vaccine.2006.03.050; Frigola X, 2012, IMMUNOL LETT, V142, P78, DOI 10.1016/j.imlet.2011.11.001; Ge WH, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317715643; Gonzalez H, 2018, GENE DEV, V32, P1267, DOI 10.1101/gad.314617.118; Gu DQ, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0449-0; Hinrichs CS, 2009, P NATL ACAD SCI USA, V106, P17469, DOI 10.1073/pnas.0907448106; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Horowitz M, 2015, NAT REV CLIN ONCOL, V12, P213, DOI 10.1038/nrclinonc.2014.224; Janssen LME, 2017, J IMMUNOTHER CANCER, V5, DOI 10.1186/s40425-017-0283-9; Kaur P, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00191; Kelly RJ, 2021, NEW ENGL J MED, V384, P1191, DOI 10.1056/NEJMoa2032125; Kumar V, 2016, TRENDS IMMUNOL, V37, P208, DOI 10.1016/j.it.2016.01.004; Leach DR, 1996, SCIENCE, V271, P1734, DOI 10.1126/science.271.5256.1734; Leijte GP, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00663; Li N, 2018, CANCER BIOMARK, V23, P341, DOI 10.3233/CBM-181278; Liu QJ, 2020, PROTEIN CELL, V11, P549, DOI 10.1007/s13238-020-00707-9; Loke P, 2003, P NATL ACAD SCI USA, V100, P5336, DOI 10.1073/pnas.0931259100; Lou FR, 2013, J THORAC ONCOL, V8, P1558, DOI 10.1097/01.JTO.0000437420.38972.fb; Macarulla T, 2020, EXPERT OPIN BIOL TH, V20, P15, DOI 10.1080/14712598.2020.1677603; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Matzner P, 2020, NAT REV CLIN ONCOL, V17, P313, DOI 10.1038/s41571-019-0319-9; Maurer M, 2004, INT J BIOCHEM CELL B, V36, P1882, DOI 10.1016/j.biocel.2003.10.019; Najafi M, 2019, J CELL BIOCHEM, V120, P2756, DOI 10.1002/jcb.27646; Nakayamada S, 2012, CURR OPIN IMMUNOL, V24, P297, DOI 10.1016/j.coi.2012.01.014; Nobel TB, 2019, ANN THORAC SURG, V108, P1640, DOI 10.1016/j.athoracsur.2019.05.066; Qian BZ, 2015, J EXP MED, V212, P1433, DOI 10.1084/jem.20141555; Rabinovich GA, 2007, ANNU REV IMMUNOL, V25, P267, DOI 10.1146/annurev.immunol.25.022106.141609; Silva TA, 2007, ONCOL REP, V18, P1107; Smyth E, 2020, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01320; Sorensen SF, 2016, LUNG CANCER, V100, P77, DOI 10.1016/j.lungcan.2016.08.001; Sukumar M, 2017, CURR OPIN IMMUNOL, V46, P14, DOI 10.1016/j.coi.2017.03.011; Tang F, 2020, CLIN TRANSL MED, V10, P199, DOI 10.1002/ctm2.24; Tomasello G, 2017, EJSO-EUR J SURG ONC, V43, P1607, DOI 10.1016/j.ejso.2017.03.001; van Hagen P, 2012, NEW ENGL J MED, V366, P2074, DOI 10.1056/NEJMoa1112088; Vanmeerbeek I, 2020, ONCOIMMUNOLOGY, V9, DOI 10.1080/2162402X.2019.1703449; Ward FJ, 2013, EUR J IMMUNOL, V43, P1274, DOI 10.1002/eji.201242529; Youngs SJ, 1997, INT J CANCER, V71, P257, DOI 10.1002/(SICI)1097-0215(19970410)71:2<257::AID-IJC22>3.0.CO;2-D	48	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 27	2022	13								823225	10.3389/fimmu.2022.823225	http://dx.doi.org/10.3389/fimmu.2022.823225			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YW9CA	35154142	Green Published, gold			2022-12-18	WOS:000753707800001
J	George, AF; Luo, XY; Neidleman, J; Hoh, R; Vohra, P; Thomas, R; Shin, MG; Lee, MDLEJ; Blish, CA; Deeks, SG; Greene, WC; Lee, SLA; Roan, NR				George, Ashley F.; Luo, Xiaoyu; Neidleman, Jason; Hoh, Rebecca; Vohra, Poonam; Thomas, Reuben; Shin, Min-Gyoung; Lee, Madeline J.; Blish, Catherine A.; Deeks, Steven G.; Greene, Warner C.; Lee, Sulggi A.; Roan, Nadia R.			Deep Phenotypic Analysis of Blood and Lymphoid T and NK Cells From HIV plus Controllers and ART-Suppressed Individuals	FRONTIERS IN IMMUNOLOGY			English	Article						HIV; lymph node; T cells; NK cells; CXCR5; controllers; CyTOF; mass cytometry	ANTIRETROVIRAL THERAPY; INFECTION; MEMORY; EXPRESSION; CD4(+); ACTIVATION; REPLICATION; VIRUS; COMPARTMENTALIZATION; IMMUNODEFICIENCY	T and natural killer (NK) cells are effector cells with key roles in anti-HIV immunity, including in lymphoid tissues, the major site of HIV persistence. However, little is known about the features of these effector cells from people living with HIV (PLWH), particularly from those who initiated antiretroviral therapy (ART) during acute infection. Our study design was to use 42-parameter CyTOF to conduct deep phenotyping of paired blood- and lymph node (LN)-derived T and NK cells from three groups of HIV+ aviremic individuals: elite controllers (N = 5), and ART-suppressed individuals who had started therapy during chronic (N = 6) vs. acute infection (N = 8), the latter of which is associated with better outcomes. We found that acute-treated individuals are enriched for specific subsets of T and NK cells, including blood-derived CD56-CD16+ NK cells previously associated with HIV control, and LN-derived CD4+ T follicular helper cells with heightened expansion potential. An in-depth comparison of the features of the cells from blood vs. LNs of individuals from our cohort revealed that T cells from blood were more activated than those from LNs. By contrast, LNs were enriched for follicle-homing CXCR5+ CD8+ T cells, which expressed increased levels of inhibitory receptors and markers of survival and proliferation as compared to their CXCR5- counterparts. In addition, a subset of memory-like CD56(bright)TCF1+ NK cells was enriched in LNs relative to blood. These results together suggest unique T and NK cell features in acute-treated individuals, and highlight the importance of examining effector cells not only in blood but also the lymphoid tissue compartment, where the reservoir mostly persists, and where these cells take on distinct phenotypic features.	[George, Ashley F.; Luo, Xiaoyu; Neidleman, Jason; Greene, Warner C.; Roan, Nadia R.] Gladstone Inst Virol, San Francisco, CA 94158 USA; [George, Ashley F.; Neidleman, Jason; Roan, Nadia R.] Univ Calif San Francisco, Dept Urol, San Francisco, CA 94118 USA; [Hoh, Rebecca; Deeks, Steven G.] Univ Calif San Francisco, Div HIV Infect Dis & Global Med, San Francisco, CA 94143 USA; [Vohra, Poonam] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94140 USA; [Thomas, Reuben; Shin, Min-Gyoung] Gladstone Inst, San Francisco, CA USA; [Lee, Madeline J.; Blish, Catherine A.] Stanford Univ, Dept Med, Sch Med, Stanford, CA 94305 USA; [Lee, Madeline J.; Blish, Catherine A.] Stanford Sch Med, Program Immunol, Stanford, CA 94305 USA; [Greene, Warner C.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; [Greene, Warner C.] Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA; [Lee, Sulggi A.] Zuckerberg San Francisco Gen Hosp, San Francisco, CA 94110 USA; [Lee, Sulggi A.] Univ Calif San Francisco, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; The J David Gladstone Institutes; Stanford University; Stanford University; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Roan, NR (corresponding author), Gladstone Inst Virol, San Francisco, CA 94158 USA.; Roan, NR (corresponding author), Univ Calif San Francisco, Dept Urol, San Francisco, CA 94118 USA.; Lee, SLA (corresponding author), Zuckerberg San Francisco Gen Hosp, San Francisco, CA 94110 USA.; Lee, SLA (corresponding author), Univ Calif San Francisco, San Francisco, CA 94143 USA.	sulggi.lee@ucsf.edu; nadia.roan@gladstone.ucsf.edu	Vohra, Poonam/CAH-4585-2022	Lee, Maddie/0000-0001-5039-6806; Blish, Catherine/0000-0001-6946-7627	National Institutes of Health [R01 AI147777, P01 AI131374]; amfAR Institute for HIV Cure Research [109380-59-RGRL]; Gilead Sciences Investigator-Initiated Grant [IN-US-236-1354]; Viiv Health Investigator-Initiated Grant [CA-0101618, UM1 AI164559, UM1 AI164567];  [P30 DK063720];  [S10 1S10OD018040-01]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); amfAR Institute for HIV Cure Research; Gilead Sciences Investigator-Initiated Grant(Gilead Sciences); Viiv Health Investigator-Initiated Grant; ; 	This work was supported by the following grants: National Institutes of Health R01 AI147777 (NRR); National Institutes of Health P01 AI131374 (WCG); amfAR Institute for HIV Cure Research 109380-59-RGRL (SGD, SAL, NRR); Gilead Sciences Investigator-Initiated Grant IN-US-236-1354 (SAL); Viiv Health Investigator-Initiated Grant CA-0101618 (SAL), UM1 AI164559 and UM1 AI164567 (NRR).	Avettand-Fenoel V, 2019, J INT AIDS SOC, V22, DOI 10.1002/jia2.25221; Ayala VI, 2017, J VIROL, V91, DOI 10.1128/JVI.02507-16; Baeyens A, 2015, TRENDS IMMUNOL, V36, P778, DOI 10.1016/j.it.2015.10.005; Banga R, 2016, NAT MED, V22, P754, DOI 10.1038/nm.4113; Bates D, 2015, J STAT SOFTW, V67, P1, DOI 10.18637/jss.v067.i01; Betts MR, 2006, BLOOD, V107, P4781, DOI 10.1182/blood-2005-12-4818; Bjorkstrom NK, 2022, NAT REV IMMUNOL, V22, P112, DOI 10.1038/s41577-021-00558-3; Bradley T, 2018, CELL, V175, P387, DOI 10.1016/j.cell.2018.08.064; Brenchley JM, 2012, BLOOD, V120, P4172, DOI 10.1182/blood-2012-06-437608; Carrega P, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00347; Casado C, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-58696-y; Cavrois M, 2017, CELL REP, V20, P984, DOI 10.1016/j.celrep.2017.06.087; Chun TW, 2007, J INFECT DIS, V195, P1762, DOI 10.1086/518250; Cibrian D, 2017, EUR J IMMUNOL, V47, P946, DOI 10.1002/eji.201646837; Cossarizza A, 1996, MECH AGEING DEV, V86, P173, DOI 10.1016/0047-6374(95)01691-0; Dogra P, 2020, CELL, V180, P749, DOI 10.1016/j.cell.2020.01.022; Doisne JM, 2004, J IMMUNOL, V173, P2410, DOI 10.4049/jimmunol.173.4.2410; Estes JD, 2017, NAT MED, V23, P1271, DOI 10.1038/nm.4411; Gaiha GD, 2019, SCIENCE, V364, P480, DOI 10.1126/science.aav5095; Haran KP, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00492; Hocqueloux L, 2013, J ANTIMICROB CHEMOTH, V68, P1169, DOI 10.1093/jac/dks533; HU PF, 1995, J ACQ IMMUN DEF SYND, V10, P331; Huot N, 2017, NAT MED, V23, P1277, DOI 10.1038/nm.4421; Jain V, 2013, J INFECT DIS, V208, P1202, DOI 10.1093/infdis/jit311; Kaech SM, 2003, NAT IMMUNOL, V4, P1191, DOI 10.1038/ni1009; Kazer SW, 2020, IMMUNITY, V53, P908, DOI 10.1016/j.immuni.2020.10.015; KESTENS L, 1992, AIDS, V6, P793, DOI 10.1097/00002030-199208000-00004; Kondrack RM, 2003, J EXP MED, V198, P1797, DOI 10.1084/jem.20030735; Korencak M, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.126675; Kumar BV, 2017, CELL REP, V20, P2921, DOI 10.1016/j.celrep.2017.08.078; Kuo CT, 1999, ANNU REV IMMUNOL, V17, P149, DOI 10.1146/annurev.immunol.17.1.149; Lee SA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160192; Leong YA, 2016, NAT IMMUNOL, V17, P1187, DOI 10.1038/ni.3543; Levine JH, 2015, CELL, V162, P184, DOI 10.1016/j.cell.2015.05.047; Leyre L, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aav3491; Lindqvist M, 2012, J CLIN INVEST, V122, P3271, DOI 10.1172/JCI64314; Lodi S, 2012, ARCH INTERN MED, V172, P1252, DOI 10.1001/archinternmed.2012.2719; Lovmar L, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-35; Ma TC, 2021, J IMMUNOL, V207, P1344, DOI 10.4049/jimmunol.2100465; Ma TC, 2020, ELIFE, V9, DOI 10.7554/eLife.55487; Maenza J, 2015, ANTIVIR THER, V20, P855, DOI 10.3851/IMP2963; Migueles SA, 2008, IMMUNITY, V29, P1009, DOI 10.1016/j.immuni.2008.10.010; Monel B, 2019, CELL REP, V27, P142, DOI 10.1016/j.celrep.2019.03.016; Moser JM, 2002, NAT IMMUNOL, V3, P189, DOI 10.1038/ni757; Nabatanzi R, 2019, CLIN IMMUNOL, V201, P55, DOI 10.1016/j.clim.2019.02.010; Nattermann J, 2006, GUT, V55, P869, DOI 10.1136/gut.2005.076463; Ndhlovu ZM, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aau0528; Neidleman J, 2021, CELL REP, V36, DOI 10.1016/j.celrep.2021.109414; Neidleman J, 2020, ELIFE, V9, DOI 10.7554/eLife.60933; Neidleman J, 2020, CELL REP MED, V1, DOI 10.1016/j.xcrm.2020.100081; Nguyen S, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aax4077; Nikzad R, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aat8116; Papagno L, 2004, PLOS BIOL, V2, P173, DOI 10.1371/journal.pbio.0020020; Peppa D, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00474; Pereyra FP, 2010, SCIENCE, V330, P1551, DOI 10.1126/science.1195271; Perreau M, 2013, J EXP MED, V210, P143, DOI 10.1084/jem.20121932; Reuter MA, 2017, CELL REP, V21, P3458, DOI 10.1016/j.celrep.2017.11.075; Saez-Cirion A, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003211; Sathaliyawala T, 2013, IMMUNITY, V38, P187, DOI 10.1016/j.immuni.2012.09.020; Satija R, 2015, NAT BIOTECHNOL, V33, P495, DOI 10.1038/nbt.3192; Saule P, 2006, MECH AGEING DEV, V127, P274, DOI 10.1016/j.mad.2005.11.001; Scott-Algara D., 2015, C RETR OPP INF; Shin MG, 2019, PLANT SCI, V285, P122, DOI 10.1016/j.plantsci.2019.04.018; Sneller MC, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aan8848; Sullivan LC, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abe9057; Takata H, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aag1809; Thome JJC, 2014, CELL, V159, P814, DOI 10.1016/j.cell.2014.10.026; Vendrame E, 2020, AIDS, V34, P801, DOI 10.1097/QAD.0000000000002488; Wang YT, 2020, NAT IMMUNOL, V21, P274, DOI 10.1038/s41590-020-0593-9; Watson DC, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1006902; Webb GM, 2018, BLOOD ADV, V2, P76, DOI 10.1182/bloodadvances.2017012971; Xie GR, 2021, CELL REP, V35, DOI 10.1016/j.celrep.2021.109038; Zhao NQ, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0238347; Zhou XY, 2010, IMMUNITY, V33, P229, DOI 10.1016/j.immuni.2010.08.002	74	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 27	2022	13								803417	10.3389/fimmu.2022.803417	http://dx.doi.org/10.3389/fimmu.2022.803417			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YX0FB	35154118	Green Published, gold			2022-12-18	WOS:000753783300001
J	Guo, MMH; Huang, YH; Wang, FS; Chang, LS; Chen, KD; Kuo, HC				Guo, Mindy Ming-Huey; Huang, Ying-Hsien; Wang, Feng-Sheng; Chang, Ling-Sai; Chen, Kuang-Den; Kuo, Ho-Chang			CD36 is Associated With the Development of Coronary Artery Lesions in Patients With Kawasaki Disease	FRONTIERS IN IMMUNOLOGY			English	Article						Kawasaki disease; coronary artery lesions; CD36; AIM2; macrophage	MITOCHONDRIAL-DNA; RECEPTOR; MANAGEMENT; CYTOKINES; DIAGNOSIS; CELLS	Kawasaki disease (KD) is an autoimmune-like vasculitis of childhood involving the coronary arteries. Macrophages require scavenger receptors such as CD36 to effectively clear cellular debris and induce self-tolerance. In this study, we hypothesized that CD36 plays an important role in the immunopathogenesis of KD, by aiding in the clearance of plasma mitochondrial DNA, and by amplifying the immune response by activating the inflammasome pathway via AIM2. Fifty-two healthy controls, 52 febrile controls, and 102 KD patients were recruited for RT-PCR of target mRNA expression and plasma mitochondrial DNA. Blood samples were obtained 24 hours prior and 21 days after the administration of intravenous immunoglobulin (IVIG) therapy. Patients with acute KD had higher plasma levels of cell-free mitochondrial DNA (ND1, ND4, and COX1), and higher mRNA expressions of CD36 and AIM2 when compared to both healthy and febrile controls. A greater decrease in both CD36 and AIM2 mRNA expression after IVIG therapy was associated with the development of coronary artery lesions. Coronary artery lesions were associated with a larger decrease of CD36 expression following IVIG therapy, which may indicate that prolonged expression of the scavenger receptor may have a protective effect against the development of coronary artery lesions in KD.	[Guo, Mindy Ming-Huey; Huang, Ying-Hsien; Chang, Ling-Sai; Chen, Kuang-Den; Kuo, Ho-Chang] Kaohsiung Chang Gung Mem Hosp, Dept Pediat, Kaohsiung, Taiwan; [Guo, Mindy Ming-Huey; Huang, Ying-Hsien; Chang, Ling-Sai; Chen, Kuang-Den; Kuo, Ho-Chang] Chang Gung Univ, Coll Med, Kaohsiung, Taiwan; [Guo, Mindy Ming-Huey; Huang, Ying-Hsien; Chang, Ling-Sai; Kuo, Ho-Chang] Kaohsiung Chang Gung Mem Hosp, Kawasaki Dis Ctr, Kaohsiung, Taiwan; [Guo, Mindy Ming-Huey; Wang, Feng-Sheng; Kuo, Ho-Chang] Chang Gung Univ, Grad Inst Clin Med Sci, Coll Med, Taoyuan, Taiwan; [Wang, Feng-Sheng] Chang Gung Univ, Dept Med Res, Kaohsiung Chang Gung Mem Hosp, Coll Med, Kaohsiung, Taiwan; [Wang, Feng-Sheng] Chang Gung Univ, Ctr Lab Anim, Kaohsiung Chang Gung Mem Hosp, Coll Med, Kaohsiung, Taiwan; [Chen, Kuang-Den] Kaohsiung Chang Gung Mem Hosp, Inst Translat Res Biomed, Liver Transplantat Ctr, Kaohsiung, Taiwan; [Chen, Kuang-Den] Kaohsiung Chang Gung Mem Hosp, Dept Surg, Kaohsiung, Taiwan; [Kuo, Ho-Chang] Kaohsiung Chang Gung Mem Hosp, Dept Resp Therapy, Kaohsiung, Taiwan	Chang Gung Memorial Hospital; Chang Gung University; Chang Gung Memorial Hospital; Chang Gung University; Chang Gung Memorial Hospital; Chang Gung University; Chang Gung Memorial Hospital; Chang Gung University; Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Chang Gung Memorial Hospital	Huang, YH; Kuo, HC (corresponding author), Kaohsiung Chang Gung Mem Hosp, Dept Pediat, Kaohsiung, Taiwan.; Huang, YH; Kuo, HC (corresponding author), Chang Gung Univ, Coll Med, Kaohsiung, Taiwan.; Huang, YH; Kuo, HC (corresponding author), Kaohsiung Chang Gung Mem Hosp, Kawasaki Dis Ctr, Kaohsiung, Taiwan.; Kuo, HC (corresponding author), Chang Gung Univ, Grad Inst Clin Med Sci, Coll Med, Taoyuan, Taiwan.; Kuo, HC (corresponding author), Kaohsiung Chang Gung Mem Hosp, Dept Resp Therapy, Kaohsiung, Taiwan.	yhhuang123@yahoo.com.tw; erickuo48@yahoo.com.tw	Kuo, Ho-Chang/AAQ-6644-2020	Kuo, Ho-Chang/0000-0002-3295-2984	Ministry of Science and Technology [MOST 108-2314-B-182 -037 -MY3]; Chang Gung Memorial Hospital [CMRPG8J0321, CMRPG8J1151, CMRPG8L0031, CMRPG8L0021]	Ministry of Science and Technology(Ministry of Science, ICT & Future Planning, Republic of Korea); Chang Gung Memorial Hospital(Chang Gung Memorial Hospital)	Funding This study received funding from the Ministry of Science and Technology MOST 108-2314-B-182 -037 -MY3 and grants provided by Chang Gung Memorial Hospital (CMRPG8J0321, CMRPG8J1151, CMRPG8L0031, CMRPG8L0021). The funders had no role in study design, collection, analysis, and interpretation of data, writing or the decision to submit this paper for publication.	Akashi-Takamura S, 2008, CURR OPIN IMMUNOL, V20, P420, DOI 10.1016/j.coi.2008.07.001; Anzai F, 2020, J MOL CELL CARDIOL, V138, P185, DOI 10.1016/j.yjmcc.2019.11.158; Burns JC, 2004, LANCET, V364, P533, DOI 10.1016/S0140-6736(04)16814-1; CAVENDER DE, 1991, J LEUKOCYTE BIOL, V49, P566, DOI 10.1002/jlb.49.6.566; Choromanska B, 2017, ADV CLIN EXP MED, V26, P717, DOI 10.17219/acem/62325; Collins LV, 2004, J LEUKOCYTE BIOL, V75, P995, DOI 10.1189/jlb.0703328; Duvvuri B, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00502; Febbraio M, 2001, J CLIN INVEST, V108, P785, DOI 10.1172/JCI200114006; Goulopoulou S, 2016, PHARMACOL REV, V68, P142, DOI 10.1124/pr.114.010090; Greenberg ME, 2006, J EXP MED, V203, P2613, DOI 10.1084/jem.20060370; Guo MMH, 2015, ALLERGY, V70, P310, DOI 10.1111/all.12558; Guo MMH, 2020, FRONT PEDIATR, V8, DOI 10.3389/fped.2020.00129; Huang LH, 2018, CLIN EPIGENETICS, V10, DOI 10.1186/s13148-018-0557-1; Huang Ying-Hsien, 2018, Oncotarget, V9, P18939, DOI 10.18632/oncotarget.24851; Huang YH, 2017, ONCOTARGET, V8, P11249, DOI 10.18632/oncotarget.14497; ISHIHARA H, 1985, Bulletin of Tokyo Medical and Dental University, V32, P77; Jia C, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-2021-3; Kim J, 2019, SCIENCE, V366, P1531, DOI 10.1126/science.aav4011; Krispin A, 2006, BLOOD, V108, P3580, DOI 10.1182/blood-2006-03-013334; Kuo HC, 2009, PEDIAT ALLERG IMM-UK, V20, P266, DOI 10.1111/j.1399-3038.2008.00779.x; Lin HY, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8101298; Lin IC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038635; Lin SH, 2018, J DERMATOL SCI, V91, P276, DOI 10.1016/j.jdermsci.2018.05.009; Lleo A, 2008, J AUTOIMMUN, V31, P257, DOI 10.1016/j.jaut.2008.04.009; Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015; McCrindle BW, 2017, CIRCULATION, V135, pE927, DOI 10.1161/CIR.0000000000000484; Nakahira K, 2011, NAT IMMUNOL, V12, P222, DOI 10.1038/ni.1980; Nakamura Y, 2010, J EPIDEMIOL, V20, P302, DOI 10.2188/jea.JE20090180; Ogawa S, 2010, CIRC J, V74, P1989, DOI 10.1253/circj.CJ-10-74-0903; Park YM, 2014, EXP MOL MED, V46, DOI 10.1038/emm.2014.38; Pennathur S, 2015, AM J PATHOL, V185, P2232, DOI 10.1016/j.ajpath.2015.04.016; Plociennikowska A, 2015, CELL MOL LIFE SCI, V72, P557, DOI 10.1007/s00018-014-1762-5; Pont J, 2018, CYTOM PART B-CLIN CY, V94, P627, DOI 10.1002/cyto.b.21643; Rowley AH, 2008, NAT REV MICROBIOL, V6, P394, DOI 10.1038/nrmicro1853; Trahtemberg U, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01356; Wang Z, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-25771-5; West AP, 2017, NAT REV IMMUNOL, V17, P363, DOI 10.1038/nri.2017.21; Wu MH, 2017, J PEDIATR-US, V180, P80, DOI 10.1016/j.jpeds.2016.09.052; Yuzefovych LV, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0222278; Zeng YY, 2021, WORLD J PEDIATR, V17, P476, DOI 10.1007/s12519-021-00452-x; Zhu Minghua, 2018, Immunohorizons, V2, P384, DOI 10.4049/immunohorizons.1800063	41	0	0	4	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 27	2022	13								790095	10.3389/fimmu.2022.790095	http://dx.doi.org/10.3389/fimmu.2022.790095			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YW0ZH	35154107	gold, Green Published			2022-12-18	WOS:000753149900001
J	Kibler, A; Budeus, B; Kueppers, R; Seifert, M				Kibler, Artur; Budeus, Bettina; Kueppers, Ralf; Seifert, Marc			The Splenic Marginal Zone in Children Is Characterized by a Subpopulation of CD27-Negative, Lowly IGHV-Mutated B Cells	FRONTIERS IN IMMUNOLOGY			English	Article						human; B cell; marginal zone (MZ) B cell; aging; spleen	EXPRESSION; RESPONSES; ACTIVATION; CD27	Young children and older adults suffer from enhanced susceptibility to infections with blood-borne pathogens. An essential step towards immunity is the establishment of a splenic marginal zone (sMZ), which is immature at below 2 years of age. At approximately 5 years of age, an adult level of protection is reached but wanes again in older adults. Although the infant sMZ is thought to contain mostly naive B cells, memory B cells are recruited to and recirculate from the sMZ throughout life, and class-switched sMZ B cells dominate in older adults. For a better resolution of naive versus memory B-cell subset accumulation in the sMZ, we performed a single cell-based gene expression analysis of (CD21(high)IgM(high)) sMZ B cells among five healthy donors (age 3 to 48 years) and validated the sMZ B-cell subset composition by flow cytometry of 147 spleen biopsies (age 0 to 82 years). We identified a major sMZ B-cell subpopulation, which is abundant at birth but decreases with age. These cells lack CD27 expression but carry a weak-to-intermediate memory B-cell signature. These CD27(neg) sMZ B cells are either IGHV-unmutated or carry only a few IGHV mutations early in life but show average memory B-cell IGHV mutation frequencies (>3%) in adults. The activation and proliferation potential of CD27(neg) sMZ B cells is significantly above that of non-sMZ B cells already in children. Our study suggests that the human sMZ B-cell pool changes with age, encompassing a major population of lowly Ig-mutated CD27neg but antigen-experienced B cells early in life.	[Kibler, Artur; Budeus, Bettina; Kueppers, Ralf; Seifert, Marc] Univ Duisburg Essen, Inst Cell Biol, Canc Res, Essen, Germany	University of Duisburg Essen	Seifert, M (corresponding author), Univ Duisburg Essen, Inst Cell Biol, Canc Res, Essen, Germany.	marc.seifert@uni-due.de		Kibler, Artur/0000-0002-4723-4993				Blanco E, 2018, J ALLERGY CLIN IMMUN, V141, P2208, DOI 10.1016/j.jaci.2018.02.017; Budeus B, 2021, J IMMUNOL, V206, P2839, DOI 10.4049/jimmunol.2100113; Cerutti A, 2013, NAT REV IMMUNOL, V13, P118, DOI 10.1038/nri3383; Descatoire M, 2014, J EXP MED, V211, P986, DOI 10.1084/jem.20132203; ECDC, 2020, ANN EPIDEMIOLOGICAL; Grimsholm O, 2020, CELL REP, V30, P2963, DOI 10.1016/j.celrep.2020.02.022; Hendricks J, 2018, CRIT REV IMMUNOL, V38, P145, DOI 10.1615/CritRevImmunol.2018024985; Kibler A, 2021, J EXP MED, V218, DOI 10.1084/jem.20201952; Klein U, 1998, J EXP MED, V188, P1679, DOI 10.1084/jem.188.9.1679; Kruetzmann S, 2003, J EXP MED, V197, P939, DOI 10.1084/jem.20022020; MONROE JG, 1983, EUR J IMMUNOL, V13, P208, DOI 10.1002/eji.1830130306; Nemazee D, 2021, J EXP MED, V218, DOI 10.1084/jem.20202700; Pillai S, 2009, NAT REV IMMUNOL, V9, P767, DOI 10.1038/nri2656; Seifert M, 2015, P NATL ACAD SCI USA, V112, pE546, DOI 10.1073/pnas.1416276112; Seifert M, 2012, J EXP MED, V209, P2183, DOI 10.1084/jem.20120833; Siegrist CA, 2009, NAT REV IMMUNOL, V9, P185, DOI 10.1038/nri2508; TIMENS W, 1989, J IMMUNOL, V143, P3200; Tull TJ, 2021, J EXP MED, V218, DOI 10.1084/jem.20202001; Weller S, 2004, BLOOD, V104, P3647, DOI 10.1182/blood-2004-01-0346; Weller S, 2008, J EXP MED, V205, P1331, DOI 10.1084/jem.20071555; Willenbrock K, 2005, EUR J IMMUNOL, V35, P3002, DOI 10.1002/eji.200535134; Wu YCB, 2011, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00081; Zandvoort A, 2001, TISSUE ANTIGENS, V58, P234, DOI 10.1034/j.1399-0039.2001.580403.x	23	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 27	2022	13								825619	10.3389/fimmu.2022.825619	http://dx.doi.org/10.3389/fimmu.2022.825619			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YW1PP	35154145	Green Published, gold			2022-12-18	WOS:000753192500001
J	Liu, HT; Gao, P; Jia, BQ; Lu, N; Zhu, BL; Zhang, FP				Liu, Hongtao; Gao, Ping; Jia, Baoqian; Lu, Na; Zhu, Baoli; Zhang, Fuping			IBD-Associated Atg16L1T300A Polymorphism Regulates Commensal Microbiota of the Intestine	FRONTIERS IN IMMUNOLOGY			English	Article						microbiota dysbiosis; goblet cells; autophagy; IBD; inflammatory bowel disease	GENOME-WIDE ASSOCIATION; AKKERMANSIA-MUCINIPHILA; GUT MICROBIOTA; EPITHELIAL-CELLS; CROHNS-DISEASE; AUTOPHAGY; INFLAMMATION; BACTERIA; VARIANT; MUCIN	The development of inflammatory bowel disease (IBD) is driven by the interaction among host genetics, microbiota, and the immune system of the entire digestive tract. Atg16L1T300A polymorphism is a genetic factor that confers increased risk for the pathogenesis of Crohn's disease. However, the exact contributions of Atg16L1T300A to intestinal mucosal homeostasis are not well understood. Here we show that Atg16L1T300A polymorphism impacts commensal bacterial flora in the intestine under a steady state. Analysis of intestinal bacteria from Atg16L1(T300A/T300A) mice showed that they harbored an altered microbiota in both the terminal ileum and colon compared to cohoused WT mice. Interestingly, Atg16L1(T300A/T300A) mice harbored a significant increase in the abundance of Tyzzerella, Mucispirillum, Ruminococcaceae, and Cyanobacteria which were known associated with IBD. Moreover, Akkermansia, a bacterium that is mucin-associated, was reduced greatly in Atg16L1(T300A/T300A) mice. Further analysis indicated that goblet cells of Atg16L1(T300A/T300A) mice had diminished mucin secretion that resulted from defective autophagy. Finally, Atg16L1(T300A/T300A) mice developed more severe inflammation in the DSS colitis model than in WT mice. These results indicate that the altered microbiota in Atg16L1(T300A/T300A) mice might be an important factor that contributed to the risk of Atg16L1T300A carriers to Crohn's disease and supports a multi-hit disease model involving specific gene-microbe interactions.	[Liu, Hongtao; Gao, Ping; Jia, Baoqian; Lu, Na; Zhu, Baoli; Zhang, Fuping] Chinese Acad Sci, CAS Key Lab Pathogen Microbiol & Immunol, Inst Microbiol, Beijing, Peoples R China; [Liu, Hongtao] Univ Chinese Acad Sci, Coll Life Sci, Beijing, Peoples R China; [Zhu, Baoli; Zhang, Fuping] Univ Chinese Acad Sci, Dept Savaid Med Sch, Beijing, Peoples R China	Chinese Academy of Sciences; Institute of Microbiology, CAS; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS	Gao, P; Zhang, FP (corresponding author), Chinese Acad Sci, CAS Key Lab Pathogen Microbiol & Immunol, Inst Microbiol, Beijing, Peoples R China.; Zhang, FP (corresponding author), Univ Chinese Acad Sci, Dept Savaid Med Sch, Beijing, Peoples R China.	gaop@im.ac.cn; zhangfp@im.ac.cn						Alam A, 2016, NAT MICROBIOL, V1, DOI [10.1038/NMICROBIOL.2015.21, 10.1038/nmicrobiol.2015.21]; Alvarado DM, 2019, GASTROENTEROLOGY, V157, P1093, DOI 10.1053/j.gastro.2019.07.013; Ansaldo E, 2019, SCIENCE, V364, P1179, DOI 10.1126/science.aaw7479; Bel S, 2017, SCIENCE, V357, P1047, DOI 10.1126/science.aal4677; Berry D, 2012, ISME J, V6, P2091, DOI 10.1038/ismej.2012.39; Brown EM, 2019, CELL HOST MICROBE, V25, P668, DOI 10.1016/j.chom.2019.04.002; Cadwell K, 2008, NATURE, V456, P259, DOI 10.1038/nature07416; Canny G, 2006, METH MOL B, V341, P17; Caruso R, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aaw4341; Conrad MA., 2017, PEDIAT INFLAMMATORY, DOI [10.1007/978-3-319-49215-5_4, DOI 10.1007/978-3-319-49215-5_4]; Conway KL, 2013, GASTROENTEROLOGY, V145, P1347, DOI 10.1053/j.gastro.2013.08.035; Davis CW, 2008, ANNU REV PHYSIOL, V70, P487, DOI 10.1146/annurev.physiol.70.113006.100638; Derrien M, 2004, INT J SYST EVOL MICR, V54, P1469, DOI 10.1099/ijs.0.02873-0; Derrien M, 2017, MICROB PATHOGENESIS, V106, P171, DOI 10.1016/j.micpath.2016.02.005; Donaldson GP, 2016, NAT REV MICROBIOL, V14, P20, DOI 10.1038/nrmicro3552; Erben U, 2014, INT J CLIN EXP PATHO, V7, P4557; Everard A, 2013, P NATL ACAD SCI USA, V110, P9066, DOI 10.1073/pnas.1219451110; Gao P, 2017, J IMMUNOL, V198, P2457, DOI 10.4049/jimmunol.1502652; Garrett WS, 2010, CELL, V140, P859, DOI 10.1016/j.cell.2010.01.023; Grander C, 2018, GUT, V67, P892, DOI 10.1136/gutjnl-2016-313432; Hall AB, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0490-5; Hampe J, 2007, NAT GENET, V39, P207, DOI 10.1038/ng1954; He B, 2007, IMMUNITY, V26, P812, DOI 10.1016/j.immuni.2007.04.014; Jellbauer S, 2014, GUT, V63, P1034, DOI 10.1136/gutjnl-2013-305589; Jin G, 2021, MSYSTEMS, V6, DOI 10.1128/mSystems.01337-20; Johansson MEV, 2011, P NATL ACAD SCI USA, V108, P4659, DOI 10.1073/pnas.1006451107; Kaser A, 2010, ANNU REV IMMUNOL, V28, P573, DOI 10.1146/annurev-immunol-030409-101225; Kostic AD, 2014, GASTROENTEROLOGY, V146, P1489, DOI 10.1053/j.gastro.2014.02.009; Kozik AJ, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0225079; Lapaquette P, 2010, J CLIN GASTROENTEROL, V44, pS26, DOI 10.1097/MCG.0b013e3181dd4fa5; Lassen KG, 2014, P NATL ACAD SCI USA, V111, P7741, DOI 10.1073/pnas.1407001111; Lavoie S, 2019, ELIFE, V8, DOI 10.7554/eLife.39982; Lee JC, 2017, NAT GENET, V49, P262, DOI 10.1038/ng.3755; Macchione IG, 2019, EUR REV MED PHARMACO, V23, P8075, DOI 10.26355/eurrev_201909_19024; Man SM, 2008, HELICOBACTER, V13, P234, DOI 10.1111/j.1523-5378.2008.00607.x; Melgar S, 2008, INT IMMUNOPHARMACOL, V8, P836, DOI 10.1016/j.intimp.2008.01.036; Murthy A, 2014, NATURE, V506, P456, DOI 10.1038/nature13044; Nagayama M, 2020, GUT MICROBES, DOI 10.1080/19490976.2020.1788898; Ni J, 2017, NAT REV GASTRO HEPAT, V14, P573, DOI 10.1038/nrgastro.2017.88; Nowarski R, 2015, CELL, V163, P1444, DOI 10.1016/j.cell.2015.10.072; Okumura R, 2018, INFLAMM REGEN, V38, DOI 10.1186/s41232-018-0063-z; Olaisen M, 2021, INFLAMM BOWEL DIS, V27, P12, DOI 10.1093/ibd/izaa107; Olli KE, 2020, INFLAMM BOWEL DIS, V26, P1353, DOI 10.1093/ibd/izaa064; Patel KK, 2013, EMBO J, V32, P3130, DOI 10.1038/emboj.2013.233; Pittayanon R, 2020, GASTROENTEROLOGY, V158, P930, DOI 10.1053/j.gastro.2019.11.294; Png CW, 2010, AM J GASTROENTEROL, V105, P2420, DOI 10.1038/ajg.2010.281; Reunanen J, 2015, APPL ENVIRON MICROB, V81, P3655, DOI 10.1128/AEM.04050-14; Saitoh T, 2008, NATURE, V456, P264, DOI 10.1038/nature07383; Salzman NH, 2010, NAT IMMUNOL, V11, P76, DOI 10.1038/ni.1825; Sartor RB, 2008, GASTROENTEROLOGY, V134, P577, DOI 10.1053/j.gastro.2007.11.059; Sun J, 2016, GENES DIS, V3, P130, DOI 10.1016/j.gendis.2016.03.004; Swidsinski A, 2009, J PHYSIOL PHARMACOL, V60, P61; Swidsinski A, 2011, GUT, V60, P34, DOI 10.1136/gut.2009.191320; Vacca M, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8040573; Veiga P, 2010, P NATL ACAD SCI USA, V107, P18132, DOI 10.1073/pnas.1011737107; Zhai ZY, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01595	56	0	0	1	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 27	2022	12								772189	10.3389/fimmu.2021.772189	http://dx.doi.org/10.3389/fimmu.2021.772189			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YW7WP	35154071	Green Published, gold			2022-12-18	WOS:000753625400001
J	Manhas, KR; Marshall, PA; Wagner, CE; Jurutka, PW; Mancenido, MV; Debray, HZ; Blattman, JN				Manhas, Kavita R.; Marshall, Pamela A.; Wagner, Carl E.; Jurutka, Peter W.; Mancenido, Michelle V.; Debray, Hannah Z.; Blattman, Joseph N.			Rexinoids Modulate Effector T Cell Expression of Mucosal Homing Markers CCR9 and alpha 4 beta 7 Integrin and Direct Their Migration In Vitro	FRONTIERS IN IMMUNOLOGY			English	Article						migration; mucosal; rexinoids; retinoic acid; retinoid; T-cell; toxicity; vitamin A	TRANS-RETINOIC ACID; ACUTE PROMYELOCYTIC LEUKEMIA; X-RECEPTOR RXR; CYCLE PROGRESSION; CLINICAL-TRIAL; VITAMIN-A; BEXAROTENE; LIGAND; DIFFERENTIATION; RESISTANCE	Altering T cell trafficking to mucosal regions can enhance immune responses towards pathogenic infections and cancers at these sites, leading to better outcomes. All-trans-retinoic acid (ATRA) promotes T cell migration to mucosal surfaces by inducing transcription of the mucosal-homing receptors CCR9 and alpha 4 beta 7 via binding to retinoic acid receptors (RARs), which heterodimerize with retinoid X receptors (RXRs) to function. However, the unstable nature and toxicity of ATRA limit its use as a widespread treatment modality for mucosal diseases. Therefore, identifying alternatives that could reduce or eliminate the use of ATRA are needed. Rexinoids are synthetically derived compounds structurally similar to ATRA. Originally named for their ability to bind RXRs, rexinoids can enhance RAR-mediated gene transcription. Furthermore, rexinoids are more stable than ATRA and possess an improved safety profile, making them attractive candidates for use in clinical settings. Here we show that select novel rexinoids act as ATRA mimics, as they cause increased CCR9 and alpha 4 beta 7 expression and enhanced migration to the CCR9 ligand, CCL25 in vitro, even in the absence of ATRA. Conversely, other rexinoids act synergistically with ATRA, as culturing cells with suboptimal doses of both compounds resulted in CCR9 expression and migration to CCL25. Overall, our findings show that rexinoids can be used independently or synergistically with ATRA to promote mucosal homing of T cells in vitro, and lends support for the prospective clinical use of these compounds in immunotherapeutic approaches for pathogenic infections or cancers at mucosal surfaces.	[Manhas, Kavita R.; Debray, Hannah Z.; Blattman, Joseph N.] Arizona State Univ, Biodesign Ctr Immunotherapy Vaccines & Virotherap, Tempe, AZ 85281 USA; [Marshall, Pamela A.; Wagner, Carl E.; Jurutka, Peter W.; Mancenido, Michelle V.] Arizona State Univ, Sch Math & Nat Sci, West Campus, Glendale, AZ USA	Arizona State University; Arizona State University-Tempe; Arizona State University	Blattman, JN (corresponding author), Arizona State Univ, Biodesign Ctr Immunotherapy Vaccines & Virotherap, Tempe, AZ 85281 USA.	joseph.blattman@asu.edu						Aranda A, 2001, PHYSIOL REV, V81, P1269, DOI 10.1152/physrev.2001.81.3.1269; Blattman JN, 2004, SCIENCE, V305, P200, DOI 10.1126/science.1100369; Burnett E, 2020, LANCET GLOB HEALTH, V8, pE1195, DOI 10.1016/S2214-109X(20)30262-X; Cancer I. A. f. R. o, 1999, RETINOIDS; Chen QY, 2004, EXP CELL RES, V297, P68, DOI 10.1016/j.yexcr.2004.02.017; Conley BA, 1997, CANCER CHEMOTH PHARM, V39, P291, DOI 10.1007/s002800050575; Dang DA, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001006; De Botton S, 1998, BLOOD, V92, P2712, DOI 10.1182/blood.V92.8.2712.420k03_2712_2718; de-Medeiros BC, 1998, BRAZ J MED BIOL RES, V31, P1537, DOI 10.1590/S0100-879X1998001200005; DeNucci CC, 2010, J IMMUNOL, V184, P2458, DOI 10.4049/jimmunol.0902407; Desai SN, 2012, CURR OPIN PEDIATR, V24, P85, DOI 10.1097/MOP.0b013e32834eb625; Dudley ME, 2002, SCIENCE, V298, P850, DOI 10.1126/science.1076514; Duvic M, 2001, J CLIN ONCOL, V19, P2456, DOI 10.1200/JCO.2001.19.9.2456; Duvic M, 2001, ARCH DERMATOL, V137, P581; Ellis CN, 2001, J AM ACAD DERMATOL, V45, pS150, DOI 10.1067/mjd.2001.113717; Elmazar MMA, 1996, TERATOLOGY, V53, P158, DOI 10.1002/(SICI)1096-9926(199603)53:3<158::AID-TERA3>3.0.CO;2-0; Fares Charlene M, 2019, Am Soc Clin Oncol Educ Book, V39, P147, DOI 10.1200/EDBK_240837; Ferla Valeria, 2020, Explor Target Antitumor Ther, V1, P109, DOI 10.37349/etat.2020.00007; FRANKEL SR, 1992, ANN INTERN MED, V117, P292, DOI 10.7326/0003-4819-117-4-292; Furmick JK, 2012, CHEMMEDCHEM, V7, P1551, DOI 10.1002/cmdc.201200319; Gorgun G, 2002, BLOOD, V100, P1399, DOI 10.1182/blood-2002-01-0300; Goverse G, 2015, EUR J IMMUNOL, V45, P89, DOI 10.1002/eji.201343340; Habtezion A, 2016, GASTROENTEROLOGY, V150, P340, DOI 10.1053/j.gastro.2015.10.046; Hansen SG, 2011, NATURE, V473, P523, DOI 10.1038/nature10003; Hansen SG, 2009, NAT MED, V15, P293, DOI 10.1038/nm.1935; Hatoum A, 2001, CARCINOGENESIS, V22, P1955, DOI 10.1093/carcin/22.12.1955; Heck MC, 2016, J MED CHEM, V59, P8924, DOI 10.1021/acs.jmedchem.6b00812; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; Holechek SA, 2016, VACCINE, V34, P5629, DOI 10.1016/j.vaccine.2016.09.013; Hu XT, 2014, CELL PROLIFERAT, V47, P200, DOI 10.1111/cpr.12100; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; Huang PX, 2014, CHEM REV, V114, P233, DOI 10.1021/cr400161b; Huang ZY, 2018, J CLIN MED, V7, DOI 10.3390/jcm7090258; Ipek Y, 2012, CASE REP MED, V2012, DOI 10.1155/2012/236174; Iwata M, 2004, IMMUNITY, V21, P527, DOI 10.1016/j.immuni.2004.08.011; Jenkins RW, 2018, BRIT J CANCER, V118, P9, DOI 10.1038/bjc.2017.434; Jurutka PW, 2013, J MED CHEM, V56, P8432, DOI 10.1021/jm4008517; Khan S, 2020, RESPIR MED CASE REP, V31, DOI 10.1016/j.rmcr.2020.101138; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KURZROCK R, 1993, J CLIN ONCOL, V11, P1489, DOI 10.1200/JCO.1993.11.8.1489; Leal Ana S, 2021, Adv Pharmacol, V91, P141, DOI 10.1016/bs.apha.2021.01.004; Lefebvre P, 2010, TRENDS ENDOCRIN MET, V21, P676, DOI 10.1016/j.tem.2010.06.009; Liby K, 2007, CLIN CANCER RES, V13, P6237, DOI 10.1158/1078-0432.CCR-07-1342; Liquori A, 2020, CANCERS, V12, DOI 10.3390/cancers12030624; LOOK J, 1995, AM J PHYSIOL-ENDOC M, V269, pE91, DOI 10.1152/ajpendo.1995.269.1.E91; Lussier DM, 2015, J IMMUNOTHER CANCER, V3, DOI 10.1186/s40425-015-0067-z; Mallory RM, 2020, VACCINE, V38, P3405, DOI 10.1016/j.vaccine.2019.12.015; Melero I, 2014, CANCER DISCOV, V4, P522, DOI 10.1158/2159-8290.CD-13-0985; Minucci S, 1997, MOL CELL BIOL, V17, P644, DOI 10.1128/MCB.17.2.644; Moerland JA, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-79260-8; Montesinos P, 2011, MEDITERR J HEMATOL I, V3, DOI 10.4084/MJHID.2011.059; Morgenstern J, 2021, METABOLITES, V11, DOI 10.3390/metabo11010060; Nagy L, 1998, CELL DEATH DIFFER, V5, P11, DOI 10.1038/sj.cdd.4400337; Ohoka Y, 2011, J IMMUNOL, V186, P733, DOI 10.4049/jimmunol.1000913; ONORATO IM, 1991, J INFECT DIS, V163, P1, DOI 10.1093/infdis/163.1.1; Park SH, 2000, CLIN CANCER RES, V6, P847; Paydas S, 1998, LEUKEMIA RES, V22, P655, DOI 10.1016/S0145-2126(98)00062-9; PILKINGTON T, 1992, DRUGS, V43, P597, DOI 10.2165/00003495-199243040-00010; Pino-Lagos K, 2010, BIOFACTORS, V36, P430, DOI 10.1002/biof.117; Plesca I, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00364; Qiu JJ, 2015, LEUKEMIA, V29, P1153, DOI 10.1038/leu.2014.334; Bono MR, 2016, NUTRIENTS, V8, DOI 10.3390/nu8060349; Rosenberg SA, 2008, NAT REV CANCER, V8, P299, DOI 10.1038/nrc2355; Rotte A, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1259-z; Ruhl R, 2018, NUTR REV, V76, P929, DOI 10.1093/nutrit/nuy057; Saluja T, 2020, HUM VACC IMMUNOTHER, V16, P42, DOI 10.1080/21645515.2019.1644882; Sato Y, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015119; Sindermann J, 1996, ACTA ONCOL, V35, P499, DOI 10.3109/02841869609109933; Stephensen CB, 2001, ANNU REV NUTR, V21, P167, DOI 10.1146/annurev.nutr.21.1.167; Takeuchi H, 2010, J IMMUNOL, V185, P5289, DOI 10.4049/jimmunol.1000101; Tan XF, 2011, J VIROL, V85, P8316, DOI 10.1128/JVI.00781-11; Thomas X, 2019, ONCOL THER, V7, P33, DOI 10.1007/s40487-018-0091-5; Wagner CE, 2009, J MED CHEM, V52, P5950, DOI 10.1021/jm900496b; Wolf G, 2006, NUTR REV, V64, P532, DOI 10.1111/j.1753-4887.2006.tb00186.x; Yang Y, 2011, NUTRITION, V27, P227, DOI 10.1016/j.nut.2009.11.024; Zhang H, 2003, CARCINOGENESIS, V24, P185, DOI 10.1093/carcin/24.2.185; Zhu WY, 1997, EXP CELL RES, V234, P293, DOI 10.1006/excr.1997.3589	77	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 27	2022	13								746484	10.3389/fimmu.2022.746484	http://dx.doi.org/10.3389/fimmu.2022.746484			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YW9AB	35154092	Green Published, gold			2022-12-18	WOS:000753702700001
J	Sun, ZY; Xie, CQ; Liu, H; Yuan, XG				Sun, Zhuanyi; Xie, Caiqin; Liu, Hui; Yuan, Xianggui			CD19 CAR-T Cell Therapy Induced Immunotherapy Associated Interstitial Pneumonitis: A Case Report	FRONTIERS IN IMMUNOLOGY			English	Article						immunotherapy-associated pneumonitis; interstitial pneumonitis; chimeric antigen receptor-modified T cell; diffuse large B-cell lymphoma; intravenous immunoglobulin	NEUROTOXICITY; MANAGEMENT; RELEASE; CANCER	BackgroundChimeric antigen receptor-modified T cells (CAR-T) targeting CD19 has produced a high durable response in refractory or relapsed diffuse large B-cell lymphoma. Besides well-known cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome during CAR-T cell therapy, there were several rarely encountered fatal complications. Case ReportA 63-year-old male patient with refractory EBV-positive diffuse large B-cell lymphoma, developed interstitial pneumonitis with prolonged hypoxemia at 16 weeks after CD19 CAR-T cell therapy. There was no evidence of CRS and any infections. The patient recovered after intravenous immunoglobulin without tocilizumab or glucocorticoid administration. Now he is still in remission without interstitial pneumonitis 3 years after CAR-T cell therapy. ConclusionThis is the first report of immunotherapy-associated interstitial pneumonitis after CAR-T cell therapy. Our finding suggested the importance of careful follow-up and proper treatments for immunotherapy-associated pneumonitis in the CAR-T cell therapy schedule.	[Sun, Zhuanyi; Xie, Caiqin; Liu, Hui; Yuan, Xianggui] Zhejiang Univ, Coll Med, Affiliated Hosp 2, Dept Hematol, Hangzhou, Peoples R China	Zhejiang University	Liu, H; Yuan, XG (corresponding author), Zhejiang Univ, Coll Med, Affiliated Hosp 2, Dept Hematol, Hangzhou, Peoples R China.	sylen@zju.edu.cn; Yuanxg@zju.edu.cn			Zhejiang Natural Science Foundation [LY18H160008]	Zhejiang Natural Science Foundation(Natural Science Foundation of Zhejiang Province)	Funding This work was financially supported by the Zhejiang Natural Science Foundation (No. LY18H160008).	Delaunay M, 2017, EUR RESPIR J, V50, DOI 10.1183/13993003.00050-2017; Giavridis T, 2018, NAT MED, V24, P731, DOI 10.1038/s41591-018-0041-7; Gust J, 2017, CANCER DISCOV, V7, P1404, DOI 10.1158/2159-8290.CD-17-0698; Haanen J B A G, 2018, Ann Oncol, V29, piv264, DOI 10.1093/annonc/mdy162; Hill JA, 2018, BLOOD, V131, P121, DOI 10.1182/blood-2017-07-793760; Hirashima T, 2019, ANTICANCER RES, V39, P6231, DOI 10.21873/anticanres.13832; Kowalski B, 2022, J CANCER RES CLIN, V148, P1711, DOI 10.1007/s00432-021-03750-z; Lee DW, 2019, BIOL BLOOD MARROW TR, V25, P625, DOI 10.1016/j.bbmt.2018.12.758; Lee DW, 2014, BLOOD, V124, P188, DOI 10.1182/blood-2014-05-552729; Lin NJ, 2020, CHINESE J CANCER RES, V32, P303, DOI 10.21147/j.issn.1000-9604.2020.03.03; Mihalyova J, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222111470; Naidoo J, 2017, J CLIN ONCOL, V35, P709, DOI 10.1200/JCO.2016.68.2005; Neelapu SS, 2017, NEW ENGL J MED, V377, P2531, DOI 10.1056/NEJMoa1707447; Neelapu SS, 2018, NAT REV CLIN ONCOL, V15, P47, DOI 10.1038/nrclinonc.2017.148; Nishino M, 2016, JAMA ONCOL, V2, P1607, DOI 10.1001/jamaoncol.2016.2453; Norelli M, 2018, NAT MED, V24, P739, DOI 10.1038/s41591-018-0036-4; Postow MA, 2018, NEW ENGL J MED, V378, P158, DOI [10.1056/NEJMra1703481, 10.1056/NEJMc1801663]; Puzanov I, 2017, J IMMUNOTHER CANCER, V5, DOI 10.1186/s40425-017-0300-z; Santomasso BD, 2018, CANCER DISCOV, V8, P958, DOI 10.1158/2159-8290.CD-17-1319; Schuster SJ, 2019, NEW ENGL J MED, V380, P45, DOI 10.1056/NEJMoa1804980; Tyan K, 2021, CANCER IMMUNOL IMMUN, V70, P2209, DOI 10.1007/s00262-021-02855-1; von Itzstein MS, 2020, CLIN CHEM, V66, P779, DOI 10.1093/clinchem/hvaa081; Wudhikarn K, 2020, BLOOD ADV, V4, P3024, DOI 10.1182/bloodadvances.2020001972	23	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 27	2022	13								778192	10.3389/fimmu.2022.778192	http://dx.doi.org/10.3389/fimmu.2022.778192			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YW9BW	35154102	Green Published, gold			2022-12-18	WOS:000753707400001
J	Wang, T; Li, TY; Li, BQ; Zhao, JH; Li, Z; Sun, MY; Li, Y; Zhao, YJ; Zhao, SD; He, WG; Guo, X; Ge, RJ; Wang, L; Ding, DS; Liu, SS; Min, SM; Zhang, XA				Wang, Tao; Li, Tianye; Li, Baiqing; Zhao, Jiahui; Li, Zhi; Sun, Mingyi; Li, Yan; Zhao, Yanjiao; Zhao, Shidi; He, Weiguang; Guo, Xiao; Ge, Rongjing; Wang, Lian; Ding, Dushan; Liu, Saisai; Min, Simin; Zhang, Xiaonan			Immunogenomic Landscape in Breast Cancer Reveals Immunotherapeutically Relevant Gene Signatures	FRONTIERS IN IMMUNOLOGY			English	Article						immune subtype; tumor microenvironment; immune escape; immunotherapy; breast cancer	ANTIGEN-PRESENTING CELLS; DIRECT STIMULATION; EXPRESSION; TUMORS; RESPONSES; BLOCKADE; MACROPHAGES; MECHANISMS; IMMUNITY; IL-12	Breast cancer is characterized by some types of heterogeneity, high aggressive behaviour, and low immunotherapeutic efficiency. Detailed immune stratification is a prerequisite for interpreting resistance to treatment and escape from immune control. Hence, the immune landscape of breast cancer needs further understanding. We systematically clustered breast cancer into six immune subtypes based on the mRNA expression patterns of immune signatures and comprehensively depicted their characteristics. The immunotherapeutic benefit score (ITBscore) was validated to be a superior predictor of the response to immunotherapy in cohorts from various datasets. Six distinct immune subtypes related to divergences in biological functions, signatures of immune or stromal cells, extent of the adaptive immune response, genomic events, and clinical prognostication were identified. These six subtypes were characterized as immunologically quiet, chemokine dominant, lymphocyte depleted, wounding dominant, innate immune dominant, and IFN-gamma dominant and exhibited features of the tumor microenvironment (TME). The high ITBscore subgroup, characterized by a high proportion of M1 macrophages:M2 macrophages, an activated inflammatory response, and increased mutational burden (such as mutations in TP53, CDH1 and CENPE), indicated better immunotherapeutic benefits. A low proportion of tumor-infiltrating lymphocytes (TILs) and an inadequate response to immune treatment were associated with the low ITBscore subgroup, which was also associated with poor survival. Analyses of four cohorts treated with immune checkpoint inhibitors (ICIs) suggested that patients with a high ITBscore received significant therapeutic advantages and clinical benefits. Our work may facilitate the understanding of immune phenotypes in shaping different TME landscapes and guide precision immuno-oncology and immunotherapy strategies.	[Wang, Tao; Li, Tianye; Zhao, Jiahui; Li, Zhi; Sun, Mingyi; Zhao, Yanjiao; Zhang, Xiaonan] Northeastern Univ, Coll Life & Hlth Sci, Shenyang, Peoples R China; [Li, Tianye] Bengbu Med Coll, Dept Immunol, Bengbu, Peoples R China; [Li, Yan; Zhao, Shidi; Ge, Rongjing; Wang, Lian; Ding, Dushan; Liu, Saisai; Min, Simin; Zhang, Xiaonan] Bengbu Med Coll, Dept Pathophysiol, Bengbu, Peoples R China; [He, Weiguang] Tian Jin Fifths Cent Hosp, Dept Radiol, Tianjin, Peoples R China; [Guo, Xiao] Beihua Univ, Coll Pharm, Jilin, Jilin, Peoples R China	Northeastern University - China; Bengbu Medical College; Bengbu Medical College; Beihua University	Zhang, XA (corresponding author), Northeastern Univ, Coll Life & Hlth Sci, Shenyang, Peoples R China.; Zhang, XA (corresponding author), Bengbu Med Coll, Dept Pathophysiol, Bengbu, Peoples R China.	zhangxn@bbmc.edu.cn		Wang, Tao/0000-0001-7087-4596	Education fund item of Anhui province [KJ2020A0588]	Education fund item of Anhui province	Funding This work was supported by the Education fund item of Anhui province under Grant KJ2020A0588.	Ali HR, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002194; Arenberg DA, 2001, CANCER IMMUNOL IMMUN, V50, P533, DOI 10.1007/s00262-001-0231-9; Asch-Kendrick R, 2016, HUM PATHOL, V48, P37, DOI 10.1016/j.humpath.2015.09.035; Barbie DA, 2009, NATURE, V462, P108, DOI 10.1038/nature08460; Breiman L, 1996, MACH LEARN, V24, P123, DOI 10.3390/risks8030083; Broz ML, 2014, CANCER CELL, V26, P638, DOI 10.1016/j.ccell.2014.09.007; Burr ML, 2017, NATURE, V549, P101, DOI 10.1038/nature23643; Chang HY, 2004, PLOS BIOL, V2, P206, DOI 10.1371/journal.pbio.0020007; CORTES C, 1995, MACH LEARN, V20, P273, DOI 10.1023/A:1022627411411; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Denton AE, 2018, ADV EXP MED BIOL, V1060, P99, DOI 10.1007/978-3-319-78127-3_6; Dieci MV, 2022, CLIN CANCER RES, V28, P308, DOI 10.1158/1078-0432.CCR-21-2260; Dong ZY, 2017, CLIN CANCER RES, V23, P3012, DOI 10.1158/1078-0432.CCR-16-2554; Dvinge H, 2013, NATURE, V497, P378, DOI 10.1038/nature12108; Edin S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047045; Emens LA, 2018, CLIN CANCER RES, V24, P511, DOI 10.1158/1078-0432.CCR-16-3001; Fraschilla I, 2017, IMMUNOL REV, V276, P178, DOI 10.1111/imr.12526; Frucht DM, 2001, TRENDS IMMUNOL, V22, P556, DOI 10.1016/S1471-4906(01)02005-1; Fuchs CS, 2018, JAMA ONCOL, V4, DOI 10.1001/jamaoncol.2018.0013; Galon J, 2013, IMMUNITY, V39, P11, DOI 10.1016/j.immuni.2013.07.008; Golab J, 2000, IMMUNOL LETT, V72, P153, DOI 10.1016/S0165-2478(00)00178-4; Gu ZG, 2016, BIOINFORMATICS, V32, P2847, DOI 10.1093/bioinformatics/btw313; Hanzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-7; Hegde M, 2016, J CLIN INVEST, V126, P3036, DOI 10.1172/JCI83416; Hugo W, 2016, CELL, V165, P35, DOI 10.1016/j.cell.2016.02.065; Iannello A, 2013, J EXP MED, V210, P2057, DOI 10.1084/jem.20130783; Katz H, 2018, MED ONCOL, V35, DOI 10.1007/s12032-017-1071-6; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Krasniqi E, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0798-2; Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-559; Lesterhuis WJ, 2015, SCI REP-UK, V5, DOI 10.1038/srep12298; Madsen RR, 2018, TRENDS MOL MED, V24, P856, DOI 10.1016/j.molmed.2018.08.003; Mariathasan S, 2018, NATURE, V554, P544, DOI 10.1038/nature25501; Mellado M, 2001, ANNU REV IMMUNOL, V19, P397, DOI 10.1146/annurev.immunol.19.1.397; Munder M, 2001, IMMUNOL LETT, V75, P159, DOI 10.1016/S0165-2478(00)00288-1; Pan JD, 2006, J IMMUNOL, V176, P1456, DOI 10.4049/jimmunol.176.3.1456; Panda Anshuman, 2018, J Natl Cancer Inst, V110, P316, DOI 10.1093/jnci/djx213; Pilger D, 2021, GENE DEV, V35, P602, DOI 10.1101/gad.348314.121; Ribas A, 2018, SCIENCE, V359, P1350, DOI 10.1126/science.aar4060; Robin X, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-77; Roh W, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aah3560; Rooney MS, 2015, CELL, V160, P48, DOI 10.1016/j.cell.2014.12.033; Samstein RM, 2019, NAT GENET, V51, P202, DOI 10.1038/s41588-018-0312-8; Savas P, 2016, NAT REV CLIN ONCOL, V13, P228, DOI 10.1038/nrclinonc.2015.215; Schreiber RD, 2011, SCIENCE, V331, P1565, DOI 10.1126/science.1203486; Scrucca L, 2016, R J, V8, P289; Shah SP, 2012, NATURE, V486, P395, DOI 10.1038/nature10933; Sotiriou C, 2006, JNCI-J NATL CANCER I, V98, P262, DOI 10.1093/jnci/djj052; Spranger S, 2016, INT IMMUNOL, V28, P383, DOI 10.1093/intimm/dxw014; Szklarczyk D, 2015, NUCLEIC ACIDS RES, V43, pD447, DOI 10.1093/nar/gku1003; Tan VYF, 2013, IEEE T PATTERN ANAL, V35, P1592, DOI 10.1109/TPAMI.2012.240; Team R.C, 2015, R LANG ENV STAT COMP; Thomas DA, 2005, CANCER CELL, V8, P369, DOI 10.1016/j.ccr.2005.10.012; Thorsson V, 2018, IMMUNITY, V48, P812, DOI 10.1016/j.immuni.2018.03.023; Tibshirani R, 2005, J COMPUT GRAPH STAT, V14, P511, DOI 10.1198/106186005X59243; Tibshirani R, 2011, J R STAT SOC B, V73, P273, DOI 10.1111/j.1467-9868.2011.00771.x; Tokunaga R, 2018, CANCER TREAT REV, V63, P40, DOI 10.1016/j.ctrv.2017.11.007; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954; Ulloa-Montoya F, 2013, J CLIN ONCOL, V31, P2388, DOI 10.1200/JCO.2012.44.3762; van der Maaten L, 2008, J MACH LEARN RES, V9, P2579; Vesely MD, 2011, ANNU REV IMMUNOL, V29, P235, DOI 10.1146/annurev-immunol-031210-101324; Wagner M, 2019, TRENDS IMMUNOL, V40, P415, DOI 10.1016/j.it.2019.03.004; Wang T, 2017, CANCER IMMUNOL RES, V5, P148, DOI 10.1158/2326-6066.CIR-16-0107; Wolf DM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088309; Wood RD, 2001, SCIENCE, V291, P1284, DOI 10.1126/science.1056154; Xiao Y, 2019, CLIN CANCER RES, V25, P5002, DOI 10.1158/1078-0432.CCR-18-3524; Yang WJ, 2013, NUCLEIC ACIDS RES, V41, pD955, DOI 10.1093/nar/gks1111; Yarchoan M, 2017, NEW ENGL J MED, V377, P2500, DOI 10.1056/NEJMc1713444; Yates LR, 2015, NAT MED, V21, P751, DOI 10.1038/nm.3886; Yuan Y, 2012, BIOINFORMATICS, V28, P1246, DOI 10.1093/bioinformatics/bts120; Zeng DQ, 2019, CANCER IMMUNOL RES, V7, P737, DOI 10.1158/2326-6066.CIR-18-0436; Zohar Y, 2018, J CLIN INVEST, V128, P1200, DOI 10.1172/JCI120358	72	0	0	2	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 27	2022	13								805184	10.3389/fimmu.2022.805184	http://dx.doi.org/10.3389/fimmu.2022.805184			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YW8XZ	35154121	gold, Green Published			2022-12-18	WOS:000753697300001
J	Del'Arco, AE; Argolo, DS; Guillemin, G; Costa, MDD; Costa, SL; Pinheiro, AM				Del'Arco, Ana Elisa; Argolo, Deivison Silva; Guillemin, Gilles; Costa, Maria de Fatima Dias; Costa, Silvia Lima; Pinheiro, Alexandre Moraes			Neurological Infection, Kynurenine Pathway, and Parasitic Infection by Neospora caninum	FRONTIERS IN IMMUNOLOGY			English	Review						kynurenic acid; glia; neuroinflammation; Neospora caninum; quinolinic acid	NECROSIS-FACTOR-ALPHA; INDOLEAMINE 2,3-DIOXYGENASE; INTERFERON-GAMMA; QUINOLINIC ACID; IMMUNE-RESPONSE; IFN-GAMMA; BRAIN; ASTROCYTES; MICROGLIA; LIPOPOLYSACCHARIDE	Neuroinflammation is one of the most frequently studied topics of neurosciences as it is a common feature in almost all neurological disorders. Although the primary function of neuroinflammation is to protect the nervous system from an insult, the complex and sequential response of activated glial cells can lead to neurological damage. Depending on the type of insults and the time post-insult, the inflammatory response can be neuroprotective, neurotoxic, or, depending on the glial cell types, both. There are multiple pathways activated and many bioactive intermediates are released during neuroinflammation. One of the most common one is the kynurenine pathway, catabolizing tryptophan, which is involved in immune regulation, neuroprotection, and neurotoxicity. Different models have been used to study the kynurenine pathway metabolites to understand their involvements in the development and maintenance of the inflammatory processes triggered by infections. Among them, the parasitic infection Neospora caninum could be used as a relevant model to study the role of the kynurenine pathway in the neuroinflammatory response and the subset of cells involved.	[Del'Arco, Ana Elisa; Pinheiro, Alexandre Moraes] Fed Univ Reconcavo Bahia UFRB, Lab Biochem & Vet Immunol, Ctr Agr Environm & Biol Sci, Cruz Das Almas, Brazil; [Argolo, Deivison Silva; Costa, Maria de Fatima Dias; Costa, Silvia Lima] Fed Univ Bahia UFBA, Lab Neurochem & Cellular Biol, Dept Biochem & Biophys, Inst Hlth Sci, Salvador, BA, Brazil; [Guillemin, Gilles] Macquarie Univ, Macquarie Med Sch, Neuroinflammat Grp, Sydney, NSW, Australia	Universidade Federal da Bahia; Macquarie University	Pinheiro, AM (corresponding author), Fed Univ Reconcavo Bahia UFRB, Lab Biochem & Vet Immunol, Ctr Agr Environm & Biol Sci, Cruz Das Almas, Brazil.; Costa, SL (corresponding author), Fed Univ Bahia UFBA, Lab Neurochem & Cellular Biol, Dept Biochem & Biophys, Inst Hlth Sci, Salvador, BA, Brazil.	costasl@ufba.br; amp@ufrb.edu.br	Guillemin, Gilles J/C-3878-2015; Costa, Silvia Lima/A-5760-2008	Guillemin, Gilles J/0000-0001-8105-4470; Costa, Silvia Lima/0000-0002-8975-3871	National Council for Scientific and Technological Development (CNPq) [431927/2016-2]; Foundation for Research Support of the State of Bahia (FAPESB) [APP 0058/2015]; NHMRC	National Council for Scientific and Technological Development (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Foundation for Research Support of the State of Bahia (FAPESB); NHMRC(National Health and Medical Research Council (NHMRC) of Australia)	This work was supported by the National Council for Scientific and Technological Development (CNPq, Process 431927/2016-2; INCT) and the Foundation for Research Support of the State of Bahia (FAPESB, Processes APP 0058/2015). GG is funded by the NHMRC.	Batista CRA, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20092293; Araque A, 1999, TRENDS NEUROSCI, V22, P208, DOI 10.1016/S0166-2236(98)01349-6; Argolo DS, 2022, INT J TRYPTOPHAN RES, V15, DOI 10.1177/11786469211069946; Baszler TV, 1999, INT J PARASITOL, V29, P1635, DOI 10.1016/S0020-7519(99)00141-1; Beiting DP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088398; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Bradley PJ, 2007, CURR OPIN MICROBIOL, V10, P582, DOI 10.1016/j.mib.2007.09.013; Cervenka I, 2017, SCIENCE, V357, DOI 10.1126/science.aaf9794; Cesura AM., 1995, PHARM RES, V31, P125, DOI [10.1016/1043-6618(95)86760-0, DOI 10.1016/1043-6618(95)86760-0]; Chao MV, 2003, NAT REV NEUROSCI, V4, P299, DOI 10.1038/nrn1078; Chiarugi A, 2001, J NEUROIMMUNOL, V120, P190, DOI 10.1016/S0165-5728(01)00418-0; Cogo A, 2021, MOL NEURODEGENER, V16, DOI 10.1186/s13024-020-00421-4; Correia A, 2013, VET RES, V44, DOI 10.1186/1297-9716-44-69; Davoli-Ferreira M, 2016, SCI REP-UK, V6, DOI 10.1038/srep29289; Debare H, 2021, CYTOKINE, V144, DOI 10.1016/j.cyto.2021.155575; Dubey J.P., 2003, KOREAN J PARASITOL, V41, P1, DOI [10.3347/kjp.2003.41.1.1, DOI 10.3347/KJP.2003.41.1.1]; Dubey JP, 1996, VET PARASITOL, V67, P1, DOI 10.1016/S0304-4017(96)01035-7; Dubey JP, 1999, VET PARASITOL, V84, P349, DOI 10.1016/S0304-4017(99)00044-8; Farina C, 2007, TRENDS IMMUNOL, V28, P138, DOI 10.1016/j.it.2007.01.005; Farzi A, 2015, BRAIN BEHAV IMMUN, V44, P106, DOI 10.1016/j.bbi.2014.08.011; Feigin VL, 2017, LANCET NEUROL, V16, P877, DOI 10.1016/S1474-4422(17)30299-5; Franco R, 2015, PROG NEUROBIOL, V131, P65, DOI 10.1016/j.pneurobio.2015.05.003; Fujigaki H, 2006, J BIOCHEM, V139, P655, DOI 10.1093/jb/mvj072; Fujigaki S, 2001, EUR J IMMUNOL, V31, P2313, DOI 10.1002/1521-4141(200108)31:8<2313::AID-IMMU2313>3.0.CO;2-S; Garcez ML, 2020, INT J TRYPTOPHAN RES, V13, DOI 10.1177/1178646920978404; Garrison AM, 2018, PSYCHONEUROENDOCRINO, V94, P1, DOI 10.1016/j.psyneuen.2018.04.019; Gilhus NE, 2019, NAT REV NEUROL, V15, P429, DOI 10.1038/s41582-019-0227-8; Grangeiro MS, 2019, J PARASITOL, V105, P313, DOI 10.1645/18-81; Groth B, 2021, FRONT MOL BIOSCI, V8, DOI 10.3389/fmolb.2021.686412; Guillemin GJ, 2007, J NEUROSCI, V27, P12884, DOI 10.1523/JNEUROSCI.4101-07.2007; Guillemin GJ, 2012, FEBS J, V279, P1356, DOI 10.1111/j.1742-4658.2012.08485.x; Guillemin GJ, 2005, GLIA, V49, P15, DOI 10.1002/glia.20090; Guillemin GJ, 2003, GLIA, V41, P371, DOI 10.1002/glia.10175; Guillemin GJ, 2001, J NEUROCHEM, V78, P842, DOI 10.1046/j.1471-4159.2001.00498.x; Heredi J, 2019, BRAIN RES BULL, V146, P185, DOI 10.1016/j.brainresbull.2018.12.014; Huang YS, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00388; Hunt NH, 2017, NEUROPHARMACOLOGY, V112, P389, DOI 10.1016/j.neuropharm.2016.02.029; Jesus EEV, 2013, EXP PARASITOL, V133, P269, DOI 10.1016/j.exppara.2012.11.016; Jesus LB, 2019, VET PARASITOL, V266, P96, DOI 10.1016/j.vetpar.2019.01.003; Jha MK, 2019, NEUROSCIENTIST, V25, P227, DOI 10.1177/1073858418783959; Jha MK, 2016, BIOCHEM PHARMACOL, V103, P1, DOI 10.1016/j.bcp.2015.11.003; Jin XX, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01393; Jones SP, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131389; Jones SP, 2013, INT J TRYPTOPHAN RES, V6, P57, DOI 10.4137/IJTR.S12626; Kaindl AM, 2012, ANN NEUROL, V72, P536, DOI 10.1002/ana.23626; Lestage J, 2002, BRAIN BEHAV IMMUN, V16, P596, DOI 10.1016/S0889-1591(02)00014-4; Long MT, 1998, J PARASITOL, V84, P316, DOI 10.2307/3284489; Ma L, 2017, VET PARASITOL, V243, P135, DOI 10.1016/j.vetpar.2017.04.020; Michinaga S, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20030571; Mineo TWP, 2010, IMMUNOL CELL BIOL, V88, P825, DOI 10.1038/icb.2010.52; Mishra A, 2021, METAB BRAIN DIS, V36, P1591, DOI 10.1007/s11011-021-00806-4; Mithaiwala MN, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10061548; Mota CM, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.01456; Muller FL, 2007, AM J PHYSIOL-REG I, V293, pR1159, DOI 10.1152/ajpregu.00767.2006; Nagy EE, 2020, EXP THER MED, V20, P2510, DOI 10.3892/etm.2020.8933; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Notarangelo FM, 2014, SCHIZOPHR RES, V152, P261, DOI 10.1016/j.schres.2013.11.011; Notarangelo FM, 2019, DEV NEUROSCI-BASEL, V41, P102, DOI 10.1159/000499736; O'Connor JC, 2009, MOL PSYCHIATR, V14, P511, DOI 10.1038/sj.mp.4002148; O'Connor JC, 2009, J NEUROSCI, V29, P4200, DOI 10.1523/JNEUROSCI.5032-08.2009; O'Farrell K, 2017, EUR J PHARMACOL, V810, P163, DOI 10.1016/j.ejphar.2017.07.008; O'Farrell K, 2017, NEUROPHARMACOLOGY, V112, P307, DOI 10.1016/j.neuropharm.2015.12.004; Pierozan P, 2010, EXP NEUROL, V224, P188, DOI 10.1016/j.expneurol.2010.03.009; Pinheiro AM, 2006, VET IMMUNOL IMMUNOP, V113, P243, DOI 10.1016/j.vetimm.2006.05.006; Pinheiro AM, 2010, EXP PARASITOL, V124, P442, DOI 10.1016/j.exppara.2009.12.018; Pinheiro AM, 2006, EXP PARASITOL, V112, P193, DOI 10.1016/j.exppara.2005.10.008; Russo MV, 2016, SCIENCE, V353, P783, DOI 10.1126/science.aaf6260; Savitz J, 2020, MOL PSYCHIATR, V25, P131, DOI 10.1038/s41380-019-0414-4; Schmid M, 2012, J BIOL CHEM, V287, P20197, DOI 10.1074/jbc.M112.351999; Schwarcz R, 2017, NEUROPHARMACOLOGY, V112, P237, DOI 10.1016/j.neuropharm.2016.08.003; Shabab T, 2017, INT J NEUROSCI, V127, P624, DOI 10.1080/00207454.2016.1212854; Spekker K, 2009, INFECT IMMUN, V77, P4496, DOI 10.1128/IAI.00310-09; STONE TW, 1993, PHARMACOL REV, V45, P309; Tanaka T, 2000, VET PARASITOL, V90, P183, DOI 10.1016/S0304-4017(00)00238-7; Toth F, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22010403; Tullius SG, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6101; Ufermann CM, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00184; Vainchtein ID, 2020, TRENDS NEUROSCI, V43, P144, DOI 10.1016/j.tins.2020.01.003; Venkatesan Dhivya, 2020, eNeurologicalSci, V21, P100270, DOI 10.1016/j.ensci.2020.100270; De Jesus EEV, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00340; Wang JQ, 2016, INT IMMUNOPHARMACOL, V39, P287, DOI 10.1016/j.intimp.2016.07.036; Wang XC, 2019, VET PARASITOL, V268, P16, DOI 10.1016/j.vetpar.2019.02.008; Wang XC, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01791; Wang YX, 2010, BRAIN BEHAV IMMUN, V24, P201, DOI 10.1016/j.bbi.2009.06.152; Yamane I, 2000, J VET MED SCI, V62, P347, DOI 10.1292/jvms.62.347; Yang QQ, 2019, GLIA, V67, P1017, DOI 10.1002/glia.23571; Zunszain PA, 2012, NEUROPSYCHOPHARMACOL, V37, P939, DOI 10.1038/npp.2011.277	87	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 26	2022	12								714248	10.3389/fimmu.2021.714248	http://dx.doi.org/10.3389/fimmu.2021.714248			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YV7SI	35154065	Green Published, gold			2022-12-18	WOS:000752926000001
J	Doria, M; Moscato, GMF; Di Cesare, S; Di Matteo, G; Sgrulletti, M; Bachelerie, F; Marin-Esteban, V; Moschese, V				Doria, Margherita; Moscato, Giusella M. F.; Di Cesare, Silvia; Di Matteo, Gigliola; Sgrulletti, Mayla; Bachelerie, Francoise; Marin-Esteban, Viviana; Moschese, Viviana			Case Report: Altered NK Cell Compartment and Reduced CXCR4 Chemotactic Response of B Lymphocytes in an Immunodeficient Patient With HPV-Related Disease	FRONTIERS IN IMMUNOLOGY			English	Article						WHIM; CXCR4; CXCL12 axis; B lymphocytes; NK cells; HPV	HUMAN-PAPILLOMAVIRUS; WHIM SYNDROME; WARTS; INSIGHTS; DESENSITIZATION; RESPONSIVENESS; INFECTIONS; NEOPLASIA; RECEPTOR; CXCL12	The study of inborn errors of immunity (IEI) provides unique opportunities to elucidate the microbiome and pathogenic mechanisms related to severe viral infection. Several immunological and genetic anomalies may contribute to the susceptibility to develop Human Papillomavirus (HPV) pathogenesis. They include different acquired immunodeficiencies, EVER1-2 or CIB1 mutations underlying epidermodysplasia verruciformis (EV) syndrome and multiple IEI. Whereas EV syndrome patients are specifically unable to control infections with beta HPV, individuals with IEI show broader infectious and immune phenotypes. The WHIM (warts, hypogammaglobulinemia, infection, and myelokathexis) syndrome caused by gain-of-CXCR4-function mutation manifests by HPV-induced extensive cutaneous warts but also anogenital lesions that eventually progress to dysplasia. Here we report alterations of B and NK cells in a female patient suffering from cutaneous and mucosal HPV-induced lesions due to an as-yet unidentified genetic defect. Despite no detected mutations in CXCR4, B but not NK cells displayed a defective CXCR4-dependent chemotactic response toward CXCL12. In addition, NK cells showed an abnormal distribution with an expanded CD56(bright) cell subset and defective cytotoxicity of CD56(dim) cells. Our observations extend the clinical and immunological spectrum of IEI associated with selective susceptibility toward HPV pathogenesis, thus providing new insight on the immune control of HPV infection and potential host susceptibility factors.	[Doria, Margherita; Di Cesare, Silvia] IRCCS, Bambino Gesu Childrens Hosp, Res Unit Primary Immunodeficiency, Ist Ric & Cura Carattere Sci, Rome, Italy; [Moscato, Giusella M. F.] Univ Tor Vergata, Infect Dis Unit, Policlin Tor Vergata, Rome, Italy; [Di Matteo, Gigliola] Univ Tor Vergata, Dept Med Syst, Rome, Italy; [Sgrulletti, Mayla; Moschese, Viviana] Univ Tor Vergata, Pediat Immunopathol & Allergol Unit, Policlin Tor Vergata, Rome, Italy; [Sgrulletti, Mayla] Univ Roma Tor Vergata, PhD Program Immunol Mol Med & Appl Biotechnol, Rome, Italy; [Bachelerie, Francoise; Marin-Esteban, Viviana] Univ Paris Saclay, INSERM, Inflammat Microbiome & Immunosurveillance, Clamart, France	IRCCS Bambino Gesu; University of Rome Tor Vergata; Policlin Tor Vergata; University of Rome Tor Vergata; University of Rome Tor Vergata; Policlin Tor Vergata; University of Rome Tor Vergata; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay	Doria, M (corresponding author), IRCCS, Bambino Gesu Childrens Hosp, Res Unit Primary Immunodeficiency, Ist Ric & Cura Carattere Sci, Rome, Italy.	doria@uniroma2.it	MOSCHESE, VIVIANA/AHE-8931-2022	MOSCHESE, VIVIANA/0000-0001-7650-0632; Marin-Esteban, Viviana/0000-0002-2358-0584; DI CESARE, SILVIA/0000-0002-9912-7997	Association Laurette Fugain; Italian Ministry of Health	Association Laurette Fugain; Italian Ministry of Health(Ministry of Health, Italy)	This work was supported by grants of the Association Laurette Fugain to FB and VM-E, and of the Italian Ministry of Health (Ricerca Corrente co-founded by Italian 5 x 1000 from Bambino Gesu Children's Hospital) to MD.	Bachelerie F, 2010, DIS MARKERS, V29, P189, DOI [10.3233/DMA-2010-0736, 10.1155/2010/475104]; Balabanian K, 2005, BLOOD, V105, P2449, DOI 10.1182/blood-2004-06-2289; Bao X, 2018, J INFECT DIS, V218, P2006, DOI 10.1093/infdis/jiy483; Bernardini G, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00402; Beziat V, 2021, CURR OPIN VIROL, V51, P9, DOI 10.1016/j.coviro.2021.09.002; Bozzano F, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9109; Cac NN, 2006, J ALLERGY CLIN IMMUN, V118, P526, DOI 10.1016/j.jaci.2006.04.023; Carrington M, 2005, J EXP MED, V201, P1069, DOI 10.1084/jem.20042158; Cifaldi C, 2020, J LEUKOCYTE BIOL, V108, P739, DOI 10.1002/JLB.5MA0220-239R; Cifaldi C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00316; De Filippo K, 2018, EUR J CLIN INVEST, V48, DOI 10.1111/eci.12949; Jong SJ, 2018, J EXP MED, V215, P2289, DOI 10.1084/jem.20170308; Diaz GA, 2005, IMMUNOL REV, V203, P235, DOI 10.1111/j.0105-2896.2005.00226.x; Dobbs K, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00798; Ebert LA, 2005, MOL IMMUNOL, V42, P799, DOI 10.1016/j.molimm.2004.06.040; Gheit T, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00355; Gulino AV, 2004, BLOOD, V104, P444, DOI 10.1182/blood-2003-10-3532; Guma M, 2004, BLOOD, V104, P3664, DOI 10.1182/blood-2004-05-2058; Hargreaves DC, 2001, J EXP MED, V194, P45, DOI 10.1084/jem.194.1.45; Heusinkveld LE, 2019, J CLIN IMMUNOL, V39, P532, DOI 10.1007/s10875-019-00665-w; Honczarenko M, 1999, BLOOD, V94, P2990, DOI 10.1182/blood.V94.9.2990.421k36_2990_2998; Domaica CI, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051677; Kawai T, 2009, CURR OPIN HEMATOL, V16, P20, DOI 10.1097/MOH.0b013e32831ac557; Kulkarni S, 2008, SEMIN IMMUNOL, V20, P343, DOI 10.1016/j.smim.2008.06.003; Lee J, 2015, IMMUNITY, V42, P431, DOI 10.1016/j.immuni.2015.02.013; Leiding JW, 2012, J ALLERGY CLIN IMMUN, V130, P1030, DOI 10.1016/j.jaci.2012.07.049; Levy E, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01262; Lisco A, 2021, NEW ENGL J MED, V385, P921, DOI 10.1056/NEJMoa2102715; Mace EM, 2019, IMMUNOL REV, V287, P202, DOI 10.1111/imr.12725; Mace EM, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00545; Maciejewski-Duval A, 2016, J LEUKOCYTE BIOL, V99, P1065, DOI 10.1189/jlb.5MA0815-388R; Majumdar S, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20010003; Mayol K, 2011, BLOOD, V118, P4863, DOI 10.1182/blood-2011-06-362574; Meuris F, 2016, J INVEST DERMATOL, V136, P473, DOI 10.1016/j.jid.2015.11.004; Miao RF, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.600127; Moscato GMF, 2016, J EUR ACAD DERMATOL, V30, P1212, DOI 10.1111/jdv.13133; Moscato GMF, 2017, FRONT PEDIATR, V5, DOI 10.3389/fped.2017.00095; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; Noda M, 2011, BLOOD, V117, P451, DOI 10.1182/blood-2010-04-277897; Palmesino E, 2006, IMMUNOBIOLOGY, V211, P377, DOI 10.1016/j.imbio.2005.12.003; Pesce S, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00414; Poli A, 2009, IMMUNOLOGY, V126, P458, DOI 10.1111/j.1365-2567.2008.03027.x; Rolle A, 2016, TRENDS IMMUNOL, V37, P233, DOI 10.1016/j.it.2016.01.005; Rosenzweig SD, 2011, CURR ALLERGY ASTHM R, V11, P369, DOI 10.1007/s11882-011-0212-9; Sokol CL, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a016303; Tangye SG, 2020, J CLIN IMMUNOL, V40, P24, DOI 10.1007/s10875-019-00737-x; Tassone L, 2009, J ALLERGY CLIN IMMUN, V123, P1170, DOI 10.1016/j.jaci.2008.12.1133	47	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 26	2022	13								799564	10.3389/fimmu.2022.799564	http://dx.doi.org/10.3389/fimmu.2022.799564			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YV6KJ	35154113	Green Published, gold			2022-12-18	WOS:000752834900001
J	Falconi-Agapito, F; Kerkhof, K; Merino, X; Bakokimi, D; Torres, F; Van Esbroeck, M; Talledo, M; Arien, KK				Falconi-Agapito, Francesca; Kerkhof, Karen; Merino, Xiomara; Bakokimi, Diana; Torres, Fiorella; Van Esbroeck, Marjan; Talledo, Michael; Arien, Kevin K.			Peptide Biomarkers for the Diagnosis of Dengue Infection	FRONTIERS IN IMMUNOLOGY			English	Article						immunoassay; luminex; dengue peptide; arbovirus; seromarkers; random forest; ROC analysis	VIRUS; ARBOVIRUSES; SIGNATURES; TRAVELERS	In a world with an increasing population at risk of exposure to arthropod-borne flaviviruses, access to timely and accurate diagnostic tests would impact profoundly on the management of cases. Twenty peptides previously identified using a flavivirus proteome-wide microarray were evaluated to determine their discriminatory potential to detect dengue virus (DENV) infection. This included nine peptides recognized by IgM antibodies (PM peptides) and 11 peptides recognized by IgG antibodies (PG peptides). A bead-based multiplex peptide immunoassay (MPIA) using the Luminex technology was set-up to determine Ab binding levels to each of these peptides in a panel of 323 carefully selected human serum samples. Sera are derived from individuals either infected with different viruses, namely, the four DENV serotypes, Zika virus (ZIKV), yellow fever virus (YFV), chikungunya virus (CHIKV), West Nile virus (WNV) and Human immunodeficiency virus (HIV), or receiving vaccination against YFV, tick-borne encephalitis (TBEV), and Japanese encephalitis virus (JEV). Additionally, a set of healthy controls were included. We targeted a minimum specificity of 80% for all the analysis. The PG-9 peptide had the best sensitivity (73%) when testing DENV sera from acute patients (A-DENV; <8 days since symptom onset). With sera from convalescent DENV patients (C-DENV; >10 days since symptom onset) the FPG-1 peptide was the best seromarker with a sensitivity of 86%. When combining all A-DENV and C-DENV samples, peptides PM-22 and FPG-1 had the best-diagnostic performance with a sensitivity of 60 and 61.1%, and areas under the curve (AUC) of 0.7865 and 0.8131, respectively. A Random forest (RF) algorithm was used to select the best combination of peptides to classify DENV infection at a targeted specificity >80%. The best RF model for PM peptides that included A-DENV and C-DENV samples, reached a sensitivity of 72.3%, while for PG peptides, the best RF models for A-DENV only, C-DENV only and A-DENV + C-DENV reached a sensitivity of 88.9%, 89.1%, and 88.3%, respectively. In conclusion, the combination of multiple peptides constitutes a founding set of seromarkers for the discrimination of DENV infected individuals from other flavivirus infections.	[Falconi-Agapito, Francesca; Kerkhof, Karen; Bakokimi, Diana; Arien, Kevin K.] Inst Trop Med, Dept Biomed Sci, Unit Virol, Antwerp, Belgium; [Falconi-Agapito, Francesca; Merino, Xiomara] Univ Peruana Cayetano Heredia, Inst Med Trop Alexander Humboldt, Virol Unit, Lima, Peru; [Torres, Fiorella] Hosp Santa Gema, Yurimaguas, Peru; [Van Esbroeck, Marjan] Natl Reference Ctr Arboviruses, Inst Trop Med, Dept Clin Sci, Antwerp, Belgium; [Arien, Kevin K.] Univ Antwerp, Dept Biomed Sci, Antwerp, Belgium	Institute of Tropical Medicine (ITM); Universidad Peruana Cayetano Heredia; Institute of Tropical Medicine (ITM); University of Antwerp	Arien, KK (corresponding author), Inst Trop Med, Dept Biomed Sci, Unit Virol, Antwerp, Belgium.; Arien, KK (corresponding author), Univ Antwerp, Dept Biomed Sci, Antwerp, Belgium.	karien@itg.be		Falconi, Francesca/0000-0003-2359-7439				Ambrosino E, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-317; Araujo SC, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030492; Arien KK, 2018, LANCET GLOB HEALTH, V6, pE830, DOI 10.1016/S2214-109X(18)30295-X; Balmaseda A, 2017, P NATL ACAD SCI USA, V114, P8384, DOI 10.1073/pnas.1704984114; Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060; Breiman L., 2018, CRAN REPOS, V29, DOI [10.1023/A:1010933404324, DOI 10.1023/A:1010933404324]; Cogan JE., 2021, DENG SEV DENG; Echegaray F, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.703887; Falconi-Agapito F, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.686691; Fumagalli MJ, 2021, FRONT CELL INFECT MI, V11, DOI 10.3389/fcimb.2021.710551; Girard M, 2020, VACCINE, V38, P3989, DOI 10.1016/j.vaccine.2020.04.011; Hertz T, 2017, J IMMUNOL, V198, P4025, DOI 10.4049/jimmunol.1700029; Hunsperger EA, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003171; Johnson BW, 2005, J CLIN MICROBIOL, V43, P4977, DOI 10.1128/JCM.43.10.4977-4983.2005; Kerkhof K, 2020, TRENDS MICROBIOL, V28, P276, DOI 10.1016/j.tim.2019.11.005; Kerkhof K, 2015, MALARIA J, V14, DOI 10.1186/s12936-015-0868-z; Lapidus Sarah, 2021, medRxiv, DOI 10.1101/2021.05.10.21256855; Leparc-Goffart I, 2009, J CLIN VIROL, V45, P61, DOI 10.1016/j.jcv.2009.02.010; Luo R, 2019, CLIN MICROBIOL INFEC, V25, P659, DOI 10.1016/j.cmi.2019.01.002; Malafa S, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0008034; Manning Jessica, 2021, medRxiv, DOI 10.1101/2021.09.27.21264000; Mercier-Delarue S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177882; Mishra N, 2018, MBIO, V9, DOI 10.1128/mBio.00095-18; Muller DA, 2017, J INFECT DIS, V215, pS89, DOI 10.1093/infdis/jiw649; Nagar PK, 2020, J IMMUNOL RES, V2020, DOI 10.1155/2020/1820325; PAHO, 2020, REP CASES DENG FEV A; Parameswaran P, 2013, CELL HOST MICROBE, V13, P691, DOI 10.1016/j.chom.2013.05.008; Premkumar L, 2018, J CLIN MICROBIOL, V56, DOI 10.1128/JCM.01504-17; Priyamvada L, 2017, EMERG MICROBES INFEC, V6, DOI 10.1038/emi.2017.42; Rastogi M, 2016, VIROL J, V13, DOI 10.1186/s12985-016-0590-7; Rosado J, 2021, LANCET MICROBE, V2, pE60, DOI 10.1016/S2666-5247(20)30197-X; Santiago GA, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002311; Simmons G, 2018, CLIN INFECT DIS, V66, P1181, DOI 10.1093/cid/cix972; Van Den Bossche D, 2015, EPIDEMIOL INFECT, V143, P2227, DOI 10.1017/S0950268814000685; Van den Bossche D, 2019, EUR J CLIN MICROBIOL, V38, P771, DOI 10.1007/s10096-019-03472-8; van Meer MPA, 2017, J CLIN VIROL, V92, P25, DOI 10.1016/j.jcv.2017.05.001; Verschueren J, 2015, CLIN MICROBIOL INFEC, V21, P867, DOI 10.1016/j.cmi.2015.05.029; Versiani AF, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11111079; Welch RJ, 2014, J VIROL METHODS, V195, P247, DOI 10.1016/j.jviromet.2013.10.019; Wilder-Smith A, 2019, LANCET, V393, P350, DOI 10.1016/S0140-6736(18)32560-1	40	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 26	2022	13								793882	10.3389/fimmu.2022.793882	http://dx.doi.org/10.3389/fimmu.2022.793882			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YV7TW	35154111	Green Published, gold			2022-12-18	WOS:000752930100001
J	Hall, BS; Hsieh, LTH; Sacre, S; Simmonds, RE				Hall, Belinda S.; Hsieh, Louise Tzung-Harn; Sacre, Sandra; Simmonds, Rachel E.			The One That Got Away: How Macrophage-Derived IL-1 beta Escapes the Mycolactone-Dependent Sec61 Blockade in Buruli Ulcer	FRONTIERS IN IMMUNOLOGY			English	Article						Buruli ulcer; Mycobacterium ulcerans; mycolactone; IL-1 beta; Sec61; protein translocation; macrophages	TOLL-LIKE RECEPTORS; MYCOBACTERIUM-ULCERANS; CYTOKINE PRODUCTION; URTICARIAL VASCULITIS; REDUCTIVE EVOLUTION; IMMUNE-RESPONSE; MACROLIDE TOXIN; INTERLEUKIN-1; INFLAMMASOME; INHIBITION	Buruli ulcer (BU), caused by Mycobacterium ulcerans, is a devastating necrotizing skin disease. Key to its pathogenesis is mycolactone, the exotoxin virulence factor that is both immunosuppressive and cytotoxic. The discovery that the essential Sec61 translocon is the major cellular target of mycolactone explains much of the disease pathology, including the immune blockade. Sec61 inhibition leads to a loss in production of nearly all cytokines from monocytes, macrophages, dendritic cells and T cells, as well as antigen presentation pathway proteins and costimulatory molecules. However, there has long been evidence that the immune system is not completely incapable of responding to M. ulcerans infection. In particular, IL-1 beta was recently shown to be present in BU lesions, and to be induced from M. ulcerans-exposed macrophages in a mycolactone-dependent manner. This has important implications for our understanding of BU, showing that mycolactone can act as the "second signal " for IL-1 beta production without inhibiting the pathways of unconventional secretion it uses for cellular release. In this Perspective article, we validate and discuss this recent advance, which is entirely in-line with our understanding of mycolactone's inhibition of the Sec61 translocon. However, we also show that the IL-1 receptor, which uses the conventional secretory pathway, is sensitive to mycolactone blockade at Sec61. Hence, a more complete understanding of the mechanisms regulating IL-1 beta function in skin tissue, including the transient intra-macrophage stage of M. ulcerans infection, is urgently needed to uncover the double-edged sword of IL-1 beta in BU pathogenesis, treatment and wound healing.	[Hall, Belinda S.; Hsieh, Louise Tzung-Harn; Simmonds, Rachel E.] Univ Surrey, Fac Hlth & Med Sci, Sch Biosci & Med, Dept Microbial Sci, Guildford, Surrey, England; [Sacre, Sandra] Univ Sussex, Brighton & Sussex Med Sch, Brighton, E Sussex, England	University of Surrey; University of Brighton; University of Sussex	Simmonds, RE (corresponding author), Univ Surrey, Fac Hlth & Med Sci, Sch Biosci & Med, Dept Microbial Sci, Guildford, Surrey, England.	rachel.simmonds@surrey.ac.uk	Hall, Belinda/AGU-6214-2022	Hall, Belinda/0000-0002-3753-1978; Sacre, Sandra/0000-0003-1665-1142	Wellcome Trust Investigator Award in Science [202843/Z/16/Z]; Kennedy Institute Trustees	Wellcome Trust Investigator Award in Science; Kennedy Institute Trustees	RS holds a Wellcome Trust Investigator Award in Science (202843/Z/16/Z). This work was also supported by a grant from the Kennedy Institute Trustees.	Adusumilli S, 2005, CELL MICROBIOL, V7, P1295, DOI 10.1111/j.1462-5822.2005.00557.x; Artlett CM, 2013, J PATHOL, V229, P157, DOI 10.1002/path.4116; Baron L, 2016, J EXP MED, V213, P2885, DOI 10.1084/jem.20160662; Barrett L, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.587929; Beissner M, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001747; Bhadra P, 2021, BIOCHEM J, V478, P4005, DOI 10.1042/BCJ20210345; Bibert S, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01903; Bieri R, 2017, ACS CHEM BIOL, V12, P1297, DOI 10.1021/acschembio.7b00053; Bolz M, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004678; Bolz M, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002968; Bondeson J, 1999, P NATL ACAD SCI USA, V96, P5668, DOI 10.1073/pnas.96.10.5668; Botsios C, 2007, SCAND J RHEUMATOL, V36, P236, DOI 10.1080/03009740600938647; Boulkroun S, 2010, J IMMUNOL, V184, P1436, DOI 10.4049/jimmunol.0902854; BRENNAN FM, 1989, J AUTOIMMUN, V2, P177, DOI 10.1016/0896-8411(89)90129-7; Capela C, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004671; Coutanceau E, 2007, J EXP MED, V204, P1395, DOI 10.1084/jem.20070234; Dana MR, 1998, CORNEA, V17, P403, DOI 10.1097/00003226-199807000-00011; Demangel C, 2009, NAT REV MICROBIOL, V7, P50, DOI 10.1038/nrmicro2077; Demangel C, 2018, BIOL CELL, V110, P237, DOI 10.1111/boc.201800030; Dinarello CA, 2018, IMMUNOL REV, V281, P8, DOI 10.1111/imr.12621; En J, 2008, INFECT IMMUN, V76, P2002, DOI 10.1128/IAI.01588-07; Fahey E, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01426; Feldmann M, 1996, ANNU REV IMMUNOL, V14, P397, DOI 10.1146/annurev.immunol.14.1.397; Fields JK, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01412; Forster B, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0008709; Foulon M, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1009107; Foulon M, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aax7781; Gama JB, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003066; George KM, 1999, SCIENCE, V283, P854, DOI 10.1126/science.283.5403.854; George KM, 2000, INFECT IMMUN, V68, P877, DOI 10.1128/IAI.68.2.877-883.2000; Gerard SF, 2020, MOL CELL, V79, P406, DOI 10.1016/j.molcel.2020.06.013; Gooding TM, 2003, CLIN INFECT DIS, V36, P1076, DOI 10.1086/368315; Gooding TM, 2002, INFECT IMMUN, V70, P5562, DOI 10.1128/IAI.70.10.5562-5567.2002; Gooding TM, 2001, INFECT IMMUN, V69, P1704, DOI 10.1128/IAI.69.3.1704-1707.2001; Gordon CL, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001290; Goto M, 2006, AM J PATHOL, V168, P805, DOI 10.2353/ajpath.2006.050375; Grayson PC, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075-017-1222-3; Greenhalgh AD, 2012, DIS MODEL MECH, V5, P823, DOI 10.1242/dmm.008557; Gronberg A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013839; Grotzke JE, 2017, P NATL ACAD SCI USA, V114, pE5910, DOI 10.1073/pnas.1705242114; Guarner J, 2003, EMERG INFECT DIS, V9, P651; Guenin-Mace L, 2013, J CLIN INVEST, V123, P1501, DOI 10.1172/JCI66576; Guenin-Mace L, 2011, P NATL ACAD SCI USA, V108, P12833, DOI 10.1073/pnas.1016496108; Gushiken LFS, 2021, LIFE-BASEL, V11, DOI 10.3390/life11070665; Hall BS, 2022, AUTOPHAGY, V18, P841, DOI 10.1080/15548627.2021.1961067; Hall BS, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004061; Hillyer P, 2009, RHEUMATOLOGY, V48, P1581, DOI 10.1093/rheumatology/kep293; Hsieh LT-H., 2021, MEDRXIV2021080421261, DOI [10.1101/2021.08.04.21261598, DOI 10.1101/2021.08.04.21261598]; Isaac C, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0006058; Johnson PDR, 2020, LANCET, V395, P1231, DOI 10.1016/S0140-6736(20)30478-5; Kay J, 2004, RHEUMATOLOGY, V43, P2, DOI 10.1093/rheumatology/keh201; Krause K, 2013, J ALLERGY CLIN IMMUN, V132, P751, DOI 10.1016/j.jaci.2013.04.008; Kwaffo YA, 2021, EXP BIOL MED, V246, P1884, DOI 10.1177/15353702211015628; Liu X, 2016, NATURE, V535, P153, DOI 10.1038/nature18629; Loglo AD, 2018, PEERJ, V6, DOI 10.7717/peerj.5294; Manry J, 2020, COMMUN BIOL, V3, DOI 10.1038/s42003-020-0920-6; Marion E, 2016, J IMMUNOL, V196, P2690, DOI 10.4049/jimmunol.1502194; Marion E, 2014, CELL, V157, P1565, DOI 10.1016/j.cell.2014.04.040; Marsollier L, 2007, PLOS PATHOG, V3, P582, DOI 10.1371/journal.ppat.0030062; Martin P, 2013, J LEUKOCYTE BIOL, V94, P791, DOI 10.1189/jlb.0113035; McKenna M, 2017, J CELL SCI, V130, P1307, DOI 10.1242/jcs.198655; McKenna M, 2016, J CELL SCI, V129, P1404, DOI 10.1242/jcs.182352; Mirza RE, 2013, DIABETES, V62, P2579, DOI 10.2337/db12-1450; Morel JD, 2018, MOL CELL PROTEOMICS, V17, P1750, DOI 10.1074/mcp.RA118.000824; Muleta AJ, 2021, PLOS NEGLECT TROP D, V15, DOI 10.1371/journal.pntd.0009678; Nausch N, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005415; Netea MG, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000661; O'Brien DP, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007178; Ogbechi J, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0427-y; Ogbechi J, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005011; Pahlevan AA, 1999, J IMMUNOL, V163, P3928; Pallotta MT, 2020, J CELL SCI, V133, DOI 10.1242/jcs.250449; Phillips R, 2009, J INFECT DIS, V200, P1675, DOI 10.1086/646615; Phillips RO, 2020, LANCET, V395, P1259, DOI 10.1016/S0140-6736(20)30047-7; Porter JL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070520; Rathinam VAK, 2012, NAT IMMUNOL, V13, P333, DOI 10.1038/ni.2237; Receveur JP, 2022, FEMS MICROBIOL REV, V46, DOI 10.1093/femsre/fuab045; Robbe-Saule M, 2021, VIRULENCE, V12, P1438, DOI 10.1080/21505594.2021.1929749; Sacre S, 2016, EUR J IMMUNOL, V46, P772, DOI 10.1002/eji.201546123; Sacre SM, 2007, J IMMUNOL, V178, P2148, DOI 10.4049/jimmunol.178.4.2148; Sacre SM, 2007, AM J PATHOL, V170, P518, DOI 10.2353/ajpath.2007.060657; Sacre SM, 2008, J IMMUNOL, V181, P8002, DOI 10.4049/jimmunol.181.11.8002; Schmidt EM, 2013, ARTHRITIS RHEUM-US, V65, P2262, DOI 10.1002/art.38055; Silva-Gomes R, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0004265; Simmonds RE, 2009, J IMMUNOL, V182, P2194, DOI 10.4049/jimmunol.0802294; Simpson H, 2019, LANCET GLOB HEALTH, V7, pE912, DOI 10.1016/S2214-109X(19)30171-8; Song AP, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19248-7; Stienstra Y, 2006, GENES IMMUN, V7, P185, DOI 10.1038/sj.gene.6364281; Stinear TP, 2007, GENOME RES, V17, P192, DOI 10.1101/gr.5942807; Stinear TP, 2004, P NATL ACAD SCI USA, V101, P1345, DOI 10.1073/pnas.0305877101; Sun Q, 2017, MOL MED, V23, P188, DOI 10.2119/molmed.2017.00077; Tai AYC, 2018, EMERG INFECT DIS, V24, P58, DOI 10.3201/eid2401.171070; Thwaites RS, 2020, RHEUMATOLOGY, V59, P3533, DOI 10.1093/rheumatology/keaa220; Torrado E, 2007, INFECT IMMUN, V75, P3979, DOI 10.1128/IAI.00290-07; Unterberger S, 2021, IMMUNOTARGETS THER, V10, P285, DOI 10.2147/ITT.S288547; Van Puyenbroeck V, 2018, CELL MOL LIFE SCI, V75, P1541, DOI 10.1007/s00018-017-2743-2; WorldHealthOrganisation, 2019, WHO M BUR ULC OTH SK; Xia SY, 2021, NATURE, V593, P607, DOI 10.1038/s41586-021-03478-3; Yotsu RR, 2018, CURR TROP MED REP, V5, P247, DOI 10.1007/s40475-018-0166-2; Zhang M, 2020, CELL, V181, P637, DOI 10.1016/j.cell.2020.03.031; Zong GH, 2019, J AM CHEM SOC, V141, P8450, DOI 10.1021/jacs.8b13506	101	0	0	2	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 26	2022	12								788146	10.3389/fimmu.2021.788146	http://dx.doi.org/10.3389/fimmu.2021.788146			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YW3SD	35154073	Green Accepted, gold, Green Published			2022-12-18	WOS:000753335000001
J	Ji, C; Bao, L; Yuan, SZ; Qi, ZH; Wang, F; You, MH; Yu, GT; Liu, JJ; Cui, X; Wang, Z; Liu, JJ; Guo, WH; Feng, MX; Chen, F; Kang, YM; Yu, SY				Ji, Ce; Bao, Li; Yuan, Shunzong; Qi, Zhihong; Wang, Fang; You, Menghao; Yu, Guotao; Liu, Jingjing; Cui, Xiao; Wang, Zhao; Liu, Juanjuan; Guo, Wenhui; Feng, Mingxia; Chen, Feng; Kang, Youmin; Yu, Shuyang			SRSF1 Deficiency Impairs the Late Thymocyte Maturation and the CD8 Single-Positive Lineage Fate Decision	FRONTIERS IN IMMUNOLOGY			English	Article						SRSF1; thymocyte; lineage choice; CD8(+) T cell; Runx3; development	SPLICING FACTOR SF2/ASF; T-CELL DEVELOPMENT; GENE-EXPRESSION; SR PROTEINS; TRANSCRIPTION; THPOK; RNA; COMMITMENT; APOPTOSIS; PROMOTE	The underlying mechanisms of thymocyte development and lineage determination remain incompletely understood, and the emerging evidences demonstrated that RNA binding proteins (RBPs) are deeply involved in governing T cell fate in thymus. Serine/arginine-rich splicing factor 1 (SRSF1), as a classical splicing factor, is a pivotal RBP for gene expression in various biological processes. Our recent study demonstrated that SRSF1 plays essential roles in the development of late thymocytes by modulating the T cell regulatory gene networks post-transcriptionally, which are critical in response to type I interferon signaling for supporting thymocyte maturation. Here, we report SRSF1 also contributes to the determination of the CD8(+) T cell fate. By specific ablation of SRSF1 in CD4(+)CD8(+) double positive (DP) thymocytes, we found that SRSF1 deficiency impaired the maturation of late thymocytes and diminished the output of both CD4(+) and CD8(+) single positive T cells. Interestingly, the ratio of mature CD4(+) to CD8(+) cells was notably altered and more severe defects were exhibited in CD8(+) lineage than those in CD4(+) lineage, reflecting the specific function of SRSF1 in CD8(+) T cell fate decision. Mechanistically, SRSF1-deficient cells downregulate their expression of Runx3, which is a crucial transcriptional regulator in sustaining CD8(+) single positive (SP) thymocyte development and lineage choice. Moreover, forced expression of Runx3 partially rectified the defects in SRSF1-deficient CD8(+) thymocyte maturation. Thus, our data uncovered the previous unknown role of SRSF1 in establishment of CD8(+) cell identity.	[Ji, Ce; Qi, Zhihong; Wang, Fang; You, Menghao; Yu, Guotao; Liu, Jingjing; Cui, Xiao; Wang, Zhao; Liu, Juanjuan; Guo, Wenhui; Feng, Mingxia; Kang, Youmin; Yu, Shuyang] China Agr Univ, Coll Biol Sci, State Key Lab Agrobiotechnol, Beijing, Peoples R China; [Bao, Li] Beijing Jishuitan Hosp, Dept Hematol, Beijing, Peoples R China; [Yuan, Shunzong] Peoples Liberat Army PLA Gen Hosp, Med Ctr 5, Dept Hematol, Beijing, Peoples R China; [Chen, Feng] Peking Univ, Sch Stomatol, Cent Lab, Beijing, Peoples R China	China Agricultural University; Peking University	Kang, YM; Yu, SY (corresponding author), China Agr Univ, Coll Biol Sci, State Key Lab Agrobiotechnol, Beijing, Peoples R China.	kym@cau.edu.cn; ysy@cau.edu.cn	Wang, Fang/GLV-0025-2022	Wang, Fang/0000-0002-2604-4429				Akira S, 2021, ANNU REV IMMUNOL, V39, P481, DOI 10.1146/annurev-immunol-101819-075147; Aliahmad P, 2012, CURR OPIN IMMUNOL, V24, P173, DOI 10.1016/j.coi.2011.12.001; Anczukow O, 2012, NAT STRUCT MOL BIOL, V19, P220, DOI 10.1038/nsmb.2207; Das S, 2012, CELL REP, V1, P110, DOI 10.1016/j.celrep.2011.12.001; Egawa T, 2008, NAT IMMUNOL, V9, P1131, DOI 10.1038/ni.1652; Han JX, 2021, J IMMUNOL, V206, P249, DOI 10.4049/jimmunol.2000889; He X, 2008, IMMUNITY, V28, P346, DOI 10.1016/j.immuni.2008.02.006; Hernandez-Hoyos G, 2003, IMMUNITY, V19, P83, DOI 10.1016/S1074-7613(03)00176-6; Hogquist KA, 2015, J IMMUNOL, V195, P1351, DOI 10.4049/jimmunol.1501050; Huang YQ, 2003, MOL CELL, V11, P837, DOI 10.1016/S1097-2765(03)00089-3; Ji X, 2013, CELL, V153, P855, DOI 10.1016/j.cell.2013.04.028; Karni R, 2008, P NATL ACAD SCI USA, V105, P15323, DOI 10.1073/pnas.0801376105; Karni R, 2007, NAT STRUCT MOL BIOL, V14, P185, DOI 10.1038/nsmb1209; Katsuyama T, 2019, J CLIN INVEST, V129, P5411, DOI 10.1172/JCI127949; Kojo S, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00768-1; Kovarik P, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.751313; Lee PP, 2001, IMMUNITY, V15, P763, DOI 10.1016/S1074-7613(01)00227-8; Lesourne R, 2009, NAT IMMUNOL, V10, P840, DOI 10.1038/ni.1768; Li XL, 2005, GENE DEV, V19, P2705, DOI 10.1101/gad.1359305; Li XL, 2005, CELL, V122, P365, DOI 10.1016/j.cell.2005.06.008; Liu JJ, 2021, CELL MOL IMMUNOL, V18, P2502, DOI 10.1038/s41423-021-00766-w; Liu JJ, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.791220; Maurice D, 2007, EMBO J, V26, P3629, DOI 10.1038/sj.emboj.7601801; Michlewski G, 2008, MOL CELL, V30, P179, DOI 10.1016/j.molcel.2008.03.013; Muroi S, 2008, NAT IMMUNOL, V9, P1113, DOI 10.1038/ni.1650; Petrie HT, 2007, ANNU REV IMMUNOL, V25, P649, DOI 10.1146/annurev.immunol.23.021704.115715; Qi ZH, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abf0753; RAMSDELL F, 1991, J IMMUNOL, V147, P1779; Rothenberg EV, 2008, NAT REV IMMUNOL, V8, P9, DOI 10.1038/nri2232; Sakaguchi S, 2010, NAT IMMUNOL, V11, P442, DOI 10.1038/ni.1860; Setoguchi R, 2008, SCIENCE, V319, P822, DOI 10.1126/science.1151844; Singer A, 2008, NAT REV IMMUNOL, V8, P788, DOI 10.1038/nri2416; Steinke FC, 2014, NAT IMMUNOL, V15, P646, DOI 10.1038/ni.2897; Sun Z, 2021, ELIFE, V10, DOI 10.7554/eLife.61406; Takahama Y, 2006, NAT REV IMMUNOL, V6, P127, DOI 10.1038/nri1781; Taniuchi I, 2016, IMMUNOL REV, V271, P98, DOI 10.1111/imr.12401; Turner M, 2018, NAT IMMUNOL, V19, P120, DOI 10.1038/s41590-017-0028-4; Wang D, 2012, NAT IMMUNOL, V13, P560, DOI 10.1038/ni.2301; Wang F, 2021, CELL MOL IMMUNOL, V18, P644, DOI 10.1038/s41423-020-00527-1; Wang JR, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00931-8; Wang L, 2008, NAT IMMUNOL, V9, P1122, DOI 10.1038/ni.1647; Yao YP, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21594-6; Yui MA, 2014, NAT REV IMMUNOL, V14, P529, DOI 10.1038/nri3702; Zhong XY, 2009, MOL CELL, V35, P1, DOI 10.1016/j.molcel.2009.06.016; Zhou XX, 2019, J CLIN INVEST, V129, P676, DOI 10.1172/JCI120279	45	0	0	3	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 26	2022	13								838719	10.3389/fimmu.2022.838719	http://dx.doi.org/10.3389/fimmu.2022.838719			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YV4TP	35154164	Green Published, gold			2022-12-18	WOS:000752722700001
J	Krayem, I; Sohrabi, Y; Javorkova, E; Volkova, V; Strnad, H; Havelkova, H; Vojtiskova, J; Aidarova, A; Holan, V; Demant, P; Lipoldova, M				Krayem, Imtissal; Sohrabi, Yahya; Javorkova, Eliska; Volkova, Valeriya; Strnad, Hynek; Havelkova, Helena; Vojtiskova, Jarmila; Aidarova, Aigerim; Holan, Vladimir; Demant, Peter; Lipoldova, Marie			Genetic Influence on Frequencies of Myeloid-Derived Cell Subpopulations in Mouse	FRONTIERS IN IMMUNOLOGY			English	Article						myeloid-derived cells; genetic control; CD11b(+)Gr1(+) subpopulation; neutrophils; relative spleen weight; spleen architecture; candidate gene	GENOME-WIDE ASSOCIATION; QUANTITATIVE TRAIT LOCI; EVOLUTIONARY CONSERVATION; PROLIFERATIVE RESPONSE; COUNT; SMAP1; DIFFERENTIATION; SUSCEPTIBILITY; IDENTIFICATION; LANDSCAPE	Differences in frequencies of blood cell subpopulations were reported to influence the course of infections, atopic and autoimmune diseases, and cancer. We have discovered a unique mouse strain B10.O20 containing extremely high frequency of myeloid-derived cells (MDC) in spleen. B10.O20 carries 3.6% of genes of the strain O20 on the C57BL/10 genetic background. It contains much higher frequency of CD11b(+)Gr1(+) cells in spleen than both its parents. B10.O20 carries O20-derived segments on chromosomes 1, 15, 17, and 18. Their linkage with frequencies of blood cell subpopulations in spleen was tested in F-2 hybrids between B10.O20 and C57BL/10. We found 3 novel loci controlling MDC frequencies: Mydc1, 2, and 3 on chromosomes 1, 15, and 17, respectively, and a locus controlling relative spleen weight (Rsw1) that co-localizes with Mydc3 and also influences proportion of white and red pulp in spleen. Mydc1 controls numbers of CD11b(+)Gr1(+) cells. Interaction of Mydc2 and Mydc3 regulates frequency of CD11b(+)Gr1(+) cells and neutrophils (Gr1(+)Siglec-F- cells from CD11b(+) cells). Interestingly, Mydc3/Rsw1 is orthologous with human segment 6q21 that was shown previously to determine counts of white blood cells. Bioinformatics analysis of genomic sequence of the chromosomal segments bearing these loci revealed polymorphisms between O20 and C57BL/10 that change RNA stability and genes' functions, and we examined expression of relevant genes. This identified potential candidate genes Smap1, Vps52, Tnxb, and Rab44. Definition of genetic control of MDC can help to personalize therapy of diseases influenced by these cells.	[Krayem, Imtissal; Sohrabi, Yahya; Volkova, Valeriya; Havelkova, Helena; Vojtiskova, Jarmila; Aidarova, Aigerim; Lipoldova, Marie] Czech Acad Sci, Lab Mol & Cellular Immunol, Inst Mol Genet, Prague, Czech Republic; [Javorkova, Eliska; Holan, Vladimir] Charles Univ Prague, Fac Sci, Dept Cell Biol, Prague, Czech Republic; [Javorkova, Eliska; Holan, Vladimir] Czech Acad Sci, Dept Nanotoxicol & Mol Epidmiol, Inst Expt Med, Prague, Czech Republic; [Strnad, Hynek] Czech Acad Sci, Dept Genom & Bioinformat, Inst Mol Genet, Prague, Czech Republic; [Demant, Peter] Roswell Pk Comprehens Canc Ctr, Dept Mol & Cellular Biol, Buffalo, NY USA	Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences; Charles University Prague; Czech Academy of Sciences; Institute of Experimental Medicine of the Czech Academy of Sciences; Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences	Lipoldova, M (corresponding author), Czech Acad Sci, Lab Mol & Cellular Immunol, Inst Mol Genet, Prague, Czech Republic.	lipoldova@img.cas.cz	Lipoldova, Marie/G-4399-2014	Lipoldova, Marie/0000-0002-2101-0334; Aidarova, Aigerim/0000-0003-2149-6191; Sohrabi, Yahya/0000-0001-5268-238X				Arvidsson S, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-465; Ashkenazy H, 2016, NUCLEIC ACIDS RES, V44, pW344, DOI 10.1093/nar/gkw408; Ashkenazy H, 2010, NUCLEIC ACIDS RES, V38, pW529, DOI 10.1093/nar/gkq399; Astle WJ, 2016, CELL, V167, P1415, DOI 10.1016/j.cell.2016.10.042; Bizymi N, 2019, HEMASPHERE, V3, DOI 10.1097/HS9.0000000000000168; Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170; Bovo S, 2020, ANIM GENET, V51, P601, DOI 10.1111/age.12959; Bovo S, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-43297-1; Bruger AM, 2019, CANCER IMMUNOL IMMUN, V68, P631, DOI 10.1007/s00262-018-2170-8; Bult CJ, 2019, NUCLEIC ACIDS RES, V47, pD801, DOI 10.1093/nar/gky1056; Carignano HA, 2018, BMC GENOMICS, V19, DOI 10.1186/s12864-018-4523-2; Casalou C, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00217; Celniker G, 2013, ISR J CHEM, V53, P199, DOI 10.1002/ijch.201200096; Ceolotto G, 2017, CARDIOVASC RES, V113, P1627, DOI 10.1093/cvr/cvx157; Cesta MF, 2006, TOXICOL PATHOL, V34, P455, DOI 10.1080/01926230600867743; Choi Y, 2015, BIOINFORMATICS, V31, P2745, DOI 10.1093/bioinformatics/btv195; Cingolani P, 2012, FLY, V6, P80, DOI 10.4161/fly.19695; Civelek M, 2014, NAT REV GENET, V15, P34, DOI 10.1038/nrg3575; Davis RC, 2013, MAMM GENOME, V24, P105, DOI 10.1007/s00335-013-9448-0; Dickinson ME, 2016, NATURE, V537, P508, DOI 10.1038/nature19356; Evans D M, 1999, Twin Res, V2, P250, DOI 10.1375/136905299320565735; Evans DM, 2004, J ALLERGY CLIN IMMUN, V114, P826, DOI 10.1016/j.jaci.2004.05.060; Ferreira MAR, 2009, AM J HUM GENET, V85, P745, DOI 10.1016/j.ajhg.2009.10.005; FIJNEMAN RJA, 1994, ONCOGENE, V9, P1417; FIJNEMAN RJA, 1995, CANCER RES, V55, P3179; Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506; Gamara J, 2020, MEDIAT INFLAMM, V2020, DOI 10.1155/2020/2713074; Gamara J, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/235170; Haddy TB, 1999, J LAB CLIN MED, V133, P15, DOI 10.1053/lc.1999.v133.a94931; Hudson J, 1997, BRIT J HAEMATOL, V99, P520, DOI 10.1046/j.1365-2141.1997.4433253.x; Ibuchi K, 2020, BRAIN RES, V1745, DOI 10.1016/j.brainres.2020.146905; *JACKS LAB, MGI MOUS GEN INF; Kadowaki T, 2020, CELL MOL IMMUNOL, V17, P1287, DOI 10.1038/s41423-020-0413-z; Keller MF, 2014, HUM MOL GENET, V23, P6944, DOI 10.1093/hmg/ddu401; Kluth M, 2017, ONCOTARGET, V8, P108923, DOI 10.18632/oncotarget.22408; Kobets T, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001667; Kon S, 2013, J CLIN INVEST, V123, P1123, DOI 10.1172/JCI63711; Korteweg R, 1940, AKAD V WETTENSCHAPPE, V43, P891; Li H, 2010, BIOINFORMATICS, V26, P589, DOI 10.1093/bioinformatics/btp698; Li R, 2017, LIFE SCI, V182, P80, DOI 10.1016/j.lfs.2017.06.008; LIPOLDOVA M, 1995, IMMUNOGENETICS, V41, P301, DOI 10.1007/BF00172155; Lipoldova M, 2005, INT J CANCER, V114, P394, DOI 10.1002/ijc.20731; Lipoldova M, 2002, IMMUNOGENETICS, V54, P174, DOI 10.1007/s00251-002-0439-7; Lipoldova M, 2010, CANCER IMMUNOL IMMUN, V59, P203, DOI 10.1007/s00262-009-0739-y; Magoc T, 2011, BIOINFORMATICS, V27, P2957, DOI 10.1093/bioinformatics/btr507; Martinez FD, 1998, AM J RESP CRIT CARE, V158, P1739, DOI 10.1164/ajrccm.158.6.9712040; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Meyer C, 2005, P NATL ACAD SCI USA, V102, P449, DOI 10.1073/pnas.0406994102; Mousas A, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1006925; Nalls MA, 2008, AM J HUM GENET, V82, P81, DOI 10.1016/j.ajhg.2007.09.003; Nalls MA, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002113; Okada Y, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002067; Palus M, 2018, BMC NEUROSCI, V19, DOI 10.1186/s12868-018-0438-8; Peters LL, 2005, MAMM GENOME, V16, P749, DOI 10.1007/s00335-005-0063-6; Pilia G, 2006, PLOS GENET, V2, P1207, DOI 10.1371/journal.pgen.0020132; Probst K, 2018, STEM CELLS, V36, P1752, DOI 10.1002/stem.2892; Reich D, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000360; Reiner AP, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002108; Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754; Roederer M, 2015, CELL, V161, P387, DOI 10.1016/j.cell.2015.02.046; Ruhle F, 2017, BLOOD, V129, P783, DOI 10.1182/blood-2016-07-728840; Sangar F, 2014, ONCOGENE, V33, P2758, DOI 10.1038/onc.2013.211; Sankaran VG, 2013, CURR OPIN GENET DEV, V23, P339, DOI 10.1016/j.gde.2013.02.006; Schindler C, 2015, NAT CELL BIOL, V17, P639, DOI 10.1038/ncb3129; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Shockley KR, 2006, MAMM GENOME, V17, P598, DOI 10.1007/s00335-005-0176-y; Sima M, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001173; Slapnickova M, 2016, BIOL SEX DIFFER, V7, DOI 10.1186/s13293-016-0117-3; Sohrabi Y, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00130; Srikanth Sonal, 2017, Small GTPases, V8, P43, DOI 10.1080/21541248.2016.1192921; Stassen APM, 1996, MAMM GENOME, V7, P55, DOI 10.1007/s003359900013; Sugimoto M, 2012, CELL REP, V2, P1363, DOI 10.1016/j.celrep.2012.10.004; Tajuddin SM, 2016, AM J HUM GENET, V99, P22, DOI 10.1016/j.ajhg.2016.05.003; Telieps T, 2016, J DIABETES RES, V2016, DOI 10.1155/2016/4208156; Tokuhisa M, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-67638-7; Valcourt U, 2015, CELL ADHES MIGR, V9, P154, DOI 10.4161/19336918.2014.994893; VANNIE R, 1978, TISSUE ANTIGENS, V12, P106, DOI 10.1111/j.1399-0039.1978.tb01305.x; VERSO M L, 1964, Med Hist, V8, P149; Wu CL, 2016, NUCLEIC ACIDS RES, V44, pD313, DOI 10.1093/nar/gkv1104; Yamaguchi Y, 2018, CELL MOL LIFE SCI, V75, P33, DOI 10.1007/s00018-017-2607-9; Yanagawa T, 2019, STEM CELLS, V37, P89, DOI 10.1002/stem.2916; Yang S, 2009, ANIM GENET, V40, P273, DOI 10.1111/j.1365-2052.2008.01830.x; Zhang J, 2017, J MOL MED, V95, P1107, DOI 10.1007/s00109-017-1572-y; Zhang ZY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063665; Zhou XY, 2015, STEM CELL REP, V5, P125, DOI 10.1016/j.stemcr.2015.05.008; Zhou Y, 2019, MOL MED REP, V20, P4303, DOI 10.3892/mmr.2019.10666	86	0	0	4	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 26	2022	12								760881	10.3389/fimmu.2021.760881	http://dx.doi.org/10.3389/fimmu.2021.760881			19	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YV8BG	35154069	gold, Green Published			2022-12-18	WOS:000752949400001
J	Lu, C; Chen, HH; Wang, C; Yang, F; Li, J; Liu, H; Chen, GC				Lu, Can; Chen, Huihui; Wang, Chang; Yang, Fei; Li, Jun; Liu, Hong; Chen, Guochun			An Emerging Role of TIM3 Expression on T Cells in Chronic Kidney Inflammation	FRONTIERS IN IMMUNOLOGY			English	Review						TIM3; T cell; macrophage; infection; chronic kidney inflammation	IMMUNE-RESPONSES; TRANSPLANT RECIPIENTS; IMMUNOGLOBULIN DOMAIN; ALLOGRAFT-REJECTION; RECEPTOR TIM-3; CO-STIMULATION; SOLUBLE TIM-3; HEPATITIS-B; MOUSE MODEL; EXHAUSTION	T cell immunoglobulin domain and mucin domain 3 (TIM3) was initially identified as an inhibitory molecule on IFN gamma-producing T cells. Further research discovered the broad expression of TIM3 on different immune cells binding to multiple ligands. Apart from its suppressive effects on the Th1 cells, recent compelling experiments highlighted the indispensable role of TIM3 in the myeloid cell-mediated inflammatory response, supporting that TIM3 exerts pleiotropic effects on both adaptive and innate immune cells in a context-dependent manner. A large number of studies have been conducted on TIM3 biology in the disease settings of infection, cancer, and autoimmunity. However, there is a lack of clinical evidence to closely evaluate the role of T cell-expressing TIM3 in the pathogenesis of chronic kidney disease (CKD). Here, we reported an intriguing case of Mycobacterium tuberculosis (Mtb) infection that was characterized by persistent overexpression of TIM3 on circulating T cells and ongoing kidney tubulointerstitial inflammation for a period of 12 months. In this case, multiple histopathological biopsies revealed a massive accumulation of recruited T cells and macrophages in the enlarged kidney and liver. After standard anti-Mtb treatment, repeated renal biopsy identified a dramatic remission of the infiltrated immune cells in the tubulointerstitial compartment. This is the first clinical report to reveal a time-course expression of TIM3 on the T cells, which is pathologically associated with the progression of severe kidney inflammation in a non-autoimmunity setting. Based on this case, we summarize the recent findings on TIM3 biology and propose a novel model of CKD progression due to the aberrant crosstalk among immune cells.	[Lu, Can; Wang, Chang; Yang, Fei; Li, Jun; Liu, Hong; Chen, Guochun] Cent South Univ, Xiangya Hosp 2, Dept Nephrol, Changsha, Peoples R China; [Lu, Can; Wang, Chang; Yang, Fei; Li, Jun; Liu, Hong; Chen, Guochun] Hunan Key Lab Kidney Dis & Blood Purificat, Changsha, Peoples R China; [Chen, Huihui] Cent South Univ, Xiangya Hosp 2, Dept Ophthalmol, Changsha, Peoples R China; [Chen, Huihui; Chen, Guochun] Cent South Univ, Clin Immunol Res Ctr, Changsha, Peoples R China	Central South University; Central South University; Central South University	Chen, GC (corresponding author), Cent South Univ, Xiangya Hosp 2, Dept Nephrol, Changsha, Peoples R China.; Chen, GC (corresponding author), Hunan Key Lab Kidney Dis & Blood Purificat, Changsha, Peoples R China.; Chen, GC (corresponding author), Cent South Univ, Clin Immunol Res Ctr, Changsha, Peoples R China.	guochunchen@csu.edu.cn			National Natural Science Foundation of China; Hunan Provincial Natural Science Foundation of China [81970804, 2020JJ4126, 81770691, 82170759]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Hunan Provincial Natural Science Foundation of China(Natural Science Foundation of Hunan Province)	This work was supported in part by grants from the National Natural Science Foundation of China and Hunan Provincial Natural Science Foundation of China to HC (81970804, 2020JJ4126) and GC (81770691, 82170759).	Anderson AC, 2007, SCIENCE, V318, P1141, DOI 10.1126/science.1148536; Andrews LP, 2019, NAT IMMUNOL, V20, P1425, DOI 10.1038/s41590-019-0512-0; Asano T, 2020, J CLIN MED, V9, DOI 10.3390/jcm9113563; Avery L, 2018, P NATL ACAD SCI USA, V115, P2455, DOI 10.1073/pnas.1712107115; Bertoletti A, 2016, J HEPATOL, V64, pS71, DOI 10.1016/j.jhep.2016.01.026; Blank CU, 2019, NAT REV IMMUNOL, V19, P665, DOI 10.1038/s41577-019-0221-9; Brennan E, 2021, NAT REV NEPHROL, V17, P725, DOI 10.1038/s41581-021-00454-y; Cao EH, 2007, IMMUNITY, V26, P311, DOI 10.1016/j.immuni.2007.01.016; Chen M, 2020, J CLIN LAB ANAL, V34, DOI 10.1002/jcla.23248; Chen XJ, 2021, FRONT PHYSIOL, V12, DOI 10.3389/fphys.2021.637480; Chiba S, 2012, NAT IMMUNOL, V13, P832, DOI 10.1038/ni.2376; Cox SN, 2012, KIDNEY INT, V82, P548, DOI 10.1038/ki.2012.147; Croft NP, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003129; D'Alessio FR, 2019, J CLIN INVEST, V129, P2608, DOI 10.1172/JCI124614; Das M, 2017, IMMUNOL REV, V276, P97, DOI 10.1111/imr.12520; DeKruyff RH, 2010, J IMMUNOL, V184, P1918, DOI 10.4049/jimmunol.0903059; Dong Q, 2019, IMMUNOL INVEST, V48, P27, DOI 10.1080/08820139.2018.1493497; Elahi S, 2012, BLOOD, V119, P4192, DOI 10.1182/blood-2011-11-389585; Fenwick C, 2019, IMMUNOL REV, V292, P149, DOI 10.1111/imr.12823; Freeman GJ, 2010, IMMUNOL REV, V235, P172, DOI 10.1111/j.0105-2896.2010.00903.x; Furman D, 2019, NAT MED, V25, P1822, DOI 10.1038/s41591-019-0675-0; Gieseck RL, 2018, NAT REV IMMUNOL, V18, P62, DOI 10.1038/nri.2017.90; Gilpin C, 2018, EUR RESPIR J, V51, DOI 10.1183/13993003.00098-2018; Golden-Mason L, 2009, J VIROL, V83, P9122, DOI 10.1128/JVI.00639-09; Gorman JV, 2014, J IMMUNOL, V192, P3133, DOI 10.4049/jimmunol.1302290; Grebinoski S, 2020, CURR OPIN IMMUNOL, V67, P1, DOI 10.1016/j.coi.2020.06.001; Gu QH, 2018, NEPHROLOGY, V23, P476, DOI 10.1111/nep.13040; Gulati A, 2011, CLIN J AM SOC NEPHRO, V6, P63, DOI 10.2215/CJN.01850310; Guo L, 2014, CLIN EXP MED, V14, P383, DOI 10.1007/s10238-013-0264-3; Guo Y, 2018, CLIN EXP IMMUNOL, V193, P113, DOI 10.1111/cei.13126; Gupta S, 2012, J CLIN INVEST, V122, P2395, DOI 10.1172/JCI45138; Ho J, 2012, AM J KIDNEY DIS, V60, P629, DOI 10.1053/j.ajkd.2012.01.028; Huang YH, 2015, NATURE, V517, P386, DOI 10.1038/nature13848; Huen SC, 2017, ANNU REV PHYSIOL, V79, P449, DOI 10.1146/annurev-physiol-022516-034219; Jayaraman P, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005490; Jayaraman P, 2010, J EXP MED, V207, P2343, DOI 10.1084/jem.20100687; Jiao QQ, 2016, ARCH DERMATOL RES, V308, P553, DOI 10.1007/s00403-016-1665-4; Jin HT, 2010, P NATL ACAD SCI USA, V107, P14733, DOI 10.1073/pnas.1009731107; Jones RB, 2008, J EXP MED, V205, P2763, DOI 10.1084/jem.20081398; Ju Y, 2014, MOL IMMUNOL, V58, P85, DOI 10.1016/j.molimm.2013.11.001; Ju Y, 2010, J HEPATOL, V52, P322, DOI 10.1016/j.jhep.2009.12.005; Ju Y, 2009, CELL MOL IMMUNOL, V6, P35, DOI 10.1038/cmi.2009.5; Kalantar-Zadeh K, 2021, LANCET, V398, P786, DOI 10.1016/S0140-6736(21)00519-5; Kassu A, 2010, J IMMUNOL, V185, P3007, DOI 10.4049/jimmunol.1000156; Khan N, 2017, CRIT REV MICROBIOL, V43, P133, DOI 10.1080/1040841X.2016.1185603; Kiryluk K, 2014, NAT GENET, V46, P1187, DOI 10.1038/ng.3118; Koguchi K, 2006, J EXP MED, V203, P1413, DOI 10.1084/jem.20060210; Kupin WL, 2017, CLIN J AM SOC NEPHRO, V12, P1529, DOI 10.2215/CJN.09180816; Kurose Y, 2013, BMC NEPHROL, V14, DOI 10.1186/1471-2369-14-23; Kurts C, 2020, NAT REV NEPHROL, V16, P391, DOI 10.1038/s41581-020-0272-y; Li YM, 2018, INT IMMUNOPHARMACOL, V55, P330, DOI 10.1016/j.intimp.2018.01.008; Liberal R, 2012, HEPATOLOGY, V56, P677, DOI 10.1002/hep.25682; Lima G, 2021, CLIN EXP IMMUNOL, V204, P285, DOI 10.1111/cei.13577; Liu Y, 2010, CLIN IMMUNOL, V137, P288, DOI 10.1016/j.clim.2010.07.012; McKinney EF, 2015, NATURE, V523, P612, DOI 10.1038/nature14468; McMahan RH, 2010, J CLIN INVEST, V120, P4546, DOI 10.1172/JCI43127; Monney L, 2002, NATURE, V415, P536, DOI 10.1038/415536a; Mori Y, 2021, CELL METAB, V33, P1042, DOI 10.1016/j.cmet.2021.04.004; Naka EL, 2009, INT IMMUNOPHARMACOL, V9, P658, DOI 10.1016/j.intimp.2008.11.013; Nakae S, 2007, BLOOD, V110, P2565, DOI 10.1182/blood-2006-11-058800; Nakae S, 2007, J LEUKOCYTE BIOL, V81, P1258, DOI 10.1189/jlb.1006610; Nakayama M, 2009, BLOOD, V113, P3821, DOI 10.1182/blood-2008-10-185884; Nebbia G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047648; Ocana-Guzman R, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00229; Peerapornratana S, 2019, KIDNEY INT, V96, P1083, DOI 10.1016/j.kint.2019.05.026; Peiseler M, 2019, J CLIN INVEST, V129, P2629, DOI 10.1172/JCI124616; Phong BL, 2015, J EXP MED, V212, P2289, DOI 10.1084/jem.20150388; Ponciano VC, 2007, TRANSPL IMMUNOL, V17, P215, DOI 10.1016/j.trim.2006.11.003; Qiu YQ, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002984; Rabb H, 2016, J AM SOC NEPHROL, V27, P371, DOI 10.1681/ASN.2015030261; Raeber ME, 2018, IMMUNOL REV, V283, P176, DOI 10.1111/imr.12644; Rangachari M, 2012, NAT MED, V18, P1394, DOI 10.1038/nm.2871; Reddy PBJ, 2011, J IMMUNOL, V187, P5745, DOI 10.4049/jimmunol.1102105; Renesto PG, 2007, AM J TRANSPLANT, V7, P1661, DOI 10.1111/j.1600-6143.2007.01795.x; Sada-Ovalle I, 2012, J IMMUNOL, V189, P5896, DOI 10.4049/jimmunol.1200990; Sakuishi K, 2011, TRENDS IMMUNOL, V32, P345, DOI 10.1016/j.it.2011.05.003; Sanchez-Fueyo A, 2003, NAT IMMUNOL, V4, P1093, DOI 10.1038/ni987; Santiago C, 2007, IMMUNITY, V26, P299, DOI 10.1016/j.immuni.2007.01.014; Sarraj B, 2014, P NATL ACAD SCI USA, V111, P12145, DOI 10.1073/pnas.1303676111; Sato Y, 2018, AM J PHYSIOL-RENAL, V315, pF1501, DOI 10.1152/ajprenal.00195.2018; Satoskar AA, 2020, NAT REV NEPHROL, V16, P32, DOI 10.1038/s41581-019-0178-8; Schietinger A, 2014, TRENDS IMMUNOL, V35, P51, DOI 10.1016/j.it.2013.10.001; Schroll A, 2010, AM J PATHOL, V176, P1716, DOI 10.2353/ajpath.2010.090859; Shahbaz SK, 2019, TRANSPL IMMUNOL, V54, P9, DOI 10.1016/j.trim.2018.10.007; Shahbaz SK, 2017, TRANSPL IMMUNOL, V43-44, P11, DOI 10.1016/j.trim.2017.07.002; Sharma R, 2018, AM J PHYSIOL-RENAL, V314, pF679, DOI 10.1152/ajprenal.00236.2017; Song LJ, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0306-0; Sonnenberg GE, 2019, NAT REV IMMUNOL, V19, P599, DOI 10.1038/s41577-019-0194-8; Su Bintao, 2021, Clin Exp Rheumatol, V39 Suppl 129, P13, DOI 10.55563/clinexprheumatol/6y0bjb; Tang RH, 2019, SEMIN IMMUNOL, V42, DOI 10.1016/j.smim.2019.101302; Thimme R, 2021, J HEPATOL, V74, P220, DOI 10.1016/j.jhep.2020.09.022; Venet F, 2018, NAT REV NEPHROL, V14, P121, DOI 10.1038/nrneph.2017.165; Ville S, 2021, KIDNEY INT, V99, P267, DOI 10.1016/j.kint.2020.10.030; Wang XJ, 2011, J INFECTION, V62, P292, DOI 10.1016/j.jinf.2011.02.013; Wang Y, 2008, SCAND J IMMUNOL, V67, P63, DOI 10.1111/j.1365-3083.2007.02038.x; Wang ZD, 2017, SCI REP-UK, V7, DOI 10.1038/srep42095; Wherry EJ, 2011, NAT IMMUNOL, V12, P492, DOI 10.1038/ni.2035; Wolf Y, 2020, NAT REV IMMUNOL, V20, P173, DOI 10.1038/s41577-019-0224-6; Wu W, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-113; Yamaguchi H, 2021, NEPHROL DIAL TRANSPL, V36, P75, DOI 10.1093/ndt/gfaa223; Yang HM, 2019, MOL METAB, V23, P24, DOI 10.1016/j.molmet.2019.02.007; Yang L, 2008, J IMMUNOL, V180, P4409, DOI 10.4049/jimmunol.180.7.4409; Yang XD, 2014, IMMUNOL RES, V60, P85, DOI 10.1007/s12026-014-8550-z; Zeggar S, 2018, ARTHRITIS RHEUMATOL, V70, P1089, DOI 10.1002/art.40467; Zhang Q, 2014, AM J PHYSIOL-RENAL, V306, pF822, DOI 10.1152/ajprenal.00294.2013; Zhao D, 2021, AUTOIMMUNITY, V54, P97, DOI 10.1080/08916934.2021.1891535; Zhao D, 2017, J LEUKOCYTE BIOL, V102, P1313, DOI 10.1189/jlb.3HI0117-005RR; Zhu C, 2005, NAT IMMUNOL, V6, P1245, DOI 10.1038/ni1271; Zhu C, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abd2710; Zoccali C, 2017, NAT REV NEPHROL, V13, DOI 10.1038/nrneph.2017.52	110	0	0	3	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 26	2022	12								798683	10.3389/fimmu.2021.798683	http://dx.doi.org/10.3389/fimmu.2021.798683			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YW0RB	35154075	gold, Green Published			2022-12-18	WOS:000753128000001
J	McDonald, C; Morrison, VL; McGloin, D; Fagerholm, SC				McDonald, Craig; Morrison, Vicky L.; McGloin, David; Fagerholm, Susanna Carola			Examining the Effect of Kindlin-3 Binding Site Mutation on LFA-1-ICAM-1 Bonds by Force Measuring Optical Tweezers	FRONTIERS IN IMMUNOLOGY			English	Article						LFA-1; kindlin-3; T cell; bond strength; ICAM-1	FUNCTION-ASSOCIATED ANTIGEN-1; T-CELL-ACTIVATION; INTEGRIN; LIGAND; ADHESION	Integrins in effector T cells are crucial for cell adhesion and play a central role in cell-mediated immunity. Leukocyte adhesion deficiency (LAD) type III, a genetic condition that can cause death in early childhood, highlights the importance of integrin/kindlin interactions for immune system function. A TTT/AAA mutation in the cytoplasmic domain of the beta 2 integrin significantly reduces kindlin-3 binding to the beta 2 tail, abolishes leukocyte adhesion to intercellular adhesion molecule 1 (ICAM-1), and decreases T cell trafficking in vivo. However, how kindlin-3 affects integrin function in T cells remains incompletely understood. We present an examination of LFA-1/ICAM-1 bonds in both wild-type effector T cells and those with a kindlin-3 binding site mutation. Adhesion assays show that effector T cells carrying the kindlin-3 binding site mutation display significantly reduced adhesion to the integrin ligand ICAM-1. Using optical trapping, combined with back focal plane interferometry, we measured a bond rupture force of 17.85 +/- 0.63 pN at a force loading rate of 30.21 +/- 4.35 pN/s, for single integrins expressed on wild-type cells. Interestingly, a significant drop in rupture force of bonds was found for TTT/AAA-mutant cells, with a measured rupture force of 10.08 +/- 0.88pN at the same pulling rate. Therefore, kindlin-3 binding to the cytoplasmic tail of the beta 2-tail directly affects catch bond formation and bond strength of integrin-ligand bonds. As a consequence of this reduced binding, CD8+ T cell activation in vitro is also significantly reduced.	[McDonald, Craig; McGloin, David] Univ Dundee, Sch Sci & Engn, SUPA, Dundee, Scotland; [Morrison, Vicky L.; Fagerholm, Susanna Carola] Univ Dundee, Sch Med, Dundee, Scotland; [McGloin, David] Univ Technol Sydney, Sch Elect & Data Engn, Sydney, NSW, Australia; [McDonald, Craig] Rockend Ltd, Jeffrey Cheah Biomed Ctr, Milner Therapeut Inst, Cambridge, England; [Morrison, Vicky L.] Univ Glasgow, Inst Infect Immun & Inflammat, Glasgow, Lanark, Scotland; [Fagerholm, Susanna Carola] Univ Helsinki, Fac Biol & Environm Sci, Mol & Integrat Biosci Res Programme, Helsinki, Finland	University of Dundee; University of Dundee; University of Technology Sydney; University of Glasgow; University of Helsinki	Fagerholm, SC (corresponding author), Univ Dundee, Sch Med, Dundee, Scotland.; Fagerholm, SC (corresponding author), Univ Helsinki, Fac Biol & Environm Sci, Mol & Integrat Biosci Res Programme, Helsinki, Finland.	susanna.fagerholm@helsinki.fi	; McGloin, David/J-6167-2018	Fagerholm, Susanna Carola/0000-0002-0354-8763; McGloin, David/0000-0002-0075-4481				Berg-Sorensen K, 2004, REV SCI INSTRUM, V75, P594, DOI 10.1063/1.1645654; Chen W, 2012, J CELL BIOL, V199, P497, DOI 10.1083/jcb.201201091; Chesla SE, 1998, BIOPHYS J, V75, P1553, DOI 10.1016/S0006-3495(98)74074-3; Etzioni A, 2009, CURR OPIN IMMUNOL, V21, P481, DOI 10.1016/j.coi.2009.07.005; Evans R, 2009, J CELL SCI, V122, P215, DOI 10.1242/jcs.019117; Harburger DS, 2009, J BIOL CHEM, V284, P11485, DOI 10.1074/jbc.M809233200; Lefort CT, 2012, BLOOD, V119, P4275, DOI 10.1182/blood-2011-08-373118; Lek HS, 2013, J BIOL CHEM, V288, P14698, DOI 10.1074/jbc.M112.430918; MacPherson M, 2013, J GENET SYNDR GENE T, V4, P154, DOI [10.4172/2157--7412.1000154, DOI 10.4172/2157-7412.1000154]; Merkel R, 1999, NATURE, V397, P50, DOI 10.1038/16219; Morrison VL, 2015, J IMMUNOL, V195, P105, DOI 10.4049/jimmunol.1402741; Morrison VL, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6359; Morrison VL, 2013, BLOOD, V122, P1428, DOI 10.1182/blood-2013-02-484998; Moser M, 2009, NAT MED, V15, P300, DOI 10.1038/nm.1921; Muller WA, 2013, VET PATHOL, V50, P7, DOI 10.1177/0300985812469883; Neuman KC, 2004, REV SCI INSTRUM, V75, P2787, DOI 10.1063/1.1785844; Nordenfelt P, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13119; Savinko TS, 2015, J INVEST DERMATOL, V135, P2249, DOI 10.1038/jid.2015.164; Shulman Z, 2012, NAT IMMUNOL, V13, P67, DOI 10.1038/ni.2173; Tees DFJ, 2001, BIOPHYS J, V80, P668, DOI 10.1016/S0006-3495(01)76047-X; Ye F, 2013, CURR BIOL, V23, P2288, DOI 10.1016/j.cub.2013.09.050	21	0	0	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 26	2022	12								792813	10.3389/fimmu.2021.792813	http://dx.doi.org/10.3389/fimmu.2021.792813			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YV7SO	35154074	Green Published, gold			2022-12-18	WOS:000752926600001
J	Ormsby, TJR; Owens, SE; Clement, L; Mills, TJ; Cronin, JG; Bromfield, JJ; Sheldon, IM				Ormsby, Thomas J. R.; Owens, Sian E.; Clement, Liam; Mills, Tom J.; Cronin, James G.; Bromfield, John J.; Sheldon, Iain Martin			Oxysterols Protect Epithelial Cells Against Pore-Forming Toxins	FRONTIERS IN IMMUNOLOGY			English	Article						oxysterol; epithelial cells; cholesterol; liver X receptor; pore-forming toxins; cholesterol-dependent cytolysin; cytoprotection	PLASMA-MEMBRANE; ACYL-COENZYME; CHOLESTEROL; ACTIVATION; RECEPTOR; PATHWAY; 27-HYDROXYCHOLESTEROL; INFLAMMATION; MECHANISM; HEMOLYSIN	Many species of bacteria produce toxins such as cholesterol-dependent cytolysins that form pores in cell membranes. Membrane pores facilitate infection by releasing nutrients, delivering virulence factors, and causing lytic cell damage - cytolysis. Oxysterols are oxidized forms of cholesterol that regulate cellular cholesterol and alter immune responses to bacteria. Whether oxysterols also influence the protection of cells against pore-forming toxins is unresolved. Here we tested the hypothesis that oxysterols stimulate the intrinsic protection of epithelial cells against damage caused by cholesterol-dependent cytolysins. We treated epithelial cells with oxysterols and then challenged them with the cholesterol-dependent cytolysin, pyolysin. Treating HeLa cells with 27-hydroxycholesterol, 25-hydroxycholesterol, 7 alpha-hydroxycholesterol, or 7 beta-hydroxycholesterol reduced pyolysin-induced leakage of lactate dehydrogenase and reduced pyolysin-induced cytolysis. Specifically, treatment with 10 ng/ml 27-hydroxycholesterol for 24 h reduced pyolysin-induced lactate dehydrogenase leakage by 88%, and reduced cytolysis from 74% to 1%. Treating HeLa cells with 27-hydroxycholesterol also reduced pyolysin-induced leakage of potassium ions, prevented mitogen-activated protein kinase cell stress responses, and limited alterations in the cytoskeleton. Furthermore, 27-hydroxycholesterol reduced pyolysin-induced damage in lung and liver epithelial cells, and protected against the cytolysins streptolysin O and Staphylococcus aureus alpha-hemolysin. Although oxysterols regulate cellular cholesterol by activating liver X receptors, cytoprotection did not depend on liver X receptors or changes in total cellular cholesterol. However, oxysterol cytoprotection was partially dependent on acyl-CoA:cholesterol acyltransferase (ACAT) reducing accessible cholesterol in cell membranes. Collectively, these findings imply that oxysterols stimulate the intrinsic protection of epithelial cells against pore-forming toxins and may help protect tissues against pathogenic bacteria.	[Ormsby, Thomas J. R.; Owens, Sian E.; Clement, Liam; Mills, Tom J.; Cronin, James G.; Sheldon, Iain Martin] Swansea Univ, Swansea Univ Med Sch, Swansea, W Glam, Wales; [Bromfield, John J.] Univ Florida, Dept Anim Sci, Gainesville, FL USA	Swansea University; State University System of Florida; University of Florida	Sheldon, IM (corresponding author), Swansea Univ, Swansea Univ Med Sch, Swansea, W Glam, Wales.	i.m.sheldon@swansea.ac.uk	Sheldon, I Martin/E-1567-2013	Sheldon, I Martin/0000-0001-7902-5558; Cronin, James/0000-0002-0590-9462				Abrams ME, 2020, NAT MICROBIOL, V5, P929, DOI 10.1038/s41564-020-0701-5; Amos MR, 2014, BIOL REPROD, V90, DOI 10.1095/biolreprod.113.115972; Andrews NW, 2018, CURR BIOL, V28, pR392, DOI 10.1016/j.cub.2017.12.034; Babiychuk EB, 2009, CELL DEATH DIFFER, V16, P1126, DOI 10.1038/cdd.2009.30; Mestre MB, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002664; BHAKDI S, 1985, INFECT IMMUN, V47, P52; Bielska AA, 2014, BIOCHEMISTRY-US, V53, P3042, DOI 10.1021/bi5000096; Billington SJ, 1997, J BACTERIOL, V179, P6100, DOI 10.1128/jb.179.19.6100-6106.1997; Bischofberger M, 2009, CURR OPIN CELL BIOL, V21, P589, DOI 10.1016/j.ceb.2009.04.003; Brito C, 2019, CELL MOL LIFE SCI, V76, P1319, DOI 10.1007/s00018-018-2992-8; Bromfield JJ, 2011, ENDOCRINOLOGY, V152, P5029, DOI 10.1210/en.2011-1124; Brown AJ, 2021, BRIT J PHARMACOL, V178, P3089, DOI 10.1111/bph.15073; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; Bustin SA, 2009, CLIN CHEM, V55, P611, DOI 10.1373/clinchem.2008.112797; Chang TY, 2009, AM J PHYSIOL-ENDOC M, V297, pE1, DOI 10.1152/ajpendo.90926.2008; Cyster JG, 2014, NAT REV IMMUNOL, V14, P731, DOI 10.1038/nri3755; Dal Peraro M, 2016, NAT REV MICROBIOL, V14, P77, DOI 10.1038/nrmicro.2015.3; Dang EV, 2017, CELL, V171, P1057, DOI 10.1016/j.cell.2017.09.029; Das A, 2014, ELIFE, V3, DOI 10.7554/eLife.02882; Das A, 2013, P NATL ACAD SCI USA, V110, P10580, DOI 10.1073/pnas.1309273110; DuSell CD, 2008, MOL ENDOCRINOL, V22, P65, DOI 10.1210/me.2007-0383; DZELETOVIC S, 1995, ANAL BIOCHEM, V225, P73, DOI 10.1006/abio.1995.1110; Endapally S, 2019, CELL, V176, P1040, DOI 10.1016/j.cell.2018.12.042; Fu X, 2001, J BIOL CHEM, V276, P38378, DOI 10.1074/jbc.M105805200; Giddings KS, 2003, P NATL ACAD SCI USA, V100, P11315, DOI 10.1073/pnas.2033520100; Gonzalez MR, 2011, CELL MICROBIOL, V13, P1026, DOI 10.1111/j.1462-5822.2011.01600.x; Griffin S, 2018, BIOL REPROD, V99, P749, DOI 10.1093/biolre/ioy099; Griffin S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17138-y; Griffiths WJ, 2021, FRONT PHYSIOL, V12, DOI 10.3389/fphys.2021.723224; Gurcel L, 2006, CELL, V126, P1135, DOI 10.1016/j.cell.2006.07.033; Huffman DL, 2004, P NATL ACAD SCI USA, V101, P10995, DOI 10.1073/pnas.0404073101; Jost BH, 2005, ANTON LEEUW INT J G, V88, P87, DOI 10.1007/s10482-005-2316-5; Keyel PA, 2011, J CELL SCI, V124, P2414, DOI 10.1242/jcs.076182; Lange Y, 2008, J BIOL CHEM, V283, P1445, DOI 10.1074/jbc.M706967200; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; Lemaire-Ewing S, 2009, CELL BIOL TOXICOL, V25, P127, DOI 10.1007/s10565-008-9063-0; Los FCO, 2013, MICROBIOL MOL BIOL R, V77, P173, DOI 10.1128/MMBR.00052-12; Medzhitov R, 2012, SCIENCE, V335, P936, DOI 10.1126/science.1214935; Niikawa H, 2008, CLIN CANCER RES, V14, P4417, DOI 10.1158/1078-0432.CCR-07-1950; Ormsby TJR, 2021, FASEB J, V35, DOI 10.1096/fj.202100036R; Pospiech M, 2021, FASEB J, V35, DOI 10.1096/fj.202100164R; Preta G, 2016, BBA-BIOMEMBRANES, V1858, P2070, DOI 10.1016/j.bbamem.2016.05.016; Preta G, 2015, FASEB J, V29, P1516, DOI 10.1096/fj.14-265207; Ratner AJ, 2006, J BIOL CHEM, V281, P12994, DOI 10.1074/jbc.M511431200; Reboldi A, 2014, SCIENCE, V345, P679, DOI 10.1126/science.1254790; Renshaw MW, 1997, EMBO J, V16, P5592, DOI 10.1093/emboj/16.18.5592; ROSS AC, 1984, J BIOL CHEM, V259, P815; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Schultz JR, 2000, GENE DEV, V14, P2831, DOI 10.1101/gad.850400; Seilie ES, 2017, SEMIN CELL DEV BIOL, V72, P101, DOI 10.1016/j.semcdb.2017.04.003; Song LZ, 1996, SCIENCE, V274, P1859, DOI 10.1126/science.274.5294.1859; Statt S, 2015, AM J RESP CELL MOL, V53, P689, DOI 10.1165/rcmb.2014-0391OC; Turner ML, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0219275; Tweten RK, 2005, INFECT IMMUN, V73, P6199, DOI 10.1128/IAI.73.10.6199-6209.2005; WALEV I, 1993, INFECT IMMUN, V61, P4972, DOI 10.1128/IAI.61.12.4972-4979.1993; Wang B, 2018, NAT REV ENDOCRINOL, V14, P452, DOI 10.1038/s41574-018-0037-x; Wang SB, 2020, EMBO J, V39, DOI 10.15252/embj.2020106057; Wippel C, 2011, J INFECT DIS, V204, P930, DOI 10.1093/infdis/jir434; Zhou QD, 2020, NAT IMMUNOL, V21, P746, DOI 10.1038/s41590-020-0695-4	59	0	0	2	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 26	2022	13								815775	10.3389/fimmu.2022.815775	http://dx.doi.org/10.3389/fimmu.2022.815775			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YV4TT	35154132	gold, Green Published			2022-12-18	WOS:000752723100001
J	Zhang, W; Song, XL; Zhai, LA; Guo, JS; Zheng, XY; Zhang, LL; Lv, M; Hu, LF; Zhou, DS; Xiong, XL; Yang, WH				Zhang, Wei; Song, Xiaolin; Zhai, Lina; Guo, Jianshu; Zheng, Xinying; Zhang, Lili; Lv, Meng; Hu, Lingfei; Zhou, Dongsheng; Xiong, Xiaolu; Yang, Wenhui			Complete Protection Against Yersinia pestis in BALB/c Mouse Model Elicited by Immunization With Inhalable Formulations of rF1-V10 Fusion Protein via Aerosolized Intratracheal Inoculation	FRONTIERS IN IMMUNOLOGY			English	Article						Yersinia pestis; pneumonic plague; subunit vaccine; rF1-V10; dry powder formulation; aerosolized intratracheal inoculation; mucosal immune response	V ANTIGEN PROTECTS; SUBUNIT VACCINE; PLAGUE VACCINE; MYCOBACTERIUM-BOVIS; PNEUMONIC PLAGUE; MICE; DELIVERY; RESPONSES; IMMUNITY; LIVE	Pneumonic plague, caused by Yersinia pestis, is an infectious disease with high mortality rates unless treated early with antibiotics. Currently, no FDA-approved vaccine against plague is available for human use. The capsular antigen F1, the low-calcium-response V antigen (LcrV), and the recombinant fusion protein (rF1-LcrV) of Y. pestis are leading subunit vaccine candidates under intense investigation; however, the inability of recombinant antigens to provide complete protection against pneumonic plague in animal models remains a significant concern. In this study, we compared immunoprotection against pneumonic plague provided by rF1, rV10 (a truncation of LcrV), and rF1-V10, and vaccinations delivered via aerosolized intratracheal (i.t.) inoculation or subcutaneous (s.c.) injection. We further considered three vaccine formulations: conventional liquid, dry powder produced by spray freeze drying, or dry powder reconstituted in PBS. The main findings are: (i) rF1-V10 immunization with any formulation via i.t. or s.c. routes conferred 100% protection against Y. pestis i.t. infection; (ii) rF1 or rV10 immunization using i.t. delivery provided significantly stronger protection than rF1 or rV10 immunization via s.c. delivery; and (iii) powder formulations of subunit vaccines induced immune responses and provided protection equivalent to those elicited by unprocessed liquid formulations of vaccines. Our data indicate that immunization with a powder formulation of rF1-V10 vaccines via an i.t. route may be a promising vaccination strategy for providing protective immunity against pneumonic plague.	[Zhang, Wei; Song, Xiaolin; Zhai, Lina; Guo, Jianshu; Zheng, Xinying; Zhang, Lili; Lv, Meng; Hu, Lingfei; Zhou, Dongsheng; Xiong, Xiaolu; Yang, Wenhui] Beijing Inst Microbiol & Epidemiol, State Key Lab Pathogen & Biosecur, Beijing, Peoples R China	Beijing Institute of Microbiology & Epidemiology	Xiong, XL; Yang, WH (corresponding author), Beijing Inst Microbiol & Epidemiol, State Key Lab Pathogen & Biosecur, Beijing, Peoples R China.	xiongxiaolu624@sohu.com; fionyoung@163.com						Amorij JP, 2007, VACCINE, V25, P8707, DOI 10.1016/j.vaccine.2007.10.035; Anderson GW, 1996, INFECT IMMUN, V64, P4580, DOI 10.1128/IAI.64.11.4580-4585.1996; Andrews GP, 1996, INFECT IMMUN, V64, P2180, DOI 10.1128/IAI.64.6.2180-2187.1996; BAKER EE, 1952, J IMMUNOL, V68, P131; Barbieri R, 2021, CLIN MICROBIOL REV, V34, DOI 10.1128/CMR.00044-19; Batra L, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003322; Beck SE, 2002, MOL THER, V6, P546, DOI 10.1006/mthe.2002.0698; Bowen W, 2019, VACCINE, V37, P5708, DOI 10.1016/j.vaccine.2019.07.103; Bramwell VW, 2005, ADV DRUG DELIVER REV, V57, P1247, DOI 10.1016/j.addr.2005.01.010; BURROWS TW, 1956, NATURE, V177, P426, DOI 10.1038/177426b0; Chen K, 2020, NAT REV IMMUNOL, V20, P427, DOI 10.1038/s41577-019-0261-1; COHEN RJ, 1967, J AMER MED ASSOC, V202, P365, DOI 10.1001/jama.202.4.365; COULANGES P, 1983, B SOC PATHOL EXOT, V76, P114; COULANGES P, 1982, Archives de l'Institut Pasteur de Madagascar, V50, P169; Dal Negro RW, 2015, MULTIDISCIP RESP MED, V10, DOI 10.1186/s40248-015-0012-5; Drancourt M, 2016, CLIN MICROBIOL INFEC, V22, P911, DOI 10.1016/j.cmi.2016.08.031; Erova TE, 2013, CLIN VACCINE IMMUNOL, V20, P227, DOI 10.1128/CVI.00597-12; Feng JX, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.00473; Feng JX, 2019, VACCINE, V37, P6076, DOI 10.1016/j.vaccine.2019.08.041; Feodorova VA, 2014, EMERG MICROBES INFEC, V3, DOI 10.1038/emi.2014.82; Feodorova VA, 2012, EMERG MICROBES INFEC, V1, DOI 10.1038/emi.2012.34; Feodorova VA, 2009, EXPERT REV VACCINES, V8, P1721, DOI [10.1586/erv.09.129, 10.1586/ERV.09.129]; Fukuyama Y, 2015, IMMUNE NETW, V15, P9, DOI 10.4110/in.2015.15.1.9; Gan CJ, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-021-00349-w; Garcia-Contreras L, 2008, P NATL ACAD SCI USA, V105, P4656, DOI 10.1073/pnas.0800043105; Garmise RJ, 2007, AAPS PHARMSCITECH, V8, DOI 10.1208/pt0804081; GIRARD G., 1963, BIOL MED [PARIS], V52, P631; Glynn A, 2005, INFECT IMMUN, V73, P5256, DOI 10.1128/IAI.73.8.5256-5261.2005; Harris JA, 2006, AAPS PHARMSCITECH, V7; Holmgren J, 2005, NAT MED, V11, pS45, DOI 10.1038/nm1213; Huang J, 2009, CLIN VACCINE IMMUNOL, V16, P719, DOI 10.1128/CVI.00447-08; Illum L, 2001, ADV DRUG DELIVER REV, V51, P81, DOI 10.1016/S0169-409X(01)00171-5; Inglesby TV, 2000, JAMA-J AM MED ASSOC, V283, P2281, DOI 10.1001/jama.283.17.2281; Jabbal-Gill I, 2010, J DRUG TARGET, V18, P771, DOI 10.3109/1061186X.2010.523790; Jones T, 2006, VACCINE, V24, P1625, DOI 10.1016/j.vaccine.2005.09.052; Ke YC, 2013, FRONT CELL INFECT MI, V3, DOI 10.3389/fcimb.2013.00106; Kobayashi R, 2005, J IMMUNOL, V174, P2190, DOI 10.4049/jimmunol.174.4.2190; Liu L, 2018, J APPL TOXICOL, V38, P408, DOI 10.1002/jat.3550; Lyadova IV, 2001, CLIN EXP IMMUNOL, V126, P274, DOI 10.1046/j.1365-2249.2001.01667.x; Lycke N, 2012, NAT REV IMMUNOL, V12, P592, DOI 10.1038/nri3251; Mantis NJ, 2011, MUCOSAL IMMUNOL, V4, P603, DOI 10.1038/mi.2011.41; Mantis NJ, 2006, INFECT IMMUN, V74, P3455, DOI 10.1128/IAI.02088-05; MEYER KF, 1974, J INFECT DIS, V129, pS85, DOI 10.1093/infdis/129.Supplement_1.S85; MEYER KF, 1970, B WORLD HEALTH ORGAN, V42, P653; NAKAJIMA R, 1995, INFECT IMMUN, V63, P3021, DOI 10.1128/IAI.63.8.3021-3029.1995; Neutra MR, 2006, NAT REV IMMUNOL, V6, P148, DOI 10.1038/nri1777; Overheim KA, 2005, INFECT IMMUN, V73, P5152, DOI 10.1128/IAI.73.8.5152-5159.2005; Patton JS, 2007, NAT REV DRUG DISCOV, V6, P67, DOI 10.1038/nrd2153; Pechous RD, 2016, TRENDS MICROBIOL, V24, P190, DOI 10.1016/j.tim.2015.11.008; Perry RD, 1997, CLIN MICROBIOL REV, V10, P35, DOI 10.1128/CMR.10.1.35; Piggott DA, 2005, J CLIN INVEST, V115, P459, DOI 10.1172/JCI200522462; Powell BS, 2005, BIOTECHNOL PROGR, V21, P1490, DOI 10.1021/bp050098r; Prentice MB, 2007, LANCET, V369, P1196, DOI 10.1016/S0140-6736(07)60566-2; Qi ZZ, 2010, VACCINE, V28, P1655, DOI 10.1016/j.vaccine.2009.02.078; Rodriguez A, 2005, VACCINE, V23, P2565, DOI 10.1016/j.vaccine.2004.11.032; RUSSELL P, 1995, VACCINE, V13, P1551, DOI 10.1016/0264-410X(95)00090-N; Sawa T, 1999, NAT MED, V5, P392, DOI 10.1038/7391; Sebbane F, 2006, P NATL ACAD SCI USA, V103, P5526, DOI 10.1073/pnas.0509544103; Sha J, 2011, J CLIN MICROBIOL, V49, P1708, DOI 10.1128/JCM.00064-11; Sing A, 2002, J EXP MED, V196, P1017, DOI 10.1084/jem.20020908; Smiley ST, 2008, EXPERT REV VACCINES, V7, P209, DOI 10.1586/14760584.7.2.209; Sou T, 2011, TRENDS BIOTECHNOL, V29, P191, DOI 10.1016/j.tibtech.2010.12.009; Tian G, 2014, HUM VACC IMMUNOTHER, V10, P3552, DOI 10.4161/hv.35119; Titball RW, 2004, EXPERT OPIN BIOL TH, V4, P965, DOI 10.1517/14712598.4.6.965; Tomar J, 2016, EXPERT REV VACCINES, V15, P1431, DOI 10.1080/14760584.2016.1182869; Tonnis WF, 2013, EXPERT OPIN DRUG DEL, V10, P1383, DOI 10.1517/17425247.2013.810622; Torge A, 2017, EUR J PHARM SCI, V104, P171, DOI 10.1016/j.ejps.2017.04.003; Verma SK, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00602; Wang XY, 2013, EXPERT REV VACCINES, V12, P677, DOI [10.1586/erv.13.42, 10.1586/ERV.13.42]; WILLIAMSON ED, 1995, FEMS IMMUNOL MED MIC, V12, P223, DOI 10.1111/j.1574-695X.1995.tb00196.x; Williamson ED, 1996, VACCINE, V14, P1613, DOI 10.1016/S0264-410X(96)00151-X; Xiong XL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087206; Yamanaka H, 2008, INFECT IMMUN, V76, P4564, DOI 10.1128/IAI.00581-08; Yang RF, 2018, J CLIN MICROBIOL, V56, DOI 10.1128/JCM.01519-17	74	0	0	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 26	2022	13								793382	10.3389/fimmu.2022.793382	http://dx.doi.org/10.3389/fimmu.2022.793382			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YV4SW	35154110	Green Published, gold			2022-12-18	WOS:000752720700001
J	Swain, B; Powell, CT; Curtiss, R				Swain, Banikalyan; Powell, Cole T.; Curtiss, Roy			Construction and Evaluation of Recombinant Attenuated Edwardsiella piscicida Vaccine (RAEV) Vector System Encoding Ichthyophthirius multifiliis (Ich) Antigen IAG52B	FRONTIERS IN IMMUNOLOGY			English	Article						fish vaccine; immunity; pathogenicity; E; piscicida; Ichthyophthirius multifiliis (Ich); innate & adaptive immune response	SEROVAR TYPHIMURIUM VACCINE; CHANNEL CATFISH; SALMONELLA-TYPHIMURIUM; INDUCTIVE EXPRESSION; ICTALURUS-PUNCTATUS; NUCLEOTIDE-SEQUENCE; STABLE MAINTENANCE; PNEUMOCOCCAL PSPA; IMMUNE-RESPONSES; AMINO-ACIDS	We have successfully designed and constructed a RAEV vector system with regulated-delayed attenuation in vivo attributes that synthesizes Ichthyophthirius multifiliis (Ich) protective antigen IAG52B to enable vaccination of fish susceptible to edwardsiellosis and white spot disease. The first feature of this vaccine delivery system is an Edwardsiella piscicida strain carrying genomic deletions of asdA. AsdA is an enzyme necessary for the synthesis of diaminopimelic acid (DAP), which is an essential component of the peptidoglycan layer of the cell wall of Gram-negative bacteria. asdA mutant strains have obligate growth requirements for DAP in the medium or a plasmid vector with the wild-type asdA gene enabling synthesis of DAP. This balanced-lethal plasmid vector-host system in E. piscicida enables as a second feature the synthesis of recombinant antigens to induce protective immunity against fish pathogens. Recombinant protective antigen IAG52B from the fish pathogen I. multifiliis was synthesized by RAEV strains harboring the AsdA(+) plasmid pG8R8029. The third feature of this vaccine strain is a regulated-delayed attenuation in vivo phenotype that is based on the replacement of an arabinose-regulated araC P-araBAD cassette for the promoters of the fur and crp genes of E. piscicida such that the expression of these genes is dependent on arabinose provided during growth. Thus, following colonization, the Fur and Crp proteins stop being synthesized due to the lack of arabinose and attenuation is progressively achieved in vivo to prevent generation of diseases symptoms. Our vaccine strain chi 16022 with the genotype Delta asdA10 Delta P-fur170::TT araC P-araBAD fur Delta P-crp68::TT araC P-araBAD crp contains the AsdA(+) plasmid, pG8R8029, which encodes the IAG52B antigen. Vaccine strain chi 16022(pG8R8029) is attenuated and induces systemic and mucosal IgM titer against E. piscicida and Ich in zebrafish. In addition, transcript levels of tnf-alpha, il-1 beta, il-6 and il-8 were significantly increased in different tissues of vaccinated zebrafish compared to unimmunized fish. Zebrafish vaccinated with chi 16022(pG8R8029) showed 60% survival upon intracoelomic (i.c.) challenge with a lethal dose of virulent E. piscicida strain J118. Our RAEV system could be used as a generalized vaccine-vector system to protect teleost fish against multiple bacterial, viral and parasitic infectious diseases.	[Swain, Banikalyan; Powell, Cole T.; Curtiss, Roy] Univ Florida, Coll Vet Med, Dept Infect Dis Immunol, Gainesville, FL 32611 USA	State University System of Florida; University of Florida	Swain, B (corresponding author), Univ Florida, Coll Vet Med, Dept Infect Dis Immunol, Gainesville, FL 32611 USA.	swainbanikalyan@yahoo.com	Swain, Banikalyan/N-1506-2016		U.S. Department of Agriculture (USDA) -National Institute of Food and Agriculture -USDA-NIFA [2018-67015-28286]	U.S. Department of Agriculture (USDA) -National Institute of Food and Agriculture -USDA-NIFA	This work was supported by the grant of U.S. Department of Agriculture (USDA) -National Institute of Food and Agriculture -USDA-NIFA Grant No. 2018-67015-28286.	Branger CG, 2007, ADV EXP MED BIOL, V603, P387; Bujan N, 2018, DIS AQUAT ORGAN, V131, P59, DOI 10.3354/dao03281; CARDINEAU GA, 1987, J BIOL CHEM, V262, P3344; Clark-Curtiss JE, 2018, J IMMUNOL, V200, P39, DOI 10.4049/jimmunol.1600608; Curtiss R. III, 2006, Virulence mechanisms of bacterial pathogens, P297; Dickerson HW, 2014, DEV COMP IMMUNOL, V43, P290, DOI 10.1016/j.dci.2013.06.004; Juarez-Rodriguez MD, 2012, INFECT IMMUN, V80, P798, DOI 10.1128/IAI.05525-11; Edwards RA, 1998, GENE, V207, P149, DOI 10.1016/S0378-1119(97)00619-7; GALAN JE, 1990, GENE, V94, P29, DOI 10.1016/0378-1119(90)90464-3; GOVEN BA, 1980, J FISH BIOL, V17, P311, DOI 10.1111/j.1095-8649.1980.tb02764.x; HALVER JE, 1957, J NUTR, V63, P95, DOI 10.1093/jn/63.1.95; Harb OS, 1998, INFECT IMMUN, V66, P1898, DOI 10.1128/IAI.66.5.1898-1903.1998; HELFTENBEIN E, 1985, NUCLEIC ACIDS RES, V13, P415, DOI 10.1093/nar/13.2.415; HINES RS, 1974, J FISH BIOL, V6, P373, DOI 10.1111/j.1095-8649.1974.tb04554.x; HOROWITZ S, 1985, P NATL ACAD SCI USA, V82, P2452, DOI 10.1073/pnas.82.8.2452; Jorgensen LV, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048129; KADONAGA JT, 1985, J BIOL CHEM, V260, P6192; Kang HY, 2002, INFECT IMMUN, V70, P1739, DOI 10.1128/IAI.70.4.1739-1749.2002; Kochi Sims K, 2003, Expert Rev Vaccines, V2, P31; Kong W, 2020, AVIAN DIS, V64, P254, DOI 10.1637/aviandiseases-D-19-00159; Leung KY, 2019, VIRULENCE, V10, P555, DOI 10.1080/21505594.2019.1621648; Li YH, 2009, P NATL ACAD SCI USA, V106, P593, DOI 10.1073/pnas.0811697106; Lin YK, 2002, GENE, V288, P85, DOI 10.1016/S0378-1119(02)00433-X; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Maki JL, 2003, CLIN DIAGN LAB IMMUN, V10, P876, DOI 10.1128/CDLI.10.5.876-881.2003; MAZID MA, 1978, B JPN SOC SCI FISH, V44, P739; NAKAYAMA K, 1988, BIO-TECHNOL, V6, P693, DOI 10.1038/nbt0688-693; Park SB, 2012, VET RES, V43, DOI 10.1186/1297-9716-43-67; Pavelka MS, 1996, J BACTERIOL, V178, P6496, DOI 10.1128/jb.178.22.6496-6507.1996; PREER JR, 1985, NATURE, V314, P188, DOI 10.1038/314188a0; REED L. J., 1938, AMER JOUR HYG, V27, P493; Roland K, 1999, AVIAN DIS, V43, P429, DOI 10.2307/1592640; Santander J, 2012, INFECT IMMUN, V80, P2689, DOI 10.1128/IAI.00013-12; Santander J, 2011, FISH SHELLFISH IMMUN, V31, P1142, DOI 10.1016/j.fsi.2011.10.009; Santander J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015944; SCHLEIFER KH, 1972, BACTERIOL REV, V36, P407, DOI 10.1128/MMBR.36.4.407-477.1972; Shi HY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011142; Shi HY, 2010, CLIN VACCINE IMMUNOL, V17, P363, DOI 10.1128/CVI.00413-09; Spreng S, 2006, METHODS, V38, P133, DOI 10.1016/j.ymeth.2005.09.012; Su HL, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2013350118; Swain B, 2012, DEV COMP IMMUNOL, V36, P93, DOI 10.1016/j.dci.2011.06.018; Swain B, 2022, MICROB PATHOGENESIS, V162, DOI 10.1016/j.micpath.2021.105355; Swain B, 2020, FISH SHELLFISH IMMUN, V107, P497, DOI 10.1016/j.fsi.2020.10.029; Swain B, 2013, J BIOSCIENCES, V38, P533, DOI 10.1007/s12038-013-9330-y; Swain B, 2012, FISH SHELLFISH IMMUN, V32, P899, DOI 10.1016/j.fsi.2012.02.018; Tamura K, 2013, MOL BIOL EVOL, V30, P2725, DOI [10.1093/molbev/mst197, 10.1093/molbev/msr121]; Torres-Escobar A, 2010, VACCINE, V28, P5810, DOI 10.1016/j.vaccine.2010.06.070; Viola RE, 2001, ACCOUNTS CHEM RES, V34, P339, DOI 10.1021/ar000057q; Wang QY, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007646; Wang SF, 2013, MICROB PATHOGENESIS, V58, P17, DOI 10.1016/j.micpath.2012.10.006; Wang XT, 2002, CLIN DIAGN LAB IMMUN, V9, P176, DOI 10.1128/CDLI.9.1.176-181.2002; Xin W, 2008, INFECT IMMUN, V76, P3241, DOI 10.1128/IAI.01623-07; Yan YJ, 2013, FISH SHELLFISH IMMUN, V34, P1188, DOI 10.1016/j.fsi.2013.01.027; Zhang ZH, 2014, J APPL ICHTHYOL, V30, P117, DOI 10.1111/jai.12358; Zhao F, 2013, FISH SHELLFISH IMMUN, V35, P993, DOI 10.1016/j.fsi.2013.05.023; Zhou P, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8040517; Zou Jun, 2016, Biology-Basel, V5, P23, DOI 10.3390/biology5020023	57	0	0	3	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 25	2022	12								802760	10.3389/fimmu.2021.802760	http://dx.doi.org/10.3389/fimmu.2021.802760			18	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YV4AI	35145512	gold, Green Published			2022-12-18	WOS:000752671600001
J	Whitesell, JC; Lindsay, RS; Olivas-Corral, JG; Yannacone, SF; Schoenbach, MH; Lucas, ED; Friedman, RS				Whitesell, Jennifer C.; Lindsay, Robin S.; Olivas-Corral, Jessica G.; Yannacone, Seth F.; Schoenbach, Mary H.; Lucas, Erin D.; Friedman, Rachel S.			Islet Lymphocytes Maintain a Stable Regulatory Phenotype Under Homeostatic Conditions and Metabolic Stress	FRONTIERS IN IMMUNOLOGY			English	Article						islet; T cell; regulatory B cell; resident lymphocyte; type 2 diabetes; type 1 diabetes; tissue homeostasis	MEMORY T-CELLS; GENETIC BACKGROUND DETERMINES; DIET-INDUCED OBESITY; B-CELLS; INSULIN-RESISTANCE; MOUSE MODEL; NONLYMPHOID TISSUES; INFLAMMATION; BETA; INTERLEUKIN-10	T cells and B cells have been identified in human and murine islets, but the phenotype and role of islet lymphocytes is unknown. Resident immune populations set the stage for responses to inflammation in the islets during homeostasis and diabetes. Thus, we sought to identify the phenotype and effector function of islet lymphocytes to better understand their role in normal islets and in islets under metabolic stress. Lymphocytes were located in the islet parenchyma, and were comprised of a mix of naive, activated, and memory T cell and B cell subsets, with an enrichment for regulatory B cell subsets. Use of a Nur77 reporter indicated that CD8 T cells and B cells both received local antigen stimulus, indicating that they responded to antigens present in the islets. Analysis of effector function showed that islet T cells and B cells produced the regulatory cytokine IL-10. The regulatory phenotype of islet T cells and B cells and their response to local antigenic stimuli remained stable under conditions of metabolic stress in the diet induced obesity (DIO) model. T cells present in human islets retained a similar activated and memory phenotype in non-diabetic and T2D donors. Under steady-state conditions, islet T cells and B cells have a regulatory phenotype, and thus may play a protective role in maintaining tissue homeostasis.	[Whitesell, Jennifer C.; Lindsay, Robin S.; Schoenbach, Mary H.; Lucas, Erin D.; Friedman, Rachel S.] Univ Colorado, Dept Immunol & Microbiol, Anschutz Med Campus, Aurora, CO 80309 USA; [Whitesell, Jennifer C.; Olivas-Corral, Jessica G.; Friedman, Rachel S.] Barbara Davis Ctr Diabet, Aurora, CO 80045 USA; [Whitesell, Jennifer C.; Lindsay, Robin S.; Olivas-Corral, Jessica G.; Yannacone, Seth F.; Schoenbach, Mary H.; Friedman, Rachel S.] Natl Jewish Hlth, Dept Immunol & Genom Med, Denver, CO 80206 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; National Jewish Health	Friedman, RS (corresponding author), Univ Colorado, Dept Immunol & Microbiol, Anschutz Med Campus, Aurora, CO 80309 USA.; Friedman, RS (corresponding author), Barbara Davis Ctr Diabet, Aurora, CO 80045 USA.; Friedman, RS (corresponding author), Natl Jewish Hlth, Dept Immunol & Genom Med, Denver, CO 80206 USA.	rachel.s.friedman@cuanschutz.edu		Lucas, Erin/0000-0001-7705-2069; Lindsay, Robin/0000-0001-7867-8653	National Institutes of Health grant [HPAP-RRID : SCR_016202, SCR_014393, UC4-DK-112217, U01-DK-123594, UC4-DK-112232, U01-DK-123716]; National Institute of Health [U01-DK-123594]; Cancer Research Institute [UC4-DK-112232]; University of Colorado Diabetes Research Center;  [5R21AI119942-02];  [5T32AI007405-27];  [P30-DK116073];  [1R01DK111733-01];  [AWD-112499]	National Institutes of Health grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Research Institute; University of Colorado Diabetes Research Center; ; ; ; ; 	Funding This research was performed with the support of National Institutes of Health grant 5R21AI119942-02 (RSF), National Institute of Health grant 1R01DK111733-01 (RSF), Cancer Research Institute #AWD-112499 (to support RSL), National Institutes of Health grant 5T32AI007405-27 (to support JCW), and the University of Colorado Diabetes Research Center (National Institutes of Health grant P30-DK116073).	Anderson AM, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2107208118; Ascon DB, 2008, J LEUKOCYTE BIOL, V84, P1400, DOI 10.1189/jlb.0907651; Ashouri JF, 2017, J IMMUNOL, V198, P657, DOI 10.4049/jimmunol.1601301; Avtanski D, 2019, ANIM MODEL EXP MED, V2, P252, DOI 10.1002/ame2.12084; Barry JC, 2016, SCI REP-UK, V6, DOI 10.1038/srep21244; Behr FM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01770; Bender C, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abc5586; Beura LK, 2018, IMMUNITY, V48, P327, DOI 10.1016/j.immuni.2018.01.015; Bock T, 2005, DIABETES, V54, P133, DOI 10.2337/diabetes.54.1.133; Boni-Schnetzler M, 2019, SEMIN IMMUNOPATHOL, V41, P501, DOI 10.1007/s00281-019-00745-4; Butcher MJ, 2014, DIABETOLOGIA, V57, P491, DOI 10.1007/s00125-013-3116-5; Centers for Disease Control and Prevention, 2020, WILDL FIR SUMM STAT; Cookenham Tres, 2021, Immunohorizons, V5, P543, DOI 10.4049/immunohorizons.2100032; Corbin KL, 2021, BIOL PROCED ONLINE, V23, DOI 10.1186/s12575-021-00143-x; Cose S, 2006, EUR J IMMUNOL, V36, P1423, DOI 10.1002/eji.200535539; Cose S, 2007, IMMUNOLOGY, V120, P1, DOI 10.1111/j.1365-2567.2006.02511.x; Couper KN, 2008, J IMMUNOL, V180, P5771, DOI 10.4049/jimmunol.180.9.5771; Culina S, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aao4013; Damond N, 2019, CELL METAB, V29, P755, DOI 10.1016/j.cmet.2018.11.014; Della Vedova MC, 2016, NUTR METAB INSIGHTS, V9, P93, DOI 10.4137/NMI.S32907; Denroche HC, 2021, IMMUN AGEING, V18, DOI 10.1186/s12979-021-00221-4; Diana J, 2013, NAT MED, V19, P65, DOI 10.1038/nm.3042; Eguchi K, 2017, J CLIN INVEST, V127, P14, DOI 10.1172/JCI88877; Ehses JA, 2008, BIOCHEM SOC T, V36, P340, DOI 10.1042/BST0360340; Ehses JA, 2007, DIABETES, V56, P2356, DOI 10.2337/db06-1650; Evans JG, 2007, J IMMUNOL, V178, P7868, DOI 10.4049/jimmunol.178.12.7868; FitzPatrick MEB, 2021, CELL REP, V34, DOI 10.1016/j.celrep.2020.108661; Friedman RS, 2014, P NATL ACAD SCI USA, V111, P9223, DOI 10.1073/pnas.1322193111; Galicia-Garcia U, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21176275; Gauthier L, 2017, CANCER RES, V77, P7072, DOI 10.1158/0008-5472.CAN-17-1487; Gurgul-Convey E, 2011, J MOL MED, V89, P785, DOI 10.1007/s00109-011-0747-1; HAYAKAWA K, 1986, EUR J IMMUNOL, V16, P450, DOI 10.1002/eji.1830160423; Hogan RJ, 2001, J IMMUNOL, V166, P1813, DOI 10.4049/jimmunol.166.3.1813; Hombrink P, 2016, NAT IMMUNOL, V17, P1467, DOI 10.1038/ni.3589; HSIEH CS, 1995, J EXP MED, V181, P713, DOI 10.1084/jem.181.2.713; Inman CF, 2012, IMMUNOL CELL BIOL, V90, P235, DOI 10.1038/icb.2011.35; Ionescu-Tirgoviste C, 2015, SCI REP-UK, V5, DOI 10.1038/srep14634; Iyer SS, 2012, CRIT REV IMMUNOL, V32, P23, DOI 10.1615/CritRevImmunol.v32.i1.30; Jager J, 2007, ENDOCRINOLOGY, V148, P241, DOI 10.1210/en.2006-0692; Kaestner KH, 2019, DIABETES, V68, P1394, DOI 10.2337/db19-0058; Kamanaka M, 2006, IMMUNITY, V25, P941, DOI 10.1016/j.immuni.2006.09.013; Keir ME, 2006, J EXP MED, V203, P883, DOI 10.1084/jem.20051776; Kleffel S, 2015, DIABETES, V64, P158, DOI 10.2337/db13-1639; Koda Y, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-24734-0; Kumar BV, 2017, CELL REP, V20, P2921, DOI 10.1016/j.celrep.2017.08.078; Laboratory J., PHENOTYPE INFORM DIE; Lindsay RS, 2015, J IMMUNOL, V194, P522, DOI 10.4049/jimmunol.1400626; Low JS, 2020, J EXP MED, V217, DOI 10.1084/jem.20192291; Lumeng CN, 2007, J CLIN INVEST, V117, P175, DOI 10.1172/JCI29881; Maedler K, 2002, J CLIN INVEST, V110, P851, DOI 10.1172/JCI200215318; Maedler K, 2004, P NATL ACAD SCI USA, V101, P8138, DOI 10.1073/pnas.0305683101; MARCHANT A, 1994, EUR J IMMUNOL, V24, P1167, DOI 10.1002/eji.1830240524; Masopust D, 2001, SCIENCE, V291, P2413, DOI 10.1126/science.1058867; Masopust D, 2019, ANNU REV IMMUNOL, V37, P521, DOI 10.1146/annurev-immunol-042617-053214; Moguche AO, 2015, J EXP MED, V212, P715, DOI 10.1084/jem.20141518; Montane J, 2014, DIABET METAB SYND OB, V7, P25, DOI 10.2147/DMSO.S37649; Moran AE, 2011, J EXP MED, V208, P1279, DOI 10.1084/jem.20110308; Nordmann TM, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06731-w; Orecchioni M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01084; Oslowski CM, 2012, CELL METAB, V16, P265, DOI 10.1016/j.cmet.2012.07.005; Ouyang WJ, 2011, ANNU REV IMMUNOL, V29, P71, DOI 10.1146/annurev-immunol-031210-101312; Park JG, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-72821-x; Purwar R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016245; Radenkovic M, 2017, CLIN EXP IMMUNOL, V187, P418, DOI 10.1111/cei.12892; Rodriguez-Calvo T, 2014, DIABETES, V63, P3880, DOI 10.2337/db14-0549; Sandor AM, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00099; Scarim AL, 1997, BBA-MOL BASIS DIS, V1361, P313, DOI 10.1016/S0925-4439(97)00039-2; Schenkel JM, 2014, SCIENCE, V346, P98, DOI 10.1126/science.1254536; Schreiner D, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02394; Sellers RS, 2012, VET PATHOL, V49, P32, DOI 10.1177/0300985811429314; Shiow LR, 2006, NATURE, V440, P540, DOI 10.1038/nature04606; Smolders J, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07053-9; Steinert EM, 2015, CELL, V161, P737, DOI 10.1016/j.cell.2015.03.031; Stewart D, 2002, SHOCK, V18, P342, DOI 10.1097/00024382-200210000-00009; Toye AA, 2005, DIABETOLOGIA, V48, P675, DOI 10.1007/s00125-005-1680-z; Ugur M, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5821; van der Putten C, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10020288; van Greevenbroek MMJ, 2013, NETH J MED, V71, P174; Wang CY, 2012, METHODS MOL BIOL, V821, P421, DOI 10.1007/978-1-61779-430-8_27; Wang QM, 2017, J IMMUNOL, V199, P3757, DOI 10.4049/jimmunol.1700822; Wang YJ, 2019, CELL METAB, V29, P769, DOI 10.1016/j.cmet.2019.01.003; Weisberg SP, 2019, CELL REP, V29, P3916, DOI 10.1016/j.celrep.2019.11.056; Weyer C, 1999, J CLIN INVEST, V104, P787, DOI 10.1172/JCI7231; Xu AJ, 2010, MOL CELL BIOCHEM, V344, P163, DOI 10.1007/s11010-010-0539-x; Yanaba K, 2009, J IMMUNOL, V182, P7459, DOI 10.4049/jimmunol.0900270; Zikherman J, 2012, NATURE, V489, P160, DOI 10.1038/nature11311	86	0	0	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 25	2022	13								814203	10.3389/fimmu.2022.814203	http://dx.doi.org/10.3389/fimmu.2022.814203			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YU6HS	35145521	gold, Green Published			2022-12-18	WOS:000752142200001
J	Xiang, WW; Xie, C; Luo, JY; Zhang, W; Zhao, XX; Yang, H; Cai, Y; Ding, J; Wang, YS; Hao, Y; Zhang, Y; Guan, YT				Xiang, Weiwei; Xie, Chong; Luo, Jiaying; Zhang, Wei; Zhao, Xinxin; Yang, Hong; Cai, Yu; Ding, Jie; Wang, Yishu; Hao, Yong; Zhang, Ying; Guan, Yangtai			Low Frequency Ultrasound With Injection of NMO-IgG and Complement Produces Lesions Different From Experimental Autoimmune Encephalomyelitis Mice (vol 12, 4150, 2021)	FRONTIERS IN IMMUNOLOGY			English	Correction						neuromyelitis optica; mouse; Aquaporin-4; blood-brain barrier; low-frequency ultrasound			[Xiang, Weiwei; Xie, Chong; Luo, Jiaying; Cai, Yu; Ding, Jie; Wang, Yishu; Hao, Yong; Zhang, Ying; Guan, Yangtai] Shanghai Jiao Tong Univ, Ren Ji Hosp, Dept Neurol, Sch Med, Shanghai, Peoples R China; [Zhang, Wei] Shanghai Jiao Tong Univ Affiliated Peoples Hosp 6, Dept Ultrasound Med, Shanghai, Peoples R China; [Zhao, Xinxin] Shanghai Jiao Tong Univ, Ren Ji Hosp, Dept Radiol, Sch Med, Shanghai, Peoples R China; [Yang, Hong] Tongji Univ, Sch Med, Dept Neurol, First Rehabil Hosp Shanghai, Shanghai, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Tongji University	Guan, YT (corresponding author), Shanghai Jiao Tong Univ, Ren Ji Hosp, Dept Neurol, Sch Med, Shanghai, Peoples R China.	yangtaiguan@sina.com		Hao, Yong/0000-0003-3652-0449				Xiang WW, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.727750	1	0	0	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 25	2022	13								842300	10.3389/fimmu.2022.842300	http://dx.doi.org/10.3389/fimmu.2022.842300			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZH3YR	35145527	gold, Green Published			2022-12-18	WOS:000760878300001
J	Xu, SM; Shi, CJ; Xia, RH; Wang, LZ; Tian, Z; Ye, WM; Liu, L; Liu, SL; Zhang, CY; Hu, YH; Zhou, R; Han, Y; Wang, Y; Zhang, ZY; Li, J				Xu, Sheng-ming; Shi, Chao-ji; Xia, Rong-hui; Wang, Li-zhen; Tian, Zhen; Ye, Wei-min; Liu, Liu; Liu, Shu-li; Zhang, Chun-ye; Hu, Yu-hua; Zhou, Rong; Han, Yong; Wang, Yu; Zhang, Zhi-yuan; Li, Jiang			Analysis of Immunological Characteristics and Genomic Alterations in HPV-Positive Oropharyngeal Squamous Cell Carcinoma Based on PD-L1 Expression	FRONTIERS IN IMMUNOLOGY			English	Article						HPV; OPSCC; PD-L1; tumor immune microenvironment (TIM); genomic alterations	HUMAN-PAPILLOMAVIRUS; FDA APPROVAL; HEAD; PEMBROLIZUMAB; RESISTANCE; MUTATIONS; RECURRENT; SURVIVAL; CANCER; ARID1A	Programmed death-ligand 1 (PD-L1) expression has been approved as an immune checkpoint inhibitor (ICI) response predictive biomarker; however, the clinicopathological and molecular features of HPV-positive oropharyngeal squamous cell carcinoma [HPV(+)OPSCC] based on PD-L1 expression are not well studied. We aimed to characterize clinicopathological, tumor immune microenvironmental, and molecular features of HPV(+)OPSCC with different PD-L1 expression scored by combined positive score (CPS). A total of 112 cases were collected from 2008-2021 and received PD-L1 and CD8 immunohistochemistry (IHC) staining. 71 samples received DNA sequencing out of which 32 samples received RNA sequencing for immune-related gene alterations or expression analysis. The 32 samples were also subjected to analysis of CD20, CD4, CD8, CD68, Foxp3 and P16 by multiplex immunofluorescence (mIF) staining, and the immune markers were evaluated in the tumor body (TB), tumor margin (TM) and normal stroma (NS) regions separately. Our results showed that of 112 HPV(+)OPSCC tumors, high(CPS >= 20), intermediate(1 <= CPS<20), and low(CPS<1) PD-L1 expression was seen in 29.5%, 43.8% and 26.8% cases respectively. Non-smoking patients and patients with tumors occurring at the tonsils or having rich lymphocytes infiltration had significantly higher PD-L1 expression. Patients with CPS >= 20 had significantly higher tumor mutation burden (TMB, p=0.0058), and PD-L1 expression correlated significantly with CD8(+) T cells infiltration, which were ample in tumor regions than in NS in mIF. CD20(+), CD4(+), CD68(+), Foxp3(+)CD4(+) cells were demonstrated to infiltrate higher in TM while CD20(+) and CD68(+) cells were also enriched in NS and TB regions respectively. However, none of them showed correlations with PD-L1 expression. ARID1A, STK11 alterations were enriched in the low PD-L1 group significantly, while anti-viral immune associated APOBEC mutation signature and immune-related genes expression such as XCL1 and IL11 were positively associated with PD-L1 expression (p<0.05). This is a comprehensive investigation revealing immune and molecular features of HPV(+)OPSCC based on PD-L1 expression. Our study suggested that 73.2% of HPV(+)OPSCC patients may benefit from immunotherapy, and high PD-L1 expression reflects immune-active status of HPV(+)OPSCC accompanied by higher immune effect factors such as TMB, CD8(+) cytotoxic T cells and immune-related genomic alterations. Our study offers valuable information for understanding the immune features of HPV(+)OPSCC.	[Xu, Sheng-ming; Shi, Chao-ji; Ye, Wei-min; Liu, Liu; Liu, Shu-li; Zhou, Rong; Han, Yong; Zhang, Zhi-yuan] Shanghai Jiao Tong Univ, Sch Med, Peoples Hosp 9, Dept Oral & Maxillofacial Head Neck Oncol, Shanghai, Peoples R China; [Xu, Sheng-ming; Shi, Chao-ji; Xia, Rong-hui; Wang, Li-zhen; Tian, Zhen; Ye, Wei-min; Liu, Liu; Liu, Shu-li; Zhang, Chun-ye; Hu, Yu-hua; Zhou, Rong; Han, Yong; Wang, Yu; Zhang, Zhi-yuan; Li, Jiang] Natl Ctr Stomatol, Natl Clin Res Ctr Oral Dis, Shanghai, Peoples R China; [Xu, Sheng-ming; Shi, Chao-ji; Xia, Rong-hui; Wang, Li-zhen; Tian, Zhen; Ye, Wei-min; Liu, Liu; Liu, Shu-li; Zhang, Chun-ye; Hu, Yu-hua; Zhou, Rong; Han, Yong; Wang, Yu; Zhang, Zhi-yuan; Li, Jiang] Shanghai Key Lab Stomatol, Shanghai, Peoples R China; [Xu, Sheng-ming; Shi, Chao-ji; Xia, Rong-hui; Wang, Li-zhen; Tian, Zhen; Ye, Wei-min; Liu, Liu; Liu, Shu-li; Zhang, Chun-ye; Hu, Yu-hua; Zhou, Rong; Han, Yong; Wang, Yu; Zhang, Zhi-yuan; Li, Jiang] Shanghai Res Inst Stomatol, Shanghai, Peoples R China; [Xu, Sheng-ming; Shi, Chao-ji; Xia, Rong-hui; Wang, Li-zhen; Tian, Zhen; Ye, Wei-min; Liu, Liu; Liu, Shu-li; Zhang, Chun-ye; Hu, Yu-hua; Zhou, Rong; Han, Yong; Wang, Yu; Zhang, Zhi-yuan; Li, Jiang] Chinese Acad Med Sci, Res Unit Oral & Maxillofacial Regenerat Med, Shanghai, Peoples R China; [Xia, Rong-hui; Wang, Li-zhen; Tian, Zhen; Zhang, Chun-ye; Hu, Yu-hua; Wang, Yu; Li, Jiang] Shanghai Jiao Tong Univ, Sch Med, Shanghai Ninth Peoples Hosp, Dept Oral Pathol,Coll Stomatol, Shanghai, Peoples R China	Shanghai Jiao Tong University; Chinese Academy of Medical Sciences - Peking Union Medical College; Shanghai Jiao Tong University	Zhang, ZY (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Peoples Hosp 9, Dept Oral & Maxillofacial Head Neck Oncol, Shanghai, Peoples R China.; Zhang, ZY; Li, J (corresponding author), Natl Ctr Stomatol, Natl Clin Res Ctr Oral Dis, Shanghai, Peoples R China.; Zhang, ZY; Li, J (corresponding author), Shanghai Key Lab Stomatol, Shanghai, Peoples R China.; Zhang, ZY; Li, J (corresponding author), Shanghai Res Inst Stomatol, Shanghai, Peoples R China.; Zhang, ZY; Li, J (corresponding author), Chinese Acad Med Sci, Res Unit Oral & Maxillofacial Regenerat Med, Shanghai, Peoples R China.; Li, J (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Shanghai Ninth Peoples Hosp, Dept Oral Pathol,Coll Stomatol, Shanghai, Peoples R China.	zhiyuan.Zhang@sh9hospital.org.cn; LIJ1042@sh9hospital.org.cn						Ang KK, 2010, NEW ENGL J MED, V363, P24, DOI 10.1056/NEJMoa0912217; Balermpas P, 2014, BRIT J CANCER, V110, P501, DOI 10.1038/bjc.2013.640; Burtness B, 2019, LANCET, V394, P1915, DOI 10.1016/S0140-6736(19)32591-7; Cha JH, 2019, MOL CELL, V76, P359, DOI 10.1016/j.molcel.2019.09.030; Cohen EEW, 2019, LANCET, V393, P156, DOI 10.1016/S0140-6736(18)31999-8; de la Iglesia JV, 2020, CLIN CANCER RES, V26, P1474, DOI 10.1158/1078-0432.CCR-19-1769; Ferris RL, 2016, NEW ENGL J MED, V375, P1856, DOI 10.1056/NEJMoa1602252; Fessas P, 2021, CANCERS, V13, DOI 10.3390/cancers13092137; Fountzilas E, 2021, JNCI-J NATL CANCER I, V113, P1634, DOI 10.1093/jnci/djab067; Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139; Gillison ML, 2019, GENOME RES, V29, P1, DOI 10.1101/gr.241141.118; Goodman AM, 2018, JAMA ONCOL, V4, P1237, DOI 10.1001/jamaoncol.2018.1701; Gu C, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.678036; Hanna GJ, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.98811; Jansen Y, 2020, CANCER IMMUNOL IMMUN, V69, P2589, DOI 10.1007/s00262-020-02618-4; Jones S, 2010, SCIENCE, V330, P228, DOI 10.1126/science.1196333; Lemery S, 2017, NEW ENGL J MED, V377, P1409, DOI 10.1056/NEJMp1709968; Liu TT, 2020, CANCER MED-US, V9, P7440, DOI 10.1002/cam4.3406; McGrail DJ, 2021, ANN ONCOL, V32, P661, DOI 10.1016/j.annonc.2021.02.006; Okamura R, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2019-000438; Peng WY, 2016, CANCER DISCOV, V6, P202, DOI 10.1158/2159-8290.CD-15-0283; Poma AM, 2021, CANCERS, V13, DOI 10.3390/cancers13153828; Pore N, 2021, CANCER DISCOV, V11, P2828, DOI 10.1158/2159-8290.CD-20-1543; Sanchez-Canteli M, 2020, CANCER IMMUNOL IMMUN, V69, P2089, DOI 10.1007/s00262-020-02604-w; Shen JF, 2018, NAT MED, V24, P556, DOI 10.1038/s41591-018-0012-z; Skoulidis F, 2018, CANCER DISCOV, V8, P822, DOI 10.1158/2159-8290.CD-18-0099; Solomon B, 2018, CANCER IMMUNOL RES, V6, P295, DOI 10.1158/2326-6066.CIR-17-0299; Subbiah V, 2020, ANN ONCOL, V31, P1115, DOI 10.1016/j.annonc.2020.07.002; Taberna M, 2017, ANN ONCOL, V28, P2386, DOI 10.1093/annonc/mdx304; Vieira VC, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/683095; Wang F, 2019, JAMA ONCOL, V5, P1504, DOI 10.1001/jamaoncol.2019.2963; Wang K, 2011, NAT GENET, V43, P1219, DOI 10.1038/ng.982; Williams JB, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14290-4; Wing JB, 2014, INT IMMUNOL, V26, P61, DOI 10.1093/intimm/dxt060; Yang WF, 2018, ORAL ONCOL, V86, P81, DOI 10.1016/j.oraloncology.2018.09.016; Young RJ, 2020, ORAL ONCOL, V101, DOI 10.1016/j.oraloncology.2019.104516; Zhu C, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2019.1621677	37	0	0	2	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 25	2022	12								798424	10.3389/fimmu.2021.798424	http://dx.doi.org/10.3389/fimmu.2021.798424			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YU5VX	35145511	gold, Green Published			2022-12-18	WOS:000752111500001
J	Zhao, T; Hu, N; Yu, XJ; Su, T				Zhao, Tao; Hu, Nan; Yu, Xiaojuan; Su, Tao			Case Report: Endocapillary Glomerulopathy Associated With Large Granular T Lymphocyte Leukemia	FRONTIERS IN IMMUNOLOGY			English	Article						large granular lymphocyte (LGL) leukemia; acute kidney injury; endocapillary glomerulonephritis; histology; immunohistochemistry	LGL	Large granular T lymphocyte leukemia (T-LGLL) is a rare indolent lymphocyte leukemia. The clonal proliferation of T cells, which is related to STAT3 gene mutation and abnormal Fas-mediated apoptosis pathway after cell activation, plays a major role in disease progression. Some studies have found that the exogenous and continuous stimulation of endogenous antigens, such as virus infection, is related to the pathogenesis of T-LGLL. The renal pathological manifestations of T-LGLL have rarely been described. In this study, we report a case of T-LGLL with kidney involvement as proteinuria, acute kidney injury, with the appearance of circulating T-LGL infiltrating intra-glomerular capillaries, and endocapillary glomerulopathy. We also summarize reported cases of renal injury associated with LGLL.	[Zhao, Tao; Hu, Nan; Yu, Xiaojuan; Su, Tao] Peking Univ First Hosp, Dept Nephrol, Beijing, Peoples R China	Peking University	Su, T (corresponding author), Peking Univ First Hosp, Dept Nephrol, Beijing, Peoples R China.	tao.su@bjmu.edu.cn			National Science and Technology Major Projects for major new drugs innovation and development [2017ZX09304028]; Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences [2019-I2M-5-046]	National Science and Technology Major Projects for major new drugs innovation and development; Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences	Funding This research was supported by the National Science and Technology Major Projects for major new drugs innovation and development (Grant 2017ZX09304028 to TS), and Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences (No. 2019-I2M-5-046).	Audemard A, 2013, SEMIN ARTHRITIS RHEU, V43, P362, DOI 10.1016/j.semarthrit.2013.07.002; Bareau B, 2010, HAEMATOL-HEMATOL J, V95, P1534, DOI 10.3324/haematol.2009.018481; Fu JL, 2019, AM J CASE REP, V20, P43, DOI 10.12659/AJCR.912282; Isnard P, 2021, KIDNEY INT REP, V6, P1174, DOI 10.1016/j.ekir.2021.01.024; Lamy T, 2011, BLOOD, V117, P2764, DOI 10.1182/blood-2010-07-296962; ORMAN SV, 1986, ARCH INTERN MED, V146, P1827, DOI 10.1001/archinte.146.9.1827; Ribes D, 2017, CLIN EXP NEPHROL, V21, P781, DOI 10.1007/s10157-016-1373-6; Saitoh T, 2008, ANN HEMATOL, V87, P585, DOI 10.1007/s00277-008-0438-3; Siebert JD, 1999, AM J CLIN PATHOL, V111, P379; Sokol L, 2005, LEUKEMIA RES, V29, P381, DOI 10.1016/j.leukres.2004.08.010; Steinway SN, 2014, BLOOD REV, V28, P87, DOI 10.1016/j.blre.2014.02.001; Yang J, 2010, BLOOD, V115, P51, DOI 10.1182/blood-2009-06-223719; Zhang M, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000016649	13	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 25	2022	12								810223	10.3389/fimmu.2021.810223	http://dx.doi.org/10.3389/fimmu.2021.810223			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YV3NT	35145513	gold, Green Published			2022-12-18	WOS:000752638500001
J	Alba, A; Vazquez, AA; Sanchez, J; Gourbal, B				Alba, Annia; Vazquez, Antonio A.; Sanchez, Jorge; Gourbal, Benjamin			Immunological Resistance of Pseudosuccinea columella Snails From Cuba to Fasciola hepatica (Trematoda) Infection: What We Know and Where We Go on Comparative Molecular and Mechanistic Immunobiology, Ecology and Evolution	FRONTIERS IN IMMUNOLOGY			English	Review						host-parasite interaction; snail immunity; cost of resistance; selection of resistance; immuno-ecology	LIFE-HISTORY TRAITS; SCHISTOSOMA-MANSONI; BIOMPHALARIA-GLABRATA; IMMUNE DEFENSE; GENETIC-VARIATION; HOST; POPULATION; LYMNAEIDAE; DIGENEA; STRESS	One of the most interesting biological models is that of snail-trematode interactions, many of which ultimately result in the transmission of several important diseases, particularly in the tropics. Herein, we review the scientific advances on a trematode-snail system in which certain populations of Pseudosuccinea columella (a common host species for trematodes) have been demonstrated naturally-resistant to Fasciola hepatica, in association with an effective encapsulation of the parasite by innate immune cells of the host, the hemocytes. Emphasis is made on the molecular and immunological features characterizing each P. columella phenotype in relation to their anti-parasitic competence, their distinctive ecological patterns and the existence of a significant cost of resistance. An integrative overview of the resistance to F. hepatica through comparative immunobiology, genetics and ecology is presented to hypothesize on the possible origins and evolution of this phenomenon and to postulate significant roles for parasite mediated-selection and environmental factors in shaping and maintaining the resistant phenotype in the field. Lastly, clues into future experimental perspectives to deeply characterize the interplay between P. columella and F. hepatica and the immunobiology of the resistance are also included. The advances revised in the present paper are only beginning to unravel mechanisms of anti-parasite innate defense responses and their evolutionary bases, and can facilitate the development of prospective approaches towards practical applications of P. columella resistance.	[Alba, Annia; Vazquez, Antonio A.; Sanchez, Jorge] Inst Pedro Kouri Med Trop, Ctr Invest Diagnost & Referencia, Havana, Cuba; [Gourbal, Benjamin] Univ Perpignan Via Domitia, Univ Montpellier, IFREMER, IHPE,CNRS, Perpignan, France	Centre National de la Recherche Scientifique (CNRS); Ifremer; Universite de Montpellier	Alba, A (corresponding author), Inst Pedro Kouri Med Trop, Ctr Invest Diagnost & Referencia, Havana, Cuba.; Gourbal, B (corresponding author), Univ Perpignan Via Domitia, Univ Montpellier, IFREMER, IHPE,CNRS, Perpignan, France.	annia.alba@gmail.com; benjamin.gourbal@univ-perp.fr	VAZQUEZ, Antonio/GXG-1314-2022	VAZQUEZ, Antonio/0000-0002-0894-1708				Alba A., 2018, THESIS U PERPIGNAN; Alba A., 2016, THESIS I PEDRO KOURI, DOI [10.13140/RG.2.2.12459.08485, DOI 10.13140/RG.2.2.12459.08485]; Alba A, 2021, PARASITOLOGY, V148, P385, DOI 10.1017/S0031182020002255; Alba A, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-50894-7; Alba A, 2020, DEV COMP IMMUNOL, V102, DOI 10.1016/j.dci.2019.103485; Alba A, 2019, DEV COMP IMMUNOL, V101, DOI 10.1016/j.dci.2019.103463; Alba A, 2018, PARASITE VECTOR, V11, DOI 10.1186/s13071-018-3155-3; Alba A, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1303-1; Allan F, 2013, ACTA TROP, V128, P234, DOI 10.1016/j.actatropica.2013.01.003; Baron OL, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003792; Biller-Takahashi JD, 2015, FISH SHELLFISH IMMUN, V47, P360, DOI 10.1016/j.fsi.2015.09.022; Brito E, 2012, REDVET, V9; Budria A, 2014, PARASITOLOGY, V141, P462, DOI 10.1017/S0031182013001881; Calienes AF, 2004, ACTA TROP, V92, P83, DOI 10.1016/j.actatropica.2004.05.014; Carius HJ, 2001, EVOLUTION, V55, P1136, DOI 10.1111/j.0014-3820.2001.tb00633.x; CONNORS VA, 1995, EXP PARASITOL, V80, P139, DOI 10.1006/expr.1995.1016; Demas GE, 2011, FUNCT ECOL, V25, P29, DOI 10.1111/j.1365-2435.2010.01738.x; Díaz Fernández René, 2011, Rev Cubana Med Trop, V63, P268; Duffy MA, 2009, J ANIM ECOL, V78, P1106, DOI 10.1111/j.1365-2656.2009.01568.x; Duffy MA, 2008, BMC EVOL BIOL, V8, DOI 10.1186/1471-2148-8-80; Duncan C. J, 1975, PULMONATES; Dybdahl MF, 1998, EVOLUTION, V52, P1057, DOI 10.1111/j.1558-5646.1998.tb01833.x; Epstein T, 2014, CANCER METAB, V2, DOI 10.1186/2049-3002-2-7; Freitas R, 2016, MAR ENVIRON RES, V117, P75, DOI 10.1016/j.marenvres.2016.04.003; Garcia AB, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001115; Geraerts W. P. M., 1984, MOLLUSCA REPROD, P142; Goodall CP, 2004, MOL BIOCHEM PARASIT, V137, P321, DOI 10.1016/j.molbiopara.2004.06.011; Gutierrez A, 2005, MEM I OSWALDO CRUZ, V100, P725, DOI 10.1590/S0074-02762005000700007; Gutierrez A, 2003, EXP PARASITOL, V105, P211, DOI 10.1016/j.exppara.2003.12.006; Gutierrez A, 2011, J HELMINTHOL, V85, P109, DOI 10.1017/S0022149X10000350; Gutierrez A, 2003, PARASITOL RES, V90, P129, DOI 10.1007/s00436-002-0824-z; Gutierrez A, 2002, PARASITOL RES, V88, P535, DOI 10.1007/s00436-002-0625-4; Gutierrez Alfredo, 2005, Haliotis, V35, P1; Hahn UK, 2001, J PARASITOL, V87, P778, DOI 10.1645/0022-3395(2001)087[0778:IONOIK]2.0.CO;2; Hawley DM, 2011, FUNCT ECOL, V25, P48, DOI 10.1111/j.1365-2435.2010.01753.x; Hurtrez-Bousses S, 2001, MICROBES INFECT, V3, P841, DOI 10.1016/S1286-4579(01)01442-3; Ittiprasert W, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002677; Knight M, 2016, INT J PARASITOL, V46, P389, DOI 10.1016/j.ijpara.2016.03.003; KOURI P, 1963, HELMINTOLOGIA HUMANA; Lacchini AH, 2006, J EXP BIOL, V209, P4829, DOI 10.1242/jeb.02561; Lafferty KD, 1999, LIMNOL OCEANOGR, V44, P925, DOI 10.4319/lo.1999.44.3_part_2.0925; Larson MK, 2014, INT J PARASITOL, V44, P343, DOI 10.1016/j.ijpara.2013.11.004; Leicht K, 2014, PARASITE VECTOR, V7, DOI 10.1186/1756-3305-7-192; Leicht K, 2013, ECOL EVOL, V3, P4861, DOI 10.1002/ece3.874; Lively CM, 2000, NATURE, V405, P679, DOI 10.1038/35015069; Lochmiller RL, 2000, OIKOS, V88, P87, DOI 10.1034/j.1600-0706.2000.880110.x; Lockyer AE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051102; Loker ES, 2010, ADV EXP MED BIOL, V708, P17; Lounnas M, 2017, MOL ECOL, V26, P887, DOI 10.1111/mec.13984; Matozzo V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033820; Mattews P. G. D, 2017, ACID BASE BALANCE NI; Meseck SL, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148477; Nikapitiya C, 2010, FISH SHELLFISH IMMUN, V29, P334, DOI 10.1016/j.fsi.2010.04.004; Perera G., 1996, THESIS U PERPIGNAN; Pila EA, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005513; Pila EA, 2016, P NATL ACAD SCI USA, V113, P5305, DOI 10.1073/pnas.1521239113; Rojas L, 2010, TRENDS PARASITOL, V26, P26, DOI 10.1016/j.pt.2009.10.005; Sarmiento Lin Wong, 2010, Revista Cubana de Medicina Tropical, V62, P16; SchmidHempel P, 2011, EVOLUTIONARY PARASITOLOGY: THE INTEGRATED STUDY OF INFECTIONS, IMMUNOLOGY, ECOLOGY, AND GENETICS, P1; Seppala O, 2010, EVOLUTION, V64, P2397, DOI 10.1111/j.1558-5646.2010.00995.x; Stearns S.C., 1992, pi; Theron A, 2005, J HELMINTHOL, V79, P187, DOI 10.1079/JOH2005299; Theron A, 2014, INFECT GENET EVOL, V26, P80, DOI 10.1016/j.meegid.2014.04.025; Vazquez AA, 2016, J HELMINTHOL, V90, P719, DOI 10.1017/S0022149X15001029; Vazquez AA, 2014, J HELMINTHOL, V88, P434, DOI 10.1017/S0022149X13000382; Vazquez AA, 2019, VET PARASITOL, V275, DOI 10.1016/j.vetpar.2019.108955; Vazquez AA, 2015, PARASITOL RES, V114, P4205, DOI 10.1007/s00436-015-4653-2; Vázquez Perera Antonio Alejandro, 2009, Rev Cubana Med Trop, V61, P248; Weinstein SB, 2018, SCIENCE, V359, P1213, DOI 10.1126/science.aas8694; Wolinska J, 2009, TRENDS PARASITOL, V25, P236, DOI 10.1016/j.pt.2009.02.004; Wu XJ, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006081; Zhang SH, 2012, DEV COMP IMMUNOL, V36, P241, DOI 10.1016/j.dci.2011.06.014	72	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 24	2022	13								794186	10.3389/fimmu.2022.794186	http://dx.doi.org/10.3389/fimmu.2022.794186			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YU5PL	35140717	Green Published, Green Submitted, gold			2022-12-18	WOS:000752094700001
J	Chiu, TLH; Leung, D; Chan, KW; Yeung, HM; Wong, CY; Mao, HW; He, JX; Vignesh, P; Liang, WL; Liew, WK; Jiang, LP; Chen, TX; Chen, XY; Tao, YB; Xu, YB; Yu, HH; Terblanche, A; Lung, DC; Li, CR; Chen, J; Tian, M; Eley, B; Yang, XT; Yang, J; Chiang, WC; Lee, BW; Suri, D; Rawat, A; Gupta, A; Singh, S; Wong, WHS; Chua, GT; Duque, JSD; Cheong, KN; Chong, PCY; Ho, MHK; Lee, TL; Yang, WL; Lee, PMLP; Lau, YL				Chiu, Timothy Lok-Hin; Leung, Daniel; Chan, Koon-Wing; Yeung, Hok Man; Wong, Chung-Yin; Mao, Huawei; He, Jianxin; Vignesh, Pandiarajan; Liang, Weiling; Liew, Woei Kang; Jiang, Li-Ping; Chen, Tong-Xin; Chen, Xiang-Yuan; Tao, Yin-Bo; Xu, Yong-Bin; Yu, Hsin-Hui; Terblanche, Alta; Lung, David Christopher; Li, Cheng-Rong; Chen, Jing; Tian, Man; Eley, Brian; Yang, Xingtian; Yang, Jing; Chiang, Wen Chin; Lee, Bee Wah; Suri, Deepti; Rawat, Amit; Gupta, Anju; Singh, Surjit; Wong, Wilfred Hing Sang; Chua, Gilbert T.; Duque, Jaime Sou Da Rosa; Cheong, Kai-Ning; Chong, Patrick Chun-Yin; Ho, Marco Hok-Kung; Lee, Tsz-Leung; Yang, Wanling; Lee, Pamela P.; Lau, Yu Lung			Phenomic Analysis of Chronic Granulomatous Disease Reveals More Severe Integumentary Infections in X-Linked Compared With Autosomal Recessive Chronic Granulomatous Disease	FRONTIERS IN IMMUNOLOGY			English	Article						chronic granulomatous disease (CGD); inborn error of immunity (IEI); human phenotype ontology (HPO); phenome; genetics	HEMATOLOGICALLY IMPORTANT MUTATIONS; LATIN-AMERICAN PATIENTS; TERM-FOLLOW-UP; CLINICAL-FEATURES; RESPIRATORY-BURST; NADPH OXIDASE; 1ST REPORT; GENE; GP91-PHOX; COMPONENT	BackgroundChronic granulomatous disease (CGD) is an inborn error of immunity (IEI), characterised by recurrent bacterial and fungal infections. It is inherited either in an X-linked (XL) or autosomal recessive (AR) mode. Phenome refers to the entire set of phenotypes expressed, and its study allows us to generate new knowledge of the disease. The objective of the study is to reveal the phenomic differences between XL and AR-CGD by using Human Phenotype Ontology (HPO) terms. MethodsWe collected data on 117 patients with genetically diagnosed CGD from Asia and Africa referred to the Asian Primary Immunodeficiency Network (APID network). Only 90 patients with sufficient clinical information were included for phenomic analysis. We used HPO terms to describe all phenotypes manifested in the patients. ResultsXL-CGD patients had a lower age of onset, referral, clinical diagnosis, and genetic diagnosis compared with AR-CGD patients. The integument and central nervous system were more frequently affected in XL-CGD patients. Regarding HPO terms, perianal abscess, cutaneous abscess, and elevated hepatic transaminase were correlated with XL-CGD. A higher percentage of XL-CGD patients presented with BCGitis/BCGosis as their first manifestation. Among our CGD patients, lung was the most frequently infected organ, with gastrointestinal system and skin ranking second and third, respectively. Aspergillus species, Mycobacterium bovis, and Mycobacteirum tuberculosis were the most frequent pathogens to be found. ConclusionPhenomic analysis confirmed that XL-CGD patients have more recurrent and aggressive infections compared with AR-CGD patients. Various phenotypic differences listed out can be used as clinical handles to distinguish XL or AR-CGD based on clinical features.	[Chiu, Timothy Lok-Hin; Leung, Daniel; Chan, Koon-Wing; Yeung, Hok Man; Wong, Chung-Yin; Yang, Xingtian; Yang, Jing; Wong, Wilfred Hing Sang; Chua, Gilbert T.; Duque, Jaime Sou Da Rosa; Yang, Wanling; Lee, Pamela P.; Lau, Yu Lung] Univ Hong Kong, Queen Mary Hosp, Dept Paediat & Adolescent Med, Hong Kong, Peoples R China; [Mao, Huawei] Capital Med Univ, Dept Immunol, Beijing Childrens Hosp, Natl Ctr Childrens Hlth, Beijing, Peoples R China; [He, Jianxin] Capital Med Univ, Dept Resp Med, Beijing Childrens Hosp, Natl Ctr Childrens Hlth, Beijing, Peoples R China; [Vignesh, Pandiarajan; Suri, Deepti; Rawat, Amit; Gupta, Anju; Singh, Surjit] Postgrad Inst Med Educ & Res, Allergy & Immunol Unit, Dept Paediat, Adv Pediat Ctr, Chandigarh, India; [Liang, Weiling] Univ Hong Kong Shenzhen Hosp, Dept Paediat & Adolescent Med, Shenzhen, Peoples R China; [Liew, Woei Kang; Chiang, Wen Chin] KK Hosp, Paediat Immunol Serv, Singapore, Singapore; [Jiang, Li-Ping] Chongqing Med Univ, Childrens Hosp, Chongqing, Peoples R China; [Chen, Tong-Xin] Shanghai Jiao Tong Univ, Sch Med, Shanghai Childrens Med Ctr, Shanghai, Peoples R China; [Chen, Xiang-Yuan; Tao, Yin-Bo] Guangzhou Childrens Hosp, Dept Allergy Immunol & Rheumatol, Guangzhou, Guangdong, Peoples R China; [Xu, Yong-Bin] Guangzhou Women & Childrens Med Ctr, Guangzhou, Peoples R China; [Yu, Hsin-Hui] Natl Taiwan Univ Childrens Hosp, Dept Paediat, Taipei, Taiwan; [Terblanche, Alta] Univ Pretoria, Paediat Gastroenterol & Hepatol Unit, Pretoria, South Africa; [Lung, David Christopher] Hong Kong Childrens Hosp, Dept Pathol, Queen Elizabeth Hosp, Hong Kong, Peoples R China; [Li, Cheng-Rong] Shenzhen Childrens Hosp, Dept Nephrol, Shenzhen, Peoples R China; [Chen, Jing] Shanghai Jiao Tong Univ, Dept Hematol Oncol, Key Lab Pediat Hematol & Oncol, Minist Hlth,Shanghai Childrens Med Ctr,Sch Med, Shanghai, Peoples R China; [Tian, Man] Nanjing Chest Hosp, Dept TB, Nanjing, Peoples R China; [Eley, Brian] Univ Cape Town, Dept Paediat & Child Hlth, Cape Town, South Africa; [Eley, Brian] Red Cross War Mem Childrens Hosp, Cape Town, South Africa; [Lee, Bee Wah] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Paediat, Singapore, Singapore; [Lee, Bee Wah] Natl Univ Hlth Syst, Khoo Teck Puat Natl Univ Childrens Med Inst, Singapore, Singapore; [Cheong, Kai-Ning; Lee, Tsz-Leung] Hong Kong Childrens Hosp, Hong Kong, Peoples R China; [Chong, Patrick Chun-Yin; Ho, Marco Hok-Kung] Virtus Med, Hong Kong, Peoples R China	University of Hong Kong; Capital Medical University; Capital Medical University; Post Graduate Institute of Medical Education & Research (PGIMER), Chandigarh; University of Hong Kong; KK Women's & Children's Hospital; Chongqing Medical University; Shanghai Jiao Tong University; National Taiwan University; University of Pretoria; Shanghai Jiao Tong University; University of Cape Town; National University of Singapore; National University of Singapore	Lee, PMLP; Lau, YL (corresponding author), Univ Hong Kong, Queen Mary Hosp, Dept Paediat & Adolescent Med, Hong Kong, Peoples R China.	ppwlee@hku.hk; lauylung@hku.hk	Yu, Hsin-Hui/AAV-2068-2020; Rosa Duque, Jaime S/HDO-5704-2022; Lau, Yu Lung/C-4322-2009	Yu, Hsin-Hui/0000-0003-2611-5175; Rosa Duque, Jaime S/0000-0002-5292-5510; Lau, Yu Lung/0000-0002-4780-0289; Leung, Daniel/0000-0002-9360-6233				Agudelo-Florez P, 2006, PEDIATR BLOOD CANCER, V46, P243, DOI 10.1002/pbc.20455; Ariga Tadashi, 1994, European Journal of Haematology, V52, P99; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Barese C, 2004, J PEDIAT HEMATOL ONC, V26, P656, DOI 10.1097/01.mph.0000139455.29962.be; Biberstine-Kinkade KJ, 2001, J BIOL CHEM, V276, P31105, DOI 10.1074/jbc.M103327200; Blancas-Galicia L, 2020, J CLIN IMMUNOL, V40, P475, DOI 10.1007/s10875-020-00750-5; Blumental S, 2011, CLIN INFECT DIS, V53, pE159, DOI 10.1093/cid/cir731; Bortoletto P, 2015, PEDIATR INFECT DIS J, V34, P1110, DOI 10.1097/INF.0000000000000840; Bowles NE, 2015, AM J MED GENET A, V167, P2975, DOI 10.1002/ajmg.a.37297; Carnide EG, 2005, PEDIATR ALLERGY IMMU, V16, P5, DOI 10.1111/j.1399-3038.2005.00225.x; Chang YH, 2010, ANN ALLERG ASTHMA IM, V105, P183, DOI 10.1016/j.anai.2010.05.013; Chinn IK, 2020, J ALLERGY CLIN IMMUN, V145, P46, DOI 10.1016/j.jaci.2019.09.009; Cross AR, 2000, BLOOD CELL MOL DIS, V26, P561, DOI 10.1006/bcmd.2000.0333; de Oliveira EB, 2015, PEDIATR BLOOD CANCER, V62, P2101, DOI 10.1002/pbc.25674; Esfandbod M, 2012, NEW ENGL J MED, V367, P753, DOI 10.1056/NEJMicm1106350; Falcone EL, 2012, CURR OPIN INFECT DIS, V25, P658, DOI 10.1097/QCO.0b013e328358b0a4; Fattahi F, 2011, J CLIN IMMUNOL, V31, P792, DOI 10.1007/s10875-011-9567-x; Gao LW, 2019, PEDIAT ALLERG IMM-UK, V30, P378, DOI 10.1111/pai.13033; Haimel M, 2022, J ALLERGY CLIN IMMUN, V149, P369, DOI 10.1016/j.jaci.2021.04.033; Hasui M, 1999, PEDIATR INT, V41, P589; Houle D, 2010, NAT REV GENET, V11, P855, DOI 10.1038/nrg2897; Hui YF, 1996, BLOOD, V88, P4021, DOI 10.1182/blood.V88.10.4021.bloodjournal88104021; Hussain N, 2007, HEPATOLOGY, V45, P675, DOI 10.1002/hep.21524; Ishibashi F, 2000, HUM GENET, V106, P473, DOI 10.1007/s004390000288; Jones LBKR, 2008, CLIN EXP IMMUNOL, V152, P211, DOI 10.1111/j.1365-2249.2008.03644.x; Kaneda M, 1999, BLOOD, V93, P2098, DOI 10.1182/blood.V93.6.2098.406k09_2098_2104; Kannengiesser C, 2008, HUM MUTAT, V29, pE132, DOI 10.1002/humu.20820; Kim-Howard X, 2014, HUM MOL GENET, V23, P1656, DOI 10.1093/hmg/ddt532; Kohler S, 2021, NUCLEIC ACIDS RES, V49, pD1207, DOI 10.1093/nar/gkaa1043; Kohler S, 2017, NUCLEIC ACIDS RES, V45, pD865, DOI 10.1093/nar/gkw1039; Kohler S, 2009, AM J HUM GENET, V85, P457, DOI 10.1016/j.ajhg.2009.09.003; Koker MY, 2009, EUR J CLIN INVEST, V39, P942, DOI 10.1111/j.1365-2362.2009.02195.x; Koker MY, 2013, J ALLERGY CLIN IMMUN, V132, P1156, DOI 10.1016/j.jaci.2013.05.039; Kuhns DB, 2010, NEW ENGL J MED, V363, P2600, DOI 10.1056/NEJMoa1007097; Kulkarni M, 2018, J CLIN IMMUNOL, V38, P898, DOI 10.1007/s10875-018-0567-y; Kuribayashi F, 1996, HUM GENET, V97, P611; Lau YL, 1998, CLIN INFECT DIS, V26, P226, DOI 10.1086/517036; Lee PPW, 2008, PEDIATR INFECT DIS J, V27, P224, DOI 10.1097/INF.0b013e31815b494c; Leung D, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01605; [梁伟玲 Liang Weiling], 2021, [中华实用儿科临床杂志, Chinese Journal of Applied Clinical Pediatrics], V36, P364; Liese J, 2000, J PEDIATR-US, V137, P687, DOI 10.1067/mpd.2000.109112; Marciano BE, 2015, CLIN INFECT DIS, V60, P1176, DOI 10.1093/cid/ciu1154; Martire B, 2008, CLIN IMMUNOL, V126, P155, DOI 10.1016/j.clim.2007.09.008; Noack D, 1999, HUM GENET, V105, P460, DOI 10.1007/s004390051131; Patino PJ, 1999, BLOOD, V94, P2505, DOI 10.1182/blood.V94.7.2505.419k10_2505_2514; Patino PJ, 1999, HUM MUTAT, V13, P29, DOI 10.1002/(SICI)1098-1004(1999)13:1<29::AID-HUMU3>3.0.CO;2-X; Pippucci T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082154; Rae J, 1998, AM J HUM GENET, V62, P1320, DOI 10.1086/301874; Rawat A, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.625320; Rawat A, 2014, J CLIN IMMUNOL, V34, P58, DOI 10.1007/s10875-013-9963-5; Roos D, 2006, HUM MUTAT, V27, P1218, DOI 10.1002/humu.20413; Roos D, 2010, BLOOD CELL MOL DIS, V45, P246, DOI 10.1016/j.bcmd.2010.07.012; Roos D, 2010, BLOOD CELL MOL DIS, V44, P291, DOI 10.1016/j.bcmd.2010.01.009; Segal BH, 2000, MEDICINE, V79, P170, DOI 10.1097/00005792-200005000-00004; Stasia MJ, 2002, BBA-MOL BASIS DIS, V1586, P316, DOI 10.1016/S0925-4439(01)00110-7; Suzuki S, 1998, P NATL ACAD SCI USA, V95, P6085, DOI 10.1073/pnas.95.11.6085; van den Berg JM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005234; Vignesh P, 2017, J CLIN IMMUNOL, V37, P109, DOI 10.1007/s10875-016-0366-2; von Goessel H, 2006, EXP HEMATOL, V34, P528, DOI 10.1016/j.exphem.2006.01.005; Wang SY, 2019, J CLIN IMMUNOL, V39, P762, DOI 10.1007/s10875-019-00680-x; Winkelstein JA, 2000, MEDICINE, V79, P155, DOI 10.1097/00005792-200005000-00003; Wolach B, 2008, CLIN IMMUNOL, V129, P103, DOI 10.1016/j.clim.2008.06.012; Wu J, 2017, J IMMUNOL RES, V2017, DOI 10.1155/2017/8745254; Xu H, 2014, J CLIN IMMUNOL, V34, P633, DOI 10.1007/s10875-014-0061-0; Zerbe CS., 2020, CHRONIC GRANULOMATOU; Zhou QH, 2018, J CLIN IMMUNOL, V38, P260, DOI 10.1007/s10875-018-0486-y	66	0	0	2	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 24	2022	12								803763	10.3389/fimmu.2021.803763	http://dx.doi.org/10.3389/fimmu.2021.803763			18	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YU1QZ	35140711	gold			2022-12-18	WOS:000751825400001
J	Hardisty, GR; Knipper, JA; Fulton, A; Hopkins, J; Dutia, BM; Taylor, MD				Hardisty, Gareth R.; Knipper, Johanna A.; Fulton, Alison; Hopkins, John; Dutia, Bernadette M.; Taylor, Matthew D.			Concurrent Infection With the Filarial Helminth Litomosoides sigmodontis Attenuates or Worsens Influenza A Virus Pathogenesis in a Stage-Dependent Manner	FRONTIERS IN IMMUNOLOGY			English	Article						helminth; coinfection; mouse; respiratory virus; filariasis; influenza A virus	RESPONSES; CYTOKINE; MICE; COINFECTION; HYPORESPONSIVENESS; INTERFERON; SUPPRESS; DISEASE; CELLS; LEADS	Filarial helminths infect approximately 120 million people worldwide initiating a type 2 immune response in the host. Influenza A viruses stimulate a virulent type 1 pro-inflammatory immune response that in some individuals can cause uncontrolled immunopathology and fatality. Although coinfection with filariasis and influenza is a common occurrence, the impact of filarial infection on respiratory viral infection is unknown. The aim of this study was to determine the impact of pre-existing filarial infection on concurrent infection with influenza A virus. A murine model of co-infection was established using the filarial helminth Litomosoides sigmodontis and the H1N1 (A/WSN/33) influenza A virus (IAV). Co-infection was performed at 3 different stages of L. sigmodontis infection (larval, juvenile adult, and patency), and the impact of co-infection was determined by IAV induced weight loss and clinical signs, quantification of viral titres, and helminth counts. Significant alterations of IAV pathogenesis, dependent upon stage of infection, was observed on co-infection with L. sigmodontis. Larval stage L. sigmodontis infection alleviated clinical signs of IAV co-infection, whilst more established juvenile adult infection also significantly delayed weight loss. Viral titres remained unaltered at either infection stage. In contrast, patent L. sigmdodontis infection led to a reversal of age-related resistance to IAV infection, significantly increasing weight loss and clinical signs of infection as well as increasing IAV titre. These data demonstrate that the progression of influenza infection can be ameliorated or worsened by pre-existing filarial infection, with the outcome dependent upon the stage of filarial infection.	[Hardisty, Gareth R.; Hopkins, John; Dutia, Bernadette M.] Univ Edinburgh, Roslin Inst, Edinburgh, Midlothian, Scotland; [Knipper, Johanna A.; Fulton, Alison; Taylor, Matthew D.] Univ Edinburgh, Inst Immunol & Infect Res, Ashworth Labs, Edinburgh, Midlothian, Scotland	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Roslin Institute; University of Edinburgh; University of Edinburgh	Taylor, MD (corresponding author), Univ Edinburgh, Inst Immunol & Infect Res, Ashworth Labs, Edinburgh, Midlothian, Scotland.	Matthew.Taylor@ed.ac.uk	Taylor, Matthew D/C-7973-2011		Biotechnology and Biological Sciences Research Council (BBSRC) Institute Strategic Program Grant [BB/J004324/1]; BBSRC Doctoral Training Grant; Medical Research Council (MRC) UK [MR/K020196/1]; Wellcome Trust [095831]	Biotechnology and Biological Sciences Research Council (BBSRC) Institute Strategic Program Grant(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); BBSRC Doctoral Training Grant(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council (MRC) UK(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome TrustEuropean Commission)	This project was funded by the Biotechnology and Biological Sciences Research Council (BBSRC) Institute Strategic Program Grant BB/J004324/1 to The Roslin Institute. GH was funded by a BBSRC Doctoral Training Grant to the Centre for Infectious Diseases, University of Edinburgh. MT, AF, and JK were funded by the Medical Research Council (MRC) UK grant number MR/K020196/1, and the Wellcome Trust grant number 095831. Open access publication costs were provided by the UKRI Open Access Fund. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Babayan S, 2003, INFECT IMMUN, V71, P6820, DOI 10.1128/IAI.71.12.6820-6829.2003; Babu S, 2014, PARASITE IMMUNOL, V36, P338, DOI 10.1111/pim.12081; Bouvier NM, 2010, VIRUSES-BASEL, V2, P1530, DOI 10.3390/v20801530; Cano J, 2014, PARASITE VECTOR, V7, DOI 10.1186/s13071-014-0466-x; Chen XY, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00320; Dietze KK, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005170; Donohue RE, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007455; Finlay CM, 2020, PARASITE IMMUNOL, V42, DOI 10.1111/pim.12708; Fulton A, 2018, METHODS MOL BIOL, V1799, P11, DOI 10.1007/978-1-4939-7896-0_2; Furze RC, 2006, INFECT IMMUN, V74, P1924, DOI 10.1128/IAI.74.3.1924-1932.2006; Graham AL, 2005, J INFECT DIS, V191, P410, DOI 10.1086/426871; Haben I, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003170; Hartmann W, 2019, CELL REP, V29, P2243, DOI 10.1016/j.celrep.2019.10.051; Hartmann W, 2015, EUR J IMMUNOL, V45, P2568, DOI 10.1002/eji.201545503; Hubner MP, 2008, INFECT IMMUN, V76, P1668, DOI 10.1128/IAI.01042-07; Hubner MP, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001970; Karadjian G, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005596; Karadjian G, 2014, PARASITE, V21, DOI 10.1051/parasite/2014017; Knipper JA, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007908; Lamb TJ, 2005, PARASITE IMMUNOL, V27, P317, DOI 10.1111/j.1365-3024.2005.00779.x; LAWRENCE RA, 1994, J IMMUNOL, V153, P1216; Liu Q, 2016, CELL MOL IMMUNOL, V13, P3, DOI 10.1038/cmi.2015.74; Lu J, 2018, AGING DIS, V9, P358, DOI 10.14336/AD.2017.0701; Lucas C, 2020, NATURE, V584, P463, DOI 10.1038/s41586-020-2588-y; Maizels RM, 2018, IMMUNITY, V49, P801, DOI 10.1016/j.immuni.2018.10.016; Maizels RM, 2016, J ALLERGY CLIN IMMUN, V138, P666, DOI 10.1016/j.jaci.2016.07.007; Maizels RM, 2003, NAT REV IMMUNOL, V3, P733, DOI 10.1038/nri1183; Marois I, 2012, J LEUKOCYTE BIOL, V92, P107, DOI 10.1189/jlb.1011490; McFarlane AJ, 2017, J ALLERGY CLIN IMMUN, V140, P1068, DOI 10.1016/j.jaci.2017.01.016; Mishra PK, 2014, MUCOSAL IMMUNOL, V7, P753, DOI 10.1038/mi.2014.23; Moreau E, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/428593; Nicol MQ, 2019, VIROLOGY, V526, P155, DOI 10.1016/j.virol.2018.10.017; Nicol MQ, 2012, J GEN VIROL, V93, P980, DOI 10.1099/vir.0.038679-0; Nutman TB, 2015, PARASITE IMMUNOL, V37, P304, DOI 10.1111/pim.12194; Osborne LC, 2014, SCIENCE, V345, P578, DOI 10.1126/science.1256942; Price I, 2015, J THEOR BIOL, V374, P83, DOI 10.1016/j.jtbi.2015.03.017; Reese TA, 2014, SCIENCE, V345, P573, DOI 10.1126/science.1254517; Ruiz DF, 2009, MICROBES INFECT, V11, P172, DOI 10.1016/j.micinf.2008.11.003; Saeftel M, 2003, INFECT IMMUN, V71, P6978, DOI 10.1128/IAI.71.12.6978-6985.2003; Schuijs MJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161885; Specht S, 2010, MICROBES INFECT, V12, P635, DOI 10.1016/j.micinf.2010.04.006; Taylor MD, 2006, J IMMUNOL, V176, P6918, DOI 10.4049/jimmunol.176.11.6918; Taylor MD, 2009, EUR J IMMUNOL, V39, P192, DOI 10.1002/eji.200838727; Taylor MD, 2005, J IMMUNOL, V174, P4924, DOI 10.4049/jimmunol.174.8.4924; Tisoncik JR, 2012, MICROBIOL MOL BIOL R, V76, P16, DOI 10.1128/MMBR.05015-11; van der Werf N, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003215	46	0	0	3	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 24	2022	12								819560	10.3389/fimmu.2021.819560	http://dx.doi.org/10.3389/fimmu.2021.819560			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YU6DM	35140712	gold, Green Published			2022-12-18	WOS:000752131200001
J	Petrikowski, L; Reinehr, S; Haupeltshofer, S; Deppe, L; Graz, F; Kleiter, I; Dick, HB; Gold, R; Faissner, S; Joachim, SC				Petrikowski, Laura; Reinehr, Sabrina; Haupeltshofer, Steffen; Deppe, Leonie; Graz, Florian; Kleiter, Ingo; Dick, H. Burkhard; Gold, Ralf; Faissner, Simon; Joachim, Stephanie C.			Progressive Retinal and Optic Nerve Damage in a Mouse Model of Spontaneous Opticospinal Encephalomyelitis	FRONTIERS IN IMMUNOLOGY			English	Article						Neuromyelitis optica; optic nerve; inflammation; demyelination; myelin oligodendrocyte glycoprotein antibodies (MOG-IgG); retinal ganglion cells; microglia; complement system	MYELIN-OLIGODENDROCYTE GLYCOPROTEIN; MULTIPLE-SCLEROSIS; NEUROMYELITIS-OPTICA; MICROGLIA; PATHOLOGY; NEURITIS; CELL; HEALTHY; MICE; DEGENERATION	Neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein-antibody-associated disease (MOGAD) are antibody mediated CNS disorders mostly affecting the optic nerve and spinal cord with potential severe impact on the visual pathway. Here, we investigated inflammation and degeneration of the visual system in a spontaneous encephalomyelitis animal model. We used double-transgenic (2D2/Th) mice which develop a spontaneous opticospinal encephalomyelitis (OSE). Retinal morphology and its function were evaluated via spectral domain optical coherence tomography (SD-OCT) and electroretinography (ERG) in 6- and 8-week-old mice. Immunohistochemistry of retina and optic nerve and examination of the retina via RT-qPCR were performed using markers for inflammation, immune cells and the complement pathway. OSE mice showed clinical signs of encephalomyelitis with an incidence of 75% at day 38. A progressive retinal thinning was detected in OSE mice via SD-OCT. An impairment in photoreceptor signal transmission occurred. This was accompanied by cellular infiltration and demyelination of optic nerves. The number of microglia/macrophages was increased in OSE optic nerves and retinas. Analysis of the retina revealed a reduced retinal ganglion cell number and downregulated Pou4f1 mRNA expression in OSE retinas. RT-qPCR revealed an elevation of microglia markers and the cytokines Tnfa and Tgfb. We also documented an upregulation of the complement system via the classical pathway. In summary, we describe characteristics of inflammation and degeneration of the visual system in a spontaneous encephalomyelitis model, characterized by coinciding inflammatory and degenerative mechanisms in both retina and optic nerve with involvement of the complement system.	[Petrikowski, Laura; Reinehr, Sabrina; Deppe, Leonie; Graz, Florian; Dick, H. Burkhard; Joachim, Stephanie C.] Ruhr Univ Bochum, Univ Eye Hosp, Expt Eye Res Inst, Bochum, Germany; [Petrikowski, Laura; Haupeltshofer, Steffen; Graz, Florian; Kleiter, Ingo; Gold, Ralf; Faissner, Simon] Ruhr Univ Bochum, St Josef Hosp, Dept Neurol, Bochum, Germany	Ruhr University Bochum; Ruhr University Bochum	Joachim, SC (corresponding author), Ruhr Univ Bochum, Univ Eye Hosp, Expt Eye Res Inst, Bochum, Germany.; Faissner, S (corresponding author), Ruhr Univ Bochum, St Josef Hosp, Dept Neurol, Bochum, Germany.	simon.faissner@rub.de; stephanie.joachim@rub.de						Axelsson M, 2011, J NEUROL, V258, P882, DOI 10.1007/s00415-010-5863-2; Bennett ML, 2016, P NATL ACAD SCI USA, V113, pE1738, DOI 10.1073/pnas.1525528113; Berger A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096494; Bettelli E, 2003, J EXP MED, V197, P1073, DOI 10.1084/jem.20021603; Borisow N, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00888; Bouyon M, 2013, MULT SCLER J, V19, P1320, DOI 10.1177/1352458513476562; Brandt AU, 2011, BRAIN, V134, DOI 10.1093/brain/awr095; Bringmann A, 2006, PROG RETIN EYE RES, V25, P397, DOI 10.1016/j.preteyeres.2006.05.003; Carpanini SM, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00362; Chen TJ, 2020, J CLIN INVEST, V130, P4025, DOI 10.1172/JCI134816; Ciotti JR, 2020, MULT SCLER RELAT DIS, V45, DOI 10.1016/j.msard.2020.102399; Clements CS, 2003, P NATL ACAD SCI USA, V100, P11059, DOI 10.1073/pnas.1833158100; Compston A, 2008, LANCET, V372, P1502, DOI 10.1016/S0140-6736(08)61620-7; Cruz-Herranz A, 2021, JCI INSIGHT, V6, DOI 10.1172/jci.insight.149228; Cruz-Herranz A, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974-019-1583-4; Delarasse C, 2003, J CLIN INVEST, V112, P544, DOI 10.1172/JCI200315861; Dong YF, 2019, NAT REV NEUROL, V15, P704, DOI 10.1038/s41582-019-0253-6; Faissner S, 2019, NAT REV DRUG DISCOV, V18, P905, DOI 10.1038/s41573-019-0035-2; Ferguson B, 1997, BRAIN, V120, P393, DOI 10.1093/brain/120.3.393; Filippatou AG, 2020, FRONT NEUROL, V11, DOI 10.3389/fneur.2020.540156; Fonseca MI, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0814-9; Fonseca MI, 2004, J NEUROSCI, V24, P6457, DOI 10.1523/JNEUROSCI.0901-04.2004; Forooghian F, 2006, DOC OPHTHALMOL, V113, P123, DOI 10.1007/s10633-006-9022-0; Gal RL, 2008, OPHTHALMOLOGY, V115, P1079, DOI 10.1016/j.ophtha.2007.08.004; Green AJ, 2010, BRAIN, V133, P1591, DOI 10.1093/brain/awq080; Guo L, 2010, INVEST OPHTH VIS SCI, V51, P6504, DOI 10.1167/iovs.10-5551; Guy J, 2008, OPHTHAL RES, V40, P212, DOI 10.1159/000119879; Halder SK, 2022, CELL MOL NEUROBIOL, V42, P1615, DOI 10.1007/s10571-021-01049-8; Hammond JW, 2020, BRAIN BEHAV IMMUN, V87, P739, DOI 10.1016/j.bbi.2020.03.004; Haupeltshofer S, 2019, P NATL ACAD SCI USA, V116, P25860, DOI 10.1073/pnas.1905955116; Hobom M, 2004, BRAIN PATHOL, V14, P148, DOI 10.1111/j.1750-3639.2004.tb00047.x; Horstmann L, 2016, J NEUROIMMUNOL, V298, P32, DOI 10.1016/j.jneuroim.2016.06.008; Horstmann L, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-120; Karlstetter M, 2015, PROG RETIN EYE RES, V45, P30, DOI 10.1016/j.preteyeres.2014.11.004; Kitley J, 2014, JAMA NEUROL, V71, P276, DOI 10.1001/jamaneurol.2013.5857; Knier B, 2015, J AUTOIMMUN, V56, P34, DOI 10.1016/j.jaut.2014.09.003; Kremers J, 2018, METHODS MOL BIOL, V1753, P27, DOI 10.1007/978-1-4939-7720-8_2; Krishnamoorthy G, 2006, J CLIN INVEST, V116, P2385, DOI 10.1172/JCI28330; Kwong JMK, 2010, INVEST OPHTH VIS SCI, V51, P1052, DOI 10.1167/iovs.09-4098; Li L, 2015, EXP EYE RES, V136, P116, DOI 10.1016/j.exer.2015.04.020; Litzenburger T, 1998, J EXP MED, V188, P169, DOI 10.1084/jem.188.1.169; Lucchinetti CF, 2014, BRAIN PATHOL, V24, P83, DOI 10.1111/bpa.12099; Mader S, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-184; Manogaran P, 2019, ACTA NEUROPATHOL COM, V7, DOI 10.1186/s40478-019-0768-5; Meyer R, 2001, J NEUROSCI, V21, P6214, DOI 10.1523/JNEUROSCI.21-16-06214.2001; Nagireddy RBR, 2021, J NEUROIMMUNOL, V361, DOI 10.1016/j.jneuroim.2021.577742; Nishioka C, 2019, MULT SCLER RELAT DIS, V27, P315, DOI 10.1016/j.msard.2018.11.010; Park KA, 2014, ACTA OPHTHALMOL, V92, pE57, DOI 10.1111/aos.12215; Pfaffl MW, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.9.e36; Plastini MJ, 2020, FRONT CELL NEUROSCI, V14, DOI 10.3389/fncel.2020.00269; Ratchford JN, 2009, NEUROLOGY, V73, P302, DOI 10.1212/WNL.0b013e3181af78b8; Reichenbach A, 2020, GLIA, V68, P768, DOI 10.1002/glia.23727; Reinehr S, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01381; Reinehr S, 2019, J CELL MOL MED, V23, P5497, DOI 10.1111/jcmm.14433; Reinehr S, 2018, CELL TISSUE RES, V371, P237, DOI 10.1007/s00441-017-2710-0; Reinehr S, 2016, FRONT CELL NEUROSCI, V10, DOI 10.3389/fncel.2016.00140; Saidha S, 2011, BRAIN, V134, P518, DOI 10.1093/brain/awq346; Shindler KS, 2006, MULT SCLER J, V12, P526, DOI 10.1177/1352458506070629; SMITH ME, 1983, BRAIN RES, V264, P241, DOI 10.1016/0006-8993(83)90822-3; Sotirchos ES, 2020, MULT SCLER J, V26, P1360, DOI 10.1177/1352458519864928; Trapp BD, 1998, NEW ENGL J MED, V338, P278, DOI 10.1056/NEJM199801293380502; Weber MS, 2018, THER ADV NEUROL DISO, V11, DOI 10.1177/1756286418762083; Weiss M, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22041997; Wildemann B, 2020, KLIN MONATSBL AUGENH, V237, P1290, DOI 10.1055/a-1219-7907; Wilmes AT, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1208-3; Wolf SA, 2017, ANNU REV PHYSIOL, V79, P619, DOI 10.1146/annurev-physiol-022516-034406; You YY, 2019, OPHTHALMOLOGY, V126, P2019, DOI 10.1016/j.ophtha.2019.01.016; Zeka B, 2016, ACTA NEUROPATHOL COM, V4, DOI 10.1186/s40478-016-0355-y; Zhang YX, 2018, EXP EYE RES, V175, P124, DOI 10.1016/j.exer.2018.06.011; Zhao GX, 2018, J NEUROL, V265, P33, DOI 10.1007/s00415-017-8651-4	70	0	0	2	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 24	2022	12								759389	10.3389/fimmu.2021.759389	http://dx.doi.org/10.3389/fimmu.2021.759389			18	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YU2KP	35140707	gold, Green Published, Green Submitted			2022-12-18	WOS:000751876600001
J	Phillips, D; Rodig, SJ; Jiang, SZ				Phillips, Darci; Rodig, Scott J.; Jiang, Sizun			Editorial: Defining the Spatial Organization of Immune Responses to Cancer and Viruses In Situ	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						spatial organization; cancer biology; viruses; immune checkpoint inhibitors; biothreat agents; tissue imaging; cell segmentation and classification	SUBCELLULAR RESOLUTION; PROTEINS; RNA		[Phillips, Darci] Stanford Univ, Dept Pathol, Sch Med, Stanford, CA 94305 USA; [Phillips, Darci] Stanford Univ, Dept Dermatol, Sch Med, Stanford, CA 94305 USA; [Rodig, Scott J.] Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA; [Rodig, Scott J.; Jiang, Sizun] Dana Farber Canc Inst, Dept Oncol Pathol, Boston, MA 02115 USA; [Jiang, Sizun] Beth Israel Deaconess Med Ctr, Ctr Virol & Vaccine Res, Boston, MA 02215 USA	Stanford University; Stanford University; Harvard University; Brigham & Women's Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard University; Beth Israel Deaconess Medical Center	Phillips, D (corresponding author), Stanford Univ, Dept Pathol, Sch Med, Stanford, CA 94305 USA.; Phillips, D (corresponding author), Stanford Univ, Dept Dermatol, Sch Med, Stanford, CA 94305 USA.; Rodig, SJ (corresponding author), Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA.; Rodig, SJ; Jiang, SZ (corresponding author), Dana Farber Canc Inst, Dept Oncol Pathol, Boston, MA 02115 USA.; Jiang, SZ (corresponding author), Beth Israel Deaconess Med Ctr, Ctr Virol & Vaccine Res, Boston, MA 02215 USA.	darciphilips@stanford.edu; srodig@partners.org; sjiang3@bidmc.harvard.edu		Phillips, Darci/0000-0002-0804-3342	National Institutes of Health (NIH) [F32CA233203, R01AI149672]; Beckman Center for Molecular and Genetic Medicine; Bristol-Myers Squibb; Merck; KITE/Gilead; Bill & Melinda Gates Foundation [INV-002704]	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Beckman Center for Molecular and Genetic Medicine; Bristol-Myers Squibb(Bristol-Myers Squibb); Merck(Merck & Company); KITE/Gilead; Bill & Melinda Gates Foundation(Bill & Melinda Gates FoundationCGIAR)	Funding This work was supported by the National Institutes of Health (NIH) F32CA233203 (DP) and R01AI149672 (SJ), The Beckman Center for Molecular and Genetic Medicine (DP), Bristol-Myers Squibb (SJR), Merck (SJR), KITE/Gilead (SJR), and the Bill & Melinda Gates Foundation INV-002704 (SJ). SJR is also a Scientific Advisory Board member for KITE/Gilead and Immunitas Therapeutics.	Angelo M, 2014, NAT MED, V20, P436, DOI 10.1038/nm.3488; Berry S, 2021, SCIENCE, V372, P1166, DOI 10.1126/science.aba2609; Black S, 2021, NAT PROTOC, V16, P3802, DOI 10.1038/s41596-021-00556-8; Bost P., 2021, OPTIMIZING MULTIPLEX, DOI [10.1101/2021.11.28.470262, DOI 10.1101/2021.11.28.470262]; Deng Y., 2021, SPATIAL ATAC SEQ SPA, DOI [10.1101/2021.06.06.447244, DOI 10.1101/2021.06.06.447244]; Eng J, 2020, METHODS MOL BIOL, V2055, P521, DOI 10.1007/978-1-4939-9773-2_24; Giesen C, 2014, NAT METHODS, V11, P417, DOI [10.1038/nmeth.2869, 10.1038/NMETH.2869]; Goltsev Y, 2018, CELL, V174, P968, DOI 10.1016/j.cell.2018.07.010; Hartmann FJ, 2021, NAT BIOTECHNOL, V39, DOI 10.1038/s41587-020-0651-8; He S, 2021, BIORXIV, V2021, DOI [10.1101/2021.11.03.467020, DOI 10.1101/2021.11.03.467020]; Jackson HW, 2020, NATURE, V578, P615, DOI 10.1038/s41586-019-1876-x; Ji AL, 2020, CELL, V182, P1661, DOI 10.1016/j.cell.2020.08.043; Jiang S., 2021, VIRUS DEPENDENT IMMU, DOI [10.1101/2021.05.21.444548, DOI 10.1101/2021.05.21.444548]; Keren L, 2018, CELL, V174, P1373, DOI 10.1016/j.cell.2018.08.039; Lin JR, 2018, ELIFE, V7, DOI 10.7554/eLife.31657; McCaffrey E.F., 2020, BIORXIV2020060814042, DOI [10.1101/2020.06.08.140426, DOI 10.1101/2020.06.08.140426]; Merritt CR, 2020, NAT BIOTECHNOL, V38, P586, DOI 10.1038/s41587-020-0472-9; Patwa A, 2021, COMMUN BIOL, V4, DOI 10.1038/s42003-021-02361-1; Phillips D, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-26974-6; Ramaglia V, 2019, ELIFE, V8, DOI 10.7554/eLife.48051; Rendeiro AF, 2021, NATURE, V593, P564, DOI 10.1038/s41586-021-03475-6; Rodriques SG, 2019, SCIENCE, V363, P1463, DOI 10.1126/science.aaw1219; Rovira-Clave X., 2021, SPATIAL EPITOPE BARC, DOI [10.1101/2021.06.29.449991, DOI 10.1101/2021.06.29.449991]; Rovira-Clave X, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-24822-1; Salmen F, 2018, NAT PROTOC, V13, P2501, DOI 10.1038/s41596-018-0045-2; Schulz D, 2018, CELL SYST, V6, P25, DOI 10.1016/j.cels.2017.12.001; Schurch CM, 2020, CELL, V182, P1341, DOI 10.1016/j.cell.2020.07.005; Stoltzfus CR, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107523; Tsujikawa T, 2017, CELL REP, V19, P203, DOI 10.1016/j.celrep.2017.03.037; Zhu B., 2021, ROBUST SINGLE CELL M, DOI [10.1101/2021.12.03.471185, DOI 10.1101/2021.12.03.471185]	30	0	0	3	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 24	2022	13								847582	10.3389/fimmu.2022.847582	http://dx.doi.org/10.3389/fimmu.2022.847582			4	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YU8QF	35140726	Green Published, gold			2022-12-18	WOS:000752300600001
J	Zou, WQ; Luo, WJ; Feng, YF; Liu, F; Liang, SB; Fang, XL; Liang, YL; Liu, N; Wang, YQ; Mao, YP				Zou, Wen-Qing; Luo, Wei-Jie; Feng, Yan-Fen; Liu, Fang; Liang, Shao-Bo; Fang, Xue-Liang; Liang, Ye-Lin; Liu, Na; Wang, Ya-Qin; Mao, Yan-Ping			Expression Profiles and Prognostic Value of Multiple Inhibitory Checkpoints in Head and Neck Lymphoepithelioma-Like Carcinoma	FRONTIERS IN IMMUNOLOGY			English	Article						head and neck lymphoepithelioma-like carcinoma; multiple inhibitory checkpoints; tumor microenvironment; TNM stage; prognosis	RENAL-CELL CARCINOMA; IMMUNE CHECKPOINT; SALIVARY-GLAND; GENETIC-BASIS; PD-L1; CANCER; PEMBROLIZUMAB; VISUALIZATION; ASSOCIATION; IPILIMUMAB	BackgroundInhibitory checkpoints are promising antitumor targets and predictive biomarkers in a variety of cancers. We aimed to identify the expression levels and prognostic value of multiple inhibitory checkpoints supported by preclinical and clinical evidence in head and neck lymphoepithelioma-like carcinoma (HNLELC). MethodsThe expression of seven inhibitory checkpoints were evaluated in the tumor nest (TN) and tumor stroma (TS) of 102 HNLELC specimens using immunohistochemistry and digital pathology, and an inhibitory checkpoint-based signature (ICS) was subsequently constructed using the LASSO Cox regression model. ResultsPD-L1, B7H3, and IDO-1 were mostly expressed in the TN, with median H-score of TN vs TS: 63.6 vs 14.6; 8.1 vs 1.0; 61.5 vs 34.7 (all P < 0.001), whereas PD-1, TIM-3, LAG-3, and VISTA were mainly observed in the TS, with median H-score of TN vs TS: 0.2 vs 12.4, 3.4 vs 7.1, 6.2 vs 11.9, 16.4 vs 47.2 (all P < 0.001), respectively. The most common simultaneously expressed combinations consisted of PD-L1 + B7H3 + IDO-1 + TIM-3 + LAG-3 + VISTA and B7H3 + IDO-1 + TIM-3 + LAG-3 in the TN (both occurring in 8.8% of patients) and PD-L1 + B7H3 + IDO-1 in the TS (4.9%). In addition, high-ICS patients had shorter 5-year disease-free (40.6% vs 81.7%; P < 0.001), regional recurrence-free (63.5% vs 88.2%; P = 0.003), and overall survival (73.5% vs 92.9%; P = 0.006) than low-ICS patients. Multivariate analysis revealed that ICS represented an independent predictor, which could significantly complement the predictive performance of TNM stage for 3-year (AUC 0.724 vs 0.619, P = 0.014), 5-year (AUC 0.727 vs 0.640, P = 0.056), and 10-year disease-free survival (AUC 0.815 vs 0.709, P = 0.023). ConclusionsThe expression of inhibitory checkpoints and ICS classifier may increase the prognostic value of the TNM staging system and guide the rational design of personalized inhibitory checkpoint blockade therapy in HNLELC.	[Zou, Wen-Qing; Fang, Xue-Liang; Liang, Ye-Lin; Liu, Na; Wang, Ya-Qin; Mao, Yan-Ping] Sun Yat Sen Univ Canc Ctr, Key Lab Nasopharyngeal Carcinoma Diag & Therapy, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med,Dept Radiat Oncol, Guangzhou, Peoples R China; [Luo, Wei-Jie] Sun Yat Sen Univ, Affiliated Hosp 7, Dept Med Oncol, Shenzhen, Peoples R China; [Feng, Yan-Fen] Sun Yat Sen Univ Canc Ctr, Collaborat Innovat Ctr Canc Med, Dept Pathol, State Key Lab Oncol South China, Guangzhou, Peoples R China; [Liu, Fang] First Peoples Hosp Foshan, Dept Pathol, Foshan, Peoples R China; [Liang, Shao-Bo] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Radiat Oncol, Guangzhou, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University; State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University	Liu, N; Wang, YQ; Mao, YP (corresponding author), Sun Yat Sen Univ Canc Ctr, Key Lab Nasopharyngeal Carcinoma Diag & Therapy, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med,Dept Radiat Oncol, Guangzhou, Peoples R China.	liun1@sysucc.org.cn; wangyaq@sysucc.org.cn; maoyp@sysucc.org.cn						Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Altan M, 2017, CLIN CANCER RES, V23, P5202, DOI 10.1158/1078-0432.CCR-16-3107; Amin MB, 2017, AJCC CANC STAGING MA; Armand P, 2019, J CLIN ONCOL, V37, P3291, DOI 10.1200/JCO.19.01389; Azuma K, 2014, ANN ONCOL, V25, P1935, DOI 10.1093/annonc/mdu242; Blackburn SD, 2009, NAT IMMUNOL, V10, P29, DOI 10.1038/ni.1679; Camp RL, 2004, CLIN CANCER RES, V10, P7252, DOI 10.1158/1078-0432.CCR-04-0713; Chan JYK, 2016, HEAD NECK-J SCI SPEC, V38, pE1294, DOI 10.1002/hed.24215; Choueiri TK, 2015, CLIN CANCER RES, V21, P1071, DOI 10.1158/1078-0432.CCR-14-1993; Cohen EEW, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0662-5; Conway JR, 2017, BIOINFORMATICS, V33, P2938, DOI 10.1093/bioinformatics/btx364; Dikshit RP, 2005, INT J CANCER, V117, P992, DOI 10.1002/ijc.21244; Dong C, 2001, NATURE, V409, P97, DOI 10.1038/35051100; Dubey P, 1998, CANCER, V82, P1556, DOI 10.1002/(SICI)1097-0142(19980415)82:8<1556::AID-CNCR18>3.0.CO;2-3; Fang WF, 2018, LANCET ONCOL, V19, P1338, DOI 10.1016/S1470-2045(18)30495-9; Friedman J, 2010, J STAT SOFTW, V33, P1, DOI 10.18637/jss.v033.i01; Gao JJ, 2017, NAT MED, V23, P551, DOI 10.1038/nm.4308; Hashibe M, 2007, J NATL CANCER I, V99, P777, DOI 10.1093/jnci/djk179; Hellmann MD, 2019, NEW ENGL J MED, V381, P2020, DOI 10.1056/NEJMoa1910231; Howitt BE, 2016, JAMA ONCOL, V2, P518, DOI 10.1001/jamaoncol.2015.6326; Hsu C, 2017, J CLIN ONCOL, V35, P4050, DOI 10.1200/JCO.2017.73.3675; Jiang XJ, 2019, MOL CANCER, V18, DOI 10.1186/s12943-018-0928-4; Jiang YM, 2018, ANN SURG, V267, P504, DOI 10.1097/SLA.0000000000002116; Kawakami F, 2017, CANCER-AM CANCER SOC, V123, P4823, DOI 10.1002/cncr.30937; Lee YH, 2017, CELL RES, V27, P1034, DOI 10.1038/cr.2017.90; Lex A, 2014, IEEE T VIS COMPUT GR, V20, P1983, DOI 10.1109/TVCG.2014.2346248; Liu SL, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2019-000205; Lob S, 2009, NAT REV CANCER, V9, P445, DOI 10.1038/nrc2639; Lv KP, 2021, INT J CANCER, V148, P759, DOI 10.1002/ijc.33358; Ma HL, 2014, HEAD NECK-J SCI SPEC, V36, P1305, DOI 10.1002/hed.23450; Mayes PA, 2018, NAT REV DRUG DISCOV, V17, P509, DOI 10.1038/nrd.2018.75; McLane LM, 2019, ANNU REV IMMUNOL, V37, P457, DOI 10.1146/annurev-immunol-041015-055318; MILLER R, 1982, BIOMETRICS, V38, P1011, DOI 10.2307/2529881; Nagao T, 1996, CANCER, V78, P695; Okamoto A, 2017, HEMATOL ONCOL, V35, P87, DOI 10.1002/hon.2245; Parra ER, 2016, CLIN CANCER RES, V22, P6278, DOI 10.1158/1078-0432.CCR-15-2443; Reck M, 2016, NEW ENGL J MED, V375, P1823, DOI 10.1056/NEJMoa1606774; Ren XY, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14053; Robert C, 2015, NEW ENGL J MED, V372, P2521, DOI 10.1056/NEJMoa1503093; Shin H, 2019, CLIN MOL HEPATOL, V25, P390, DOI 10.3350/cmh.2018.0103; Silva IG, 2017, EBIOMEDICINE, V22, P44, DOI 10.1016/j.ebiom.2017.07.018; Sledzinska A, 2015, MOL ONCOL, V9, P1936, DOI 10.1016/j.molonc.2015.10.008; Snyder A, 2014, NEW ENGL J MED, V371, P2189, DOI 10.1056/NEJMoa1406498; Taube JM, 2014, CLIN CANCER RES, V20, P5064, DOI 10.1158/1078-0432.CCR-13-3271; Tibshirani R, 1997, STAT MED, V16, P385, DOI 10.1002/(SICI)1097-0258(19970228)16:4<385::AID-SIM380>3.0.CO;2-3; Vu MD, 2007, BLOOD, V110, P2501, DOI 10.1182/blood-2007-01-070748; Wang YQ, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0752-4; Wasen C, 2017, J AUTOIMMUN, V78, P101, DOI 10.1016/j.jaut.2016.12.009; Wenig BM, 2015, SEMIN DIAGN PATHOL, V32, P74, DOI 10.1053/j.semdp.2014.12.004; Woo SR, 2012, CANCER RES, V72, P917, DOI 10.1158/0008-5472.CAN-11-1620; Zhan KY, 2016, ORAL ONCOL, V52, P24, DOI 10.1016/j.oraloncology.2015.10.019	51	0	0	5	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 24	2022	13								818411	10.3389/fimmu.2022.818411	http://dx.doi.org/10.3389/fimmu.2022.818411			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YU2KH	35140722	gold, Green Published			2022-12-18	WOS:000751875800001
J	Lee, YS; Yeo, IJ; Kim, KC; Han, SB; Hong, JT				Lee, Yong Sun; Yeo, In Jun; Kim, Ki Cheon; Han, Sang-Bae; Hong, Jin Tae			Inhibition of Lung Tumor Development in ApoE Knockout Mice via Enhancement of TREM-1 Dependent NK Cell Cytotoxicity (vol 10, 1379, 2019)	FRONTIERS IN IMMUNOLOGY			English	Correction						Lung tumor development; apolipoprotein E; TREM-1; T-bet; NK cells			[Lee, Yong Sun; Yeo, In Jun; Kim, Ki Cheon; Han, Sang-Bae; Hong, Jin Tae] Chungbuk Natl Univ, Coll Pharm, Cheongju, South Korea; [Lee, Yong Sun; Yeo, In Jun; Kim, Ki Cheon; Han, Sang-Bae; Hong, Jin Tae] Chungbuk Natl Univ, Med Res Ctr, Cheongju, South Korea	Chungbuk National University; Chungbuk National University	Hong, JT (corresponding author), Chungbuk Natl Univ, Coll Pharm, Cheongju, South Korea.; Hong, JT (corresponding author), Chungbuk Natl Univ, Med Res Ctr, Cheongju, South Korea.	jinthong@chungbuk.ac.kr						Lee YS, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01379	1	0	0	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 21	2022	12								840856	10.3389/fimmu.2021.840856	http://dx.doi.org/10.3389/fimmu.2021.840856			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YV4NI	35126387	Green Published, gold			2022-12-18	WOS:000752706100001
J	Li, H; Song, P; Yang, W; Yang, L; Diao, SS; Huang, SC; Wang, YQ; Xu, XS; Yang, Y				Li, Hao; Song, Pu; Yang, Wei; Yang, Le; Diao, Shanshan; Huang, Shicun; Wang, Yiqing; Xu, Xingshun; Yang, Yi			Association Between Autoimmune Diseases and Spontaneous Cervicocranial Arterial Dissection	FRONTIERS IN IMMUNOLOGY			English	Article						cervicocranial arterial dissection; autoimmune; inflammatory autoimmune disease; inflammatory; neurological disease	THYROID AUTOIMMUNITY	A series of biopsies and reports showed autoimmune diseases might be involved in the process of local inflammation related to spontaneous cervicocranial arterial dissection (SCCAD) occurrence. This retrospective case-control study examined the association between SCCADs and autoimmune diseases in patients and control subjects from 2014 to 2020. SCCAD patients and age/sex-matched control subjects were recruited, and clinical data were collected. SCCAD was confirmed by digital subtraction angiography or high-resolution magnetic resonance imaging. The study included 215 SCCAD patients and 430 control subjects. Totally, 135 (62.8%) of the 215 cases were found SCCAD in the anterior circulation, 26 (12.0%) patients involved multiple vessels. Autoimmune disease occurred in 27 (12.6%) cases with SCCAD and 4 (0.9%) control subjects (p<0.001). A conditional multivariable logistic regression model was used to calculate the odds ratio for SCCAD among patients with a history of autoimmune disease, adjusting for hypertension, diabetes, hyperlipidemia, and smoking. After adjustment, autoimmune diseases were associated with SCCAD (p<0.001). After sub-analysis by a similar modeling strategy, significant associations were still observed in different subgroups, such as female group and male group as well as intramural hematoma (IMH) group and Non-IHM group. The association of SCCAD with autoimmune disease suggested that autoimmune mechanisms may be involved in some etiologies of SCCAD.	[Li, Hao; Song, Pu; Yang, Wei; Diao, Shanshan; Huang, Shicun; Wang, Yiqing; Xu, Xingshun; Yang, Yi] Soochow Univ, Dept Neurol, Affiliated Hosp 1, Suzhou, Peoples R China; [Yang, Le] Fujian Med Univ, Sch Publ Hlth, Fuzhou, Peoples R China; [Xu, Xingshun] Soochow Univ, Inst Neurosci, Suzhou, Peoples R China	Soochow University - China; Fujian Medical University; Soochow University - China	Xu, XS; Yang, Y (corresponding author), Soochow Univ, Dept Neurol, Affiliated Hosp 1, Suzhou, Peoples R China.; Xu, XS (corresponding author), Soochow Univ, Inst Neurosci, Suzhou, Peoples R China.	Xingshunxu@suda.edu.cn; 13656229395@163.com						Blum CA, 2015, ARCH NEUROSCI, V2, DOI 10.5812/archneurosci.26670; Choi YJ, 2015, J STROKE, V17, P238, DOI 10.5853/jos.2015.17.3.238; Collamer Angelique N, 2013, Mil Med, V178, pe851, DOI 10.7205/MILMED-D-12-00414; Cooper GS, 2009, J AUTOIMMUN, V33, P197, DOI 10.1016/j.jaut.2009.09.008; Forster K, 2006, J NEUROL, V253, P741, DOI 10.1007/s00415-006-0109-z; Gao PH, 2016, CLIN NEURORADIOL, V26, P81, DOI 10.1007/s00062-014-0337-z; Herath HMMTB, 2017, BMC CARDIOVASC DISOR, V17, DOI 10.1186/s12872-017-0638-7; Kaneko H, 2011, ATHEROSCLEROSIS, V218, P470, DOI 10.1016/j.atherosclerosis.2011.06.008; Koller PT, 1998, CLIN CARDIOL, V21, P40, DOI 10.1002/clc.4960210108; Kronzer VL, 2020, J AM COLL CARDIOL, V76, P2226, DOI 10.1016/j.jacc.2020.09.533; Lee SH, 2020, CEREBROVASC DIS, V49, P269, DOI 10.1159/000508027; Lichy C, 2009, CEREBROVASC DIS, V28, P203, DOI 10.1159/000226581; Naggara O, 2009, EUR RADIOL, V19, P2255, DOI 10.1007/s00330-009-1415-5; Ortona Elena, 2016, Ann Ist Super Sanita, V52, P205, DOI 10.4415/ANN_16_02_12; Pezzini A, 2006, STROKE, V37, P2375, DOI 10.1161/01.STR.0000236500.15976.f3; Saliou V, 2018, SAGE OPEN MED CASE R, V6, DOI 10.1177/2050313X18777176; Sun GB, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.598055; Tsai YD, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2018-022326; Volker W, 2005, NEUROLOGY, V64, P1508, DOI 10.1212/01.WNL.0000159739.24607.98; Wu Y, 2019, STROKE, V50, P3101, DOI 10.1161/STROKEAHA.119.026362	20	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 21	2022	12								820039	10.3389/fimmu.2021.820039	http://dx.doi.org/10.3389/fimmu.2021.820039			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YT3NK	35126376	Green Published, gold			2022-12-18	WOS:000751270300001
J	Li, QH; Yang, SW; Zhang, XL; Liu, XH; Wu, ZH; Qi, YA; Guan, WT; Ren, M; Zhang, SH				Li, Qihui; Yang, Siwang; Zhang, Xiaoli; Liu, Xinghong; Wu, Zhihui; Qi, Yingao; Guan, Wutai; Ren, Man; Zhang, Shihai			Maternal Nutrition During Late Gestation and Lactation: Association With Immunity and the Inflammatory Response in the Offspring	FRONTIERS IN IMMUNOLOGY			English	Review						maternal nutrition; neonate; growth; disease resistance; inflammatory; immunoglobulin	VITAMIN-E SUPPLEMENTATION; SEAWEED EXTRACT SUPPLEMENTATION; IMPROVES GROWTH-PERFORMANCE; FORSYTHIA-SUSPENSA EXTRACT; OXIDATIVE STRESS; FISH-OIL; FATTY-ACIDS; ANTIOXIDANT CAPACITY; PIGLET PERFORMANCE; BARRIER FUNCTION	The immature immune system at birth and environmental stress increase the risk of infection in nursing pigs. Severe infection subsequently induces intestinal and respiratory diseases and even cause death of pigs. The nutritional and physiological conditions of sows directly affect the growth, development and disease resistance of the fetus and newborn. Many studies have shown that providing sows with nutrients such as functional oligosaccharides, oils, antioxidants, and trace elements could regulate immunity and the inflammatory response of piglets. Here, we reviewed the positive effects of certain nutrients on milk quality, immunoglobulin inflammatory response, oxidative stress, and intestinal microflora of sows, and further discuss the effects of these nutrients on immunity and the inflammatory response in the offspring.	[Li, Qihui; Yang, Siwang; Zhang, Xiaoli; Liu, Xinghong; Wu, Zhihui; Qi, Yingao; Guan, Wutai; Zhang, Shihai] South China Agr Univ, Coll Anim Sci, Guangdong Prov Key Lab Anim Nutr Control, Guangzhou, Peoples R China; [Guan, Wutai; Zhang, Shihai] South China Agr Univ, Coll Anim Sci, Natl Engn Res Ctr Breeding Swine Ind, Guangzhou, Peoples R China; [Guan, Wutai; Zhang, Shihai] South China Agr Univ, Guangdong Lab Lingnan Modern Agr, Guangzhou, Peoples R China; [Ren, Man] Anhui Sci & Technol Univ, Coll Anim Sci, Anhui Prov Key Lab Anim Nutr Regulat & Hlth, Fengyang, Peoples R China	South China Agricultural University; South China Agricultural University; South China Agricultural University; Anhui Science & Technology University	Zhang, SH (corresponding author), South China Agr Univ, Coll Anim Sci, Guangdong Prov Key Lab Anim Nutr Control, Guangzhou, Peoples R China.; Zhang, SH (corresponding author), South China Agr Univ, Coll Anim Sci, Natl Engn Res Ctr Breeding Swine Ind, Guangzhou, Peoples R China.; Zhang, SH (corresponding author), South China Agr Univ, Guangdong Lab Lingnan Modern Agr, Guangzhou, Peoples R China.; Ren, M (corresponding author), Anhui Sci & Technol Univ, Coll Anim Sci, Anhui Prov Key Lab Anim Nutr Regulat & Hlth, Fengyang, Peoples R China.	renman@yeah.net; zhangshihai@scau.edu.cn			National Natural Science Foundation of the P.R. of China [31872364, 31802067]; Guangdong Basic and Applied Basic Research Foundation [2021A1515010440]; Science and Technology Program of Guangzhou [202102020056]; Anhui Provincial Science and Technology Major Special Project [201903a06020002]	National Natural Science Foundation of the P.R. of China(National Natural Science Foundation of China (NSFC)); Guangdong Basic and Applied Basic Research Foundation; Science and Technology Program of Guangzhou; Anhui Provincial Science and Technology Major Special Project	Funding This study was financially supported by the National Natural Science Foundation of the P.R. of China (No. 31872364 and No. 31802067), Guangdong Basic and Applied Basic Research Foundation (No. 2021A1515010440), Science and Technology Program of Guangzhou (No. 202102020056), Anhui Provincial Science and Technology Major Special Project (201903a06020002).	Agyekum AK, 2017, ENGINEERING-PRC, V3, P716, DOI 10.1016/J.ENG.2017.03.010; Avery JC, 2018, NUTRIENTS, V10, DOI 10.3390/nu10091203; Beloosesky R, 2010, AM J OBSTET GYNECOL, V203, DOI 10.1016/j.ajog.2010.04.033; Berchieri-Ronchi CB, 2011, ANIMAL, V5, P1774, DOI 10.1017/S1751731111000772; Bosi P, 2004, J ANIM SCI, V82, P1764; Brennan LA, 2000, BRIT J NUTR, V84, P195, DOI 10.1017/S0007114500001422; Briens M, 2014, POULTRY SCI, V93, P85, DOI 10.3382/ps.2013-03182; BRUCE DW, 1963, TOXICOL APPL PHARM, V5, P750, DOI 10.1016/0041-008X(63)90067-X; Bunders MJ, 2014, SCI REP-UK, V4, DOI 10.1038/srep06690; Calder PC, 2001, LIPIDS, V36, P1007, DOI 10.1007/s11745-001-0812-7; Casanueva E, 2003, J NUTR, V133, p1700S, DOI 10.1093/jn/133.5.1700S; Challier JC, 2008, PLACENTA, V29, P274, DOI 10.1016/j.placenta.2007.12.010; Chaudhari N, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00213; Che LQ, 2016, LIPIDS HEALTH DIS, V15, DOI 10.1186/s12944-016-0261-0; Chen JC, 2019, J ANIM SCI, V97, P4256, DOI 10.1093/jas/skz284; Chen J, 2021, BRIT J NUTR, V125, P62, DOI 10.1017/S0007114520002652; Cheng CS, 2020, ANIMALS-BASEL, V10, DOI 10.3390/ani10010049; Cheng CS, 2018, APPL ENVIRON MICROB, V84, DOI [10.1128/AEM.001047-18, 10.1128/aem.01047-18, 10.1128/AEM.01047-18]; Cicerale S, 2012, CURR OPIN BIOTECH, V23, P129, DOI 10.1016/j.copbio.2011.09.006; Cools A, 2011, J ANIM PHYSIOL AN N, V95, P125, DOI 10.1111/j.1439-0396.2010.01119.x; Cooper CA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058409; Couloigner F, 2015, POULTRY SCI, V94, P2708, DOI 10.3382/ps/pev282; Diep TA, 2011, FASEB J, V25, P765, DOI 10.1096/fj.10-166595; Ding DJ, 2021, FOOD FUNCT, V12, P11214, DOI [10.1039/d1fo01653a, 10.1039/D1FO01653A]; Duan XD, 2016, ANIM FEED SCI TECH, V218, P17, DOI 10.1016/j.anifeedsci.2016.05.002; Duan XD, 2020, LIVEST SCI, V239, DOI 10.1016/j.livsci.2020.104114; Duan XD, 2019, J ANIM SCI, V97, P4548, DOI 10.1093/jas/skz318; Fang CL, 2014, J ANIM PHYSIOL AN N, V98, P680, DOI 10.1111/jpn.12122; Fukuda S, 2011, NATURE, V469, P543, DOI 10.1038/nature09646; Fuongfuchat A, 2012, J FOOD ENG, V109, P571, DOI 10.1016/j.jfoodeng.2011.10.022; Gahan DA, 2009, ANIMAL, V3, P24, DOI 10.1017/S1751731108003017; Gaines AM, 2003, DOMEST ANIM ENDOCRIN, V24, P353, DOI 10.1016/S0739-7240(03)00016-X; Gao LM, 2021, ANIM NUTR, V7, P84, DOI 10.1016/j.aninu.2020.06.009; Gomez B, 2016, J FUNCT FOODS, V20, P108, DOI 10.1016/j.jff.2015.10.029; Gomez-Gallego C, 2016, SEMIN FETAL NEONAT M, V21, P400, DOI 10.1016/j.siny.2016.05.003; Gu XL, 2019, J SCI FOOD AGR, V99, P5646, DOI 10.1002/jsfa.9821; Guo F, 2011, BIOL TRACE ELEM RES, V142, P693, DOI 10.1007/s12011-010-8792-0; Han X, 2012, ASIAN AUSTRAL J ANIM, V25, P569, DOI 10.5713/ajas.2011.11425; HAYEK MG, 1989, J ANIM SCI, V67, P1299; Heim G, 2015, J NUTR SCI, V4, DOI 10.1017/jns.2015.16; Hess JR, 2012, NUTR CLIN PRACT, V27, P281, DOI 10.1177/0884533611434933; HIDIROGLOU M, 1995, REPROD NUTR DEV, V35, P443, DOI 10.1051/rnd:19950409; Ho T, 2020, ANIM NUTR, V6, P134, DOI 10.1016/j.aninu.2020.02.001; Hong M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7588; Huang C, 2015, J NUTR, V145, P2774, DOI 10.3945/jn.115.217406; Hung I., 2015, THESIS GRADWORKS U K; Innis SM, 2010, AM J PHYSIOL-GASTR L, V299, pG1376, DOI 10.1152/ajpgi.00258.2010; Jarrett S, 2018, J ANIM SCI BIOTECHNO, V9, DOI 10.1186/s40104-018-0270-0; Jarvie E, 2010, CLIN SCI, V119, P123, DOI 10.1042/CS20090640; Jin C, 2017, ANIM SCI J, V88, P1768, DOI 10.1111/asj.12836; Jones GM, 2002, ANIM SCI, V75, P57, DOI 10.1017/S1357729800052838; Kim K, 2021, J ANIM SCI TECHNOL, V63, P1076, DOI 10.5187/jast.2021.e83; KNAZEK RA, 1980, J NATL CANCER I, V64, P377, DOI 10.1093/jnci/64.2.377; Kraatz M, 2006, J ANIM PHYSIOL AN N, V90, P361, DOI 10.1111/j.1439-0396.2005.00594.x; Lauridsen C, 2007, PROSTAG OTH LIPID M, V84, P66, DOI 10.1016/j.prostaglandins.2007.04.003; Le Dividich J, 2005, J AGR SCI-CAMBRIDGE, V143, P469, DOI 10.1017/S0021859605005642; Leblois J, 2020, ANIMALS-BASEL, V10, DOI 10.3390/ani10112051; Lee SD, 2013, LIVEST SCI, V154, P117, DOI 10.1016/j.livsci.2013.02.001; Leonard SG, 2012, J ANIM SCI, V90, P505, DOI 10.2527/jas.2010-3243; Leonard SG, 2010, J ANIM SCI, V88, P2988, DOI 10.2527/jas.2009-2764; Li JQ, 2009, AQUACULTURE, V291, P35, DOI 10.1016/j.aquaculture.2009.03.005; Li NY, 2020, BIOL TRACE ELEM RES, V194, P159, DOI 10.1007/s12011-019-01754-y; Liu YL, 2015, J ANIM SCI BIOTECHNO, V6, DOI 10.1186/s40104-015-0040-1; Long SF, 2021, ANIM FEED SCI TECH, V271, DOI 10.1016/j.anifeedsci.2020.114700; Lourenco R, 2002, Nutr Hosp, V17, P262; Luo J, 2009, LIVEST SCI, V126, P286, DOI 10.1016/j.livsci.2009.08.002; Luo J, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/905918; Luo WL, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/6765803; Ma P, 2011, CARBOHYD POLYM, V84, P1391, DOI 10.1016/j.carbpol.2011.01.045; Masschalck B, 2003, CRIT REV MICROBIOL, V29, P191, DOI 10.1080/713610448; Mataix J, 2008, MEDITERR J NUTR META, V1, P69, DOI 10.1007/s12349-008-0012-5; Matamoros S, 2013, TRENDS MICROBIOL, V21, P167, DOI 10.1016/j.tim.2012.12.001; Meng QW, 2019, FOOD FUNCT, V10, P5626, DOI [10.1039/C9FO00637K, 10.1039/c9fo00637k]; Meng QW, 2018, J ANIM SCI BIOTECHNO, V9, DOI 10.1186/s40104-018-0248-y; Mitre R, 2005, BRIT J NUTR, V94, P753, DOI 10.1079/BJN20051569; Mor G, 2017, NAT REV IMMUNOL, V17, P469, DOI 10.1038/nri.2017.64; Mou DL, 2020, FOOD FUNCT, V11, P7748, DOI 10.1039/d0fo00832j; Mudgil D, 2013, INT J BIOL MACROMOL, V61, P1, DOI 10.1016/j.ijbiomac.2013.06.044; Nakajima A, 2017, J IMMUNOL, V199, P3516, DOI 10.4049/jimmunol.1700248; Nguyen TV, 2007, VET IMMUNOL IMMUNOP, V117, P236, DOI 10.1016/j.vetimm.2007.02.013; Nyachoti CM, 2012, J ANIM SCI, V90, P252, DOI 10.2527/jas.2010-3596; Oliva K, 2012, J MOL ENDOCRINOL, V48, P139, DOI 10.1530/JME-11-0123; Oliver WT, 2013, J ANIM SCI, V91, P3129, DOI 10.2527/jas.2012-5782; Onipe OO, 2015, INT J FOOD SCI TECH, V50, P2509, DOI 10.1111/ijfs.12935; Patel S, 2011, WORLD J MICROB BIOT, V27, P1119, DOI 10.1007/s11274-010-0558-5; Peng X, 2019, ANIMALS-BASEL, V9, DOI 10.3390/ani9040125; Pereira AC, 2014, CELL BIOL TOXICOL, V30, P301, DOI 10.1007/s10565-014-9285-2; Pettigrew JE, 2006, ANIM BIOTECHNOL, V17, P207, DOI 10.1080/10495390600956946; Phan PV, 2005, J ALTERN COMPLEM MED, V11, P149, DOI 10.1089/acm.2005.11.149; Pluske JR, 1997, LIVEST PROD SCI, V51, P215, DOI 10.1016/S0301-6226(97)00057-2; POULSEN HD, 1989, ACTA VET SCAND, V30, P371; Rainone V, 2016, INT J OBESITY, V40, P1026, DOI 10.1038/ijo.2016.26; Rooke JA, 2000, ANIM SCI, V71, P289, DOI 10.1017/S1357729800055132; Rooke JA, 2002, LIVEST PROD SCI, V78, P13, DOI 10.1016/S0301-6226(02)00182-3; Rosero DS, 2016, J ANIM SCI BIOTECHNO, V7, DOI 10.1186/s40104-016-0092-x; Saben J, 2014, PLACENTA, V35, P171, DOI 10.1016/j.placenta.2014.01.003; Schellingerhout A.B, 2002, THESIS U UTRETCH NET; Shang QH, 2021, J ANIM SCI BIOTECHNO, V12, DOI 10.1186/s40104-021-00573-3; Shang QH, 2019, J ANIM SCI, V97, P4922, DOI 10.1093/jas/skz278; Shen Y, 2015, LIPIDS, V50, P647, DOI [10.1007/s11745-015-4024-x, 10.1007]; Short SP, 2018, FREE RADICAL BIO MED, V127, P26, DOI 10.1016/j.freeradbiomed.2018.05.066; Spring P., 2015, Journal of Applied Animal Nutrition, V2015, pe8; Sukhotnik I, 2016, PEDIATR SURG INT, V32, P161, DOI 10.1007/s00383-015-3828-3; Sweeney T, 2012, BRIT J NUTR, V108, P1226, DOI 10.1017/S0007114511006751; Tan CQ, 2016, APPL ENVIRON MICROB, V82, P5899, DOI 10.1128/AEM.01374-16; Tanghe S, 2015, J ANIM PHYSIOL AN N, V99, P938, DOI 10.1111/jpn.12243; Theil PK, 2014, ANIMAL, V8, P1021, DOI 10.1017/S1751731114000950; Tilton SL, 1999, J ANIM SCI, V77, P2491; Tuchscherer M, 2012, BMC VET RES, V8, DOI 10.1186/1746-6148-8-232; UAUY R, 1990, J PEDIATR GASTR NUTR, V10, P497, DOI 10.1097/00005176-199005000-00014; Wan J, 2018, ITAL J ANIM SCI, V17, P994, DOI [10.1080/1828051X.2018.1435313, 10.1080/1828051x.2018.1435313]; Wang L, 2017, J DAIRY RES, V84, P8, DOI 10.1017/S0022029916000650; Wang XR, 2019, J ANIM SCI, V97, P2515, DOI 10.1093/jas/skz128; Wang Y, 2016, NEUROCHEM RES, V41, P659, DOI 10.1007/s11064-015-1731-x; Wells JE, 2015, J APPL MICROBIOL, V118, P1489, DOI 10.1111/jam.12803; Wenk C, 2001, ANIM FEED SCI TECH, V90, P21, DOI 10.1016/S0377-8401(01)00194-8; Wilson RM, 2015, MOL CELL ENDOCRINOL, V418, P134, DOI 10.1016/j.mce.2015.07.028; Winiarska K, 2009, BIOCHIMIE, V91, P261, DOI 10.1016/j.biochi.2008.09.006; Wu Y, 2017, ANIM FEED SCI TECH, V230, P126, DOI 10.1016/j.anifeedsci.2017.05.013; Xiong Y, 2019, ANIMALS-BASEL, V9, DOI 10.3390/ani9100738; Xu MM, 2019, ANIMALS-BASEL, V9, DOI 10.3390/ani9050220; Xu SY, 2018, J ANIM SCI, V96, P4768, DOI 10.1093/jas/sky338; Xue Y, 2014, J NUTR BIOCHEM, V25, P758, DOI 10.1016/j.jnutbio.2014.03.009; Yao W, 2012, J ANIM SCI BIOTECHNO, V3, DOI 10.1186/2049-1891-3-43; Yen MT, 2008, CARBOHYD POLYM, V74, P840, DOI 10.1016/j.carbpol.2008.05.003; Zhang H, 2016, CURR OPIN FOOD SCI, V8, P33, DOI 10.1016/j.cofs.2016.02.002; Zhang LL, 2021, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.588986; Zhao PF, 2017, ANIM SCI J, V88, P854, DOI 10.1111/asj.12656; Zhou YF, 2019, ANIMALS-BASEL, V9, DOI 10.3390/ani9100796; Zhou YF, 2018, J ANIM SCI, V96, P250, DOI 10.1093/jas/skx041	130	0	0	12	17	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 21	2022	12								758525	10.3389/fimmu.2021.758525	http://dx.doi.org/10.3389/fimmu.2021.758525			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YT3NW	35126349	Green Published, gold			2022-12-18	WOS:000751271600001
J	Rajasinghe, LD; Bates, MA; Benninghoff, AD; Wierenga, KA; Harkema, JR; Pestka, JJ				Rajasinghe, Lichchavi D.; Bates, Melissa A.; Benninghoff, Abby D.; Wierenga, Kathryn A.; Harkema, Jack R.; Pestka, James J.			Silica Induction of Diverse Inflammatory Proteome in Lungs of Lupus-Prone Mice Quelled by Dietary Docosahexaenoic Acid Supplementation	FRONTIERS IN IMMUNOLOGY			English	Article						systemic lupus erythematosus; chemokine; metalloproteinase; TNF superfamily; omega-3 fatty acid; autoimmunity; inflammation	ATTENUATES KIDNEY-DISEASE; FISH-OIL; E-SELECTIN; LIFE-SPAN; OMEGA-3-FATTY-ACIDS; N-3; ERYTHEMATOSUS; PATHOGENESIS; PROGRESSION; RESTRICTION	Repeated short-term intranasal instillation of lupus-prone mice with crystalline silica (cSiO(2)) induces inflammatory gene expression and ectopic lymphoid neogenesis in the lung, leading to early onset of systemic autoimmunity and rapid progression to glomerulonephritis. These responses are suppressed by dietary supplementation with the omega-3 polyunsaturated fatty acid docosahexaenoic acid (DHA). Here, we tested the hypothesis that dietary DHA supplementation suppresses cSiO(2)-induced inflammatory proteins in bronchoalveolar alveolar lavage fluid (BALF) and plasma of lupus-prone mice. Archived tissue fluid samples were used from a prior investigation in which 6 wk-old lupus-prone female NZBWF1 mice were fed isocaloric diets containing 0 or 10 g/kg DHA for 2 wks and then intranasally instilled with 1 mg cSiO(2) or vehicle once weekly for 4 wks. Cohorts were terminated at 1, 5, 9 or 13 wk post-instillation (PI). BALF and plasma from each cohort were analyzed by high density multiplex array profiling of 200 inflammatory proteins. cSiO(2) time-dependently induced increases in the BALF protein signatures that were highly reflective of unresolved lung inflammation, although responses in the plasma were much less robust. Induced proteins in BALF included chemokines (e.g., MIP-2, MCP-5), enzymes (e.g., MMP-10, granzyme B), adhesion molecules (e.g., sE-selectin, sVCAM-1), co-stimulatory molecules (e.g., sCD40L, sCD48), TNF superfamily proteins (e.g., sTNFRI, sBAFF-R), growth factors (e.g., IGF-1, IGFBP-3), and signal transduction proteins (e.g., MFG-E8, FcgRIIB), many of which were blocked or delayed by DHA supplementation. The BALF inflammatory proteome correlated positively with prior measurements of gene expression, pulmonary ectopic lymphoid tissue neogenesis, and induction of autoantibodies in the lungs of the control and treatment groups. Ingenuity Pathway Analysis (IPA) revealed that IL-1 beta, TNF-alpha, and IL-6 were among the top upstream regulators of the cSiO(2)-induced protein response. Furthermore, DHA's effects were associated with downregulation of cSiO(2)-induced pathways involving i) inhibition of ARE-mediated mRNA decay, ii) bacterial and viral pattern recognition receptor activation, or iii) TREM1, STAT3, NF-kappa B, and VEGF signaling and with upregulation of PPAR, LXR/RXR and PPAR alpha/RXR alpha signaling. Altogether, these preclinical findings further support the contention that dietary DHA supplementation could be applicable as an intervention against inflammation-driven autoimmune triggering by cSiO(2) or potentially other environmental agents.	[Rajasinghe, Lichchavi D.; Bates, Melissa A.; Pestka, James J.] Michigan State Univ, Dept Food Sci & Human Nutr, E Lansing, MI 48824 USA; [Rajasinghe, Lichchavi D.; Bates, Melissa A.; Pestka, James J.] Michigan State Univ, Inst Integrat Toxicol, E Lansing, MI 48824 USA; [Benninghoff, Abby D.] Utah State Univ, Sch Vet Med, Dept Anim Dairy & Vet Sci, Logan, UT 84322 USA; [Wierenga, Kathryn A.] Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA; [Harkema, Jack R.] Michigan State Univ, Dept Pathobiol & Diagnost Invest, E Lansing, MI 48824 USA; [Pestka, James J.] Michigan State Univ, Dept Microbiol & Mol Genet, E Lansing, MI 48824 USA; [Rajasinghe, Lichchavi D.] AstraZeneca, Gaithersburg, MD USA	Michigan State University; Michigan State University; Utah System of Higher Education; Utah State University; Michigan State University; Michigan State University; Michigan State University; AstraZeneca	Pestka, JJ (corresponding author), Michigan State Univ, Dept Food Sci & Human Nutr, E Lansing, MI 48824 USA.; Pestka, JJ (corresponding author), Michigan State Univ, Inst Integrat Toxicol, E Lansing, MI 48824 USA.; Pestka, JJ (corresponding author), Michigan State Univ, Dept Microbiol & Mol Genet, E Lansing, MI 48824 USA.	pestka@msu.edu		Benninghoff, Abby/0000-0002-7993-0117				Agostoni C, 2014, EFSA J, V12, DOI 10.2903/j.efsa.2014.3843; Akbar U, 2017, JCR-J CLIN RHEUMATOL, V23, P330, DOI 10.1097/RHU.0000000000000563; An JN, 2019, J IMMUNOL RES, V2019, DOI 10.1155/2019/1780567; Baker EJ, 2018, MOL ASPECTS MED, V64, P169, DOI 10.1016/j.mam.2018.08.002; Barnes H, 2019, RESPIROLOGY, V24, P1165, DOI 10.1111/resp.13695; Basta F, 2020, RHEUMATOL THER, V7, P433, DOI 10.1007/s40744-020-00212-9; Bates MA, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02002; Bates MA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160622; Bates MA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125481; Bellan M, 2021, CLIN EXP RHEUMATOL, V39, P132, DOI 10.55563/clinexprheumatol/xyylza; Benninghoff AD, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02851; Bhattacharya A, 2003, J AM COLL NUTR, V22, P388, DOI 10.1080/07315724.2003.10719322; Brown Jared M, 2005, J Immunotoxicol, V1, P177, DOI 10.1080/15476910490911922; Brown JM, 2004, INHAL TOXICOL, V16, P133, DOI 10.1080/08958370490270936; Brown JM, 2003, CLIN EXP IMMUNOL, V131, P415, DOI 10.1046/j.1365-2249.2003.02094.x; Calder PC, 2017, BIOCHEM SOC T, V45, P1105, DOI 10.1042/BST20160474; Carrasco E, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00769; Chang HY, 2015, LIFE SCI, V120, P39, DOI 10.1016/j.lfs.2014.10.014; Charoenwoodhipong P, 2020, ARTHRIT CARE RES, V72, P874, DOI 10.1002/acr.23925; Chauhan PS, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.635138; Christie WW, 2020, ESSAYS BIOCHEM, V64, P401, DOI 10.1042/EBC20190082; Clark A, 2017, J IMMUNOL, V198; Duarte-Garcia A, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102688; Duvall MG, 2016, EUR J PHARMACOL, V785, P144, DOI 10.1016/j.ejphar.2015.11.001; Ferreira HB, 2019, J PHARMACEUT BIOMED, V174, P386, DOI 10.1016/j.jpba.2019.06.005; Flores-Mendoza G, 2018, TRENDS MOL MED, V24, P364, DOI 10.1016/j.molmed.2018.02.003; Foster MH, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02336; Gao XM, 2019, EXP PHYSIOL, V104, P1562, DOI 10.1113/EP087515; Goules A, 2006, J AUTOIMMUN, V26, P165, DOI 10.1016/j.jaut.2006.02.002; Grytting VS, 2021, PART FIBRE TOXICOL, V18, DOI 10.1186/s12989-021-00409-y; Halade GV, 2013, EXP BIOL MED, V238, P610, DOI 10.1177/1535370213489485; Halade GV, 2010, J IMMUNOL, V184, P5280, DOI 10.4049/jimmunol.0903282; Harris WS, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22370-2; Harris WS, 2018, J CLIN LIPIDOL, V12, P718, DOI 10.1016/j.jacl.2018.02.010; Herseth JI, 2008, HUM EXP TOXICOL, V27, P387, DOI 10.1177/0960327108094610; Ivetic A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01068; Jolly CA, 2001, J NUTR, V131, P2753, DOI 10.1093/jn/131.10.2753; Karin N, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00976; Kawasaki H, 2015, INHAL TOXICOL, V27, P363, DOI 10.3109/08958378.2015.1066905; Kruger P, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004651; Kuryliszyn-Moskal A, 2005, CLIN RHEUMATOL, V24, P111, DOI 10.1007/s10067-004-0987-3; Lands B, 2018, PROSTAG LEUKOTR ESS, V136, P15, DOI 10.1016/j.plefa.2017.01.012; Li SM, 2020, TOXICOL APPL PHARM, V408, DOI 10.1016/j.taap.2020.115255; Li XX, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02241; Li XZ, 2013, FASEB J, V27, P4987, DOI 10.1096/fj.13-235333; Lim BO, 2000, J NUTR, V130, P1657, DOI 10.1093/jn/130.7.1657; Liphaus BL, 2017, CLIN RHEUMATOL, V36, P2847, DOI 10.1007/s10067-017-3615-8; Liu J, 2017, PROG MOL BIOL TRANSL, V148, P355, DOI 10.1016/bs.pmbts.2017.04.003; Lub-de Hooge MN, 2005, ANN RHEUM DIS, V64, P854, DOI 10.1136/ard.2004.029058; Metsalu T, 2015, NUCLEIC ACIDS RES, V43, pW566, DOI 10.1093/nar/gkv468; Morotti A, 2021, RHEUMATOLOGY, V60, P81, DOI 10.1093/rheumatology/keaa444; Moulton VR, 2017, TRENDS MOL MED, V23, P615, DOI 10.1016/j.molmed.2017.05.006; Nakatani K, 2013, IMMUN INFLAMM DIS, V1, P37, DOI 10.1002/iid3.6; Norris PC, 2014, P NATL ACAD SCI USA, V111, P12746, DOI 10.1073/pnas.1404372111; Norris PC, 2012, P NATL ACAD SCI USA, V109, P8517, DOI 10.1073/pnas.1200189109; Nyberg F, 1999, ADV EXP MED BIOL, V455, P153; Parks CG, 2002, ARTHRITIS RHEUM-US, V46, P1840, DOI 10.1002/art.10368; Parks CG, 2017, BEST PRACT RES CL RH, V31, P306, DOI 10.1016/j.berh.2017.09.005; Patel M, 2016, LUPUS, V25, P1040, DOI 10.1177/0961203316631634; Pestka JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100255; Pollard KM, 2021, ANNU REV PHARMACOL, V61, P135, DOI 10.1146/annurev-pharmtox-031320-111453; Pollard KM, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00097; Pons-Estel GJ, 2017, EXPERT REV CLIN IMMU, V13, P799, DOI 10.1080/1744666X.2017.1327352; Qidwai T, 2016, IMMUNOL LETT, V176, P128, DOI 10.1016/j.imlet.2016.05.018; Rajasinghe LD, 2020, AUTOIMMUNITY, V53, P415, DOI 10.1080/08916934.2020.1801651; Ramos-Casals M, 2001, RHEUMATOLOGY, V40, P1056, DOI 10.1093/rheumatology/40.9.1056; Ricote M, 2007, BBA-MOL CELL BIOL L, V1771, P926, DOI 10.1016/j.bbalip.2007.02.013; ROBINSON DR, 1986, ARTHRITIS RHEUM, V29, P539, DOI 10.1002/art.1780290412; ROBINSON DR, 1993, J LIPID RES, V34, P1423; Rodgers GP, 2020, JAMA-J AM MED ASSOC, V324, P735, DOI 10.1001/jama.2020.13601; Russell AI, 2005, GENES IMMUN, V6, P422, DOI 10.1038/sj.gene.6364222; Saeed Amal M, 2016, Egypt J Immunol, V23, P75; Sarafi MN, 1997, J EXP MED, V185, P99, DOI 10.1084/jem.185.1.99; Scapini P, 2001, EUR J IMMUNOL, V31, P1981, DOI 10.1002/1521-4141(200107)31:7<1981::AID-IMMU1981>3.3.CO;2-O; Sfikakis PP, 1999, CLIN RHEUMATOL, V18, P28, DOI 10.1007/s100670050047; Silva M, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01878; Simoes IT, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2019-000172; Skuland T, 2020, PART FIBRE TOXICOL, V17, DOI 10.1186/s12989-020-00345-3; SVETIC A, 1991, J IMMUNOL, V147, P2391; Wierenga KA, 2019, TOXICOL PATHOL, V47, P1004, DOI 10.1177/0192623319878398; Wong SW, 2009, J BIOL CHEM, V284, P27384, DOI 10.1074/jbc.M109.044065; Yan YQ, 2013, IMMUNITY, V38, P1154, DOI 10.1016/j.immuni.2013.05.015; Zhang BN, 2019, CURR MED SCI, V39, P551, DOI 10.1007/s11596-019-2073-8	83	0	0	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 21	2022	12								781446	10.3389/fimmu.2021.781446	http://dx.doi.org/10.3389/fimmu.2021.781446			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YT3BM	35126352	Green Published, gold			2022-12-18	WOS:000751239000001
J	Wang, YA; Guan, Y; Hu, Y; Li, Y; Lu, N; Zhang, C				Wang, Yanan; Guan, Yun; Hu, Yuan; Li, Yan; Lu, Nan; Zhang, Cai			Murine CXCR3(+)CXCR6(+)gamma delta T Cells Reside in the Liver and Provide Protection Against HBV Infection	FRONTIERS IN IMMUNOLOGY			English	Article						liver; gamma delta T cells; residency; liver-resident gamma delta T cells; chemotaxis; HBV infection	DELTA-T-CELLS; GAMMA-DELTA; FUNCTIONAL PLASTICITY; NK CELLS; SURVEILLANCE; DEFENSE; THYMUS; LINE	Gamma delta (gamma delta) T cells play a key role in the innate immune response and serve as the first line of defense against infection and tumors. These cells are defined as tissue-resident lymphocytes in skin, lung, and intestinal mucosa. They are also relatively abundant in the liver; however, little is known about the residency of hepatic gamma delta T cells. By comparing the phenotype of murine gamma delta T cells in liver, spleen, thymus, and small intestine, a CXCR3(+)CXCR6(+) gamma delta T-cell subset with tissue-resident characteristics was found in liver tissue from embryos through adults. Liver sinusoidal endothelial cells mediated retention of CXCR3(+)CXCR6(+) gamma delta T cells through the interactions between CXCR3 and CXCR6 and their chemokines. During acute HBV infection, CXCR3(+)CXCR6(+) gamma delta T cells produced high levels of IFN-gamma and adoptive transfer of CXCR3(+)CXCR6(+) gamma delta T cells into acute HBV-infected TCR delta(-/-) mice leading to lower HBsAg and HBeAg expression. It is suggested that liver resident CXCR3(+)CXCR6(+) gamma delta T cells play a protective role during acute HBV infection. Strategies aimed at expanding and activating liver resident CXCR3(+)CXCR6(+) gamma delta T cells both in vivo or in vitro have great prospects for use in immunotherapy that specifically targets acute HBV infection.	[Wang, Yanan; Guan, Yun; Hu, Yuan; Zhang, Cai] Shandong Univ, Inst Immunopharmaceut Sci, Cheeloo Coll Med, Sch Pharmaceut Sci, Jinan, Peoples R China; [Guan, Yun] Jining 1 Peoples Hosp, Jining, Peoples R China; [Li, Yan] Shandong Normal Univ, Inst Biomed Sci, Coll Life Sci, Jinan, Peoples R China; [Lu, Nan] Shandong Univ, Inst Diagnost, Cheeloo Coll Med, Sch Med, Jinan, Peoples R China	Shandong University; Shandong Normal University; Shandong University	Zhang, C (corresponding author), Shandong Univ, Inst Immunopharmaceut Sci, Cheeloo Coll Med, Sch Pharmaceut Sci, Jinan, Peoples R China.; Lu, N (corresponding author), Shandong Univ, Inst Diagnost, Cheeloo Coll Med, Sch Med, Jinan, Peoples R China.	lunan@sdu.edu.cn; caizhangsd@sdu.edu.cn			National Natural Science Foundation of China [91842305, 81771686]; Shandong Provincial Natural Science Foundation [ZR2020MH260]; Shandong Provincial Key Research and Development Program (Major Scientific and Technological Innovation Project) [2019JZZY021013]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shandong Provincial Natural Science Foundation(Natural Science Foundation of Shandong Province); Shandong Provincial Key Research and Development Program (Major Scientific and Technological Innovation Project)	This work was supported by grants from the National Natural Science Foundation of China (91842305, 81771686), the Shandong Provincial Natural Science Foundation (ZR2020MH260), and the Shandong Provincial Key Research and Development Program (Major Scientific and Technological Innovation Project) (2019JZZY021013).	Bai L, 2021, SCIENCE, V371, P1332, DOI 10.1126/science.aba4177; Brownlie D, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2016580118; Carding SR, 2002, NAT REV IMMUNOL, V2, P336, DOI 10.1038/nri797; Chang KM, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007715; Chang L, 2020, EXP THER MED, V19, P67, DOI 10.3892/etm.2019.8197; Chen YY, 2021, CELL MOL IMMUNOL, V18, P57, DOI 10.1038/s41423-020-00561-z; Cheng M, 2017, IMMUNOLOGY, V151, P375, DOI 10.1111/imm.12764; Chien YH, 2014, ANNU REV IMMUNOL, V32, P121, DOI 10.1146/annurev-immunol-032713-120216; Crane GM, 2017, NAT REV IMMUNOL, V17, P573, DOI 10.1038/nri.2017.53; Davis ASW, 2015, J IMMUNOL, V194, P2260, DOI 10.4049/jimmunol.1402438; Duan YY, 2021, CELL MOL IMMUNOL, V18, P1934, DOI 10.1038/s41423-020-0499-3; Dudek M, 2021, NATURE, V592, DOI 10.1038/s41586-021-03233-8; Fan X, 2016, CELL, V164, P1198, DOI 10.1016/j.cell.2016.02.048; Feng DC, 2021, CELL MOL IMMUNOL, V18, P1, DOI 10.1038/s41423-020-00607-2; Fernandez-Ruiz D, 2016, IMMUNITY, V45, P889, DOI 10.1016/j.immuni.2016.08.011; Gao B, 2008, HEPATOLOGY, V47, P729, DOI 10.1002/hep.22034; Gehring AJ, 2019, GASTROENTEROLOGY, V156, P325, DOI 10.1053/j.gastro.2018.10.032; Geissmann F, 2005, PLOS BIOL, V3, P650, DOI 10.1371/journal.pbio.0030113; Harmon C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01502; Hayday AC, 2019, J IMMUNOL, V203, P311, DOI 10.4049/jimmunol.1800934; Hess LU, 2020, HEPATOL COMMUN, V4, P409, DOI 10.1002/hep4.1463; Holz LE, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.aaz8035; Hu Y, 2021, CELL MOL IMMUNOL, V18, P954, DOI 10.1038/s41423-021-00656-1; Hudspeth K, 2016, J AUTOIMMUN, V66, P40, DOI 10.1016/j.jaut.2015.08.011; Hunter S, 2018, J HEPATOL, V69, P654, DOI 10.1016/j.jhep.2018.05.007; Kabelitz D, 2020, CELL MOL IMMUNOL, V17, P925, DOI 10.1038/s41423-020-0504-x; Kamran P, 2013, JOVE-J VIS EXP, DOI 10.3791/50556; Khairallah C, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02636; Kotton DN, 2005, BLOOD, V106, P1574, DOI 10.1182/blood-2005-03-1017; Kubes P, 2018, ANNU REV IMMUNOL, V36, P247, DOI 10.1146/annurev-immunol-051116-052415; Laky K, 2000, J EXP MED, V191, P1569, DOI 10.1084/jem.191.9.1569; Li FL, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms13839; Li H, 2013, CELL MOL IMMUNOL, V10, P159, DOI 10.1038/cmi.2012.70; Li Y, 2017, J IMMUNOL, V199, P761, DOI 10.4049/jimmunol.1601416; Li ZY, 2012, INFECT IMMUN, V80, P565, DOI 10.1128/IAI.05078-11; Liu YX, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9051206; Lo Presti E, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01401; Losurdo G, 2021, CELL MOL IMMUNOL, V18, P1620, DOI 10.1038/s41423-020-00614-3; Mackay LK, 2017, TRENDS IMMUNOL, V38, P94, DOI 10.1016/j.it.2016.11.004; Marra F, 2014, GASTROENTEROLOGY, V147, P577, DOI 10.1053/j.gastro.2014.06.043; Meng DP, 2019, STEM CELLS INT, V2019, DOI 10.1155/2019/4848279; Meng ZJ, 2020, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.03127; Nielsen MM, 2017, NAT REV IMMUNOL, V17, P733, DOI 10.1038/nri.2017.101; Nonaka S, 2005, J IMMUNOL, V174, P1906, DOI 10.4049/jimmunol.174.4.1906; Oida T, 2000, J IMMUNOL, V164, P3616, DOI 10.4049/jimmunol.164.7.3616; Paul S, 2014, INT REV IMMUNOL, V33, P537, DOI 10.3109/08830185.2013.863306; Peng H, 2016, SCI CHINA LIFE SCI, V59, P1218, DOI 10.1007/s11427-016-0334-2; Peng H, 2013, J CLIN INVEST, V123, P1444, DOI 10.1172/JCI66381; Qin YH, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287-019-1311-0; Ribot JC, 2009, NAT IMMUNOL, V10, P427, DOI 10.1038/ni.1717; Romagnoli PA, 2016, P NATL ACAD SCI USA, V113, P8502, DOI 10.1073/pnas.1600713113; Ruf B, 2021, CELL MOL IMMUNOL, V18, P112, DOI 10.1038/s41423-020-00572-w; Sebestyen Z, 2020, NAT REV DRUG DISCOV, V19, P169, DOI 10.1038/s41573-019-0038-z; Shetty S, 2018, NAT REV GASTRO HEPAT, V15, P555, DOI 10.1038/s41575-018-0020-y; Shibata K, 2008, J IMMUNOL, V181, P5940, DOI 10.4049/jimmunol.181.9.5940; Sun HY, 2019, CELL MOL IMMUNOL, V16, P205, DOI 10.1038/s41423-018-0192-y; Sung CC, 2021, CELL MOL IMMUNOL, V18, P1772, DOI 10.1038/s41423-020-0376-0; Swadling L, 2020, J HEPATOL, V72, P1049, DOI 10.1016/j.jhep.2020.02.001; Thomas SY, 2011, J EXP MED, V208, P1179, DOI 10.1084/jem.20102630; Tramonti D, 2008, J PATHOL, V216, P262, DOI 10.1002/path.2412; Wada I, 2014, CANCER MED-US, V3, P362, DOI 10.1002/cam4.196; Wang XQ, 2012, HEPATOLOGY, V56, P1557, DOI 10.1002/hep.25820; Wang YN, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01582; Wu B, 2021, CELL MOL IMMUNOL, V18, P2410, DOI 10.1038/s41423-020-0495-7; Xie XH, 2021, CELL MOL IMMUNOL, V18, P2572, DOI 10.1038/s41423-021-00769-7; Xu Y, 2021, CELL MOL IMMUNOL, V18, P427, DOI 10.1038/s41423-020-0515-7; Yano T, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186997; Zhang C, 2021, CELL MOL IMMUNOL, V18, P2083, DOI 10.1038/s41423-021-00732-6; Zhao JJ, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0157-z; Zheng MJ, 2016, J IMMUNOL, V196, P4122, DOI 10.4049/jimmunol.1500846	70	0	0	5	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 21	2022	12								757379	10.3389/fimmu.2021.757379	http://dx.doi.org/10.3389/fimmu.2021.757379			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YU1YP	35126348	Green Published, gold			2022-12-18	WOS:000751845200001
J	Kerntke, C; Nimmerjahn, F; Biburger, M				Kerntke, Christina; Nimmerjahn, Falk; Biburger, Markus			There Is (Scientific) Strength in Numbers: A Comprehensive Quantitation of Fc Gamma Receptor Numbers on Human and Murine Peripheral Blood Leukocytes (vol 11, 118, 2020)	FRONTIERS IN IMMUNOLOGY			English	Correction						Fc receptors; antibodies; human leukocytes; murine leukocytes; quantification; receptor numbers; neutrophils; monocytes			[Kerntke, Christina; Nimmerjahn, Falk; Biburger, Markus] Friedrich Alexander Univ Erlangen Nurnberg, Div Genet, Dept Biol, Erlangen, Germany; [Nimmerjahn, Falk; Biburger, Markus] Friedrich Alexander Univ Erlangen Nurnberg, Med Immunol Campus Erlangen, Erlangen, Germany	University of Erlangen Nuremberg; University of Erlangen Nuremberg	Nimmerjahn, F; Biburger, M (corresponding author), Friedrich Alexander Univ Erlangen Nurnberg, Div Genet, Dept Biol, Erlangen, Germany.; Nimmerjahn, F; Biburger, M (corresponding author), Friedrich Alexander Univ Erlangen Nurnberg, Med Immunol Campus Erlangen, Erlangen, Germany.	falk.nimmerjahn@fau.de; markus.biburger@fau.de							0	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 20	2022	12								840026	10.3389/fimmu.2021.840026	http://dx.doi.org/10.3389/fimmu.2021.840026			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YS7WN	35126386	Green Published, gold			2022-12-18	WOS:000750884000001
J	Liu, PP; Kuang, YH; Ye, L; Peng, C; Chen, WQ; Shen, MX; Zhang, M; Zhu, W; Lv, CZ; Chen, X				Liu, Panpan; Kuang, Yehong; Ye, Li; Peng, Cong; Chen, Wangqing; Shen, Minxue; Zhang, Mi; Zhu, Wu; Lv, Chengzhi; Chen, Xiang			Predicting the Risk of Psoriatic Arthritis in Plaque Psoriasis Patients: Development and Assessment of a New Predictive Nomogram	FRONTIERS IN IMMUNOLOGY			English	Article						psoriasis; psoriatic arthritis; predictive model; nomogram; nail involvement	NAIL; PATHOGENESIS; ASSOCIATION; ULTRASOUND; SMOKING; DISEASE; OBESITY; DELAY; INDEX	ObjectiveThis study aimed to develop a risk of psoriatic arthritis (PsA) predictive model for plaque psoriasis patients based on the available features. MethodsPatients with plaque psoriasis or PsA were recruited. The characteristics, skin lesions, and nail clinical manifestations of the patients have been collected. The least absolute shrinkage was used to optimize feature selection, and logistic regression analysis was applied to further select features and build a PsA risk predictive model. Calibration, discrimination, and clinical utility of the prediction model were evaluated by using the calibration plot, C-index, the area under the curve (AUC), and decision curve analysis. Internal validation was performed using bootstrapping validation. The model was subjected to external validation with two separate cohorts. ResultsAge at onset, duration, nail involvement, erythematous lunula, onychorrhexis, oil drop, and subungual hyperkeratosis were presented as predictors to perform the prediction nomogram. The predictive model showed good calibration and discrimination (C-index: 0.759; 95% CI: 0.707-0.811). The AUC of this prediction model was 0.7578092. Excellent performances of the C-index were reached in the internal validation and external cohort validation (0.741, 0.844, and 0.845). The decision curve indicated good effect of the PsA nomogram in guiding clinical practice. ConclusionThis novel PsA nomogram could assess the risk of PsA in plaque psoriasis patients with good efficiency.	[Liu, Panpan; Kuang, Yehong; Peng, Cong; Chen, Wangqing; Shen, Minxue; Zhang, Mi; Zhu, Wu; Chen, Xiang] Cent South Univ, Xiangya Hosp, Dept Dermatol, Changsha, Peoples R China; [Liu, Panpan; Kuang, Yehong; Peng, Cong; Chen, Wangqing; Shen, Minxue; Zhang, Mi; Zhu, Wu; Chen, Xiang] Hunan Key Lab Skin Canc & Psoriasis, Changsha, Peoples R China; [Liu, Panpan; Kuang, Yehong; Peng, Cong; Chen, Wangqing; Shen, Minxue; Zhang, Mi; Zhu, Wu; Chen, Xiang] Hunan Engn Res Ctr Skin Hlth & Dis, Changsha, Peoples R China; [Ye, Li; Lv, Chengzhi] Dalian Dermatosis Hosp, Dalian, Peoples R China; [Zhu, Wu; Chen, Xiang] Cent South Univ, Gerontol Ctr Xiangya Hosp, Changsha, Peoples R China	Central South University; Central South University	Zhu, W; Chen, X (corresponding author), Cent South Univ, Xiangya Hosp, Dept Dermatol, Changsha, Peoples R China.; Zhu, W; Chen, X (corresponding author), Hunan Key Lab Skin Canc & Psoriasis, Changsha, Peoples R China.; Zhu, W; Chen, X (corresponding author), Hunan Engn Res Ctr Skin Hlth & Dis, Changsha, Peoples R China.; Lv, CZ (corresponding author), Dalian Dermatosis Hosp, Dalian, Peoples R China.; Zhu, W; Chen, X (corresponding author), Cent South Univ, Gerontol Ctr Xiangya Hosp, Changsha, Peoples R China.	zhuwu70@hotmail.com; dlpfb@126.com; chenxiangck@126.com	Shen, Minxue/P-5140-2019	Shen, Minxue/0000-0003-0441-9303				ACHTEN G, 1983, INT J DERMATOL, V22, P556, DOI 10.1111/j.1365-4362.1983.tb02124.x; Aydin SZ, 2017, CLIN EXP RHEUMATOL, V35, P872; Aydin SZ, 2013, DERMATOLOGY, V227, P45, DOI 10.1159/000351702; Boehncke WH, 2015, LANCET, V386, P983, DOI 10.1016/S0140-6736(14)61909-7; Castellanos-Gonzalez M, 2016, J DTSCH DERMATOL GES, V14, DOI 10.1111/ddg.12989; Chandran V, 2009, ANN RHEUM DIS, V68, P664, DOI 10.1136/ard.2008.089367; Eder L, 2016, ARTHRITIS RHEUMATOL, V68, P915, DOI 10.1002/art.39494; Eder L, 2012, ANN RHEUM DIS, V71, P219, DOI 10.1136/ard.2010.147793; Egeberg A, 2018, ACTA DERM-VENEREOL, V98, P546, DOI 10.2340/00015555-2912; Gladman DD, 2011, ANN RHEUM DIS, V70, P2152, DOI 10.1136/ard.2011.150938; Green A, 2020, BRIT J DERMATOL, V182, P714, DOI 10.1111/bjd.18227; Griffiths CEM, 2007, LANCET, V370, P263, DOI 10.1016/S0140-6736(07)61128-3; Haroon M, 2015, ANN RHEUM DIS, V74, P1045, DOI 10.1136/annrheumdis-2013-204858; Hijazi Z, 2016, LANCET, V387, P2302, DOI 10.1016/S0140-6736(16)00741-8; Huang YQ, 2016, J CLIN ONCOL, V34, P2157, DOI 10.1200/JCO.2015.65.9128; Iasonos A, 2008, J CLIN ONCOL, V26, P1364, DOI 10.1200/JCO.2007.12.9791; Jha S, 2019, RHEUMATOLOGY, V58, P2250, DOI 10.1093/rheumatology/kez183; Jiaravuthisan MM, 2007, J AM ACAD DERMATOL, V57, P1, DOI 10.1016/j.jaad.2005.07.073; Lee S, 2016, J R STAT SOC B, V78, P193, DOI 10.1111/rssb.12108; Li WQ, 2012, ANN RHEUM DIS, V71, P1267, DOI 10.1136/annrheumdis-2011-201273; McArdle A, 2018, CLIN REV ALLERG IMMU, V55, P271, DOI 10.1007/s12016-017-8630-7; Pencina MJ, 2004, STAT MED, V23, P2109, DOI 10.1002/sim.1802; Pittam B, 2020, RHEUMATOLOGY, V59, P2199, DOI 10.1093/rheumatology/keaa062; Reich K, 2009, BRIT J DERMATOL, V160, P1040, DOI 10.1111/j.1365-2133.2008.09023.x; Ritchlin CT, 2017, NEW ENGL J MED, V376, P957, DOI 10.1056/NEJMra1505557; Robinson A, 2012, J AM ACAD DERMATOL, V66, P369, DOI 10.1016/j.jaad.2011.01.022; Rouzaud M, 2014, J EUR ACAD DERMATOL, V28, P17, DOI 10.1111/jdv.12562; Sauerbrei W, 2007, STAT MED, V26, P5512, DOI 10.1002/sim.3148; Scher JU, 2019, NAT REV RHEUMATOL, V15, P153, DOI 10.1038/s41584-019-0175-0; Simon D, 2022, ARTHRITIS RHEUMATOL, V74, P253, DOI 10.1002/art.41239; Solmaz D, 2020, ARTHRIT CARE RES, V72, P63, DOI 10.1002/acr.23836; Soltani-Arabshahi R, 2010, ARCH DERMATOL, V146, P721, DOI 10.1001/archdermatol.2010.141; Song PG, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-41986-5; Stuart PE, 2015, AM J HUM GENET, V97, P816, DOI 10.1016/j.ajhg.2015.10.019; Tan AL, 2007, RHEUMATOLOGY, V46, P253, DOI 10.1093/rheumatology/kel214; Tey HL, 2010, J DERMATOL, V37, P426, DOI 10.1111/j.1346-8138.2009.00745.x; THAM S N, 1988, Annals Academy of Medicine Singapore, V17, P482; Theander E, 2014, ANN RHEUM DIS, V73, P407, DOI 10.1136/annrheumdis-2012-201972; Tillett W, 2013, ANN RHEUM DIS, V72, P1358, DOI 10.1136/annrheumdis-2012-202608; Tsuruta N, 2017, J DERMATOL, V44, P1349, DOI 10.1111/1346-8138.13968; Van den Bosch F, 2018, LANCET, V391, P2285, DOI 10.1016/S0140-6736(18)30949-8; Veale DJ, 2018, LANCET, V391, P2273, DOI 10.1016/S0140-6736(18)30830-4; Wu J, 2020, CANCER COMMUN, V40, P301, DOI 10.1002/cac2.12067; Yan D, 2018, DERMATOLOGY THER, V8, P593, DOI 10.1007/s13555-018-0266-x; Yang Q, 2011, J EUR ACAD DERMATOL, V25, P1409, DOI 10.1111/j.1468-3083.2011.03985.x; ZAIAS N, 1969, ARCH DERMATOL, V99, P567, DOI 10.1001/archderm.99.5.567; Zenke Y, 2017, J AM ACAD DERMATOL, V77, P863, DOI 10.1016/j.jaad.2017.04.001; Zhou BF, 2002, BIOMED ENVIRON SCI, V15, P83	48	0	0	3	12	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 20	2022	12								740968	10.3389/fimmu.2021.740968	http://dx.doi.org/10.3389/fimmu.2021.740968			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YS3MH	35126345	Green Published, gold			2022-12-18	WOS:000750583900001
J	Tian, YX; Huang, BQ; Li, J; Tian, XP; Zeng, XF				Tian, Yixiao; Huang, Biqing; Li, Jing; Tian, Xinping; Zeng, Xiaofeng			Identification of the Association Between Toll-Like Receptors and T-Cell Activation in Takayasu's Arteritis	FRONTIERS IN IMMUNOLOGY			English	Article						T-cell activation; Toll-like receptor; Takayasu's arteritis; disease activity; co-stimulatory molecule; immune checkpoint; biomarker; miRNA; microRNA	DENDRITIC CELLS; GENE-CLUSTER; MURINE MODEL; EXPRESSION; COEXPRESSION; CANCER; INFLAMMATION; RESPONSES; NETWORKS; UNC93B1	To explore the relationships between Toll-like receptors (TLRs) and the activation and differentiation of T-cells in Takayasu's arteritis (TAK), using real-time fluorescence quantitative polymerase chain reaction, mRNA abundance of 29 target genes in peripheral blood mononuclear cells (PBMCs) were detected from 27 TAK patients and 10 healthy controls. Compared with the healthy control group, the untreated TAK group and the treated TAK group had an increased mRNA level of TLR2 and TLR4. A sample-to-sample matrix revealed that 80% of healthy controls could be separated from the TAK patients. Correlation analysis showed that the inactive-treated TAK group exhibited a unique pattern of inverse correlations between the TLRs gene clusters (including TLR1/2/4/6/8, BCL6, TIGIT, NR4A1, etc) and the gene cluster associated with T-cell activation and differentiation (including TCR, CD28, T-bet, GATA3, FOXP3, CCL5, etc). The dynamic gene co-expression network indicated the TAK groups had more active communication between TLRs and T-cell activation than healthy controls. BCL6, CCL5, FOXP3, GATA3, CD28, T-bet, TIGIT, I kappa B alpha, and NR4A1 were likely to have a close functional relation with TLRs at the inactive stage. The co-expression of TLR4 and TLR6 could serve as a biomarker of disease activity in treated TAK (the area under curve/sensitivity/specificity, 0.919/100%/90.9%). The largest gene co-expression cluster of the inactive-treated TAK group was associated with TLR signaling pathways, while the largest gene co-expression cluster of the active-treated TAK group was associated with the activation and differentiation of T-cells. The miRNA sequencing of the plasma exosomes combining miRDB, DIANA-TarBase, and miRTarBase databases suggested that the miR-548 family miR-584, miR-3613, and miR-335 might play an important role in the cross-talk between TLRs and T-cells at the inactive stage. This study found a novel relation between TLRs and T-cell in the pathogenesis of autoimmune diseases, proposed a new concept of TLR-co-expression signature which might distinguish different disease activity of TAK, and highlighted the miRNA of exosomes in TLR signaling pathway in TAK.	[Tian, Yixiao; Huang, Biqing; Li, Jing; Tian, Xinping; Zeng, Xiaofeng] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp PUMCH, Dept Rheumatol & Clin Immunol, Beijing, Peoples R China; [Tian, Yixiao; Huang, Biqing; Li, Jing; Tian, Xinping; Zeng, Xiaofeng] Minist Sci & Technol, Natl Clin Res Ctr Dermatol & Immunol Dis NCRC DID, Beijing, Peoples R China; [Tian, Yixiao; Huang, Biqing; Li, Jing; Tian, Xinping; Zeng, Xiaofeng] Peking Union Med Coll Hosp PUMCH, State Key Lab Complex Severe & Rare Dis, Beijing, Peoples R China; [Tian, Yixiao; Huang, Biqing; Li, Jing; Tian, Xinping; Zeng, Xiaofeng] Minist Educ, Key Lab Rheumatol & Clin Immunol, Beijing, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College	Li, J; Zeng, XF (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp PUMCH, Dept Rheumatol & Clin Immunol, Beijing, Peoples R China.; Li, J; Zeng, XF (corresponding author), Minist Sci & Technol, Natl Clin Res Ctr Dermatol & Immunol Dis NCRC DID, Beijing, Peoples R China.; Li, J; Zeng, XF (corresponding author), Peking Union Med Coll Hosp PUMCH, State Key Lab Complex Severe & Rare Dis, Beijing, Peoples R China.; Li, J; Zeng, XF (corresponding author), Minist Educ, Key Lab Rheumatol & Clin Immunol, Beijing, Peoples R China.	lijing6515@pumch.cn; xiaofeng.zeng@cstar.org.cn			National Science Foundation of China [81401333]; National Clinical Research Center for Dermatologic and Immunologic Diseases; Chinese National Key Research and Development Program [2017YFC0907600, 2008BAI59B02]; Chinese National High Technology Research and Development Program, Ministry of Science and Technology [2012AA02A513]	National Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Clinical Research Center for Dermatologic and Immunologic Diseases; Chinese National Key Research and Development Program; Chinese National High Technology Research and Development Program, Ministry of Science and Technology(National High Technology Research and Development Program of China)	This study was supported by National Science Foundation of China to JL with (grant numbers 81401333), and XZ with National Clinical Research Center for Dermatologic and Immunologic Diseases, the Chinese National Key Research and Development Program (grant number 2017YFC0907600, 2008BAI59B02) and the Chinese National High Technology Research and Development Program, Ministry of Science and Technology (grant number 2012AA02A513).	Agalave NM, 2014, PAIN, V155, P1802, DOI 10.1016/j.pain.2014.06.007; Andersen CL, 2004, CANCER RES, V64, P5245, DOI 10.1158/0008-5472.CAN-04-0496; Arleevskaya MI, 2020, CLIN REV ALLERG IMMU, V58, P172, DOI 10.1007/s12016-019-08742-z; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Barabasi AL, 2004, NAT REV GENET, V5, P101, DOI 10.1038/nrg1272; Barish GD, 2010, GENE DEV, V24, P2760, DOI 10.1101/gad.1998010; Bateman A, 2015, NUCLEIC ACIDS RES, V43, pD204, DOI 10.1093/nar/gku989; BLOCH DA, 1990, ARTHRITIS RHEUM, V33, P1068; Boccaletti S, 2006, PHYS REP, V424, P175, DOI 10.1016/j.physrep.2005.10.009; Bray D, 2003, SCIENCE, V301, P1864, DOI 10.1126/science.1089118; Butte AJ, 2000, P NATL ACAD SCI USA, V97, P12182, DOI 10.1073/pnas.220392197; Celhar T, 2018, ARTHRITIS RHEUMATOL, V70, P1597, DOI 10.1002/art.40535; Chen JQ, 2016, CLIN REV ALLERG IMMU, V50, P1, DOI 10.1007/s12016-015-8473-z; Chen J, 2019, NATURE, V567, P530, DOI 10.1038/s41586-019-0985-x; Chen YH, 2020, NUCLEIC ACIDS RES, V48, pD127, DOI 10.1093/nar/gkz757; Chodaczek G, 2021, J AUTOIMMUN, V116, DOI 10.1016/j.jaut.2020.102563; Chou CH, 2016, NUCLEIC ACIDS RES, V44, pD239, DOI 10.1093/nar/gkv1258; Christensen SR, 2006, IMMUNITY, V25, P417, DOI 10.1016/j.immuni.2006.07.013; D'haeseleer P, 2000, BIOINFORMATICS, V16, P707, DOI 10.1093/bioinformatics/16.8.707; Sobrinho HMD, 2021, J NEUROSCI RES, V99, P2511, DOI 10.1002/jnr.24916; Deng JS, 2009, CIRC RES, V104, P488, DOI 10.1161/CIRCRESAHA.108.185777; Desbois AC, 2021, ARTHRITIS RHEUMATOL, V73, P1233, DOI 10.1002/art.41672; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Feng XE, 2021, CANCER BIOTHER RADIO, V36, P189, DOI 10.1089/cbr.2019.3507; Figueroa-Hall LK, 2020, PSYCHONEUROENDOCRINO, V121, DOI 10.1016/j.psyneuen.2020.104843; Fillatreau S, 2021, NAT REV RHEUMATOL, V17, P98, DOI 10.1038/s41584-020-00544-4; Fontenot JD, 2017, J IMMUNOL, V198, P986, DOI 10.1038/ni904; Fukui R, 2009, J EXP MED, V206, P1339, DOI 10.1084/jem.20082316; Gao Na, 2020, Clin Exp Rheumatol, V38 Suppl 124, P48; Gong T, 2020, NAT REV IMMUNOL, V20, P95, DOI 10.1038/s41577-019-0215-7; He XB, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/945169; Hellmann DB., 2013, PHILADELPHIA TEXTBOO, VNinth Edition, P1461; Jin MS, 2007, CELL, V130, P1071, DOI 10.1016/j.cell.2007.09.008; Jin MM, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-01697-6; Joosten LAB, 2016, NAT REV RHEUMATOL, V12, P344, DOI 10.1038/nrrheum.2016.61; Kabeerdoss J, 2022, RHEUMATOL INT, V42, P535, DOI 10.1007/s00296-020-04785-0; Kabeerdoss J, 2019, CYTOKINE, V114, P61, DOI 10.1016/j.cyto.2018.11.033; Kalhorzadeh P, 2014, PLANT CELL, V26, P3680, DOI 10.1105/tpc.114.128108; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; Kerr Gail, 1994, Current Opinion in Rheumatology, V6, P32, DOI 10.1097/00002281-199401000-00006; Kumari S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050411; Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-559; Lee HK, 2004, GENOME RES, V14, P1085, DOI 10.1101/gr.1910904; Liang TM, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/679563; Lin L, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/7385426; Liu D, 2021, IMMUNITY, V54, P2245, DOI 10.1016/j.immuni.2021.08.003; Majer O, 2019, NATURE, V575, P366, DOI 10.1038/s41586-019-1612-6; Majer O, 2019, NATURE, V575, P371, DOI 10.1038/s41586-019-1611-7; Mansson A, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-36; Marks KE, 2021, CELL REP, V35, DOI 10.1016/j.celrep.2021.109303; Migita K, 2007, J RHEUMATOL, V34, P493; Miyashita Y, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0219510; Monnet E, 2020, ANN RHEUM DIS, V79, P316, DOI 10.1136/annrheumdis-2019-216487; Mukherjee A, 2021, IMMUNOLOGY, V164, P318, DOI 10.1111/imm.13373; Tran NL, 2015, IMMUNOLOGY, V145, P60, DOI 10.1111/imm.12426; Nickerson KM, 2010, J IMMUNOL, V184, P1840, DOI 10.4049/jimmunol.0902592; Obayashi T, 2009, DNA RES, V16, P249, DOI 10.1093/dnares/dsp016; Oshiumi H, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.685344; Pan LL, 2016, CLIN RHEUMATOL, V35, P3031, DOI 10.1007/s10067-016-3399-2; Pan YZ, 2016, NEUROREPORT, V27, P1266, DOI 10.1097/WNR.0000000000000690; Park HY, 2014, J CLIN INVEST, V124, P4976, DOI 10.1172/JCI75667; Pfaffl MW, 2004, BIOTECHNOL LETT, V26, P509, DOI 10.1023/B:BILE.0000019559.84305.47; Piriyapongsa J, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000203; Prieto C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003911; Proctor RH, 2003, FUNGAL GENET BIOL, V38, P237, DOI 10.1016/S1087-1845(02)00525-X; Qiu HL, 2019, EXP THER MED, V18, P2332, DOI 10.3892/etm.2019.7812; Rio D.C., 2010, COLD SPRING HARB PRO, V2010, ppdb.prot5439, DOI [10.1101/pdb.prot5439, DOI 10.1101/PDB.PROT5439]; Rosenberger CM, 2012, J IMMUNOL, V189, P5965, DOI 10.4049/jimmunol.1201437; Saadoun D, 2015, ARTHRITIS RHEUMATOL, V67, P1353, DOI 10.1002/art.39037; Santiago-Raber ML, 2010, J AUTOIMMUN, V34, P339, DOI 10.1016/j.jaut.2009.11.001; Santos SD, 2014, BRIEF BIOINFORM, V15, P906, DOI 10.1093/bib/bbt051; Sasai M, 2011, IMMUNITY, V35, P3, DOI 10.1016/j.immuni.2011.07.006; Sha MX, 2020, EUR REV MED PHARMACO, V24, P3105, DOI 10.26355/eurrev_202003_20675; Shmuel-Galia L, 2017, J BIOL CHEM, V292, P13415, DOI 10.1074/jbc.M117.784983; Slenter DN, 2018, NUCLEIC ACIDS RES, V46, pD661, DOI 10.1093/nar/gkx1064; Soni C, 2020, IMMUNITY, V52, P1022, DOI 10.1016/j.immuni.2020.04.015; Spitzer JH, 2002, EUR J IMMUNOL, V32, P1182, DOI 10.1002/1521-4141(200204)32:4<1182::AID-IMMU1182>3.0.CO;2-9; Stewart CR, 2010, NAT IMMUNOL, V11, P155, DOI 10.1038/ni.1836; Sun JL, 2005, JNCI-J NATL CANCER I, V97, P525, DOI 10.1093/jnci/dji070; Suthers AN, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00775; Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI 10.1093/nar/gky1131; Tabeta K, 2006, NAT IMMUNOL, V7, P156, DOI 10.1038/ni1297; Takashima Y, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0229577; Tao K, 2007, ANN RHEUM DIS, V66, P905, DOI 10.1136/ard.2006.065961; Tian YX, 2021, ARTHRITIS RES THER, V23, DOI 10.1186/s13075-021-02636-2; Truong R, 2021, EXPERT REV CLIN IMMU, V17, P37, DOI 10.1080/1744666X.2020.1860757; Tsukamoto H, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2020.101520; van der Houwen TB, 2020, RHEUMATOLOGY, V59, P3971, DOI 10.1093/rheumatology/keaa251; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Vidal M, 2011, CELL, V144, P986, DOI 10.1016/j.cell.2011.02.016; Vlachos IS, 2015, NUCLEIC ACIDS RES, V43, pD153, DOI 10.1093/nar/gku1215; Voboril M, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16081-3; Vollmer J, 2005, J EXP MED, V202, P1575, DOI 10.1084/jem.20051696; Watanabe R, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.587089; Wei SC, 2018, CANCER DISCOV, V8, P1069, DOI 10.1158/2159-8290.CD-18-0367; Wong N, 2015, NUCLEIC ACIDS RES, V43, pD146, DOI 10.1093/nar/gku1104; Wu XB, 2006, ARTHRITIS RHEUM-US, V54, P336, DOI 10.1002/art.21553; Xia LY, 2019, CELL METAB, V29, P103, DOI 10.1016/j.cmet.2018.09.020; Xu Y, 2020, EUR REV MED PHARMACO, V24, P10535, DOI 10.26355/eurrev_202010_23406; Yang S, 2017, NUCLEIC ACIDS RES, V45, pD389, DOI 10.1093/nar/gkw868; Ye J, 2017, J IMMUNOL, V199, P941, DOI 10.4049/jimmunol.1601890; Zeng Z, 2022, GENES DIS, V9, P12, DOI 10.1016/j.gendis.2021.08.004; Zhou T, 1996, J EXP MED, V183, P1879, DOI 10.1084/jem.183.4.1879; Zhou XH, 2002, P NATL ACAD SCI USA, V99, P12783, DOI 10.1073/pnas.192159399; Zhou YY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09234-6	105	0	0	1	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 20	2022	12								792901	10.3389/fimmu.2021.792901	http://dx.doi.org/10.3389/fimmu.2021.792901			27	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YV4DK	35126357	gold, Green Published			2022-12-18	WOS:000752680000001
J	Balam, S; Buchtler, S; Winter, F; Schmidbauer, K; Neumayer, S; Talke, Y; Renner, K; Geissler, EK; Mack, M				Balam, Saidou; Buchtler, Simone; Winter, Frederike; Schmidbauer, Kathrin; Neumayer, Sophia; Talke, Yvonne; Renner, Kerstin; Geissler, Edward K.; Mack, Matthias			Donor-But Not Recipient-Derived Cells Produce Collagen-1 in Chronically Rejected Cardiac Allografts	FRONTIERS IN IMMUNOLOGY			English	Article						transplantation; fibrocytes; collagen-1; allograft fibrosis; chronic rejection	MACROPHAGE ACTIVATION; T-CELLS; EXPRESSION; FIBROSIS; MYOFIBROBLASTS; CONTRIBUTE; CHEMOKINES; HEARTS; CSF-1; MICE	Fibrosis is a prominent feature of chronic allograft rejection, caused by an excessive production of matrix proteins, including collagen-1. Several cell types produce collagen-1, including mesenchymal fibroblasts and cells of hematopoietic origin. Here, we sought to determine whether tissue-resident donor-derived cells or allograft-infiltrating recipient-derived cells are responsible for allograft fibrosis, and whether hematopoietic cells contribute to collagen production. A fully MHC-mismatched mouse heterotopic heart transplantation model was used, with transient depletion of CD4(+) T cells to prevent acute rejection. Collagen-1 was selectively knocked out in recipients or donors. In addition, collagen-1 was specifically deleted in hematopoietic cells. Tissue-resident macrophages were depleted using anti-CSF1R antibody. Allograft fibrosis and inflammation were quantified 20 days post-transplantation. Selective collagen-1 knock-out in recipients or donors showed that tissue-resident cells from donor hearts, but not infiltrating recipient-derived cells, are responsible for production of collagen-1 in allografts. Cell-type-specific knock-out experiments showed that hematopoietic tissue-resident cells in donor hearts substantially contributed to graft fibrosis. Tissue resident macrophages, however, were not responsible for collagen-production, as their deletion worsened allograft fibrosis. Donor-derived cells including those of hematopoietic origin determine allograft fibrosis, making them attractive targets for organ preconditioning to improve long-term transplantation outcomes.	[Balam, Saidou; Buchtler, Simone; Winter, Frederike; Schmidbauer, Kathrin; Neumayer, Sophia; Talke, Yvonne; Renner, Kerstin; Mack, Matthias] Univ Hosp Regensburg, Dept Nephrol, Regensburg, Germany; [Balam, Saidou; Winter, Frederike; Mack, Matthias] Univ Regensburg, Regensburg Ctr Intervent Immunol RCI, Regensburg, Germany; [Geissler, Edward K.] Univ Hosp Regensburg, Dept Surg, Regensburg, Germany	University of Regensburg; University of Regensburg; University of Regensburg	Mack, M (corresponding author), Univ Hosp Regensburg, Dept Nephrol, Regensburg, Germany.; Mack, M (corresponding author), Univ Regensburg, Regensburg Ctr Intervent Immunol RCI, Regensburg, Germany.			BALAM, Dr Saidou/0000-0002-7178-7758	Deutsche Forschungsgemeinschaft [MA2198/9-1]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	Funding This work was supported by a grant from the Deutsche Forschungsgemeinschaft (MA2198/9-1).	Aghajanian H, 2019, NATURE, V573, P430, DOI 10.1038/s41586-019-1546-z; Bachmann M, 2019, PHYSIOL REV, V99, P1655, DOI 10.1152/physrev.00036.2018; Bai B, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007869; Balam S, 2019, J IMMUNOL, V202, P3514, DOI 10.4049/jimmunol.1801269; BARONDES SH, 1994, J BIOL CHEM, V269, P20807; Bhattacharjee A, 2013, FREE RADICAL BIO MED, V54, P1, DOI 10.1016/j.freeradbiomed.2012.10.553; Broekema M, 2007, J AM SOC NEPHROL, V18, P165, DOI 10.1681/ASN.2005070730; Buchtler S, 2018, J AM SOC NEPHROL, V29, P1859, DOI 10.1681/ASN.2018020138; de Boer J, 2003, EUR J IMMUNOL, V33, P314, DOI 10.1002/immu.200310005; Fan D, 2012, FIBROGENESIS TISSUE, V5, DOI 10.1186/1755-1536-5-15; Frangogiannis NG, 2004, INFLAMM RES, V53, P585, DOI 10.1007/s00011-004-1298-5; Frangogiannis NG, 2007, THROMB HAEMOSTASIS, V97, P738, DOI 10.1160/TH07-01-0022; Frangogiannis Nikolaos G, 2016, Curr Pathobiol Rep, V4, P11; Hasegawa T, 2007, NAT PROTOC, V2, P471, DOI 10.1038/nprot.2007.48; Hume DA, 2012, BLOOD, V119, P1810, DOI 10.1182/blood-2011-09-379214; Irvine KM, 2006, FASEB J, V20, P1921, DOI 10.1096/fj.06-5848fje; Kramann R, 2013, J PATHOL, V231, P273, DOI 10.1002/path.4253; Kuppe C, 2021, NATURE, V589, P281, DOI 10.1038/s41586-020-2941-1; LIU FT, 1995, AM J PATHOL, V147, P1016; Liu Yianzhu, 2016, Curr Transplant Rep, V3, P303, DOI 10.1007/s40472-016-0130-9; Mack M, 2001, J IMMUNOL, V166, P4697, DOI 10.4049/jimmunol.166.7.4697; MacKinnon AC, 2008, J IMMUNOL, V180, P2650, DOI 10.4049/jimmunol.180.4.2650; Martinez FO, 2008, FRONT BIOSCI-LANDMRK, V13, P453, DOI 10.2741/2692; Niedermeier M, 2009, P NATL ACAD SCI USA, V106, P17892, DOI 10.1073/pnas.0906070106; Pichler M, 2012, J AM COLL CARDIOL, V59, P1008, DOI 10.1016/j.jacc.2011.11.036; Piera-Velazquez S, 2016, J CLIN MED, V5, DOI 10.3390/jcm5040045; Piera-Velazquez S, 2011, AM J PATHOL, V179, P1074, DOI 10.1016/j.ajpath.2011.06.001; Pollard JW, 2009, NAT REV IMMUNOL, V9, P259, DOI 10.1038/nri2528; Reich B, 2013, KIDNEY INT, V84, P78, DOI 10.1038/ki.2013.84; Sauter KA, 2014, J LEUKOCYTE BIOL, V96, P265, DOI 10.1189/jlb.2A0114-006R; Schiechl G, 2016, AM J TRANSPLANT, V16, P2574, DOI 10.1111/ajt.13764; SCHNIEKE A, 1983, NATURE, V304, P315, DOI 10.1038/304315a0; Sehgal A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03638-6; Sharma UC, 2004, CIRCULATION, V110, P3121, DOI 10.1161/01.CIR.0000147181.65298.4D; Soroosh P, 2013, J EXP MED, V210, P775, DOI 10.1084/jem.20121849; van den Bosch TPP, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00153; Wu C, 2016, AM J TRANSPLANT, V16, P2563, DOI 10.1111/ajt.13808; Wu GD, 2005, J HEART LUNG TRANSPL, V24, P2160, DOI 10.1016/j.healun.2005.05.017; Wu GD, 2003, TRANSPLANTATION, V76, P609, DOI 10.1097/01.TP.0000066362.37931.6D; You Q, 2008, HEPATOLOGY, V48, P978, DOI 10.1002/hep.22395; Zhao Y, 2018, AM J TRANSPLANT, V18, P604, DOI 10.1111/ajt.14543; Zigmond E, 2014, IMMUNITY, V40, P720, DOI 10.1016/j.immuni.2014.03.012	42	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 19	2022	12								816509	10.3389/fimmu.2021.816509	http://dx.doi.org/10.3389/fimmu.2021.816509			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZC5YM	35126373	gold, Green Published			2022-12-18	WOS:000757595300001
J	Hendrawan, K; Khoo, MLM; Visweswaran, M; Massey, JC; Withers, B; Sutton, I; Ma, DDF; Moore, JJ				Hendrawan, Kevin; Khoo, Melissa L. M.; Visweswaran, Malini; Massey, Jennifer C.; Withers, Barbara; Sutton, Ian; Ma, David D. F.; Moore, John J.			Long-Term Suppression of Circulating Proinflammatory Cytokines in Multiple Sclerosis Patients Following Autologous Haematopoietic Stem Cell Transplantation	FRONTIERS IN IMMUNOLOGY			English	Article						cytokines; AHSCT; multiple sclerosis; T helper 17; long-term suppression	BONE-MARROW-TRANSPLANTATION; T-CELLS; CLINICAL-RESPONSE; VIRAL-INFECTIONS; GENE-EXPRESSION; MESSENGER-RNA; TH17 CELLS; TNF-ALPHA; DISEASE; LYMPHOMA	Autologous haematopoietic stem cell transplantation (AHSCT) is a therapeutic option for haematological malignancies, such as non-Hodgkin's lymphoma (NHL), and more recently, for autoimmune diseases, such as treatment-refractory multiple sclerosis (MS). The immunological mechanisms underlying remission in MS patients following AHSCT likely involve an anti-inflammatory shift in the milieu of circulating cytokines. We hypothesised that immunological tolerance in MS patients post-AHSCT is reflected by an increase in anti-inflammatory cytokines and a suppression of proinflammatory cytokines in the patient blood. We investigated this hypothesis using a multiplex-ELISA assay to compare the concentrations of secreted cytokine in the peripheral blood of MS patients and NHL patients undergoing AHSCT. In MS patients, we detected significant reductions in proinflammatory T helper (Th)17 cytokines interleukin (IL)-17, IL-23, IL-1 beta, and IL-21, and Th1 cytokines interferon (IFN)gamma and IL-12p70 in MS patients from day 8 to 24 months post-AHSCT. These changes were not observed in the NHL patients despite similar pre-conditioning treatment for AHSCT. Some proinflammatory cytokines show similar trends in both cohorts, such as IL-8 and tumour necrosis factor (TNF)-alpha, indicating a probable treatment-related AHSCT response. Anti-inflammatory cytokines (IL-10, IL-4, and IL-2) were only transiently reduced post-AHSCT, with only IL-10 exhibiting a significant surge at day 14 post-AHSCT. MS patients that relapsed post-AHSCT exhibited significantly elevated levels of IL-17 at 12 months post-AHSCT, unlike non-relapse patients which displayed sustained suppression of Th17 cytokines at all post-AHSCT timepoints up to 24 months. These findings suggest that suppression of Th17 cytokines is essential for the induction of long-term remission in MS patients following AHSCT.	[Hendrawan, Kevin; Khoo, Melissa L. M.; Visweswaran, Malini; Massey, Jennifer C.; Withers, Barbara; Sutton, Ian; Ma, David D. F.; Moore, John J.] St Vincents Ctr Appl Med Res, Blood Stem Cells & Canc Res Programme, Darlinghurst, NSW, Australia; [Hendrawan, Kevin; Khoo, Melissa L. M.; Visweswaran, Malini; Massey, Jennifer C.; Withers, Barbara; Sutton, Ian; Ma, David D. F.; Moore, John J.] Univ New South Wales, St Vincents Clin Sch, Fac Med, Sydney, NSW, Australia; [Massey, Jennifer C.; Sutton, Ian] St Vincents Hosp, Dept Neurol, Darlinghurst, NSW, Australia; [Massey, Jennifer C.; Withers, Barbara; Ma, David D. F.; Moore, John J.] St Vincents Hosp, Dept Haematol, Darlinghurst, NSW, Australia	University of New South Wales Sydney; St Vincents Hospital Sydney; St Vincents Hospital Sydney	Moore, JJ (corresponding author), St Vincents Ctr Appl Med Res, Blood Stem Cells & Canc Res Programme, Darlinghurst, NSW, Australia.; Moore, JJ (corresponding author), Univ New South Wales, St Vincents Clin Sch, Fac Med, Sydney, NSW, Australia.; Moore, JJ (corresponding author), St Vincents Hosp, Dept Haematol, Darlinghurst, NSW, Australia.	jmoore@stvincents.com.au	Massey, Jennifer/HCI-2064-2022	Hendrawan, Kevin/0000-0002-1549-3130; Visweswaran, Malini/0000-0003-1200-0131; Massey, Jennifer/0000-0002-3238-4630				Abrahamsson SV, 2013, BRAIN, V136, P2888, DOI 10.1093/brain/awt182; Al-Shammri S, 2004, J NEUROL SCI, V222, P21, DOI 10.1016/j.jns.2004.03.027; Alexander T, 2021, ANNU REV MED, V72, P215, DOI 10.1146/annurev-med-070119-115617; Annacker O, 2001, J IMMUNOL, V166, P3008, DOI 10.4049/jimmunol.166.5.3008; Apert C, 2018, PROTEIN CELL, V9, P322, DOI 10.1007/s13238-017-0425-3; Arruda LCM, 2016, CURR RES TRANSL MED, V64, P107, DOI 10.1016/j.retram.2016.03.004; Arruda LCM, 2015, BONE MARROW TRANSPL, V50, P380, DOI 10.1038/bmt.2014.277; Arruda LCM, 2018, BLOOD ADV, V2, P126, DOI 10.1182/bloodadvances.2017011072; Arruda LCM, 2016, CLIN IMMUNOL, V169, P47, DOI 10.1016/j.clim.2016.06.005; Askenasy N, 2008, AUTOIMMUN REV, V7, P370, DOI 10.1016/j.autrev.2008.03.001; Beebe AM, 2002, CYTOKINE GROWTH F R, V13, P403, DOI 10.1016/S1359-6101(02)00025-4; Bower M, 2009, BLOOD, V113, P4521, DOI 10.1182/blood-2008-12-197053; Burt RK, 2019, JAMA-J AM MED ASSOC, V321, P165, DOI 10.1001/jama.2018.18743; Chang JH, 2009, EUR J IMMUNOL, V39, P1241, DOI 10.1002/eji.200838913; Chinen T, 2016, NAT IMMUNOL, V17, P1322, DOI 10.1038/ni.3540; D'Souza A, 2020, BIOL BLOOD MARROW TR, V26, pE177, DOI 10.1016/j.bbmt.2020.04.013; Dreyling M, 2005, BLOOD, V105, P2677, DOI 10.1182/blood-2004-10-3883; Fletcher JM, 2009, J IMMUNOL, V183, P7602, DOI 10.4049/jimmunol.0901881; Fujita A, 2008, J INFECTION, V57, P241, DOI 10.1016/j.jinf.2008.06.014; GAJEWSKI TF, 1988, J IMMUNOL, V140, P4245; Gernert M, 2019, ARTHRITIS RES THER, V21, DOI 10.1186/s13075-019-1889-8; Greco R, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01570; Gu J, 2017, CELL MOL IMMUNOL, V14, P521, DOI 10.1038/cmi.2016.30; Gu YA, 2010, CANCER CAUSE CONTROL, V21, P1323, DOI 10.1007/s10552-010-9560-3; Gutierrez-Murgas YM, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0741-1; Hendrawan K, 2020, BONE MARROW TRANSPL, V55, P857, DOI 10.1038/s41409-019-0710-2; Jackman RP, 2011, CLIN VACCINE IMMUNOL, V18, P318, DOI 10.1128/CVI.00465-10; Jaime-Perez JC, 2020, CLIN TRANSPLANT, V34, DOI 10.1111/ctr.14114; Jamani K, 2019, BIOL BLOOD MARROW TR, V25, P639, DOI 10.1016/j.bbmt.2018.12.065; Jones EA, 2002, LEUKEMIA LYMPHOMA, V43, P1313, DOI 10.1080/10428190290026385; Kato H, 1998, LEUKEMIA LYMPHOMA, V29, P71, DOI 10.3109/10428199809058383; Khaibullin T, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00531; Kim SY, 2010, NAT REV RHEUMATOL, V6, P165, DOI 10.1038/nrrheum.2009.279; Kimura K, 2016, NEUROL-NEUROIMMUNOL, V3, DOI 10.1212/NXI.0000000000000210; Koenen HJPM, 2008, BLOOD, V112, P2340, DOI 10.1182/blood-2008-01-133967; KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444; Lasiglie D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020014; Lassmann H, 2004, TRENDS IMMUNOL, V25, P132, DOI 10.1016/j.it.2004.01.007; Li YF, 2017, MULT SCLER RELAT DIS, V18, P20, DOI 10.1016/j.msard.2017.09.003; LINCH DC, 1993, LANCET, V341, P1051, DOI 10.1016/0140-6736(93)92411-L; Ma A, 2006, ANNU REV IMMUNOL, V24, P657, DOI 10.1146/annurev.immunol.24.021605.090727; Malmegrim KCR, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00167; Massey JC, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00410; Matusevicius D, 1999, MULT SCLER J, V5, P101, DOI 10.1177/135245859900500206; Michel L, 2016, BONE MARROW TRANSPL, V51, P1146, DOI 10.1038/bmt.2016.77; Min CK, 2001, BONE MARROW TRANSPL, V28, P935, DOI 10.1038/sj.bmt.1703258; Moore JJ, 2019, J NEUROL NEUROSUR PS, V90, P514, DOI 10.1136/jnnp-2018-319446; Muraro PA, 2017, NAT REV NEUROL, V13, P391, DOI 10.1038/nrneurol.2017.81; Ng SA, 2019, CURR OPIN HEMATOL, V26, P392, DOI 10.1097/MOH.0000000000000531; Nogai H, 2011, J CLIN ONCOL, V29, P1803, DOI 10.1200/JCO.2010.33.3252; Ozenci V, 2000, CLIN EXP IMMUNOL, V120, P147, DOI 10.1046/j.1365-2249.2000.01175.x; Pappu R, 2012, TRENDS IMMUNOL, V33, P343, DOI 10.1016/j.it.2012.02.008; Passweg JR, 2021, BONE MARROW TRANSPL, V56, P1651, DOI 10.1038/s41409-021-01227-8; PHILIP T, 1995, NEW ENGL J MED, V333, P1540, DOI 10.1056/NEJM199512073332305; Pino-Martinez AM, 2019, J LEUKOCYTE BIOL, V105, P163, DOI 10.1002/JLB.3A0318-111RR; Polman CH, 2011, ANN NEUROL, V69, P292, DOI 10.1002/ana.22366; Rebeiro P, 2016, INTERN MED J, V46, P17, DOI 10.1111/imj.12944; Sasaki K, 2009, J IMMUNOTHER, V32, P793, DOI 10.1097/CJI.0b013e3181acec1e; Seddiki N, 2006, J EXP MED, V203, P1693, DOI 10.1084/jem.20060468; Sekine Y, 1997, J IMMUNOL, V159, P4084; Simon T, 2003, CLIN TRANSPLANT, V17, P217, DOI 10.1034/j.1399-0012.2003.00031.x; Singh RK, 2000, EXP HEMATOL, V28, P499, DOI 10.1016/S0301-472X(00)00145-4; Smith SR, 2001, AM J KIDNEY DIS, V37, P659, DOI 10.1016/S0272-6386(01)80114-1; STASI R, 1995, EUR J HAEMATOL, V54, P9; SWAIN SL, 1990, J IMMUNOL, V145, P3796; Tsai VW, 2018, INT J OBESITY, V42, P561, DOI 10.1038/ijo.2017.258; Valenzuela RM, 2016, J NEUROIMMUNOL, V300, P59, DOI 10.1016/j.jneuroim.2016.06.005; van Boxel-Dezaire AHH, 1999, ANN NEUROL, V45, P695, DOI 10.1002/1531-8249(199906)45:6<695::AID-ANA3>3.0.CO;2-R; van Munster CEP, 2017, CNS DRUGS, V31, P217, DOI 10.1007/s40263-017-0412-5; Visentainer JEL, 2003, EXP HEMATOL, V31, P1044, DOI 10.1016/j.exphem.2003.08.005; Wagner CA, 2020, J EXP MED, V217, DOI 10.1084/jem.20190460; Wagner M, 2004, J IMMUNOL, V172, P954, DOI 10.4049/jimmunol.172.2.954; Wang XS, 2014, CLIN CANCER RES, V20, P1366, DOI 10.1158/1078-0432.CCR-13-2442; WASSERMAN R, 1988, PEDIATR INFECT DIS J, V7, P109, DOI 10.1097/00006454-198802000-00009; Wiberg A, 2020, BIOL BLOOD MARROW TR, V26, P50, DOI 10.1016/j.bbmt.2019.09.010; Willing A, 2018, J IMMUNOL, V200, P974, DOI 10.4049/jimmunol.1701213; Zhang L, 2009, J IMMUNOL, V183, P6346, DOI 10.4049/jimmunol.0901773; Zhang P, 2019, BONE MARROW TRANSPL, V54, P2110, DOI 10.1038/s41409-019-0505-5; Zhou LA, 2007, NAT IMMUNOL, V8, P967, DOI 10.1038/ni1488	79	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 19	2022	12								782935	10.3389/fimmu.2021.782935	http://dx.doi.org/10.3389/fimmu.2021.782935			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YQ6OV	35126353	Green Published, gold			2022-12-18	WOS:000749427700001
J	Polyiam, K; Ruengjitchatchawalya, M; Mekvichitsaeng, P; Kaeoket, K; Hoonsuwan, T; Joiphaeng, P; Roshorm, YM				Polyiam, Kanokporn; Ruengjitchatchawalya, Marasri; Mekvichitsaeng, Phenjun; Kaeoket, Kampon; Hoonsuwan, Tawatchai; Joiphaeng, Pichai; Roshorm, Yaowaluck Maprang			Immunodominant and neutralizing linear B cell epitopes spanning the spike and membrane proteins of Porcine Epidemic Diarrhea Virus	FRONTIERS IN IMMUNOLOGY			English	Article						Porcine Epidemic Diarrhea Virus; spike protein; membrane protein; neutralizing epitope; immunoinformatics; epitope prediction	FUNCTIONAL-CHARACTERIZATION; FUSION PROTEIN; IDENTIFICATION; PREDICTION; ANTIBODIES; INDUCTION; SUBUNIT; DOMAIN	Porcine Epidemic Diarrhea Virus (PEDV) is the causative agent of PED, an enteric disease that causes high mortality rates in piglets. PEDV is an alphacoronavirus that has high genetic diversity. Insights into neutralizing B cell epitopes of all genetically diverse PEDV strains are of importance, particularly for designing a vaccine that can provide broad protection against PEDV. In this work, we aimed to explore the landscape of linear B cell epitopes on the spike (S) and membrane (M) proteins of global PEDV strains. All amino acid sequences of the PEDV S and M proteins were retrieved from the NCBI database and grouped. Immunoinformatics-based methods were next developed and used to identify putative linear B cell epitopes from 14 and 5 consensus sequences generated from distinct groups of the S and M proteins, respectively. ELISA testing predicted peptides with PEDV-positive sera revealed 9 novel immunodominant epitopes on the S protein. Importantly, 7 of these novel immunodominant epitopes and other subdominant epitopes were demonstrated to be neutralizing epitopes by neutralization-inhibition assay. Additionally, our study shows the first time that M protein is also the target of neutralizing antibodies as 7 neutralizing epitopes in the M protein were identified. Conservancy analysis revealed that epitopes in the 51 subunit are more variable than those in the S2 subunit and M protein. In this study, we offer the immunoinformatics approach for linear B cell epitope identification and a more complete profile of linear B cell epitopes across the PEDV S and M proteins, which may contribute to the development of a greater PEDV vaccine as well as peptide-based immunoassays.	[Polyiam, Kanokporn; Ruengjitchatchawalya, Marasri; Roshorm, Yaowaluck Maprang] King Mongkuts Univ Technol Thonburi, Sch Bioresources & Technol, Div Biotechnol, Bangkok, Thailand; [Ruengjitchatchawalya, Marasri] King Mongkuts Univ Technol Thonburi, Sch Bioresources & Technol, Bioinformat & Syst Biol Program, Bangkok, Thailand; [Mekvichitsaeng, Phenjun] King Mongkuts Univ Technol Thonburi, Pilot Plant Dev & Training Inst, Bangkok, Thailand; [Kaeoket, Kampon] Mahidol Univ, Fac Vet Sci, Dept Clin Sci & Publ Hlth, Phutthamonthon, Nakhon Pathom, Thailand; [Hoonsuwan, Tawatchai; Joiphaeng, Pichai] BF Feed Co Ltd, Prachachuen Rd, Bangkok, Thailand	King Mongkuts University of Technology Thonburi; King Mongkuts University of Technology Thonburi; King Mongkuts University of Technology Thonburi; Mahidol University	Roshorm, YM (corresponding author), King Mongkuts Univ Technol Thonburi, Sch Bioresources & Technol, Div Biotechnol, Bangkok, Thailand.	yaowaluck.ros@kmutt.ac.th			Development and Promotion of Science and Technology (DPST) [486]; B.F. Feed Company Limited	Development and Promotion of Science and Technology (DPST); B.F. Feed Company Limited	We would like to thank B.F. Feed Company Limited for providing financial support and providing 485 blood samples from PEDV-infected pigs. Kanokporn Polyiam's PhD study is funded by Development and Promotion of Science and Technology Talents Project486 (DPST).	Adam KM, 2021, TROP DIS TRAVEL MED, V7, DOI 10.1186/s40794-021-00147-1; Arndt AL, 2010, J VIROL, V84, P11418, DOI 10.1128/JVI.01131-10; Behmard E, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-77547-4; Bosch BJ, 2003, J VIROL, V77, P8801, DOI 10.1128/JVI.77.16.8801-8811.2003; Bueno LL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021289; Cao LY, 2015, VIRUS GENES, V51, P217, DOI 10.1007/s11262-015-1234-5; Chan WE, 2006, J VIROL, V80, P3225, DOI 10.1128/JVI.80.7.3225-3237.2006; Chang CY, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39844-5; Chang SH, 2002, MOL CELLS, V14, P295; Cruz DJM, 2008, VIRUS RES, V132, P192, DOI 10.1016/j.virusres.2007.10.015; Cruz DJM, 2006, VIROLOGY, V354, P28, DOI 10.1016/j.virol.2006.04.027; Deng F, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8030055; Dhanda SK, 2017, BRIEF BIOINFORM, V18, P467, DOI 10.1093/bib/bbw025; Dosztanyi Z, 2005, J MOL BIOL, V347, P827, DOI 10.1016/j.jmb.2005.01.071; EMINI EA, 1985, J VIROL, V55, P836, DOI 10.1128/JVI.55.3.836-839.1985; Golosova O, 2014, PEERJ, V2, DOI 10.7717/peerj.644; Huang YW, 2013, MBIO, V4, DOI 10.1128/mBio.00737-13; IEDB, IMM EP DAT AN RES; Jespersen MC, 2017, NUCLEIC ACIDS RES, V45, pW24, DOI 10.1093/nar/gkx346; Kirchdoerfer RN, 2021, STRUCTURE, V29, P385, DOI 10.1016/j.str.2020.12.003; KOLASKAR AS, 1990, FEBS LETT, V276, P172, DOI 10.1016/0014-5793(90)80535-Q; Kong N, 2020, VIROL J, V17, DOI 10.1186/s12985-020-01305-1; Kringelum JV, 2013, MOL IMMUNOL, V53, P24, DOI 10.1016/j.molimm.2012.06.001; Lee C, 2015, VIROL J, V12, DOI 10.1186/s12985-015-0421-2; Li CH, 2017, J VIROL, V91, DOI [10.1128/JVI.00273-17, 10.1128/jvi.00273-17]; Li QN, 2018, VACCINE, V36, P1381, DOI 10.1016/j.vaccine.2018.01.086; Li WT, 2016, VIRUS RES, V226, P117, DOI 10.1016/j.virusres.2016.05.031; Li Y, 2021, CELL REP, V34, DOI 10.1016/j.celrep.2021.108915; Li Y, 2020, CELL MOL IMMUNOL, V17, P1095, DOI 10.1038/s41423-020-00523-5; Lv Chaochao, 2016, VIRUS ADAPTATION TRE, V8, P1, DOI [10.2147/VAAT.S107275, DOI 10.2147/VAAT.S107275]; Ma ST, 2018, MICROB CELL FACT, V17, DOI 10.1186/s12934-018-0861-7; Matsuyama S, 2009, J VIROL, V83, P11133, DOI 10.1128/JVI.00959-09; Okda FA, 2017, VIROLOGY, V509, P185, DOI 10.1016/j.virol.2017.06.013; Okonechnikov K, 2012, BIOINFORMATICS, V28, P1166, DOI 10.1093/bioinformatics/bts091; Paarlberg PL, 2014, WORKING PAPERS, V14, P1; Pollard AJ, 2021, NAT REV IMMUNOL, V21, P83, DOI 10.1038/s41577-020-00479-7; Ponomarenko JV, 2009, STRUCTURAL BIOINFORM, V2, P849; Shey RA, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-40833-x; Shi JP, 2013, VACCINE, V31, P2130, DOI 10.1016/j.vaccine.2013.02.051; Shirato K, 2011, VIRUS RES, V161, P188, DOI 10.1016/j.virusres.2011.07.019; Shrock E, 2020, SCIENCE, V370, P1058, DOI 10.1126/science.abd4250; Song D, 2012, VIRUS GENES, V44, P167, DOI 10.1007/s11262-012-0713-1; Sun DB, 2007, ACTA VIROL, V51, P149; Sun DB, 2008, VET MICROBIOL, V131, P73, DOI 10.1016/j.vetmic.2008.02.022; Sun RQ, 2012, EMERG INFECT DIS, V18, P161, DOI 10.3201/eid1801.111259; Sun YG, 2019, VIRUS RES, V266, P34, DOI 10.1016/j.virusres.2019.04.003; Temeeyasen G, 2014, INFECT GENET EVOL, V21, P205, DOI 10.1016/j.meegid.2013.11.001; Do VT, 2020, ARCH VIROL, V165, P609, DOI 10.1007/s00705-019-04492-7; Wicht O, 2014, J VIROL, V88, P7952, DOI 10.1128/JVI.00297-14; Yi ZG, 2020, EMERG MICROBES INFEC, V9, P1988, DOI 10.1080/22221751.2020.1815591; Zhang ZB, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-225	51	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 19	2022	13									10.1101/2021.10.05.463270	http://dx.doi.org/10.1101/2021.10.05.463270			26	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6G8QA		Green Submitted			2022-12-18	WOS:000885015300001
J	Sanchez-Trincado, JL; Pelaez-Prestel, HF; Lafuente, EM; Reche, PA				Sanchez-Trincado, Jose L.; Pelaez-Prestel, Hector F.; Lafuente, Esther M.; Reche, Pedro A.			Human Oral Epithelial Cells Suppress T Cell Function via Prostaglandin E2 Secretion	FRONTIERS IN IMMUNOLOGY			English	Article						oral epithelial cells; dendritic cells; T cells; immunomodulation; PGE2; viral infection	ANTIGEN PRESENTATION; ANTERIOR-CHAMBER; EXPRESSION; RECEPTOR; E-2; LYMPHOCYTE; ACTIVATION; PROTEIN; CD40; DIFFERENTIATION	The oral mucosa is constantly exposed to a plethora of stimuli including food antigens, commensal microbiota and pathogens, requiring distinct immune responses. We previously reported that human oral epithelial cells (OECs) suppress immune responses to bacteria, using H413 and TR146 OEC lines and primary OECs in co-culture with dendritic cells (DCs) and T cells (OEC-conditioned cells). OECs reduced DCs expression of CD80/CD86 and IL-12/TNF alpha release and impaired T cell activation. Here, we further evaluated the immunosuppression by these OECs and investigated the underlying mechanisms. OEC-conditioned DCs did not induce CD4 T cell polarization towards Treg, judging by the absence of FoxP3 expression. OECs also repressed T-bet/IFN gamma expression in CD4 and CD8 T cells activated by DCs or anti-CD3/CD28 antibodies. This inhibition depended on OEC:T cell ratio and IFN gamma repression occurred at the transcriptional level. Time-lapse experiments showed that OECs inhibited early steps of T cell activation, consistent with OECs inability to suppress T cells stimulated with PMA/ionomycin. Blocking CD40/CD40L, CD58/CD2 and PD-L1/PD-1 interactions with specific antibodies did not disrupt T cell suppression by OECs. However, preventing prostaglandin E2 (PGE2) synthesis or blocking PGE2 binding to the cognate EP2/EP4 receptors, restored IFN gamma and TNF alpha production in OEC-conditioned T cells. Finally, treating OECs with poly(I:C), which simulates viral infections, limited T cell suppression. Overall, these results point to an inherent ability of OECs to suppress immune responses, which can nonetheless be eluded when OECs are under direct assault.	[Sanchez-Trincado, Jose L.; Pelaez-Prestel, Hector F.; Lafuente, Esther M.; Reche, Pedro A.] Univ Complutense Madrid, Sch Med, Dept Immunol & O2, Lab Immunomed, Madrid, Spain	Complutense University of Madrid	Lafuente, EM; Reche, PA (corresponding author), Univ Complutense Madrid, Sch Med, Dept Immunol & O2, Lab Immunomed, Madrid, Spain.	melafuente@med.ucm.es; parecheg@med.ucm.es	Reche, Pedro A/B-1881-2013	Reche, Pedro A/0000-0003-3966-5838; Pelaez-Prestel, Hector/0000-0003-1378-883X	University Complutense [B AE21/20/20-23164]; Comunidad de Madrid Research Agency [IND2020/BMD-17364]; Complutense University of Madrid [CT17/17 - CT18/17]; FPU 2019 Grants	University Complutense; Comunidad de Madrid Research Agency(Comunidad de Madrid); Complutense University of Madrid; FPU 2019 Grants	We wish to thank the University Complutense and the Comunidad de Madrid Research Agency for financial support through grants B AE21/20/20-23164 and IND2020/BMD-17364, respectively, to PAR. JS-T and HP-P were supported by Complutense University of Madrid through CT17/17 - CT18/17 and FPU 2019 Grants, respectively.	af Forselles KJ, 2011, BRIT J PHARMACOL, V164, P1847, DOI 10.1111/j.1476-5381.2011.01495.x; Aldajani WA, 2016, ONCOTARGET, V7, P57606, DOI 10.18632/oncotarget.11586; Aoudjit L, 2006, AM J PHYSIOL-RENAL, V290, pF1534, DOI 10.1152/ajprenal.00267.2005; Baratelli F, 2005, J IMMUNOL, V175, P1483, DOI 10.4049/jimmunol.175.3.1483; Blumberg RS, 1999, IMMUNOL LETT, V69, P7, DOI 10.1016/S0165-2478(99)00093-0; Boniface K, 2009, J EXP MED, V206, P535, DOI 10.1084/jem.20082293; Brzozowski T, 2005, J Physiol Pharmacol, V56 Suppl 5, P33; Chinen T, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1181; Cruickshank SM, 2004, GUT, V53, P678, DOI 10.1136/gut.2003.029967; Dejani NN, 2018, P NATL ACAD SCI USA, V115, pE8469, DOI 10.1073/pnas.1722016115; Demmers MWHJ, 2015, CLIN EXP IMMUNOL, V179, P509, DOI 10.1111/cei.12469; Dey I, 2006, BRIT J PHARMACOL, V149, P611, DOI 10.1038/sj.bjp.0706923; Ding HL, 2005, CLIN IMMUNOL, V115, P184, DOI 10.1016/j.clim.2005.01.005; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; Dugger K, 2009, SEMIN IMMUNOL, V21, P289, DOI 10.1016/j.smim.2009.06.002; Framson PE, 1999, GASTROENTEROLOGY, V116, P1054, DOI 10.1016/S0016-5085(99)70008-9; GALY AHM, 1992, J IMMUNOL, V149, P775; Groeger S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00208; Guo YC, 2013, MOLECULES, V18, P6584, DOI 10.3390/molecules18066584; Hattori T, 2009, EXP EYE RES, V89, P358, DOI 10.1016/j.exer.2009.04.004; Hirosako S, 2009, CLIN EXP IMMUNOL, V155, P266, DOI 10.1111/j.1365-2249.2008.03811.x; Iliev ID, 2009, GUT, V58, P1481, DOI 10.1136/gut.2008.175166; Kabashima K, 2002, J CLIN INVEST, V109, P883, DOI 10.1172/JCI14459; Kamihira T, 2005, HEPATOLOGY, V41, P151, DOI 10.1002/hep.20494; Maan Amrit S, 2019, J Orthod Sci, V8, P16, DOI 10.4103/jos.JOS_13_19; Michalczyk A, 2004, BIOTECHNIQUES, V37, P262, DOI 10.2144/04372RR03; Molero-Abraham M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01434; Motedayyen H, 2018, REPROD BIOL, V18, P182, DOI 10.1016/j.repbio.2018.04.002; Mulder DJ, 2011, AM J PATHOL, V178, P744, DOI 10.1016/j.ajpath.2010.10.027; Murai M, 2009, NAT IMMUNOL, V10, P1178, DOI 10.1038/ni.1791; Nagashima H, 2014, NAT IMMUNOL, V15, P449, DOI 10.1038/ni.2863; Namba K, 2002, J LEUKOCYTE BIOL, V72, P946; NIEDEL JE, 1983, P NATL ACAD SCI-BIOL, V80, P36, DOI 10.1073/pnas.80.1.36; NIEDERKORN JY, 1983, J IMMUNOL, V131, P2670; Novak N, 2008, TRENDS MOL MED, V14, P191, DOI 10.1016/j.molmed.2008.03.001; Park JY, 2006, CLIN IMMUNOL, V119, P229, DOI 10.1016/j.clim.2006.01.016; Park JY, 2018, MUCOSAL IMMUNOL, V11, P1092, DOI 10.1038/s41385-018-0027-2; Propst SM, 2000, J IMMUNOL, V165, P2214, DOI 10.4049/jimmunol.165.4.2214; Reche PA, 2001, J IMMUNOL, V167, P336, DOI 10.4049/jimmunol.167.1.336; Rescigno Maria, 2008, J Pediatr Gastroenterol Nutr, V46 Suppl 1, pE17, DOI 10.1097/01.mpg.0000313831.09089.36; Rimoldi M, 2005, NAT IMMUNOL, V6, P507, DOI 10.1038/ni1192; RINCON M, 1988, EUR J IMMUNOL, V18, P1791, DOI 10.1002/eji.1830181121; Schau I, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-40032-8; Schmalz G, 2000, EUR J ORAL SCI, V108, P442, DOI 10.1034/j.1600-0722.2000.108005442.x; Schmidt LM, 2011, J IMMUNOL, V186, P2095, DOI 10.4049/jimmunol.1002414; Schwarze J, 2016, EUR RESPIR J, V48, P1785, DOI 10.1183/13993003.00841-2016; SELVARAJ P, 1987, NATURE, V326, P400, DOI 10.1038/326400a0; Soumelis V, 2002, NAT IMMUNOL, V3, P673, DOI 10.1038/ni805; Sreeramkumar V, 2012, IMMUNOL CELL BIOL, V90, P579, DOI 10.1038/icb.2011.75; Sultan H, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-001224; Swamy M, 2010, NAT IMMUNOL, V11, P656, DOI 10.1038/ni.1905; Tanaka Y, 2017, MUCOSAL IMMUNOL, V10, P79, DOI 10.1038/mi.2016.46; Telega GW, 2000, GASTROENTEROLOGY, V119, P1548, DOI 10.1053/gast.2000.20168; Thelemann C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086844; Tsushima F, 2007, BLOOD, V110, P180, DOI 10.1182/blood-2006-11-060087; Vang T, 2001, J EXP MED, V193, P497, DOI 10.1084/jem.193.4.497; WALKER C, 1983, J IMMUNOL, V130, P1770; Wallace CA, 2013, INVEST OPHTH VIS SCI, V54, P722, DOI 10.1167/iovs.12-10602; Wang DZ, 2016, TRENDS MOL MED, V22, P1, DOI 10.1016/j.molmed.2015.11.003; Wang HM, 2005, WORLD J GASTROENTERO, V11, P340, DOI 10.3748/wjg.v11.i3.340; Wiemer AJ, 2011, J IMMUNOL, V187, P3663, DOI 10.4049/jimmunol.1100103; WILBANKS GA, 1992, EUR J IMMUNOL, V22, P165, DOI 10.1002/eji.1830220125; Wosen JE, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02144; Yamamoto M, 1998, J IMMUNOL, V160, P2188; Yellin MJ, 1997, ARTHRITIS RHEUM, V40, P124, DOI 10.1002/art.1780400117; YOSHIDA S, 1992, J PHYSIOL-LONDON, V458, P307, DOI 10.1113/jphysiol.1992.sp019419	66	0	0	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 19	2022	12								740613	10.3389/fimmu.2021.740613	http://dx.doi.org/10.3389/fimmu.2021.740613			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YR1WP	35126344	Green Published, gold			2022-12-18	WOS:000749789100001
J	Silva, MJ; Dellavance, A; Baldo, DC; Rodrigues, SH; Grecco, M; Prado, MS; Agustinelli, R; Andrade, LEC				Silva, Monica Jesus; Dellavance, Alessandra; Baldo, Danielle Cristiane; Rodrigues, Silvia Helena; Grecco, Marcelle; Prado, Monica Simon; Agustinelli, Renan; Andrade, Luis Eduardo Coelho			Interkit Reproducibility of the Indirect Immunofluorescence Assay on HEp-2 Cells Depends on the Immunofluorescence Reactivity Intensity and Pattern	FRONTIERS IN IMMUNOLOGY			English	Article						autoantibody; antinuclear antibodies; immunofluorescence; HEp-2 cells; autoimmune diseases	CLINICAL-PRACTICE GUIDELINES; ANTINUCLEAR ANTIBODIES; RHEUMATOLOGY/EUROPEAN LEAGUE; CLASSIFICATION CRITERIA; INTERNATIONAL CONSENSUS; SJOGRENS-SYNDROME; AMERICAN-COLLEGE; AUTOANTIBODIES; IDENTIFICATION; PREVALENCE	IntroductionThe indirect immunofluorescence assay on HEp-2 cells (HEp-2/IFA) is used worldwide for screening for autoantibodies to cellular antigens. Cell culture and fixation methods influence the cell distribution of autoantigens and the preservation of epitopes. Therefore, discrepancy of results obtained using different HEp-2/IFA kits (interkit nonreproducibility) is a common phenomenon in the clinical laboratory routine. ObjectiveThis study evaluated the interkit nonreproducibility of HEp-2/IFA results using samples from patients with systemic autoimmune disease (SAD), nonautoimmune diseases (NAD), and healthy blood donors (HBD). MethodsSerum from 275 SAD patients, 293 NAD patients, and 300 HBD were processed at 1:80 dilution using four HEp-2 kits according to the manufacturers' instructions. Interkit reproducibility was determined for positive/negative results and patterns. The agreement of positive/negative results among kits for each sample was determined as the reactivity agreement score (RAS). The pattern reproducibility score (PRS) in each sample was calculated as a function of the number of kits showing equivalent patterns. Qualitative variables and ordinal variables were analyzed by the Chi-square and Mann-Whitney U tests, respectively. ResultsA total of 402 samples were nonreactive in all kits and were considered devoid of autoantibodies. Further analysis included the 466 reactive samples (238 SAD, 119 NAD, 109 HBD). Reactivity to the nucleus had the highest interkit reproducibility (RAS = 83.6), followed by the metaphase plate (RAS = 78.9), cytoplasm (RAS = 77.4), and nucleolus (RAS = 72.4). Interkit reproducibility was higher in SAD (RAS = 78.0) than in NAD (RAS = 70.6) and HBD (RAS = 71.3) groups. Samples with strong reactivity (++++/4 and +++/4) had higher interkit reproducibility than those with weak reactivity (+/4). In the SAD group, RAS for nuclear reactivity was 87.5% for strongly reactive samples as opposed to 4.4% for weakly reactive samples, and the same was observed for NAD and HBD samples. The most robust patterns were the centromere AC-3 (PRS = 78.4), multiple nuclear dots AC-6 (PRS = 73.6), nuclear coarse speckled AC-5 (PRS = 71.3), nuclear homogeneous AC-1 (PRS = 67.9), and the reticular cytoplasmic AC-21 (PRS = 68.6). ConclusionInterkit nonreproducibility in HEp-2/IFA is prevalent and occurs with the highest frequency with weakly reactive samples. International initiatives with the engagement of in vitro diagnostic industry are encouraged to promote the harmonization of the properties and performance of HEp-2/IFA commercial kits.	[Silva, Monica Jesus; Rodrigues, Silvia Helena; Grecco, Marcelle; Prado, Monica Simon; Agustinelli, Renan; Andrade, Luis Eduardo Coelho] Univ Fed Sao Paulo, Div Rheumatol, Escola Paulista Med, Sao Paulo, Brazil; [Dellavance, Alessandra; Baldo, Danielle Cristiane] Fleury Med & Hlth Labs, Div Res & Dev, Sao Paulo, Brazil	Universidade Federal de Sao Paulo (UNIFESP)	Andrade, LEC (corresponding author), Univ Fed Sao Paulo, Div Rheumatol, Escola Paulista Med, Sao Paulo, Brazil.	luis.andrade@unifesp.br		Rodrigues, Silvia/0000-0001-5005-2771	Fleury Medicine and Health Laboratories, Sao Paulo, Brazil; Brazilian National funding agency CNPq [PQ-1D 310334/2019-5]	Fleury Medicine and Health Laboratories, Sao Paulo, Brazil; Brazilian National funding agency CNPq	This study was partially supported by Fleury Medicine and Health Laboratories, Sao Paulo, Brazil. LECA receives a research grant (PQ-1D 310334/2019-5) from the Brazilian National funding agency CNPq.	Agustinelli RA, 2019, LUPUS, V28, P629, DOI 10.1177/0961203319838348; American College of Rheumatology, 2009, CURR PRACT ISS ACR T; Andrade LEC, 2018, CLIN CHEM LAB MED, V56, P1783, DOI 10.1515/cclm-2018-0188; Aringer M, 2019, ARTHRITIS RHEUMATOL, V71, P1400, DOI [10.1136/annrheumdis-2018-214819, 10.1002/art.40930]; Brand F, 2005, CELL PROLIFERAT, V38, P205; Francescantonio PLC, 2014, REV BRAS REUMATOL, V54, P44, DOI [10.1016/j.rbre.2014.02.006, 10.1016/j.rbr.2013.10.001]; Chan EKL, 2007, AUTOIMMUN REV, V6, P577, DOI 10.1016/j.autrev.2007.05.001; Chan EKL, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00412; CLARKE MC, 1986, DIAGN CLIN IMMUNOL, V4, P288; Copple SS, 2012, AM J CLIN PATHOL, V137, P825, DOI 10.1309/AJCPICNFG7UCES1S; Pereira KMC, 2014, CLIN CHIM ACTA, V437, P203, DOI 10.1016/j.cca.2014.07.031; Damoiseaux J, 2019, ANN RHEUM DIS, V78, P879, DOI 10.1136/annrheumdis-2018-214436; Dellavance A, 2005, J RHEUMATOL, V32, P2144; Dellavance Alessandra, 2013, J. Bras. Patol. Med. Lab., V49, P182, DOI 10.1590/S1676-24442013000300005; Dellavance Alessandra, 2003, Rev. Bras. Reumatol., V43, P129, DOI 10.1590/S0482-50042003000300002; Dellavance A, 2019, METHODS MOL BIOL, V1901, P19, DOI 10.1007/978-1-4939-8949-2_3; Dellavance A, 2013, J IMMUNOL METHODS, V390, P35, DOI 10.1016/j.jim.2013.01.006; Dellavance A, 2009, RHEUMATOLOGY, V48, P632, DOI 10.1093/rheumatology/kep070; DEVLAM K, 1993, CLIN EXP RHEUMATOL, V11, P393; Du LP, 2002, CLIN DIAGN LAB IMMUN, V9, P287, DOI 10.1128/CDLI.9.2.287-294.2002; Fernandez Solange Assuncion Villagra, 2003, Rev. Hosp. Clin., V58, P315, DOI 10.1590/S0041-87812003000600005; FORSLID J, 1994, CLIN EXP RHEUMATOL, V12, P137; FRITZLER MJ, 1980, AM J MED, V69, P520, DOI 10.1016/0002-9343(80)90462-3; FRITZLER MJ, 1985, CLIN IMMUNOL IMMUNOP, V36, P120, DOI 10.1016/0090-1229(85)90045-5; Guillot PV, 2004, EXP CELL RES, V295, P460, DOI 10.1016/j.yexcr.2004.01.020; Hahm D, 2006, CYTOM PART A, V69A, P178, DOI 10.1002/cyto.a.20223; Hirschfield GM, 2017, J HEPATOL, V67, P145, DOI 10.1016/j.jhep.2017.03.022; Ihn H, 1999, CLIN EXP IMMUNOL, V117, P383; Infantino M, 2018, J IMMUNOL METHODS, V461, P110, DOI 10.1016/j.jim.2018.07.001; Infantino M, 2017, IMMUNOL RES, V65, P345, DOI 10.1007/s12026-016-8845-3; JASKOWSKI TD, 1995, J CLIN LAB ANAL, V9, P166, DOI 10.1002/jcla.1860090304; Jaskowski TD, 1996, AM J CLIN PATHOL, V105, P466; Li T, 2015, RHEUMATOLOGY, V54, P449, DOI 10.1093/rheumatology/keu326; Lohse AW, 2015, J HEPATOL, V63, P971, DOI 10.1016/j.jhep.2015.06.030; Mariz HA, 2011, ARTHRITIS RHEUM-US, V63, P191, DOI 10.1002/art.30084; Meroni PL, 2010, ANN RHEUM DIS, V69, P1420, DOI 10.1136/ard.2009.127100; MONCE NM, 1994, J IMMUNOASSAY, V15, P55, DOI 10.1080/15321819408009571; Ng KP, 2006, ARTHRIT RHEUM-ARTHR, V55, P900, DOI 10.1002/art.22356; Pisetsky DS, 2018, ANN RHEUM DIS, V77, P911, DOI 10.1136/annrheumdis-2017-212599; Pisetsky DS, 2017, NAT REV RHEUMATOL, V13, P495, DOI 10.1038/nrrheum.2017.74; Sack U, 2009, ANN NY ACAD SCI, V1173, P166, DOI 10.1111/j.1749-6632.2009.04735.x; Satoh M, 2012, ARTHRITIS RHEUM-US, V64, P2319, DOI 10.1002/art.34380; Shiboski CH, 2017, ANN RHEUM DIS, V76, P9, DOI [10.1136/annrheumdis-2016-210571, 10.1002/art.39859]; Solomon DH, 2002, ARTHRIT RHEUM-ARTHR, V47, P434, DOI 10.1002/art.10561; Stadler C, 2010, J PROTEOMICS, V73, P1067, DOI 10.1016/j.jprot.2009.10.012; Tan EM, 1997, ARTHRITIS RHEUM-US, V40, P1601, DOI 10.1002/art.1780400909; van den Hoogen F, 2013, ARTHRITIS RHEUM-US, V65, P2737, DOI 10.1002/art.38098; Van Duijnhoven HLP, 1999, CLIN BIOCHEM, V32, P179, DOI 10.1016/S0009-9120(99)00006-5; VRETHEM M, 1992, J RHEUMATOL, V19, P1919; Watanabe A, 2004, ARTHRITIS RHEUM-US, V50, P892, DOI 10.1002/art.20096; Wiik AS, 2010, J AUTOIMMUN, V35, P276, DOI 10.1016/j.jaut.2010.06.019	51	0	0	2	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 19	2022	12								798322	10.3389/fimmu.2021.798322	http://dx.doi.org/10.3389/fimmu.2021.798322			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YR3CV	35126363	gold, Green Published			2022-12-18	WOS:000749873400001
J	Song, X; Li, FJ; Zhang, MS; Xia, YJ; Ai, LZ; Wang, GQ				Song, Xin; Li, Fengjiao; Zhang, Mingshu; Xia, Yongjun; Ai, Lianzhong; Wang, Guangqiang			Effect of D-Ala-Ended Peptidoglycan Precursors on the Immune Regulation of Lactobacillus plantarum Strains	FRONTIERS IN IMMUNOLOGY			English	Article						Ddl ligase; Lactobacillus plantarum; D-alanine; vancomycin; immune pathways	LACTIC-ACID; D-LACTATE; KAPPA-B; VANCOMYCIN; PATHWAY	The resistance of Lactobacillus plantarum to vancomycin depends on its peptidoglycan composition. Vancomycin has poor binding affinity with peptidoglycan precursors ending in D-alanyl-D-lactate (D-Ala-D-Lac) but binds strongly to peptidoglycan precursors ending in D-alanyl-D-alanine (D-Ala-D-Ala), resulting in resistance and sensitivity, respectively. The ligase Ddl, which generates D-Ala-D-Lac or D-Ala-D-Ala incorporated into the peptidoglycan precursor chain, is responsible for this specificity. To study the effect of peptidoglycan precursors on immunity, we constructed several strains of L. plantarum expressing the ddl gene of Lactococcus lactis to change their peptidoglycan precursors. The change in the termini of the peptidoglycan precursors was determined by the sensitivity of the strains to vancomycin. The overexpression of ddl increased the susceptibility of the strains to vancomycin. We further explored the regulation of the macrophage inflammatory response pathway by the wild-type and constructed strains, and found that these strains induced the MyD88-dependent TRAF6/MAPK pathway, and the increase in D-Ala L. plantarum peptidoglycan precursors increased the secretion of the inflammatory factors IL-6, IL-1 beta and TNF-alpha. These results indicate that D-Ala-ended peptidoglycan precursors play a central role in the variable immunomodulatory ability of L. plantarum.	[Song, Xin; Li, Fengjiao; Zhang, Mingshu; Xia, Yongjun; Ai, Lianzhong; Wang, Guangqiang] Univ Shanghai Sci & Technol, Sch Hlth Sci & Engn, Shanghai Engn Res Ctr Food Microbiol, Shanghai, Peoples R China	University of Shanghai for Science & Technology	Wang, GQ (corresponding author), Univ Shanghai Sci & Technol, Sch Hlth Sci & Engn, Shanghai Engn Res Ctr Food Microbiol, Shanghai, Peoples R China.	1015wanggq@163.com			Shanghai Agriculture Applied Technology Development Program, China [2019-02-08-00-07-F01152]; National Science Foundation for Distinguished Young Scholars of China [32025029]	Shanghai Agriculture Applied Technology Development Program, China; National Science Foundation for Distinguished Young Scholars of China(National Natural Science Foundation of China (NSFC)National Science Fund for Distinguished Young Scholars)	This study was funded by Shanghai Agriculture Applied Technology Development Program, China (grant 2019-02-08-00-07-F01152), National Science Foundation for Distinguished Young Scholars of China (No. 32025029).	Chen XH, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0064227, 10.1371/journal.pone.0067120]; Deghorain M, 2007, J BACTERIOL, V189, P4332, DOI 10.1128/JB.01829-06; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Ferain T, 1996, J BACTERIOL, V178, P5431, DOI 10.1128/JB.178.18.5431-5437.1996; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Goffin P, 2005, J BACTERIOL, V187, P6750, DOI 10.1128/JB.187.19.6750-6761.2005; Grangette C, 2005, P NATL ACAD SCI USA, V102, P10321, DOI 10.1073/pnas.0504084102; HANDWERGER S, 1994, J BACTERIOL, V176, P260, DOI 10.1128/JB.176.1.260-264.1994; Hazebrouck S, 2009, VACCINE, V27, P5800, DOI 10.1016/j.vaccine.2009.07.064; Kahne D, 2005, CHEM REV, V105, P425, DOI 10.1021/cr030103a; Kaji R, 2010, J IMMUNOL, V184, P3505, DOI 10.4049/jimmunol.0901569; Karpuzoglu E, 2006, NITRIC OXIDE-BIOL CH, V15, P177, DOI 10.1016/j.niox.2006.03.009; Kozakova H, 2016, CELL MOL IMMUNOL, V13, P251, DOI 10.1038/cmi.2015.09; Lazarevic V, 2011, NAT IMMUNOL, V12, P597, DOI 10.1038/ni.2059; Malinin NL., 1997, IMMUNOL TODAY, V18, P148, DOI [10.1016/S0167-5699(97)84658-0, DOI 10.1016/S0167-5699(97)84658-0]; Menard S, 2004, GUT, V53, P821, DOI 10.1136/gut.2003.026252; Morath S, 2001, J EXP MED, V193, P393, DOI 10.1084/jem.193.3.393; NAGARAJAN R, 1991, ANTIMICROB AGENTS CH, V35, P605, DOI 10.1128/AAC.35.4.605; Rao SC, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-3684; STETTER KO, 1973, ARCH MIKROBIOL, V94, P221, DOI 10.1007/BF00417453; Vollmer W, 2008, FEMS MICROBIOL REV, V32, P149, DOI 10.1111/j.1574-6976.2007.00094.x; Wang GQ, 2019, FOOD FUNCT, V10, P5843, DOI [10.1039/c9fo01390c, 10.1039/C9FO01390C]; Wells JM, 2011, MICROB CELL FACT, V10, DOI 10.1186/1475-2859-10-S1-S17; Xia YJ, 2020, J FUNCT FOODS, V67, DOI 10.1016/j.jff.2020.103854; Xue QJ, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19123805; Yang P, 2015, MICROB CELL FACT, V14, DOI 10.1186/s12934-015-0344-z	26	0	0	5	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 19	2022	12								825825	10.3389/fimmu.2021.825825	http://dx.doi.org/10.3389/fimmu.2021.825825			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZV0TD	35126378	gold, Green Published			2022-12-18	WOS:000770247500001
J	Hirooka, Y; Okuda, S; Sugiyama, M; Shiga, T; Nozaki, Y; Kinoshita, K; Funauchi, M; Matsumura, I				Hirooka, Yasuaki; Okuda, Saki; Sugiyama, Masafumi; Shiga, Toshihiko; Nozaki, Yuji; Kinoshita, Koji; Funauchi, Masanori; Matsumura, Itaru			Case Report: A Rare Case of Elderly-Onset Adult-Onset Still's Disease in a Patient With Systemic Lupus Erythematosus	FRONTIERS IN IMMUNOLOGY			English	Article						adult-onset Still's disease; rheumatic diseases; systemic lupus erythematosus; overlap; case report	CLASSIFICATION; DIAGNOSIS; SJOGRENS; CRITERIA; ERA	The rare systemic inflammatory disorder 'adult-onset Still's disease (AOSD)' is characterized by recurrent fever, evanescent rash, arthralgia, and leukocytosis with neutrophilia. The Yamaguchi criteria are widely used to diagnose AOSD; these criteria can be used for diagnosis after a wide range of infectious, rheumatic, and neoplastic diseases have been excluded. AOSD generally does not overlap with other rheumatic diseases. We present the rare case of an 80-year-old Japanese woman who presented with arthralgia, fever, and skin rash during treatment for systemic lupus erythematosus (SLE), which was finally diagnosed as an overlap of AOSD. Blood tests revealed leukocytosis with neutrophilia, high C-reactive protein (CRP), and liver dysfunction. Her anti-ds-DNA antibody titer and serum complement titer were at the same level as before and remained stable. We suspected AOSD based on the high serum ferritin level but hesitated to diagnose AOSD because of the patient's SLE history. We measured serum interleukin (IL)-18; it was extremely high at 161,221 pg/mL, which was strongly suggestive of AOSD. We thus diagnosed AOSD complicated during the course of treatment for SLE. The patient's arthralgia and high CRP level persisted after we increased her oral prednisolone dose and added oral methotrexate, but her symptoms eventually improved with the addition of intravenous tocilizumab. We note that the presence of autoantibodies or other rheumatic diseases cannot be absolutely ruled out in the diagnosis of AOSD. Although high serum IL-18 levels are not specific for AOSD, the measurement of serum IL-18 may aid in the diagnosis of AOSD in similar rare cases.	[Hirooka, Yasuaki; Okuda, Saki; Sugiyama, Masafumi] Kindai Univ, Nara Hosp, Dept Rheumatol, Nara, Japan; [Shiga, Toshihiko; Nozaki, Yuji; Kinoshita, Koji; Funauchi, Masanori; Matsumura, Itaru] Kindai Univ, Sch Med, Dept Hematol & Rheumatol, Osaka, Japan	Kindai University (Kinki University); Kindai University (Kinki University)	Sugiyama, M (corresponding author), Kindai Univ, Nara Hosp, Dept Rheumatol, Nara, Japan.	m-sugi@med.kindai.ac.jp						Awad J, 2007, EUR J INTERN MED, V18, P155, DOI 10.1016/j.ejim.2006.07.025; Brow JD, 2021, BMC RHEUMATOL, V5, DOI 10.1186/s41927-021-00212-4; Crayne CB, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00119; Efthimiou P, 2021, SEMIN ARTHRITIS RHEU, V51, P858, DOI 10.1016/j.semarthrit.2021.06.004; Fautrel B, 2002, MEDICINE, V81, P194, DOI 10.1097/00005792-200205000-00003; Feist E, 2018, NAT REV RHEUMATOL, V14, P603, DOI 10.1038/s41584-018-0081-x; Frutos AR, 2021, RHEUMATOLOGY, V60, P1793, DOI 10.1093/rheumatology/keaa477; Garcia FJN, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006318; Gerfaud-Valentin M, 2014, AUTOIMMUN REV, V13, P708, DOI 10.1016/j.autrev.2014.01.058; Han PY, 2022, RHEUMATOL INT, V42, P1281, DOI 10.1007/s00296-021-04900-9; Hashimoto M, 1995, Nihon Rinsho Meneki Gakkai Kaishi, V18, P45; Lakshman H., 2020, CUREUS J MED SCIENCE, V12, P4, DOI [10.7759/cureus.10761, DOI 10.7759/CUREUS.10761]; Loria DMS, 1996, CLIN RHEUMATOL, V15, P133, DOI 10.1007/BF02230329; Maria ATJ, 2014, AUTOIMMUN REV, V13, P1149, DOI 10.1016/j.autrev.2014.08.032; Maruyama A, 2021, MOD RHEUMATOL, V31, P862, DOI 10.1080/14397595.2020.1829340; Mazodier K, 2005, BLOOD, V106, P3483, DOI 10.1182/blood-2005-05-1980; Medhat BM, 2020, CLIN RHEUMATOL, V39, P435, DOI 10.1007/s10067-019-04776-y; Mende R, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01250; Minoia F, 2019, ANN RHEUM DIS, V78, P1357, DOI 10.1136/annrheumdis-2019-215211; Mobini Maryam, 2016, Acta Med Iran, V54, P683; Mollaeian A, 2021, BMC RHEUMATOL, V5, DOI 10.1186/s41927-021-00183-6; Mzabi Anis, 2021, Reumatologia (Warsaw), V59, P188, DOI 10.5114/reum.2021.107323; Niranvichaiya Sakunee, 2017, Case Rep Dermatol Med, V2017, P3768603, DOI 10.1155/2017/3768603; Placais L, 2018, SEMIN ARTHRITIS RHEU, V47, P575, DOI 10.1016/j.semarthrit.2017.07.003; Qiao JJ, 2019, HISTOPATHOLOGY, V74, P759, DOI 10.1111/his.13785; Ravelli A, 2016, ARTHRITIS RHEUMATOL, V68, P566, DOI 10.1002/art.39332; Riera E, 2011, CLIN EXP RHEUMATOL, V29, P331; Rovensky J, 2008, AUTOIMMUN REV, V7, P235, DOI 10.1016/j.autrev.2007.11.014; Saghafi M, 2013, RHEUMATOL INT, V33, P571, DOI 10.1007/s00296-012-2377-5; SATO M, 1993, INTERNAL MED, V32, P730, DOI 10.2169/internalmedicine.32.730; Shiga T, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.750114; Sodavarapu S, 2019, CUREUS, V11, DOI 10.7759/cureus.6055; YAMAGUCHI M, 1992, J RHEUMATOL, V19, P424; Yamamoto T, 2012, RHEUMATOL INT, V32, P2233, DOI 10.1007/s00296-011-2330-z; Zeng T, 2009, J RHEUMATOL, V36, P1026, DOI 10.3899/jrheum.080365	35	0	0	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 18	2022	13								822169	10.3389/fimmu.2022.822169	http://dx.doi.org/10.3389/fimmu.2022.822169			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YS5AW	35116046	Green Published, gold			2022-12-18	WOS:000750690600001
J	Jiang, J; Zhan, XL; Liang, T; Chen, LY; Huang, SS; Sun, XH; Jiang, WY; Chen, JR; Chen, TY; Li, H; Yao, YL; Wu, SF; Zhu, JC; Liu, C				Jiang, Jie; Zhan, Xinli; Liang, Tuo; Chen, Liyi; Huang, Shengsheng; Sun, Xuhua; Jiang, Wenyong; Chen, Jiarui; Chen, Tianyou; Li, Hao; Yao, Yuanlin; Wu, Shaofeng; Zhu, Jichong; Liu, Chong			Dysregulation of SAA1, TUBA8 and Monocytes Are Key Factors in Ankylosing Spondylitis With Femoral Head Necrosis	FRONTIERS IN IMMUNOLOGY			English	Article						ankylosing spondylitis; immune cell infiltration; immune cell composition analysis; femoral head necrosis; protein park analysis; weighted gene co-expression network analysis; drug sensitivity analysis; routine blood tests	R PACKAGE; IMMUNITY; HYPOXIA; CELLS	IntroductionThe mechanism of ankylosing spondylitis with femoral head necrosis is unknown, and our study aimed investigate the effects of genetic and immune cell dysregulation on ankylosing spondylitis. Materials and MethodsThe protein expression of all ligaments in ankylosing spondylitis with femoral head necrosis was obtained using label-free quantification protein park analysis of six pairs of specimens. The possible pathogenesis was explored using differential protein analysis, weighted gene co-expression network analysis, recording intersections with hypoxia-related genes, immune cell correlation analysis, and drug sensitivity analysis. Finally, routine blood test data from 502 AS and 162 healthy controls were collected to examine immune cell differential analysis. ResultsSAA1 and TUBA8 were significantly expressed differentially in these two groups and correlated quite strongly with macrophage M0 and resting mast cells (P < 0.05). Routine blood data showed that monocytes were significantly more expressed in AS than in healthy controls (P < 0.05). SAA1 and TUBA8 were closely related to the sensitivity of various drugs, which might lead to altered drug sensitivity. ConclusionDysregulation of SAA1, TUBA8 and monocytes are key factors in ankylosing spondylitis with femoral head necrosis.	[Jiang, Jie; Zhan, Xinli; Liang, Tuo; Chen, Liyi; Huang, Shengsheng; Sun, Xuhua; Jiang, Wenyong; Chen, Jiarui; Chen, Tianyou; Li, Hao; Yao, Yuanlin; Wu, Shaofeng; Zhu, Jichong; Liu, Chong] Guangxi Med Univ, Clin Affiliated Hosp 1, Nanning, Peoples R China	Guangxi Medical University	Liu, C (corresponding author), Guangxi Med Univ, Clin Affiliated Hosp 1, Nanning, Peoples R China.	lcgxykdx@163.com						Abji F, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.629726; Bahi-Buisson N, 2014, BRAIN, V137, P1676, DOI 10.1093/brain/awu082; Braun A, 2010, AM J HUM GENET, V86, P819, DOI 10.1016/j.ajhg.2010.03.019; Bukowski BR, 2020, J ARTHROPLASTY, V35, P2573, DOI 10.1016/j.arth.2020.04.071; Chen BB, 2018, METHODS MOL BIOL, V1711, P243, DOI 10.1007/978-1-4939-7493-1_12; Cheng N, 2018, EMBO REP, V19, DOI 10.15252/embr.201745517; Cheng YQ, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.577072; Di Donato N, 2018, GENET MED, V20, P1354, DOI 10.1038/gim.2018.8; Hsueh MF, 2021, ARTHRITIS RHEUMATOL, V73, P89, DOI 10.1002/art.41486; Jiang J, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.621430; Kawauchi T, 2017, J CELL BIOL, V216, P2247, DOI 10.1083/jcb.201705172; Kerber EL, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21228551; Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-559; Lee EJ, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1363-6; Lee JY, 2020, CELL, V180, P79, DOI 10.1016/j.cell.2019.11.026; McGettrick AF, 2020, CELL METAB, V32, P524, DOI 10.1016/j.cmet.2020.08.002; Nath A, 2020, BIOINFORMATICS, V36, P2608, DOI 10.1093/bioinformatics/btz939; Newman AM, 2015, NAT METHODS, V12, P453, DOI [10.1038/NMETH.3337, 10.1038/nmeth.3337]; Niemira M, 2020, CANCERS, V12, DOI 10.3390/cancers12010037; Nys G, 2019, TALANTA, V204, P507, DOI 10.1016/j.talanta.2019.06.044; Parnham MJ, 2014, PHARMACOL THERAPEUT, V143, P225, DOI 10.1016/j.pharmthera.2014.03.003; Peng PJ, 2021, FEBS OPEN BIO, V11, P312, DOI 10.1002/2211-5463.13037; Quaranta M, 2021, BRIT MED BULL, V137, P98, DOI 10.1093/bmb/ldaa044; Rein-Fischboeck L, 2017, MOL CELL BIOCHEM, V428, P161, DOI 10.1007/s11010-016-2926-4; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Robinson A, 2021, TRENDS IMMUNOL, V42, P104, DOI 10.1016/j.it.2020.12.001; Singhal R, 2020, J BIOL CHEM, V295, P10493, DOI 10.1074/jbc.REV120.011188; Smith JA, 2015, CURR ALLERGY ASTHM R, V15, DOI 10.1007/s11882-014-0489-6; Tang MS, 2017, INFLAMM BOWEL DIS, V23, P1544, DOI 10.1097/MIB.0000000000001208; Taylor CT, 2017, NAT REV IMMUNOL, V17, P774, DOI 10.1038/nri.2017.103; van der Heijde D, 2019, RHEUMATOLOGY, V58, P388, DOI 10.1093/rheumatology/key128; Voruganti A, 2020, IMMUNOLOGY, V161, P94, DOI 10.1111/imm.13242; Walter W, 2015, BIOINFORMATICS, V31, P2912, DOI 10.1093/bioinformatics/btv300; Wenker K. J., 2021, ANKYLOSING SPONDYLIT; Whitehead MJ, 2019, BIOINFORMATICS, V35, P4528, DOI 10.1093/bioinformatics/btz403	35	0	0	2	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 18	2022	12								814278	10.3389/fimmu.2021.814278	http://dx.doi.org/10.3389/fimmu.2021.814278			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZD9JN	35126370	gold, Green Published			2022-12-18	WOS:000758510600001
J	Li, WY; Jia, YJ; Wang, YP; Zhao, Q; Yang, L; Zeng, T; Niu, LL; Dai, RX; Li, YA; Zhao, XD; Wu, JF				Li, Wenyan; Jia, Yanjun; Wang, Yanping; Zhao, Qin; Yang, Lu; Zeng, Ting; Niu, Linlin; Dai, Rongxin; Li, Yanan; Zhao, Xiaodong; Wu, Junfeng			WASp Deficiency Selectively Affects the TCR Diversity of Different Memory T Cell Subsets in WAS Chimeric Mice	FRONTIERS IN IMMUNOLOGY			English	Article						Wiskott-Aldrich Syndrome; memory T cell; T cell receptor repertoire; high-throughput sequencing; chimeric mouse model	WISKOTT-ALDRICH-SYNDROME; REPERTOIRE DIVERSITY; LYMPHOCYTES; POPULATIONS; MECHANISMS	BackgroundThe T cell receptor (TCR) diversity is essential for effective T cell immunity. Previous studies showed that TCR diversity in Wiskott-Aldrich Syndrome (WAS) patients was severely impaired, especially in the memory T cell populations. Whether this defect was caused by intrinsic WASp deficiency or extrinsic reasons is still unclear. MethodsWe sorted different T cell subsets from the bone marrow chimeric mice model using both magnetic beads and flow cytometry. TCR repertoires of memory T cells, especially CD4(+) effector memory T (TEM) cells and CD8(+) central memory T (TCM) cells, were analyzed using the UMI quantitative high-throughput sequencing (HTS). ResultsAn average of 5.51 million sequencing reads of 32 samples was obtained from the Illumina sequencing platform. Bioinformatic analyses showed that compared with wild type (WT), WAS knock out (KO)-CD4(+) TEM cells exhibited increased Simpson index and decreased D50 index (P <0.05); The rank abundance curve of KO-CD4(+) TEM cells was shorter and steeper than that of WT, and the angle of D-q and q in KO-CD4(+) TEM cells was lower than that of WT, while these indexes showed few changes between WT and KO chimeric mice in the CD8(+)TCM population. Therefore, it indicated that the restriction on the TCRV beta repertoires is majorly in KO-CD4(+) TEM cells but not KO- CD8(+) TCM cells. Principal Component Analysis (PCA), a comprehensive parameter for TCRV beta diversity, successfully segregated CD4(+) TEM cells from WT and KO, but failed in CD8(+) TCM cells. Among the total sequences of TRB, the usage of TRBV12.2, TRBV30, TRBV31, TRBV4, TRBD1, TRBD2, TRBJ1.1, and TRBJ1.4 showed a significant difference between WT-CD4(+) TEM cells and KO-CD4(+) TEM cells (P <0.05), while in CD8(+) TCM cells, only the usage of TRBV12.2 and TRBV20 showed a substantial difference between WT and KO (P <0.05). No significant differences in the hydrophobicity and sequence length of TCRV beta were found between the WT and KO groups. ConclusionWASp deficiency selectively affected the TCR diversity of different memory T cell subsets, and it had more impact on the TCRV beta diversity of CD4(+) TEM cells than CD8(+) TCM cells. Moreover, the limitation of TCRV beta diversity of CD4(+) TEM cells and CD8(+) TCM cells in WAS was not severe but intrinsic.	[Li, Wenyan; Jia, Yanjun; Wang, Yanping; Zhao, Qin; Yang, Lu; Zeng, Ting; Niu, Linlin; Dai, Rongxin; Li, Yanan; Zhao, Xiaodong; Wu, Junfeng] Chongqing Med Univ, Childrens Hosp, Chongqing Key Lab Pediat, Key Lab Child Dev & Disorders,Chongqing Key Lab C, Chongqing, Peoples R China; [Dai, Rongxin; Li, Yanan; Wu, Junfeng] Chongqing Med Univ, Dept Rheumatol & Immunol, Childrens Hosp, Chongqing, Peoples R China	Chongqing Medical University; Chongqing Medical University	Zhao, XD; Wu, JF (corresponding author), Chongqing Med Univ, Childrens Hosp, Chongqing Key Lab Pediat, Key Lab Child Dev & Disorders,Chongqing Key Lab C, Chongqing, Peoples R China.; Wu, JF (corresponding author), Chongqing Med Univ, Dept Rheumatol & Immunol, Childrens Hosp, Chongqing, Peoples R China.	zhaoxd530@aliyun.com; junfengwu@hospital.cqmu.edu.cn			National Natural Science Foundation of China [81601438]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	Funding This work was supported by the National Natural Science Foundation of China (81601438).	Adriani M, 2007, CLIN IMMUNOL, V124, P41, DOI 10.1016/j.clim.2007.02.001; Bassing CH, 2002, CELL, V109, pS45, DOI 10.1016/S0092-8674(02)00675-X; Braun CJ, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007280; Britanova OV, 2014, J IMMUNOL, V192, P2689, DOI 10.4049/jimmunol.1302064; Burkhardt JK, 2008, ANNU REV IMMUNOL, V26, P233, DOI 10.1146/annurev.immunol.26.021607.090347; Candotti F, 2018, J CLIN IMMUNOL, V38, P13, DOI 10.1007/s10875-017-0453-z; Daley SR, 2019, J ALLERGY CLIN IMMUN, V144, P333, DOI 10.1016/j.jaci.2019.03.022; Davidson AJ, 2018, J CELL BIOL, V217, P701, DOI 10.1083/jcb.201705160; De Meester J, 2010, J LEUKOCYTE BIOL, V88, P1031, DOI 10.1189/jlb.0410197; Gomez-Tourino I, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01925-2; Hill TCJ, 2003, FEMS MICROBIOL ECOL, V43, P1, DOI 10.1111/j.1574-6941.2003.tb01040.x; Izraelson M, 2018, IMMUNOLOGY, V153, P133, DOI 10.1111/imm.12857; Kim AS, 2000, NATURE, V404, P151, DOI 10.1038/35004513; Lee YN, 2016, SCI IMMUNOL, V1, DOI 10.1126/sciimmunol.aah6109; Li D, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-1788-4; Mahlaoui N, 2013, BLOOD, V121, P1510, DOI 10.1182/blood-2012-08-448118; Massaad MJ, 2013, ANN NY ACAD SCI, V1285, P26, DOI 10.1111/nyas.12049; O'Connell AE, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00340; OCHS HD, 1980, BLOOD, V55, P243; PANNETIER C, 1993, P NATL ACAD SCI USA, V90, P4319, DOI 10.1073/pnas.90.9.4319; Park JY, 2004, CLIN EXP IMMUNOL, V136, P104, DOI 10.1111/j.1365-2249.2004.02409.x; Petersen SH, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00539; Stadinski BD, 2016, NAT IMMUNOL, V17, P946, DOI 10.1038/ni.3491; Strom TS, 2003, GENE THER, V10, P803, DOI 10.1038/sj.gt.3301950; Thrasher AJ, 2010, NAT REV IMMUNOL, V10, P182, DOI 10.1038/nri2724; Wada T, 2005, BLOOD, V106, P3895, DOI 10.1182/blood-2005-06-2336; Westerberg L, 2005, BLOOD, V105, P1144, DOI 10.1182/blood-2004-03-1003; Westerberg LS, 2008, BLOOD, V112, P4139, DOI 10.1182/blood-2008-02-140715; White JT, 2017, NAT REV IMMUNOL, V17, P391, DOI 10.1038/nri.2017.34; Woodsworth DJ, 2013, GENOME MED, V5, DOI 10.1186/gm502; Wu JF, 2015, J ALLERGY CLIN IMMUN, V135, P209, DOI 10.1016/j.jaci.2014.06.025; Zhang JY, 2009, IMMUNOL REV, V232, P175, DOI 10.1111/j.1600-065X.2009.00846.x; Zhang X, 2016, BLOOD, V127, P3180, DOI 10.1182/blood-2015-06-652636	33	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 18	2022	12								794795	10.3389/fimmu.2021.794795	http://dx.doi.org/10.3389/fimmu.2021.794795			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YV3GL	35116029	gold, Green Published			2022-12-18	WOS:000752619000001
J	Lin, JL; Lin, JX; Lin, JP; Zheng, CH; Li, P; Xie, JW; Wang, JB; Lu, J; Chen, QY; Huang, CM				Lin, Ju-Li; Lin, Jian-Xian; Lin, Jun Peng; Zheng, Chao-Hui; Li, Ping; Xie, Jian-Wei; Wang, Jia-bin; Lu, Jun; Chen, Qi-Yue; Huang, Chang-Ming			Safety and Efficacy of Camrelizumab in Combination With Nab-Paclitaxel Plus S-1 for the Treatment of Gastric Cancer With Serosal Invasion	FRONTIERS IN IMMUNOLOGY			English	Article						gastric cancer; camrelizumab (SHR-1210); neoadjuvant chemotherapy; tumor regression rate; pCR	OPEN-LABEL; CHEMOTHERAPY; REGRESSION; ADENOCARCINOMA; CLASSIFICATION; COMPLICATIONS; CAPECITABINE; OXALIPLATIN	ObjectiveTo investigate the safety and efficacy of camrelizumab in combination with nab-paclitaxel plus S-1 for the treatment of gastric cancer with serosal invasion. MethodTwo hundred patients with gastric cancer with serosal invasion who received neoadjuvant therapy from January 2012 to December 2020 were retrospectively analyzed. According to the different neoadjuvant therapy regimens, the patients were divided into the following three groups: the SOX group (S-1 + oxaliplatin) (72 patients), SAP group (S-1 + nab-paclitaxel) (95 patients) and C-SAP group (camrelizumab + S-1 + nab-paclitaxel) (33 patients). ResultThe pathological response (TRG 1a/1b) in the C-SAP group (39.4%) was not significantly different from that in the SAP group (26.3%) and was significantly higher than that in the SOX group (18.1%). The rate of ypT0 in the C-SAP group (24.2%) was higher than that in the SAP group (6.3%) and the SOX group (5.6%). The rate of ypN0 in the C-SAP group (66.7%) was also higher than that in the SAP group (38.9%) and the SOX group (36.1%). The rate of pCR in the C-SAP group (21.2%) was higher than that in the SAP group (5.3%) and the SOX group (2.8%). The use of an anti-PD-1 monoclonal antibody was an independent protective factor for TRG grade (1a/1b). The use of camrelizumab did not increase postoperative complications or the adverse effects of neoadjuvant therapy. ConclusionCamrelizumab combined with nab-paclitaxel plus S-1 could significantly improve the rate of tumor regression grade (TRG 1a/1b) and the rate of pCR in gastric cancer with serosal invasion.	[Lin, Ju-Li; Lin, Jian-Xian; Lin, Jun Peng; Zheng, Chao-Hui; Li, Ping; Xie, Jian-Wei; Wang, Jia-bin; Lu, Jun; Chen, Qi-Yue; Huang, Chang-Ming] Fujian Med Univ, Dept Gastr Surg, Union Hosp, Fuzhou, Peoples R China; [Lin, Ju-Li; Lin, Jian-Xian; Lin, Jun Peng; Zheng, Chao-Hui; Li, Ping; Xie, Jian-Wei; Wang, Jia-bin; Lu, Jun; Chen, Qi-Yue; Huang, Chang-Ming] Fujian Med Univ, Dept Gen Surg, Union Hosp, Fuzhou, Peoples R China; [Lin, Jian-Xian; Li, Ping; Wang, Jia-bin; Huang, Chang-Ming] Fujian Med Univ, Key Lab Gastrointestinal Canc, Minist Educ, Fuzhou, Peoples R China	Fujian Medical University; Fujian Medical University; Fujian Medical University	Huang, CM (corresponding author), Fujian Med Univ, Dept Gastr Surg, Union Hosp, Fuzhou, Peoples R China.; Huang, CM (corresponding author), Fujian Med Univ, Dept Gen Surg, Union Hosp, Fuzhou, Peoples R China.; Huang, CM (corresponding author), Fujian Med Univ, Key Lab Gastrointestinal Canc, Minist Educ, Fuzhou, Peoples R China.	hcmlr2002@163.com	Zheng, Chao-hui/HGE-3348-2022	Zheng, Chao-hui/0000-0001-8680-3127	Fujian Province innovation and entrepreneurship talents [2016B013]	Fujian Province innovation and entrepreneurship talents	& nbsp;The second batch of special support funds for Fujian Province innovation and entrepreneurship talents (2016B013).	Al-Batran SE, 2019, LANCET, V393, P1948, DOI 10.1016/S0140-6736(18)32557-1; Al-Batran SE, 2016, LANCET ONCOL, V17, P1697, DOI 10.1016/S1470-2045(16)30531-9; Becker K, 2003, CANCER-AM CANCER SOC, V98, P1521, DOI 10.1002/cncr.11660; Becker K, 2011, ANN SURG, V253, P934, DOI 10.1097/SLA.0b013e318216f449; CLAVIEN PA, 1992, SURGERY, V111, P518; Dindo D, 2004, ANN SURG, V240, P205, DOI 10.1097/01.sla.0000133083.54934.ae; Doescher J, 2017, HNO, V65, P956, DOI 10.1007/s00106-017-0391-3; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Fuchs CS, 2018, JAMA ONCOL, V4, DOI 10.1001/jamaoncol.2018.0013; Japanese Gastr Canc Assoc, 2021, GASTRIC CANCER, V24, P1, DOI [10.1007/s10120-020-01042-y, 10.1007/s10120-016-0622-4]; Ji J, 2019, ANN ONCOL, V30, P877; Jiang HP, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.3_suppl.211; Kang YK, 2017, LANCET, V390, P2461, DOI 10.1016/S0140-6736(17)31827-5; Li N, 2020, ANN ONCOL, V31, pS1302, DOI 10.1016/j.annonc.2020.10.181; Li ZY, 2019, JAMA SURG, V154, P1093, DOI 10.1001/jamasurg.2019.3473; Li ZY, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0189294; Liu Y, 2020, J CLIN ONCOL, V38; Sah BK, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19965-6; Shitara K, 2017, LANCET GASTROENTEROL, V2, P277, DOI 10.1016/S2468-1253(16)30219-9; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442	21	0	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 18	2022	12								783243	10.3389/fimmu.2021.783243	http://dx.doi.org/10.3389/fimmu.2021.783243			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZE8EV	35116023	Green Published, gold			2022-12-18	WOS:000759112300001
J	Liu, D; Lin, CR; Liu, BD; Qi, J; Wen, HQ; Tu, LD; Wei, QJ; Kong, QC; Xie, Y; Gu, JR				Liu, Dong; Lin, Churong; Liu, Budian; Qi, Jun; Wen, Huiquan; Tu, Liudan; Wei, Qiujing; Kong, Qingcong; Xie, Ya; Gu, Jieruo			Quantification of Fat Metaplasia in the Sacroiliac Joints of Patients With Axial Spondyloarthritis by Chemical Shift-Encoded MRI: A Diagnostic Trial	FRONTIERS IN IMMUNOLOGY			English	Article						axial spondyloarthritis; magnetic resonance imaging; fat metaplasia; chemical shift-encoded sequence; quantitative imaging	RESONANCE-IMAGING PREDICT; INFLAMMATORY LESIONS; CLASSIFICATION; SYNDESMOPHYTES; CRITERIA; SPINE	ObjectiveTo study the diagnostic performance of chemical shift-encoded MRI (CSE-MRI) in the diagnosis of axial spondyloarthritis (axSpA). MethodsCSE-MRI images were acquired for consecutive patients complaining of back pain as well as healthy volunteers. Proton density fat fraction (PDFF) values were measured independently by two readers. Diagnostic performance of CSE-MRI was analyzed by sensitivity analysis and ROC curve analysis. Logistic regression analysis was employed to investigate the risk factors of extensive fat deposition in the SIJs. ResultsA total of 52 r-axSpA patients, 37 nr-axSpA patients, 24 non-SpA patients and 34 healthy volunteers were included. Mean PDFF values in the SIJs of patients with r-axSpA and nr-axSpA (72.7% and 64.5%) were significantly higher than non-SpA patients and healthy volunteers (56.0% and 57.6%) (p<0.001). By defining extensive fat deposition in the SIJs as >= 8 ROIs with PDFF values over 70%, its sensitivity and specificity in diagnosing axSpA reached 72.47% and 86.21%%. By joining bone marrow edema (BME) with >= 8 ROIs (PDFF>70%), 22 (24.71%) and 23 (25.84%) more axSpA patients were classified as SIJ MRI (+) by reader 1 and 2, but specificities decreased by 15.52% and 10.34%. Multivariate logistic regression analysis confirmed longer disease duration as the independent risk factor of extensive fat deposition in SIJs (OR=1.15, 95%CI[1.03, 1.32]), while bDMARDs medication was a protective factor (OR=0.15, 95%CI[0.04, 0.51]). ConclusionCSE-MRI is a reliable tool to quantitively assess the fat metaplasia in the SIJs of axSpA patients. Extensive fat deposition in the SIJs could add incremental diagnostic value to BME, but at the cost of decreased specificities.	[Liu, Dong; Liu, Budian; Qi, Jun; Tu, Liudan; Wei, Qiujing; Xie, Ya; Gu, Jieruo] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Rheumatol, Guangzhou, Peoples R China; [Lin, Churong; Wen, Huiquan; Kong, Qingcong] Sun Yat Sen Univ, Affiliated Hosp 3, Radiol Dept, Guangzhou, Peoples R China	Sun Yat Sen University; Sun Yat Sen University	Gu, JR (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 3, Dept Rheumatol, Guangzhou, Peoples R China.	gujieruo@163.com						Bakker PAC, 2017, ANN RHEUM DIS, V76, P392, DOI 10.1136/annrheumdis-2016-209405; Baraliakos X, 2014, ANN RHEUM DIS, V73, P1819, DOI 10.1136/annrheumdis-2013-203425; Baraliakos X., 2021, ARTHRITIS RHEUMATOL, V73, P800, DOI DOI 10.1002/ART.41595; Baraliakos X, 2020, ANN RHEUM DIS, V79, P186, DOI 10.1136/annrheumdis-2019-215553; Boisserand LSB, 2017, J CEREBR BLOOD F MET, V37, P2196, DOI 10.1177/0271678X16662044; Bray TJP, 2020, EUR RADIOL, V30, P5099, DOI 10.1007/s00330-020-06785-x; Chiowchanwisawakit P, 2011, ARTHRITIS RHEUM-US, V63, P2215, DOI 10.1002/art.30393; Corrias G, 2018, CLIN IMAG, V52, P193, DOI 10.1016/j.clinimag.2018.08.002; D'Agostino MA, 2011, ANN RHEUM DIS, V70, P1433, DOI 10.1136/ard.2010.138701; d'Assignies G, 2018, EUR RADIOL, V28, P2022, DOI 10.1007/s00330-017-5106-3; Dougados M, 2018, ANN RHEUM DIS, V77, P221, DOI 10.1136/annrheumdis-2017-212008; Dougados M, 2012, RHEUMATOLOGY, V51, P1687, DOI 10.1093/rheumatology/kes125; Eskreis-Winkler S, 2018, CANCER IMAGING, V18, DOI 10.1186/s40644-018-0167-3; Franca M, 2020, ABDOM RADIOL, V45, P3400, DOI 10.1007/s00261-020-02574-8; Fukui H, 2019, EUR J RADIOL, V118, P25, DOI 10.1016/j.ejrad.2019.06.024; Haroon N, 2013, ARTHRITIS RHEUM-US, V65, P2645, DOI 10.1002/art.38070; Jimenez-Pastor A, 2021, EUR RADIOL, V31, P7876, DOI 10.1007/s00330-021-07838-5; Machado PM, 2016, ANN RHEUM DIS, V75, P1486, DOI 10.1136/annrheumdis-2015-208011; Maksymowych WP, 2017, RMD OPEN, V3, DOI 10.1136/rmdopen-2016-000399; Maksymowych WP, 2019, ANN RHEUM DIS, V78, P1550, DOI 10.1136/annrheumdis-2019-215589; Maksymowych WP, 2014, ARTHRITIS RHEUMATOL, V66, P2958, DOI 10.1002/art.38792; Maksymowych WP, 2009, ARTHRITIS RHEUM-US, V60, P93, DOI 10.1002/art.24132; Oppenheim C, 2001, STROKE, V32, P2486, DOI 10.1161/hs1101.098331; Rajlawot K, 2021, J MAGN RESON IMAGING, V53, P1791, DOI 10.1002/jmri.27539; Reeder SB, 2004, MAGNET RESON MED, V51, P35, DOI 10.1002/mrm.10675; Ren C, 2018, CLIN RHEUMATOL, V37, P3069, DOI 10.1007/s10067-018-4321-x; Rudwaleit M, 2009, ANN RHEUM DIS, V68, P1520, DOI 10.1136/ard.2009.110767; Rudwaleit M, 2009, ANN RHEUM DIS, V68, P777, DOI 10.1136/ard.2009.108233; Song IH, 2011, ANN RHEUM DIS, V70, P1257, DOI 10.1136/ard.2010.147033; Starekova J, 2021, RADIOLOGY, V301, P250, DOI 10.1148/radiol.2021204288; Tu LD, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.700260; Wang DD, 2020, SKELETAL RADIOL, V49, P1597, DOI 10.1007/s00256-020-03442-8; Xu L, 2018, EUR RADIOL, V28, P2003, DOI 10.1007/s00330-017-5189-x; Zeng ZL, 2021, J MAGN RESON IMAGING, V54, P1754, DOI 10.1002/jmri.27769; Zhang QH, 2021, QUANT IMAG MED SURG, V11, P2933, DOI 10.21037/qims-20-989	35	0	0	3	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 18	2022	12								811672	10.3389/fimmu.2021.811672	http://dx.doi.org/10.3389/fimmu.2021.811672			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YR5KV	35116037	gold, Green Published			2022-12-18	WOS:000750032000001
J	Mkrtchian, S; Ebberyd, A; Veerman, RE; Mendez-Lago, M; Gabrielsson, S; Eriksson, LI; Gomez-Galan, M				Mkrtchian, Souren; Ebberyd, Anette; Veerman, Rosanne E.; Mendez-Lago, Maria; Gabrielsson, Susanne; Eriksson, Lars I.; Gomez-Galan, Marta			Surgical Trauma in Mice Modifies the Content of Circulating Extracellular Vesicles	FRONTIERS IN IMMUNOLOGY			English	Article						circulating extracellular vesicles; surgery; proteomics; miRNA; alpha-synuclein	POSTOPERATIVE COGNITIVE DYSFUNCTION; ALPHA-SYNUCLEIN; PARKINSONS-DISEASE; SURGERY; EXOSOMES; PROTEIN; MECHANISMS; ANESTHESIA; EXPRESSION; BIOMARKERS	Surgical interventions rapidly trigger a cascade of molecular, cellular, and neural signaling responses that ultimately reach remote organs, including the brain. Using a mouse model of orthopedic surgery, we have previously demonstrated hippocampal metabolic, structural, and functional changes associated with cognitive impairment. However, the nature of the underlying signals responsible for such periphery-to-brain communication remains hitherto elusive. Here we present the first exploratory study that tests the hypothesis of extracellular vesicles (EVs) as potential mediators carrying information from the injured tissue to the distal organs including the brain. The primary goal was to investigate whether the cargo of circulating EVs after surgery can undergo quantitative changes that could potentially trigger phenotypic modifications in the target tissues. EVs were isolated from the serum of the mice subjected to a tibia surgery after 6, 24, and 72 h, and the proteome and miRNAome were investigated using mass spectrometry and RNA-seq approaches. We found substantial differential expression of proteins and miRNAs starting at 6 h post-surgery and peaking at 24 h. Interestingly, one of the up-regulated proteins at 24 h was alpha-synuclein, a pathogenic hallmark of certain neurodegenerative syndromes. Analysis of miRNA target mRNA and corresponding biological pathways indicate the potential of post-surgery EVs to modify the extracellular matrix of the recipient cells and regulate metabolic processes including fatty acid metabolism. We conclude that surgery alters the cargo of circulating EVs in the blood, and our results suggest EVs as potential systemic signal carriers mediating remote effects of surgery on the brain.	[Mkrtchian, Souren; Ebberyd, Anette; Eriksson, Lars I.; Gomez-Galan, Marta] Karolinska Inst, Sect Anesthesiol & Intens Care Med, Dept Physiol & Pharmacol, Stockholm, Sweden; [Veerman, Rosanne E.; Gabrielsson, Susanne] Dept Clin Immunol & Transfus Med, Solna, Sweden; [Veerman, Rosanne E.; Gabrielsson, Susanne] Dept Med, Div Immunol & Allergy, Solna, Sweden; [Veerman, Rosanne E.; Gabrielsson, Susanne] Karolinska Univ Hosp, Stockholm, Sweden; [Veerman, Rosanne E.; Gabrielsson, Susanne] Karolinska Inst, Stockholm, Sweden; [Mendez-Lago, Maria] Inst Mol Biol gGmbH IMB, Genom Core Facil, Mainz, Germany; [Eriksson, Lars I.] Karolinska Univ Hosp, Funct Perioperat Med & Intens Care, Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Institute of Molecular Biology (IMB); Karolinska Institutet; Karolinska University Hospital	Gomez-Galan, M (corresponding author), Karolinska Inst, Sect Anesthesiol & Intens Care Med, Dept Physiol & Pharmacol, Stockholm, Sweden.	marta.gomez@ki.se			Swedish Medical Research Council; Swedish Brain Foundation;  [INST 247/870-1 FUGG]	Swedish Medical Research Council(Swedish Medical Research Council (SMRC)); Swedish Brain Foundation; 	& nbsp;This work was funded by The Swedish Medical Research Council and The Swedish Brain Foundation.	Albacete-Albacete L, 2020, J CELL BIOL, V219, DOI 10.1083/jcb.202006178; Aparicio-Puerta E, 2019, NUCLEIC ACIDS RES, V47, pW530, DOI 10.1093/nar/gkz415; Askanas V, 2000, J NEUROPATH EXP NEUR, V59, P592, DOI 10.1093/jnen/59.7.592; Barbour R, 2008, NEURODEGENER DIS, V5, P55, DOI 10.1159/000112832; Bartel DP, 2018, CELL, V173, P20, DOI 10.1016/j.cell.2018.03.006; Brennan K, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-57497-7; Burre J, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a024091; Chen PL, 2014, BRIT J PSYCHIAT, V204, P188, DOI 10.1192/bjp.bp.112.119610; Eckenhoff RG, 2013, PROG NEURO-PSYCHOPH, V47, P162, DOI 10.1016/j.pnpbp.2012.06.011; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Eldh M, 2021, CANCERS, V13, DOI 10.3390/cancers13133242; Emmanouilidou E, 2010, J NEUROSCI, V30, P6838, DOI 10.1523/JNEUROSCI.5699-09.2010; Eriksson LI, 2019, ALZHEIMERS DEMENT, V15, P534, DOI 10.1016/j.jalz.2018.12.005; Femenia T, 2018, J NEUROSCI, V38, P452, DOI 10.1523/JNEUROSCI.1797-17.2017; Forsberg A, 2017, ANN NEUROL, V81, P572, DOI 10.1002/ana.24909; Glass CK, 2010, CELL, V140, P918, DOI 10.1016/j.cell.2010.02.016; Goedert M, 2001, NAT REV NEUROSCI, V2, P492, DOI 10.1038/35081564; Grey M, 2015, J BIOL CHEM, V290, P2969, DOI 10.1074/jbc.M114.585703; Johnson T, 2002, ANESTHESIOLOGY, V96, P1351, DOI 10.1097/00000542-200206000-00014; KOBAYASHI M, 1986, J INHERIT METAB DIS, V9, P301, DOI 10.1007/BF01799670; Kriegel AJ, 2012, PHYSIOL GENOMICS, V44, P237, DOI 10.1152/physiolgenomics.00141.2011; Lage C, 2021, J ALZHEIMERS DIS, V79, P863, DOI 10.3233/JAD-191229; Lang AE, 1998, NEW ENGL J MED, V339, P1044, DOI 10.1056/NEJM199810083391506; Li QX, 2002, J ALZHEIMERS DIS, V4, P309, DOI 10.3233/JAD-2002-4406; Maquart FX, 2014, PATHOL BIOL, V62, P91, DOI 10.1016/j.patbio.2014.02.007; Margraf A, 2020, ANESTH ANALG, V131, P1693, DOI 10.1213/ANE.0000000000005175; Matsumoto J, 2017, ACTA NEUROPATHOL COM, V5, DOI 10.1186/s40478-017-0470-4; Michell AW, 2005, NEUROSCI LETT, V381, P294, DOI 10.1016/j.neulet.2005.02.030; Moller JT, 1998, LANCET, V351, P857, DOI 10.1016/S0140-6736(97)07382-0; Monk TG, 2008, ANESTHESIOLOGY, V108, P18, DOI 10.1097/01.anes.0000296071.19434.1e; Ngolab J, 2020, ACTA NEUROPATHOL COM, V8, DOI 10.1186/s40478-020-01006-4; Pei Y, 2019, HELIYON, V5, DOI 10.1016/j.heliyon.2019.e02590; Perez-Riverol Y, 2019, NUCLEIC ACIDS RES, V47, pD442, DOI 10.1093/nar/gky1106; Pultz BD, 2017, INT J CANCER, V140, P2397, DOI 10.1002/ijc.30595; Rackov G, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00651; Ridder K, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001874; Schmid H, 2009, NEUROCHEM RES, V34, P581, DOI 10.1007/s11064-008-9825-3; Serrano-Pertierra E, 2019, BIOENGINEERING-BASEL, V6, DOI 10.3390/bioengineering6010008; Shi M, 2019, PROG NEUROBIOL, V175, P96, DOI 10.1016/j.pneurobio.2019.01.005; Shimaoka M, 2019, CANCERS, V11, DOI 10.3390/cancers11010106; Soler L, 2016, VET IMMUNOL IMMUNOP, V179, P26, DOI 10.1016/j.vetimm.2016.07.010; Stuendl A, 2016, BRAIN, V139, P481, DOI 10.1093/brain/awv346; Tang YT, 2017, INT J MOL MED, V40, P834, DOI 10.3892/ijmm.2017.3080; Terrando N, 2013, FASEB J, V27, P3564, DOI 10.1096/fj.13-230276; Terrando N, 2011, ANN NEUROL, V70, P986, DOI 10.1002/ana.22664; Terrando N, 2010, P NATL ACAD SCI USA, V107, P20518, DOI 10.1073/pnas.1014557107; Van Cromphaut SJ, 2009, BEST PRACT RES-CLIN, V23, P375, DOI 10.1016/j.bpa.2009.08.005; Van Deun J, 2017, NAT METHODS, V14, P228, DOI 10.1038/nmeth.4185; Veerman RE, 2021, J EXTRACELL VESICLES, V10, DOI 10.1002/jev2.12128; Veerman RE, 2019, TRENDS MOL MED, V25, P382, DOI 10.1016/j.molmed.2019.02.003; Vlachos IS, 2015, NUCLEIC ACIDS RES, V43, pW460, DOI 10.1093/nar/gkv403; Yanez-Mo M, 2015, J EXTRACELL VESICLES, V4, DOI 10.3402/jev.v4.27066; Yarana C, 2018, CLIN CANCER RES, V24, P1644, DOI 10.1158/1078-0432.CCR-17-2046; Zappulli V, 2016, J CLIN INVEST, V126, P1198, DOI 10.1172/JCI81134	54	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 18	2022	12								824696	10.3389/fimmu.2021.824696	http://dx.doi.org/10.3389/fimmu.2021.824696			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YV7CM	35116043	gold, Green Published			2022-12-18	WOS:000752884400001
J	Qiu, KL; Zeng, TS; Liao, YF; Min, J; Zhang, N; Peng, MM; Kong, W; Chen, LL				Qiu, Kangli; Zeng, Tianshu; Liao, Yunfei; Min, Jie; Zhang, Nan; Peng, Miaomiao; Kong, Wen; Chen, Lu-Lu			Identification of Inflammation-Related Biomarker Pro-ADM for Male Patients With Gout by Comprehensive Analysis	FRONTIERS IN IMMUNOLOGY			English	Article						gout; pro-ADM; comprehensive analysis; inflammation; biomarker	ADRENOMEDULLIN PRODUCTION; PLASMA ADRENOMEDULLIN; GENETIC ASSOCIATION; PREVALENCE; PROGNOSIS; INTERLEUKIN-8; CHALLENGES; PREVENTION; MANAGEMENT; DIAGNOSIS	ObjectiveGout is a local inflammatory disease caused by the deposition of monosodium urate (MSU) crystals in joints or adjacent tissues. When some gout occurs without hyperuricemia, or its clinical symptoms and signs are not typical, the diagnosis of gout will be delayed, so there is an urgent need to find a new biomarker to predict and diagnose of gout flare. Our research attempts to find the key genes and potential molecular mechanisms of gout through bioinformatics analysis, and collected general data and blood biochemical samples of patients with gout and healthy, then analyzed and compared the expression of factors regulated by key genes. MethodGSE160170 were downloaded from GEO database for analysis. The data were normalized to identify the differentially expressed genes (DEGs), then GO and KEGG enrichment analysis were applied. Protein-protein interaction (PPI) networks and hub genes between DEGs were identified. Then collect general information and blood samples from male patients with acute gout, hyperuricemia and healthy. ELISA method was used to detect pro-ADM levels of different groups, and the data was input into SPSS statistical software for analysis. ResultWe identified 266 DEGs (179 up-regulated and 87 down-regulated) between gout patients and healthy controls. GO analysis results show that DEGs are mostly enriched in inflammatory response, growth factor activity, cytokine activity, chemokine activity, S100 protein binding and CXCR chemokine receptor binding. KEGG pathway analysis showed that DEGs are mainly related to Chemokine signaling pathway and Cytokine-cytokine receptor interaction. ADM, CXCR1, CXCR6, CXCL3, CCL3, CCL18, CCL3L3, CCL4L1, CD69, CD83, AREG, EREG, B7RP1, HBEGF, NAMPT and S100B are the most important hub genes in the PPI network. We found that the expression of pro-ADM in the gout group and hyperuricemia group was higher than that in the healthy group, and the difference was statistically significant. ConclusionIn this study, a series of bioinformatics analyses were performed on DEGs to identify key genes and pathways related to gout. Through clinical verification, we found that pro-ADM can be used as an inflammation-related biomarker for acute attacks of gout, providing new ideas for the diagnosis and treatment of gout.	[Qiu, Kangli; Zeng, Tianshu; Liao, Yunfei; Min, Jie; Zhang, Nan; Peng, Miaomiao; Kong, Wen; Chen, Lu-Lu] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Endocrinol, Wuhan, Peoples R China; [Qiu, Kangli; Zeng, Tianshu; Liao, Yunfei; Min, Jie; Zhang, Nan; Peng, Miaomiao; Kong, Wen; Chen, Lu-Lu] Hubei Prov Clin Res Ctr Diabet & Metab Disorders, Wuhan, Peoples R China	Huazhong University of Science & Technology	Kong, W; Chen, LL (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Endocrinol, Wuhan, Peoples R China.; Kong, W; Chen, LL (corresponding author), Hubei Prov Clin Res Ctr Diabet & Metab Disorders, Wuhan, Peoples R China.	wenly-kong@163.com; cheria_chen@126.com						Angeletti S, 2016, J INFECTION, V72, P395, DOI 10.1016/j.jinf.2015.12.006; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Bai XS, 2020, RHEUMATOLOGY, V59, P2872, DOI 10.1093/rheumatology/keaa046; Bhole V, 2010, ARTHRITIS RHEUM-US, V62, P1069, DOI 10.1002/art.27338; Campion E W, 1987, Am J Med, V82, P421, DOI 10.1016/0002-9343(87)90441-4; Chen YH, 2011, ANN RHEUM DIS, V70, P1655, DOI 10.1136/ard.2010.145821; Chen-Xu M, 2019, ARTHRITIS RHEUMATOL, V71, P991, DOI 10.1002/art.40807; Cho YN, 2020, RHEUMATOLOGY, V59, P2124, DOI 10.1093/rheumatology/keaa020; Dalbeth N, 2021, LANCET, V397, P1843, DOI 10.1016/S0140-6736(21)00569-9; Dalbeth N, 2016, LANCET, V388, P2039, DOI 10.1016/S0140-6736(16)00346-9; Dehlin M, 2016, ARTHRITIS RES THER, V18, DOI 10.1186/s13075-016-1062-6; Deng L, 2010, BBA-REV CANCER, V1806, P42, DOI 10.1016/j.bbcan.2010.01.004; Elliot AJ, 2009, ANN RHEUM DIS, V68, P1728, DOI 10.1136/ard.2008.096693; HACHICHA M, 1995, J EXP MED, V182, P2019, DOI 10.1084/jem.182.6.2019; Hainer BL, 2014, AM FAM PHYSICIAN, V90, P831; Isumi Y, 1998, ENDOCRINOLOGY, V139, P838, DOI 10.1210/en.139.3.838; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; Kharche S, 2021, PLOS COMPUT BIOL, V17, DOI 10.1371/journal.pcbi.1008593; Kienhorst LBE, 2015, ARTHRITIS RHEUMATOL, V67, P3303, DOI 10.1002/art.39318; Kim JW, 2017, RHEUMATOL INT, V37, P1499, DOI 10.1007/s00296-017-3768-4; KITAMURA K, 1993, BIOCHEM BIOPH RES CO, V192, P553, DOI 10.1006/bbrc.1993.1451; KITAMURA K, 1993, BIOCHEM BIOPH RES CO, V194, P720, DOI 10.1006/bbrc.1993.1881; Kitamura K, 1998, BIOCHEM BIOPH RES CO, V244, P551, DOI 10.1006/bbrc.1998.8310; Kubo A, 1998, FEBS LETT, V426, P233, DOI 10.1016/S0014-5793(98)00349-4; Kuo CF, 2015, ANN RHEUM DIS, V74, P661, DOI 10.1136/annrheumdis-2013-204463; La Porta CAM, 2012, STEM CELL REV REP, V8, P1282, DOI 10.1007/s12015-012-9383-6; Limou S, 2010, J INFECT DIS, V202, P908, DOI 10.1086/655782; Liu L, 2016, ARTHRITIS RES THER, V18, DOI 10.1186/s13075-016-1167-y; Liu Q, 2016, CYTOKINE GROWTH F R, V31, P61, DOI 10.1016/j.cytogfr.2016.08.002; Nagaya N, 1999, HEART, V81, P483, DOI 10.1136/hrt.81.5.483; Ntanasis-Stathopoulos I, 2020, ADV EXP MED BIOL, V1231, P13, DOI 10.1007/978-3-030-36667-4_2; Perez-Mazliah D, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00295; Pio R, 2001, J BIOL CHEM, V276, P12292, DOI 10.1074/jbc.M007822200; Popa-Nita O, 2010, IMMUNOL CELL BIOL, V88, P32, DOI 10.1038/icb.2009.98; Pousset F, 2000, EUR HEART J, V21, P1009, DOI 10.1053/euhj.1999.1904; Rai SK, 2017, SEMIN ARTHRITIS RHEU, V46, P451, DOI 10.1016/j.semarthrit.2016.08.006; Ruth JH, 2010, ARTHRITIS RHEUM-US, V62, P2536, DOI 10.1002/art.27518; Singh JA, 2017, ARTHRIT CARE RES, V69, P1724, DOI 10.1002/acr.23202; Singh JA, 2011, CURR OPIN RHEUMATOL, V23, P192, DOI 10.1097/BOR.0b013e3283438e13; So AK, 2017, NAT REV RHEUMATOL, V13, P639, DOI 10.1038/nrrheum.2017.155; SUGO S, 1995, BIOCHEM BIOPH RES CO, V207, P25, DOI 10.1006/bbrc.1995.1148; ter Horst R, 2016, CELL, V167, P1111, DOI 10.1016/j.cell.2016.10.018; Tin A, 2019, NAT GENET, V51, P1459, DOI 10.1038/s41588-019-0504-x; Voors AA, 2019, EUR J HEART FAIL, V21, P163, DOI 10.1002/ejhf.1366; Wang WQ, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-006843; Wang YG, 2020, CENT EUR J IMMUNOL, V45, P80, DOI 10.5114/ceji.2020.94702; Wang Y, 2019, J CLIN LAB ANAL, V33, DOI 10.1002/jcla.22868; WASHIMINE H, 1994, BIOCHEM BIOPH RES CO, V202, P1081, DOI 10.1006/bbrc.1994.2039; Ye Y, 2018, BIOMED PHARMACOTHER, V107, P1142, DOI 10.1016/j.biopha.2018.07.077	49	0	0	4	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 18	2022	12								798719	10.3389/fimmu.2021.798719	http://dx.doi.org/10.3389/fimmu.2021.798719			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2C4YS	35116032	Green Published, gold			2022-12-18	WOS:000810876500001
J	Chen, X; Liu, F; Zheng, BY; Kang, XH; Wang, XL; Mou, WJ; Zhang, H; Jiao, AX; Zhao, SY; Gui, JA				Chen, Xi; Liu, Fang; Zheng, Baoying; Kang, Xiaohui; Wang, Xiaolin; Mou, Wenjun; Zhang, Hui; Jiao, Anxia; Zhao, Shunying; Gui, Jingang			Exhausted and Apoptotic BALF T Cells in Proinflammatory Airway Milieu at Acute Phase of Severe Mycoplasma Pneumoniae Pneumonia in Children	FRONTIERS IN IMMUNOLOGY			English	Article						mycoplasma pneumoniae pneumonia (MPP); children; bronchoalveolar lavage fluid (BALF); T cells; proinflammatory milieu; cell exhaustion		Severe mycoplasma pneumoniae pneumonia (MPP) in children presents with serious clinical complications. Without proper and prompt intervention, it could lead to deadly consequences. Dynamics of the inflammatory airway milieu and activation status of immune cells were believed to be the hallmark of the pathogenesis and progress of the disease. In this study, by employing the T-cell sorting and mRNA microarray, we were able to define the main feature of the chemokine/cytokine expression and the unique characteristics of T cells in the bronchoalveolar lavage fluid (BALF) from severe MPP patients at acute phase. Our study for the first time delineated the molecular changes in isolated BALF T cells in severe MPP children with respect to the cytokine/chemokine expression, cell activation, exhaustion, and apoptosis. By comparing the BALF aqueous expression of cytokines/chemokines with that in sorted T cells, our data give a preliminary clue capable of finishing out the possible cell source of the proinflammatory cytokines/chemokines from the BALF mixture. Meanwhile, our data provide a distinctively pellucid expression profile particularly belonging to the isolated BALF T cells demonstrating that in the inflammatory airway, overactivated T cells were exhausted and on the verge of apoptotic progress.	[Chen, Xi; Wang, Xiaolin; Mou, Wenjun; Zhang, Hui; Gui, Jingang] Capital Med Univ, Beijing Pediat Res Inst, Natl Ctr Childrens Hlth, Beijing Childrens Hosp,Lab Tumor Immunol, Beijing, Peoples R China; [Liu, Fang; Jiao, Anxia] Capital Med Univ, Natl Clin Res Ctr Resp Dis, Beijing Childrens Hosp, Dept Intervent Pulmonol,Natl Ctr Childrens Hlth, Beijing, Peoples R China; [Zheng, Baoying; Kang, Xiaohui] Childrens Hosp, Dept Pulmonol, Capital Inst Pediat, Beijing, Peoples R China; [Zhao, Shunying] Capital Med Univ, Natl Clin Res Ctr Resp Dis, Natl Ctr Childrens Hlth, Dept Resp Dis,Beijing Childrens Hosp, Beijing, Peoples R China	Capital Medical University; Capital Medical University; Capital Institute of Pediatrics (CIP); Capital Medical University	Gui, JA (corresponding author), Capital Med Univ, Beijing Pediat Res Inst, Natl Ctr Childrens Hlth, Beijing Childrens Hosp,Lab Tumor Immunol, Beijing, Peoples R China.; Jiao, AX (corresponding author), Capital Med Univ, Natl Clin Res Ctr Resp Dis, Beijing Childrens Hosp, Dept Intervent Pulmonol,Natl Ctr Childrens Hlth, Beijing, Peoples R China.; Zhao, SY (corresponding author), Capital Med Univ, Natl Clin Res Ctr Resp Dis, Natl Ctr Childrens Hlth, Dept Resp Dis,Beijing Childrens Hosp, Beijing, Peoples R China.	anxiajiao@aliyun.com; zhaoshunying2001@163.com; guijingang@bch.com.cn	Gui, Jingang/GPW-6809-2022	Gui, Jingang/0000-0003-3431-8749				Appay V, 2001, TRENDS IMMUNOL, V22, P83, DOI 10.1016/S1471-4906(00)01812-3; Chen ZR, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1555-6; Gao M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01403; Guo L, 2015, PEDIATR PULM, V50, P814, DOI 10.1002/ppul.23095; Jin XQ, 2018, EXP THER MED, V16, P5025, DOI 10.3892/etm.2018.6873; Kaur D, 2021, CLIN TRANSL IMMUNOL, V10, DOI 10.1002/cti2.1301; Koh YY, 2001, PEDIATRICS, V107, DOI 10.1542/peds.107.3.e39; Kurai D, 2013, INFLAMMATION, V36, P285, DOI 10.1007/s10753-012-9545-3; Kutty PK, 2019, CLIN INFECT DIS, V68, P5, DOI 10.1093/cid/ciy419; Martin-Leal A, 2020, EMBO J, V39, DOI 10.15252/embj.2020104749; Matsuo K, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02775; Murai H, 2015, BIOCHEM BIOPH RES CO, V464, P969, DOI 10.1016/j.bbrc.2015.05.076; Odeh AN, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155648; Panisova E, 2021, AM J RESP CELL MOL, V64, P143, DOI 10.1165/rcmb.2020-0237LE; Rivino L, 2010, J EXP MED, V207, P565, DOI 10.1084/jem.20091021; Saraya T, 2014, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00410; Wang XC, 2019, J HEPATOL, V71, P731, DOI 10.1016/j.jhep.2019.05.015; Wang Y, 2018, CAN RESPIR J, V2018, DOI 10.1155/2018/8354892; Wherry EJ, 2011, NAT IMMUNOL, V12, P492, DOI 10.1038/ni.2035; Xu P, 2021, J NEUROINFLAMM, V18, DOI 10.1186/s12974-021-02115-0; Yang MY, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-54313-9; Zhan YF, 2020, CELL MOL IMMUNOL, V17, P123, DOI 10.1038/s41423-018-0187-8; Zhao J, 2020, BMC INFECT DIS, V20, DOI 10.1186/s12879-020-05017-3	23	0	0	4	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 17	2022	12								760488	10.3389/fimmu.2021.760488	http://dx.doi.org/10.3389/fimmu.2021.760488			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YT3KL	35111152	gold, Green Published			2022-12-18	WOS:000751262500001
J	Chen, Y; Chen, DD; Wang, Q; Xu, YJ; Huang, XW; Haglund, F; Su, HF				Chen, Yi; Chen, Didi; Wang, Qiang; Xu, Yajing; Huang, Xiaowei; Haglund, Felix; Su, Huafang			Immunological Classification of Pancreatic Carcinomas to Identify Immune Index and Provide a Strategy for Patient Stratification	FRONTIERS IN IMMUNOLOGY			English	Article						pancreatic ductal adenocarcinoma (PDAC); immune characteristics; immune subtypes; immune index; immunotherapy	CGAS-STING PATHWAY; CYCLIC GMP-AMP; ALTERNATIVE POLYADENYLATION; CANCER-IMMUNOTHERAPY; DENDRITIC CELLS; I INTERFERONS; RNA; INFLAMMATION; COMBINATION; RESISTANCE	Background: Cancer immunotherapy has produced significant positive clinical effects in a variety of tumor types. However, pancreatic ductal adenocarcinoma (PDAC) is widely considered to be a "cold" cancer with poor immunogenicity. Our aim is to determine the detailed immune features of PDAC to seek new treatment strategies. Methods: The immune cell abundance of PDAC patients was evaluated with the single-sample gene set enrichment analysis (ssGSEA) using 119 immune gene signatures. Based on these data, patients were classified into different immune subtypes (ISs) according to immune gene signatures. We analyzed their response patterns to immunotherapy in the datasets, then established an immune index to reflect the different degrees of immune infiltration through linear discriminant analysis (LDA). Finally, potential prognostic markers associated with the immune index were identified based on weighted correlation network analysis (WGCNA) that was functionally validated in vitro. Results: Three ISs were identified in PDAC, of which IS3 had the best prognosis across all three cohorts. The different expressions of immune profiles among the three ISs indicated a distinct responsiveness to immunotherapies in PDAC subtypes. By calculating the immune index, we found that the IS3 represented higher immune infiltration, while IS1 represented lower immune infiltration. Among the investigated signatures, we identified ZNF185, FANCG, and CSTF2 as risk factors associated with immune index that could potentially facilitate diagnosis and could be therapeutic target markers in PDAC patients. Conclusions: Our findings identified immunologic subtypes of PDAC with distinct prognostic implications, which allowed us to establish an immune index to represent the immune infiltration in each subtype. These results show the importance of continuing investigation of immunotherapy and will allow clinical workers to personalized treatment more effectively in PDAC patients.	[Chen, Yi; Haglund, Felix] Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden; [Chen, Yi; Haglund, Felix] Karolinska Univ Hosp Solna, Clin Pathol & Canc Diagnost, Stockholm, Sweden; [Chen, Didi; Xu, Yajing; Huang, Xiaowei; Su, Huafang] Wenzhou Med Univ, Dept Radiat Oncol, Affiliated Hosp 1, Wenzhou, Peoples R China; [Wang, Qiang] Karolinska Inst, Dept Clin Sci Intervent & Technol CLINTEC, Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; Wenzhou Medical University; Karolinska Institutet	Su, HF (corresponding author), Wenzhou Med Univ, Dept Radiat Oncol, Affiliated Hosp 1, Wenzhou, Peoples R China.	suhuafang@wzhospital.cn	wang, qiang/AAE-3761-2022; Wang, Qiang/GQH-9795-2022	wang, qiang/0000-0001-6686-6630; Wang, Qiang/0000-0001-6686-6630	ZheJiang Province Public Welfare Technology Application Research Project [2021KY782]; Wenzhou Municipal Science and Technology Bureau [Y2020151]	ZheJiang Province Public Welfare Technology Application Research Project; Wenzhou Municipal Science and Technology Bureau	This work was supported by the ZheJiang Province Public Welfare Technology Application Research Project (number 2021KY782) and the Wenzhou Municipal Science and Technology Bureau (number Y2020151).	Aragaki M, 2011, CLIN CANCER RES, V17, P5889, DOI 10.1158/1078-0432.CCR-11-0240; Bai F, 2019, AGING-US, V11, P9328, DOI 10.18632/aging.102373; Bailey P, 2016, NATURE, V531, P47, DOI 10.1038/nature16965; Balachandran VP, 2019, GASTROENTEROLOGY, V156, P2056, DOI 10.1053/j.gastro.2018.12.038; Blaauboer A, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-07420-0; Booy S, 2014, J CELL MOL MED, V18, P492, DOI 10.1111/jcmm.12200; Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694; Cerboni S, 2017, J EXP MED, V214, P1769, DOI 10.1084/jem.20161674; Charoentong P, 2017, CELL REP, V18, P248, DOI 10.1016/j.celrep.2016.12.019; Chen DS, 2013, IMMUNITY, V39, P1, DOI 10.1016/j.immuni.2013.07.012; Chen DT, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133562; Chen PL, 2016, CANCER DISCOV, V6, P827, DOI 10.1158/2159-8290.CD-15-1545; Chen Q, 2016, NAT IMMUNOL, V17, P1142, DOI 10.1038/ni.3558; Cho C, 2020, ONCOGENE, V39, P6129, DOI 10.1038/s41388-020-01424-7; Collisson EA, 2019, NAT REV GASTRO HEPAT, V16, P207, DOI 10.1038/s41575-019-0109-y; Crusz SM, 2015, NAT REV CLIN ONCOL, V12, P584, DOI 10.1038/nrclinonc.2015.105; Danilova L, 2019, CANCER IMMUNOL RES, V7, P886, DOI 10.1158/2326-6066.CIR-18-0822; de Santiago I, 2019, INT J CANCER, V145, P1125, DOI 10.1002/ijc.32186; Fang Y, 2020, J ONCOL, V2020, DOI 10.1155/2020/3181596; GIOVARELLI M, 1986, INT J CANCER, V37, P141, DOI 10.1002/ijc.2910370122; Guthrie GJK, 2013, CRIT REV ONCOL HEMAT, V88, P218, DOI 10.1016/j.critrevonc.2013.03.010; Hanzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-7; Hu QJ, 2021, CANCER MED-US, V10, P3129, DOI 10.1002/cam4.3828; Jang JE, 2017, CELL REP, V20, P558, DOI 10.1016/j.celrep.2017.06.062; Jiang P, 2018, NAT MED, V24, P1550, DOI 10.1038/s41591-018-0136-1; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; Kwon J, 2020, CANCER DISCOV, V10, P26, DOI 10.1158/2159-8290.CD-19-0761; Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-559; Larkin J, 2015, NEW ENGL J MED, V373, P23, DOI [10.1056/NEJMoa1504030, 10.1056/NEJMc1509660]; Li JY, 2018, IMMUNITY, V49, P178, DOI 10.1016/j.immuni.2018.06.006; Li TJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep19049; Ma J, 2020, AGING-US, V12, P22152, DOI 10.18632/aging.104083; Macherla S, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113505; Mackenzie KJ, 2017, NATURE, V548, P461, DOI 10.1038/nature23449; Mahoney KM, 2015, NAT REV DRUG DISCOV, V14, P561, DOI 10.1038/nrd4591; Makohon-Moore A, 2016, NAT REV CANCER, V16, P553, DOI 10.1038/nrc.2016.66; Mariathasan S, 2018, NATURE, V554, P544, DOI 10.1038/nature25501; Masiero M, 2013, CANCER CELL, V24, P229, DOI 10.1016/j.ccr.2013.06.004; Morak MJM, 2011, EUR J CANCER, V47, P1938, DOI 10.1016/j.ejca.2011.03.009; Morrison AH, 2018, TRENDS CANCER, V4, P418, DOI 10.1016/j.trecan.2018.04.001; Motwani M, 2019, NAT REV GENET, V20, P657, DOI 10.1038/s41576-019-0151-1; Neoptolemos JP, 2018, NAT REV GASTRO HEPAT, V15, P332, DOI 10.1038/s41575-018-0005-x; Netanely D, 2021, ONCOGENE, V40, P1792, DOI 10.1038/s41388-021-01665-0; Newman AM, 2015, NAT METHODS, V12, P453, DOI [10.1038/NMETH.3337, 10.1038/nmeth.3337]; O'Reilly EM, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.4_suppl.217; Pergamo M, 2017, CANCER GENE THER, V24, P100, DOI 10.1038/cgt.2016.65; Perriere G, 2003, COMPUT METH PROG BIO, V70, P99, DOI 10.1016/S0169-2607(02)00011-1; Petersen GM, 2015, HEMATOL ONCOL CLIN N, V29, P641, DOI 10.1016/j.hoc.2015.04.007; Piehler J, 2012, IMMUNOL REV, V250, P317, DOI 10.1111/imr.12001; Pourshams A, 2019, LANCET GASTROENTEROL, V4, P934, DOI 10.1016/S2468-1253(19)30347-4; Reck M, 2016, NEW ENGL J MED, V375, P1823, DOI 10.1056/NEJMoa1606774; Riaz N, 2017, CELL, V171, P934, DOI 10.1016/j.cell.2017.09.028; Ribas A, 2018, SCIENCE, V359, P1350, DOI 10.1126/science.aar4060; Rody A, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2234; Rooney MS, 2015, CELL, V160, P48, DOI 10.1016/j.cell.2014.12.033; Royal RE, 2010, J IMMUNOTHER, V33, P828, DOI 10.1097/CJI.0b013e3181eec14c; Shacter E, 2002, ONCOLOGY-NY, V16, P217; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Siddiqi MH, 2015, IEEE T IMAGE PROCESS, V24, P1386, DOI 10.1109/TIP.2015.2405346; Siegel RL, 2021, CA-CANCER J CLIN, V71, P7, DOI 10.3322/caac.21654; Smirnov A, 2018, AGING-US, V10, P3308, DOI 10.18632/aging.101639; Sun LJ, 2013, SCIENCE, V339, P786, DOI 10.1126/science.1232458; Takahashi H, 2020, CANCERS, V12, DOI 10.3390/cancers12051221; Triulzi T, 2018, BRIT J CANCER, V119, P1487, DOI 10.1038/s41416-018-0318-0; Wang ZL, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01756; Wang ZN, 2019, J CLIN INVEST, V129, P4850, DOI 10.1172/JCI127471; Wilkerson MD, 2010, BIOINFORMATICS, V26, P1572, DOI 10.1093/bioinformatics/btq170; Winograd R, 2015, CANCER IMMUNOL RES, V3, P399, DOI 10.1158/2326-6066.CIR-14-0215; Wu JX, 2013, SCIENCE, V339, P826, DOI 10.1126/science.1229963; Xia Z, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6274; Yang SH, 2016, CANCER RES, V76, P3838, DOI 10.1158/0008-5472.CAN-15-2841; Yoshihara K, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3612; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Zeng DQ, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.687975; Zhang G, 2013, CLIN CANCER RES, V19, P4983, DOI 10.1158/1078-0432.CCR-13-0209; Zhang HF, 2015, CANCER IMMUNOL RES, V3, P196, DOI 10.1158/2326-6066.CIR-14-0177; Zhang SR, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-1986-0	77	0	0	2	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 17	2022	12								719105	10.3389/fimmu.2021.719105	http://dx.doi.org/10.3389/fimmu.2021.719105			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1F8OS	35111149	Green Published, gold			2022-12-18	WOS:000795421900001
J	Dietz, S; Schwarz, J; Velic, A; Gonzalez-Menendez, I; Quintanilla-Martinez, L; Casadei, N; Marme, A; Poets, CF; Gille, C; Koestlin-Gille, N				Dietz, Stefanie; Schwarz, Julian; Velic, Ana; Gonzalez-Menendez, Irene; Quintanilla-Martinez, Leticia; Casadei, Nicolas; Marme, Alexander; Poets, Christian F.; Gille, Christian; Koestlin-Gille, Natascha			Human Leucocyte Antigen G and Murine Qa-2 Are Critical for Myeloid Derived Suppressor Cell Expansion and Activation and for Successful Pregnancy Outcome	FRONTIERS IN IMMUNOLOGY			English	Article						HLA-G; Qa-2; pregnancy; myeloid-derived suppressor cells; abortion; preeclampsia	HLA-G; T-CELL; EXTRAVILLOUS TROPHOBLASTS; G EXPRESSION; G GENOTYPE; GENE; MOUSE; PREECLAMPSIA; MICE; TOLERANCE	During pregnancy, maternal immune system has to balance tightly between protection against pathogens and tolerance towards a semi-allogeneic organism. Dysfunction of this immune adaptation can lead to severe complications such as pregnancy loss, preeclampsia or fetal growth restriction. In the present study we analyzed the impact of the murine MHC class Ib molecule Qa-2 on pregnancy outcome in vivo. We demonstrate that lack of Qa-2 led to intrauterine growth restriction and increased abortion rates especially in late pregnancy accompanied by a disturbed trophoblast invasion and altered spiral artery remodeling as well as protein aggregation in trophoblast cells indicating a preeclampsia-like phenotype. Furthermore, lack of Qa-2 caused imbalanced immunological adaptation to pregnancy with altered immune cell and especially T-cell homeostasis, reduced T-reg numbers and decreased accumulation and functional activation of myeloid-derived suppressor cells. Lastly, we show that application of sHLA-G reduced abortion rates in Qa-2 deficient mice by inducing MDSC. Our results highlight the importance of an interaction between HLA-G and MDSC for pregnancy success and the therapeutic potential of HLA-G for treatment of immunological pregnancy complications.	[Dietz, Stefanie; Schwarz, Julian; Poets, Christian F.; Gille, Christian; Koestlin-Gille, Natascha] Tuebingen Univ Childrens Hosp, Dept Neonatol, Tubingen, Germany; [Velic, Ana] Univ Tubingen, Interfac Inst Cell Biol, Proteome Ctr Tuebingen PCT, Tubingen, Germany; [Gonzalez-Menendez, Irene; Quintanilla-Martinez, Leticia] Univ Tubingen, Dept Pathol, Tubingen, Germany; [Casadei, Nicolas] Next Generat Sequencing NGS Competence Ctr Tuebin, Tubingen, Germany; [Casadei, Nicolas] Univ Tubingen, Inst Med Genet & Appl Gen, Tubingen, Germany; [Marme, Alexander] Gynecol & Obstet Practice, Tubingen, Germany; [Gille, Christian; Koestlin-Gille, Natascha] Heidelberg Univ Childrens Hosp, Dept Neonatol, Heidelberg, Germany	Eberhard Karls University of Tubingen; TUBINGEN UNIVERSITY CHILDRENS HOSPITAL; Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Eberhard Karls University of Tubingen	Koestlin-Gille, N (corresponding author), Tuebingen Univ Childrens Hosp, Dept Neonatol, Tubingen, Germany.; Koestlin-Gille, N (corresponding author), Heidelberg Univ Childrens Hosp, Dept Neonatol, Heidelberg, Germany.	natascha.koestlin@med.uni-tuebingen.de			Ministerium fuer Wissenschaft, Forschung und Kunst Baden-Wuerttemberg and the European Social Fund and the Deutsche Forschungsgemeinschaft (DFG) [GI 1094/4-1, GI 1094/4-2]	Ministerium fuer Wissenschaft, Forschung und Kunst Baden-Wuerttemberg and the European Social Fund and the Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG))	This work was supported by research grants of the Ministerium fuer Wissenschaft, Forschung und Kunst Baden-Wuerttemberg and the European Social Fund and the Deutsche Forschungsgemeinschaft (DFG) (Grants no. GI 1094/4-1 and GI 1094/4-2).	Agaugue S, 2011, BLOOD, V117, P7021, DOI 10.1182/blood-2010-07-294389; Aluvihare VR, 2004, NAT IMMUNOL, V5, P266, DOI 10.1038/ni1037; Ander SE, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aat6114; Arenas-Hernandez M, 2019, J IMMUNOL, V202, P2585, DOI 10.4049/jimmunol.1801350; Borchert N, 2010, GENOME RES, V20, P837, DOI 10.1101/gr.103119.109; Buhimschi IA, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008808; Byers SL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035538; Byrne MJ, 2007, MAMM GENOME, V18, P767, DOI 10.1007/s00335-007-9067-8; Cai WY, 1996, IMMUNOGENETICS, V45, P97, DOI 10.1007/s002510050177; Cater JH, 2019, P NATL ACAD SCI USA, V116, P6101, DOI 10.1073/pnas.1817298116; Comiskey M, 2003, HUM IMMUNOL, V64, P999, DOI 10.1016/j.humimm.2003.08.352; Contini P, 2003, EUR J IMMUNOL, V33, P125, DOI 10.1002/immu.200390015; Corzo CA, 2010, J EXP MED, V207, P2439, DOI 10.1084/jem.20100587; Cui YJ, 2012, NATURE, V484, P246, DOI 10.1038/nature10897; da Silva IL, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02894; Dietz S, 2019, PEDIATR RES, V86, P608, DOI 10.1038/s41390-019-0504-7; Du MY, 2018, CLIN CHIM ACTA, V486, P341, DOI 10.1016/j.cca.2018.08.024; Emmery J, 2017, J REPROD IMMUNOL, V120, P8, DOI 10.1016/j.jri.2017.02.002; Exley GE, 1999, IMMUNOGENETICS, V49, P653, DOI 10.1007/s002510050661; Favier B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021011; FLAHERTY L, 1976, IMMUNOGENETICS, V3, P533, DOI 10.1007/BF01576983; Fuzzi B, 2002, EUR J IMMUNOL, V32, P311, DOI 10.1002/1521-4141(200202)32:2<311::AID-IMMU311>3.3.CO;2-#; Gabrilovich DI, 2017, CANCER IMMUNOL RES, V5, P3, DOI 10.1158/2326-6066.CIR-16-0297; Garziera M, 2017, J IMMUNOL RES, V2017, DOI 10.1155/2017/4587520; GERAGHTY DE, 1987, P NATL ACAD SCI USA, V84, P9145, DOI 10.1073/pnas.84.24.9145; Goldman-Wohl DS, 2000, MOL HUM REPROD, V6, P88, DOI 10.1093/molehr/6.1.88; Gomes AQ, 2007, EMBO REP, V8, P1024, DOI 10.1038/sj.embor.7401090; Gonzalez A, 2012, CRIT REV CL LAB SCI, V49, P63, DOI 10.3109/10408363.2012.677947; Goodall KJ, 2019, MOL IMMUNOL, V115, P31, DOI [10.1016/jmolimm.2018.05.001, 10.1016/j.molimm.2018.05.001]; Guleria I, 2007, J IMMUNOL, V178, P3345, DOI 10.4049/jimmunol.178.6.3345; Haist M, 2021, CANCERS, V13, DOI 10.3390/cancers13020210; Hanson EM, 2009, J IMMUNOL, V183, P937, DOI 10.4049/jimmunol.0804253; Hara N, 1996, AM J REPROD IMMUNOL, V36, P349; Hosseini A, 2018, J CELL PHYSIOL, V233, P6561, DOI 10.1002/jcp.26604; Hviid TVF, 2004, TISSUE ANTIGENS, V64, P66, DOI 10.1111/j.1399-0039.2004.00239.x; Kang XM, 2016, MOL HUM REPROD, V22, P499, DOI 10.1093/molehr/gaw026; Kieckbusch J, 2015, JOVE-J VIS EXP, DOI 10.3791/53534; Kliza K, 2017, NAT METHODS, V14, P504, DOI [10.1038/nmeth.4228, 10.1038/NMETH.4228]; Koehn BH, 2015, BLOOD, V126, P1621, DOI 10.1182/blood-2015-03-634691; Kostlin N, 2017, IMMUNOLOGY, V152, P89, DOI 10.1111/imm.12751; Kostlin N, 2017, EUR J IMMUNOL, V47, P374, DOI 10.1002/eji.201646564; Kostlin N, 2016, J IMMUNOL, V196, P1132, DOI 10.4049/jimmunol.1500340; Kostlin N, 2014, EUR J IMMUNOL, V44, P2582, DOI 10.1002/eji.201344200; Kostlin-Gille N, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.584712; Kostlin-Gille N, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00161; Kofod L, 2017, AM J REPROD IMMUNOL, V78, DOI 10.1111/aji.12684; KOVATS S, 1990, SCIENCE, V248, P220, DOI 10.1126/science.2326636; Kozasa Katsumi, 2019, Oncotarget, V10, P1887, DOI 10.18632/oncotarget.26711; Kuroki K, 2013, HUM IMMUNOL, V74, P433, DOI 10.1016/j.humimm.2012.11.060; LeMaoult J, 2004, P NATL ACAD SCI USA, V101, P7064, DOI 10.1073/pnas.0401922101; Liang SY, 2002, EUR J IMMUNOL, V32, P2418, DOI 10.1002/1521-4141(200209)32:9<2418::AID-IMMU2418>3.0.CO;2-L; Loumagne L, 2014, INT J CANCER, V135, P2107, DOI 10.1002/ijc.28845; Luppi P, 2006, AM J REPROD IMMUNOL, V56, P135, DOI 10.1111/j.1600-0897.2006.00386.x; McElhinny AS, 1998, MOL HUM REPROD, V4, P966, DOI 10.1093/molehr/4.10.966; McElhinny AS, 2000, AM J REPROD IMMUNOL, V44, P52, DOI 10.1111/j.8755-8920.2000.440108.x; Newmark JA, 2002, J EXP ZOOL, V293, P179, DOI 10.1002/jez.10117; Nilsson LL, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00198; Ostrand-Rosenberg S, 2017, J LEUKOCYTE BIOL, V101, P1091, DOI 10.1189/jlb.1HI1016-306RR; Ozerova M, 2019, LEUKEMIA LYMPHOMA, V60, P1557, DOI 10.1080/10428194.2018.1538511; Pan T, 2016, J LEUKOCYTE BIOL, V100, P499, DOI 10.1189/jlb.1A1015-481RR; Pawelec G, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01099; Polanczyk MJ, 2004, J IMMUNOL, V173, P2227, DOI 10.4049/jimmunol.173.4.2227; Rai R, 2006, LANCET, V368, P601, DOI 10.1016/S0140-6736(06)69204-0; Rebmann V, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/297073; Ribechini E, 2009, EUR J IMMUNOL, V39, P3538, DOI 10.1002/eji.200939530; Ridder A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20133263; Riteau B, 2001, J IMMUNOL, V166, P5018, DOI 10.4049/jimmunol.166.8.5018; Rizzo R, 2009, AM J REPROD IMMUNOL, V62, P320, DOI 10.1111/j.1600-0897.2009.00742.x; Romero R, 2014, SCIENCE, V345, P760, DOI 10.1126/science.1251816; Selmani Z, 2008, STEM CELLS, V26, P212, DOI 10.1634/stemcells.2007-0554; Steinborn A, 2007, AM J REPROD IMMUNOL, V57, P277, DOI 10.1111/j.1600-0897.2007.00475.x; Sulistyowati S, 2017, J PERINAT MED, V45, P245, DOI 10.1515/jpm-2016-0149; Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI 10.1093/nar/gky1131; Takai T, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/275302; Tong M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07017-x; Ungchusri T, 2001, IMMUNOGENETICS, V53, P455, DOI 10.1007/s002510100347; Wang C, 2009, IMMUNOLOGY, V126, P329, DOI 10.1111/j.1365-2567.2008.03051.x; Warner CA, 2001, CURR TOP DEV BIOL, V52, P151, DOI 10.1016/S0070-2153(01)52011-6; WARNER CM, 1986, J ANIM SCI, V63, P279, DOI 10.2527/jas1986.631279x; WARNER CM, 1991, J REPROD IMMUNOL, V19, P303, DOI 10.1016/0165-0378(91)90042-O; WARNER CM, 1993, J REPROD FERTIL, V99, P145, DOI 10.1530/jrf.0.0990145; Watkins A, 2006, J PHYSIOL-LONDON, V571, P211, DOI 10.1113/jphysiol.2005.099192; Yaghi L, 2016, ONCOTARGET, V7, P63690, DOI 10.18632/oncotarget.11628; Yang J, 2015, P NATL ACAD SCI USA, V112, P15172, DOI 10.1073/pnas.1422015112; Yie SM, 2004, AM J OBSTET GYNECOL, V191, P525, DOI 10.1016/j.ajog.2004.01.033; Youn JI, 2008, J IMMUNOL, V181, P5791, DOI 10.4049/jimmunol.181.8.5791; Zenclussen AC, 2005, AM J PATHOL, V166, P811, DOI 10.1016/S0002-9440(10)62302-4; Zhang W, 2008, TRANSPLANTATION, V86, P1125, DOI 10.1097/TP.0b013e318186fccd	88	0	0	3	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 17	2022	12								787468	10.3389/fimmu.2021.787468	http://dx.doi.org/10.3389/fimmu.2021.787468			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YR3CX	35111157	gold, Green Published			2022-12-18	WOS:000749873600001
J	Fuseini, H; Smith, R; Nochowicz, CH; Simmons, JD; Hannah, L; Wanjalla, CN; Gabriel, CL; Mashayekhi, M; Bailin, SS; Castilho, JL; Hasty, AH; Koethe, JR; Kalams, SA				Fuseini, Hubaida; Smith, Rita; Nochowicz, Cindy H.; Simmons, Joshua D.; Hannah, LaToya; Wanjalla, Celestine N.; Gabriel, Curtis L.; Mashayekhi, Mona; Bailin, Samuel S.; Castilho, Jessica L.; Hasty, Alyssa H.; Koethe, John R.; Kalams, Spyros A.			Leptin Promotes Greater Ki67 Expression in CD4(+) T Cells From Obese Compared to Lean Persons Living With HIV	FRONTIERS IN IMMUNOLOGY			English	Article						leptin; body mass index; obesity; HIV; CD4(+) T cell; Ki67; IL-17A	BODY-MASS INDEX; ANTIRETROVIRAL THERAPY; INFECTED PATIENTS; ACTIVATION; ASSOCIATION; RECEPTOR; TERM; LIPOATROPHY; PREVALENCE; OVERWEIGHT	While antiretroviral therapy (ART) has proven effective in suppressing viremia and disease progression among people living with human immunodeficiency virus (HIV; PLWH), suboptimal CD4(+) T cell reconstitution remains a major obstacle in nearly 30% of ART-treated individuals. Epidemiological studies demonstrate that obesity, or a body mass index (BMI) >= 30 kg/m(2), is positively correlated with greater CD4(+) T cell recovery in PLWH on ART. Leptin is a known immunomodulator that is produced in proportion to fat mass and is increased in obese individuals, including PLWH. We hypothesized that CD4(+) T cells from obese PLWH have increased cell proliferation and cytokine production compared to cells from lean PLWH, potentially modulated by differential effects of leptin signaling. To test this hypothesis, peripheral blood mononuclear cells from obese and lean PLWH with long-term virologic suppression on the same ART regimen were pretreated with recombinant leptin and then stimulated with anti-CD3/CD28 or PMA/ionomycin to measure Ki67 expression, leptin receptor (LepR) surface expression and cytokine production. In the absence of leptin, Ki67 expression and IL-17A production were significantly higher in CD4(+) T cells from obese compared to lean PLWH. However, LepR expression was significantly lower on CD4(+) T cells from obese compared to lean PLWH. After leptin treatment, Ki67 expression was significantly increased in CD4(+) T cells from obese PLWH compared to the lean participants. Leptin also increased IL-17A production in CD4(+) T cells from obese healthy controls. In contrast, leptin decreased IL-17A production in CD4(+) T cells from both obese and lean PLWH. Combined, these results demonstrate that obesity is associated with greater CD4(+) T cell proliferation among PLWH, and that higher circulating leptin levels in obesity may contribute to improved CD4(+) T reconstitution in PLWH initiating ART.	[Fuseini, Hubaida; Wanjalla, Celestine N.; Bailin, Samuel S.; Castilho, Jessica L.; Koethe, John R.; Kalams, Spyros A.] Vanderbilt Univ, Med Ctr, Div Infect Dis, Nashville, TN 37235 USA; [Smith, Rita; Nochowicz, Cindy H.; Simmons, Joshua D.; Wanjalla, Celestine N.; Gabriel, Curtis L.; Koethe, John R.; Kalams, Spyros A.] Vanderbilt Univ, Med Ctr, Tennessee Ctr AIDS Res, Nashville, TN USA; [Hannah, LaToya; Mashayekhi, Mona] Vanderbilt Univ, Med Ctr, Div Diabet Endocrinol & Metab, Nashville, TN USA; [Gabriel, Curtis L.] Vanderbilt Univ, Med Ctr, Div Gastroenterol Hepatol & Nutr, Nashville, TN USA; [Hasty, Alyssa H.] Vanderbilt Univ, Med Ctr, Dept Mol Physiol & Biophys, Nashville, TN USA; [Hasty, Alyssa H.; Kalams, Spyros A.] Vet Affairs Tennessee Healthcare Syst, Nashville, TN USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Fuseini, H (corresponding author), Vanderbilt Univ, Med Ctr, Div Infect Dis, Nashville, TN 37235 USA.	hubaida.fuseini.1@vumc.org		Wanjalla, Celestine/0000-0001-9159-5414	National Institutes of Health [K23 AI100700, R01 DK112262]; Vanderbilt Clinical and Translational Science award from NCRR/NIH [UL1 RR024975]; Tennessee Center for AIDS Research [P30 AI110527]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Vanderbilt Clinical and Translational Science award from NCRR/NIH; Tennessee Center for AIDS Research	This work was supported by National Institutes of Health grants K23 AI100700 and R01 DK112262, the Vanderbilt Clinical and Translational Science award from NCRR/NIH grant UL1 RR024975, and the Tennessee Center for AIDS Research grant P30 AI110527. The funding authorities had no role in study design; data collection, analysis, or interpretation; decision to publish; or preparation of the manuscript.	Ahmed M, 2010, CYTOKINE GROWTH F R, V21, P449, DOI 10.1016/j.cytogfr.2010.10.005; Al-Fadhli M, 2013, MED PRIN PRACT, V22, P54, DOI 10.1159/000339201; Baker JV, 2008, JAIDS-J ACQ IMM DEF, V48, P541, DOI 10.1097/QAI.0b013e31817bebb3; Banks AS, 2000, J BIOL CHEM, V275, P14563, DOI 10.1074/jbc.275.19.14563; Batra A, 2010, ENDOCRINOLOGY, V151, P56, DOI 10.1210/en.2009-0565; Bjorbaek C, 1998, MOL CELL, V1, P619, DOI 10.1016/S1097-2765(00)80062-3; Brennan AM, 2009, EUR J ENDOCRINOL, V160, P173, DOI 10.1530/EJE-08-0597; Brown TT, 2010, DIABETES CARE, V33, P2244, DOI 10.2337/dc10-0633; Brown TT, 2005, ARCH INTERN MED, V165, P1179, DOI 10.1001/archinte.165.10.1179; Capeau J, 2012, AIDS, V26, P303, DOI 10.1097/QAD.0b013e32834e8776; Chevalier MF, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00395; Cottam MA, 2018, J IMMUNOL, V200, P3681, DOI 10.4049/jimmunol.1701713; Crum-Cianflone NF, 2011, CLIN VACCINE IMMUNOL, V18, P940, DOI 10.1128/CVI.00020-11; Douzandeh-Mobarrez B, 2019, PROBIOTICS ANTIMICRO, V11, P1, DOI 10.1007/s12602-017-9329-z; ElHed A, 2010, CURR OPIN HIV AIDS, V5, P146, DOI 10.1097/COH.0b013e32833647a8; Engin A, 2017, ADV EXP MED BIOL, V960, P221, DOI 10.1007/978-3-319-48382-5_9; Farooqi IS, 2002, J CLIN INVEST, V110, P1093, DOI 10.1172/JCI200215693; Fenwick C, 2019, IMMUNOL REV, V292, P149, DOI 10.1111/imr.12823; Francisco V, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00640; Fuseini H, 2021, CURR HIV-AIDS REP, V18, P87, DOI 10.1007/s11904-021-00541-6; Fuseini H, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02740; Gazzola L, 2009, CLIN INFECT DIS, V48, P328, DOI 10.1086/595851; Gibson WT, 2004, J CLIN ENDOCR METAB, V89, P4821, DOI 10.1210/jc.2004-0376; Grome HN, 2017, AIDS RES HUM RETROV, V33, P181, DOI [10.1089/aid.2016.0113, 10.1089/AID.2016.0113]; Jaedicke KM, 2013, J LEUKOCYTE BIOL, V93, P561, DOI 10.1189/jlb.1211606; Jones CY, 2003, CLIN INFECT DIS, V37, pS69, DOI 10.1086/375889; Kiernan K, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.622468; Koethe JR, 2022, CLIN INFECT DIS, V74, P857, DOI 10.1093/cid/ciab542; Koethe JR, 2017, COMPR PHYSIOL, V7, P1339, DOI 10.1002/cphy.c160028; Koethe JR, 2016, JAIDS-J ACQ IMM DEF, V73, P197, DOI 10.1097/QAI.0000000000001035; Koethe JR, 2016, AIDS, V30, P83, DOI 10.1097/QAD.0000000000000893; Koethe JR, 2011, CLIN INFECT DIS, V53, P952, DOI 10.1093/cid/cir606; Liu R, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01587; Martin-Romero C, 2000, CELL IMMUNOL, V199, P15, DOI 10.1006/cimm.1999.1594; Mattioli B, 2005, J IMMUNOL, V174, P6820, DOI 10.4049/jimmunol.174.11.6820; McCune JM, 2001, NATURE, V410, P974, DOI 10.1038/35073648; Mulligan K, 2009, J CLIN ENDOCR METAB, V94, P1137, DOI 10.1210/jc.2008-1588; Naylor C, 2016, TRENDS MOL MED, V22, P88, DOI 10.1016/j.molmed.2015.12.001; Nyambuya TM, 2020, CLIN IMMUNOL, V210, DOI 10.1016/j.clim.2019.108313; Ogier V, 2002, INT J OBESITY, V26, P496, DOI 10.1038/sj.ijo.0801951; Osuji FN, 2018, J BIOMED SCI, V25, DOI 10.1186/s12929-018-0490-9; Perez-Perez A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21165887; Reis BS, 2015, J IMMUNOL, V194, P5253, DOI 10.4049/jimmunol.1402996; Rodriguez L, 2007, CLIN EXP IMMUNOL, V148, P478, DOI 10.1111/j.1365-2249.2007.03361.x; Sanchez-Margalet V, 2002, CLIN EXP IMMUNOL, V129, P119, DOI 10.1046/j.1365-2249.2002.01900.x; Sanchez-Pozo C, 2003, CLIN EXP IMMUNOL, V134, P464, DOI 10.1111/j.1365-2249.2003.02321.x; Shor-Posner G, 2000, J ACQ IMMUN DEF SYND, V23, P81; Shuter J, 2001, J ACQ IMMUN DEF SYND, V26, P291, DOI 10.1097/00126334-200103010-00013; Sun XM, 2018, CHROMOSOMA, V127, P175, DOI 10.1007/s00412-018-0659-8; Teijeiro A, 2021, NAT METAB, V3, P496, DOI 10.1038/s42255-021-00371-1; Torti C, 2012, CLIN MICROBIOL INFEC, V18, P449, DOI 10.1111/j.1469-0691.2011.03650.x; van der Weerd K, 2012, DIABETES, V61, P401, DOI 10.2337/db11-1065; Wrann CD, 2012, AM J PHYSIOL-ENDOC M, V302, pE108, DOI 10.1152/ajpendo.00057.2011; Yang RH, 2007, CIRC RES, V101, P545, DOI 10.1161/CIRCRESAHA.107.156596; Yang XD, 2020, J LEUKOCYTE BIOL, V107, P597, DOI 10.1002/JLB.4MR1019-189R; Zhao YS, 2018, CELL IMMUNOL, V332, P1, DOI 10.1016/j.cellimm.2018.08.013; Zou JH, 2018, CELL MOL IMMUNOL, V15, P630, DOI 10.1038/cmi.2017.36	57	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 17	2022	12								796898	10.3389/fimmu.2021.796898	http://dx.doi.org/10.3389/fimmu.2021.796898			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YR3EF	35111163	Green Published, gold			2022-12-18	WOS:000749877000001
J	Jiang, LW; Yilmaz, M; Uehara, M; Cavazzoni, CB; Kasinath, V; Zhao, J; Naini, SM; Li, XF; Banouni, N; Fiorina, P; Shin, SR; Tullius, SG; Bromberg, JS; Sage, PT; Abdi, R				Jiang, Liwei; Yilmaz, Mine; Uehara, Mayuko; Cavazzoni, Cecilia B.; Kasinath, Vivek; Zhao, Jing; Naini, Said Movahedi; Li, Xiaofei; Banouni, Naima; Fiorina, Paolo; Shin, Su Ryon; Tullius, Stefan G.; Bromberg, Jonathan S.; Sage, Peter T.; Abdi, Reza			Characterization of Leptin Receptor(+) Stromal Cells in Lymph Node	FRONTIERS IN IMMUNOLOGY			English	Article						lymph node; stromal cell; leptin receptor; type 2 diabetes; matrix structure	FIBROBLASTIC RETICULAR CELLS; INFLAMMATION; PROLIFERATION; EXPRESSION; TOLERANCE; PERICYTES; HOMEOSTASIS; MATURATION; ADIPOKINES; APOPTOSIS	Lymph node (LN)-resident stromal cells play an essential role in the proper functioning of LNs. The stromal compartment of the LN undergoes significant compensatory changes to produce a milieu amenable for regulation of the immune response. We have identified a distinct population of leptin receptor-expressing (LepR(+)) stromal cells, located in the vicinity of the high endothelial venules (HEVs) and lymphatics. These LepR(+) stromal cells expressed markers for fibroblastic reticular cells (FRCs), but they lacked markers for follicular dendritic cells (FDCs) and marginal reticular cells (MRCs). Leptin signaling deficiency led to heightened inflammatory responses within the LNs of db/db mice, leakiness of HEVs, and lymphatic fragmentation. Leptin signaling through the JAK/STAT pathway supported LN stromal cell survival and promoted the anti-inflammatory properties of these cells. Conditional knockout of the LepR(+) stromal cells in LNs resulted in HEV and extracellular matrix (ECM) abnormalities. Treatment of ob/ob mice with an agonist leptin fusion protein restored the microarchitecture of LNs, reduced intra-LN inflammatory responses, and corrected metabolic abnormalities. Future studies are needed to study the importance of LN stomal cell dysfunction to the pathogenesis of inflammatory responses in type 2 diabetes (T2D) in humans.	[Jiang, Liwei; Yilmaz, Mine; Uehara, Mayuko; Cavazzoni, Cecilia B.; Kasinath, Vivek; Zhao, Jing; Naini, Said Movahedi; Li, Xiaofei; Banouni, Naima; Sage, Peter T.; Abdi, Reza] Harvard Med Sch, Transplantat Res Ctr, Div Renal, Brigham & Womens Hosp, Boston, MA 02115 USA; [Jiang, Liwei] Chinese Acad Sci, Inst Hlth & Med Technol, Hefei Inst Phys Sci, Hefei, Peoples R China; [Fiorina, Paolo] Harvard Med Sch, Div Nephrol, Boston Childrens Hosp, Boston, MA 02115 USA; [Shin, Su Ryon] Harvard Med Sch, Biomat Innovat Res Ctr, Div Biomed Engn, Dept Med,Brigham & Womens Hosp, Cambridge, MA USA; [Tullius, Stefan G.] Harvard Med Sch, Div Transplant Surg, Brigham & Womens Hosp, Boston, MA 02115 USA; [Bromberg, Jonathan S.] Univ Maryland, Sch Med, Dept Surg, Baltimore, MD 21201 USA; [Bromberg, Jonathan S.] Univ Maryland, Sch Med, Dept Microbiol & Immunol, Baltimore, MD 21201 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Chinese Academy of Sciences; Hefei Institutes of Physical Science, CAS; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard Medical School; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Jiang, LW; Abdi, R (corresponding author), Harvard Med Sch, Transplantat Res Ctr, Div Renal, Brigham & Womens Hosp, Boston, MA 02115 USA.; Jiang, LW (corresponding author), Chinese Acad Sci, Inst Hlth & Med Technol, Hefei Inst Phys Sci, Hefei, Peoples R China.	jlw0531@cmpt.ac.cn; rabdi@rics.bwh.harvard.edu	Shin, Su Ryon/GRO-3950-2022; Li, xiaofei/GXF-7187-2022	Shin, Su Ryon/0000-0003-0864-6482; Yilmaz, Mine/0000-0002-2962-8542	National Heart, Lung, and Blood Institute of the National Institutes of Health (NIH) [R01HL145813, R01HL141815, R01AI126596, R01AI156084, P01AI153003, K24AI116925]; Hundred-Talent Youth Program (Chinese Academy of Sciences) [E1BDEDF6241]; National Institute of Allergy and Infectious Diseases	National Heart, Lung, and Blood Institute of the National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Hundred-Talent Youth Program (Chinese Academy of Sciences); National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	& nbsp;This work was supported in part by the National Institute of Allergy and Infectious Diseases and National Heart, Lung, and Blood Institute of the National Institutes of Health (NIH) under award numbers R01HL145813(RA), R01HL141815(RA), R01AI126596 (RA), R01AI156084 (RA), P01AI153003 (RA), and K24AI116925 (RA). This work was also supported by Hundred-Talent Youth Program (Chinese Academy of Sciences) under award numbers E1BDEDF6241.	Abella V, 2017, NAT REV RHEUMATOL, V13, P100, DOI 10.1038/nrrheum.2016.209; Andrade-Oliveira V, 2015, J DIABETES RES, V2015, DOI 10.1155/2015/681612; Arasanz H, 2017, ONCOTARGET, V8, P51936, DOI 10.18632/oncotarget.17232; Artwohl M, 2002, INT J OBESITY, V26, P577, DOI 10.1038/sj.ijo.0801947; Azzi J, 2016, CELL REP, V15, P1202, DOI 10.1016/j.celrep.2016.04.007; Bahgat MM, 2020, CENT EUR J IMMUNOL, V45, P170, DOI 10.5114/ceji.2020.97904; Bahmani B, 2018, J CLIN INVEST, V128, P4770, DOI 10.1172/JCI120923; Basak S, 2012, EUR J OBSTET GYN R B, V164, P24, DOI 10.1016/j.ejogrb.2012.05.033; Berbudi A, 2020, CURR DIABETES REV, V16, P442, DOI 10.2174/1573399815666191024085838; Bergers G, 2005, NEURO-ONCOLOGY, V7, P452, DOI 10.1215/S1152851705000232; Brown FD, 2015, J IMMUNOL, V194, P1389, DOI 10.4049/jimmunol.1402520; Carvalho LA, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/986742; Chai Q, 2013, IMMUNITY, V38, P1013, DOI 10.1016/j.immuni.2013.03.012; Chang JE, 2015, TRENDS IMMUNOL, V36, P30, DOI 10.1016/j.it.2014.11.003; Comazzetto S, 2019, CELL STEM CELL, V24, P477, DOI 10.1016/j.stem.2018.11.022; Cremasco V, 2014, NAT IMMUNOL, V15, P973, DOI 10.1038/ni.2965; Cyster JG, 1999, SCIENCE, V286, P2098, DOI 10.1126/science.286.5447.2098; Enge M, 2002, EMBO J, V21, P4307, DOI 10.1093/emboj/cdf418; Ferla R, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-303; Fletcher AL, 2015, NAT REV IMMUNOL, V15, P350, DOI 10.1038/nri3846; Flier JS, 2004, CELL, V116, P337, DOI 10.1016/S0092-8674(03)01081-X; Fruhbeck G, 2006, BIOCHEM J, V393, P7, DOI 10.1042/BJ20051578; Fu YX, 1999, ANNU REV IMMUNOL, V17, P399, DOI 10.1146/annurev.immunol.17.1.399; Fujita Y, 2002, CLIN EXP IMMUNOL, V128, P21, DOI 10.1046/j.1365-2249.2002.01797.x; Hellstrom M, 2001, J CELL BIOL, V153, P543, DOI 10.1083/jcb.153.3.543; Hespe GE, 2016, J PHYSIOL-LONDON, V594, P4267, DOI 10.1113/JP271757; Jacobs M, 2009, EUR J CLIN INVEST, V39, P437, DOI 10.1111/j.1365-2362.2009.02129.x; Jacobs SR, 2010, J IMMUNOL, V184, P3461, DOI 10.4049/jimmunol.0902593; Jiang LW, 2021, NANO TODAY, V36, DOI 10.1016/j.nantod.2020.101045; Jiang XG, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.01402; Katakai T, 2004, J EXP MED, V200, P783, DOI 10.1084/jem.20040254; Keir ME, 2008, ANNU REV IMMUNOL, V26, P677, DOI 10.1146/annurev.immunol.26.021607.090331; Kennedy AJ, 2010, DIS MODEL MECH, V3, P156, DOI 10.1242/dmm.003467; Krishnamurty AT, 2020, NAT IMMUNOL, V21, P369, DOI 10.1038/s41590-020-0635-3; La Cava A, 2017, CYTOKINE, V98, P51, DOI 10.1016/j.cyto.2016.10.011; Lago F, 2007, CYTOKINE GROWTH F R, V18, P313, DOI 10.1016/j.cytogfr.2007.04.007; Li XF, 2020, J CLIN INVEST, V130, P4182, DOI [10.1172/JCl136618, 10.1172/JCI136618]; Link A, 2007, NAT IMMUNOL, V8, P1255, DOI 10.1038/ni1513; Lord GM, 2002, J LEUKOCYTE BIOL, V72, P330; Lu TT, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00047; Maarouf OH, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.120546; Mathis D, 2013, CELL METAB, V17, P851, DOI 10.1016/j.cmet.2013.05.008; Norden PR, 2020, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.00404; O'Neill NA, 2018, CURR OPIN ORGAN TRAN, V23, P73, DOI 10.1097/MOT.0000000000000488; Onder L, 2012, BLOOD, V120, P4675, DOI 10.1182/blood-2012-03-416859; Ouchi N, 2011, NAT REV IMMUNOL, V11, P85, DOI 10.1038/nri2921; Park HY, 2001, EXP MOL MED, V33, P95, DOI 10.1038/emm.2001.17; Rodda LB, 2018, IMMUNITY, V48, P1014, DOI 10.1016/j.immuni.2018.04.006; Siegert S, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00285; Song JH, 2009, J IMMUNOL, V182, P6851, DOI 10.4049/jimmunol.0803568; Takeuchi A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02196; Tartaglia LA, 1997, J BIOL CHEM, V272, P6093, DOI 10.1074/jbc.272.10.6093; Tewalt EF, 2012, BLOOD, V120, P4772, DOI 10.1182/blood-2012-04-427013; Tostanoski LH, 2016, CELL REP, V16, P2940, DOI 10.1016/j.celrep.2016.08.033; von Tell D, 2006, EXP CELL RES, V312, P623, DOI 10.1016/j.yexcr.2005.10.019; Wang YD, 2010, GENE DEV, V24, P2115, DOI 10.1101/gad.1955910; Webster B, 2006, J EXP MED, V203, P1903, DOI 10.1084/jem.20052272; Zarkesh-Esfahani H, 2001, J IMMUNOL, V167, P4593, DOI 10.4049/jimmunol.167.8.4593; Zhou BO, 2014, CELL STEM CELL, V15, P154, DOI 10.1016/j.stem.2014.06.008; Zinkernagel RM, 1997, IMMUNOL REV, V156, P199, DOI 10.1111/j.1600-065X.1997.tb00969.x	60	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 17	2022	12								730438	10.3389/fimmu.2021.730438	http://dx.doi.org/10.3389/fimmu.2021.730438			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YR3CJ	35111151	gold, Green Published			2022-12-18	WOS:000749872200001
J	Chitty-Lopez, M; Duff, C; Vaughn, G; Trotter, J; Monforte, H; Lindsay, D; Haddad, E; Keller, MD; Oshrine, BR; Leiding, JW				Chitty-Lopez, Maria; Duff, Carla; Vaughn, Gretchen; Trotter, Jessica; Monforte, Hector; Lindsay, David; Haddad, Elie; Keller, Michael D.; Oshrine, Benjamin R.; Leiding, Jennifer W.			Case Report: Unmanipulated Matched Sibling Donor Hematopoietic Cell Transplantation In TBX1 Congenital Athymia: A Lifesaving Therapeutic Approach When Facing a Systemic Viral Infection	FRONTIERS IN IMMUNOLOGY			English	Article						TBX1 congenital athymia; hematopoietic-stem-cell-transplantation; definitive treatment; newborn screening (NBS); adenoviremia	SEVERE COMBINED IMMUNODEFICIENCY; DIGEORGE-SYNDROME; IMMUNE RECONSTITUTION; T-CELLS; MUTATIONS; GENE; DEFICIENCY; MANAGEMENT; PHENOTYPE; DELETION	Congenital athymia can present with severe T cell lymphopenia (TCL) in the newborn period, which can be detected by decreased T cell receptor excision circles (TRECs) on newborn screening (NBS). The most common thymic stromal defect causing selective TCL is 22q11.2 deletion syndrome (22q11.2DS). T-box transcription factor 1 (TBX1), present on chromosome 22, is responsible for thymic epithelial development. Single variants in TBX1 causing haploinsufficiency cause a clinical syndrome that mimics 22q11.2DS. Definitive therapy for congenital athymia is allogeneic thymic transplantation. However, universal availability of such therapy is limited. We present a patient with early diagnosis of congenital athymia due to TBX1 haploinsufficiency. While evaluating for thymic transplantation, she developed Omenn Syndrome (OS) and life-threatening adenoviremia. Despite treatment with anti-virals and cytotoxic T lymphocytes (CTLs), life threatening adenoviremia persisted. Given the imminent need for rapid establishment of T cell immunity and viral clearance, the patient underwent an unmanipulated matched sibling donor (MSD) hematopoietic cell transplant (HCT), ultimately achieving post-thymic donor-derived engraftment, viral clearance, and immune reconstitution. This case illustrates that because of the slower immune recovery that occurs following thymus transplantation and the restricted availability of thymus transplantation globally, clinicians may consider CTL therapy and HCT to treat congenital athymia patients with severe infections.	[Chitty-Lopez, Maria; Duff, Carla; Trotter, Jessica] Univ S Florida, Div Pediat Allergy & Immunol, Tampa, FL 33620 USA; [Vaughn, Gretchen; Oshrine, Benjamin R.] Johns Hopkins All Childrens Hosp, Ctr Cell & Gene Therapy Nonmalignant Condit, Canc & Blood Disorders Inst, St Petersburg, FL USA; [Monforte, Hector] Johns Hopkins All Childrens Hosp, Dept Pathol, St Petersburg, FL USA; [Monforte, Hector; Lindsay, David] Univ Texas Med Branch, Dept Pediat, Div Allergy & Immunol, Galveston, TX 77555 USA; [Lindsay, David; Haddad, Elie] CHU St Justine, Div Immunoallergy & Rheumatol, Montreal, PQ, Canada; [Haddad, Elie; Keller, Michael D.] Childrens Natl Hosp, Div Allergy & Immunol, Washington, DC USA; [Leiding, Jennifer W.] Johns Hopkins Univ, Dept Pediat, Div Allergy & Immunol, Baltimore, MD 21218 USA; [Leiding, Jennifer W.] Arnold Palmer Hosp Children, Infect Dis & Immunol Div, Orlando, FL 32806 USA	State University System of Florida; University of South Florida; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; University of Texas System; University of Texas Medical Branch Galveston; Universite de Montreal; Centre Hospitalier Universitaire Sainte-Justine; Children's National Health System; Johns Hopkins University	Chitty-Lopez, M (corresponding author), Univ S Florida, Div Pediat Allergy & Immunol, Tampa, FL 33620 USA.; Leiding, JW (corresponding author), Johns Hopkins Univ, Dept Pediat, Div Allergy & Immunol, Baltimore, MD 21218 USA.; Leiding, JW (corresponding author), Arnold Palmer Hosp Children, Infect Dis & Immunol Div, Orlando, FL 32806 USA.	auxichitty@gmail.com; jleidin1@jhmi.edu						Aleman K, 2001, EUR J PEDIATR, V160, P718, DOI 10.1007/s004310100816; Arai Y, 2016, BONE MARROW TRANSPL, V51, P96, DOI 10.1038/bmt.2015.205; Arnold JS, 2006, HUM MOL GENET, V15, P1629, DOI 10.1093/hmg/ddl084; Bamshad M, 1997, NAT GENET, V16, P311, DOI 10.1038/ng0797-311; Bensoussan D, 2002, BRIT J HAEMATOL, V117, P899, DOI 10.1046/j.1365-2141.2002.03496.x; Bifsha P, 2020, BLOOD ADV, V4, P2606, DOI 10.1182/bloodadvances.2020001736; Blackburn CC, 2004, NAT REV IMMUNOL, V4, P278, DOI 10.1038/nri1331; Bosticardo M, 2020, BLOOD ADV, V4, P2611, DOI 10.1182/bloodadvances.2020001730; Bousfiha A, 2020, J CLIN IMMUNOL, V40, P66, DOI 10.1007/s10875-020-00758-x; Braybrook C, 2001, NAT GENET, V29, P179, DOI 10.1038/ng730; Collard HR, 1999, CLIN IMMUNOL, V91, P156, DOI 10.1006/clim.1999.4691; Collins C, 2021, J CLIN IMMUNOL, V41, P881, DOI 10.1007/s10875-021-01059-7; Davies EG, 2017, J ALLERGY CLIN IMMUN, V140, P1660, DOI 10.1016/j.jaci.2017.03.020; Davies EG, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00322; DELACHAPELLE A, 1981, HUM GENET, V57, P253, DOI 10.1007/BF00278938; Fujimaki K, 2001, BONE MARROW TRANSPL, V27, P1275, DOI 10.1038/sj.bmt.1703056; Gennery AR, 2008, CLIN EXP IMMUNOL, V153, P75, DOI 10.1111/j.1365-2249.2008.03681.x; Gennery AR, 2010, J ALLERGY CLIN IMMUN, V126, P602, DOI 10.1016/j.jaci.2010.06.015; Giardino G, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01837; Heimall J, 2017, BLOOD, V130, P2718, DOI 10.1182/blood-2017-05-781849; Heimall J, 2017, BIOL BLOOD MARROW TR, V23, P1229, DOI 10.1016/j.bbmt.2017.04.026; Hoenig M, 2021, TRANSPL CELL THER, V27, DOI 10.1016/j.bbmt.2020.09.037; Ip W, 2013, J PEDIATR-US, V163, P908, DOI 10.1016/j.jpeds.2013.03.070; Janda A, 2007, PEDIATR TRANSPLANT, V11, P441, DOI 10.1111/j.1399-3046.2007.00702.x; Janda A, 2010, BLOOD, V116, P2229, DOI 10.1182/blood-2010-03-275966; Jerome LA, 2001, NAT GENET, V27, P286, DOI 10.1038/85845; Keller MD, 2019, BRIT J HAEMATOL, V187, P206, DOI 10.1111/bjh.16053; KELLEY RI, 1982, J PEDIATR-US, V101, P197, DOI 10.1016/S0022-3476(82)80116-9; Kelly Brian T, 2013, Clin Epidemiol, V5, P363, DOI 10.2147/CLEP.S48890; Land MH, 2007, J ALLERGY CLIN IMMUN, V120, P908, DOI 10.1016/j.jaci.2007.08.048; Lee DW, 2014, BLOOD, V124, P188, DOI 10.1182/blood-2014-05-552729; Li QY, 1997, NAT GENET, V15, P21; Liu DF, 2014, IMMUNOL CELL BIOL, V92, P80, DOI 10.1038/icb.2013.64; Marcovecchio GE, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00447; Markert ML, 2008, J IMMUNOL, V180, P6354, DOI 10.4049/jimmunol.180.9.6354; Markert ML, 2007, BLOOD, V109, P4539, DOI 10.1182/blood-2006-10-048652; Markert ML, 2010, CLIN IMMUNOL, V135, P236, DOI 10.1016/j.clim.2010.02.007; Markert ML, 2004, J ALLERGY CLIN IMMUN, V113, P734, DOI 10.1016/j.jaci.2004.01.766; Matsumoto T, 1998, BONE MARROW TRANSPL, V22, P927, DOI 10.1038/sj.bmt.1701475; McDonald GB, 2008, GUT, V57, P987, DOI 10.1136/gut.2007.131136; McDonald-McGinn DM, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.71; McGhee SA, 2009, IMMUNOL RES, V45, P37, DOI 10.1007/s12026-009-8108-7; Nakasone H, 2013, AM J HEMATOL, V88, P477, DOI 10.1002/ajh.23436; Newbern J, 2008, P NATL ACAD SCI USA, V105, P17115, DOI 10.1073/pnas.0805239105; Pai SY, 2014, NEW ENGL J MED, V371, P434, DOI 10.1056/NEJMoa1401177; Pulichino AM, 2003, GENE DEV, V17, P711, DOI 10.1101/gad.1065603; Shearer WT, 2014, J ALLERGY CLIN IMMUN, V133, P1092, DOI 10.1016/j.jaci.2013.09.044; Stoller JZ, 2005, HUM MOL GENET, V14, P885, DOI 10.1093/hmg/ddi081; Yagi H, 2003, LANCET, V362, P1366, DOI 10.1016/S0140-6736(03)14632-6; Zweier C, 2007, AM J HUM GENET, V80, P510, DOI 10.1086/511993	50	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 14	2022	12								721917	10.3389/fimmu.2021.721917	http://dx.doi.org/10.3389/fimmu.2021.721917			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YO7QA	35095830	Green Published, gold			2022-12-18	WOS:000748129900001
J	Do, AD; Su, CH; Hsu, YM				Do, Anh Duy; Su, Chiu-Hsian; Hsu, Yuan-Man			Antagonistic Activities of Lactobacillus rhamnosus JB3 Against Helicobacter pylori Infection Through Lipid Raft Formation	FRONTIERS IN IMMUNOLOGY			English	Article						Helicobacter pylori; Lactobacillus rhamnosus; mucus; lipid raft; Lewis x antigen; alpha 5 beta 1 integrin	PSEUDOMONAS-AERUGINOSA; ANTIBIOTIC-RESISTANCE; GENE-EXPRESSION; VACA; ADHESION; RECEPTOR; MUCUS	Helicobacter pylori is a Gram-negative pathogen that can increase the risk of stomach cancer in infected patients. H. pylori exploits lipid rafts to infect host cells. Infection triggers clustering of Lewis x antigen (Le(x)) and integrins in lipid rafts to facilitate H. pylori adherence to the gastric epithelium. H. pylori infection can be treated with probiotics containing lactic acid bacteria that offer numerous benefits to the host while lacking the side effects associated with antibiotic therapy. Previously, we showed that the cell-free supernatant (CFS) derived from Lactobacillus rhamnosus JB3 (LR-JB3) at a multiplicity of infection (MOI) of 25 attenuated the pathogenicity of H. pylori. In this study, we established a mucin model to simulate the gastric environment and to further understand the influence of mucin on the pathogenesis of H. pylori. Porcine stomach mucin dramatically upregulated H. pylori virulence gene expression, including that of babA, sabA, fucT, vacA, hp0499, cagA, and cagL, as well as the adhesion and invasion ability of H. pylori and induced increased levels of IL-8 in infected-AGS cells. The CFS derived from LR-JB3 at a MOI of 25 reduced the expression of H. pylori sabA, fucT, and hp0499 in mucin, as well as that of the Le(x) antigen and the alpha 5 beta 1 integrin in AGS cells during co-cultivation. These inhibitory effects of LR-JB3 also suppressed lipid raft clustering and attenuated Lewis antigen-dependent adherence, type IV secretion system-mediated cell contact, and lipid raft-mediated entry of VacA to host cells. In conclusion, LR-JB3 could affect H. pylori infection through mediating lipid raft formation of the host cells. The currently unknown cues secreted from LR-JB3 are valuable not only for treating H. pylori infection, but also for treating diseases that are also mediated by lipid raft signaling, such as cancer and aging-associated and neurodegenerative conditions.	[Do, Anh Duy; Su, Chiu-Hsian; Hsu, Yuan-Man] China Med Univ, Dept Biol Sci & Technol, Taichung, Taiwan; [Su, Chiu-Hsian; Hsu, Yuan-Man] Tunghai Univ, Dept Anim Sci & Technol, Taichung, Taiwan	China Medical University Taiwan; Tunghai University	Hsu, YM (corresponding author), China Med Univ, Dept Biol Sci & Technol, Taichung, Taiwan.; Hsu, YM (corresponding author), Tunghai Univ, Dept Anim Sci & Technol, Taichung, Taiwan.	yuanmh@thu.edu.tw	; Hsu, Yuan-Man/K-7074-2015	Do, Anh Duy/0000-0002-3198-3383; Hsu, Yuan-Man/0000-0002-4575-7475	Ministry of Science and Technology (Taiwan) [MOST109-2320-B-039-009-MY3]; China Medical University Hospital [DMR-108-141]	Ministry of Science and Technology (Taiwan)(Ministry of Science and Technology, Taiwan); China Medical University Hospital	This research was funded by Ministry of Science and Technology (Taiwan) grant number MOST109-2320-B-039-009-MY3 and China Medical University Hospital grant number DMR-108-141.	Alba C, 2017, CURR OPIN INFECT DIS, V30, P489, DOI 10.1097/QCO.0000000000000396; Aristoteli LP, 2003, INFECT IMMUN, V71, P5565, DOI 10.1128/IAI.71.10.5565-5575.2003; Backert S, 2017, TOXINS, V9, DOI 10.3390/toxins9040115; Baj J, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10010027; Banno A, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-56031-8; Celli JP, 2009, P NATL ACAD SCI USA, V106, P14321, DOI 10.1073/pnas.0903438106; Chen ME, 2018, J FOOD SCI, V83, P3118, DOI 10.1111/1750-3841.14372; Chen Y, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01675; Do AD, 2021, HELICOBACTER, V26, DOI 10.1111/hel.12806; Fazeli Zeinab, 2016, Gastroenterol Hepatol Bed Bench, V9, pS42; Frisan T, 2016, BBA-BIOMEMBRANES, V1858, P567, DOI 10.1016/j.bbamem.2015.08.016; Hansson GC, 2012, CURR OPIN MICROBIOL, V15, P57, DOI 10.1016/j.mib.2011.11.002; HESSEY SJ, 1990, GUT, V31, P134, DOI 10.1136/gut.31.2.134; Huang Y, 2016, FRONT CELL INFECT MI, V6, DOI 10.3389/fcimb.2016.00159; Jan HM, 2020, COMMUN BIOL, V3, DOI 10.1038/s42003-020-0855-y; Kamiya S, 2019, ADV EXP MED BIOL, V1149, P243, DOI 10.1007/5584_2019_369; Kao CY, 2016, BIOMED J, V39, P14, DOI 10.1016/j.bj.2015.06.002; Kwok T, 2007, NATURE, V449, P862, DOI 10.1038/nature06187; Lai CH, 2006, J ANTIMICROB CHEMOTH, V57, P466, DOI 10.1093/jac/dki479; Li L, 1999, AM J GASTROENTEROL, V94, P1502, DOI 10.1111/j.1572-0241.1999.01133.x; Lin CC, 2020, NUTRIENTS, V12, DOI 10.3390/nu12082476; Lin CJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146432; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lory S, 1996, AM J RESP CRIT CARE, V154, pS183, DOI 10.1164/ajrccm/154.4_Pt_2.S183; Lu DY, 2012, INFECT IMMUN, V80, P1823, DOI 10.1128/IAI.05856-11; Macfarlane S, 2001, INFECT IMMUN, V69, P1120, DOI 10.1128/IAI.69.2.1120-1126.2001; Malfertheiner P, 2017, GUT, V66, P6, DOI 10.1136/gutjnl-2016-312288; Marcos NT, 2008, J CLIN INVEST, V118, P2325, DOI [10.1172/JC134324, 10.1172/JCI34324]; Mesa-Herrera F, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20153810; Molinari M, 1998, BIOCHEM BIOPH RES CO, V248, P334, DOI 10.1006/bbrc.1998.8808; Moreno-Altamirano MMB, 2007, IMMUNOLOGY, V120, P536, DOI 10.1111/j.1365-2567.2006.02531.x; Murata-Kamiya N, 2010, CELL HOST MICROBE, V7, P399, DOI 10.1016/j.chom.2010.04.005; Nakayama M, 2004, J BIOL CHEM, V279, P7024, DOI 10.1074/jbc.M308898200; Nakayama M, 2006, INFECT IMMUN, V74, P6571, DOI 10.1128/IAI.00356-06; Oleastro Monica, 2013, Biology (Basel), V2, P1110, DOI 10.3390/biology2031110; Patel HK, 2002, INFECT IMMUN, V70, P4112, DOI 10.1128/IAI.70.8.4112-4123.2002; Ramirez J, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.572912; Roche N, 2007, MICROBES INFECT, V9, P605, DOI 10.1016/j.micinf.2007.01.023; Rolando M, 2019, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00168; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Van Tassell ML, 2011, NUTRIENTS, V3, P613, DOI 10.3390/nu3050613; Vangay P, 2015, CELL HOST MICROBE, V17, P553, DOI 10.1016/j.chom.2015.04.006; Wang M, 2008, CELL MICROBIOL, V10, P2029, DOI 10.1111/j.1462-5822.2008.01185.x; Wu JY, 2019, EXPERT REV GASTROENT, V13, P17, DOI 10.1080/17474124.2019.1542299; Yeh YC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072735; Zou YZ, 2020, HELICOBACTER, V25, DOI 10.1111/hel.12714	46	0	0	3	9	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 14	2022	12								796177	10.3389/fimmu.2021.796177	http://dx.doi.org/10.3389/fimmu.2021.796177			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YP2VC	35095872	gold, Green Published			2022-12-18	WOS:000748483400001
J	Endmayr, V; Tunc, C; Ergin, L; de Rosa, A; Weng, R; Wagner, L; Yu, TY; Fichtenbaum, A; Perkmann, T; Haslacher, H; Kozakowski, N; Schwaigerl, C; Rickert, G; Hametnerl, S; Dutra, LA; Lechnerl, C; de Simoni, D; Poppert, KN; Muller, GJ; Pirkerl, S; Pirker, W; Angelovski, A; Valach, M; Maestri, M; Guida, M; Ricciardi, R; Frommlet, F; Sieghart, D; Pinter, M; Hoftbergerl, R; Koneczny, I				Endmayr, Verena; Tunc, Cansu; Ergin, Lara; de Rosa, Anna; Weng, Rosa; Wagner, Lukas; Yu, Thin-Yau; Fichtenbaum, Andreas; Perkmann, Thomas; Haslacher, Helmuth; Kozakowski, Nicolas; Schwaigerl, Carmen; Rickert, Gerda; Hametnerl, Simon; Dutra, Livia Almeida; Lechnerl, Christian; de Simoni, Desiree; Poppert, Kai-Nicolas; Mueller, Georg Johannes; Pirkerl, Susanne; Pirker, Walter; Angelovski, Aleksandra; Valach, Matus; Maestri, Michelangelo; Guida, Melania; Ricciardi, Roberta; Frommlet, Florian; Sieghart, Daniela; Pinter, Miklos; Hoftbergerl, Romana; Koneczny, Inga			Anti-neuronal IgG4 autoimmune diseases and IgG4-related diseases may not be part of the same spectrum: a comparative study	FRONTIERS IN IMMUNOLOGY			English	Article						IgG4-related diseases; IgG4 autoimmune diseases; MuSK myasthenia gravis; CIDP; LGI1; Caspr2	INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY; MEMBRANOUS GLOMERULONEPHRITIS; SERUM IGG4; GRANULOMATOSIS; OVERLAP	Background IgG4 is associated with two emerging groups of rare diseases: 1) IgG4 autoimmune diseases (IgG4-AID) and 2) IgG4-related diseases (IgG4-RLD). Anti-neuronal IgG4-AID include MuSK myasthenia gravis, LGI1- and Caspr2-encephalitis and autoimmune nodo-/paranodopathies (CNTN1 or NF155 antibodies). IgG4-RLD is a multiorgan disease hallmarked by tissue-destructive fibrotic lesions with lymphocyte and IgG4 plasma cell infiltrates and increased serum IgG4 concentrations. It is unclear, whether IgG4-AID and IgG4-RLD share relevant clinical and immunopathological features. Methods We collected and analysed serological, clinical, and histopathological data in 50 patients with anti-neuronal IgG4-AID and 16 patients with IgG4-RLD. Results A significantly higher proportion of IgG4-RLD patients had serum IgG4 elevation when compared to IgG4-AID patients (50% vs. 16%, p = .015). Moreover, those IgG4-AID patients with elevated IgG4 did not meet the diagnostic criteria of IgG4-RLD, and their autoantibody titres did not correlate with their serum IgG4 concentrations. In addition, patients with IgG4-RLD were negative for anti-neuronal/neuromuscular autoantibodies and among these patients, men showed a significantly higher propensity for IgG4 elevation, when compared to women (p = .041). Last, a kidney biopsy from a patient with autoimmune paranodopathy due to CNTN1/Caspr1-complex IgG4 autoantibodies and concomitant nephrotic syndrome did not show fibrosis or IgG4(+) plasma cells, which are diagnostic hallmarks of IgG4-RLD. Conclusion Our observations suggest that anti-neuronal IgG4-AID and IgG4-RLD are most likely distinct disease entities.	[Endmayr, Verena; Tunc, Cansu; Ergin, Lara; Wagner, Lukas; Yu, Thin-Yau; Schwaigerl, Carmen; Rickert, Gerda; Hametnerl, Simon; Lechnerl, Christian; de Simoni, Desiree; Hoftbergerl, Romana; Koneczny, Inga] Med Univ Vienna, Dept Neurol, Div Neuropathol & Neurochem, Vienna, Austria; [de Rosa, Anna; Maestri, Michelangelo; Guida, Melania; Ricciardi, Roberta] Univ Pisa, Dept Clin & Expt Med, Neurol Unit, Via Paradisa 2, I-56124 Pisa, Italy; [Weng, Rosa] Med Univ Vienna, Dept Neurol, Vienna, Austria; [Fichtenbaum, Andreas; Perkmann, Thomas; Haslacher, Helmuth] Med Univ Vienna, Dept Lab Med, Vienna, Austria; [Kozakowski, Nicolas] Med Univ Vienna, Dept Pathol, Vienna, Austria; [Dutra, Livia Almeida] Hosp Israelita Albert Einstein, Dept Neurol & Neurosurg, Sao Paulo, Brazil; [Lechnerl, Christian] Med Univ Innsbruck, Dept Pediat & Adolescent Med, Pediat Neurol, Innsbruck, Austria; [de Simoni, Desiree] Univ Hosp St Poelten, Dept Neurol, St Polten, Austria; [Poppert, Kai-Nicolas] Paracelsus Med Univ, Christian Doppler Univ Hosp, Dept Neurol, Salzburg, Austria; [Mueller, Georg Johannes] Klin Donaustadt, Dept Neurol, Vienna, Austria; [Mueller, Georg Johannes] Klin Donaustadt, Karl Landsteiner Inst Neuroimmunol & Neurodegener, Vienna, Austria; [Pirkerl, Susanne] Klin Hietzing, Dept Neurol, Vienna, Austria; [Pirker, Walter; Angelovski, Aleksandra] Klin Ottakring, Dept Neurol, Vienna, Austria; [Valach, Matus] Klin Landstr, Dept Pathol, Vienna, Austria; [Frommlet, Florian] Med Univ Vienna, Ctr Med Stat Informat & Intelligent Syst, Sect Med Stat, Vienna, Austria; [Sieghart, Daniela] Med Univ Vienna, Dept Internal Med 3, Div Rheumatol, Vienna, Austria; [Pinter, Miklos] Wiener Privatklin Hlth Ctr, Lazarettgasse 25, Vienna, Austria	Medical University of Vienna; University of Pisa; Medical University of Vienna; Medical University of Vienna; Medical University of Vienna; Hospital Israelita Albert Einstein; Medical University of Innsbruck; Paracelsus Private Medical University; Medical University of Vienna; Medical University of Vienna	Koneczny, I (corresponding author), Med Univ Vienna, Dept Neurol, Div Neuropathol & Neurochem, Vienna, Austria.	inga.koneczny@meduniwien.ac.at		Lechner, Christian/0000-0002-2720-1019	Austrian Science Fund (FWF) [T996-B30, I4685-B, DOC33-B27]; Austrian Society of Neurology (Osterreichische Gesellschaft fur Neurologie)	Austrian Science Fund (FWF)(Austrian Science Fund (FWF)); Austrian Society of Neurology (Osterreichische Gesellschaft fur Neurologie)	This work was supported by grants from the Austrian Science Fund (FWF), project number T996-B30, SYNABS project number I4685-B, DOC33-B27 and the Austrian Society of Neurology (Osterreichische Gesellschaft fur Neurologie). Figure 6 was created with BioRender software (license IK).	AUCOUTURIER P, 1984, J IMMUNOL METHODS, V74, P151, DOI 10.1016/0022-1759(84)90376-4; Bando H, 2015, PITUITARY, V18, P722, DOI 10.1007/s11102-015-0650-9; BAYLE F, 1995, TRANSPLANTATION, V59, P719, DOI 10.1097/00007890-199503150-00014; Breu M, 2019, NEUROPEDIATRICS, V50, P193, DOI 10.1055/s-0039-1684004; Bukhari S, 2020, KIDNEY MED, V2, P797, DOI 10.1016/j.xkme.2020.06.016; Chang SY, 2012, INT J RHEUMATOL, V2012, DOI 10.1155/2012/121702; Chen KH, 2006, RENAL FAILURE, V28, P255, DOI 10.1080/08860220600580415; Della-Torre E, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004633; Emsley HCA, 2002, CLIN NEUROL NEUROSUR, V105, P23, DOI 10.1016/S0303-8467(02)00087-2; Funakoshi T, 2012, BRIT J DERMATOL, V167, P1245, DOI 10.1111/j.1365-2133.2012.11144.x; Gilhus NE, 2019, NAT REV DIS PRIMERS, V5, DOI 10.1038/s41572-019-0079-y; Goulabchand R, 2018, AUTOIMMUN REV, V17, P431, DOI 10.1016/j.autrev.2017.12.003; Gu Y, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11040513; Harkness T, 2020, ANN ALLERG ASTHMA IM, V125, P190, DOI 10.1016/j.anai.2020.03.018; Hashimoto Y, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00997; Haslacher H, 2018, BIOPRESERV BIOBANK, V16, P477, DOI 10.1089/bio.2018.0032; Hubers LM, 2018, GUT, V67, P728, DOI 10.1136/gutjnl-2017-314548; Huijbers MG, 2015, EUR J NEUROL, V22, P1151, DOI 10.1111/ene.12758; Kanemoto K, 1999, Nihon Jinzo Gakkai Shi, V41, P511; Kaushik P, 2018, INT J RHEUM DIS, V21, P885, DOI 10.1111/1756-185X.12687; Kawashima H, 2019, IMMUNOL RES, V67, P99, DOI 10.1007/s12026-019-9070-7; KOHLI A, 1992, CLIN NEUROL NEUROSUR, V94, P31, DOI 10.1016/0303-8467(92)90115-J; Kolfschoten MV, 2007, SCIENCE, V317, P1554, DOI 10.1126/science.1144603; Koneczny I, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.605214; Koneczny I, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102646; Mobbs RJ, 2000, J CLIN NEUROSCI, V7, P454, DOI 10.1054/jocn.1999.0235; Palazzo E, 2014, JOINT BONE SPINE, V81, P27, DOI 10.1016/j.jbspin.2013.06.001; Panjwani M, 1996, AM J KIDNEY DIS, V27, P279, DOI 10.1016/S0272-6386(96)90554-5; Raibagkar P, 2017, J NEUROIMMUNOL, V305, P82, DOI 10.1016/j.jneuroim.2017.02.004; REID RA, 1994, MOL BRAIN RES, V21, P1, DOI 10.1016/0169-328X(94)90372-7; Saeki T, 2011, ARTHRIT CARE RES, V63, P1209, DOI 10.1002/acr.20484; Salant DJ, 2019, CURR OPIN NEPHROL HY, V28, P70, DOI 10.1097/MNH.0000000000000459; Schloer S, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19061781; Shiokawa M, 2016, GUT, V65, P1322, DOI 10.1136/gutjnl-2015-310336; Sistani L, 2013, KIDNEY INT, V83, P63, DOI 10.1038/ki.2012.321; Stone JH, 2012, ARTHRITIS RHEUM-US, V64, P3061, DOI 10.1002/art.34593; Tominaga K, 2018, BMC NEPHROL, V19, DOI 10.1186/s12882-018-0922-5; Umehara H, 2019, MOD RHEUMATOL, V29, P214, DOI 10.1080/14397595.2018.1558519; WITTE AS, 1987, NEUROLOGY, V37, P342, DOI 10.1212/WNL.37.2.342; Wu A D, 2001, J Clin Neuromuscul Dis, V3, P70, DOI 10.1097/00131402-200112000-00004; Yoo J, 2019, CLIN RHEUMATOL, V38, P1147, DOI 10.1007/s10067-018-4402-x	41	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 14	2022	13									10.1101/2021.09.30.21264258	http://dx.doi.org/10.1101/2021.09.30.21264258			30	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6G8SS		Green Submitted			2022-12-18	WOS:000885022900001
J	Lory, NC; Nawrocki, M; Corazza, M; Schmid, J; Schumacher, V; Bedke, T; Menzel, S; Koch-Nolte, F; Guse, AH; Huber, S; Mittruecker, HW				Lory, Niels C.; Nawrocki, Mikolaj; Corazza, Martina; Schmid, Joanna; Schumacher, Valea; Bedke, Tanja; Menzel, Stephan; Koch-Nolte, Friedrich; Guse, Andreas H.; Huber, Samuel; Mittruecker, Hans-Willi			TRPM2 Is Not Required for T-Cell Activation and Differentiation	FRONTIERS IN IMMUNOLOGY			English	Article						TRPM2; T cells; T-cell activation; TCR signaling; ADPR; calcium signaling	ADP-RIBOSE; INNATE IMMUNITY; ION-CHANNEL; RECEPTOR; INFLUX; CHEMOTAXIS; AFFINITY; SYSTEM; CD38; TIME	Antigen recognition by the T-cell receptor induces a cytosolic Ca2+ signal that is crucial for T-cell function. The Ca2+ channel TRPM2 (transient receptor potential cation channel subfamily M member 2) has been shown to facilitate influx of extracellular Ca2+ through the plasma membrane of T cells. Therefore, it was suggested that TRPM2 is involved in T-cell activation and differentiation. However, these results are largely derived from in vitro studies using T-cell lines and non-physiologic means of TRPM2 activation. Thus, the relevance of TRPM2-mediated Ca2+ signaling in T cells remains unclear. Here, we use TRPM2-deficient mice to investigate the function of TRPM2 in T-cell activation and differentiation. In response to TCR stimulation in vitro, Trpm2(-/-) and WT CD4(+) and CD8(+) T cells similarly upregulated the early activation markers NUR77, IRF4, and CD69. We also observed regular proliferation of Trpm2(-/-) CD8(+) T cells and unimpaired differentiation of CD4(+) T cells into Th1, Th17, and Treg cells under specific polarizing conditions. In vivo, Trpm2(-/-) and WT CD8(+) T cells showed equal specific responses to Listeria monocytogenes after infection of WT and Trpm2(-/-) mice and after transfer of WT and Trpm2(-/-) CD8(+) T cells into infected recipients. CD4(+) T-cell responses were investigated in the model of anti-CD3 mAb-induced intestinal inflammation, which allows analysis of Th1, Th17, Treg, and Tr1-cell differentiation. Here again, we detected similar responses of WT and Trpm2(-/-) CD4(+) T cells. In conclusion, our results argue against a major function of TRPM2 in T-cell activation and differentiation.	[Lory, Niels C.; Schmid, Joanna; Schumacher, Valea; Menzel, Stephan; Koch-Nolte, Friedrich; Mittruecker, Hans-Willi] Univ Med Ctr Hamburg Eppendorf, Dept Immunol, Hamburg, Germany; [Lory, Niels C.; Nawrocki, Mikolaj; Corazza, Martina; Bedke, Tanja; Huber, Samuel; Mittruecker, Hans-Willi] Univ Med Ctr Hamburg Eppendorf, Hamburg Ctr Translat Immunol HCTI, Hamburg, Germany; [Nawrocki, Mikolaj; Corazza, Martina; Bedke, Tanja; Huber, Samuel] Univ Med Ctr Hamburg Eppendorf, Dept Med, Sect Mol Immunol & Gastroenterol 1, Hamburg, Germany; [Menzel, Stephan] Univ Med Ctr Hamburg Eppendorf, Dept Biochem & Mol Cell Biol, Calcium Signalling Grp, Hamburg, Germany; [Guse, Andreas H.] Univ Med Ctr Hamburg Eppendorf, Mildred Scheel Canc Career Ctr HaTriCS4, Hamburg, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf	Mittruecker, HW (corresponding author), Univ Med Ctr Hamburg Eppendorf, Dept Immunol, Hamburg, Germany.; Mittruecker, HW (corresponding author), Univ Med Ctr Hamburg Eppendorf, Hamburg Ctr Translat Immunol HCTI, Hamburg, Germany.	h.mittruecker@uke.de		Huber, Samuel/0000-0001-9325-8227; Lory, Niels Christian/0000-0003-4735-4968				Beceiro S, 2017, MUCOSAL IMMUNOL, V10, P493, DOI 10.1038/mi.2016.60; Beck A, 2006, FASEB J, V20, P962, DOI 10.1096/fj.05-5538fje; Brockmann L, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07581-4; Corse E, 2011, J IMMUNOL, V186, P5039, DOI 10.4049/jimmunol.1003650; Di A, 2017, J CELL SCI, V130, P735, DOI 10.1242/jcs.196014; Diercks BP, 2018, SCI SIGNAL, V11, DOI 10.1126/scisignal.aat0358; Ernst IMA, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00259; Esplugues E, 2011, NATURE, V475, P514, DOI 10.1038/nature10228; Fliegert R, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.02018; Fliegert R, 2017, NAT CHEM BIOL, V13, P1036, DOI [10.1038/nchembio.2415, 10.1038/NCHEMBIO.2415]; Gagliani N, 2015, NATURE, V523, P221, DOI 10.1038/nature14452; Garcia-Rodriguez S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21337-6; Gasser A, 2006, J BIOL CHEM, V281, P2489, DOI 10.1074/jbc.M506525200; Gelderblom M, 2014, STROKE, V45, P3395, DOI 10.1161/STROKEAHA.114.005836; Guichard V, 2017, ELIFE, V6, DOI 10.7554/e.Life.27215; Hara Y, 2002, MOL CELL, V9, P163, DOI 10.1016/S1097-2765(01)00438-5; Heng TSP, 2008, NAT IMMUNOL, V9, P1091, DOI 10.1038/ni1008-1091; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; Huang YH, 2018, NATURE, V562, P145, DOI 10.1038/s41586-018-0558-4; Huber S, 2011, IMMUNITY, V34, P554, DOI 10.1016/j.immuni.2011.01.020; Knowles H, 2013, IMMUNOL RES, V55, P241, DOI 10.1007/s12026-012-8373-8; Knowles H, 2011, P NATL ACAD SCI USA, V108, P11578, DOI 10.1073/pnas.1010678108; Le Borgne M, 2016, J IMMUNOL, V196, P1471, DOI 10.4049/jimmunol.1502414; Malavasi F, 2006, MOL MED, V12, P334, DOI 10.2119/2006-00094.Malavasi; Melzer N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047617; Mercado R, 2000, J IMMUNOL, V165, P6833, DOI 10.4049/jimmunol.165.12.6833; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; Morad H, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-88224-5; Partida-Sanchez S, 2007, J IMMUNOL, V179, P7827, DOI 10.4049/jimmunol.179.11.7827; Perraud AL, 2001, NATURE, V411, P595, DOI 10.1038/35079100; Qian XW, 2018, INNATE IMMUN-LONDON, V24, P122, DOI 10.1177/1753425918759181; Robledo-Avila FH, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00097; Rogers PR, 1999, J IMMUNOL, V163, P1205; Sano Y, 2001, SCIENCE, V293, P1327, DOI 10.1126/science.1062473; Sumoza-Toledo A, 2011, FASEB J, V25, P3529, DOI 10.1096/fj.10-178483; Trebak M, 2019, NAT REV IMMUNOL, V19, P154, DOI 10.1038/s41577-018-0110-7; Tripathi JK, 2018, FASEB J, V32, P6848, DOI 10.1096/fj.201800605; Wang G, 2016, DEV CELL, V38, P453, DOI 10.1016/j.devcel.2016.07.014; Wang LF, 2018, SCIENCE, V362, P1377, DOI 10.1126/science.aav4809; Wolf IMA, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aab0863; Yamamoto S, 2008, NAT MED, V14, P738, DOI 10.1038/nm1758; Yu PL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051028; Zehn D, 2009, NATURE, V458, P211, DOI 10.1038/nature07657; Zhao YJ, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002700	44	0	0	1	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 14	2022	12								778916	10.3389/fimmu.2021.778916	http://dx.doi.org/10.3389/fimmu.2021.778916			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YQ7JG	35095852	Green Published, gold			2022-12-18	WOS:000749481400001
J	Noerenberg, J; Jakso, P; Barakonyi, A				Noerenberg, Jasper; Jakso, Pal; Barakonyi, Aliz			Gamma/Delta T Cells in the Course of Healthy Human Pregnancy: Cytotoxic Potential and the Tendency of CD8 Expression Make CD56+ ?dT Cells a Unique Lymphocyte Subset (vol 11, 596489, 2021)	FRONTIERS IN IMMUNOLOGY			English	Correction						gamma/delta T cells; human pregnancy; CD4; CD8; CD56; PD-1; cytotoxicity; flow cytometry			[Noerenberg, Jasper; Barakonyi, Aliz] Univ Pecs, Med Sch, Dept Med Microbiol & Immunol, Pecs, Hungary; [Jakso, Pal] Univ Pecs, Med Sch, Dept Pathol, Pecs, Hungary; [Barakonyi, Aliz] Univ Pecs, Jan Szentagotha Res Ctr, Pecs, Hungary	University of Pecs; University of Pecs; University of Pecs	Noerenberg, J (corresponding author), Univ Pecs, Med Sch, Dept Med Microbiol & Immunol, Pecs, Hungary.	jaspernoerenberg@gmail.com							0	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 14	2022	12								819968	10.3389/fimmu.2021.819968	http://dx.doi.org/10.3389/fimmu.2021.819968			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YS7DZ		gold, Green Published			2022-12-18	WOS:000750834200001
J	Qiang, XL; Li, JH; Zhu, S; He, MZ; Chen, WQ; Al-Abed, Y; Brenner, M; Tracey, KJ; Wang, P; Wang, HC				Qiang, Xiaoling; Li, Jianhua; Zhu, Shu; He, Mingzhu; Chen, Weiqiang; Al-Abed, Yousef; Brenner, Max; Tracey, Kevin J.; Wang, Ping; Wang, Haichao			Human Dermcidin Protects Mice Against Hepatic Ischemia- Reperfusion-Induced Local and Remote Inflammatory Injury	FRONTIERS IN IMMUNOLOGY			English	Article						dermcidin; chemokine; neutrophil; inflammation; tissue injury; EGFR	NITRIC-OXIDE SYNTHASE; ANTIMICROBIAL PEPTIDES; LETHAL SEPSIS; LIVER-INJURY; LUNG INJURY; SWEAT; MEDIATOR; EXPRESSION; RECOVERY; SURVIVAL	Background: Hepatic ischemia and reperfusion (I/R) injury is commonly associated with surgical liver resection or transplantation, and represents a major cause of liver damage and graft failure. Currently, there are no effective therapies to prevent hepatic I/R injury other than ischemic preconditioning and some preventative strategies. Previously, we have revealed the anti-inflammatory activity of a sweat gland-derived peptide, dermcidin (DCD), in macrophage/monocyte cultures. Here, we sought to explore its therapeutic potential and protective mechanisms in a murine model of hepatic I/R. Methods: Male C57BL/6 mice were subjected to hepatic ischemia by clamping the hepatic artery and portal vein for 60 min, which was then removed to initiate reperfusion. At the beginning of reperfusion, 0.2 ml saline control or solution of DCD (0.5 mg/kg BW) or DCD-C34S analog (0.25 or 0.5 mg/kg BW) containing a Cys (C)-> Ser (S) substitution at residue 34 was injected via the internal jugular vein. For survival experiments, mice were subjected to additional resection to remove non-ischemic liver lobes, and animal survival was monitored for 10 days. For mechanistic studies, blood and tissue samples were collected at 24 h after the onset of reperfusion, and subjected to measurements of various markers of inflammation and tissue injury by real-time RT-PCR, immunoassays, and histological analysis. Results: Recombinant DCD or DCD-C34S analog conferred a significant protection against lethal hepatic I/R when given intravenously at the beginning of reperfusion. This protection was associated with a significant reduction in hepatic injury, neutrophilic CXC chemokine (Mip-2) expression, neutrophil infiltration, and associated inflammation. Furthermore, the administration of DCD also resulted in a significant attenuation of remote lung inflammatory injury. Mechanistically, DCD interacted with epidermal growth factor receptor (EGFR), a key regulator of liver inflammation, and significantly inhibited hepatic I/R-induced phosphorylation of EGFR as well as a downstream signaling molecule, protein kinase B (AKT). The suppression of EGFR expression by transducing Egfr-specific shRNA plasmid into macrophages abrogated the DCD-mediated inhibition of nitric oxide (NO) production induced by a damage-associated molecular pattern (DAMP), cold-inducible RNA-binding protein, CIRP. Conclusions: The present study suggests that human DCD and its analog may be developed as novel therapeutics to attenuate hepatic I/R-induced inflammatory injury possibly by impairing EGFR signaling.	[Qiang, Xiaoling; Li, Jianhua; Zhu, Shu; He, Mingzhu; Chen, Weiqiang; Al-Abed, Yousef; Brenner, Max; Tracey, Kevin J.; Wang, Ping; Wang, Haichao] Northwell Hlth, Feinstein Inst Med Res, Manhasset, NY 11030 USA; [Qiang, Xiaoling; Zhu, Shu; Chen, Weiqiang; Al-Abed, Yousef; Brenner, Max; Tracey, Kevin J.; Wang, Ping; Wang, Haichao] Donald & Barbara Zucker Sch Med Hofstra Northwell, Hempstead, NY 11549 USA; [Brenner, Max; Wang, Ping] TheraSource LLC, Manhasset, NY 11030 USA	Northwell Health	Wang, P; Wang, HC (corresponding author), Northwell Hlth, Feinstein Inst Med Res, Manhasset, NY 11030 USA.; Wang, P; Wang, HC (corresponding author), Donald & Barbara Zucker Sch Med Hofstra Northwell, Hempstead, NY 11549 USA.; Wang, P (corresponding author), TheraSource LLC, Manhasset, NY 11030 USA.	pwang@northwell.edu; hwang@northwell.edu	Qiang, Lynn Xiaoling/GRS-4786-2022; Wang, Haichao/K-6310-2012	Qiang, Lynn Xiaoling/0000-0001-9176-7407; Wang, Haichao/0000-0002-0211-9000	National Institutes of Health (NIH) [R01GM063075, R01AT005076, R35GM118337, R01HL076179]; NIH capital equipment grant [1S10RR033072]	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH capital equipment grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported in part by the National Institutes of Health (NIH) grants R01GM063075 (to HW), R01AT005076 (to HW), R35GM118337 (to PW), and R01HL076179 (to PW). The Biacore T200 instrument was purchased with a NIH capital equipment grant (1S10RR033072 to YA-A).	Abu-Amara M, 2010, LIVER TRANSPLANT, V16, P1016, DOI 10.1002/lt.22117; Ahmed O, 2021, CELL MOL IMMUNOL, V18, P1375, DOI 10.1038/s41423-021-00639-2; Berasain C, 2014, J GASTROENTEROL, V49, P9, DOI 10.1007/s00535-013-0907-x; Brenner C, 2013, J HEPATOL, V59, P583, DOI 10.1016/j.jhep.2013.03.033; Burian M, 2015, INT J MED MICROBIOL, V305, P283, DOI 10.1016/j.ijmm.2014.12.012; de Oliveira THC, 2018, LAB INVEST, V98, P51, DOI 10.1038/labinvest.2017.90; Cannistra M, 2016, INT J SURG, V33, pS57, DOI 10.1016/j.ijsu.2016.05.050; Chen WQ, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aaz3833; Chen WQ, 2019, SHOCK, V52, P550, DOI 10.1097/SHK.0000000000001361; Clarke CN, 2009, AM J SURG, V198, P415, DOI 10.1016/j.amjsurg.2009.01.025; Godwin A, 2015, SHOCK, V43, P24, DOI 10.1097/SHK.0000000000000251; Hato S, 2001, EUR SURG RES, V33, P202, DOI 10.1159/000049707; Hon WM, 2002, ANN NY ACAD SCI, V962, P275, DOI 10.1111/j.1749-6632.2002.tb04074.x; Hoyer FF, 2019, IMMUNITY, V51, P899, DOI 10.1016/j.immuni.2019.10.010; Husted TL, 2006, CURR PHARM DESIGN, V12, P2867, DOI 10.2174/138161206777947597; Khader A, 2016, CRIT CARE MED, V44, pE651, DOI 10.1097/CCM.0000000000001637; Lentsch AB, 1999, GASTROENTEROLOGY, V117, P953, DOI 10.1016/S0016-5085(99)70355-0; Letson HL, 2021, SHOCK, V55, P379, DOI 10.1097/SHK.0000000000001630; Li M, 2009, ANTIMICROB AGENTS CH, V53, P4200, DOI 10.1128/AAC.00428-09; Li W, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001153; Li W, 2007, J IMMUNOL, V178, P3856, DOI 10.4049/jimmunol.178.6.3856; Li W, 2013, MOL MED, V19, P203, DOI 10.2119/molmed.2013.00064; Liu XH, 2018, LAB INVEST, V98, P1588, DOI 10.1038/s41374-018-0111-y; Lousada MB, 2021, BRIT J DERMATOL, V184, P802, DOI 10.1111/bjd.19461; Lu L, 2016, TRANSPLANTATION, V100, P2601, DOI 10.1097/TP.0000000000001411; Matute-Bello G, 2011, AM J RESP CELL MOL, V44, P725, DOI 10.1165/rcmb.2009-0210ST; Nakano T, 2015, ACTA DERM-VENEREOL, V95, P783, DOI 10.2340/00015555-2068; Niyonsaba F, 2017, EXP DERMATOL, V26, P989, DOI 10.1111/exd.13314; Okaya T, 2003, J INVEST SURG, V16, P141, DOI 10.1080/08941930390205782; Pathak S, 2009, SCAND J IMMUNOL, V70, P264, DOI 10.1111/j.1365-3083.2009.02299.x; Qiang XL, 2022, J LEUKOCYTE BIOL, V111, P261, DOI 10.1002/JLB.3COVCRA0920-628RR; Qiang XL, 2013, NAT MED, V19, P1489, DOI 10.1038/nm.3368; Qin CC, 2017, WORLD J GASTROENTERO, V23, P3043, DOI 10.3748/wjg.v23.i17.3043; Rieg S, 2005, J IMMUNOL, V174, P8003, DOI 10.4049/jimmunol.174.12.8003; Rieg S, 2006, J INVEST DERMATOL, V126, P354, DOI 10.1038/sj.jid.5700041; Schittek B, 2001, NAT IMMUNOL, V2, P1133, DOI 10.1038/ni732; Schittek B, 2012, J INNATE IMMUN, V4, P349, DOI 10.1159/000336844; Selzner N, 2003, GASTROENTEROLOGY, V125, P917, DOI 10.1016/S0016-5085(03)01048-5; Stewart GD, 2007, PROSTATE, V67, P1308, DOI 10.1002/pros.20618; Taylor BS, 1998, BIOCHEMISTRY-MOSCOW+, V63, P766; Tsung A, 2005, J EXP MED, V201, P1135, DOI 10.1084/jem.20042614; van Golen RF, 2013, J GASTROEN HEPATOL, V28, P394, DOI 10.1111/jgh.12072; Wang E, 2016, SHOCK, V45, P28, DOI 10.1097/SHK.0000000000000488; Wang HC, 1999, SCIENCE, V285, P248, DOI 10.1126/science.285.5425.248; Wang Y, 2012, BRIT J ANAESTH, V109, P529, DOI 10.1093/bja/aes209; Yang H, 2017, J INTERN MED, V282, P76, DOI 10.1111/joim.12619; Yang LQ, 2011, ANESTHESIOLOGY, V114, P1036, DOI 10.1097/ALN.0b013e3182104956; Zhai Y, 2013, NAT REV GASTRO HEPAT, V10, P79, DOI 10.1038/nrgastro.2012.225; Zhang HJ, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00987; Zhu CS, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10092220; Zhu S, 2009, MOL MED, V15, P275, DOI 10.2119/molmed.2009.00062	51	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 14	2022	13								821154	10.3389/fimmu.2021.821154	http://dx.doi.org/10.3389/fimmu.2021.821154			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6G9GJ	35095926	gold, Green Published			2022-12-18	WOS:000885058700001
J	Zhang, H; Cao, S; Gao, Y; Sun, X; Jiang, FM; Zhao, B; Ding, HB; Dong, T; Han, XX; Shang, H				Zhang, Hui; Cao, Shuang; Gao, Yang; Sun, Xiao; Jiang, Fanming; Zhao, Bin; Ding, Haibo; Dong, Tao; Han, Xiaoxu; Shang, Hong			HIV-1-Specific Immunodominant T-Cell Responses Drive the Dynamics of HIV-1 Recombination Following Superinfection	FRONTIERS IN IMMUNOLOGY			English	Article						HIV-1; recombination; break points; T cell responses; escape mutation	IMMUNODEFICIENCY-VIRUS TYPE-1; PROGRESSION; EVOLUTION	A series of HIV-1 CRF01_AE/CRF07_BC recombinants were previously found to have emerged gradually in a superinfected patient (patient LNA819). However, the extent to which T-cell responses influenced the development of these recombinants after superinfection is unclear. In this study, we undertook a recombination structure analysis of the gag, pol, and nef genes from longitudinal samples of patient LNA819. A total of 9 pol and 5 nef CRF01_AE/CRF07_BC recombinants were detected. The quasispecies makeup and the composition of the pol and nef gene recombinants changed continuously, suggestive of continuous evolution in vivo. T-cell responses targeting peptides of the primary strain and the recombination regions were screened. The results showed that Pol-LY10, Pol-RY9, and Nef-GL9 were the immunodominant epitopes. Pol-LY10 overlapped with the recombination breakpoints in multiple recombinants. For the LY10 epitope, escape from T-cell responses was mediated by both recombination with a CRF07_BC insertion carrying the T467E/T472V variants and T467N/T472V mutations originating in the CRF01_AE strain. In pol recombinants R8 and R9, the recombination breakpoints were located ~23 amino acids upstream of the RY9 epitope. The appearance of new recombination breakpoints harboring a CRF07_BC insertion carrying a R984K variant was associated with escape from RY9-specific T-cell responses. Although the Nef-GL9 epitope was located either within or 10~11 amino acids downstream of the recombination breakpoints, no variant of this epitope was observed in the nef recombinants. Instead, a F85V mutation originating in the CRF01_AE strain was the main immune escape mechanism. Understanding the cellular immune pressure on recombination is critical for monitoring the new circulating recombinant forms of HIV and designing epitope-based vaccines. Vaccines targeting antigens that are less likely to escape immune pressure by recombination and/or mutation are likely to be of benefit to patients with HIV-1.	[Zhang, Hui; Cao, Shuang; Gao, Yang; Sun, Xiao; Jiang, Fanming; Zhao, Bin; Ding, Haibo; Han, Xiaoxu; Shang, Hong] China Med Univ, Natl Hlth Commiss NHC, Key Lab AIDS Immunol, Natl Clin Res Ctr Lab Med,Affiliated Hosp 1, Shenyang, Peoples R China; [Zhang, Hui; Cao, Shuang; Gao, Yang; Sun, Xiao; Jiang, Fanming; Zhao, Bin; Ding, Haibo; Han, Xiaoxu; Shang, Hong] Chinese Acad Med Sci, Key Lab AIDS Immunol, Shenyang, Peoples R China; [Zhang, Hui; Cao, Shuang; Gao, Yang; Sun, Xiao; Jiang, Fanming; Zhao, Bin; Ding, Haibo; Han, Xiaoxu; Shang, Hong] Key Lab AIDS Immunol Liaoning Prov, Shenyang, Peoples R China; [Cao, Shuang] China Med Univ, Shengjing Hosp, Nanhu Branch, Clin Lab, Shenyang, Peoples R China; [Dong, Tao; Shang, Hong] Univ Oxford, Chinese Acad Med Sci, Oxford Inst, Nuffield Dept Med, Oxford, England; [Dong, Tao] Univ Oxford, Med Res Council Human Immunol Unit, Weatherall Inst Mol Med, John Radcliffe Hosp, Oxford, England	China Medical University; Chinese Academy of Medical Sciences - Peking Union Medical College; China Medical University; University of Oxford; University of Oxford	Han, XX; Shang, H (corresponding author), China Med Univ, Natl Hlth Commiss NHC, Key Lab AIDS Immunol, Natl Clin Res Ctr Lab Med,Affiliated Hosp 1, Shenyang, Peoples R China.; Han, XX; Shang, H (corresponding author), Chinese Acad Med Sci, Key Lab AIDS Immunol, Shenyang, Peoples R China.; Han, XX; Shang, H (corresponding author), Key Lab AIDS Immunol Liaoning Prov, Shenyang, Peoples R China.; Shang, H (corresponding author), Univ Oxford, Chinese Acad Med Sci, Oxford Inst, Nuffield Dept Med, Oxford, England.	xxhan@yeah.net; hongshang100@hotmail.com		Dong, Tao/0000-0003-3545-3758	Mega Projects of National Science Research for the 13th Five-Year Plan [2017ZX10201101]; Natural Science Foundation [81371787]	Mega Projects of National Science Research for the 13th Five-Year Plan; Natural Science Foundation(National Natural Science Foundation of China (NSFC))	Funding This work was supported by the Mega Projects of National Science Research for the 13th Five-Year Plan to HS (2017ZX10201101) and the Natural Science Foundation to XH (81371787).	Altfeld M, 2002, NATURE, V420, P434, DOI 10.1038/nature01200; Baird HA, 2006, NUCLEIC ACIDS RES, V34, P5203, DOI 10.1093/nar/gkl669; Batorsky R, 2011, P NATL ACAD SCI USA, V108, P5661, DOI 10.1073/pnas.1102036108; Chaillon A, 2013, J VIROL, V87, P12737, DOI 10.1128/JVI.02260-13; Cheong HT, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133883; Cromer D, 2016, AIDS, V30, P185, DOI 10.1097/QAD.0000000000000936; Donahue DA, 2013, J VIROL, V87, P9620, DOI 10.1128/JVI.01165-13; Du VY, 2016, J IMMUNOL, V196, P3276, DOI 10.4049/jimmunol.1502411; Gao Y, 2021, PLOS PATHOG, V17, DOI 10.1371/journal.ppat.1009258; Gottlieb GS, 2004, LANCET, V363, P619, DOI 10.1016/S0140-6736(04)15596-7; Gu ZX, 1995, J BIOL CHEM, V270, P31046, DOI 10.1074/jbc.270.52.31046; He C, 2019, MED MICROBIOL IMMUN, V208, P239, DOI 10.1007/s00430-019-00585-x; Jiang FM, 2016, BMC IMMUNOL, V17, DOI 10.1186/s12865-016-0166-8; Buzon MJ, 2011, JAIDS-J ACQ IMM DEF, V57, P109, DOI 10.1097/QAI.0b013e318215ab0a; Kijak Gustavo H, 2005, Curr Infect Dis Rep, V7, P480, DOI 10.1007/s11908-005-0051-8; Koning FA, 2013, AIDS RES HUM RETROV, V29, P963, DOI [10.1089/aid.2013.0009, 10.1089/AID.2013.0009]; Lau KA, 2010, CURR HIV RES, V8, P259, DOI 10.2174/157016210791111151; Levy DN, 2004, P NATL ACAD SCI USA, V101, P4204, DOI 10.1073/pnas.0306764101; Li H, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000890; Luan H, 2017, JAIDS-J ACQ IMM DEF, V75, P480, DOI 10.1097/QAI.0000000000001420; Mann JK, 2015, VIROL J, V12, DOI 10.1186/s12985-015-0429-7; Milicic A, 2005, J IMMUNOL, V175, P4618, DOI 10.4049/jimmunol.175.7.4618; Mo AXY, 2000, J IMMUNOL, V164, P4003, DOI 10.4049/jimmunol.164.8.4003; Nikolaitchik OA, 2011, J MOL BIOL, V407, P521, DOI 10.1016/j.jmb.2011.01.052; Nora T, 2007, J VIROL, V81, P7620, DOI 10.1128/JVI.00083-07; Rambaut A, 2004, NAT REV GENET, V5, P52, DOI 10.1038/nrg1246; Ramirez BC, 2008, VIRUS RES, V134, P64, DOI 10.1016/j.virusres.2008.01.007; Ranasinghe SRF, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001341; Ritchie AJ, 2014, RETROVIROLOGY, V11, DOI 10.1186/s12977-014-0069-9; Simon-Loriere E, 2010, J VIROL, V84, P12675, DOI 10.1128/JVI.01302-10; Streeck H, 2008, J EXP MED, V205, P1789, DOI 10.1084/jem.20080281; Turk G, 2015, EBIOMEDICINE, V2, P188, DOI 10.1016/j.ebiom.2015.02.011; Watts JM, 2009, NATURE, V460, P711, DOI 10.1038/nature08237; Yang OO, 2005, J VIROL, V79, P860, DOI 10.1128/JVI.79.2.860-868.2005; Yebra G, 2012, J CLIN MICROBIOL, V50, P407, DOI 10.1128/JCM.05798-11; Zhang H, 2015, AIDS, V29, P993, DOI 10.1097/QAD.0000000000000652	36	0	0	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 14	2022	12								820628	10.3389/fimmu.2021.820628	http://dx.doi.org/10.3389/fimmu.2021.820628			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YO7QT	35095925	Green Published, gold			2022-12-18	WOS:000748131800001
J	Zhu, CT; Zhao, Y; Yu, F; Huang, WJ; Wu, WJ; He, JS; Cai, Z; He, DH				Zhu, Chunting; Zhao, Yi; Yu, Fang; Huang, Weijia; Wu, Wenjun; He, Jingsong; Cai, Zhen; He, Donghua			Tumor Flare Reaction in a Classic Hodgkin Lymphoma Patient Treated With Brentuximab Vedotin and Tislelizumab: A Case Report	FRONTIERS IN IMMUNOLOGY			English	Article						brentuximab vedotin; tislelizumab; tumor flare reaction; classic Hodgkin lymphoma; immune related adverse event	LENALIDOMIDE; ACTIVATION; THERAPY; CANCER; SGN-35	BackgroundTumor flare reaction (TFR) is a clinical syndrome, which is mainly associated with painful and swollen lymph nodes or splenomegaly, slight fever, bone pain, and skin rash during treatment with immune-related drugs, causing difficulty in distinguishing TFR from disease progression. Brentuximab vedotin (BV) and programmed death 1 (PD-1) inhibitor are two ideal drugs used for the treatment of classic Hodgkin lymphoma, but few studies have reported their adverse effects in association with TFR. The efficacy and safety of monotherapy or combination therapy with these drugs needs to be further evaluated. It is essential to determine whether treated patients can develop TFR, thus enabling more accurate diagnosis and treatment. Case presentationA 26-year-old female patient, diagnosed with classic Hodgkin lymphoma, had received 2 + 3 cycles of ABVD chemotherapy (a combination of adriamycin, bleomycin, vinblastine, and dacarbazine) and 4 cycles of PD-1 inhibitor (tislelizumab) therapy but exhibited poor efficacy. Subsequently, she was given combination therapy of BV (100 mg) + tislelizumab (200 mg). However, a slight fever, painful and swollen axillary lymph nodes, multiple skin rashes with pruritus, joint pain, and fatigue with poor appetite appeared during the treatment. Ultrasound (US) scans revealed that multiple lymph nodes were significantly enlarged. After treatment with low-dose dexamethasone and cetirizine, the symptoms were alleviated. A biopsy of the left axillary lymph node revealed that lymphoid tissue exhibited proliferative changes, without tumor cell infiltration. These findings were consistent with the clinical and pathological manifestations of TFR. ConclusionCombination therapy with BV and PD-1 inhibitor was effective in the treatment of relapsed or refractory classic Hodgkin lymphoma. The results suggest that the combination therapy may cause TFR, and biopsy and also continuous imaging observation are important to determine the disease stage. This approach allows clinicians to decide whether to continue the current treatment plan, and alerts them to the occurrence of excessive activation of the immune system.	[Zhu, Chunting; Zhao, Yi; Huang, Weijia; Wu, Wenjun; He, Jingsong; Cai, Zhen; He, Donghua] Zhejiang Univ, Affiliated Hosp 1, Coll Med, Bone Marrow Transplantat Ctr, Hangzhou, Peoples R China; [Yu, Fang] Zhejiang Univ, Affiliated Hosp 1, Coll Med, Pathol Dept, Hangzhou, Peoples R China	Zhejiang University; Zhejiang University	He, DH (corresponding author), Zhejiang Univ, Affiliated Hosp 1, Coll Med, Bone Marrow Transplantat Ctr, Hangzhou, Peoples R China.	hedonghua@zju.edu.cn			National Natural Science Foundation of China [81770217]; Natural Science Foundation of Zhejiang Province [LY16H080001]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Zhejiang Province(Natural Science Foundation of Zhejiang Province)	Funding This work was supported by the National Natural Science Foundation of China (81770217), and the Natural Science Foundation of Zhejiang Province (LY16H080001).	Aoki T, 2018, CANCER J, V24, P206, DOI 10.1097/PPO.0000000000000334; Chanan-Khan A, 2011, CANCER-AM CANCER SOC, V117, P2127, DOI 10.1002/cncr.25748; Chanan-Khan AA, 2011, BRIT J HAEMATOL, V155, P457, DOI 10.1111/j.1365-2141.2011.08882.x; Chen CI, 2011, J CLIN ONCOL, V29, P1175, DOI 10.1200/JCO.2010.29.8133; Chunhui W., 2019, ADVERSE DRUG REACT J, V4, P315, DOI [10.3760/cma.j.issn.1008-5734.2019.04.022, DOI 10.3760/CMA.J.ISSN.1008-5734.2019.04.022]; Connors JM, 2018, NEW ENGL J MED, V378, P331, DOI 10.1056/NEJMoa1708984; Corazzelli G, 2010, AM J HEMATOL, V85, P87, DOI 10.1002/ajh.21571; Danlos FX, 2018, EUR J CANCER, V91, P21, DOI 10.1016/j.ejca.2017.12.008; Dimopoulos MA, 2018, NEW ENGL J MED, V378, P2399, DOI 10.1056/NEJMoa1802917; Eve HE, 2010, BRIT J HAEMATOL, V151, P410, DOI 10.1111/j.1365-2141.2010.08376.x; Ferrari C, 2021, J PERS MED, V11, DOI 10.3390/jpm11030217; Gandhi MD, 2014, BLOOD, V123, P2895, DOI 10.1182/blood-2014-03-561878; Gibb A, 2021, BRIT J HAEMATOL, V193, P63, DOI 10.1111/bjh.17073; Hematology Oncology Committee of China Anti-Cancer Association, 2016, Zhonghua Xue Ye Xue Za Zhi, V37, P729, DOI 10.3760/cma.j.issn.0253-2727.2016.09.001; Herrera AF, 2018, BLOOD, V131, P1183, DOI 10.1182/blood-2017-10-811224; Kayar Y, 2014, BLOOD RES, V49, P279, DOI 10.5045/br.2014.49.4.279; Kirienko M, 2018, CLIN TRANSL IMAGING, V6, P417, DOI 10.1007/s40336-018-0294-7; Lee AN, 2020, DRUGS, V80, P617, DOI 10.1007/s40265-020-01286-z; Moskowitz CH, 2015, LANCET, V385, P1853, DOI 10.1016/S0140-6736(15)60165-9; Okeley NM, 2010, CLIN CANCER RES, V16, P888, DOI 10.1158/1078-0432.CCR-09-2069; Gonzalez-Rodriguez AP, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/932010; Pro B, 2012, J CLIN ONCOL, V30, P2190, DOI 10.1200/JCO.2011.38.0402; Sharman JP, 2019, INVEST NEW DRUG, V37, P738, DOI 10.1007/s10637-019-00768-6; Skoura E, 2016, CLIN NUCL MED, V41, pE171, DOI 10.1097/RLU.0000000000001083; Song YQ, 2020, LEUKEMIA, V34, P533, DOI 10.1038/s41375-019-0545-2; Straus DJ, 2020, BLOOD, V135, P735, DOI 10.1182/blood.2019003127; Suyama T, 2021, J CLIN EXP HEMATOP, V61, P48, DOI 10.3960/jslrt.20045; Vassilakopoulos TP, 2019, CANCERS, V11, DOI 10.3390/cancers11081071; Wagner-Johnston ND, 2012, LEUKEMIA LYMPHOMA, V53, P2283, DOI 10.3109/10428194.2012.676170; Wang GX, 2017, RADIOGRAPHICS, V37, P2132, DOI 10.1148/rg.2017170085; Wang YC, 2019, JAMA ONCOL, V5, P1008, DOI 10.1001/jamaoncol.2019.0393; Wang YC, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0601-9; William BM, 2019, BLOOD, V134, DOI 10.1182/blood-2019-123801; Withycombe JS, 2021, J PEDIATR ONCOL NURS, V38, P16, DOI 10.1177/1043454220966590	34	0	0	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 14	2022	12								756583	10.3389/fimmu.2021.756583	http://dx.doi.org/10.3389/fimmu.2021.756583			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YV4NU	35095839	gold, Green Published			2022-12-18	WOS:000752707300001
J	Almishri, W; Swain, LA; D'Mello, C; Le, TS; Urbanski, SJ; Nguyen, HH				Almishri, Wagdi; Swain, Liam A.; D'Mello, Charlotte; Le, Tyson S.; Urbanski, Stefan J.; Nguyen, Henry H.			ADAM Metalloproteinase Domain 17 Regulates Cholestasis-Associated Liver Injury and Sickness Behavior Development in Mice	FRONTIERS IN IMMUNOLOGY			English	Article						ADAM17 (a disintegrin and metalloprotease 17); TACE (TNF-alpha converting enzyme); cholestasis; autoimmune liver disease; inflammation; sickness behavior; therapeutic	TUMOR-NECROSIS-FACTOR; ALPHA-CONVERTING-ENZYME; PRIMARY BILIARY-CIRRHOSIS; QUALITY-OF-LIFE; TNF-ALPHA; IMMUNE-SYSTEM; INFLAMMATION; FATIGUE; ACTIVATION; CELLS	Disintegrin and metalloproteinase domain-containing protein 17 (ADAM17) is a ubiquitously expressed membrane-bound enzyme that mediates shedding of a wide variety of important regulators in inflammation including cytokines and adhesion molecules. Hepatic expression of numerous cytokines and adhesion molecules are increased in cholestatic liver diseases including primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC), however, the pathophysiological role of ADAM17 in regulating these conditions remains unknown. Therefore, we evaluated the role of ADAM17 in a mouse model of cholestatic liver injury due to bile duct ligation (BDL). We found that BDL enhanced hepatic ADAM17 protein expression, paralleled by increased ADAM17 bioactivity. Moreover, inhibition of ADAM17 bioactivity with the specific inhibitor DPC 333 significantly improved both biochemical and histological evidence of liver damage in BDL mice. Patients with cholestatic liver disease commonly experience adverse behavioral symptoms, termed sickness behaviors. Similarly, BDL in mice induces reproducible sickness behavior development, driven by the upregulated expression of cytokines and adhesion molecules that are in turn regulated by ADAM17 activity. Indeed, inhibition of ADAM17 activity significantly ameliorated BDL-associated sickness behavior development. In translational studies, we evaluated changes in ADAM17 protein expression in liver biopsies obtained from patients with PBC and PSC, compared to normal control livers. PSC and PBC patients demonstrated increased hepatic ADAM17 expression in hepatocytes, cholangiocytes and in association with liver-infiltrating immune cells compared to normal controls. In summary, cholestatic liver injury in mice and humans is associated with increased hepatic ADAM17 expression. Furthermore, inhibition of ADAM17 activity improves both cholestatic liver injury and associated sickness behavior development, suggesting that ADAM17 inhibition may represent a novel therapeutic approach for treating patients with PBC/PSC.	[Almishri, Wagdi; Nguyen, Henry H.] Univ Calgary, Cumming Sch Med, Snyder Inst Chron Dis, Dept Microbiol Immunol & Infect Dis, Calgary, AB, Canada; [Almishri, Wagdi; Swain, Liam A.; D'Mello, Charlotte; Le, Tyson S.] Univ Calgary, Snyder Inst Chron Dis, Cumming Sch Med, Calgary, AB, Canada; [Urbanski, Stefan J.] Univ Calgary, Cumming Sch Med, Snyder Inst Chron Dis, Dept Pathol & Lab Med, Calgary, AB, Canada; [Nguyen, Henry H.] Univ Calgary, Cumming Sch Med, Snyder Inst Chron Dis, Div Gastroenterol & Hepatol, Calgary, AB, Canada	University of Calgary; University of Calgary; University of Calgary; University of Calgary	Nguyen, HH (corresponding author), Univ Calgary, Cumming Sch Med, Snyder Inst Chron Dis, Dept Microbiol Immunol & Infect Dis, Calgary, AB, Canada.; Nguyen, HH (corresponding author), Univ Calgary, Cumming Sch Med, Snyder Inst Chron Dis, Div Gastroenterol & Hepatol, Calgary, AB, Canada.	hhnguye@ucalgary.ca		Nguyen, Henry/0000-0002-2205-3205	Cal Wenzel Family Foundation Chair in Hepatology	Cal Wenzel Family Foundation Chair in Hepatology	Funding from Cal Wenzel Family Foundation Chair in Hepatology.	Alexopoulou L, 2006, EUR J IMMUNOL, V36, P2768, DOI 10.1002/eji.200635921; Almishri W, 2015, J HEPATOL, V63, P943, DOI 10.1016/j.jhep.2015.06.007; Alpini G, 2003, AM J PHYSIOL-CELL PH, V285, pC183, DOI 10.1152/ajpcell.00497.2002; Aron JH, 2009, SEMIN IMMUNOPATHOL, V31, P383, DOI 10.1007/s00281-009-0154-7; Arribas J, 2009, CURR PHARM DESIGN, V15, P2319, DOI 10.2174/138161209788682398; Atreya R, 2000, NAT MED, V6, P583, DOI 10.1038/75068; Bai HB, 2012, HEPATOLOGY, V56, P1097, DOI 10.1002/hep.25769; Barak V, 2009, J AUTOIMMUN, V33, P178, DOI 10.1016/j.jaut.2009.09.010; Bell JH, 2007, J LEUKOCYTE BIOL, V82, P173, DOI 10.1189/jlb.0307193; BEMELMANS MHA, 1992, HEPATOLOGY, V15, P1132, DOI 10.1002/hep.1840150626; Black RA, 2002, INT J BIOCHEM CELL B, V34, P1, DOI 10.1016/S1357-2725(01)00097-8; Briso EM, 2008, J IMMUNOL, V180, P7102, DOI 10.4049/jimmunol.180.11.7102; Burton MD, 2013, BRAIN BEHAV IMMUN, V30, P66, DOI 10.1016/j.bbi.2013.01.002; Buryova H, 2013, BMC GASTROENTEROL, V13, DOI 10.1186/1471-230X-13-155; Cai BS, 2020, CELL METAB, V31, P406, DOI 10.1016/j.cmet.2019.11.013; Calligaris M, 2021, MOLECULES, V26, DOI 10.3390/molecules26040944; Cao H, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02815; Casagrande V, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06439-x; Cesaro A, 2009, AM J PHYSIOL-GASTR L, V296, pG1332, DOI 10.1152/ajpgi.90641.2008; Chanthaphavong RS, 2012, J BIOL CHEM, V287, P35887, DOI 10.1074/jbc.M112.365171; Cheung AC, 2016, DIGEST DIS SCI, V61, P1692, DOI 10.1007/s10620-015-4013-1; Costelli P, 2003, CELL DEATH DIFFER, V10, P997, DOI 10.1038/sj.cdd.4401281; D'Mello C, 2015, J NEUROSCI, V35, P10821, DOI 10.1523/JNEUROSCI.0575-15.2015; D'Mello C, 2014, BRAIN BEHAV IMMUN, V35, P9, DOI 10.1016/j.bbi.2013.10.009; D'Mello C, 2013, J NEUROSCI, V33, P14878, DOI 10.1523/JNEUROSCI.1329-13.2013; D'Mello C, 2009, J NEUROSCI, V29, P2089, DOI 10.1523/JNEUROSCI.3567-08.2009; Dantzer R, 2008, NAT REV NEUROSCI, V9, P46, DOI 10.1038/nrn2297; DeBerge MP, 2015, J LEUKOCYTE BIOL, V98, P423, DOI 10.1189/jlb.3A0914-432RR; Ebsen H, 2015, MOL IMMUNOL, V65, P416, DOI 10.1016/j.molimm.2015.02.008; Ebsen H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076853; Fiorentino L, 2010, HEPATOLOGY, V51, P103, DOI 10.1002/hep.23250; Gabele E, 2009, BIOCHEM BIOPH RES CO, V378, P348, DOI 10.1016/j.bbrc.2008.10.155; Gao LX, 2020, CLIN REV ALLERG IMMU, V59, P175, DOI 10.1007/s12016-019-08772-7; Garton KJ, 2003, J BIOL CHEM, V278, P37459, DOI 10.1074/jbc.M305877200; Gerber LH, 2019, WORLD J GASTROENTERO, V25, P3669, DOI 10.3748/wjg.v25.i28.3669; Gooz M, 2010, CRIT REV BIOCHEM MOL, V45, P146, DOI 10.3109/10409231003628015; Hohenester S, 2009, SEMIN IMMUNOPATHOL, V31, P283, DOI 10.1007/s00281-009-0164-5; Huet PM, 2000, AM J GASTROENTEROL, V95, P760; Ishizawa M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051664; Isse K, 2007, LIVER INT, V27, P672, DOI 10.1111/j.1478-3231.2007.01465.x; Johnson Christopher, 2012, Transl Gastrointest Cancer, V1, P58; Jones DE, 2010, J HEPATOL, V53, P911, DOI 10.1016/j.jhep.2010.05.026; Jones DEJ, 2007, GUT, V56, P1615, DOI 10.1136/gut.2007.122150; Jopson L, 2016, CLIN LIVER DIS, V20, P131, DOI 10.1016/j.cld.2015.08.007; Juran BD, 2010, HEPATOLOGY, V52, P223, DOI 10.1002/hep.23667; Karlsen TH, 2013, J HEPATOL, V59, P571, DOI 10.1016/j.jhep.2013.03.015; Kawaguchi M, 2005, BRIT J DERMATOL, V152, P915, DOI 10.1111/j.1365-2133.2005.06440.x; Kerfoot SM, 2006, HEPATOLOGY, V43, P154, DOI 10.1002/hep.21003; Khanna A, 2018, BEST PRACT RES CL GA, V34-35, P41, DOI 10.1016/j.bpg.2018.06.007; Langedijk J, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-85660-1; Lechner AJ, 1998, AM J RESP CRIT CARE, V157, P1550, DOI 10.1164/ajrccm.157.5.9709067; Liaskou E, 2014, GASTROENTEROLOGY, V147, P221, DOI 10.1053/j.gastro.2014.04.003; Lisi S, 2014, IMMUNOL LETT, V162, P159, DOI 10.1016/j.imlet.2014.08.008; Mariotti V, 2019, BBA-MOL BASIS DIS, V1865, P954, DOI 10.1016/j.bbadis.2018.07.025; McMahan RS, 2013, AM J PHYSIOL-GASTR L, V305, pG25, DOI 10.1152/ajpgi.00326.2012; Mells GF, 2013, HEPATOLOGY, V58, P273, DOI 10.1002/hep.26365; Mohammed FF, 2004, NAT GENET, V36, P969, DOI 10.1038/ng1413; Neuman M, 2002, J GASTROEN HEPATOL, V17, P196, DOI 10.1046/j.1440-1746.2002.02672.x; Nevzorova YA, 2020, J HEPATOL, V73, P423, DOI 10.1016/j.jhep.2020.04.011; Nguyen K, 2012, J HEPATOL, V56, P626, DOI 10.1016/j.jhep.2011.09.014; Onofrio Fernanda Q, 2020, Clin Liver Dis (Hoboken), V15, P110, DOI 10.1002/cld.894; Palin K, 2007, J NEUROIMMUNOL, V187, P55, DOI 10.1016/j.jneuroim.2007.04.011; Pinto C, 2018, BBA-MOL BASIS DIS, V1864, P1270, DOI 10.1016/j.bbadis.2017.07.024; Qian MX, 2007, DRUG METAB DISPOS, V35, P1916, DOI 10.1124/dmd.107.015933; Robertshaw HJ, 2005, BRIT J ANAESTH, V94, P222, DOI 10.1093/bja/aei021; Rose-John S, 2013, PHARMACOL RES, V71, P19, DOI 10.1016/j.phrs.2013.01.012; Rovida E, 2001, J IMMUNOL, V166, P1583, DOI 10.4049/jimmunol.166.3.1583; Schaff U, 2008, J LEUKOCYTE BIOL, V83, P99, DOI 10.1189/jlb.0507304; Scheller J, 2011, TRENDS IMMUNOL, V32, P380, DOI 10.1016/j.it.2011.05.005; Schmidt-Arras D, 2016, J HEPATOL, V64, P1403, DOI 10.1016/j.jhep.2016.02.004; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Sharma M, 2013, INT IMMUNOPHARMACOL, V17, P229, DOI 10.1016/j.intimp.2013.06.014; Simeonova PP, 2001, TOXICOL APPL PHARM, V177, P112, DOI 10.1006/taap.2001.9304; Sun QN, 2019, ANN TRANSL MED, V7, DOI 10.21037/atm.2019.07.100; Tag CG, 2015, JOVE-J VIS EXP, DOI 10.3791/52438; Tang ZY, 2006, TRANSPLANTATION, V82, P1518, DOI 10.1097/01.tp.0000243381.41777.c7; Thabet MM, 2006, CURR OPIN INVEST DR, V7, P1014; Tsakadze NL, 2006, J BIOL CHEM, V281, P3157, DOI 10.1074/jbc.M510797200; von Maltzan K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029890; Wang YJ, 2006, J BIOL CHEM, V281, P15258, DOI 10.1074/jbc.M512953200; Wondimu Z, 2010, AM J PATHOL, V177, P2334, DOI 10.2353/ajpath.2010.100028; Zarrin AA, 2021, NAT REV DRUG DISCOV, V20, P39, DOI 10.1038/s41573-020-0082-8	82	0	0	1	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 13	2022	12								779119	10.3389/fimmu.2021.779119	http://dx.doi.org/10.3389/fimmu.2021.779119			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YP2PD	35095853	gold, Green Published			2022-12-18	WOS:000748467800001
J	Huang, LT; Wu, W; Zhu, YJ; Yu, HL; Tang, LL; Fang, XL				Huang, Lingtong; Wu, Wei; Zhu, Yijing; Yu, Huili; Tang, Lingling; Fang, Xueling			Case Report: Hemophagocytic Lymphocytosis in a Patient With Glutaric Aciduria Type IIC	FRONTIERS IN IMMUNOLOGY			English	Article						glutaric aciduria; hemophagocytic lymphocytosis; hemophagocytic syndrome; cytopenia; inborn errors of metabolism; IEM	COENZYME-A DEHYDROGENASE; GAUCHER-DISEASE; WOLMANS-DISEASE; LYMPHOHISTIOCYTOSIS; DEFICIENCY	Hemophagocytic lymphocytosis (HLH) is a rare disease caused by inborn errors of immunity (IEI), secondary to infection, lymphoma or autoimmune disorders, but we often overlook the fact that HLH can be secondary to inborn errors of metabolism (IEM). Here, we describe a patient who was diagnosed with glutaric aciduria type IIC complicated by features suggestive of possible HLH. The diagnosis of glutaric aciduria type IIC, a IEM, was confirmed by whole exome sequencing. The patient was treated with coenzyme Q10 and riboflavin which effectively improved her liver function. During treatment, the patient developed severe anemia and thrombocytopenia. Persistent fever, splenomegaly, cytopenias, increased ferritin, hypertriglyceridemia, hypofibrinogenemia, and hemophagocytosis in the bone marrow pointed to the diagnosis of HLH; however, the patient eventually died of gastrointestinal bleeding. After other potential causes were ruled out, the patient was diagnosed with glutaric aciduria type IIC complicated by features suggestive of possible HLH. When cytopenias occurs in IEM patients, HLH is a possible complication that cannot be ignored. This case suggests a possible relationship between IEM and risk for immune dysregulation.	[Huang, Lingtong; Yu, Huili; Fang, Xueling] Zhejiang Univ, Affiliated Hosp 1, Sch Med, Dept Crit Care Units, Hangzhou, Peoples R China; [Wu, Wei] Zhejiang Univ, Affiliated Hosp 1, Sch Med, Dept Infect Dis, Hangzhou, Peoples R China; [Zhu, Yijing] Zhejiang Univ, Affiliated Hosp 1, Sch Med, Dept Hematol, Hangzhou, Peoples R China; [Tang, Lingling] Zhejiang Shuren Univ, Shulan Int Med Coll, Shulan Hangzhou Hosp, Dept Infect Dis, Hangzhou, Peoples R China	Zhejiang University; Zhejiang University; Zhejiang University; Zhejiang Shuren University	Fang, XL (corresponding author), Zhejiang Univ, Affiliated Hosp 1, Sch Med, Dept Crit Care Units, Hangzhou, Peoples R China.; Tang, LL (corresponding author), Zhejiang Shuren Univ, Shulan Int Med Coll, Shulan Hangzhou Hosp, Dept Infect Dis, Hangzhou, Peoples R China.	lltang@126.com; xuelingfang@zju.edu.cn						Al Essa M, 1998, ANN SAUDI MED, V18, P120, DOI 10.5144/0256-4947.1998.120; ANTOZZI C, 1994, NEUROLOGY, V44, P2153, DOI 10.1212/WNL.44.11.2153; Canna SW, 2020, BLOOD, V135, P1332, DOI 10.1182/blood.2019000936; Chokchaiwong S, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8020106; Dell'Acqua F, 2019, J ALLER CL IMM-PRACT, V7, P2476, DOI 10.1016/j.jaip.2019.04.001; DUSHEIKO G, 1979, NEW ENGL J MED, V301, P1405, DOI 10.1056/NEJM197912273012601; Duval M, 1999, J PEDIATR-US, V134, P236, DOI 10.1016/S0022-3476(99)70423-3; Enders A, 2006, BLOOD, V108, P81, DOI 10.1182/blood-2005-11-4413; Erdol S, 2016, J PEDIAT HEMATOL ONC, V38, P661, DOI 10.1097/MPH.0000000000000626; Fakhouri F, 2021, NAT REV NEPHROL, V17, P543, DOI 10.1038/s41581-021-00424-4; Gempel K, 2007, BRAIN, V130, P2037, DOI 10.1093/brain/awm054; Gokce M, 2012, PEDIATR HEMAT ONCOL, V29, P92, DOI 10.3109/08880018.2011.601402; GOLDBERG J, 1986, HEMATOL ONCOL, V4, P275, DOI 10.1002/hon.2900040405; Huang LT, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.618830; Jung J, 2019, NAT CELL BIOL, V21, P85, DOI 10.1038/s41556-018-0217-x; Kar YD, 2019, J PEDIAT HEMATOL ONC, V41, pE260, DOI 10.1097/MPH.0000000000001208; Kardas F, 2012, PEDIATR BLOOD CANCER, V59, P191, DOI 10.1002/pbc.23247; Koker SA, 2020, ARCH ARGENT PEDIATR, V118, pE174, DOI 10.5546/aap.2020.eng.e174; Kolker S, 2004, ANN NEUROL, V55, P7, DOI 10.1002/ana.10784; Mauhin W, 2017, ORPHANET J RARE DIS, V12, DOI 10.1186/s13023-016-0550-8; Ouederni M, 2017, MEDITERR J HEMATOL I, V9, DOI 10.4084/MJHID.2017.057; Perez-Torras S, 2019, BBA-MOL BASIS DIS, V1865, P1182, DOI 10.1016/j.bbadis.2019.01.013; Rabah F, 2014, PEDIATR HEMAT ONCOL, V31, P576, DOI 10.3109/08880018.2014.920942; Rigante D, 2007, ARTHRITIS RHEUM-US, V56, P658, DOI 10.1002/art.22409; Rossignol F, 2021, GENET MED, V23, P1604, DOI 10.1038/s41436-021-01200-2; RUBIN CM, 1985, CANCER, V56, P524, DOI 10.1002/1097-0142(19850801)56:3<524::AID-CNCR2820560320>3.0.CO;2-Z; Schuller S, 2016, PEDIATR HEMAT ONCOL, V33, P462, DOI 10.1080/08880018.2016.1234011; Sharpe LR, 2009, J INHERIT METAB DIS, V32, pS107, DOI 10.1007/s10545-009-1091-2; Tanaka T, 2019, MOD RHEUMATOL, V29, P181, DOI 10.1080/14397595.2018.1442639; Taurisano R, 2014, EUR J PEDIATR, V173, P1391, DOI 10.1007/s00431-014-2338-y; Voss K, 2021, NAT REV IMMUNOL, V21, P637, DOI 10.1038/s41577-021-00529-8; Wei A, 2020, J PEDIAT HEMATOL ONC, V42, P368, DOI 10.1097/MPH.0000000000001694; WILCKEN B, 1993, LANCET, V341, P407, DOI 10.1016/0140-6736(93)92993-4; Wu S, 2005, PEDIATR HEMAT ONCOL, V22, P717, DOI 10.1080/08880010500278871; Xi JY, 2014, J INHERIT METAB DIS, V37, P399, DOI 10.1007/s10545-013-9671-6; Yang Z, 2002, JAMA-J AM MED ASSOC, V288, P2163, DOI 10.1001/jama.288.17.2163; Yokoyama S, 2007, TRANSPLANTATION, V84, P1067, DOI 10.1097/01.tp.0000285993.73978.54	37	0	0	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 13	2022	12								810677	10.3389/fimmu.2021.810677	http://dx.doi.org/10.3389/fimmu.2021.810677			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZC5YA	35095902	Green Published, gold			2022-12-18	WOS:000757594100001
J	Hussein, BA; Hallner, A; Wennstrom, L; Brune, M; Martner, A; Hellstrand, K; Bernson, E; Thoren, F				Hussein, Brwa Ali; Hallner, Alexander; Wennstrom, Lovisa; Brune, Mats; Martner, Anna; Hellstrand, Kristoffer; Bernson, Elin; Thoren, Fredrik B.			Impact of NK Cell Activating Receptor Gene Variants on Receptor Expression and Outcome of Immunotherapy in Acute Myeloid Leukemia (vol 12, 5300, 2021)	FRONTIERS IN IMMUNOLOGY			English	Correction						NK cell receptors; gene variants; single nucleotide polymorphism; acute myeloid leukemia; histamine/IL-2; Re:Mission trial; immunotherapy			[Hussein, Brwa Ali; Hallner, Alexander; Martner, Anna; Hellstrand, Kristoffer; Bernson, Elin; Thoren, Fredrik B.] Univ Gothenburg, Sahlgrenska Ctr Canc Res, Tumor Immunol TIMM Lab, Gothenburg, Sweden; [Hussein, Brwa Ali; Thoren, Fredrik B.] Univ Gothenburg, Inst Biomed, Dept Med Biochem & Cell Biol, Gothenburg, Sweden; [Hallner, Alexander; Martner, Anna; Hellstrand, Kristoffer] Univ Gothenburg, Inst Biomed, Dept Infect Dis, Gothenburg, Sweden; [Wennstrom, Lovisa; Brune, Mats] Univ Gothenburg, Inst Med, Dept Hematol, Gothenburg, Sweden; [Bernson, Elin] Univ Gothenburg, Inst Clin Sci, Dept Obstet & Gynecol, Gothenburg, Sweden	University of Gothenburg; University of Gothenburg; University of Gothenburg; University of Gothenburg; University of Gothenburg	Thoren, F (corresponding author), Univ Gothenburg, Sahlgrenska Ctr Canc Res, Tumor Immunol TIMM Lab, Gothenburg, Sweden.; Thoren, F (corresponding author), Univ Gothenburg, Inst Biomed, Dept Med Biochem & Cell Biol, Gothenburg, Sweden.	fredrik.thoren@gu.se						Hussein BA, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.796072	1	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 13	2022	12								843461	10.3389/fimmu.2021.843461	http://dx.doi.org/10.3389/fimmu.2021.843461			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	5X8UC	35095937	gold, Green Published			2022-12-18	WOS:000878870800001
J	Juchem, KW; Gounder, AP; Gao, JP; Seccareccia, E; Yeddula, N; Huffmaster, NJ; Cote-Martin, A; Fogal, SE; Souza, D; Wang, SS; Glynn, ERA; Yung, I; Ritchie, J; Li, L; Zheng, J; Mbow, ML; Li, J; Chanda, SK				Juchem, Kathryn W.; Gounder, Anshu P.; Gao, Jian Ping; Seccareccia, Elise; Yeddula, Narayana; Huffmaster, Nicholas J.; Cote-Martin, Alexandra; Fogal, Steven E.; Souza, Donald; Wang, Sarah Sirui; Glynn, Elizabeth R. A.; Yung, Ivy; Ritchie, Julie; Li, Li; Zheng, Jie; Mbow, M. Lamine; Li, Jun; Chanda, Sumit K.			NFAM1 Promotes Pro-Inflammatory Cytokine Production in Mouse and Human Monocytes	FRONTIERS IN IMMUNOLOGY			English	Article						NFAM1; Crohn's disease; inflammatory bowel disease; monocytes; inflammation; CD40L; B cells; knockout mice	T-CELLS; ACTIVATION; EXPRESSION; DISEASE; PROTEIN	NFAT activating protein with ITAM motif 1 (NFAM1) is an ITAM bearing-transmembrane receptor that has been reported to play a role in B cell signaling and development. We performed expression analysis of NFAM1 using publicly available gene expression data sets and found that NFAM1 expression is significantly induced in intestinal biopsies from Crohn's disease (CD) and ulcerative colitis (UC) patients. At the cellular level, we further observed high expression of NFAM1 in monocytes and neutrophils, and low expression in B and T cells. To explore the role of NFAM1 in multiple immune cells and its potential role in IBD, we generated NFAM1(-/-) mice. In contrast with previous reports using NFAM1-transgenic mice, NFAM1(-/-) mice have no obvious defects in immune cell development, or B cell responses. Interestingly, NFAM1(-/-) monocytes produce reduced levels of TNF-alpha in response to activation by multiple IBD-relevant stimuli, including CD40L, TLR ligands and MDP. Additional cytokines and chemokines such as IL-6, IL-12, CCL3 and CCL4 are also reduced in CD40L stimulated NFAM1(-/-) monocytes. Collectively, these findings indicate that NFAM1 promotes monocyte activation, thereby amplifying the response to diverse stimuli. Similarly, we observed that deletion of NFAM1 in human monocytes reduces expression of CD40L-induced CCL4. Lastly, to assess the role of NFAM1 in IBD, we compared development of anti-CD40 induced colitis in NFAM1(+/+) and NFAM1(-/-) mice. We found that although NFAM1 deletion had no impact on development of gut pathology, we did observe a decrease in serum TNF-alpha, confirming that NFAM1 promotes pro-inflammatory cytokine production in vivo. Taken together, we conclude that NFAM1 functions to amplify cytokine production and should be further evaluated as a therapeutic target for treatment of autoimmune disease.	[Juchem, Kathryn W.; Gao, Jian Ping; Seccareccia, Elise; Cote-Martin, Alexandra; Fogal, Steven E.; Souza, Donald; Wang, Sarah Sirui; Glynn, Elizabeth R. A.; Yung, Ivy; Zheng, Jie; Mbow, M. Lamine] Boehringer Ingelheim Pharmaceut Inc, Dept Immunol & Resp Dis Res, 90 E Ridge POB 368, Ridgefield, CT 06877 USA; [Gounder, Anshu P.; Yeddula, Narayana; Huffmaster, Nicholas J.; Chanda, Sumit K.] Sanford Burnham Prebys Med Discovery Inst, Infect & Inflammatory Dis Ctr, Immun & Pathogenesis Program, La Jolla, CA USA; [Ritchie, Julie] Boehringer Ingelheim Pharmaceut Inc, Dept Biotherapeut Discovery, 90 E Ridge POB 368, Ridgefield, CT 06877 USA; [Li, Li] Boehringer Ingelheim Pharmaceut Inc, Dept Global Computat Biol & Digital Sci, 90 E Ridge POB 368, Ridgefield, CT 06877 USA	Boehringer Ingelheim; Sanford Burnham Prebys Medical Discovery Institute; Boehringer Ingelheim; Boehringer Ingelheim	Juchem, KW (corresponding author), Boehringer Ingelheim Pharmaceut Inc, Dept Immunol & Resp Dis Res, 90 E Ridge POB 368, Ridgefield, CT 06877 USA.	kathryn.juchem@boehringer-ingelheim.com						Bendickova K, 2020, J LEUKOCYTE BIOL, V107, P497, DOI 10.1002/JLB.4VMA0318-138R; Catherinet C, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0254184; Ethiraj P, 2021, J CELL BIOCHEM, V122, P1534, DOI 10.1002/jcb.30076; Fric J, 2012, BLOOD, V120, P1380, DOI 10.1182/blood-2012-02-404475; Goodridge HS, 2007, J IMMUNOL, V178, P3107, DOI 10.4049/jimmunol.178.5.3107; Gourhant L, 2021, REPROD BIOMED ONLINE, V42, P789, DOI 10.1016/j.rbmo.2021.01.008; Guan QD, 2019, J IMMUNOL RES, V2019, DOI 10.1155/2019/7247238; Haberman Y, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-07841-3; Hultquist JF, 2019, NAT PROTOC, V14, P1, DOI 10.1038/s41596-018-0069-7; Joyce-Shaikh B, 2019, BIO-PROTOCOL, V9, DOI 10.21769/BioProtoc.3153; Kawamura T, 2004, CIRC RES, V94, P1492, DOI 10.1161/01.RES.0000129701.14494.52; Kuprash DV, 2002, BLOOD, V100, P1721; Kurtas N, 2018, J MED GENET, V55, P269, DOI 10.1136/jmedgenet-2017-105125; Long J, 2020, ATHEROSCLEROSIS, V307, P39, DOI 10.1016/j.atherosclerosis.2020.06.001; Luo C, 1996, MOL CELL BIOL, V16, P3955; Lv W, 2015, MOL MED REP, V11, P2299, DOI 10.3892/mmr.2014.2978; Ma HD, 2019, CELL MOL IMMUNOL, V16, P216, DOI 10.1038/s41423-019-0208-2; Mognol GP, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.97; Ohtsuka M, 2004, P NATL ACAD SCI USA, V101, P8126, DOI 10.1073/pnas.0401119101; Pelia RS., 2020, PROFILING NONCODING, DOI [10.21203/rs.3.rs-88594/v1, DOI 10.21203/RS.3.RS-88594/V1]; Sambandam Y, 2017, BONE, V101, P236, DOI 10.1016/j.bone.2017.05.013; Schroder K, 2004, J LEUKOCYTE BIOL, V75, P163, DOI 10.1189/jlb.0603252; Strober W, 2011, MUCOSAL IMMUNOL, V4, P484, DOI 10.1038/mi.2011.29; Yang JH, 2003, J BIOL CHEM, V278, P16797, DOI 10.1074/jbc.M211060200; Zanoni I, 2009, NATURE, V460, P264, DOI 10.1038/nature08118; Zhu C, 2003, J BIOL CHEM, V278, P39372, DOI 10.1074/jbc.M306441200	26	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 13	2022	12								773445	10.3389/fimmu.2021.773445	http://dx.doi.org/10.3389/fimmu.2021.773445			19	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YR7CF	35095847	Green Published, gold			2022-12-18	WOS:000750149300001
J	Matsuda, S; Kotani, T; Saito, T; Suzuka, T; Mori, T; Takeuchi, T				Matsuda, Shogo; Kotani, Takuya; Saito, Takashi; Suzuka, Takayasu; Mori, Tatsuhiko; Takeuchi, Tohru			Low-Molecular-Weight Heparin Enhanced Therapeutic Effects of Human Adipose-Derived Stem Cell Administration in a Mouse Model of Lupus Nephritis	FRONTIERS IN IMMUNOLOGY			English	Article						adipose-derived stem cells; systemic lupus erythematosus; low-molecular-weight heparin (LMWH); lupus nephritis; anti-inflammation	HEPATOCYTE GROWTH-FACTOR; DISEASE; TRANSPLANTATION; ERYTHEMATOSUS; PREVENTION; PROTECTS; MICE	BackgroundLupus nephritis is a life-threatening complication in systemic lupus erythematosus (SLE), but the efficiency of current therapies involving corticosteroids, immunosuppressants, and biological agents is limited. Adipose-derived mesenchymal stem cells (ASCs) are gaining attention as a novel treatment for inflammation in SLE. Low-molecular-weight heparin (LMWH) exhibits multiple functions including anti-inflammatory, anti-fibrotic, and cell function-promoting effects. LMWH stimulation is expected to increase the therapeutic effect of ASCs by promoting cellular functions. In this study, we investigated the effects of LMWH on ASC functions and the therapeutic effect of LMWH-activated human-ASCs (hep-hASCs) in an SLE mouse model. MethodsThe cellular functions of human-derived ASCs stimulated with different LMWH concentrations were observed, and the optimum LMWH dose was selected. The mice were assigned to control, human-ASC, and hep-hASC groups; treatments were performed on week 20. Twenty-six week-old mice were sacrificed, and urine protein score, serum blood urea nitrogen, creatinine (Cr), anti-ds DNA IgG antibody, and serum IL-6 levels were analyzed in each group. Mice kidneys were evaluated via histological examination, immunohistochemical staining, and gene expression levels. ResultsLMWH significantly promoted ASC migration and proliferation and hepatocyte growth factor production and upregulated immunomodulatory factors in vitro. Hep-hASC administration resulted in significant disease activity improvement including proteinuria, serum Cr and IL-6 levels, anti-ds DNA IgG antibody, glomerulonephritis, and immune complex in mice. Inflammation and fibrosis in kidneys was significantly suppressed in the hep-hASC group; the gene expression levels of TNF-alpha, TIMP-2, and MMP-2 was significantly downregulated in the hep-hASC group compared with the control group. ConclusionsHep-hASC exhibited higher anti-inflammatory and anti-fibrotic effects than hASCs and may be a candidate tool for SLE treatment in future.	[Matsuda, Shogo; Kotani, Takuya; Suzuka, Takayasu; Takeuchi, Tohru] Osaka Med & Pharmaceut Univ, Dept Internal Med 4, Takatsuki, Osaka, Japan; [Saito, Takashi] Osaka Med & Pharmaceut Univ, Dept Legal Med, Takatsuki, Osaka, Japan; [Mori, Tatsuhiko] Osaka Med & Pharmaceut Univ, Med Educ Ctr, Takatsuki, Osaka, Japan		Kotani, T (corresponding author), Osaka Med & Pharmaceut Univ, Dept Internal Med 4, Takatsuki, Osaka, Japan.	takuya.kotani@ompu.ac.jp	Saito, Takashi/AAD-6765-2022	Saito, Takashi/0000-0001-8049-1943				Anderson P, 2013, GUT, V62, P1131, DOI 10.1136/gutjnl-2012-302152; Bao LH, 2003, J AM SOC NEPHROL, V14, P670, DOI 10.1097/01.ASN.0000051597.27127.A1; Bethunaickan R, 2012, ARTHRITIS RHEUM-US, V64, P3399, DOI 10.1002/art.34553; Casu B, 2015, CARBOHYD RES, V403, P60, DOI 10.1016/j.carres.2014.06.023; Chen PM, 2014, J LEUKOCYTE BIOL, V96, P295, DOI 10.1189/jlb.3A0513-242R; Choi EW, 2012, ARTHRITIS RHEUM-US, V64, P243, DOI 10.1002/art.33313; Coudriet GM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015384; Cunnane G, 2004, ARTHRITIS RHEUM-US, V50, P1539, DOI 10.1002/art.20147; Fanouriakis A, 2019, ANN RHEUM DIS, V78, P736, DOI 10.1136/annrheumdis-2019-215089; Fenton K, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008474; Forte G, 2006, STEM CELLS, V24, P23, DOI 10.1634/stemcells.2004-0176; Giannopoulou M, 2008, AM J PATHOL, V173, P30, DOI 10.2353/ajpath.2008.070583; Gong RJ, 2006, J AM SOC NEPHROL, V17, P2464, DOI 10.1681/ASN.2006020185; Gu F, 2014, CLIN RHEUMATOL, V33, P1611, DOI 10.1007/s10067-014-2754-4; Jiang ZX, 2010, RHEUMATOL INT, V30, P1219, DOI 10.1007/s00296-009-1135-9; Kollet O, 2003, J CLIN INVEST, V112, P160, DOI 10.1172/JCI200317902; Kotani T, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15022-3; Ling L, 2016, GENE, V576, P292, DOI 10.1016/j.gene.2015.10.039; Liu HB, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0034608, 10.1371/journal.pone.0050785]; Liu L, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18509-1; Maroz N, 2013, AM J MED SCI, V346, P319, DOI 10.1097/MAJ.0b013e31827f4ee3; MATSUMOTO K, 1993, J BIOCHEM-TOKYO, V114, P820, DOI 10.1093/oxfordjournals.jbchem.a124262; Neubert K, 2008, NAT MED, V14, P748, DOI 10.1038/nm1763; Noriega-Guerra H, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113300; Planat-Benard V, 2004, CIRCULATION, V109, P656, DOI 10.1161/01.CIR.0000114522.38265.61; Rahman A, 2008, NEW ENGL J MED, V358, P929, DOI 10.1056/NEJMra071297; Ribeiro A, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt336; Saito T, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-76034-0; Sakiyama R, 2007, J BIOCHEM, V141, P653, DOI 10.1093/jb/mvm067; Sattwika PD, 2018, LUPUS, V27, P1881, DOI 10.1177/0961203318793206; Schena F, 2010, ARTHRITIS RHEUM-US, V62, P2776, DOI 10.1002/art.27560; Schievenbusch S, 2009, BIOCHEM BIOPH RES CO, V385, P55, DOI 10.1016/j.bbrc.2009.05.010; Schulman S, 2008, CHEST, V133, p257S, DOI 10.1378/chest.08-0674; Singh RR, 2005, TRENDS IMMUNOL, V26, P572, DOI 10.1016/j.it.2005.08.013; Sun LY, 2007, LUPUS, V16, P121, DOI 10.1177/0961203306075793; Sun LY, 2010, ARTHRITIS RHEUM-US, V62, P2467, DOI 10.1002/art.27548; Thiel A, 2015, SCI REP-UK, V5, DOI 10.1038/srep17685; Toyserkani NM, 2017, STEM CELL TRANSL MED, V6, P1786, DOI 10.1002/sctm.17-0031; Tripathi V, 2014, CELL COMMUN ADHES, V21, P221, DOI 10.3109/15419061.2013.876013; Turpie AGG, 2001, NEW ENGL J MED, V344, P619, DOI 10.1056/NEJM200103013440901; Tveita AA, 2008, KIDNEY INT, V74, P1150, DOI 10.1038/ki.2008.308; Uysal CA, 2014, ADV WOUND CARE, V3, P405, DOI 10.1089/wound.2014.0539; Wang DD, 2013, CELL TRANSPLANT, V22, P2267, DOI [10.3727/096368911X582769, 10.3727/096368911X582769c]; Wellmann U, 2001, INT IMMUNOL, V13, P1461, DOI 10.1093/intimm/13.12.1461; Wu MH, 2004, GENE THER, V11, P170, DOI 10.1038/sj.gt.3302165; Wysoczynki M, 2018, CIRC RES, V123, P138, DOI 10.1161/CIRCRESAHA.118.313251; Zhuang L, 2019, ONCOL REP, V42, P1781, DOI 10.3892/or.2019.7293	47	0	0	2	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 13	2022	12								792739	10.3389/fimmu.2021.792739	http://dx.doi.org/10.3389/fimmu.2021.792739			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YO5UJ	35095868	Green Published, gold			2022-12-18	WOS:000748006000001
J	Mukherjee, S; Ray, G; Saha, B; Kar, SK				Mukherjee, Sitabja; Ray, Gopesh; Saha, Bhaskar; Kar, Santosh K.			Oral Therapy Using a Combination of Nanotized Antimalarials and Immunomodulatory Molecules Reduces Inflammation and Prevents Parasite Induced Pathology in the Brain and Spleen of P. berghei ANKA Infected C57BL/6 Mice	FRONTIERS IN IMMUNOLOGY			English	Article						experimental cerebral malaria (ECM); P; berghei ANKA; inflammation control; recrudescence; combination therapy	PLASMODIUM-BERGHEI; CEREBRAL MALARIA; IN-VITRO; T-BET; ARTEMISININ; CURCUMIN; FALCIPARUM; EFFICACY; MECHANISMS; IMMUNITY	In malaria, anti-parasite immune response of the host may lead to dysregulated inflammation causing severe neuropathology arising from extensive damage to the Blood Brain Barrier (BBB). Use of anti-malarial drugs alone can control parasitemia and reduce inflammation but it cannot reduce pathology if chronic inflammation has already set in. In the present study, we have tested the efficacy of a new oral artemsinin based combination therapy (ACT) regimen using a combination of anti-malarial compounds like nanoartemisinin and nanoallylated-chalcone9 [{1-(4-Chlorophenyl)-3-[3-methoxy-4-(prop-2-en-1-yloxy) phenyl]-prop-2-en-1-one}]given together with anti-inflammatory-cum- anti-malarial compounds like nanoandrographolide and nanocurcumin to C57BL/6 mice infected with P. berghei ANKA. Untreated infected mice developed Experimental Cerebral Malaria (ECM) and died between 10 to 12 days after infection from severe BBB damage. We observed that oral treatments with nanoartemisinin or nano allylated chalcone 9 or nanoandrographolide alone, for 4 days after the onset of ECM, delayed the development of severe neurolopathology but could not prevent it. Nanocurcumin treatment for 4 days on the other hand, prevented damage to the BBB but the mice died because of hyperparasitemia. A single time oral administration of our ACT controlled blood parasitemia and prevented damage to the BBB, but recrudescence occurred due to persistence of parasites in the spleen. However the recrudescent parasites failed to induce ECM and BBB damage, leading to prolonged survival of the animals. A second time treatment at the start of recrudescence led to complete parasite clearance and survival of mice without pathology or parasitemia for 90 days. FACS analysis of spleen cells and gene expression profile in brain and spleen as well as quantitation of serum cytokine by ELISA showed that P. berghei ANKA infection in C57Bl/6 mice leads to a Th1-skewed immune response that result in severe inflammation and early death from ECM. Oral treatment with our ACT prevented a heightened pro-inflammatory response by modulating the Th1, Th2 and Treg immune responses and prevented ECM and death.	[Mukherjee, Sitabja] KIIT Deemed Univ, Sch Biotechnol, Bhubaneswar, India; [Ray, Gopesh; Kar, Santosh K.] KIIT Deemed Univ, Nano Herb Res Lab, Kalinga Inst Ind Technol KIIT Technol Business In, Bhubaneswar, India; [Saha, Bhaskar] Natl Ctr Cell Sci, Pune, Maharashtra, India	Kalinga Institute of Industrial Technology (KIIT); Kalinga Institute of Industrial Technology (KIIT); Department of Biotechnology (DBT) India; National Centre for Cell Science, Pune (NCCS)	Kar, SK (corresponding author), KIIT Deemed Univ, Nano Herb Res Lab, Kalinga Inst Ind Technol KIIT Technol Business In, Bhubaneswar, India.	santoshkariis@rediffmail.com			department of Biotechnology [BT/PR12943/MED/29/934/2015]	department of Biotechnology	Funding SM was supported by UGC, Govt. of India and GR was supported by the grant to SK (BT/PR12943/MED/29/934/2015) from the Department of Biotechnology, Ministry of Science and Technology, Government of India.	Akhtar F, 2012, BIOTECHNOL ADV, V30, P310, DOI 10.1016/j.biotechadv.2011.05.009; Al-Quraishy S, 2021, SAUDI J BIOL SCI, V28, P1374, DOI 10.1016/j.sjbs.2020.11.069; Alven S, 2019, MOLECULES, V24, DOI 10.3390/molecules24193601; Amani V, 1998, INFECT IMMUN, V66, P4093; Artavanis-Tsakonas K, 2003, CLIN EXP IMMUNOL, V133, P145, DOI 10.1046/j.1365-2249.2003.02174.x; Balint GA, 2001, PHARMACOL THERAPEUT, V90, P261, DOI 10.1016/S0163-7258(01)00140-1; Brown H, 1999, NEUROPATH APPL NEURO, V25, P331; Chakrabarti R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057302; Chen M, 1997, J INFECT DIS, V176, P1327, DOI 10.1086/514129; Couper KN, 2008, J IMMUNOL, V180, P5771, DOI 10.4049/jimmunol.180.9.5771; D'Alessandro U, 2001, TROP MED INT HEALTH, V6, P845, DOI 10.1046/j.1365-3156.2001.00819.x; Das S, 2018, NEW ENGL J MED, V379, P1962, DOI 10.1056/NEJMc1713777; de Oca Marcela Montes, 2013, Methods Mol Biol, V1031, P203, DOI 10.1007/978-1-62703-481-4_23; Dende C, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10672-9; Dende C, 2015, SCI REP-UK, V5, DOI 10.1038/srep12671; Deroost K, 2016, FEMS MICROBIOL REV, V40, P208, DOI 10.1093/femsre/fuv046; Dkhil MA, 2021, SAUDI J BIOL SCI, V28, P1723, DOI 10.1016/j.sjbs.2020.12.014; Dunst J, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00324; Engwerda C, 2005, CURR TOP MICROBIOL, V297, P103; Fairhurst RM, 2016, MICROBIOL SPECTR, V4, DOI 10.1128/microbiolspec.EI10-0013-2016; Fidock DA, 2004, NAT REV DRUG DISCOV, V3, P509, DOI 10.1038/nrd1416; Golenser J, 2006, INT J PARASITOL, V36, P583, DOI 10.1016/j.ijpara.2006.02.009; Good MF, 2005, ANNU REV IMMUNOL, V23, P69, DOI 10.1146/annurev.immunol.23.021704.115638; Greenwood B, 2021, MALARIA J, V20, DOI 10.1186/s12936-021-03888-8; Gupta SC, 2013, AAPS J, V15, P195, DOI 10.1208/s12248-012-9432-8; Gutteridge CE, 2011, PHARMACOLOGY, V87, P96, DOI 10.1159/000322532; Hastings IM, 2004, TRENDS PARASITOL, V20, P512, DOI 10.1016/j.pt.2004.08.006; Idro R, 2010, PEDIATR RES, V68, P267, DOI 10.1203/00006450-201011001-00524; Isacchi B, 2012, EUR J PHARM BIOPHARM, V80, P528, DOI 10.1016/j.ejpb.2011.11.015; Keswani T, 2013, PARASITE IMMUNOL, V35, P73, DOI 10.1111/pim.12005; Khandare AV, 2017, ACTA TROP, V172, P58, DOI 10.1016/j.actatropica.2017.04.025; Kossodo S, 1997, IMMUNOLOGY, V91, P536, DOI 10.1046/j.1365-2567.1997.00290.x; Lazarevic V, 2011, NAT IMMUNOL, V12, P597, DOI 10.1038/ni.2059; Lee RS, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04108-9; Miller LH, 2002, NATURE, V415, P673, DOI 10.1038/415673a; Mishra K, 2011, J TROP MED-US, V2011, DOI 10.1155/2011/579518; Mishra K, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-26; Mok S, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-391; Nandakumar DN, 2006, ANTIMICROB AGENTS CH, V50, P1859, DOI 10.1128/AAC.50.5.1859-1860.2006; Nie CQ, 2007, INFECT IMMUN, V75, P2275, DOI 10.1128/IAI.01783-06; Oakley MS, 2013, J IMMUNOL, V191, P4699, DOI 10.4049/jimmunol.1300396; Packard RM, 2014, NEW ENGL J MED, V371, P397, DOI 10.1056/NEJMp1403340; Reddy RC, 2005, BIOCHEM BIOPH RES CO, V326, P472, DOI 10.1016/j.bbrc.2004.11.051; Rosenthal PJ, 2018, AM J TROP MED HYG, V99, P1357, DOI 10.4269/ajtmh.18-0845; Schofield L, 2005, NAT REV IMMUNOL, V5, P722, DOI 10.1038/nri1686; Sharma N, 2014, EUR J MED CHEM, V79, P350, DOI 10.1016/j.ejmech.2014.03.079; Shaw TN, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00248; Shevach EM, 2009, IMMUNITY, V30, P636, DOI 10.1016/j.immuni.2009.04.010; Shibui A, 2009, PARASITOL RES, V105, P281, DOI 10.1007/s00436-009-1435-8; Strangward P, 2018, P NATL ACAD SCI USA, V115, P7404, DOI 10.1073/pnas.1801737115; Teuscher F, 2010, J INFECT DIS, V202, P1362, DOI 10.1086/656476; Tilley L, 2016, TRENDS PARASITOL, V32, P682, DOI 10.1016/j.pt.2016.05.010; Tousif S, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00739; Waknine-Grinberg JH, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-227; Waknine-Grinberg JH, 2010, EXP PARASITOL, V125, P141, DOI 10.1016/j.exppara.2010.01.005; WHO, 2021, WORLD MALARIA REPORT; Witkowski B, 2010, ANTIMICROB AGENTS CH, V54, P1872, DOI 10.1128/AAC.01636-09; Wu XZ, 2021, J IMMUNOL, V206, P118, DOI 10.4049/jimmunol.2000779	58	0	0	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 13	2022	12								819469	10.3389/fimmu.2021.819469	http://dx.doi.org/10.3389/fimmu.2021.819469			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YO6VK	35095923				2022-12-18	WOS:000748076300001
J	Ng, HS; Graf, J; Zhu, F; Kingwell, E; Aktas, O; Albrecht, P; Hartung, HP; Meuth, SG; Evans, C; Fisk, JD; Marrie, RA; Zhao, YS; Tremlett, H				Ng, Huah Shin; Graf, Jonas; Zhu, Feng; Kingwell, Elaine; Aktas, Orhan; Albrecht, Philipp; Hartung, Hans-Peter; Meuth, Sven G.; Evans, Charity; Fisk, John D.; Marrie, Ruth Ann; Zhao, Yinshan; Tremlett, Helen			Disease-Modifying Drug Uptake and Health Service Use in the Ageing MS Population	FRONTIERS IN IMMUNOLOGY			English	Article						ageing; cohort studies; disease-modifying drugs; health services; hospitalization; multiple sclerosis; physician services	MULTIPLE-SCLEROSIS; THERAPIES; HOSPITALIZATIONS; PREVALENCE; RELAPSES; PATTERNS; EVENTS; ADULTS; AGE	BackgroundEvidence regarding the efficacy or effectiveness of the disease-modifying drugs (DMDs) in the older multiple sclerosis (MS) population is scarce. This has contributed to a lack of evidence-based treatment recommendations for the ageing MS population in practice guidelines. We examined the relationship between age (<55 and >= 55 years), DMD exposure and health service use in the MS population. MethodsWe conducted a population-based observational study using linked administrative health data from British Columbia, Canada. We selected all persons with MS and followed from the most recent of their first MS or demyelinating event, 18(th) birthday or 01-January-1996 (index date) until the earliest of emigration, death or 31-December-2017 (study end). We assessed DMD exposure status over time, initially as any versus no DMD, then by generation (first or second) and finally by each individual DMD. Age-specific analyses were conducted with all-cause hospitalizations and number of physician visits assessed using proportional means model and negative binomial regression with generalized estimating equations. ResultsWe included 19,360 persons with MS (72% were women); 10,741/19,360 (56%) had ever reached their 55th birthday. Person-years of follow-up whilst aged <55 was 132,283, and 93,594 whilst aged >= 55. Any DMD, versus no DMD in the <55-year-olds was associated with a 23% lower hazard of hospitalization (adjusted hazard ratio, aHR0.77; 95%CI 0.72-0.82), but not in the >= 55-year-olds (aHR0.95; 95%CI 0.87-1.04). Similar patterns were observed for the first and second generation DMDs. Exposure to any (versus no) DMD was not associated with rates of physician visits in either age group (<55 years: adjusted rate ratio, aRR1.02; 95%CI 1.00-1.04 and >= 55 years: aRR1.00; 95%CI 0.96-1.03), but variation in aRR was observed across the individual DMDs. ConclusionOur study showed beneficial effects of the DMDs used to treat MS on hospitalizations for those aged <55 at the time of exposure. In contrast, for individuals >= 55 years of age exposed to a DMD, the hazard of hospitalization was not significantly lowered. Our study contributes to the broader understanding of the potential benefits and risks of DMD use in the ageing MS population.	[Ng, Huah Shin; Graf, Jonas; Zhu, Feng; Kingwell, Elaine; Zhao, Yinshan; Tremlett, Helen] Univ British Columbia, Dept Med, Div Neurol, Vancouver, BC, Canada; [Ng, Huah Shin; Graf, Jonas; Zhu, Feng; Kingwell, Elaine; Zhao, Yinshan; Tremlett, Helen] Univ British Columbia, Djavad Mowafaghian Ctr Brain Hlth, Vancouver, BC, Canada; [Graf, Jonas; Aktas, Orhan; Albrecht, Philipp; Hartung, Hans-Peter; Meuth, Sven G.] Heinrich Heine Univ, Dept Neurol, Fac Med, Univ Hosp, Dusseldorf, Germany; [Kingwell, Elaine] UCL, Res Dept Primary Care & Populat Hlth, London, England; [Hartung, Hans-Peter] Univ Sydney, Brain & Mind Ctr, Sydney, NSW, Australia; [Hartung, Hans-Peter] Med Univ Vienna, Dept Neurol, Vienna, Austria; [Hartung, Hans-Peter] Palacky Univ Olomouc, Dept Neurol, Olomouc, Czech Republic; [Evans, Charity] Univ Saskatchewan, Coll Pharm & Nutr, Saskatoon, SK, Canada; [Fisk, John D.] Dalhousie Univ, Nova Scotia Hlth Author, Halifax, NS, Canada; [Fisk, John D.] Dalhousie Univ, Dept Psychiat, Halifax, NS, Canada; [Fisk, John D.] Dalhousie Univ, Dept Psychol & Neurosci, Halifax, NS, Canada; [Fisk, John D.] Dalhousie Univ, Dept Med, Halifax, NS, Canada; [Marrie, Ruth Ann] Univ Manitoba, Max Rady Coll Med, Rady Fac Hlth Sci, Dept Internal Med, Winnipeg, MB, Canada; [Marrie, Ruth Ann] Univ Manitoba, Max Rady Coll Med, Rady Fac Hlth Sci, Dept Community Hlth Sci, Winnipeg, MB, Canada	University of British Columbia; University of British Columbia; Heinrich Heine University Dusseldorf; University of London; University College London; University of Sydney; Medical University of Vienna; Palacky University Olomouc; University of Saskatchewan; Dalhousie University; Dalhousie University; Dalhousie University; Dalhousie University; University of Manitoba; University of Manitoba	Tremlett, H (corresponding author), Univ British Columbia, Dept Med, Div Neurol, Vancouver, BC, Canada.; Tremlett, H (corresponding author), Univ British Columbia, Djavad Mowafaghian Ctr Brain Hlth, Vancouver, BC, Canada.	helen.tremlett@ubc.ca	Ng, Huah Shin/G-6533-2018; Meuth, Sven G/HHM-8941-2022	Ng, Huah Shin/0000-0001-8381-5253; Meuth, Sven G/0000-0003-2571-3501	Canadian Institutes of Health Research (CIHR) [PJT-156363, FDN-159934]	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR))	This study was supported by the Canadian Institutes of Health Research (CIHR) Project and Foundation grant (PJT-156363 and FDN-159934, PI: Tremlett).	Al-Sakran L, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2019-033599; Awad A, 2010, DRUG AGING, V27, P283, DOI 10.2165/11532120-000000000-00000; Baldassari LE, 2018, DRUGS, V78, P1549, DOI 10.1007/s40265-018-0984-5; Ballinger GA, 2004, ORGAN RES METHODS, V7, P127, DOI 10.1177/1094428104263672; BC Ministry of Health [creator], 2015, PHARMANET V2; BC Vital Statistics Agency, 2017, VIT STAT DEATHS V2; Bonafede MM, 2014, CLINICOECONOMIC OUTC, V6, P11, DOI 10.2147/CEOR.S55779; British Columbia Ministry of Health [creator], 2017, CONS FIL MSP REG PRE; British Columbia Ministry of Health [creator], 2017, MED SERV PLAN MSP PA; Canadian Institute for Health Information, 2017, DISCH ABSTR DAY HOSP; Canadian Institute for Health Information Statistics Canada, 2013, HLTH IND 2013; Cisternas M, 2021, CURR MED RES OPIN, V37, P597, DOI 10.1080/03007995.2021.1885367; D'Amico E, 2018, EUR J NEUROL, V25, P1425, DOI 10.1111/ene.13745; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; Evans C, 2014, PHARMACOEPIDEM DR S, V23, P1213, DOI 10.1002/pds.3667; Faissner S, 2019, NAT REV DRUG DISCOV, V18, P905, DOI 10.1038/s41573-019-0035-2; Giovannoni G, 2015, CLIN THER, V37, P2543, DOI 10.1016/j.clinthera.2015.09.011; Graham DJ, 2004, JAMA-J AM MED ASSOC, V292, P2585, DOI 10.1001/jama.292.21.2585; Kingwell E, 2015, J NEUROL, V262, P2352, DOI 10.1007/s00415-015-7842-0; Lin DY, 2000, J ROY STAT SOC B, V62, P711, DOI 10.1111/1467-9868.00259; Marrie RA, 2010, NEUROLOGY, V74, P465, DOI 10.1212/WNL.0b013e3181cf6ec0; Marrie RA, 2014, NEUROLOGY, V83, P929, DOI 10.1212/WNL.0000000000000753; Marrie RA, 2014, NEUROLOGY, V82, P2112, DOI 10.1212/WNL.0000000000000495; Ng HS, 2022, MULT SCLER J, V28, P583, DOI 10.1177/13524585211063403; Ng HS, 2021, EXPERT REV NEUROTHER, V21, P131, DOI 10.1080/14737175.2021.1847085; Nicholas J, 2018, PHARMACOECON-OPEN, V2, P31, DOI 10.1007/s41669-017-0035-2; Novartis Pharmaceuticals Canada Inc, 2019, GILENYA FING CAPS 0; O'Connor PW, 2013, J NEUROL, V260, P2472, DOI 10.1007/s00415-013-6979-y; Pirttisalo AL, 2018, ANN MED, V50, P354, DOI 10.1080/07853890.2018.1461919; Prosperini L, 2021, MULT SCLER J, V27, P1391, DOI 10.1177/1352458520964778; Rae-Grant A, 2018, NEUROLOGY, V90, P789, DOI 10.1212/WNL.0000000000005345; Rae-Grant A, 2018, NEUROLOGY, V90, P777, DOI 10.1212/WNL.0000000000005347; Rommer PS, 2014, CLIN EXP IMMUNOL, V175, P397, DOI 10.1111/cei.12206; Sanchirico M, 2019, NEUROL THER, V8, P121, DOI 10.1007/s40120-018-0123-y; Sanofi Genzyme A and Division of Sanofi-Aventis Canada Inc, 2020, LEMTRADA AL 12MG 1 2; Shirani A, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/451912; Simbrich A, 2019, NEUROPSYCH DIS TREAT, V15, P1439, DOI 10.2147/NDT.S200930; Statistics Canada, 2019, CENSUS PROFILE 2016; Teva Canada Limited, 2018, COPAXONE GLAT AC INJ; Tramacere I, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011381.pub2; Tremlett H, 2008, J NEUROL NEUROSUR PS, V79, P1368, DOI 10.1136/jnnp.2008.145805; Tremlett H, 2010, NEUROLOGY, V74, P2004, DOI 10.1212/WNL.0b013e3181e3973f; U.S National Library of Medicine ClinicalTrials.gov, 2021, DISC DIS MOD THER DM; Vaughn CB, 2019, NAT REV NEUROL, V15, P329, DOI 10.1038/s41582-019-0183-3; Wallin MT, 2019, NEUROLOGY, V92, pE1029, DOI 10.1212/WNL.0000000000007035; Weideman AM, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00577; Weinstock-Guttman B, 2012, J NEUROL, V259, P898, DOI 10.1007/s00415-011-6275-7; Zanghi A, 2021, EUR J NEUROL, V28, P4117, DOI 10.1111/ene.15006; Zhang YA, 2021, THER ADV NEUROL DISO, V14, DOI 10.1177/17562864211006499; Zhang YA, 2020, THER ADV NEUROL DISO, V13, DOI 10.1177/1756286420969016; Ziemssen T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138243	51	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 13	2022	12								794075	10.3389/fimmu.2021.794075	http://dx.doi.org/10.3389/fimmu.2021.794075			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YO7AM	35095869	Green Published, gold			2022-12-18	WOS:000748089500001
J	Sasahara, Y; Uchida, T; Suzuki, T; Abukawa, D				Sasahara, Yoji; Uchida, Takashi; Suzuki, Tasuku; Abukawa, Daiki			Primary Immunodeficiencies Associated With Early-Onset Inflammatory Bowel Disease in Southeast and East Asia	FRONTIERS IN IMMUNOLOGY			English	Review						early-onset inflammatory bowel diseases; primary immunodeficiency diseases; exome sequencing; allogeneic hematopoietic stem cell transplantation; IL-10RA deficiency; XIAP deficiency	WISKOTT-ALDRICH-SYNDROME; STEM-CELL TRANSPLANTATION; XIAP DEFICIENCY; PEDIATRIC IBD; DIAGNOSIS; VARIANTS; COLITIS; MUTATIONS; CHILDREN; GENES	BackgroundCauses of early-onset inflammatory bowel disease (IBD) vary, and primary immunodeficiency diseases (PIDs) are associated with early-onset IBD as monogenic disorders. AimThis review investigates the prevalence, clinical manifestation, genetic profile, and treatment of patients with early-onset IBD in Southeast and East Asia. MethodsA systemic review of articles reporting PID patients associated with early-onset IBD in Southeast and East Asia was conducted. ResultsThe prevalence of PID associated with IBD was higher than that reported in western nations, and the frequency of patients with bloody stools as an early symptom was relatively higher in monogenic diseases. A total 13 (12.0%) of 108 patients with early-onset IBD were diagnosed as PID by exome sequencing and targeted gene panel analysis in Japan, including four patients with XIAP, three with IL10RA, and two or one patient with other gene mutations. In addition, ten patients were reported as having IL-10 receptor alpha (IL-10RA) deficiency in China and Hong Kong. Allogeneic hematopoietic stem cell transplantation was performed in patients with X-linked inhibitor of apoptosis deficiency, IL-10RA deficiency, or other PID as a curative treatment, and the preferable outcome of reduced-intensity conditioning and complete resolution of IBD symptoms and dysbiosis were achieved. ConclusionComprehensive molecular diagnosis has been widely applied to screen for patients with PID-associated IBD in Southeast and East Asia. These results contributed to the awareness of monogenic PID in early-onset IBD patients and their differences in clinical manifestations and genetic profiles compared to the patients in western counties.	[Sasahara, Yoji; Uchida, Takashi; Suzuki, Tasuku] Tohoku Univ, Dept Pediat, Grad Sch Med, Sendai, Miyagi, Japan; [Abukawa, Daiki] Miyagi Childrens Hosp, Dept Gen Pediat, Gastroenterol & Hepatol, Sendai, Miyagi, Japan	Tohoku University	Sasahara, Y (corresponding author), Tohoku Univ, Dept Pediat, Grad Sch Med, Sendai, Miyagi, Japan.	ysasahara@med.tohoku.ac.jp			Japanese Ministry of Health, Labour and Welfare [20FC1047, 20FC1053]; Japan Agency for Medical Research and Development [JP21gk01104h0003]; Japan Blood Products Organization	Japanese Ministry of Health, Labour and Welfare(Ministry of Health, Labour and Welfare, Japan); Japan Agency for Medical Research and Development(Japan Agency for Medical Research and Development (AMED)); Japan Blood Products Organization	Funding This work was supported by grants from the Japanese Ministry of Health, Labour and Welfare (20FC1047, 20FC1053); the Japan Agency for Medical Research and Development (JP21gk01104h0003); and the Japan Blood Products Organization to YS.	Abraham C, 2009, NEW ENGL J MED, V361, P2066, DOI 10.1056/NEJMra0804647; Aguilar C, 2014, J ALLERGY CLIN IMMUN, V134, P1131, DOI 10.1016/j.jaci.2014.04.031; Benchimol EI, 2014, GASTROENTEROLOGY, V147, P803, DOI 10.1053/j.gastro.2014.06.023; Chang JT, 2020, NEW ENGL J MED, V383, P2652, DOI 10.1056/NEJMra2002697; Christodoulou K, 2013, GUT, V62, P977, DOI 10.1136/gutjnl-2011-301833; Crowley E, 2020, GASTROENTEROLOGY, V158, P2208, DOI 10.1053/j.gastro.2020.02.023; de la Fuente MA, 2007, P NATL ACAD SCI USA, V104, P926, DOI 10.1073/pnas.0610275104; Engelhardt KR, 2013, J ALLERGY CLIN IMMUN, V131, P825, DOI 10.1016/j.jaci.2012.09.025; Glocker EO, 2010, LANCET, V376, P1272, DOI 10.1016/S0140-6736(10)61008-2; Glocker EO, 2009, NEW ENGL J MED, V361, P2033, DOI 10.1056/NEJMoa0907206; Horino S, 2014, PEDIATR TRANSPLANT, V18, pE25, DOI 10.1111/petr.12184; Ishige T, 2018, PEDIATRICS, V141, DOI 10.1542/peds.2017-3548; Ishige T, 2010, J GASTROENTEROL, V45, P911, DOI 10.1007/s00535-010-0223-7; Ishihara J, 2019, BMC GASTROENTEROL, V19, DOI 10.1186/s12876-019-0929-9; Jostins L, 2012, NATURE, V491, P119, DOI 10.1038/nature11582; Kammermeier J, 2014, J MED GENET, V51, P748, DOI 10.1136/jmedgenet-2014-102624; Kelsen JR, 2015, GASTROENTEROLOGY, V149, P1415, DOI 10.1053/j.gastro.2015.07.006; Kotlarz D, 2012, GASTROENTEROLOGY, V143, P347, DOI 10.1053/j.gastro.2012.04.045; Lee WS, 2016, WORLD J GASTROENTERO, V22, P10653, DOI 10.3748/wjg.v22.i48.10653; Maisawa S, 2013, J GASTROEN HEPATOL, V28, P499, DOI 10.1111/jgh.12071; Mao H, 2012, GENES IMMUN, V13, P437, DOI 10.1038/gene.2012.8; Massaad MJ, 2013, ANN NY ACAD SCI, V1285, P26, DOI 10.1111/nyas.12049; Neven B, 2013, BLOOD, V122, P3713, DOI 10.1182/blood-2013-06-508267; Nguyen DD, 2007, GASTROENTEROLOGY, V133, P1188, DOI 10.1053/j.gastro.2007.07.010; Nguyen DD, 2012, GASTROENTEROLOGY, V143, P719, DOI 10.1053/j.gastro.2012.06.008; Nochi T, 2020, CELL MOL GASTROENTER, V10, P83, DOI 10.1016/j.jcmgh.2020.01.011; Ono S, 2021, J ALLER CL IMM-PRACT, V9, P3767, DOI 10.1016/j.jaip.2021.05.045; Ono S, 2017, J CLIN IMMUNOL, V37, P85, DOI 10.1007/s10875-016-0348-4; Osumi T, 2020, BIOL BLOOD MARROW TR, V26, pE286, DOI 10.1016/j.bbmt.2020.08.008; Peng KY, 2018, INFLAMM BOWEL DIS, V24, P1416, DOI 10.1093/ibd/izy028; Sasahara Y, 2002, MOL CELL, V10, P1269, DOI 10.1016/S1097-2765(02)00728-1; Sasahara Y, 2016, PEDIATR INT, V58, P4, DOI 10.1111/ped.12819; Shouval DS, 2018, J CLIN IMMUNOL, V38, P579, DOI 10.1007/s10875-018-0524-9; Speckmann C, 2014, GUT, V63, P1031, DOI 10.1136/gutjnl-2013-306474; Suzuki T, 2017, J CLIN IMMUNOL, V37, P67, DOI 10.1007/s10875-016-0339-5; Taylor MD, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000813; Uchida T, 2020, J PEDIATR GASTR NUTR, V71, P333, DOI 10.1097/MPG.0000000000002796; Uhlig HH, 2021, J PEDIATR GASTR NUTR, V72, P456, DOI 10.1097/MPG.0000000000003017; Uhlig HH, 2014, GASTROENTEROLOGY, V147, P990, DOI 10.1053/j.gastro.2014.07.023; Uhlig HH, 2013, GUT, V62, P1795, DOI 10.1136/gutjnl-2012-303956; Watanabe Y, 2013, J ALLERGY CLIN IMMUN, V132, P648, DOI 10.1016/j.jaci.2013.03.046; Yanagi T, 2016, BMC GASTROENTEROL, V16, DOI 10.1186/s12876-016-0424-5; Yang L, 2021, GENES DIS, V8, P662, DOI 10.1016/j.gendis.2020.03.001; Yang X, 2012, J CLIN IMMUNOL, V32, P411, DOI 10.1007/s10875-011-9638-z; Ye ZQ, 2021, J PEDIATR GASTR NUTR, V72, P276, DOI 10.1097/MPG.0000000000002937; Zeissig Y, 2015, GUT, V64, P66, DOI 10.1136/gutjnl-2013-306520	46	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 13	2022	12								786538	10.3389/fimmu.2021.786538	http://dx.doi.org/10.3389/fimmu.2021.786538			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YR6TW	35095863	gold, Green Published			2022-12-18	WOS:000750127100001
J	Tang, LL; Li, G; Zheng, Y; Hou, CM; Gao, Y; Hao, Y; Gao, ZF; Mo, RL; Li, YX; Shen, BF; Wang, RX; Wang, ZD; Han, GC				Tang, Lili; Li, Ge; Zheng, Yang; Hou, Chunmei; Gao, Yang; Hao, Ying; Gao, Zhenfang; Mo, Rongliang; Li, Yuxiang; Shen, Beifen; Wang, Renxi; Wang, Zhiding; Han, Gencheng			Tim-3 Relieves Experimental Autoimmune Encephalomyelitis by Suppressing MHC-II	FRONTIERS IN IMMUNOLOGY			English	Article						TIM-3; MHC-II; CIITA; EAE; antigen presentation; multiple sclerosis; T cell; macrophage	GENETIC POLYMORPHISMS; EXPRESSION	Tim-3, an immune checkpoint inhibitor, is widely expressed on the immune cells and contributes to immune tolerance. However, the mechanisms by which Tim-3 induces immune tolerance remain to be determined. Major histocompatibility complex II (MHC-II) plays a key role in antigen presentation and CD4(+)T cell activation. Dysregulated expressions of Tim-3 and MHC-II are associated with the pathogenesis of many autoimmune diseases including multiple sclerosis. Here we demonstrated that, by suppressing MHC-II expression in macrophages via the STAT1/CIITA pathway, Tim-3 inhibits MHC-II-mediated autoantigen presentation and CD4(+)T cell activation. As a result, overexpression or blockade of Tim-3 signaling in mice with experimental autoimmune encephalomyelitis (EAE) inhibited or increased MHC-II expression respectively and finally altered clinical outcomes. We thus identified a new mechanism by which Tim-3 induces immune tolerance in vivo and regulating the Tim-3-MHC-II signaling pathway is expected to provide a new solution for multiple sclerosis treatment.	[Tang, Lili; Li, Ge; Hou, Chunmei; Gao, Yang; Hao, Ying; Gao, Zhenfang; Mo, Rongliang; Li, Yuxiang; Shen, Beifen; Wang, Zhiding; Han, Gencheng] Beijing Inst Basic Med Sci, Beijing, Peoples R China; [Zheng, Yang] Jilin Univ, Hosp 1, Dept Oncol, Changchun, Peoples R China; [Wang, Zhiding] Shenzhen Univ, Dept Hematol & Oncol, Shenzhen Key Lab Precis Med Hematol Malignancies, Int Canc Ctr,Gen Hosp,Clin Med Acad,Hlth Sci Ctr, Shenzhen, Peoples R China; [Wang, Renxi] Capital Med Univ, Beijing Inst Brain Disorders, Collaborat Innovat Ctr Brain Disorders, Lab Brain Disorders, Beijing, Peoples R China	Academy of Military Medical Sciences - China; Jilin University; Shenzhen University; Capital Medical University	Wang, ZD; Han, GC (corresponding author), Beijing Inst Basic Med Sci, Beijing, Peoples R China.; Wang, ZD (corresponding author), Shenzhen Univ, Dept Hematol & Oncol, Shenzhen Key Lab Precis Med Hematol Malignancies, Int Canc Ctr,Gen Hosp,Clin Med Acad,Hlth Sci Ctr, Shenzhen, Peoples R China.; Wang, RX (corresponding author), Capital Med Univ, Beijing Inst Brain Disorders, Collaborat Innovat Ctr Brain Disorders, Lab Brain Disorders, Beijing, Peoples R China.	renxi_wang@ccmu.edu.cn; wzdfjfn@126.com; genchenghan@163.com	Wang, Zhiding/K-4121-2013	Wang, Zhiding/0000-0001-8170-1359	National Natural Sciences Foundation of China [81971473, 81771684, 82171753]; Beijing Natural Sciences Foundation [7192145]	National Natural Sciences Foundation of China(National Natural Science Foundation of China (NSFC)); Beijing Natural Sciences Foundation(Beijing Natural Science Foundation)	Funding This work was supported by the National Natural Sciences Foundation of China (grant nos. 81971473, 81771684, 82171753) and the Beijing Natural Sciences Foundation (grant no. 7192145).	Afshar B, 2019, J NEUROIMMUNOL, V337, DOI 10.1016/j.jneuroim.2019.577061; Androdias G, 2010, ANN NEUROL, V68, P465, DOI 10.1002/ana.22054; Badawi Ahmed H, 2015, J Mult Scler (Foster City), V2; Barreiro LB, 2012, P NATL ACAD SCI USA, V109, P1204, DOI 10.1073/pnas.1115761109; Coste C, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10091266; DeNardo DG, 2019, NAT REV IMMUNOL, V19, P369, DOI 10.1038/s41577-019-0127-6; Enders U, 1998, BRAIN, V121, P1257, DOI 10.1093/brain/121.7.1257; Faissner S, 2019, NAT REV DRUG DISCOV, V18, P905, DOI 10.1038/s41573-019-0035-2; Fernando MMA, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000024; Giralt M, 2018, METHODS MOL BIOL, V1791, P227, DOI 10.1007/978-1-4939-7862-5_17; Glatigny S, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a028977; Han GC, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00449; Kaskow BJ, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a029025; Li G, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.667478; Liang JY, 2020, CANCER IMMUNOL RES, V8, P952, DOI 10.1158/2326-6066.CIR-19-0159; Lodygin D, 2019, NATURE, V567, pE15, DOI 10.1038/s41586-019-1047-0; Masternak K, 2000, GENE DEV, V14, P1156; Miller S, 2019, ANN RHEUM DIS, V78, P519, DOI 10.1136/annrheumdis-2018-214323; Mohammadzadeh A, 2018, J NEUROIMMUNOL, V323, P105, DOI 10.1016/j.jneuroim.2018.08.004; Ocana-Guzman R, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00229; Sawcer S, 2011, NATURE, V476, P214, DOI 10.1038/nature10251; Schmitz K, 2020, CELL MOL IMMUNOL, V17, P1077, DOI 10.1038/s41423-019-0274-5; Stys PK, 2012, NAT REV NEUROSCI, V13, P507, DOI 10.1038/nrn3275; Tintore M, 2019, NAT REV NEUROL, V15, P53, DOI 10.1038/s41582-018-0082-z; Unanue ER, 2016, ANNU REV IMMUNOL, V34, P265, DOI 10.1146/annurev-immunol-041015-055420; Wang ZD, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.618710; Wang ZD, 2021, LEUKEMIA LYMPHOMA, V62, P937, DOI 10.1080/10428194.2020.1849680; Wang ZD, 2020, J INFECT DIS, V221, P830, DOI 10.1093/infdis/jiz512; Wang ZD, 2017, SCI REP-UK, V7, DOI 10.1038/srep42095; Wilmes AT, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1208-3; Xiao Y, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.751834; Yau ACY, 2017, IMMUNOLOGY, V150, P408, DOI 10.1111/imm.12692; Zhang R, 2019, IMMUNOL INVEST, V48, P563, DOI 10.1080/08820139.2019.1599009	33	0	0	5	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 13	2022	12								770402	10.3389/fimmu.2021.770402	http://dx.doi.org/10.3389/fimmu.2021.770402			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YO6HI	35095844	gold, Green Published			2022-12-18	WOS:000748039700001
J	Wen, SD; Chen, YZ; Hu, CP; Du, XY; Xia, JW; Wang, X; Zhu, W; Wang, QB; Zhu, ML; Chen, Y; Shen, B				Wen, Shaodi; Chen, Yuzhong; Hu, Chupeng; Du, Xiaoyue; Xia, Jingwei; Wang, Xin; Zhu, Wei; Wang, Qingbo; Zhu, Miaolin; Chen, Yun; Shen, Bo			Combination of Tertiary Lymphoid Structure and Neutrophil-to-Lymphocyte Ratio Predicts Survival in Patients With Hepatocellular Carcinoma	FRONTIERS IN IMMUNOLOGY			English	Article						hepatocellular carcinoma; tertiary lymphoid structure; neutrophil-to-lymphocyte ratio (NLR); overall survival; inflammation	LIVER-TRANSPLANTATION; INFLAMMATORY MARKERS; PROGNOSTIC RELEVANCE; CELLS; INDEX; IMMUNOTHERAPY; INFILTRATION; TOXICITY; CANCER	BackgroundHepatocellular carcinoma (HCC) is the most common pathological type of primary liver cancer. The lack of prognosis indicators is one of the challenges in HCC. In this study, we investigated the combination of tertiary lymphoid structure (TLS) and several systemic inflammation parameters as a prognosis indicator for HCC. Materials and MethodsWe retrospectively recruited 126 postoperative patients with primary HCC. The paraffin section was collected for TLS density assessment. In addition, we collected the systemic inflammation parameters from peripheral blood samples. We evaluated the prognostic values of those parameters on overall survival (OS) using Kaplan-Meier curves, univariate and multivariate Cox regression. Last, we plotted a nomogram to predict the survival of HCC patients. ResultsWe first found TLS density was positively correlated with HCC patients' survival (HR=0.16, 95% CI: 0.06 - 0.39, p < 0.0001), but the power of TLS density for survival prediction was found to be limited (AUC=0.776, 95% CI:0.772 - 0.806). Thus, we further introduced several systemic inflammation parameters for survival analysis, we found neutrophil-to-lymphocyte ratio (NLR) was positively associated with OS in univariate Cox regression analysis. However, the combination of TLS density and NLR better predicts patient's survival (AUC=0.800, 95% CI: 0.698-0.902, p < 0.001) compared with using any single indicator alone. Last, we incorporated TLS density, NLR, and other parameters into the nomogram to provide a reproducible approach for survival prediction in HCC clinical practice. ConclusionThe combination of TLS density and NLR was shown to be a good predictor of HCC patient survival. It also provides a novel direction for the evaluation of immunotherapies in HCC.	[Wen, Shaodi; Chen, Yuzhong; Du, Xiaoyue; Xia, Jingwei; Wang, Xin; Zhu, Miaolin; Chen, Yun; Shen, Bo] Nanjing Med Univ, Jiangsu Canc Hosp, Affiliated Canc Hosp, Jiangsu Inst Canc Res, Nanjing, Peoples R China; [Hu, Chupeng; Chen, Yun] Nanjing Med Univ, Dept Immunol, Key Lab Microenvironm & Major Dis, Nanjing, Peoples R China; [Zhu, Wei] Jiangsu Univ, Sch Med, Zhenjiang, Jiangsu, Peoples R China; [Wang, Qingbo] Nanjing Univ Chinese Med, Hosp Nanjing 2, Dept Chemotherapy, Nanjing, Peoples R China; [Chen, Yun] Nanjing Med Univ, Collaborat Innovat Ctr Canc Personalized Med, Jiangsu Key Lab Canc Biomarkers Prevent & Treatme, Nanjing, Peoples R China	Nanjing Medical University; Nanjing Medical University; Jiangsu University; Nanjing University of Chinese Medicine; Nanjing Medical University	Zhu, ML; Chen, Y; Shen, B (corresponding author), Nanjing Med Univ, Jiangsu Canc Hosp, Affiliated Canc Hosp, Jiangsu Inst Canc Res, Nanjing, Peoples R China.; Chen, Y (corresponding author), Nanjing Med Univ, Dept Immunol, Key Lab Microenvironm & Major Dis, Nanjing, Peoples R China.; Chen, Y (corresponding author), Nanjing Med Univ, Collaborat Innovat Ctr Canc Personalized Med, Jiangsu Key Lab Canc Biomarkers Prevent & Treatme, Nanjing, Peoples R China.	Zhumiaolin829@126.com; Chenyun@njmu.edu.cn; shenbo987@126.com		Shen, Bo/0000-0001-9708-6098; wen, shaodi/0000-0001-7951-0123				Bruix J, 2017, J HEPATOL, V67, P999, DOI 10.1016/j.jhep.2017.06.026; Cabrita R, 2020, NATURE, V577, P561, DOI 10.1038/s41586-019-1914-8; Calderaro J, 2019, J HEPATOL, V70, P58, DOI 10.1016/j.jhep.2018.09.003; Calderaro J, 2017, J HEPATOL, V67, P727, DOI 10.1016/j.jhep.2017.05.014; Chan SL, 2020, LIVER CANCER, V9, P167, DOI 10.1159/000504252; Conroy G, 2017, ONCOTARGET, V8, P95853, DOI 10.18632/oncotarget.21401; Di Caro G, 2014, CLIN CANCER RES, V20, P2147, DOI 10.1158/1078-0432.CCR-13-2590; Duffy AG, 2017, DIGEST DIS, V35, P390, DOI 10.1159/000456593; Finkin S, 2015, NAT IMMUNOL, V16, P1235, DOI 10.1038/ni.3290; Fu HY, 2018, CELL PHYSIOL BIOCHEM, V47, P293, DOI 10.1159/000489807; Fu YJ, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1396-4; Goc J, 2014, CANCER RES, V74, P705, DOI 10.1158/0008-5472.CAN-13-1342; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; He GX, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0256-0; He GB, 2011, CELL RES, V21, P159, DOI 10.1038/cr.2010.183; Hennequin A, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1054598; Hiraoka N, 2015, BRIT J CANCER, V112, P1782, DOI 10.1038/bjc.2015.145; Hu B, 2014, CLIN CANCER RES, V20, P6212, DOI 10.1158/1078-0432.CCR-14-0442; Kuang DM, 2011, J HEPATOL, V54, P948, DOI 10.1016/j.jhep.2010.08.041; Lee M, 2019, MODERN PATHOL, V32, P70, DOI 10.1038/s41379-018-0113-8; Li H, 2020, AGING-US, V12, P3451, DOI 10.18632/aging.102821; Liu X, 2017, ONCOLOGIST, V22, P1316, DOI 10.1634/theoncologist.2017-0029; Lo CH, 2021, INT J RADIAT ONCOL, V109, P474, DOI 10.1016/j.ijrobp.2020.09.001; Ma WC, 2016, SCI REP-UK, V6, DOI 10.1038/srep35378; Mano Y, 2013, ANN SURG, V258, P301, DOI 10.1097/SLA.0b013e318297ad6b; Mantovani A, 2009, CANCER CELL, V16, P173, DOI 10.1016/j.ccr.2009.08.014; Margetts J, 2018, BRIT J CANCER, V118, P248, DOI 10.1038/bjc.2017.386; McNally ME, 2013, ANN SURG ONCOL, V20, P923, DOI 10.1245/s10434-012-2639-1; Motomura T, 2013, J HEPATOL, V58, P58, DOI 10.1016/j.jhep.2012.08.017; Pavana A, 2019, ONCOLOGIST, V24, P1128, DOI 10.1634/theoncologist.2018-0563; Payton Sarah, 2014, Nat Rev Urol, V11, P188, DOI 10.1038/nrurol.2014.68; Rai V, 2018, MOL CELL BIOCHEM, V437, P13, DOI 10.1007/s11010-017-3092-z; Rungsakulkij Narongsak, 2018, Asian Pac J Cancer Prev, V19, P3435; Sautes-Fridman C, 2019, NAT REV CANCER, V19, P307, DOI 10.1038/s41568-019-0144-6; Silina K, 2018, CANCER RES, V78, P1308, DOI 10.1158/0008-5472.CAN-17-1987; Truxova I, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0446-3; Wang CW, 2020, LIVER INT, V40, P229, DOI 10.1111/liv.14281; Wirsing AM, 2018, MODERN PATHOL, V31, P910, DOI 10.1038/s41379-018-0019-5; Xie YJ, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/8740976; Yang TB, 2017, J SURG ONCOL, V115, P718, DOI 10.1002/jso.24549; Yang ZG, 2015, ONCOTARGET, V6, P43090, DOI 10.18632/oncotarget.5719; Younossi Z, 2019, CLIN GASTROENTEROL H, V17, P748, DOI 10.1016/j.cgh.2018.05.057; Zheng J, 2017, ANN SURG ONCOL, V24, P3706, DOI 10.1245/s10434-017-6060-7; Zhou DS, 2015, WORLD J GASTROENTERO, V21, P5582, DOI 10.3748/wjg.v21.i18.5582	44	0	0	4	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 13	2022	12								788640	10.3389/fimmu.2021.788640	http://dx.doi.org/10.3389/fimmu.2021.788640			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YS3NY	35095864	Green Published, gold			2022-12-18	WOS:000750588200001
J	Zhang, LA; Shi, XY; Zhang, Q; Mao, ZL; Shi, XY; Zhou, J; Jian, AL; Zhu, RY; Jiang, SS; Lu, WS				Zhang, Lina; Shi, Xinyi; Zhang, Qing; Mao, Zhilei; Shi, Xiaoyu; Zhou, Jun; Jian, Aili; Zhu, Renying; Jiang, Shisong; Lu, Wenshu			HPV-16 E7-Specific Cellular Immune Response in Women With Cervical Intraepithelial Lesion Contributes to Viral Clearance: A Cross-Sectional and Longitudinal Clinical Study	FRONTIERS IN IMMUNOLOGY			English	Article						recombinant overlapping peptide; human papillomavirus; cervical intraepithelial neoplasia; immune responses; cervical cancer	INFECTION; E6; ONCOPROTEINS; REGRESSION; NEOPLASIA; CANCER; HPV16	High-risk human papillomavirus (HPV) infection is the cause of almost all cervical cancers. HPV16 is one of the main risk subtypes. Although screening programs have greatly reduced the prevalence of cervical cancer in developed countries, current diagnostic tests cannot predict if mild lesions may progress into invasive lesions or not. In the current cross-sectional and longitudinal clinical study, we found that the HPV16 E7-specific T cell response in peripheral blood mononuclear cells of HPV16-infected patients is related to HPV16 clearance. It contributes to protecting the squamous interaepithelial lesion (SIL) from further malignant development. Of the HPV16 infected women enrolled (n = 131), 42 had neither intraepithelial lesion nor malignancy (NILM), 33 had low-grade SIL, 39 had high-grade SIL, and 17 had cervical cancer. Only one of 17 (5.9%) cancer patients had a positive HPV16 E7-specific T cell response, dramatically lower than the groups of precancer patients. After one year of follow-up, most women (28/33, 84.8%) with persistent HPV infection did not exhibit a HPV16 E7-specific T cell response. Furthermore, 3 malignantly progressed women, one progressed to high-grade SIL and two progressed to low-grade SIL, were negative to the HPV16 E7-specific T cell response. None of the patients with a positive HPV16 E7-specific T cell response progressed to further deterioration. Our observation suggests that HPV16 E7-specific T cell immunity is significant in viral clearance and contributes in protection against progression to malignancy.	[Zhang, Lina; Mao, Zhilei; Shi, Xiaoyu; Zhou, Jun] Nanjing Med Univ, Changzhou Maternal & Child Hlth Care Hosp, Ctr Diag & Treatment Cerv Dis, Changzhou, Jiangsu, Peoples R China; [Shi, Xinyi; Zhang, Qing; Jian, Aili; Zhu, Renying; Lu, Wenshu] Oxford Vacmedix Changzhou Co Ltd, R&D Dept, Changzhou, Jiangsu, Peoples R China; [Jian, Aili] Dali Univ, Sch Basic Med, Dept Microbiol & Immunol, Dali, Peoples R China; [Jiang, Shisong] Univ Oxford, Dept Oncol, Oxford, England; [Lu, Wenshu] Shanghai Jia Wen JW Inflinhix Co Ltd, R&D Dept, Shanghai, Peoples R China	Nanjing Medical University; Dali University; University of Oxford	Lu, WS (corresponding author), Oxford Vacmedix Changzhou Co Ltd, R&D Dept, Changzhou, Jiangsu, Peoples R China.; Jiang, SS (corresponding author), Univ Oxford, Dept Oncol, Oxford, England.; Lu, WS (corresponding author), Shanghai Jia Wen JW Inflinhix Co Ltd, R&D Dept, Shanghai, Peoples R China.	shisong.jiang@oncology.ox.ac.uk; wenshu.lu@oncology.ox.ac.uk						Ahdieh L, 2000, AM J EPIDEMIOL, V151, P1148, DOI 10.1093/oxfordjournals.aje.a010165; Cai LL, 2017, ONCOTARGET, V8, P76516, DOI 10.18632/oncotarget.20407; Choi YJ, 2016, J GYNECOL ONCOL, V27, DOI 10.3802/jgo.2016.27.e21; Hildesheim A, 2007, JAMA-J AM MED ASSOC, V298, P743, DOI 10.1001/jama.298.7.743; Hu Z, 2018, CANCER MED-US, V7, P5217, DOI 10.1002/cam4.1501; Jain S, 2006, VIROLOGY, V356, P23, DOI 10.1016/j.virol.2006.07.032; Josefsson AM, 2000, LANCET, V355, P2189, DOI 10.1016/S0140-6736(00)02401-6; Kenter GG, 2009, NEW ENGL J MED, V361, P1838, DOI 10.1056/NEJMoa0810097; Lee SJ, 2016, J GYNECOL ONCOL, V27, DOI 10.3802/jgo.2016.27.e51; Massarelli E, 2019, JAMA ONCOL, V5, P67, DOI 10.1001/jamaoncol.2018.4051; Mirabello L, 2017, CELL, V170, P1164, DOI 10.1016/j.cell.2017.08.001; Morrow MP, 2018, CLIN CANCER RES, V24, P276, DOI [10.1158/1078-0432.CCR-17-2335, 10.1158/1078-0432.ccr-17-2335]; Moscicki AB, 2004, LANCET, V364, P1678, DOI 10.1016/S0140-6736(04)17354-6; Nakagawa M, 2000, J INFECT DIS, V182, P595, DOI 10.1086/315706; Nakagawa M, 1999, CLIN DIAGN LAB IMMUN, V6, P494, DOI 10.1128/CDLI.6.4.494-498.1999; Sarkar AK, 2005, GYNECOL ONCOL, V99, pS251, DOI 10.1016/j.ygyno.2005.07.099; Shalapour S, 2015, J CLIN INVEST, V125, P3347, DOI 10.1172/JCI80007; Smola S, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9090254; 谢建渝, 2015, [中国妇产科临床杂志, Chinese Journal of Clinical Obstetrics and Gynecology], V16, P550	19	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 13	2022	12								768144	10.3389/fimmu.2021.768144	http://dx.doi.org/10.3389/fimmu.2021.768144			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YR7CK	35095843	Green Published, gold			2022-12-18	WOS:000750149800001
J	Zhao, SH; Xu, BY; Ma, WB; Chen, H; Jiang, CL; Cai, JQ; Meng, XQ				Zhao, Shihong; Xu, Boya; Ma, Wenbin; Chen, Hao; Jiang, Chuanlu; Cai, Jinquan; Meng, Xiangqi			DNA Damage Repair in Brain Tumor Immunotherapy	FRONTIERS IN IMMUNOLOGY			English	Review						DNA damage repair; brain tumor; immunotherapy; TME; TAMs; ICI; biomarker; combination therapy	REPLICATION PROTEIN-A; NUCLEOTIDE EXCISION-REPAIR; GLIOBLASTOMA STEM-CELLS; DOUBLE-BLIND; T-CELLS; CANCER; GLIOMA; PATHWAYS; THERAPY; TRANSCRIPTION	With the gradual understanding of tumor development, many tumor therapies have been invented and applied in clinical work, and immunotherapy has been widely concerned as an emerging hot topic in the last decade. It is worth noting that immunotherapy is nowadays applied under too harsh conditions, and many tumors are defined as "cold tumors" that are not sensitive to immunotherapy, and brain tumors are typical of them. However, there is much evidence that suggests a link between DNA damage repair mechanisms and immunotherapy. This may be a breakthrough for the application of immunotherapy in brain tumors. Therefore, in this review, first, we will describe the common pathways of DNA damage repair. Second, we will focus on immunotherapy and analyze the mechanisms of DNA damage repair involved in the immune process. Third, we will review biomarkers that have been or may be used to evaluate immunotherapy for brain tumors, such as TAMs, RPA, and other molecules that may provide a precursor assessment for the rational implementation of immunotherapy for brain tumors. Finally, we will discuss the rational combination of immunotherapy with other therapeutic approaches that have an impact on the DNA damage repair process in order to open new pathways for the application of immunotherapy in brain tumors, to maximize the effect of immunotherapy on DNA damage repair mechanisms, and to provide ideas and guidance for immunotherapy in brain tumors.	[Zhao, Shihong; Xu, Boya; Ma, Wenbin; Chen, Hao; Jiang, Chuanlu; Cai, Jinquan; Meng, Xiangqi] Harbin Med Univ, Affiliated Hosp 2, Dept Neurosurg, Harbin, Peoples R China	Harbin Medical University	Cai, JQ; Meng, XQ (corresponding author), Harbin Med Univ, Affiliated Hosp 2, Dept Neurosurg, Harbin, Peoples R China.	caijinquan666777@126.com; neptune_mxq@126.com			National Natural Science Foundation of China [81874204, 81772666, 81972817, 82073298, 82003022]; Excellent Young Talents Project of Central Government Supporting Local University Reform and Development Fund [0202-300011190006]; Karolinska Institute Research Foundation [FS-2020:0007]; China Postdoctoral Science Foundation [2018M640305, 2019M660074, 2020T130157]; Heilongjiang Postdoctoral Science Foundation [LBH-Z18103, LBH-Z19029]; Research Project of the Health and Family Planning Commission of Heilongjiang Province [2019-102]; Young and Middle-aged Innovative Scientific Research Fund of the Second AffiliatedHospital of Harbin Medical University [KYCX2018-08]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Excellent Young Talents Project of Central Government Supporting Local University Reform and Development Fund; Karolinska Institute Research Foundation(Karolinska Institutet); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Heilongjiang Postdoctoral Science Foundation; Research Project of the Health and Family Planning Commission of Heilongjiang Province; Young and Middle-aged Innovative Scientific Research Fund of the Second AffiliatedHospital of Harbin Medical University	This study was supported by 1. The National Natural Science Foundation of China (No. 81874204, No. 81772666, No. 81972817, No. 82073298, No. 82003022); 2. Excellent Young Talents Project of Central Government Supporting Local University Reform and Development Fund (0202-300011190006); 3. Karolinska Institute Research Foundation Grants 2020-2021 (No. FS-2020:0007); 4. The China Postdoctoral Science Foundation (2018M640305, 2019M660074, 2020T130157); 5. The Heilongjiang Postdoctoral Science Foundation (LBH-Z18103, LBH-Z19029); 6. The Research Project of the Health and Family Planning Commission of Heilongjiang Province (2019-102); 7. The Young and Middle-aged Innovative Scientific Research Fund of the Second AffiliatedHospital of Harbin Medical University (KYCX2018-08).	Aceytuno RD, 2017, NUCLEIC ACIDS RES, V45, P6238, DOI 10.1093/nar/gkx275; Aldape K, 2019, NAT REV CLIN ONCOL, V16, P509, DOI 10.1038/s41571-019-0177-5; Alsaab HO, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00561; Apostolidis SA, 2016, NAT IMMUNOL, V17, P556, DOI 10.1038/ni.3390; Arrichiello Gianluca, 2021, Cancer Treat Res Commun, V28, P100442, DOI 10.1016/j.ctarc.2021.100442; Azizi E, 2018, CELL, V174, P1293, DOI 10.1016/j.cell.2018.05.060; Bezu L, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00187; Bracci L, 2014, CELL DEATH DIFFER, V21, P15, DOI 10.1038/cdd.2013.67; Brockelmann PJ, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9102287; Caglayan M, 2020, DNA REPAIR, V95, DOI 10.1016/j.dnarep.2020.102945; Caglayan M, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14045; Casal-Mourino A, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-78051-5; Cassetta L, 2018, NAT REV DRUG DISCOV, V17, P887, DOI 10.1038/nrd.2018.169; Chang HHY, 2017, NAT REV MOL CELL BIO, V18, P495, DOI 10.1038/nrm.2017.48; Chen R, 2014, BIOESSAYS, V36, P1156, DOI 10.1002/bies.201400107; Chen XY, 2021, CANCER MED-US, V10, P317, DOI 10.1002/cam4.3602; Chen Y, 2020, MOL ONCOL, V14, P2096, DOI 10.1002/1878-0261.12739; Chen ZH, 2017, CANCER RES, V77, P2266, DOI 10.1158/0008-5472.CAN-16-2310; Choe EA, 2019, LUNG CANCER, V136, P30, DOI 10.1016/j.lungcan.2019.07.027; Choudhary SK, 2002, J CELL BIOCHEM, V84, P666, DOI 10.1002/jcb.10081; Clausi MG, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-84600-3; Coleman RL, 2017, LANCET, V390, P1949, DOI 10.1016/S0140-6736(17)32440-6; Colton M, 2020, RADIAT ONCOL, V15, DOI 10.1186/s13014-020-01678-1; Daro-Faye M, 2021, WORLD J UROL, V39, P1131, DOI DOI 10.1007/s00345-020-03440-4; DeNardo DG, 2019, NAT REV IMMUNOL, V19, P369, DOI 10.1038/s41577-019-0127-6; Dianov GL, 2013, NUCLEIC ACIDS RES, V41, P3483, DOI 10.1093/nar/gkt076; Dovedi SJ, 2021, CANCER DISCOV, V11, P1100, DOI 10.1158/2159-8290.CD-20-1445; Dubensky TW, 2010, SEMIN IMMUNOL, V22, P155, DOI 10.1016/j.smim.2010.04.007; Eich M, 2013, MOL CANCER THER, V12, P2529, DOI 10.1158/1535-7163.MCT-13-0136; Fourcade J, 2010, J EXP MED, V207, P2175, DOI 10.1084/jem.20100637; Fukuhara H, 2016, CANCER SCI, V107, P1373, DOI 10.1111/cas.13027; Fukurnura D, 2018, NAT REV CLIN ONCOL, V15, P325, DOI 10.1038/nrclinonc.2018.29; Gangoso E, 2021, CELL, V184, P2454, DOI 10.1016/j.cell.2021.03.023; Giavina-Bianchi MH, 2017, AN BRAS DERMATOL, V92, P156, DOI 10.1590/abd1806-4841.20176183; Golden EB, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/onci.28518; Gourley C, 2019, J CLIN ONCOL, V37, P2257, DOI 10.1200/JCO.18.02050; Grassberger C, 2019, NAT REV CLIN ONCOL, V16, P729, DOI 10.1038/s41571-019-0238-9; Griffin WC, 2019, DNA REPAIR, V76, P1, DOI 10.1016/j.dnarep.2019.02.003; Gupta SK, 2019, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00670; Han S, 2014, DNA CELL BIOL, V33, P245, DOI 10.1089/dna.2013.2306; Hasan MN, 2021, THERANOSTICS, V11, P1295, DOI 10.7150/thno.50150; Hazra TK, 2001, PROG NUCLEIC ACID RE, V68, P193; Herrera FG, 2019, LANCET ONCOL, V20, pE417, DOI 10.1016/S1470-2045(19)30401-2; Hirata A, 2019, CANCER GENE THER, V26, P334, DOI 10.1038/s41417-018-0059-5; Hu MJ, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI139333; Huang RX, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00648-7; Ishikawa H, 2008, NATURE, V455, P674, DOI 10.1038/nature07317; Iyama T, 2013, DNA REPAIR, V12, P620, DOI 10.1016/j.dnarep.2013.04.015; Jain RK, 2014, CANCER CELL, V26, P605, DOI 10.1016/j.ccell.2014.10.006; Jasin M, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a012740; Jordan M, 2016, CANCER LETT, V373, P88, DOI 10.1016/j.canlet.2015.11.029; Kachikwu EL, 2011, INT J RADIAT ONCOL, V81, P1128, DOI 10.1016/j.ijrobp.2010.09.034; Kang TH, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11050715; Karachi A, 2018, NEURO-ONCOLOGY, V20, P1566, DOI 10.1093/neuonc/noy072; Khosravi N, 2020, LIFE SCI, V256, DOI 10.1016/j.lfs.2020.118005; Kim CC, 2020, ELIFE, V9, DOI 10.7554/eLife.60637; Kim JE, 2017, CLIN CANCER RES, V23, P124, DOI 10.1158/1078-0432.CCR-15-1535; Kishore C, 2021, EUR J PHARMACOL, V893, DOI 10.1016/j.ejphar.2020.173819; Kolesnikova O, 2019, ADV PROTEIN CHEM STR, V115, P21, DOI 10.1016/bs.apcsb.2019.01.003; Krieg AM, 2012, NUCLEIC ACID THER, V22, P77, DOI 10.1089/nat.2012.0340; Kroemer G, 2013, ANNU REV IMMUNOL, V31, P51, DOI 10.1146/annurev-immunol-032712-100008; Kuang NF, 2021, J NEURORESTORATOLOGY, V9, P94, DOI 10.26599/JNR.2021.9040008; Kumar V, 2016, TRENDS IMMUNOL, V37, P208, DOI 10.1016/j.it.2016.01.004; Lamas B, 2012, CELL IMMUNOL, V280, P182, DOI 10.1016/j.cellimm.2012.11.018; Lang FF, 2018, J CLIN ONCOL, V36, P1419, DOI 10.1200/JCO.2017.75.8219; Larrea AA, 2010, CELL, V141, DOI 10.1016/j.cell.2010.05.002; Laumont CM, 2021, CLIN CANCER RES, V27, P4089, DOI 10.1158/1078-0432.CCR-20-4394; Le DT, 2012, CANCER RES, V72, P3439, DOI 10.1158/0008-5472.CAN-11-3912; Lee C, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4457-8; Li LL, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00849-7; Li SP, 2021, MOL CANCER, V20, DOI 10.1186/s12943-021-01436-1; Li XY, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.750857; Li YQ, 2011, P NATL ACAD SCI USA, V108, P9951, DOI 10.1073/pnas.1016912108; Li ZM, 2009, AM J TRANSL RES, V1, P326; Li ZW, 2021, CANCER IMMUNOL RES, V9, P1383, DOI 10.1158/2326-6066.CIR-21-0258; Liang H, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01566-5; Liu T, 2016, ACTA BIOCH BIOPH SIN, V48, P665, DOI 10.1093/abbs/gmw041; Lord CJ, 2017, SCIENCE, V355, P1152, DOI 10.1126/science.aam7344; Ma Q, 2021, TRANSL ONCOL, V14, DOI 10.1016/j.tranon.2020.100929; Ma TJ, 2021, CANCER RES, V81, P2457, DOI 10.1158/0008-5472.CAN-20-2489; Ma YX, 2018, BBA-MOL CELL RES, V1865, P1293, DOI 10.1016/j.bbamcr.2018.06.011; Mackenzie KJ, 2017, NATURE, V548, P461, DOI 10.1038/nature23449; Maekawa N, 2021, NPJ PRECIS ONCOL, V5, DOI 10.1038/s41698-021-00147-6; Maggio D, 2020, J NEURO-ONCOL, V148, P231, DOI 10.1007/s11060-020-03517-5; Majidinia M, 2017, DNA REPAIR, V54, P22, DOI 10.1016/j.dnarep.2017.03.009; Marcus A, 2018, IMMUNITY, V49, P754, DOI 10.1016/j.immuni.2018.09.016; Marteijn JA, 2014, NAT REV MOL CELL BIO, V15, P465, DOI 10.1038/nrm3822; Mathios D, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aag2942; Mathivet T, 2017, EMBO MOL MED, V9, P1629, DOI 10.15252/emmm.201607445; Mazzone M, 2019, ANNU REV PHYSIOL, V81, P535, DOI 10.1146/annurev-physiol-020518-114721; McLaughlin M, 2020, NAT REV CANCER, V20, P203, DOI 10.1038/s41568-020-0246-1; Meng XQ, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-14036-x; Mi YJ, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00737; Min YZ, 2017, NAT NANOTECHNOL, V12, P877, DOI [10.1038/NNANO.2017.113, 10.1038/nnano.2017.113]; Mitchem JB, 2013, CANCER RES, V73, P1128, DOI 10.1158/0008-5472.CAN-12-2731; Moser J, 2007, MOL CELL, V27, P311, DOI 10.1016/j.molcel.2007.06.014; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Mouw KW, 2017, CANCER DISCOV, V7, P675, DOI 10.1158/2159-8290.CD-17-0226; Moviglia G, 2021, J NEURORESTORATOLOGY, V9, P81, DOI 10.26599/JNR.2021.9040018; Muik A, 2014, CANCER RES, V74, P3567, DOI 10.1158/0008-5472.CAN-13-3306; Mullard A, 2018, NAT REV DRUG DISCOV, V17, P847, DOI 10.1038/nrd.2018.201; Munster P, 2019, CANCER MANAG RES, V11, P10463, DOI 10.2147/CMAR.S208720; Murnyak B, 2017, ONCOTARGET, V8, P46348, DOI 10.18632/oncotarget.18013; Nair S, 2021, JCI INSIGHT, V6, DOI 10.1172/jci.insight.144619; Nakazawa M, 2021, ARTHRITIS RHEUMATOL, V73, P576, DOI 10.1002/art.41554; Nicolai CJ, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.aaz2738; Nogueira A, 2019, CANCERS, V11, DOI 10.3390/cancers11111622; O'Connor MJ, 2015, MOL CELL, V60, P547, DOI 10.1016/j.molcel.2015.10.040; Ortensi B, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt166; Owiti NA, 2021, TRENDS CANCER, V7, P240, DOI 10.1016/j.trecan.2020.10.006; Oyewole-Said D, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.608024; Pantel K, 2019, CLIN CHEM, V65, P87, DOI 10.1373/clinchem.2018.287102; Park JE, 2019, ONCOGENE, V38, P5158, DOI 10.1038/s41388-019-0782-x; Pathria P, 2019, TRENDS IMMUNOL, V40, P310, DOI 10.1016/j.it.2019.02.003; Patsoukis N, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abd2712; Pedersen H, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21051588; Peng LR, 2019, CANCER MED-US, V8, P7161, DOI 10.1002/cam4.2583; Persa E, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082391; Pilanc P, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.703465; Pujade-Lauraine E, 2017, LANCET ONCOL, V18, P1274, DOI 10.1016/S1470-2045(17)30469-2; Qi L, 2016, ONCOTARGET, V7, P71673, DOI 10.18632/oncotarget.12317; Qian MY, 2020, ONCOGENE, V39, P428, DOI 10.1038/s41388-019-0996-y; Qiu B, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.674596; Qureshi OS, 2011, SCIENCE, V332, P600, DOI 10.1126/science.1202947; Ratti SG, 2021, J NEURORESTORATOLOGY, V9, P72, DOI 10.26599/JNR.2021.9040004; Ribas A, 2018, SCIENCE, V359, P1350, DOI 10.1126/science.aar4060; Riegler J, 2019, NEOPLASIA, V21, P1036, DOI 10.1016/j.neo.2019.08.003; Riley RS, 2019, NAT REV DRUG DISCOV, V18, P175, DOI 10.1038/s41573-018-0006-z; Sato H, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01883-9; Scarbrough PM, 2016, CANCER EPIDEM BIOMAR, V25, P193, DOI 10.1158/1055-9965.EPI-15-0649; Scharer OD, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a012609; Scott CL, 2015, J CLIN ONCOL, V33, P1397, DOI 10.1200/JCO.2014.58.8848; Shevtsov M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00454; Shevtsov MA, 2015, NANOSCALE, V7, P20652, DOI 10.1039/c5nr06521f; Shirota Y, 2012, J IMMUNOL, V188, P1592, DOI 10.4049/jimmunol.1101304; Simiczyjew A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21218359; Sobhani N, 2021, CANCERS, V13, DOI 10.3390/cancers13061440; Spivak G, 2015, DNA REPAIR, V36, P13, DOI 10.1016/j.dnarep.2015.09.003; Spivak G, 2014, DNA REPAIR, V19, P64, DOI 10.1016/j.dnarep.2014.03.025; Sundar SJ, 2014, NEUROSURG FOCUS, V37, DOI 10.3171/2014.9.FOCUS14494; Suryadevara CM, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1434464; Tan KT, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2019-000485; Tanaka A, 2017, CELL RES, V27, P109, DOI 10.1038/cr.2016.151; Terkelsen T, 2019, FAM CANCER, V18, P381, DOI 10.1007/s10689-019-00141-9; Togashi Y, 2019, NAT REV CLIN ONCOL, V16, P356, DOI 10.1038/s41571-019-0175-7; Topalian SL, 2015, CANCER CELL, V27, P450, DOI 10.1016/j.ccell.2015.03.001; Van Praagh R, 1989, Eur J Cardiothorac Surg, V3, P381, DOI 10.1016/1010-7940(89)90044-4; Vanpouille-Box C, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15618; Viel A, 2017, EBIOMEDICINE, V20, P39, DOI 10.1016/j.ebiom.2017.04.022; Waldman AD, 2020, NAT REV IMMUNOL, V20, P651, DOI 10.1038/s41577-020-0306-5; Walker LSK, 2015, TRENDS IMMUNOL, V36, P63, DOI 10.1016/j.it.2014.12.001; Wang J, 2021, J NEURORESTORATOLOGY, V9, P83, DOI 10.26599/JNR.2021.9040012; Wang LL, 2020, J CLIN INVEST, V130, P5951, DOI 10.1172/JCI130445; Wang XY, 2020, J NEURORESTORATOLOGY, V8, P172, DOI 10.26599/JNR.2020.9040018; Wang Y, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01247-w; Wang YL, 2021, J NEURORESTORATOLOGY, V9, P137, DOI 10.26599/JNR.2021.9040011; Watters JJ, 2005, J NEUROSCI RES, V81, P447, DOI 10.1002/jnr.20485; Wick W, 2001, J NEURO-ONCOL, V53, P177, DOI 10.1023/A:1012209518843; Wong JMS, 2003, ONCOGENE, V22, P28, DOI 10.1038/sj.onc.1206071; Wu PF, 2020, CANCER IMMUNOL RES, V8, P1470, DOI 10.1158/2326-6066.CIR-20-0113; Xavier MA, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11081188; Yang HT, 2020, CANCERS, V12, DOI 10.3390/cancers12113389; Zhai Y, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.581209; Zhang J, 2012, CARCINOGENESIS, V33, P312, DOI 10.1093/carcin/bgr289; Zhang J, 2019, ONCOTARGETS THER, V12, P9395, DOI 10.2147/OTT.S205017; Zhang L, 2017, ONCOTARGET, V8, P819, DOI 10.18632/oncotarget.13661; Zhang P, 2008, MOL IMMUNOL, V45, P1470, DOI 10.1016/j.molimm.2007.08.013; Zhang Q, 2019, CANCER RES, V79, P3940, DOI 10.1158/0008-5472.CAN-19-0761; Zhang XZ, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-24769-3; Zhou PH, 2014, NATURE, V506, P52, DOI 10.1038/nature12988; Zhou WC, 2015, NAT CELL BIOL, V17, P170, DOI 10.1038/ncb3090; Zhu C, 2011, CURR TOP MICROBIOL, V350, P1, DOI 10.1007/82_2010_84; Zhu Z, 2020, CELL STEM CELL, V26, P187, DOI 10.1016/j.stem.2019.11.016; Zitvogel L, 2015, NAT REV IMMUNOL, V15, P405, DOI 10.1038/nri3845	174	0	0	17	24	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 13	2022	12								829268	10.3389/fimmu.2021.829268	http://dx.doi.org/10.3389/fimmu.2021.829268			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZE8FT	35095931	gold, Green Published			2022-12-18	WOS:000759114700001
J	Ahmed, F; Husain, M				Ahmed, Farjana; Husain, Matloob			Human N-Alpha-Acetyltransferase 60 Promotes Influenza A Virus Infection by Dampening the Interferon Alpha Signaling	FRONTIERS IN IMMUNOLOGY			English	Article						N-alpha-acetyltransferase 60; HAT; N-terminal acetylation; influenza virus; interferon alpha; CH25H; viperin; NAA60 gene	HISTONE ACETYLTRANSFERASE; PROTEINS; ACETYLATION; EXPRESSION; MEMBRANE; RELEASE; INNATE; NAA60; DRUG	N-alpha-acetyltransferase 60 (NAA60) is the most recently discovered N-terminal acetyltransferase and found only in multicellular eukaryotes. NAA60 localizes to the Golgi complex and is one of the only two N-terminal acetyltransferases known to localize to an organelle. Furthermore, NAA60 possesses a unique ability of catalyzing the acetylation of membrane-anchored proteins at the N-terminus and histones at the lysine side chains. Herein, we demonstrate that NAA60 exhibits proviral properties during influenza A virus (IAV) infection by interfering with the interferon (IFN) alpha signaling. We found that the depletion and overexpression of NAA60 reduced and enhanced, respectively, the IAV growth in a cell type- and IAV strain-independent manner. Mechanistically, the IAV-induced expression of IFN alpha was increased and decreased in NAA60-depleted and -overexpressing cells, respectively. Furthermore, the depletion of NAA60 enhanced the level of phosphorylated STAT1 transcription factor as well as the expression of several IFN-stimulated genes (ISGs) such as MX1, CH25H, IFITM3, ISG15 and viperin in infected cells. Whereas the overexpression of NAA60 produced opposite results. Finally, similar results were obtained when the NAA60-depleted cells were treated with purified IFN alpha. These findings, in conjunction with our recent findings where N-terminal acetylation of many host proteins increased in response to the IAV infection, indicate an important role of N-terminal acetylation during IAV replication.	[Ahmed, Farjana; Husain, Matloob] Univ Otago, Dept Microbiol & Immunol, Dunedin, New Zealand	University of Otago	Husain, M (corresponding author), Univ Otago, Dept Microbiol & Immunol, Dunedin, New Zealand.	matloob.husain@otago.ac.nz		ahmed, farjana/0000-0001-5256-4666	University of Otago; Dept. of Microbiology and Immunology; Putea Tautoko	University of Otago; Dept. of Microbiology and Immunology; Putea Tautoko	We thank the University of Otago for doctoral scholarship and the Dept. of Microbiology and Immunology and Putea Tautoko for additional financial support to FA. We also thank Dr Torsten Kleffmann for support, suggestions, and advise during this study.	Ahmed F, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13071415; Aksnes H, 2019, MOL CELL, V73, P1097, DOI 10.1016/j.molcel.2019.02.007; Aksnes H, 2017, J BIOL CHEM, V292, P6821, DOI 10.1074/jbc.M116.770362; Aksnes H, 2015, CELL REP, V10, P1362, DOI 10.1016/j.celrep.2015.01.053; Bolen CR, 2014, HEPATOLOGY, V59, P1262, DOI 10.1002/hep.26657; Chen XY, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00320; Chin KC, 2001, P NATL ACAD SCI USA, V98, P15125, DOI 10.1073/pnas.011593298; Ciminski K, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008384; Cyster JG, 2014, NAT REV IMMUNOL, V14, P731, DOI 10.1038/nri3755; Diallo I, 2019, EXPERT REV PROTEOMIC, V16, P139, DOI 10.1080/14789450.2019.1559061; Drazic A, 2016, BBA-PROTEINS PROTEOM, V1864, P1372, DOI 10.1016/j.bbapap.2016.06.007; Feeley EM, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002337; Galvin HD, 2019, J BIOL CHEM, V294, P20207, DOI 10.1074/jbc.RA119.010650; Grunkemeyer TJ, 2021, J BIOL CHEM, V297, DOI 10.1016/j.jbc.2021.100824; Hatakeyama D, 2022, FEBS J, V289, P231, DOI 10.1111/febs.16123; Hatakeyama D, 2018, J BIOL CHEM, V293, P7126, DOI 10.1074/jbc.RA117.001683; Hsiang TY, 2009, J VIROL, V83, P5971, DOI 10.1128/JVI.01667-08; Husain M, 2020, EMERG TOP LIFE SCI, V4, P401, DOI 10.1042/ETLS20200232; Husain M, 2014, J VIROL, V88, P11229, DOI 10.1128/JVI.00727-14; Husain M, 2011, FEBS LETT, V585, P128, DOI 10.1016/j.febslet.2010.11.023; Hussain M, 2017, INFECT DRUG RESIST, V10, P121, DOI 10.2147/IDR.S105473; Iwasaki A, 2014, NAT REV IMMUNOL, V14, P315, DOI 10.1038/nri3665; Jin QH, 2014, EMBO REP, V15, P1192, DOI 10.15252/embr.201438990; Koyuncu E, 2014, MBIO, V5, DOI 10.1128/mBio.02249-14; Liu SY, 2013, IMMUNITY, V38, P92, DOI 10.1016/j.immuni.2012.11.005; Lund EG, 1998, J BIOL CHEM, V273, P34316, DOI 10.1074/jbc.273.51.34316; Nagesh PT, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01315; Nagesh PT, 2016, J VIROL, V90, P4614, DOI 10.1128/JVI.00126-16; Nutsford AN, 2019, CELL MICROBIOL, V21, DOI 10.1111/cmi.12989; O'Hanlon R, 2019, CURR OPIN VIROL, V35, P14, DOI 10.1016/j.coviro.2019.01.006; Oishi K, 2018, CELL REP, V24, P851, DOI 10.1016/j.celrep.2018.06.078; Rathore OS, 2016, SCI REP-UK, V6, DOI 10.1038/srep21304; RONNI T, 1995, J IMMUNOL, V154, P2764; Stanifer ML, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.608645; Wang XY, 2007, CELL HOST MICROBE, V2, P96, DOI 10.1016/j.chom.2007.06.009; Yang XH, 2011, MOL CELL, V44, P39, DOI 10.1016/j.molcel.2011.07.032; Zanin M, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12070728; Zhao DM, 2016, ANTIMICROB AGENTS CH, V60, P1902, DOI 10.1128/AAC.02055-15	38	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 12	2022	12								771792	10.3389/fimmu.2021.771792	http://dx.doi.org/10.3389/fimmu.2021.771792			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YO7OE	35095845				2022-12-18	WOS:000748125100001
J	Arnold, J; Vital, EM; Dass, S; Aslam, A; Rawstron, AC; Savic, S; Emery, P; Yusof, MYM				Arnold, Jack; Vital, Edward M.; Dass, Shouvik; Aslam, Aamir; Rawstron, Andy C.; Savic, Sinisa; Emery, Paul; Yusof, Md Yuzaiful Md			A Personalized Rituximab Retreatment Approach Based on Clinical and B-Cell Biomarkers in ANCA-Associated Vasculitis	FRONTIERS IN IMMUNOLOGY			English	Article						B cell; rituximab; cyclophosphamide; immunoglobulin; vasculitis	TERM MAINTENANCE THERAPY; RHEUMATOID-ARTHRITIS; RISK-FACTORS; DEPLETION; GRANULOMATOSIS; MANAGEMENT; INDUCTION; EFFICACY	Background: Time to relapse after rituximab for the treatment of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is variable, and optimal retreatment strategy has remained unclear. In AAV following rituximab induction, the study objective was to evaluate clinical and B-cell predictors of relapse in order to develop a retreatment algorithm. Methods: A retrospective observational study was conducted in 70 rituximab-treated ANCA-associated vasculitis patients followed up for over 10 years. Complete response (CR) was defined as Birmingham Vasculitis Activity Score v3.0 = 0. Retreatment was given on clinical relapse, defined as new features or worsening of persistent disease (not by biomarker status). Peripheral B-cell subsets were measured using highly sensitive flow cytometry. Predictors were tested using multivariable Cox regression. Results: Median time to retreatment for cycles 1-5 were 84, 73, 67, 60, and 73 weeks. Over 467 patient-years follow-up, 158 relapses occurred in 60 patients; 16 (in 15 patients) were major (renal = 7, neurological = 4, ENT = 3, and respiratory = 2). The major-relapse rate was 3.4/100 patient-years. In multivariable analysis, concomitant immunosuppressant [HR, 0.48 (95% CI, 0.24-0.94)], achieving CR [0.24 (0.12-0.50)], and naive B-cell repopulation at 6 months [0.43 (0.22-0.84)] were associated with longer time to relapse. Personalized retreatment using these three predictors in this cohort would have avoided an unnecessary fixed retreatment in 24% of patients. Area under the receiver operating characteristic for prediction of time to relapse was greater if guided by naive B-cell repopulation than if previously evaluated ANCA and/or CD19(+) cells return at 6 months had been used, 0.82 and 0.53, respectively. Conclusion: Our findings suggest that all patients should be coprescribed oral immunosuppressant. Those with incomplete response or with absent naive B cells should be retreated at 6 months. Patients with complete response and naive repopulation should not receive fixed retreatment. This algorithm could reduce unnecessary retreatment and warrant investigation in clinical trials.	[Arnold, Jack; Vital, Edward M.; Dass, Shouvik; Aslam, Aamir; Savic, Sinisa; Emery, Paul; Yusof, Md Yuzaiful Md] Univ Leeds, Chapel Allerton Hosp, Leeds Inst Rheumat & Musculoskeletal Med, Leeds, W Yorkshire, England; [Vital, Edward M.; Dass, Shouvik; Aslam, Aamir; Savic, Sinisa; Emery, Paul; Yusof, Md Yuzaiful Md] Leeds Teaching Hosp NHS Trust, Leeds Biomed Res Ctr, Natl Inst Hlth Res NIHR, Leeds, W Yorkshire, England; [Rawstron, Andy C.] Leeds Teaching Hosp NHS Trust, Haematol Malignancy Diagnost Serv, Leeds, W Yorkshire, England	Chapel Allerton Hospital; University of Leeds; Leeds Biomedical Research Centre; University of Leeds; University of Leeds	Yusof, MYM (corresponding author), Univ Leeds, Chapel Allerton Hosp, Leeds Inst Rheumat & Musculoskeletal Med, Leeds, W Yorkshire, England.; Yusof, MYM (corresponding author), Leeds Teaching Hosp NHS Trust, Leeds Biomed Res Ctr, Natl Inst Hlth Res NIHR, Leeds, W Yorkshire, England.	y.yusof@leeds.ac.uk			Wellcome Trust Institutional Strategic Support Fund [204825/Z/16/Z]; National Institute for Health Research (NIHR) Doctoral Research Fellowship [DRF-2014-07-155]; NIHR Clinician Scientist [CS-2013-13-032]; NIHR Leeds Biomedical Research Centre	Wellcome Trust Institutional Strategic Support Fund(Wellcome Trust); National Institute for Health Research (NIHR) Doctoral Research Fellowship(National Institute for Health Research (NIHR)); NIHR Clinician Scientist; NIHR Leeds Biomedical Research Centre	This research was funded/supported by the the Wellcome Trust Institutional Strategic Support Fund to MYMY (204825/Z/16/Z), National Institute for Health Research (NIHR) Doctoral Research Fellowship to MYMY (DRF-2014-07-155), and NIHR Clinician Scientist to EV (CS-2013-13-032). This article/paper/report also presents independent research funded/supported by the NIHR Leeds Biomedical Research Centre. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.	Bastian H, 2010, J RHEUMATOL, V37, P1069, DOI 10.3899/jrheum.091127; Besada E, 2014, RHEUMATOLOGY, V53, P1818, DOI 10.1093/rheumatology/keu194; Breedveld F, 2007, J CLIN PHARMACOL, V47, P1119, DOI 10.1177/0091270007305297; Cartin-Ceba R, 2012, ARTHRITIS RHEUM-US, V64, P3770, DOI 10.1002/art.34584; Charles P, 2018, ANN RHEUM DIS, V77, P1144, DOI 10.1136/annrheumdis-2017-212878; Charles P, 2014, RHEUMATOLOGY, V53, P532, DOI 10.1093/rheumatology/ket381; Chung SA, 2021, ARTHRITIS RHEUMATOL, V73, P1366, DOI 10.1002/art.41773; Dass S, 2008, ARTHRITIS RHEUM-US, V58, P2993, DOI 10.1002/art.23902; Edwards JCW, 2004, NEW ENGL J MED, V350, P2572, DOI 10.1056/NEJMoa032534; Emery P, 2006, ARTHRITIS RHEUM, V54, P1390, DOI 10.1002/art.21778; Ferraro AJ, 2008, NEPHROL DIAL TRANSPL, V23, P3030, DOI 10.1093/ndt/gfn318; Gottenberg JE, 2010, ARTHRITIS RHEUM-US, V62, P2625, DOI 10.1002/art.27555; Guillevin L, 2014, NEW ENGL J MED, V371, P1771, DOI 10.1056/NEJMoa1404231; Jennette JC, 2013, ARTHRITIS RHEUM-US, V65, P1, DOI 10.1002/art.37715; Karras A, 2017, ANN RHEUM DIS, V76, P1662, DOI 10.1136/annrheumdis-2017-211123; Leandro MJ, 2006, ARTHRITIS RHEUM-US, V54, P613, DOI 10.1002/art.21617; McClure ME, 2021, RHEUMATOLOGY, V60, P1491, DOI 10.1093/rheumatology/keaa541; Miloslavsky EM, 2014, ARTHRITIS RHEUMATOL, V66, P3151, DOI 10.1002/art.38788; Mukhtyar C, 2009, ANN RHEUM DIS, V68, P1827, DOI 10.1136/ard.2008.101279; Pendergraft WF, 2014, CLIN J AM SOC NEPHRO, V9, P736, DOI 10.2215/CJN.07340713; Roll P, 2006, ARTHRITIS RHEUM-US, V54, P2377, DOI 10.1002/art.22019; Sarantopoulos S, 2011, BLOOD, V117, P2275, DOI 10.1182/blood-2010-10-307819; Smith RM, 2012, ARTHRITIS RHEUM-US, V64, P3760, DOI 10.1002/art.34583; Terrier B, 2020, ORPHANET J RARE DIS, V15, DOI 10.1186/s13023-020-01621-3; Terrier B, 2018, ANN RHEUM DIS, V77, P1151, DOI 10.1136/annrheumdis-2017-212768; Tieu J, 2020, RHEUMATOLOGY, V59, pe24, DOI 10.1093/rheumatology/kez640; Todd SK, 2014, RHEUMATOLOGY, V53, P1693, DOI 10.1093/rheumatology/keu136; van Dam LS, 2021, NEPHROL DIAL TRANSPL, V36, P1408, DOI 10.1093/ndt/gfaa066; Venhoff N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037626; Vital EM, 2010, ARTHRITIS RHEUM-US, V62, P1273, DOI 10.1002/art.27359; Vital EM, 2011, ARTHRITIS RHEUM-US, V63, P3038, DOI 10.1002/art.30466; Yusof MYM, 2019, ARTHRITIS RHEUMATOL, V71, P1812, DOI 10.1002/art.40937; Yusof MYM, 2017, ANN RHEUM DIS, V76, P1829, DOI 10.1136/annrheumdis-2017-211191; Yusof MYM, 2015, ANN RHEUM DIS, V74, P1734, DOI 10.1136/annrheumdis-2014-206496	34	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 12	2022	13								803175	10.3389/fimmu.2021.803175	http://dx.doi.org/10.3389/fimmu.2021.803175			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6G9MG		gold, Green Published			2022-12-18	WOS:000885074100001
J	Arnold, J; Vital, EM; Dass, S; Aslam, A; Rawstron, AC; Savic, S; Emery, P; Yusof, MYM				Arnold, Jack; Vital, Edward M.; Dass, Shouvik; Aslam, Aamir; Rawstron, Andy C.; Savic, Sinisa; Emery, Paul; Md Yusof, Md Yuzaiful			A Personalized Rituximab Retreatment Approach Based on Clinical and B-Cell Biomarkers in ANCA-Associated Vasculitis	FRONTIERS IN IMMUNOLOGY			English	Article						B cell; rituximab; cyclophosphamide; immunoglobulin; vasculitis	TERM MAINTENANCE THERAPY; RHEUMATOID-ARTHRITIS; RISK-FACTORS; DEPLETION; GRANULOMATOSIS; MANAGEMENT; INDUCTION; EFFICACY	BackgroundTime to relapse after rituximab for the treatment of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is variable, and optimal retreatment strategy has remained unclear. In AAV following rituximab induction, the study objective was to evaluate clinical and B-cell predictors of relapse in order to develop a retreatment algorithm. MethodsA retrospective observational study was conducted in 70 rituximab-treated ANCA-associated vasculitis patients followed up for over 10 years. Complete response (CR) was defined as Birmingham Vasculitis Activity Score v3.0 = 0. Retreatment was given on clinical relapse, defined as new features or worsening of persistent disease (not by biomarker status). Peripheral B-cell subsets were measured using highly sensitive flow cytometry. Predictors were tested using multivariable Cox regression. ResultsMedian time to retreatment for cycles 1-5 were 84, 73, 67, 60, and 73 weeks. Over 467 patient-years follow-up, 158 relapses occurred in 60 patients; 16 (in 15 patients) were major (renal = 7, neurological = 4, ENT = 3, and respiratory = 2). The major-relapse rate was 3.4/100 patient-years. In multivariable analysis, concomitant immunosuppressant [HR, 0.48 (95% CI, 0.24-0.94)], achieving CR [0.24 (0.12-0.50)], and naive B-cell repopulation at 6 months [0.43 (0.22-0.84)] were associated with longer time to relapse. Personalized retreatment using these three predictors in this cohort would have avoided an unnecessary fixed retreatment in 24% of patients. Area under the receiver operating characteristic for prediction of time to relapse was greater if guided by naive B-cell repopulation than if previously evaluated ANCA and/or CD19(+) cells return at 6 months had been used, 0.82 and 0.53, respectively. ConclusionOur findings suggest that all patients should be coprescribed oral immunosuppressant. Those with incomplete response or with absent naive B cells should be retreated at 6 months. Patients with complete response and naive repopulation should not receive fixed retreatment. This algorithm could reduce unnecessary retreatment and warrant investigation in clinical trials.	[Arnold, Jack; Vital, Edward M.; Dass, Shouvik; Aslam, Aamir; Savic, Sinisa; Emery, Paul; Md Yusof, Md Yuzaiful] Univ Leeds, Chapel Allerton Hosp, Leeds Inst Rheumat & Musculoskeletal Med, Leeds, England; [Vital, Edward M.; Dass, Shouvik; Aslam, Aamir; Savic, Sinisa; Emery, Paul; Md Yusof, Md Yuzaiful] Leeds Teaching Hosp NHS Trust, Natl Inst Hlth Res NIHR Leeds Biomed Res Ctr, Leeds, England; [Rawstron, Andy C.] Leeds Teaching Hosp NHS Trust, Haematol Malignancy Diagnost Serv, Leeds, England	Chapel Allerton Hospital; University of Leeds; University of Leeds; University of Leeds	Yusof, MYM (corresponding author), Univ Leeds, Chapel Allerton Hosp, Leeds Inst Rheumat & Musculoskeletal Med, Leeds, England.; Yusof, MYM (corresponding author), Leeds Teaching Hosp NHS Trust, Natl Inst Hlth Res NIHR Leeds Biomed Res Ctr, Leeds, England.	y.yusof@leeds.ac.uk		Savic, Sinisa/0000-0001-7910-0554				Bastian H, 2010, J RHEUMATOL, V37, P1069, DOI 10.3899/jrheum.091127; Besada E, 2014, RHEUMATOLOGY, V53, P1818, DOI 10.1093/rheumatology/keu194; Breedveld F, 2007, J CLIN PHARMACOL, V47, P1119, DOI 10.1177/0091270007305297; Cartin-Ceba R, 2012, ARTHRITIS RHEUM-US, V64, P3770, DOI 10.1002/art.34584; Charles P, 2018, ANN RHEUM DIS, V77, P1144, DOI 10.1136/annrheumdis-2017-212878; Charles P, 2014, RHEUMATOLOGY, V53, P532, DOI 10.1093/rheumatology/ket381; Chung SA, 2021, ARTHRITIS RHEUMATOL, V73, P1366, DOI 10.1002/art.41773; Dass S, 2008, ARTHRITIS RHEUM-US, V58, P2993, DOI 10.1002/art.23902; Edwards JCW, 2004, NEW ENGL J MED, V350, P2572, DOI 10.1056/NEJMoa032534; Emery P, 2006, ARTHRITIS RHEUM, V54, P1390, DOI 10.1002/art.21778; Ferraro AJ, 2008, NEPHROL DIAL TRANSPL, V23, P3030, DOI 10.1093/ndt/gfn318; Gottenberg JE, 2010, ARTHRITIS RHEUM-US, V62, P2625, DOI 10.1002/art.27555; Guillevin L, 2014, NEW ENGL J MED, V371, P1771, DOI 10.1056/NEJMoa1404231; Jennette JC, 2013, ARTHRITIS RHEUM-US, V65, P1, DOI 10.1002/art.37715; Karras A, 2017, ANN RHEUM DIS, V76, P1662, DOI 10.1136/annrheumdis-2017-211123; Leandro MJ, 2006, ARTHRITIS RHEUM-US, V54, P613, DOI 10.1002/art.21617; McClure ME, 2021, RHEUMATOLOGY, V60, P1491, DOI 10.1093/rheumatology/keaa541; Miloslavsky EM, 2014, ARTHRITIS RHEUMATOL, V66, P3151, DOI 10.1002/art.38788; Mukhtyar C, 2009, ANN RHEUM DIS, V68, P1827, DOI 10.1136/ard.2008.101279; Pendergraft WF, 2014, CLIN J AM SOC NEPHRO, V9, P736, DOI 10.2215/CJN.07340713; Roll P, 2006, ARTHRITIS RHEUM-US, V54, P2377, DOI 10.1002/art.22019; Sarantopoulos S, 2011, BLOOD, V117, P2275, DOI 10.1182/blood-2010-10-307819; Smith RM, 2012, ARTHRITIS RHEUM-US, V64, P3760, DOI 10.1002/art.34583; Terrier B, 2020, ORPHANET J RARE DIS, V15, DOI 10.1186/s13023-020-01621-3; Terrier B, 2018, ANN RHEUM DIS, V77, P1151, DOI 10.1136/annrheumdis-2017-212768; Tieu J, 2020, RHEUMATOLOGY, V59, pe24, DOI 10.1093/rheumatology/kez640; Todd SK, 2014, RHEUMATOLOGY, V53, P1693, DOI 10.1093/rheumatology/keu136; van Dam LS, 2021, NEPHROL DIAL TRANSPL, V36, P1408, DOI 10.1093/ndt/gfaa066; Venhoff N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037626; Vital EM, 2010, ARTHRITIS RHEUM-US, V62, P1273, DOI 10.1002/art.27359; Vital EM, 2011, ARTHRITIS RHEUM-US, V63, P3038, DOI 10.1002/art.30466; Yusof MYM, 2019, ARTHRITIS RHEUMATOL, V71, P1812, DOI 10.1002/art.40937; Yusof MYM, 2017, ANN RHEUM DIS, V76, P1829, DOI 10.1136/annrheumdis-2017-211191; Yusof MYM, 2015, ANN RHEUM DIS, V74, P1734, DOI 10.1136/annrheumdis-2014-206496	34	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 12	2022	12								803175	10.3389/fimmu.2021.803175	http://dx.doi.org/10.3389/fimmu.2021.803175			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6H9HK		gold, Green Published			2022-12-18	WOS:000885741200001
J	Conceicao-Silva, F; Morgado, FN; Pinheiro, RO; Tacchini-Cottier, F				Conceicao-Silva, Fatima; Morgado, Fernanda N.; Pinheiro, Roberta O.; Tacchini-Cottier, Fabienne			Editorial: The Skin Immune Response to Infectious Agents	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						skin; immune response; infectious diseases; skin immune system; skin-associated lymphoid tissues (SALT)	SYSTEM		[Conceicao-Silva, Fatima; Morgado, Fernanda N.] Fundacao Oswaldo Cruz, Immunoparasitol Lab, Inst Oswaldo Cruz, Rio De Janeiro, Brazil; [Pinheiro, Roberta O.] Fundacao Oswaldo Cruz, Leprosy Lab, Inst Oswaldo Cruz, Rio De Janeiro, Brazil; [Tacchini-Cottier, Fabienne] Univ Lausanne, Biochem Dept, Lausanne, Switzerland	Fundacao Oswaldo Cruz; Fundacao Oswaldo Cruz; University of Lausanne	Conceicao-Silva, F (corresponding author), Fundacao Oswaldo Cruz, Immunoparasitol Lab, Inst Oswaldo Cruz, Rio De Janeiro, Brazil.	fconcei@ioc.fiocruz.br	Morgado, Fernanda N/K-2527-2013; Morgado, Fernanda/AAV-4435-2021; Morgado, Fernanda/O-3577-2017; Pinheiro, Roberta/A-2525-2013	Morgado, Fernanda N/0000-0002-7188-251X; Morgado, Fernanda/0000-0002-7188-251X; Morgado, Fernanda/0000-0002-7188-251X; Pinheiro, Roberta/0000-0001-8471-4227	PAEF-Fiocruz e Programa Jovem Cientista do Nosso Estado - Faperj [E-26/202.760/2019]	PAEF-Fiocruz e Programa Jovem Cientista do Nosso Estado - Faperj(Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio De Janeiro (FAPERJ))	Funding This work was supported by PAEF-Fiocruz e Programa Jovem Cientista do Nosso Estado - Faperj (E-26/202.760/2019).	Abdallah F, 2017, MEDIAT INFLAMM, V2017, DOI 10.1155/2017/5095293; BOS JD, 1986, IMMUNOL TODAY, V7, P235, DOI 10.1016/0167-5699(86)90111-8; BOS JD, 1987, J INVEST DERMATOL, V88, P569, DOI 10.1111/1523-1747.ep12470172; BOS JD, 1993, IMMUNOL TODAY, V14, P75, DOI 10.1016/0167-5699(93)90062-P; Conceicao-Silva F, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00330; Jarrett R, 2016, BRIT J DERMATOL, V175, P19, DOI 10.1111/bjd.14908; Matejuk A, 2018, ARCH IMMUNOL THER EX, V66, P45, DOI 10.1007/s00005-017-0477-3; Noske K, 2018, J DERMATOL SCI, V89, P3, DOI 10.1016/j.jdermsci.2017.10.008; Paus R, 2005, TRENDS IMMUNOL, V26, P32, DOI 10.1016/j.it.2004.09.014; Spellberg B, 2000, LIFE SCI, V67, P477, DOI 10.1016/S0024-3205(00)00653-6; STREILEIN JW, 1983, J INVEST DERMATOL, V80, pS12, DOI 10.1111/1523-1747.ep12536743; STREILEIN JW, 1985, J INVEST DERMATOL, V85, pS10	12	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 12	2022	12								810059	10.3389/fimmu.2021.810059	http://dx.doi.org/10.3389/fimmu.2021.810059			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YO7AK	35095901	Green Published, gold			2022-12-18	WOS:000748089300001
J	Gonzalez-Mancha, N; Rodriguez-Rodriguez, C; Alcover, A; Merida, I				Gonzalez-Mancha, Natalia; Rodriguez-Rodriguez, Cristina; Alcover, Andres; Merida, Isabel			Sorting Nexin 27 Enables MTOC and Secretory Machinery Translocation to the Immune Synapse	FRONTIERS IN IMMUNOLOGY			English	Article						T lymphocytes; polarization; immune response; centrosome; diacylglycerol kinase zeta; retromer; SNX27	MICROTUBULE-ORGANIZING CENTER; T-CELL-ACTIVATION; NF-KAPPA-B; IMMUNOLOGICAL SYNAPSE; CYTOPLASMIC DYNEIN; CENTROSOME POLARIZATION; PROTEIN; DIACYLGLYCEROL; COMPLEX; TCR	Sorting nexin 27 (SNX27) association to the retromer complex mediates intracellular trafficking of cargoes containing PSD95/Dlg1/ZO-1 (PDZ)-binding C-terminal sequences from endosomes to the cell surface, preventing their lysosomal degradation. Antigen recognition by T lymphocyte leads to the formation of a highly organized structure named the immune synapse (IS), which ensures cell-cell communication and sustained T cell activation. At the neuronal synapse, SNX27 recycles PDZ-binding receptors and its defective expression is associated with synaptic dysfunction and cognitive impairment. In T lymphocytes, SNX27 was found localized at recycling endosomal compartments that polarized to the IS, suggesting a function in polarized traffic to this structure. Proteomic analysis of PDZ-SNX27 interactors during IS formation identify proteins with known functions in cytoskeletal reorganization and lipid regulation, such as diacylglycerol (DAG) kinase (DGK) zeta, as well as components of the retromer and WASH complex. In this study, we investigated the consequences of SNX27 deficiency in cytoskeletal reorganization during IS formation. Our analyses demonstrate that SNX27 controls the polarization towards the cell-cell interface of the PDZ-interacting cargoes DGK zeta and the retromer subunit vacuolar protein sorting protein 26, among others. SNX27 silencing abolishes the formation of a DAG gradient at the IS and prevents re-localization of the dynactin complex component dynactin-1/p150(Glued), two events that correlate with impaired microtubule organizing center translocation (MTOC). SNX27 silenced cells show marked alteration in cytoskeleton organization including a failure in the organization of the microtubule network and defects in actin clearance at the IS. Reduced SNX27 expression was also found to hinder the arrangement of signaling microclusters at the IS, as well as the polarization of the secretory machinery towards the antigen presenting cells. Our results broaden the knowledge of SNX27 function in T lymphocytes by showing a function in modulating IS organization through regulated trafficking of cargoes.	[Gonzalez-Mancha, Natalia; Rodriguez-Rodriguez, Cristina; Merida, Isabel] CSIC, CNB, Dept Immunol & Oncol, Madrid, Spain; [Alcover, Andres] Univ Paris, Inst Pasteur, Unite Biol Cellulaire Lymphocytes, INSERM U1224,Ligue Natl Canc,Equipe Labellisee Li, Paris, France	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Universite Paris Cite	Merida, I (corresponding author), CSIC, CNB, Dept Immunol & Oncol, Madrid, Spain.	imerida@cnb.csic.es			European Union Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant [713673]; "La Caixa" Foundation [100010434, LCF/BQ/DI17/11620027]; EMBO short-term fellowship; Spanish Association Against Cancer (AECC) [CICPF18]; Aplastic Anemia and MDS International Foundation (AAMDSIF) [OPE01644]; Spanish Ministry of Science and Innovation [PID2019-108357RB-100/AEI/10.13039/501100011033]; Madrid regional government (IMMUNOTHERCAM Consortium) [S2010/BMD-2326]; French Ligue Nationale Contre le Cancer, Equipe Labellisee 2018)	European Union Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant; "La Caixa" Foundation(La Caixa Foundation); EMBO short-term fellowship(European Molecular Biology Organization (EMBO)); Spanish Association Against Cancer (AECC); Aplastic Anemia and MDS International Foundation (AAMDSIF); Spanish Ministry of Science and Innovation(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Madrid regional government (IMMUNOTHERCAM Consortium); French Ligue Nationale Contre le Cancer, Equipe Labellisee 2018)	NG-M received funding from the European Union Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant agreement 713673 and "La Caixa" Foundation (ID 100010434), with the fellowship code being LCF/BQ/DI17/11620027, as well as an EMBO short-term fellowship. CR-R held a predoctoral fellow of theA ' lvaro Entrecanales and Jerome Lejeune Foundations. Research in IM's lab is funded by grants from the Spanish Association Against Cancer (AECC, CICPF18), Aplastic Anemia and MDS International Foundation (AAMDSIF, OPE01644), Spanish Ministry of Science and Innovation (PID2019-108357RB-100/AEI/10.13039/501100011033), and the Madrid regional government (IMMUNOTHERCAM Consortium S2010/BMD-2326) to IM. Research in AA's lab is funded by the French Ligue Nationale Contre le Cancer, Equipe Labellise ' e 2018).	Aguera-Gonzalez S, 2017, CELL REP, V21, P181, DOI 10.1016/j.celrep.2017.09.020; Al-Dosari MS, 2010, J MED GENET, V47, P411, DOI 10.1136/jmg.2009.076646; Andrada E, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aaf7714; Arranz-Nicolas J, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-001521; Attar N, 2010, ADV ENZYME REGUL, V50, P216, DOI 10.1016/j.advenzreg.2009.10.002; Avila-Flores A, 2017, IMMUNOL CELL BIOL, V95, P549, DOI 10.1038/icb.2017.7; Baron CL, 2002, SCIENCE, V295, P325, DOI 10.1126/science.1066759; Bello-Gamboa A, 2020, J EXTRACELL VESICLES, V9, DOI 10.1080/20013078.2020.1759926; Blott EJ, 2002, NAT REV MOL CELL BIO, V3, P122, DOI 10.1038/nrm732; Bolte S, 2006, J MICROSC-OXFORD, V224, P213, DOI 10.1111/j.1365-2818.2006.01706.x; Bond J, 2005, NAT GENET, V37, P353, DOI 10.1038/ng1539; Bonello G, 2004, J CELL SCI, V117, P1009, DOI 10.1242/jcs.00968; Bouchet J, 2017, J IMMUNOL, V198, P2967, DOI 10.4049/jimmunol.1600671; Burd C, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a016774; Bustos-Moran E, 2017, J CELL SCI, V130, P1217, DOI 10.1242/jcs.199042; Carpier JM, 2018, J EXP MED, V215, P1245, DOI 10.1084/jem.20162042; Carrasco S, 2004, MOL BIOL CELL, V15, P2932, DOI 10.1091/mbc.E03-11-0844; Chauveau A, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005287; Chemin K, 2012, J IMMUNOL, V189, P2159, DOI 10.4049/jimmunol.1200156; Clairfeuille T, 2016, NAT STRUCT MOL BIOL, V23, P921, DOI 10.1038/nsmb.3290; Combs J, 2006, P NATL ACAD SCI USA, V103, P14883, DOI 10.1073/pnas.0600914103; Das V, 2004, IMMUNITY, V20, P577, DOI 10.1016/S1074-7613(04)00106-2; Di Cunto F, 2000, NEURON, V28, P115, DOI 10.1016/S0896-6273(00)00090-8; Ehrlich LIR, 2002, IMMUNITY, V17, P809, DOI 10.1016/S1074-7613(02)00481-8; Farina F, 2016, NAT CELL BIOL, V18, P65, DOI 10.1038/ncb3285; Finetti F, 2009, NAT CELL BIOL, V11, P1332, DOI 10.1038/ncb1977; Gallon M, 2015, BIOCHEM SOC T, V43, P33, DOI 10.1042/BST20140290; Gallon M, 2014, P NATL ACAD SCI USA, V111, pE3604, DOI 10.1073/pnas.1410552111; Gawden-Bone CM, 2018, IMMUNITY, V49, P427, DOI 10.1016/j.immuni.2018.08.017; Gomez TS, 2007, IMMUNITY, V26, P177, DOI 10.1016/j.immuni.2007.01.008; Griffiths GM, 2010, J CELL BIOL, V189, P397, DOI 10.1083/jcb.201002027; Haft CR, 2000, MOL BIOL CELL, V11, P4105, DOI 10.1091/mbc.11.12.4105; Hashimoto-Tane A, 2011, IMMUNITY, V34, P919, DOI 10.1016/j.immuni.2011.05.012; Hierro A, 2007, NATURE, V449, P1063, DOI 10.1038/nature06216; Hong ST, 2015, EXP NEUROBIOL, V24, P8, DOI 10.5607/en.2015.24.1.8; Horazdovsky BF, 1997, MOL BIOL CELL, V8, P1529, DOI 10.1091/mbc.8.8.1529; Huse M, 2006, NAT IMMUNOL, V7, P247, DOI 10.1038/ni1304; Huse M, 2008, NAT IMMUNOL, V9, P1105, DOI 10.1038/ni.f.215; Jutz S, 2016, J IMMUNOL METHODS, V430, P10, DOI 10.1016/j.jim.2016.01.007; Juzans Marie, 2020, Immunohorizons, V4, P363, DOI 10.4049/immunohorizons.2000044; Kardon JR, 2009, NAT REV MOL CELL BIO, V10, P854, DOI 10.1038/nrm2804; Kerr MC, 2005, TRAFFIC, V6, P991, DOI 10.1111/j.1600-0854.2005.00328.x; Krummel MF, 2006, NAT IMMUNOL, V7, P1143, DOI 10.1038/ni1404; Kuhn JR, 2002, IMMUNITY, V16, P111, DOI 10.1016/S1074-7613(02)00262-5; Kuhne MR, 2003, J IMMUNOL, V171, P860, DOI 10.4049/jimmunol.171.2.860; KUPFER A, 1991, P NATL ACAD SCI USA, V88, P775, DOI 10.1073/pnas.88.3.775; KUPFER A, 1983, P NATL ACAD SCI-BIOL, V80, P7224, DOI 10.1073/pnas.80.23.7224; KUPFER H, 1994, J EXP MED, V179, P1507, DOI 10.1084/jem.179.5.1507; Larghi P, 2013, NAT IMMUNOL, V14, P723, DOI 10.1038/ni.2609; Lasiecka ZM, 2011, MOL CELL NEUROSCI, V48, P278, DOI 10.1016/j.mcn.2011.06.013; Lasserre R, 2010, EMBO J, V29, P2301, DOI 10.1038/emboj.2010.127; Lauffer BEL, 2010, J CELL BIOL, V190, P565, DOI 10.1083/jcb.201004060; Leitner J, 2010, J IMMUNOL METHODS, V362, P131, DOI 10.1016/j.jim.2010.09.020; Li HD, 2016, AM J HUM GENET, V99, P501, DOI 10.1016/j.ajhg.2016.07.004; Liu X, 2013, P NATL ACAD SCI USA, V110, P11976, DOI 10.1073/pnas.1306180110; Loo LS, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4176; Ludford-Menting MJ, 2005, IMMUNITY, V22, P737, DOI 10.1016/j.immuni.2005.04.009; Mao LJ, 2021, J CELL BIOL, V220, DOI 10.1083/jcb.202010048; Martin-Cofreces NB, 2008, J CELL BIOL, V182, P951, DOI 10.1083/jcb.200801014; Martin-Cofreces NB, 2012, EMBO J, V31, P4140, DOI 10.1038/emboj.2012.242; Mastrogiovanni M, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.591348; McIntyre RE, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1003022; McKenney RJ, 2014, SCIENCE, V345, P337, DOI 10.1126/science.1254198; Menon P, 2010, BRAIN RES, V1317, P218, DOI 10.1016/j.brainres.2009.11.084; Merino-Cortes SV, 2020, SCI SIGNAL, V13, DOI 10.1126/scisignal.aaw8214; Mittelbrunn M, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1285; Monks CRF, 1998, NATURE, V395, P82, DOI 10.1038/25764; Nath S, 2016, J IMMUNOL, V197, P2090, DOI 10.4049/jimmunol.1600180; Obino D, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10969; Onnis A, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00050; Paz PE, 2001, BIOCHEM J, V356, P461, DOI 10.1042/0264-6021:3560461; Pols MS, 2009, EXP CELL RES, V315, P1584, DOI 10.1016/j.yexcr.2008.09.020; Quann EJ, 2011, NAT IMMUNOL, V12, P647, DOI 10.1038/ni.2033; Quann EJ, 2009, NAT IMMUNOL, V10, P627, DOI 10.1038/ni.1734; Randzavola LO, 2019, J CLIN INVEST, V129, P5600, DOI 10.1172/JCI129388; Reichert P, 2001, J IMMUNOL, V166, P4278, DOI 10.4049/jimmunol.166.7.4278; Rincon E, 2007, MOL CELL PROTEOMICS, V6, P1073, DOI 10.1074/mcp.M700047-MCP200; Rincon E, 2011, J CELL SCI, V124, P776, DOI 10.1242/jcs.072447; Ritter AT, 2015, IMMUNITY, V42, P864, DOI 10.1016/j.immuni.2015.04.013; Round JL, 2007, NAT IMMUNOL, V8, P154, DOI 10.1038/ni1422; Sanchez E, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0210377; Sann S, 2009, TRENDS CELL BIOL, V19, P317, DOI 10.1016/j.tcb.2009.05.001; Santos T, 2002, J BIOL CHEM, V277, P30300, DOI 10.1074/jbc.M200999200; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Schmalzigaug R, 2009, NEUROSCI LETT, V458, P79, DOI 10.1016/j.neulet.2009.04.037; Schroer TA, 2004, ANNU REV CELL DEV BI, V20, P759, DOI 10.1146/annurev.cellbio.20.012103.094623; Seaman MNJ, 2012, J CELL SCI, V125, P4693, DOI 10.1242/jcs.103440; Seaman MNJ, 1998, J CELL BIOL, V142, P665, DOI 10.1083/jcb.142.3.665; Sedwick CE, 1999, J IMMUNOL, V162, P1367; Soares H, 2013, J EXP MED, V210, P2415, DOI 10.1084/jem.20130150; Soares H, 2013, IMMUNOL REV, V256, P118, DOI 10.1111/imr.12110; Steinberg F, 2013, NAT CELL BIOL, V15, P461, DOI 10.1038/ncb2721; Stinchcombe JC, 2006, NATURE, V443, P462, DOI 10.1038/nature05071; Tello-Lafoz M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16370-w; Tello-Lafoz M, 2017, TRAFFIC, V18, P491, DOI 10.1111/tra.12492; Temkin P, 2011, NAT CELL BIOL, V13, P715, DOI 10.1038/ncb2252; Tourret M, 2010, J IMMUNOL, V185, P6809, DOI 10.4049/jimmunol.1001501; Walczak-Sztulpa J, 2008, AM J MED GENET A, V146A, P337, DOI 10.1002/ajmg.a.32127; Wassmer T, 2009, DEV CELL, V17, P110, DOI 10.1016/j.devcel.2009.04.016; Won H, 2011, NAT MED, V17, P566, DOI 10.1038/nm.2330; Yi JS, 2013, J CELL BIOL, V202, P779, DOI 10.1083/jcb.201301004; Zhang K, 2017, CELL, V169, P1303, DOI 10.1016/j.cell.2017.05.025; Zhang WG, 1999, INT IMMUNOL, V11, P943, DOI 10.1093/intimm/11.6.943; Zimmerman SP, 2013, BIOCHEM J, V455, P95, DOI 10.1042/BJ20121755	104	0	0	3	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 12	2022	12								814570	10.3389/fimmu.2021.814570	http://dx.doi.org/10.3389/fimmu.2021.814570			19	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YO7PX	35095913	Green Published, gold			2022-12-18	WOS:000748129600001
J	Levite, M; Goldberg, H				Levite, Mia; Goldberg, Hadassa			Autoimmune Epilepsy-Novel Multidisciplinary Analysis, Discoveries and Insights	FRONTIERS IN IMMUNOLOGY			English	Article						epilepsy; autoimmune epilepsy; autoimmunity; glutamate receptor antibodies; GluR3B antibodies; HLA; T cells; neurological diseases	GLUTAMATE-RECEPTOR ANTIBODIES; METHYL-D-ASPARTATE; HUMAN T-CELLS; SYSTEMIC-LUPUS-ERYTHEMATOSUS; VOLTAGE-GATED POTASSIUM; FUNCTION IN-VITRO; PEPTIDE B GLUR3B; CASE SERIES; BETA-2-ADRENERGIC RECEPTOR; NEUROTRANSMITTER GLUTAMATE	Epilepsy affects ~50 million people. In ~30% of patients the etiology is unknown, and ~30% are unresponsive to anti-epileptic drugs. Intractable epilepsy often leads to multiple seizures daily or weekly, lasting for years, and accompanied by cognitive, behavioral, and psychiatric problems. This multidisciplinary scientific (not clinical) 'Perspective' article discusses Autoimmune Epilepsy from immunological, neurological and basic-science angles. The article includes summaries and novel discoveries, ideas, insights and recommendations. We summarize the characteristic features of the respective antigens, and the pathological activity in vitro and in animal models of autoimmune antibodies to: Glutamate/AMPA-GluR3, Glutamate/NMDA-NR1, Glutamate/NMDA-NR2, GAD-65, GABA-R, GLY-R, VGKC, LGI1, CASPR2, and beta 2 GP1, found in subpopulations of epilepsy patients. Glutamate receptor antibodies: AMPA-GluR3B peptide antibodies, seem so far as the most exclusive and pathogenic autoimmune antibodies in Autoimmune Epilepsy. They kill neural cells by three mechanisms: excitotoxicity, Reactive-Oxygen-Species, and complement-fixation, and induce and/or facilitate brain damage, seizures, and behavioral impairments. In this article we raise and discuss many more topics and new insights related to Autoimmune Epilepsy. 1. Few autoimmune antibodies tilt the balance between excitatory Glutamate and inhibitory GABA, thereby promoting neuropathology and epilepsy; 2. Many autoantigens are synaptic, and have extracellular domains. These features increase the likelihood of autoimmunity against them, and the ease with which autoimmune antibodies can reach and harm these self-proteins. 3. Several autoantigens have 'frenetic character'- undergoing dynamic changes that can increase their antigenicity; 4. The mRNAs of the autoantigens are widely expressed in multiple organs outside the brain. If translated by default to proteins, broad spectrum detrimental autoimmunity is expected; 5. The autoimmunity can precede seizures, cause them, and be detrimental whether primary or epiphenomenon; 6. Some autoimmune antibodies induce, and associate with, cognitive, behavioral and psychiatric impairments; 7. There are evidences for epitope spreading in Autoimmune Epilepsy; 8. T cells have different 'faces' in the brain, and in Autoimmune Epilepsy: Normal T cells are needed for the healthy brain. Normal T cells are damaged by autoimmune antibodies to Glutamate/AMPA GluR3, which they express, and maybe by additional autoantibodies to: Dopamine-R, GABA-R, Ach-R, Serotonin-R, and Adrenergic-R, present in various neurological diseases (summarized herein), since T cells express all these Neurotransmitter receptors. However, autoimmune and/or cytotoxic T cells damage the brain; 9. The HLA molecules are important for normal brain function. The HLA haplotype can confer susceptibility or protection from Autoimmune Epilepsy; 10. There are several therapeutic strategies for Autoimmune Epilepsy.	[Levite, Mia] Hebrew Univ Jerusalem, Fac Med, Jerusalem, Israel; [Levite, Mia] Hadassah Hebrew Univ Hosp, Goldyne Savad Inst Gene Therapy, Jerusalem, Israel; [Goldberg, Hadassa] Schneider Childrens Med Ctr Israel, Epilepsy Ctr, Petah Tiqwa, Israel; [Goldberg, Hadassa] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hadassah University Medical Center; Tel Aviv University; Sackler Faculty of Medicine	Levite, M (corresponding author), Hebrew Univ Jerusalem, Fac Med, Jerusalem, Israel.; Levite, M (corresponding author), Hadassah Hebrew Univ Hosp, Goldyne Savad Inst Gene Therapy, Jerusalem, Israel.	mialevite@mta.ac.il						Al Nimer F, 2018, NEUROL-NEUROIMMUNOL, V5, DOI 10.1212/NXI.0000000000000419; Andrews PI, 1996, CURR OPIN NEUROBIOL, V6, P673; Appenzeller S, 2011, RHEUMATOLOGY, V50, P1540, DOI 10.1093/rheumatology/ker015; Arinuma Y, 2008, ARTHRITIS RHEUM-US, V58, P1130, DOI 10.1002/art.23399; AUNE TM, 1993, J IMMUNOL, V151, P1175; AUNE TM, 1994, J IMMUNOL, V153, P489; Baysal-Kirac L, 2016, J NEUROL, V263, P455, DOI 10.1007/s00415-015-8002-2; Benedek G, 2021, PLOS NEGLECT TROP D, V15, DOI 10.1371/journal.pntd.0009821; Benedek G, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0008436; Besser MJ, 2005, J NEUROIMMUNOL, V169, P161, DOI 10.1016/j.jneuroim.2005.07.013; Bhandage AK, 2018, EBIOMEDICINE, V30, P283, DOI 10.1016/j.ebiom.2018.03.019; Bien CG, 2002, ANN NEUROL, V51, P311, DOI 10.1002/ana.10100; Bien CG, 2017, EPILEPSY CURR, V17, P134, DOI 10.5698/1535-7511.17.3.134; Bjurstrom H, 2008, J NEUROIMMUNOL, V205, P44, DOI 10.1016/j.jneuroim.2008.08.017; Borger P, 1998, AM J RESP CELL MOL, V19, P400, DOI 10.1165/ajrcmb.19.3.2765; Borusiak P, 2016, EUR J PAEDIATR NEURO, V20, P573, DOI 10.1016/j.ejpn.2016.03.005; Brenner T, 2013, EPILEPSIA, V54, P1028, DOI 10.1111/epi.12127; Britton J, 2016, HAND CLINIC, V133, P219, DOI 10.1016/B978-0-444-63432-0.00013-X; Callenbach PMC, 2003, CLIN EXP IMMUNOL, V132, P144, DOI 10.1046/j.1365-2249.2003.02097.x; Carlson NG, 1997, J BIOL CHEM, V272, P11295; Carvajal-Gonzalez A, 2021, NEUROPATH APPL NEURO, V47, P316, DOI 10.1111/nan.12666; Carvajal-Gonzalez A, 2014, BRAIN, V137, P2178, DOI 10.1093/brain/awu142; Casillas-Espinosa PM, 2012, EPILEPSIA, V53, P41, DOI 10.1111/epi.12034; Cebrian C, 2014, FRONT NEUROANAT, V8, DOI 10.3389/fnana.2014.00114; Chiocchetti A, 2006, BRIT J PHARMACOL, V148, P760, DOI 10.1038/sj.bjp.0706746; Choi DW, 2020, FRONT NEUROSCI-SWITZ, V14, DOI 10.3389/fnins.2020.579953; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; Cimaz R, 2002, EPILEPSIA, V43, P52, DOI 10.1046/j.1528-1157.2002.00701.x; Cosentino M, 2007, BLOOD, V109, P632, DOI 10.1182/blood-2006-01-028423; Coutinho E, 2017, ACTA NEUROPATHOL, V134, P567, DOI 10.1007/s00401-017-1751-5; Cui JZ, 2018, INT J NEUROSCI, V128, P627, DOI 10.1080/00207454.2017.1408618; Cullheim S, 2010, NEUROSCIENTIST, V16, P600, DOI 10.1177/1073858410381534; D'Souza CE, 2018, EPILEPTIC DISORD, V20, P204, DOI 10.1684/epd.2018.0971; Dalmau J, 2019, LANCET NEUROL, V18, P1045, DOI 10.1016/S1474-4422(19)30244-3; Dalmau J, 2008, LANCET NEUROL, V7, P1091, DOI 10.1016/S1474-4422(08)70224-2; Dantzer R, 2018, PHYSIOL REV, V98, P477, DOI 10.1152/physrev.00039.2016; de Bruijn MAAM, 2019, NEUROLOGY, V92, pE2185, DOI 10.1212/WNL.0000000000007475; DeGiorgio LA, 2001, NAT MED, V7, P1189, DOI 10.1038/nm1101-1189; Didona D, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00779; Dubey D, 2018, J NEUROIMMUNOL, V323, P62, DOI 10.1016/j.jneuroim.2018.07.009; Dubey D, 2017, JAMA NEUROL, V74, P397, DOI 10.1001/jamaneurol.2016.5429; Evans FL, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02171; Fan ZL, 2018, MOL MED REP, V18, P169, DOI 10.3892/mmr.2018.9004; Faust TW, 2010, P NATL ACAD SCI USA, V107, P18569, DOI 10.1073/pnas.1006980107; Fellerhoff-Losch B, 2016, J NEURAL TRANSM, V123, P137, DOI 10.1007/s00702-015-1446-9; Feyissa AM, 2020, EPILEPSIA OPEN, V5, P307, DOI 10.1002/epi4.12395; Feyissa Anteneh M, 2018, Epilepsia Open, V3, P348, DOI 10.1002/epi4.12226; Feyissa AM, 2017, NEUROL-NEUROIMMUNOL, V4, DOI 10.1212/NXI.0000000000000353; Filiano AJ, 2017, NAT REV NEUROSCI, V18, P375, DOI 10.1038/nrn.2017.39; Finke C, 2012, J NEUROL NEUROSUR PS, V83, P195, DOI 10.1136/jnnp-2011-300411; Frisullo G, 2007, EXP NEUROL, V204, P808, DOI 10.1016/j.expneurol.2007.01.012; Fujii T, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01085; Ganor Y, 2005, AUTOIMMUNITY, V38, P417, DOI 10.1080/08916930500246339; Ganor Y, 2005, EXP NEUROL, V195, P92, DOI 10.1016/j.expneurol.2005.04.002; Ganor Y, 2005, EPILEPSY RES, V65, P11, DOI 10.1016/j.eplepsyres.2005.03.011; Ganor Y, 2005, AUTOIMMUNITY, V38, P139, DOI 10.1080/08916930500100825; Ganor Y, 2003, J IMMUNOL, V170, P4362, DOI 10.4049/jimmunol.170.8.4362; Ganor Y, 2007, J IMMUNOL, V178, P683, DOI 10.4049/jimmunol.178.2.683; Ganor Yonatan, 2004, Clin Dev Immunol, V11, P241, DOI 10.1080/17402520400001736; Ganor Y, 2014, J NEURAL TRANSM, V121, P983, DOI 10.1007/s00702-014-1167-5; Ganor Y, 2014, PSYCHONEUROENDOCRINO, V42, P106, DOI 10.1016/j.psyneuen.2014.01.005; Ganor Y, 2012, NERVE-DRIVEN IMMUNITY: NEUROTRANSMITTERS AND NEUROPEPTIDES IN THE IMMUNE SYSTEM, P121, DOI 10.1007/978-3-7091-0888-8_4; Ganor Y, 2009, LEUKEMIA LYMPHOMA, V50, P985, DOI 10.1080/10428190902878448; Gao HX, 2010, J NEUROIMMUNOL, V229, P112, DOI 10.1016/j.jneuroim.2010.07.020; Gao LH, 2016, EPILEPSY BEHAV, V56, P165, DOI 10.1016/j.yebeh.2015.12.041; Giannoccaro MP, 2019, BRAIN, V142, P2000, DOI 10.1093/brain/awz119; Goldberg-Stern H, 2014, PSYCHONEUROENDOCRINO, V40, P221, DOI 10.1016/j.psyneuen.2013.11.007; Greco A, 2016, AUTOIMMUN REV, V15, P221, DOI 10.1016/j.autrev.2015.11.007; Guereschi MG, 2013, EUR J IMMUNOL, V43, P1001, DOI 10.1002/eji.201243005; Hacohen Y, 2015, NEUROLOGY, V85, P967, DOI 10.1212/WNL.0000000000001922; Hanly JG, 2006, J RHEUMATOL, V33, P1553; Hansen N, 2013, EXP NEUROL, V239, P202, DOI 10.1016/j.expneurol.2012.10.013; Harrison MJ, 2006, ARTHRITIS RHEUM, V54, P2515, DOI 10.1002/art.22030; He XP, 1998, NEURON, V20, P153, DOI 10.1016/S0896-6273(00)80443-2; Hoftberger R, 2013, NEUROLOGY, V81, P1500, DOI 10.1212/WNL.0b013e3182a9585f; Huang HW, 2015, NEUROIMMUNOMODULAT, V22, P138, DOI 10.1159/000360579; Huerta PT, 2006, P NATL ACAD SCI USA, V103, P678, DOI 10.1073/pnas.0510055103; Hughes EG, 2010, J NEUROSCI, V30, P5866, DOI 10.1523/JNEUROSCI.0167-10.2010; Husari KS, 2019, NEUROTHERAPEUTICS, V16, P685, DOI 10.1007/s13311-019-00750-3; Iffland PH, 2013, NEUROBIOL DIS, V59, P206, DOI 10.1016/j.nbd.2013.07.006; Irani SR, 2010, BRAIN, V133, P1655, DOI 10.1093/brain/awq113; Ishida K, 1999, ANN NEUROL, V46, P263, DOI 10.1002/1531-8249(199908)46:2<263::AID-ANA19>3.0.CO;2-0; Jin Z, 2013, AMINO ACIDS, V45, P87, DOI 10.1007/s00726-011-1193-7; Jurek B, 2019, ANN NEUROL, V86, P656, DOI 10.1002/ana.25552; Keren A, 2019, IMMUNOLOGY, V158, P171, DOI 10.1111/imm.13109; Kim TJ, 2014, J NEUROIMMUNOL, V270, P45, DOI 10.1016/j.jneuroim.2014.02.011; Kipnis J, 2004, J NEUROSCI, V24, P6133, DOI 10.1523/JNEUROSCI.0600-04.2004; Kipnis J, 2012, NAT REV IMMUNOL, V12, P662, DOI 10.1038/nri3280; Kohm AP, 2001, PHARMACOL REV, V53, P487; Korichneva I L, 1990, Biomed Sci, V1, P84; Kowal C, 2004, IMMUNITY, V21, P179, DOI 10.1016/j.immuni.2004.07.011; Kowal C, 2006, P NATL ACAD SCI USA, V103, P19854, DOI 10.1073/pnas.0608397104; Kowal Czeslawa, 2012, Methods Mol Biol, V900, P181, DOI 10.1007/978-1-60761-720-4_9; Kozora E, 2010, J NEUROL SCI, V295, P87, DOI 10.1016/j.jns.2010.04.016; Kustrimovic N, 2014, J NEUROIMMUNE PHARM, V9, P302, DOI 10.1007/s11481-014-9541-5; Kvaratskhelia E, 2009, NEUROIMMUNOMODULAT, V16, P201, DOI 10.1159/000204234; Lai MZ, 2010, LANCET NEUROL, V9, P776, DOI 10.1016/S1474-4422(10)70137-X; Lancaster E, 2010, LANCET NEUROL, V9, P67, DOI 10.1016/S1474-4422(09)70324-2; Lang B, 2003, CURR OPIN NEUROL, V16, P351, DOI 10.1097/00019052-200306000-00016; Lapteva L, 2006, ARTHRITIS RHEUM, V54, P2505, DOI 10.1002/art.22031; Lauvsnes MB, 2014, ARTHRITIS RHEUMATOL, V66, P3387, DOI 10.1002/art.38852; Lauvsnes MB, 2013, ARTHRITIS RHEUM-US, V65, P3209, DOI 10.1002/art.38127; Lauvsnes MB, 2012, J NEUROL, V259, P622, DOI 10.1007/s00415-011-6232-5; Dao LM, 2021, J NEUROL, V268, P2123, DOI 10.1007/s00415-020-10371-y; Levite M, 1999, J AUTOIMMUN, V13, P73, DOI 10.1006/jaut.1999.0297; Levite M, 1999, J AUTOIMMUN, V13, P61, DOI 10.1006/jaut.1999.0301; Levite M, 2016, ACTA PHYSIOL, V216, P42, DOI 10.1111/apha.12476; Levite M, 2012, NERVE-DRIVEN IMMUNITY: NEUROTRANSMITTERS AND NEUROPEPTIDES IN THE IMMUNE SYSTEM, P1, DOI 10.1007/978-3-7091-0888-8; Levite M, 2002, NAT IMMUNOL, V3, P500, DOI 10.1038/ni0602-500; Levite M, 2001, EUR J IMMUNOL, V31, P3504, DOI 10.1002/1521-4141(200112)31:12<3504::AID-IMMU3504>3.0.CO;2-F; Levite M, 2000, ANN NY ACAD SCI, V917, P307; Levite Mia, 2008, Expert Rev Neurother, V8, P1141, DOI 10.1586/14737175.8.7.1141; Levite M, 2008, CURR OPIN PHARMACOL, V8, P460, DOI 10.1016/j.coph.2008.05.001; Levite M, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.617658; Levite M, 2020, J AUTOIMMUN, V112, DOI 10.1016/j.jaut.2020.102462; Levite M, 2014, J NEURAL TRANSM, V121, P1029, DOI 10.1007/s00702-014-1193-3; Levite M, 2017, J NEURAL TRANSM, V124, P775, DOI 10.1007/s00702-016-1661-z; Levite M, 2012, NERVE-DRIVEN IMMUNITY: NEUROTRANSMITTERS AND NEUROPEPTIDES IN THE IMMUNE SYSTEM, P1, DOI 10.1007/978-3-7091-0888-8_1; Levite Mia, 2002, Expert Rev Neurother, V2, P809, DOI 10.1586/14737175.2.6.809; Lin JF, 2019, FRONT NEUROL, V10, DOI 10.3389/fneur.2019.01030; Lombardi G, 2001, BRIT J PHARMACOL, V133, P936, DOI 10.1038/sj.bjp.0704134; Loza MJ, 2006, BLOOD, V107, P2052, DOI 10.1182/blood-2005-08-3265; Lu Y, 2019, J CLIN NEUROSCI, V68, P73, DOI 10.1016/j.jocn.2019.07.049; Majoie HJM, 2006, EPILEPSY RES, V71, P135, DOI 10.1016/j.eplepsyres.2006.06.003; Malina KCK, 2006, NEUROCHEM RES, V31, P1181, DOI 10.1007/s11064-006-9143-6; Mantegazza R, 2002, J NEUROIMMUNOL, V131, P179, DOI 10.1016/S0165-5728(02)00261-8; Manto M, 2010, ORPHANET J RARE DIS, V5, DOI 10.1186/1750-1172-5-31; Manto MU, 2007, ANN NEUROL, V61, P544, DOI 10.1002/ana.21123; Mashimo M, 2020, INT IMMUNOPHARMACOL, V82, DOI 10.1016/j.intimp.2020.106306; Mashkina AP, 2007, NEUROCHEM INT, V51, P356, DOI 10.1016/j.neuint.2007.04.009; McKenna F, 2002, J NEUROIMMUNOL, V132, P34, DOI 10.1016/S0165-5728(02)00280-1; McKnight K, 2005, NEUROLOGY, V65, P1730, DOI 10.1212/01.wnl.0000187129.66353.13; Mendu SK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042959; Mendu SK, 2011, MOL IMMUNOL, V48, P399, DOI 10.1016/j.molimm.2010.08.005; Miglio G, 2005, BIOCHEM BIOPH RES CO, V338, P1875, DOI 10.1016/j.bbrc.2005.10.164; Miglio G, 2005, BIOCHEM PHARMACOL, V70, P189, DOI 10.1016/j.bcp.2005.04.038; Miglio G, 2007, BIOCHEM BIOPH RES CO, V361, P404, DOI 10.1016/j.bbrc.2007.07.015; Mitoma H, 2000, J NEUROL SCI, V175, P40, DOI 10.1016/S0022-510X(00)00272-0; Moga DE, 2003, J COMP NEUROL, V462, P15, DOI 10.1002/cne.10710; Nibber Anjan, 2017, Epilepsia Open, V2, P355, DOI 10.1002/epi4.12067; Nizri E, 2009, J IMMUNOL, V183, P6681, DOI 10.4049/jimmunol.0902212; O'Connor K, 2019, NEUROL-NEUROIMMUNOL, V6, DOI 10.1212/NXI.0000000000000552; Omdal R, 2005, EUR J NEUROL, V12, P392, DOI 10.1111/j.1468-1331.2004.00976.x; Owens GC, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00121; Pacheco R, 2004, J BIOL CHEM, V279, P33352, DOI 10.1074/jbc.M401761200; Pacheco R, 2006, J IMMUNOL, V177, P6695, DOI 10.4049/jimmunol.177.10.6695; Pan H, 2019, MOL PSYCHIATR, V24, P1489, DOI 10.1038/s41380-017-0011-3; Pardo CA, 2004, EPILEPSIA, V45, P516, DOI 10.1111/j.0013-9580.2004.33103.x; Petit-Pedrol M, 2018, BRAIN, V141, P3144, DOI 10.1093/brain/awy253; Petit-Pedrol M, 2014, LANCET NEUROL, V13, P276, DOI 10.1016/S1474-4422(13)70299-0; Petroff OAC, 2002, NEUROSCIENTIST, V8, P562, DOI 10.1177/1073858402238515; Poulopoulou C, 2005, ANN NEUROL, V58, P946, DOI 10.1002/ana.20675; Poulopoulou C, 2008, J NEUROIMMUNOL, V194, P191, DOI 10.1016/j.jneuroim.2007.10.005; Prabowo AS, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-12; Pruss H, 2012, NEUROLOGY, V78, P1743, DOI 10.1212/WNL.0b013e318258300d; Quek AML, 2012, ARCH NEUROL-CHICAGO, V69, P582, DOI 10.1001/archneurol.2011.2985; Quintero-Villegas A, 2019, MOL MED, V26, DOI 10.1186/s10020-019-0126-x; Ramaswamy V, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-152; Ramberger M, 2020, BRAIN, V143, P1731, DOI 10.1093/brain/awaa104; Ramer-Quinn DS, 1997, J IMMUNOL, V159, P4857; Rice JS, 2005, CURR TOP MICROBIOL, V296, P137; ROGERS SW, 1994, SCIENCE, V265, P648, DOI 10.1126/science.8036512; Romoli M, 2019, ANN CLIN TRANSL NEUR, V6, P2261, DOI 10.1002/acn3.50919; Sarchielli P, 2007, J NEUROIMMUNOL, V188, P146, DOI 10.1016/j.jneuroim.2007.05.021; Sato S, 2011, RHEUMATOLOGY, V50, P2142, DOI 10.1093/rheumatology/ker272; Schwab N, 2009, BRAIN, V132, P1236, DOI 10.1093/brain/awp003; Shen CH, 2020, ANN CLIN TRANSL NEUR, V7, P1392, DOI 10.1002/acn3.51137; Sierra-Paredes German, 2007, CNS & Neurological Disorders-Drug Targets, V6, P288; Slota C, 2015, BRAIN BEHAV IMMUN, V46, P168, DOI 10.1016/j.bbi.2015.01.015; Solaro Claudio, 2006, Haematologica, V91, pECR62; Spatola M, 2017, CURR OPIN NEUROL, V30, P345, DOI 10.1097/WCO.0000000000000449; Spatola M, 2017, NEUROLOGY, V88, P1012, DOI 10.1212/WNL.0000000000003713; Steenland HW, 2008, EUR J NEUROSCI, V27, P1166, DOI 10.1111/j.1460-9568.2008.06078.x; Steup-Beekman GM, 2007, LUPUS, V16, P329, DOI 10.1177/0961203307078224; Suleiman J, 2013, EPILEPSIA, V54, P2091, DOI 10.1111/epi.12405; Tan THL, 2021, EPILEPSIA, V62, P303, DOI 10.1111/epi.16788; Tang C, 2019, FRONT PSYCHIATRY, V10, DOI 10.3389/fpsyt.2019.00913; Tian J, 1999, J NEUROIMMUNOL, V96, P21, DOI 10.1016/S0165-5728(98)00264-1; Tian JD, 2004, J IMMUNOL, V173, P5298, DOI 10.4049/jimmunol.173.8.5298; TWYMAN RE, 1995, NEURON, V14, P755, DOI 10.1016/0896-6273(95)90219-8; van Sonderen A, 2016, NEUROLOGY, V87, P1449; Wahle M, 2001, CYTOKINE, V16, P205, DOI 10.1006/cyto.2001.0965; Whitney KD, 2000, J NEUROSCI, V20, P7307; Wiendl H, 2001, NEUROLOGY, V57, P1511, DOI 10.1212/WNL.57.8.1511; Wright S, 2016, EPILEPSIA, V57, P823, DOI 10.1111/epi.13356; Wu H, 2020, INT IMMUNOPHARMACOL, V88, DOI 10.1016/j.intimp.2020.106922; Yoshio T, 2013, ARTHRITIS RHEUM-US, V65, P457, DOI 10.1002/art.37745	187	0	1	4	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 12	2022	12								762743	10.3389/fimmu.2021.762743	http://dx.doi.org/10.3389/fimmu.2021.762743			28	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YO4NT	35095841	gold, Green Published			2022-12-18	WOS:000747918700001
J	Masuda, A; Lee, JM; Miyata, T; Mon, H; Sato, K; Oyama, K; Sakurai, Y; Yasuda, J; Takahashi, D; Ueda, T; Kato, Y; Nishida, M; Karasaki, N; Kakino, K; Ebihara, T; Nagasato, T; Hino, M; Nakashima, A; Suzuki, K; Tonooka, Y; Tanaka, M; Moriyama, T; Nakatake, H; Fujita, R; Kusakabe, T				Masuda, Akitsu; Lee, Jae Man; Miyata, Takeshi; Mon, Hiroaki; Sato, Keita; Oyama, Kosuke; Sakurai, Yasuteru; Yasuda, Jiro; Takahashi, Daisuke; Ueda, Tadashi; Kato, Yuri; Nishida, Motohiro; Karasaki, Noriko; Kakino, Kohei; Ebihara, Takeru; Nagasato, Takumi; Hino, Masato; Nakashima, Ayaka; Suzuki, Kengo; Tonooka, Yoshino; Tanaka, Miyu; Moriyama, Takato; Nakatake, Hirokazu; Fujita, Ryosuke; Kusakabe, Takahiro			Optimization of SARS-CoV-2 Spike Protein Expression in the Silkworm and Induction of Efficient Protective Immunity by Inoculation With Alum Adjuvants	FRONTIERS IN IMMUNOLOGY			English	Article						SARS-CoV-2; spike (S) protein; silkworm-baculovirus expression vector system; COVID-19; adjuvant; paramylon; Alum	RESPIRATORY SYNDROME CORONAVIRUS; DOUBLE-BLIND; VACCINE; IMMUNOGENICITY; GLYCOPROTEIN; PURIFICATION; ACTIVATION; CLEAVAGE; TRIMERS; PHASE-1	The newly emerged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is causing a spread of coronavirus disease 2019 (COVID-19) globally. In order to end the COVID-19 pandemic, an effective vaccine against SARS-CoV-2 must be produced at low cost and disseminated worldwide. The spike (S) protein of coronaviruses plays a pivotal role in the infection to host cells. Therefore, targeting the S protein is one of the most rational approaches in developing vaccines and therapeutic agents. In this study, we optimized the expression of secreted trimerized S protein of SARS-CoV-2 using a silkworm-baculovirus expression vector system and evaluated its immunogenicity in mice. The results showed that the S protein forming the trimeric structure was the most stable when the chicken cartilage matrix protein was used as the trimeric motif and could be purified in large amounts from the serum of silkworm larvae. The purified S protein efficiently induced antigen-specific antibodies in mouse serum without adjuvant, but its ability to induce neutralizing antibodies was low. After examining several adjuvants, the use of Alum adjuvant was the most effective in inducing strong neutralizing antibody induction. We also examined the adjuvant effect of paramylon from Euglena gracilis when administered with the S protein. Our results highlight the effectiveness and suitable construct design of the S protein produced in silkworms for the subunit vaccine development against SARS-CoV-2.	[Masuda, Akitsu; Mon, Hiroaki; Karasaki, Noriko; Kakino, Kohei; Ebihara, Takeru; Nagasato, Takumi; Tonooka, Yoshino; Tanaka, Miyu; Moriyama, Takato; Kusakabe, Takahiro] Kyushu Univ, Grad Sch Bioresource & Bioenvironm Sci, Lab Insect Genome Sci, Fukuoka, Japan; [Lee, Jae Man] Kyushu Univ, Grad Sch Bioresource & Bioenvironm Sci, Lab Creat Sci Insect Ind, Fukuoka, Japan; [Miyata, Takeshi; Sato, Keita] Kagoshima Univ, Fac Agr, Dept Biochem & Biotechnol, Kagoshima, Japan; [Oyama, Kosuke; Takahashi, Daisuke; Ueda, Tadashi] Kyushu Univ, Fac Pharmaceut Sci, Lab Prot Struct, Funct & Design, Fukuoka, Japan; [Sakurai, Yasuteru; Yasuda, Jiro] Nagasaki Univ, Inst Trop Med, Dept Emerging Infect Dis, Nagasaki, Japan; [Sakurai, Yasuteru; Yasuda, Jiro] Nagasaki Univ, Natl Res Ctr Control & Prevent Infect Dis, Nagasaki, Japan; [Kato, Yuri; Nishida, Motohiro] Kyushu Univ, Grad Sch Pharmaceut Sci, Fukuoka, Japan; [Hino, Masato; Fujita, Ryosuke] Kyushu Univ, Grad Sch Bioresource & Bioenvironm Sci, Lab Sanit Entomol, Fukuoka, Japan; [Nakashima, Ayaka; Suzuki, Kengo] Euglena Co Ltd, Res & Dev Dept, Tokyo, Japan; [Nakatake, Hirokazu] KAICO Ltd, Prod Dept, Fukuoka, Japan	Kyushu University; Kyushu University; Kagoshima University; Kyushu University; Nagasaki University; Nagasaki University; Kyushu University; Kyushu University	Kusakabe, T (corresponding author), Kyushu Univ, Grad Sch Bioresource & Bioenvironm Sci, Lab Insect Genome Sci, Fukuoka, Japan.	kusaleibe@agr.kyushu-u.ac.jp		Masuda, Akitsu/0000-0001-9402-924X	MEXT (Ministry of Education, Culture, Sports, Science, and Technology) Grant; Kyushu University; Sumitomo Mitsui Trust Bank	MEXT (Ministry of Education, Culture, Sports, Science, and Technology) Grant(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Kyushu University; Sumitomo Mitsui Trust Bank	This work was supported by MEXT (Ministry of Education, Culture, Sports, Science, and Technology) Grant, Kyushu University operating expenses, and under the "COVID-19 Drug and Vaccine Development Donation Account" Project from Sumitomo Mitsui Trust Bank.	Arunachalam PS, 2021, NATURE, V594, P253, DOI 10.1038/s41586-021-03530-2; Belouzard S, 2009, P NATL ACAD SCI USA, V106, P5871, DOI 10.1073/pnas.0809524106; Bolles M, 2011, J VIROL, V85, P12201, DOI 10.1128/JVI.06048-11; Budroni S, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-021-00337-0; Burkard C, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004502; Chan GCF, 2009, J HEMATOL ONCOL, V2, DOI 10.1186/1756-8722-2-25; Chappell KJ, 2021, LANCET INFECT DIS, V21, P1383, DOI 10.1016/S1473-3099(21)00200-0; Chi XY, 2020, SCIENCE, V369, P650, DOI 10.1126/science.abc6952; Coffman RL, 2010, IMMUNITY, V33, P492, DOI 10.1016/j.immuni.2010.10.002; Dames SA, 1998, NAT STRUCT BIOL, V5, P687, DOI 10.1038/1382; Dejnirattisai W, 2021, CELL, V184, P2183, DOI 10.1016/j.cell.2021.02.032; Engler C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003647; Esposito D, 2020, PROTEIN EXPRES PURIF, V174, DOI 10.1016/j.pep.2020.105686; Fujita R, 2020, BIOCHEM BIOPH RES CO, V529, P257, DOI 10.1016/j.bbrc.2020.06.020; HAUDENSCHILD DR, 1995, J BIOL CHEM, V270, P23150, DOI 10.1074/jbc.270.39.23150; Hino M, 2016, J ASIA-PAC ENTOMOL, V19, P313, DOI 10.1016/j.aspen.2016.03.014; Hoffmann M, 2020, MOL CELL, V78, P779, DOI 10.1016/j.molcel.2020.04.022; Hsieh CL, 2020, SCIENCE, V369, P1501, DOI 10.1126/science.abd0826; Tan HX, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21665-8; INUI H, 1982, FEBS LETT, V150, P89, DOI 10.1016/0014-5793(82)81310-0; Iwasaki A, 2015, NAT IMMUNOL, V16, P343, DOI 10.1038/ni.3123; Kato T, 2010, APPL MICROBIOL BIOT, V85, P459, DOI 10.1007/s00253-009-2267-2; Krammer F, 2020, NATURE, V586, P516, DOI 10.1038/s41586-020-2798-3; Kuo TY, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-77077-z; Letko M, 2020, NAT MICROBIOL, V5, P562, DOI [10.1038/s41564-020-0688-y, 10.1101/2020.01.22.915660]; Li TT, 2020, EMERG MICROBES INFEC, V9, P2076, DOI 10.1080/22221751.2020.1821583; Liang JG, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21634-1; Liang ZH, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.589833; Liu LH, 2020, NATURE, V584, P450, DOI 10.1038/s41586-020-2571-7; Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8; Maeda Takuji, 2005, Journal of Insect Biotechnology and Sericology, V74, P21; Malladi SK, 2021, ACS INFECT DIS, V7, P2546, DOI 10.1021/acsinfecdis.1c00276; Masuda A, 2021, VET RES, V52, DOI 10.1186/s13567-021-00971-5; Masuda A, 2018, J GEN VIROL, V99, P917, DOI 10.1099/jgv.0.001087; Masuda A, 2015, MOL BIOTECHNOL, V57, P735, DOI 10.1007/s12033-015-9866-1; Matsuyama S, 2020, P NATL ACAD SCI USA, V117, P7001, DOI 10.1073/pnas.2002589117; Mitsudome T, 2014, APPL BIOCHEM BIOTECH, V172, P3978, DOI 10.1007/s12010-014-0814-5; Miyata T, 2011, INFECT IMMUN, V79, P4260, DOI 10.1128/IAI.05214-11; Morokuma D, 2015, J ASIA-PAC ENTOMOL, V18, P303, DOI 10.1016/j.aspen.2015.03.006; Mulligan MJ, 2020, NATURE, V586, P589, DOI 10.1038/s41586-020-2639-4; Nerome K, 2015, VACCINE, V33, P117, DOI 10.1016/j.vaccine.2014.11.009; Ono Chikako, 2007, Journal of Insect Biotechnology and Sericology, V76, P161; Park JE, 2016, P NATL ACAD SCI USA, V113, P12262, DOI 10.1073/pnas.1608147113; Peng S, 2020, ADV MATER, V32, DOI 10.1002/adma.202004210; Petkar KC, 2021, PHARMACEUTICS, V13, DOI 10.3390/pharmaceutics13040455; Pulendran B, 2021, NAT REV DRUG DISCOV, V20, P454, DOI 10.1038/s41573-021-00163-y; Ramasamy MN, 2020, LANCET, V396, P1979, DOI 10.1016/S0140-6736(20)32466-1; Rendic D, 2008, CROAT CHEM ACTA, V81, P7; Richmond P, 2021, LANCET, V397, P682, DOI 10.1016/S0140-6736(21)00241-5; Rogers TF, 2020, SCIENCE, V369, P956, DOI 10.1126/science.abc7520; Russo R, 2017, FOOD SCI NUTR, V5, P205, DOI 10.1002/fsn3.383; Selvarajah S, 2008, AIDS RES HUM RETROV, V24, P301, DOI 10.1089/aid.2007.0158; Shalash AO, 2021, ADV SCI, V8, DOI 10.1002/advs.202100985; Shang J, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007009; Sliepen K, 2015, J BIOL CHEM, V290, P7436, DOI 10.1074/jbc.M114.620534; Tseng CT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035421; Utomo DIS, 2020, AMB EXPRESS, V10, DOI 10.1186/s13568-020-01087-3; Walls AC, 2020, CELL, V181, P281, DOI [10.1016/j.cell.2020.02.058, 10.1016/j.cell.2020.11.032]; Walls AC, 2016, NAT STRUCT MOL BIOL, V23, P899, DOI 10.1038/nsmb.3293; Watanabe Y, 2020, SCIENCE, V369, P330, DOI 10.1126/science.abb9983; Worzner K, 2021, EBIOMEDICINE, V63, DOI 10.1016/j.ebiom.2020.103197; Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]; Wrapp D, 2019, J VIROL, V93, DOI 10.1128/JVI.00923-19; Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3; Yang JY, 2020, NATURE, V586, P572, DOI 10.1038/s41586-020-2599-8; Yang XZ, 2002, J VIROL, V76, P4634, DOI 10.1128/JVI.76.9.4634-4642.2002; Yang XZ, 2000, J VIROL, V74, P5716, DOI 10.1128/JVI.74.12.5716-5725.2000; Zhang Y, 2021, MOL CELL PROTEOMICS, V20, DOI 10.1074/mcp.RA120.002295; Zheng ZH, 2020, J INFECTION, V81, pE16, DOI 10.1016/j.jinf.2020.04.021	70	0	0	4	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 12	2022	12								803647	10.3389/fimmu.2021.803647	http://dx.doi.org/10.3389/fimmu.2021.803647			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2C5BA	35095889	gold, Green Published			2022-12-18	WOS:000810882700001
J	Moreira, TG; Matos, KTF; De Paula, GS; Santana, TMM; Da Mata, RG; Pansera, FC; Cortina, AS; Spinola, MG; Baecher-Allan, CM; Keppeke, GD; Jacob, J; Palejwala, V; Chen, KR; Izzy, S; Healey, BC; Rezende, RM; Dedivitis, RA; Shailubhai, K; Weiner, HL				Moreira, Thais G.; Matos, Kimble T. F.; De Paula, Giovana S.; Santana, Thais M. M.; Da Mata, Raquel G.; Pansera, Fernando C.; Cortina, Andre S.; Spinola, Marcelle G.; Baecher-Allan, Clare M.; Keppeke, Gerson D.; Jacob, Jules; Palejwala, Vaseem; Chen, Karen; Izzy, Saef; Healey, Brian C.; Rezende, Rafael M.; Dedivitis, Rogerio A.; Shailubhai, Kunwar; Weiner, Howard L.			Nasal Administration of Anti-CD3 Monoclonal Antibody (Foralumab) Reduces Lung Inflammation and Blood Inflammatory Biomarkers in Mild to Moderate COVID-19 Patients: A Pilot Study (vol 12, 709861, 2021)	FRONTIERS IN IMMUNOLOGY			English	Correction						foralumab; anti-CD3; COVID-19; SARS-CoV-2; immune responses			[Moreira, Thais G.; Baecher-Allan, Clare M.; Izzy, Saef; Healey, Brian C.; Rezende, Rafael M.; Weiner, Howard L.] Harvard Med Sch, Brigham & Womens Hosp, Ann Romney Ctr Neurol Dis, Dept Neurol, Boston, MA 02115 USA; [Matos, Kimble T. F.; Spinola, Marcelle G.; Keppeke, Gerson D.] Univ Fed Sao Paulo, Escola Paulista Med, Sao Paulo, Brazil; [De Paula, Giovana S.; Santana, Thais M. M.; Da Mata, Raquel G.; Pansera, Fernando C.; Cortina, Andre S.; Dedivitis, Rogerio A.] Santa Casa Misericordia Santos, Santos, Brazil; [Jacob, Jules; Palejwala, Vaseem; Shailubhai, Kunwar] Tiziana Life Sci, Doylestown, PA USA; [Chen, Karen] Harvard Med Sch, Boston Childrens Hosp, Dept Radiol, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Universidade Federal de Sao Paulo (UNIFESP); Harvard University; Boston Children's Hospital; Harvard Medical School	Weiner, HL (corresponding author), Harvard Med Sch, Brigham & Womens Hosp, Ann Romney Ctr Neurol Dis, Dept Neurol, Boston, MA 02115 USA.	hweiner@rics.bwh.harvard.edu						MOREIRA TG, 2022, FRONTIERS IMMUNOLOGY	1	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 12	2022	12								815812	10.3389/fimmu.2021.815812	http://dx.doi.org/10.3389/fimmu.2021.815812			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YO7RA	35095916	Green Published, gold			2022-12-18	WOS:000748132500001
J	Sesti-Costa, R; Silva, JL; Barcellini, W; Le Van Kim, C; Conran, N				Sesti-Costa, Renata; Silva-Filho, Joao Luiz; Barcellini, Wilma; Le Van Kim, Caroline; Conran, Nicola			Editorial: Inflammatory Mechanisms of Hemolytic Diseases	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						hemolysis; inflammation; anemia; DAMP; immune response			[Sesti-Costa, Renata; Conran, Nicola] Univ Campinas UNICAMP, Hematol & Hemotherapy Ctr, Campinas, Brazil; [Silva-Filho, Joao Luiz] Univ Glasgow, Inst Infect Immun & Inflammat, Wellcome Ctr Mol Parasitol, Glasgow, Lanark, Scotland; [Barcellini, Wilma] Fdn Ist Ricovero Cura Carattere Sci IRCCS Ca Gran, Hematol Unit, Milan, Italy; [Le Van Kim, Caroline] Univ Paris, Paris, France; [Le Van Kim, Caroline] Univ Antilles, INSERM, BIGR, Paris, France	Universidade Estadual de Campinas; University of Glasgow; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Sesti-Costa, R (corresponding author), Univ Campinas UNICAMP, Hematol & Hemotherapy Ctr, Campinas, Brazil.	renata.sesti@gmail.com	Sesti-Costa, Renata/H-9115-2012	Sesti-Costa, Renata/0000-0002-7098-2850	FAPESP [2019/09704-7, 2021/05191-5, 2019/18886-1]	FAPESP(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP))	Funding RS-C and NC are funded by FAPESP, grant numbers 2019/09704-7 and 2021/05191-5 granted to RS-C, and 2019/18886-1 granted to NC.		0	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 12	2022	12								834527	10.3389/fimmu.2021.834527	http://dx.doi.org/10.3389/fimmu.2021.834527			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YO7AV	35095935	gold, Green Accepted, Green Published			2022-12-18	WOS:000748090400001
J	Tian, GY; Li, MQ; Lv, GY				Tian, Guangyao; Li, Mingqian; Lv, Guoyue			Analysis of T-Cell Receptor Repertoire in Transplantation: Fingerprint of T Cell-mediated Alloresponse	FRONTIERS IN IMMUNOLOGY			English	Review						alloreactive; T-cell receptor repertoire; transplant; biomarker; high-throughput sequencing	VERSUS-HOST-DISEASE; TCR REPERTOIRE; OPERATIONAL TOLERANCE; CROSS-REACTIVITY; IN-VIVO; MEMORY; ANTIGEN; REJECTION; NAIVE; ALLORECOGNITION	T cells play a key role in determining allograft function by mediating allogeneic immune responses to cause rejection, and recent work pointed their role in mediating tolerance in transplantation. The unique T-cell receptor (TCR) expressed on the surface of each T cell determines the antigen specificity of the cell and can be the specific fingerprint for identifying and monitoring. Next-generation sequencing (NGS) techniques provide powerful tools for deep and high-throughput TCR profiling, and facilitate to depict the entire T cell repertoire profile and trace antigen-specific T cells in circulation and local tissues. Tailing T cell transcriptomes and TCR sequences at the single cell level provides a full landscape of alloreactive T-cell clones development and biofunction in alloresponse. Here, we review the recent advances in TCR sequencing techniques and computational tools, as well as the recent discovery in overall TCR profile and antigen-specific T cells tracking in transplantation. We further discuss the challenges and potential of using TCR sequencing-based assays to profile alloreactive TCR repertoire as the fingerprint for immune monitoring and prediction of rejection and tolerance.	[Tian, Guangyao; Li, Mingqian; Lv, Guoyue] First Hosp Jilin Univ, Dept Hepatobiliary & Pancreat Surg, Changchun, Peoples R China	Jilin University	Li, MQ; Lv, GY (corresponding author), First Hosp Jilin Univ, Dept Hepatobiliary & Pancreat Surg, Changchun, Peoples R China.	mingqianli@jlu.edu.cn; lvgy@jlu.edu.cn			National Natural Science Foundation of China [81901627, U20A20360]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	Funding Grants from Natural Science Foundation of China (grant number: 81901627 and U20A20360) will provide financial support for the open access publication fees of this paper.	Akue AD, 2012, J IMMUNOL, V188, P2516, DOI 10.4049/jimmunol.1102213; Alachkar H, 2016, BMC NEPHROL, V17, DOI 10.1186/s12882-016-0395-3; Arstila TP, 1999, SCIENCE, V286, P958, DOI 10.1126/science.286.5441.958; Attaf M, 2015, CELL MOL IMMUNOL, V12, P391, DOI 10.1038/cmi.2014.134; Bagaev DV, 2020, NUCLEIC ACIDS RES, V48, pD1057, DOI 10.1093/nar/gkz874; Beck RC, 2005, BRIT J HAEMATOL, V129, P411, DOI 10.1111/j.1365-2141.2005.05472.x; Benichou G, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00170; Bestard O, 2008, J AM SOC NEPHROL, V19, P1419, DOI 10.1681/ASN.2007050539; Bettens F, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.588741; Briney B, 2019, NATURE, V566, P393, DOI 10.1038/s41586-019-0879-y; Brook MO, 2006, TRANSPLANTATION, V82, P1, DOI 10.1097/01.tp.0000226082.17507.da; Brouard S, 2005, AM J TRANSPLANT, V5, P330, DOI 10.1111/j.1600-6143.2004.00700.x; Brunstein CG, 2011, BLOOD, V117, P1061, DOI 10.1182/blood-2010-07-293795; Chalasani G, 2002, P NATL ACAD SCI USA, V99, P6175, DOI 10.1073/pnas.092596999; Christley S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00976; COCHET M, 1992, EUR J IMMUNOL, V22, P2639, DOI 10.1002/eji.1830221025; Cole DK, 2014, J BIOL CHEM, V289, P628, DOI 10.1074/jbc.M113.522110; Correia-Neves M, 2001, IMMUNITY, V14, P21, DOI 10.1016/S1074-7613(01)00086-3; Corrie BD, 2018, IMMUNOL REV, V284, P24, DOI 10.1111/imr.12666; Cui JH, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02729; D'Orsogna LJ, 2012, IMMUNOGENETICS, V64, P77, DOI 10.1007/s00251-011-0590-0; Dash P, 2017, NATURE, V547, P89, DOI 10.1038/nature22383; De Simone M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01638; DeWolf S, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.121256; Di Ianni M, 2011, BLOOD, V117, P3921, DOI 10.1182/blood-2010-10-311894; Dziubianau M, 2013, AM J TRANSPLANT, V13, P2842, DOI 10.1111/ajt.12431; Egorov ES, 2015, J IMMUNOL, V194, P6155, DOI 10.4049/jimmunol.1500215; Elhanati Y, 2014, P NATL ACAD SCI USA, V111, P9875, DOI 10.1073/pnas.1409572111; Emerson RO, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111943; Faint JM, 1999, J IMMUNOL METHODS, V225, P53, DOI 10.1016/S0022-1759(99)00027-7; Felix NJ, 2007, NAT REV IMMUNOL, V7, P942, DOI 10.1038/nri2200; Ferreira LMR, 2013, INT REV IMMUNOL, V32, P223, DOI 10.3109/08830185.2013.783831; Fischer M, 2017, EUR J IMMUNOL, V47, P1220, DOI 10.1002/eji.201646826; Fontenot JD, 2017, J IMMUNOL, V198, P986, DOI 10.1038/ni904; Frentsch M, 2005, NAT MED, V11, P1118, DOI 10.1038/nm1292; Fribourg M, 2019, KIDNEY INT, V96, P436, DOI 10.1016/j.kint.2019.01.040; Fu JN, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI141698; Fu JN, 2019, CELL STEM CELL, V24, P227, DOI 10.1016/j.stem.2018.11.007; GALLON L, 1995, TRANSPLANTATION, V59, P612; Gascoigne NRJ, 2016, ANNU REV CELL DEV BI, V32, P327, DOI 10.1146/annurev-cellbio-111315-125324; Giudicelli W, 2005, NUCLEIC ACIDS RES, V33, pD256, DOI 10.1093/nar/gki010; Glanville J, 2017, NATURE, V547, P94, DOI 10.1038/nature22976; Golshayan D, 2010, AM J TRANSPLANT, V10, P1749, DOI 10.1111/j.1600-6143.2010.03180.x; Gould DS, 1999, IMMUNOL TODAY, V20, P77, DOI 10.1016/S0167-5699(98)01394-2; Habal MV, 2021, AM J TRANSPLANT, V21, P1465, DOI 10.1111/ajt.16333; Haigh OL, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22041625; Han A, 2014, NAT BIOTECHNOL, V32, P684, DOI 10.1038/nbt.2938; Han FF, 2020, SCAND J IMMUNOL, V92, DOI 10.1111/sji.12912; Heeger PS, 1999, J IMMUNOL, V163, P2267; Heutinck KM, 2016, AM J TRANSPLANT, V16, P1480, DOI 10.1111/ajt.13618; Hirokawa M, 2002, BONE MARROW TRANSPL, V30, P915, DOI 10.1038/sj.bmt.1703730; Huang H, 2020, NAT BIOTECHNOL, V38, P1194, DOI 10.1038/s41587-020-0505-4; Ignatowicz L, 1996, CELL, V84, P521, DOI 10.1016/S0092-8674(00)81028-4; Jackson KJL, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00263; Jung D, 2004, CELL, V116, P299, DOI 10.1016/S0092-8674(04)00039-X; Kanakry CG, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.86252; Kim SM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037338; Knight SC, 1998, EUR J IMMUNOL, V28, P1636; Koyama D, 2019, BIOL BLOOD MARROW TR, V25, P417, DOI 10.1016/j.bbmt.2018.10.012; Krangel MS, 2009, CURR OPIN IMMUNOL, V21, P133, DOI 10.1016/j.coi.2009.03.009; Li S, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3333; Lim MQ, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02225; Liu JJ, 2021, CELL BIOL INT, V45, P1220, DOI 10.1002/cbin.11562; Looney TJ, 2020, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02985; Lu JH, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08906-7; Macdonald WA, 2009, IMMUNITY, V31, P897, DOI 10.1016/j.immuni.2009.09.025; Macedo C, 2009, AM J TRANSPLANT, V9, P2057, DOI 10.1111/j.1600-6143.2009.02742.x; Madi A, 2017, ELIFE, V6, DOI 10.7554/eLife.22057; Mahe E, 2018, J CLIN PATHOL, V71, P195, DOI 10.1136/jclinpath-2017-204761; Margolis DA, 2000, BIOL BLOOD MARROW TR, V6, P408, DOI 10.1016/S1083-8791(00)70017-6; Martelli MF, 2014, BLOOD, V124, P638, DOI 10.1182/blood-2014-03-564401; Mateus J, 2020, SCIENCE, V370, P89, DOI 10.1126/science.abd3871; McDaniel JR, 2016, NAT PROTOC, V11, P429, DOI 10.1038/nprot.2016.024; Mederacke YS, 2021, J HEPATOL, V74, P1167, DOI 10.1016/j.jhep.2020.12.014; Mederacke YS, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-37218-x; Michalek J, 2003, LANCET, V361, P1183, DOI 10.1016/S0140-6736(03)12917-0; Mifsud NA, 2010, TRANSPLANTATION, V90, P1439, DOI 10.1097/TP.0b013e3181ff4ff3; Miqueu P, 2010, EUR J IMMUNOL, V40, P3280, DOI 10.1002/eji.201040301; Moore C, 2020, AM J TRANSPLANT, V20, P1431, DOI 10.1111/ajt.15737; Morris GP, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005452; Morris GP, 2009, J IMMUNOL, V182, P6639, DOI 10.4049/jimmunol.0900638; Morris H, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.3010760; Munson DJ, 2016, P NATL ACAD SCI USA, V113, P8272, DOI 10.1073/pnas.1606994113; Nadazdin O, 2010, AM J TRANSPLANT, V10, P1375, DOI 10.1111/j.1600-6143.2010.03119.x; Nguyen Phuong, 2011, BMC Genomics, V12, P106, DOI 10.1186/1471-2164-12-106; Ni PP, 2014, J IMMUNOL, V193, P1778, DOI 10.4049/jimmunol.1400532; Oberbarnscheidt MH, 2008, AM J TRANSPLANT, V8, P1809, DOI 10.1111/j.1600-6143.2008.02335.x; Pasetto A, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.689091; Patel SR, 2013, TRANSFUS MED REV, V27, P241, DOI 10.1016/j.tmrv.2013.08.002; Pogorelyy MV, 2019, PLOS BIOL, V17, DOI 10.1371/journal.pbio.3000314; Pulko V, 2016, NAT IMMUNOL, V17, P966, DOI 10.1038/ni.3483; Qi Q, 2014, P NATL ACAD SCI USA, V111, P13139, DOI 10.1073/pnas.1409155111; Rechavi E, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa0072; Redmond D, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0335-7; Rossjohn J, 2015, ANNU REV IMMUNOL, V33, P169, DOI 10.1146/annurev-immunol-032414-112334; Roussey-Kesler G, 2006, AM J TRANSPLANT, V6, P736, DOI 10.1111/j.1600-6143.2006.01280.x; Rubelt F, 2017, NAT IMMUNOL, V18, P1274, DOI 10.1038/ni.3873; Rudd BD, 2010, J IMMUNOL, V184, P2958, DOI 10.4049/jimmunol.0903493; Salameire D, 2009, CYTOM PART A, V75A, P743, DOI 10.1002/cyto.a.20767; Sanchez-Fueyo A, 2016, AM J TRANSPLANT, V16, P1953, DOI 10.1111/ajt.13702; Sant'Angelo DB, 1998, IMMUNITY, V9, P179, DOI 10.1016/S1074-7613(00)80600-7; Savage TM, 2020, AM J TRANSPLANT, V20, P538, DOI 10.1111/ajt.15592; Schenk AD, 2008, AM J TRANSPLANT, V8, P1652, DOI 10.1111/j.1600-6143.2008.02302.x; Schober K, 2018, IMMUNOL REV, V283, P113, DOI 10.1111/imr.12654; Schuldt NJ, 2019, J IMMUNOL, V202, P637, DOI 10.4049/jimmunol.1800904; Scott DR, 2011, J MOL BIOL, V414, P385, DOI 10.1016/j.jmb.2011.10.006; Setliff I, 2019, CELL, V179, P1636, DOI 10.1016/j.cell.2019.11.003; Sewell AK, 2012, NAT REV IMMUNOL, V12, P668, DOI 10.1038/nri3279; Shalek AK, 2013, NATURE, V498, P236, DOI 10.1038/nature12172; Shugay M, 2018, NUCLEIC ACIDS RES, V46, pD419, DOI 10.1093/nar/gkx760; Sims JS, 2016, P NATL ACAD SCI USA, V113, pE3529, DOI 10.1073/pnas.1601012113; Six A, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00413; Smith-Garvin JE, 2009, ANNU REV IMMUNOL, V27, P591, DOI 10.1146/annurev.immunol.021908.132706; Smyth LA, 2006, TRANSPLANTATION, V82, pS15, DOI 10.1097/01.tp.0000231347.06149.ca; Son ET, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI146771; Spindler MJ, 2020, NAT BIOTECHNOL, V38, P609, DOI 10.1038/s41587-020-0438-y; Steger U, 2008, TRANSPLANTATION, V85, P1339, DOI 10.1097/TP.0b013e31816dd64a; Stervbo U, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00767; Suchin EJ, 2001, J IMMUNOL, V166, P973, DOI 10.4049/jimmunol.166.2.973; Surh CD, 2008, IMMUNITY, V29, P848, DOI 10.1016/j.immuni.2008.11.002; Taubert R, 2016, AM J TRANSPLANT, V16, P1285, DOI 10.1111/ajt.13617; Theil A, 2015, CYTOTHERAPY, V17, P473, DOI 10.1016/j.jcyt.2014.11.005; Tickotsky N, 2017, BIOINFORMATICS, V33, P2924, DOI 10.1093/bioinformatics/btx286; Todo S, 2016, HEPATOLOGY, V64, P632, DOI 10.1002/hep.28459; Tran DQ, 2009, P NATL ACAD SCI USA, V106, P13445, DOI 10.1073/pnas.0901944106; Trapnell C, 2015, GENOME RES, V25, P1491, DOI 10.1101/gr.190595.115; Valujskikh A, 2010, AM J TRANSPLANT, V10, P1117, DOI 10.1111/j.1600-6143.2010.03087.x; van der Merwe PA, 2011, NAT REV IMMUNOL, V11, P47, DOI 10.1038/nri2887; van Dijk EL, 2014, TRENDS GENET, V30, P418, DOI 10.1016/j.tig.2014.07.001; Venturini S, 2006, EUR J IMMUNOL, V36, P27, DOI 10.1002/eji.200425767; Verdijk RM, 2004, BLOOD, V103, P1961, DOI 10.1182/blood-2003-05-1625; Wang B, 2018, NAT BIOTECHNOL, V36, P152, DOI 10.1038/nbt.4052; Wang PP, 2021, GENOMICS, V113, P456, DOI 10.1016/j.ygeno.2020.12.036; Wang Y, 2017, P NATL ACAD SCI USA, V114, pE4792, DOI 10.1073/pnas.1700459114; Warren RL, 2011, GENOME RES, V21, P790, DOI 10.1101/gr.115428.110; Weinreich MA, 2008, J IMMUNOL, V181, P2265, DOI 10.4049/jimmunol.181.4.2265; Wu AR, 2014, NAT METHODS, V11, P41, DOI 10.1038/nmeth.2694; Xu XY, 2020, CELL MOL IMMUNOL, V17, P193, DOI 10.1038/s41423-020-0367-1; Yap M, 2014, J AM SOC NEPHROL, V25, P1856, DOI 10.1681/ASN.2013080848; Yew PY, 2015, BONE MARROW TRANSPL, V50, P1227, DOI 10.1038/bmt.2015.133; Zhang HY, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-25006-7; Zhang HY, 2020, CLIN CANCER RES, V26, P1359, DOI 10.1158/1078-0432.CCR-19-3249; Zhang L, 2018, NATURE, V564, P268, DOI 10.1038/s41586-018-0694-x; Zhang W, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abf5835; Zhang Y, 2005, J IMMUNOL, V174, P3051, DOI 10.4049/jimmunol.174.5.3051; Ziegenhain C, 2017, MOL CELL, V65, P631, DOI 10.1016/j.molcel.2017.01.023; Zuber J, 2016, SCI IMMUNOL, V1, DOI 10.1126/sciimmunol.aah3732; Zuniga-Pflucker JC, 2004, NAT REV IMMUNOL, V4, P67, DOI 10.1038/nri1257; Zvyagin IV, 2014, P NATL ACAD SCI USA, V111, P5980, DOI 10.1073/pnas.1319389111	149	0	0	5	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 12	2022	12								778559	10.3389/fimmu.2021.778559	http://dx.doi.org/10.3389/fimmu.2021.778559			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YO4PS	35095851	Green Published, gold			2022-12-18	WOS:000747923800001
J	Wang, YL; Cil, C; Harnett, MM; Pineda, MA				Wang, Yilin; cil, Caglar; Harnett, Margaret M.; Pineda, Miguel A.			Cytohesin-2/ARNO: A Novel Bridge Between Cell Migration and Immunoregulation in Synovial Fibroblasts	FRONTIERS IN IMMUNOLOGY			English	Article						ARNO; synovial fibroblast (FLS); inflammation; arthritis (including rheumatoid arthritis); cytohesin 2	SMALL GTPASE ARF6; DOWNSTREAM ACTIVATION; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; ACTIN CYTOSKELETON; E-CADHERIN; ADHESION; ARTHRITIS; CYTOKINE; PROTEIN; DIFFERENTIATION	The guanine nucleotide exchange factor cytohesin-2 (ARNO) is a major activator of the small GTPase ARF6 that has been shown to play an important role(s) in cell adhesion, migration and cytoskeleton reorganization in various cell types and models of disease. Interestingly, dysregulated cell migration, in tandem with hyper-inflammatory responses, is one of the hallmarks associated with activated synovial fibroblasts (SFs) during chronic inflammatory joint diseases, like rheumatoid arthritis. The role of ARNO in this process has previously been unexplored but we hypothesized that the pro-inflammatory milieu of inflamed joints locally induces activation of ARNO-mediated pathways in SFs, promoting an invasive cell phenotype that ultimately leads to bone and cartilage damage. Thus, we used small interference RNA to investigate the impact of ARNO on the pathological migration and inflammatory responses of murine SFs, revealing a fully functional ARNO-ARF6 pathway which can be rapidly activated by IL-1 beta. Such signalling promotes cell migration and formation of focal adhesions. Unexpectedly, ARNO was also shown to modulate SF-inflammatory responses, dictating their precise cytokine and chemokine expression profile. Our results uncover a novel role for ARNO in SF-dependent inflammation, that potentially links pathogenic migration with initiation of local joint inflammation, offering new approaches for targeting the fibroblast compartment in chronic arthritis and joint disease.	[Wang, Yilin; cil, Caglar; Harnett, Margaret M.; Pineda, Miguel A.] Univ Glasgow, Inst Infect Immun & Inflammat, Glasgow, Lanark, Scotland; [Pineda, Miguel A.] Res Inflammatory Arthrit Ctr Versus Arthrit RACE, Glasgow, Lanark, Scotland	University of Glasgow	Pineda, MA (corresponding author), Univ Glasgow, Inst Infect Immun & Inflammat, Glasgow, Lanark, Scotland.; Pineda, MA (corresponding author), Res Inflammatory Arthrit Ctr Versus Arthrit RACE, Glasgow, Lanark, Scotland.	miguel.pineda@glasgow.ac.uk		Cil, Caglar/0000-0001-7142-0342	Versus Arthritis [21221]; China Scholarship Council (CSC); YLSY Turkish Ministry of National Education Study Abroad Programme	Versus Arthritis(Versus Arthritis); China Scholarship Council (CSC)(China Scholarship Council); YLSY Turkish Ministry of National Education Study Abroad Programme	The work was funded by a Career Development award to MP from Versus Arthritis (21221), a China Scholarship Council (CSC) PhD scholarship awarded to YW and a YLSY Turkish Ministry of National Education Study Abroad Programme awarded to CC.	Al-Riyami L, 2013, J MED CHEM, V56, P9982, DOI 10.1021/jm401251p; Barilla ML, 2000, SEMIN ARTHRITIS RHEU, V29, P252, DOI 10.1016/S0049-0172(00)80012-8; Boehm T, 2003, EMBO J, V22, P1014, DOI 10.1093/emboj/cdg101; Brown FD, 2001, J CELL BIOL, V154, P1007, DOI 10.1083/jcb.200103107; Chang HY, 2002, P NATL ACAD SCI USA, V99, P12877, DOI 10.1073/pnas.162488599; Chang SK, 2011, P NATL ACAD SCI USA, V108, P8402, DOI 10.1073/pnas.1019437108; Chen PW, 2014, J BIOL CHEM, V289, P30237, DOI 10.1074/jbc.M114.596155; Cheng F, 2016, P NATL ACAD SCI USA, V113, pE4320, DOI 10.1073/pnas.1519197113; Corbet M, 2021, PLOS PATHOG, V17, DOI 10.1371/journal.ppat.1010069; Croft AP, 2019, NATURE, V570, P246, DOI 10.1038/s41586-019-1263-7; Culemann S, 2019, NATURE, V572, P670, DOI 10.1038/s41586-019-1471-1; Dana RR, 2000, J BIOL CHEM, V275, P32566, DOI 10.1074/jbc.M005406200; Davis CT, 2014, J IMMUNOL, V192, P6045, DOI 10.4049/jimmunol.1400309; Dennis G, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/ar4555; Deon D, 2001, J IMMUNOL, V167, P5395, DOI 10.4049/jimmunol.167.9.5395; Dunphy JL, 2006, CURR BIOL, V16, P315, DOI 10.1016/j.cub.2005.12.032; Emori T, 2017, J IMMUNOL, V199, P3427, DOI 10.4049/jimmunol.1700941; Ewert P, 2010, ARTHRITIS RHEUM-US, V62, P1280, DOI 10.1002/art.27362; Filer A, 2009, ARTHRITIS RHEUM, V60, P1604, DOI 10.1002/art.24574; Frank SR, 1998, MOL BIOL CELL, V9, P3133, DOI 10.1091/mbc.9.11.3133; Frank-Bertoncelj M, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14852; Gamara J, 2020, MEDIAT INFLAMM, V2020, DOI 10.1155/2020/2713074; Heun Y, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-60446-z; Hirano T, 2021, INT IMMUNOL, V33, P127, DOI 10.1093/intimm/dxaa078; Hiroi T, 2006, P NATL ACAD SCI USA, V103, P10672, DOI 10.1073/pnas.0604091103; Kiener HP, 2009, ARTHRITIS RHEUM-US, V60, P1305, DOI 10.1002/art.24453; Klein K, 2015, CURR OPIN RHEUMATOL, V27, P76, DOI 10.1097/BOR.0000000000000128; Koliaraki V, 2020, NAT IMMUNOL, V21, P974, DOI 10.1038/s41590-020-0741-2; Kortylewski M, 2005, NAT MED, V11, P1314, DOI 10.1038/nm1325; Kucukural A, 2019, BMC GENOMICS, V20, DOI 10.1186/s12864-018-5362-x; le Duc Q, 2010, J CELL BIOL, V189, P1107, DOI 10.1083/jcb.201001149; Lee DM, 2007, SCIENCE, V315, P1006, DOI 10.1126/science.1137306; Lee S, 2021, JCI INSIGHT, V6, DOI 10.1172/jci.insight.139190; Lewis MJ, 2019, CELL REP, V28, P2455, DOI 10.1016/j.celrep.2019.07.091; Li CC, 2007, MOL BIOL CELL, V18, P4420, DOI 10.1091/mbc.E07-02-0149; London NR, 2022, ENT-EAR NOSE THROAT, V101, p1S, DOI 10.1177/0145561320986055; Mannell HK, 2012, CARDIOVASC RES, V93, P111, DOI 10.1093/cvr/cvr265; Mizoguchi F, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-02892-y; Moreau K, 2012, J CELL BIOL, V196, P483, DOI 10.1083/jcb.201110114; Morgan EL, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007835; Neumann E, 2018, ANN RHEUM DIS, V77, P1619, DOI 10.1136/annrheumdis-2018-212954; Oh SJ, 2010, J BIOL CHEM, V285, P14610, DOI 10.1074/jbc.M109.043935; Luong P, 2018, ELIFE, V7, DOI 10.7554/eLife.38539; Pineda MA, 2012, ARTHRITIS RHEUM-US, V64, P3168, DOI 10.1002/art.34581; Powelka AM, 2004, TRAFFIC, V5, P20, DOI 10.1111/j.1600-0854.2004.00150.x; Quast T, 2009, BLOOD, V113, P5801, DOI 10.1182/blood-2008-08-176123; Ren CG, 2020, J IMMUNOL, V204, P1012, DOI 10.4049/jimmunol.1901080; Rzepecka J, 2015, J AUTOIMMUN, V60, P59, DOI 10.1016/j.jaut.2015.04.005; Salem JC, 2015, MOL BIOL CELL, V26, P4265, DOI 10.1091/mbc.E15-05-0278; Santy LC, 2001, J CELL BIOL, V154, P599, DOI 10.1083/jcb.200104019; Santy LC, 2005, CURR BIOL, V15, P1749, DOI 10.1016/j.cub.2005.08.052; Sauteur L, 2014, CELL REP, V9, P504, DOI 10.1016/j.celrep.2014.09.024; Shen XY, 2012, P NATL ACAD SCI USA, V109, P14464, DOI 10.1073/pnas.1211877109; Simon AR, 2000, SCIENCE, V290, P144, DOI 10.1126/science.290.5489.144; Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI 10.1093/nar/gky1131; Tat SK, 2009, RHEUMATOLOGY, V48, P1482, DOI 10.1093/rheumatology/kep300; Torii T, 2010, J BIOL CHEM, V285, P24270, DOI 10.1074/jbc.M110.125658; Tunyogi-Csapo M, 2008, ARTHRITIS RHEUM-US, V58, P2397, DOI 10.1002/art.23653; Ufer F, 2016, SCI IMMUNOL, V1, DOI 10.1126/sciimmunol.aaf8665; Van Acker T, 2014, J BIOL CHEM, V289, P1364, DOI 10.1074/jbc.M113.499194; Wang YL, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22365-z; Wei KV, 2020, NATURE, V582, P259, DOI 10.1038/s41586-020-2222-z; Xu XJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004783; Yang J, 2019, MOL MED REP, V20, P4993, DOI 10.3892/mmr.2019.10759; Yang LF, 2017, TOXICOLOGY, V389, P74, DOI 10.1016/j.tox.2017.07.010; Yu HY, 2021, BRIT J CANCER, V125, P1420, DOI 10.1038/s41416-021-01537-0; Zegeye MM, 2018, CELL COMMUN SIGNAL, V16, DOI 10.1186/s12964-018-0268-4; Zhang F, 2019, NAT IMMUNOL, V20, P928, DOI 10.1038/s41590-019-0378-1; Zhou YY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09234-6; Zhu WQ, 2012, NATURE, V492, P252, DOI 10.1038/nature11603	70	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 12	2022	12								809896	10.3389/fimmu.2021.809896	http://dx.doi.org/10.3389/fimmu.2021.809896			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YO5BM	35095899	Green Published, gold, Green Accepted			2022-12-18	WOS:000747954400001
J	Yoshida, KI; Midwood, KS; Orend, G				Yoshida, Kyoko Imanaka; Midwood, Kim S.; Orend, Gertraud			Editorial: Tenascins - Key Players in Tissue Homeostasis and Defense	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						tenascins; extracellular matrix; inflammation; infection; cancer; fibrosis; tissue homeostasis; defense	EXTRACELLULAR-MATRIX PROTEIN; CELLS; ANTIGEN; TENDON; GENE		[Yoshida, Kyoko Imanaka] Mie Univ, Dept Pathol & Matrix Biol, Grad Sch Med, Tsu, Mie, Japan; [Midwood, Kim S.] Univ Oxford, Kennedy Inst Rheumatol, Oxford, England; [Orend, Gertraud] Univ Strasbourg, Inst Hematol & Immunol Federat Med Translat Stras, Tumor Microenvironm Lab, INSERM U1109,Hop Civil, 1 Pl Hop, Strasbourg, France	Mie University; University of Oxford; CHU Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Yoshida, KI (corresponding author), Mie Univ, Dept Pathol & Matrix Biol, Grad Sch Med, Tsu, Mie, Japan.; Midwood, KS (corresponding author), Univ Oxford, Kennedy Inst Rheumatol, Oxford, England.; Orend, G (corresponding author), Univ Strasbourg, Inst Hematol & Immunol Federat Med Translat Stras, Tumor Microenvironm Lab, INSERM U1109,Hop Civil, 1 Pl Hop, Strasbourg, France.	imanaka@med.mie-u.ac.jp; kim.midwood@kennedy.ox.ac.uk; gertraud.orend@inserm.fr	Orend, Gertraud/E-8446-2015	Orend, Gertraud/0000-0003-2522-1195	ANR-MatrixNash; INCa-PLBIO TENMAX; Aviesan Radio 3R; Ligue contre le Cancer CCIRGE;  [INCa-PLBIO TENMAX]	ANR-MatrixNash; INCa-PLBIO TENMAX; Aviesan Radio 3R; Ligue contre le Cancer CCIRGE; 	Funding GO was supported by ANR-MatrixNash, INCa-PLBIO TENMAX, Aviesan Radio 3R, Ligue contre le Cancer CCIRGE.	Albacete-Albacete L, 2020, J CELL BIOL, V219, DOI 10.1083/jcb.202006178; BOURDON MA, 1983, CANCER RES, V43, P2796; BRISTOW J, 1993, J CELL BIOL, V122, P265, DOI 10.1083/jcb.122.1.265; CHIQUET M, 1984, J CELL BIOL, V98, P1926, DOI 10.1083/jcb.98.6.1926; CHIQUETEHRISMANN R, 1986, CELL, V47, P131, DOI 10.1016/0092-8674(86)90374-0; Dawson MRL, 2003, MOL CELL NEUROSCI, V24, P476, DOI 10.1016/S1044-7431(03)00210-0; Deligne C, 2020, CANCER IMMUNOL RES, V8, P368, DOI 10.1158/2326-6066.CIR-19-0276; Dufresne D, 2012, J MED GENET, V49, P451, DOI 10.1136/jmedgenet-2012-100831; Erickson HP, 1993, CURR OPIN CELL BIOL, V5, P869, DOI 10.1016/0955-0674(93)90037-Q; ERICKSON HP, 1984, NATURE, V311, P267, DOI 10.1038/311267a0; Evers MR, 2002, J NEUROSCI, V22, P7177; Forsberg E, 1996, P NATL ACAD SCI USA, V93, P6594, DOI 10.1073/pnas.93.13.6594; Fouda GG, 2013, P NATL ACAD SCI USA, V110, P18220, DOI 10.1073/pnas.1307336110; GRUMET M, 1985, P NATL ACAD SCI USA, V82, P8075, DOI 10.1073/pnas.82.23.8075; Jachetti E, 2015, CANCER RES, V75, P2095, DOI 10.1158/0008-5472.CAN-14-2346; KRUSE J, 1985, NATURE, V316, P146, DOI 10.1038/316146a0; Midwood K, 2009, NAT MED, V15, P774, DOI 10.1038/nm.1987; Mills JT, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01987; Mokone GG, 2005, AM J SPORT MED, V33, P1016, DOI 10.1177/0363546504271986; MOREL Y, 1989, P NATL ACAD SCI USA, V86, P6582, DOI 10.1073/pnas.86.17.6582; Murdamoothoo D, 2021, EMBO MOL MED, V13, DOI 10.15252/emmm.202013270; Pires A, 2020, CANCER IMMUNOL RES, V8, P1520, DOI 10.1158/2326-6066.CIR-20-0070; RATHJEN FG, 1991, DEVELOPMENT, V113, P151; Rauch U, 2005, BIOCHEM BIOPH RES CO, V328, P608, DOI 10.1016/j.bbrc.2005.01.026; SAGA Y, 1992, GENE DEV, V6, P1821, DOI 10.1101/gad.6.10.1821; Saxena M, 2021, J CELL SCI, V134, DOI 10.1242/jcs.258418; Schalkwijk J, 2001, NEW ENGL J MED, V345, P1167, DOI 10.1056/NEJMoa002939; Spenle C, 2020, CANCER IMMUNOL RES, V8, P1122, DOI 10.1158/2326-6066.CIR-20-0074; Weber P, 1998, J NEUROBIOL, V35, P1; Zeng HL, 2021, FEBS J, V288, P5190, DOI 10.1111/febs.15609; Zhao YL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069549	31	0	0	2	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 12	2022	12								834353	10.3389/fimmu.2021.834353	http://dx.doi.org/10.3389/fimmu.2021.834353			4	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YO7PV	35095934	gold, Green Published			2022-12-18	WOS:000748129400001
J	Alim, MA; Njenda, D; Lundmark, A; Kaminska, M; Jansson, L; Eriksson, K; Kats, A; Johannsen, G; Arvidsson, CK; Mydel, PM; Yucel-Lindberg, T				Alim, M. Abdul; Njenda, Duncan; Lundmark, Anna; Kaminska, Marta; Jansson, Leif; Eriksson, Kaja; Kats, Anna; Johannsen, Gunnar; Arvidsson, Catalin Koro; Mydel, Piotr M.; Yucel-Lindberg, Tulay			Pleckstrin Levels Are Increased in Patients with Chronic Periodontitis and Regulated via the MAP Kinase-p38 alpha Signaling Pathway in Gingival Fibroblasts	FRONTIERS IN IMMUNOLOGY			English	Article						chronic periodontitis; pleckstrin; PLEK; inflammation; MAP kinase pathway; gingival fibroblasts; mPGES-1	PROTEIN-KINASE-C; PROSTAGLANDIN-E SYNTHASE-1; P47 PHOSPHOPROTEIN; PHOSPHORYLATION; INHIBITION; BIOMARKERS; INDUCTION; SUBSTRATE; TARGET; CELLS	Chronic periodontitis (CP) is a bacteria-driven inflammatory disease characterized by the breakdown of gingival tissue, the periodontal ligament, and alveolar bone, leading ultimately to tooth loss. We previously reported the pleckstrin gene (PLEK) to be highly upregulated in gingival tissue of patients with CP and the only gene concurrently upregulated in other inflammatory diseases including rheumatoid arthritis and cardiovascular diseases. Using saliva from 169 individuals diagnosed with CP and healthy controls, we investigated whether pleckstrin could serve as a novel biomarker of periodontitis. Additionally, we explored signal pathways involved in the regulation of PLEK using human gingival fibroblasts (HGFs). Pleckstrin levels were significantly higher (p < 0.001) in the saliva samples of patients with CP compared to controls and closely associated with CP severity. Immunohistochemical analysis revealed the expression of pleckstrin in inflammatory cells and gingival fibroblasts of CP patients. To explore the signal pathways involved in pleckstrin regulation, we stimulated HGFs with either interleukin-1 beta (IL-1 beta) or lipopolysaccharides (LPS) alone, or in combination with inhibitors targeting c-Jun N-terminal kinase, tyrosine kinase, protein kinase C, or p38 MAP kinase. Results showed that IL-1 beta and LPS significantly increased PLEK mRNA and pleckstrin protein levels. VX-745, the p38 MAP kinase inhibitor significantly decreased IL-1 beta- and LPS-induced pleckstrin levels at both the mRNA and the protein level. Together, these findings show that pleckstrin could serve as a salivary biomarker for the chronic inflammatory disease periodontitis and a regulator of inflammation via the p38 MAP kinase pathway.	[Alim, M. Abdul; Lundmark, Anna; Eriksson, Kaja; Yucel-Lindberg, Tulay] Karolinska Inst, Dept Dent Med, Div Pediat Dent, Huddinge, Sweden; [Njenda, Duncan; Lundmark, Anna; Jansson, Leif; Eriksson, Kaja; Kats, Anna; Johannsen, Gunnar; Arvidsson, Catalin Koro] Karolinska Inst, Dept Dent Med, Div Periodontol, Huddinge, Sweden; [Kaminska, Marta; Mydel, Piotr M.] Jagiellonian Univ, Fac Biochem Biophys & Biotechnol, Dept Microbiol, Krakow, Poland; [Jansson, Leif] Folktandvarden Stockholms lan AB, Folktandvarden Eastmaninst, Dept Periodontol, Stockholm, Sweden; [Mydel, Piotr M.] Univ Bergen, Dept Clin Sci, Broegelmann Lab, Bergen, Norway	Karolinska Institutet; Karolinska Institutet; Jagiellonian University; University of Bergen	Yucel-Lindberg, T (corresponding author), Karolinska Inst, Dept Dent Med, Div Pediat Dent, Huddinge, Sweden.	tulay.lindberg@ki.se		Alim, Dr. Md Abdul/0000-0002-6631-6249	Swedish Research Council [2017-02084]; Patent Revenue Fund; steering group KI/Region Stockholm; Broegelmann Foundation; Norwegian Research Council [296129]; Karolinska Institutet, Stockholm, Sweden	Swedish Research Council(Swedish Research CouncilEuropean Commission); Patent Revenue Fund; steering group KI/Region Stockholm; Broegelmann Foundation; Norwegian Research Council(Research Council of NorwayEuropean Commission); Karolinska Institutet, Stockholm, Sweden	& nbsp;This study was supported by grants from the Swedish Research Council (2017-02084); the Patent Revenue Fund for Research in Preventive Odontology; the steering group KI/Region Stockholm for dental research (SOF); the Broegelmann Foundation; the Norwegian Research Council (296129); and Karolinska Institutet, Stockholm, Sweden.	Alim MA, 2021, CELL MOL IMMUNOL, V18, P2383, DOI 10.1038/s41423-020-0421-z; Alim MA, 2017, CELL TISSUE RES, V370, P451, DOI 10.1007/s00441-017-2684-y; Bage T, 2007, BBA-MOL CELL RES, V1773, P1589, DOI 10.1016/j.bbamcr.2007.07.008; Bage T, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-241; Baig A, 2009, PLATELETS, V20, P446, DOI 10.3109/09537100903137314; Beikler T, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-30; Bourgeois D, 2019, MICROORGANISMS, V7, DOI 10.3390/microorganisms7100424; Burotto M, 2014, CANCER-AM CANCER SOC, V120, P3446, DOI 10.1002/cncr.28864; Canovas B, 2021, NAT REV MOL CELL BIO, V22, P346, DOI 10.1038/s41580-020-00322-w; Cargnello M, 2011, MICROBIOL MOL BIOL R, V75, P50, DOI 10.1128/MMBR.00031-10; Cekici A, 2014, PERIODONTOL 2000, V64, P57, DOI 10.1111/prd.12002; Christian F, 2016, CELLS-BASEL, V5, DOI 10.3390/cells5010012; Cremonesi P, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-540; Ding Y, 2007, J IMMUNOL, V179, P647, DOI 10.4049/jimmunol.179.1.647; Engstrom M, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1588-2; Frencken JE, 2017, J CLIN PERIODONTOL, V44, pS94, DOI 10.1111/jcpe.12677; GAILANI D, 1990, BRIT J HAEMATOL, V74, P192, DOI 10.1111/j.1365-2141.1990.tb02565.x; Hajishengallis G, 2021, NAT REV IMMUNOL, V21, P426, DOI 10.1038/s41577-020-00488-6; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; He XJ, 2019, EBIOMEDICINE, V41, P538, DOI 10.1016/j.ebiom.2019.02.009; Hienz SA, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/615486; Jonsson D, 2011, J CLIN PERIODONTOL, V38, P599, DOI 10.1111/j.1600-051X.2011.01719.x; Kassebaum NJ, 2014, J DENT RES, V93, P1045, DOI 10.1177/0022034514552491; Kats A, 2013, FASEB J, V27, P2328, DOI 10.1096/fj.12-214445; Kinney JS, 2014, J CLIN PERIODONTOL, V41, P113, DOI 10.1111/jcpe.12194; Kirkwood KL, 2009, CURR DRUG METAB, V10, P55, DOI 10.2174/138920009787048347; Koeberle A, 2015, BIOCHEM PHARMACOL, V98, P1, DOI 10.1016/j.bcp.2015.06.022; Kononen E, 2019, J CLIN MED, V8, DOI 10.3390/jcm8081135; Lian LR, 2009, BLOOD, V113, P3577, DOI 10.1182/blood-2008-09-178913; Lundmark A, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00216; Lundmark A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-27627-3; Lundmark A, 2015, SCI REP-UK, V5, DOI 10.1038/srep18475; Ma AD, 1997, J CELL BIOL, V136, P1071, DOI 10.1083/jcb.136.5.1071; Medrano LM, 2019, ANN HUM GENET, V83, P86, DOI 10.1111/ahg.12293; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Offenbacher S, 2009, J PERIODONTOL, V80, P1963, DOI 10.1902/jop.2009.080645; Pascual V, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146276; Peng Q, 2018, ONCOL LETT, V15, P1379, DOI 10.3892/ol.2017.7491; Plotnikov A, 2011, BBA-MOL CELL RES, V1813, P1619, DOI 10.1016/j.bbamcr.2010.12.012; Rangbulla V, 2017, CHIN J DENT RES, V20, P43, DOI [10.3290/j.cjdr.a37742, 10.3290/j.cjdr.a37741]; Roll RL, 2000, J CELL BIOL, V150, P1461, DOI 10.1083/jcb.150.6.1461; Silva N, 2015, J APPL ORAL SCI, V23, P329, DOI 10.1590/1678-775720140259; Sloan DC, 2002, BIOCHEM BIOPH RES CO, V293, P640, DOI 10.1016/S0006-291X(02)00260-7; Song L, 2015, BMC ORAL HEALTH, V15, DOI 10.1186/s12903-015-0086-7; Suzuki A, 2019, BMC ORAL HEALTH, V19, DOI 10.1186/s12903-019-0738-0; Thalhamer T, 2008, RHEUMATOLOGY, V47, P409, DOI 10.1093/rheumatology/kem297; TOKER A, 1995, J BIOL CHEM, V270, P29525, DOI 10.1074/jbc.270.49.29525; TYERS M, 1987, BIOCHEM J, V243, P249, DOI 10.1042/bj2430249; Wang PL, 2002, CRIT REV ORAL BIOL M, V13, P132, DOI 10.1177/154411130201300204; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175; Yucel-Lindberg T, 2006, CELL SIGNAL, V18, P2131, DOI 10.1016/j.cellsig.2006.04.003	51	0	0	3	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 11	2022	12								801096	10.3389/fimmu.2021.801096	http://dx.doi.org/10.3389/fimmu.2021.801096			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YO6DA	35087525	gold, Green Published			2022-12-18	WOS:000748028500001
J	Barbouche, MR; Eley, BS				Barbouche, Mohamed-Ridha; Eley, Brian Stephen			Editorial: Immune-Related Non-Communicable Diseases in Africa	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						immune-related; non-communicable; diseases; Africa; research			[Barbouche, Mohamed-Ridha] Pasteur Inst Tunis, Dept Immunol, Tunis, Tunisia; [Barbouche, Mohamed-Ridha] Tunis El Manar Univ, Tunis, Tunisia; [Eley, Brian Stephen] Red Cross War Mem Childrens Hosp, Paediat Infect Dis Unit, Cape Town, South Africa; [Eley, Brian Stephen] Univ Cape Town, Dept Paediat & Child Hlth, Cape Town, South Africa	Le Reseau International des Instituts Pasteur (RIIP); Universite de Tunis-El-Manar; Institut Pasteur Tunis; Universite de Tunis-El-Manar; University of Cape Town	Barbouche, MR (corresponding author), Pasteur Inst Tunis, Dept Immunol, Tunis, Tunisia.; Barbouche, MR (corresponding author), Tunis El Manar Univ, Tunis, Tunisia.	ridha.barbouche@laposte.net			Research Topic by the International Union of Immunological Societies (IUIS)	Research Topic by the International Union of Immunological Societies (IUIS)	We acknowledge the initiation and support of this Research Topic by the International Union of Immunological Societies (IUIS).		0	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 11	2022	12								816257	10.3389/fimmu.2021.816257	http://dx.doi.org/10.3389/fimmu.2021.816257			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZC6CF	35087535	Green Published, gold			2022-12-18	WOS:000757605000001
J	Bilderbeek, RJC; Baranov, MV; van den Bogaart, G; Bianchi, F				Bilderbeek, Richel J. C.; Baranov, Maksim V.; van den Bogaart, Geert; Bianchi, Frans			Transmembrane Helices Are an Over-Presented and Evolutionarily Conserved Source of Major Histocompatibility Complex Class I and II Epitopes	FRONTIERS IN IMMUNOLOGY			English	Article						antigen presentation; membrane proteins; adaptive immunity; transmembrane domain; epitopes; MHC-I; MHC-II; evolutionary conservation	MHC CLASS-I; PROTEIN TOPOLOGY; PREDICTION; RECOGNITION; MOLECULES; SUPERTYPES; ANTIGENS; BODIES; MODEL	Cytolytic T cell responses are predicted to be biased towards membrane proteins. The peptide-binding grooves of most alleles of histocompatibility complex class I (MHC-I) are relatively hydrophobic, therefore peptide fragments derived from human transmembrane helices (TMHs) are predicted to be presented more often as would be expected based on their abundance in the proteome. However, the physiological reason of why membrane proteins might be over-presented is unclear. In this study, we show that the predicted over-presentation of TMH-derived peptides is general, as it is predicted for bacteria and viruses and for both MHC-I and MHC-II, and confirmed by re-analysis of epitope databases. Moreover, we show that TMHs are evolutionarily more conserved, because single nucleotide polymorphisms (SNPs) are present relatively less frequently in TMH-coding chromosomal regions compared to regions coding for extracellular and cytoplasmic protein regions. Thus, our findings suggest that both cytolytic and helper T cells are more tuned to respond to membrane proteins, because these are evolutionary more conserved. We speculate that TMHs are less prone to mutations that enable pathogens to evade T cell responses.	[Bilderbeek, Richel J. C.; Baranov, Maksim V.; van den Bogaart, Geert; Bianchi, Frans] Univ Groningen, Groningen Biomol Sci & Biotechnol GBB Inst, Dept Mol Immunol, Groningen, Netherlands	University of Groningen	Bianchi, F (corresponding author), Univ Groningen, Groningen Biomol Sci & Biotechnol GBB Inst, Dept Mol Immunol, Groningen, Netherlands.	f.bianchi@rug.nl	van den Bogaart, Geert/GLV-3283-2022; Bianchi, Frans/E-8796-2018; Baranov, Maksim (Maxim) V./E-6824-2017	van den Bogaart, Geert/0000-0003-2180-6735; Bianchi, Frans/0000-0002-9385-9695; Bilderbeek, Richel/0000-0003-1107-7049; Baranov, Maksim (Maxim) V./0000-0002-9903-9495				Ahram Mamoun, 2006, In Silico Biology, V6, P379; Arai M, 2004, NUCLEIC ACIDS RES, V32, pW390, DOI 10.1093/nar/gkh380; Bergseng E, 2015, IMMUNOGENETICS, V67, P73, DOI 10.1007/s00251-014-0819-9; Bianchi F, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01118; Blees A, 2017, NATURE, V551, P525, DOI 10.1038/nature24627; Bougneres L, 2009, IMMUNITY, V31, P232, DOI 10.1016/j.immuni.2009.06.022; Brown GR, 2015, NUCLEIC ACIDS RES, V43, pD36, DOI 10.1093/nar/gku1055; Dingjan I, 2016, SCI REP-UK, V6, DOI 10.1038/srep22064; Fujimoto T, 2006, AUTOPHAGY, V2, P299, DOI 10.4161/auto.2904; Gilleron M, 2016, CELL CHEM BIOL, V23, P1147, DOI 10.1016/j.chembiol.2016.07.021; Greenbaum J, 2011, IMMUNOGENETICS, V63, P325, DOI 10.1007/s00251-011-0513-0; Gruenberg J, 2020, TRAFFIC, V21, P76, DOI 10.1111/tra.12715; Han AX, 2019, NAT ECOL EVOL, V3, P302, DOI 10.1038/s41559-018-0741-x; Hessa T, 2007, NATURE, V450, P1026, DOI 10.1038/nature06387; Istrail S, 2004, P NATL ACAD SCI USA, V101, P13268, DOI 10.1073/pnas.0404740101; Jones DT, 2007, BIOINFORMATICS, V23, P538, DOI 10.1093/bioinformatics/btl677; JONES DT, 1994, BIOCHEMISTRY-US, V33, P3038, DOI 10.1021/bi00176a037; Kall L, 2004, J MOL BIOL, V338, P1027, DOI 10.1016/j.jmb.2004.03.016; Klammer M, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-314; Kleijmeer M, 2001, J CELL BIOL, V155, P53, DOI 10.1083/jcb.200103071; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Larsen MV, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012697; Lautscham G, 2001, J EXP MED, V194, P1053, DOI 10.1084/jem.194.8.1053; Lund O, 2004, IMMUNOGENETICS, V55, P797, DOI 10.1007/s00251-004-0647-4; Marsh SGE, 2010, TISSUE ANTIGENS, V75, P291, DOI 10.1111/j.1399-0039.2010.01466.x; Meusser B, 2005, NAT CELL BIOL, V7, P766, DOI 10.1038/ncb0805-766; Oberai A, 2009, P NATL ACAD SCI USA, V106, P17747, DOI 10.1073/pnas.0906390106; Oliveira CC, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00298; PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0; Preston GM, 2017, BIOCHEM J, V474, P445, DOI 10.1042/BCJ20160582; Qing W., 2019, BIORXIV PREPRINT, P627307, DOI [10.1101/627307, DOI 10.1101/627307]; Rock KL, 2016, TRENDS IMMUNOL, V37, P724, DOI 10.1016/j.it.2016.08.010; Sander P, 2016, CELL CHEM BIOL, V23, P1044, DOI 10.1016/j.chembiol.2016.09.005; Sayers EW, 2010, NUCLEIC ACIDS RES, V38, pD5, DOI 10.1093/nar/gkp967; Scheliens IMM, 2008, AIDS, V22, P33, DOI 10.1097/QAD.0b013e3282f15622; Sette A, 1999, IMMUNOGENETICS, V50, P201, DOI 10.1007/s002510050594; Shao XM, 2020, CANCER IMMUNOL RES, V8, P396, DOI 10.1158/2326-6066.CIR-19-0464; Sherry ST, 2001, NUCLEIC ACIDS RES, V29, P308, DOI 10.1093/nar/29.1.308; Sommer Simone, 2005, Frontiers in Zoology, V2, P1, DOI 10.1186/1742-9994-2-16; Stevens TJ, 2001, PROTEIN SCI, V10, P2507, DOI 10.1110/ps.ps.10501; Tang ST, 2011, J IMMUNOL, V186, P1068, DOI 10.4049/jimmunol.1002212; Velazquez-Salinas L., 2020, FRONT MICROBIOL, V4, DOI 10.1101/2020.04.10.035964; Vita R, 2019, NUCLEIC ACIDS RES, V47, pD339, DOI 10.1093/nar/gky1006; Zwart W, 2005, IMMUNITY, V22, P221, DOI 10.1016/j.immuni.2005.01.006	44	0	0	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 11	2022	12								763044	10.3389/fimmu.2021.763044	http://dx.doi.org/10.3389/fimmu.2021.763044			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YO6AJ	35087515	gold, Green Published			2022-12-18	WOS:000748021600001
J	Huang, WT; Li, X; Huang, C; Tang, YK; Zhou, Q; Chen, WL				Huang, Wentao; Li, Xue; Huang, Chen; Tang, Yukuan; Zhou, Quan; Chen, Wenli			LncRNAs and Rheumatoid Arthritis: From Identifying Mechanisms to Clinical Investigation	FRONTIERS IN IMMUNOLOGY			English	Review						LncRNAs; rheumatoid arthritis; pathological features; diagnosis; therapy	LONG NONCODING RNA; FIBROBLAST-LIKE SYNOVIOCYTES; T-CELLS; PROLIFERATION; OSTEOCLAST; PROMOTES; IMPACTS; HOTAIR; GROWTH; TISSUE	Rheumatoid arthritis (RA) is a systemic chronic autoinflammatory disease, and the synovial hyperplasia, pannus formation, articular cartilage damage and bone matrix destruction caused by immune system abnormalities are the main features of RA. The use of Disease Modifying Anti-Rheumatic Drugs (DMARDs) has achieved great advances in the therapy of RA. Yet there are still patients facing the problem of poor response to drug therapy or drug intolerance. Current therapy methods can only moderate RA progress, but cannot stop or reverse the damage it has caused. Recent studies have reported that there are a variety of long non-coding RNAs (LncRNAs) that have been implicated in mediating many aspects of RA. Understanding the mechanism of LncRNAs in RA is therefore critical for the development of new therapy strategies and prevention strategies. In this review, we systematically elucidate the biological roles and mechanisms of action of LncRNAs and their mechanisms of action in RA. Additionally, we also highlight the potential value of LncRNAs in the clinical diagnosis and therapy of RA.	[Huang, Wentao; Li, Xue; Chen, Wenli] South China Normal Univ, Coll Biophoton, Minist Educ, MOE Key Lab Laser Life Sci, Guangzhou, Peoples R China; [Huang, Wentao; Li, Xue; Chen, Wenli] South China Normal Univ, Inst Laser Life Sci, Guangzhou, Peoples R China; [Huang, Wentao; Li, Xue; Chen, Wenli] South China Normal Univ, Coll Biophoton, Guangdong Prov Key Lab Laser Life Sci, Guangzhou, Peoples R China; [Huang, Wentao; Li, Xue; Chen, Wenli] South China Normal Univ, Guangzhou Key Lab Spectral Anal & Funct Probes, Coll Biophoton, Guangzhou, Peoples R China; [Huang, Chen; Tang, Yukuan] Guangzhou Panyu Cent Hosp, Dept Minimally Invas Intervent Radiol, Guangzhou, Peoples R China; [Zhou, Quan] Southern Med Univ, Dept Radiol, Affiliated Hosp 3, Guangzhou, Peoples R China	South China Normal University; South China Normal University; South China Normal University; South China Normal University; Southern Medical University - China	Chen, WL (corresponding author), South China Normal Univ, Coll Biophoton, Minist Educ, MOE Key Lab Laser Life Sci, Guangzhou, Peoples R China.; Chen, WL (corresponding author), South China Normal Univ, Inst Laser Life Sci, Guangzhou, Peoples R China.; Chen, WL (corresponding author), South China Normal Univ, Coll Biophoton, Guangdong Prov Key Lab Laser Life Sci, Guangzhou, Peoples R China.; Chen, WL (corresponding author), South China Normal Univ, Guangzhou Key Lab Spectral Anal & Funct Probes, Coll Biophoton, Guangzhou, Peoples R China.; Zhou, Q (corresponding author), Southern Med Univ, Dept Radiol, Affiliated Hosp 3, Guangzhou, Peoples R China.	zhouquan3777@smu.edu.cn; chenwl@scnu.edu.cn	Huang, Chen/AAY-9455-2020; Tang, Yukuan/GQB-1761-2022		National Natural Science Foundation of China [81471659]; Guangzhou Science and Technology Planning Project [202103000002]; Guangdong Medical Science and Technology Research Foundation [B2021376]; Panyu Major Science and Technology Planning Project [2020-Z04-002]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangzhou Science and Technology Planning Project; Guangdong Medical Science and Technology Research Foundation; Panyu Major Science and Technology Planning Project	This work was supported by the National Natural Science Foundation of China (81471659), Guangzhou Science and Technology Planning Project (202103000002), Guangdong Medical Science and Technology Research Foundation (B2021376) and Panyu Major Science and Technology Planning Project (2020-Z04-002).	Abou-Raya A, 2018, ANN RHEUM DIS, V77, DOI 10.1136/annrheumdis-2013-204856; Ahmed MS, 2016, IMMUNE NETW, V16, P44, DOI 10.4110/in.2016.16.1.44; Andujar I, 2013, PLANTA MED, V79, P1685, DOI 10.1055/s-0033-1350934; AREND WP, 1995, ARTHRITIS RHEUM, V38, P151, DOI 10.1002/art.1780380202; Bannwarth B, 2005, EXPERT OPIN INV DRUG, V14, P521, DOI 10.1517/13543784.14.4.521; Bi X, 2019, EBIOMEDICINE, V50, P408, DOI 10.1016/j.ebiom.2019.11.024; BORSANI G, 1991, NATURE, V351, P325, DOI 10.1038/351325a0; Chang LH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045378; Chen J, 2021, RNA BIOL, V18, P657, DOI 10.1080/15476286.2020.1857941; Chen RS, 2019, EUR REV MED PHARMACO, V23, P9199, DOI 10.26355/eurrev_201911_19411; Cheng L, 2018, CANCER BIOL THER, V19, P676, DOI 10.1080/15384047.2018.1450113; Colaprico A, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13803-0; Coulthard LG, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3278; Daraghmeh DN, 2021, PHARMACOL RES, V173, DOI 10.1016/j.phrs.2021.105887; Dinarello CA, 2007, EUR J IMMUNOL, V37, pS34, DOI 10.1002/eji.200737772; Fan ZJ, 2018, ACS APPL MATER INTER, V10, P23595, DOI 10.1021/acsami.8b06236; FASSBENDER HG, 1983, J PATHOL, V139, P399, DOI 10.1002/path.1711390314; Gao LH, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.00048; Gerstner B, 2007, ANN NEUROL, V61, P562, DOI 10.1002/ana.21118; Gibbons HR, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02512; Houtman M, 2018, J AUTOIMMUN, V90, P28, DOI 10.1016/j.jaut.2018.01.003; Hu XM, 2020, MOL THER-NUCL ACIDS, V19, P468, DOI 10.1016/j.omtn.2019.11.015; Huang H, 2021, INT IMMUNOPHARMACOL, V93, DOI 10.1016/j.intimp.2021.107434; Huang N, 2020, INT J MOL MED, V46, P859, DOI 10.3892/ijmm.2020.4618; Huang YL, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20082023; Jiang H, 2021, INT J MOL MED, V48, DOI 10.3892/ijmm.2021.4963; Jiang H, 2021, INT J MOL MED, V47, DOI 10.3892/ijmm.2021.4850; Jung YK, 2019, IMMUNE NETW, V19, DOI 10.4110/in.2019.19.e2; Kapoor B, 2014, SCI WORLD J, DOI 10.1155/2014/978351; Khasru Moshiur Rahman, 2021, Case Rep Rheumatol, V2021, P8491717, DOI 10.1155/2021/8491717; Kopp F, 2018, CELL, V172, P393, DOI 10.1016/j.cell.2018.01.011; Lachaud CC, 2015, FRONT BIOENG BIOTECH, V3, DOI 10.3389/fbioe.2015.00117; Lee CP, 2019, ENVIRON TOXICOL, V34, P179, DOI 10.1002/tox.22672; Li GQ, 2019, HUM GENE THER, V30, P1008, DOI 10.1089/hum.2018.212; Li GQ, 2019, J CELL MOL MED, V23, P7116, DOI 10.1111/jcmm.14591; Li GQ, 2018, BIOSCIENCE REP, V38, DOI 10.1042/BSR20180626; Li JH, 2018, ADV SCI, V5, DOI 10.1002/advs.201700678; Li M, 2020, CLIN EXP RHEUMATOL, V38, P1145; Li SS, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287-021-02317-6; Li W, 2018, EUR REV MED PHARMACO, V22, P5815, DOI 10.26355/eurrev_201809_15907; Li XY, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.716081; Li XN, 2019, CELL DEATH DISCOV, V5, DOI 10.1038/s41420-018-0134-6; Liang YJ, 2020, INFLAMMATION, V43, P1044, DOI 10.1007/s10753-020-01189-x; Liu W, 2021, AUTOIMMUNITY, V54, P326, DOI 10.1080/08916934.2021.1937608; Liu Y, 2010, DIABETOLOGIA, V53, P2600, DOI 10.1007/s00125-010-1882-x; Liu YR, 2019, J CELL PHYSIOL, V234, P14270, DOI 10.1002/jcp.28126; Lu J, 2021, CELL IMMUNOL, V367, DOI 10.1016/j.cellimm.2021.104400; Lu MC, 2016, IMMUNOL RES, V64, P576, DOI 10.1007/s12026-015-8756-8; Ma CL, 2019, CLIN RHEUMATOL, V38, P3275, DOI 10.1007/s10067-019-04691-2; Maderbacher G, 2018, Z RHEUMATOL, V77, P882, DOI 10.1007/s00393-018-0534-2; Gomez-Olivan LM, 2014, DRUG CHEM TOXICOL, V37, P391, DOI 10.3109/01480545.2013.870191; McInnes IB, 2011, NEW ENGL J MED, V365, P2205, DOI 10.1056/NEJMra1004965; Mo BY, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00702; Mu N, 2020, ARTHRITIS RHEUMATOL, V72, P943, DOI 10.1002/art.41205; Murphy CL, 2010, CELL RES, V20, P977, DOI 10.1038/cr.2010.99; Mysler E, 2021, OPEN ACCESS RHEUMATO, V13, P139, DOI 10.2147/OARRR.S282627; Okin D, 2012, CURR BIOL, V22, pR733, DOI 10.1016/j.cub.2012.07.029; Otero M, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2292; Peng HY, 2020, J IMMUNOL RES, V2020, DOI 10.1155/2020/6401978; Peng HY, 2015, SCI REP-UK, V5, DOI 10.1038/srep17702; Peng T, 2021, MOL CELL BIOCHEM, V476, P2491, DOI 10.1007/s11010-021-04098-1; Piao XM, 2020, AM J TRANSL RES, V12, P1397; Qing PY, 2020, EXP PHYSIOL, V105, P1708, DOI 10.1113/EP088608; Ringe J, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2572; Schroder AE, 1996, P NATL ACAD SCI USA, V93, P221, DOI 10.1073/pnas.93.1.221; Shui XL, 2019, J CELL PHYSIOL, V234, P22477, DOI 10.1002/jcp.28811; Singh A, 2021, INT IMMUNOPHARMACOL, V99, DOI 10.1016/j.intimp.2021.108078; Smolen JS, 2005, ARTHRITIS RHEUM, V52, P1020, DOI 10.1002/art.20982; Song J, 2015, CLIN EXP MED, V15, P121, DOI 10.1007/s10238-013-0271-4; Sparks JA, 2019, ANN INTERN MED, V170, pITC1, DOI 10.7326/AITC201901010; Strehl C, 2016, ANN RHEUM DIS, V75, P952, DOI 10.1136/annrheumdis-2015-208916; Sun Y, 2021, Nan Fang Yi Ke Da Xue Xue Bao, V41, P965, DOI 10.12122/j.issn.1673-4254.2021.07.01; Suzuki Y, 2010, MOL CELL BIOL, V30, P5123, DOI 10.1128/MCB.00619-10; Tandon VR, 2014, INDIAN J PHARMACOL, V46, P555, DOI 10.4103/0253-7613.140597; Tang JJ, 2020, HUM CELL, V33, P1081, DOI 10.1007/s13577-020-00419-6; Tang W, 2012, ACTA PHARMACOL SIN, V33, P1112, DOI 10.1038/aps.2012.108; Tardito S, 2019, AUTOIMMUN REV, V18, DOI 10.1016/j.autrev.2019.102397; Turk MA, 2021, J RHEUMATOL, V48, P25, DOI 10.3899/jrheum.190768; van der Velden VHJ, 1998, MEDIAT INFLAMM, V7, P229, DOI 10.1080/09629359890910; Vigneau S, 2003, J VIROL, V77, P5632, DOI 10.1128/JVI.77.10.5632-5638.2003; Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007; Wahba AS, 2022, ARCH PHYSIOL BIOCHEM, V128, P1571, DOI 10.1080/13813455.2020.1784951; Wang G, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20182374; Wang J, 2020, INT IMMUNOPHARMACOL, V84, DOI 10.1016/j.intimp.2020.106497; Wang KC, 2011, MOL CELL, V43, P904, DOI 10.1016/j.molcel.2011.08.018; Wang ZY, 2021, CELL CYCLE, V20, P194, DOI 10.1080/15384101.2020.1867788; Wen JT, 2021, PHYTOTHER RES, V35, P4334, DOI 10.1002/ptr.7129; Wu GC, 2015, AUTOIMMUN REV, V14, P798, DOI 10.1016/j.autrev.2015.05.004; Wu L, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01934; Wu SY, 2018, EUR J PHARMACOL, V831, P38, DOI 10.1016/j.ejphar.2018.04.028; Xie BC, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.697442; Yamaguchi Y, 2005, BRIT J DERMATOL, V152, P664, DOI 10.1111/j.1365-2133.2005.06401.x; Yamakawa H, 2021, J CLIN MED, V10, DOI 10.3390/jcm10173806; Yan SS, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02218; Yan ZF, 2018, EUR REV MED PHARMACO, V22, P914, DOI 10.26355/eurrev_201802_14370; Yang CA, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19092806; Yang JL, 2020, BIOFACTORS, V46, P813, DOI 10.1002/biof.1659; Yang KY, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/631737; Yang SS, 2020, BIOSCIENCE REP, V40, DOI 10.1042/BSR20201273; Ye L, 2020, INT IMMUNOPHARMACOL, V88, DOI 10.1016/j.intimp.2020.106992; Ye Y, 2018, HUM CELL, V31, P14, DOI 10.1007/s13577-017-0179-5; Ye Z, 2017, MOL MED REP, V15, P1412, DOI 10.3892/mmr.2017.6150; You Y, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.615859; Yu B, 2018, THERANOSTICS, V8, P3654, DOI 10.7150/thno.26024; Yu H, 2020, CLIN EXP RHEUMATOL, V38, P713; Zeng Y, 2002, RNA, V8, P855, DOI 10.1017/S1355838202020071; Zhang CW, 2019, J BIOL ENG, V13, DOI 10.1186/s13036-019-0184-1; Zhang HJ, 2017, INT IMMUNOPHARMACOL, V50, P283, DOI 10.1016/j.intimp.2017.06.021; Zhang J, 2021, IMMUN INFLAMM DIS, V9, P681, DOI 10.1002/iid3.417; Zhang JH, 2021, ENVIRON TOXICOL, V36, P2484, DOI 10.1002/tox.23361; Zhang TP, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02529; Zhang T, 2016, ARTHRITIS RES THER, V18, DOI 10.1186/s13075-016-1161-4; Zhao F, 2020, EXP CELL RES, V394, DOI 10.1016/j.yexcr.2020.112136; Zhou XP, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.605616; Zhu JF, 2006, CELL RES, V16, P3, DOI 10.1038/sj.cr.7310002; Zhu XD, 2021, INT IMMUNOPHARMACOL, V93, DOI 10.1016/j.intimp.2021.107402; Zhuo Q, 2021, AUTOIMMUNITY, V54, P406, DOI 10.1080/08916934.2021.1966770; Zou YY, 2018, J CLIN INVEST, V128, P4510, DOI 10.1172/JCI97965	118	0	0	4	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 11	2022	12								807738	10.3389/fimmu.2021.807738	http://dx.doi.org/10.3389/fimmu.2021.807738			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YO6WU	35087527	gold, Green Published			2022-12-18	WOS:000748079900001
J	Jing, W; Tuxiu, X; Xiaobing, L; Guijun, J; Lulu, K; Jie, J; Lu, Y; Liying, Z; Xiaoxing, X; Jingjun, L				Jing, Wang; Tuxiu, Xie; Xiaobing, Long; Guijun, Jiang; Lulu, Kang; Jie, Jiang; Lu, Ye; Liying, Zhan; Xiaoxing, Xiong; Jingjun, Lyu			LncRNA GAS5/miR-137 Is a Hypoxia-Responsive Axis Involved in Cardiac Arrest and Cardiopulmonary Cerebral Resuscitation	FRONTIERS IN IMMUNOLOGY			English	Article						neuroinflammation; exosome; microglia; astrocyte; crosstalk; cardaic arrest; cardiopulmonary cerebral resuscitation	MICRORNA-137; TARGETS; PHOSPHATASES; ISCHEMIA; STROKE; INJURY; HEART; MODEL; CERNA	BackgroundCardiac arrest/cardiopulmonary resuscitation (CA/CPR) represents one of the devastating medical emergencies and is associated with high mortality and neuro-disability. Post-cardiac arrest syndrome (PCAS) is mechanistically ascribed to acute systemic ischemia/reperfusion(I/R) injury. The lncRNA/microRNA/mRNA networks have been found to play crucial roles in the pathogenesis of the hypoxia-responsive diseases. Nonetheless, the precise molecular mechanisms by which lncRNA/miRNA/mRNA axes are involved in the astrocyte-microglia crosstalk in CA/CPR have not been fully elucidated. MethodsWe collected and purified the exosomes from the blood of CA/CPR patients and supernatant of OGD/R-stimulated astrocytes. On the basis of microarray analysis, bioinformatic study, and luciferase activity determination, we speculated that lncRNA GAS5/miR-137 is implicated in the astrocyte-microglia crosstalk under the insult of systemic I/R injury. The regulation of lncRNA GAS5/miR-137 on INPP4B was examined by cellular transfection in OGD/R cell culture and by lateral ventricle injection with miR-137 agomir in CA/CPR mice model. Flow cytometry and immunofluorescence staining were performed to detect the microglial apoptosis, M1/M2 phenotype transformation, and neuroinflammation. Neurological scoring and behavior tests were conducted in CA/CPR group, with miR-137 agomir lateral-ventricle infusion and in their controls. ResultsIn all the micRNAs, miR-137 was among the top 10 micRNAs that experienced greatest changes, in both the blood of CA/CPR patients and supernatant of OGD/R-stimulated astrocytes. Bioinformatic analysis revealed that miR-137 was sponged by lncRNA GAS5, targeting INPP4B, and the result was confirmed by Luciferase activity assay. qRT-PCR and Western blotting showed that lncRNA GAS5 and INPP4B were over-expressed whereas miR-137 was downregulated in the blood of CA/CPR patients, OGD/R-stimulated astrocytes, and brain tissue of CA/CPR mice. Silencing lncRNA GAS5 suppressed INPP4B expression, but over-expression of miR-137 negatively modulated its expression. Western blotting exhibited that PI3K and Akt phosphorylation was increased when lncRNA GAS5 was silenced or miR-137 was over-expressed. However, PI3K and Akt phosphorylation was notably suppressed in the absence of miR-137, almost reversing their phosphorylation in the silencing lncRNA GAS5 group. Then we found that GAS5 siRNA or miR-137 mimic significantly increased cell viability and alleviated apoptosis after OGD/R injury. Furthermore, over-expression of miR-137 attenuated microglial apoptosis and neuroinflammation in CA/CPR mice model, exhibiting significantly better behavioral tests after CA/CPR. ConclusionLncRNA GAS5/miR-137 may be involved in the astrocyte-microglia communication that inhibits PI3K/Akt signaling activation via regulation of INPP4B during CA/CPR.	[Jing, Wang; Tuxiu, Xie; Xiaobing, Long; Guijun, Jiang; Lulu, Kang; Jie, Jiang; Lu, Ye; Jingjun, Lyu] Wuhan Univ, Dept Emergency, Renmin Hosp, Wuhan, Peoples R China; [Tuxiu, Xie] Wuhan Univ, Dept Gen Practice, Renmin Hosp, Wuhan, Peoples R China; [Guijun, Jiang; Liying, Zhan] Wuhan Univ, Dept Crit Care Med, Renmin Hosp, Wuhan, Peoples R China; [Xiaoxing, Xiong] Wuhan Univ, Dept Neurosurg, Renmin Hosp, Wuhan, Peoples R China	Wuhan University; Wuhan University; Wuhan University; Wuhan University	Jingjun, L (corresponding author), Wuhan Univ, Dept Emergency, Renmin Hosp, Wuhan, Peoples R China.	lvjingjun@whu.edu.cn	jie, jie/HGT-7778-2022		National Key Research and Development Plan [2020YFC0846600]; National Natural Science Foundation of China [NSFC 81372020]; Renmin Hospital of Wuhan University [RMYD 2018Z15]; Young Talent Physician Training Project in Wuhan City [2014ZX0001]	National Key Research and Development Plan; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Renmin Hospital of Wuhan University; Young Talent Physician Training Project in Wuhan City	This work was supported by a grant from National Key Research and Development Plan (2020YFC0846600), a grant from the National Natural Science Foundation of China (NSFC 81372020), a grant from Renmin Hospital of Wuhan University (RMYD 2018Z15) and a grant of Young Talent Physician Training Project in Wuhan City (2014ZX0001).	Adrie C, 2002, CIRCULATION, V106, P562, DOI 10.1161/01.CIR.0000023891.80661.AD; Andersen LW, 2019, JAMA-J AM MED ASSOC, V321, P1200, DOI 10.1001/jama.2019.1696; Betel D, 2008, NUCLEIC ACIDS RES, V36, pD149, DOI 10.1093/nar/gkm995; Chen FH, 2018, BIOCHEM BIOPH RES CO, V496, P184, DOI 10.1016/j.bbrc.2018.01.022; Chen MM, 2021, FRONT MOL NEUROSCI, V14, DOI 10.3389/fnmol.2021.745066; Chen M, 2014, CLIN CANCER RES, V20, P3057, DOI 10.1158/1078-0432.CCR-12-3680; Cheng YQ, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.577072; Elgebaly SA, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11030368; Eltzschig HK, 2011, NAT MED, V17, P1391, DOI 10.1038/nm.2507; Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108; Gao ST, 2020, EUR REV MED PHARMACO, V24, P10984, DOI 10.26355/eurrev_202011_23582; Geekiyanage H, 2011, J NEUROSCI, V31, P14820, DOI 10.1523/JNEUROSCI.3883-11.2011; Gong CW, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/8838524; Hassager C, 2018, LANCET, V391, P989, DOI 10.1016/S0140-6736(18)30315-5; Huang LX, 2021, BIOENGINEERED, V12, P4136, DOI 10.1080/21655979.2021.1953218; Jacobs LA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080844; Jiang MR, 2020, J NEUROINFLAMM, V17, DOI 10.1186/s12974-020-01933-y; Jiang M, 2018, CELL PHYSIOL BIOCHEM, V47, P864, DOI [10.1159/000490078and, 10.1159/000490078]; Lanzillotti C, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.646032; Lascarrou JB, 2015, SCAND J TRAUMA RESUS, V23, DOI 10.1186/s13049-015-0103-5; Li HZ, 2015, CELL SIGNAL, V27, P1789, DOI 10.1016/j.cellsig.2015.05.013; Li W, 2014, J BIOL CHEM, V289, P10691, DOI 10.1074/jbc.M113.537050; Liddelow SA, 2017, NATURE, V541, P481, DOI 10.1038/nature21029; Lindner TW, 2013, CRIT CARE, V17, DOI 10.1186/cc12826; Liu HQ, 2018, AGING DIS, V9, P31, DOI 10.14336/AD.2017.0221; Liu ZB, 2020, INT J CARDIOL, V306, P9, DOI 10.1016/j.ijcard.2020.01.067; Lok SI, 2013, CIRC-HEART FAIL, V6, P853, DOI 10.1161/CIRCHEARTFAILURE.112.000255; Long XB, 2020, J NEUROINFLAMM, V17, DOI 10.1186/s12974-020-01761-0; Lv JL, 2020, BRAIN BEHAV IMMUN, V90, P55, DOI 10.1016/j.bbi.2020.07.041; Masvekar R, 2019, MULT SCLER RELAT DIS, V28, P34, DOI 10.1016/j.msard.2018.11.032; Neumar RW, 2008, CIRCULATION, V118, P2452, DOI 10.1161/CIRCULATIONAHA.108.190652; Mai N, 2019, J CEREBR BLOOD F MET, V39, P939, DOI 10.1177/0271678X19835552; Qi XL, 2015, J MED GENET, V52, P710, DOI 10.1136/jmedgenet-2015-103334; Ren NS, 2020, AGING-US, V12, P11025, DOI 10.18632/aging.103314; Sandroni C, 2021, INTENS CARE MED, V47, P1393, DOI 10.1007/s00134-021-06548-2; Sanmarco LM, 2021, NATURE, V590, P473, DOI 10.1038/s41586-020-03116-4; Shen SY, 2020, MED SCI MONITOR, V26, DOI 10.12659/MSM.924781; Shen YT, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.118.009634; Shi FK, 2017, EXP CELL RES, V352, P1, DOI 10.1016/j.yexcr.2017.01.015; Tay Y, 2014, NATURE, V505, P344, DOI 10.1038/nature12986; Tian RH, 2020, AGING-US, V12, P10873, DOI 10.18632/aging.103301; Wang W, 2021, J AM HEART ASSOC, V10, DOI 10.1161/JAHA.120.019142; Xia XH, 2019, PROG NEUROBIOL, V183, DOI 10.1016/j.pneurobio.2019.101694; Yao ZH, 2020, AGING-US, V12, P19520, DOI 10.18632/aging.103901; Yin X, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1127-3; Yu SJ, 2019, AGING CELL, V18, DOI 10.1111/acel.12940; Zagrean AM, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00811; Zhang L, 2021, BIOENGINEERED, V12, P9949, DOI 10.1080/21655979.2021.1985342; Zhao Q, 2021, J CEREBR BLOOD F MET, V41, P1091, DOI 10.1177/0271678X20948612; Zheng K, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22196-y	50	0	0	13	33	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 11	2022	12								790750	10.3389/fimmu.2021.790750	http://dx.doi.org/10.3389/fimmu.2021.790750			21	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YS4NG	35087519	gold, Green Published			2022-12-18	WOS:000750655100001
J	Klewinghaus, D; Pekar, L; Arras, P; Krah, S; Valldorf, B; Kolmar, H; Zielonka, S				Klewinghaus, Daniel; Pekar, Lukas; Arras, Paul; Krah, Simon; Valldorf, Bernhard; Kolmar, Harald; Zielonka, Stefan			Grabbing the Bull by Both Horns: Bovine Ultralong CDR-H3 Paratopes Enable Engineering of 'Almost Natural' Common Light Chain Bispecific Antibodies Suitable For Effector Cell Redirection	FRONTIERS IN IMMUNOLOGY			English	Article						bovine ultralong CDR-H3 antibodies; bispecific antibodies; effector cell redirection; NK cell engagers; common light chain; antibody engineering; yeast surface display	VARIABLE-DOMAIN IMMUNOGLOBULIN; GENERATION; LIGAND; NKP30; SPECIFICITY; DERIVATIVES; B7-H6	A subset of antibodies found in cattle comprises ultralong CDR-H3 regions of up to 70 amino acids. Interestingly, this type of immunoglobulin usually pairs with the single germline VL gene, V30 that is typically very conserved in sequence. In this work, we have engineered ultralong CDR-H3 common light chain bispecific antibodies targeting Epidermal Growth Factor Receptor (EGFR) on tumor cells as well as Natural Cytotoxicity Receptor NKp30 on Natural Killer (NK) cells. Antigen-specific common light chain antibodies were isolated by yeast surface display by means of pairing CDR-H3 diversities following immunization with a single V30 light chain. After selection, EGFR-targeting paratopes as well as NKp30-specific binders were combined into common light chain bispecific antibodies by exploiting the strand-exchange engineered domain (SEED) technology for heavy chain heterodimerization. Biochemical characterization of resulting bispecifics revealed highly specific binding to the respective antigens as well as simultaneous binding to both targets. Most importantly, engineered cattle-derived bispecific common light chain molecules elicited potent NK cell redirection and consequently tumor cell lysis of EGFR-overexpressing cells as well as robust release of proinflammatory cytokine interferon-gamma. Taken together, this data is giving clear evidence that bovine bispecific ultralong CDR-H3 common light chain antibodies are versatile for biotechnological applications.	[Klewinghaus, Daniel; Pekar, Lukas; Arras, Paul; Krah, Simon; Zielonka, Stefan] Merck Healthcare KGaA, Prot Engn & Antibody Technol, Darmstadt, Germany; [Valldorf, Bernhard] Merck KGaA, Chem & Pharmaceut Dev, Darmstadt, Germany; [Kolmar, Harald] Tech Univ Darmstadt, Inst Organ Chem & Biochem, Darmstadt, Germany	Merck KGaA; Technical University of Darmstadt	Zielonka, S (corresponding author), Merck Healthcare KGaA, Prot Engn & Antibody Technol, Darmstadt, Germany.	stefan.zielonka@merckgroup.com						Benatuil L, 2010, PROTEIN ENG DES SEL, V23, P155, DOI 10.1093/protein/gzq002; Bogen JP, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01892; Brandt CS, 2009, J EXP MED, V206, P1495, DOI 10.1084/jem.20090681; Brinkmann U, 2021, SCIENCE, V372, P916, DOI 10.1126/science.abg1209; Brinkmann U, 2017, MABS-AUSTIN, V9, P182, DOI 10.1080/19420862.2016.1268307; Cai WQ, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01249; Chanier T, 2019, ANTIBODIES, V8, DOI 10.3390/antib8010013; Chen W, 2021, MABS-AUSTIN, V13, DOI 10.1080/19420862.2020.1871171; Chiu ML, 2019, ANTIBODIES, V8, DOI 10.3390/antib8040055; Davis JH, 2010, PROTEIN ENG DES SEL, V23, P195, DOI 10.1093/protein/gzp094; de Taeye SW, 2019, ANTIBODIES, V8, DOI 10.3390/antib8020030; Deiss TC, 2019, CELL MOL IMMUNOL, V16, P53, DOI 10.1038/cmi.2017.117; DiGiammarino EL, 2011, MABS-AUSTIN, V3, P487, DOI 10.4161/mabs.3.5.16326; Doerner A, 2014, FEBS LETT, V588, P278, DOI 10.1016/j.febslet.2013.11.025; Dolgin E, 2021, CANCER DISCOV, V11, P1604, DOI 10.1158/2159-8290.CD-NB2021-0351; Dong JH, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00558; Gonzalez-Rodriguez AP, 2019, J CLIN MED, V8, DOI 10.3390/jcm8101557; Groom JR, 2011, IMMUNOL CELL BIOL, V89, P207, DOI 10.1038/icb.2010.158; Guardiola S, 2019, TRENDS PHARMACOL SCI, V40, P941, DOI 10.1016/j.tips.2019.10.004; Haakenson JK, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01262; Jovcevska I, 2020, BIODRUGS, V34, P11, DOI 10.1007/s40259-019-00392-z; Kellner C, 2012, J IMMUNOL, V189, P5037, DOI 10.4049/jimmunol.1201321; KIESSLING R, 1975, EUR J IMMUNOL, V5, P117, DOI 10.1002/eji.1830050209; Konning D, 2017, CURR OPIN STRUC BIOL, V45, P10, DOI 10.1016/j.sbi.2016.10.019; Krah S, 2018, ANTIBODIES, V7, DOI 10.3390/antib7030028; Krah S, 2017, NEW BIOTECHNOL, V39, P167, DOI 10.1016/j.nbt.2016.12.010; Labrijn AF, 2019, NAT REV DRUG DISCOV, V18, P585, DOI 10.1038/s41573-019-0028-1; Mayer K, 2015, INT J MOL SCI, V16, P27497, DOI 10.3390/ijms161126037; Medina-Echeverz J, 2014, EUR J IMMUNOL, V44, P2457, DOI 10.1002/eji.201444497; Metz S, 2012, PROTEIN ENG DES SEL, V25, P571, DOI 10.1093/protein/gzs064; Mullard A, 2021, NAT REV DRUG DISCOV, V20, P491, DOI 10.1038/d41573-021-00079-7; Nie Siwei, 2020, Antib Ther, V3, P18, DOI 10.1093/abt/tbaa003; Overacre-Delgoffe AE, 2017, CELL, V169, P1130, DOI 10.1016/j.cell.2017.05.005; Peipp M, 2015, ONCOTARGET, V6, P32075, DOI 10.18632/oncotarget.5135; Pekar L, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.742418; Pekar L, 2021, J IMMUNOL, V206, P225, DOI 10.4049/jimmunol.2001004; Pekar L, 2020, MABS-AUSTIN, V12, DOI 10.1080/19420862.2020.1812210; Rosowski S, 2018, MICROB CELL FACT, V17, DOI 10.1186/s12934-017-0853-z; Roth L, 2019, BIOL CHEM, V400, P383, DOI 10.1515/hsz-2018-0347; Schlothauer T, 2016, PROTEIN ENG DES SEL, V29, P457, DOI 10.1093/protein/gzw040; Seshacharyulu P, 2012, EXPERT OPIN THER TAR, V16, P15, DOI 10.1517/14728222.2011.648617; Sheridan C, 2021, NAT BIOTECHNOL, V39, P251, DOI 10.1038/s41587-021-00850-6; Sok D, 2017, NATURE, V548, P108, DOI 10.1038/nature23301; Stanfield R, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aba0468; Stanfield RL, 2016, SCI IMMUNOL, V1, DOI 10.1126/sciimmunol.aaf7962; Ubah OC, 2018, BIOCHEM SOC T, V46, P1559, DOI 10.1042/BST20180177; Valldorf B, 2022, BIOL CHEM, V403, P455, DOI 10.1515/hsz-2020-0377; Wang F, 2013, CELL, V153, P1379, DOI 10.1016/j.cell.2013.04.049; WARD ES, 1995, MOL IMMUNOL, V32, P147, DOI 10.1016/0161-5890(94)00119-L; Weaver-Feldhaus JM, 2004, FEBS LETT, V564, P24, DOI 10.1016/S0014-5793(04)00309-6; Wu CB, 2007, NAT BIOTECHNOL, V25, P1290, DOI 10.1038/nbt1345; Wu CB, 2009, MABS, V1, P339, DOI 10.4161/mabs.1.4.8755; Zielonka S, 2015, MABS-AUSTIN, V7, P15, DOI 10.4161/19420862.2015.989032	53	0	0	0	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 11	2022	12								801368	10.3389/fimmu.2021.801368	http://dx.doi.org/10.3389/fimmu.2021.801368			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZC5WV	35087526	Green Published, gold, Green Submitted			2022-12-18	WOS:000757591000001
J	McCall, JL; Varney, ME; Rice, E; Dziadowicz, SA; Hall, C; Blethen, KE; Hu, GQ; Barnett, JB; Martinez, I				McCall, Jamie L.; Varney, Melinda E.; Rice, Emily; Dziadowicz, Sebastian A.; Hall, Casey; Blethen, Kathryn E.; Hu, Gangqing; Barnett, John B.; Martinez, Ivan			Prenatal Cadmium Exposure Alters Proliferation in Mouse CD4(+) T Cells via LncRNA Snhg7	FRONTIERS IN IMMUNOLOGY			English	Article						long non-coding RNA; Snhg7; CD4(+) T cells; cadmium; GALNT7; miR-34a	LONG NONCODING RNA; ARSENIC EXPOSURE; HOST GENES; EXPRESSION; CANCER; PROMOTES; BLOOD; ZINC; PROGRESSION; ACTIVATION	ObjectivePrenatal cadmium (Cd) exposure leads to immunotoxic phenotypes in the offspring affecting coding and non-coding genes. Recent studies have shown that long non-coding RNAs (lncRNAs) are integral to T cell regulation. Here, we investigated the role of long non-coding RNA small nucleolar RNA host gene 7 (lncSnhg7) in T cell proliferation. MethodsRNA sequencing was used to analyze the expression of lncRNAs in splenic CD4(+) T cells with and without CD3/CD28 stimulation. Next, T cells isolated from offspring exposed to control or Cd water throughout mating and gestation were analyzed with and without stimulation with anti-CD3/CD28 beads. Quantitative qPCR and western blotting were used to detect RNA and protein levels of specific genes. Overexpression of a miR-34a mimic was achieved using nucleofection. Apoptosis was measured using flow cytometry and luminescence assays. Flow cytometry was also used to measure T cell proliferation in culture. Finally, lncSnhg7 was knocked down in splenic CD4(+) T cells with lentivirus to assess its effect on proliferation. ResultsWe identified 23 lncRNAs that were differentially expressed in stimulated versus unstimulated T cells, including lncSnhg7. LncSnhg7 and a downstream protein, GALNT7, are upregulated in T cells from offspring exposed to Cd during gestation. Overexpression of miR-34a, a regulator of lncSnhg7 and GALNT7, suppresses GALNT7 protein levels in primary T cells, but not in a mouse T lymphocyte cell line. The T cells isolated from Cd-exposed offspring exhibit increased proliferation after activation in vitro, but Treg suppression and CD4(+) T cell apoptosis are not affected by prenatal Cd exposure. Knockdown on lncSnhg7 inhibits proliferation of CD4(+) T cells. ConclusionPrenatal Cd exposure alters the expression of lncRNAs during T cell activation. The induction of lncSnhg7 is enhanced in splenic T cells from Cd offspring resulting in the upregulation of GALNT7 protein and increased proliferation following activation. miR-34a overexpression decreased GALNT7 expression and knockdown of lncSnhg7 inhibited proliferation suggesting that the lncSnhg7/miR-34a/GALNT7 is an important pathway in primary CD4(+) T cells. These data highlight the need to understand the consequences of environmental exposures on lncRNA functions in non-cancerous cells as well as the effects in utero.	[McCall, Jamie L.; Varney, Melinda E.; Dziadowicz, Sebastian A.; Hall, Casey; Blethen, Kathryn E.; Hu, Gangqing; Barnett, John B.; Martinez, Ivan] West Virginia Univ, Dept Microbiol Immunol & Cell Biol, Sch Med, Morgantown, WV 26506 USA; [Rice, Emily; Hu, Gangqing; Barnett, John B.; Martinez, Ivan] West Virginia Univ, West Virginia Univ Canc Inst, Sch Med, Morgantown, WV 26506 USA; [Hu, Gangqing] West Virginia Univ, Bioinformat Core, Morgantown, WV 26506 USA	West Virginia University; West Virginia University; West Virginia University	Martinez, I (corresponding author), West Virginia Univ, Dept Microbiol Immunol & Cell Biol, Sch Med, Morgantown, WV 26506 USA.; Martinez, I (corresponding author), West Virginia Univ, West Virginia Univ Canc Inst, Sch Med, Morgantown, WV 26506 USA.	ivmartinez@hsc.wvu.edu	McCall, Jamie/K-8085-2019	McCall, Jamie/0000-0001-5914-6336; Dziadowicz, Sebastian/0000-0001-6277-9310; Barnett, John/0000-0001-6547-2381; Blethen, Kathryn/0000-0003-4602-9514; Martinez, Ivan/0000-0002-2187-5119	National Institution of Environmental Health Sciences [ES023845]; National Institutes of Health [S10OD016165, RRID : SCR_017738]; Institutional Development Awards (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health [P30GM121322, P20GM103434]; West Virginia IDeA-CTR (NIH/NIGMS) [2U54 GM104942-03]; National Science Foundation [NSF/1920920, NSF/1761792]; WV-INBRE [P20 GM103434]; NIGMS [U54 GM-104942];  [SCR_017738]	National Institution of Environmental Health Sciences; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Institutional Development Awards (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health; West Virginia IDeA-CTR (NIH/NIGMS); National Science Foundation(National Science Foundation (NSF)); WV-INBRE; NIGMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); 	The experiments and personnel were supported by a National Institution of Environmental Health Sciences Grant ES023845 to JB. Flow Cytometry experiments were performed in the West Virginia University Flow Cytometry & Single Cell Core Facility (RRID : SCR_017738), which is supported by the National Institutes of Health equipment grant numbers S10OD016165 and the Institutional Development Awards (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health under grant numbers P30GM121322 (TME CoBRE) and P20GM103434 (INBRE). IM was supported by West Virginia IDeA-CTR (NIH/NIGMS 2U54 GM104942-03) and National Science Foundation (NSF/1920920, NSF/1761792). The WVU Bioinformatics Core is supported by WV-INBRE grant P20 GM103434 and NIGMS grant U54 GM-104942.	Agency for Toxic Substances & Disease Registry, 2019, AGENCY TOXIC SUBSTAN; Ahmed S, 2014, TOXICOL SCI, V141, P166, DOI 10.1093/toxsci/kfu113; Bachmanov AA, 2002, BEHAV GENET, V32, P435, DOI 10.1023/A:1020884312053; Benbrahim-Tallaa L, 2007, ENVIRON HEALTH PERSP, V115, P1454, DOI 10.1289/ehp.10207; Boone DN, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-65109-7; Bulat Z, 2009, TOXICOL IND HEALTH, V25, P129, DOI 10.1177/0748233709104488; Cao QX, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-01209-8; Chaudhry MA, 2014, CANCER BIOTHER RADIO, V29, P135, DOI 10.1089/cbr.2013.1574; Chaudhry MA, 2013, INT J MOL SCI, V14, P9099, DOI 10.3390/ijms14059099; Chen Y, 2019, PATHOL RES PRACT, V215, P302, DOI 10.1016/j.prp.2018.11.015; Chen Z, 2014, J EXPO SCI ENV EPID, V24, P537, DOI 10.1038/jes.2014.26; Cheng DF, 2019, CELL BIOSCI, V9, DOI 10.1186/s13578-019-0290-2; Chi RJ, 2019, J CELL PHYSIOL, V234, P13403, DOI 10.1002/jcp.28017; Deng YQ, 2018, CANCER BIOTHER RADIO, V33, P365, DOI 10.1089/cbr.2018.2503; Devaux Y, 2015, NAT REV CARDIOL, V12, P415, DOI 10.1038/nrcardio.2015.55; DeWitt Jamie C, 2012, Curr Protoc Toxicol, VChapter 18, DOI 10.1002/0471140856.tx1815s51; Faroon O, 2012, AGENCY TOXIC SUBSTAN, P1; Gao JJ, 2015, ENVIRON RES, V136, P462, DOI 10.1016/j.envres.2014.09.040; Geisler S, 2013, NAT REV MOL CELL BIO, V14, P699, DOI 10.1038/nrm3679; Hanson ML, 2012, TOXICOL APPL PHARM, V261, P196, DOI 10.1016/j.taap.2012.04.002; Hanson ML, 2010, TOXICOL APPL PHARM, V242, P136, DOI 10.1016/j.taap.2009.09.023; Hart M, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0670-5; Hart M, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-018-1295-1; Hellemans J, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-2-r19; Hobbs SJ, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00600; Holaskova I, 2012, TOXICOL APPL PHARM, V265, P181, DOI 10.1016/j.taap.2012.10.009; Hua S, 2018, ONCOL LETT, V16, P6307, DOI 10.3892/ol.2018.9498; Huang DJ, 2008, TOXICOL LETT, V179, P43, DOI 10.1016/j.toxlet.2008.03.018; Iyer MK, 2015, NAT GENET, V47, P199, DOI 10.1038/ng.3192; Kantola M, 2000, ENVIRON RES, V83, P54, DOI 10.1006/enrs.1999.4043; Kim SH, 2017, J TRACE ELEM MED BIO, V43, P209, DOI 10.1016/j.jtemb.2017.04.010; Kippler M, 2012, REPROD TOXICOL, V34, P504, DOI 10.1016/j.reprotox.2012.08.002; Kumaki Y, 2008, NUCLEIC ACIDS RES, V36, pW170, DOI 10.1093/nar/gkn294; Lafuente A, 2004, BIOMETALS, V17, P451, DOI 10.1023/B:BIOM.0000029441.20037.72; Larriba E, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-31032-1; Levin A A, 1981, Placenta Suppl, V3, P303; Li W, 2014, MOL MED REP, V9, P1293, DOI 10.3892/mmr.2014.1929; Li XQ, 2020, FASEB J, V34, P5077, DOI 10.1096/fj.201902379R; Li Y, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0632-2; Liao Y, 2019, NUCLEIC ACIDS RES, V47, DOI 10.1093/nar/gkz114; Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656; Liu JL, 2016, REPROD SCI, V23, P687, DOI 10.1177/1933719115612131; Luo X, 2018, EUR REV MED PHARMACO, V22, P7788, DOI 10.26355/eurrev_201811_16403; McCall JL, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0249442; McCall JL, 2016, MOL CELL BIOL, V36, P2246, DOI 10.1128/MCB.00087-16; McCarthy DJ, 2012, NUCLEIC ACIDS RES, V40, P4288, DOI 10.1093/nar/gks042; Mohanty AF, 2015, ENVIRON RES, V138, P74, DOI 10.1016/j.envres.2015.02.004; Nelson BH, 2004, J IMMUNOL, V172, P3983, DOI 10.4049/jimmunol.172.7.3983; Osada Mitsuru, 2011, Environmental Health and Preventive Medicine, V16, P341, DOI 10.1007/s12199-010-0204-8; Palus J, 2003, MUTAT RES-GEN TOX EN, V540, P19, DOI 10.1016/S1383-5718(03)00167-0; Pellizzari ED, 1999, J EXPO ANAL ENV EPID, V9, P49, DOI 10.1038/sj.jea.7500025; Poirier LA, 2002, ENVIRON HEALTH PERSP, V110, P793, DOI 10.1289/ehp.02110s5793; Ponjavic J, 2007, GENOME RES, V17, P556, DOI 10.1101/gr.6036807; Powell JD, 1998, IMMUNOL REV, V165, P287, DOI 10.1111/j.1600-065X.1998.tb01246.x; Prakash V, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10100-8; Qi HG, 2018, BIOMED PHARMACOTHER, V102, P326, DOI 10.1016/j.biopha.2018.03.011; ROELFZEMA WH, 1989, ARCH TOXICOL, V63, P38, DOI 10.1007/BF00334632; Saintilnord WN, 2021, TOXICOL SCI, V180, P262, DOI 10.1093/toxsci/kfab002; SASSER LB, 1985, TOXICOL APPL PHARM, V80, P299, DOI 10.1016/0041-008X(85)90087-0; Schoeters G, 2006, ACTA PAEDIATR, V95, P50, DOI 10.1080/08035320600886232; Shan YJ, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0759-7; Shin J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077983; Sood P, 2006, P NATL ACAD SCI USA, V103, P2746, DOI 10.1073/pnas.0511045103; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sun XF, 2019, EUR J PHARMACOL, V856, DOI 10.1016/j.ejphar.2019.172407; Szafranska AE, 2007, ONCOGENE, V26, P4442, DOI 10.1038/sj.onc.1210228; Takiguchi M, 2003, EXP CELL RES, V286, P355, DOI 10.1016/S0014-4827(03)00062-4; Waalkes MP, 2003, MUTAT RES-FUND MOL M, V533, P107, DOI 10.1016/j.mrfmmm.2003.07.011; Wang MW, 2017, EUR REV MED PHARMACO, V21, P4613; West KA, 2019, NON-CODING RNA, V5, DOI 10.3390/ncrna5030043; Wu F, 2020, ONCOTARGETS THER, V13, P685, DOI 10.2147/OTT.S232542; Wu P, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00143; Xie ZY, 2021, CLIN RES HEPATOL GAS, V45, DOI 10.1016/j.clinre.2020.05.017; Xu B, 2018, MOL MED REP, V18, P882, DOI 10.3892/mmr.2018.9034; Xu CJ, 2019, J CANCER, V10, P539, DOI 10.7150/jca.25507; Xu RD, 2018, CELL PROLIFERAT, V51, DOI 10.1111/cpr.12515; Yu FJ, 2019, MOL THER-NUCL ACIDS, V17, P235, DOI 10.1016/j.omtn.2019.05.026; Yu MC, 2011, J EXP MED, V208, P775, DOI 10.1084/jem.20100031; Zhang GD, 2019, EUR REV MED PHARMACO, V23, P3602, DOI 10.26355/eurrev_201905_17782; Zhang JW, 2007, J CLIN INVEST, V117, P871, DOI 10.1172/JCI31860; Zhang YD, 2016, TOXICOL APPL PHARM, V313, P24, DOI 10.1016/j.taap.2016.10.016; Zhao YF, 2018, TOXICOL SCI, V165, P254, DOI 10.1093/toxsci/kfy166; Zhong XT, 2018, J BUON, V23, P776	83	0	0	6	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 11	2022	12								720635	10.3389/fimmu.2021.720635	http://dx.doi.org/10.3389/fimmu.2021.720635			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YO6WX	35087510	gold, Green Published, Green Submitted			2022-12-18	WOS:000748080200001
J	Radakovics, K; Battin, C; Leitner, J; Geiselhart, S; Paster, W; Stoeckl, J; Hoffmann-Sommergruber, K; Steinberger, P				Radakovics, Katharina; Battin, Claire; Leitner, Judith; Geiselhart, Sabine; Paster, Wolfgang; Stoeckl, Johannes; Hoffmann-Sommergruber, Karin; Steinberger, Peter			A Highly Sensitive Cell-Based TLR Reporter Platform for the Specific Detection of Bacterial TLR Ligands	FRONTIERS IN IMMUNOLOGY			English	Article						toll-like receptor; TLR; biosensor; bacterial contamination; reporter cell	TOLL-LIKE RECEPTORS; GENOME-WIDE ASSOCIATION; TUMOR-NECROSIS-FACTOR; ENDOTOXIN CONTAMINATION; ENDOGENOUS LIGANDS; FLAGELLIN; ADJUVANT; HEAT-SHOCK-PROTEIN-70; INNATE; IMMUNOGENICITY	Toll-like receptors (TLRs) are primary pattern recognition receptors (PRRs), which recognize conserved microbial components. They play important roles in innate immunity but also in the initiation of adaptive immune responses. Impurities containing TLR ligands are a frequent problem in research but also for the production of therapeutics since TLR ligands can exert strong immunomodulatory properties even in minute amounts. Consequently, there is a need for sensitive tools to detect TLR ligands with high sensitivity and specificity. Here we describe the development of a platform based on a highly sensitive NF-kappa B::eGFP reporter Jurkat JE6-1 T cell line for the detection of TLR ligands. Ectopic expression of TLRs and their coreceptors and CRISPR/Cas9-mediated deletion of endogenously expressed TLRs was deployed to generate reporter cell lines selectively expressing functional human TLR2/1, TLR2/6, TLR4 or TLR5 complexes. Using well-defined agonists for the respective TLR complexes we could demonstrate high specificity and sensitivity of the individual reporter lines. The limit of detection for LPS was below 1 pg/mL and ligands for TLR2/1 (Pam3CSK4), TLR2/6 (Fsl-1) and TLR5 (flagellin) were detected at concentrations as low as 1.0 ng/mL, 0.2 ng/mL and 10 pg/mL, respectively. We showed that the JE6-1 TLR reporter cells have the utility to characterize different commercially available TLR ligands as well as more complex samples like bacterially expressed proteins or allergen extracts. Impurities in preparations of microbial compounds as well as the lack of specificity of detection systems can lead to erroneous results and currently there is no consensus regarding the involvement of TLRs in the recognition of several molecules with proposed immunostimulatory functions. This reporter system represents a highly suitable tool for the definition of structural requirements for agonists of distinct TLR complexes.	[Radakovics, Katharina; Battin, Claire; Leitner, Judith; Steinberger, Peter] Med Univ Vienna, Inst Immunol, Div Immune Receptors & T Cell Activat, Ctr Pathophysiol Infectiol & Immunol, Vienna, Austria; [Geiselhart, Sabine; Hoffmann-Sommergruber, Karin] Med Univ Vienna, Dept Pathophysiol & Allergy Res, Ctr Pathophysiol Infectiol & Immunol, Vienna, Austria; [Paster, Wolfgang] St Anna Childrens Canc Res Inst CCRI, Clin Cell Biol & FACS Core Unit, Vienna, Austria; [Stoeckl, Johannes] Med Univ Vienna, Ctr Pathophysiol Infectiol & Immunol, Inst Immunol, Div Regulat Immune Syst, Vienna, Austria	Medical University of Vienna; Medical University of Vienna; Saint Anna Children's Hospital; Medical University of Vienna	Steinberger, P (corresponding author), Med Univ Vienna, Inst Immunol, Div Immune Receptors & T Cell Activat, Ctr Pathophysiol Infectiol & Immunol, Vienna, Austria.							ANDERSON KV, 1985, CELL, V42, P791, DOI 10.1016/0092-8674(85)90275-2; Battin C, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178220; Bausinger H, 2002, EUR J IMMUNOL, V32, P3708, DOI 10.1002/1521-4141(200212)32:12<3708::AID-IMMU3708>3.0.CO;2-C; Bonnelykke K, 2013, NAT GENET, V45, P902, DOI 10.1038/ng.2694; Chicaybam L, 2017, FRONT BIOENG BIOTECH, V4, DOI 10.3389/fbioe.2016.00099; Cui BF, 2018, EXPERT REV VACCINES, V17, P335, DOI 10.1080/14760584.2018.1457443; Dajon M, 2017, IMMUNOBIOLOGY, V222, P89, DOI 10.1016/j.imbio.2016.06.009; Das D, 2015, CHEMPHYSCHEM, V16, P753, DOI 10.1002/cphc.201402739; Dehus O, 2006, J ENDOTOXIN RES, V12, P171, DOI 10.1179/096805106X102156; Didierlaurent AM, 2009, J IMMUNOL, V183, P6186, DOI 10.4049/jimmunol.0901474; Erridge C, 2009, ARTERIOSCL THROM VAS, V29, P1944, DOI 10.1161/ATVBAHA.109.194050; Gao BC, 2003, J BIOL CHEM, V278, P22523, DOI 10.1074/jbc.M303161200; Gao BC, 2003, J BIOL CHEM, V278, P174, DOI 10.1074/jbc.M208742200; Gutjahr A, 2017, J IMMUNOL, V198, P4205, DOI 10.4049/jimmunol.1602131; Gutsmann T, 2010, INNATE IMMUN-LONDON, V16, P39, DOI 10.1177/1753425909106447; Haile LA, 2017, J PHARM SCI-US, V106, P751, DOI 10.1016/j.xphs.2016.11.001; Haile LA, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09981-w; Halliday A, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1381-0; Hinds DA, 2013, NAT GENET, V45, P907, DOI 10.1038/ng.2686; Iwasaki A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112; Jacquet A, 2011, TRENDS MOL MED, V17, P604, DOI 10.1016/j.molmed.2011.05.014; Jawa V, 2016, AAPS J, V18, P1439, DOI 10.1208/s12248-016-9948-4; Jutz S, 2017, ONCOTARGET, V8, P64892, DOI 10.18632/oncotarget.17615; Kaczanowska S, 2013, J LEUKOCYTE BIOL, V93, P847, DOI 10.1189/jlb.1012501; Kaisho T, 2002, BBA-MOL CELL RES, V1589, P1, DOI 10.1016/S0167-4889(01)00182-3; Kawasaki T, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00461; Kiura K, 2006, FEMS IMMUNOL MED MIC, V48, P44, DOI 10.1111/j.1574-695X.2006.00119.x; Kouwen TRHM, 2007, MOL MICROBIOL, V64, P984, DOI 10.1111/j.1365-2958.2007.05707.x; Kurokawa K, 2012, J BACTERIOL, V194, P3299, DOI 10.1128/JB.00314-12; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; Lin DH, 2018, SENSOR ACTUAT B-CHEM, V257, P324, DOI 10.1016/j.snb.2017.10.140; Mamat U, 2008, MOL MICROBIOL, V67, P633, DOI 10.1111/j.1365-2958.2007.06074.x; Mamat U, 2015, MICROB CELL FACT, V14, DOI 10.1186/s12934-015-0241-5; Mizel SB, 2010, J IMMUNOL, V185, P5677, DOI 10.4049/jimmunol.1002156; Olguin Y, 2013, ANAL BIOANAL CHEM, V405, P1267, DOI 10.1007/s00216-012-6523-4; Pasare C, 2005, ADV EXP MED BIOL, V560, P11; Pelst MP, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01033; Ponce R, 2009, REGUL TOXICOL PHARM, V54, P164, DOI 10.1016/j.yrtph.2009.03.012; Rakoff-Nahoum S, 2009, NAT REV CANCER, V9, P57, DOI 10.1038/nrc2541; Reich J, 2016, BIOLOGICALS, V44, P417, DOI 10.1016/j.biologicals.2016.04.012; Rosskopf S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-31757-z; Rosskopf Sandra, 2018, Oncotarget, V9, P17608, DOI 10.18632/oncotarget.24807; Rosskopf S, 2016, SCI REP-UK, V6, DOI 10.1038/srep31580; Schlichting E, 1996, SCAND J CLIN LAB INV, V56, P167, DOI 10.3109/00365519609088604; Schwarz H, 2017, SCI REP-UK, V7, DOI 10.1038/srep44750; Schwarz H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113840; Singh I, 2021, CHEM COMMUN, V57, P8421, DOI 10.1039/d1cc03030b; SPITZAUER S, 1993, INT ARCH ALLERGY IMM, V100, P60, DOI 10.1159/000236389; Su LJ, 2019, J MED CHEM, V62, P2938, DOI 10.1021/acs.jmedchem.8b01583; Thomas V, 2002, VECTOR-BORNE ZOONOT, V2, P217, DOI 10.1089/153036602321653798; Traidl-Hoffmann C, 2009, J ALLERGY CLIN IMMUN, V123, P558, DOI 10.1016/j.jaci.2008.12.003; Travassos LH, 2004, EMBO REP, V5, P1000, DOI 10.1038/sj.embor.7400248; Tsan MF, 2004, J LEUKOCYTE BIOL, V76, P514, DOI 10.1189/jlb.0304127; Tsan MF, 2007, J ENDOTOXIN RES, V13, P6, DOI 10.1177/0968051907078604; Tsuji S, 2000, INFECT IMMUN, V68, P6883, DOI 10.1128/IAI.68.12.6883-6890.2000; Ulrich J T, 1995, Pharm Biotechnol, V6, P495; Urban-Wojciuk Z, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02388; Verthelyi D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015252; Wakelin SJ, 2006, IMMUNOL LETT, V106, P1, DOI 10.1016/j.imlet.2006.04.007; Watanabe J, 2003, J BIOL CHEM, V278, P42361, DOI 10.1074/jbc.M307752200; Ye ZY, 2007, J BIOL CHEM, V282, P4479, DOI 10.1074/jbc.M606802200; Zahringer U, 2008, IMMUNOBIOLOGY, V213, P205, DOI 10.1016/j.imbio.2008.02.005; Zaitseva M, 2012, VACCINE, V30, P4859, DOI 10.1016/j.vaccine.2012.05.002; Zuo LL, 2009, J ZHEJIANG UNIV-SC B, V10, P67, DOI 10.1631/jzus.B0820256	64	0	0	2	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 11	2022	12								817604	10.3389/fimmu.2021.817604	http://dx.doi.org/10.3389/fimmu.2021.817604			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YR8RH	35087538	Green Published, gold			2022-12-18	WOS:000750257300001
J	Sim, KY; Ko, GH; Bae, SE; Choi, KY; Lee, JS; Kim, BC; Lee, KH; Song, MR; Park, SG				Sim, Kyu-Young; Ko, Gwang-Hoon; Bae, So-Eun; Choi, Kyu Yeong; Lee, Jung Sup; Kim, Byeong C.; Lee, Kun Ho; Song, Mi-Ryoung; Park, Sung-Gyoo			Two Opposing Roles of SARS-CoV-2 RBD-Reactive Antibodies in Pre-Pandemic Plasma Samples From Elderly People in ACE2-Mediated Pseudovirus Infection	FRONTIERS IN IMMUNOLOGY			English	Article						SARS-CoV-2; pre-pandemic samples; cross-reactive antibodies; receptor binding domain (RBD); neutralizing activity	SPIKE; IMMUNITY	A novel coronavirus designated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged and caused an outbreak of unusual viral pneumonia. Several reports have shown that cross-reactive antibodies against SARS-CoV-2 also exist in people unexposed to this virus. However, the neutralizing activity of cross-reactive antibodies is controversial. Here, we subjected plasma samples from SARS-CoV-2-unexposed elderly Korean people (n = 119) to bead-based IgG antibody analysis. SARS-CoV-2 S1 subunit-reactive IgG antibody analysis detected positive signals in some samples (59 of 119, 49.6%). SARS-CoV-2 receptor-binding domain (RBD)-reactive antibody levels were most significantly correlated with human coronavirus-HKU1 S1 subunit-reactive antibody levels. To check the neutralizing activity of plasma samples, the SARS-CoV-2 spike pseudotype neutralizing assay was used. However, the levels of cross-reactive antibodies did not correlate with neutralizing activity. Instead, SARS-CoV-2 pseudovirus infection was neutralized by some RBD-reactive plasma samples (n = 9, neutralization >= 25%, P <= 0.05), but enhanced by other RBD-reactive plasma samples (n = 4, neutralization <= -25%, P <= 0.05). Interestingly, the blood plasma groups with enhancing and neutralizing effects had high levels of SARS-CoV-2 RBD-reactive antibodies than the plasma group that had no effect. These results suggest that some SARS-CoV-2 RBD-reactive antibodies from pre-pandemic elderly people exert two opposing functions during SARS-CoV-2 pseudovirus infection. In conclusion, preformed RBD-reactive antibodies may have two opposing functions, namely, protecting against and enhancing viral infection. Analysis of the epitopes of preformed antibodies will be useful to elucidate the underlying mechanism.	[Sim, Kyu-Young; Bae, So-Eun; Park, Sung-Gyoo] Seoul Natl Univ, Coll Pharm, Seoul, South Korea; [Sim, Kyu-Young; Bae, So-Eun; Park, Sung-Gyoo] Seoul Natl Univ, Pharmaceut Sci Res Inst, Seoul, South Korea; [Sim, Kyu-Young; Ko, Gwang-Hoon; Song, Mi-Ryoung] Gwangju Inst Sci & Technol GIST, Sch Life Sci, Gwangju, South Korea; [Choi, Kyu Yeong; Lee, Jung Sup; Kim, Byeong C.; Lee, Kun Ho] Chosun Univ, Natl Res Ctr Dementia, Gwangju, South Korea; [Lee, Jung Sup] Chosun Univ, BK21 Plus Res Team Bioact Control Technol, Gwangju, South Korea; [Lee, Jung Sup; Lee, Kun Ho] Chosun Univ, Dept Biomed Sci, Gwangju, South Korea; [Kim, Byeong C.] Chonnam Natl Univ, Dept Neurol, Sch Med, Gwangju, South Korea; [Lee, Kun Ho] Chosun Univ, Res Team Bioact Control Technol, Gwangju, South Korea	Seoul National University (SNU); Seoul National University (SNU); Gwangju Institute of Science & Technology (GIST); Chosun University; Chosun University; Chosun University; Chonnam National University; Chosun University	Park, SG (corresponding author), Seoul Natl Univ, Coll Pharm, Seoul, South Korea.; Park, SG (corresponding author), Seoul Natl Univ, Pharmaceut Sci Res Inst, Seoul, South Korea.	riceo2@snu.ac.kr						Karim SAS, 2021, NEW ENGL J MED, V384, P1866, DOI 10.1056/NEJMc2100362; Anderson EM, 2021, CELL, V184, P1858, DOI 10.1016/j.cell.2021.02.010; Crawford KHD, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12050513; Echeverria G, 2021, INT J INFECT DIS, V105, DOI 10.1016/j.ijid.2021.02.034; Edridge AWD, 2020, NAT MED, V26, P1691, DOI 10.1038/s41591-020-1083-1; Fraley E, 2021, CELL MOL IMMUNOL, V18, P1826, DOI 10.1038/s41423-021-00700-0; Guo L, 2021, EMERG MICROBES INFEC, V10, P664, DOI 10.1080/22221751.2021.1905488; Isho B, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abe5511; Jiang SB, 2020, TRENDS IMMUNOL, V41, P545, DOI 10.1016/j.it.2020.04.008; Mateus J, 2020, SCIENCE, V370, P89, DOI 10.1126/science.abd3871; Ng KW, 2020, SCIENCE, V370, P1339, DOI 10.1126/science.abe1107; Cruz MP, 2021, REV CLIN ESP, V221, P55, DOI [10.1016/j.rce.2020.03.001, 10.1016/j.rceng.2020.03.001]; Pinto D, 2020, NATURE, V583, P290, DOI 10.1038/s41586-020-2349-y; Roltgen K, 2021, CELL HOST MICROBE, V29, P1063, DOI 10.1016/j.chom.2021.06.009; Sagar M, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI143380; Sariol A, 2020, IMMUNITY, V53, P248, DOI 10.1016/j.immuni.2020.07.005; Shah M, 2020, COMPUT STRUCT BIOTEC, V18, P3402, DOI 10.1016/j.csbj.2020.11.002; Shrivastava A., 2011, CHRON YOUNG SCI, V2, P21, DOI [10.4103/2229-5186.79345, DOI 10.4103/2229-5186.79345]; Shrock E, 2020, SCIENCE, V370, P1058, DOI 10.1126/science.abd4250; Su S, 2021, CLIN TRANSL MED, V11, DOI 10.1002/ctm2.284; Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]; Xu C, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abe5575; Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017	23	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 11	2022	12								813240	10.3389/fimmu.2021.813240	http://dx.doi.org/10.3389/fimmu.2021.813240			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YO5YU	35087532	gold, Green Published			2022-12-18	WOS:000748017500001
J	Cao, L; Zhang, RX; Wang, YR; Hu, X; Yong, L; Li, B; Ge, HY; Chen, WW; Zhen, Q; Yu, YF; Mao, YW; Li, Z; Fan, WC; Sun, LD				Cao, Lu; Zhang, Ruixue; Wang, Yirui; Hu, Xia; Yong, Liang; Li, Bao; Ge, Huiyao; Chen, Weiwei; Zhen, Qi; Yu, Yafen; Mao, Yiwen; Li, Zhuo; Fan, Wencheng; Sun, Liangdan			Fine Mapping Analysis of the MHC Region to Identify Variants Associated With Chinese Vitiligo and SLE and Association Across These Diseases	FRONTIERS IN IMMUNOLOGY			English	Article						vitiligo; systemic lupus erythematosus; imputation; MHC; fine mapping	SYSTEMIC-LUPUS-ERYTHEMATOSUS; GENOME-WIDE ASSOCIATION; GENERALIZED VITILIGO; SUSCEPTIBILITY LOCI; AUTOIMMUNE-DISEASES; HLA ALLELES; EXPRESSION; IMPUTATION; DISORDERS; WOMEN	The important role of MHC in the pathogenesis of vitiligo and SLE has been confirmed in various populations. To map the most significant MHC variants associated with the risk of vitiligo and SLE, we conducted fine mapping analysis using 1117 vitiligo cases, 1046 SLE cases and 1693 healthy control subjects in the Han-MHC reference panel and 1000 Genomes Project phase 3. rs113465897 (P=1.03x10(-13), OR=1.64, 95%CI =1.44-1.87) and rs3129898 (P=4.21x10(-17), OR=1.93, 95%CI=1.66-2.25) were identified as being most strongly associated with vitiligo and SLE, respectively. Stepwise conditional analysis revealed additional independent signals at rs3130969(p=1.48x10(-7), OR=0.69, 95%CI=0.60-0.79), HLA-DPB1*03:01 (p=1.07x10(-6), OR=1.94, 95%CI=1.49-2.53) being linked to vitiligo and HLA-DQB1*0301 (P=4.53x10(-7), OR=0.62, 95%CI=0.52-0.75) to SLE. Considering that epidemiological studies have confirmed comorbidities of vitiligo and SLE, we used the GCTA tool to analyse the genetic correlation between these two diseases in the HLA region, the correlation coefficient was 0.79 (P=5.99x10(-10), SE=0.07), confirming their similar genetic backgrounds. Our findings highlight the value of the MHC region in vitiligo and SLE and provide a new perspective for comorbidities among autoimmune diseases.	[Cao, Lu; Zhang, Ruixue; Wang, Yirui; Hu, Xia; Yong, Liang; Ge, Huiyao; Chen, Weiwei; Zhen, Qi; Yu, Yafen; Mao, Yiwen; Li, Zhuo; Fan, Wencheng; Sun, Liangdan] Anhui Med Univ, Dept Dermatol, Affiliated Hosp 1, Hefei, Peoples R China; [Cao, Lu; Zhang, Ruixue; Wang, Yirui; Hu, Xia; Yong, Liang; Ge, Huiyao; Chen, Weiwei; Zhen, Qi; Yu, Yafen; Mao, Yiwen; Li, Zhuo; Fan, Wencheng; Sun, Liangdan] Anhui Med Univ, Inst Dermatol, Hefei, Peoples R China; [Cao, Lu; Zhang, Ruixue; Wang, Yirui; Hu, Xia; Yong, Liang; Ge, Huiyao; Chen, Weiwei; Zhen, Qi; Yu, Yafen; Mao, Yiwen; Li, Zhuo; Fan, Wencheng; Sun, Liangdan] Anhui Med Univ, Key Lab Dermatol, Minist Educ, Hefei, Peoples R China; [Cao, Lu; Zhang, Ruixue; Wang, Yirui; Hu, Xia; Yong, Liang; Ge, Huiyao; Chen, Weiwei; Zhen, Qi; Yu, Yafen; Mao, Yiwen; Li, Zhuo; Fan, Wencheng; Sun, Liangdan] Anhui Med Univ, Inflammat & Immune Mediated Dis Lab Anhui Prov, Hefei, Peoples R China; [Cao, Lu; Zhang, Ruixue; Wang, Yirui; Hu, Xia; Yong, Liang; Ge, Huiyao; Chen, Weiwei; Zhen, Qi; Yu, Yafen; Mao, Yiwen; Li, Zhuo; Fan, Wencheng; Sun, Liangdan] Anhui Med Univ, Anhui Prov Inst Translat Med, Hefei, Peoples R China; [Li, Bao] Anhui Med Univ, Coll Basic Med, Comprehens Lab, Hefei, Peoples R China	Anhui Medical University; Anhui Medical University; Anhui Medical University; Anhui Medical University; Anhui Medical University; Anhui Medical University	Sun, LD (corresponding author), Anhui Med Univ, Dept Dermatol, Affiliated Hosp 1, Hefei, Peoples R China.; Sun, LD (corresponding author), Anhui Med Univ, Inst Dermatol, Hefei, Peoples R China.; Sun, LD (corresponding author), Anhui Med Univ, Key Lab Dermatol, Minist Educ, Hefei, Peoples R China.; Sun, LD (corresponding author), Anhui Med Univ, Inflammat & Immune Mediated Dis Lab Anhui Prov, Hefei, Peoples R China.; Sun, LD (corresponding author), Anhui Med Univ, Anhui Prov Inst Translat Med, Hefei, Peoples R China.	ahmusld@163.com						Akay BN, 2010, J EUR ACAD DERMATOL, V24, P1144, DOI 10.1111/j.1468-3083.2010.03605.x; Birlea SA, 2013, J INVEST DERMATOL, V133, P1369, DOI 10.1038/jid.2012.501; Bouayad A, 2013, ARCH DERMATOL RES, V305, P925, DOI 10.1007/s00403-013-1368-z; Browning BL, 2009, AM J HUM GENET, V84, P210, DOI 10.1016/j.ajhg.2009.01.005; Buc M, 1998, EUR J DERMATOL, V8, P13; Carter EE, 2016, NAT REV RHEUMATOL, V12, P605, DOI 10.1038/nrrheum.2016.137; Cavalli G, 2016, P NATL ACAD SCI USA, V113, P1363, DOI 10.1073/pnas.1523482113; Chen YT, 2015, J EUR ACAD DERMATOL, V29, P1362, DOI 10.1111/jdv.12870; Choi CW, 2017, J DERMATOL, V44, P909, DOI 10.1111/1346-8138.13846; Chung SA, 2014, J AM SOC NEPHROL, V25, P2859, DOI 10.1681/ASN.2013050446; Cortes A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8146; Ezzedine K, 2015, LANCET, V386, P74, DOI 10.1016/S0140-6736(14)60763-7; Fu SM, 2011, J AUTOIMMUN, V37, P104, DOI 10.1016/j.jaut.2011.05.004; Gill L, 2016, J AM ACAD DERMATOL, V74, P295, DOI 10.1016/j.jaad.2015.08.063; Hadi A, 2020, J AM ACAD DERMATOL, V82, P628, DOI 10.1016/j.jaad.2019.07.036; Han JW, 2009, NAT GENET, V41, P1234, DOI 10.1038/ng.472; Harley JB, 2008, NAT GENET, V40, P204, DOI 10.1038/ng.81; Hayashi M, 2016, P NATL ACAD SCI USA, V113, P1357, DOI 10.1073/pnas.1525001113; Hayran Y, 2021, INT J CLIN PRACT, V75, DOI 10.1111/ijcp.14024; Hu DY, 2011, J EUR ACAD DERMATOL, V25, P1299, DOI 10.1111/j.1468-3083.2010.03971.x; Jia XM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064683; Jin Y, 2015, PIGM CELL MELANOMA R, V28, DOI 10.1111/pcmr.12356; Lee SH, 2012, BIOINFORMATICS, V28, P2540, DOI 10.1093/bioinformatics/bts474; Liu CW, 2018, J DTSCH DERMATOL GES, V16, P845, DOI 10.1111/ddg.13574; Louthrenoo W, 2013, INT J IMMUNOGENET, V40, P126, DOI 10.1111/j.1744-313X.2012.01145.x; Mohd-Yusuf Y, 2011, IMMUNOL LETT, V139, P68, DOI 10.1016/j.imlet.2011.05.001; Molineros JE, 2014, AUTOIMMUN DIS, V2014, DOI 10.1155/2014/305436; Morris DL, 2012, AM J HUM GENET, V91, P778, DOI 10.1016/j.ajhg.2012.08.026; Narita Tomohiko, 2011, Allergology International, V60, P505, DOI 10.2332/allergolint.11-OA-0303; Okada Y, 2015, NAT GENET, V47, P798, DOI 10.1038/ng.3310; Okada Y, 2014, AM J HUM GENET, V95, P162, DOI 10.1016/j.ajhg.2014.07.002; Poojary SA, 2011, ALLERGOL IMMUNOPATH, V39, P356, DOI 10.1016/j.aller.2010.12.007; Quan C, 2010, NAT GENET, V42, P614, DOI 10.1038/ng.603; Sheth VM, 2013, DERMATOLOGY, V227, P311, DOI 10.1159/000354607; Singh A, 2012, J INVEST DERMATOL, V132, P124, DOI 10.1038/jid.2011.240; Spritz RA, 2017, DERMATOL CLIN, V35, P245, DOI 10.1016/j.det.2016.11.013; Spritz RA, 2010, THYROID, V20, P745, DOI 10.1089/thy.2010.1643; Sun JY, 2018, MOL GENET GENOM MED, V6, P541, DOI 10.1002/mgg3.403; Taieb A, 2007, PIGM CELL RES, V20, P27, DOI 10.1111/j.1600-0749.2006.00355.x; Tang XF, 2013, J INVEST DERMATOL, V133, P403, DOI 10.1038/jid.2012.320; van Geel N, 2014, J EUR ACAD DERMATOL, V28, P741, DOI 10.1111/jdv.12169; Xu RC, 2017, J AM SOC NEPHROL, V28, P3383, DOI 10.1681/ASN.2016121331; Yang C, 2018, GENE, V648, P76, DOI 10.1016/j.gene.2018.01.053; Yang JA, 2011, AM J HUM GENET, V88, P76, DOI 10.1016/j.ajhg.2010.11.011; Zhou FS, 2016, NAT GENET, V48, P740, DOI 10.1038/ng.3576	45	0	0	4	12	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 10	2022	12								758652	10.3389/fimmu.2021.758652	http://dx.doi.org/10.3389/fimmu.2021.758652			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZA9LM	35082778	gold, Green Published			2022-12-18	WOS:000756476800001
J	Diez-Feijoo, R; Rodriguez-Sevilla, JJ; Fernandez-Rodriguez, C; Flores, S; Raya, C; Ferrer, A; Colomo, L; Salar, A				Diez-Feijoo, Ramon; Rodriguez-Sevilla, Juan Jose; Fernandez-Rodriguez, Concepcion; Flores, Solange; Raya, Carmen; Ferrer, Ana; Colomo, Luis; Salar, Antonio			Case Report: High Doses of Intravenous Immunoglobulins as a Successful Treatment for Late Onset Immune Agranulocytosis After Rituximab Plus Bendamustine	FRONTIERS IN IMMUNOLOGY			English	Article						immunoglobulin; Waldenstrom's macroglobulinemia; bendamustine; agranulocytosis; rituximab	DRUG-INDUCED AGRANULOCYTOSIS; B-CELL LYMPHOMA; AUTOIMMUNE NEUTROPENIA; THERAPY; INDOLENT	Late onset neutropenia (LON) related to rituximab or rituximab plus chemotherapy is defined as an unexplained absolute neutrophil count of <= 1.5 x 10(9)/L starting at least four weeks after the last rituximab administration. LON is infrequent and its pathophysiology remains unknown. There are no guidelines or consensus strategies for the optimal management of patients developing LON. The majority of the patients recover promptly with no specific treatment and only some cases need to be managed with granulocytic colony stimulating factor (G-CSF), usually with a rapid response. Here, we describe a 69-year-old patient with Waldenstrom's macroglobulinemia who presented a septic event in the context of severe LON after rituximab plus bendamustine. The diagnosed of agranulocytosis was established by bone marrow examination. Interestingly, anti-neutrophil antibodies bound to the patient's granulocytes were found suggesting an autoimmune mechanism. The patient did not respond to G-CSF but achieved a rapid response after high doses of intravenous immunoglobulins with full white blood cell recovery.	[Diez-Feijoo, Ramon; Rodriguez-Sevilla, Juan Jose; Flores, Solange; Salar, Antonio] Hosp Mar, Dept Hematol, Barcelona, Spain; [Diez-Feijoo, Ramon; Rodriguez-Sevilla, Juan Jose; Flores, Solange; Salar, Antonio] Hosp Mar Med Res Inst IMIM, Appl Clin Res Hematol Malignancies, Barcelona, Spain; [Raya, Carmen] Hosp Mar, Banc Sang & Teixits, Barcelona, Spain; [Fernandez-Rodriguez, Concepcion; Ferrer, Ana; Colomo, Luis] Hosp Mar, Dept Pathol, Barcelona, Spain	Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar	Rodriguez-Sevilla, JJ (corresponding author), Hosp Mar, Dept Hematol, Barcelona, Spain.; Rodriguez-Sevilla, JJ (corresponding author), Hosp Mar Med Res Inst IMIM, Appl Clin Res Hematol Malignancies, Barcelona, Spain.	jrodsevilla@gmail.com	Colomo, Luis/A-2259-2016; Rodriguez, Juan/HGD-7121-2022	Colomo, Luis/0000-0001-5236-5085; Flores-Moran, Marie Solange/0000-0002-4822-0147; Diez-Feijoo Varela, Ramon/0000-0003-3137-3443; Rodriguez-Sevilla, Juanjo/0000-0002-4741-7925				Aguiar-Bujanda D, 2015, CL LYMPH MYELOM LEUK, V15, P761, DOI 10.1016/j.clml.2015.07.635; Akhtari M, 2009, AUTOIMMUN REV, V9, P62, DOI 10.1016/j.autrev.2009.03.006; Anolik JH, 2003, ARTHRITIS RHEUM, V48, P455, DOI 10.1002/art.10764; Arai Y, 2015, HEMATOLOGY, V20, P196, DOI 10.1179/1607845414Y.0000000188; Baek GT, 2021, LEUKEMIA LYMPHOMA, V62, P3138, DOI 10.1080/10428194.2021.1953014; Chaiwatanatorn K, 2003, BRIT J HAEMATOL, V121, P913, DOI 10.1046/j.1365-2141.2003.04385.x; Fioredda F, 2020, BLOOD ADV, V4, P5644, DOI 10.1182/bloodadvances.2020002793; Freifeld AG, 2011, CLIN INFECT DIS, V52, pE56, DOI 10.1093/cid/cir073; Fukuno K, 2006, INT J HEMATOL, V84, P242, DOI 10.1532/IJH97.05105; Gibson C, 2014, BLOOD, V124, P1251, DOI 10.1182/blood-2014-02-482612; Giraud C, 2016, CLIN RHEUMATOL, V35, P2615, DOI 10.1007/s10067-016-3379-6; Herzog-Tzarfati K, 2006, EUR J INTERN MED, V17, P439, DOI 10.1016/j.ejim.2006.02.014; Li SC, 2010, AM J HEMATOL, V85, P810, DOI 10.1002/ajh.21818; MARINONE G, 1991, SEMIN HEMATOL, V28, P298; Moore Donald C, 2016, P T, V41, P765; Mosyagin I, 2005, J CLIN PSYCHOPHARM, V25, P435, DOI 10.1097/01.jcp.0000177551.13714.33; Rose AL, 2003, BLOOD, V101, P4225, DOI 10.1182/blood-2003-02-0450; Rozman S, 2012, LEUKEMIA LYMPHOMA, V53, P1945, DOI 10.3109/10428194.2012.679266; Rummel MJ, 2013, LANCET, V381, P1203, DOI 10.1016/S0140-6736(12)61763-2; Saikia TK, 2001, ANN ONCOL, V12, P1493, DOI 10.1023/A:1012500524758; Stamatopoulos K, 2008, LEUKEMIA, V22, P1446, DOI 10.1038/sj.leu.2405077; Terrier B, 2007, HAEMATOLOGICA, V92, P20, DOI 10.3324/haematol.11031; Tesfa D, 2011, EXPERT REV HEMATOL, V4, P619, DOI 10.1586/EHM.11.62; Tesfa D, 2009, AM J HEMATOL, V84, P428, DOI 10.1002/ajh.21433; Tesfa D, 2008, MED ONCOL, V25, P374, DOI 10.1007/s12032-008-9049-z; U.S.D.o.H.a.H, 2017, SERV COMM TERM CRIT; Verriere B, 2018, HEMATOL ONCOL, V36, P144, DOI 10.1002/hon.2458; Vilches C, 2008, TISSUE ANTIGENS, V71, P242, DOI 10.1111/j.1399-0039.2007.00998.x; Voog E, 2003, NEW ENGL J MED, V348, P2691; Weng WK, 2010, J CLIN ONCOL, V28, P279, DOI 10.1200/JCO.2009.25.0274; Wolach O, 2010, MEDICINE, V89, P308, DOI 10.1097/MD.0b013e3181f2caef	31	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 10	2022	12								798251	10.3389/fimmu.2021.798251	http://dx.doi.org/10.3389/fimmu.2021.798251			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YO6YG	35082788	gold, Green Published			2022-12-18	WOS:000748083700001
J	Fisher, BS; Fancher, KA; Gustin, AT; Fisher, C; Wood, MP; Gale, M; Burwitz, BJ; Smedley, J; Klatt, NR; Derby, N; Sodora, DL				Fisher, Bridget S.; Fancher, Katherine A.; Gustin, Andrew T.; Fisher, Cole; Wood, Matthew P.; Gale, Michael; Burwitz, Benjamin J.; Smedley, Jeremy; Klatt, Nichole R.; Derby, Nina; Sodora, Donald L.			Liver Bacterial Dysbiosis With Non-Tuberculosis Mycobacteria Occurs in SIV-Infected Macaques and Persists During Antiretroviral Therapy	FRONTIERS IN IMMUNOLOGY			English	Article						HIV; SIV; microbiome; liver; 16S rRNA gene; neutrophils	GUT MICROBIOME; LIFE EXPECTANCY; HIV-INFECTION; KANSASII; FIBROSIS; INDIVIDUALS; FORTUITUM; SMEGMATIS; CIRRHOSIS; DEATH	Liver disease is a significant contributor to morbidity and mortality in HIV-infected individuals, even during successful viral suppression with combination antiretroviral therapy (cART). Similar to HIV infection, SIV infection of rhesus macaques is associated with gut microbiome dysbiosis and microbial translocation that can be detected systemically in the blood. As microbes leaving the intestines must first pass through the liver via the portal vein, we evaluated the livers of both SIV-infected (SIV+) and SIV-infected cART treated (SIV+cART) rhesus macaques for evidence of microbial changes compared to uninfected macaques. Dysbiosis was observed in both the SIV+ and SIV+cART macaques, encompassing changes in the relative abundance of several genera, including a reduction in the levels of Lactobacillus and Staphylococcus. Most strikingly, we found an increase in the relative abundance and absolute quantity of bacteria within the Mycobacterium genus in both SIV+ and SIV+cART macaques. Multi-gene sequencing identified a species of atypical mycobacteria similar to the opportunistic pathogen M. smegmatis. Phosphatidyl inositol lipoarabinomannan (PILAM) (a glycolipid cell wall component found in atypical mycobacteria) stimulation in primary human hepatocytes resulted in an upregulation of inflammatory transcriptional responses, including an increase in the chemokines associated with neutrophil recruitment (CXCL1, CXCL5, and CXCL6). These studies provide key insights into SIV associated changes in hepatic microbial composition and indicate a link between microbial components and immune cell recruitment in SIV+ and SIV+cART treated macaques.	[Fisher, Bridget S.; Fancher, Katherine A.; Fisher, Cole; Wood, Matthew P.; Derby, Nina; Sodora, Donald L.] Ctr Global Infect Dis Res, Seattle Childrens Res Inst, Seattle, WA 98109 USA; [Gustin, Andrew T.; Wood, Matthew P.] Univ Washington, Dept Immunol, Ctr Innate Immun & Immune Dis, Seattle, WA 98195 USA; [Burwitz, Benjamin J.] Oregon Hlth & Sci Univ, Vaccine & Gene Therapy Inst, Beaverton, OR USA; [Smedley, Jeremy] Oregon Hlth & Sci Univ, Oregon Natl Primate Res Ctr, Beaverton, OR USA; [Klatt, Nichole R.] Univ Minnesota, Dept Surg, Box 242 UMHC, Minneapolis, MN 55455 USA	Seattle Children's Hospital; University of Washington; University of Washington Seattle; Oregon Health & Science University; Oregon Health & Science University; Oregon National Primate Research Center; University of Minnesota System; University of Minnesota Twin Cities	Derby, N; Sodora, DL (corresponding author), Ctr Global Infect Dis Res, Seattle Childrens Res Inst, Seattle, WA 98109 USA.	Nina.Derby@seattlechildrens.org; Don.Sodora@seattlechildrens.org		Fancher, Katherine/0000-0002-2719-1797; Gustin, Andrew/0000-0002-8760-8320	National Institute of Allergy and Infectious Diseases, National Institutes of Health grants [R21AI100782, R01AI134630]; National Institute of Allergy and Infectious Diseases, National Institutes of Health [5K22AI098440, HHSN272201300010C]; National Institutes of Health, Office of the Director [P51OD010425];  [NR-14849];  [NR-14848]	National Institute of Allergy and Infectious Diseases, National Institutes of Health grants; National Institute of Allergy and Infectious Diseases, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Institutes of Health, Office of the Director(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ; 	This project was supported by funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health grants R21AI100782 (DS) and R01AI134630 (DS). Research was also supported in part with funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, including 5K22AI098440 (NK) and Contract No. HHSN272201300010C (MG), by the National Institutes of Health, Office of the Director P51OD010425 (MG) and under award P51OD010425 (Washington National Primate Research Center).	Albillos A, 2020, J HEPATOL, V72, P558, DOI 10.1016/j.jhep.2019.10.003; Amaral WZ, 2017, PSYCHOSOM MED, V79, P888, DOI 10.1097/PSY.0000000000000454; Anadol E, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191118; Anhe FF, 2020, NAT METAB, V2, P233, DOI 10.1038/s42255-020-0178-9; Bajaj JS, 2017, ALCOHOL CLIN EXP RES, V41, P1857, DOI 10.1111/acer.13498; Bajaj JS, 2014, J HEPATOL, V60, P940, DOI 10.1016/j.jhep.2013.12.019; Bandera A, 2018, CURR OPIN HIV AIDS, V13, P73, DOI [10.1097/COH.0000000000000429, 10.1097/coh.0000000000000429]; Bischoff J, 2021, ECLINICALMEDICINE, V40, DOI 10.1016/j.eclinm.2021.101116; Blackard JT, 2011, CLIN INFECT DIS, V52, P674, DOI 10.1093/cid/ciq199; Brun P, 2007, AM J PHYSIOL-GASTR L, V292, pG518, DOI 10.1152/ajpgi.00024.2006; Caporaso JG, 2011, P NATL ACAD SCI USA, V108, P4516, DOI 10.1073/pnas.1000080107; Cervo A, 2020, CURR HIV-AIDS REP, V17, P601, DOI 10.1007/s11904-020-00531-0; Chan AW, 2016, CURR HIV-AIDS REP, V13, P309, DOI 10.1007/s11904-016-0332-x; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; Croxford S, 2017, LANCET PUBLIC HEALTH, V2, pE35, DOI 10.1016/S2468-2667(16)30020-2; Dettmer AM, 2019, AM J PRIMATOL, V81, DOI 10.1002/ajp.22969; Duan JJ, 2019, AGING-US, V11, P12080, DOI 10.18632/aging.102541; Erridge C, 2007, AM J CLIN NUTR, V86, P1286, DOI 10.1093/ajcn/86.5.1286; Estes JD, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001052; Etienne-Mesmin L, 2016, CELL MOL GASTROENTER, V2, P584, DOI 10.1016/j.jcmgh.2016.04.007; Evans TI, 2016, J INFECT DIS, V213, P361, DOI 10.1093/infdis/jiv404; Farahani M, 2017, INT J STD AIDS, V28, P636, DOI 10.1177/0956462416632428; FEINGOLD KR, 1992, J LIPID RES, V33, P1765; Fisher BS, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1006871; Forrester JE, 2012, J VIRAL HEPATITIS, V19, pE202, DOI 10.1111/j.1365-2893.2011.01529.x; Gideon HP, 2019, MUCOSAL IMMUNOL, V12, P1370, DOI 10.1038/s41385-019-0195-8; He TY, 2019, J CLIN INVEST, V129, P5474, DOI 10.1172/JCI121208; Hensley-McBain T, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007672; Heymann F, 2016, NAT REV GASTRO HEPAT, V13, P88, DOI 10.1038/nrgastro.2015.200; Honda JR, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.02029; Honda M, 2018, NAT REV GASTRO HEPAT, V15, P206, DOI 10.1038/nrgastro.2017.183; Hyun J, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007883; Jones R, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-93918-x; Kazankov K, 2019, NAT REV GASTRO HEPAT, V16, P145, DOI 10.1038/s41575-018-0082-x; Kim HN, 2016, JAIDS-J ACQ IMM DEF, V72, P437, DOI 10.1097/QAI.0000000000000992; Klase Z, 2015, MUCOSAL IMMUNOL, V8, P1009, DOI 10.1038/mi.2014.128; Koyama Y, 2017, J CLIN INVEST, V127, P55, DOI 10.1172/JCI88881; Le Dantec C, 2002, APPL ENVIRON MICROB, V68, P5318, DOI 10.1128/AEM.68.11.5318-5325.2002; LEVINE B, 1991, ANN INTERN MED, V114, P861, DOI 10.7326/0003-4819-114-10-861; Macovei L, 2015, J ORAL MICROBIOL, V7, DOI 10.3402/jom.v7.26094; Manuzak JA, 2020, MUCOSAL IMMUNOL, V13, P471, DOI 10.1038/s41385-019-0238-1; Marcus JL, 2016, JAIDS-J ACQ IMM DEF, V73, P39, DOI 10.1097/QAI.0000000000001014; Nasi M, 2017, CLIN EXP IMMUNOL, V187, P44, DOI 10.1111/cei.12814; Ott SJ, 2004, J CLIN MICROBIOL, V42, P2566, DOI 10.1128/JCM.42.6.2566-2572.2004; Pandrea I, 2015, CURR HIV-AIDS REP, V12, P54, DOI 10.1007/s11904-014-0245-5; Panesar N, 1999, J SURG RES, V85, P251, DOI 10.1006/jsre.1999.5648; PierreAudigier C, 1997, CLIN INFECT DIS, V24, P982, DOI 10.1093/clinids/24.5.982; Primm TP, 2004, CLIN MICROBIOL REV, V17, P98, DOI 10.1128/CMR.17.1.98-106.2004; Procop GW, 2017, SEMIN DIAGN PATHOL, V34, P332, DOI [10.1053/j.seindp.2017.04.006, 10.1053/j.semdp.2017.04.006]; Radomski N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078749; Ruzicka DJ, 2019, J INFECT CHEMOTHER, V25, P89, DOI 10.1016/j.jiac.2018.10.006; SHAFER RW, 1992, CLIN INFECT DIS, V15, P161, DOI 10.1093/clinids/15.1.161; Siddiqui S, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-76145-8; Sivanandham R, 2018, J CLIN INVEST, V128, P5178, DOI 10.1172/JCI99420; Smith MB, 2003, ARCH PATHOL LAB MED, V127, P554; Suarez-Zarracina T, 2012, J VIRAL HEPATITIS, V19, P685, DOI 10.1111/j.1365-2893.2012.01596.x; Talaat AM, 1999, VET MICROBIOL, V66, P151, DOI 10.1016/S0378-1135(99)00002-4; Tanes C, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13081567; Wandeler G, 2016, CURR OPIN HIV AIDS, V11, P492, DOI 10.1097/COH.0000000000000298; Wei Q, 2017, BIOSCI TRENDS, V11, P274, DOI 10.5582/bst.2017.01071; who, HIV AIDS FACT SHEET; Zevin AS, 2017, FEMS MICROBIOL LETT, V364, DOI 10.1093/femsle/fnx228	62	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 10	2022	12								793842	10.3389/fimmu.2021.793842	http://dx.doi.org/10.3389/fimmu.2021.793842			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZC2MY	35082782	Green Published, gold			2022-12-18	WOS:000757361800001
J	Jiang, L; Yu, XQ; Swevers, L				Jiang, Liang; Yu, Xiao-Qiang; Swevers, Luc			Editorial: Novel Insights Into Insect Antiviral Immunity	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						insect; virus; infection; immunity; antiviral			[Jiang, Liang] Southwest Univ, State Key Lab Silkworm Genome Biol, Chongqing Key Lab Sericultural Sci, Chongqing Engn & Technol Res Ctr Novel Silk Mat, Chongqing, Peoples R China; [Jiang, Liang] Southwest Univ, Biol Sci Res Ctr, Chongqing, Peoples R China; [Yu, Xiao-Qiang] South China Normal Univ, Sch Life Sci, Inst Insect Sci & Technol, Guangdong Prov Key Lab Insect Dev Biol & Appl Tec, Guangzhou, Peoples R China; [Yu, Xiao-Qiang] Univ Missouri, Sch Biol & Chem Sci, Div Cell Biol & Biophys, Kansas City, MO 64110 USA; [Swevers, Luc] Natl Ctr Sci Res Demokritos, Insect Mol Genet & Biotechnol, Inst Biosci & Applicat, Athens, Greece	Southwest University - China; Southwest University - China; South China Normal University; University of Missouri System; University of Missouri Kansas City; National Centre of Scientific Research "Demokritos"	Jiang, L (corresponding author), Southwest Univ, State Key Lab Silkworm Genome Biol, Chongqing Key Lab Sericultural Sci, Chongqing Engn & Technol Res Ctr Novel Silk Mat, Chongqing, Peoples R China.; Jiang, L (corresponding author), Southwest Univ, Biol Sci Res Ctr, Chongqing, Peoples R China.	jiangliang@swu.edu.cn	YU, XiaoQiang/GRJ-1077-2022; YU, XIAO-QIANG/AAL-1797-2021	YU, XIAO-QIANG/0000-0003-1419-9009	National Natural Science Foundation of China [32170524, 31970474]; Natural Science Foundation of Chongqing, China [cstc2020jcyj-cxttX0001]; An Open-Access Research Infrastructure of Chemical Biology and Target-Based Screening Technologies for Human and Animal Health, Agriculture and the Environment (OPENSCREEN-GR) - Operational Programme ` Competitiveness, Entrepreneurship and Innovation' (NSR [MIS 5002691]; European Union (European Regional Development Fund)	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Chongqing, China(Natural Science Foundation of Chongqing); An Open-Access Research Infrastructure of Chemical Biology and Target-Based Screening Technologies for Human and Animal Health, Agriculture and the Environment (OPENSCREEN-GR) - Operational Programme ` Competitiveness, Entrepreneurship and Innovation' (NSR; European Union (European Regional Development Fund)(European Commission)	This work was funded by the National Natural Science Foundation of China (No. 32170524 and No. 31970474) and the Natural Science Foundation of Chongqing, China (cstc2020jcyj-cxttX0001). Luc Swevers acknowledges support of this work by the project ` An Open-Access Research Infrastructure of Chemical Biology and Target-Based Screening Technologies for Human and Animal Health, Agriculture and the Environment (OPENSCREEN-GR)' (MIS 5002691) which is implemented under the Action `Reinforcement of the Research and Innovation Infrastructure', funded by the Operational Programme ` Competitiveness, Entrepreneurship and Innovation' (NSRF 2014-2020) and co-financed by Greece and the European Union (European Regional Development Fund).		0	0	0	7	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 10	2022	12								740989	10.3389/fimmu.2021.740989	http://dx.doi.org/10.3389/fimmu.2021.740989			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZD1YL	35082776	gold, Green Published			2022-12-18	WOS:000758001300001
J	Lin, ZC; Liu, XZ; Liu, T; Gao, HX; Wang, ST; Zhu, XL; Rong, LJ; Cheng, JB; Cai, ZG; Xu, F; Tan, X; Lv, LJ; Li, Z; Sun, Y; Qian, QJ				Lin, Zhicai; Liu, Xiangzhen; Liu, Tao; Gao, Haixia; Wang, Sitong; Zhu, Xingli; Rong, Lijie; Cheng, Jingbo; Cai, Zhigang; Xu, Fu; Tan, Xue; Lv, Linjie; Li, Zhong; Sun, Yan; Qian, Qijun			Evaluation of Nonviral piggyBac and lentiviral Vector in Functions of CD19chimeric Antigen Receptor T Cells and Their Antitumor Activity for CD19(+) Tumor Cells	FRONTIERS IN IMMUNOLOGY			English	Article						chimeric antigen receptor; CD19; B lymphoma; piggyBac; T cells; lentiviral	TRANSPOSON SYSTEM; GENOME; IFP2	Nonviral transposon piggyBac (PB) and lentiviral (LV) vectors have been used to deliver chimeric antigen receptor (CAR) to T cells. To understand the differences in the effects of PB and LV on CAR T-cell functions, a CAR targeting CD19 was cloned into PB and LV vectors, and the resulting pbCAR and lvCAR were delivered to T cells to generate CD19pbCAR and CD19lvCAR T cells. Both CD19CAR T-cell types were strongly cytotoxic and secreted high IFN-gamma levels when incubated with Raji cells. TNF-alpha increased in CD19pbCAR T cells, whereas IL-10 increased in CD19lvCAR T cells. CD19pbCAR and CD19lvCAR T cells showed similar strong anti-tumor activity in Raji cell-induced mouse models, slightly reducing mouse weight while enhancing mouse survival. High, but not low or moderate, concentrations of CD19pbCAR T cells significantly inhibited Raji cell-induced tumor growth in vivo. These CD19pbCAR T cells were distributed mostly in mesenteric lymph nodes, bone marrow of the femur, spleen, kidneys, and lungs, specifically accumulating at CD19-rich sites and CD19-positive tumors, with CAR copy number being increased on day 7. These results indicate that pbCAR has its specific activities and functions in pbCAR T cells, making it a valuable tool for CAR T-cell immunotherapy.	[Lin, Zhicai; Liu, Xiangzhen; Wang, Sitong; Zhu, Xingli; Rong, Lijie; Cheng, Jingbo; Cai, Zhigang; Xu, Fu; Tan, Xue; Lv, Linjie; Li, Zhong; Sun, Yan; Qian, Qijun] Shanghai Cell Therapy Grp, Ctr Cell Pharmaceut, Med Cell Prod & R&D Dept, Shanghai, Peoples R China; [Liu, Tao; Gao, Haixia] Shanghai Cell Therapy Grp, R&D Dept, Nucleotide Ctr, Shanghai, Peoples R China; [Li, Zhong; Qian, Qijun] Shanghai Cell Therapy Res Inst, Dept Immunotherapy, Shanghai, Peoples R China; [Qian, Qijun] Shanghai Univ, Shanghai Menchao Canc Hosp, Shanghai, Peoples R China	Shanghai University	Li, Z; Sun, Y; Qian, QJ (corresponding author), Shanghai Cell Therapy Grp, Ctr Cell Pharmaceut, Med Cell Prod & R&D Dept, Shanghai, Peoples R China.; Li, Z; Qian, QJ (corresponding author), Shanghai Cell Therapy Res Inst, Dept Immunotherapy, Shanghai, Peoples R China.; Qian, QJ (corresponding author), Shanghai Univ, Shanghai Menchao Canc Hosp, Shanghai, Peoples R China.				Shanghai Cell Therapy Corporation [BZ019-Phase I]; National Key R&D Program of China [2019YFC316202, 2019YFC1316205]	Shanghai Cell Therapy Corporation; National Key R&D Program of China	This study was funded by Shanghai Cell Therapy Corporation (BZ019-Phase I) and the National Key R & D Program of China (2019YFC316202, 2019YFC1316205). The funders were not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication.	CARY LC, 1989, VIROLOGY, V172, P156, DOI 10.1016/0042-6822(89)90117-7; Davila ML, 2016, CLIN ADV HEMATOL ONC, V14, P802; FRASER MJ, 1995, VIROLOGY, V211, P397, DOI 10.1006/viro.1995.1422; Galvan DL, 2009, J IMMUNOTHER, V32, P837, DOI 10.1097/CJI.0b013e3181b2914c; He JC, 2018, CELL IMMUNOL, V329, P31, DOI 10.1016/j.cellimm.2018.04.007; Hu B, 2019, HUM GENE THER, V30, P446, DOI 10.1089/hum.2017.234; Labbe RP, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13081528; Li H, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0238-6; Liu QJ, 2020, PROTEIN CELL, V11, P549, DOI 10.1007/s13238-020-00707-9; Manuri PVR, 2010, HUM GENE THER, V21, P427, DOI 10.1089/hum.2009.114; Morita D, 2018, MOL THER-METH CLIN D, V8, P131, DOI 10.1016/j.omtm.2017.12.003; Nakazawa Y, 2016, J HEMATOL ONCOL, V9, DOI 10.1186/s13045-016-0256-3; Nakazawa Y, 2009, J IMMUNOTHER, V32, P826, DOI 10.1097/CJI.0b013e3181ad762b; Pathak Atul, 2009, Biotechnology Journal, V4, P1559, DOI 10.1002/biot.200900161; Ren H, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.745109; Saha S, 2012, JOVE-J VIS EXP, DOI 10.3791/4235; Saito S, 2014, CYTOTHERAPY, V16, P1257, DOI 10.1016/j.jcyt.2014.05.022; Sato M, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12030277; Wang P, 2020, IMMUNOBIOLOGY, V225, DOI 10.1016/j.imbio.2019.09.009; Wang W, 2008, P NATL ACAD SCI USA, V105, P9290, DOI 10.1073/pnas.0801017105; Wen W, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21093064; Whittington MD, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.0035; Whittington MD, 2018, JAMA PEDIATR, V172, P1161, DOI 10.1001/jamapediatrics.2018.2530; Wu SCY, 2006, P NATL ACAD SCI USA, V103, P15008, DOI 10.1073/pnas.0606979103; Xu JY, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317695949; Yoshida J, 2017, SCI REP-UK, V7, DOI 10.1038/srep43613; Yusa K, 2015, MICROBIOL SPECTR, V3, DOI 10.1128/microbiolspec.MDNA3-0028-2014; Zhang ZW, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1711-1	28	0	1	2	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 10	2022	12								802705	10.3389/fimmu.2021.802705	http://dx.doi.org/10.3389/fimmu.2021.802705			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YO6XU	35082789	gold, Green Published			2022-12-18	WOS:000748082500001
J	Liu, XQ; Jiang, TT; Wang, MY; Liu, WT; Huang, Y; Huang, YL; Jin, FY; Zhao, Q; Wang, GH; Ruan, XZ; Liu, BC; Ma, KL				Liu, Xiao Qi; Jiang, Ting Ting; Wang, Meng Ying; Liu, Wen Tao; Huang, Yang; Huang, Yu Lin; Jin, Feng Yong; Zhao, Qing; Wang, Gui Hua; Ruan, Xiong Zhong; Liu, Bi Cheng; Ma, Kun Ling			Using Machine Learning to Evaluate the Role of Microinflammation in Cardiovascular Events in Patients With Chronic Kidney Disease	FRONTIERS IN IMMUNOLOGY			English	Article						chronic kidney disease; cardiovascular disease; microinflammation; machine learning; lipid disorder	EXACERBATES LIPID-ACCUMULATION; ASSOCIATION; MORTALITY; HDL	BackgroundLipid metabolism disorder, as one major complication in patients with chronic kidney disease (CKD), is tied to an increased risk for cardiovascular disease (CVD). Traditional lipid-lowering statins have been found to have limited benefit for the final CVD outcome of CKD patients. Therefore, the purpose of this study was to investigate the effect of microinflammation on CVD in statin-treated CKD patients. MethodsWe retrospectively analysed statin-treated CKD patients from January 2013 to September 2020. Machine learning algorithms were employed to develop models of low-density lipoprotein (LDL) levels and CVD indices. A fivefold cross-validation method was employed against the problem of overfitting. The accuracy and area under the receiver operating characteristic (ROC) curve (AUC) were acquired for evaluation. The Gini impurity index of the predictors for the random forest (RF) model was ranked to perform an analysis of importance. ResultsThe RF algorithm performed best for both the LDL and CVD models, with accuracies of 82.27% and 74.15%, respectively, and is therefore the most suitable method for clinical data processing. The Gini impurity ranking of the LDL model revealed that hypersensitive C-reactive protein (hs-CRP) was highly relevant, whereas statin use and sex had the least important effects on the outcomes of both the LDL and CVD models. hs-CRP was the strongest predictor of CVD events. ConclusionMicroinflammation is closely associated with potential CVD events in CKD patients, suggesting that therapeutic strategies against microinflammation should be implemented to prevent CVD events in CKD patients treated by statin.	[Liu, Xiao Qi; Jiang, Ting Ting; Wang, Meng Ying; Liu, Wen Tao; Huang, Yang; Huang, Yu Lin; Jin, Feng Yong; Zhao, Qing; Wang, Gui Hua; Liu, Bi Cheng; Ma, Kun Ling] Southeast Univ, Zhongda Hosp, Inst Nephrol, Sch Med, Nanjing, Peoples R China; [Ruan, Xiong Zhong] Univ Coll London UCL, John Moorhead Res Lab, Dept Renal Med, Sch Med, London, England	Southeast University - China; University of London; University College London; UCL Medical School	Ma, KL (corresponding author), Southeast Univ, Zhongda Hosp, Inst Nephrol, Sch Med, Nanjing, Peoples R China.	klma05@163.com	Ruan, Xiong Zhong/GZA-5963-2022	Ruan, Xiong Zhong/0000-0001-5199-4971	National Natural Science Foundation of China [82170736, 81970629]; Jiangsu Province Social Development Project [BE2018744]; Project for Jiangsu Provincial Medical Talent [ZDRCA2016077]; Fundamental Research Funds for the Central Universities [3224002110D]; Jiangsu Province Ordinary University Graduate Research Innovation Project [SJCX20-0055]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Jiangsu Province Social Development Project; Project for Jiangsu Provincial Medical Talent; Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); Jiangsu Province Ordinary University Graduate Research Innovation Project	& nbsp;This study was supported by the National Natural Science Foundation of China (82170736, 81970629), the Jiangsu Province Social Development Project (BE2018744), the Project for Jiangsu Provincial Medical Talent (ZDRCA2016077), the Fundamental Research Funds for the Central Universities (3224002110D), and the Jiangsu Province Ordinary University Graduate Research Innovation Project (SJCX20-0055).	Basso PJ, 2021, NAT REV NEPHROL, V17, P465, DOI 10.1038/s41581-021-00413-7; Bohula EA, 2018, CIRCULATION, V138, P131, DOI [10.1, 10.1161/CIRCULATIONAHA.118.034032]; Calabresi L, 2015, J INTERN MED, V277, P552, DOI 10.1111/joim.12290; Chang CC, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-66542-4; Charytan DM, 2019, J AM COLL CARDIOL, V73, P2961, DOI 10.1016/j.jacc.2019.03.513; Chen YX, 2014, NEPHROL DIAL TRANSPL, V29, P1864, DOI 10.1093/ndt/gfu203; Chen YX, 2014, ARTERIOSCL THROM VAS, V34, P365, DOI 10.1161/ATVBAHA.113.301301; Chmielewski M, 2008, J NEPHROL, V21, P635; Dormuth CR, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f880; Fellstrom BC, 2009, NEW ENGL J MED, V360, P1395, DOI 10.1056/NEJMoa0810177; Go AS, 2004, NEW ENGL J MED, V351, P1296, DOI 10.1056/NEJMoa041031; Hagen E, 2021, NEUROINFORMATICS, V19, P493, DOI 10.1007/s12021-020-09496-2; Hu ZB, 2018, ACTA PHARMACOL SIN, V39, P1022, DOI 10.1038/aps.2017.177; Iatropoulos P, 2018, J AM SOC NEPHROL, V29, P283, DOI 10.1681/ASN.2017030258; Kronenberg F, 2018, J AM SOC NEPHROL, V29, P1356, DOI 10.1681/ASN.2017070798; Leung RKK, 2013, BMC NEPHROL, V14, DOI 10.1186/1471-2369-14-162; Liu YM, 2004, JAMA-J AM MED ASSOC, V291, P451, DOI 10.1001/jama.291.4.451; Ma KL, 2008, HEPATOLOGY, V48, P770, DOI 10.1002/hep.22423; Ma KL, 2015, ACTA BIOCH BIOPH SIN, V47, P767, DOI 10.1093/abbs/gmv079; Ma KL, 2013, CARDIOVASC RES, V100, P450, DOI 10.1093/cvr/cvt203; Matsushita K, 2010, LANCET, V375, P2073, DOI 10.1016/S0140-6736(10)60674-5; Ridker PM, 2017, NEW ENGL J MED, V377, P1119, DOI 10.1056/NEJMoa1707914; Ridker PM, 2009, LANCET, V373, P1175, DOI 10.1016/S0140-6736(09)60447-5; Shao BH, 2021, J LIPID RES, V62, DOI 10.1016/j.jlr.2021.100135; Shih CJ, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.116.004613; Sipper M, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-83247-4; Tomasev N, 2019, NATURE, V572, P116, DOI 10.1038/s41586-019-1390-1; Untersteller K, 2018, J LIPID RES, V59, P1256, DOI 10.1194/jlr.P085076; Wanner C, 2005, NEW ENGL J MED, V353, P238, DOI 10.1056/NEJMoa043545; Zhang Y, 2015, ACTA DIABETOL, V52, P1045, DOI 10.1007/s00592-015-0753-9	30	0	0	3	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 10	2022	12								796383	10.3389/fimmu.2021.796383	http://dx.doi.org/10.3389/fimmu.2021.796383			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZE2ZJ	35082785	gold, Green Published			2022-12-18	WOS:000758756600001
J	Murin, CD; Gilchuk, P; Jr, JCE; Ward, AB				Murin, Charles D.; Gilchuk, Pavlo; Crowe Jr, James E.; Ward, Andrew B.			Structural Biology Illuminates Molecular Determinants of Broad Ebolavirus Neutralization by Human Antibodies for Pan-Ebolavirus Therapeutic Development	FRONTIERS IN IMMUNOLOGY			English	Review						antibody; Ebola virus; structural biology; antibody therapeutics; filovirus and viral hemorrhagic fever	VIRUS ENTRY REQUIRES; NIEMANN-PICK C1; MONOCLONAL-ANTIBODIES; HEMORRHAGIC-FEVER; NONHUMAN-PRIMATES; MEDIATED NEUTRALIZATION; ENVELOPE GLYCOPROTEIN; PROTECTIVE ANTIBODY; FUSION LOOP; COCKTAIL	Monoclonal antibodies (mAbs) have proven effective for the treatment of ebolavirus infection in humans, with two mAb-based drugs Inmazeb (TM) and Ebanga (TM) receiving FDA approval in 2020. While these drugs represent a major advance in the field of filoviral therapeutics, they are composed of antibodies with single-species specificity for Zaire ebolavirus. The Ebolavirus genus includes five additional species, two of which, Bundibugyo ebolavirus and Sudan ebolavirus, have caused severe disease and significant outbreaks in the past. There are several recently identified broadly neutralizing ebolavirus antibodies, including some in the clinical development pipeline, that have demonstrated broad protection in preclinical studies. In this review, we describe how structural biology has illuminated the molecular basis of broad ebolavirus neutralization, including details of common antigenic sites of vulnerability on the glycoprotein surface. We begin with a discussion outlining the history of monoclonal antibody therapeutics for ebolaviruses, with an emphasis on how structural biology has contributed to these efforts. Next, we highlight key structural studies that have advanced our understanding of ebolavirus glycoprotein structures and mechanisms of antibody-mediated neutralization. Finally, we offer examples of how structural biology has contributed to advances in anti-viral medicines and discuss what opportunities the future holds, including rationally designed next-generation therapeutics with increased potency, breadth, and specificity against ebolaviruses.	[Murin, Charles D.; Ward, Andrew B.] Scripps Res Inst, Dept Integrat Struct & Computat Biol, La Jolla, CA 92037 USA; [Gilchuk, Pavlo; Crowe Jr, James E.] Vanderbilt Univ Sch Med, Vanderbilt Vaccine Ctr, Nashville, TN USA; [Crowe Jr, James E.] Vanderbilt Univ Sch Med, Dept Pathol Microbiol & Immunol, Nashville, TN USA; [Crowe Jr, James E.] Vanderbilt Univ Sch Med, Dept Pediat, Nashville, TN USA	Scripps Research Institute; Vanderbilt University; Vanderbilt University; Vanderbilt University	Murin, CD (corresponding author), Scripps Res Inst, Dept Integrat Struct & Computat Biol, La Jolla, CA 92037 USA.	cmurin@scripps.edu			NIH [U19 AI142785, U19 AI109711]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Funding This work was supported by the NIH (U19 AI142785 and U19 AI109711).	[Anonymous], CORONAVIRUS COVID 19; Antanasijevic A., 2021, STRUCTURE SEQUENCE I, DOI [10.1101/2021.04.13.439712, DOI 10.1101/2021.04.13.439712]; Antanasijevic A, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-25087-4; Bale S, 2012, VIRUSES-BASEL, V4, P447, DOI 10.3390/v4040447; Bianchi M, 2018, IMMUNITY, V49, P288, DOI 10.1016/j.immuni.2018.07.009; Biering SB, 2021, SCIENCE, V371, P194, DOI 10.1126/science.abc0476; Bornholdt ZA, 2019, CELL HOST MICROBE, V25, P49, DOI 10.1016/j.chom.2018.12.005; Bornholdt ZA, 2016, MBIO, V7, DOI 10.1128/mBio.02154-15; Bornholdt ZA, 2016, SCIENCE, V351, P1078, DOI 10.1126/science.aad5788; Breman JG, 2016, J INFECT DIS, V214, pS93, DOI 10.1093/infdis/jiw207; Burke J, 1978, B WORLD HEALTH ORGAN, V56, P271; Carette JE, 2011, NATURE, V477, P340, DOI 10.1038/nature10348; Chandran K, 2005, SCIENCE, V308, P1643, DOI 10.1126/science.1110656; Correia BE, 2014, NATURE, V507, P201, DOI 10.1038/nature12966; Corti D, 2016, SCIENCE, V351, P1339, DOI 10.1126/science.aad5224; Cote M, 2011, NATURE, V477, P344, DOI 10.1038/nature10380; Cressey D, 2017, NATURE, V546, P16, DOI 10.1038/nature.2017.22738; Cross RW, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22132-0; Davey RT, 2016, NEW ENGL J MED, V375, P1448, DOI 10.1056/NEJMoa1604330; Deng IM, 1978, B WORLD HEALTH ORGAN, V56, P247; Diamant E, 2015, TOXINS, V7, P1854, DOI 10.3390/toxins7061854; Dias JM, 2011, NAT STRUCT MOL BIOL, V18, P1424, DOI 10.1038/nsmb.2150; Dimitrov A, 2007, CURR OPIN INVEST DR, V8, P653; Dong JH, 2020, J CLIN INVEST, V130, P4734, DOI 10.1172/JCI136032; Dye JM, 2012, P NATL ACAD SCI USA, V109, P5034, DOI 10.1073/pnas.1200409109; EMOND RTD, 1977, BMJ-BRIT MED J, V2, P541, DOI 10.1136/bmj.2.6086.541; Erasmus JH, 2020, MOL THER-METH CLIN D, V18, P402, DOI 10.1016/j.omtm.2020.06.011; Fan PF, 2020, MABS-AUSTIN, V12, DOI 10.1080/19420862.2020.1742457; FDA, APPR TREATM EB VIR; FDA, APPR 1 TREATM EB VIR; Flyak AI, 2016, CELL, V164, P392, DOI 10.1016/j.cell.2015.12.022; Flyak AI, 2015, CELL, V160, P893, DOI 10.1016/j.cell.2015.01.031; Gilchuk P, 2021, CELL, V184, P5593, DOI 10.1016/j.cell.2021.09.035; Gilchuk P, 2020, IMMUNITY, V52, P388, DOI 10.1016/j.immuni.2020.01.001; Gilchuk P, 2018, IMMUNITY, V49, P363, DOI 10.1016/j.immuni.2018.06.018; Gong X, 2016, CELL, V165, P1467, DOI 10.1016/j.cell.2016.05.022; Graham BS, 2019, ANNU REV MED, V70, P91, DOI 10.1146/annurev-med-121217-094234; Gwosch KC, 2020, NAT METHODS, V17, P217, DOI 10.1038/s41592-019-0688-0; Han J, 2021, CELL REP, V34, DOI 10.1016/j.celrep.2020.108682; Hashiguchi T, 2015, CELL, V160, P904, DOI 10.1016/j.cell.2015.01.041; Hershberger E, 2019, EBIOMEDICINE, V40, P574, DOI 10.1016/j.ebiom.2018.12.051; Howell KA, 2017, CELL REP, V19, P413, DOI 10.1016/j.celrep.2017.03.049; Howell KA, 2016, CELL REP, V15, P1514, DOI 10.1016/j.celrep.2016.04.026; Hu D, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007836; Huo JD, 2020, CELL HOST MICROBE, V28, P445, DOI [10.1016/j.chom.2020.06.010, 10.1016/j.chom.2020.07.002]; Jahrling PB, 1999, J INFECT DIS, V179, pS224, DOI 10.1086/514310; Jahrling PB., IMPORTED VIRUS INFEC, V11, DOI [10.1007/978-3-7091-7482-1_12, DOI 10.1007/978-3-7091-7482-1_12]; Janus BM, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06113-4; Jaworski JP, 2018, LANCET HIV, V5, pE723, DOI 10.1016/S2352-3018(18)30174-7; Jensen B, 2021, LANCET REG HEALTH-EU, V8, DOI 10.1016/j.lanepe.2021.100164; Jiang SB, 2019, CELL MOL IMMUNOL, V16, P96, DOI 10.1038/s41423-018-0043-x; Johnson S, 1997, J INFECT DIS, V176, P1215, DOI 10.1086/514115; Julien JP, 2013, SCIENCE, V342, P1477, DOI 10.1126/science.1245625; Keck ZY, 2016, J VIROL, V90, P279, DOI 10.1128/JVI.02172-15; King LB, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09732-7; King LB, 2018, CELL HOST MICROBE, V23, P101, DOI 10.1016/j.chom.2017.12.003; KISSLING RE, 1968, SCIENCE, V160, P888, DOI 10.1126/science.160.3830.888; Kuhlbrandt W, 2014, SCIENCE, V343, P1443, DOI 10.1126/science.1251652; Kunz C, 1968, Wien Klin Wochenschr, V80, P161; Kwong PD, 2020, SEMIN IMMUNOL, V50, DOI 10.1016/j.smim.2020.101428; Lee JE, 2008, NATURE, V454, P177, DOI 10.1038/nature07082; Lee JE, 2008, J MOL BIOL, V375, P202, DOI 10.1016/j.jmb.2007.10.017; Lee JE, 2009, FUTURE VIROL, V4, P621, DOI 10.2217/FVL.09.56; Lee JE, 2009, ACTA CRYSTALLOGR D, V65, P1162, DOI 10.1107/S0907444909032314; Lee J, 2017, P NATL ACAD SCI USA, V114, pE7987, DOI 10.1073/pnas.1708052114; Lyumkis D, 2013, SCIENCE, V342, P1484, DOI 10.1126/science.1245627; Malashkevich VN, 1999, P NATL ACAD SCI USA, V96, P2662, DOI 10.1073/pnas.96.6.2662; Mankowski MC, 2018, P NATL ACAD SCI USA, V115, pE82, DOI 10.1073/pnas.1718441115; Marasco WA, 2007, NAT BIOTECHNOL, V25, DOI 10.1038/nbt1363; Margolis DM, 2017, IMMUNOL REV, V275, P313, DOI 10.1111/imr.12506; Maruyama T, 1999, J VIROL, V73, P6024, DOI 10.1128/JVI.73.7.6024-6030.1999; Marx V, 2018, NAT METHODS, V15, P575, DOI 10.1038/s41592-018-0079-y; Marzi A, 2018, J INFECT DIS, V218, pS662, DOI 10.1093/infdis/jiy235; Miller EH, 2012, EMBO J, V31, P1947, DOI 10.1038/emboj.2012.53; Mire CE, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aai8711; Misasi J, 2016, SCIENCE, V351, P1343, DOI 10.1126/science.aad6117; Mulangu S, 2019, NEW ENGL J MED, V381, P2293, DOI 10.1056/NEJMoa1910993; Mupapa K, 1999, J INFECT DIS, V179, pS18, DOI 10.1086/514298; Murin CD, 2021, CELL REP, V35, DOI 10.1016/j.celrep.2021.108984; Murin CD, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01635; Murin CD, 2019, NAT MICROBIOL, V4, P734, DOI 10.1038/s41564-019-0392-y; Murin CD, 2018, CELL REP, V24, P2723, DOI 10.1016/j.celrep.2018.08.009; Murin CD, 2014, P NATL ACAD SCI USA, V111, P17182, DOI 10.1073/pnas.1414164111; Nachbagauer R, 2017, CLIN MICROBIOL INFEC, V23, P222, DOI 10.1016/j.cmi.2017.02.009; Nogal B, 2020, CELL REP, V30, P3755, DOI 10.1016/j.celrep.2020.02.061; Oikonomou CM., 2016, ANNU REV BIOCHEM, V86, P1; Olal D, 2012, J VIROL, V86, P2809, DOI 10.1128/JVI.05549-11; Olinger GG, 2012, P NATL ACAD SCI USA, V109, P18030, DOI 10.1073/pnas.1213709109; Oswald WB, 2007, PLOS PATHOG, V3, P62, DOI 10.1371/journal.ppat.0030009; Pallesen J, 2016, NAT MICROBIOL, V1, DOI [10.1038/NMICROBIOL.2016.128, 10.1038/nmicrobiol.2016.128]; Pascal KE, 2018, J INFECT DIS, V218, pS612, DOI 10.1093/infdis/jiy285; Planas D, 2021, NATURE, V596, P276, DOI 10.1038/s41586-021-03777-9; Qiu XG, 2014, NATURE, V514, P47, DOI 10.1038/nature13777; Qiu XG, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003876; Qiu XG, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001575; Qiu XG, 2011, CLIN IMMUNOL, V141, P218, DOI 10.1016/j.clim.2011.08.008; Schornberg K, 2006, J VIROL, V80, P4174, DOI 10.1128/JVI.80.8.4174-4178.2006; Sedeyn K, 2019, ANTIVIR RES, V170, DOI 10.1016/j.antiviral.2019.104562; Shedlock DJ, 2010, VIROLOGY, V401, P228, DOI 10.1016/j.virol.2010.02.029; Siegert R, 1968, Ger Med Mon, V13, P1; Smith SA, 2015, MICROBIOL SPECTR, V3, DOI 10.1128/microbiolspec.AID-0027-2014; STILLE W, 1968, DEUT MED WOCHENSCHR, V93, P572, DOI 10.1055/s-0028-1105099; Stille W., 1971, MARBURG VIRUS DIS, DOI [10.1007/978-3-662-01593-3_2, DOI 10.1007/978-3-662-01593-3_2]; Suder E, 2018, HUM VACC IMMUNOTHER, V14, P2107, DOI 10.1080/21645515.2018.1473698; Taylor PC, 2021, NAT REV IMMUNOL, V21, P382, DOI 10.1038/s41577-021-00542-x; ter Meulen J, 2006, PLOS MED, V3, P1071, DOI 10.1371/journal.pmed.0030237; Todorovitch K., 1971, MARBURG VIRUS DIS, DOI [10.1007/978-3-662-01593-3_3, DOI 10.1007/978-3-662-01593-3_3]; Tran EEH, 2016, J VIROL, V90, P7618, DOI 10.1128/JVI.00406-16; Tran EEH, 2014, J VIROL, V88, P10958, DOI 10.1128/JVI.00870-14; Turner HL, 2021, SCI ADV, V7, DOI [10.1126/sciadv.abh2791, 10.1101/2021.02.16.431310]; Turner HL, 2019, PLOS BIOL, V17, DOI 10.1371/journal.pbio.3000139; Volchkov V., ACTIVATION VIRUSES H, DOI [10.1007/978-3-319-75474-1_5, DOI 10.1007/978-3-319-75474-1_5]; Volchkov VE, 1998, P NATL ACAD SCI USA, V95, P5762, DOI 10.1073/pnas.95.10.5762; Wang H, 2016, CELL, V164, P258, DOI 10.1016/j.cell.2015.12.044; Wang QH, 2017, J VIROL, V91, DOI 10.1128/JVI.01049-17; Wec AZ, 2019, CELL HOST MICROBE, V25, P39, DOI 10.1016/j.chom.2018.12.004; Wec AZ, 2017, CELL, V169, P878, DOI 10.1016/j.cell.2017.04.037; Wec AZ, 2016, SCIENCE, V354, P350, DOI 10.1126/science.aag3267; Weinreich DM, 2021, NEW ENGL J MED, V384, P238, DOI 10.1056/NEJMoa2035002; Weissenberger G, 2021, NAT METHODS, V18, P463, DOI 10.1038/s41592-021-01130-6; West BR, 2019, NAT STRUCT MOL BIOL, V26, P204, DOI 10.1038/s41594-019-0191-4; West BR, 2018, MBIO, V9, DOI [10.1128/mBio.01674-18, 10.1128/mbio.01674-18]; Wirchnianski AS, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.729851; Wool-Lewis RJ, 1999, J VIROL, V73, P1419, DOI 10.1128/JVI.73.2.1419-1426.1999; Xu MH, 2017, NPJ VACCINES, V2, DOI 10.1038/s41541-016-0003-3; Zhang YJ, 2019, J VIROL, V93, DOI 10.1128/JVI.01446-18; Zhao XL, 2017, CELL, V169, P891, DOI 10.1016/j.cell.2017.04.038; Zhao YG, 2016, NATURE, V535, P169, DOI 10.1038/nature18615; Zost SJ, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI146791; Zost SJ, 2020, NAT MED, V26, DOI [10.1038/s41591-020-0998-x, 10.1101/2020.05.12.091462]	131	0	0	2	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 10	2022	12								808047	10.3389/fimmu.2021.808047	http://dx.doi.org/10.3389/fimmu.2021.808047			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZC5UL	35082794	Green Published, gold			2022-12-18	WOS:000757584800001
J	Negrini, S; Contini, P; Murdaca, G; Puppo, F				Negrini, Simone; Contini, Paola; Murdaca, Giuseppe; Puppo, Francesco			HLA-G in Allergy: Does It Play an Immunoregulatory Role?	FRONTIERS IN IMMUNOLOGY			English	Review						HLA-G; soluble HLA-G; allergy; allergic rhinitis; allergic asthma	LEUKOCYTE-ANTIGEN-G; HLA-A,-B,-C SERUM-LEVELS; BLOOD MONONUCLEAR-CELLS; REGULATORY T-CELLS; G EXPRESSION; INSERTION/DELETION POLYMORPHISM; PERIPHERAL-BLOOD; G MOLECULE; SUBLINGUAL IMMUNOTHERAPY; INTERLEUKIN-10 LEVELS	Allergy is an inflammatory process determined by a cascade of immune events characterized by T-helper 2 lymphocytes polarization leading to interleukin-4 upregulation, IgE secretion, and mast cell and eosinophil activation. HLA-G molecules, both in membrane-bound and in soluble forms, are known to play a key immunoregulatory role and their involvement in allergic diseases is supported by increasing literature data. HLA-G expression and secretion is specifically induced in peripheral blood mononuclear cells of allergic patients after in vitro incubation with the causal allergen. Elevated levels of soluble HLA-G molecules are detected in serum of patients with allergic rhinitis correlating with allergen-specific IgE levels, clinical severity, drug consumption and response to allergen-specific immunotherapy. HLA-G genetic polymorphisms confer susceptibility to allergic asthma development and high levels of soluble HLA-G molecules are found in plasma and bronchoalveolar lavage fluid of patients with allergic asthma correlating with allergen-specific IgE levels. Interestingly, allergic pregnant women have lower plasma sHLA-G levels than non-allergic women during the 3(rd) trimester of pregnancy and at delivery. Finally, in allergic patients with atopic dermatitis HLA-G molecules are expressed by T cells, monocytes-macrophages and Langerhans cells infiltrating the dermis. Although at present is difficult to completely define the role of HLA-G molecules in allergic diseases, it may be suggested that they are specifically expressed and secreted by immune cells during the allergic reaction in an attempt to suppress allergic inflammation.	[Negrini, Simone; Contini, Paola; Murdaca, Giuseppe; Puppo, Francesco] Univ Genoa, Dept Internal Med, Genoa, Italy	University of Genoa	Puppo, F (corresponding author), Univ Genoa, Dept Internal Med, Genoa, Italy.	puppof@unige.it						Alves CC, 2018, MOL IMMUNOL, V101, P500, DOI 10.1016/j.molimm.2018.08.013; Aractingi S, 2001, AM J PATHOL, V159, P71, DOI 10.1016/S0002-9440(10)61675-6; Borghi A, 2014, DERMATOL THER, V27, P284, DOI 10.1111/dth.12140; Carlini F, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00006; Carosella ED, 2015, ADV IMMUNOL, V127, P33, DOI 10.1016/bs.ai.2015.04.001; Carosella ED, 2011, BLOOD, V118, P6499, DOI 10.1182/blood-2011-07-370742; Carosella ED, 2008, HUM IMMUNOL, V69, P700, DOI 10.1016/j.humimm.2008.08.280; Catamo E, 2014, TISSUE ANTIGENS, V84, P308, DOI 10.1111/tan.12396; Catamo E, 2015, HUM IMMUNOL, V76, P36, DOI 10.1016/j.humimm.2014.12.006; Caumartin J, 2007, EMBO J, V26, P1423, DOI 10.1038/sj.emboj.7601570; Ciprandi G, 2008, ALLERGY, V63, P1335, DOI 10.1111/j.1398-9995.2008.01741.x; Ciprandi G, 2014, INFLAMMATION, V37, P1630, DOI 10.1007/s10753-014-9890-5; Ciprandi G, 2010, J BIOL REG HOMEOS AG, V24, P221; Ciprandi G, 2008, HUM IMMUNOL, V69, P409, DOI 10.1016/j.humimm.2008.05.009; Ciprandi G, 2014, ALLERGY RHINOL, V5, pE9, DOI 10.2500/ar.2014.5.0076; Ciprandi G, 2009, INT ARCH ALLERGY IMM, V150, P278, DOI 10.1159/000222680; Ciprandi G, 2009, INT IMMUNOPHARMACOL, V9, P1058, DOI 10.1016/j.intimp.2009.04.014; Ciprandi G, 2009, INT IMMUNOPHARMACOL, V9, P253, DOI 10.1016/j.intimp.2008.11.009; Cirulli V, 2006, DIABETES, V55, P1214, DOI 10.2337/db05-0731; Contini P, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01613; Contini P, 2005, J IMMUNOL, V175, P7244, DOI 10.4049/jimmunol.175.11.7244; Contini P, 2003, EUR J IMMUNOL, V33, P125, DOI 10.1002/immu.200390015; Contini P, 2018, CLIN EXP IMMUNOL, V193, P152, DOI 10.1111/cei.13134; Contini P, 2016, HUM IMMUNOL, V77, P1172, DOI 10.1016/j.humimm.2016.08.005; El-Shahaway Alia A, 2018, Egypt J Immunol, V25, P125; Fainardi E, 2016, MULT SCLER J, V22, P245, DOI 10.1177/1352458515590647; Favoino E, 2015, CLIN EXP IMMUNOL, V181, P100, DOI 10.1111/cei.12633; Feger U, 2007, BLOOD, V110, P568, DOI 10.1182/blood-2006-11-057125; Fournel S, 2000, J IMMUNOL, V164, P6100, DOI 10.4049/jimmunol.164.12.6100; Giuliani M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002241; Gonzalez A, 2012, CRIT REV CL LAB SCI, V49, P63, DOI 10.3109/10408363.2012.677947; Granada M, 2012, J ALLERGY CLIN IMMUN, V129, P840, DOI 10.1016/j.jaci.2011.09.029; Guo ZY, 2015, CELL IMMUNOL, V293, P10, DOI 10.1016/j.cellimm.2014.10.003; Han MY, 2014, INFLAMMATION, V37, P1718, DOI 10.1007/s10753-014-9900-7; HoWangYin KY, 2010, CELL MOL LIFE SCI, V67, P1133, DOI 10.1007/s00018-009-0239-4; Huang YH, 2009, J LEUKOCYTE BIOL, V86, P273, DOI 10.1189/jlb.1008649; Johansen LL, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/6829283; Kanai T, 2001, MOL HUM REPROD, V7, P195, DOI 10.1093/molehr/7.2.195; Kanai T, 2001, AM J REPROD IMMUNOL, V45, P94, DOI 10.1111/j.8755-8920.2001.450205.x; Khosrotehrani K, 2001, J INVEST DERMATOL, V117, P750, DOI 10.1046/j.0022-202x.2001.01487.x; Konig L, 2016, HUM IMMUNOL, V77, P791, DOI 10.1016/j.humimm.2016.01.002; KOVATS S, 1990, SCIENCE, V248, P220, DOI 10.1126/science.2326636; Laaribi AB, 2015, J VIRAL HEPATITIS, V22, P835, DOI 10.1111/jvh.12395; Lafon M, 2005, J VIROL, V79, P15226, DOI 10.1128/JVI.79.24.15226-15237.2005; Le Discorde M, 2003, HUM IMMUNOL, V64, P1039, DOI 10.1016/j.humimm.2003.08.346; Le Friec G, 2003, HUM IMMUNOL, V64, P752, DOI 10.1016/S0198-8859(03)00091-0; Le Page MEL, 2013, TISSUE ANTIGENS, V82, P276, DOI 10.1111/tan.12185; LeMaoult J, 2007, BLOOD, V109, P2040, DOI 10.1182/blood-2006-05-024547; LeMaoult J, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.649344; Lila N, 2000, LANCET, V355, P2138, DOI 10.1016/S0140-6736(00)02386-2; Lila N, 2001, P NATL ACAD SCI USA, V98, P12150, DOI 10.1073/pnas.201407398; Lin AF, 2019, CLIN TRANSL IMMUNOL, V8, DOI 10.1002/cti2.1077; Lin AF, 2016, METHODS MOL BIOL, V1371, P3, DOI 10.1007/978-1-4939-3139-2_1; Lozano JM, 2002, AIDS, V16, P347, DOI 10.1097/00002030-200202150-00005; Maeda N, 2017, INT IMMUNOPHARMACOL, V50, P202, DOI 10.1016/j.intimp.2017.06.026; Mallet V, 1999, INT IMMUNOL, V11, P889, DOI 10.1093/intimm/11.6.889; Mapp CE, 2009, CLIN EXP ALLERGY, V39, P812, DOI 10.1111/j.1365-2222.2009.03215.x; Menier C, 2004, BLOOD, V104, P3153, DOI 10.1182/blood-2004-03-0809; Mohammadi N, 2016, J NEUROIMMUNOL, V290, P115, DOI 10.1016/j.jneuroim.2015.11.019; Moreau P, 1999, INT IMMUNOL, V11, P803, DOI 10.1093/intimm/11.5.803; Murdaca G, 2018, VIRCHOWS ARCH, V473, P425, DOI 10.1007/s00428-018-2379-0; Murdaca G, 2017, CLIN EXP MED, V17, P93, DOI 10.1007/s10238-015-0399-5; Murdaca G, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/6865758; Murdaca G, 2009, CLIN IMMUNOL, V133, P238, DOI 10.1016/j.clim.2009.08.002; Naji A, 2014, J IMMUNOL, V192, P1536, DOI 10.4049/jimmunol.1300438; Negrini S, 2020, HUM IMMUNOL, V81, P162, DOI 10.1016/j.humimm.2019.12.004; Nicodemus-Johnson J, 2013, J ALLERGY CLIN IMMUN, V131, P1496, DOI 10.1016/j.jaci.2013.01.037; Nicolae D, 2005, AM J HUM GENET, V76, P349, DOI 10.1086/427763; Ober C, 2005, IMMUNOL ALLERGY CLIN, V25, P669, DOI 10.1016/j.iac.2005.08.001; Oettgen H, 2012, ALLERGY, V4th, P1; Souza DMBO, 2016, SCAND J IMMUNOL, V83, P38, DOI 10.1111/sji.12385; Pankratz S, 2014, FASEB J, V28, P3435, DOI 10.1096/fj.14-251074; Ribeyre C, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00278; Ristich V, 2005, EUR J IMMUNOL, V35, P1133, DOI 10.1002/eji.200425741; Rizzo R, 2009, AM J REPROD IMMUNOL, V61, P368, DOI 10.1111/j.1600-0897.2009.00703.x; Rouas-Freiss N, 2005, CANCER RES, V65, P10139, DOI 10.1158/0008-5472.CAN-05-0097; Sadissou I, 2014, MALARIA J, V13, DOI 10.1186/1475-2875-13-312; Sorensen AE, 2013, INT ARCH ALLERGY IMM, V162, P237, DOI 10.1159/000353281; Tahan F, 2006, INT ARCH ALLERGY IMM, V141, P213, DOI 10.1159/000095290; Tahan F, 2017, PEDIATR INT, V59, P530, DOI 10.1111/ped.13207; Tan Z, 2007, AM J HUM GENET, V81, P829, DOI 10.1086/521200; White SR, 2010, EUR RESPIR J, V35, P925, DOI 10.1183/09031936.00164809; White SR, 2017, J ALLERGY CLIN IMMUN, V140, P857, DOI 10.1016/j.jaci.2017.02.031; Wiendl H, 2005, BRAIN, V128, P2689, DOI 10.1093/brain/awh609; Wisniewski A, 2015, TISSUE ANTIGENS, V85, P466, DOI 10.1111/tan.12561; Xu DP, 2016, HUM IMMUNOL, V77, P800, DOI 10.1016/j.humimm.2016.01.003; Yang YP, 1996, J IMMUNOL, V156, P4224; Yao Y, 2021, ALLERGY, V76, P456, DOI 10.1111/all.14639; Zhang XL, 2014, HUM IMMUNOL, V75, P1171, DOI 10.1016/j.humimm.2014.10.008; Zhao H, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01578; Zheng JY, 2014, IMMUNOL LETT, V161, P13, DOI 10.1016/j.imlet.2014.04.007; Zheng XQ, 2010, HUM IMMUNOL, V71, P982, DOI 10.1016/j.humimm.2010.06.018	92	0	0	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 10	2022	12								789684	10.3389/fimmu.2021.789684	http://dx.doi.org/10.3389/fimmu.2021.789684			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YO6KT	35082780	Green Published, gold			2022-12-18	WOS:000748048600001
J	Shang, BQ; Cao, CZ; Jiang, WX; Shi, HZ; Bi, XA; Cui, CX; Shou, JZ; Zheng, S; Zhang, J; Zhou, AP; Li, CL; Ma, JH				Shang, Bingqing; Cao, Chuanzhen; Jiang, Weixing; Shi, Hongzhe; Bi, Xingang; Cui, Chengxu; Shou, Jianzhong; Zheng, Shan; Zhang, Jin; Zhou, Aiping; Li, Changling; Ma, Jianhui			Promising Immunotherapy in Metastatic Testicular Sex Cord Stromal Tumours After First-Line Chemotherapy	FRONTIERS IN IMMUNOLOGY			English	Article						testicular sex cord stromal tumours; metastasis; immunotherapy; immune checkpoint inhibitors; PD-1 inhibitor; prognosis	SERTOLI-CELL TUMORS; CLINICOPATHOLOGICAL ANALYSIS; TESTIS; OUTCOMES	BackgroundTesticular sex cord stromal tumours (TSCSTs) are rare, with few studies focusing on the metastatic TSCST prognosis. The value of treatments, including radical orchiectomy (RO) and retroperitoneal lymph node dissection (RPLND), in preventing metastasis is controversial. Additionally, metastatic TSCSTs are resistant to chemotherapy. We aimed to assess the effectiveness and safety of immunotherapy in metastatic TSCSTs after first-line chemotherapy. MethodsWe retrospectively screened patients with testicular tumours undergoing testis surgery between January 2005 and January 2019. Patients with TSCSTs who had undergone testis-sparing surgery (TSS) or RO were identified. The malignant type was defined as metastasis confirmed by pathology. Treatment responses, progression-free survival (PFS), overall survival (OS) and safety were analysed. ResultsAmong the 494 testicular tumour patients who received TSS or RO, 11 (2.2%) patients with histologically proven TSCSTs were identified. At the last follow-up, 7 patients survived without tumours, and 4 patients developed metastasis and received first-line cisplatin-based chemotherapy, with 1 of them achieving an objective response. Their PFS times were 1.5, 2.2, 9.0, and 17.0 months, respectively. Two patients received immune checkpoint inhibitors (ICIs) after developing chemotherapy resistance and achieved a partial response up to the last follow-up; one of them experienced Grade 1 adverse events, and the other experienced Grade 2 adverse events during immunotherapy. The median OS time of the 4 patients with metastatic TSCSTs was 32 months. ConclusionsTSCSTs are rare, and most are benign with a good prognosis. ICIs represent a promising option for improving clinical outcomes in metastatic TSCSTs.	[Shang, Bingqing; Cao, Chuanzhen; Jiang, Weixing; Shi, Hongzhe; Bi, Xingang; Shou, Jianzhong; Li, Changling; Ma, Jianhui] Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Dept Urol, Natl Canc Ctr,Canc Hosp, Beijing, Peoples R China; [Cui, Chengxu; Zhou, Aiping] Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Dept Med Oncol, Natl Canc Ctr,Canc Hosp, Beijing, Peoples R China; [Zheng, Shan] Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Dept Pathol, Natl Canc Ctr,Canc Hosp, Beijing, Peoples R China; [Zhang, Jin] Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Dept Radiol, Natl Canc Ctr,Canc Hosp, Beijing, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; Peking Union Medical College	Shou, JZ (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Dept Urol, Natl Canc Ctr,Canc Hosp, Beijing, Peoples R China.; Cui, CX (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Dept Med Oncol, Natl Canc Ctr,Canc Hosp, Beijing, Peoples R China.	13701212251@139.com; shoujzh2021@163.com		Shi, Hongzhe/0000-0001-6660-7081				Acar C, 2009, UROLOGY, V73, P1165, DOI 10.1016/j.urology.2008.10.036; Adayener C, 2008, INT UROL NEPHROL, V40, P1005, DOI 10.1007/s11255-008-9396-x; Aguilar R, 2017, J IMMUNOTHER CANCER, V5, DOI 10.1186/s40425-017-0237-2; Albany C, 2018, ONCOLOGIST, V23, P316, DOI 10.1634/theoncologist.2017-0544; Banerji JS, 2016, J UROLOGY, V196, P1117, DOI 10.1016/j.juro.2016.03.143; Bansal P, 2016, FRONT ONCOL, V6, DOI 10.3389/fonc.2016.00239; BERTRAM KA, 1991, CANCER, V68, P2324, DOI 10.1002/1097-0142(19911115)68:10<2324::AID-CNCR2820681036>3.0.CO;2-K; DAVIS S, 1981, CANCER, V47, P425, DOI 10.1002/1097-0142(19810115)47:2<425::AID-CNCR2820470234>3.0.CO;2-S; Fankhauser CD, 2020, J UROLOGY, V203, P949, DOI 10.1097/JU.0000000000000705; Froehner M, 2006, CANCER CHEMOTH PHARM, V58, P716, DOI 10.1007/s00280-005-0181-6; Giglio M, 2003, UROL INT, V70, P205, DOI 10.1159/000068770; Grogg J, 2020, ONCOLOGIST, V25, P585, DOI 10.1634/theoncologist.2019-0692; Jou P, 2009, J UROLOGY, V181, P2299, DOI 10.1016/j.juro.2009.02.051; KIM I, 1985, AM J SURG PATHOL, V9, P177, DOI 10.1097/00000478-198503000-00002; Luke JJ, 2017, NAT REV CLIN ONCOL, V14, P463, DOI 10.1038/nrclinonc.2017.43; MADSEN EL, 1990, ACTA ONCOL, V29, P946, DOI 10.3109/02841869009096396; Mosharafa AA, 2003, CANCER, V98, P753, DOI 10.1002/cncr.11573; Motzer RJ, 2018, NEW ENGL J MED, V378, P1277, DOI 10.1056/NEJMoa1712126; Necchi A, 2019, EUR UROL FOCUS, V5, P748, DOI 10.1016/j.euf.2019.05.012; Nicolai N, 2015, UROLOGY, V85, P402, DOI 10.1016/j.urology.2014.10.021; Silberstein JL, 2014, J UROLOGY, V192, P415, DOI 10.1016/j.juro.2014.01.104; UNLUER E, 1990, International Urology and Nephrology, V22, P455, DOI 10.1007/BF02549777; Young RH, 1998, AM J SURG PATHOL, V22, P709, DOI 10.1097/00000478-199806000-00008	23	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 10	2022	12								720359	10.3389/fimmu.2021.720359	http://dx.doi.org/10.3389/fimmu.2021.720359			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YO7BT	35082775	Green Published, gold			2022-12-18	WOS:000748092800001
J	Soponpong, S; Amparyup, P; Kawai, T; Tassanakajon, A				Soponpong, Suthinee; Amparyup, Piti; Kawai, Taro; Tassanakajon, Anchalee			Penaeus monodon Interferon Regulatory Factor (PmIRF) Activates IFNs and Antimicrobial Peptide Expression via a STING-Dependent DNA Sensing Pathway	FRONTIERS IN IMMUNOLOGY			English	Article						IRF; STING; DNA sensing pathway; antiviral response; interferon; shrimp immunity	PATTERN-RECOGNITION RECEPTORS; INNATE IMMUNE RECOGNITION; CYCLIC GMP-AMP; I INTERFERON; INTRACELLULAR DNA; TRANSCRIPTION FACTORS; IRF FAMILY; RIG-I; REVEALS; SENSOR	Interferon regulatory factors (IRFs) are transcription factors found in both vertebrates and invertebrates that were recently identified and found to play an important role in antiviral immunity in black tiger shrimp Penaeus monodon. In this study, we investigated the mechanism by which P. monodon IRF (PmIRF) regulates the immune-related genes downstream of the cytosolic DNA sensing pathway. Depletion of PmIRF by double-stranded RNA-mediated gene silencing significantly reduced the mRNA expression levels of the IFN-like factors PmVago1, PmVago4, and PmVago5 and antilipopolysaccharide factor 6 (ALFPm6) in shrimp. In human embryonic kidney (HEK293T) cells transfected with PmIRF or co-transfected with DEAD-box polypeptide (PmDDX41) and simulator of IFN genes (PmSTING) expression plasmids, the promoter activity of IFN-beta, nuclear factor (NF-kappa B), and ALFPm6 was synergistically enhanced following stimulation with the nucleic acid mimics deoxyadenylic-deoxythymidylic acid sodium salt [poly(dA:dT)] and high molecular weight (HMW) polyinosinic-polycytidylic acid [poly(I:C)]. Both nucleic acid mimics also significantly induced PmSTING, PmIRF, and ALFPm6 gene expression. Co-immunoprecipitation experiments showed that PmIRF interacted with PmSTING in cells stimulated with poly(dA:dT). PmSTING, PmIRF, and PmDDX41 were localized in the cytoplasm of unstimulated HEK293T cells and PmIRF and PmDDX41 were translocated to the nucleus upon stimulation with the nucleic acid mimics while PmSTING remained in the cytoplasm. These results indicate that PmIRF transduces the pathogen signal via the PmDDX41-PmSTING DNA sensing pathway to induce downstream production of interferon-like molecules and antimicrobial peptides.	[Soponpong, Suthinee; Tassanakajon, Anchalee] Chulalongkorn Univ, Ctr Excellence Mol Biol & Genom Shrimp, Dept Biochem, Fac Sci, Bangkok, Thailand; [Amparyup, Piti] Natl Sci & Technol Dev Agcy NSTDA, Marine Biotechnol Res Team, Integrat Aquaculture Biotechnol Res Grp, Natl Ctr Genet Engn & Biotechnol BIOTEC, Pathum Thani, Thailand; [Amparyup, Piti] Chulalongkorn Univ, Ctr Excellence Marine Biotechnol, Dept Marine Sci, Fac Sci, Bangkok, Thailand; [Kawai, Taro] Nara Inst Sci & Technol NAIST, Lab Mol Immunobiol, Div Biol Sci, Grad Sch Sci & Technol, Ikoma, Japan	Chulalongkorn University; National Science & Technology Development Agency - Thailand; National Center Genetic Engineering & Biotechnology (BIOTEC); Chulalongkorn University; Nara Institute of Science & Technology	Tassanakajon, A (corresponding author), Chulalongkorn Univ, Ctr Excellence Mol Biol & Genom Shrimp, Dept Biochem, Fac Sci, Bangkok, Thailand.	Anchalee.k@chula.ac.th						Ablasser A, 2019, SCIENCE, V363, P1055, DOI 10.1126/science.aat8657; Ablasser A, 2013, NATURE, V498, P380, DOI 10.1038/nature12306; Amparyup P, 2009, DEV COMP IMMUNOL, V33, P247, DOI 10.1016/j.dci.2008.09.003; Amparyup P, 2007, FISH SHELLFISH IMMUN, V22, P535, DOI 10.1016/j.fsi.2006.07.004; Amparyup P, 2021, FISH SHELLFISH IMMUN, V117, P240, DOI 10.1016/j.fsi.2021.08.016; Amparyup P, 2010, DEV COMP IMMUNOL, V34, P168, DOI 10.1016/j.dci.2009.09.004; Balkhi MY, 2008, MOL CELL BIOL, V28, P7296, DOI 10.1128/MCB.00662-08; Barnes B, 2002, J INTERF CYTOK RES, V22, P59, DOI 10.1089/107999002753452665; Brubaker SW, 2015, ANNU REV IMMUNOL, V33, P257, DOI 10.1146/annurev-immunol-032414-112240; Deddouche S, 2008, NAT IMMUNOL, V9, P1425, DOI 10.1038/ni.1664; Dempsey A, 2015, VIROLOGY, V479, P146, DOI 10.1016/j.virol.2015.03.013; Escalante CR, 1998, NATURE, V391, P103, DOI 10.1038/34224; Ferguson BJ, 2012, ELIFE, V1, DOI 10.7554/eLife.00047; Gao DX, 2013, SCIENCE, V341, P903, DOI 10.1126/science.1240933; Goto A, 2018, IMMUNITY, V49, P225, DOI 10.1016/j.immuni.2018.07.013; Honda K, 2006, NAT REV IMMUNOL, V6, P644, DOI 10.1038/nri1900; Ikushima H, 2013, COLD SH Q B, V78, P105, DOI 10.1101/sqb.2013.78.020321; Ishikawa H, 2009, NATURE, V461, P788, DOI 10.1038/nature08476; Jones JW, 2010, P NATL ACAD SCI USA, V107, P9771, DOI 10.1073/pnas.1003738107; Kargbo Robert B, 2021, ACS Med Chem Lett, V12, P328, DOI 10.1021/acsmedchemlett.1c00085; Kato H, 2005, IMMUNITY, V23, P19, DOI 10.1016/j.immuni.2005.04.010; Kawai T, 2005, NAT IMMUNOL, V6, P981, DOI 10.1038/ni1243; Kawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863; Kawasaki T, 2011, IMMUNOL REV, V243, P61, DOI 10.1111/j.1600-065X.2011.01048.x; Kondo T, 2013, P NATL ACAD SCI USA, V110, P2969, DOI 10.1073/pnas.1222694110; Kumar H, 2011, INT REV IMMUNOL, V30, P16, DOI 10.3109/08830185.2010.529976; Li CZ, 2015, SCI REP-UK, V5, DOI 10.1038/srep15078; Li HY, 2017, FEBS LETT, V591, P1010, DOI 10.1002/1873-3468.12607; Liu SQ, 2015, SCIENCE, V347, P1217, DOI 10.1126/science.aaa2630; Ma JX, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01327; Margolis SR, 2017, TRENDS IMMUNOL, V38, P733, DOI 10.1016/j.it.2017.03.004; Martin M, 2018, CELL REP, V23, P3537, DOI 10.1016/j.celrep.2018.05.029; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; Motwani M, 2019, NAT REV GENET, V20, P657, DOI 10.1038/s41576-019-0151-1; Nehyba J, 2009, MOL BIOL EVOL, V26, P2539, DOI 10.1093/molbev/msp167; Nhnhkorn Z, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01430; Paludan SR, 2013, IMMUNITY, V38, P870, DOI 10.1016/j.immuni.2013.05.004; Paradkar PN, 2012, P NATL ACAD SCI USA, V109, P18915, DOI 10.1073/pnas.1205231109; Parvatiyar K, 2012, NAT IMMUNOL, V13, P1155, DOI 10.1038/ni.2460; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Ponprateep S, 2012, FISH SHELLFISH IMMUN, V32, P26, DOI 10.1016/j.fsi.2011.10.010; Soponpong S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02069; Soponpong S, 2018, DEV COMP IMMUNOL, V81, P291, DOI 10.1016/j.dci.2017.12.013; Sun F, 2011, J IMMUNOL, V187, P2531, DOI 10.4049/jimmunol.1100642; Sun F, 2010, J IMMUNOL, V185, P7573, DOI 10.4049/jimmunol.1002401; Tanaka Y, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002521; Taniguchi T, 2001, ANNU REV IMMUNOL, V19, P623, DOI 10.1146/annurev.immunol.19.1.623; Thompson MR, 2014, J BIOL CHEM, V289, P23568, DOI 10.1074/jbc.M114.554147; Tsuchida T, 2010, IMMUNITY, V33, P765, DOI 10.1016/j.immuni.2010.10.013; Unterholzner L, 2013, IMMUNOBIOLOGY, V218, P1312, DOI 10.1016/j.imbio.2013.07.007; West AP, 2015, NATURE, V520, P553, DOI 10.1038/nature14156; Wu JX, 2013, SCIENCE, V339, P826, DOI 10.1126/science.1229963; Yanai H, 2012, ONCOIMMUNOLOGY, V1, P1376, DOI 10.4161/onci.22475; Yum S, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2100225118; Zahid A, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.613039; Zhang XJ, 2015, BRIT J PHARMACOL, V172, P5457, DOI 10.1111/bph.12881; Zhang ZQ, 2011, NAT IMMUNOL, V12, P959, DOI 10.1038/ni.2091	57	0	0	2	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 10	2022	12								818267	10.3389/fimmu.2021.818267	http://dx.doi.org/10.3389/fimmu.2021.818267			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YO6EN	35082798	gold, Green Published			2022-12-18	WOS:000748032400001
J	Zhang, DF; Liu, CH; Nakatsukasa, H; Chen, WJ				Zhang, Dunfang; Liu, Chaohong; Nakatsukasa, Hiroko; Chen, Wan Jun			Editorial: Hexose Uptake and Metabolism in Immune Homeostasis and Inflammation	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						glucose; mannose; fructose; autoimmunity; glycometabolism	CELLS		[Zhang, Dunfang] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Dept Biotherapy, Chengdu, Peoples R China; [Zhang, Dunfang] Sichuan Univ, West China Hosp, Ctr Canc, Chengdu, Peoples R China; [Liu, Chaohong] Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Basic Med, Dept Pathogen Biol, Wuhan, Peoples R China; [Nakatsukasa, Hiroko] Keio Univ, Dept Pathogen Biol, Sch Med, Tokyo, Japan; [Chen, Wan Jun] Natl Inst Dent & Craniofacial Res NIDCR, Mucosal Immunol Sect, NIH, Bethesda, MD USA	Sichuan University; Sichuan University; Huazhong University of Science & Technology; Keio University; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Zhang, DF (corresponding author), Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Dept Biotherapy, Chengdu, Peoples R China.; Zhang, DF (corresponding author), Sichuan Univ, West China Hosp, Ctr Canc, Chengdu, Peoples R China.; Chen, WJ (corresponding author), Natl Inst Dent & Craniofacial Res NIDCR, Mucosal Immunol Sect, NIH, Bethesda, MD USA.	izdf@163.com; wchen@dir.nidcr.nih.gov		Zhang, Dunfang/0000-0001-7545-9930	National Natural Science Foundation of China [82171829, 81600876]; Key Project of the Science and Technology Department of Sichuan Province [22GJHZ0141]; 1.3.5 Project for Disciplines of Excellence, West China Hospital, Sichuan University [ZYYC21012]; Fundamental Research Funds for the Central Universities [20822041E4084]; Intramural Research Program of the U.S. National Institutes of Health (NIH), NIDCR	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Key Project of the Science and Technology Department of Sichuan Province; 1.3.5 Project for Disciplines of Excellence, West China Hospital, Sichuan University; Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); Intramural Research Program of the U.S. National Institutes of Health (NIH), NIDCR	DZ is supported by the National Natural Science Foundation of China (NO. 82171829, 81600876), the Key Project of the Science and Technology Department of Sichuan Province (NO. 22GJHZ0141), the 1 center dot 3 center dot 5 Project for Disciplines of Excellence, West China Hospital, Sichuan University (NO. ZYYC21012), and the Fundamental Research Funds for the Central Universities (20822041E4084). WC is supported by the Intramural Research Program of the U.S. National Institutes of Health (NIH), NIDCR.	Chang CH, 2013, CELL, V153, P1239, DOI 10.1016/j.cell.2013.05.016; Ghesquiere B, 2014, NATURE, V511, P167, DOI 10.1038/nature13312; Jones N, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21461-4; Khan S, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aay6218; Ley SH, 2014, LANCET, V383, P1999, DOI 10.1016/S0140-6736(14)60613-9; Palmer CS, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00001; Reily C, 2019, NAT REV NEPHROL, V15, P346, DOI 10.1038/s41581-019-0129-4; Zhang DF, 2019, IMMUNITY, V51, P671, DOI 10.1016/j.immuni.2019.08.001; Zhang DF, 2017, NAT MED, V23, P1036, DOI 10.1038/nm.4375	9	0	0	3	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 10	2022	12								832293	10.3389/fimmu.2021.832293	http://dx.doi.org/10.3389/fimmu.2021.832293			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZD2AP	35082801	Green Published, gold			2022-12-18	WOS:000758006900001
J	Lv, NY; Jin, SF; Liang, ZH; Wu, XH; Kang, YH; Su, L; Dong, YP; Wang, BW; Ma, TH; Shi, LY				Lv, Nianyin; Jin, Sufeng; Liang, Zihao; Wu, Xiaohui; Kang, Yanhua; Su, Lan; Dong, Yeping; Wang, Bingwei; Ma, Tonghui; Shi, Liyun			PP2C delta Controls the Differentiation and Function of Dendritic Cells Through Regulating the NSD2/mTORC2/ACLY Pathway	FRONTIERS IN IMMUNOLOGY			English	Article						autoimmunity; dendritic cells; differentiation; PP2C delta; mTORC2	WIP1 PHOSPHATASE; MAMMALIAN TARGET; METABOLISM; RAPAMYCIN; MTORC2; GROWTH; MICE; AKT	Dendritic cells (DCs) are recognized as a key orchestrator of immune response and homeostasis, deregulation of which may lead to autoimmunity such as experimental autoimmune encephalomyelitis (EAE). Herein we show that the phosphatase PP2C delta played a pivotal role in regulating DC activation and function, as PP2C delta ablation caused aberrant maturation, activation, and Th1/Th17-priming of DCs, and hence induced onset of exacerbated EAE. Mechanistically, PP2C delta restrained the expression of the essential subunit of mTORC2, Rictor, primarily through de-phosphorylating and proteasomal degradation of the methyltransferase NSD2 via CRL4(DCAF2) E3 ligase. Loss of PP2C delta in DCs accordingly sustained activation of the Rictor/mTORC2 pathway and boosted glycolytic and mitochondrial metabolism. Consequently, ATP-citrate lyse (ACLY) was increasingly activated and catalyzed acetyl-CoA for expression of the genes compatible with hyperactivated DCs under PP2C delta deletion. Collectively, our findings demonstrate that PP2C delta has an essential role in controlling DCs activation and function, which is critical for prevention of autoimmunity.	[Lv, Nianyin; Liang, Zihao; Wu, Xiaohui; Kang, Yanhua; Shi, Liyun] Nanjing Univ Chinese Med, Dept Immunol, Nanjing, Peoples R China; [Jin, Sufeng] Zhejiang Univ, Childrens Hosp, Dept Clin Lab, Natl Clin Res Ctr Child Hlth,Sch Med, Hangzhou, Peoples R China; [Jin, Sufeng; Kang, Yanhua] Hangzhou Normal Univ, Key Lab Inflammat & Immunoregulat, Sch Med, Hangzhou, Peoples R China; [Su, Lan; Dong, Yeping; Shi, Liyun] Zhejiang Shuren Univ, Inst Translat Med, Hangzhou, Peoples R China; [Wang, Bingwei; Ma, Tonghui] Nanjing Univ Chinese Med, Coll Med & Integrated Med, Nanjing, Peoples R China	Nanjing University of Chinese Medicine; Zhejiang University; Hangzhou Normal University; Zhejiang Shuren University; Nanjing University of Chinese Medicine	Shi, LY (corresponding author), Nanjing Univ Chinese Med, Dept Immunol, Nanjing, Peoples R China.; Shi, LY (corresponding author), Zhejiang Shuren Univ, Inst Translat Med, Hangzhou, Peoples R China.	shi_liyun@njucm.edu.cn			National Natural Scientific FundsNational Natural Scientific Funds [81770014, 81991523, 82000014]; National Key Research and Development Program Project [2018YFC1705900]	National Natural Scientific FundsNational Natural Scientific Funds; National Key Research and Development Program Project	This work was supported by National Natural Scientific Funds (81770014, 81991523, and 82000014), the National Key Research and Development Program Project (2018YFC1705900), and the priority academic program development of Jiangsu higher education institutions.	Anderson DA, 2020, P NATL ACAD SCI USA, V117, P4885, DOI 10.1073/pnas.1915060117; Aytes A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07511-4; Bantug GR, 2018, IMMUNITY, V48, P542, DOI 10.1016/j.immuni.2018.02.012; Betz C, 2013, P NATL ACAD SCI USA, V110, P12526, DOI 10.1073/pnas.1302455110; Boulet S, 2019, P NATL ACAD SCI USA, V116, P15150, DOI 10.1073/pnas.1821296116; Britt EC, 2020, CURR OPIN BIOTECH, V63, P111, DOI 10.1016/j.copbio.2019.12.008; Calejman CM, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18510-9; Centore RC, 2010, MOL CELL, V40, P22, DOI 10.1016/j.molcel.2010.09.015; Charbonnier LM, 2019, NAT IMMUNOL, V20, P1208, DOI 10.1038/s41590-019-0442-x; Chen CJ, 2019, NAT MED, V25, P1684, DOI 10.1038/s41591-019-0608-y; Chen ZY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7808; Chew J, 2009, NAT CELL BIOL, V11, P659, DOI 10.1038/ncb1873; Chopin M, 2019, IMMUNITY, V50, P77, DOI 10.1016/j.immuni.2018.11.010; Cook SA, 2020, SCIENCE, V369, P202, DOI 10.1126/science.aay5663; Covarrubias AJ, 2016, ELIFE, V5, DOI 10.7554/eLife.11612; Dobenecker MW, 2020, FEBS LETT, V594, P3324, DOI 10.1002/1873-3468.13903; Esashi E, 2008, IMMUNITY, V28, P509, DOI 10.1016/j.immuni.2008.02.013; Everts B, 2014, NAT IMMUNOL, V15, P323, DOI 10.1038/ni.2833; Fiscella M, 1997, P NATL ACAD SCI USA, V94, P6048, DOI 10.1073/pnas.94.12.6048; Gaubitz C, 2016, TRENDS BIOCHEM SCI, V41, P532, DOI 10.1016/j.tibs.2016.04.001; Giles DA, 2018, J CLIN INVEST, V128, P5322, DOI 10.1172/JCI123708; Hagiwara A, 2012, CELL METAB, V15, P725, DOI 10.1016/j.cmet.2012.03.015; Huang SCC, 2016, IMMUNITY, V45, P817, DOI 10.1016/j.immuni.2016.09.016; Huang T, 2018, J EXP MED, V215, P1999, DOI 10.1084/jem.20180210; Iberg CA, 2017, TRENDS IMMUNOL, V38, P793, DOI 10.1016/j.it.2017.07.007; Jiang Y, 2019, ONCOGENE, V38, P3989, DOI 10.1038/s41388-019-0713-x; Jung J, 2019, NAT CELL BIOL, V21, P85, DOI 10.1038/s41556-018-0217-x; Kang SA, 2013, SCIENCE, V341, P364, DOI 10.1126/science.1236566; Kazyken D, 2019, SCI SIGNAL, V12, DOI 10.1126/scisignal.aav3249; Kim D, 2020, IMMUNITY, V53, P581, DOI 10.1016/j.immuni.2020.07.002; Kuo AJ, 2011, MOL CELL, V44, P609, DOI 10.1016/j.molcel.2011.08.042; Lanzavecchia A, 2001, CELL, V106, P263, DOI 10.1016/S0092-8674(01)00455-X; Lauterbach MA, 2019, IMMUNITY, V51, P997, DOI 10.1016/j.immuni.2019.11.009; Li N, 2017, J CLIN INVEST, V127, P1284, DOI 10.1172/JCI91144; Li Q, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aaw8417; Li WQ, 2020, NATURE, DOI 10.1038/s41586-020-03069-8; Liu GW, 2013, BLOOD, V121, P519, DOI 10.1182/blood-2012-05-432674; McDonnell E, 2016, CELL REP, V17, P1463, DOI 10.1016/j.celrep.2016.10.012; Morante-Palacios O, 2021, TRENDS IMMUNOL, V42, P59, DOI 10.1016/j.it.2020.11.001; Mundt S, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aau8380; Ohtani M, 2008, BLOOD, V112, P635, DOI 10.1182/blood-2008-02-137430; Pearce EJ, 2015, NAT REV IMMUNOL, V15, P18, DOI 10.1038/nri3771; Pelgrom LR, 2019, CELL RES, V29, P406, DOI 10.1038/s41422-019-0161-8; Peng B, 2015, NUCLEIC ACIDS RES, V43, P5936, DOI 10.1093/nar/gkv528; Pfanner N, 2019, NAT REV MOL CELL BIO, V20, P267, DOI 10.1038/s41580-018-0092-0; Sancak Y, 2008, SCIENCE, V320, P1496, DOI 10.1126/science.1157535; Santos PM, 2019, CANCER IMMUNOL RES, V7, P1001, DOI 10.1158/2326-6066.CIR-18-0513; Sathaliyawala T, 2010, IMMUNITY, V33, P597, DOI 10.1016/j.immuni.2010.09.012; Saxton RA, 2017, CELL, V168, P960, DOI [10.1016/j.cell.2017.02.004, 10.1016/j.cell.2017.03.035]; Schito ML, 2006, J IMMUNOL, V176, P4818, DOI 10.4049/jimmunol.176.8.4818; Shi L, 2019, PLOS BIOL, V17, DOI 10.1371/journal.pbio.3000420; Shi L, 2020, INT REV IMMUNOL, V39, P280, DOI 10.1080/08830185.2020.1795153; Shreeram S, 2006, MOL CELL, V23, P757, DOI 10.1016/j.molcel.2006.07.010; STEINMAN RM, 1991, ANNU REV IMMUNOL, V9, P271, DOI 10.1146/annurev.iy.09.040191.001415; Sukhbaatar N, 2016, TRENDS IMMUNOL, V37, P778, DOI 10.1016/j.it.2016.08.009; Wang P, 2018, J ALLERGY CLIN IMMUN, V141, P2168, DOI 10.1016/j.jaci.2017.06.026; Wang YY, 2013, P NATL ACAD SCI USA, V110, pE4894, DOI 10.1073/pnas.1308905110; Watson AR, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01451; Wei HJ, 2018, JOVE-J VIS EXP, DOI 10.3791/57637; Weichhart T, 2015, NAT REV IMMUNOL, V15, P599, DOI 10.1038/nri3901; Wilhelm K, 2016, NATURE, V529, P216, DOI 10.1038/nature16498; Willcockson MA, 2021, NATURE, V589, P293, DOI 10.1038/s41586-020-3032-z; Ye CQ, 2019, MOL CELL, V73, P1115, DOI 10.1016/j.molcel.2019.01.012; Yi WW, 2015, BLOOD, V126, P620, DOI 10.1182/blood-2015-02-624114; Zhang LL, 2015, HEPATOLOGY, V61, P2030, DOI 10.1002/hep.27755; Zhou QQ, 2020, CELL MOL IMMUNOL, V17, P834, DOI 10.1038/s41423-019-0251-z; Zhu YH, 2014, J CLIN INVEST, V124, P3263, DOI 10.1172/JCI73015	67	0	0	3	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 7	2022	12								751409	10.3389/fimmu.2021.751409	http://dx.doi.org/10.3389/fimmu.2021.751409			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZE0DC	35069527	Green Published, gold			2022-12-18	WOS:000758561900001
J	Sepulveda-Yanez, JH; Saravia, DA; Pilzecker, B; van Schouwenburg, PA; van den Burg, M; Veelken, H; Navarrete, MA; Jacobs, H; Koning, MT				Sepulveda-Yanez, Julieta H.; Alvarez Saravia, Diego; Pilzecker, Bas; van Schouwenburg, Pauline A.; van den Burg, Mirjam; Veelken, Hendrik; Navarrete, Marcelo A.; Jacobs, Heinz; Koning, Marvyn T.			Tandem Substitutions in Somatic Hypermutation	FRONTIERS IN IMMUNOLOGY			English	Article						apyrimidinic site; tandem dinucleotide substitutions (TDNS); strand slippage; tandem substitution; translesion synthesis (TLS); uracil-N-glycosylase (UNG)	DNA-POLYMERASE-ETA; CLASS-SWITCH RECOMBINATION; CYTIDINE DEAMINASE AID; IMMUNOGLOBULIN GENES; MISMATCH REPAIR; MUTATIONAL SIGNATURES; CHAIN GENES; ACTIVATION; URACIL; BASE	Upon antigen recognition, activation-induced cytosine deaminase initiates affinity maturation of the B-cell receptor by somatic hypermutation (SHM) through error-prone DNA repair pathways. SHM typically creates single nucleotide substitutions, but tandem substitutions may also occur. We investigated incidence and sequence context of tandem substitutions by massive parallel sequencing of V(D)J repertoires in healthy human donors. Mutation patterns were congruent with SHM-derived single nucleotide mutations, delineating initiation of the tandem substitution by AID. Tandem substitutions comprised 5,7% of AID-induced mutations. The majority of tandem substitutions represents single nucleotide juxtalocations of directly adjacent sequences. These observations were confirmed in an independent cohort of healthy donors. We propose a model where tandem substitutions are predominantly generated by translesion synthesis across an apyramidinic site that is typically created by UNG. During replication, apyrimidinic sites transiently adapt an extruded configuration, causing skipping of the extruded base. Consequent strand decontraction leads to the juxtalocation, after which exonucleases repair the apyramidinic site and any directly adjacent mismatched base pairs. The mismatch repair pathway appears to account for the remainder of tandem substitutions. Tandem substitutions may enhance affinity maturation and expedite the adaptive immune response by overcoming amino acid codon degeneracies or mutating two adjacent amino acid residues simultaneously.	[Sepulveda-Yanez, Julieta H.; Veelken, Hendrik; Koning, Marvyn T.] Leiden Univ, Med Ctr, Dept Hematol, Leiden, Netherlands; [Sepulveda-Yanez, Julieta H.; Alvarez Saravia, Diego; Navarrete, Marcelo A.] Univ Magallanes, Sch Med, Punta Arenas, Chile; [Pilzecker, Bas] Radboud Inst Mol Life Sci, Dept Tumor Immunol, Nijmegen, Netherlands; [Pilzecker, Bas; Jacobs, Heinz] Netherlands Canc Inst, Div Tumor Biol & Immunol, Amsterdam, Netherlands; [van Schouwenburg, Pauline A.; van den Burg, Mirjam] Leiden Univ, Med Ctr, Dept Pediat, Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Universidad de Magallanes; Netherlands Cancer Institute; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Koning, MT (corresponding author), Leiden Univ, Med Ctr, Dept Hematol, Leiden, Netherlands.	m.t.koning@lumc.nl	Navarrete, Marcelo/D-7935-2013; Sepulveda-Yanez, Julieta Haydee/AAJ-7468-2020	Navarrete, Marcelo/0000-0002-2044-9548; Sepulveda-Yanez, Julieta Haydee/0000-0001-6354-3609; Alvarez Saravia, Diego/0000-0003-0753-274X	Professor Steenhuis Fonds; Dutch Scientific Organization NWO-ZonMW [[91213018]; Agency for Research and Development (ANID) [2016-72170683]; Fondo Nacional de Desarrollo Cientifico y Tecnologico (Fondecyt) [1180882, 11140542, MAG1895];  [91213018]	Professor Steenhuis Fonds; Dutch Scientific Organization NWO-ZonMW(Netherlands Organization for Scientific Research (NWO)); Agency for Research and Development (ANID); Fondo Nacional de Desarrollo Cientifico y Tecnologico (Fondecyt)(Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT)CONICYT FONDECYT); 	& nbsp;MK was supported by a grant from the Professor Steenhuis Fonds. HJ received TOP Grant [91213018] from the Dutch Scientific Organization NWO-ZonMW. JS-Y received a Doctorado Becas Chile [2016-72170683] from Agency for Research and Development (ANID). MN and DA-S work was supported by Fondo Nacional de Desarrollo Cientifico y Tecnologico (Fondecyt) [1180882], [11140542], and [MAG1895].	Alamyar Eltaf, 2012, Methods Mol Biol, V882, P569, DOI 10.1007/978-1-61779-842-9_32; Alexandrov LB, 2020, NATURE, V578, P94, DOI 10.1038/s41586-020-1943-3; Alvarez-Prado AF, 2018, J EXP MED, V215, P761, DOI 10.1084/jem.20171738; Au RY, 2012, J PHYS CHEM B, V116, P14781, DOI 10.1021/jp308759k; Bahjat M., 2020, DNA POLYMERASE BETA, DOI [10.1101/2020.01.30.926964, DOI 10.1101/2020.01.30.926964]; Bardwell PD, 2004, NAT IMMUNOL, V5, P224, DOI 10.1038/ni1031; Biertumpfel C, 2010, NATURE, V465, P1044, DOI 10.1038/nature09196; Cao CY, 2004, NAT STRUCT MOL BIOL, V11, P1230, DOI 10.1038/nsmb864; Carr CE, 2018, BIOCHEMISTRY-US, V57, P5666, DOI 10.1021/acs.biochem.8b00676; Chen JM, 2014, HUM MUTAT, V35, P392, DOI 10.1002/humu.22501; Chen JM, 2013, HUM MUTAT, V34, P1119, DOI 10.1002/humu.22341; Corbella M, 2018, PHYS CHEM CHEM PHYS, V20, P23123, DOI 10.1039/c8cp03572e; Davies EG, 2010, BRIT J HAEMATOL, V149, P167, DOI 10.1111/j.1365-2141.2010.08077.x; Delbos F, 2007, J EXP MED, V204, P17, DOI 10.1084/jem.20062131; Di Noia J, 2002, NATURE, V419, P43, DOI 10.1038/nature00981; Dorner T, 1998, EUR J IMMUNOL, V28, P3384; Driessen GJ, 2013, J ALLERGY CLIN IMMUN, V131, P1367, DOI 10.1016/j.jaci.2013.01.053; Faili A, 2002, NATURE, V419, P944, DOI 10.1038/nature01117; Francioli LC, 2015, NAT GENET, V47, P822, DOI 10.1038/ng.3292; Fuxreiter M, 2002, J MOL BIOL, V323, P823, DOI 10.1016/S0022-2836(02)00999-3; Harris K, 2014, GENOME RES, V24, P1445, DOI 10.1101/gr.170696.113; IJspeert H, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01913; IJspeert H, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00410; Imai K, 2003, NAT IMMUNOL, V4, P1023, DOI 10.1038/ni974; Imhof P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053305; Jacobs H, 1998, J EXP MED, V187, P1735, DOI 10.1084/jem.187.11.1735; Jansen JG, 2006, J EXP MED, V203, P319, DOI 10.1084/jem.20052227; Kasar S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9866; Kinoshita K, 2001, NAT REV MOL CELL BIO, V2, P493, DOI 10.1038/35080033; Koning MT, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01543; Koning MT, 2017, BRIT J HAEMATOL, V178, P983, DOI 10.1111/bjh.14180; Krijger PHL, 2011, DNA REPAIR, V10, P1051, DOI 10.1016/j.dnarep.2011.08.005; Krijger PHL, 2009, J EXP MED, V206, P2603, DOI 10.1084/jem.20091707; Krijger PHL, 2013, EUR J IMMUNOL, V43, P2765, DOI 10.1002/eji.201243191; Kunkel TA, 2015, ANNU REV GENET, V49, P291, DOI 10.1146/annurev-genet-112414-054722; Langerak P, 2007, J EXP MED, V204, P1989, DOI 10.1084/jem.20070902; Lee SS, 2002, IMMUNITY, V16, P571, DOI 10.1016/S1074-7613(02)00300-X; Malecek K, 2005, J IMMUNOL, V175, P8105, DOI 10.4049/jimmunol.175.12.8105; Martomo SA, 2005, P NATL ACAD SCI USA, V102, P8656, DOI 10.1073/pnas.0501852102; Matsuda T, 2001, J MOL BIOL, V312, P335, DOI 10.1006/jmbi.2001.4937; Maul RW, 2016, J EXP MED, V213, P1675, DOI 10.1084/jem.20151227; Maul RW, 2014, EUR J IMMUNOL, V44, P1913, DOI 10.1002/eji.201444813; Muramatsu M, 1999, J BIOL CHEM, V274, P18470, DOI 10.1074/jbc.274.26.18470; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; Neuberger MS, 2005, NAT REV IMMUNOL, V5, P171, DOI 10.1038/nri1553; NEUBERGER MS, 1995, CURR OPIN IMMUNOL, V7, P248, DOI 10.1016/0952-7915(95)80010-7; Papavasiliou FN, 2002, CELL, V109, pS35, DOI 10.1016/S0092-8674(02)00706-7; Parker JB, 2007, NATURE, V449, P433, DOI 10.1038/nature06131; Pena-Diaz J, 2012, MOL CELL, V47, P669, DOI 10.1016/j.molcel.2012.07.006; Perez-Duran P, 2012, J EXP MED, V209, P1379, DOI 10.1084/jem.20112253; Pilzecker B, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00438; R Development Core Team, 2018, R LANG ENV STAT COMP; Rada C, 2004, MOL CELL, V16, P163, DOI 10.1016/j.molcel.2004.10.011; Rada C, 2002, CURR BIOL, V12, P1748, DOI 10.1016/S0960-9822(02)01215-0; Rajewsky K, 1996, NATURE, V381, P751, DOI 10.1038/381751a0; Rogozin IB, 2001, NAT IMMUNOL, V2, P530, DOI 10.1038/88732; Rogozin IB, 2004, J IMMUNOL, V172, P3382, DOI 10.4049/jimmunol.172.6.3382; ROGOZIN IB, 1992, BIOCHIM BIOPHYS ACTA, V1171, P11, DOI 10.1016/0167-4781(92)90134-L; Sale JE, 2012, NAT REV MOL CELL BIO, V13, P141, DOI 10.1038/nrm3289; Saribasak H, 2012, J EXP MED, V209, P1075, DOI 10.1084/jem.20112234; Schrider DR, 2011, CURR BIOL, V21, P1051, DOI 10.1016/j.cub.2011.05.013; Seki M, 2005, EMBO REP, V6, P1143, DOI 10.1038/sj.embor.7400582; Sohail A, 2003, NUCLEIC ACIDS RES, V31, P2990, DOI 10.1093/nar/gkg464; Stavnezer J, 2008, ANNU REV IMMUNOL, V26, P261, DOI 10.1146/annurev.immunol.26.021607.090248; Stone JE, 2012, ENVIRON MOL MUTAGEN, V53, P777, DOI 10.1002/em.21728; Storb U, 1999, COLD SPRING HARB SYM, V64, P227, DOI 10.1101/sqb.1999.64.227; Tesch VK, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01506; Tissier A, 2004, DNA REPAIR, V3, P1503, DOI 10.1016/j.dnarep.2004.06.015; Varnai P, 2004, J AM CHEM SOC, V126, P14659, DOI 10.1021/ja0470721; Weill JC, 2008, NAT REV IMMUNOL, V8, P302, DOI 10.1038/nri2281; Wiesendanger M, 2000, J EXP MED, V191, P579, DOI 10.1084/jem.191.3.579; Wilson TM, 2005, J EXP MED, V201, P637, DOI 10.1084/jem.20042066; Wimmer K, 2014, J MED GENET, V51, P355, DOI 10.1136/jmedgenet-2014-102284; Yin YD, 2014, P NATL ACAD SCI USA, V111, P8043, DOI 10.1073/pnas.1400667111; Zeng XM, 2001, NAT IMMUNOL, V2, P537, DOI 10.1038/88740; Zharkov DO, 2010, MUTAT RES-FUND MOL M, V685, P11, DOI 10.1016/j.mrfmmm.2009.10.017	76	0	0	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 7	2022	12								807015	10.3389/fimmu.2021.807015	http://dx.doi.org/10.3389/fimmu.2021.807015			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YR4FT	35069591	Green Published, gold			2022-12-18	WOS:000749948700001
J	Seshadri, C; Sutherland, JS; Arlehamn, CLS; Burel, JG				Seshadri, Chetan; Sutherland, Jayne S.; Lindestam Arlehamn, Cecilia S.; Burel, Julie G.			Editorial: Exploring Immune Variability in Susceptibility to Tuberculosis Infection in Humans	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						Mycobacterium tuberculosis; infection; resistance; T cells; biomarkers; co-morbid illness; human immunity			[Seshadri, Chetan] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA; [Seshadri, Chetan] Univ Washington, TB Res & Training Ctr, Seattle, WA 98195 USA; [Sutherland, Jayne S.] Gambia London Sch Hyg & Trop Med, Med Res Council MRC Unit, Vaccines & Immun Theme, Banjul, Gambia; [Lindestam Arlehamn, Cecilia S.; Burel, Julie G.] La Jolla Inst Immunol, Ctr Infect Dis & Vaccine Res, La Jolla, CA USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of London; London School of Hygiene & Tropical Medicine; La Jolla Institute for Immunology	Seshadri, C (corresponding author), Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA.; Seshadri, C (corresponding author), Univ Washington, TB Res & Training Ctr, Seattle, WA 98195 USA.	seshadri@uw.edu		Sutherland, Jayne/0000-0002-7083-4997	National Institutes of Health [R01-AI146072]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Funding National Institutes of Health R01-AI146072 to CS.	Andrews JR, 2017, LANCET RESP MED, V5, P282, DOI [10.1016/s2213-2600(17)30060-7, 10.1016/S2213-2600(17)30060-7]; Behr MA, 2021, AM J RESP CRIT CARE, V204, P142, DOI 10.1164/rccm.202011-4239PP; Behr MA, 2019, BMJ-BRIT MED J, V367, DOI 10.1136/bmj.l5770; Drain PK, 2018, CLIN MICROBIOL REV, V31, DOI 10.1128/CMR.00021-18; Khan N, 2020, CELL, V183, P752, DOI 10.1016/j.cell.2020.09.062; Simmons JD, 2018, NAT REV IMMUNOL, V18, P575, DOI 10.1038/s41577-018-0025-3; Stein CM., 2018, CLIN INFECT DIS, V44106, P1, DOI [10.1093/cid/ciy751/5085255, DOI 10.1093/CID/CIY751/5085255]; Turner CT, 2020, LANCET RESP MED, V8, P407, DOI 10.1016/S2213-2600(19)30469-2	8	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 7	2022	12								830920	10.3389/fimmu.2021.830920	http://dx.doi.org/10.3389/fimmu.2021.830920			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YS6SG	35069606	Green Published, gold, Green Accepted			2022-12-18	WOS:000750803600001
J	Sherpa, MT; Kiwamoto, T; Matsuyama, M; Tsunoda, Y; Yazaki, K; Yoshida, K; Nakajima, M; Matsuno, Y; Morishima, Y; Ishii, Y; Hizawa, N				Sherpa, Mingma Thsering; Kiwamoto, Takumi; Matsuyama, Masashi; Tsunoda, Yoshiya; Yazaki, Kai; Yoshida, Kazufumi; Nakajima, Masayuki; Matsuno, Yosuke; Morishima, Yuko; Ishii, Yukio; Hizawa, Nobuyuki			Has2 Regulates the Development of Ovalbumin-Induced Airway Remodeling and Steroid Insensitivity in Mice	FRONTIERS IN IMMUNOLOGY			English	Article						ER stress response; HAS2; IL-17; TGF-beta 1; airway remodeling; asthma; mouse model	SEVERE ASTHMA; INFLAMMATION; HYALURONAN; DIVERSITY; PROTEINS; DRIVES; CELLS; IL-17; GENE	HAS2 is a member of the gene family encoding the hyaluronan synthase 2, which can generate high-molecular-weight hyaluronan (HMW-HA). Our previous study identified HAS2 as a candidate gene for increased susceptibility to adult asthma. However, whether HAS2 dysfunction affects airway remodeling and steroid insensitivity is still limited. Therefore, this study aimed to clarify the Has2 dysfunction, triggering severe airway remodeling and steroid insensitivity in a murine model of asthma. Has2 heterozygous-deficient (Has2 (+/-)) mice and their wild-type littermates have been evaluated in a model of chronic ovalbumin (OVA) sensitization and challenge. Mice present a higher sensitivity to OVA and higher IL-17 release as well as eosinophilic infiltration. RNA sequencing demonstrated the downregulation of EIF2 signaling pathways, TGF-beta signaling pathways, and heat shock proteins with Th17 bias in Has2 (+/-)-OVA mice. The combined treatment with anti-IL-17A antibody and dexamethasone reduces steroid insensitivity in Has2 (+/-)-OVA mice. Has2 attenuation worsens eosinophilic airway inflammation, airway remodeling, and steroid insensitivity. These data highlight that HAS2 and HMW-HA are important for controlling intractable eosinophilic airway inflammation and remodeling and could potentially be exploited for their therapeutic benefits in patients with asthma.	[Sherpa, Mingma Thsering; Kiwamoto, Takumi; Matsuyama, Masashi; Tsunoda, Yoshiya; Yazaki, Kai; Yoshida, Kazufumi; Nakajima, Masayuki; Matsuno, Yosuke; Morishima, Yuko; Ishii, Yukio; Hizawa, Nobuyuki] Univ Tsukuba, Fac Med, Dept Resp Med, Tsukuba, Ibaraki, Japan	University of Tsukuba	Kiwamoto, T (corresponding author), Univ Tsukuba, Fac Med, Dept Resp Med, Tsukuba, Ibaraki, Japan.	t-kiwamoto@md.tsukuba.ac.jp		Nakajima, Masayuki/0000-0002-5866-5588	Ministry of Education, Culture, Sports, Science, and Technology of Japan [18K08139, 21K08150]; Basic Research Support Program from Japanese Society of Allergology	Ministry of Education, Culture, Sports, Science, and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Basic Research Support Program from Japanese Society of Allergology	This research was supported in part by grants-in-aid from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (18K08139 and 21K08150 to TK) and the Basic Research Support Program from Japanese Society of Allergology (to TK).	Al-Ramli W, 2009, J ALLERGY CLIN IMMUN, V123, P1185, DOI 10.1016/j.jaci.2009.02.024; Alnahas S, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01562; Bradley KL, 2021, THORAX, V76, P92, DOI 10.1136/thoraxjnl-2019-213738; Camenisch TD, 2000, J CLIN INVEST, V106, P349, DOI 10.1172/JCI10272; Chen ZY, 2017, SCI REP-UK, V7, DOI 10.1038/srep40508; Cheng G, 2013, GLYCOBIOLOGY, V23, P43, DOI 10.1093/glycob/cws122; Cheng G, 2011, MATRIX BIOL, V30, P126, DOI 10.1016/j.matbio.2010.12.003; Chesne J, 2014, AM J RESP CRIT CARE, V190, P1094, DOI 10.1164/rccm.201405-0859PP; Cho JY, 2001, J ALLERGY CLIN IMMUN, V108, P697, DOI 10.1067/mai.2001.119918; Faust O, 2020, NATURE, V587, P489, DOI 10.1038/s41586-020-2906-4; Fujisawa T, 2009, J IMMUNOL, V183, P6236, DOI 10.4049/jimmunol.0900614; Garantziotis S, 2019, MATRIX BIOL, V78-79, P1, DOI 10.1016/j.matbio.2019.02.002; Greb JE, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.82; Hansen G, 2000, J CLIN INVEST, V105, P61, DOI 10.1172/JCI7589; Hinks TSC, 2021, EUR RESPIR J, V57, DOI 10.1183/13993003.00528-2020; Jirmo AC, 2020, EUR J IMMUNOL, V50, P1019, DOI 10.1002/eji.201948409; Joetham A, 2020, J ALLERGY CLIN IMMUN, V145, P933, DOI 10.1016/j.jaci.2019.09.032; Karamanos NK, 2018, CHEM REV, V118, P9152, DOI 10.1021/acs.chemrev.8b00354; Kim SR, 2013, J ALLERGY CLIN IMMUN, V132, P1397, DOI 10.1016/j.jaci.2013.08.041; Kinyanjui MW, 2013, J IMMUNOL, V190, P3859, DOI 10.4049/jimmunol.1200506; Kiwamoto T, 2006, AM J RESP CRIT CARE, V174, P142, DOI 10.1164/rccm.200601-079OC; Kiwamoto T, 2014, J ALLERGY CLIN IMMUN, V133, P240, DOI 10.1016/j.jaci.2013.05.018; Liang JR, 2007, J IMMUNOL, V178, P2469, DOI 10.4049/jimmunol.178.4.2469; Liang JR, 2016, ADV DRUG DELIVER REV, V97, P186, DOI 10.1016/j.addr.2015.10.017; Liu G, 2021, PHARMACOL THERAPEUT, V225, DOI 10.1016/j.pharmthera.2021.107839; Matuska B, 2016, AM J RESP CELL MOL, V55, P576, DOI 10.1165/rcmb.2015-0358OC; Menson KE, 2020, AM J PHYSIOL-LUNG C, V319, pL693, DOI 10.1152/ajplung.00204.2020; Menzies-Gow A, 2020, J ALLERGY CLIN IMMUN, V145, P757, DOI 10.1016/j.jaci.2019.12.006; Mycko MP, 2015, J NEUROSCI, V35, P16504, DOI 10.1523/JNEUROSCI.2830-15.2015; Myers JMB, 2014, J ALLERGY CLIN IMMUN, V134, P891, DOI 10.1016/j.jaci.2014.03.037; Nakao A, 2000, J EXP MED, V192, P151, DOI 10.1084/jem.192.2.151; Nanzer AM, 2013, J ALLERGY CLIN IMMUN, V132, P297, DOI 10.1016/j.jaci.2013.03.037; Newman AM, 2019, NAT BIOTECHNOL, V37, P773, DOI 10.1038/s41587-019-0114-2; Ostling J, 2019, J ALLERGY CLIN IMMUN, V144, P1198, DOI 10.1016/j.jaci.2019.03.027; Pathinayake PS, 2022, THORAX, V77, P443, DOI 10.1136/thoraxjnl-2020-215979; Prakash YS, 2017, AM J RESP CRIT CARE, V195, P247, DOI 10.1164/rccm.201611-2248ST; Ricciardolo FLM, 2017, J ALLERGY CLIN IMMUN, V140, P395, DOI 10.1016/j.jaci.2016.10.034; Singhania A, 2018, AM J RESP CELL MOL, V58, P261, DOI 10.1165/rcmb.2017-0162OC; Teder P, 2002, SCIENCE, V296, P155, DOI 10.1126/science.1069659; Tsunoda Y, 2021, ALLERGY, V76, P2214, DOI 10.1111/all.14715; Tukaj S, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.614320; Wesolowska-Andersen A, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-016-1140-8; Yatagai Y, 2014, CLIN EXP ALLERGY, V44, P1327, DOI 10.1111/cea.12415	43	0	0	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 7	2022	12								770305	10.3389/fimmu.2021.770305	http://dx.doi.org/10.3389/fimmu.2021.770305			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZE0BD	35069543	gold, Green Published			2022-12-18	WOS:000758556700001
J	Tang, ZY; Wang, XP; Xia, ZJ; Wang, ZM; Zhao, Y; Liu, Y				Tang, Ziyi; Wang, Xiangpeng; Xia, Zijing; Wang, Zhongming; Zhao, Yi; Liu, Yi			Case Report: Multicentric Reticulohistiocytosis Associated With Posterior Mediastinal Adenosquamous Carcinoma, Antinuclear Antibody Positivity and Lupus Anticoagulant Positivity	FRONTIERS IN IMMUNOLOGY			English	Article						multicentric reticulohistiocytosis; mediastinal malignancy; paraneoplastic syndrome; rare disease; case report		Multicentric reticulohistiocytosis (MRH) is a rare systemic disease of non-Langerhans cell histiocytosis. A number of studies in the literature have documented that it can coexist with malignancy or autoimmune disease, making it difficult to determine the most appropriate therapy. Here, we present a case study of MRH associated with posterior mediastinal adenosquamous carcinoma along with antinuclear antibody positivity and lupus anticoagulant positivity. The patient experienced 6 months of clinical benefit after surgical resection and chemoradiotherapy of the mediastinal malignancy. This case adds to the available literature on multicentric reticulohistiocytosis associated with different types of malignancy and provides supplementary clinical data on the coexistence of this syndrome with malignancy and immune system abnormalities. To the best of our knowledge, this is the first case study describing MRH accompanied by posterior mediastinal adenosquamous carcinoma and lupus anticoagulant positivity. The unknown aetiology and polymorphic clinical presentation of MRH warrants further investigation.	[Tang, Ziyi; Wang, Xiangpeng; Xia, Zijing; Wang, Zhongming; Zhao, Yi; Liu, Yi] Sichuan Univ, West China Hosp, Dept Rheumatol & Immunol, Chengdu, Peoples R China; [Tang, Ziyi; Xia, Zijing; Liu, Yi] Sichuan Univ, West China Hosp, Lab Rheumatol & Immunol, Chengdu, Peoples R China	Sichuan University; Sichuan University	Liu, Y (corresponding author), Sichuan Univ, West China Hosp, Dept Rheumatol & Immunol, Chengdu, Peoples R China.; Liu, Y (corresponding author), Sichuan Univ, West China Hosp, Lab Rheumatol & Immunol, Chengdu, Peoples R China.	yi2006liu@163.com						Asano T, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000011449; BARROW MV, 1969, MEDICINE, V48, P287, DOI 10.1097/00005792-196907000-00002; Bennassar A, 2011, J DERMATOL, V38, P905, DOI 10.1111/j.1346-8138.2010.01146.x; Izu CB, 2021, MED CLIN-BARCELONA, V156, P310, DOI 10.1016/j.medcli.2019.12.011; Chetty R, 2020, J CLIN PATHOL, V73, P257, DOI 10.1136/jclinpath-2020-206451; Crombe A, 2019, EUR RADIOL, V29, P4730, DOI 10.1007/s00330-019-06017-x; de Jonge H, 2021, CANCERS, V13, DOI 10.3390/cancers13040813; Dell'Antonia M, 2021, AUSTRALAS J DERMATOL, V62, P527, DOI 10.1111/ajd.13687; Dietz M, 2021, CLIN NUCL MED, V46, pE253, DOI 10.1097/RLU.0000000000003417; Gauderon A, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.00165; Ge JS, 2018, J DERMATOL, V45, pE138, DOI 10.1111/1346-8138.14182; Islam MA, 2020, SEMIN CANCER BIOL, V64, P108, DOI 10.1016/j.semcancer.2019.07.019; Kacar N, 2010, CLIN EXP DERMATOL, V35, pe120, DOI 10.1111/j.1365-2230.2009.03738.x; Kamiya K, 2017, INT J DERMATOL, V56, pE173, DOI 10.1111/ijd.13661; Kim S, 2020, CLIN CASE REP, V8, P1560, DOI 10.1002/ccr3.2926; Kumar B, 2018, JCR-J CLIN RHEUMATOL, V24, P45, DOI 10.1097/RHU.0000000000000594; Le Loarer F, 2015, NAT GENET, V47, P1200, DOI 10.1038/ng.3399; Malhotra K, 2017, J STROKE CEREBROVASC, V26, pE22, DOI 10.1016/j.jstrokecerebrovasdis.2016.10.023; Mavrogenis AF, 2018, EFORT OPEN REV, V3, P381, DOI 10.1302/2058-5241.3.170047; Murakami N, 2020, HAEMATOLOGICA, V105, pE61, DOI 10.3324/haematol.2019.218735; Niaki OZ, 2021, JAMA DERMATOL, V157, P735, DOI 10.1001/jamadermatol.2021.0996; Olabi B, 2021, CLIN EXP DERMATOL, V46, P554, DOI 10.1111/ced.14433; Orlando G, 2019, ACTA DERM-VENEREOL, V99, P844, DOI 10.2340/00015555-3210; Ozawa Y, 2021, JPN J RADIOL, V39, P15, DOI 10.1007/s11604-020-01025-0; Rekhtman N, 2020, J THORAC ONCOL, V15, P231, DOI 10.1016/j.jtho.2019.10.023; Rentsch JL, 1998, J RHEUMATOL, V25, P1012; Rudha Y, 2017, RHEUMATOLOGY, V56, P1706, DOI 10.1093/rheumatology/kex224; Sanchez-Alvarez C, 2020, RHEUMATOLOGY, V59, P1898, DOI 10.1093/rheumatology/kez555; Selmi C, 2015, CURR RHEUMATOL REP, V17, DOI 10.1007/s11926-015-0511-6; Shwe Samantha, 2019, JAAD Case Rep, V5, P720, DOI 10.1016/j.jdcr.2019.06.012; Sobjanek M, 2017, J EUR ACAD DERMATOL, V31, pE442, DOI 10.1111/jdv.14260; Toz B, 2016, BEST PRACT RES CL RH, V30, P250, DOI 10.1016/j.berh.2016.07.002; Worm M, 1998, ACTA DERM-VENEREOL, V78, P67; Wu J, 2017, AUTOIMMUN REV, V16, P1270, DOI 10.1016/j.autrev.2017.10.012; Yoshida A, 2017, MODERN PATHOL, V30, P797, DOI 10.1038/modpathol.2017.11; Zhang B, 2016, CLIN NUCL MED, V41, P333, DOI 10.1097/RLU.0000000000001071; Zinn Daniel J, 2019, Dermatol Case Rep, V4, DOI 10.35248/2684-124X.19.4.152	37	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 7	2022	12								749669	10.3389/fimmu.2021.749669	http://dx.doi.org/10.3389/fimmu.2021.749669			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YR2KV	35069525	gold, Green Published			2022-12-18	WOS:000749826300001
J	Avery, L; Robertson, TF; Wu, CF; Roy, NH; Chauvin, SD; Perkey, E; Vanderbeck, A; Maillard, I; Burkhardt, JK				Avery, Lyndsay; Robertson, Tanner F.; Wu, Christine F.; Roy, Nathan H.; Chauvin, Samuel D.; Perkey, Eric; Vanderbeck, Ashley; Maillard, Ivan; Burkhardt, Janis K.			A Murine Model of X-Linked Moesin-Associated Immunodeficiency (X-MAID) Reveals Defects in T Cell Homeostasis and Migration	FRONTIERS IN IMMUNOLOGY			English	Article						T cell; immunodeficiency; actin; moesin; migration; cytoskeleton; hematopoiesis; development	HEMATOPOIETIC STEM-CELLS; F-ACTIN BINDING; THREONINE 558; ERM PROTEINS; PHOSPHORYLATION; CYTOSKELETON; LYMPHOCYTES; ACTIVATION; EZRIN; DOMAIN	X-linked moesin associated immunodeficiency (X-MAID) is a primary immunodeficiency disease in which patients suffer from profound lymphopenia leading to recurrent infections. The disease is caused by a single point mutation leading to a R171W amino acid change in the protein moesin (moesin(R171W)). Moesin is a member of the ERM family of proteins, which reversibly link the cortical actin cytoskeleton to the plasma membrane. Here, we describe a novel mouse model with global expression of moesin(R171W) that recapitulates multiple facets of patient disease, including severe lymphopenia. Further analysis reveals that these mice have diminished numbers of thymocytes and bone marrow precursors. X-MAID mice also exhibit systemic inflammation that is ameliorated by elimination of mature lymphocytes through breeding to a Rag1-deficient background. The few T cells in the periphery of X-MAID mice are highly activated and have mostly lost moesin(R171W) expression. In contrast, single-positive (SP) thymocytes do not appear activated and retain high expression levels of moesin(R171W). Analysis of ex vivo CD4 SP thymocytes reveals defects in chemotactic responses and reduced migration on integrin ligands. While chemokine signaling appears intact, CD4 SP thymocytes from X-MAID mice are unable to polarize and rearrange cytoskeletal elements. This mouse model will be a valuable tool for teasing apart the complexity of the immunodeficiency caused by moesin(R171W), and will provide new insights into how the actin cortex regulates lymphocyte function.	[Avery, Lyndsay; Robertson, Tanner F.; Wu, Christine F.; Roy, Nathan H.; Chauvin, Samuel D.; Burkhardt, Janis K.] Childrens Hosp Philadelphia, Res Inst, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; [Avery, Lyndsay; Robertson, Tanner F.; Wu, Christine F.; Roy, Nathan H.; Chauvin, Samuel D.; Burkhardt, Janis K.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA; [Perkey, Eric] Univ Michigan, Grad Program Cellular & Mol Biol & Med Scientist, Ann Arbor, MI 48109 USA; [Vanderbeck, Ashley; Maillard, Ivan] Univ Penn, Div Hematol Oncol, Dept Med, Philadelphia, PA 19104 USA; [Vanderbeck, Ashley; Maillard, Ivan] Univ Penn, Abramson Family Canc Res Inst, Perelman Sch Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; University of Michigan System; University of Michigan; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine	Burkhardt, JK (corresponding author), Childrens Hosp Philadelphia, Res Inst, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA.; Burkhardt, JK (corresponding author), Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.	jburkhar@pennmedicine.upenn.edu		Avery, Lyndsay/0000-0002-8148-1648; Chauvin, Samuel/0000-0003-0232-751X				Allenspach EJ, 2001, IMMUNITY, V15, P739, DOI 10.1016/S1074-7613(01)00224-2; Ansa-Addo EA, 2017, J CLIN INVEST, V127, P1321, DOI 10.1172/JCI89281; Baker MW, 2009, J ALLERGY CLIN IMMUN, V124, P522, DOI 10.1016/j.jaci.2009.04.007; Beemiller P, 2013, IMMUNOL REV, V256, P148, DOI 10.1111/imr.12120; Belkina NV, 2009, P NATL ACAD SCI USA, V106, P4707, DOI 10.1073/pnas.0805963106; Bradshaw G, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00420; Brown MJ, 2003, BLOOD, V102, P3890, DOI 10.1182/blood-2002-12-3807; Burkhardt JK, 2008, ANNU REV IMMUNOL, V26, P233, DOI 10.1146/annurev.immunol.26.021607.090347; Chen EJH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0052368; Delmonte OM, 2017, J CLIN IMMUNOL, V37, P336, DOI 10.1007/s10875-017-0391-9; Delon J, 2001, IMMUNITY, V15, P691, DOI 10.1016/S1074-7613(01)00231-X; Doi Y, 1999, J BIOL CHEM, V274, P2315, DOI 10.1074/jbc.274.4.2315; Fievet BT, 2004, J CELL BIOL, V164, P653, DOI 10.1083/jcb.200307032; Garcia-Ortiz A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21041502; GARY R, 1995, MOL BIOL CELL, V6, P1061, DOI 10.1091/mbc.6.8.1061; Ham H, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00002; Hebert M, 2008, J IMMUNOL, V181, P5963, DOI 10.4049/jimmunol.181.9.5963; Henao-Mejia J, 2016, COLD SPRING HARB PRO, V2016, P150, DOI [DOI 10.1101/PDB.PROT090704, 10.1101/pdb.prot090704]; Henrickson SE, 2019, FRONT PEDIATR, V7, DOI 10.3389/fped.2019.00170; Hirata T, 2012, INT IMMUNOL, V24, P705, DOI 10.1093/intimm/dxs077; Janssen WJM, 2016, CLIN IMMUNOL, V164, P34, DOI 10.1016/j.clim.2016.01.009; Kondo T, 1997, J CELL BIOL, V139, P749, DOI 10.1083/jcb.139.3.749; Kumari S, 2014, BBA-BIOMEMBRANES, V1838, P546, DOI 10.1016/j.bbamem.2013.05.004; Kunda P, 2008, CURR BIOL, V18, P91, DOI 10.1016/j.cub.2007.12.051; Lagresle-Peyrou C, 2016, J ALLERGY CLIN IMMUN, V138, P1681, DOI 10.1016/j.jaci.2016.04.032; Le Floc'h A, 2015, CELL MOL LIFE SCI, V72, P537, DOI 10.1007/s00018-014-1760-7; Liu Y, 2012, BLOOD, V119, P445, DOI 10.1182/blood-2011-07-368860; Mattila PK, 2016, J CELL BIOL, V212, P267, DOI 10.1083/jcb.201504137; Michie KA, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20081996; Moulding DA, 2013, IMMUNOL REV, V256, P282, DOI 10.1111/imr.12114; Nakamura F, 1995, J BIOL CHEM, V270, P31377, DOI 10.1074/jbc.270.52.31377; Nakamura F, 1999, MOL BIOL CELL, V10, P2669, DOI 10.1091/mbc.10.8.2669; Oguro H, 2013, CELL STEM CELL, V13, P102, DOI 10.1016/j.stem.2013.05.014; Parameswaran N, 2011, J IMMUNOL, V186, P4088, DOI 10.4049/jimmunol.1001139; Pietras EM, 2016, NAT CELL BIOL, V18, P607, DOI 10.1038/ncb3346; Pronk CJH, 2007, CELL STEM CELL, V1, P428, DOI 10.1016/j.stem.2007.07.005; Pronk CJH, 2018, METHODS MOL BIOL, V1678, P301, DOI 10.1007/978-1-4939-7346-0_13; Robertson TF, 2021, J CELL BIOL, V220, DOI 10.1083/jcb.202007182; Roubinet C, 2011, J CELL BIOL, V195, P99, DOI 10.1083/jcb.201106048; Roy NH, 2020, J CELL SCI, V133, DOI 10.1242/jcs.248328; Serrador JM, 1997, J CELL BIOL, V138, P1409, DOI 10.1083/jcb.138.6.1409; Shaffer MH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012404; Yonemura S, 1998, J CELL BIOL, V140, P885, DOI 10.1083/jcb.140.4.885; Yonemura S, 2002, J CELL SCI, V115, P2569	44	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 6	2022	12								726406	10.3389/fimmu.2021.726406	http://dx.doi.org/10.3389/fimmu.2021.726406			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YK4PF	35069520	gold, Green Published			2022-12-18	WOS:000745196100001
J	Huang, D; Shen, JY; Zhai, LY; Chen, HH; Fei, J; Zhu, XQ; Zhou, JW				Huang, Da; Shen, Jiayu; Zhai, Lingyun; Chen, Huanhuan; Fei, Jing; Zhu, Xiaoqing; Zhou, Jianwei			Insights Into the Prognostic Value and Immunological Role of NAAA in Pan-Cancer	FRONTIERS IN IMMUNOLOGY			English	Article						N-Acylethanolamine Acid Amidase (NAAA); pan-cancer; prognosis; immune infiltration; tumor immunosuppressive status	HYDROLYZING ACID AMIDASE; TOLL-LIKE RECEPTORS; INFLAMMATION; ATEZOLIZUMAB; MECHANISMS; INHIBITORS; MUTATION; CELLS; MODEL	N-Acylethanolamine Acid Amidase (NAAA) is an N-terminal cysteine hydrolase and plays a vital physiological role in inflammatory response. However, the roles of NAAA in tumor immunity are still unclear. By using a series of bioinformatics approaches, we study combined data from different databases, including the Cancer Genome Atlas, the Cancer Cell Line Encyclopedia, Genotype Tissue-Expression, cBioPortal, Human Protein Atlas, TIMER, and ImmuCellAI to investigate the role of NAAA expression in prognosis and tumor immunity response. We would like to reveal the potential correlations between NAAA expression and gene alterations, tumor mutational burden (TMB), microsatellite instability (MSI), DNA methylation, tumor microenvironment (TME), immune infiltration levels, and various immune-related genes across different cancers. The results show that NAAA displayed abnormal expression within most malignant tumors, and overexpression of NAAA was associated with the poor prognosis of tumor patients. Through gene set enrichment analysis (GSEA), we found that NAAA was significantly associated with cell cycle and immune regulation-related signaling pathways, such as in innate immune system, adaptive immune system, neutrophil degranulation, and Toll-like receptor signaling pathways (TLRs). Further, the expression of NAAA was also confirmed to be correlated with tumor microenvironment and diverse infiltration of immune cells, especially tumor-associated macrophage (TAM). In addition to this, we found that NAAA is co-expressed with genes encoding major histocompatibility complex (MHC), immune activation, immune suppression, chemokine, and chemokine receptors. Meanwhile, we demonstrate that NAAA expression was correlated with TMB in 4 cancers and with MSI in 10 cancers. Our study reveals that NAAA plays an important role in tumorigenesis and cancer immunity, which may be used to function as a prognostic biomarker and potential target for cancer immunotherapy.	[Huang, Da; Zhai, Lingyun; Chen, Huanhuan; Fei, Jing; Zhu, Xiaoqing; Zhou, Jianwei] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Gynecol, Hangzhou, Peoples R China; [Shen, Jiayu] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Obstet, Hangzhou, Peoples R China	Zhejiang University; Zhejiang University	Zhou, JW (corresponding author), Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Gynecol, Hangzhou, Peoples R China.	2195045@zju.edu.cn			National Nature Science Foundation of China [81902633]; Natural Science Foundation of Zhejiang Province [Y20H160278]	National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Zhejiang Province(Natural Science Foundation of Zhejiang Province)	Funding This study was supported by the National Nature Science Foundation of China (grant numbers 81902633) and the Natural Science Foundation of Zhejiang Province (grant number Y20H160278).	Alhouayek M, 2015, FASEB J, V29, P650, DOI 10.1096/fj.14-255208; Alhouayek M, 2014, DRUG DISCOV TODAY, V19, P1632, DOI 10.1016/j.drudis.2014.06.007; Bailey MH, 2018, CELL, V173, P371, DOI [10.1016/j.cell.2018.02.060, 10.1016/j.cell.2018.07.034]; Balar AV, 2017, LANCET, V389, P67, DOI 10.1016/S0140-6736(16)32455-2; Belli C, 2018, CANCER TREAT REV, V65, P22, DOI 10.1016/j.ctrv.2018.02.004; Binnewies M, 2018, NAT MED, V24, P541, DOI 10.1038/s41591-018-0014-x; Bonezzi FT, 2016, J PHARMACOL EXP THER, V356, P656, DOI 10.1124/jpet.115.230516; Bonneville R, 2017, JCO PRECIS ONCOL, V1, DOI 10.1200/PO.17.00073; Borghaei H, 2015, NEW ENGL J MED, V373, P1627, DOI 10.1056/NEJMoa1507643; Bukowski K, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21093233; Bunt SK, 2006, J IMMUNOL, V176, P284, DOI 10.4049/jimmunol.176.1.284; Calabrese C, 2020, NATURE, V578, P129, DOI 10.1038/s41586-020-1970-0; Campbell PJ, 2020, NATURE, V578, P82, DOI 10.1038/s41586-020-1969-6; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen M, 2021, CANCER CELL INT, V21, DOI 10.1186/s12935-021-02260-9; Chen YB, 2019, J BIOMED SCI, V26, DOI 10.1186/s12929-019-0568-z; Crusz SM, 2015, NAT REV CLIN ONCOL, V12, P584, DOI 10.1038/nrclinonc.2015.105; Dehnel N, 2017, CURR OPIN PHARMACOL, V35, P12, DOI 10.1016/j.coph.2017.04.007; Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0; Duan JC, 2020, JAMA ONCOL, V6, P375, DOI 10.1001/jamaoncol.2019.5367; Erin N, 2020, DRUG RESIST UPDATE, V53, DOI 10.1016/j.drup.2020.100715; Galdiero MR, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a028662; Galluzzi L, 2020, NAT REV CLIN ONCOL, V17, P725, DOI 10.1038/s41571-020-0413-z; Galon J, 2019, NAT REV DRUG DISCOV, V18, P197, DOI 10.1038/s41573-018-0007-y; Ge QY, 2021, J CANCER, V12, P595, DOI 10.7150/jca.50785; Gong Z, 2020, CANCER MED-US, V9, P9052, DOI 10.1002/cam4.3505; Gottesman MM, 2002, ANNU REV MED, V53, P615, DOI 10.1146/annurev.med.53.082901.103929; Greten FR, 2019, IMMUNITY, V51, P27, DOI 10.1016/j.immuni.2019.06.025; Gun SY, 2019, REDOX BIOL, V25, DOI 10.1016/j.redox.2019.101174; He X, 2020, CELL RES, V30, P660, DOI [10.19678/j.issn.1000-3428.0058876, 10.1038/s41422-020-0343-4]; Kalbasi A, 2020, NAT REV IMMUNOL, V20, P25, DOI 10.1038/s41577-019-0218-4; Koch A, 2018, NAT REV CLIN ONCOL, V15, P467, DOI 10.1038/s41571-018-0028-9; Korenjak M, 2019, CANCER SCI, V110, P3622, DOI 10.1111/cas.14210; Kowanetz M, 2017, J THORAC ONCOL, V12, pS321, DOI 10.1016/j.jtho.2016.11.343; Li R, 2020, BBA-REV CANCER, V1874, DOI 10.1016/j.bbcan.2020.188420; Li XL, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1102-3; Liu YS, 2014, MOL CELL PROTEOMICS, V13, P1753, DOI 10.1074/mcp.M114.038273; LoVerme J, 2006, J PHARMACOL EXP THER, V319, P1051, DOI 10.1124/jpet.106.111385; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Martincorena I, 2015, SCIENCE, V349, P1483, DOI 10.1126/science.aab4082; Piomelli D, 2020, J MED CHEM, V63, P7475, DOI 10.1021/acs.jmedchem.0c00191; Rakoff-Nahoum S, 2009, NAT REV CANCER, V9, P57, DOI 10.1038/nrc2541; Riaz N, 2017, CELL, V171, P934, DOI 10.1016/j.cell.2017.09.028; Rodriguez-Paredes M, 2011, NAT MED, V17, P330, DOI 10.1038/nm.2305; Romano B, 2022, BRIT J PHARMACOL, V179, P1679, DOI 10.1111/bph.15737; Sakura Y, 2016, BBA-MOL CELL BIOL L, V1861, P1951, DOI 10.1016/j.bbalip.2016.09.018; Sasso O, 2018, J INVEST DERMATOL, V138, P562, DOI 10.1016/j.jid.2017.07.853; Seiwert TY, 2018, CANCER RES, V78, DOI 10.1158/1538-7445.AM2018-LB-339; Shaked Y, 2019, NAT REV CANCER, V19, P667, DOI 10.1038/s41568-019-0209-6; Shiao SL, 2016, CANCER LETT, V380, P340, DOI 10.1016/j.canlet.2015.12.022; Snyder A, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002309; Snyder A, 2014, NEW ENGL J MED, V371, P2189, DOI 10.1056/NEJMoa1406498; Srivastava S, 2019, NAT REV CANCER, V19, P349, DOI 10.1038/s41568-019-0142-8; Sun YX, 2005, BBA-MOL CELL BIOL L, V1736, P211, DOI 10.1016/j.bbalip.2005.08.010; Tsai Ming-Ju, 2014, ISRN Biochem, V2014, P351959, DOI 10.1155/2014/351959; Tsan MF, 2006, SEMIN CANCER BIOL, V16, P32, DOI 10.1016/j.semcancer.2005.07.004; Tsuboi K, 2005, J BIOL CHEM, V280, P11082, DOI 10.1074/jbc.M413473200; Vago R, 2017, BIOORGAN MED CHEM, V25, P1242, DOI 10.1016/j.bmc.2016.12.042; Wang J, 2008, J BIOCHEM, V144, P685, DOI 10.1093/jb/mvn122; Wilky BA, 2019, IMMUNOL REV, V290, P6, DOI 10.1111/imr.12766; Wu KN, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00818; Zhang YY, 2020, CELL MOL IMMUNOL, V17, P807, DOI 10.1038/s41423-020-0488-6; Zhou P, 2019, PHARMACOL RES, V145, DOI 10.1016/j.phrs.2019.104264	63	0	0	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 6	2022	12								812713	10.3389/fimmu.2021.812713	http://dx.doi.org/10.3389/fimmu.2021.812713			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YK4MS	35069601	gold, Green Published			2022-12-18	WOS:000745189600001
J	Koenig, A; Vaeth, M; Xiao, Y; Chiarolla, CM; Erapaneedi, R; Klein, M; Dietz, L; Hundhausen, N; Majumder, S; Schuessler, F; Bopp, T; Klein-Hessling, S; Rosenwald, A; Berberich, I; Berberich-Siebelt, F				Koenig, Anika; Vaeth, Martin; Xiao, Yin; Chiarolla, Cristina M.; Erapaneedi, Raghu; Klein, Matthias; Dietz, Lena; Hundhausen, Nadine; Majumder, Snigdha; Schuessler, Felix; Bopp, Tobias; Klein-Hessling, Stefan; Rosenwald, Andreas; Berberich, Ingolf; Berberich-Siebelt, Friederike			NFATc1/alpha A and Blimp-1 Support the Follicular and Effector Phenotype of Tregs	FRONTIERS IN IMMUNOLOGY			English	Article						Blimp-1; CXCR5; effector Treg (eTreg); ex-Treg; T-follicular regulatory (T-FR) cell; germinal center response (GCR); NFATc1; NFATc1/aA (short isoform of NFATc1)	REGULATORY T-CELLS; GENE-EXPRESSION; CUTTING EDGE; B-CELLS; HELPER; DIFFERENTIATION; FOXP3; SUPPRESSION; HOMEOSTASIS; ACTIVATION	CD4(+)CXCR5(+)Foxp3(+) T-follicular regulatory (T-FR) cells control the germinal center responses. Like T-follicular helper cells, they express high levels of Nuclear Factor of Activated T-cells c1 , predominantly its short isoform NFATc1/alpha A. Ablation of NFATc1 in Tregs prevents upregulation of CXCR5 and migration of T-FR cells into B-cell follicles. By contrast, constitutive active NFATc1/alpha A defines the surface density of CXCR5, whose level determines how deep a T-FR migrates into the GC and how effectively it controls antibody production. As one type of effector Treg, T-FR cells express B lymphocyte-induced maturation protein-1 (Blimp-1). Blimp-1 can directly repress Cxcr5 and NFATc1/alpha A is necessary to overcome this Blimp-1-mediated repression. Interestingly, Blimp-1 even reinforces the recruitment of NFATc1 to Cxcr5 by protein-protein interaction and by those means cooperates with NFATc1 for Cxcr5 transactivation. On the contrary, Blimp-1 is necessary to counterbalance NFATc1/alpha A and preserve the Treg identity. This is because although NFATc1/alpha A strengthens the follicular development of Tregs, it bears the inherent risk of causing an ex-Treg phenotype.	[Koenig, Anika; Vaeth, Martin; Xiao, Yin; Chiarolla, Cristina M.; Erapaneedi, Raghu; Dietz, Lena; Hundhausen, Nadine; Majumder, Snigdha; Schuessler, Felix; Rosenwald, Andreas; Berberich-Siebelt, Friederike] Univ Wurzburg, Inst Pathol, Wurzburg, Germany; [Klein, Matthias; Bopp, Tobias] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Inst Immunol, Mainz, Germany; [Bopp, Tobias] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Res Ctr Immunotherapy FZI, Mainz, Germany; [Bopp, Tobias] Johannes Gutenberg Univ Mainz, Univ Canc Ctr Mainz, Univ Med Ctr, Mainz, Germany; [Bopp, Tobias] German Canc Consortium DKTK, Mainz, Germany; [Klein-Hessling, Stefan] Univ Wurzburg, Inst Pathol, Dept Mol Pathol, Wurzburg, Germany; [Rosenwald, Andreas] Univ Wurzburg, Comprehens Canc Ctr Mainfranken, Wurzburg, Germany; [Berberich, Ingolf] Univ Wurzburg, Inst Virol & Immunobiol, Wurzburg, Germany	University of Wurzburg; Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz; Helmholtz Association; German Cancer Research Center (DKFZ); University of Wurzburg; University of Wurzburg; University of Wurzburg	Berberich-Siebelt, F (corresponding author), Univ Wurzburg, Inst Pathol, Wurzburg, Germany.	path230@mail.uni-wuerzburg.de			Fritz Thyssen Stiftung [10.13.2.215, 10.17.2.012MN]; Wilhelm Sander-Foundation [2012.047.2 (FB-S)]; Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) [324392634]; Else Kroener-Fresenius Foundation [2015_A232]; Open Access Publication Fund of the University of Wuerzburg	Fritz Thyssen Stiftung; Wilhelm Sander-Foundation; Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)(German Research Foundation (DFG)); Else Kroener-Fresenius Foundation; Open Access Publication Fund of the University of Wuerzburg	This work was mainly supported by the Fritz Thyssen Stiftung (Az. 10.13.2.215 and 10.17.2.012MN to FB-S). Additional funding was received by the Wilhelm Sander-Foundation/2012.047.2 (FB-S), the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation), project number 324392634 - TRR 221, and the Else Kroener-Fresenius Foundation 2015_A232. This publication was supported by the Open Access Publication Fund of the University of Wuerzburg.	Aloulou M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10579; Ansel KM, 2000, NATURE, V406, P309, DOI 10.1038/35018581; Bankoti R, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12171-3; Baumgart S, 2014, CANCER DISCOV, V4, P688, DOI 10.1158/2159-8290.CD-13-0593; Bell L, 2020, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.03090; Bhattacharyya S, 2011, J EXP MED, V208, P823, DOI 10.1084/jem.20100945; BRABLETZ T, 1991, NUCLEIC ACIDS RES, V19, P61, DOI 10.1093/nar/19.1.61; Breitfeld D, 2000, J EXP MED, V192, P1545, DOI 10.1084/jem.192.11.1545; Chung Y, 2011, NAT MED, V17, P983, DOI 10.1038/nm.2426; Chuvpilo S, 2002, IMMUNITY, V16, P881, DOI 10.1016/S1074-7613(02)00329-1; Cretney E, 2018, J AUTOIMMUN, V91, P73, DOI 10.1016/j.jaut.2018.04.003; Cretney E, 2013, TRENDS IMMUNOL, V34, P74, DOI 10.1016/j.it.2012.11.002; Cretney E, 2011, NAT IMMUNOL, V12, P304, DOI 10.1038/ni.2006; Crotty S, 2019, IMMUNITY, V50, P1132, DOI 10.1016/j.immuni.2019.04.011; Crotty S, 2011, ANNU REV IMMUNOL, V29, P621, DOI 10.1146/annurev-immunol-031210-101400; Crotty S, 2010, NAT IMMUNOL, V11, P114, DOI 10.1038/ni.1837; Garg G, 2019, CELL REP, V26, P1854, DOI 10.1016/j.celrep.2019.01.070; Heinen AP, 2014, CYTOM PART A, V85A, P621, DOI 10.1002/cyto.a.22451; Hock M, 2013, J IMMUNOL, V190, P2345, DOI 10.4049/jimmunol.1201591; Johnston RJ, 2009, SCIENCE, V325, P1006, DOI 10.1126/science.1175870; Kallies A, 2004, J EXP MED, V200, P967, DOI 10.1084/jem.20040973; KELLER AD, 1992, MOL CELL BIOL, V12, P1940, DOI 10.1128/MCB.12.5.1940; Klein-Hessling S, 2003, J IMMUNOL, V170, P2956, DOI 10.4049/jimmunol.170.6.2956; Klein-Hessling S, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00612-6; Klein-Hessling S, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11841; Kuo TC, 2004, J IMMUNOL, V173, P5556, DOI 10.4049/jimmunol.173.9.5556; Lahl K, 2007, J EXP MED, V204, P57, DOI 10.1084/jem.20061852; Laidlaw BJ, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aan4767; Leon B, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4495; Leong YA, 2016, NAT IMMUNOL, V17, P1187, DOI 10.1038/ni.3543; Lim HW, 2005, J IMMUNOL, V175, P4180, DOI 10.4049/jimmunol.175.7.4180; Linterman MA, 2011, NAT MED, V17, P975, DOI 10.1038/nm.2425; Liu XD, 2014, NATURE, V507, P513, DOI 10.1038/nature12910; Lu PY, 2014, J EXP MED, V211, P515, DOI 10.1084/jem.20130208; Ma CS, 2012, J EXP MED, V209, P1241, DOI 10.1084/jem.20120994; Magnusdottir E, 2013, NAT CELL BIOL, V15, P905, DOI 10.1038/ncb2798; Martinez GJ, 2016, J IMMUNOL, V196, P2015, DOI 10.4049/jimmunol.1501841; Martinez GJ, 2015, IMMUNITY, V42, P265, DOI 10.1016/j.immuni.2015.01.006; Martins GA, 2006, NAT IMMUNOL, V7, P457, DOI 10.1038/ni1320; Minnich M, 2016, NAT IMMUNOL, V17, P331, DOI 10.1038/ni.3349; Nayak A, 2009, J BIOL CHEM, V284, P10935, DOI 10.1074/jbc.M900465200; Oestreich KJ, 2012, NAT IMMUNOL, V13, P405, DOI 10.1038/ni.2242; Okada T, 2005, PLOS BIOL, V3, P1047, DOI 10.1371/journal.pbio.0030150; Rasheed AU, 2006, EUR J IMMUNOL, V36, P1892, DOI 10.1002/eji.200636136; Ritvo PGG, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aan0368; Sage PT, 2016, NAT IMMUNOL, V17, P1436, DOI 10.1038/ni.3578; Sage PT, 2014, IMMUNITY, V41, P1026, DOI 10.1016/j.immuni.2014.12.005; Sage PT, 2013, NAT IMMUNOL, V14, P152, DOI 10.1038/ni.2496; Sakaguchi S, 2008, CELL, V133, P775, DOI 10.1016/j.cell.2008.05.009; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Schmidt D, 2008, EXP CELL RES, V314, P3614, DOI 10.1016/j.yexcr.2008.09.008; Serfling E, 2012, CELL COMMUN SIGNAL, V10, DOI 10.1186/1478-811X-10-16; Shaffer AL, 2002, IMMUNITY, V17, P51, DOI 10.1016/S1074-7613(02)00335-7; Shapiro-Shelef M, 2003, IMMUNITY, V19, P607, DOI 10.1016/S1074-7613(03)00267-X; Smigiel KS, 2014, J EXP MED, V211, P121, DOI 10.1084/jem.20131142; Srinivas S, 2001, BMC Dev Biol, V1, P4, DOI 10.1186/1471-213X-1-4; Teh PP, 2015, PROG MOL BIOL TRANSL, V136, P155, DOI 10.1016/bs.pmbts.2015.08.005; Vaeth Martin, 2018, F1000Res, V7, P260, DOI 10.12688/f1000research.13426.1; Vaeth M, 2015, P NATL ACAD SCI USA, V112, P1125, DOI 10.1073/pnas.1409290112; Vaeth M, 2014, J EXP MED, V211, P545, DOI 10.1084/jem.20130604; Vaeth M, 2012, P NATL ACAD SCI USA, V109, P16258, DOI 10.1073/pnas.1203870109; Vinuesa CG, 2016, ANNU REV IMMUNOL, V34, P335, DOI 10.1146/annurev-immunol-041015-055605; Wang L, 2019, CELL REP, V29, P1848, DOI 10.1016/j.celrep.2019.10.012; Wing JB, 2017, P NATL ACAD SCI USA, V114, pE6400, DOI 10.1073/pnas.1705551114; Wing JB, 2014, IMMUNITY, V41, P1013, DOI 10.1016/j.immuni.2014.12.006; Wing K, 2008, SCIENCE, V322, P271, DOI 10.1126/science.1160062; Wolf I, 1998, J BIOL CHEM, V273, P28831, DOI 10.1074/jbc.273.44.28831; Wollenberg I, 2011, J IMMUNOL, V187, P4553, DOI 10.4049/jimmunol.1101328; Xiao Y, 2021, J EXP MED, V218, DOI 10.1084/jem.20181853; Xie MM, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.128076; Yang G, 2018, IMMUNOLOGY, V153, P105, DOI 10.1111/imm.12815; Yu J, 2000, MOL CELL BIOL, V20, P2592, DOI 10.1128/MCB.20.7.2592-2603.2000; Yu X, 2009, NAT IMMUNOL, V10, P48, DOI 10.1038/ni.1674; Zheng Y, 2007, NATURE, V445, P936, DOI 10.1038/nature05563	74	0	0	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 6	2022	12								791100	10.3389/fimmu.2021.791100	http://dx.doi.org/10.3389/fimmu.2021.791100			18	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YO1CY	35069572	gold, Green Published			2022-12-18	WOS:000747685800001
J	Seo, JW; Lee, YH; Tae, DH; Park, SH; Moon, JY; Jeong, KH; Kim, CD; Chung, BH; Park, JB; Kim, YH; Seok, J; Joo, SH; Lee, SH; Lee, JS; Lee, SH				Seo, Jung-Woo; Lee, Yu-Ho; Tae, Dong Hyun; Park, Seon Hwa; Moon, Ju-Young; Jeong, Kyung Hwan; Kim, Chan-Duck; Chung, Byung Ha; Park, Jae Berm; Kim, Yeong Hoon; Seok, Junhee; Joo, Sun Hyung; Lee, Seung Hwan; Lee, Jong Soo; Lee, Sang-Ho			Non-Invasive Diagnosis for Acute Rejection Using Urinary mRNA Signature Reflecting Allograft Status in Kidney Transplantation (vol 12, 656632, 2021)	FRONTIERS IN IMMUNOLOGY			English	Correction						kidney; transplantation; non-invasive diagnosis; acute rejection; urinary mRNA			[Seo, Jung-Woo] Kyung Hee Univ, Med Sci Inst, Core Res Lab, Hosp Gangdong, Seoul, South Korea; [Seo, Jung-Woo; Lee, Yu-Ho; Park, Seon Hwa; Moon, Ju-Young; Lee, Sang-Ho] Kyung Hee Univ Hosp Gangdong, Dept Internal Med, Div Nephrol, Seoul, South Korea; [Tae, Dong Hyun; Seok, Junhee] Korea Univ, Sch Elect Engn, Seoul, South Korea; [Moon, Ju-Young; Jeong, Kyung Hwan; Lee, Sang-Ho] Kyung Hee Univ, Coll Med, Dept Internal Med, Div Nephrol, Seoul, South Korea; [Kim, Chan-Duck] Kyungpook Natl Univ, Dept Internal Med, Div Nephrol, Sch Med, Daegu, South Korea; [Chung, Byung Ha] Catholic Univ Korea, Coll Med, Seoul St Marys Hosp, Dept Internal Med,Div Nephrol, Seoul, South Korea; [Park, Jae Berm] Sungkyunkwan Univ, Dept Surg, Samsung Hosp, Seoul, South Korea; [Kim, Yeong Hoon] Inje Univ, Coll Med, Dept Internal Med, Div Nephrol,Busan Paik Hosp, Busan, South Korea; [Joo, Sun Hyung; Lee, Seung Hwan] Kyung Hee Univ, Dept Surg, Hosp Gangdong, Seoul, South Korea; [Lee, Jong Soo] Univ Ulsan, Dept Internal Med, Div Nephrol, Coll Med, Ulsan, South Korea	Kyung Hee University; Kyung Hee University Hospital; Kyung Hee University; Kyung Hee University Hospital; Korea University; Kyung Hee University; Kyungpook National University; Catholic University of Korea; Seoul St. Mary's Hospital; Samsung; Sungkyunkwan University (SKKU); Samsung Medical Center; Inje University; Kyung Hee University; Kyung Hee University Hospital; University of Ulsan	Lee, SH (corresponding author), Kyung Hee Univ Hosp Gangdong, Dept Internal Med, Div Nephrol, Seoul, South Korea.; Lee, SH (corresponding author), Kyung Hee Univ, Coll Med, Dept Internal Med, Div Nephrol, Seoul, South Korea.	lshkidney@khu.ac.kr			Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea [HI13C1232]; National Research Foundation of Korea Grant - Korean government, Ministry of Science, and ICT [2018M3A9E8078807]	Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea; National Research Foundation of Korea Grant - Korean government, Ministry of Science, and ICT	"This work was supported by the Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (grant no. HI13C1232) and by the National Research Foundation of Korea Grant funded by the Korean government, Ministry of Science, and ICT (grant no. 2018M3A9E8078807)".	Seo JW, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.656632	1	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 6	2022	12								825243	10.3389/fimmu.2021.825243	http://dx.doi.org/10.3389/fimmu.2021.825243			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YO1DP	35069605	gold, Green Published			2022-12-18	WOS:000747687500001
J	Tolbert, WD; Nguyen, DN; Tuyishime, M; Crowley, AR; Chen, YZ; Jha, S; Goodman, D; Bekker, V; Mudrak, SV; DeVico, AL; Lewis, GK; Theis, JF; Pinter, A; Moody, MA; Easterhoff, D; Wiehe, K; Pollara, J; Saunders, KO; Tomaras, GD; Ackerman, M; Ferrari, G; Pazgier, M				Tolbert, William D.; Nguyen, Dung N.; Tuyishime, Marina; Crowley, Andrew R.; Chen, Yaozong; Jha, Shalini; Goodman, Derrick; Bekker, Valerie; Mudrak, Sarah V.; DeVico, Anthony L.; Lewis, George K.; Theis, James F.; Pinter, Abraham; Moody, M. Anthony; Easterhoff, David; Wiehe, Kevin; Pollara, Justin; Saunders, Kevin O.; Tomaras, Georgia D.; Ackerman, Margaret; Ferrari, Guido; Pazgier, Marzena			Structure and Fc-Effector Function of Rhesusized Variants of Human Anti-HIV-1 IgG1s	FRONTIERS IN IMMUNOLOGY			English	Article						antibody engineering; rhesusization; Fc-effector function; non-human primates; HIV	HIV-1 VACCINE EFFICACY; BROADLY NEUTRALIZING ANTIBODY; MONOCLONAL-ANTIBODIES; ENVELOPE PROTEIN; PASSIVE TRANSFER; VIRION CAPTURE; PROTECTION; RECEPTOR; BINDING; SIV	Passive transfer of monoclonal antibodies (mAbs) of human origin into Non-Human Primates (NHPs), especially those which function predominantly by a Fc-effector mechanism, requires an a priori preparation step, in which the human mAb is reengineered to an equivalent NHP IgG subclass. This can be achieved by changing both the Fc and Fab sequence while simultaneously maintaining the epitope specificity of the parent antibody. This Ab reengineering process, referred to as rhesusization, can be challenging because the simple grafting of the complementarity determining regions (CDRs) into an NHP IgG subclass may impact the functionality of the mAb. Here we describe the successful rhesusization of a set of human mAbs targeting HIV-1 envelope (Env) epitopes involved in potent Fc-effector function against the virus. This set includes a mAb targeting a linear gp120 V1V2 epitope isolated from a RV144 vaccinee, a gp120 conformational epitope within the Cluster A region isolated from a RV305 vaccinated individual, and a linear gp41 epitope within the immunodominant Cys-loop region commonly targeted by most HIV-1 infected individuals. Structural analyses confirm that the rhesusized variants bind their respective Env antigens with almost identical specificity preserving epitope footprints and most antigen-Fab atomic contacts with constant regions folded as in control RM IgG1s. In addition, functional analyses confirm preservation of the Fc effector function of the rhesusized mAbs including the ability to mediate Antibody Dependent Cell-mediated Cytotoxicity (ADCC) and antibody dependent cellular phagocytosis by monocytes (ADCP) and neutrophils (ADNP) with potencies comparable to native macaque antibodies of similar specificity. While the antibodies chosen here are relevant for the examination of the correlates of protection in HIV-1 vaccine trials, the methods used are generally applicable to antibodies for other purposes.	[Tolbert, William D.; Nguyen, Dung N.; Chen, Yaozong; Pazgier, Marzena] Uniformed Serv Univ Hlth Sci, Div Infect Dis, Dept Med, Bethesda, MD USA; [Tuyishime, Marina; Jha, Shalini; Goodman, Derrick; Bekker, Valerie; Mudrak, Sarah V.; Pollara, Justin; Saunders, Kevin O.; Tomaras, Georgia D.; Ferrari, Guido] Duke Univ, Sch Med, Dept Surg, Durham, NC USA; [Tuyishime, Marina; Jha, Shalini; Goodman, Derrick; Bekker, Valerie; Mudrak, Sarah V.; Moody, M. Anthony; Easterhoff, David; Wiehe, Kevin; Pollara, Justin; Saunders, Kevin O.; Tomaras, Georgia D.; Ferrari, Guido] Duke Univ, Human Vaccine Inst, Sch Med, Durham, NC USA; [Tuyishime, Marina; Goodman, Derrick; Bekker, Valerie; Mudrak, Sarah V.; Pollara, Justin; Tomaras, Georgia D.; Ferrari, Guido] Duke Univ, Ctr Human Syst Immunol, Sch Med, Durham, NC USA; [Crowley, Andrew R.; Ackerman, Margaret] Dartmouth Coll, Thayer Sch Engn, Hanover, NH USA; [DeVico, Anthony L.; Lewis, George K.] Univ Maryland, Inst Human Virol, Sch Med, Div Vaccine Res, Baltimore, MD USA; [Theis, James F.; Pinter, Abraham] Rutgers State Univ, Publ Hlth Res Inst, New Jersey Med Sch, Newark, NJ USA; [Moody, M. Anthony] Duke Univ, Sch Med, Dept Pediat, Durham, NC USA; [Wiehe, Kevin] Duke Univ, Sch Med, Dept Med, Durham, NC USA	Uniformed Services University of the Health Sciences - USA; Duke University; Duke University; Duke University; Dartmouth College; University System of Maryland; University of Maryland Baltimore; Rutgers State University Newark; Rutgers State University New Brunswick; Rutgers State University Medical Center; Duke University; Duke University	Pazgier, M (corresponding author), Uniformed Serv Univ Hlth Sci, Div Infect Dis, Dept Med, Bethesda, MD USA.	marzena.pazgier@usuhs.edu	Crowley, Andrew/AGY-7454-2022; Ferrari, Guido/Z-2137-2019	Crowley, Andrew/0000-0002-5011-5362; Chen, Yaozong/0000-0001-5380-2339	National Institute of Health [R01 AI116274, R01 AI129769]; Duke Center for AIDS Research [P30 AI064518];  [DE-AC02-76SF00515];  [P01 AI120756]	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Duke Center for AIDS Research; ; 	Funding for this study was provided by the National Institute of Health grants: P01 AI120756 to GT, R01 AI116274 to MP, R01 AI129769 to MP, with support from the Duke Center for AIDS Research P30 AI064518. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript and the contents of this publication are solely the responsibility of the authors.	Ackerman ME, 2011, J IMMUNOL METHODS, V366, P8, DOI 10.1016/j.jim.2010.12.016; Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925; Almagro JC, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01751; Arthos J, 2008, NAT IMMUNOL, V9, P301, DOI 10.1038/ni1566; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Barouch DH, 2012, NATURE, V482, P89, DOI 10.1038/nature10766; Boesch AW, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00589; Bonsignori M, 2016, CELL, V165, P449, DOI 10.1016/j.cell.2016.02.022; Bonsignori M, 2012, J VIROL, V86, P11521, DOI 10.1128/JVI.01023-12; Bonsignori M, 2012, J VIROL, V86, P4688, DOI 10.1128/JVI.07163-11; Brunger AT, 1997, METHOD ENZYMOL, V277, P366, DOI 10.1016/S0076-6879(97)77021-6; BUCHACHER A, 1994, AIDS RES HUM RETROV, V10, P359, DOI 10.1089/aid.1994.10.359; Burton DR, 2011, P NATL ACAD SCI USA, V108, P11181, DOI 10.1073/pnas.1103012108; Casazza JP., 2021, C RETR OPP INF; Chan YN, 2016, J IMMUNOL, V197, P2936, DOI 10.4049/jimmunol.1502252; Easterhoff D, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.131437; Easterhoff D, 2020, J VIROL, V94, DOI 10.1128/JVI.01120-19; Felber BK, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107624; Fouts TR, 2000, J VIROL, V74, P11427, DOI 10.1128/JVI.74.24.11427-11436.2000; Fuchs SP, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005090; Gohain N, 2015, J VIROL, V89, P8840, DOI 10.1128/JVI.01232-15; Gordon SN, 2016, J IMMUNOL, V197, P2726, DOI 10.4049/jimmunol.1600674; Gordon SN, 2014, J IMMUNOL, V193, P6172, DOI 10.4049/jimmunol.1401504; Gottardo R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075665; Gray GE, 2021, NEW ENGL J MED, V384, P1089, DOI 10.1056/NEJMoa2031499; Harding FA, 2010, MABS-AUSTIN, V2, P256, DOI 10.4161/mabs.2.3.11641; Haynes BF, 2012, NEW ENGL J MED, V366, P1275, DOI 10.1056/NEJMoa1113425; Hoxie JA, 1998, J REPROD IMMUNOL, V41, P197, DOI 10.1016/S0165-0378(98)00059-X; Johnson S, 1997, J INFECT DIS, V176, P1215, DOI 10.1086/514115; Karasavvas N, 2012, AIDS RES HUM RETROV, V28, P1444, DOI 10.1089/aid.2012.0103; Karplus PA, 2012, SCIENCE, V336, P1030, DOI [10.1126/science.1218231, 10.1126/science.121823]; Lejeune J, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01297; Li H, 2016, P NATL ACAD SCI USA, V113, pE3413, DOI 10.1073/pnas.1606636113; Li SYS, 2014, J CLIN INVEST, V124, P3879, DOI 10.1172/JCI75539; Liu PH, 2014, J VIROL, V88, P5165, DOI 10.1128/JVI.03765-13; Liu PH, 2013, J VIROL, V87, P7828, DOI 10.1128/JVI.02737-12; Lu RM, 2020, J BIOMED SCI, V27, DOI 10.1186/s12929-019-0592-z; Luo K, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.88522; Malherbe DC, 2018, J VIROL, V92, DOI 10.1128/JVI.01092-17; Martinez-Navio JM, 2016, MOL THER, V24, P76, DOI 10.1038/mt.2015.191; Mascola JR, 1999, J VIROL, V73, P4009, DOI 10.1128/JVI.73.5.4009-4018.1999; Mayer KH, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002435; Mielke D, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02875; Neidich SD, 2019, J CLIN INVEST, V129, P4838, DOI 10.1172/JCI126391; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Peachman KK, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143895; Pegu P, 2013, J VIROL, V87, P1708, DOI 10.1128/JVI.02544-12; Pollara J, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.678511; Pollara J, 2014, J VIROL, V88, P7715, DOI 10.1128/JVI.00156-14; Pollara J, 2011, CYTOM PART A, V79A, P603, DOI 10.1002/cyto.a.21084; Popov AN, 2003, ACTA CRYSTALLOGR D, V59, P1145, DOI 10.1107/S0907444903008163; Priddy FH, 2019, LANCET HIV, V6, pE230, DOI 10.1016/S2352-3018(19)30003-7; Ramesh A, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01407; Rerks-Ngarm S, 2017, J INFECT DIS, V215, P1255, DOI 10.1093/infdis/jix099; Rerks-Ngarm S, 2009, NEW ENGL J MED, V361, P2209, DOI 10.1056/NEJMoa0908492; Roederer M, 2014, NATURE, V505, P502, DOI 10.1038/nature12893; Rolland M, 2012, NATURE, V490, P417, DOI 10.1038/nature11519; Santra S, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005042; Saunders KO, 2015, J VIROL, V89, P5895, DOI 10.1128/JVI.00210-15; Schouest B, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0225420; Shen XY, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-57491-z; Shingai M, 2014, J EXP MED, V211, P2061, DOI 10.1084/jem.20132494; Singh S, 2018, J VIROL, V92, DOI 10.1128/JVI.00281-18; Song RJ, 2006, J VIROL, V80, P8729, DOI 10.1128/JVI.00558-06; Tassaneetrithep B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108446; Tay MZ, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005817; Tolbert WD, 2020, MBIO, V11, DOI 10.1128/mBio.00208-20; Tolbert WD, 2019, MABS-AUSTIN, V11, P709, DOI 10.1080/19420862.2019.1589852; Tomaras GD, 2013, P NATL ACAD SCI USA, V110, P9019, DOI 10.1073/pnas.1301456110; Vaccari M, 2016, NAT MED, V22, P762, DOI 10.1038/nm.4105; Weiss MS, 2001, J APPL CRYSTALLOGR, V34, P130, DOI 10.1107/S0021889800018227; Whittle JRR, 2011, P NATL ACAD SCI USA, V108, P14216, DOI 10.1073/pnas.1111497108; Wiehe K, 2014, IMMUNITY, V41, P909, DOI 10.1016/j.immuni.2014.11.014; Worley MJ, 2018, J IMMUNOL METHODS, V457, P41, DOI 10.1016/j.jim.2018.03.007; Zolla-Pazner S, 2019, CURR OPIN HIV AIDS, V14, P309, DOI 10.1097/COH.0000000000000551; Zolla-Pazner S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053629	76	0	0	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 6	2022	12								787603	10.3389/fimmu.2021.787603	http://dx.doi.org/10.3389/fimmu.2021.787603			20	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YL5DT	35069563	Green Published, gold			2022-12-18	WOS:000745912000001
J	de Jong, S; de Breuk, A; Bakker, B; Katti, S; Hoyng, CB; Nilsson, SC; Blom, AM; van den Heuvel, LP; den Hollander, AI; Volokhina, EB				de Jong, Sarah; de Breuk, Anita; Bakker, Bjorn; Katti, Suresh; Hoyng, Carel B.; Nilsson, Sara C.; Blom, Anna M.; van den Heuvel, Lambert P.; den Hollander, Anneke I.; Volokhina, Elena B.			Functional Analysis of Variants in Complement Factor I Identified in Age-Related Macular Degeneration and Atypical Hemolytic Uremic Syndrome	FRONTIERS IN IMMUNOLOGY			English	Article						complement factor I; genetic variants; age-related macular degeneration; atypical hemolytic uremic syndrome; functional analysis	RARE GENETIC-VARIANTS; CFI GENE; MUTATIONS; MACULOPATHY; ACTIVATION; DISEASES	Complement factor I (FI) is a central inhibitor of the complement system, and impaired FI function increases complement activation, contributing to diseases such as age-related macular degeneration (AMD) and atypical hemolytic uremic syndrome (aHUS). Genetic variation in complement factor I (CFI) has been identified in both AMD and aHUS, with more than half of these variants leading to reduced FI secretion levels. For many of the variants with normal FI secretion, however, functional implications are not yet known. Here we studied 11 rare missense variants, with FI secretion levels comparable to wildtype, but a predicted damaging effects based on the Combined Annotation Dependent Depletion (CADD) score. Three variants (p.Pro50Ala, p.Arg339Gln, and p.Ser570Thr) were analyzed in plasma and serum samples of carriers affected by AMD. All 11 variants (nine for the first time in this study) were recombinantly expressed and the ability to degrade C3b was studied with the C3b degradation assay. The amount of degradation was determined by measuring the degradation product iC3b with ELISA. Eight of 11 (73%) mutant proteins (p.Pro50Ala, p.Arg339Gln, p.Ile340Thr, p.Gly342Glu, p.Gly349Arg, p.Arg474Gln, p.Gly487Cys, and p.Gly512Ser) showed significantly impaired C3b degradation, and were therefore classified as likely pathogenic. Our data indicate that genetic variants in CFI with a CADD score >20 are likely to affect FI function, and that monitoring iC3b in a degradation assay is a useful tool to establish the pathogenicity of CFI variants in functional studies.	[de Jong, Sarah; de Breuk, Anita; Bakker, Bjorn; Hoyng, Carel B.; den Hollander, Anneke I.] Radboud Univ Nijmegen Med Ctr, Donders Inst Brain Cognit & Behav, Dept Ophthalmol, Nijmegen, Netherlands; [Katti, Suresh] Gemini Therapeut Inc, Cambridge, MA USA; [Nilsson, Sara C.; Blom, Anna M.] Lund Univ, Dept Translat Med, Malmo, Sweden; [van den Heuvel, Lambert P.; Volokhina, Elena B.] Radboud Univ Nijmegen Med Ctr, Amalia Childrens Hosp, Nijmegen, Netherlands; [van den Heuvel, Lambert P.; Volokhina, Elena B.] Radboud Univ Nijmegen Med Ctr, Radboud Inst Mol Life Sci, Nijmegen, Netherlands; [van den Heuvel, Lambert P.; Volokhina, Elena B.] Radboud Univ Nijmegen Med Ctr, Dept Lab Med, Nijmegen, Netherlands; [den Hollander, Anneke I.] Radboud Univ Nijmegen Med Ctr, Dept Human Genet, Nijmegen, Netherlands	Radboud University Nijmegen; Lund University; Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen	Volokhina, EB (corresponding author), Radboud Univ Nijmegen Med Ctr, Amalia Childrens Hosp, Nijmegen, Netherlands.; Volokhina, EB (corresponding author), Radboud Univ Nijmegen Med Ctr, Radboud Inst Mol Life Sci, Nijmegen, Netherlands.; Volokhina, EB (corresponding author), Radboud Univ Nijmegen Med Ctr, Dept Lab Med, Nijmegen, Netherlands.		Blom, Anna/AFS-7343-2022; Blom, Anna/AFS-7369-2022; Blom, Anna/B-9607-2009	Blom, Anna/0000-0002-1348-1734				Bergseth G, 2013, MOL IMMUNOL, V56, P232, DOI 10.1016/j.molimm.2013.05.221; Bienaime F, 2010, KIDNEY INT, V77, P339, DOI 10.1038/ki.2009.472; BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X; Bresin E, 2013, J AM SOC NEPHROL, V24, P475, DOI 10.1681/ASN.2012090884; Corominas J, 2018, OPHTHALMOLOGY, V125, P1433, DOI 10.1016/j.ophtha.2018.03.040; de Breuk A, 2021, OPHTHALMOLOGY, V128, P1604, DOI 10.1016/j.ophtha.2020.07.037; de Jong S, 2020, HUM MOL GENET, V29, P2313, DOI 10.1093/hmg/ddaa114; Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448; Geerlings MJ, 2017, JAMA OPHTHALMOL, V135, P39, DOI 10.1001/jamaophthalmol.2016.4604; Haerynck F, 2013, J CLIN IMMUNOL, V33, P1293, DOI 10.1007/s10875-013-9944-8; Hallam TM, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.6.18; Java A, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.9.37; Kavanagh D, 2008, MOL IMMUNOL, V45, P95, DOI 10.1016/j.molimm.2007.05.004; Kavanagh D, 2015, HUM MOL GENET, V24, P3861, DOI 10.1093/hmg/ddv091; Khan AH, 2021, HUM MUTAT, V42, P1139, DOI 10.1002/humu.24242; KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128; Krieger E, 2014, BIOINFORMATICS, V30, P2981, DOI 10.1093/bioinformatics/btu426; Manders P., 2018, OPEN J BIORESOUR, V5, P2, DOI [10.5334/ojb.36, DOI 10.5334/OJB.36]; Merle NS, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00262; Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2; Nilsson SC, 2007, MOL IMMUNOL, V44, P1835, DOI 10.1016/j.molimm.2006.10.005; Nilsson SC, 2011, MOL IMMUNOL, V48, P1611, DOI 10.1016/j.molimm.2011.04.004; Nilsson SC, 2010, J BIOL CHEM, V285, P6235, DOI 10.1074/jbc.M109.097212; Nilsson SC, 2010, EUR J IMMUNOL, V40, P172, DOI 10.1002/eji.200939280; Noris M, 2010, AM J TRANSPLANT, V10, P1517, DOI 10.1111/j.1600-6143.2010.03156.x; Noris M, 2015, AM J KIDNEY DIS, V66, P359, DOI 10.1053/j.ajkd.2015.03.040; Ristau T, 2014, INVEST OPHTH VIS SCI, V55, P210, DOI 10.1167/iovs.13-13248; Saksens NTM, 2016, JAMA OPHTHALMOL, V134, P287, DOI 10.1001/jamaophthalmol.2015.5592; Szarvas N, 2016, MOL IMMUNOL, V71, P10, DOI 10.1016/j.molimm.2016.01.003; van de Ven JPH, 2013, NAT GENET, V45, P813, DOI 10.1038/ng.2640; van Leeuwen R, 2003, OPHTHALMOLOGY, V110, P1540, DOI 10.1016/S0161-6420(03)00501-3; Wong EKS, 2018, SEMIN IMMUNOPATHOL, V40, P49, DOI 10.1007/s00281-017-0663-8; WONG MJ, 1995, MOL IMMUNOL, V32, P379, DOI 10.1016/0161-5890(94)00151-P; Xue XG, 2017, NAT STRUCT MOL BIOL, V24, P643, DOI 10.1038/nsmb.3427	34	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 5	2022	12								789897	10.3389/fimmu.2021.789897	http://dx.doi.org/10.3389/fimmu.2021.789897			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YK4RC	35069568	Green Published, gold			2022-12-18	WOS:000745201000001
J	Khanolkar, RC; Zhang, C; Al-Fatyan, F; Lawson, L; Depasquale, I; Meredith, FM; Muller, F; Nicolson, M; Dahal, LN; Abu-Eid, R; Rajpara, S; Barker, RN; Ormerod, AD; Ward, FJ				Khanolkar, Rahul C.; Zhang, Chu; Al-Fatyan, Farah; Lawson, Linda; Depasquale, Ivan; Meredith, Fiona M.; Muller, Frank; Nicolson, Marianne; Dahal, Lekh Nath; Abu-Eid, Rasha; Rajpara, Sanjay; Barker, Robert Norman; Ormerod, Anthony D.; Ward, Frank James			TGF beta 2 Induces the Soluble Isoform of CTLA-4-Implications for CTLA-4 Based Checkpoint Inhibitor Antibodies in Malignant Melanoma	FRONTIERS IN IMMUNOLOGY			English	Article						checkpoint inhibitor; CTLA-4 (cytotoxic T lymphocyte-associated antigen 4); sCTLA-4; melanoma; TGF beta 2; T cells	REGULATORY T-CELLS; TGF-BETA; IPILIMUMAB; EXPRESSION; NIVOLUMAB; PEMBROLIZUMAB; SIGNATURES; EFFICACY; IMMUNITY; THERAPY	Malignant melanoma is an aggressive form of cancer, which can be treated with anti-CTLA-4 and anti-PD-1 checkpoint inhibitor antibodies but while anti-CTLA-4 antibodies have clear benefits for some patients with melanoma, productive responses are difficult to predict and often associated with serious immune related adverse events. Antibodies specific to CTLA-4 bind two major isoforms of CTLA-4 in humans, the receptor isoform and a second naturally secretable, soluble isoform - sCTLA-4. The primary aim here was to examine the effect of selectively blocking the function of sCTLA-4 on in vitro immune responses from volunteer healthy or melanoma patient PBMC samples. Addition of recombinant sCTLA-4 to healthy PBMC samples demonstrated sCTLA-4 to have immunosuppressive capacity comparable to recombinant CTLA4-Ig, partially reversible upon antibody blockade. Further, we identified a mechanistic relationship where melanoma patient TGF beta 2 serum levels correlated with sCTLA-4 levels and provided the basis for a novel protocol to enhance sCTLA-4 production and secretion by T cells with TGF beta 2. Finally, a comparison of selective antibody blockade of sCTLA-4 demonstrated that both healthy and melanoma patient effector cytokine responses can be significantly increased. Overall, the data support the notion that sCTLA-4 is a contributory factor in cancer immune evasion.	[Khanolkar, Rahul C.; Zhang, Chu; Al-Fatyan, Farah; Abu-Eid, Rasha; Barker, Robert Norman; Ward, Frank James] Univ Aberdeen, Sch Med Med Sci & Nutr, Inst Med Sci, Aberdeen, Scotland; [Lawson, Linda; Meredith, Fiona M.; Muller, Frank; Rajpara, Sanjay; Ormerod, Anthony D.] Aberdeen Royal Infirm, Burnside House, Aberdeen, Scotland; [Depasquale, Ivan] Aberdeen Royal Infirm, Ward 214 Plast Reconstruct Surg & Burns Unit, Aberdeen, Scotland; [Nicolson, Marianne] Aberdeen Royal Infirm, Anchor Unit, Clin D, Aberdeen, Scotland; [Dahal, Lekh Nath] Univ Liverpool, Inst Translat Med, Med Res Council MRC, Ctr Drug Safety Sci, Liverpool, Merseyside, England; [Abu-Eid, Rasha] Univ Aberdeen, Sch Med Med Sci & Nutr, Inst Dent, Aberdeen, Scotland	University of Aberdeen; University of Aberdeen; University of Aberdeen; University of Aberdeen; University of Liverpool; University of Aberdeen	Ward, FJ (corresponding author), Univ Aberdeen, Sch Med Med Sci & Nutr, Inst Med Sci, Aberdeen, Scotland.	mmmd475@abdn.ac.uk			Chief Scientist's office, Scotland [ETM/280]	Chief Scientist's office, Scotland	This work was funded by the Chief Scientist's office, Scotland grant no. ETM/280.	Abdulkhaleq F., IMMUNO ONCOL INSIGHT, V2, p151?169, DOI [10.18609/ioi.2021.024, DOI 10.18609/IOI.2021.024]; Alexandrov LB, 2016, SCIENCE, V354, P618, DOI 10.1126/science.aag0299; Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Batlle E, 2019, IMMUNITY, V50, P924, DOI 10.1016/j.immuni.2019.03.024; Bauche D, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-001584; BRUNET JF, 1987, NATURE, V328, P267, DOI 10.1038/328267a0; Chen WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152; Dahal LN, 2016, ARTHRITIS RES THER, V18, DOI 10.1186/s13075-016-1075-1; Daud AI, 2016, J CLIN ONCOL, V34, P4102, DOI 10.1200/JCO.2016.67.2477; David CJ, 2018, NAT REV MOL CELL BIO, V19, P419, DOI 10.1038/s41580-018-0007-0; David CJ, 2016, CELL, V164, P1015, DOI 10.1016/j.cell.2016.01.009; Greenwald RJ, 2005, ANNU REV IMMUNOL, V23, P515, DOI 10.1146/annurev.immunol.23.021704.115611; Hall AM, 2002, BLOOD, V100, P4529, DOI 10.1182/blood-2002-05-1383; Heldin CH, 2012, FEBS LETT, V586, P1959, DOI 10.1016/j.febslet.2012.02.037; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Iwama S, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008002; Kaufman HL, 2016, LANCET ONCOL, V17, P1374, DOI 10.1016/S1470-2045(16)30364-3; KRUMMEL MF, 1995, J EXP MED, V182, P459, DOI 10.1084/jem.182.2.459; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Laurent S, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-108; Leach DR, 1996, SCIENCE, V271, P1734, DOI 10.1126/science.271.5256.1734; Leung AM, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00110; Magistrelli G, 1999, EUR J IMMUNOL, V29, P3596, DOI 10.1002/(SICI)1521-4141(199911)29:11<3596::AID-IMMU3596>3.3.CO;2-P; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Massard C, 2016, J CLIN ONCOL, V34, P3119, DOI 10.1200/JCO.2016.67.9761; Michot JM, 2016, EUR J CANCER, V54, P139, DOI 10.1016/j.ejca.2015.11.016; Motzer RJ, 2018, NEW ENGL J MED, V378, P1277, DOI 10.1056/NEJMoa1712126; Oaks MK, 2000, CELL IMMUNOL, V201, P144, DOI 10.1006/cimm.2000.1649; Overman MJ, 2018, J CLIN ONCOL, V36, P773, DOI 10.1200/JCO.2017.76.9901; Pistillo MP, 2019, CANCER IMMUNOL IMMUN, V68, P97, DOI 10.1007/s00262-018-2258-1; Postow MA, 2015, NEW ENGL J MED, V372, P2006, DOI 10.1056/NEJMoa1414428; REED JA, 1994, AM J PATHOL, V145, P97; Rizvi NA, 2015, LANCET ONCOL, V16, P257, DOI 10.1016/S1470-2045(15)70054-9; Robert C, 2014, LANCET, V384, P1109, DOI 10.1016/S0140-6736(14)60958-2; Roncella S, 2016, CANCER IMMUNOL IMMUN, V65, P909, DOI 10.1007/s00262-016-1844-3; Rosenberg JE, 2016, LANCET, V387, P1909, DOI 10.1016/S0140-6736(16)00561-4; Schadendorf D, 2015, J CLIN ONCOL, V33, P1889, DOI 10.1200/JCO.2014.56.2736; Schlingensiepen KH, 2006, CYTOKINE GROWTH F R, V17, P129, DOI 10.1016/j.cytogfr.2005.09.002; Sekiya T, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-43068-y; Sharma P, 2015, SCIENCE, V348, P56, DOI 10.1126/science.aaa8172; Simone R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044654; Simpson TR, 2013, J EXP MED, V210, P1695, DOI 10.1084/jem.20130579; Sung HH, 2022, CLIN EXP HYPERTENS, V44, P146, DOI 10.1080/10641963.2021.2007943; WALUNAS TL, 1994, IMMUNITY, V1, P405, DOI 10.1016/1074-7613(94)90071-X; Ward FJ, 2013, EUR J IMMUNOL, V43, P1274, DOI 10.1002/eji.201242529	45	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 5	2022	12								763877	10.3389/fimmu.2021.763877	http://dx.doi.org/10.3389/fimmu.2021.763877			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YN9DA	35069536	Green Published, gold			2022-12-18	WOS:000747549900001
J	Lo, SM; Hwang, YS; Liu, CL; Shen, CN; Hong, WH; Yang, WC; Lee, MH; Shen, CR				Lo, Sheng-Min; Hwang, Yih-Shiou; Liu, Chao-Lin; Shen, Chia-Ning; Hong, Wei-Hsin; Yang, Wei-Cheng; Lee, Meng-Hua; Shen, Chia-Rui			Inhibiting TLR7 Expression in the Retinal Pigment Epithelium Suppresses Experimental Autoimmune Uveitis	FRONTIERS IN IMMUNOLOGY			English	Article						autoimmune uveitis; barrier function; EAU; IL-17; RPE; TLR7	T-CELLS; UVEORETINITIS EAU; PERTUSSIS TOXIN; GROWTH-FACTOR; RPE CELLS; DISEASE; ANTIGEN; MODEL; INDUCTION; INNATE	Experimental autoimmune uveitis (EAU), a model of human uveitis, is an organ-specific, T cell-mediated autoimmune disease. Autoreactive T cells can penetrate the blood-retinal barrier, which is a physical defense composed of tight junction-linked retinal pigment epithelial (RPE) cells. RPE cells serve as antigen-presenting cells (APCs) in the eye since they express MHC class I and II and Toll-like receptors (TLRs). Although previous studies have shown that supplementation with TLR agonists exacerbates uveitis, little is known about how TLR signaling in the RPE contributes to the development of uveitis. In this study, we isolated the RPE from EAU mice, which were induced by active immunization (aEAU) or adoptive transfer of antigen-specific T cells (tEAU). The expression of TLRs on RPE was determined, and both aEAU and tEAU mice exhibited induced tlr7 expression. The TLR7 agonist R848 was shown to induce aggressive disease progression, along with significantly elevated levels of the uveopathogenic cytokine IL-17. Furthermore, not only IL-17 but also R848 appeared to enhance the inflammatory response and to impair the barrier function of the RPE, indicating that TLR7 signaling is involved in the pathogenesis of EAU by affecting the behaviors of the RPE and consequently allowing the infiltration of autoreactive T cells intraocularly. Finally, local application of shRNA against TLR7 delivered by recombinant AAV effectively inhibited disease severity and reduced IFN-gamma and IL-17. Our findings highlight an immunomodulatory role of RPE TLR7 in EAU development and provide a potential therapeutic strategy for autoimmune uveitis.	[Lo, Sheng-Min; Hong, Wei-Hsin; Yang, Wei-Cheng; Lee, Meng-Hua; Shen, Chia-Rui] Chang Gung Univ, Dept & Grad Inst Med Biotechnol & Lab Sci, Coll Med, Taoyuan, Taiwan; [Lo, Sheng-Min; Yang, Wei-Cheng; Lee, Meng-Hua; Shen, Chia-Rui] Chang Gung Univ, Grad Inst Biomed Sci, Coll Med, Taoyuan, Taiwan; [Hwang, Yih-Shiou] Chang Gung Univ, Coll Med, Sch Med, Taoyuan, Taiwan; [Hwang, Yih-Shiou; Shen, Chia-Rui] Lin Kou Chang Gung Mem Hosp, Dept Ophthalmol, Taoyuan, Taiwan; [Liu, Chao-Lin] Ming Chi Univ Technol, Dept Chem Engn, New Taipei, Taiwan; [Liu, Chao-Lin] Ming Chi Univ Technol, Biochem Technol R&D Ctr, New Taipei, Taiwan; [Shen, Chia-Ning] Acad Sinica, Genom Res Ctr, Taipei, Taiwan; [Shen, Chia-Rui] Chang Gung Univ, Ctr Mol & Clin Immunol, Taoyuan, Taiwan	Chang Gung University; Chang Gung University; Chang Gung University; Chang Gung Memorial Hospital; Ming Chi University of Technology; Ming Chi University of Technology; Academia Sinica - Taiwan; Chang Gung University	Shen, CR (corresponding author), Chang Gung Univ, Dept & Grad Inst Med Biotechnol & Lab Sci, Coll Med, Taoyuan, Taiwan.; Shen, CR (corresponding author), Chang Gung Univ, Grad Inst Biomed Sci, Coll Med, Taoyuan, Taiwan.; Shen, CR (corresponding author), Lin Kou Chang Gung Mem Hosp, Dept Ophthalmol, Taoyuan, Taiwan.; Shen, CR (corresponding author), Chang Gung Univ, Ctr Mol & Clin Immunol, Taoyuan, Taiwan.	crshen@mail.cgu.edu.tw			Chang Gung Memorial Hospital [CMRPD1I0071-2, CMRPD1K0491-2, BMRP440]; Taiwan Ministry of Science and Technology [MOST 110-2320-B-182-018]	Chang Gung Memorial Hospital(Chang Gung Memorial Hospital); Taiwan Ministry of Science and Technology	Funding This study was financially supported by grants from Chang Gung Memorial Hospital (CMRPD1I0071-2, CMRPD1K0491-2 and BMRP440) and from the Taiwan Ministry of Science and Technology (MOST 110-2320-B-182-018).	Agarwal RK, 2002, J NEUROIMMUNOL, V129, P133, DOI 10.1016/S0165-5728(02)00203-5; Allensworth JJ, 2011, J LEUKOCYTE BIOL, V90, P1159, DOI 10.1189/jlb.0511249; Amasheh M, 2010, J CELL SCI, V123, P4145, DOI 10.1242/jcs.070896; Babu K, 2013, INDIAN J OPHTHALMOL, V61, P277, DOI 10.4103/0301-4738.114099; Benhar I, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00296; Cario E, 2010, INFLAMM BOWEL DIS, V16, P1583, DOI 10.1002/ibd.21282; CASPI RR, 1988, J IMMUNOL, V140, P1490; CASPI RR, 1986, J IMMUNOL, V136, P928; CHANG CW, 1991, CURR EYE RES, V10, P1081, DOI 10.3109/02713689109020348; Chen S, 2013, EUR J PHARM BIOPHARM, V85, P726, DOI 10.1016/j.ejpb.2013.09.005; Chen Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018139; Chong CM, 2016, REDOX BIOL, V9, P50, DOI 10.1016/j.redox.2016.06.002; Copland DA, 2008, INVEST OPHTH VIS SCI, V49, P5458, DOI 10.1167/iovs.08-2348; Cordero-Coma M, 2015, SURV OPHTHALMOL, V60, P575, DOI 10.1016/j.survophthal.2015.06.004; DETRICK B, 1986, AM J OPHTHALMOL, V101, P584, DOI 10.1016/0002-9394(86)90949-9; Diebold SS, 2004, SCIENCE, V303, P1529, DOI 10.1126/science.1093616; Ella R, 2021, LANCET INFECT DIS, V21, P637, DOI [10.1016/S1473-3099(20)30942-7, 10.1016/S1473-3099(21)00070-0]; Fang JZ, 2010, INVEST OPHTH VIS SCI, V51, P3092, DOI 10.1167/iovs.09-4754; Fox R, 1996, LUPUS, V5, pS4, DOI 10.1177/096120339600500103; FUJINO Y, 1988, CLIN IMMUNOL IMMUNOP, V46, P234, DOI 10.1016/0090-1229(88)90186-9; Ganneru B, 2021, ISCIENCE, V24, DOI 10.1016/j.isci.2021.102298; Garzorz-Stark N, 2018, J ALLERGY CLIN IMMUN, V141, P1320, DOI 10.1016/j.jaci.2017.07.045; Gibbs D, 2003, ADV EXP MED BIOL, V533, P347; Gottschalk TA, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00550; Hoffmann MH, 2011, J AUTOIMMUN, V36, P288, DOI 10.1016/j.jaut.2011.02.007; KAWASHIMA H, 1990, EXP EYE RES, V51, P565, DOI 10.1016/0014-4835(90)90087-B; Kuek A, 2007, POSTGRAD MED J, V83, P251, DOI 10.1136/pgmj.2006.052688; Kumar MV, 2004, J NEUROIMMUNOL, V153, P7, DOI 10.1016/j.jneuroim.2004.04.018; Lamagna C, 2013, P NATL ACAD SCI USA, V110, pE3311, DOI 10.1073/pnas.1300617110; Luger D, 2008, J EXP MED, V205, P799, DOI 10.1084/jem.20071258; Luna JD, 1997, J NEUROSCI RES, V49, P268, DOI 10.1002/(SICI)1097-4547(19970801)49:3<268::AID-JNR2>3.0.CO;2-A; Mangan PR, 2006, NATURE, V441, P231, DOI 10.1038/nature04754; MCGHEE CNJ, 1992, BRIT J OPHTHALMOL, V76, P681, DOI 10.1136/bjo.76.11.681; MEDAWAR PB, 1948, BRIT J EXP PATHOL, V29, P58; Miserocchi E, 2013, EUR J OPHTHALMOL, V23, P705, DOI 10.5301/ejo.5000278; Neal MD, 2012, J BIOL CHEM, V287, P37296, DOI 10.1074/jbc.M112.375881; Nosaka T, 1999, EMBO J, V18, P4754, DOI 10.1093/emboj/18.17.4754; O'Neill PM, 1998, PHARMACOL THERAPEUT, V77, P29, DOI 10.1016/S0163-7258(97)00084-3; Peng Y, 2007, INVEST OPHTH VIS SCI, V48, P4153, DOI 10.1167/iovs.07-0251; Qin HW, 2009, J IMMUNOL, V183, P97, DOI 10.4049/jimmunol.0801986; Quigley M, 2009, BLOOD, V113, P2256, DOI 10.1182/blood-2008-03-148809; Ramezanpour M, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/9798206; Reiling N, 2002, J IMMUNOL, V169, P3480, DOI 10.4049/jimmunol.169.7.3480; Rizzo LV, 1996, J IMMUNOL, V156, P1654; Sacre SM, 2007, AM J PATHOL, V170, P518, DOI 10.2353/ajpath.2007.060657; Santiago-Raber ML, 2009, J AUTOIMMUN, V33, P231, DOI 10.1016/j.jaut.2009.10.001; Seoudi N, 2014, INNATE IMMUN-LONDON, V20, P412, DOI 10.1177/1753425913498042; Shao H, 2006, EXP EYE RES, V82, P323, DOI 10.1016/j.exer.2005.07.008; Stern EM, 2017, OCHSNER J, V17, P280; Su SB, 2005, J IMMUNOL, V175, P6303, DOI 10.4049/jimmunol.175.10.6303; Sugita S, 2013, INVEST OPHTH VIS SCI, V54, P6926, DOI 10.1167/iovs.13-12703; Sugita S, 2009, ARCH IMMUNOL THER EX, V57, P263, DOI 10.1007/s00005-009-0030-0; Sun Siquan, 2007, Inflammation & Allergy Drug Targets, V6, P223; Takeda A, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01431; Thurau SR, 1997, CLIN EXP IMMUNOL, V109, P370, DOI 10.1046/j.1365-2249.1997.4571356.x; van der Made CI, 2020, JAMA-J AM MED ASSOC, V324, P663, DOI 10.1001/jama.2020.13719; Wang CXZ, 2012, EXP EYE RES, V102, P1, DOI 10.1016/j.exer.2012.06.003; Wang ZY, 2006, EXP HEMATOL, V34, P1115, DOI 10.1016/j.exphem.2006.04.025; West MA, 2004, SCIENCE, V305, P1153, DOI 10.1126/science.1099153; Xu H, 1997, CELL IMMUNOL, V178, P69, DOI 10.1006/cimm.1997.1121; Ye J, 2017, J IMMUNOL, V199, P941, DOI 10.4049/jimmunol.1601890; Yoshimura T, 2008, INT IMMUNOL, V20, P209, DOI 10.1093/intimm/dxm135; Yun J, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00142; Zarate-Blades CR, 2017, GUT MICROBES, V8, P59, DOI 10.1080/19490976.2016.1273996; Zhai XY, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.622316; Zhang LW, 2016, J DENT RES, V95, P784, DOI 10.1177/0022034516634647; Zhang R, 2009, CURR EYE RES, V34, P297, DOI 10.1080/02713680902741696	67	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 5	2022	12								736261	10.3389/fimmu.2021.736261	http://dx.doi.org/10.3389/fimmu.2021.736261			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YK4HZ	35069523	Green Published, gold			2022-12-18	WOS:000745177300001
J	Nagai, K; Ishii, T; Ohno, T; Nishii, Y				Nagai, Kohei; Ishii, Takenobu; Ohno, Tatsukuni; Nishii, Yasushi			Overload of the Temporomandibular Joints Accumulates gamma delta T Cells in a Mouse Model of Rheumatoid Arthritis: A Morphological and Histological Evaluation	FRONTIERS IN IMMUNOLOGY			English	Article						temporomandibular joint; rheumatoid arthritis; CAIA; mechanical stress; gamma delta T cell	COLLAGEN-INDUCED ARTHRITIS; MONOCLONAL-ANTIBODIES; TNF-ALPHA; RESORPTION; CYTOKINES	Recently, it has been reported that gamma delta T cells are associated with the pathology of rheumatoid arthritis (RA). However, there are many uncertainties about their relationship. In this study, we investigated the morphological and histological properties of peripheral as well as temporomandibular joints (TMJ) in a mouse model of rheumatoid arthritis with and without exposure to mechanical strain on the TMJ. Collagen antibody-induced arthritis (CAIA) was induced by administering collagen type II antibody and lipopolysaccharide to male DBA/1JNCrlj mice at 9-12 weeks of age, and mechanical stress (MS) was applied to the mandibular condyle. After 14 days, 3D morphological evaluation by micro-CT, histological staining (Hematoxylin Eosin, Safranin O, and Tartrate-Resistant Acid Phosphatase staining), and immunohistochemical staining (ADAMTS-5 antibody, CD3 antibody, CD45 antibody, ROR gamma t antibody, gamma delta T cell receptor antibody) were performed. The lower jawbone was collected. The mandibular condyle showed a rough change in the surface of the mandibular condyle based on three-dimensional analysis by micro-CT imaging. Histological examination revealed bone and cartilage destruction, such as a decrease in chondrocyte layer width and an increase in the number of osteoclasts in the mandibular condyle. Then, immune-histological staining revealed accumulation of T and gamma delta T cells in the subchondral bone. The temporomandibular joint is less sensitive to the onset of RA, but it has been suggested that it is exacerbated by mechanical stimulation. Additionally, the involvement of gamma delta T cells was suggested as the etiology of rheumatoid arthritis.	[Nagai, Kohei; Ishii, Takenobu; Nishii, Yasushi] Tokyo Dent Coll, Dept Orthodont, Tokyo, Japan; [Ohno, Tatsukuni] Tokyo Dent Coll, Oral Hlth Sci Ctr, Tokyo, Japan; [Ohno, Tatsukuni] Tokyo Dent Coll, Res Branding Project, Tokyo, Japan	Tokyo Dental College; Tokyo Dental College; Tokyo Dental College	Ishii, T (corresponding author), Tokyo Dent Coll, Dept Orthodont, Tokyo, Japan.	ishiit@tdc.ac.jp			Department of Orthodontics, Tokyo Dental College	Department of Orthodontics, Tokyo Dental College	Funding The work was supported by the Department of Orthodontics, Tokyo Dental College.	Ahmed N, 2015, ACTA ODONTOL SCAND, V73, P232, DOI 10.3109/00016357.2014.994561; Bank I, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9020462; Bonnefoy F, 2016, ARTHRITIS RES THER, V18, DOI 10.1186/s13075-016-1084-0; Cambre I, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06933-4; Caplazi P, 2015, VET PATHOL, V52, P819, DOI 10.1177/0300985815588612; Crossman J, 2019, ARCH ORAL BIOL, V104, P112, DOI 10.1016/j.archoralbio.2019.05.032; Ghassemi-Nejad S, 2011, OSTEOARTHR CARTILAGE, V19, P458, DOI 10.1016/j.joca.2011.01.012; Grahnemo L, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075-015-0703-5; Holers VM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01057; Ikeda Y, 2014, ARCH ORAL BIOL, V59, P1368, DOI 10.1016/j.archoralbio.2014.08.010; Kagari T, 2002, J IMMUNOL, V169, P1459, DOI 10.4049/jimmunol.169.3.1459; Katsumata Y, 2018, POLYMERS-BASEL, V10, DOI 10.3390/polym10121384; Koh JH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135409; Kuchler-Bopp S, 2020, INT J ORAL SCI, V12, DOI 10.1038/s41368-019-0072-z; Lin Yi-Chun, 2007, J Chin Med Assoc, V70, P527, DOI 10.1016/S1726-4901(08)70055-8; Liu WW, 2015, EXP THER MED, V10, P895, DOI 10.3892/etm.2015.2629; Liu YD, 2016, OSTEOARTHR CARTILAGE, V24, P178, DOI 10.1016/j.joca.2015.07.022; Liu YD, 2014, OSTEOARTHR CARTILAGE, V22, P302, DOI 10.1016/j.joca.2013.11.014; Macias I, 2005, J RHEUMATOL, V32, P2102; Mitamura M, 2007, INT IMMUNOPHARMACOL, V7, P1360, DOI 10.1016/j.intimp.2007.05.021; Nandakumar KS, 2005, J IMMUNOL METHODS, V304, P126, DOI 10.1016/j.jim.2005.06.017; Nandakumar KS, 2004, ARTHRITIS RES THER, V6, pR544, DOI 10.1186/ar1217; Nejad SG, 2017, JOINT BONE SPINE, V84, P145, DOI 10.1016/j.jbspin.2016.05.016; Nie H, 2013, NAT MED, V19, P322, DOI 10.1038/nm.3085; Roark CL, 2007, J IMMUNOL, V179, P5576, DOI 10.4049/jimmunol.179.8.5576; Robinson JL, 2017, OSTEOARTHR CARTILAGE, V25, P533, DOI 10.1016/j.joca.2016.11.008; Safi S, 2019, INT J RHEUM DIS, V22, P636, DOI 10.1111/1756-185X.13486; Sekiguchi Y, 2010, GENES NUTR, V5, P89, DOI 10.1007/s12263-009-0144-3; Shirakura M, 2010, BIOCHEM BIOPH RES CO, V393, P800, DOI 10.1016/j.bbrc.2010.02.086; Smolen JS, 2016, LANCET, V388, P2023, DOI 10.1016/S0140-6736(16)30173-8; Strand V, 2004, RHEUMATOLOGY, V43, P10, DOI 10.1093/rheumatology/keh202; Szkudlarek M, 2016, J RHEUMATOL, V43, P12, DOI 10.3899/jrheum.141416; TERATO K, 1992, J IMMUNOL, V148, P2103; Wang RN, 2019, MOL MED REP, V19, P1471, DOI 10.3892/mmr.2019.9831; Weaver CT, 2007, ANNU REV IMMUNOL, V25, P821, DOI 10.1146/annurev.immunol.25.022106.141557; Yoneda T, 2004, ENDOCRINOLOGY, V145, P2384, DOI 10.1210/en.2003-1536; Zou C, 2017, ONCOTARGET, V8, P8900, DOI 10.18632/oncotarget.13051	37	0	0	4	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 5	2022	12								753754	10.3389/fimmu.2021.753754	http://dx.doi.org/10.3389/fimmu.2021.753754			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YO1DK	35069529	gold, Green Published			2022-12-18	WOS:000747687000001
J	Okumo, T; Takayama, Y; Maruyama, K; Kato, M; Sunagawa, M				Okumo, Takayuki; Takayama, Yasunori; Maruyama, Kenta; Kato, Mami; Sunagawa, Masataka			Senso-Immunologic Prospects for Complex Regional Pain Syndrome Treatment	FRONTIERS IN IMMUNOLOGY			English	Review						complex regional pain syndrome; TRPA1; CGRP; Sudeck atrophy; nociceptor; magnoflorine; Kampo formula; senso-immunology	SYNDROME-TYPE-I; REFLEX SYMPATHETIC DYSTROPHY; SPINAL-CORD STIMULATION; GRADED MOTOR IMAGERY; NEUROPATHIC PAIN; CHANNEL ACTIVATION; DOUBLE-BLIND; DORSAL-HORN; TRPA1; RECEPTOR	Complex regional pain syndrome (CRPS) is a chronic pain syndrome that occurs in tissue injuries as the result of surgery, trauma, or ischemia. The clinical features of this severely painful condition include redness and swelling of the affected skin. Intriguingly, it was recently suggested that transient receptor potential ankyrin 1 (TRPA1) is involved in chronic post-ischemia pain, a CRPS model. TRPA1 is a non-selective cation channel expressed in calcitonin gene-related peptide (CGRP)-positive primary nociceptors that becomes highly activated in ischemic conditions, leading to the generation of pain. In this review, we summarize the history of TRPA1 and its involvement in pain sensation, inflammation, and CRPS. Furthermore, bone atrophy is also thought to be a characteristic clinical sign of CRPS. The altered bone microstructure of CRPS patients is thought to be caused by aggravated bone resorption via enhanced osteoclast differentiation and activation. Although TRPA1 could be a target for pain treatment in CRPS patients, we also discuss the paradoxical situation in this review. Nociceptor activation decreases the risk of bone destruction via CGRP secretion from free nerve endings. Thus, TRPA1 inhibition could cause severe bone atrophy. However, the suitable therapeutic strategy is controversial because the pathologic mechanisms of bone atrophy in CRPS are unclear. Therefore, we propose focusing on the remission of abnormal bone turnover observed in CRPS using a recently developed concept: senso-immunology.	[Okumo, Takayuki; Takayama, Yasunori; Maruyama, Kenta; Kato, Mami; Sunagawa, Masataka] Showa Univ, Dept Physiol, Sch Med, Shinagawa, Japan; [Maruyama, Kenta] Nat Inst Nat Sci, Div Cell Signaling, Natl Inst Physiol Sci, Okazaki, Japan; [Kato, Mami] Kyushu Univ, Grad Sch Pharmaceut Sci, Dept Mol & Syst Pharmacol, Fukuoka, Japan	Showa University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS); Kyushu University	Okumo, T; Takayama, Y; Maruyama, K; Sunagawa, M (corresponding author), Showa Univ, Dept Physiol, Sch Med, Shinagawa, Japan.; Maruyama, K (corresponding author), Nat Inst Nat Sci, Div Cell Signaling, Natl Inst Physiol Sci, Okazaki, Japan.	tokumo@med.showa-u.ac.jp; ytakayama@med.showa-u.ac.jp; maruken@nips.ac.jp; suna@med.showa-u.ac.jp						Aielli F, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20020280; Andersson DA, 2008, J NEUROSCI, V28, P2485, DOI 10.1523/JNEUROSCI.5369-07.2008; Aubdool AA, 2016, BRIT J PHARMACOL, V173, P2419, DOI 10.1111/bph.13519; Bandell M, 2004, NEURON, V41, P849, DOI 10.1016/S0896-6273(04)00150-3; Baral P, 2019, NAT REV IMMUNOL, V19, P433, DOI 10.1038/s41577-019-0147-2; Bautista DM, 2006, CELL, V124, P1269, DOI 10.1016/j.cell.2006.02.023; Birklein F, 2000, ACTA NEUROL SCAND, V101, P262, DOI 10.1034/j.1600-0404.2000.101004262x./; Birklein F, 2018, NAT REV NEUROL, V14, P272, DOI 10.1038/nrneurol.2018.20; Birklein F, 2015, PAIN, V156, pS94, DOI 10.1097/01.j.pain.0000460344.54470.20; Birklein F, 2015, NEUROLOGY, V84, P89, DOI 10.1212/WNL.0000000000001095; Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658; Breuer AJ, 2014, PAIN PHYSICIAN, V17, P127; Brown S, 2016, SCAND J PAIN, V13, P156, DOI 10.1016/j.sjpain.2016.05.039; Bruehl S, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h2730; Bussa M, 2015, ACTA ANAESTH SCAND, V59, P685, DOI 10.1111/aas.12489; Bussa M, 2017, PM&R, V9, P707, DOI 10.1016/j.pmrj.2016.11.006; Chen L, 2014, SCI REP-UK, V4, DOI 10.1038/srep05676; Chen RX, 2020, J NEUROINFLAMM, V17, DOI 10.1186/s12974-020-01834-0; Chevreau M, 2017, JOINT BONE SPINE, V84, P393, DOI 10.1016/j.jbspin.2017.03.009; CHRISTENSEN K, 1982, ACTA CHIR SCAND, V148, P653; Clapham DE, 2003, NATURE, V426, P517, DOI 10.1038/nature02196; Clark JD, 2018, MOL PAIN, V14, DOI 10.1177/1744806918799127; Coderre TJ, 2011, J PAIN, V12, P2, DOI 10.1016/j.jpain.2010.06.001; Coderre TJ, 2004, PAIN, V112, P94, DOI 10.1016/j.pain.2004.08.001; Coull JAM, 2005, NATURE, V438, P1017, DOI 10.1038/nature04223; De Logu F, 2020, BRAIN BEHAV IMMUN, V88, P535, DOI 10.1016/j.bbi.2020.04.037; De Logu F, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01739-2; de Mos M, 2008, PAIN, V139, P458, DOI 10.1016/j.pain.2008.07.002; de Mos M, 2007, PAIN, V129, P12, DOI 10.1016/j.pain.2006.09.008; Deer TR, 2019, NEUROMODULATION, V22, P1, DOI 10.1111/ner.12845; Deer TR, 2017, PAIN, V158, P669, DOI 10.1097/j.pain.0000000000000814; Del Valle L, 2009, BRAIN BEHAV IMMUN, V23, P85, DOI 10.1016/j.bbi.2008.08.004; Di Pietro F, 2013, J PAIN, V14, P1001, DOI 10.1016/j.jpain.2013.04.001; Dworkin RH, 2007, PAIN, V132, P237, DOI 10.1016/j.pain.2007.08.033; Eberhardt M, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5381; Eberle T, 2009, NEUROLOGY, V72, P505, DOI 10.1212/01.wnl.0000341930.35494.66; Feliu MH, 2010, CLIN J PAIN, V26, P258, DOI 10.1097/AJP.0b013e3181bff815; Ferrini F, 2013, NAT NEUROSCI, V16, P183, DOI 10.1038/nn.3295; Finch PM, 2014, PAIN MED, V15, P1945, DOI 10.1111/pme.12548; Fujii T., 2020, Traditional & Kampo Medicine, V7, P180, DOI 10.1002/tkm2.1257; Fukuda T, 2013, NATURE, V497, P490, DOI 10.1038/nature12115; Gao X, 2021, NATURE, V589, P591, DOI 10.1038/s41586-020-03057-y; Gees M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a003962; Goh EL, 2017, BURNS TRAUMA, V5, DOI 10.1186/s41038-016-0066-4; Guo HT, 2015, NAT MED, V21, P677, DOI 10.1038/nm.3893; Guo S, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00982; Harden RN, 2013, PAIN MED, V14, P180, DOI 10.1111/pme.12033; Harden RN, 2010, PAIN, V151, P870, DOI 10.1016/j.pain.2010.09.031; Harden RN, 2010, PAIN, V150, P268, DOI 10.1016/j.pain.2010.04.030; Harke H, 2001, ANESTH ANALG, V92, P488, DOI 10.1213/00000539-200102000-00039; Helyes Z, 2019, P NATL ACAD SCI USA, V116, P13067, DOI 10.1073/pnas.1820168116; Hinman A, 2006, P NATL ACAD SCI USA, V103, P19564, DOI 10.1073/pnas.0609598103; Hu QM, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00453; Im JJ, 2021, ARCH PHYS MED REHAB, V102, P216, DOI 10.1016/j.apmr.2020.07.006; Inoue K, 2018, NAT REV NEUROSCI, V19, P138, DOI 10.1038/nrn.2018.2; Iolascon G, 2015, CLIN CASES MINER BON, V12, P4, DOI 10.11138/ccmbm/2015.12.3s.004; Ishikawa T, 2000, NEUROSCIENCE, V95, P781; Iwata K, 2021, J GEN FAM MED, V22, P347, DOI 10.1002/jgf2.436; Janig W, 2003, LANCET NEUROL, V2, P687, DOI 10.1016/S1474-4422(03)00557-X; Jeon SG, 2014, KOREAN J PAIN, V27, P339, DOI 10.3344/kjp.2014.27.4.339; Jiang W, 2020, PAIN RES MANAG, V2020, DOI 10.1155/2020/1876862; Jin EH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079435; Kalita J, 2006, QJM-INT J MED, V99, P89, DOI 10.1093/qjmed/hcl004; Kalita J, 2016, PAIN PHYSICIAN, V19, P565; Kato M, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.628968; Kato Y, 2017, P NATL ACAD SCI USA, V114, pE6297, DOI 10.1073/pnas.1704847114; Kemler MA, 1999, NEUROLOGY, V53, P1350, DOI 10.1212/WNL.53.6.1350; Kim H, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198147; Kingery WS, 2010, PAIN MED, V11, P1239, DOI 10.1111/j.1526-4637.2010.00913.x; Kingery WS, 1997, PAIN, V73, P123, DOI 10.1016/S0304-3959(97)00049-3; Klafke JZ, 2016, PFLUG ARCH EUR J PHY, V468, P229, DOI 10.1007/s00424-015-1746-9; Kohr D, 2011, PAIN, V152, P2690, DOI 10.1016/j.pain.2011.06.012; Kohr D, 2009, PAIN, V143, P246, DOI 10.1016/j.pain.2009.03.009; Kunieda Y, 2021, APPL SCI-BASEL, V11, DOI 10.3390/app11188421; Lau FH, 2004, J HAND SURG-AM, V29A, P181, DOI 10.1016/j.jhsa.2003.08.016; Lee GS, 2012, NATURE, V492, P123, DOI 10.1038/nature11588; Liu SB, 2021, NATURE, V598, P641, DOI 10.1038/s41586-021-04001-4; Macpherson LJ, 2007, NATURE, V445, P541, DOI 10.1038/nature05544; Majima T, 2012, BMC SPORTS SCI MED R, V4, DOI 10.1186/1758-2555-4-3; Maruyama K, 2022, FEBS J, V289, P4132, DOI 10.1111/febs.15846; Maruyama K, 2018, ISCIENCE, V6, P306, DOI 10.1016/j.isci.2018.08.007; Maruyama K, 2017, CELL REP, V19, P2730, DOI 10.1016/j.celrep.2017.06.002; Masuda T, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12529; McCabe C, 2011, J HAND THER, V24, P170, DOI 10.1016/j.jht.2010.08.003; McCormick ZL, 2015, PAIN MED, V16, P2357, DOI 10.1111/pme.12817; McDonald MM, 2021, CELL, V184, P1330, DOI 10.1016/j.cell.2021.02.002; Meseguer V, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4125; Moseley GL, 2006, NEUROLOGY, V67, P2129, DOI 10.1212/01.wnl.0000249112.56935.32; Moseley GL, 2004, PAIN, V108, P192, DOI 10.1016/j.pain.2004.01.006; Munts AG, 2010, EUR J PAIN, V14, P523, DOI 10.1016/j.ejpain.2009.11.004; Mussawy H, 2017, CLIN CASES MINER BON, V14, P54, DOI 10.11138/ccmbm/2017.14.1.054; Ni HD, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00436; Nicholson CK, 2010, PHARMACOL RES, V62, P289, DOI 10.1016/j.phrs.2010.06.002; O'Connell NE, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004598.pub4; O'Connell NE, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009416.pub2; Oehler N, 2019, J BONE MINER METAB, V37, P741, DOI 10.1007/s00774-018-0976-2; Ohashi N, 2015, SCI REP-UK, V5, DOI 10.1038/srep13458; Oike Jun, 2020, Medicines (Basel), V7, DOI 10.3390/medicines7120074; Ott S, 2018, J PAIN, V19, P599, DOI 10.1016/j.jpain.2018.01.004; Papapetrou PD, 2009, HORM-INT J ENDOCRINO, V8, P96, DOI 10.14310/horm.2002.1226; Park CK, 2014, NEURON, V82, P47, DOI 10.1016/j.neuron.2014.02.011; Patel SK, 2020, J NEUROSURG-SPINE, V32, P133, DOI 10.3171/2019.6.SPINE181099; Paulsen CE, 2015, NATURE, V520, P511, DOI 10.1038/nature14367; Petersen PB, 2018, PAIN PRACT, V18, P341, DOI 10.1111/papr.12610; Petitjean H, 2015, CELL REP, V13, P1246, DOI 10.1016/j.celrep.2015.09.080; Ramachandran VS, 1996, P ROY SOC B-BIOL SCI, V263, P377, DOI 10.1098/rspb.1996.0058; Reinders MF, 2002, CLIN J PAIN, V18, P207, DOI 10.1097/00002508-200207000-00001; Ringer R, 2012, EUR J PAIN, V16, P1347, DOI 10.1002/j.1532-2149.2012.00137.x; Rivera C, 2004, J NEUROSCI, V24, P4683, DOI 10.1523/JNEUROSCI.5265-03.2004; Rivera C, 2002, J CELL BIOL, V159, P747, DOI 10.1083/jcb.200209011; Saloman JL, 2020, CURR OPIN NEUROBIOL, V62, P60, DOI 10.1016/j.conb.2019.11.021; SAMBROOK P, 1990, J RHEUMATOL, V17, P1425; Sandroni P, 2003, PAIN, V103, P199, DOI 10.1016/S0304-3959(03)00065-4; Sawada Y, 2008, EUR J NEUROSCI, V27, P1131, DOI 10.1111/j.1460-9568.2008.06093.x; Serpell MG, 2002, PAIN, V99, P557, DOI 10.1016/S0304-3959(02)00255-5; Smart KM, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010853.pub2; So K, 2016, SCI REP-UK, V6, DOI 10.1038/srep23261; Speck V, 2017, EUR J PAIN, V21, P466, DOI 10.1002/ejp.940; Sun XJ, 2018, EXP CELL RES, V369, P112, DOI 10.1016/j.yexcr.2018.05.012; Sun ZY, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00389; Swanson KV, 2019, NAT REV IMMUNOL, V19, P477, DOI 10.1038/s41577-019-0165-0; Takahashi N, 2016, SCI REP-UK, V6, DOI 10.1038/srep29294; Takahashi N, 2008, CHANNELS, V2, P287, DOI 10.4161/chan.2.4.6745; Talavera K, 2020, PHYSIOL REV, V100, P725, DOI 10.1152/physrev.00005.2019; Tashima R, 2018, ENEURO, V5, DOI 10.1523/ENEURO.0450-17.2018; Tekus V, 2014, PAIN, V155, P299, DOI 10.1016/j.pain.2013.10.011; Torres-Rosas R, 2014, NAT MED, V20, P291, DOI 10.1038/nm.3479; Tsukada R., 2014, JUNTENDO MED J, V60, P552, DOI [10.14789/jmj.60.552, DOI 10.14789/JMJ.60.552]; Van Buyten JP, 2015, PAIN PRACT, V15, P208, DOI 10.1111/papr.12170; van de Vusse AC, 2004, BMC NEUROL, V4, DOI 10.1186/1471-2377-4-13; Van Hilten BJ, 2000, NEW ENGL J MED, V343, P625, DOI 10.1056/NEJM200008313430905; van Rijn MA, 2007, PAIN, V130, P287, DOI 10.1016/j.pain.2007.03.027; Varenna M, 2014, CLIN EXP RHEUMATOL, V32, P451; Varenna M, 2021, THER ADV MUSCULOSKEL, V13, DOI 10.1177/1759720X211014020; Vieira G, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00584; Visnjevac O, 2017, PAIN PRACT, V17, P533, DOI 10.1111/papr.12513; Wang HL, 2015, INFLAMMATION, V38, P2269, DOI 10.1007/s10753-015-0212-3; Wang J, 2020, FRONT NEUROL, V11, DOI 10.3389/fneur.2020.580997; Wasner G, 2001, BRAIN, V124, P587, DOI 10.1093/brain/124.3.587; Watanabe M, 2019, SCI SIGNAL, V12, DOI 10.1126/scisignal.aaw9315; Watanabe M, 2009, J BIOL CHEM, V284, P27980, DOI 10.1074/jbc.M109.043620; Wertli MM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173688; Wertli MM, 2014, PAIN MED, V15, P1575, DOI 10.1111/pme.12466; Wilson SR, 2013, CELL, V155, P285, DOI 10.1016/j.cell.2013.08.057; Wilson SR, 2011, NAT NEUROSCI, V14, P595, DOI 10.1038/nn.2789; Woolf CJ, 2011, PAIN, V152, pS2, DOI 10.1016/j.pain.2010.09.030; Wu CL, 2015, BIOCHEM PHARMACOL, V93, P59, DOI 10.1016/j.bcp.2014.10.019; Xiao BL, 2011, NAT NEUROSCI, V14, P540, DOI 10.1038/nn.2813; Xu JJ, 2016, EUR J NEUROSCI, V44, P3046, DOI 10.1111/ejn.13414; Yan YQ, 2015, CELL, V160, P62, DOI 10.1016/j.cell.2014.11.047; Yu C, 2020, EUR J PHARMACOL, V881, DOI 10.1016/j.ejphar.2020.173184; Zhang MT, 2017, BIOMED PHARMACOTHER, V95, P186, DOI 10.1016/j.biopha.2017.07.167	152	0	0	0	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 5	2022	12								786511	10.3389/fimmu.2021.786511	http://dx.doi.org/10.3389/fimmu.2021.786511			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YL2WY	35069559	Green Published, gold			2022-12-18	WOS:000745758200001
J	Podesta, MA; Sykes, M				Podesta, Manuel Alfredo; Sykes, Megan			Chimerism-Based Tolerance to Kidney Allografts in Humans: Novel Insights and Future Perspectives	FRONTIERS IN IMMUNOLOGY			English	Review						chimerism and tolerance; kidney; transplantation; mixed chimerism; clinical protocol	BONE-MARROW-TRANSPLANTATION; T-CELL TOLERANCE; ANTIBODY MAB INJECTIONS; LIVING DONOR KIDNEY; MIXED CHIMERISM; HEMATOPOIETIC CHIMERISM; COSTIMULATORY BLOCKADE; MONOCLONAL-ANTIBODY; CLONAL DELETION; RENAL-TRANSPLANTATION	Chronic rejection and immunosuppression-related toxicity severely affect long-term outcomes of kidney transplantation. The induction of transplantation tolerance - the lack of destructive immune responses to a transplanted organ in the absence of immunosuppression - could potentially overcome these limitations. Immune tolerance to kidney allografts from living donors has been successfully achieved in humans through clinical protocols based on chimerism induction with hematopoietic cell transplantation after non-myeloablative conditioning. Notably, two of these protocols have led to immune tolerance in a significant fraction of HLA-mismatched donor-recipient combinations, which represent the large majority of cases in clinical practice. Studies in mice and large animals have been critical in dissecting tolerance mechanisms and in selecting the most promising approaches for human translation. However, there are several key differences in tolerance induction between these models and humans, including the rate of success and stability of donor chimerism, as well as the relative contribution of different mechanisms in inducing donor-specific unresponsiveness. Kidney allograft tolerance achieved through durable full-donor chimerism may be due to central deletion of graft-reactive donor T cells, even though mechanistic data from patient series are lacking. On the other hand, immune tolerance attained with transient mixed chimerism-based protocols initially relies on Treg-mediated suppression, followed by peripheral deletion of donor-reactive recipient T-cell clones under antigenic pressure from the graft. These conclusions were supported by data deriving from novel high-throughput T-cell receptor sequencing approaches that allowed tracking of alloreactive repertoires over time. In this review, we summarize the most important mechanistic studies on tolerance induction with combined kidney-bone marrow transplantation in humans, discussing open issues that still need to be addressed and focusing on techniques developed in recent years to efficiently monitor the alloresponse in tolerance trials. These cutting-edge methods will be instrumental for the development of immune tolerance protocols with improved efficacy and to identify patients amenable to safe immunosuppression withdrawal.	[Podesta, Manuel Alfredo] Univ Milan, Dept Hlth Sci, ASST Santi Paolo & Carlo, Renal Div, Milan, Italy; [Sykes, Megan] Columbia Univ, Dept Microbiol & Immunol, Columbia Ctr Translat Immunol, Dept Med,Dept Surg, New York, NY 10027 USA	University of Milan; Columbia University	Sykes, M (corresponding author), Columbia Univ, Dept Microbiol & Immunol, Columbia Ctr Translat Immunol, Dept Med,Dept Surg, New York, NY 10027 USA.	megan.sykes@columbia.edu	Podestà, Manuel Alfredo/AAC-6270-2019	Podestà, Manuel Alfredo/0000-0001-6684-2524				Abe M, 2002, J IMMUNOL, V168, P621, DOI 10.4049/jimmunol.168.2.621; Adams AB, 2003, J CLIN INVEST, V111, P1887, DOI 10.1172/JCI200317477; Andreola G, 2011, AM J TRANSPLANT, V11, P1236, DOI 10.1111/j.1600-6143.2011.03566.x; Basker M, 2001, TRANSPLANTATION, V72, P1278, DOI 10.1097/00007890-200110150-00017; Bemelman F, 1998, J IMMUNOL, V160, P2645; Binder C, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.592553; Busque S, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aax8863; Cippa PE, 2013, BLOOD, V122, P1669, DOI 10.1182/blood-2012-09-453944; COBBOLD SP, 1986, NATURE, V323, P164, DOI 10.1038/323164a0; DeWolf S, 2017, J CLIN INVEST, V127, P2473, DOI 10.1172/JCI90595; Domenig C, 2005, J IMMUNOL, V175, P51, DOI 10.4049/jimmunol.175.1.51; Duran-Struuck R, 2017, TRANSPLANTATION, V101, P274, DOI 10.1097/TP.0000000000001559; Fehr T, 2005, EUR J IMMUNOL, V35, P2679, DOI 10.1002/eji.200526190; Fehr T, 2008, J IMMUNOL, V181, P4371, DOI 10.4049/jimmunol.181.6.4371; Fehr T, 2008, J IMMUNOL, V181, P165, DOI 10.4049/jimmunol.181.1.165; Fugier-Vivier IJ, 2005, J EXP MED, V201, P373, DOI 10.1084/jem.20041399; Gallon L, 2018, J AM SOC NEPHROL, V29, P423, DOI 10.1681/ASN.2017030348; GAO EK, 1990, J EXP MED, V171, P1101, DOI 10.1084/jem.171.4.1101; Gondos A, 2013, TRANSPLANTATION, V95, P267, DOI 10.1097/TP.0b013e3182708ea8; Hariharan S, 2021, NEW ENGL J MED, V385, P729, DOI 10.1056/NEJMra2014530; Haspot F, 2008, BLOOD, V112, P2149, DOI 10.1182/blood-2007-12-127449; Hauri-Hohl MM, 2007, BLOOD, V109, P4080, DOI 10.1182/blood-2006-07-034157; HOLLANDER GA, 1994, J IMMUNOL, V152, P1609; Huang Y, 2016, AM J TRANSPLANT, V16, P440, DOI 10.1111/ajt.13511; Huang YM, 2011, BLOOD, V117, P2494, DOI 10.1182/blood-2010-06-291187; Ide K, 2007, P NATL ACAD SCI USA, V104, P5062, DOI 10.1073/pnas.0609661104; Issa F, 2021, AM J TRANSPLANT, V21, P21, DOI 10.1111/ajt.16139; Karuthu S, 2012, CLIN J AM SOC NEPHRO, V7, P2058, DOI 10.2215/CJN.04410512; KAUFMAN CL, 1994, BLOOD, V84, P2436; Kawahara T, 2007, AM J TRANSPLANT, V7, P2090, DOI 10.1111/j.1600-6143.2007.01905.x; Kawahara T, 2005, AM J TRANSPLANT, V5, P2821, DOI 10.1111/j.1600-6143.2005.01121.x; Kawai T, 2014, AM J TRANSPLANT, V14, P1599, DOI 10.1111/ajt.12731; KAWAI T, 1995, TRANSPLANTATION, V59, P256, DOI 10.1097/00007890-199501270-00018; Kawai T, 2008, NEW ENGL J MED, V358, P353, DOI 10.1056/NEJMoa071074; Khan A, 1996, TRANSPLANTATION, V62, P380, DOI 10.1097/00007890-199608150-00014; Koehn BH, 2007, J IMMUNOL, V179, P2616, DOI 10.4049/jimmunol.179.4.2616; Krenger W, 2011, BLOOD, V117, P6768, DOI 10.1182/blood-2011-02-334623; Kurtz J, 2004, BLOOD, V103, P4336, DOI 10.1182/blood-2003-08-2642; Kurtz J, 2009, BLOOD, V113, P3475, DOI 10.1182/blood-2008-01-133736; Lan P, 2004, BLOOD, V103, P3964, DOI 10.1182/blood-2003-10-3697; Lee KW, 2020, TRANSPLANTATION, V104, P1472, DOI 10.1097/TP.0000000000003006; Leventhal J, 2013, TRANSPLANTATION, V95, P169, DOI 10.1097/TP.0b013e3182782fc1; Leventhal J, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003509; Leventhal JR, 2015, TRANSPLANTATION, V99, P288, DOI 10.1097/TP.0000000000000605; Li HW, 2017, AM J TRANSPLANT, V17, P353, DOI 10.1111/ajt.13957; Lucas CL, 2011, BLOOD, V117, P5532, DOI 10.1182/blood-2010-11-318675; Luznik L, 2001, BLOOD, V98, P3456, DOI 10.1182/blood.V98.12.3456; MAIN JM, 1955, J NATL CANCER I, V15, P1023; Miyara M, 2009, IMMUNITY, V30, P899, DOI 10.1016/j.immuni.2009.03.019; Morris H, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.3010760; Na IK, 2010, J CLIN INVEST, V120, P343, DOI 10.1172/JCI39395; Newell KA, 2018, HUM IMMUNOL, V79, P380, DOI 10.1016/j.humimm.2018.02.007; Nikolic B, 1998, TRANSPLANTATION, V65, P1216, DOI 10.1097/00007890-199805150-00013; Ohdan H, 1999, J CLIN INVEST, V104, P281, DOI 10.1172/JCI6656; Ohdan H, 2001, TRANSPLANTATION, V71, P1532, DOI 10.1097/00007890-200106150-00009; Pilat N, 2010, AM J TRANSPLANT, V10, P751, DOI 10.1111/j.1600-6143.2010.03018.x; Podesta MA, 2020, AM J TRANSPLANT, V20, P88, DOI 10.1111/ajt.15533; Rama I, 2010, NAT REV NEPHROL, V6, P511, DOI 10.1038/nrneph.2010.102; RAMSDELL F, 1989, SCIENCE, V246, P1038, DOI 10.1126/science.2511629; RUEDI E, 1989, CELL IMMUNOL, V121, P185, DOI 10.1016/0008-8749(89)90016-6; Sasaki H, 2018, HUM IMMUNOL, V79, P258, DOI 10.1016/j.humimm.2017.11.008; Savage TM, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.124086; Scandling JD, 2015, AM J TRANSPLANT, V15, P695, DOI 10.1111/ajt.13091; Scandling JD, 2018, HUM IMMUNOL, V79, P266, DOI 10.1016/j.humimm.2018.01.002; Shaffer J, 2007, EXP HEMATOL, V35, P1140, DOI 10.1016/j.exphem.2007.03.018; SHARABI Y, 1989, J EXP MED, V169, P493, DOI 10.1084/jem.169.2.493; Shimizu I, 2007, BLOOD, V109, P1773, DOI 10.1182/blood-2006-02-002386; SINGER A, 1981, J EXP MED, V153, P1286, DOI 10.1084/jem.153.5.1286; Sprangers B, 2017, AM J TRANSPLANT, V17, P2020, DOI 10.1111/ajt.14251; Sykes M, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aau6298; Sykes M, 2018, HUM IMMUNOL, V79, P334, DOI 10.1016/j.humimm.2017.12.011; Tantisattamo E, 2021, CURR OPIN NEPHROL HY, V30, P63, DOI 10.1097/MNH.0000000000000666; Tena AA, 2017, TRANSPLANTATION, V101, P316, DOI 10.1097/TP.0000000000001267; Tomita Y, 1996, TRANSPLANTATION, V61, P477, DOI 10.1097/00007890-199602150-00028; TOMITA Y, 1994, J IMMUNOL, V153, P1087; Tomita Y, 1996, TRANSPLANTATION, V61, P469, DOI 10.1097/00007890-199602150-00027; Waffarn EE, 2021, XENOTRANSPLANTATION, V28, DOI 10.1111/xen.12691; Watanabe H, 2018, XENOTRANSPLANTATION, V25, DOI 10.1111/xen.12391; Wekerle T, 1998, J EXP MED, V187, P2037, DOI 10.1084/jem.187.12.2037; Wekerle T, 2001, J IMMUNOL, V166, P2311, DOI 10.4049/jimmunol.166.4.2311; Wen YJ, 2014, STEM CELLS, V32, P2732, DOI 10.1002/stem.1780; Werkele T, 2000, NAT MED, V6, P464, DOI 10.1038/74731; Yamada Y, 2014, AM J TRANSPLANT, V14, P2704, DOI 10.1111/ajt.12936; Yamada Y, 2012, AM J TRANSPLANT, V12, P330, DOI 10.1111/j.1600-6143.2011.03795.x; Ying T, 2020, J AM SOC NEPHROL, V31, P2887, DOI 10.1681/ASN.2020050566; Zuber J, 2017, TRENDS IMMUNOL, V38, P829, DOI 10.1016/j.it.2017.07.008	86	0	0	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 5	2022	12								791725	10.3389/fimmu.2021.791725	http://dx.doi.org/10.3389/fimmu.2021.791725			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZA3ZT	35069574	Green Published, gold			2022-12-18	WOS:000756106500001
J	Ye, LF; Zuo, Y; Chen, F; Peng, QL; Lu, X; Wang, GC; Shu, XM				Ye, Lifang; Zuo, Yu; Chen, Fang; Peng, Qinglin; Lu, Xin; Wang, Guochun; Shu, Xiaoming			miR-18a-3p and Its Target Protein HuR May Regulate Myogenic Differentiation in Immune-Mediated Necrotizing Myopathy	FRONTIERS IN IMMUNOLOGY			English	Article						HuR; miR-18a-3p; RNA binding protein; immune-mediated necrotizing myopathy; myogenic differentiation	SKELETAL-MUSCLE; EXPRESSION; MICRORNAS; DISEASE; INHIBITION; ROLES	Immune-mediated necrotizing myopathy (IMNM) is characterized by manifestation of myonecrosis and regeneration of muscle fibers; however, the underlying pathogenesis remains unclear. This study aimed to investigate the role and mechanism of miR-18a-3p and its target RNA-binding protein HuR in IMNM. HuR and miR-18a-3p levels were detected in the skeletal muscles of 18 patients with IMNM using quantitative reverse-transcription real-time polymerase chain reaction (qRT-PCR) and western blotting analysis. Human myoblasts were transfected with small interfering RNA targeting HuR and miR-18a-3p mimic or inhibitor. Myogenic differentiation markers, myogenin and myosin heavy chain, were analyzed by qRT-PCR, western blotting analysis, and immunofluorescence staining. The results showed that miR-18a-3p was upregulated (p=0.0002), whereas HuR was downregulated (p=0.002) in the skeletal muscles of patients with IMNM. The expression of miR-18a-3p in patients with IMNM was negatively correlated with those of HuR (r = -0.512, p = 0.029). We also found that disease activity was positively correlated with HuR expression (r = 0.576, p = 0.012) but muscle activity was negatively correlated with miR-18a-3p expression (r = -0.550, p = 0.017). Besides, bioinformatics analysis and dual-luciferase reporter assays suggested that miR-18a-3p could directly target HuR. Cellular experiments showed that overexpression of miR-18a-3p inhibited myogenic differentiation by targeting HuR, whereas inhibition of miR-18a-3p led to opposite results. Therefore, miR-18a-3p and its target protein HuR may be responsible for modulating the myogenic process in IMNM and can thus be therapeutic targets for the same.	[Ye, Lifang; Zuo, Yu; Chen, Fang; Peng, Qinglin; Lu, Xin; Wang, Guochun; Shu, Xiaoming] China Japan Friendship Hosp, Key Lab Myositis, Dept Rheumatol, Beijing, Peoples R China; [Ye, Lifang; Wang, Guochun] Chinese Acad Med Sci, Peking Union Med Coll, Beijing, Peoples R China	China-Japan Friendship Hospital; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College	Wang, GC; Shu, XM (corresponding author), China Japan Friendship Hosp, Key Lab Myositis, Dept Rheumatol, Beijing, Peoples R China.; Wang, GC (corresponding author), Chinese Acad Med Sci, Peking Union Med Coll, Beijing, Peoples R China.	guochunwang@hotmail.com; sxm992283@hotmail.com		Shu, Xiao ming/0000-0001-5425-6157				Allenbach Y, 2020, NAT REV RHEUMATOL, V16, P689, DOI 10.1038/s41584-020-00515-9; Allenbach Y, 2018, NEUROMUSCULAR DISORD, V28, P87, DOI 10.1016/j.nmd.2017.09.016; Arouche-Delaperche L, 2017, ANN NEUROL, V81, P538, DOI 10.1002/ana.24902; Bassel-Duby R, 2006, ANNU REV BIOCHEM, V75, P19, DOI 10.1146/annurev.biochem.75.103004.142622; Chen WL, 2019, EPIGENOMICS-UK, V11, P821, DOI 10.2217/epi-2018-0135; Eisenberg I, 2007, P NATL ACAD SCI USA, V104, P17016, DOI 10.1073/pnas.0708115104; Figueroa A, 2003, MOL CELL BIOL, V23, P4991, DOI 10.1128/MCB.23.14.4991-5004.2003; Gao SM, 2017, AUTOIMMUN REV, V16, P1044, DOI 10.1016/j.autrev.2017.07.021; Georgantas RW, 2014, ARTHRITIS RHEUMATOL, V66, P1022, DOI 10.1002/art.38292; Guller I, 2010, J PHYSIOL-LONDON, V588, P4075, DOI 10.1113/jphysiol.2010.194175; Jiang TW, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00037; Kim M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00738; Kinder TB, 2020, ARTHRITIS RHEUMATOL, V72, P1170, DOI 10.1002/art.41215; Kong DL, 2019, CELL MOL LIFE SCI, V76, P5041, DOI 10.1007/s00018-019-03165-7; Kozomara A, 2019, NUCLEIC ACIDS RES, V47, pD155, DOI 10.1093/nar/gky1141; Liu QC, 2012, J MOL CELL BIOL, V4, P386, DOI 10.1093/jmcb/mjs045; Mogilyansky E, 2013, CELL DEATH DIFFER, V20, P1603, DOI 10.1038/cdd.2013.125; Mok GF, 2017, SEMIN CELL DEV BIOL, V72, P67, DOI 10.1016/j.semcdb.2017.10.032; Parkes JE, 2015, CURR OPIN RHEUMATOL, V27, P608, DOI 10.1097/BOR.0000000000000225; Pinal-Fernandez I, 2018, CURR RHEUMATOL REP, V20, DOI 10.1007/s11926-018-0732-6; Qiu H, 2016, CELL DEATH DIFFER, V23, P1658, DOI 10.1038/cdd.2016.56; Rider LG, 1997, ARTHRITIS RHEUM-US, V40, P1976, DOI 10.1002/art.1780401109; Schultz CW, 2020, WIRES RNA, V11, DOI 10.1002/wrna.1581; Srikantan S, 2012, FRONT BIOSCI-LANDMRK, V17, P189, DOI 10.2741/3921; Sugiyama Y, 2020, MOD RHEUMATOL, V30, P878, DOI 10.1080/14397595.2019.1661584; Suzuki E, 2006, INT J MOL MED, V18, P273; van der Giessen K, 2003, J BIOL CHEM, V278, P47119, DOI 10.1074/jbc.M308889200; van der Giessen K, 2007, MOL BIOL CELL, V18, P2619, DOI 10.1091/mbc.E07-02-0167; Ventura A, 2008, CELL, V132, P875, DOI 10.1016/j.cell.2008.02.019; von Roretz C, 2011, BBA-MOL CELL RES, V1813, P1663, DOI 10.1016/j.bbamcr.2011.01.036; Xiao CC, 2008, NAT IMMUNOL, V9, P405, DOI 10.1038/ni1575; Ye LF, 2019, J IMMUNOL RES, V2019, DOI 10.1155/2019/2927061	32	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 5	2022	12								780237	10.3389/fimmu.2021.780237	http://dx.doi.org/10.3389/fimmu.2021.780237			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZB6IV	35069550	Green Published, gold			2022-12-18	WOS:000756944500001
J	Zhang, XY; Zhuo, XY; Cheng, J; Wang, XH; Liang, KX; Chen, XH				Zhang, Xiang-Yang; Zhuo, Xinyue; Cheng, Jie; Wang, Xiaohong; Liang, Kexin; Chen, Xinhua			PU.1 Regulates Cathepsin S Expression in Large Yellow Croaker (Larimichthys crocea) Macrophages	FRONTIERS IN IMMUNOLOGY			English	Article						Large yellow croaker (Larmichthys crocea); macrophage; PU.1; cathepsin S; IFN-	KIDNEY-DERIVED MACROPHAGES; CELL-LINE; PERIPHERAL-BLOOD; CYPRINUS-CARPIO; ESTABLISHMENT; FISH; MONOCYTE/MACROPHAGE; IDENTIFICATION; POLARIZATION; GENERATION	Different morphologies have been detected in teleost macrophages. In this study, two macrophage cell lines were sub-cloned from a large yellow croaker head kidney cell line, LYCK. One type of sub-cloned cells was fusiform but the other was round, named LYC-FM and LYC-RM cells respectively, based on their morphologies. Both types showed the characteristics of macrophages, including expression of macrophage-specific marker genes, possession of phagocytic and bactericidal activities, and production of reactive oxygen species (ROS) and nitric oxide (NO). The transcription factor PU.1, crucial for the development of macrophages in mammals, was found to exist in two transcripts, PU.1a and PU.1b, in large yellow croaker, and constitutively expressed in LYC-FM and LYC-RM cells. The expression levels of PU.1a and PU.1b could be upregulated by recombinant large yellow croaker IFN-gamma protein (rLcIFN-gamma). Further studies showed that both PU.1a and PU.1b increased the expression of cathepsin S (CTSS) by binding to different E26-transformation-specific (Ets) motifs of the CTSS promoter. Additionally, we demonstrated that all three domains of PU.1a and PU.1b were essential for initiating CTSS expression by truncated mutation experiments. Our results therefore provide the first evidence that teleost PU.1 has a role in regulating the expression of CTSS.	[Zhang, Xiang-Yang; Zhuo, Xinyue; Cheng, Jie; Wang, Xiaohong; Liang, Kexin; Chen, Xinhua] Fujian Agr & Forestry Univ, Coll Bee Sci, Key Lab Marine Biotechnol Fujian Prov, Coll Anim Sci,Inst Oceanol, Fuzhou, Peoples R China; [Chen, Xinhua] Southern Marine Sci & Engn Guangdong Lab Zhuhai, Zhuhai, Peoples R China	Fujian Agriculture & Forestry University; Southern Marine Science & Engineering Guangdong Laboratory	Chen, XH (corresponding author), Fujian Agr & Forestry Univ, Coll Bee Sci, Key Lab Marine Biotechnol Fujian Prov, Coll Anim Sci,Inst Oceanol, Fuzhou, Peoples R China.; Chen, XH (corresponding author), Southern Marine Sci & Engn Guangdong Lab Zhuhai, Zhuhai, Peoples R China.	chenxinhua@tio.org.cn	zhang, xiang/GQI-2806-2022		National Natural Science Foundation of China [U1905204, 32102837]; Natural Science Foundation of Fujian Province [2021J05021]; Fujian Science and Technology Department [2021N5008]; National Training Program of Innovation and Entrepreneurship for Undergraduates [202110389010]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Fujian Province(Natural Science Foundation of Fujian Province); Fujian Science and Technology Department; National Training Program of Innovation and Entrepreneurship for Undergraduates	This work was supported by the National Natural Science Foundation of China (U1905204, 32102837), Natural Science Foundation of Fujian Province (2021J05021), grant from the Fujian Science and Technology Department (2021N5008), and National Training Program of Innovation and Entrepreneurship for Undergraduates (202110389010).	Anderson KL, 1998, BLOOD, V91, P3702, DOI 10.1182/blood.V91.10.3702; Ao JQ, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005118; Awasthi A, 2015, CYTOTECHNOLOGY, V67, P85, DOI 10.1007/s10616-013-9660-5; Awasthi A, 2014, J ENVIRON BIOL, V35, P949; BAYNE CJ, 1986, VET IMMUNOL IMMUNOP, V12, P141, DOI 10.1016/0165-2427(86)90118-2; Biswas SK, 2010, NAT IMMUNOL, V11, P889, DOI 10.1038/ni.1937; BRAUNNESJE R, 1982, DEV COMP IMMUNOL, V6, P281, DOI 10.1016/S0145-305X(82)80011-6; BRAUNNESJE R, 1981, J FISH DIS, V4, P141, DOI 10.1111/j.1365-2761.1981.tb01118.x; Celada A, 1996, J EXP MED, V184, P61, DOI 10.1084/jem.184.1.61; Cerezuela R, 2009, FISH SHELLFISH IMMUN, V26, P243, DOI 10.1016/j.fsi.2008.11.004; Chaudhary DK, 2012, IN VITRO CELL DEV-AN, V48, P340, DOI 10.1007/s11626-012-9516-x; Cui K, 2020, DEV COMP IMMUNOL, V102, DOI 10.1016/j.dci.2019.103477; Datta S, 2009, AQUAT TOXICOL, V92, P86, DOI 10.1016/j.aquatox.2009.01.002; DeKoter RP, 2002, IMMUNITY, V16, P297, DOI 10.1016/S1074-7613(02)00269-8; Forlenza M, 2009, MOL IMMUNOL, V46, P3188, DOI 10.1016/j.molimm.2009.08.011; Gan Z, 2020, REV AQUACULT, V12, P773, DOI 10.1111/raq.12349; Ganassin RC, 1998, FISH SHELLFISH IMMUN, V8, P457, DOI 10.1006/fsim.1998.0153; Ghisletti S, 2010, IMMUNITY, V32, P317, DOI 10.1016/j.immuni.2010.02.008; Hanington PC, 2007, DEV COMP IMMUNOL, V31, P817, DOI 10.1016/j.dci.2006.12.001; Hermann AC, 2005, MAR BIOTECHNOL, V7, P494, DOI 10.1007/s10126-004-4109-7; Hodgkinson Jordan W., 2015, Biology-Basel, V4, P881, DOI 10.3390/biology4040881; Hsieh CS, 2002, J IMMUNOL, V168, P2618, DOI 10.4049/jimmunol.168.6.2618; Joerink M, 2006, J IMMUNOL, V177, P61, DOI 10.4049/jimmunol.177.1.61; Karpurapu M, 2011, BLOOD, V118, P5255, DOI 10.1182/blood-2011-03-341123; Li CW, 2020, J FISH DIS, V43, P1353, DOI 10.1111/jfd.13206; Li QingFei, 2013, Acta Hydrobiologica Sinica, V37, P885; Li QH, 2015, FISH SHELLFISH IMMUN, V47, P743, DOI 10.1016/j.fsi.2015.10.009; Lu XJ, 2017, J IMMUNOL, V198, P4692, DOI 10.4049/jimmunol.1700101; Lugo-Villarino G, 2010, P NATL ACAD SCI USA, V107, P15850, DOI 10.1073/pnas.1000494107; Mao KQ, 2018, FISH SHELLFISH IMMUN, V80, P180, DOI 10.1016/j.fsi.2018.06.002; Marecki S, 2000, CELL BIOCHEM BIOPHYS, V33, P127, DOI 10.1385/CBB:33:2:127; Mu YN, 2018, COMMUN BIOL, V1, DOI 10.1038/s42003-018-0207-3; Neumann NF, 2000, FISH SHELLFISH IMMUN, V10, P1, DOI 10.1006/fsim.1999.0221; Rebello SC, 2014, IN VITRO CELL DEV-AN, V50, P22, DOI 10.1007/s11626-013-9674-5; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Sha ZX, 2017, FISH SHELLFISH IMMUN, V65, P256, DOI 10.1016/j.fsi.2017.04.015; Sinder BP, 2015, J BONE MINER RES, V30, P2140, DOI 10.1002/jbmr.2735; Sorensen KK, 1997, J FISH DIS, V20, P93, DOI 10.1046/j.1365-2761.1997.d01-112.x; Tahir A, 1996, FISH SHELLFISH IMMUN, V6, P135, DOI 10.1006/fsim.1996.0014; Takizawa F, 2016, J IMMUNOL, V196, P4522, DOI 10.4049/jimmunol.1600222; van's Gravesande KS, 2002, J IMMUNOL, V168, P4488, DOI 10.4049/jimmunol.168.9.4488; WANG R, 1995, FISH SHELLFISH IMMUN, V5, P329, DOI 10.1006/fsim.1995.0032; Wang XH, 2014, J FISH BIOL, V84, P1551, DOI 10.1111/jfb.12386; Wang Y, 2006, J IMMUNOL, V176, P275, DOI 10.4049/jimmunol.176.1.275; WEEKS BA, 1986, VET IMMUNOL IMMUNOP, V12, P313, DOI 10.1016/0165-2427(86)90135-2; Wynn TA, 2013, NATURE, V496, P445, DOI 10.1038/nature12034; Yang SS, 2017, FISH SHELLFISH IMMUN, V70, P545, DOI 10.1016/j.fsi.2017.09.051; Zhang XY, 2021, DEV COMP IMMUNOL, V121, DOI 10.1016/j.dci.2021.104103	48	0	0	5	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 5	2022	12								819029	10.3389/fimmu.2021.819029	http://dx.doi.org/10.3389/fimmu.2021.819029			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YN2IO	35069603	Green Published, gold			2022-12-18	WOS:000747087000001
J	Feraoun, Y; Palgen, JL; Joly, C; Tchitchek, N; Marcos-Lopez, E; Dereuddre-Bosquet, N; Gallouet, AS; Contreras, V; Levy, Y; Martinon, F; Le Grand, R; Beignon, AS				Feraoun, Yanis; Palgen, Jean-Louis; Joly, Candie; Tchitchek, Nicolas; Marcos-Lopez, Ernesto; Dereuddre-Bosquet, Nathalie; Gallouet, Anne-Sophie; Contreras, Vanessa; Levy, Yves; Martinon, Frederic; Le Grand, Roger; Beignon, Anne-Sophie			The Route of Vaccine Administration Determines Whether Blood Neutrophils Undergo Long-Term Phenotypic Modifications	FRONTIERS IN IMMUNOLOGY			English	Article						vaccine; innate immunity; innate immune memory; trained immunity; Modified vaccinia virus Ankara (MVA); administration routes; mass cytometry (CyTOF)	MASS CYTOMETRY; INNATE IMMUNITY; CELL RESPONSES; ANTIGEN; PROTEIN; MEMORY; PROTECTION; INDUCTION; ANKARA; NEF	Innate immunity modulates adaptive immunity and defines the magnitude, quality, and longevity of antigen-specific T- and B- cell immune memory. Various vaccine and administration factors influence the immune response to vaccination, including the route of vaccine delivery. We studied the dynamics of innate cell responses in blood using a preclinical model of non-human primates immunized with a live attenuated vaccinia virus, a recombinant Modified vaccinia virus Ankara (MVA) expressing a gag-pol-nef fusion of HIV-1, and mass cytometry. We previously showed that it induces a strong, early, and transient innate response, but also late phenotypic modifications of blood myeloid cells after two months when injected subcutaneously. Here, we show that the early innate effector cell responses and plasma inflammatory cytokine profiles differ between subcutaneous and intradermal vaccine injection. Additionally, we show that the intradermal administration fails to induce more highly activated/mature neutrophils long after immunization, in contrast to subcutaneous administration. Different batches of antibodies, staining protocols and generations of mass cytometers were used to generate the two datasets. Mass cytometry data were analyzed in parallel using the same analytical pipeline based on three successive clustering steps, including SPADE, and categorical heatmaps were compared using the Manhattan distance to measure the similarity between cell cluster phenotypes. Overall, we show that the vaccine per se is not sufficient for the late phenotypic modifications of innate myeloid cells, which are evocative of innate immune training. Its route of administration is also crucial, likely by influencing the early innate response, and systemic inflammation, and vaccine biodistribution.	[Feraoun, Yanis; Palgen, Jean-Louis; Joly, Candie; Marcos-Lopez, Ernesto; Dereuddre-Bosquet, Nathalie; Gallouet, Anne-Sophie; Contreras, Vanessa; Martinon, Frederic; Le Grand, Roger; Beignon, Anne-Sophie] Univ Paris Saclay, INSERM, CEA, Ctr Immunol Viral AutoImmune Hematol & Bacterial, Fontenay Aux Roses, France; [Tchitchek, Nicolas] Sorbonne Univ, INSERM, UMRS 959, Immunol Immunopathol Immunotherapy i3, Paris, France; [Levy, Yves] Univ Paris East, INSERM U955, Henri Mondor Hosp, Creteil, France; [Levy, Yves] Vaccine Res Inst VRI, Creteil, France	CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)	Beignon, AS (corresponding author), Univ Paris Saclay, INSERM, CEA, Ctr Immunol Viral AutoImmune Hematol & Bacterial, Fontenay Aux Roses, France.	anne-sophie.beignon@cea.fr	Martinon, Frederic/Y-3684-2018	Martinon, Frederic/0000-0001-9634-442X; Tchitchek, Nicolas/0000-0003-3307-0446	IDMIT infrastructure; ANR [ANR-11-INBS-0008]; "Investissements d'Avenir" programs [ANR10-LABX-77-01, ANR-10-EQPX-02-01]; European Commission [FP7-HEALTH-2011-280873]; Transvac, EU H2020 [GA 730964]; EHVA, EU H2020 [GA 681032]; ANRS (France Recherche Nord&Sud Sida-HIV Hepatites)	IDMIT infrastructure; ANR(French National Research Agency (ANR)); "Investissements d'Avenir" programs(French National Research Agency (ANR)); European Commission(European CommissionEuropean Commission Joint Research Centre); Transvac, EU H2020; EHVA, EU H2020; ANRS (France Recherche Nord&Sud Sida-HIV Hepatites)(French National Research Agency (ANR))	This work was supported by the IDMIT infrastructure and funded by the ANR via grant No ANR-11-INBS-0008. NT held a fellowship from the ANRS (France Recherche Nord&Sud Sida-HIV Hepatites). This work was also supported by the "Investissements d'Avenir" programs managed by the ANR under reference ANR10-LABX-77-01 funding the Vaccine Research Institute (VRI), Cr ' eteil (ImMemory research program) and ANR-10-EQPX-02-01 funding the FlowCyTech facility (IDMIT, Fontenay-aux-Roses, France). Funds were also received from the European Commission: ADITEC, FP7-HEALTH-2011-280873; Transvac, EU H2020 GA 730964; EHVA, EU H2020 GA 681032.	AntalSzalmas P, 1997, J LEUKOCYTE BIOL, V61, P721, DOI 10.1002/jlb.61.6.721; Arts RJW, 2018, CELL HOST MICROBE, V23, P89, DOI 10.1016/j.chom.2017.12.010; Arunachalam PS, 2021, NATURE, V596, P410, DOI 10.1038/s41586-021-03791-x; Cheng SM, 2009, BLOOD, V113, P5192, DOI 10.1182/blood-2008-10-183525; Cirovic B, 2020, CELL HOST MICROBE, V28, P322, DOI 10.1016/j.chom.2020.05.014; Conti L, 2004, IMMUNOBIOLOGY, V209, P99, DOI 10.1016/j.imbio.2004.02.008; Costa S, 2019, IMMUNOLOGY, V156, P23, DOI 10.1111/imm.13005; Cross DL, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.574057; de Bree LCJ, 2018, SEMIN IMMUNOL, V39, P35, DOI 10.1016/j.smim.2018.06.002; DeGottardi Q, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-72610-6; Divangahi M, 2021, NAT IMMUNOL, V22, P2, DOI 10.1038/s41590-020-00845-6; Duffy D, 2012, IMMUNITY, V37, P917, DOI 10.1016/j.immuni.2012.07.015; Finck R, 2013, CYTOM PART A, V83A, P483, DOI 10.1002/cyto.a.22271; Gautreau G, 2017, BIOINFORMATICS, V33, P779, DOI 10.1093/bioinformatics/btw708; Hamilton SE, 2020, J IMMUNOL, V205, P3, DOI 10.4049/jimmunol.2000171; Herzog C, 2014, EXPERT REV VACCINES, V13, P399, DOI 10.1586/14760584.2014.883285; Kaufmann E, 2018, CELL, V172, P176, DOI 10.1016/j.cell.2017.12.031; Khader SA, 2019, J CLIN INVEST, V129, P3482, DOI 10.1172/JCI128877; Kirchhoff F, 2008, CELL MOL LIFE SCI, V65, P2621, DOI 10.1007/s00018-008-8094-2; Kleinnijenhuis J, 2012, P NATL ACAD SCI USA, V109, P17537, DOI 10.1073/pnas.1202870109; Ng LG, 2019, NAT REV IMMUNOL, V19, P255, DOI 10.1038/s41577-019-0141-8; Leliefeld PHC, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00471; Liard C, 2011, VACCINE, V29, P6379, DOI 10.1016/j.vaccine.2011.04.080; Lim HS, 2021, PLOS COMPUT BIOL, V17, DOI 10.1371/journal.pcbi.1008804; Lin A, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01781; Lingblom CMD, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1528-1; Marlin R, 2017, J IMMUNOL, V199, P1923, DOI 10.4049/jimmunol.1700320; Mitroulis I, 2018, CELL, V172, P147, DOI 10.1016/j.cell.2017.11.034; Moorlag SJCFM, 2020, CELL REP, V33, DOI 10.1016/j.celrep.2020.108387; Mueller S, 2020, J CLIN INVEST, V130, P6325, DOI 10.1172/JCI140378; Musich T, 2018, J IMMUNOL, V201, P2287, DOI 10.4049/jimmunol.1800677; Nair MPN, 2000, CLIN DIAGN LAB IMMUN, V7, P101, DOI 10.1128/CDLI.7.1.101-105.2000; Naranjo-Gomez M, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.97339; Ogishi M, 2021, J IMMUNOL, V206, P206, DOI 10.4049/jimmunol.2000854; Ols S, 2020, CELL REP, V30, P3964, DOI 10.1016/j.celrep.2020.02.111; Olsen LR, 2019, CYTOM PART A, V95A, P156, DOI 10.1002/cyto.a.23621; Orlova DY, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21444-4; Palgen JL, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.612747; Palgen JL, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-0175-8; Palgen JL, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21222-2; Parsa R, 2016, J EXP MED, V213, P1537, DOI 10.1084/jem.20150577; Pejoski D, 2016, J IMMUNOL, V196, P4814, DOI 10.4049/jimmunol.1502005; Pittman PR, 2019, NEW ENGL J MED, V381, P1897, DOI 10.1056/NEJMoa1817307; Platon L, 2018, METHODS, V132, P66, DOI 10.1016/j.ymeth.2017.09.005; Plotkin SA, 2010, CLIN VACCINE IMMUNOL, V17, P1055, DOI 10.1128/CVI.00131-10; Qiu P, 2011, NAT BIOTECHNOL, V29, P886, DOI 10.1038/nbt.1991; Quaranta MG, 2009, BIOFACTORS, V35, P169, DOI 10.1002/biof.28; Rahman AH, 2016, CYTOM PART A, V89A, P601, DOI 10.1002/cyto.a.22826; Reeves PM, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-69327-x; Rosenbaum P, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.645210; Sallusto F, 2010, IMMUNITY, V33, P451, DOI 10.1016/j.immuni.2010.10.008; Sanchez-Ramon S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02936; Schmidt ST, 2016, J CONTROL RELEASE, V239, P107, DOI 10.1016/j.jconrel.2016.08.034; Spitzer MH, 2015, SCIENCE, V349, DOI 10.1126/science.1259425; Swadling L, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009185; Trussart M, 2020, ELIFE, V9, DOI 10.7554/eLife.59630; Van Tilbeurgh M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060579; Vierboom MPM, 2021, CELL REP MED, V2, DOI 10.1016/j.xcrm.2020.100185; Vono M, 2017, BLOOD, V129, P1991, DOI 10.1182/blood-2016-10-744441; Xing Z, 2020, J LEUKOCYTE BIOL, V108, P825, DOI 10.1002/JLB.4MR0220-446R; Yu HB, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9070765; Yu Qigui, 2009, V515, P309, DOI 10.1007/978-1-59745-559-6_22; Zimmermann P, 2019, CLIN MICROBIOL REV, V32, DOI 10.1128/CMR.00084-18	63	0	0	3	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 4	2022	12								784813	10.3389/fimmu.2021.784813	http://dx.doi.org/10.3389/fimmu.2021.784813			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YL6FO	35058925	Green Published, gold, Green Submitted			2022-12-18	WOS:000745985200001
J	Jayewickreme, R; Mao, TY; Philbrick, W; Kong, Y; Treger, RS; Lu, PW; Rakib, T; Dong, HP; Dang-Lawson, M; Guild, WA; Lau, TJ; Iwasaki, A; Tokuyama, M				Jayewickreme, Radeesha; Mao, Tianyang; Philbrick, William; Kong, Yong; Treger, Rebecca S.; Lu, Peiwen; Rakib, Tasfia; Dong, Huiping; Dang-Lawson, May; Guild, W. Austin; Lau, Tatiana J.; Iwasaki, Akiko; Tokuyama, Maria			Endogenous Retroviruses Provide Protection Against Vaginal HSV-2 Disease	FRONTIERS IN IMMUNOLOGY			English	Article						HSV-2 (herpes simplex virus type-2); endogenous retroviruses (ERVs); sexually transmitted infections; antiviral response; vaginal infection	IMMUNE-RESPONSES; ANTIVIRAL DRUGS; GENITAL HERPES; SIMPLEX; RESISTANCE; INFECTION; ANTIBODY; ENTRY	Endogenous retroviruses (ERVs) are genomic sequences that originated from retroviruses and are present in most eukaryotic genomes. Both beneficial and detrimental functions are attributed to ERVs, but whether ERVs contribute to antiviral immunity is not well understood. Here, we used herpes simplex virus type 2 (HSV-2) infection as a model and found that Toll-like receptor 7 (Tlr7(-/-)) deficient mice that have high systemic levels of infectious ERVs are protected from intravaginal HSV-2 infection and disease, compared to wildtype C57BL/6 mice. We deleted the endogenous ecotropic murine leukemia virus (Emv2) locus on the Tlr7(-/-) background (Emv2(-/-)Tlr7(-/-)) and found that Emv2(-/-)Tlr7(-/-) mice lose protection against HSV-2 infection. Intravaginal application of purified ERVs from Tlr7(-/-) mice prior to HSV-2 infection delays disease in both wildtype and highly susceptible interferon-alpha receptor-deficient (Ifnar1(-) (/-)) mice. However, intravaginal ERV treatment did not protect Emv2(-/-)Tlr7(-/-) mice from HSV-2 disease, suggesting that the protective mechanism mediated by exogenous ERV treatment may differ from that of constitutively and systemically expressed ERVs in Tlr7(-/-) mice. We did not observe enhanced type I interferon (IFN-I) signaling in the vaginal tissues from Tlr7-/- mice, and instead found enrichment in genes associated with extracellular matrix organization. Together, our results revealed that constitutive and/or systemic expression of ERVs protect mice against vaginal HSV-2 infection and delay disease.	[Jayewickreme, Radeesha; Mao, Tianyang; Treger, Rebecca S.; Lu, Peiwen; Rakib, Tasfia; Dong, Huiping; Iwasaki, Akiko; Tokuyama, Maria] Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT 06510 USA; [Philbrick, William] Yale Sch Med, Dept Internal Med, Sect Endocrinol, New Haven, CT USA; [Kong, Yong] Yale Univ, WM Keck Fdn Biotechnol Resource Lab, Dept Mol Biophys & Biochem, Sch Med, New Haven, CT USA; [Dang-Lawson, May; Guild, W. Austin; Lau, Tatiana J.; Tokuyama, Maria] Univ British Columbia, Inst Life Sci, Dept Microbiol & Immunol, Vancouver, BC, Canada; [Iwasaki, Akiko] Howard Hughes Med Inst, Chevy Chase, MD USA	Yale University; Yale University; Yale University; University of British Columbia; Howard Hughes Medical Institute	Tokuyama, M (corresponding author), Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT 06510 USA.; Tokuyama, M (corresponding author), Univ British Columbia, Inst Life Sci, Dept Microbiol & Immunol, Vancouver, BC, Canada.	maria.tokuyama@ubc.ca	Kong, Yong/B-5105-2014	Kong, Yong/0000-0002-2881-5274				Agelidis AM, 2015, FUTURE VIROL, V10, P1145, DOI 10.2217/fvl.15.85; Bernstein David I, 2014, Antivir Chem Chemother, V23, P189, DOI 10.3851/IMP2499; Bhardwaj N, 2015, VIRUSES-BASEL, V7, P939, DOI 10.3390/v7030939; Bosurgi L, 2017, SCIENCE, V356, P1072, DOI 10.1126/science.aai8132; Browne EP, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8111787; Chakrabarti S, 2000, J INFECT DIS, V181, P2055, DOI 10.1086/315524; Chiappinelli KB, 2015, CELL, V162, P974, DOI 10.1016/j.cell.2015.07.011; Chuong EB, 2017, NAT REV GENET, V18, P71, DOI 10.1038/nrg.2016.139; Corey L, 2009, NEW ENGL J MED, V361, P1376, DOI 10.1056/NEJMra0807633; Danve-Szatanek C, 2004, J CLIN MICROBIOL, V42, P242, DOI 10.1128/JCM.42.1.242-249.2004; Esber A, 2015, J INFECT DIS, V212, P8, DOI 10.1093/infdis/jiv017; Evans LH, 2014, J VIROL METHODS, V200, P47, DOI 10.1016/j.jviromet.2014.02.006; Gopinath S, 2018, NAT MICROBIOL, V3, P611, DOI 10.1038/s41564-018-0138-2; Grow EJ, 2015, NATURE, V522, P221, DOI 10.1038/nature14308; Henao-Mejia Jorge, 2016, Cold Spring Harb Protoc, V2016, DOI 10.1101/pdb.prot090704; Iijima N, 2011, P NATL ACAD SCI USA, V108, P284, DOI 10.1073/pnas.1005201108; James C, 2020, B WORLD HEALTH ORGAN, V98, P315, DOI 10.2471/BLT.19.237149; Jern P, 2008, ANNU REV GENET, V42, P709, DOI 10.1146/annurev.genet.42.110807.091501; Johnson WE, 2019, NAT REV MICROBIOL, V17, P355, DOI 10.1038/s41579-019-0189-2; Kane M, 2011, IMMUNITY, V35, P135, DOI 10.1016/j.immuni.2011.05.011; Kassiotis G, 2016, NAT REV IMMUNOL, V16, P207, DOI 10.1038/nri.2016.27; Kaushic C, 2003, J VIROL, V77, P4558, DOI 10.1128/JVI.77.8.4558-4565.2003; Kumamoto Y, 2012, CURR OPIN IMMUNOL, V24, P411, DOI 10.1016/j.coi.2012.05.006; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Linehan MM, 2004, J VIROL, V78, P2530, DOI 10.1128/JVI.78.5.2530-2536.2004; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Lund JM, 2004, P NATL ACAD SCI USA, V101, P5598, DOI 10.1073/pnas.0400937101; Mark KE, 2007, J INFECT DIS, V195, P1324, DOI 10.1086/513276; Pillai PS, 2016, SCIENCE, V352, P463, DOI 10.1126/science.aaf3926; Pompili S, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.610189; R Core Team, 2021, COMPUTER SOFTWARE; Schiffer JT, 2013, NAT MED, V19, P280, DOI 10.1038/nm.3103; Schneider WM, 2014, ANNU REV IMMUNOL, V32, P513, DOI 10.1146/annurev-immunol-032713-120231; Shin HN, 2012, NATURE, V491, P463, DOI 10.1038/nature11522; Stetson DB, 2008, CELL, V134, P587, DOI 10.1016/j.cell.2008.06.032; Stocking C, 2008, CELL MOL LIFE SCI, V65, P3383, DOI 10.1007/s00018-008-8497-0; Stoye JP, 2012, NAT REV MICROBIOL, V10, P395, DOI 10.1038/nrmicro2783; Treger RS, 2019, J VIROL, V93, DOI 10.1128/JVI.00728-19; Treger RS, 2019, IMMUNITY, V50, P334, DOI 10.1016/j.immuni.2018.12.022; Wells JN, 2020, ANNU REV GENET, V54, P539, DOI 10.1146/annurev-genet-040620-022145; Whitley R, 2007, HUMAN HERPESVIRUSES: BIOLOGY, THERAPY, AND IMMUNOPROPHYLAXIS, P589; Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1; Young GR, 2012, NATURE, V491, P774, DOI 10.1038/nature11599; Young GR, 2012, RETROVIROLOGY, V9, DOI 10.1186/1742-4690-9-23; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Yu P, 2012, IMMUNITY, V37, P867, DOI 10.1016/j.immuni.2012.07.018	46	0	0	3	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 4	2022	12								758721	10.3389/fimmu.2021.758721	http://dx.doi.org/10.3389/fimmu.2021.758721			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZG5MC	35058919	Green Published, gold			2022-12-18	WOS:000760300700001
J	Kim, N; Yi, E; Kwon, SJ; Park, HJ; Kwon, HJ; Kim, HS				Kim, Nayoung; Yi, Eunbi; Kwon, Soon Jae; Park, Hyo Jin; Kwon, Hyung-Joon; Kim, Hun Sik			Filamin A Is Required for NK Cell Cytotoxicity at the Expense of Cytokine Production via Synaptic Filamentous Actin Modulation	FRONTIERS IN IMMUNOLOGY			English	Article						NK cells; filamin A; filamentous actin; cytotoxicity; cytokine; immune synapse	NATURAL-KILLER-CELLS; F-ACTIN; GRANULE POLARIZATION; ACTIVATION; RECEPTOR; SIGNALS; COMPLEX; DEGRANULATION; CHECKPOINTS; ORGANIZERS	Natural killer (NK) cells are innate cytotoxic lymphocytes that efficiently eliminate malignant and virus-infected cells without prior activation via the directed and focused release of lytic granule contents for target cell lysis. This cytolytic process is tightly regulated at discrete checkpoint stages to ensure the selective killing of diseased target cells and is highly dependent on the coordinated regulation of cytoskeletal components. The actin-binding protein filamin crosslinks cortical actin filaments into orthogonal networks and links actin filament webs to cellular membranes to modulate cell migration, adhesion, and signaling. However, its role in the regulation of NK cell functions remains poorly understood. Here, we show that filamin A (FLNa), a filamin isoform with preferential expression in leukocytes, is recruited to the NK cell lytic synapse and is required for NK cell cytotoxicity through the modulation of conjugate formation with target cells, synaptic filamentous actin (F-actin) accumulation, and cytotoxic degranulation, but not granule polarization. Interestingly, we also find that the loss of FLNa augments the target cell-induced expression of IFN-gamma and TNF-alpha by NK cells, correlating with enhanced activation signals such as Ca2+ mobilization, ERK, and NF-kappa B, and a delayed down-modulation of the NKG2D receptor. Thus, our results identify FLNa as a new regulator of NK cell effector functions during their decision to kill target cells through a balanced regulation of NK cell cytotoxicity vs cytokine production. Moreover, this study implicates the cross-linking/bundling of F-actin mediated by FLNa as a necessary process coordinating optimal NK effector functions.	[Kim, Nayoung] Univ Ulsan, Coll Med, Asan Med Ctr, Asan Inst Life Sci,Dept Convergence Med, Seoul, South Korea; [Yi, Eunbi; Kwon, Soon Jae; Park, Hyo Jin; Kwon, Hyung-Joon] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Biomed Sci, Seoul, South Korea; [Kim, Hun Sik] Univ Ulsan, Coll Med, SCIRC, Seoul, South Korea	University of Ulsan; Asan Medical Center; University of Ulsan; Asan Medical Center; University of Ulsan	Kim, HS (corresponding author), Univ Ulsan, Coll Med, SCIRC, Seoul, South Korea.	hunkim@amc.seoul.kr			National Research Foundation of Korea (NRF) - Korea government (MSIT) [2019R1A2C2006475, 2020R1I1A1A01069754]; MRC [2018R1A5A2020732]; Korea government (MSIT); Asan Institute for Life Sciences, Asan Medical Center, Seoul, Korea [2021IP0003, 2021IL0013]; Korea Healthy Technology R&D Project, Ministry of Health Welfare [HI21C1568]	National Research Foundation of Korea (NRF) - Korea government (MSIT); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Korea government (MSIT)(Korean Government); Asan Institute for Life Sciences, Asan Medical Center, Seoul, Korea; Korea Healthy Technology R&D Project, Ministry of Health Welfare	This study was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (2019R1A2C2006475, 2020R1I1A1A01069754), MRC grant (2018R1A5A2020732) funded by the Korea government (MSIT), grant from the Korea Healthy Technology R & D Project, Ministry of Health & Welfare (HI21C1568), and partly by a grant (2021IP0003, 2021IL0013) from the Asan Institute for Life Sciences, Asan Medical Center, Seoul, Korea.	Abeyweera TP, 2011, J CELL BIOL, V192, P675, DOI 10.1083/jcb.201009135; Arnon TI, 2001, EUR J IMMUNOL, V31, P2680, DOI 10.1002/1521-4141(200109)31:9<2680::AID-IMMU2680>3.0.CO;2-A; Bald T, 2020, NAT IMMUNOL, V21, P835, DOI 10.1038/s41590-020-0728-z; Banerjee PP, 2010, J IMMUNOL METHODS, V355, P1, DOI 10.1016/j.jim.2010.02.003; Barber DF, 2004, J IMMUNOL, V173, P3653, DOI 10.4049/jimmunol.173.6.3653; Ben-Shmuel A, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.609532; Brandt CS, 2009, J EXP MED, V206, P1495, DOI 10.1084/jem.20090681; Brown ACN, 2012, BLOOD, V120, P3729, DOI 10.1182/blood-2012-05-429977; Brown ACN, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001152; Bryceson YT, 2006, IMMUNOL REV, V214, P73, DOI 10.1111/j.1600-065X.2006.00457.x; Bryceson YT, 2009, BLOOD, V114, P2657, DOI 10.1182/blood-2009-01-201632; Bryceson YT, 2005, J EXP MED, V202, P1001, DOI 10.1084/jem.20051143; Butler B, 2009, CURR BIOL, V19, P1886, DOI 10.1016/j.cub.2009.10.029; Calderwood DA, 2001, NAT CELL BIOL, V3, P1060, DOI 10.1038/ncb1201-1060; Cerwenka A, 2016, NAT REV IMMUNOL, V16, P112, DOI 10.1038/nri.2015.9; Colucci F, 2001, J EXP MED, V193, P1413, DOI 10.1084/jem.193.12.1413; Crotta S, 2006, EUR J IMMUNOL, V36, P919, DOI 10.1002/eji.200535527; DANCKER P, 1975, BIOCHIM BIOPHYS ACTA, V400, P407, DOI 10.1016/0005-2795(75)90196-8; Dupuy S, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002486; Fauriat C, 2010, BLOOD, V115, P2167, DOI 10.1182/blood-2009-08-238469; Flanagan LA, 2001, J CELL BIOL, V155, P511, DOI 10.1083/jcb.200105148; Gil-Krzewska A, 2016, J ALLERGY CLIN IMMUN, V137, P1165, DOI 10.1016/j.jaci.2015.08.039; Hammer JA, 2019, ANNU REV IMMUNOL, V37, P201, DOI 10.1146/annurev-immunol-042718-041341; Hayashi K, 2006, J IMMUNOL, V177, P1721, DOI 10.4049/jimmunol.177.3.1721; Kanwar N, 2011, EUR J IMMUNOL, V41, P2763, DOI 10.1002/eji.201040444; Kim HS, 2010, IMMUNITY, V32, P175, DOI 10.1016/j.immuni.2010.02.004; Kim N, 2007, BLOOD, V110, P3202, DOI 10.1182/blood-2007-02-075366; Kim N, 2020, CANCERS, V12, DOI 10.3390/cancers12071923; Kim N, 2019, INT IMMUNOPHARMACOL, V67, P152, DOI 10.1016/j.intimp.2018.12.020; Kopcow HD, 2005, P NATL ACAD SCI USA, V102, P15563, DOI 10.1073/pnas.0507835102; Krzewski K, 2006, J CELL BIOL, V173, P121, DOI 10.1083/jcb.200509076; Krzewski K, 2008, CURR OPIN CELL BIOL, V20, P597, DOI 10.1016/j.ceb.2008.05.006; Kwon HJ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11686; Kwon HJ, 2015, CELL SIGNAL, V27, P1731, DOI 10.1016/j.cellsig.2015.05.012; Lamsoul I, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.591323; Liu DF, 2009, IMMUNITY, V31, P99, DOI 10.1016/j.immuni.2009.05.009; Long EO, 2013, ANNU REV IMMUNOL, V31, P227, DOI 10.1146/annurev-immunol-020711-075005; Lopez-Soto A, 2017, CANCER CELL, V32, P135, DOI 10.1016/j.ccell.2017.06.009; Mace EM, 2014, P NATL ACAD SCI USA, V111, P6708, DOI 10.1073/pnas.1314975111; Mace EM, 2014, IMMUNOL CELL BIOL, V92, P245, DOI 10.1038/icb.2013.96; Mace EM, 2010, BLOOD, V116, P1272, DOI 10.1182/blood-2009-12-261487; Maul-Pavicic A, 2011, P NATL ACAD SCI USA, V108, P3324, DOI 10.1073/pnas.1013285108; Mentlik AN, 2010, MOL BIOL CELL, V21, P2241, DOI 10.1091/mbc.E09-11-0930; Minsaas L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012212; Moretta L, 2004, EMBO J, V23, P255, DOI 10.1038/sj.emboj.7600019; Muriel O, 2011, J CELL SCI, V124, P2763, DOI 10.1242/jcs.080804; Nakamura F, 2011, CELL ADHES MIGR, V5, P160, DOI 10.4161/cam.5.2.14401; Onoprishvili I, 2003, MOL PHARMACOL, V64, P1092, DOI 10.1124/mol.64.5.1092; Orange JS, 2008, NAT REV IMMUNOL, V8, P713, DOI 10.1038/nri2381; Orange JS, 2011, J CLIN INVEST, V121, P1535, DOI 10.1172/JCI44862; Orange JS, 2003, P NATL ACAD SCI USA, V100, P14151, DOI 10.1073/pnas.1835830100; Orange JS, 2002, P NATL ACAD SCI USA, V99, P11351, DOI 10.1073/pnas.162376099; Parolini S, 2000, J EXP MED, V192, P337, DOI 10.1084/jem.192.3.337; Perez-Quintero LA, 2014, J EXP MED, V211, P727, DOI 10.1084/jem.20132038; Pollard TD, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a018226; Popowicz GM, 2006, TRENDS BIOCHEM SCI, V31, P411, DOI 10.1016/j.tibs.2006.05.006; Rak GD, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001151; Reefman E, 2010, J IMMUNOL, V184, P4852, DOI 10.4049/jimmunol.0803954; Rivas FV, 2004, MOL CELL BIOL, V24, P1628, DOI 10.1128/MCB.24.4.1628-1639.2004; Roda-Navarro P, 2009, J BIOL CHEM, V284, P16463, DOI 10.1074/jbc.M808561200; Salih HR, 2003, BLOOD, V102, P1389, DOI 10.1182/blood-2003-01-0019; Savinko T, 2018, J IMMUNOL, V200, P3109, DOI 10.4049/jimmunol.1700913; Schmoller KM, 2009, BIOPHYS J, V97, P83, DOI 10.1016/j.bpj.2009.04.040; Seck T, 2003, J BIOL CHEM, V278, P10408, DOI 10.1074/jbc.M209655200; Serrano-Pertierra E, 2014, J LEUKOCYTE BIOL, V96, P437, DOI 10.1189/jlb.2A1013-564R; Shin JH, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.624284; Stossel TP, 2001, NAT REV MOL CELL BIO, V2, P138, DOI 10.1038/35052082; Tomassian T, 2011, J IMMUNOL, V187, P2993, DOI 10.4049/jimmunol.1101447; Tseng Y, 2004, J BIOL CHEM, V279, P1819, DOI 10.1074/jbc.M306090200; Vivier E, 2008, NAT IMMUNOL, V9, P503, DOI 10.1038/ni1582; Waldt N, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02852; WANG K, 1977, P NATL ACAD SCI USA, V74, P2021, DOI 10.1073/pnas.74.5.2021; Wulfing C, 2003, P NATL ACAD SCI USA, V100, P7767, DOI 10.1073/pnas.1336920100; Zhang ML, 2005, J BIOL CHEM, V280, P11140, DOI 10.1074/jbc.M412242200; Zhou AX, 2010, TRENDS CELL BIOL, V20, P113, DOI 10.1016/j.tcb.2009.12.001	75	0	0	2	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 4	2022	12								792334	10.3389/fimmu.2021.792334	http://dx.doi.org/10.3389/fimmu.2021.792334			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YM2VN	35058930	Green Published, gold			2022-12-18	WOS:000746437000001
J	Shepard, JD; Freitas, BT; Rodriguez, SE; Scholte, FEM; Baker, K; Hutchison, MR; Longo, JE; Miller, HC; O'Boyle, BM; Tandon, A; Zhao, P; Grimsey, NJ; Wells, L; Bergeron, E; Pegan, SD				Shepard, Justin D.; Freitas, Brendan T.; Rodriguez, Sergio E.; Scholte, Florine E. M.; Baker, Kailee; Hutchison, Madelyn R.; Longo, Jaron E.; Miller, Holden C.; O'Boyle, Brady M.; Tandon, Aarushi; Zhao, Peng; Grimsey, Neil J.; Wells, Lance; Bergeron, Eric; Pegan, Scott D.			The Structure and Immune Regulatory Implications of the Ubiquitin-Like Tandem Domain Within an Avian 2'-5' Oligoadenylate Synthetase-Like Protein	FRONTIERS IN IMMUNOLOGY			English	Article						OASL; ISG15; UBL; avian immunity; Nairovirus; protease; ubiquitin	GENE-PRODUCT 15; 2'-5'-OLIGOADENYLATE SYNTHETASE; INNATE IMMUNITY; VIRUS; OASL; RNA; SECRETION; PROTEASES; INSIGHTS; ISG15	Post-translational modification of host and viral proteins by ubiquitin and ubiquitin-like proteins plays a key role in a host's ability to mount an effective immune response. Avian species lack a ubiquitin-like protein found in mammals and other non-avian reptiles; interferon stimulated gene product 15 (ISG15). ISG15 serves as a messenger molecule and can be conjugated to both host and viral proteins leading them to be stabilized, degraded, or sequestered. Structurally, ISG15 is comprised of a tandem ubiquitin-like domain (Ubl), which serves as the motif for post-translational modification. The 2'-5' oligoadenylate synthetase-like proteins (OASL) also encode two Ubl domains in series near its C-terminus which binds OASL to retinoic acid inducible gene-I (RIG-I). This protein-protein interaction increases the sensitivity of RIG-I and results in an enhanced production of type 1 interferons and a robust immune response. Unlike human and other mammalian OASL homologues, avian OASLs terminate their tandem Ubl domains with the same LRLRGG motif found in ubiquitin and ISG15, a motif required for their conjugation to proteins. Chickens, however, lack RIG-I, raising the question of structural and functional characteristics of chicken OASL (chOASL). By investigating chOASL, the evolutionary history of viruses with deubiquitinases can be explored and drivers of species specificity for these viruses may be uncovered. Here we show that the chOASL tandem Ubl domains shares structural characteristics with mammalian ISG15, and that chOASL can oligomerize and conjugate to itself. In addition, the ISG15-like features of avian OASLs and how they impact interactions with viral deubiquitinases and deISGylases are explored.	[Shepard, Justin D.; O'Boyle, Brady M.] Univ Georgia, Dept Infect Dis, Athens, GA 30602 USA; [Freitas, Brendan T.; Baker, Kailee; Hutchison, Madelyn R.; Longo, Jaron E.; Miller, Holden C.; Tandon, Aarushi; Grimsey, Neil J.; Bergeron, Eric] Univ Georgia, Dept Pharmaceut & Biomed Sci, Athens, GA 30602 USA; [Rodriguez, Sergio E.; Scholte, Florine E. M.; Bergeron, Eric] Ctr Dis Control & Prevent, Viral Special Pathogens Branch, Div High Consequence Pathogens & Pathol, Atlanta, GA 30602 USA; [Rodriguez, Sergio E.] Univ Texas Med Branch, Inst Human Infect & Immun, Galveston Natl Lab, Dept Microbiol & Immunol, Galveston, TX 77555 USA; [Zhao, Peng; Wells, Lance] Univ Georgia, Complex Carbohydrate Res Ctr, 220 Riverbend Rd, Athens, GA 30602 USA; [Wells, Lance] Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA; [Pegan, Scott D.] Univ Calif Riverside, Div Biomed Sci, Riverside, CA 92521 USA	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia; Centers for Disease Control & Prevention - USA; University of Texas System; University of Texas Medical Branch Galveston; University System of Georgia; University of Georgia; University System of Georgia; University of Georgia; University of California System; University of California Riverside	Bergeron, E (corresponding author), Univ Georgia, Dept Pharmaceut & Biomed Sci, Athens, GA 30602 USA.; Bergeron, E (corresponding author), Ctr Dis Control & Prevent, Viral Special Pathogens Branch, Div High Consequence Pathogens & Pathol, Atlanta, GA 30602 USA.; Pegan, SD (corresponding author), Univ Calif Riverside, Div Biomed Sci, Riverside, CA 92521 USA.	exj8@cdc.gov; scott.pegan@medsch.ucr.edu	Pegan, Scott/AFH-8002-2022	Wells, Lance/0000-0003-4956-5363	NIH [R01AI151006]; DoD HDTRA [12110005]; CDC Emerging Infectious Disease Research Core Funds; Oak Ridge Institute for Science and Education (ORISE)	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DoD HDTRA; CDC Emerging Infectious Disease Research Core Funds; Oak Ridge Institute for Science and Education (ORISE)	Data were collected the National Synchrotron Light Source II (NSLS-II) AMX-17-ID beamline at Brookhaven National Laboratory (BNL). This work was supported by NIH R01AI151006 (SP and EB) as well as DoD HDTRA 12110005 (SP). This work was also supported in part by CDC Emerging Infectious Disease Research Core Funds and by the Oak Ridge Institute for Science and Education (ORISE) through an interagency agreement between the U.S. Department of Energy (DOE) and the U.S. Department of Agriculture-Agricultural Research Service (SR). ORISE is managed by Oak Ridge Associate Universities (ORAU) under contract with DOE. The authors thank the Genetics Systems Team of the Viral Special Pathogens Branch (CDC/NCEZID/DHCPP/), specifically Drs. Cesar Albarino and Shilpi Jain for expert assistance in next generation sequencing.	Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925; Bergeron E, 2010, J VIROL, V84, P216, DOI 10.1128/JVI.01859-09; Cavanagh D, 2007, VET RES, V38, P281, DOI 10.1051/vetres:2006055; Choi UY, 2015, EXP MOL MED, V47, DOI 10.1038/emm.2014.110; CONVERSE JD, 1975, AM J TROP MED HYG, V24, P1010, DOI 10.4269/ajtmh.1975.24.1010; Daczkowski CM, 2017, J VIROL, V91, DOI 10.1128/JVI.01067-17; Daczkowski CM, 2017, J MOL BIOL, V429, P1661, DOI 10.1016/j.jmb.2017.04.011; Deaton MK, 2016, J VIROL, V90, P8314, DOI 10.1128/JVI.00975-16; DENISON MR, 1986, J VIROL, V60, P12, DOI 10.1128/JVI.60.1.12-18.1986; Devaraj SG, 2007, J BIOL CHEM, V282, P32208, DOI 10.1074/jbc.M704870200; Dhar J, 2015, J VIROL, V89, P10115, DOI 10.1128/JVI.01076-15; Dzimianski JV, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0226415; Dzimianski JV, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007515; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Eskildsen S, 2003, NUCLEIC ACIDS RES, V31, P3166, DOI 10.1093/nar/gkg427; Webb Benjamin, 2016, Curr Protoc Bioinformatics, V54, DOI [10.1002/0471140864.ps0209s50, 10.1002/cpps.20, 10.1002/0471250953.bi0506s15, 10.1002/cpbi.3]; Freitas BT, 2020, VIRUS RES, V286, DOI 10.1016/j.virusres.2020.198036; Frias-Staheli N, 2007, CELL HOST MICROBE, V2, P404, DOI 10.1016/j.chom.2007.09.014; Frieman M, 2009, J VIROL, V83, P6689, DOI 10.1128/JVI.02220-08; Holzer B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028594; Ibsen MS, 2015, NUCLEIC ACIDS RES, V43, P5236, DOI 10.1093/nar/gkv389; Kim YJ, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005850; Krissinel E, 2007, J MOL BIOL, V372, P774, DOI 10.1016/j.jmb.2007.05.022; Kristiansen H, 2011, J INTERF CYTOK RES, V31, P41, DOI 10.1089/jir.2010.0107; Kwon YT, 2017, TRENDS BIOCHEM SCI, V42, P873, DOI 10.1016/j.tibs.2017.09.002; Langley C, 2019, ACTA CRYSTALLOGR D, V75, P21, DOI 10.1107/S2059798318015322; Li XL, 2011, WIRES RNA, V2, P58, DOI 10.1002/wrna.32; Magor KE, 2013, DEV COMP IMMUNOL, V41, P377, DOI 10.1016/j.dci.2013.04.010; Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206; Napolitano A, 2018, J IMMUNOL, V201, P604, DOI 10.4049/jimmunol.1701322; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Palomar AM, 2016, TICKS TICK-BORNE DIS, V7, P983, DOI 10.1016/j.ttbdis.2016.05.004; Pandey S, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a016246; RECHT M, 1991, J IMMUNOL, V147, P2617; Rhee SG, 2016, MOL CELLS, V39, P1, DOI 10.14348/molcells.2016.2368; Rong EG, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01398; Spengler JR, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006248; Swaim CD, 2017, MOL CELL, V68, P581, DOI 10.1016/j.molcel.2017.10.003; Tag-EL-Din-Hassan HT, 2018, INFECT GENET EVOL, V62, P220, DOI 10.1016/j.meegid.2018.04.036; Tang YJ, 2010, J IMMUNOL, V184, P5777, DOI 10.4049/jimmunol.0903588; Tatsumi R, 2003, J INTERF CYTOK RES, V23, P667, DOI 10.1089/107999003322558809; Terwilliger TC, 2008, ACTA CRYSTALLOGR D, V64, P61, DOI 10.1107/S090744490705024X; Vajjhala PR, 2017, MOL IMMUNOL, V86, P23, DOI 10.1016/j.molimm.2017.02.012; Winn MD, 2011, ACTA CRYSTALLOGR D, V67, P235, DOI 10.1107/S0907444910045749; Yamaguchi R, 2016, HELIYON, V2, DOI 10.1016/j.heliyon.2016.e00080; Zhu JZ, 2015, CURR OPIN VIROL, V12, P15, DOI 10.1016/j.coviro.2015.01.010; Zhu JZ, 2014, IMMUNITY, V40, P936, DOI 10.1016/j.immuni.2014.05.007	47	0	0	2	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 4	2022	12								794664	10.3389/fimmu.2021.794664	http://dx.doi.org/10.3389/fimmu.2021.794664			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YL5ZQ	35058932	Green Published, gold			2022-12-18	WOS:000745969800001
J	Thakur, L; Madaan, P; Jain, A; Shankar, V; Negi, A; Chauhan, SB; Sundar, S; Singh, OP; Jain, M				Thakur, Lovlesh; Madaan, Priyanka; Jain, Aklank; Shankar, Vinay; Negi, Ajeet; Chauhan, Shashi Bhushan; Sundar, Shyam; Singh, Om Prakash; Jain, Manju			An Insight Into Systemic Immune Response in Leishmania donovani Mediated Atypical Cutaneous Leishmaniasis in the New Endemic State of Himachal Pradesh, India	FRONTIERS IN IMMUNOLOGY			English	Article						atypical cutaneous leishmaniasis; Leishmania donovani; host immunity; Himachal Pradesh; India; cytokine profile; IgG isotyping	VISCERAL LEISHMANIASIS; KALA-AZAR; ANTIINFLAMMATORY CYTOKINES; INTERFERON-GAMMA; CLINICAL FORMS; IL-10; CELLS; IL-27; IGG; INTERLEUKIN-10	Leishmaniasis continues to afflict known and newer endemic sites despite global efforts towards its control and elimination. In this regard, the emergence of newer endemic sites with unusual disease formats is recognized wherein Leishmania donovani complex classically known to cause visceral disease is demonstrated to cause cutaneous manifestation. In this context, atypical cutaneous leishmaniasis (CL) cases caused by L. donovani genetic variants from the newer endemic state of Himachal Pradesh (HP) in India are beginning to be understood in terms of parasite determinants. The atypical CL manifestation further needs to be explored to define host immune correlates with a possible role in driving the unusual disease progression. In the given study, we performed comprehensive systemic-immune profiling of the atypical CL patients from the study area in HP, India, in comparison with the classical visceral leishmaniasis (VL) patients from the northeast region of India. The systemic immune response was studied using ELISA-based assessment of Th1, Th2, Th17, Treg, and Th22 specific plasma cytokine expression pattern and parasite-specific total serum IgG/IgG subclasses. The specified immune correlates are known to exhibit heterogeneous association with the different infecting parasite species, infection load, and co-lateral host immunopathology in classical CL and VL. In the atypical CL patient group, altered expression of IL-10 emerged as the key finding that could potentially fine-tune the Th1/Th17/Th22 effector cytokine axis towards a localized cutaneous manifestation. A reduced expression of IL-10 along with a high IFN-gamma/IL-10 ratio as a readout of effective parasite killing defined atypical cutaneous outcome. In contrast, high circulatory IL-10 levels and a depressed IFN-gamma/IL-10 ratio were seen in classical VL patients in line with an ineffective parasite-killing cytokine response. Overall, the study highlights new knowledge on host immune correlates in terms of cytokine expression pattern and IgG subclasses that underline atypical disease manifestation such that L. donovani, a generally visceralizing parasite species cause skin localized cutaneous lesions.	[Thakur, Lovlesh; Jain, Aklank] Cent Univ Punjab, Dept Zool, Bathinda, India; [Madaan, Priyanka; Jain, Manju] Cent Univ Punjab, Dept Biochem, Bathinda, India; [Shankar, Vinay] Maharishi Markandeshwar Med Coll & Hosp, Dept Dermatol, Kumarhatti, Solan, India; [Negi, Ajeet] Indira Gandhi Med Coll, Dept Dermatol, Shimla, India; [Chauhan, Shashi Bhushan; Sundar, Shyam] Banaras Hindu Univ, Inst Med Sci, Dept Med, Varanasi, Uttar Pradesh, India; [Singh, Om Prakash] Banaras Hindu Univ, Inst Sci, Dept Biochem, Varanasi, Uttar Pradesh, India	Central University of Punjab; Central University of Punjab; Maharishi Markandeshwar University; Indira Gandhi Medical College & Hospital Shimla; Banaras Hindu University (BHU); Banaras Hindu University (BHU)	Jain, M (corresponding author), Cent Univ Punjab, Dept Biochem, Bathinda, India.	manjujainmda@gmail.com	thakur, lovlesh/GXA-2332-2022	Singh, Om Prakash/0000-0003-2146-8107; Chauhan, Shashi Bhushan/0000-0002-3268-852X	ICGEB, Trieste (Central University of Punjab) [CRP/IND19-01, 163]; doctoral fellowship, Central University of Punjab, Bathinda; DBT Senior Research Fellowship	ICGEB, Trieste (Central University of Punjab); doctoral fellowship, Central University of Punjab, Bathinda; DBT Senior Research Fellowship	This work was supported by Collaborative Research Project Grant from ICGEB, Trieste (Project CRP/IND19-01, GP#163, Central University of Punjab) to MJ. LT was funded with a doctoral fellowship, Central University of Punjab, Bathinda. PM is supported by DBT Senior Research Fellowship.	Ajdary S, 2000, INFECT IMMUN, V68, P1760, DOI 10.1128/IAI.68.4.1760-1764.2000; Akdis M, 2012, J ALLERGY CLIN IMMUN, V129, P1438, DOI 10.1016/j.jaci.2012.05.003; Alexander J, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00080; Alvar J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035671; Anam K, 1999, CLIN DIAGN LAB IMMUN, V6, P231, DOI 10.1128/CDLI.6.2.231-235.1999; Anderson CF, 2009, J IMMUNOL, V183, P4619, DOI 10.4049/jimmunol.0804024; Costa ASA, 2012, MEM I OSWALDO CRUZ, V107, P735, DOI 10.1590/S0074-02762012000600005; Ansari NA, 2006, CLIN IMMUNOL, V119, P339, DOI 10.1016/j.clim.2006.01.017; Ansari NA, 2011, J IMMUNOL, V186, P3977, DOI 10.4049/jimmunol.1003588; Atapattu D., 2017, SRI LANKAN J INFECT, V7, P76, DOI [10.4038/sljid.v7i2.8128, DOI 10.4038/SLJID.V7I2.8128]; Bastola A, 2020, PARASITOL INT, V74, DOI 10.1016/j.parint.2019.101991; Bhattacharya P, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004422; Caldas A, 2005, BMC INFECT DIS, V5, DOI 10.1186/1471-2334-5-113; Castellano LR, 2009, HUM IMMUNOL, V70, P383, DOI 10.1016/j.humimm.2009.01.007; CDC, 2020, PARASITES HOME LEISH; Chatterjee M, 1998, CLIN EXP IMMUNOL, V114, P408; Dayakar A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00670; Deepachandi B, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/5271657; dos Santos PL, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004375; Galgamuwa LS, 2019, BMC MICROBIOL, V19, DOI 10.1186/s12866-018-1384-4; Gautam S, 2011, J INFECT DIS, V204, P1134, DOI 10.1093/infdis/jir461; GHALIB HW, 1993, J CLIN INVEST, V92, P324, DOI 10.1172/JCI116570; GHOSH AK, 1995, CLIN DIAGN LAB IMMUN, V2, P291, DOI 10.1128/CDLI.2.3.291-296.1995; Gimblet C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134698; Goncalves-de-Albuquerque SD, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01437; Hailu A, 2005, CLIN IMMUNOL, V117, P182, DOI 10.1016/j.clim.2005.06.015; Hjelholt A, 2013, PATHOG DIS, V67, P206, DOI 10.1111/2049-632X.12034; Hunter CA, 2012, IMMUNITY, V37, P960, DOI 10.1016/j.immuni.2012.11.003; Katara GK, 2013, BMC IMMUNOL, V14, DOI 10.1186/1471-2172-14-52; Khan MAA, 2019, PARASITE VECTOR, V12, DOI 10.1186/s13071-019-3771-6; Khoshdel A, 2009, BRAZ J INFECT DIS, V13, P44, DOI 10.1590/S1413-86702009000100010; Kumar NP, 2015, J MED MICROBIOL, V64, P157, DOI 10.1099/jmm.0.076695-0; Kumar R, 2007, AM J TROP MED HYG, V76, P896, DOI 10.4269/ajtmh.2007.76.896; Kumar R, 2010, IMMUNOLOGY, V130, P193, DOI 10.1111/j.1365-2567.2009.03223.x; Kumar R, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00251; Kurkjian KM, 2006, CYTOM PART A, V69A, P353, DOI 10.1002/cyto.a.20256; Lypaczewski P, 2021, LANCET MICROBE, V2, pE250, DOI 10.1016/S2666-5247(21)00028-8; Mahanta A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00296; Manamperi NH, 2017, PARASITE IMMUNOL, V39, DOI 10.1111/pim.12413; Maspi N, 2016, PATHOG GLOB HEALTH, V110, P247, DOI 10.1080/20477724.2016.1232042; Moens L, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00065; Murphy ML, 2001, EUR J IMMUNOL, V31, P2848, DOI 10.1002/1521-4141(2001010)31:10&lt;2848::AID-IMMU2848&gt;3.0.CO;2-T; Murugaiyan G, 2009, J IMMUNOL, V183, P2435, DOI 10.4049/jimmunol.0900568; Novoa R, 2011, PARASITE IMMUNOL, V33, P132, DOI 10.1111/j.1365-3024.2010.01256.x; Nylen S, 2007, TRENDS IMMUNOL, V28, P378, DOI 10.1016/j.it.2007.07.004; Nylen S, 2010, J GLOB INFECT DIS, V2, P135, DOI 10.4103/0974-777X.62876; O'Garra A, 2007, NAT REV IMMUNOL, V7, P425, DOI 10.1038/nri2097; Oliveira WN, 2014, CYTOKINE, V66, P127, DOI 10.1016/j.cyto.2013.12.016; Ozbilge H, 2006, J MED MICROBIOL, V55, P1329, DOI 10.1099/jmm.0.46667-0; Pitta MGR, 2009, J CLIN INVEST, V119, P2379, DOI 10.1172/JCI38813; Pot C, 2009, J IMMUNOL, V183, P797, DOI 10.4049/jimmunol.0901233; Das VNR, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0008272; Rijal S, 2019, BMJ-BRIT MED J, V364, DOI 10.1136/bmj.k5224; Rodrigues V, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1412-x; Rodriguez V, 1996, PARASITE IMMUNOL, V18, P341, DOI 10.1046/j.1365-3024.1996.d01-113.x; Sacks D, 2002, NAT REV IMMUNOL, V2, P845, DOI 10.1038/nri933; Salhi A, 2008, J IMMUNOL, V180, P6139, DOI 10.4049/jimmunol.180.9.6139; Samant M, 2021, FRONT CELL INFECT MI, V11, DOI 10.3389/fcimb.2021.624009; Scorza BM, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061296; Scott P, 2016, NAT REV IMMUNOL, V16, P581, DOI 10.1038/nri.2016.72; Siriwardana HVYD, 2017, PATHOG GLOB HEALTH, V111, P317, DOI [10.1080/20477724.2017.1361564, 10.108]; Siriwardana Y, 2019, J TROP MED-US, V2019, DOI 10.1155/2019/4538597; Siriwardana YD, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/9320367; Stumhofer JS, 2007, NAT IMMUNOL, V8, P1363, DOI 10.1038/ni1537; Tangye SG, 2002, J IMMUNOL, V169, P4298, DOI 10.4049/jimmunol.169.8.4298; Thakur L, 2020, EMERG INFECT DIS, V26, P1864, DOI 10.3201/eid2608.191761; Thakur L, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006659; Vidarsson G, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00520; Vikash Paudel, 2020, Our Dermatology Online, V11, P76, DOI 10.7241/ourd.20201.20; Villarino AV, 2005, J IMMUNOL, V174, P7684, DOI 10.4049/jimmunol.174.12.7684; World Health Organization, 2021, NEWSROOMFACT SHEETSD; Yoshida H, 2008, IMMUNOL REV, V226, P234, DOI 10.1111/j.1600-065X.2008.00710.x; Yoshimura T, 2006, J IMMUNOL, V177, P5377, DOI 10.4049/jimmunol.177.8.5377; Zenewicz LA, 2007, IMMUNITY, V27, P647, DOI 10.1016/j.immuni.2007.07.023	74	0	0	13	13	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 4	2022	12								765684	10.3389/fimmu.2021.765684	http://dx.doi.org/10.3389/fimmu.2021.765684			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZE3CM	35087516	gold, Green Published			2022-12-18	WOS:000758764700001
J	Bos, S; Daniels, L; Michaux, L; Vanden Bempt, I; Vermeer, S; Woei-A-Jin, FSH; Schoffski, P; Weynand, B; Sciot, R; Declercq, S; Ceulemans, LJ; Godinas, L; Verleden, GM; Van Raemdonck, DE; Dupont, LJ; Vos, R				Bos, Saskia; Daniels, Liesbeth; Michaux, Lucienne; Vanden Bempt, Isabelle; Vermeer, Sascha; Woei-A-Jin, F. J. Sherida H.; Schoffski, Patrick; Weynand, Birgit; Sciot, Raf; Declercq, Sabine; Ceulemans, Laurens J.; Godinas, Laurent; Verleden, Geert M.; Van Raemdonck, Dirk E.; Dupont, Lieven J.; Vos, Robin		Leuven Lung Transplant Grp	Case Report: An Unusual Course of Angiosarcoma After Lung Transplantation	FRONTIERS IN IMMUNOLOGY			English	Article						donor-related; lung transplantation; malignancy; case report; angiosarcoma	DISEASE TRANSMISSION; ORGAN-TRANSPLANTATION; DONOR; MALIGNANCY; PROLIFERATION; PROCUREMENT; HEMANGIOMA; REGISTRY; EVENTS; CANCER	A 35-year-old woman underwent bilateral lung transplantation for primary ciliary dyskinesia and developed vascular tumors over a slow time course. Initial presentation of non-specific vascular tumors in the lungs and liver for up to 6 years after transplantation evolved toward bilateral ovarian angiosarcoma. Tumor analysis by haplotyping and human leukocyte antigen typing showed mixed donor chimerism, proving donor origin of the tumoral lesions. In retrospect, the donor became brain dead following neurosurgical complications for a previously biopsy-proven cerebral hemangioma, which is believed to have been a precursor lesion of the vascular malignancy in the recipient. Donor-transmitted tumors should always be suspected in solid organ transplant recipients in case of uncommon disease course or histology, and proper tissue-based diagnosis using sensitive techniques should be pursued.	[Bos, Saskia; Godinas, Laurent; Verleden, Geert M.; Dupont, Lieven J.; Vos, Robin] Univ Hosp Leuven, Dept Resp Dis, Leuven, Belgium; [Bos, Saskia] Newcastle Univ, Translat & Clin Res Inst, Newcastle Upon Tyne, Tyne & Wear, England; [Daniels, Liesbeth] Histocompatibil & Immunogenet Lab HILA, Red Cross Flanders, Leuven, Belgium; [Michaux, Lucienne; Vanden Bempt, Isabelle; Vermeer, Sascha] Univ Hosp Leuven, Ctr Human Genet, Leuven, Belgium; [Woei-A-Jin, F. J. Sherida H.; Schoffski, Patrick] Katholieke Univ Leuven, Univ Hosp Leuven, Leuven Canc Inst, Dept Gen Med Oncol, Leuven, Belgium; [Weynand, Birgit; Sciot, Raf] Univ Hosp Leuven, Dept Pathol, Leuven, Belgium; [Declercq, Sabine] ZNA Middelheim Hosp, Dept Pathol, Antwerp, Belgium; [Ceulemans, Laurens J.; Van Raemdonck, Dirk E.] Univ Hosp Leuven, Dept Thorac Surg, Leuven, Belgium; [Ceulemans, Laurens J.; Godinas, Laurent; Verleden, Geert M.; Van Raemdonck, Dirk E.; Dupont, Lieven J.; Vos, Robin] Katholieke Univ Leuven, Dept CHROMETA, Lab Resp Dis & Thorac Surg BREATHE, Leuven, Belgium	KU Leuven; University Hospital Leuven; Newcastle University - UK; KU Leuven; University Hospital Leuven; KU Leuven; University Hospital Leuven; KU Leuven; University Hospital Leuven; ZNA Middelheim Hospital; KU Leuven; University Hospital Leuven; KU Leuven	Bos, S (corresponding author), Univ Hosp Leuven, Dept Resp Dis, Leuven, Belgium.; Bos, S (corresponding author), Newcastle Univ, Translat & Clin Res Inst, Newcastle Upon Tyne, Tyne & Wear, England.	saskia.bos@uzleuven.be	Vanden Bempt, Isabelle/AFM-0163-2022; Vanden Bempt, Isabelle/AAH-2501-2022	Vanden Bempt, Isabelle/0000-0002-3433-555X; Vanden Bempt, Isabelle/0000-0002-3433-555X; Van Raemdonck, Dirk/0000-0003-1261-0992; Ceulemans, Laurens/0000-0002-4261-7100; Godinas, Laurent/0000-0003-2214-5879; Vermeer, Sascha/0000-0001-7625-1912; Woei-A-Jin, F.J. Sherida H./0000-0001-7840-6156	Broere Charitable Foundation; KU Leuven University Chair - Medtronic	Broere Charitable Foundation; KU Leuven University Chair - Medtronic	& nbsp;The following authors are supported by a research fellowship but received no specific funding for the current study: RV is a senior clinical research fellow of the Fund for Scientific Research Flanders (FWO). GV and DV are supported by the Broere Charitable Foundation. LC is supported by a KU Leuven University Chair funded by Medtronic.	Bos S, 2020, CURR OPIN ORGAN TRAN, V25, P268, DOI 10.1097/MOT.0000000000000753; Chambers DC, 2019, J HEART LUNG TRANSPL, V38, P1042, DOI 10.1016/j.healun.2019.08.001; Desai R, 2014, WORLD J GASTROENTERO, V20, P6170, DOI 10.3748/wjg.v20.i20.6170; Desai R, 2012, TRANSPLANTATION, V94, P1200, DOI 10.1097/TP.0b013e318272df41; Detry O, 2009, LIVER TRANSPLANT, V15, P670, DOI 10.1002/lt.21749; Gandhi Manish J., 2007, Cell and Tissue Banking, V8, P267, DOI 10.1007/s10561-007-9036-1; Green M, 2015, TRANSPLANTATION, V99, P282, DOI 10.1097/TP.0000000000000584; Ison MG, 2011, AM J TRANSPLANT, V11, P1123, DOI 10.1111/j.1600-6143.2011.03493.x; Ison MG, 2009, AM J TRANSPLANT, V9, P1929, DOI 10.1111/j.1600-6143.2009.02700.x; Kauffman HM, 2002, TRANSPLANTATION, V74, P358, DOI 10.1097/00007890-200208150-00011; McDermott Jennifer K, 2018, Glob Cardiol Sci Pract, V2018, P5, DOI 10.21542/gcsp.2018.5; Morath C, 2005, TRANSPLANTATION, V80, pS164, DOI 10.1097/01.tp.0000186911.54901.21; Nadal M, 2016, ACTA DERM-VENEREOL, V96, P448, DOI 10.2340/00015555-2300; Nalesnik MA, 2011, AM J TRANSPLANT, V11, P1140, DOI 10.1111/j.1600-6143.2011.03565.x; PENN I, 1975, TRANSPLANT P, V7, P323; Raskin J, 2020, TRANSPL INT, V33, P130, DOI 10.1111/tri.13540; Thoning J, 2013, AM J TRANSPLANT, V13, P167, DOI 10.1111/j.1600-6143.2012.04301.x; Van Raemdonck D, 2016, J THORAC DIS, V8, pS915, DOI 10.21037/jtd.2016.11.05; Wang Y, 2017, BIOMED PHARMACOTHER, V85, P272, DOI 10.1016/j.biopha.2016.11.021; Watson CJE, 2010, AM J TRANSPLANT, V10, P1437, DOI 10.1111/j.1600-6143.2010.03130.x; Zhang S, 2014, TRANSPLANT REV-ORLAN, V28, P169, DOI 10.1016/j.trre.2014.06.002; Zheng Ningning, 2014, Curr Ther Res Clin Exp, V76, P99, DOI 10.1016/j.curtheres.2014.09.004	22	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 3	2022	12								789851	10.3389/fimmu.2021.789851	http://dx.doi.org/10.3389/fimmu.2021.789851			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YL2BZ	35046948	Green Published, gold			2022-12-18	WOS:000745703700001
J	Ge, LT; Zhao, J; Deng, HY; Chen, CL; Hu, ZP; Zeng, LW				Ge, Lite; Zhao, Jing; Deng, Huiyin; Chen, Chunli; Hu, Zhiping; Zeng, Liuwang			Effect of Bone Marrow Mesenchymal Stromal Cell Therapies in Rodent Models of Sepsis: A Meta-Analysis	FRONTIERS IN IMMUNOLOGY			English	Article						sepsis; meta-analysis; efficacy; animal experimentation; bone marrow stromal cell (BMSC)	STEM-CELLS; MITOCHONDRIAL TRANSFER; BACTERIAL CLEARANCE; SURVIVAL; INJURY; ENDOTOXEMIA; BIAS	Background: Multiple preclinical studies have demonstrated that bone-marrow derived mesenchymal stromal (stem) cells [MSC(M)] positively influence the severity of sepsis symptoms and mortality in rodent models. However, this remains an inconclusive finding.Objective: To review the effect of naive MSC(M) in rodent models of sepsis.Methods: The PubMed, EMBASE, and Web of Science databases were searched up to August 31, 2021. Inclusion criteria according to PICOS criteria were as follows: (1) population: rodents; (2) intervention: unmodified MSC(M); (3) comparison: not specified; (4) primary outcome: the effects of MSC(M) cell therapy on the mortality of rodent models of sepsis and endotoxemia; (5) study: experimental studies. Multiple prespecified subgroup and meta-regression analysis were conducted. Following quality assessment, random effects models were used for this meta-analysis.The inverse variance method of the fixed effects model was used to calculate the pooled odds ratios (ORs) and their 95% confidence intervals (CIs).Results: twenty-four animal studies met the inclusion criteria. Our results revealed an overall OR difference between animals treated with naive MSC(M) and controls for mortality rate was 0.34(95% confidence interval: 0.27-0.44; P < 0.0001). Significant heterogeneity among studies was observed.Conclusions: The findings of this meta-analysis suggest that naive MSC(M) therapy decreased mortality in rodent models of sepsis. Additionally, we identified several key knowledge gaps, including the lack of large animal studies and uncertainty regarding the optimal dose of MSC(M) transplantation in sepsis. Before MSC(M) treatment can advance to clinical trials, these knowledge gaps must be addressed.	[Ge, Lite; Zhao, Jing; Chen, Chunli; Hu, Zhiping; Zeng, Liuwang] Cent South Univ, Xiangya Hosp 2, Dept Neurol, Changsha, Peoples R China; [Ge, Lite] Hunan Normal Univ, Affiliated Hosp 2, Hunan Prov Key Lab Neurorestoratol, Changsha, Peoples R China; [Deng, Huiyin] Cent South Univ, Xiangya Hosp 3, Dept Anesthesiol, Changsha, Peoples R China	Central South University; Hunan Normal University; Central South University	Zeng, LW (corresponding author), Cent South Univ, Xiangya Hosp 2, Dept Neurol, Changsha, Peoples R China.	zengliuwang@csu.edu.cn			National Natural Science Foundation of China [31670838, 32000151, 81371358, 81974213]; Key Project of Hunan Provincial Science and Technology Innovation [2020SK2102]; Hunan Provincial Natural Science Foundation of China [2021JJ40830]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Key Project of Hunan Provincial Science and Technology Innovation; Hunan Provincial Natural Science Foundation of China(Natural Science Foundation of Hunan Province)	Funding This work was supported by National Natural Science Foundation of China (No. 31670838, No.32000151, No.81371358, No.81974213), Key Project of Hunan Provincial Science and Technology Innovation (2020SK2102), Hunan Provincial Natural Science Foundation of China (2021JJ40830).	Adhikari NKJ, 2010, LANCET, V376, P1339, DOI 10.1016/S0140-6736(10)60446-1; Bi LK, 2010, PROG BIOCHEM BIOPHYS, V37, P678, DOI 10.3724/SP.J.1206.2010.00107; Sepulveda JC, 2014, STEM CELLS, V32, P1865, DOI 10.1002/stem.1654; Chao YH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110338; Durlak JA, 2009, J PEDIATR PSYCHOL, V34, P917, DOI 10.1093/jpepsy/jsp004; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Fleischmann C, 2016, AM J RESP CRIT CARE, V193, P259, DOI 10.1164/rccm.201504-0781OC; FRIEDENSTEIN AJ, 1968, TRANSPLANTATION, V6, P230, DOI 10.1097/00007890-196803000-00009; Gotts JE, 2016, BMJ-BRIT MED J, V353, DOI 10.1136/bmj.i1585; Guldner A, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0226-7; Guo J, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.639165; Gupta N, 2012, THORAX, V67, P533, DOI 10.1136/thoraxjnl-2011-201176; Hall SRR, 2013, STEM CELLS, V31, P397, DOI 10.1002/stem.1270; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Ho MSH, 2015, J CELL PHYSIOL, V230, P2606, DOI 10.1002/jcp.25028; Hooijmans CR, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-43; Islam MN, 2012, NAT MED, V18, P759, DOI 10.1038/nm.2736; Jackson MV, 2016, STEM CELLS, V34, P2210, DOI 10.1002/stem.2372; Jiang XX, 2005, BLOOD, V105, P4120, DOI 10.1182/blood-2004-02-0586; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; Kaukonen KM, 2014, JAMA-J AM MED ASSOC, V311, P1308, DOI 10.1001/jama.2014.2637; Kim H, 2014, BMC IMMUNOL, V15, DOI 10.1186/1471-2172-15-1; Krasnodembskaya A, 2012, AM J PHYSIOL-LUNG C, V302, pL1003, DOI 10.1152/ajplung.00180.2011; Krasnodembskaya A, 2010, STEM CELLS, V28, P2229, DOI 10.1002/stem.544; Lalu MM, 2016, ELIFE, V5, DOI 10.7554/eLife.17850; Laroye C, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287-019-1295-9; Laroye C, 2017, STEM CELLS, V35, P2331, DOI 10.1002/stem.2695; Lau J, 2006, BMJ-BRIT MED J, V333, P597, DOI 10.1136/bmj.333.7568.597; Li S, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/3537609; Liang ZX, 2011, CHINESE MED J-PEKING, V124, P2715, DOI 10.3760/cma.j.issn.0366-6999.2011.17.027; Liu V, 2014, JAMA-J AM MED ASSOC, V312, P90, DOI 10.1001/jama.2014.5804; Liu WH, 2016, INT J BIOCHEM CELL B, V79, P93, DOI 10.1016/j.biocel.2016.08.013; Lombardo E, 2015, WORLD J STEM CELLS, V7, P368, DOI 10.4252/wjsc.v7.i2.368; Luo CJ, 2014, SHOCK, V41, P123, DOI 10.1097/SHK.0000000000000080; Luo F, 2020, CURR THER RES CLIN E, V93, DOI 10.1016/j.curtheres.2020.100593; Maggini J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009252; Mehta S, 2019, J THORAC DIS, V11, P21, DOI 10.21037/jtd.2018.11.74; Mei SHJ, 2010, AM J RESP CRIT CARE, V182, P1047, DOI 10.1164/rccm.201001-0010OC; Moher David, 2009, Ann Intern Med, V151, P264, DOI [10.1136/bmj.b2535, 10.1016/j.ijsu.2010.02.007]; Nauta AJ, 2006, J IMMUNOL, V177, P2080, DOI 10.4049/jimmunol.177.4.2080; Nemeth K, 2009, NAT MED, V15, P42, DOI 10.1038/nm.1905; Ou H, 2016, MOL MED REP, V14, P3862, DOI 10.3892/mmr.2016.5694; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Poggi A, 2005, J IMMUNOL, V175, P6352, DOI 10.4049/jimmunol.175.10.6352; Riva John J, 2012, J Can Chiropr Assoc, V56, P167; Saeedi P, 2019, CYTOTHERAPY, V21, P41, DOI 10.1016/j.jcyt.2018.11.002; Saeedi P, 2019, J CELL PHYSIOL, V234, P4970, DOI 10.1002/jcp.27298; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Silva AYO, 2020, CRIT CARE MED, V48, pE290, DOI 10.1097/CCM.0000000000004219; Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287; Sterne JAC, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d4002; Sun XY, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287-020-01730-7; Varkouhi AK, 2021, EXP CELL RES, V399, DOI 10.1016/j.yexcr.2021.112473; Xu SY, 2018, J CELL SCI, V131, DOI 10.1242/jcs.211151; Zhao YJ, 2013, INT IMMUNOPHARMACOL, V15, P246, DOI 10.1016/j.intimp.2012.12.008	56	0	0	6	9	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 3	2022	12								792098	10.3389/fimmu.2021.792098	http://dx.doi.org/10.3389/fimmu.2021.792098			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YN1ZU	35046951	gold, Green Published			2022-12-18	WOS:000747064100001
J	Gong, X; Liu, Y; Liu, X; Li, AQ; Guo, KD; Zhou, D; Hong, Z				Gong, Xue; Liu, Yue; Liu, Xu; Li, Aiqing; Guo, Kundian; Zhou, Dong; Hong, Zhen			Disturbance of Gut Bacteria and Metabolites Are Associated with Disease Severity and Predict Outcome of NMDAR Encephalitis: A Prospective Case-Control Study	FRONTIERS IN IMMUNOLOGY			English	Article						NMDAR encephalitis; microbiome; metabolomics; prognosis marker; multi-omic analysis	ASPARTATE RECEPTOR ENCEPHALITIS; MOLECULAR MIMICRY; MICROBIOME; RESISTANCE; DIAGNOSIS; REVEALS	ObjectiveWe aimed to investigate the associations between the intestinal microbiota, metabolites, cytokines, and clinical severity in anti-N-methyl-d-aspartate receptor (NMDAR) encephalitis and to further determine the predictive value of the intestinal microbiota or metabolites in clinical prognosis. MethodsIn this prospective observational cohort study of 58 NMDAR encephalitis patients and 49 healthy controls, fecal microbiota, metabolites, and cytokines were quantified and characterized by16S rRNA gene sequencing, liquid chromatography-mass spectrometry, and the Luminex assay, respectively. ResultsThere were marked variations in the gut microbiota composition and metabolites in critically ill patients. We identified 8 metabolite modules (mainly characterized by fatty acid, glycerophosphoethanolamines, and glycerophosphocholines) that were distinctly classified as negatively or positively associated with bacterial co-abundance groups (CAGs). These CAGs were mainly composed of Bacteroides, Eubacterium_hallii_group, Anaerostipes, Ruminococcus, Butyricicoccus, and Faecalibacterium, which were substantially altered in patients. In addition, these fecal and serum metabolic modules were further correlated with the serum cytokines. Additionally, the combination of clinical features, microbial marker (Granulicatella), and a panel of metabolic markers could further enhance the performance of prognosis discrimination significantly, which yielded an area under the receiver operating characteristic curve of (AUC) of 0.94 (95%CI = 0.7-0.9). Patients with low bacterial diversity are more likely to develop relapse than those with higher bacterial diversity (log-rank p = 0.04, HR = 2.7, 95%CI = 1.0-7.0). InterpretationThe associations between the multi-omics data suggested that certain bacteria might affect the pathogenesis of NMDAR encephalitis by modulating the metabolic pathways of the host and affecting the production of pro-inflammatory cytokines. Furthermore, the disturbance of fecal bacteria may predict the long-term outcome and relapse in NMDAR encephalitis.	[Gong, Xue; Liu, Yue; Liu, Xu; Li, Aiqing; Guo, Kundian; Zhou, Dong; Hong, Zhen] Sichuan Univ, West China Hosp, Dept Neurol, Chengdu, Peoples R China; [Gong, Xue; Liu, Yue; Liu, Xu; Li, Aiqing; Guo, Kundian; Zhou, Dong; Hong, Zhen] Sichuan Univ, West China Hosp, Inst Brain Sci & Brain Inspired Technol, Chengdu, Peoples R China; [Gong, Xue; Liu, Yue; Liu, Xu; Li, Aiqing; Guo, Kundian; Hong, Zhen] Chengdu Shangjin Nanfu Hosp, Dept Neurol, Chengdu, Peoples R China	Sichuan University; Sichuan University	Hong, Z (corresponding author), Sichuan Univ, West China Hosp, Dept Neurol, Chengdu, Peoples R China.; Hong, Z (corresponding author), Sichuan Univ, West China Hosp, Inst Brain Sci & Brain Inspired Technol, Chengdu, Peoples R China.; Hong, Z (corresponding author), Chengdu Shangjin Nanfu Hosp, Dept Neurol, Chengdu, Peoples R China.	hongzhengoog@aliyun.com	gong, xue/GYQ-8649-2022	Guo, Kundian/0000-0003-4512-4296				Allaband C, 2021, MSYSTEMS, V6, DOI 10.1128/mSystems.00116-21; Balu R, 2019, NEUROLOGY, V92, pE244, DOI 10.1212/WNL.0000000000006783; Berliner JA, 2001, TRENDS CARDIOVAS MED, V11, P142, DOI 10.1016/S1050-1738(01)00098-6; Blank M, 2007, CLIN REV ALLERG IMMU, V32, P111; Brooks PT, 2017, MICROBIOME, V5, DOI 10.1186/s40168-017-0284-4; Buffie CG, 2013, NAT REV IMMUNOL, V13, P790, DOI 10.1038/nri3535; Chang MK, 2002, P NATL ACAD SCI USA, V99, P13043, DOI 10.1073/pnas.192399699; Chen BD, 2021, ARTHRITIS RHEUMATOL, V73, P232, DOI 10.1002/art.41511; Chen H, 2020, CELL DEATH DISCOV, V6, DOI 10.1038/s41420-020-00309-8; Chen JY, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00727; Cho I, 2012, NAT REV GENET, V13, P260, DOI 10.1038/nrg3182; Choi SC, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aax2220; Cree BAC, 2016, ANN NEUROL, V80, P443, DOI 10.1002/ana.24718; Cusick MF, 2012, CLIN REV ALLERG IMMU, V42, P102, DOI [10.1007/s12016-011-8294-7, 10.1007/s12016-011-8293-8]; Dalmau J, 2008, LANCET NEUROL, V7, P1091, DOI 10.1016/S1474-4422(08)70224-2; Emoto S, 2017, J LIPID RES, V58, P763, DOI 10.1194/jlr.P072090; Fatkhullina AR, 2018, IMMUNITY, V49, P943, DOI 10.1016/j.immuni.2018.09.011; Faust K, 2012, NAT REV MICROBIOL, V10, P538, DOI 10.1038/nrmicro2832; Frost F, 2021, GUT, V70, P522, DOI 10.1136/gutjnl-2020-322753; Gable MS, 2012, CLIN INFECT DIS, V54, P899, DOI 10.1093/cid/cir1038; Gevers D, 2014, CELL HOST MICROBE, V15, P382, DOI 10.1016/j.chom.2014.02.005; Gong X, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.517797; Gong X, 2019, ANN CLIN TRANSL NEUR, V6, P1771, DOI 10.1002/acn3.50874; Goutman SA, 2020, J NEUROL NEUROSUR PS, V91, P1329, DOI 10.1136/jnnp-2020-323611; Graus F, 2016, LANCET NEUROL, V15, P391, DOI 10.1016/S1474-4422(15)00401-9; Gresa-Arribas N, 2014, LANCET NEUROL, V13, P167, DOI 10.1016/S1474-4422(13)70282-5; Guo MC, 2020, GUT MICROBES, V11, P1758, DOI 10.1080/19490976.2020.1768644; Heinzel S, 2020, ANN NEUROL, V88, P320, DOI 10.1002/ana.25788; Herken J, 2019, NEUROL-NEUROIMMUNOL, V6, DOI 10.1212/NXI.0000000000000632; Holmes E, 2012, CELL METAB, V16, P559, DOI 10.1016/j.cmet.2012.10.007; Iizuka T, 2016, JAMA NEUROL, V73, P706, DOI 10.1001/jamaneurol.2016.0232; Kadowaki A, 2019, BRAIN, V142, P916, DOI 10.1093/brain/awz012; Kamada N, 2013, NAT IMMUNOL, V14, P685, DOI 10.1038/ni.2608; Kuczynski Justin, 2012, Curr Protoc Microbiol, VChapter 1, DOI [10.1002/0471250953.bi1007s36, 10.1002/9780471729259.mc01e05s27]; Lee WJ, 2021, NEUROTHERAPEUTICS, V18, P474, DOI 10.1007/s13311-020-00921-7; Leypoldt F, 2015, JAMA NEUROL, V72, P180, DOI 10.1001/jamaneurol.2014.2956; Li AQ, 2020, NEUROL-NEUROIMMUNOL, V7, DOI 10.1212/NXI.0000000000000891; Li SS, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.644376; Liu HH, 2019, MICROBIOME, V7, DOI 10.1186/s40168-019-0683-9; Magoc T, 2011, BIOINFORMATICS, V27, P2957, DOI 10.1093/bioinformatics/btr507; Mota SI, 2021, ARCH TOXICOL, V95, P2769, DOI 10.1007/s00204-021-03104-1; Moudgil KD, 2015, CYTOKINE, V74, P1, DOI 10.1016/j.cyto.2015.05.006; Naz S, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.02322-2016; Ou JY, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.630791; Peng YJ, 2020, NEUROL-NEUROIMMUNOL, V7, DOI 10.1212/NXI.0000000000000860; Pruss H, 2010, NEUROLOGY, V75, P1735, DOI 10.1212/WNL.0b013e3181fc2a06; Quehenberger O, 2010, J LIPID RES, V51, P3299, DOI 10.1194/jlr.M009449; Rosenblum MD, 2015, J CLIN INVEST, V125, P2228, DOI 10.1172/JCI78088; Schirmer M, 2016, CELL, V167, P1125, DOI 10.1016/j.cell.2016.10.020; Shah ASV, 2020, CIRCULATION, V141, P2067, DOI 10.1161/CIRCULATIONAHA.119.044913; Song SJ, 2013, ELIFE, V2, DOI 10.7554/eLife.00458; Stefan KL, 2020, CELL, V183, P1312, DOI 10.1016/j.cell.2020.10.047; Titulaer MJ, 2013, LANCET NEUROL, V12, P157, DOI 10.1016/S1474-4422(12)70310-1; Tremlett H, 2017, ANN NEUROL, V81, P369, DOI 10.1002/ana.24901; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604; Velazquez R, 2019, AGING CELL, V18, DOI 10.1111/acel.13037; Xu RT, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01994; Yeoh YK, 2021, GUT, V70, P698, DOI 10.1136/gutjnl-2020-323020; Zhong CK, 2021, STROKE, V52, P887, DOI 10.1161/STROKEAHA.120.031903	59	0	1	3	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 3	2022	12								791780	10.3389/fimmu.2021.791780	http://dx.doi.org/10.3389/fimmu.2021.791780			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YK3TG	35046950	gold, Green Published			2022-12-18	WOS:000745139000001
J	Han, XR; Cao, WT; Wu, L; Liang, CH				Han, Xiaorui; Cao, Wuteng; Wu, Lei; Liang, Changhong			Radiomics Assessment of the Tumor Immune Microenvironment to Predict Outcomes in Breast Cancer	FRONTIERS IN IMMUNOLOGY			English	Article						radiomics; breast cancer; DCE-MRI; immune microenvironment; immunoscore		BackgroundThe immune microenvironment of tumors provides information on prognosis and prediction. A prior validation of the immunoscore for breast cancer (ISBC) was made on the basis of a systematic assessment of immune landscapes extrapolated from a large number of neoplastic transcripts. Our goal was to develop a non-invasive radiomics-based ISBC predictive factor. MethodsImmunocell fractions of 22 different categories were evaluated using CIBERSORT on the basis of a large, open breast cancer cohort derived from comprehensive information on gene expression. The ISBC was constructed using the LASSO Cox regression model derived from the Immunocell type scores, with 479 quantified features in the intratumoral and peritumoral regions as observed from DCE-MRI. A radiomics signature [radiomics ImmunoScore (RIS)] was developed for the prediction of ISBC using a random forest machine-learning algorithm, and we further evaluated its relationship with prognosis. ResultsAn ISBC consisting of seven different immune cells was established through the use of a LASSO model. Multivariate analyses showed that the ISBC was an independent risk factor in prognosis (HR=2.42, with a 95% CI of 1.49-3.93; P<0.01). A radiomic signature of 21 features of the ISBC was then exploited and validated (the areas under the curve [AUC] were 0.899 and 0.815). We uncovered statistical associations between the RIS signature with recurrence-free and overall survival rates (both P<0.05). ConclusionsThe RIS is a valuable instrument with which to assess the immunoscore, and offers important implications for the prognosis of breast cancer.	[Han, Xiaorui; Liang, Changhong] South China Univ Technol, Sch Med, Guangzhou, Peoples R China; [Han, Xiaorui; Wu, Lei; Liang, Changhong] Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Dept Radiol, Guangzhou, Peoples R China; [Cao, Wuteng] Sun Yat Sen Univ, Affiliated Hosp 6, Dept Radiol, Guangzhou, Peoples R China; [Wu, Lei; Liang, Changhong] Guangdong Prov Key Lab Artificial Intelligence Me, Guangzhou, Peoples R China	South China University of Technology; Guangdong Academy of Medical Sciences & Guangdong General Hospital; Sun Yat Sen University	Liang, CH (corresponding author), South China Univ Technol, Sch Med, Guangzhou, Peoples R China.; Liang, CH (corresponding author), Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Dept Radiol, Guangzhou, Peoples R China.; Liang, CH (corresponding author), Guangdong Prov Key Lab Artificial Intelligence Me, Guangzhou, Peoples R China.	liangchanghong@gdph.org.cn						Azizi E, 2018, CELL, V174, P1293, DOI 10.1016/j.cell.2018.05.060; Binnewies M, 2018, NAT MED, V24, P541, DOI 10.1038/s41591-018-0014-x; Bruni D, 2020, NAT REV CANCER, V20, P662, DOI 10.1038/s41568-020-0285-7; Burugu S, 2017, BREAST CANCER-TOKYO, V24, P3, DOI 10.1007/s12282-016-0698-z; Dai WX, 2018, CARCINOGENESIS, V39, P1235, DOI 10.1093/carcin/bgy087; Fournier MV, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-51335-1; Fu HC, 2018, CLIN CANCER RES, V24, P3069, DOI 10.1158/1078-0432.CCR-17-2687; Gentles AJ, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv211; Gillies RJ, 2016, RADIOLOGY, V278, P563, DOI 10.1148/radiol.2015151169; Ha S, 2019, NUCL MED MOLEC IMAG, V53, P164, DOI 10.1007/s13139-019-00578-x; He AB, 2019, AGING-US, V11, P6237, DOI 10.18632/aging.102185; Jiang Y, 2020, ANN ONCOL, V31, P760, DOI 10.1016/j.annonc.2020.03.295; Jiang YM, 2021, ANN SURG, V274, pE1153, DOI 10.1097/SLA.0000000000003778; Lanzi A, 2020, ONCOIMMUNOLOGY, V9, DOI 10.1080/2162402X.2020.1789032; Lesterhuis WJ, 2017, NAT REV DRUG DISCOV, V16, P264, DOI 10.1038/nrd.2016.233; Li LH, 2019, PEERJ, V7, DOI 10.7717/peerj.7993; Manuel M, 2012, ONCOIMMUNOLOGY, V1, DOI 10.4161/onci.19545; Mao YH, 2018, INT J CANCER, V143, P2271, DOI 10.1002/ijc.31613; Newman AM, 2015, NAT METHODS, V12, P453, DOI [10.1038/NMETH.3337, 10.1038/nmeth.3337]; Soysal SD, 2015, PATHOBIOLOGY, V82, P142, DOI 10.1159/000430499; Sui SL, 2020, THERANOSTICS, V10, P11938, DOI 10.7150/thno.49451; Sun R, 2018, LANCET ONCOL, V19, P1180, DOI 10.1016/S1470-2045(18)30413-3; Tang C, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20471-5; Tang WJ, 2021, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.611571; Tekpli X, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13329-5; Tran WT, 2019, J MED IMAGING RADIAT, V50, pS32, DOI 10.1016/j.jmir.2019.07.010; van Griethuysen JJM, 2017, CANCER RES, V77, pE104, DOI 10.1158/0008-5472.CAN-17-0339; Wang K, 2019, CANCER MED-US, V8, P686, DOI 10.1002/cam4.1880; Winters S, 2017, PROG MOL BIOL TRANSL, V151, P1, DOI 10.1016/bs.pmbts.2017.07.002; Yang Fang, 2015, Zhongguo Fei Ai Za Zhi, V18, P48, DOI 10.3779/j.issn.1009-3419.2015.01.08; Yoon HJ, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0231227; Zeng D, 2018, BRIT J SURG, V105, P1338, DOI 10.1002/bjs.10871; Zhou L, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1293211; Zhou R, 2019, CANCER IMMUNOL IMMUN, V68, P433, DOI 10.1007/s00262-018-2289-7; Zuo SG, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01218	35	0	0	6	12	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 3	2022	12								773581	10.3389/fimmu.2021.773581	http://dx.doi.org/10.3389/fimmu.2021.773581			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YK3TM	35046937	Green Published, gold			2022-12-18	WOS:000745139600001
J	Hansen, N; Stocker, W; Wiltfang, J; Bartels, C; Rentzsch, K; Bouter, C				Hansen, Niels; Stoecker, Winfried; Wiltfang, Jens; Bartels, Claudia; Rentzsch, Kristin; Bouter, Caroline			Case Report: Semantic Variant of Primary Progressive Aphasia Associated With Anti-Glial Fibrillary Acid Protein Autoantibodies	FRONTIERS IN IMMUNOLOGY			English	Article						frontotemporal lobar degeneration (FTLD); semantic variant of primary progressive aphasia (svPPA); autoimmunity; anti-GFAP antibody; immunotherapy	SERUM; GFAP	BackgroundFrontotemporal lobar degeneration is a heterogeneous disorder entailing a semantic variant of primary progressive aphasia (svPPA). A subtype of frontotemporal dementia associated with glutamate receptor subunit 3 (GluA3) antibody of the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) was recently identified. Here, we describe the novelty of a svPPA associated with anti-glial fibrillary acid protein (GFAP) antibodies. MethodsTo diagnose this 68-year-old woman we conducted a clinical examination, neuropsychological testing, CSF analysis, MRI and 18F-fluorodeoxyglucose (18F-FDG) Positron Emission Tomography (PET)/computed tomography (CT) imaging. ResultsThe clinical phenotype corresponds to a svPPA based on impaired confrontation naming and single-word comprehension. In addition, we observed spared speech production, impaired object knowledge, and surface dyslexia - further supporting the diagnosis of svPPA. Additional characteristic imaging features such as anterior temporal hypometabolism in 18F-FDG PET/CT confirmed patient's svPPA diagnosis. CSF analysis revealed signs of axonal degeneration, as both tau and phosphorylated tau proteins exceeded normal levels. Her serum showed anti-GFAP autoantibodies. ConclusionWe diagnosed a svPPA in this patient and report an association between serum anti-GFAP antibodies and svPPA never reported in the literature so far, thereby expanding the clinical spectrum of svPPA and anti-GFAP-antibody related disease. Further research is needed to elucidate the underlying immunopathology of this disease entity to ultimately improve treatment.	[Hansen, Niels; Wiltfang, Jens; Bartels, Claudia] Univ Med Ctr Goettingen, Dept Psychiat & Psychotherapy, Gottingen, Germany; [Stoecker, Winfried; Rentzsch, Kristin] Euroimmun Reference Lab, Lubeck, Germany; [Wiltfang, Jens] German Ctr Neurodegenerat Dis DZNE, Gottingen, Germany; [Wiltfang, Jens] Univ Aveiro, Dept Med Sci, Inst Biomed iBiMED, Neurosci & Signaling Grp, Aveiro, Portugal; [Bouter, Caroline] Univ Med Ctr Gottingen, Dept Nucl Med, Gottingen, Germany	University of Gottingen; Helmholtz Association; German Center for Neurodegenerative Diseases (DZNE); Universidade de Aveiro; University of Gottingen	Hansen, N (corresponding author), Univ Med Ctr Goettingen, Dept Psychiat & Psychotherapy, Gottingen, Germany.	niels.hansen@med.uni-goettingen.de			University of Gottingen	University of Gottingen	Funding is derived from the Open access fund of the University of Gottingen.	Borghesani V, 2021, ELIFE, V10, DOI 10.7554/eLife.63905; Borroni B, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06117-y; Bouwman F, 2018, EUR J NUCL MED MOL I, V45, P1526, DOI 10.1007/s00259-018-4034-z; Bright F, 2019, NAT REV NEUROL, V15, P540, DOI 10.1038/s41582-019-0231-z; Di H, 2021, BMC NEUROL, V21, DOI 10.1186/s12883-021-02070-6; Endres D, 2022, PSYCHOL MED, V52, P1135, DOI 10.1017/S0033291720002895; Flanagan EP, 2010, MAYO CLIN PROC, V85, P881, DOI 10.4065/mcp.2010.0326; Gorno-Tempini ML, 2011, NEUROLOGY, V76, P1006, DOI 10.1212/WNL.0b013e31821103e6; Gravier-Dumonceau A, 2022, NEUROLOGY, V98, pE653, DOI 10.1212/WNL.0000000000013087; Hansen Niels, 2020, Brain Behav Immun Health, V9, P100154, DOI 10.1016/j.bbih.2020.100154; Hansen N, 2020, FRONT PSYCHIATRY, V11, DOI 10.3389/fpsyt.2020.00576; Henderson SK, 2021, BRAIN COMMUN, V3, DOI 10.1093/braincomms/fcab210; Iorio R, 2018, J NEUROL NEUROSUR PS, V89, P138, DOI 10.1136/jnnp-2017-316583; Lin H, 2020, NEUROIMMUNOMODULAT, V27, P69, DOI 10.1159/000505730; Lombardi J, 2021, ALZHEIMERS DEMENT, V17, P1595, DOI 10.1002/alz.12323; Lu JY, 2021, EUR J NEUROL, V28, P2927, DOI 10.1111/ene.14919; Mabrouki FZ, 2021, CUREUS, V13, DOI 10.7759/cureus.17588; Macoir Joel, 2021, Dement. neuropsychol., V15, P405, DOI 10.1590/1980-57642021dn15-030014; Matias-Guiu JA, 2014, DEMENT GERIATR COGN, V38, P147, DOI 10.1159/000358233; McCauley ME, 2020, NATURE, V585, P96, DOI 10.1038/s41586-020-2625-x; MECOCCI P, 1995, J NEUROIMMUNOL, V57, P165, DOI 10.1016/0165-5728(94)00180-V; Miller ZA, 2016, NEUROL-NEUROIMMUNOL, V3, DOI 10.1212/NXI.0000000000000301; Nomura S, 2009, PROTEOMICS, V9, P4029, DOI 10.1002/pmic.200900066; Novo AC, 2021, BMJ NEUROL OPEN, V3, DOI 10.1136/bmjno-2021-000142; Nuvoli Susanna, 2019, Dement Geriatr Cogn Disord, V48, P250, DOI 10.1159/000504938; Palese F, 2020, NEUROBIOL AGING, V86, P143, DOI 10.1016/j.neurobiolaging.2019.10.015; Papa A, 2020, EUR J NEUROL, V27, P2381, DOI 10.1111/ene.14244; Sajjadi SA, 2017, AM J NEURORADIOL, V38, P954, DOI 10.3174/ajnr.A5126; Shan FL, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02802; Sogorb-Esteve A, 2021, J NEUROINFLAMM, V18, DOI 10.1186/s12974-021-02247-3; Stockbridge MD, 2021, CORTEX, V145, P201, DOI 10.1016/j.cortex.2021.09.015; TANAKA J, 1989, ACTA NEUROL SCAND, V80, P554, DOI 10.1111/j.1600-0404.1989.tb03926.x; Toledano-Illan C, 2021, J NEUROL, V268, P2256, DOI 10.1007/s00415-021-10484-y; Yuan ZM, 2021, EUR J NEUROL, V28, P2121, DOI 10.1111/ene.14778; Zhang ZQ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092698	35	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 3	2022	12								760021	10.3389/fimmu.2021.760021	http://dx.doi.org/10.3389/fimmu.2021.760021			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YL1NY	35046935	gold, Green Published			2022-12-18	WOS:000745667100001
J	Linnerbauer, M; Loesslein, L; Farrenkopf, D; Vandrey, O; Tsaktanis, T; Naumann, U; Rothhammer, V				Linnerbauer, Mathias; Loesslein, Lena; Farrenkopf, Daniel; Vandrey, Oliver; Tsaktanis, Thanos; Naumann, Ulrike; Rothhammer, Veit			Astrocyte-Derived Pleiotrophin Mitigates Late-Stage Autoimmune CNS Inflammation	FRONTIERS IN IMMUNOLOGY			English	Article						astrocytes; multiple sclerosis; autoimmunity; CNS inflammation; protective	NECROSIS-FACTOR-ALPHA; GENE-EXPRESSION; TNF; BETA; TRANSDIFFERENTIATION; PROLIFERATION; TRANSCRIPTION; INACTIVATION; ACTIVATION; RECEPTORS	Astrocytes are the most abundant glial cells in the central nervous system (CNS) with the capacity to sense and react to injury and inflammatory events. While it has been widely documented that astrocytes can exert tissue-degenerative functions, less is known about their protective and disease-limiting roles. Here, we report the upregulation of pleiotrophin (PTN) by mouse and human astrocytes in multiple sclerosis (MS) and its preclinical model experimental autoimmune encephalomyelitis (EAE). Using CRISPR-Cas9-based genetic perturbation systems, we demonstrate in vivo that astrocyte-derived PTN is critical for the recovery phase of EAE and limits chronic CNS inflammation. PTN reduces pro-inflammatory signaling in astrocytes and microglia and promotes neuronal survival following inflammatory challenge. Finally, we show that intranasal administration of PTN during the late phase of EAE successfully reduces disease severity, making it a potential therapeutic candidate for the treatment of progressive MS, for which existing therapies are limited.	[Linnerbauer, Mathias; Loesslein, Lena; Farrenkopf, Daniel; Vandrey, Oliver; Tsaktanis, Thanos; Naumann, Ulrike; Rothhammer, Veit] Friedrich Alexander Univ Erlangen Nurnberg, Univ Hosp Erlangen, Dept Neurol, Erlangen, Germany	University of Erlangen Nuremberg	Rothhammer, V (corresponding author), Friedrich Alexander Univ Erlangen Nurnberg, Univ Hosp Erlangen, Dept Neurol, Erlangen, Germany.	veit.rothhammer@fau.de		Losslein, Lena/0000-0001-5705-9175; Linnerbauer, Mathias/0000-0002-5528-5141				Arnett HA, 2001, NAT NEUROSCI, V4, P1116, DOI 10.1038/nn738; BOHLEN P, 1991, Progress in Growth Factor Research, V3, P143, DOI 10.1016/S0955-2235(05)80005-5; Calabrese M, 2010, NAT REV NEUROL, V6, P438, DOI 10.1038/nrneurol.2010.93; Chao CC, 2019, CELL, V179, P1483, DOI 10.1016/j.cell.2019.11.016; Chen HM, 2009, BLOOD, V113, P1992, DOI 10.1182/blood-2008-02-133751; Clark IC, 2021, SCIENCE, V372, P360, DOI 10.1126/science.abf1230; Comi G, 2022, MULT SCLER J, V28, P608, DOI 10.1177/13524585211032803; De Stefano N, 2003, NEUROLOGY, V60, P1157, DOI 10.1212/01.WNL.0000055926.69643.03; Dendrou CA, 2015, NAT REV IMMUNOL, V15, P545, DOI 10.1038/nri3871; Dong Y, 2016, P NATL ACAD SCI USA, V113, P12304, DOI 10.1073/pnas.1605195113; FANG WJ, 1992, J BIOL CHEM, V267, P25889; Fernandez-Calle R, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0823-8; Fornes O, 2020, NUCLEIC ACIDS RES, V48, pD87, DOI 10.1093/nar/gkz1001; Frei K, 1997, J EXP MED, V185, P2177, DOI 10.1084/jem.185.12.2177; Garcia-Perez D, 2016, INT J NEUROPSYCHOPH, V19, DOI 10.1093/ijnp/pyv077; Gramage E, 2010, NEUROSCIENCE, V170, P308, DOI 10.1016/j.neuroscience.2010.06.078; Hasel P, 2021, NAT NEUROSCI, V24, P1475, DOI 10.1038/s41593-021-00905-6; Iwasaki S, 2019, PHARM RES-DORDR, V36, DOI 10.1007/s11095-019-2613-8; Kassiotis G, 1999, EUR J IMMUNOL, V29, P774, DOI 10.1002/(SICI)1521-4141(199903)29:03<774::AID-IMMU774>3.0.CO;2-T; Kuboyama K, 2015, J NEUROSCI, V35, P12162, DOI 10.1523/JNEUROSCI.2127-15.2015; Le Greves P, 2005, BRAIN RES BULL, V65, P529, DOI 10.1016/j.brainresbull.2005.03.010; Linnerbauer M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.573256; Liu JL, 1998, NAT MED, V4, P78, DOI 10.1038/nm0198-078; Liu X, 1998, GLIA, V24, P390, DOI 10.1002/(SICI)1098-1136(199812)24:4<390::AID-GLIA4>3.0.CO;2-1; Magliozzi R, 2007, BRAIN, V130, P1089, DOI 10.1093/brain/awm038; Marchionini DM, 2007, BRAIN RES, V1147, P77, DOI 10.1016/j.brainres.2007.02.028; Miao JY, 2012, NEUROSCI RES, V74, P269, DOI 10.1016/j.neures.2012.09.001; Nakamura K., 2014, EFFECT LAQUINIMOD GR; Nikolakopoulou AM, 2019, NAT NEUROSCI, V22, P1089, DOI 10.1038/s41593-019-0434-z; Papadimitriou E, 2016, BBA-REV CANCER, V1866, P252, DOI 10.1016/j.bbcan.2016.09.007; Papazian I, 2021, J NEUROINFLAMM, V18, DOI 10.1186/s12974-021-02200-4; Probert L, 2015, NEUROSCIENCE, V302, P2, DOI 10.1016/j.neuroscience.2015.06.038; Qin EY, 2017, CELL, V170, P845, DOI 10.1016/j.cell.2017.07.016; Raphael I, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.132527; Ross TM, 2004, J NEUROIMMUNOL, V151, P66, DOI 10.1016/j.jneuroim.2004.02.011; Rothhammer V, 2021, NEUROL-NEUROIMMUNOL, V8, DOI 10.1212/NXI.0000000000000946; Rothhammer V, 2018, NATURE, V557, P724, DOI 10.1038/s41586-018-0119-x; Rothhammer V, 2017, NEUROL-NEUROIMMUNOL, V4, DOI 10.1212/NXI.0000000000000359; Rothhammer V, 2017, P NATL ACAD SCI USA, V114, P2012, DOI 10.1073/pnas.1615413114; Rothhammer V, 2016, NAT MED, V22, P586, DOI 10.1038/nm.4106; Sandelin A, 2004, NUCLEIC ACIDS RES, V32, pD91, DOI 10.1093/nar/gkh012; Sanfilipo MP, 2006, NEUROLOGY, V66, P685, DOI 10.1212/01.wnl.0000201238.93586.d9; Sanmarco LM, 2021, NATURE, V590, P473, DOI 10.1038/s41586-020-03116-4; Satoh J, 2001, NEUROLOGY, V57, P681, DOI 10.1212/WNL.57.4.681; Sharifi BG, 2006, ARTERIOSCL THROM VAS, V26, P1273, DOI 10.1161/01.ATV.0000222017.05085.8e; Shi Y, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15080; SilosSantiago I, 1996, J NEUROBIOL, V31, P283, DOI 10.1002/(SICI)1097-4695(199611)31:3<283::AID-NEU2>3.0.CO;2-6; Skillback T, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-13831-0; Sofroniew MV, 2015, NAT REV NEUROSCI, V16, P249, DOI 10.1038/nrn3898; TAKEDA A, 1995, NEUROSCIENCE, V68, P57, DOI 10.1016/0306-4522(95)00110-5; Tsaktanis T, 2021, NEUROL-NEUROIMMUNOL, V8, DOI 10.1212/NXI.0000000000000933; Turrin NP, 2006, J NEUROSCI, V26, P143, DOI 10.1523/JNEUROSCI.4032-05.2006; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Wang X, 2020, ADV CLIN CHEM, V98, P51, DOI 10.1016/bs.acc.2020.02.003; Wheeler MA, 2020, NATURE, V578, P593, DOI 10.1038/s41586-020-1999-0; Wheeler MA, 2019, CSH PERSPECT MED, V9, DOI 10.1101/cshperspect.a029009; Yeh HJ, 1998, J NEUROSCI, V18, P3699; Zamanian JL, 2012, J NEUROSCI, V32, P6391, DOI 10.1523/JNEUROSCI.6221-11.2012; Zhao SM, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2264-z	59	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 3	2022	12								800128	10.3389/fimmu.2021.800128	http://dx.doi.org/10.3389/fimmu.2021.800128			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YV6VZ	35046956	gold, Green Published			2022-12-18	WOS:000752866900001
J	Penter, L; Gohil, SH; Wu, CJ				Penter, Livius; Gohil, Satyen H.; Wu, Catherine J.			Natural Barcodes for Longitudinal Single Cell Tracking of Leukemic and Immune Cell Dynamics	FRONTIERS IN IMMUNOLOGY			English	Review						copy number variants (CNV); somatic nuclear mutation; mitochondrial DNA mutation; single nucleotide polymorphism; B cell receptor sequence; T cell receptor sequence; allogeneic hematopoietic stem cell transplantation (allo-HCT); single-cell sequencing	ACUTE LYMPHOBLASTIC-LEUKEMIA; DEPLETED BONE-MARROW; FOLLICULAR LYMPHOMA; MUTATIONS; TRANSPLANTATION; CHIMERISM; EVOLUTION; REVEALS; LINEAGE; AML	Blood malignancies provide unique opportunities for longitudinal tracking of disease evolution following therapeutic bottlenecks and for the monitoring of changes in anti-tumor immunity. The expanding development of multi-modal single-cell sequencing technologies affords newer platforms to elucidate the mechanisms underlying these processes at unprecedented resolution. Furthermore, the identification of molecular events that can serve as in-vivo barcodes now facilitate the tracking of the trajectories of malignant and of immune cell populations over time within primary human samples, as these permit unambiguous identification of the clonal lineage of cell populations within heterogeneous phenotypes. Here, we provide an overview of the potential for chromosomal copy number changes, somatic nuclear and mitochondrial DNA mutations, single nucleotide polymorphisms, and T and B cell receptor sequences to serve as personal natural barcodes and review technical implementations in single-cell analysis workflows. Applications of these methodologies include the study of acquired therapeutic resistance and the dissection of donor- and host cellular interactions in the context of allogeneic hematopoietic stem cell transplantation.	[Penter, Livius; Wu, Catherine J.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Penter, Livius; Wu, Catherine J.] Broad Inst Massachusetts Inst Technol & Harvard U, 77 Massachusetts Ave, Cambridge, MA 02139 USA; [Penter, Livius; Wu, Catherine J.] Harvard Med Sch, Boston, MA 02115 USA; [Penter, Livius] Charite Univ Med Berlin, Dept Hematol Oncol & Tumorimmunol, Campus Virchow Klinikum, Berlin, Germany; [Penter, Livius] Free Univ Berlin, Berlin, Germany; [Penter, Livius] Humboldt Univ, Berlin, Germany; [Gohil, Satyen H.] UCL, Canc Inst, Dept Acad Haematol, London, England; [Gohil, Satyen H.] Univ Coll London Hosp NHS Fdn Trust, Dept Haematol, London, England; [Wu, Catherine J.] Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Harvard Medical School; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; University of London; University College London; University College London Hospitals NHS Foundation Trust; University of London; University College London; Harvard University; Brigham & Women's Hospital	Wu, CJ (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.; Wu, CJ (corresponding author), Broad Inst Massachusetts Inst Technol & Harvard U, 77 Massachusetts Ave, Cambridge, MA 02139 USA.; Wu, CJ (corresponding author), Harvard Med Sch, Boston, MA 02115 USA.; Wu, CJ (corresponding author), Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA.	cwu@partners.org		Penter, Livius/0000-0002-9060-0207				Abbas HA, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-26282-z; Alberti-Servera L, 2021, BLOOD, V137, P801, DOI 10.1182/blood.2020006996; Alexandrov LB, 2020, NATURE, V578, P94, DOI 10.1038/s41586-020-1943-3; Bachireddy P, 2021, CELL REP, V37, DOI 10.1016/j.celrep.2021.109992; Bachireddy P, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abb7661; Bielorai B, 2004, BONE MARROW TRANSPL, V34, P317, DOI 10.1038/sj.bmt.1704565; Black JRM, 2021, NAT REV CANCER, V21, P379, DOI 10.1038/s41568-021-00336-2; Bokemeyer A, 2014, HAEMATOLOGICA, V99, P706, DOI 10.3324/haematol.2012.072470; Bolotin DA, 2017, NAT BIOTECHNOL, V35, P908, DOI 10.1038/nbt.3979; Borcherding N, 2019, CLIN CANCER RES, V25, P2996, DOI 10.1158/1078-0432.CCR-18-3309; Byrne A, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms16027; Byrneee AJ, 2020, J EXP MED, V217, DOI 10.1084/jem.20191236; Cabaniols JP, 2001, J EXP MED, V194, P1385, DOI 10.1084/jem.194.9.1385; Chaligne R, 2021, NAT GENET, V53, P1469, DOI 10.1038/s41588-021-00927-7; Chan YL, 2018, GENOME MED, V10, DOI 10.1186/s13073-018-0541-6; Chen J, 2020, GENOME BIOL, V21, DOI 10.1186/s13059-020-02064-6; Chen X, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07771-0; Choi S, 2007, BLOOD, V110, P632, DOI 10.1182/blood-2007-01-067785; Cieri N, 2021, CANCER RES, V81, P4373, DOI 10.1158/0008-5472.CAN-21-0301; Couturier CP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17186-5; Delhommeau F, 2009, NEW ENGL J MED, V360, P2289, DOI 10.1056/NEJMoa0810069; Demaree B, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21810-3; Dillon LW, 2021, BLOOD CANCER DISCOV, V2, P319, DOI 10.1158/2643-3230.BCD-21-0046; Ding L, 2012, NATURE, V481, P506, DOI 10.1038/nature10738; Durante MA, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-14256-1; Ediriwickrema A, 2020, BLOOD ADV, V4, P943, DOI 10.1182/bloodadvances.2019001181; Fan J, 2018, GENOME RES, V28, P1217, DOI 10.1101/gr.228080.117; Frick M, 2019, J CLIN ONCOL, V37, P375, DOI 10.1200/JCO.2018.79.2184; Fu YS, 2019, COMMUN BIOL, V2, DOI 10.1038/s42003-019-0401-y; Gaiti F, 2019, NATURE, V569, P576, DOI 10.1038/s41586-019-1198-z; Gao RL, 2021, NAT BIOTECHNOL, V39, P599, DOI 10.1038/s41587-020-00795-2; Gawad C, 2014, P NATL ACAD SCI USA, V111, P17947, DOI 10.1073/pnas.1420822111; Gawad C, 2012, BLOOD, V120, P4407, DOI 10.1182/blood-2012-05-429811; Giustacchini A, 2017, NAT MED, V23, P692, DOI 10.1038/nm.4336; Grimaldi F, 2017, BIOL BLOOD MARROW TR, V23, P293, DOI 10.1016/j.bbmt.2016.11.003; Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00547-2020; Hagemann-Jensen M., 2021, SCALABLE FULL TRANSC, DOI [10.1101/2021.07.10.451889, DOI 10.1101/2021.07.10.451889]; Hagemann-Jensen M, 2020, NAT BIOTECHNOL, V38, P708, DOI 10.1038/s41587-020-0497-0; Han A, 2014, NAT BIOTECHNOL, V32, P684, DOI 10.1038/nbt.2938; Hansmann L, 2017, CANCER IMMUNOL RES, V5, P744, DOI 10.1158/2326-6066.CIR-17-0012; Harmanci AS, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13779-x; Heaton H, 2020, NAT METHODS, V17, P615, DOI 10.1038/s41592-020-0820-1; Herrera A, 2021, BLOOD, V138, P1456, DOI 10.1182/blood.2020009346; Hu QT, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22300-2; Hu ZT, 2021, NAT MED, V27, P515, DOI 10.1038/s41591-020-01206-4; Huang YH, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-019-1865-2; Hutt D, 2018, EUROPEAN BLOOD MARRO, P259, DOI 10.1007/978-3-319-50026-3_13; Jiang YW, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0432-0; Kang HM, 2018, NAT BIOTECHNOL, V36, P89, DOI 10.1038/nbt.4042; Karamitros D, 2018, NAT IMMUNOL, V19, P85, DOI 10.1038/s41590-017-0001-2; Kebschull JM, 2018, NAT METHODS, V15, P871, DOI 10.1038/s41592-018-0185-x; Kester L, 2018, CELL STEM CELL, V23, P166, DOI 10.1016/j.stem.2018.04.014; Kim D, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16115-w; King HW, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abe6291; Kohlmann A, 2010, LEUKEMIA, V24, P1216, DOI 10.1038/leu.2010.73; Laks E, 2019, CELL, V179, P1207, DOI 10.1016/j.cell.2019.10.026; Landau DA, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-02329-y; Landau DA, 2015, NATURE, V526, P525, DOI 10.1038/nature15395; Landau DA, 2013, CELL, V152, P714, DOI 10.1016/j.cell.2013.01.019; Lareau CA, 2021, NAT BIOTECHNOL, V39, P451, DOI 10.1038/s41587-020-0645-6; Lareau CA, 2019, BLOOD ADV, V3, P4161, DOI 10.1182/bloodadvances.2019001196; Lawless C, 2020, OPEN BIOL, V10, DOI 10.1098/rsob.200061; Le J, 2020, IMMUNITY, V52, P1105, DOI 10.1016/j.immuni.2020.05.010; Levine RL, 2005, CANCER CELL, V7, P387, DOI 10.1016/j.ccr.2005.03.023; Ley TJ, 2010, NEW ENGL J MED, V363, P2424, DOI 10.1056/NEJMoa1005143; LINDER D, 1965, SCIENCE, V150, P67, DOI 10.1126/science.150.3692.67; Ludwig LS, 2019, CELL, V176, P1325, DOI 10.1016/j.cell.2019.01.022; Luo YC, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-24213-6; Luquette LJ, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11857-8; Malcovati L, 2020, BLOOD, V136, P157, DOI 10.1182/blood.2020004850; Mallory XF, 2020, GENOME BIOL, V21, DOI 10.1186/s13059-020-02119-8; Malone AF, 2020, J AM SOC NEPHROL, V31, P1977, DOI 10.1681/ASN.2020030326; Marshall AS, 2021, BIOLOGY-BASEL, V10, DOI 10.3390/biology10060503; Martin CL, 2015, ANNU REV GENOM HUM G, V16, P309, DOI 10.1146/annurev-genom-090413-025346; Massarat AR, 2021, NUCLEIC ACIDS RES, V49, P7986, DOI 10.1093/nar/gkab621; Mathew NR, 2021, CELL REP, V35, DOI 10.1016/j.celrep.2021.109286; McKenna A, 2019, DEVELOPMENT, V146, DOI 10.1242/dev.169730; Miles LA, 2020, NATURE, V587, P477, DOI 10.1038/s41586-020-2864-x; Miller T.E., 2021, MITOCHONDRIAL VARIAN, DOI [10.1101/2021.03.08.434450, DOI 10.1101/2021.03.08.434450]; Mishra AK, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00117; Mitchell SL, 2014, HUM GENET, V133, P861, DOI 10.1007/s00439-014-1421-9; Mlynarczyk C, 2019, IMMUNOL REV, V288, P214, DOI 10.1111/imr.12755; Morita K, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19119-8; Nam AS, 2019, NATURE, V571, P355, DOI 10.1038/s41586-019-1367-0; Negrin RS, 2015, HEMATOL-AM SOC HEMAT, P225, DOI 10.1182/asheducation-2015.1.225; Nik-Zainal S, 2012, CELL, V149, DOI 10.1016/j.cell.2012.04.023; Noviello M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08871-1; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; O'Hare T, 2007, BLOOD, V110, P2242, DOI 10.1182/blood-2007-03-066936; Ogonek J, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00507; Oliveira G, 2021, NATURE, V596, P119, DOI 10.1038/s41586-021-03704-y; Ottensmeier CH, 1998, BLOOD, V91, P4292, DOI 10.1182/blood.V91.11.4292.411a02_4292_4299; Papaemmanuil E, 2016, NEW ENGL J MED, V374, P2209, DOI 10.1056/NEJMoa1516192; Papavasiliou FN, 2002, CELL, V109, pS35, DOI 10.1016/S0092-8674(02)00706-7; Park JE, 2020, SCIENCE, V367, P868, DOI 10.1126/science.aay3224; Pasqualucci L, 2014, CELL REP, V6, P130, DOI 10.1016/j.celrep.2013.12.027; Patel AP, 2014, SCIENCE, V344, P1396, DOI 10.1126/science.1254257; Pellin D, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10291-0; Penter L, 2021, BLOOD ADV, V5, P4701, DOI 10.1182/bloodadvances.2021004335; Penter L, 2021, CANCER DISCOV, V11, P3048, DOI 10.1158/2159-8290.CD-21-0276; Penter L, 2021, BLOOD, V137, P3212, DOI 10.1182/blood.2021010867; Penter L, 2020, J CLIN INVEST, V130, P1595, DOI 10.1172/JCI129209; Penter L, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2019.1586409; Penter L, 2018, EUR J IMMUNOL, V48, P1248, DOI 10.1002/eji.201847507; Picelli S, 2013, NAT METHODS, V10, P1096, DOI [10.1038/nmeth.2639, 10.1038/NMETH.2639]; Poe JC, 2019, BLOOD, V134, DOI 10.1182/blood-2019-130928; Pula B, 2019, CANCERS, V11, DOI 10.3390/cancers11121834; Randolph SSB, 2004, BLOOD, V103, P347, DOI 10.1182/blood-2003-07-2603; Regev A, 2017, ELIFE, V6, DOI 10.7554/eLife.27041; Ribera J, 2017, GENE CHROMOSOME CANC, V56, P810, DOI 10.1002/gcc.22486; Rizzetto S, 2018, BIOINFORMATICS, V34, P2846, DOI 10.1093/bioinformatics/bty203; Rodriguez-Fraticelli AE, 2020, NATURE, V583, P585, DOI 10.1038/s41586-020-2503-6; Sachidanandam R, 2001, NATURE, V409, P928, DOI 10.1038/35057149; Satpathy AT, 2019, NAT BIOTECHNOL, V37, P925, DOI 10.1038/s41587-019-0206-z; Schaap N, 2000, BRIT J HAEMATOL, V108, P116, DOI 10.1046/j.1365-2141.2000.01803.x; SCHATTENBERG A, 1989, BLOOD, V73, P1367; Schopf B, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15237-5; Singh M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11049-4; Smith ALM, 2020, NAT CANCER, V1, P976, DOI 10.1038/s43018-020-00112-5; Song L, 2021, NAT METHODS, V18, P627, DOI 10.1038/s41592-021-01142-2; Staedtler F, 2013, BIOMARKERS, V18, P436, DOI 10.3109/1354750X.2013.811538; Stewart JB, 2021, NAT REV GENET, V22, P106, DOI 10.1038/s41576-020-00284-x; Van der Auwera Geraldine A, 2013, Curr Protoc Bioinformatics, V43, DOI [10.1002/0471250953.bi1201s43, 10.1002/0471250953.bi1110s43]; Thiele J, 2003, ACTA HAEMATOL-BASEL, V109, P176, DOI 10.1159/000070966; Tirosh I, 2016, SCIENCE, V352, P189, DOI 10.1126/science.aad0501; van Galen P, 2019, CELL, V176, P1265, DOI 10.1016/j.cell.2019.01.031; Velazquez-Villarreal EI, 2020, COMMUN BIOL, V3, DOI 10.1038/s42003-020-1044-8; Velten L, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21650-1; Velten L, 2017, NAT CELL BIOL, V19, P271, DOI 10.1038/ncb3493; Wagner DE, 2020, NAT REV GENET, V21, P410, DOI 10.1038/s41576-020-0223-2; Wan YZ, 2013, BLOOD, V121, P4627, DOI 10.1182/blood-2013-02-427641; Wang CL, 2012, GENETICS, V192, P651, DOI 10.1534/genetics.112.139519; Wang LL, 2017, GENOME RES, V27, P1300, DOI 10.1101/gr.217331.116; Wiseman DH, 2020, EBIOMEDICINE, V58, DOI 10.1016/j.ebiom.2020.102904; Woodworth MB, 2017, NAT REV GENET, V18, P230, DOI 10.1038/nrg.2016.159; Xia CL, 2019, P NATL ACAD SCI USA, V116, P19490, DOI 10.1073/pnas.1912459116; Xu J, 2019, ELIFE, V8, DOI 10.7554/eLife.45105; Xu J, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-019-1852-7; Xu LW, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-47297-z; Yao WQ, 2020, J PATHOL, V250, P346, DOI 10.1002/path.5376; Zavidij O, 2020, NAT CANCER, V1, DOI 10.1038/s43018-020-0053-3; Zeiser R, 2019, BLOOD, V133, P1290, DOI 10.1182/blood-2018-10-846824; ZELENETZ AD, 1991, J EXP MED, V173, P197, DOI 10.1084/jem.173.1.197; Zhang L, 2019, P NATL ACAD SCI USA, V116, P9014, DOI 10.1073/pnas.1902510116; Zhang L, 2018, NATURE, V564, P268, DOI 10.1038/s41586-018-0694-x; Zhang SQ, 2018, NAT BIOTECHNOL, V36, P1156, DOI 10.1038/nbt.4282; Zheng GXY, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14049; Zhou ZL, 2020, GENOME BIOL, V21, DOI 10.1186/s13059-019-1922-x	148	0	0	4	9	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 3	2022	12								788891	10.3389/fimmu.2021.788891	http://dx.doi.org/10.3389/fimmu.2021.788891			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YV6WD	35046946	Green Published, gold			2022-12-18	WOS:000752867300001
J	Pizzagalli, DU; Pulfer, A; Thelen, M; Krause, R; Gonzalez, SF				Pizzagalli, Diego Ulisse; Pulfer, Alain; Thelen, Marcus; Krause, Rolf; Gonzalez, Santiago F.			In Vivo Motility Patterns Displayed by Immune Cells Under Inflammatory Conditions	FRONTIERS IN IMMUNOLOGY			English	Review						cell actions; computer vision; inflammation; intravital imaging; leukocytes; motility patterns	NATURAL-KILLER-CELLS; LYMPH-NODES; DENDRITIC CELLS; INTRAVITAL MICROSCOPY; NEUTROPHIL MIGRATION; INTERACTION DYNAMICS; LEUKOCYTE MIGRATION; IMAGING REVEALS; MACROPHAGES; MONOCYTES	The migration of immune cells plays a key role in inflammation. This is evident in the fact that inflammatory stimuli elicit a broad range of migration patterns in immune cells. Since these patterns are pivotal for initiating the immune response, their dysregulation is associated with life-threatening conditions including organ failure, chronic inflammation, autoimmunity, and cancer, amongst others. Over the last two decades, thanks to advancements in the intravital microscopy technology, it has become possible to visualize cell migration in living organisms with unprecedented resolution, helping to deconstruct hitherto unexplored aspects of the immune response associated with the dynamism of cells. However, a comprehensive classification of the main motility patterns of immune cells observed in vivo, along with their relevance to the inflammatory process, is still lacking. In this review we defined cell actions as motility patterns displayed by immune cells, which are associated with a specific role during the immune response. In this regard, we summarize the main actions performed by immune cells during intravital microscopy studies. For each of these actions, we provide a consensus name, a definition based on morphodynamic properties, and the biological contexts in which it was reported. Moreover, we provide an overview of the computational methods that were employed for the quantification, fostering an interdisciplinary approach to study the immune system from imaging data.	[Pizzagalli, Diego Ulisse; Pulfer, Alain; Thelen, Marcus; Gonzalez, Santiago F.] Univ Svizzera Italiana, Ist Ric Biomed IRB, Bellinzona, Switzerland; [Pizzagalli, Diego Ulisse; Krause, Rolf] Univ Svizzera Italiana, Euler Inst, Lugano, Switzerland; [Pulfer, Alain] Swiss Fed Inst Technol Zurich ETHZ, Dept Informat Technol & Elect Engn, Zurich, Switzerland	Universita della Svizzera Italiana; Universita della Svizzera Italiana; Swiss Federal Institutes of Technology Domain; ETH Zurich	Gonzalez, SF (corresponding author), Univ Svizzera Italiana, Ist Ric Biomed IRB, Bellinzona, Switzerland.	santiago.gonzalez@irb.usi.ch	Pizzagalli, Diego Ulisse/AHA-2138-2022	Pizzagalli, Diego Ulisse/0000-0001-7158-5323	Swiss National Foundation (SNF) [176124]; SystemsX.ch [2013/124]; Biolink [189699]	Swiss National Foundation (SNF)(Swiss National Science Foundation (SNSF)); SystemsX.ch; Biolink	This work was supported by the Swiss National Foundation (SNF) grants, 176124, SystemsX.ch (2013/124), Biolink (189699).	Alex H, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15834-4; Arasa J, 2021, J EXP MED, V218, DOI 10.1084/jem.20201413; Audoy-Remus J, 2008, J NEUROSCI, V28, P10187, DOI 10.1523/JNEUROSCI.3510-08.2008; Auffray C, 2007, SCIENCE, V317, P666, DOI 10.1126/science.1142883; Bajenoff M, 2006, J EXP MED, V203, P619, DOI 10.1084/jem.20051474; Bajenoff M, 2006, IMMUNITY, V25, P989, DOI 10.1016/j.immuni.2006.10.011; Barton GM, 2008, J CLIN INVEST, V118, P413, DOI 10.1172/JCI34431; Beal AM, 2009, IMMUNITY, V31, P632, DOI 10.1016/j.immuni.2009.09.004; Beltman JB, 2009, NAT REV IMMUNOL, V9, P789, DOI 10.1038/nri2638; Beltman JB, 2009, J IMMUNOL METHODS, V347, P54, DOI 10.1016/j.jim.2009.05.013; Beuneu H, 2009, BLOOD, V114, P3227, DOI 10.1182/blood-2009-06-228759; Bistrian B, 2007, NUTR REV, V65, pS170, DOI 10.1301/nr.2007.dec.S170-S172; Boissonnas A, 2007, J EXP MED, V204, P345, DOI 10.1084/jem.20061890; Borg C, 2004, BLOOD, V104, P3267, DOI 10.1182/blood-2004-01-0380; Bougherara H, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00500; Bousso P, 2003, NAT IMMUNOL, V4, P579, DOI 10.1038/ni928; Brilot F, 2007, J CLIN INVEST, V117, P3316, DOI 10.1172/JCI31751; Buscher K, 2017, FRONT CARDIOVASC MED, V4, DOI 10.3389/fcvm.2017.00080; Cahalan MD, 2002, NAT REV IMMUNOL, V2, P872, DOI 10.1038/nri935; Cahalan MD, 2008, ANNU REV IMMUNOL, V26, P585, DOI 10.1146/annurev.immunol.24.021605.090620; Carlin LM, 2013, CELL, V153, P362, DOI 10.1016/j.cell.2013.03.010; Celli S, 2007, IMMUNITY, V27, P625, DOI 10.1016/j.immuni.2007.08.018; Chatziandreou N, 2017, CELL REP, V18, P2427, DOI 10.1016/j.celrep.2017.02.026; Chojnacki A, 2019, COMMUN BIOL, V2, DOI 10.1038/s42003-019-0425-3; Chtanova T, 2008, IMMUNITY, V29, P487, DOI 10.1016/j.immuni.2008.07.012; Coombes JL, 2013, P NATL ACAD SCI USA, V110, pE1913, DOI 10.1073/pnas.1220272110; Coombes JL, 2012, CELL REP, V2, P124, DOI 10.1016/j.celrep.2012.06.001; Cyrille B., 2015, P BRIT MACH VIS C BM, DOI [10.5244/c.29.118, DOI 10.5244/C.29.118]; Cyster JG, 2019, CELL, V177, P524, DOI 10.1016/j.cell.2019.03.016; De Filippo K, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.603230; de Oliveira S, 2016, NAT REV IMMUNOL, V16, P378, DOI 10.1038/nri.2016.49; Deguine J, 2013, IMMUNOL REV, V251, P154, DOI 10.1111/imr.12015; Doi A, 2018, BIOMED OPT EXPRESS, V9, P202, DOI 10.1364/BOE.9.000202; Dunn KW, 2008, ILAR J, V49, P66, DOI 10.1093/ilar.49.1.66; Dustin ML, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a002311; Dustin ML, 2010, IMMUNOL REV, V235, P24, DOI 10.1111/j.0105-2896.2010.00904.x; Farsakoglu Y, 2019, CELL REP, V26, P2307, DOI 10.1016/j.celrep.2019.01.104; Figge MT, 2015, CYTOM PART A, V87A, P459, DOI 10.1002/cyto.a.22663; Finsterbusch M, 2016, P NATL ACAD SCI USA, V113, pE5172, DOI 10.1073/pnas.1606253113; Friedl P, 2008, NAT IMMUNOL, V9, P960, DOI 10.1038/ni.f.212; Garrod KR, 2007, P NATL ACAD SCI USA, V104, P12081, DOI 10.1073/pnas.0702867104; Gregory CD, 2011, J PATHOL, V223, P177, DOI 10.1002/path.2792; Hallett MB., 1989, NEUTROPHIL CELLULAR; Hampton HR, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01168; Hanna RN, 2015, SCIENCE, V350, P985, DOI 10.1126/science.aac9407; Helmchen F, 2005, NAT METHODS, V2, P932, DOI 10.1038/NMETH818; Hugues S, 2004, NAT IMMUNOL, V5, P1235, DOI 10.1038/ni1134; Hunter MC, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00520; Jahromi NH, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00406; Jorch SK, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.623906; Kamenyeva O, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004827; Katakai T, 2016, FRONT IMMUNOL, V7, P1, DOI 10.3389/fimmu.2016.00194; Kawakami N, 2010, SEMIN IMMUNOPATHOL, V32, P275, DOI 10.1007/s00281-010-0216-x; Kienle K, 2021, SCIENCE, V372, P1303, DOI 10.1126/science.abe7729; Kienle K, 2016, IMMUNOL REV, V273, P76, DOI 10.1111/imr.12458; Kitano M, 2016, P NATL ACAD SCI USA, V113, P1044, DOI 10.1073/pnas.1513607113; Kolaczkowska E, 2013, NAT REV IMMUNOL, V13, P159, DOI 10.1038/nri3399; Kreisel D, 2010, P NATL ACAD SCI USA, V107, P18073, DOI 10.1073/pnas.1008737107; Krummel MF, 2010, J CLIN IMMUNOL, V30, P364, DOI 10.1007/s10875-010-9393-6; Lammermann T, 2013, NATURE, V498, P371, DOI 10.1038/nature12175; Lee SH, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.aaz4415; Leliefeld PHC, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00471; Ley K, 2007, NAT REV IMMUNOL, V7, P678, DOI 10.1038/nri2156; Lindquist RL, 2004, NAT IMMUNOL, V5, P1243, DOI 10.1038/ni1139; Loosley AJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127425; Louie DAP, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00347; Luster AD, 2005, NAT IMMUNOL, V6, P1182, DOI 10.1038/ni1275; Marques PE, 2015, J HEPATOL, V63, P733, DOI 10.1016/j.jhep.2015.05.027; Mayadas TN, 2014, ANNU REV PATHOL-MECH, V9, P181, DOI 10.1146/annurev-pathol-020712-164023; McDonald B, 2010, SCIENCE, V330, P362, DOI 10.1126/science.1195491; Mempel TR, 2006, IMMUNITY, V25, P129, DOI 10.1016/j.immuni.2006.04.015; Mempel TR, 2004, NATURE, V427, P154, DOI 10.1038/nature02238; Miller MJ, 2004, P NATL ACAD SCI USA, V101, P998, DOI 10.1073/pnas.0306407101; Miller MJ, 2003, P NATL ACAD SCI USA, V100, P2604, DOI 10.1073/pnas.2628040100; Miller MJ, 2002, SCIENCE, V296, P1869, DOI 10.1126/science.1070051; Modi MN, 2019, OPT EXPRESS, V27, P35830, DOI 10.1364/OE.27.035830; Monks CRF, 1998, NATURE, V395, P82, DOI 10.1038/25764; Moreau HD, 2014, CURR OPIN IMMUNOL, V26, P56, DOI 10.1016/j.coi.2013.10.013; Moseman EA, 2012, IMMUNITY, V36, P415, DOI 10.1016/j.immuni.2012.01.013; Mrass P, 2006, J EXP MED, V203, P2749, DOI 10.1084/jem.20060710; Mulazzani M, 2019, P NATL ACAD SCI USA, V116, P24275, DOI 10.1073/pnas.1903854116; Ng LG, 2011, J INVEST DERMATOL, V131, P2058, DOI 10.1038/jid.2011.179; Nguyen NT, 2005, PROC CVPR IEEE, P955; Nguyen WNT, 2020, J LEUKOCYTE BIOL, V108, P83, DOI 10.1002/JLB.3HR0220-396R; Nourshargh S, 2014, IMMUNITY, V41, P694, DOI 10.1016/j.immuni.2014.10.008; Nowarski R, 2013, CANCER IMMUNOL RES, V1, P77, DOI 10.1158/2326-6066.CIR-13-0081; Park SA, 2018, CELL ADHES MIGR, V12, P424, DOI 10.1080/19336918.2018.1471322; Peters NC, 2008, SCIENCE, V321, P970, DOI 10.1126/science.1159194; Phillipson M, 2006, J EXP MED, V203, P2569, DOI 10.1084/jem.20060925; Phillipson M, 2011, NAT MED, V17, P1381, DOI 10.1038/nm.2514; Pittet MJ, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aaq0491; Pizzagalli DU, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02621; Pizzagalli DU, 2018, SCI DATA, V5, DOI 10.1038/sdata.2018.129; Pizzagalli DU, 2019, BIORXIV, DOI [10.1101/829838, DOI 10.1101/829838]; Poppe R, 2010, IMAGE VISION COMPUT, V28, P976, DOI 10.1016/j.imavis.2009.11.014; Qi H, 2008, NATURE, V455, P764, DOI 10.1038/nature07345; Rakhilin N, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13699-w; Ravichandran KS, 2010, J EXP MED, V207, P1807, DOI 10.1084/jem.20101157; Ricard C, 2018, BRAIN STRUCT FUNCT, V223, P3011, DOI 10.1007/s00429-018-1678-1; Schienstock D, 2022, IMMUNOL REV, V306, P123, DOI 10.1111/imr.13038; Secklehner J, 2017, IMMUNOL CELL BIOL, V95, P506, DOI 10.1038/icb.2017.25; Selmeczi D, 2005, BIOPHYS J, V89, P912, DOI 10.1529/biophysj.105.061150; SenGupta S, 2021, NAT REV MOL CELL BIO, V22, P529, DOI 10.1038/s41580-021-00366-6; Shakhar G, 2005, NAT IMMUNOL, V6, P707, DOI 10.1038/ni1210; Shaner NC, 2005, NAT METHODS, V2, P905, DOI 10.1038/NMETH819; Shannon JG, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004734; Shellard A, 2019, J CELL SCI, V132, DOI 10.1242/jcs.226142; Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006; Soulet D, 2020, J MICROSC-OXFORD, V278, P3, DOI 10.1111/jmi.12880; Stein JV, 2017, J ALLERGY CLIN IMMUN, V139, P12, DOI 10.1016/j.jaci.2016.11.008; Sumen C, 2004, IMMUNITY, V21, P315, DOI 10.1016/S1074-7613(04)00237-7; Teijeira A, 2017, CELL REP, V18, P857, DOI 10.1016/j.celrep.2016.12.078; Teixido J, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02560; Trapani JA, 2002, NAT REV IMMUNOL, V2, P735, DOI 10.1038/nri911; Ulman V, 2017, NAT METHODS, V14, P1141, DOI 10.1038/nmeth.4473; Vaghela R, 2021, FRONT BIOENG BIOTECH, V9, DOI 10.3389/fbioe.2021.627462; Vladymyrov M, 2020, FRONT PHYS-LAUSANNE, V7, DOI 10.3389/fphy.2019.00222; Voisin MB, 2013, J INNATE IMMUN, V5, P336, DOI 10.1159/000346659; Waite JC, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001326; Wang HT, 2021, THERANOSTICS, V11, P2149, DOI 10.7150/thno.51369; Wei SH, 2003, IMMUNOL REV, V195, P136, DOI 10.1034/j.1600-065X.2003.00076.x; Westhorpe CLV, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03181-4; Xie JM, 2013, IMMUNOL REV, V251, P65, DOI 10.1111/imr.12017; Xu Najia, 2011, J Vis Exp, DOI 10.3791/3296; Zhang WL, 2021, NEOPLASIA, V23, P1089, DOI 10.1016/j.neo.2021.09.001; Zhang Y, 2008, J IMMUNOL, V181, P2155, DOI 10.4049/jimmunol.181.3.2155; Zinselmeyer BH, 2008, INFLAMM RES, V57, P93, DOI 10.1007/s00011-007-7195-y; Zipfel WR, 2003, NAT BIOTECHNOL, V21, P1368, DOI 10.1038/nbt899	128	0	0	1	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 3	2022	12								804159	10.3389/fimmu.2021.804159	http://dx.doi.org/10.3389/fimmu.2021.804159			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YL1XV	35046959	gold, Green Published			2022-12-18	WOS:000745692900001
J	Sheng, ZZ; Bimela, JS; Katsamba, PS; Patel, SD; Guo, YC; Zhao, HQ; Guo, YZ; Kwong, PD; Shapiro, L				Sheng, Zizhang; Bimela, Jude S.; Katsamba, Phinikoula S.; Patel, Saurabh D.; Guo, Yicheng; Zhao, Haiqing; Guo, Youzhong; Kwong, Peter D.; Shapiro, Lawrence			Structural Basis of Antibody Conformation and Stability Modulation by Framework Somatic Hypermutation	FRONTIERS IN IMMUNOLOGY			English	Article						antibody; broadly HIV-1 neutralizing antibody; conformation modulation; epistasis; INDEL; molecular dynamics simulation; somatic hypermutation; stability	AFFINITY MATURATION; THERMODYNAMIC STABILITY; BINDING; HUMANIZATION; GERMLINE; DYNAMICS; ORIENTATION; PLASTICITY; PREDICTION; MUTATIONS	Accumulation of somatic hypermutation (SHM) is the primary mechanism to enhance the binding affinity of antibodies to antigens in vivo. However, the structural basis of the effects of many SHMs remains elusive. Here, we integrated atomistic molecular dynamics (MD) simulation and data mining to build a high-throughput structural bioinformatics pipeline to study the effects of individual and combination SHMs on antibody conformation, flexibility, stability, and affinity. By applying this pipeline, we characterized a common mechanism of modulation of heavy-light pairing orientation by frequent SHMs at framework positions 39(H), 91(H), 38(L), and 87(L) through disruption of a conserved hydrogen-bond network. Q39L(H) alone and in combination with light chain framework 4 (FWR4(L)) insertions further modulated the elbow angle between variable and constant domains of many antibodies, resulting in improved binding affinity for a subset of anti-HIV-1 antibodies. Q39L(H) also alleviated aggregation induced by FWR4(L) insertion, suggesting remote epistasis between these SHMs. Altogether, this study provides tools and insights for understanding antibody affinity maturation and for engineering functionally improved antibodies.	[Sheng, Zizhang; Bimela, Jude S.; Katsamba, Phinikoula S.; Patel, Saurabh D.; Guo, Yicheng; Shapiro, Lawrence] Columbia Univ, Zuckerman Mind Brain Behav Inst, New York, NY 10027 USA; [Sheng, Zizhang; Guo, Yicheng; Shapiro, Lawrence] Columbia Univ, Aaron Diamond AIDS Res Ctr, Vagelos Coll Phys & Surg, New York, NY 10027 USA; [Zhao, Haiqing] Columbia Univ, Dept Syst Biol, New York, NY USA; [Guo, Youzhong] Virginia Commonwealth Univ, Dept Med Chem, Richmond, VA 23298 USA; [Guo, Youzhong] Virginia Commonwealth Univ, Inst Struct Biol Drug Discovery & Dev, Richmond, VA USA; [Kwong, Peter D.] NIAID, Vaccine Res Ctr, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Kwong, Peter D.; Shapiro, Lawrence] Columbia Univ, Dept Biochem & Mol Biophys, New York, NY 10027 USA	Columbia University; Columbia University; Columbia University; Virginia Commonwealth University; Virginia Commonwealth University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Columbia University	Sheng, ZZ; Shapiro, L (corresponding author), Columbia Univ, Zuckerman Mind Brain Behav Inst, New York, NY 10027 USA.; Sheng, ZZ; Shapiro, L (corresponding author), Columbia Univ, Aaron Diamond AIDS Res Ctr, Vagelos Coll Phys & Surg, New York, NY 10027 USA.; Shapiro, L (corresponding author), Columbia Univ, Dept Biochem & Mol Biophys, New York, NY 10027 USA.	zs2248@cumc.columbia.edu; lss8@columbia.edu	Sheng, Zizhang/AFR-8049-2022	Sheng, Zizhang/0000-0002-3253-3309	National Institute of Allergy and Infectious Diseases (NIAID) [R21 1R21AI138024-01A1, UR010655/70003/ZS2248]; Intramural Research Program of the Vaccine Research Center, NIAID, NIH	National Institute of Allergy and Infectious Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Intramural Research Program of the Vaccine Research Center, NIAID, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Support for this work was provided by the National Institute of Allergy and Infectious Diseases (NIAID) grant R21 1R21AI138024-01A1 and the startup fund UR010655/70003/ZS2248 to ZS; support was also provided by the Intramural Research Program of the Vaccine Research Center, NIAID, NIH.	Abhinandan KR, 2010, PROTEIN ENG DES SEL, V23, P689, DOI 10.1093/protein/gzq043; Bonsignori M, 2016, CELL, V165, P449, DOI 10.1016/j.cell.2016.02.022; Bujotzek A, 2016, MABS-AUSTIN, V8, P288, DOI 10.1080/19420862.2015.1117720; Burnett DL, 2020, P NATL ACAD SCI USA, V117, P22341, DOI 10.1073/pnas.2005102117; Case DA, 2005, J COMPUT CHEM, V26, P1668, DOI 10.1002/jcc.20290; Cauerhff A, 2004, P NATL ACAD SCI USA, V101, P3539, DOI 10.1073/pnas.0400060101; CHOTHIA C, 1987, J MOL BIOL, V196, P901, DOI 10.1016/0022-2836(87)90412-8; Dimitrov JD, 2014, TRENDS BIOCHEM SCI, V39, P221, DOI 10.1016/j.tibs.2014.02.010; Dunbar J, 2013, PROTEIN ENG DES SEL, V26, P611, DOI 10.1093/protein/gzt020; Dunbar J, 2014, NUCLEIC ACIDS RES, V42, pD1140, DOI 10.1093/nar/gkt1043; Edgar RC, 2010, BIOINFORMATICS, V26, P2460, DOI 10.1093/bioinformatics/btq461; Webb Benjamin, 2016, Curr Protoc Bioinformatics, V54, DOI [10.1002/0471140864.ps0209s50, 10.1002/cpps.20, 10.1002/0471250953.bi0506s15, 10.1002/cpbi.3]; Fernandez-Quintero ML, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.675655; Finlay WJ, 2009, J MOL BIOL, V388, P541, DOI 10.1016/j.jmb.2009.03.019; Grossfield A, 2009, ANN REP COMP CHEM, V5, P23, DOI 10.1016/S1574-1400(09)00502-7; Guerois R, 2002, J MOL BIOL, V320, P369, DOI 10.1016/S0022-2836(02)00442-4; Gulla K, 2021, VACCINE, V39, P3379, DOI 10.1016/j.vaccine.2021.04.063; Guo YC, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02365; Henderson R, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08415-7; James LC, 2003, SCIENCE, V299, P1362, DOI 10.1126/science.1079731; Jardine JG, 2016, SCIENCE, V351, P1458, DOI 10.1126/science.aad9195; Jardine JG, 2015, SCIENCE, V349, P156, DOI 10.1126/science.aac5894; Klein F, 2013, CELL, V153, P126, DOI 10.1016/j.cell.2013.03.018; Koenig P, 2017, P NATL ACAD SCI USA, V114, pE486, DOI 10.1073/pnas.1613231114; Krissinel E, 2007, J MOL BIOL, V372, P774, DOI 10.1016/j.jmb.2007.05.022; Lefranc MP, 2009, NUCLEIC ACIDS RES, V37, pD1006, DOI 10.1093/nar/gkn838; Lord DM, 2018, MABS-AUSTIN, V10, P444, DOI 10.1080/19420862.2018.1426421; Manivel V, 2000, IMMUNITY, V13, P611, DOI 10.1016/S1074-7613(00)00061-3; Margreitter C, 2016, J MOL RECOGNIT, V29, P266, DOI 10.1002/jmr.2527; Masuda K, 2006, FEBS J, V273, P2184, DOI 10.1111/j.1742-4658.2006.05232.x; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; Nakanishi T, 2008, PROTEIN SCI, V17, P261, DOI 10.1110/ps.073156708; Ovchinnikov V, 2018, ELIFE, V7, DOI 10.7554/eLife.33038; Paci E, 2001, J MOL BIOL, V314, P589, DOI 10.1006/jmbi.2001.5103; Schmidt AG, 2013, P NATL ACAD SCI USA, V110, P264, DOI 10.1073/pnas.1218256109; Schrodinger L., 2015, PYMOL MOL GRAPHICS S, DOI DOI 10.1007/S13398-014-0173-7.2; Sheng ZZ, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00537; SIMON T, 1992, PROTEIN ENG, V5, P229, DOI 10.1093/protein/5.3.229; Singh A, 2016, CAN J CHEM, V94, P927, DOI 10.1139/cjc-2015-0606; Stanfield RL, 2006, J MOL BIOL, V357, P1566, DOI 10.1016/j.jmb.2006.01.023; Victora GD, 2012, ANNU REV IMMUNOL, V30, P429, DOI 10.1146/annurev-immunol-020711-075032; Wang F, 2013, P NATL ACAD SCI USA, V110, P4261, DOI 10.1073/pnas.1301810110; Wood G S, 1990, Prog AIDS Pathol, V2, P25; WU TT, 1970, J EXP MED, V132, P211, DOI 10.1084/jem.132.2.211; Xu HF, 2015, PROTEINS, V83, P771, DOI 10.1002/prot.24745; Yin J, 2003, J MOL BIOL, V330, P651, DOI 10.1016/S0022-2836(03)00631-4; Zhang YF, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.717496; Zhou JO, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01529	48	0	0	2	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 3	2022	12								811632	10.3389/fimmu.2021.811632	http://dx.doi.org/10.3389/fimmu.2021.811632			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YS6QX	35046963	Green Published, gold			2022-12-18	WOS:000750799900001
J	Takeichi, T; Lee, JYW; Okuno, Y; Miyasaka, Y; Murase, Y; Yoshikawa, T; Tanahashi, K; Nishida, E; Okamoto, T; Ito, K; Muro, Y; Sugiura, K; Ohno, T; McGrath, JA; Akiyama, M				Takeichi, Takuya; Lee, John Y. W.; Okuno, Yusuke; Miyasaka, Yuki; Murase, Yuya; Yoshikawa, Takenori; Tanahashi, Kana; Nishida, Emi; Okamoto, Tatsuya; Ito, Komei; Muro, Yoshinao; Sugiura, Kazumitsu; Ohno, Tamio; McGrath, John A.; Akiyama, Masashi			Autoinflammatory Keratinization Disease With Hepatitis and Autism Reveals Roles for JAK1 Kinase Hyperactivity in Autoinflammation	FRONTIERS IN IMMUNOLOGY			English	Article						inflammation; brain; liver; skin; STAT	TYROSINE KINASE; MUTATIONS; COMT; TBX1; ASSOCIATION; PATHWAY; GENES; MODEL; PRODH; GAIN	Heterozygous mutations in JAK1 which result in JAK-STAT hyperactivity have been implicated in an autosomal dominant disorder that features multi-organ immune dysregulation. This study identifies another previously unreported heterozygous missense JAK1 mutation, H596D, in an individual with a unique autoinflammatory keratinization disease associated with early-onset liver dysfunction and autism. Using CRISPR-Cas9 gene targeting, we generated mice with an identical Jak1 knock-in missense mutation (Jak1(H595D/+;I596I/+;Y597Y/+) mice) that recapitulated key aspects of the human phenotype. RNA sequencing of samples isolated from the Jak1(H595D/+;I596I/+;Y597Y/+) mice revealed the upregulation of genes associated with the hyperactivation of tyrosine kinases and NF-kappa B signaling. Interestingly, there was a strong correlation between genes downregulated in Jak1(H595D/+;I596I/+;Y597Y/+) mice and those downregulated in the brain of model mice with 22q11.2 deletion syndrome that showed cognitive and behavioral deficits, such as autism spectrum disorders. Our findings expand the phenotypic spectrum of JAK1-associated disease and underscore how JAK1 dysfunction contributes to this autoinflammatory disorder.	[Takeichi, Takuya; Murase, Yuya; Yoshikawa, Takenori; Tanahashi, Kana; Muro, Yoshinao; Akiyama, Masashi] Nagoya Univ, Dept Dermatol, Grad Sch Med, Nagoya, Aichi, Japan; [Lee, John Y. W.; McGrath, John A.] Kings Coll London, St Johns Inst Dermatol, London, England; [Okuno, Yusuke] Nagoya Univ Hosp, Med Genom Ctr, Nagoya, Aichi, Japan; [Okuno, Yusuke] Nagoya Univ, Dept Pediat, Grad Sch Med, Nagoya, Aichi, Japan; [Okuno, Yusuke] Nagoya City Univ, Dept Virol, Grad Sch Med Sci, Nagoya, Aichi, Japan; [Miyasaka, Yuki; Ohno, Tamio] Nagoya Univ, Div Expt Anim, Grad Sch Med, Nagoya, Aichi, Japan; [Nishida, Emi] Nagoya City Univ, Dept Geriatr & Environm Dermatol, Grad Sch Med Sci, Nagoya, Aichi, Japan; [Okamoto, Tatsuya] Kyoto Univ, Grad Sch Med, Dept Surg, Div Pediat Surg, Kyoto, Japan; [Ito, Komei] Aichi Childrens Hlth & Med Ctr, Dept Allergol, Obu, Japan; [Sugiura, Kazumitsu] Fujita Hlth Univ, Dept Dermatol, Sch Med, Toyoake, Aichi, Japan	Nagoya University; University of London; King's College London; Nagoya University; Nagoya University; Nagoya City University; Nagoya University; Nagoya City University; Kyoto University; Fujita Health University	Akiyama, M (corresponding author), Nagoya Univ, Dept Dermatol, Grad Sch Med, Nagoya, Aichi, Japan.	makiyama@med.nagoya-u.ac.jp	McGrath, John/D-6824-2012	McGrath, John/0000-0002-3708-9964				Ahmad SF, 2017, PROG NEURO-PSYCHOPH, V79, P472, DOI 10.1016/j.pnpbp.2017.08.002; Akiyama M, 2017, J ALLERGY CLIN IMMUN, V140, P1545, DOI 10.1016/j.jaci.2017.05.019; Armando M, 2012, CNS NEUROL DISORD-DR, V11, P273, DOI 10.2174/187152712800672526; Bassett AS, 2011, J PEDIATR-US, V159, P332, DOI 10.1016/j.jpeds.2011.02.039; Baxter EJ, 2005, LANCET, V365, P1054, DOI 10.1016/S0140-6736(05)71142-9; Carmel M, 2014, J PSYCHIATR RES, V56, P28, DOI 10.1016/j.jpsychires.2014.04.019; Del Bel KL, 2017, J ALLERGY CLIN IMMUN, V139, P2016, DOI 10.1016/j.jaci.2016.12.957; Eletto D, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13992; Feng JX, 2012, BIOINFORMATICS, V28, P2782, DOI 10.1093/bioinformatics/bts515; Ferreira S, 2020, AM J CLIN DERMATOL, V21, P783, DOI 10.1007/s40257-020-00548-6; Flex E, 2008, J EXP MED, V205, P751, DOI 10.1084/jem.20072182; Franconi CP, 2016, AM J MED GENET B, V171, P1112, DOI 10.1002/ajmg.b.32492; Gruber CN, 2020, IMMUNITY, V53, P672, DOI 10.1016/j.immuni.2020.07.006; Guris DL, 2006, DEV CELL, V10, P81, DOI 10.1016/j.devcel.2005.12.002; Guris DL, 2001, NAT GENET, V27, P293, DOI 10.1038/85855; Haeussler M, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1012-2; Jeong EG, 2008, CLIN CANCER RES, V14, P3716, DOI 10.1158/1078-0432.CCR-07-4839; Karczewski KJ, 2020, NATURE, V581, P434, DOI 10.1038/s41586-020-2308-7; Li H, 2010, BIOINFORMATICS, V26, P589, DOI 10.1093/bioinformatics/btp698; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Marshall CR, 2008, AM J HUM GENET, V82, P477, DOI 10.1016/j.ajhg.2007.12.009; McDonald-McGinn DM, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.71; Mekori-Domachevsky E, 2017, J CLIN PSYCHIAT, V78, pE1219, DOI 10.4088/JCP.16m11207; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Morrow BE, 2018, AM J MED GENET A, V176, P2070, DOI 10.1002/ajmg.a.40504; O'Shea JJ, 2015, ANNU REV MED, V66, P311, DOI 10.1146/annurev-med-051113-024537; Radoeva PD, 2014, PSYCHIAT GENET, V24, P269, DOI 10.1097/YPG.0000000000000062; Raivola J, 2020, CANCERS, V12, DOI 10.3390/cancers12010078; Sabrautzki S, 2013, AM J PATHOL, V183, P352, DOI 10.1016/j.ajpath.2013.04.027; Saghazadeh A, 2019, J PSYCHIATR RES, V115, P90, DOI 10.1016/j.jpsychires.2019.05.019; Saharinen P, 2000, MOL CELL BIOL, V20, P3387, DOI 10.1128/MCB.20.10.3387-3395.2000; Schindler C, 2007, J BIOL CHEM, V282, P20059, DOI 10.1074/jbc.R700016200; Schwarz JM, 2014, NAT METHODS, V11, P361, DOI 10.1038/nmeth.2890; Stark KL, 2008, NAT GENET, V40, P751, DOI 10.1038/ng.138; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Takeichi T, 2020, J CLIN INVEST, V130, P890, DOI 10.1172/JCI130675; Teixeira M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18826-5; Wei HG, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-52; Xiang ZF, 2008, BLOOD, V111, P4809, DOI 10.1182/blood-2007-05-090308; Yagi H, 2003, LANCET, V362, P1366, DOI 10.1016/S0140-6736(03)14632-6; Yasuda T, 2016, J CLIN INVEST, V126, P2064, DOI 10.1172/JCI82887; Zweier C, 2007, AM J HUM GENET, V80, P510, DOI 10.1086/511993	42	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 3	2022	12								737747	10.3389/fimmu.2021.737747	http://dx.doi.org/10.3389/fimmu.2021.737747			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology	YK3WA	35046931	Green Published, gold			2022-12-18	WOS:000745146200001
J	Zhang, YL; Liu, QF; Cui, M; Wang, MY; Hua, SR; Gao, JY; Liao, Q				Zhang, Yalu; Liu, Qiaofei; Cui, Ming; Wang, Mengyi; Hua, Surong; Gao, Junyi; Liao, Quan			Comprehensive Analysis of Expression, Prognostic Value, and Immune Infiltration for Ubiquitination-Related FBXOs in Pancreatic Ductal Adenocarcinoma	FRONTIERS IN IMMUNOLOGY			English	Article						FBXOs; pancreatic ductal adenocarcinoma; prognostic value; immune infiltration; bioinformatics analysis	CANCER PROGRESSION; TUMOR-SUPPRESSOR; GENE-EXPRESSION; TARGET GENE; WEB SERVER; TRANSCRIPTION; DEGRADATION; TUMORIGENESIS; ACTIVATION; CARCINOMA	Pancreatic ductal adenocarcinoma (PDAC) is one of the most refractory human malignancies. F-box only proteins (FBXO) are the core components of SKP1-cullin 1-F-box E3 ubiquitin ligase, which have been reported to play crucial roles in tumor initiation and progression via ubiquitination-mediated proteasomal degradation. However, the clinical implications and biological functions of FBXOs in PDAC have not been fully clarified. Herein we perform a comprehensive analysis for the clinical values and functional roles of FBXOs in PDAC using different public databases. We found that FBXO1 (CCNF), FBXO20 (LMO7), FBXO22, FBXO28, FBXO32, and FBXO45 (designated six-FBXOs) were robustly upregulated in PDAC tissues, which predicted an adverse prognosis of PDAC patients. There was a significant correlation between the expression levels of six-FBXOs and the clinicopathological features in PDAC. The transcriptional levels of six-FBXOs were subjected to the influence of promoter methylation levels. There were more than 40% genetic alterations and mutations of six-FBXOs, which affected the clinical outcome of PDAC patients. Furthermore, the expression of six-FBXOs was associated with immune infiltrations and activated status, including B cells, CD8(+) T cells, CD4(+) T cells, NK cells, macrophages, and dendritic cells. The functional prediction revealed that the six-FBXOs were involved in ubiquitination-related pathways and other vital signaling pathways, such as p53, PI3K/Akt, and Hippo pathway. Therefore, six-FBXOs are the promising prognostic biomarkers or potential targets for PDAC diagnosis and treatment.	[Zhang, Yalu; Liu, Qiaofei; Cui, Ming; Wang, Mengyi; Hua, Surong; Gao, Junyi; Liao, Quan] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, State Key Lab Complex Severe & Rare Dis, Dept Gen Surg, Beijing, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Peking Union Medical College Hospital	Liao, Q (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, State Key Lab Complex Severe & Rare Dis, Dept Gen Surg, Beijing, Peoples R China.	liaoq@pumch.cn		Liu, Qiao-fei/0000-0001-7148-2850				Aguirre-Gamboa R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074250; Cepeda D, 2013, EMBO MOL MED, V5, P1067, DOI 10.1002/emmm.201202341; Chandrashekar DS, 2017, NEOPLASIA, V19, P649, DOI 10.1016/j.neo.2017.05.002; Chang SC, 2021, CANCERS, V13, DOI 10.3390/cancers13122873; Chen X, 2014, CELL DEATH DIFFER, V21, P1535, DOI 10.1038/cdd.2014.92; Cheng JT, 2020, CELL DEATH DISCOV, V6, DOI 10.1038/s41420-020-00303-0; Chou JL, 2010, LAB INVEST, V90, P414, DOI 10.1038/labinvest.2009.138; Ciechanover A, 2017, BEST PRACT RES CL HA, V30, P341, DOI 10.1016/j.beha.2017.09.001; D'Angiolella V, 2012, CELL, V149, P1023, DOI 10.1016/j.cell.2012.03.043; Fagerholm R, 2017, ONCOTARGET, V8, P18381, DOI 10.18632/oncotarget.15110; Fu J, 2013, CANCER SCI, V104, P508, DOI 10.1111/cas.12100; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Ge MK, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15578-1; Guo F, 2019, INT J BIOL SCI, V15, P647, DOI 10.7150/ijbs.31293; Guo W, 2014, CANCER-AM CANCER SOC, V120, P2412, DOI 10.1002/cncr.28764; Hashimoto A, 2021, CELL COMMUN SIGNAL, V19, DOI 10.1186/s12964-021-00733-y; Hu QD, 2011, MOL CELL BIOL, V31, P3223, DOI 10.1128/MCB.01365-10; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Hussain SP, 2016, INT J BIOL SCI, V12, P270, DOI 10.7150/ijbs.14950; Kamisawa T, 2016, LANCET, V388, P73, DOI 10.1016/S0140-6736(16)00141-0; Klimaszewska-Wisniewska A, 2021, CANCERS, V13, DOI 10.3390/cancers13040859; Kogure N, 2017, ANTICANCER RES, V37, P191, DOI 10.21873/anticanres.11305; Lee A, 2018, CELL MOL LIFE SCI, V75, P335, DOI 10.1007/s00018-017-2632-8; Leonhardt C.S., 2020, J PANCREATOLOGY, V3, P1, DOI 10.1097/JP9.0000000000000040; Li TW, 2017, CANCER RES, V77, pE108, DOI 10.1158/0008-5472.CAN-17-0307; Li YW, 2020, EXP CELL RES, V395, DOI 10.1016/j.yexcr.2020.112212; Lin M, 2020, CELL DEATH DISCOV, V6, DOI 10.1038/s41420-020-0291-2; Liu XJ, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.647387; Liu YQ, 2021, CANCER CELL INT, V21, DOI 10.1186/s12935-021-01833-y; Liu YS, 2021, BIOINFORMATICS, V37, P4014, DOI 10.1093/bioinformatics/btab443; Nagy A, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-84787-5; Nakamura H, 2011, EXP THER MED, V2, P1053, DOI 10.3892/etm.2011.329; Neoptolemos JP, 2018, NAT REV GASTRO HEPAT, V15, P332, DOI 10.1038/s41575-018-0005-x; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Ru BB, 2019, BIOINFORMATICS, V35, P4200, DOI 10.1093/bioinformatics/btz210; Schofield HK, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.97422; Skaar JR, 2013, NAT REV MOL CELL BIO, V14, P369, DOI 10.1038/nrm3582; Sun R, 2018, CANCER RES, V78, P5274, DOI 10.1158/0008-5472.CAN-17-3647; Tanaka-Okamoto M, 2009, CANCER SCI, V100, P608, DOI 10.1111/j.1349-7006.2009.01091.x; Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247; Tekcham DS, 2020, THERANOSTICS, V10, P4150, DOI 10.7150/thno.42735; Tzeng YW, 2018, INT J BIOCHEM CELL B, V94, P22, DOI 10.1016/j.biocel.2017.11.006; Vasaikar SV, 2018, NUCLEIC ACIDS RES, V46, pD956, DOI 10.1093/nar/gkx1090; Wang JL, 2021, MOL THER-NUCL ACIDS, V24, P310, DOI 10.1016/j.omtn.2021.02.034; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Xu M, 2015, ONCOTARGET, V6, P979, DOI 10.18632/oncotarget.2825; Yang Y, 2021, J PANCREATOL, V4, P49; Zhang L, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1058-6; Zhang YL, 2021, CANCER CELL INT, V21, DOI 10.1186/s12935-021-02037-0; Zhang YL, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.705260; Zhang YL, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-01727-3; Zheng QQ, 2021, BIOSCIENCE REP, V41, DOI 10.1042/BSR20204370; Zhou H, 2017, ONCOGENE, V36, P3312, DOI 10.1038/onc.2016.479	53	0	0	3	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 3	2022	12								774435	10.3389/fimmu.2021.774435	http://dx.doi.org/10.3389/fimmu.2021.774435			19	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YK3XZ	35046938	gold, Green Published			2022-12-18	WOS:000745151300001
J	Lei, OHP; Zhang, L; Wang, ZY; Peltier, R; Xie, YS; Chen, GC; Lin, SQ; Miao, K; Deng, CX; Sun, HY				Lei, Josh Haipeng; Zhang, Lei; Wang, Zhenyi; Peltier, Raoul; Xie, Yusheng; Chen, Ganchao; Lin, Shiqi; Miao, Kai; Deng, Chu-Xia; Sun, Hongyan			FGFR2-BRD4 Axis Regulates Transcriptional Networks of Histone 3 Modification and Synergy Between Its Inhibitors and PD-1/PD-L1 in a TNBC Mouse Model	FRONTIERS IN IMMUNOLOGY			English	Article						epigenetic; BRD4; FGFR2; TNBC; posttranslational modifications; immunotherapy	SYNTHETIC LETHAL; EPIGENOMICS; EPIGENETICS; RESISTANCE; CHROMATIN; CANCER; ACETYLATION; PATHWAY	Epigenetic reprogramming is an independent mode of gene expression that often involves changes in the transcription and chromatin structure due to tumor initiation and development. In this study, we developed a specifically modified peptide array and searched for a recognized epigenetic reader. Our results demonstrated that BRD4 is not only an acetylation reader but of propionylation as well. We also studied the quantitative binding affinities between modified peptides and epigenetic regulators by isothermal titration calorimetry (ITC). Furthermore, we introduced the Fgfr2-S252W transgenic mouse model to confirm that this acetylation is associated with the activation of c-Myc and drives tumor formation. Targeted disruption of BRD4 in Fgfr2-S252W mouse tumor cells also confirmed that BRD4 is a key regulator of histone 3 acetylation. Finally, we developed a tumor slice culture system and demonstrated the synergy between immune checkpoint blockade and targeted therapy in triple-negative breast cancer (TNBC). These data extend our understanding of epigenetic reprogramming and epigenetics-based therapies.	[Lei, Josh Haipeng; Zhang, Lei; Lin, Shiqi; Miao, Kai; Deng, Chu-Xia] Univ Macau, Fac Hlth Sci, Canc Ctr, Taipa, Macao, Peoples R China; [Lei, Josh Haipeng; Lin, Shiqi; Miao, Kai; Deng, Chu-Xia] Univ Macau, Minist Educ MOE, Frontier Sci Ctr Precis Oncol, Taipa, Macao, Peoples R China; [Lei, Josh Haipeng; Peltier, Raoul; Xie, Yusheng; Chen, Ganchao; Sun, Hongyan] City Univ Hong Kong, Dept Chem, Kowloon, Hong Kong, Peoples R China; [Zhang, Lei] Southwest Med Univ, Dept Vasc Surg, Affiliated Hosp, Luzhou, Peoples R China; [Wang, Zhenyi] Univ Sci & Technol China, Hefei Natl Lab Phys Sci Microscale, Hefei, Peoples R China; [Wang, Zhenyi] Univ Sci & Technol China, Sch Life Sci, Hefei, Peoples R China; [Xie, Yusheng] Shandong Univ, Sch Basic Med Sci, Dept Pharmacol, Jinan, Peoples R China; [Sun, Hongyan] City Univ Hong Kong, Biotech & Hlth Ctr, Shenzhen Res Inst, Key Lab Biochip Technol, Shenzhen, Peoples R China	University of Macau; University of Macau; City University of Hong Kong; Southwest Medical University; Chinese Academy of Sciences; University of Science & Technology of China, CAS; Chinese Academy of Sciences; University of Science & Technology of China, CAS; Shandong University; City University of Hong Kong	Deng, CX (corresponding author), Univ Macau, Fac Hlth Sci, Canc Ctr, Taipa, Macao, Peoples R China.; Deng, CX (corresponding author), Univ Macau, Minist Educ MOE, Frontier Sci Ctr Precis Oncol, Taipa, Macao, Peoples R China.; Sun, HY (corresponding author), City Univ Hong Kong, Dept Chem, Kowloon, Hong Kong, Peoples R China.; Sun, HY (corresponding author), City Univ Hong Kong, Biotech & Hlth Ctr, Shenzhen Res Inst, Key Lab Biochip Technol, Shenzhen, Peoples R China.	cxdeng@um.edu.mo; hongysun@cityu.edu.hk		XIE, Yusheng/0000-0002-8581-4614; Lei, Josh/0000-0002-2058-8054	Science Technology and Innovation Committee of Shenzhen Municipality [JCYJ20180507181654823]; National Natural Science Foundation of China [32122003, 21572190]; Science and Technology Development Fund, Macau SAR [FDCT-0048/2019/A1]; Natural Science Foundation of China (NSFC) [82030094]	Science Technology and Innovation Committee of Shenzhen Municipality; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Development Fund, Macau SAR; Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC))	This work was supported by the following grants: the Science Technology and Innovation Committee of Shenzhen Municipality (JCYJ20180507181654823), the National Natural Science Foundation of China (32122003, 21572190), the Science and Technology Development Fund, Macau SAR (no. FDCT-0048/2019/A1), and the Natural Science Foundation of China (NSFC) (82030094).	Alhamwe BA, 2018, ALLERGY ASTHMA CL IM, V14, DOI 10.1186/s13223-018-0259-4; Bannister AJ, 2011, CELL RES, V21, P381, DOI 10.1038/cr.2011.22; Dancy BM, 2015, CHEM REV, V115, P2419, DOI 10.1021/cr500452k; Dawson MA, 2012, CELL, V150, P12, DOI 10.1016/j.cell.2012.06.013; Devaiah BN, 2017, NAT STRUCT MOL BIOL, V24, P194, DOI 10.1038/nsmb0217-194c; Fernandez-Barrena MG, 2020, JHEP REP, V2, DOI 10.1016/j.jhepr.2020.100167; Ferri E, 2016, BIOCHEM PHARMACOL, V106, P1, DOI 10.1016/j.bcp.2015.12.005; Filippakopoulos P, 2014, NAT REV DRUG DISCOV, V13, P339, DOI 10.1038/nrd4286; Filippakopoulos P, 2012, FEBS LETT, V586, P2692, DOI 10.1016/j.febslet.2012.04.045; Filippakopoulos P, 2012, CELL, V149, P214, DOI 10.1016/j.cell.2012.02.013; Flynn EM, 2015, STRUCTURE, V23, P1801, DOI 10.1016/j.str.2015.08.004; Fu JJ, 2021, ONCOGENE, V40, P465, DOI 10.1038/s41388-020-01556-w; Graff J, 2013, NAT REV NEUROSCI, V14, P97, DOI 10.1038/nrn3427; Hanahan D, 2022, CANCER DISCOV, V12, P31, DOI 10.1158/2159-8290.CD-21-1059; Henshall DC, 2020, EUR J PAEDIATR NEURO, V24, P30, DOI 10.1016/j.ejpn.2019.06.002; Huang H, 2014, CELL, V159, P458, DOI 10.1016/j.cell.2014.09.037; Jing X, 2020, EXP CELL RES, V392, DOI 10.1016/j.yexcr.2020.112034; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Kaelin WG, 2013, CELL, V153, P56, DOI 10.1016/j.cell.2013.03.004; Lei JH, 2021, ADV SCI, V8, DOI 10.1002/advs.202100974; Liu R, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-02998-6; Lo PK, 2008, PHARMACOGENOMICS, V9, P1879, DOI 10.2217/14622416.9.12.1879; Morgan MAJ, 2020, NAT GENET, V52, P1271, DOI 10.1038/s41588-020-00736-4; Nussinov R, 2017, TRENDS PHARMACOL SCI, V38, P427, DOI 10.1016/j.tips.2017.02.001; O'Donnell KJ, 2020, ANNU REV CLIN PSYCHO, V16, P327, DOI 10.1146/annurev-clinpsy-050718-095530; Shu SK, 2020, MOL CELL, V78, P1096, DOI 10.1016/j.molcel.2020.04.027; Sun CY, 2018, CANCER CELL, V33, P401, DOI 10.1016/j.ccell.2018.01.019; Toyota M, 2009, CANCER SCI, V100, P787, DOI 10.1111/j.1349-7006.2009.01095.x; Vaughan RM, 2021, TRENDS BIOCHEM SCI, V46, P258, DOI 10.1016/j.tibs.2020.11.005; Vollmuth F, 2010, ANGEW CHEM INT EDIT, V49, P6768, DOI 10.1002/anie.201002724; Zhang BY, 2018, ONCOGENE, V37, P6341, DOI 10.1038/s41388-018-0408-8; Zhang CJ, 2013, ANGEW CHEM INT EDIT, V52, P14060, DOI 10.1002/anie.201307803; Zhang K, 2009, J PROTEOME RES, V8, P900, DOI 10.1021/pr8005155; Zhang Y, 2020, CELL ONCOL, V43, P1049, DOI 10.1007/s13402-020-00537-1	34	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.		2022	13								861221	10.3389/fimmu.2022.861221	http://dx.doi.org/10.3389/fimmu.2022.861221			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6G8MB	35547739	gold, Green Published			2022-12-18	WOS:000885004600001
J	Li, Q; Sun, LD; Liu, L; Ran, QS; Du, XK; Yang, Q; Wang, YJ; Li, YJ; Chen, Y; Weng, XG; Cai, WY; Zhu, XX				Li, Qi; Sun, Lidong; Liu, Li; Ran, Qingsen; Du, Xinke; Yang, Qing; Wang, Yajie; Li, Yujie; Chen, Ying; Weng, Xiaogang; Cai, Weiyan; Zhu, Xiaoxin			Chamaejasmenin B, an Inhibitor for Metastatic Outgrowth, Reversed M2-Dominant Macrophage Polarization in Breast Tumor Microenvironment	FRONTIERS IN IMMUNOLOGY			English	Article						Chamaejasmin B; breast cancer; macrophage polarization; metastatic outgrowth; mTOR	EPITHELIAL-MESENCHYMAL TRANSITION; CANCER; LUNG; STRATEGIES; SURVIVAL; DORMANCY; COMPLEX; CELLS	Metastasis is a multistep process that depends on the interactions between tumor cells and their microenvironment. Macrophages in the tumor microenvironment show high polarization plasticity and have a paradoxical role in cancer progression. Hijacked by tumor-promoting signals, the polarization status of macrophages was pathologically disturbed and believed to be the decisive mechanism forcing the progression of metastasis. In this study, we explored the immunological activity of Chamaejasmin B (ICJ), a previously proved inhibitor for metastasis, in macrophages from metastatic microenvironment. When intravenously injected of 4T1 cells in mice, ICJ significantly inhibited its metastatic outgrowth. Taking tumor cell and macrophage as a functional integrity, an adoptive transfer model was established in vitro to exclude the direct effect of ICJ on tumor. The findings suggest a dual influence of ICJ on both tumors and macrophages, as indicated by the rebalance of macrophage polarization and suppression of clonogenic potential in tumor cells. Mechanistically, ICJ redirected M2-dominant polarization of tumor-associated macrophage in an IL-4-mTOR-dependent manner. Collectively, our study revealed that ICJ rebalanced macrophage polarization in malignant microenvironment and showed promising effect in suppressing metastatic outgrowth in breast cancer model.	[Li, Qi; Sun, Lidong; Liu, Li; Ran, Qingsen; Du, Xinke; Yang, Qing; Wang, Yajie; Li, Yujie; Chen, Ying; Weng, Xiaogang; Cai, Weiyan; Zhu, Xiaoxin] China Acad Chinese Med Sci, Inst Chinese Mat Med, Beijing, Peoples R China	China Academy of Chinese Medical Sciences; Institute of Chinese Materia Medica, CACMS	Zhu, XX (corresponding author), China Acad Chinese Med Sci, Inst Chinese Mat Med, Beijing, Peoples R China.	zhuxx@icmm.ac.cn	Li, YuJie/HGT-8657-2022		China Academy of Chinese Medical Sciences Innovation Fund [CI2021A05105]; Special training program for outstanding young scientific and technological talents of China Academy of Chinese Medical Science [ZZ13-YQ-044]; National Science and Technology Major Projects for Major New Drugs Innovation and Development [2017ZX09101002-002-002]; Belt and Road" Cooperation Project of China Academy of Traditional Chinese Medicine [GH201914]; National Science Foundation for Young Scientists of China [81303272]	China Academy of Chinese Medical Sciences Innovation Fund; Special training program for outstanding young scientific and technological talents of China Academy of Chinese Medical Science; National Science and Technology Major Projects for Major New Drugs Innovation and Development; Belt and Road" Cooperation Project of China Academy of Traditional Chinese Medicine; National Science Foundation for Young Scientists of China	The present study was supported by the China Academy of Chinese Medical Sciences Innovation Fund (grant numbers: CI2021A05105); Special training program for outstanding young scientific and technological talents of China Academy of Chinese Medical Science (grant numbers: ZZ13-YQ-044); The National Science and Technology Major Projects for Major New Drugs Innovation and Development (grant numbers: 2017ZX09101002-002-002); "the Belt and Road" Cooperation Project of China Academy of Traditional Chinese Medicine (grant numbers: GH201914); The National Science Foundation for Young Scientists of China (grant numbers: 81303272).	Biswas SK, 2010, NAT IMMUNOL, V11, P889, DOI 10.1038/ni.1937; Bragado Paloma, 2012, Recent Results Cancer Res, V195, P25, DOI 10.1007/978-3-642-28160-0_3; Bravo-Cordero JJ, 2012, CURR OPIN CELL BIOL, V24, P277, DOI 10.1016/j.ceb.2011.12.004; Brenot A, 2018, ONCOGENESIS, V7, DOI 10.1038/s41389-018-0042-x; Cameron MD, 2000, CANCER RES, V60, P2541; Cao M, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0817-4; Demicheli R, 2019, BREAST, V45, P61, DOI 10.1016/j.breast.2019.03.001; Garon EB, 2015, NEW ENGL J MED, V372, P2018, DOI 10.1056/NEJMoa1501824; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hill BS, 2020, SEMIN CANCER BIOL, V60, P202, DOI 10.1016/j.semcancer.2019.07.028; Lee CC, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06268-0; Li HY, 2012, BREAST CANCER RES TR, V134, P1057, DOI 10.1007/s10549-012-2036-2; Li Q, 2018, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00963; Li Q, 2016, ONCOTARGET, V7, P48180, DOI 10.18632/oncotarget.10193; Lou YY, 2016, CLIN CANCER RES, V22, P3630, DOI 10.1158/1078-0432.CCR-15-1434; Luzzi KJ, 1998, AM J PATHOL, V153, P865, DOI 10.1016/S0002-9440(10)65628-3; Ma JL, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-112; Mantovani A, 2017, NAT REV CLIN ONCOL, V14, P399, DOI 10.1038/nrclinonc.2016.217; Ngambenjawong C, 2017, ADV DRUG DELIVER REV, V114, P206, DOI 10.1016/j.addr.2017.04.010; Noy R, 2014, IMMUNITY, V41, P49, DOI 10.1016/j.immuni.2014.06.010; Obeid E, 2013, INT J ONCOL, V43, P5, DOI 10.3892/ijo.2013.1938; Ong SM, 2012, EUR J IMMUNOL, V42, P89, DOI 10.1002/eji.201141825; Peart O, 2017, RADIOL TECHNOL, V88, p519M; Schmall A, 2015, AM J RESP CRIT CARE, V191, P437, DOI 10.1164/rccm.201406-1137OC; Serrano I, 2013, ONCOGENE, V32, P50, DOI 10.1038/onc.2012.30; Shapouri-Moghaddam A, 2018, J CELL PHYSIOL, V233, P6425, DOI 10.1002/jcp.26429; Steelman LS, 2016, BRIT J CLIN PHARMACO, V82, P1189, DOI 10.1111/bcp.12958; Tang XQ, 2013, IMMUNOLOGY, V138, P93, DOI 10.1111/imm.12023; Xu LP, 2021, EUR J CELL BIOL, V100, DOI 10.1016/j.ejcb.2021.151153; Zhang F, 2010, CANCER RES, V70, P9360, DOI 10.1158/0008-5472.CAN-10-0207; Zhang MY, 2014, J OVARIAN RES, V7, DOI 10.1186/1757-2215-7-19; Zheng AY, 2019, ONCOL REP, V41, P2833, DOI 10.3892/or.2019.7053	32	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 28	2021	12								774230	10.3389/fimmu.2021.774230	http://dx.doi.org/10.3389/fimmu.2021.774230			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YS3LU	35027915	Green Published, gold			2022-12-18	WOS:000750582600001
J	Li, XF; Zhao, J; Naini, SM; Sabiu, G; Tullius, SG; Shin, SR; Bromberg, JS; Fiorina, P; Tsokos, GC; Abdi, R; Kasinath, V				Li, Xiaofei; Zhao, Jing; Naini, Said Movahedi; Sabiu, Gianmarco; Tullius, Stefan G.; Shin, Su Ryon; Bromberg, Jonathan S.; Fiorina, Paolo; Tsokos, George C.; Abdi, Reza; Kasinath, Vivek			Kidney-Draining Lymph Node Fibrosis Following Unilateral Ureteral Obstruction	FRONTIERS IN IMMUNOLOGY			English	Article						unilateral ureteral obstruction (UUO); lymph node; fibroblastic reticular cell (FRC); renal immune homeostasis; kidney fibrosis; chronic kidney disease; acute kidney injury	FIBROBLASTIC RETICULAR CELLS; DENDRITIC CELLS; RELIEF	Although the primary organ has been the subject of intense investigation in the field of organ fibrosis over the past several decades, the presence of lymph node fibrosis due to persistent activation of the immune response in its partner organ remains largely unknown. Previously, we demonstrated that activation of the immune response following ischemia-reperfusion injury (IRI) and crescentic glomerulonephritis (CGN) in the kidney was associated with extracellular matrix (ECM) production by fibroblastic reticular cells (FRCs) of the kidney-draining lymph node (KLN). Here, we sought to determine whether FRCs in the KLN become similarly fibrogenic following unilateral ureteral obstruction (UUO) of the kidney. We subjected 6-8-week-old C57BL/6J mice to UUO for 2, 7, and 14 days. We examined the microarchitecture of the kidney and KLN by immunofluorescence staining at each timepoint, and we quantified immune cell populations in the KLN by flow cytometry. The contralateral kidney unaffected by UUO and its partner KLN were used as controls. We found through immunofluorescence staining that FRCs increased production of ECM fibers and remodeled the microarchitecture of the UUO KLN, contributing to fibrosis that mirrored the changes in the kidney. We also observed by flow cytometry that the populations of CD11b(+) antigen-presenting cells, CD11c(+) dendritic cells, and activated CD4(+) and CD8(+) T cells were significantly higher in the UUO KLN than the KLN draining the unaffected contralateral kidney. Expression of the TGF beta/TGF beta R signaling pathway was upregulated and colocalized with FRCs in the UUO KLNs, suggesting a possible mechanism behind the fibrosis. Both release of ureteral ligation at 2 days following UUO and depletion of FRCs at the time of injury onset halted the progression of fibrosis in both the kidney and the KLN. These findings for the first time highlight the association between fibrosis both in the kidney and the KLN during UUO, and they lay the groundwork for future studies that will investigate more deeply the mechanisms behind the connection between FRCs and KLN fibrosis.	[Li, Xiaofei; Zhao, Jing; Naini, Said Movahedi; Sabiu, Gianmarco; Tullius, Stefan G.; Fiorina, Paolo; Abdi, Reza; Kasinath, Vivek] Harvard Med Sch, Brigham & Womens Hosp, Transplantat Res Ctr, Boston, MA 02115 USA; [Li, Xiaofei] Minist Educ, Key Lab Combinatorial Biosynth & Drug Discovery, Wuhan, Peoples R China; [Li, Xiaofei] Wuhan Univ, Sch Pharmaceut Sci, Wuhan, Peoples R China; [Shin, Su Ryon] Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Div Engn Med, Cambridge, MA USA; [Bromberg, Jonathan S.] Univ Maryland, Sch Med, Dept Surg, Ctr Vasc & Inflammatory Dis, Baltimore, MD 21201 USA; [Bromberg, Jonathan S.] Univ Maryland, Sch Med, Dept Microbiol & Immunol, Ctr Vasc & Inflammatory Dis, Baltimore, MD 21201 USA; [Tsokos, George C.] Beth Israel Deaconess Med Ctr, Div Rheumatol, Boston, MA 02215 USA; [Tsokos, George C.] Beth Israel Deaconess Med Ctr, Dept Immunol, Boston, MA 02215 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Wuhan University; Harvard University; Brigham & Women's Hospital; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center	Abdi, R; Kasinath, V (corresponding author), Harvard Med Sch, Brigham & Womens Hosp, Transplantat Res Ctr, Boston, MA 02115 USA.	rabdi@rics.bwh.harvard.edu; vkasinath@bwh.harvard.edu	Shin, Su Ryon/GRO-3950-2022; Li, xiaofei/GXF-7187-2022; Sabiu, Gianmarco/AAC-4716-2021	Shin, Su Ryon/0000-0003-0864-6482; Sabiu, Gianmarco/0000-0002-9514-1652				Chevalier RL, 2006, NAT CLIN PRACT NEPHR, V2, P157, DOI 10.1038/ncpneph0098; Cochrane AL, 2005, J AM SOC NEPHROL, V16, P3623, DOI 10.1681/ASN.2004090771; Cremasco V, 2014, NAT IMMUNOL, V15, P973, DOI 10.1038/ni.2965; Dong XY, 2005, KIDNEY INT, V68, P1096, DOI 10.1111/j.1523-1755.2005.00502.x; Estes JD, 2013, IMMUNOL REV, V254, P65, DOI 10.1111/imr.12070; Girard JP, 2012, NAT REV IMMUNOL, V12, P762, DOI 10.1038/nri3298; Gregory JL, 2017, CELL REP, V18, P406, DOI 10.1016/j.celrep.2016.12.038; Ito K, 2004, AM J PHYSIOL-RENAL, V287, pF1283, DOI 10.1152/ajprenal.00441.2003; Kasinath V, 2019, KIDNEY INT, V95, P310, DOI 10.1016/j.kint.2018.08.040; Katakai T, 2004, J EXP MED, V200, P783, DOI 10.1084/jem.20040254; Knoblich K, 2018, PLOS BIOL, V16, DOI 10.1371/journal.pbio.2005046; Kurts C, 2020, NAT REV NEPHROL, V16, P391, DOI 10.1038/s41581-020-0272-y; Lu TT, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00047; Maarouf OH, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.120546; Malhotra D, 2012, NAT IMMUNOL, V13, P499, DOI 10.1038/ni.2262; Martinez-Klimova E, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9040141; Mempel TR, 2004, NATURE, V427, P154, DOI 10.1038/nature02238; Perez-Shibayama C, 2019, IMMUNOL REV, V289, P31, DOI 10.1111/imr.12748; Saxena V, 2019, IMMUNOL REV, V292, P9, DOI 10.1111/imr.12799; Schacker TW, 2006, CLIN VACCINE IMMUNOL, V13, P556, DOI 10.1128/CVI.13.5.556-560.2006; Snelgrove SL, 2017, TRANSPLANTATION, V101, P1013, DOI 10.1097/TP.0000000000001427; Song J, 2019, RENAL FAILURE, V41, P497, DOI 10.1080/0886022X.2019.1624263; Ucero AC, 2014, INT UROL NEPHROL, V46, P765, DOI 10.1007/s11255-013-0520-1; Zeng M, 2012, TRENDS IMMUNOL, V33, P306, DOI 10.1016/j.it.2012.04.002	24	0	0	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 27	2021	12								768412	10.3389/fimmu.2021.768412	http://dx.doi.org/10.3389/fimmu.2021.768412			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YE0MO	35024041	Green Published, gold			2022-12-18	WOS:000740826900001
J	Bennstein, SB; Weinhold, S; Degistirici, O; Oostendorp, RAJ; Raba, K; Koegler, G; Meisel, R; Walter, L; Uhrberg, M				Bennstein, Sabrina B.; Weinhold, Sandra; Degistirici, Oezer; Oostendorp, Robert A. J.; Raba, Katharina; Koegler, Gesine; Meisel, Roland; Walter, Lutz; Uhrberg, Markus			Efficient In Vitro Generation of IL-22-Secreting ILC3 From CD34(+) Hematopoietic Progenitors in a Human Mesenchymal Stem Cell Niche	FRONTIERS IN IMMUNOLOGY			English	Article						CD34 cells(+); mesenchymal stem cells; umbilical cord stem cells (UCSC); innate lymphoid cells (ILCs); ILC3; hematopoietic stem and progenitor cells; GMP-Good Manufacturing Practice	INNATE LYMPHOID-CELLS; NATURAL-KILLER-CELLS; T-CELL; INTESTINAL-MUCOSA; STROMAL CELLS; EXPRESSION; INDUCTION; IMMUNITY; LINES	Innate lymphoid cells (ILCs) and in particular ILC3s have been described to be vital for mucosal barrier functions and homeostasis within the gastrointestinal (GI) tract. Importantly, IL-22-secreting ILC3 have been implicated in the control of inflammatory bowel disease (IBD) and were shown to reduce the incidence of graft-versus-host disease (GvHD) as well as the risk of transplant rejection. Unfortunately, IL-22-secreting ILC3 are primarily located in mucosal tissues and are not found within the circulation, making access to them in humans challenging. On this account, there is a growing desire for clinically applicable protocols for in vitro generation of effector ILC3. Here, we present an approach for faithful generation of functionally competent human ILC3s from cord blood-derived CD34(+) hematopoietic progenitors on layers of human mesenchymal stem cells (MSCs) generated in good manufacturing practice (GMP) quality. The in vitro-generated ILC3s phenotypically, functionally, and transcriptionally resemble bona fide tissue ILC3 with high expression of the transcription factors (TF) Ror gamma T, AHR, and ID2, as well as the surface receptors CD117, CD56, and NKp44. Importantly, the majority of ILC3 belonged to the desired effector subtype with high IL-22 and low IL-17 production. The protocol thus combines the advantages of avoiding xenogeneic components, which were necessary in previous protocols, with a high propensity for generation of IL-22-producing ILC3. The present approach is suitable for the generation of large amounts of ILC3 in an all-human system, which could facilitate development of clinical strategies for ILC3-based therapy in inflammatory diseases and cancer.	[Bennstein, Sabrina B.; Weinhold, Sandra; Raba, Katharina; Koegler, Gesine; Uhrberg, Markus] Heinrich Heine Univ Dusseldorf, Med Fac, Inst Transplantat Diagnost & Cell Therapeut, Dusseldorf, Germany; [Degistirici, Oezer; Meisel, Roland] Heinrich Heine Univ Dusseldorf, Med Fac, Clin Pediat Oncol Hematol & Clin Immunol, Div Pediat Stem Cell Therapy,Ctr Children & Adole, Dusseldorf, Germany; [Oostendorp, Robert A. J.] Tech Univ Munich, Klinikum Rechts Isar, Sch Med, Dept Internal Med Hematol & Oncol 3,Lab Stem Cell, Munich, Germany; [Walter, Lutz] German Primate Ctr, Leibniz Inst Primate Res, Primate Genet Lab, Gottingen, Germany	Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf; Technical University of Munich; Deutsches Primatenzentrum (DPZ)	Uhrberg, M (corresponding author), Heinrich Heine Univ Dusseldorf, Med Fac, Inst Transplantat Diagnost & Cell Therapeut, Dusseldorf, Germany.	markus.uhrberg@med.uni-duesseldorf.de	Bennstein, Sabrina B./AFP-6522-2022; Oostendorp, Robert A.J./K-9841-2018; Walter, Lutz/I-2606-2017	Bennstein, Sabrina B./0000-0003-0477-2748; Oostendorp, Robert A.J./0000-0002-4947-0412; Walter, Lutz/0000-0001-9408-3131				Ahn D, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.00300; Ahn YO, 2015, EUR J IMMUNOL, V45, P2335, DOI 10.1002/eji.201445213; Ahn YO, 2013, BLOOD, V121, P2234, DOI 10.1182/blood-2012-07-440099; Bennstein SB, 2022, FEBS J, V289, P3967, DOI 10.1111/febs.15866; Bennstein SB, 2021, STEM CELL TRANSL MED, V10, P867, DOI 10.1002/sctm.20-0300; Bennstein SB, 2020, ELIFE, V9, DOI 10.7554/eLife.55232; Bennstein SB, 2019, CYTOM PART A, V95A, P427, DOI 10.1002/cyto.a.23741; Bernink JH, 2013, NAT IMMUNOL, V14, P221, DOI 10.1038/ni.2534; Cella M, 2010, P NATL ACAD SCI USA, V107, P10961, DOI 10.1073/pnas.1005641107; Cella M, 2009, NATURE, V457, P722, DOI 10.1038/nature07537; Chen LX, 2018, IMMUNITY, V49, P464, DOI 10.1016/j.immuni.2018.08.010; Cobb LM, 2021, JCI INSIGHT, V6, DOI 10.1172/jci.insight.146006; Crittenden S, 2018, IMMUNOL CELL BIOL, V96, P1049, DOI 10.1111/imcb.12167; Crome SQ, 2013, TRENDS IMMUNOL, V34, P342, DOI 10.1016/j.it.2013.03.002; Damele L, 2021, CANCERS, V13, DOI 10.3390/cancers13020319; Damele L, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02433; Eyerich S, 2010, TRENDS IMMUNOL, V31, P354, DOI 10.1016/j.it.2010.06.004; Ferrara JLM, 2009, LANCET, V373, P1550, DOI 10.1016/S0140-6736(09)60237-3; Forkel M, 2019, J CROHNS COLITIS, V13, P67, DOI 10.1093/ecco-jcc/jjy119; Frenette PS, 2013, ANNU REV IMMUNOL, V31, P285, DOI 10.1146/annurev-immunol-032712-095919; Galipeau J, 2018, CELL STEM CELL, V22, P824, DOI 10.1016/j.stem.2018.05.004; Gasteiger G, 2015, SCIENCE, V350, P981, DOI 10.1126/science.aac9593; Gentek R, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00334; Geremia A, 2011, J EXP MED, V208, P1127, DOI 10.1084/jem.20101712; Gomez-Massa E, 2020, TRANSPL INT, V33, P1016, DOI 10.1111/tri.13609; Gronke K, 2019, NATURE, V566, P249, DOI 10.1038/s41586-019-0899-7; Hanash AM, 2012, IMMUNITY, V37, P339, DOI 10.1016/j.immuni.2012.05.028; Hazenberg MD, 2019, BLOOD ADV, V3, P3650, DOI 10.1182/bloodadvances.2019000176; Heemskerk MHM, 1997, J EXP MED, V186, P1597, DOI 10.1084/jem.186.9.1597; Hernandez DC, 2021, IMMUNITY, V54, P2417, DOI 10.1016/j.immuni.2021.07.019; Hernandez PP, 2015, NAT IMMUNOL, V16, P698, DOI 10.1038/ni.3180; Hoorweg K, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00072; Ibiza S, 2016, NATURE, V535, P440, DOI 10.1038/nature18644; Jarade A, 2021, CURR OPIN MICROBIOL, V63, P83, DOI 10.1016/j.mib.2021.06.005; Kang J, 2021, AM J TRANSPLANT, V21, P787, DOI 10.1111/ajt.16163; Klose CSN, 2020, CELL RES, V30, P475, DOI 10.1038/s41422-020-0323-8; Lehmann FM, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15612-2; Li J, 2016, CELL IMMUNOL, V304, P63, DOI 10.1016/j.cellimm.2016.05.001; Lim AI, 2017, CELL, V168, P1086, DOI 10.1016/j.cell.2017.02.021; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Miller JS, 2019, ANNU REV CANC BIOL, V3, P77, DOI 10.1146/annurev-cancerbio-030518-055653; MILLER JS, 1994, BLOOD, V83, P2594; Miller JS, 2001, BLOOD, V98, P705, DOI 10.1182/blood.V98.3.705; Monier B., 2020, VIDGER CREATE RAPID; Montaldo E, 2014, IMMUNITY, V41, P988, DOI 10.1016/j.immuni.2014.11.010; Moretta F, 2016, EUR J IMMUNOL, V46, P1271, DOI 10.1002/eji.201546079; Munneke JM, 2014, BLOOD, V124, P812, DOI 10.1182/blood-2013-11-536888; Nalin AP, 2020, J IMMUNOL, V205, P2679, DOI 10.4049/jimmunol.2000434; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Oostendorp RAJ, 2002, J CELL SCI, V115, P2099; Oostendorp RAJ, 2002, BLOOD, V99, P1183, DOI 10.1182/blood.V99.4.1183; Pian YY, 2020, J IMMUNOL, V205, P853, DOI 10.4049/jimmunol.2000197; Schmitt TM, 2002, IMMUNITY, V17, P749, DOI 10.1016/S1074-7613(02)00474-0; Seidelin JB, 2021, CELL MOL GASTROENTER, V12, P1281, DOI 10.1016/j.jcmgh.2021.06.002; Seillet C, 2020, NAT IMMUNOL, V21, P168, DOI 10.1038/s41590-019-0567-y; Shatizadeh Malekshahi S, 2016, INFECT DIS-NOR, V5, DOI [10.5812/pedinfect.36953., DOI 10.1093/CID/CIAA344, DOI 10.1093/cid/ciaa344]; Sonnenberg GF, 2011, NAT IMMUNOL, V12, P383, DOI 10.1038/ni.2025; Takayama T, 2010, GASTROENTEROLOGY, V139, P882, DOI 10.1053/j.gastro.2010.05.040; Talbot J, 2020, NATURE, V579, P575, DOI 10.1038/s41586-020-2039-9; Tanaka S, 2020, AM J TRANSPLANT, V20, P1251, DOI 10.1111/ajt.15701; Tang Q, 2011, BLOOD, V117, P4052, DOI 10.1182/blood-2010-09-303081; van Hoeven V, 2018, J IMMUNOL, V201, P1165, DOI 10.4049/jimmunol.1700901; Vivier E, 2018, CELL, V174, P1054, DOI 10.1016/j.cell.2018.07.017; Wuchter P, 2015, CYTOTHERAPY, V17, P128, DOI 10.1016/j.jcyt.2014.04.002; Yokota Y, 1999, NATURE, V397, P702, DOI 10.1038/17812; Zhang LL, 2016, J LEUKOCYTE BIOL, V99, P279, DOI 10.1189/jlb.4RU0615-254RR; Zhao XY, 2018, BLOOD ADV, V2, P2452, DOI 10.1182/bloodadvances.2018019059; Zuniga-Pflucker JC, 2004, NAT REV IMMUNOL, V4, P67, DOI 10.1038/nri1257	68	0	0	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 24	2021	12								797432	10.3389/fimmu.2021.797432	http://dx.doi.org/10.3389/fimmu.2021.797432			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YH5QB	35003122	Green Published, gold			2022-12-18	WOS:000743221000001
J							Frontiers Prod Off	Immunoregulatory Effects of Myeloid-Derived Suppressor Cell Exosomes in Mouse Model of Autoimmune Alopecia Areata (vol 9, 1279, 2018)	FRONTIERS IN IMMUNOLOGY			English	Correction						myeloid-derived suppressor cells; exosomes; alopecia areata; therapy; regulatory T cells			[Frontiers Prod Off] Frontiers Media SA, Lausanne, Switzerland		Frontiers Media SA, Lausanne, Switzerland.								0	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 24	2021	12								832980	10.3389/fimmu.2021.832980	http://dx.doi.org/10.3389/fimmu.2021.832980			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YK4VV	35003146	gold, Green Published			2022-12-18	WOS:000745213300001
J	Giovannoni, G; Coyle, PK; Vermersch, P; Walker, B; Aldridge, J; Nolting, A; Galazka, A; Lemieux, C; Leist, TP				Giovannoni, Gavin; Coyle, Patricia K.; Vermersch, Patrick; Walker, Bryan; Aldridge, Julie; Nolting, Axel; Galazka, Andrew; Lemieux, Caroline; Leist, Thomas P.			Integrated Lymphopenia Analysis in Younger and Older Patients With Multiple Sclerosis Treated With Cladribine Tablets	FRONTIERS IN IMMUNOLOGY			English	Article						cladribine tablets; lymphocyte subsets; lymphopenia; multiple sclerosis; age	ORAL CLADRIBINE; RELAPSING FORMS; IMMUNE-SYSTEM; MS; RECONSTITUTION; ANTIBODY; VIRUS; CELL	Cladribine tablets (CladT) preferentially reduce B and T lymphocyte levels. As aging is associated with a decline in immune function, the effect of CladT on lymphocyte levels may differ by age. This post hoc analysis combined data from the Phase 3 CLARITY, CLARITY Extension, and ORACLE-MS studies to examine the effect of age (<= 50 or >50 years) on lymphopenia following CladT 3.5 mg/kg (CladT3.5; cumulative dose over 2 years) treatment over 96 weeks. Both CladT3.5 and placebo were given over Weeks 1 and 5 (Year 1 treatment) and Weeks 48 and 52 (Year 2 treatment) from the start of the studies. Absolute lymphocyte count (ALC) and levels of lymphocyte subsets were examined in 1564 patients (Age <= 50 [placebo: N=566; CladT3.5: N=813]; Age >50 [placebo: N=75; CladT3.5: N=110]). In both age groups, following CladT3.5 treatment, nadir for ALC occurred at Week 9 (8 weeks following start of Year 1 treatment) and Week 55 (7 weeks following start of Year 2 treatment) of the 96-week period; for CD19+ B lymphocytes, nadir occurred at Week 9 (Year 1) and Week 52 (Year 2). For CD4+ T lymphocytes, nadir occurred at Week 16 (Year 1) in both age groups, and at Weeks 60 and 72 (Year 2) in the Age <= 50 and >50 groups, respectively. Nadir for CD8+ T lymphocytes occurred at Week 16 (Year 1) and Week 72 (Year 2) in the Age <= 50 group and levels remained in the normal range; nadir occurred at Week 9 (Year 1) and Week 96 (Year 2) in the Age >50 group. Lymphocyte recovery began soon after nadir following CladT3.5 treatment and median levels reached normal range by end of the treatment year in both age groups. By Week 96, ~25% of patients treated with CladT3.5 reported >= 1 episode of Grade >= 3 lymphopenia (Gr >= 3L). The rate of certain infections was numerically higher in older versus younger patients who experienced Gr >= 3L. In conclusion, CladT3.5 had a similar effect on ALC and lymphocyte subsets in both younger and older patient groups.	[Giovannoni, Gavin] Queen Mary Univ London, Blizard Inst, Barts & London Sch Med & Dent, London, England; [Coyle, Patricia K.] SUNY Stony Brook, Dept Neurol, Stony Brook, NY 11794 USA; [Vermersch, Patrick] Univ Lille, INSERM U1172, Lille Neurosci & Cognit, CHU Lille,FHU Precise, Lille, France; [Walker, Bryan] Duke Univ, Sch Med, Dept Neurol, Durham, NC USA; [Aldridge, Julie] EMD Serono Res & Dev Inst Inc, Res & Dev Global Biostat, Billerica, MA USA; [Nolting, Axel] Merck Healthcare KGaA, Global Patient Safety, Darmstadt, Germany; [Galazka, Andrew] Ares Trading SA, Global Clin Dev, Eysins, Switzerland; [Lemieux, Caroline] EMD Inc, North Amer Med Affairs, Mississauga, ON, Canada; [Leist, Thomas P.] Jefferson Univ, Comprehens Multiple Sclerosis Ctr, Philadelphia, PA USA	University of London; Queen Mary University London; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; CHU Lille; Universite de Lille; Duke University; Merck KGaA; EMD Serono Inc.; Jefferson University	Giovannoni, G (corresponding author), Queen Mary Univ London, Blizard Inst, Barts & London Sch Med & Dent, London, England.	g.giovannoni@qmul.ac.uk		Nolting, Axel/0000-0002-7480-113X				Aiello A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02247; [Anonymous], 2019, MAVENCLAD PACKAGE IN; Bauer ME, 2015, ANN NY ACAD SCI, V1351, P11, DOI 10.1111/nyas.12786; Comi G, 2019, MULT SCLER RELAT DIS, V29, P168, DOI 10.1016/j.msard.2019.01.038; Fox EJ, 2019, NEUROL-CLIN PRACT, V9, P53, DOI 10.1212/CPJ.0000000000000567; Fox RJ, 2016, NEUROL-CLIN PRACT, V6, P220, DOI 10.1212/CPJ.0000000000000238; Freedman Mark S, 2017, Mult Scler J Exp Transl Clin, V3, p2055217317732802, DOI 10.1177/2055217317732802; Fulop T, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01960; Gagliardi AMZ, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008858.pub3; Giovannoni G, 2018, MULT SCLER J, V24, P1594, DOI 10.1177/1352458517727603; Giovannoni G, 2017, NEUROTHERAPEUTICS, V14, P874, DOI 10.1007/s13311-017-0573-4; Giovannoni G, 2011, LANCET NEUROL, V10, P329, DOI 10.1016/S1474-4422(11)70023-0; Giovannoni G, 2010, NEW ENGL J MED, V362, P416, DOI 10.1056/NEJMoa0902533; Hill-Cawthorne GA, 2012, J NEUROL NEUROSUR PS, V83, P298, DOI 10.1136/jnnp-2011-300826; Leist TP, 2014, LANCET NEUROL, V13, P257, DOI 10.1016/S1474-4422(14)70005-5; Leist TP, 2011, CLIN NEUROPHARMACOL, V34, P28, DOI 10.1097/WNF.0b013e318204cd90; Merck Europe B.V., 2020, MAVENCLAD SUMMARY PR; Mills EA, 2018, MULT SCLER J, V24, P1014, DOI 10.1177/1352458518775550; Min HY, 2005, IMMUNOL REV, V205, P7, DOI 10.1111/j.0105-2896.2005.00263.x; Montalban X, 2018, NEUROL-NEUROIMMUNOL, V5, DOI 10.1212/NXI.0000000000000477; Oh SJ, 2019, IMMUNE NETW, V19, DOI 10.4110/in.2019.19.e37; Olsson T, 2013, MULT SCLER J, V19, P1533, DOI 10.1177/1352458513477925; Pfeuffer S, 2022, MULT SCLER J, V28, P257, DOI 10.1177/13524585211012227; Prosperini L, 2017, J NEUROVIROL, V23, P742, DOI 10.1007/s13365-017-0561-9; Rammohan K, 2020, DRUGS, V80, P1901, DOI 10.1007/s40265-020-01422-9; Schweitzer F, 2019, CURR OPIN NEUROL, V32, P305, DOI 10.1097/WCO.0000000000000701; Simon AK, 2015, P ROY SOC B-BIOL SCI, V282, DOI 10.1098/rspb.2014.3085; Thomas K, 2016, NEUROL-NEUROIMMUNOL, V3, DOI 10.1212/NXI.0000000000000228; Thompson WW, 2003, JAMA-J AM MED ASSOC, V289, P179, DOI 10.1001/jama.289.2.179; Valiathan R, 2016, SCAND J IMMUNOL, V83, P255, DOI 10.1111/sji.12413; Wallin MT, 2019, NEUROLOGY, V92, pE1029, DOI 10.1212/WNL.0000000000007035; Weideman AM, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00577; Weng NP, 2006, IMMUNITY, V24, P495, DOI 10.1016/j.immuni.2006.05.001; Zanghi A, 2021, NEUROTHERAPEUTICS, V18, P1166, DOI 10.1007/s13311-021-01037-2; Zhang X, 2013, J IMMUNOL, V191, P5867, DOI 10.4049/jimmunol.1301926	35	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 24	2021	12								763433	10.3389/fimmu.2021.763433	http://dx.doi.org/10.3389/fimmu.2021.763433			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YH2WH	35003076	gold, Green Published			2022-12-18	WOS:000743031700001
J	Holt, MF; Michelsen, AE; Shahini, N; Bjorkelund, E; Bendz, CH; Massey, RJ; Schjalm, C; Halvorsen, B; Broch, K; Ueland, T; Gullestad, L; Nilsson, PH; Aukrust, P; Mollnes, TE; Louwe, MC				Holt, Margrethe Flesvig; Michelsen, Annika E.; Shahini, Negar; Bjorkelund, Elisabeth; Bendz, Christina Holt; Massey, Richard J.; Schjalm, Camilla; Halvorsen, Bente; Broch, Kaspar; Ueland, Thor; Gullestad, Lars; Nilsson, Per H.; Aukrust, Pal; Mollnes, Tom Eirik; Louwe, Mieke C.			The Alternative Complement Pathway Is Activated Without a Corresponding Terminal Pathway Activation in Patients With Heart Failure	FRONTIERS IN IMMUNOLOGY			English	Article						heart failure; complement; alternative pathway; complement Factor B; C3bBbP; terminal complement complex	FAILING HEART; SYSTEM	ObjectiveDysregulation of the complement system has been described in patients with heart failure (HF). However, data on the alternative pathway are scarce and it is unknown if levels of factor B (FB) and the C3 convertase C3bBbP are elevated in these patients. We hypothesized that plasma levels of FB and C3bBbP would be associated with disease severity and survival in patients with HF. MethodsWe analyzed plasma levels of FB, C3bBbP, and terminal C5b-9 complement complex (TCC) in 343 HF patients and 27 healthy controls. ResultsCompared with controls, patients with HF had elevated levels of circulating FB (1.6-fold, p < 0.001) and C3bBbP (1.3-fold, p < 0.001). In contrast, TCC, reflecting the terminal pathway, was not significantly increased (p = 0.15 vs controls). FB was associated with NT-proBNP, troponin, eGFR, and i.e., C-reactive protein. FB, C3bBbP and TCC were not associated with mortality in HF during a mean follow up of 4.3 years. ConclusionOur findings suggest that in patients with HF, the alternative pathway is activated. However, this is not accompanied by activation of the terminal pathway.	[Holt, Margrethe Flesvig; Michelsen, Annika E.; Shahini, Negar; Halvorsen, Bente; Ueland, Thor; Aukrust, Pal; Louwe, Mieke C.] Oslo Univ Hosp, Internal Med Res Inst, Oslo, Norway; [Holt, Margrethe Flesvig; Bjorkelund, Elisabeth; Bendz, Christina Holt; Massey, Richard J.; Broch, Kaspar; Gullestad, Lars] Oslo Univ Hosp, Dept Cardiol, Rikshosp, Oslo, Norway; [Michelsen, Annika E.; Massey, Richard J.; Halvorsen, Bente; Ueland, Thor; Gullestad, Lars; Aukrust, Pal] Univ Oslo, Fac Med, Inst Clin Med, Oslo, Norway; [Schjalm, Camilla; Nilsson, Per H.; Mollnes, Tom Eirik] Univ Oslo, Dept Immunol, Oslo, Norway; [Schjalm, Camilla; Nilsson, Per H.; Mollnes, Tom Eirik] Oslo Univ Hosp Rikshosp, Dept Immunol, Oslo, Norway; [Broch, Kaspar; Gullestad, Lars] Univ Oslo, Fac Med, Ctr Heart Failure Res, KG Jebsen Cardiac Res Ctr, Oslo, Norway; [Ueland, Thor; Mollnes, Tom Eirik] Arct Univ Norway, Univ Tromso, Fac Hlth Sci, KG Jebsen Thrombosis Res Ctr, Tromso, Norway; [Nilsson, Per H.] Linnaeus Univ, Linnaeus Ctr Biomat Chem, Kalmar, Sweden; [Aukrust, Pal] Oslo Univ Hosp Rikshosp, Sect Clin Immunol & Infect Dis, Oslo, Norway; [Mollnes, Tom Eirik] Nordland Hosp, Res Lab, Bodo, Norway; [Mollnes, Tom Eirik] Norwegian Univ Sci & Technol, Ctr Mol Inflammat Res, Trondheim, Norway	University of Oslo; University of Oslo; National Hospital Norway; University of Oslo; University of Oslo; University of Oslo; National Hospital Norway; University of Oslo; UiT The Arctic University of Tromso; Linnaeus University; University of Oslo; National Hospital Norway; Norwegian University of Science & Technology (NTNU)	Louwe, MC (corresponding author), Oslo Univ Hosp, Internal Med Res Inst, Oslo, Norway.	m.c.louwe@ous-research.no	Louwe, Mieke C./ABC-2290-2020	Louwe, Mieke C./0000-0002-4797-4991	South-Eastern Norway Regional Health Authority [2019058]	South-Eastern Norway Regional Health Authority	Funding This work was supported by the South-Eastern Norway Regional Health Authority (grant 2019058 to ML).	Aukrust P, 2001, CIRCULATION, V104, P1494, DOI 10.1161/hc3801.096353; Barratt-Due A, 2012, IMMUNOBIOLOGY, V217, P1047, DOI 10.1016/j.imbio.2012.07.019; Bergseth G, 2013, MOL IMMUNOL, V56, P232, DOI 10.1016/j.molimm.2013.05.221; Bexborn F, 2008, MOL IMMUNOL, V45, P2370, DOI 10.1016/j.molimm.2007.11.003; Bozkurt B, 2021, EUR J HEART FAIL, V23, P352, DOI 10.1002/ejhf.2115; Clark DJ, 2001, AM HEART J, V141, P684, DOI 10.1067/mhj.2001.113758; Garred P, 2021, PHARMACOL REV, V73, P792, DOI 10.1124/pharmrev.120.000072; Gombos T, 2012, CLIN RES CARDIOL, V101, P607, DOI 10.1007/s00392-012-0432-6; Hajishengallis G, 2017, NAT IMMUNOL, V18, P1288, DOI 10.1038/ni.3858; Harboe M, 2008, J CELL MOL MED, V12, P1074, DOI 10.1111/j.1582-4934.2008.00350.x; Hartupee J, 2017, NAT REV CARDIOL, V14, P30, DOI 10.1038/nrcardio.2016.163; Hertle E, 2016, THROMB HAEMOSTASIS, V115, P446, DOI 10.1160/TH15-05-0439; Lappegard KT, 2014, MOL IMMUNOL, V61, P126, DOI 10.1016/j.molimm.2014.06.036; Levey AS, 2009, ANN INTERN MED, V150, P604, DOI 10.7326/0003-4819-150-9-200905050-00006; Mann DL, 2002, CIRC RES, V91, P988, DOI 10.1161/01.RES.0000043825.01705.1B; Mann DL, 2015, CIRC RES, V116, P1254, DOI 10.1161/CIRCRESAHA.116.302317; MOLLNES TE, 1985, SCAND J IMMUNOL, V22, P197, DOI 10.1111/j.1365-3083.1985.tb01871.x; Mollnes TE, 2002, BLOOD, V100, P1869; MOLLNES TE, 1986, CLIN EXP IMMUNOL, V65, P73; Noris M, 2013, SEMIN NEPHROL, V33, P479, DOI 10.1016/j.semnephrol.2013.08.001; Orrem HL, 2018, ESC HEART FAIL, V5, P292, DOI 10.1002/ehf2.12266; Reis ES, 2019, NAT REV IMMUNOL, V19, P503, DOI 10.1038/s41577-019-0168-x; Ricklin D, 2013, J IMMUNOL, V190, P3831, DOI 10.4049/jimmunol.1203487; Semeraro N, 2010, MEDITERR J HEMATOL I, V2, DOI 10.4084/MJHID.2010.024; Shahini N, 2019, J IMMUNOL, V203, P1973, DOI 10.4049/jimmunol.1801244; Shahini N, 2017, SCI REP-UK, V7, DOI 10.1038/srep42532; Singh MV, 2009, J CLIN INVEST, V119, P986, DOI 10.1172/JCI35814; TACK BF, 1980, P NATL ACAD SCI-BIOL, V77, P5764, DOI 10.1073/pnas.77.10.5764; VAKEVA A, 1993, AM J PATHOL, V143, P65; Yasojima K, 1998, CIRC RES, V83, P860, DOI 10.1161/01.RES.83.8.860; YASUDA M, 1990, CIRCULATION, V81, P156, DOI 10.1161/01.CIR.81.1.156; Yndestad Arne, 2007, Curr Cardiol Rep, V9, P236, DOI 10.1007/BF02938356	32	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 24	2021	12								800978	10.3389/fimmu.2021.800978	http://dx.doi.org/10.3389/fimmu.2021.800978			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YH6UE	35003128	Green Published, gold			2022-12-18	WOS:000743299500001
J	Li, CY; Dong, XF; Wang, HQ; Shao, ZH				Li, Chenyuan; Dong, Xifeng; Wang, Huaquan; Shao, Zonghong			The Role of T Lymphocytes in the Pathogenesis of Paroxysmal Nocturnal Hemoglobinuria	FRONTIERS IN IMMUNOLOGY			English	Review						paroxysmal nocturnal hemoglobinuria; aplastic anemia; T lymphocytes; pathogenesis; immune escape	APLASTIC-ANEMIA; BONE-MARROW; ANTITHYMOCYTE GLOBULIN; FAS ANTIGEN; CELL-CLONE; STEM-CELLS; PNH; EXPRESSION; TARGET; CD59	Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired hematopoietic stem cell genetic mutation disease that causes defective erythrocyte membrane hemolysis. Its pathologic basis is the mutation of the PIG-A gene, whose product is necessary for the synthesis of glycosylphosphatidylinositol (GPI) anchors; the mutation of PIG-A gene results in the reduction or deletion of the GPI anchor, which leads to the deficiency of GPI-anchored proteins (GPI-APs), such as CD55 and CD59, which are complement inhibitors. The deficiency of complement inhibitors causes chronic complement-mediated intravascular hemolysis of GPI-anchor-deficient erythrocyte. PIG-A gene mutation could also be found in bone marrow hematopoietic stem cells (HSCs) of healthy people, but they have no growth advantage; only the HSCs with PIG-A gene mutation in PNH patients have this advantage and expand. Besides, HSCs from PIG-A-knockout mice do not show clonal expansion in bone marrow, so PIG-A mutation cannot explain the clonal advantage of the PNH clone and some additional factors are needed; thus, in recent years, many scholars have put forward the theories of the second hit, and immune escape theory is one of them. In this paper, we focus on how T lymphocytes are involved in immune escape hypothesis in the pathogenesis of PNH.	[Li, Chenyuan; Dong, Xifeng; Wang, Huaquan; Shao, Zonghong] Tianjin Med Univ, Gen Hosp, Dept Hematol & Oncol, Tianjin, Peoples R China	Tianjin Medical University	Shao, ZH (corresponding author), Tianjin Med Univ, Gen Hosp, Dept Hematol & Oncol, Tianjin, Peoples R China.	shaozonghong@sina.com			National Natural Science Foundation of China [32100656]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	Funding This study is supported by the grant (32100656 to XD) from the National Natural Science Foundation of China.	Brodsky RA, 2014, BLOOD, V124, P2804, DOI 10.1182/blood-2014-02-522128; Cai GF, 2008, NAT IMMUNOL, V9, P176, DOI 10.1038/ni1554; DECKERT M, 1995, EUR J IMMUNOL, V25, P1815, DOI 10.1002/eji.1830250704; Frickhofen N, 2000, SEMIN HEMATOL, V37, P56, DOI 10.1053/shem.2000.0370056; Gargiulo L, 2007, BLOOD, V109, P5036, DOI 10.1182/blood-2006-10-052381; Gargiulo L, 2013, BLOOD, V121, P2753, DOI 10.1182/blood-2012-11-469353; Gavriilaki Eleni, 2022, Blood, V139, P3571, DOI 10.1182/blood.2021012860; Gavriilaki E, 2020, J CLIN INVEST, V130, P2152, DOI 10.1172/JCI136094; Han Bing, 2002, Zhonghua Xue Ye Xue Za Zhi, V23, P233; Ikeda K, 2007, EXP HEMATOL, V35, P618, DOI 10.1016/j.exphem.2007.01.045; Illingworth AJ, 2019, METHODS MOL BIOL, V2032, P323, DOI 10.1007/978-1-4939-9650-6_18; Ismail MM, 2003, BRIT J HAEMATOL, V123, P545, DOI 10.1046/j.1365-2141.2003.04643.x; ISSARAGRISIL S, 1986, EXP HEMATOL, V14, P861; Joyce S, 1998, SCIENCE, V279, P1541, DOI 10.1126/science.279.5356.1541; Karadimitris A, 2001, LEUKEMIA, V15, P1148, DOI 10.1038/sj.leu.2402180; Katagiri T, 2011, EUR J HAEMATOL, V86, P226, DOI 10.1111/j.1600-0609.2010.01563.x; Kinoshita T, 2018, SEMIN HEMATOL, V55, P136, DOI 10.1053/j.seminhematol.2018.04.004; Kojima R, 2011, J MOL BIOL, V413, P762, DOI 10.1016/j.jmb.2011.09.018; Kordasti S, 2012, BLOOD, V119, P2033, DOI 10.1182/blood-2011-08-368308; Kulagin A, 2014, BRIT J HAEMATOL, V164, P546, DOI 10.1111/bjh.12661; Kumar H, 2000, J IMMUNOL, V165, P4797, DOI 10.4049/jimmunol.165.9.4797; Kunyaboon Rajita, 2012, Hematol Oncol Stem Cell Ther, V5, P138, DOI 10.5144/1658-3876.2012.138; Le Bouteiller P, 2011, IMMUNOL LETT, V138, P93, DOI 10.1016/j.imlet.2011.02.003; Li Ying-Mei, 2012, Zhonghua Xue Ye Xue Za Zhi, V33, P117; Liu SY, 2020, CANCER IMMUNOL IMMUN, V69, P789, DOI 10.1007/s00262-020-02500-3; Lukacik P, 2004, P NATL ACAD SCI USA, V101, P1279, DOI 10.1073/pnas.0307200101; Luzzatto L, 2020, BRIT J HAEMATOL, V191, P579, DOI 10.1111/bjh.17147; Luzzatto L, 2018, BRIT J HAEMATOL, V182, P758, DOI 10.1111/bjh.15443; Luzzatto Lucio, 2016, F1000Res, V5, DOI 10.12688/f1000research.7288.1; MACIEJEWSKI JP, 1995, BRIT J HAEMATOL, V91, P245, DOI 10.1111/j.1365-2141.1995.tb05277.x; Markiewicz M, 2020, BIOL BLOOD MARROW TR, V26, P1833, DOI 10.1016/j.bbmt.2020.05.024; Murakami Y, 2002, BLOOD, V100, P4116, DOI 10.1182/blood-2002-06-1669; Nagata S, 1996, GENES CELLS, V1, P873, DOI 10.1046/j.1365-2443.1996.d01-214.x; Nagata S, 1999, ANNU REV GENET, V33, P29, DOI 10.1146/annurev.genet.33.1.29; Nakao S, 1997, BLOOD, V89, P3691, DOI 10.1182/blood.V89.10.3691.3691_3691_3699; Nakasone Hideki, 2008, Rinsho Ketsueki, V49, P498; Nishimura Jun-ichi, 2008, Nihon Rinsho, V66, P490; Paquette RL, 1997, BRIT J HAEMATOL, V96, P92, DOI 10.1046/j.1365-2141.1997.d01-1984.x; Rachidi S, 2010, EUR J INTERN MED, V21, P260, DOI 10.1016/j.ejim.2010.04.002; Ren X, 2020, HEMATOLOGY, V25, P348, DOI 10.1080/16078454.2020.1821495; Richards SJ, 2021, EUR J HAEMATOL, V107, P211, DOI 10.1111/ejh.13640; Risitano AM, 2005, LEUKEMIA, V19, P217, DOI 10.1038/sj.leu.2403617; Risitano AM, 2002, BLOOD, V100, P178, DOI 10.1182/blood-2002-01-0236; Rosti V, 1997, J CLIN INVEST, V100, P1028, DOI 10.1172/JCI119613; ROTOLI B, 1989, SEMIN HEMATOL, V26, P201; Schrezenmeier H, 2014, HAEMATOLOGICA, V99, P922, DOI 10.3324/haematol.2013.093161; SCHUBERT J, 1994, BLOOD, V83, P2323; STALDER T, 1994, J IMMUNOL, V152, P1127; Szeto C, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22010068; Takami A, 1999, BRIT J HAEMATOL, V107, P791, DOI 10.1046/j.1365-2141.1999.01790.x; Young NS, 2002, INT J HEMATOL, V76, P168, DOI 10.1007/BF03165111; Zeng Y, 2015, CLIN EXP IMMUNOL, V180, P361, DOI 10.1111/cei.12605; Zhang Jing, 2016, Zhonghua Xue Ye Xue Za Zhi, V37, P124, DOI 10.3760/cma.j.issn.0253-2727.2016.02.008	53	0	0	4	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 24	2021	12								777649	10.3389/fimmu.2021.777649	http://dx.doi.org/10.3389/fimmu.2021.777649			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YH6UD	35003092	Green Published, gold			2022-12-18	WOS:000743299400001
J	Lyu, XL; Lin, TT; Gao, JT; Jia, HY; Zhu, CZ; Li, ZH; Dong, J; Sun, Q; Shu, W; Pan, LP; Zhang, ZD; Li, Q				Lyu, Xia-Li; Lin, Ting-Ting; Gao, Jing-Tao; Jia, Hong-Yan; Zhu, Chuan-Zhi; Li, Zi-Hui; Dong, Jing; Sun, Qi; Shu, Wei; Pan, Li-Ping; Zhang, Zong-De; Li, Qi			The Activities and Secretion of Cytokines Caused by Delamanid on Macrophages Infected by Multidrug-Resistant Mycobacterium tuberculosis Strains	FRONTIERS IN IMMUNOLOGY			English	Article						multidrug-resistant Mycobacterium tuberculosis (MDR-MTB) strains; macrophages; cytokines; Delamanid (Dlm); immune mechanism		Background: Delamanid (Dlm) is an effective drug against drug-susceptible and drugresistant Mycobacterium tuberculosis strains, including Multidrug- resistant Mycobacterium tuberculosis (MDR-MTB). There are few reports on the activity and secretion of cytokines caused by Dlm on macrophages infected by MDR-MTB strains. Therefore, this article aims to observe the bactericidal activity and secretion of cytokines of the macrophages infected by MDR-MTB strains after Dlm was administered, so as to provide a basis for further perfecting the mechanism of Dlm. Methods: Samples were respectively collected to count the intracellular colony-forming unit (CFU) of macrophages infected by MDR-MTB or H37Rv strains at 4, 8, 24, and 48 h after Dlm at MIC, 10MIC, and 20MIC were administered. Samples were respectively collected to detect the level of IL-12/23 p40, TNF-a, IL-6, and IL-10 in the culture supernatant of macrophages infected by MDR-MTB or H37Rv strains at 4, 24, and 48 h after Dlm at MIC were administered. The levels of four cytokines in the culture supernatant were measured using the Luminex (R) 200 T (Luminex, USA) according to the manufacturer's instructions. Data were analyzed by SPSS 25.0 software. The continuous data in normal distribution were expressed as mean +/- standard deviation (similar to x +/- s) and analyzed by t or F test. P<0.05 was considered statistically significant. Results: (1) After Dlm was applied to macrophages infected by MDR-MTB strains:(A) The intracellular CFU gradually decreased, reached the lowest value at 48 h, and was lower than that of Dlm before administration and infection group (P<0.05). (B) The intracellular CFU was further reduced after increasing Dlm dose to 10MIC and 20MIC, and the latter was lower than that of the former (P<0.05). (C) The intracellular CFU of MDR-MTB group was higher than that of H37Rv group at 4 similar to 48 h after administration (P<0.05). (2) After Dlm at MIC dose was applied to macrophages infected by MDR-MTB strains: (A) The level of IL-12/23 p40 at any time didn't change compared with that of Dlm before administration (P>0.05), while the level of IL-12/23 p40 at 4 h was higher than that of the infection groupP<0.05). The levels of TNF-a at 24 and 48 h were higher than that of Dlm before administration (P<0.05), but were similar to that of the infection group (P>0.05). In addition, the levels of IL-12/23 p40 and TNF-a at any time were similar to that of the H37Rv group after administration (P>0.05). (B) The levels of IL-6 at 24 and 48 h were higher than that of Dlm before administration (P<0.05), but were similar to that of H37Rv group (P>0.05) and were lower than that of infection group (P<0.05). The level of IL-10 at any time didn't change compared with that of Dlm before administration (P>0.05), but was lower than that of the infection group at 4 similar to 48 h and was lower than that of the H37Rv group at 24 h (P<0.05). (C) The level of IL-12/23 p40 and IL-10 didn't change with the change of intracellular CFU (P<0.05), while the level of TNF-a and IL-6 increased with the intracellular CFU decreasing, and the increase level of TNF-a was lower than that of the infection group (P<0.05). Conclusions: Dlm had strong bactericidal activity against intracellular MDR-MTB, which was time-dependent and concentration-dependent. Its bactericidal activity against intracellular MDR-MTB strains was weaker than that against drug-susceptible tuberculosis strains. Dlm might have immunomodulatory effect, inducing low expression of Th2 cytokines IL-6 and IL-10 at different times after administration.	[Lyu, Xia-Li; Lin, Ting-Ting; Gao, Jing-Tao; Jia, Hong-Yan; Zhu, Chuan-Zhi; Li, Zi-Hui; Dong, Jing; Sun, Qi; Shu, Wei; Pan, Li-Ping; Zhang, Zong-De; Li, Qi] Capital Med Univ, Beijing Chest Hosp, Beijing TB & Thorac Tumor Res Inst, Beijing, Peoples R China	Capital Medical University	Li, Q (corresponding author), Capital Med Univ, Beijing Chest Hosp, Beijing TB & Thorac Tumor Res Inst, Beijing, Peoples R China.	lq0703@hotmail.com			Beijing Municipal Science and Technology Major Project [D181100000418005];  [2018ZX10722301-001]	Beijing Municipal Science and Technology Major Project; 	` This study was financially supported by Research and Evaluation of New Protocols and Technologies for the Treatment ofDrug-resistant Tuberculosis (2018ZX10722301-001) and the Beijing Municipal Science and Technology Major Project (D181100000418005).	[程枫 Cheng Feng], 2018, [微生物学杂志, Journal of Mirobiology], V38, P123; Chinese Society of Tuberculosis of Chinese Medical Association, 2019, Zhonghua Jie He He Hu Xi Za Zhi, V42, P733, DOI 10.3760/cma.j.issn.1001-0939.2019.10.006; Dan-Dan D, 2010, J MICROBES INFECT, V5, P106; Diacon AH, 2012, LANCET, V380, P986, DOI 10.1016/S0140-6736(12)61080-0; Dutta RK, 2012, INT J BIOCHEM CELL B, V44, P942, DOI 10.1016/j.biocel.2012.02.021; Khoshnood S, 2021, FRONT MICROBIOL, V12, DOI 10.3389/fmicb.2021.717045; [李琦 Li Qi], 2019, [中国防痨杂志, Chinese Journal of Antituberculosis], V41, P294; Li Y-y., 2017, CHINESE J ANTITUBERC, V39, P1014, DOI [10.3969/j.issn.1000-6621.2017.09.022, DOI 10.3969/J.ISSN.1000-6621.2017.09.022]; Liang S-m., 2018, J NINGXIA MED U, V40, P115, DOI 10.16050/j.cnki.issn1674-6309.2018.01.034; Lyu L N, 2017, Zhonghua Jie He He Hu Xi Za Zhi, V40, P509, DOI 10.3760/cma.j.issn.1001-0939.2017.07.006; Meng Q-l., 2016, CHIN J ANTITUBERC, V38, P116, DOI [10.3969/j.issn.1000-6621.2016.02.009, DOI 10.3969/J.ISSN.1000-6621.2016.02.009]; Muvva JR, 2021, J INFECT DIS, V224, P332, DOI 10.1093/infdis/jiab100; Ren W-c, 2009, THESIS BEIJING TUBER; Silva A, 2016, P NATL ACAD SCI USA, V113, pE2172, DOI 10.1073/pnas.1600812113; [王小茜 Wang Xiaoqian], 2015, [军事医学, Military Medical Sciences], V39, P637; Wang Y., 2018, CHINESE J ANTITUBERC, V40, P218, DOI [10.3969/j.issn.1000-6621.2018.02.020, DOI 10.3969/J.ISSN.1000-6621.2018.02.020]; WHO, 2021, TUBERCULOSIS; Zhao Y-f., 2015, LETT BIOTECHNOLOGY, V26, P294, DOI [10.3969/j.issn.1009-0002.2015.02.033, DOI 10.3969/J.ISSN.1009-0002.2015.02.033]	18	0	0	12	15	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 24	2021	12								796677	10.3389/fimmu.2021.796677	http://dx.doi.org/10.3389/fimmu.2021.796677			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YK4WU	35003120	Green Published, gold			2022-12-18	WOS:000745215800001
J	Madden, PJ; Arif, MS; Becker, ME; McRaven, MD; Carias, AM; Lorenzo-Redondo, R; Xiao, SX; Midkiff, CC; Blair, RV; Potter, EL; Martin-Sancho, L; Dodson, A; Martinelli, E; Todd, JPM; Villinger, FJ; Chanda, SK; Aye, PP; Roy, CJ; Roederer, M; Lewis, MG; Veazey, RS; Hope, TJ				Madden, Patrick J.; Arif, Muhammad S.; Becker, Mark E.; McRaven, Michael D.; Carias, Ann M.; Lorenzo-Redondo, Ramon; Xiao, Sixia; Midkiff, Cecily C.; Blair, Robert V.; Potter, Elizabeth Lake; Martin-Sancho, Laura; Dodson, Alan; Martinelli, Elena; Todd, John-Paul M.; Villinger, Francois J.; Chanda, Sumit K.; Aye, Pyone Pyone; Roy, Chad J.; Roederer, Mario; Lewis, Mark G.; Veazey, Ronald S.; Hope, Thomas J.			Development of an In Vivo Probe to Track SARS-CoV-2 Infection in Rhesus Macaques	FRONTIERS IN IMMUNOLOGY			English	Article						SARS-CoV-2; nonhuman primates; rhesus macaque; antibodies; COVID-19; antibody probes	MONOCLONAL-ANTIBODY; IMMUNO-PET; REVEALS	Infection with the novel coronavirus, SARS-CoV-2, results in pneumonia and other respiratory symptoms as well as pathologies at diverse anatomical sites. An outstanding question is whether these diverse pathologies are due to replication of the virus in these anatomical compartments and how and when the virus reaches those sites. To answer these outstanding questions and study the spatiotemporal dynamics of SARS-CoV-2 infection a method for tracking viral spread in vivo is needed. We developed a novel, fluorescently labeled, antibody-based in vivo probe system using the anti-spike monoclonal antibody CR3022 and demonstrated that it could successfully identify sites of SARS-CoV-2 infection in a rhesus macaque model of COVID-19. Our results showed that the fluorescent signal from our antibody-based probe could differentiate whole lungs of macaques infected for 9 days from those infected for 2 or 3 days. Additionally, the probe signal corroborated the frequency and density of infected cells in individual tissue blocks from infected macaques. These results provide proof of concept for the use of in vivo antibody-based probes to study SARS-CoV-2 infection dynamics in rhesus macaques.	[Madden, Patrick J.; Arif, Muhammad S.; Becker, Mark E.; McRaven, Michael D.; Carias, Ann M.; Xiao, Sixia; Martinelli, Elena; Hope, Thomas J.] Northwestern Univ, Dept Cell & Dev Biol, Feinberg Sch Med, Chicago, IL 60611 USA; [Lorenzo-Redondo, Ramon] Northwestern Univ, Dept Med, Div Infect Dis, Feinberg Sch Med, Chicago, IL 60611 USA; [Lorenzo-Redondo, Ramon] Northwestern Univ, Ctr Pathogen Genom & Microbial Evolut, Inst Global Hlth, Chicago, IL 60611 USA; [Midkiff, Cecily C.; Blair, Robert V.; Aye, Pyone Pyone; Veazey, Ronald S.] Tulane Natl Primate Res Ctr, Div Comparat Pathol, Covington, LA USA; [Potter, Elizabeth Lake; Todd, John-Paul M.; Roederer, Mario] NIAID, Vaccine Res Ctr, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Martin-Sancho, Laura; Chanda, Sumit K.] Sanford Burnham Prebys Med Discovery Inst, Immun & Pathogenesis Program, La Jolla, CA USA; [Dodson, Alan; Lewis, Mark G.] Bioqual Inc, Rockville, MD USA; [Villinger, Francois J.] Univ Louisiana Lafayette, New Iberia Res Ctr, New Iberia, LA USA; [Roy, Chad J.] Tulane Natl Primate Res Ctr, Div Microbiol, Covington, LA USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Northwestern University; Tulane University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Sanford Burnham Prebys Medical Discovery Institute; BIOQUAL Inc.; University of Louisiana Lafayette; New Iberia Research Center; Tulane University	Hope, TJ (corresponding author), Northwestern Univ, Dept Cell & Dev Biol, Feinberg Sch Med, Chicago, IL 60611 USA.	thope@northwestern.edu		Aye, Pyone Pyone/0000-0002-4764-3965	National Institutes of Health [R37 AI 094595-09S1, HHSN272201700033I]; NIH [OD011104]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by National Institutes of Health grant R37 AI 094595-09S1 and in part by HHSN272201700033I (CR). This work was also supported in part by NIH grant OD011104. AC was supported in part by K01 OD026571-01.	Bankhead P, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17204-5; Basso C, 2020, EUR HEART J, V41, P3827, DOI 10.1093/eurheartj/ehaa664; Beddingfield BJ, 2021, FRONT CELL INFECT MI, V11, DOI 10.3389/fcimb.2021.753444; Blair RV, 2021, AM J PATHOL, V191, P274, DOI 10.1016/j.ajpath.2020.10.016; Chandrashekar A, 2020, SCIENCE, V369, P812, DOI 10.1126/science.abc4776; Corbett KS, 2020, NEW ENGL J MED, V383, P1544, DOI 10.1056/NEJMoa2024671; Davies G, 2017, THERANOSTICS, V7, P3398, DOI 10.7150/thno.20919; Deng W, 2020, SCIENCE, V369, P818, DOI 10.1126/science.abc5343; Diao B, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22781-1; Duan LW, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.576622; Duvenhage J, 2020, MOL IMAGING BIOL, V22, P115, DOI 10.1007/s11307-019-01360-3; El Moheb M, 2020, JAMA-J AM MED ASSOC, V324, P1899, DOI 10.1001/jama.2020.19400; Fahlberg MD, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19967-4; Fortin MA, 2007, EUR J NUCL MED MOL I, V34, P1376, DOI 10.1007/s00259-006-0346-5; Fu RS, 2018, CHEMMEDCHEM, V13, P2466, DOI 10.1002/cmdc.201800624; Gaebler C, 2021, NATURE, V591, P639, DOI [10.1038/s41586-021-03207-w, 10.1101/2020.11.03.367391]; Grant RA, 2021, NATURE, V590, P635, DOI 10.1038/s41586-020-03148-w; Hoffmann M, 2020, MOL CELL, V78, P779, DOI 10.1016/j.molcel.2020.04.022; Huo JD, 2020, CELL HOST MICROBE, V28, P445, DOI [10.1016/j.chom.2020.06.010, 10.1016/j.chom.2020.07.002]; Kresch E, 2021, WORLD J MENS HEALTH, V39, P466, DOI 10.5534/wjmh.210055; Lee I, 2021, EJNMMI RES, V11, DOI 10.1186/s13550-021-00746-1; Lin L, 2020, GUT, V69, P997, DOI 10.1136/gutjnl-2020-321013; Lindsay KE, 2019, NAT BIOMED ENG, V3, P371, DOI 10.1038/s41551-019-0378-3; Lu SY, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00269-6; Ma XX, 2021, CELL MOL IMMUNOL, V18, P487, DOI 10.1038/s41423-020-00604-5; Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127; Martin-Sancho L, 2021, MOL CELL, V81, P2656, DOI 10.1016/j.molcel.2021.04.008; McElroy M, 2009, J SURG RES, V151, P68, DOI 10.1016/j.jss.2007.12.769; Morad HOJ, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.01996; Mortimer JE, 2019, J NUCL MED, V60, P23, DOI 10.2967/jnumed.118.220905; Munster VJ, 2020, NATURE, V585, P268, DOI [10.1038/s41586-020-2324-7, 10.1101/2020.03.21.001628]; Pei GC, 2020, J AM SOC NEPHROL, V31, P1157, DOI 10.1681/ASN.2020030276; Pesnel S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030690; Pickett JE, 2018, BONE RES, V6, DOI 10.1038/s41413-018-0014-y; Ramjiawan B, 2000, CANCER, V89, P1134, DOI 10.1002/1097-0142(20000901)89:5<1134::AID-CNCR23>3.0.CO;2-3; Rockx Barry, 2020, Science, V368, P1012, DOI 10.1126/science.abb7314; Rolle AM, 2016, P NATL ACAD SCI USA, V113, pE1026, DOI 10.1073/pnas.1518836113; Sansone A, 2021, ANDROLOGY-US, V9, P1053, DOI 10.1111/andr.13003; Santangelo PJ, 2018, MUCOSAL IMMUNOL, V11, P932, DOI 10.1038/mi.2017.112; Santangelo PJ, 2015, NAT METHODS, V12, P427, DOI [10.1038/nmeth.3320, 10.1038/NMETH.3320]; Schmidt U, 2018, LECT NOTES COMPUT SC, V11071, P265, DOI 10.1007/978-3-030-00934-2_30; Schneider JR, 2017, J IMMUNOL METHODS, V450, P66, DOI 10.1016/j.jim.2017.07.009; Tamura K, 2013, J NUCL MED, V54, P1869, DOI 10.2967/jnumed.112.118612; Ullah I, 2021, IMMUNITY, V54, P2143, DOI 10.1016/j.immuni.2021.08.015; V'kovski P, 2021, NAT REV MICROBIOL, V19, P155, DOI 10.1038/s41579-020-00468-6; Voloch CM, 2021, VIRUS EVOL, V7, DOI 10.1093/ve/veab078; Wei WJ, 2020, CHEM REV, V120, P3787, DOI 10.1021/acs.chemrev.9b00738; Williamson BN, 2020, NATURE, V585, P273, DOI 10.1038/s41586-020-2423-5; Wong NA, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22031308; Yuan M, 2021, SCIENCE, V373, P818, DOI 10.1126/science.abh1139; Yuan M, 2020, SCIENCE, V368, P630, DOI 10.1126/science.abb7269; Zaderer V, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8101292; Zahn T, 2022, ALLERGY, V77, P2053, DOI 10.1111/all.15138; Zettlitz KA, 2019, J NUCL MED, V60, P1467, DOI 10.2967/jnumed.118.223560; Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7; Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017	56	0	0	3	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 24	2021	12								810047	10.3389/fimmu.2021.810047	http://dx.doi.org/10.3389/fimmu.2021.810047			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YI0AS	35003140	gold, Green Published			2022-12-18	WOS:000743520800001
J	Mao, R; Yang, F; Zhang, TT; Li, J				Mao, Rui; Yang, Fan; Zhang, Tongtong; Li, Ji			Landscape and Clinical Significance of Immune Checkpoint in Cutaneous Melanoma	FRONTIERS IN IMMUNOLOGY			English	Article						skin cutaneous melanoma; immune checkpoint; prognosis; nomogram; immunotherapy	CANCER-IMMUNOTHERAPY; T-CELLS; EXPRESSION; RECEPTORS; THERAPY; LIGAND	BackgroundThe incidence of cutaneous melanoma (CM) is increasing, and its prognosis is not optimistic. Although immune checkpoint (ICP) inhibitors are effective in the treatment of CM patients, they are not effective for all CM patients. There is an urgent need for a marker to predict both the prognosis and the immunotherapy effect in patients with CM. ApproachesTwo groups of patients with greatly different prognosis and response to immunotherapy were identified by unwatched cluster exploration of TCGA on the basis of 34 ICPs. The prognosis and immunotherapy effect of CM were predicted by developing a precise and given signature on the basis of ICPs, and a multivariate Cox risk regression model was established from the TCGA cohort consisting of 454 CM samples. The model was validated in 210 and 231 samples in the test and verification cohorts, respectively. ResultsThe prognosis in clinical subgroups was predicted by the classification system. High-risk patients had poorer responses to chemotherapy and immunotherapy. Finally, the signature was recognized as an independent prognostic factor. Based on checkpoint-based signature (ICPBS) and clinical characteristics, we constructed a nomogram for the prognosis in patients with CM, which was superior to ICPBS in efficacy than ICPBS alone. ConclusionAs a useful prognostic tool to further improve cancer immunotherapy, the signature can accurately predict recurrence and overall survival among patients with CM.	[Mao, Rui; Li, Ji] Cent South Univ, Xiangya Hosp, Dept Dermatol, Changsha, Peoples R China; [Yang, Fan] Peking Univ, Sch Med, Peking Univ Third Hosp, Emergency Dept, Beijing, Peoples R China; [Zhang, Tongtong] Third Peoples Hosp Chengdu, Ctr Gastrointestinal & Minimally Invas Surg, Chengdu, Peoples R China; [Zhang, Tongtong] Chongqing Med Univ, Med Res Ctr, Third Peoples Hosp Chengdu, Affiliated Hosp,Southwest Jiaotong Univ,Second Ch, Chengdu, Peoples R China; [Li, Ji] Cent South Univ, Xiangya Hosp, Hunan Key Lab Aging Biol, Changsha, Peoples R China	Central South University; Peking University; Chongqing Medical University; Southwest Jiaotong University; Central South University	Li, J (corresponding author), Cent South Univ, Xiangya Hosp, Dept Dermatol, Changsha, Peoples R China.; Li, J (corresponding author), Cent South Univ, Xiangya Hosp, Hunan Key Lab Aging Biol, Changsha, Peoples R China.	liji_xy@csu.edu.cn	Zhang, Tong/HGC-1090-2022	Mao, Rui/0000-0002-0135-8579				[Anonymous], 2018, N Engl J Med, V379, P2185, DOI 10.1056/NEJMx180040; Bakker ABH, 1998, J IMMUNOL, V160, P5239; Bindea G, 2009, BIOINFORMATICS, V25, P1091, DOI 10.1093/bioinformatics/btp101; Chretien S, 2019, CANCERS, V11, DOI 10.3390/cancers11050628; Curran MA, 2010, P NATL ACAD SCI USA, V107, P4275, DOI 10.1073/pnas.0915174107; Czarnecka AM, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21134576; Daassi D, 2020, NAT REV IMMUNOL, V20, P209, DOI 10.1038/s41577-019-0264-y; Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730; Edwards J, 2018, CLIN CANCER RES, V24, P3036, DOI 10.1158/1078-0432.CCR-17-2257; Fu JX, 2020, GENOME MED, V12, DOI 10.1186/s13073-020-0721-z; Furue M, 2016, J DERMATOL, V43, P121, DOI 10.1111/1346-8138.13257; Hemon P, 2011, J IMMUNOL, V186, P5173, DOI 10.4049/jimmunol.1002050; HOCHBERG Y, 1990, STAT MED, V9, P811, DOI 10.1002/sim.4780090710; Horn LA, 2018, CANCER IMMUNOL RES, V6, P59, DOI 10.1158/2326-6066.CIR-17-0026; Huang YQ, 2016, J CLIN ONCOL, V34, P2157, DOI 10.1200/JCO.2015.65.9128; Imbert C, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-14218-7; Janakiram M, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2015.1026534; Janakiram M, 2015, CLIN CANCER RES, V21, P2359, DOI 10.1158/1078-0432.CCR-14-1495; Juneja VR, 2017, J EXP MED, V214, P895, DOI 10.1084/jem.20160801; Kaufman HL, 2013, NAT REV CLIN ONCOL, V10, P588, DOI 10.1038/nrclinonc.2013.153; Koyama S, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10501; Leonardi GC, 2020, INT J ONCOL, V57, P609, DOI 10.3892/ijo.2020.5088; Leonardi GC, 2018, INT J ONCOL, V52, P1071, DOI 10.3892/ijo.2018.4287; Li CW, 2021, NUCLEIC ACIDS RES, V49, pW242, DOI 10.1093/nar/gkab418; Liu CW, 2008, J CLIN INVEST, V118, P1165, DOI 10.1172/JCI33583; Liu-Smith F, 2020, J AM ACAD DERMATOL, V82, P1102, DOI [10.1016/j.jaad.2017.11.049, 10.1016/j.jaad.2016.08.027]; Mao R, 2020, AGING-US, V12, P22233, DOI 10.18632/aging.104161; Mao R, 2020, AGING-US, V12, P20778, DOI 10.18632/aging.104014; Mao R, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01673; Martin-Orozco N, 2010, CANCER RES, V70, P9581, DOI 10.1158/0008-5472.CAN-10-1379; McLachlan GJ, 2017, METHODS MOL BIOL, V1526, P345, DOI 10.1007/978-1-4939-6613-4_19; Naumova E, 2005, CANCER IMMUNOL IMMUN, V54, P172, DOI 10.1007/s00262-004-0575-z; Newman AM, 2015, NAT METHODS, V12, P453, DOI [10.1038/NMETH.3337, 10.1038/nmeth.3337]; Patel M, 2021, CANCERS, V13, DOI 10.3390/cancers13051115; Pentcheva-Hoang T, 2014, CANCER IMMUNOL RES, V2, P970, DOI 10.1158/2326-6066.CIR-14-0104; Richman LP, 2014, CANCER IMMUNOL RES, V2, P19, DOI 10.1158/2326-6066.CIR-13-0152; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Romero D, 2016, NAT REV CLIN ONCOL, V13, DOI 10.1038/nrclinonc.2016.40; Roszik J, 2019, CANCER IMMUNOL IMMUN, V68, P1493, DOI 10.1007/s00262-019-02382-0; Runa F, 2017, Curr Mol Biol Rep, V3, P218, DOI 10.1007/s40610-017-0073-7; Seth R, 2020, J CLIN ONCOL, V38, DOI 10.1200/JCO.20.00198; Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI [10.3322/caac.21332, 10.3322/caac.21590, 10.3322/caac.21708]; Tumis ME, 2016, IMMUNITY, V44, P316, DOI 10.1016/j.immuni.2016.01.013; Vesely MD, 2020, J INVEST DERMATOL, V140, P1134, DOI 10.1016/j.jid.2020.02.005; Vickers AJ, 2008, BMC MED INFORM DECIS, V8, DOI 10.1186/1472-6947-8-53; Vonderheide RH, 2020, ANNU REV MED, V71, P47, DOI 10.1146/annurev-med-062518-045435; Wang J, 2019, NAT MED, V25, P656, DOI 10.1038/s41591-019-0374-x; Wang J, 2019, CELL, V176, P334, DOI 10.1016/j.cell.2018.11.010; Ward-Kavanagh LK, 2016, IMMUNITY, V44, P1005, DOI 10.1016/j.immuni.2016.04.019; Wilkerson MD, 2010, BIOINFORMATICS, V26, P1572, DOI 10.1093/bioinformatics/btq170; Xiao YP, 2015, CLIN CANCER RES, V21, P2201, DOI 10.1158/1078-0432.CCR-14-2658; Yang S, 2020, J CELL PHYSIOL, V235, P1025, DOI 10.1002/jcp.29018; Zhang CQ, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1461304	53	0	0	2	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 24	2021	12								756282	10.3389/fimmu.2021.756282	http://dx.doi.org/10.3389/fimmu.2021.756282			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YH6TC	35003069	gold, Green Published			2022-12-18	WOS:000743296700001
J	Ye, YZ; Gu, LJ; Jian, ZH; Xiong, XX				Ye, YingZe; Gu, Lijuan; Jian, Zhihong; Xiong, Xiaoxing			Editorial: Immune Response to Cerebral Ischemia: Exploring Mechanisms and Potential Treatment Targets	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						cerebral ischemia; neuroinflammation; peripheral immune system; immune cells; immune mediators; immunotherapy			[Ye, YingZe; Gu, Lijuan; Jian, Zhihong; Xiong, Xiaoxing] Wuhan Univ, Cent Lab, Renmin Hosp, Wuhan, Peoples R China; [Jian, Zhihong; Xiong, Xiaoxing] Wuhan Univ, Dept Neurosurg, Renmin Hosp, Wuhan, Peoples R China	Wuhan University; Wuhan University	Gu, LJ (corresponding author), Wuhan Univ, Cent Lab, Renmin Hosp, Wuhan, Peoples R China.	gulijuan@whu.edu.cn			National Natural Science Foundation of China [82171336, 81870939, 82071339, 81771283]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	Funding This study was supported by the National Natural Science Foundation of China (Nos. 82171336 and 81870939 to XX; 82071339 and 81771283 to LG).		0	0	0	4	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 24	2021	12								813836	10.3389/fimmu.2021.813836	http://dx.doi.org/10.3389/fimmu.2021.813836			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YH9PV	35003142	gold, Green Published			2022-12-18	WOS:000743492200001
J	Bradley, D; Xu, AM; Hsueh, WLA				Bradley, David; Xu, Aimin; Hsueh, Willa A.			Editorial: The Immunomodulatory Roles of Adipocytes	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						adipocyte; innate and adaptive immune response; exosomes; adipokine cytokines; metabolic disease	INSULIN-RESISTANCE; INFLAMMATION; OBESITY; MECHANISMS; GLUCOSE; DISEASE		[Bradley, David; Hsueh, Willa A.] Ohio State Univ, Dept Internal Med, Div Endocrinol Diabet & Metab, Diabet & Metab Res Ctr,Wexner Med Ctr, Columbus, OH 43210 USA; [Xu, Aimin] Univ Hong Kong, State Key Lab Pharmaceut Biotechnol, Hong Kong, Peoples R China; [Xu, Aimin] Univ Hong Kong, Dept Med, Hong Kong, Peoples R China	University System of Ohio; Ohio State University; University of Hong Kong; University of Hong Kong	Bradley, D; Hsueh, WLA (corresponding author), Ohio State Univ, Dept Internal Med, Div Endocrinol Diabet & Metab, Diabet & Metab Res Ctr,Wexner Med Ctr, Columbus, OH 43210 USA.	Dbradley3@pennstatehealth.psu.edu; Willa.Hsueh@osumc.edu			American Diabetes Association [1-16-ICTS-049]; National Institutes of Health [KL2TR001068, HL135622];  [KL2]	American Diabetes Association(American Diabetes Association); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); 	This study was supported by grants from the American Diabetes Association 1-16-ICTS-049, The National Institutes of Health KL2 Scholar Award KL2TR001068 and HL135622.	Agwunobi AO, 2000, J CLIN ENDOCR METAB, V85, P3770, DOI 10.1210/jc.85.10.3770; Akhtar DH, 2019, J CLIN TRANSL HEPATO, V7, P362, DOI 10.14218/JCTH.2019.00028; Boden Guenther, 2006, Curr Diab Rep, V6, P177, DOI 10.1007/s11892-006-0031-x; Bradley D, 2019, DIABETES CARE, V42, P466, DOI 10.2337/dc18-0870; Chaurasia B, 2019, SCIENCE, V365, P386, DOI 10.1126/science.aav3722; Chawla A, 2011, NAT REV IMMUNOL, V11, P738, DOI 10.1038/nri3071; Chow WS, 2013, J AM HEART ASSOC, V2, DOI 10.1161/JAHA.112.004176; Crewe C, 2017, J CLIN INVEST, V127, P74, DOI 10.1172/JCI88883; Deng T, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15725; Deng T, 2016, ANNU REV PATHOL-MECH, V11, P421, DOI 10.1146/annurev-pathol-012615-044359; Deng T, 2013, CELL METAB, V17, P411, DOI 10.1016/j.cmet.2013.02.009; Deng ZB, 2009, DIABETES, V58, P2498, DOI 10.2337/db09-0216; FERRANNINI E, 1983, J CLIN INVEST, V72, P1737, DOI 10.1172/JCI111133; Flaherty SE, 2019, SCIENCE, V363, P989, DOI 10.1126/science.aaw2586; Francque SM, 2016, J HEPATOL, V65, P425, DOI 10.1016/j.jhep.2016.04.005; Holland WL, 2011, J CLIN INVEST, V121, P1858, DOI 10.1172/JCI43378; Hoo RLC, 2013, J HEPATOL, V58, P358, DOI 10.1016/j.jhep.2012.10.022; Huh JY, 2017, DIABETES, V66, P835, DOI 10.2337/db16-1122; KELLEY DE, 1993, J CLIN INVEST, V92, P91, DOI 10.1172/JCI116603; Kiliaan AJ, 2014, LANCET NEUROL, V13, P913, DOI 10.1016/S1474-4422(14)70085-7; Kwok KHM, 2016, CLIN SCI, V130, P2087, DOI 10.1042/CS20160465; Lee CH, 2018, CLIN CHEM, V64, P1496, DOI 10.1373/clinchem.2018.289157; Liu ZJ, 2018, J PINEAL RES, V64, DOI 10.1111/jpi.12455; Miyoshi T, 2010, ATHEROSCLEROSIS, V211, P164, DOI 10.1016/j.atherosclerosis.2010.01.032; Olefsky JM, 2010, ANNU REV PHYSIOL, V72, P219, DOI 10.1146/annurev-physiol-021909-135846; Powell-Wiley TM, 2021, CIRCULATION, V143, pE984, DOI 10.1161/CIR.0000000000000973; Satoh M, 2016, SCI REP-UK, V6, DOI 10.1038/srep28473; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Shulman GI, 2000, J CLIN INVEST, V106, P171, DOI 10.1172/JCI10583; Thomou T, 2017, NATURE, V542, P450, DOI 10.1038/nature21365; Tso AWK, 2011, NEUROLOGY, V76, P1968, DOI 10.1212/WNL.0b013e31821e54b3; Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246; Zhang YQ, 2016, J MOL CELL BIOL, V8, P505, DOI 10.1093/jmcb/mjw040	33	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 23	2021	12								827281	10.3389/fimmu.2021.827281	http://dx.doi.org/10.3389/fimmu.2021.827281			4	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YK6CS	35003144	Green Published, gold			2022-12-18	WOS:000745299200001
J	Chen, CW; Wei, JCC; Gu, JR; Yu, D				Chen, Chih-Wei; Wei, James Cheng-Chung; Gu, Jieruo; Yu, David			Editorial: Advances in Pathogenesis, Etiology, and Therapies for Ankylosing Spondylitis	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						ankylosing spondylitis; acquired immunity; diagnosis; innate immunity; therapy	EXPRESSION		[Chen, Chih-Wei; Wei, James Cheng-Chung] Chung Shan Med Univ, Inst Med, Taichung, Taiwan; [Wei, James Cheng-Chung] Chung Shan Med Univ Hosp, Dept Allergy Immunol & Rheumatol, Taichung, Taiwan; [Wei, James Cheng-Chung] China Med Univ, Grad Inst Integrated Med, Taichung, Taiwan; [Gu, Jieruo] Sun Yat Sen Univ, Affiliated Hosp 3, Rheumatol Dept, Guangzhou, Peoples R China; [Yu, David] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA	Chung Shan Medical University; Chung Shan Medical University; Chung Shan Medical University Hospital; China Medical University Taiwan; Sun Yat Sen University; University of California System; University of California Los Angeles	Gu, JR (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 3, Rheumatol Dept, Guangzhou, Peoples R China.	gujieruo@163.com		Chen, Chih-Wei/0000-0003-4004-7826				Baeten D, 2018, ANN RHEUM DIS, V77, P1295, DOI 10.1136/annrheumdis-2018-213328; Braun J, 2007, LANCET, V369, P1379, DOI 10.1016/S0140-6736(07)60635-7; Brown MA, 1997, ARTHRITIS RHEUM, V40, P1823, DOI 10.1002/art.1780401015; Burgos-Varga R, 2016, ARTHRITIS RES THER, V18, DOI 10.1186/s13075-016-1027-9; Dulic S, 2018, PATHOBIOLOGY, V85, P201, DOI 10.1159/000484250; Gu JR, 2009, ARTHRITIS RHEUM-US, V60, P3269, DOI 10.1002/art.24968; Huang CH, 2014, J RHEUMATOL, V41, P1104, DOI 10.3899/jrheum.130515; Huang CH, 2011, RHEUMATOLOGY, V50, P1809, DOI 10.1093/rheumatology/ker211; van der Heijde D, 2018, LANCET, V392, P2441, DOI 10.1016/S0140-6736(18)31946-9; van der Heijde D, 2017, ANN RHEUM DIS, V76, P1340, DOI 10.1136/annrheumdis-2016-210322; Wei JCC, 2020, INT J RHEUM DIS, V23, P24, DOI 10.1111/1756-185X.13679; Yeremenko N, 2014, CURR OPIN RHEUMATOL, V26, P361, DOI 10.1097/BOR.0000000000000069	12	0	0	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 23	2021	12								822582	10.3389/fimmu.2021.822582	http://dx.doi.org/10.3389/fimmu.2021.822582			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YK6AZ	35003143	gold, Green Published			2022-12-18	WOS:000745294600001
J	Ito, K; Kanaseki, T; Tokita, S; Torigoe, T; Hirasawa, N; Ogasawara, K				Ito, Koyu; Kanaseki, Takayuki; Tokita, Serina; Torigoe, Toshihiko; Hirasawa, Noriyasu; Ogasawara, Kouetsu			Palladium-Induced Temporal Internalization of MHC Class I Contributes to T Cell-Mediated Antigenicity	FRONTIERS IN IMMUNOLOGY			English	Article						metal allergy; palladium; MHC class I internalization; alternative peptide presentation; dental biomaterials	CROSS-PRESENTATION; CONTACT ALLERGY; NICKEL; SELF; AUTOIMMUNITY; RECOGNITION; REACTIVITY; COBALT; MODEL	Palladium (Pd) is a widely used metal and extremely important biomaterial for the reconstruction of occlusions during dental restorations. However, metallic biomaterials can cause serious allergic reactions, such as Pd-related oral mucositis seen in dentistry. Metal allergy is categorized as a type IV allergy and we demonstrated that CD8 T cells play an important role in Pd allergy previously. As TCR of CD8 T cells recognizes MHC class I/peptide complex, the antigen specificity to this complex seems to be generated during Pd allergy. However, it remains unknown if Pd affects the MHC class I/peptide complex. In this study, we investigated the behavior of the MHC class I/peptide complex in response to Pd treatment. We found that PdCl2 treatment altered peptide presentation on MHC class I and that co-culture with Pd-treated DC2.4 cells induced activation of Pd-responsive TCR-expressing T cell line. Furthermore, PdCl2 treatment induced temporal MHC class I internalization and inhibition of membrane movement suppressed Pd-induced T cell-mediated antigenicity. These data suggest that Pd-induced MHC class I internalization is critical for generation of antigenicity through a mechanism including differential peptide loading on MHC class I, which results in Pd allergy.	[Ito, Koyu; Ogasawara, Kouetsu] Tohoku Univ, Inst Dev Aging & Canc, Dept Immunobiol, Sendai, Miyagi, Japan; [Kanaseki, Takayuki; Tokita, Serina; Torigoe, Toshihiko] Sapporo Med Univ, Sch Med, Dept Pathol, Sapporo, Hokkaido, Japan; [Tokita, Serina] Sapporo Dohto Hosp, Acad Ctr, Sapporo, Hokkaido, Japan; [Hirasawa, Noriyasu] Tohoku Univ, Grad Sch Pharmaceut Sci, Lab Pharmacotherapy Life Style Related Dis, Sendai, Miyagi, Japan	Tohoku University; Sapporo Medical University; Tohoku University	Ito, K; Ogasawara, K (corresponding author), Tohoku Univ, Inst Dev Aging & Canc, Dept Immunobiol, Sendai, Miyagi, Japan.	koyu.ito.c6@tohoku.ac.jp; immunobiology@grp.tohoku.ac.jp	Ito, Koyu/CAH-5669-2022	Torigoe, Toshihiko/0000-0002-9463-5917; Kanaseki, Takayuki/0000-0001-7294-6880	Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (JSPS) KAKENHI [16H06497, 19H03835, JP19094976, JP20240606]; Japan Agency for Medical Research and Development (AMED) [JP19cm0106352]; Cooperative Research Project Program Joint Usage/Research Center at the Institute of Development, Aging and Cancer, Tohoku University	Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (JSPS) KAKENHI; Japan Agency for Medical Research and Development (AMED)(Japan Agency for Medical Research and Development (AMED)); Cooperative Research Project Program Joint Usage/Research Center at the Institute of Development, Aging and Cancer, Tohoku University	This work was supported by Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (JSPS) KAKENHI to KO (16H06497, 19H03835) and TK (JP19094976 and JP20240606) and the Japan Agency for Medical Research and Development (AMED) Grant to TK (JP19cm0106352) and partly supported by the Cooperative Research Project Program Joint Usage/Research Center at the Institute of Development, Aging and Cancer, Tohoku University to NH.	Amicosante M, 2006, CLIN IMMUNOL, V121, P134, DOI 10.1016/j.clim.2006.03.012; Bill JR, 2005, J IMMUNOL, V175, P7029, DOI 10.4049/jimmunol.175.10.7029; Cebrian I, 2016, EMBO REP, V17, P1753, DOI 10.15252/embr.201642358; Chervona Y, 2012, METALLOMICS, V4, P619, DOI 10.1039/c2mt20033c; Garau V, 2005, J PROSTHET DENT, V93, P318, DOI 10.1016/j.prosdent.2005.01.002; Griem P, 1996, EUR J IMMUNOL, V26, P279, DOI 10.1002/eji.1830260202; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; Hongo A, 2019, J IMMUNOL, V202, P2849, DOI 10.4049/jimmunol.1900029; Iguchi N, 2016, INT IMMUNOPHARMACOL, V35, P70, DOI 10.1016/j.intimp.2016.03.021; Illing PT, 2012, NATURE, V486, P554, DOI 10.1038/nature11147; Jensen PE, 1999, IMMUNOL REV, V172, P229, DOI 10.1111/j.1600-065X.1999.tb01368.x; KALISH RS, 1995, J AM ACAD DERMATOL, V32, P640, DOI 10.1016/0190-9622(95)90351-8; Kashiwa K, 2012, J ARTIF ORGANS, V15, P207, DOI 10.1007/s10047-012-0632-x; Kawano M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086810; Kobayashi H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076385; LANGLADEDEMOYEN P, 1994, INT IMMUNOL, V6, P1759, DOI 10.1093/intimm/6.11.1759; Lohr J, 2005, IMMUNOL REV, V204, P116, DOI 10.1111/j.0105-2896.2005.00241.x; Lu L, 2003, J EXP MED, V197, P567, DOI 10.1084/jem.20021762; Mayorga LS, 2019, MOL IMMUNOL, V113, P87, DOI 10.1016/j.molimm.2018.03.028; Minang JT, 2006, CLIN EXP IMMUNOL, V146, P417, DOI 10.1111/j.1365-2249.2006.03226.x; Muris J, 2012, ALLERGY, V67, P1605, DOI 10.1111/all.12046; Okada M, 2019, DENT MATER, V35, P169, DOI 10.1016/j.dental.2018.11.009; Ostrov DA, 2012, P NATL ACAD SCI USA, V109, P9959, DOI 10.1073/pnas.1207934109; PISTOOR FHM, 1995, J INVEST DERMATOL, V105, P92, DOI 10.1111/1523-1747.ep12313366; Potolicchio L, 1999, EUR J IMMUNOL, V29, P2140; Redwood AJ, 2018, HLA, V91, P3, DOI 10.1111/tan.13183; Saito M, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17020202; Schmidt M, 2015, J DTSCH DERMATOL GES, V13, P653, DOI 10.1111/ddg.12673; Schnuch A, 2008, ALLERGY, V63, P156, DOI 10.1111/j.1398-9995.2007.01590.x; Takeda Y, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061162; Thierse HJ, 2004, J IMMUNOL, V172, P1926, DOI 10.4049/jimmunol.172.3.1926; Thomas C, 2019, CURR OPIN IMMUNOL, V58, P9, DOI 10.1016/j.coi.2019.01.001; Tsuchiya K, 2012, AM J PHYSIOL-LUNG C, V303, pL54, DOI 10.1152/ajplung.00208.2011; Ueda T, 2019, J BIOMED MATER RES A, V107, P991, DOI 10.1002/jbm.a.36624; van Endert P, 2016, IMMUNOL REV, V272, P80, DOI 10.1111/imr.12424; Yin L, 2013, PROTEIN CELL, V4, P8, DOI 10.1007/s13238-012-2077-7; Yoshihisa Y, 2012, DERMAT RES PRACT, V2012, DOI 10.1155/2012/749561	37	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 23	2021	12								736936	10.3389/fimmu.2021.736936	http://dx.doi.org/10.3389/fimmu.2021.736936			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YN3VK	35003059	gold, Green Published			2022-12-18	WOS:000747188700001
J	Nakagawa, T; Tanino, T; Onishi, M; Tofukuji, S; Kanazawa, T; Ishioka, Y; Itoh, T; Kugimiya, A; Katayama, K; Yamamoto, T; Nagira, M; Ishii, KJ				Nakagawa, Takayuki; Tanino, Tetsuya; Onishi, Motoyasu; Tofukuji, Soichi; Kanazawa, Takayuki; Ishioka, Yukichi; Itoh, Takeshi; Kugimiya, Akira; Katayama, Kazufumi; Yamamoto, Takuya; Nagira, Morio; Ishii, Ken J.			S-540956, a CpG Oligonucleotide Annealed to a Complementary Strand With an Amphiphilic Chain Unit, Acts as a Potent Cancer Vaccine Adjuvant by Targeting Draining Lymph Nodes	FRONTIERS IN IMMUNOLOGY			English	Article						cancer peptide vaccine; adjuvant; CpG oligonucleotide; delivery system; draining lymph node	OLIGODEOXYNUCLEOTIDE; AGONISTS; CPG-7909; DELIVERY; CELLS	Robust induction of cancer-antigen-specific CD8(+) T cells is essential for the success of cancer peptide vaccines, which are composed of a peptide derived from a cancer-specific antigen and an immune-potentiating adjuvant, such as a Toll-like receptor (TLR) agonist. Efficient delivery of a vaccine antigen and an adjuvant to antigen-presenting cells in the draining lymph nodes (LNs) holds key to maximize vaccine efficacy. Here, we developed S-540956, a novel TLR9-agonistic adjuvant consisting of B-type CpG ODN2006 (also known as CpG7909), annealed to its complementary sequence oligodeoxynucleotide (ODN) conjugated to a lipid; it could target both a cancer peptide antigen and a CpG-adjuvant in the draining LNs. S-540956 accumulation in the draining LNs and activation of plasmacytoid dendritic cells (pDCs) were significantly higher than that of ODN2006. Mechanistic analysis revealed that S-540956 enhanced the induction of MHC class I peptide-specific CD8(+) T cell responses via TLR9 in a CD4(+) T cell-independent manner. In mice, the therapeutic effect of S-540956-adjuvanted with a human papillomavirus (HPV)-E7 peptide vaccine against HPV-E7-expressing TC-1 tumors was significantly better than that of an ODN2006-adjuvanted vaccine. Our findings demonstrate a novel adjuvant discovery with the complementary strand conjugated to a lipid, which enabled draining LN targeting and increased ODN2006 accumulation in draining LNs, thereby enhancing the adjuvant effect. Our findings imply that S-540956 is a promising adjuvant for cancer peptide vaccines and has a high potential for applications in various vaccines, including recombinant protein vaccines.	[Nakagawa, Takayuki; Tanino, Tetsuya; Onishi, Motoyasu; Tofukuji, Soichi; Kanazawa, Takayuki; Ishioka, Yukichi; Itoh, Takeshi; Kugimiya, Akira; Katayama, Kazufumi; Nagira, Morio] Shionogi & Co Ltd, Pharmaceut Res Div, Osaka, Japan; [Yamamoto, Takuya; Ishii, Ken J.] Natl Inst Biomed Innovat Hlth & Nutr NIBIOHN, Ctr Vaccine & Adjuvant Res CVAR, Lab Adjuvant Innovat, Osaka, Japan; [Ishii, Ken J.] Natl Inst Biomed Innovat Hlth & Nutr NIBIOHN, Ctr Vaccine & Adjuvant Res CVAR, Lab Mockup Vaccine Project, Osaka, Japan; [Ishii, Ken J.] Univ Tokyo IMSUT, Inst Med Sci, Div Vaccine Sci, Dept Microbiol & Immunol, Tokyo, Japan	Shionogi & Company Limited	Ishii, KJ (corresponding author), Natl Inst Biomed Innovat Hlth & Nutr NIBIOHN, Ctr Vaccine & Adjuvant Res CVAR, Lab Adjuvant Innovat, Osaka, Japan.; Ishii, KJ (corresponding author), Natl Inst Biomed Innovat Hlth & Nutr NIBIOHN, Ctr Vaccine & Adjuvant Res CVAR, Lab Mockup Vaccine Project, Osaka, Japan.; Ishii, KJ (corresponding author), Univ Tokyo IMSUT, Inst Med Sci, Div Vaccine Sci, Dept Microbiol & Immunol, Tokyo, Japan.	kenishii@ims.u-tokyo.ac.jp	; Yamamoto, Takuya/L-2642-2013	Nakagawa, Takayuki/0000-0002-6247-3191; Yamamoto, Takuya/0000-0003-3753-1211				Akira K., 2017, Patent, Patent No. [WO2017/057540 Al, 2017057540]; Ammi R, 2015, PHARMACOL THERAPEUT, V146, P120, DOI 10.1016/j.pharmthera.2014.09.010; Bachmann MF, 2010, NAT REV IMMUNOL, V10, P787, DOI 10.1038/nri2868; Bezu L, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1511506; Chan MP, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6853; Cooper CL, 2004, VACCINE, V22, P3136, DOI 10.1016/j.vaccine.2004.01.058; De Groot R, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2019.1648170; Eisenbarth SC, 2019, NAT REV IMMUNOL, V19, P89, DOI 10.1038/s41577-018-0088-1; Eng NF, 2013, HUM VACC IMMUNOTHER, V9, P1661, DOI 10.4161/hv.24715; Faries MB, 2000, ANN SURG ONCOL, V7, P98, DOI 10.1007/s10434-000-0098-6; Hanson MC, 2015, J CLIN INVEST, V125, P2532, DOI 10.1172/JCI79915; Hartmann G, 2000, J IMMUNOL, V164, P1617, DOI 10.4049/jimmunol.164.3.1617; Heikenwalder M, 2004, NAT MED, V10, P187, DOI 10.1038/nm987; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Hollingsworth RE, 2019, NPJ VACCINES, V4, DOI 10.1038/s41541-019-0103-y; Iwasaki A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112; Jurk M, 2006, CHEMMEDCHEM, V1, P1007, DOI 10.1002/cmdc.200600064; Karapetyan L, 2020, ONCOTARGETS THER, V13, P10039, DOI 10.2147/OTT.S247050; Khong H, 2016, J IMMUNOTHER CANCER, V4, DOI 10.1186/s40425-016-0160-y; Klinman DM, 1999, IMMUNITY, V11, P123, DOI 10.1016/S1074-7613(00)80087-4; Klinman DM, 2004, NAT REV IMMUNOL, V4, P248, DOI 10.1038/nri1329; Kobiyama K, 2014, P NATL ACAD SCI USA, V111, P3086, DOI 10.1073/pnas.1319268111; Krieg AM, 2004, J IMMUNOTHER, V27, P460, DOI 10.1097/00002371-200411000-00006; Krieg AM, 2007, J CLIN INVEST, V117, P1184, DOI 10.1172/JCI31414; Krieg AM, 2006, NAT REV DRUG DISCOV, V5, P471, DOI 10.1038/nrd2059; Liu HP, 2014, NATURE, V507, P519, DOI 10.1038/nature12978; Loschko J, 2011, J IMMUNOL, V186, P6718, DOI 10.4049/jimmunol.1004029; Lynn GM, 2020, NAT BIOTECHNOL, V38, P320, DOI 10.1038/s41587-019-0390-x; Momota M, 2020, INT IMMUNOL, V32, P203, DOI 10.1093/intimm/dxz070; Mullen GED, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002940; Mutwiri GK, 2004, J CONTROL RELEASE, V97, P1, DOI 10.1016/j.jcornel.2004.02.022; Onishi R, 2015, ANAL SCI, V31, P1255, DOI 10.2116/analsci.31.1255; Sauder DN, 2003, ANTIMICROB AGENTS CH, V47, P3846, DOI 10.1128/AAC.47.12.3846-3852.2003; Scheiermann J, 2014, VACCINE, V32, P6377, DOI 10.1016/j.vaccine.2014.06.065; Sparwasser T, 1999, J IMMUNOL, V162, P2368; Steinbuck MP, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abe5819; Swiecki M, 2015, NAT REV IMMUNOL, V15, P471, DOI 10.1038/nri3865; Thomas SN, 2014, BIOMATERIALS, V35, P814, DOI 10.1016/j.biomaterials.2013.10.003; Wimmers F, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1067745; Zhao J, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01184	40	0	0	3	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 23	2021	12								803090	10.3389/fimmu.2021.803090	http://dx.doi.org/10.3389/fimmu.2021.803090			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YH9VE	35003132	Green Published, gold			2022-12-18	WOS:000743506300001
J	Nyanhete, TE; Edwards, RJ; LaBranche, CC; Mansouri, K; Eaton, A; Dennison, SM; Saunders, KO; Goodman, D; Janowska, K; Spreng, RL; Zhang, L; Mudrak, SV; Hope, TJ; Hora, B; Bradley, T; Georgiev, IS; Montefiori, DC; Acharya, P; Tomaras, GD				Nyanhete, Tinashe E.; Edwards, Robert J.; LaBranche, Celia C.; Mansouri, Katayoun; Eaton, Amanda; Dennison, S. Moses; Saunders, Kevin O.; Goodman, Derrick; Janowska, Katarzyna; Spreng, Rachel L.; Zhang, Lu; Mudrak, Sarah V.; Hope, Thomas J.; Hora, Bhavna; Bradley, Todd; Georgiev, Ivelin S.; Montefiori, David C.; Acharya, Priyamvada; Tomaras, Georgia D.			Polyclonal Broadly Neutralizing Antibody Activity Characterized by CD4 Binding Site and V3-Glycan Antibodies in a Subset of HIV-1 Virus Controllers	FRONTIERS IN IMMUNOLOGY			English	Article						HIV-1 Virus Controllers; broadly neutralizing antibodies; antibody-dependent cellular phagocytosis (ADCP); CD4-binding site antibodies; negative-stain electron microscopy; neutralization fingerprinting assay	SEQUENCE ALIGNMENT; T-CELLS; TYPE-1; INFECTION; BREADTH; MAGNITUDE; RESPONSES	Broadly neutralizing antibodies (bNAbs), known to mediate immune control of HIV-1 infection, only develop in a small subset of HIV-1 infected individuals. Despite being traditionally associated with patients with high viral loads, bNAbs have also been observed in therapy naive HIV-1+ patients naturally controlling virus replication [Virus Controllers (VCs)]. Thus, dissecting the bNAb response in VCs will provide key information about what constitutes an effective humoral response to natural HIV-1 infection. In this study, we identified a polyclonal bNAb response to natural HIV-1 infection targeting CD4 binding site (CD4bs), V3-glycan, gp120-gp41 interface and membrane-proximal external region (MPER) epitopes on the HIV-1 envelope (Env). The polyclonal antiviral antibody (Ab) response also included antibody-dependent cellular phagocytosis of clade AE, B and C viruses, consistent with both the Fv and Fc domain contributing to function. Sequence analysis of envs from one of the VCs revealed features consistent with potential immune pressure and virus escape from V3-glycan targeting bNAbs. Epitope mapping of the polyclonal bNAb response in VCs with bNAb activity highlighted the presence of gp120-gp41 interface and CD4bs antibody classes with similar binding profiles to known potent bNAbs. Thus, these findings reveal the induction of a broad and polyfunctional humoral response in VCs in response to natural HIV-1 infection.	[Nyanhete, Tinashe E.; Dennison, S. Moses; Goodman, Derrick; Spreng, Rachel L.; Zhang, Lu; Mudrak, Sarah V.; Tomaras, Georgia D.] Duke Univ, Sch Med, Ctr Human Syst Immunol, Durham, NC 27706 USA; [Nyanhete, Tinashe E.; Edwards, Robert J.; Mansouri, Katayoun; Dennison, S. Moses; Saunders, Kevin O.; Goodman, Derrick; Janowska, Katarzyna; Spreng, Rachel L.; Zhang, Lu; Mudrak, Sarah V.; Hora, Bhavna; Bradley, Todd; Montefiori, David C.; Acharya, Priyamvada; Tomaras, Georgia D.] Duke Univ, Sch Med, Duke Human Vaccine Inst, Durham, NC 27706 USA; [Nyanhete, Tinashe E.; Tomaras, Georgia D.] Duke Univ, Sch Med, Dept Immunol, Durham, NC 27706 USA; [Edwards, Robert J.; Spreng, Rachel L.; Hora, Bhavna; Bradley, Todd] Duke Univ, Sch Med, Dept Med, Durham, NC 27706 USA; [LaBranche, Celia C.; Eaton, Amanda; Dennison, S. Moses; Saunders, Kevin O.; Goodman, Derrick; Zhang, Lu; Mudrak, Sarah V.; Montefiori, David C.; Acharya, Priyamvada; Tomaras, Georgia D.] Duke Univ, Sch Med, Dept Surg, Durham, NC 27706 USA; [Hope, Thomas J.] Northwestern Univ, Feinberg Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA; [Georgiev, Ivelin S.] Vanderbilt Univ, Med Ctr, Vanderbilt Vaccine Ctr, Nashville, TN USA; [Tomaras, Georgia D.] Duke Univ, Sch Med, Dept Mol Genet & Microbiol, Durham, NC 27706 USA; [Bradley, Todd] Childrens Mercy Kansas City, Kansas City, MO USA	Duke University; Duke University; Duke University; Duke University; Duke University; Northwestern University; Feinberg School of Medicine; Vanderbilt University; Duke University; Children's Mercy Hospital	Tomaras, GD (corresponding author), Duke Univ, Sch Med, Ctr Human Syst Immunol, Durham, NC 27706 USA.; Tomaras, GD (corresponding author), Duke Univ, Sch Med, Duke Human Vaccine Inst, Durham, NC 27706 USA.; Tomaras, GD (corresponding author), Duke Univ, Sch Med, Dept Immunol, Durham, NC 27706 USA.; Tomaras, GD (corresponding author), Duke Univ, Sch Med, Dept Surg, Durham, NC 27706 USA.; Tomaras, GD (corresponding author), Duke Univ, Sch Med, Dept Mol Genet & Microbiol, Durham, NC 27706 USA.	gdt@duke.edu			NIH/NIAID [1P01A1120756, R01AI145687, R01AI131722, R56AI052779]; Center for HIV-1/AIDS Vaccine Immunology and Immunogen Discovery [UMI-AI100645]; Center for AIDS Research [P30 AI064518]	NIH/NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Center for HIV-1/AIDS Vaccine Immunology and Immunogen Discovery; Center for AIDS Research	This work was supported by the NIH/NIAID-funded 1P01A1120756, R01AI145687, R01AI131722, R56AI052779, Center for HIV-1/AIDS Vaccine Immunology and Immunogen Discovery (Grant UMI-AI100645), and the Center for AIDS Research (P30 AI064518).	Anthony C, 2017, J VIROL, V91, DOI 10.1128/JVI.00828-17; Bailey JR, 2006, J VIROL, V80, P4758, DOI 10.1128/JVI.80.10.4758-4770.2006; Bianchi M, 2018, IMMUNITY, V49, P288, DOI 10.1016/j.immuni.2018.07.009; Bonsignori M, 2016, CELL, V165, P449, DOI 10.1016/j.cell.2016.02.022; Butler AL, 2019, CURR HIV-AIDS REP, V16, P169, DOI 10.1007/s11904-019-00432-x; Carotenuto P, 1998, AIDS, V12, P1591, DOI 10.1097/00002030-199813000-00005; Caskey M, 2015, NATURE, V522, P487, DOI 10.1038/nature14411; Cecilia D, 1999, J INFECT DIS, V179, P1365, DOI 10.1086/314773; Cornelissen M, 2016, AIDS RES HUM RETROV, V32, P1135, DOI 10.1089/aid.2015.0324; deCamp A, 2014, J VIROL, V88, P2489, DOI 10.1128/JVI.02853-13; Dennison SM, 2018, J IMMUNOL, V201, P1315, DOI 10.4049/jimmunol.1800323; Deshpande S, 2016, RETROVIROLOGY, V13, DOI 10.1186/s12977-016-0297-2; Diskin R, 2013, J EXP MED, V210, P1235, DOI 10.1084/jem.20130221; Doria-Rose NA, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006148; Doria-Rose NA, 2010, J VIROL, V84, P1631, DOI 10.1128/JVI.01482-09; Dugast AS, 2017, CLIN INFECT DIS, V64, P1098, DOI 10.1093/cid/cix057; Euler Z, 2010, J INFECT DIS, V201, P1045, DOI 10.1086/651144; Freel SA, 2010, J VIROL, V84, P4998, DOI 10.1128/JVI.00138-10; Freund NT, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal2144; Gilbert P, 2010, J INFECT DIS, V202, P595, DOI 10.1086/654816; Gonzalez N, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193773; Gouy M, 2010, MOL BIOL EVOL, V27, P221, DOI 10.1093/molbev/msp259; Hancock G, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004658; Henderson R, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-14196-w; Huang YD, 2009, STAT BIOPHARM RES, V1, P81, DOI 10.1198/sbr.2009.0008; Hutchinson JM, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01021; KIMURA M, 1980, J MOL EVOL, V16, P111, DOI 10.1007/BF01731581; Kouyos RD, 2018, NATURE, V561, P406, DOI 10.1038/s41586-018-0517-0; Lambotte O, 2009, AIDS, V23, P897, DOI 10.1097/QAD.0b013e328329f97d; Landais E, 2018, RETROVIROLOGY, V15, DOI 10.1186/s12977-018-0443-0; Liu PH, 2014, J VIROL, V88, P5165, DOI 10.1128/JVI.03765-13; Liu PH, 2011, J VIROL, V85, P11196, DOI 10.1128/JVI.05601-11; Lynch RM, 2012, J VIROL, V86, P7588, DOI 10.1128/JVI.00734-12; Martin-Gayo E, 2020, CELL REP, V30, P984, DOI 10.1016/j.celrep.2019.12.087; McCoy LE, 2018, RETROVIROLOGY, V15, DOI 10.1186/s12977-018-0453-y; Medina-Ramirez M, 2011, J VIROL, V85, P5804, DOI 10.1128/JVI.02482-10; Montefiori David C., 2009, V485, P395, DOI 10.1007/978-1-59745-170-3_26; Moris A, 2019, CURR OPIN HIV AIDS, V14, P265, DOI 10.1097/COH.0000000000000554; Nyanhete TE, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-46462-8; Payne TL, 2014, J VIROL, V88, P9514, DOI 10.1128/JVI.00802-14; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Pilgrim AK, 1997, J INFECT DIS, V176, P924, DOI 10.1086/516508; Richardson SI, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1006987; Rusert P, 2016, NAT MED, V22, P1260, DOI 10.1038/nm.4187; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sajadi MM, 2011, JAIDS-J ACQ IMM DEF, V57, P9, DOI 10.1097/QAI.0b013e3182100c1b; Salazar-Gonzalez JF, 2008, J VIROL, V82, P3952, DOI 10.1128/JVI.02660-07; Sanchez-Merino V, 2016, J VIROL, V90, P5231, DOI 10.1128/JVI.00049-16; Sanders RW, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003618; Scheid JF, 2009, NATURE, V458, P636, DOI 10.1038/nature07930; Seaton KE, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.94355; Silver ZA, 2019, J VIROL, V93, DOI 10.1128/JVI.00094-19; Tay MZ, 2019, J VIROL, V93, DOI 10.1128/JVI.02084-18; Tay MZ, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005817; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Todd CA, 2012, J IMMUNOL METHODS, V375, P57, DOI 10.1016/j.jim.2011.09.007; van den Kerkhof TLGM, 2016, RETROVIROLOGY, V13, DOI 10.1186/s12977-016-0279-4; Walker BD, 2013, NAT REV IMMUNOL, V13, P487, DOI 10.1038/nri3478; Whittle JRR, 2011, P NATL ACAD SCI USA, V108, P14216, DOI 10.1073/pnas.1111497108; Wills S, 2018, J VIROL, V92, DOI 10.1128/JVI.01552-17; Wu XL, 2010, SCIENCE, V329, P856, DOI 10.1126/science.1187659; Yasmeen A, 2014, RETROVIROLOGY, V11, DOI 10.1186/1742-4690-11-41; Yates NL, 2018, J VIROL, V92, DOI 10.1128/JVI.01843-17; Zhang YJ, 1997, J INFECT DIS, V176, P1180, DOI 10.1086/514111	64	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 23	2021	12								670561	10.3389/fimmu.2021.670561	http://dx.doi.org/10.3389/fimmu.2021.670561			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YK1RV	35003053	Green Published, gold			2022-12-18	WOS:000744999700001
J	Shang, K; Cheng, C; Qin, C; Xiao, J; Deng, G; Bu, BT; Xu, SB; Tian, DS				Shang, Ke; Cheng, Chang; Qin, Chuan; Xiao, Jun; Deng, Gang; Bu, Bi-Tao; Xu, Sha-Bei; Tian, Dai-Shi			Case Report: Clinical and Imaging Characteristics of a Patient with Anti-flotillin Autoantibodies: Neuromyelitis Optica or Multiple Sclerosis?	FRONTIERS IN IMMUNOLOGY			English	Article						demyelination; flotillin; neuromyelitis optica; multiple sclerosis; anti-flotillin autoantibody; case report	ADHESION; PROTEINS; REGGIE-2; CRITERIA; BRAIN	BackgroundDemyelination diseases are complex puzzles that are not always straightforward to diagnose. Multiple sclerosis and neuromyelitis optica are two that are frequently encountered. Numerous autoantibodies newly discovered in recent years have significantly aided clinical reasoning and diagnosis in differentiating demyelination disorders. Here we report a case of demyelination disease with anti-flotillin autoantibodies positive, which is not common in past references. Case summaryThe patient presented with characteristic neuromyelitis optica symptoms and had remission and relapse. But his images exhibited characteristics of both neuromyelitis optica spectrum illness and multiple sclerosis. ConclusionThis is the first case report describing the clinical course and imaging characteristics of demyelination illness associated with anti-flotillin autoantibodies. Although so far it appears to be a subtype of multiple sclerosis, there is still a potential that it is separate from MS and NMOSD.	[Shang, Ke; Cheng, Chang; Qin, Chuan; Xiao, Jun; Deng, Gang; Bu, Bi-Tao; Xu, Sha-Bei; Tian, Dai-Shi] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Neurol, Wuhan, Peoples R China	Huazhong University of Science & Technology	Xu, SB; Tian, DS (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Neurol, Wuhan, Peoples R China.	shabei_xu@163.com; tiandaishi@126.com		Tian, Dai-shi/0000-0002-7627-0811				Abdullah M, 2019, J ALZHEIMERS DIS, V72, P1165, DOI 10.3233/JAD-190908; Abdullah M, 2016, J ALZHEIMERS DIS, V53, P1433, DOI 10.3233/JAD-160292; Barnett MH, 2012, MULT SCLER J, V18, P108, DOI 10.1177/1352458511421185; Bauer M, 2006, FEBS LETT, V580, P5559, DOI 10.1016/j.febslet.2006.08.077; Bodin S, 2014, J CELL SCI, V127, P5139, DOI 10.1242/jcs.159764; Filippi M, 2016, LANCET NEUROL, V15, P292, DOI 10.1016/S1474-4422(15)00393-2; Hahn S, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0900-z; Hansen N, 2021, FRONT PSYCHIATRY, V12, DOI 10.3389/fpsyt.2021.626121; Lang DM, 1998, J NEUROBIOL, V37, P502, DOI 10.1002/(SICI)1097-4695(199812)37:4<502::AID-NEU2>3.0.CO;2-S; Langhorst MF, 2008, EUR J CELL BIOL, V87, P211, DOI 10.1016/j.ejcb.2007.12.001; Min JH, 2012, MULT SCLER J, V18, P113, DOI 10.1177/1352458511431973; Munderloh C, 2009, J NEUROSCI, V29, P6607, DOI 10.1523/JNEUROSCI.0870-09.2009; Sastre-Garriga J, 2020, NAT REV NEUROL, V16, P171, DOI 10.1038/s41582-020-0314-x; Schulte T, 1997, DEVELOPMENT, V124, P577; Shimizu J, 2010, NEUROLOGY, V75, P1423, DOI 10.1212/WNL.0b013e3181f8832e; Stuermer CAO, 2010, TRENDS CELL BIOL, V20, P6, DOI 10.1016/j.tcb.2009.10.003; Wingerchuk DM, 2015, NEUROLOGY, V85, P177, DOI 10.1212/WNL.0000000000001729; Yamout BI, 2017, MULT SCLER J, V23, P1297, DOI 10.1177/1352458517694086; Zhao F, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-479; Zou K, 2020, J PERS MED, V10, DOI 10.3390/jpm10030085	20	0	0	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 23	2021	12								808420	10.3389/fimmu.2021.808420	http://dx.doi.org/10.3389/fimmu.2021.808420			5	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YF4UU	35003138	Green Published, gold			2022-12-18	WOS:000741804300001
J	Sun, Y; Hu, LH; Yang, P; Zhang, M; Wang, XW; Xiao, H; Qiao, CX; Wang, J; Luo, LL; Feng, JN; Zheng, YQ; Wang, Y; Shi, YC; Chen, GJ				Sun, Ying; Hu, Linhan; Yang, Peng; Zhang, Min; Wang, Xinwei; Xiao, He; Qiao, Chunxia; Wang, Jing; Luo, Longlong; Feng, Jiannan; Zheng, Yuanqiang; Wang, Yi; Shi, Yanchun; Chen, Guojiang			pH Low Insertion Peptide-Modified Programmed Cell Death-Ligand 1 Potently Suppresses T-Cell Activation Under Acidic Condition	FRONTIERS IN IMMUNOLOGY			English	Article						PD-L1; pHLIP; inflammation; acidic; immunosuppression	B7 FAMILY; DILATED CARDIOMYOPATHY; CANCER-IMMUNOTHERAPY; CHRONIC INFLAMMATION; PD-L1; RECEPTOR; MICE; AUTOIMMUNITY; METABOLISM; CHECKPOINT	Programmed cell death-ligand 1 (PD-L1)/PD-1 axis is critical for maintenance of immune homeostasis by limiting overactivation of effector T-cell responses. The impairment of PD-L1/PD-1 signals play an important role in the pathogenesis of inflammatory diseases, making this pathway an ideal target for novel therapeutics to induce immune tolerance. Given weakly acidic environment as a putative hallmark of inflammation, in this study we designed a new cargo by linking the ectodomain of murine PD-L1 to the N terminus of pHLIPs, a low pH-responding and membrane-insertion peptide, and demonstrated its potent immune-suppressive activity. Specifically, PD-L1-pHLIP spanned the cellular membrane and perfectly recognized its ligand PD-1 in acidic buffer. Immobile PD-L1-pHLIP actively inhibited T-cell proliferation and IFN-gamma production. Importantly, soluble PD-L1-pHLIP retained its function to dampen T-cell responses under acidic condition instead of neutral aqueous solution. Overall, these data suggest that PD-L1-pHLIP has potentials to be a novel therapeutic avenue for T-cell-mediated inflammatory diseases.	[Sun, Ying; Hu, Linhan; Yang, Peng; Wang, Xinwei; Zheng, Yuanqiang; Shi, Yanchun] Inner Mongolia Med Univ, Sch Basic Med Sci, Inner Mongolia Key Lab Mol Biol, Hohhot, Peoples R China; [Sun, Ying; Hu, Linhan; Zhang, Min; Xiao, He; Qiao, Chunxia; Wang, Jing; Luo, Longlong; Feng, Jiannan; Chen, Guojiang] Inst Pharmacol & Toxicol, State Key Lab Toxicol & Med Countermeasures, Beijing, Peoples R China; [Wang, Yi] Chinese Peoples Liberat Army Gen Hosp, Dept Hematol, Med Ctr 5, Beijing, Peoples R China	Inner Mongolia Medical University; Chinese People's Liberation Army General Hospital; Fifth Medical Center of Chinese PLA General Hospital	Shi, YC (corresponding author), Inner Mongolia Med Univ, Sch Basic Med Sci, Inner Mongolia Key Lab Mol Biol, Hohhot, Peoples R China.; Chen, GJ (corresponding author), Inst Pharmacol & Toxicol, State Key Lab Toxicol & Med Countermeasures, Beijing, Peoples R China.; Wang, Y (corresponding author), Chinese Peoples Liberat Army Gen Hosp, Dept Hematol, Med Ctr 5, Beijing, Peoples R China.	yk091023@163.com; ycshi5388@163.com; jyk62033@163.com			National Natural Science Foundation of China [81672803, 81871252]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	Funding This work is supported by the National Natural Science Foundation of China (81672803, 81871252).	Ansari MJI, 2003, J EXP MED, V198, P63, DOI 10.1084/jem.20022125; Arase N, 2003, J IMMUNOL, V170, P3054, DOI 10.4049/jimmunol.170.6.3054; Ben Nasr M, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aam7543; Deacon JC, 2015, ARCH BIOCHEM BIOPHYS, V565, P40, DOI 10.1016/j.abb.2014.11.002; Dong HD, 1999, NAT MED, V5, P1365; Donnelly RP, 2014, J IMMUNOL, V193, P4477, DOI 10.4049/jimmunol.1401558; Dougan M, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01547; Doughty CA, 2006, BLOOD, V107, P4458, DOI 10.1182/blood-2005-12-4788; Everts B, 2014, NAT IMMUNOL, V15, P323, DOI 10.1038/ni.2833; Freeman GJ, 2000, J EXP MED, V192, P1027, DOI 10.1084/jem.192.7.1027; Frigola X, 2011, CLIN CANCER RES, V17, P1915, DOI 10.1158/1078-0432.CCR-10-0250; Gong B, 2019, J EXP MED, V216, P982, DOI 10.1084/jem.20180870; Greenwald RJ, 2005, ANNU REV IMMUNOL, V23, P515, DOI 10.1146/annurev.immunol.23.021704.115611; Haas R, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002202; Hassounah NB, 2019, CANCER IMMUNOL IMMUN, V68, P407, DOI 10.1007/s00262-018-2284-z; Hirahara K, 2012, IMMUNITY, V36, P1017, DOI 10.1016/j.immuni.2012.03.024; Holmdahl R, 2014, EUR J IMMUNOL, V44, P1593, DOI 10.1002/eji.201444486; Hunt JF, 1997, BIOCHEMISTRY-US, V36, P15177, DOI 10.1021/bi970147b; Jiang XJ, 2019, MOL CANCER, V18, DOI 10.1186/s12943-018-0928-4; Keir ME, 2006, J EXP MED, V203, P883, DOI 10.1084/jem.20051776; Khoury SJ, 2004, IMMUNITY, V20, P529, DOI 10.1016/S1074-7613(04)00116-5; Krawczyk CM, 2010, BLOOD, V115, P4742, DOI 10.1182/blood-2009-10-249540; Kroemer G, 2021, J EXP MED, V218, DOI 10.1084/jem.20201979; Latchman YE, 2004, P NATL ACAD SCI USA, V101, P10691, DOI 10.1073/pnas.0307252101; Mahoney KM, 2015, NAT REV DRUG DISCOV, V14, P561, DOI 10.1038/nrd4591; Michalek RD, 2011, J IMMUNOL, V186, P3299, DOI 10.4049/jimmunol.1003613; Munoz LE, 2010, AUTOIMMUN REV, V10, P38, DOI 10.1016/j.autrev.2010.08.015; Ng KW, 2019, ELIFE, V8, DOI 10.7554/eLife.50256; Nishimura H, 2001, SCIENCE, V291, P319, DOI 10.1126/science.291.5502.319; Nishimura H, 1999, IMMUNITY, V11, P141, DOI 10.1016/S1074-7613(00)80089-8; Nugent SG, 2001, GUT, V48, P571, DOI 10.1136/gut.48.4.571; Okazaki T, 2003, NAT MED, V9, P1477, DOI 10.1038/nm955; Ozkaynak E, 2002, J IMMUNOL, V169, P6546, DOI 10.4049/jimmunol.169.11.6546; Holgado MP, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02814; Reshetnyak YK, 2006, P NATL ACAD SCI USA, V103, P6460, DOI 10.1073/pnas.0601463103; Rodriguez-Prados JC, 2010, J IMMUNOL, V185, P605, DOI 10.4049/jimmunol.0901698; Sanmamed MF, 2018, CELL, V175, P313, DOI 10.1016/j.cell.2018.09.035; Schwartz DM, 2016, NAT REV RHEUMATOL, V12, P25, DOI 10.1038/nrrheum.2015.167; Serio I, 2018, DRUG TODAY, V54, P219, DOI 10.1358/dot.2018.54.3.2788019; Shi LZ, 2011, J EXP MED, V208, P1367, DOI 10.1084/jem.20110278; Shu NS, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8787; Song MY, 2015, GUT, V64, P260, DOI 10.1136/gutjnl-2014-307311; Suetrong B, 2016, CHEST, V149, P252, DOI 10.1378/chest.15-1703; Thompson C, 2016, CYTOKINE, V86, P92, DOI 10.1016/j.cyto.2016.07.015; Tian M, 2016, SCI REP-UK, V6, DOI 10.1038/srep27683; Wang CJ, 2008, DIABETES, V57, P1861, DOI 10.2337/db07-1260; Wang DY, 2018, JAMA ONCOL, V4, P1721, DOI 10.1001/jamaoncol.2018.3923; Wang GH, 2011, RHEUMATOL INT, V31, P513, DOI 10.1007/s00296-009-1249-0; Wang J, 2005, P NATL ACAD SCI USA, V102, P11823, DOI 10.1073/pnas.0505497102; Wehr J, 2020, J MED CHEM, V63, P3713, DOI 10.1021/acs.jmedchem.0c00016; Wyatt LC, 2017, TRENDS BIOTECHNOL, V35, P653, DOI 10.1016/j.tibtech.2017.03.014; Young A, 2018, CANCER IMMUNOL RES, V6, P1445, DOI 10.1158/2326-6066.CIR-18-0487; Zhang XW, 2004, IMMUNITY, V20, P337, DOI 10.1016/S1074-7613(04)00051-2; Zhou J, 2017, CANCER IMMUNOL RES, V5, P480, DOI 10.1158/2326-6066.CIR-16-0329	54	0	0	4	9	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 23	2021	12								794226	10.3389/fimmu.2021.794226	http://dx.doi.org/10.3389/fimmu.2021.794226			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YD6NI	35003115	Green Published, gold			2022-12-18	WOS:000740556400001
J	Alexeeva, M; Moen, MN; Xu, XM; Rasmussen, A; Leiros, I; Kirpekar, F; Klungland, A; Alsoe, L; Nilsen, H; Bjelland, S				Alexeeva, Marina; Moen, Marivi Nabong; Xu, Xiang Ming; Rasmussen, Anette; Leiros, Ingar; Kirpekar, Finn; Klungland, Arne; Alsoe, Lene; Nilsen, Hilde; Bjelland, Svein			Intrinsic Strand-Incision Activity of Human UNG: Implications for Nick Generation in Immunoglobulin Gene Diversification	FRONTIERS IN IMMUNOLOGY			English	Article						human UNG; class switch recombination; somatic hypermutation; immunoglobulin diversification; cytosine deamination	URACIL-DNA GLYCOSYLASE; BASE-EXCISION-REPAIR; ACTIVATION-INDUCED DEAMINASE; SOMATIC HYPERMUTATION; MUTATIONAL ANALYSIS; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; ABASIC SITES; APE1; RECOGNITION	Uracil arises in cellular DNA by cytosine (C) deamination and erroneous replicative incorporation of deoxyuridine monophosphate opposite adenine. The former generates C -> thymine transition mutations if uracil is not removed by uracil-DNA glycosylase (UDG) and replaced by C by the base excision repair (BER) pathway. The primary human UDG is hUNG. During immunoglobulin gene diversification in activated B cells, targeted cytosine deamination by activation-induced cytidine deaminase followed by uracil excision by hUNG is important for class switch recombination (CSR) and somatic hypermutation by providing the substrate for DNA double-strand breaks and mutagenesis, respectively. However, considerable uncertainty remains regarding the mechanisms leading to DNA incision following uracil excision: based on the general BER scheme, apurinic/apyrimidinic (AP) endonuclease (APE1 and/or APE2) is believed to generate the strand break by incising the AP site generated by hUNG. We report here that hUNG may incise the DNA backbone subsequent to uracil excision resulting in a 3 '-alpha,beta-unsaturated aldehyde designated uracil-DNA incision product (UIP), and a 5 '-phosphate. The formation of UIP accords with an elimination (E2) reaction where deprotonation of C2 ' occurs via the formation of a C1 ' enolate intermediate. UIP is removed from the 3 '-end by hAPE1. This shows that the first two steps in uracil BER can be performed by hUNG, which might explain the significant residual CSR activity in cells deficient in APE1 and APE2.	[Alexeeva, Marina; Moen, Marivi Nabong; Xu, Xiang Ming; Bjelland, Svein] Univ Stavanger, Dept Chem Biosci & Environm Technol, Stavanger, Norway; [Moen, Marivi Nabong; Klungland, Arne] Oslo Univ Hosp, Dept Microbiol, Oslo, Norway; [Rasmussen, Anette; Kirpekar, Finn] Univ Southern Denmark, Dept Biochem & Mol Biol, Odense, Denmark; [Leiros, Ingar] Arctic Univ Norway, Univ Tromso, Dept Chem, Tromso, Norway; [Alsoe, Lene; Nilsen, Hilde] Univ Oslo, Dept Clin Mol Biol, Oslo, Norway; [Alsoe, Lene; Nilsen, Hilde; Bjelland, Svein] Akershus Univ Hosp, Sect Clin Mol Biol, Lorenskog, Norway	Universitetet i Stavanger; University of Oslo; University of Southern Denmark; UiT The Arctic University of Tromso; University of Oslo; University of Oslo	Bjelland, S (corresponding author), Univ Stavanger, Dept Chem Biosci & Environm Technol, Stavanger, Norway.; Nilsen, H (corresponding author), Univ Oslo, Dept Clin Mol Biol, Oslo, Norway.; Nilsen, H; Bjelland, S (corresponding author), Akershus Univ Hosp, Sect Clin Mol Biol, Lorenskog, Norway.	h.l.nilsen@medisin.uio.no; svein.bjelland@ahus.no		Leiros, Ingar/0000-0001-9333-4541; Kirpekar, Finn/0000-0003-1901-2266				Alexeeva M, 2019, NUCLEIC ACIDS RES, V47, P779, DOI 10.1093/nar/gky1184; Alsoe L, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07314-5; Batebi H, 2018, PROTEINS, V86, P439, DOI 10.1002/prot.25460; Bauer NC, 2015, NUCLEIC ACIDS RES, V43, P10083, DOI 10.1093/nar/gkv1136; Beard WA, 2014, BIOCHEMISTRY-US, V53, P2768, DOI 10.1021/bi500139h; Beger RD, 1998, J BIOL CHEM, V273, P15565, DOI 10.1074/jbc.273.25.15565; Bjelland S, 2003, MUTAT RES-FUND MOL M, V531, P37, DOI 10.1016/j.mrfmmm.2003.07.002; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Boiteux S, 2017, FREE RADICAL BIO MED, V107, P179, DOI 10.1016/j.freeradbiomed.2016.11.042; Burkovics P, 2006, NUCLEIC ACIDS RES, V34, P2508, DOI 10.1093/nar/gkl259; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Darwanto A, 2009, ANAL BIOCHEM, V394, P13, DOI 10.1016/j.ab.2009.07.015; Darwanto A, 2009, J BIOL CHEM, V284, P15835, DOI 10.1074/jbc.M807846200; Di Noia J, 2002, NATURE, V419, P43, DOI 10.1038/nature00981; Di Noia JM, 2007, J EXP MED, V204, P3209, DOI 10.1084/jem.20071768; Di Noia JM, 2006, EMBO J, V25, P585, DOI 10.1038/sj.emboj.7600939; Dingler FA, 2014, EUR J IMMUNOL, V44, P1925, DOI 10.1002/eji.201444482; Dinner AR, 2001, NATURE, V413, P752, DOI 10.1038/35099587; Douthwaite S, 2007, METHOD ENZYMOL, V425, P3, DOI 10.1016/S0076-6879(07)25001-3; Durandy A, 2005, IMMUNOL REV, V203, P67, DOI 10.1111/j.0105-2896.2005.00222.x; Friedberg E. C., 2006, DNA REPAIR MUTAGENES; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; Gorman MA, 1997, EMBO J, V16, P6548, DOI 10.1093/emboj/16.21.6548; Grigera F, 2017, MOL CELL BIOL, V37, DOI 10.1128/MCB.00316-16; Guikema JEJ, 2007, J EXP MED, V204, P3017, DOI 10.1084/jem.20071289; Hadi MZ, 2002, J MOL BIOL, V316, P853, DOI 10.1006/jmbi.2001.5382; Haushalter KA, 1999, CURR BIOL, V9, P174, DOI 10.1016/S0960-9822(99)80087-6; Holliday GL, 2009, J MOL BIOL, V390, P560, DOI 10.1016/j.jmb.2009.05.015; Imai K, 2003, NAT IMMUNOL, V4, P1023, DOI 10.1038/ni974; Kavli B, 2005, J EXP MED, V201, P2011, DOI 10.1084/jem.20050042; Kavli B, 2002, J BIOL CHEM, V277, P39926, DOI 10.1074/jbc.M207107200; Khodyreva SN, 2010, P NATL ACAD SCI USA, V107, P22090, DOI 10.1073/pnas.1009182107; Kim Yun-Jeong, 2012, Curr Mol Pharmacol, V5, P3; Kohli RM, 2013, NATURE, V502, P472, DOI 10.1038/nature12750; Kornberg A., 1992, DNA REPLICATION; Krokan HE, 2014, DNA REPAIR, V19, P38, DOI 10.1016/j.dnarep.2014.03.028; Larijani M, 2012, SEMIN IMMUNOL, V24, P255, DOI 10.1016/j.smim.2012.05.003; Lee B, 2002, NUCLEIC ACIDS RES, V30, P942, DOI 10.1093/nar/30.4.942; Li MX, 2014, ANTIOXID REDOX SIGN, V20, P678, DOI 10.1089/ars.2013.5492; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; Lucas-Lledo JI, 2011, MOL BIOL EVOL, V28, P1307, DOI 10.1093/molbev/msq318; Maiti A, 2012, P NATL ACAD SCI USA, V109, P8091, DOI 10.1073/pnas.1201010109; Malfatti MC, 2017, NUCLEIC ACIDS RES, V45, P11193, DOI 10.1093/nar/gkx723; MANOHARAN M, 1988, J AM CHEM SOC, V110, P1620, DOI 10.1021/ja00213a044; Masani S, 2013, MOL CELL BIOL, V33, P1468, DOI 10.1128/MCB.00026-13; Matsubara M, 2004, NUCLEIC ACIDS RES, V32, P5291, DOI 10.1093/nar/gkh859; Methot SP, 2017, ADV IMMUNOL, V133, P37, DOI 10.1016/bs.ai.2016.11.002; Modrich P, 2016, ANGEW CHEM INT EDIT, V55, P8490, DOI 10.1002/anie.201601412; MOL CD, 1995, CELL, V80, P869, DOI 10.1016/0092-8674(95)90290-2; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; Neuberger MS, 2007, J EXP MED, V204, P7, DOI 10.1084/jem.20062409; Nilsen H, 1997, NUCLEIC ACIDS RES, V25, P750, DOI 10.1093/nar/25.4.750; Parikh SS, 2000, P NATL ACAD SCI USA, V97, P5083, DOI 10.1073/pnas.97.10.5083; Parikh SS, 1998, EMBO J, V17, P5214, DOI 10.1093/emboj/17.17.5214; Pearl LH, 2000, MUTAT RES-DNA REPAIR, V460, P165, DOI 10.1016/S0921-8777(00)00025-2; Pettersen HS, 2007, NUCLEIC ACIDS RES, V35, P3879, DOI 10.1093/nar/gkm372; Prorok P, 2013, P NATL ACAD SCI USA, V110, pE3695, DOI 10.1073/pnas.1305624110; Przybylski JL, 2011, BIOCHEMISTRY-US, V50, P4218, DOI 10.1021/bi2003394; Rada C, 2004, MOL CELL, V16, P163, DOI 10.1016/j.molcel.2004.10.011; Rada C, 2002, CURR BIOL, V12, P1748, DOI 10.1016/S0960-9822(02)01215-0; SAVVA R, 1995, NATURE, V373, P487, DOI 10.1038/373487a0; Schanz S, 2009, P NATL ACAD SCI USA, V106, P5593, DOI 10.1073/pnas.0901726106; Schormann N, 2014, PROTEIN SCI, V23, P1667, DOI 10.1002/pro.2554; Shalhout S, 2014, MOL CELL BIOL, V34, P4019, DOI 10.1128/MCB.00589-14; Slupphaug G, 1996, NATURE, V384, P87, DOI 10.1038/384087a0; SLUPPHAUG G, 1995, BIOCHEMISTRY-US, V34, P128, DOI 10.1021/bi00001a016; Stavnezer J, 2014, P NATL ACAD SCI USA, V111, P9217, DOI 10.1073/pnas.1405590111; Steullet V, 1999, BIOORGAN MED CHEM, V7, P2531, DOI 10.1016/S0968-0896(99)00193-5; WARNER HR, 1980, P NATL ACAD SCI-BIOL, V77, P4602, DOI 10.1073/pnas.77.8.4602; Weber AR, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10806; Wiederhold L, 2004, MOL CELL, V15, P209, DOI 10.1016/j.molcel.2004.06.003; Xu JL, 2014, P NATL ACAD SCI USA, V111, P17242, DOI 10.1073/pnas.1420221111; Zarrin AA, 2007, SCIENCE, V315, P377, DOI 10.1126/science.1136386; Zharkov DO, 1997, J BIOL CHEM, V272, P5335, DOI 10.1074/jbc.272.8.5335	74	0	0	4	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 22	2021	12								762032	10.3389/fimmu.2021.762032	http://dx.doi.org/10.3389/fimmu.2021.762032			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YI2XB	35003074	Green Published, gold			2022-12-18	WOS:000743715700001
J	Coppola, M; Lai, RPJ; Wilkinson, RJ; Ottenhoff, THM				Coppola, Mariateresa; Lai, Rachel P-J.; Wilkinson, Robert J.; Ottenhoff, Tom H. M.			The In Vivo Transcriptomic Blueprint of Mycobacterium tuberculosis in the Lung	FRONTIERS IN IMMUNOLOGY			English	Article						Mycobacterium tuberculosis (MTB); transcriptomic; tuberculosis; vaccine; therapy; antigen discovery	GENE-EXPRESSION; ADAPTATION; INFECTION; VACCINE; SPUTUM; END	Mycobacterium tuberculosis (Mtb) genes encoding proteins targeted by vaccines and drugs should be expressed in the lung, the main organ affected by Mtb, for these to be effective. However, the pulmonary expression of most Mtb genes and their proteins remains poorly characterized. The aim of this study is to fill this knowledge gap. We analyzed large scale transcriptomic datasets from specimens of Mtb-infected humans, TB-hypersusceptible (C3H/FeJ) and TB-resistant (C57BL/6J) mice and compared data to in vitro cultured Mtb gene-expression profiles. Results revealed high concordance in the most abundantly in vivo expressed genes between pulmonary Mtb transcriptomes from different datasets and different species. As expected, this contrasted with a lower correlation found with the highest expressed Mtb genes from in vitro datasets. Among the most consistently and highly in vivo expressed genes, 35 have not yet been explored as targets for vaccination or treatment. More than half of these genes are involved in protein synthesis or metabolic pathways. This first lung-oriented multi-study analysis of the in vivo expressed Mtb-transcriptome provides essential data that considerably increase our understanding of pulmonary TB infection biology, and identifies novel molecules for target-based TB-vaccine and drug development.	[Coppola, Mariateresa; Ottenhoff, Tom H. M.] LUMC, Dept Infect Dis, Leiden, Netherlands; [Lai, Rachel P-J.; Wilkinson, Robert J.] Francis Crick Inst, London, England; [Lai, Rachel P-J.; Wilkinson, Robert J.] Imperial Coll London, Dept Infect Dis, London, England; [Wilkinson, Robert J.] Inst Infect Dis & Mol Med, Wellcome Ctr Infect Dis Res Africa, Dept Med, Cape Town, South Africa	Leiden University; Leiden University Medical Center (LUMC); Francis Crick Institute; Imperial College London; University of Cape Town	Coppola, M (corresponding author), LUMC, Dept Infect Dis, Leiden, Netherlands.	m.coppola@lumc.nl		Wilkinson, Robert/0000-0002-2753-1800; Lai, Rachel/0000-0003-3418-850X	EC ITN FP7 VACTRAIN project; NWO-TOP project Grant [91214038]; Francis Crick Institute - URI grant; Cancer Research UK [FC0010218]; Wellcome [FC0010218];  [EC HORIZON2020 TBVAC2020];  [643381];  [104803];  [203135]	EC ITN FP7 VACTRAIN project; NWO-TOP project Grant; Francis Crick Institute - URI grant; Cancer Research UK(Cancer Research UK); Wellcome; ; ; ; 	& nbsp;EC HORIZON2020 TBVAC2020, Grant Agreement No. 643381(MC, TO); EC ITN FP7 VACTRAIN project (MC, TO); NWO-TOP project Grant Agreement No. 91214038 (TO). Francis Crick Institute funded by URI grant FC0010218, Cancer Research UK (FC0010218) and Wellcome (FC0010218) (RP-JL, RW); Wellcome grant 104803 (RW); Wellcome grant 203135 (RW).	Aagaard C, 2004, J INFECT DIS, V189, P812, DOI 10.1086/381679; Arlehamn CSL, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005760; Arlehamn CSL, 2012, J IMMUNOL, V188, P5020, DOI 10.4049/jimmunol.1103556; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; Brock I, 2004, J CLIN MICROBIOL, V42, P2379, DOI 10.1128/JCM.42.6.2379-2387.2004; Bullard JH, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-94; Choi S, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/3525302; Commandeur S, 2013, J IMMUNOL, V190, P1659, DOI 10.4049/jimmunol.1201593; Coppola M, 2018, SEMIN IMMUNOL, V39, P88, DOI 10.1016/j.smim.2018.07.001; Coppola M, 2016, SCI REP-UK, V6, DOI 10.1038/srep37793; Coscolla M, 2014, SEMIN IMMUNOL, V26, P431, DOI 10.1016/j.smim.2014.09.012; Galagan JE, 2013, NATURE, V499, P178, DOI 10.1038/nature12337; Garcia BJ, 2016, TUBERCULOSIS, V100, P89, DOI 10.1016/j.tube.2016.07.004; Garton NJ, 2008, PLOS MED, V5, P634, DOI 10.1371/journal.pmed.0050075; Haks MC, 2015, VACCINE, V33, P5282, DOI 10.1016/j.vaccine.2015.04.054; Honeyborne I, 2016, BMC MED, V14, DOI 10.1186/s12916-016-0609-3; Lai RP., 2020, TRANSCRIPTOMIC CHARA, V2020.03.09.983163, DOI [10.1101/2020.03.09.983163, DOI 10.1101/2020.03.09.983163]; Lenaerts A, 2015, IMMUNOL REV, V264, P288, DOI 10.1111/imr.12252; Lin PL, 2018, J IMMUNOL, V201, P2541, DOI 10.4049/jimmunol.1800993; Liu YS, 2016, CELL, V165, P535, DOI 10.1016/j.cell.2016.03.014; Nemes E, 2018, NEW ENGL J MED, V379, P138, DOI [10.1056/nejmoa1714021, 10.1056/NEJMoa1714021]; Paska C, 2017, AM J RESP CELL MOL, V57, P626, DOI 10.1165/rcmb.2017-0198LE; Pisu D, 2020, CELL REP, V30, P335, DOI 10.1016/j.celrep.2019.12.033; Rachman H, 2006, INFECT IMMUN, V74, P1233, DOI 10.1128/IAI.74.2.1233-1242.2006; Ruhwald M, 2017, SCI REP-UK, V7, DOI 10.1038/srep45969; Sharma S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173508; Skvortsov TA, 2013, ACTA NATURAE, V5, P62, DOI 10.32607/20758251-2013-5-2-62-69; Sundaramurthi JC, 2016, TUBERCULOSIS, V100, P69, DOI 10.1016/j.tube.2016.06.006; Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI 10.1093/nar/gky1131; Tait DR, 2019, NEW ENGL J MED, V381, P2429, DOI 10.1056/NEJMoa1909953; Talaat AM, 2004, P NATL ACAD SCI USA, V101, P4602, DOI 10.1073/pnas.0306023101; Tameris MD, 2013, LANCET, V381, P1021, DOI 10.1016/S0140-6736(13)60177-4; TBVI, 2019, PIPEL VACC; Tian Y, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02778; Uplekar M, 2015, LANCET, V385, P1799, DOI 10.1016/S0140-6736(15)60570-0; Walter ND, 2016, J INFECT DIS, V214, P1205, DOI 10.1093/infdis/jiw364; Walter ND, 2015, J INFECT DIS, V212, P990, DOI 10.1093/infdis/jiv149; Ward SK, 2010, FRONT MICROBIOL, V1, DOI 10.3389/fmicb.2010.00121; WHO, 2021, TUBERCULOSIS; Wipperman MF, 2014, CRIT REV BIOCHEM MOL, V49, P269, DOI 10.3109/10409238.2014.895700	41	0	0	3	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 22	2021	12								763364	10.3389/fimmu.2021.763364	http://dx.doi.org/10.3389/fimmu.2021.763364			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YH9LV	35003075	Green Published, Green Submitted, gold			2022-12-18	WOS:000743481800001
J	Inaba, S; Aizawa, Y; Miwa, Y; Imai, C; Ohnishi, H; Kanegane, H; Saitoh, A				Inaba, Satoshi; Aizawa, Yuta; Miwa, Yuki; Imai, Chihaya; Ohnishi, Hidenori; Kanegane, Hirokazu; Saitoh, Akihiko			Case Report: Analysis of Preserved Umbilical Cord Clarified X-Linked Anhidrotic Ectodermal Dysplasia With Immunodeficiency in Deceased, Undiagnosed Uncles	FRONTIERS IN IMMUNOLOGY			English	Article						preserved umbilical cord; hyper IgM syndrome; anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID); NEMO; case report	FACTOR-KAPPA-B; INCONTINENTIA PIGMENTI; MUTATIONS; MOSAICISM	Family history is one key in diagnosing inborn errors of immunity (IEI); however, disease status is difficult to determine in deceased relatives. X-linked anhidrotic ectodermal dysplasia with immunodeficiency is one of the hyper IgM syndromes that is caused by a hypomorphic variant in the nuclear factor kappa beta essential modulator. We identified a novel IKBKG variant in a 7-month-old boy with pneumococcal rib osteomyelitis and later found that his mother has incontinentia pigmenti. Genetic analysis of preserved umbilical cords revealed the same variant in two of his deceased maternal uncles. Analysis of preserved umbilical cord tissue from deceased relatives can provide important information for diagnosing IEI in their descendants.	[Inaba, Satoshi; Aizawa, Yuta; Imai, Chihaya; Saitoh, Akihiko] Niigata Univ, Dept Pediat, Grad Sch Med & Dent Sci, Niigata, Japan; [Aizawa, Yuta] Niigata Univ, Inst Res Promot, Niigata, Japan; [Miwa, Yuki; Ohnishi, Hidenori] Gifu Univ, Grad Sch Med, Dept Pediat, Gifu, Japan; [Kanegane, Hirokazu] Tokyo Med & Dent Univ TMDU, Grad Sch Med & Dent Sci, Dept Child Hlth & Dev, Tokyo, Japan	Niigata University; Niigata University; Gifu University; Tokyo Medical & Dental University (TMDU)	Aizawa, Y (corresponding author), Niigata Univ, Dept Pediat, Grad Sch Med & Dent Sci, Niigata, Japan.; Aizawa, Y (corresponding author), Niigata Univ, Inst Res Promot, Niigata, Japan.	yaizawa@med.niigata-u.ac.jp	Aizawa, Yuta/AAD-2310-2022					Chia KY, 2013, J EUR ACAD DERMATOL, V27, P799, DOI 10.1111/jdv.12014; Claes KBM, 2014, METHODS MOL BIOL, V1167, P303, DOI 10.1007/978-1-4939-0835-6_21; Doffinger R, 2001, NAT GENET, V27, P277, DOI 10.1038/85837; Fusco F, 2004, HUM MOL GENET, V13, P1763, DOI 10.1093/hmg/ddh192; Hanson EP, 2008, J ALLERGY CLIN IMMUN, V122, P1169, DOI 10.1016/j.jaci.2008.08.018; Heller S, 2020, J CLIN IMMUNOL, V40, P421, DOI 10.1007/s10875-019-00728-y; Koyano S, 2009, CLIN INFECT DIS, V48, pE93, DOI 10.1086/598506; Maubach G, 2017, TRENDS MOL MED, V23, P1138, DOI 10.1016/j.molmed.2017.10.004; Miyata I, 2015, CLIN INFECT DIS, V60, P605, DOI 10.1093/cid/ciu882; Miyata I, 2013, J CLIN VIROL, V56, P274, DOI 10.1016/j.jcv.2012.11.008; Ohnishi H, 2017, J CLIN IMMUNOL, V37, P529, DOI 10.1007/s10875-017-0417-3; Okamoto T, 2021, PEDIATR INT, V63, P1243, DOI 10.1111/ped.14583; OMarcaigh AS, 1997, J CLIN IMMUNOL, V17, P29, DOI 10.1023/A:1027332327827; Orange JS, 2005, IMMUNOL REV, V203, P21, DOI 10.1111/j.0105-2896.2005.00221.x; Sakamoto M, 2001, AM J MED GENET, V99, P234, DOI 10.1002/1096-8628(2001)9999:9999<::AID-AJMG1159>3.0.CO;2-M; Smahi A, 2000, NATURE, V405, P466; Subbarayan A, 2011, PEDIATRICS, V127, P810, DOI 10.1542/peds.2010-3680; Toyohara M, 2021, CLIN CASE REP, V9, DOI 10.1002/ccr3.5093; Yamashita M, 2021, INFLAMM REGEN, V41, DOI 10.1186/s41232-021-00159-6; Zonana J, 2000, AM J HUM GENET, V67, P1555, DOI 10.1086/316914	20	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 22	2021	12								786164	10.3389/fimmu.2021.786164	http://dx.doi.org/10.3389/fimmu.2021.786164			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YI2SY	35003103	gold, Green Published			2022-12-18	WOS:000743705000001
J	Jarvela-Stolting, M; Vesala, L; Maasdorp, MK; Ciantar, J; Ramet, M; Valanne, S				Jarvela-Stolting, Mirva; Vesala, Laura; Maasdorp, Matthew K.; Ciantar, Joanna; Ramet, Mika; Valanne, Susanna			Proteasome alpha 6 Subunit Negatively Regulates the JAK/STAT Pathway and Blood Cell Activation in Drosophila melanogaster	FRONTIERS IN IMMUNOLOGY			English	Article						Drosophila melanogaster; fruit fly; JAK; STAT pathway; Eye Transformer; the proteasome complex; hemocyte; lamellocyte; RNA interference	PROTEIN PHOSPHATASE 2A; SIGNALING PATHWAY; KINASE; HEMOCYTES; BINDING; GENES; PHOSPHORYLATION; DIFFERENTIATION; TRANSFORMATION; PROLIFERATION	JAK/STAT signaling regulates central biological functions such as development, cell differentiation and immune responses. In Drosophila, misregulated JAK/STAT signaling in blood cells (hemocytes) induces their aberrant activation. Using mass spectrometry to analyze proteins associated with a negative regulator of the JAK/STAT pathway, and by performing a genome-wide RNAi screen, we identified several components of the proteasome complex as negative regulators of JAK/STAT signaling in Drosophila. A selected proteasome component, Pros alpha 6, was studied further. In S2 cells, Pros alpha 6 silencing decreased the amount of the known negative regulator of the pathway, ET, leading to enhanced expression of a JAK/STAT pathway reporter gene. Silencing of Pros alpha 6 in vivo resulted in activation of the JAK/STAT pathway, leading to the formation of lamellocytes, a specific hemocyte type indicative of hemocyte activation. This hemocyte phenotype could be partially rescued by simultaneous knockdown of either the Drosophila STAT transcription factor, or MAPKK in the JNK-pathway. Our results suggest a role for the proteasome complex components in the JAK/STAT pathway in Drosophila blood cells both in vitro and in vivo.	[Jarvela-Stolting, Mirva; Vesala, Laura; Maasdorp, Matthew K.; Ciantar, Joanna; Ramet, Mika; Valanne, Susanna] Tampere Univ, Fac Med & Hlth Technol, Lab Expt Immunol, Tampere, Finland; [Ramet, Mika] Univ Oulu, Res Unit Pediat Pediat Neurol Pediat Surg Child P, Fac Med, Otorhinolaryngol & Ophthalmol, Oulu, Finland; [Ramet, Mika] Univ Oulu, Med Res Ctr Oulu, Oulu, Finland; [Ramet, Mika] Univ Oulu, Oulu Univ Hosp, Dept Children & Adolescents, Oulu, Finland	Tampere University; University of Oulu; University of Oulu; University of Oulu	Valanne, S (corresponding author), Tampere Univ, Fac Med & Hlth Technol, Lab Expt Immunol, Tampere, Finland.	susanna.valanne@tuni.fi	Valanne, Susanna/GZK-2381-2022	Valanne, Susanna/0000-0003-0898-8423; Maasdorp, Matthew/0000-0002-6519-1755; Ciantar, Joanna/0000-0002-3715-480X	Tampere University Doctoral Programme in Medicine and Life Sciences; The Finnish Cultural Foundation; The Sigrid Juselius Foundation; Academy of Finland [277495]; Competitive State Research Financing of the Expert Responsibility Area of Oulu University Hospita; Tampere Tuberculosis Foundation; Tuberculosis foundation; Biocenter Finland	Tampere University Doctoral Programme in Medicine and Life Sciences; The Finnish Cultural Foundation(Finnish Cultural Foundation); The Sigrid Juselius Foundation(Sigrid Juselius Foundation); Academy of Finland(Academy of Finland); Competitive State Research Financing of the Expert Responsibility Area of Oulu University Hospita; Tampere Tuberculosis Foundation; Tuberculosis foundation; Biocenter Finland	This work was supported by the Tampere University Doctoral Programme in Medicine and Life Sciences and The Finnish Cultural Foundation (to MJ-S); The Sigrid Juselius Foundation, the Academy of Finland (Grant 277495), the Competitive State Research Financing of the Expert Responsibility Area of Oulu University Hospital and the Tampere Tuberculosis Foundation (to MR); and the Tuberculosis foundation (to SV). The Tampere Drosophila Facility, the Tampere Imaging Facility and the Tampere Facility of Flow Cytometry are all partially funded by Biocenter Finland.	Ahmed-de-Prado S, 2018, DEV BIOL, V441, P31, DOI 10.1016/j.ydbio.2018.05.021; Aittomaki S, 2017, FASEB J, V31, P4770, DOI 10.1096/fj.201700296R; Aldaz S, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2763; Amoyel M, 2014, SEMIN CELL DEV BIOL, V28, P96, DOI 10.1016/j.semcdb.2014.03.023; Anderl I, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005746; Arbouzova NI, 2006, DEVELOPMENT, V133, P2605, DOI 10.1242/dev.02411; Avet-Rochex A, 2010, BMC DEV BIOL, V10, DOI 10.1186/1471-213X-10-65; Bach EA, 2007, GENE EXPR PATTERNS, V7, P323, DOI 10.1016/j.modgep.2006.08.003; Baeg GH, 2005, GENE DEV, V19, P1861, DOI 10.1101/gad.1320705; Baillat D, 2005, CELL, V123, P265, DOI 10.1016/j.cell.2005.08.019; Belvin MP, 1996, ANNU REV CELL DEV BI, V12, P393, DOI 10.1146/annurev.cellbio.12.1.393; BINARI R, 1994, GENE DEV, V8, P300, DOI 10.1101/gad.8.3.300; BRAND AH, 1993, DEVELOPMENT, V118, P401; BREHELIN M, 1982, CELL TISSUE RES, V221, P607; Budenholzer L, 2017, J MOL BIOL, V429, P3500, DOI 10.1016/j.jmb.2017.05.027; Callus BA, 1998, BLOOD, V91, P3182, DOI 10.1182/blood.V91.9.3182.3182_3182_3192; Chabu C, 2009, DEV BIOL, V330, P399, DOI 10.1016/j.ydbio.2009.04.014; Chen JD, 2010, BIOCHEM SOC T, V38, P1082, DOI 10.1042/BST0381082; Cokic VP, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/453020; Corre I, 1999, ONCOGENE, V18, P6335, DOI 10.1038/sj.onc.1203010; Daigneault J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075150; Dansereau DA, 2002, DEVELOPMENT, V129, P5553, DOI 10.1242/dev.00153; Evans CJ, 2003, DEV CELL, V5, P673, DOI 10.1016/S1534-5807(03)00335-6; Galko MJ, 2004, PLOS BIOL, V2, P1114, DOI 10.1371/journal.pbio.0020239; Ghiglione C, 2008, EMBO REP, V9, P676, DOI 10.1038/embor.2008.79; Grice GL, 2016, CELL MOL LIFE SCI, V73, P3497, DOI 10.1007/s00018-016-2255-5; Haan S, 2008, J IMMUNOL, V180, P998, DOI 10.4049/jimmunol.180.2.998; HANRATTY WP, 1981, DEV BIOL, V83, P238, DOI 10.1016/0012-1606(81)90470-X; HARRISON DA, 1995, EMBO J, V14, P2857, DOI 10.1002/j.1460-2075.1995.tb07285.x; Harrison DA, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a011205; Hashimoto Y, 2009, J IMMUNOL, V183, P7451, DOI 10.4049/jimmunol.0901032; Hatakeyama Shigetsugu, 2012, JAKSTAT, V1, P168, DOI 10.4161/jkst.21560; Hombria JCG, 2002, CURR BIOL, V12, pR569, DOI 10.1016/S0960-9822(02)01057-6; Horwitz DA, 2019, TRENDS IMMUNOL, V40, P888, DOI 10.1016/j.it.2019.08.003; Hou XS, 1996, CELL, V84, P411, DOI 10.1016/S0092-8674(00)81286-6; Jang You-Na, 2013, JAKSTAT, V2, pe23282, DOI 10.4161/jkst.23282; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Kallio J, 2010, FASEB J, V24, P4467, DOI 10.1096/fj.10-162784; Khush RS, 2002, CURR BIOL, V12, P1728, DOI 10.1016/S0960-9822(02)01214-9; Kim TK, 1996, SCIENCE, V273, P1717, DOI 10.1126/science.273.5282.1717; Kleino A, 2005, EMBO J, V24, P3423, DOI 10.1038/sj.emboj.7600807; Kucinski I, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00145-y; Kuraishi T, 2009, EMBO J, V28, P3868, DOI 10.1038/emboj.2009.343; Linossi EM, 2018, GROWTH FACTORS, V36, P104, DOI 10.1080/08977194.2018.1518324; Luo H, 2002, MOL GENET GENOMICS, V267, P57, DOI 10.1007/s00438-001-0632-7; Makhijani K, 2011, DEVELOPMENT, V138, P5379, DOI 10.1242/dev.067322; Makki R, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000441; Markus R, 2009, P NATL ACAD SCI USA, V106, P4805, DOI 10.1073/pnas.0801766106; Meister M, 2003, CELL MICROBIOL, V5, P573, DOI 10.1046/j.1462-5822.2003.00302.x; Milligan G, 2006, BRIT J PHARMACOL, V147, pS46, DOI 10.1038/sj.bjp.0706405; Minakhina S, 2006, GENETICS, V174, P253, DOI 10.1534/genetics.106.061978; Murray PJ, 2007, J IMMUNOL, V178, P2623, DOI 10.4049/jimmunol.178.5.2623; Myllymaki H, 2014, SCAND J IMMUNOL, V79, P377, DOI 10.1111/sji.12170; NARAZAKI M, 1993, BLOOD, V82, P1120, DOI 10.1182/blood.V82.4.1120.bloodjournal8241120; O'Sullivan JM, 2017, MOL CELL ENDOCRINOL, V451, P71, DOI 10.1016/j.mce.2017.01.050; Paquette N, 2010, MOL CELL, V37, P172, DOI 10.1016/j.molcel.2009.12.036; Radtke F, 2005, BIOESSAYS, V27, P1117, DOI 10.1002/bies.20315; Ram PT, 2000, SCIENCE, V287, P142, DOI 10.1126/science.287.5450.142; Ramet M, 2002, DEV BIOL, V241, P145, DOI 10.1006/dbio.2001.0502; RIZKI TM, 1980, EXPERIENTIA, V36, P1223, DOI 10.1007/BF01976142; RIZKI TM, 1992, DEV COMP IMMUNOL, V16, P103, DOI 10.1016/0145-305X(92)90011-Z; Ross JA, 2010, J BIOL CHEM, V285, P3582, DOI 10.1074/jbc.M109.053843; Sachan N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068247; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; Seif F, 2017, CELL COMMUN SIGNAL, V15, DOI 10.1186/s12964-017-0177-y; Shi YG, 2009, CELL, V139, P468, DOI 10.1016/j.cell.2009.10.006; Sinenko SA, 2004, ONCOGENE, V23, P9120, DOI 10.1038/sj.onc.1208156; Sorrentino RP, 2007, DEV BIOL, V311, P311, DOI 10.1016/j.ydbio.2007.08.011; Stec W, 2013, MOL BIOL CELL, V24, P3000, DOI 10.1091/mbc.E13-05-0275; TEPASS U, 1994, DEVELOPMENT, V120, P1829; Tokusumi T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006429; Tomko RJ, 2013, ANNU REV BIOCHEM, V82, P415, DOI 10.1146/annurev-biochem-060410-150257; Trempe JF, 2011, CURR OPIN STRUC BIOL, V21, P792, DOI 10.1016/j.sbi.2011.09.009; Turpeinen H, 2013, CURR GENOMICS, V14, P453, DOI 10.2174/1389202911314050010; Ungureanu D, 2002, MOL CELL BIOL, V22, P3316, DOI 10.1128/MCB.22.10.3316-3326.2002; Valanne S, 2020, J IMMUNOL, V204, P2143, DOI 10.4049/jimmunol.1900571; Valanne S, 2010, J IMMUNOL, V184, P6188, DOI 10.4049/jimmunol.1000261; Valimaki E, 2013, MOL CELL PROTEOMICS, V12, P749, DOI 10.1074/mcp.M112.024661; Vanha-aho LM, 2016, IMMUNOL LETT, V170, P42, DOI 10.1016/j.imlet.2015.12.005; Verdier F, 2000, J BIOL CHEM, V275, P18375, DOI 10.1074/jbc.275.24.18375; Vigano S, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/485781; Vilmos P, 2009, EUR J CELL BIOL, V88, P609, DOI 10.1016/j.ejcb.2009.05.006; Vlisidou I, 2015, FEBS J, V282, P1368, DOI 10.1111/febs.13235; Wang DM, 2000, EMBO J, V19, P392, DOI 10.1093/emboj/19.3.392; Wang HB, 2013, GENETICS, V195, P1291, DOI 10.1534/genetics.113.155945; Wertz IE, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a003350; Williams MJ, 2007, J IMMUNOL, V178, P4711, DOI 10.4049/jimmunol.178.8.4711; Woetmann A, 2003, J BIOL CHEM, V278, P2787, DOI 10.1074/jbc.M210196200; Woetmann A, 1999, P NATL ACAD SCI USA, V96, P10620, DOI 10.1073/pnas.96.19.10620; Yu CL, 1997, J BIOL CHEM, V272, P14017, DOI 10.1074/jbc.272.22.14017; Zeidler Martin P, 2013, JAKSTAT, V2, pe25353, DOI 10.4161/jkst.25353; Zettervall CJ, 2004, P NATL ACAD SCI USA, V101, P14192, DOI 10.1073/pnas.0403789101; Zoranovic Tamara, 2013, JAKSTAT, V2, pe25408, DOI 10.4161/jkst.25408	93	0	0	2	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 22	2021	12								729631	10.3389/fimmu.2021.729631	http://dx.doi.org/10.3389/fimmu.2021.729631			18	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YK5MV	35003057	Green Published, gold			2022-12-18	WOS:000745257500001
J	Liu, F; Wu, MM; Wang, J; Wen, HY; An, R; Cai, HJ; Yu, L; Shen, JL; Chen, LJ; Du, J				Liu, Fang; Wu, Minmin; Wang, Jie; Wen, Hongyang; An, Ran; Cai, Haijian; Yu, Li; Shen, Jilong; Chen, Lijian; Du, Jian			Protective Effect Against Toxoplasmosis in BALB/c Mice Vaccinated With Recombinant Toxoplasma gondii MIF, CDPK3, and 14-3-3 Protein Cocktail Vaccine	FRONTIERS IN IMMUNOLOGY			English	Article						Toxoplasma gondii; TgMIF; TgCDPK3; Tg14-3-3; cocktail vaccine; protective efficacy	MIGRATION INHIBITORY FACTOR; IMMUNE-RESPONSES; ADJUVANT; ROP2; GRA4; SAG1; MODULATION; HOMOLOGS; CELLS	Toxoplasma gondii can infect almost all endotherm organisms including humans and cause life-threatening toxoplasmosis in immunocompromised individuals, which leads to serious public health problems. Developing an excellent vaccine against this disease is impending. In present study, we formulated a cocktail protein vaccine including the TgMIF, TgCDPK3, and Tg14-3-3 proteins, which play critical roles in T. gondii infection. The recombinant protein vaccines were constructed and assessed by vaccination in BALB/c mice. We organized the mice in various protein combination groups of vaccines, and all mice were immunized with corresponding proteins at 0, 2, and 4 weeks. The specific protective effects of the vaccines on mice against T. gondii were analyzed by the mensuration of cytokines, serum antibodies, splenocyte proliferation assay, survival time, and parasite cyst burden of mice after the challenge. The study indicated that mice immunized with all three multicomponent proteins vaccine triggered a strong immune response with highest levels of IFN-gamma production and IgG antibody compared with the other two protein combinations and controls. Moreover, there was an increase in IL-4 production and antigen-specific lymphocyte proliferation. The parasite cysts were significantly reduced (resulting in an 82.7% reduction), and survival time was longer in immunized mice with three multicomponent proteins compared with the other groups of mice. The enhanced humoral and cell-mediated immunity indicated that the protein cocktail vaccine containing three antigens provided effective protection for mice. These results indicated that recombinant TgMIF, TgCDPK3, and Tg14-3-3 multicomponent proteins were potential candidates for vaccine against toxoplasmosis.	[Liu, Fang; Wu, Minmin; Wang, Jie; Wen, Hongyang; An, Ran; Cai, Haijian; Du, Jian] Anhui Med Univ, Sch Basic Med Sci, Dept Biochem & Mol Biol, Hefei, Peoples R China; [Liu, Fang; Wu, Minmin; Wang, Jie; Wen, Hongyang; An, Ran; Cai, Haijian; Du, Jian] Anhui Med Univ, Res Ctr Infect Dis, Sch Basic Med Sci, Hefei, Peoples R China; [Liu, Fang; Wu, Minmin; Wang, Jie; Wen, Hongyang; An, Ran; Cai, Haijian; Yu, Li; Shen, Jilong; Du, Jian] Anhui Med Univ, Prov Key Lab Zoonoses High Inst Anhui, Hefei, Peoples R China; [Liu, Fang; Wu, Minmin; Wang, Jie; Wen, Hongyang; An, Ran; Cai, Haijian; Yu, Li; Shen, Jilong; Du, Jian] Anhui Med Univ, Key Lab Microbiol & Parasitol Anhui Prov, Hefei, Peoples R China; [Chen, Lijian] Anhui Med Univ, Dept Anesthesiol, Affiliated Hosp 1, Hefei, Peoples R China	Anhui Medical University; Anhui Medical University; Anhui Medical University; Anhui Medical University; Anhui Medical University	Du, J (corresponding author), Anhui Med Univ, Sch Basic Med Sci, Dept Biochem & Mol Biol, Hefei, Peoples R China.; Du, J (corresponding author), Anhui Med Univ, Res Ctr Infect Dis, Sch Basic Med Sci, Hefei, Peoples R China.; Du, J (corresponding author), Anhui Med Univ, Prov Key Lab Zoonoses High Inst Anhui, Hefei, Peoples R China.; Du, J (corresponding author), Anhui Med Univ, Key Lab Microbiol & Parasitol Anhui Prov, Hefei, Peoples R China.; Chen, LJ (corresponding author), Anhui Med Univ, Dept Anesthesiol, Affiliated Hosp 1, Hefei, Peoples R China.	chenlijian77@126.com; dujane@163.com		Du, Jian/0000-0003-3871-5645	National Natural Science Foundation of China [82072300, 81871674, 81902084]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	Funding This work was supported by the National Natural Science Foundation of China (No. 82072300, No. 81871674, and No. 81902084).	Assossou O, 2004, FEMS MICROBIOL LETT, V234, P19, DOI 10.1111/j.1574-6968.2004.tb09508.x; Assossou O, 2003, FEMS MICROBIOL LETT, V224, P161, DOI 10.1016/S0378-1097(03)00479-8; Augustijn KD, 2007, INFECT IMMUN, V75, P1116, DOI 10.1128/IAI.00902-06; Bozza Marcelo T, 2012, J Parasitol Res, V2012, P413052, DOI 10.1155/2012/413052; Burrells A, 2015, VET RES, V46, DOI 10.1186/s13567-015-0177-0; BUXTON D, 1995, PARASITOLOGY, V110, pS11, DOI 10.1017/S003118200000144X; Calabro S, 2013, VACCINE, V31, P3363, DOI 10.1016/j.vaccine.2013.05.007; Chellan P, 2017, BIOORG MED CHEM LETT, V27, P1491, DOI 10.1016/j.bmcl.2017.01.046; Chen J, 2015, EXPERT REV VACCINES, V14, P617, DOI 10.1586/14760584.2015.1011133; Ching XT, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00609; Chuang SC, 2013, PARASITE VECTOR, V6, DOI 10.1186/1756-3305-6-34; Czarnewski P, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00142; D'Argenio DA, 2010, IMMUNITY, V33, P437, DOI 10.1016/j.immuni.2010.10.011; Ruiz-Rosado JD, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/9101762; Dodangeh S, 2021, MICROB PATHOGENESIS, V153, DOI 10.1016/j.micpath.2021.104764; Dupont CD, 2012, SEMIN IMMUNOPATHOL, V34, P793, DOI 10.1007/s00281-012-0339-3; Dziadek B, 2012, EXP PARASITOL, V131, P133, DOI 10.1016/j.exppara.2012.02.026; Dziadek B, 2009, EXP PARASITOL, V123, P81, DOI 10.1016/j.exppara.2009.06.002; Fang RNH, 2016, ANNU REV CHEM BIOMOL, V7, P305, DOI 10.1146/annurev-chembioeng-080615-034446; Flaster H, 2007, MOL ENDOCRINOL, V21, P1267, DOI 10.1210/me.2007-0065; Garcon N, 2012, EXPERT REV VACCINES, V11, P349, DOI [10.1586/erv.11.192, 10.1586/ERV.11.192]; Garrison E, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1003049; Golkar M, 2007, VACCINE, V25, P4301, DOI 10.1016/j.vaccine.2007.02.057; Gomes AO, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.00906; Grenfell RFQ, 2015, CLIN VACCINE IMMUNOL, V22, P336, DOI 10.1128/CVI.00714-14; Grzybowski MM, 2015, PARASITOL RES, V114, P4553, DOI 10.1007/s00436-015-4701-y; Hertelendy J, 2018, CURR MED CHEM, V25, P601, DOI 10.2174/0929867324666170714114200; Hiszczynska-Sawicka E, 2014, PARASITOLOGY, V141, P1365, DOI 10.1017/S0031182014000481; Hunter CA, 2012, NAT REV MICROBIOL, V10, P766, DOI 10.1038/nrmicro2858; Innes EA, 2010, EXPERT REV VACCINES, V9, P1117, DOI 10.1586/ERV.10.113; Jongert E, 2008, VACCINE, V26, P5289, DOI 10.1016/j.vaccine.2008.07.032; Kur J, 2009, EXPERT REV VACCINES, V8, P791, DOI [10.1586/erv.09.27, 10.1586/ERV.09.27]; Leroux LP, 2015, INT J PARASITOL, V45, P319, DOI 10.1016/j.ijpara.2015.01.003; Li YW, 2018, EXPERT OPIN BIOL TH, V18, P273, DOI 10.1080/14712598.2018.1413086; Liu K, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.00813; Majidiani H, 2020, CLIN EXP VACCINE RES, V9, P146, DOI 10.7774/cevr.2020.9.2.146; Martin V, 2004, CLIN DIAGN LAB IMMUN, V11, P704, DOI 10.1128/CDLI.11.4.704-710.2004; Mendonca-Previato L, 2005, CURR OPIN STRUC BIOL, V15, P499, DOI 10.1016/j.sbi.2005.08.011; Meng M, 2012, PARASITE VECTOR, V5, DOI 10.1186/1756-3305-5-273; Nie H, 2011, VET PARASITOL, V181, P215, DOI 10.1016/j.vetpar.2011.04.039; Pappas G, 2009, INT J PARASITOL, V39, P1385, DOI 10.1016/j.ijpara.2009.04.003; Picchio MS, 2018, EXP PARASITOL, V185, P62, DOI 10.1016/j.exppara.2018.01.006; Pinzan CF, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143087; Qu DF, 2011, VET PARASITOL, V179, P28, DOI 10.1016/j.vetpar.2011.02.008; Qu DF, 2009, VET PARASITOL, V166, P220, DOI 10.1016/j.vetpar.2009.08.016; Richardson JM, 2009, BIOCHEM BIOPH RES CO, V380, P442, DOI 10.1016/j.bbrc.2009.01.030; Sahar EA, 2020, BMC INFECT DIS, V20, DOI 10.1186/s12879-020-05220-2; Sayles PC, 2000, INFECT IMMUN, V68, P1026, DOI 10.1128/IAI.68.3.1026-1033.2000; Sluchanko NN, 2010, BIOCHEMISTRY-MOSCOW+, V75, P1528, DOI 10.1134/S0006297910130031; Sommerville C, 2013, J BIOL CHEM, V288, P12733, DOI 10.1074/jbc.M112.419911; Sonaimuthu P, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00808; Toussi DN, 2014, VACCINES, V2, P323, DOI 10.3390/vaccines2020323; van Doremalen N, 2020, NATURE, V586, P578, DOI [10.1038/s41586-020-2608-y, 10.1101/2020.05.13.093195]; Wallbank BA, 2019, MOL MICROBIOL, V111, P1167, DOI 10.1111/mmi.14156; Wang JL, 2015, PARASITE VECTOR, V8, DOI 10.1186/s13071-015-0917-z; Weidner JM, 2016, CELL MICROBIOL, V18, P1537, DOI 10.1111/cmi.12595; Wu MM, 2019, ACTA TROP, V199, DOI 10.1016/j.actatropica.2019.105148; Xu XP, 2019, PARASITE, V26, DOI 10.1051/parasite/2019050; Xu Y, 2015, PARASITOL RES, V114, P4195, DOI 10.1007/s00436-015-4652-3; Zang XX, 2002, J BIOL CHEM, V277, P44261, DOI 10.1074/jbc.M204655200; Zhang NZ, 2015, EXPERT REV VACCINES, V14, P1609, DOI 10.1586/14760584.2015.1098539	61	0	0	3	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 22	2021	12								755792	10.3389/fimmu.2021.755792	http://dx.doi.org/10.3389/fimmu.2021.755792			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2C5BJ	35003067	Green Published, gold			2022-12-18	WOS:000810883600001
J	Liu, SQ; Guo, WJ; Jia, YX; Ye, BJ; Liu, S; Fu, SP; Liu, JX; Hu, GQ				Liu, Songqi; Guo, Wenjin; Jia, Yuxi; Ye, Bojian; Liu, Shu; Fu, Shoupeng; Liu, Juxiong; Hu, Guiqiu			Menthol Targeting AMPK Alleviates the Inflammatory Response of Bovine Mammary Epithelial Cells and Restores the Synthesis of Milk Fat and Milk Protein	FRONTIERS IN IMMUNOLOGY			English	Article						mastitis; menthol; BMECs; AMPK; autophagy	AUTOPHAGY; MASTITIS; INHIBITION; CHANNEL; STRESS; DEATH	Mastitis is one of the most serious diseases that causes losses in the dairy industry, seriously impairing milk production and milk quality, and even affecting human health. Menthol is a cyclic monoterpene compound obtained from the stem and leaves of peppermint, which has a variety of biological activities, including anti-inflammatory and antioxidant activity. The purpose of this study was to investigate the preventive effect of menthol on the lipopolysaccharide-induced inflammatory response in primary bovine mammary gland epithelial cells (BMECs) and its anti-inflammatory mechanism. First, BMECs were isolated and amplified from the udders of Holstein cows by enzymatic hydrolysis. BMECs were treated with menthol (10, 50, 100, 200 mu M) for 1h, followed by lipopolysaccharide (5 mu g/ml) for 12 h. Lipopolysaccharide treatment upregulated the protein levels of cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (INOS) and the mRNA abundance of tumor necrosis factor alpha (TNF-alpha), interleukin-6 (IL-6), and interleukin-1 beta (IL-1 beta), while menthol was able to inhibit this effect. The inhibitory effect of menthol on proinflammatory factors was significantly reduced when autophagy was blocked using 3-Methyladenine (5 mu g/ml), an inhibitor of autophagy. Furthermore, lipopolysaccharide treatment reduced the expression levels of milk lipids and milk proteins, which were inhibited by menthol. In addition, menthol (200 mu M) treatment was able to significantly upregulate the expression level of autophagy-related protein LC3B, downregulate the expression level of P62, promote the expression abundance of autophagy-related gene mRNA, and enhance significantly enhance autophagic flux. Interestingly, treatment of BMECs with menthol (200 mu M) promoted the phosphorylation of AMP-activated protein kinase (AMPK) and unc-51 like kinase 1 (ULK1) and increased the nuclear localization of nuclear factor-E2 associated factor 2 (Nrf-2). When the AMPK pathway was blocked using compound C (10 mu g/ml), an inhibitor of AMPK, autophagy was significantly inhibited. Autophagy levels were significantly decreased after blocking the Nrf-2 pathway using ML385 (5 mu g/ml), an inhibitor of Nrf-2. Overall, the data suggest that menthol activates the AMPK-ULK1 pathway to initiate the onset of autophagy and maintains the level of autophagy through the AMPK-Nrf-2 pathway. In conclusion, the findings suggest that menthol may alleviate the inflammatory response in BMECs via the AMPK/ULK1/Nrf-2/autophagy pathway.	[Liu, Songqi; Guo, Wenjin; Ye, Bojian; Liu, Shu; Fu, Shoupeng; Liu, Juxiong; Hu, Guiqiu] Jilin Univ, Coll Vet Med, Changchun, Peoples R China; [Jia, Yuxi] Second Hosp Jilin Univ, Dept Orthped, Changchun, Peoples R China; [Jia, Yuxi] Second Hosp Jilin Univ, Applict Demonstrat Ctr Precis Med Mol Diag, Changchun, Peoples R China	Jilin University; Jilin University; Jilin University	Hu, GQ (corresponding author), Jilin Univ, Coll Vet Med, Changchun, Peoples R China.	huguiqiu@jlu.edu.cn	Guo, Wenjin/ACZ-0335-2022; jia, yu/HHR-9047-2022	Guo, Wenjin/0000-0002-7679-7138; 	National Natural Science Foundation of China [31873004, 32172807, 32102624]; Jilin Young Scientific and Technological Talents Promotion Project [QT202127]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Jilin Young Scientific and Technological Talents Promotion Project	Funding This work was supported by the National Natural Science Foundation of China. Grant/Award Numbers: 31873004, 32172807, 32102624; Jilin Young Scientific and Technological Talents Promotion Project: QT202127.	ANTALIS TM, 1991, NUCLEIC ACIDS RES, V19, P4301, DOI 10.1093/nar/19.15.4301; Arab HH, 2021, CHEM-BIOL INTERACT, V335, DOI 10.1016/j.cbi.2021.109368; Brenaut P, 2014, VET RES, V45, DOI 10.1186/1297-9716-45-16; Bruckmaier RM, 2017, J ANIM SCI, V95, P5720, DOI 10.2527/jas2017.1845; Cai J, 2020, J CELL MOL MED, V24, P3460, DOI 10.1111/jcmm.15027; Cao Y, 2021, J AGR FOOD CHEM, V69, P4093, DOI 10.1021/acs.jafc.0c07613; Detilleux J, 2015, PREV VET MED, V118, P449, DOI 10.1016/j.prevetmed.2015.01.009; Du J, 2020, INT IMMUNOPHARMACOL, V85, DOI 10.1016/j.intimp.2020.106679; Geng N, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00746; Ghasemi-Pirbaluti M, 2017, EUR J PHARMACOL, V805, P101, DOI 10.1016/j.ejphar.2017.03.003; Glick D, 2010, J PATHOL, V221, P3, DOI 10.1002/path.2697; Go YY, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-59290-y; Guo WJ, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21093321; Guo WJ, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00287; Heng YQ, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.671180; Horst EA, 2020, J DAIRY SCI, V103, P9620, DOI 10.3168/jds.2020-18686; Huang J, 2020, J DAIRY SCI, V103, P340, DOI 10.3168/jds.2019-16343; Hung CM, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abg4544; Karashima Y, 2007, J NEUROSCI, V27, P9874, DOI 10.1523/JNEUROSCI.2221-07.2007; Kim KH, 2014, NAT REV ENDOCRINOL, V10, P322, DOI 10.1038/nrendo.2014.35; Kromker V, 2017, REPROD DOMEST ANIM, V52, P21, DOI 10.1111/rda.13032; Lapaquette P, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/398483; Li Q, 2009, ONCOLOGY-BASEL, V77, P335, DOI 10.1159/000264627; Li Z, 2021, ECOTOX ENVIRON SAFE, V217, DOI 10.1016/j.ecoenv.2021.112219; Liu LX, 2016, EXP THER MED, V11, P1279, DOI 10.3892/etm.2016.3029; Liu ZG, 2015, FOOD CHEM TOXICOL, V82, P12, DOI 10.1016/j.fct.2015.04.025; MacDougall JM, 2003, CHEM RES TOXICOL, V16, P988, DOI 10.1021/tx0340551; Mao K, 2011, CIRC RES, V108, P787, DOI 10.1161/RES.0b013e3182194c29; Martins L, 2021, J DAIRY SCI, V104, P12030, DOI 10.3168/jds.2021-20177; Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026; Ning LT, 2018, J ANIM PHYSIOL AN N, V102, pE262, DOI 10.1111/jpn.12737; O'Brien J, 2012, DEVELOPMENT, V139, P269, DOI 10.1242/dev.071696; Pajares M, 2016, AUTOPHAGY, V12, P1902, DOI 10.1080/15548627.2016.1208889; Plaks V, 2015, DEV CELL, V34, P493, DOI 10.1016/j.devcel.2015.07.015; Rahman MA, 2021, ANTIOXIDANTS-BASEL, V10, DOI 10.3390/antiox10030408; Ravanan P, 2017, LIFE SCI, V188, P53, DOI 10.1016/j.lfs.2017.08.029; Ruegg PL, 2017, J DAIRY SCI, V100, P10381, DOI 10.3168/jds.2017-13023; Saenger T, 2019, BBA-GEN SUBJECTS, V1863, P632, DOI 10.1016/j.bbagen.2018.12.007; Scrivo A, 2018, LANCET NEUROL, V17, P802, DOI 10.1016/S1474-4422(18)30238-2; Seegers H, 2003, VET RES, V34, P475, DOI 10.1051/vetres:2003027; Shangraw EM, 2020, J DAIRY SCI, V103, P7487, DOI 10.3168/jds.2019-18022; Sun XD, 2019, FOOD FUNCT, V10, P6276, DOI 10.1039/c9fo01922g; Tsugami Y, 2021, EXP CELL RES, V400, DOI 10.1016/j.yexcr.2021.112472; Wang H, 2019, J DAIRY SCI, V102, P8264, DOI [10.316, 10.3168/jds.2019-16414]; Wang ZL, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.631113; Xiong W, 2021, THERANOSTICS, V11, P4637, DOI 10.7150/thno.56082; Xu DW, 2020, INT IMMUNOPHARMACOL, V78, DOI 10.1016/j.intimp.2019.105983; Zhang XY, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/3214196	48	0	0	5	18	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 22	2021	12								782989	10.3389/fimmu.2021.782989	http://dx.doi.org/10.3389/fimmu.2021.782989			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YH2NX	35003099	gold, Green Published			2022-12-18	WOS:000743009900001
J	Ozakman, Y; Raval, D; Eleftherianos, I				Ozakman, Yaprak; Raval, Dhaivat; Eleftherianos, Ioannis			Activin and BMP Signaling Activity Affects Different Aspects of Host Anti-Nematode Immunity in Drosophila melanogaster	FRONTIERS IN IMMUNOLOGY			English	Article						Drosophila; innate immunity; Heterorhabditis; Photorhabdus; TGF-ss	BLOOD-CELLS; INFECTION; BACTERIAL; RECOGNITION; SYSTEM; FLIES; MODEL; GENE; TOLL; IMD	The multifaceted functions ranging from cellular and developmental mechanisms to inflammation and immunity have rendered TGF-ss signaling pathways as critical regulators of conserved biological processes. Recent studies have indicated that this evolutionary conserved signaling pathway among metazoans contributes to the Drosophila melanogaster anti-nematode immune response. However, functional characterization of the interaction between TGF-ss signaling activity and the mechanisms activated by the D. melanogaster immune response against parasitic nematode infection remains unexplored. Also, it is essential to evaluate the precise effect of entomopathogenic nematode parasites on the host immune system by separating them from their mutualistic bacteria. Here, we investigated the participation of the TGF-ss signaling branches, activin and bone morphogenetic protein (BMP), to host immune function against axenic or symbiotic Heterorhabditis bacteriophora nematodes (parasites lacking or containing their mutualistic bacteria, respectively). Using D. melanogaster larvae carrying mutations in the genes coding for the TGF-ss extracellular ligands Daw and Dpp, we analyzed the changes in survival ability, cellular immune response, and phenoloxidase (PO) activity during nematode infection. We show that infection with axenic H. bacteriophora decreases the mortality rate of dpp mutants, but not daw mutants. Following axenic or symbiotic H. bacteriophora infection, both daw and dpp mutants contain only plasmatocytes. We further detect higher levels of Dual oxidase gene expression in dpp mutants upon infection with axenic nematodes and Diptericin and Cecropin gene expression in daw mutants upon infection with symbiotic nematodes compared to controls. Finally, following symbiotic H. bacteriophora infection, daw mutants have higher PO activity relative to controls. Together, our findings reveal that while D. melanogaster Dpp/BMP signaling activity modulates the DUOX/ROS response to axenic H. bacteriophora infection, Daw/activin signaling activity modulates the antimicrobial peptide and melanization responses to axenic H. bacteriophora infection. Results from this study expand our current understanding of the molecular and mechanistic interplay between nematode parasites and the host immune system, and the involvement of TGF-ss signaling branches in this process. Such findings will provide valuable insight on the evolution of the immune role of TGF-ss signaling, which could lead to the development of novel strategies for the effective management of human parasitic nematodes.	[Ozakman, Yaprak; Raval, Dhaivat; Eleftherianos, Ioannis] George Washington Univ, Dept Biol Sci, Infect & Innate Immun Lab, Washington, DC 20052 USA	George Washington University	Eleftherianos, I (corresponding author), George Washington Univ, Dept Biol Sci, Infect & Innate Immun Lab, Washington, DC 20052 USA.	ioannise@gwu.edu						Bidla G, 2005, DEV COMP IMMUNOL, V29, P669, DOI 10.1016/j.dci.2004.11.007; Binggeli O, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004067; Campbell G, 2002, NATURE, V418, P781, DOI 10.1038/nature00971; Castillo JC, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1690-2; Castillo JC, 2012, VIRULENCE, V3, P339, DOI 10.4161/viru.20244; Castillo JC, 2011, TRENDS PARASITOL, V27, P537, DOI 10.1016/j.pt.2011.09.001; Ciche TA, 2003, APPL ENVIRON MICROB, V69, P1890, DOI 10.1128/AEM.69.4.1890-1897.2003; Clark RI, 2011, CURR BIOL, V21, P1672, DOI 10.1016/j.cub.2011.08.048; Cooper D, 2019, MOL IMMUNOL, V109, P88, DOI 10.1016/j.molimm.2019.03.008; Diemert DJ, 2008, CLIN INFECT DIS, V46, P282, DOI 10.1086/524070; Dobens LL, 1998, ANN NY ACAD SCI, V857, P245, DOI 10.1111/j.1749-6632.1998.tb10123.x; Dudzic JP, 2019, CELL REP, V27, P1050, DOI 10.1016/j.celrep.2019.03.101; Dziedziech A, 2020, INSECTS, V11, DOI 10.3390/insects11010060; Eleftherianos I, 2016, IMMUNOBIOLOGY, V221, P1362, DOI 10.1016/j.imbio.2016.07.011; Eleftherianos I, 2014, INFECT IMMUN, V82, P4169, DOI 10.1128/IAI.02318-14; Ferrandon D, 2007, NAT REV IMMUNOL, V7, P862, DOI 10.1038/nri2194; Garriga A, 2020, INSECTS, V11, DOI 10.3390/insects11040210; Gold KS, 2015, SEMIN IMMUNOL, V27, P357, DOI 10.1016/j.smim.2016.03.010; Gottar M, 2006, CELL, V127, P1425, DOI 10.1016/j.cell.2006.10.046; Hallem EA, 2007, CURR BIOL, V17, P898, DOI 10.1016/j.cub.2007.04.027; Honti V, 2014, DEV COMP IMMUNOL, V42, P47, DOI 10.1016/j.dci.2013.06.005; Huminiecki L, 2009, BMC EVOL BIOL, V9, DOI 10.1186/1471-2148-9-28; Hyrsl P, 2011, J INNATE IMMUN, V3, P65, DOI 10.1159/000320634; Imler Jean-Luc, 2005, V86, P1, DOI 10.1159/000086648; Kenney E, 2021, DEV COMP IMMUNOL, V114, DOI 10.1016/j.dci.2020.103820; Kenney E, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-69306-2; Kenney E, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02372; Kim SH, 2014, FRONT CELL INFECT MI, V3, DOI 10.3389/fcimb.2013.00116; Kleino A, 2014, DEV COMP IMMUNOL, V42, P25, DOI 10.1016/j.dci.2013.05.014; Lee KA, 2018, CELL HOST MICROBE, V23, P338, DOI 10.1016/j.chom.2018.01.011; Lemaitre B, 1997, P NATL ACAD SCI USA, V94, P14614, DOI 10.1073/pnas.94.26.14614; LEMAITRE B, 1995, P NATL ACAD SCI USA, V92, P9465, DOI 10.1073/pnas.92.21.9465; MASUCCI JD, 1990, GENE DEV, V4, P2011, DOI 10.1101/gad.4.11.2011; Michel T, 2001, NATURE, V414, P756, DOI 10.1038/414756a; Montanari MP, 2022, DEV DYNAM, V251, P198, DOI 10.1002/dvdy.397; Myers AL, 2018, BIOCHEM BIOPH RES CO, V505, P726, DOI 10.1016/j.bbrc.2018.09.126; Ozakman Y, 2021, TRENDS PARASITOL, V37, P1002, DOI 10.1016/j.pt.2021.06.001; Ozakman Y, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.00716; Pang K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024152; Panuska C, 2006, VET CLIN N AM-FOOD A, V22, P583, DOI 10.1016/j.cvfa.2006.06.002; Patrnogic J, 2019, IMMUNOGENETICS, V71, P501, DOI 10.1007/s00251-019-01119-8; Patrnogic J, 2018, INNATE IMMUN-LONDON, V24, P349, DOI 10.1177/1753425918790663; Patrnogic J, 2018, GENE, V673, P112, DOI 10.1016/j.gene.2018.06.052; Pechmann M, 2021, ELIFE, V10, DOI 10.7554/eLife.68287; RIZKI RM, 1991, J EXP ZOOL, V257, P236, DOI 10.1002/jez.1402570214; RIZKI TM, 1992, DEV COMP IMMUNOL, V16, P103, DOI 10.1016/0145-305X(92)90011-Z; Shokal U, 2017, VIRULENCE, V8, P1668, DOI 10.1080/21505594.2017.1330240; Stock SP, 2008, SYMBIOSIS, V46, P65; Strand MR, 2008, INSECT IMMUNOLOGY, P25, DOI 10.1016/S0965-1748(02)00092-9; Tzavlaki K, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10030487; Upadhyay A, 2017, CSH PERSPECT BIOL, V9, DOI 10.1101/cshperspect.a022152; Vieson MD, 2012, VET MED-RES REP, V3, P25, DOI 10.2147/VMRR.S25021; Vlisidou I, 2015, FEBS J, V282, P1368, DOI 10.1111/febs.13235; Wang Z, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000763; WHITE G. F., 1927, SCIENCE, V66, P302, DOI 10.1126/science.66.1709.302-a; Williams MJ, 2007, J IMMUNOL, V178, P4711, DOI 10.4049/jimmunol.178.8.4711; Xiao CC, 2003, GENE DEV, V17, P2933, DOI 10.1101/gad.1145603; Zi ZK, 2012, FEBS LETT, V586, P1921, DOI 10.1016/j.febslet.2012.03.063	58	0	0	4	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 22	2021	12								795331	10.3389/fimmu.2021.795331	http://dx.doi.org/10.3389/fimmu.2021.795331			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YI2XU	35003118	Green Published, gold			2022-12-18	WOS:000743717600001
J	Shanthikumar, S; Neeland, MR; Saffery, R; Ranganathan, SC; Oshlack, A; Maksimovic, J				Shanthikumar, Shivanthan; Neeland, Melanie R.; Saffery, Richard; Ranganathan, Sarath C.; Oshlack, Alicia; Maksimovic, Jovana			DNA Methylation Profiles of Purified Cell Types in Bronchoalveolar Lavage: Applications for Mixed Cell Paediatric Pulmonary Studies	FRONTIERS IN IMMUNOLOGY			English	Article						DNA methylation; bronchoalveolar lavage; paediatrics; cystic fibrosis; pulmonary disease; epigenetics	EPIGENOME-WIDE ASSOCIATION; NORMALIZATION; INFLAMMATION; CHILDREN; PACKAGE; TOOL	In epigenome-wide association studies analysing DNA methylation from samples containing multiple cell types, it is essential to adjust the analysis for cell type composition. One well established strategy for achieving this is reference-based cell type deconvolution, which relies on knowledge of the DNA methylation profiles of purified constituent cell types. These are then used to estimate the cell type proportions of each sample, which can then be incorporated to adjust the association analysis. Bronchoalveolar lavage is commonly used to sample the lung in clinical practice and contains a mixture of different cell types that can vary in proportion across samples, affecting the overall methylation profile. A current barrier to the use of bronchoalveolar lavage in DNA methylation-based research is the lack of reference DNA methylation profiles for each of the constituent cell types, thus making reference-based cell composition estimation difficult. Herein, we use bronchoalveolar lavage samples collected from children with cystic fibrosis to define DNA methylation profiles for the four most common and clinically relevant cell types: alveolar macrophages, granulocytes, lymphocytes and alveolar epithelial cells. We then demonstrate the use of these methylation profiles in conjunction with an established reference-based methylation deconvolution method to estimate the cell type composition of two different tissue types; a publicly available dataset derived from artificial blood-based cell mixtures and further bronchoalveolar lavage samples. The reference DNA methylation profiles developed in this work can be used for future reference-based cell type composition estimation of bronchoalveolar lavage. This will facilitate the use of this tissue in studies examining the role of DNA methylation in lung health and disease.	[Shanthikumar, Shivanthan; Ranganathan, Sarath C.] Royal Childrens Hosp, Resp & Sleep Med, Parkville, Vic, Australia; [Shanthikumar, Shivanthan; Neeland, Melanie R.; Saffery, Richard; Ranganathan, Sarath C.; Maksimovic, Jovana] Univ Melbourne, Dept Paediat, Parkville, Vic, Australia; [Shanthikumar, Shivanthan; Ranganathan, Sarath C.; Maksimovic, Jovana] Murdoch Childrens Res Inst, Resp Dis, Parkville, Vic, Australia; [Neeland, Melanie R.; Saffery, Richard] Murdoch Childrens Res Inst, Mol Immun, Parkville, Vic, Australia; [Oshlack, Alicia; Maksimovic, Jovana] Peter MacCallum Canc Ctr, Computat Biol Program, Parkville, Vic, Australia; [Oshlack, Alicia] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Parkville, Vic, Australia; [Oshlack, Alicia] Univ Melbourne, Sch BioSci, Parkville, Vic, Australia	Royal Children's Hospital Melbourne; University of Melbourne; Murdoch Children's Research Institute; Murdoch Children's Research Institute; Peter Maccallum Cancer Center; Peter Maccallum Cancer Center; University of Melbourne; University of Melbourne	Shanthikumar, S (corresponding author), Royal Childrens Hosp, Resp & Sleep Med, Parkville, Vic, Australia.; Shanthikumar, S (corresponding author), Univ Melbourne, Dept Paediat, Parkville, Vic, Australia.; Shanthikumar, S (corresponding author), Murdoch Childrens Res Inst, Resp Dis, Parkville, Vic, Australia.	Shivanthan.shanthikumar@rch.org.au	Saffery, Richard/GLS-1976-2022	Saffery, Richard/0000-0002-9510-4181; Neeland, Melanie/0000-0001-7301-9982; Shanthikumar, Shivanthan/0000-0001-6000-3180	Vertex Pharmaceuticals Research Innovation Award	Vertex Pharmaceuticals Research Innovation Award(Vertex Pharmaceuticals)	& nbsp;This work was funded by a Vertex Pharmaceuticals Research Innovation Award (Ranganathan 2017).	Armstrong DS, 1997, AM J RESP CRIT CARE, V156, P1197, DOI 10.1164/ajrccm.156.4.96-11058; Aryee MJ, 2014, BIOINFORMATICS, V30, P1363, DOI 10.1093/bioinformatics/btu049; Bakulski KM, 2016, EPIGENETICS-US, V11, P354, DOI 10.1080/15592294.2016.1161875; Baler K., 2020, BIORXIV, DOI [10.1101/2020.05.28.121541, DOI 10.1101/2020.05.28.121541]; Bleriot C, 2020, IMMUNITY, V52, P957, DOI 10.1016/j.immuni.2020.05.014; Blischak John D, 2019, F1000Res, V8, P1749, DOI 10.12688/f1000research.20843.1; Breeze CE, 2016, CELL REP, V17, P2137, DOI 10.1016/j.celrep.2016.10.059; Bundo M, 2012, CLIN EPIGENETICS, V4, DOI 10.1186/1868-7083-4-22; Calle-Fabregat CD, 2020, GENES-BASEL, V11, DOI 10.3390/genes11010110; Chen YDH, 2018, CLIN EPIGENETICS, V10, DOI 10.1186/s13148-018-0580-2; Dekkers KF, 2019, EPIGENET CHROMATIN, V12, DOI 10.1186/s13072-019-0279-4; Feinberg AP, 2018, NEW ENGL J MED, V378, P1323, DOI [10.1056/NEJMra1402513, 10.1056/nejmra1402513]; Fortin JP, 2017, BIOINFORMATICS, V33, P558, DOI 10.1093/bioinformatics/btw691; Ghosh S, 2010, EPIGENETICS-US, V5, DOI 10.4161/epi.5.6.12228; Guo SC, 2017, NAT GENET, V49, P635, DOI 10.1038/ng.3805; Hodge SJ, 2004, CYTOM PART B-CLIN CY, V61B, P27, DOI 10.1002/cyto.b.20020; Houseman E Andres, 2015, Curr Environ Health Rep, V2, P145, DOI 10.1007/s40572-015-0050-3; Houseman EA, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-86; Jaffe AE, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-2-r31; Koestler DC, 2017, CANCER EPIDEM BIOMAR, V26, P328, DOI 10.1158/1055-9965.EPI-16-0461; Levy L, 2018, RESP RES, V19, DOI 10.1186/s12931-018-0786-z; Maksimovic J, 2021, GENOME BIOL, V22, DOI 10.1186/s13059-021-02388-x; Maksimovic Jovana, 2016, F1000Res, V5, P1281, DOI 10.12688/f1000research.8839.3; Marguet C, 1999, AM J RESP CRIT CARE, V159, P1533, DOI 10.1164/ajrccm.159.5.9805028; Michels KB, 2013, NAT METHODS, V10, P949, DOI 10.1038/nmeth.2632; Olova N, 2018, GENOME BIOL, V19, DOI 10.1186/s13059-018-1408-2; Phipson B, 2016, BIOINFORMATICS, V32, P286, DOI 10.1093/bioinformatics/btv560; Pidsley R, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1066-1; R Core Team, 2021, COMPUTER SOFTWARE; Ratjen F, 2000, EUR RESPIR J, V15, P141, DOI 10.1183/09031936.00.15114100; Ringh MV, 2019, EBIOMEDICINE, V46, P290, DOI 10.1016/j.ebiom.2019.07.006; Salas LA, 2018, GENOME BIOL, V19, DOI 10.1186/s13059-018-1448-7; Shanthikumar Shivanthan, 2020, Mol Cell Pediatr, V7, P7, DOI 10.1186/s40348-020-00099-0; Shanthikumar S, 2020, AM J RESP CELL MOL, V63, P152, DOI 10.1165/rcmb.2019-0453MA; Tan SYS, 2016, DEVELOPMENT, V143, P1318, DOI 10.1242/dev.129122; Teschendorff AE, 2017, EPIGENOMICS-UK, V9, P757, DOI 10.2217/epi-2016-0153; Touleimat N, 2012, EPIGENOMICS-UK, V4, P325, DOI [10.2217/epi.12.21, 10.2217/EPI.12.21]; Tricas L, 2012, CYTOM PART B-CLIN CY, V82B, P61, DOI 10.1002/cyto.b.20630; Wiencke JK, 2017, CLIN EPIGENETICS, V9, DOI 10.1186/s13148-017-0316-8; Yang IV, 2019, AM J RESP CELL MOL, V60, P96, DOI 10.1165/rcmb.2018-0177OC; Zheng SC, 2017, NAT METHODS, V14, P216, DOI 10.1038/nmeth.4187	41	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 22	2021	12								788705	10.3389/fimmu.2021.788705	http://dx.doi.org/10.3389/fimmu.2021.788705			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YG5DT	35003108	Green Published, gold			2022-12-18	WOS:000742509800001
J	Shi, HX; Li, D; Shi, Q; Han, ZX; Tan, YW; Mu, XD; Qin, M; Li, ZJ				Shi, Haoxin; Li, Dong; Shi, Qing; Han, Zhenxia; Tan, Yuwei; Mu, Xiaodong; Qin, Miao; Li, Zengjun			Three-Dimensional Culture Decreases the Angiogenic Ability of Mouse Macrophages	FRONTIERS IN IMMUNOLOGY			English	Article						3D culture; macrophage; angiogenesis; collagen microcarrier; VEGFA; ANG2	ENDOTHELIAL GROWTH-FACTOR; BIOLOGY; VEGF	Macrophages play important roles in angiogenesis; however, previous studies on macrophage angiogenesis have focused on traditional 2D cultures. In this study, we established a 3D culture system for macrophages using collagen microcarriers and assessed the effect of 3D culture on their angiogenic capabilities. Macrophages grown in 3D culture displayed a significantly different morphology and arrangement under electron microscopy compared to those grown in 2D culture. Tube formation assays and chick embryo chorioallantoic membrane assays further revealed that 3D-cultured macrophages were less angiogenic than those in 2D culture. Whole-transcriptome sequencing showed that nearly 40% of genes were significantly differently expressed, including nine important angiogenic factors of which seven had been downregulated. In addition, the expression of almost all genes related to two important angiogenic pathways was decreased in 3D-cultured macrophages, including the two key angiogenic factors, VEGFA and ANG2. Together, the findings of our study improve our understanding of angiogenesis and 3D macrophage culture in tissues, and provide new avenues and methods for future research on macrophages.	[Shi, Haoxin; Qin, Miao; Li, Zengjun] Shandong First Med Univ, Dept Gastroenterol, Shandong Canc Hosp & Inst, Endoscopy Room, Jinan, Peoples R China; [Shi, Haoxin; Qin, Miao; Li, Zengjun] Shandong Acad Med Sci, Dept Gastroenterol, Shandong Canc Hosp & Inst, Endoscopy Room, Jinan, Peoples R China; [Li, Dong; Shi, Qing] Shandong Univ, Qilu Hosp, Cryomed Lab, Jinan, Peoples R China; [Han, Zhenxia; Tan, Yuwei] Shandong Univ, Dept Geriatr Med, Qilu Hosp, Jinan, Peoples R China; [Mu, Xiaodong] Shandong First Med Univ, Shandong Acad Med Sci, Coll Pharm & Pharmaceut Sci, Jinan, Peoples R China	Shandong First Medical University & Shandong Academy of Medical Sciences; Shandong First Medical University & Shandong Academy of Medical Sciences; University of Jinan; Shandong University; Shandong University; Shandong First Medical University & Shandong Academy of Medical Sciences; University of Jinan	Li, ZJ (corresponding author), Shandong First Med Univ, Dept Gastroenterol, Shandong Canc Hosp & Inst, Endoscopy Room, Jinan, Peoples R China.; Li, ZJ (corresponding author), Shandong Acad Med Sci, Dept Gastroenterol, Shandong Canc Hosp & Inst, Endoscopy Room, Jinan, Peoples R China.	zjli@sdfmu.edu.cn			National Key R&D Program of China [2018YFC0114707]; Key R&D Program of Shandong Province [2018GSF118047]; Science and Technology Project of the Jilin Provincial Department of Science and Technology [20180201029YY]	National Key R&D Program of China; Key R&D Program of Shandong Province; Science and Technology Project of the Jilin Provincial Department of Science and Technology	Funding This work was supported by the National Key R&D Program of China [grant number 2018YFC0114707]; the Key R&D Program of Shandong Province [grant number 2018GSF118047]; and the Science and Technology Project of the Jilin Provincial Department of Science and Technology [grant number 20180201029YY].	Conway EM, 2001, CARDIOVASC RES, V49, P507, DOI 10.1016/S0008-6363(00)00281-9; Cui X, 2018, BIOMATERIALS, V161, P164, DOI 10.1016/j.biomaterials.2018.01.053; Cukierman E, 2002, CURR OPIN CELL BIOL, V14, P633, DOI 10.1016/S0955-0674(02)00364-2; Edmondson R, 2014, ASSAY DRUG DEV TECHN, V12, P207, DOI 10.1089/adt.2014.573; Elshabrawy HA, 2015, ANGIOGENESIS, V18, P433, DOI 10.1007/s10456-015-9477-2; Fagiani E, 2013, CANCER LETT, V328, P18, DOI 10.1016/j.canlet.2012.08.018; Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027; Fu LQ, 2020, CELL IMMUNOL, V353, DOI 10.1016/j.cellimm.2020.104119; Garcia A, 2012, HISTOL HISTOPATHOL, V27, P151, DOI 10.14670/HH-27.151; Gordon S, 2010, IMMUNITY, V32, P593, DOI 10.1016/j.immuni.2010.05.007; Gurevich DB, 2018, EMBO J, V37, DOI 10.15252/embj.201797786; Haringman JJ, 2005, ANN RHEUM DIS, V64, P834, DOI 10.1136/ard.2004.029751; Huang YB, 2018, MOL MED REP, V17, P250, DOI 10.3892/mmr.2017.7888; Hutchinson L, 2011, NAT REV CLIN ONCOL, V8, P189, DOI [10.1038/nrclinonc.2011.34, 10.1038/nrclinonc.2010.204]; Knight E, 2015, J ANAT, V227, P746, DOI 10.1111/joa.12257; Koch S, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006502; Lavin Y, 2014, CELL, V159, P1312, DOI 10.1016/j.cell.2014.11.018; LEENE W, 1973, Z ZELLFORSCH MIK ANA, V136, P521, DOI 10.1007/BF00307368; Li QJ, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.707784; Li XD, 2018, 3 BIOTECH, V8, DOI 10.1007/s13205-018-1341-9; Li ZW, 2016, CELL STEM CELL, V19, P516, DOI 10.1016/j.stem.2016.07.016; Liu ZG, 2014, J CANCER RES CLIN, V140, P525, DOI 10.1007/s00432-013-1534-x; Lv DL, 2016, ONCOTARGET, V7, P56904, DOI 10.18632/oncotarget.10885; Ma YG, 2018, TRANSL RES, V191, P15, DOI 10.1016/j.trsl.2017.10.001; Melincovici CS, 2018, ROM J MORPHOL EMBRYO, V59, P455; Ribatti D, 2020, MICROVASC RES, V131, DOI 10.1016/j.mvr.2020.104026; Serra H, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8935; Shibuya M, 2006, EXP CELL RES, V312, P549, DOI 10.1016/j.yexcr.2005.11.012; Sun HH, 2019, BIOL REPROD, V100, P649, DOI 10.1093/biolre/ioy212; Sun ZQ, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0831-z; Takahashi H, 2005, CLIN SCI, V109, P227, DOI 10.1042/CS20040370; Tetzlaff F, 2018, ELIFE, V7, DOI 10.7554/eLife.32860; Vergani L, 2004, INT J BIOCHEM CELL B, V36, P1447, DOI 10.1016/j.biocel.2003.11.015; Wang XZ, 2018, COLLOID SURFACE B, V171, P629, DOI 10.1016/j.colsurfb.2018.08.006; Wynn TA, 2013, NATURE, V496, P445, DOI 10.1038/nature12034; Zhu LN, 2015, INT REV IMMUNOL, V34, P82, DOI 10.3109/08830185.2014.969421	36	0	0	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 22	2021	12								795066	10.3389/fimmu.2021.795066	http://dx.doi.org/10.3389/fimmu.2021.795066			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YB8UI	35003117	gold, Green Published			2022-12-18	WOS:000739279600001
J	Supriya, R; Gao, Y; Gu, YD; Baker, JS				Supriya, Rashmi; Gao, Yang; Gu, Yaodong; Baker, Julien S.			Role of Exercise Intensity on Th1/Th2 Immune Modulations During the COVID-19 Pandemic	FRONTIERS IN IMMUNOLOGY			English	Review						COVID-19; Th1; Th2 ratio; immunomodulation; intermittent hypoxic preconditioning; hypoxia	TUMOR-NECROSIS-FACTOR; GROWTH-FACTOR-BETA; CELLS IN-VITRO; T-CELLS; INTERMITTENT HYPOXIA; INTERFERON-GAMMA; PHYSICAL-ACTIVITY; PATHOPHYSIOLOGICAL RESPONSES; EOSINOPHIL RECRUITMENT; CORONAVIRUS COVID-19	The COVID-19 pandemic has led to several pioneering scientific discoveries resulting in no effective solutions with the exception of vaccination. Moderate exercise is a significant non-pharmacological strategy, to reduce the infection-related burden of COVID-19, especially in patients who are obese, elderly, and with additional comorbidities. The imbalance of T helper type 1 (Th1) or T helper type 2 (Th2) cells has been well documented among populations who have suffered as a result of the COVID-19 pandemic, and who are at maximum risk of infection and mortality. Moderate and low intensity exercise can benefit persons at risk from the disease and survivors by favorable modulation in Th1/Th2 ratios. Moreover, in COVID-19 patients, mild to moderate intensity aerobic exercise also increases immune system function but high intensity aerobic exercise may have adverse effects on immune responses. In addition, sustained hypoxia in COVID-19 patients has been reported to cause organ failure and cell death. Hypoxic conditions have also been highlighted to be triggered in COVID-19-susceptible individuals and COVID-19 survivors. This suggests that hypoxia inducible factor (HIF 1 alpha) might be an important focus for researchers investigating effective strategies to minimize the effects of the pandemic. Intermittent hypoxic preconditioning (IHP) is a method of exposing subjects to short bouts of moderate hypoxia interspersed with brief periods of normal oxygen concentrations (recovery). This methodology inhibits the production of pro-inflammatory factors, activates HIF-1 alpha to activate target genes, and subsequently leads to a higher production of red blood cells and hemoglobin. This increases angiogenesis and increases oxygen transport capacity. These factors can help alleviate virus induced cardiopulmonary hemodynamic disorders and endothelial dysfunction. Therefore, during the COVID-19 pandemic we propose that populations should engage in low to moderate exercise individually designed, prescribed and specific, that utilizes IHP including pranayama (yoga), swimming and high-altitude hiking exercise. This would be beneficial in affecting HIF-1 alpha to combat the disease and its severity. Therefore, the promotion of certain exercises should be considered by all sections of the population. However, exercise recommendations and prescription for COVID-19 patients should be structured to match individual levels of capability and adaptability.	[Supriya, Rashmi; Gao, Yang; Gu, Yaodong; Baker, Julien S.] Ningbo Univ, Fac Sports Sci, Ningbo, Zhejiang, Peoples R China; [Supriya, Rashmi; Gao, Yang; Gu, Yaodong; Baker, Julien S.] Hong Kong Baptist Univ, Ctr Hlth & Exercise Sci Res, Dept Sport Phys Educ & Hlth, Kowloon Tong, Hong Kong, Peoples R China	Ningbo University; Hong Kong Baptist University	Supriya, R (corresponding author), Ningbo Univ, Fac Sports Sci, Ningbo, Zhejiang, Peoples R China.; Supriya, R (corresponding author), Hong Kong Baptist Univ, Ctr Hlth & Exercise Sci Res, Dept Sport Phys Educ & Hlth, Kowloon Tong, Hong Kong, Peoples R China.	Rashmisupriya@hkbu.edu.hk		Gao, Yang (Gemma)/0000-0003-0439-4804; Supriya, Rashmi/0000-0003-2995-1910	Hong Kong Research Grants Council Post-doctoral Fellowship Scheme [PDFS2021-2H01]	Hong Kong Research Grants Council Post-doctoral Fellowship Scheme	Funding Key Project of the National Social Science Foundation of China (19ZDA352), NSFC-RSE Joint Project (81911530253), Zhejiang Province Science Fund for Distinguished Young Scholars (R22A021199) and K. C. Wong Magna Fund in Ningbo University.	Abd El-Kader SM, 2018, AFR HEALTH SCI, V18, P120, DOI 10.4314/ahs.v18i1.16; Afsar B, 2020, MED HYPOTHESES, V143, DOI 10.1016/j.mehy.2020.109857; Ayala A, 2001, CYTOKINE, V14, P37, DOI 10.1006/cyto.2001.0848; Baumann CA, 1997, MECH AGEING DEV, V94, P85, DOI 10.1016/S0047-6374(96)01860-X; Bhargav H., 2014, J STEM CELLS, V7, P1556; Blume J, 2011, BRAIN BEHAV IMMUN, V25, P221, DOI 10.1016/j.bbi.2010.10.008; BOUISSOU P, 1988, HORM METAB RES, V20, P517, DOI 10.1055/s-2007-1010872; Buer J, 1998, J EXP MED, V187, P177, DOI 10.1084/jem.187.2.177; Cai M, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.643619; Candan SA, 2020, PHYSIOTHER THEOR PR, V36, P663, DOI 10.1080/09593985.2020.1766181; Carson WF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020385; Chan JSY, 2019, J PSYCHOL, V153, P102, DOI 10.1080/00223980.2018.1470487; Chandrashekara S, 2007, J PSYCHOSOM RES, V63, P65, DOI 10.1016/j.jpsychores.2007.03.001; Chen PJ, 2017, COMPLEMENT THER MED, V31, P109, DOI 10.1016/j.ctim.2017.03.003; CHEN YH, 1994, SCIENCE, V265, P1237, DOI 10.1126/science.7520605; Czuba M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180380; D'Ignazio L, 2016, FEBS J, V283, P413, DOI 10.1111/febs.13578; Dang EV, 2011, CELL, V146, P772, DOI 10.1016/j.cell.2011.07.033; Dellacasagrande J, 1999, J IMMUNOL, V162, P2259; DIAMOND RD, 1991, J CLIN INVEST, V87, P711, DOI 10.1172/JCI115050; Dick NA, 2014, SPORTS HEALTH, V6, P225, DOI 10.1177/1941738113508373; Ding HL, 2004, LIFE SCI, V75, P2587, DOI 10.1016/j.lfs.2004.07.005; Eda N, 2018, J WOMEN AGING, V30, P227, DOI 10.1080/08952841.2017.1295689; Esch T, 2007, MED SCI MONITOR, V13, pCR488; Fathi F, 2020, INT J IMMUNOPATH PH, V34, DOI 10.1177/2058738420966497; Ferguson NR, 1999, INTENS CARE MED, V25, P106, DOI 10.1007/s001340050795; Finaud J, 2006, SPORTS MED, V36, P327, DOI 10.2165/00007256-200636040-00004; FIRESTEIN GS, 1989, J IMMUNOL, V143, P518; Fukaura H, 1996, J CLIN INVEST, V98, P70, DOI 10.1172/JCI118779; Gage JR, 2004, NEUROIMMUNOMODULAT, V11, P173, DOI 10.1159/000076766; Gangwar A, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-64848-x; Gaspersz R, 2017, TRANSL PSYCHIAT, V7, DOI 10.1038/s41398-017-0016-3; Gil-Etayo FJ, 2021, FRONT CELL INFECT MI, V11, DOI 10.3389/fcimb.2021.624483; Gleeson Michael, 2005, Ann Transplant, V10, P43; Godfraind C, 1998, J IMMUNOL, V160, P3989; Goebeler M, 1997, J INVEST DERMATOL, V108, P445, DOI 10.1111/1523-1747.ep12289711; Groux H, 1997, NATURE, V389, P737, DOI 10.1038/39614; Gunton JE, 2020, J CLIN INVEST, V130, P5063, DOI 10.1172/JCI137556; Hafler DA, 1997, ANN NY ACAD SCI, V835, P120, DOI 10.1111/j.1749-6632.1997.tb48623.x; He Q, 2011, AM J PHYSIOL-ENDOC M, V300, pE877, DOI 10.1152/ajpendo.00626.2010; Hill EE, 2008, J ENDOCRINOL INVEST, V31, P587, DOI 10.1007/BF03345606; Huang HW, 2013, NEUROIMMUNOMODULAT, V20, P1, DOI 10.1159/000343099; Huang YE, 2020, PSYCHIAT RES, V288, DOI 10.1016/j.psychres.2020.112954; Intensive Care National Audit Research Centre, 2020, ICNARC 2020; Jia X., 2020, 2 THINGS COVID 19 MI, P2020020315, DOI [10.20944/preprints202002.0315.v1, DOI 10.20944/PREPRINTS202002.0315.V1]; JOHNSON DR, 1990, P NATL ACAD SCI USA, V87, P5183, DOI 10.1073/pnas.87.13.5183; JOHNSTON RB, 1985, FED PROC, V44, P2927; Jose A, 2016, J PHYSIOTHER, V62, P96, DOI 10.1016/j.jphys.2016.02.014; Kern DM, 2021, NAT STRUCT MOL BIOL, V28, P573, DOI 10.1038/s41594-021-00619-0; Kim YK, 2003, ACTA NEUROPSYCHIATR, V15, P148, DOI 10.1034/j.1601-5215.2003.00026.x; Kloting N, 2020, OBESITY, V28, P2266, DOI 10.1002/oby.23041; Kruk J, 2020, FREE RADICAL RES, V54, P105, DOI 10.1080/10715762.2020.1726343; LAFRENIERE R, 1985, CANCER RES, V45, P3735; Lai YH, 1999, J IMMUNOL, V162, P78; LAPIERRE LA, 1988, J EXP MED, V167, P794, DOI 10.1084/jem.167.3.794; Larsen T, 2019, PHYSIOTHER CAN, V71, P82, DOI 10.3138/ptc.2017-51.ep; Lewis JS, 1999, J LEUKOCYTE BIOL, V66, P889, DOI 10.1002/jlb.66.6.889; Li JN, 2020, EUR J PHYS REHAB MED, V56, P335, DOI 10.23736/S1973-9087.20.06292-9; Lie WJH, 1998, J ALLERGY CLIN IMMUN, V101, P683, DOI 10.1016/S0091-6749(98)70178-2; Liu DX, 2014, ANTIVIR RES, V109, P97, DOI 10.1016/j.antiviral.2014.06.013; LIVINGSTON DH, 1989, J SURG RES, V46, P322, DOI 10.1016/0022-4804(89)90195-9; LUKACS NW, 1994, AM J RESP CELL MOL, V10, P526, DOI 10.1165/ajrcmb.10.5.8179915; LUNDGREN M, 1989, EUR J IMMUNOL, V19, P1311, DOI 10.1002/eji.1830190724; Mackenzie R, 2012, J CLIN ENDOCR METAB, V97, pE546, DOI 10.1210/jc.2011-2829; Magalhaes DM, 2020, HELIYON, V6, DOI 10.1016/j.heliyon.2020.e03208; MALE DK, 1987, IMMUNOLOGY, V60, P453; Manukhina EB, 2016, EXP BIOL MED, V241, P1351, DOI 10.1177/1535370216649060; Marshall GD, 2011, IMMUNOL ALLERGY CLIN, V31, P133, DOI 10.1016/j.iac.2010.09.013; Masoud GN, 2015, ACTA PHARM SIN B, V5, P378, DOI 10.1016/j.apsb.2015.05.007; Mathew D, 2020, SCIENCE, V369, P1209, DOI 10.1126/science.abc8511; McBride R, 2012, VIRUSES-BASEL, V4, P2902, DOI 10.3390/v4112902; McGeachy MJ, 2007, IMMUNITY, V26, P547, DOI 10.1016/j.immuni.2007.05.003; Mezzani A, 2013, EUR J PREV CARDIOL, V20, P442, DOI 10.1177/2047487312460484; Milburn HJ, 1997, CLIN EXP IMMUNOL, V108, P105, DOI 10.1046/j.1365-2249.1997.d01-979.x; Mohamed AA, 2020, DIABETES METAB SYND, V14, P489, DOI 10.1016/j.dsx.2020.04.038; Moriguchi S., 2007, JAPANESE J COMPLEMEN, V4, P71, DOI [10.1625/jcam.4.71, DOI 10.1625/JCAM.4.71]; Myint AM, 2005, J AFFECT DISORDERS, V88, P167, DOI 10.1016/j.jad.2005.07.008; Nabkasorn C, 2006, EUR J PUBLIC HEALTH, V16, P179, DOI 10.1093/eurpub/cki159; Neubauer JA, 2001, J APPL PHYSIOL, V90, P1593, DOI 10.1152/jappl.2001.90.4.1593; NEWBURGER PE, 1988, P NATL ACAD SCI USA, V85, P5215, DOI 10.1073/pnas.85.14.5215; Nicolaides NC, 1997, P NATL ACAD SCI USA, V94, P13175, DOI 10.1073/pnas.94.24.13175; Nieman DC, 2019, J SPORT HEALTH SCI, V8, P201, DOI 10.1016/j.jshs.2018.09.009; Nieman DC, 2005, MED SCI SPORT EXER, V37, P57, DOI 10.1249/01.MSS.0000149808.38194.21; OHNISHI T, 1993, J ALLERGY CLIN IMMUN, V92, P607, DOI 10.1016/0091-6749(93)90085-T; Ostrowski K, 1999, J PHYSIOL-LONDON, V515, P287, DOI 10.1111/j.1469-7793.1999.287ad.x; PARSONS JC, 1993, PARASITE IMMUNOL, V15, P501, DOI 10.1111/j.1365-3024.1993.tb00637.x; Pedersen BK, 2002, MED SCI SPORT EXER, V34, P2004, DOI 10.1097/00005768-200212000-00022; Pedersen BK, 2001, J PHYSIOL-LONDON, V536, P329, DOI 10.1111/j.1469-7793.2001.0329c.xd; Perera PY, 2012, MICROBES INFECT, V14, P247, DOI 10.1016/j.micinf.2011.10.006; Pettit NN, 2020, OBESITY, V28, P1806, DOI 10.1002/oby.22941; Platten M, 2009, P NATL ACAD SCI USA, V106, P14948, DOI 10.1073/pnas.0903958106; Ponsot E, 2006, J APPL PHYSIOL, V100, P1249, DOI 10.1152/japplphysiol.00361.2005; Powell F L, 2000, High Alt Med Biol, V1, P125, DOI 10.1089/15270290050074279; Powrie F, 1996, J EXP MED, V183, P2669, DOI 10.1084/jem.183.6.2669; PUNNONEN J, 1994, J IMMUNOL, V152, P1094; Raghavendra RM, 2009, INTEGR CANCER THER, V8, P37, DOI 10.1177/1534735409331456; Rahmati-Ahmadabad Saleh, 2020, Obes Med, V19, P100245, DOI 10.1016/j.obmed.2020.100245; Ratajczak MZ, 2020, LEUKEMIA, V34, P1726, DOI 10.1038/s41375-020-0887-9; RATHANASWAMI P, 1993, J BIOL CHEM, V268, P5834; Redondo N, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.708264; Reed J, 2009, PSYCHOL SPORT EXERC, V10, P581, DOI 10.1016/j.psychsport.2009.05.009; RENAULD JC, 1995, J LEUKOCYTE BIOL, V57, P353, DOI 10.1002/jlb.57.3.353; Righetti RF, 2020, CLINICS, V75, DOI 10.6061/clinics/2020/e2017; ROBINSON D, 1993, J ALLERGY CLIN IMMUN, V92, P313, DOI 10.1016/0091-6749(93)90175-F; ROCKEN M, 1991, J IMMUNOL, V146, P577; Roth G, 2003, BIOCHEM BIOPH RES CO, V308, P840, DOI 10.1016/S0006-291X(03)01482-7; SAD S, 1994, J IMMUNOL, V153, P3514; Saha B, 2001, NEUROIMMUNOMODULAT, V9, P23, DOI 10.1159/000049004; Santos SA, 2019, CLIN RESPIR J, V13, P583, DOI 10.1111/crj.13061; SARMIENTO EU, 1995, J IMMUNOL, V155, P2211; SATOH T, 1994, IMMUNOLOGY, V83, P308; Semenza GL, 2000, J APPL PHYSIOL, V88, P1474, DOI 10.1152/jappl.2000.88.4.1474; Serebrovska ZO, 2020, ACTA PHARMACOL SIN, V41, P1539, DOI 10.1038/s41401-020-00554-8; Serebrovskaya TV, 2002, HIGH ALT MED BIOL, V3, P205, DOI 10.1089/15270290260131939; Sharif K, 2018, AUTOIMMUN REV, V17, P53, DOI 10.1016/j.autrev.2017.11.010; Shenoy S, 2020, INFLAMM RES, V69, P1077, DOI 10.1007/s00011-020-01389-z; Shi HZ, 1998, AM J RESP CRIT CARE, V157, P1818, DOI 10.1164/ajrccm.157.6.9710023; Shi HZ, 1999, CLIN IMMUNOL, V91, P163, DOI 10.1006/clim.1999.4699; Shi M, 2015, J INFLAMM-LOND, V12, DOI 10.1186/s12950-015-0068-1; Shimizu K, 2008, EXERC IMMUNOL REV, V14, P24; Simiantonaki N, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-320; Simon HU, 1999, NEW ENGL J MED, V341, P1112, DOI 10.1056/NEJM199910073411503; Singh M, 2013, APPL BIOCHEM BIOTECH, V169, P2405, DOI 10.1007/s12010-013-0141-2; Song PP, 2020, CLIN CHIM ACTA, V509, P280, DOI 10.1016/j.cca.2020.06.017; STOCK C, 1995, EUR J APPL PHYSIOL O, V71, P166, DOI 10.1007/BF00854975; STREET NE, 1990, J IMMUNOL, V144, P1629; Suzuki K, 2002, EXERC IMMUNOL REV, V8, P6; SZULC B, 1988, ARCH IMMUNOL THER EX, V36, P537; Takeda N, 2010, GENE DEV, V24, P491, DOI 10.1101/gad.1881410; Teran LM, 1999, AM J RESP CELL MOL, V20, P777, DOI 10.1165/ajrcmb.20.4.3508; Teunissen MBM, 1998, J INVEST DERMATOL, V111, P645, DOI 10.1046/j.1523-1747.1998.00347.x; Thangarajah H, 2010, CELL CYCLE, V9, P75, DOI 10.4161/cc.9.1.10371; Thevarajan I, 2020, NAT MED, V26, P453, DOI 10.1038/s41591-020-0819-2; Tian MF, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00726-w; de Sousa BVO, 2021, MOL BIOL REP, V48, P4625, DOI 10.1007/s11033-021-06400-2; Velasquez SY, 2016, J BIOL CHEM, V291, P12960, DOI 10.1074/jbc.M116.721753; Vitacca M, 2020, RESPIRATION, V99, P493, DOI 10.1159/000508399; VOLK HD, 1986, IMMUNOL LETT, V13, P209, DOI 10.1016/0165-2478(86)90057-X; Wang R, 2013, CANCER NURS, V36, pE27, DOI 10.1097/NCC.0b013e318268f7d5; WARRINGA RAJ, 1992, AM J RESP CELL MOL, V7, P631, DOI 10.1165/ajrcmb/7.6.631; Watts D, 2021, CELL MOL LIFE SCI, V78, P3577, DOI 10.1007/s00018-020-03750-1; Wittmer VL, 2021, COMPLEMENT THER CLIN, V43, DOI 10.1016/j.ctcp.2021.101364; Xiang LB, 2012, NEUROPSYCHOBIOLOGY, V65, P12, DOI 10.1159/000328160; Yeh SH, 2009, BRIT J SPORT MED, V43, P845, DOI 10.1136/bjsm.2007.043562; Yeo EJ, 2019, EXP MOL MED, V51, DOI 10.1038/s12276-019-0233-3; Yu Q, 2018, CANCER LETT, V418, P20, DOI 10.1016/j.canlet.2017.12.035; Zarneshan Azam, 2019, Tanaffos, V18, P230; Zhang RF, 2009, AM J PHYSIOL-LUNG C, V297, pL631, DOI 10.1152/ajplung.90415.2008; Zhao HM, 2020, CHINESE MED J-PEKING, V133, P1595, DOI 10.1097/CM9.0000000000000848; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3; Zhu Yuetong, 2020, J Phys Ther Sci, V32, P545, DOI 10.1589/jpts.32.545	151	0	0	2	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 22	2021	12								761382	10.3389/fimmu.2021.761382	http://dx.doi.org/10.3389/fimmu.2021.761382			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YH2NN	35003073	gold, Green Published			2022-12-18	WOS:000743008900001
J	Wang, QL; Zeng, HK; Zhu, Y; Wang, MH; Zhang, YF; Yang, XJ; Tang, HP; Li, HL; Chen, Y; Ma, CY; Lan, CH; Liu, B; Yang, W; Yu, XQ; Zhang, ZH				Wang, Qilong; Zeng, Huikun; Zhu, Yan; Wang, Minhui; Zhang, Yanfang; Yang, Xiujia; Tang, Haipei; Li, Hongliang; Chen, Yuan; Ma, Cuiyu; Lan, Chunhong; Liu, Bin; Yang, Wei; Yu, Xueqing; Zhang, Zhenhai			Dual UMIs and Dual Barcodes With Minimal PCR Amplification Removes Artifacts and Acquires Accurate Antibody Repertoire	FRONTIERS IN IMMUNOLOGY			English	Article						antibody repertoire; rep-seq; chimera; sequencing error; unique molecular identifier (UMI)	RIBOSOMAL-RNA GENES; CHIMERIC MOLECULES; CELL; FREQUENCY; COAMPLIFICATION; IMMUNOGENETICS; RECOMBINATION; CONSEQUENCE; SIGNATURES; SEQUENCES	Antibody repertoire sequencing (Rep-seq) has been widely used to reveal repertoire dynamics and to interrogate antibodies of interest at single nucleotide-level resolution. However, polymerase chain reaction (PCR) amplification introduces extensive artifacts including chimeras and nucleotide errors, leading to false discovery of antibodies and incorrect assessment of somatic hypermutations (SHMs) which subsequently mislead downstream investigations. Here, a novel approach named DUMPArts, which improves the accuracy of antibody repertoires by labeling each sample with dual barcodes and each molecule with dual unique molecular identifiers (UMIs) via minimal PCR amplification to remove artifacts, is developed. Tested by ultra-deep Rep-seq data, DUMPArts removed inter-sample chimeras, which cause artifactual shared clones and constitute approximately 15% of reads in the library, as well as intra-sample chimeras with erroneous SHMs and constituting approximately 20% of the reads, and corrected base errors and amplification biases by consensus building. The removal of these artifacts will provide an accurate assessment of antibody repertoires and benefit related studies, especially mAb discovery and antibody-guided vaccine design.	[Wang, Qilong; Zeng, Huikun; Zhu, Yan; Tang, Haipei; Chen, Yuan; Lan, Chunhong; Zhang, Zhenhai] Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Ctr Precis Med, Guangzhou, Peoples R China; [Wang, Qilong; Zeng, Huikun; Zhu, Yan; Tang, Haipei; Chen, Yuan; Lan, Chunhong; Yu, Xueqing; Zhang, Zhenhai] Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Guangdong Hong Kong Joint Lab Immunol & Genet Kid, Guangzhou, Peoples R China; [Wang, Minhui; Zhang, Yanfang; Yang, Xiujia; Lan, Chunhong; Zhang, Zhenhai] Southern Med Univ, Nanfang Hosp, Natl Clin Res Ctr Kidney Dis, Div Nephrol,State Key Lab Organ Failure Res, Guangzhou, Peoples R China; [Zhang, Yanfang; Yang, Xiujia; Ma, Cuiyu; Lan, Chunhong; Zhang, Zhenhai] Southern Med Univ, Sch Basic Med Sci, Dept Bioinformat, Guangzhou, Peoples R China; [Li, Hongliang; Liu, Bin] Beijing Inst Technol, Sch Comp Sci & Technol, Beijing, Peoples R China; [Yang, Wei] Southern Med Univ, Sch Basic Med Sci, Dept Pathol, Guangzhou, Peoples R China; [Yu, Xueqing] Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Div Nephrol, Guangzhou, Peoples R China; [Zhang, Zhenhai] Southern Med Univ, Guangdong Hong Kong Macao Greater Bay Area Ctr Br, Minist Educ, Key Lab Mental Hlth, Guangzhou, Peoples R China	Guangdong Academy of Medical Sciences & Guangdong General Hospital; Guangdong Academy of Medical Sciences & Guangdong General Hospital; Southern Medical University - China; Southern Medical University - China; Beijing Institute of Technology; Southern Medical University - China; Guangdong Academy of Medical Sciences & Guangdong General Hospital; Southern Medical University - China	Zhang, ZH (corresponding author), Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Ctr Precis Med, Guangzhou, Peoples R China.; Yu, XQ; Zhang, ZH (corresponding author), Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Guangdong Hong Kong Joint Lab Immunol & Genet Kid, Guangzhou, Peoples R China.; Zhang, ZH (corresponding author), Southern Med Univ, Nanfang Hosp, Natl Clin Res Ctr Kidney Dis, Div Nephrol,State Key Lab Organ Failure Res, Guangzhou, Peoples R China.; Zhang, ZH (corresponding author), Southern Med Univ, Sch Basic Med Sci, Dept Bioinformat, Guangzhou, Peoples R China.; Yang, W (corresponding author), Southern Med Univ, Sch Basic Med Sci, Dept Pathol, Guangzhou, Peoples R China.; Yu, XQ (corresponding author), Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Div Nephrol, Guangzhou, Peoples R China.; Zhang, ZH (corresponding author), Southern Med Univ, Guangdong Hong Kong Macao Greater Bay Area Ctr Br, Minist Educ, Key Lab Mental Hlth, Guangzhou, Peoples R China.	yanglab@smu.edu.cn; yuxueqing@gdph.org.cn; zhangzhenhai@gdph.org.cn	Zhang, Zhenhai/GRX-5887-2022	Zhang, Zhenhai/0000-0002-4310-0525				Bashford-Rogers RJM, 2019, NATURE, V574, P122, DOI 10.1038/s41586-019-1595-3; Benichou J, 2012, IMMUNOLOGY, V135, P183, DOI 10.1111/j.1365-2567.2011.03527.x; Bertioli DJ, 2016, NAT GENET, V48, P438, DOI 10.1038/ng.3517; Cabatingan MS, 2002, J IMMUNOL, V169, P6795, DOI 10.4049/jimmunol.169.12.6795; Cao YL, 2020, CELL, V182, P73, DOI 10.1016/j.cell.2020.05.025; Cronn R, 2002, THEOR APPL GENET, V104, P482, DOI 10.1007/s001220100741; Cyster JG, 2019, CELL, V177, P524, DOI 10.1016/j.cell.2019.03.016; Dupic T, 2021, PLOS GENET, V17, DOI 10.1371/journal.pgen.1009301; Egorov ES, 2015, J IMMUNOL, V194, P6155, DOI 10.4049/jimmunol.1500215; Fonseca VG, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks002; Friedensohn S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01401; Friedensohn S, 2017, TRENDS BIOTECHNOL, V35, P203, DOI 10.1016/j.tibtech.2016.09.010; Galson JD, 2014, TRENDS IMMUNOL, V35, P319, DOI 10.1016/j.it.2014.04.005; Georgiou G, 2014, NAT BIOTECHNOL, V32, P158, DOI 10.1038/nbt.2782; Haas BJ, 2011, GENOME RES, V21, P494, DOI 10.1101/gr.112730.110; Harris CR, 2020, NATURE, V585, P357, DOI 10.1038/s41586-020-2649-2; Hunter JD, 2007, COMPUT SCI ENG, V9, P90, DOI 10.1109/MCSE.2007.55; Imkeller K, 2018, IMMUNOL REV, V284, P51, DOI 10.1111/imr.12670; Johansson G, 2020, CLIN CHEM, V66, P1228, DOI 10.1093/clinchem/hvaa159; Khan TA, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1501371; Kircher M, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gkr771; Kivioja T, 2012, NAT METHODS, V9, P72, DOI [10.1038/NMETH.1778, 10.1038/nmeth.1778]; KOCKS C, 1988, P NATL ACAD SCI USA, V85, P8206, DOI 10.1073/pnas.85.21.8206; Krawczyk K, 2019, MABS-AUSTIN, V11, P1197, DOI 10.1080/19420862.2019.1633884; Kreer C, 2020, CELL, V182, P843, DOI 10.1016/j.cell.2020.06.044; Langerak AW, 2017, J IMMUNOL, V198, P3765, DOI 10.4049/jimmunol.1602050; Lefranc MP, 2015, NUCLEIC ACIDS RES, V43, pD413, DOI 10.1093/nar/gku1056; Lu N, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20081953; Ma KY, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00033; MacConaill LE, 2018, BMC GENOMICS, V19, DOI 10.1186/s12864-017-4428-5; Omelina ES, 2019, BMC GENOMICS, V20, DOI 10.1186/s12864-019-5847-2; Parameswaran P, 2013, CELL HOST MICROBE, V13, P691, DOI 10.1016/j.chom.2013.05.008; Perez-Andres M, 2010, CYTOM PART B-CLIN CY, V78B, pS47, DOI 10.1002/cyto.b.20547; Potapov V, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169774; Quigley MF, 2010, P NATL ACAD SCI USA, V107, P19414, DOI 10.1073/pnas.1010586107; Robinson WH, 2015, NAT REV RHEUMATOL, V11, P171, DOI 10.1038/nrrheum.2014.220; Rubelt F, 2017, NAT IMMUNOL, V18, P1274, DOI 10.1038/ni.3873; Schirmer M, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gku1341; Schultheiss C, 2020, IMMUNITY, V53, P442, DOI 10.1016/j.immuni.2020.06.024; Setliff I, 2019, CELL, V179, P1636, DOI 10.1016/j.cell.2019.11.003; Shao W, 2013, RETROVIROLOGY, V10, DOI 10.1186/1742-4690-10-18; Shugay M, 2014, NAT METHODS, V11, P653, DOI [10.1038/nmeth.2960, 10.1038/NMETH.2960]; Sinkora M, 2000, MOL IMMUNOL, V37, P1025, DOI 10.1016/S0161-5890(01)00022-0; Soto C, 2019, NATURE, V566, P398, DOI 10.1038/s41586-019-0934-8; Tanno H, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aay9093; Turchaninova MA, 2016, NAT PROTOC, V11, P1599, DOI 10.1038/nprot.2016.093; van der Valk T, 2020, MOL ECOL RESOUR, V20, P1171, DOI 10.1111/1755-0998.13009; Vander Heiden JA, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02206; Virtanen P, 2020, NAT METHODS, V17, P261, DOI 10.1038/s41592-019-0686-2; Vollmers C, 2013, P NATL ACAD SCI USA, V110, P13463, DOI 10.1073/pnas.1312146110; Wang GCY, 1996, MICROBIOL-SGM, V142, P1107, DOI 10.1099/13500872-142-5-1107; Wang GCY, 1997, APPL ENVIRON MICROB, V63, P4645, DOI 10.1128/AEM.63.12.4645-4650.1997; Wendel BS, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00645-x; Yang XJ, 2021, CELL REP, V35, DOI 10.1016/j.celrep.2021.109110; Ye J, 2013, NUCLEIC ACIDS RES, V41, pW34, DOI 10.1093/nar/gkt382; Zhang JJ, 2014, BIOINFORMATICS, V30, P614, DOI 10.1093/bioinformatics/btt593; Zhao L, 2018, BMC GENOMICS, V19, DOI 10.1186/s12864-018-5272-y; Zhou JL, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.02686	58	0	0	3	15	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 22	2021	12								778298	10.3389/fimmu.2021.778298	http://dx.doi.org/10.3389/fimmu.2021.778298			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YI3DQ	35003093	gold, Green Published			2022-12-18	WOS:000743732800001
J	Wu, YJ; Wu, Y; Yang, Y; Chen, BC; Li, JQ; Guo, GP; Xiong, F				Wu, Yuanjun; Wu, Yong; Yang, Yong; Chen, Baochan; Li, Jianqun; Guo, Ganping; Xiong, Fu			Case Report: First Case of Cefotaxime-Sulbactam-Induced Acute Intravascular Hemolysis in a Newborn With ABO Blood Type Incompatibility by the Mechanism of Non-Immunologic Protein Adsorption	FRONTIERS IN IMMUNOLOGY			English	Article						hemolytic disease of newborn (HDN); cefotaxime; sulbactam; drug-induced immune hemolytic anemia (DIIHA); non-immunologic protein adsorption (NIPA); acute intravascular hemolysis	DIRECT ANTIGLOBULIN TESTS; BETA-LACTAMASE INHIBITOR; ANEMIA FOLLOWING THERAPY; POSITIVE DIRECT; DISEASE; FETUS; ANTIBODIES; MANAGEMENT; THROMBOCYTOPENIA; TAZOBACTAM	BackgroundABO blood type incompatibility hemolytic disease of newborn (ABO-HDN) and drug-induced immune hemolytic anemia (DIIHA) due to non-immunologic protein adsorption (NIPA) mainly cause extravascular hemolysis. All the reported severe DIIHA were caused by drug-induced antibodies, and rare report of acute intravascular hemolysis was caused by the NIPA mechanism or ABO-HDN. Case presentationWe report the first case of acute intravascular hemolysis induced by cefotaxime sodium - sulbactam sodium (CTX - SBT) in a case of ABO-HDN which resulted in death at 55 h after birth. The mother's blood type was O and RhD-positive, and the newborn's blood type was B and RhD-positive. No irregular red blood cell (RBC) antibodies or drug-dependent antibodies related to CTX or SBT was detected in the mother's plasma and the plasma or the RBC acid eluent of the newborn. Before the newborn received CTX - SBT treatment, the result of direct antiglobulin test (DAT) was negative while anti-B was positive (2 +) in both plasma and acid eluent. After the newborn received CTX - SBT treatment, the results of DAT for anti-IgG and anti-C3d were both positive, while anti-B was not detected in plasma, but stronger anti-B (3 +) was detected in acid eluent. In vitro experiments confirmed that NIPA of SBT promoted the specific binding of maternal-derived IgG anti-B to B antigen on RBCs of the newborn, thereby inducing acute intravascular hemolysis. ConclusionThe NIPA effect of SBT promoted the specific binding of mother-derived IgG anti-B in newborn's plasma to the newborn's RBC B antigens and formed an immune complex, and then activated complement, which led to acute intravascular hemolysis. Drugs such as SBT with NIPA effect should not be used for newborns with HDN.	[Wu, Yuanjun; Li, Jianqun; Guo, Ganping] Dongguan Maternal & Child Hlth Hosp, Dept Blood Transfus, Dongguan, Peoples R China; [Wu, Yong; Chen, Baochan] Dongguan Tungwah Hosp, Dept Blood Transfus, Dongguan, Peoples R China; [Yang, Yong] Dongguan Maternal & Child Hlth Hosp, Dept Neonatol, Dongguan, Peoples R China; [Xiong, Fu] Southern Med Univ, Sch Basic Med Sci, Dept Med Genet, Guangzhou, Peoples R China; [Xiong, Fu] Key Lab Single Cell Technol & Applicat Guangdong, Guangzhou, Peoples R China	Southern Medical University - China	Wu, YJ (corresponding author), Dongguan Maternal & Child Hlth Hosp, Dept Blood Transfus, Dongguan, Peoples R China.; Xiong, F (corresponding author), Southern Med Univ, Sch Basic Med Sci, Dept Med Genet, Guangzhou, Peoples R China.; Xiong, F (corresponding author), Key Lab Single Cell Technol & Applicat Guangdong, Guangzhou, Peoples R China.	wuyuanjun199@126.com; xiongfu@smu.edu.cn		Wu, Yuanjun/0000-0002-9459-9688				Afra F, 2021, DARU, V29, P211, DOI 10.1007/s40199-020-00386-1; Arndt PA, 2003, VOX SANG, V85, P53, DOI 10.1046/j.1423-0410.2003.00323.x; Arndt P, 2009, TRANSFUSION, V49, P711, DOI 10.1111/j.1537-2995.2008.02028.x; Arndt Patricia A, 2014, Immunohematology, V30, P44; Arnold DM, 2013, J THROMB HAEMOST, V11, P169, DOI 10.1111/jth.12052; Behmard E, 2019, J BIOMOL STRUCT DYN, V37, P741, DOI 10.1080/07391102.2018.1439404; Bhat YR, 2012, PAEDIATR INT CHILD H, V32, P93, DOI 10.1179/2046905512Y.0000000002; Bougie DW, 2006, BLOOD, V108, P922, DOI 10.1182/blood-2006-01-009803; Broadberry RE, 2004, TRANSFUSION MED, V14, P53, DOI 10.1111/j.0958-7578.2004.00481.x; Pratx LB, 2019, TRANSFUSION, V59, P1657, DOI 10.1111/trf.15226; Chan M, 2020, BLOOD ADV, V4, P1756, DOI 10.1182/bloodadvances.2020001726; Christensen RD, 2018, J PERINATOL, V38, P517, DOI 10.1038/s41372-018-0048-4; Curtis Brian R, 2014, Immunohematology, V30, P55; D'Angelo G, 2018, ITAL J PEDIATR, V44, DOI 10.1186/s13052-018-0528-3; de Haas M, 2015, VOX SANG, V109, P99, DOI 10.1111/vox.12265; DELIMA LMA, 1982, TRANSFUSION, V22, P246; Drabik-Clary K, 2006, ANN CLIN LAB SCI, V36, P205; Franklin IM, 2009, LANCET, V373, P1082, DOI 10.1016/S0140-6736(09)60651-6; Garratty G, 2007, Immunohematology, V23, P105; Garratty G, 1998, BRIT J HAEMATOL, V100, P777, DOI 10.1046/j.1365-2141.1998.00615.x; Garratty George, 2014, Immunohematology, V30, P66; Garratty G, 2010, BLOOD REV, V24, P143, DOI 10.1016/j.blre.2010.06.004; Jain A, 2018, ASIAN J TRANSF SCI, V12, P176, DOI 10.4103/ajts.AJTS_106_17; Kam Teresa, 2014, J Pharm Pract, V27, P430, DOI 10.1177/0897190014546099; Kaur K, 2014, J CLIN DIAGN RES, V8, DOI [10.7860/JCDR/2014/9742.5090, 10.7860/lcdr/2014/9742.5090]; KUSNIERZALEJSKA G, 1992, VOX SANG, V62, P124; Leger Regina M, 2014, Immunohematology, V30, P85; Li S, 2021, TRANSFUSION, V61, P1908, DOI 10.1111/trf.16350; Li S, 2021, BLOOD TRANSFUS-ITALY, V19, P135, DOI 10.2450/2020.0058-20; Li S, 2020, BMC PREGNANCY CHILDB, V20, DOI 10.1186/s12884-020-03235-w; Li S, 2019, TRANSFUSION, V59, P385, DOI 10.1111/trf.15054; Lin KS, 2020, AIDS, V34, P326, DOI 10.1097/QAD.0000000000002425; LIN M, 1995, VOX SANG, V68, P136, DOI 10.1111/j.1423-0410.1995.tb02569.x; Linnik YA, 2017, TRANSFUSION, V57, P2937, DOI 10.1111/trf.14315; Markham KB, 2015, AM J OBSTET GYNECOL, V213, DOI 10.1016/j.ajog.2015.01.049; MOLLNES TE, 1988, CLIN EXP IMMUNOL, V73, P484; Moosavi M, 2020, TRANSFUS MED REV, V34, P124, DOI 10.1016/j.tmrv.2020.02.002; Nguyen TN, 2021, TRANSFUSION, V61, P1609, DOI 10.1111/trf.16360; Ochoa PS, 2013, PHARMACOTHERAPY, V33, pE162, DOI 10.1002/phar.1279; Pareek A, 2008, EXPERT OPIN PHARMACO, V9, P2751, DOI [10.1517/14656566.9.16.2751, 10.1517/14656566.9.16.2751 ]; Quintanilla-Bordas C, 2019, TRANSFUSION, V59, P1648, DOI 10.1111/trf.15151; SALAMA A, 1987, TRANSFUSION, V27, P460, DOI 10.1046/j.1537-2995.1987.27688071694.x; SHULMAN IA, 1990, TRANSFUSION, V30, P263, DOI 10.1046/j.1537-2995.1990.30390194351.x; Slootweg YM, 2018, AM J OBSTET GYNECOL, V219, DOI 10.1016/j.ajog.2018.07.020; TOY PTCY, 1988, VOX SANG, V54, P181, DOI 10.1111/j.1423-0410.1988.tb03897.x; Ueda H, 2015, TRANSFUSION MED, V25, P42, DOI 10.1111/tme.12178; Vaughan JI, 1998, NEW ENGL J MED, V338, P798, DOI 10.1056/NEJM199803193381204; Wu YJ, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.723167; Wu YJ, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.697192; Ziprin JH, 2005, TRANSFUSION MED, V15, P57, DOI 10.1111/j.1365-3148.2005.00549.x	50	0	0	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 22	2021	12								698541	10.3389/fimmu.2021.698541	http://dx.doi.org/10.3389/fimmu.2021.698541			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YI2PI	35003054	gold, Green Published			2022-12-18	WOS:000743695600001
J	Bartens, MC; Gibson, AJ; Etherington, GJ; Di Palma, F; Holder, A; Werling, D; Willcocks, S				Bartens, Marie-Christine; Gibson, Amanda J.; Etherington, Graham J.; Di Palma, Federica; Holder, Angela; Werling, Dirk; Willcocks, Sam			Single Nucleotide Polymorphisms in the Bovine TLR2 Extracellular Domain Contribute to 2 Breed and Species-Specific Innate Immune Functionality	FRONTIERS IN IMMUNOLOGY			English	Article						Toll-like Receptor 2 (TLR2); Mycobacteria; Pattern Recognition; Macrophage; Innate Immunity	MYCOBACTERIUM-TUBERCULOSIS; PATHOGEN RECOGNITION; BOS-TAURUS; GENE; RESPONSES; CATTLE; SUSCEPTIBILITY; EXPRESSION; AUTOPHAGY; CELLS	Recent evidence suggests that several cattle breeds may be more resistant to infection with the zoonotic pathogen Mycobacterium bovis than others. Our data presented here suggests that the response to mycobacterial antigens varies in macrophages generated from Brown Swiss (BS) and Holstein Frisian (HF) cattle, two breeds belonging to the Bos taurus family. Whole genome sequencing of the Brown Swiss genome identified several potential candidate genes, in particular Toll-like Receptor-2 (TLR2) a pattern recognition receptor (PRR) that has previously been described to be involved in mycobacterial recognition. Further investigation revealed single nucleotide polymorphisms (SNP) in TLR2 that were identified between DNA isolated from cells of BS and HF cows. Interestingly, one specific SNP, H326Q, showed a different genotype frequency in two cattle subspecies, Bos taurus and Bos indicus. Cloning of the TLR2 gene and subsequent gene-reporter and chemokine assays revealed that this SNP, present in BS and Bos indicus breeds, resulted in a significantly higher response to mycobacterial antigens as well as tri-acylated lipopeptide ligands in general. Comparing wild-type and H326Q containing TLR2 responses, wild-type bovine TLR2 response showed clear, diminished mycobacterial antigen responses compared to human TLR2, however bovine TLR2 responses containing H326Q were found to be partially recovered compared to human TLR2. The creation of human:bovine TLR2 chimeras increased the response to mycobacterial antigens compared to the full-length bovine TLR2, but significantly reduced the response compared to the full-length human TLR2. Thus, our data, not only present evidence that TLR2 is a major PRR in the mammalian species-specific response to mycobacterial antigens, but furthermore, that there are clear differences between the response seen in different cattle breeds, which may contribute to their enhanced or reduced susceptibility to mycobacterial infection.	[Bartens, Marie-Christine; Gibson, Amanda J.; Holder, Angela; Werling, Dirk] Royal Vet Coll, Dept Pathobiol & Populat Sci, Mol Immunol Grp, London, England; [Bartens, Marie-Christine; Willcocks, Sam] London Sch Hyg & Trop Med, Dept Infect Biol, London, England; [Etherington, Graham J.] Earlham Inst, Norwich, Norfolk, England; [Di Palma, Federica] Univ East Anglia, Dept Biol Sci, Norwich, Norfolk, England; [Gibson, Amanda J.] Aberystwyth Univ, Inst Biol & Rural Sci, Aberystwyth, Dyfed, Wales; [Di Palma, Federica] Genome British Columbia, Vancouver, BC, Canada	University of London; University of London Royal Veterinary College; University of London; London School of Hygiene & Tropical Medicine; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Earlham Institute; University of East Anglia; Aberystwyth University	Werling, D (corresponding author), Royal Vet Coll, Dept Pathobiol & Populat Sci, Mol Immunol Grp, London, England.							Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Alfano F, 2014, BMC GENET, V15, DOI 10.1186/s12863-014-0139-y; [Anonymous], 2017, ROADM ZOON TUB; Basu J, 2012, FRONT CELL INFECT MI, V2, DOI 10.3389/fcimb.2012.00145; Ben-Ali M, 2004, CLIN DIAGN LAB IMMUN, V11, P625, DOI 10.1128/CDLI.11.3.625-626.2004; Beutler BA, 2009, BLOOD, V113, P1399, DOI 10.1182/blood-2008-07-019307; Bhaladhare A, 2016, VET WORLD, V9, P458, DOI 10.14202/vetworld.2016.458-464; Bilgen N., 2016, DETERMINATION GENETI, DOI [10.20944/preprints201609.0080.v1, DOI 10.20944/PREPRINTS201609.0080.V1]; Blanc L, 2017, P NATL ACAD SCI USA, V114, P11205, DOI 10.1073/pnas.1707840114; Burger-Kentischer A, 2010, J IMMUNOL METHODS, V358, P93, DOI 10.1016/j.jim.2010.03.020; Chatterjee S, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002378; Drage MG, 2009, CELL IMMUNOL, V258, P29, DOI 10.1016/j.cellimm.2009.03.008; Drennan MB, 2004, AM J PATHOL, V164, P49, DOI 10.1016/S0002-9440(10)63095-7; Faber E, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-29371-0; Farhat K, 2008, J LEUKOCYTE BIOL, V83, P692, DOI 10.1189/jlb.0807586; Felius Marleen, 2014, Diversity-Basel, V6, P705, DOI 10.3390/d6040705; Fisher CA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027744; Forman Henry Jay, 2001, Molecular Aspects of Medicine, V22, P189; Gehring AJ, 2003, INFECT IMMUN, V71, P4487, DOI 10.1128/IAI.71.8.4487-4497.2003; Godfray C, 2018, STRATEGY CHIEVING BO; Gutierrez MG, 2004, CELL, V119, P753, DOI 10.1016/j.cell.2004.11.038; Hanotte O, 2000, MOL ECOL, V9, P387, DOI 10.1046/j.1365-294x.2000.00858.x; Harding CV, 2010, NAT REV MICROBIOL, V8, P296, DOI 10.1038/nrmicro2321; Jann OC, 2008, BMC EVOL BIOL, V8, DOI 10.1186/1471-2148-8-288; Jimenez-Dalmaroni MJ, 2015, INNATE IMMUN-LONDON, V21, P175, DOI 10.1177/1753425914524077; Jin MS, 2007, CELL, V130, P1071, DOI 10.1016/j.cell.2007.09.008; Jo EK, 2007, CELL MICROBIOL, V9, P1087, DOI 10.1111/j.1462-5822.2007.00914.x; Karimi K, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-66; Kawai T, 2007, SEMIN IMMUNOL, V19, P24, DOI 10.1016/j.smim.2006.12.004; Killick KE, 2013, CELL MICROBIOL, V15, P1484, DOI 10.1111/cmi.12161; Kinsella RJ, 2011, DATABASE-OXFORD, DOI 10.1093/database/bar030; Kleinnijenhuis J, 2011, CLIN DEV IMMUNOL, DOI 10.1155/2011/405310; Koets A, 2010, PREV VET MED, V93, P305, DOI 10.1016/j.prevetmed.2009.11.008; KUNSCH C, 1993, MOL CELL BIOL, V13, P6137, DOI 10.1128/MCB.13.10.6137; Lawrence T, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a001651; Mapleson D, 2017, BIOINFORMATICS, V33, P574, DOI 10.1093/bioinformatics/btw663; Massari S, 1998, CHROMOSOME RES, V6, P419, DOI 10.1023/A:1009245830804; Mishra BB, 2013, NAT IMMUNOL, V14, P52, DOI 10.1038/ni.2474; Morris CA, 2007, VET J, V174, P481, DOI 10.1016/j.tvjl.2006.09.006; Mortaz E, 2015, J CLIN IMMUNOL, V35, P1, DOI 10.1007/s10875-014-0103-7; MUKAIDA N, 1994, J LEUKOCYTE BIOL, V56, P554, DOI 10.1002/jlb.56.5.554; Nair S, 2009, J IMMUNOL, V183, P6269, DOI 10.4049/jimmunol.0901367; Nie L, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01523; O'Neill LAJ, 2007, NAT REV IMMUNOL, V7, P353, DOI 10.1038/nri2079; Ogus AC, 2004, EUR RESPIR J, V23, P219, DOI 10.1183/09031936.03.00061703; Oliveira-Nascimento L, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00079; Opsal MA, 2008, J ANIM BREED GENET, V125, P110, DOI 10.1111/j.1439-0388.2007.00704.x; Pahari S, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00906; Parveen N, 2013, J BIOL CHEM, V288, P24956, DOI 10.1074/jbc.M113.461004; Pathak SK, 2007, NAT IMMUNOL, V8, P610, DOI 10.1038/ni1468; Pattabiraman G, 2017, J BIOL CHEM, V292, P10685, DOI 10.1074/jbc.M117.784470; Ponath V, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170347; Reiling N, 2002, J IMMUNOL, V169, P3480, DOI 10.4049/jimmunol.169.7.3480; Research L., ZEB CATTL KEN US PER; Rocha-Ramirez LM, 2008, TUBERCULOSIS, V88, P212, DOI 10.1016/j.tube.2007.10.003; Rogers AN, 2005, J IMMUNOL, V174, P3386, DOI 10.4049/jimmunol.174.6.3386; Seppey M, 2019, METHODS MOL BIOL, V1962, P227, DOI 10.1007/978-1-4939-9173-0_14; Shin DM, 2010, CELL MICROBIOL, V12, P1648, DOI 10.1111/j.1462-5822.2010.01497.x; Shumate A, 2021, BIOINFORMATICS, V37, P1639, DOI 10.1093/bioinformatics/btaa1016; Singh SB, 2006, SCIENCE, V313, P1438, DOI 10.1126/science.1129577; Skjot RLV, 2002, INFECT IMMUN, V70, P5446, DOI 10.1128/IAI.70.10.5446-5453.2002; Smit AFA., REPEATMODELER OPEN 1; Song YP, 2014, ACTA HISTOCHEM, V116, P1159, DOI 10.1016/j.acthis.2014.06.004; Stamm CE, 2015, IMMUNOL REV, V264, P204, DOI 10.1111/imr.12263; Tahoun A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17935-5; Takeuchi O, 2001, INT IMMUNOL, V13, P933, DOI 10.1093/intimm/13.7.933; Tombacz K, 2017, INNATE IMMUN-LONDON, V23, P329, DOI 10.1177/1753425917695445; Torrado E, 2013, ADV EXP MED BIOL, V783, P121, DOI 10.1007/978-1-4614-6111-1_7; Vaccarelli G, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-81; Villarreal-Ramos B, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18575-5; Vordermeier M, 2012, COMP IMMUNOL MICROB, V35, P227, DOI 10.1016/j.cimid.2012.01.003; Wang Y, 2011, FEMS MICROBIOL LETT, V321, P30, DOI 10.1111/j.1574-6968.2011.02304.x; Weisenfeld NI, 2017, GENOME RES, V27, P757, DOI 10.1101/gr.214874.116; Welsh MD, 2002, INFECT IMMUN, V70, P6114, DOI 10.1128/IAI.70.11.6114-6120.2002; Werling D, 2003, VET IMMUNOL IMMUNOP, V91, P1, DOI 10.1016/S0165-2427(02)00228-3; Werling D, 2006, VET IMMUNOL IMMUNOP, V112, P2, DOI 10.1016/j.vetimm.2006.03.007; Werling D, 2009, TRENDS IMMUNOL, V30, P124, DOI 10.1016/j.it.2008.12.001; Willcocks S, 2006, VET IMMUNOL IMMUNOP, V113, P234, DOI 10.1016/j.vetimm.2006.04.007; Willcocks S, 2013, J LEUKOCYTE BIOL, V94, P449, DOI 10.1189/jlb.0812390; Wu BJ, 2011, J GENET, V90, P401; Yoshida A, 2009, ANTICANCER RES, V29, P907; Zhang LP, 2009, ANIM BIOTECHNOL, V20, P87, DOI 10.1080/10495390902873096; Zhou RB, 2011, NATURE, V469, P221, DOI 10.1038/nature09663	83	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 21	2021	12									10.1101/2021.08.23.457326	http://dx.doi.org/10.1101/2021.08.23.457326			26	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6I1MH		Green Accepted, Green Submitted			2022-12-18	WOS:000885892500001
J	Gazzinelli-Guimaraes, AC; Nogueira, DS; Amorim, CCO; Oliveira, FMS; Coqueiro-Dos-Santos, A; Carvalho, SAP; Kraemer, L; Barbosa, FS; Fraga, VG; Santos, FV; de Castro, JC; Russo, RC; Akamatsu, MA; Ho, PL; Bottazzi, ME; Hotez, PJ; Zhan, B; Bartholomeu, DC; Bueno, LL; Fujiwara, RT				Gazzinelli-Guimaraes, Ana Clara; Nogueira, Denise Silva; Amorim, Chiara Cassia Oliveira; Oliveira, Fabricio Marcus Silva; Coqueiro-Dos-Santos, Anderson; Carvalho, Samuel Alexandre Pimenta; Kraemer, Lucas; Barbosa, Fernando Sergio; Fraga, Vanessa Gomes; Santos, Flaviane Vieira; de Castro, Joseane Camilla; Russo, Remo Castro; Akamatsu, Milena Apetito; Ho, Paulo Lee; Bottazzi, Maria Elena; Hotez, Peter J.; Zhan, Bin; Bartholomeu, Daniella Castanheira; Bueno, Lilian Lacerda; Fujiwara, Ricardo Toshio			ASCVac-1, a Multi-Peptide Chimeric Vaccine, Protects Mice Against Ascaris suum Infection	FRONTIERS IN IMMUNOLOGY			English	Article						epitopes; vaccine; chimera; vaccinology; ascariasis	LARVAL STRONGYLOIDES-STERCORALIS; IMMUNITY; ANTIGEN; INNATE; MECHANISMS; RESPONSES; CELLS; PIGS	Control of human ascariasis, the most prevalent neglected tropical disease globally affecting 450 million people, mostly relies on mass drug administration of anthelmintics. However, chemotherapy alone is not efficient due to the high re-infection rate for people who live in the endemic area. The development of a vaccine that reduces the intensity of infection and maintains lower morbidity should be the primary target for infection control. Previously, our group demonstrated that immunization with crude Ascaris antigens in mice induced an IgG-mediated protective response with significant worm reduction. Here, we aimed to develop a multipeptide chimera vaccine based on conserved B-cell epitopes predicted from 17 common helminth proteomes using a bioinformatics algorithm. More than 480 B-cell epitopes were identified that are conserved in all 17 helminths. The Ascaris-specific epitopes were selected based on their reactivity to the pooled sera of mice immunized with Ascaris crude antigens or infected three times with A. suum infective eggs. The top 35 peptides with the strongest reactivity to Ascaris immune serum were selected to construct a chimeric antigen connected in sequence based on conformation. This chimera, called ASCVac-1, was produced as a soluble recombinant protein in an Escherichia coli expression system and, formulated with MPLA, was used to immunize mice. Mice immunized with ASCVac-1/MPLA showed around 50% reduced larvae production in the lungs after being challenged with A. suum infective eggs, along with significantly reduced inflammation and lung tissue/function damage. The reduced parasite count and pathology in infected lungs were associated with strong Th2 immune responses characterized by the high titers of antigen-specific IgG and its subclasses (IgG1, IgG2a, and IgG3) in the sera and significantly increased IL-4, IL-5, IL-13 levels in lung tissues. The reduced IL-33 titers and stimulated eosinophils were also observed in lung tissues and may also contribute to the ASCVac-1-induced protection. Taken together, the preclinical trial with ASCVac-1 chimera in a mouse model demonstrated its significant vaccine efficacy associated with strong IgG-based Th2 responses, without IgE induction, thus reducing the risk of an allergic response. All results suggest that the multiepitope-based ASCVac-1 chimera is a promising vaccine candidate against Ascaris sp. infections.	[Gazzinelli-Guimaraes, Ana Clara; Nogueira, Denise Silva; Amorim, Chiara Cassia Oliveira; Oliveira, Fabricio Marcus Silva; Coqueiro-Dos-Santos, Anderson; Carvalho, Samuel Alexandre Pimenta; Kraemer, Lucas; Barbosa, Fernando Sergio; Fraga, Vanessa Gomes; Santos, Flaviane Vieira; de Castro, Joseane Camilla; Russo, Remo Castro; Bartholomeu, Daniella Castanheira; Bueno, Lilian Lacerda; Fujiwara, Ricardo Toshio] Univ Fed Minas Gerais, Biol Sci Inst, Belo Horizonte, MG, Brazil; [Akamatsu, Milena Apetito; Ho, Paulo Lee] Sao Paulo Secretary Hlth, Butantan Inst, BioInd Div, Sao Paulo, Brazil; [Bottazzi, Maria Elena; Hotez, Peter J.; Zhan, Bin] Texas Childrens Hosp, Baylor Coll Med, Ctr Vaccine Dev, Dept Pediat Trop Med,Natl Sch Trop Med, Houston, TX 77030 USA	Universidade Federal de Minas Gerais; Instituto Butantan; Baylor College of Medicine	Fujiwara, RT (corresponding author), Univ Fed Minas Gerais, Biol Sci Inst, Belo Horizonte, MG, Brazil.	fujiwara@icb.ufmg.br	Russo, Remo Castro/O-8980-2019; Akamatsu, Milena Apetito/V-8084-2017; Barbosa, Fernando/DXW-3185-2022; Bartholomeu, Daniella/J-4714-2015	Russo, Remo Castro/0000-0002-1715-3834; Akamatsu, Milena Apetito/0000-0002-8193-3448; Bueno, Lilian/0000-0003-3510-4590; Bartholomeu, Daniella/0000-0003-0974-7357; Coqueiro-dos-Santos, Anderson/0000-0002-7079-3224; Pimenta Carvalho, Samuel Alexandre/0000-0003-4465-9002				Allen JE, 2011, NAT REV IMMUNOL, V11, P375, DOI 10.1038/nri2992; AMIRI P, 1994, J EXP MED, V180, P43, DOI 10.1084/jem.180.1.43; Bethony J, 2006, LANCET, V367, P1521, DOI 10.1016/S0140-6736(06)68653-4; Chen N, 2012, VACCINE, V30, P3478, DOI 10.1016/j.vaccine.2012.02.075; CRANDALL CA, 1971, EXP PARASITOL, V30, P426, DOI 10.1016/0014-4894(71)90107-X; Culley FJ, 2002, EUR J IMMUNOL, V32, P1376, DOI 10.1002/1521-4141(200205)32:5<1376::AID-IMMU1376>3.0.CO;2-8; de Castro JC, 2021, VACCINE, V39, P394, DOI 10.1016/j.vaccine.2020.11.046; Disease GB of, 2020, ASCARIASIS LEVEL 4 C; Easton A, 2020, ELIFE, V9, DOI 10.7554/eLife.61562; Galioto AM, 2006, INFECT IMMUN, V74, P5730, DOI 10.1128/IAI.01958-05; Gazzinelli-Guimaraes AC, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02535; Gazzinelli-Guimaraes PH, 2019, J CLIN INVEST, V129, P3686, DOI 10.1172/JCI127963; Gazzinelli-Guimaraes PH, 2013, INT J PARASITOL, V43, P697, DOI 10.1016/j.ijpara.2013.02.009; Herbert DR, 2000, J IMMUNOL, V165, P4544, DOI 10.4049/jimmunol.165.8.4544; Islam MK, 2005, INT J PARASITOL, V35, P1023, DOI 10.1016/j.ijpara.2005.03.019; Islam MK, 2005, INFECT IMMUN, V73, P1995, DOI 10.1128/IAI.73.4.1995-2004.2005; Jia TW, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001621; KHOURY PB, 1977, IMMUNOLOGY, V32, P405; Kringel H, 2015, VET PARASITOL, V211, P306, DOI 10.1016/j.vetpar.2015.06.008; Masure D, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002588; Masure D, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002138; Mccoy KD, 2008, CELL HOST MICROBE, V4, P362, DOI 10.1016/j.chom.2008.08.014; Metrics GH., 2020, ASCARIASIS LEVEL 4 C, P3; Nogueira DS, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004382; Rotman HL, 1996, EXP PARASITOL, V82, P267, DOI 10.1006/expr.1996.0034; SAROBE P, 1993, RES IMMUNOL, V144, P257, DOI 10.1016/0923-2494(93)80102-5; Tsuji N, 2003, INFECT IMMUN, V71, P5314, DOI 10.1128/IAI.71.9.5314-5323.2003; Tsuji N, 2002, INT J PARASITOL, V32, P1739, DOI 10.1016/S0020-7519(02)00179-0; Tsuji N, 2001, INFECT IMMUN, V69, P7285, DOI 10.1128/IAI.69.12.7285-7292.2001; URBAN JF, 1988, EXP PARASITOL, V66, P66, DOI 10.1016/0014-4894(88)90051-3; Versteeg L, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0008057; Vieira-Santos F, 2021, MALARIA J, V20, DOI 10.1186/s12936-021-03824-w; Wei JF, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005769; WHO, 2013, SUSTAINING THE DRIVE TO OVERCOME THE GLOBAL IMPACT OF NEGLECTED TROPICAL DISEASES: SECOND WHO REPORT ON NEGLECTED TROPICAL DISEASES, P1; WHO, 2019, GUIDELINE PREVENTIVE; Zhan B, 2014, EXPERT REV VACCINES, V13, P321, DOI 10.1586/14760584.2014.872035	36	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 21	2021	12								788185	10.3389/fimmu.2021.788185	http://dx.doi.org/10.3389/fimmu.2021.788185			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YB5AB	34992603	Green Published, gold			2022-12-18	WOS:000739024000001
J	Oliveira, KC; Brancaglion, GA; Santos, NCM; Araujo, LP; Novaes, E; Santos, RD; Oliveira, SC; Corsetti, PP; de Almeida, LA				Oliveira, Karen Cristina; Brancaglion, Gustavo Andrade; Santos, Natalia C. M.; Araujo, Leonardo P.; Novaes, Evandro; Santos, Renato de Lima; Oliveira, Sergio Costa; Corsetti, Patricia Paiva; de Almeida, Leonardo Augusto			Epitope-Based Vaccine of a Brucella abortus Putative Small RNA Target Induces Protection and Less Tissue Damage in Mice	FRONTIERS IN IMMUNOLOGY			English	Article						Brucella abortus; vaccine; immune response; reverse vaccinology; brucellosis; apolipoprotein N-acyltransferase	CD4(+) TH1 CELLS; BALB/C MICE; CONFERS PROTECTION; IMMUNE-RESPONSE; T-CELL; PROTEIN; MELITENSIS; INFECTION; IMMUNIZATION; IDENTIFICATION	Brucella spp. are Gram-negative, facultative intracellular bacteria that cause brucellosis in humans and animals. Currently available live attenuated vaccines against brucellosis still have drawbacks. Therefore, subunit vaccines, produced using epitope-based antigens, have the advantage of being safe, cost-effective and efficacious. Here, we identified B. abortus small RNAs expressed during early infection with bone marrow-derived macrophages (BMDMs) and an apolipoprotein N-acyltransferase (Int) was identified as the putative target of the greatest expressed small RNA. Decreased expression of Int was observed during BMDM infection and the protein sequence was evaluated to rationally select a putative immunogenic epitope by immunoinformatic, which was explored as a vaccinal candidate. C57BL/6 mice were immunized and challenged with B. abortus, showing lower recovery in the number of viable bacteria in the liver, spleen, and axillary lymph node and greater production of IgG and fractions when compared to non-vaccinated mice. The vaccinated and infected mice showed the increased expression of TNF-alpha, IFN-gamma, and IL-6 following expression of the anti-inflammatory genes IL-10 and TGF-beta in the liver, justifying the reduction in the number and size of the observed granulomas. BMDMs stimulated with splenocyte supernatants from vaccinated and infected mice increase the CD86+ marker, as well as expressing greater amounts of iNOS and the consequent increase in NO production, suggesting an increase in the phagocytic and microbicidal capacity of these cells to eliminate the bacteria.	[Oliveira, Karen Cristina; Brancaglion, Gustavo Andrade; Santos, Natalia C. M.; Araujo, Leonardo P.; Corsetti, Patricia Paiva; de Almeida, Leonardo Augusto] Univ Fed Alfenas, Lab Mol Biol Microorganisms, Alfenas, Brazil; [Novaes, Evandro] Univ Fed Lavras, Dept Biol, Lavras, Brazil; [Santos, Renato de Lima] Univ Fed Minas Gerais, Sch Vet, Dept Clin & Vet Surg, Belo Horizonte, MG, Brazil; [Oliveira, Sergio Costa] Univ Fed Minas Gerais, Dept Biochem & Immunol, Belo Horizonte, MG, Brazil	Universidade Federal de Alfenas; Universidade Federal de Lavras; Universidade Federal de Minas Gerais; Universidade Federal de Minas Gerais	Corsetti, PP; de Almeida, LA (corresponding author), Univ Fed Alfenas, Lab Mol Biol Microorganisms, Alfenas, Brazil.	ppcorsetti@hotmail.com; leonardo.almeida@unifal-mg.edu.br	de Almeida, Leonardo A/G-2482-2012; Novaes, Evandro/O-6939-2019; Oliveira, Sergio Costa/AAG-5408-2021; Oliveira, Karen/AAE-3473-2022; Novaes, Evandro/GRS-0186-2022	de Almeida, Leonardo A/0000-0003-1886-5080; Novaes, Evandro/0000-0003-3803-0339; Oliveira, Sergio Costa/0000-0003-4062-5577; Novaes, Evandro/0000-0003-3803-0339; Pereira de Araujo, Leonardo/0000-0003-0212-3365	Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior-Brasil (CAPES) [001]; Fundacao de Amparo a Pesquisa do Estado de Minas Gerais [864/14]; Universidade Federal de Alfenas; Brazilian Ministry of Education (MEC) [002/2020 - PRPPG/REITORIA]	Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior-Brasil (CAPES)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); Fundacao de Amparo a Pesquisa do Estado de Minas Gerais(Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG)); Universidade Federal de Alfenas; Brazilian Ministry of Education (MEC)(National Health and Medical Research Council (NHMRC) of Australia)	This study was supported in part by the Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior-Brasil (CAPES) (Finance Code 001) and Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (Grant 864/14) and Universidade Federal de Alfenas and the Brazilian Ministry of Education (MEC) (EDITAL N degrees 002/2020 - PRPPG/REITORIA).	Adone R, 2005, INFECT IMMUN, V73, P4198, DOI 10.1128/IAI.73.7.4198-4204.2005; Ahmed W, 2016, FRONT CELL INFECT MI, V6, DOI 10.3389/fcimb.2016.00030; Al-Mariri A, 2012, BIOLOGICALS, V40, P140, DOI 10.1016/j.biologicals.2012.01.002; Armenteros JJA, 2019, NAT BIOTECHNOL, V37, P420, DOI 10.1038/s41587-019-0036-z; Aslam M, 2020, GENOMICS, V112, P1734, DOI 10.1016/j.ygeno.2019.10.009; Bao YQ, 2017, VET RES, V48, DOI 10.1186/s13567-017-0422-9; Belo VA, 2021, CELL TISSUE RES, V383, P1123, DOI 10.1007/s00441-020-03308-4; Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170; Brandao APMS, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/589494; Cardoso PCG, 2006, MICROB CELL FACT, V5, DOI 10.1186/1475-2859-5-13; Carvalho TF, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166582; Cassataro J, 2005, INFECT IMMUN, V73, P8079, DOI 10.1128/IAI.73.12.8079-8088.2005; Caswell CC, 2012, MOL MICROBIOL, V85, P345, DOI 10.1111/j.1365-2958.2012.08117.x; Clausse M, 2013, VACCINE, V31, P6129, DOI 10.1016/j.vaccine.2013.07.041; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; Corsetti PP, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01331; Corsetti PP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074729; Dadar M, 2021, TRANSBOUND EMERG DIS, V68, P715, DOI 10.1111/tbed.13735; Avila-Calderon ED, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/743509; de Almeida LA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023135; Delany I, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a012476; Dong H, 2014, FEMS MICROBIOL LETT, V354, P119, DOI 10.1111/1574-6968.12433; Dorneles EMS, 2015, VET RES, V46, DOI 10.1186/s13567-015-0199-7; Doytchinova IA, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-4; Durward M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034925; ENRIGHT FM, 1990, VET IMMUNOL IMMUNOP, V26, P171, DOI 10.1016/0165-2427(90)90065-Z; Ficht T, 2010, FUTURE MICROBIOL, V5, P859, DOI 10.2217/FMB.10.52; Forestier C, 1999, J IMMUNOL, V162, P6784; Forestier C, 2000, J IMMUNOL, V165, P5202, DOI 10.4049/jimmunol.165.9.5202; Franc KA, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-017-5016-y; Franco MP, 2007, LANCET INFECT DIS, V7, P775, DOI 10.1016/S1473-3099(07)70286-4; Gasteiger E, 2003, NUCLEIC ACIDS RES, V31, P3784, DOI 10.1093/nar/gkg563; Ghasemi A, 2015, VACCINE, V33, P5532, DOI 10.1016/j.vaccine.2015.09.013; Goel D, 2013, VACCINE, V31, P1231, DOI 10.1016/j.vaccine.2012.12.043; Goel D, 2012, MOL IMMUNOL, V51, P159, DOI 10.1016/j.molimm.2012.02.126; Golshani M, 2016, VET MICROBIOL, V197, P47, DOI 10.1016/j.vetmic.2016.10.027; Gomes MT, 2016, J LEUKOCYTE BIOL, V99, P771, DOI 10.1189/jlb.4A0815-346R; Goodwin ZI, 2016, VET IMMUNOL IMMUNOP, V181, P54, DOI 10.1016/j.vetimm.2016.03.011; Goolab S, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.01189; Gortazar C, 2007, EUR J WILDLIFE RES, V53, P241, DOI 10.1007/s10344-007-0098-y; Guimaraes ES, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9121040; Gupta S, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9020152; Hanna N, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-459; Giambartolomei GH, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00423; Herrou J, 2019, J BACTERIOL, V201, DOI 10.1128/JB.00134-19; Hisham Y, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/1474517; Hu H, 2020, J IMMUNOL, V204, P632, DOI 10.4049/jimmunol.1801550; Huy TXN, 2021, FRONT VET SCI, V7, DOI 10.3389/fvets.2020.577026; Hop HT, 2019, INFECT IMMUN, V87, DOI 10.1128/IAI.00431-19; Hop HT, 2018, VACCINE, V36, P3027, DOI 10.1016/j.vaccine.2018.04.019; Ikeda M, 2003, NUCLEIC ACIDS RES, V31, P406, DOI 10.1093/nar/gkg020; Kelley LA, 2015, NAT PROTOC, V10, P845, DOI 10.1038/nprot.2015.053; Khan MZ, 2018, TROP MED INFECT DIS, V3, DOI 10.3390/tropicalmed3020065; Khurana SK, 2021, VET QUART, V41, P61, DOI 10.1080/01652176.2020.1868616; Ko KY, 2012, VET MICROBIOL, V156, P374, DOI 10.1016/j.vetmic.2011.11.011; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Lalsiamthara J, 2020, BIOLOGICALS, V63, P62, DOI 10.1016/j.biologicals.2019.11.005; Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25; Lapaque N, 2005, CURR OPIN MICROBIOL, V8, P60, DOI 10.1016/j.mib.2004.12.003; Laskowski RA, 2011, J CHEM INF MODEL, V51, P2778, DOI 10.1021/ci200227u; Lim JJ, 2012, J VET SCI, V13, P287, DOI 10.4142/jvs.2012.13.3.287; Magrane M, 2011, DATABASE-OXFORD, DOI 10.1093/database/bar009; Mallick AI, 2007, VACCINE, V25, P3692, DOI 10.1016/j.vaccine.2007.01.066; Martin M., 2011, EMBNET J, V17, P5, DOI 10.14806/ej.17.1.200; Martirosyan A, 2011, IMMUNOL REV, V240, P211, DOI 10.1111/j.1600-065X.2010.00982.x; Mitaku S, 2002, BIOINFORMATICS, V18, P608, DOI 10.1093/bioinformatics/18.4.608; MORENO E, 1981, INFECT IMMUN, V31, P362, DOI 10.1128/IAI.31.1.362-370.1981; Mraheil MA, 2011, NUCLEIC ACIDS RES, V39, P4235, DOI 10.1093/nar/gkr033; Murphy EA, 2001, IMMUNOLOGY, V103, P511, DOI 10.1046/j.1365-2567.2001.01258.x; Musallam II, 2016, EPIDEMIOL INFECT, V144, P671, DOI 10.1017/S0950268815002575; Nielsen M, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-296; O'Boyle NM, 2011, J CHEMINFORMATICS, V3, DOI 10.1186/1758-2946-3-33; Oliveira SC, 1996, VACCINE, V14, P959, DOI 10.1016/0264-410X(96)00018-7; Olsen SC, 2013, REV SCI TECH OIE, V32, P207; Ormo M, 1996, SCIENCE, V273, P1392, DOI 10.1126/science.273.5280.1392; Pal M., 2017, AM J EPIDEMIOL INFEC, V5, P27, DOI [DOI 10.12691/ajeid-5-2-2, 10.12691/ajeid-5-2-2, DOI 10.12691/AJEID-5-2-2]; Pappas G, 2006, LANCET INFECT DIS, V6, P91, DOI 10.1016/S1473-3099(06)70382-6; Pasquevich KA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016203; Pasquevich KA, 2009, INFECT IMMUN, V77, P436, DOI 10.1128/IAI.01151-08; Paul S, 2018, MOL IMMUNOL, V99, P9, DOI 10.1016/j.molimm.2018.04.002; Pizza M, 2000, SCIENCE, V287, P1816, DOI 10.1126/science.287.5459.1816; Quinlan AR, 2010, BIOINFORMATICS, V26, P841, DOI 10.1093/bioinformatics/btq033; Rammensee HG, 1999, IMMUNOGENETICS, V50, P213, DOI 10.1007/s002510050595; Rappuoli R, 2000, CURR OPIN MICROBIOL, V3, P445, DOI 10.1016/S1369-5274(00)00119-3; Reche PA, 2004, IMMUNOGENETICS, V56, P405, DOI 10.1007/s00251-004-0709-7; Rigsby RE, 2016, BIOCHEM MOL BIOL EDU, V44, P433, DOI 10.1002/bmb.20966; Saha S, 2006, NUCLEIC ACIDS RES, V34, pW202, DOI 10.1093/nar/gkl343; Sanner MF, 1999, J MOL GRAPH MODEL, V17, P57; Lacerda TLS, 2010, VACCINE, V28, P5627, DOI 10.1016/j.vaccine.2010.06.023; Saraiva M, 2010, NAT REV IMMUNOL, V10, P170, DOI 10.1038/nri2711; Saxena HM, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006393; Schurig GG, 2002, VET MICROBIOL, V90, P479, DOI 10.1016/S0378-1135(02)00255-9; Seib KL, 2012, CLIN MICROBIOL INFEC, V18, P109, DOI 10.1111/j.1469-0691.2012.03939.x; Seleem MN, 2010, VET MICROBIOL, V140, P392, DOI 10.1016/j.vetmic.2009.06.021; Skendros P, 2013, REV SCI TECH OIE, V32, P137; Smits HL, 2013, REV SCI TECH OIE, V32, P219; Sternon JF, 2018, INFECT IMMUN, V86, DOI [10.1128/IAI.00312-18, 10.1128/iai.00312-18]; Stranahan LW, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0218809; Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334; Vishnu US, 2015, OMICS, V19, P722, DOI 10.1089/omi.2015.0105; Vitry MA, 2014, J IMMUNOL, V192, P3740, DOI 10.4049/jimmunol.1302561; Vitry MA, 2012, INFECT IMMUN, V80, P4271, DOI 10.1128/IAI.00761-12; Wang XH, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.01193; Xavier MN, 2009, J COMP PATHOL, V140, P149, DOI 10.1016/j.jcpa.2008.10.004; Xavier MN, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003454; Yang XH, 2007, VACCINE, V25, P2261, DOI 10.1016/j.vaccine.2006.12.004; Yang Xinghong, 2013, Front Biol (Beijing), V8, P60; Yang YL, 2011, MOL IMMUNOL, V49, P175, DOI 10.1016/j.molimm.2011.08.009; Yu NY, 2010, BIOINFORMATICS, V26, P1608, DOI 10.1093/bioinformatics/btq249; Zai XD, 2021, VET RES, V52, DOI 10.1186/s13567-021-00939-5; Zhan YF, 1998, J IMMUNOL, V161, P1447; Zhao ZP, 2011, SCI CHINA LIFE SCI, V54, P880, DOI 10.1007/s11427-011-4218-2	112	0	0	3	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 21	2021	12								778475	10.3389/fimmu.2021.778475	http://dx.doi.org/10.3389/fimmu.2021.778475			18	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YB6GY	34992597	gold, Green Published			2022-12-18	WOS:000739109600001
J	Ouyang, LC; Wu, M; Shen, ZJ; Cheng, X; Wang, W; Jiang, L; Zhao, J; Gong, YL; Liang, ZH; Weng, XF; Yu, MQ; Wu, XW				Ouyang, Lichen; Wu, Mi; Shen, Zhijun; Cheng, Xue; Wang, Wei; Jiang, Lang; Zhao, Juan; Gong, Yeli; Liang, Zhihui; Weng, Xiufang; Yu, Muqing; Wu, Xiongwen			Activation and Functional Alteration of Mucosal-Associated Invariant T Cells in Adult Patients With Community-Acquired Pneumonia	FRONTIERS IN IMMUNOLOGY			English	Article						community-acquired pneumonia (CAP); mucosal-associated invariant T cells (MAIT); bronchoalveolar lavage fluid (BALF); high-sensitivity C-reactive protein (hsCRP); immunopathogenesis		Community-acquired pneumonia (CAP) remains the significant infectious cause of morbidity and mortality worldwide. Although mucosal-associated invariant T cells (MAIT) play roles in the pathogenesis of children CAP and ICU-associated pneumonia, their roles in adult CAP are largely unexplored. In this study, we investigated the frequency, phenotype, and function of MAIT cells in peripheral blood and bronchoalveolar lavage fluid (BALF) of adult CAP patients. Our data indicate that MAIT-cell frequency is profoundly lower in the peripheral blood of CAP patients compared to that in healthy individuals. Furthermore, the circulatory MAIT cells express higher levels of CD69 and PD-1 compared to those in healthy individuals. In BALF of CAP patients, MAIT-cell frequency is higher and MAIT cells express higher levels of CD69 and PD-1 compared to their matched blood counterparts. Levels of IL-17A and IFN-gamma are increased in BALF of CAP patients compared to those in BALF of patients with pulmonary small nodules. The IL-17A/IFN-gamma ratio is significantly positively correlated with MAIT frequency in BALF of CAP patients, suggesting a pathogenic role of MAIT-17 cells in CAP. Of note, blood MAIT-cell frequency in CAP patients is strongly negatively correlated with high-sensitivity C-reactive protein (hsCRP) and neutrophil count percentage in blood. The ability of circulating MAIT cells in CAP patients to produce IFN-gamma is significantly impaired compared to those in healthy individuals. In summary, our findings suggest the possible involvement of MAIT cells in the immunopathogenesis of adult CAP.	[Ouyang, Lichen; Wu, Mi; Shen, Zhijun; Cheng, Xue; Wang, Wei; Jiang, Lang; Zhao, Juan; Liang, Zhihui; Weng, Xiufang; Wu, Xiongwen] Huazhong Univ Sci & Technol, Sch Basic Med, Dept Immunol, Tongji Med Coll, Wuhan, Peoples R China; [Ouyang, Lichen; Gong, Yeli] Jianghan Univ, Sch Med, Dept Immunol, Wuhan, Peoples R China; [Yu, Muqing] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Resp & Crit Care Med, Wuhan, Peoples R China	Huazhong University of Science & Technology; Jianghan University; Huazhong University of Science & Technology	Wu, XW (corresponding author), Huazhong Univ Sci & Technol, Sch Basic Med, Dept Immunol, Tongji Med Coll, Wuhan, Peoples R China.; Yu, MQ (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Resp & Crit Care Med, Wuhan, Peoples R China.	mqyu@tjh.tjmu.edu.cn; xiongwenwu@hotmail.com			National Natural Science Foundation of China [81871235, 81871226]; Scientific Research Foundation of Jianghan University	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Scientific Research Foundation of Jianghan University	Funding This work was supported by the National Natural Science Foundation of China (81871235, 81871226) and the Scientific Research Foundation of Jianghan University.	Chiba A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01333; Chiba A, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075-017-1257-5; Cho YN, 2014, J IMMUNOL, V193, P3891, DOI 10.4049/jimmunol.1302701; Eckle SBG, 2014, J EXP MED, V211, P1585, DOI 10.1084/jem.20140484; Flament H, 2021, EUR J IMMUNOL, V51, P298, DOI 10.1038/s41590-021-00870-z; Godfrey DI, 2019, NAT IMMUNOL, V20, P1110, DOI 10.1038/s41590-019-0444-8; Grudzinska FS, 2020, THORAX, V75, P164, DOI 10.1136/thoraxjnl-2018-212826; Hannaway RF, 2020, CLIN EXP IMMUNOL, V199, P201, DOI 10.1111/cei.13377; Ivanov S, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004300; Jouan Y, 2020, J EXP MED, V217, DOI 10.1084/jem.20200872; Jubel JM, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00487; Lamichhane R, 2019, CELL REP, V28, P3061, DOI 10.1016/j.celrep.2019.08.054; Leeansyah E, 2021, TRENDS MICROBIOL, V29, P504, DOI 10.1016/j.tim.2020.11.008; Liu Y, 2021, HEPATOLOGY, V73, P1671, DOI 10.1002/hep.31602; Lu BT, 2020, MUCOSAL IMMUNOL, V13, P824, DOI 10.1038/s41385-020-0273-y; Malka-Ruimy C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00206; Matsuyama H, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-49903-6; Nel I, 2021, MUCOSAL IMMUNOL, V14, P803, DOI 10.1038/s41385-021-00391-w; Paats MS, 2013, THORAX, V68, P468, DOI 10.1136/thoraxjnl-2012-202168; Paget C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00336; Parrot T, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abe1670; Qiu WJ, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.640455; Rider AC, 2018, EMERG MED CLIN N AM, V36, P665, DOI 10.1016/j.emc.2018.07.001; Ticona Javier H, 2021, Am J Med Case Rep, V9, P45, DOI 10.12691/ajmcr-9-1-12; Trivedi S, 2020, ELIFE, V9, DOI 10.7554/eLife.55615; Uldrich AP, 2005, J IMMUNOL, V175, P3092, DOI 10.4049/jimmunol.175.5.3092; van Wilgenburg B, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07207-9; Vij R, 2013, CHEST, V143, P814, DOI 10.1378/chest.12-0741; Wang HM, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05202-8	29	0	0	3	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 21	2021	12								788406	10.3389/fimmu.2021.788406	http://dx.doi.org/10.3389/fimmu.2021.788406			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YB4YN	34992604	gold, Green Published			2022-12-18	WOS:000739020000001
J	Yin, ZX; Tian, X; Zou, RY; He, XL; Chen, KK; Zhu, CG				Yin, Zexi; Tian, Xin; Zou, Runying; He, Xiangling; Chen, Keke; Zhu, Chengguang			Case Report: First Occurrence of Plasmablastic Lymphoma in Activated Phosphoinositide 3-Kinase delta Syndrome	FRONTIERS IN IMMUNOLOGY			English	Article						children; PIK3CD gene; activated phosphoinositide 3-kinase delta syndrome; EBV; plasmablastic lymphoma	MUTATIONS	Activated phosphoinositide 3-kinase delta syndrome (APDS) is an autosomal dominant primary immunodeficiency caused by acquired gene function mutation (GOF). APDS has a variety of clinical phenotypes, particularly recurrent respiratory infections and lymphoproliferation. Here we report a pediatric patient with APDS who presented with recurrent respiratory infections, lymphoproliferation, hepatosplenomegaly, bronchoscopy suggesting numerous nodular protrusions in the airways and a decrease in both T and B lymphocytes, and progression to plasmablastic lymphoma (PBL) after 1 year. Whole exome sequencing revealed a heterozygous mutation in the PIK3CD gene (c.3061 G>A p.E1021K). This is the first reported case of APDS combined with PBL and pediatricians should follow up patients with APDS regularly to be alert for secondary tumours.	[Yin, Zexi; Tian, Xin; Zou, Runying; He, Xiangling; Chen, Keke; Zhu, Chengguang] Hunan Normal Univ, Affiliated Hosp 1, Hunan Prov Peoples Hosp, Childrens Med Ctr,Dept Hematol & Oncol, Changsha, Peoples R China	Hunan Normal University	Zou, RY (corresponding author), Hunan Normal Univ, Affiliated Hosp 1, Hunan Prov Peoples Hosp, Childrens Med Ctr,Dept Hematol & Oncol, Changsha, Peoples R China.	zourunying@163.com			Hunan Provincial Science and Technology Department project [2018SK21216]	Hunan Provincial Science and Technology Department project	Funding This work was supported by the Hunan Provincial Science and Technology Department project (2018SK21216).	Al-Herz W, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00162; Ando K, 2020, ONCOL RES TREAT, V43, P112, DOI 10.1159/000504608; Castillo JJ, 2019, BRIT J HAEMATOL, V184, P679, DOI 10.1111/bjh.15156; ComansBitter WM, 1997, J PEDIATR-US, V130, P388, DOI 10.1016/S0022-3476(97)70200-2; Coulter TI, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02043; Coulter TI, 2017, J ALLERGY CLIN IMMUN, V139, P597, DOI 10.1016/j.jaci.2016.06.021; Dimitrova D, 2022, J ALLERGY CLIN IMMUN, V149, P410, DOI 10.1016/j.jaci.2021.04.036; Dittus C, 2018, LEUKEMIA LYMPHOMA, V59, P2121, DOI 10.1080/10428194.2017.1416365; Elgizouli M, 2016, CLIN EXP IMMUNOL, V183, P221, DOI 10.1111/cei.12706; Elkaim E, 2016, J ALLERGY CLIN IMMUN, V138, P210, DOI 10.1016/j.jaci.2016.03.022; Loghavi S, 2015, J HEMATOL ONCOL, V8, DOI 10.1186/s13045-015-0163-z; Makady NF, 2021, CL LYMPH MYELOM LEUK, V21, pE255, DOI 10.1016/j.clml.2020.11.025; Michalovich D, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00369; Takeda AJ, 2017, J ALLERGY CLIN IMMUN, V140, P1152, DOI 10.1016/j.jaci.2017.03.026	14	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 21	2021	12								813261	10.3389/fimmu.2021.813261	http://dx.doi.org/10.3389/fimmu.2021.813261			5	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YB7AP	34992612	gold, Green Published			2022-12-18	WOS:000739160700001
J	Barreira-Silva, P; Melo-Miranda, R; Nobrega, C; Roque, S; Serre-Miranda, C; Borges, M; Armada, G; Calcada, DD; Behar, SM; Appelberg, R; Correia-Neves, M				Barreira-Silva, Palmira; Melo-Miranda, Rita; Nobrega, Claudia; Roque, Susana; Serre-Miranda, Claudia; Borges, Margarida; Armada, Gisela; de Sa Calcada, Daniela; Behar, Samuel M.; Appelberg, Rui; Correia-Neves, Margarida			IFN gamma and iNOS-Mediated Alterations in the Bone Marrow and Thymus and Its Impact on Mycobacterium avium-Induced Thymic Atrophy	FRONTIERS IN IMMUNOLOGY			English	Article						thymus premature atrophy; Mycobacterium avium infection; IFN gamma; nitric oxide; BM T cell precursors; thymocyte differentiation	HEMATOPOIETIC STEM-CELLS; IMMUNODEFICIENCY-VIRUS-INFECTION; TUMOR-NECROSIS-FACTOR; AGE-RELATED-CHANGES; THYMOCYTE APOPTOSIS; INTERFERON-GAMMA; BACTERIAL-INFECTION; MICE; PROLIFERATION; INDUCTION	Disseminated infection with the high virulence strain of Mycobacterium avium 25291 leads to progressive thymic atrophy. We previously showed that M. avium-induced thymic atrophy results from increased glucocorticoid levels that synergize with nitric oxide (NO) produced by interferon gamma (IFN gamma) activated macrophages. Where and how these mediators act is not understood. We hypothesized that IFN gamma and NO promote thymic atrophy through their effects on bone marrow (BM) T cell precursors and T cell differentiation in the thymus. We show that M. avium infection cause a reduction in the percentage and number of common lymphoid progenitors (CLP). Additionally, BM precursors from infected mice show an overall impaired ability to reconstitute thymi of RAGKO mice, in part due to IFN gamma. Thymi from infected mice present an IFN gamma and NO-driven inflammation. When transplanted under the kidney capsule of uninfected mice, thymi from infected mice are unable to sustain T cell differentiation. Finally, we observed increased thymocyte death via apoptosis after infection, independent of both IFN gamma and iNOS; and a decrease on active caspase-3 positive thymocytes, which is not observed in the absence of iNOS expression. Together our data suggests that M. avium-induced thymic atrophy results from a combination of defects mediated by IFN gamma and NO, including alterations in the BM T cell precursors, the thymic structure and the thymocyte differentiation.	[Barreira-Silva, Palmira; Melo-Miranda, Rita; Nobrega, Claudia; Roque, Susana; Serre-Miranda, Claudia; Armada, Gisela; de Sa Calcada, Daniela; Correia-Neves, Margarida] Univ Minho, Life & Hlth Sci Res Inst ICVS, Sch Med, Braga, Portugal; [Barreira-Silva, Palmira; Melo-Miranda, Rita; Nobrega, Claudia; Roque, Susana; Serre-Miranda, Claudia; Armada, Gisela; de Sa Calcada, Daniela; Correia-Neves, Margarida] PT Govt Associate Lab, Life & Hlth Sci Res Inst, Biomat Biodegradables & Biomimet Res Grp ICVS 3Bs, Braga, Portugal; [Borges, Margarida] Univ Porto, Res Unit Appl Mol Biosci UCIBIO, Rede Quim & Tecnol REQUINTE, Dept Ciencias Biol,Fac Farm, Porto, Portugal; [Behar, Samuel M.] Univ Massachusetts, Dept Microbiol & Physiol Syst, Sch Med, Worcester, MA USA; [Appelberg, Rui] Univ Porto, Inst Invest & Inovacao Saude i3S, Inst Invest & Inovacao Saude, Porto, Portugal; [Appelberg, Rui] Univ Porto, IBMC Inst Biol Mol Celular, Porto, Portugal; [Appelberg, Rui] Univ Porto, ICBAS Inst Ciencias Biomed Abel Salazar, Porto, Portugal; [Correia-Neves, Margarida] Karolinska Inst, Dept Med Solna, Div Infect Dis, Stockholm, Sweden	Universidade do Minho; Universidade do Porto; University of Massachusetts System; University of Massachusetts Worcester; Universidade do Porto; i3S - Instituto de Investigacao e Inovacao em Saude, Universidade do Porto; Universidade do Porto; Universidade do Porto; Karolinska Institutet	Barreira-Silva, P; Correia-Neves, M (corresponding author), Univ Minho, Life & Hlth Sci Res Inst ICVS, Sch Med, Braga, Portugal.; Barreira-Silva, P; Correia-Neves, M (corresponding author), PT Govt Associate Lab, Life & Hlth Sci Res Inst, Biomat Biodegradables & Biomimet Res Grp ICVS 3Bs, Braga, Portugal.; Correia-Neves, M (corresponding author), Karolinska Inst, Dept Med Solna, Div Infect Dis, Stockholm, Sweden.	palmirasilva@med.uminho.pt; mcorreianeves@med.uminho.pt	borges, margarida/GWR-0803-2022; Melo-Miranda, Rita/GQR-0942-2022; Nóbrega, Cláudia/T-6430-2018; Roque, Susana/F-1400-2010; Correia-Neves, Margarida/AAH-4636-2020; Armada, Gisela/AAE-8339-2022; Borges, Margarida/E-9021-2013; Barreira-Silva, Palmira/T-5360-2018	Nóbrega, Cláudia/0000-0002-0282-9619; Roque, Susana/0000-0002-6512-996X; Correia-Neves, Margarida/0000-0002-2202-5431; Borges, Margarida/0000-0001-6035-4095; Behar, Samuel/0000-0002-3374-6699; Barreira-Silva, Palmira/0000-0002-8070-1856; Melo-Miranda, Rita/0000-0001-7845-5767				Andrade CF, 2008, CELL IMMUNOL, V253, P1, DOI 10.1016/j.cellimm.2008.06.001; Aspinall R, 2003, MICROSC RES TECHNIQ, V62, P508, DOI 10.1002/jemt.10412; Baldridge MT, 2010, NATURE, V465, P793, DOI 10.1038/nature09135; Belhacene N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047321; Belyaev NN, 2010, NAT IMMUNOL, V11, P477, DOI 10.1038/ni.1869; Borges M, 2012, J IMMUNOL, V189, P3600, DOI 10.4049/jimmunol.1201525; Brito VN, 2003, MED MYCOL, V41, P83, DOI 10.1080/714043902; Burberry A, 2014, CELL HOST MICROBE, V15, P779, DOI 10.1016/j.chom.2014.05.004; Carbajosa S, 2017, ONCOTARGET, V8, P17551, DOI 10.18632/oncotarget.14886; Cardenas Palomo L F, 1995, J Clin Lab Immunol, V46, P49; Chen WX, 2005, MICROB PATHOGENESIS, V39, P189, DOI 10.1016/j.micpath.2005.08.005; Choi HH, 2011, MICROBES INFECT, V13, P1252, DOI 10.1016/j.micinf.2011.08.001; Cohen O, 2009, INT IMMUNOL, V21, P1113, DOI 10.1093/intimm/dxp079; de Bruin AM, 2013, BLOOD, V121, P3578, DOI 10.1182/blood-2012-05-432906; de Meis Juliana, 2012, J Parasitol Res, V2012, P574020, DOI 10.1155/2012/574020; DELEVAL L, 1995, PATHOL RES PRACT, V191, P506, DOI 10.1016/S0344-0338(11)80869-1; DEMORAES MDCL, 1994, SCAND J IMMUNOL, V39, P51; Deobagkar-Lele M, 2013, IMMUNOLOGY, V138, P307, DOI 10.1111/imm.12047; Dooley J, 2012, EUR J IMMUNOL, V42, P1073, DOI 10.1002/eji.201142305; Douek DC, 1998, NATURE, V396, P690, DOI 10.1038/25374; Douek DC, 2001, J IMMUNOL, V167, P6663, DOI 10.4049/jimmunol.167.11.6663; Essers MAG, 2009, NATURE, V458, P904, DOI 10.1038/nature07815; Farias-de-Oliveira DA, 2013, J LEUKOCYTE BIOL, V93, P227, DOI 10.1189/jlb.1211589; Fayad R, 2005, EUR J IMMUNOL, V35, P2304, DOI 10.1002/eji.200526062; Florido M, 1999, INFECT IMMUN, V67, P3610; Florido M, 2005, INFECT IMMUN, V73, P3577, DOI 10.1128/IAI.73.6.3577-3586.2005; FRANCIS IR, 1985, AM J ROENTGENOL, V145, P249, DOI 10.2214/ajr.145.2.249; FRANKENBURG S, 1980, CELL IMMUNOL, V55, P185, DOI 10.1016/0008-8749(80)90149-5; Gameiro J, 2010, IMMUNOLOGY, V129, P248, DOI 10.1111/j.1365-2567.2009.03177.x; Gomes AC, 2019, J IMMUNOL, V203, P2485, DOI 10.4049/jimmunol.1900382; Gordon SA, 2001, J LEUKOCYTE BIOL, V70, P87; Heitger A, 1997, BLOOD, V90, P850, DOI 10.1182/blood.V90.2.850.850_850_857; HERNANDEZCASELLES T, 1993, J IMMUNOL, V151, P3999; Iwasaki H, 2007, ONCOGENE, V26, P6687, DOI 10.1038/sj.onc.1210754; Jiang D, 1999, CELL DEATH DIFFER, V6, P402, DOI 10.1038/sj.cdd.4400513; Kaur S, 2017, SEMIN CELL DEV BIOL, V61, P12, DOI 10.1016/j.semcdb.2016.08.009; Klei TRL, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00073; Kong YX, 2016, STEM CELLS, V34, P2902, DOI 10.1002/stem.2464; Krueger A, 2017, TRENDS IMMUNOL, V38, P128, DOI 10.1016/j.it.2016.10.007; Laan M, 2016, EUR J IMMUNOL, V46, P2008, DOI 10.1002/eji.201646309; LEITEDEMORAES MC, 1992, IMMUNOLOGY, V77, P95; Lepletier A, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003203; Losada-Barragan M, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00252; Luo ML, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.652538; Lykens JE, 2010, J IMMUNOL, V184, P877, DOI 10.4049/jimmunol.0902346; MABBOTT N, 1995, INFECT IMMUN, V63, P1563, DOI 10.1128/IAI.63.4.1563-1566.1995; MACMICKING JD, 1995, CELL, V81, P641, DOI 10.1016/0092-8674(95)90085-3; MacNamara KC, 2011, J IMMUNOL, V186, P1032, DOI 10.4049/jimmunol.1001893; Maltby S, 2014, J IMMUNOL, V193, P4072, DOI 10.4049/jimmunol.1400669; MARCOVISTZ R, 1994, BRAZ J MED BIOL RES, V27, P1599; Matsumura T, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1677; McCabe A, 2015, STEM CELLS, V33, P2294, DOI 10.1002/stem.2040; Morrot A, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001268; Morrot Alexandre, 2012, J Trop Med, V2012, P747185, DOI 10.1155/2012/747185; Moses AV, 1996, BLOOD, V87, P919, DOI 10.1182/blood.V87.3.919.bloodjournal873919; Nobrega C, 2007, MICROBES INFECT, V9, P1521, DOI 10.1016/j.micinf.2007.08.006; Nunes-Alves C, 2013, TRENDS IMMUNOL, V34, P502, DOI 10.1016/j.it.2013.06.004; Pietras EM, 2014, J EXP MED, V211, P245, DOI 10.1084/jem.20131043; Pronk CJH, 2011, J EXP MED, V208, P1563, DOI 10.1084/jem.20110752; Raykova VD, 2003, ANN CLIN LAB SCI, V33, P62; Perez AR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034360; Sauce D, 2009, J CLIN INVEST, V119, P3070, DOI 10.1172/JCI39269; SAVINO W, 1989, EUR J IMMUNOL, V19, P1727, DOI 10.1002/eji.1830190930; SAVINO W, 1986, AM J PATHOL, V122, P302; Savino W, 2007, BRIT J NUTR, V98, pS11, DOI 10.1017/S0007114507832880; Schmitt N, 2006, AIDS, V20, P533, DOI 10.1097/01.aids.0000210607.63138.bc; Seixas E, 2005, EXP PARASITOL, V110, P394, DOI 10.1016/j.exppara.2005.03.024; Singh P, 2008, STEM CELLS, V26, P1009, DOI 10.1634/stemcells.2007-0461; Smith JNP, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007234; Smith KY, 2000, J INFECT DIS, V181, P141, DOI 10.1086/315169; Souto PCS, 2003, MED MICROBIOL IMMUN, V192, P225, DOI 10.1007/s00430-003-0180-3; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; STANLEY SK, 1993, J EXP MED, V178, P1151, DOI 10.1084/jem.178.4.1151; Tai XG, 1997, J IMMUNOL, V158, P4696; WATSON SR, 1984, INFECT IMMUN, V45, P372, DOI 10.1128/IAI.45.2.372-377.1984; Winkler IG, 2010, BLOOD, V116, P4815, DOI 10.1182/blood-2009-11-253534; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Zhao X, 2010, STEM CELLS, V28, P122, DOI 10.1002/stem.252	78	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 20	2021	12								696415	10.3389/fimmu.2021.696415	http://dx.doi.org/10.3389/fimmu.2021.696415			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YB2OM	34987496	Green Published, gold, Green Submitted			2022-12-18	WOS:000738858300001
J	Buijsers, B; Garishah, FM; Riswari, SF; van Ast, RM; Pramudo, SG; Tunjungputri, RN; Overheul, GJ; van Rij, RP; van der Ven, A; Alisjahbana, B; Gasem, MH; de Mast, Q; van der Vlag, J				Buijsers, Baranca; Garishah, Fadel Muhammad; Riswari, Silvita Fitri; van Ast, Rosalie M.; Pramudo, Setyo Gundi; Tunjungputri, Rahajeng N.; Overheul, Gijs J.; van Rij, Ronald P.; van der Ven, Andre; Alisjahbana, Bachti; Gasem, Muhammad Hussein; de Mast, Quirijn; van der Vlag, Johan			Increased Plasma Heparanase Activity and Endothelial Glycocalyx Degradation in Dengue Patients Is Associated With Plasma Leakage	FRONTIERS IN IMMUNOLOGY			English	Article						dengue; platelets; heparanase; endothelial glycocalyx degradation; vascular permeability syndrome; DENV2	PLATELETS; COAGULATION; ACTIVATION; EXPRESSION; CELLS; FIBRINOLYSIS; DYSFUNCTION; JUNCTIONS; THROMBIN; SULFATE	BackgroundEndothelial hyper-permeability with plasma leakage and thrombocytopenia are predominant features of severe dengue virus infection. It is well established that heparanase, the endothelial glycocalyx degrading enzyme, plays a major role in various diseases with vascular leakage. It is yet to be elucidated whether heparanase activity plays a major role in dengue-associated plasma leakage. Moreover, the major source of heparanase secretion and activation in dengue remains elusive. Since a relatively high amount of heparanase is stored in platelets, we postulate that heparanase released by activated platelets contributes to the increased plasma heparanase activity during dengue virus infection. MethodsHeparanase activity (plasma and urine), and heparan sulfate and syndecan-1 (plasma levels) were measured in dengue patients with thrombocytopenia in acute phase (n=30), during course of disease (n=10) and in convalescent phase (n=25). Associations with clinical parameters and plasma leakage markers were explored. Platelets from healthy donors were stimulated with dengue non-structural protein-1, DENV2 virus and thrombin to evaluate heparanase release and activity ex vivo. ResultsHeparanase activity was elevated in acute dengue and normalized during convalescence. Similarly, glycocalyx components, such as heparan sulfate and syndecan-1, were increased in acute dengue and restored during convalescence. Increased heparanase activity correlated with the endothelial dysfunction markers heparan sulfate and syndecan-1, as well as clinical markers of plasma leakage such as ascites, hematocrit concentration and gall-bladder wall thickening. Notably, platelet number inversely correlated with heparanase activity. Ex vivo incubation of platelets with thrombin and live DENV2 virus, but not dengue virus-2-derived non-structural protein 1 induced heparanase release from platelets. ConclusionTaken together, our findings suggest that the increase of heparanase activity in dengue patients is associated with endothelial glycocalyx degradation and plasma leakage. Furthermore, thrombin or DENV2 activated platelets may be considered as a potential source of heparanase.	[Buijsers, Baranca; van Ast, Rosalie M.; van der Vlag, Johan] Radboud Univ Nijmegen, Radboud Inst Mol Life Sci, Dept Nephrol, Med Ctr, Nijmegen, Netherlands; [Garishah, Fadel Muhammad; Riswari, Silvita Fitri; Tunjungputri, Rahajeng N.; van der Ven, Andre; de Mast, Quirijn] Radboud Univ Nijmegen, Radboud Ctr Infect Dis, Dept Internal Med, Med Ctr, Nijmegen, Netherlands; [Garishah, Fadel Muhammad; Tunjungputri, Rahajeng N.; Gasem, Muhammad Hussein] Diponegoro Univ, Dr Kariadi Hosp, Fac Med, Ctr Trop & Infect Dis CENTRID, Semarang, Indonesia; [Riswari, Silvita Fitri; Alisjahbana, Bachti] Univ Padjadjaran, Res Ctr Care & Control Infect Dis RC3ID, Bandung, Indonesia; [Riswari, Silvita Fitri] Univ Padjadjaran, Fac Med, Dept Biomed Sci, Bandung, Indonesia; [Pramudo, Setyo Gundi; Gasem, Muhammad Hussein] Diponegoro Univ, Fac Med, Diponegoro Natl Univ Hosp, Dept Internal Med, Semarang, Indonesia; [Pramudo, Setyo Gundi] William Booth Hosp, Dept Internal Med, Semarang, Indonesia; [Overheul, Gijs J.; van Rij, Ronald P.] Radboud Univ Nijmegen, Med Ctr, Radboud Inst Mol Life Sci, Dept Med Microbiol, Nijmegen, Netherlands; [Alisjahbana, Bachti] Univ Padjadjaran, Fac Med, Hasan Sadikin Gen Hosp, Dept Internal Med, Bandung, Indonesia	Radboud University Nijmegen; Radboud University Nijmegen; Diponegoro University; Universitas Padjadjaran; Universitas Padjadjaran; Diponegoro University; Radboud University Nijmegen; Dr Hasan Sadikin General Hospital; Universitas Padjadjaran	van der Vlag, J (corresponding author), Radboud Univ Nijmegen, Radboud Inst Mol Life Sci, Dept Nephrol, Med Ctr, Nijmegen, Netherlands.	Johan.vanderVlag@radboudumc.nl		de Mast, Quirijn/0000-0001-6056-157X	Radboud Institute of Molecular Life Sciences (RIMLS) PhD-program; Indonesian Endowment Fund for Education (LPDP) Scholarship from the Ministry of Finance Republic of Indonesia; ZonMW [451001005]	Radboud Institute of Molecular Life Sciences (RIMLS) PhD-program; Indonesian Endowment Fund for Education (LPDP) Scholarship from the Ministry of Finance Republic of Indonesia; ZonMW(Netherlands Organization for Health Research and Development)	BB was supported by the Radboud Institute of Molecular Life Sciences (RIMLS) PhD-program. FG is financially supported by the Indonesian Endowment Fund for Education (LPDP) Scholarship from the Ministry of Finance Republic of Indonesia. Patient inclusion was financially supported by ZonMW (grant 451001005). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Becker BF, 2015, BRIT J CLIN PHARMACO, V80, P389, DOI 10.1111/bcp.12629; BHAMARAP.N, 1967, ANN TROP MED PARASIT, V61, P500, DOI 10.1080/00034983.1967.11686519; Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060; Buijsers B, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.575047; Buijsers B, 2020, EBIOMEDICINE, V59, DOI 10.1016/j.ebiom.2020.102969; Chagan-Yasutan H, 2014, THROMB RES, V134, P449, DOI 10.1016/j.thromres.2014.05.003; Chao CH, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007625; Chappell D, 2008, BIOL CHEM, V389, P79, DOI 10.1515/BC.2008.005; Chen HR, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007033; Claushuis TAM, 2019, PLATELETS, V30, P296, DOI 10.1080/09537104.2018.1445841; Cohen-Mazor M, 2008, AM J PHYSIOL-HEART C, V294, pH651, DOI 10.1152/ajpheart.00952.2007; Cui H, 2016, ONCOTARGET, V7, P39486, DOI 10.18632/oncotarget.8960; Dane MJC, 2015, AM J PHYSIOL-RENAL, V308, pF956, DOI 10.1152/ajprenal.00532.2014; Dejana E, 2004, NAT REV MOL CELL BIO, V5, P261, DOI 10.1038/nrm1357; Eustes AS, 2021, J THROMB HAEMOST, V19, P1319, DOI 10.1111/jth.15266; Garcia-Larragoiti N, 2021, J THROMB HAEMOST, V19, P2572, DOI 10.1111/jth.15431; Garishah FM, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.629167; Garsen M, 2016, AM J PATHOL, V186, P805, DOI 10.1016/j.ajpath.2015.12.008; Gil N, 2012, DIABETES, V61, P208, DOI 10.2337/db11-1024; Guzman MG, 2010, NAT REV MICROBIOL, pS7, DOI 10.1038/nrmicro2460; Hottz ED, 2013, J THROMB HAEMOST, V11, P951, DOI 10.1111/jth.12178; Nguyen-Pouplin J, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001282; Kim OV, 2019, HAEMATOLOGICA, V104, P1866, DOI 10.3324/haematol.2018.202309; Kiyan Y, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-50068-5; Mehta D, 2014, AM J PHYSIOL-LUNG C, V307, pL924, DOI 10.1152/ajplung.00318.2014; Modhiran N, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa3863; Muller DA, 2017, J INFECT DIS, V215, pS89, DOI 10.1093/infdis/jiw649; Nachman RL, 2008, NEW ENGL J MED, V359, P1261, DOI 10.1056/NEJMra0800887; Opasawatchai A, 2019, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03007; Lam PK, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.545813; Lam PK, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005498; Pieterse E, 2018, ANN RHEUM DIS, V77, P1790, DOI 10.1136/annrheumdis-2018-213223; Puerta-Guardo H, 2019, CELL REP, V26, P1598, DOI 10.1016/j.celrep.2019.01.036; Puerta-Guardo H, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005738; Purushothaman A, 2008, J BIOL CHEM, V283, P32628, DOI 10.1074/jbc.M806266200; Quirino-Teixeira AC, 2020, BLOOD ADV, V4, P2018, DOI 10.1182/bloodadvances.2019001169; Radeva MY, 2018, ACTA PHYSIOL, V222, DOI 10.1111/apha.12860; Ramani VC, 2016, MATRIX BIOL, V55, P22, DOI 10.1016/j.matbio.2016.03.006; Rathore APS, 2019, J CLIN INVEST, V129, P4180, DOI 10.1172/JCI128426; Reitsma S, 2007, PFLUG ARCH EUR J PHY, V454, P345, DOI 10.1007/s00424-007-0212-8; Rops AL, 2008, KIDNEY INT, V73, P52, DOI 10.1038/sj.ki.5002573; Schmidt EP, 2012, NAT MED, V18, P1217, DOI 10.1038/nm.2843; Sosothikul D, 2007, THROMB HAEMOSTASIS, V97, P627, DOI 10.1160/TH06-02-0094; Srikiatkhachorn A, 2007, PEDIATR INFECT DIS J, V26, P283, DOI 10.1097/01.inf.0000258612.26743.10; Suharti C, 2002, THROMB HAEMOSTASIS, V87, P42, DOI 10.1055/s-0037-1612941; Suwarto S, 2017, J INFECT DIS, V215, P992, DOI 10.1093/infdis/jix041; Tatour M, 2017, THROMB HAEMOSTASIS, V117, P1391, DOI 10.1160/TH16-10-0766; Tunjungputri RN, 2015, THROMB HAEMOSTASIS, V113, P1035, DOI 10.1160/TH14-07-0579; UTTAYOPAS C, 1987, Southeast Asian Journal of Tropical Medicine and Public Health, V18, P380; Vasanwala FF, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002712; Vlag J, 2019, GLOMERULAR ENDOTHELI, P153, DOI DOI 10.1007/978-3-319-93521-8_10; VLODAVSKY I, 1992, INVAS METAST, V12, P112; Weinbaum S, 2007, ANNU REV BIOMED ENG, V9, P121, DOI 10.1146/annurev.bioeng.9.060906.151959; Zhan N, 2021, BMC INFECT DIS, V21, DOI 10.1186/s12879-021-05856-8	54	0	0	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 20	2021	12								759570	10.3389/fimmu.2021.759570	http://dx.doi.org/10.3389/fimmu.2021.759570			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YB2JZ	34987504	Green Published, gold			2022-12-18	WOS:000738846600001
J	Gao, Y; Shan, W; Gu, TN; Zhang, J; Wu, YB; Li, XQ; Zeng, XJ; Zhou, HY; Chen, Z; Xiao, HW				Gao, Yang; Shan, Wei; Gu, Tianning; Zhang, Jie; Wu, Yibo; Li, Xiaoqing; Zeng, Xiangjun; Zhou, Hongyu; Chen, Zhi; Xiao, Haowen			Daratumumab Prevents Experimental Xenogeneic Graft-Versus-Host Disease by Skewing Proportions of T Cell Functional Subsets and Inhibiting T Cell Activation and Migration	FRONTIERS IN IMMUNOLOGY			English	Article						daratumumab; CD38; graft-versus-host disease; graft-versus-leukemia; chemokine; chemoattractant receptor	TRANSPLANTATION; EXPRESSION; LEUKEMIA; IMPACT; MODEL	Graft-versus-host disease (GVHD) remains the major cause of mortality and morbidity in non-relapse patients after allogeneic hematopoietic cell transplantation (allo-HCT). As the number of patients undergoing allo-HCT increases, it will become imperative to determine safe and effective treatment options for patients with GVHD, especially those who become refractory to systemic steroid therapy. Daratumumab (Dara), a humanized IgG1 (kappa subclass) monoclonal antibody targeting the CD38 epitope, is used for the treatment of multiple myeloma. CD38 is a multifunctional ectoenzyme that behaves either as an enzyme, a cell adhesion molecule or a cell surface receptor involved in cell signaling. CD38 is also expressed on various immune effector and suppressor cells. However, the role of CD38 in the immune response remains elusive. We questioned whether CD38 is a potential therapeutic target against alloreactive T cells in the GVHD pathological process. Here, we investigated the impact of Dara on xenogeneic GVHD (xeno-GVHD) and graft-versus-leukemia (GVL) effects in a humanized murine model of transplantation, where human peripheral blood mononuclear cells were adoptively transplanted into immunocompromised NOD.SCID.gc-null (NSG) mice. Mice receiving Dara treatment experienced less weight loss, longer survival and lower GVHD scores compared with those in the control group. Histological evaluations, flow cytometry, RNA-sequencing and RT-qPCR analysis revealed that Dara efficaciously mitigated GVHD through multiple mechanisms including inhibition of the proliferation, activation and differentiation of CD8(+) cytotoxic T cells, reduced expression of cytotoxic effector molecules, pro-inflammatory cytokines, chemokines and chemoattractant receptors by T cells and promotion of immunosuppressive T cells. More importantly, Dara preserved the GVL effect in a humanized mouse model of leukemia by metabolic reprograming of T cells to promote the induction of Th17, Th1/17and Tc1/17 cells. Our findings indicate that Dara may be an attractive therapeutic option to separate GVHD from GVL effects in patients with hematopoietic malignancies receiving allo-HCT.	[Gao, Yang; Zhang, Jie; Zhou, Hongyu; Chen, Zhi; Xiao, Haowen] Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Hematol, Sch Med, Hangzhou, Peoples R China; [Shan, Wei; Gu, Tianning; Wu, Yibo; Li, Xiaoqing; Zeng, Xiangjun] Zhejiang Univ, Affiliated Hosp 1, Bone Marrow Transplantat Ctr, Sch Med, Hangzhou, Peoples R China; [Shan, Wei; Gu, Tianning; Wu, Yibo; Li, Xiaoqing; Zeng, Xiangjun] Zhejiang Univ, Liangzhu Lab, Med Ctr, Hangzhou, Peoples R China; [Shan, Wei; Gu, Tianning; Wu, Yibo; Li, Xiaoqing; Zeng, Xiangjun; Xiao, Haowen] Zhejiang Univ, Inst Hematol, Hangzhou, Peoples R China; [Shan, Wei; Gu, Tianning; Wu, Yibo; Li, Xiaoqing; Zeng, Xiangjun] Zhejiang Prov Engn Lab Stem Cell & Immun Therapy, Hangzhou, Peoples R China	Zhejiang University; Zhejiang University; Zhejiang University; Zhejiang University	Xiao, HW (corresponding author), Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Hematol, Sch Med, Hangzhou, Peoples R China.; Xiao, HW (corresponding author), Zhejiang Univ, Inst Hematol, Hangzhou, Peoples R China.	haowenxiaoxiao@zju.edu.cn		Gu, Tianning/0000-0003-1550-1011				Assi R, 2018, CURR OPIN HEMATOL, V25, P136, DOI 10.1097/MOH.0000000000000401; Ausiello CM, 1996, CELL IMMUNOL, V173, P192, DOI 10.1006/cimm.1996.0267; Axt L, 2019, BONE MARROW TRANSPL, V54, P1805, DOI 10.1038/s41409-019-0544-y; Bruck F, 2013, CYTOTHERAPY, V15, P267, DOI 10.1016/j.jcyt.2012.09.003; Burel JG, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005839; Burlion A, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00756; Casneuf T, 2017, BLOOD ADV, V1, P2105, DOI 10.1182/bloodadvances.2017006866; Chatterjee S, 2018, CELL METAB, V27, P85, DOI 10.1016/j.cmet.2017.10.006; Chen XC, 2013, BIOL BLOOD MARROW TR, V19, P28, DOI 10.1016/j.bbmt.2012.09.015; Cooke KR, 1996, BLOOD, V88, P3230, DOI 10.1182/blood.V88.8.3230.bloodjournal8883230; Cuende J, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa1983; Dal Collo G, 2020, STEM CELLS, V38, P698, DOI 10.1002/stem.3160; Deshpande DA, 2018, MEDIAT INFLAMM, V2018, DOI 10.1155/2018/8942042; Ehx G, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1314425; Golden-Mason L, 2000, HEPATOLOGY, V31, P1251, DOI 10.1053/jhep.2000.7713; Guerreiro S, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9020471; Hippen KL, 2012, BLOOD, V119, P619, DOI 10.1182/blood-2011-07-368027; Hogan KA, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01187; Horenstein AL, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.26246; Jing H, 2015, CHEM REV, V115, P2350, DOI 10.1021/cr500457h; Kar A, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9071716; Katsuyama E, 2020, CELL REP, V30, P112, DOI 10.1016/j.celrep.2019.12.014; Khandelwal P, 2020, BIOL BLOOD MARROW TR, V26, P1, DOI 10.1016/j.bbmt.2019.08.008; Khandelwal P, 2015, BIOL BLOOD MARROW TR, V21, P1215, DOI 10.1016/j.bbmt.2015.04.010; Klein-Hessling S, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00612-6; Krejcik J, 2017, CLIN CANCER RES, V23, P7498, DOI 10.1158/1078-0432.CCR-17-2027; Krejcik J, 2016, BLOOD, V128, P384, DOI 10.1182/blood-2015-12-687749; Lu C, 2012, CELL METAB, V16, P9, DOI 10.1016/j.cmet.2012.06.001; Malard F, 2020, LEUKEMIA, V34, P1229, DOI 10.1038/s41375-020-0804-2; Martelli MF, 2014, BLOOD, V124, P638, DOI 10.1182/blood-2014-03-564401; Naik J, 2019, HAEMATOLOGICA, V104, pE100, DOI 10.3324/haematol.2018.192757; Nikolaenko L, 2020, CL LYMPH MYELOM LEUK, V20, P407, DOI 10.1016/j.clml.2020.01.010; Ning LG, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/3950628; Partida-Sanchez S, 2001, NAT MED, V7, P1209, DOI 10.1038/nm1101-1209; Saenz L, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-171; Shallis RM, 2017, CANCER IMMUNOL IMMUN, V66, P697, DOI 10.1007/s00262-017-1990-2; Viegas MS, 2007, MICROBES INFECT, V9, P847, DOI 10.1016/j.micinf.2007.03.003; Xiao XY, 2020, J AUTOIMMUN, V108, DOI 10.1016/j.jaut.2020.102404; Yang XP, 2015, SCI REP-UK, V5, DOI 10.1038/srep10643; Zeiser R, 2006, BLOOD, V108, P390, DOI 10.1182/blood-2006-01-0329; Zeiser R, 2017, NEW ENGL J MED, V377, P2167, DOI 10.1056/NEJMra1609337	41	0	0	2	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 20	2021	12								785774	10.3389/fimmu.2021.785774	http://dx.doi.org/10.3389/fimmu.2021.785774			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YB2RM	34987512	Green Published, gold			2022-12-18	WOS:000738866100001
J	Kordelas, L; Claas, FHJ; Rebmann, V				Kordelas, Lambros; Claas, Frans H. J.; Rebmann, Vera			Editorial: "The Role of Immune Checkpoint Molecules in Solid and Hematopoietic Stem Cell Transplantation"	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						immune checkpoint molecules; hematopoietic stem cell transplantation; solid transplantation; tolerance; HLA			[Kordelas, Lambros] Univ Hosp Essen, Dept Hematol & Stem Cell Transplantat, Essen, Germany; [Claas, Frans H. J.] Leiden Univ, Med Ctr, Leiden, Netherlands; [Rebmann, Vera] Univ Hosp Essen, Inst Transfus Med, Essen, Germany	University of Duisburg Essen; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; University of Duisburg Essen	Kordelas, L (corresponding author), Univ Hosp Essen, Dept Hematol & Stem Cell Transplantat, Essen, Germany.	lambros.kordelas@uk-essen.de							0	0	0	4	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 20	2021	12								822558	10.3389/fimmu.2021.822558	http://dx.doi.org/10.3389/fimmu.2021.822558			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YB6WX	34987526	gold, Green Published			2022-12-18	WOS:000739151100001
J	Li, CW; Osman, R; Menconi, F; Faustino, LC; Kim, K; Clarke, OB; Hou, HX; Tomer, Y				Li, Cheuk Wun; Osman, Roman; Menconi, Francesca; Faustino, Larissa C.; Kim, Kookjoo; Clarke, Oliver B.; Hou, Hanxi; Tomer, Yaron			Cepharanthine Blocks Presentation of Thyroid and Islet Peptides in a Novel Humanized Autoimmune Diabetes and Thyroiditis Mouse Model	FRONTIERS IN IMMUNOLOGY			English	Article						autoimmune thyroiditis; type 1 diabetes; autoimmune polyglandular syndrome; cepharanthine; immune therapy	JOINT GENETIC SUSCEPTIBILITY; EPIDEMIOLOGY; ASSOCIATIONS; EXPRESSION; RESISTANCE; REVERSAL; DISEASE; CELLS	Autoimmune polyglandular syndrome type 3 variant (APS3v) refers to an autoimmune condition in which both type 1 diabetes (T1D) and autoimmune thyroiditis (AITD) develop in the same individual. HLA-DR3 confers the strongest susceptibility to APS3v. Previously we reported a unique amino acid signature pocket that predisposes to APS3v. We found that this pocket is flexible and can trigger APS3v by presenting both thyroid (Tg.1571, TPO.758) and islet (GAD.492) peptides to induce autoimmune response. We hypothesized that blocking the specific APS3v-HLA-DR3 pocket from presenting thyroid/islet antigens can block the autoimmune response in APS3v. To test this hypothesis we performed a virtual screen of small molecules blocking APS3v-HLA-DR3, and identified 11 small molecules hits that were predicted to block APS3v-HLA-DR3. Using the baculovirus-produced recombinant APS3v-HLA-DR3 protein we tested the 11 small molecules in an in vitro binding assay. We validated 4 small molecule hits, S9, S5, S53 and S15, that could block the APS3v-HLA-DR3 pocket in vitro. We then developed a novel humanized APS3v mouse model induced by co-immunizing a peptide mix of Tg.1571, TPO.758 and GAD.492. The immunized mice developed strong T-cell and antibody responses to the thyroid/islet peptides, as well as mouse thyroglobulin. In addition, the mice showed significantly lower free T4 levels compared to controls. Using the APS3v mouse model, we showed that one of the 4 small molecules, Cepharanthine (S53), blocked T-cell activation by thyroid/islet peptides ex vivo and in vivo. These findings suggested Cepharanthine may have a therapeutic potential in APS3v patients carrying the specific APS3v-HLA-DR3 pocket.	[Li, Cheuk Wun; Faustino, Larissa C.; Hou, Hanxi; Tomer, Yaron] Albert Einstein Coll Med, Dept Med, Fleischer Inst Diabet & Metab, New York, NY 10461 USA; [Osman, Roman] Icahn Sch Med Mt Sinai, Dept Pharmacol Sci, New York, NY 10029 USA; [Menconi, Francesca] Univ Pisa, Endocrinol Unit, Pisa, Italy; [Kim, Kookjoo; Clarke, Oliver B.] Columbia Univ, Dept Anesthesiol, New York, NY USA; [Kim, Kookjoo; Clarke, Oliver B.] Columbia Univ, Dept Physiol, New York, NY 10027 USA	Yeshiva University; Icahn School of Medicine at Mount Sinai; University of Pisa; Columbia University; Columbia University	Tomer, Y (corresponding author), Albert Einstein Coll Med, Dept Med, Fleischer Inst Diabet & Metab, New York, NY 10461 USA.	ytomer@montefiore.org	Tomer, Yaron/GWU-8933-2022		NIDDK [DK067555, DK073681]; American Thyroid Association	NIDDK(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); American Thyroid Association	This work was supported in part by grants DK067555 and DK073681 from NIDDK (to YT) and by a research grant from the American Thyroid Association (to CL).	Bailly C, 2019, PHYTOMEDICINE, V62, DOI 10.1016/j.phymed.2019.152956; Betterle Corrado, 2003, Acta Biomed, V74, P9; CHICZ RM, 1993, J EXP MED, V178, P27, DOI 10.1084/jem.178.1.27; Dittmar M, 2010, THYROID, V20, P737, DOI 10.1089/thy.2010.1639; Ebina T, 1990, Gan To Kagaku Ryoho, V17, P1165; EDASHIGE K, 1991, BIOCHEM PHARMACOL, V41, P71, DOI 10.1016/0006-2952(91)90012-T; Eisenbarth GS, 2004, NEW ENGL J MED, V350, P2068, DOI 10.1056/NEJMra030158; Flesch BK, 2014, J CLIN ENDOCR METAB, V99, pE177, DOI 10.1210/jc.2013-2852; Friesner RA, 2006, J MED CHEM, V49, P6177, DOI 10.1021/jm051256o; FUJIMURA T, 1990, JPN J PHARMACOL, V54, P464, DOI 10.1254/jjp.54.464; Furusawa S, 2007, LIFE SCI, V80, P1073, DOI 10.1016/j.lfs.2006.12.001; Golden B, 2005, J CLIN ENDOCR METAB, V90, P4904, DOI 10.1210/jc.2004-2236; Gough SCL, 2007, CURR GENOMICS, V8, P453, DOI 10.2174/138920207783591690; Harada K, 2009, INT J ONCOL, V35, P1025, DOI 10.3892/ijo_00000417; Howson JMM, 2011, DIABETES, V60, P2645, DOI 10.2337/db11-0364; Huber A, 2008, ENDOCR REV, V29, P697, DOI 10.1210/er.2008-0015; Jacobson DL, 1997, CLIN IMMUNOL IMMUNOP, V84, P223, DOI 10.1006/clin.1997.4412; Jacobson EM, 2009, J BIOL CHEM, V284, P34231, DOI 10.1074/jbc.M109.041574; Jenkins RC, 2002, THYROID, V12, P977, DOI 10.1089/105072502320908312; Johnson SB, 2021, DIABETOLOGIA, V64, P591, DOI 10.1007/s00125-020-05344-9; Karvonen M, 2000, DIABETES CARE, V23, P1516, DOI 10.2337/diacare.23.10.1516; Kimoto T, 1997, Nihon Geka Hokan, V66, P71; KOHNO H, 1986, FOLIA PHARMACOL JPN, V88, P71, DOI 10.1254/fpj.88.71; KOHNO H, 1987, FOLIA PHARMACOL JPN, V90, P205, DOI 10.1254/fpj.90.205; Kong YM, 1997, IMMUNOGENETICS, V46, P312, DOI 10.1007/s002510050277; Krischer JP, 2017, DIABETES CARE, V40, P1194, DOI 10.2337/dc17-0238; Krischer JP, 2015, DIABETOLOGIA, V58, P980, DOI 10.1007/s00125-015-3514-y; Li CW, 2020, J AUTOIMMUN, V108, DOI 10.1016/j.jaut.2020.102402; Li CW, 2017, J AUTOIMMUN, V76, P1, DOI 10.1016/j.jaut.2016.09.007; Li CW, 2016, J BIOL CHEM, V291, P4079, DOI 10.1074/jbc.M115.694687; Lombardi A, 2020, J AUTOIMMUN, V115, DOI 10.1016/j.jaut.2020.102543; Menconi F, 2008, P NATL ACAD SCI USA, V105, P14034, DOI 10.1073/pnas.0806584105; Menconi F, 2010, P NATL ACAD SCI USA, V107, P16899, DOI 10.1073/pnas.1009511107; Morita K, 2002, J DERMATOL, V29, P661, DOI 10.1111/j.1346-8138.2002.tb00199.x; Mukai M, 2003, CANCER SCI, V94, P557, DOI 10.1111/j.1349-7006.2003.tb01482.x; Niwa Y, 1969, Hifuka Kiyo, V64, P47; Ohta T, 1990, Rinsho Hoshasen, V35, P471; Ostrov DA, 2018, J CLIN INVEST, V128, P1888, DOI 10.1172/JCI97739; Regnell SE, 2017, DIABETOLOGIA, V60, P1370, DOI 10.1007/s00125-017-4308-1; Rogosnitzky M, 2011, PHARMACOL REP, V63, P337, DOI 10.1016/S1734-1140(11)70500-X; Saito R, 1989, Nihon Gan Chiryo Gakkai Shi, V24, P2587; Suzuki R, 1992, Gan To Kagaku Ryoho, V19, P647; Tabata R, 2012, INT IMMUNOPHARMACOL, V13, P242, DOI 10.1016/j.intimp.2012.04.015; Tomer Y, 2015, J AUTOIMMUN, V60, P32, DOI 10.1016/j.jaut.2015.03.006; Ushiki N, 1988, Gan To Kagaku Ryoho, V15, P2701; Villano MJB, 2009, J CLIN ENDOCR METAB, V94, P1458, DOI 10.1210/jc.2008-2193; Yamazaki T, 2017, PEDIATR INT, V59, P303, DOI 10.1111/ped.13151	47	0	0	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 20	2021	12								796552	10.3389/fimmu.2021.796552	http://dx.doi.org/10.3389/fimmu.2021.796552			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YB2MJ	34987519	Green Published, gold			2022-12-18	WOS:000738852800001
J	Mellinghoff, SC; Vanshylla, K; Dahlke, C; Addo, MM; Cornely, OA; Klein, F; Persigehl, T; Rybniker, J; Gruell, H; Brockelmann, PJ				Mellinghoff, Sibylle C.; Vanshylla, Kanika; Dahlke, Christine; Addo, Marylyn M.; Cornely, Oliver A.; Klein, Florian; Persigehl, Thorsten; Rybniker, Jan; Gruell, Henning; Broeckelmann, Paul J.			Case Report: Clinical Management of a Patient With Metastatic Non-Small Cell Lung Cancer Newly Receiving Immune Checkpoint Inhibition During Symptomatic COVID-19	FRONTIERS IN IMMUNOLOGY			English	Article						SARS-CoV-2; COVID-19; NSCLC; anti-PD1; immune checkpoint; immunotherapy; pneumonitis		Effects of initiation of programmed-death-protein 1 (PD1) blockade during active SARS-CoV-2 infection on antiviral immunity, COVID-19 course, and underlying malignancy are unclear. We report on the management of a male in his early 40s presenting with highly symptomatic metastatic lung cancer and active COVID-19 pneumonia. After treatment initiation with pembrolizumab, carboplatin, and pemetrexed, the respiratory situation initially worsened and high-dose corticosteroids were initiated due to suspected pneumonitis. After improvement and SARS-CoV-2 clearance, anti-cancer treatment was resumed without pembrolizumab. Immunological analyses with comparison to otherwise healthy SARS-CoV-2-infected ambulatory patients revealed a strong humoral immune response with higher levels of SARS-CoV-2-reactive IgG and neutralizing serum activity. Additionally, sustained increase of Tfh as well as activated CD4(+) and CD8(+) T cells was observed. Sequential CT scans showed regression of tumor lesions and marked improvement of the pulmonary situation, with no signs of pneumonitis after pembrolizumab re-challenge as maintenance. At the latest follow-up, the patient is ambulatory and in ongoing partial remission on pembrolizumab. In conclusion, anti-PD1 initiation during active COVID-19 pneumonia was feasible and cellular and humoral immune responses to SARS-CoV-2 appeared enhanced in our hospitalized patient. However, distinguishing COVID-19-associated changes from anti-PD1-associated immune-related pneumonitis posed a considerable clinical, radiographic, and immunologic challenge.	[Mellinghoff, Sibylle C.; Cornely, Oliver A.; Rybniker, Jan; Broeckelmann, Paul J.] Univ Cologne, Fac Med, Cologne, Germany; [Mellinghoff, Sibylle C.; Cornely, Oliver A.; Rybniker, Jan; Broeckelmann, Paul J.] Univ Cologne, Univ Hosp Cologne, Dept Internal Med 1, Ctr Integrated Oncol Aachen Bonn Cologne Dusseldo, Cologne, Germany; [Mellinghoff, Sibylle C.; Cornely, Oliver A.] Univ Cologne, Cologne Cluster Excellence Cellular Stress Respon, Cologne, Germany; [Mellinghoff, Sibylle C.; Cornely, Oliver A.; Klein, Florian] Partner Site BonnCologne, German Ctr Infect Res DZIF, Cologne, Germany; [Mellinghoff, Sibylle C.; Dahlke, Christine; Addo, Marylyn M.] Bernhard Nocht Inst Trop Med, Dept Clin Immunol Infect Dis, Hamburg, Germany; [Vanshylla, Kanika; Klein, Florian; Gruell, Henning] Univ Cologne, Inst Virol, Fac Med, Cologne, Germany; [Vanshylla, Kanika; Klein, Florian; Gruell, Henning] Univ Cologne, Univ Hosp Cologne, Cologne, Germany; [Dahlke, Christine; Addo, Marylyn M.] Univ Med Ctr Hamburg Eppendorf, Dept Med 1, Div Infect Dis, Hamburg, Germany; [Dahlke, Christine; Addo, Marylyn M.] Partner Site Hamburg Lubeck Borstel Riems, German Ctr Infect Res DZIF, Hamburg, Germany; [Cornely, Oliver A.] Clin Trials Ctr Cologne ZKS Koln, Cologne, Germany; [Klein, Florian] Univ Cologne, Ctr Mol Med Cologne CMMC, Cologne, Germany; [Persigehl, Thorsten] Univ Cologne, Fac Med, Inst Diagnost & Intervent Radiol, Cologne, Germany; [Persigehl, Thorsten] Univ Cologne, Univ Hosp Cologne, Cologne, Germany; [Broeckelmann, Paul J.] MaxPlanck Inst Biol Ageing, Cologne, Germany; [Broeckelmann, Paul J.] Aachen Bonn Cologne Dusseldorf, MildredScheel Sch Oncol MSSO, Cologne, Germany	University of Cologne; University of Cologne; University of Cologne; German Center for Infection Research; University of Cologne; Bernhard Nocht Institut fur Tropenmedizin; University of Cologne; University of Cologne; University of Hamburg; University Medical Center Hamburg-Eppendorf; German Center for Infection Research; University of Cologne; University of Cologne; University of Cologne; University of Cologne	Brockelmann, PJ (corresponding author), Univ Cologne, Fac Med, Cologne, Germany.; Brockelmann, PJ (corresponding author), Univ Cologne, Univ Hosp Cologne, Dept Internal Med 1, Ctr Integrated Oncol Aachen Bonn Cologne Dusseldo, Cologne, Germany.; Brockelmann, PJ (corresponding author), MaxPlanck Inst Biol Ageing, Cologne, Germany.; Brockelmann, PJ (corresponding author), Aachen Bonn Cologne Dusseldorf, MildredScheel Sch Oncol MSSO, Cologne, Germany.	paul.broeckelmann@uk-koeln.de	Cornely, Oliver A./J-5095-2013; Mellinghoff, Sibylle/H-8105-2019; Addo, Marylyn M./GNP-2548-2022	Cornely, Oliver A./0000-0001-9599-3137; Mellinghoff, Sibylle/0000-0003-3928-2503; Grull, Henning/0000-0002-0725-7138; Vanshylla, Kanika/0000-0003-4552-9170; Dahlke, Christine/0000-0002-2056-9195	Mildred Scheel School of Oncology (MSSO 202 Postgraduate Program, German Cancer Aid) [70113307]	Mildred Scheel School of Oncology (MSSO 202 Postgraduate Program, German Cancer Aid)	SM is supported by a DZIF clinical leave stipend and PB is supported by the Mildred Scheel School of Oncology (MSSO 202 Postgraduate Program, German Cancer Aid, Grant No. 70113307).	Abdul-Jawad S, 2021, CANCER CELL, V39, P257, DOI 10.1016/j.ccell.2021.01.001; Diao B, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00827; Giesen N, 2020, EUR J CANCER, V140, P86, DOI 10.1016/j.ejca.2020.09.009; Koch T, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030238; Luo J, 2020, CANCER DISCOV, V10, P1121, DOI 10.1158/2159-8290.CD-20-0596; Masia M, 2021, OPEN FORUM INFECT DI, V8, DOI 10.1093/ofid/ofab005; Moore JB, 2020, SCIENCE, V368, P473, DOI 10.1126/science.abb8925; Sullivan RJ, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-000933; Vanshylla K, 2021, CELL HOST MICROBE, V29, P917, DOI 10.1016/j.chom.2021.04.015; Wang YQ, 2020, J CLIN INVEST, V130, P5235, DOI [10.1172/JCI138759, 10.1172/JCI138759.]; Yatim N, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abg4081	11	0	0	1	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 20	2021	12								798276	10.3389/fimmu.2021.798276	http://dx.doi.org/10.3389/fimmu.2021.798276			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YB2OG	34987520	Green Published, gold			2022-12-18	WOS:000738857700001
J	Nguyen, HCB; Chao, TN; Cohen, NA; Mirza, N				Nguyen, Hoang C. B.; Chao, Tiffany N.; Cohen, Noam A.; Mirza, Natasha			Persistent Inflammation and Nitric Oxide Dysregulation Are Transcriptomic Blueprints of Subglottic Stenosis	FRONTIERS IN IMMUNOLOGY			English	Article						subglottic stenosis; mucosal swab; transcriptomic profiling; granulomatous disease; nitric oxide	SET ENRICHMENT ANALYSIS; MECHANISMS; EXPRESSION; OXIDANTS	Subglottic stenosis (SGS) is a recurrent, obstructive, fibroinflammatory disease of the upper airway resulting in severe dyspnea, dysphonia, as well as other potentially fatal complications. Although aberrant inflammation and wound-healing are commonly associated with pathogenesis, the mechanism through which such processes occur and recur in affected patients remains poorly studied. Here we report that transcriptomic profiling of laryngotracheal regions from minimally-invasive mucosal swabs of SGS patients reveals a distinctively pro-inflammatory gene signature. Surprisingly, comparative genomics between SGS patients and mice with direct laryngotracheal injury suggest that SGS patients bear more resemblance to the acute than chronic phase of injury. Furthermore, functional and regulatory network analyses identify neutrophilic involvement through hyper-activation of NF-kappa B and its downstream inflammasome as a potential master regulator. Interestingly, nitric oxide synthesis was found to be downregulated in SGS patients compared to healthy controls. Thus, SGS represents a state of immunodeficiency whereby defective immune clearance triggers recurrent, long-lasting production of pro-inflammatory cytokines.	[Nguyen, Hoang C. B.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA; [Chao, Tiffany N.; Cohen, Noam A.; Mirza, Natasha] Univ Penn, Dept Otorhinolaryngol, Head & Neck Surg, Philadelphia, PA 19104 USA; [Chao, Tiffany N.; Cohen, Noam A.; Mirza, Natasha] Philadelphia Vet Affairs Med Ctr, Div Otolaryngol, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Philadelphia Veterans Affairs Medical Center	Mirza, N (corresponding author), Univ Penn, Dept Otorhinolaryngol, Head & Neck Surg, Philadelphia, PA 19104 USA.; Mirza, N (corresponding author), Philadelphia Vet Affairs Med Ctr, Div Otolaryngol, Philadelphia, PA 19104 USA.	natasha.mirza@pennmedicine.upenn.edu		Chao, Tiffany/0000-0003-1963-0275; Bui Nguyen, Hoang/0000-0001-6975-3084				Bertelsen C, 2018, JAMA OTOLARYNGOL, V144, P203, DOI 10.1001/jamaoto.2017.2800; Branski RC, 2004, ANN OTO RHINOL LARYN, V113, P23, DOI 10.1177/000348940411300105; D'Autreaux B, 2007, NAT REV MOL CELL BIO, V8, P813, DOI 10.1038/nrm2256; Dahlgren C, 2019, J IMMUNOL, V202, P3127, DOI 10.4049/jimmunol.1900235; Davis RJ, 2021, OTOLARYNG HEAD NECK, V164, P1257, DOI 10.1177/0194599820978271; Davis RJ, 2021, LARYNGOSCOPE, V131, P967, DOI 10.1002/lary.28790; Devadoss D, 2021, MUCOSAL IMMUNOL, V14, P630, DOI 10.1038/s41385-020-00352-9; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Erdman SE, 2009, P NATL ACAD SCI USA, V106, P1027, DOI 10.1073/pnas.0812347106; Flannagan RS, 2009, NAT REV MICROBIOL, V7, P355, DOI 10.1038/nrmicro2128; Fonseca GJ, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08236-0; Gelbard A, 2021, LARYNGOSCOPE, V131, P610, DOI 10.1002/lary.28840; Gelbard A, 2020, JAMA OTOLARYNGOL, V146, P20, DOI 10.1001/jamaoto.2019.3022; Gelbard A, 2015, LARYNGOSCOPE, V125, P1137, DOI 10.1002/lary.24956; Ghosh A, 2013, OTOLARYNG HEAD NECK, V148, P284, DOI 10.1177/0194599812466533; Ghosh A, 2011, OTOLARYNG HEAD NECK, V144, P927, DOI 10.1177/0194599810397750; Haft S, 2014, ANN OTO RHINOL LARYN, V123, P65, DOI 10.1177/0003489414521146; Han H, 2018, NUCLEIC ACIDS RES, V46, pD380, DOI 10.1093/nar/gkx1013; He Y, 2016, TRENDS BIOCHEM SCI, V41, P1012, DOI 10.1016/j.tibs.2016.09.002; Hillel AT, 2019, MSPHERE, V4, DOI 10.1128/mSphereDirect.00211-19; Ichinose F, 2004, CIRCULATION, V109, P3106, DOI 10.1161/01.CIR.0000134595.80170.62; Ji Z, 2019, P NATL ACAD SCI USA, V116, P9453, DOI 10.1073/pnas.1821068116; Kuleshov MV, 2016, NUCLEIC ACIDS RES, V44, pW90, DOI 10.1093/nar/gkw377; Li Y, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8060576; Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656; LIU HP, 1995, PEDIATR PATHOL LAB M, V15, P655, DOI 10.3109/15513819509027004; Liu MM, 2021, LARYNGOSCOPE, V131, P342, DOI 10.1002/lary.28712; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Miller CHT, 2009, ANN NY ACAD SCI, V1182, P69, DOI 10.1111/j.1749-6632.2009.05069.x; Mishra BB, 2017, NAT MICROBIOL, V2, DOI 10.1038/nmicrobiol.2017.72; Mittal M, 2014, ANTIOXID REDOX SIGN, V20, P1126, DOI 10.1089/ars.2012.5149; Nguyen HCB, 2020, NATURE, V584, P286, DOI 10.1038/s41586-020-2576-2; Olivera GC, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005442; Paul-Clark MJ, 2001, J IMMUNOL, V166, P1169, DOI 10.4049/jimmunol.166.2.1169; Puyo CA, 2012, ARCH OTOLARYNGOL, V138, P854, DOI 10.1001/archoto.2012.1746; Schett G, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05800-6; Scioscia KA, 1996, ANN OTO RHINOL LARYN, V105, P936, DOI 10.1177/000348949610501202; Sharma J. N., 2007, Inflammopharmacology, V15, P252, DOI 10.1007/s10787-007-0013-x; Song R, 2021, CELL REP, V34, DOI 10.1016/j.celrep.2021.108891; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tessari P, 2010, DIABETES, V59, P2152, DOI 10.2337/db09-1772; Trevelin SC, 2020, IMMUNOL LETT, V221, P39, DOI 10.1016/j.imlet.2020.02.009; Yang KC, 2015, CIRC RES, V116, P1937, DOI 10.1161/CIRCRESAHA.116.304691; Yang YH, 2013, INT REV IMMUNOL, V32, P249, DOI 10.3109/08830185.2012.755176; Yu HH, 2021, CLIN REV ALLERG IMMU, V61, P101, DOI 10.1007/s12016-020-08800-x; Yu JE, 2018, J PEDIAT INF DIS SOC, V7, pS6, DOI 10.1093/jpids/piy007	46	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 20	2021	12								748533	10.3389/fimmu.2021.748533	http://dx.doi.org/10.3389/fimmu.2021.748533			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YA9MT	34987502	Green Published, gold			2022-12-18	WOS:000738649500001
J	Picton, ACP; Paximadis, M; Koor, GW; Bharuthram, A; Shalekoff, S; Lassauniere, R; Ive, P; Tiemessen, CT				Picton, Anabela C. P.; Paximadis, Maria; Koor, Gemma W.; Bharuthram, Avani; Shalekoff, Sharon; Lassauniere, Ria; Ive, Prudence; Tiemessen, Caroline T.			Reduced CCR5 Expression and Immune Quiescence in Black South African HIV-1 Controllers	FRONTIERS IN IMMUNOLOGY			English	Article						HIV-1 control; CCR5 expression; immune activation; CCR5 ligands; IL-10	IMMUNODEFICIENCY-VIRUS TYPE-1; T-LYMPHOCYTE ACTIVATION; SERUM CHEMOKINE LEVELS; BETA-CHEMOKINES; DISEASE PROGRESSION; PLASMA-LEVELS; CELL SUBSETS; SOLUBLE CD14; INFECTION; SUSCEPTIBILITY	Unique Individuals who exhibit either suppressive HIV-1 control, or the ability to maintain low viral load set-points and preserve their CD4+ T cell counts for extended time periods in the absence of antiretroviral therapy, are broadly termed HIV-1 controllers. We assessed the extent to which black South African controllers (n=9), differ from uninfected healthy controls (HCs, n=22) in terms of lymphocyte and monocyte CCR5 expression (density and frequency of CCR5-expressing cells), immune activation as well as peripheral blood mononuclear cell (PBMC) mitogen-induced chemokine/cytokine production. In addition, relative CD4+ T cell CCR5 mRNA expression was assessed in a larger group of controllers (n=20) compared to HCs (n=10) and HIV-1 progressors (n=12). Despite controllers having significantly higher frequencies of activated CD4+ and CD8+ T cells (HLA-DR+) compared to HCs, CCR5 density was significantly lower in these T cell populations (P=0.039 and P=0.064, respectively). This lower CCR5 density was largely attributable to controllers with higher VLs (>400 RNA copies/ml). Significantly lower CD4+ T cell CCR5 density in controllers was maintained (P=0.036) when HCs (n=12) and controllers (n=9) were matched for age. CD4+ T cell CCR5 mRNA expression was significantly less in controllers compared to HCs (P=0.007) and progressors (P=0.002), whereas HCs and progressors were similar (P=0.223). The levels of soluble CD14 in plasma did not differ between controllers and HCs, suggesting no demonstrable monocyte activation. While controllers had lower monocyte CCR5 density compared to the HCs (P=0.02), significance was lost when groups were age-matched (P=0.804). However, when groups were matched for both CCR5 promoter haplotype and age (n=6 for both) reduced CCR5 density on monocytes in controllers relative to HCs was highly significant (P=0.009). Phytohemagglutinin-stimulated PBMCs from the controllers produced significantly less CCL3 (P=0.029), CCL4 (P=0.008) and IL-10 (P=0.028) compared to the HCs, which was largely attributable to the controllers with lower VLs (<400 RNA copies/ml). Our findings support a hypothesis of an inherent (genetic) predisposition to lower CCR5 expression in individuals who naturally control HIV-1, as has been suggested for Caucasian controllers, and thus, likely involves a mechanism shared between ethnically divergent population groups.	[Picton, Anabela C. P.; Paximadis, Maria; Koor, Gemma W.; Bharuthram, Avani; Shalekoff, Sharon; Tiemessen, Caroline T.] Natl Inst Communicable Dis, Ctr HIV & STIs, Johannesburg, South Africa; [Paximadis, Maria; Koor, Gemma W.; Bharuthram, Avani; Shalekoff, Sharon; Ive, Prudence; Tiemessen, Caroline T.] Univ Witwatersrand, Sch Pathol, Dept Virol, Fac Hlth Sci, Johannesburg, South Africa; [Lassauniere, Ria] Statens Serum Inst, Dept Virus & Microbiol Special Diagnost, Virus Res & Dev Lab, Copenhagen, Denmark; [Ive, Prudence] Univ Witwatersrand, Sch Clin Med, Dept Internal Med, Clin HIV Res Unit, Johannesburg, South Africa	National Institute for Communicable Diseases (NICD); University of Witwatersrand; Statens Serum Institut; University of Witwatersrand	Paximadis, M (corresponding author), Natl Inst Communicable Dis, Ctr HIV & STIs, Johannesburg, South Africa.; Paximadis, M (corresponding author), Univ Witwatersrand, Sch Pathol, Dept Virol, Fac Hlth Sci, Johannesburg, South Africa.	paxim@nicd.ac.za						1000 Genomes Project Consortium, 2015, Nature, V526, P68, DOI 10.1038/nature15393; Alexander L, 2000, J VIROL, V74, P4361, DOI 10.1128/JVI.74.9.4361-4376.2000; Amella CA, 2005, J VIROL, V79, P5625, DOI 10.1128/JVI.79.9.5625-5631.2005; Blankson JN, 2007, J VIROL, V81, P2508, DOI 10.1128/JVI.02165-06; Brockman MA, 2009, BLOOD, V114, P346, DOI 10.1182/blood-2008-12-191296; Camargo JF, 2009, J IMMUNOL, V182, P171, DOI 10.4049/jimmunol.182.1.171; Card CM, 2012, JAIDS-J ACQ IMM DEF, V59, P427, DOI 10.1097/QAI.0b013e3182454fcd; Clerici M, 1996, AIDS RES HUM RETROV, V12, P1053, DOI 10.1089/aid.1996.12.1053; CLERICI M, 1994, J CLIN INVEST, V93, P768, DOI 10.1172/JCI117031; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Cohen OJ, 1998, J VIROL, V72, P6215, DOI 10.1128/JVI.72.7.6215-6217.1998; Contento RL, 2008, P NATL ACAD SCI USA, V105, P10101, DOI 10.1073/pnas.0804286105; Dolan MJ, 2007, NAT IMMUNOL, V8, P1324, DOI 10.1038/ni1521; Garzino-Demo A, 1999, P NATL ACAD SCI USA, V96, P11986, DOI 10.1073/pnas.96.21.11986; GIORGI JV, 1993, J ACQ IMMUN DEF SYND, V6, P904; Giorgi JV, 1999, J INFECT DIS, V179, P859, DOI 10.1086/314660; Gonzalez E, 2005, SCIENCE, V307, P1434, DOI 10.1126/science.1101160; Gonzalez E, 1999, P NATL ACAD SCI USA, V96, P12004, DOI 10.1073/pnas.96.21.12004; Gonzalo-Gil E, 2019, ELIFE, V8, DOI 10.7554/eLife.44360; Gornalusse GG, 2015, P NATL ACAD SCI USA, V112, pE4762, DOI 10.1073/pnas.1423228112; Govender Y, 2021, CLIN IMMUNOL, V230, DOI 10.1016/j.clim.2021.108824; Hazenberg MD, 2003, AIDS, V17, P1881, DOI 10.1097/00002030-200309050-00006; Kakkanaiah VN, 1998, CLIN DIAGN LAB IMMUN, V5, P499, DOI 10.1128/CDLI.5.4.499-502.1998; KIRCHHOFF F, 1995, NEW ENGL J MED, V332, P228, DOI 10.1056/NEJM199501263320405; Koor GW, 2019, CLIN IMMUNOL, V205, P16, DOI 10.1016/j.clim.2019.05.009; Krowka JF, 1997, CLIN IMMUNOL IMMUNOP, V85, P21, DOI 10.1006/clin.1997.4411; Kwon DS, 2010, EUR CYTOKINE NETW, V21, P208, DOI 10.1684/ecn.2010.0201; Lama J, 2007, RETROVIROLOGY, V4, DOI 10.1186/1742-4690-4-52; Lamine A, 2007, AIDS, V21, P1043, DOI 10.1097/QAD.0b013e3280d5a7ac; Landay AL, 1996, J INFECT DIS, V173, P1085, DOI 10.1093/infdis/173.5.1085; LEARMONT J, 1992, LANCET, V340, P863, DOI 10.1016/0140-6736(92)93281-Q; Lederman MM, 2011, J INFECT DIS, V204, P1217, DOI 10.1093/infdis/jir507; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; Locher CP, 2005, J GEN VIROL, V86, P1171, DOI 10.1099/vir.0.80674-0; Mamtani M, 2011, J INFECT DIS, V203, P1590, DOI 10.1093/infdis/jir145; Marchetti G, 2011, AIDS, V25, P1385, DOI 10.1097/QAD.0b013e3283471d10; McKenzie SW, 1996, AIDS, V10, pF29, DOI 10.1097/00002030-199610090-00001; Meddows-Taylor S, 2006, J GEN VIROL, V87, P2055, DOI 10.1099/vir.0.81709-0; Meditz AL, 2011, J VIROL, V85, P10189, DOI 10.1128/JVI.02529-10; Metzemaekers M, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00483; Molon B, 2005, NAT IMMUNOL, V6, P465, DOI 10.1038/ni1191; Moriuchi H, 1997, J IMMUNOL, V159, P5441; Naicker DD, 2012, CLIN INFECT DIS, V54, P294, DOI 10.1093/cid/cir811; Naicker DD, 2009, J INFECT DIS, V200, P448, DOI 10.1086/600072; Naif HM, 1998, J VIROL, V72, P830, DOI 10.1128/JVI.72.1.830-836.1998; Nicholson JKA, 2001, J ACQ IMMUN DEF SYND, V27, P105, DOI 10.1097/00126334-200106010-00002; Novembre J, 2005, PLOS BIOL, V3, P1954, DOI 10.1371/journal.pbio.0030339; Ostrowski MA, 1998, J IMMUNOL, V161, P3195; Paiardini M, 2009, ANNU REV MED, V60, P485, DOI 10.1146/annurev.med.60.041807.123753; Pereyra F, 2008, J INFECT DIS, V197, P563, DOI 10.1086/526786; Picton ACP, 2013, INFECT GENET EVOL, V14, P347, DOI 10.1016/j.meegid.2012.12.016; Picton ACP, 2012, IMMUNOGENETICS, V64, P795, DOI 10.1007/s00251-012-0642-0; Picton ACP, 2012, IMMUNOLOGY, V136, P397, DOI 10.1111/j.1365-2567.2012.03592.x; Picton ACP, 2010, INFECT GENET EVOL, V10, P487, DOI 10.1016/j.meegid.2010.02.012; Polo S, 1999, AIDS, V13, P447, DOI 10.1097/00002030-199903110-00002; Poropatich K, 2011, J GEN VIROL, V92, P247, DOI 10.1099/vir.0.027102-0; Portales P, 2012, IMMUNOLOGY, V137, P89, DOI 10.1111/j.1365-2567.2012.03609.x; Potter SJ, 2007, J VIROL, V81, P13904, DOI 10.1128/JVI.01401-07; Reynes J, 2000, J INFECT DIS, V181, P927, DOI 10.1086/315315; Reynes J, 2001, AIDS, V15, P1627, DOI 10.1097/00002030-200109070-00004; Sabin CA, 2013, CURR OPIN HIV AIDS, V8, P311, DOI 10.1097/COH.0b013e328361fa66; Sandler NG, 2011, J INFECT DIS, V203, P780, DOI 10.1093/infdis/jiq118; Shalekoff S, 2001, J CLIN IMMUNOL, V21, P390, DOI 10.1023/A:1013121625962; Shostakovich-Koretskaya L, 2009, AIDS, V23, P679, DOI 10.1097/QAD.0b013e3283270b3f; Smith MW, 1997, SCIENCE, V277, P959, DOI 10.1126/science.277.5328.959; Stephens JC, 1998, AM J HUM GENET, V62, P1507, DOI 10.1086/301867; Stewart GJ, 1997, AIDS, V11, P1833, DOI 10.1097/00002030-199715000-00007; Stylianou E, 1999, CLIN EXP IMMUNOL, V116, P115; Taub DD, 1996, J IMMUNOL, V156, P2095; Thiebaut R, 2012, CLIN INFECT DIS, V55, P1417, DOI 10.1093/cid/cis708; Trkola A, 1998, J VIROL, V72, P396, DOI 10.1128/JVI.72.1.396-404.1998; Tuttle DL, 1998, J VIROL, V72, P4962, DOI 10.1128/JVI.72.6.4962-4969.1998; Uitenbrook D.G., 1997, SISA BINOMIAL; Ullum H, 1998, J INFECT DIS, V177, P331, DOI 10.1086/514192; UNAIDS, 2019, UNAIDS DAT 2019; Wu LJ, 1997, J EXP MED, V185, P1681, DOI 10.1084/jem.185.9.1681; Ye P, 2004, J LAB CLIN MED, V143, P310, DOI 10.1016/j.lab.2004.01.012; Zou WP, 2000, J IMMUNOL, V165, P4388, DOI 10.4049/jimmunol.165.8.4388	78	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 20	2021	12								781263	10.3389/fimmu.2021.781263	http://dx.doi.org/10.3389/fimmu.2021.781263			18	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YA9JE	34987508	gold, Green Published			2022-12-18	WOS:000738639900001
J	Romaru, J; Bahuaud, M; Lejeune, G; Hentzien, M; Berger, JL; Robbins, A; Lebrun, D; N'Guyen, Y; Bani-Sadr, F; Batteux, F; Servettaz, A				Romaru, Juliette; Bahuaud, Mathilde; Lejeune, Gauthier; Hentzien, Maxime; Berger, Jean-Luc; Robbins, Ailsa; Lebrun, Delphine; N'Guyen, Yohan; Bani-Sadr, Firouze; Batteux, Frederic; Servettaz, Amelie			Single-Dose 13-Valent Conjugate Pneumococcal Vaccine in People Living With HIV - Immunological Response and Protection	FRONTIERS IN IMMUNOLOGY			English	Article						HIV infection; pneumococcal conjugate vaccine (PCV); immunogenicity; immunological protection; immunological response; France; cohort study	ACTIVE ANTIRETROVIRAL THERAPY; POLYSACCHARIDE VACCINE; INFECTED ADULTS; ANTIBODY-RESPONSES; AMERICAN-ACADEMY; IMMUNE-RESPONSE; TRIAL; IMMUNODEFICIENCY; IMMUNOGENICITY; ERA	BackgroundPatients living with HIV (PLHIV) are prone to invasive pneumococcal disease. The 13-valent conjugated pneumococcal vaccine (PCV13) is currently recommended for all PLHIV, followed in most guidelines by a 23-valent polysaccharide pneumococcal vaccine. Data are scarce concerning the immunological efficacy of PCV13 among PLHIV. ObjectiveTo assess the immunological response at one month, and the immunological protection at 1-, 6-, and 12 months in PLHIV with a CD4 cell count above 200 cells/mu l after a single dose of PCV13, as measured by both ELISA and opsonophagocytic assay (OPA). MethodsPLHIV with CD4 cell count >200 cells/mu l were included. Specific IgG serum concentrations for eight serotypes by ELISA and seven serotypes by OPA were measured at baseline, 1-, 6-, and 12 months after the PCV13 vaccination. Global response was defined as a two-fold increase from baseline of specific IgG antibody levels (mu g/ml) assayed by ELISA or as a four-fold increase in OPA titer from baseline, for at least five serotypes targeted by PCV13. Global protection was defined as an IgG-concentration >= 1 mu g/ml by ELISA or as an opsonization titer >= LLOQ by OPA for at least five tested serotypes targeted by PCV13. Factors associated with global response and global protection were assessed using logistic regression. ResultsOf the 38 PLHIV included, 57.9% and 63.2% were global responders, 92.1% and 78.9% were globally protected at one month, and 64.7% and 55.9% were still protected at 12 months, by ELISA and OPA respectively. A CD4/CD8 ratio of >0.8 was significantly associated with a better global response by OPA (OR=6.11, p=0.02), and a CD4 nadir <200 was significantly associated with a poorer global response by ELISA (OR=0.22, p=0.04). A CD4 cell count nadir <200 and age over 50 years were associated with poorer global protection by OPA at M1 (OR=0.18, p=0.04) and M12 (OR= 0.15, p=0.02), respectively. Plasma HIV RNA viral load <40 copies/ml was significantly associated with a better global protection at M1 by ELISA and OPA (OR=21.33, p=0.025 and OR=8.40, p=0.04) ConclusionVaccination with PCV13 in these patients induced immunological response and protection at one month. At one year, more than half of patients were still immunologically protected.	[Romaru, Juliette; Lejeune, Gauthier; Hentzien, Maxime; Berger, Jean-Luc; Robbins, Ailsa; N'Guyen, Yohan; Bani-Sadr, Firouze; Servettaz, Amelie] Reims Univ Hosp, Dept Internal Med Clin Immunol & Infect Dis, Reims, France; [Bahuaud, Mathilde; Batteux, Frederic] Univ Paris, Cochin Hosp, APHP, Lab Immunol,Plateforme Immunomonitoring Vaccina, Descartes, Paris, France; [Lejeune, Gauthier; Lebrun, Delphine] CH Charleville Mezieres, Dept Internal Med & Infect Dis, Mezieres, France; [Robbins, Ailsa; Servettaz, Amelie] Univ Reims Champagne Ardenne URCA, Lab Immunol, IRMAC EA7509, Reims, France	CHU de Reims; Universite de Reims Champagne-Ardenne; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Universite de Reims Champagne-Ardenne	Hentzien, M (corresponding author), Reims Univ Hosp, Dept Internal Med Clin Immunol & Infect Dis, Reims, France.	mhentzien@chu-reims.fr	Hentzien, Maxime/H-8730-2019	Hentzien, Maxime/0000-0003-2729-9420				Bahuaud M, 2017, HELIYON, V3, DOI 10.1016/j.heliyon.2017.e00441; Barte H, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010929.pub2; Belmonti S, 2019, INFECT DIS THER, V8, P453, DOI 10.1007/s40121-019-0256-z; Bennett Nancy M., 2012, Morbidity and Mortality Weekly Report, V61, P816; Blanc A., 2018, PRISE CHARGE MEDICAL, P46; Bupp MRG, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01269; Burton RL, 2006, CLIN VACCINE IMMUNOL, V13, P1004, DOI 10.1128/CVI.00112-06; Burton RL, 2012, CLIN VACCINE IMMUNOL, V19, P835, DOI 10.1128/CVI.00086-12; Chen M, 2008, VACCINE, V26, P4962, DOI 10.1016/j.vaccine.2008.06.093; Cohen AL, 2010, AIDS, V24, P2253, DOI 10.1097/QAD.0b013e32833d46fd; Crum-Cianflone NF, 2010, J INFECT DIS, V202, P1114, DOI 10.1086/656147; Farmaki PF, 2018, J INFECT DIS, V218, P26, DOI 10.1093/infdis/jiy135; Feikin DR, 2001, VACCINE, V20, P545, DOI 10.1016/S0264-410X(01)00347-4; French N, 2004, J INFECT DIS, V190, P707, DOI 10.1086/421911; Fritzsche C, 2019, VACCINE, V37, P2278, DOI 10.1016/j.vaccine.2019.02.064; Fuster F, 2016, VACCINE, V34, P1889, DOI 10.1016/j.vaccine.2016.02.055; Garrido HMG, 2020, ECLINICALMEDICINE, V29-30, DOI 10.1016/j.eclinm.2020.100576; Glesby MJ, 2015, J INFECT DIS, V212, P18, DOI 10.1093/infdis/jiu631; Goldblatt D, 2009, CLIN INFECT DIS, V49, P1318, DOI 10.1086/606046; Heffernan RT, 2005, J INFECT DIS, V191, P2038, DOI 10.1086/430356; Ho YL, 2013, VACCINE, V31, P4047, DOI 10.1016/j.vaccine.2013.04.065; Home, HOMEYS EC ENERGIE DU; Hung CC, 2010, HIV MED, V11, P54, DOI 10.1111/j.1468-1293.2009.00744.x; Jauneikaite E, 2015, J MICROBIOL METH, V113, P41, DOI 10.1016/j.mimet.2015.03.006; Juergens C, 2014, CLIN VACCINE IMMUNOL, V21, P1277, DOI 10.1128/CVI.00172-14; Kamchaisatian W, 2006, J ALLERGY CLIN IMMUN, V118, P1336, DOI 10.1016/j.jaci.2006.09.036; Lange CG, 2003, AIDS, V17, P2015, DOI 10.1097/00002030-200309260-00002; Lazarus R, 2011, CLIN INFECT DIS, V52, P736, DOI 10.1093/cid/cir003; Leggat David J, 2015, J AIDS Clin Res, V6; Leggat DJ, 2013, J INFECT DIS, V208, P101, DOI 10.1093/infdis/jit139; Lesprit P, 2007, AIDS, V21, P2425, DOI 10.1097/QAD.0b013e3282887e91; Lombardi F, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156523; Lu CL, 2012, J FORMOS MED ASSOC, V111, P445, DOI 10.1016/j.jfma.2011.06.027; Lu CL, 2012, VACCINE, V30, P3526, DOI 10.1016/j.vaccine.2012.03.070; Noel L, 2021, INFECT DIS NOW, V51, P94, DOI 10.1016/j.medmal.2020.09.016; Orange JS, 2012, J ALLERGY CLIN IMMUN, V130, pS1, DOI 10.1016/j.jaci.2012.07.002; Penaranda M, 2010, AIDS, V24, P1226, DOI 10.1097/QAD.0b013e3283389de5; Pensieroso S, 2013, AIDS, V27, P1209, DOI 10.1097/QAD.0b013e32835edc47; Rabian C, 2010, CLIN INFECT DIS, V50, P1174, DOI 10.1086/651418; Robbins A, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.697128; Rodriguez-Barradas MC, 2003, CLIN INFECT DIS, V37, P438, DOI 10.1086/375841; Romero-Steiner S, 2006, CLIN VACCINE IMMUNOL, V13, P165, DOI 10.1128/CVI.13.2.165-169.2006; Rubin LG, 2014, CLIN INFECT DIS, V58, P309, DOI [10.1093/cid/cit684, 10.1093/cid/cit816]; Sadlier C, 2016, SCI REP-UK, V6, DOI 10.1038/srep32076; Schober P, 2018, ANESTH ANALG, V126, P1763, DOI 10.1213/ANE.0000000000002864; Siemieniuk RAC, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-314; Song JY, 2020, HUM VACC IMMUNOTHER, V16, P169, DOI 10.1080/21645515.2019.1643677; Song JY, 2013, J INFECT CHEMOTHER, V19, P412, DOI 10.1007/s10156-013-0601-1; Tchalla EYI, 2020, J INFECT DIS, V222, P1363, DOI 10.1093/infdis/jiaa242; Tsachouridou O, 2017, COMP IMMUNOL MICROB, V54, P27, DOI 10.1016/j.cimid.2017.07.006; Vaccination, EACS GUID; van Deursen AMM, 2017, CLIN INFECT DIS, V65, P787, DOI 10.1093/cid/cix419	52	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 20	2021	12								791147	10.3389/fimmu.2021.791147	http://dx.doi.org/10.3389/fimmu.2021.791147			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YB2NT	34987514	gold, Green Published			2022-12-18	WOS:000738856400001
J	Shim, D; Cho, HJ; Hwang, I; Jung, TY; Kim, HS; Ryu, JH; Yu, JW				Shim, Do-Wan; Cho, Hyo-Joung; Hwang, Inhwa; Jung, Taek-Yeol; Kim, Hyun-Seok; Ryu, Ju Hee; Yu, Je-Wook			Intracellular NAD(+) Depletion Confers a Priming Signal for NLRP3 Inflammasome Activation	FRONTIERS IN IMMUNOLOGY			English	Article						NAD; aging; macrophage; proinflammatory; inflammasome	MITOCHONDRIA; HOMEOSTASIS; HEALTH	Nicotinamide adenine dinucleotide (NAD(+)) is an important cofactor in many redox and non-redox NAD(+)-consuming enzyme reactions. Intracellular NAD(+) level steadily declines with age, but its role in the innate immune potential of myeloid cells remains elusive. In this study, we explored whether NAD(+) depletion by FK866, a highly specific inhibitor of the NAD salvage pathway, can affect pattern recognition receptor-mediated responses in macrophages. NAD(+)-depleted mouse bone marrow-derived macrophages (BMDMs) exhibited similar levels of proinflammatory cytokine production in response to LPS or poly (I:C) stimulation compared with untreated cells. Instead, FK866 facilitated robust caspase-1 activation in BMDMs in the presence of NLRP3-activating signals such as ATP and nigericin, a potassium ionophore. However, this FK866-mediated caspase-1 activation was completely abolished in Nlrp3-deficient macrophages. FK866 plus nigericin stimulation caused an NLRP3-dependent assembly of inflammasome complex. In contrast, restoration of NAD(+) level by supplementation with nicotinamide mononucleotide abrogated the FK866-mediated caspase-1 cleavage. FK866 did not induce or increase the expression levels of NLRP3 and interleukin (IL)-1 beta but drove mitochondrial retrograde transport into the perinuclear region. FK866-nigericin-induced mitochondrial transport is critical for caspase-1 cleavage in macrophages. Consistent with the in vitro experiments, intradermal coinjection of FK866 and ATP resulted in robust IL-1 beta expression and caspase-1 activation in the skin of wild-type, but not Nlrp3-deficient mice. Collectively, our data suggest that NAD(+) depletion provides a non-transcriptional priming signal for NLRP3 activation via mitochondrial perinuclear clustering, and aging-associated NAD(+) decline can trigger NLRP3 inflammasome activation in ATP-rich environments.	[Shim, Do-Wan; Cho, Hyo-Joung; Hwang, Inhwa; Yu, Je-Wook] Yonsei Univ, Coll Med, Brain Korea Project Med Sci 21, Dept Microbiol & Immunol Inst Immunol & Immunol D, Seoul, South Korea; [Jung, Taek-Yeol; Kim, Hyun-Seok] Ewha Womans Univ, Coll Nat Sci, Res Ctr Cellular Homeostasis, Dept Life Sci, Seoul, South Korea; [Ryu, Ju Hee] Korea Inst Sci & Technol KIST, Theragnosis Res Ctr, Biomed Res Div, Seoul, South Korea	Yonsei University; Yonsei University Health System; Ewha Womans University; Korea Institute of Science & Technology (KIST)	Yu, JW (corresponding author), Yonsei Univ, Coll Med, Brain Korea Project Med Sci 21, Dept Microbiol & Immunol Inst Immunol & Immunol D, Seoul, South Korea.	jewookyu@yuhs.ac		Hwang, Inhwa/0000-0001-5235-3519; Shim, Do-Wan/0000-0003-1893-8323; Yu, Je-Wook/0000-0001-5943-4071	National Research Foundation of Korea Grant - Korean Government [2020R1A2B5B02001823, 2020R1A4A1019009, 2019R1I1A1A01060316, 2021R1I1A1A01055624]	National Research Foundation of Korea Grant - Korean Government	& nbsp;This work was supported by the National Research Foundation of Korea Grant funded by the Korean Government (2020R1A2B5B02001823, 2020R1A4A1019009, 2019R1I1A1A01060316, 2021R1I1A1A01055624).	Agarwal S, 2020, J CELL SCI, V133, DOI 10.1242/jcs.245589; Arnoult D, 2011, EMBO REP, V12, P901, DOI 10.1038/embor.2011.157; Bauernfeind F, 2016, J IMMUNOL, V197, P2900, DOI 10.4049/jimmunol.1501336; Calabrese V, 2018, FREE RADICAL BIO MED, V115, P80, DOI 10.1016/j.freeradbiomed.2017.10.379; Cameron AM, 2019, NAT IMMUNOL, V20, P420, DOI 10.1038/s41590-019-0336-y; Canto C, 2015, CELL METAB, V22, P31, DOI 10.1016/j.cmet.2015.05.023; Fernandes-Alnemri T, 2009, NATURE, V458, P509, DOI 10.1038/nature07710; Franceschi C, 2018, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00061; Franceschi C, 2014, J GERONTOL A-BIOL, V69, pS4, DOI 10.1093/gerona/glu057; Gim E, 2019, IMMUNE NETW, V19, DOI 10.4110/in.2019.19.e40; He M, 2020, CELL METAB, V31, P580, DOI 10.1016/j.cmet.2020.01.009; Huang J, 2015, AGEING RES REV, V24, P3, DOI 10.1016/j.arr.2014.10.004; Johnson Sean, 2018, F1000Res, V7, P132, DOI 10.12688/f1000research.12120.1; Katsyuba E, 2020, NAT METAB, V2, P9, DOI 10.1038/s42255-019-0161-5; Ko YJ, 2020, BIOMATERIALS, V226, DOI 10.1016/j.biomaterials.2019.119543; Li XQ, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00736; McReynolds MR, 2020, EXP GERONTOL, V134, DOI 10.1016/j.exger.2020.110888; Misawa T, 2013, NAT IMMUNOL, V14, P454, DOI 10.1038/ni.2550; Munoz-Planillo R, 2013, IMMUNITY, V38, P1142, DOI 10.1016/j.immuni.2013.05.016; Neves J, 2020, FEBS J, V287, P43, DOI 10.1111/febs.15061; Niccoli T, 2012, CURR BIOL, V22, pR741, DOI 10.1016/j.cub.2012.07.024; Shim DW, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01054; Stein LR, 2014, EMBO J, V33, P1321, DOI 10.1002/embj.201386917; Strowig T, 2012, NATURE, V481, P278, DOI 10.1038/nature10759; Tsai CY, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20163878; Van Gool F, 2009, NAT MED, V15, P206, DOI 10.1038/nm.1906; Venter G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097378; Xiao WS, 2018, ANTIOXID REDOX SIGN, V28, P251, DOI 10.1089/ars.2017.7216; Yang K, 2019, J IMMUNOL, V203, P1598, DOI 10.4049/jimmunol.1801382; Yegutkin GG, 2008, BBA-MOL CELL RES, V1783, P673, DOI 10.1016/j.bbamcr.2008.01.024; Yoshino J, 2011, CELL METAB, V14, P528, DOI 10.1016/j.cmet.2011.08.014; Yu JW, 2016, ARCH PHARM RES, V39, P1503, DOI 10.1007/s12272-016-0827-4; Zhou RB, 2011, NATURE, V469, P221, DOI 10.1038/nature09663	33	0	0	4	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 20	2021	12								765477	10.3389/fimmu.2021.765477	http://dx.doi.org/10.3389/fimmu.2021.765477			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YB2KH	34987507	Green Published, gold			2022-12-18	WOS:000738847400001
J	Sierra, A; Paolicelli, RC				Sierra, Amanda; Paolicelli, Rosa Chiara			Editorial: Assessing Microglial Function and Identity	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						microglia; methods; central nervous system (CNS); disease; neuroimmunology and neuropathology	REVEALS		[Sierra, Amanda] Achucarro Basque Ctr Neurosci, Glial Cell Biol Lab, Leioa, Spain; [Sierra, Amanda] Univ Basque Country EHU UPV, Dept Neurosci, Leioa, Spain; [Sierra, Amanda] Ikerbasque Fdn, Bilbao, Spain; [Paolicelli, Rosa Chiara] Univ Lausanne, Dept Biomed Sci, Lausanne, Switzerland	University of Basque Country; Basque Foundation for Science; University of Lausanne	Sierra, A (corresponding author), Achucarro Basque Ctr Neurosci, Glial Cell Biol Lab, Leioa, Spain.; Sierra, A (corresponding author), Univ Basque Country EHU UPV, Dept Neurosci, Leioa, Spain.; Sierra, A (corresponding author), Ikerbasque Fdn, Bilbao, Spain.; Paolicelli, RC (corresponding author), Univ Lausanne, Dept Biomed Sci, Lausanne, Switzerland.	amanda.sierra@ehu.eus; rosachiara.paolicelli@unil.ch			Spanish Ministry of Science and Innovation [CompetitivenessMCIN/AEI/10.13039/501100011033]; FEDER "A way to make Europe" [RTI2018-099267-B-I00, RYC-201312817]; Tatiana Foundation Award [P-048-FTPGB 2018]; Basque Government Department of Education project [PIBA 2020_1_0030]; Synapsis Foundation -Alzheimer Research Switzerland ARS; Swiss National Science Foundation [SNSF 310030_197940]; European Research Council [ERC StGrant REMIND 804949]	Spanish Ministry of Science and Innovation(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); FEDER "A way to make Europe"; Tatiana Foundation Award; Basque Government Department of Education project; Synapsis Foundation -Alzheimer Research Switzerland ARS; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); European Research Council(European Research Council (ERC)European Commission)	This work was supported by the Spanish Ministry of Science and Innovation CompetitivenessMCIN/AEI/10.13039/501100011033 (https://www.ciencia.gob.es/) and FEDER "A way to make Europe" (RTI2018-099267-B-I00 and RYC-201312817), a Tatiana Foundation Award (P-048-FTPGB 2018), and a Basque Government Department of Education project (PIBA 2020_1_0030; http://www.euskadi.eus/basque-government/department-education/) to AS; by grants from the Synapsis Foundation -Alzheimer Research Switzerland ARS, the Swiss National Science Foundation (SNSF 310030_197940) and the European Research Council (ERC StGrant REMIND 804949) to RCP.	Cserep C, 2020, SCIENCE, V367, P528, DOI 10.1126/science.aax6752; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; Ginhoux F, 2010, SCIENCE, V330, P841, DOI 10.1126/science.1194637; Goldmann T, 2013, NAT NEUROSCI, V16, P1618, DOI 10.1038/nn.3531; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Sierra A, 2019, TRENDS NEUROSCI, V42, P778, DOI 10.1016/j.tins.2019.09.004; Yona S, 2013, IMMUNITY, V38, P79, DOI 10.1016/j.immuni.2012.12.001	7	0	0	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 20	2021	12								824866	10.3389/fimmu.2021.824866	http://dx.doi.org/10.3389/fimmu.2021.824866			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YB6VN	34987527	Green Published, gold			2022-12-18	WOS:000739147500001
J	Steininger, J; Rossmanith, R; Geier, CB; Leiss-Piller, A; Thonhauser, L; Weiss, S; Hainfellner, JA; Freilinger, M; Schmidt, WM; Eibl, MM; Wolf, HM				Steininger, Jolanda; Rossmanith, Raphael; Geier, Christoph B.; Leiss-Piller, Alexander; Thonhauser, Lukas; Weiss, Simone; Hainfellner, Johannes A.; Freilinger, Michael; Schmidt, Wolfgang M.; Eibl, Martha M.; Wolf, Hermann M.			Case Report: Meningoencephalitis With Thrombotic Occlusive Vasculopathy in a Young EBV-Naive Boy Is Associated With a Novel SH2D1A Mutation	FRONTIERS IN IMMUNOLOGY			English	Article						CNS vasculopathy; meningoencephalitis; primary immunodeficiency; X-linked lymphoproliferative disease type 1; XLP1; multiple cerebral aneurysms	LINKED LYMPHOPROLIFERATIVE-DISEASE; NERVOUS-SYSTEM INVOLVEMENT; HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; LYMPHOCYTIC VASCULITIS; TRANSLATION INITIATION; CEREBRAL VASCULITIS; DEFICIENCY; SAP; ENCEPHALITIS; MENINGITIS	X-linked lymphoproliferative disease (XLP1) is a combined immunodeficiency characterized by severe immune dysregulation caused by mutations in the SH2D1A/SAP gene. Loss or dysfunction of SH2D1A is associated with the inability in clearing Epstein-Barr-Virus (EBV) infections. Clinical manifestation is diverse and ranges from life-threatening hemophagocytic lymphohistiocytosis (HLH) and fulminant infectious mononucleosis (FIM) to lymphoma and antibody deficiency. Rare manifestations include aplastic anemia, chronic gastritis and vasculitis. Herein, we describe the case of a previously healthy eight-year old boy diagnosed with XLP1 presenting with acute non-EBV acute meningoencephalitis with thrombotic occlusive vasculopathy. The patient developed multiple cerebral aneurysms leading to repeated intracerebral hemorrhage and severe cerebral damage. Immunological examination was initiated after development of a susceptibility to infections with recurrent bronchitis and one episode of severe pneumonia and showed antibody deficiency with pronounced IgG1-3-4 subclass deficiency. We could identify a novel hemizygous SH2D1A point mutation affecting the start codon. Basal levels of SAP protein seemed to be detectable in CD8(+) and CD4(+) T- and CD56(+) NK-cells of the patient what indicated an incomplete absence of SAP. In conclusion, we could demonstrate a novel SH2D1A mutation leading to deficient SAP protein expression and a rare clinical phenotype of non-EBV associated acute meningoencephalitis with thrombotic occlusive vasculopathy.	[Steininger, Jolanda; Rossmanith, Raphael; Geier, Christoph B.; Leiss-Piller, Alexander; Eibl, Martha M.; Wolf, Hermann M.] Immunol Outpatient Clin, Vienna, Austria; [Rossmanith, Raphael] Karl Franzens Univ Graz, Inst Mol Biosci, Doctoral Sch Mol Biol & Biochem, Graz, Austria; [Thonhauser, Lukas; Weiss, Simone] Klin Favoriten, Dept Pediat, Vienna, Austria; [Hainfellner, Johannes A.] Med Univ Vienna, Dept Neurol, Div Neuropathol & Neurochem, Vienna, Austria; [Freilinger, Michael] Med Univ Vienna, Dept Pediat & Adolescent Med, Vienna, Austria; [Schmidt, Wolfgang M.] Med Univ Vienna, Ctr Anat & Cell Biol, Neuromuscular Res Dept, Vienna, Austria; [Eibl, Martha M.] Biomed Forsch GmbH, Vienna, Austria; [Wolf, Hermann M.] Sigmund Freud Private Univ, Med Sch, Vienna, Austria	University of Graz; Medical University of Vienna; Medical University of Vienna; Medical University of Vienna	Wolf, HM (corresponding author), Immunol Outpatient Clin, Vienna, Austria.; Wolf, HM (corresponding author), Sigmund Freud Private Univ, Med Sch, Vienna, Austria.			Schmidt, Wolfgang/0000-0002-6944-2443				Atedzoe BN, 1999, J LEUKOCYTE BIOL, V66, P822, DOI 10.1002/jlb.66.5.822; Booth C, 2011, BLOOD, V117, P53, DOI 10.1182/blood-2010-06-284935; Casrouge A, 2006, SCIENCE, V314, P308, DOI 10.1126/science.1128346; Chang CP, 2010, BMC MICROBIOL, V10, DOI 10.1186/1471-2180-10-188; Chapel H, 2005, CLIN INFECT DIS, V40, P1227, DOI 10.1086/428733; Cid E, 2017, SCI REP-UK, V7, DOI 10.1038/srep41720; de la Salle H, 1999, J CLIN INVEST, V103, pR9, DOI 10.1172/JCI5687; Dutz JP, 2001, BLOOD, V97, P95, DOI 10.1182/blood.V97.1.95; Elkan PN, 2014, NEW ENGL J MED, V370, P921, DOI 10.1056/NEJMoa1307362; Enders A, 2004, J PEDIATR-US, V145, P698, DOI 10.1016/j.jpeds.2004.06.065; Filipovich AH, 2010, BLOOD, V116, P3398, DOI 10.1182/blood-2010-03-275909; Geier CB, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.574738; Gilmour KC, 2000, EUR J IMMUNOL, V30, P1691, DOI 10.1002/1521-4141(200006)30:6<1691::AID-IMMU1691>3.0.CO;2-K; Gray PE, 2015, J CLIN IMMUNOL, V35, P604, DOI 10.1007/s10875-015-0194-9; Honig M, 2007, BLOOD, V109, P3595, DOI 10.1182/blood-2006-07-034678; Jiang YK, 2020, CASE REP IMMUNOL, V2020, DOI 10.1155/2020/8841571; Jovanovic A, 2014, PEDIATR NEUROL, V50, P233, DOI 10.1016/j.pediatrneurol.2013.10.014; Kim Tae-Shin, 2019, Exp Mol Med, V51, P1, DOI 10.1038/s12276-019-0316-1; Le Borgne M, 2012, IMMUNITY, V36, P899, DOI 10.1016/j.immuni.2012.06.002; Liu LY, 2011, J EXP MED, V208, P1635, DOI 10.1084/jem.20110958; McCluggage WG, 1999, J CLIN PATHOL, V52, P390, DOI 10.1136/jcp.52.5.390; Nanthapisal S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00735; Negroni A, 2018, J INFLAMM RES, V11, P49, DOI 10.2147/JIR.S137606; Nichols KE, 2005, NAT MED, V11, P340, DOI 10.1038/nm1189; Nofech-Mozes Y, 2007, PEDIATR NEUROL, V37, P218, DOI 10.1016/j.pediatrneurol.2007.03.011; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Ongradi J, 2017, J NEUROVIROL, V23, P1, DOI 10.1007/s13365-016-0473-0; Panchal N, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00666; Parolini S, 2000, J EXP MED, V192, P337, DOI 10.1084/jem.192.3.337; PEABODY DS, 1989, J BIOL CHEM, V264, P5031; PEABODY DS, 1987, J BIOL CHEM, V262, P11847; PURTILO D T, 1975, Lancet, V1, P935; PURTILO DT, 1991, SPRINGER SEMIN IMMUN, V13, P181; Rougemont AL, 2008, AM J SURG PATHOL, V32, P323, DOI 10.1097/PAS.0b013e318141fca1; Sayos J, 1998, NATURE, V395, P462, DOI 10.1038/26683; Schwartz KL, 2014, PEDIATRICS, V133, pE1541, DOI 10.1542/peds.2013-3344; SEEMAYER TA, 1995, PEDIATR RES, V38, P471, DOI 10.1203/00006450-199510000-00001; Song Y, 2018, CHINESE MED J-PEKING, V131, P776, DOI 10.4103/0366-6999.228234; Sumegi J, 2000, BLOOD, V96, P3118; Talaat KR, 2009, PEDIATR BLOOD CANCER, V53, P1120, DOI 10.1002/pbc.22185; Verhelst H, 2007, NEUROLOGY, V69, P218, DOI 10.1212/01.wnl.0000265597.56202.6c; Zhang SY, 2007, SCIENCE, V317, P1522, DOI 10.1126/science.1139522; Zhu J, 2013, CHIN J CANCER, V32, P673, DOI 10.5732/cjc.012.10238	43	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 20	2021	12								747738	10.3389/fimmu.2021.747738	http://dx.doi.org/10.3389/fimmu.2021.747738			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YB2TF	34987501	gold, Green Published			2022-12-18	WOS:000738870600001
J	Zghaebi, M; Byazrova, M; Flicker, S; Villazala-Merino, S; Campion, NJ; Stanek, V; Tu, ALE; Breiteneder, H; Filatov, A; Khaitov, M; Niederberger-Leppin, V; Eckl-Dorna, J; Valenta, R				Zghaebi, Mohammed; Byazrova, Maria; Flicker, Sabine; Villazala-Merino, Sergio; Campion, Nicholas J.; Stanek, Victoria; Tu, Aldine; Breiteneder, Heimo; Filatov, Alexander; Khaitov, Musa; Niederberger-Leppin, Verena; Eckl-Dorna, Julia; Valenta, Rudolf			Tracing Human IgE B Cell Antigen Receptor-Bearing Cells With a Monoclonal Anti-Human IgE Antibody That Specifically Recognizes Non-Receptor-Bound IgE	FRONTIERS IN IMMUNOLOGY			English	Article						omalizumab; IgE; B cells; allergy; CD23; spiking; PBMCs; Fc epsilon RI	PLASMA-CELLS; ALLERGIC-ASTHMA; BONE-MARROW; BLOOD; HETEROGENEITY; ORIGINATE; SAFETY; RNA	Up to 30% of the population suffers from immunoglobulin E (IgE)-mediated allergies. Despite current stepwise gating approaches, the unambiguous identification of human IgE-producing cells by flow cytometry and immunohistology remains challenging. This is mainly due to the scarcity of these cells and the fact that IgE is not only expressed in a membrane-bound form on the surface of IgE-producing cells in form of the B cell antigen receptor (BCR), but is more frequently found on various cell types bound to the low and high affinity receptors, CD23 and Fc epsilon RI, respectively. Here we sought to develop a sequential gating strategy for unambiguous detection of cells bearing the IgE BCR on their surface. To that aim we first tested the monoclonal anti-IgE antibody omalizumab for its ability to discriminate between IgE BCR and receptor-bound IgE using cells producing IgE or bearing IgE bound to CD23 as well as basophils exhibiting Fc epsilon RI receptor-bound IgE. Using flow cytometry, we demonstrated that omalizumab recognized IgE producing cells with a high sensitivity of up to 1 IgE(+) cell in 1000 human peripheral blood mononuclear cells (PBMCs). These results were confirmed by confocal microscopy both in cell suspensions as well as in nasal polyp tissue sections. Finally, we established a consecutive gating strategy allowing the clear identification of class-switched, allergen-specific IgE(+) memory B cells and plasmablasts/plasma cells in human PBMCs. Birch pollen specific IgE(+) memory B cells represented on average 0.734% of total CD19(+) B cells in allergic patients after allergen exposure. Thus, we developed a new protocol for exclusive staining of non-receptor bound allergen-specific IgE(+) B cell subsets in human samples.	[Zghaebi, Mohammed; Villazala-Merino, Sergio; Campion, Nicholas J.; Stanek, Victoria; Tu, Aldine; Niederberger-Leppin, Verena; Eckl-Dorna, Julia] Med Univ Vienna, Dept Otorhinolaryngol, Vienna, Austria; [Byazrova, Maria; Filatov, Alexander; Khaitov, Musa; Valenta, Rudolf] Fed Med Biol Agcy FMBA Russia, Inst Immunol, Natl Res Ctr NRC, Moscow, Russia; [Byazrova, Maria; Filatov, Alexander] Lomonosov Moscow State Univ, Fac Biol, Dept Immunol, Moscow, Russia; [Flicker, Sabine; Valenta, Rudolf] Med Univ Vienna, Ctr Pathophysiol Infectiol & Immunol, Dept Pathophysiol & Allergy Res, Div Immunopathol, Vienna, Austria; [Breiteneder, Heimo] Med Univ Vienna, Ctr Pathophysiol Infectiol & Immunol, Dept Pathophysiol & Allergy Res, Div Med Biotechnol, Vienna, Austria; [Khaitov, Musa] Pirogov Russian Natl Res Med Univ, Immunol Dept, Moscow, Russia; [Valenta, Rudolf] Sechenov First Moscow State Med Univ, Dept Clin Immunol & Allergy, Moscow, Russia; [Valenta, Rudolf] Karl Landsteiner Univ Hlth Sci, Krems, Austria	Medical University of Vienna; NRC Institute of Immunology FMBA of Russia; Lomonosov Moscow State University; Medical University of Vienna; Medical University of Vienna; Pirogov Russian National Research Medical University; Sechenov First Moscow State Medical University	Eckl-Dorna, J (corresponding author), Med Univ Vienna, Dept Otorhinolaryngol, Vienna, Austria.	Julia.eckl-dorna@meduniwien.ac.at	Byazrova, Maria/GWM-5288-2022; Khaitov, Musa/AAC-1516-2021	Khaitov, Musa/0000-0003-4961-9640; Eckl-Dorna, Julia/0000-0001-5981-1607; Byazrova, Maria/0000-0002-9858-7596; Flicker, Sabine/0000-0003-4768-8693	Austrian Science Fund (FWF) [DK W 1248B30, SFB F4613]; Megagrant of the Government of the Russian Federation [14.W03.31.0024]; Russian Science Foundation [21-15-00286]; Country of Lower Austria	Austrian Science Fund (FWF)(Austrian Science Fund (FWF)); Megagrant of the Government of the Russian Federation; Russian Science Foundation(Russian Science Foundation (RSF)); Country of Lower Austria	This work was supported by the Country of Lower Austria's funded Danube Allergy research cluster, by grants DK W 1248B30 and SFB F4613 from the Austrian Science Fund (FWF), by a Megagrant of the Government of the Russian Federation, grant No 14.W03.31.0024 and in part by the Russian Science Foundation, grant No 21-15-00286.	Adelroth E, 2000, J ALLERGY CLIN IMMUN, V106, P253, DOI 10.1067/mai.2000.108310; Arm JP, 2014, CLIN EXP ALLERGY, V44, P1371, DOI 10.1111/cea.12400; Asrat S, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.aav8402; Berkowska MA, 2014, J ALLERGY CLIN IMMUN, V134, P688, DOI 10.1016/j.jaci.2014.03.036; Berkowska MA, 2011, BLOOD, V118, P2150, DOI 10.1182/blood-2011-04-345579; Brightbill HD, 2010, J CLIN INVEST, V120, P2218, DOI 10.1172/JCI40141; Busse W, 2001, J ALLERGY CLIN IMMUN, V108, P184, DOI 10.1067/mai.2001.117880; Caraux A, 2010, HAEMATOL-HEMATOL J, V95, P1016, DOI 10.3324/haematol.2009.018689; Chattopadhyay PK, 2012, CYTOM PART A, V81A, P456, DOI 10.1002/cyto.a.22043; Chu SY, 2012, J ALLERGY CLIN IMMUN, V129, P1102, DOI 10.1016/j.jaci.2011.11.029; Croote D, 2018, SCIENCE, V362, P1306, DOI 10.1126/science.aau2599; Eckl-Dorna J, 2012, CLIN EXP ALLERGY, V42, P1347, DOI 10.1111/j.1365-2222.2012.04030.x; Eckl-Dorna J, 2012, ALLERGY, V67, P601, DOI 10.1111/j.1398-9995.2012.02792.x; Eckl-Dorna J, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8090994; Eckl-Dorna J, 2013, CURR ALLERGY ASTHM R, V13, P281, DOI 10.1007/s11882-013-0348-x; Engels N, 2018, IMMUNOL REV, V283, P150, DOI 10.1111/imr.12651; Erazo A, 2007, IMMUNITY, V26, P191, DOI 10.1016/j.immuni.2006.12.006; Franz B, 2011, BLOOD, V118, P348, DOI 10.1182/blood-2011-03-341917; FRIGERI LG, 1992, J IMMUNOL, V148, P861; Galeotti C, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21020510; Gasser P, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13815-w; Guzelbey O, 2008, ALLERGY, V63, P1563, DOI 10.1111/j.1398-9995.2008.01879.x; Hedley BD, 2013, INT J LAB HEMATOL, V35, P344, DOI 10.1111/ijlh.12068; Heeringa JJ, 2018, ALLERGY, V73, P1331, DOI 10.1111/all.13421; Horst A, 2002, CLIN EXP IMMUNOL, V130, P370, DOI 10.1046/j.1365-2249.2002.02025.x; Jimenez-Saiz R, 2019, J ALLERGY CLIN IMMUN, V144, P336, DOI 10.1016/j.jaci.2019.04.001; JOHANSSON SG, 1967, IMMUNOLOGY, V13, P381; Karnowski A, 2006, EUR J IMMUNOL, V36, P1917, DOI 10.1002/eji.200535495; KATONA IM, 1983, J IMMUNOL, V130, P350; Laffer S, 2008, ALLERGY, V63, P695, DOI 10.1111/j.1398-9995.2008.01664.x; Laffer S, 2001, J ALLERGY CLIN IMMUN, V108, P409, DOI 10.1067/mai.2001.117593; Lupinek C, 2017, EBIOMEDICINE, V17, P119, DOI 10.1016/j.ebiom.2017.02.007; Medina F, 2002, BLOOD, V99, P2154, DOI 10.1182/blood.V99.6.2154; Milgrom H, 1999, NEW ENGL J MED, V341, P1966, DOI 10.1056/NEJM199912233412603; NILSSON K, 1970, CLIN EXP IMMUNOL, V7, P477; Oliveria JP, 2017, AM J RESP CRIT CARE, V196, P107, DOI 10.1164/rccm.201611-2274LE; Rai S, 2018, INT J LAB HEMATOL, V40, pE52, DOI 10.1111/ijlh.12809; Ramadani F, 2017, ALLERGY, V72, P66, DOI 10.1111/all.12911; Rosales C, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00280; Sanz I, 2008, SEMIN IMMUNOL, V20, P67, DOI 10.1016/j.smim.2007.12.006; Schmitt MER, 2020, J ALLERGY CLIN IMMUN, V146, P642, DOI 10.1016/j.jaci.2020.02.015; Selb R, 2017, J ALLERGY CLIN IMMUN, V139, P290, DOI 10.1016/j.jaci.2016.03.042; Selb R, 2017, J ALLERGY CLIN IMMUN, V139, P281, DOI 10.1016/j.jaci.2016.04.015; Shamji MH, 2021, ALLERGY, V76, P3627, DOI 10.1111/all.14908; Valenta R, 2018, ADV IMMUNOL, V138, P195, DOI 10.1016/bs.ai.2018.03.002; Veri MC, 2007, IMMUNOLOGY, V121, P392, DOI 10.1111/j.1365-2567.2007.02588.x; Villazala-Merino S, 2020, J ALLERGY CLIN IMMUN, V145, P958, DOI 10.1016/j.jaci.2019.11.019; Wu LC, 2014, NAT REV IMMUNOL, V14, P247, DOI 10.1038/nri3632; Wu YCB, 2011, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00081; ZHANG K, 1992, J EXP MED, V176, P233, DOI 10.1084/jem.176.1.233	50	0	0	2	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 20	2021	12								803236	10.3389/fimmu.2021.803236	http://dx.doi.org/10.3389/fimmu.2021.803236			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YB6ZI	34987522	gold, Green Published			2022-12-18	WOS:000739157400001
J	Bou-Tayeh, B; Laletin, V; Salem, N; Just-Landi, S; Fares, J; Leblanc, R; Balzano, M; Kerdiles, YM; Bidaut, G; Herault, O; Olive, D; Aurrand-Lions, M; Walzer, T; Nunes, JA; Fauriat, C				Bou-Tayeh, Berna; Laletin, Vladimir; Salem, Nassim; Just-Landi, Sylvaine; Fares, Joanna; Leblanc, Raphael; Balzano, Marielle; Kerdiles, Yann M.; Bidaut, Ghislain; Herault, Olivier; Olive, Daniel; Aurrand-Lions, Michel; Walzer, Thierry; Nunes, Jacques A.; Fauriat, Cyril			Chronic IL-15 Stimulation and Impaired mTOR Signaling and Metabolism in Natural Killer Cells During Acute Myeloid Leukemia	FRONTIERS IN IMMUNOLOGY			English	Article						natural killer cells; acute myeloid leukemia; IL-15; mTOR signaling; metabolism; chronic stimulation; exhaustion	NK CELLS; FREQUENT COEXPRESSION; DENDRITIC CELLS; BONE-MARROW; EXPRESSION; TRANS; MATURATION; GENES; HOMEOSTASIS; ACTIVATION	Natural Killer (NK) cells are potent anti-leukemic immune effectors. However, they display multiple defects in acute myeloid leukemia (AML) patients leading to reduced anti-tumor potential. Our limited understanding of the mechanisms underlying these defects hampers the development of strategies to restore NK cell potential. Here, we have used a mouse model of AML to gain insight into these mechanisms. We found that leukemia progression resulted in NK cell maturation defects and functional alterations. Next, we assessed NK cell cytokine signaling governing their behavior. We showed that NK cells from leukemic mice exhibit constitutive IL-15/mTOR signaling and type I IFN signaling. However, these cells failed to respond to IL-15 stimulation in vitro as illustrated by reduced activation of the mTOR pathway. Moreover, our data suggest that mTOR-mediated metabolic responses were reduced in NK cells from AML-bearing mice. Noteworthy, the reduction of mTOR-mediated activation of NK cells during AML development partially rescued NK cell metabolic and functional defects. Altogether, our data strongly suggest that NK cells from leukemic mice are metabolically and functionally exhausted as a result of a chronic cytokine activation, at least partially IL-15/mTOR signaling. NK cells from AML patients also displayed reduced IL-2/15R beta expression and showed cues of reduced metabolic response to IL-15 stimulation in vitro, suggesting that a similar mechanism might occur in AML patients. Our study pinpoints the dysregulation of cytokine stimulation pathways as a new mechanism leading to NK cell defects in AML.	[Bou-Tayeh, Berna; Laletin, Vladimir; Salem, Nassim; Just-Landi, Sylvaine; Fares, Joanna; Leblanc, Raphael; Balzano, Marielle; Bidaut, Ghislain; Olive, Daniel; Aurrand-Lions, Michel; Nunes, Jacques A.; Fauriat, Cyril] Aix Marseille Univ UM105, Ctr Natl Rech Sci CNRS UMR7258, Inserm UMR1068, Inst Paoli Calmettes,Canc Res Ctr Marseille CRCM, Marseille, France; [Just-Landi, Sylvaine; Olive, Daniel] Canc Res Ctr Marseille CRCM, Inst Paoli Calmettes, IBiSA Immunomonitoring Platform, Marseille, France; [Kerdiles, Yann M.] Aix Marseille Univ, Ctr Natl Rech Sci CNRS, Inst Natl Sante & Rech Med INSERM, Ctr Immunol Marseille Luminy CIML, Marseille, France; [Bidaut, Ghislain] Canc Res Ctr Marseille CRCM, Cibi Technol Platform, Marseille, France; [Herault, Olivier] Francois Rabelais Univ, Ctr Natl Rech Sci CNRS UMR 7292, LNOx Team, Tours, France; [Walzer, Thierry] Univ Lyon 1, CNRS UMR5308, Ecole Normale Super Lyon, Ctr Int Rech Infectiol CIRI,Inserm U1111, Lyon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; UNICANCER; Institut Paoli-Calmette (IPC); UNICANCER; Institut Paoli-Calmette (IPC); Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Ecole Normale Superieure de Lyon (ENS de LYON); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Fauriat, C (corresponding author), Aix Marseille Univ UM105, Ctr Natl Rech Sci CNRS UMR7258, Inserm UMR1068, Inst Paoli Calmettes,Canc Res Ctr Marseille CRCM, Marseille, France.	cyril.fauriat@inserm.fr	Walzer, Thierry/L-9418-2014; Fauriat, Cyril/S-2318-2019; kerdiles, yann/U-2190-2018; NUNES, Jacques A/F-4952-2013	Walzer, Thierry/0000-0002-0857-8179; Fauriat, Cyril/0000-0002-4850-6831; kerdiles, yann/0000-0002-8605-1073; NUNES, Jacques A/0000-0003-4865-0400; Leblanc, Raphael/0000-0002-1976-9587	Institut National de la Sante et de la Recherche Medicale (Inserm), Centre National de la Recherche Scientifique (CNRS); Aix-Marseille Universite; Fondation pour la Recherche Medicale [Equipe FRM DEQ20180339209]; specific grants as the programme "Projets Fondation ARC pour la Recherche sur le Cancer [PJA 20191209406]; Canceropole Provence-Alpes-Cote d'Azur; GEFLUC-Marseille; SIRIC-Marseille (SIRIC-INCa-DGOS-Inserm ) [6038]; Ligue Nationale contre le Cancer; Immunology & Cancer Institute (Marseille); AP-HM	Institut National de la Sante et de la Recherche Medicale (Inserm), Centre National de la Recherche Scientifique (CNRS); Aix-Marseille Universite; Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale); specific grants as the programme "Projets Fondation ARC pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le Cancer); Canceropole Provence-Alpes-Cote d'Azur; GEFLUC-Marseille; SIRIC-Marseille (SIRIC-INCa-DGOS-Inserm ); Ligue Nationale contre le Cancer(Ligue nationale contre le cancer); Immunology & Cancer Institute (Marseille); AP-HM	This work was supported by institutional grants from the Institut National de la Sante et de la Recherche Medicale (Inserm), Centre National de la Recherche Scientifique (CNRS) and Aix-Marseille Universite to CRCM; by the Fondation pour la Recherche Medicale (Equipe FRM DEQ20180339209, Equipe "Immunity & Cancer" for DO). This project was supported by specific grants as the programme "Projets Fondation ARC pour la Recherche sur le Cancer PJA 20191209406" (for NJA), by research funding (for CF) from the Canceropole Provence-Alpes-Cote d'Azur, GEFLUC-Marseille and SIRIC-Marseille (SIRIC-INCa-DGOS-Inserm 6038). BB-T was supported by a doctoral fellowship from Aix-Marseille Universite, the Ligue Nationale contre le Cancer, and by a fellowship from Immunology & Cancer Institute (Marseille), VL is supported by a doctoral fellowship from Aix-Marseille Universite, NS is supported by a doctoral fellowship from AP-HM.	Ahl PJ, 2020, COMMUN BIOL, V3, DOI 10.1038/s42003-020-1027-9; Alvarez M, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.127729; Arguello RJ, 2020, CELL METAB, V32, DOI 10.1016/j.cmet.2020.11.007; Bergmann L, 1995, EXP HEMATOL, V23, P1574; Bewersdorf JP, 2019, LEUKEMIA LYMPHOMA, V60, P1354, DOI 10.1080/10428194.2018.1546854; Biederstadt A, 2021, INT J HEMATOL, V114, P554, DOI 10.1007/s12185-021-03209-4; Caligiuri MA, 2008, BLOOD, V112, P461, DOI 10.1182/blood-2007-09-077438; Celik H, 2020, BLOOD ADV, V4, P367, DOI 10.1182/bloodadvances.2019001124; Chiossone L, 2018, NAT REV IMMUNOL, V18, P671, DOI 10.1038/s41577-018-0061-z; Chiossone L, 2009, BLOOD, V113, P5488, DOI 10.1182/blood-2008-10-187179; Chretien AS, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2020459118; Chretien AS, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1307491; Chretien AS, 2017, ONCOTARGET, V8, P49548, DOI 10.18632/oncotarget.17747; Chretien AS, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00573; Cortez VS, 2017, NAT IMMUNOL, V18, P995, DOI 10.1038/ni.3809; Crinier A, 2021, CELL MOL IMMUNOL, V18, P1290, DOI 10.1038/s41423-020-00574-8; Delconte RB, 2016, NAT IMMUNOL, V17, P816, DOI 10.1038/ni.3470; Dohner H, 2015, NEW ENGL J MED, V373, P1136, DOI 10.1056/NEJMra1406184; Donnelly RP, 2014, J IMMUNOL, V193, P4477, DOI 10.4049/jimmunol.1401558; Dubois S, 2002, IMMUNITY, V17, P537, DOI 10.1016/S1074-7613(02)00429-6; Dulphy N, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00094; Elpek KG, 2010, P NATL ACAD SCI USA, V107, P21647, DOI 10.1073/pnas.1012128107; Fauriat C, 2007, BLOOD, V109, P323, DOI 10.1182/blood-2005-08-027979; Felices M, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.96219; Frutoso M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20184514; Frutoso M, 2018, J IMMUNOL, V201, P493, DOI 10.4049/jimmunol.1800086; Gao YL, 2017, NAT IMMUNOL, V18, P1004, DOI 10.1038/ni.3800; Geiger TL, 2016, CURR OPIN IMMUNOL, V39, P82, DOI 10.1016/j.coi.2016.01.007; Gill S, 2012, BLOOD, V119, P5758, DOI 10.1182/blood-2012-03-415364; Guasch G, 2007, CANCER CELL, V12, P313, DOI 10.1016/j.ccr.2007.08.020; Hong CS, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00160; Huntington ND, 2014, IMMUNOL CELL BIOL, V92, P210, DOI 10.1038/icb.2014.1; Imamura T, 2002, BRIT J HAEMATOL, V119, P119, DOI 10.1046/j.1365-2141.2002.03803.x; Keating N, 2019, CYTOKINE, V118, P64, DOI 10.1016/j.cyto.2018.03.033; Kuleshov MV, 2016, NUCLEIC ACIDS RES, V44, pW90, DOI 10.1093/nar/gkw377; Lawrence HJ, 1999, LEUKEMIA, V13, P1993, DOI 10.1038/sj.leu.2401578; Leveen P, 2002, BLOOD, V100, P560, DOI 10.1182/blood.V100.2.560; Limongello R, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.695051; Locatelli F, 2018, TRENDS IMMUNOL, V39, P577, DOI 10.1016/j.it.2018.04.009; Lordo MR, 2021, J IMMUNOL, V207, P1672, DOI 10.4049/jimmunol.2100023; Lucas M, 2007, IMMUNITY, V26, P503, DOI 10.1016/j.immuni.2007.03.006; Mao YM, 2016, BLOOD, V128, P1475, DOI 10.1182/blood-2016-02-698027; Marais A, 2014, NAT IMMUNOL, V15, P749, DOI 10.1038/ni.2936; Marcais A, 2014, CELL CYCLE, V13, P3315, DOI 10.4161/15384101.2014.972919; Marcais A, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00450; Mattei F, 2001, J IMMUNOL, V167, P1179, DOI 10.4049/jimmunol.167.3.1179; Merino A, 2019, J CLIN INVEST, V129, P3770, DOI 10.1172/JCI125916; Mishra A, 2014, CLIN CANCER RES, V20, P2044, DOI 10.1158/1078-0432.CCR-12-3603; Mopin A, 2016, JOVE-J VIS EXP, DOI 10.3791/54270; Mortier E, 2008, J EXP MED, V205, P1213, DOI 10.1084/jem.20071913; Mundy-Bosse BL, 2016, J CLIN INVEST, V126, P4404, DOI 10.1172/JCI85413; Nandagopal N, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00187; Narni-Mancinelli E, 2011, P NATL ACAD SCI USA, V108, P18324, DOI 10.1073/pnas.1112064108; O'Brien KL, 2019, NAT REV IMMUNOL, V19, P282, DOI 10.1038/s41577-019-0139-2; Perdreau H, 2010, EUR CYTOKINE NETW, V21, P297, DOI 10.1684/ecn.2010.0207; Rautela J, 2017, CURR OPIN IMMUNOL, V44, P1, DOI 10.1016/j.coi.2016.10.004; Rey J, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00064; Romee R, 2018, BLOOD, V131, P2515, DOI 10.1182/blood-2017-12-823757; Salzberger W, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201170; Sanchez-Correa B, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00931; Sanchez-Correa B, 2013, CYTOKINE, V61, P885, DOI 10.1016/j.cyto.2012.12.023; Schluns KS, 2004, P NATL ACAD SCI USA, V101, P5616, DOI 10.1073/pnas.0307442101; Scoville SD, 2019, CURR OPIN IMMUNOL, V56, P100, DOI 10.1016/j.coi.2018.11.003; Scoville SD, 2018, BLOOD, V132, P1792, DOI 10.1182/blood-2018-03-838474; Sheppard S, 2021, CELL REP, V35, DOI 10.1016/j.celrep.2021.109210; Short NJ, 2018, LANCET, V392, P593, DOI 10.1016/S0140-6736(18)31041-9; Slattery K., 2019, TGFSS DRIVES MITOCHO, DOI [10.1101/648501, DOI 10.1101/648501]; Stavropoulou V, 2016, CANCER CELL, V30, P43, DOI 10.1016/j.ccell.2016.05.011; Stringaris K, 2014, HAEMATOLOGICA, V99, P836, DOI 10.3324/haematol.2013.087536; Sun JC, 2011, NAT REV IMMUNOL, V11, P645, DOI 10.1038/nri3044; Sun YX, 2014, HUM IMMUNOL, V75, P113, DOI 10.1016/j.humimm.2013.11.014; Viel S, 2017, CANCERS, V9, DOI 10.3390/cancers9100132; Viel S, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aad1884; Vivier E, 2008, NAT IMMUNOL, V9, P503, DOI 10.1038/ni1582; Vivier E, 2018, CELL, V174, P1054, DOI 10.1016/j.cell.2018.07.017; Wagner JA, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107720; Wang AD, 2018, HEMATOLOGY, V23, P729, DOI 10.1080/10245332.2018.1486064; Wilhelm BT, 2011, BLOOD, V117, pE27, DOI 10.1182/blood-2010-07-293332; Yang MX, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12730; Zaiatz-Bittencourt V, 2018, J IMMUNOL, V200, P3934, DOI 10.4049/jimmunol.1701461; Zhang J, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-25758-2; Zhang J, 2018, EUR J IMMUNOL, V48, P738, DOI 10.1002/eji.201747299; Zhang Q, 2018, NAT IMMUNOL, V19, P723, DOI 10.1038/s41590-018-0132-0; Zhu H, 2020, CELL STEM CELL, V27, P224, DOI 10.1016/j.stem.2020.05.008	84	0	0	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 17	2021	12								730970	10.3389/fimmu.2021.730970	http://dx.doi.org/10.3389/fimmu.2021.730970			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YB1TZ	34975835	gold, Green Published			2022-12-18	WOS:000738804900001
J	Fazil, MHUT; Prasannan, P; Wong, BHS; Kottaiswamy, A; Salim, NSBM; Sze, SK; Verma, NK				Fazil, Mobashar Hussain Urf Turabe; Prasannan, Praseetha; Wong, Brandon Han Siang; Kottaiswamy, Amuthavalli; Salim, Nur Syazwani Binte Mohamed; Sze, Siu Kwan; Verma, Navin Kumar			GSK3 beta Interacts With CRMP2 and Notch1 and Controls T-Cell Motility	FRONTIERS IN IMMUNOLOGY			English	Article						GSK3 beta; NOTCH1; T-lymphocytes; LFA-1; T-cell migration	GLYCOGEN-SYNTHASE KINASE-3; RESPONSE MEDIATOR PROTEIN-2; BETA-CATENIN; PHOSPHORYLATION; PROMOTES; MIGRATION; DIFFERENTIATION; POLARIZATION; REGENERATION; INHIBITION	The trafficking of T-cells through peripheral tissues and into afferent lymphatic vessels is essential for immune surveillance and an adaptive immune response. Glycogen synthase kinase 3 beta (GSK3 beta) is a serine/threonine kinase and regulates numerous cell/tissue-specific functions, including cell survival, metabolism, and differentiation. Here, we report a crucial involvement of GSK3 beta in T-cell motility. Inhibition of GSK3 beta by CHIR-99021 or siRNA-mediated knockdown augmented the migratory behavior of human T-lymphocytes stimulated via an engagement of the T-cell integrin LFA-1 with its ligand ICAM-1. Proteomics and protein network analysis revealed ongoing interactions among GSK3 beta, the surface receptor Notch1 and the cytoskeletal regulator CRMP2. LFA-1 stimulation in T-cells reduced Notch1-dependent GSK3 beta activity by inducing phosphorylation at Ser9 and its nuclear translocation accompanied by the cleaved Notch1 intracellular domain and decreased GSK3 beta-CRMP2 association. LFA-1-induced or pharmacologic inhibition of GSK3 beta in T-cells diminished CRMP2 phosphorylation at Thr514. Although substantial amounts of CRMP2 were localized to the microtubule-organizing center in resting T-cells, this colocalization of CRMP2 was lost following LFA-1 stimulation. Moreover, the migratory advantage conferred by GSK3 beta inhibition in T-cells by CHIR-99021 was lost when CRMP2 expression was knocked-down by siRNA-induced gene silencing. We therefore conclude that GSK3 beta controls T-cell motility through interactions with CRMP2 and Notch1, which has important implications in adaptive immunity, T-cell mediated diseases and LFA-1-targeted therapies.	[Fazil, Mobashar Hussain Urf Turabe; Prasannan, Praseetha; Wong, Brandon Han Siang; Kottaiswamy, Amuthavalli; Salim, Nur Syazwani Binte Mohamed; Verma, Navin Kumar] Nanyang Technol Univ Singapore, Lee Kong Chian Sch Med, Singapore, Singapore; [Wong, Brandon Han Siang] Nanyang Technol Univ Singapore, NTU Inst Hlth Technol HealthTech NTU, Interdisciplinary Grad Programme, Singapore, Singapore; [Sze, Siu Kwan] Nanyang Technol Univ Singapore, Sch Biol Sci, Singapore, Singapore	Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University; Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University; Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University	Verma, NK (corresponding author), Nanyang Technol Univ Singapore, Lee Kong Chian Sch Med, Singapore, Singapore.	nkverma@ntu.edu.sg	Verma, Navin Kumar/B-7641-2008	Verma, Navin Kumar/0000-0002-5940-6633	Singapore Ministry of Education (MOE) Academic Research Fund (AcRF) Tier 1 [2014-T1-001-141, 2020-T1-001-062]; National Research Foundation Singapore under its Open Fund Large Collaborative Grant [OFLCG18May-0028]	Singapore Ministry of Education (MOE) Academic Research Fund (AcRF) Tier 1(Ministry of Education, Singapore); National Research Foundation Singapore under its Open Fund Large Collaborative Grant	This work was supported by the grants from the Singapore Ministry of Education (MOE) Academic Research Fund (AcRF) Tier 1 (2014-T1-001-141 and 2020-T1-001-062) and the National Research Foundation Singapore under its Open Fund Large Collaborative Grant (OFLCG18May-0028) and administered by the Singapore Ministry of Health's National Medical Research Council (NMRC).	Arimura N, 2005, MOL CELL BIOL, V25, P9973, DOI 10.1128/MCB.25.22.9973-9984.2005; Bain J, 2007, BIOCHEM J, V408, P297, DOI 10.1042/BJ20070797; Bautista SJ, 2018, J BIOL CHEM, V293, P14723, DOI 10.1074/jbc.RA118.002800; Bedsaul JR, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02105; Beurel E, 2014, NEUROIMMUNOMODULAT, V21, P140, DOI 10.1159/000356550; Brandstadter JD, 2019, OPEN BIOL, V9, DOI 10.1098/rsob.190187; Brittain JM, 2012, FEBS LETT, V586, P3813, DOI 10.1016/j.febslet.2012.09.022; Chan O, 2012, J BIOL CHEM, V287, P29406, DOI 10.1074/jbc.M112.348946; Cheng TT, 2017, ONCOTARGET, V8, P7814, DOI 10.18632/oncotarget.13958; Chu QY, 2021, CANCER MED-US, V10, P3689, DOI 10.1002/cam4.3916; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; Cole AR, 2006, J BIOL CHEM, V281, P16591, DOI 10.1074/jbc.M513344200; Cormier Kevin W, 2017, F1000Res, V6, DOI 10.12688/f1000research.10557.1; D'Uva G, 2015, NAT CELL BIOL, V17, P627, DOI 10.1038/ncb3149; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; DeJonge RE, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162508; Dong BX, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080500; Eagar TN, 2004, IMMUNITY, V20, P407, DOI 10.1016/S1074-7613(04)00081-0; Espinosa L, 2003, J BIOL CHEM, V278, P32227, DOI 10.1074/jbc.M304001200; Fan CM, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.132796; Fan CM, 2020, J MOL CELL CARDIOL, V141, P1, DOI 10.1016/j.yjmcc.2020.03.003; Fei Y, 2018, CELL SIGNAL, V44, P62, DOI 10.1016/j.cellsig.2018.01.012; Foltz DR, 2002, CURR BIOL, V12, P1006, DOI 10.1016/S0960-9822(02)00888-6; Fryer CJ, 2004, MOL CELL, V16, P509, DOI 10.1016/j.molcel.2004.10.014; Fukata Y, 2002, NAT CELL BIOL, V4, P583, DOI 10.1038/ncb825; Govarthanan K, 2020, CYTOTHERAPY, V22, P91, DOI 10.1016/j.jcyt.2019.12.007; Huang JQ, 2017, SCI REP-UK, V7, DOI 10.1038/srep40716; Hur EM, 2010, NAT REV NEUROSCI, V11, P539, DOI 10.1038/nrn2870; Ishihama Y, 2005, MOL CELL PROTEOMICS, V4, P1265, DOI 10.1074/mcp.M500061-MCP200; Kizhakeyil A, 2019, METHODS MOL BIOL, V1930, P11, DOI 10.1007/978-1-4939-9036-8_2; Kondo S, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-43658-w; Krummel MF, 2016, NAT REV IMMUNOL, V16, P193, DOI 10.1038/nri.2015.16; Li CY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084659; Lin PC, 2011, J BIOL CHEM, V286, P41466, DOI 10.1074/jbc.M111.283580; Ma YJ, 2019, J CELL SCI, V132, DOI 10.1242/jcs.229948; Malagon SGG, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03512-5; Maurer U, 2014, J CELL SCI, V127, P1369, DOI 10.1242/jcs.138057; Mimura F, 2006, J BIOL CHEM, V281, P15970, DOI 10.1074/jbc.M510934200; Morrugares R, 2020, CELL MOL LIFE SCI, V77, P2621, DOI 10.1007/s00018-019-03309-9; Nakamura F, 2020, FRONT CELL NEUROSCI, V14, DOI 10.3389/fncel.2020.00188; Niwa S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11031-4; Ong ST, 2019, METHODS MOL BIOL, V1930, P33, DOI 10.1007/978-1-4939-9036-8_5; Ong ST, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00397; Prasannan P, 2019, METHODS MOL BIOL, V1930, P51, DOI 10.1007/978-1-4939-9036-8_7; RUEL L, 1993, NATURE, V362, P557, DOI 10.1038/362557a0; Salmond RJ, 2009, J IMMUNOL, V183, P7388, DOI 10.4049/jimmunol.0902294; Schroeder JH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058501; Senoo H, 2019, NAT CELL BIOL, V21, P867, DOI 10.1038/s41556-019-0348-8; Sineva GS, 2010, BIOL CELL, V102, P549, DOI 10.1042/BC20100016; Sumi T, 2018, CELL STRUCT FUNCT, V43, P15, DOI 10.1247/csf.17025; Taylor A, 2020, BMC RES NOTES, V13, DOI 10.1186/s13104-020-04971-0; Taylor A, 2016, IMMUNITY, V44, P274, DOI 10.1016/j.immuni.2016.01.018; ter Haar E, 2001, NAT STRUCT BIOL, V8, P593, DOI 10.1038/89624; Uchida Y, 2005, GENES CELLS, V10, P165, DOI 10.1111/j.1365-2443.2005.00827.x; Varrin-Doyer M, 2012, J IMMUNOL, V188, P1222, DOI 10.4049/jimmunol.1101562; Varrin-Doyer M, 2009, J BIOL CHEM, V284, P13265, DOI 10.1074/jbc.M807664200; Verma NK, 2016, J IMMUNOL, V197, P108, DOI 10.4049/jimmunol.1501264; Verma NK, 2011, J CELL PHYSIOL, V226, P1489, DOI 10.1002/jcp.22478; Verma NK, 2019, METHODS MOL BIOL, V1930, P19, DOI 10.1007/978-1-4939-9036-8_3; Verma NK, 2017, J IMMUNOL, V199, P1213, DOI 10.4049/jimmunol.1700495; Vincent P, 2005, J IMMUNOL, V175, P7650, DOI 10.4049/jimmunol.175.11.7650; von Andrian UH, 2000, NEW ENGL J MED, V343, P1020, DOI 10.1056/NEJM200010053431407; Vuaillat C, 2008, J NEUROIMMUNOL, V193, P38, DOI 10.1016/j.jneuroim.2007.09.033; Wang SB, 2016, J CARDIOVASC PHARM, V68, P425, DOI 10.1097/FJC.0000000000000429; Wang YP, 2020, BIOCHEM BIOPH RES CO, V531, P543, DOI 10.1016/j.bbrc.2020.07.142; Wu YY, 2015, SCI REP-UK, V5, DOI 10.1038/srep08666; Yoshida Y, 2019, BIOCHEM BIOPH RES CO, V516, P599, DOI 10.1016/j.bbrc.2019.06.038; Yoshimura T, 2005, CELL, V120, P137, DOI 10.1016/j.cell.2004.11.012; Zhang P, 2018, FASEB J, V32, P3924, DOI 10.1096/fj.201701078R	69	0	0	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 17	2021	12								680071	10.3389/fimmu.2021.680071	http://dx.doi.org/10.3389/fimmu.2021.680071			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YB6JO	34975828	gold, Green Published			2022-12-18	WOS:000739116400001
J	Fu, WY; Liu, Y; Liu, FJ; Liu, CH; Li, JJ; Niu, JL; Han, P; Xu, D; Hou, JJ; Ma, YF; Feng, JN; Li, ZG; Mu, R; Yang, G				Fu, Wenyan; Liu, Yu; Liu, Fangjie; Liu, Chenghua; Li, Jingjing; Niu, Jiali; Han, Peng; Xu, Dan; Hou, Jiaojiao; Ma, Yuanfang; Feng, Jiannan; Li, Zhanguo; Mu, Rong; Yang, Guang			A Novel Autoantibody Induced by Bacterial Biofilm Conserved Components Aggravates Lupus Nephritis (vol 12, 656090, 2021)	FRONTIERS IN IMMUNOLOGY			English	Correction						bacterial biofilm; DNABII; autoantibody; lupus nephritis; protein disulfide isomerase			[Fu, Wenyan; Liu, Yu; Liu, Fangjie; Liu, Chenghua; Feng, Jiannan; Yang, Guang] Beijing Inst Pharmacol & Toxicol, Beijing, Peoples R China; [Fu, Wenyan; Liu, Yu; Liu, Fangjie; Liu, Chenghua; Feng, Jiannan; Yang, Guang] State Key Lab Toxicol & Med Countermeasures, Beijing, Peoples R China; [Li, Jingjing; Niu, Jiali; Hou, Jiaojiao; Ma, Yuanfang] Henan Univ, Joint Natl Lab Antibody Drug Engn, Kaifeng, Peoples R China; [Han, Peng; Xu, Dan; Li, Zhanguo; Mu, Rong] Peking Univ, Peoples Hosp, Dept Rheumatol & Immunol, Beijing, Peoples R China	Academy of Military Medical Sciences - China; Henan University; Peking University	Yang, G (corresponding author), Beijing Inst Pharmacol & Toxicol, Beijing, Peoples R China.; Yang, G (corresponding author), State Key Lab Toxicol & Med Countermeasures, Beijing, Peoples R China.; Mu, R (corresponding author), Peking Univ, Peoples Hosp, Dept Rheumatol & Immunol, Beijing, Peoples R China.	murongster@163.com; yangg62033@outlook.com	Li, Jing/GYU-5036-2022					Fu WY, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.656090	1	0	0	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 17	2021	12								819846	10.3389/fimmu.2021.819846	http://dx.doi.org/10.3389/fimmu.2021.819846			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YB6QP	34975928	Green Published, gold			2022-12-18	WOS:000739134700001
J	Holland, EM; Gonzalez, C; Levy, E; Valera, VA; Chalfin, H; Klicka-Skeels, J; Yates, B; Kleiner, DE; Hadigan, C; Dave, H; Shalabi, H; Hickstein, DD; Su, HLC; Grimley, M; Freeman, AF; Shah, NRLN				Holland, Elizabeth M.; Gonzalez, Corina; Levy, Elliot; Valera, Vladimir A.; Chalfin, Heather; Klicka-Skeels, Jacquelyn; Yates, Bonnie; Kleiner, David E.; Hadigan, Colleen; Dave, Hema; Shalabi, Haneen; Hickstein, Dennis D.; Su, Helen C.; Grimley, Michael; Freeman, Alexandra F.; Shah, Nirali N.			Case Report: Fatal Complications of BK Virus-Hemorrhagic Cystitis and Severe Cytokine Release Syndrome Following BK Virus-Specific T-Cells	FRONTIERS IN IMMUNOLOGY			English	Article						DOCK8 immunodeficiency syndrome; HSCT = hematopoietic stem cell transplant; BK virus associated hemorrhagic cystitis; virus specific T-cells; cytokine release syndrome	NON-HODGKIN-LYMPHOMA; TRANSPLANTATION; CHILDREN; VASCULOPATHY; INFECTION; DEDICATOR	BK virus (BKV)-hemorrhagic cystitis (HC) is a well-known and rarely fatal complication of hematopoietic stem cell transplantation (HSCT). Treatment for BKV-HC is limited, but virus-specific T-cells (VST) represent a promising therapeutic option feasible for use posttransplant. We report on the case of a 16-year-old male with dedicator of cytokinesis 8 (DOCK8) deficiency who underwent haploidentical HSCT complicated by severe BKV-HC, catastrophic renal hemorrhage, and VST-associated cytokine release syndrome (CRS). Gross hematuria refractory to multiple interventions began with initiation of posttransplant cyclophosphamide (PT/Cy). Complete left renal arterial embolization (day +43) was ultimately indicated to control intractable renal hemorrhage. Subsequent infusion of anti-BK VSTs was complicated by CRS and progressive multiorgan failure, with postmortem analysis confirming diagnosis of hepatic sinusoidal obstruction syndrome (SOS). This case illustrates opportunities for improvement in the management of severe BKV-HC posttransplant while highlighting rare and potentially life-threatening complications of BKV-HC and VST therapy.	[Holland, Elizabeth M.; Gonzalez, Corina; Yates, Bonnie; Shalabi, Haneen; Shah, Nirali N.] NCI, Pediat Oncol Branch, Ctr Canc Res CCR, NIH, Bethesda, MD 20892 USA; [Gonzalez, Corina; Hickstein, Dennis D.] NCI, Immune Deficiency Cellular Therapy Program, Ctr Canc Res CCR, NIH, Bethesda, MD 20892 USA; [Levy, Elliot] NIH, Radiol & Imaging Sci, Clin Ctr CC, Bldg 10, Bethesda, MD 20892 USA; [Valera, Vladimir A.; Chalfin, Heather] NCI, Urol Oncol Branch, Ctr Canc Res CCR, NIH, Bethesda, MD 20892 USA; [Klicka-Skeels, Jacquelyn; Dave, Hema] Childrens Natl Med Ctr, Pediat Oncol, Washington, DC USA; [Kleiner, David E.] NCI, Pathol Lab, NIH, Bethesda, MD 20892 USA; [Hadigan, Colleen] NIH, Pediat Gastroenterol, Clin Ctr CC, Bldg 10, Bethesda, MD 20892 USA; [Su, Helen C.; Freeman, Alexandra F.] NIAID, Lab Clin Immunol & Microbiol, NIH, Clin Ctr CC, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Grimley, Michael] Cincinnati Childrens Hosp, Div Bone Marrow Transplantat & Immune Deficiency, Cincinnati, OH USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Children's National Health System; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Cincinnati Children's Hospital Medical Center	Shah, NRLN (corresponding author), NCI, Pediat Oncol Branch, Ctr Canc Res CCR, NIH, Bethesda, MD 20892 USA.	Nirali.Shah@nih.gov			Intramural Research Program, Center of Cancer Research, National Cancer Institute, National Institutes of Health [ZIA BC 011823]; National Institute of Allergy and Infectious Diseases, National Institutes of Health [ZIA BC 011823]; NIH Clinical Center, National Institutes of Health [ZIA BC 011823]	Intramural Research Program, Center of Cancer Research, National Cancer Institute, National Institutes of Health; National Institute of Allergy and Infectious Diseases, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIH Clinical Center, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	The authors gratefully acknowledge the study participants reported on in this case (family provided consent for publication), and the faculty and staff and care providers at the National Institutes of Health Clinical Center, Children's National Medical Center, and Cincinnati Children's Hospital who provided their support and expertise in the care of this patient. This work was supported in part by the Intramural Research Program, Center of Cancer Research, National Cancer Institute, National Institute of Allergy and Infectious Diseases, and NIH Clinical Center, National Institutes of Health (ZIA BC 011823).	Al-Herz W, 2016, J ALLERGY CLIN IMMUN, V138, P852, DOI 10.1016/j.jaci.2016.02.022; AlKhater SA, 2016, BMC NEUROL, V16, DOI 10.1186/s12883-016-0578-3; Aydin SE, 2019, J ALLER CL IMM-PRACT, V7, P848, DOI 10.1016/j.jaip.2018.10.035; Aydin SE, 2015, J CLIN IMMUNOL, V35, P189, DOI 10.1007/s10875-014-0126-0; Cohen JM, 2007, LEUKEMIA LYMPHOMA, V48, P256, DOI 10.1080/10428190601059837; Cuellar-Rodriguez J, 2015, BIOL BLOOD MARROW TR, V21, P1037, DOI 10.1016/j.bbmt.2015.01.022; Fajgenbaum DC, 2020, NEW ENGL J MED, V383, P2255, DOI 10.1056/NEJMra2026131; Foster JH, 2018, PEDIATR TRANSPLANT, V22, DOI 10.1111/petr.13141; Goldman S, 2013, LEUKEMIA, V27, P1174, DOI 10.1038/leu.2012.255; Harkensee C, 2008, BRIT J HAEMATOL, V142, P717, DOI 10.1111/j.1365-2141.2008.07254.x; Keller MD, 2020, BLOOD, V135, P620, DOI 10.1182/blood.2019000924; Laskin BL, 2020, CLIN INFECT DIS, V71, P3044, DOI 10.1093/cid/ciz1194; Naik S, 2016, J ALLERGY CLIN IMMUN, V137, P1498, DOI 10.1016/j.jaci.2015.12.1311; Nelson AS, 2020, BLOOD ADV, V4, P5745, DOI 10.1182/bloodadvances.2020003073; Olson A, 2021, J CLIN ONCOL, V39, P2710, DOI 10.1200/JCO.20.02608; Patte C, 2007, BLOOD, V109, P2773, DOI 10.1182/blood-2006-07-036673; Petrogiannis-Haliotis T, 2001, NEW ENGL J MED, V345, P1250, DOI 10.1056/NEJMoa010319; Pillay BA, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.127527; Sabry A, 2014, J ALLERGY CLIN IMMUN, V133, P1225, DOI 10.1016/j.jaci.2013.11.031; Shah A, 2019, TRANSPL INFECT DIS, V21, DOI 10.1111/tid.13083; Shah NN, 2017, BIOL BLOOD MARROW TR, V23, P980, DOI 10.1016/j.bbmt.2017.03.016; Su HC, 2019, IMMUNOL REV, V287, P9, DOI 10.1111/imr.12723; Vigil Darlene, 2016, World J Transplant, V6, P472, DOI 10.5500/wjt.v6.i3.472; Wiesend WN, 2010, ANN CLIN LAB SCI, V40, P324; Zhang Q, 2009, NEW ENGL J MED, V361, P2046, DOI 10.1056/NEJMoa0905506	25	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 17	2021	12								801281	10.3389/fimmu.2021.801281	http://dx.doi.org/10.3389/fimmu.2021.801281			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YB0ZW	34975916	Green Published, gold			2022-12-18	WOS:000738752100001
J	Kourtzelis, I; Hewitson, J; Roger, T				Kourtzelis, Ioannis; Hewitson, James; Roger, Thierry			Editorial: Macrophage Plasticity in Sterile and Pathogen-Induced Inflammation	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						macrophage plasticity; resolution of inflammation; reprograming; memory; sterile inflammation			[Kourtzelis, Ioannis] Univ York, York Biomed Res Inst, Hull York Med Sch, York, N Yorkshire, England; [Hewitson, James] Univ York, York Biomed Res Inst, Dept Biol, York, N Yorkshire, England; [Roger, Thierry] Lausanne Univ Hosp, Dept Med, Infect Dis Serv, Epalinges, Switzerland; Univ Lausanne, Epalinges, Switzerland	University of Hull; University of York - UK; University of York - UK; University of Lausanne	Kourtzelis, I (corresponding author), Univ York, York Biomed Res Inst, Hull York Med Sch, York, N Yorkshire, England.	ioannis.kourtzelis@york.ac.uk	Roger, Thierry/G-2007-2012	Roger, Thierry/0000-0002-9358-0109	Royal Society [RGS\R2\202032]; Academy of Medical Science and Global Challenges Research Fund [SBF003\1096]; Swiss National Science Foundation [173123]; Carigest Foundation (Switzerland); European Union; Marie Sklodowska-Curie Action Innovative Training Network European Sepsis Academy [676129]; ImmunoSep [847422]; HDM-FUN [847507]	Royal Society(Royal Society of London); Academy of Medical Science and Global Challenges Research Fund; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Carigest Foundation (Switzerland); European Union(European Commission); Marie Sklodowska-Curie Action Innovative Training Network European Sepsis Academy; ImmunoSep; HDM-FUN	IK acknowledges support from grant from the Royal Society (RGS\R2\202032). JH was supported by the Academy of Medical Science and Global Challenges Research Fund (SBF003\1096). TR was supported by the Swiss National Science Foundation (173123), the Carigest Foundation (Switzerland), and the European Union Horizon 2020 Marie Sklodowska-Curie Action Innovative Training Network European Sepsis Academy (676129), and Horizon 2020 grants ImmunoSep (847422) and HDM-FUN (847507).		0	0	0	3	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 17	2021	12								823023	10.3389/fimmu.2021.823023	http://dx.doi.org/10.3389/fimmu.2021.823023			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YB6JH	34975930	Green Published, gold			2022-12-18	WOS:000739115700001
J	Riaz, S; Steinsland, H; Thorsing, M; Andersen, AZ; Boysen, A; Hanevik, K				Riaz, Saman; Steinsland, Hans; Thorsing, Mette; Andersen, Ann Z.; Boysen, Anders; Hanevik, Kurt			Characterization of Glycosylation-Specific Systemic and Mucosal IgA Antibody Responses to Escherichia coli Mucinase YghJ (SslE)	FRONTIERS IN IMMUNOLOGY			English	Article						enterotoxigenic Escherichia coli; immunogenicity; vaccine development; protein glycosylation; IgA; SslE; YghJ	II SECRETION SYSTEM; IDENTIFICATION; METALLOPROTEASE; RECOGNITION; COMPLEX; EPITOPE	Efforts to develop broadly protective vaccines against pathogenic Escherichia coli are ongoing. A potential antigen candidate for vaccine development is the metalloprotease YghJ, or SslE. YghJ is a conserved mucinase that is immunogenic, heavily glycosylated, and produced by most pathogenic E. coli. To develop efficacious YghJ-based vaccines, there is a need to investigate to what extent potentially protective antibody responses target glycosylated epitopes in YghJ and to describe variations in the quality of YghJ glycosylation in the E. coli population. In this study we estimated the proportion of anti-YghJ IgA antibodies that targeted glycosylated epitopes in serum and intestinal lavage samples from 21 volunteers experimentally infected with wild-type enterotoxigenic E. coli (ETEC) strain TW10722. Glycosylated and non-glycosylated YghJ was expressed, purified, and then gycosylation pattern was verified by BEMAP analysis. Then we used a multiplex bead flow cytometric assay to analyse samples from before and 10 days after TW10722 was ingested. We found that 20 (95%) of the 21 volunteers had IgA antibody responses to homologous, glycosylated YghJ, with a median fold increase in IgA levels of 7.9 (interquartile range [IQR]: 7.1, 11.1) in serum and 3.7 (IQR: 2.1, 10.7) in lavage. The median proportion of anti-YghJ IgA response that specifically targeted glycosylated epitopes was 0.45 (IQR: 0.30, 0.59) in serum and 0.07 (IQR: 0.01, 0.22) in lavage. Our findings suggest that a substantial, but variable, proportion of the IgA antibody response to YghJ in serum during ETEC infection is targeted against glycosylated epitopes, but that gut IgA responses largely target non-glycosylated epitopes. Further research into IgA targeting glycosylated YghJ epitopes is of interest to the vaccine development efforts.	[Riaz, Saman; Hanevik, Kurt] Univ Bergen, Dept Clin Sci, Bergen, Norway; [Riaz, Saman] Univ Bergen, Dept Global Publ Hlth & Primary Care, Ctr Int Hlth, Bergen, Norway; [Steinsland, Hans] Univ Bergen, Dept Global Publ Hlth & Primary Care, Ctr Intervent Sci Maternal & Child Hlth CISMAC, Ctr Int Hlth, Bergen, Norway; [Steinsland, Hans] Univ Bergen, Dept Biomed, Bergen, Norway; [Thorsing, Mette; Andersen, Ann Z.; Boysen, Anders] GlyProVac ApS, Odense, Denmark; [Hanevik, Kurt] Haukeland Hosp, Dept Med, Norwegian Natl Advisory Unit Trop Infect Dis, Bergen, Norway	University of Bergen; University of Bergen; University of Bergen; University of Bergen; University of Bergen; Haukeland University Hospital	Hanevik, K (corresponding author), Univ Bergen, Dept Clin Sci, Bergen, Norway.; Hanevik, K (corresponding author), Haukeland Hosp, Dept Med, Norwegian Natl Advisory Unit Trop Infect Dis, Bergen, Norway.	Kurt.Hanevik@uib.no	Hanevik, Kurt/I-1159-2012	Hanevik, Kurt/0000-0002-1466-2326	University of Bergen; Research Council of Norway [234364]; Innovation Fund Denmark [7041-00220]	University of Bergen; Research Council of Norway(Research Council of Norway); Innovation Fund Denmark	This work was supported by the University of Bergen, The Research Council of Norway (project number 234364), and Innovation Fund Denmark (Grant # 7041-00220).	Aase A, 2016, MUCOSAL IMMUNOL, V9, P884, DOI 10.1038/mi.2015.107; Alam SM, 2013, P NATL ACAD SCI USA, V110, P18214, DOI 10.1073/pnas.1317855110; Baldi DL, 2012, INFECT IMMUN, V80, P2042, DOI 10.1128/IAI.06160-11; Benz I, 2001, MOL MICROBIOL, V40, P1403, DOI 10.1046/j.1365-2958.2001.02487.x; Boysen A, 2016, SCI REP-UK, V6, DOI 10.1038/srep32016; Boysen A, 2010, J BIOL CHEM, V285, P10690, DOI 10.1074/jbc.M109.089755; Chakraborty S, 2018, J INFECT DIS, V218, P1436, DOI 10.1093/infdis/jiy312; Corsini PM., 2021, MOL CELLULAR INSIGHT, DOI [10.1101/2021.02.07.430137, DOI 10.1101/2021.02.07.430137]; Falkowska E, 2014, IMMUNITY, V40, P657, DOI 10.1016/j.immuni.2014.04.009; Fleckenstein JM, 2006, INFECT IMMUN, V74, P2245, DOI 10.1128/IAI.74.4.2245-2258.2006; Hermansen GMM, 2018, FRONT CELL INFECT MI, V8, DOI [10.1146/ANNUREV-BI0CHEM-060713-035600, 10.3389/fcimb.2018.00253]; Kaper JB, 2004, NAT REV MICROBIOL, V2, P123, DOI 10.1038/nrmicro818; Levine MM, 2019, HUM VACC IMMUNOTHER, V15, P1357, DOI 10.1080/21645515.2019.1578922; Lindenthal C, 1999, INFECT IMMUN, V67, P4084, DOI 10.1128/IAI.67.8.4084-4091.1999; Lindenthal C, 2001, INFECT IMMUN, V69, P52, DOI 10.1128/IAI.69.1.52-57.2001; Lisowska E, 2002, CELL MOL LIFE SCI, V59, P445, DOI 10.1007/s00018-002-8437-3; Lithgow KV, 2014, MOL MICROBIOL, V92, P116, DOI 10.1111/mmi.12540; Ljungberg KR, 2020, ARTHRITIS RES THER, V22, DOI 10.1186/s13075-020-02363-0; Lu QH, 2015, TRENDS MICROBIOL, V23, P630, DOI 10.1016/j.tim.2015.07.003; Luo QW, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003446; Luo QW, 2014, INFECT IMMUN, V82, P509, DOI 10.1128/IAI.01106-13; Mirhoseini A, 2018, MICROB PATHOGENESIS, V117, P162, DOI 10.1016/j.micpath.2018.02.032; Moriel DG, 2010, P NATL ACAD SCI USA, V107, P9072, DOI 10.1073/pnas.0915077107; Nesta B, 2018, CURR TOP MICROBIOL, V416, P213, DOI 10.1007/82_2018_111; Nesta B, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004124; Perez-Riverol Y, 2019, NUCLEIC ACIDS RES, V47, pD442, DOI 10.1093/nar/gky1106; Romain F, 1999, INFECT IMMUN, V67, P5567, DOI 10.1128/IAI.67.11.5567-5572.1999; Sakkestad ST, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007823; Sakkestad ST, 2019, PATHOGENS, V8, DOI 10.3390/pathogens8020084; Strozen TG, 2012, INFECT IMMUN, V80, P2608, DOI 10.1128/IAI.06394-11; Tapader R, 2019, INT J MED MICROBIOL, V309, P159, DOI 10.1016/j.ijmm.2019.03.002; Tapader R, 2017, MICROB PATHOGENESIS, V105, P96, DOI 10.1016/j.micpath.2017.02.020; Urban JH, 2007, NUCLEIC ACIDS RES, V35, P1018, DOI 10.1093/nar/gkl1040; Uzzau S, 2001, P NATL ACAD SCI USA, V98, P15264, DOI 10.1073/pnas.261348198; Valeri M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117486	35	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 17	2021	12								760135	10.3389/fimmu.2021.760135	http://dx.doi.org/10.3389/fimmu.2021.760135			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YB2DP	34975849	gold, Green Published			2022-12-18	WOS:000738830000001
J	Cosma, G; McArdle, SE; Foulds, GA; Hood, SP; Reeder, S; Johnson, C; Khan, MA; Pockley, AG				Cosma, Georgina; McArdle, Stephanie E.; Foulds, Gemma A.; Hood, Simon P.; Reeder, Stephen; Johnson, Catherine; Khan, Masood A.; Pockley, A. Graham			Prostate Cancer: Early Detection and Assessing Clinical Risk Using Deep Machine Learning of High Dimensional Peripheral Blood Flow Cytometric Phenotyping Data	FRONTIERS IN IMMUNOLOGY			English	Article						prostate cancer; predictive modeling; immunophenotyping data; flow cytometry; PSA level; computational analysis; machine learning	BIOPSIES; ANTIGEN; SERUM	Detecting the presence of prostate cancer (PCa) and distinguishing low- or intermediate-risk disease from high-risk disease early, and without the need for potentially unnecessary invasive biopsies remains a significant clinical challenge. The aim of this study is to determine whether the T and B cell phenotypic features which we have previously identified as being able to distinguish between benign prostate disease and PCa in asymptomatic men having Prostate-Specific Antigen (PSA) levels < 20 ng/ml can also be used to detect the presence and clinical risk of PCa in a larger cohort of patients whose PSA levels ranged between 3 and 2617 ng/ml. The peripheral blood of 130 asymptomatic men having elevated Prostate-Specific Antigen (PSA) levels was immune profiled using multiparametric whole blood flow cytometry. Of these men, 42 were subsequently diagnosed as having benign prostate disease and 88 as having PCa on biopsy-based evidence. We built a bidirectional Long Short-Term Memory Deep Neural Network (biLSTM) model for detecting the presence of PCa in men which combined the previously-identified phenotypic features (CD8(+)CD45RA(-)CD27(-)CD28(-) (CD8(+) Effector Memory cells), CD4(+)CD45RA(-)CD27(-)CD28(-) (CD4(+) Effector Memory cells), CD4(+)CD45RA(+)CD27(-)CD28(-) (CD4(+) Terminally Differentiated Effector Memory Cells re-expressing CD45RA), CD3(-)CD19(+) (B cells), CD3(+)CD56(+)CD8(+)CD4(+) (NKT cells) with Age. The performance of the PCa presence 'detection' model was: Acc: 86.79 ( +/- 0.10), Sensitivity: 82.78% (+/- 0.15); Specificity: 95.83% (+/- 0.11) on the test set (test set that was not used during training and validation); AUC: 89.31% (+/- 0.07), ORP-FPR: 7.50% (+/- 0.20), ORP-TPR: 84.44% (+/- 0.14). A second biLSTM 'risk' model combined the immunophenotypic features with PSA to predict whether a patient with PCa has high-risk disease (defined by the D'Amico Risk Classification) achieved the following: Acc: 94.90% (+/- 6.29), Sensitivity: 92% (+/- 21.39); Specificity: 96.11 (+/- 0.00); AUC: 94.06% (+/- 10.69), ORP-FPR: 3.89% (+/- 0.00), ORP-TPR: 92% (+/- 21.39). The ORP-FPR for predicting the presence of PCa when combining FC+PSA was lower than that of PSA alone. This study demonstrates that AI approaches based on peripheral blood phenotyping profiles can distinguish between benign prostate disease and PCa and predict clinical risk in asymptomatic men having elevated PSA levels.	[Cosma, Georgina] Loughborough Univ, Dept Comp Sci, Loughborough, Leics, England; [McArdle, Stephanie E.; Foulds, Gemma A.; Hood, Simon P.; Reeder, Stephen; Johnson, Catherine; Pockley, A. Graham] Nottingham Trent Univ, John Van Geest Canc Res Ctr, Sch Sci & Technol, Nottingham, England; [McArdle, Stephanie E.; Foulds, Gemma A.; Reeder, Stephen; Johnson, Catherine; Pockley, A. Graham] Nottingham Trent Univ, Sch Sci & Technol, Ctr Hlth Ageing & Understanding Dis CHAUD, Nottingham, England; [Khan, Masood A.] Univ Hosp Leicester Natl Hlth NHS Trust, Dept Urol, Leicester, Leics, England	Loughborough University; Nottingham Trent University; Nottingham Trent University	Cosma, G (corresponding author), Loughborough Univ, Dept Comp Sci, Loughborough, Leics, England.; Pockley, AG (corresponding author), Nottingham Trent Univ, John Van Geest Canc Res Ctr, Sch Sci & Technol, Nottingham, England.; Pockley, AG (corresponding author), Nottingham Trent Univ, Sch Sci & Technol, Ctr Hlth Ageing & Understanding Dis CHAUD, Nottingham, England.	g.cosma@lboro.ac.uk; graham.pockley@ntu.ac.uk	Pockley, Alan/I-4704-2015	Pockley, Alan/0000-0001-9593-6431; Cosma, Georgina/0000-0002-4663-6907	John and Lucille van Geest Foundation; Healthcare and Bioscience iNet; ERDF; Leverhulme Trust [RPG-2016-252]	John and Lucille van Geest Foundation; Healthcare and Bioscience iNet; ERDF(European Commission); Leverhulme Trust(Leverhulme Trust)	& nbsp;The authors acknowledge the financial support of the John and Lucille van Geest Foundation and the Healthcare and Bioscience iNet, an ERDF funded initiative managed by Medilink East Midlands. GC acknowledges the financial support of The Leverhulme Trust (Research Project Grant RPG-2016-252). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bjurlin MA, 2014, CURR OPIN UROL, V24, P155, DOI 10.1097/MOU.0000000000000031; Carlson WH, 2010, CAN J UROL, V17, P5135; CATALONA WJ, 1991, NEW ENGL J MED, V324, P1156, DOI 10.1056/NEJM199104253241702; Cohen J., 1992, CURRENT DIRECTIONS P, V1, P98, DOI [https://doi.org/10.1111/1467-8721.ep10768783, DOI 10.1111/1467-8721.EP10768783]; Cosma G, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01771; Cossarizza A, 2019, EUR J IMMUNOL, V49, P1457, DOI 10.1002/eji.201970107; D'Amico AV, 1998, JAMA-J AM MED ASSOC, V280, P969, DOI 10.1001/jama.280.11.969; Djavan B, 2001, J UROLOGY, V166, P1679, DOI 10.1016/S0022-5347(05)65652-2; Hood SP, 2020, ELIFE, V9, DOI 10.7554/eLife.50936; Hugosson J, 2019, EUR UROL, V76, P43, DOI 10.1016/j.eururo.2019.02.009; Martin RM, 2018, JAMA-J AM MED ASSOC, V319, P883, DOI 10.1001/jama.2018.0154; Nafie S, 2014, PROSTATE CANCER P D, V17, P170, DOI 10.1038/pcan.2014.4; Nafie S, 2014, WORLD J UROL, V32, P971, DOI 10.1007/s00345-013-1225-x; Pockley AG., 2021, MENDELEY DATA, DOI [10.17632/wmgtzw2w8f.1, DOI 10.17632/WMGTZW2W8F.1]; Raaijmakers R, 2002, UROLOGY, V60, P826, DOI 10.1016/S0090-4295(02)01958-1; Schuster M, 1997, IEEE T SIGNAL PROCES, V45, P2673, DOI 10.1109/78.650093; Serag H, 2012, BRIT J CANCER, V106, P436, DOI 10.1038/bjc.2011.596; STAMEY TA, 1987, NEW ENGL J MED, V317, P909, DOI 10.1056/NEJM198710083171501	18	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 16	2021	12								786828	10.3389/fimmu.2021.786828	http://dx.doi.org/10.3389/fimmu.2021.786828			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YB1IW	34975879	gold, Green Published, Green Accepted			2022-12-18	WOS:000738775800001
J	Cossu, D; Watson, RO; Farina, C				Cossu, Davide; Watson, Robert O.; Farina, Cinthia			Editorial: A Microbial View of Central Nervous System Disorders: Interplay Between Microorganisms, Neuroinflammation and Behaviour	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						pathogens; multiple sclerosis; Alzheimer's disease; neuroinflammation; Parkinson's disease; microbiota; cognitive and psychiatric disorders			[Cossu, Davide] Juntendo Univ, Dept Neurol, Tokyo, Japan; [Cossu, Davide] Sassari Univ, Dept Biomed Sci, Sassari, Italy; [Watson, Robert O.] Texas Agr & Mech A&M Hlth Sci Ctr, Coll Med, Dept Microbial Pathogenesis & Immunol, Bryan, TX USA; [Farina, Cinthia] Ist Sci San Raffaele, IRCCS, Inst Expt Neurol, Milan, Italy; [Farina, Cinthia] Ist Sci San Raffaele, IRCCS, Div Neurosci, Milan, Italy	Juntendo University; University of Sassari; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	Farina, C (corresponding author), Ist Sci San Raffaele, IRCCS, Inst Expt Neurol, Milan, Italy.; Farina, C (corresponding author), Ist Sci San Raffaele, IRCCS, Div Neurosci, Milan, Italy.	farina.cinthia@hsr.it	Cossu, Davide/AAD-7958-2019	Cossu, Davide/0000-0002-0557-9467	JSPS KAKENHI [JP 20K16468]; Italian Ministry for Health [RF-201812367731]; FISM (Fondazione Italiana Sclerosi Multipla) [2016/R/14]	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Italian Ministry for Health(Ministry of Health, Italy); FISM (Fondazione Italiana Sclerosi Multipla)(Fondazione Italiana Sclerosi Multipla (FISM))	Davide Cossu's research is supported by JSPS KAKENHI (grant number: JP 20K16468). Cinthia Farina's research is supported by Italian Ministry for Health (Ricerca Corrente and RF-201812367731), FISM (Fondazione Italiana Sclerosi Multipla, grant number 2016/R/14) and cofinanced with the 5 per mille public funding.	Chevalier G, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19931-2; Cossu D, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.02966; Davis BK, 2011, ANNU REV IMMUNOL, V29, P707, DOI 10.1146/annurev-immunol-031210-101405; Foster JA, 2017, NEUROBIOL STRESS, V7, P124, DOI 10.1016/j.ynstr.2017.03.001; Heijtza RD, 2011, P NATL ACAD SCI USA, V108, P3047, DOI 10.1073/pnas.1010529108; Macpherson AJ, 2004, NAT REV IMMUNOL, V4, P478, DOI 10.1038/nri1373; Montgomery TL, 2020, P NATL ACAD SCI USA, V117, P27516, DOI 10.1073/pnas.2002817117; Virtanen JO, 2012, CNS NEUROL DISORD-DR, V11, P528; Wu X, 2018, NEUROCHEM RES, V43, P886, DOI 10.1007/s11064-018-2494-y	9	0	0	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 16	2021	12								816227	10.3389/fimmu.2021.816227	http://dx.doi.org/10.3389/fimmu.2021.816227			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YB6CA	34975927	gold, Green Published			2022-12-18	WOS:000739096700001
J	Desombere, I; Van Houtte, F; Farhoudi, A; Verhoye, L; Buysschaert, C; Gijbels, Y; Couvent, S; Swinnen, W; Van Vlierberghe, H; Elewaut, A; Magri, A; Stamataki, Z; Meuleman, P; McKeating, JA; Leroux-Roels, G				Desombere, Isabelle; Van Houtte, Freya; Farhoudi, Ali; Verhoye, Lieven; Buysschaert, Caroline; Gijbels, Yvonne; Couvent, Sibyl; Swinnen, Wilfried; Van Vlierberghe, Hans; Elewaut, Andre; Magri, Andrea; Stamataki, Zania; Meuleman, Philip; McKeating, Jane A.; Leroux-Roels, Geert			A Role for B Cells to Transmit Hepatitis C Virus Infection	FRONTIERS IN IMMUNOLOGY			English	Article						hepatitis C virus; B cell; transmission; infection; persistence; immune response	NEUTRALIZING ANTIBODIES; ANTIVIRAL THERAPY; HUMAN LIVER; HCV; REPLICATION; MICE; HEPATOCYTES; ASSOCIATION; CHIMPANZEES; PREVENTION	Hepatitis C virus (HCV) is highly variable and transmits through infected blood to establish a chronic liver infection in the majority of patients. Our knowledge on the infectivity of clinical HCV strains is hampered by the lack of in vitro cell culture systems that support efficient viral replication. We and others have reported that HCV can associate with and infect immune cells and may thereby evade host immune surveillance and elimination. To evaluate whether B cells play a role in HCV transmission, we assessed the ability of B cells and sera from recent (<2 years) or chronic (>= 2 years) HCV patients to infect humanized liver chimeric mice. HCV was transmitted by B cells from chronic infected patients whereas the sera were non-infectious. In contrast, B cells from recently infected patients failed to transmit HCV to the mice, whereas all serum samples were infectious. We observed an association between circulating anti-glycoprotein E1E2 antibodies and B cell HCV transmission. Taken together, our studies provide evidence for HCV transmission by B cells, findings that have clinical implications for prophylactic and therapeutic antibody-based vaccine design.	[Desombere, Isabelle; Van Houtte, Freya; Farhoudi, Ali; Verhoye, Lieven; Buysschaert, Caroline; Gijbels, Yvonne; Couvent, Sibyl; Meuleman, Philip; Leroux-Roels, Geert] Univ Ghent, Dept Diagnost Sci, Ghent, Belgium; [Swinnen, Wilfried] Med Sociaal Opvangctr MSOC Gent, Ghent, Belgium; [Van Vlierberghe, Hans; Elewaut, Andre] Ghent Univ Hosp, Dept Hepatol & Gastroenterol, Ghent, Belgium; [Van Vlierberghe, Hans; Elewaut, Andre] Univ Ghent, Lab Hepatol Res, Ghent, Belgium; [Magri, Andrea; McKeating, Jane A.] Univ Oxford, Nuffield Dept Med, Oxford, England; [Stamataki, Zania] Univ Birmingham, Ctr Liver & Gastrointestinal Res, Inst Immunol & Immunotherapy, Birmingham, W Midlands, England; [Stamataki, Zania] Univ Hosp Birmingham Natl Hlth Serv NHS Fdn Trust, Birmingham Liver Biomed Res Ctr, Natl Inst Hlth Researc NIHR, Birmingham, W Midlands, England; [Desombere, Isabelle; Farhoudi, Ali] Sciensano Publ Hlth Belgium, Infect Dis Humans, Immune Response, Brussels, Belgium	Ghent University; Ghent University; Ghent University Hospital; Ghent University; University of Oxford; University of Birmingham; Sciensano	Leroux-Roels, G (corresponding author), Univ Ghent, Dept Diagnost Sci, Ghent, Belgium.	geert.lerouxroels@ugent.be		Stamataki, Zania/0000-0003-3823-4497; Magri, Andrea/0000-0002-7143-7168	Research Foundation Flanders (FWO project) [G.0212]; Ghent University [GOA_01G01712]; City of Ghent; Wellcome Trust [IA 200838/Z/16/Z]; MRC [MR/R022011/1]; European Union	Research Foundation Flanders (FWO project)(FWO); Ghent University(Ghent University); City of Ghent; Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); European Union(European Commission)	The authors acknowledge financial support of their work by the Research Foundation Flanders (FWO project G.0212.N), the Ghent University (GOA_01G01712), the City of Ghent and the European Union (FP7_HepaMab). JM laboratory is funded by Wellcome Trust IA 200838/Z/16/Z and MRC project grant MR/R022011/1.	Bailey JR, 2019, GASTROENTEROLOGY, V156, P418, DOI 10.1053/j.gastro.2018.08.060; Ball JK, 2014, ANTIVIR RES, V105, P100, DOI 10.1016/j.antiviral.2014.02.013; Banerjee D, 2016, ALIMENT PHARM THER, V43, P674, DOI 10.1111/apt.13514; Blackard JT, 2006, HEPATOLOGY, V44, P15, DOI 10.1002/hep.21283; Bukh J, 2010, J INFECT DIS, V201, P1381, DOI 10.1086/651579; Chen F, 2020, GASTROENTEROLOGY, V158, P1058, DOI 10.1053/j.gastro.2019.11.282; Cox AL, 2005, CLIN INFECT DIS, V40, P951, DOI 10.1086/428578; Dai B, 2016, ONCOGENE, V35, P2979, DOI 10.1038/onc.2015.364; Desombere I, 2017, ANTIVIR RES, V148, P53, DOI 10.1016/j.antiviral.2017.10.015; Desombere I, 2016, HEPATOLOGY, V63, P1120, DOI 10.1002/hep.28428; Douglas DN, 2019, METHODS MOL BIOL, V1911, P459, DOI 10.1007/978-1-4939-8976-8_32; Fabrizi F, 2013, J MED VIROL, V85, P1019, DOI 10.1002/jmv.23562; Fafi-Kremer S, 2010, J EXP MED, V207, P2019, DOI 10.1084/jem.20090766; Farci P, 1996, P NATL ACAD SCI USA, V93, P15394, DOI 10.1073/pnas.93.26.15394; Farci P, 2000, SCIENCE, V288, P339, DOI 10.1126/science.288.5464.339; Farci P, 2011, SEMIN LIVER DIS, V31, P356, DOI 10.1055/s-0031-1297925; Fuerst TR, 2018, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.02692; Fujiwara K, 2013, HEPATOLOGY, V57, P483, DOI 10.1002/hep.25921; Guindon S, 2010, SYST BIOL, V59, P307, DOI 10.1093/sysbio/syq010; Gutierrez JA, 2015, J VIRAL HEPATITIS, V22, P861, DOI 10.1111/jvh.12422; Heydtmann M, 2009, HEPATOLOGY, V49, P676, DOI 10.1002/hep.22763; HIJIKATA M, 1993, J VIROL, V67, P1953, DOI 10.1128/JVI.67.4.1953-1958.1993; Hsu M, 2003, P NATL ACAD SCI USA, V100, P7271, DOI 10.1073/pnas.0832180100; Iqbal T, 2016, INT J CANCER, V138, P1035, DOI 10.1002/ijc.29845; Ito M, 2010, J INNATE IMMUN, V2, P607, DOI 10.1159/000317690; Kanwal F, 2017, GASTROENTEROLOGY, V153, P996, DOI 10.1053/j.gastro.2017.06.012; Kong FY, 2017, EXP THER MED, V14, P1846, DOI 10.3892/etm.2017.4682; Kugelberg E, 2015, NAT REV IMMUNOL, V15, P133, DOI 10.1038/nri3822; Kuna L, 2019, J CLIN TRANSL HEPATO, V7, P172, DOI 10.14218/JCTH.2018.00049; Lanford RE, 1999, METH MOLEC MED, V19, P471, DOI 10.1385/0-89603-521-2:471; Law M, 2008, NAT MED, V14, P25, DOI 10.1038/nm1698; Le SQ, 2008, MOL BIOL EVOL, V25, P1307, DOI 10.1093/molbev/msn067; Li K, 2012, HEPATOLOGY, V55, P666, DOI 10.1002/hep.24763; Lindenbach BD, 2005, SCIENCE, V309, P623, DOI 10.1126/science.1114016; Mailly L, 2013, FRONT MICROBIOL, V4, DOI 10.3389/fmicb.2013.00212; Manns MP, 2013, NAT REV DRUG DISCOV, V12, P595, DOI 10.1038/nrd4050; Masarone M, 2019, LIVER INT, V39, P1292, DOI 10.1111/liv.14119; McConnell Matthew, 2018, Clin Liver Dis (Hoboken), V12, P118, DOI 10.1002/cld.753; Mercer DF, 2001, NAT MED, V7, P927, DOI 10.1038/90968; Meuleman P, 2003, BIOCHEM BIOPH RES CO, V308, P375, DOI 10.1016/S0006-291X(03)01388-3; Meuleman P, 2005, HEPATOLOGY, V41, P847, DOI 10.1002/hep.20657; Mina MM, 2015, LANCET INFECT DIS, V15, P451, DOI 10.1016/S1473-3099(14)70965-X; Mizuochi T, 2010, J INTERF CYTOK RES, V30, P243, DOI 10.1089/jir.2009.0047; Oliviero B, 2011, J HEPATOL, V55, P53, DOI 10.1016/j.jhep.2010.10.016; Osburn WO, 2014, HEPATOLOGY, V59, P2140, DOI 10.1002/hep.27013; Pal S, 2006, GASTROENTEROLOGY, V130, P1107, DOI 10.1053/j.gastro.2005.12.039; Pestka JM, 2007, P NATL ACAD SCI USA, V104, P6025, DOI 10.1073/pnas.0607026104; Peveling-Oberhag J, 2016, J VIRAL HEPATITIS, V23, P536, DOI 10.1111/jvh.12518; Pham TNQ, 2008, GASTROENTEROLOGY, V134, P812, DOI 10.1053/j.gastro.2007.12.011; Radkowski M, 2005, HEPATOLOGY, V41, P106, DOI 10.1002/hep.20518; Revie D, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-346; Saeed M, 2015, NATURE, V524, P471, DOI 10.1038/nature14899; Seifert M, 2015, P NATL ACAD SCI USA, V112, pE546, DOI 10.1073/pnas.1416276112; Spearman CW, 2019, LANCET, V394, P1451, DOI 10.1016/S0140-6736(19)32320-7; Stamataki Z, 2011, J INFECT DIS, V204, P811, DOI 10.1093/infdis/jir399; Stamataki Z, 2009, BLOOD, V113, P585, DOI 10.1182/blood-2008-05-158824; Steinmann E, 2013, CURR TOP MICROBIOL, V369, P17, DOI 10.1007/978-3-642-27340-7_2; Steyaert S, 2007, ANTIVIR RES, V75, P129, DOI 10.1016/j.antiviral.2006.10.013; Tangye SG, 2007, J IMMUNOL, V179, P13, DOI 10.4049/jimmunol.179.1.13; Tucci FA, 2018, BLOOD, V131, P546, DOI 10.1182/blood-2017-09-805762; van der Meer AJ, 2017, J HEPATOL, V66, P485, DOI 10.1016/j.jhep.2016.10.017; Von Hahn T, 2007, GASTROENTEROLOGY, V132, P667, DOI 10.1053/j.gastro.2006.12.008; Wakita T, 2005, NAT MED, V11, P791, DOI 10.1038/nm1268; Walker CM, 2017, CURR OPIN VIROL, V23, P113, DOI 10.1016/j.coviro.2017.03.014; Ward JW, 2019, GASTROENTEROLOGY, V156, P297, DOI 10.1053/j.gastro.2018.10.048; Wilson GK, 2015, J GEN VIROL, V96, P1369, DOI 10.1099/vir.0.000085; World Health Organization (WHO), 2016, COMB HEP B C REACH E; World Health Organization (WHO), 2017, GLOB HEP REP; Yu MYW, 2004, P NATL ACAD SCI USA, V101, P7705, DOI 10.1073/pnas.0402458101	69	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 16	2021	12								775098	10.3389/fimmu.2021.775098	http://dx.doi.org/10.3389/fimmu.2021.775098			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2T4DV	34975862	Green Submitted, gold, Green Published			2022-12-18	WOS:000822428300001
J	Doritchamou, JYA; Aitken, EH; Luty, AJF				Doritchamou, Justin Y. A.; Aitken, Elizabeth H.; Luty, Adrian J. F.			Editorial: Immunity to Parasitic Infections in Pregnancy	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						pregnancy; parasitic infections; immunity; therapeutics; vaccine; malaria; toxoplasmosis; trypanosomiasis	MALARIA		[Doritchamou, Justin Y. A.] NIAID, Lab Malaria Immunol & Vaccinol, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Aitken, Elizabeth H.] Univ Melbourne, Peter Doherty Inst Infect & Immun, Dept Infect Dis, Parkville, Vic, Australia; [Aitken, Elizabeth H.] Univ Melbourne, Peter Doherty Inst Infect & Immun, Dept Microbiol & Immunol, Parkville, Vic, Australia; [Luty, Adrian J. F.] Univ Paris, MERIT, IRD, Paris, France	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Melbourne; University of Melbourne; Institut de Recherche pour le Developpement (IRD); UDICE-French Research Universities; Universite Paris Cite	Doritchamou, JYA (corresponding author), NIAID, Lab Malaria Immunol & Vaccinol, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.	yai.doritchamou@nih.gov	Aitken, Elizabeth/I-8756-2019; Luty, Adrian/CAH-2547-2022	Aitken, Elizabeth/0000-0002-2677-6208; Luty, Adrian John Frederick/0000-0001-8830-3425	Intramural Research Program of the National Institute of Allergy and Infectious Diseases, National Institutes of Health; National Health and Medical Research Council of Australia [GNT1143946]	Intramural Research Program of the National Institute of Allergy and Infectious Diseases, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia)	JD is supported by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases, National Institutes of Health. EA is supported by a grant from the National Health and Medical Research Council of Australia (GNT1143946).	Blaszkowska Joanna, 2014, Annals of Parasitology, V60, P225; BRABIN BJ, 1983, B WORLD HEALTH ORGAN, V61, P1005; Carlier Y, 2012, ACTA TROP, V121, P55, DOI 10.1016/j.actatropica.2011.10.018; Lo Tutterrow Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040049; Mordmuller B, 2019, CLIN INFECT DIS, V69, P1509, DOI 10.1093/cid/ciy1140; Salanti A, 2003, MOL MICROBIOL, V49, P179, DOI 10.1046/j.1365-2958.2003.03570.x; Sirima SB, 2020, LANCET INFECT DIS, V20, P585, DOI 10.1016/S1473-3099(19)30739-X	7	0	0	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 16	2021	12								813446	10.3389/fimmu.2021.813446	http://dx.doi.org/10.3389/fimmu.2021.813446			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YB5WX	34975925	gold, Green Published			2022-12-18	WOS:000739083400001
J	Kottom, TJ; Carmona, EM; Limper, AH				Kottom, Theodore J.; Carmona, Eva M.; Limper, Andrew H.			Current State of Carbohydrate Recognition and C-Type Lectin Receptors in Pneumocystis Innate Immunity	FRONTIERS IN IMMUNOLOGY			English	Review						beta-glucans; CLR; inflammation; Pneumocystis; pneumonia	SURFACTANT PROTEIN-D; MANNOSE-BINDING LECTIN; HOST-DEFENSE; ALVEOLAR MACROPHAGES; CARINII INFECTION; MINCLE; GLYCOPROTEIN; PHAGOCYTOSIS; EXPRESSION; DECTIN-2	Pneumocystis jirovecii is one of the most common fungal pathogens in immunocompromised individuals. Pneumocystis jirovecii pneumonia (PJP) causes a significant host immune response that is driven greatly by the organism's cell wall components including beta-glucans and major surface glycoprotein (Msg). These ligands interact with a number of C-type lectin receptors (CLRs) leading to downstream activation of proinflammatory signaling pathways. This minireview provides a brief overview summarizing known CLR/Pneumocystis interactions.	[Kottom, Theodore J.; Carmona, Eva M.; Limper, Andrew H.] Mayo Clin, Dept Med, Thorac Dis Res Unit, Rochester, MN 55905 USA; [Kottom, Theodore J.; Carmona, Eva M.; Limper, Andrew H.] Mayo Clin, Dept Biochem, Thorac Dis Res Unit, Rochester, MN 55905 USA; [Kottom, Theodore J.; Carmona, Eva M.; Limper, Andrew H.] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	Kottom, TJ (corresponding author), Mayo Clin, Dept Med, Thorac Dis Res Unit, Rochester, MN 55905 USA.; Kottom, TJ (corresponding author), Mayo Clin, Dept Biochem, Thorac Dis Res Unit, Rochester, MN 55905 USA.; Kottom, TJ (corresponding author), Mayo Clin, Dept Lab Med & Pathol, Rochester, MN 55905 USA.	kottom.theodore@mayo.edu			National Heart, Lung, and Blood Institute [R01-HL62150-100]	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Funding National Heart, Lung, and Blood Institute R01-HL62150-100% funding source.	Atochina EN, 2004, J INFECT DIS, V189, P1528, DOI 10.1086/383130; Beers MF, 1999, J LAB CLIN MED, V133, P423, DOI 10.1016/S0022-2143(99)90019-7; Borriello F, 2020, EUR J IMMUNOL, V50, P317, DOI 10.1002/eji.201848054; Brown GD, 2001, NATURE, V413, P36, DOI 10.1038/35092620; Brown GD, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004404; Brummer E, 2010, MED MYCOL, V48, P16, DOI 10.3109/13693780903117473; Cambi A, 2008, J BIOL CHEM, V283, P20590, DOI 10.1074/jbc.M709334200; Carmona EM, 2006, J IMMUNOL, V177, P459, DOI 10.4049/jimmunol.177.1.459; Crouch E C, 2000, Respir Res, V1, P93; Dai GX, 2021, JCI INSIGHT, V6, DOI 10.1172/jci.insight.139573; Elsegeiny W, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.91894; EZEKOWITZ RAB, 1991, NATURE, V351, P155, DOI 10.1038/351155a0; Francoise S, 2010, MED MYCOL, V48, P35, DOI 10.3109/13693780802713356; Garcia-Rubio R, 2020, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.02993; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; Goyal S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01261; HOGAN LH, 1994, INFECT IMMUN, V62, P3543, DOI 10.1128/IAI.62.8.3543-3546.1994; Hoving JC, 2014, CELL MICROBIOL, V16, P185, DOI 10.1111/cmi.12249; Hoving JC, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1006807; Inoue M, 2011, J IMMUNOL, V186, P19, DOI 10.4049/jimmunol.1002735; Iriart X, 2010, MED MYCOL, V48, P1075, DOI 10.3109/13693786.2010.484027; Kerrigan AM, 2009, IMMUNOBIOLOGY, V214, P562, DOI 10.1016/j.imbio.2008.11.003; Kirkland TN, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020303; Kiyotake R, 2015, J BIOL CHEM, V290, P25322, DOI 10.1074/jbc.M115.645234; Konomi M, 2003, YEAST, V20, P427, DOI 10.1002/yea.974; Kottom TJ, 2020, J INFECT DIS, V222, P1213, DOI 10.1093/infdis/jiaa218; Kottom TJ, 2019, J MED MICROBIOL, V68, P1649, DOI 10.1099/jmm.0.001062; Kottom TJ, 2018, AM J RESP CELL MOL, V58, P232, DOI 10.1165/rcmb.2016-0335OC; Kottom TJ, 2017, J IMMUNOL, V198, P3515, DOI 10.4049/jimmunol.1600744; Kottom TJ, 2015, INFECT IMMUN, V83, P2816, DOI 10.1128/IAI.00196-15; Kottom TJ, 2000, J BIOL CHEM, V275, P40628, DOI 10.1074/jbc.M002103200; Koziel H, 1998, J CLIN INVEST, V102, P1332, DOI 10.1172/JCI560; Koziel H, 1998, AM J RESP CELL MOL, V18, P834, DOI 10.1165/ajrcmb.18.6.3059; KRUSKAL BA, 1992, J EXP MED, V176, P1673, DOI 10.1084/jem.176.6.1673; Lee RT, 2011, GLYCOBIOLOGY, V21, P512, DOI 10.1093/glycob/cwq193; LIMPER AH, 1994, J EUKARYOT MICROBIOL, V41, pS98; Linke MJ, 2001, J INFECT DIS, V183, P943, DOI 10.1086/319252; Lobato-Pascual A, 2013, EUR J IMMUNOL, V43, P3167, DOI 10.1002/eji.201343752; Ma L, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10740; Matsunaga I, 2009, J EXP MED, V206, P2865, DOI 10.1084/jem.20092533; McGreal EP, 2006, GLYCOBIOLOGY, V16, P422, DOI 10.1093/glycob/cwj077; Miyake Y, 2015, J IMMUNOL, V194, P5366, DOI 10.4049/jimmunol.1402429; Monteiro JT, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9030059; Nadesalingam J, 2005, J IMMUNOL, V175, P1785, DOI 10.4049/jimmunol.175.3.1785; ORIORDAN DM, 1995, INFECT IMMUN, V63, P779, DOI 10.1128/IAI.63.3.779-784.1995; ORIORDAN DM, 1995, J CLIN INVEST, V95, P2699, DOI 10.1172/JCI117972; Rapaka RR, 2007, J IMMUNOL, V178, P3702, DOI 10.4049/jimmunol.178.6.3702; Saijo S, 2007, NAT IMMUNOL, V8, P39, DOI 10.1038/ni1425; Saijo S, 2010, IMMUNITY, V32, P681, DOI 10.1016/j.immuni.2010.05.001; Sassi M, 2018, J INFECT DIS, V218, P1631, DOI 10.1093/infdis/jiy342; Schmidt R, 2006, CRIT CARE MED, V34, P2370, DOI 10.1097/01.CCM.0000234036.19145.52; Sealy PI, 2008, MED MYCOL, V46, P531, DOI 10.1080/13693780801961329; Steele C, 2003, J EXP MED, V198, P1677, DOI 10.1084/jem.20030932; Stehle SE, 2000, SCAND J IMMUNOL, V52, P131; STERNBERG RI, 1995, J LAB CLIN MED, V125, P462; Swain SD, 2003, INFECT IMMUN, V71, P6213, DOI 10.1128/IAI.71.11.6213-6221.2003; Tanne A, 2009, J EXP MED, V206, P2205, DOI 10.1084/jem.20090188; Truong J, 2021, STATPEARLS; Vendele I, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1007927; Vuk-Pavlovic Z, 2001, AM J RESP CELL MOL, V24, P475, DOI 10.1165/ajrcmb.24.4.3504; Wells CA, 2008, J IMMUNOL, V180, P7404, DOI 10.4049/jimmunol.180.11.7404; Williams MD, 1996, AM J RESP CELL MOL, V14, P232, DOI 10.1165/ajrcmb.14.3.8845173; Yamasaki S, 2009, P NATL ACAD SCI USA, V106, P1897, DOI 10.1073/pnas.0805177106; Yanagisawa K, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0242438; Yanagisawa K, 2015, J INFECT CHEMOTHER, V21, P769, DOI 10.1016/j.jiac.2015.07.006; Yong SJ, 2003, INFECT IMMUN, V71, P1662, DOI 10.1128/IAI.71.4.1662-1671.2003; Zhang JM, 2004, INFECT IMMUN, V72, P3147, DOI 10.1128/IAI.72.6.3147-3160.2004; Zhu LL, 2013, IMMUNITY, V39, P324, DOI 10.1016/j.immuni.2013.05.017; ZIMMERMAN PE, 1992, J CLIN INVEST, V89, P143, DOI 10.1172/JCI115554	69	0	0	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 16	2021	12								798214	10.3389/fimmu.2021.798214	http://dx.doi.org/10.3389/fimmu.2021.798214			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YB1MP	34975910	Green Published, gold			2022-12-18	WOS:000738785600001
J	Le Gallou, S; Lhomme, F; Irish, JM; Mingam, A; Pangault, C; Monvoisin, C; Ferrant, J; Azzaoui, I; Rossille, D; Bouabdallah, K; Damaj, G; Cartron, G; Godmer, P; Le Gouill, S; Casasnovas, RO; Molina, TJ; Houot, R; Lamy, T; Tarte, K; Fest, T; Roussel, M				Le Gallou, Simon; Lhomme, Faustine; Irish, Jonathan M.; Mingam, Anna; Pangault, Celine; Monvoisin, Celine; Ferrant, Juliette; Azzaoui, Imane; Rossille, Delphine; Bouabdallah, Krimo; Damaj, Gandhi; Cartron, Guillaume; Godmer, Pascal; Le Gouill, Steven; Casasnovas, Rene-Olivier; Molina, Thierry Jo; Houot, Roch; Lamy, Thierry; Tarte, Karin; Fest, Thierry; Roussel, Mikael			Nonclassical Monocytes Are Prone to Migrate Into Tumor in Diffuse Large B-Cell Lymphoma	FRONTIERS IN IMMUNOLOGY			English	Article						B cell lymphoma; DLBCL; biomarker; monocyte; immune suppression	MICROENVIRONMENT; MACROPHAGES; SURVIVAL; PHAGOCYTES; DIAGNOSIS; COUNT; BLOOD	Absolute count of circulating monocytes has been proposed as an independent prognostic factor in diffuse large B-cell lymphoma (DLBCL). However, monocyte nomenclature includes various subsets with pro-, anti-inflammatory, or suppressive functions, and their clinical relevance in DLBCL has been poorly explored. Herein, we broadly assessed circulating monocyte heterogeneity in 91 DLBCL patients. Classical- (cMO, CD14(pos) CD16(neg)) and intermediate- (iMO, CD14(pos) CD16(pos)) monocytes accumulated in DLBCL peripheral blood and exhibited an inflammatory phenotype. On the opposite, nonclassical monocytes (ncMOSlan(pos), CD14(low) CD16(pos) Slan(neg) and ncMOSlan(neg), CD14(low) CD16(pos), Slan(neg)) were decreased in peripheral blood. Tumor-conditioned monocytes presented similarities with ncMO phenotype from DLBCL and were prone to migrate in response to CCL5 and CXCL12, and presented similarities with DLBCL-infiltrated myeloid cells, as defined by mass cytometry. Finally, we demonstrated the adverse value of an accumulation of nonclassical monocytes in 2 independent cohorts of DLBCL.	[Le Gallou, Simon; Lhomme, Faustine; Mingam, Anna; Pangault, Celine; Azzaoui, Imane; Rossille, Delphine; Tarte, Karin; Fest, Thierry; Roussel, Mikael] CHU Rennes, Pole Biol, Rennes, France; [Le Gallou, Simon; Pangault, Celine; Monvoisin, Celine; Ferrant, Juliette; Rossille, Delphine; Houot, Roch; Lamy, Thierry; Tarte, Karin; Fest, Thierry; Roussel, Mikael] Univ Rennes 1, INSERM, UMR U1236, Etab Francais Sang Bretagne, Rennes, France; [Lhomme, Faustine; Irish, Jonathan M.] Vanderbilt Univ, Sch Med, Dept Cell & Dev Biol, Nashville, TN 37212 USA; [Irish, Jonathan M.] Vanderbilt Univ, Sch Med, Dept Pathol Microbiol & Immunol, Nashville, TN 37212 USA; [Bouabdallah, Krimo] CHU Bordeaux, Serv Hematol Clin, Bordeaux, France; [Damaj, Gandhi] CHU Caen, Serv Hematol Clin, Caen, France; [Cartron, Guillaume] CHU Montpellier, Serv Hematol Clin, Montpellier, France; [Godmer, Pascal] Ctr Hosp Bretagne Atlantique, Unite Hematol Clin, Vannes, France; [Le Gouill, Steven] NeXT Univ Nantes, CHU Nantes, Ctr Rech Cancerol & Immunol Nantes Angers INSERM, INSERM,Serv Hematol Clin, Nantes, France; [Casasnovas, Rene-Olivier] CHU Dijon, Serv Hematol Clin, Dijon, France; [Molina, Thierry Jo] Sorbonne Univ, AP HP, Serv Anatomopathol, Paris, France; [Houot, Roch; Lamy, Thierry] CHU Rennes, Serv Hematol Clin, Rennes, France	CHU Rennes; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Rennes; Vanderbilt University; Vanderbilt University; CHU Bordeaux; CHU de Caen NORMANDIE; Universite de Caen Normandie; Universite de Montpellier; CHU de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; CHU de Nantes; CHU Dijon Bourgogne; Assistance Publique Hopitaux Paris (APHP); UDICE-French Research Universities; Sorbonne Universite; CHU Rennes	Roussel, M (corresponding author), CHU Rennes, Pole Biol, Rennes, France.; Roussel, M (corresponding author), Univ Rennes 1, INSERM, UMR U1236, Etab Francais Sang Bretagne, Rennes, France.	mikael.roussel@univ-rennes1.fr	Pangault, Celine/C-3254-2017; tarte, karin/GXV-1815-2022	Pangault, Celine/0000-0003-3978-2209; tarte, karin/0000-0002-6809-917X	Nuovo-Soldati Foundation (Switzerland); Ligue contre le Cancer; COmite de la REcherche Clinique et Translationnelle, CHU of Rennes; Association pour le Developpement de lHematologie Oncologie; National Institute of Cancer (INCa Recherche Translationnelle 2010); Groupe Ouest-Est des Leucemies et des Autres Maladies du Sang (GOELAMS); Agence Nationale de la Recherche [ANR-17-CE15-0015 StroMAC]; Fondation ARC [PGA1 RF20190208534]	Nuovo-Soldati Foundation (Switzerland); Ligue contre le Cancer(Ligue nationale contre le cancer); COmite de la REcherche Clinique et Translationnelle, CHU of Rennes; Association pour le Developpement de lHematologie Oncologie; National Institute of Cancer (INCa Recherche Translationnelle 2010); Groupe Ouest-Est des Leucemies et des Autres Maladies du Sang (GOELAMS); Agence Nationale de la Recherche(French National Research Agency (ANR)); Fondation ARC	This work was supported by a fellowship from the Nuovo-Soldati Foundation (Switzerland) (MR), from the Ligue contre le Cancer (MR), from the COmite de la REcherche Clinique et Translationnelle, CHU of Rennes (FL), from the Association pour le Developpement de lHematologie Oncologie (FL), from the National Institute of Cancer (INCa Recherche Translationnelle 2010) (TF), from the Groupe Ouest-Est des Leucemies et des Autres Maladies du Sang (GOELAMS) (TF), from the Agence Nationale de la Recherche (ANR-17-CE15-0015 StroMAC) (KT), and from the Fondation ARC (PGA1 RF20190208534) (KT and MR).	Ahmad F, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00948; Azzaoui I, 2016, BLOOD, V128, P1081, DOI 10.1182/blood-2015-08-662783; Bronte V, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12150; Cassetta L, 2019, CANCER CELL, V35, P588, DOI 10.1016/j.ccell.2019.02.009; Charbonneau B, 2012, CYTOKINE, V60, P882, DOI 10.1016/j.cyto.2012.08.028; Cros J, 2010, IMMUNITY, V33, P375, DOI 10.1016/j.immuni.2010.08.012; Eljaszewicz A, 2012, CENT EUR J IMMUNOL, V37, P355, DOI 10.5114/ceji.2012.32725; Ferrant J, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.623993; Gallou SL., 2021, NONCLASSICAL MONOCY, DOI [10.1101/2021.04.10.439292, DOI 10.1101/2021.04.10.439292]; Ginhoux F, 2014, NAT REV IMMUNOL, V14, P392, DOI 10.1038/nri3671; Gros A, 2012, CLIN CANCER RES, V18, P5212, DOI 10.1158/1078-0432.CCR-12-1108; Guilliams M, 2018, IMMUNITY, V49, P595, DOI 10.1016/j.immuni.2018.10.005; Han X, 2017, ONCOTARGET, V8, P47790, DOI 10.18632/oncotarget.17830; Hanna RN, 2015, SCIENCE, V350, P985, DOI 10.1126/science.aac9407; Jung K, 2017, J CLIN INVEST, V127, P3039, DOI 10.1172/JCI93182; Lavin Y, 2017, CELL, V169, P750, DOI 10.1016/j.cell.2017.04.014; Le Gouill S, 2021, BLOOD, V137, P2307, DOI 10.1182/blood.2020008750; Lenz G, 2008, NEW ENGL J MED, V359, P2313, DOI 10.1056/NEJMoa0802885; Lin Y, 2011, BLOOD, V117, P872, DOI 10.1182/blood-2010-05-283820; Maffei R, 2013, HAEMATOLOGICA, V98, P1115, DOI 10.3324/haematol.2012.073080; Manfroi B, 2021, BLOOD ADV, V5, P4338, DOI 10.1182/bloodadvances.2021004203; Maurer MJ, 2016, AM J HEMATOL, V91, P179, DOI 10.1002/ajh.24223; McKee SJ, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2017.1393599; Nagarsheth N, 2017, NAT REV IMMUNOL, V17, P559, DOI 10.1038/nri.2017.49; Nam SJ, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1442164; Nitta H, 2015, HAEMATOLOGICA, V100, P87, DOI 10.3324/haematol.2014.114934; Ong SM, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0327-1; Riihijarvi S, 2015, HAEMATOLOGICA, V100, P238, DOI 10.3324/haematol.2014.113472; Rossille D, 2017, LEUKEMIA, V31, P988, DOI 10.1038/leu.2016.385; Roussel M, 2020, CANCER IMMUNOL IMMUN, V69, P407, DOI 10.1007/s00262-019-02464-z; Roussel M, 2019, METHODS MOL BIOL, V1989, P217, DOI 10.1007/978-1-4939-9454-0_14; Roussel M, 2017, J LEUKOCYTE BIOL, V102, P437, DOI 10.1189/jlb.5MA1116-457R; Scott DW, 2014, NAT REV CANCER, V14, P517, DOI 10.1038/nrc3774; Tadmor T, 2014, HAEMATOLOGICA, V99, P125, DOI 10.3324/haematol.2013.088161; Takahashi K, 2015, BRIT J HAEMATOL, V171, P726, DOI 10.1111/bjh.13659; Troppan K, 2014, BRIT J CANCER, V110, P369, DOI 10.1038/bjc.2013.763; Vari F, 2018, BLOOD, V131, P1809, DOI 10.1182/blood-2017-07-796342; Vermi W, 2018, CANCER RES, V78, P3544, DOI 10.1158/0008-5472.CAN-17-2344; Wilcox RA, 2011, LEUKEMIA, V25, P1502, DOI 10.1038/leu.2011.112; Witkowski MT, 2020, CANCER CELL, V37, P867, DOI 10.1016/j.ccell.2020.04.015; Wong KL, 2011, BLOOD, V118, pE15, DOI 10.1182/blood-2010-12-326355; Xiu B, 2015, BLOOD CANCER J, V5, DOI 10.1038/bcj.2015.56; Yhim HY, 2017, ONCOTARGET, V8, P92289, DOI 10.18632/oncotarget.21241; Ziegler-Heitbrock L, 2010, BLOOD, V116, pE74, DOI 10.1182/blood-2010-02-258558	44	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 16	2021	12								755623	10.3389/fimmu.2021.755623	http://dx.doi.org/10.3389/fimmu.2021.755623			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YK5OG	34975843	Green Published, gold, Green Submitted			2022-12-18	WOS:000745261200001
J	Lin, WW; Ho, KW; Su, HH; Fang, TF; Tzou, SC; Chen, IJ; Lu, YC; Chang, MS; Tsai, YC; Liu, ES; Su, YC; Wang, YT; Cheng, TL; Huang, HK				Lin, Wen-Wei; Ho, Kai-Wen; Su, Hsiang-Han; Fang, Tien-Fang; Tzou, Shey-Cherng; Chen, I-Ju; Lu, Yun-Chi; Chang, Mu-Shen; Tsai, Yun-Chen; Liu, En-Shuo; Su, Yu-Cheng; Wang, Yen-Tseng; Cheng, Tian-Lu; Huang, Hsin-Kai			Fibrinogen-Like Protein 1 Serves as an Anti-Inflammatory Agent for Collagen-Induced Arthritis Therapy in Mice	FRONTIERS IN IMMUNOLOGY			English	Article						fibrinogen-like protein 1 (FGL1); lymphocyte-activation gene-3 (LAG-3); rheumatoid arthritis (RA); T cell; collagen-induced arthritis (CIA) model	RHEUMATOID-ARTHRITIS; T-CELLS; HEPASSOCIN; LAG-3; PROLIFERATION; INFLAMMATION; MODULATION; GALECTIN-3; ANTIBODIES; RATS	Fibrinogen-like protein 1 (FGL1) was recently identified as a major ligand of lymphocyte-activation gene-3 (LAG-3) on activated T cells and serves as an immune suppressive molecule for regulation of immune homeostasis. However, whether FGL1 has therapeutic potential for use in the T cell-induced the autoimmune disease, rheumatoid arthritis (RA), is still unknown. Here, we attempted to evaluate the effect of FGL1 protein on arthritis progression. We also evaluated potential adverse events in a collagen-induced arthritis (CIA) mouse model. We first confirmed that soluble Fgl1 protein could specifically bind to surface Lag-3 receptor on 3T3-Lag-3 cells and further inhibit interleukin (IL-2) and interferon gamma (IFN gamma) secretion from activated primary mouse T cells by 95% and 43%, respectively. Intraperitoneal administration of Fgl1 protein significantly decreased the inflammatory cytokine level (i.e., IL-1 beta and IL-6) in local paw tissue, and prevented joint inflammation, cellular infiltration, bone deformation and attenuated collagen-induced arthritis progression in vivo. We further demonstrated that exogenous Fgl1 does not cause obvious adverse events during treatment by monitoring body weight and liver weight, and assessing the morphology of several organs (i.e., heart, liver, spleen, lung and kidney) by pathological studies. We expect that Fgl1 protein may be suitable to serve as a potential therapeutic agent for treatment of RA or even other types of T cell-induced autoimmune or inflammatory diseases in the future.	[Lin, Wen-Wei] Kaohsiung Med Univ, Sch Post Baccalaureate Med, Dept Lab Med, Coll Med, Kaohsiung, Taiwan; [Lin, Wen-Wei] Kaohsiung Med Univ, Sch Med, Dept Lab Med, Coll Med, Kaohsiung, Taiwan; [Lin, Wen-Wei; Su, Hsiang-Han; Liu, En-Shuo; Cheng, Tian-Lu] Kaohsiung Med Univ, Grad Inst Med, Coll Med, Kaohsiung, Taiwan; [Lin, Wen-Wei] Kaohsiung Med Univ Hosp, Dept Med Res, Kaohsiung, Taiwan; [Lin, Wen-Wei; Ho, Kai-Wen; Tzou, Shey-Cherng; Chen, I-Ju; Lu, Yun-Chi; Su, Yu-Cheng; Wang, Yen-Tseng; Cheng, Tian-Lu] Kaohsiung Med Univ, Drug Dev & Value Creat Res Ctr, Kaohsiung, Taiwan; [Fang, Tien-Fang; Tsai, Yun-Chen] Kaohsiung Med Univ, Dept Biotechnol, Kaohsiung, Taiwan; [Tzou, Shey-Cherng; Su, Yu-Cheng] Natl Yang Ming Chiao Tung Univ, Dept Biol Sci & Technol, Hsinchu, Taiwan; [Chang, Mu-Shen; Cheng, Tian-Lu] Kaohsiung Med Univ, Dept Biomed Sci & Environm Biol, Kaohsiung, Taiwan; [Wang, Yen-Tseng] Kaohsiung Med Univ, Sch Post Baccalaureate Med, Dept Biochem, Coll Med, Kaohsiung, Taiwan; [Huang, Hsin-Kai] Kaohsiung Armed Forces Gen Hosp, Dept Lab Med, Kaohsiung, Taiwan	Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; Kaohsiung Medical University; National Yang Ming Chiao Tung University; Kaohsiung Medical University; Kaohsiung Medical University	Lin, WW (corresponding author), Kaohsiung Med Univ, Sch Post Baccalaureate Med, Dept Lab Med, Coll Med, Kaohsiung, Taiwan.; Lin, WW (corresponding author), Kaohsiung Med Univ, Sch Med, Dept Lab Med, Coll Med, Kaohsiung, Taiwan.; Lin, WW (corresponding author), Kaohsiung Med Univ, Grad Inst Med, Coll Med, Kaohsiung, Taiwan.; Lin, WW (corresponding author), Kaohsiung Med Univ Hosp, Dept Med Res, Kaohsiung, Taiwan.; Lin, WW (corresponding author), Kaohsiung Med Univ, Drug Dev & Value Creat Res Ctr, Kaohsiung, Taiwan.; Huang, HK (corresponding author), Kaohsiung Armed Forces Gen Hosp, Dept Lab Med, Kaohsiung, Taiwan.	weber06272000@gmail.com; seikenhuang@gmail.com		Su, Yu-Cheng/0000-0001-7056-6315	Ministry of Science and Technology, Taiwan; KMU-KMUH Co-Project of Key Research; Kaohsiung Medical University, Taiwan; NSYSU-KMU joint research project; Medical Research Fund of Kaohsiung Armed Forces General Hospital	Ministry of Science and Technology, Taiwan(Ministry of Science and Technology, Taiwan); KMU-KMUH Co-Project of Key Research; Kaohsiung Medical University, Taiwan; NSYSU-KMU joint research project; Medical Research Fund of Kaohsiung Armed Forces General Hospital	This work was supported by grants from the Ministry of Science and Technology, Taiwan (MOST-110-2628-B-037-010); the KMU-KMUH Co-Project of Key Research (KMU-DK(B)110006) and Research Foundation (KMU-KI110004) from Kaohsiung Medical University, Taiwan; NSYSU-KMU joint research project (NSYSUKMU 110-I002); the Medical Research Fund of Kaohsiung Armed Forces General Hospital (802KB109388).	Alfarra H, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.575609; Alzabin S, 2011, FEBS LETT, V585, P3649, DOI 10.1016/j.febslet.2011.04.034; Andersson AK, 2008, SCAND J IMMUNOL, V68, P103, DOI 10.1111/j.1365-3083.2008.02118.x; Angin M, 2020, J IMMUNOL, V204, P810, DOI 10.4049/jimmunol.1900823; Bettini M, 2011, J IMMUNOL, V187, P3493, DOI 10.4049/jimmunol.1100714; Blackburn SD, 2009, NAT IMMUNOL, V10, P29, DOI 10.1038/ni.1679; BRENNAN FM, 1989, LANCET, V2, P244; Butler DM, 1995, EUR CYTOKINE NETW, V6, P225; Calvaruso V, 2010, GUT, V59, P709, DOI 10.1136/gut.2009.201020; Chemin K, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00353; Conigliaro P, 2016, AUTOIMMUN REV, V15, P673, DOI 10.1016/j.autrev.2016.03.003; Cope AP, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2412; Demchev V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058084; Dumic J, 2006, BBA-GEN SUBJECTS, V1760, P616, DOI 10.1016/j.bbagen.2005.12.020; Feldmann M, 1996, ANNU REV IMMUNOL, V14, P397, DOI 10.1146/annurev.immunol.14.1.397; Gao M, 2014, CELL SIGNAL, V26, P2161, DOI 10.1016/j.cellsig.2014.04.013; HAWORTH C, 1991, EUR J IMMUNOL, V21, P2575, DOI 10.1002/eji.1830211039; Huang CT, 2004, IMMUNITY, V21, P503, DOI 10.1016/j.immuni.2004.08.010; Huard B, 1997, P NATL ACAD SCI USA, V94, P5744, DOI 10.1073/pnas.94.11.5744; Kaplan MJ, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4325; Klarenbeek PL, 2012, ANN RHEUM DIS, V71, P1088, DOI 10.1136/annrheumdis-2011-200612; Kotake S, 1999, J CLIN INVEST, V103, P1345, DOI 10.1172/JCI5703; Kouo T, 2015, CANCER IMMUNOL RES, V3, P412, DOI 10.1158/2326-6066.CIR-14-0150; Li CY, 2010, GUT, V59, P817, DOI 10.1136/gut.2008.171124; Li XB, 2021, INT J BIOL SCI, V17, P1079, DOI 10.7150/ijbs.56748; Li YP, 2020, ARTHRITIS RES THER, V22, DOI 10.1186/s13075-020-02169-0; Li YT, 2012, ARTHRITIS RHEUM-US, V64, P3240, DOI 10.1002/art.34550; Lundy SK, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2107; Narazaki M, 2017, EXPERT REV CLIN IMMU, V13, P535, DOI 10.1080/1744666X.2017.1295850; Pandolfi F, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21155238; Reynisdottir G, 2016, ANN RHEUM DIS, V75, P1722, DOI 10.1136/annrheumdis-2015-208216; Ruffo E, 2019, SEMIN IMMUNOL, V42, DOI 10.1016/j.smim.2019.101305; Shealy DJ, 2002, ARTHRITIS RES, V4, DOI 10.1186/ar430; Smolen JS, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/nrdp.2018.1; THOMAS R, 1992, ARTHRITIS RHEUM-US, V35, P1455, DOI 10.1002/art.1780351209; Wang J, 2019, CELL, V176, P334, DOI 10.1016/j.cell.2018.11.010; Wasserman A, 2018, AM FAM PHYSICIAN, V97, P455; WILLIAMS RO, 1992, P NATL ACAD SCI USA, V89, P9784, DOI 10.1073/pnas.89.20.9784; Xiong L, 2021, IMMUN INFLAMM DIS, V9, P37, DOI 10.1002/iid3.377; Xu F, 2014, CANCER RES, V74, P3418, DOI 10.1158/0008-5472.CAN-13-2690; Yang YH, 2004, ARTHRITIS RHEUM-US, V50, P976, DOI 10.1002/art.20201	41	0	0	5	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 16	2021	12								767868	10.3389/fimmu.2021.767868	http://dx.doi.org/10.3389/fimmu.2021.767868			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YB1NB	34975855	gold, Green Published			2022-12-18	WOS:000738786800001
J	Ramirez-Toloza, G; Aguilar-Guzman, L; Valck, C; Menon, SS; Ferreira, VP; Ferreira, A				Ramirez-Toloza, Galia; Aguilar-Guzman, Lorena; Valck, Carolina; Menon, Smrithi S.; Ferreira, Viviana P.; Ferreira, Arturo			Is It Possible to Intervene in the Capacity of Trypanosoma cruzi to Elicit and Evade the Complement System?	FRONTIERS IN IMMUNOLOGY			English	Review						Trypanosoma cruzi; host-parasite interaction; complement system; complement regulatory proteins; host-immune evasion	LECTIN PATHWAY ACTIVATION; CHAGAS-DISEASE; FACTOR-H; REGULATORY PROTEIN; EXTRACELLULAR VESICLES; SIALIC-ACID; CAPSULAR POLYSACCHARIDE; TRANS-SIALIDASE; 1ST COMPONENT; BINDING-SITES	Chagas' disease is a zoonotic parasitic ailment now affecting more than 6 million people, mainly in Latin America. Its agent, the protozoan Trypanosoma cruzi, is primarily transmitted by endemic hematophagous triatomine insects. Transplacental transmission is also important and a main source for the emerging global expansion of this disease. In the host, the parasite undergoes intra (amastigotes) and extracellular infective (trypomastigotes) stages, both eliciting complex immune responses that, in about 70% of the cases, culminate in permanent immunity, concomitant with the asymptomatic presence of the parasite. The remaining 30% of those infected individuals will develop a syndrome, with variable pathological effects on the circulatory, nervous, and digestive systems. Herein, we review an important number of T. cruzi molecules, mainly located on its surface, that have been characterized as immunogenic and protective in various experimental setups. We also discuss a variety of parasite strategies to evade the complement system - mediated immune responses. Within this context, we also discuss the capacity of the T. cruzi infective trypomastigote to translocate the ER-resident chaperone calreticulin to its surface as a key evasive strategy. Herein, it is described that T. cruzi calreticulin inhibits the initial stages of activation of the host complement system, with obvious benefits for the parasite. Finally, we speculate on the possibility to experimentally intervene in the interaction of calreticulin and other T. cruzi molecules that interact with the complement system; thus resulting in significant inhibition of T. cruzi infectivity.	[Ramirez-Toloza, Galia] Univ Chile, Fac Vet Med & Livestock Sci, Dept Vet Prevent Med, Santiago, Chile; [Aguilar-Guzman, Lorena] Univ Chile, Fac Vet Med & Livestock Sci, Dept Pathol, Santiago, Chile; [Valck, Carolina; Ferreira, Arturo] Univ Chile, Dept Immunol, Inst Biomed Sci ICBM, Fac Med, Santiago, Chile; [Menon, Smrithi S.; Ferreira, Viviana P.] Univ Toledo, Coll Med & Life Sci, Dept Med Microbiol & Immunol, 2801 W Bancroft St, Toledo, OH 43606 USA	Universidad de Chile; Universidad de Chile; Universidad de Chile; University System of Ohio; University of Toledo	Ramirez-Toloza, G (corresponding author), Univ Chile, Fac Vet Med & Livestock Sci, Dept Vet Prevent Med, Santiago, Chile.; Ferreira, A (corresponding author), Univ Chile, Dept Immunol, Inst Biomed Sci ICBM, Fac Med, Santiago, Chile.; Ferreira, VP (corresponding author), Univ Toledo, Coll Med & Life Sci, Dept Med Microbiol & Immunol, 2801 W Bancroft St, Toledo, OH 43606 USA.	galiaram@uchile.cl; viviana.ferreira@utoledo.edu; aferreir@med.uchile.cl	RAMIREZ, GALIA/H-9500-2013	RAMIREZ, GALIA/0000-0001-8415-7918	University of Toledo Biomedical Research Innovation Program, Toledo, Ohio, USA; VID, University of Chile; FONDECYT-Chile [1130099]; CONICYT-REDES [170126]; FIV-FAVET [12101701-9102-181]	University of Toledo Biomedical Research Innovation Program, Toledo, Ohio, USA; VID, University of Chile; FONDECYT-Chile(Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT)CONICYT FONDECYT); CONICYT-REDES; FIV-FAVET	The University of Toledo Biomedical Research Innovation Program (VF), Toledo, Ohio, USA; VID, University of Chile (AF); FONDECYT-Chile 1130099 (AF), CONICYT-REDES 170126 and FIV-FAVET 12101701-9102-181 (GR-T).	Abello-Caceres P, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2764-5; Aguilar L, 2005, BIOL RES, V38, P187, DOI 10.4067/S0716-97602005000200008; Al-Nedawi K, 2008, NAT CELL BIOL, V10, P619, DOI 10.1038/ncb1725; ALSENZ J, 1984, BIOCHEM J, V224, P389, DOI 10.1042/bj2240389; ALSENZ J, 1985, BIOCHEM J, V232, P841, DOI 10.1042/bj2320841; Alvarez JP, 2020, IMMUNOBIOLOGY, V225, DOI 10.1016/j.imbio.2019.10.012; Alvedro A, 2021, PARASITE VECTOR, V14, DOI 10.1186/s13071-020-04534-z; Angheben A, 2015, BLOOD TRANSFUS-ITALY, V13, P540, DOI 10.2450/2015.0040-15; Ansa-Addo EA, 2010, J IMMUNOL, V185, P5236, DOI 10.4049/jimmunol.1001656; Araujo-Jorge TC, 2002, J INFECT DIS, V186, P1823, DOI 10.1086/345882; Arroyo-Olarte RD, 2018, MEM I OSWALDO CRUZ, V113, DOI 10.1590/0074-02760170332; Bayer-Santos E, 2013, J PROTEOME RES, V12, P883, DOI 10.1021/pr300947g; Bebawy M, 2009, LEUKEMIA, V23, P1643, DOI 10.1038/leu.2009.76; Beucher M, 2008, INFECT IMMUN, V76, P750, DOI 10.1128/IAI.01104-07; Beucher M, 2003, PROTEIN EXPRES PURIF, V27, P19, DOI 10.1016/S1046-5928(02)00562-4; Castillo C, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002376; Cestari I, 2012, J IMMUNOL, V188, P1942, DOI 10.4049/jimmunol.1102053; Cestari I, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009721; Cestari ID, 2008, J INFECT DIS, V198, P1276, DOI 10.1086/592167; Cestari ID, 2009, MOL IMMUNOL, V47, P426, DOI 10.1016/j.molimm.2009.08.030; CETRON MS, 1993, AM J TROP MED HYG, V49, P370, DOI 10.4269/ajtmh.1993.49.370; Coltel N, 2006, MICROBES INFECT, V8, P2305, DOI 10.1016/j.micinf.2006.04.006; Combes V, 1999, J CLIN INVEST, V104, P93, DOI 10.1172/JCI4985; Combes V, 2005, AM J PATHOL, V166, P295, DOI 10.1016/S0002-9440(10)62253-5; Crawford KE, 2012, PLACENTA, V33, P416, DOI 10.1016/j.placenta.2012.02.003; Diaz A, 1997, J IMMUNOL, V158, P3779; Dumonteil E, 2012, EXPERT REV VACCINES, V11, P1043, DOI [10.1586/erv.12.85, 10.1586/ERV.12.85]; EDWARDS MS, 1982, J IMMUNOL, V128, P1278; EDWARDS MS, 1993, INFECT IMMUN, V61, P2866, DOI 10.1128/IAI.61.7.2866-2871.1993; Evans-Osses I, 2014, FEBS LETT, V588, P956, DOI 10.1016/j.febslet.2014.01.054; Fabrizio MC, 2014, PARASITOLOGY, V141, P837, DOI 10.1017/S0031182013002199; Faille D, 2009, FASEB J, V23, P3449, DOI 10.1096/fj.09-135822; Fernandes HJ, 2017, AM J TROP MED HYG, V96, P292, DOI 10.4269/ajtmh.16-0225; Ferreira V, 2004, J IMMUNOL, V172, P3042, DOI 10.4049/jimmunol.172.5.3042; FISCHER E, 1988, IMMUNOLOGY, V65, P299; Fonseca SG, 2005, MICROBES INFECT, V7, P688, DOI 10.1016/j.micinf.2005.01.001; Freire-de-Lima L, 2015, GLYCOBIOLOGY, V25, P1142, DOI 10.1093/glycob/cwv057; Freitas LM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025914; FUJITA T, 1987, J EXP MED, V166, P1221, DOI 10.1084/jem.166.5.1221; Gardai SJ, 2005, CELL, V123, P321, DOI 10.1016/j.cell.2005.08.032; Garg N, 1997, J IMMUNOL, V158, P3293; Gasser O, 2003, EXP CELL RES, V285, P243, DOI 10.1016/S0014-4827(03)00055-7; Gaur P, 2016, PEERJ, V4, DOI 10.7717/peerj.2693; Gonzalez A, 2015, AM J TROP MED HYG, V92, P887, DOI 10.4269/ajtmh.14-0497; Gu VY, 2008, MOL HUM REPROD, V14, P309, DOI 10.1093/molehr/gan017; Haque A, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01728; HAUSCHKA TS, 1948, SCIENCE, V107, P600, DOI 10.1126/science.107.2788.600; HAYES MM, 1981, INFECT IMMUN, V31, P1117, DOI 10.1128/IAI.31.3.1117-1124.1981; Henrique PM, 2016, EXP PARASITOL, V170, P66, DOI 10.1016/j.exppara.2016.09.001; HOUEN G, 1994, ACTA CHEM SCAND, V48, P905, DOI 10.3891/acta.chem.scand.48-0905; Inal JM, 2005, SPRINGER SEMIN IMMUN, V27, P320, DOI 10.1007/s00281-005-0009-9; Inal JM, 2002, J IMMUNOL, V168, P5213, DOI 10.4049/jimmunol.168.10.5213; Inal JM, 2000, FEBS LETT, V470, P131, DOI 10.1016/S0014-5793(00)01304-1; Ingber A, 2018, J RACIAL ETHN HEALTH, V5, P229, DOI 10.1007/s40615-017-0362-0; JOINER KA, 1988, J BIOL CHEM, V263, P11327; Jokiranta TS, 2000, J BIOL CHEM, V275, P27657; Kallinikova VD, 2001, BIOL BULL+, V28, P244, DOI 10.1023/A:1016636419597; Kennedy AT, 2016, J IMMUNOL, V196, P1239, DOI 10.4049/jimmunol.1501581; Kipnis T L, 1988, Mem Inst Oswaldo Cruz, V83 Suppl 1, P571, DOI 10.1590/S0074-02761988000500069; KIPNIS TL, 1981, P NATL ACAD SCI-BIOL, V78, P602, DOI 10.1073/pnas.78.1.602; KRISTENSEN T, 1986, P NATL ACAD SCI USA, V83, P3963, DOI 10.1073/pnas.83.11.3963; KUHN S, 1995, J IMMUNOL, V155, P5663; LAMBRIS JD, 1988, J BIOL CHEM, V263, P12147; Lidani KCF, 2018, PARASITE IMMUNOL, V40, DOI 10.1111/pim.12537; Llenas-Garcia J, 2021, PLOS NEGLECT TROP D, V15, DOI 10.1371/journal.pntd.0009281; Lopez NC, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000730; Luz PR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060237; Maguire BJ, 2021, PLOS NEGLECT TROP D, V15, DOI 10.1371/journal.pntd.0009697; Malhotra R, 1993, Behring Inst Mitt, P254; Mantel PY, 2014, CELL MICROBIOL, V16, P344, DOI 10.1111/cmi.12259; MARQUES MB, 1992, INFECT IMMUN, V60, P3986, DOI 10.1128/IAI.60.10.3986-3993.1992; Marques T, 2018, EXP PARASITOL, V184, P103, DOI 10.1016/j.exppara.2017.12.003; MARTINS MS, 1985, CLIN EXP IMMUNOL, V61, P343; Mathieu-Daude F, 2008, INFECT GENET EVOL, V8, P258, DOI 10.1016/j.meegid.2007.12.010; Molina MC, 2005, MOL BIOCHEM PARASIT, V140, P133, DOI 10.1016/j.molbiopara.2004.12.014; Moreau C, 2016, IUCRJ, V3, P408, DOI 10.1107/S2052252516012847; Muniz Julio, 1945, REV BRASIL BIOL, V5, P563; NORRIS KA, 1994, INFECT IMMUN, V62, P236, DOI 10.1128/IAI.62.1.236-243.1994; NORRIS KA, 1991, J IMMUNOL, V147, P2240; Norris KA, 1998, INFECT IMMUN, V66, P2460, DOI 10.1128/IAI.66.6.2460-2465.1998; Zamora YO, 2017, EXPERT REV CARDIOVAS, V15, P367, DOI 10.1080/14779072.2017.1317591; Pangburn MK, 2008, VACCINE, V26, pI15, DOI 10.1016/j.vaccine.2008.11.023; Pangburn MK, 2000, IMMUNOPHARMACOLOGY, V49, P149, DOI 10.1016/S0162-3109(00)80300-8; Perez CJ, 2015, TRENDS PARASITOL, V31, P595, DOI 10.1016/j.pt.2015.06.006; Pilzer D, 2005, SPRINGER SEMIN IMMUN, V27, P375, DOI 10.1007/s00281-005-0004-1; PREVIATO JO, 1985, MOL BIOCHEM PARASIT, V16, P85, DOI 10.1016/0166-6851(85)90051-9; Ramirez G, 2011, IMMUNOBIOLOGY, V216, P265, DOI 10.1016/j.imbio.2010.04.001; Ramirez MI, 2017, CELL MICROBIOL, V19, DOI 10.1111/cmi.12672; Ribeiro CH, 2015, AM J TROP MED HYG, V92, P320, DOI 10.4269/ajtmh.14-0236; Ribeiro KS, 2018, J EXTRACELL VESICLES, V7, DOI 10.1080/20013078.2018.1463779; RIPOCHE J, 1988, BIOCHEM J, V249, P593, DOI 10.1042/bj2490593; Rosa TFA, 2016, CELL MICROBIOL, V18, P573, DOI 10.1111/cmi.12535; Rossi IV, 2019, METHODS MOL BIOL, V1955, P89, DOI 10.1007/978-1-4939-9148-8_7; RUBIO M., 1956, BOL CHILENO PARASITOL, V11, P62; Valdez FJS, 2013, MOL IMMUNOL, V53, P198, DOI 10.1016/j.molimm.2012.08.001; Sanchez-Valdez FJ, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002696; SCHENKMAN S, 1991, CELL, V65, P1117, DOI 10.1016/0092-8674(91)90008-M; SCHENKMAN S, 1986, J IMMUNOL, V137, P1623; Sepulveda P, 2000, INFECT IMMUN, V68, P4986, DOI 10.1128/IAI.68.9.4986-4991.2000; Sharma AK, 1996, P NATL ACAD SCI USA, V93, P10996, DOI 10.1073/pnas.93.20.10996; SHER A, 1986, J IMMUNOL, V137, P2961; Sikorski PM, 2020, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.03105; Sosoniuk E, 2014, MOL IMMUNOL, V60, P80, DOI 10.1016/j.molimm.2014.03.014; Sosoniuk-Roche E, 2017, IMMUNOBIOLOGY, V222, P529, DOI 10.1016/j.imbio.2016.10.020; Souto-Padron T, 2004, HISTOCHEM CELL BIOL, V122, P563, DOI 10.1007/s00418-004-0724-7; TAMBOURGI DV, 1993, INFECT IMMUN, V61, P3656, DOI 10.1128/IAI.61.9.3656-3663.1993; TAMBOURGI DV, 1989, EXP PARASITOL, V68, P192, DOI 10.1016/0014-4894(89)90097-0; TAMBOURGI DV, 1995, AM J TROP MED HYG, V52, P516, DOI 10.4269/ajtmh.1995.52.516; Toledo V, 2010, BIOL RES, V43, P287, DOI [10.4067/S0716-97602010000300004, /S0716-97602010000300004]; TOMLINSON S, 1994, J IMMUNOL, V153, P3141; Torrecilhas ACT, 2009, MICROBES INFECT, V11, P29, DOI 10.1016/j.micinf.2008.10.003; Valck C, 2010, MOL IMMUNOL, V47, P1516, DOI 10.1016/j.molimm.2010.01.019; van Beek AE, 2018, OPEN FORUM INFECT DI, V5, DOI 10.1093/ofid/ofy166; VELGE P, 1988, PARASITOLOGY, V97, P255, DOI 10.1017/S0031182000058467; Weinberger K, 2017, AM J TROP MED HYG, V96, P295, DOI 10.4269/ajtmh.16-0642; WETZLER LM, 1992, INFECT IMMUN, V60, P39, DOI 10.1128/IAI.60.1.39-43.1992; World Health Organization (WHO), 2021, CHAG DIS ALS KNOW AM; Wyllie MP, 2017, PATHOG DIS, V75, DOI 10.1093/femspd/ftx077; Zipfel PF, 2009, NAT REV IMMUNOL, V9, P729, DOI 10.1038/nri2620; Zuniga E, 2000, CLIN EXP IMMUNOL, V119, P507, DOI 10.1046/j.1365-2249.2000.01150.x	120	0	0	3	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 16	2021	12								789145	10.3389/fimmu.2021.789145	http://dx.doi.org/10.3389/fimmu.2021.789145			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YB1KJ	34975884	Green Published, gold			2022-12-18	WOS:000738779700001
J	Yang, CL; Zhao, HD; Tebbutt, SJ				Yang, Chengliang; Zhao, Hedi; Tebbutt, Scott J.			Balancing the Risks and Benefits of COVID-19 Vaccination for Pregnant Women and Their Children	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						COVID-19; SARS-CoV-2; vaccine; pregnant women; newborns	EPIDEMIOLOGY		[Yang, Chengliang; Tebbutt, Scott J.] Univ British Columbia, St Pauls Hosp, Prevent Organ Failure PROOF Ctr Excellence, Vancouver, BC, Canada; [Yang, Chengliang; Tebbutt, Scott J.] Univ British Columbia, St Pauls Hosp, Ctr Heart Lung Innovat, Vancouver, BC, Canada; [Zhao, Hedi] McGill Univ, Fac Med, Montreal, PQ, Canada; [Tebbutt, Scott J.] Univ British Columbia, Div Resp Med, Dept Med, Vancouver, BC, Canada	St. Paul's Hospital; University of British Columbia; University of Saskatchewan; St. Paul's Hospital; University of British Columbia; University of Saskatchewan; McGill University; University of British Columbia	Tebbutt, SJ (corresponding author), Univ British Columbia, St Pauls Hosp, Prevent Organ Failure PROOF Ctr Excellence, Vancouver, BC, Canada.; Tebbutt, SJ (corresponding author), Univ British Columbia, St Pauls Hosp, Ctr Heart Lung Innovat, Vancouver, BC, Canada.	Scott.Tebbutt@hli.ubc.ca		Yang, Chengliang/0000-0002-5182-4494	Canadian Institutes of Health Research (CIHR) [177747]	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR))	Funding This study was supported by the Canadian Institutes of Health Research (CIHR) (Grant No. 177747).	Chmielewska B, 2021, LANCET GLOB HEALTH, V9, pE759, DOI 10.1016/S2214-109X(21)00079-6; Collier ARY, 2021, JAMA-J AM MED ASSOC, V325, P2370, DOI 10.1001/jama.2021.7563; Cummings MJ, 2020, LANCET, V395, P1763, DOI 10.1016/S0140-6736(20)31189-2; Galang Romeo R, 2021, Clin Infect Dis, V73, pS17, DOI 10.1093/cid/ciab432; Gou XY, 2019, AUST NZ J PSYCHIAT, V53, P195, DOI 10.1177/0004867418823276; Graham JM, 2020, BIRTH DEFECTS RES, V112, P943, DOI 10.1002/bdr2.1696; Kim L, 2020, MMWR-MORBID MORTAL W, V69, P1081, DOI 10.15585/mmwr.mm6932e3; Liew Z, 2016, AUTISM RES, V9, P951, DOI 10.1002/aur.1591; Liew Z, 2014, JAMA PEDIATR, V168, P313, DOI 10.1001/jamapediatrics.2013.4914; Malizia BA, 2009, NEW ENGL J MED, V360, P236, DOI 10.1056/NEJMoa0803072; Perl SH, 2021, JAMA-J AM MED ASSOC, V325, P2013, DOI 10.1001/jama.2021.5782; Poston L, 2016, LANCET DIABETES ENDO, V4, P1025, DOI 10.1016/S2213-8587(16)30217-0; PrabhuDas M, 2011, NAT IMMUNOL, V12, P189, DOI 10.1038/ni0311-189; Shimabukuro TT, 2021, OBSTET GYNECOL SURV, V76, P729, DOI [10.1056/NEJMoa2104983, 10.1097/01.ogx.0000802676.57373.17, 10.1056/NEJMx210016]; Snook ML, 2021, FERTIL STERIL, V116, P16, DOI 10.1016/j.fertnstert.2021.05.083; Tiegs G, 2014, EXPERT REV CLIN PHAR, V7, P655, DOI 10.1586/17512433.2014.944502; Waller DK, 2018, BIRTH DEFECTS RES, V110, P342, DOI 10.1002/bdr2.1147	17	0	0	0	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 16	2021	12								748456	10.3389/fimmu.2021.748456	http://dx.doi.org/10.3389/fimmu.2021.748456			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YB5MO	34975839	Green Published, gold			2022-12-18	WOS:000739056500001
J	Abji, F; Rasti, M; Gomez-Aristizabal, A; Muytjens, C; Saifeddine, M; Mihara, K; Motahhari, M; Gandhi, R; Viswanathan, S; Hollenberg, MD; Oikonomopoulou, K; Chandran, V				Abji, Fatima; Rasti, Mozhgan; Gomez-Aristizabal, Alejandro; Muytjens, Carla; Saifeddine, Mahmoud; Mihara, Koichiro; Motahhari, Majid; Gandhi, Rajiv; Viswanathan, Sowmya; Hollenberg, Morley D.; Oikonomopoulou, Katerina; Chandran, Vinod			Proteinase-Mediated Macrophage Signaling in Psoriatic Arthritis (vol 11, 629726, 2021)	FRONTIERS IN IMMUNOLOGY			English	Correction						serine proteinase; spondyloarthritis; monocyte; macrophage; synovial fluid; PAR2; tryptase-6			[Abji, Fatima; Rasti, Mozhgan; Gomez-Aristizabal, Alejandro; Muytjens, Carla; Gandhi, Rajiv; Viswanathan, Sowmya; Oikonomopoulou, Katerina; Chandran, Vinod] Univ Hlth Network, Krembil Res Inst, Schroeder Arthrit Inst, Toronto, ON, Canada; [Saifeddine, Mahmoud; Mihara, Koichiro; Motahhari, Majid; Hollenberg, Morley D.] Univ Calgary, Dept Physiol & Pharmacol, Cumming Sch Med, Calgary, AB, Canada; [Gandhi, Rajiv] Toronto Western Hosp, Dept Surg, Div Orthopaed Surg, Toronto, ON, Canada; [Viswanathan, Sowmya] Univ Toronto, Inst Biomed Engn, Toronto, ON, Canada; [Viswanathan, Sowmya] Univ Toronto, Dept Med, Div Hematol, Toronto, ON, Canada; [Hollenberg, Morley D.] Univ Calgary, Dept Med, Cumming Sch Med, Calgary, AB, Canada; [Chandran, Vinod] Univ Toronto, Dept Med, Div Rheumatol, Toronto, ON, Canada; [Chandran, Vinod] Univ Toronto, Inst Med Sci, Toronto, ON, Canada; [Chandran, Vinod] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada; [Chandran, Vinod] Mem Univ Newfoundland, Dept Med, St John, NF, Canada	Krembil Research Institute; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Calgary; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto; University of Calgary; University of Toronto; University of Toronto; University of Toronto; Memorial University Newfoundland	Oikonomopoulou, K; Chandran, V (corresponding author), Univ Hlth Network, Krembil Res Inst, Schroeder Arthrit Inst, Toronto, ON, Canada.; Chandran, V (corresponding author), Univ Toronto, Dept Med, Div Rheumatol, Toronto, ON, Canada.; Chandran, V (corresponding author), Univ Toronto, Inst Med Sci, Toronto, ON, Canada.; Chandran, V (corresponding author), Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada.; Chandran, V (corresponding author), Mem Univ Newfoundland, Dept Med, St John, NF, Canada.	katerina.oikonomopoulou@uhnresearch.ca; vinod.chandran@uhnresearch.ca	Viswanathan, Sowmya/GRO-4533-2022; Hollenberg, Morley/AFV-6966-2022						0	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 15	2021	12								814072	10.3389/fimmu.2021.814072	http://dx.doi.org/10.3389/fimmu.2021.814072			5	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YB5DD	34975926	Green Published, gold			2022-12-18	WOS:000739032000001
J	Bernarde, PS; Pucca, MB; Mota-da-Silva, A; da Fonseca, WL; de Almeida, MRN; de Oliveira, IS; Cerni, FA; Grazziotin, FG; Sartim, MA; Sachett, J; Wen, FH; Moura-da-Silva, AM; Monteiro, WM				Bernarde, Paulo Sergio; Pucca, Manuela Berto; Mota-da-Silva, Ageane; da Fonseca, Wirven Lima; de Almeida, Marllus Rafael Negreiros; de Oliveira, Isadora Sousa; Cerni, Felipe Augusto; Gobbi Grazziotin, Felipe; Sartim, Marco A.; Sachett, Jacqueline; Wen, Fan Hui; Moura-da-Silva, Ana Maria; Monteiro, Wuelton M.			Bothrops bilineatus: An Arboreal Pitviper in the Amazon and Atlantic Forest	FRONTIERS IN IMMUNOLOGY			English	Review						two-striped forest-pitviper; Amazon palm pitviper; snakebite; envenoming; venom; antivenom	ASP49 PHOSPHOLIPASE A(2); ACUTE KIDNEY INJURY; LOWER PURUS RIVER; SNAKE-VENOM; BOTHRIOPSIS-BILINEATA; SMARAGDINUS HOGE; VIPER VENOM; (PRO)THROMBIN INHIBITOR; MOLECULAR SYSTEMATICS; PLATELET-AGGREGATION	The two-striped forest-pitviper (Bothrops bilineatus) is an arboreal snake that is currently represented by two subspecies (B. b. bilineatus and B. b. smaragdinus) that comprise a species complex, and its distribution is in the Amazon and the Atlantic Forest. The rarity of encounters with this snake is reflected in the low occurrence of cases of snakebites throughout its geographic distribution and the resulting low number of published clinical reports. However, in some areas, B. bilineatus proves to be more frequent and causes envenomations in a greater proportion. Herein, we review the main aspects of the species complex B. bilineatus, including its biology, ecology, taxonomy, morphology, genetic and molecular studies, geographic distribution, conservation status, venom, pathophysiology and clinical aspects, and epidemiology. In addition, the different antivenoms available for the treatment of envenomations caused by B. bilineatus are presented along with suggestions for future studies that are needed for a better understanding of the snakebites caused by this snake.	[Bernarde, Paulo Sergio; da Fonseca, Wirven Lima; de Almeida, Marllus Rafael Negreiros] Univ Fed Acre, Lab Herpetol, Cruzeiro Do Sul, Brazil; [Pucca, Manuela Berto] Univ Fed Roraima, Curso Med, Boa Vista, Brazil; [Pucca, Manuela Berto; Cerni, Felipe Augusto] Univ Fed Roraima, Programa Posgrad Ciencias, Boa Vista, Brazil; [Mota-da-Silva, Ageane] Inst Fed Acre, Campus Cruzeiro Sul, Cruzeiro Do Sul, Brazil; [de Oliveira, Isadora Sousa] Univ Sao Paulo, Fac Ciencias Farmaceut Ribeirao Preto, Dept Ciencias Biomol, Ribeirao Preto, Brazil; [Gobbi Grazziotin, Felipe] Inst Butantan, Lab Colecoes Zool, Sao Paulo, Brazil; [Sartim, Marco A.; Moura-da-Silva, Ana Maria; Monteiro, Wuelton M.] Fdn Med Trop Dr Heitor Vieira Dourado, Dept Ensino & Pesquisa, Manaus, Brazil; [Sartim, Marco A.] Univ Fed Amazonas, Inst Ciencias Biol, Manaus, Brazil; [Sartim, Marco A.] Univ Nilton Lins, Dept Posgrad, Manaus, Brazil; [Sachett, Jacqueline; Monteiro, Wuelton M.] Univ Estado Amazonas, Escola Super Ciencias Saude, Manaus, Brazil; [Sachett, Jacqueline] Fundacao Alfredo Matta, Dept Ensino & Pesquisa, Manaus, Brazil; [Wen, Fan Hui] Inst Butantan, Nucl Estrateg Venenos & Antivenenos, Sao Paulo, Brazil; [Moura-da-Silva, Ana Maria] Inst Butantan, Lab Imunopatol, Sao Paulo, Brazil	Universidade Federal de Roraima; Universidade Federal de Roraima; Instituto Federal do Acre (IFAC); Universidade de Sao Paulo; Instituto Butantan; Universidade Federal de Amazonas; Centro Universitario Nilton Lins; Universidade do Estado do Amazonas; Instituto Butantan; Instituto Butantan	Bernarde, PS (corresponding author), Univ Fed Acre, Lab Herpetol, Cruzeiro Do Sul, Brazil.; Monteiro, WM (corresponding author), Fdn Med Trop Dr Heitor Vieira Dourado, Dept Ensino & Pesquisa, Manaus, Brazil.; Monteiro, WM (corresponding author), Univ Estado Amazonas, Escola Super Ciencias Saude, Manaus, Brazil.	SnakeBernarde@hotmail.com; wueltonmm@gmail.com	Grazziotin, Felipe G/D-7525-2015; Fan, Hui Wen/F-8649-2015; Sartim, Marco/X-4086-2019; Sachett, Jacqueline/I-5642-2017	Grazziotin, Felipe G/0000-0001-9896-9722; Fan, Hui Wen/0000-0002-8191-559X; Sartim, Marco/0000-0003-4572-3109; /0000-0002-2036-1191; Sachett, Jacqueline/0000-0001-5723-9977; Negreiros Almeida, Marllus Rafael/0000-0001-5990-9401; Lima da Fonseca, Wirven/0000-0002-2893-0627	Conselho Nacional de Desenvolvimento Cientifico e Tecnolo gico (CNPq) (National Council for Scientific and Technological Development, scholarship) [307184/2020-0, 309207/2020-7, 303958/2018-9, PS 311509/2020-7]; Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP, Sao Paulo Research Foundation) [2016/50127-5, 2020/13176-3]; Fundacao de Amparo a Pesquisa do Estado do Amazonas (PAPAC) [005/2019]; Hamish Ogston Foundation - Global Snakebite Initiative; Fundacao de Amparo a Pesquisa do Estado do Amazonas (PRO-ESTADO); Fundacao de Amparo a Pesquisa do Estado do Amazonas (Posgrad calls)	Conselho Nacional de Desenvolvimento Cientifico e Tecnolo gico (CNPq) (National Council for Scientific and Technological Development, scholarship)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)Fundacao de Apoio a Pesquisa do Distrito Federal (FAPDF)); Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP, Sao Paulo Research Foundation)(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); Fundacao de Amparo a Pesquisa do Estado do Amazonas (PAPAC); Hamish Ogston Foundation - Global Snakebite Initiative; Fundacao de Amparo a Pesquisa do Estado do Amazonas (PRO-ESTADO); Fundacao de Amparo a Pesquisa do Estado do Amazonas (Posgrad calls)	We thank Conselho Nacional de Desenvolvimento Cientifico e Tecnolo gico (CNPq, The National Council for Scientific and Technological Development, scholarship to MP no. 307184/2020-0, WM n. 309207/2020-7, to AMM-d-S no. 303958/2018-9, and PS 311509/2020-7) and Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP, Sao Paulo Research Foundation; research grant 2016/50127-5; scholarship to IO no. 2020/13176-3). WM acknowledges funding support from Fundacao de Amparo a Pesquisa do Estado do Amazonas (PAPAC, 005/2019, PRO-ESTADO and Posgrad calls). MP (Snakebite Roraima project coordinator) acknowledges funding support from Hamish Ogston Foundation - Global Snakebite Initiative.	Albuquerque PLMM, 2013, REV INST MED TROP SP, V55, P295, DOI 10.1590/S0036-46652013000500001; Almeida BJL., 2019, HERPETOLOGICAL REV, V50, P385; Almeida MTD, 2020, TOXINS, V12, DOI 10.3390/toxins12020096; Almeida-Santos S.M., 2002, BIOL VIPERS, P445; Argolo A. J. S., 2004, SERPENTES CACAUAIS S; Assafim M, 2016, TOXICON, V119, P46, DOI 10.1016/j.toxicon.2016.05.007; Avila-Pires Teresa Cristina Sauer, 2009, Boletim do Museu Paraense Emilio Goeldi Ciencias Naturais, V4, P99; Beebe W, 1964, ZOOLOGICA-N Y, V31, P11, DOI [10.5962/p.203521, DOI 10.5962/P.203521]; Berling I, 2015, TRANSFUS MED REV, V29, P82, DOI 10.1016/j.tmrv.2014.09.005; Bernarde Paulo Sergio, 2006, South American Journal of Herpetology, V1, P102, DOI 10.2994/1808-9798(2006)1[102:ASCAED]2.0.CO;2; Bernarde PS, 2011, BIOTA NEOTROP, V11, P117, DOI 10.1590/S1676-06032011000300010; Bernarde Paulo Sergio, 2011, Check List, V7, P343; Bernarde PS, 2014, SERPENTES PE ONHENTA; Bernardoni JL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109651; Bernils RS., 2019, FAUNA FLORA AMEAEADA, P271; Bon C., 1996, ACTA MED COLOMB, V34, P142; Burger WL, 1971, THESIS U KANSA UNPUB; Butantan-British Bothrops Systematics Project, 1996, Symposia of the Zoological Society of London, V70, P89; Butantan-British Bothrops Systematics Project, 1999, Kaupia Darmstaedter Beitraege zur Naturgeschichte, V8, P127; Butantan-British IBothrops/I Systematics Project, 2002, P111; Campbell J.A., 1989, VENOMOUS REPTILES LA; Campbell J. A., 2004, VENOMOUS REPTILES W; Cardoso DF, 2001, MEDIAT INFLAMM, V10, P125, DOI 10.1080/09629350120072699; Carrasco PA, 2019, ZOOTAXA, V4565, P301, DOI 10.11646/zootaxa.4565.3.1; Carrasco PA, 2012, ZOOL SCR, V41, P109, DOI 10.1111/j.1463-6409.2011.00511.x; Carregari VC, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/612649; Castoe TA, 2006, MOL PHYLOGENET EVOL, V39, P91, DOI 10.1016/j.ympev.2005.12.014; Clemetson KJ, 2007, CURR PHARM DESIGN, V13, P2887, DOI 10.2174/138161207782023702; CMBio, 2018, LIVRO VERMELHO FAUNA, VI; Cunha O.R., 1978, B MUSEU PARAENSE EMI, V31, P1; Cunha O. R., 1985, PUBLICACOES AVULSAS, V40, P9; Prudente Ana Lúcia da Costa, 2010, Acta Amaz., V40, P381, DOI 10.1590/S0044-59672010000200016; da Cunha OR, 1967, B MUSEU PARAENSE EM, V66, P1; da Cunha Osvaldo Rodrigues, 1993, Boletim do Museu Paraense Emilio Goeldi Serie Zoologia, V9, P1; da Fonseca Wirven Lima, 2021, Herpetology Notes, V14, P567; da Fonseca Wirven Lima, 2019, Herpetology Notes, V12, P365; da Silva AM, 2019, TOXICON, V171, P66, DOI 10.1016/j.toxicon.2019.10.238; da Silva AM, 2019, REV SOC BRAS MED TRO, V52, DOI 10.1590/0037-8682-0195-2018; da Silva JL, 2020, TOXICON, V187, P232, DOI 10.1016/j.toxicon.2020.09.007; da Silva Nelson Jorge Jr., 1993, Herpetological Natural History, V1, P37; Dal Vechio FH, 2014, REVISAO SISTEMATICA, DOI [10.11606/D.41.2015.tde-24032015-083805, DOI 10.11606/D.41.2015.TDE-24032015-083805]; Dal Vechio F, 2018, J BIOGEOGR, V45, P2415, DOI 10.1111/jbi.13421; de Oliveira IS, 2019, J PROTEOMICS, V191, P153, DOI 10.1016/j.jprot.2018.02.020; de Oliveira LP, 2020, REV SOC BRAS MED TRO, V53, DOI 10.1590/0037-8682-0214-2020; de Oliveira SS, 2020, CLIN TOXICOL, V58, P266, DOI 10.1080/15563650.2019.1634273; de Oliveira SS, 2017, TOXICON, V138, P102, DOI 10.1016/j.toxicon.2017.08.021; Debien Iury Valente, 2019, Herpetology Notes, V12, P1051; DEESPINOZA NC, 1983, PUBLICACIONES MUSEO, V30, P1; Dias Luiz Gustavo, 2008, Lundiana, V9, P75; Dixon J.R., 1986, REPTILES UPPER AMAZO; DUBEUX M.J.M., 2019, HERPETOL REV, V50, P385; DUELLMAN W E, 1978, University of Kansas Museum of Natural History Miscellaneous Publication, P1; Feio Renato Neves, 2002, Phyllomedusa, V1, P105; Fenwick AM, 2009, ZOOL J LINN SOC-LOND, V156, P617, DOI 10.1111/j.1096-3642.2008.00495.x; Floriano RS, 2015, TOXICON, V96, P24, DOI 10.1016/j.toxicon.2015.01.001; Floriano RS, 2013, TOXICON, V69, P191, DOI 10.1016/j.toxicon.2013.03.006; Fox JW, 2008, FEBS J, V275, P3016, DOI 10.1111/j.1742-4658.2008.06466.x; Franca RC, 2020, ZOOKEYS, P115, DOI 10.3897/zookeys.1002.50997; Frazao L, 2020, BIOTA NEOTROP, V20, DOI [10.1590/1676-0611-BN-2018-0661, 10.1590/1676-0611-bn-2018-0661]; Freitas-de-Sousa LA, 2017, TOXINS, V9, DOI 10.3390/toxins9080239; Frota J. G., 2005, BIOCIENCIAS, V13, P211; Fry BG, 2009, ANNU REV GENOM HUM G, V10, P483, DOI 10.1146/annurev.genom.9.081307.164356; Gras S, 2012, J VENOM ANIM TOXINS, V18, P467, DOI 10.1590/S1678-91992012000400019; GREENE H W, 1972, Herpetologica, V28, P32; Grego Kathleen F., 2012, Herpetological Review, V43, P492; Griffith G.E., 1998, ECOLOGICAL CLA UNPUB, P49; Haad J.S., 1981, MEM I BUTANTAN, V44/45, P403; Harvey MB, 2005, ANN CARNEGIE MUS, V74, P1, DOI 10.2992/0097-4463(2005)74[1:ROTVSO]2.0.CO;2; Higuchi DA, 2011, TOXICON, V58, P123, DOI 10.1016/j.toxicon.2011.05.013; Hoge A. R., 1962, Pub Oc Mus Cienc Nat Caracas Zool, VNo. 1, P1; HOGE ALPHONSE RICHARD, 1965, MEMORIAS INST BUTANTAN, V32, P109; International Union for Conservation of Nature and Natural Resources, 2019, IUCN RED LIST THREAT; Kamiguti AS, 1996, BIOCHEM J, V320, P635, DOI 10.1042/bj3200635; Kini RM, 2011, J THROMB HAEMOST, V9, P195, DOI 10.1111/j.1538-7836.2011.04279.x; Kini RM, 2001, HAEMOSTASIS, V31, P218; Lancini AR., 1979, SERPIENTES VENEZUELA; Laustsen AH, 2018, TOXICON, V146, P151, DOI 10.1016/j.toxicon.2018.03.004; Lomonte B, 2012, TOXICON, V60, P520, DOI 10.1016/j.toxicon.2012.02.007; Lomonte B, 2009, PROTEIN PEPTIDE LETT, V16, P860, DOI 10.2174/092986609788923356; Macedo E., 2019, COMPREHENSIVE CLIN N, P830; MAGNUSSON W. E., 2013, GUIDE SNAKES MANAUS; Gutierrez JM, 2018, TOXINS, V10, DOI 10.3390/toxins10050182; Marques OAV, 2001, AMPHIBIA-REPTILIA, V22, P103, DOI 10.1163/156853801750096213; Martinez Cadillo E, 1991, Rev Biol Trop, V39, P311; Martins Marcio, 2002, P307; Martins Marcio, 1999, Herpetological Natural History, V6, P78; Masseli GS, 2019, AN ACAD BRAS CIENC, V91, DOI 10.1590/0001-3765201920190080; Melare R, 2016, MICROSC RES TECHNIQ, V79, P1082, DOI 10.1002/jemt.22748; Modesto JCD, 2005, BIOL CHEM, V386, P589, DOI 10.1515/BC.2005.069; Moraes LJCL, 2017, ZOOKEYS, P103, DOI 10.3897/zookeys.715.20288; Albuquerque PLMM, 2019, TOXINS, V11, DOI 10.3390/toxins11030148; Moura-Da-Silva AM, 2007, CURR PHARM DESIGN, V13, P2893, DOI 10.2174/138161207782023711; Moura-da-Silva AM, 2001, THROMB RES, V102, P153, DOI 10.1016/S0049-3848(01)00216-X; Muniz EG, 2000, TOXICON, V38, P1859, DOI 10.1016/S0041-0101(00)00082-9; Mamede CCN, 2020, TOXICON, V187, P10, DOI 10.1016/j.toxicon.2020.08.016; Nogueira CC, 2019, S AM J HERPETOL, V14, pS1, DOI 10.2994/SAJH-D-19-00120.1; Oliveira M. Ermelinda, 2001, Herpetological Natural History, V8, P101; Otero-Patino R, 2009, TOXICON, V54, P998, DOI 10.1016/j.toxicon.2009.07.001; PANTOJA DL., 2012, CHECK LIST, V8, P360, DOI DOI 10.15560/8.3.360; Parkinson Christopher L., 2002, P93; Parkinson CL, 1999, COPEIA, P576, DOI 10.2307/1447591; Roriz KRPS, 2018, REV SOC BRAS MED TRO, V51, P338, DOI 10.1590/0037-8682-0489-2017; Peters J. A, 1970, Bull. U.S. natn. Mus., VNo. 297, P1; Pierini SV, 1996, TOXICON, V34, P225, DOI 10.1016/0041-0101(95)00125-5; Porto BN, 2007, TOXICON, V50, P270, DOI 10.1016/j.toxicon.2007.03.020; Ribeiro Camila Bastos, 2014, ISRN Inflamm, V2014, P563628, DOI 10.1155/2014/563628; Rodrigues CR, 2018, J PROTEOMICS, V187, P171, DOI 10.1016/j.jprot.2018.07.016; Rodrigues-Simioni L, 2011, TOXICON, V58, P140, DOI 10.1016/j.toxicon.2011.05.002; Rodriguez E., 2010, REV SOC QUIM PERU, V76, P7; Rodríguez Edith, 2012, Rev. Soc. Quím. Perú, V78, P3; Rucavado A, 2016, TOXINS, V8, DOI 10.3390/toxins8120349; Sandner-Montilla F, 1994, MINI INFORMACION SER; Sanz L, 2020, J PROTEOME RES, V19, P3518, DOI 10.1021/acs.jproteome.0c00337; Sazima Ivan, 1992, P199; Serrano SMT, 2013, TOXICON, V62, P19, DOI 10.1016/j.toxicon.2012.09.003; Setubal SD, 2013, TOXICON, V76, P143, DOI 10.1016/j.toxicon.2013.09.019; Silva FS, 2021, REV SOC BRAS MED TRO, V54, DOI 10.1590/0037-8682-0374-2020; Silva-Soares T., 2016, CHECK LIST, V7, P290, DOI [10.15560/7.3.290, DOI 10.15560/7.3.290]; Smalligan R, 2004, BMJ-BRIT MED J, V329, P1129, DOI 10.1136/bmj.329.7475.1129; Sousa LF, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002442; Souza RCG., 2007, B CHICAGO HERP SOC, V42, P161; Souza-Costa Carlos Augusto, 2020, Bonn Zoological Bulletin, V69, P85, DOI 10.20363/BZB-2020.69.1.085; Torrez PPQ, 2014, TOXICON, V85, P27, DOI 10.1016/j.toxicon.2014.04.001; Tozetti AM., 2017, REVISOES ZOOLOGIA MA, P309; Turci LCB., 2012, TITULOS NAO CORRENTE; Turci Luiz Carlos Batista, 2009, Biota Neotrop., V9, P197, DOI 10.1590/S1676-06032009000300020; Valencia J, 2016, SERPIENTES VENENOSAS; Venegas Pablo J., 2019, Cuadernos de Herpetologia, V33, P29; Vidal N, 1997, CR ACAD SCI III-VIE, V320, P95, DOI 10.1016/S0764-4469(99)80091-2; Waldez F, 2013, BIOTA NEOTROP, V13, P300, DOI 10.1590/S1676-06032013000100029; Waldez Fabiano, 2009, Acta Amaz., V39, P681, DOI 10.1590/S0044-59672009000300025; Wallace AR, 1853, PALM TREES AMAZON TH; Wen FH, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003701; Yu CL, 2020, INT J BIOL MACROMOL, V165, P2994, DOI 10.1016/j.ijbiomac.2020.10.190; Zimmerman B.L., 1990, P426; Zingali RB, 2005, PATHOPHYSIOL HAEMO T, V34, P160, DOI 10.1159/000092416; Zoccal KF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088174; Zuliani JP, 2020, TOXICON, V187, P188, DOI 10.1016/j.toxicon.2020.09.006	138	0	0	2	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 15	2021	12								778302	10.3389/fimmu.2021.778302	http://dx.doi.org/10.3389/fimmu.2021.778302			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YB0YL	34975866	gold, Green Published			2022-12-18	WOS:000738748400001
J	Johanson, TM; Keenan, CR; Allan, RS				Johanson, Timothy M.; Keenan, Christine R.; Allan, Rhys S.			Shedding Structured Light on Molecular Immunity: The Past, Present and Future of Immune Cell Super Resolution Microscopy	FRONTIERS IN IMMUNOLOGY			English	Review						super resolution microscopy; immune cells; immune cell activation; recombination; single molecule microscopy	IMMUNOLOGICAL SYNAPSE; TRANSCRIPTION FACTORS; SPATIAL-ORGANIZATION; GRANULE SECRETION; IMMUNOGLOBULIN; ACTIN; RECEPTOR; SUPERRESOLUTION; COMPARTMENTALIZATION; NANOCLUSTERS	In the two decades since the invention of laser-based super resolution microscopy this family of technologies has revolutionised the way life is viewed and understood. Its unparalleled resolution, speed, and accessibility makes super resolution imaging particularly useful in examining the highly complex and dynamic immune system. Here we introduce the super resolution technologies and studies that have already fundamentally changed our understanding of a number of central immunological processes and highlight other immunological puzzles only addressable in super resolution.	[Johanson, Timothy M.; Keenan, Christine R.; Allan, Rhys S.] Walter & Eliza Hall Inst Med Res, Parkville, Vic, Australia; [Johanson, Timothy M.; Keenan, Christine R.; Allan, Rhys S.] Univ Melbourne, Dept Med Biol, Parkville, Vic, Australia	Walter & Eliza Hall Institute; University of Melbourne	Johanson, TM (corresponding author), Walter & Eliza Hall Inst Med Res, Parkville, Vic, Australia.; Johanson, TM (corresponding author), Univ Melbourne, Dept Med Biol, Parkville, Vic, Australia.	johanson@wehi.edu.au		Keenan, Christine/0000-0002-6057-1855	National Health and Medical Research Council of Australia [1124081, 1049307, 1100451, 1125436]	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia)	This work was supported by grants and fellowships from the National Health and Medical Research Council of Australia (TJ #1124081, RA and TJ #1049307, #1100451, CK #1125436). This study was made possible through Victorian State Government Operational Infrastructure Support and Australian Government NHMRC Independent Research Institute Infrastructure Support scheme. The funders had no role in the decision to publish or preparation of the manuscript.	Aaron JS, 2012, SMALL, V8, P3041, DOI 10.1002/smll.201200106; ABBAS AK, 1975, J IMMUNOL, V114, P1197; AMBROSE EJ, 1956, NATURE, V178, P1194, DOI 10.1038/1781194a0; Ashdown GW, 2017, BIOPHYS J, V112, P1703, DOI 10.1016/j.bpj.2017.01.038; Avalos AM, 2014, J EXP MED, V211, P365, DOI 10.1084/jem.20131603; AXELROD D, 1976, BIOPHYS J, V16, P1055, DOI 10.1016/S0006-3495(76)85755-4; Balint S, 2018, SCI SIGNAL, V11, DOI 10.1126/scisignal.aal3606; BAUMAN JGJ, 1980, EXP CELL RES, V128, P485, DOI 10.1016/0014-4827(80)90087-7; Betzig E, 2006, SCIENCE, V313, P1642, DOI 10.1126/science.1127344; Bhat R, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000326; Bintu B, 2018, SCIENCE, V362, P419, DOI 10.1126/science.aau1783; Brown ACN, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001152; Brown G., 2018, CELL LINEAGE CHOICE; Gizzi AMC, 2019, MOL CELL, V74, P212, DOI 10.1016/j.molcel.2019.01.011; Carisey AF, 2018, CURR BIOL, V28, P489, DOI 10.1016/j.cub.2017.12.044; Carr AR, 2017, BIOPHYS J, V112, P1444, DOI 10.1016/j.bpj.2017.02.023; Chen BH, 2013, CELL, V155, P1479, DOI 10.1016/j.cell.2013.12.001; Chen BC, 2014, SCIENCE, V346, P439, DOI 10.1126/science.1257998; Chen KH, 2015, SCIENCE, V348, DOI 10.1126/science.aaa6090; Cools-Lartigue J, 2013, J CLIN INVEST, V123, P3446, DOI 10.1172/JCI67484; Fan ZC, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12658; Finn EH, 2019, CELL, V176, P1502, DOI 10.1016/j.cell.2019.01.020; Fowler T, 2015, EPIGENET CHROMATIN, V8, DOI 10.1186/s13072-015-0012-x; Freeman SA, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7168; Fritzsche M, 2017, SCI ADV, V3, DOI 10.1126/sciadv.1603032; Fuxa M, 2004, GENE DEV, V18, P411, DOI 10.1101/gad.291504; Gatto F, 2017, NANOMATERIALS-BASEL, V7, DOI 10.3390/nano7100332; Gordon S., 1999, PHAGOCYTOSIS HOST; Gowrishankar K, 2012, CELL, V149, P1353, DOI 10.1016/j.cell.2012.05.008; Gu B, 2018, SCIENCE, V359, P1050, DOI 10.1126/science.aao3136; Gustafsson MGL, 2000, J MICROSC-OXFORD, V198, P82, DOI 10.1046/j.1365-2818.2000.00710.x; Gwalani LA, 2018, J IMMUNOL, V200, P3231, DOI 10.4049/jimmunol.1701500; Hammer JA, 2019, ANNU REV IMMUNOL, V37, P201, DOI 10.1146/annurev-immunol-042718-041341; Harney AS, 2015, CANCER DISCOV, V5, P932, DOI 10.1158/2159-8290.CD-15-0012; Hawkins ED, 2017, IMMUNOL CELL BIOL, V95, P499, DOI 10.1038/icb.2017.34; Hawkins ED, 2016, NATURE, V538, P518, DOI 10.1038/nature19801; Headley MB, 2016, NATURE, V531, P513, DOI 10.1038/nature16985; Hsu HT, 2016, J CELL BIOL, V215, P875, DOI 10.1083/jcb.201604136; Hu YS, 2016, P NATL ACAD SCI USA, V113, P7201, DOI 10.1073/pnas.1512331113; Jain S, 2018, CELL, V174, P102, DOI 10.1016/j.cell.2018.04.035; Jang JH, 2015, J IMMUNOL, V195, P1320, DOI 10.4049/jimmunol.1403143; Johanson TM, 2019, NAT REV IMMUNOL, V19, P448, DOI 10.1038/s41577-019-0155-2; Kieffer-Kwon KR, 2017, MOL CELL, V67, P566, DOI 10.1016/j.molcel.2017.07.013; Klasener K, 2014, ELIFE, V3, DOI 10.7554/eLife.02069; Klar TA, 2000, P NATL ACAD SCI USA, V97, P8206, DOI 10.1073/pnas.97.15.8206; Kosak ST, 2002, SCIENCE, V296, P158, DOI 10.1126/science.1068768; Kruger CL, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aan1308; Kusumi A, 2005, SEMIN IMMUNOL, V17, P3, DOI 10.1016/j.smim.2004.09.004; LAKOWICZ JR, 1992, ANAL BIOCHEM, V202, P316, DOI 10.1016/0003-2697(92)90112-K; LANGERSAFER PR, 1982, P NATL ACAD SCI-BIOL, V79, P4381, DOI 10.1073/pnas.79.14.4381; Lee J, 2017, MOL BIOL CELL, V28, P511, DOI 10.1091/mbc.E16-06-0452; Li H, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01175; Li JR, 2019, CELL, V178, P491, DOI 10.1016/j.cell.2019.05.029; Lieutaud J., 1749, ELEMENTA PHYSIOL; Lillemeier BF, 2006, P NATL ACAD SCI USA, V103, P18992, DOI 10.1073/pnas.0609009103; Liu TL, 2018, SCIENCE, V360, DOI 10.1126/science.aaq1392; Lohela M, 2014, P NATL ACAD SCI USA, V111, pE5086, DOI 10.1073/pnas.1419899111; Lopes FB, 2017, J CELL BIOL, V216, P1123, DOI 10.1083/jcb.201608094; Lucas JS, 2014, CELL, V158, P339, DOI 10.1016/j.cell.2014.05.036; Lukes T, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01857-x; Ma YQ, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15100; Maity PC, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.2005887; Mateo LJ, 2019, NATURE, V568, P49, DOI 10.1038/s41586-019-1035-4; Mattila PK, 2013, IMMUNITY, V38, P461, DOI 10.1016/j.immuni.2012.11.019; Mempel TR, 2006, IMMUNITY, V25, P129, DOI 10.1016/j.immuni.2006.04.015; Miller H, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01073; Ming M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135994; Mingozzi F, 2016, EMBO MOL MED, V8, P1039, DOI 10.15252/emmm.201506164; Moalli F, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00114; Morrish RB, 2019, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00141; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Mrass P, 2006, J EXP MED, V203, P2749, DOI 10.1084/jem.20060710; Neumann J, 2019, NANOSCALE, V11, P9769, DOI 10.1039/c9nr00943d; Nir G, 2018, PLOS GENET, V14, DOI 10.1371/journal.pgen.1007872; Nutt SL, 2011, SEMIN IMMUNOL, V23, P341, DOI 10.1016/j.smim.2011.08.010; Pierce SK, 2010, NAT REV IMMUNOL, V10, P767, DOI 10.1038/nri2853; POGO BGT, 1966, P NATL ACAD SCI USA, V55, P805, DOI 10.1073/pnas.55.4.805; Proudhon C, 2015, ADV IMMUNOL, V128, P123, DOI 10.1016/bs.ai.2015.07.003; Rak GD, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001151; Ritter AT, 2017, P NATL ACAD SCI USA, V114, pE6585, DOI 10.1073/pnas.1710751114; Ritter AT, 2015, IMMUNITY, V42, P864, DOI 10.1016/j.immuni.2015.04.013; Roberts EW, 2016, CANCER CELL, V30, P324, DOI 10.1016/j.ccell.2016.06.003; Roh KH, 2015, P NATL ACAD SCI USA, V112, pE1604, DOI 10.1073/pnas.1503532112; Roldan E, 2005, NAT IMMUNOL, V6, P31, DOI 10.1038/ni1150; Rossy J, 2013, NAT IMMUNOL, V14, P82, DOI 10.1038/ni.2488; Rothenberg EV, 2014, TRENDS IMMUNOL, V35, P195, DOI 10.1016/j.it.2014.03.001; Rust MJ, 2006, NAT METHODS, V3, P793, DOI 10.1038/nmeth929; Sayegh C, 2005, GENE DEV, V19, P322, DOI 10.1101/gad.1254305; Schietinger A, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.26677; Senac JB, 1749, D TRAITE STRUCTURE C; Shelby SA, 2013, BIOPHYS J, V105, P2343, DOI 10.1016/j.bpj.2013.09.049; Sherman E, 2011, IMMUNITY, V35, P705, DOI 10.1016/j.immuni.2011.10.004; Skok JA, 2007, NAT IMMUNOL, V8, P378, DOI 10.1038/ni1448; Specht EA, 2017, ANNU REV PHYSIOL, V79, P93, DOI 10.1146/annurev-physiol-022516-034055; Spicer JD, 2012, CANCER RES, V72, P3919, DOI 10.1158/0008-5472.CAN-11-2393; Stadhouders R, 2019, NATURE, V569, P345, DOI 10.1038/s41586-019-1182-7; Stone MB, 2017, CHEM REV, V117, P7457, DOI 10.1021/acs.chemrev.6b00716; Stone MB, 2017, ELIFE, V6, DOI 10.7554/eLife.19891; Torcellan T, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00309; Treanor B, 2010, IMMUNITY, V32, P187, DOI 10.1016/j.immuni.2009.12.005; van Zanten TS, 2010, BBA-BIOMEMBRANES, V1798, P777, DOI 10.1016/j.bbamem.2009.09.012; Vicidomini G, 2018, NAT METHODS, V15, P173, DOI [10.1038/NMETH.4593, 10.1038/nmeth.4593]; Volkmann C, 2016, EMBO J, V35, P2371, DOI 10.15252/embj.201694177; Waller A., 1846, LONDON EDINBURGH PHI, V29, P397, DOI DOI 10.1080/14786444608645527; Wang SY, 2016, SCIENCE, V353, P598, DOI 10.1126/science.aaf8084; Weiss LE, 2018, BIOCHEM SOC T, V46, P729, DOI 10.1042/BST20170301; Xiao L, 2015, ANAL METHODS-UK, V7, P7290, DOI 10.1039/c5ay00500k; Zhang YM, 2016, SCI REP-UK, V6, DOI 10.1038/srep37988	109	0	0	9	16	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 15	2021	12								754200	10.3389/fimmu.2021.754200	http://dx.doi.org/10.3389/fimmu.2021.754200			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YB0YE	34975842	gold, Green Published			2022-12-18	WOS:000738747700001
J	Silva-Bermudez, LS; Sevastyanova, TN; Schmuttermaier, C; de la Torre, C; Schumacher, L; Kluter, H; Kzhyshkowska, J				Silva-Bermudez, Lina S.; Sevastyanova, Tatyana N.; Schmuttermaier, Christina; De La Torre, Carolina; Schumacher, Leonie; Klueter, Harald; Kzhyshkowska, Julia			Titanium Nanoparticles Enhance Production and Suppress Stabilin-1-Mediated Clearance of GDF-15 in Human Primary Macrophages	FRONTIERS IN IMMUNOLOGY			English	Article						titanium; nanoparticle; macrophage; endocytosis; scavenger receptor; growth factor	ALTERNATIVELY ACTIVATED MACROPHAGES; TGF-BETA; INHIBITORY CYTOKINE-1; IN-VITRO; RECEPTOR; DIFFERENTIATION; EXPRESSION; PROTECTS; GDF15; MICE	Macrophages are key innate immune cells that mediate implant acceptance or rejection. Titanium implants degrade over time inside the body, which results in the release of implant wear-off particles. Titanium nanoparticles (TiNPs) favor pro-inflammatory macrophage polarization (M1) and lower tolerogenic activation (M2). GDF-15 regulates immune tolerance and fibrosis and is endocytosed by stabilin-1. How TiNPs affect the healing activities of macrophages and their release of circulating cytokines is an open question in regenerative medicine. In this study for the first time, we identified the transcriptional program induced and suppressed by TiNPs in human pro-inflammatory and healing macrophages. Microarray analysis revealed that TiNPs altered the expression of 5098 genes in M1 (IFN-gamma-stimulated) and 4380 genes in M2 (IL-4-stimulated) macrophages. 1980 genes were differentially regulated in both M1 and M2. Affymetrix analysis, confirmed by RT-PCR, demonstrated that TiNPs upregulate expression of GDF-15 and suppress stabilin-1, scavenger receptor of GDF-15. TiNPs also significantly stimulated GDF-15 protein secretion in inflammatory and healing macrophages. Flow cytometry demonstrated, that scavenging activity of stabilin-1 was significantly suppressed by TiNPs. Confocal microscopy analysis showed that TiNPs impair internalization of stabilin-1 ligand acLDL and its transport to the endocytic pathway. Our data demonstrate that TiNPs have a dual effect on the GDF-15/stabilin-1 interaction in macrophage system, by increasing the production of GDF-15 and suppressing stabilin-1-mediated clearance function. In summary, this process can result in a significant increase of GDF-15 in the extracellular space and in circulation leading to unbalanced pro-fibrotic reactions and implant complications.	[Silva-Bermudez, Lina S.; Sevastyanova, Tatyana N.; Schmuttermaier, Christina; Schumacher, Leonie; Klueter, Harald; Kzhyshkowska, Julia] Heidelberg Univ, Inst Transfus Med & Immunol, Med Fac Mannheim, Mannheim, Germany; [Silva-Bermudez, Lina S.; Klueter, Harald; Kzhyshkowska, Julia] German Red Cross Blood Serv Baden Wurttemberg Hes, Mannheim, Germany; [De La Torre, Carolina] Heidelberg Univ, Med Fac Mannheim, Microarray Analyt NGS Core Facil IKC, Mannheim, Germany	Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg	Kzhyshkowska, J (corresponding author), Heidelberg Univ, Inst Transfus Med & Immunol, Med Fac Mannheim, Mannheim, Germany.; Kzhyshkowska, J (corresponding author), German Red Cross Blood Serv Baden Wurttemberg Hes, Mannheim, Germany.	Julia.Kzhyshkowska@medma.uni-heidelberg.de						Alinovi R, 2015, TOXICOL IN VITRO, V29, P426, DOI 10.1016/j.tiv.2014.12.007; Amengual-Penafiel L, 2021, JPN DENT SCI REV, V57, P12, DOI 10.1016/j.jdsr.2021.01.001; Bellora F, 2012, EUR J IMMUNOL, V42, P1618, DOI 10.1002/eji.201142173; Bootcov MR, 1997, P NATL ACAD SCI USA, V94, P11514, DOI 10.1073/pnas.94.21.11514; Chakravorty N, 2014, CLIN ORAL IMPLAN RES, V25, P475, DOI 10.1111/clr.12178; Cimino I, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2106868118; Conte M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00915; Curtin JP, 2017, J BIOL INORG CHEM, V22, P799, DOI 10.1007/s00775-017-1464-1; Dunkel J, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02257; Dux KE, 2019, CLIN PODIATR MED SUR, V36, P535, DOI 10.1016/j.cpm.2019.06.001; Eger M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02963; Elani HW, 2018, J DENT RES, V97, P1424, DOI 10.1177/0022034518792567; Emmerson PJ, 2017, NAT MED, V23, P1215, DOI 10.1038/nm.4393; Fort BP, 2021, J ORTHOP RES, V39, P493, DOI 10.1002/jor.24826; Govaere O, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aba4448; Hagstrom E, 2017, CLIN CHEM, V63, P325, DOI 10.1373/clinchem.2016.260570; Han SG, 2013, TOXICOLOGY, V306, P1, DOI 10.1016/j.tox.2013.01.014; He JH, 2020, MAT SCI ENG C-MATER, V108, DOI 10.1016/j.msec.2019.110411; Hinoi E, 2012, J BONE MINER RES, V27, P938, DOI 10.1002/jbmr.1538; Hong F, 2016, J BIOMED MATER RES A, V104, P1452, DOI 10.1002/jbm.a.35678; Hsu JY, 2017, NATURE, V550, P255, DOI 10.1038/nature24042; Hu QL, 2019, COMP BIOCHEM PHYS C, V223, P42, DOI 10.1016/j.cbpc.2019.05.006; Huang MG, 2021, CANCER COMMUN, V41, P389, DOI 10.1002/cac2.12137; Johnen H, 2012, CARDIOVASC PATHOL, V21, P499, DOI 10.1016/j.carpath.2012.02.003; Jonas K, 2020, ARCH ORTHOP TRAUM SU, V140, P1265, DOI 10.1007/s00402-020-03514-3; Jung SB, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03998-z; Kersting M, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-78550-5; Khan MR, 2012, BONE, V50, P1, DOI 10.1016/j.bone.2011.07.040; Kheder W, 2021, ARCH ORAL BIOL, V127, DOI 10.1016/j.archoralbio.2021.105133; Kim J, 2021, NAT METAB, V3, P410, DOI 10.1038/s42255-021-00368-w; Kim KH, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25098-0; Kulshrestha V, 2019, INDIAN J ORTHOP, V53, P282, DOI 10.4103/ortho.IJOrtho_127_17; Kzhyshkowska J, 2005, IMMUNOBIOLOGY, V210, P161, DOI 10.1016/j.imbio.2005.05.022; Kzhyshkowska J, 2004, J LEUKOCYTE BIOL, V76, P1151, DOI 10.1189/jlb.0504300; Kzhyshkowska J, 2006, BLOOD, V107, P3221, DOI 10.1182/blood-2005-07-2843; Kzhyshkowska J, 2008, J IMMUNOL, V180, P3028, DOI 10.4049/jimmunol.180.5.3028; Kzhyshkowska J, 2006, J CELL MOL MED, V10, P635, DOI 10.1111/j.1582-4934.2006.tb00425.x; Kzhyshkowska J, 2006, J IMMUNOL, V176, P5825, DOI 10.4049/jimmunol.176.10.5825; Kzhyshkowska J, 2015, J LEUKOCYTE BIOL, V98, P953, DOI 10.1189/jlb.5VMR0415-166R; Kzhyshkowska J, 2010, THESCIENTIFICWORLDJO, V10, P2039, DOI 10.1100/tsw.2010.189; Laurens C, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.131870; Lee J, 2021, J CELL PHYSIOL, V236, P4008, DOI 10.1002/jcp.30144; Liu TF, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1436922; Lockhart SM, 2020, ENDOCR REV, V41, DOI 10.1210/endrev/bnaa007; Luan HH, 2019, CELL, V178, P1231, DOI 10.1016/j.cell.2019.07.033; Matusiewicz H, 2014, ACTA BIOMATER, V10, P2379, DOI 10.1016/j.actbio.2014.02.027; Miller RJH, 2019, ANNU REV MED, V70, P33, DOI 10.1146/annurev-med-041217-011015; Mullican SE, 2017, NAT MED, V23, P1150, DOI 10.1038/nm.4392; Oliveira MN, 2018, J PERIODONTAL RES, V53, P1, DOI 10.1111/jre.12479; Orecchioni M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01084; Ost M, 2020, EMBO REP, V21, DOI 10.15252/embr.201948804; Pajarinen J, 2013, ACTA BIOMATER, V9, P9229, DOI 10.1016/j.actbio.2013.06.027; Park SY, 2009, J CELL SCI, V122, P3365, DOI 10.1242/jcs.049569; Politz O, 2002, BIOCHEM J, V362, P155, DOI 10.1042/0264-6021:3620155; Ratnam NM, 2017, J CLIN INVEST, V127, P3796, DOI 10.1172/JCI91561; Riley HJ, 2021, AM J PHYSIOL-HEART C, V320, pH604, DOI 10.1152/ajpheart.00552.2020; Santos I, 2020, P NATL ACAD SCI USA, V117, P12281, DOI [10.1073/pnas.1918508117/-/DCSupplemental, 10.1073/pnas.1918508117]; Schledzewski K, 2011, J CLIN INVEST, V121, P703, DOI 10.1172/JCI44740; Strelau J, 2000, ADV RES NEURODEGENER, V8, P273; Tarique AA, 2015, AM J RESP CELL MOL, V53, P676, DOI 10.1165/rcmb.2015-0012OC; Teng XY, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.662465; Vanhara P, 2009, DIFFERENTIATION, V78, P213, DOI 10.1016/j.diff.2009.07.008; Vanhegan IS, 2012, J BONE JOINT SURG BR, V94B, P619, DOI 10.1302/0301-620X.94B5.27073; Wakchoure S, 2009, PROSTATE, V69, P652, DOI 10.1002/pros.20913; Westhrin M, 2015, HAEMATOLOGICA, V100, pE511, DOI 10.3324/haematol.2015.124511; Wischhusen J, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00951; Yang M, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-81349-7; Yu KN, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131208; Yu QL, 2017, J HAZARD MATER, V335, P125, DOI 10.1016/j.jhazmat.2017.04.026; Zhang YX, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02407	70	0	0	2	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 15	2021	12								760577	10.3389/fimmu.2021.760577	http://dx.doi.org/10.3389/fimmu.2021.760577			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YA4CL	34975851	gold, Green Published			2022-12-18	WOS:000738283200001
J	Wu, CH; Gan, CH; Li, LH; Chang, JC; Chen, ST; Menon, MP; Cheng, SM; Yang, SP; Ho, CL; Chernikov, OV; Lin, CH; Lam, Y; Hua, KF				Wu, Chun-Hsien; Gan, Chin Heng; Li, Lan-Hui; Chang, Jen-Che; Chen, Shin-Tai; Menon, Mridula P.; Cheng, Shu-Meng; Yang, Shih-Ping; Ho, Chen-Lung; Chernikov, Oleg V.; Lin, Chi-Hung; Lam, Yulin; Hua, Kuo-Feng			A Synthetic Small Molecule F240B Decreases NLRP3 Inflammasome Activation by Autophagy Induction (vol 11, 607564, 2020)	FRONTIERS IN IMMUNOLOGY			English	Correction						NLRP3 inflammasome; conjugated polyenes; autophagy; mitochondria; peritonitis			[Wu, Chun-Hsien; Cheng, Shu-Meng; Yang, Shih-Ping] Triserv Gen Hosp, Div Cardiol, Dept Internal Med, Natl Def Med Ctr, Taipei, Taiwan; [Wu, Chun-Hsien; Lin, Chi-Hung] Natl Yang Ming Univ, Inst Microbiol & Immunol, Taipei, Taiwan; [Gan, Chin Heng; Lam, Yulin] Natl Univ Singapore, Dept Chem, Singapore, Singapore; [Li, Lan-Hui] Taipei City Hosp, Dept Lab Med, Linsen Chinese Med & Kunming Branch, Taipei, Taiwan; [Li, Lan-Hui; Hua, Kuo-Feng] Triserv Gen Hosp, Dept Pathol, Natl Def Med Ctr, Taipei, Taiwan; [Chang, Jen-Che; Chen, Shin-Tai; Menon, Mridula P.; Hua, Kuo-Feng] Natl Ilan Univ, Dept Biotechnol & Anim Sci, Ilan, Taiwan; [Ho, Chen-Lung] Taiwan Forestry Res Inst, Div Wood Cellulose, Taipei, Taiwan; [Chernikov, Oleg V.] GB Elyakov Pacific Inst Bioorgan Chem FEB RAS, Vladivostok, Russia; [Lin, Chi-Hung] Natl Chiao Tung Univ, Dept Biol Sci & Technol, Hsinchu, Taiwan; [Hua, Kuo-Feng] China Med Univ, China Med Univ Hosp, Dept Med Res, Taichung, Taiwan	National Defense Medical Center; Tri-Service General Hospital; National Yang Ming Chiao Tung University; National University of Singapore; Taipei City Hospital; National Defense Medical Center; Tri-Service General Hospital; National Ilan University; Elyakov Pacific Institute of Bioorganic Chemistry; National Yang Ming Chiao Tung University; China Medical University Taiwan; China Medical University Hospital - Taiwan	Lam, Y (corresponding author), Natl Univ Singapore, Dept Chem, Singapore, Singapore.; Hua, KF (corresponding author), Triserv Gen Hosp, Dept Pathol, Natl Def Med Ctr, Taipei, Taiwan.; Hua, KF (corresponding author), Natl Ilan Univ, Dept Biotechnol & Anim Sci, Ilan, Taiwan.; Hua, KF (corresponding author), China Med Univ, China Med Univ Hosp, Dept Med Res, Taichung, Taiwan.	chmlamyl@nus.edu.sg; kuofenghua@gmail.com	Chernikov, Oleg/B-9093-2014	Chernikov, Oleg/0000-0002-3076-3637				Wu CH, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.607564	1	0	0	0	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 15	2021	12								738591	10.3389/fimmu.2021.738591	http://dx.doi.org/10.3389/fimmu.2021.738591			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YB5DC	34975836	gold, Green Published			2022-12-18	WOS:000739031900001
J	Yang, F; Wu, SC; Ling, ZX; Chao, S; Zhang, LJ; Yan, XM; He, L; Yu, LM; Zhao, LY				Yang, Fan; Wu, Shao-chang; Ling, Zong-xin; Chao, Shan; Zhang, Li-juan; Yan, Xiu-mei; He, Lin; Yu, Li-mei; Zhao, Long-you			Altered Plasma Metabolic Profiles in Chinese Patients With Multiple Sclerosis	FRONTIERS IN IMMUNOLOGY			English	Article						multiple sclerosis; differentially abundant metabolite; cytokine; chemokine; peripheral immunoinflammatory response; disease course	REGULATORY T-CELLS; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; CEREBROSPINAL-FLUID; FATTY-ACIDS; AMINO-ACID; TH17 CELLS; SERUM; RISK; DIFFERENTIATION; BIOMARKERS	Multiple sclerosis (MS) is an autoimmune disease that leads to the demyelination of nerve axons. An increasing number of studies suggest that patients with MS exhibit altered metabolic profiles, which might contribute to the course of MS. However, the alteration of metabolic profiles in Chinese patients with MS and their potential roles in regulating the immune system remain elusive. In this study, we performed a global untargeted metabolomics approach in plasma samples from 22 MS-affected Chinese patients and 21 healthy subjects. A total of 42 differentially abundant metabolites (DAMs) belonging to amino acids, lipids, and carbohydrates were identified in the plasma of MS patients and compared with those in healthy controls. We observed an evident reduction in the levels of amino acids, such as L-tyrosine, L-isoleucine, and L-tryptophan, whereas there was a great increase in the levels of L-glutamic acid and L-valine in MS-affected patients. The levels of lipid and carbohydrate metabolites, such as sphingosine 1-phosphate and myo-inositol, were also reduced in patients with MS. In addition, the concentrations of proinflammatory cytokines, such as IL-17 and TNF-alpha, were significantly increased, whereas those of several anti-inflammatory cytokines and chemokines, such as IL-1ra, IL-7, and MIP-1 alpha, were distinctly reduced in the plasma of MS patients compared with those in healthy subjects. Interestingly, some DAMs, such as L-tryptophan and sphingosine 1-phosphate, showed an evident negative correlation with changes in the level of TNF-alpha and IL-17, while tightly positively correlating with altered concentrations of anti-inflammatory cytokines and chemokines, such as MIP-1 alpha and RANTES. Our results revealed that altered metabolomic profiles might contribute to the pathogenesis and course of MS disease by modulating immuno-inflammatory responses in the peripheral system, which is essential for eliciting autoimmune responses in the central nervous system, thus resulting in the progression of MS. This study provides potential clues for developing therapeutic strategies for MS in the near future.	[Yang, Fan; Yu, Li-mei] Zunyi Med Univ, Affiliated Hosp, Key Lab Cell Engn Guizhou Prov, Zunyi, Guizhou, Peoples R China; [Yang, Fan; He, Lin] Shanghai Jiao Tong Univ, Bio X Inst, Minist Educ, Key Lab Genet Dev & Neuropsychiat Disorders, Shanghai, Peoples R China; [Yang, Fan; Chao, Shan] Inst Shanghai Pudong Decoding Life, Res Ctr Lin He Acad New Med, Shanghai, Peoples R China; [Wu, Shao-chang; Zhang, Li-juan; Yan, Xiu-mei; Zhao, Long-you] Lishui Second Peoples Hosp, Dept Geriatr & Clin Lab, Lishui, Peoples R China; [Ling, Zong-xin] Zhejiang Univ, Collaborat Innovat Ctr Diag & Treatment Infect Di, Sch Med,State Key Lab Diag & Treatment Infect Dis, Natl Clin Res Ctr Infect Dis,Affiliated Hosp 1, Hangzhou, Peoples R China; [Ling, Zong-xin] Linyi Univ, Inst Microbe & Host Hlth, Linyi, Shandong, Peoples R China	Zunyi Medical University; Shanghai Jiao Tong University; Collaborative Innovation Center for Diagnosis & Treatment of Infectious Diseases; Zhejiang University; Linyi University	Yu, LM (corresponding author), Zunyi Med Univ, Affiliated Hosp, Key Lab Cell Engn Guizhou Prov, Zunyi, Guizhou, Peoples R China.; Zhao, LY (corresponding author), Lishui Second Peoples Hosp, Dept Geriatr & Clin Lab, Lishui, Peoples R China.	ylm720@sina.com; zly8897@126.com	Ling, Zongxin/M-1657-2018	Ling, Zongxin/0000-0001-9662-099X; YANG, FAN/0000-0002-1659-956X				Aranami Toshimasa, 2008, Allergol Int, V57, P115, DOI 10.2332/allergolint.R-07-159; Arpaia N, 2013, NATURE, V504, P451, DOI 10.1038/nature12726; Aryanpour R, 2021, NEUROSCIENCE, V463, P116, DOI 10.1016/j.neuroscience.2021.03.025; Ascherio A, 2014, JAMA NEUROL, V71, P306, DOI 10.1001/jamaneurol.2013.5993; Atarashi K, 2011, SCIENCE, V331, P337, DOI 10.1126/science.1198469; Beischlag TV, 2008, CRIT REV EUKAR GENE, V18, P207, DOI 10.1615/CritRevEukarGeneExpr.v18.i3.20; Berer K, 2011, NATURE, V479, P538, DOI 10.1038/nature10554; Bhargava P, 2019, ANN CLIN TRANSL NEUR, V6, P33, DOI 10.1002/acn3.676; Bhargava P, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.95302; Blaho VA, 2015, NATURE, V523, P342, DOI 10.1038/nature14462; Boghozian R, 2017, GLIA, V65, P1590, DOI 10.1002/glia.23179; Brown J, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01741; Bujak R, 2015, J PHARMACEUT BIOMED, V113, P108, DOI 10.1016/j.jpba.2014.12.017; Carlsson H, 2020, METABOLOMICS, V16, DOI 10.1007/s11306-020-1648-5; Caruso D, 2014, J NEUROCHEM, V130, P591, DOI 10.1111/jnc.12745; Chao CC, 2019, CELL, V179, P1483, DOI 10.1016/j.cell.2019.11.016; Chen X, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136612; Chen YH, 2017, ANAL CHEM, V89, P6954, DOI 10.1021/acs.analchem.6b04727; Cheng Q, 2007, NEUROLOGY, V68, P1495, DOI 10.1212/01.wnl.0000260695.72980.b7; Cheong WL, 2018, FRONT NEUROL, V9, DOI [10.3389/fneur2018.00432, 10.3389/fneur.2018.00432]; CHERAYIL GD, 1984, J NEUROL SCI, V63, P1, DOI 10.1016/0022-510X(84)90104-7; Christianson MS, 2015, MATURITAS, V80, P133, DOI 10.1016/j.maturitas.2014.11.013; Cicalini I, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061265; Cocco E, 2016, NEUROL-NEUROIMMUNOL, V3, DOI 10.1212/NXI.0000000000000185; CRAELIUS W, 1981, ACTA NEUROL SCAND, V63, P197; Cua DJ, 2003, NATURE, V421, P744, DOI 10.1038/nature01355; Dickens AM, 2014, NEUROLOGY, V83, P1492, DOI 10.1212/WNL.0000000000000905; Du CG, 2001, J IMMUNOL, V167, P7094, DOI 10.4049/jimmunol.167.12.7094; Du XR, 2018, NATURE, V558, P141, DOI 10.1038/s41586-018-0177-0; Dunn WB, 2011, NAT PROTOC, V6, P1060, DOI 10.1038/nprot.2011.335; Dunn WB, 2011, CHEM SOC REV, V40, P387, DOI 10.1039/b906712b; Duscha A, 2020, CELL, V180, P1067, DOI 10.1016/j.cell.2020.02.035; Eskandarieh S, 2016, NEUROEPIDEMIOLOGY, V46, P209, DOI 10.1159/000444019; Fallarino F, 2003, ADV EXP MED BIOL, V527, P183; Fitzgerald DC, 2007, J IMMUNOL, V179, P3268, DOI 10.4049/jimmunol.179.5.3268; Fitzgerald KC, 2021, CELL REP MED, V2, DOI 10.1016/j.xcrm.2021.100424; Gaetani L, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00157; Garris CS, 2013, NAT IMMUNOL, V14, P1166, DOI 10.1038/ni.2730; Gebregiworgis T, 2016, J PROTEOME RES, V15, P659, DOI 10.1021/acs.jproteome.5b01111; Geiger R, 2016, CELL, V167, P829, DOI 10.1016/j.cell.2016.09.031; Guo XL, 2011, INVEST OPHTH VIS SCI, V52, P2696, DOI 10.1167/iovs.10-6015; Hafler DA, 2007, NEW ENGL J MED, V357, P851, DOI 10.1056/NEJMoa073493; Haghikia A, 2015, IMMUNITY, V43, P817, DOI 10.1016/j.immuni.2015.09.007; Haghikia A, 2015, AMINO ACIDS, V47, P1837, DOI 10.1007/s00726-015-2015-0; Haghikia A, 2013, TRENDS MOL MED, V19, P309, DOI 10.1016/j.molmed.2013.03.004; Hannun YA, 2008, NAT REV MOL CELL BIO, V9, P139, DOI 10.1038/nrm2329; Hemmer B, 2015, LANCET NEUROL, V14, P406, DOI 10.1016/S1474-4422(14)70305-9; Herman S, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8020084; Hla T, 2012, CELL METAB, V16, P420, DOI 10.1016/j.cmet.2012.06.017; Hung CC, 2013, MOL MICROBIOL, V87, P1045, DOI 10.1111/mmi.12149; Jacob S, 2017, J NEUROIMMUNOL, V305, P5, DOI 10.1016/j.jneuroim.2017.01.008; Jin UH, 2014, MOL PHARMACOL, V85, P777, DOI 10.1124/mol.113.091165; Kalafatakis I, 2021, J NEUROSCI RES, V99, P1474, DOI 10.1002/jnr.24809; Kasakin MF, 2020, MULT SCLER INT, V2020, DOI 10.1155/2020/9010937; Kasakin MF, 2019, MEDCHEMCOMM, V10, P1803, DOI 10.1039/c9md00253g; Keller J, 2021, ANN CLIN TRANSL NEUR, V8, P1308, DOI 10.1002/acn3.51368; Kim HH, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181758; Kornberg MD, 2018, SCIENCE, V360, P449, DOI 10.1126/science.aan4665; Kwon HK, 2013, CLIN IMMUNOL, V146, P217, DOI 10.1016/j.clim.2013.01.001; Ling ZX, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.590783; Liu GW, 2010, NAT IMMUNOL, V11, P1047, DOI 10.1038/ni.1939; Liu X, 2016, ORPHANET J RARE DIS, V11, DOI 10.1186/s13023-016-0457-4; Lovelace MD, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00246; Lutz NW, 2011, CURR PHARM BIOTECHNO, V12, P1016; Lutz NW, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000595; LYNCH J, 1993, CAN J NEUROL SCI, V20, P194, DOI 10.1017/S0317167100047922; Maceyka M, 2014, NATURE, V510, P58, DOI 10.1038/nature13475; MacMillan EL, 2016, MULT SCLER J, V22, P112, DOI 10.1177/1352458515586086; Maffei M, 2008, NEURORADIOL J, V21, P228, DOI 10.1177/197140090802100212; Maglione A, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8101280; Makhani N, 2014, MULT SCLER RELAT DIS, V3, P48, DOI 10.1016/j.msard.2013.06.015; Mangalam Ak, 2013, J Clin Cell Immunol, V4, DOI 10.4172/2155-9899.1000150; Markianos M, 2009, J NEUROCHEM, V108, P158, DOI 10.1111/j.1471-4159.2008.05750.x; Marrie RA, 2004, LANCET NEUROL, V3, P709, DOI 10.1016/S1474-4422(04)00933-0; Mascanfroni ID, 2015, NAT MED, V21, P638, DOI 10.1038/nm.3868; Mayo L, 2014, NAT MED, V20, P1147, DOI 10.1038/nm.3681; Mehrpour M, 2013, MAGN RESON CHEM, V51, P102, DOI 10.1002/mrc.3915; Mellor AL, 2004, NAT REV IMMUNOL, V4, P762, DOI 10.1038/nri1457; Miller DH, 2007, LANCET NEUROL, V6, P903, DOI 10.1016/S1474-4422(07)70243-0; Mills EL, 2018, NATURE, V556, P113, DOI 10.1038/nature25986; Mondanelli G, 2020, P NATL ACAD SCI USA, V117, P3848, DOI 10.1073/pnas.1918215117; Negrotto L, 2017, J IMMUNOL, V198, P1900, DOI 10.4049/jimmunol.1601139; Nezhad RHB, 2018, IRAN J BASIC MED SCI, V21, P936, DOI 10.22038/IJBMS.2018.29438.7115; Noga MJ, 2012, METABOLOMICS, V8, P253, DOI 10.1007/s11306-011-0306-3; Nourbakhsh B, 2018, ANN CLIN TRANSL NEUR, V5, P1211, DOI 10.1002/acn3.637; Obert D, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162583; Olsson T, 2017, NAT REV NEUROL, V13, P25, DOI 10.1038/nrneurol.2016.187; Patsopoulos NA, 2019, SCIENCE, V365, P1417, DOI 10.1126/science.aav7188; Pieragostino D, 2015, MOL BIOSYST, V11, P1563, DOI 10.1039/c4mb00700j; Platten M, 2005, SCIENCE, V310, P850, DOI 10.1126/science.1117634; Poddighe S, 2017, INT J BIOCHEM CELL B, V93, P148, DOI 10.1016/j.biocel.2017.07.004; Polman CH, 2005, ANN NEUROL, V58, P840, DOI 10.1002/ana.20703; Probert F, 2021, BRAIN COMMUN, V3, DOI 10.1093/braincomms/fcab084; Proietti E, 2020, TRENDS IMMUNOL, V41, P1037, DOI 10.1016/j.it.2020.09.007; Quintana FJ, 2008, NATURE, V453, P65, DOI 10.1038/nature06880; Ragerdi Kashani Iraj, 2012, Acta Med Iran, V50, P789; Ramanujam R, 2015, JAMA NEUROL, V72, P1117, DOI 10.1001/jamaneurol.2015.1788; Rao GD, 2016, BIOL OPEN, V5, P829, DOI 10.1242/bio.017863; Reich DS, 2018, NEW ENGL J MED, V378, P169, DOI 10.1056/NEJMra1401483; Reinke SN, 2014, MULT SCLER J, V20, P1396, DOI 10.1177/1352458513516528; Rothhammer V, 2018, NATURE, V557, P724, DOI 10.1038/s41586-018-0119-x; Rothhammer V, 2016, NAT MED, V22, P586, DOI 10.1038/nm.4106; Sangster T, 2006, ANALYST, V131, P1075, DOI 10.1039/b604498k; Sawcer S, 2011, NATURE, V476, P214, DOI 10.1038/nature10251; Segal BA, 2003, CURR ALLERGY ASTHM R, V3, P86, DOI 10.1007/s11882-003-0017-6; Senanayake VK, 2015, BMC NEUROL, V15, DOI 10.1186/s12883-015-0411-4; Shevach EM, 1999, SPRINGER SEMIN IMMUN, V21, P249, DOI 10.1007/s002810050066; Sinclair AJ, 2010, NMR BIOMED, V23, P123, DOI 10.1002/nbm.1428; Singh J, 2019, J NEUROIMMUNE PHARM, V14, P241, DOI 10.1007/s11481-018-9815-4; Singh NP, 2016, J IMMUNOL, V196, P1108, DOI 10.4049/jimmunol.1501727; Smith PM, 2013, SCIENCE, V341, P569, DOI 10.1126/science.1241165; Smolinska A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038163; Spiegel S, 2011, NAT REV IMMUNOL, V11, P403, DOI 10.1038/nri2974; Sylvestre DA, 2020, BRAIN RES, V1732, DOI 10.1016/j.brainres.2019.146589; Tavazzi B, 2011, MULT SCLER INT, V2011, DOI 10.1155/2011/167156; Tortorella C, 2011, J NEUROL NEUROSUR PS, V82, P1355, DOI 10.1136/jnnp.2011.241836; Trepanier MO, 2018, J NEUROCHEM, V145, P504, DOI 10.1111/jnc.14335; Ulland TK, 2017, CELL, V170, P649, DOI 10.1016/j.cell.2017.07.023; Veldhoen M, 2008, NATURE, V453, P106, DOI 10.1038/nature06881; Villoslada Pablo, 2017, Neurol Neuroimmunol Neuroinflamm, V4, pe321, DOI 10.1212/NXI.0000000000000321; Walton C, 2020, MULT SCLER J, V26, P1816, DOI 10.1177/1352458520970841; Yan YP, 2010, J IMMUNOL, V185, P5953, DOI 10.4049/jimmunol.1001628; Yang Q, 2016, CELL DEATH DIFFER, V23, P1850, DOI 10.1038/cdd.2016.71; Yilmaz C, 2019, FRONT NEUROENDOCRIN, V55, DOI 10.1016/j.yfrne.2019.100788; Yong H, 2018, J NEUROSCI RES, V96, P927, DOI 10.1002/jnr.24090; YOUNG GB, 1986, J NEUROL NEUROSUR PS, V49, P265, DOI 10.1136/jnnp.49.3.265; Zelena E, 2009, ANAL CHEM, V81, P1357, DOI 10.1021/ac8019366	127	0	0	5	12	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 15	2021	12								792711	10.3389/fimmu.2021.792711	http://dx.doi.org/10.3389/fimmu.2021.792711			18	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YA6SZ	34975894	gold, Green Published			2022-12-18	WOS:000738461800001
J	Liu, AN; Wei, Q; Lin, HJ; Ding, YY; Sun, YV; Zhao, D; He, JY; Ma, ZH; Li, FH; Zhou, SJ; Chen, XX; Shen, WW; Gao, MY; He, N				Liu, Anni; Wei, Qian; Lin, Haijiang; Ding, Yingying; Sun, Yan V.; Zhao, Dan; He, Jiayu; Ma, Zhonghui; Li, Feihu; Zhou, Sujuan; Chen, Xiaoxiao; Shen, Weiwei; Gao, Meiyang; He, Na			Baseline Characteristics of Mitochondrial DNA and Mutations Associated With Short-Term Posttreatment CD4+T-Cell Recovery in Chinese People With HIV	FRONTIERS IN IMMUNOLOGY			English	Article						mitochondrial DNA; HIV; PLWH; CD4+T cell; ART	SEQUENTIAL 3-DRUG REGIMENS; ANTIRETROVIRAL THERAPY; INFECTED PATIENTS; COLLABORATIVE ANALYSIS; IMMUNE ACTIVATION; OXIDATIVE STRESS; INITIAL THERAPY; CELL; APOPTOSIS; DISEASE	BackgroundMitochondrial DNA (mtDNA) profiles and contributions of mtDNA variants to CD4+T-cell recovery in Euramerican people living with HIV (PLWH) may not be transferred to East-Asian PLWH, highlighting the need to consider more regional studies. We aimed to identify mtDNA characteristics and mutations that explain the variability of short-term CD4+T-cell recovery in East-Asian PLWH. MethodEight hundred fifty-six newly reported antiretroviral therapy (ART)-naive Chinese PLWH from the Comparative HIV and Aging Research in Taizhou (CHART) cohort (Zhejiang Province, Eastern China) were enrolled. MtDNA was extracted from peripheral whole blood of those PLWH at HIV diagnosis, amplified, and sequenced using polymerase chain reaction and gene array. Characterization metrics such as mutational diversity and momentum were developed to delineate baseline mtDNA mutational patterns in ART-naive PLWH. The associations between mtDNA genome-wide single nucleotide variants and CD4+T-cell recovery after short-term (within ~48 weeks) ART in 724 PLWH were examined using bootstrapping median regressions. ResultsOf 856 participants, 74.18% and 25.82% were male and female, respectively. The median age was 37 years; 94.51% were of the major Han ethnicity, and 69.04% and 28.62% were of the heterosexual and homosexual transmission, respectively. We identified 2,352 types of mtDNA mutations and mtDNA regions D-loop, ND5, CYB, or RNR1 with highest mutational diversity or volume. Female PLWH rather than male PLWH at the baseline showed remarkable age-related uptrends of momentum and mutational diversity as well as correlations between CD4+T <200 (cells/mu l) and age-related uptrends of mutational diversity in many mtDNA regions. After adjustments of important sociodemographic and clinical variables, m.1005T>C, m.1824T>C, m.3394T>C, m.4491G>A, m.7828A>G, m.9814T>C, m.10586G>A, m.12338T>C, m.13708G>A, and m.14308T>C (at the Bonferroni-corrected significance) were negatively associated with short-term CD4+T-cell recovery whereas m.93A>G, m.15218A>G, and m.16399A>G were positively associated with short-term CD4+T-cell recovery. ConclusionOur baseline mtDNA characterization stresses the attention to East-Asian female PLWH at risk of CD4+T-cell loss-related aging and noncommunicable chronic diseases. Furthermore, mtDNA variants identified in regression analyses account for heterogeneity in short-term CD4+T-cell recovery of East-Asian PLWH. These results may help individualize the East-Asian immune recovery strategies under complicated HIV management caused by CD4+T-cell loss.	[Liu, Anni; Wei, Qian; Lin, Haijiang; Ding, Yingying; Zhao, Dan; He, Jiayu; Ma, Zhonghui; Zhou, Sujuan; Gao, Meiyang; He, Na] Fudan Univ, Sch Publ Hlth, Dept Epidmiol, Shanghai, Peoples R China; [Liu, Anni; Wei, Qian; Lin, Haijiang; Ding, Yingying; Zhao, Dan; He, Jiayu; Ma, Zhonghui; Zhou, Sujuan; Gao, Meiyang; He, Na] Fudan Univ, Key Lab Publ Hlth Safety, Minist Educ, Shanghai, Peoples R China; [Liu, Anni] Cornell Univ, Weill Cornell Grad Sch Med Sci, New York, NY USA; [Lin, Haijiang; Chen, Xiaoxiao; Shen, Weiwei] Taizhou City Ctr Dis Control & Prevent, Dept AIDS STD Control & Prevent, Taizhou, Peoples R China; [Sun, Yan V.] Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, Atlanta, GA USA; [Sun, Yan V.] Emory Univ, Sch Med, Dept Biomed Informat, Atlanta, GA USA; [Li, Feihu] Fudan Univ, Sch Math Sci, Shanghai, Peoples R China; [He, Na] Fudan Univ, Natl Commiss Hlth, Key Lab Hlth Technol Assessment, Shanghai, Peoples R China	Fudan University; Fudan University; Cornell University; Qatar Foundation (QF); Weill Cornell Medical College Qatar; Emory University; Rollins School Public Health; Emory University; Fudan University; Fudan University	He, N (corresponding author), Fudan Univ, Sch Publ Hlth, Dept Epidmiol, Shanghai, Peoples R China.; He, N (corresponding author), Fudan Univ, Key Lab Publ Hlth Safety, Minist Educ, Shanghai, Peoples R China.; He, N (corresponding author), Fudan Univ, Natl Commiss Hlth, Key Lab Hlth Technol Assessment, Shanghai, Peoples R China.	nhe@fudan.edu.cn	Chen, xiaoxiao/GRS-0925-2022		China National Science and Technology Major Projects on Infectious Diseases [2018ZX10721102-004]; National Natural Science Foundation of China [81773485, 81872671, 81803291]; Shanghai Municipal Health Commission [GWV-10.1-XK16, GWTD2015S05]	China National Science and Technology Major Projects on Infectious Diseases; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Municipal Health Commission	This work was supported by the China National Science and Technology Major Projects on Infectious Diseases (2018ZX10721102-004) and the National Natural Science Foundation of China (81773485, 81872671, 81803291) and partially supported by the Shanghai Municipal Health Commission (GWV-10.1-XK16; GWTD2015S05).	Ali SS, 2006, AGING CELL, V5, P565, DOI 10.1111/j.1474-9726.2006.00252.x; Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779; [Anonymous], Sequencher version 5.4.6 DNA sequence analysis software; Ashar FN, 2017, JAMA CARDIOL, V2, P1247, DOI 10.1001/jamacardio.2017.3683; Baker JV, 2008, JAIDS-J ACQ IMM DEF, V48, P541, DOI 10.1097/QAI.0b013e31817bebb3; Bensasson D, 2001, TRENDS ECOL EVOL, V16, P314, DOI 10.1016/S0169-5347(01)02151-6; Bonora E, 2006, CANCER RES, V66, P6087, DOI 10.1158/0008-5472.CAN-06-0171; CANN RL, 1987, NATURE, V325, P31, DOI 10.1038/325031a0; Cardoso SW, 2013, BRAZ J INFECT DIS, V17, P464, DOI 10.1016/j.bjid.2012.11.007; Chalkia D, 2018, BBA-BIOENERGETICS, V1859, P878, DOI 10.1016/j.bbabio.2018.07.002; Chinnery PF, 2005, LANCET, V366, P1650, DOI 10.1016/S0140-6736(05)67492-2; Chistiakov DA, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/238463; DeBalsi KL, 2017, AGEING RES REV, V33, P89, DOI 10.1016/j.arr.2016.04.006; Deeks SG, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.35; DENARO M, 1981, P NATL ACAD SCI-BIOL, V78, P5768, DOI 10.1073/pnas.78.9.5768; Desdin-Mico G, 2018, MITOCHONDRION, V41, P51, DOI 10.1016/j.mito.2017.10.006; DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567; Doitsh G, 2014, NATURE, V505, P509, DOI 10.1038/nature12940; El-Amine R, 2018, REDOX BIOL, V15, P97, DOI 10.1016/j.redox.2017.11.024; El-Sadr WM, 2006, NEW ENGL J MED, V355, P2283, DOI 10.1056/NEJMoa062360; Elson JL, 2001, AM J HUM GENET, V68, P802, DOI 10.1086/318801; Ferri KF, 2000, ANN NY ACAD SCI, V926, P149; Fidler S, 2013, NEW ENGL J MED, V368, P207, DOI 10.1056/NEJMoa1110039; Gill J, 2010, CLIN INFECT DIS, V50, P1387, DOI 10.1086/652283; Grabar S, 2000, ANN INTERN MED, V133, P401, DOI 10.7326/0003-4819-133-6-200009190-00007; Grady BJ, 2011, JAIDS-J ACQ IMM DEF, V58, P363, DOI 10.1097/QAI.0b013e31822c688b; Guzman-Fulgencio M, 2013, J ANTIMICROB CHEMOTH, V68, P2349, DOI 10.1093/jac/dkt206; Guzman-Fulgencio M, 2013, JAIDS-J ACQ IMM DEF, V63, P178, DOI 10.1097/QAI.0b013e3182893f74; Hahn A, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8090392; Hao L, 2007, QUANTILE REGRESSION; HARMAN D, 1983, AGE, V6, P86, DOI 10.1007/BF02432509; Hendrickson SL, 2008, AIDS, V22, P2429, DOI 10.1097/QAD.0b013e32831940bb; Hildeman DA, 1999, IMMUNITY, V10, P735, DOI 10.1016/S1074-7613(00)80072-2; Ishikawa K, 2008, SCIENCE, V320, P661, DOI 10.1126/science.1156906; Ivanov AV, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/8910396; Kimchi-Sarfaty C, 2007, SCIENCE, V315, P525, DOI 10.1126/science.1135308; Kong QP, 2003, AM J HUM GENET, V73, P671, DOI 10.1086/377718; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125; Kutner M.H., 2005, APPL LINEAR STAT MOD; Lagouge M, 2013, J INTERN MED, V273, P529, DOI 10.1111/joim.12055; Le T, 2013, NEW ENGL J MED, V368, P218, DOI 10.1056/NEJMoa1110187; Li M, 2017, HIV MED, V18, P45, DOI 10.1111/hiv.12390; Lin HJ, 2019, LANCET HIV, V6, pE860, DOI 10.1016/S2352-3018(19)30263-2; LINNANE AW, 1989, LANCET, V1, P642, DOI 10.1016/S0140-6736(89)92145-4; Liu CY, 2004, ANN NY ACAD SCI, V1011, P133, DOI 10.1196/annals.1293.014; Madeira F, 2019, NUCLEIC ACIDS RES, V47, pW636, DOI 10.1093/nar/gkz268; Malorni W, 2007, ANTIOXID REDOX SIGN, V9, P1779, DOI 10.1089/ars.2007.1596; Mandas A, 2009, J BIOMED BIOTECHNOL, DOI 10.1155/2009/749575; Mao YR, 2010, INT J EPIDEMIOL, V39, pII79, DOI 10.1093/ije/dyq213; Martin AM, 2003, AM J HUM GENET, V72, P549, DOI 10.1086/367849; Matarrese P, 2011, ANTIOXID REDOX SIGN, V15, P2825, DOI 10.1089/ars.2011.3942; McComsey G, 2005, JAIDS-J ACQ IMM DEF, V39, P181; McComsey G, 2002, AIDS, V16, P513, DOI 10.1097/00002030-200203080-00001; Mills EL, 2017, NAT IMMUNOL, V18, P488, DOI 10.1038/ni.3704; Moore DM, 2006, AIDS, V20, P371, DOI 10.1097/01.aids.0000196180.11293.9a; Nomenclature Committee of the International Union of Biochemistry, 1986, Proceedings of the National Academy of Sciences of the United States of America, V83, P4, DOI 10.1073/pnas.83.1.4; Okoye AA, 2013, IMMUNOL REV, V254, P54, DOI 10.1111/imr.12066; Ouyang YB, 2018, J ANTIMICROB CHEMOTH, V73, P3114, DOI 10.1093/jac/dky282; Palmer CD, 2014, AIDS, V28, P2162, DOI 10.1097/QAD.0000000000000386; Panneerselvam P, 2013, CELL DEATH DIFFER, V20, P478, DOI 10.1038/cdd.2012.144; Pasta D.J., 2009, SAS GLOB FOR 2009 IC; Pereira L, 2009, AM J HUM GENET, V84, P628, DOI 10.1016/j.ajhg.2009.04.013; Pommie C, 2004, J MOL RECOGNIT, V17, P17, DOI 10.1002/jmr.647; Rathmell JC, 2002, CELL, V109, pS97, DOI 10.1016/S0092-8674(02)00704-3; Robbins GK, 2003, NEW ENGL J MED, V349, P2293, DOI 10.1056/NEJMoa030264; Ross JM, 2013, NATURE, V501, P412, DOI 10.1038/nature12474; Shafer RW, 2003, NEW ENGL J MED, V349, P2304, DOI 10.1056/NEJMoa030265; Smit C, 2006, AIDS, V20, P741, DOI 10.1097/01.aids.0000216375.99560.a2; Smit M, 2020, CLIN INFECT DIS, V71, P1864, DOI 10.1093/cid/ciz1103; Smit M, 2015, LANCET INFECT DIS, V15, P810, DOI 10.1016/S1473-3099(15)00056-0; STONEKING M, 1991, AM J HUM GENET, V48, P370; Tang Dong-ling, 2005, Zhonghua Yixue Yichuanxue Zazhi, V22, P636; Trickey A, 2017, LANCET HIV, V4, pE349, DOI 10.1016/S2352-3018(17)30066-8; Trifunovic A, 2006, BBA-BIOENERGETICS, V1757, P611, DOI 10.1016/j.bbabio.2006.03.003; van Leth F, 2004, LANCET, V363, P1253, DOI 10.1016/S0140-6736(04)15997-7; van Oven M, 2009, HUM MUTAT, V30, pE386, DOI 10.1002/humu.20921; Walker MA, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/164309; WALLACE DC, 1995, AM J HUM GENET, V57, P201; Wallace DC., 2005, ENCY GENETICS GENOMI, DOI [10.1002/047001153X.g105317, DOI 10.1002/047001153X.G105317]; Wallace DC., 2013, MITOCHONDRIAL MED EM, P1; Wallace DC, 2018, NAT GENET, V50, P1642, DOI 10.1038/s41588-018-0264-z; Wang HW, 2008, MUTAT RES-FUND MOL M, V643, P48, DOI 10.1016/j.mrfmmm.2008.06.004; Wang Sui-jun, 2009, Zhonghua Yixue Yichuanxue Zazhi, V26, P6, DOI 10.3760/cma.j.issn.1003-9406.2009.01.002; Weinberg SE, 2015, IMMUNITY, V42, P406, DOI 10.1016/j.immuni.2015.02.002; Weissensteiner H, 2016, NUCLEIC ACIDS RES, V44, pW58, DOI 10.1093/nar/gkw233; WHO, HIV AIDS 2020; World Health Organization, CONS GUID US ANT DRU; Xie HBM, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-402; Yao YG, 2002, AM J HUM GENET, V70, P635, DOI 10.1086/338999; Zhang AM, 2016, MOL NEUROBIOL, V53, P3873, DOI 10.1007/s12035-015-9323-y; Zhang N, 2005, CELL RES, V15, P749, DOI 10.1038/sj.cr.7290345; Ziada AS, 2019, AGING CELL, V18, DOI 10.1111/acel.13018	93	0	0	4	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 14	2021	12								793375	10.3389/fimmu.2021.793375	http://dx.doi.org/10.3389/fimmu.2021.793375			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XY8XH	34970271	Green Published, gold			2022-12-18	WOS:000737247800001
J	Luo, JM; Zhang, JC; Lai, WX; Wang, SF; Zhou, LZ; Shi, YF; Ba, JH; Hu, JJ; Wang, YH; Li, LS; Wu, BQ				Luo, Jinmei; Zhang, Jingcong; Lai, Wenxing; Wang, Shaofang; Zhou, Laizhi; Shi, Yunfeng; Ba, Junhui; Hu, Jiajia; Wang, Yanhong; Li, Laisheng; Wu, Ben-Quan			Disseminated Human Parvovirus B19 Infection Induced Multiple Organ Dysfunction Syndrome in an Adult Patient With Alcoholic Hepatitis Complicated by Hemolytic Anemia: A Case Report and Literature Review	FRONTIERS IN IMMUNOLOGY			English	Review						human parvovirus B19; erythema infectiosum; acute aplastic crisis; hemophagocytic syndrome; multiple organ dysfunction syndrome; alcoholic hepatitis; hemolytic anemia	HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; DISEASE; MYOCARDITIS; MECHANISMS; DIAGNOSIS	BackgroundHuman parvovirus B19 (B19) can cause acute hepatitis and is attributed to the high mortality of alcoholic hepatitis (AH). B19 infection is generally self-healing in previously healthy people, but it can cause fatal effects in some high-risk groups and increase its virulence and infectivity. Disseminated B19 infection-induced multiple organ dysfunction syndrome (MODS) in patients with AH has not been reported yet. Here, we described B19 viremia in an adult patient with AH accompanied by hemolytic anemia (HA), leading to disseminated infection and secondary MODS, as well as self-limiting B19 infections in seven nurses caring for him. Meanwhile, we reviewed the literature on AH and B19 infection. Case PresentationA 43-year-old male patient with AH accompanied by HA was transferred to the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China, on March 31, 2021. After supportive treatment, his transaminase and bilirubin levels were reduced, but his anemia worsened. He received a red blood cell (RBC) infusion on April 9 for hemoglobin (Hb) lower than 6 g/dl. On April 13, he suddenly had a high fever. Under empirical anti-infection, his high fever dropped and maintained at a low fever level; however, his anemia worsened. On April 25, he was transferred to the medical intensive care unit (MICU) due to severe pneumonia, acute respiratory distress syndrome (ARDS), acute aplastic crisis (AAC), and hemophagocytic syndrome (HPS), which were subsequently confirmed to be related to B19 infection. After methylprednisolone, intravenous immunoglobulin (IVIG), empirical anti-infection, and supportive treatment, the lung infection improved, but hematopoietic and liver abnormalities aggravated, and systemic B19 infection occurred. Finally, the patient developed a refractory arrhythmia, heart failure, and shock and was referred to a local hospital by his family on May 8, 2021. Unfortunately, he died the next day. Fourteen days after he was transferred to MICU, seven nurses caring for him in his first two days in the MICU developed self-limiting erythema infectiosum (EI). ConclusionsB19 infection is self-limiting in healthy people, with low virulence and infectivity; however, in AH patients with HA, it can lead to fatal consequences and high contagion.	[Luo, Jinmei; Zhang, Jingcong; Wang, Shaofang; Zhou, Laizhi; Shi, Yunfeng; Ba, Junhui; Hu, Jiajia; Wang, Yanhong; Wu, Ben-Quan] Sun Yat Sen Univ, Affiliated Hosp 3, Med Intens Care Unit, Dept Internal Med, Guangzhou, Peoples R China; [Luo, Jinmei; Zhang, Jingcong; Wang, Shaofang; Zhou, Laizhi; Shi, Yunfeng; Ba, Junhui; Hu, Jiajia; Wang, Yanhong; Wu, Ben-Quan] Sun Yat Sen Univ, Affiliated Hosp 3, Div Resp Dis, Guangzhou, Peoples R China; [Lai, Wenxing] Sun Yat Sen Univ, Affiliated Hosp 3, Div Hematol, Guangzhou, Peoples R China; [Li, Laisheng] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Lab Med, Guangzhou, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University	Wu, BQ (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 3, Med Intens Care Unit, Dept Internal Med, Guangzhou, Peoples R China.; Wu, BQ (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 3, Div Resp Dis, Guangzhou, Peoples R China.	wubq@mail.sysu.edu.cn						Ardalan MR, 2008, AM J TRANSPLANT, V8, P1340, DOI 10.1111/j.1600-6143.2008.02244.x; Bianco C, 2021, J CLIN MED, V10, DOI 10.3390/jcm10030423; Bieri J, 2021, PLOS PATHOG, V17, DOI 10.1371/journal.ppat.1009434; Bihari Chhagan, 2013, Hepat Res Treat, V2013, P472027, DOI 10.1155/2013/472027; Bonsch C, 2010, J VIROL, V84, P11737, DOI 10.1128/JVI.01143-10; Bonsch C, 2008, J VIROL, V82, P11784, DOI 10.1128/JVI.01399-08; Bousvaros A, 1998, PEDIATR PULM, V26, P365, DOI 10.1002/(SICI)1099-0496(199811)26:5<365::AID-PPUL11>3.3.CO;2-W; BROWN KE, 1995, BLOOD REV, V9, P176, DOI 10.1016/0268-960X(95)90023-3; Garcia RDC, 2021, FUTURE MICROBIOL, V16, P37, DOI 10.2217/fmb-2020-0123; COSSART YE, 1975, LANCET, V1, P72; Espinoza JL, 2018, BLOOD ADV, V2, P390, DOI 10.1182/bloodadvances.2017013342; Ferraz C, 2005, PEDIATR INFECT DIS J, V24, P1009, DOI 10.1097/01.inf.0000183768.84890.ae; Ho JK, 2005, CAN J GASTROENTEROL, V19, P161, DOI 10.1155/2005/853947; Isa A, 2005, PLOS MED, V2, P1280, DOI 10.1371/journal.pmed.0020343; Kishore J, 2018, INDIAN J MED RES, V148, P373, DOI 10.4103/ijmr.IJMR_533_18; Koliou M, 2014, BMC PEDIATR, V14, DOI 10.1186/1471-2431-14-6; Lehmann HW, 2003, AUTOIMMUN REV, V2, P218, DOI 10.1016/S1568-9972(03)00014-4; Longo G, 1998, CLIN INFECT DIS, V26, P994, DOI 10.1086/517644; Lucey MR, 2009, NEW ENGL J MED, V360, P2758, DOI 10.1056/NEJMra0805786; Manaresi E, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11070659; Mayama M, 2014, OBSTET GYNECOL, V124, P438, DOI 10.1097/AOG.0000000000000385; Menon KVN, 2001, MAYO CLIN PROC, V76, P1021, DOI 10.4065/76.10.1021; OZAWA K, 1988, J BIOL CHEM, V263, P10922; PLUMMER FA, 1985, NEW ENGL J MED, V313, P74, DOI 10.1056/NEJM198507113130203; Qiu JM, 2017, CLIN MICROBIOL REV, V30, P43, DOI 10.1128/CMR.00040-16; Regaya F, 2007, BMC INFECT DIS, V7, DOI 10.1186/1471-2334-7-123; Sehulster Lynne, 2003, MMWR Recomm Rep, V52, P1; Shauer A, 2013, ISR MED ASSOC J, V15, P180; Siegel JD, 2007, AM J INFECT CONTROL, V35, pS65, DOI 10.1016/j.ajic.2007.10.007; Sim JY, 2019, J MICROBIOL IMMUNOL, V52, P534, DOI 10.1016/j.jmii.2019.05.009; Singal AK, 2014, CLIN GASTROENTEROL H, V12, P555, DOI 10.1016/j.cgh.2013.06.013; Sokal EM, 1998, LANCET, V352, P1739, DOI 10.1016/S0140-6736(98)06165-0; Tanaka Yuka, 2018, Rinsho Ketsueki, V59, P682, DOI 10.11406/rinketsu.59.682; Verdonschot J, 2016, EUR J HEART FAIL, V18, P1430, DOI 10.1002/ejhf.665; Wang Ying-Chao, 2015, Zhongguo Dang Dai Er Ke Za Zhi, V17, P26; WATANABE M, 1994, CLIN LAB HAEMATOL, V16, P179; Wu Dongbo, 2018, J Evid Based Med, V11, P95, DOI 10.1111/jebm.12293; Yilmaz S, 2006, PEDIATR BLOOD CANCER, V47, P861, DOI 10.1002/pbc.20807; Yoto Y, 1996, LANCET, V347, P868, DOI 10.1016/S0140-6736(96)91348-3; Young NS, 2004, NEW ENGL J MED, V350, P586, DOI 10.1056/NEJMra030840; Zou W, 2021, J VIROL, V95, DOI 10.1128/JVI.00466-21	41	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 14	2021	12								742990	10.3389/fimmu.2021.742990	http://dx.doi.org/10.3389/fimmu.2021.742990			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XY9AS	34970255	Green Published, gold			2022-12-18	WOS:000737256800001
J	Taguchi, M; Tanaka, C; Tsutsui, S; Nakamura, O				Taguchi, Mizuki; Tanaka, Chikaya; Tsutsui, Shigeyuki; Nakamura, Osamu			Galactose-Binding C-Type Lectin Promotes Cellular Aggregation of Coelomocytes in Sea Cucumber	FRONTIERS IN IMMUNOLOGY			English	Article						coelomocytes; cellular aggregation; lectin; cell migration; sea cucumber	URCHINS STRONGYLOCENTROTUS; CELOMIC ELEMENTS; CHEMOATTRACTANT; MIGRATION; PROTEIN; TISSUE	Echinoderms have a large coelomic cavity containing coelomocytes. When the coelomic fluid is removed from the cavity, the cells aggregate immediately. We found that a fraction or an extract of the intestine of the sea cucumber, Apostichopus japonicus, markedly accelerated cellular movement and aggregation on a glass slide, and this effect was clearly inhibited by galactose. We successfully purified the aggregation-promoting factor, a 16 kDa protein, from the intestine. TOF-MS analysis followed by de novo sequencing revealed that the protein is a C-type lectin. RNA-seq data and cDNA cloning demonstrated the factor to be a novel lectin, named AjGBCL, consisting of 158 aa residues in the mature form. Microscopic observation revealed that most of the aggregating cells moved toward aggregates and not to an intestinal fragment, suggesting that AjGBCL is not a chemoattractant but a cellular aggregation-inducing factor that may induce aggregates to release chemoattractant. We report, for the first time, an endogenous molecule that promotes coelomocyte aggregation in echinoderms.	[Taguchi, Mizuki; Tsutsui, Shigeyuki; Nakamura, Osamu] Kitasato Univ, Sch Marine Biosci, Sagamihara, Kanagawa, Japan; [Tanaka, Chikaya] Tokyo Med Univ, Dept Biol, Tokyo, Japan	Kitasato University; Tokyo Medical University	Nakamura, O (corresponding author), Kitasato Univ, Sch Marine Biosci, Sagamihara, Kanagawa, Japan.	naosamu@kitasato-u.ac.jp						Arizza V, 2007, COMP BIOCHEM PHYS A, V147, P389, DOI 10.1016/j.cbpa.2007.01.022; BOOLOOTIAN RA, 1959, J EXP ZOOL, V140, P207, DOI 10.1002/jez.1401400203; D'Andrea-Winslow L, 2012, INTEGR ZOOL, V7, P61, DOI [10.1111/j.1749-4877.2012.00276.x, 10.1111/j.1749-4877.2011.00279.x]; DeVries ME, 2006, J IMMUNOL, V176, P401, DOI 10.4049/jimmunol.176.1.401; DRAKE TA, 1989, AM J PATHOL, V134, P1087; Endean R., 1966, P301; Furukawa R, 2016, IMMUNOL CELL BIOL, V94, P315, DOI 10.1038/icb.2016.6; Geddes P., 1880, P R SOC B LOND BIO, V30, P252, DOI [10.1098/rspl.1879.0114, DOI 10.1098/RSPL.1879.0114]; Grabherr MG, 2011, NAT BIOTECHNOL, V29, P644, DOI 10.1038/nbt.1883; Hillier BJ, 2003, J CELL BIOL, V160, P597, DOI 10.1083/jcb.200210053; HOLLAND LZ, 1967, COMP BIOCHEM PHYSIOL, V21, P361, DOI 10.1016/0010-406X(67)90798-0; ISHIMODATAKAGI T, 1983, J BIOCHEM, V93, P801, DOI 10.1093/jb/93.3.801; JOHNSON PT, 1969, J INVERTEBR PATHOL, V13, P25, DOI 10.1016/0022-2011(69)90236-5; JOHNSON PT, 1969, J INVERTEBR PATHOL, V13, P42, DOI 10.1016/0022-2011(69)90237-7; Li Q, 2013, FISH SHELLFISH IMMUN, V35, P1654, DOI 10.1016/j.fsi.2013.07.020; Lu JK, 2017, FISH SHELLFISH IMMUN, V64, P185, DOI 10.1016/j.fsi.2017.03.013; Lv ZM, 2019, FISH SHELLFISH IMMUN, V87, P839, DOI 10.1016/j.fsi.2019.02.040; Majeske AJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061419; Matsumoto R, 1998, J BIOL CHEM, V273, P16976, DOI 10.1074/jbc.273.27.16976; Moreno AN, 2005, J HISTOCHEM CYTOCHEM, V53, P715, DOI 10.1369/jhc.4A6562.2005; Morgan M, 2009, BIOINFORMATICS, V25, P2607, DOI 10.1093/bioinformatics/btp450; Muta T, 1996, CURR OPIN IMMUNOL, V8, P41, DOI 10.1016/S0952-7915(96)80103-8; NICHOLS D, 1972, Palaeontology (Oxford), V15, P519; Pages H., 2017, BIOSTRINGS STRING OB; Poget SF, 1999, J MOL BIOL, V290, P867, DOI 10.1006/jmbi.1999.2910; R Core Team, 2018, R LANG ENV STAT COMP, P10, DOI [DOI 10.1038/SJ.HDY.6800737, 10.1108/eb003648]; Ramirez-Gomez F, 2010, ISJ-INVERT SURVIV J, V7, P211; Ramirez-Gomez F, 2008, IMMUNOGENETICS, V60, P57, DOI 10.1007/s00251-007-0258-y; Sano H, 2000, J IMMUNOL, V165, P2156, DOI 10.4049/jimmunol.165.4.2156; Taguchi M, 2016, FISH SHELLFISH IMMUN, V58, P203, DOI 10.1016/j.fsi.2016.06.060; Vitved L, 2000, IMMUNOGENETICS, V51, P955, DOI 10.1007/s002510000232	31	0	0	2	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 14	2021	12								783798	10.3389/fimmu.2021.783798	http://dx.doi.org/10.3389/fimmu.2021.783798			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YA9ZT	34970266	Green Published, gold			2022-12-18	WOS:000738683700001
J	Zhang, J; Sun, Y; Zheng, JT				Zhang, Jing; Sun, Ying; Zheng, Jingtong			The State of Art of Extracellular Traps in Protozoan Infections (Review)	FRONTIERS IN IMMUNOLOGY			English	Review						extracellular traps; protozoan parasites; antimicrobial defense; NETs; METs	VIRUS-LIKE-PARTICLES; VIRAL PARTICLES; GIARDIA-LAMBLIA; CAPTURE; NETOSIS	Protozoan parasite infection causes severe diseases in humans and animals, leading to tremendous economic and medical pressure. Natural immunity is the first line of defence against parasitic infection. Currently, the role of natural host immunity in combatting parasitic infection is unclear, so further research on natural host immunity against parasites will provide a theoretical basis for the prevention and treatment of related parasitic diseases. Extracellular traps (ETs) are an important natural mechanism of immunity involving resistance to pathogens. When immune cells such as neutrophils and macrophages are stimulated by external pathogens, they release a fibrous network structure, consisting mainly of DNA and protein, that can capture and kill a variety of extracellular pathogenic microorganisms. In this review, we discuss the relevant recently reported data on ET formation induced by protozoan parasite infection, including the molecular mechanisms involved, and discuss the role of ETs in the occurrence and development of parasitic diseases.	[Zhang, Jing] First Hosp Jilin Univ, Intens Care Unit, Changchun, Peoples R China; [Zhang, Jing; Zheng, Jingtong] Jilin Univ, Coll Basic Med Sci, Dept Pathogenobiol, Changchun, Peoples R China; [Sun, Ying] First Hosp Jilin Univ, Dept Resp & Crit Care Med, Changchun, Peoples R China	Jilin University; Jilin University; Jilin University	Zheng, JT (corresponding author), Jilin Univ, Coll Basic Med Sci, Dept Pathogenobiol, Changchun, Peoples R China.	zhengjingtong@jlu.edu.cn			Bethune Research Plan of Jilin University [2020-31]; training plan for Lixin excellent young teachers of Jilin University [2021]	Bethune Research Plan of Jilin University; training plan for Lixin excellent young teachers of Jilin University	Funding This work was supported by the Bethune Research Plan of Jilin University (grant number: 2020-31), and the training plan for Lixin excellent young teachers of Jilin University (grant number: 2021) to JTZ.	Abdallah DSA, 2012, INFECT IMMUN, V80, P768, DOI 10.1128/IAI.05730-11; Abhyankar MM, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.683157; Adam RD, 2021, CLIN MICROBIOL REV, V34, DOI 10.1128/CMR.00024-19; Aitken EH, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03005; Al-Hindi AI, 2021, EXP PARASITOL, V226, DOI 10.1016/j.exppara.2021.108126; Arcanjo A, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-76781-0; Baker VS, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-41; Basso W, 2011, VET PARASITOL, V178, P223, DOI 10.1016/j.vetpar.2011.01.027; Benchimol M, 2002, TISSUE CELL, V34, P406, DOI 10.1016/S0040816602000757; Bharadwaj R, 2021, MOL MICROBIOL, V116, P974, DOI 10.1111/mmi.14787; BIRD RG, 1974, T ROY SOC TROP MED H, V68, P2, DOI 10.1016/0035-9203(74)90214-4; Boeltz S, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00874; Boura M, 2013, TRENDS PARASITOL, V29, P469, DOI 10.1016/j.pt.2013.07.005; Cai J, 2020, Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi, V32, P432, DOI 10.16250/j.32.1374.2019252; Calomeno NA, 2021, VET PARASITOL, V290, DOI 10.1016/j.vetpar.2021.109342; Caro TM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091415; Conejeros I, 2019, BIOLOGY-BASEL, V8, DOI 10.3390/biology8040078; Cong W, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-3307-2; de Oca ACM, 2016, PARASITE IMMUNOL, V38, P481, DOI 10.1111/pim.12337; Coordinating Office of the National Survey on the Important Human Parasitic Diseases, 2005, Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi, V23, P332; Corbett Y, 2021, MALARIA J, V20, DOI 10.1186/s12936-021-03589-2; Croft SL, 2006, CLIN MICROBIOL REV, V19, P111, DOI 10.1128/CMR.19.1.111-126.2006; Dassonville-Klimpt A, 2022, EUR J MED CHEM, V228, DOI 10.1016/j.ejmech.2021.113981; de Buhr N, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.00966; del Cacho E, 2001, INT J PARASITOL, V31, P1269, DOI 10.1016/S0020-7519(01)00241-7; Diaz-Godinez C, 2021, ANTIOXIDANTS-BASEL, V10, DOI 10.3390/antiox10060974; Diaz-Godinez C, 2018, FRONT CELL INFECT MI, V8, DOI 10.3389/fcimb.2018.00184; Djokic V, 2021, FRONT CELL INFECT MI, V11, DOI 10.3389/fcimb.2021.685239; Egwu CO, 2022, FREE RADICAL BIO MED, V179, P317, DOI 10.1016/j.freeradbiomed.2021.08.016; Eiset Andreas Halgreen, 2020, J Migr Health, V1-2, P100016, DOI 10.1016/j.jmh.2020.100016; Fehlberg HF, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0256199; Feintuch CM, 2016, MBIO, V7, DOI 10.1128/mBio.01300-15; Fereig RM, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9050384; Flaih MH, 2021, COMP IMMUNOL MICROB, V78, DOI 10.1016/j.cimid.2021.101696; Fonseca Z, 2019, J LEUKOCYTE BIOL, V105, P1167, DOI 10.1002/JLB.MA0818-309RRR; Gabriel C, 2010, J IMMUNOL, V185, P4319, DOI 10.4049/jimmunol.1000893; Gao CH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132493; Gao YH, 2021, ACTA BIOCH BIOPH SIN, V53, P1736, DOI 10.1093/abbs/gmab139; Gomes RS, 2022, CELL IMMUNOL, V371, DOI 10.1016/j.cellimm.2021.104449; Grob D, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.559561; Guerrero OM, 1997, REV BIOL TROP, V45, P131; Herman EK, 2021, BMC BIOL, V19, DOI 10.1186/s12915-021-01078-1; Iwabuchi Kazuhisa, 2018, Med Mycol J, V59, pJ51, DOI 10.3314/mmj.18.008; Jimenez M, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.685865; Joseph SJ, 2021, MSPHERE, V6, DOI 10.1128/mSphere.00637-21; Kho S, 2019, J INFECT DIS, V219, P1994, DOI 10.1093/infdis/jiy661; Knackstedt SL, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aaw0336; Kohler S, 1997, RES VIROLOGY, V148, P311, DOI 10.1016/S0923-2516(97)89127-3; Larrazabal C, 2022, PARASITOL RES, V121, P1169, DOI 10.1007/s00436-021-07260-2; Li F, 2019, PARASITOL RES, V118, P267, DOI 10.1007/s00436-018-6139-5; Li L, 2018, DEV COMP IMMUNOL, V88, P206, DOI 10.1016/j.dci.2018.07.024; Lima TS, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00103; Macedo IS, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8111628; Mao FZ, 2021, FRONT CELL INFECT MI, V11, DOI 10.3389/fcimb.2021.783654; Fernandez-Presas AM, 2017, REV INST MED TROP SP, V59, DOI [10.1590/S1678-9946201759046, 10.1590/s1678-9946201759046]; Carrasco-Yepez MM, 2019, PARASITE IMMUNOL, V41, DOI 10.1111/pim.12610; Meireles CB, 2017, ACTA TROP, V172, P240, DOI 10.1016/j.actatropica.2017.05.022; Mercer F, 2018, PLOS BIOL, V16, DOI 10.1371/journal.pbio.2003885; Mojoli A, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-75357-2; de Oca ACM, 2020, PARASITE IMMUNOL, V42, DOI 10.1111/pim.12714; Munoz-Caro T, 2014, PARASITOL RES, V113, P4189, DOI 10.1007/s00436-014-4094-3; Naqvi N, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12753-1; Chau NVV, 2016, CLIN INFECT DIS, V62, P1002, DOI 10.1093/cid/ciw052; Ogega OM, 2021, AAS OPEN RES, V3, P22, DOI [10.12688/aasopenres.13074.3, DOI 10.12688/AASOPENRES.13074.3]; Oliyier M, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00025; Pieterse E, 2016, SCI REP-UK, V6, DOI 10.1038/srep38229; Rodrigues DAS, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008230; Rosales C, 2021, J LEUKOCYTE BIOL, V110, P1241, DOI 10.1002/JLB.4MR0521-849RR; Rudd JM, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00108; Sherrard J, 2021, INT J STD AIDS, V32, P1274, DOI 10.1177/09564624211034767; Lautenschlager SDS, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9010093; Smith NL, 2013, FRONT MICROBIOL, V4, DOI 10.3389/fmicb.2013.00179; Sousa-Rocha D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139569; Staneva DP, 2021, GENOME RES, V31, P2138, DOI 10.1101/gr.275368.121; Uddin MJ, 2022, MUCOSAL IMMUNOL, V15, P165, DOI 10.1038/s41385-021-00442-2; Urban CF, 2006, CELL MICROBIOL, V8, P668, DOI 10.1111/j.1462-5822.2005.00659.x; Verdaguer IB, 2019, MOLECULES, V24, DOI 10.3390/molecules24203721; Villa L, 2021, PARASITE VECTOR, V14, DOI 10.1186/s13071-021-04626-4; Villagra-Blanco R, 2017, INT J PARASITOL-PAR, V6, P287, DOI 10.1016/j.ijppaw.2017.09.002; Villagra-Blanco R, 2017, DEV COMP IMMUNOL, V72, P119, DOI 10.1016/j.dci.2017.02.020; Villagra-Blanco R, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00606; Wardini AB, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-42687-9; Weber JI, 2021, BIOMED PHARMACOTHER, V139, DOI 10.1016/j.biopha.2021.111611; WEEKS R, 1992, J VIROL, V66, P1389, DOI 10.1128/JVI.66.3.1389-1393.1992; Wei FR, 2019, PARASITE VECTOR, V12, DOI 10.1186/s13071-019-3530-8; Wei R, 2021, VET PARASITOL, V296, DOI 10.1016/j.vetpar.2021.109502; Wei ZK, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.00429; Wei ZK, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00436; Yang ZT, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.02016	89	0	0	4	11	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 14	2021	12								770246	10.3389/fimmu.2021.770246	http://dx.doi.org/10.3389/fimmu.2021.770246			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XZ1KV	34970259	Green Published, gold			2022-12-18	WOS:000737420200001
J	Deng, XM; Guo, J; Sun, ZH; Liu, LZ; Zhao, TY; Li, J; Tang, GC; Zhang, H; Wang, WJ; Cao, SZ; Zhu, DX; Tao, TT; Cao, G; Baryshnikov, PI; Chen, CF; Zhao, ZS; Chen, LH; Zhang, H				Deng, Xingmei; Guo, Jia; Sun, Zhihua; Liu, Laizhen; Zhao, Tianyi; Li, Jia; Tang, Guochao; Zhang, Hai; Wang, Wenjing; Cao, Shuzhu; Zhu, Dexin; Tao, Tingting; Cao, Gang; Baryshnikov, P. I.; Chen, Chuangfu; Zhao, Zongsheng; Chen, Lihua; Zhang, Hui			B Pathway (vol 11, 581517, 2020)	FRONTIERS IN IMMUNOLOGY			English	Correction						LncRNA Gm28309; Brucella; inflammation; miR-3068-5p; NF-kappa B			[Deng, Xingmei; Guo, Jia; Sun, Zhihua; Zhao, Tianyi; Li, Jia; Zhu, Dexin; Tao, Tingting; Chen, Chuangfu; Zhao, Zongsheng; Zhang, Hui] Shihezi Univ, Coll Anim Sci & Technol, State Int Joint Res Ctr Anim Hlth Breeding, Shihezi, Peoples R China; [Liu, Laizhen] Xinjiang Agr Univ, Coll Vet Med, Urumqi, Peoples R China; [Tang, Guochao] Xinjiang Tianrun Dairy Biol Prod Co Ltd, Ctr Technol, Urumqi, Peoples R China; [Zhang, Hai; Wang, Wenjing; Cao, Shuzhu] Southern Med Univ, Dept Transfus Med, Guangzhou, Peoples R China; [Cao, Gang] Huazhong Agr Univ, State Key Lab Agr Microbiol, Wuhan, Peoples R China; [Baryshnikov, P. I.] Altai Natl Agr Univ, Coll Vet, Barnaul, Russia; [Chen, Lihua] Qingdao Univ Sci & Technol, Coll Chem & Mol Engn, Qingdao, Peoples R China	Shihezi University; Xinjiang Agricultural University; Southern Medical University - China; Huazhong Agricultural University; Qingdao University of Science & Technology	Zhang, H (corresponding author), Shihezi Univ, Coll Anim Sci & Technol, State Int Joint Res Ctr Anim Hlth Breeding, Shihezi, Peoples R China.; Chen, LH (corresponding author), Qingdao Univ Sci & Technol, Coll Chem & Mol Engn, Qingdao, Peoples R China.	30375476@qq.com; prof.zhang@foxmail.com						Deng XM, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.581517	1	0	0	2	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 13	2021	12								805275	10.3389/fimmu.2021.805275	http://dx.doi.org/10.3389/fimmu.2021.805275			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YB3JB	34966394	Green Published, gold			2022-12-18	WOS:000738911800001
J							Frontiers Prod Off	Sustained Post-Developmental T-Bet Expression Is Critical for the Maintenance of Type One Innate Lymphoid Cells In Vivo (vol 12, 760198, 2021)	FRONTIERS IN IMMUNOLOGY			English	Correction						T-bet; innate lymphoid cells; ILCs; intestinal inflammation; mucosal homeostasis 4			[Frontiers Prod Off] Frontiers Media SA, Lausanne, Switzerland		Frontiers Media SA, Lausanne, Switzerland.								0	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 10	2021	12								822468	10.3389/fimmu.2021.822468	http://dx.doi.org/10.3389/fimmu.2021.822468			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XX5VG	34956245	gold, Green Published			2022-12-18	WOS:000736362300001
J	Mitchell, J; Kannourakis, G				Mitchell, Jenee; Kannourakis, George			Does CD1a Expression Influence T Cell Function in Patients With Langerhans Cell Histiocytosis?	FRONTIERS IN IMMUNOLOGY			English	Article						CD1a-restricted T cells; CD1a; T cells; LCH cells; Langerhans cell histiocytosis (LCH)	ANTIGEN RECEPTOR RECOGNITION; DENDRITIC CELLS; MUTATIONS; SKIN; MAP2K1; LIPIDS; DIFFERENTIATION; MATURATION; MOLECULE; DISEASE	Langerhans cell histiocytosis lesions are characterized by CD1a+ myeloid lineage LCH cells and an inflammatory infiltrate of cytokines and immune cells, including T cells. T cells that recognize CD1a may be implicated in the pathology of many disease states including cancer and autoimmunity but have not been studied in the context of LCH despite the expression of CD1a by LCH cells. In this perspective article, we discuss the expression of CD1a by LCH cells, and we explore the potential for T cells that recognize CD1a to be involved in LCH pathogenesis.	[Mitchell, Jenee; Kannourakis, George] Fiona Elsey Canc Res Inst, Ballarat, Vic, Australia; [Kannourakis, George] Federat Univ Australia, Ballarat, Vic, Australia	Federation University Australia	Kannourakis, G (corresponding author), Fiona Elsey Canc Res Inst, Ballarat, Vic, Australia.; Kannourakis, G (corresponding author), Federat Univ Australia, Ballarat, Vic, Australia.	george@fecri.org.au						Agea E, 2005, J EXP MED, V202, P295, DOI 10.1084/jem.20050773; Al-amodi O, 2018, INFLAMM BOWEL DIS, V24, P1225, DOI 10.1093/ibd/izy073; Allen CE, 2010, J IMMUNOL, V184, P4557, DOI 10.4049/jimmunol.0902336; Alshenawy HA, 2011, CELL IMMUNOL, V269, P115, DOI 10.1016/j.cellimm.2011.03.015; Badalian-Very G, 2012, BRIT J HAEMATOL, V156, P163, DOI 10.1111/j.1365-2141.2011.08915.x; Baek H, 2020, TOXINS, V12, DOI 10.3390/toxins12030198; Berzins SP, 2011, NAT REV IMMUNOL, V11, P131, DOI 10.1038/nri2904; Birkinshaw RW, 2015, NAT IMMUNOL, V16, P258, DOI 10.1038/ni.3098; Bourgeois EA, 2015, J EXP MED, V212, P149, DOI 10.1084/jem.20141505; Brown NA, 2014, BLOOD, V124, P1655, DOI 10.1182/blood-2014-05-577361; Bubolz AM, 2014, ONCOTARGET, V5, P4060, DOI 10.18632/oncotarget.2061; Silva EAC, 2017, BLOOD, V130, P1898, DOI 10.1182/blood-2017-05-782730; Chakraborty R, 2014, BLOOD, V124, P3007, DOI 10.1182/blood-2014-05-577825; Cheng JMH, 2017, CHEM-EUR J, V23, P1694, DOI 10.1002/chem.201605287; Chikwava K, 2004, PEDIATR DEVEL PATHOL, V7, P607, DOI 10.1007/s10024-004-3027-z; Cortelazzo S, 2017, CRIT REV ONCOL HEMAT, V113, P304, DOI 10.1016/j.critrevonc.2017.03.020; Cotton RN, 2021, J EXP MED, V218, DOI 10.1084/jem.20202699; Cotton RN, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI140706; de Jong A, 2021, MOL IMMUNOL, V130, P14, DOI 10.1016/j.molimm.2020.12.006; de Jong A, 2014, NAT IMMUNOL, V15, P177, DOI 10.1038/ni.2790; de Jong A, 2010, NAT IMMUNOL, V11, P1102, DOI 10.1038/ni.1956; de Lalla C, 2011, EUR J IMMUNOL, V41, P602, DOI 10.1002/eji.201041211; DEPANFILIS G, 1988, CANCER, V61, P52, DOI 10.1002/1097-0142(19880101)61:1<52::AID-CNCR2820610110>3.0.CO;2-2; Egeler RM, 1999, BLOOD, V94, P4195; Geissmann F, 2001, BLOOD, V97, P1241, DOI 10.1182/blood.V97.5.1241; Gherardin NA, 2018, IMMUNOL CELL BIOL, V96, P507, DOI 10.1111/imcb.12021; Godfrey DI, 2018, IMMUNITY, V48, P453, DOI 10.1016/j.immuni.2018.03.009; Godfrey DI, 2015, NAT IMMUNOL, V16, P1114, DOI 10.1038/ni.3298; Hussein MR, 2008, J CUTAN PATHOL, V35, P554, DOI 10.1111/j.1600-0560.2007.00861.x; Hutter C, 2012, BLOOD, V120, P5199, DOI 10.1182/blood-2012-02-410241; Jarrett R, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad6833; Jayawardena-Wolf J, 2001, IMMUNITY, V15, P897, DOI 10.1016/S1074-7613(01)00240-0; Kannourakis G., 1994, BR J CANC S, V23, P37; Kasmar AG, 2013, J IMMUNOL, V191, P4499, DOI 10.4049/jimmunol.1301660; Kim JH, 2016, NAT IMMUNOL, V17, P1159, DOI 10.1038/ni.3523; Laupeze W, 2002, J IMMUNOL, V168, P2652, DOI 10.4049/jimmunol.168.6.2652; Lepore M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01365; Lepore M, 2015, ONCOIMMUNOLOGY, V4, DOI 10.4161/21624011.2014.970463; Lepore M, 2014, J EXP MED, V211, P1360, DOI 10.1084/jem.20140410; Leslie DS, 2008, IMMUNOLOGY, V125, P289, DOI 10.1111/j.1365-2567.2008.02842.x; Milne P, 2017, BLOOD, V130, P167, DOI 10.1182/blood-2016-12-757823; Milne P, 2015, BLOOD, V125, P470, DOI 10.1182/blood-2014-08-593582; Mitchell J, 2020, CLIN IMMUNOL, V215, DOI 10.1016/j.clim.2020.108418; Mitchell J, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34873-y; Mori L, 2016, ANNU REV IMMUNOL, V34, P479, DOI 10.1146/annurev-immunol-032414-112008; MURPHY GF, 1981, NEW ENGL J MED, V304, P791; Nelson DS, 2015, GENE CHROMOSOME CANC, V54, P361, DOI 10.1002/gcc.22247; Oji V, 2009, BRIT J DERMATOL, V160, P771, DOI 10.1111/j.1365-2133.2008.08999.x; Pellicci DG, 2020, NAT REV IMMUNOL, V20, P756, DOI 10.1038/s41577-020-0345-y; Poch R, 2021, BRIT J HAEMATOL, V194, P745, DOI 10.1111/bjh.17721; PORCELLI S, 1992, NATURE, V360, P593, DOI 10.1038/360593a0; Quispel WT, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1084463; Redd L, 2016, J HEMATOP, V9, P107, DOI 10.1007/s12308-016-0272-9; Rossjohn J, 2015, ANNU REV IMMUNOL, V33, P169, DOI 10.1146/annurev-immunol-032414-112334; Sahm F, 2012, BLOOD, V120, pE28, DOI 10.1182/blood-2012-06-429597; Sanchez-Martinez D, 2019, BLOOD, V133, P2291, DOI 10.1182/blood-2018-10-882944; Satoh T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033891; Schwentner R, 2019, J LEUKOCYTE BIOL, V105, P101, DOI 10.1002/JLB.1A0318-098R; Senechal B, 2007, PLOS MED, V4, P1374, DOI 10.1371/journal.pmed.0040253; Shamshiev A, 2002, J EXP MED, V195, P1013, DOI 10.1084/jem.20011963; Siddiqui S, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00337; Teyton L, 2018, J LIPID RES, V59, P1367, DOI 10.1194/jlr.R083212; Van Acker HH, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00892; Van Rhijn I, 2015, NAT REV IMMUNOL, V15, P643, DOI 10.1038/nri3889; Xiao YL, 2020, BLOOD, V136, P2188, DOI 10.1182/blood.2020005209; Yousem SA, 2013, CHEST, V143, P1679, DOI 10.1378/chest.12-1917; Yu RC, 1997, ARCH DERMATOL RES, V289, P352, DOI 10.1007/s004030050204; Zajonc DM, 2005, J EXP MED, V202, P1517, DOI 10.1084/jem.20051625; Zeng ZH, 1997, SCIENCE, V277, P339, DOI 10.1126/science.277.5324.339	69	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 10	2021	12								773598	10.3389/fimmu.2021.773598	http://dx.doi.org/10.3389/fimmu.2021.773598			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YI7MY	34956202	Green Published, gold			2022-12-18	WOS:000744030200001
J	Petitdemange, C; Funderburg, N; Zaunders, J; Corbeau, P				Petitdemange, Caroline; Funderburg, Nicholas; Zaunders, John; Corbeau, Pierre			Editorial: Infectious Agent-Induced Chronic Immune Activation: Causes, Phenotypes, and Consequences	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						inflammation; comorbidity; pathogen; immune cell; immune system	DOWN-REGULATION; T-CELLS; CYTOMEGALOVIRUS; EXPRESSION; TRANSCRIPTION; HOMOLOG; VIREMIA; GUT		[Petitdemange, Caroline] Inst Pasteur, HIV Inflammat & Persistence Unit, Paris, France; [Funderburg, Nicholas] Ohio State Univ, Sch Hlth & Rehabil Sci, Columbus, OH 43210 USA; [Zaunders, John] St Vincents Hosp, St Vincents Ctr Appl Med Res, Sydney, NSW, Australia; [Corbeau, Pierre] Univ Montpellier, CNRS, Inst Genet Humaine, CHU Nimes,UMR9002, Montpellier, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University System of Ohio; Ohio State University; St Vincents Hospital Sydney; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; CHU de Nimes	Corbeau, P (corresponding author), Univ Montpellier, CNRS, Inst Genet Humaine, CHU Nimes,UMR9002, Montpellier, France.	pierre.corbeau@igh.cnrs.fr	Zaunders, John/J-6553-2012	Zaunders, John/0000-0002-5912-5989; Funderburg, Nicholas/0000-0003-3113-1217	MSDAvenir [DS-2016-0010]	MSDAvenir	Funding PC was supported by MSDAvenir (DS-2016-0010).	Ahn KS, 1996, P NATL ACAD SCI USA, V93, P10990, DOI 10.1073/pnas.93.20.10990; Atalay R, 2002, J VIROL, V76, P8596, DOI 10.1128/JVI.76.17.8596-8608.2002; BARNES PD, 1992, J GEN VIROL, V73, P2395, DOI 10.1099/0022-1317-73-9-2395; Beignon AS, 2005, J CLIN INVEST, V115, P3265, DOI 10.1172/JCI26032; Bowman ER, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008869; Chevalier MF, 2013, BLOOD, V121, P29, DOI 10.1182/blood-2012-07-409755; Costiniuk CT, 2018, AIDS, V32, P2279, DOI [10.1097/QAD.0000000000001962, 10.1097/qad.0000000000001962]; Cribbs SK, 2015, AIDS RES HUM RETROV, V31, P64, DOI [10.1089/aid.2014.0133, 10.1089/AID.2014.0133]; Doitsh G, 2010, CELL, V143, P789, DOI 10.1016/j.cell.2010.11.001; El-Amine R, 2018, REDOX BIOL, V15, P97, DOI 10.1016/j.redox.2017.11.024; Frascaroli G, 2009, J IMMUNOL, V182, P477, DOI 10.4049/jimmunol.182.1.477; Hellmuth J, 2015, J VIRUS ERAD, V1, P67; Hunt PW, 2010, CURR OPIN HIV AIDS, V5, P189, DOI 10.1097/COH.0b013e32833647d9; Kotenko SV, 2000, P NATL ACAD SCI USA, V97, P1695, DOI 10.1073/pnas.97.4.1695; Maidji E, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006202; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; Palmer S, 2008, P NATL ACAD SCI USA, V105, P3879, DOI 10.1073/pnas.0800050105; Pasternak AO, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.134196; Planes R, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-35478-1; Reyburn HT, 1997, NATURE, V386, P514, DOI 10.1038/386514a0; Richman DD, 2003, P NATL ACAD SCI USA, V100, P4144, DOI 10.1073/pnas.0630530100; Scott C, 2008, INT J STD AIDS, V19, P493, DOI 10.1258/ijsa.2008.008026; Sencio V, 2020, CELL REP, V30, P2934, DOI 10.1016/j.celrep.2020.02.013; Sester U, 2008, AM J TRANSPLANT, V8, P1486, DOI 10.1111/j.1600-6143.2008.02279.x; Sette A, 2021, CELL, V184, P861, DOI 10.1016/j.cell.2021.01.007; Spiller OB, 1997, J INFECT DIS, V176, P339, DOI 10.1086/514050; Suzuki K, 2021, AIDS, V35, P2095, DOI 10.1097/QAD.0000000000003001; Varin A, 2005, J BIOL CHEM, V280, P42557, DOI 10.1074/jbc.M502211200; Yakovian O, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28114-5; Younas M, 2016, HIV MED, V17, P89, DOI 10.1111/hiv.12310; Zaunders J, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00495; Zhao W, 2019, CIRCULATION, V139, P2003, DOI 10.1161/CIRCULATIONAHA.118.037487	32	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 10	2021	12								740556	10.3389/fimmu.2021.740556	http://dx.doi.org/10.3389/fimmu.2021.740556			5	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YG8CF	34956176	Green Published, gold			2022-12-18	WOS:000742708600001
J	Dabee, S; Tanko, RF; Brown, BP; Bunjun, R; Balle, C; Feng, CL; Konstantinus, IN; Jaumdally, SZ; Onono, M; Nair, G; Palanee-Phillips, T; Gill, K; Baeten, JM; Bekker, LG; Passmore, JAS; Heffron, R; Jaspan, HB; Happel, AU				Dabee, Smritee; Tanko, Ramla F.; Brown, Bryan P.; Bunjun, Rubina; Balle, Christina; Feng, Colin; Konstantinus, Iyaloo N.; Jaumdally, Shameem Z.; Onono, Maricianah; Nair, Gonasagrie; Palanee-Phillips, Thesla; Gill, Katherine; Baeten, Jared M.; Bekker, Linda-Gail; Passmore, Jo-Ann S.; Heffron, Renee; Jaspan, Heather B.; Happel, Anna-Ursula			Comparison of Female Genital Tract Cytokine and Microbiota Signatures Induced by Initiation of Intramuscular DMPA and NET-EN Hormonal Contraceptives-a Prospective Cohort Analysis	FRONTIERS IN IMMUNOLOGY			English	Article						female genital tract; inflammation; microbiome; hormonal contraception; HIV risk; Sub-Saharan Africa	HIV ACQUISITION; INFLAMMATORY CYTOKINES; VAGINAL MICROBIOME; RISK; WOMEN; SUSCEPTIBILITY; ACTIVATION; BACTERIA	BackgroundCervicovaginal inflammation, bacterial microbiota and hormonal contraceptives all influence sexual and reproductive health. To date, the effects of intramuscular depo-medroxyprogesterone acetate (DMPA-IM) versus injectable norethisterone enanthate (NET-EN) on vaginal microbiota or cytokines have not been compared back-to-back, although in-vitro data suggest that DMPA-IM and NET-EN have different pharmacokinetic and biologic activities. This study aimed at comparing the effects of DMPA-IM versus NET-EN initiation on cervicovaginal cytokines and microbiota in women at high risk for sexually transmitted infections (STIs) assigned to the respective contraceptives. MethodsWe collected socio-demographic characteristics and vaginal samples from women initiating DMPA-IM (ECHO Trial; n = 53) and NET-EN (UChoose Trial; n = 44) at baseline and after two consecutive injections to assess cytokine concentrations by Luminex, vaginal microbiota by 16S rRNA gene sequencing, STIs, bacterial vaginosis (BV) and candidiasis. ResultsCytokine concentrations did not change significantly after initiating DMPA-IM or NET-EN, although NET-EN versus DMPA-IM-associated profiles were distinct. While the abundance of bacterial taxa associated with optimal and non-optimal microbiota fluctuated with DMPA-IM use, overall community composition did not significantly change with either contraceptive. HSV-2 serology, chlamydial infection, gonorrhoea and candidiasis did not influence the associations between contraceptive type and cervicovaginal cytokines or microbiota. ConclusionsBoth DMPA-IM and NET-EN use did not lead to broad inflammatory or microbiota changes in the female genital tract of sub-Saharan African women. This suggests that NET-EN is likely a viable option for contraception in African women at high risk of BV and STIs.	[Dabee, Smritee; Brown, Bryan P.; Feng, Colin; Jaspan, Heather B.] Seattle Childrens Res Inst, Ctr Global Infect Dis, Seattle, WA 98121 USA; [Tanko, Ramla F.; Bunjun, Rubina; Balle, Christina; Jaumdally, Shameem Z.; Passmore, Jo-Ann S.; Jaspan, Heather B.; Happel, Anna-Ursula] Univ Cape Town, Inst Infect Dis & Mol Med IDM, Cape Town, South Africa; [Tanko, Ramla F.; Passmore, Jo-Ann S.] Univ Cape Town, CAPRISA, Ctr Excellence HIV Prevent, Cape Town, South Africa; [Tanko, Ramla F.] Minist Sci Res & Innovat, Med Res Ctr, Inst Med Res & Med Plant Studies IMPM, Yaounde, Cameroon; [Konstantinus, Iyaloo N.] Namibia Inst Pathol, Windhoek, Namibia; [Onono, Maricianah] Kenya Govt Med Res Ctr, Kisumu, Kenya; [Nair, Gonasagrie; Gill, Katherine; Bekker, Linda-Gail] Desmond Tutu HIV Ctr, Cape Town, South Africa; [Palanee-Phillips, Thesla] Univ Witwatersrand, Wits Reprod Hlth & HIV Inst, Johannesburg, South Africa; [Baeten, Jared M.; Heffron, Renee; Jaspan, Heather B.] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA; [Baeten, Jared M.] Gilead Sci, Foster City, CA USA; [Passmore, Jo-Ann S.] Natl Hlth Lab Serv, Cape Town, South Africa	Seattle Children's Hospital; University of Cape Town; University of Cape Town; Kenya Medical Research Institute; University of Witwatersrand; University of Washington; University of Washington Seattle; Gilead Sciences	Jaspan, HB (corresponding author), Seattle Childrens Res Inst, Ctr Global Infect Dis, Seattle, WA 98121 USA.; Jaspan, HB (corresponding author), Univ Cape Town, Inst Infect Dis & Mol Med IDM, Cape Town, South Africa.; Jaspan, HB (corresponding author), Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA.	hbjaspan@gmail.com		Happel, Anna-Ursula/0000-0003-3658-8638	NIH [R01 HD083040]; Bill & Melinda Gates Foundation [OPP1032115]; United States Agency for International Development [AID-OAA-A-15-00045]; Swedish International Development Cooperation Agency [2017/762965-0]; United Nations Population Fund; US National Institute of Child Health and Human Development [R01 HD089831]; University of Washington [R01HD089831]; South Africa Medical Research Council	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Bill & Melinda Gates Foundation(Bill & Melinda Gates FoundationCGIAR); United States Agency for International Development(United States Agency for International Development (USAID)); Swedish International Development Cooperation Agency; United Nations Population Fund; US National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); University of Washington(University of Washington); South Africa Medical Research Council	This Uchoose Trial was funded by grant NIH R01 HD083040 (PIs Jaspan and Passmore). This work and the Evidence for Contraceptive Options and HIV Outcomes (ECHO) Study were made possible by the combined generous support of the Bill & Melinda Gates Foundation (Grant OPP1032115), the American people through the United States Agency for International Development (Grant AID-OAA-A-15-00045), the Swedish International Development Cooperation Agency (Grant 2017/762965-0), the South Africa Medical Research Council, and the United Nations Population Fund. Contraceptive supplies were donated by the Government of South Africa and US Agency for International Development. Funding to support this ancillary study of biological mechanisms was from the US National Institute of Child Health and Human Development R01 HD089831 (PIs: Heffron and Jaspan). The content is the sole responsibility of the authors and does not necessarily represent the official views of the study funders. Members of the R01HD089831 ECHO Biological Mechanisms Ancillary Study Team include the Coordinating Center (University of Washington): RH, HJ (principle investigators); JB, Caitlin Scoville, Kate Heller, Harald Haugen, Colin Pappajohn.	Ahmed S, 2019, LANCET GLOB HEALTH, V7, pE904, DOI 10.1016/S2214-109X(19)30200-1; Arnold KB, 2016, MUCOSAL IMMUNOL, V9, P194, DOI 10.1038/mi.2015.51; Baeten JM, 2019, LANCET, V394, P303, DOI 10.1016/S0140-6736(19)31288-7; Balle C, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19382-9; Brind J, 2015, ISSUES LAW MED, V30, P129; Callahan BJ, 2016, NAT METHODS, V13, P581, DOI [10.1038/nmeth.3869, 10.1038/NMETH.3869]; Columb MO, 2006, CURR ANAESTH CRIT CA, V17, P233, DOI DOI 10.1016/J.CACC.2006.03.005; Deese J, 2015, AM J REPROD IMMUNOL, V74, P357, DOI 10.1111/aji.12415; DiGiulio DB, 2015, P NATL ACAD SCI USA, V112, P11060, DOI 10.1073/pnas.1502875112; Fettweis JM, 2014, MICROBIOL-SGM, V160, P2272, DOI 10.1099/mic.0.081034-0; Fichorova RN, 2015, MBIO, V6, DOI 10.1128/mBio.00221-15; Fredricks DN, 2005, NEW ENGL J MED, V353, P1899, DOI 10.1056/NEJMoa043802; Gaujoux R, 2014, GENERATING HEATMAPS; Gill K, 2020, J INT AIDS SOC, V23, DOI 10.1002/jia2.25626; Gohl D., 2016, PROTOC EXCH, P1, DOI [10.1038/protex.2016.030, DOI 10.1038/PROTEX.2016.030]; Hall OJ, 2017, MUCOSAL IMMUNOL, V10, P1097, DOI 10.1038/mi.2017.35; Hankins CA, 2017, ANTIVIR THER, V22, P179, DOI 10.3851/IMP3165; Heffron R, 2019, CONTRACEPTION, V99, P199, DOI 10.1016/j.contraception.2018.12.001; Holtan SG, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/952571; Koning FA, 2005, J IMMUNOL, V175, P6117, DOI 10.4049/jimmunol.175.9.6117; Lennard K, 2018, INFECT IMMUN, V86, DOI 10.1128/IAI.00410-17; Lewis DA, 2012, SEX TRANSM DIS, V39, P880, DOI 10.1097/OLQ.0b013e318269cf90; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Maechler M., 2019, R PACKAGE VERSION; Mamik MK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092145; Marangoni A, 2021, FRONT MOL BIOSCI, V8, DOI 10.3389/fmolb.2021.656844; Masson L, 2015, CLIN INFECT DIS, V61, P260, DOI 10.1093/cid/civ298; McClelland RS, 2018, LANCET INFECT DIS, V18, P554, DOI 10.1016/S1473-3099(18)30058-6; McKinnon LR, 2018, NAT MED, V24, P491, DOI 10.1038/nm.4506; McMurdie PJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061217; Michel KG, 2015, JAIDS-J ACQ IMM DEF, V68, P511, DOI 10.1097/QAI.0000000000000531; Mwatelah R, 2019, J INT AIDS SOC, V22, DOI 10.1002/jia2.25346; Naicker N, 2015, AIDS BEHAV, V19, P1305, DOI 10.1007/s10461-015-1002-5; Ngcapu S, 2015, J REPROD IMMUNOL, V110, P14, DOI 10.1016/j.jri.2015.03.007; Oksanen J, 2008, VEGAN COMMUNITY ECOL; Omollo K, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.598307; Passmore JAS, 2016, CURR OPIN HIV AIDS, V11, P156, DOI 10.1097/COH.0000000000000232; Paulson JN, 2013, NAT METHODS, V10, P1200, DOI [10.1038/NMETH.2658, 10.1038/nmeth.2658]; Polis CB, 2016, AIDS, V30, P2665, DOI 10.1097/QAD.0000000000001228; Quast Christian, 2013, Nucleic Acids Res, V41, pD590, DOI 10.1093/nar/gks1219; Ravel J, 2013, MICROBIOME, V1, DOI 10.1186/2049-2618-1-29; Ravel J, 2011, P NATL ACAD SCI USA, V108, P4680, DOI 10.1073/pnas.1002611107; Singh A, 2019, BIOINFORMATICS, V35, P3055, DOI 10.1093/bioinformatics/bty1054; Torrone EA, 2018, PLOS MED, V15, DOI 10.1371/journal.pmed.1002511; Tsui AO, 2017, POPUL DEV REV, V43, P166, DOI 10.1111/padr.12051; Wang Q, 2007, APPL ENVIRON MICROB, V73, P5261, DOI 10.1128/AEM.00062-07; WHO, 2018, GLOB AIDS UPD; Zhou X, 2007, ISME J, V1, P121, DOI 10.1038/ismej.2007.12	48	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 9	2021	12								760504	10.3389/fimmu.2021.760504	http://dx.doi.org/10.3389/fimmu.2021.760504			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology	YA9OI	34956191	Green Published, gold			2022-12-18	WOS:000738653600001
J	de Azevedo, JTC; Costa, TCD; Lima, KC; Maciel, TT; Palma, PVB; Darrigo-Junior, LG; Grecco, CES; Stracieri, ABPL; Elias, JB; Pieroni, F; Guerino-Cunha, RL; Pinto, ACS; De Santis, GC; Covas, DT; Hermine, O; Simoes, BP; Oliveira, MC; Malmegrim, KCR				de Azevedo, Julia Teixeira Cottas; Costa, Thalita Cristina de Mello; Lima, Keli Cristina; Maciel, Thiago Trovati; Palma, Patricia Vianna Bonini; Darrigo-Junior, Luiz Guilherme; Setanni Grecco, Carlos Eduardo; Stracieri, Ana Beatriz P. L.; Elias, Juliana Bernardes; Pieroni, Fabiano; Guerino-Cunha, Renato Luiz; Pinto, Ana Cristina Silva; De Santis, Gil Cunha; Covas, Dimas Tadeu; Hermine, Olivier; Simoes, Belinda Pinto; Oliveira, Maria Carolina; Malmegrim, Kelen Cristina Ribeiro			Long-Term Effects of Allogeneic Hematopoietic Stem Cell Transplantation on Systemic Inflammation in Sickle Cell Disease Patients	FRONTIERS IN IMMUNOLOGY			English	Article						sickle cell disease; chronic inflammation; allogeneic hematopoietic stem cell transplantation; hematological reconstitution; adhesion molecules	BONE-MARROW-TRANSPLANTATION; VERSUS-HOST-DISEASE; PULMONARY-HYPERTENSION; ADHESION MOLECULE-1; POTENTIAL ROLE; GROWTH-FACTOR; P-SELECTIN; ACTIVATION; BLOOD; ENDOTHELIN-1	Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only currently available curative treatment for sickle cell disease (SCD). However, the effects of HSCT on SCD pathophysiology are poorly elucidated. Here, we assessed red blood cell (RBC) adhesiveness, intensity of hemolysis, vascular tone markers and systemic inflammation, in SCD patients treated with allogeneic HSCT. Thirty-two SCD patients were evaluated before and on long-term follow-up after HSCT. Overall survival was 94% with no severe (grade III-IV) graft-vs-host disease and a 22% rejection rate (graft failure). Hematological parameters, reticulocyte counts, and levels of lactate dehydrogenase (LDH), endothelin-1 and VCAM-1 normalized in SCD patients post-HSCT. Expression of adhesion molecules on reticulocytes and RBC was lower in patients with sustained engraftment. Levels of IL-18, IL-15 and LDH were higher in patients that developed graft failure. Increased levels of plasma pro-inflammatory cytokines, mainly TNF-alpha, were found in SCD patients long-term after transplantation. SCD patients with sustained engraftment after allo-HSCT showed decreased reticulocyte counts and adhesiveness, diminished hemolysis, and lower levels of vascular tonus markers. Nevertheless, systemic inflammation persists for at least five years after transplantation, indicating that allo-HSCT does not equally affect all aspects of SCD pathophysiology.	[de Azevedo, Julia Teixeira Cottas; Lima, Keli Cristina; Palma, Patricia Vianna Bonini; Guerino-Cunha, Renato Luiz; Pinto, Ana Cristina Silva; De Santis, Gil Cunha; Covas, Dimas Tadeu; Simoes, Belinda Pinto; Oliveira, Maria Carolina; Malmegrim, Kelen Cristina Ribeiro] Univ Sao Paulo, Reg Blood Ctr Ribeirao Preto, Ribeirao Preto Med Sch, Ctr Cell Based Therapy, Ribeirao Preto, Brazil; [de Azevedo, Julia Teixeira Cottas] Univ Sao Paulo, Ribeirao Preto Med Sch, Grad Program Basic & Appl Immunol, Ribeirao Preto, Brazil; [Costa, Thalita Cristina de Mello; Darrigo-Junior, Luiz Guilherme; Stracieri, Ana Beatriz P. L.; Elias, Juliana Bernardes; Pieroni, Fabiano] Univ Sao Paulo, Ribeirao Preto Med Sch, Univ Hosp, Bone Marrow Transplantat & Cellular Therapy Unit, Ribeirao Preto, Brazil; [Lima, Keli Cristina] Univ Sao Paulo, Sch Pharmaceut Sci Ribeirao Preto, Grad Program Biosci & Biotechnol, Ribeirao Preto, Brazil; [Maciel, Thiago Trovati; Hermine, Olivier] CNRS, Lab Cellular & Mol Mech Hematol Disorders & Thera, Equipe Rech Labellisee 8254, INSERM,Imagine Inst,Unite Mixte Rech UMR 1163, Paris, France; [Maciel, Thiago Trovati; Hermine, Olivier] Univ Paris 05, Sorbonne Paris Cite, Imagine Inst, Paris, France; [Maciel, Thiago Trovati; Hermine, Olivier] Hop Necker Enfants Malad, AP HP, Paris, France; [Darrigo-Junior, Luiz Guilherme; Setanni Grecco, Carlos Eduardo] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Pediat, Ribeirao Preto, Brazil; [Guerino-Cunha, Renato Luiz; Covas, Dimas Tadeu] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Med Imaging Hematol & Clin Oncol, Ribeirao Preto, Brazil; [Oliveira, Maria Carolina] Univ Sao Paulo, Ribeirao Preto Med Sch, Div Clin Immunol, Dept Internal Med, Ribeirao Preto, Brazil; [Malmegrim, Kelen Cristina Ribeiro] Univ Sao Paulo, Sch Pharmaceut Sci Ribeirao Preto, Dept Clin Anal Toxicol & Food Sci, Ribeirao Preto, Brazil	Universidade de Sao Paulo; Universidade de Sao Paulo; Universidade de Sao Paulo; Universidade de Sao Paulo; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Universidade de Sao Paulo; Universidade Federal de Sao Paulo (UNIFESP); Universidade de Sao Paulo; Universidade de Sao Paulo; Universidade de Sao Paulo	Malmegrim, KCR (corresponding author), Univ Sao Paulo, Reg Blood Ctr Ribeirao Preto, Ribeirao Preto Med Sch, Ctr Cell Based Therapy, Ribeirao Preto, Brazil.; Malmegrim, KCR (corresponding author), Univ Sao Paulo, Sch Pharmaceut Sci Ribeirao Preto, Dept Clin Anal Toxicol & Food Sci, Ribeirao Preto, Brazil.	kelenfarias@fcfrp.usp.br	Rodrigues, Maria Carolina Oliveira/A-2302-2012; Malmegrim, Kelen/H-1016-2015; Maciel, Thiago/A-4475-2013	Rodrigues, Maria Carolina Oliveira/0000-0003-0691-2222; Malmegrim, Kelen/0000-0002-9303-0086; Lima, Keli Cristina de/0000-0002-5498-7539; Maciel, Thiago/0000-0002-9347-981X				Ataga KI, 2010, EUR J HAEMATOL, V85, P257, DOI 10.1111/j.1600-0609.2010.01471.x; Bai BC, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-02985-x; Barbu EA, 2020, CYTOKINE, V127, DOI 10.1016/j.cyto.2019.154933; Belcher JD, 2014, BLOOD, V123, P377, DOI 10.1182/blood-2013-04-495887; Bernaudin F, 2007, BLOOD, V110, P2749, DOI 10.1182/blood-2007-03-079665; Blann AD, 2008, J THROMB THROMBOLYS, V25, P185, DOI 10.1007/s11239-007-0177-7; Brittain JE, 2004, J BIOL CHEM, V279, P42393, DOI 10.1074/jbc.M407631200; Brittain JE, 2001, J CLIN INVEST, V107, P1555, DOI 10.1172/JCI10817; Cerqueira BAV, 2011, CYTOKINE, V56, P471, DOI 10.1016/j.cyto.2011.08.013; Chirico EN, 2012, IUBMB LIFE, V64, P72, DOI 10.1002/iub.584; Conran N, 2004, AM J HEMATOL, V76, P343, DOI 10.1002/ajh.20129; Conran N, 2009, HEMOGLOBIN, V33, P1, DOI 10.1080/03630260802625709; Dworkis DA, 2011, AM J HEMATOL, V86, P220, DOI 10.1002/ajh.21928; Ghosh S, 2013, J CLIN INVEST, V123, P4809, DOI 10.1172/JCI64578; Gluckman E, 2017, BLOOD, V129, P1548, DOI 10.1182/blood-2016-10-745711; GLUCKSBERG H, 1974, TRANSPLANTATION, V18, P295, DOI 10.1097/00007890-197410000-00001; Graido-Gonzalez E, 1998, BLOOD, V92, P2551, DOI 10.1182/blood.V92.7.2551.2551_2551_2555; GREEN LC, 1981, P NATL ACAD SCI-BIOL, V78, P7764, DOI 10.1073/pnas.78.12.7764; Hayasaki Y, 1996, BIOCHEM BIOPH RES CO, V229, P817, DOI 10.1006/bbrc.1996.1886; HELSET E, 1993, MEDIAT INFLAMM, V2, P417, DOI 10.1155/S0962935193000596; Hildebrandt GC, 2020, BRIT J HAEMATOL, V190, P508, DOI 10.1111/bjh.16621; Hsieh MM, 2009, NEW ENGL J MED, V361, P2309, DOI 10.1056/NEJMoa0904971; HURIBAL M, 1994, SHOCK, V1, P184, DOI 10.1097/00024382-199403000-00005; ISHIDA K, 1990, BIOCHEM BIOPH RES CO, V173, P496, DOI 10.1016/S0006-291X(05)80061-0; Ishizuka T, 1999, EUR J PHARMACOL, V369, P237, DOI 10.1016/S0014-2999(99)00042-4; Jagasia MH, 2015, BIOL BLOOD MARROW TR, V21, P389, DOI 10.1016/j.bbmt.2014.12.001; Janciauskiene S, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01964; Kato GJ, 2006, BLOOD, V107, P2279, DOI 10.1182/blood-2005-06-2373; Kato GJ, 2005, BRIT J HAEMATOL, V130, P943, DOI 10.1111/j.1365-2141.2005.05701.x; Kato GJ, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/nrdp.2018.10; Kato GJ, 2017, J CLIN INVEST, V127, P750, DOI 10.1172/JCI89741; Khosla J, 2018, BONE MARROW TRANSPL, V53, P129, DOI 10.1038/bmt.2017.207; Kogel F, 2021, PEDIATR TRANSPLANT, V25, DOI 10.1111/petr.13892; Krishnamurti L, 2021, FRONT PEDIATR, V8, DOI 10.3389/fped.2020.551170; Kroemer A, 2008, J IMMUNOL, V180, P7818, DOI 10.4049/jimmunol.180.12.7818; Liu C, 2018, EUR CYTOKINE NETW, V29, P48, DOI 10.1684/ecn.2018.0410; Locatelli F, 2013, BLOOD, V122, P1072, DOI 10.1182/blood-2013-03-489112; Lucarelli G, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a011825; Manwani D, 2013, BLOOD, V122, P3892, DOI 10.1182/blood-2013-05-498311; Matsui NM, 2001, BLOOD, V98, P1955, DOI 10.1182/blood.V98.6.1955; McCavit TL, 2012, PEDIATR REV, V33, P195, DOI 10.1542/pir.33-5-195; Odievre MH, 2008, HAEMATOLOGICA, V93, P502, DOI 10.3324/haematol.12070; Odievre Marie-Helene, 2011, Indian J Med Res, V134, P532; Okamoto T, 2001, BONE MARROW TRANSPL, V28, P197, DOI 10.1038/sj.bmt.1703095; Oldenborg PA, 2001, J EXP MED, V193, P855, DOI 10.1084/jem.193.7.855; Oldenborg PA, 2000, SCIENCE, V288, P2051, DOI 10.1126/science.288.5473.2051; Paczesny S, 2009, BLOOD, V113, P273, DOI 10.1182/blood-2008-07-167098; Pagliuca S, 2019, BLOOD ADV, V3, P2424, DOI 10.1182/bloodadvances.2019000143; Panepinto JA, 2007, BRIT J HAEMATOL, V137, P479, DOI 10.1111/j.1365-2141.2007.06592.x; Passweg JR, 2019, BONE MARROW TRANSPL, V54, P1575, DOI 10.1038/s41409-019-0465-9; Piel FB, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001484; Piel FB, 2017, NEW ENGL J MED, V376, P1561, DOI 10.1056/NEJMra1510865; Pleasants S, 2014, NATURE, V515, pS2, DOI 10.1038/515S2a; Radujkovic A, 2020, CANCERS, V12, DOI 10.3390/cancers12102789; Radujkovic A, 2019, EBIOMEDICINE, V49, P202, DOI 10.1016/j.ebiom.2019.10.024; Rees DC, 2012, BRIT J HAEMATOL, V156, P433, DOI 10.1111/j.1365-2141.2011.08961.x; Sakamoto TM, 2013, CLIN BIOCHEM, V46, P1798, DOI 10.1016/j.clinbiochem.2013.09.011; Setty BNY, 1996, BLOOD, V88, P2311, DOI 10.1182/blood.V88.6.2311.bloodjournal8862311; Simoes BP, 2016, REV ASSOC MED BRAS, V62, P16, DOI [10.1590/1806-9282.62.Suppl1.16, 10.1590/1806-9282.62.suppl1.16]; Styles LA, 1997, BLOOD, V89, P2554, DOI 10.1182/blood.V89.7.2554; Telen MJ, 2016, BLOOD, V127, P810, DOI 10.1182/blood-2015-09-618553; UGOZZOLI L, 1991, BLOOD, V77, P1607; Vermylen C, 1998, BONE MARROW TRANSPL, V22, P1, DOI 10.1038/sj.bmt.1701291; Walters MC, 1996, NEW ENGL J MED, V335, P369, DOI 10.1056/NEJM199608083350601; Wu B, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00825; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0	66	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 9	2021	12								774442	10.3389/fimmu.2021.774442	http://dx.doi.org/10.3389/fimmu.2021.774442			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZH5ML	34956203	Green Published, gold			2022-12-18	WOS:000760982800001
J	Hernandez-Bello, J; Banos-Hernandez, CJ; Munoz-Valle, JF				Hernandez-Bello, Jorge; Banos-Hernandez, Christian Johana; Munoz-Valle, Jose Francisco			Commentary: Long Non-Coding RNA Gene Polymorphisms and Their Expression Levels in Patients With Rheumatoid Arthritis	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						ANRIL; lnc-DC; single-nucleotide polymorphism; rheumatoid arthritis; ZFAS1; MALAT1			[Hernandez-Bello, Jorge; Banos-Hernandez, Christian Johana; Munoz-Valle, Jose Francisco] Univ Guadalajara, Univ Ctr Hlth Sci, Inst Res Biomed Sci IICB, Guadalajara, Mexico	Universidad de Guadalajara	Munoz-Valle, JF (corresponding author), Univ Guadalajara, Univ Ctr Hlth Sci, Inst Res Biomed Sci IICB, Guadalajara, Mexico.	biologiamolecular@hotmail.com						Sato Y, 2006, J HUM GENET, V51, P772, DOI 10.1007/s10038-006-0020-6; Zhang TP, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02529	2	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 9	2021	12								801266	10.3389/fimmu.2021.801266	http://dx.doi.org/10.3389/fimmu.2021.801266			4	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YB5RV	34956240	gold, Green Published			2022-12-18	WOS:000739070200001
J	Muhammad, K; Xavier, D; Klein-Hessling, S; Azeem, M; Rauschenberger, T; Murti, K; Avots, A; Goebeler, M; Klein, M; Bopp, T; Sielaff, M; Tenzer, S; Mockel, S; Aramburu, J; Lopez-Rodriguez, C; Kerstan, A; Serfling, E				Muhammad, Khalid; Xavier, Delicia; Klein-Hessling, Stefan; Azeem, Muhammad; Rauschenberger, Tabea; Murti, Krisna; Avots, Andris; Goebeler, Matthias; Klein, Matthias; Bopp, Tobias; Sielaff, Malte; Tenzer, Stefan; Moeckel, Sigrid; Aramburu, Jose; Lopez-Rodriguez, Cristina; Kerstan, Andreas; Serfling, Edgar			NFAT5 Controls the Integrity of Epidermis	FRONTIERS IN IMMUNOLOGY			English	Article						epidermis; keratinocytes; kallikrein 7; matrix proteases; Mmp3; NFAT5; skin	TERMINAL DIFFERENTIATION; STRATUM-CORNEUM; GENE-EXPRESSION; STEM-CELLS; TRANSCRIPTION; SKIN; KERATINOCYTES; PROTEINS; FAMILY; KLK7	The skin protects the human body against dehydration and harmful challenges. Keratinocytes (KCs) are the most abundant epidermal cells, and it is anticipated that KC-mediated transport of Na+ ions creates a physiological barrier of high osmolality against the external environment. Here, we studied the role of NFAT5, a transcription factor whose activity is controlled by osmotic stress in KCs. Cultured KCs from adult mice were found to secrete more than 300 proteins, and upon NFAT5 ablation, the secretion of several matrix proteinases, including metalloproteinase-3 (Mmp3) and kallikrein-related peptidase 7 (Klk7), was markedly enhanced. An increase in Mmp3 and Klk7 RNA levels was also detected in transcriptomes of Nfat5(-/-) KCs, along with increases of numerous members of the 'Epidermal Differentiation Complex' (EDC), such as small proline-rich (Sprr) and S100 proteins. NFAT5 and Mmp3 as well as NFAT5 and Klk7 are co-expressed in the basal KCs of fetal and adult epidermis but not in basal KCs of newborn (NB) mice. The poor NFAT5 expression in NB KCs is correlated with a strong increase in Mmp3 and Klk7 expression in KCs of NB mice. These data suggests that, along with the fragile epidermis of adult Nfat5(-/-) mice, NFAT5 keeps in check the expression of matrix proteases in epidermis. The NFAT5-mediated control of matrix proteases in epidermis contributes to the manifold changes in skin development in embryos before and during birth, and to the integrity of epidermis in adults.	[Muhammad, Khalid; Xavier, Delicia; Klein-Hessling, Stefan; Azeem, Muhammad; Rauschenberger, Tabea; Murti, Krisna; Avots, Andris; Goebeler, Matthias; Serfling, Edgar] Univ Wurzburg, Inst Pathol, Dept Mol Pathol, Wurzburg, Germany; [Klein-Hessling, Stefan; Avots, Andris; Serfling, Edgar] Comprehens Canc Ctr Mainfranken, Wurzburg, Germany; [Azeem, Muhammad; Goebeler, Matthias; Kerstan, Andreas] Univ Hosp Wuerzburg, Dept Dermatol Venereol & Allergol, Wurzburg, Germany; [Klein, Matthias; Bopp, Tobias; Sielaff, Malte; Tenzer, Stefan] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Inst Immunol, Mainz, Germany; [Bopp, Tobias] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Res Ctr Immunotherapy, Mainz, Germany; [Bopp, Tobias] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Univ Canc Ctr Mainz, Mainz, Germany; [Moeckel, Sigrid] Univ Wurzburg, Inst Pathol, Wurzburg, Germany; [Aramburu, Jose; Lopez-Rodriguez, Cristina] Univ Pompeu Fabra, Dept Expt & Hlth Sci, Immunol Unit, Barcelona, Spain; [Muhammad, Khalid] UAE Univ, Coll Sci, Dept Biol, Al Ain, U Arab Emirates	University of Wurzburg; University of Wurzburg; University of Wurzburg; Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz; University of Wurzburg; Pompeu Fabra University; United Arab Emirates University	Serfling, E (corresponding author), Univ Wurzburg, Inst Pathol, Dept Mol Pathol, Wurzburg, Germany.; Serfling, E (corresponding author), Comprehens Canc Ctr Mainfranken, Wurzburg, Germany.	serfling.e@mail.uni-wuerzburg.de	; Lopez Rodriguez, Cristina/G-4482-2014	Muhammad, Khalid/0000-0001-6488-1722; Lopez Rodriguez, Cristina/0000-0002-2311-2406				Aumailley M, 2005, MATRIX BIOL, V24, P326, DOI 10.1016/j.matbio.2005.05.006; Berberich-Siebelt F, 2000, EUR J IMMUNOL, V30, P2576, DOI 10.1002/1521-4141(200009)30:9<2576::AID-IMMU2576>3.0.CO;2-N; Berga-Bolanos R, 2010, J IMMUNOL, V185, P6624, DOI 10.4049/jimmunol.1001232; Birnbaum RY, 2006, NAT GENET, V38, P749, DOI 10.1038/ng1813; Bragulla HH, 2009, J ANAT, V214, P516, DOI 10.1111/j.1469-7580.2009.01066.x; Brooke MA, 2012, J PATHOL, V226, P158, DOI 10.1002/path.3027; Buxade M, 2012, J EXP MED, V209, P379, DOI 10.1084/jem.20111569; Chakraborti S, 2003, MOL CELL BIOCHEM, V253, P269, DOI 10.1023/A:1026028303196; Dayem MA, 2003, COMP FUNCT GENOM, V4, P47, DOI 10.1002/cfg.239; Dieterich DC, 2007, NAT PROTOC, V2, P532, DOI 10.1038/nprot.2007.52; Distler U, 2014, NAT METHODS, V11, P167, DOI [10.1038/NMETH.2767, 10.1038/nmeth.2767]; Eisenhaber B, 2011, CELL CYCLE, V10, P3897, DOI 10.4161/cc.10.22.18043; Gallo V, 2017, J CLIN IMMUNOL, V37, P751, DOI 10.1007/s10875-017-0445-z; Go WY, 2004, P NATL ACAD SCI USA, V101, P10673, DOI 10.1073/pnas.0403139101; Gonzales KAU, 2017, DEV CELL, V43, P387, DOI 10.1016/j.devcel.2017.10.001; Gordon WM, 2014, J CLIN INVEST, V124, P5205, DOI 10.1172/JCI77138; Hofmeister L, 2015, PFLUG ARCH EUR J PHY, V467, P551, DOI 10.1007/s00424-014-1685-x; Igawa S, 2017, J INVEST DERMATOL, V137, P449, DOI 10.1016/j.jid.2016.10.015; Ishida-Yamamoto A, 2015, CELL TISSUE RES, V360, P477, DOI 10.1007/s00441-014-2037-z; Ishida-Yamamoto A, 2014, J DERMATOL SCI, V74, P99, DOI 10.1016/j.jdermsci.2014.02.005; Janes SM, 2004, J CELL SCI, V117, P4157, DOI 10.1242/jcs.01302; Jantsch J, 2015, CELL METAB, V21, P493, DOI 10.1016/j.cmet.2015.02.003; Jeong SH, 2014, EXP DERMATOL, V23, P890, DOI 10.1111/exd.12554; Jobin K, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aay3850; Keermann M, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1508-2; Kim SY, 2002, NEUROCHEM INT, V40, P85, DOI 10.1016/S0197-0186(01)00064-X; Kur-Piotrowska A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-23794-5; Kypriotou M, 2012, EXP DERMATOL, V21, P643, DOI 10.1111/j.1600-0625.2012.01472.x; Lademann J, 2009, EUR J PHARM BIOPHARM, V72, P317, DOI 10.1016/j.ejpb.2008.08.008; Leclerc EA, 2014, J CELL SCI, V127, P2862, DOI 10.1242/jcs.144808; Lichti U, 2008, NAT PROTOC, V3, P799, DOI 10.1038/nprot.2008.50; Lopez-Rodriguez C, 1999, COLD SPRING HARB SYM, V64, P517, DOI 10.1101/sqb.1999.64.517; Lopez-Rodriguez C, 2004, P NATL ACAD SCI USA, V101, P2392, DOI 10.1073/pnas.0308703100; Lopez-Rodriguez C, 2001, IMMUNITY, V15, P47, DOI 10.1016/S1074-7613(01)00165-0; Lymboussaki A, 1996, BRIT J CANCER, V73, P1347, DOI 10.1038/bjc.1996.257; Magnusdottir E, 2007, P NATL ACAD SCI USA, V104, P14988, DOI 10.1073/pnas.0707323104; Malaguarnera L, 2006, CELL MOL LIFE SCI, V63, P3018, DOI 10.1007/s00018-006-6269-2; Margadant C, 2010, FASEB J, V24, P4133, DOI 10.1096/fj.09-151449; Mariotto A, 2016, J INVEST DERMATOL, V136, P905, DOI 10.1016/j.jid.2016.01.032; Matthias J, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aau0683; McManus S, 2011, EMBO J, V30, P2388, DOI 10.1038/emboj.2011.140; Miao Q, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11880-9; Mirastschijski U, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20205234; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; NEHLS M, 1994, NATURE, V372, P103, DOI 10.1038/372103a0; Olson LE, 2005, P NATL ACAD SCI USA, V102, P3708, DOI 10.1073/pnas.0500519102; Ovaere P, 2009, TRENDS BIOCHEM SCI, V34, P453, DOI 10.1016/j.tibs.2009.08.001; Park GT, 2002, J BIOL CHEM, V277, P45195, DOI 10.1074/jbc.M205380200; Proksch E, 2008, EXP DERMATOL, V17, P1063, DOI 10.1111/j.1600-0625.2008.00786.x; Sharifi S, 2018, ANNU REV BIOCHEM, V87, P51, DOI 10.1146/annurev-biochem-062917-012612; Song KD, 2012, BIOCHEM BIOPH RES CO, V419, P388, DOI 10.1016/j.bbrc.2012.02.032; Szondy Z, 2017, BIOMEDICINE-TAIWAN, V7, P1, DOI 10.1051/bmdcn/2017070315; Takeda N, 2013, DEVELOPMENT, V140, P1655, DOI 10.1242/dev.093005; Wang FR, 2016, METHOD ENZYMOL, V568, P303, DOI 10.1016/bs.mie.2015.09.032; Ye S, 1996, J BIOL CHEM, V271, P13055, DOI 10.1074/jbc.271.22.13055; Yeo H, 2021, BIOCHEM BIOPH RES CO, V534, P303, DOI 10.1016/j.bbrc.2020.11.089; Yousef GM, 2000, GENE, V254, P119, DOI 10.1016/S0378-1119(00)00280-8; YUSPA SH, 1989, J CELL BIOL, V109, P1207, DOI 10.1083/jcb.109.3.1207; Zolotarenko A, 2017, METHODS MOL BIOL, V1613, P355, DOI 10.1007/978-1-4939-7027-8_14	59	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 9	2021	12								780727	10.3389/fimmu.2021.780727	http://dx.doi.org/10.3389/fimmu.2021.780727			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YA5VS	34956208	Green Published, gold			2022-12-18	WOS:000738401100001
J	Parthasarathy, R; Hagglof, T; Hadley, JT; McLennan, A; Mattke, A; Dudley, EA; Kumagai, A; Dong, LLQ; Leadbetter, EA				Parthasarathy, Raksha; Haeggloef, Thomas; Hadley, Jason T.; McLennan, Alexandra; Mattke, Aiden; Dudley, Elizabeth A.; Kumagai, Abigail; Dong, Lily Q.; Leadbetter, Elizabeth A.			Receptor Interacting Protein Kinase Pathways Regulate Innate B Cell Developmental Checkpoints But Not Effector Function in Mice	FRONTIERS IN IMMUNOLOGY			English	Article						B cell development and differentiation; RIPK1; RIPK3; B-1 cell development; marginal zone B cells; caspase 8	MARGINAL ZONE MACROPHAGES; NECROSIS-FACTOR FAMILY; KAPPA-B; ACTIVATING FACTOR; CUTTING EDGE; T-CELLS; BAFF; CASPASE-8; DEATH; RIPK1	Mutations in the scaffolding domain of Receptor Interacting Protein kinases (RIP) underlie the recently described human autoimmune syndrome, CRIA, characterized by lymphadenopathy, splenomegaly, and autoantibody production. While disease mechanisms for CRIA remain undescribed, RIP kinases work together with caspase-8 to regulate cell death, which is critical for normal differentiation of many cell types. Here, we describe a key role for RIP1 in facilitating innate B cell differentiation and subsequent activation. By comparing RIP1, RIP3, and caspase-8 triple deficient and RIP3, caspase-8 double deficient mice, we identified selective contributions of RIP1 to an accumulation of murine splenic Marginal Zone (MZ) B cells and B1-b cells. We used mixed bone-marrow chimeras to determine that innate B cell commitment required B cell-intrinsic RIP1, RIP3, and caspase-8 sufficiency. RIP1 regulated MZ B cell development rather than differentiation and RIP1 mediates its innate immune effects independent of the RIP1 kinase domain. NP-KLH/alum and NP-Ficoll vaccination of mice doubly deficient in both caspase-8 and RIP3 or deficient in all three proteins (RIP3, caspase-8, and RIP1) revealed uniquely delayed T-dependent and T-independent IgG responses, abnormal splenic germinal center architecture, and reduced extrafollicular plasmablast formation compared to WT mice. Thus, RIP kinases and caspase-8 jointly orchestrate B cell fate and delayed effector function through a B cell-intrinsic mechanism.	[Parthasarathy, Raksha; Haeggloef, Thomas; McLennan, Alexandra; Mattke, Aiden; Dudley, Elizabeth A.; Kumagai, Abigail; Leadbetter, Elizabeth A.] Univ Texas Hlth San Antonio, Dept Microbiol Immunol & Mol Genet, San Antonio, TX 78229 USA; [Hadley, Jason T.; Dong, Lily Q.] Univ Texas Hlth San Antonio, Dept Cell Syst & Anat, San Antonio, TX USA; [McLennan, Alexandra] St Marys Univ, Dept Engn, San Antonio, TX USA; [Haeggloef, Thomas] Rockefeller Univ, Lab Mol Immunol, 1230 York Ave, New York, NY 10021 USA; [Mattke, Aiden] Univ Puget Sound, Tacoma, WA 98416 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; Rockefeller University	Leadbetter, EA (corresponding author), Univ Texas Hlth San Antonio, Dept Microbiol Immunol & Mol Genet, San Antonio, TX 78229 USA.	leadbetter@uthscsa.edu		Hagglof, Thomas/0000-0002-7751-0928	Swedish Research Council; US National Institutes of Health [R01 AI132798]; University of Texas Health Science Center at San Antonio; UT Health; NIH-NCI [P30 CA054174-20, UL1 TR001120]	Swedish Research Council(Swedish Research CouncilEuropean Commission); US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Texas Health Science Center at San Antonio; UT Health; NIH-NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the Swedish Research Council (TH), the US National Institutes of Health (R01 AI132798 to EL), and the University of Texas Health Science Center at San Antonio (EL). Some data was collected in the Flow Cytometry Shared Resource Facility, which is supported by UT Health, NIH-NCI P30 CA054174-20 (CTRC at UT Health) and UL1 TR001120 (CTSA grant).	Baumgarth N, 2017, J IMMUNOL, V199, P3387, DOI 10.4049/jimmunol.1700943; Beisner DR, 2005, J IMMUNOL, V175, P3469, DOI 10.4049/jimmunol.175.6.3469; Cariappa A, 2000, J EXP MED, V192, P1175, DOI 10.1084/jem.192.8.1175; Casola S, 2004, NAT IMMUNOL, V5, P317, DOI 10.1038/ni1036; Cinamon G, 2008, NAT IMMUNOL, V9, P54, DOI 10.1038/ni1542; Cuchet-Lourenco D, 2018, SCIENCE, V361, P810, DOI 10.1126/science.aar2641; Cusson N, 2002, J EXP MED, V196, P15, DOI 10.1084/jem.20011470; Degterev A, 2019, P NATL ACAD SCI USA, V116, P9714, DOI 10.1073/pnas.1901179116; Dostert C, 2019, PHYSIOL REV, V99, P115, DOI 10.1152/physrev.00045.2017; Dowling JP, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.307; Fritsch M, 2019, NATURE, V575, P683, DOI 10.1038/s41586-019-1770-6; GIESE T, 1995, INT IMMUNOL, V7, P1213, DOI 10.1093/intimm/7.8.1213; Gross JA, 2001, IMMUNITY, V15, P289, DOI 10.1016/S1074-7613(01)00183-2; Hagglof T, 2016, NAT IMMUNOL, V17, P1407, DOI 10.1038/ni.3583; Kaiser WJ, 2014, P NATL ACAD SCI USA, V111, P7753, DOI 10.1073/pnas.1401857111; Kaiser WJ, 2011, NATURE, V471, P368, DOI 10.1038/nature09857; Kang TB, 2004, J IMMUNOL, V173, P2976, DOI 10.4049/jimmunol.173.5.2976; King IL, 2012, NAT IMMUNOL, V13, P44, DOI 10.1038/ni.2172; Koppel EA, 2008, MOL IMMUNOL, V45, P2881, DOI 10.1016/j.molimm.2008.01.032; Kroemer G, 2009, CELL DEATH DIFFER, V16, P3, DOI 10.1038/cdd.2008.150; Lalaoui N, 2020, NATURE, V577, P103, DOI 10.1038/s41586-019-1828-5; Li Y, 2019, P NATL ACAD SCI USA, V116, P970, DOI 10.1073/pnas.1813582116; Lim VY, 2017, ADV IMMUNOL, V134, P47, DOI 10.1016/bs.ai.2017.02.001; Mackay F, 2009, NAT REV IMMUNOL, V9, P491, DOI 10.1038/nri2572; Martin F, 2002, NAT REV IMMUNOL, V2, P323, DOI 10.1038/nri799; Meffre E, 2008, CURR OPIN IMMUNOL, V20, P632, DOI 10.1016/j.coi.2008.09.001; Nailwal H, 2019, CELL DEATH DIFFER, V26, P4, DOI 10.1038/s41418-018-0172-x; Najjar M, 2016, IMMUNITY, V45, P46, DOI 10.1016/j.immuni.2016.06.007; Newton K, 2004, MOL CELL BIOL, V24, P1464, DOI 10.1128/MCB.24.4.1464-1469.2004; Newton K, 2015, TRENDS CELL BIOL, V25, P347, DOI 10.1016/j.tcb.2015.01.001; Oberst A, 2011, NATURE, V471, P363, DOI 10.1038/nature09852; Orzalli MH, 2017, TRENDS CELL BIOL, V27, P810, DOI 10.1016/j.tcb.2017.05.007; Peterson LW, 2017, J EXP MED, V214, P3171, DOI 10.1084/jem.20170347; Pillai S, 2005, ANNU REV IMMUNOL, V23, P161, DOI 10.1146/annurev.immunol.23.021704.115728; Prokopec KE, 2016, J IMMUNOL, V197, P2063, DOI 10.4049/jimmunol.1502282; Salmena L, 2005, J EXP MED, V202, P727, DOI 10.1084/jem.20050683; Sasaki Y, 2006, IMMUNITY, V24, P729, DOI 10.1016/j.immuni.2006.04.005; Schiemann B, 2001, SCIENCE, V293, P2111, DOI 10.1126/science.1061964; Schneider P, 2001, J EXP MED, V194, P1691, DOI 10.1084/jem.194.11.1691; Silke J, 2015, NAT IMMUNOL, V16, P689, DOI [10.1038/ni.3206, 10.1038/ni0815-889b]; Smulski CR, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02285; Steri M, 2017, NEW ENGL J MED, V376, P1615, DOI 10.1056/NEJMoa1610528; Su H, 2005, SCIENCE, V307, P1465, DOI 10.1126/science.1104765; Suzuki K, 2008, CYTOKINE, V44, P44, DOI 10.1016/j.cyto.2008.06.005; Tanigakik K, 2002, NAT IMMUNOL, V3, P443, DOI 10.1038/ni793; Thien M, 2004, IMMUNITY, V20, P785, DOI 10.1016/j.immuni.2004.05.010; Tummers B, 2017, IMMUNOL REV, V277, P76, DOI 10.1111/imr.12541; Webb LV, 2019, IMMUNITY, V50, P348, DOI 10.1016/j.immuni.2019.01.004; Zhang HB, 2011, NATURE, V471, P373, DOI 10.1038/nature09878; Zhang JK, 2011, IMMUNOL RES, V51, P227, DOI 10.1007/s12026-011-8249-3	50	0	0	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 9	2021	12								758407	10.3389/fimmu.2021.758407	http://dx.doi.org/10.3389/fimmu.2021.758407			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YB0GT	34956189	gold, Green Published			2022-12-18	WOS:000738702200001
J	Sangesland, M; Lingwood, D				Sangesland, Maya; Lingwood, Daniel			Public Immunity: Evolutionary Spandrels for Pathway-Amplifying Protective Antibodies	FRONTIERS IN IMMUNOLOGY			English	Review						B cells; broadly neutralizing antibodies; vaccination; immunity; evolution	BROADLY NEUTRALIZING ANTIBODIES; B-CELLS; CANONICAL STRUCTURES; V(D)J RECOMBINATION; PROTEIN-STRUCTURE; SAN-MARCO; HIV; VACCINE; GENE; REGION	Humoral immunity is seeded by affinity between the B cell receptor (BCR) and cognate antigen. While the BCR is a chimeric display of diverse antigen engagement solutions, we discuss its functional activity as an 'innate-like' immune receptor, wherein genetically hardwired antigen complementarity can serve as reproducible templates for pathway-amplifying otherwise immunologically recessive antibody responses. We propose that the capacity for germline reactivity to new antigen emerged as a set of evolutionary spandrels or coupled traits, which can now be exploited by rational vaccine design to focus humoral immunity upon conventionally immune-subdominant antibody targets. Accordingly, we suggest that evolutionary spandrels account for the necessary but unanticipated antigen reactivity of the germline antibody repertoire.	[Lingwood, Daniel] MIT, Massachusetts Gen Hosp, Ragon Inst, 77 Massachusetts Ave, Cambridge, MA 02139 USA; Harvard Univ, Cambridge, MA 02138 USA	Harvard University; Massachusetts General Hospital; Massachusetts Institute of Technology (MIT); Ragon Institute; Harvard University	Lingwood, D (corresponding author), MIT, Massachusetts Gen Hosp, Ragon Inst, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	dlingwood@mgh.harvard.edu		Sangesland, Maya/0000-0001-8316-039X				Abbott RK, 2020, IMMUNOL REV, V296, P120, DOI 10.1111/imr.12861; Abbott RK, 2018, IMMUNITY, V48, P133, DOI 10.1016/j.immuni.2017.11.023; AlLazikani B, 1997, J MOL BIOL, V273, P927, DOI 10.1006/jmbi.1997.1354; Altman MO, 2018, VIRAL IMMUNOL, V31, P142, DOI 10.1089/vim.2017.0129; Altman MO, 2015, ELIFE, V4, DOI 10.7554/eLife.07467; Amitai A, 2020, CELL SYST, V11, P573, DOI 10.1016/j.cels.2020.09.005; Andreano E, 2021, J EXP MED, V218, DOI 10.1084/jem.20210281; Angeletti D, 2019, P NATL ACAD SCI USA, V116, P13474, DOI 10.1073/pnas.1816300116; Avnir Y, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004103; Bekker LG, 2020, LANCET, V395, P384, DOI 10.1016/S0140-6736(19)32682-0; Briney B, 2019, NATURE, V566, P393, DOI 10.1038/s41586-019-0879-y; Briney B, 2016, CELL, V166, P1459, DOI 10.1016/j.cell.2016.08.005; Brorson K, 1999, J IMMUNOL, V163, P6694; Burton DR, 2015, NAT IMMUNOL, V16, P571, DOI 10.1038/ni.3158; Chen F, 2021, IMMUNITY, V54, P781, DOI 10.1016/j.immuni.2021.02.013; Chen XJ, 2021, IMMUNITY, V54, P324, DOI 10.1016/j.immuni.2020.12.014; CHOTHIA C, 1987, J MOL BIOL, V196, P901, DOI 10.1016/0022-2836(87)90412-8; CHOTHIA C, 1989, NATURE, V342, P877, DOI 10.1038/342877a0; COHN M, 1990, IMMUNOL REV, V115, P7, DOI 10.1111/j.1600-065X.1990.tb00783.x; Cooper MD, 2010, NAT REV IMMUNOL, V10, P2, DOI 10.1038/nri2686; CREWS S, 1981, CELL, V25, P59, DOI 10.1016/0092-8674(81)90231-2; Dosenovic P, 2019, J EXP MED, V216, P2316, DOI 10.1084/jem.20190446; Dosenovic P, 2018, P NATL ACAD SCI USA, V115, P4743, DOI 10.1073/pnas.1803457115; Dosenovic P, 2015, CELL, V161, P1505, DOI 10.1016/j.cell.2015.06.003; Duan HY, 2018, IMMUNITY, V49, P301, DOI 10.1016/j.immuni.2018.07.005; Dunand CJH, 2015, PHILOS T R SOC B, V370, DOI 10.1098/rstb.2014.0238; Ehrlich P, 1902, LUDWIG MAXIMILIANS U, V3, P381; Ehrlich P., 1900, P R SOC            B, V66, P424, DOI DOI 10.1098/RSPL.1899.0121; Ekiert DC, 2009, SCIENCE, V324, P246, DOI 10.1126/science.1171491; Erbelding EJ, 2018, J INFECT DIS, V218, P347, DOI 10.1093/infdis/jiy103; Erlich P, 1897, KLIN JB JENA, V6, P299; Escolano A, 2019, NATURE, V570, P468, DOI 10.1038/s41586-019-1250-z; Escolano A, 2016, CELL, V166, P1445, DOI 10.1016/j.cell.2016.07.030; Flyak AI, 2018, CELL HOST MICROBE, V24, P703, DOI 10.1016/j.chom.2018.10.009; GEARHART PJ, 1981, NATURE, V291, P29, DOI 10.1038/291029a0; Golsaz-Shirazi F, 2015, VIRAL IMMUNOL, V28, P425, DOI 10.1089/vim.2015.0023; GOULD SJ, 1979, PROC R SOC SER B-BIO, V205, P581, DOI 10.1098/rspb.1979.0086; GOULD SJ, 1982, PALEOBIOLOGY, V8, P4, DOI 10.1017/S0094837300004310; Gould SJ, 1997, P NATL ACAD SCI USA, V94, P10750, DOI 10.1073/pnas.94.20.10750; Havenar-Daughton C, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aat0381; Haynes BF, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aaz2686; Haynes BF, 2017, IMMUNOL REV, V275, P5, DOI 10.1111/imr.12517; Hehle V, 2020, J EXP MED, V217, DOI 10.1084/jem.20200840; Hirano M, 2013, NATURE, V501, P435, DOI 10.1038/nature12467; Hirano M, 2011, ADV IMMUNOL, V109, P125, DOI 10.1016/B978-0-12-387664-5.00004-2; Holodick NE, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00872; Huang DL, 2020, P NATL ACAD SCI USA, V117, P22920, DOI 10.1073/pnas.2004489117; Hwang KK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090725; Imkeller K, 2018, SCIENCE, V360, P1358, DOI 10.1126/science.aar5304; Jardine J, 2013, SCIENCE, V340, P711, DOI 10.1126/science.1234150; Jardine JG, 2016, SCIENCE, V351, P1458, DOI 10.1126/science.aad9195; Jardine JG, 2015, SCIENCE, V349, P156, DOI 10.1126/science.aac5894; Joyce MG, 2016, CELL, V166, P609, DOI 10.1016/j.cell.2016.06.043; Jung D, 2004, CELL, V116, P299, DOI 10.1016/S0092-8674(04)00039-X; Kirik U, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01433; Koonin EV, 2016, BMC BIOL, V14, DOI 10.1186/s12915-016-0338-2; Kraus M, 2004, CELL, V117, P787, DOI 10.1016/j.cell.2004.05.014; Kuroda D, 2008, PROTEINS, V73, P608, DOI 10.1002/prot.22087; Lam KP, 1997, CELL, V90, P1073, DOI 10.1016/S0092-8674(00)80373-6; Lerner RA, 2011, MOL BIOSYST, V7, P1004, DOI 10.1039/c0mb00310g; Lin YR, 2020, IMMUNITY, V53, P840, DOI 10.1016/j.immuni.2020.09.007; Lingwood D, 2012, NATURE, V489, P566, DOI 10.1038/nature11371; Lonberg N, 2005, NAT BIOTECHNOL, V23, P1117, DOI 10.1038/nbt1135; LUCAS AH, 1991, J CLIN INVEST, V88, P1811, DOI 10.1172/JCI115502; Manhart M, 2015, P NATL ACAD SCI USA, V112, P1797, DOI 10.1073/pnas.1415895112; Market E, 2003, PLOS BIOL, V1, P24, DOI 10.1371/journal.pbio.0000016; Martin ACR, 1996, J MOL BIOL, V263, P800, DOI 10.1006/jmbi.1996.0617; McGuire AT, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10618; Medina-Ramirez M, 2017, J EXP MED, V214, P2573, DOI 10.1084/jem.20161160; Mi QS, 2000, P NATL ACAD SCI USA, V97, P6031, DOI 10.1073/pnas.110039497; Mora Thierry, 2019, Current Opinion in Systems Biology, V18, P104, DOI 10.1016/j.coisb.2019.10.001; Morea V, 1998, J MOL BIOL, V275, P269, DOI 10.1006/jmbi.1997.1442; Mukhamedova M, 2021, IMMUNITY, V54, P769, DOI 10.1016/j.immuni.2021.03.004; Murugan R, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aap8029; Nabel GJ, 2010, NAT MED, V16, P1389, DOI 10.1038/nm1210-1389; Nachbagauer R, 2020, ANNU REV MED, V71, P315, DOI 10.1146/annurev-med-120617-041310; Nicolas Laura, 2018, F1000Res, V7, P458, DOI 10.12688/f1000research.13247.1; North B, 2011, J MOL BIOL, V406, P228, DOI 10.1016/j.jmb.2010.10.030; Oliva B, 1998, J MOL BIOL, V279, P1193, DOI 10.1006/jmbi.1998.1847; Otipoby KL, 2015, P NATL ACAD SCI USA, V112, P12145, DOI 10.1073/pnas.1516428112; Pancer Z, 2006, ANNU REV IMMUNOL, V24, P497, DOI 10.1146/annurev.immunol.24.021605.090542; Pape KA, 2018, IMMUNITY, V48, P1135, DOI 10.1016/j.immuni.2018.04.019; Pappas L, 2014, NATURE, V516, P418, DOI 10.1038/nature13764; Peterhoff D, 2017, CURR OPIN HIV AIDS, V12, P257, DOI 10.1097/COH.0000000000000356; Pievani T, 2011, J ANTHROPOL SCI, V89, P9, DOI 10.4436/jass.89015; Pigliucci M, 2000, TRENDS ECOL EVOL, V15, P66, DOI 10.1016/S0169-5347(99)01762-0; Robbiani DF, 2020, NATURE, V584, P437, DOI 10.1038/s41586-020-2456-9; Saada R, 2007, IMMUNOL CELL BIOL, V85, P323, DOI 10.1038/sj.icb.7100055; Sangesland M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020125; Sangesland M, 2020, CELL REP, V32, DOI 10.1016/j.celrep.2020.108065; Sangesland M, 2019, IMMUNITY, V51, P735, DOI 10.1016/j.immuni.2019.09.001; Savage HP, 2015, ANN NY ACAD SCI, V1362, P132, DOI 10.1111/nyas.12799; Schickel JN, 2017, J EXP MED, V214, P1991, DOI 10.1084/jem.20160201; Schroeder HW, 2010, J ALLERGY CLIN IMMUN, V125, pS41, DOI 10.1016/j.jaci.2009.09.046; Sharp PM, 2011, CSH PERSPECT MED, V1, DOI 10.1101/cshperspect.a006841; Shirai H, 1999, FEBS LETT, V455, P188, DOI 10.1016/S0014-5793(99)00821-2; Sober E, 2011, J EVOLUTION BIOL, V24, P462, DOI 10.1111/j.1420-9101.2010.02162.x; Sok D, 2017, NATURE, V548, P108, DOI 10.1038/nature23301; Sok D, 2016, SCIENCE, V353, P1557, DOI 10.1126/science.aah3945; Stamatatos L, 2017, IMMUNOL REV, V275, P203, DOI 10.1111/imr.12483; Steichen JM, 2019, SCIENCE, V366, P1216, DOI 10.1126/science.aax4380; Sui JH, 2009, NAT STRUCT MOL BIOL, V16, P265, DOI 10.1038/nsmb.1566; Thomson CA, 2008, EMBO J, V27, P2592, DOI 10.1038/emboj.2008.179; Tian M, 2016, CELL, V166, P1471, DOI 10.1016/j.cell.2016.07.029; Tzarum N, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aav1882; Verkoczy L, 2017, IMMUNOL REV, V275, P89, DOI 10.1111/imr.12505; Wang XS, 2021, EMBO J, V40, DOI 10.15252/embj.2020105926; Wec AZ, 2020, P NATL ACAD SCI USA, V117, P6675, DOI 10.1073/pnas.1921388117; Weiss MA, 2002, BIOCHEMISTRY-US, V41, P809, DOI 10.1021/bi011839+; West AP, 2012, P NATL ACAD SCI USA, V109, pE2083, DOI 10.1073/pnas.1208984109; Wheatley AK, 2015, EXPERT REV VACCINES, V14, P1227, DOI 10.1586/14760584.2015.1068125; Willis JR, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003045; Wu XL, 2011, SCIENCE, V333, P1593, DOI 10.1126/science.1207532; Xu JL, 2000, IMMUNITY, V13, P37, DOI 10.1016/S1074-7613(00)00006-6; Yaseen MM, 2017, VIRAL IMMUNOL, V30, P708, DOI 10.1089/vim.2017.0065; Yuan M, 2020, SCIENCE, V369, P1119, DOI 10.1126/science.abd2321; Zhou TQ, 2015, CELL, V161, P1280, DOI 10.1016/j.cell.2015.05.007; Zhou TQ, 2013, IMMUNITY, V39, P245, DOI 10.1016/j.immuni.2013.04.012	119	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 9	2021	12								708882	10.3389/fimmu.2021.708882	http://dx.doi.org/10.3389/fimmu.2021.708882			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YA4RG	34956170	gold, Green Published			2022-12-18	WOS:000738321700001
J	Sun, YA; Zhang, L; Hong, L; Zheng, WW; Cui, JX; Liu, XZ; Xu, TJ				Sun, Yuena; Zhang, Lei; Hong, Ling; Zheng, Weiwei; Cui, Junxia; Liu, Xuezhu; Xu, Tianjun			MicroRNA-181b-2 and MicroRNA-21-1 Negatively Regulate NF-kappa B and IRF3-Mediated Innate Immune Responses via Targeting TRIF in Teleost	FRONTIERS IN IMMUNOLOGY			English	Article						microRNA; TRIF; gene regulation; immune response; innate immune	BREAST-CANCER; SMALL RNAS; INTERFERON; GENE; IFN; IDENTIFICATION; PROTEIN; INFLAMMATION; CONTRIBUTES; RECOGNITION	Upon recognition of bacterial or viral components by Toll-like receptors (TLRs), cells could be activated to induce a series of reactions to produce inflammatory cytokines, type I interferon (IFN), and IFN stimulating genes (ISG). MicroRNAs (miRNAs) are an important regulatory molecules that are widely involved in the regulatory networks of mammalian inflammation and immune responses; however, in lower vertebrates, the regulatory network of miRNA-mediated immune responses is poorly understood. Here, we report two miRNAs form Miichthys miiuy, namely, miR-181b-2 and miR-21-1, that play a negative role in host antiviral and antibacterial immunity. We found that miR-181b-2 and miR-21-1 are abundantly expressed in gram-negative bacteria, as well as RNA rhabdovirus infection. Inducible miR-181b-2 and miR-21-1 suppress the production of inflammatory cytokines and type I IFN by targeting TRIF, thereby avoiding excessive inflammation. We further revealed that miR-181b-2 and miR-21-1 modulate antibacterial and antiviral immunity through the TRIF-mediated NF-kappa B and IRF3 signaling pathways. The overall results indicate that miR-181b-2 and miR-21-1 act as negative feedback regulators and participate in host antibacterial and antiviral immune responses; this finding could provide information for a deeper understanding of the resistance of lower vertebrates to the invasion of pathogens and to avoidance of excessive immunity.	[Sun, Yuena; Zhang, Lei; Zheng, Weiwei; Cui, Junxia; Xu, Tianjun] Shanghai Ocean Univ, Coll Fisheries & Life Sci, Lab Fish Mol Immunol, Shanghai, Peoples R China; [Sun, Yuena; Xu, Tianjun] Qingdao Natl Lab Marine Sci & Technol, Lab Marine Biol & Biotechnol, Qingdao, Peoples R China; [Hong, Ling] Tongji Univ, Sch Med, Shanghai, Peoples R China; [Liu, Xuezhu] Zhejiang Ocean Univ, Coll Marine Sci, Lab Fish Biogenet Immune Evolut, Zhoushan, Peoples R China; [Xu, Tianjun] Key Lab Explorat & Utilizat Aquat Genet Resources, Minist Educ, Shanghai, Peoples R China; [Xu, Tianjun] Shanghai Ocean Univ, Natl Pathogen Collect Ctr Aquat Animals, Shanghai, Peoples R China	Shanghai Ocean University; Qingdao National Laboratory for Marine Science & Technology; Tongji University; Zhejiang Ocean University; Shanghai Ocean University	Xu, TJ (corresponding author), Shanghai Ocean Univ, Coll Fisheries & Life Sci, Lab Fish Mol Immunol, Shanghai, Peoples R China.; Xu, TJ (corresponding author), Qingdao Natl Lab Marine Sci & Technol, Lab Marine Biol & Biotechnol, Qingdao, Peoples R China.; Hong, L (corresponding author), Tongji Univ, Sch Med, Shanghai, Peoples R China.; Xu, TJ (corresponding author), Key Lab Explorat & Utilizat Aquat Genet Resources, Minist Educ, Shanghai, Peoples R China.; Xu, TJ (corresponding author), Shanghai Ocean Univ, Natl Pathogen Collect Ctr Aquat Animals, Shanghai, Peoples R China.	hongling789@163.com; tianjunxu@163.com			National Natural Science Foundation of China [31802325, 31822057]; Open Fund of CAS Key Laboratory of Experimental Marine Biology, Institute of Oceanology, Chinese Academy of Sciences [KF2019NO1]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Open Fund of CAS Key Laboratory of Experimental Marine Biology, Institute of Oceanology, Chinese Academy of Sciences	Funding This study was supported by the National Natural Science Foundation of China (31802325 and 31822057) and Open Fund of CAS Key Laboratory of Experimental Marine Biology, Institute of Oceanology, Chinese Academy of Sciences (KF2019NO1).	Ahmed S, 2013, J IMMUNOL, V190, P2217, DOI 10.4049/jimmunol.1201630; Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; An HZ, 2006, IMMUNITY, V25, P919, DOI 10.1016/j.immuni.2006.10.014; Bakshi S, 2017, BIOCHEM J, V474, P1163, DOI 10.1042/BCJ20160992; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bi DK, 2017, MOL IMMUNOL, V83, P107, DOI 10.1016/j.molimm.2017.01.016; Carty M, 2006, NAT IMMUNOL, V7, P1074, DOI 10.1038/ni1382; Chin AR, 2016, CELL RES, V26, P217, DOI 10.1038/cr.2016.13; Chu Q, 2021, SCI CHINA LIFE SCI, V64, P803, DOI 10.1007/s11427-020-1777-y; Chu Q, 2017, J IMMUNOL, V198, P3274, DOI 10.4049/jimmunol.1602064; Chu Q, 2017, J BIOL CHEM, V292, P5282, DOI [10.1074/jbc.M117.777078, 10.1074/jbc.m117.777078]; Chu Q, 2017, DEV COMP IMMUNOL, V67, P117, DOI 10.1016/j.dci.2016.11.004; Fan S, 2008, J IMMUNOL, V180, P5373, DOI 10.4049/jimmunol.180.8.5373; Han JJ, 2016, FISH SHELLFISH IMMUN, V54, P419, DOI 10.1016/j.fsi.2016.04.126; Hirotani T, 2005, BIOCHEM BIOPH RES CO, V328, P383, DOI 10.1016/j.bbrc.2004.12.184; Hoebe K, 2003, NATURE, V424, P743, DOI 10.1038/nature01889; Huang BY, 2014, MOL BIOL REP, V41, P6481, DOI 10.1007/s11033-014-3531-9; Iliopoulos D, 2010, MOL CELL, V39, P493, DOI 10.1016/j.molcel.2010.07.023; Jiang JT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023271; John B, 2004, PLOS BIOL, V2, P1862, DOI 10.1371/journal.pbio.0020363; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; Lee RC, 2001, SCIENCE, V294, P862, DOI 10.1126/science.1065329; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Li SJ, 2020, CLIN SCI, V134, P1319, DOI 10.1042/CS20200249; Lin Q, 2011, J IMMUNOL, V186, P3710, DOI 10.4049/jimmunol.1003007; Liu Q, 2016, IMMUNOL CELL BIOL, V94, P538, DOI 10.1038/icb.2016.18; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Matsuo A, 2008, J IMMUNOL, V181, P3474, DOI 10.4049/jimmunol.181.5.3474; McClure C, 2017, IMMUNOL CELL BIOL, V95, P42, DOI 10.1038/icb.2016.63; Meylan E, 2004, NAT IMMUNOL, V5, P503, DOI 10.1038/ni1061; O'Connell RM, 2010, NAT REV IMMUNOL, V10, P111, DOI 10.1038/nri2708; Oshiumi H, 2003, NAT IMMUNOL, V4, P161, DOI 10.1038/ni886; Palsson-McDermott EM, 2009, NAT IMMUNOL, V10, P579, DOI 10.1038/ni.1727; Pasquinelli AE, 2000, NATURE, V408, P86, DOI 10.1038/35040556; Rauta PR, 2014, IMMUNOL LETT, V158, P14, DOI 10.1016/j.imlet.2013.11.013; Rusinov V, 2005, NUCLEIC ACIDS RES, V33, pW696, DOI 10.1093/nar/gki364; Ruvkun G, 2001, SCIENCE, V294, P797, DOI 10.1126/science.1066315; Sato S, 2003, J IMMUNOL, V171, P4304, DOI 10.4049/jimmunol.171.8.4304; Shahid S, 2018, NATURE, V553, P82, DOI 10.1038/nature25027; Sharma S, 2003, SCIENCE, V300, P1148, DOI 10.1126/science.1081315; Takeda K, 2004, SEMIN IMMUNOL, V16, P3, DOI 10.1016/j.smim.2003.10.003; Takeuchi O, 2010, CELL, V140, P805, DOI 10.1016/j.cell.2010.01.022; Tartey S, 2017, INT REV IMMUNOL, V36, P57, DOI 10.1080/08830185.2016.1261318; Tsutsui H, 2010, GASTROENT RES PRACT, V2010, DOI 10.1155/2010/641865; West AP, 2006, ANNU REV CELL DEV BI, V22, P409, DOI 10.1146/annurev.cellbio.21.122303.115827; Yamamoto M, 2002, NATURE, V420, P324, DOI 10.1038/nature01182; Yamamoto M, 2003, SCIENCE, V301, P640, DOI 10.1126/science.1087262; Yang CR, 2013, DEV COMP IMMUNOL, V41, P222, DOI 10.1016/j.dci.2013.05.018; Zhang KY, 2014, INT J ONCOL, V45, P950, DOI 10.3892/ijo.2014.2487; Zhang L, 2012, CELL RES, V22, P107, DOI 10.1038/cr.2011.158; Zhao XY, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00867; Zhou Z, 2015, CELL RES, V25, P39, DOI 10.1038/cr.2014.130; Zhu W, 2010, INT J CANCER, V127, P2520, DOI 10.1002/ijc.25260	54	0	0	5	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 9	2021	12								734520	10.3389/fimmu.2021.734520	http://dx.doi.org/10.3389/fimmu.2021.734520			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YA4KH	34956174	gold, Green Published			2022-12-18	WOS:000738303600001
J	Valdivia, E; Bertolin, M; Breda, C; Oliveira, MC; Salz, AK; Hofmann, N; Boergel, M; Blasczyk, R; Ferrari, S; Figueiredo, C				Valdivia, Emilio; Bertolin, Marina; Breda, Claudia; Carvalho Oliveira, Marco; Salz, Anna Katharina; Hofmann, Nicola; Boergel, Martin; Blasczyk, Rainer; Ferrari, Stefano; Figueiredo, Constanca			Genetic Modification of Limbal Stem Cells to Decrease Allogeneic Immune Responses	FRONTIERS IN IMMUNOLOGY			English	Article						limbal stem cell; RNA interference; HLA; limbal stem cell deficiency; allotransplantation; lentiviral vector; gene therapy	CORNEAL EPITHELIAL-CELLS; TRANSPLANTATION; REJECTION; MANAGEMENT; THERAPY; MARKER; FUTURE; RISK	Limbal stem cell (LSC) transplantation is the only efficient treatment for patients affected by LSC deficiency (LSCD). Allogeneic LSC transplantation is one of the most successful alternative for patients with bilateral LSCD. Nevertheless, the high variability of the human leukocyte antigens (HLA) remains a relevant obstacle to long-term allogeneic graft survival. This study characterized the immunologic properties of LSCs and proposed a genetic engineering strategy to reduce the immunogenicity of LSCs and of their derivatives. Hence, LSC HLA expression was silenced using lentiviral vectors encoding for short hairpin (sh) RNAs targeting beta 2-microglobulin (beta 2M) or class II major histocompatibility complex transactivator (CIITA) to silence HLA class I and II respectively. Beside the constitutive expression of HLA class I, LSCs showed the capability to upregulate HLA class II expression under inflammatory conditions. Furthermore, LSCs demonstrated the capability to induce T-cell mediated immune responses. LSCs phenotypical and functional characteristics are not disturbed after genetic modification. However, HLA silenced LSC showed to prevent T cell activation, proliferation and cytotoxicity in comparison to fully HLA-expressing LSCs. Additionally; HLA-silenced LSCs were protected against antibody-mediated cellular-dependent cytotoxicity. Our data is a proof-of-concept of the feasibility to generate low immunogenic human LSCs without affecting their typical features. The use of low immunogenic LSCs may support for long-term survival of LSCs and their derivatives after allogeneic transplantation.	[Valdivia, Emilio; Carvalho Oliveira, Marco; Blasczyk, Rainer; Figueiredo, Constanca] Inst Transfus Med & Transplant Engn, Hannover, Germany; [Bertolin, Marina; Breda, Claudia; Ferrari, Stefano] Fdn Banca Occhi Veneto, Venice, Italy; [Salz, Anna Katharina; Hofmann, Nicola; Boergel, Martin] German Soc Tissue Transplantat DGFG, Hannover, Germany		Figueiredo, C (corresponding author), Inst Transfus Med & Transplant Engn, Hannover, Germany.	Figueiredo.constanca@mh-hannover.de		Bertolin, Marina/0000-0002-6941-8419				Abud Tulio B, 2017, J Ophthalmic Vis Res, V12, P81, DOI 10.4103/2008-322X.200156; Altan-Bonnet G, 2019, NAT REV IMMUNOL, V19, P205, DOI 10.1038/s41577-019-0131-x; Alter G, 2004, J IMMUNOL METHODS, V294, P15, DOI 10.1016/j.jim.2004.08.008; Armitage WJ, 2019, TRANSPLANTATION, V103, P2468, DOI 10.1097/TP.0000000000002938; Atallah MR, 2016, CLIN OPHTHALMOL, V10, P593, DOI 10.2147/OPTH.S83676; Bains KK, 2019, CONTACT LENS ANTERIO, V42, P350, DOI 10.1016/j.clae.2019.04.006; Ballios BG, 2018, CAN J OPHTHALMOL, V53, P314, DOI 10.1016/j.jcjo.2017.10.040; Beaver CM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089834; Borger AK, 2016, MOL MED, V22, P274, DOI 10.2119/molmed.2015.00235; Brunet M, 2016, THER DRUG MONIT, V38, pS21, DOI 10.1097/FTD.0000000000000253; Cunnusamy K, 2010, INVEST OPHTH VIS SCI, V51, P6566, DOI 10.1167/iovs.10-6161; Cunnusamy K, 2010, J IMMUNOL, V185, P4651, DOI 10.4049/jimmunol.1001576; de Oliveira LA, 2010, ARQ BRAS OFTALMOL, V73, P447, DOI 10.1590/S0004-27492010000500012; DeWolf S, 2017, J CLIN INVEST, V127, P2473, DOI 10.1172/JCI90595; Di Iorio E, 2005, P NATL ACAD SCI USA, V102, P9523, DOI 10.1073/pnas.0503437102; Di Iorio E, 2010, OCUL SURF, V8, P146, DOI 10.1016/S1542-0124(12)70225-2; Dua HS, 2000, SURV OPHTHALMOL, V44, P415, DOI 10.1016/S0039-6257(00)00109-0; Eslani M, 2017, CORNEA, V36, P26, DOI 10.1097/ICO.0000000000000970; Figueiredo C, 2012, TRANSPLANTATION, V94, P955, DOI 10.1097/00007890-201211271-01888; Figueiredo C, 2015, TISSUE ANTIGENS, V85, P443, DOI 10.1111/tan.12564; Figueiredo C, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-47780-7; Figueiredo C, 2019, J CELL MOL MED, V23, P5705, DOI 10.1111/jcmm.14484; Figueiredo C, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/796046; Garbutcheon-Singh KB, 2019, CURR EYE RES, V44, P1, DOI 10.1080/02713683.2018.1519834; Garces JC, 2017, OCHSNER J, V17, P46; Gonzalez G, 2018, WIRES DEV BIOL, V7, DOI 10.1002/wdev.303; Guo ZH, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19071982; Haagdorens M, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/9798374; Harthan JS, 2018, CLIN OPTOM, V10, P65, DOI 10.2147/OPTO.S144357; Kot M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20225680; Ksander BR, 2014, NATURE, V511, P353, DOI 10.1038/nature13426; Kumar S, 2018, IMMUNOLOGY, V154, P383, DOI 10.1111/imm.12921; Lee HJ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-32914-0; Machado JAL, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22031074; Li L, 2016, CHINESE MED J-PEKING, V129, P448, DOI 10.4103/0366-6999.176084; Li W, 2007, CELL RES, V17, P26, DOI 10.1038/sj.cr.7310137; Liu X, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00645; Ljubimov AV, 2014, INVEST OPHTH VIS SCI, V55; Luznik Z, 2017, CELL TISSUE BANK, V18, P461, DOI 10.1007/s10561-017-9632-7; Merli P, 2019, HAEMATOLOGICA, V104, P2314, DOI 10.3324/haematol.2019.216101; Nieto-Nicolau N, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287-019-1501-9; Norrick A, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287-021-02272-2; Notara M, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/8620172; Oliveira MC, 2020, J CELL MOL MED, V24, P5070, DOI 10.1111/jcmm.15136; Panda A, 2007, SURV OPHTHALMOL, V52, P375, DOI 10.1016/j.survophthal.2007.04.008; Paul S, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01124; Pellegrini G, 1997, LANCET, V349, P990, DOI 10.1016/S0140-6736(96)11188-0; Pellegrini G, 1999, J CELL BIOL, V145, P769, DOI 10.1083/jcb.145.4.769; Repique CJ, 2003, SCAND J IMMUNOL, V58, P15, DOI 10.1046/j.1365-3083.2003.01266.x; Royer DJ, 2018, INVEST OPHTH VIS SCI, V59, P1512, DOI 10.1167/iovs.17-23279; Sacchetti M, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/8086269; Samoila O, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.00043; Scozzi D, 2017, AM J TRANSPLANT, V17, P328, DOI 10.1111/ajt.13940; Selver OB, 2017, TURK OFTALMOL DERG, V47, P285, DOI 10.4274/tjo.72593; Shaharuddin B, 2017, STEM CELL TRANSL MED, V6, P761, DOI 10.5966/sctm.2016-0175; Sharma N, 2018, CLIN OPHTHALMOL, V12, P2103, DOI 10.2147/OPTH.S181035; Song LJ, 2019, HUM GENE THER, V30, P1336, DOI 10.1089/hum.2019.071; Squissato Victoria, 2015, BMJ Case Rep, V2015, DOI 10.1136/bcr-2015-210733; Tahvildari Maryam, 2018, Curr Ophthalmol Rep, V6, P266; Tan JCK, 2016, BRIT J OPHTHALMOL, V100, P944, DOI 10.1136/bjophthalmol-2015-307411; Taylor AW, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00037; Thrall SA, 2017, AM J HEALTH-SYST PH, V74, pS67, DOI 10.2146/ajhp160872; Uddin F, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01387; van Essen TH, 2015, PROG RETIN EYE RES, V46, P84, DOI 10.1016/j.preteyeres.2015.01.001; Vasania VS, 2011, EXP EYE RES, V92, P47, DOI 10.1016/j.exer.2010.11.001; Vazirani J, 2016, OCUL SURF, V14, P350, DOI 10.1016/j.jtos.2016.02.006; Wang HF, 2016, ANNU REV BIOCHEM, V85, P227, DOI 10.1146/annurev-biochem-060815-014607; Wiedemann P., 2013, RETINA-J RET VIT DIS, VFifth, P2058; Wiegmann B, 2014, BIOMATERIALS, V35, P8123, DOI 10.1016/j.biomaterials.2014.06.007; Yang LL, 2019, STEM CELL TRANSL MED, V8, P46, DOI 10.1002/sctm.18-0005; Yin J, 2018, SEMIN OPHTHALMOL, V33, P134, DOI 10.1080/08820538.2017.1353834; Yin XT, 2015, J IMMUNOL, V194, P4029, DOI 10.4049/jimmunol.1401922	72	0	0	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 9	2021	12								747357	10.3389/fimmu.2021.747357	http://dx.doi.org/10.3389/fimmu.2021.747357			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZH5QD	34956181	Green Published, gold			2022-12-18	WOS:000760992400001
J	Alahdal, M; Huang, RX; Duan, L; Zhiqin, D; Hongwei, O; Li, WC; Wang, DP				Alahdal, Murad; Huang, Rongxiang; Duan, Li; Zhiqin, Deng; Hongwei, Ouyang; Li, Wencui; Wang, Daping			Indoleamine 2, 3 Dioxygenase 1 Impairs Chondrogenic Differentiation of Mesenchymal Stem Cells in the Joint of Osteoarthritis Mice Model	FRONTIERS IN IMMUNOLOGY			English	Article						osteoarthritis; cartilage regeneration; IDO1 inhibitor; MSCs; miR-122-5p	BETA-CATENIN; MOUSE MODEL; ARTHRITIS; IDO2	Osteoarthritis (OA) is a serious joint inflammation that leads to cartilage degeneration and joint dysfunction. Mesenchymal stem cells (MSCs) are used as a cell-based therapy that showed promising results in promoting cartilage repair. However, recent studies and clinical trials explored unsatisfied outcomes because of slow chondrogenic differentiation and increased calcification without clear reasons. Here, we report that the overexpression of indoleamine 2,3 dioxygenase 1 (IDO1) in the synovial fluid of OA patients impairs chondrogenic differentiation of MSCs in the joint of the OA mice model. The effect of MSCs mixed with IDO1 inhibitor on the cartilage regeneration was tested compared to MSCs mixed with IDO1 in the OA animal model. Further, the mechanism exploring the effect of IDO1 on chondrogenic differentiation was investigated. Subsequently, miRNA transcriptome sequencing was performed for MSCs cocultured with IDO1, and then TargetScan was used to verify the target of miR-122-5p in the SF-MSCs. Interestingly, we found that MSCs mixed with IDO1 inhibitor showed a significant performance to promote cartilage regeneration in the OA animal model, while MSCs mixed with IDO1 failed to stimulate cartilage regeneration. Importantly, the overexpression of IDO1 showed significant inhibition to Sox9 and Collagen type II (COL2A1) through activating the expression of beta-catenin, since inhibiting of IDO1 significantly promoted chondrogenic signaling of MSCs (Sox9, COL2A1, Aggrecan). Further, miRNA transcriptome sequencing of SF-MSCs that treated with IDO1 showed significant downregulation of miR-122-5p which perfectly targets Wnt1. The expression of Wnt1 was noticed high when IDO1 was overexpressed. In summary, our results suggest that IDO1 overexpression in the synovial fluid of OA patients impairs chondrogenic differentiation of MSCs and cartilage regeneration through downregulation of miR-122-5p that activates the Wnt1/beta-catenin pathway.	[Alahdal, Murad; Huang, Rongxiang; Zhiqin, Deng; Li, Wencui] Shenzhen Univ, Hosp Affiliated 1, Shenzhen Peoples Hosp 2, Hand & Foot Surg Dept, Shenzhen, Peoples R China; [Alahdal, Murad; Duan, Li; Wang, Daping] Shenzhen Univ, Hosp Affiliated 1, Shenzhen Peoples Hosp 2,Hlth Sci Ctr,Shenzhen Lab, Guangdong Prov Res Ctr Artificial Intelligence &, Shenzhen, Peoples R China; [Hongwei, Ouyang; Wang, Daping] Zhejiang Univ, Sch Med, Dr Li Dak Sum & Yip Yio Chin Ctr Stem Cells & Reg, Hangzhou, Peoples R China	Shenzhen University; Shenzhen University; Zhejiang University	Li, WC (corresponding author), Shenzhen Univ, Hosp Affiliated 1, Shenzhen Peoples Hosp 2, Hand & Foot Surg Dept, Shenzhen, Peoples R China.; Wang, DP (corresponding author), Shenzhen Univ, Hosp Affiliated 1, Shenzhen Peoples Hosp 2,Hlth Sci Ctr,Shenzhen Lab, Guangdong Prov Res Ctr Artificial Intelligence &, Shenzhen, Peoples R China.; Hongwei, O; Wang, DP (corresponding author), Zhejiang Univ, Sch Med, Dr Li Dak Sum & Yip Yio Chin Ctr Stem Cells & Reg, Hangzhou, Peoples R China.	hwoy@zju.edu.cn; 13923750767@163.com; wangdp@mail.sustech.edu.cn	Alahdal, Murad/AAO-2213-2020	Alahdal, Murad/0000-0003-1444-6014				Alahdal M, 2020, AM J TRANSL RES, V12, P2322; Alahdal M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28238-8; Barry F, 2019, J ORTHOP RES, V37, P1229, DOI 10.1002/jor.24343; Bell DM, 1997, NAT GENET, V16, P174, DOI 10.1038/ng0697-174; Buhrmann C, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3065; Byrnes CC, 2019, MOL CANCER RES, V17, P299, DOI 10.1158/1541-7786.MCR-18-0460; Criado G, 2009, ARTHRITIS RHEUM-US, V60, P1342, DOI 10.1002/art.24446; Diekman BO, 2013, CURR OPIN RHEUMATOL, V25, P119, DOI 10.1097/BOR.0b013e32835aa28d; Fang M, 2014, ARTERIOSCL THROM VAS, V34, P2601, DOI 10.1161/ATVBAHA.114.304579; Gupta PK, 2012, STEM CELL RES THER, V3, DOI 10.1186/scrt116; Huang XJ, 2014, BIOCHEM BIOPH RES CO, V453, P810, DOI 10.1016/j.bbrc.2014.10.021; Hunter DJ, 2019, LANCET, V393, P1745, DOI 10.1016/S0140-6736(19)30417-9; Im GI, 2018, BIODRUGS, V32, P183, DOI 10.1007/s40259-018-0276-3; Jiang YZ, 2015, NAT REV RHEUMATOL, V11, P206, DOI 10.1038/nrrheum.2014.200; Kazi A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07644-6; Kon E, 2012, CURR REV MUSCULOSKE, V5, P236, DOI 10.1007/s12178-012-9135-x; Kormish JD, 2010, DEV DYNAM, V239, P56, DOI 10.1002/dvdy.22046; Le HX, 2020, J TISSUE ENG, V11, DOI 10.1177/2041731420943839; Makris EA, 2015, NAT REV RHEUMATOL, V11, P21, DOI 10.1038/nrrheum.2014.157; Merlo LMF, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01861; Merlo LMF, 2017, CLIN IMMUNOL, V179, P8, DOI 10.1016/j.clim.2017.01.016; Merlo LMF, 2014, J IMMUNOL, V192, P2082, DOI 10.4049/jimmunol.1303012; Neybecker P, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287-018-1071-2; Parada-Turska J, 2013, J RHEUMATOL, V40, P903, DOI 10.3899/jrheum.121035; Pigott E, 2014, AUTOIMMUNITY, V47, P409, DOI 10.3109/08916934.2014.914507; Shen SY, 2019, ANN RHEUM DIS, V78, P826, DOI 10.1136/annrheumdis-2018-214786; Sineva GS, 2010, BIOL CELL, V102, P549, DOI 10.1042/BC20100016; Szanto S, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2205; Tew SR, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2311; Thomas E, 2014, RHEUMATOLOGY, V53, P338, DOI 10.1093/rheumatology/ket346; Wallace IJ, 2017, P NATL ACAD SCI USA, V114, P9332, DOI 10.1073/pnas.1703856114; Williams RO, 2013, INT J TRYPTOPHAN RES, P67, DOI 10.4137/IJTR.S11737; Zhou YC, 2017, CURR RHEUMATOL REP, V19, DOI 10.1007/s11926-017-0679-z	33	0	0	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 8	2021	12								781185	10.3389/fimmu.2021.781185	http://dx.doi.org/10.3389/fimmu.2021.781185			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XS3NW	34956209	Green Published, gold			2022-12-18	WOS:000732820900001
J	Clinton, M; Krol, E; Sepulveda, D; Andersen, NR; Brierley, AS; Ferrier, DEK; Hansen, PJ; Lorenzen, N; Martin, SAM				Clinton, Morag; Krol, Elzbieta; Sepulveda, Dagoberto; Andersen, Nikolaj R.; Brierley, Andrew S.; Ferrier, David E. K.; Hansen, Per Juel; Lorenzen, Niels; Martin, Samuel A. M.			Gill Transcriptomic Responses to Toxin-producing Alga Prymnesium parvum in Rainbow Trout	FRONTIERS IN IMMUNOLOGY			English	Article						gill health; gill inflammation; microarray; cytokines; hypoxia; harmful algal bloom (HAB); golden alga	SALMON SALMO-SALAR; ATLANTIC SALMON; FISH MORTALITY; IL-10 FAMILY; GOLDEN ALGA; INFLAMMATION; BLOOMS; ACID; SUSCEPTIBILITY; IDENTIFICATION	The gill of teleost fish is a multifunctional organ involved in many physiological processes, including protection of the mucosal gill surface against pathogens and other environmental antigens by the gill-associated lymphoid tissue (GIALT). Climate change associated phenomena, such as increasing frequency and magnitude of harmful algal blooms (HABs) put extra strain on gill function, contributing to enhanced fish mortality and fish kills. However, the molecular basis of the HAB-induced gill injury remains largely unknown due to the lack of high-throughput transcriptomic studies performed on teleost fish in laboratory conditions. We used juvenile rainbow trout (Oncorhynchus mykiss) to investigate the transcriptomic responses of the gill tissue to two (high and low) sublethal densities of the toxin-producing alga Prymnesium parvum, in relation to non-exposed control fish. The exposure time to P. parvum (4-5 h) was sufficient to identify three different phenotypic responses among the exposed fish, enabling us to focus on the common gill transcriptomic responses to P. parvum that were independent of dose and phenotype. The inspection of common differentially expressed genes (DEGs), canonical pathways, upstream regulators and downstream effects pointed towards P. parvum-induced inflammatory response and gill inflammation driven by alterations of Acute Phase Response Signalling, IL-6 Signalling, IL-10 Signalling, Role of PKR in Interferon Induction and Antiviral Response, IL-8 Signalling and IL-17 Signalling pathways. While we could not determine if the inferred gill inflammation was progressing or resolving, our study clearly suggests that P. parvum blooms may contribute to the serious gill disorders in fish. By providing insights into the gill transcriptomic responses to toxin-producing P. parvum in teleost fish, our research opens new avenues for investigating how to monitor and mitigate toxicity of HABs before they become lethal.	[Clinton, Morag; Krol, Elzbieta; Martin, Samuel A. M.] Univ Aberdeen, Sch Biol Sci, Aberdeen, Scotland; [Clinton, Morag; Brierley, Andrew S.; Ferrier, David E. K.] Univ St Andrews, Scottish Oceans Inst, St Andrews, Fife, Scotland; [Clinton, Morag] Univ Alaska Fairbanks, Dept Vet Med, Fairbanks, AK USA; [Sepulveda, Dagoberto; Lorenzen, Niels] Tech Univ Denmark, Natl Inst Aquat Resources, Lyngby, Denmark; [Andersen, Nikolaj R.] Aarhus Univ, Dept Biosci, Roskilde, Denmark; [Hansen, Per Juel] Univ Copenhagen, Dept Biol, Marine Biol Sect, Helsingor, Denmark	University of Aberdeen; University of St Andrews; University of Alaska System; University of Alaska Fairbanks; Technical University of Denmark; Aarhus University; University of Copenhagen	Martin, SAM (corresponding author), Univ Aberdeen, Sch Biol Sci, Aberdeen, Scotland.	sam.martin@abdn.ac.uk	Hansen, Per Juel/AAX-6193-2020; Hansen, Per J/E-9969-2011; Ferrier, David/D-7595-2013; Brierley, Andrew/G-8019-2011	Hansen, Per Juel/0000-0003-0228-9621; Hansen, Per J/0000-0003-0228-9621; Ferrier, David/0000-0003-3247-6233; Sepulveda, Dagoberto/0000-0001-8553-5861; Brierley, Andrew/0000-0002-6438-6892; Clinton, Morag/0000-0002-6600-8078				Andersen NG, 2016, DIS AQUAT ORGAN, V117, P187, DOI 10.3354/dao02946; Anttila K, 2015, J EXP BIOL, V218, P1471, DOI 10.1242/jeb.119115; BAGGIOLINI M, 1992, FEBS LETT, V307, P97, DOI 10.1016/0014-5793(92)80909-Z; Barnabei L, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.716469; Bayne CJ, 2001, DEV COMP IMMUNOL, V25, P725, DOI 10.1016/S0145-305X(01)00033-7; Bergsson H, 2019, FISHES-BASEL, V4, DOI 10.3390/fishes4020032; Bernhard S, 2021, J INNATE IMMUN, V13, P225, DOI 10.1159/000514885; Bertin MJ, 2014, AQUAT TOXICOL, V146, P1, DOI 10.1016/j.aquatox.2013.09.026; Bertin MJ, 2012, HARMFUL ALGAE, V20, P111, DOI 10.1016/j.hal.2012.08.005; Beszteri S, 2012, HARMFUL ALGAE, V18, P1, DOI 10.1016/j.hal.2012.03.003; Bhunia A, 2010, J BIOL CHEM, V285, P3883, DOI 10.1074/jbc.M109.065672; Binzer SB, 2019, HARMFUL ALGAE, V81, P10, DOI 10.1016/j.hal.2018.11.010; Blanco J, 2002, AQUAT TOXICOL, V60, P111, DOI 10.1016/S0166-445X(01)00274-0; Blossom HE, 2014, AQUAT TOXICOL, V157, P159, DOI 10.1016/j.aquatox.2014.10.006; Boerlage AS, 2020, REV AQUACULT, V12, P2140, DOI 10.1111/raq.12426; Bradner JE, 2017, CELL, V168, P629, DOI 10.1016/j.cell.2016.12.013; Breitburg D, 2018, SCIENCE, V359, P46, DOI 10.1126/science.aam7240; Browning CL, 2021, NANOTOXICOLOGY, V15, P400, DOI 10.1080/17435390.2021.1874562; Camacho C, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-421; Piazzon MC, 2019, BMC GENOMICS, V20, DOI 10.1186/s12864-019-5581-9; Castro R, 2015, SCI REP-UK, V5, DOI 10.1038/srep15458; Cheedipudi SM, 2020, CARDIOVASC RES, V116, P1199, DOI 10.1093/cvr/cvz199; Clinton M, 2021, ICES J MAR SCI, V78, P1557, DOI 10.1093/icesjms/fsaa254; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Dong C, 2021, ANNU REV IMMUNOL, V39, P51, DOI 10.1146/annurev-immunol-061020-053702; Dorantes-Aranda JJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133549; Elias A, 2018, BEHAVIOUR, V155, P205, DOI 10.1163/1568539X-00003483; Enders EC, 2016, J FISH BIOL, V88, P344, DOI 10.1111/jfb.12786; Evans DH, 2005, PHYSIOL REV, V85, P97, DOI 10.1152/physrev.00050.2003; Flood SL, 2018, HARMFUL ALGAE, V75, P57, DOI 10.1016/j.hal.2018.04.006; Foyle KL, 2020, FRONT MAR SCI, V7, DOI 10.3389/fmars.2020.00400; Franco ME, 2019, AQUAT TOXICOL, V213, DOI [10.1016/j.aquatox.2019.05.016, 10.101]; Gobler CJ, 2020, HARMFUL ALGAE, V91, DOI 10.1016/j.hal.2019.101731; Grover JP, 2013, WATER RES, V47, P4274, DOI 10.1016/j.watres.2013.05.001; Hill BN, 2020, HARMFUL ALGAE, V93, DOI 10.1016/j.hal.2020.101795; James SV, 2011, J PLANKTON RES, V33, P265, DOI 10.1093/plankt/fbq082; Johnsen TM, 2010, J AM WATER RESOUR AS, V46, P6, DOI 10.1111/j.1752-1688.2009.00386.x; Jonsson PR, 2009, P NATL ACAD SCI USA, V106, P11177, DOI 10.1073/pnas.0900964106; Kintner A, 2019, J MAR BIOL ASSOC UK, V99, P539, DOI 10.1017/S002531541800022X; Kleinow Kevin M., 2008, P55, DOI 10.1201/9780203647295.ch3; Koppang EO., 2015, MUCOSAL HLTH AQUACUL, V1, P93, DOI [DOI 10.1016/B978-0-12-417186-2.00005-4, 10.1016/B978-0-12-417186-2.00005-4]; Kragh ML, 2020, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.03132; Krol E, 2020, FRONT GENET, V11, DOI 10.3389/fgene.2020.00610; Krol E, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-2473-0; Lahiani A, 2017, TOXINS, V9, DOI 10.3390/toxins9030107; Lawrence T, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a001651; LeBlanc F, 2019, J FISH DIS, V42, P315, DOI 10.1111/jfd.12922; Levi M, 2003, CARDIOVASC RES, V60, P26, DOI 10.1016/S0008-6363(02)00857-X; Li XX, 2019, NAT IMMUNOL, V20, P1594, DOI 10.1038/s41590-019-0514-y; Lindholm T, 1999, HYDROBIOLOGIA, V397, P109, DOI 10.1023/A:1003667728458; Lord JM, 1999, CELL MICROBIOL, V1, P85, DOI 10.1046/j.1462-5822.1999.00015.x; Manning SR, 2010, MAR DRUGS, V8, P678, DOI 10.3390/md8030678; Martin SAM, 2016, DEV COMP IMMUNOL, V64, P103, DOI 10.1016/j.dci.2016.03.014; McIntyre JK, 2018, ENVIRON POLLUT, V238, P196, DOI 10.1016/j.envpol.2018.03.012; Metcalfe NB, 2016, J FISH BIOL, V88, P298, DOI 10.1111/jfb.12699; Montgomery MT, 2020, AM J RESP CELL MOL, V63, P172, DOI 10.1165/rcmb.2019-0454OC; Moore SK, 2008, ENVIRON HEALTH-GLOB, V7, DOI 10.1186/1476-069X-7-S2-S4; Murakami M, 2019, IMMUNITY, V50, P812, DOI 10.1016/j.immuni.2019.03.027; Neurath MF, 2019, SEMIN IMMUNOPATHOL, V41, P627, DOI 10.1007/s00281-019-00771-2; Nilsson GE, 2007, J EXP BIOL, V210, P2403, DOI 10.1242/jeb.000281; Oakley RH, 2013, J ALLERGY CLIN IMMUN, V132, P1033, DOI 10.1016/j.jaci.2013.09.007; Ouyang WJ, 2019, IMMUNITY, V50, P871, DOI 10.1016/j.immuni.2019.03.020; Ouyang WJ, 2011, ANNU REV IMMUNOL, V29, P71, DOI 10.1146/annurev-immunol-031210-101312; Pinsky ML, 2013, SCIENCE, V341, P1239, DOI 10.1126/science.1239352; Pooley NJ, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-747; Powell MD, 2005, DIS AQUAT ORGAN, V63, P169, DOI 10.3354/dao063169; Qin JL, 2020, HARMFUL ALGAE, V96, DOI 10.1016/j.hal.2020.101844; R Core Team, 2021, R LANG ENV STAT COMP; Remmel EJ, 2012, ECOL LETT, V15, P126, DOI 10.1111/j.1461-0248.2011.01718.x; Resseguier J, 2020, BIOLOGY-BASEL, V9, DOI 10.3390/biology9060127; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Robertsen G, 2019, ECOL EVOL, V9, P212, DOI 10.1002/ece3.4716; Rodger H. D., 2007, Fish Veterinary Journal, P38; Sales CF, 2017, FISH SHELLFISH IMMUN, V68, P10, DOI 10.1016/j.fsi.2017.07.001; Salinas I, 2021, DEV COMP IMMUNOL, V121, DOI 10.1016/j.dci.2021.104079; Salinas Irene, 2015, Biology-Basel, V4, P525, DOI 10.3390/biology4030525; Sandvig K, 2005, GENE THER, V12, P865, DOI 10.1038/sj.gt.3302525; Sanjabi S, 2009, CURR OPIN PHARMACOL, V9, P447, DOI 10.1016/j.coph.2009.04.008; Schug KA, 2010, J AM WATER RESOUR AS, V46, P33, DOI 10.1111/j.1752-1688.2009.00389.x; Serhan CN, 2020, MOL ASPECTS MED, V74, DOI 10.1016/j.mam.2020.100894; SHILO M, 1967, BACTERIOL REV, V31, P180, DOI 10.1128/MMBR.31.3.180-193.1967; Song Y, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-694; Southard GM, 2010, J AM WATER RESOUR AS, V46, P14, DOI 10.1111/j.1752-1688.2009.00387.x; Svendsen MBS, 2018, FISHES-BASEL, V3, DOI 10.3390/fishes3010011; Tarnawski AS, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10081964; Taylor RB, 2021, CHEMOSPHERE, V263, DOI 10.1016/j.chemosphere.2020.127927; Taylor RB, 2020, SCI TOTAL ENVIRON, V715, DOI 10.1016/j.scitotenv.2020.136835; Tillmann U, 2003, AQUAT MICROB ECOL, V32, P73, DOI 10.3354/ame032073; Timmermans S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01545; Wang M, 2019, INT IMMUNOPHARMACOL, V75, DOI 10.1016/j.intimp.2019.105792; Wang Y, 2021, GENES-BASEL, V12, DOI 10.3390/genes12020255; Wells ML, 2020, HARMFUL ALGAE, V91, DOI 10.1016/j.hal.2019.101632; West AC, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.669889; Wood CM, 2021, COMP BIOCHEM PHYS A, V254, DOI 10.1016/j.cbpa.2021.110895; Yu JJ, 2008, FRONT BIOSCI-LANDMRK, V13, P170, DOI 10.2741/2667; Zou Jun, 2016, Biology-Basel, V5, P23, DOI 10.3390/biology5020023	96	0	0	7	11	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 8	2021	12								794593	10.3389/fimmu.2021.794593	http://dx.doi.org/10.3389/fimmu.2021.794593			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XS3OC	34956228	Green Published, gold			2022-12-18	WOS:000732821500001
J	Grumach, AS; Veronez, CL; Csuka, D; Farkas, H				Grumach, Anete S.; Veronez, Camila L.; Csuka, Dorottya; Farkas, Henriette			Angioedema Without Wheals: Challenges in Laboratorial Diagnosis	FRONTIERS IN IMMUNOLOGY			English	Review						hereditary angioedema (HAE); angioedema without wheals; C1 inhibitor (C1-INH); C4; biomarker; diagnosis	HEREDITARY ANGIONEUROTIC-EDEMA; MOLECULAR-WEIGHT KININOGEN; C1 INHIBITOR DEFICIENCY; ACQUIRED ANGIOEDEMA; BRADYKININ; PLASMA; ACTIVATION; DISEASE; SYSTEM; ASSAY	Angioedema is a prevailing symptom in different diseases, frequently occurring in the presence of urticaria. Recurrent angioedema without urticaria (AE) can be hereditary (HAE) and acquired (AAE), and several subtypes can be distinguished, although clinical presentation is quite similar in some of them. They present with subcutaneous and mucosal swellings, affecting extremities, face, genitals, bowels, and upper airways. AE is commonly misdiagnosed due to restricted access and availability of appropriate laboratorial tests. HAE with C1 inhibitor defect is associated with quantitative and/or functional deficiency. Although bradykinin-mediated disease results mainly from disturbance in the kallikrein-kinin system, traditionally complement evaluation has been used for diagnosis. Diagnosis is established by nephelometry, turbidimetry, or radial immunodiffusion for quantitative measurement of C1 inhibitor, and chromogenic assay or ELISA has been used for functional C1-INH analysis. Wrong handling of the samples can lead to misdiagnosis and, consequently, mistaken inappropriate approaches. Dried blood spot (DBS) tests have been used for decades in newborn screening for certain metabolic diseases, and there has been growing interest in their use for other congenital conditions. Recently, DBS is now proposed as an efficient tool to diagnose HAE with C1 inhibitor deficiency, and its use would improve the access to outbound areas and family members. Regarding HAE with normal C1 inhibitor, complement assays' results are normal and the genetic sequencing of target genes, such as exon 9 of F12 and PLG, is the only available method. New methods to measure cleaved high-molecular-weight kininogen and activated plasma kallikrein have emerged as potential biochemical tests to identify bradykinin-mediated angioedema. Validated biomarkers of kallikrein-kinin system activation could be helpful in differentiating mechanisms of angioedema. Our aim is to focus on the capability to differentiate histaminergic AE from bradykinin-mediated AE. In addition, we will describe the challenges developing specific tests like direct bradykinin measurements. The need for quality tests to improve the diagnosis is well represented by the variability of results in functional assays.	[Grumach, Anete S.] Ctr Univ Fac Med ABC FMABC, Fac Med, Clin Immunol, Santo Andre, SP, Brazil; [Veronez, Camila L.] Univ Calif San Diego, Dept Med, Div Rheumatol Allergy & Immunol, San Diego, CA 92103 USA; [Veronez, Camila L.] San Diego Vet Affairs Healthcare, Res Serv, San Diego, CA USA; [Csuka, Dorottya; Farkas, Henriette] Semmelweis Univ, Dept Internal Med & Haematol, Hungarian Angioedema Ctr Reference & Excellence, Budapest, Hungary	University of California System; University of California San Diego; Semmelweis University	Farkas, H (corresponding author), Semmelweis Univ, Dept Internal Med & Haematol, Hungarian Angioedema Ctr Reference & Excellence, Budapest, Hungary.	farkas.henriette@med.semmelweis-univ.hu	Veronez, Camila Lopes/O-6134-2015	Veronez, Camila Lopes/0000-0001-9565-1911	National Research Development and Innovation Office (NRDIO) [K124557]	National Research Development and Innovation Office (NRDIO)(National Research, Development & Innovation Office (NRDIO) - Hungary)	Funding HF was supported by the National Research Development and Innovation Office (NRDIO) Grant No: K124557.	Agostoni A, 2004, J ALLERGY CLIN IMMUN, V114, pS51, DOI 10.1016/j.jaci.2004.06.047; ALSENZ J, 1987, NEW ENGL J MED, V316, P1360, DOI 10.1056/NEJM198705283162202; Ariano A, 2020, ALLERGY, V75, P2989, DOI 10.1111/all.14454; Bafunno V, 2018, J ALLERGY CLIN IMMUN, V141, P1009, DOI 10.1016/j.jaci.2017.05.020; Balla Z, 2021, J ALLER CL IMM-PRACT, V9, P947, DOI 10.1016/j.jaip.2020.08.052; Banerji A, 2008, ANN ALLERG ASTHMA IM, V100, P327, DOI 10.1016/S1081-1206(10)60594-7; Barbosa AA, 2019, ALLERGY ASTHMA PROC, V40, P193, DOI 10.2500/aap.2019.40.4207; Baroso R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163958; Betschel S, 2019, ALLERGY ASTHMA CL IM, V15, DOI 10.1186/s13223-019-0376-8; Binkley KE, 2000, J ALLERGY CLIN IMMUN, V106, P546; Bjorkqvist J, 2015, J CLIN INVEST, V125, P3132, DOI 10.1172/JCI77139; Bork K, 2000, LANCET, V356, P213, DOI 10.1016/S0140-6736(00)02483-1; Bork K, 2018, ALLERGY, V73, P442, DOI 10.1111/all.13270; Bork K, 2021, J ALLERGY CLIN IMMUN, V148, P1041, DOI 10.1016/j.jaci.2021.01.011; Bork K, 2019, ALLERGY, V74, P2479, DOI 10.1111/all.13869; Bork K, 2019, ORPHANET J RARE DIS, V14, DOI 10.1186/s13023-019-1043-3; Bucher MC, 2017, CLIN TRANSL ALLERGY, V7, DOI 10.1186/s13601-017-0164-9; Butler TAJ, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/5214821; Castelli R, 2007, HAEMATOL-HEMATOL J, V92, P716, DOI 10.3324/haematol.10769; CAT R, 1993, EUR J PEDIATR, V152, P205, DOI 10.1007/BF01956145; Cicardi M, 2014, ALLERGY, V69, P602, DOI 10.1111/all.12380; Cicardi M, 1996, CLIN EXP IMMUNOL, V106, P475, DOI 10.1046/j.1365-2249.1996.d01-866.x; Cichon S, 2006, AM J HUM GENET, V79, P1098, DOI 10.1086/509899; Cyr M, 2001, AM J PHYSIOL-HEART C, V281, pH275, DOI 10.1152/ajpheart.2001.281.1.H275; D'Incan M, 1999, DERMATOLOGY, V199, P227, DOI 10.1159/000018252; Defendi F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070140; Dewald G, 2006, BIOCHEM BIOPH RES CO, V343, P1286, DOI 10.1016/j.bbrc.2006.03.092; DONALDSON VH, 1963, AM J MED, V35, P37, DOI 10.1016/0002-9343(63)90162-1; DONALDSON VH, 1966, PEDIATRICS, V37, P1017; Engel R, 2015, J IMMUNOL METHODS, V426, P114, DOI 10.1016/j.jim.2015.08.011; Farkas H, 2017, ALLERGY, V72, P300, DOI 10.1111/all.13001; Farkas H, 2021, GENES-BASEL, V12, DOI 10.3390/genes12030402; Farkas H, 2016, ANN ALLERG ASTHMA IM, V117, P508, DOI 10.1016/j.anai.2016.08.025; Ghannam A, 2015, ALLERGY, V70, P1103, DOI 10.1111/all.12657; Gompels MM, 2007, ANN CLIN BIOCHEM, V44, P75, DOI 10.1258/000456307779596020; Grumach AS, 2014, SCAND J IMMUNOL, V79, P276, DOI 10.1111/sji.12154; Ivanov I, 2019, BLOOD, V133, P1152, DOI 10.1182/blood-2018-06-860270; JACKSON J, 1986, NATURE, V323, P722, DOI 10.1038/323722a0; JOHNSON U, 1983, ACTA PATH MICRO IM C, V91, P147; Joseph K, 2015, ALLERGY, V70, P115, DOI 10.1111/all.12520; Joseph K, 2013, J ALLERGY CLIN IMMUN, V132, P470, DOI 10.1016/j.jaci.2013.03.026; Kaplan AP, 2017, FRONT MED-LAUSANNE, V4, DOI 10.3389/fmed.2017.00206; Lai YQ, 2021, J PHARMACEUT BIOMED, V195, DOI 10.1016/j.jpba.2020.113844; Lai YQ, 2020, CLIN CHIM ACTA, V504, P155, DOI 10.1016/j.cca.2020.02.010; Lara-Marquez ML, 2018, CLIN EXP ALLERGY, V48, P1429, DOI 10.1111/cea.13219; Larrauri B, 2020, MOL IMMUNOL, V119, P27, DOI 10.1016/j.molimm.2020.01.003; Li HH, 2015, J ALLER CL IMM-PRACT, V3, P200, DOI 10.1016/j.jaip.2014.08.002; Lopez-Lera A, 2019, CLIN EXP IMMUNOL, V198, P341, DOI 10.1111/cei.13361; Magerl M, 2020, ORPHANET J RARE DIS, V15, DOI 10.1186/s13023-020-01506-5; Marceau F, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.00358; Maurer M, 2018, ALLERGY, V73, P1575, DOI 10.1111/all.13384; McDonough AA, 2015, AM J PHYSIOL-CELL PH, V308, pC426, DOI 10.1152/ajpcell.00400.2014; McGreal EP, 2012, IMMUNOBIOLOGY, V217, P176, DOI 10.1016/j.imbio.2011.07.027; Nettis E, 2019, ALLERGY, V74, P1389, DOI 10.1111/all.13737; Nussberger J, 1998, LANCET, V351, P1693, DOI 10.1016/S0140-6736(97)09137-X; Osler W, 2010, AM J MED SCI, V339, P175, DOI 10.1097/MAJ.0b013e3181b2803f; Pereira KMC, 2016, RHEUMATOLOGY, V55, P869, DOI 10.1093/rheumatology/kev436; Prohaszka Z, 2016, IMMUNOBIOLOGY, V221, P1247, DOI 10.1016/j.imbio.2016.06.008; ROSEN FS, 1965, SCIENCE, V148, P957, DOI 10.1126/science.148.3672.957; SAAMELI K, 1962, AM J PHYSIOL, V203, P261, DOI 10.1152/ajplegacy.1962.203.2.261; Sabate-Bresco M, 2021, J ALLER CL IMM-PRACT, V9, P2284, DOI 10.1016/j.jaip.2021.03.038; Suffritti C, 2014, CLIN EXP ALLERGY, V44, P1503, DOI 10.1111/cea.12293; Varga L, 2007, MOL IMMUNOL, V44, P1454, DOI 10.1016/j.molimm.2006.04.020; Veronez CL, 2021, J ALLER CL IMM-PRACT, V9, P2293, DOI 10.1016/j.jaip.2020.11.039; Veronez CL, 2017, ANN ALLERG ASTHMA IM, V118, P743, DOI 10.1016/j.anai.2017.04.014; Wagenaar-Bos IGA, 2008, J IMMUNOL METHODS, V338, P14, DOI 10.1016/j.jim.2008.06.004; Wu MA, 2016, CLIN CHEM LAB MED, V54, P207, DOI 10.1515/cclm-2015-0195; Zanichelli A, 2017, J ALLER CL IMM-PRACT, V5, P1307, DOI 10.1016/j.jaip.2016.12.032; Zanichelli A, 2016, ANN ALLERG ASTHMA IM, V117, P394, DOI 10.1016/j.anai.2016.08.014; Zhang GD, 2017, BIOANALYSIS, V9, P1477, DOI 10.4155/bio-2017-0105; Zingale LC, 2006, CAN MED ASSOC J, V175, P1065, DOI 10.1503/cmaj.060535	71	0	0	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 8	2021	12								785736	10.3389/fimmu.2021.785736	http://dx.doi.org/10.3389/fimmu.2021.785736			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XS2CL	34956216	gold, Green Published			2022-12-18	WOS:000732723200001
J	Lai, YH; Tsai, BY; Hsu, CY; Chen, YH; Chou, PH; Chen, YL; Liu, HC; Ko, WC; Tsai, PJ; Hung, YP				Lai, Yi-Hsin; Tsai, Bo-Yang; Hsu, Chih-Yu; Chen, Yi-Hsuan; Chou, Po-Han; Chen, Yueh-Lin; Liu, Hsiao-Chieh; Ko, Wen-Chien; Tsai, Pei-Jane; Hung, Yuan-Pin			The Role of Toll-Like Receptor-2 in Clostridioides difficile Infection: Evidence From a Mouse Model and Clinical Patients (vol 12, 691039, 2021)	FRONTIERS IN IMMUNOLOGY			English	Correction						Clostridioides difficile infection; toll-like receptor; TLR2; rs3804099; tight junction; mouse model			[Lai, Yi-Hsin; Tsai, Bo-Yang; Tsai, Pei-Jane] Natl Cheng Kung Univ, Inst Basic Med Sci, Coll Med, Tainan, Taiwan; [Hsu, Chih-Yu; Chen, Yi-Hsuan; Chou, Po-Han; Chen, Yueh-Lin; Tsai, Pei-Jane] Natl Cheng Kung Univ, Dept Med Lab Sci & Biotechnol, Tainan, Taiwan; [Liu, Hsiao-Chieh; Ko, Wen-Chien; Hung, Yuan-Pin] Natl Cheng Kung Univ Hosp, Dept Internal Med, Tainan, Taiwan; [Liu, Hsiao-Chieh; Hung, Yuan-Pin] Tainan Hosp, Dept Internal Med, Minist Hlth & Welf, Tainan, Taiwan; [Ko, Wen-Chien; Hung, Yuan-Pin] Natl Cheng Kung Univ, Coll Med, Dept Med, Tainan, Taiwan; [Tsai, Pei-Jane] Natl Cheng Kung Univ, Ctr Infect Dis & Signaling Res, Tainan, Taiwan; [Tsai, Pei-Jane] Natl Cheng Kung Univ Hosp, Dept Pathol, Tainan, Taiwan	National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University Hospital; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University Hospital	Tsai, PJ (corresponding author), Natl Cheng Kung Univ, Inst Basic Med Sci, Coll Med, Tainan, Taiwan.; Tsai, PJ (corresponding author), Natl Cheng Kung Univ, Dept Med Lab Sci & Biotechnol, Tainan, Taiwan.; Hung, YP (corresponding author), Natl Cheng Kung Univ Hosp, Dept Internal Med, Tainan, Taiwan.; Hung, YP (corresponding author), Tainan Hosp, Dept Internal Med, Minist Hlth & Welf, Tainan, Taiwan.; Hung, YP (corresponding author), Natl Cheng Kung Univ, Coll Med, Dept Med, Tainan, Taiwan.; Tsai, PJ (corresponding author), Natl Cheng Kung Univ, Ctr Infect Dis & Signaling Res, Tainan, Taiwan.; Tsai, PJ (corresponding author), Natl Cheng Kung Univ Hosp, Dept Pathol, Tainan, Taiwan.	peijtsai@mail.ncku.edu.com; yuebin16@yahoo.com.tw	hong, hesse/EUM-0179-2022	hong, hesse/0000-0003-1006-705X				LAI YH, 2021, FRONTIERS IMMUNOLOGY	1	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 8	2021	12								803805	10.3389/fimmu.2021.803805	http://dx.doi.org/10.3389/fimmu.2021.803805			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XS6DH	34956242	Green Published, gold			2022-12-18	WOS:000732996600001
J	Liu, X; Xia, FP; Wu, X; Tang, Y; Wang, L; Sun, Q; Xue, M; Chang, W; Liu, L; Guo, FM; Yang, Y; Qiu, HB				Liu, Xu; Xia, Feiping; Wu, Xiao; Tang, Ying; Wang, Lu; Sun, Qin; Xue, Ming; Chang, Wei; Liu, Ling; Guo, Fengmei; Yang, Yi; Qiu, Haibo			Isolation of Primary Mouse Pulmonary Microvascular Endothelial Cells and Generation of an Immortalized Cell Line to Obtain Sufficient Extracellular Vesicles	FRONTIERS IN IMMUNOLOGY			English	Article						pulmonary microvascular endothelial cells; immortalized cell line; extracellular vesicles; cell culture; pulmonary inflammation	VASCULAR SMOOTH-MUSCLE; T-ANTIGEN; LUNG; CULTURE; MICROPARTICLES; TRANSFORMATION; FIBROBLASTS; HEPARIN; MARKERS	Pulmonary microvascular endothelial cells (PMECs) and the extracellular vesicles (EVs) derived from PMECs participate in maintaining pulmonary homeostasis and mediating the inflammatory response. However, obtaining a high-purity population of PMECs and their EVs from mouse is still notoriously difficult. Herein we provide a method to isolate primary mouse PMECs (pMPMECs) and to transduce SV40 lentivirus into pMPMECs to establish an immortalized cell line (iMPMECs), which provides sufficient quantities of EVs for further studies. pMPMECs and iMPMECs can be identified using morphologic criteria, a phenotypic expression profile (e.g., CD31, CD144, G. simplicifolia lectin binding), and functional properties (e.g., Dil-acetylated low-density protein uptake, Matrigel angiogenesis). Furthermore, pMPMEC-EVs and iMPMEC-EVs can be identified and compared. The characteristics of pMPMEC-EVs and iMPMEC-EVs are ascertained by transmission electron microscopy, nanoparticle tracking analysis, and specific protein markers. iMPMECs produce far more EVs than pMPMECs, while their particle size distribution is similar. Our detailed protocol to isolate and immortalize MPMECs will provide researchers with an in vitro model to investigate the specific roles of EVs in pulmonary physiology and diseases.	[Liu, Xu; Xia, Feiping; Wu, Xiao; Tang, Ying; Wang, Lu; Sun, Qin; Xue, Ming; Chang, Wei; Liu, Ling; Guo, Fengmei; Yang, Yi; Qiu, Haibo] Southeast Univ, Zhongda Hosp, Jiangsu Prov Key Lab Crit Care Med, Sch Med,Dept Crit Care Med, Nanjing, Peoples R China	Southeast University - China	Qiu, HB (corresponding author), Southeast Univ, Zhongda Hosp, Jiangsu Prov Key Lab Crit Care Med, Sch Med,Dept Crit Care Med, Nanjing, Peoples R China.	haiboq2000@163.com	yang, yang/HGT-7999-2022; yang, yang/GVT-5210-2022	Guo, Fengmei/0000-0002-7279-2946	National Natural Science Foundation of China [81930058]; National Science and Technology Major Project of the Ministry of Science and Technology of China [2020YFC0843700]; Jiangsu Provincial Special Program of Medical Science [BE2018743, BE2019749]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Science and Technology Major Project of the Ministry of Science and Technology of China; Jiangsu Provincial Special Program of Medical Science	This research was supported by grants from the National Natural Science Foundation of China (grant number: 81930058), the National Science and Technology Major Project of the Ministry of Science and Technology of China (2020YFC0843700), and the Jiangsu Provincial Special Program of Medical Science (BE2018743, BE2019749).	Alphonse RS, 2015, NAT PROTOC, V10, P1697, DOI 10.1038/nprot.2015.107; Alvarez DF, 2008, AM J PHYSIOL-LUNG C, V294, pL419, DOI 10.1152/ajplung.00314.2007; BIKEL I, 1987, CELL, V48, P321, DOI 10.1016/0092-8674(87)90435-1; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Cabrera-Benitez NE, 2015, CRIT CARE MED, V43, pE551, DOI 10.1097/CCM.0000000000001280; Claser C, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12017-8; Comhair SAA, 2012, AM J RESP CELL MOL, V46, P723, DOI 10.1165/rcmb.2011-0416TE; Danese S, 2007, J IMMUNOL, V178, P6017, DOI 10.4049/jimmunol.178.10.6017; Dong QG, 1997, ARTERIOSCL THROM VAS, V17, P1599, DOI 10.1161/01.ATV.17.8.1599; Engler AJ, 2019, BIOMATERIALS, V217, DOI 10.1016/j.biomaterials.2019.119313; Fehrenbach ML, 2009, AM J PHYSIOL-LUNG C, V296, pL1096, DOI 10.1152/ajplung.90613.2008; GILBERT SF, 1975, CELL, V5, P11, DOI 10.1016/0092-8674(75)90086-0; Giordano A, 2012, MOL CANCER THER, V11, P2526, DOI 10.1158/1535-7163.MCT-12-0460; Gordon C, 2011, AM J RESP CRIT CARE, V184, P224, DOI 10.1164/rccm.201012-2061OC; Harrington EO, 2020, PULM CIRC, V10, DOI 10.1177/2045894020951759; Hegewisch-Becker S, 2003, CLIN CANCER RES, V9, P2079; IDE H, 1988, MICROBIOL IMMUNOL, V32, P45, DOI 10.1111/j.1348-0421.1988.tb01364.x; Joffre J, 2020, AM J RESP CRIT CARE, V202, P361, DOI 10.1164/rccm.201910-1911TR; Kaewkhaw R, 2012, NAT PROTOC, V7, P1996, DOI 10.1038/nprot.2012.118; Kalluri R, 2020, SCIENCE, V367, P640, DOI 10.1126/science.aau6977; Khan AI, 2004, J IMMUNOL, V173, P7594, DOI 10.4049/jimmunol.173.12.7594; Kogan I, 2006, CANCER RES, V66, P3531, DOI 10.1158/0008-5472.CAN-05-2183; Kuhlencordt PJ, 2004, AM J PHYSIOL-CELL PH, V286, pC1195, DOI 10.1152/ajpcell.00546.2002; Lv Y, 2018, CIRC RES, V123, P43, DOI 10.1161/CIRCRESAHA.118.313143; Ma JQ, 2015, INT J CLIN EXP MED, V8, P5547; Mai JT, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-61; Marar C, 2021, NAT IMMUNOL, V22, P560, DOI 10.1038/s41590-021-00899-0; Matsumura T, 2004, TRANSPLANTATION, V77, P1357, DOI 10.1097/01.TP.0000124286.82961.7E; Moraes DA, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287-016-0359-3; OCONNELL KA, 1990, J IMMUNOL, V144, P521; Plouffe BD, 2015, REP PROG PHYS, V78, DOI 10.1088/0034-4885/78/1/016601; Pober JS, 2007, NAT REV IMMUNOL, V7, P803, DOI 10.1038/nri2171; REILLY CF, 1989, J BIOL CHEM, V264, P6990; Tang HY, 2020, FASEB J, V34, P2011, DOI 10.1096/fj.201902063R; Traktuev DO, 2008, CIRC RES, V102, P77, DOI 10.1161/CIRCRESAHA.107.159475; Weber SC, 2011, PEDIATR RES, V70, P236, DOI 10.1203/PDR.0b013e318225f748; Xiao L, 2014, AM J PHYSIOL-HEART C, V306, pH317, DOI 10.1152/ajpheart.00182.2013; Yang SJ, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abb0606; Zhang XC, 2006, FASEB J, V20, P2156, DOI 10.1096/fj.06-5668fje; ZHU JY, 1991, J VIROL, V65, P6872, DOI 10.1128/JVI.65.12.6872-6880.1991	40	0	0	5	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 8	2021	12								759176	10.3389/fimmu.2021.759176	http://dx.doi.org/10.3389/fimmu.2021.759176			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XS6CS	34956190	Green Published, gold			2022-12-18	WOS:000732995100001
J	Wang, WL; Li, Y; Fan, SQ; Lian, XY; Cao, WQ; Song, XR; Yi, QL; Wang, LL; Song, LS				Wang, Weilin; Li, Yan; Fan, Siqi; Lian, Xingye; Cao, Wanqing; Song, Xiaorui; Yi, Qilin; Wang, Lingling; Song, Linsheng			The Elevated Expressions of Anti-lipopolysaccharide Factors After Priming Stimulation Confer Lastingly Humoral Protection in Crab Eriocheir sinensis	FRONTIERS IN IMMUNOLOGY			English	Article						immune memory; humoral immune protection; Chinese mitten crab; anti-lipopolysaccharide factor (ALF); TLR signal	TOLL-LIKE RECEPTORS; IMMUNE MEMORY; HEMOLYMPH TRANSFER; PASSIVE TRANSFER; CHALLENGE; INDUCTION	Evidence of immune memory in invertebrates (immune priming) has accumulated in various organisms, and both cellular and humoral immune reactions are speculated to be involved in immune priming. However, there is a lack of understanding of the molecular mechanisms involved. In the present study, the protective effect of primed haemolymph was further validated by the increased survival rate of naive crabs receiving a transfusion of primed haemolymph. By proteomic analysis, there were 474 proteins identified from the primed haemolymph, and most of them were functionally annotated in transport and metabolism classes. A total of 70 proteins were found to be differentially expressed in haemolymph at 12 hours and 7 days after priming stimulation with Aeromonas hydrophila, among which anti-lipopolysaccharide factor 1 (EsALF-1) and 3 (EsALF-3) were identified as the most significant (p < 0.05). After being challenged with A. hydrophila, EsALF-1 and EsALF-3 were highly expressed at both mRNA (in haemocytes) and protein (in haemolymph) levels compared with blank crabs, and the mRNA expressions of components in the EsTLR1-EsMyd88-EsPelle-EsALF pathway also increased significantly (p < 0.05). The EsALF-3 and EsMyd88 were even significantly higher expressed in response to the second A. hydrophila challenge, but their expressions all decreased (p < 0.05) when EsTLR1 was knocked down by RNAi. After the naive crabs received an injection with the recombinant protein of EsALF-1 (rEsALF-1) or EsALF-3 (rEsALF-3), their survival rate increased significantly (p < 0.05) upon A. hydrophila stimulation. In contrast, the survival rate of the primed crabs reduced significantly (p < 0.05) after they received an injection with the antibody of EsALF-1 or EsALF-3. The enhanced expressions of EsALF-1 and EsALF-3 after A. hydrophilap riming stimulation could sustain for four weeks. All the results suggested that the EsTLR1-mediated productions of EsALF-1 and EsALF-3 in haemolymph played an indispensable role in the month-long humoral immune protection induced by A. hydrophila, which provides solid evidence of immune priming in crabs and a valuable reference for further understanding immune memory in invertebrates.	[Wang, Weilin; Li, Yan; Fan, Siqi; Lian, Xingye; Cao, Wanqing; Song, Xiaorui; Yi, Qilin; Wang, Lingling; Song, Linsheng] Dalian Ocean Univ, Liaoning Key Lab Marine Anim Immunol & Dis Contro, Dalian, Peoples R China; [Wang, Weilin; Li, Yan; Fan, Siqi; Lian, Xingye; Cao, Wanqing; Song, Xiaorui; Yi, Qilin; Wang, Lingling; Song, Linsheng] Dalian Ocean Univ, Liaoning Key Lab Marine Anim Immunol, Dalian, Peoples R China; [Wang, Weilin; Li, Yan; Fan, Siqi; Lian, Xingye; Cao, Wanqing; Song, Xiaorui; Yi, Qilin; Wang, Lingling; Song, Linsheng] Dalian Ocean Univ, Dalian Key Lab Aquat Anim Dis Prevent & Control, Dalian, Peoples R China; [Song, Linsheng] Qingdao Natl Lab Marine Sci & Technol, Funct Lab Marine Fisheries Sci & Food Prod Proc, Qingdao, Peoples R China	Dalian Ocean University; Dalian Ocean University; Dalian Ocean University; Qingdao National Laboratory for Marine Science & Technology	Wang, LL; Song, LS (corresponding author), Dalian Ocean Univ, Liaoning Key Lab Marine Anim Immunol & Dis Contro, Dalian, Peoples R China.; Wang, LL; Song, LS (corresponding author), Dalian Ocean Univ, Liaoning Key Lab Marine Anim Immunol, Dalian, Peoples R China.; Wang, LL; Song, LS (corresponding author), Dalian Ocean Univ, Dalian Key Lab Aquat Anim Dis Prevent & Control, Dalian, Peoples R China.; Song, LS (corresponding author), Qingdao Natl Lab Marine Sci & Technol, Funct Lab Marine Fisheries Sci & Food Prod Proc, Qingdao, Peoples R China.	wanglingling@dlou.edu.cn; lshsong@dlou.edu.cn						ARAYA LN, 1990, INFECT IMMUN, V58, P254, DOI 10.1128/IAI.58.1.254-256.1990; Armitage SAO, 2015, DEV COMP IMMUNOL, V48, P315, DOI 10.1016/j.dci.2014.03.004; Bevan MJ, 2011, NAT IMMUNOL, V12, P463, DOI 10.1038/ni.2041; Burdin N, 2017, CSH PERSPECT BIOL, V9, DOI 10.1101/cshperspect.a029454; Christofi Theodoulakis, 2013, F1000Res, V2, P76, DOI 10.12688/f1000research.2-76.v1; Cohen J, 2019, SCIENCE, V364, P224, DOI 10.1126/science.364.6437.224; Cong M, 2008, COMP BIOCHEM PHYS B, V151, P191, DOI 10.1016/j.cbpb.2008.06.014; Contreras-Garduno J, 2016, ECOL ENTOMOL, V41, P351, DOI 10.1111/een.12300; Coscia MR, 2011, ISJ-INVERT SURVIV J, V8, P210; Heffernan JM, 2009, P ROY SOC B-BIOL SCI, V276, P2071, DOI 10.1098/rspb.2009.0057; Imler JL, 2014, DEV COMP IMMUNOL, V42, P3, DOI 10.1016/j.dci.2013.08.018; Lafont M, 2020, MBIO, V11, DOI 10.1128/mBio.02777-19; Lanz-Mendoza H., 2018, ADV COMP IMMUNOLOGY, P193, DOI [10.1007/978-3-319-76768-0_9, DOI 10.1007/978-3-319-76768-0_9]; Li CH, 2008, DEV COMP IMMUNOL, V32, P784, DOI 10.1016/j.dci.2007.11.008; Lin YC, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0069722, 10.1371/journal.pone.0054466]; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Melillo D, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01915; Meng QG, 2014, FISH SHELLFISH IMMUN, V40, P182, DOI 10.1016/j.fsi.2014.06.029; Milutinovic B, 2016, SEMIN IMMUNOL, V28, P328, DOI 10.1016/j.smim.2016.05.004; Pham LN, 2007, PLOS PATHOG, V3, DOI 10.1371/journal.ppat.0030026; Pinaud S, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005361; Rauta PR, 2014, IMMUNOL LETT, V158, P14, DOI 10.1016/j.imlet.2013.11.013; Rodrigues J, 2010, SCIENCE, V329, P1353, DOI 10.1126/science.1190689; Sack BK, 2014, INFECT IMMUN, V82, P808, DOI 10.1128/IAI.01249-13; Sadd BM, 2006, CURR BIOL, V16, P1206, DOI 10.1016/j.cub.2006.04.047; Sun JC, 2014, EMBO J, V33, P1295, DOI 10.1002/embj.201387651; Wang JJ, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02041; Wang LL, 2011, AFR J BIOTECHNOL, V10, P17678, DOI 10.5897/AJB11.2017; Wang WL, 2020, DEV COMP IMMUNOL, V103, DOI 10.1016/j.dci.2019.103498; Wang WL, 2016, DEV COMP IMMUNOL, V65, P182, DOI 10.1016/j.dci.2016.07.010; WIESNER A, 1991, DEV COMP IMMUNOL, V15, P241, DOI 10.1016/0145-305X(91)90017-S; WIESNER A, 1993, DEV COMP IMMUNOL, V17, P291, DOI 10.1016/0145-305X(93)90001-7; Yang B, 2018, DEV COMP IMMUNOL, V81, P156, DOI 10.1016/j.dci.2017.11.022; Yu AQ, 2013, FISH SHELLFISH IMMUN, V35, P1282, DOI 10.1016/j.fsi.2013.07.044; Zhang T, 2014, DEV COMP IMMUNOL, V45, P141, DOI 10.1016/j.dci.2014.02.015; Zhang Y, 2010, DEV COMP IMMUNOL, V34, P945, DOI 10.1016/j.dci.2010.04.002	36	0	0	7	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 8	2021	12								757434	10.3389/fimmu.2021.757434	http://dx.doi.org/10.3389/fimmu.2021.757434			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XS2LE	34956187	gold, Green Published			2022-12-18	WOS:000732745900001
J	Blanco, R; de Cedron, MG; Gamez-Reche, L; Martin-Leal, A; Gonzalez-Martin, A; Lacalle, RA; de Molina, AR; Manes, S				Blanco, Raquel; de Cedron, Marta Gomez; Gamez-Reche, Laura; Martin-Leal, Ana; Gonzalez-Martin, Alicia; Lacalle, Rosa A.; de Molina, Ana Ramirez; Manes, Santos			The Chemokine Receptor CCR5 Links Memory CD4(+) T Cell Metabolism to T Cell Antigen Receptor Nanoclustering	FRONTIERS IN IMMUNOLOGY			English	Article						memory CD4+T cells; efector CD4+T cells; metabolic reprogramming; chemokine signaling; CCR5; BCL6; glycolysis	INFLUENZA; RESPONSES; REQUIREMENTS; SENSITIVITY; ACTIVATION; EXPRESSION; TCR	The inhibition of anabolic pathways, such as aerobic glycolysis, is a metabolic cornerstone of memory T cell differentiation and function. However, the signals that hamper these anabolic pathways are not completely known. Recent evidence pinpoints the chemokine receptor CCR5 as an important player in CD4(+) T cell memory responses by regulating T cell antigen receptor (TCR) nanoclustering in an antigen-independent manner. This paper reports that CCR5 specifically restrains aerobic glycolysis in memory-like CD4(+) T cells, but not in effector CD4(+) T cells. CCR5-deficient memory CD4(+) T cells thus show an abnormally high glycolytic/oxidative metabolism ratio. No CCR5-dependent change in glucose uptake nor in the expression of the main glucose transporters was detected in any of the examined cell types, although CCR5-deficient memory cells did show increased expression of the hexokinase 2 and pyruvate kinase M2 isoforms, plus the concomitant downregulation of Bcl-6, a transcriptional repressor of these key glycolytic enzymes. Further, the TCR nanoclustering defects observed in CCR5-deficient antigen-experienced CD4(+) T cells were partially reversed by incubation with 2-deoxyglucose (2-DG), suggesting a link between inhibition of the glycolytic pathway and TCR nanoscopic organization. Indeed, the treatment of CCR5-deficient lymphoblasts with 2-DG enhanced IL-2 production after antigen re-stimulation. These results identify CCR5 as an important regulator of the metabolic fitness of memory CD4(+) T cells, and reveal an unexpected link between T cell metabolism and TCR organization with potential influence on the response of memory T cells upon antigen re-encounter.	[Blanco, Raquel; Gamez-Reche, Laura; Martin-Leal, Ana; Lacalle, Rosa A.; Manes, Santos] CSIC, Ctr Nacl Biotecnol CNB, Dept Immunol & Oncol, Madrid, Spain; [de Cedron, Marta Gomez; de Molina, Ana Ramirez] UAM, CEI, CSIC,Mol Oncol Grp, IMDEA Food Inst,Precis Nutr & Canc Program, Madrid, Spain; [Gamez-Reche, Laura; Gonzalez-Martin, Alicia] Univ Autonoma Madrid, Dept Biochem, Madrid, Spain; [Gamez-Reche, Laura; Gonzalez-Martin, Alicia] CSIC, Inst Invest Biomed Alberto Sols IIB, Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)	Blanco, R; Manes, S (corresponding author), CSIC, Ctr Nacl Biotecnol CNB, Dept Immunol & Oncol, Madrid, Spain.	raquel.blancof@gmail.com; smanes@cnb.csic.es	Gámez Reche, Laura Gámez/AEY-7271-2022; Gonzalez-Martin, Alicia/B-1702-2017; Blanco, Raquel/M-4290-2015	Gonzalez-Martin, Alicia/0000-0002-6179-089X; Blanco, Raquel/0000-0001-5477-5379; Manes, Santos/0000-0001-8023-957X				Beck-Garcia K, 2015, BBA-MOL CELL RES, V1853, P802, DOI 10.1016/j.bbamcr.2014.12.017; Buck MD, 2016, CELL, V166, P63, DOI 10.1016/j.cell.2016.05.035; Buck MD, 2015, J EXP MED, V212, P1345, DOI 10.1084/jem.20151159; Camargo JF, 2009, J IMMUNOL, V182, P171, DOI 10.4049/jimmunol.182.1.171; Chan O, 2012, J BIOL CHEM, V287, P29406, DOI 10.1074/jbc.M112.348946; Chang CH, 2013, CELL, V153, P1239, DOI 10.1016/j.cell.2013.05.016; Choi WT, 2011, EXP BIOL MED, V236, P637, DOI 10.1258/ebm.2011.010389; Cui WG, 2011, IMMUNITY, V35, P792, DOI 10.1016/j.immuni.2011.09.017; Falcon A, 2015, J GEN VIROL, V96, P2074, DOI 10.1099/vir.0.000165; Floto RA, 2006, SCIENCE, V314, P454, DOI 10.1126/science.1133515; Franciszkiewicz K, 2009, CANCER RES, V69, P6249, DOI 10.1158/0008-5472.CAN-08-3571; Gonzalez-Martin A, 2011, CANCER RES, V71, P5455, DOI 10.1158/0008-5472.CAN-11-1687; Kumar R, 2011, IMMUNITY, V35, P375, DOI 10.1016/j.immuni.2011.08.010; Lacalle RA, 2017, INT REV CEL MOL BIO, V331, P181, DOI 10.1016/bs.ircmb.2016.09.011; Li WH, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01834; Lillemeier BF, 2010, NAT IMMUNOL, V11, P90, DOI 10.1038/ni.1832; London CA, 2000, J IMMUNOL, V164, P265, DOI 10.4049/jimmunol.164.1.265; LUQMAN M, 1992, J IMMUNOL, V149, P2300; MacIver NJ, 2013, ANNU REV IMMUNOL, V31, P259, DOI 10.1146/annurev-immunol-032712-095956; MacLeod MKL, 2009, SEMIN IMMUNOL, V21, P53, DOI 10.1016/j.smim.2009.02.006; Man K, 2015, NAT REV IMMUNOL, V15, P574, DOI 10.1038/nri3874; Marko AJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015425; Martin-Blanco N, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05050-6; Martin-Leal A, 2020, EMBO J, V39, DOI 10.15252/embj.2020104749; Matti C, 2020, EMBO J, V39, DOI 10.15252/embj.2020105854; McKinstry KK, 2012, J CLIN INVEST, V122, P2847, DOI 10.1172/JCI63689; Molnar E, 2012, J BIOL CHEM, V287, P42664, DOI 10.1074/jbc.M112.386045; Molon B, 2005, NAT IMMUNOL, V6, P465, DOI 10.1038/ni1191; de Oca MM, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008994; Nelson SA, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00932; O'Sullivan D, 2014, IMMUNITY, V41, P75, DOI 10.1016/j.immuni.2014.06.005; Oestreich KJ, 2014, NAT IMMUNOL, V15, P957, DOI 10.1038/ni.2985; Ogando J, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0628-7; Ohradanova-Repic A, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00527; Paik S, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.603951; Rogers PR, 2000, J IMMUNOL, V164, P2338, DOI 10.4049/jimmunol.164.5.2338; Ruiz-Iglesias A, 2021, CANCERS, V13, DOI 10.3390/cancers13071488; Schamel WW, 2019, IMMUNOL REV, V291, P8, DOI 10.1111/imr.12788; Schamel WWA, 2005, J EXP MED, V202, P493, DOI 10.1084/jem.20042155; Sena LA, 2013, IMMUNITY, V38, P225, DOI 10.1016/j.immuni.2012.10.020; Siegel AM, 2011, IMMUNITY, V35, P806, DOI 10.1016/j.immuni.2011.09.016; Soto-Heredero G, 2020, FEBS J, V287, P3350, DOI 10.1111/febs.15327; Stark JM, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02318; Sukumar M, 2013, J CLIN INVEST, V123, P4479, DOI 10.1172/JCI69589; Taub DD, 2013, FASEB J, V27, P342, DOI 10.1096/fj.12-217620; van der Windt GJW, 2013, P NATL ACAD SCI USA, V110, P14336, DOI 10.1073/pnas.1221740110; Wang F, 2016, NAT IMMUNOL, V17, P844, DOI 10.1038/ni.3462; Wang RN, 2011, IMMUNITY, V35, P871, DOI 10.1016/j.immuni.2011.09.021; Zhang JX, 2017, ADV EXP MED BIOL, V1011, P131, DOI 10.1007/978-94-024-1170-6_3	49	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 7	2021	12								722320	10.3389/fimmu.2021.722320	http://dx.doi.org/10.3389/fimmu.2021.722320			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XT5QA	34950130	gold, Green Published			2022-12-18	WOS:000733640800001
J	Fontes, MD; Neves, FMD; Santos, KS; Fusco-Almeida, AM; Giannini, MJSM; Felisbino, SL; Deffune, E; Moroz, A				de Lima Fontes, Marina; Neves, Franciny Mara de Lima; Santos, Kelvin Sousa; Fusco-Almeida, Ana Marisa; Giannini, Maria Jose Soares Mendes; Felisbino, Sergio Luis; Deffune, Elenice; Moroz, Andrei			Multiple Tolerization Subtractive Immunization (MTSI) Protocol: Effects on Mice and Monoclonal Antibody Specificity	FRONTIERS IN IMMUNOLOGY			English	Article						monoclonal antibody; multiple tolerization subtractive immunization; cyclophosphamide; surface-epitope masking; tumor biomarkers	CELL-SURFACE ANTIGENS; CYCLOPHOSPHAMIDE; IDENTIFICATION; STRATEGIES	Monoclonal antibodies (mAbs) have been a valuable tool to elucidate several biological processes, such as stem cell differentiation and cancer, and contributed to virtually all areas of biomedical sciences. Yet, it remains a challenge to obtain mAbs specific to poorly expressed epitopes, or to epitopes that are actually involved in important biological phenomena, such as cell differentiation and metastasis. Drug-induced subtractive immunization, and recently the multiple tolerization subtractive immunization (MTSI) technique, reported by our group, have the potential to level up the field, as they direct the host ' s immune response towards these epitopes. However, due to cyclophosphamide (CY) treatment, high mice mortality can be observed, and only a few data are available on how these techniques affect the immune system of mice. Tolerogen and immunogen cells, RWPE-1 and PC-3 cells, respectively, were individually seeded at 2 x 10(4) cells/cm(2), and then adjusted to 2 x 10(6) cells per mouse before immunization, which was conducted in a subtractive approach (MTSI) with CY. Immunosuppression of mice was recorded via total white blood counting, as well the reactivity of circulating polyclonal antibodies (pAbs). General parameters, including weight, physical appearance, and behavior on mice subjected to three different concentrations of CY were recorded. mAbs were obtained using classical hybridoma techniques, using the spleen of immunized mice. After purification, antibodies were characterized by Western blotting, and Indirect immunofluorescence. In conclusion, all CY dosage were efficient in creating an immunosuppression state, but only the 100 mg/kg body weight was feasible, as the others resulted in extensive mice mortality. pAbs obtained in the peripheral blood of mice showed more reactivity towards tumor cells. MAbs 2-7A50 and 2-5C11 recognized antigens from tumor cells, but not from their non-tumor counterparts, as shown in western blotting and immunofluorescence assays. MTSI technique was successful in generating mAbs that recognize tumor-specific antigens.	[de Lima Fontes, Marina; Neves, Franciny Mara de Lima; Santos, Kelvin Sousa; Fusco-Almeida, Ana Marisa; Giannini, Maria Jose Soares Mendes; Moroz, Andrei] Sao Paulo State Univ UNESP, Sch Pharmaceut Sci, Monoclonal Antibody Lab, Dept Clin Anal, Araraquara, SP, Brazil; [Felisbino, Sergio Luis] Sao Paulo State Univ UNESP, Inst Biosci, Extracellular Matrix Lab, Dept Morphol, Botucatu, SP, Brazil; [Deffune, Elenice] Sao Paulo State Univ UNESP, Sch Med, Tissue Engn Lab, Dept Urol, Botucatu, SP, Brazil	Universidade Estadual Paulista; Universidade Estadual Paulista; Universidade Estadual Paulista	Moroz, A (corresponding author), Sao Paulo State Univ UNESP, Sch Pharmaceut Sci, Monoclonal Antibody Lab, Dept Clin Anal, Araraquara, SP, Brazil.	andrei.moroz@unesp.br		de Lima Fontes, Marina/0000-0003-2984-9561	Sao Paulo Research Foundation (FAPESP) [2017/20404-0, 2018/19083-7]	Sao Paulo Research Foundation (FAPESP)(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP))	This article was supported by the Sao Paulo Research Foundation (FAPESP), grant number: 2017/20404-0 and a research funding (2018/19083-7).	BROOKS PC, 1993, J CELL BIOL, V122, P1351, DOI 10.1083/jcb.122.6.1351; Carter P, 2004, ENDOCR-RELAT CANCER, V11, P659, DOI 10.1677/erc.1.00766; Choi HS, 2008, CELL TISSUE RES, V333, P197, DOI 10.1007/s00441-008-0632-6; CROOK TR, 1986, CANCER RES, V46, P5029; Dammes N, 2020, THERANOSTICS, V10, P938, DOI 10.7150/thno.37443; de Almeida Rodrigo, 2018, Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, V37, P100, DOI 10.1089/mab.2017.0055; de Almeida R, 2018, MABS-AUSTIN, V10, P46, DOI 10.1080/19420862.2017.1331804; Dumbrava EI, 2018, EXPERT OPIN DRUG DIS, V13, P685, DOI 10.1080/17460441.2018.1479740; Elangovan N, 2006, TOXICOLOGY, V222, P60, DOI 10.1016/j.tox.2006.01.027; Gerashchenko TS, 2019, J CLIN MED, V8, DOI 10.3390/jcm8081092; Goldstein Neil I., 2007, V383, P245, DOI 10.1007/978-1-59745-335-6_16; Hooper JD, 2003, ONCOGENE, V22, P1783, DOI 10.1038/sj.onc.1206220; Kaplon H, 2019, MABS-AUSTIN, V11, P219, DOI 10.1080/19420862.2018.1556465; Kennedy PJ, 2017, PHARMACOL THERAPEUT, V177, P129, DOI 10.1016/j.pharmthera.2017.03.004; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; Kulasingam V, 2008, NAT CLIN PRACT ONCOL, V5, P588, DOI 10.1038/ncponc1187; Levesque JP, 2002, EXP HEMATOL, V30, P440, DOI 10.1016/S0301-472X(02)00788-9; Liu JKH, 2014, ANN MED SURG, V3, P113, DOI 10.1016/j.amsu.2014.09.001; Loo DT, 2008, CURR OPIN PHARMACOL, V8, P627, DOI 10.1016/j.coph.2008.08.011; Mahmuda A, 2017, TROP J PHARM RES, V16, P713, DOI 10.4314/tjpr.v16i3.29; MATTHEW WD, 1987, J IMMUNOL METHODS, V100, P73, DOI 10.1016/0022-1759(87)90174-8; O'Connell KE, 2015, COMPARATIVE MED, V65, P96; SABBELE NR, 1988, IMMUNOPHARMACOLOGY, V15, P21, DOI 10.1016/0162-3109(88)90039-2; Weiner GJ, 2015, NAT REV CANCER, V15, P361, DOI 10.1038/nrc3930; WILLIAMS CV, 1992, BIOTECHNIQUES, V12, P842; Xu XF, 2015, MICROBIOL RES, V171, P97, DOI 10.1016/j.micres.2014.11.002; Zijlstra A, 2003, BIOCHEM BIOPH RES CO, V303, P733, DOI 10.1016/S0006-291X(03)00357-7	27	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 7	2021	12								760817	10.3389/fimmu.2021.760817	http://dx.doi.org/10.3389/fimmu.2021.760817			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YH2YJ	34950138	gold, Green Published			2022-12-18	WOS:000743037100001
J	Gao, FX; Huang, JJ; Li, TT; Hu, C; Shen, MY; Mu, S; Luo, FY; Song, SY; Hao, YA; Wang, W; Han, XJ; Qian, C; Wang, YM; Wu, RX; Li, L; Li, SL; Jin, AS				Gao, Fengxia; Huang, Jingjing; Li, Tingting; Hu, Chao; Shen, Meiying; Mu, Song; Luo, Feiyang; Song, Shuyi; Hao, Yanan; Wang, Wang; Han, Xiaojian; Qian, Chen; Wang, Yingming; Wu, Ruixin; Li, Luo; Li, Shenglong; Jin, Aishun			A Highly Conserved Peptide Vaccine Candidate Activates Both Humoral and Cellular Immunity Against SARS-CoV-2 Variant Strains	FRONTIERS IN IMMUNOLOGY			English	Article						SARS-CoV-2 variants; RBD9; 1; vaccine; humoral immune response; cellular immune response; immunological memory	ANTIBODIES	Facing the imminent need for vaccine candidates with cross-protection against globally circulating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mutants, we present a conserved antigenic peptide RBD9.1 with both T-cell and B-cell epitopes. RBD9.1 can be recognized by coronavirus disease 2019 (COVID-19) convalescent serum, particularly for those with high neutralizing potency. Immunization with RBD9.1 can successfully induce the production of the receptor-binding domain (RBD)-specific antibodies in Balb/c mice. Importantly, the immunized sera exhibit sustained neutralizing efficacy against multiple dominant SARS-CoV-2 variant strains, including B.1.617.2 that carries a point mutation (S-L452R) within the sequence of RBD9.1. Specifically, S-Y451 and S-Y454 are identified as the key amino acids for the binding of the induced RBD-specific antibodies to RBD9.1. Furthermore, we have confirmed that the RBD9.1 antigenic peptide can induce a S448-456 (NYNYLYRLF)-specific CD8(+) T-cell response. Both RBD9.1-specific B cells and the S448-456-specific T cells can still be activated more than 3 months post the last immunization. This study provides a potential vaccine candidate that can generate long-term protective efficacy over SARS-CoV-2 variants, with the unique functional mechanism of activating both humoral and cellular immunity.	[Gao, Fengxia; Huang, Jingjing; Li, Tingting; Hu, Chao; Mu, Song; Luo, Feiyang; Song, Shuyi; Hao, Yanan; Wang, Wang; Han, Xiaojian; Qian, Chen; Wang, Yingming; Wu, Ruixin; Li, Luo; Li, Shenglong; Jin, Aishun] Chongqing Med Univ, Coll Basic Med, Dept Immunol, Chongqing, Peoples R China; [Gao, Fengxia; Huang, Jingjing; Li, Tingting; Hu, Chao; Mu, Song; Luo, Feiyang; Song, Shuyi; Hao, Yanan; Wang, Wang; Han, Xiaojian; Qian, Chen; Wang, Yingming; Wu, Ruixin; Li, Luo; Li, Shenglong; Jin, Aishun] Chongqing Med Univ, Chongqing Key Lab Basic & Translat Res Tumor Immu, Chongqing, Peoples R China; [Shen, Meiying] Chongqing Med Univ, Affiliated Hosp 1, Dept Endocrine Breast Surg, Chongqing, Peoples R China	Chongqing Medical University; Chongqing Medical University; Chongqing Medical University	Jin, AS (corresponding author), Chongqing Med Univ, Coll Basic Med, Dept Immunol, Chongqing, Peoples R China.; Jin, AS (corresponding author), Chongqing Med Univ, Chongqing Key Lab Basic & Translat Res Tumor Immu, Chongqing, Peoples R China.	aishunjin@cqmu.edu.cn	wang, yan/GSE-6489-2022; wang, ying/GQY-5077-2022; wang, yingying/GRS-3058-2022					Annavajhala MK, 2021, NATURE, V597, P703, DOI [10.1038/s41586-021-03908-2, 10.1101/2021.02.23.21252259]; Autheman D, 2021, NATURE, V595, P96, DOI 10.1038/s41586-021-03597-x; Bernal JL, 2021, NEW ENGL J MED, V385, P585, DOI 10.1056/NEJMoa2108891; Chan SK, 2021, ACS NANO, V15, P1259, DOI 10.1021/acsnano.0c08430; Cho A, 2021, NATURE, V600, P517, DOI 10.1038/s41586-021-04060-7; Dai LP, 2021, NAT IMMUNOL, V22, P958, DOI 10.1038/s41590-021-00966-6; Deng XD, 2021, CELL, V184, P3426, DOI 10.1016/j.cell.2021.04.025; Faria NR, 2021, SCIENCE, V372, P815, DOI [10.1126/science.abh2644, 10.1101/2021.02.26.21252554, 10.1126/science.abh2644Article]; Gilbert SC, 2021, LANCET INFECT DIS, V21, P1337, DOI 10.1016/S1473-3099(21)00227-9; Gobeil SMC, 2021, SCIENCE, V373, P641, DOI [10.1126/science.abi6226, 10.1101/2021.03.11.435037]; Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00547-2020; Haabeth OAW, 2021, ACS CENTRAL SCI, V7, P1191, DOI 10.1021/acscentsci.1c00361; Han XJ, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.653189; Hu C, 2022, GENES DIS, V9, P216, DOI 10.1016/j.gendis.2021.05.006; Kantarcioglu B., 2021, CLIN APPL THROMB-HEM, P27, DOI DOI 10.1177/10760296211021498; Li TT, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-26539-7; Liu C, 2021, CELL, V184, P4220, DOI 10.1016/j.cell.2021.06.020; Liu YF, 2021, CELL, V184, P3452, DOI 10.1016/j.cell.2021.05.032; Martin DP, 2021, CELL, V184, P5189, DOI 10.1016/j.cell.2021.09.003; Meng ZJ, 2013, NANOSCALE RES LETT, V8, DOI 10.1186/1556-276X-8-118; Mlcochova P, 2021, NATURE, V599, P114, DOI 10.1038/s41586-021-03944-y; Motozono C, 2021, CELL HOST MICROBE, V29, P1124, DOI 10.1016/j.chom.2021.06.006; Nathan A, 2021, CELL, V184, P4401, DOI 10.1016/j.cell.2021.06.029; Oberhardt V, 2021, NATURE, V597, P268, DOI 10.1038/s41586-021-03841-4; Painter MM, 2021, IMMUNITY, V54, P2133, DOI 10.1016/j.immuni.2021.08.001; Pegu A, 2021, SCIENCE, V373, P1372, DOI 10.1126/science.abj4176; Planas D, 2021, NATURE, V596, P276, DOI 10.1038/s41586-021-03777-9; Schmitz AJ, 2021, IMMUNITY, V54, P2159, DOI [10.1016/j.immuni.2021.08.013, 10.1101/2021.03.24.436864]; Tanriover MD, 2021, LANCET, V398, P213, DOI 10.1016/S0140-6736(21)01429-X; Tegally H, 2021, NATURE, V592, P438, DOI 10.1038/s41586-021-03402-9; Wu YT, 2017, VACCINE, V35, P2728, DOI 10.1016/j.vaccine.2017.03.065; Xu JL, 2021, NATURE, V595, P278, DOI 10.1038/s41586-021-03676-z; Xu Jianliang, 2021, bioRxiv, DOI 10.1101/2021.03.04.433768; Yang JY, 2021, NATURE, DOI 10.1038/s41586-020-03108-4; Zhang BZ, 2020, CELL RES, V30, P702, DOI 10.1038/s41422-020-0366-x; Zhou DM, 2021, CELL, V184, P2348, DOI 10.1016/j.cell.2021.02.037; Zhou QQ, 2021, ADV MATER, V33, DOI 10.1002/adma.202102528	37	0	0	0	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 7	2021	12								789905	10.3389/fimmu.2021.789905	http://dx.doi.org/10.3389/fimmu.2021.789905			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XW1BK	34950151	gold, Green Published			2022-12-18	WOS:000735363200001
J	Kim, H; Lee, BH; Do, HS; Kim, GH; Kang, S; Koh, KN; Im, HJ				Kim, Hyery; Lee, Beom Hee; Do, Hyo-Sang; Kim, Gu-Hwan; Kang, Sunghan; Koh, Kyung-Nam; Im, Ho Joon			Case Report: Mevalonic Aciduria Complicated by Acute Myeloid Leukemia After Hematopoietic Stem Cell Transplantation	FRONTIERS IN IMMUNOLOGY			English	Article						mevalonic aciduria; mavalonic kinase deficiency; hematopoietic stem cell transplantation; acute myeloid leukemia; inflammation	T-CELL; PATHWAY; REGIMEN	Mevalonic aciduria (MA) is the most severe clinical subtype of mevalonate kinase deficiency (MKD) caused by an inherited defect in the mevalonate pathway. The treatment of MKD focuses on the suppression of recurrent hyperinflammatory attacks using anti-inflammatory drugs. Recently, allogeneic hematopoietic stem cell transplantation (HCT) was shown to successfully ameliorate autoinflammatory attacks in patients with MKD. Here, we report a case of an infant who showed severe recurrent systemic inflammation and was diagnosed with MA. Although she responded to steroids, her symptoms relapsed after the dose was tapered, and organ deterioration occurred. Therefore, at the age of 11 months, HCT from a matched, unrelated donor was performed for curative treatment. However, at 50 days after transplantation, acute myeloid leukemia was diagnosed, which was chemo-refractory. A second HCT from her haploidentical father was performed to treat the acute myeloid leukemia, but the patient died of sepsis on day 4 after transplantation. This is the first report of malignancy following HCT for MA. Our findings suggest that normalizing the mevalonate pathway after HCT in patients with MKD impacts patients differently depending on the clinical spectrum and severity of disease.	[Kim, Hyery; Kang, Sunghan; Koh, Kyung-Nam; Im, Ho Joon] Univ Ulsan, Div Pediat Hematol Oncol, Dept Pediat, Asan Med Ctr,Childrens Hosp,Coll Med, Seoul, South Korea; [Kim, Hyery; Lee, Beom Hee; Kang, Sunghan; Koh, Kyung-Nam; Im, Ho Joon] Univ Ulsan, Dept Pediat, Asan Med Ctr, Childrens Hosp,Coll Med, Seoul, South Korea; [Lee, Beom Hee; Kim, Gu-Hwan] Univ Ulsan, Ctr Med Genet, Asan Med Ctr, Coll Med, Seoul, South Korea; [Do, Hyo-Sang] Univ Ulsan, Asan Inst Life Sci, Asan Med Ctr, Coll Med, Seoul, South Korea	University of Ulsan; Asan Medical Center; University of Ulsan; Asan Medical Center; University of Ulsan; Asan Medical Center; University of Ulsan; Asan Medical Center	Kim, H (corresponding author), Univ Ulsan, Div Pediat Hematol Oncol, Dept Pediat, Asan Med Ctr,Childrens Hosp,Coll Med, Seoul, South Korea.; Kim, H (corresponding author), Univ Ulsan, Dept Pediat, Asan Med Ctr, Childrens Hosp,Coll Med, Seoul, South Korea.	taban@hanmail.net	Koh, Kyung-Nam/AAA-2747-2022	Koh, Kyung-Nam/0000-0002-6376-672X	National Research Foundation of Korea (NRF); Korean government (MSIT) [NRF-2018M3A9H1078335, NRF-2021R1A2C1095874]	National Research Foundation of Korea (NRF)(National Research Foundation of Korea); Korean government (MSIT)(Korean Government)	This work was supported by a National Research Foundation of Korea (NRF) grant, funded by the Korean government (MSIT) (No. NRF-2018M3A9H1078335 and NRF-2021R1A2C1095874).	Arkwright PD, 2007, NEW ENGL J MED, V357, P1350, DOI 10.1056/NEJMc072018; Bhatia S, 1996, BLOOD, V87, P3633, DOI 10.1182/blood.V87.9.3633.bloodjournal8793633; Burnett AK, 2010, J CLIN ONCOL, V28, P586, DOI 10.1200/JCO.2009.22.9088; Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289; Chaudhury S, 2012, AM J TRANSPLANT, V12, P1627, DOI 10.1111/j.1600-6143.2011.03989.x; Clendening JW, 2010, BLOOD, V115, P4787, DOI 10.1182/blood-2009-07-230508; Drenth JPH, 1999, NAT GENET, V22, P178, DOI 10.1038/9696; Duncan RE, 2004, J BIOL CHEM, V279, P33079, DOI 10.1074/jbc.M400732200; Erdol S, 2016, RHEUMATOL INT, V36, P1011, DOI 10.1007/s00296-016-3456-9; Faraci M., 2021, RHEUMATOL OXFORD, V60, P4850, DOI [10.1093/rheumatology/keab208, DOI 10.1093/RHEUMATOLOGY/KEAB208]; Favier LA, 2016, APPL CLIN GENET, V9, DOI 10.2147/TACG.S93933; Giardino S, 2015, PEDIATRICS, V135, pE211, DOI 10.1542/peds.2014-2553; Gruenbacher G, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00394; Haas D, 2006, ORPHANET J RARE DIS, V1, DOI 10.1186/1750-1172-1-13; Im HJ, 2016, BONE MARROW TRANSPL, V51, P1217, DOI 10.1038/bmt.2016.114; Inaba T, 2018, BLOOD, V131, P2891, DOI 10.1182/blood-2017-12-822262; Kang HJ, 2004, LEUKEMIA RES, V28, P167, DOI 10.1016/S0145-2126(03)00217-0; Kim H, 2019, BIOL BLOOD MARROW TR, V25, P965, DOI 10.1016/j.bbmt.2019.01.010; LARSON RA, 1984, BLOOD, V64, P257; Longo J, 2021, LEUKEMIA, V35, P796, DOI 10.1038/s41375-020-0962-2; Mullen PJ, 2016, NAT REV CANCER, V16, P718, DOI 10.1038/nrc.2016.76; Neven B, 2007, NEW ENGL J MED, V356, P2700, DOI 10.1056/NEJMoa070715; Pandyra A, 2014, CANCER RES, V74, P4772, DOI 10.1158/0008-5472.CAN-14-0130; Pietrasanta C, 2019, CLIN IMMUNOL, V205, P25, DOI 10.1016/j.clim.2019.05.002; Rakszawski K, 2018, INT J HEMATOL, V108, P348, DOI 10.1007/s12185-018-2431-5; Rio-Machin A, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14829-5; Shimoni A, 2013, LEUKEMIA, V27, P829, DOI 10.1038/leu.2012.299; Szymanski AM, 2020, PEDIATR TRANSPLANT, V24, DOI 10.1111/petr.13604	28	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 7	2021	12								782780	10.3389/fimmu.2021.782780	http://dx.doi.org/10.3389/fimmu.2021.782780			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XT4WT	34950147	Green Published, gold			2022-12-18	WOS:000733590400001
J	Wu, YX; Fu, JN; Wang, HZ; Yu, XZ				Wu, Yongxia; Fu, Jianing; Wang, Haizhen; Yu, Xue-Zhong			Donor T-Cell Repertoire Profiling in Recipient Lymphoid and Parenchyma Organs Reveals GVHD Pathogenesis at Clonal Levels After Bone Marrow Transplantation in Mice	FRONTIERS IN IMMUNOLOGY			English	Article						bone marrow transplantation; allogeneic hematopoietic stem cell transplantation; TCR repertoire; graft-versus-host disease; T cells	VERSUS-HOST-DISEASE	The diversity and composition of T-cell receptor (TCR) repertoire, which is the result of V, (D), and J gene recombination in TCR gene locus, has been found to be implicated in T-cell responses in autoimmunity, cancer, and organ transplantation. The correlation of T-cell repertoire with the pathogenesis of graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation remains largely undefined. Here, by utilizing high-throughput sequencing of the genes encoding TCR beta-chain, we comprehensively analyzed the profile of T-cell repertoire in recipient lymphoid and GVHD target organs after bone marrow transplantation (BMT) in mice. In lymphoid organs, TCR diversity was narrowed, accompanied with reduced numbers of unique clones while increased accumulation of dominant clones in allogeneic T cells compared to syngeneic T cells. In an individual allogeneic recipient, donor-derived TCR clones were highly overlapped among tissue sites, and the degree of overlapping was increasing from day 7 to 14 after allogeneic BMT. The top clones in peripheral blood, gut, liver, and lungs were highly mutually shared in an allogenic recipient, indicating that blood has the potential to predict dominant clones in these GVHD target organs. T cells in GVHD target organs from allogeneic recipients had fewer overlapped clones with pre-transplant donor T cells compared to those from syngeneic recipients. Importantly, the top 10 clones in allogeneic recipients were not detectable in pre-transplant donor T cells, indicating clonal expansion of rare rearrangements. Interestingly, even starting from the same pool of donor repertoires, T cells had very few overlapped clones between each allogeneic recipient who developed completely different dominant clones. We were only able to trace a single clone shared by three replicate allogeneic recipients within the top 500 clones. Although dominant clones were different among allogeneic recipients, V26 genes were consistently used more frequently by TCR clones in allogeneic than syngeneic recipients. This is the first study to extensively examine the feature of T-cell repertoire in multiple lymphoid and parenchyma organs, which establishes the association between T-cell activation and GVHD pathogenesis at the level of TCR clones. Immune repertoire sequencing-based methods may represent a novel personalized strategy to guide diagnosis and therapy in GVHD.	[Wu, Yongxia; Yu, Xue-Zhong] Med Univ South Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA; [Fu, Jianing] Columbia Univ, Dept Med, Columbia Ctr Translat Immunol, New York, NY USA; [Wang, Haizhen] Med Univ South Carolina, Dept Cell & Mol Pharmacol & Expt Therapeut, Charleston, SC 29425 USA; [Wang, Haizhen; Yu, Xue-Zhong] Med Univ South Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA; [Yu, Xue-Zhong] Med Univ South Carolina, Dept Med, Charleston, SC 29425 USA	Medical University of South Carolina; Columbia University; Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina	Yu, XZ (corresponding author), Med Univ South Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA.; Yu, XZ (corresponding author), Med Univ South Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA.; Yu, XZ (corresponding author), Med Univ South Carolina, Dept Med, Charleston, SC 29425 USA.	yux@musc.edu						Bolton HA, 2015, J CLIN INVEST, V125, P3627, DOI 10.1172/JCI76031; DeWolf S, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.121256; Do JS, 2012, CELL IMMUNOL, V272, P117, DOI 10.1016/j.cellimm.2011.11.002; Fu JN, 2014, ARCH IMMUNOL THER EX, V62, P277, DOI 10.1007/s00005-014-0284-z; Hill GR, 2021, ANNU REV IMMUNOL, V39, P19, DOI 10.1146/annurev-immunol-102119-073227; Kanakry CG, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.86252; Koyama D, 2019, BIOL BLOOD MARROW TR, V25, P417, DOI 10.1016/j.bbmt.2018.10.012; Meier JA, 2019, BIOL BLOOD MARROW TR, V25, P868, DOI 10.1016/j.bbmt.2019.01.021; Meyer EH, 2013, BLOOD, V121, P4955, DOI 10.1182/blood-2013-03-489757; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; Morris H, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.3010760; Ostanin DV, 2009, AM J PHYSIOL-GASTR L, V296, pG135, DOI 10.1152/ajpgi.90462.2008; Pagliuca S, 2021, JCI INSIGHT, V6, DOI 10.1172/jci.insight.149080; Savage TM, 2020, AM J TRANSPLANT, V20, P538, DOI 10.1111/ajt.15592; Shah O, 2020, BIOL BLOOD MARROW TR, V26, P1050, DOI 10.1016/j.bbmt.2020.01.020; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954; van Heijst JWJ, 2013, NAT MED, V19, P372, DOI 10.1038/nm.3100; Woodsworth DJ, 2013, GENOME MED, V5, DOI 10.1186/gm502; Yew PY, 2015, BONE MARROW TRANSPL, V50, P1227, DOI 10.1038/bmt.2015.133; Zeiser R, 2017, NEW ENGL J MED, V377, P2167, DOI 10.1056/NEJMra1609337; Zheng PP, 2020, BLOOD ADV, V4, P4232, DOI 10.1182/bloodadvances.2019000977	21	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 7	2021	12								778996	10.3389/fimmu.2021.778996	http://dx.doi.org/10.3389/fimmu.2021.778996			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YH1PX	34950143	Green Published, gold			2022-12-18	WOS:000742947500001
J	Abeynaike, S; Paust, S				Abeynaike, Shawn; Paust, Silke			Humanized Mice for the Evaluation of Novel HIV-1 Therapies (vol 12, 636775, 2021)	FRONTIERS IN IMMUNOLOGY			English	Correction						humanized mice; BLT; DRAG; HIV-1 infection; viral latency; latency reversal; immunotherapy; gene therapy			[Abeynaike, Shawn; Paust, Silke] Scripps Res Inst, Dept Immunol & MicroBiol, La Jolla, CA 92037 USA; [Abeynaike, Shawn; Paust, Silke] Scripps Res Inst, Skaggs Grad Program Chem & Biol Sci, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Paust, S (corresponding author), Scripps Res Inst, Dept Immunol & MicroBiol, La Jolla, CA 92037 USA.; Paust, S (corresponding author), Scripps Res Inst, Skaggs Grad Program Chem & Biol Sci, La Jolla, CA 92037 USA.	paust@scripps.edu	Abeynaike, Shawn/AGR-8674-2022	Paust, Silke/0000-0002-0526-3999				NAMIKAWA R, 1990, J EXP MED, V172, P1055, DOI 10.1084/jem.172.4.1055	1	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 6	2021	12								808068	10.3389/fimmu.2021.808068	http://dx.doi.org/10.3389/fimmu.2021.808068			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XR0NS	34938301	gold, Green Published			2022-12-18	WOS:000731937600001
J	Amdam, H; Madsen, A; Zhou, F; Bansal, A; Trieu, MC; Cox, RJ				Amdam, Hakon; Madsen, Anders; Zhou, Fan; Bansal, Amit; Trieu, Mai-Chi; Cox, Rebecca Jane			Functional and Binding H1N1pdm09-Specific Antibody Responses in Occasionally and Repeatedly Vaccinated Healthcare Workers: A Five-Year Study (2009-2014)	FRONTIERS IN IMMUNOLOGY			English	Article						influenza; pandemic vaccination; repeated vaccination; HI; MN; ELISA; healthcare workers	PANDEMIC INFLUENZA VACCINE; VIRUS; A(H1N1)PDM09; PROTECTION; SAFETY	BackgroundIn 2009, a novel influenza A/H1N1pdm09 emerged and caused a pandemic. This strain continued to circulate and was therefore included in the seasonal vaccines up to the 2016/2017-season. This provided a unique opportunity to study the long-term antibody responses to H1N1pdm09 in healthcare workers (HCW) with a different vaccination history. MethodsHCW at Haukeland University Hospital, Bergen, Norway were immunized with the AS03-adjuvanted H1N1pdm09 vaccine in 2009 (N=55) and divided into groups according to their vaccination history; one vaccination (N=10), two vaccinations (N=15), three vaccinations (N=5), four vaccinations (N=15) and five vaccinations (N=10). HCW are recommended for influenza vaccination to protect both themselves and their patients, but it is voluntary in Norway. Blood samples were collected pre- and at 21 days, 3, 6, and 12 months after each vaccination, or annually from 2010 HCW without vaccination. ELISA, haemagglutination inhibition (HI) and microneutralization (MN) assays were used to determine the antibody response. ResultsPandemic vaccination induced a significant increase in the H1N1-specific antibodies measured by ELISA, HI and MN. Seasonal vaccination boosted the antibody response, both in HCW with only the current vaccination and those with prior and current vaccination during 2010/11-2013/14. We observed a trend of increased antibody responses in HCW with only the current vaccination in 2013/14. A two- and three-year gap before vaccination in 2013/14 provided a more potent antibody response compared to annually vaccinated HCW. ConclusionsOur long term follow up study elucidates the antibody response in HCW with different vaccination histories. Our findings contribute to our understanding of the impact of repeated vaccination upon antibody responses.	[Amdam, Hakon; Madsen, Anders; Zhou, Fan; Bansal, Amit; Trieu, Mai-Chi; Cox, Rebecca Jane] Univ Bergen, Influenza Ctr, Dept Clin Sci, Bergen, Norway; [Cox, Rebecca Jane] Haukeland Hosp, Dept MicroBiol, Bergen, Norway	University of Bergen; University of Bergen; Haukeland University Hospital	Cox, RJ (corresponding author), Univ Bergen, Influenza Ctr, Dept Clin Sci, Bergen, Norway.; Cox, RJ (corresponding author), Haukeland Hosp, Dept MicroBiol, Bergen, Norway.	rebecca.cox@uib.no		Trieu, Mai-Chi/0000-0001-9181-5843				Andrews SF, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aad0522; Belongia Edward A, 2017, Expert Rev Vaccines, V16, P1, DOI 10.1080/14760584.2017.1334554; Beyer WEP, 1999, ARCH INTERN MED, V159, P182, DOI 10.1001/archinte.159.2.182; Castrucci MR, 2018, HUM VACC IMMUNOTHER, V14, P637, DOI 10.1080/21645515.2017.1338547; Cohet C, 2019, VACCINE, V37, P3006, DOI 10.1016/j.vaccine.2019.04.048; Ellebedy AH, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6040068; Ferguson M, 2012, J INFECT DIS, V205, P733, DOI 10.1093/infdis/jir641; Folkehelseinstituttet, 2019, INFL VACC COV NORW 2; Francis T., 1960, P AM PHILOS SOC, V104, P572, DOI DOI 10.1371/JOURNAL.PPAT.1005806; Gaglani M, 2014, J INFECT DIS, V209, P1705, DOI 10.1093/infdis/jit825; Galson JD, 2016, SCI REP-UK, V6, DOI 10.1038/srep37229; Hauge SH, 2019, INFLUENZA OTHER RESP, V13, P240, DOI 10.1111/irv.12627; Helse og omsorgsdepartementet, BER MOT PAND INFL ME; HOBSON D, 1972, J HYG-CAMBRIDGE, V70, P767, DOI 10.1017/S0022172400022610; Jorgensen P, 2018, VACCINE, V36, P442, DOI 10.1016/j.vaccine.2017.12.019; Kim SS, 2021, CLIN INFECT DIS, V73, P497, DOI 10.1093/cid/ciaa706; Krammer F, 2013, J VIROL, V87, P6542, DOI [10.1128/JVI.00641-13, 10.1128/JVI.03183-13]; Kunzel W, 1996, VACCINE, V14, P1108, DOI 10.1016/0264-410X(96)00061-8; Kuster SP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026239; Leung VKY, 2017, VACCINE, V35, P2558, DOI 10.1016/j.vaccine.2017.03.063; Linderman SL, 2021, CSH PERSPECT MED, V11, DOI 10.1101/cshperspect.a040964; Madhun AS, 2010, VACCINE, V29, P266, DOI 10.1016/j.vaccine.2010.10.038; Madsen A, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-021-00308-5; Paget J, 2019, J GLOB HEALTH, V9, DOI 10.7189/jogh.09.020421; Poland GA, 2005, VACCINE, V23, P2251, DOI 10.1016/j.vaccine.2005.01.043; Rowe T, 1999, J CLIN MICROBIOL, V37, P937, DOI 10.1128/JCM.37.4.937-943.1999; Sanyal M, 2019, J INFECT DIS, V219, P1586, DOI 10.1093/infdis/jiy685; Sherman AC, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040663; Strengell M, 2013, INFLUENZA OTHER RESP, V7, P431, DOI 10.1111/j.1750-2659.2012.00415.x; Herrera MT, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-544; Tete SM, 2016, NPJ VACCINES, V1, DOI 10.1038/npjvaccines.2016.1; Trieu MC, 2019, CLIN INFECT DIS, V68, P382, DOI 10.1093/cid/ciy487; van der Most RG, 2017, CLIN VACCINE IMMUNOL, V24, DOI [10.1128/CVI.00553-16, 10.1128/cvi.00553-16]; Veguilla V, 2011, J CLIN MICROBIOL, V49, P2210, DOI 10.1128/JCM.00229-11; World Health Organization, PAND H1N1 2009 UPD 6 PAND H1N1 2009 UPD 6; Zhang Y, 2016, IMMUNOL REV, V270, P8, DOI 10.1111/imr.12396	36	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 6	2021	12								748281	10.3389/fimmu.2021.748281	http://dx.doi.org/10.3389/fimmu.2021.748281			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XR1OO	34938285	Green Published, gold			2022-12-18	WOS:000732007900001
J	Donaldson, DS; Shih, BB; Mabbott, NA				Donaldson, David S.; Shih, Barbara B.; Mabbott, Neil A.			Aging-Related Impairments to M Cells in Peyer's Patches Coincide With Disturbances to Paneth Cells	FRONTIERS IN IMMUNOLOGY			English	Article						aging; M cells; follicle-associated epithelium; Paneth cells; ACE2; transcriptomics	FOLLICLE-ASSOCIATED EPITHELIUM; INTESTINAL M CELLS; MULTIPLE MOUSE-CELL; STEM-CELLS; FUNCTIONAL MATURATION; GENE SIGNATURES; B-CELLS; EXPRESSION; PROTEIN; DIFFERENTIATION	The decline in mucosal immunity during aging increases susceptibility, morbidity and mortality to infections acquired via the gastrointestinal and respiratory tracts in the elderly. We previously showed that this immunosenescence includes a reduction in the functional maturation of M cells in the follicle-associated epithelia (FAE) covering the Peyer's patches, diminishing the ability to sample of antigens and pathogens from the gut lumen. Here, co-expression analysis of mRNA-seq data sets revealed a general down-regulation of most FAE- and M cell-related genes in Peyer's patches from aged mice, including key transcription factors known to be essential for M cell differentiation. Conversely, expression of ACE2, the cellular receptor for SARS-Cov-2 virus, was increased in the aged FAE. This raises the possibility that the susceptibility of aged Peyer's patches to infection with the SARS-Cov-2 virus is increased. Expression of key Paneth cell-related genes was also reduced in the ileum of aged mice, consistent with the adverse effects of aging on their function. However, the increased expression of these genes in the villous epithelium of aged mice suggested a disturbed distribution of Paneth cells in the aged intestine. Aging effects on Paneth cells negatively impact on the regenerative ability of the gut epithelium and could indirectly impede M cell differentiation. Thus, restoring Paneth cell function may represent a novel means to improve M cell differentiation in the aging intestine and increase mucosal vaccination efficacy in the elderly.	[Mabbott, Neil A.] Univ Edinburgh Easter Bush, Roslin Inst, Roslin, Midlothian, Scotland; Univ Edinburgh Easter Bush, Royal Dick Sch Vet Studies, Roslin, Midlothian, Scotland	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Roslin Institute; University of Edinburgh; University of Edinburgh	Mabbott, NA (corresponding author), Univ Edinburgh Easter Bush, Roslin Inst, Roslin, Midlothian, Scotland.	neil.mabbott@roslin.ed.ac.uk		Donaldson, David/0000-0002-8523-7853; Shih, Barbara/0000-0002-3676-3304				Batista CR, 2017, J IMMUNOL, V198, P1565, DOI 10.4049/jimmunol.1601709; Choi J, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-29230-y; Cobaleda C, 2007, NAT IMMUNOL, V8, P463, DOI 10.1038/ni1454; de Lau W, 2012, MOL CELL BIOL, V32, P3639, DOI 10.1128/MCB.00434-12; de Lau W, 2011, NATURE, V476, P293, DOI 10.1038/nature10337; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Docherty AB, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1985; Donaldson DS, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2020.101147; Donaldson DS, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1006075; Durand A, 2012, P NATL ACAD SCI USA, V109, P8965, DOI 10.1073/pnas.1201652109; Ebisawa M, 2011, INT IMMUNOL, V23, P261, DOI 10.1093/intimm/dxq478; Forrest ARR, 2014, NATURE, V507, P462, DOI 10.1038/nature13182; Freeman TC, 2007, PLOS COMPUT BIOL, V3, P2032, DOI 10.1371/journal.pcbi.0030206; Ghaleb AM, 2017, GENE, V611, P27, DOI 10.1016/j.gene.2017.02.025; Gonzalez-Hernandez MB, 2014, J VIROL, V88, P6934, DOI 10.1128/JVI.00204-14; Haber AL, 2017, NATURE, V551, P333, DOI 10.1038/nature24489; Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570; Han YL, 2021, NATURE, V589, P270, DOI 10.1038/s41586-020-2901-9; Hase K, 2005, DNA RES, V12, P127, DOI 10.1093/dnares/12.2.127; Hase K, 2009, NAT CELL BIOL, V11, P1427, DOI 10.1038/ncb1990; Hase K, 2009, NATURE, V462, P226, DOI 10.1038/nature08529; Inman CF, 2005, J IMMUNOL METHODS, V302, P156, DOI 10.1016/j.jim.2005.05.005; Kanaya T, 2018, J EXP MED, V215, P501, DOI 10.1084/jem.20160659; Kanaya T, 2012, NAT IMMUNOL, V13, P729, DOI 10.1038/ni.2352; Karpus ON, 2019, CELL REP, V26, P3698, DOI 10.1016/j.celrep.2019.02.101; Kazakevych J, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-46966-3; Kim SH, 2018, IMMUNE NETW, V18, DOI 10.4110/in.2018.18.e21; Kimura S, 2015, MUCOSAL IMMUNOL, V8, P650, DOI 10.1038/mi.2014.99; Kimura S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13883-y; Kimura S, 2019, J EXP MED, V216, P831, DOI 10.1084/jem.20181604; Knoop KA, 2009, J IMMUNOL, V183, P5738, DOI 10.4049/jimmunol.0901563; Kobayashi A, 2013, MUCOSAL IMMUNOL, V6, P1027, DOI 10.1038/mi.2012.141; Kobayashi A, 2012, DNA RES, V19, P407, DOI 10.1093/dnares/dss022; Kolawole AO, 2016, J VIROL, V90, P1499, DOI 10.1128/JVI.02872-15; Komban RJ, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10144-w; Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270; Kosinski C, 2007, P NATL ACAD SCI USA, V104, P15418, DOI 10.1073/pnas.0707210104; Lamers MM, 2020, SCIENCE, V369, P50, DOI 10.1126/science.abc1669; Li SR, 2012, DEVELOPMENT, V139, P2500, DOI 10.1242/dev.079699; Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656; Lowe ME, 2000, BIOCHIMIE, V82, P997, DOI 10.1016/S0300-9084(00)01184-6; Lu MM, 2002, MECH DEVELOP, V119, pS197, DOI 10.1016/S0925-4773(03)00116-3; Lueschow SR, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00587; Mabbott NA, 2013, MUCOSAL IMMUNOL, V6, P666, DOI 10.1038/mi.2013.30; Mabbott NA, 2015, BIOGERONTOLOGY, V16, P133, DOI 10.1007/s10522-014-9498-z; Mabbott NA, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-632; Mabbott NA, 2011, IMMUNOLOGY, V133, P482, DOI 10.1111/j.1365-2567.2011.03461.x; Mabbott NA, 2010, IMMUNOBIOLOGY, V215, P724, DOI 10.1016/j.imbio.2010.05.012; Martin M., 2011, EMBNET J, V17, P10, DOI [10.14806/ej.17.1.200, DOI 10.14806/EJ.17.1.200]; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; Nagashima K, 2017, NAT IMMUNOL, V18, P675, DOI 10.1038/ni.3732; Nakamura Y, 2020, MUCOSAL IMMUNOL, V13, P679, DOI 10.1038/s41385-020-0263-0; Nakato G, 2012, J IMMUNOL, V189, P1540, DOI 10.4049/jimmunol.1103332; Nalapareddy K, 2017, CELL REP, V18, P2608, DOI 10.1016/j.celrep.2017.02.056; Niemi MEK, 2021, NATURE, V600, P472, DOI 10.1038/s41586-021-03767-x; Pentinmikko N, 2019, NATURE, V571, P398, DOI 10.1038/s41586-019-1383-0; Raudvere U, 2019, NUCLEIC ACIDS RES, V47, pW191, DOI 10.1093/nar/gkz369; Riehl TE, 2015, AM J PHYSIOL-GASTR L, V309, pG874, DOI 10.1152/ajpgi.00123.2015; Rios D, 2016, MUCOSAL IMMUNOL, V9, P907, DOI 10.1038/mi.2015.121; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Sakhony OS, 2015, TISSUE BARRIERS, V3, DOI 10.1080/21688370.2015.1004975; Sato T, 2011, NATURE, V469, P415, DOI 10.1038/nature09637; Sato T, 2009, NATURE, V459, P262, DOI 10.1038/nature07935; Sehgal A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03638-6; Sehgal A, 2017, IMMUNOBIOLOGY, V222, P316, DOI 10.1016/j.imbio.2016.09.008; Shih BB, 2017, J PATHOL, V241, P600, DOI 10.1002/path.4864; Theocharidis A, 2009, NAT PROTOC, V4, P1535, DOI 10.1038/nprot.2009.177; Tiwari N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057329; van der Meer-van Kraaij C, 2007, GENES NUTR, V2, P275, DOI 10.1007/s12263-007-0058-x; van Es JH, 2005, NAT CELL BIOL, V7, P381, DOI 10.1038/ncb1240; Wark PAB, 2021, RESPIROLOGY, V26, P442, DOI 10.1111/resp.14003; Wrackmeyer U, 2006, BIOCHEMISTRY-US, V45, P9188, DOI 10.1021/bi060570x; Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3; Yanagihara S, 2017, INT IMMUNOL, V29, P357, DOI 10.1093/intimm/dxx043; Yang Q, 2001, SCIENCE, V294, P2155, DOI 10.1126/science.1065718	75	0	0	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 6	2021	12								761949	10.3389/fimmu.2021.761949	http://dx.doi.org/10.3389/fimmu.2021.761949			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XR1QZ	34938288	gold, Green Published			2022-12-18	WOS:000732014200001
J	Green, K; Wittenborn, TR; Fahlquist-Hagert, C; Terczynska-Dyla, E; van Campen, N; Jensen, L; Reinert, L; Hartmann, R; Paludan, SR; Degn, SE				Green, Kenneth; Wittenborn, Thomas R.; Fahlquist-Hagert, Cecilia; Terczynska-Dyla, Ewa; van Campen, Nina; Jensen, Lisbeth; Reinert, Line; Hartmann, Rune; Paludan, Soren R.; Degn, Soren E.			B Cell Intrinsic STING Signaling Is Not Required for Autoreactive Germinal Center Participation	FRONTIERS IN IMMUNOLOGY			English	Article						B cells; germinal centers; autoreactivity; autoimmunity; cGAS; STING; IFNAR; TLR7	IFN-GAMMA RECEPTOR; T-CELLS; INNATE; TOLERANCE; RESPONSES; TLR7; RECOGNITION; ACTIVATION; MECHANISMS; PROTECTION	Germinal centers (GCs) are induced microanatomical structures wherein B cells undergo affinity maturation to improve the quality of the antibody response. Although GCs are crucial to appropriate humoral responses to infectious challenges and vaccines, many questions remain about the molecular signals driving B cell participation in GC responses. The cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway is an important mediator of type I interferon and proinflammatory cytokine responses during infection and cellular stress. Recent studies have reported important roles for STING in B cell responses, including an impact on GC B cells and downstream antibody responses, which could have great consequences for vaccine design and understanding STING-associated interferonopathies. GCs are also involved in untoward reactions to autoantigens in a plethora of autoimmune disorders, and it is generally thought that these responses coopt the mechanisms used in foreign antigen-directed GCs. Here, we set out to investigate the importance of the cGAS-STING pathway in autoreactive B cell responses. In a direct competition scenario in a murine mixed bone marrow chimera model of autoreactive GCs, we find that B cell intrinsic deficiency of cGAS, STING, or the type I interferon receptor IFNAR, does not impair GC participation, whereas Toll-like receptor (TLR)-7 deficiency mediates a near-complete block. Our findings suggest that physiological B cell responses are strictly sustained by signals linked to BCR-mediated endocytosis. This wiring of B cell signals may enable appropriate antibody responses, while at the same time restricting aberrant antibody responses during infections and in autoimmune or autoinflammatory settings.	[Green, Kenneth; Wittenborn, Thomas R.; Fahlquist-Hagert, Cecilia; Terczynska-Dyla, Ewa; van Campen, Nina; Jensen, Lisbeth; Reinert, Line; Paludan, Soren R.; Degn, Soren E.] Aarhus Univ, Dept Biomed, Aarhus, Denmark; [Green, Kenneth; Hartmann, Rune] Aarhus Univ, Dept Mol Biol & Genet, Aarhus, Denmark; [van Campen, Nina] Radboud Univ Nijmegen, Dept BioMed Sci, Med Ctr, Nijmegen, Netherlands	Aarhus University; Aarhus University; Radboud University Nijmegen	Degn, SE (corresponding author), Aarhus Univ, Dept Biomed, Aarhus, Denmark.	sdegn@biomed.au.dk	Fahlquist-Hagert, Cecilia/M-6248-2019; Green, Kenneth/GXG-7646-2022; Degn, Soren/G-7936-2017	Fahlquist-Hagert, Cecilia/0000-0003-3850-4848; Green, Kenneth/0000-0001-7798-4763; Degn, Soren/0000-0001-5409-045X; Reinert, Line/0000-0002-8317-0886; Hartmann, Rune/0000-0003-1159-066X				Aarreberg LD, 2019, MOL CELL, V74, P801, DOI 10.1016/j.molcel.2019.02.038; Akkaya M, 2020, NAT REV IMMUNOL, V20, P229, DOI 10.1038/s41577-019-0244-2; Arbuckle MR, 2003, NEW ENGL J MED, V349, P1526, DOI 10.1056/NEJMoa021933; Berland R, 2006, IMMUNITY, V25, P429, DOI 10.1016/j.immuni.2006.07.014; Cerboni S, 2017, J EXP MED, V214, P1769, DOI 10.1084/jem.20161674; Chatterjee P, 2013, EUR J IMMUNOL, V43, P2441, DOI 10.1002/eji.201343412; Chin KH, 2013, ACTA CRYSTALLOGR D, V69, P352, DOI 10.1107/S0907444912047269; Chodisetti SB, 2020, J IMMUNOL, V204, P796, DOI 10.4049/jimmunol.1901175; Cornaby C, 2015, IMMUNOL LETT, V163, P56, DOI 10.1016/j.imlet.2014.11.001; Crow YJ, 2015, NAT REV IMMUNOL, V15, P429, DOI 10.1038/nri3850; Degn SE, 2017, CELL, V170, P913, DOI 10.1016/j.cell.2017.07.026; Deshmukh US, 2005, CLIN IMMUNOL, V117, P112, DOI 10.1016/j.clim.2005.07.002; Domeier PP, 2018, CELL REP, V24, P406, DOI 10.1016/j.celrep.2018.06.046; Domeier PP, 2017, AUTOIMMUNITY, V50, P4, DOI 10.1080/08916934.2017.1280671; Domeier PP, 2016, J EXP MED, V213, P715, DOI 10.1084/jem.20151722; Firl DJ, 2018, ELIFE, V7, DOI 10.7554/eLife.33051; Gao DX, 2015, P NATL ACAD SCI USA, V112, pE5699, DOI 10.1073/pnas.1516465112; Green NM, 2012, J BIOL CHEM, V287, DOI 10.1074/jbc.M112.383000; Green NM, 2009, J IMMUNOL, V183, P1569, DOI 10.4049/jimmunol.0803899; Gulen MF, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00573-w; Hua ZL, 2014, J IMMUNOL, V192, P875, DOI 10.4049/jimmunol.1300683; Ishikawa H, 2009, NATURE, V461, P788, DOI 10.1038/nature08476; Jackson SW, 2016, J EXP MED, V213, P733, DOI 10.1084/jem.20151724; Jackson SW, 2014, J IMMUNOL, V192, P4525, DOI 10.4049/jimmunol.1400098; Jeremiah N, 2014, J CLIN INVEST, V124, P5516, DOI 10.1172/JCI79100; Jing YK, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aax9455; Keller EJ, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.616064; Laimer J, 2016, BIOINFORMATICS, V32, P1414, DOI 10.1093/bioinformatics/btv769; Larkin B, 2017, J IMMUNOL, V199, P397, DOI 10.4049/jimmunol.1601999; Lau CM, 2005, J EXP MED, V202, P1171, DOI 10.1084/jem.20050630; Le Naour J, 2020, ONCOIMMUNOLOGY, V9, DOI 10.1080/2162402X.2020.1777624; Li XD, 2013, SCIENCE, V341, P1390, DOI 10.1126/science.1244040; Lund JM, 2004, P NATL ACAD SCI USA, V101, P5598, DOI 10.1073/pnas.0400937101; Mesin L, 2016, IMMUNITY, V45, P471, DOI 10.1016/j.immuni.2016.09.001; Motwani M, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.605930; Oh JZ, 2014, IMMUNITY, V41, P478, DOI 10.1016/j.immuni.2014.08.009; Okude H, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.625833; Paludan SR, 2019, NAT REV IMMUNOL, V19, P141, DOI 10.1038/s41577-018-0117-0; Powell AM, 2001, CLIN EXP DERMATOL, V26, P427, DOI 10.1046/j.1365-2230.2001.00852.x; Rahman A, 2008, NEW ENGL J MED, V358, P929, DOI 10.1056/NEJMra071297; Sauer JD, 2011, INFECT IMMUN, V79, P688, DOI 10.1128/IAI.00999-10; Schoggins JW, 2014, NATURE, V505, P691, DOI 10.1038/nature12862; Soni C, 2014, J IMMUNOL, V193, P4400, DOI 10.4049/jimmunol.1401720; Suthers AN, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00775; Suurmond J, 2016, CURR OPIN IMMUNOL, V43, P1, DOI 10.1016/j.coi.2016.07.002; Sweet RA, 2011, P NATL ACAD SCI USA, V108, P7932, DOI 10.1073/pnas.1018571108; Tan XJ, 2018, ANNU REV MICROBIOL, V72, P447, DOI 10.1146/annurev-micro-102215-095605; Tang CHA, 2021, CELL MOL IMMUNOL, V18, P1016, DOI 10.1038/s41423-020-00552-0; Thim-Uam A, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2020.101530; Vanderlugt CL, 2002, NAT REV IMMUNOL, V2, P85, DOI 10.1038/nri724; Victora GD, 2012, ANNU REV IMMUNOL, V30, P429, DOI 10.1146/annurev-immunol-020711-075032; Victora GD, 2010, CELL, V143, P592, DOI 10.1016/j.cell.2010.10.032; Vinuesa CG, 2009, NAT REV IMMUNOL, V9, P845, DOI 10.1038/nri2637; Walker MM, 2018, J IMMUNOL, V201, P2641, DOI 10.4049/jimmunol.1701405; Walsh ER, 2012, P NATL ACAD SCI USA, V109, P16276, DOI 10.1073/pnas.1209372109; Wittenborn TR, 2019, JOVE-J VIS EXP, DOI 10.3791/59397	56	0	0	2	12	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 6	2021	12								782558	10.3389/fimmu.2021.782558	http://dx.doi.org/10.3389/fimmu.2021.782558			18	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XR1RE	34938294	Green Published, gold			2022-12-18	WOS:000732014700001
J	Chen, M; Zhang, H; Chen, ZY; Dai, SM				Chen, Miao; Zhang, Hua; Chen, Zhiyong; Dai, Sheng-Ming			Perceptions of Rheumatologists on Diagnosis of Psoriatic Arthritis in China	FRONTIERS IN IMMUNOLOGY			English	Article						psoriatic arthritis; early diagnosis; rheumatologists' perceptions; questionnaire; survey	DACTYLITIS; EPIDEMIOLOGY; DELAY	ObjectiveHigh prevalence of undiagnosed psoriatic arthritis (PsA) and prolonged diagnostic delay are key troubles in the appropriate management of PsA. To analyze the possible causes for this phenomenon, a web-based nationwide survey was conducted to investigate rheumatologists' perceptions on PsA diagnosis in China. MethodsThe electronic questionnaire consisting of 38 questions were designed by an expert panel and distributed with the online survey tool Sojump, which is a professional online survey platform. The completed questionnaires by real-name rheumatologists were collected. ResultsA total of 1594 valid questionnaires were included. More than half of Chinese rheumatologists reported it was challenging to make a diagnosis of PsA. The four major challenges were "Difficulties in identification of atypical or hidden psoriasis", "Absence of diagnostic biomarkers", "No active self-report of history or family history of psoriasis" and "Various musculoskeletal manifestations". In diagnosing PsA, minor participants had incorrect knowledge of inflammatory arthropathy (13.7%), acute phase reactant (23.8%), and rheumatoid factor (28.7%). There were no significant differences in the knowledge of PsA and practice habits in diagnosing PsA between modern western medicine (WM)- and traditional Chinese medicine (TCM)-rheumatologists. The part-time rheumatologists were not as good as full-time rheumatologists in diagnosing PsA. ConclusionsAbout three quarters of Chinese rheumatologists are familiar with the elements in PsA diagnosis and have good practice habits in diagnosing PsA. Four main challenges in making PsA diagnosis are revealed. There was no significant difference in the knowledge of PsA between WM- and TCM-rheumatologists.	[Chen, Miao; Zhang, Hua; Chen, Zhiyong; Dai, Sheng-Ming] Shanghai Jiao Tong Univ, Dept Rheumatol & Immunol, Affiliated Peoples Hosp 6, Shanghai, Peoples R China	Shanghai Jiao Tong University	Dai, SM (corresponding author), Shanghai Jiao Tong Univ, Dept Rheumatol & Immunol, Affiliated Peoples Hosp 6, Shanghai, Peoples R China.	shengmingdai@163.com						Alinaghi F, 2019, J AM ACAD DERMATOL, V80, P251, DOI 10.1016/j.jaad.2018.06.027; Anandarajah AP, 2009, NAT REV RHEUMATOL, V5, P634, DOI 10.1038/nrrheum.2009.210; Brockbank JE, 2005, ANN RHEUM DIS, V64, P188, DOI 10.1136/ard.2003.018184; Coates LC, 2017, CLIN MED, V17, P65, DOI 10.7861/clinmedicine.17-1-65; D'Angelo S, 2016, EXPERT REV CLIN IMMU, V12, P1209, DOI 10.1080/1744666X.2016.1193436; Gladman DD, 2009, DERMATOL THER, V22, P40, DOI 10.1111/j.1529-8019.2008.01215.x; Gladman DD, 2005, ANN RHEUM DIS, V64, P14, DOI 10.1136/ard.2004.032482; GLADMAN DD, 1987, Q J MED, V62, P127; Gruber C, 2020, BIOMED REP, V13, DOI 10.3892/br.2020.1343; Haroon M, 2015, ANN RHEUM DIS, V74, P1045, DOI 10.1136/annrheumdis-2013-204858; Husni ME, 2015, RHEUM DIS CLIN N AM, V41, P677, DOI 10.1016/j.rdc.2015.07.008; Karmacharya P, 2021, J RHEUMATOL, V48, P1410, DOI 10.3899/jrheum.201199; Khondker L, 2014, Mymensingh Med J, V23, P609; Li R, 2012, RHEUMATOLOGY, V51, P721, DOI 10.1093/rheumatology/ker370; McGonagle D, 2019, NAT REV RHEUMATOL, V15, P113, DOI 10.1038/s41584-018-0147-9; Ocampo D Vanessa, 2019, F1000Res, V8, DOI 10.12688/f1000research.19144.1; Olivieri I, 2006, SCAND J RHEUMATOL, V35, P333, DOI 10.1080/03009740600906677; Perez-Alamino R, 2014, RHEUMATOL INT, V34, P1211, DOI 10.1007/s00296-014-2956-8; Punzi L, 2007, REUMATISMO, V59, P52, DOI 10.4081/reumatismo.2007.1s.52; Rida MA, 2020, CLIN IMMUNOL, V214, DOI 10.1016/j.clim.2020.108390; Rothschild BM, 1998, SEMIN ARTHRITIS RHEU, V28, P41, DOI 10.1016/S0049-0172(98)80027-9; Sukhov A, 2016, CLIN REV ALLERG IMMU, V51, P87, DOI 10.1007/s12016-016-8529-8; Taylor W, 2006, ARTHRITIS RHEUM, V54, P2665, DOI 10.1002/art.21972; Tencent, MONTHL ACT ACC WECHA; Theander E, 2014, ANN RHEUM DIS, V73, P407, DOI 10.1136/annrheumdis-2012-201972; Tillett W, 2013, ANN RHEUM DIS, V72, P1358, DOI 10.1136/annrheumdis-2012-202608; Veale DJ, 2018, LANCET, V391, P2273, DOI 10.1016/S0140-6736(18)30830-4; Yang Q, 2011, J EUR ACAD DERMATOL, V25, P1409, DOI 10.1111/j.1468-3083.2011.03985.x; Zhang FC., 2014, CHIN J ALLERGY CLIN, V8, P165, DOI 10.3969/j.issn.1673-8705.2014.03.001; Zhang XT, 2017, BMC MED INFORM DECIS, V17, DOI 10.1186/s12911-017-0470-0	30	0	0	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 3	2021	12								733708	10.3389/fimmu.2021.733708	http://dx.doi.org/10.3389/fimmu.2021.733708			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XP6XU	34925316	Green Published, gold			2022-12-18	WOS:000731007100001
J	Zhang, HN; Xue, JB; Wang, AZL; Jiang, HW; Merugu, SB; Li, DW; Tao, SC				Zhang, Hai-nan; Xue, Jun-biao; Wang, Aru Ze-ling; Jiang, He-wei; Merugu, Siva Bhararth; Li, Da-wei; Tao, Sheng-ce			EASINESS: E. coli Assisted Speedy affINity-maturation Evolution SyStem	FRONTIERS IN IMMUNOLOGY			English	Article						antibody affinity improvement; directed evolution; error-prone DNA polymerase I; protein-fragment complementation assay	ANTIBODIES IN-VITRO; ESCHERICHIA-COLI; DIHYDROFOLATE-REDUCTASE; ERROR-PRONE; DISPLAY; PROTEIN; CONSTRUCTION	Antibodies are one of the most important groups of biomolecules for both clinical and basic research and have been developed as potential therapeutics. Affinity is the key feature for biological activity and clinical efficacy of an antibody, especially of therapeutic antibodies, and thus antibody affinity improvement is indispensable and still remains challenging. To address this issue, we developed the E. coli Assisted Speed affINity-maturation Evolution SyStem (EASINESS) for continuous directed evolution of Ag-Ab interactions. Two key components of EASINESS include a mutation system modified from error-prone DNA polymerase I (Pol I) that selectively mutates ColE1 plasmids in E. coli and a protein-protein interaction selection system from mDHFR split fragments. We designed a GCN4 variant which barely forms a homodimer, and during a single round of evolution, we reversed the homodimer formation activity from the GCN4 variant to verify the feasibility of EASINESS. We then selected a potential therapeutic antibody 18A4Hu and improved the affinity of the antibody (18A4Hu) to its target (ARG2) 12-fold in 7 days while requiring very limited hands-on time. Remarkably, these variants of 18A4Hu revealed a significant improved ability to inhibit melanoma pulmonary metastasis in a mouse model. These results indicate EASINESS could be as an attractive choice for antibody affinity maturation.	[Zhang, Hai-nan; Xue, Jun-biao; Jiang, He-wei; Tao, Sheng-ce] Shanghai Jiao Tong Univ, Shanghai Ctr Syst Biomed, Key Lab Syst Biomed, Minist Educ, Shanghai, Peoples R China; [Wang, Aru Ze-ling; Merugu, Siva Bhararth; Li, Da-wei] Shanghai Jiao Tong Univ, Engn Res Ctr Cell & Therapeut Antibody, Minist Educ, Sch Pharm, Shanghai, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University	Tao, SC (corresponding author), Shanghai Jiao Tong Univ, Shanghai Ctr Syst Biomed, Key Lab Syst Biomed, Minist Educ, Shanghai, Peoples R China.; Li, DW (corresponding author), Shanghai Jiao Tong Univ, Engn Res Ctr Cell & Therapeut Antibody, Minist Educ, Sch Pharm, Shanghai, Peoples R China.	daweili@sjtu.edu.cn; taosc@sjtu.edu.cn		Xue, Junbiao/0000-0003-2975-4095				Adams GP, 2005, NAT BIOTECHNOL, V23, P1147, DOI 10.1038/nbt1137; Ahmad ZA, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/980250; Baym M, 2016, SCIENCE, V353, P1147, DOI 10.1126/science.aag0822; Boder ET, 1997, NAT BIOTECHNOL, V15, P553, DOI 10.1038/nbt0697-553; Borrebaeck CAK, 2000, IMMUNOL TODAY, V21, P379, DOI 10.1016/S0167-5699(00)01683-2; Brychtova V, 2011, CANCER LETT, V304, P1, DOI 10.1016/j.canlet.2010.12.023; Camps M, 2003, P NATL ACAD SCI USA, V100, P9727, DOI 10.1073/pnas.1333928100; Che T, 2018, CELL, V172, P55, DOI 10.1016/j.cell.2017.12.011; Chen F, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06271-5; Chen SP, 2012, PROTEIN CELL, V3, P460, DOI 10.1007/s13238-012-2024-7; Crameri A, 1996, NAT MED, V2, P100, DOI 10.1038/nm0196-100; Cumbers SJ, 2002, NAT BIOTECHNOL, V20, P1129, DOI 10.1038/nbt752; Esvelt KM, 2011, NATURE, V472, P499, DOI 10.1038/nature09929; Fessart D, 2016, ELIFE, V5, DOI 10.7554/eLife.13887; Guo H, 2016, BIOCHEM BIOPH RES CO, V475, P57, DOI 10.1016/j.bbrc.2016.05.033; Halperin SO, 2018, NATURE, V560, P248, DOI 10.1038/s41586-018-0384-8; Hanes J, 1998, P NATL ACAD SCI USA, V95, P14130, DOI 10.1073/pnas.95.24.14130; HOPE IA, 1987, EMBO J, V6, P2781, DOI 10.1002/j.1460-2075.1987.tb02573.x; HOWELL EE, 1988, J BACTERIOL, V170, P3040, DOI 10.1128/jb.170.7.3040-3045.1988; Kani K, 2013, PROSTATE, V73, P306, DOI 10.1002/pros.22569; Kaplon H, 2021, MABS-AUSTIN, V13, DOI 10.1080/19420862.2020.1860476; Kaplon H, 2020, MABS-AUSTIN, V12, DOI 10.1080/19420862.2019.1703531; Lewis L, 2012, METHODS MOL BIOL, V805, P139, DOI 10.1007/978-1-61779-379-0_9; Liu NK, 1998, PROTEIN SCI, V7, P1214, DOI 10.1002/pro.5560070517; Lu RM, 2020, J BIOMED SCI, V27, DOI 10.1186/s12929-019-0592-z; MARKS JD, 1992, BIO-TECHNOL, V10, P779, DOI 10.1038/nbt0792-779; MCCAFFERTY J, 1990, NATURE, V348, P552, DOI 10.1038/348552a0; Mosberg JA, 2010, GENETICS, V186, P791, DOI 10.1534/genetics.110.120782; Negi H, 2019, CANCER LETT, V449, P125, DOI 10.1016/j.canlet.2019.01.025; Pelletier JN, 1998, P NATL ACAD SCI USA, V95, P12141, DOI 10.1073/pnas.95.21.12141; Quan Shu, 2013, Methods Mol Biol, V966, P359, DOI 10.1007/978-1-62703-245-2_22; Qudsia S, 2018, BIOCHEM BIOPH RES CO, V499, P71, DOI 10.1016/j.bbrc.2018.03.131; Rafiq S, 2018, NAT BIOTECHNOL, V36, P847, DOI 10.1038/nbt.4195; Ravikumar A, 2018, CELL, V175, P1946, DOI 10.1016/j.cell.2018.10.021; Reader RH, 2019, MOL BIOTECHNOL, V61, P801, DOI 10.1007/s12033-019-00207-0; Richter MF, 2020, NAT BIOTECHNOL, V38, P883, DOI 10.1038/s41587-020-0453-z; Rix G, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19539-6; Shi R, 2020, NATURE, V584, P120, DOI 10.1038/s41586-020-2381-y; Singh A, 2006, P NATL ACAD SCI USA, V103, P11346, DOI 10.1073/pnas.0602817103; SKERRA A, 1988, SCIENCE, V240, P1038, DOI 10.1126/science.3285470; Thul PJ, 2017, SCIENCE, V356, DOI 10.1126/science.aal3321; Uhlen M, 2015, SCIENCE, V347, DOI 10.1126/science.1260419; Walker LM, 2009, SCIENCE, V326, P285, DOI 10.1126/science.1178746; Wellner A, 2021, NAT CHEM BIOL, V17, P1057, DOI [10.1038/s41589-021-00832-4, 10.1101/2020.11.11.378778]; Wu YL, 2020, CELL HOST MICROBE, V27, P891, DOI 10.1016/j.chom.2020.04.023; Wu Zheng-Hua, 2010, Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, V26, P49; YANG WP, 1995, J MOL BIOL, V254, P392, DOI 10.1006/jmbi.1995.0626; Zhao N, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10846-1; Zhou YZ, 2016, MICROB CELL FACT, V15, DOI 10.1186/s12934-016-0445-3	49	0	0	7	16	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 3	2021	12								747267	10.3389/fimmu.2021.747267	http://dx.doi.org/10.3389/fimmu.2021.747267			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XP7CY	34925322	Green Published, gold			2022-12-18	WOS:000731020700001
J	Cevey, AC; Mascolo, PD; Penas, FN; Pieralisi, AV; Sequeyra, AS; Mirkin, GA; Goren, NB				Cevey, Agata C.; Mascolo, Paula D.; Penas, Federico N.; Pieralisi, Azul V.; Sequeyra, Aldana S.; Mirkin, Gerardo A.; Goren, Nora B.			Benznidazole Anti-Inflammatory Effects in Murine Cardiomyocytes and Macrophages Are Mediated by Class I PI3K delta	FRONTIERS IN IMMUNOLOGY			English	Article						benznidazole; anti-inflammatory effects; PI3K; AKT pathway; macrophages (M1; M2); inflammatory mediators; cardiomyocytes	INDUCED INFLAMMATORY RESPONSE; NITRIC-OXIDE SYNTHASE; CHAGAS-DISEASE; ALTERNATIVE ACTIVATION; ETIOLOGIC TREATMENT; TRYPANOSOMA-CRUZI; SIGNALING PATHWAY; INNATE; PI3K; DIFFERENTIATION	Benznidazole (Bzl), the drug of choice in many countries for the treatment of Chagas disease, leads to parasite clearance in the early stages of infection and contributes to immunomodulation. In addition to its parasiticidal effect, Bzl inhibits the NF-kappa B pathway. In this regard, we have previously described that this occurs through IL-10/STAT3/SOCS3 pathway. PI3K pathway is involved in the regulation of the immune system by inhibiting NF-kappa B pathway through STAT3. In this work, the participation of PI3K in the immunomodulatory effects of Bzl in cardiac and immune cells, the main targets of Chagas disease, was further studied. For that, we use a murine primary cardiomyocyte culture and a monocyte/macrophage cell line (RAW 264.7), stimulated with LPS in presence of LY294002, an inhibitor of PI3K. Under these conditions, Bzl could neither increase SOCS3 expression nor inhibit the NOS2 mRNA expression and the release of NOx, both in cardiomyocytes and macrophages. Macrophages are crucial in the development of Chronic Chagas Cardiomyopathy. Thus, to deepen our understanding of how Bzl acts, the expression profile of M1-M2 macrophage markers was evaluated. Bzl inhibited the release of NOx (M1 marker) and increased the expression of Arginase I (M2 marker) and a negative correlation was found between them. Besides, LPS increased the expression of pro-inflammatory cytokines. Bzl treatment not only inhibited this effect but also increased the expression of typical M2-macrophage markers like Mannose Receptor, TGF-beta, and VEGF-A. Moreover, Bzl increased the expression of PPAR-gamma and PPAR-alpha, known as key regulators of macrophage polarization. PI3K directly regulates M1-to-M2 macrophage polarization. Since p110 delta, catalytic subunit of PI3K delta, is highly expressed in immune cells, experiments were carried out in presence of CAL-101, a specific inhibitor of this subunit. Under this condition, Bzl could neither increase SOCS3 expression nor inhibit NF-kappa B pathway. Moreover, Bzl not only failed to inhibit the expression of pro-inflammatory cytokines (M1 markers) but also could not increase M2 markers. Taken together these results demonstrate, for the first time, that the anti-inflammatory effect of Bzl depends on PI3K activity in a cell line of murine macrophages and in primary culture of neonatal cardiomyocytes. Furthermore, Bzl-mediated increase expression of M2-macrophage markers involves the participation of the p110 delta catalytic subunit of PI3K delta.	[Cevey, Agata C.; Penas, Federico N.; Mirkin, Gerardo A.; Goren, Nora B.] Univ Buenos Aires, Fac Med, Dept Microbiol Parasitol & Inmunol, Buenos Aires, DF, Argentina; [Cevey, Agata C.; Mascolo, Paula D.; Penas, Federico N.; Pieralisi, Azul V.; Sequeyra, Aldana S.; Goren, Nora B.] Univ Buenos Aires, CONICET, Inst Invest Biomed Retrovirus & SIDA, Buenos Aires, DF, Argentina; [Mirkin, Gerardo A.] Univ Buenos Aires, CONICET, Inst Invest Microbiol & Parasitol Med, Buenos Aires, DF, Argentina	University of Buenos Aires; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires	Cevey, AC; Goren, NB (corresponding author), Univ Buenos Aires, Fac Med, Dept Microbiol Parasitol & Inmunol, Buenos Aires, DF, Argentina.; Cevey, AC; Goren, NB (corresponding author), Univ Buenos Aires, CONICET, Inst Invest Biomed Retrovirus & SIDA, Buenos Aires, DF, Argentina.	acevey@fmed.uba.ar; ngoren@fmed.uba.ar						Aksoy E, 2012, NAT IMMUNOL, V13, P1045, DOI 10.1038/ni.2426; Bai WJ, 2014, CELL SIGNAL, V26, P942, DOI 10.1016/j.cellsig.2014.01.015; Beaver BV, 2001, J AM VET MED ASSOC, V218, P669, DOI 10.2460/javma.2001.218.669; Bryan NS, 2007, FREE RADICAL BIO MED, V43, P645, DOI 10.1016/j.freeradbiomed.2007.04.026; Bustin SA, 2009, CLIN CHEM, V55, P611, DOI 10.1373/clinchem.2008.112797; Campi-Azevedo AC, 2015, IMMUNOBIOLOGY, V220, P564, DOI 10.1016/j.imbio.2014.12.006; Cevey AC, 2016, INT J PARASITOL-DRUG, V6, P12, DOI 10.1016/j.ijpddr.2015.12.001; Cevey AC, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01267; Chen XS, 2021, INT IMMUNOPHARMACOL, V96, DOI 10.1016/j.intimp.2021.107791; Christofides A, 2021, METABOLISM, V114, DOI 10.1016/j.metabol.2020.154338; Coste A, 2003, IMMUNITY, V19, P329, DOI 10.1016/S1074-7613(03)00229-2; Covarrubias AJ, 2015, SEMIN IMMUNOL, V27, P286, DOI 10.1016/j.smim.2015.08.001; Cunha-Neto E, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/683230; DiazGuerra MJM, 1996, J BIOL CHEM, V271, P30114, DOI 10.1074/jbc.271.47.30114; Dos-Santos ALA, 2016, EXP PARASITOL, V167, P67, DOI 10.1016/j.exppara.2016.05.005; Du Y, 2021, J CELL MOL MED, V25, P7524, DOI 10.1111/jcmm.16788; Fallah MP, 2011, MECH AGEING DEV, V132, P274, DOI 10.1016/j.mad.2011.05.003; Gharbi SI, 2007, BIOCHEM J, V404, P15, DOI 10.1042/BJ20061489; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Gordon S, 2010, IMMUNITY, V32, P593, DOI 10.1016/j.immuni.2010.05.007; Hawkins PT, 2015, BBA-MOL CELL BIOL L, V1851, P882, DOI 10.1016/j.bbalip.2014.12.006; Jackson Y, 2020, J ANTIMICROB CHEMOTH, V75, P690, DOI 10.1093/jac/dkz473; Jantsch J, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00146; Kaneda MM, 2016, NATURE, V539, P437, DOI 10.1038/nature19834; Kruger NJ, 2009, SPRINGER PROTOC HAND, P17, DOI 10.1007/978-1-59745-198-7_4; Lafuse WP, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10010051; Lambertucci F, 2017, TOXICOL APPL PHARM, V315, P12, DOI 10.1016/j.taap.2016.11.015; Long Y, 2018, BIOMED PHARMACOTHER, V105, P781, DOI 10.1016/j.biopha.2018.06.011; Lopez-Pelaez M, 2011, EUR J IMMUNOL, V41, P1733, DOI 10.1002/eji.201041101; Luo L, 2018, CELL REP, V24, P3033, DOI 10.1016/j.celrep.2018.08.028; Machado FS, 2012, CARDIOL REV, V20, P53, DOI 10.1097/CRD.0b013e31823efde2; Manning BD, 2017, CELL, V169, P381, DOI 10.1016/j.cell.2017.04.001; Marin JA, 2007, CIRCULATION, V115, P1109, DOI 10.1161/CIRCULATIONAHA.106.624296; Matheny RW, 2009, EXP BIOL MED, V234, P1264, DOI 10.3181/0904-MR-138; Mills CD, 2012, CRIT REV IMMUNOL, V32, P463, DOI 10.1615/CritRevImmunol.v32.i6.10; Ministerio de Salud de la Nacion Argentina, 2018, AT PAC INF CON TRYP; Mitelman J., 2011, ARGENTINIAN J CARDIO, V79, P544; Murray PJ, 2011, NAT REV IMMUNOL, V11, P723, DOI 10.1038/nri3073; Penas FN, 2020, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02955; Nishikoba N, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.02135; O'Neill LAJ, 2013, NATURE, V493, P346, DOI 10.1038/nature11862; Odegaard JI, 2007, NATURE, V447, P1116, DOI 10.1038/nature05894; Okkenhaug K, 2003, NAT REV IMMUNOL, V3, P317, DOI 10.1038/nri1056; Orecchioni M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01084; Rigalli JP, 2016, TOXICOL APPL PHARM, V304, P90, DOI 10.1016/j.taap.2016.05.007; Pascutti MF, 2004, LIFE SCI, V76, P685, DOI 10.1016/j.lfs.2004.09.013; Perino A, 2011, MOL CELL, V42, P84, DOI 10.1016/j.molcel.2011.01.030; Piaggio E, 2001, J IMMUNOL, V167, P3422, DOI 10.4049/jimmunol.167.6.3422; Pillai-Kastoori L, 2020, ANAL BIOCHEM, V593, DOI 10.1016/j.ab.2020.113608; Rada J, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.572178; Raether W, 2003, PARASITOL RES, V90, pS19, DOI 10.1007/s00436-002-0754-9; Rathinaswamy Manoj K., 2020, Advances in Biological Regulation, V75, P100657, DOI 10.1016/j.jbior.2019.100657; Revelli S, 1999, CLIN EXP IMMUNOL, V118, P271; Rocher C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084009; Rosadini CV, 2017, CURR OPIN IMMUNOL, V44, P14, DOI 10.1016/j.coi.2016.10.005; Sahin E, 2014, J IMMUNOL, V193, P1717, DOI 10.4049/jimmunol.1302167; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Shimizu-Hirota R, 2012, GENE DEV, V26, P395, DOI 10.1101/gad.178749.111; Song J, 2017, SCI REP-UK, V7, DOI [10.1038/s41598-017-07199-4, 10.1038/srep42521]; Sosa-Estani S, 2006, CURR OPIN INFECT DIS, V19, P583, DOI 10.1097/01.qco.0000247592.21295.a5; Thorpe LM, 2015, NAT REV CANCER, V15, P7, DOI 10.1038/nrc3860; Torrico F, 2021, LANCET INFECT DIS, V21, P1129, DOI 10.1016/S1473-3099(20)30844-6; Trachtenberg BH, 2017, CIRC RES, V121, P803, DOI 10.1161/CIRCRESAHA.117.310221; Traves PG, 2014, CHEM BIOL, V21, P955, DOI 10.1016/j.chembiol.2014.06.005; Troutman TD, 2012, CELL CYCLE, V11, P3559, DOI 10.4161/cc.21572; Tsukamoto K, 2008, J IMMUNOL, V180, P2054, DOI 10.4049/jimmunol.180.4.2054; Vecile E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053265; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Wei Y, 2021, EXP CELL RES, V402, DOI 10.1016/j.yexcr.2021.112575; Weichhart T, 2008, IMMUNITY, V29, P565, DOI 10.1016/j.immuni.2008.08.012; Weisser SB, 2011, EUR J IMMUNOL, V41, P1742, DOI 10.1002/eji.201041105; Wilkinson SR, 2011, CURR TOP MED CHEM, V11, P2072; World Health Organization (WHO), 2019, CHAG DIS AM TRYP; Wynn TA, 2013, NATURE, V496, P445, DOI 10.1038/nature12034; Xie A, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.117.007805; Zhang B, 2016, MOL IMMUNOL, V76, P98, DOI 10.1016/j.molimm.2016.06.016; Zhang DL, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09014-2; Zhou Ting, 2018, Zhonghua Wei Zhong Bing Ji Jiu Yi Xue, V30, P1091, DOI 10.3760/cma.j.issn.2095-4352.2018.011.016	78	0	0	2	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 2	2021	12								782891	10.3389/fimmu.2021.782891	http://dx.doi.org/10.3389/fimmu.2021.782891			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XO8NN	34925364	gold, Green Published			2022-12-18	WOS:000730435500001
J	Kim, M; Cheong, Y; Lee, J; Lim, J; Byun, S; Jang, YH; Seong, BL				Kim, Minjin; Cheong, Yucheol; Lee, Jinhee; Lim, Jongkwan; Byun, Sanguine; Jang, Yo Han; Seong, Baik Lin			A Host-Restricted Self-Attenuated Influenza Virus Provides Broad Pan-Influenza A Protection in a Mouse Model	FRONTIERS IN IMMUNOLOGY			English	Article						influenza virus; universal vaccine; host-restriction; live-attenuated vaccine; cross-protection	FC-GAMMA-RIV; CONFORMATIONAL-CHANGE; CASPASE FAMILY; SECRETORY IGA; VACCINE; PROTEIN; ANTIBODIES; CHALLENGE; INFECTION; NUCLEOPROTEIN	Influenza virus infections can cause a broad range of symptoms, form mild respiratory problems to severe and fatal complications. While influenza virus poses a global health threat, the frequent antigenic change often significantly compromises the protective efficacy of seasonal vaccines, further increasing the vulnerability to viral infection. Therefore, it is in great need to employ strategies for the development of universal influenza vaccines (UIVs) which can elicit broad protection against diverse influenza viruses. Using a mouse infection model, we examined the breadth of protection of the caspase-triggered live attenuated influenza vaccine (ctLAIV), which was self-attenuated by the host caspase-dependent cleavage of internal viral proteins. A single vaccination in mice induced a broad reactive antibody response against four different influenza viruses, H1 and rH5 (HA group 1) and H3 and rH7 subtypes (HA group 2). Notably, despite the lack of detectable neutralizing antibodies, the vaccination provided heterosubtypic protection against the lethal challenge with the viruses. Sterile protection was confirmed by the complete absence of viral titers in the lungs and nasal turbinates after the challenge. Antibody-dependent cellular cytotoxicity (ADCC) activities of non-neutralizing antibodies contributed to cross-protection. The cross-protection remained robust even after in vivo depletion of T cells or NK cells, reflecting the strength and breadth of the antibody-dependent effector function. The robust mucosal secretion of sIgA reflects an additional level of cross-protection. Our data show that the host-restricted designer vaccine serves an option for developing a UIV, providing pan-influenza A protection against both group 1 and 2 influenza viruses. The present results of potency and breadth of protection from wild type and reassortant viruses addressed in the mouse model by single immunization merits further confirmation and validation, preferably in clinically relevant ferret models with wild type challenges.	[Kim, Minjin; Byun, Sanguine] Yonsei Univ, Coll Life Sci & Biotechnol, Grad Program Biomat Sci & Engn, Seoul, South Korea; [Cheong, Yucheol; Lim, Jongkwan; Byun, Sanguine] Yonsei Univ, Coll Life Sci & Biotechnol, Dept Biotechnol, Seoul, South Korea; [Lee, Jinhee] Yonsei Univ, Coll Life Sci & Biotechnol, Dept Integrated OMICS Biomed Sci, Seoul, South Korea; [Jang, Yo Han] Andong Natl Univ, Dept Biol Sci & Biotechnol Major Biovaccine Engn, Andong, South Korea; [Jang, Yo Han] Andong Natl Univ, Vaccine Ind Res Inst, Andong, South Korea; [Seong, Baik Lin] Yonsei Univ, Coll Med, Dept Microbiol, Seoul, South Korea; [Seong, Baik Lin] Yonsei Univ, Vaccine Innovat Technol ALliance VITAL Korea, Seoul, South Korea	Yonsei University; Yonsei University; Yonsei University; Andong National University; Andong National University; Yonsei University; Yonsei University Health System; Yonsei University	Byun, S (corresponding author), Yonsei Univ, Coll Life Sci & Biotechnol, Grad Program Biomat Sci & Engn, Seoul, South Korea.; Byun, S (corresponding author), Yonsei Univ, Coll Life Sci & Biotechnol, Dept Biotechnol, Seoul, South Korea.; Jang, YH (corresponding author), Andong Natl Univ, Dept Biol Sci & Biotechnol Major Biovaccine Engn, Andong, South Korea.; Jang, YH (corresponding author), Andong Natl Univ, Vaccine Ind Res Inst, Andong, South Korea.; Seong, BL (corresponding author), Yonsei Univ, Coll Med, Dept Microbiol, Seoul, South Korea.; Seong, BL (corresponding author), Yonsei Univ, Vaccine Innovat Technol ALliance VITAL Korea, Seoul, South Korea.	sanguine@yonsei.ac.kr; yhjh0323@anu.ac.kr; blseong@yonsei.ac.kr						Asahi-Ozaki Y, 2004, J MED VIROL, V74, P328, DOI 10.1002/jmv.20173; Balz K, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00513; Barber GN, 2001, CELL DEATH DIFFER, V8, P113, DOI 10.1038/sj.cdd.4400823; BASTIN J, 1987, J EXP MED, V165, P1508, DOI 10.1084/jem.165.6.1508; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; Carrat F, 2007, VACCINE, V25, P6852, DOI 10.1016/j.vaccine.2007.07.027; Chae W, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-56169-5; Chae W, 2019, VACCINE, V37, P1457, DOI 10.1016/j.vaccine.2019.01.068; Clemens EB, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6020018; Coughlan L, 2018, CELL HOST MICROBE, V24, P18, DOI 10.1016/j.chom.2018.06.016; Deng L, 2015, VACCINES-BASEL, V3, P105, DOI 10.3390/vaccines3010105; Erbelding EJ, 2018, J INFECT DIS, V218, P347, DOI 10.1093/infdis/jiy103; Fiers W, 2009, VACCINE, V27, P6280, DOI 10.1016/j.vaccine.2009.07.007; Fu TM, 2009, VIROLOGY, V385, P218, DOI 10.1016/j.virol.2008.11.035; Gerdil C, 2003, VACCINE, V21, P1776, DOI 10.1016/S0264-410X(03)00071-9; GREENBERG SB, 1978, INFECT IMMUN, V20, P640, DOI 10.1128/IAI.20.3.640-645.1978; Guo L, 2014, EMERG INFECT DIS, V20, P192, DOI 10.3201/eid2002.131094; Hai R, 2012, J VIROL, V86, P5774, DOI 10.1128/JVI.00137-12; Hale BG, 2008, J GEN VIROL, V89, P2359, DOI 10.1099/vir.0.2008/004606-0; Hamilton BS, 2012, VIRUSES-BASEL, V4, P1144, DOI 10.3390/v4071144; Hampson AW, 2006, MED J AUSTRALIA, V185, pS39; Harrison SC, 2008, NAT STRUCT MOL BIOL, V15, P690, DOI 10.1038/nsmb.1456; Horimoto T, 2005, NAT REV MICROBIOL, V3, P591, DOI 10.1038/nrmicro1208; Huber VC, 2001, J IMMUNOL, V166, P7381, DOI 10.4049/jimmunol.166.12.7381; Isakova-Sivak I, 2011, VIROLOGY, V412, P297, DOI 10.1016/j.virol.2011.01.004; Iuliano AD, 2018, LANCET, V391, P1285, DOI 10.1016/S0140-6736(17)33293-2; Jang YH, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040353; Jang YH, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00344; Jang YH, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00116; Jang YH, 2014, VIRUSES-BASEL, V6, P3159, DOI 10.3390/v6083159; Jang YH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075043; Jang YH, 2012, CLIN EXP VACCINE RES, V1, P35, DOI 10.7774/cevr.2012.1.1.35; Jang YH, 2013, YONSEI MED J, V54, P271, DOI 10.3349/ymj.2013.54.2.271; Jegaskanda S, 2017, J INFECT DIS, V215, P818, DOI 10.1093/infdis/jiw629; Jegaskanda S, 2014, J IMMUNOL, V193, P469, DOI 10.4049/jimmunol.1400432; Krammer F, 2019, NAT REV IMMUNOL, V19, P383, DOI 10.1038/s41577-019-0143-6; Krammer F, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a028845; Krammer F, 2015, CURR TOP MICROBIOL, V386, P301, DOI 10.1007/82_2014_408; Kumar A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00600; Labbe K, 2008, CELL DEATH DIFFER, V15, P1339, DOI 10.1038/cdd.2008.91; Lee YJ, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.00083; Liao TL, 2010, EMBO J, V29, P3879, DOI 10.1038/emboj.2010.250; LUYTJES W, 1989, CELL, V59, P1107, DOI 10.1016/0092-8674(89)90766-6; MELLMAN I, 1988, J CELL SCI, P45; Muramatsu M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085582; Nachbagauer R, 2017, NPJ VACCINES, V2, DOI 10.1038/s41541-017-0026-4; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Nimmerjahn F, 2005, IMMUNITY, V23, P41, DOI 10.1016/j.immuni.2005.05.010; Nimmerjahn F, 2010, P NATL ACAD SCI USA, V107, P19396, DOI 10.1073/pnas.1014515107; Otten MA, 2004, IMMUNOL LETT, V92, P23, DOI 10.1016/j.imlet.2003.11.018; Palese P, 2004, NAT MED, V10, pS82, DOI 10.1038/nm1141; Palese P, 1996, P NATL ACAD SCI USA, V93, P11354, DOI 10.1073/pnas.93.21.11354; Powell TJ, 2007, J IMMUNOL, V178, P1030, DOI 10.4049/jimmunol.178.2.1030; Reljic R, 2006, IMMUNOL LETT, V107, P80, DOI 10.1016/j.imlet.2006.04.014; Roulston A, 1999, ANNU REV MICROBIOL, V53, P577, DOI 10.1146/annurev.micro.53.1.577; Schmeisser F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117108; Schotsaert M, 2009, EXPERT REV VACCINES, V8, P499, DOI [10.1586/erv.09.6, 10.1586/ERV.09.6]; Seo SU, 2007, VACCINE, V25, P8067, DOI 10.1016/j.vaccine.2007.09.012; Suzuki T, 2015, P NATL ACAD SCI USA, V112, P7809, DOI 10.1073/pnas.1503885112; Talanian RV, 1997, J BIOL CHEM, V272, P9677; Tamm A, 1997, Int Rev Immunol, V16, P57, DOI 10.3109/08830189709045703; Tan GS, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005578; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; Treanor J, 2004, NEW ENGL J MED, V350, P218, DOI 10.1056/NEJMp038238; Tricco AC, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-153; VIRELIZIER JL, 1977, NATURE, V266, P52, DOI 10.1038/266052a0; Von Holle TA, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01457; WEBSTER RG, 1992, MICROBIOL REV, V56, P152, DOI 10.1128/MMBR.56.1.152-179.1992; WHITE JM, 1987, J CELL BIOL, V105, P2887, DOI 10.1083/jcb.105.6.2887; Zheng M, 2014, INFECTION, V42, P251, DOI 10.1007/s15010-013-0546-4; Zhou B, 2016, J VIROL, V90, P8454, DOI 10.1128/JVI.00163-16; Zhu QY, 2008, J VIROL, V82, P220, DOI 10.1128/JVI.00978-07; Zwick A, 2019, J IMMUNOL METHODS, V473, DOI 10.1016/j.jim.2019.112644	74	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 2	2021	12								779223	10.3389/fimmu.2021.779223	http://dx.doi.org/10.3389/fimmu.2021.779223			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XP0UL	34925355	gold, Green Published			2022-12-18	WOS:000730589800001
J	Gunther, RC; Bharathi, V; Miles, SD; Tumey, LR; Schmedes, CM; Tatsumi, K; Bridges, MD; Martinez, D; Montgomery, SA; Beck, MA; Camerer, E; Mackman, N; Antoniak, S				Gunther, Randall C.; Bharathi, Vanthana; Miles, Stephen D.; Tumey, Lauryn R.; Schmedes, Clare M.; Tatsumi, Kohei; Bridges, Meagan D.; Martinez, David; Montgomery, Stephanie A.; Beck, Melinda A.; Camerer, Eric; Mackman, Nigel; Antoniak, Silvio			Myeloid Protease-Activated Receptor-2 Contributes to Influenza A Virus Pathology in Mice	FRONTIERS IN IMMUNOLOGY			English	Article						toll-like receptor 3; influenza A virus; innate immune response; macrophage; lung epithelial cell; protease-activated receptor 2 (PAR2); F2rl1	ANCHORED SERINE-PROTEASE; INNATE IMMUNE-RESPONSE; ALVEOLAR MACROPHAGES; EPITHELIAL-CELLS; UP-REGULATION; INFECTION; INFLAMMATION; REPLICATION; MATRIPTASE; RNA	BackgroundInnate immune responses to influenza A virus (IAV) infection are initiated in part by toll-like receptor 3 (TLR3). TLR3-dependent signaling induces an antiviral immune response and an NF kappa B-dependent inflammatory response. Protease-activated receptor 2 (PAR2) inhibits the antiviral response and enhances the inflammatory response. PAR2 deficiency protected mice during IAV infection. However, the PAR2 expressing cell-types contributing to IAV pathology in mice and the mechanism by which PAR2 contributes to IAV infection is unknown. MethodsIAV infection was analyzed in global (Par2(-/-)), myeloid (Par2(fl/fl);LysM(Cre+)) and lung epithelial cell (EpC) Par2 deficient (Par2(fl/fl);SPCCre+) mice and their respective controls (Par2(+/+) and Par2(fl/fl)). In addition, the effect of PAR2 activation on polyinosinic-polycytidylic acid (poly I:C) activation of TLR3 was analyzed in bone marrow-derived macrophages (BMDM). Lastly, we determined the effect of PAR2 inhibition in wild-type (WT) mice. ResultsAfter IAV infection, Par2(-/-) and mice with myeloid Par2 deficiency exhibited increased survival compared to infected controls. The improved survival was associated with reduced proinflammatory mediators and reduced cellular infiltration in bronchoalveolar lavage fluid (BALF) of Par2(-/-) and Par2(fl/fl);LysM(Cre+) 3 days post infection (dpi) compared to infected control mice. Interestingly, Par2(fl/fl);SPCCre+ mice showed no survival benefit compared to Par2(fl/fl). In vitro studies showed that Par2(-/-) BMDM produced less IL6 and IL12p40 than Par2(+/+) BMDM after poly I:C stimulation. In addition, activation of PAR2 on Par2(+/+) BMDM increased poly I:C induction of IL6 and IL12p40 compared to poly I:C stimulation alone. Importantly, PAR2 inhibition prior to IAV infection protect WT mice. ConclusionGlobal Par2 or myeloid cell but not lung EpC Par2 deficiency was associated with reduced BALF inflammatory markers and reduced IAV-induced mortality. Our study suggests that PAR2 may be a therapeutic target to reduce IAV pathology.	[Gunther, Randall C.; Bharathi, Vanthana; Miles, Stephen D.; Tumey, Lauryn R.; Schmedes, Clare M.; Tatsumi, Kohei; Martinez, David; Mackman, Nigel] Univ North Carolina Chapel Hill, UNC Blood Res Ctr, Dept Med, Chapel Hill, NC USA; [Bridges, Meagan D.] Univ North Carolina Chapel Hill, UNC Blood Res Ctr, Dept Pathol & Lab Med, Chapel Hill, NC USA; [Montgomery, Stephanie A.] Univ North Carolina Chapel Hill, UNC Lineberger Comprehens Canc Ctr, Dept Pathol & Lab Med, Chapel Hill, NC USA; [Beck, Melinda A.] Univ North Carolina Chapel Hill, Gillings Sch Global Publ Hlth, Sch Med, Dept Nutr, Chapel Hill, NC USA; [Camerer, Eric] Univ Paris, Paris Cardiovasc Res Ctr PARCC, INSERM UMR 970, Dept Med, Paris, France; [Antoniak, Silvio] Univ North Carolina Chapel Hill, UNC Blood Res Ctr, UNC Lineberger Comprehens Canc Ctr, UNC McAllister Heart Inst,Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Institut National de la Sante et de la Recherche Medicale (Inserm); Sanofi-Aventis; Sanofi France; UDICE-French Research Universities; Universite Paris Cite; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Antoniak, S (corresponding author), Univ North Carolina Chapel Hill, UNC Blood Res Ctr, UNC Lineberger Comprehens Canc Ctr, UNC McAllister Heart Inst,Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA.	antoniak@email.unc.edu	martinez, david/GQI-0849-2022; Camerer, Eric/K-4161-2017	Camerer, Eric/0000-0002-6271-7125				Abram CL, 2014, J IMMUNOL METHODS, V408, P89, DOI 10.1016/j.jim.2014.05.009; Adlhoch C, 2019, OPEN FORUM INFECT DI, V6, DOI 10.1093/ofid/ofz462; Antoniak S, 2016, J THROMB HAEMOST, V14, P1238, DOI 10.1111/jth.13307; Antoniak S, 2021, J THROMB HAEMOST, V19, P1103, DOI 10.1111/jth.15221; Antoniak S, 2017, J INNATE IMMUN, V9, P181, DOI 10.1159/000450853; Antoniak S, 2014, BLOOD, V123, P2605, DOI 10.1182/blood-2013-09-526277; Antoniak S, 2014, J CARDIOVASC TRANSL, V7, P203, DOI 10.1007/s12265-013-9515-7; Antoniak S, 2013, J CLIN INVEST, V123, P1310, DOI 10.1172/JCI66125; Asaduzzaman M, 2015, CLIN EXP ALLERGY, V45, P1844, DOI 10.1111/cea.12628; Balachandran S, 2020, J VIROL, V94, DOI 10.1128/JVI.01101-19; Bandara M, 2022, TISSUE BARRIERS, V10, DOI 10.1080/21688370.2021.1968763; Bardou O, 2016, AM J RESP CRIT CARE, V193, P847, DOI 10.1164/rccm.201502-0299OC; Baron J, 2013, J VIROL, V87, P1811, DOI 10.1128/JVI.02320-12; Beaulieu A, 2013, J VIROL, V87, P4237, DOI 10.1128/JVI.03005-12; Betts RJ, 2012, J PHARMACOL EXP THER, V343, P725, DOI 10.1124/jpet.112.196485; Carroll EL, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22115817; Chang AY, 2016, RESP RES, V17, DOI 10.1186/s12931-016-0378-8; Cline TD, 2017, J GEN VIROL, V98, P2401, DOI 10.1099/jgv.0.000922; Cole SL, 2017, CLIN SCI, V131, P269, DOI 10.1042/CS20160484; Damiano BP, 1999, J PHARMACOL EXP THER, V288, P671; Davenport ML, 2020, JOVE-J VIS EXP, DOI 10.3791/60605; Dinnon KH, 2020, NATURE, V586, P560, DOI 10.1038/s41586-020-2708-8; Feld M, 2008, J IMMUNOL, V180, P6903, DOI 10.4049/jimmunol.180.10.6903; Feld M, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/879080; George ST, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060597; Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9; Graf C, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aaw8405; Hagan RS, 2019, AM J RESP CELL MOL, V60, P335, DOI 10.1165/rcmb.2018-0122OC; Han X, 2021, RES PRACT THROMB HAE, V5, P17, DOI 10.1002/rth2.12454; Herold S, 2008, J EXP MED, V205, P3065, DOI 10.1084/jem.20080201; Hogner K, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003188; Homma T, 2016, AM J RESP CELL MOL, V54, P60, DOI 10.1165/rcmb.2015-0062OC; Iwasaki A, 2014, NAT REV IMMUNOL, V14, P315, DOI 10.1038/nri3665; Iwata-Yoshikawa N, 2019, J VIROL, V93, DOI 10.1128/JVI.01815-18; Kalil AC, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2539-x; Khoufache K, 2009, J IMMUNOL, V182, P7795, DOI 10.4049/jimmunol.0803743; Kim HM, 2008, J VIROL, V82, P4265, DOI 10.1128/JVI.02602-07; Kumagai Y, 2007, IMMUNITY, V27, P240, DOI 10.1016/j.immuni.2007.07.013; Lafond KE, 2021, PLOS MED, V18, DOI 10.1371/journal.pmed.1003550; Lan RS, 2004, AM J PHYSIOL-LUNG C, V286, pL388, DOI 10.1152/ajplung.00286.2003; Le Goffic R, 2006, PLOS PATHOG, V2, P526, DOI 10.1371/journal.ppat.0020053; Lee MG, 1996, ARCH VIROL, V141, P1979, DOI 10.1007/BF01718208; Londrigan SL, 2020, VIROLOGY, V540, P17, DOI 10.1016/j.virol.2019.11.003; Major J, 2020, SCIENCE, V369, P712, DOI 10.1126/science.abc2061; Manicassamy B, 2010, P NATL ACAD SCI USA, V107, P11531, DOI 10.1073/pnas.0914994107; Mateer E, 2019, JOVE-J VIS EXP, DOI 10.3791/59095; McGuirea VA, 2017, MOL CELL BIOL, V37, DOI 10.1128/MCB.00454-16; Menachery VD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131451; Miki M, 2019, ARCH BIOCHEM BIOPHYS, V664, P167, DOI 10.1016/j.abb.2019.01.019; Moretti S, 2008, MUCOSAL IMMUNOL, V1, P156, DOI 10.1038/mi.2007.13; Natiello M., 2009, COMP CLIN PATHOL, V18, P101, DOI [10.1007/s00580-008-0772-9, DOI 10.1007/S00580-008-0772-9]; Nhu QM, 2010, MUCOSAL IMMUNOL, V3, P29, DOI 10.1038/mi.2009.120; OVCHARENKO AV, 1994, ANTIVIR RES, V23, P107, DOI 10.1016/0166-3542(94)90038-8; Pan HY, 2014, AM J PHYSIOL-HEART C, V307, pH922, DOI 10.1152/ajpheart.00076.2014; Pan HY, 2011, J MED INVESTIG, V58, P19, DOI 10.2152/jmi.58.19; Pan HY, 2011, CARDIOVASC RES, V89, P595, DOI 10.1093/cvr/cvq358; Rallabhandi P, 2008, J BIOL CHEM, V283, P24314, DOI 10.1074/jbc.M804800200; Ruf W, 2021, J THROMB THROMBOLYS, V52, P391, DOI 10.1007/s11239-021-02458-8; Saban Ricardo, 2007, BMC Physiology, V7, P4, DOI 10.1186/1472-6793-7-4; Saffarzadeh M, 2020, BLOOD ADV, V4, P5810, DOI 10.1182/bloodadvances.2020003299; Sanders CJ, 2013, AM J PHYSIOL-LUNG C, V304, pL481, DOI 10.1152/ajplung.00343.2012; Schmidlin F, 2002, J IMMUNOL, V169, P5315, DOI 10.4049/jimmunol.169.9.5315; Schneider C, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004053; Schweickert PG, 2021, J THROMB HAEMOST, V19, P161, DOI 10.1111/jth.15115; Seo SU, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001304; Skarnes WC, 2011, NATURE, V474, P337, DOI 10.1038/nature10163; Son KN, 2015, J VIROL, V89, P9383, DOI 10.1128/JVI.01299-15; Subramaniam S, 2021, BLOOD ADV, V5, P2760, DOI 10.1182/bloodadvances.2021004360; Subramaniam S, 2022, BRIT J PHARMACOL, V179, P2086, DOI 10.1111/bph.15587; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Tatsumi K, 2019, CELL IMMUNOL, V344, DOI 10.1016/j.cellimm.2019.103949; Tatsumi K, 2016, PHYSIOL REP, V4, DOI 10.14814/phy2.13071; Terrier O, 2021, ADV EXP MED BIOL, V1322, P195, DOI 10.1007/978-981-16-0267-2_8; Weithauser A, 2013, J AM COLL CARDIOL, V62, P1737, DOI 10.1016/j.jacc.2013.05.076; Wilson S, 2005, BIOCHEM J, V388, P967, DOI 10.1042/BJ20041066; Yin H, 2021, MOLECULES, V26, DOI 10.3390/molecules26040810; You M, 2001, J EXP MED, V193, P101, DOI 10.1084/jem.193.1.101; Zang N, 2016, J VIROL, V90, P2536, DOI 10.1128/JVI.02534-15; Zhou G, 2019, J IMMUNOL, V203, P441, DOI 10.4049/jimmunol.1800915	80	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 1	2021	12								791017	10.3389/fimmu.2021.791017	http://dx.doi.org/10.3389/fimmu.2021.791017			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XO4RE	34925374	Green Published			2022-12-18	WOS:000730173600001
J	Reijmen, E; De Mey, S; Van Damme, H; De Ridder, K; Gevaert, T; De Blay, E; Bouwens, L; Collen, C; Decoster, L; De Couck, M; Laoui, D; De Greve, J; De Ridder, M; Gidron, Y; Goyvaerts, C				Reijmen, Eva; De Mey, Sven; Van Damme, Helena; De Ridder, Kirsten; Gevaert, Thierry; De Blay, Emmy; Bouwens, Luc; Collen, Christine; Decoster, Lore; De Couck, Marijke; Laoui, Damya; De Greve, Jacques; De Ridder, Mark; Gidron, Yori; Goyvaerts, Cleo			Transcutaneous Vagal Nerve Stimulation Alone or in Combination With Radiotherapy Stimulates Lung Tumor Infiltrating Lymphocytes But Fails to Suppress Tumor Growth	FRONTIERS IN IMMUNOLOGY			English	Article						neuromodulation; transcutaneous vagal nerve stimulation; radiotherapy; immunosuppressive tumor microenvironment (TME); lung cancer; tumor infiltrating lymphocytes	REGULATORY T-CELLS; BREAST-CANCER; IMMUNE CELLS; VAGUS NERVE; RATIO NLR; TGF-BETA; MICROENVIRONMENT; IMMUNOTHERAPY; SURVIVAL; NSCLC	The combination of radiotherapy (RT) with immunotherapy represents a promising treatment modality for non-small cell lung cancer (NSCLC) patients. As only a minority of patients shows a persistent response today, a spacious optimization window remains to be explored. Previously we showed that fractionated RT can induce a local immunosuppressive profile. Based on the evolving concept of an immunomodulatory role for vagal nerve stimulation (VNS), we tested its therapeutic and immunological effects alone and in combination with fractionated RT in a preclinical-translational study. Lewis lung carcinoma-bearing C57Bl/6 mice were treated with VNS, fractionated RT or the combination while a patient cohort with locally advanced NSCLC receiving concurrent radiochemotherapy (ccRTCT) was enrolled in a clinical trial to receive either sham or effective VNS daily during their 6 weeks of ccRTCT treatment. Preclinically, VNS alone or with RT showed no therapeutic effect yet VNS alone significantly enhanced the activation profile of intratumoral CD8(+) T cells by upregulating their IFN-gamma and CD137 expression. In the periphery, VNS reduced the RT-mediated rise of splenic, but not blood-derived, regulatory T cells (Treg) and monocytes. In accordance, the serological levels of protumoral CXCL5 next to two Treg-attracting chemokines CCL1 and CCL22 were reduced upon VNS monotherapy. In line with our preclinical findings on the lack of immunological changes in blood circulating immune cells upon VNS, immune monitoring of the peripheral blood of VNS treated NSCLC patients (n=7) did not show any significant changes compared to ccRTCT alone. As our preclinical data do suggest that VNS intensifies the stimulatory profile of the tumor infiltrated CD8(+) T cells, this favors further research into non-invasive VNS to optimize current response rates to RT-immunotherapy in lung cancer patients.	[Reijmen, Eva; De Ridder, Kirsten; Goyvaerts, Cleo] Vrije Univ Brussel, Dept Biomed Sci, Lab Mol & Cellular Therapy, Brussels, Belgium; [De Mey, Sven; Gevaert, Thierry; Collen, Christine; De Ridder, Mark] Univ Ziekenhuis UZ Brussel, Univ Hosp Brussels, Ctr Oncol, Dept Radiotherapy, Brussels, Belgium; [Van Damme, Helena; Laoui, Damya] Vlaams Inst Biotechnol VIB, Myeloid Cell Immunol Lab, Ctr Inflammat Res, Brussels, Belgium; [Van Damme, Helena; Laoui, Damya] Vrije Univ Brussel, Lab Cellular & Mol Immunol, Brussels, Belgium; [De Blay, Emmy; Bouwens, Luc] Vrije Univ Brussel, Cell Differentiat Lab, Brussels, Belgium; [Decoster, Lore; De Greve, Jacques] Vrije Univ Brussel VUB, Univ Ziekenhuis UZ Brussel, Lab Med & Mol Oncol LMMO, Dept Med Oncol,Oncol Ctr, Brussels, Belgium; [De Couck, Marijke] Vrije Univ Brussel, Fac Med & Pharm, Dept Publ Hlth, Mental Hlth & Wellbeing Res Grp, Brussels, Belgium; [De Couck, Marijke] Univ Coll Odisee, Fac Hlth Care, Aalst, Belgium; [Gidron, Yori] Univ Haifa, Fac Social Welf & Hlth Sci, Haifa, Israel	Vrije Universiteit Brussel; University Hospital Brussels; Flanders Institute for Biotechnology (VIB); Vrije Universiteit Brussel; Vrije Universiteit Brussel; University Hospital Brussels; Vrije Universiteit Brussel; Vrije Universiteit Brussel; University of Haifa	Goyvaerts, C (corresponding author), Vrije Univ Brussel, Dept Biomed Sci, Lab Mol & Cellular Therapy, Brussels, Belgium.	cleo.goyvaerts@vub.be	De Ridder, Mark/F-4794-2013; Goyvaerts, Cleo/G-1591-2019	De Ridder, Mark/0000-0003-4433-8807; De Ridder, Kirsten/0000-0003-1482-1742; Decoster, Lore/0000-0001-7563-0179; Laoui, Damya/0000-0002-3373-1403; DE MEY, SVEN LUK/0000-0001-8444-0836; Collen, Christine/0000-0002-5717-7136; Bouwens, Luc/0000-0001-5767-7002; Van Damme, Helena/0000-0002-1042-2907; Goyvaerts, Cleo/0000-0002-1725-7772	Kom op Tegen Kanker (Stand up to Cancer); Fonds Wetenschappelijk Onderzoek Vlaanderen [1515718N]; Wetenschappelijk Fonds Willy Gepts; Vrije Universiteit Brussel [SRP48]	Kom op Tegen Kanker (Stand up to Cancer); Fonds Wetenschappelijk Onderzoek Vlaanderen(FWO); Wetenschappelijk Fonds Willy Gepts; Vrije Universiteit Brussel	This research was funded by research grants from Kom op Tegen Kanker (Stand up to Cancer), Fonds Wetenschappelijk Onderzoek Vlaanderen (FWO-V -grant number: 1515718N), Wetenschappelijk Fonds Willy Gepts and the Vrije Universiteit Brussel under the strategic research program scheme (grant SRP48).	Andersson U, 2012, ANNU REV IMMUNOL, V30, P313, DOI 10.1146/annurev-immunol-020711-075015; Antoni MH, 2006, NAT REV CANCER, V6, P240, DOI 10.1038/nrc1820; Arenberg DA, 1998, J CLIN INVEST, V102, P465, DOI 10.1172/JCI3145; Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; Barsheshet Y, 2017, P NATL ACAD SCI USA, V114, P6086, DOI 10.1073/pnas.1621280114; Caja F, 2015, J IMMUNOTOXICOL, V12, P300, DOI 10.3109/1547691X.2014.945667; Chen BC, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0242173; Chen HM, 2015, CLIN CANCER RES, V21, P4073, DOI 10.1158/1078-0432.CCR-14-2742; Cole SW, 2015, NAT REV CANCER, V15, P563, DOI 10.1038/nrc3978; Cole SW, 2012, CLIN CANCER RES, V18, P1201, DOI 10.1158/1078-0432.CCR-11-0641; Diem S, 2017, LUNG CANCER, V111, P176, DOI 10.1016/j.lungcan.2017.07.024; Dubeykovskaya Z, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10517; Eng JWL, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7426; Eng JWL, 2014, CANCER IMMUNOL IMMUN, V63, P1115, DOI 10.1007/s00262-014-1617-9; Erin N, 2004, ANTICANCER RES, V24, P1003; Erin N, 2020, CANCER IMMUNOL IMMUN, V69, P307, DOI 10.1007/s00262-019-02463-0; Erin N, 2012, REGUL PEPTIDES, V179, P101, DOI 10.1016/j.regpep.2012.08.001; Erin N, 2008, REGUL PEPTIDES, V151, P35, DOI 10.1016/j.regpep.2008.03.012; Farber DL, 2021, NATURE, V593, P506, DOI 10.1038/d41586-021-01396-y; Gidron Y, 2018, J IMMUNOL RES, V2018, DOI [10.1155/2018/1874193, 10.1155/2018/4874193]; Giese-Davis J, 2015, PSYCHOSOM MED, V77, P346, DOI 10.1097/PSY.0000000000000167; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hastir JF, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.547013; Higgs BW, 2018, CLIN CANCER RES, V24, P3857, DOI 10.1158/1078-0432.CCR-17-3451; Hoelzinger DB, 2010, J IMMUNOL, V184, P6833, DOI 10.4049/jimmunol.0904084; Huang A, 2013, CANCER IMMUNOL IMMUN, V62, P1439, DOI 10.1007/s00262-013-1450-6; Kamiya A, 2019, NAT NEUROSCI, V22, P1289, DOI 10.1038/s41593-019-0430-3; Keyaerts M, 2008, EUR J NUCL MED MOL I, V35, P999, DOI 10.1007/s00259-007-0664-2; Kotsakis A, 2016, SCI REP-UK, V6, DOI 10.1038/srep39247; Lambrechts D, 2018, NAT MED, V24, P1277, DOI 10.1038/s41591-018-0096-5; Lavin Y, 2017, CELL, V169, P750, DOI 10.1016/j.cell.2017.04.014; Liu LH, 2021, J THORAC ONCOL, V16, P1099, DOI 10.1016/j.jtho.2021.03.016; Liu YA, 2012, J IMMUNOTHER, V35, P299, DOI 10.1097/CJI.0b013e3182518e83; Magnon C, 2013, SCIENCE, V341, P143, DOI 10.1126/science.1236361; Mailloux AW, 2009, J IMMUNOL, V182, P2753, DOI 10.4049/jimmunol.0801124; Marino F, 2013, AMINO ACIDS, V45, P55, DOI 10.1007/s00726-011-1186-6; Maruyama T, 2010, DIS ESOPHAGUS, V23, P422, DOI 10.1111/j.1442-2050.2009.01029.x; Mellman I, 2011, NATURE, V480, P480, DOI 10.1038/nature10673; Memmott RM, 2021, J THORAC ONCOL, V16, P1086, DOI 10.1016/j.jtho.2021.03.017; Mengos AE, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01147; Mittal D, 2014, CURR OPIN IMMUNOL, V27, P16, DOI 10.1016/j.coi.2014.01.004; Mohammadpour H, 2019, J CLIN INVEST, V129, P5537, DOI 10.1172/JCI129502; Mouton C, 2012, AUTON NEUROSCI-BASIC, V166, P96, DOI 10.1016/j.autneu.2011.10.002; Nance DM, 2007, BRAIN BEHAV IMMUN, V21, P736, DOI 10.1016/j.bbi.2007.03.008; Ngiow SF, 2015, CANCER RES, V75, P3800, DOI 10.1158/0008-5472.CAN-15-1082; Ngwa W, 2018, NAT REV CANCER, V18, P313, DOI 10.1038/nrc.2018.6; Palucka K, 2012, NAT REV CANCER, V12, P265, DOI 10.1038/nrc3258; Park Hae-Young, 2009, Immune Netw, V9, P122, DOI 10.4110/in.2009.9.4.122; Qiao GX, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00164; Reijmen E, 2021, INT J RADIAT ONCOL, V111, P272, DOI 10.1016/j.ijrobp.2021.04.009; Reijmen E, 2018, IMMUNOL LETT, V202, P38, DOI 10.1016/j.imlet.2018.07.006; Ren FP, 2019, ONCOTARGETS THER, V12, P4235, DOI 10.2147/OTT.S199176; Rosas-Ballina M, 2008, P NATL ACAD SCI USA, V105, P11008, DOI 10.1073/pnas.0803237105; Rosas-Ballina M, 2011, SCIENCE, V334, P98, DOI 10.1126/science.1209985; Sakaguchi S, 2008, CELL, V133, P775, DOI 10.1016/j.cell.2008.05.009; Sanders TH, 2019, J NEUROSCI, V39, P3454, DOI 10.1523/JNEUROSCI.2407-18.2019; Sanjabi S, 2017, CSH PERSPECT BIOL, V9, DOI 10.1101/cshperspect.a022236; Schreiber RD, 2011, SCIENCE, V331, P1565, DOI 10.1126/science.1203486; Sherwood L., 2019, CENGAGE LEARNING, V9th; Siegel Rebecca L, 2019, CA Cancer J Clin, V69, P7, DOI 10.3322/caac.21551; Sloan EK, 2010, CANCER RES, V70, P7042, DOI 10.1158/0008-5472.CAN-10-0522; Tracey KJ, 2016, CELL, V164, P343, DOI 10.1016/j.cell.2016.01.018; Wang J, 2011, TUMOR BIOL, V32, P689, DOI 10.1007/s13277-011-0169-2; Weber R, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01310; Wennerberg E, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00229; Winkler I, 2015, J OVARIAN RES, V8, DOI 10.1186/s13048-015-0164-0; Wu M, 2016, ONCOTARGET, V7, P44534, DOI 10.18632/oncotarget.10003; Xu YX, 2017, STEM CELLS, V35, P2351, DOI 10.1002/stem.2720; Yan D, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-88694-7; Yang L, 2010, TRENDS IMMUNOL, V31, P220, DOI 10.1016/j.it.2010.04.002; Ye QR, 2014, CLIN CANCER RES, V20, P44, DOI 10.1158/1078-0432.CCR-13-0945; Zhang H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126496; Zhou JM, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/751392	73	0	0	5	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 1	2021	12								772555	10.3389/fimmu.2021.772555	http://dx.doi.org/10.3389/fimmu.2021.772555			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XO2VD	34925341	Green Published, gold			2022-12-18	WOS:000730047500001
J	Shehwana, H; Ijaz, S; Fatima, A; Walton, S; Sheikh, ZI; Haider, W; Naz, S				Shehwana, Huma; Ijaz, Sadaf; Fatima, Abeera; Walton, Shelley; Sheikh, Zafar Iqbal; Haider, Waseem; Naz, Shumaila			Transcriptome Analysis of Host Inflammatory Responses to the Ectoparasitic Mite Sarcoptes scabiei var. hominis	FRONTIERS IN IMMUNOLOGY			English	Article						RNA-seq data analysis; Sarcoptes scabiei; var; hominis; inflammatory responses; scabies; differentially expressed genes; JAK-STAT pathways	IMMUNE-RESPONSE; ATOPIC-DERMATITIS; CYTOKINE EXPRESSION; SKIN DISEASES; PSORIASIS; CELLS; PATHOGENESIS; PROTEIN; KERATINOCYTES; NEUTROPHILS	Scabies, a human skin infestation caused by the ectoparasitic mite Sarcoptes scabiei var. hominis, affects more than 200 million people globally. The prevailing knowledge of the disease process and host immune response mechanisms is limited. A better understanding of the host-parasite relationship is essential for the identification of novel vaccine and drug targets. Here we aimed to interrogate the transcriptomic profiles of mite-infested human skin biopsies with clinical manifestations of ordinary scabies subjects ("OS"; n = 05) and subjects naive to scabies ("control"; n = 03) using RNASeq data analysis. A combined clustering, network, and pathway mapping approach enabled us to identify key signaling events in the host immune and pro-inflammatory responses to S. scabiei infestation. The clustering patterns showed various differentially expressed genes including inflammatory responses and innate immunity genes (DEFB4A, IL-19, CXCL8, CSF3, SERPINB4, S100A7A, HRNR) and notably upregulation of the JAK-STAT pathway in scabies-infested samples. Mite-infested human skin biopsies (GSE178563) were compared with an ex-vivo porcine infested model (E-MTAB-6433) and human skin equivalents (GSE48459). Marked enrichment of immune response pathways (JAK-STAT signaling, IL-4 and IL-13 pathway, and Toll receptor cascade), chemokine ligands and receptors (CCL17, CCL18, CCL3L1, CCL3L3, CCR7), and cytokines (IL-13 and IL-20) were observed. Additionally, genes known for their role in psoriasis and atopic dermatitis were upregulated, e.g., IL-19. The detailed transcriptomic profile has provided an insight into molecular functions, biological processes, and immunological responses and increased our understanding about transcriptomic regulation of scabies in human.	[Shehwana, Huma; Naz, Shumaila] Natl Univ Med Sci, Dept Biol Sci, Rawalpindi, Pakistan; [Ijaz, Sadaf; Fatima, Abeera] Natl Univ Sci & Technol, Res Ctr Modelling & Simulat, Islamabad, Pakistan; [Walton, Shelley] Univ Sunshine Coast, Sch Hlth & Sport Sci, Inflammat & Healing Res Cluster, Maroochydore, Qld, Australia; [Sheikh, Zafar Iqbal] Pak Emirates Mil Hosp, Dept Dermatol, Rawalpindi, Pakistan; [Haider, Waseem] COMSATS Univ Islamabad, Dept Biosci, Islamabad, Pakistan	National University of Sciences & Technology - Pakistan; University of the Sunshine Coast; COMSATS University Islamabad (CUI)	Naz, S (corresponding author), Natl Univ Med Sci, Dept Biol Sci, Rawalpindi, Pakistan.	shumaila.naz@numspak.edu.pk			Higher Education Commission (HEC), Pakistan [1640]	Higher Education Commission (HEC), Pakistan(Higher Education Commission of Pakistan)	The project is funded by Higher Education Commission (HEC), Pakistan, under Startup Research Grant Program (SRGP) to SN (SRGP # 1640). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	Ahn R, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-29472-w; Akdis M, 2001, ACTA ODONTOL SCAND, V59, P178, DOI 10.1080/000163501750266783; Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Andrews Ross M, 2009, Pediatr Clin North Am, V56, P1421, DOI 10.1016/j.pcl.2009.09.002; Archer NK, 2017, J INVEST DERMATOL, V137, P2257, DOI 10.1016/j.jid.2017.08.026; Arlian LG, 2004, J MED ENTOMOL, V41, P69, DOI 10.1603/0022-2585-41.1.69; Arlian LG, 2003, AM J TROP MED HYG, V69, P652, DOI 10.4269/ajtmh.2003.69.652; Arlian LG, 1997, VET PARASITOL, V68, P347, DOI 10.1016/S0304-4017(96)01093-X; ARLIAN LG, 1994, EXP PARASITOL, V78, P51, DOI 10.1006/expr.1994.1005; Arlian LG, 2001, J ALLERGY CLIN IMMUN, V107, pS406, DOI 10.1067/mai.2001.113670; Bandi KM, 2013, J CLIN DIAGN RES, V7, P156, DOI 10.7860/JCDR/2012/4839.2694; Bao Lei, 2013, JAKSTAT, V2, pe24137, DOI 10.4161/jkst.24137; Barrett NA, 2009, IMMUNITY, V31, P425, DOI 10.1016/j.immuni.2009.08.014; Bergboer JGM, 2011, AM J PATHOL, V178, P1470, DOI 10.1016/j.ajpath.2010.12.017; Bhat SA, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0008601; Bhat SA, 2017, PARASITE VECTOR, V10, DOI 10.1186/s13071-017-2320-4; Borchers NS, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.636061; Bowcock AM, 2004, HUM MOL GENET, V13, pR43, DOI 10.1093/hmg/ddh094; Brombacher F, 2000, BIOESSAYS, V22, P646, DOI 10.1002/1521-1878(200007)22:7&lt;646::AID-BIES7&gt;3.0.CO;2-9; Burgess STG, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024402; Burgess STG, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-624; CABRERA R, 1993, SEMIN DERMATOL, V12, P15; Cadman ET, 2010, PARASITE IMMUNOL, V32, P1, DOI 10.1111/j.1365-3024.2009.01147.x; Casais R, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1717-9; Chandra A, 2016, SCI REP-UK, V6, DOI 10.1038/srep24059; Chiricozzi A, 2016, BRIT J DERMATOL, V174, P136, DOI 10.1111/bjd.14034; Chng L, 2021, PLOS NEGLECT TROP D, V15, DOI 10.1371/journal.pntd.0009149; Chovatiya R, 2019, CHILDREN-BASEL, V6, DOI 10.3390/children6100108; Chow M, 2016, J DRUGS DERMATOL, V15, P988; Collins AM, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00235; Cowan A, 2015, HANDB EXP PHARMACOL, V226, P291, DOI 10.1007/978-3-662-44605-8_16; Crivellato E, 2010, INT ARCH ALLERGY IMM, V151, P89, DOI 10.1159/000235998; Dagleish MP, 2007, J WILDLIFE DIS, V43, P512, DOI 10.7589/0090-3558-43.3.512; Dainichi T, 2014, J DERMATOL SCI, V76, P81, DOI 10.1016/j.jdermsci.2014.08.010; Duan H, 2001, J DERMATOL SCI, V26, P119, DOI 10.1016/S0923-1811(00)00167-5; Eming SA, 2010, J PROTEOME RES, V9, P4758, DOI 10.1021/pr100456d; Engelman D, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002167; Garreis F, 2017, INVEST OPHTH VIS SCI, V58, P5968, DOI 10.1167/iovs.17-22637; Gowda DC, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03006; Gudjonsson JE, 2010, J INVEST DERMATOL, V130, P1849, DOI 10.1038/jid.2010.67; Ha H, 2017, THERANOSTICS, V7, P1543, DOI 10.7150/thno.15625; Hahn J, 2016, CLIN EXP RHEUMATOL, V34, pS6; Has C, 2016, J DTSCH DERMATOL GES, V14, P123, DOI 10.1111/ddg.12930; Hatter AD, 2016, APPL CLIN GENET, V9, P1, DOI 10.2147/TACG.S90713; He R, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177733; Henry J, 2011, FASEB J, V25, P1567, DOI 10.1096/fj.10-168658; Holt DC, 2013, CELL TISSUE RES, V351, P339, DOI 10.1007/s00441-012-1369-9; Huang DW, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-9-r183; Huber W, 2021, ACCESSING ENSEMBL AN; Iversen OJ, 2017, CLIN IMMUNOL, V174, P10, DOI 10.1016/j.clim.2016.11.006; Jiao XL, 2012, BIOINFORMATICS, V28, P1805, DOI 10.1093/bioinformatics/bts251; Kolbinger F, 2017, J ALLERGY CLIN IMMUN, V139, P923, DOI 10.1016/j.jaci.2016.06.038; Konrad RJ, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-41609-z; Krueger JG, 2019, J ALLERGY CLIN IMMUN, V144, P750, DOI 10.1016/j.jaci.2019.04.029; Lalli PN, 2004, J PARASITOL, V90, P711, DOI 10.1645/GE-214R; Lembo S, 2018, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00252; Li CX, 2019, MOL GENET GENOM MED, V7, DOI 10.1002/mgg3.703; Li H, 2009, BIOINFORMATICS, V25, P1094, DOI [10.1093/bioinformatics/btp100, 10.1093/bioinformatics/btp324]; Li J, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/964842; Liao SC, 2004, J IMMUNOL, V173, P6712, DOI 10.4049/jimmunol.173.11.6712; Lim XH, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a008029; Lowes MA, 2013, TRENDS IMMUNOL, V34, P174, DOI 10.1016/j.it.2012.11.005; Luo DQ, 2016, AM J TROP MED HYG, V95, P689, DOI 10.4269/ajtmh.16-0273; Martin MJ, 2020, GENES-BASEL, V11, DOI 10.3390/genes11040442; Morgan MAJ, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0071974, 10.1371/journal.pone.0056738, 10.1371/journal.pone.0069936]; Morgan MS, 2010, J MED ENTOMOL, V47, P877, DOI 10.1603/ME10012; Nattkemper LA, 2018, J INVEST DERMATOL, V138, P1311, DOI 10.1016/j.jid.2017.12.029; Nedoszytko B, 2014, POSTEP DERM ALERGOL, V31, P84, DOI 10.5114/pdia.2014.40920; Neisius U, 2002, J AM ACAD DERMATOL, V47, P28, DOI 10.1067/mjd.2002.120462; Oetjen LK, 2017, CELL, V171, P217, DOI 10.1016/j.cell.2017.08.006; Pence DB, 2002, REV SCI TECH OIE, V21, P385, DOI 10.20506/rst.21.2.1335; Quaranta M, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008946; Renert-Yuval Y, 2021, J ALLERGY CLIN IMMUN, V147, P1174, DOI 10.1016/j.jaci.2021.01.013; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Roberts LJ, 2005, J INFECTION, V50, P375, DOI 10.1016/j.jinf.2004.08.033; Rossbach K, 2011, NEUROSCIENCE, V190, P89, DOI 10.1016/j.neuroscience.2011.06.002; Russo RC, 2014, EXPERT REV CLIN IMMU, V10, P593, DOI 10.1586/1744666X.2014.894886; Rutz S, 2014, NAT REV IMMUNOL, V14, P783, DOI 10.1038/nri3766; Sabat R, 2007, EXP DERMATOL, V16, P779, DOI 10.1111/j.1600-0625.2007.00629.x; Schroeder JT, 2011, IMMUNOL REV, V242, P144, DOI 10.1111/j.1600-065X.2011.01023.x; Seif F, 2017, CELL COMMUN SIGNAL, V15, DOI 10.1186/s12964-017-0177-y; Shim WS, 2007, J NEUROSCI, V27, P2331, DOI 10.1523/JNEUROSCI.4643-06.2007; Sinno Hani, 2013, Plast Surg Int, V2013, P146764, DOI 10.1155/2013/146764; Sivaprasad U, 2015, J INVEST DERMATOL, V135, P160, DOI 10.1038/jid.2014.353; Smits J, 2017, J INVEST DERMATOL, V137, pS212, DOI 10.1016/j.jid.2017.06.003; Stemmer BL, 1996, VET PARASITOL, V67, P247, DOI 10.1016/S0304-4017(96)01038-2; Suarez-Farinas M, 2015, J ALLERGY CLIN IMMUN, V135, P1218, DOI 10.1016/j.jaci.2015.03.003; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Swe PM, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005437; Swe PM, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002928; Takamori A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25094-4; Tanji T, 2007, MOL CELL BIOL, V27, P4578, DOI 10.1128/MCB.01814-06; Tatarkiewicz J, 2019, ARCH MED SCI, V15, P537, DOI 10.5114/aoms.2017.68534; Trzeciak M, 2020, NUTRIENTS, V12, DOI 10.3390/nu12030862; Veltri A, 2018, STEM CELLS, V36, P22, DOI 10.1002/stem.2723; Walton SF, 2008, BRIT J DERMATOL, V158, P1247, DOI 10.1111/j.1365-2133.2008.08541.x; Walton SF, 2007, CLIN MICROBIOL REV, V20, P268, DOI 10.1128/CMR.00042-06; Walton SF, 2010, CLIN VACCINE IMMUNOL, V17, P1428, DOI 10.1128/CVI.00195-10; Witte E, 2014, J INVEST DERMATOL, V134, P2757, DOI 10.1038/jid.2014.308	99	0	0	2	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 1	2021	12								778840	10.3389/fimmu.2021.778840	http://dx.doi.org/10.3389/fimmu.2021.778840			19	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XO4XE	34925353	Green Published, gold			2022-12-18	WOS:000730189300001
J	Wong, CS; Buckner, CM; Lage, SL; Pei, LX; Assis, FL; Dahlstrom, EW; Anzick, SL; Virtaneva, K; Rupert, A; Davis, JL; Zhou, T; Laidlaw, E; Manion, M; Galindo, F; Anderson, M; Seamon, CA; Sneller, MC; Lisco, A; Deleage, C; Pittaluga, S; Moir, S; Sereti, I				Wong, Chun-Shu; Buckner, Clarisa M.; Lage, Silvia Lucena; Pei, Luxin; Assis, Felipe L.; Dahlstrom, Eric W.; Anzick, Sarah L.; Virtaneva, Kimmo; Rupert, Adam; Davis, Jeremy L.; Zhou, Ting; Laidlaw, Elizabeth; Manion, Maura; Galindo, Frances; Anderson, Megan; Seamon, Catherine A.; Sneller, Michael C.; Lisco, Andrea; Deleage, Claire; Pittaluga, Stefania; Moir, Susan; Sereti, Irini			Rapid Emergence of T Follicular Helper and Germinal Center B Cells Following Antiretroviral Therapy in Advanced HIV Disease	FRONTIERS IN IMMUNOLOGY			English	Article						HIV; T follicular helper cells; germinal centers; interferon; reconstitution	VIRUS TYPE-1 INFECTION; IMMUNE ACTIVATION; IMMUNODEFICIENCY; RESPONSES; DYNAMICS; CD4(+); DIFFERENTIATION; DEPLETION; HAPLOINSUFFICIENCY; PATHOGENESIS	Low nadir CD4 T-cell counts in HIV+ patients are associated with high morbidity and mortality and lasting immune dysfunction, even after antiretroviral therapy (ART). The early events of immune recovery of T cells and B cells in severely lymphopenic HIV+ patients have not been fully characterized. In a cohort of lymphopenic (CD4 T-cell count < 100/mu L) HIV+ patients, we studied mononuclear cells isolated from peripheral blood (PB) and lymph nodes (LN) pre-ART (n = 40) and 6-8 weeks post-ART (n = 30) with evaluation of cellular immunophenotypes; histology on LN sections; functionality of circulating T follicular helper (cTfh) cells; transcriptional and B-cell receptor profile on unfractionated LN and PB samples; and plasma biomarker measurements. A group of 19 healthy controls (HC, n = 19) was used as a comparator. T-cell and B-cell lymphopenia was present in PB pre-ART in HIV+ patients. CD4:CD8 and CD4 T- and B-cell PB subsets partly normalized compared to HC post-ART as viral load decreased. Strikingly in LN, ART led to a rapid decrease in interferon signaling pathways and an increase in Tfh, germinal center and IgD(-)CD27(-) B cells, consistent with histological findings of post-ART follicular hyperplasia. However, there was evidence of cTfh cells with decreased helper capacity and of limited B-cell receptor diversification post-ART. In conclusion, we found early signs of immune reconstitution, evidenced by a surge in LN germinal center cells, albeit limited in functionality, in HIV+ patients who initiate ART late in disease.	[Wong, Chun-Shu; Buckner, Clarisa M.; Lage, Silvia Lucena; Pei, Luxin; Assis, Felipe L.; Laidlaw, Elizabeth; Manion, Maura; Anderson, Megan; Sneller, Michael C.; Lisco, Andrea; Moir, Susan; Sereti, Irini] NIAID, Lab Immunoregulat, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Wong, Chun-Shu; Buckner, Clarisa M.; Lage, Silvia Lucena; Pei, Luxin; Assis, Felipe L.; Dahlstrom, Eric W.; Anzick, Sarah L.; Virtaneva, Kimmo; Laidlaw, Elizabeth; Manion, Maura; Anderson, Megan; Sneller, Michael C.; Lisco, Andrea; Moir, Susan; Sereti, Irini] NIAID, Rocky Mt Lab, NIH, Hamilton, MT 59840 USA; [Rupert, Adam] Leidos Biomedical Res Inc, Frederick Natl Lab Canc Res, Frederick, MD USA; [Davis, Jeremy L.] NCI, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; [Zhou, Ting; Pittaluga, Stefania] NCI, Lab Pathol, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; [Galindo, Frances] NIAID, Intramural Clin Management & Operat Branch, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Seamon, Catherine A.] NIH, Crit Care Med, Clin Ctr, Bldg 10, Bethesda, MD 20892 USA; [Deleage, Claire] Frederick Natl Lab Canc Res, AIDS & Canc Virus Program, Leidos Biomed Res, Frederick, MD USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Moir, S; Sereti, I (corresponding author), NIAID, Lab Immunoregulat, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.; Moir, S; Sereti, I (corresponding author), NIAID, Rocky Mt Lab, NIH, Hamilton, MT 59840 USA.		Davis, Jeremy/GQA-5941-2022; Davis, Jeremy/GLT-7151-2022	Davis, Jeremy/0000-0002-6334-6936; Davis, Jeremy/0000-0002-6334-6936				[Anonymous], 2010, FASTX TOOLK FASTQ SH; Austin JW, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aax0904; Belkina AC, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13055-y; Bickel M, 2011, CLIN INFECT DIS, V52, P122, DOI 10.1093/cid/ciq003; Bosinger SE, 2015, CURR HIV-AIDS REP, V12, P41, DOI 10.1007/s11904-014-0244-6; Boswell KL, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003853; Boulle A, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001718; Braitstein P, 2006, LANCET, V367, P817, DOI 10.1016/S0140-6736(06)68337-2; Burbelo Peter D, 2009, J Vis Exp, DOI 10.3791/1549; Carlson CS, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3680; Castilho JL, 2019, AIDS RES HUM RETROV, V35, P960, DOI [10.1089/aid.2019.0064, 10.1089/AID.2019.0064]; Chang C, 2014, CURR HIV-AIDS REP, V11, P223, DOI 10.1007/s11904-014-0213-0; Chao A, 2006, BIOMETRICS, V62, P361, DOI 10.1111/j.1541-0420.2005.00489.x; Crotty S, 2014, IMMUNITY, V41, P529, DOI 10.1016/j.immuni.2014.10.004; Cubas RA, 2013, NAT MED, V19, P494, DOI 10.1038/nm.3109; Cyster JG, 2019, CELL, V177, P524, DOI 10.1016/j.cell.2019.03.016; Deleage C, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.87065; Demontes M, 2020, CLIN INFECT DIS, V71, P2880, DOI 10.1093/cid/ciz1171; Dimopoulos Y, 2017, CURR HIV-AIDS REP, V14, P133, DOI 10.1007/s11904-017-0359-7; Doyle T, 2015, NAT REV MICROBIOL, V13, P403, DOI 10.1038/nrmicro3449; Efron B, 1993, MONOGRAPHS STAT APPL, V57, DOI [10.1007/978-1-4899-4541-9, DOI 10.1007/978-1-4899-4541-9]; Estes JD, 2013, IMMUNOL REV, V254, P65, DOI 10.1111/imr.12070; Gao BS, 2017, TRANSPLANTATION, V101, P2722, DOI 10.1097/TP.0000000000001789; Ghraichy M, 2018, IMMUNOLOGY, V153, P145, DOI 10.1111/imm.12865; Hardy GAD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056527; Haynes BF, 1999, J CLIN INVEST, V103, P921, DOI 10.1172/JCI5201E1; Hazenberg MD, 2000, NAT IMMUNOL, V1, P285, DOI 10.1038/79724; Hyrcza MD, 2007, J VIROL, V81, P3477, DOI 10.1128/JVI.01552-06; Jenks SA, 2019, IMMUNOL REV, V288, P136, DOI 10.1111/imr.12741; Kaneko N, 2020, CELL, V183, P143, DOI 10.1016/j.cell.2020.08.025; Kardava L, 2018, NAT IMMUNOL, V19, P1001, DOI 10.1038/s41590-018-0180-5; Kohl M., 2020, PACKAGE MKINFER INFE; Kucuk ZY, 2017, J ALLERGY CLIN IMMUN, V140, P862, DOI 10.1016/j.jaci.2017.02.032; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/nmeth.1923, 10.1038/NMETH.1923]; Larimore K, 2012, J IMMUNOL, V189, P3221, DOI 10.4049/jimmunol.1201303; Li FY, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2014562118; Lindqvist M, 2012, J CLIN INVEST, V122, P3271, DOI 10.1172/JCI64314; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Malaspina A, 2006, P NATL ACAD SCI USA, V103, P2262, DOI 10.1073/pnas.0511094103; Malaspina A, 2005, J INFECT DIS, V191, P1442, DOI 10.1086/429298; Martin M., 2011, EMBNET J, V17, P10, DOI [10.14806/ej.17.1.200, DOI 10.14806/EJ.17.1.200]; McCune JM, 2001, NATURE, V410, P974, DOI 10.1038/35073648; Mehta RS, 2016, VIRULENCE, V7, P901, DOI 10.1080/21505594.2016.1208866; Moir S, 2008, J INFECT DIS, V197, P572, DOI 10.1086/526789; Moir S, 2017, IMMUNOL REV, V275, P33, DOI 10.1111/imr.12502; Moir S, 2010, BLOOD, V116, P5571, DOI 10.1182/blood-2010-05-285528; Moir S, 2009, NAT REV IMMUNOL, V9, P235, DOI 10.1038/nri2524; Monod MY, 2004, BIOINFORMATICS, V20, P379, DOI 10.1093/bioinformatics/bth945; Morita R, 2011, IMMUNITY, V34, P108, DOI 10.1016/j.immuni.2010.12.012; Moysi E, 2018, J CLIN INVEST, V128, P3171, DOI 10.1172/JCI99884; Nakagawa F, 2012, AIDS, V26, P335, DOI 10.1097/QAD.0b013e32834dcec9; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Pensieroso S, 2013, AIDS, V27, P1209, DOI 10.1097/QAD.0b013e32835edc47; Perreau M, 2013, J EXP MED, V210, P143, DOI 10.1084/jem.20121932; Petrovas C, 2012, J CLIN INVEST, V122, P3281, DOI 10.1172/JCI63039; Pugh-Bernard AE, 2001, J CLIN INVEST, V108, P1061, DOI 10.1172/JCI200112462; Ray JP, 2014, IMMUNITY, V40, P367, DOI 10.1016/j.immuni.2014.02.005; Robins HS, 2009, BLOOD, V114, P4099, DOI 10.1182/blood-2009-04-217604; Rotger M, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000781; Sage PT, 2014, IMMUNITY, V41, P1026, DOI 10.1016/j.immuni.2014.12.005; Sanz I, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02458; Schacker TW, 2002, J INFECT DIS, V186, P1092, DOI 10.1086/343802; Schindler MK, 2020, J CLIN INVEST, V130, P5551, DOI 10.1172/JCI135947; Sedaghat AR, 2008, J VIROL, V82, P1870, DOI 10.1128/JVI.02228-07; Sereti I, 2016, CURR OPIN HIV AIDS, V11, P129, DOI 10.1097/COH.0000000000000244; Stacey AR, 2009, J VIROL, V83, P3719, DOI 10.1128/JVI.01844-08; Tebas P, 2010, AIDS, V24, P2187, DOI 10.1097/QAD.0b013e32833c6d5c; Teixeira L, 2001, AIDS, V15, P1749, DOI 10.1097/00002030-200109280-00002; Trickey A, 2017, LANCET HIV, V4, pE349, DOI 10.1016/S2352-3018(17)30066-8; Utay NS, 2016, CURR OPIN HIV AIDS, V11, P131, DOI 10.1097/COH.0000000000000242; Van Gassen S, 2015, CYTOM PART A, V87A, P636, DOI 10.1002/cyto.a.22625; Virot E, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000005769; Watson CT, 2017, TRENDS IMMUNOL, V38, P459, DOI 10.1016/j.it.2017.04.003; Xu HB, 2016, J VIROL, V90, P1578, DOI 10.1128/JVI.02471-15; Zeng M, 2011, J CLIN INVEST, V121, P998, DOI 10.1172/JCI45157	75	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 1	2021	12								752782	10.3389/fimmu.2021.752782	http://dx.doi.org/10.3389/fimmu.2021.752782			19	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XQ7AA	34938286	Green Published, gold			2022-12-18	WOS:000731696000001
J	Zhu, TY; Chen, X; Qiu, H; Liu, Y; Mwangi, J; Zhao, L; Ding, WJ; Lai, R; Jin, L				Zhu, Tengyu; Chen, Xue; Qiu, Huan; Liu, Yang; Mwangi, James; Zhao, Ling; Ding, Wenjun; Lai, Ren; Jin, Lin			Aspirin Alleviates Particulate Matter Induced Asymptomatic Orchitis of Mice via Suppression of cGAS-STING Signaling	FRONTIERS IN IMMUNOLOGY			English	Article						male infertility; particulate matter; orchitis; aspirin; cGAS-STING pathway	NF-KAPPA-B; EXPOSURE; PERSPECTIVE; INFERTILITY; FERTILITY; POLLUTION; ADAPTER; INJURY; MODEL; PDTC	As an important source of air pollutant, airborne particulate matter (PM) has become a major threat to public health. Orchitis is characterized by acute or chronic testicular inflammation and is a primary cause of male infertility. Although accumulating evidence indicates that PM exposure is associated with increased male infertility rates, the mechanism by which PM is involved is not well understood. Here, we found that short-term PM exposure activated NF-kappa B signaling in mouse Leydig cells and testes and leading to asymptomatic orchitis. Analyzing the mitochondrial abundance and cGAMP levels in PM exposed mouse Leydig cells, we found that PM exposure induced mitochondrial injury and mtDNA release, leading to inflammation via the cGAS-STING axis. We also found that aspirin-induced acetylation of cGAS inhibited the inflammation in mice after PM exposure, especially in the testes. Moreover, aspirin pretreatment rescued offspring growth in PM-exposed mice. In summary, our study not only provides evidence that PM-induced asymptomatic orchitis in mice may be amenable to aspirin pre-treatment by acetylating cGAS, but also provides a potential explanation for male infertility caused by air pollutants.	[Zhu, Tengyu; Chen, Xue; Qiu, Huan; Liu, Yang; Mwangi, James; Lai, Ren; Jin, Lin] Chinese Acad Sci, Key Lab Anim Models & Human Dis Mech, Key Lab Bioact Peptides Yunnan Prov, Kunming Inst Zool, Kunming, Yunnan, Peoples R China; [Zhu, Tengyu; Chen, Xue; Qiu, Huan; Liu, Yang; Mwangi, James; Lai, Ren; Jin, Lin] Univ Chinese Acad Sci, Kunming Coll Life Sci, Kunming, Yunnan, Peoples R China; [Zhu, Tengyu] Nanjing Agr Univ, Coll Life Sci, Nanjing, Peoples R China; [Zhao, Ling] Chinese Acad Sci, Ctr Expt Anim, Kunming Inst Zool, Kunming, Yunnan, Peoples R China; [Ding, Wenjun] Univ Chinese Acad Sci, Lab Environm & Hlth, Beijing, Peoples R China; [Lai, Ren] Chinese Acad Sci, Kunming Inst Zool Chinese Univ Hong Kong KIZ CUHK, Kunming Inst Zool, Kunming, Yunnan, Peoples R China	Chinese Academy of Sciences; Kunming Institute of Zoology; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Nanjing Agricultural University; Chinese Academy of Sciences; Kunming Institute of Zoology; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Chinese Academy of Sciences; Kunming Institute of Zoology	Lai, R; Jin, L (corresponding author), Chinese Acad Sci, Key Lab Anim Models & Human Dis Mech, Key Lab Bioact Peptides Yunnan Prov, Kunming Inst Zool, Kunming, Yunnan, Peoples R China.; Lai, R; Jin, L (corresponding author), Univ Chinese Acad Sci, Kunming Coll Life Sci, Kunming, Yunnan, Peoples R China.; Lai, R (corresponding author), Chinese Acad Sci, Kunming Inst Zool Chinese Univ Hong Kong KIZ CUHK, Kunming Inst Zool, Kunming, Yunnan, Peoples R China.	rlai@mail.kiz.ac.cn; jinlin@mail.kiz.ac.cn		Jin, Lin/0000-0001-6273-9140	National Natural Science Foundation of China (NSFC) [31900331, 32070444]; Science and Technology Department of Yunnan Province [202001AW070019]; Chinese Academy of Sciences "Light of West China" program; Youth Innovation Promotion Association [2019378]; NSFC [31930015]; CAS [XDB31000000, SAJC202103, KFJ-PTXM-28]; Yunnan Province [2019-YT-053, 202002AA100007, 2019ZF003]	National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); Science and Technology Department of Yunnan Province; Chinese Academy of Sciences "Light of West China" program; Youth Innovation Promotion Association; NSFC(National Natural Science Foundation of China (NSFC)); CAS(Chinese Academy of Sciences); Yunnan Province	This work was supported by the National Natural Science Foundation of China (NSFC) Grant (31900331, 32070444), Science and Technology Department of Yunnan Province (202001AW070019), Chinese Academy of Sciences "Light of West China" program and Youth Innovation Promotion Association (2019378) to LJ and funding from the NSFC (31930015), the CAS (XDB31000000, SAJC202103 and KFJ-PTXM-28), and Yunnan Province (2019-YT-053, 202002AA100007 and 2019ZF003) to RL.	Ablasser A, 2019, SCIENCE, V363, P1055, DOI 10.1126/science.aat8657; Aladamat N., 2021, STATPEARLS; Aly HAA, 2020, ENDOCR J, V67, P969, DOI 10.1507/endocrj.EJ20-0149; Bhushan S, 2017, J REPROD IMMUNOL, V119, P107, DOI 10.1016/j.jri.2016.06.008; Cao XN, 2015, TOXICOL LETT, V237, P181, DOI 10.1016/j.toxlet.2015.06.015; Carre J, 2017, ENVIRON HEALTH-GLOB, V16, DOI 10.1186/s12940-017-0291-8; Chen QY, 2016, SEMIN CELL DEV BIOL, V59, P157, DOI 10.1016/j.semcdb.2016.01.019; Cho CC, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15071380; Crowl JT, 2017, ANNU REV IMMUNOL, V35, P313, DOI 10.1146/annurev-immunol-051116-052331; Dai J, 2019, CELL, V176, P1447, DOI 10.1016/j.cell.2019.01.016; Deng XB, 2014, APOPTOSIS, V19, P1099, DOI 10.1007/s10495-014-0980-5; Fijak M, 2018, HUM REPROD UPDATE, V24, P416, DOI 10.1093/humupd/dmy009; Filipponi D, 2009, EPIGENETICS-US, V4, P27, DOI 10.4161/epi.4.1.7311; Gorelick PB, 2005, STROKE, V36, P1801, DOI 10.1161/01.STR.0000174189.81153.85; Hayden MS, 2011, CELL RES, V21, P223, DOI 10.1038/cr.2011.13; Ishikawa H, 2008, NATURE, V455, P674, DOI 10.1038/nature07317; Jia YY, 2017, INT J ENV RES PUB HE, V14, DOI 10.3390/ijerph14030232; Jin L, 2018, NAT IMMUNOL, V19, P342, DOI 10.1038/s41590-018-0063-9; Kim JH, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17228410; Lee EH, 2017, BIOCHEM PHARMACOL, V143, P107, DOI 10.1016/j.bcp.2017.07.011; Li RY, 2018, ONCOL LETT, V15, P7506, DOI 10.3892/ol.2018.8355; Li Tao, 2018, Chronic Dis Transl Med, V4, P176, DOI 10.1016/j.cdtm.2018.07.002; Li XD, 2013, SCIENCE, V341, P1390, DOI 10.1126/science.1244040; Mukherjee A, 2018, REV ENVIRON CONTAM T, V244, P5, DOI 10.1007/398_2017_3; Naito M, 2012, MED MOL MORPHOL, V45, P185, DOI 10.1007/s00795-012-0587-2; Pilatz A, 2019, UROLOGE, V58, P697, DOI 10.1007/s00120-019-0951-0; Pope CA, 2016, CIRC RES, V119, P1204, DOI 10.1161/CIRCRESAHA.116.309279; Qiu LL, 2018, TOXICOL SCI, V162, P318, DOI 10.1093/toxsci/kfx261; Semet M, 2017, ANDROLOGY-US, V5, P640, DOI 10.1111/andr.12366; Sifakis S, 2017, ENVIRON TOXICOL PHAR, V51, P56, DOI 10.1016/j.etap.2017.02.024; Simpson E, 2006, IMMUNOL REV, V213, P12, DOI 10.1111/j.1600-065X.2006.00434.x; Slomski A, 2021, JAMA-J AM MED ASSOC, V325, P1135, DOI 10.1001/jama.2021.1788; Stein-Streilein J, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00110; Sun WX, 2009, P NATL ACAD SCI USA, V106, P8653, DOI 10.1073/pnas.0900850106; Tanwar V, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.118.010797; Tiboni GM, 1998, AM J OBSTET GYNECOL, V178, P270, DOI 10.1016/S0002-9378(98)80012-4; Wang XX, 2013, J EXP MED, V210, P1559, DOI 10.1084/jem.20121806; West AP, 2015, NATURE, V520, P553, DOI 10.1038/nature14156; Xue T, 2018, ENVIRON POLLUT, V235, P497, DOI 10.1016/j.envpol.2018.01.009; Zhai JX, 2012, MOL BIOL REP, V39, P6763, DOI 10.1007/s11033-012-1501-7; Zhang GW, 2020, ENVIRON INT, V136, DOI 10.1016/j.envint.2020.105483; Zhang Q, 2017, CELL, V168, P37, DOI 10.1016/j.cell.2016.12.012; Zhong B, 2008, IMMUNITY, V29, P538, DOI 10.1016/j.immuni.2008.09.003; Zhou Z, 2018, BJOG-INT J OBSTET GY, V125, P432, DOI 10.1111/1471-0528.14966; Zhu TY, 2021, ZOOL RES, V42, P335, DOI 10.24272/j.issn.2095-8137.2021.088	45	0	0	6	9	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 1	2021	12								734546	10.3389/fimmu.2021.734546	http://dx.doi.org/10.3389/fimmu.2021.734546			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XO4YH	34925318	Green Published, gold			2022-12-18	WOS:000730192200001
J	Ceglia, V; Kelley, EJ; Boyle, AS; Zurawski, S; Mead, HL; Harms, CE; Blanck, JP; Flamar, AL; Kirschman, JH; Ogongo, P; Ernst, JD; Levy, Y; Zurawski, G; Altin, JA				Ceglia, Valentina; Kelley, Erin J.; Boyle, Annalee S.; Zurawski, Sandra; Mead, Heather L.; Harms, Caroline E.; Blanck, Jean-Philippe; Flamar, Anne-Laure; Kirschman, Jung Hwa; Ogongo, Paul; Ernst, Joel D.; Levy, Yves; Zurawski, Gerard; Altin, John A.			A Framework to Identify Antigen-Expanded T Cell Receptor Clusters Within Complex Repertoires	FRONTIERS IN IMMUNOLOGY			English	Article						T cell receptor (TCR); T cell responses; vaccines; dendritic cells; monoclonal antibodies; TCR sequencing	CD8(+); CD4(+); RESPONSES; CD40	Common approaches for monitoring T cell responses are limited in their multiplexity and sensitivity. In contrast, deep sequencing of the T Cell Receptor (TCR) repertoire provides a global view that is limited only in terms of theoretical sensitivity due to the depth of available sampling; however, the assignment of antigen specificities within TCR repertoires has become a bottleneck. This study combines antigen-driven expansion, deep TCR sequencing, and a novel analysis framework to show that homologous 'Clusters of Expanded TCRs (CETs)' can be confidently identified without cell isolation, and assigned to antigen against a background of non-specific clones. We show that clonotypes within each CET respond to the same epitope, and that protein antigens stimulate multiple CETs reactive to constituent peptides. Finally, we demonstrate the personalized assignment of antigen-specificity to rare clones within fully-diverse uncultured repertoires. The method presented here may be used to monitor T cell responses to vaccination and immunotherapy with high fidelity.	[Ceglia, Valentina; Zurawski, Sandra; Blanck, Jean-Philippe; Flamar, Anne-Laure; Zurawski, Gerard] Baylor Inst Immunol Res, Dallas, TX 75204 USA; [Ceglia, Valentina; Flamar, Anne-Laure; Levy, Yves] Univ Paris Est Creteil, Sci Vie & Sante, Creteil, France; [Ceglia, Valentina; Zurawski, Sandra; Flamar, Anne-Laure; Levy, Yves; Zurawski, Gerard] INSERM, Unite U955, Vaccine Res Inst, Inst Mondor Rech Biomed, Creteil, France; [Kelley, Erin J.; Boyle, Annalee S.; Mead, Heather L.; Harms, Caroline E.; Kirschman, Jung Hwa; Altin, John A.] Translat Genom Res Inst, Flagstaff, AZ 85004 USA; [Ogongo, Paul; Ernst, Joel D.] Univ Calif San Francisco, Dept Med, Div Expt Med, San Francisco, CA 94143 USA; [Flamar, Anne-Laure] Mem Sloan Kettering Canc Ctr, Parker Inst Canc Immunotherapy, 1275 York Ave, New York, NY 10021 USA	Baylor Scott & White Health; Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Translational Genomics Research Institute; University of California System; University of California San Francisco; Memorial Sloan Kettering Cancer Center	Zurawski, G (corresponding author), Baylor Inst Immunol Res, Dallas, TX 75204 USA.; Zurawski, G (corresponding author), INSERM, Unite U955, Vaccine Res Inst, Inst Mondor Rech Biomed, Creteil, France.; Altin, JA (corresponding author), Translat Genom Res Inst, Flagstaff, AZ 85004 USA.	gerardz@baylorhealth.edu; jaltin@tgen.org		Mead, Heather/0000-0002-5680-0758; Ogongo, Paul/0000-0002-0093-5768	Roche Collaborative Research Grant to the Baylor Scott and White Research Institute; Vaccine Research Institute [ANR-10-LABX-77]; NIH [U19 AI111211]	Roche Collaborative Research Grant to the Baylor Scott and White Research Institute; Vaccine Research Institute; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Funding We acknowledge funding support from the Roche Collaborative Research Grant to the Baylor Scott and White Research Institute (supporting the initial development of anti-CD40 antibodies with enhanced agonist potency), the Vaccine Research Institute via the ANR-10-LABX-77 grant, and the NIH grant U19 AI111211. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication.	Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; Bagaev DV, 2020, NUCLEIC ACIDS RES, V48, pD1057, DOI 10.1093/nar/gkz874; Bozzacco L, 2007, P NATL ACAD SCI USA, V104, P1289, DOI 10.1073/pnas.0610383104; Ceglia V, 2021, J IMMUNOL, V207, P2060, DOI 10.4049/jimmunol.2000704; Cheng L, 2018, J CLIN INVEST, V128, P4387, DOI 10.1172/JCI99005; Dan JM, 2016, J IMMUNOL, V197, P983, DOI 10.4049/jimmunol.1600318; Danilova L, 2018, CANCER IMMUNOL RES, V6, P888, DOI 10.1158/2326-6066.CIR-18-0129; Dash P, 2017, NATURE, V547, P89, DOI 10.1038/nature22383; DAVIS MM, 1984, IMMUNOL REV, V81, P235, DOI 10.1111/j.1600-065X.1984.tb01113.x; Emerson RO, 2017, NAT GENET, V49, P659, DOI 10.1038/ng.3822; Fischer DS, 2020, MOL SYST BIOL, V16, DOI 10.15252/msb.20199416; Flamar AL, 2013, AIDS, V27, P2041, DOI 10.1097/QAD.0b013e3283624305; Flamar AL, 2012, J IMMUNOL, V189, P2645, DOI 10.4049/jimmunol.1102390; Flaxman A, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6030043; Furuya-Kanamori L, 2016, EMERG INFECT DIS, V22, P1052, DOI 10.3201/eid2206.151080; Glanville J, 2017, NATURE, V547, P94, DOI 10.1038/nature22976; Howie B, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac5624; Joo H, 2014, IMMUNITY, V41, P592, DOI 10.1016/j.immuni.2014.09.009; Klinger M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141561; Klinger M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074231; Lee LYH, 2008, J CLIN INVEST, V118, P3478, DOI 10.1172/JCI32460; Lovelace P, 2011, METHODS MOL BIOL, V699, P165, DOI 10.1007/978-1-61737-950-5_8; Nyendak MR, 2009, CURR OPIN INFECT DIS, V22, P174, DOI 10.1097/QCO.0b013e3283262fe9; Oseroff C, 2008, J IMMUNOL, V180, P7193, DOI 10.4049/jimmunol.180.11.7193; Sewell AK, 2012, NAT REV IMMUNOL, V12, P668, DOI 10.1038/nri3279; Sidney J, 2020, SEMIN IMMUNOL, V50, DOI 10.1016/j.smim.2020.101418; Snyder Thomas M, 2020, medRxiv, DOI 10.1101/2020.07.31.20165647; Terajima M, 2008, J VIROL, V82, P9283, DOI 10.1128/JVI.01047-08; Tong Y, 2020, COMPUT BIOL CHEM, V87, DOI 10.1016/j.compbiolchem.2020.107281; Warren RL, 2011, GENOME RES, V21, P790, DOI 10.1101/gr.115428.110; Yin WJ, 2016, EBIOMEDICINE, V5, P46, DOI 10.1016/j.ebiom.2016.01.029; Yost KE, 2020, VACCINE, V38, P4487, DOI 10.1016/j.vaccine.2019.11.035; Zurawski G, 2017, J VIROL, V91, DOI 10.1128/JVI.01596-16	33	0	0	0	9	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 30	2021	12								735584	10.3389/fimmu.2021.735584	http://dx.doi.org/10.3389/fimmu.2021.735584			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XO1QB	34917073	gold, Green Published			2022-12-18	WOS:000729966600001
J	Faia, C; Plaisance-Bonstaff, K; Vittori, C; Wyczechowska, D; Lassak, A; Meyaski-Schluter, M; Reiss, K; Peruzzi, F				Faia, Celeste; Plaisance-Bonstaff, Karlie; Vittori, Cecilia; Wyczechowska, Dorota; Lassak, Adam; Meyaski-Schluter, Mary; Reiss, Krzysztof; Peruzzi, Francesca			Attenuated Negative Feedback in Monocyte-Derived Macrophages From Persons Living With HIV: A Role for IKAROS	FRONTIERS IN IMMUNOLOGY			English	Article						HIV-1; Ikaros; monocytes; immune dysfunction; endotoxin tolerance	TRAINED IMMUNITY; ACTIVATED MACROPHAGES; TARGETING TRAF6; MICRORNAS; MIR-155; DISEASE; DIFFERENTIATION; INFLAMMATION; DYSFUNCTION; REINFECTION	Persons living with HIV (PLWH) are at higher risk of developing secondary illnesses than their uninfected counterparts, suggestive of a dysfunctional immune system in these individuals. Upon exposure to pathogens, monocytes undergo epigenetic remodeling that results in either a trained or a tolerant phenotype, characterized by hyper-responsiveness or hypo-responsiveness to secondary stimuli, respectively. We utilized CD14(+) monocytes from virally suppressed PLWH and healthy controls for in vitro analysis following polarization of these cells toward a pro-inflammatory monocyte-derived macrophage (MDM) phenotype. We found that in PLWH-derived MDMs, pro-inflammatory signals (TNFA, IL6, IL1B, miR-155-5p, and IDO1) dominate over negative feedback signals (NCOR2, GSN, MSC, BIN1, and miR-146a-5p), favoring an abnormally trained phenotype. The mechanism of this reduction in negative feedback involves the attenuated expression of IKZF1, a transcription factor required for de novo synthesis of RELA during LPS-induced inflammatory responses. Furthermore, restoring IKZF1 expression in PLWH-MDMs partially reinstated expression of negative regulators of inflammation and lowered the expression of pro-inflammatory cytokines. Overall, this mechanism may provide a link between dysfunctional immune responses and susceptibility to co-morbidities in PLWH with low or undetectable viral load.	[Faia, Celeste; Peruzzi, Francesca] Louisiana State Univ, Dept Microbiol Immunol & Parasitol, Hlth Sci Ctr, New Orleans, LA 70112 USA; [Plaisance-Bonstaff, Karlie; Vittori, Cecilia; Wyczechowska, Dorota; Lassak, Adam] Louisiana State Univ, Stanley S Scott Canc Ctr, Hlth Sci Ctr, New Orleans, LA USA; [Meyaski-Schluter, Mary] Louisiana State Univ, Clin & Translat Res Ctr, Hlth Sci Ctr, New Orleans, LA USA; [Reiss, Krzysztof] Louisiana State Univ, Dept Interdisciplinary Oncol, Hlth Sci Ctr, New Orleans, LA USA; [Peruzzi, Francesca] Louisiana State Univ, Dept Med, Hlth Sci Ctr, New Orleans, LA 70112 USA; [Peruzzi, Francesca] Louisiana State Univ, Dept Interdisciplinary Oncol, Hlth Sci Ctr, New Orleans, LA 70112 USA	Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	Peruzzi, F (corresponding author), Louisiana State Univ, Dept Microbiol Immunol & Parasitol, Hlth Sci Ctr, New Orleans, LA 70112 USA.; Peruzzi, F (corresponding author), Louisiana State Univ, Dept Med, Hlth Sci Ctr, New Orleans, LA 70112 USA.; Peruzzi, F (corresponding author), Louisiana State Univ, Dept Interdisciplinary Oncol, Hlth Sci Ctr, New Orleans, LA 70112 USA.	fperuz@lsuhsc.edu			NIH [P20GM121288, P30GM114732]; National Institute of General Medical Sciences of the National Institutes of Health [U54 GM104940]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of General Medical Sciences of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	FP, CF, CV, KP-B, AL, and KR were supported by NIH P20GM121288. DW was supported by NIH P20GM121288 and NIH P30GM114732. MMS was supported by U54 GM104940 from the National Institute of General Medical Sciences of the National Institutes of Health, which funds the Louisiana Clinical and Translational Science Center.	Alivernini S, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01932; Ancona G, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.639291; BALDWIN AS, 1990, MOL CELL BIOL, V10, P1406, DOI 10.1128/MCB.10.4.1406; Bekkering S, 2020, TRENDS ENDOCRIN MET, V31, P378, DOI 10.1016/j.tem.2020.01.008; Biswas SK, 2009, TRENDS IMMUNOL, V30, P475, DOI 10.1016/j.it.2009.07.009; Bowman ER, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008869; Brass AL, 2008, SCIENCE, V319, P921, DOI 10.1126/science.1152725; Brenchley JM, 2006, NAT MED, V12, P1365, DOI 10.1038/nm1511; Brenchley JM, 2006, NAT IMMUNOL, V7, P235, DOI 10.1038/ni1316; Chen J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088232; Chen J, 2019, CLIN INFECT DIS, V68, P1274, DOI 10.1093/cid/ciy676; Chen SY, 2020, CELL MOL IMMUNOL, V17, P36, DOI 10.1038/s41423-019-0315-0; Cheng Y, 2017, CELL PHYSIOL BIOCHEM, V41, P205, DOI 10.1159/000456043; Chinn LW, 2010, J INFECT DIS, V202, P1836, DOI 10.1086/657322; Curtale G, 2013, P NATL ACAD SCI USA, V110, P11499, DOI 10.1073/pnas.1219852110; d'Ettorre G, 2011, CURR HIV RES, V9, P148, DOI 10.2174/157016211795945296; Davidson-Moncada J, 2010, ANN NY ACAD SCI, V1183, P183, DOI 10.1111/j.1749-6632.2009.05121.x; del Fresno C, 2009, J IMMUNOL, V182, P6494, DOI 10.4049/jimmunol.0803350; Doxaki C, 2015, J IMMUNOL, V195, P5750, DOI 10.4049/jimmunol.1500615; Duncan SA, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.02431; Eletto D, 2008, J CELL PHYSIOL, V216, P764, DOI 10.1002/jcp.21452; Fang CM, 2012, GENES IMMUN, V13, P421, DOI 10.1038/gene.2012.10; Glass CK, 2010, NAT REV IMMUNOL, V10, P365, DOI 10.1038/nri2748; Gracias DT, 2011, ADV EXP MED BIOL, V780, P15, DOI 10.1007/978-1-4419-5632-3_2; Heizmann B, 2018, CURR OPIN IMMUNOL, V51, P14, DOI 10.1016/j.coi.2017.11.005; Hou J, 2009, J IMMUNOL, V183, P2150, DOI 10.4049/jimmunol.0900707; Hume DA, 2008, MUCOSAL IMMUNOL, V1, P432, DOI 10.1038/mi.2008.36; Ifrim DC, 2014, CLIN VACCINE IMMUNOL, V21, P534, DOI 10.1128/CVI.00688-13; Jaguin M, 2013, CELL IMMUNOL, V281, P51, DOI 10.1016/j.cellimm.2013.01.010; Jenabian MA, 2015, J INFECT DIS, V212, P355, DOI 10.1093/infdis/jiv037; Jia SJ, 2014, DISCOV MED, V18, P237; Jin C, 2017, HIV MED, V18, P354, DOI 10.1111/hiv.12470; Kadri F, 2016, J CELL PHYSIOL, V231, P829, DOI 10.1002/jcp.25131; Kleinnijenhuis J, 2012, P NATL ACAD SCI USA, V109, P17537, DOI 10.1073/pnas.1202870109; Kroesen BJ, 2015, IMMUNOLOGY, V144, P1, DOI 10.1111/imm.12367; Lind EF, 2014, EUR J IMMUNOL, V44, P11, DOI 10.1002/eji.201343962; Lindsay MA, 2008, TRENDS IMMUNOL, V29, P343, DOI 10.1016/j.coph.2009.05.003; Ma XD, 2011, J MOL CELL BIOL, V3, P159, DOI 10.1093/jmcb/mjr007; Mashima R, 2015, IMMUNOLOGY, V145, P323, DOI 10.1111/imm.12468; Mehraj V, 2020, CLIN INFECT DIS, V70, P232, DOI 10.1093/cid/ciz212; Muller AJ, 2005, NAT MED, V11, P312, DOI 10.1038/nm1196; Nahid MA, 2011, CELL MOL IMMUNOL, V8, P388, DOI 10.1038/cmi.2011.26; Nahid MA, 2009, J BIOL CHEM, V284, P34590, DOI 10.1074/jbc.M109.056317; Netea MG, 2011, CELL HOST MICROBE, V9, P355, DOI 10.1016/j.chom.2011.04.006; Nichogiannopoulou A, 1999, J EXP MED, V190, P1201, DOI 10.1084/jem.190.9.1201; O'Connell RM, 2011, BLOOD, V118, P2960, DOI 10.1182/blood-2011-03-291971; O'Connell RM, 2010, NAT REV IMMUNOL, V10, P111, DOI 10.1038/nri2708; Oh KS, 2018, J IMMUNOL, V201, P757, DOI 10.4049/jimmunol.1800158; Pacifici M, 2014, JOVE-J VIS EXP, DOI 10.3791/51172; Pacifici M, 2013, J CELL PHYSIOL, V228, P1070, DOI 10.1002/jcp.24254; Park H, 2015, J BIOL CHEM, V290, P2831, DOI 10.1074/jbc.M114.591420; Pedersen I, 2008, CYTOKINE, V43, P391, DOI 10.1016/j.cyto.2008.07.016; Perissi V, 2010, NAT REV GENET, V11, P109, DOI 10.1038/nrg2736; Plaisance-Bonstaff K, 2019, JOVE-J VIS EXP, DOI 10.3791/59967; Qi QB, 2018, CLIN INFECT DIS, V67, P235, DOI 10.1093/cid/ciy053; Quinn SR, 2011, INT IMMUNOL, V23, P421, DOI 10.1093/intimm/dxr034; Quintin J, 2012, CELL HOST MICROBE, V12, P223, DOI 10.1016/j.chom.2012.06.006; Ramendra R, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00465; Read KA, 2021, IMMUNOL REV, V300, P82, DOI 10.1111/imr.12936; Rouillard AD, 2016, DATABASE-OXFORD, DOI 10.1093/database/baw100; Roy S, 2015, NUCLEIC ACIDS RES, V43, P6969, DOI 10.1093/nar/gkv646; Saba R, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00578; Saeed S, 2014, SCIENCE, V345, P1578, DOI 10.1126/science.1251086; Sandler NG, 2011, J INFECT DIS, V203, P780, DOI 10.1093/infdis/jiq118; Schulte LN, 2013, NUCLEIC ACIDS RES, V41, P542, DOI 10.1093/nar/gks1030; SEELER JS, 1994, J VIROL, V68, P1002, DOI 10.1128/JVI.68.2.1002-1009.1994; Sinha KK, 2017, AIDS RES HUM RETROV, V33, P254, DOI [10.1089/aid.2016.0154, 10.1089/AID.2016.0154]; Sung MH, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2004764; Taganov KD, 2006, P NATL ACAD SCI USA, V103, P12481, DOI 10.1073/pnas.0605298103; Tan MS, 2013, TRENDS MOL MED, V19, P594, DOI 10.1016/j.molmed.2013.06.004; Taylor SC, 2019, TRENDS BIOTECHNOL, V37, P761, DOI 10.1016/j.tibtech.2018.12.002; Testa Ugo, 2017, Non-Coding RNA, V3, P22, DOI 10.3390/ncrna3030022; Treuter E, 2017, FEBS LETT, V591, P2959, DOI 10.1002/1873-3468.12850; Turner ML, 2011, J IMMUNOL, V187, P3911, DOI 10.4049/jimmunol.1101137; van der Heijden WA, 2021, JCI INSIGHT, V6, DOI 10.1172/jci.insight.145928; Vergadi E, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02705; Watson PJ, 2012, MOL CELL ENDOCRINOL, V348, P440, DOI 10.1016/j.mce.2011.08.033; WINANDY S, 1995, CELL, V83, P289, DOI 10.1016/0092-8674(95)90170-1; Wlodarczyk M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20102565; Wu NN, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1008093; Wyczechowska D, 2017, FRONT MOL NEUROSCI, V10, DOI 10.3389/fnmol.2017.00385; Zhong C, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00284	82	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 30	2021	12								785905	10.3389/fimmu.2021.785905	http://dx.doi.org/10.3389/fimmu.2021.785905			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XO0NC	34917094	gold, Green Published			2022-12-18	WOS:000729891100001
J	Gomez-Henao, W; Saavedra, R; Chavez-Sanchez, FR; Lascurain, R; Zenteno, E; Tenorio, EP				Gomez-Henao, Wilton; Saavedra, Rafael; Chavez-Sanchez, Francisco Raul; Lascurain, Ricardo; Zenteno, Edgar; Tenorio, Eda Patricia			Expression Dynamics of the O-Glycosylated Proteins Recognized by Amaranthus leucocarpus Lectin in T Lymphocytes and Its Relationship With Moesin as an Alternative Mechanism of Cell Activation	FRONTIERS IN IMMUNOLOGY			English	Article						O-glycosylation; Amaranthus leucocarpus lectin; moesin; T lymphocytes; costimulatory molecules	ERM PROTEIN; DIFFERENTIAL EXPRESSION; EZRIN; CD28; PHOSPHORYLATION; COSTIMULATION; RECEPTOR; NAIVE; SUSCEPTIBILITY; GLYCOPROTEIN	T lymphocyte activation begins with antigen/MHC recognition by the TCR/CD3 complex followed by a costimulatory signal provided by CD28. The search for novel costimulatory molecules has been extensive due to their potential use as immunotherapeutic targets. Although some molecules have been identified, they are unable to provide sustainable signaling to allow for proper T cell activation and proliferation. It has been shown that the Amaranthus leucocarpus lectin (ALL) can be used as an in vitro costimulator of CD4(+) lymphocytes in the presence of anti-CD3 mAb; this lectin specifically recognizes O-glycans of the Gal beta 1-3GalNAc-O-Ser/Thr type, including a 70-kDa moesin-like protein that has been suggested as the costimulatory molecule. However, the identity of this molecule has not been confirmed and such costimulation has not been analyzed in CD8(+) lymphocytes. We show herein that the expression kinetics of the glycoproteins recognized by ALL (gpALL) is different in CD4(+) and CD8(+) T cells, unlike moesin expression. Results from IP experiments demonstrate that the previously described 70-kDa moesin-like protein is an O-glycosylated form of moesin (O-moesin) and that in vitro stimulation with anti-CD3 and anti-moesin mAb induces expression of the activation molecules CD69 and CD25, proliferation and IL-2 production as efficiently as cells costimulated with ALL or anti-CD28. Overall, our results demonstrate that O-moesin is expressed in CD4(+) and CD8(+) T lymphocytes and that moesin provides a new costimulatory activation signal in both T cell subsets.	[Gomez-Henao, Wilton; Chavez-Sanchez, Francisco Raul; Lascurain, Ricardo; Zenteno, Edgar; Tenorio, Eda Patricia] Univ Nacl Autonoma Mexico, Fac Med, Dept Bioquim, Mexico City, DF, Mexico; [Saavedra, Rafael] Univ Nacl Autonoma Mexico, Inst Invest Biomed, Dept Inmunol, Mexico City, DF, Mexico	Universidad Nacional Autonoma de Mexico; Universidad Nacional Autonoma de Mexico	Zenteno, E; Tenorio, EP (corresponding author), Univ Nacl Autonoma Mexico, Fac Med, Dept Bioquim, Mexico City, DF, Mexico.	ezenteno@unam.mx; ep.tenorio@unam.mx		Tenorio, Eda/0000-0002-4725-2286				Alvarez G, 2006, BBA-GEN SUBJECTS, V1760, P1235, DOI 10.1016/j.bbagen.2006.03.024; [Anonymous], Moesin. Mus Musculus. Available at:; Appleman LJ, 2003, IMMUNOL REV, V192, P161, DOI 10.1034/j.1600-065X.2003.00009.x; Angel MAD, 2015, IMMUN INFLAMM DIS, V3, P182, DOI 10.1002/iid3.58; Bachmann MF, 1997, IMMUNITY, V7, P549, DOI 10.1016/S1074-7613(00)80376-3; BERRYMAN M, 1993, J CELL SCI, V105, P1025; Bretscher PA, 1999, P NATL ACAD SCI USA, V96, P185, DOI 10.1073/pnas.96.1.185; Butkinaree C, 2010, BBA-GEN SUBJECTS, V1800, P96, DOI 10.1016/j.bbagen.2009.07.018; Cejas RB, 2019, J BIOL CHEM, V294, P2997, DOI 10.1074/jbc.RA118.005524; Cheng RY, 2019, FRONT CHEM, V7, DOI 10.3389/fchem.2019.00588; Comelli EM, 2006, J IMMUNOL, V177, P2431, DOI 10.4049/jimmunol.177.4.2431; Delon J, 2001, IMMUNITY, V15, P691, DOI 10.1016/S1074-7613(01)00231-X; DUNSTER LM, 1994, VIROLOGY, V198, P265, DOI 10.1006/viro.1994.1029; Dustin ML, 2014, CANCER IMMUNOL RES, V2, P1023, DOI 10.1158/2326-6066.CIR-14-0161; Edner Natalie M, 2021, Immunother Adv, V1, pltaa003, DOI 10.1093/immadv/ltaa003; Esensten JH, 2016, IMMUNITY, V44, P973, DOI 10.1016/j.immuni.2016.04.020; Gomez-Henao W, 2021, INT REV IMMUNOL, V40, P274, DOI 10.1080/08830185.2020.1845331; Goral S, 2011, DIALYSIS TRANSPLANT, V40, P14, DOI 10.1002/dat.20527; Gorocica P, 1998, GLYCOCONJUGATE J, V15, P809, DOI 10.1023/A:1006916100414; Graf B, 2007, J IMMUNOL, V179, P1616, DOI 10.4049/jimmunol.179.3.1616; Hirata T, 2012, INT IMMUNOL, V24, P705, DOI 10.1093/intimm/dxs077; Ilani T, 2007, J CELL BIOL, V179, P733, DOI 10.1083/jcb.200707199; Jeong S, 2020, IMMUNE NETW, V20, DOI 10.4110/in.2020.20.e3; Kawaguchi K, 2017, BIOL PHARM BULL, V40, P381, DOI 10.1248/bpb.b16-01011; Kim SO, 2017, NANO CONVERG, V4, DOI 10.1186/s40580-017-0099-9; Lagresle-Peyrou C, 2016, J ALLERGY CLIN IMMUN, V138, P1681, DOI 10.1016/j.jaci.2016.04.032; LANKES WT, 1991, P NATL ACAD SCI USA, V88, P8297, DOI 10.1073/pnas.88.19.8297; Leitner J, 2015, J IMMUNOL, V195, P477, DOI 10.4049/jimmunol.1401917; Lyons AB, 2000, J IMMUNOL METHODS, V243, P147, DOI 10.1016/S0022-1759(00)00231-3; Masumoto J, 1998, HISTOCHEM CELL BIOL, V110, P33, DOI 10.1007/s004180050262; Mescher MF, 2006, IMMUNOL REV, V211, P81, DOI 10.1111/j.0105-2896.2006.00382.x; Nakamura F, 1995, J BIOL CHEM, V270, P31377, DOI 10.1074/jbc.270.52.31377; Ortiz B, 2002, CELL IMMUNOL, V218, P34, DOI 10.1016/S0008-8749(02)00518-X; Pearson MA, 2000, CELL, V101, P259, DOI 10.1016/S0092-8674(00)80836-3; Pedro H, 2004, BBA-GEN SUBJECTS, V1674, P282, DOI 10.1016/j.bbagen.2004.07.008; Porras F, 2000, GLYCOBIOLOGY, V10, P459, DOI 10.1093/glycob/10.5.459; Riley JL, 2002, P NATL ACAD SCI USA, V99, P11790, DOI 10.1073/pnas.162359999; Satooka H, 2017, J IMMUNOL, V199, P3418, DOI 10.4049/jimmunol.1700074; SCHNEIDERSCHAULIES J, 1995, J VIROL, V69, P2248, DOI 10.1128/JVI.69.4.2248-2256.1995; SCHWARTZ RH, 1992, CELL, V71, P1065, DOI 10.1016/S0092-8674(05)80055-8; Shaffer MH, 2009, J IMMUNOL, V182, P1021, DOI 10.4049/jimmunol.182.2.1021; Shcherbina A, 1999, FEBS LETT, V443, P31, DOI 10.1016/S0014-5793(98)01674-3; Tenorio EP, 2011, EUR J IMMUNOL, V41, P3529, DOI 10.1002/eji.201141507; Toscano MA, 2007, NAT IMMUNOL, V8, P825, DOI 10.1038/ni1482; Urrea F, 2011, IMMUNOL INVEST, V40, P113, DOI 10.3109/08820139.2010.503767; Urrea F, 2010, TOHOKU J EXP MED, V221, P271, DOI 10.1620/tjem.221.271; Watts TH, 1999, CURR OPIN IMMUNOL, V11, P286, DOI 10.1016/S0952-7915(99)80046-6; Wei ZY, 2015, J BIOL CHEM, V290, P11384, DOI 10.1074/jbc.M115.643791; ZENTENO E, 1988, PHYTOCHEMISTRY, V27, P313, DOI 10.1016/0031-9422(88)83088-7	49	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 30	2021	12								788880	10.3389/fimmu.2021.788880	http://dx.doi.org/10.3389/fimmu.2021.788880			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XO0NB	34917095	gold, Green Published			2022-12-18	WOS:000729891000001
J	Han, DP; Sun, P; Hu, YX; Wang, J; Hua, GY; Chen, JF; Shao, CY; Tian, F; Darwish, HYA; Tai, YR; Yang, X; Chang, JY; Ma, YF				Han, Deping; Sun, Peng; Hu, Yanxin; Wang, Jing; Hua, Guoying; Chen, Jianfei; Shao, Chuyun; Tian, Fan; Darwish, Hesham Y. A.; Tai, Yurong; Yang, Xue; Chang, Jianyu; Ma, Yunfei			The Immune Barrier of Porcine Uterine Mucosa Differs Dramatically at Proliferative and Secretory Phases and Could Be Positively Modulated by Colonizing Microbiota	FRONTIERS IN IMMUNOLOGY			English	Article						mucosal immunity; intraepithelial lymphocyte; reproduction; macrophage; cell migration	T-CELLS; INTRAEPITHELIAL LYMPHOCYTES; GENERATION; SEARCH	Endometrial immune response is highly associated with the homeostatic balance of the uterus and embryo development; however, the underlying molecular regulatory mechanisms are not fully elucidated. Herein, the porcine endometrium showed significant variation in mucosal immunity in proliferative and secretory phases by single-cell RNA sequencing. The loose arrangement and high motility of the uterine epithelium in the proliferative phase gave opportunities for epithelial cells and dendritic cells to cross talk with colonizing microbial community, guiding lymphocyte migration into the mucosal and glandular epithelium. The migrating lymphocytes were primarily NK and CD8(+) T cells, which were robustly modulated by the chemokine signaling. In the secretory phase, the significantly strengthened mechanical mucosal barrier and increased immunoglobulin A alleviated the migration of lymphocytes into the epithelium when the neuro-modulation, mineral uptake, and amino acid metabolism were strongly upregulated. The noticeably increased intraepithelial lymphocytes were positively modulated by the bacteria in the uterine cavity. Our findings illustrated that significant mucosal immunity variation in the endometrium in the proliferative and secretory phases was closely related to intraepithelial lymphocyte migration, which could be modulated by the colonizing bacteria after cross talk with epithelial cells with higher expressions of chemokine.	[Han, Deping; Hu, Yanxin; Chang, Jianyu; Ma, Yunfei] China Agr Univ, Coll Vet Med, Beijing, Peoples R China; [Sun, Peng] Shandong Hekangyuan Biol Breeding Co Ltd, Res & Dev Dept Breeding Poultry Feed, Jinan, Peoples R China; [Wang, Jing; Hua, Guoying; Chen, Jianfei; Tai, Yurong; Yang, Xue] China Agr Univ, Coll Anim Sci & Technol, Beijing, Peoples R China; [Shao, Chuyun; Tian, Fan] Northwest Agr & Forestry Univ, Coll Vet Med, Yangling, Shaanxi, Peoples R China; [Darwish, Hesham Y. A.] Assiut Univ, Mol Biol Res & Studies Inst, Dept Appl Biotechnol, Assiut, Egypt	China Agricultural University; China Agricultural University; Northwest A&F University - China; Egyptian Knowledge Bank (EKB); Assiut University	Han, DP; Ma, YF (corresponding author), China Agr Univ, Coll Vet Med, Beijing, Peoples R China.	handeping1984@cau.edu.cn; yunfeima@cau.edu.cn		Darwish, Hesham Y. A./0000-0002-4965-3630	National Natural Science Foundation of China [31772686, 21027094]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	Funding This work was supported by grants from the National Natural Science Foundation of China: 31772686 and 21027094.	Altmae S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10098-3; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Ardain A, 2019, NATURE, V570, P528, DOI 10.1038/s41586-019-1276-2; Bush A, 2017, RESPIROLOGY, V22, P886, DOI 10.1111/resp.13085; Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303; Cervantes-Barragan L, 2017, SCIENCE, V357, P806, DOI 10.1126/science.aah5825; Duerkop BA, 2009, IMMUNITY, V31, P368, DOI 10.1016/j.immuni.2009.08.009; Edgar RC, 2010, BIOINFORMATICS, V26, P2460, DOI 10.1093/bioinformatics/btq461; Gamliel M, 2018, IMMUNITY, V48, P951, DOI 10.1016/j.immuni.2018.03.030; Gosmann C, 2017, IMMUNITY, V46, P29, DOI 10.1016/j.immuni.2016.12.013; Griffith OW, 2017, P NATL ACAD SCI USA, V114, pE6566, DOI 10.1073/pnas.1701129114; Huang CY, 2017, AM J REPROD IMMUNOL, V78, DOI 10.1111/aji.12713; Innocentin YLS, 2011, CELL, V147, P629, DOI 10.1016/j.cell.2011.09.025; Jin CC, 2019, CELL, V176, P998, DOI 10.1016/j.cell.2018.12.040; Kadowaki A, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11639; Kelleher AM, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04848-8; Kobayashi T, 2019, CELL, V176, P982, DOI 10.1016/j.cell.2018.12.031; Kulkarni S, 2019, NAT IMMUNOL, V20, P824, DOI 10.1038/s41590-019-0406-1; Kurd N, 2014, IMMUNITY, V41, P167, DOI 10.1016/j.immuni.2014.08.004; Ladinsky MS, 2019, SCIENCE, V363, P1058, DOI 10.1126/science.aat4042; Lee K, 2006, NAT GENET, V38, P1204, DOI 10.1038/ng1874; Li RH, 2019, CELL, V179, P687, DOI 10.1016/j.cell.2019.09.029; Lozupone C, 2005, APPL ENVIRON MICROB, V71, P8228, DOI 10.1128/AEM.71.12.8228-8235.2005; Mayassi T, 2018, MUCOSAL IMMUNOL, V11, P1281, DOI 10.1038/s41385-018-0016-5; McDonald BD, 2018, NAT REV IMMUNOL, V18, P514, DOI 10.1038/s41577-018-0013-7; Morita N, 2019, NATURE, V566, P110, DOI 10.1038/s41586-019-0884-1; Nielsen MM, 2017, NAT REV IMMUNOL, V17, P733, DOI 10.1038/nri.2017.101; Niu YY, 2019, SCIENCE, V366, P837, DOI 10.1126/science.aaw5754; Olivares-Villagomez D, 2018, TRENDS IMMUNOL, V39, P264, DOI 10.1016/j.it.2017.11.003; Owusu-Akyaw A, 2019, HUM REPROD UPDATE, V25, P114, DOI 10.1093/humupd/dmy035; Peng JY, 2019, CELL RES, V29, P725, DOI 10.1038/s41422-019-0195-y; Pennisi E, 2018, SCIENCE, V359, P260, DOI 10.1126/science.359.6373.260; Qi XY, 2019, NAT MED, V25, P1225, DOI 10.1038/s41591-019-0509-0; Raine T, 2015, GUT, V64, P250, DOI 10.1136/gutjnl-2013-306657; Ramette A, 2007, FEMS MICROBIOL ECOL, V62, P142, DOI 10.1111/j.1574-6941.2007.00375.x; Rivas MN, 2019, IMMUNITY, V51, P508, DOI 10.1016/j.immuni.2019.05.021; Sujino T, 2016, SCIENCE, V352, P1581, DOI 10.1126/science.aaf3892; Sun MM, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05901-2; Van Gorp H, 2010, J VIROL, V84, P3101, DOI 10.1128/JVI.02093-09; van Konijnenburg DPH, 2017, CELL, V171, P783, DOI 10.1016/j.cell.2017.08.046; Vento-Tormo R, 2018, NATURE, V563, P347, DOI 10.1038/s41586-018-0698-6; Wang WX, 2020, NAT MED, V26, P1644, DOI 10.1038/s41591-020-1040-z; Wang YF, 2019, NAT IMMUNOL, V20, P10, DOI 10.1038/s41590-018-0265-1; Zhang S, 2014, CELL RES, V24, P925, DOI 10.1038/cr.2014.82; Zhao Y, 2018, MUCOSAL IMMUNOL, V11, P752, DOI 10.1038/mi.2017.118; Zhou XF, 2019, NAT IMMUNOL, V20, P879, DOI 10.1038/s41590-019-0405-2	46	0	0	1	12	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 30	2021	12								750808	10.3389/fimmu.2021.750808	http://dx.doi.org/10.3389/fimmu.2021.750808			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XO1PD	34917075	Green Published, gold			2022-12-18	WOS:000729964100001
J	Martin, D; Perdiguero, P; Morel, E; Soleto, I; Herranz-Jusdado, JG; Ramon, LA; Abos, B; Wang, TH; Diaz-Rosales, P; Tafalla, C				Martin, Diana; Perdiguero, Pedro; Morel, Esther; Soleto, Irene; Herranz-Jusdado, J. German; Ramon, Luis A.; Abos, Beatriz; Wang, Tiehui; Diaz-Rosales, Patricia; Tafalla, Carolina			CD38 Defines a Subset of B Cells in Rainbow Trout Kidney With High IgM Secreting Capacities	FRONTIERS IN IMMUNOLOGY			English	Article						teleosts; B cells; CD38; IgM; plasmablasts; kidney	INNATE IMMUNE-RESPONSE; T-CELLS; EXPRESSION; ACTIVATION; FAMILY; CHAIN; DIFFERENTIATION; HETEROGENEITY; LYMPHOCYTES; NEUTROPHILS	CD38 is a multifunctional molecule that functions both as a transmembrane signaling receptor and as an ectoenzyme with important roles in cell adhesion, calcium regulation and signal transduction. Within the B cell linage, CD38 is expressed in diverse murine B cell subsets, with highest levels in innate B cell subpopulations such as marginal zone (MZ) B cells or B1 cells. In humans, however, CD38 is transiently expressed on early lymphocyte precursors, is lost on mature B cells and is consistently expressed on terminally differentiated plasma cells. In the present work, we have identified two homologues of mammalian CD38 in rainbow trout (Oncorhynchus mykiss), designating them as CD38A and CD38B. Although constitutively transcribed throughout different tissues in homeostasis, both CD38A and CD38B mRNA levels were significantly up-regulated in head kidney (HK) in response to a viral infection. In this organ, after the generation of a specific monoclonal antibody (mAb) against CD38A, the presence of CD38A(+) populations among IgM(+) B cells and IgM(-) leukocytes was investigated by flow cytometry. Interestingly, the percentage of IgM(+)CD38A(+) B cells increased in response to an in vitro stimulation with inactivated Aeromonas salmonicida. Finally, we demonstrated that HK IgM(+)CD38A(+) B cells had an increased IgM secreting capacity than that of cells lacking CD38A on the cell surface, also showing increased transcription levels of genes associated with B cell differentiation. This study strongly suggests a role for CD38 on the B cell differentiation process in teleosts, and provides us with novel tools to discern between B cell subsets in these species.	[Martin, Diana; Perdiguero, Pedro; Morel, Esther; Soleto, Irene; Herranz-Jusdado, J. German; Ramon, Luis A.; Abos, Beatriz; Diaz-Rosales, Patricia; Tafalla, Carolina] Consejo Super Invest Cient CISA INIA CSIC, Inst Nacl Invest & Tecnol Agr & Alimentaria, Anim Hlth Res Ctr, Madrid, Spain; [Wang, Tiehui] Univ Aberdeen, Sch Biol Sci, Scottish Fish Immunol Res Ctr, Aberdeen, Scotland	Instituto Nacional Investigacion Tecnologia Agraria Alimentaria (INIA); University of Aberdeen	Tafalla, C (corresponding author), Consejo Super Invest Cient CISA INIA CSIC, Inst Nacl Invest & Tecnol Agr & Alimentaria, Anim Hlth Res Ctr, Madrid, Spain.	tafalla@inia.es	Díaz-Rosales, Patricia/GPG-6820-2022; Herranz-Jusdado, Juan German/AAA-8160-2020; Perdiguero, Pedro/H-5234-2015	Herranz-Jusdado, Juan German/0000-0001-8773-4637; Perdiguero, Pedro/0000-0002-5471-9550; Martin Lorenzo, Diana/0000-0003-3065-2870				Abos B, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01203; Abos B, 2018, J IMMUNOL, V201, P465, DOI 10.4049/jimmunol.1701546; Abos B, 2015, J VIROL, V89, P1768, DOI 10.1128/JVI.03080-14; Abos B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082737; ALESSIO M, 1990, J IMMUNOL, V145, P878; Baumgarth N, 2011, NAT REV IMMUNOL, V11, P34, DOI 10.1038/nri2901; BEAN AGD, 1995, INT IMMUNOL, V7, P213, DOI 10.1093/intimm/7.2.213; Berthelot C, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4657; BouchetBernet C, 1996, BREAST CANCER RES TR, V41, P141, DOI 10.1007/BF01807159; Castro R, 2015, DEV COMP IMMUNOL, V51, P116, DOI 10.1016/j.dci.2015.03.002; Cerutti A, 2011, TRENDS IMMUNOL, V32, P202, DOI 10.1016/j.it.2011.02.004; Cuesta A, 2008, MOL IMMUNOL, V45, P2333, DOI 10.1016/j.molimm.2007.11.007; Deaglio S, 1998, J IMMUNOL, V160, P395; DELUCA D, 1983, EUR J IMMUNOL, V13, P546, DOI 10.1002/eji.1830130706; DUNNWALTERS DK, 1995, J EXP MED, V182, P559, DOI 10.1084/jem.182.2.559; Estrada-Figueroa LA, 2011, PARASITE IMMUNOL, V33, P661, DOI 10.1111/j.1365-3024.2011.01333.x; FARRELL AP, 1983, J EXP BIOL, V107, P415; Galfre G, 1981, Methods Enzymol, V73, P3; Ganassin RC, 1998, FISH SHELLFISH IMMUN, V8, P457, DOI 10.1006/fsim.1998.0153; Gao JX, 2012, EUR J IMMUNOL, V42, P982, DOI 10.1002/eji.201141519; Han JH, 2007, IMMUNITY, V27, P64, DOI 10.1016/j.immuni.2007.05.018; HAYAKAWA K, 1986, EUR J IMMUNOL, V16, P450, DOI 10.1002/eji.1830160423; HOWARD M, 1993, SCIENCE, V262, P1056, DOI 10.1126/science.8235624; Kelley LA, 2015, NAT PROTOC, V10, P845, DOI 10.1038/nprot.2015.053; KIKUCHI Y, 1995, P NATL ACAD SCI USA, V92, P11814, DOI 10.1073/pnas.92.25.11814; Kumar S, 2018, MOL BIOL EVOL, V35, P1547, DOI 10.1093/molbev/msy096; Li J, 2006, NAT IMMUNOL, V7, P1116, DOI 10.1038/ni1389; Li Y, 2020, DEV COMP IMMUNOL, V103, DOI 10.1016/j.dci.2019.103515; Lischke T, 2013, INFECT IMMUN, V81, P4091, DOI 10.1128/IAI.00340-13; Liu YJ, 1996, IMMUNITY, V4, P241, DOI 10.1016/S1074-7613(00)80432-X; Liu ZY, 1996, CYTOMETRY, V26, P1; Lu LQ, 2021, AIDS RES THER, V18, DOI 10.1186/s12981-021-00330-6; Malavasi F, 2008, PHYSIOL REV, V88, P841, DOI 10.1152/physrev.00035.2007; Martin F, 2001, CURR OPIN IMMUNOL, V13, P195, DOI 10.1016/S0952-7915(00)00204-1; Martin-Martin A, 2020, DEV COMP IMMUNOL, V109, DOI 10.1016/j.dci.2020.103715; Montero J, 2011, J VIROL, V85, P4046, DOI 10.1128/JVI.02519-10; Musso T, 2001, J LEUKOCYTE BIOL, V69, P605; Parra D, 2012, J LEUKOCYTE BIOL, V91, P525, DOI 10.1189/jlb.0711372; Partida-Sanchez S, 2001, NAT MED, V7, P1209, DOI 10.1038/nm1101-1209; REINHERZ EL, 1980, P NATL ACAD SCI-BIOL, V77, P1588, DOI 10.1073/pnas.77.3.1588; Rodriguez-Alba JC, 2019, BIOESSAYS, V41, DOI 10.1002/bies.201800128; Rothstein TL, 2013, ANN NY ACAD SCI, V1285, P97, DOI 10.1111/nyas.12137; Sandoval-Montes C, 2005, J LEUKOCYTE BIOL, V77, P513, DOI 10.1189/jlb.0404262; SANTOSARGUMEDO L, 1993, J IMMUNOL, V151, P3119; Scapigliati G, 2018, FRONT IMMUNOL, V9, DOI [10.3389/fimmu.2018.00971, 10.3389/fimmu.0018.00971]; Sconocchia G, 1999, BLOOD, V94, P3864, DOI 10.1182/blood.V94.11.3864.423k14_3864_3871; Shubinsky G, 1997, IMMUNITY, V7, P315, DOI 10.1016/S1074-7613(00)80353-2; Soleto I, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-73999-w; Vences-Catalan F, 2011, IUBMB LIFE, V63, P840, DOI 10.1002/iub.549; Viegas MS, 2007, MICROBES INFECT, V9, P847, DOI 10.1016/j.micinf.2007.03.003; Wang TH, 2009, J IMMUNOL, V183, P962, DOI 10.4049/jimmunol.0802953; ZUPO S, 1994, EUR J IMMUNOL, V24, P1218, DOI 10.1002/eji.1830240532; Zwollo P, 2005, J IMMUNOL, V174, P6608, DOI 10.4049/jimmunol.174.11.6608	53	0	0	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 30	2021	12								773888	10.3389/fimmu.2021.773888	http://dx.doi.org/10.3389/fimmu.2021.773888			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XO0NG	34917087	Green Published, gold			2022-12-18	WOS:000729891500001
J	Nunes, JPS; Moraes-Vieira, PM; Chevillard, C; Cunha-Neto, E				Nunes, Joao Paulo Silva; Moraes-Vieira, Pedro M.; Chevillard, Christophe; Cunha-Neto, Edecio			Mitochondria at the Crossroads of Immunity and Inflammatory Tissue Damage	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						tissue damage; mitochondria; immunity; inflammation; Chagas			[Nunes, Joao Paulo Silva; Cunha-Neto, Edecio] Univ Sao Paulo, Sch Med, Heart Inst InCor, Lab Immunol, Sao Paulo, Brazil; [Nunes, Joao Paulo Silva; Cunha-Neto, Edecio] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil; [Nunes, Joao Paulo Silva; Cunha-Neto, Edecio] Inst Nacl Ciencia & Tecnol INCT, Inst Invest Immunol Iii, Sao Paulo, Brazil; [Nunes, Joao Paulo Silva; Chevillard, Christophe] Aix Marseille Univ, TAGC Theories & Approaches Genom Complex, Inst MarMaRa, INSERM,UMR 1090, Marseille, France; [Moraes-Vieira, Pedro M.] Univ Estadual Campinas, Expt Med Res Cluster EMRC, Inst Biol, Dept Genet Evolut Microbiol & Immunol, Campinas, Brazil; [Moraes-Vieira, Pedro M.] Univ Estadual Campinas, Obes & Comorbid Res Ctr OCRC, Campinas, Brazil	Universidade de Sao Paulo; Universidade de Sao Paulo; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Universidade de Sao Paulo; Universidade Estadual de Campinas; Universidade Estadual de Campinas	Cunha-Neto, E (corresponding author), Univ Sao Paulo, Sch Med, Heart Inst InCor, Lab Immunol, Sao Paulo, Brazil.; Cunha-Neto, E (corresponding author), Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.; Cunha-Neto, E (corresponding author), Inst Nacl Ciencia & Tecnol INCT, Inst Invest Immunol Iii, Sao Paulo, Brazil.; Chevillard, C (corresponding author), Aix Marseille Univ, TAGC Theories & Approaches Genom Complex, Inst MarMaRa, INSERM,UMR 1090, Marseille, France.; Moraes-Vieira, PM (corresponding author), Univ Estadual Campinas, Expt Med Res Cluster EMRC, Inst Biol, Dept Genet Evolut Microbiol & Immunol, Campinas, Brazil.; Moraes-Vieira, PM (corresponding author), Univ Estadual Campinas, Obes & Comorbid Res Ctr OCRC, Campinas, Brazil.	pmvieira@unicamp.br; christophe.chevillard@univ-amu.fr; edecunha@gmail.com	Moraes-Vieira, Pedro/C-8701-2014; Cunha-Neto, Edecio/B-4157-2009; Nunes, João Paulo/AGW-2974-2022; CHEVILLARD, CHRISTOPHE/A-7087-2015	Moraes-Vieira, Pedro/0000-0002-8263-786X; Cunha-Neto, Edecio/0000-0002-3699-3345; Nunes, João Paulo/0000-0003-4355-6669; CHEVILLARD, CHRISTOPHE/0000-0002-5269-8813	Institut National de la Sante et de la Recherche Medicale (INSERM); Aix-Marseille University; French Agency for Research (Agence Nationale de la Recherche-ANR); CNPq (Brazilian Council for Scientific and Technological Development); FAPESP (Sao Paulo State Research Funding Agency Brazil) [2013/50302-3, 2014/50890-5, 2015/15626-8, 2019/25973-8, 2019/19435-3]; National Institutes of Health/USA [2 P50 AI098461-02, 2U19AI09846106]; Excellence Initiative of Aix-Marseille University -A*Midex a French "Investissements d'Avenir programme"-Institute MarMaRa [AMX-19-IET-007]; MarMaRa fellowship	Institut National de la Sante et de la Recherche Medicale (INSERM)(Institut National de la Sante et de la Recherche Medicale (Inserm)); Aix-Marseille University; French Agency for Research (Agence Nationale de la Recherche-ANR)(French National Research Agency (ANR)); CNPq (Brazilian Council for Scientific and Technological Development)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); FAPESP (Sao Paulo State Research Funding Agency Brazil)(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); National Institutes of Health/USA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Excellence Initiative of Aix-Marseille University -A*Midex a French "Investissements d'Avenir programme"-Institute MarMaRa(French National Research Agency (ANR)); MarMaRa fellowship	This work was supported by the Institut National de la Sante et de la Recherche Medicale (INSERM); the Aix-Marseille University (grant number: AMIDEX "International_2018" MITOMUTCHAGAS); the French Agency for Research (Agence Nationale de la Recherche-ANR (grant numbers: "Br-Fr-Chagas", "landscardio"); the CNPq (Brazilian Council for Scientific and Technological Development); and the FAPESP (Sao Paulo State Research Funding Agency Brazil (grant numbers: 2013/50302-3, 2014/50890-5, 2015/15626-8, 2019/25973-8, 2019/19435-3); the National Institutes of Health/USA (grant numbers: 2 P50 AI098461-02 and 2U19AI09846106). This work was founded by the Inserm Cross-Cutting Project GOLD. This project has received funding from the Excellence Initiative of Aix-Marseille University -A*Midex a French "Investissements d'Avenir programme"-Institute MarMaRa AMX-19-IET-007. JPSN was a recipient of a MarMaRa fellowship.		0	0	0	2	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 30	2021	12								810787	10.3389/fimmu.2021.810787	http://dx.doi.org/10.3389/fimmu.2021.810787			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XO1TD	34917101	gold, Green Published			2022-12-18	WOS:000729974600001
J	Almutairi, F; Sarr, D; Tucker, SL; Fantone, K; Lee, JK; Rada, B				Almutairi, Faris; Sarr, Demba; Tucker, Samantha L.; Fantone, Kayla; Lee, Jae-Kyung; Rada, Balazs			RGS10 Reduces Lethal Influenza Infection and Associated Lung Inflammation in Mice	FRONTIERS IN IMMUNOLOGY			English	Article						regulator of G-protein signaling (RGS)10; G-proteins; influenza A virus; monocytes; neutrophils; lung inflammation; cytokines; chemokines	NEUTROPHIL EXTRACELLULAR TRAPS; PROTEIN SIGNALING 10; A VIRUS-INFECTION; NF-KAPPA-B; CYSTIC-FIBROSIS; REGULATOR; EXPRESSION; IMMUNITY; ELASTASE; INJURY	Seasonal influenza epidemics represent a significant global health threat. The exacerbated immune response triggered by respiratory influenza virus infection causes severe pulmonary damage and contributes to substantial morbidity and mortality. Regulator of G-protein signaling 10 (RGS10) belongs to the RGS protein family that act as GTPase activating proteins for heterotrimeric G proteins to terminate signaling pathways downstream of G protein-coupled receptors. While RGS10 is highly expressed in immune cells, in particular monocytes and macrophages, where it has strong anti-inflammatory effects, its physiological role in the respiratory immune system has not been explored yet. Here, we show that Rgs10 negatively modulates lung immune and inflammatory responses associated with severe influenza H1N1 virus respiratory infection in a mouse model. In response to influenza A virus challenge, mice lacking RGS10 experience enhanced weight loss and lung viral titers, higher mortality and significantly faster disease onset. Deficiency of Rgs10 upregulates the levels of several proinflammatory cytokines and chemokines and increases myeloid leukocyte accumulation in the infected lung, markedly neutrophils, monocytes, and inflammatory monocytes, which is associated with more pronounced lung damage. Consistent with this, influenza-infected Rgs10-deficent lungs contain more neutrophil extracellular traps and exhibit higher neutrophil elastase activities than wild-type lungs. Overall, these findings propose a novel, in vivo role for RGS10 in the respiratory immune system controlling myeloid leukocyte infiltration, viral clearance and associated clinical symptoms following lethal influenza challenge. RGS10 also holds promise as a new, potential therapeutic target for respiratory infections.	[Almutairi, Faris; Sarr, Demba; Tucker, Samantha L.; Fantone, Kayla; Rada, Balazs] Univ Georgia, Dept Infect Dis, Coll Vet Med, Athens, GA 30602 USA; [Almutairi, Faris] Univ Georgia, Dept Pharmaceut & Biomed Sci, Coll Pharm, Athens, GA USA; [Lee, Jae-Kyung] Univ Georgia, Dept Physiol & Pharmacol, Coll Vet Med, Athens, GA USA	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia; University System of Georgia; University of Georgia	Rada, B (corresponding author), Univ Georgia, Dept Infect Dis, Coll Vet Med, Athens, GA 30602 USA.	radab@uga.edu	Sarr, Demba/GOG-9376-2022; Sarr, Demba/AAP-7125-2020	Sarr, Demba/0000-0002-8306-0433				Aguilera ER, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00105; Ali MW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060185; Almutairi F, 2021, CELL SIGNAL, V86, DOI 10.1016/j.cellsig.2021.110099; Almutairi F, 2020, CELL SIGNAL, V75, DOI 10.1016/j.cellsig.2020.109765; Alqinyah M, 2018, MOL PHARMACOL, V94, P1103, DOI 10.1124/mol.118.111674; Altman MK, 2015, CANCER LETT, V369, P175, DOI 10.1016/j.canlet.2015.08.012; Betakova T, 2017, CURR PHARM DESIGN, V23, P2616, DOI 10.2174/1381612823666170316123736; Block H, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10081932; Brandes M, 2013, CELL, V154, P197, DOI 10.1016/j.cell.2013.06.013; Brinkmann V, 2004, SCIENCE, V303, P1532, DOI 10.1126/science.1092385; Brinkmann V, 2007, NAT REV MICROBIOL, V5, P577, DOI 10.1038/nrmicro1710; Cacan E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087455; Capucetti A, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01259; Chan EC, 2018, J BIOL CHEM, V293, P12690, DOI 10.1074/jbc.RA118.002404; Chan MCW, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-135; Cho H, 2012, MOL CELL BIOL, V32, P4561, DOI 10.1128/MCB.00651-12; de Jong MD, 2006, NAT MED, V12, P1203, DOI 10.1038/nm1477; DeHelian D, 2020, BLOOD, V136, P1773, DOI 10.1182/blood.2019003251; Dieu-Nosjean MC, 2000, J EXP MED, V192, P705, DOI 10.1084/jem.192.5.705; Dunning J, 2020, MUCOSAL IMMUNOL, V13, P566, DOI 10.1038/s41385-020-0287-5; Fang X, 2019, NUTR RES, V70, P50, DOI 10.1016/j.nutres.2018.06.004; Garcia-Bernal D, 2011, J IMMUNOL, V187, P1264, DOI 10.4049/jimmunol.1002960; George T, 2018, ALLERGY ASTHMA CL IM, V14, DOI 10.1186/s13223-018-0266-5; George T, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170269; Gu YN, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13071362; Hensch NR, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165984; Herold S, 2008, J EXP MED, V205, P3065, DOI 10.1084/jem.20080201; Hollinger S, 2002, PHARMACOL REV, V54, P527, DOI 10.1124/pr.54.3.527; Hooks SB, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-289; Houser MC, 2021, ACTA NEUROPATHOL COM, V9, DOI 10.1186/s40478-021-01240-4; Hunt TW, 1996, NATURE, V383, P175, DOI 10.1038/383175a0; Hussain M, 2017, INFECT DRUG RESIST, V10, P121, DOI 10.2147/IDR.S105473; Kannarkat GT, 2015, NEUROBIOL AGING, V36, P1982, DOI 10.1016/j.neurobiolaging.2015.02.006; Kaufmann A, 2001, IMMUNOBIOLOGY, V204, P603, DOI 10.1078/0171-2985-00099; Kim H, 2018, VIRAL IMMUNOL, V31, P174, DOI 10.1089/vim.2017.0141; Kim KS, 2015, J MED VIROL, V87, P1104, DOI 10.1002/jmv.24138; Kobayashi Y, 2006, CRIT REV IMMUNOL, V26, P307, DOI 10.1615/CritRevImmunol.v26.i4.20; Konrad FM, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/740987; Lee JK, 2008, J NEUROSCI, V28, P8517, DOI 10.1523/JNEUROSCI.1806-08.2008; Lee JK, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0491-0; Lee JK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081785; Lee JK, 2012, J NEUROCHEM, V122, P333, DOI 10.1111/j.1471-4159.2012.07780.x; Lee JK, 2011, J NEUROSCI, V31, P11879, DOI 10.1523/JNEUROSCI.1002-11.2011; Li CG, 2012, CELL RES, V22, P528, DOI 10.1038/cr.2011.165; Lin KL, 2011, J IMMUNOL, V186, P508, DOI 10.4049/jimmunol.1001002; Liu Q, 2016, CELL MOL IMMUNOL, V13, P3, DOI 10.1038/cmi.2015.74; Ma P, 2018, BLOOD ADV, V2, P2145, DOI 10.1182/bloodadvances.2017008508; Ma PS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119496; Ma PS, 2012, BLOOD, V119, P1935, DOI 10.1182/blood-2011-10-387910; Ma WT, 2019, OPEN BIOL, V9, DOI 10.1098/rsob.190109; Masuho I, 2020, CELL, V183, P503, DOI 10.1016/j.cell.2020.08.052; Meitei HT, 2021, AUTOIMMUN REV, V20, DOI 10.1016/j.autrev.2021.102846; Miao RJ, 2016, HYPERTENSION, V67, P86, DOI 10.1161/HYPERTENSIONAHA.115.05957; Narasaraju T, 2011, AM J PATHOL, V179, P199, DOI 10.1016/j.ajpath.2011.03.013; Pamer EG, 2009, P NATL ACAD SCI USA, V106, P4961, DOI 10.1073/pnas.0901574106; Papayannopoulos V, 2018, NAT REV IMMUNOL, V18, P134, DOI 10.1038/nri.2017.105; Papayannopoulos V, 2010, J CELL BIOL, V191, P677, DOI 10.1083/jcb.201006052; Paquette SG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038214; Perrone LA, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000115; Popov S, 1997, P NATL ACAD SCI USA, V94, P7216, DOI 10.1073/pnas.94.14.7216; Pulendran B, 2015, CURR TOP MICROBIOL, V386, P23, DOI 10.1007/82_2014_405; Ren J, 2021, MOL IMMUNOL, V134, P236, DOI 10.1016/j.molimm.2021.03.024; Roghanian A, 2008, J AEROSOL MED PULM D, V21, P125, DOI 10.1089/jamp.2007.0653; Sabbaghi A, 2020, VIROL J, V17, DOI 10.1186/s12985-020-01449-0; Samet SJ, 2017, YALE J BIOL MED, V90, P471; Sarr D, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2017130118; Sautto GA, 2018, VIROL J, V15, DOI 10.1186/s12985-017-0918-y; Schmitz N, 2005, J VIROL, V79, P6441, DOI 10.1128/JVI.79.10.6441-6448.2005; Seki M, 2010, J IMMUNOL, V184, P1410, DOI 10.4049/jimmunol.0901709; Shi GX, 2004, J IMMUNOL, V172, P5175, DOI 10.4049/jimmunol.172.9.5175; Short KR, 2014, LANCET INFECT DIS, V14, P57, DOI 10.1016/S1473-3099(13)70286-X; Sil P, 2016, JOVE-J VIS EXP, DOI 10.3791/52779; Sokol CL, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a016303; Squires KE, 2018, PHARMACOL REV, V70, P446, DOI 10.1124/pr.117.015354; Szturmowicz M, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22168854; Tate MD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017618; Tucker SL, 2021, BMC IMMUNOL, V22, DOI 10.1186/s12865-021-00397-w; Tumpey TM, 2005, J VIROL, V79, P14933, DOI 10.1128/JVI.79.23.14933-14944.2005; van Helden MJG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052027; Voynow JA, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11081065; Vural A, 2019, J IMMUNOL, V202, P1510, DOI 10.4049/jimmunol.1801145; Wareing MD, 2007, VIRAL IMMUNOL, V20, P369, DOI 10.1089/vim.2006.0101; Wareing MD, 2004, J LEUKOCYTE BIOL, V76, P886, DOI 10.1189/jlb.1203644; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; Waugh JL, 2005, J COMP NEUROL, V481, P299, DOI 10.1002/cne.20372; Way EE, 2013, EUR J IMMUNOL, V43, P3116, DOI 10.1002/eji.201343713; Xue KS, 2020, VIRUS EVOL, V6, DOI 10.1093/ve/veaa010; Yang S, 2013, BONE RES, V1, P260, DOI 10.4248/BR201303005; Yang SY, 2007, J CELL SCI, V120, P3362, DOI 10.1242/jcs.008300; Yang SY, 2007, GENE DEV, V21, P1803, DOI 10.1101/gad.1544107; Yoo DG, 2014, IMMUNOL LETT, V160, P186, DOI 10.1016/j.imlet.2014.03.003; Zhu BB, 2019, P NATL ACAD SCI USA, V116, P11888, DOI 10.1073/pnas.1902310116; Zhu LL, 2018, J INFECT DIS, V217, P428, DOI 10.1093/infdis/jix475	94	0	0	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 29	2021	12								772288	10.3389/fimmu.2021.772288	http://dx.doi.org/10.3389/fimmu.2021.772288			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XT5QS	34912341	Green Published, gold			2022-12-18	WOS:000733642600001
J	Gao, QX; Yi, SK; Li, Y; Luo, JP; Xing, QQ; Yang, X; Zhao, M; Min, MH; Wang, Q; Wang, YB; Ma, LB; Peng, SM				Gao, Quanxin; Yi, Shaokui; Li, Yang; Luo, Jinping; Xing, Qianqian; Yang, Xia; Zhao, Ming; Min, Minghua; Wang, Qian; Wang, Yabing; Ma, Lingbo; Peng, Shiming			The Role of Flagellin B in Vibrio anguillarum-Induced Intestinal Immunity and Functional Domain Identification	FRONTIERS IN IMMUNOLOGY			English	Article						Vibrio anguillarum; flagellin; flaB; TLR5; structure-activity relationship; protein-protein interaction	POMFRET PAMPUS-ARGENTEUS; ND1 DOMAIN; FISH; MACROPHAGES; ACTIVATION; EXPRESSION; CYTOKINES; VIRULENCE; MUTANT	Vibrio anguillarum, an opportunistic pathogen of aquatic animals, moves using a filament comprised of polymerised flagellin proteins. Flagellins are essential virulence factors for V. anguillarum infection. Herein, we investigated the effects of flagellins (flaA, flaB, flaC, flaD and flaE) on cell apoptosis, TLR5 expression, and production of IL-8 and TNF-alpha. FlaB exhibited the strongest immunostimulation effects. To explore the functions of flaB in infection, we constructed a flaB deletion mutant using a two-step recombination method, and in vitro experiments showed a significant decrease in the expression of TLR5 and inflammatory cytokines compared with wild-type cells. However in the in vivo study, expression of inflammatory cytokines and intestinal mucosal structure showed no significant differences between groups. Additionally, flaB induced a significant increase in TLR5 expression based on microscopy analysis of fluorescently labelled TLR5, indicating interactions between the two proteins, which was confirmed by native PAGE and yeast two-hybrid assay. Molecular simulation of interactions between flaB and TLR5 was performed to identify the residues involved in binding, revealing two binding sites. Then, based on molecular dynamics simulations, we carried out thirteen site-directed mutations occurring at the amino acid sites of Q57, N83, N87, R91, D94, E122, D152, N312, R313, N320, L97, H316, I324 in binding regions of flaB protein by TLR5, respectively. Surface plasmon resonance (SPR) was employed to compare the affinities of flaB mutants for TLR5, and D152, D94, I324, N87, R313, N320 and H316 were found to mediate interactions between flaB and TLR5. Our comprehensive and systematic analysis of V. anguillarum flagellins establishes the groundwork for future design of flagellin-based vaccines.	[Zhao, Ming; Min, Minghua; Wang, Qian; Wang, Yabing; Ma, Lingbo; Peng, Shiming] Chinese Acad Fishery Sci, East China Sea Fisheries Res Inst, Minist Agr, Key Lab Marine & Estuarine Fisheries, Shanghai, Peoples R China; [Gao, Quanxin; Yi, Shaokui; Li, Yang; Luo, Jinping; Xing, Qianqian; Yang, Xia] Huzhou Univ, Chinese Acad Fishery Sci, Zhejiang Prov Key Lab Aquat Resources Conservat &, Coll Life Sci,Key Lab Aquat Anim Genet Breeding &, Huzhou, Peoples R China	Chinese Academy of Fishery Sciences; East China Sea Fisheries Research Institute, CAFS; Ministry of Agriculture & Rural Affairs; Chinese Academy of Fishery Sciences; Huzhou University	Peng, SM (corresponding author), Chinese Acad Fishery Sci, East China Sea Fisheries Res Inst, Minist Agr, Key Lab Marine & Estuarine Fisheries, Shanghai, Peoples R China.	pengsm2008@163.com			Natural Science Foundation of Shanghai [19ZR1470000]; National Natural Science Foundation of China [31772870]; Central Nonprofit Basic Scientific Research Project for the Scientific Research Institutes of China [2420-2019]	Natural Science Foundation of Shanghai(Natural Science Foundation of Shanghai); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Central Nonprofit Basic Scientific Research Project for the Scientific Research Institutes of China	This work was supported by grants from the Natural Science Foundation of Shanghai (No.19ZR1470000), National Natural Science Foundation of China (31772870); the Central Nonprofit Basic Scientific Research Project for the Scientific Research Institutes of China (2420-2019).	Akter T, 2020, J AQUAT ANIM HEALTH, V32, P21, DOI 10.1002/aah.10093; Andersen-Nissen E, 2005, P NATL ACAD SCI USA, V102, P9247, DOI 10.1073/pnas.0502040102; Barbosa FD, 2021, BRAZ J MICROBIOL, V52, P419, DOI 10.1007/s42770-020-00399-7; Biedma ME, 2019, VACCINE, V37, P652, DOI 10.1016/j.vaccine.2018.12.009; Chen H, 2019, FISH SHELLFISH IMMUN, V93, P354, DOI 10.1016/j.fsi.2019.07.032; Cui BF, 2018, EXPERT REV VACCINES, V17, P335, DOI 10.1080/14760584.2018.1457443; Neto OCD, 2013, VET MICROBIOL, V165, P425, DOI 10.1016/j.vetmic.2013.04.015; Dickey AK, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007354; Doan TD, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020283; dos Reis EC, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01291; Fauzi IA, 2020, AQUACULTURE, V528, DOI 10.1016/j.aquaculture.2020.735491; Frans I, 2011, J FISH DIS, V34, P643, DOI 10.1111/j.1365-2761.2011.01279.x; Gao QX, 2021, INT J BIOL MACROMOL, V174, P457, DOI 10.1016/j.ijbiomac.2021.01.146; Gao QX, 2017, INT J BIOL MACROMOL, V103, P327, DOI 10.1016/j.ijbiomac.2017.05.039; Gao QX, 2016, FISH SHELLFISH IMMUN, V58, P1, DOI 10.1016/j.fsi.2016.08.057; Gao QX, 2016, FISH SHELLFISH IMMUN, V54, P573, DOI 10.1016/j.fsi.2016.05.013; Gonzalez-Stegmaier R, 2019, FISH SHELLFISH IMMUN, V91, P412, DOI 10.1016/j.fsi.2019.04.133; Gonzalez-Stegmaier R, 2021, DEV COMP IMMUNOL, V117, DOI 10.1016/j.dci.2020.103988; Gonzalez-Stegmaier R, 2015, FISH SHELLFISH IMMUN, V47, P239, DOI 10.1016/j.fsi.2015.09.016; Gonzalez-Stegmaier R, 2015, FISH SHELLFISH IMMUN, V42, P144, DOI 10.1016/j.fsi.2014.10.034; Gries CM, 2019, BMC BIOTECHNOL, V19, DOI 10.1186/s12896-019-0545-3; Ivicak-Kocjan K, 2018, J LEUKOCYTE BIOL, V104, P767, DOI 10.1002/JLB.3VMA0118-035R; Ivicak-Kocjan K, 2013, BIOCHEM BIOPH RES CO, V435, P40, DOI 10.1016/j.bbrc.2013.04.030; Kaliamurthi S, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010063; Kim MI, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-24254-w; Kim SY, 2014, INFECT IMMUN, V82, P29, DOI 10.1128/IAI.00654-13; Lages MA, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.02335; Lee C, 2017, BIOCHEM BIOPH RES CO, V487, P381, DOI 10.1016/j.bbrc.2017.04.070; Li QN, 2018, VACCINE, V36, P1381, DOI 10.1016/j.vaccine.2018.01.086; Hung NB, 2016, RES MICROBIOL, V167, P262, DOI 10.1016/j.resmic.2016.01.006; Ning XH, 2020, FISH SHELLFISH IMMUN, V98, P800, DOI 10.1016/j.fsi.2019.11.033; Senevirathne A, 2020, MICROB PATHOGENESIS, V147, DOI 10.1016/j.micpath.2020.104252; Sharma P, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00171; Song WS, 2017, SCI REP-UK, V7, DOI 10.1038/srep40878; Steimle A, 2019, PLOS BIOL, V17, DOI 10.1371/journal.pbio.3000334; Westermann AJ, 2021, NAT REV GENET, V22, P361, DOI 10.1038/s41576-021-00326-y; Xie SW, 2020, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.01024; Xu M, 2019, J CELL MOL MED, V23, P7490, DOI 10.1111/jcmm.14617; Yang JM, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.581165; Zhao BL, 2021, CELL REP, V36, DOI 10.1016/j.celrep.2021.109401; Zhao YW, 2020, BIOMATERIALS, V249, DOI 10.1016/j.biomaterials.2020.120030	41	0	0	5	11	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 29	2021	12								774233	10.3389/fimmu.2021.774233	http://dx.doi.org/10.3389/fimmu.2021.774233			18	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YG5UZ	34912344	Green Published, gold			2022-12-18	WOS:000742554600001
J	Raghavan, S; Tovbis-Shifrin, N; Kochel, C; Sawant, A; Mello, M; Sathe, M; Blumenschein, W; Muise, ES; Chackerian, A; Pinheiro, EM; Rosahl, TW; Luche, H; Malefyt, RD				Raghavan, Sukanya; Tovbis-Shifrin, Nataliya; Kochel, Christina; Sawant, Anandi; Mello, Marielle; Sathe, Manjiri; Blumenschein, Wendy; Muise, Eric S.; Chackerian, Alissa; Pinheiro, Elaine M.; Rosahl, Thomas W.; Luche, Herve; de Waal Malefyt, Rene			Conditional Deletion of Pdcd1 Identifies the Cell-Intrinsic Action of PD-1 on Functional CD8 T Cell Subsets for Antitumor Efficacy	FRONTIERS IN IMMUNOLOGY			English	Article						conditional KO mice; IFN gamma; PD-1; mass cytometry (CyTOF); tumor immunity and immunotherapy; CD8 T cell	EXPRESSION; CTLA-4	Programmed cell death-1 (PD-1) blockade has a profound effect on the ability of the immune system to eliminate tumors, but many questions remain about the cell types involved and the underlying mechanisms of immune activation. To shed some light on this, the cellular and molecular events following inhibition of PD-1 signaling was investigated in the MC-38 colon carcinoma model using constitutive (PD-1 KO) and conditional (PD1cKO) mice and in wild-type mice treated with PD-1 antibody. The impact on both tumor growth and the development of tumor immunity was assessed. In the PD-1cKO mice, a complete deletion of Pdcd1 in tumor-infiltrating T cells (TILs) after tamoxifen treatment led to the inhibition of tumor growth of both small and large tumors. Extensive immune phenotypic analysis of the TILs by flow and mass cytometry identified 20-different T cell subsets of which specifically 5-CD8 positive ones expanded in all three models after PD-1 blockade. All five subsets expressed granzyme B and interferon gamma (IFN gamma). Gene expression analysis of the tumor further supported the phenotypic analysis in both PD-1cKO- and PD-1 Ab-treated mice and showed an upregulation of pathways related to CD4 and CD8 T-cell activation, enhanced signaling through costimulatory molecules and IFN gamma, and non-T-cell processes. Altogether, using PD-1cKO mice, we define the intrinsic nature of PD-1 suppression of CD8 T-cell responses in tumor immunity.	[Raghavan, Sukanya; Tovbis-Shifrin, Nataliya; Kochel, Christina; Sawant, Anandi; Sathe, Manjiri; Blumenschein, Wendy; Chackerian, Alissa; de Waal Malefyt, Rene] Merck & Co Inc, Dept Immunol, Palo Alto, CA 94304 USA; [Raghavan, Sukanya] Univ Gothenburg, Inst Biomed, Dept Microbiol & Immunol, Gothenburg, Sweden; [Mello, Marielle; Luche, Herve] Aix Marseille Univ, French Natl Ctr Sci Res, Ctr Immunophen CIPHE PHENOMIN,US012, Natl Inst Hlth & Med Res,INSERM,CNRS,UMS3367, Marseille, France; [Muise, Eric S.; Pinheiro, Elaine M.] Merck & Co Inc, Boston, MA USA; [Rosahl, Thomas W.] Merck & Co Inc, Kenilworth, NJ USA	Merck & Company; University of Gothenburg; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Merck & Company; Merck & Company	Malefyt, RD (corresponding author), Merck & Co Inc, Dept Immunol, Palo Alto, CA 94304 USA.	rdewaalm@synthekine.com	LUCHE, Herve/GLT-1401-2022					Arlauckas SP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3604; Ayers M, 2017, J CLIN INVEST, V127, P2930, DOI 10.1172/JCI91190; Burmeister Y, 2008, J IMMUNOL, V180, P774, DOI 10.4049/jimmunol.180.2.774; Dyck L, 2016, CANCER IMMUNOL IMMUN, V65, P1491, DOI 10.1007/s00262-016-1906-6; Hameyer D, 2007, PHYSIOL GENOMICS, V31, P32, DOI 10.1152/physiolgenomics.00019.2007; Hossain DMS, 2018, J CLIN INVEST, V128, P644, DOI 10.1172/JCI94586; Hsu PD, 2013, NAT BIOTECHNOL, V31, P827, DOI 10.1038/nbt.2647; Juneja VR, 2017, J EXP MED, V214, P895, DOI 10.1084/jem.20160801; Kamphorst AO, 2017, P NATL ACAD SCI USA, V114, P4993, DOI 10.1073/pnas.1705327114; Keir ME, 2005, J IMMUNOL, V175, P7372, DOI 10.4049/jimmunol.175.11.7372; Kim JM, 2016, ANN ONCOL, V27, P1492, DOI 10.1093/annonc/mdw217; Klein JP., 2003, NONPARAMETRIC ESTIMA, P538; Klocke K, 2016, P NATL ACAD SCI USA, V113, pE2383, DOI 10.1073/pnas.1603892113; Kumagai S, 2020, NAT IMMUNOL, V21, P1346, DOI 10.1038/s41590-020-0769-3; LaFleur MW, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09656-2; Lau J, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14572; Levine JH, 2015, CELL, V162, P184, DOI 10.1016/j.cell.2015.05.047; Lewandoski M, 2001, NAT REV GENET, V2, P743, DOI 10.1038/35093537; Manguso RT, 2017, NATURE, V547, P413, DOI 10.1038/nature23270; Nishimura H, 1999, IMMUNITY, V11, P141, DOI 10.1016/S1074-7613(00)80089-8; Paterson AM, 2015, J EXP MED, V212, P1603, DOI 10.1084/jem.20141030; Rashidian M, 2019, P NATL ACAD SCI USA, V116, P16971, DOI 10.1073/pnas.1905005116; Spitzer MH, 2015, SCIENCE, V349, DOI 10.1126/science.1259425; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tagliabracci VS, 2015, CELL, V161, P1619, DOI 10.1016/j.cell.2015.05.028; Tretina K, 2019, J EXP MED, V216, P482, DOI 10.1084/jem.20182031; Wei SC, 2019, IMMUNITY, V50, P1084, DOI 10.1016/j.immuni.2019.03.004; Wei SC, 2017, CELL, V170, P1120, DOI 10.1016/j.cell.2017.07.024; Woo SR, 2012, CANCER RES, V72, P917, DOI 10.1158/0008-5472.CAN-11-1620; Yost KE, 2019, NAT MED, V25, P1251, DOI 10.1038/s41591-019-0522-3; Zappasodi R, 2018, CANCER CELL, V33, P581, DOI 10.1016/j.ccell.2018.03.005; Zemek RM, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aav7816	32	0	0	2	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 29	2021	12								752348	10.3389/fimmu.2021.752348	http://dx.doi.org/10.3389/fimmu.2021.752348			18	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XQ6LF	34912335	Green Published, gold			2022-12-18	WOS:000731657000001
J	Steiner, R; Weijler, AM; Wekerle, T; Sprent, J; Pilat, N				Steiner, Romy; Weijler, Anna M.; Wekerle, Thomas; Sprent, Jonathan; Pilat, Nina			Impact of Graft-Resident Leucocytes on Treg Mediated Skin Graft Survival	FRONTIERS IN IMMUNOLOGY			English	Article						transplantation; allo-recognition; Regulatory T cells (Tregs); tolerance; IL-2 complexes; passenger leucocytes; graft-resident leucocytes	HEART ALLOGRAFT SURVIVAL; HUMAN LANGERHANS CELLS; MEMORY T-CELLS; PASSENGER LEUKOCYTES; DENDRITIC CELLS; DONOR ORGANS; IMMUNOGENICITY; REJECTION; TRANSPLANTATION; MICROCHIMERISM	The importance and exact role of graft-resident leucocytes (also referred to as passenger leucocytes) in transplantation is controversial as these cells have been reported to either initiate or retard graft rejection. T cell activation to allografts is mediated via recognition of intact or processed donor MHC molecules on antigen-presenting cells (APC) as well as through interaction with donor-derived extracellular vesicles. Reduction of graft-resident leucocytes before transplantation is a well-known approach for prolonging organ survival without interfering with the recipient's immune system. As previously shown by our group, injecting mice with IL-2/anti-IL-2 complexes (IL-2cplx) to augment expansion of CD4 T regulatory cells (Tregs) induces tolerance towards islet allografts, and also to skin allografts when IL-2cplx treatment is supplemented with rapamycin and a short-term treatment of anti-IL-6. In this study, we investigated the mechanisms by which graft-resident leucocytes impact graft survival by studying the combined effects of IL-2cplx-mediated Treg expansion and passenger leucocyte depletion. For the latter, effective depletion of APC and T cells within the graft was induced by prior total body irradiation (TBI) of the graft donor. Surprisingly, substantial depletion of donor-derived leucocytes by TBI did not prolong graft survival in naive mice, although it did result in augmented recipient leucocyte graft infiltration, presumably through irradiation-induced nonspecific inflammation. Notably, treatment with the IL-2cplx protocol prevented early inflammation of irradiated grafts, which correlated with an influx of Tregs into the grafts. This finding suggested there might be a synergistic effect of Treg expansion and graft-resident leucocyte depletion. In support of this idea, significant prolongation of skin graft survival was achieved if we combined graft-resident leucocyte depletion with the IL-2cplx protocol; this finding correlated along with a progressive shift in the composition of T cells subsets in the grafts towards a more tolerogenic environment. Donor-specific humoral responses remained unchanged, indicating minor importance of graft-resident leucocytes in anti-donor antibody development. These results demonstrate the importance of donor-derived leucocytes as well as Tregs in allograft survival, which might give rise to new clinical approaches.	[Steiner, Romy; Weijler, Anna M.; Wekerle, Thomas; Pilat, Nina] Med Univ Vienna, Dept Gen Surg, Vienna, Austria; [Sprent, Jonathan; Pilat, Nina] Garvan Inst Med Res, Div Immunol, Sydney, NSW, Australia; [Sprent, Jonathan] Univ New South Wales, St Vincents Clin Sch, Sydney, NSW, Australia	Medical University of Vienna; Garvan Institute of Medical Research; University of New South Wales Sydney	Pilat, N (corresponding author), Med Univ Vienna, Dept Gen Surg, Vienna, Austria.; Pilat, N (corresponding author), Garvan Inst Med Res, Div Immunol, Sydney, NSW, Australia.	nina.pilat@meduniwien.ac.at			Austrian Science Fund [J3671-B19, P31186-B28]; National Health and Medical Research Council of Australia	Austrian Science Fund(Austrian Science Fund (FWF)); National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia)	Funding This work was supported by the Austrian Science Fund (J3671-B19 and P31186-B28 to NP) and grants from the National Health and Medical Research Council of Australia to JS.	Baldwin WM, 2016, CURR OPIN ORGAN TRAN, V21, P7, DOI 10.1097/MOT.0000000000000262; BARKER CF, 1968, J EXP MED, V128, P197, DOI 10.1084/jem.128.1.197; Benichou G, 1999, J IMMUNOL, V162, P352; Benichou G, 2011, IMMUNOTHERAPY-UK, V3, P757, DOI [10.2217/IMT.11.2, 10.2217/imt.11.2]; Bennett CL, 2007, TRENDS IMMUNOL, V28, P525, DOI 10.1016/j.it.2007.08.011; Bingaman AW, 2004, AM J TRANSPLANT, V4, P846, DOI 10.1111/j.1600-6143.2004.00453.x; Bruggenwirth IMA, 2020, AM J TRANSPLANT, V20, P931, DOI 10.1111/ajt.15689; Fujita H, 2009, P NATL ACAD SCI USA, V106, P21795, DOI 10.1073/pnas.0911472106; Furio L, 2010, J INVEST DERMATOL, V130, P1345, DOI 10.1038/jid.2009.424; Harper IG, 2016, CELL REP, V15, P1214, DOI 10.1016/j.celrep.2016.04.009; Herrera OB, 2004, J IMMUNOL, V173, P4828, DOI 10.4049/jimmunol.173.8.4828; Hu B, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0207-x; Klechevsky E, 2008, IMMUNITY, V29, P497, DOI 10.1016/j.immuni.2008.07.013; Ko S, 1999, NAT MED, V5, P1292, DOI 10.1038/15248; Kvietkauskas M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00192; LAFFERTY KJ, 1975, SCIENCE, V188, P259, DOI 10.1126/science.1118726; LARSEN CP, 1990, ANN SURG, V212, P308, DOI 10.1097/00000658-199009000-00009; LECHLER R, 1991, CURR OPIN IMMUNOL, V3, P715, DOI 10.1016/0952-7915(91)90102-7; Lechler R, 2001, IMMUNITY, V14, P357, DOI 10.1016/S1074-7613(01)00116-9; LECHLER RI, 1982, J EXP MED, V156, P1835, DOI 10.1084/jem.156.6.1835; Liu Q, 2016, J CLIN INVEST, V126, P2805, DOI 10.1172/JCI84577; Marino J, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00582; Marino J, 2016, SCI IMMUNOL, V1, DOI 10.1126/sciimmunol.aaf8759; Mathers AR, 2009, J IMMUNOL, V182, P921, DOI 10.4049/jimmunol.182.2.921; OESTERWITZ H, 1989, Z VERSUCHSTIERKD, V32, P77; Ohl L, 2004, IMMUNITY, V21, P279, DOI 10.1016/j.immuni.2004.06.014; OLUWOLE S, 1980, TRANSPLANTATION, V30, P31, DOI 10.1097/00007890-198007000-00006; Pilat N, 2019, P NATL ACAD SCI USA, V116, P13508, DOI 10.1073/pnas.1903165116; Price JG, 2015, NAT IMMUNOL, V16, P1060, DOI 10.1038/ni.3270; Reed J, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10061478; Schenk AD, 2008, AM J TRANSPLANT, V8, P1652, DOI 10.1111/j.1600-6143.2008.02302.x; SCOTHORNE RJ, 1958, ANN NY ACAD SCI, V73, P673, DOI 10.1111/j.1749-6632.1959.tb40843.x; SNELL GD, 1957, ANNU REV MICROBIOL, V11, P439, DOI 10.1146/annurev.mi.11.100157.002255; Sprent Jonathan, 2005, Sci STKE, V2005, ppe8, DOI 10.1126/stke.2732005pe8; SRIWATANAWONGSA V, 1995, NAT MED, V1, P428, DOI 10.1038/nm0595-428; STEINMULLER D, 1980, J INVEST DERMATOL, V75, P107, DOI 10.1111/1523-1747.ep12521331; Stone JP, 2016, AM J TRANSPLANT, V16, P33, DOI 10.1111/ajt.13446; Wang HM, 2016, SCI REP-UK, V6, DOI 10.1038/srep33869; Webster KE, 2009, J EXP MED, V206, P751, DOI 10.1084/jem.20082824; Wei JL, 2019, CANCER MANAG RES, V11, P167, DOI 10.2147/CMAR.S188655; Weijler AM, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.586856; Wood KJ, 2003, TRANSPLANTATION, V75, p17S, DOI 10.1097/01.TP.0000067946.90241.2F; Yang C, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0387-2; Zhang MM, 2021, BIOCHEM PHARMACOL, V189, DOI 10.1016/j.bcp.2021.114432; Zheng XF, 2016, TRANSPLANTATION, V100, P743, DOI 10.1097/TP.0000000000000960; Zheng XF, 2009, CIRCULATION, V120, P1099, DOI 10.1161/CIRCULATIONAHA.108.787390	46	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 29	2021	12								801595	10.3389/fimmu.2021.801595	http://dx.doi.org/10.3389/fimmu.2021.801595			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YF8EX	34912349	gold, Green Published			2022-12-18	WOS:000742035200001
J	Florou, DT; Mavropoulos, A; Dardiotis, E; Tsimourtou, V; Siokas, V; Aloizou, AM; Liaskos, C; Tsigalou, C; Katsiari, C; Sakkas, LI; Hadjigeorgiou, G; Bogdanos, DP				Florou, Despoina T.; Mavropoulos, Athanasios; Dardiotis, Efthymios; Tsimourtou, Vana; Siokas, Vasileios; Aloizou, Athina-Maria; Liaskos, Christos; Tsigalou, Christina; Katsiari, Christina; Sakkas, Lazaros, I; Hadjigeorgiou, Georgios; Bogdanos, Dimitrios P.			Tetracyclines Diminish In Vitro IFN-gamma and IL-17-Producing Adaptive and Innate Immune Cells in Multiple Sclerosis	FRONTIERS IN IMMUNOLOGY			English	Article						multiple sclerosis; doxycycline; minocycline; proinflammatory; interferon-gamma; interleukin-17; NKT cells	ACTIVE RHEUMATOID-ARTHRITIS; T-CELLS; CYTOKINE PRODUCTION; INTERFERON-GAMMA; DISEASE-ACTIVITY; TH17 CELLS; MINOCYCLINE; DOXYCYCLINE; COMBINATION; ENCEPHALOMYELITIS	Introduction: Limited data from clinical trials in multiple sclerosis (MS) reported that minocycline, a widely used antibiotic belonging to the family of tetracyclines (TCs), exerts a beneficial short-lived clinical effect A similar anti-inflammatory effect of minocycline attributed to a deviation from Th1 to Th2 immune response has been reported in experimental models of MS. Whether such an immunomodulatory mechanism is operated in the human disease remains largely unknown. Aim: To assess the in vitro immunomodulatory effect of tetracyclines, and in particular minocycline and doxycycline, in naive and treated patients with MS. Material and Methods: Peripheral blood mononuclear cells from 45 individuals (35 MS patients, amongst which 15 naive patients and 10 healthy controls, HCs) were cultured with minocycline or doxycycline and conventional stimulants (PMA/Ionomycin or IL-12/ IL-18). IFN-gamma and IL-17 producing T-, NK- and NKT cells were assessed by flow cytometry. The effect of TCs on cell viability and apoptosis was further assessed by flow cytometry with Annexin V staining. Results: Both tetracyclines significantly decreased, in a dose dependent manner, IFN-gamma production in NKT and CD4(+) T lymphocytes from MS patients (naive or treated) stimulated with IL-12/IL-18 but did not decrease IFN-gamma producing CD8(+) T cells from naive MS or treated RRMS patients. They also decreased IL-17(+) T and NKT cells following PMA and lonomycin-stimulation. Tetracyclines did not affect the viability of cell subsets. Conclusion: Tetracyclines can in vitro suppress IFN-gamma and IL-17- producing cells from MS patients, and this may explain their potential therapeutic effect in vivo.	[Florou, Despoina T.; Mavropoulos, Athanasios; Liaskos, Christos; Katsiari, Christina; Sakkas, Lazaros, I; Bogdanos, Dimitrios P.] Univ Thessaly, Fac Med, Sch Hlth Sci, Dept Rheumatol & Clin Immunol, Larisa, Greece; [Florou, Despoina T.; Dardiotis, Efthymios; Tsimourtou, Vana; Siokas, Vasileios; Aloizou, Athina-Maria; Hadjigeorgiou, Georgios] Univ Thessaly, Fac Med, Sch Hlth Sci, Dept Neurol, Larisa, Greece; [Tsigalou, Christina] Democritus Univ Thrace, Fac Med, Lab Microbiol, Alexandroupolis, Greece; [Hadjigeorgiou, Georgios] Univ Cyprus, Med Sch, Nicosia, Cyprus	University of Thessaly; University of Thessaly; Democritus University of Thrace; University of Cyprus	Bogdanos, DP (corresponding author), Univ Thessaly, Fac Med, Sch Hlth Sci, Dept Rheumatol & Clin Immunol, Larisa, Greece.	bogdanos@med.uth.gr		MAVROPOULOS, ATHANASIOS/0000-0002-5328-1323; TSIGALOU, CHRISTINA/0000-0002-7869-6824; Aloizou, Athina Maria/0000-0001-9354-774X	Special Account for Research Grants University of Thessaly [6357, 5158, 5847]	Special Account for Research Grants University of Thessaly	We would like to thank Dr Zisis Tsouris for his contribution in clinical data collection, and Prof Eirini Rigopoulou for critical comments regarding data presentation and interpretation. This research was funded in part by the Special Account for Research Grants University of Thessaly, grant number 6357, 5158 and 5847.	Araki M, 2003, INT IMMUNOL, V15, P279, DOI 10.1093/intimm/dxg029; Avasarala Jagannadha, 2017, Innov Clin Neurosci, V14, P28; Brundula V, 2002, BRAIN, V125, P1297, DOI 10.1093/brain/awf133; Cazalis J, 2009, INFLAMMATION, V32, P130, DOI 10.1007/s10753-009-9111-9; Chen XH, 2011, J NEUROIMMUNOL, V235, P1, DOI 10.1016/j.jneuroim.2011.04.006; Chen XH, 2010, J NEUROIMMUNOL, V226, P104, DOI 10.1016/j.jneuroim.2010.05.039; CHOPRA I, 1992, J ANTIMICROB CHEMOTH, V29, P245, DOI 10.1093/jac/29.3.245; Comabella M, 1998, J CLIN INVEST, V102, P671, DOI 10.1172/JCI3125; Dargahi N, 2017, BRAIN SCI, V7, DOI 10.3390/brainsci7070078; Dettke M, 1997, J CLIN IMMUNOL, V17, P293, DOI 10.1023/A:1027374615106; Domae E, 2017, ONCOTARGET, V8, P45928, DOI 10.18632/oncotarget.17498; Dumitrescu L, 2018, EXPERT OPIN BIOL TH, V18, P665, DOI 10.1080/14712598.2018.1462793; El-Behi M, 2011, NAT IMMUNOL, V12, P568, DOI 10.1038/ni.2031; Fassbender K, 1999, NEUROLOGY, V53, P1104, DOI 10.1212/WNL.53.5.1104; Fujii C, 2016, SCI REP-UK, V6, DOI 10.1038/srep35314; Garrido-Mesa J, 2018, BRIT J PHARMACOL, V175, P4353, DOI 10.1111/bph.14494; Garrido-Mesa N, 2013, BRIT J PHARMACOL, V169, P337, DOI 10.1111/bph.12139; Ghasemi N, 2017, CELL J, V19, P1; Giuliani F, 2005, J NEUROIMMUNOL, V165, P83, DOI 10.1016/j.jneuroim.2005.04.020; Giuliani F, 2005, J LEUKOCYTE BIOL, V78, P135, DOI 10.1189/jlb.0804477; Giuliani F, 2005, J NEUROIMMUNOL, V158, P213, DOI 10.1016/j.jneuroim.2004.09.006; KLOPPENBURG M, 1994, ARTHRITIS RHEUM, V37, P629, DOI 10.1002/art.1780370505; Kloppenburg M, 1996, ANTIMICROB AGENTS CH, V40, P934, DOI 10.1128/AAC.40.4.934; KLOPPENBURG M, 1994, ANN NY ACAD SCI, V732, P422, DOI 10.1111/j.1749-6632.1994.tb24773.x; Kloppenburg M, 1995, CLIN EXP IMMUNOL, V102, P635; KLOPPENBURG M, 1995, J RHEUMATOL, V22, P611; Krakauer T, 2003, ANTIMICROB AGENTS CH, V47, P3630, DOI 10.1128/AAC.47.11.3630-3633.2003; Longbrake EE, 2009, EXPERT REV NEUROTHER, V9, P319, DOI 10.1586/14737175.9.3.319; Lublin FD, 2014, NEUROLOGY, V83, P278, DOI 10.1212/WNL.0000000000000560; Luccanini I, 2008, EXP NEUROL, V211, P214, DOI 10.1016/j.expneurol.2008.01.022; Maier K, 2007, NEUROBIOL DIS, V25, P514, DOI 10.1016/j.nbd.2006.10.022; Mastorodemos V, 2015, NEUROIMMUNOMODULAT, V22, P181, DOI 10.1159/000362370; Mavropoulos A, 2005, BLOOD, V105, P282, DOI 10.1182/blood-2004-07-2782; Mavropoulos A, 2019, RHEUMATOLOGY, V58, P2240, DOI 10.1093/rheumatology/kez204; Mavropoulos A, 2016, ARTHRITIS RHEUMATOL, V68, P494, DOI 10.1002/art.39437; McGinley AM, 2018, J AUTOIMMUN, V87, P97, DOI 10.1016/j.jaut.2018.01.001; da Costa DSMM, 2016, J NEUROIMMUNOL, V299, P8, DOI 10.1016/j.jneuroim.2016.08.005; Metz LM, 2017, NEW ENGL J MED, V376, P2122, DOI 10.1056/NEJMoa1608889; Milano S, 1997, ANTIMICROB AGENTS CH, V41, P117, DOI 10.1128/AAC.41.1.117; Minagar A, 2008, ARCH NEUROL-CHICAGO, V65, P199, DOI 10.1001/archneurol.2007.41; Newton PN, 2005, ANTIMICROB AGENTS CH, V49, P1622, DOI 10.1128/AAC.49.4.1622-1625.2005; Nikodemova M, 2007, J BIOL CHEM, V282, P15208, DOI 10.1074/jbc.M611907200; Nikodemova M, 2010, J NEUROIMMUNOL, V219, P33, DOI 10.1016/j.jneuroim.2009.11.009; Ottum PA, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00539; Petek-Balci B, 2015, INT J NEUROSCI, V125, P352, DOI 10.3109/00207454.2014.939747; Popovic N, 2002, ANN NEUROL, V51, P215, DOI 10.1002/ana.10092; Rostami A, 2013, J NEUROL SCI, V333, P76, DOI 10.1016/j.jns.2013.03.002; SAIVIN S, 1988, CLIN PHARMACOKINET, V15, P355, DOI 10.2165/00003088-198815060-00001; Sapadin AN, 2006, J AM ACAD DERMATOL, V54, P258, DOI 10.1016/j.jaad.2005.10.004; Skyvalidas DN, 2020, NUTR RES, V75, P95, DOI 10.1016/j.nutres.2020.01.005; Sorensen PS, 2016, EUR J NEUROL, V23, P861, DOI 10.1111/ene.12953; Tai K, 2013, TRANSL RES, V161, P99, DOI 10.1016/j.trsl.2012.10.001; Thompson AJ, 2018, LANCET NEUROL, V17, P162, DOI 10.1016/S1474-4422(17)30470-2; Van Kaer L, 2019, CELL MOL IMMUNOL, V16, P531, DOI 10.1038/s41423-019-0221-5; WELLING PG, 1977, ANTIMICROB AGENTS CH, V11, P462, DOI 10.1128/AAC.11.3.462; Wing AC, 2016, IMMUNOLOGY, V147, P212, DOI 10.1111/imm.12552; Yi CJ, 2011, NEUROCHEM RES, V36, P1984, DOI 10.1007/s11064-011-0522-2; Zabad RK, 2007, MULT SCLER, V13, P517, DOI 10.1177/1352458506070319; Zaguia F, 2013, J IMMUNOL, V190, P2510, DOI 10.4049/jimmunol.1202725	59	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 26	2021	12								739186	10.3389/fimmu.2021.739186	http://dx.doi.org/10.3389/fimmu.2021.739186			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6I1JR	34899697	Green Published, gold			2022-12-18	WOS:000885883000001
J							Frontiers Editorial Off	RETRACTION: Curcumin Blunts IL-6 Dependent Endothelial-to-Mesenchymal Transition to Alleviate Renal Allograft Fibrosis Through Autophagy Activation (Retraction of Vol 12, art no 656242, 2021)	FRONTIERS IN IMMUNOLOGY			English	Retraction																		Zhou JJ, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.656242	1	0	0	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 26	2021	12								818539	10.3389/fimmu.2021.818539	http://dx.doi.org/10.3389/fimmu.2021.818539			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YG6FZ		Green Published, gold			2022-12-18	WOS:000742583200001
J	Manivasagam, S; Klein, RS				Manivasagam, Sindhu; Klein, Robyn S.			Type III Interferons: Emerging Roles in Autoimmunity	FRONTIERS IN IMMUNOLOGY			English	Review						interferon lambda; autoimmune diseases; Th1 cells; IFNLR; neuroimmunology and neuropathology	IFN-LAMBDA; INTESTINAL INFLAMMATION; STIMULATED GENES; MESSENGER-RNA; CELLS; IFN-LAMBDA-1; EXPRESSION; ALPHA; RESPONSES; IL-29	Type III interferons (IFNs) or the lambda IFNs (IFNLs or IFN-lambda s) are antimicrobial cytokines that play key roles in immune host defense at endothelial and epithelial barriers. IFNLs signal via their heterodimeric receptor, comprised of two subunits, IFNLR1 and interleukin (IL)10R beta, which defines the cellular specificity of the responses to the cytokines. Recent studies show that IFNL signaling regulates CD4+ T cell differentiation, favoring Th1 cells, which has led to the identification of IFNL as a putative therapeutic target for autoimmune diseases. Here, we summarize the IFNL signaling pathways during antimicrobial immunity, IFNL-mediated immunomodulation of both innate and adaptive immune cells, and induction of autoimmunity.	[Manivasagam, Sindhu; Klein, Robyn S.] Washington Univ, Sch Med, Ctr Neuroimmunol & Neuroinfectious Dis, St Louis, MO 63110 USA; [Manivasagam, Sindhu; Klein, Robyn S.] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; [Klein, Robyn S.] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA; [Klein, Robyn S.] Washington Univ, Sch Med, Dept Neurosci, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Klein, RS (corresponding author), Washington Univ, Sch Med, Ctr Neuroimmunol & Neuroinfectious Dis, St Louis, MO 63110 USA.; Klein, RS (corresponding author), Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA.; Klein, RS (corresponding author), Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA.; Klein, RS (corresponding author), Washington Univ, Sch Med, Dept Neurosci, St Louis, MO 63110 USA.	rklein@wustl.edu			National Multiple Sclerosis Society [RG 1801-29766]; National Institutes of Health [R56AI147623, R35NS122310, R01NS104471, R01NS116788, R01NS052632, F31 NS108629-01A1]	National Multiple Sclerosis Society(National Multiple Sclerosis Society); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Funding This work was supported by a grant from the National Multiple Sclerosis Society (RG 1801-29766), and grants from the National Institutes of Health (R56AI147623, R35NS122310, R01NS104471, R01NS116788, and R01NS052632; all to RK, and F31 NS108629-01A1; to SM).	Ai, TARGETING INTERFERON, DOI [10.1101/2021.08.17.456642, DOI 10.1101/2021.08.17.456642]; Blazek K, 2015, J EXP MED, V212, P845, DOI 10.1084/jem.20140995; Broggi A, 2017, NAT IMMUNOL, V18, P1084, DOI 10.1038/ni.3821; Bullens DMA, 2008, CLIN EXP ALLERGY, V38, P1459, DOI 10.1111/j.1365-2222.2008.03045.x; Castillo JR, 2017, J ALLER CL IMM-PRACT, V5, P918, DOI 10.1016/j.jaip.2017.05.001; Castillo-Martinez D, 2017, AUTOIMMUNITY, V50, P82, DOI 10.1080/08916934.2017.1289181; Chang QJ, 2017, TOHOKU J EXP MED, V241, P89, DOI 10.1620/tjem.241.89; Chen JY, 2018, ARTHRITIS RES THER, V20, DOI 10.1186/s13075-018-1683-z; Chiriac MT, 2017, GASTROENTEROLOGY, V153, P123, DOI 10.1053/j.gastro.2017.03.015; Cole AM, 2001, J IMMUNOL, V167, P623, DOI 10.4049/jimmunol.167.2.623; Contoli M, 2006, NAT MED, V12, P1023, DOI 10.1038/nm1462; da Silva J, 2017, CLIN EXP ALLERGY, V47, P313, DOI 10.1111/cea.12809; Dai JH, 2009, BLOOD, V113, P5829, DOI 10.1182/blood-2008-09-179507; de Groen RA, 2015, J LEUKOCYTE BIOL, V98, P623, DOI 10.1189/jlb.3A0215-041RR; de Groen RA, 2015, EUR J IMMUNOL, V45, P250, DOI 10.1002/eji.201444903; Dolganiuc A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044915; Dufour JH, 2002, J IMMUNOL, V168, P3195, DOI 10.4049/jimmunol.168.7.3195; Egli A, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004556; Egli A, 2014, EMERG MICROBES INFEC, V3, DOI 10.1038/emi.2014.51; Eslam M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7422; Espinosa V, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aan5357; Forero A, 2019, IMMUNITY, V51, P451, DOI 10.1016/j.immuni.2019.07.007; Ge DL, 2009, NATURE, V461, P399, DOI 10.1038/nature08309; Goel RR, 2021, NAT REV RHEUMATOL, V17, P349, DOI 10.1038/s41584-021-00606-1; Goel RR, 2020, P NATL ACAD SCI USA, V117, P5409, DOI 10.1073/pnas.1916897117; Hemann EA, 2019, NAT IMMUNOL, V20, P1035, DOI 10.1038/s41590-019-0408-z; Henden AS, 2021, BLOOD, V138, P722, DOI 10.1182/blood.2020006375; Hou W, 2009, J VIROL, V83, P3834, DOI 10.1128/JVI.01773-08; Hubert M, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.aav3942; Jilg N, 2014, HEPATOLOGY, V59, P1250, DOI 10.1002/hep.26653; Jordan WJ, 2007, GENES IMMUN, V8, P254, DOI 10.1038/sj.gene.6364382; Kelly A, 2016, J INTERF CYTOK RES, V36, P671, DOI 10.1089/jir.2015.0169; Koltsida O, 2011, EMBO MOL MED, V3, P348, DOI 10.1002/emmm.201100142; Koper OM, 2018, ADV CLIN EXP MED, V27, P849, DOI 10.17219/acem/68846; Kotenko SV, 2003, NAT IMMUNOL, V4, P69, DOI 10.1038/ni875; Krasnova TN, 2015, TERAPEVT ARKH, V87, P40, DOI 10.17116/terarkh201587640-44; Lauterbach H, 2010, J EXP MED, V207, P2703, DOI 10.1084/jem.20092720; Lazear HM, 2015, IMMUNITY, V43, P15, DOI 10.1016/j.immuni.2015.07.001; Lazear HM, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa4304; Li E, 2019, ADV IMMUNOL, V142, P85, DOI 10.1016/bs.ai.2019.05.002; Li Y, 2014, INT IMMUNOPHARMACOL, V21, P156, DOI 10.1016/j.intimp.2014.04.022; Lin SC, 2012, EUR J CLIN INVEST, V42, P61, DOI 10.1111/j.1365-2362.2011.02557.x; Liu BS, 2011, BLOOD, V117, P2385, DOI 10.1182/blood-2010-07-298976; Liu MQ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035902; Manson JJ, 2006, ORPHANET J RARE DIS, V1, DOI 10.1186/1750-1172-1-6; Marcello T, 2006, GASTROENTEROLOGY, V131, P1887, DOI 10.1053/j.gastro.2006.09.052; McElrath C, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22928-0; Mennechet FJD, 2006, BLOOD, V107, P4417, DOI 10.1182/blood-2005-10-4129; Misumi I, 2014, J IMMUNOL, V192, P3596, DOI 10.4049/jimmunol.1301705; Morand EF, 2020, NEW ENGL J MED, V382, P211, DOI 10.1056/NEJMoa1912196; Morrow MP, 2010, CLIN VACCINE IMMUNOL, V17, P1493, DOI 10.1128/CVI.00181-10; Mustila A, 2011, CLIN EXP RHEUMATOL, V29, P500; Novak AJ, 2008, LEUKEMIA, V22, P2240, DOI 10.1038/leu.2008.263; Parodis I, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.00316; Pekarek V, 2007, GENES IMMUN, V8, P177, DOI 10.1038/sj.gene.6364372; Prokunina-Olsson L, 2013, NAT GENET, V45, P164, DOI 10.1038/ng.2521; Rauch I, 2015, MOL CELL BIOL, V35, P2332, DOI 10.1128/MCB.01498-14; Read SA, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02674; Scott DL, 2010, LANCET, V376, P1094, DOI 10.1016/S0140-6736(10)60826-4; Sheppard P, 2003, NAT IMMUNOL, V4, P63, DOI 10.1038/ni873; Sommereyns C, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000017; Srinivas S, 2008, IMMUNOLOGY, V125, P492, DOI 10.1111/j.1365-2567.2008.02862.x; Suppiah V, 2009, NAT GENET, V41, P1100, DOI 10.1038/ng.447; Syedbasha M, 2020, CELL REP, V33, DOI 10.1016/j.celrep.2020.108211; Syedbasha M, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00119; Vasquez RE, 2008, INFECT IMMUN, V76, P161, DOI 10.1128/IAI.00825-07; Wallace DJ, 2015, NAT REV RHEUMATOL, V11, P616, DOI 10.1038/nrrheum.2015.86; Wang F, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar4067; Wang YS, 2017, J IMMUNOL, V199, P1012, DOI 10.4049/jimmunol.1601430; Wells AI, 2018, TRENDS IMMUNOL, V39, P848, DOI 10.1016/j.it.2018.08.008; Witte K, 2009, GENES IMMUN, V10, P702, DOI 10.1038/gene.2009.72; Won J, 2019, CYTOKINE, V119, P32, DOI 10.1016/j.cyto.2019.02.010; Wu Q, 2013, AUTOIMMUNITY, V46, P40, DOI 10.3109/08916934.2012.730587; Wu Q, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3363; Xu LX, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/9631510; Ye L, 2019, NAT REV IMMUNOL, V19, P614, DOI 10.1038/s41577-019-0182-z; Yin ZW, 2012, J IMMUNOL, V189, P2735, DOI 10.4049/jimmunol.1102038; Zahn S, 2011, J INVEST DERMATOL, V131, P133, DOI 10.1038/jid.2010.244; Zhang SY, 2013, GASTROENTEROLOGY, V144, P414, DOI 10.1053/j.gastro.2012.10.034; Zhou ZL, 2007, J VIROL, V81, P7749, DOI 10.1128/JVI.02438-06; Zickert A, 2016, LUPUS SCI MED, V3, DOI 10.1136/lupus-2016-000170	81	0	0	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 26	2021	12								764062	10.3389/fimmu.2021.764062	http://dx.doi.org/10.3389/fimmu.2021.764062			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XM4FJ	34899712	Green Published, gold			2022-12-18	WOS:000728784900001
J	Molyer, B; Kumar, A; Angel, JB				Molyer, Bengisu; Kumar, Ashok; Angel, Jonathan B.			SMAC Mimetics as Therapeutic Agents in HIV Infection	FRONTIERS IN IMMUNOLOGY			English	Review						SMAC mimetics; HIV; HIV latency; apoptosis; HIV therapeutics	NF-KAPPA-B; IAP ANTAGONISTS; INTERACTING PROTEIN; CASPASE ACTIVATION; LATENT RESERVOIR; APOPTOSIS; VIRUS; BINDING; CELLS; IDENTIFICATION	Although combination antiretroviral therapy is extremely effective in lowering HIV RNA to undetectable levels in the blood, HIV persists in latently infected CD4(+) T-cells and persistently infected macrophages. In latently/persistently infected cells, HIV proteins have shown to affect the expression of proteins involved in the apoptosis pathway, notably the inhibitors of apoptosis proteins (IAPs), and thereby influence cell survival. IAPs, which are inhibited by endogenous second mitochondrial-derived activators of caspases (SMAC), can serve as targets for SMAC mimetics, synthetic compounds capable of inducing apoptosis. There is increasing evidence that SMAC mimetics can be used to reverse HIV latency and/or kill cells that are latently/persistently infected with HIV. Here, we review the current state of knowledge of SMAC mimetics as an approach to eliminate HIV infected cells and discuss the potential future use of SMAC mimetics as part of an HIV cure strategy.	[Molyer, Bengisu; Angel, Jonathan B.] Ottawa Hosp Res Inst, Chron Dis Program, Ottawa, ON, Canada; [Molyer, Bengisu; Kumar, Ashok; Angel, Jonathan B.] Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON, Canada; [Kumar, Ashok] Childrens Hosp Eastern Ontario, Dept Microbiol & Immunol, Apoptosis Res Ctr, Ottawa, ON, Canada; [Angel, Jonathan B.] Ottawa Hosp, Div Infect Dis, Ottawa, ON, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; University of Ottawa; Children's Hospital of Eastern Ontario; University of Ottawa; Ottawa Hospital Research Institute	Angel, JB (corresponding author), Ottawa Hosp Res Inst, Chron Dis Program, Ottawa, ON, Canada.; Angel, JB (corresponding author), Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON, Canada.; Angel, JB (corresponding author), Ottawa Hosp, Div Infect Dis, Ottawa, ON, Canada.	jangel@ohri.ca						Abhari BA, 2013, ONCOGENE, V32, P3263, DOI 10.1038/onc.2012.337; Akiyama H, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12070711; Andersen JL, 2008, EXP MOL PATHOL, V85, P2, DOI 10.1016/j.yexmp.2008.03.015; Bai LC, 2014, PHARMACOL THERAPEUT, V144, P82, DOI 10.1016/j.pharmthera.2014.05.007; Bartz SR, 1999, J VIROL, V73, P1956, DOI 10.1128/JVI.73.3.1956-1963.1999; Bashyam MD, 2005, NEOPLASIA, V7, P556, DOI 10.1593/neo.04586; Beaudouin J, 2013, CELL DEATH DIFFER, V20, P599, DOI 10.1038/cdd.2012.156; Berro R, 2007, J BIOL CHEM, V282, P8207, DOI 10.1074/jbc.M606324200; Beug ST, 2018, MOL THER-ONCOLYTICS, V10, P28, DOI 10.1016/j.omto.2018.06.002; Beug ST, 2012, TRENDS IMMUNOL, V33, P535, DOI 10.1016/j.it.2012.06.004; Bobardt M, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0211746; Brun J, 2010, MOL THER, V18, P1440, DOI 10.1038/mt.2010.103; Brunelle JK, 2009, J CELL SCI, V122, P437, DOI 10.1242/jcs.031682; Busca A, 2012, J BIOL CHEM, V287, P15118, DOI 10.1074/jbc.M111.312660; Cain K, 1999, J BIOL CHEM, V274, P22686, DOI 10.1074/jbc.274.32.22686; Campbell GR, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-02761-x; Campbell GR, 2019, MBIO, V10, DOI 10.1128/mBio.02638-19; Campbell GR, 2018, CELL HOST MICROBE, V24, P689, DOI 10.1016/j.chom.2018.09.007; Chun TW, 1997, NATURE, V387, P183, DOI 10.1038/387183a0; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; CLEM RJ, 1994, MOL CELL BIOL, V14, P5212, DOI 10.1128/MCB.14.8.5212; Cummins NW, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.77; Davey RT, 1999, P NATL ACAD SCI USA, V96, P15109, DOI 10.1073/pnas.96.26.15109; Dickens LS, 2012, MOL CELL, V47, P291, DOI 10.1016/j.molcel.2012.05.004; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Ebert G, 2015, P NATL ACAD SCI USA, V112, P5803, DOI 10.1073/pnas.1502400112; Ebina H, 2013, SCI REP-UK, V3, DOI 10.1038/srep02510; Estornes Y, 2015, SEMIN CELL DEV BIOL, V39, P106, DOI 10.1016/j.semcdb.2014.03.035; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; Frenkel LM, 2003, J VIROL, V77, P5721, DOI 10.1128/JVI.77.10.5721-5730.2003; Fullsack S, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1396-5; GALLO RC, 1983, SCIENCE, V220, P865, DOI 10.1126/science.6601823; Ganor Y, 2019, NAT MICROBIOL, V4, P633, DOI 10.1038/s41564-018-0335-z; Green DR, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a006080; Grossman Z, 1999, NAT MED, V5, P1099, DOI 10.1038/13410; Guillemard E, 2004, VIROLOGY, V329, P371, DOI 10.1016/j.virol.2004.08.030; Gyrd-Hansen M, 2008, NAT CELL BIOL, V10, P1309, DOI 10.1038/ncb1789; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hattori S, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.02022; He SD, 2009, CELL, V137, P1100, DOI 10.1016/j.cell.2009.05.021; Henderson LJ, 2020, J VIROL, V94, DOI 10.1128/JVI.00375-19; Hu SM, 2003, J BIOL CHEM, V278, P10055, DOI 10.1074/jbc.M207197200; Igarashi T, 2001, P NATL ACAD SCI USA, V98, P658, DOI 10.1073/pnas.021551798; Imamichi H, 2016, P NATL ACAD SCI USA, V113, P8783, DOI 10.1073/pnas.1609057113; Infante JR, 2014, J CLIN ONCOL, V32, P3103, DOI 10.1200/JCO.2013.52.3993; Kim DS, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00324-x; Kim Y, 2018, CELL HOST MICROBE, V23, P14, DOI 10.1016/j.chom.2017.12.004; Kipp RA, 2002, BIOCHEMISTRY-US, V41, P7344, DOI 10.1021/bi0121454; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Ko A, 2019, J NEUROIMMUNE PHARM, V14, P110, DOI 10.1007/s11481-018-9809-2; Koppensteiner H, 2012, RETROVIROLOGY, V9, DOI 10.1186/1742-4690-9-82; Kuo HH, 2018, IMMUNITY, V48, P1183, DOI 10.1016/j.immuni.2018.04.004; Larrosa PNF, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-19; Laukens B, 2011, NEOPLASIA, V13, P971, DOI 10.1593/neo.11610; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Liu ZH, 2000, NATURE, V408, P1004, DOI 10.1038/35050006; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Margolis DM, 2020, CELL, V181, P189, DOI 10.1016/j.cell.2020.03.005; Moore PA, 2011, BLOOD, V117, P4542, DOI 10.1182/blood-2010-09-306449; Morrish E, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9020406; Murphy J, 2008, AM J RESP CELL MOL, V38, P380, DOI 10.1165/rcmb.2007-0224RC; Nixon CC, 2020, NATURE, V578, P160, DOI 10.1038/s41586-020-1951-3; Noonan AM, 2016, CANCER-AM CANCER SOC, V122, P588, DOI 10.1002/cncr.29783; Pache L, 2020, CELL REP MED, V1, DOI 10.1016/j.xcrm.2020.100037; Pache L, 2015, CELL HOST MICROBE, V18, P345, DOI 10.1016/j.chom.2015.08.009; Petersen SL, 2007, CANCER CELL, V12, P445, DOI 10.1016/j.ccr.2007.08.029; Ranganath N, 2018, J INFECT DIS, V217, P721, DOI 10.1093/infdis/jix639; Ren YQ, 2020, J CLIN INVEST, V130, P2542, DOI 10.1172/JCI132374; Lopez-Huertas MR, 2013, J BIOL CHEM, V288, P7626, DOI 10.1074/jbc.M112.408294; Sandstrom TS, 2021, J VIROL, V95, DOI 10.1128/JVI.01953-20; Scott FL, 2005, EMBO J, V24, P645, DOI 10.1038/sj.emboj.7600544; Shepard BD, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003096; Shiozaki EN, 2003, MOL CELL, V11, P519, DOI 10.1016/S1097-2765(03)00054-6; Siliciano JD, 2003, NAT MED, V9, P727, DOI 10.1038/nm880; Sun Xu-Shan, 2020, Lancet Oncol, V21, P1173, DOI 10.1016/S1470-2045(20)30327-2; Swingler S, 2007, PLOS PATHOG, V3, P1281, DOI 10.1371/journal.ppat.0030134; Tateishi H, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09129-w; Timilsina U, 2016, J GEN VIROL, V97, P813, DOI 10.1099/jgv.0.000402; Tso FY, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201325; Varfolomeev E, 2007, CELL, V131, P669, DOI 10.1016/j.cell.2007.10.030; Veenstra M, 2017, MBIO, V8, DOI 10.1128/mBio.01280-17; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Vince JE, 2007, CELL, V131, P682, DOI 10.1016/j.cell.2007.10.037; Yang YD, 2003, J VIROL, V77, P6700, DOI 10.1128/JVI.77.12.6700-6708.2003; Yang YL, 2000, CELL RES, V10, P169, DOI 10.1038/sj.cr.7290046; Zender L, 2006, CELL, V125, P1253, DOI 10.1016/j.cell.2006.05.030; Zheng C, 2010, MOL CELL, V38, P101, DOI 10.1016/j.molcel.2010.03.009; Zhu Y, 2003, APOPTOSIS, V8, P71, DOI 10.1023/A:1021653119934; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	89	0	0	1	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 26	2021	12								780400	10.3389/fimmu.2021.780400	http://dx.doi.org/10.3389/fimmu.2021.780400			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XM8LK	34899741	gold, Green Published			2022-12-18	WOS:000729071100001
J	Pal, L; Nandani, R; Kumar, P; Swami, B; Roy, G; Bhaskar, S				Pal, Lalit; Nandani, Raj; Kumar, Pawan; Swami, Bharati; Roy, Gargi; Bhaskar, Sangeeta			Macrophages Are the Key Players in Promoting Hyper-Inflammatory Response in a Mouse Model of TB-IRIS	FRONTIERS IN IMMUNOLOGY			English	Article						TB-IRIS-tuberculosis-associated IRIS; macrophage; Mycobacterium tuberculosis; inflammation; HIV-human immunodeficiency virus	IMMUNE RECONSTITUTION DISEASE; MATRIX METALLOPROTEINASES; ANTIRETROVIRAL THERAPY; TUBERCULOSIS; HYPOTHERMIA; ACTIVATION; UNMASKING; DEFENSE; EVENTS; CELLS	TB-IRIS is an abnormal inflammatory response in a subset of HIV-TB co-infected patients shortly after initiation of anti-retroviral therapy (ART). Therapy in these patients could have greatly improved the life expectancy as ART reconstitutes the function and number of CD4+ T cells and many patients see improvement in symptoms but paradoxically up to 54% of co-infected patients develop TB-IRIS. Different studies have indicated that both innate and adaptive immunity are involved in the pathology of IRIS but the role of macrophages in abnormal activation of CD4+ T cells is poorly understood. Since macrophages are one of the major antigen-presenting cells and are infected by M.tb at a high frequency, they are very much likely to be involved in the development of TB-IRIS. In this study, we have developed a mouse model of experimental IRIS, in which M.tb-infected T-cell knockout mice undergo a fatal inflammatory disease after CD4+ T cell reconstitution. Lung macrophages and blood monocytes from M.tb-infected TCR beta(-/-) mice showed upregulated expression of cell surface activation markers and also showed higher mRNA expression of inflammation-associated chemokines and matrix metalloproteases responsible for tissue damage. Furthermore, cytokine and TLR signaling feedback mechanism to control excessive inflammation was also found to be dysregulated in these macrophages under lymphopenic conditions. Previous studies have shown that hyperactive CD4+ T cells are responsible for disease induction and our study shows that somehow macrophages are in a higher activated state when infected with M.tb in an immune-deficient condition, which results in excessive activation of the adoptively transferred CD4+ T cells. Understanding of the mechanisms underlying the pathophysiology of TB-IRIS would facilitate identification of prospective biomarkers for disease development in HIV-TB co-infected patients before starting antiretroviral therapy.	[Pal, Lalit; Nandani, Raj; Kumar, Pawan; Swami, Bharati; Roy, Gargi; Bhaskar, Sangeeta] Natl Inst Immunol, Prod Dev Cell 1, New Delhi, India; [Nandani, Raj] South Dakota States Univ, Dept Pharmaceut Sci, Brookings, SD USA; [Kumar, Pawan] All India Inst Med Sci, Rotary Canc Hosp, Dr BR Ambedkar Inst, Dept Prevent Oncol, New Delhi, India	Department of Biotechnology (DBT) India; National Institute of Immunology (NII); All India Institute of Medical Sciences (AIIMS) New Delhi; DR. B.R.A. Institute Rotary Cancer Hospital	Bhaskar, S (corresponding author), Natl Inst Immunol, Prod Dev Cell 1, New Delhi, India.	sangeeta@nii.ac.in			Department of Biotechnology, Government of India [102/IFD/SAN/3646/2017-2018]; National Institute of Immunology, New Delhi, India	Department of Biotechnology, Government of India(Department of Biotechnology (DBT) India); National Institute of Immunology, New Delhi, India	This work was supported by a grant from the Department of Biotechnology, Government of India (102/IFD/SAN/3646/2017-2018) and a core research grant of the National Institute of Immunology, New Delhi, India.	Andrade BB, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004433; Antonelli LRV, 2010, BLOOD, V116, P3818, DOI 10.1182/blood-2010-05-285080; Baalwa J, 2008, AFR HEALTH SCI, V8, P190; Barber DL, 2010, BLOOD, V116, P3485, DOI 10.1182/blood-2010-05-286336; Blanchette J, 2003, IMMUNOLOGY, V108, P513, DOI 10.1046/j.1365-2567.2003.01620.x; Bourgarit A, 2006, AIDS, V20, pF1, DOI 10.1097/01.aids.0000202648.18526.bf; Burman W, 2007, INT J TUBERC LUNG D, V11, P1282; Cambier CJ, 2014, CELL, V159, P1497, DOI 10.1016/j.cell.2014.11.024; Chen LP, 2004, NAT REV IMMUNOL, V4, P336, DOI 10.1038/nri1349; Cheng SL, 2007, INT J TUBERC LUNG D, V11, P1290; Cheng VCC, 2002, EUR J CLIN MICROBIOL, V21, P803, DOI 10.1007/s10096-002-0821-2; Chu SF, 2007, GENES IMMUN, V8, P475, DOI 10.1038/sj.gene.6364412; Comerford I, 2011, IMMUNOL CELL BIOL, V89, P183, DOI 10.1038/icb.2010.164; de Martino M, 2019, FRONT PEDIATR, V7, DOI 10.3389/fped.2019.00350; Ehrt S, 2009, CELL MICROBIOL, V11, P1170, DOI 10.1111/j.1462-5822.2009.01335.x; Elkington PTG, 2006, THORAX, V61, P259, DOI 10.1136/thx.2005.051979; Garami A, 2018, HAND CLINIC, V157, P565, DOI 10.1016/B978-0-444-64074-1.00034-3; Gouwy M, 2004, J LEUKOCYTE BIOL, V76, P185, DOI 10.1189/jlb.1003479; Grohmann U, 2001, J IMMUNOL, V167, P221, DOI 10.4049/jimmunol.167.1.221; Houghton AM, 2015, MATRIX BIOL, V44-46, P167, DOI 10.1016/j.matbio.2015.02.002; Tran HTT, 2014, IMMUNOBIOLOGY, V219, P37, DOI 10.1016/j.imbio.2013.07.004; Jimenez-Uribe AP, 2019, J IMMUNOL RES, V2019, DOI 10.1155/2019/2198508; Kleinnijenhuis J, 2011, CLIN DEV IMMUNOL, DOI 10.1155/2011/405310; Korn T, 2008, P NATL ACAD SCI USA, V105, P18460, DOI 10.1073/pnas.0809850105; Lawn SD, 2009, AIDS, V23, P143, DOI 10.1097/QAD.0b013e32831d2a98; Lee HJ, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8091298; Leon LR, 2004, FRONT BIOSCI, V9, P1877, DOI 10.2741/1381; Ma J, 2003, CELL MOL LIFE SCI, V60, P2334, DOI 10.1007/s00018-003-3020-0; Marais S, 2014, CLIN INFECT DIS, V59, P1638, DOI 10.1093/cid/ciu641; Meintjes G, 2008, LANCET INFECT DIS, V8, P516, DOI 10.1016/S1473-3099(08)70184-1; Meintjes G, 2012, AM J RESP CRIT CARE, V186, P369, DOI 10.1164/rccm.201201-0094OC; Min B, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00547; Muller M, 2010, LANCET INFECT DIS, V10, P251, DOI 10.1016/S1473-3099(10)70026-8; Narendran G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063541; Narita M, 1998, AM J RESP CRIT CARE, V158, P157, DOI 10.1164/ajrccm.158.1.9712001; Patel NR, 2007, J IMMUNOL, V179, P6973, DOI 10.4049/jimmunol.179.10.6973; Rumbus Z, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170152; Sharpe AH, 2002, NAT REV IMMUNOL, V2, P116, DOI 10.1038/nri727; SHU U, 1995, EUR J IMMUNOL, V25, P1125, DOI 10.1002/eji.1830250442; Sia JK, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006530; Sokol CL, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a016303; Tadokera R, 2014, EUR J IMMUNOL, V44, P127, DOI 10.1002/eji.201343593; Tan HY, 2016, J IMMUNOL, V196, P4052, DOI 10.4049/jimmunol.1502203; Tanaka T, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a016295; Van den Bergh R, 2006, LANCET INFECT DIS, V6, P2, DOI 10.1016/S1473-3099(05)70302-9; Walker NF, 2017, CLIN INFECT DIS, V65, P121, DOI 10.1093/cid/cix231; Wang JJ, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/4607197; Warner DF, 2007, NAT MED, V13, P282, DOI 10.1038/nm0307-282; Weiss G, 2015, IMMUNOL REV, V264, P182, DOI 10.1111/imr.12266; Yoshimura A, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00020	50	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 26	2021	12								775177	10.3389/fimmu.2021.775177	http://dx.doi.org/10.3389/fimmu.2021.775177			18	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6I1JL	34899731	Green Published, gold			2022-12-18	WOS:000885882300001
J	Rayasam, A; Drobyski, WR				Rayasam, Aditya; Drobyski, William R.			Translational Clinical Strategies for the Prevention of Gastrointestinal Tract Graft Versus Host Disease	FRONTIERS IN IMMUNOLOGY			English	Review						graft versus host disease; inflammatory cytokines; gastrointestinal tract; translational clinical trials; allogeneic hematopoietic stem cell transplantation; mouse models	REGULATORY T-CELLS; INTERLEUKIN-1 RECEPTOR ANTAGONIST; HISTONE-DEACETYLASE INHIBITORS; BONE-MARROW-TRANSPLANTATION; NF-KAPPA-B; MURINE ACUTE; ACUTE GVHD; PROTEASOME INHIBITION; RADIATION PROTOCOLS; AUTOIMMUNE-DISEASES	Graft versus host disease (GVHD) is the major non-relapse complication associated with allogeneic hematopoietic stem cell transplantation (HSCT). Unfortunately, GVHD occurs in roughly half of patients following this therapy and can induce severe life-threatening side effects and premature mortality. The pathophysiology of GVHD is driven by alloreactive donor T cells that induce a proinflammatory environment to cause pathological damage in the skin, gastrointestinal (GI) tract, lung, and liver during the acute phase of this disease. Recent work has demonstrated that the GI tract is a pivotal target organ and a primary driver of morbidity and mortality in patients. Prevention of this complication has therefore emerged as an important goal of prophylaxis strategies given the primacy of this tissue site in GVHD pathophysiology. In this review, we summarize foundational pre-clinical studies that have been conducted in animal models to prevent GI tract GVHD and examine the efficacy of these approaches upon subsequent translation into the clinic. Specifically, we focus on therapies designed to block inflammatory cytokine pathways, inhibit cellular trafficking of alloreactive donor T cells to the GI tract, and reconstitute impaired regulatory networks for the prevention of GVHD in the GI tract.	[Rayasam, Aditya; Drobyski, William R.] Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA; [Drobyski, William R.] Med Coll Wisconsin, Bone Marrow Transplant Program, Milwaukee, WI 53226 USA	Medical College of Wisconsin; Medical College of Wisconsin	Drobyski, WR (corresponding author), Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA.; Drobyski, WR (corresponding author), Med Coll Wisconsin, Bone Marrow Transplant Program, Milwaukee, WI 53226 USA.	wdrobysk@mcw.edu			National Institutes of Health [HL064605, HL126166, HL139008]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Funding This research was supported by grants from the National Institutes of Health (HL064605, HL126166, and HL139008).	ABHYANKAR S, 1993, TRANSPLANTATION, V56, P1518, DOI 10.1097/00007890-199312000-00045; Adams J, 1999, CANCER RES, V59, P2615; Adams J, 2004, CANCER INVEST, V22, P304, DOI 10.1081/CNV-120030218; Ajuebor MN, 2007, AM J PATHOL, V170, P1975, DOI 10.2353/ajpath.2007.060690; AKIRA S, 1993, ADV IMMUNOL, V54, P1, DOI 10.1016/S0065-2776(08)60532-5; ANTIN JH, 1994, BLOOD, V84, P1342, DOI 10.1182/blood.V84.4.1342.bloodjournal8441342; Antin JH, 2002, BLOOD, V100, P3479, DOI 10.1182/blood-2002-03-0985; Baker MB, 1996, J EXP MED, V183, P2645, DOI 10.1084/jem.183.6.2645; Bastian D, 2021, AM J TRANSPLANT, V21, P3538, DOI 10.1111/ajt.16624; Beres AJ, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00163; Blazar BR, 2012, NAT REV IMMUNOL, V12, P443, DOI 10.1038/nri3212; Bolanos-Meade J, 2019, LANCET HAEMATOL, V6, pE132, DOI 10.1016/S2352-3026(18)30221-7; Bradley JR, 2008, J PATHOL, V214, P149, DOI 10.1002/path.2287; Brunstein CG, 2011, BLOOD, V117, P1061, DOI 10.1182/blood-2010-07-293795; Carniti C, 2015, CLIN CANCER RES, V21, P3740, DOI 10.1158/1078-0432.CCR-14-2758; Chen WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152; Chen X, 2009, BLOOD, V114, P891, DOI 10.1182/blood-2009-01-197178; Chen YB, 2013, BONE MARROW TRANSPL, V48, P598, DOI 10.1038/bmt.2012.191; Choi J, 2018, LEUKEMIA, V32, P2483, DOI 10.1038/s41375-018-0123-z; Choi J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109799; Choi S, 2011, MOL MED, V17, P404, DOI 10.2119/molmed.2011.00007; Choi SW, 2012, BIOL BLOOD MARROW TR, V18, P1525, DOI 10.1016/j.bbmt.2012.03.013; Choi SW, 2017, BLOOD, V130, P1760, DOI 10.1182/blood-2017-06-790469; Choi SW, 2014, LANCET ONCOL, V15, P87, DOI 10.1016/S1470-2045(13)70512-6; Coltoff A, 2018, BONE MARROW TRANSPL, V53, P900, DOI 10.1038/s41409-018-0094-8; Danylesko I, 2019, BONE MARROW TRANSPL, V54, P987, DOI 10.1038/s41409-018-0364-5; Das R, 2010, BLOOD, V115, P5249, DOI 10.1182/blood-2009-11-255422; Das R, 2009, BLOOD, V113, P2352, DOI 10.1182/blood-2008-08-175448; DEEG HJ, 1991, BONE MARROW TRANSPL, V7, P193; Di Ianni M, 2011, BEST PRACT RES CL HA, V24, P459, DOI 10.1016/j.beha.2011.05.005; Dignan FL, 2012, BRIT J HAEMATOL, V158, P30, DOI 10.1111/j.1365-2141.2012.09129.x; Drobyski WR, 2018, HAEMATOLOGICA, V103, P717, DOI 10.3324/haematol.2017.183434; Dutt S, 2005, BLOOD, V106, P4009, DOI 10.1182/blood-2005-06-2339; Edinger M, 2003, NAT MED, V9, P1144, DOI 10.1038/nm915; Elliott PJ, 1999, J ALLERGY CLIN IMMUN, V104, P294, DOI 10.1016/S0091-6749(99)70369-6; Fantini MC, 2004, J IMMUNOL, V172, P5149, DOI 10.4049/jimmunol.172.9.5149; Ferrara JLM, 2009, LANCET, V373, P1550, DOI 10.1016/S0140-6736(09)60237-3; Floisand Y, 2021, BONE MARROW TRANSPL, V56, P2477, DOI 10.1038/s41409-021-01356-0; Floisand Y, 2019, BIOL BLOOD MARROW TR, V25, P720, DOI 10.1016/j.bbmt.2018.11.013; Fontenot JD, 2005, IMMUNITY, V22, P329, DOI 10.1016/j.immuni.2005.01.016; Fricker LD, 2020, ANNU REV PHARMACOL, V60, P457, DOI 10.1146/annurev-pharmtox-010919-023603; Friedrich M, 2019, MUCOSAL IMMUNOL, V12, P656, DOI 10.1038/s41385-019-0135-7; Fu YY, 2019, IMMUNITY, V51, P90, DOI 10.1016/j.immuni.2019.06.003; Fukada K, 2002, J IMMUNOL, V168, P2225, DOI 10.4049/jimmunol.168.5.2225; Garcia-Cadenas I, 2017, BONE MARROW TRANSPL, V52, P107, DOI 10.1038/bmt.2016.225; Gergoudis SC, 2020, BLOOD ADV, V4, P6098, DOI 10.1182/bloodadvances.2020003336; Hahnen E, 2008, EXPERT OPIN INV DRUG, V17, P169, DOI 10.1517/13543784.17.2.169; Hamadani M, 2008, BIOL BLOOD MARROW TR, V14, P783, DOI 10.1016/j.bbmt.2008.04.006; Hill GR, 1997, BLOOD, V90, P3204, DOI 10.1182/blood.V90.8.3204; Ho LJ, 2015, BIOCHEM PHARMACOL, V97, P16, DOI 10.1016/j.bcp.2015.06.009; HOLLER E, 1990, BLOOD, V75, P1011; Jankovic D, 2013, J EXP MED, V210, P1899, DOI 10.1084/jem.20130084; Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772; Jordan SC, 2017, TRANSPLANTATION, V101, P32, DOI 10.1097/TP.0000000000001452; Joshi M, 2020, CURR PHARM DESIGN, V26, P4934, DOI 10.2174/1381612826666200625101442; Kennedy GA, 2021, BLOOD, V137, P1970, DOI 10.1182/blood.2020009050; Kennedy GA, 2014, LANCET ONCOL, V15, P1451, DOI 10.1016/S1470-2045(14)71017-4; Kim Sena, 2020, Int J Mol Sci, V21, DOI 10.3390/ijms21124281; Kohlmeier JE, 2008, IMMUNITY, V29, P101, DOI 10.1016/j.immuni.2008.05.011; Koreth J, 2018, HAEMATOLOGICA, V103, P522, DOI 10.3324/haematol.2017.176859; Koreth J, 2015, BIOL BLOOD MARROW TR, V21, P1907, DOI 10.1016/j.bbmt.2015.05.027; Koreth J, 2012, J CLIN ONCOL, V30, P3202, DOI 10.1200/JCO.2012.42.0984; KORNGOLD R, 1992, BONE MARROW TRANSPL, V9, P355; Leng C, 2006, EXP HEMATOL, V34, P776, DOI 10.1016/j.exphem.2006.02.014; Li Z, 2013, TRANSPL P, V45, P2527, DOI 10.1016/j.transproceed.2013.03.042; Ma HH, 2011, J CLIN INVEST, V121, P2554, DOI 10.1172/JCI43706; Machado-Vieira R, 2011, CNS NEUROSCI THER, V17, P699, DOI 10.1111/j.1755-5949.2010.00203.x; MacMillan ML, 2021, BLOOD ADV, V5, P1425, DOI 10.1182/bloodadvances.2020003219; Malard F, 2020, LEUKEMIA, V34, P1229, DOI 10.1038/s41375-020-0804-2; Marcondes AM, 2016, BIOL BLOOD MARROW TR, V22, P1596, DOI 10.1016/j.bbmt.2016.05.011; Marcondes AM, 2011, BLOOD, V118, P5031, DOI 10.1182/blood-2011-07-365247; Martin PJ, 2012, BIOL BLOOD MARROW TR, V18, P1150, DOI 10.1016/j.bbmt.2012.04.005; Marty FM, 2003, BLOOD, V102, P2768, DOI 10.1182/blood-2003-01-0267; MCCARTHY PL, 1991, BLOOD, V78, P1915; McCarthy PL, 1996, TRANSPLANTATION, V62, P626, DOI 10.1097/00007890-199609150-00015; Mehta RS, 2021, TRANSPL CELL THER, V27, DOI 10.1016/j.jtct.2020.12.011; Mertens M, 2009, J RHEUMATOL, V36, P1118, DOI 10.3899/jrheum.090074; Meyer EH, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.127244; Min CK, 2001, BONE MARROW TRANSPL, V28, P935, DOI 10.1038/sj.bmt.1703258; Moy RH, 2017, BLOOD, V129, P906, DOI 10.1182/blood-2016-08-735076; Murai M, 2003, NAT IMMUNOL, V4, P154, DOI 10.1038/ni879; Nicklin MJH, 2002, GENOMICS, V79, P718, DOI 10.1006/geno.2002.6751; O'Shea JJ, 2008, IMMUNITY, V28, P477, DOI 10.1016/j.immuni.2008.03.002; Park MJ, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/631384; Perez L, 2021, BLOOD ADV, V5, P2740, DOI 10.1182/bloodadvances.2021004225; Perez L, 2018, BONE MARROW TRANSPL, V53, P1434, DOI 10.1038/s41409-018-0163-z; Petrovic A, 2004, BLOOD, V103, P1542, DOI 10.1182/blood-2003-03-0957; Pidala J, 2018, HAEMATOLOGICA, V103, P531, DOI 10.3324/haematol.2017.171199; PIGUET PF, 1987, J EXP MED, V166, P1280, DOI 10.1084/jem.166.5.1280; Reddy P, 2004, P NATL ACAD SCI USA, V101, P3921, DOI 10.1073/pnas.0400380101; Reddy P, 2008, J CLIN INVEST, V118, P2562, DOI 10.1172/JCI34712; Reshef R, 2019, BIOL BLOOD MARROW TR, V25, P515, DOI 10.1016/j.bbmt.2018.09.034; Reshef R, 2012, NEW ENGL J MED, V367, P135, DOI 10.1056/NEJMoa1201248; Richardson Paul G, 2003, Cancer Control, V10, P361; Sakaguchi S, 2006, IMMUNOL REV, V212, P8, DOI 10.1111/j.0105-2896.2006.00427.x; Salim SY, 2011, INFLAMM BOWEL DIS, V17, P362, DOI 10.1002/ibd.21403; Schmaltz C, 2003, BLOOD, V101, P2440, DOI 10.1182/blood-2002-07-2109; Schroeder MA, 2020, BLOOD ADV, V4, P1656, DOI 10.1182/bloodadvances.2019001043; Schroeder MA, 2011, DIS MODEL MECH, V4, P318, DOI 10.1242/dmm.006668; Schwarte S, 2005, METH MOLEC MED, V109, P445; Schwarte S, 2007, INT J RADIAT BIOL, V83, P625, DOI 10.1080/09553000701534572; Shlomchik WD, 2007, NAT REV IMMUNOL, V7, P340, DOI 10.1038/nri2000; Sims JE, 2010, NAT REV IMMUNOL, V10, P89, DOI 10.1038/nri2691; Socie G, 2014, BLOOD, V124, P374, DOI 10.1182/blood-2014-01-514752; Spoerl S, 2014, BLOOD, V123, P3832, DOI 10.1182/blood-2013-12-543736; Stickel N, 2014, BLOOD, V124, P2586, DOI 10.1182/blood-2014-04-569046; Sugerman PB, 2004, AM J PATHOL, V164, P2189, DOI 10.1016/S0002-9440(10)63776-5; Sun K, 2004, P NATL ACAD SCI USA, V101, P8120, DOI 10.1073/pnas.0401563101; Sun K, 2008, BLOOD, V112, P1522, DOI 10.1182/blood-2008-03-143461; Sun X, 2021, CELL TRANSPLANT, V30, DOI 10.1177/09636897211033778; Tan MCB, 2009, J IMMUNOL, V182, P1746, DOI 10.4049/jimmunol.182.3.1746; Tawara I, 2012, J LEUKOCYTE BIOL, V91, P667, DOI 10.1189/jlb.1011510; Tawara I, 2011, CLIN CANCER RES, V17, P77, DOI 10.1158/1078-0432.CCR-10-1198; Tawara I, 2010, J IMMUNOL, V185, P3866, DOI 10.4049/jimmunol.1001625; Taylor PA, 2002, BLOOD, V99, P3493, DOI 10.1182/blood.V99.10.3493; Taylor PA, 2004, BLOOD, V104, P3804, DOI 10.1182/blood-2004-05-1850; Taylor SL, 2002, GENOMICS, V79, P726, DOI 10.1006/geno.2002.6752; Tkachev V, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abc0227; Trinchieri G, 1998, ADV IMMUNOL, V70, P83, DOI 10.1016/S0065-2776(08)60387-9; Ueha S, 2007, J LEUKOCYTE BIOL, V81, P176, DOI 10.1189/jlb.0306231; Vallera DA, 1995, TRANSPLANTATION, V60, P1371; Vodanovic-Jankovic S, 2006, BLOOD, V107, P827, DOI 10.1182/blood-2005-05-1820; Vriesendorp HM, 2016, EXP HEMATOL, V44, P674, DOI 10.1016/j.exphem.2016.05.011; Waldman E, 2006, BLOOD, V107, P1703, DOI 10.1182/blood-2005-08-3445; Wang JS, 2006, CELL MOL IMMUNOL, V3, P255; Welniak LA, 2004, EXP HEMATOL, V32, P318, DOI 10.1016/j.exphem.2003.12.003; Wilkinson AN, 2019, BLOOD, V134, P2092, DOI 10.1182/blood.2019000396; Williams MB, 1997, J IMMUNOL, V159, P1746; Wu HX, 2016, JOINT BONE SPINE, V83, P525, DOI 10.1016/j.jbspin.2015.09.002; Wysocki CA, 2005, BLOOD, V106, P3300, DOI 10.1182/blood-2005-04-1632; Xu WS, 2007, ONCOGENE, V26, P5541, DOI 10.1038/sj.onc.1210620; Xu XX, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.641910; Yao X, 2014, PHARMACOL THERAPEUT, V141, P125, DOI 10.1016/j.pharmthera.2013.09.004; Zeiser R, 2015, LEUKEMIA, V29, P2062, DOI 10.1038/leu.2015.212; Zeiser R, 2020, NEW ENGL J MED, V382, P1800, DOI 10.1056/NEJMoa1917635; Zeiser R, 2016, BRIT J HAEMATOL, V175, P191, DOI 10.1111/bjh.14295; Zhou V, 2016, J CLIN INVEST, V126, P3541, DOI 10.1172/JCI80874; Zollner TM, 2002, J CLIN INVEST, V109, P671, DOI 10.1172/JCI200212736	138	0	0	4	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 26	2021	12								779076	10.3389/fimmu.2021.779076	http://dx.doi.org/10.3389/fimmu.2021.779076			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YF5WH	34899738	Green Published, gold			2022-12-18	WOS:000741876000001
J	Schiavoni, G; Munitz, A; Strid, J				Schiavoni, Giovanna; Munitz, Ariel; Strid, Jessica			Editorial: Emerging Roles for Type 2-Associated Cells and Cytokines in Cancer Immunity	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						cancer immunity; type 2 associated cells; Th2 cytokines; tumor microenvironment; granulocytes			[Schiavoni, Giovanna] Ist Super Sanita, Dept Oncol & Mol Med, Rome, Italy; [Munitz, Ariel] Tel Aviv Univ, Dept Clin Microbiol & Immunol, Tel Aviv, Israel; [Strid, Jessica] Imperial Coll London, Dept Immunol & Inflammat, London, England	Istituto Superiore di Sanita (ISS); Tel Aviv University; Imperial College London	Schiavoni, G (corresponding author), Ist Super Sanita, Dept Oncol & Mol Med, Rome, Italy.; Munitz, A (corresponding author), Tel Aviv Univ, Dept Clin Microbiol & Immunol, Tel Aviv, Israel.; Strid, J (corresponding author), Imperial Coll London, Dept Immunol & Inflammat, London, England.	giovanna.schiavoni@iss.it; arielm@tauex.tau.ac.il; j.strid@imperial.ac.uk	Schiavoni, Giovanna/K-2448-2019; Schiavoni, Giovanna/T-4418-2017	Schiavoni, Giovanna/0000-0001-9135-0556; Schiavoni, Giovanna/0000-0001-9135-0556	AIRC [IG 21366]; US-Israel Bi-national Science Foundation [2015163]; Israel Science Foundation [886/15, 542/20]; Israel Cancer Research Fund; Richard Eimert Research Fund on Solid Tumors (TAU); Israel Cancer Association Avraham Rotstein Donation; Cancer Biology Research Center (TAU); Wellcome Trust [215488/Z/19/Z]; British Skin Foundation [043/S/18]	AIRC(Fondazione AIRC per la ricerca sul cancro); US-Israel Bi-national Science Foundation(US-Israel Binational Science Foundation); Israel Science Foundation(Israel Science Foundation); Israel Cancer Research Fund; Richard Eimert Research Fund on Solid Tumors (TAU); Israel Cancer Association Avraham Rotstein Donation; Cancer Biology Research Center (TAU); Wellcome Trust(Wellcome TrustEuropean Commission); British Skin Foundation	GS is supported by AIRC (IG 21366). AM is supported by the US-Israel Bi-national Science Foundation (grant no. 2015163), by the Israel Science Foundation (grants no. 886/15 and 542/20), the Israel Cancer Research Fund, the Richard Eimert Research Fund on Solid Tumors (TAU), the Israel Cancer Association Avraham Rotstein Donation, the Cancer Biology Research Center (TAU) and the Emerson Collective. JS is supported by the Wellcome Trust (215488/Z/19/Z) and the British Skin Foundation (043/S/18).	Lloyd CM, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aat1604	1	0	0	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 26	2021	12								811125	10.3389/fimmu.2021.811125	http://dx.doi.org/10.3389/fimmu.2021.811125			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XN3JJ	34899766	Green Published, gold			2022-12-18	WOS:000729404300001
J	Singh, AK; Haque, M; Madarampalli, B; Shi, YY; Wildman, BJ; Basit, A; Khuder, SA; Prasad, B; Hassan, Q; Ouseph, MM; Ahmed, S				Singh, Anil K.; Haque, Mahamudul; Madarampalli, Bhanupriya; Shi, Yuanyuan; Wildman, Benjamin J.; Basit, Abdul; Khuder, Sadik A.; Prasad, Bhagwat; Hassan, Quamarul; Ouseph, Madhu M.; Ahmed, Salahuddin			Ets-2 Propagates IL-6 Trans-Signaling Mediated Osteoclast-Like Changes in Human Rheumatoid Arthritis Synovial Fibroblast (vol 12, 746503, 2021)	FRONTIERS IN IMMUNOLOGY			English	Correction						osteoclast; interleukin-6; synovial fibroblasts; rheumatoid arthritis; reprogramming			[Singh, Anil K.; Haque, Mahamudul; Madarampalli, Bhanupriya; Basit, Abdul; Prasad, Bhagwat; Ahmed, Salahuddin] Washington State Univ, Dept Pharmaceut Sci, Coll Pharm, Spokane, WA 99202 USA; [Shi, Yuanyuan] Univ Washington, Sch Med, Seattle, WA USA; [Wildman, Benjamin J.; Hassan, Quamarul] Univ Alabama Birmingham, Sch Dent, Dept Oral & Maxillofacial Surg, Birmingham, AL USA; [Khuder, Sadik A.] Univ Toledo, Dept Med & Publ Hlth, Toledo, OH USA; [Ouseph, Madhu M.] Weill Cornell, Dept Pathol, Lab Med, Med Coll, New York, NY USA; [Ahmed, Salahuddin] Univ Washington, Div Rheumatol, Sch Med, Seattle, WA 98195 USA	Washington State University; University of Washington; University of Washington Seattle; University of Alabama System; University of Alabama Birmingham; University System of Ohio; University of Toledo; University of Washington; University of Washington Seattle	Singh, AK; Ahmed, S (corresponding author), Washington State Univ, Dept Pharmaceut Sci, Coll Pharm, Spokane, WA 99202 USA.; Ahmed, S (corresponding author), Univ Washington, Div Rheumatol, Sch Med, Seattle, WA 98195 USA.	anil.singh@wsu.edu; salah.ahmed@wsu.edu	Ouseph, Madhu/B-8940-2009	Ouseph, Madhu/0000-0002-3422-1675				Singh AK, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.746503	1	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 26	2021	12								808756	10.3389/fimmu.2021.808756	http://dx.doi.org/10.3389/fimmu.2021.808756			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YG6GB	34899765	Green Published, gold			2022-12-18	WOS:000742583400001
J	Fonseca, CT; Pereira, TA; Stothard, JR; Caldeira, RL; Mourao, MM				Fonseca, Cristina Toscano; Pereira, Thiago Almeida; Stothard, J. Russell; Caldeira, Roberta Lima; Mourao, Marina Moraes			Editorial: Pre-Conference Research Topic: 16th International Symposium on Schistosomiasis	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						host-parasite interactions; vaccines; immunobiology; Biomphalaria sp; Schistosoma sp; schistosomicides; burden of disease; schistosomiasis control			[Fonseca, Cristina Toscano] Fundacao Oswaldo Cruz, Inst Rene Rachou, Grp Biol & Imunol Doencas Infecciosas & Parasitar, Belo Horizonte, MG, Brazil; [Pereira, Thiago Almeida] Stanford Univ, Sch Med, Inst Stem Cell Biol & Regenerat Med, Stanford, CA 94305 USA; [Stothard, J. Russell] Univ Liverpool Liverpool Sch Trop Med, Dept Trop Dis Biol, Liverpool, Merseyside, England; [Caldeira, Roberta Lima; Mourao, Marina Moraes] Fundacao Oswaldo Cruz, Inst Rene Rachou, Grp Helmintol & Malacol Med, Belo Horizonte, MG, Brazil	Fundacao Oswaldo Cruz; Stanford University; Liverpool School of Tropical Medicine; Fundacao Oswaldo Cruz	Caldeira, RL; Mourao, MM (corresponding author), Fundacao Oswaldo Cruz, Inst Rene Rachou, Grp Helmintol & Malacol Med, Belo Horizonte, MG, Brazil.	roberta.caldeira@fiocruz.br; marina.mourao@fiocruz.br	Mourao, Marina M/B-9314-2014; Toscano Fonseca, Cristina/C-4571-2015	Mourao, Marina M/0000-0003-1348-5521; Toscano Fonseca, Cristina/0000-0003-1527-5050	Conselho Nacional de Desenvolvimento Cientifico e Tecnologico-Brasil (CNPq) [303131/2018-7, 302518/2018-5]	Conselho Nacional de Desenvolvimento Cientifico e Tecnologico-Brasil (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	Productivity Fellowship from Conselho Nacional de Desenvolvimento Cientifico e Tecnologico-Brasil (CNPq) (Grant 303131/2018-7 granted to CTF and 302518/2018-5 granted to MMM).	CHIEFFI PP, 1992, MEM I OSWALDO CRUZ, V87, P291, DOI 10.1590/S0074-02761992000800045; King CH, 2008, CHRONIC ILLN, V4, P65, DOI 10.1177/1742395307084407; World Health Organization, 2021, SCHIST FACT SHEET	3	0	0	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 25	2021	12								774311	10.3389/fimmu.2021.774311	http://dx.doi.org/10.3389/fimmu.2021.774311			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XN1RL	34899729	gold, Green Accepted, Green Published			2022-12-18	WOS:000729289900001
J	Jan, MW; Su, HL; Chang, TH; Tsai, KJ				Jan, Ming-Wei; Su, Hong-Lin; Chang, Tsung-Hsien; Tsai, Kuen-Jer			Characterization of Pathogenesis and Inflammatory Responses to Experimental Parechovirus Encephalitis	FRONTIERS IN IMMUNOLOGY			English	Article						parechovirus A3; cytopathic effect; inflammation; neuronal diseases; infectious model	MOUSE MODEL; ENTEROVIRUS; INFECTION; TYPE-3; MENINGITIS; AUTOPHAGY; SEQUENCE; MICE; CHILDREN; INFANTS	Human parechovirus type 3 (PeV-A3) infection has been recognized as an emerging etiologic factor causing severe nerve disease or sepsis in infants and young children. But the neuropathogenic mechanisms of PeV-A3 remain unknown. To understand the pathogenesis of PeV-A3 infection in the neuronal system, PeV-A3-mediated cytopathic effects were analyzed in human glioblastoma cells and neuroblastoma cells. PeV-A3 induced interferons and inflammatory cytokine expression in these neuronal cells. The pronounced cytopathic effects accompanied with activation of death signaling pathways of apoptosis, autophagy, and pyroptosis were detected. A new experimental disease model of parechovirus encephalitis was established. In the disease model, intracranial inoculation with PeV-A3 in C57BL/6 neonatal mice showed body weight loss, hindlimb paralysis, and approximately 20% mortality. PeV-A3 infection in the hippocampus and cortex regions of the neonatal mouse brain was revealed. Mechanistic assay supported the in vitro results, indicating detection of PeV-A3 replication, inflammatory cytokine expression, and death signaling transduction in mouse brain tissues. These in vitro and in vivo studies revealed that the activation of death signaling and inflammation responses is involved in PeV-A3-mediated neurological disorders. The present results might account for some of the PeV-A3-associated clinical manifestations.	[Jan, Ming-Wei; Tsai, Kuen-Jer] Natl Cheng Kung Univ, Inst Clin Med, Coll Med, Tainan, Taiwan; [Jan, Ming-Wei] Kaohsiung Vet Gen Hosp, Dept Med Educ & Res, Kaohsiung, Taiwan; [Su, Hong-Lin] Natl Chung Hsing Univ, Dept Life Sci, Agr Biotechnol Ctr, Taichung, Taiwan; [Chang, Tsung-Hsien] Natl Def Med Ctr, Dept & Grad Inst Microbiol & Immunol, Taipei, Taiwan; [Tsai, Kuen-Jer] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Res Ctr Clin Med, Tainan, Taiwan	National Cheng Kung University; Kaohsiung Veterans General Hospital; National Chung Hsing University; National Defense Medical Center; National Cheng Kung University; National Cheng Kung University Hospital	Tsai, KJ (corresponding author), Natl Cheng Kung Univ, Inst Clin Med, Coll Med, Tainan, Taiwan.; Chang, TH (corresponding author), Natl Def Med Ctr, Dept & Grad Inst Microbiol & Immunol, Taipei, Taiwan.; Tsai, KJ (corresponding author), Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Res Ctr Clin Med, Tainan, Taiwan.	changth@mail.ndmctsgh.edu.tw; kjtsai@mail.ncku.edu.tw	Tsai, Kuen-Jer/B-9393-2009; Chang, Tsung-Hsien/AAG-9384-2019	Tsai, Kuen-Jer/0000-0002-2170-9735; Chang, Tsung-Hsien/0000-0003-4806-7864; Jan, Ming-Wei/0000-0002-1956-045X				Ahmad L, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00155; Aizawa Y, 2015, J CLIN VIROL, V70, P105, DOI 10.1016/j.jcv.2015.07.300; Benschop KSM, 2008, J GEN VIROL, V89, P1030, DOI 10.1099/vir.0.83498-0; Benschop K, 2010, DIAGN MICR INFEC DIS, V68, P166, DOI 10.1016/j.diagmicrobio.2010.05.016; Bergsbaken T, 2009, NAT REV MICROBIOL, V7, P99, DOI 10.1038/nrmicro2070; Bissel SJ, 2015, J NEUROPATH EXP NEUR, V74, P767, DOI 10.1097/NEN.0000000000000215; Britton PN, 2018, MED J AUSTRALIA, V208, P365, DOI 10.5694/mja18.00149; Chang JT, 2017, J CHIN MED ASSOC, V80, P737, DOI 10.1016/j.jcma.2017.07.007; Chang JT, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116158; Chen BC, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10120711; Chen BC, 2009, DIAGN MICR INFEC DIS, V65, P254, DOI 10.1016/j.diagmicrobio.2009.07.014; Criollo A, 2012, CELL CYCLE, V11, P194, DOI 10.4161/cc.11.1.18669; Danthi P, 2016, ANNU REV VIROL, V3, P533, DOI 10.1146/annurev-virology-110615-042435; Denton D, 2019, CELL DEATH DIFFER, V26, P605, DOI 10.1038/s41418-018-0252-y; Deretic V, 2021, IMMUNITY, V54, P437, DOI 10.1016/j.immuni.2021.01.018; Garcia-Sastre A, 2017, CELL HOST MICROBE, V22, P176, DOI 10.1016/j.chom.2017.07.012; Ghanem-Zoubi N, 2013, J CLIN VIROL, V58, P205, DOI 10.1016/j.jcv.2013.06.001; Ghazi F, 1998, J GEN VIROL, V79, P2641, DOI 10.1099/0022-1317-79-11-2641; Habuka R, 2020, J INFECT DIS, V222, P681, DOI 10.1093/infdis/jiaa131; Harvala H, 2009, J INFECT DIS, V199, P1753, DOI 10.1086/599094; Hiscott J, 2003, ANN NY ACAD SCI, V1010, P237, DOI 10.1196/annals.1299.042; Hughes SA, 2003, P NATL ACAD SCI USA, V100, P15906, DOI 10.1073/pnas.2535934100; HYYPIA T, 1992, P NATL ACAD SCI USA, V89, P8847, DOI 10.1073/pnas.89.18.8847; Imre G, 2020, CELL SIGNAL, V76, DOI 10.1016/j.cellsig.2020.109772; Ishibashi D, 2019, BRAIN, V142, P1035, DOI 10.1093/brain/awz016; Izumita R, 2019, J PEDIAT INF DIS SOC, V8, P501, DOI 10.1093/jpids/piy079; Kadambari S, 2019, ARCH DIS CHILD, V104, P552, DOI 10.1136/archdischild-2018-315643; Karelehto E, 2018, FRONT CELL INFECT MI, V8, DOI 10.3389/fcimb.2018.00294; Khong WX, 2012, J VIROL, V86, P2121, DOI 10.1128/JVI.06103-11; Kim JY, 2013, EUR J NEUROSCI, V37, P1203, DOI 10.1111/ejn.12126; Kofahi HM, 2016, SCI REP-UK, V6, DOI 10.1038/srep37433; Kroemer G, 2009, CELL DEATH DIFFER, V16, P3, DOI 10.1038/cdd.2008.150; Kung MH, 2020, THERANOSTICS, V10, P9200, DOI 10.7150/thno.47077; Lane LM, 2021, PEDIATR DEVEL PATHOL, V24, P460, DOI 10.1177/10935266211001645; Lin JY, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-71970-3; Lin TH, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00440; Liu ML, 2005, J GEN VIROL, V86, P3263, DOI 10.1099/vir.0.81195-0; Liu T, 2019, J ALLERGY CLIN IMMUN, V144, P777, DOI 10.1016/j.jaci.2019.05.006; Mazar J, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0200358; Merilahti P, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147168; Mesev EV, 2019, NAT MICROBIOL, V4, P914, DOI 10.1038/s41564-019-0421-x; Mizuta K, 2021, JPN J INFECT DIS, V74, P259, DOI [10.7883/yoken.JJID.2020.967, 10.7783/yoken.JJID.2020.967]; Nateri AS, 2000, J VIROL, V74, P6269, DOI 10.1128/JVI.74.14.6269-6277.2000; Neumann S, 2015, VIRUS RES, V209, P45, DOI 10.1016/j.virusres.2015.02.026; Olijve L, 2018, CLIN MICROBIOL REV, V31, DOI 10.1128/CMR.00047-17; Perera N, 2017, CELL MICROBIOL, V19, DOI 10.1111/cmi.12734; Ranjitha HB, 2021, J CELL SCI, V134, DOI 10.1242/jcs.240622; Sasidharan A, 2021, J CLIN MICROBIOL, V59, DOI 10.1128/JCM.02935-20; Shih SR, 2008, J NEUROVIROL, V14, P53, DOI 10.1080/13550280701798980; Siltz LAF, 2014, J VIROL, V88, P11091, DOI 10.1128/JVI.01877-14; Sridhar A, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11111062; STANWAY G, 1994, J VIROL, V68, P8232, DOI 10.1128/JVI.68.12.8232-8238.1994; Swanson KV, 2019, NAT REV IMMUNOL, V19, P477, DOI 10.1038/s41577-019-0165-0; Triantafilou K, 2005, EUR J IMMUNOL, V35, P2416, DOI 10.1002/eji.200526149; Triantafilou K, 2000, J VIROL, V74, P5856, DOI 10.1128/JVI.74.13.5856-5862.2000; van Hinsbergh TMT, 2020, LANCET CHILD ADOLESC, V4, P592, DOI 10.1016/S2352-4642(20)30181-4; Verboon-Maciolek MA, 2008, NEUROLOGY, V71, P536, DOI 10.1212/01.wnl.0000324706.94229.88; Volpe JJ, 2008, ANN NEUROL, V64, P232, DOI 10.1002/ana.21466; Wang BX, 2021, LIFE SCI, V271, DOI 10.1016/j.lfs.2021.119188; Wang Y, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20958-1; Wang YF, 2004, J VIROL, V78, P7916, DOI 10.1128/JVI.78.15.7916-7924.2004; Watanabe K, 2016, EPIDEMIOL INFECT, V144, P3451, DOI 10.1017/S0950268816001795; Westerhuis BM, 2012, J GEN VIROL, V93, P2363, DOI 10.1099/vir.0.043323-0; WIGAND REINHARD, 1961, ARCH GES VIRUSFORSCH, V11, P224, DOI 10.1007/BF01241688; Wolthers KC, 2008, CLIN INFECT DIS, V47, P358, DOI 10.1086/589752; Xu LJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065948; Zhang XL, 2020, EUR J IMMUNOL, V50, P1268, DOI 10.1002/eji.202048785; Zhu XJ, 2018, VIROLOGY, V521, P69, DOI 10.1016/j.virol.2018.05.025; Zhu Z, 2020, CELL STEM CELL, V26, P187, DOI 10.1016/j.stem.2019.11.016	69	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 25	2021	12								753683	10.3389/fimmu.2021.753683	http://dx.doi.org/10.3389/fimmu.2021.753683			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XM6PT	34899705	gold, Green Published			2022-12-18	WOS:000728947200001
J	Ogawa, T; Kan-o, K; Shiota, A; Fujita, A; Ishii, Y; Fukuyama, S; Matsumoto, K				Ogawa, Tomohiro; Kan-o, Keiko; Shiota, Ayaka; Fujita, Akitaka; Ishii, Yumiko; Fukuyama, Satoru; Matsumoto, Koichiro			Inhibition of PI3K delta Differentially Regulates Poly I:C- and Human Metapneumovirus-Induced PD-L1 and PD-L2 Expression in Human Bronchial Epithelial Cells	FRONTIERS IN IMMUNOLOGY			English	Article						programmed cell death 1 ligand 1; programmed cell death 1 ligand 2; interferon; phosphoinositide 3-kinase delta; bronchial epithelial cells; human metapneumovirus	DOUBLE-STRANDED-RNA; INDUCED UP-REGULATION; RIG-I; INTERFERON; B7-H1; RECOGNITION; ACTIVATION; LIGAND; VIRUS	Bronchial epithelial cells are front sentinels eliciting innate and adaptive immunity to respiratory viral pathogens. Recognition of viral double-stranded RNA induces antiviral interferon (IFN) responses in bronchial epithelial cells. Co-inhibitory molecules programmed cell death 1 ligand 1 (PD-L1) and ligand 2 (PD-L2) were also induced on bronchial epithelial cells, which bind programmed cell death 1 on T cell and inhibit the function of virus-specific cytotoxic T lymphocyte. A previous study showed that antiviral type I IFN increased PD-L1 and PD-L2 expression in cultured melanoma cells. However, it remains unknown whether antiviral IFNs affect PD-L1 and PD-L2 expression in bronchial epithelial cells. In addition, we previously reported that inhibition of PI3K delta signaling enhanced antiviral IFN responses in human primary bronchial epithelial cells (PBECs). Here we assessed the effect of exogenous IFNs or a selective PI3K delta inhibitor IC87114 on PD-L1 and PD-L2 in PBECs stimulated with a synthetic double-stranded RNA poly I:C or human metapneumovirus. Treatment with IFN beta or IFN lambda increased PD-L1 and PD-L2, and IFN beta or IFN lambda treatment plus poly I:C further increased both expressions. Treatment with IC87114 or transfection with siRNA targeting PI3K p110 delta enhanced poly I:C-induced gene and protein expression of PD-L2, whereas IC87114 suppressed poly I:C-induced PD-L1. IC87114 enhanced poly I:C-induced gene expression of IFN beta, IFN lambda, and IFN-regulated genes via increased TBK1 and IRF3 phosphorylation. Transfection with siIRF3 counteracted the enhancement of poly I:C-induced PD-L2 by IC87114, whereas IC87114 suppressed poly I:C-induced PD-L1 regardless of transfection with siNC or siIRF3. Similar effects of IC87114 on PD-L1 and PD-L2 expression were observed in human metapneumovirus-infected PBECs. We showed for the first time that type I and type III IFNs induced the expression of PD-L1 and PD-L2 in PBECs. Our findings suggest that during viral infections, inhibition of PI3K delta differentially regulates PD-L1 and PD-L2 expression in bronchial epithelial cells.	[Ogawa, Tomohiro; Kan-o, Keiko; Shiota, Ayaka; Fujita, Akitaka; Ishii, Yumiko; Fukuyama, Satoru; Matsumoto, Koichiro] Kyushu Univ, Grad Sch Med Sci, Res Inst Dis Chest, Fukuoka, Japan; [Kan-o, Keiko] Kyushu Univ Hosp, Dept Endoscop Diagnost & Therapeut, Fukuoka, Japan	Kyushu University; Kyushu University	Kan-o, K (corresponding author), Kyushu Univ, Grad Sch Med Sci, Res Inst Dis Chest, Fukuoka, Japan.; Kan-o, K (corresponding author), Kyushu Univ Hosp, Dept Endoscop Diagnost & Therapeut, Fukuoka, Japan.	kan-o.keiko.641@m.kyushu-u.ac.jp	Kan-o, Keiko/ABF-7827-2021	Ishii, Yumiko/0000-0002-7438-3695				Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Eppihimer MJ, 2002, MICROCIRCULATION, V9, P133, DOI 10.1038/sj/mn/7800123; Erickson JJ, 2012, J CLIN INVEST, V122, P2967, DOI 10.1172/JCI62860; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Foster MW, 2015, ANAL CHEM, V87, P10247, DOI 10.1021/acs.analchem.5b01544; Fujita A, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00432; Fumarola C, 2014, BIOCHEM PHARMACOL, V90, P197, DOI 10.1016/j.bcp.2014.05.011; Garcia CC, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00975; Garcia-Diaz A, 2017, CELL REP, V19, P1189, DOI 10.1016/j.celrep.2017.04.031; Hastings AK, 2015, J VIROL, V89, P4405, DOI 10.1128/JVI.03275-14; Jackson DJ, 2011, J ALLERGY CLIN IMMUN, V128, P1165, DOI 10.1016/j.jaci.2011.10.024; Kan-o K, 2013, INT ARCH ALLERGY IMM, V160, P27, DOI 10.1159/000338430; Kan-o K, 2017, J INFECT DIS, V215, P1536, DOI 10.1093/infdis/jix167; Kan-o K, 2013, BIOCHEM BIOPH RES CO, V435, P195, DOI 10.1016/j.bbrc.2013.04.082; Karunarathne DS, 2016, IMMUNITY, V45, P333, DOI 10.1016/j.immuni.2016.07.017; Kato H, 2006, NATURE, V441, P101, DOI 10.1038/nature04734; Kawai T, 2006, NAT IMMUNOL, V7, P131, DOI 10.1038/ni1303; Levy DE, 2011, CURR OPIN VIROL, V1, P476, DOI 10.1016/j.coviro.2011.11.001; Linden D, 2019, EUR RESPIR REV, V28, DOI 10.1183/16000617.0063-2018; McNally B, 2013, J VIROL, V87, P12916, DOI 10.1128/JVI.02423-13; Nie XX, 2018, CELL MOL IMMUNOL, V15, P888, DOI 10.1038/cmi.2017.17; Okkenhaug K, 2013, ANNU REV IMMUNOL, V31, P675, DOI 10.1146/annurev-immunol-032712-095946; Pauken KE, 2015, TRENDS IMMUNOL, V36, P265, DOI 10.1016/j.it.2015.02.008; Rogers MC, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007387; Sadler AJ, 2008, NAT REV IMMUNOL, V8, P559, DOI 10.1038/nri2314; Schonrich G, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00207; Schreiner B, 2004, J NEUROIMMUNOL, V155, P172, DOI 10.1016/j.jneuroim.2004.06.013; Stanciu LA, 2006, J INFECT DIS, V193, P404, DOI 10.1086/499275; Tsuda M, 2005, BIOCHEM BIOPH RES CO, V330, P263, DOI 10.1016/j.bbrc.2005.02.161; Wang GZ, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08887-7; Xiao YP, 2014, J EXP MED, V211, P943, DOI 10.1084/jem.20130790; Yoneyama M, 2004, NAT IMMUNOL, V5, P730, DOI 10.1038/ni1087; Zhou JH, 2018, CELL PHYSIOL BIOCHEM, V51, P173, DOI 10.1159/000495172	33	0	0	3	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 25	2021	12								767666	10.3389/fimmu.2021.767666	http://dx.doi.org/10.3389/fimmu.2021.767666			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XM4GV	34899719	gold, Green Published			2022-12-18	WOS:000728788700001
J	Tirado, TC; Moura, LL; Shigunov, P; Figueiredo, FB				Tirado, Thais Cristina; Moura, Larine Lowry; Shigunov, Patricia; Figueiredo, Fabiano Borges			Methodological Appraisal of Literature Concerning the Analysis of Genetic Variants or Protein Levels of Complement Components on Susceptibility to Infection by Trypanosomatids: A Systematic Review	FRONTIERS IN IMMUNOLOGY			English	Article						complement system; polymorphism; expression levels; susceptibility; leishmaniasis; Chagas Disease; trypanosomatids; systematic review	MANNOSE-BINDING LECTIN; VISCERAL LEISHMANIASIS; CHAGAS-DISEASE; PATHWAY ACTIVATION; POLYMORPHISMS; PROMOTER; PRINCIPLES; RISK; CARDIOMYOPATHY; MECHANISMS	Background: Trypanosomatids are protozoa responsible for a wide range of diseases, with emphasis on Chagas Disease (CD) and Leishmaniasis, which are in the list of most relevant Neglected Tropical Diseases (NTD) according to World Health Organization (WHO). During the infectious process, immune system is immediately activated, and parasites can invade nucleated cells through a broad diversity of receptors. The complement system - through classical, alternative and lectin pathways - plays a role in the first line of defense against these pathogens, acting in opsonization, phagocytosis and lysis of parasites. Genetic modifications in complement genes, such as Single Nucleotide Polymorphisms (SNPs), can influence host susceptibility to these parasites and modulate protein expression. Methods: In March and April 2021, a literature search was conducted at the PubMed and Google Scholar databases and the reference lists obtained were verified. After applying the inclusion and exclusion criteria, the selected studies were evaluated and scored according to eleven established criteria regarding their thematic approach and design, aiming at the good quality of publications. Results: Twelve papers were included in this systematic review: seven investigating CD and five focusing on Leishmaniasis. Most articles presented gene and protein approaches, careful determination of experimental groups, and adequate choice of experimental techniques, although several of them were not up-to-date. Ten studies explored the association of polymorphisms and haplotypes with disease progression, with emphasis on lectin complement pathway genes. Decreased and increased patient serum protein levels were associated with susceptibility to CD and Visceral Leishmaniasis, respectively. Conclusion: This systematic review shows the influence of genetic alterations in complement genes on the progression of several infectious diseases, with a focus on conditions caused by trypanosomatids, and contributes suggestions and evidence to improve experimental design in future research proposals.	[Tirado, Thais Cristina; Moura, Larine Lowry; Figueiredo, Fabiano Borges] Fundacao Oswaldo Cruz FIOCRUZ, Lab Biol Celular, Inst Carlos Chagas, Curitiba, Parana, Brazil; [Shigunov, Patricia] Fundacao Oswaldo Cruz FIOCRUZ, Lab Biol Basica Celulas Tronco, Inst Carlos Chagas, Curitiba, Parana, Brazil	Fundacao Oswaldo Cruz; Fundacao Oswaldo Cruz	Tirado, TC; Figueiredo, FB (corresponding author), Fundacao Oswaldo Cruz FIOCRUZ, Lab Biol Celular, Inst Carlos Chagas, Curitiba, Parana, Brazil.	thais.tirado@gmail.com; fabiano.figueiredo@fiocruz.br			Fundacao Oswaldo Cruz (FIOCRUZ); Conselho Nacional de Pesquisa e Desenvolvimento (CNPq) (PROEP) [442055/2019-6]; CNPq [309862/2015-9]	Fundacao Oswaldo Cruz (FIOCRUZ); Conselho Nacional de Pesquisa e Desenvolvimento (CNPq) (PROEP)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)Fundacao de Apoio a Pesquisa do Distrito Federal (FAPDF)); CNPq(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	This study was supported by Fundacao Oswaldo Cruz (FIOCRUZ) and Conselho Nacional de Pesquisa e Desenvolvimento (CNPq) (PROEP) (442055/2019-6). FF holds a grant from CNPq for productivity in research (309862/2015-9).	Abramovs N, 2020, FRONT GENET, V11, DOI 10.3389/fgene.2020.00210; ALBERTI S, 1993, INFECT IMMUN, V61, P852; Alonso DP, 2007, J INFECT DIS, V195, P1212, DOI 10.1086/512683; Ambrosio AR, 2021, LIFE SCI, V282, DOI 10.1016/j.lfs.2021.119793; Garrido-Cardenas JA, 2017, SENSORS-BASEL, V17, DOI 10.3390/s17030588; Aronson NE, 2019, INFECT DIS CLIN N AM, V33, P101, DOI 10.1016/j.idc.2018.10.004; Asgharzadeh Mohammad, 2007, Pak J Biol Sci, V10, P1850, DOI 10.3923/pjbs.2007.1850.1854; Assaf A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034113; Aydin S, 2015, PEPTIDES, V72, P4, DOI 10.1016/j.peptides.2015.04.012; Bayarri-Olmos R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0114883; Beck TF, 2016, CLIN CHEM, V62, P647, DOI 10.1373/clinchem.2015.249623; de Vasconcelos TCB, 2019, INFECT GENET EVOL, V74, DOI 10.1016/j.meegid.2017.10.005; Beltrame MH, 2014, FRONT PEDIATR, V2, DOI 10.3389/fped.2014.00148; Benfodil K, 2020, VET PARASITOL, V280, DOI 10.1016/j.vetpar.2020.109089; Bolarinwa OA, 2020, NIGER POSTGRAD MED J, V27, P67, DOI 10.4103/npmj.npmj_19_20; Boldt ABW, 2011, CLIN IMMUNOL, V140, P63, DOI 10.1016/j.clim.2011.03.008; Bradley DT, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120757; Cestari I, 2013, MOL IMMUNOL, V53, P328, DOI 10.1016/j.molimm.2012.08.015; Chen JL, 2019, GENE, V693, P69, DOI 10.1016/j.gene.2019.01.023; Evans-Osses I, 2013, SCI WORLD J, DOI 10.1155/2013/675898; Garred P, 2006, GENES IMMUN, V7, P85, DOI 10.1038/sj.gene.6364283; GARRED P, 1994, EUR J IMMUNOGENET, V21, P125, DOI 10.1111/j.1744-313X.1994.tb00183.x; Garred P, 2016, IMMUNOL REV, V274, P74, DOI 10.1111/imr.12468; Geyer PE, 2016, CELL SYST, V2, P185, DOI 10.1016/j.cels.2016.02.015; Hao XF, 2015, INT J CLIN EXP PATHO, V8, P3186; Heja D, 2012, P NATL ACAD SCI USA, V109, P10498, DOI 10.1073/pnas.1202588109; Herpers BL, 2006, MOL IMMUNOL, V43, P851, DOI 10.1016/j.molimm.2005.06.035; Hodeib S, 2020, HUM GENET, V139, P961, DOI 10.1007/s00439-020-02128-4; Hornbeck Peter V, 2015, Curr Protoc Immunol, V110, DOI 10.1002/0471142735.im0201s110; Hui TYJ, 2020, BMC GENET, V21, DOI 10.1186/s12863-020-0818-9; Hummelshoj T, 2005, HUM MOL GENET, V14, P1651, DOI 10.1093/hmg/ddi173; Jia PL, 2017, BRIEF BIOINFORM, V18, P413, DOI 10.1093/bib/bbw037; Kamangar F, 2013, ARCH IRAN MED, V16, P295, DOI 013165/AIM.0010; Kisserli A, 2017, JOVE-J VIS EXP, DOI 10.3791/56012; Kretzschmar GC, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006705; Krige AS, 2019, TRENDS PARASITOL, V35, P596, DOI 10.1016/j.pt.2019.05.008; Kumar KR, 2019, SEMIN THROMB HEMOST, V45, P661, DOI 10.1055/s-0039-1688446; Leban N, 2013, DIAGN PATHOL, V8, DOI 10.1186/1746-1596-8-93; Lee K, 2009, GLOB INST, P1; Lewis MJ, 2017, RHEUMATOLOGY, V56, P67, DOI 10.1093/rheumatology/kew399; Li YH, 2001, ATHEROSCLEROSIS, V154, P713, DOI 10.1016/S0021-9150(00)00639-0; Lidani KCF, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.00607; Luz PR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060237; Luz PR, 2010, INT J CARDIOL, V143, P448, DOI 10.1016/j.ijcard.2009.09.467; Luz PR, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004257; Madsen HO, 1998, J IMMUNOL, V161, P3169; MADSEN HO, 1995, J IMMUNOL, V155, P3013; Maggi RG, 2014, PARASITE VECTOR, V7, DOI 10.1186/1756-3305-7-127; Mayilyan KR, 2008, DRUG NEWS PERSPECT, V21, P200, DOI 10.1358/dnp.2008.21.4.1213349; Merle NS, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00262; Messias-Reason IJ, 2003, TISSUE ANTIGENS, V62, P308, DOI 10.1034/j.1399-0039.2003.00101.x; Mishra A, 2015, PARASITOL INT, V64, P591, DOI 10.1016/j.parint.2015.08.003; Mishra A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125940; Nichols LO, 2012, CLIN TRIALS, V9, P588, DOI 10.1177/1740774512455876; Noordzij M, 2011, NEPHRON CLIN PRACT, V118, pC319, DOI 10.1159/000322830; Page MJ, 2021, BMJ-BRIT MED J, V372, DOI [10.1016/j.ijsu.2021.105906, 10.1136/bmj.n71]; Rahim-Williams B, 2012, PAIN MED, V13, P522, DOI 10.1111/j.1526-4637.2012.01336.x; Ready PD, 2014, CLIN EPIDEMIOL, V6, P147, DOI 10.2147/CLEP.S44267; Rhodes JM, 2021, J INTERN MED, V289, P97, DOI 10.1111/joim.13149; Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923; Sandri TL, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007324; Sandri TL, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18937-z; Sandri TL, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175973; Sangenito LS, 2019, CURR TOP MED CHEM, V19, P174, DOI 10.2174/156802661903190328155136; Santos IKFD, 2001, INFECT IMMUN, V69, P5212, DOI 10.1128/IAI.69.8.5212-5215.2001; Scarim CB, 2019, EUR J MED CHEM, V162, P378, DOI 10.1016/j.ejmech.2018.11.013; Schijman AG, 2018, ACTA TROP, V184, P59, DOI 10.1016/j.actatropica.2018.02.019; Romano PS, 2012, IUBMB LIFE, V64, P387, DOI 10.1002/iub.1019; Slatkin M, 2008, NAT REV GENET, V9, P477, DOI 10.1038/nrg2361; Steffensen R, 2000, J IMMUNOL METHODS, V241, P33, DOI 10.1016/S0022-1759(00)00198-8; Stuart K, 2008, J CLIN INVEST, V118, P1301, DOI 10.1172/JCI33945; Sundar S, 2018, MOL DIAGN THER, V22, P443, DOI 10.1007/s40291-018-0343-y; Thiel S, 2007, MOL IMMUNOL, V44, P3875, DOI 10.1016/j.molimm.2007.06.005; Tinkov AA, 2021, BIOL TRACE ELEM RES, V199, P490, DOI 10.1007/s12011-020-02177-w; Tong HV, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028113; van Griensven J, 2019, INFECT DIS CLIN N AM, V33, P79, DOI 10.1016/j.idc.2018.10.005; Weitzel T, 2012, AM J TROP MED HYG, V86, P229, DOI 10.4269/ajtmh.2012.11-0539; Werneck GL, 2014, REV SAUDE PUBL, V48, P851, DOI 10.1590/S0034-8910.2014048005615; Woo JJ, 2020, MOL PSYCHIATR, V25, P114, DOI 10.1038/s41380-019-0479-0; Wu H, 2016, ARQ NEURO-PSIQUIAT, V74, P881, DOI [10.1590/0004-282X20160139, 10.1590/0004-282x20160139]; Zumla A, 2012, INFECT DIS CLIN N AM, V26, P195, DOI 10.1016/j.idc.2012.02.007	81	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 25	2021	12								780810	10.3389/fimmu.2021.780810	http://dx.doi.org/10.3389/fimmu.2021.780810			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6I1JF	34899745	gold, Green Published			2022-12-18	WOS:000885881600001
J	Huang, YB; Huang, SS; Ma, L; Wang, YL; Wang, X; Xiao, LY; Qin, W; Li, L; Yuan, XL				Huang, Yongbiao; Huang, Shanshan; Ma, Li; Wang, Yali; Wang, Xi; Xiao, Lingyan; Qin, Wan; Li, Long; Yuan, Xianglin			Exploring the Prognostic Value, Immune Implication and Biological Function of H2AFY Gene in Hepatocellular Carcinoma	FRONTIERS IN IMMUNOLOGY			English	Article						hepatocellular carcinoma; H2AFY; prognosis; immune infiltration; biomarker	MACROH2A SUPPRESSES; CANCER; EXPRESSION; PROGRESSION; ISOFORMS; KINASE; TARGET; CELLS	BackgroundHepatocellular carcinoma (HCC) is an extremely malignant cancer with poor survival. H2AFY gene encodes for a variant of H2A histone, and it has been found to be dysregulated in various tumors. However, the clinical value, biological functions and correlations with immune infiltration of H2AFY in HCC remain unclear. MethodsWe analyzed the expression and clinical significance of H2AFY in HCC using multiple databases, including Oncomine, HCCDB, TCGA, ICGC, and so on. The genetic alterations of H2AFY were analyzed by cBioPortal and COSMIC databases. Co-expression networks of H2AFY and its regulators were investigated by LinkedOmics. The correlations between H2AFY and tumor immune infiltration were explored using TIMER, TISIDB databases, and CIBERSORT method. Finally, H2AFY was knocked down with shRNA lentiviruses in HCC cell lines for functional assays in vitro. ResultsH2AFY expression was upregulated in the HCC tissues and cells. Kaplan-Meier and Cox regression analyses revealed that high H2AFY expression was an independent prognostic factor for poor survival in HCC patients. Functional network analysis indicated that H2AFY and its co-expressed genes regulates cell cycle, mitosis, spliceosome and chromatin assembly through pathways involving many cancer-related kinases and E2F family. Furthermore, we observed significant correlations between H2AFY expression and immune infiltration in HCC. H2AFY knockdown suppressed the cell proliferation and migration, promoted cycle arrest, and apoptosis of HCC cells in vitro. ConclusionOur study revealed that H2AFY is a potential biomarker for unfavorable prognosis and correlates with immune infiltration in HCC.	[Huang, Yongbiao; Huang, Shanshan; Ma, Li; Wang, Yali; Wang, Xi; Xiao, Lingyan; Qin, Wan; Li, Long; Yuan, Xianglin] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Oncol, Wuhan, Peoples R China	Huazhong University of Science & Technology	Yuan, XL (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Oncol, Wuhan, Peoples R China.	yuanxianglin@hust.edu.cn			National Natural Science Foundation of China [81773360]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study was supported by National Natural Science Foundation of China (2018, 81773360).	Bindea G, 2013, IMMUNITY, V39, P782, DOI 10.1016/j.immuni.2013.10.003; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Bremnes RM, 2016, J THORAC ONCOL, V11, P789, DOI 10.1016/j.jtho.2016.01.015; Broggi G, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01519; Bruix J, 2014, GUT, V63, P844, DOI 10.1136/gutjnl-2013-306627; Buschbeck M, 2017, NAT REV MOL CELL BIO, V18, P299, DOI 10.1038/nrm.2016.166; Cantarino N, 2013, CANCER LETT, V336, P247, DOI 10.1016/j.canlet.2013.03.022; Carpenter RL, 2014, CANCERS, V6, P897, DOI 10.3390/cancers6020897; Chaisaingmongkol J, 2017, CANCER CELL, V32, P57, DOI 10.1016/j.ccell.2017.05.009; Chen J, 2021, EXPERT REV ANTICANC, V21, P795, DOI 10.1080/14737140.2021.1908132; Corujo D, 2018, CANCERS, V10, DOI 10.3390/cancers10030059; Forbes SA, 2015, NUCLEIC ACIDS RES, V43, pD805, DOI 10.1093/nar/gku1075; Forner A, 2018, LANCET, V391, P1301, DOI 10.1016/S0140-6736(18)30010-2; Franz M, 2018, NUCLEIC ACIDS RES, V46, pW60, DOI 10.1093/nar/gky311; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Giallongo S, 2020, AGING-US, V12, P9745, DOI 10.18632/aging.103241; Hammond CM, 2017, NAT REV MOL CELL BIO, V18, P141, DOI 10.1038/nrm.2016.159; He LE, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1109-9; Jiao Y, 2020, EXPERT OPIN INV DRUG, V29, P1295, DOI 10.1080/13543784.2020.1814253; Kapoor A, 2010, NATURE, V468, P1105, DOI 10.1038/nature09590; Kent LN, 2019, NAT REV CANCER, V19, P326, DOI 10.1038/s41568-019-0143-7; Koch A, 2018, NAT REV CLIN ONCOL, V15, P459, DOI 10.1038/s41571-018-0004-4; Kozlowski M, 2018, EMBO REP, V19, DOI 10.15252/embr.201744445; Laudisi F, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19061787; Lei SR, 2014, MOL MED REP, V10, P1845, DOI 10.3892/mmr.2014.2482; Lens SMA, 2010, NAT REV CANCER, V10, P825, DOI 10.1038/nrc2964; Li TW, 2017, CANCER RES, V77, pE108, DOI 10.1158/0008-5472.CAN-17-0307; Li XF, 2012, J BIOL CHEM, V287, P23171, DOI 10.1074/jbc.M112.379412; Lian QY, 2018, GENOM PROTEOM BIOINF, V16, P269, DOI 10.1016/j.gpb.2018.07.003; Liao Y, 2021, IMMUNOGENETICS, V73, P369, DOI 10.1007/s00251-021-01223-8; Liu Y, 2020, ACTA PHARMACOL SIN B, V10, P2299, DOI 10.1016/j.apsb.2020.06.014; Liu YY, 2019, CLIN CANCER RES, V25, P4141, DOI 10.1158/1078-0432.CCR-18-3510; Llovet JM, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.18, 10.1038/nrdp.2016.19]; Ma XY, 2021, BMC CANCER, V21, DOI 10.1186/s12885-021-08161-4; Martire S, 2020, NAT REV MOL CELL BIO, V21, P522, DOI 10.1038/s41580-020-0262-8; Nagy A, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-84787-5; Newman AM, 2015, NAT METHODS, V12, P453, DOI [10.1038/NMETH.3337, 10.1038/nmeth.3337]; Novikov L, 2011, MOL CELL BIOL, V31, P4244, DOI 10.1128/MCB.05244-11; Park SJ, 2016, ONCOGENE, V35, P1292, DOI 10.1038/onc.2015.187; Polager S, 2008, TRENDS CELL BIOL, V18, P528, DOI 10.1016/j.tcb.2008.08.003; Prevo R, 2018, CELL CYCLE, V17, P1513, DOI 10.1080/15384101.2018.1491236; Rappa F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054458; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Ru BB, 2019, BIOINFORMATICS, V35, P4200, DOI 10.1093/bioinformatics/btz210; Schlachterman A, 2015, WORLD J GASTROENTERO, V21, P8478, DOI 10.3748/wjg.v21.i28.8478; Singh S, 2020, DRUG DISCOV TODAY, V25, P223, DOI 10.1016/j.drudis.2019.11.003; Sporn JC, 2009, ONCOGENE, V28, P3423, DOI 10.1038/onc.2009.26; Sporn JC, 2012, AM J PATHOL, V180, P2516, DOI 10.1016/j.ajpath.2012.02.027; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tang ZF, 2019, NUCLEIC ACIDS RES, V47, pW556, DOI 10.1093/nar/gkz430; Vardabasso C, 2014, CELL MOL LIFE SCI, V71, P379, DOI 10.1007/s00018-013-1343-z; Vasaikar SV, 2018, NUCLEIC ACIDS RES, V46, pD956, DOI 10.1093/nar/gkx1090; Wang Q, 2011, CURR MED CHEM, V18, P2025, DOI 10.2174/092986711795590110; Wu WY, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-506; Yan M, 2016, MED RES REV, V36, P1036, DOI 10.1002/med.21399; Zhou QQ, 2021, CANCER RES, V81, P1361, DOI 10.1158/0008-5472.CAN-20-2480; Zhu ZX, 2016, JPN J CLIN ONCOL, V46, P1075, DOI 10.1093/jjco/hyw134	57	0	0	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 24	2021	12								723293	10.3389/fimmu.2021.723293	http://dx.doi.org/10.3389/fimmu.2021.723293			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YA9QK	34899687	gold, Green Published			2022-12-18	WOS:000738659100001
J	Stairiker, CJ; Pfister, SX; Hendrickson, E; Yang, WJ; Xie, T; Lee, CTRE; Zhang, HK; Dillon, C; Thomas, GD; Salek-Ardakani, S				Stairiker, Christopher J.; Pfister, Sophia Xiao; Hendrickson, Eleanore; Yang, Wenjing; Xie, Tao; Lee, Catherine; Zhang, Haikuo; Dillon, Christopher; Thomas, Graham D.; Salek-Ardakani, Shahram			EZH2 Inhibition Compromises alpha 4-1BB-Mediated Antitumor Efficacy by Reducing the Survival and Effector Programming of CD8(+) T Cells	FRONTIERS IN IMMUNOLOGY			English	Article						EZH2; CD8; T cell; Bim; CD137 (4-1BB)	HISTONE METHYLTRANSFERASE EZH2; TARGETING EZH2; EXPRESSION; DIFFERENTIATION; IMMUNOTHERAPY	Enhancer of Zeste Homolog 2 (EZH2) inhibitors (EZH2i) are approved to treat certain cancer types. Previous studies have suggested the potential to combine EZH2i with immune checkpoint blockade targeting coinhibitory receptors like PD-(L)1 and CTLA-4, but whether it can also enhance the activity of agents targeting costimulatory receptors is not known. Here, we explore the combination between EZH2i and an agonist antibody targeting the T cell costimulatory receptor 4-1BB (alpha 4-1BB). Our data show that EZH2i compromise the efficacy of alpha 4-1BB in both CT26 colon carcinoma and in an in vivo protein immunization model. We link this to reduced effector survival and increased BIM expression in CD8(+) T cells upon EZH2i treatment. These data support the requirement of EZH2 function in 4-1BB-mediated CD8(+) T cell expansion and effector programming and emphasize the consideration that must be given when combining such antitumoral therapies.	[Stairiker, Christopher J.; Pfister, Sophia Xiao; Thomas, Graham D.; Salek-Ardakani, Shahram] Pfizer Inc, Dev Med, Worldwide Res, Canc Immunol Discovery, San Diego, CA 92121 USA; [Hendrickson, Eleanore; Lee, Catherine; Zhang, Haikuo; Dillon, Christopher] Pfizer Inc, Dev Med, Worldwide Res, Translat Sci, San Diego, CA USA; [Yang, Wenjing; Xie, Tao] Pfizer Inc, Dev Med, Worldwide Res, Computat Biol, San Diego, CA USA	Pfizer; Pfizer; Pfizer	Thomas, GD; Salek-Ardakani, S (corresponding author), Pfizer Inc, Dev Med, Worldwide Res, Canc Immunol Discovery, San Diego, CA 92121 USA.	Graham.Thomas@Pfizer.com; ssalekardakani@gmail.com			Worldwide Research, and Development and Medical group of Pfizer Inc	Worldwide Research, and Development and Medical group of Pfizer Inc	Funding for this work was provided by Worldwide Research, and Development and Medical group of Pfizer Inc.	Chester C, 2018, BLOOD, V131, P49, DOI 10.1182/blood-2017-06-741041; Curran MA, 2013, J EXP MED, V210, P743, DOI 10.1084/jem.20121190; Duan R, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00937-8; DuPage M, 2015, IMMUNITY, V42, P227, DOI 10.1016/j.immuni.2015.01.007; Eich ML, 2020, CANCER RES, V80, P5449, DOI 10.1158/0008-5472.CAN-20-2147; Escuin-Ordinas H, 2013, J IMMUNOTHER CANCER, V1, DOI 10.1186/2051-1426-1-14; Goswami S, 2018, J CLIN INVEST, V128, P3813, DOI 10.1172/JCI99760; Gray SM, 2017, IMMUNITY, V46, P596, DOI 10.1016/j.immuni.2017.03.012; Harao M, 2017, CANCER IMMUNOL RES, V5, P439, DOI 10.1158/2326-6066.CIR-16-0364; He S, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-02187-8; He S, 2013, BLOOD, V122, P4119, DOI 10.1182/blood-2013-05-505180; He S, 2012, BLOOD, V119, P1274, DOI 10.1182/blood-2011-06-364422; Hope JL, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01696; House IG, 2020, CLIN CANCER RES, V26, P487, DOI 10.1158/1078-0432.CCR-19-1868; Joshi NS, 2007, IMMUNITY, V27, P281, DOI 10.1016/j.immuni.2007.07.010; Julia E, 2021, FUTURE ONCOL, V17, P2127, DOI 10.2217/fon-2020-1244; Kakaradov B, 2017, NAT IMMUNOL, V18, P422, DOI 10.1038/ni.3688; Kim KH, 2016, NAT MED, V22, P128, DOI 10.1038/nm.4036; Krishna S, 2020, SCIENCE, V370, P1328, DOI 10.1126/science.abb9847; Kung PP, 2018, J MED CHEM, V61, P650, DOI 10.1021/acs.jmedchem.7b01375; Kurtulus S, 2011, J IMMUNOL, V186, P5729, DOI 10.4049/jimmunol.1100102; Lee HW, 2002, J IMMUNOL, V169, P4882, DOI 10.4049/jimmunol.169.9.4882; Margueron R, 2011, NATURE, V469, P343, DOI 10.1038/nature09784; Melero I, 1997, NAT MED, V3, P682, DOI 10.1038/nm0697-682; Michelini RH, 2013, J EXP MED, V210, P1189, DOI 10.1084/jem.20130392; Morel KL, 2021, NAT CANCER, V2, P444, DOI 10.1038/s43018-021-00185-w; Pfannenstiel LW, 2019, CANCER IMMUNOL RES, V7, P510, DOI 10.1158/2326-6066.CIR-18-0054; Qu Y, 2020, CELL REP, V32, DOI 10.1016/j.celrep.2020.108115; Wang D, 2018, CELL REP, V23, P3262, DOI 10.1016/j.celrep.2018.05.050; Zhao ED, 2016, NAT IMMUNOL, V17, P95, DOI 10.1038/ni.3313; Zhou LY, 2020, CLIN CANCER RES, V26, P290, DOI 10.1158/1078-0432.CCR-19-1351; Zingg D, 2017, CELL REP, V20, P854, DOI 10.1016/j.celrep.2017.07.007	32	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 24	2021	12								770080	10.3389/fimmu.2021.770080	http://dx.doi.org/10.3389/fimmu.2021.770080			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XQ3JO	34925340	gold, Green Published			2022-12-18	WOS:000731444700001
J	Sun, ZY; Huang, WH; Zheng, YL; Liu, P; Yang, WB; Guo, ZA; Kong, DC; Lv, QY; Zhou, XY; Du, ZM; Jiang, H; Jiang, YQ				Sun, Zeyu; Huang, Wenhua; Zheng, Yuling; Liu, Peng; Yang, Wenbo; Guo, Zinan; Kong, Decong; Lv, Qingyu; Zhou, Xinyu; Du, Zongmin; Jiang, Hua; Jiang, Yongqiang			Fpr2/CXCL1/2 Controls Rapid Neutrophil Infiltration to Inhibit Streptococcus agalactiae Infection	FRONTIERS IN IMMUNOLOGY			English	Article						Streptococcus agalactiae; (GBS); formyl peptide receptor 2 (FPR2); CXCL1=chemokine (CXC) ligand 1; chemokine (C-X-C motif) ligand 2; neutrophil (PMN)	INFLAMMATION; RECEPTORS	Streptococcus agalactiae, also known as group B streptococcus (GBS), can cause pneumonia, meningitis, and bacteremia, making it a pathogen that can increase the risk of death in newborns and immunodeficient individuals. Neutrophils are the first barrier to a host's innate immune defense against these infections. Fpr2(Formyl peptide receptor 2) is an important chemotactic receptor of neutrophils, though its activation would cause pro- and anti-inflammatory effects. In this study, we found that mice without Fpr2 receptor were highly susceptible to GBS infections. These mice demonstrated decreased chemotaxis to neutrophils, decreased bactericidal ability of neutrophils, and high mortality. RNA-seq and Luminex assay indicated that Fpr2 activates key signal molecules downstream and produces chemokines CXCL1/2 to chemotaxis neutrophils. Like Fpr2(-/-), CXCL1/2 or neutrophil depletion impairs host's ability to defend against GBS infection. Altogether, these data indicate that Fpr2 contributes to a host's ability to control GBS infection and that a lack of Fpr2 was associated with selective impairment during the production of chemokines CXCL1 and CXCL2 as well as neutrophil recruitment. Here, We clarified that Fpr2, as a chemotactic receptor, could not only directly chemotactic neutrophils, but also regulate the production of chemokines to control infection by chemotactic neutrophils.	[Sun, Zeyu; Huang, Wenhua; Zheng, Yuling; Liu, Peng; Guo, Zinan; Kong, Decong; Lv, Qingyu; Zhou, Xinyu; Du, Zongmin; Jiang, Hua; Jiang, Yongqiang] Acad Mil Med Sci, Inst Microbiol & Epidemiol, State Key Lab Pathogen & Biosecur, Beijing, Peoples R China; [Yang, Wenbo] Changchun Univ Chinese Med, Changchun, Peoples R China	Academy of Military Medical Sciences - China; Changchun University of Chinese Medicine	Du, ZM; Jiang, H; Jiang, YQ (corresponding author), Acad Mil Med Sci, Inst Microbiol & Epidemiol, State Key Lab Pathogen & Biosecur, Beijing, Peoples R China.	zmduams@163.com; jhua76@126.com; jiangyq@bmi.ac.cn			National Natural Science Foundation of China [82002116]; State Key Laboratory of Pathogen and Biosecurity [SKLPBS2119]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); State Key Laboratory of Pathogen and Biosecurity	This work was supported by grants from the National Natural Science Foundation of China (82002116), the State Key Laboratory of Pathogen and Biosecurity (SKLPBS2119). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bajrami B, 2016, J EXP MED, V213, P1999, DOI 10.1084/jem.20160393; Biondo C, 2014, INFECT IMMUN, V82, P4508, DOI 10.1128/IAI.02104-14; Biondo C, 2014, MBIO, V5, DOI 10.1128/mBio.01428-14; Borregaard N, 2010, IMMUNITY, V33, P657, DOI 10.1016/j.immuni.2010.11.011; Brinkmann V, 2004, SCIENCE, V303, P1532, DOI 10.1126/science.1092385; Brinkmann V, 2007, NAT REV MICROBIOL, V5, P577, DOI 10.1038/nrmicro1710; Carvelli J, 2020, NATURE, V588, P146, DOI 10.1038/s41586-020-2600-6; Chen KQ, 2017, J AUTOIMMUN, V85, P64, DOI 10.1016/j.jaut.2017.06.012; Chen KQ, 2010, J IMMUNOL, V184, P3331, DOI 10.4049/jimmunol.0903022; Cooray SN, 2013, P NATL ACAD SCI USA, V110, P18232, DOI 10.1073/pnas.1308253110; De Buck M, 2016, CYTOKINE GROWTH F R, V30, P55, DOI 10.1016/j.cytogfr.2015.12.010; Ford JW, 2009, CURR OPIN IMMUNOL, V21, P38, DOI 10.1016/j.coi.2009.01.009; Futosi K, 2013, INT IMMUNOPHARMACOL, V17, P638, DOI 10.1016/j.intimp.2013.06.034; Giebeler A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100522; Kolaczkowska E, 2013, NAT REV IMMUNOL, V13, P159, DOI 10.1038/nri3399; Kretschmer D, 2010, CELL HOST MICROBE, V7, P463, DOI 10.1016/j.chom.2010.05.012; Li LZ, 2016, J LEUKOCYTE BIOL, V99, P425, DOI 10.1189/jlb.2RI0815-354RR; Li L, 2016, SCI REP-UK, V6, DOI 10.1038/srep29373; Liu GY, 2004, P NATL ACAD SCI USA, V101, P14491, DOI 10.1073/pnas.0406143101; Liu MY, 2012, SCI REP-UK, V2, DOI 10.1038/srep00786; Machado MG, 2020, FASEB J, V34, P2749, DOI 10.1096/fj.201902172R; MCFALL TL, 1987, PEDIATR RES, V21, P517, DOI 10.1203/00006450-198706000-00001; McKenna DS, 1998, SEMIN PERINATOL, V22, P267, DOI 10.1016/S0146-0005(98)80015-3; Nanduri SA, 2019, JAMA PEDIATR, V173, P224, DOI 10.1001/jamapediatrics.2018.4826; Ni CP, 2021, INFECT IMMUN, V89, DOI 10.1128/IAI.00680-20; Oldekamp S, 2014, IMMUNOLOGY, V143, P447, DOI 10.1111/imm.12324; Pellme S, 2006, J LEUKOCYTE BIOL, V79, P564, DOI 10.1189/jlb.0505248; Phares CR, 2008, JAMA-J AM MED ASSOC, V299, P2056, DOI 10.1001/jama.299.17.2056; Rautenberg M, 2011, FASEB J, V25, P1254, DOI 10.1096/fj.10-175208; Scott NR, 2020, J CLIN INVEST, V130, P3098, DOI 10.1172/JCI130546; Wang SW, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01298; Weiss E, 2020, J INFECT DIS, V221, P668, DOI 10.1093/infdis/jiz498; Weiss E, 2018, FASEB J, V32, P26, DOI 10.1096/fj.201700441R; Xirakia C, 2010, AM J RESP CRIT CARE, V181, P1207, DOI 10.1164/rccm.200908-1255OC; Yan J, 2014, INT REV IMMUNOL, V33, P498, DOI 10.3109/08830185.2014.889129; Zhang MH, 2020, J IMMUNOL, V204, P2464, DOI 10.4049/jimmunol.1900430	36	0	0	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 24	2021	12								786602	10.3389/fimmu.2021.786602	http://dx.doi.org/10.3389/fimmu.2021.786602			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YB0JI	34899755	Green Published, gold			2022-12-18	WOS:000738709000001
J	Bai, GG; Ge, YH; Su, YH; Chen, S; Zeng, XC; Lu, HX; Ma, BY				Bai, Ganggang; Ge, Yanhong; Su, Yuhong; Chen, Shuo; Zeng, Xingcheng; Lu, Huixia; Ma, Buyong			Computational Construction of a Single-Chain Bi-Paratopic Antibody Allosterically Inhibiting TCR-Staphylococcal Enterotoxin B Binding	FRONTIERS IN IMMUNOLOGY			English	Article						bispecific antibody; staphylococcal enterotoxin B; superantigen; TCR; antibody design; molecular dynamics simulation; allostery	BISPECIFIC ANTIBODIES; MONOCLONAL-ANTIBODY; 3-DIMENSIONAL STRUCTURE; MOLECULAR-DYNAMICS; SOFTWARE NEWS; PROTEIN; FLUCTUATIONS; RECOGNITION; MECHANISMS; EPITOPES	Staphylococcal enterotoxin B (SEB) simultaneously crosslinks MHC class II antigen and TCR, promoting proliferation of T cells and releasing a large number of toxic cytokines. In this report, we computationally examined the possibility of using a single-chain biparatopic bispecific antibody to target SEB and prevent TCR binding. The design was inspired by the observation that mixing two anti-SEB antibodies 14G8 and 6D3 can block SEB-TCR activation, and we used 14G8-6D3-SEB tertiary crystal structure as a template. Twelve simulation systems were constructed to systematically examine the effects of the designed bispecific scFV MB102a, including isolated SEB, MB102a with different linkers, MB102a-SEB complex, MB102a-SEB-TCR beta complex, MB102a-SEB-TCR-MHC II complex, and MB102a-SEB-MHC II. Our all atom molecular dynamics simulations (total 18,900 ns) confirmed that the designed single-chain bispecific antibody may allosterically prevent SEB-TCR beta chain binding and inhibit SEB-TCR-MHC II formation. Subsequent analysis indicated that the binding of scFV to SEB correlates with SEB-TCR binding site motion and weakens SEB-TCR interactions.	[Bai, Ganggang; Ge, Yanhong; Su, Yuhong; Chen, Shuo; Zeng, Xingcheng; Lu, Huixia; Ma, Buyong] Shanghai Jiao Tong Univ, Sch Pharm, Engn Res Ctr Cell & Therapeut Antibody MOE, Shanghai, Peoples R China; [Ma, Buyong] Molcell Biodesign Inc, Frederick, MD 21704 USA	Shanghai Jiao Tong University	Ma, BY (corresponding author), Shanghai Jiao Tong Univ, Sch Pharm, Engn Res Ctr Cell & Therapeut Antibody MOE, Shanghai, Peoples R China.; Ma, BY (corresponding author), Molcell Biodesign Inc, Frederick, MD 21704 USA.	mabuyong@sjtu.edu.cn		LU, HUIXIA/0000-0003-2731-5283	Shanghai Jiao Tong University; Shanghai municipal government; Center for High Performance Computing at Shanghai Jiao Tong University	Shanghai Jiao Tong University; Shanghai municipal government; Center for High Performance Computing at Shanghai Jiao Tong University	BM thanks support from Shanghai Jiao Tong University and Shanghai municipal government. The computations in this paper were run on the computers supported by the Center for High Performance Computing at Shanghai Jiao Tong University.	Akiba H., 2020, T REGUL SCI, V2, P1, DOI [10.33611/trs.2_1, DOI 10.33611/TRS.2_1]; Asokan M, 2015, J VIROL, V89, P12501, DOI 10.1128/JVI.02097-15; Baeuerle PA, 2009, CANCER RES, V69, P4941, DOI 10.1158/0008-5472.CAN-09-0547; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bogen JP, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.606878; Bracken CJ, 2021, NAT CHEM BIOL, V17, P113, DOI 10.1038/s41589-020-00679-1; Brinkmann U, 2017, MABS-AUSTIN, V9, P182, DOI 10.1080/19420862.2016.1268307; Case DA, 2005, J COMPUT CHEM, V26, P1668, DOI 10.1002/jcc.20290; Cheng Mary Hongying, 2020, bioRxiv, DOI [10.1016/j.str.2021.04.005, 10.1101/2020.11.24.395079]; CHOTHIA C, 1987, J MOL BIOL, V196, P901, DOI 10.1016/0022-2836(87)90412-8; Dutta K, 2015, J BIOL CHEM, V290, P6715, DOI 10.1074/jbc.M114.630715; Fernandez-Quintero ML, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.675655; Fernandez-Quintero ML, 2021, FRONT MOL BIOSCI, V8, DOI 10.3389/fmolb.2021.639166; Fernandez-Quintero ML, 2020, COMMUN BIOL, V3, DOI 10.1038/s42003-020-01319-z; Fernandez-Quintero ML, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-61433-0; Gilchuk P, 2020, IMMUNITY, V52, P388, DOI 10.1016/j.immuni.2020.01.001; Glykos NM, 2006, J COMPUT CHEM, V27, P1765, DOI 10.1002/jcc.20482; Gunasekaran K, 2004, PROTEINS, V57, P433, DOI 10.1002/prot.20232; Hsiue EHC, 2021, SCIENCE, V371, P1009, DOI 10.1126/science.abc8697; Hu NJ, 2021, BIOCHEM BIOPH RES CO, V549, P120, DOI 10.1016/j.bbrc.2021.02.057; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; ICHIYE T, 1991, PROTEINS, V11, P205, DOI 10.1002/prot.340110305; JARDETZKY TS, 1994, NATURE, V368, P711, DOI 10.1038/368711a0; Jo S, 2008, J COMPUT CHEM, V29, P1859, DOI 10.1002/jcc.20945; Kamboj DV, 2006, ELECTRON J BIOTECHN, V9, P551, DOI 10.2225/vol9-issue5-fulltext-8; Kast F, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-23948-6; Kellmann SJ, 2017, MABS-AUSTIN, V9, P404, DOI 10.1080/19420862.2016.1277302; Kong C, 2016, TOXINS, V8, DOI 10.3390/toxins8030072; Krishnamurthy A, 2018, PHARMACOL THERAPEUT, V185, P122, DOI 10.1016/j.pharmthera.2017.12.002; KUNG JT, 1982, J IMMUNOL, V128, P2049; Li HM, 1998, IMMUNITY, V9, P807, DOI 10.1016/S1074-7613(00)80646-9; MacIntyre JL, 2015, INT IMMUNOPHARMACOL, V28, P354, DOI 10.1016/j.intimp.2015.06.025; Maun HR, 2019, CELL, V179, P417, DOI 10.1016/j.cell.2019.09.009; Mercadante D, 2018, BIOPHYS J, V114, P1267, DOI 10.1016/j.bpj.2018.01.033; Mujtaba MG, 2021, VIRAL IMMUNOL, V34, P392, DOI 10.1089/vim.2020.0310; Mukund S, 2013, J BIOL CHEM, V288, P36168, DOI 10.1074/jbc.M113.496984; Mullard A, 2020, NAT REV DRUG DISCOV, V19, P827, DOI 10.1038/d41573-020-00197-8; NISONOFF A, 1961, ARCH BIOCHEM BIOPHYS, V93, P460, DOI 10.1016/0003-9861(61)90296-X; Pavlinkova G, 1999, J NUCL MED, V40, P1536; Ramaprasad ASE, 2017, J AM CHEM SOC, V139, P17508, DOI 10.1021/jacs.7b09268; Raybould MIJ, 2019, P NATL ACAD SCI USA, V116, P4025, DOI 10.1073/pnas.1810576116; Ren-Heidenreich L, 2000, HUM GENE THER, V11, P9, DOI 10.1089/10430340050016111; Rodstrom KEJ, 2014, J IMMUNOL, V193, P1998, DOI 10.4049/jimmunol.1401268; Sedykh SE, 2018, DRUG DES DEV THER, V12, P195, DOI 10.2147/DDDT.S151282; Steinhardt JJ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03335-4; Sun TQ, 2020, ANAL CHIM ACTA, V1108, P28, DOI 10.1016/j.aca.2020.01.032; Varshney AK, 2013, J INFECT DIS, V208, P2058, DOI 10.1093/infdis/jit421; Wang Q, 2019, ANTIBODIES, V8, DOI 10.3390/antib8030043; Wei GH, 2016, CHEM REV, V116, P6516, DOI 10.1021/acs.chemrev.5b00562; Wong WK, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02454; Zhao J, 2019, MABS-AUSTIN, V11, P58, DOI 10.1080/19420862.2018.1522178; Zhao J, 2017, J BIOL CHEM, V292, P18325, DOI 10.1074/jbc.M117.801514; Zhao J, 2017, PROTEIN ENG DES SEL, V30, P67, DOI 10.1093/protein/gzw065; Zhou SJ, 2017, J CANCER, V8, P3689, DOI 10.7150/jca.19501	54	0	0	20	29	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 23	2021	12								732938	10.3389/fimmu.2021.732938	http://dx.doi.org/10.3389/fimmu.2021.732938			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XK7UC	34887850	gold, Green Published			2022-12-18	WOS:000727664700001
J	Li, JY; Yang, S; Liu, SH; Chen, YL; Liu, HY; Su, YZ; Liu, RC; Cui, YJ; Song, YJ; Teng, Y; Wang, T				Li, Jinyu; Yang, Shan; Liu, Sihua; Chen, Yulu; Liu, Hongyun; Su, Yazhi; Liu, Ruicun; Cui, Yujun; Song, Yajun; Teng, Yue; Wang, Tao			Transcriptomic Profiling Reveals a Role for TREM-1 Activation in Enterovirus D68 Infection-Induced Proinflammatory Responses	FRONTIERS IN IMMUNOLOGY			English	Article						Enterovirus D68; transcriptome; TREM-1 signaling; proinflammatory response; NF-kappa B signaling	NF-KAPPA-B; SIGNALING PATHWAYS; HUMAN NEUTROPHILS; MYELOID CELLS-1; MODULATION; EXPRESSION; RECEPTORS	Increasing cases related to the pathogenicity of Enterovirus D68 (EV-D68) have made it a growing worldwide public health concern, especially due to increased severe respiratory illness and acute flaccid myelitis (AFM) in children. There are currently no vaccines or medicines to prevent or treat EV-D68 infections. Herein, we performed genome-wide transcriptional profiling of EV-D68-infected human rhabdomyosarcoma (RD) cells to investigate host-pathogen interplay. RNA sequencing and subsequent experiments revealed that EV-D68 infection induced a profound transcriptional dysregulation of host genes, causing significantly elevated inflammatory responses and altered antiviral immune responses. In particular, triggering receptor expressed on myeloid cells 1 (TREM-1) is involved in highly activated TREM-1 signaling processes, acting as an important mediator in EV-D68 infection, and it is related to upregulation of interleukin 8 (IL-8), IL-6, IL-12p70, IL-1 beta, and tumor necrosis factor alpha (TNF-alpha). Further results demonstrated that NF-kappa B p65 was essential for EV-D68-induced TREM-1 upregulation. Moreover, inhibition of the TREM1 signaling pathway by the specific inhibitor LP17 dampened activation of the p38 mitogen-activated protein kinase (MAPK) signaling cascade, suggesting that TREM-1 mainly transmits activation signals to phosphorylate p38 MAPK. Interestingly, treatment with LP17 to inhibit TREM-1 inhibited viral replication and infection. These findings imply the pathogenic mechanisms of EV-D68 and provide critical insight into therapeutic intervention in enterovirus diseases.	[Li, Jinyu; Liu, Sihua; Liu, Hongyun; Su, Yazhi; Wang, Tao] Tianjin Univ, Sch Life Sci, Tianjin, Peoples R China; [Li, Jinyu; Yang, Shan; Chen, Yulu; Liu, Ruicun; Cui, Yujun; Song, Yajun; Teng, Yue] Beijing Inst Microbiol & Epidemiol, State Key Lab Pathogen & Biosecur, Beijing, Peoples R China; [Wang, Tao] Inst Tianjin Key Lab Funct & Applicat Biol Macrom, Tianjin, Peoples R China	Tianjin University; Beijing Institute of Microbiology & Epidemiology	Wang, T (corresponding author), Tianjin Univ, Sch Life Sci, Tianjin, Peoples R China.; Song, YJ; Teng, Y (corresponding author), Beijing Inst Microbiol & Epidemiol, State Key Lab Pathogen & Biosecur, Beijing, Peoples R China.; Wang, T (corresponding author), Inst Tianjin Key Lab Funct & Applicat Biol Macrom, Tianjin, Peoples R China.	songyajun88@aliyun.com; yueteng@sklpb.org; wangtaobio@tju.edu.cn	Wang, Tao/B-1331-2016		National Key Research and Development Program of China [2017YFA0205102]; State Key Laboratory of Pathogen and Biosecurity Program [SKLPBS2110]; National Science and Technology Major Project [2018ZX10101003-002-011]	National Key Research and Development Program of China; State Key Laboratory of Pathogen and Biosecurity Program; National Science and Technology Major Project	This work was supported by the National Key Research and Development Program of China (2017YFA0205102), the State Key Laboratory of Pathogen and Biosecurity Program (SKLPBS2110), and the National Science and Technology Major Project (2018ZX10101003-002-011).	Amrun SN, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-60761-5; Arts RJW, 2013, J LEUKOCYTE BIOL, V93, P209, DOI 10.1189/jlb.0312145; Beaurepaire C, 2005, MOL MICROBIOL, V57, P132, DOI 10.1111/j.1365-2958.2005.04688.x; Bouchon A, 2000, J IMMUNOL, V164, P4991, DOI 10.4049/jimmunol.164.10.4991; Cheng JY, 2020, J VIROL, V94, DOI 10.1128/JVI.02041-19; Colonna M, 2003, NAT REV IMMUNOL, V3, P445, DOI 10.1038/nri1106; Dyrdak R, 2016, EUROSURVEILLANCE, V21, P5, DOI 10.2807/1560-7917.ES.2016.21.46.30403; Elrick MJ, 2021, J BIOL CHEM, V296, DOI 10.1016/j.jbc.2021.100317; Evans WJ, 2019, ANTIVIR RES, V162, P61, DOI 10.1016/j.antiviral.2018.11.012; Ford JW, 2009, CURR OPIN IMMUNOL, V21, P38, DOI 10.1016/j.coi.2009.01.009; Fortin CF, 2007, INT IMMUNOL, V19, P41, DOI 10.1093/intimm/dxl119; Gibot S, 2008, CRIT CARE MED, V36, P504, DOI 10.1097/01.CCM.0B013E318161FAF3; Haselmayer P, 2007, BLOOD, V110, P1029, DOI 10.1182/blood-2007-01-069195; Haselmayer P, 2009, J INNATE IMMUN, V1, P582, DOI 10.1159/000231973; Hyun J, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007883; Ikuse T, 2021, PEDIATR INFECT DIS J, V40, P6, DOI 10.1097/INF.0000000000002889; Kang J, 2021, J VIROL, V95, DOI 10.1128/JVI.01856-20; Kramer A, 2014, BIOINFORMATICS, V30, P523, DOI 10.1093/bioinformatics/btt703; Kramer R, 2018, EUROSURVEILLANCE, V23, P12, DOI [10.2807/1560-7917, 10.2807/1560-7917.ES.2018.23.37.1700711]; Lei XB, 2010, J VIROL, V84, P8051, DOI 10.1128/JVI.02491-09; Li Y, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10100556; Liu ZZ, 2015, INT J NANOMED, V10, P2735, DOI 10.2147/IJN.S75188; Mohamadzadeh M, 2006, J VIROL, V80, P7235, DOI 10.1128/JVI.00543-06; Mukherjee A, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001311; Netea MG, 2006, J LEUKOCYTE BIOL, V80, P1454, DOI 10.1189/jlb.1205758; Oberste MS, 2004, J GEN VIROL, V85, P2577, DOI 10.1099/vir.0.79925-0; Rajput C, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.121882; Rao L, 2020, P NATL ACAD SCI USA, V117, P27141, DOI 10.1073/pnas.2014352117; Ruiz-Pacheco JA, 2014, IMMUNOL LETT, V158, P183, DOI 10.1016/j.imlet.2014.01.003; Saito T, 2007, CURR OPIN IMMUNOL, V19, P17, DOI 10.1016/j.coi.2006.11.003; SCHIEBLE JH, 1967, AM J EPIDEMIOL, V85, P297, DOI 10.1093/oxfordjournals.aje.a120693; Smee DF, 2016, ANTIVIR RES, V131, P61, DOI 10.1016/j.antiviral.2016.04.003; Suthar MS, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003168; Teng Y, 2019, BIOSAFETY HLTH, V1, P105, DOI [10.1016/j.bsheal.2019.11.001, DOI 10.1016/J.BSHEAL.2019.11.001]; Teng Y, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00327; Teng Y, 2015, SCI REP-UK, V5, DOI 10.1038/srep09912; Tessarz AAS, 2008, IMMUNOL LETT, V116, P111, DOI 10.1016/j.imlet.2007.11.021; Thompson AJ, 2007, IMMUNOL CELL BIOL, V85, P435, DOI 10.1038/sj.icb.7100100; Weber B, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003900; Xiang ZC, 2016, J VIROL, V90, P1613, DOI 10.1128/JVI.02395-15; Zarubin T, 2005, CELL RES, V15, P11, DOI 10.1038/sj.cr.7290257; Zeng H, 2007, EUR J IMMUNOL, V37, P2300, DOI 10.1002/eji.200737270; Zheng HW, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9050104	43	0	0	3	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 23	2021	12								749618	10.3389/fimmu.2021.749618	http://dx.doi.org/10.3389/fimmu.2021.749618			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XL2VC	34887856	gold, Green Published			2022-12-18	WOS:000728005900001
J	Marinelli, S; Maiaru, M; Colciago, A				Marinelli, Sara; Maiaru, Maria; Colciago, Alessandra			Editorial: Neuroinflammation and Neuroautoimmunity in Peripheral Neuropathies: Old Players, New Roles	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						peripheral neurodegeneration; neuropathic pain; neuroimmune crosstalk; glia; autoimme diseases; innate immunity; chronic and inflammatory pain; biomarkers			[Marinelli, Sara] CNR, Inst Biochem & Cell Biol, Monterotondo, Italy; [Maiaru, Maria] Univ Reading, Dept Pharmacol, Sch Pharm, Reading, Berks, England; [Colciago, Alessandra] Univ Milan, Dept Pharmacol & Biomol Sci, Milan, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Reading; University of Milan	Marinelli, S (corresponding author), CNR, Inst Biochem & Cell Biol, Monterotondo, Italy.	sara.marinelli@cnr.it	colciago, alessandra/GNP-1490-2022	colciago, alessandra/0000-0001-6281-514X; Marinelli, Sara/0000-0001-5393-4796				Baral P, 2019, NAT REV IMMUNOL, V19, P433, DOI 10.1038/s41577-019-0147-2; Bennett GJ, 2000, CLIN J PAIN, V16, pS139; Colciago A, 2020, FRONT NEUROSCI-SWITZ, V14, DOI 10.3389/fnins.2020.00796; Maiaru M, 2018, PAIN, V159, P1224, DOI 10.1097/j.pain.0000000000001204; Vacca V, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22094397	5	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 23	2021	12								801760	10.3389/fimmu.2021.801760	http://dx.doi.org/10.3389/fimmu.2021.801760			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XL2OQ	34887876	gold, Green Published			2022-12-18	WOS:000727988900001
J	Muefong, CN; Owolabi, O; Donkor, S; Charalambous, S; Mendy, J; Sey, ICM; Bakuli, A; Rachow, A; Geldmacher, C; Sutherland, JS				Muefong, Caleb Nwongbouwoh; Owolabi, Olumuyiwa; Donkor, Simon; Charalambous, Salome; Mendy, Joseph; Sey, Isatou C. M.; Bakuli, Abhishek; Rachow, Andrea; Geldmacher, Christof; Sutherland, Jayne S.			Major Neutrophil-Derived Soluble Mediators Associate With Baseline Lung Pathology and Post-Treatment Recovery in Tuberculosis Patients	FRONTIERS IN IMMUNOLOGY			English	Article						tuberculosis; neutrophils; myeloperoxidase; 9; MMP8; lung pathology	T-CELL RESPONSES; MYCOBACTERIUM-TUBERCULOSIS; INFLAMMATION; SUPPRESSION; SEVERITY; ELASTASE	BackgroundThe inflammatory response to Mycobacterium tuberculosis results in variable degrees of lung pathology during active TB (ATB) with central involvement of neutrophils. Little is known about neutrophil-derived mediators and their role in disease severity at baseline and recovery upon TB treatment initiation. Methods107 adults with confirmed pulmonary TB were categorised based on lung pathology at baseline and following successful therapy using chest X-ray scores (Ralph scores) and GeneXpert bacterial load (Ct values). Plasma, sputum, and antigen-stimulated levels of MMP1, MMP3, MMP8, MMP9, MPO, S100A8/9, IL8, IL10, IL12/23(p40), GM-CSF, IFN gamma, and TNF were analysed using multiplex cytokine arrays. ResultsAt baseline, neutrophil counts correlated with plasma levels of MMP8 (rho = 0.45, p = 2.80E-06), S100A8 (rho = 0.52, p = 3.00E-08) and GM-CSF (rho = 0.43, p = 7.90E-06). Levels of MMP8 (p = 3.00E-03), MMP1 (p = 1.40E-02), S100A8 (p = 1.80E-02) and IL12/23(p40) (p = 1.00E-02) were associated with severe lung damage, while sputum MPO levels were directly linked to lung damage (p = 1.80E-03), Mtb load (p = 2.10E-02) and lung recovery (p = 2.40E-02). Six months of TB therapy significantly decreased levels of major neutrophil-derived pro-inflammatory mediators: MMP1 (p = 4.90E-12 and p = 2.20E-07), MMP8 (p = 3.40E-14 and p = 1.30E-05) and MMP9 (p = 1.60E-04 and p = 1.50E-03) in plasma and sputum, respectively. Interestingly, following H37Rv whole cell lysate stimulation, S100A8 (p = 2.80E-02), MMP9 (p = 3.60E-02) and MPO (p = 9.10E-03) levels at month 6 were significantly higher compared to baseline. Sputum MMP1 (p = 1.50E-03), MMP3 (p = 7.58E-04), MMP9 (p = 2.60E-02) and TNF (p = 3.80E-02) levels were lower at month 6 compared to baseline in patients with good lung recovery. ConclusionIn this study, patients with severe lung pathology at baseline and persistent lung damage after treatment were associated with higher plasma and sputum levels of major pro-inflammatory neutrophil-derived mediators. Interestingly, low sputum MPO levels were associated with severe lung damage, higher Mtb burden and low recovery. Our data suggest that therapeutic agents which target these mediators should be considered for future studies on biomarkers and host-directed therapeutic approaches against TB-related lung pathology and/or lung recovery.	[Muefong, Caleb Nwongbouwoh; Owolabi, Olumuyiwa; Donkor, Simon; Mendy, Joseph; Sey, Isatou C. M.; Sutherland, Jayne S.] London Sch Hyg & Trop Med LSHTM, Med Res Council MRC Unit Gambia, Vaccines & Immun Theme, Fajara, Gambia; [Muefong, Caleb Nwongbouwoh; Bakuli, Abhishek; Rachow, Andrea; Geldmacher, Christof] Ludwig Maximilian Univ LMU Munich, Univ Hosp, Div Infect Dis & Trop Med, Munich, Germany; [Charalambous, Salome] Aurum Inst, Sch Publ Hlth, Johannesburg, South Africa; [Bakuli, Abhishek; Rachow, Andrea; Geldmacher, Christof] German Ctr Infect Res DZIF, Int Clin Trials Unit, Partner Site Munich, Munich, Germany	University of London; London School of Hygiene & Tropical Medicine; University of Munich; German Center for Infection Research	Muefong, CN (corresponding author), London Sch Hyg & Trop Med LSHTM, Med Res Council MRC Unit Gambia, Vaccines & Immun Theme, Fajara, Gambia.; Muefong, CN (corresponding author), Ludwig Maximilian Univ LMU Munich, Univ Hosp, Div Infect Dis & Trop Med, Munich, Germany.			Charalambous, Salome/0000-0001-7143-1009; Nwongbouwoh Muefong, Caleb/0000-0001-8817-9188; Sutherland, Jayne/0000-0002-7083-4997; Bakuli, Abhishek/0000-0001-5123-1974; Sey, Isatou/0000-0003-1590-2464	German Ministry for Education and Research (BMBF) [66.3010.7-002.00]	German Ministry for Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF))	This work was supported by a PhD student stipend from TB Sequel (grant number 66.3010.7-002.00) funded by the German Ministry for Education and Research (BMBF).	Andersson AM, 2020, J INNATE IMMUN, V12, P235, DOI 10.1159/000500861; Aomatsu M, 2013, BIOCHEM BIOPH RES CO, V441, P220, DOI 10.1016/j.bbrc.2013.10.042; Arnhold J, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21218057; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Berry MPR, 2010, NATURE, V466, P973, DOI 10.1038/nature09247; Borkute RR, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22094801; Cadena AM, 2017, NAT REV IMMUNOL, V17, P691, DOI 10.1038/nri.2017.69; Cassetta L, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-001223; Chakravorty S, 2017, MBIO, V8, DOI [10.1128/mBio.00812-17, 10.1128/mbio.00812-17]; Cheemarla NR, 2017, J LEUKOCYTE BIOL, V101, P1383, DOI 10.1189/jlb.4A1216-519RR; Cho YH, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-58237-7; Corleis B, 2012, CELL MICROBIOL, V14, P1109, DOI 10.1111/j.1462-5822.2012.01783.x; Day CL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094949; Day CL, 2011, J IMMUNOL, V187, P2222, DOI 10.4049/jimmunol.1101122; Dorhoi A, 2020, J CLIN INVEST, V130, P2789, DOI 10.1172/JCI136288; Doss PMIA, 2021, CELL REP, V34, DOI 10.1016/j.celrep.2021.108833; ELHAG A, 1987, J IMMUNOL, V139, P2406; Elkington PTG, 2006, THORAX, V61, P259, DOI 10.1136/thx.2005.051979; Ferrer G, 2021, LEUKEMIA, V35, P3163, DOI 10.1038/s41375-021-01249-7; Galeas-Pena M, 2019, BIOL CHEM, V400, P443, DOI 10.1515/hsz-2018-0304; Gemmati D, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21103474; Gideon HP, 2019, MUCOSAL IMMUNOL, V12, P1370, DOI 10.1038/s41385-019-0195-8; Gopal R, 2013, AM J RESP CRIT CARE, V188, P1137, DOI 10.1164/rccm.201304-0803OC; Greene CM, 2020, J INNATE IMMUN, V12, P1, DOI 10.1159/000504621; Hnizdo E, 2000, THORAX, V55, P32, DOI 10.1136/thorax.55.1.32; Horton KC, 2016, PLOS MED, V13, DOI [10.1371/journal.pmed.1002152, 10.1371/journal.pmed.1002119]; Jayaraman P, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005490; Khan N, 2017, CRIT REV MICROBIOL, V43, P133, DOI 10.1080/1040841X.2016.1185603; Khosa C, 2020, BMC PULM MED, V20, DOI 10.1186/s12890-020-1167-1; Klein SL, 2016, NAT REV IMMUNOL, V16, P626, DOI 10.1038/nri.2016.90; Kroon EE, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02637; Kumar NP, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-54803-w; Kumar NP, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-3246-y; Kumar V, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01722; Leem AY, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19523-7; Leukes V, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00451; Long R, 1998, CHEST, V113, P933, DOI 10.1378/chest.113.4.933; Lowe DM, 2013, EUR RESPIR J, V42, P1752, DOI 10.1183/09031936.00140913; Lyadova IV, 2017, MEDIAT INFLAMM, V2017, DOI 10.1155/2017/8619307; MacLean E, 2019, NAT MICROBIOL, V4, P748, DOI 10.1038/s41564-019-0380-2; Magcwebeba T, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00917; Mattila JT, 2015, CELL MICROBIOL, V17, P1085, DOI 10.1111/cmi.12428; Metzler KD, 2014, CELL REP, V8, P883, DOI 10.1016/j.celrep.2014.06.044; de Melo MGM, 2019, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03147; Mishra BB, 2017, NAT MICROBIOL, V2, DOI 10.1038/nmicrobiol.2017.72; Morrison H, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.640916; Muefong CN, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00962; Muefong CN, 2022, CLIN INFECT DIS, V74, P1757, DOI 10.1093/cid/ciab729; Munder M, 2006, BLOOD, V108, P1627, DOI 10.1182/blood-2006-11-010389; Murthy SE, 2018, BMC MED, V16, DOI 10.1186/s12916-018-1053-3; Neyrolles O, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000199; O'Garra A, 2013, ANNU REV IMMUNOL, V31, P475, DOI 10.1146/annurev-immunol-032712-095939; Ong CWM, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-29659-1; Ong CWM, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004917; Papayannopoulos V, 2010, J CELL BIOL, V191, P677, DOI 10.1083/jcb.201006052; Parveen S, 2021, J INFECT DIS, V224, P1962, DOI 10.1093/infdis/jiab235; Pillay J, 2013, CELL MOL LIFE SCI, V70, P3813, DOI 10.1007/s00018-013-1286-4; Pillay J, 2012, J CLIN INVEST, V122, P327, DOI 10.1172/JCI57990; R Core Team, 2021, R LANG ENV STAT COMP; Rachow A, 2019, BMC PULM MED, V19, DOI 10.1186/s12890-018-0777-3; Ralph AP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080302; Ralph AP, 2010, THORAX, V65, P863, DOI 10.1136/thx.2010.136242; Riou C, 2020, CLIN TRANSL IMMUNOL, V9, DOI 10.1002/cti2.1176; Sagiv JY, 2015, CELL REP, V10, P562, DOI 10.1016/j.celrep.2014.12.039; Scott NR, 2020, J CLIN INVEST, V130, P3098, DOI 10.1172/JCI130546; Shi S, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-43451-9; Sigal GB, 2017, EBIOMEDICINE, V25, P112, DOI 10.1016/j.ebiom.2017.10.018; Takeuchi K, 2012, INFLAMM RES, V61, P197, DOI 10.1007/s00011-011-0401-y; Ugarte-Gil CA, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0069514, 10.1371/journal.pone.0061333]; WHO, 2020, GLOBAL TUBERCULOSIS, V66, P37; Yang PQ, 2019, J IMMUNOL RES, V2019, DOI 10.1155/2019/8016254; Yang YH, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01371; Yipp BG, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aam8929; Yong YK, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.02789; Young C, 2020, MUCOSAL IMMUNOL, V13, P190, DOI 10.1038/s41385-019-0226-5	75	0	0	2	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 23	2021	12								740933	10.3389/fimmu.2021.740933	http://dx.doi.org/10.3389/fimmu.2021.740933			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XK7XJ	34887853	Green Published, gold, Green Accepted			2022-12-18	WOS:000727673200001
J	Smith, CIE; Brown, JR; Zain, R				Smith, C. I. Edvard; Brown, Jennifer R.; Zain, Rula			New Insights on Bruton's Tyrosine Kinase Inhibitors	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						BTK; ibrutinib; inhibitors; leukemia; lymphoma; Waldenstrom's macroglobulinemia; autoimmunity; structure-function			[Smith, C. I. Edvard; Zain, Rula] Karolinska Inst KI, Biomol & Cellular Med Clin Res Ctr, Dept Lab Med, Huddinge, Sweden; [Brown, Jennifer R.] Dana Farber Canc Inst, Chron Lymphocyt Leukemia Ctr, Div Med Oncol, Boston, MA 02115 USA; [Brown, Jennifer R.] Harvard Med Sch, Boston, MA 02115 USA; [Zain, Rula] Karolinska Univ Hosp, Ctr Rare Dis, Dept Clin Genet, Stockholm, Sweden	Karolinska Institutet; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Karolinska Institutet; Karolinska University Hospital	Smith, CIE (corresponding author), Karolinska Inst KI, Biomol & Cellular Med Clin Res Ctr, Dept Lab Med, Huddinge, Sweden.	edvard.smith@ki.se		SMITH, C. I. Edvard/0000-0003-1907-3392	Swedish Cancer Society; Stockholm County Council (ALF-project); Swedish Medical Research Council	Swedish Cancer Society(Swedish Cancer Society); Stockholm County Council (ALF-project)(Stockholm County Council); Swedish Medical Research Council(Swedish Medical Research Council (SMRC))	This work was supported by the Swedish Cancer Society, Stockholm County Council (ALF-project) and Swedish Medical Research Council.		0	0	0	1	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 23	2021	12								804735	10.3389/fimmu.2021.804735	http://dx.doi.org/10.3389/fimmu.2021.804735			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XL2UY	34887877	gold, Green Published			2022-12-18	WOS:000728005500001
J	Takasawa, K; Kanegane, H; Kashimada, K; Morio, T				Takasawa, Kei; Kanegane, Hirokazu; Kashimada, Kenichi; Morio, Tomohiro			Endocrinopathies in Inborn Errors of Immunity	FRONTIERS IN IMMUNOLOGY			English	Review						endocrinopathy; thyroiditis; diabetes mellitus; growth failure; inborn errors of immunity (IEIs); HCT	CHRONIC MUCOCUTANEOUS CANDIDIASIS; PRIMARY ADRENAL INSUFFICIENCY; STEM-CELL TRANSPLANTATION; LINKED SYNDROME IPEX; NF-KAPPA-B; GERMLINE MUTATIONS; DIABETES-MELLITUS; AUTOIMMUNE REGULATOR; CUSHINGS-SYNDROME; DEFICIENCY CAUSES	Inborn errors of immunity (IEI), caused by hereditary or genetic defects, are a group of more than 400 disorders, in which the immune system, including lymphocytes, neutrophils, macrophages, and complements, does not function properly. The endocrine system is frequently affected by IEI as an associated clinical feature and a complex network of glands which regulate many important body functions, including growth, reproduction, homeostasis, and energy regulation. Most endocrine disorders associated with IEI are hypofunction which would be treated with supplementation therapy, and early diagnosis and appropriate management are essential for favorable long-term outcomes in patients with IEI. In this review, we aimed to comprehensively summarize and discuss the current understanding on the clinical features and the pathophysiology of endocrine disorders in IEI. This review is composed with three parts. First, we discuss the two major pathophysiology of endocrinopathy in IEI, autoimmune response and direct effects of the responsible genes. Next, the details of each endocrinopathy, such as growth failure, hypothyroidism, hypoparathyroidism, adrenal insufficiency, diabetes mellitus (DM) are specified. We also illustrated potential endocrinopathy due to hematopoietic stem cell transplantation, including hypogonadism and adrenal insufficiency due to glucocorticoid therapy.	[Takasawa, Kei; Kashimada, Kenichi; Morio, Tomohiro] Tokyo Med & Dent Univ TMDU, Dept Pediat & Dev Biol, Tokyo, Japan; [Kanegane, Hirokazu] Tokyo Med & Dent Univ TMDU, Deparment Child Hlth Dev, Tokyo, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU)	Kashimada, K (corresponding author), Tokyo Med & Dent Univ TMDU, Dept Pediat & Dev Biol, Tokyo, Japan.			Takasawa, Kei/0000-0001-6947-4034				Aaltonen J, 1997, NAT GENET, V17, P399, DOI 10.1038/ng1297-399; AHONEN P, 1990, NEW ENGL J MED, V322, P1829, DOI 10.1056/NEJM199006283222601; Albarel F, 2015, EUR J ENDOCRINOL, V172, DOI 10.1530/EJE-14-0845; Amaya-Uribe L, 2019, J AUTOIMMUN, V99, P52, DOI 10.1016/j.jaut.2019.01.011; Bacchetta R, 2018, ANN NY ACAD SCI, V1417, P5, DOI 10.1111/nyas.13011; Barlow C, 1998, DEVELOPMENT, V125, P4007; Baud O, 2001, NEW ENGL J MED, V344, P1758, DOI 10.1056/NEJM200106073442304; Beltrand J, 2020, FRONT PEDIATR, V8, DOI 10.3389/fped.2020.540718; Bennett CL, 2001, NAT GENET, V27, P20, DOI 10.1038/83713; Blansfield JA, 2005, J IMMUNOTHER, V28, P593, DOI 10.1097/01.cji.0000178913.41256.06; Bonilla F., 2020, STIEHMS IMMUNE DEFIC, V2, P1157; Bornstein SR, 2016, J CLIN ENDOCR METAB, V101, P364, DOI 10.1210/jc.2015-1710; Bousfiha A, 2018, J CLIN IMMUNOL, V38, P129, DOI 10.1007/s10875-017-0465-8; Buonocore F, 2017, J CLIN INVEST, V127, P1700, DOI 10.1172/JCI91913; Caudy AA, 2007, J ALLERGY CLIN IMMUN, V119, P482, DOI 10.1016/j.jaci.2006.10.007; Cekic S, 2017, J CLIN IMMUNOL, V37, P524, DOI 10.1007/s10875-017-0412-8; Cepika AM, 2018, J ALLERGY CLIN IMMUN, V142, P1679, DOI 10.1016/j.jaci.2018.10.026; Chaimowitz NS, 2020, NEW ENGL J MED, V383, P1494, DOI 10.1056/NEJMc2022226; Charbonnier LM, 2015, J ALLERGY CLIN IMMUN, V135, P217, DOI 10.1016/j.jaci.2014.10.019; Chen K, 2013, AM J HUM GENET, V93, P812, DOI 10.1016/j.ajhg.2013.09.009; Cheng MH, 2013, CURR OPIN ENDOCRINOL, V20, P271, DOI 10.1097/MED.0b013e32836313eb; Chinn IK, 2020, J ALLERGY CLIN IMMUN, V145, P46, DOI 10.1016/j.jaci.2019.09.009; Cohen AC, 2006, J IMMUNOL, V177, P2770, DOI 10.4049/jimmunol.177.5.2770; Constantine GM, 2019, IMMUNOL REV, V287, P103, DOI 10.1111/imr.12714; Daw SCM, 1996, NAT GENET, V13, P458, DOI 10.1038/ng0896-458; Deau MC, 2014, J CLIN INVEST, V124, P3923, DOI 10.1172/JCI75746; Dittmar M, 2003, J CLIN ENDOCR METAB, V88, P2983, DOI 10.1210/jc.2002-021845; Donath H, 2020, FRONT PEDIATR, V8, DOI 10.3389/fped.2020.00317; Farmer JR, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01740; Flanagan SE, 2014, NAT GENET, V46, P812, DOI 10.1038/ng.3040; Fluck CE, 2017, EUR J ENDOCRINOL, V177, pR99, DOI 10.1530/EJE-17-0128; Fontenot JD, 2017, J IMMUNOL, V198, P986, DOI 10.1038/ni904; Fujino H, 2019, INT J HEMATOL, V109, P578, DOI 10.1007/s12185-019-02627-9; Gambineri E, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02411; Gilmore TD, 2006, ONCOGENE, V25, P6680, DOI 10.1038/sj.onc.1209954; Gineau L, 2012, J CLIN INVEST, V122, P821, DOI 10.1172/JCI61014; Goyal R, 2009, CURR OPIN RHEUMATOL, V21, P78, DOI 10.1097/BOR.0b013e32831cb939; Green DM, 2014, LANCET ONCOL, V15, P1215, DOI 10.1016/S1470-2045(14)70408-5; Haapaniemi EM, 2015, BLOOD, V125, P639, DOI 10.1182/blood-2014-04-570101; Hage C, 2021, NAT REV ENDOCRINOL, V17, P608, DOI 10.1038/s41574-021-00539-5; HALL BD, 1979, J PEDIATR-US, V95, P395, DOI 10.1016/S0022-3476(79)80513-2; Hasegawa T, 1997, AM J MED GENET, V73, P416, DOI 10.1002/(SICI)1096-8628(19971231)73:4<416::AID-AJMG9>3.0.CO;2-L; Heino M, 2001, HUM MUTAT, V18, P205, DOI 10.1002/humu.1176; Herrington J, 2000, ONCOGENE, V19, P2585, DOI 10.1038/sj.onc.1203526; HITTNER HM, 1979, J PEDIAT OPHTH STRAB, V16, P122; Hopkins RL, 2005, ENDOCRIN METAB CLIN, V34, P371, DOI 10.1016/j.ecl.2005.01.013; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Hori T, 2019, CLIN PEDIATR ENDOCRI, V28, P91, DOI 10.1297/cpe.28.91; Huber G, 2002, J CLIN ENDOCR METAB, V87, P3221, DOI 10.1210/jc.87.7.3221; Hughes CR, 2012, J CLIN INVEST, V122, P814, DOI 10.1172/JCI60224; Husebye ES, 2021, LANCET, V397, P613, DOI 10.1016/S0140-6736(21)00136-7; Husebye ES, 2010, IMMUNITY, V32, P479, DOI 10.1016/j.immuni.2010.03.016; Hwa V, 2016, GROWTH HORM IGF RES, V28, P16, DOI 10.1016/j.ghir.2015.12.006; Johnson MB, 2017, DIABETES, V66, P2316, DOI 10.2337/db17-0040; Kadowaki S, 2021, ARTHRITIS RES THER, V23, DOI 10.1186/s13075-021-02434-w; Kahn JM, 2020, BLOOD ADV, V4, P2084, DOI 10.1182/bloodadvances.2019000839; Kim S, 2007, DIABETES, V56, P2561, DOI 10.2337/db06-1372; Kisand K, 2010, J EXP MED, V207, P299, DOI 10.1084/jem.20091669; Klein C, 2007, NAT GENET, V39, P86, DOI 10.1038/ng1940; Klemann C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00297; Kuehn HS, 2014, SCIENCE, V345, P1623, DOI 10.1126/science.1255904; Lalani SR, 2006, AM J HUM GENET, V78, P303, DOI 10.1086/500273; Lee CE, 2014, BLOOD, V124, P2964, DOI 10.1182/blood-2014-06-578542; Leger J, 2014, BEST PRACT RES CL EN, V28, P233, DOI 10.1016/j.beem.2013.08.008; Leiper A, 2020, BONE MARROW TRANSPL, V55, P1985, DOI 10.1038/s41409-020-0866-9; Lima K, 2011, EUR J ENDOCRINOL, V165, P345, DOI 10.1530/EJE-10-1206; Limbach M, 2016, J AUTOIMMUN, V67, P46, DOI 10.1016/j.jaut.2015.09.006; Liu LY, 2011, J EXP MED, V208, P1635, DOI 10.1084/jem.20110958; Lodish MB, 2018, ENDOCRIN METAB CLIN, V47, P451, DOI 10.1016/j.ecl.2018.02.008; Lowe CE, 2007, NAT GENET, V39, P1074, DOI 10.1038/ng2102; Madden LM, 2016, BIOL BLOOD MARROW TR, V22, P1467, DOI 10.1016/j.bbmt.2016.04.025; Mannstadt M, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.55; Mehr S, 2017, AM J MED GENET C, V175, P516, DOI 10.1002/ajmg.c.31594; Minegishi Y, 2007, NATURE, V448, P1058, DOI 10.1038/nature06096; Miyamoto S, 2021, J CLIN IMMUNOL, V41, P1865, DOI 10.1007/s10875-021-01112-5; Mohammadi J, 2010, J CLIN IMMUNOL, V30, P138, DOI 10.1007/s10875-009-9336-2; MORI S, 1990, CLIN GENET, V38, P387; Nagamachi A, 2013, CANCER CELL, V24, P305, DOI 10.1016/j.ccr.2013.08.011; Nagamine K, 1997, NAT GENET, V17, P393, DOI 10.1038/ng1297-393; Nakagawa R, 2018, J DIABETES, V10, P421, DOI 10.1111/1753-0407.12638; Narumi S, 2016, NAT GENET, V48, P792, DOI 10.1038/ng.3569; Nissenkorn A, 2016, PEDIATR RES, V79, P889, DOI 10.1038/pr.2016.19; Nistico L, 1996, HUM MOL GENET, V5, P1075, DOI 10.1093/hmg/5.7.1075; Ochs HD, 2009, J ALLERGY CLIN IMMUN, V123, P977, DOI 10.1016/j.jaci.2009.03.030; Ogishi M, 2021, NAT MED, V27, P1646, DOI 10.1038/s41591-021-01388-5; Ono S, 2021, J ALLER CL IMM-PRACT, V9, P3767, DOI 10.1016/j.jaip.2021.05.045; Park JH, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102526; Peters C, 2018, EUR J ENDOCRINOL, V179, pR297, DOI 10.1530/EJE-18-0383; Pinto G, 2005, J CLIN ENDOCR METAB, V90, P5621, DOI 10.1210/jc.2004-2474; Puel A, 2010, J EXP MED, V207, P291, DOI 10.1084/jem.20091983; Ragusa F, 2019, BEST PRACT RES CL EN, V33, DOI 10.1016/j.beem.2019.101367; Rao K, 2005, BLOOD, V105, P879, DOI 10.1182/blood-2004-03-0960; Leonel ECR, 2019, TRANSFUS MED HEMOTH, V46, P173, DOI 10.1159/000499054; Rushworth RL, 2019, NEW ENGL J MED, V381, P852, DOI 10.1056/NEJMra1807486; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Schubert D, 2014, NAT MED, V20, P1410, DOI 10.1038/nm.3746; Singh K, 2014, AUTOIMMUN REV, V13, P163, DOI 10.1016/j.autrev.2013.10.005; Struja T, 2017, BMC MED, V15, DOI 10.1186/s12916-017-0939-9; Sullivan Keith M., 2000, Hematology Am Soc Hematol Educ Program, P319; Sutani A, 2019, CLIN PEDIATR ENDOCRI, V28, P105, DOI 10.1297/cpe.28.105; Svensson M, 2006, DIABETES CARE, V29, P538, DOI 10.2337/diacare.29.03.06.dc05-1531; Szeliga A, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22052594; Takagi M, 2015, CELL REP, V10, P957, DOI 10.1016/j.celrep.2015.01.027; Tangye SG, 2020, J CLIN IMMUNOL, V40, P24, DOI 10.1007/s10875-019-00737-x; Uzel G, 2013, J ALLERGY CLIN IMMUN, V131, P1611, DOI 10.1016/j.jaci.2012.11.054; VANDERPUMP MPJ, 1995, CLIN ENDOCRINOL, V43, P55, DOI 10.1111/j.1365-2265.1995.tb01894.x; Verma N, 2017, CLIN EXP IMMUNOL, V190, P1, DOI 10.1111/cei.12997; Walter JE, 2019, CURR OPIN PEDIATR, V31, P851, DOI 10.1097/MOP.0000000000000833; Westermann-Clark E, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.649182; Wildin RS, 2001, NAT GENET, V27, P18, DOI 10.1038/83707; WINQVIST O, 1992, LANCET, V339, P1559, DOI 10.1016/0140-6736(92)91829-W; Wit JM, 2021, HORM RES PAEDIAT, DOI 10.1159/000516407; Wolff ASB, 2015, GENES IMMUN, V16, P430, DOI 10.1038/gene.2015.27; Wong JC, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.121086; Yamashita M, 2021, INFLAMM REGEN, V41, DOI 10.1186/s41232-021-00159-6; Yamauchi T, 2019, PEDIATR DIABETES, V20, P1035, DOI 10.1111/pedi.12895; Yin XM, 2007, ANN NY ACAD SCI, V1110, P193, DOI 10.1196/annals.1423.021; Zaloga GP, 2001, CRIT CARE CLIN, V17, P25, DOI 10.1016/S0749-0704(05)70150-0; Zhang WJ, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.654406	119	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 23	2021	12								786241	10.3389/fimmu.2021.786241	http://dx.doi.org/10.3389/fimmu.2021.786241			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XK7GK	34887872	gold, Green Published			2022-12-18	WOS:000727629100001
J	Tu, TY; Yeh, CY; Hung, YM; Chang, RN; Chen, HH; Wei, JCC				Tu, Ting-Yu; Yeh, Chiu-Yu; Hung, Yao-Min; Chang, Renin; Chen, Hsin-Hua; Wei, James Cheng-Chung			Association Between a History of Nontyphoidal Salmonella and the Risk of Systemic Lupus Erythematosus: A Population-Based, Case-Control Study	FRONTIERS IN IMMUNOLOGY			English	Article						nontyphoidal Salmonella; systemic lupus erythematosus; NHIRD; case-control study; immunology; NTS; SLE; epidemiology	RHEUMATOID-ARTHRITIS; GLOBAL BURDEN; CELLS; INTERFERON; DISEASE; IL-17; INFECTIONS; SYMPTOMS; OUTBREAK; MICE	ObjectiveWe investigated the correlation between nontyphoidal Salmonella (NTS) infection and systemic lupus erythematosus (SLE) risk. MethodsThis case-control study comprised 6,517 patients with newly diagnosed SLE between 2006 and 2013. Patients without SLE were randomly selected as the control group and were matched at a case-control ratio of 1:20 by age, sex, and index year. All study individuals were traced from the index date back to their NTS exposure, other relevant covariates, or to the beginning of year 2000. Conditional logistic regression analysis was used to analyze the risk of SLE with adjusted odds ratios (aORs) and 95% confidence intervals (CIs) between the NTS and control groups. ResultsThe mean age was 37.8 years in the case and control groups. Females accounted for 85.5%. The aOR of having NTS infection were significantly increased in SLE relative to controls (aOR, 9.20; 95% CI, 4.51-18.78) in 1:20 sex-age matching analysis and (aOR, 7.47; 95% CI=2.08-26.82) in propensity score matching analysis. Subgroup analysis indicated that the SLE risk was high among those who dwelled in rural areas; had rheumatoid arthritis, multiple sclerosis, or Sjogren's syndrome; and developed intensive and severe NTS infection during admission. ConclusionsExposure to NTS infection is associated with the development of subsequent SLE in Taiwanese individuals. Severe NTS infection and other autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, or Sjogren's syndrome also contributed to the risk of developing SLE.	[Tu, Ting-Yu] Kaohsiung Vet Gen Hosp, Dept Orthped, Kaohsiung, Taiwan; [Yeh, Chiu-Yu] Kaohsiung Med Univ, Sch Med, Dept Med, Kaohsiung, Taiwan; [Hung, Yao-Min] Meiho Univ, Coll Hlth & Nursing, Pingtung, Taiwan; [Hung, Yao-Min; Wei, James Cheng-Chung] Chung Shan Med Univ, Inst Med, Taichung, Taiwan; [Hung, Yao-Min] Kaohsiung Municipal United Hosp, Dept Internal Med, Kaohsiung, Taiwan; [Hung, Yao-Min; Chen, Hsin-Hua] Natl Yang Ming Univ, Sch Med, Taipei, Taiwan; [Chang, Renin] Kaohsiung Vet Gen Hosp, Dept Emergency Med, Kaohsiung, Taiwan; [Chen, Hsin-Hua] Taichung Vet Gen Hosp, Dept Internal Med, Div Allergy Immunol & Rheumatol, Div Gen Internal Med, Taichung, Taiwan; [Chen, Hsin-Hua] Chung Hsing Univ, Inst Biomed Sci, Taichung, Taiwan; [Chen, Hsin-Hua] Chung Hsing Univ, Rong Hsing Res Ctr Translat Med, Taichung, Taiwan; [Chen, Hsin-Hua] Tunghai Univ, Dept Ind Engn & Enterprise Informat, Taichung, Taiwan; [Chen, Hsin-Hua] Natl Yang Ming Univ, Inst Publ Hlth, Taipei, Taiwan; [Chen, Hsin-Hua] Natl Yang Ming Univ, Community Med Res Ctr, Taipei, Taiwan; [Wei, James Cheng-Chung] China Med Univ, Grad Inst Integrated Med, Taichung, Taiwan; [Wei, James Cheng-Chung] Chung Shan Med Univ Immunol & Rheumatol, Div Allergy, Taichung, Taiwan; [Wei, James Cheng-Chung] Chung Shan Med Univ Immunol & Rheumatol, Inst Med, Taichung, Taiwan	Kaohsiung Veterans General Hospital; Kaohsiung Medical University; Chung Shan Medical University; National Yang Ming Chiao Tung University; Kaohsiung Veterans General Hospital; Taichung Veterans General Hospital; National Chung Hsing University; National Chung Hsing University; Tunghai University; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; China Medical University Taiwan	Wei, JCC (corresponding author), Chung Shan Med Univ, Inst Med, Taichung, Taiwan.; Chen, HH (corresponding author), Natl Yang Ming Univ, Sch Med, Taipei, Taiwan.; Chang, RN (corresponding author), Kaohsiung Vet Gen Hosp, Dept Emergency Med, Kaohsiung, Taiwan.; Chen, HH (corresponding author), Taichung Vet Gen Hosp, Dept Internal Med, Div Allergy Immunol & Rheumatol, Div Gen Internal Med, Taichung, Taiwan.; Chen, HH (corresponding author), Chung Hsing Univ, Inst Biomed Sci, Taichung, Taiwan.; Chen, HH (corresponding author), Chung Hsing Univ, Rong Hsing Res Ctr Translat Med, Taichung, Taiwan.; Chen, HH (corresponding author), Tunghai Univ, Dept Ind Engn & Enterprise Informat, Taichung, Taiwan.; Chen, HH (corresponding author), Natl Yang Ming Univ, Inst Publ Hlth, Taipei, Taiwan.; Chen, HH (corresponding author), Natl Yang Ming Univ, Community Med Res Ctr, Taipei, Taiwan.; Wei, JCC (corresponding author), China Med Univ, Grad Inst Integrated Med, Taichung, Taiwan.; Wei, JCC (corresponding author), Chung Shan Med Univ Immunol & Rheumatol, Div Allergy, Taichung, Taiwan.; Wei, JCC (corresponding author), Chung Shan Med Univ Immunol & Rheumatol, Inst Med, Taichung, Taiwan.	rhapsody1881@gmail.com; shc5555@hotmail.com; wei3228@gmail.com						Apostolidis SA, 2011, J INTERF CYTOK RES, V31, P769, DOI 10.1089/jir.2011.0029; Azzouz D, 2019, ANN RHEUM DIS, V78, P947, DOI 10.1136/annrheumdis-2018-214856; Bae SC, 2020, Z RHEUMATOL, V79, P929, DOI 10.1007/s00393-019-00742-w; Behnsen J, 2015, TRENDS IMMUNOL, V36, P112, DOI 10.1016/j.it.2014.12.003; Burstyn I, 2014, INT J ENV RES PUB HE, V11, P10951, DOI 10.3390/ijerph111010951; Carter EE, 2016, NAT REV RHEUMATOL, V12, P605, DOI 10.1038/nrrheum.2016.137; Chan VSF, 2012, AUTOIMMUN REV, V11, P890, DOI 10.1016/j.autrev.2012.03.004; Chung WS, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-08858-4; Cooper GS, 1999, ENVIRON HEALTH PERSP, V107, P693, DOI 10.2307/3434329; Costa-Reis P, 2013, CLIN IMMUNOL, V149, P442, DOI 10.1016/j.clim.2013.08.009; Crispin JC, 2008, J IMMUNOL, V181, P8761, DOI 10.4049/jimmunol.181.12.8761; de Jong HK, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002933; DEAPEN D, 1992, ARTHRITIS RHEUM, V35, P311; Dhanoa A, 2009, ANN CLIN MICROB ANTI, V8, DOI 10.1186/1476-0711-8-15; Doreau A, 2009, NAT IMMUNOL, V10, P778, DOI 10.1038/ni.1741; EP A., 2021, REAL TIM AIR QUAL PO; FROLOV VM, 1989, KLIN MED MOSCOW+, V67, P108; Fu ZQ, 2020, ENVIRON SCI POLLUT R, V27, P29218, DOI 10.1007/s11356-020-09242-w; Gallo PM, 2015, IMMUNITY, V42, P1171, DOI 10.1016/j.immuni.2015.06.002; Gomez A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036095; Gould LH, 2013, MMWR SURVEILL SUMM, V62, P1; Gulati G, 2018, SEMIN ARTHRITIS RHEU, V47, P710, DOI 10.1016/j.semarthrit.2017.10.001; Hannu T, 2002, ANN RHEUM DIS, V61, P264, DOI 10.1136/ard.61.3.264; Huang HH, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-330; Issac JM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01384; Kerstein A, 2017, J AUTOIMMUN, V78, P79, DOI 10.1016/j.jaut.2016.12.004; Kuo CF, 2015, JAMA INTERN MED, V175, P1518, DOI 10.1001/jamainternmed.2015.3528; Langrish CL, 2005, J EXP MED, V201, P233, DOI 10.1084/jem.20041257; Lee CC, 2020, ANTIBIOTICS-BASEL, V9, DOI 10.3390/antibiotics9110807; Lee YH, 2015, RHEUMATOL INT, V35, P953, DOI 10.1007/s00296-014-3155-3; Li H, 2015, J CLIN INVEST, V125, P2877, DOI 10.1172/JCI81059; Lit LCW, 2007, J RHEUMATOL, V34, P89; Liu X, 2017, ADV IMMUNOL, V135, P81, DOI 10.1016/bs.ai.2017.02.002; Locht H, 2002, J RHEUMATOL, V29, P767; Ma CY, 2019, CLIN IMMUNOL, V207, P1, DOI 10.1016/j.clim.2019.06.009; Majowicz SE, 2010, CLIN INFECT DIS, V50, P882, DOI 10.1086/650733; Mastroeni P, 1999, INFECT IMMUN, V67, P478, DOI 10.1128/IAI.67.2.478-483.1999; Mauri C, 2015, J CLIN INVEST, V125, P2562, DOI 10.1172/JCI82574; Meszaros ZS, 2012, J CLIN PSYCHIAT, V73, P993, DOI [10.4088/JCP.11r07425, 10.4088/JCP.11m07043]; Mitsdoerffer M, 2010, P NATL ACAD SCI USA, V107, P14292, DOI 10.1073/pnas.1009234107; MoHa W., 2021, NUMBER LOW INCOME HO; Monack DM, 2004, J EXP MED, V199, P231, DOI 10.1084/jem.20031319; Balbi GGM, 2018, CURR OPIN RHEUMATOL, V30, P395, DOI 10.1097/BOR.0000000000000493; Navarra SV, 2010, LUPUS, V19, P1419, DOI 10.1177/0961203310374486; Nikitakis NG, 2017, ORAL DIS, V23, P828, DOI 10.1111/odi.12589; O'Donnell H, 2014, IMMUNITY, V40, P213, DOI 10.1016/j.immuni.2013.12.013; Ochoa-Reparaz J, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a029017; Ouyang WJ, 2008, IMMUNITY, V28, P454, DOI 10.1016/j.immuni.2008.03.004; Pasoto SG, 2019, OPEN ACCESS RHEUMATO, V11, P33, DOI 10.2147/OARRR.S167783; Qiu CC, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02608; Ramsey Scott D, 2006, Proc Am Thorac Soc, V3, P635, DOI 10.1513/pats.200603-094SS; SELA O, 1987, ARTHRITIS RHEUM-US, V30, P50, DOI 10.1002/art.1780300107; Sepulveda-Toepfer JA, 2019, HUM VACC IMMUNOTHER, V15, P179, DOI 10.1080/21645515.2018.1514223; Shah D, 2014, J BIOMED SCI, V21, DOI 10.1186/1423-0127-21-23; Soloski Mark J, 2007, EcoSal Plus, V2, DOI 10.1128/ecosalplus.8.8.13; Stern ME, 2013, INT REV IMMUNOL, V32, P19, DOI 10.3109/08830185.2012.748052; Sun FF, 2019, LUPUS SCI MED, V6, DOI 10.1136/lupus-2019-000339; Takatori H, 2009, J EXP MED, V206, P35, DOI 10.1084/jem.20072713; UPTODATE, 2021, NONTYPH SALM GASTR I; Weinstein A, 1980, Prog Clin Immunol, V4, P1; Wong CK, 2000, LUPUS, V9, P589, DOI 10.1191/096120300678828703; World Health Organization,, 2006, REG OFF E AIR Q GUID; Yen EY, 2018, ARTHRITIS RHEUMATOL, V70, P1251, DOI 10.1002/art.40512; Zhang X, 2015, NAT MED, V21, P895, DOI 10.1038/nm.3914; Zhong HJ, 2020, LUPUS, V29, P1189, DOI 10.1177/0961203320938447	65	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 23	2021	12								725996	10.3389/fimmu.2021.725996	http://dx.doi.org/10.3389/fimmu.2021.725996			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XK7WE	34887848	gold, Green Published			2022-12-18	WOS:000727670100001
J	Zhang, HX; Zhang, YY; Li, YF; Wang, YL; Yan, S; Xu, S; Deng, ZL; Yang, XL; Xie, HF; Li, J				Zhang, Huaxiong; Zhang, Yiya; Li, Yangfan; Wang, Yaling; Yan, Sha; Xu, San; Deng, Zhili; Yang, Xinling; Xie, Hongfu; Li, Ji			Bioinformatics and Network Pharmacology Identify the Therapeutic Role and Potential Mechanism of Melatonin in AD and Rosacea	FRONTIERS IN IMMUNOLOGY			English	Article						rosacea; AD; MLT; network pharmacology; inflammation; angiogenesis	ENDOTHELIAL-CELLS; ANGIOGENESIS; EXPRESSION; PATHOPHYSIOLOGY; PATHOGENESIS; RISK	Rosacea is significantly associated with dementia, particularly Alzheimer's disease (AD). However, the common underlying molecular mechanism connecting these two diseases remains limited. This study aimed to reveal the common molecular regulatory networks and identify the potential therapeutic drugs for rosacea and AD. There were 747 overlapped DEGs (ol-DEGs) that were detected in AD and rosacea, enriched in inflammation-, metabolism-, and apoptosis-related pathways. Using the TF regulatory network analysis, 37 common TFs and target genes were identified as hub genes. They were used to predict the therapeutic drugs for rosacea and AD using the DGIdb/CMap database. Among the 113 predicted drugs, melatonin (MLT) was co-associated with both RORA and IFN-gamma in AD and rosacea. Subsequently, network pharmacology analysis identified 19 pharmacological targets of MLT and demonstrated that MLT could help in treating AD/rosacea partly by modulating inflammatory and vascular signaling pathways. Finally, we verified the therapeutic role and mechanism of MLT on rosacea in vivo and in vitro. We found that MLT treatment significantly improved rosacea-like skin lesion by reducing keratinocyte-mediated inflammatory cytokine secretion and repressing the migration of HUVEC cells. In conclusion, this study contributes to common pathologies shared by rosacea and AD and identified MLT as an effective treatment strategy for rosacea and AD via regulating inflammation and angiogenesis.	[Zhang, Huaxiong; Xie, Hongfu; Li, Ji] Xinjiang Med Univ, Affiliated Hosp 2, Dept Dermatol, Urumqi, Peoples R China; [Zhang, Huaxiong; Zhang, Yiya; Li, Yangfan; Wang, Yaling; Yan, Sha; Xu, San; Deng, Zhili; Xie, Hongfu; Li, Ji] Cent South Univ, Xiangya Hosp, Dept Dermatol, Changsha, Peoples R China; [Zhang, Huaxiong; Yang, Xinling] Xinjiang Med Univ, Affiliated Hosp 2, Dept Neurol, Urumqi, Peoples R China; [Zhang, Yiya; Li, Yangfan; Wang, Yaling; Yan, Sha; Xu, San; Deng, Zhili; Xie, Hongfu; Li, Ji] Cent South Univ, Xiangya Hosp, Hunan Key Lab Aging Biol, Changsha, Peoples R China; [Zhang, Yiya; Xu, San; Deng, Zhili; Li, Ji] Cent South Univ, Xiangya Hosp, Natl Clin Res Ctr Geriatr Disorders, Changsha, Peoples R China	Xinjiang Medical University; Central South University; Xinjiang Medical University; Central South University; Central South University	Zhang, HX; Li, J (corresponding author), Xinjiang Med Univ, Affiliated Hosp 2, Dept Dermatol, Urumqi, Peoples R China.; Zhang, HX; Li, J (corresponding author), Cent South Univ, Xiangya Hosp, Dept Dermatol, Changsha, Peoples R China.; Li, J (corresponding author), Cent South Univ, Xiangya Hosp, Hunan Key Lab Aging Biol, Changsha, Peoples R China.; Li, J (corresponding author), Cent South Univ, Xiangya Hosp, Natl Clin Res Ctr Geriatr Disorders, Changsha, Peoples R China.	yiya0108@csu.edu.cn; liji_xy@csu.edu.cn	Yang, xinling/HHC-1621-2022		National Natural Sciences Foundation of Hunan Province [2020JJ5950]; National Natural Science Foundation of China [81703149, 82073457]; Science and Technology Innovation Plan of Hunan Province [2018SK2087]	National Natural Sciences Foundation of Hunan Province; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Innovation Plan of Hunan Province	Funding This work was supported by the National Natural Sciences Foundation of Hunan Province (2020JJ5950), the National Natural Science Foundation of China (81703149 and 82073457), and the Science and Technology Innovation Plan of Hunan Province (No. 2018SK2087).	Acquaah-Mensah GK, 2015, J ALZHEIMERS DIS, V44, P827, DOI 10.3233/JAD-141731; Ali T, 2015, J PINEAL RES, V58, P71, DOI 10.1111/jpi.12194; Aroni K, 2008, ARCH DERMATOL RES, V300, P125, DOI 10.1007/s00403-007-0816-z; Bandyopadhyay S, 2021, FRONT AGING NEUROSCI, V13, DOI 10.3389/fnagi.2021.653334; Binion DG, 2008, GUT, V57, P1509, DOI 10.1136/gut.2008.152496; Buhl T, 2015, J INVEST DERMATOL, V135, P2198, DOI 10.1038/jid.2015.141; Bui TM, 2020, J LEUKOCYTE BIOL, V108, P787, DOI 10.1002/JLB.2MR0220-549R; Byun JK, 2015, HEPATOLOGY, V61, P953, DOI 10.1002/hep.27577; Chen DM, 2020, J PINEAL RES, V69, DOI 10.1111/jpi.12665; Chen JJ, 2020, FRONT AGING NEUROSCI, V12, DOI 10.3389/fnagi.2020.566922; Chen MT, 2019, BIOMED PHARMACOTHER, V116, DOI 10.1016/j.biopha.2019.109011; Chen Q, 2020, J AM ACAD DERMATOL, V83, P1331, DOI 10.1016/j.jaad.2020.04.113; Cotto Kelsy C, 2018, Nucleic Acids Res, V46, pD1068, DOI 10.1093/nar/gkx1143; Dekens DW, 2021, AGEING RES REV, V70, DOI 10.1016/j.arr.2021.101414; Dong XM, 2021, ARTHRITIS RHEUMATOL, V73, P478, DOI 10.1002/art.41532; Egeberg A, 2016, ANN NEUROL, V79, P921, DOI 10.1002/ana.24645; Ferracioli-Oda E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063773; Freshour SL, 2021, NUCLEIC ACIDS RES, V49, pD1144, DOI 10.1093/nar/gkaa1084; Gether L, 2018, BRIT J DERMATOL, V179, P282, DOI 10.1111/bjd.16481; Guo QY, 2015, ACTA HISTOCHEM, V117, P559, DOI 10.1016/j.acthis.2015.05.002; Hara-Chikuma M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8454; Hardeland R, 2018, J PINEAL RES, V65, DOI 10.1111/jpi.12525; Harden JL, 2021, J INVEST DERMATOL, V141, P800, DOI 10.1016/j.jid.2020.08.013; He F, 2021, J MED CHEM, V64, P3794, DOI 10.1021/acs.jmedchem.0c01940; Hossain MF, 2021, AGEING RES REV, V67, DOI 10.1016/j.arr.2021.101304; Jamwal S, 2021, PHARMACOL THERAPEUT, V219, DOI 10.1016/j.pharmthera.2020.107705; Janelidze S, 2018, NEUROLOGY, V91, pE867, DOI 10.1212/WNL.0000000000006082; Jauhari A, 2020, J CLIN INVEST, V130, P3124, DOI 10.1172/JCI135026; Jirawatnotai S, 2012, CANCER RES, V72, P4289, DOI 10.1158/0008-5472.CAN-11-3549; Kaltschmidt B, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a001271; Koy EHS, 2021, THER ADV MUSCULOSKEL, V13, DOI 10.1177/1759720X211025894; Kuklina EM, 2014, MED HYPOTHESES, V83, P404, DOI 10.1016/j.mehy.2014.07.006; Kulkarni NN, 2020, J INVEST DERMATOL, V140, P645, DOI 10.1016/j.jid.2019.08.436; Li R, 2021, BRIEF BIOINFORM, V22, P1279, DOI 10.1093/bib/bbaa300; Lian H, 2015, NEURON, V85, P101, DOI 10.1016/j.neuron.2014.11.018; Linford NJ, 2007, AGING CELL, V6, P673, DOI 10.1111/j.1474-9726.2007.00319.x; Liu B, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-24352-w; Lok R, 2019, J PINEAL RES, V67, DOI 10.1111/jpi.12583; Ma Q, 2020, ANGIOGENESIS, V23, P91, DOI 10.1007/s10456-019-09689-7; Majidinia M, 2018, AGEING RES REV, V47, P198, DOI 10.1016/j.arr.2018.07.010; Mann AP, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01096-0; Marseglia L, 2015, J Biol Regul Homeost Agents, V29, P142; McQuade A, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19227-5; Mobius C, 2005, EJSO, V31, P755, DOI 10.1016/j.ejso.2005.01.006; Morinobu A, 2002, P NATL ACAD SCI USA, V99, P12281, DOI 10.1073/pnas.182618999; Pei JP, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.705511; Pi JJ, 2018, THERANOSTICS, V8, P1511, DOI 10.7150/thno.21986; Pober JS, 2001, ANN NY ACAD SCI, V941, P12; Proto JD, 2018, IMMUNITY, V49, P666, DOI 10.1016/j.immuni.2018.07.015; Ringland C, 2021, BMC NEUROSCI, V22, DOI 10.1186/s12868-021-00643-2; Rosales-Corral S, 2003, J PINEAL RES, V35, P80, DOI 10.1034/j.1600-079X.2003.00057.x; Salimi M, 2013, J EXP MED, V210, P2939, DOI 10.1084/jem.20130351; Salvador LA, 2013, J MED CHEM, V56, P1276, DOI 10.1021/jm3017305; Schwab VD, 2011, J INVEST DERM SYMP P, V15, P53, DOI 10.1038/jidsymp.2011.6; Second J, 2017, J EUR ACAD DERMATOL, V31, pE542, DOI 10.1111/jdv.14413; Sethi G, 2009, TRENDS PHARMACOL SCI, V30, P313, DOI 10.1016/j.tips.2009.03.004; Smith MA, 1998, J NEUROCHEM, V70, P2212, DOI 10.1046/j.1471-4159.1998.70052212.x; Steinhoff M, 2011, J INVEST DERM SYMP P, V15, P2, DOI 10.1038/jidsymp.2011.7; Subramanian A, 2017, CELL, V171, P1437, DOI 10.1016/j.cell.2017.10.049; Sugita K, 2018, J ALLERGY CLIN IMMUN, V141, P300, DOI 10.1016/j.jaci.2017.02.038; Sun Y, 2015, P NATL ACAD SCI USA, V112, P10401, DOI 10.1073/pnas.1504387112; Thiboutot D, 2020, J AM ACAD DERMATOL, V82, P1501, DOI 10.1016/j.jaad.2020.01.077; Tordjman S, 2017, CURR NEUROPHARMACOL, V15, P434, DOI 10.2174/1570159X14666161228122115; Tsiskarishvili N I, 2016, Georgian Med News, P47; Two AM, 2015, J AM ACAD DERMATOL, V72, P749, DOI 10.1016/j.jaad.2014.08.028; Vahdani FG, 2020, BIOMED J, V43, P496, DOI 10.1016/j.bj.2020.10.006; Wang Q, 2020, J PINEAL RES, V69, DOI 10.1111/jpi.12674; Wang ZQ, 2020, J DERMATOL, V47, P592, DOI 10.1111/1346-8138.15339; Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037; Wollina U, 2019, CLIN DERMATOL, V37, P629, DOI 10.1016/j.clindermatol.2019.07.032; Wu YH, 2003, J CLIN ENDOCR METAB, V88, P5898, DOI 10.1210/jc.2003-030833; Wu YH, 2005, J PINEAL RES, V38, P145, DOI 10.1111/j.1600-079X.2004.00196.x; Xu LW, 2019, J PINEAL RES, V67, DOI 10.1111/jpi.12579; Yamasaki K, 2007, NAT MED, V13, P975, DOI 10.1038/nm1616; Yang HS, 2022, ALZHEIMERS DEMENT, V18, P645, DOI 10.1002/alz.12399; Yuan X, 2019, BIOMED PHARMACOTHER, V117, DOI 10.1016/j.biopha.2019.109181; Zhang HL, 2021, DERMATOLOGY THER, V11, P13, DOI 10.1007/s13555-020-00461-0; Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3	78	0	0	11	24	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 23	2021	12								756550	10.3389/fimmu.2021.756550	http://dx.doi.org/10.3389/fimmu.2021.756550			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XM4GX	34899707	gold, Green Published			2022-12-18	WOS:000728788900001
J	Isola, I; Braso-Maristany, F; Moreno, DF; Mena, MP; Oliver-Calders, A; Pare, L; Rodriguez-Lobato, LG; Martin-Antonio, B; Cibeira, MT; Blade, J; Rosinol, L; Prat, A; Lozano, E; de Larrea, CF				Isola, Ignacio; Braso-Maristany, Fara; Moreno, David F.; Mena, Mari-Pau; Oliver-Calders, Aina; Pare, Laia; Rodriguez-Lobato, Luis Gerardo; Martin-Antonio, Beatriz; Cibeira, Maria Teresa; Blade, Joan; Rosinol, Laura; Prat, Aleix; Lozano, Ester; Fernandez de Larrea, Carlos			Gene Expression Analysis of the Bone Marrow Microenvironment Reveals Distinct Immunotypes in Smoldering Multiple Myeloma Associated to Progression to Symptomatic Disease	FRONTIERS IN IMMUNOLOGY			English	Article						smoldering multiple myeloma; immunotherapy; immune checkpoints; TIGIT; pronostic factors; bone marrow microenvironment	MONOCLONAL GAMMOPATHY; RECOGNITION; IMMUNE; TIGIT	BackgroundWe previously reported algorithms based on clinical parameters and plasma cell characteristics to identify patients with smoldering multiple myeloma (SMM) with higher risk of progressing who could benefit from early treatment. In this work, we analyzed differences in the immune bone marrow (BM) microenvironment in SMM to better understand the role of immune surveillance in disease progression and to identify immune biomarkers associated to higher risk of progression. MethodsGene expression analysis of BM cells from 28 patients with SMM, 22 patients with monoclonal gammopathy of undetermined significance (MGUS) and 22 patients with symptomatic MM was performed by using Nanostring Technology. ResultsBM cells in SMM compared to both MGUS and symptomatic MM showed upregulation of genes encoding for key molecules in cytotoxicity. However, some of these cytotoxic molecules positively correlated with inhibitory immune checkpoints, which may impair the effector function of BM cytotoxic cells. Analysis of 28 patients with SMM revealed 4 distinct clusters based on immune composition and activation markers. Patients in cluster 2 showed a significant increase in expression of cytotoxic molecules but also inhibitory immune checkpoints compared to cluster 3, suggesting the presence of cytotoxic cells with an exhausted phenotype. Accordingly, patients in cluster 3 had a significantly longer progression free survival. Finally, individual gene expression analysis showed that higher expression of TNF superfamily members (TNF, TNFAIP3, TNFRSF14) was associated with shorter progression free survival. ConclusionsOur results suggest that exhausted cytotoxic cells are associated to high-risk patients with SMM. Biomarkers overexpressed in patients with this immune gene profile in combination with clinical parameters and PC characterization may be useful to identify SMM patients with higher risk of progression.	[Isola, Ignacio; Moreno, David F.; Mena, Mari-Pau; Oliver-Calders, Aina; Rodriguez-Lobato, Luis Gerardo; Martin-Antonio, Beatriz; Cibeira, Maria Teresa; Blade, Joan; Rosinol, Laura; Lozano, Ester; Fernandez de Larrea, Carlos] Univ Barcelona, Inst Invest Biomed August Pi i Sunyer IDIBAPS, Hosp Clin Barcelona, Dept Hematol, Barcelona, Spain; [Braso-Maristany, Fara; Pare, Laia; Prat, Aleix] Hosp Clin Barcelona, Inst Invest Biomed August Pi i Sunyer IDIBAPS, Dept Med Oncol, Barcelona, Spain; [Lozano, Ester] Univ Barcelona, Dept Cell Biol Physiol & Immunol, Fac Biol, Barcelona, Spain; [Lozano, Ester] Univ Barcelona, Inst Biomed Univ Barcelona IBUB, Barcelona, Spain; [Fernandez de Larrea, Carlos] Josep Carreras Leukaemia Res Inst, Expt & Clin Hematol Program PHEC, Barcelona, Spain	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona; University of Barcelona; Institut de Recerca Contra la Leucemia Josep Carreras (IJC)	Lozano, E; de Larrea, CF (corresponding author), Univ Barcelona, Inst Invest Biomed August Pi i Sunyer IDIBAPS, Hosp Clin Barcelona, Dept Hematol, Barcelona, Spain.; Lozano, E (corresponding author), Univ Barcelona, Dept Cell Biol Physiol & Immunol, Fac Biol, Barcelona, Spain.; Lozano, E (corresponding author), Univ Barcelona, Inst Biomed Univ Barcelona IBUB, Barcelona, Spain.; de Larrea, CF (corresponding author), Josep Carreras Leukaemia Res Inst, Expt & Clin Hematol Program PHEC, Barcelona, Spain.	cfernan1@clinic.cat; elozano@ub.edu	Martín-Antonio, Beatriz/D-4963-2014; Lozano, Ester/H-2215-2014	Martín-Antonio, Beatriz/0000-0003-0612-2693; Lozano, Ester/0000-0002-6307-9807; Braso Maristany, Fara/0000-0001-5440-9643; Pare, Laia/0000-0002-4904-558X				Auslander N, 2018, NAT MED, V24, P1545, DOI 10.1038/s41591-018-0157-9; Ayers M, 2017, J CLIN INVEST, V127, P2930, DOI 10.1172/JCI91190; Bailur JK, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.127807; Blade J, 2008, LEUKEMIA, V22, P1651, DOI 10.1038/leu.2008.203; Blake SJ, 2016, CLIN CANCER RES, V22, P5183, DOI 10.1158/1078-0432.CCR-16-0933; Bolli N, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05058-y; Bustoros M, 2020, J CLIN ONCOL, V38, P2380, DOI 10.1200/JCO.20.00437; Caers J, 2018, HAEMATOLOGICA, V103, P1772, DOI 10.3324/haematol.2018.189159; Chauvin JM, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-000957; D'Souza C, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.632399; Dosani T, 2015, BLOOD CANCER J, V5, DOI 10.1038/bcj.2015.32; Dutta AK, 2019, LEUKEMIA, V33, P457, DOI 10.1038/s41375-018-0206-x; de Larrea CF, 2018, LEUKEMIA, V32, P1427, DOI 10.1038/s41375-018-0013-4; Ho M, 2020, CL LYMPH MYELOM LEUK, V20, pE752, DOI 10.1016/j.clml.2020.05.026; Lejeune M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00762; Lonial S, 2020, J CLIN ONCOL, V38, P1126, DOI 10.1200/JCO.19.01740; Lopez-Corral L, 2012, HAEMATOL-HEMATOL J, V97, P1439, DOI 10.3324/haematol.2011.060780; Lozano E, 2020, CLIN CANCER RES, V26, P4688, DOI 10.1158/1078-0432.CCR-19-3673; Manasanch EE, 2019, BLOOD ADV, V3, P2400, DOI 10.1182/bloodadvances.2019000300; Mateos MV, 2020, BLOOD CANCER J, V10, DOI 10.1038/s41408-020-00366-3; Mateos MV, 2019, BRIT J HAEMATOL, V186, pE117, DOI 10.1111/bjh.15946; Mateos MV, 2013, NEW ENGL J MED, V369, P438, DOI 10.1056/NEJMoa1300439; McCachren SS, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.632564; Merz M, 2020, LEUKEMIA, V34, P1192, DOI 10.1038/s41375-019-0634-2; Paiva B, 2016, BLOOD, V127, P1151, DOI 10.1182/blood-2015-10-662320; Rajkumar SV, 2014, LANCET ONCOL, V15, pE538, DOI 10.1016/S1470-2045(14)70442-5; Rosinol L, 2003, BRIT J HAEMATOL, V123, P631, DOI 10.1046/j.1365-2141.2003.04654.x; Rosinol L, 2007, MAYO CLIN PROC, V82, P428, DOI 10.4065/82.4.428; Shah NI, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-000734; van de Donk NWCJ, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02134; Walker BA, 2014, LEUKEMIA, V28, P384, DOI 10.1038/leu.2013.199; Zavidij O, 2020, NAT CANCER, V1, DOI 10.1038/s43018-020-0053-3; Zelle-Rieser C, 2016, J HEMATOL ONCOL, V9, DOI 10.1186/s13045-016-0345-3	33	0	0	1	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 22	2021	12								792609	10.3389/fimmu.2021.792609	http://dx.doi.org/10.3389/fimmu.2021.792609			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YI7OF	34880879	Green Published, gold			2022-12-18	WOS:000744033500001
J	Oya, Y; Kimura, S; Nakamura, Y; Ishihara, N; Takano, S; Morita, R; Endo, M; Hase, K				Oya, Yuki; Kimura, Shunsuke; Nakamura, Yutaka; Ishihara, Narumi; Takano, Shunsuke; Morita, Ryo; Endo, Mayumi; Hase, Koji			Characterization of M Cells in Tear Duct-Associated Lymphoid Tissue of Mice: A Potential Role in Immunosurveillance on the Ocular Surface	FRONTIERS IN IMMUNOLOGY			English	Article						tear duct-associated lymphoid tissue; microfold cell; RANKL; osteoprotegerin; IgA	PATCH M-CELLS; FACTOR SPI-B; MICROFOLD CELLS; DIFFERENTIATION; MUCOSA; IDENTIFICATION; LOCALIZATION; CONJUNCTIVA; RANKL; IGA	The ocular mucosal tissues are exposed to potentially harmful foreign antigens in the air and tear fluid. The tear duct-associated lymphoid tissue (TALT) may contribute to immune surveillance in the eye region. Follicle-associated epithelium (FAE) of TALTs is classified as stratified squamous epithelium and consists of squamous epithelial cells arranged in layers on the basement membrane. In contrast, most mucosa-associated lymphoid tissue is covered by a monolayer of epithelium containing microfold (M) cells. Therefore, antigen uptake and the presence of M cells in TALT are not fully understood. The present study found that a small population of FAE cells in the TALT expressed intestinal M-cell markers, namely Sox8, Tnfaip2, GP2, and OPG. This cell population was identified as functional M cells because of their uptake capacity of luminal nanoparticles. In addition, RANKL, which is essential for M-cell differentiation, was expressed by stroma-like cells at the subepithelial region and its receptor RANK by the FAE in the TALT. The administration of RANKL markedly increased the number of Sox8(+) M cells. In contrast, deficiency in OPG, an endogenous inhibitor of RANKL, increased the number of M cells in the TALT. These data demonstrate that the RANKL-RANK axis is essential for M-cell differentiation in the TALT. Furthermore, immunization via eye drops elicited the production of antigen-specific antibodies in tears, which was enhanced by RANKL administration. Thus, TALT M cells play an important role in the immunosurveillance of the eye region.	[Oya, Yuki; Kimura, Shunsuke; Nakamura, Yutaka; Ishihara, Narumi; Takano, Shunsuke; Morita, Ryo; Endo, Mayumi; Hase, Koji] Keio Univ, Fac Pharm, Div Biochem, Tokyo, Japan; [Oya, Yuki; Kimura, Shunsuke; Nakamura, Yutaka; Ishihara, Narumi; Takano, Shunsuke; Morita, Ryo; Endo, Mayumi; Hase, Koji] Keio Univ, Grad Sch Pharmaceut Sci, Tokyo, Japan; [Kimura, Shunsuke] Japan Sci & Technol Agcy, Precursory Res Embryon Sci & Technol PRESTO, Saitama, Japan; [Hase, Koji] Univ Tokyo, Inst Med Sci, Int Res & Dev Ctr Mucosal Vaccines, Tokyo, Japan	Keio University; Keio University; Japan Science & Technology Agency (JST); University of Tokyo	Kimura, S; Hase, K (corresponding author), Keio Univ, Fac Pharm, Div Biochem, Tokyo, Japan.; Kimura, S; Hase, K (corresponding author), Keio Univ, Grad Sch Pharmaceut Sci, Tokyo, Japan.; Kimura, S (corresponding author), Japan Sci & Technol Agcy, Precursory Res Embryon Sci & Technol PRESTO, Saitama, Japan.; Hase, K (corresponding author), Univ Tokyo, Inst Med Sci, Int Res & Dev Ctr Mucosal Vaccines, Tokyo, Japan.	kimura-sn@pha.keio.ac.jp; hase-kj@pha.keio.ac.jp						Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; Betzler BK, 2021, CLIN EXP OPHTHALMOL, V49, P146, DOI 10.1111/ceo.13847; Brandtzaeg P, 2008, MUCOSAL IMMUNOL, V1, P31, DOI 10.1038/mi.2007.9; de Lau W, 2012, MOL CELL BIOL, V32, P3639, DOI 10.1128/MCB.00434-12; Deng Wei, 2020, Nat Commun, V11, P4400, DOI 10.1038/s41467-020-18149-6; Ghosh S, 1995, J Indian Med Assoc, V93, P132; Hase K, 2005, DNA RES, V12, P127, DOI 10.1093/dnares/12.2.127; Hase K, 2009, NATURE, V462, P226, DOI 10.1038/nature08529; Iwasaki A, 2000, J EXP MED, V191, P1381, DOI 10.1084/jem.191.8.1381; Kanaya T, 2012, NAT IMMUNOL, V13, P729, DOI 10.1038/ni.2352; Kawai S, 2011, EXP ANIM TOKYO, V60, P481, DOI 10.1538/expanim.60.481; Kimura S, 2015, MUCOSAL IMMUNOL, V8, P650, DOI 10.1038/mi.2014.99; Kimura S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13883-y; Kimura S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01323; Kimura S, 2019, J EXP MED, V216, P831, DOI 10.1084/jem.20181604; Kimura S, 2016, BIOMED RES-TOKYO, V37, P351, DOI 10.2220/biomedres.37.351; Kimura S, 2015, BIOMED RES-TOKYO, V36, P263, DOI 10.2220/biomedres.36.263; Kishikawa S, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14509; Knoop KA, 2009, J IMMUNOL, V183, P5738, DOI 10.4049/jimmunol.0901563; Kubo A, 2009, J EXP MED, V206, P2937, DOI 10.1084/jem.20091527; Logeswaran A, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.716939; Lugering A, 2005, AM J PATHOL, V166, P1647, DOI 10.1016/S0002-9440(10)62475-3; Mabbott NA, 2013, MUCOSAL IMMUNOL, V6, P666, DOI 10.1038/mi.2013.30; Mizuno A, 1998, BIOCHEM BIOPH RES CO, V247, P610, DOI 10.1006/bbrc.1998.8697; Mutoh M, 2016, CELL TISSUE RES, V364, P175, DOI 10.1007/s00441-015-2309-2; Nagashima K, 2017, NAT IMMUNOL, V18, P675, DOI 10.1038/ni.3732; Nagatake T, 2009, J EXP MED, V206, P2351, DOI 10.1084/jem.20091436; Nair VR, 2016, CELL REP, V16, P1253, DOI 10.1016/j.celrep.2016.06.080; Owen RL, 1999, SEMIN IMMUNOL, V11, P157, DOI 10.1006/smim.1999.0171; Paulsen F, 1998, ANAT EMBRYOL, V198, P1, DOI 10.1007/s004290050160; Paulsen F, 2003, ADV ANAT EMBRYOL CEL, V170, P1; Paulsen FP, 2000, VIRCHOWS ARCH, V437, P185, DOI 10.1007/s004280000248; Paulsen Friedrich P, 2003, Ocul Surf, V1, P180; Petris CK, 2007, INVEST OPHTH VIS SCI, V48, P2172, DOI 10.1167/iovs.06-1202; Quinet B, 2010, ARCH PEDIATRIE, V17, pS145, DOI 10.1016/S0929-693X(10)70916-7; Rios D, 2016, MUCOSAL IMMUNOL, V9, P907, DOI 10.1038/mi.2015.121; Rouch JD, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148216; Sato S, 2013, MUCOSAL IMMUNOL, V6, P838, DOI 10.1038/mi.2012.122; Seo KY, 2010, J IMMUNOL, V185, P3610, DOI 10.4049/jimmunol.1000680; Steven P, 2008, INVEST OPHTH VIS SCI, V49, P1512, DOI 10.1167/iovs.07-0809; Terahara K, 2008, J IMMUNOL, V180, P7840, DOI 10.4049/jimmunol.180.12.7840; Tsukasaki M, 2020, CELL REP, V32, DOI 10.1016/j.celrep.2020.108124; Verbrugghe P, 2008, HISTOCHEM CELL BIOL, V129, P311, DOI 10.1007/s00418-007-0369-4; Willcox MDP, 2007, OPTOMETRY VISION SCI, V84, P273, DOI 10.1097/OPX.0b013e3180439c3e; Yamamoto M, 2012, CURR TOP MICROBIOL, V354, P39, DOI 10.1007/82_2011_134; Yanagihara S, 2017, INT IMMUNOL, V29, P357, DOI 10.1093/intimm/dxx043	46	0	0	2	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 22	2021	12								779709	10.3389/fimmu.2021.779709	http://dx.doi.org/10.3389/fimmu.2021.779709			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XQ6YV	34880872	Green Published, gold			2022-12-18	WOS:000731692900001
J	Xu, SH; Luo, J; Zhu, CW; Jiang, JC; Cheng, H; Wang, P; Hong, JW; Fang, JX; Pan, JJ; Brown, MA; Zhu, XC; Wang, XB				Xu, Shihao; Luo, Jing; Zhu, Chengwei; Jiang, Jiachun; Cheng, Hui; Wang, Ping; Hong, Jingwei; Fang, Jinxia; Pan, Jingjing; Brown, Matthew A.; Zhu, Xiaochun; Wang, Xiaobing			Performance Evaluation of Multiple Ultrasonographical Methods for the Detection of Primary Sjogren's Syndrome	FRONTIERS IN IMMUNOLOGY			English	Article						primary Sjogren's syndrome; grayscale ultrasonography; color Doppler sonography; contrast-enhanced ultrasonography; diagnostic model	SALIVARY-GLAND ULTRASONOGRAPHY; CONTRAST-ENHANCED ULTRASOUND; COLOR DOPPLER SONOGRAPHY; CLASSIFICATION CRITERIA; DIAGNOSTIC-VALUE; AMERICAN-COLLEGE; LYMPH-NODES; DATA-DRIVEN; GRAY-SCALE; CEUS	Major salivary gland ultrasonography (SGUS) is increasingly being recognized as having critical roles in differentiating primary Sjogren's syndrome (pSS) from other connective tissue disorders. Contrast-enhanced ultrasonography (CEUS) has been reported to evaluate microvascularity of lesions in different tissues with objective angiographic index, eliminating the observer-dependent defect of ultrasonography. However, there are few relevant studies concentrating on the application of CEUS in the diagnosis and assessment for pSS, and their clinical utility prospect remains uncertain. In this study, a total of 227 eligible patients were enrolled, including 161 pSS and 66 non-pSS patients with comprehensive ultrasonographic evaluation of the parotid and submandibular glands, including grayscale ultrasonography, color Doppler sonography (CDS), and CEUS. Compared with non-pSS, pSS patients had significantly higher grayscale ultrasound (US) scores and CDS blood grades in the parotid gland and significantly higher grayscale US and CEUS scores in the submandibular glands. Diagnostic model combining ultrasonographic signatures, anti-SSA/Ro60, and keratoconjunctivitis sicca (KCS) tests showed a remarkable discrimination [mean area under the curve (AUC)0.963 in submandibular glands and 0.934 in parotid glands] for pSS, and the nomogram provided excellent prediction accuracy and good calibration in individualized prediction of pSS. A combination of multiple ultrasonographical examinations of the major salivary glands (SGs) is a promising technique that may be used as a practical alternative to minor SG biopsy in the detection of pSS.	[Xu, Shihao; Jiang, Jiachun] Wenzhou Med Univ, Dept Ultrasonog, Affiliated Hosp 1, Wenzhou, Peoples R China; [Luo, Jing] Tsinghua Univ, Beijing Tsinghua Changgung Hosp, Sch Clin Med, Beijing, Peoples R China; [Zhu, Chengwei; Cheng, Hui; Wang, Ping; Hong, Jingwei; Zhu, Xiaochun; Wang, Xiaobing] Wenzhou Med Univ, Dept Rheumatol, Affiliated Hosp 1, Wenzhou, Peoples R China; [Fang, Jinxia] Zhejiang Univ, Dept Rheumatol, Taizhou Hosp, Linhai, Peoples R China; [Pan, Jingjing] Wenzhou Med Univ, Dept Lab Med, Affiliated Hosp 1, Wenzhou, Peoples R China; [Brown, Matthew A.] Guys & St Thomas Hosp NHS Trust, Dept Med, London, England; [Brown, Matthew A.] Kings Coll London, NIHR Biomed Res Ctr, London, England; [Wang, Xiaobing] Naval Med Univ, Shanghai Changzheng Hosp, Dept Rheumatol & Immunol, Affiliated Hosp 2, Shanghai, Peoples R China	Wenzhou Medical University; Tsinghua University; Wenzhou Medical University; Zhejiang University; Wenzhou Medical University; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Naval Medical University	Wang, XB (corresponding author), Wenzhou Med Univ, Dept Rheumatol, Affiliated Hosp 1, Wenzhou, Peoples R China.; Wang, XB (corresponding author), Naval Med Univ, Shanghai Changzheng Hosp, Dept Rheumatol & Immunol, Affiliated Hosp 2, Shanghai, Peoples R China.	gale820907@163.com	Luo, Jing/AAX-2991-2021	Luo, Jing/0000-0001-5821-5846				Alderden J, 2018, AM J CRIT CARE, V27, P461, DOI 10.4037/ajcc2018525; Baldini C, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075-015-0657-7; Bhatia KSS, 2018, NEUROIMAG CLIN N AM, V28, P273, DOI 10.1016/j.nic.2018.01.007; Brito-Zeron P, 2017, ANN RHEUM DIS, V76, P1042, DOI 10.1136/annrheumdis-2016-209952; Cantisani V, 2015, EUR J RADIOL, V84, P1675, DOI 10.1016/j.ejrad.2015.05.008; Cao XL, 2012, ULTRASOUND MED BIOL, V38, P2065, DOI 10.1016/j.ultrasmedbio.2012.07.027; Carotti M, 2001, CLIN RHEUMATOL, V20, P213, DOI 10.1007/s100670170068; Carotti M, 2019, GLAND SURG, V8, pS159, DOI 10.21037/gs.2019.05.03; Claudon M, 2013, ULTRASCHALL MED, V34, P11, DOI 10.1055/s-0032-1325499; Colella G, 2010, RHEUMATOLOGY, V49, P2117, DOI 10.1093/rheumatology/keq225; La Paglia GMC, 2020, CLIN RHEUMATOL, V39, P1207, DOI 10.1007/s10067-019-04780-2; Cornec D, 2013, ARTHRITIS RHEUM-US, V65, P216, DOI [10.1002/art.37698, 10.1002/art.37944]; David E, 2016, ULTRASOUND, V24, P104, DOI 10.1177/1742271X15626611; Delli K, 2015, ORAL DIS, V21, P792, DOI 10.1111/odi.12349; DEVITA S, 1992, CLIN EXP RHEUMATOL, V10, P351; Finzel S, 2021, RHEUMATOLOGY, V60, P2169, DOI 10.1093/rheumatology/keaa471; Giuseppetti GM, 2005, EUR J RADIOL, V54, P225, DOI 10.1016/j.ejrad.2004.04.018; HILTON SM, 1955, J PHYSIOL-LONDON, V128, P235, DOI 10.1113/jphysiol.1955.sp005302; Hocevar A, 2005, RHEUMATOLOGY, V44, P768, DOI 10.1093/rheumatology/keh588; Hornung M, 2011, CLIN HEMORHEOL MICRO, V49, P83, DOI 10.3233/CH-2011-1459; Jousse-Joulin S, 2017, RMD OPEN, V3, DOI 10.1136/rmdopen-2016-000364; Jousse-Joulin S, 2007, BIOL-TARGETS THER, V1, P311; Kang HJ, 2020, RADIOLOGY, V297, P108, DOI 10.1148/radiol.2020200115; Kerr KF, 2016, J CLIN ONCOL, V34, P2534, DOI 10.1200/JCO.2015.65.5654; Konttinen YT, 2006, AUTOIMMUN REV, V6, P16, DOI 10.1016/j.autrev.2006.03.003; Luciano Nicoletta, 2018, Clin Exp Rheumatol, V36 Suppl 114, P159; Maldini C, 2014, ARTHRIT CARE RES, V66, P454, DOI 10.1002/acr.22115; MARTINOLI C, 1994, AM J ROENTGENOL, V163, P933, DOI 10.2214/ajr.163.4.8092039; Maxeiner A, 2019, ULTRASCHALL MED, V40, P340, DOI 10.1055/a-0594-2093; Milic VD, 2010, SCAND J RHEUMATOL, V39, P160, DOI 10.3109/03009740903270623; Milic V, 2012, RHEUMATOLOGY, V51, P1081, DOI 10.1093/rheumatology/ker431; Mossel E, 2018, ANN RHEUM DIS, V77, P556, DOI 10.1136/annrheumdis-2017-211992; Niemela RK, 2004, RHEUMATOLOGY, V43, P875, DOI 10.1093/rheumatology/keh187; Ramos-Casals M, 2015, RHEUMATOLOGY, V54, P2230, DOI 10.1093/rheumatology/kev200; RColorBrewer S., 2018, PACKAGE RANDOMFOREST; Salaffi F, 2000, J RHEUMATOL, V27, P1229; Santiago ML, 2012, REUMATOL CLIN, V8, P255, DOI 10.1016/j.reuma.2012.03.006; Segal B, 2009, HEALTH QUAL LIFE OUT, V7, DOI 10.1186/1477-7525-7-46; Seror R, 2010, ANN RHEUM DIS, V69, P1103, DOI 10.1136/ard.2009.110619; Sezer I, 2019, ARCH RHEUMATOL, V34, P371, DOI 10.5606/ArchRheumatol.2019.7120; Shiboski CH, 2017, ANN RHEUM DIS, V76, P9, DOI [10.1136/annrheumdis-2016-210571, 10.1002/art.39859]; Shiboski SC, 2012, ARTHRIT CARE RES, V64, P475, DOI 10.1002/acr.21591; Sing T, 2005, BIOINFORMATICS, V21, P3940, DOI 10.1093/bioinformatics/bti623; STEINER E, 1994, ROFO FORTSCHR RONTG, V160, P294, DOI 10.1055/s-2008-1032427; Takagi Y, 2010, ANN RHEUM DIS, V69, P1321, DOI 10.1136/ard.2009.123836; Theander E, 2014, ARTHRIT CARE RES, V66, P1102, DOI 10.1002/acr.22264; Ustabasioglu FE, 2020, BALK MED J, V37, P203, DOI 10.4274/balkanmedj.galenos.2020.2019.11.91; Wei X, 2013, CLIN HEMORHEOL MICRO, V54, P259, DOI 10.3233/CH-131732; Xin L, 2017, MED SCI MONITOR, V23, P5430, DOI 10.12659/MSM.907293; Zabotti A, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.581248; Zhou XH, 2018, J ULTRAS MED, V37, P425, DOI 10.1002/jum.14347	51	0	0	2	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 22	2021	12								777322	10.3389/fimmu.2021.777322	http://dx.doi.org/10.3389/fimmu.2021.777322			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XJ6YE	34880870	gold, Green Published			2022-12-18	WOS:000726929900001
J	Zhang, ZC; Guo, JN; Zhang, N; Wang, ZQ; Lou, G; Cui, BB; Yang, C				Zhang, Zhao-Cong; Guo, Jun-Nan; Zhang, Ning; Wang, Zhi-Qiang; Lou, Ge; Cui, Bin-Bin; Yang, Chang			Identification and Validation of Immune-Related Gene for Predicting Prognosis and Therapeutic Response in Ovarian Cancer	FRONTIERS IN IMMUNOLOGY			English	Article						ovarian cancer; immune-related genes (IRGs); prognosis; tumor immune microenvironment; immune checkpoint inhibitors (ICI)	CELLS; CARCINOMA	Ovarian cancer (OC) is a devastating malignancy with a poor prognosis. The complex tumor immune microenvironment results in only a small number of patients benefiting from immunotherapy. To explore the different factors that lead to immune invasion and determine prognosis and response to immune checkpoint inhibitors (ICIs), we established a prognostic risk scoring model (PRSM) with differential expression of immune-related genes (IRGs) to identify key prognostic IRGs. Patients were divided into high-risk and low-risk groups according to their immune and stromal scores. We used a bioinformatics method to identify four key IRGs that had differences in expression between the two groups and affected prognosis. We evaluated the sensitivity of treatment from three aspects, namely chemotherapy, targeted inhibitors (TIs), and immunotherapy, to evaluate the value of prediction models and key prognostic IRGs in the clinical treatment of OC. Univariate and multivariate Cox regression analyses revealed that these four key IRGs were independent prognostic factors of overall survival in OC patients. In the high-risk group comprising four genes, macrophage M0 cells, macrophage M2 cells, and regulatory T cells, observed to be associated with poor overall survival in our study, were higher. The high-risk group had a high immunophenoscore, indicating a better response to ICIs. Taken together, we constructed a PRSM and identified four key prognostic IRGs for predicting survival and response to ICIs. Finally, the expression of these key genes in OC was evaluated using RT-qPCR. Thus, these genes provide a novel predictive biomarker for immunotherapy and immunomodulation.	[Zhang, Zhao-Cong; Zhang, Ning; Wang, Zhi-Qiang; Lou, Ge; Yang, Chang] Harbin Med Univ, Canc Hosp, Dept Gynecol Oncol, Harbin, Peoples R China; [Guo, Jun-Nan; Cui, Bin-Bin] Harbin Med Univ, Canc Hosp, Dept Colorectal Surg, Harbin, Peoples R China	Harbin Medical University; Harbin Medical University	Lou, G; Yang, C (corresponding author), Harbin Med Univ, Canc Hosp, Dept Gynecol Oncol, Harbin, Peoples R China.; Cui, BB (corresponding author), Harbin Med Univ, Canc Hosp, Dept Colorectal Surg, Harbin, Peoples R China.	louge@ems.hrbmu.edu.cn; cbbhrb@163.com; yangchang@hrbmu.edu.cn	Guo, Junnan/GNH-1753-2022					Ali HR, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002194; Asgharzadeh S, 2012, J CLIN ONCOL, V30, P3525, DOI 10.1200/JCO.2011.40.9169; Batich K, 2018, NEURO-ONCOLOGY, V20, P126; Cejalvo T, 2018, CANCER RES, V78, P4891, DOI [10.1158/0008-5472.CAN-17-3754, 10.1158/0008-5472.can-17-3754]; Charoentong P, 2017, CELL REP, V18, P248, DOI 10.1016/j.celrep.2016.12.019; Cheng SH, 2020, ADV SCI, V7, DOI 10.1002/advs.201903301; Cooks T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03224-w; Efremova M, 2020, ANNU REV IMMUNOL, V38, P727, DOI 10.1146/annurev-immunol-090419-020340; Ruiz-Aparicio PF, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21103705; Friedman J, 2010, J STAT SOFTW, V33, P1, DOI 10.18637/jss.v033.i01; Furstenau M, 2019, HAEMATOLOGICA, V104, P2144, DOI 10.3324/haematol.2018.208603; Geeleher P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107468; Gomez-Tourino I, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01925-2; Grunewald TGP, 2020, EMBO MOL MED, V12, DOI 10.15252/emmm.201911131; Guo JN, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.640196; Hasan M, 2008, IMMUNOLOGY, V123, P239, DOI 10.1111/j.1365-2567.2007.02693.x; Heagerty PJ, 2005, BIOMETRICS, V61, P92, DOI 10.1111/j.0006-341X.2005.030814.x; Huang B, 2021, OPEN LIFE SCI, V16, P667, DOI 10.1515/biol-2021-0058; Huyghe L, 2020, EMBO MOL MED, V12, DOI 10.15252/emmm.201911223; Izar B, 2020, NAT MED, V26, P1271, DOI 10.1038/s41591-020-0926-0; Kandalaft LE, 2011, J CLIN ONCOL, V29, P925, DOI 10.1200/JCO.2009.27.2369; Kang YN, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.573497; Koliaraki V, 2019, CELL REP, V26, P536, DOI 10.1016/j.celrep.2018.12.072; Komohara Y, 2016, ADV DRUG DELIVER REV, V99, P180, DOI 10.1016/j.addr.2015.11.009; Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-559; Laska E, 2012, STAT MED, V31, P3178, DOI 10.1002/sim.5384; Le Y, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04567-0; Leen AM, 2007, ANNU REV IMMUNOL, V25, P243, DOI 10.1146/annurev.immunol.25.022106.141527; Liu D, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03590-5; Marigo I, 2016, CANCER CELL, V30, P377, DOI 10.1016/j.ccell.2016.08.004; Matsumoto N, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01046; Menzel J, 2020, CANCER DISCOV, V10, P179, DOI 10.1158/2159-8290.CD-19-1349; Meyer LA, 2016, J CLIN ONCOL, V34, P3854, DOI 10.1200/JCO.2016.68.1239; Monk BJ, 2016, ANN ONCOL, V27, P33, DOI 10.1093/annonc/mdw093; Monk BJ, 2016, J CLIN ONCOL, V34, P2279, DOI 10.1200/JCO.2015.65.8153; Newman AM, 2015, NAT METHODS, V12, P453, DOI [10.1038/NMETH.3337, 10.1038/nmeth.3337]; Ogino S, 2018, GUT, V67, P1168, DOI 10.1136/gutjnl-2017-315537; Qiao X, 2019, DEV COMP IMMUNOL, V98, P189, DOI 10.1016/j.dci.2019.05.005; Garcia MGR, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/352414; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Saha B, 2019, HEPATOLOGY, V70, P1134, DOI 10.1002/hep.30617; Salminen A, 2020, AGEING RES REV, V57, DOI 10.1016/j.arr.2019.100998; Schroder MS, 2011, BIOINFORMATICS, V27, P3206, DOI 10.1093/bioinformatics/btr511; Shen YC, 2020, J HEPATOL, V72, P489, DOI 10.1016/j.jhep.2019.09.032; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tekpli X, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13329-5; Wu J, 2018, NEURO-ONCOLOGY, V20, P92, DOI 10.1093/neuonc/nox111; Xiong Y, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-1116-3; Xu Y, 2021, TRANSL ONCOL, V14, DOI 10.1016/j.tranon.2020.100957; Yang C, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.577869; Yang C, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-01594-0; Yi M, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0864-3; Yoshihara K, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3612; Yu T, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12384-2; Zha HR, 2019, CANCER IMMUNOL RES, V7, P193, DOI 10.1158/2326-6066.CIR-18-0272; Zhang JY, 2018, HEPATOLOGY, V67, P1872, DOI 10.1002/hep.29681; Zou TN, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.642615	57	0	0	3	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 22	2021	12								763791	10.3389/fimmu.2021.763791	http://dx.doi.org/10.3389/fimmu.2021.763791			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XM4PF	34880862	Green Published, gold			2022-12-18	WOS:000728810500001
J	Liu, CM; Wang, SH; Zheng, SF; Xu, F; Cao, Z; Feng, XL; Wang, Y; Xue, Q; Sun, N; He, J				Liu, Chengming; Wang, Sihui; Zheng, Sufei; Xu, Fei; Cao, Zheng; Feng, Xiaoli; Wang, Yan; Xue, Qi; Sun, Nan; He, Jie			Avoiding Absolute Quantification Trap: A Novel Predictive Signature of Clinical Benefit to Anti-PD-1 Immunotherapy in Non-Small Cell Lung Cancer	FRONTIERS IN IMMUNOLOGY			English	Article						NSCLC; immune checkpoint inhibitors; clinical benefit; prognosis; BRGPI	IMMUNE CHECKPOINT INHIBITORS; NIVOLUMAB; DOCETAXEL; EXPRESSION; CARCINOMA; BLOCKADE	Immunotherapy has been focused on by many oncologists and researchers. While, due to technical biases of absolute quantification, few traditional biomarkers for anti-PD-1 immunotherapy have been applied in regular clinical practice of non-small cell lung cancer (NSCLC). Therefore, there is an urgent and unmet need for a feasible tool-immune to data source bias-for identifying patients who might benefit from ICIs in clinical practice. Using the strategy based on the relative ranking of gene expression levels, we herein proposed the novel BRGP index (BRGPI): four BRGPs significantly related with progression-free survival of NSCLC patients treated with anti-PD-1 immunotherapy in the multicohort analysis. Moreover, stratification and multivariate Cox regression analyses demonstrated that BRGPI was an independent prognostic factor. Notably, compared to PD-L1, BRGPI exerted the best predictive ability. Further analysis showed that the patients in the BRGPI-low and PD-L1-high subgroup derived more clinical benefits from anti-PD-1 immunotherapy. In conclusion, the prospect of applying the BRGPI to real clinical practice is promising owing to its powerful and reliable predictive value.	[Liu, Chengming; Wang, Sihui; Zheng, Sufei; Xue, Qi; Sun, Nan; He, Jie] Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Natl Canc Ctr, Dept Thorac Surg,Canc Hosp, Beijing, Peoples R China; [Liu, Chengming; Wang, Sihui; Zheng, Sufei; Sun, Nan; He, Jie] Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Natl Canc Ctr, State Key Lab Mol Oncol,Canc Hosp, Beijing, Peoples R China; [Xu, Fei; Wang, Yan] Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Natl Canc Ctr, Dept Med Oncol,Canc Hosp, Beijing, Peoples R China; [Cao, Zheng; Feng, Xiaoli] Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Natl Canc Ctr, Dept Pathol,Canc Hosp, Beijing, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; Peking Union Medical College	Sun, N; He, J (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Natl Canc Ctr, Dept Thorac Surg,Canc Hosp, Beijing, Peoples R China.; Sun, N; He, J (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Natl Canc Ctr, State Key Lab Mol Oncol,Canc Hosp, Beijing, Peoples R China.	sunnan@vip.126.com; prof.jiehe@gmail.com			National Key Basic Research Development Plan [2018YFC1312105]; National Natural Science Foundation of China [81802299, 81502514]; Graduate Innovation Funds of Peking Union Medical College [2019-1002-06]; National Key R&D Program of China [2018YFC1312100, 2018YFC1312102]; CAMS Innovation Fund for Medical Sciences [2016-I2M-1-001, 2017-I2M-1-005]; Fundamental Research Funds for the Central Universities [3332018070]	National Key Basic Research Development Plan(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Graduate Innovation Funds of Peking Union Medical College; National Key R&D Program of China; CAMS Innovation Fund for Medical Sciences; Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities)	Funding This work was supported by the National Key Basic Research Development Plan (grant number 2018YFC1312105), the National Natural Science Foundation of China (grant numbers 81802299, 81502514), the Graduate Innovation Funds of Peking Union Medical College (grant number 2019-1002-06), the National Key R&D Program of China (grant numbers 2018YFC1312100, 2018YFC1312102), the CAMS Innovation Fund for Medical Sciences (grant numbers 2016-I2M-1-001, 2017-I2M-1-005), and the Fundamental Research Funds for the Central Universities (grant number 3332018070).	Ahn BC, 2019, J CANCER RES CLIN, V145, P1613, DOI 10.1007/s00432-019-02899-y; Alsaleem MA, 2020, MODERN PATHOL, V33, P2208, DOI 10.1038/s41379-020-0563-7; Bodor JN, 2020, CANCER-AM CANCER SOC, V126, P260, DOI 10.1002/cncr.32468; Borghaei H, 2015, NEW ENGL J MED, V373, P1627, DOI 10.1056/NEJMoa1507643; Brahmer J, 2015, NEW ENGL J MED, V373, P123, DOI 10.1056/NEJMoa1504627; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Brustugun OT, 2017, ACTA ONCOL, V56, P438, DOI 10.1080/0284186X.2016.1253865; Cesano A, 2015, J IMMUNOTHER CANCER, V3, DOI 10.1186/s40425-015-0088-7; Choucair K, 2020, CANCER GENE THER, V27, P841, DOI 10.1038/s41417-020-0174-y; Ciccarese C, 2017, IMMUNOTHERAPY-UK, V9, P579, DOI 10.2217/imt-2017-0018; Dudnik E, 2018, LUNG CANCER, V126, P217, DOI 10.1016/j.lungcan.2017.11.015; Ettinger DS, 2018, J NATL COMPR CANC NE, V16, P807, DOI 10.6004/jnccn.2018.0062; Gainor JF, 2013, J CLIN ONCOL, V31, P3987, DOI 10.1200/JCO.2012.45.2029; Hellmann MD, 2018, NEW ENGL J MED, V378, P2093, DOI 10.1056/NEJMoa1801946; Hellmann MD, 2018, CANCER CELL, V33, P843, DOI 10.1016/j.ccell.2018.03.018; Herbst RS, 2016, LANCET, V387, P1540, DOI 10.1016/S0140-6736(15)01281-7; Lee CK, 2018, JAMA ONCOL, V4, P210, DOI 10.1001/jamaoncol.2017.4427; Leek JT, 2010, NAT REV GENET, V11, P733, DOI 10.1038/nrg2825; Li BL, 2017, JAMA ONCOL, V3, P1529, DOI 10.1001/jamaoncol.2017.1609; Liu CM, 2021, THER ADV MED ONCOL, V13, DOI 10.1177/17588359211006949; Liu CM, 2020, CANCER LETT, V470, P95, DOI 10.1016/j.canlet.2019.10.027; Long JY, 2019, EBIOMEDICINE, V42, P363, DOI 10.1016/j.ebiom.2019.03.022; Mehnert JM, 2017, CLIN CANCER RES, V23, P4970, DOI 10.1158/1078-0432.CCR-16-3063; Miller KD, 2019, CA-CANCER J CLIN, V69, P363, DOI 10.3322/caac.21565; Popovici V, 2012, J CLIN ONCOL, V30, P1288, DOI 10.1200/JCO.2011.39.5814; Prat A, 2017, CANCER RES, V77, P3540, DOI 10.1158/0008-5472.CAN-16-3556; Prelaj A, 2019, EUR J CANCER, V106, P144, DOI 10.1016/j.ejca.2018.11.002; Ribas A, 2018, SCIENCE, V359, P1350, DOI 10.1126/science.aar4060; Rittmeyer A, 2017, LANCET, V389, P255, DOI 10.1016/S0140-6736(16)32517-X; Rizvi H, 2018, J CLIN ONCOL, V36, P633, DOI 10.1200/JCO.2017.75.3384; Schoenfeld AJ, 2020, ANN ONCOL, V31, P599, DOI 10.1016/j.annonc.2020.01.065; Sun XY, 2020, CANCER MED-US, V9, P2868, DOI 10.1002/cam4.2921; Wang ZJ, 2019, JAMA ONCOL, V5, P696, DOI 10.1001/jamaoncol.2018.7098; Wu YL, 2019, J THORAC ONCOL, V14, P867, DOI 10.1016/j.jtho.2019.01.006; Xiong Y, 2020, UROL ONCOL-SEMIN ORI, V38, DOI 10.1016/j.urolonc.2019.09.014; Yoneda Kazue, 2018, Journal of UOEH, V40, P173, DOI 10.7888/juoeh.40.173	36	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 19	2021	12								782106	10.3389/fimmu.2021.782106	http://dx.doi.org/10.3389/fimmu.2021.782106			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XK7FO	34868057	gold, Green Published			2022-12-18	WOS:000727626900001
J	Okajima, T; Shigemori, S; Namai, F; Ogita, T; Sato, T; Shimosato, T				Okajima, Takuma; Shigemori, Suguru; Namai, Fu; Ogita, Tasuku; Sato, Takashi; Shimosato, Takeshi			Free Feeding of CpG-Oligodeoxynucleotide Particles Prophylactically Attenuates Allergic Airway Inflammation and Hyperresponsiveness in Mice	FRONTIERS IN IMMUNOLOGY			English	Article						CpG-ODNs; oral delivery; mouse model of allergic asthma; airway inflammation; airway hyperresponsiveness; pulmonary vein cardiomyocytes; Reg3 gamma; gut microbiota	TISSUE-SPECIFIC EXPRESSION; INDUCED ASTHMA; IN-HOUSE; PROTEIN; CTNNA3; MODEL; GENE; LUNG; DNA; DIFFERENTIATION	CpG-oligodeoxynucleotides (CpG-ODNs) constitute an attractive alternative for asthma treatment. However, very little evidence is available from studies on the oral administration of CpG-ODNs in animals. Previously, we developed acid-resistant particles (named ODNcap) as an oral delivery device for ODNs. Here, we showed that free feeding of an ODNcap-containing feed prophylactically attenuates allergic airway inflammation, hyperresponsiveness, and goblet cell hyperplasia in an ovalbumin-induced asthma model. Using transcriptomics-driven approaches, we demonstrated that injury of pulmonary vein cardiomyocytes accompanies allergen inhalation challenge, but is inhibited by ODNcap feeding. We also showed the participation of an airway antimicrobial peptide (Reg3 gamma) and fecal microbiota in the ODNcap-mediated effects. Collectively, our findings suggest that daily oral ingestion of ODNcap may provide preventive effects on allergic bronchopulmonary insults via regulation of mechanisms involved in the gut-lung connection.	[Okajima, Takuma; Shigemori, Suguru; Namai, Fu; Ogita, Tasuku; Sato, Takashi; Shimosato, Takeshi] Shinshu Univ, Inst Biomed Sci, Dept Biomol Innovat, Nagano, Japan	Shinshu University	Shigemori, S; Shimosato, T (corresponding author), Shinshu Univ, Inst Biomed Sci, Dept Biomol Innovat, Nagano, Japan.	shigemoris@shinshu-u.ac.jp; shimot@shinshu-u.ac.jp			JSPS KAKENHI [17H03907, 20H03125]; LOTTE Foundation; Kobayashi Foundation; Urakami Foundation for Food and Food Culture Promotion	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); LOTTE Foundation; Kobayashi Foundation; Urakami Foundation for Food and Food Culture Promotion	This study was supported by JSPS KAKENHI Grant Nos. 17H03907 and 20H03125, and by a grant from the LOTTE Foundation, Kobayashi Foundation, and Urakami Foundation for Food and Food Culture Promotion to TSh.	Abbafati C, 2020, LANCET, V396, P1204, DOI 10.1016/S0140-6736(20)30925-9; Arrieta MC, 2018, J ALLERGY CLIN IMMUN, V142, P424, DOI 10.1016/j.jaci.2017.08.041; Barcik W, 2020, IMMUNITY, V52, P241, DOI 10.1016/j.immuni.2020.01.007; Beeh KM, 2013, J ALLERGY CLIN IMMUN, V131, P866, DOI 10.1016/j.jaci.2012.12.1561; Bjorksten B, 1999, CLIN EXP ALLERGY, V29, P342, DOI 10.1046/j.1365-2222.1999.00560.x; Bolyen E, 2019, NAT BIOTECHNOL, V37, P852, DOI 10.1038/s41587-019-0209-9; Branchett WJ, 2019, MUCOSAL IMMUNOL, V12, P589, DOI 10.1038/s41385-019-0158-0; Choi SM, 2013, J EXP MED, V210, P551, DOI 10.1084/jem.20120260; Fagerberg L, 2014, MOL CELL PROTEOMICS, V13, P397, DOI 10.1074/mcp.M113.035600; Folmsbee SS, 2016, J ALLERGY CLIN IMMUN, V138, P123, DOI 10.1016/j.jaci.2015.11.037; Folmsbee SS, 2015, AM J PHYSIOL-LUNG C, V308, pL253, DOI 10.1152/ajplung.00331.2014; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; HEUCKEROTH RO, 1987, J BIOL CHEM, V262, P9709; Huttemann M, 2012, MITOCHONDRION, V12, P294, DOI 10.1016/j.mito.2011.11.002; Ito T, 2017, J EXP MED, V214, P3037, DOI 10.1084/jem.20162108; Kayraklioglu N, 2021, METHODS MOL BIOL, V2197, P51, DOI 10.1007/978-1-0716-0872-2_4; Kayraklioglu N, 2017, MOL THER-NUCL ACIDS, V8, P243, DOI 10.1016/j.omtn.2017.06.015; Kim SH, 2009, CLIN EXP ALLERGY, V39, P203, DOI 10.1111/j.1365-2222.2008.03117.x; Kitagaki K, 2006, CLIN EXP IMMUNOL, V143, P249, DOI 10.1111/j.1365-2249.2005.03003.x; Klinman DM, 2016, WIRES NANOMED NANOBI, V8, P631, DOI 10.1002/wnan.1382; Klinman DM, 2015, MOL THER, V23, P222, DOI 10.1038/mt.2014.251; Kobayashi S, 2000, J BIOL CHEM, V275, P10723, DOI 10.1074/jbc.275.15.10723; KUBALAK SW, 1994, J BIOL CHEM, V269, P16961; Lai YP, 2012, IMMUNITY, V37, P74, DOI 10.1016/j.immuni.2012.04.010; Levetan Claresa S, 2008, Endocr Pract, V14, P1075; Majewska-Szczepanik M, 2016, J ALLERGY CLIN IMMUN, V138, P262, DOI 10.1016/j.jaci.2015.11.018; McGeachie MJ, 2015, J ALLERGY CLIN IMMUN, V136, P1503, DOI 10.1016/j.jaci.2015.04.039; Mikami A, 2020, MOL BIOL REP, V47, P6717, DOI 10.1007/s11033-020-05727-6; Montamat G, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.590054; Mueller-Hoecker Josef, 2008, Int J Med Sci, V5, P152; Namai F, 2020, EXP MOL MED, V52, P1627, DOI 10.1038/s12276-020-00507-5; Ogita T, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00379; OMENN GS, 1974, AM J HUM GENET, V26, P393; Ouyang WJ, 2019, IMMUNITY, V50, P871, DOI 10.1016/j.immuni.2019.03.020; Papi A, 2018, LANCET, V391, P783, DOI 10.1016/S0140-6736(17)33311-1; Pawankar R, 2014, WORLD ALLERGY ORGAN, V7, DOI 10.1186/1939-4551-7-12; Perin P, 2014, IMMUNOGENETICS, V66, P143, DOI 10.1007/s00251-013-0755-0; R Core Team, 2018, R LANG ENV STAT COMP, P10, DOI [DOI 10.1038/SJ.HDY.6800737, 10.1108/eb003648]; Rachmilewitz D, 2004, GASTROENTEROLOGY, V126, P520, DOI 10.1053/j.gastro.2003.11.019; Reikvam DH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017996; Roy SR, 2003, J ALLERGY CLIN IMMUN, V112, P571, DOI 10.1067/mai.2003.1711; Sabatel C, 2017, IMMUNITY, V46, P457, DOI 10.1016/j.immuni.2017.02.016; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Schubbert R, 1997, P NATL ACAD SCI USA, V94, P961, DOI 10.1073/pnas.94.3.961; Shigemori S, 2020, ANIM SCI J, V91, DOI 10.1111/asj.13468; Shigemori S, 2015, MICROB CELL FACT, V14, DOI 10.1186/s12934-015-0378-2; Shimosato T, 2010, BIOCHEM BIOPH RES CO, V394, P81, DOI 10.1016/j.bbrc.2010.02.110; Shin JH, 2019, ENDOCRINOLOGY, V160, P1506, DOI 10.1210/en.2019-00073; Srivastava KD, 2016, J ALLERGY CLIN IMMUN, V138, P536, DOI 10.1016/j.jaci.2016.01.047; Stein MM, 2016, NEW ENGL J MED, V375, P411, DOI 10.1056/NEJMoa1508749; Steiner NC, 2021, INT ARCH ALLERGY IMM, V182, P807, DOI 10.1159/000515352; Sur S, 1999, J IMMUNOL, V162, P6284; Vangheluwe P, 2005, BIOCHEM J, V389, P151, DOI 10.1042/BJ20050068; Vatanen T, 2016, CELL, V165, P842, DOI 10.1016/j.cell.2016.04.007; von Beust BR, 2005, EUR J IMMUNOL, V35, P1869, DOI 10.1002/eji.200526124; Wang YQ, 2015, MOL THER, V23, P297, DOI 10.1038/mt.2014.239; Warkman AS, 2012, CYTOSKELETON, V69, P324, DOI 10.1002/cm.21029; Wu CY, 2006, INT IMMUNOPHARMACOL, V6, P610, DOI 10.1016/j.intimp.2005.09.010; Wu YL, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13393; Yamamoto H, 2015, SCI REP-UK, V5, DOI 10.1038/srep07742; Yasuda T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167952; Yee M, 2018, AM J PHYSIOL-LUNG C, V314, pL846, DOI 10.1152/ajplung.00409.2017; Yumoto K, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9111049	63	0	0	3	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 19	2021	12								738041	10.3389/fimmu.2021.738041	http://dx.doi.org/10.3389/fimmu.2021.738041			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XJ6HO	34867960	Green Published, gold			2022-12-18	WOS:000726886700001
J	Wang, J; Guo, C; Cai, L; Liao, CH; Yi, HM; Li, QL; Hu, H; Deng, Q; Lu, YY; Guo, ZM; Chen, ZL; Lu, JH				Wang, Jin; Guo, Cheng; Cai, Lin; Liao, Conghui; Yi, Huaimin; Li, Qianlin; Hu, Huan; Deng, Qiang; Lu, Yuying; Guo, Zhongmin; Chen, Zeliang; Lu, Jiahai			Pre-Existing Cross-Reactive Antibody Responses Do Not Significantly Impact Inactivated COVID-19 Vaccine-Induced Neutralization	FRONTIERS IN IMMUNOLOGY			English	Article						SARS-CoV-2; seasonal coronavirus; inactivated vaccine; neutralization; cross-reactive antibody immunity	T-CELLS; SARS-COV-2; IMMUNITY	Recent exposure to seasonal coronaviruses (sCoVs) may stimulate cross-reactive antibody responses against severe acute respiratory syndrome CoV 2 (SARS-CoV-2). However, previous studies have produced divergent results regarding protective or damaging immunity induced by prior sCoV exposure. It remains unknown whether pre-existing humoral immunity plays a role in vaccine-induced neutralization and antibody responses. In this study, we collected 36 paired sera samples from 36 healthy volunteers before and after immunization with inactivated whole-virion SARS-CoV-2 vaccines for COVID-19, and analyzed the distribution and intensity of pre-existing antibody responses at the epitope level pre-vaccination as well as the relationship between pre-existing sCoV immunity and vaccine-induced neutralization. We observed large amounts of pre-existing cross-reactive antibodies in the conserved regions among sCoVs, especially the S2 subunit. Excep t for a few peptides, the IgG and IgM fluorescence intensities against S, M and N peptides did not differ significantly between pre-vaccination and post-vaccination sera of vaccinees who developed a neutralization inhibition rate (%inhibition) <40 and %inhibition >= 40 after two doses of the COVID-19 vaccine. Participants with strong and weak pre-existing cross-reactive antibodies (strong pre-CRA; weak pre-CRA) had similar %inhibition pre-vaccination (10.9% +/- 2.9% vs. 12.0% +/- 2.2%, P=0.990) and post-vaccination (43.8% +/- 25.1% vs. 44.6% +/- 21.5%, P=0.997). Overall, the strong pre-CRA group did not show a significantly greater increase in antibody responses to the S protein linear peptides post-vaccination compared with the weak pre-CRA group. Therefore, we found no evidence for a significant impact of pre-existing antibody responses on inactivated vaccine-induced neutralization and antibody responses. Our research provides an important basis for inactivated SARS-CoV-2 vaccine use in the context of high sCoV seroprevalence.	[Wang, Jin; Liao, Conghui; Yi, Huaimin; Li, Qianlin; Hu, Huan; Deng, Qiang; Lu, Yuying; Chen, Zeliang; Lu, Jiahai] Sun Yat Sen Univ, Sch Publ Hlth, Dept Epidemiol, Guangzhou, Peoples R China; [Wang, Jin; Liao, Conghui; Yi, Huaimin; Li, Qianlin; Hu, Huan; Deng, Qiang; Lu, Yuying; Chen, Zeliang; Lu, Jiahai] Natl Med Prod Adm NMPA, Key Lab Qual Monitoring & Evaluat Vaccines & Biol, Guangzhou, Peoples R China; [Guo, Cheng] Columbia Univ, Mailman Sch Publ Hlth, Ctr Infect & Immun, New York, NY USA; [Cai, Lin] Futian Dist Ctr Dis Control & Prevent, Shenzhen, Peoples R China; [Guo, Zhongmin] Sun Yat Sen Univ, Lab Anim Ctr, Guangzhou, Peoples R China	Sun Yat Sen University; Columbia University; Sun Yat Sen University	Chen, ZL; Lu, JH (corresponding author), Sun Yat Sen Univ, Sch Publ Hlth, Dept Epidemiol, Guangzhou, Peoples R China.; Chen, ZL; Lu, JH (corresponding author), Natl Med Prod Adm NMPA, Key Lab Qual Monitoring & Evaluat Vaccines & Biol, Guangzhou, Peoples R China.; Guo, ZM (corresponding author), Sun Yat Sen Univ, Lab Anim Ctr, Guangzhou, Peoples R China.	chenzliang5@mail.sysu.edu.cn; guozhm@mail.sysu.edu.cn						Anderson EM, 2021, CELL, V184, P1858, DOI 10.1016/j.cell.2021.02.010; Anichini G, 2021, NEW ENGL J MED, V385, P90, DOI 10.1056/NEJMc2103825; Braun J, 2020, NATURE, V587, P270, DOI 10.1038/s41586-020-2598-9; Dugas M, 2021, J CLIN VIROL, V139, DOI 10.1016/j.jcv.2021.104847; Dugas M, 2021, INT J INFECT DIS, V105, DOI 10.1016/j.ijid.2021.02.085; Edridge AWD, 2020, NAT MED, V26, P1691, DOI 10.1038/s41591-020-1083-1; Focosi D, 2021, LIFE-BASEL, V11, DOI 10.3390/life11040298; Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015; Grifoni A, 2020, CELL HOST MICROBE, V27, P671, DOI 10.1016/j.chom.2020.03.002; Guo L, 2021, EMERG MICROBES INFEC, V10, P664, DOI 10.1080/22221751.2021.1905488; Haslwanter D, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006643; Henry C, 2018, TRENDS IMMUNOL, V39, P70, DOI 10.1016/j.it.2017.08.003; Huang AT, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18450-4; Imai K, 2021, INT J INFECT DIS, V111, P68, DOI 10.1016/j.ijid.2021.08.026; Klompus S, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abe9950; Krammer F, 2021, NEW ENGL J MED, V384, P1372, DOI 10.1056/NEJMc2101667; Le Bert N, 2020, NATURE, V584, P457, DOI 10.1038/s41586-020-2550-z; Lee WS, 2020, NAT MICROBIOL, V5, P1185, DOI 10.1038/s41564-020-00789-5; Li Y, 2021, CELL REP, V34, DOI 10.1016/j.celrep.2021.108915; Lineburg KE, 2021, IMMUNITY, V54, P1055, DOI 10.1016/j.immuni.2021.04.006; Lu S, 2021, CELL REP, V34, DOI 10.1016/j.celrep.2020.108666; Manisty C, 2021, LANCET, V397, P1057, DOI 10.1016/S0140-6736(21)00501-8; Mateus J, 2020, SCIENCE, V370, P89, DOI 10.1126/science.abd3871; Mishra N, 2021, COMMUN BIOL, V4, DOI 10.1038/s42003-021-01743-9; Ng KW, 2020, SCIENCE, V370, P1339, DOI 10.1126/science.abe1107; Paules CI, 2020, JAMA-J AM MED ASSOC, V323, P707, DOI 10.1001/jama.2020.0757; Piccoli L, 2020, CELL, V183, P1024, DOI 10.1016/j.cell.2020.09.037; Quiros-Fernandez I, 2021, EBIOMEDICINE, V72, DOI 10.1016/j.ebiom.2021.103610; Ruetalo N, 2021, MSPHERE, V6, DOI 10.1128/mSphere.01145-20; Saadat S, 2021, JAMA-J AM MED ASSOC, V325, P1467, DOI 10.1001/jama.2021.3341; Sagar M, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI143380; Sermet-Gaudelus I, 2021, EUROSURVEILLANCE, V26, P9, DOI 10.2807/1560-7917.ES.2021.26.13.2001782; Song G, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-23074-3; Tan CW, 2021, NEW ENGL J MED, V385, P1401, DOI 10.1056/NEJMoa2108453; Walls AC, 2020, CELL, V181, P281, DOI [10.1016/j.cell.2020.02.058, 10.1016/j.cell.2020.11.032]; Wang J, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.696370; Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045; Woudenberg T, 2021, EBIOMEDICINE, V70, DOI 10.1016/j.ebiom.2021.103495; Y. Galipeau, 2021, medRxiv, DOI 10.1101/2021.07.16.21260079; Yamaguchi T, 2021, INT J INFECT DIS, V109, P261, DOI 10.1016/j.ijid.2021.07.015; Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3	41	0	0	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 19	2021	12								772511	10.3389/fimmu.2021.772511	http://dx.doi.org/10.3389/fimmu.2021.772511			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YG4OP	34868035	Green Published, gold			2022-12-18	WOS:000742470400001
J	Weiss, E; Vlahos, A; Kim, B; Wijegunasekara, S; Shanmuganathan, D; Aitken, T; Joo, JHE; Imran, S; Shepherd, R; Craig, JM; Green, M; Hiden, U; Novakovic, B; Saffery, R				Weiss, Elisa; Vlahos, Amanda; Kim, Bowon; Wijegunasekara, Sachintha; Shanmuganathan, Dhanya; Aitken, Thomas; Joo, Ji-Hoon E.; Imran, Samira; Shepherd, Rebecca; Craig, Jeffrey M.; Green, Mark; Hiden, Ursula; Novakovic, Boris; Saffery, Richard			Transcriptomic Remodelling of Fetal Endothelial Cells During Establishment of Inflammatory Memory	FRONTIERS IN IMMUNOLOGY			English	Article						endothelial progenitor cell; endothelial cells; inflammation; trained immunity; inflammatory memory; innate immune memory; HUVEC (human umbilical vein endothelial cells); transcriptome (RNA-seq)	PROGENITOR CELLS; IDENTIFICATION; INDUCTION; TOLERANCE; INFECTION; IMMUNITY; PACKAGE	Inflammatory memory involves the molecular and cellular 'reprogramming' of innate immune cells following exogenous stimuli, leading to non-specific protection against subsequent pathogen exposure. This phenomenon has now also been described in non-hematopoietic cells, such as human fetal and adult endothelial cells. In this study we mapped the cell-specific DNA methylation profile and the transcriptomic remodelling during the establishment of inflammatory memory in two distinct fetal endothelial cell types - a progenitor cell (ECFC) and a differentiated cell (HUVEC) population. We show that both cell types have a core transcriptional response to an initial exposure to a viral-like ligand, Poly(I:C), characterised by interferon responsive genes. There was also an ECFC specific response, marked by the transcription factor ELF1, suggesting a non-canonical viral response pathway in progenitor endothelial cells. Next, we show that both ECFCs and HUVECs establish memory in response to an initial viral exposure, resulting in an altered subsequent response to lipopolysaccharide. While the capacity to train or tolerize the induction of specific sets of genes was similar between the two cell types, the progenitor ECFCs show a higher capacity to establish memory. Among tolerized cellular pathways are those involved in endothelial barrier establishment and leukocyte migration, both important for regulating systemic immune-endothelial cell interactions. These findings suggest that the capacity for inflammatory memory may be a common trait across different endothelial cell types but also indicate that the specific downstream targets may vary by developmental stage.	[Weiss, Elisa; Hiden, Ursula] Med Univ Graz, Dept Obstet & Gynaecol, Perinatal Res Lab, Graz, Austria; [Vlahos, Amanda; Kim, Bowon; Wijegunasekara, Sachintha; Shanmuganathan, Dhanya; Aitken, Thomas; Imran, Samira; Shepherd, Rebecca; Novakovic, Boris; Saffery, Richard] Murdoch Childrens Res Inst, Mol Immun Infect & Immun Theme, Parkville, Vic, Australia; [Aitken, Thomas; Green, Mark] Univ Melbourne, Dept Biosci, Parkville, Vic, Australia; [Joo, Ji-Hoon E.] Univ Melbourne, Dept Clin Pathol, Colorectal Oncgen Grp, Melbourne, Vic, Australia; [Joo, Ji-Hoon E.] Univ Melbourne, Ctr Canc Res, Melbourne, Vic, Australia; [Imran, Samira; Craig, Jeffrey M.; Novakovic, Boris; Saffery, Richard] Univ Melbourne, Royal Childrens Hosp, Dept Paediat, Parkville, Vic, Australia; [Craig, Jeffrey M.] Murdoch Childrens Res Inst, Mol Epidemiol, Parkville, Vic, Australia; [Craig, Jeffrey M.] Deakin Univ, Inst Mental & Phys Hlth & Clin Translat IMPACT, Sch Med, Geelong, Vic, Australia	Medical University of Graz; Murdoch Children's Research Institute; University of Melbourne; University of Melbourne; University of Melbourne; Royal Children's Hospital Melbourne; University of Melbourne; Murdoch Children's Research Institute; Deakin University	Hiden, U (corresponding author), Med Univ Graz, Dept Obstet & Gynaecol, Perinatal Res Lab, Graz, Austria.; Novakovic, B (corresponding author), Murdoch Childrens Res Inst, Mol Immun Infect & Immun Theme, Parkville, Vic, Australia.; Novakovic, B (corresponding author), Univ Melbourne, Royal Childrens Hosp, Dept Paediat, Parkville, Vic, Australia.	ursula.hiden@medunigraz.at; boris.novakovic@mcri.edu.au	Saffery, Richard/GLS-1976-2022	Saffery, Richard/0000-0002-9510-4181; Hiden, Ursula/0000-0001-8009-020X; Weiss, Elisa/0000-0002-0958-8280	NHMRC [APP1173314, APP1157556]; Austrian Science Fund FWF [Doc 31-B26]; Medical University of Graz, Austria;  [31-B26]	NHMRC(National Health and Medical Research Council (NHMRC) of Australia); Austrian Science Fund FWF(Austrian Science Fund (FWF)); Medical University of Graz, Austria; 	BN is supported by an NHMRC Investigator Grant (APP1173314) and an NHMRC Project Grant (APP1157556). UH and EW are supported through the PhD program Inflammatory Disorders in Pregnancy (DP-iDP) by the Austrian Science Fund FWF (Doc 31-B26) and the Medical University of Graz, Austria.	Arts RJW, 2018, CELL HOST MICROBE, V23, P89, DOI 10.1016/j.chom.2017.12.010; Arts RJW, 2016, CELL METAB, V24, P807, DOI 10.1016/j.cmet.2016.10.008; Aryee MJ, 2014, BIOINFORMATICS, V30, P1363, DOI 10.1093/bioinformatics/btu049; Beck GC, 1999, CLIN EXP IMMUNOL, V118, P298; Bekkering S, 2019, CELL METAB, V30, P1, DOI 10.1016/j.cmet.2019.05.014; Bekkering S, 2018, CELL, V172, P135, DOI 10.1016/j.cell.2017.11.025; Biswas SK, 2009, TRENDS IMMUNOL, V30, P475, DOI 10.1016/j.it.2009.07.009; Bompais H, 2004, BLOOD, V103, P2577, DOI 10.1182/blood-2003-08-2770; Bonilla FA, 2010, J ALLERGY CLIN IMMUN, V125, pS33, DOI 10.1016/j.jaci.2009.09.017; Brass AL, 2009, CELL, V139, P1243, DOI 10.1016/j.cell.2009.12.017; Brodowski L, 2019, FRONT CELL DEV BIOL, V7, DOI [10.3389/fceil.2019.00032, 10.3389/fcell.2019.00032]; Burgner DP, 2015, ATHEROSCLEROSIS, V239, P496, DOI 10.1016/j.atherosclerosis.2015.02.024; Cheent KS, 2013, P NATL ACAD SCI USA, V110, P16981, DOI 10.1073/pnas.1304366110; Comoglio F, 2019, GENE DEV, V33, P1159, DOI 10.1101/gad.326348.119; Cvitic S, 2018, DIABETOLOGIA, V61, P2398, DOI 10.1007/s00125-018-4699-7; DAAR AS, 1984, TRANSPLANTATION, V38, P293, DOI 10.1097/00007890-198409000-00019; Danese S, 2007, J IMMUNOL, V178, P6017, DOI 10.4049/jimmunol.178.10.6017; Divangahi M, 2021, NAT IMMUNOL, V22, P2, DOI 10.1038/s41590-020-00845-6; Drummer C, 2021, ARTERIOSCL THROM VAS, V41, P1032, DOI 10.1161/ATVBAHA.120.315452; Endemann DH, 2004, J AM SOC NEPHROL, V15, P1983, DOI 10.1097/01.ASN.0000132474.50966.DA; Foster SL, 2007, NATURE, V447, P972, DOI 10.1038/nature05836; Guijarro-Munoz I, 2014, J BIOL CHEM, V289, P2457, DOI 10.1074/jbc.M113.521161; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Herzog EM, 2017, PLACENTA, V58, P122, DOI 10.1016/j.placenta.2017.08.070; Hirschi KK, 2008, ARTERIOSCL THROM VAS, V28, P1584, DOI 10.1161/ATVBAHA.107.155960; Hjort L, 2019, LANCET DIABETES ENDO, V7, P796, DOI 10.1016/S2213-8587(19)30078-6; Indraccolo S, 2007, J IMMUNOL, V178, P1122, DOI 10.4049/jimmunol.178.2.1122; Ingram DA, 2004, BLOOD, V104, P2752, DOI 10.1182/blood-2004-04-1396; Joo JE, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-475; Keating ST, 2020, J MOL MED, V98, P819, DOI 10.1007/s00109-020-01915-w; Keating ST, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107548; Kleinnijenhuis J, 2012, P NATL ACAD SCI USA, V109, P17537, DOI 10.1073/pnas.1202870109; Koch SR, 2017, TRANSL RES, V180, P53, DOI 10.1016/j.trsl.2016.08.001; Krausgruber T, 2020, NATURE, V583, P296, DOI 10.1038/s41586-020-2424-4; Langmead Ben, 2010, Curr Protoc Bioinformatics, VChapter 11, DOI 10.1002/0471250953.bi1107s32; Leopold B, 2019, HISTOCHEM CELL BIOL, V152, P377, DOI 10.1007/s00418-019-01815-2; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Maksimovic J, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-6-r44; McLean CY, 2010, NAT BIOTECHNOL, V28, P495, DOI 10.1038/nbt.1630; Mourits VP, 2021, CLIN TRANSL IMMUNOL, V10, DOI 10.1002/cti2.1253; Naik S, 2017, NATURE, V550, P475, DOI 10.1038/nature24271; Netea MG, 2020, NAT REV IMMUNOL, V20, P375, DOI 10.1038/s41577-020-0285-6; Netea MG, 2016, SCIENCE, V352, DOI 10.1126/science.aaf1098; Novakovic B, 2016, CELL, V167, P1354, DOI 10.1016/j.cell.2016.09.034; Nuzzolo ER, 2014, BLOOD TRANSFUS-ITALY, V12, pS367, DOI 10.2450/2013.0042-13; Oliveira SDS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023547; Parkin J, 2001, LANCET, V357, P1777, DOI 10.1016/S0140-6736(00)04904-7; Pepin ME, 2021, EXP CELL RES, V400, DOI 10.1016/j.yexcr.2021.112485; Phipson B, 2016, BIOINFORMATICS, V32, P286, DOI 10.1093/bioinformatics/btv560; Pidsley R, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1066-1; Pober JS, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01907; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Rose ML, 1998, CELL MOL LIFE SCI, V54, P965, DOI 10.1007/s000180050226; Saffery R, 2012, INT J EPIDEMIOL, V41, P55, DOI 10.1093/ije/dyr140; Seifert LL, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007634; Shalova IN, 2015, IMMUNITY, V42, P484, DOI 10.1016/j.immuni.2015.02.001; Shao Y, 2014, J HEMATOL ONCOL, V7, DOI 10.1186/s13045-014-0080-6; Shiao SL, 2007, J IMMUNOL, V179, P4397, DOI 10.4049/jimmunol.179.7.4397; Sohrabi Y, 2020, J MOL CELL CARDIOL, V146, P121, DOI 10.1016/j.yjmcc.2020.07.006; Stark RJ, 2016, CLIN SCI, V130, P451, DOI 10.1042/CS20150592; Toshner M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091334; Turro E, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-2-r13; Wang WM, 2011, INFLAMMATION, V34, P509, DOI 10.1007/s10753-010-9258-4; Xiao L, 2014, AM J PHYSIOL-HEART C, V306, pH317, DOI 10.1152/ajpheart.00182.2013; Yuan L, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10160; Zakrzewicz A, 1997, BLOOD, V89, P3228, DOI 10.1182/blood.V89.9.3228	66	0	0	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 19	2021	12								757393	10.3389/fimmu.2021.757393	http://dx.doi.org/10.3389/fimmu.2021.757393			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XJ1UX	34867995	Green Published, gold			2022-12-18	WOS:000726583100001
J	Jacquelot, N; Narni-Mancinelli, E; Barrow, AD				Jacquelot, Nicolas; Narni-Mancinelli, Emilie; Barrow, Alexander D.			Editorial: Innate Lymphoid Cells in Cancer: Friends or Foes?	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						innate lymphoid cells; natural killer cells; immunotherapy; cancer; innate immunity			[Jacquelot, Nicolas] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada; [Narni-Mancinelli, Emilie] Aix Marseille Univ, CNRS, Ctr Immunol Marseille Luminy, INSERM, Marseille, France; [Barrow, Alexander D.] Univ Melbourne, Dept Microbiol & Immunol, Melbourne, Vic, Australia; [Barrow, Alexander D.] Peter Doherty Inst Infect & Immun, Melbourne, Vic, Australia	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; University of Melbourne	Jacquelot, N (corresponding author), Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada.; Narni-Mancinelli, E (corresponding author), Aix Marseille Univ, CNRS, Ctr Immunol Marseille Luminy, INSERM, Marseille, France.; Barrow, AD (corresponding author), Univ Melbourne, Dept Microbiol & Immunol, Melbourne, Vic, Australia.; Barrow, AD (corresponding author), Peter Doherty Inst Infect & Immun, Melbourne, Vic, Australia.	nicolas.jacquelot@uhnresearch.ca; narni@ciml.univ-mrs.fr; alexanderdavid.barrow@unimelb.edu.au	Narni-Mancinelli, Emilie/X-1888-2018	Narni-Mancinelli, Emilie/0000-0002-7001-1026					0	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 18	2021	12								804156	10.3389/fimmu.2021.804156	http://dx.doi.org/10.3389/fimmu.2021.804156			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6I1FR	34868090	gold, Green Published			2022-12-18	WOS:000885872200001
J	Lajoie, JL; Kowatsch, MM; Mwangi, LW; Boily-Larouche, G; Oyugi, J; Chen, YF; Kimani, M; Ho, EA; Kimani, J; Fowke, KR				Lajoie, Julie; Kowatsch, Monika M.; Mwangi, Lucy W.; Boily-Larouche, Genevieve; Oyugi, Julius; Chen, Yufei; Kimani, Makobu; Ho, Emmanuel A.; Kimani, Joshua; Fowke, Keith R.			Low-Dose Acetylsalicylic Acid Reduces T Cell Immune Activation: Potential Implications for HIV Prevention	FRONTIERS IN IMMUNOLOGY			English	Article						HIV; immune activation (IA); HIV risk; aspirin; Acetylsalicylic acid; inflammation; immune quiescence; HIV prevention	ASPIRIN; INFLAMMATION; ACQUISITION; EXPRESSION; INHIBIT; CD4(+); WOMEN; GEL	Introduction: Acetylsalicylic acid (ASA) is a well-known and safe anti-inflammatory. At low-dose, it is prescribed to prevent secondary cardiovascular events in those with preexisting conditions and to prevent preeclampsia. Little is known about how low-dose ASA affects the immune response. In this study, we followed women to assess how ASA use modifies T cells immune phenotypes in the blood and at the genital tract. Methods: HIV uninfected women from Kenya were enrolled in this study and followed for one month to assess baseline responses including systemic/mucosal baseline immune activation. Participants then received 81mg of ASA daily for 6 weeks to assess changes to T cell immune activation (systemic and mucosal) relative to baseline levels. Results: The concentration of ASA measured in the blood was 58% higher than the level measured at the female genital tract. In the blood, the level of ASA was inversely correlated with the following: the proportion of Th17 expressing HLA-DR (p=0.04), the proportion of effector CD4(+) T cells expressing CCR5 (p=0.03) and the proportion of CD8(+)Tc17 expressing CCR5 (p=0.04). At the genital tract, ASA use correlated with a decreased of activated CD4(+)T cells [CD4(+)CCR5(+)CD161(+) (p=0.02) and CD4(+)CCR5(+)CD95(+) (p=0.001)]. Conclusion: This study shows that ASA use impacts the immune response in both the systemic and genital tract compartments. This could have major implications for the prevention of infectious diseases such as HIV, in which the virus targets activated T cells to establish an infection. This could inform guidelines on ASA use in women.	[Lajoie, Julie; Kowatsch, Monika M.; Boily-Larouche, Genevieve; Oyugi, Julius; Kimani, Joshua; Fowke, Keith R.] Univ Manitoba, Dept Med Microbiol & Infect Dis, Lab Viral Immunol, Winnipeg, MB, Canada; [Lajoie, Julie; Mwangi, Lucy W.; Oyugi, Julius; Fowke, Keith R.] Univ Nairobi, Dept Med Microbiol, Nairobi, Kenya; [Oyugi, Julius; Kimani, Joshua] Univ Nairobi, Inst Trop & Infect Dis, Nairobi, Kenya; [Chen, Yufei; Ho, Emmanuel A.] Univ Manitoba, Coll Pharm, Winnipeg, MB, Canada; [Kimani, Makobu; Kimani, Joshua; Fowke, Keith R.] Partners Hlth & Dev Africa, Nairobi, Kenya; [Ho, Emmanuel A.] Univ Waterloo, Sch Pharm, Lab Drug Delivery & Biomat, Waterloo, ON, Canada; [Fowke, Keith R.] Univ Manitoba, Dept Community Hlth Sci, Winnipeg, MB, Canada	University of Manitoba; University of Nairobi; University of Nairobi; University of Manitoba; University of Waterloo; University of Manitoba	Fowke, KR (corresponding author), Univ Manitoba, Dept Med Microbiol & Infect Dis, Lab Viral Immunol, Winnipeg, MB, Canada.; Fowke, KR (corresponding author), Univ Nairobi, Dept Med Microbiol, Nairobi, Kenya.; Fowke, KR (corresponding author), Partners Hlth & Dev Africa, Nairobi, Kenya.; Fowke, KR (corresponding author), Univ Manitoba, Dept Community Hlth Sci, Winnipeg, MB, Canada.	keith.fowke@umanitoba.ca		Kowatsch, Monika/0000-0002-8481-5068	Canadian Institutes of Health Research (CIHR) OCH [126275]; CIHR [PJT166153, HB3-164065]; Grand Challenge Canada [S5 386-01]	Canadian Institutes of Health Research (CIHR) OCH(Canadian Institutes of Health Research (CIHR)); CIHR(Canadian Institutes of Health Research (CIHR)); Grand Challenge Canada	Funding support was provided by the Canadian Institutes of Health Research (CIHR) OCH # 126275 (KF, JL), CIHR HB3-164065 (KF, JL, JO, JK), Grand Challenge Canada S5 386-01 (JL) and CIHR PJT166153 (EH).	Card CM, 2013, RETROVIROLOGY, V10, DOI 10.1186/1742-4690-10-141; Chan MMY, 2010, J IMMUNOL, V184, P6418, DOI 10.4049/jimmunol.0903816; Esquivias P, 2014, ONCOL REP, V31, P2785, DOI 10.3892/or.2014.3137; Gerli R, 2001, J IMMUNOL, V166, P832, DOI 10.4049/jimmunol.166.2.832; Groom JR, 2011, EXP CELL RES, V317, P620, DOI 10.1016/j.yexcr.2010.12.017; Juno JA, 2014, JOVE-J VIS EXP, DOI 10.3791/51906; Kees F, 1996, J CHROMATOGR B, V677, P172, DOI 10.1016/0378-4347(95)00464-5; Kondo T, 2007, EUR J IMMUNOL, V37, P54, DOI 10.1002/eji.200636251; Lajoie J, 2019, AIDS RES HUM RETROV, V35, P236, DOI [10.1089/aid.2018.0188, 10.1089/AID.2018.0188]; Lajoie J, 2018, J INT AIDS SOC, V21, DOI 10.1002/jia2.25150; Lanas A, 2011, DRUGS R&D, V11, P277, DOI 10.2165/11593880-000000000-00000; Loprete L, 2014, CLIN DRUG INVEST, V34, P19, DOI 10.1007/s40261-013-0145-2; Machura E, 2008, ARCH IMMUNOL THER EX, V56, P55, DOI 10.1007/s00005-008-0005-6; Mckie J., 2019, MEDS QA MARCH 2016; McKinnon LR, 2018, NAT MED, V24, P491, DOI 10.1038/nm.4506; Moon HG, 2013, EXP MOL MED, V45, DOI 10.1038/emm.2013.10; Naranbhai V, 2012, J INFECT DIS, V206, P993, DOI 10.1093/infdis/jis465; O'Brien M, 2013, JAIDS-J ACQ IMM DEF, V63, P280, DOI 10.1097/QAI.0b013e31828a292c; O'Brien MP, 2017, OPEN FORUM INFECT DI, V4, DOI 10.1093/ofid/ofw278; Omollo K, 2016, AIDS RES HUM RETROV, V32, P1072, DOI 10.1089/aid.2015.0332; Pan XY, 2013, CELL RES, V23, P876, DOI 10.1038/cr.2013.74; Raber I, 2019, LANCET, V393, P2155, DOI 10.1016/S0140-6736(19)30541-0; Saka B, 2013, TURK J BIOCHEM, V38, P63, DOI 10.5505/tjb.2013.75437; Sathaliyawala T, 2013, IMMUNITY, V38, P187, DOI 10.1016/j.immuni.2012.09.020; Saxena A, 2013, EUR J PHARMACOL, V721, P215, DOI 10.1016/j.ejphar.2013.09.032; Sivro A, 2013, IMMUN AGEING, V10, DOI 10.1186/1742-4933-10-42; U.S. Preventive Services Task Force, 2017, LOW DOS ASP US PREV; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948; Zhou G, 2011, J BIOL CHEM, V286, P34820, DOI 10.1074/jbc.M111.267161	29	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 18	2021	12								778455	10.3389/fimmu.2021.778455	http://dx.doi.org/10.3389/fimmu.2021.778455			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6I1GR	34868050	Green Published, gold			2022-12-18	WOS:000885874800001
J	Liang, JQ; Hong, Z; Sun, BY; Guo, ZX; Wang, C; Zhu, JJ				Liang, Jiaqian; Hong, Ze; Sun, Boyue; Guo, Zhaoxi; Wang, Chen; Zhu, Juanjuan			The Alternatively Spliced Isoforms of Key Molecules in the cGAS-STING Signaling Pathway	FRONTIERS IN IMMUNOLOGY			English	Review						alternative splicing; spliced isoforms; cGAS-STING signaling pathway; IFN response; antiviral response	PRE-MESSENGER-RNA; CYTOSOLIC DNA SENSOR; I INTERFERON; GENE-EXPRESSION; ABNORMALITIES; REGULATOR; IMMUNITY	Alternative splicing of pre-mRNA increases transcriptome and proteome diversity by generating distinct isoforms that encode functionally diverse proteins, thus affecting many biological processes, including innate immunity. cGAS-STING signaling pathway, whose key molecules also undergo alternative splicing, plays a crucial role in regulating innate immunity. Protein isoforms of key components in the cGAS-STING-TBK1-IRF3 axis have been detected in a variety of species. A chain of evidence showed that these protein isoforms exhibit distinct functions compared to their normal counterparts. The mentioned isoforms act as positive or negative modulators in interferon response via distinct mechanisms. Particularly, we highlight that alternative splicing serves a vital function for the host to avoid the overactivation of the cGAS-STING signaling pathway and that viruses can utilize alternative splicing to resist antiviral response by the host. These findings could provide insights for potential alternative splicing-targeting therapeutic applications.	[Liang, Jiaqian; Hong, Ze; Guo, Zhaoxi; Wang, Chen; Zhu, Juanjuan] China Pharmaceut Univ, Sch Life Sci & Technol, State Key Lab Nat Medicines, Nanjing, Peoples R China; [Sun, Boyue] Weizmann Inst Sci, Dept Biomol Sci, Rehovot, Israel	China Pharmaceutical University; Weizmann Institute of Science	Wang, C; Zhu, JJ (corresponding author), China Pharmaceut Univ, Sch Life Sci & Technol, State Key Lab Nat Medicines, Nanjing, Peoples R China.				National Natural Science Foundation of China [31730018]; Project Program of State Key Laboratory of Natural Medicines, China Pharmaceutical University [SKLNMZZ202002]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Project Program of State Key Laboratory of Natural Medicines, China Pharmaceutical University	Funding The following grants supported this work, National Natural Science Foundation of China (No. 31730018) and Project Program of State Key Laboratory of Natural Medicines, China Pharmaceutical University (No. SKLNMZZ202002).	Ablasser A, 2013, NATURE, V498, P380, DOI 10.1038/nature12306; ARCH R, 1992, SCIENCE, V257, P682, DOI 10.1126/science.1496383; Ayoubi TAY, 1996, FASEB J, V10, P453, DOI 10.1096/fasebj.10.4.8647344; Baralle FE, 2017, NAT REV MOL CELL BIO, V18, P437, DOI 10.1038/nrm.2017.27; Biamonti G, 2021, AGING CLIN EXP RES, V33, P747, DOI 10.1007/s40520-019-01360-x; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Bonnal SC, 2020, NAT REV CLIN ONCOL, V17, P457, DOI 10.1038/s41571-020-0350-x; Burdette DL, 2011, NATURE, V478, P515, DOI 10.1038/nature10429; Carpenter S, 2014, NAT REV IMMUNOL, V14, P361, DOI 10.1038/nri3682; Chen HH, 2014, J IMMUNOL, V192, P1162, DOI 10.4049/jimmunol.1300798; CHOW LT, 1977, CELL, V12, P1, DOI 10.1016/0092-8674(77)90180-5; DABHOLKAR M, 1995, ONCOL REP, V2, P209; Deng WW, 2008, J BIOL CHEM, V283, P35590, DOI 10.1074/jbc.M805775200; Dlamini Z, 2017, J MOL ENDOCRINOL, V59, pR93, DOI 10.1530/JME-17-0049; Faustino NA, 2003, GENE DEV, V17, P419, DOI 10.1101/gad.1048803; Fernandez-Nogales M, 2016, BRAIN PATHOL, V26, P772, DOI 10.1111/bpa.12430; Gallego-Paez LM, 2017, HUM GENET, V136, P1015, DOI 10.1007/s00439-017-1790-y; Hancks DC, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005203; Hartlova A, 2015, IMMUNITY, V42, P332, DOI 10.1016/j.immuni.2015.01.012; Hertel KJ., 2014, SPLICEOSOMAL PRE MRN; Hu YW, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00084; Ishikawa H, 2008, NATURE, V455, P674, DOI 10.1038/nature07317; Ishikawa H, 2009, NATURE, V461, P788, DOI 10.1038/nature08476; Iwasaki A, 2010, SCIENCE, V327, P291, DOI 10.1126/science.1183021; Jeremiah N, 2014, J CLIN INVEST, V124, P5516, DOI 10.1172/JCI79100; Karpova AY, 2001, MOL CELL BIOL, V21, P4169, DOI 10.1128/MCB.21.13.4169-4176.2001; Karpova AY, 2000, GENE DEV, V14, P2813, DOI 10.1101/gad.813800; Kawai T, 2009, INT IMMUNOL, V21, P317, DOI 10.1093/intimm/dxp017; Keren H, 2010, NAT REV GENET, V11, P345, DOI 10.1038/nrg2776; Li CH, 2011, CELL MOL IMMUNOL, V8, P67, DOI 10.1038/cmi.2010.55; Li Y, 2011, BBA-GENE REGUL MECH, V1809, P166, DOI 10.1016/j.bbagrm.2011.01.006; Liu Y, 2014, NEW ENGL J MED, V371, P507, DOI 10.1056/NEJMoa1312625; Lopez AJ, 1998, ANNU REV GENET, V32, P279, DOI 10.1146/annurev.genet.32.1.279; Marozin S, 2008, MOL THER, V16, P1789, DOI 10.1038/mt.2008.201; Onomoto K, 2021, CELL MOL IMMUNOL, V18, P539, DOI 10.1038/s41423-020-00602-7; Postal M, 2020, CURR OPIN IMMUNOL, V67, P87, DOI 10.1016/j.coi.2020.10.014; Ren W, 2011, MOL BIOL REP, V38, P4415, DOI 10.1007/s11033-010-0569-1; Rodriguez-Garcia Estefania, 2018, Immunohorizons, V2, P363, DOI 10.4049/immunohorizons.1800068; Rothrock C, 2003, MOL CELL, V12, P1317, DOI 10.1016/S1097-2765(03)00434-9; Stamm S, 2005, GENE, V344, P1, DOI 10.1016/j.gene.2004.10.022; Sun LJ, 2013, SCIENCE, V339, P786, DOI 10.1126/science.1232458; Takeuchi O, 2009, IMMUNOL REV, V227, P75, DOI 10.1111/j.1600-065X.2008.00737.x; Tian B, 2017, NAT REV MOL CELL BIO, V18, P18, DOI 10.1038/nrm.2016.116; Urbanski LM, 2018, WIRES RNA, V9, DOI 10.1002/wrna.1476; Wan LL, 2017, CELL, V170, P5, DOI 10.1016/j.cell.2017.06.028; Wang JH, 2018, ARTHRITIS RHEUMATOL, V70, P2036, DOI 10.1002/art.40576; Wang PH, 2018, NUCLEIC ACIDS RES, V46, P4054, DOI 10.1093/nar/gky186; Xu L, 2020, J IMMUNOL, V204, P3191, DOI 10.4049/jimmunol.1901320; Zhai JW, 2008, BIOCHEM BIOPH RES CO, V377, P384, DOI 10.1016/j.bbrc.2008.09.147; Zhang J, 2013, CANCER DISCOV, V3, P1228, DOI 10.1158/2159-8290.CD-13-0253; Zhang J, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.580864; Zhang YJ, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00486-7	52	0	0	7	15	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 18	2021	12								771744	10.3389/fimmu.2021.771744	http://dx.doi.org/10.3389/fimmu.2021.771744			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XI5OR	34868032	Green Published, gold			2022-12-18	WOS:000726161200001
J	Ma, ML; Sun, QP; Li, XJ; Deng, GG; Zhang, YN; Yang, Z; Han, F; Huang, ZY; Fang, YQ; Liao, T; Sun, QQ				Ma, Maolin; Sun, Qipeng; Li, Xiujie; Deng, Gengguo; Zhang, Yannan; Yang, Zhe; Han, Fei; Huang, Zhengyu; Fang, Youqiang; Liao, Tao; Sun, Qiquan			Blockade of IL-6/IL-6R Signaling Attenuates Acute Antibody-Mediated Rejection in a Mouse Cardiac Transplantation Model (vol 12, 778359. 2021)	FRONTIERS IN IMMUNOLOGY			English	Correction						antibody-mediated rejection; IL-6; IL-6R; mouse model; cardiac transplantation			[Ma, Maolin; Deng, Gengguo; Yang, Zhe; Han, Fei; Huang, Zhengyu] Sun Yat Sen Univ, Affiliated Hosp 3, Organ Transplantat Res Inst, Guangzhou, Guangdong, Peoples R China; [Sun, Qipeng; Zhang, Yannan; Liao, Tao; Sun, Qiquan] Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Dept Kidney Transplantat, Guangzhou, Guangdong, Peoples R China; [Li, Xiujie] Sun Yat Sen Univ, Dept Obstet & Gynecol, Affiliated Hosp 3, Guangzhou, Guangdong, Peoples R China; [Fang, Youqiang] Sun Yat Sen Univ, Dept Urol, Affiliated Hosp 3, Guangzhou, Guangdong, Peoples R China	Sun Yat Sen University; Guangdong Academy of Medical Sciences & Guangdong General Hospital; Sun Yat Sen University; Sun Yat Sen University	Liao, T; Sun, QQ (corresponding author), Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Dept Kidney Transplantat, Guangzhou, Guangdong, Peoples R China.; Fang, YQ (corresponding author), Sun Yat Sen Univ, Dept Urol, Affiliated Hosp 3, Guangzhou, Guangdong, Peoples R China.	fangyq@mail.sysu.edu.cn; liaot@mail2.sysu.edu.cn; sunqiq@mail.sysu.edu.cn		Sun, Qiquan/0000-0002-7296-316X				Ma ML, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.778359	1	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 18	2021	12								808329	10.3389/fimmu.2021.808329	http://dx.doi.org/10.3389/fimmu.2021.808329			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6I1IN	34868092	Green Published, gold			2022-12-18	WOS:000885879800001
J	Ma, TT; Shi, J; Xiao, YX; Bian, TY; Wang, JC; Hui, LY; Wang, MC; Liu, HS				Ma, Tiantian; Shi, Jing; Xiao, Yuxia; Bian, Tianyue; Wang, Jincheng; Hui, Lingyun; Wang, Mengchang; Liu, Huasheng			Study on the Relationship Between the Expression of B Cell Mature Antigen and the Classification, Stage, and Prognostic Factors of Multiple Myeloma	FRONTIERS IN IMMUNOLOGY			English	Article						B cell mature antigen; BCMA; multiple myeloma; MM; chimeric antigen receptor T cells therapy; CAR-T	MATURATION ANTIGEN; THERAPY	The expression level of BCMA in bone marrow of 54 MM patients was detected in this study to explore the relationship between the BCMA expression and the classification, stage, and prognostic factors of MM. The BCMA expression level of the stable group and remission group was lower than that of the newly diagnosed group and relapse group (P=0.001). There was no significant difference in BCMA expression of MM patients in different types and stages (P>0.05), but it was found that for the newly diagnosed MM patients, the BCMA expression level of IgG patients was higher than that of IgA or light-chain patients (rank average 11.20 vs 5.44, P=0.014). There was no significant correlation between the BCMA expression and the age and serum creatinine of MM patients (P>0.05). And there was no significant difference in BCMA expression between patients with different levels of age and serum creatinine (P>0.05). But it was found that the BCMA expression level of the newly diagnosed MM patients was moderately positively correlated with their age (P=0.025, r=0.595). There was no significant correlation between the BCMA expression and serum beta 2-microglobulin, serum lactate dehydrogenase, free kap/lam ratio, and urine beta 2-microglobulin (P>0.05). But we found that the BCMA expression of patients with high serum beta 2-microglobulin was higher than that of patients with low serum beta 2-microglobulin (rank average 28.89 vs 17.54, P=0.017). And the BCMA expression of patients with abnormal serum free kap/lam ratio was higher than that of patients with normal ratio (rank average 28.49 vs 13.55, P=0.004). The BCMA expression was strongly positively correlated with 24-h urine protein, was moderately positively correlated with serum M protein and the percentage of plasma cells in bone marrow, was moderately negatively correlated with albumin and hemoglobin count, and was weakly positively correlated with serum corrected calcium (P<0.05). And it was found that the BCMA expression of positive serum immunofixation electrophoresis patients was higher than that of negative patients (rank average 29.94 vs 16.75, P=0.017). And we try to clarify the relationship between the bone marrow BCMA expression and the peripheral blood sBCMA expression. However, we have not found a clear correlation between them so far (P>0.05).	[Ma, Tiantian; Xiao, Yuxia; Bian, Tianyue; Wang, Jincheng; Wang, Mengchang; Liu, Huasheng] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Hematol, Xian, Peoples R China; [Ma, Tiantian] Xi An Jiao Tong Univ, Affiliated Hosp, Xian Hosp 3, Dept Hematol, Xian, Peoples R China; [Shi, Jing] Xi An Jiao Tong Univ, Affiliated Hosp 2, Dept Resp & Endocrinol, Xian, Peoples R China; [Hui, Lingyun] Xi An Jiao Tong Univ, Affiliated Hosp 1, Clin Lab, Xian, Peoples R China; [Liu, Huasheng] Xi An Jiao Tong Univ, Affiliated Hosp 1, Biobank, Xian, Peoples R China	Xi'an Jiaotong University; Xi'an Jiaotong University; Xi'an Jiaotong University; Xi'an Jiaotong University; Xi'an Jiaotong University	Liu, HS (corresponding author), Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Hematol, Xian, Peoples R China.; Liu, HS (corresponding author), Xi An Jiao Tong Univ, Affiliated Hosp 1, Biobank, Xian, Peoples R China.	Lhs681995@126.com			EUREKA BJ Therapeutics, Inc; Shaanxi Province Science and Technology research Projects [2016SF-122]; Provincial University Joint Project - General Project [No.2020GXLH-Y-006]	EUREKA BJ Therapeutics, Inc; Shaanxi Province Science and Technology research Projects; Provincial University Joint Project - General Project	This study received funding from EUREKA BJ Therapeutics, Inc, the Shaanxi Province Science and Technology research Projects (Grant No.2016SF-122) and The Provincial University Joint Project - General Project (Grant No.2020GXLH-Y-006). The funders were not involved in the study design, collection, analysis, interpretation of data, the writing of this article, or the decision to submit it for publication.	Ali SA, 2016, BLOOD, V128, P1688, DOI 10.1182/blood-2016-04-711903; Bhole MV, 2014, ANN CLIN BIOCHEM, V51, P528, DOI 10.1177/0004563213518758; Braunstein M, 2021, EXPERT REV HEMATOL, V14, P377, DOI 10.1080/17474086.2021.1909469; Brudno JN, 2018, J CLIN ONCOL, V36, P2267, DOI 10.1200/JCO.2018.77.8084; Cardona-Benavides IJ, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10020336; Carpenter RO, 2013, CLIN CANCER RES, V19, P2048, DOI 10.1158/1078-0432.CCR-12-2422; Chen HM, 2017, BLOOD, V130; Chen YX, 2021, PANMINERVA MED, V63, P28, DOI 10.23736/S0031-0808.20.04121-X; Chinese Hematology Association, 2020, Zhonghua Nei Ke Za Zhi, V59, P341, DOI 10.3760/cma.j.cn112138-20200304-00179; Chinese Hematology Association, 2017, Zhonghua Nei Ke Za Zhi, V56, P866, DOI 10.3760/cma.j.issn.0578-1426.2017.11.021; Cho SF, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01821; Cohen AD, 2019, J CLIN INVEST, V129, P2210, DOI 10.1172/JCI126397; D'Agostino M, 2020, LEUKEMIA, V34, P21, DOI 10.1038/s41375-019-0669-4; D'Anastasi M, 2014, AM J ROENTGENOL, V203, P854, DOI 10.2214/AJR.13.10724; Ding Lijuan, 2021, Stem Cell Investig, V8, P1, DOI 10.21037/sci-2020-029; Friedman KM, 2018, HUM GENE THER, V29, P585, DOI 10.1089/hum.2018.001; Hose D, 2021, J CANCER RES CLIN, V147, P205, DOI 10.1007/s00432-020-03323-6; Hosen N, 2019, CANCERS, V11, DOI 10.3390/cancers11122024; Jasinski M, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.632937; Kazandjian D, 2016, SEMIN ONCOL, V43, P676, DOI 10.1053/j.seminoncol.2016.11.004; Kumar SK, 2014, LEUKEMIA, V28, P1122, DOI 10.1038/leu.2013.313; Kyle RA, 2003, MAYO CLIN PROC, V78, P21, DOI 10.4065/78.1.21; Li CR, 2018, BLOOD, V132, DOI 10.1182/blood-2018-99-116898; Luan Chun-Yan, 2019, Zhongguo Shi Yan Xue Ye Xue Za Zhi, V27, P1701, DOI 10.19746/j.cnki.issn.1009-2137.2019.05.053; Ma TT, 2019, ANN HEMATOL, V98, P813, DOI 10.1007/s00277-018-03592-9; Manier S, 2017, NAT REV CLIN ONCOL, V14, P100, DOI 10.1038/nrclinonc.2016.122; Martin TG, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8121522; Mateos MV, 2018, NEW ENGL J MED, V378, P518, DOI 10.1056/NEJMoa1714678; Offidani M, 2021, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.624661; Okabe S, 2019, ANN HEMATOL, V98, P723, DOI 10.1007/s00277-018-3547-7; Ormhoj M, 2017, CURR HEMATOL MALIG R, V12, P119, DOI 10.1007/s11899-017-0373-2; Palumbo A, 2011, NEW ENGL J MED, V364, P1046, DOI 10.1056/NEJMra1011442; Pont MJ, 2019, BLOOD, V134, P1585, DOI 10.1182/blood.2019000050; Raje N, 2019, NEW ENGL J MED, V380, P1726, DOI 10.1056/NEJMoa1817226; Rasche L, 2017, CANCER TREAT REV, V55, P190, DOI 10.1016/j.ctrv.2017.03.010; Richardson PG, 2019, LANCET ONCOL, V20, P781, DOI 10.1016/S1470-2045(19)30152-4; Rosenblatt J, 2017, BLOOD, V129, P275, DOI 10.1182/blood-2016-08-731885; Ross FM, 2012, HAEMATOL-HEMATOL J, V97, P1272, DOI 10.3324/haematol.2011.056176; Xu LM, 2020, ANN HEMATOL, V99, P581, DOI 10.1007/s00277-020-03915-9	39	0	0	4	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 18	2021	12								724411	10.3389/fimmu.2021.724411	http://dx.doi.org/10.3389/fimmu.2021.724411			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6I1HS	34867949	Green Published, gold			2022-12-18	WOS:000885877500001
J	Martin, PJ; Levine, DM; Storer, BE; Zheng, XW; Jain, D; Heavner, B; Norris, BM; Geraghty, DE; Spellman, SR; Sather, CL; Wu, FA; Hansen, JA				Martin, Paul J.; Levine, David M.; Storer, Barry E.; Zheng, Xiuwen; Jain, Deepti; Heavner, Ben; Norris, Brandon M.; Geraghty, Daniel E.; Spellman, Stephen R.; Sather, Cassie L.; Wu, Feinan; Hansen, John A.			A Model of Minor Histocompatibility Antigens in Allogeneic Hematopoietic Cell Transplantation	FRONTIERS IN IMMUNOLOGY			English	Article						genetic variation; graft-versus-host disease; single nucleotide polymorphisms (SNPs); hematopoietic cell transplantation; minor histocompatibility antigens	VERSUS-HOST-DISEASE; HLA; MHC; PEPTIDES; IMMUNOTHERAPY; AFFINITY; ALLELES; RISK	Minor histocompatibility antigens (mHAg) composed of peptides presented by HLA molecules can cause immune responses involved in graft-versus-host disease (GVHD) and graft-versus-leukemia effects after allogeneic hematopoietic cell transplantation (HCT). The current study was designed to identify individual graft-versus-host genomic mismatches associated with altered risks of acute or chronic GVHD or relapse after HCT between HLA-genotypically identical siblings. Our results demonstrate that in allogeneic HCT between a pair of HLA-identical siblings, a mHAg manifests as a set of peptides originating from annotated proteins and non-annotated open reading frames, which i) are encoded by a group of highly associated recipient genomic mismatches, ii) bind to HLA allotypes in the recipient, and iii) evoke a donor immune response. Attribution of the immune response and consequent clinical outcomes to individual peptide components within this set will likely differ from patient to patient according to their HLA types.	[Martin, Paul J.; Storer, Barry E.; Norris, Brandon M.; Geraghty, Daniel E.; Hansen, John A.] Fred Hutchinson Canc Res Ctr, Div Clin Res, 1124 Columbia St, Seattle, WA 98104 USA; [Martin, Paul J.; Hansen, John A.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA; [Levine, David M.; Zheng, Xiuwen; Jain, Deepti; Heavner, Ben] Univ Washington, Dept Biostat, Seattle, WA 98195 USA; [Spellman, Stephen R.] Ctr Int Blood & Marrow Transplant Res, Natl Marrow Donor Program, Minneapolis, MN USA; [Sather, Cassie L.; Wu, Feinan] Fred Hutchinson Canc Res Ctr, Genom & Bioinformat Shared Resource, 1124 Columbia St, Seattle, WA 98104 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Center for International Blood & Marrow Transplant Research; National Marrow Donor Program; Fred Hutchinson Cancer Center	Martin, PJ (corresponding author), Fred Hutchinson Canc Res Ctr, Div Clin Res, 1124 Columbia St, Seattle, WA 98104 USA.; Martin, PJ (corresponding author), Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA.	pmartin@fredhutch.org		Zheng, Xiuwen/0000-0002-1390-0708				Akatsuka Y, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00257; [Anonymous], GERMLINE SHORT VARIA; Apcher S, 2013, P NATL ACAD SCI USA, V110, P17951, DOI 10.1073/pnas.1309956110; Broad Institute, 2020, I AM UN US VQSR REC; Broad Institute, PIC TOOLS; Broad Institute, 2021, FILT VAR EITH VQSR H; Broad Institute, 2021, HARD FILT GERML SHOR; Bykova NA, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01819; Cuevas MVR, 2021, CELL REP, V34, DOI 10.1016/j.celrep.2021.108815; DePristo MA., 2018, SCALING ACCURATE GEN, DOI [DOI 10.1101/201178, 10.1101/201178]; Dossa RG, 2018, BLOOD, V131, P108, DOI 10.1182/blood-2017-07-791608; Finton KAK, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.658372; Flowers MED, 2011, BLOOD, V117, P3214, DOI 10.1182/blood-2010-08-302109; Fuchs KJ, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00659; Gonzalez-Galarza FF, 2020, NUCLEIC ACIDS RES, V48, pD783, DOI 10.1093/nar/gkz1029; Gragert L, 2013, HUM IMMUNOL, V74, P1313, DOI 10.1016/j.humimm.2013.06.025; Granados DP, 2016, LEUKEMIA, V30, P1344, DOI 10.1038/leu.2016.22; Granados DP, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4600; Griffioen M, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00100; Hardy MP, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02934; Janelle V, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00276; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; Laumont CM, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10238; Lee SJ, 2003, BIOL BLOOD MARROW TR, V9, P215, DOI 10.1053/bbmt.2003.50026; Leisenring WM, 2006, BLOOD, V108, P749, DOI 10.1182/blood-2006-01-0254; Li H., 2013, ARXIV13033997 Q BIO, P1303, DOI DOI 10.6084/M9.FIGSHARE.963153.V1; Machiela MJ, 2015, BIOINFORMATICS, V31, P3555, DOI 10.1093/bioinformatics/btv402; Martin PJ, 2017, BLOOD, V129, P791, DOI 10.1182/blood-2016-09-737700; Martin PJ, 2004, BIOL BLOOD MARROW TR, V10, P320, DOI 10.1016/j.bbmt.2003.12.304; Martins RP, 2019, NUCLEIC ACIDS RES, V47, P3086, DOI 10.1093/nar/gky1296; McLaren W, 2010, BIOINFORMATICS, V26, P2069, DOI 10.1093/bioinformatics/btq330; Mielcarek M, 2009, BLOOD, V113, P2888, DOI 10.1182/blood-2008-07-168401; Mullally A, 2007, BLOOD, V109, P1355, DOI 10.1182/blood-2006-06-030858; National Heart Lung and Blood Institute National Institutes of Health US Department of Health and Human Services, 2020, NHLBI BIOD CAT, DOI [10.5281/zenodo.3822858, DOI 10.5281/ZENODO.3822858]; Paul S, 2013, J IMMUNOL, V191, P5831, DOI 10.4049/jimmunol.1302101; Rao XY, 2011, IMMUNOGENETICS, V63, P691, DOI 10.1007/s00251-011-0552-6; Reynisson B, 2020, NUCLEIC ACIDS RES, V48, pW449, DOI 10.1093/nar/gkaa379; Ritari J, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01625; Salman A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02284; Sarkizova S, 2020, NAT BIOTECHNOL, V38, P199, DOI 10.1038/s41587-019-0322-9; Sherry ST, 2001, NUCLEIC ACIDS RES, V29, P308, DOI 10.1093/nar/29.1.308; Sidney J, 2001, HUM IMMUNOL, V62, P1200, DOI 10.1016/S0198-8859(01)00319-6; Sidney J, 2008, BMC IMMUNOL, V9, DOI 10.1186/1471-2172-9-1; Spierings E, 2014, TISSUE ANTIGENS, V84, P347, DOI 10.1111/tan.12445; Spooner W, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06542-1; Story CM, 2021, TRANSPL CELL THER, V27, P591, DOI 10.1016/j.jtct.2021.04.003; Summers C, 2020, FRONT PEDIATR, V8, DOI 10.3389/fped.2020.00284; van Balen P, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01804; Van der Auwera GA, 2020, GENOMICS CLOUD USING, V1st; Wang SF, 2016, BMC IMMUNOL, V17, DOI 10.1186/s12865-016-0156-x; Warren EH, 2012, BLOOD, V120, P2796, DOI 10.1182/blood-2012-04-347286; Yewdell JW, 2003, SCIENCE, V301, P1334, DOI 10.1126/science.1089553; Zhang SL, 2020, J IMMUNOL METHODS, V476, DOI 10.1016/j.jim.2019.112685; Zhu QQ, 2018, BLOOD, V131, P2490, DOI 10.1182/blood-2017-11-817973	54	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 18	2021	12								782152	10.3389/fimmu.2021.782152	http://dx.doi.org/10.3389/fimmu.2021.782152			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XI5OZ	34868058	gold, Green Published			2022-12-18	WOS:000726162000001
J	Patrick, AE; Lyons, EM; Ishii, L; Boyd, AS; Choi, JM; Dewan, AK; Markle, JG				Patrick, Anna E.; Lyons, Eden M.; Ishii, Lisa; Boyd, Alan S.; Choi, Joseph M.; Dewan, Anna K.; Markle, Janet G.			Case Report: Infantile Urticaria as a Herald of Neonatal Onset Multisystem Inflammatory Disease With a Novel Mutation in NLRP3	FRONTIERS IN IMMUNOLOGY			English	Article						Urticaria; NOMID; NLRP3; gene variant; pediatric autoinflammatory disease; inflammasome; IL-1 pathway; monogenic diseases	AUTOINFLAMMATORY DISEASES	Neonatal multisystem onset inflammatory disorder (NOMID) is a severe autoinflammatory syndrome that can have an initial presentation as infantile urticaria. Thus, an immediate recognition of the clinical symptoms is essential for obtaining a genetic diagnosis and initiation of early therapies to prevent morbidity and mortality. Herein, we describe a neonate presenting with urticaria and systemic inflammation within hours after birth who developed arthropathy and neurologic findings. Pathologic evaluation of the skin revealed an infiltration of lymphocytes, eosinophils, and scattered neutrophils. Genetic analysis identified a novel heterozygous germline variant of unknown significance in the NLRP3 gene, causing the missense mutation M408T. Variants of unknown significance are common in genetic sequencing studies and are diagnostically challenging. Functional studies of the M408T variant demonstrated enhanced formation and activity of the NLRP3 inflammasome, with increased cleavage of the inflammatory cytokine IL-1 beta. Upon initiation of IL-1 pathway blockade, the infant had a robust response and improvement in clinical and laboratory findings. Our experimental data support that this novel variant in NLRP3 is causal for this infant's diagnosis of NOMID. Rapid assessment of infantile urticaria with biopsy and genetic diagnosis led to early recognition and targeted anti-cytokine therapy. This observation expands the NOMID-causing variants in NLRP3 and underscores the role of genetic sequencing in rapidly identifying and treating autoinflammatory disease in infants. In addition, these findings highlight the importance of establishing the functional impact of variants of unknown significance, and the impact this knowledge may have on therapeutic decision making.	[Patrick, Anna E.] Vanderbilt Univ Sch Med, Dept Pediat, Nashville, TN USA; [Lyons, Eden M.] Vanderbilt Univ, Sch Med, 221 Kirkland Hall, Nashville, TN 37235 USA; [Ishii, Lisa; Boyd, Alan S.; Dewan, Anna K.] Vanderbilt Univ Sch Med, Dept Dermatol, Nashville, TN USA; [Choi, Joseph M.; Markle, Janet G.] Vanderbilt Univ Sch Med, Dept Pathol Microbiol & Immunol, Nashville, TN USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Markle, JG (corresponding author), Vanderbilt Univ Sch Med, Dept Pathol Microbiol & Immunol, Nashville, TN USA.			Markle, Janet/0000-0003-2189-4368	National Institutes of Health [K12HD087023, P30DK058404]; Vanderbilt Human Immunology Discovery Initiative	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Vanderbilt Human Immunology Discovery Initiative	Funding This work was supported by the National Institutes of Health with K12HD087023 (AP) and a pilot and feasibility award from P30DK058404 (JM) and the Vanderbilt Human Immunology Discovery Initiative (AP, JM).	Aksentijevich I, 2002, ARTHRITIS RHEUM-US, V46, P3340, DOI 10.1002/art.10688; Broekaert SMC, 2016, AM J DERMATOPATH, V38, P39, DOI 10.1097/DAD.0000000000000390; Carta S, 2015, P NATL ACAD SCI USA, V112, P2835, DOI 10.1073/pnas.1424741112; Conforti-Andreoni C, 2011, CELL MOL IMMUNOL, V8, P135, DOI 10.1038/cmi.2010.81; Davis MDP, 2018, J ALLER CL IMM-PRACT, V6, P1162, DOI 10.1016/j.jaip.2018.05.006; de Torre-Minguela C, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00043; Goldbach-Mansky R, 2006, NEW ENGL J MED, V355, P581, DOI 10.1056/NEJMoa055137; Hornung V, 2009, NATURE, V458, P514, DOI 10.1038/nature07725; Karczewski KJ, 2020, NATURE, V581, P434, DOI 10.1038/s41586-020-2308-7; Malcova H, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.619257; Manthiram K, 2017, NAT IMMUNOL, V18, P832, DOI 10.1038/ni.3777; Meng GX, 2009, IMMUNITY, V30, P860, DOI 10.1016/j.immuni.2009.04.012; Nakanishi H, 2017, P NATL ACAD SCI USA, V114, pE7766, DOI 10.1073/pnas.1702946114; Prieur A M, 1987, Scand J Rheumatol Suppl, V66, P57; Tassi S, 2010, P NATL ACAD SCI USA, V107, P9789, DOI 10.1073/pnas.1000779107; Tripathi SV, 2013, DERMATOL CLIN, V31, P387, DOI 10.1016/j.det.2013.04.005	16	0	0	2	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 18	2021	12								775140	10.3389/fimmu.2021.775140	http://dx.doi.org/10.3389/fimmu.2021.775140			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XI5OO	34868041	Green Published, gold			2022-12-18	WOS:000726160900001
J	Tabor, AE; Santos, IKFD; Boulanger, N				Tabor, Ala E.; de Miranda Santos, Isabel K. F.; Boulanger, Nathalie			Editorial: Ticks and Host Immunity - New Strategies for Controlling Ticks and Tick-Borne Pathogens	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						ticks; tick-borne diseases; immunity; vaccines; host genetic resistance			[Tabor, Ala E.] Univ Queensland, Queensland Alliance Agr & Food Innovat, Ctr Anim Sci, St Lucia, Qld, Australia; [Tabor, Ala E.] Univ Queensland, Sch Chem & Mol Biosci, St Lucia, Qld, Australia; [de Miranda Santos, Isabel K. F.] Ribeirao Preto Sch Med, Dept Biochem & Immunol, Ribeirao Preto, Brazil; [Boulanger, Nathalie] Univ Strasbourg, FMTS, UR7290 Virulence Bacterienne Precoce Grp Borrelia, Strasbourg, France; [Boulanger, Nathalie] CHRU Strasbourg, French Reference Ctr Lyme Borreliosis, Strasbourg, France	University of Queensland; University of Queensland; Universidade de Sao Paulo; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Tabor, AE (corresponding author), Univ Queensland, Queensland Alliance Agr & Food Innovat, Ctr Anim Sci, St Lucia, Qld, Australia.; Tabor, AE (corresponding author), Univ Queensland, Sch Chem & Mol Biosci, St Lucia, Qld, Australia.; Santos, IKFD (corresponding author), Ribeirao Preto Sch Med, Dept Biochem & Immunol, Ribeirao Preto, Brazil.; Boulanger, N (corresponding author), Univ Strasbourg, FMTS, UR7290 Virulence Bacterienne Precoce Grp Borrelia, Strasbourg, France.; Boulanger, N (corresponding author), CHRU Strasbourg, French Reference Ctr Lyme Borreliosis, Strasbourg, France.	a.tabor@uq.edu.au; imsantos@fmrp.usp.br; nboulanger@unistra.fr	; Tabor, Ala/A-5286-2010	Kinney Ferreira de Miranda Santos, Isabel/0000-0002-0438-4430; Tabor, Ala/0000-0001-7147-1078	French Ministry of Research, Agence Nationale de la Recherche [ANR-16-CE17-0003-01]	French Ministry of Research, Agence Nationale de la Recherche(French National Research Agency (ANR))	NBs research was funded by the French Ministry of Research, Agence Nationale de la Recherche No ANR-16-CE17-0003-01.		0	0	0	1	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 18	2021	12								796558	10.3389/fimmu.2021.796558	http://dx.doi.org/10.3389/fimmu.2021.796558			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XI8BL	34868085	Green Published, gold			2022-12-18	WOS:000726329600001
J	Zhang, ZH; Wu, P; Zhang, CQ; Luo, YJ; Zhang, GC; Zeng, QP; Wang, LD; Yang, ZY; Sun, N; He, J				Zhang, Zhihui; Wu, Peng; Zhang, Chaoqi; Luo, Yuejun; Zhang, Guochao; Zeng, Qingpeng; Wang, Lide; Yang, Zhaoyang; Sun, Nan; He, Jie			Tumor Necrosis Factor Family Member Profile Predicts Prognosis and Adjuvant Chemotherapy Benefit for Patients With Small-Cell Lung Cancer	FRONTIERS IN IMMUNOLOGY			English	Article						small cell lung cancer; antitumor immunity; tumor necrosis factor family; prognostic prediction; chemotherapy response	FACTOR RECEPTOR SUPERFAMILY; TNF SUPERFAMILY; FACTOR-ALPHA; PHASE-I; ANTITUMOR; DEATH; EXPRESSION; IDENTIFICATION; COSTIMULATION; THERAPY	Tumor necrosis factor (TNF) family members participate in the body's antitumor immunity response and influence tumor prognosis and treatment response. However, little is known about the roles of TNF family members in small cell lung cancer (SCLC). Therefore, we conducted the first comprehensive investigation of TNF family members in patients with SCLC, with the goal of using them to predict prognosis and chemotherapy benefit. Abnormal genetic alterations and expression of TNF family members were found to be widespread in SCLC patients. Using LASSO Cox regression analysis, we constructed a TNF family-based signature that separated SCLC patients in the training set (n=77) into high- and low-risk groups with distinct survival and chemotherapy benefit, and the signature was well-validated in the validation set (n=137) by RT-qPCR. Importantly, the signature exhibited superior predictive performance and was identified as a novel independent prognostic factor. Additionally, different immune phenotypes were found between the low-risk and high-risk groups, and high-risk patients had higher CMTM6 expression, suggesting that these patients could benefit from therapeutic methods targeting CMTM6. We constructed the first clinically applicable TNF family-based signature for predicting prognosis and chemotherapy benefit for patients with SCLC. The findings reported here provide a new method for predicting the prognosis of SCLC patients and optimizing clinical management.	[Zhang, Zhihui; Wu, Peng; Zhang, Chaoqi; Luo, Yuejun; Zhang, Guochao; Zeng, Qingpeng; Wang, Lide; Sun, Nan; He, Jie] Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Dept Thorac Surg, Natl Clin Res Ctr Canc,Canc Hosp, Beijing, Peoples R China; [Yang, Zhaoyang] Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Dept Pathol, Natl Clin Res Ctr Canc,Canc Hosp, Beijing, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; Peking Union Medical College	Sun, N; He, J (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Dept Thorac Surg, Natl Clin Res Ctr Canc,Canc Hosp, Beijing, Peoples R China.	sunnan@vip.126.com; prof.jiehe@gmail.com			CAMS Innovation Fund for Medical Sciences [2017-I2M-1-005]; National Key R&D Program of China [2016YFC1303201]; National Natural Science Foundation of China [81802299, 81502514]; Fundamental Research Funds for the Central Universities [3332018070]; National Key Basic Research Development Plan [2018YFC1312105]	CAMS Innovation Fund for Medical Sciences; National Key R&D Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); National Key Basic Research Development Plan(National Basic Research Program of China)	This work was supported by the CAMS Innovation Fund for Medical Sciences (2017-I2M-1-005), the National Key R&D Program of China (2016YFC1303201), the National Natural Science Foundation of China (81802299, 81502514), the Fundamental Research Funds for the Central Universities (3332018070), and the National Key Basic Research Development Plan (2018YFC1312105).	Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184; An N, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-02160-7; Balkwill F, 2009, NAT REV CANCER, V9, P361, DOI 10.1038/nrc2628; Benoot T, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22168691; Benschop R, 2009, ADV EXP MED BIOL, V647, P186, DOI 10.1007/978-0-387-89520-8_13; Binnewies M, 2018, NAT MED, V24, P541, DOI 10.1038/s41591-018-0014-x; BLICK M, 1987, CANCER RES, V47, P2986; Burr ML, 2017, NATURE, V549, P101, DOI 10.1038/nature23643; Byers LA, 2015, CANCER-AM CANCER SOC, V121, P664, DOI 10.1002/cncr.29098; Calzascia T, 2007, J CLIN INVEST, V117, P3833, DOI 10.1172/JCI32567; Casares N, 2005, J EXP MED, V202, P1691, DOI 10.1084/jem.20050915; Chen L, 2020, CANCER IMMUNOL RES, V8, P179, DOI 10.1158/2326-6066.CIR-19-0394; Cho Y, 2003, CANCER RES, V63, P1555; Choi BK, 2018, EUR J IMMUNOL, V48, P1739, DOI 10.1002/eji.201847633; Coulie PG, 2014, NAT REV CANCER, V14, P135, DOI 10.1038/nrc3670; Croft M, 2013, NAT REV DRUG DISCOV, V12, P147, DOI 10.1038/nrd3930; Croft M, 2009, NAT REV IMMUNOL, V9, P271, DOI 10.1038/nri2526; Cusick JK, 2010, CELL IMMUNOL, V261, P1, DOI 10.1016/j.cellimm.2009.10.013; Dostert C, 2019, PHYSIOL REV, V99, P115, DOI 10.1152/physrev.00045.2017; Dubuisson A, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1343-5; Dubuisson A, 2017, ANTIBODIES, V6, DOI 10.3390/antib6040016; Egberts JH, 2008, CANCER RES, V68, P1443, DOI 10.1158/0008-5472.CAN-07-5704; Fan HF, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.614781; Feldmann M, 2001, ANNU REV IMMUNOL, V19, P163, DOI 10.1146/annurev.immunol.19.1.163; Mercogliano MF, 2021, CANCERS, V13, DOI 10.3390/cancers13030564; FURMAN WL, 1993, J CLIN ONCOL, V11, P2205, DOI 10.1200/JCO.1993.11.11.2205; Gadgeel SM, 2018, J THORAC ONCOL, V13, P1393, DOI 10.1016/j.jtho.2018.05.002; Galluzzi L, 2015, CANCER CELL, V28, P690, DOI 10.1016/j.ccell.2015.10.012; Gazdar AF, 2017, NAT REV CANCER, V17, P725, DOI 10.1038/nrc.2017.87; George J, 2015, NATURE, V524, P47, DOI 10.1038/nature14664; Giles DA, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02585; Guan XX, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-447; Hanzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-7; Herbst RS, 2016, LANCET, V387, P1540, DOI 10.1016/S0140-6736(15)01281-7; Horn L, 2018, NEW ENGL J MED, V379, P2220, DOI 10.1056/NEJMoa1809064; Jiang YM, 2019, CANCER IMMUNOL RES, V7, P2065, DOI 10.1158/2326-6066.CIR-19-0311; Kasof GM, 2001, ONCOGENE, V20, P7965, DOI 10.1038/sj.onc.1204985; Kim S, 2009, NATURE, V457, P102, DOI 10.1038/nature07623; Kitson J, 1996, NATURE, V384, P372, DOI 10.1038/384372a0; Lu S, 2019, JAMA ONCOL, V5, P1195, DOI 10.1001/jamaoncol.2019.1549; Mezzadra R, 2017, NATURE, V549, P106, DOI 10.1038/nature23669; Montfort A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01818; Mu Chuan-Yong, 2015, Chronic Dis Transl Med, V1, P36, DOI 10.1016/j.cdtm.2015.02.010; Oguma K, 2008, EMBO J, V27, P1671, DOI 10.1038/emboj.2008.105; OROSZ P, 1993, J EXP MED, V177, P1391, DOI 10.1084/jem.177.5.1391; Pan GH, 1998, FEBS LETT, V431, P351, DOI 10.1016/S0014-5793(98)00791-1; Pavan A, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0690-1; Paz-Ares L, 2019, LANCET, V394, P1929, DOI 10.1016/S0140-6736(19)32222-6; Pietanza MC, 2015, CLIN CANCER RES, V21, P2244, DOI 10.1158/1078-0432.CCR-14-2958; Pikarsky E, 2004, NATURE, V431, P461, DOI 10.1038/nature02924; Popivanova BK, 2008, J CLIN INVEST, V118, P560, DOI [10.1172/JC132453, 10.1172/JCI32453]; Qin S, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1091-2; Ramalingam SS, 2016, J ONCOL PRACT, V12, P119, DOI 10.1200/JOP.2015.009225; Reck M, 2016, J CLIN ONCOL, V34, P3740, DOI 10.1200/JCO.2016.67.6601; Ricciuti B, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0572-6; Rody A, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2234; Rudin CM, 2020, J CLIN ONCOL, V38, P2369, DOI 10.1200/JCO.20.00793; Sabbagh L, 2007, TRENDS IMMUNOL, V28, P333, DOI 10.1016/j.it.2007.06.001; Sakai J, 2017, CLIN MICROBIOL REV, V30, P991, DOI 10.1128/CMR.00046-17; Saleh R, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-001294; SELBY P, 1987, BRIT J CANCER, V56, P803, DOI 10.1038/bjc.1987.294; Sica GL, 2001, BLOOD, V97, P2702, DOI 10.1182/blood.V97.9.2702; Skeate JG, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00922; Slebioda TJ, 2011, EUR J IMMUNOL, V41, P2606, DOI 10.1002/eji.201141477; Spigel DR, 2013, J THORAC ONCOL, V8, P587, DOI 10.1097/JTO.0b013e318286cf88; St Paul M, 2020, TRENDS CELL BIOL, V30, P695, DOI 10.1016/j.tcb.2020.06.003; Stinchcombe TE, 2010, ONCOLOGIST, V15, P187, DOI 10.1634/theoncologist.2009-0298; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Thommen DS, 2018, NAT MED, V24, P994, DOI 10.1038/s41591-018-0057-z; Tian YR, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0753-2; Vadakekolathu J, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aaz0463; van Meerbeeck JP, 2011, LANCET, V378, P1741, DOI 10.1016/S0140-6736(11)60165-7; Vinay DS, 2009, CELL BIOL INT, V33, P453, DOI 10.1016/j.cellbi.2009.02.001; Wallach D, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a028431; Watts TH, 2005, ANNU REV IMMUNOL, V23, P23, DOI 10.1146/annurev.immunol.23.021704.115839; Yoshihara K, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3612; Zhang CQ, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00221-8; Zhu CQ, 2010, J CLIN ONCOL, V28, P4417, DOI 10.1200/JCO.2009.26.4325	79	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 18	2021	12								745769	10.3389/fimmu.2021.745769	http://dx.doi.org/10.3389/fimmu.2021.745769			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6I1GN	34867972	gold, Green Published			2022-12-18	WOS:000885874400001
J	Hogendorf, A; Zielinski, M; Constantinou, M; Smigiel, R; Wierzba, J; Wyka, K; Wedrychowicz, A; Jakubiuk-Tomaszuk, A; Budzynska, E; Piotrowicz, M; Lipska-Zietkiewicz, BS; Kaczorowska, E; Cieslikowska, A; Kutkowska-Kazmierczak, A; Fijak-Moskal, J; Kugaudo, M; Kosinska-Urbanska, M; Szadkowska, A; Borowiec, M; Niedzwiecki, M; Trzonkowski, P; Mlynarski, W				Hogendorf, Anna; Zielinski, Maciej; Constantinou, Maria; Smigiel, Robert; Wierzba, Jolanta; Wyka, Krystyna; Wedrychowicz, Anna; Jakubiuk-Tomaszuk, Anna; Budzynska, Edyta; Piotrowicz, Malgorzata; Lipska-Zietkiewicz, Beata S.; Kaczorowska, Ewa; Cieslikowska, Agata; Kutkowska-Kazmierczak, Anna; Fijak-Moskal, Jolanta; Kugaudo, Monika; Kosinska-Urbanska, Malgorzata; Szadkowska, Agnieszka; Borowiec, Maciej; Niedzwiecki, Maciej; Trzonkowski, Piotr; Mlynarski, Wojciech			Immune Dysregulation in Patients With Chromosome 18q Deletions-Searching for Putative Loci for Autoimmunity and Immunodeficiency	FRONTIERS IN IMMUNOLOGY			English	Article						18q deletion syndrome; immune deficiency; type 1 diabetes; autoimmune diseases; thyroiditis; T regulatory cells; antibody deficiency	COMMON VARIABLE IMMUNODEFICIENCY; T-CELL; EPITHELIAL-CELLS; IGA DEFICIENCY; MALT1; LEADS	IntroductionAutoimmune disorders, IgA deficiency, and allergies seem to be common among individuals with 18q deletion syndrome [OMIM 601808]. We aimed to determine the prevalence, mechanism, and genetic background of autoimmunity, immune deficiency, and allergy in a cohort of patients with 18q deletions. Material and MethodsMedical registries and social media were used to recruit the patients. Microarray oligonucleotide comparative genomic hybridization (aCGH) (Agilent, Santa Clara, CA, USA) was performed in all patients to identify size and location of chromosome 18 deletion. Clinical evaluation and medical record collection were performed in each of the study participants. The history of autoimmune disorders, severe and/or recurrent infections, and symptoms of allergy were noted. Total immunoglobulin IgG, IgA, IgM, IgE, and IgG(1-4) serum levels were measured using nephelometry and ELISA methods. Lymphocyte T subset phenotyping was performed in 24 subjects from 18q del cohort. To predict the most promising candidate genes, we used the ENDEAVOUR-a free web resource for gene prioritization. Results18q deletion was confirmed by means of array CGH analysis in 27 individuals, 15 (55.6%) females and 12 males, referred to the project by specialists in medical genetics, diabetology, or pediatric endocrinology between May 2015 and December 2019. The mean age at examination was 11.8 years (min-max: 4.0-33.5). Autoimmune disorders were present in 14/27 (51.8%) of the cohort. In eight of patients, symptoms of immune deficiency coexisted with autoimmunity. Allergy was reported in nine of 27 (33.4%) patients. Over 89% of patients presented with at list one type of immunoglobulin (IgA, IgM, IgG, IgE, and IgG(1-4)) deficiency and eight of 25 (32%) had abnormalities in at least two major immunoglobulin (IgG, IgA, IgM) measurements (CVID-like phenotype). Patients with 18q del exhibited a significantly decreased CD4, Treg FOXP3+, TregFOXP3+Helios+, and TemCD4 cell numbers in comparison with the control groups of 24 T1DM patients and 28 healthy controls. ConclusionsPatients with 18q deletions frequently suffer from autoimmune disorders, recurrent infections, and allergy due to immune dysregulation presenting with variable antibody deficiencies and T-regulatory cell deficiency (CD4+CD25+CD127lowFOXP3+). The spectrum of speculations regarding which gene might be responsible for such phenotype ranges from single gene haploinsufficiency to deletion of a cluster of immunogenes located distally to 18q21.	[Hogendorf, Anna; Szadkowska, Agnieszka] Med Univ Lodz, Dept Pediat Diabetol Endocrinol & Nephrol, Lodz, Poland; [Zielinski, Maciej; Trzonkowski, Piotr] Med Univ Gdansk, Dept Med Immunol, Gdansk, Poland; [Constantinou, Maria; Budzynska, Edyta; Borowiec, Maciej] Med Univ Lodz, Dept Clin Genet, Lodz, Poland; [Smigiel, Robert] Wroclaw Med Univ, Dept Pediat, Div Pediat & Rare Disorders, Warsaw, Poland; [Wierzba, Jolanta] Med Univ Gdansk, Dept Internal & Pediat Nursing, Gdansk, Poland; [Wyka, Krystyna; Mlynarski, Wojciech] Med Univ Lodz, Dept Pediat Oncol & Hematol, Lodz, Poland; [Wedrychowicz, Anna] Jagiellonian Univ Coll Med, Polish Amer Pediat Inst, Dept Pediat & Adolescent Endocrinol, Krakow, Poland; [Jakubiuk-Tomaszuk, Anna] Med Univ Bialystok, Dept Pediat Neurol & Rehabil, Bialystok, Poland; [Piotrowicz, Malgorzata] Polish Mothers Mem Hosp, Dept Genet, Res Inst, Lodz, Poland; [Lipska-Zietkiewicz, Beata S.] Med Univ Gdansk, Dept Biol & Med Genet, Clin Genet Unit, Gdansk, Poland; [Kaczorowska, Ewa] Med Univ Gdansk, Dept Biol & Med Genet, Gdansk, Poland; [Cieslikowska, Agata] Childrens Mem Hlth Inst, Dept Med Genet, Warsaw, Poland; [Kutkowska-Kazmierczak, Anna] Inst Mother & Child Hlth, Dept Med Genet, Warsaw, Poland; [Fijak-Moskal, Jolanta] Univ Childrens Hosp Cracow, Outpatient Genet Clin, Krakow, Poland; [Kugaudo, Monika] Univ Clin Ctr, Pediat Teaching Clin Hosp Warsaw, Dept Children & Adolescent Psychiat, Warsaw, Poland; [Kosinska-Urbanska, Malgorzata] Univ Zielona Gora, Dept Pediat, Zielona Gora, Poland; [Niedzwiecki, Maciej] Med Univ Gdansk, Dept Pediat Hematol & Oncol, Gdansk, Poland	Medical University Lodz; Fahrenheit Universities; Medical University Gdansk; Medical University Lodz; Wroclaw Medical University; Fahrenheit Universities; Medical University Gdansk; Medical University Lodz; Jagiellonian University; Collegium Medicum Jagiellonian University; Medical University of Bialystok; Polish Mother's Memorial Hospital - Research Institute; Fahrenheit Universities; Medical University Gdansk; Fahrenheit Universities; Medical University Gdansk; Children's Memorial Health Institute; University of Zielona Gora; Fahrenheit Universities; Medical University Gdansk	Hogendorf, A (corresponding author), Med Univ Lodz, Dept Pediat Diabetol Endocrinol & Nephrol, Lodz, Poland.; Mlynarski, W (corresponding author), Med Univ Lodz, Dept Pediat Oncol & Hematol, Lodz, Poland.	anna.hogendorf@gmail.com; wojciech.mlynarski@umed.lodz.pl	CONSTANTINOU, MARIA/GXV-1684-2022; Szadkowska, Agnieszka/AHA-9351-2022; Kutkowska-Kazmierczak, Anna/X-6011-2018	Lipska-Zietkiewicz, Beata S./0000-0002-4169-9685; Wyka, Krystyna/0000-0002-6599-8188; Szadkowska, Agnieszka/0000-0002-8281-4408; Mlynarski, Wojciech/0000-0003-2714-5851; Hogendorf, Anna/0000-0001-8536-9381; Kutkowska-Kazmierczak, Anna/0000-0001-5295-7363; Borowiec, Maciej/0000-0003-2812-5676				Anderson G, 2012, TRENDS IMMUNOL, V33, P256, DOI 10.1016/j.it.2012.03.005; ANDLER W, 1992, MONATSSCHR KINDERH, V140, P303; Baine I, 2013, J IMMUNOL, V190, P1008, DOI 10.4049/jimmunol.1200792; Bennett CL, 2001, NAT GENET, V27, P20, DOI 10.1038/83713; Brustle A, 2017, CELL DEATH DIFFER, V24, P1214, DOI 10.1038/cdd.2015.104; Campoverde KC, 2016, ALLERGOL IMMUNOPATH, V44, P257, DOI 10.1016/j.aller.2015.07.007; Castigli E, 2005, NAT GENET, V37, P829, DOI 10.1038/ng1601; Cepika AM, 2018, J ALLERGY CLIN IMMUN, V142, P1679, DOI 10.1016/j.jaci.2018.10.026; Cody JD, 2015, AM J MED GENET C, V169, P265, DOI 10.1002/ajmg.c.31446; Cody JD, 2014, HUM GENET, V133, P199, DOI 10.1007/s00439-013-1364-6; Cody JD, 2009, AM J MED GENET A, V149A, P1421, DOI 10.1002/ajmg.a.32899; Cody JD, 1999, AM J MED GENET, V85, P455, DOI 10.1002/(SICI)1096-8628(19990827)85:5<455::AID-AJMG5>3.0.CO;2-Z; DE GROUCHY J, 1964, Pathol Biol, V12, P579; de Valles-Ibanez G, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00636; Molina LD, 2021, CLIN EXP IMMUNOL, V203, P341, DOI 10.1111/cei.13522; Dostal A, 2007, INT J IMMUNOGENET, V34, P143, DOI 10.1111/j.1744-313X.2007.00652.x; Ferastraoaru D, 2020, CLIN TRANSL ALLERGY, V10, DOI 10.1186/s13601-020-00335-w; Gao S, 2009, MOL CELL, V36, P457, DOI 10.1016/j.molcel.2009.09.043; Giri PS, 2020, EXP DERMATOL, V29, P759, DOI 10.1111/exd.14157; Grimbacher B, 1999, NEW ENGL J MED, V340, P692, DOI 10.1056/NEJM199903043400904; Guerrini MM, 2008, AM J HUM GENET, V83, P64, DOI 10.1016/j.ajhg.2008.06.015; Heard PL, 2009, AM J MED GENET A, V149A, P1431, DOI 10.1002/ajmg.a.32900; Hogendorf A, 2016, PEDIATR DIABETES, V17, P153, DOI 10.1111/pedi.12235; Jabara HH, 2013, J ALLERGY CLIN IMMUN, V132, P151, DOI 10.1016/j.jaci.2013.04.047; KAMADA S, 1995, CANCER RES, V55, P354; Klein J, 2006, J IMMUNOL, V176, P2389, DOI 10.4049/jimmunol.176.4.2389; Lawrence MG, 2018, J CLIN IMMUNOL, V38, P225, DOI 10.1007/s10875-018-0476-0; Linnankivi T, 2006, AM J MED GENET A, V140A, P331, DOI 10.1002/ajmg.a.31072; Lomenick JP, 2005, J PEDIATR-US, V147, P541, DOI 10.1016/j.jpeds.2005.04.064; Magen E, 2014, ALLERGY ASTHMA PROC, V35, pE27, DOI 10.2500/aap.2014.35.3734; Malhotra N, 2013, IMMUNOLOGY, V139, P1, DOI 10.1111/imm.12076; Nagamine K, 1997, NAT GENET, V17, P393, DOI 10.1038/ng1297-393; Pate Mariah B, 2010, Clin Mol Allergy, V8, P3, DOI 10.1186/1476-7961-8-3; Piatosa B., 2010, STANDARDY MEDYCZNE, V7, P524; Rosen P, 2004, J RHEUMATOL, V31, P998; Rossi SW, 2007, J EXP MED, V204, P1267, DOI 10.1084/jem.20062497; Ruland J, 2003, IMMUNITY, V19, P749, DOI 10.1016/S1074-7613(03)00293-0; Sabouni MA, 2018, OXF MED CASE REP, P346, DOI 10.1093/omcr/omy076; Seidel MG, 2019, J ALLER CL IMM-PRACT, V7, P1763, DOI 10.1016/j.jaip.2019.02.004; Shamriz O, 2018, CLIN IMMUNOL, V197, P219, DOI 10.1016/j.clim.2018.10.005; Shioda T, 1998, P NATL ACAD SCI USA, V95, P9785, DOI 10.1073/pnas.95.17.9785; Simons FER, 2011, WORLD ALLERGY ORGAN, V4, P13, DOI 10.1097/WOX.0b013e318211496c; Slyper AH, 1997, EUR J PEDIATR, V156, P155; Sobacchi C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00629; STRICKER RB, 1982, JAMA-J AM MED ASSOC, V248, P1359, DOI 10.1001/jama.248.11.1359; Tranchevent LC, 2016, NUCLEIC ACIDS RES, V44, pW117, DOI 10.1093/nar/gkw365; Tutunculer F, 2005, J PEDIATR ENDOCR MET, V18, P419; Vaeth M, 2012, P NATL ACAD SCI USA, V109, P16258, DOI 10.1073/pnas.1203870109; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; Yang G, 2021, AUTOPHAGY, V17, P1193, DOI 10.1080/15548627.2020.1752979; Yasharpour M., 2014, MOJ IMMUNOL, V1, P10, DOI [10.15406/moji.2014.01.00010, DOI 10.15406/MOJI.2014.01.00010]; Yoshimura A, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00020	52	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 17	2021	12								742834	10.3389/fimmu.2021.742834	http://dx.doi.org/10.3389/fimmu.2021.742834			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XH9JC	34867966	gold, Green Published			2022-12-18	WOS:000725740900001
J	Bothammal, P; Ganesh, M; Vigneshwaran, V; Anbarasu, K; Ponmurugan, K; Al-Dhabi, NA; Natarajaseenivasan, K				Bothammal, Palanisamy; Ganesh, Mohan; Vigneshwaran, Vellaisamy; Anbarasu, Kumarasamy; Ponmurugan, Karuppiah; Al-Dhabi, Naif Abdullah; Natarajaseenivasan, Kalimuthusamy			Construction of Genomic Library and Screening of Edwardsiella tarda Immunogenic Proteins for Their Protective Efficacy Against Edwardsiellosis	FRONTIERS IN IMMUNOLOGY			English	Article						Edwardsiella tarda; edwardsiellosis; immunoreactive protein; vaccine; IL-10; IFN-gamma	N-ACETYLNEURAMINIC ACID; IN-VIVO; FTSH HFLB; VACCINE; ACETYLGLUCOSAMINE; SECRETION; PATHWAYS; PROTEASE; COMPLEX; ANTIGEN	Edwardsiella tarda is a severe aquaculture pathogen that can infect many hosts including humans, animals, and fish. Timely diagnosis and treatment are crucial for the control of edwardsiellosis in the aqua industry. By using rabbit polyclonal antibody, an expression gene library of virulent Edwardsiella tarda strain ED-BDU 1 isolated in south India was constructed and screened. The identified immune expressive proteins were characterized, and the corresponding coding sequences were cloned, expressed, and the purified recombinant proteins were used as antigens. The identified immunoreactive proteins namely HflC, HflK, and YhcI were studied for their immune protective potential in vivo by challenge experiments. The protective efficacy of HflC, HflK, and YhcI showed that the clearance of Edwardsiella from the host with ~ 60% survivability. Further, the immunoreactive proteins induce a strong immune response upon infection and elicit the significant production of IL-10, IFN-gamma, Th1, and Th2 mediated mRNA expression and were therefore effective in vaccine production for edwardsiellosis.	[Bothammal, Palanisamy; Ganesh, Mohan; Vigneshwaran, Vellaisamy; Natarajaseenivasan, Kalimuthusamy] Bharathidasan Univ, Ctr Excellence Life Sci, Dept Microbiol, Med Microbiol Lab, Tiruchirappalli, India; [Anbarasu, Kumarasamy] Bharathidasan Univ, Sch Marine Sci, Dept Marine Biotechnol, Microbial Biotechnol Lab, Tiruchirappalli, India; [Ponmurugan, Karuppiah; Al-Dhabi, Naif Abdullah] King Saud Univ, Coll Sci, Dept Bot & Microbiol, Riyadh, Saudi Arabia	Bharathidasan University; Bharathidasan University; King Saud University	Natarajaseenivasan, K (corresponding author), Bharathidasan Univ, Ctr Excellence Life Sci, Dept Microbiol, Med Microbiol Lab, Tiruchirappalli, India.	natarajaseenivasan@gmail.com	Mohan, Ganesh/AFK-2888-2022; Kumarasamy, Anbarasu/K-4703-2015	Kumarasamy, Anbarasu/0000-0002-1666-6742; Mohan, Ganesh/0000-0003-4636-1250	Department of Biotechnology (DBT); Government of India [BT/PR12133/AAQ/3/707/2014, RSP-2021/20]; King Saud University, Riyadh, Saudi Arabia	Department of Biotechnology (DBT)(Department of Biotechnology (DBT) India); Government of India; King Saud University, Riyadh, Saudi Arabia(King Saud University)	Funding We acknowledge the Department of Biotechnology (DBT), the Government of India for the research and development grant (BT/PR12133/AAQ/3/707/2014 dated 02-09-2016) and the Researchers Supporting Project (RSP-2021/20) of King Saud University, Riyadh, Saudi Arabia.	Castro N, 2008, FISH SHELLFISH IMMUN, V25, P208, DOI 10.1016/j.fsi.2008.05.008; Chen JD, 1996, ARCH MICROBIOL, V165, P9, DOI 10.1007/s002030050290; Chiba S, 2006, MOL MICROBIOL, V60, P448, DOI 10.1111/j.1365-2958.2006.05104.x; Chu CY, 2016, MBIO, V7, DOI 10.1128/mBio.00404-16; Hinderlich S, 1997, J BIOL CHEM, V272, P24313, DOI 10.1074/jbc.272.39.24313; Hinz A, 2011, J BACTERIOL, V193, P4790, DOI 10.1128/JB.05133-11; JANDA JM, 1991, INFECT IMMUN, V59, P154, DOI 10.1128/IAI.59.1.154-161.1991; Kawai K, 2004, VACCINE, V22, P3411, DOI 10.1016/j.vaccine.2004.02.026; Kihara A, 1996, EMBO J, V15, P6122, DOI 10.1002/j.1460-2075.1996.tb01000.x; Kihara A, 1997, P NATL ACAD SCI USA, V94, P5544, DOI 10.1073/pnas.94.11.5544; Kihara A, 1998, J BIOL CHEM, V273, P29770, DOI 10.1074/jbc.273.45.29770; Leung KY, 2012, MICROBES INFECT, V14, P26, DOI 10.1016/j.micinf.2011.08.005; Ling SHM, 2000, MICROBIOL-SGM, V146, P7, DOI 10.1099/00221287-146-1-7; Maiti B, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01362; Miller L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021950; Mohanty BR, 2007, J BIOSCIENCES, V32, P1331, DOI 10.1007/s12038-007-0143-8; Mohanty BR, 2010, FISH SHELLFISH IMMUN, V28, P613, DOI 10.1016/j.fsi.2009.12.025; Morrow IC, 2005, TRAFFIC, V6, P725, DOI 10.1111/j.1600-0854.2005.00318.x; Plumbridge J, 1999, J BACTERIOL, V181, P47, DOI 10.1128/JB.181.1.47-54.1999; Raja V, 2016, CLIN VACCINE IMMUNOL, V23, P65, DOI 10.1128/CVI.00509-15; Rao PSS, 2001, INFECT IMMUN, V69, P5689, DOI 10.1128/IAI.69.9.5689-5697.2001; Robinson A., 2003, VACCINE PROTOCOLS, DOI [10.1385/0896033341, DOI 10.1385/0896033341]; Stock I, 2001, ANTIMICROB AGENTS CH, V45, P2245, DOI 10.1128/AAC.45.8.2245-2255.2001; Sun Y, 2012, INFECT IMMUN, V80, P2948, DOI 10.1128/IAI.00063-12; Sun Y, 2011, VACCINE, V29, P2051, DOI 10.1016/j.vaccine.2011.01.013; Sun Y, 2010, VACCINE, V28, P6603, DOI 10.1016/j.vaccine.2010.07.050; Swain P, 2003, FISH SHELLFISH IMMUN, V15, P333, DOI 10.1016/S1050-4648(02)00178-X; Tan YP, 2005, MICROBIOL-SGM, V151, P2301, DOI 10.1099/mic.0.28005-0; TITGEMEYER F, 1994, MICROBIOL-UK, V140, P2349, DOI 10.1099/13500872-140-9-2349; van Bloois E, 2008, FEBS LETT, V582, P1419, DOI 10.1016/j.febslet.2008.02.082; Verjan N, 2005, APPL ENVIRON MICROB, V71, P5654, DOI 10.1128/AEM.71.9.5654-5658.2005; Wang C, 2013, FISH SHELLFISH IMMUN, V35, P858, DOI 10.1016/j.fsi.2013.06.021; Zheng J, 2007, MOL MICROBIOL, V66, P1192, DOI 10.1111/j.1365-2958.2007.05993.x	33	0	0	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 16	2021	12								764662	10.3389/fimmu.2021.764662	http://dx.doi.org/10.3389/fimmu.2021.764662			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XI0HR	34868012	Green Published, gold			2022-12-18	WOS:000725804800001
J	Casali, P; Li, SL; Morales, G; Daw, CC; Chupp, DP; Fisher, AD; Zan, H				Casali, Paolo; Li, Shili; Morales, Grecia; Daw, Cassidy C.; Chupp, Daniel P.; Fisher, Amanda D.; Zan, Hong			Epigenetic Modulation of Class-Switch DNA Recombination to IgA by miR-146a Through Downregulation of Smad2, Smad3 and Smad4	FRONTIERS IN IMMUNOLOGY			English	Article						AID; B cell; class switch DNA recombination (CSR); epigenetics; IgA; miR-146a; microRNA; Smad2; Smad3; Smad4	NF-KAPPA-B; CONSTANT-REGION GENE; MOUSE GERMLINE IG; TGF-BETA; MEDIATED REGULATION; IMMUNOGLOBULIN-A; GUT MICROBIOTA; HYPER-IGA; EXPRESSION; INDUCTION	IgA is the predominant antibody isotype at intestinal mucosae, where it plays a critical role in homeostasis and provides a first line of immune protection. Dysregulation of IgA production, however, can contribute to immunopathology, particularly in kidneys in which IgA deposition can cause nephropathy. Class-switch DNA recombination (CSR) to IgA is directed by TGF-beta signaling, which activates Smad2 and Smad3. Activated Smad2/Smad3 dimers are recruited together with Smad4 to the IgH alpha locus I alpha promoter to activate germline I alpha-C alpha transcription, the first step in the unfolding of CSR to IgA. Epigenetic factors, such as non-coding RNAs, particularly microRNAs, have been shown to regulate T cells, dendritic cells and other immune elements, as well as modulate the antibody response, including CSR, in a B cell-intrinsic fashion. Here we showed that the most abundant miRNA in resting B cells, miR-146a targets Smad2, Smad3 and Smad4 mRNA 3'UTRs and keeps CSR to IgA in check in resting B cells. Indeed, enforced miR-146a expression in B cells aborted induction of IgA CSR by decreasing Smad levels. By contrast, upon induction of CSR to IgA, as directed by TGF-beta, B cells downregulated miR-146a, thereby reversing the silencing of Smad2, Smad3 and Smad4, which, once expressed, led to recruitment of Smad2, Smad3 and Smad4 to the I alpha promoter for activation of germline I alpha-C alpha transcription. Deletion of miR-146a in miR-146a(-/-) mice significantly increased circulating levels of steady state total IgA, but not IgM, IgG or IgE, and heightened the specific IgA antibody response to OVA. In miR-146a(-/-) mice, the elevated systemic IgA levels were associated with increased IgA(+) B cells in intestinal mucosae, increased amounts of fecal free and bacteria-bound IgA as well as kidney IgA deposition, a hallmark of IgA nephropathy. Increased germline I alpha-C alpha transcription and CSR to IgA in miR-146a (-/-) B cells in vitro proved that miR-146a-induced Smad2, Smad3 and Smad4 repression is B cell intrinsic. The B cell-intrinsic role of miR-146a in the modulation of CSR to IgA was formally confirmed in vivo by construction and OVA immunization of mixed bone marrow mu MT/miR-146a(-/-) chimeric mice. Thus, by inhibiting Smad2, Smad3 and Smad4 expression, miR-146a plays an important and B cell intrinsic role in modulation of CSR to IgA and the IgA antibody response.	[Casali, Paolo; Li, Shili; Morales, Grecia; Daw, Cassidy C.; Chupp, Daniel P.; Fisher, Amanda D.; Zan, Hong] UT Hlth Sci Ctr, Dept Microbiol Immunol & Mol Genet, Univ Texas Long Sch Med, San Antonio, TX 78229 USA; [Li, Shili] Cent South Univ, Dept Immunol, Sch Basic Med Sci, Changsha, Peoples R China	University of Texas System; University of Texas Health San Antonio; Central South University	Casali, P; Zan, H (corresponding author), UT Hlth Sci Ctr, Dept Microbiol Immunol & Mol Genet, Univ Texas Long Sch Med, San Antonio, TX 78229 USA.	pcasali@uthscsa.edu; zan@uthscsa.edu						Amrouche L, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-51985-1; Batlle E, 2019, IMMUNITY, V50, P924, DOI 10.1016/j.immuni.2019.03.024; Blahna MT, 2012, FEBS LETT, V586, P1906, DOI 10.1016/j.febslet.2012.01.041; Boldin MP, 2011, J EXP MED, V208, P1189, DOI 10.1084/jem.20101823; Budi EH, 2017, TRENDS CELL BIOL, V27, P658, DOI 10.1016/j.tcb.2017.04.005; Bunker JJ, 2018, IMMUNITY, V49, P211, DOI 10.1016/j.immuni.2018.08.011; Casali P, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00491; Catanzaro JR, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-49923-2; Cerutti A, 2008, NAT REV IMMUNOL, V8, P421, DOI 10.1038/nri2322; Cerutti A, 2011, ANN NY ACAD SCI, V1238, P132, DOI 10.1111/j.1749-6632.2011.06266.x; Cerutti A, 2011, ANNU REV IMMUNOL, V29, P273, DOI 10.1146/annurev-immunol-031210-101317; Chang TC, 2008, NAT GENET, V40, P43, DOI 10.1038/ng.2007.30; Chen K, 2020, NAT REV IMMUNOL, V20, P427, DOI 10.1038/s41577-019-0261-1; Cho S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05196-3; Copetti V, 2014, ARCH DIS CHILD, V99, P1114, DOI 10.1136/archdischild-2014-306607; Danger R, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00098; Davis BN, 2008, NATURE, V454, P56, DOI 10.1038/nature07086; de Yebenes VG, 2013, IMMUNOL REV, V253, P25, DOI 10.1111/imr.12046; Donaldson GP, 2018, SCIENCE, V360, P795, DOI 10.1126/science.aaq0926; Gan HQ, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aay2793; Guo LL, 2016, TUMOR BIOL, V37, P115, DOI 10.1007/s13277-015-4374-2; Gutzeit C, 2014, IMMUNOL REV, V260, P76, DOI 10.1111/imr.12189; Hall JA, 2011, IMMUNITY, V35, P13, DOI 10.1016/j.immuni.2011.07.002; Hata A, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a022061; Huus KE, 2021, NAT REV IMMUNOL, V21, P514, DOI 10.1038/s41577-021-00506-1; Jazdzewski K, 2008, P NATL ACAD SCI USA, V105, P7269, DOI 10.1073/pnas.0802682105; Kaidonis G, 2016, ACTA DIABETOL, V53, P643, DOI 10.1007/s00592-016-0850-4; Kamata T, 2000, J IMMUNOL, V165, P1387, DOI 10.4049/jimmunol.165.3.1387; Kawai T, 2007, TRENDS MOL MED, V13, P460, DOI 10.1016/j.molmed.2007.09.002; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; Klasen IS, 2001, CLIN DIAGN LAB IMMUN, V8, P58, DOI 10.1128/CDLI.8.1.58-61.2001; Klein J, 2006, J IMMUNOL, V176, P2389, DOI 10.4049/jimmunol.176.4.2389; Kubinak JL, 2016, NAT REV IMMUNOL, V16, P767, DOI 10.1038/nri.2016.114; Kuchen S, 2010, IMMUNITY, V32, P828, DOI 10.1016/j.immuni.2010.05.009; Li B, 2017, J CLIN INVEST, V127, P3702, DOI 10.1172/JCI94012; Li J, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3798; Li ZN, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.02006; Lin JH, 2014, PEDIATR NEPHROL, V29, P1979, DOI 10.1007/s00467-014-2818-3; LIN YCA, 1992, J IMMUNOL, V149, P2914; Liu Z, 2012, ARCH DERMATOL RES, V304, P195, DOI 10.1007/s00403-011-1178-0; Lu LF, 2010, CELL, V142, P914, DOI 10.1016/j.cell.2010.08.012; Macpherson AJ, 2008, MUCOSAL IMMUNOL, V1, P11, DOI 10.1038/mi.2007.6; Macpherson AJ, 2018, ANNU REV IMMUNOL, V36, P359, DOI 10.1146/annurev-immunol-042617-053238; Macpherson AJ, 2012, TRENDS IMMUNOL, V33, P160, DOI 10.1016/j.it.2012.02.002; Martin-Malpartida P, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-02054-6; Massague J, 2000, GENE DEV, V14, P627; Mehta A, 2016, NAT REV IMMUNOL, V16, P279, DOI 10.1038/nri.2016.40; Moroney JB, 2020, CURR OPIN IMMUNOL, V67, P75, DOI 10.1016/j.coi.2020.09.004; Moroney JB, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19242-6; Mortazavi-Jahromi SS, 2020, IMMUNOL LETT, V227, P8, DOI 10.1016/j.imlet.2020.07.008; Mu YB, 2012, CELL TISSUE RES, V347, P11, DOI 10.1007/s00441-011-1201-y; Muroi M, 2008, J LEUKOCYTE BIOL, V83, P702, DOI 10.1189/jlb.0907629; O'Connell RM, 2012, ANNU REV IMMUNOL, V30, P295, DOI 10.1146/annurev-immunol-020711-075013; Park H, 2015, J BIOL CHEM, V290, P2831, DOI 10.1074/jbc.M114.591420; Park SR, 2009, NAT IMMUNOL, V10, P540, DOI 10.1038/ni.1725; Park SR, 2001, EUR J IMMUNOL, V31, P1706, DOI 10.1002/1521-4141(200106)31:6<1706::AID-IMMU1706>3.0.CO;2-Z; Planer JD, 2016, NATURE, V534, P263, DOI 10.1038/nature17940; Rawla P., 2021, STATPEARLS; Rinninella E, 2019, MICROORGANISMS, V7, DOI 10.3390/microorganisms7010014; Runtsch MC, 2015, ONCOTARGET, V6, P28556, DOI 10.18632/oncotarget.5597; Rusca N, 2012, MOL CELL BIOL, V32, P4432, DOI 10.1128/MCB.00824-12; Saba R, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00578; Sanchez HN, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13603-6; Schmolka N, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aao1392; Schofield WB, 2018, CURR BIOL, V28, pR1117, DOI 10.1016/j.cub.2018.08.019; Shen T, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00627; Shi MJ, 1998, J IMMUNOL, V161, P6751; Shi MJ, 2001, INT IMMUNOL, V13, P733, DOI 10.1093/intimm/13.6.733; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Stavnezer J, 2009, J IMMUNOL, V182, P5, DOI 10.4049/jimmunol.182.1.5; Sun YY, 2017, ACTA BIOCH BIOPH SIN, V49, P628, DOI 10.1093/abbs/gmx052; Sutherland DB, 2016, IMMUNOL REV, V270, P20, DOI 10.1111/imr.12384; Taganov KD, 2006, P NATL ACAD SCI USA, V103, P12481, DOI 10.1073/pnas.0605298103; Testa Ugo, 2017, Non-Coding RNA, V3, P22, DOI 10.3390/ncrna3030022; Wang Q, 2007, APPL ENVIRON MICROB, V73, P5261, DOI 10.1128/AEM.00062-07; White CA, 2014, J IMMUNOL, V193, P5933, DOI 10.4049/jimmunol.1401702; Xu ZM, 2012, NAT REV IMMUNOL, V12, P517, DOI 10.1038/nri3216; Yamashita M, 2008, MOL CELL, V31, P918, DOI 10.1016/j.molcel.2008.09.002; Yang C, 2020, CELL HOST MICROBE, V27, P467, DOI 10.1016/j.chom.2020.01.016; Yang LL, 2012, J EXP MED, V209, P1655, DOI 10.1084/jem.20112218; Yang Y, 2020, CURR OPIN MICROBIOL, V56, P89, DOI 10.1016/j.mib.2020.08.003; Zan H, 1998, J IMMUNOL, V161, P5217; Zan H, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14244; Zan H, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00631; Zan H, 2014, AUTOIMMUNITY, V47, P272, DOI 10.3109/08916934.2014.915955; Zan H, 2013, AUTOIMMUNITY, V46, P83, DOI 10.3109/08916934.2012.749244; Zan H, 2012, CELL REP, V2, P1220, DOI 10.1016/j.celrep.2012.09.029; Zhang Q, 2021, J ANIM SCI BIOTECHNO, V12, DOI 10.1186/s40104-020-00525-3; Zhang Y, 2000, J BIOL CHEM, V275, P16979, DOI 10.1074/jbc.M001526200; Zheng B, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00936; Zhong H, 2010, INT J HEMATOL, V92, P129, DOI 10.1007/s12185-010-0626-5	91	0	0	2	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 16	2021	12								761450	10.3389/fimmu.2021.761450	http://dx.doi.org/10.3389/fimmu.2021.761450			18	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XH7RP	34868004	Green Published, gold			2022-12-18	WOS:000725627400001
J	Gernert, M; Kiesel, M; Froehlich, M; Renner, R; Strunz, PP; Portegys, J; Tony, HP; Schmalzing, M; Schwaneck, EC				Gernert, Michael; Kiesel, Matthias; Froehlich, Matthias; Renner, Regina; Strunz, Patrick-Pascal; Portegys, Jan; Tony, Hans-Peter; Schmalzing, Marc; Schwaneck, Eva Christina			High Prevalence of Genital Human Papillomavirus Infection in Patients With Primary Immunodeficiencies	FRONTIERS IN IMMUNOLOGY			English	Article						human papillomavirus; primary immunodeficiency; inborn errors of immunity (IEIs); common variable immunodeficiency (CVID); genital warts	POSITIVE WOMEN; LESIONS	BackgroundGenital human papillomavirus (HPV)-infections are common in the general population and are responsible for relevant numbers of epithelial malignancies. Much data on the HPV-prevalence is available for secondary immunodeficiencies, especially for patients with human immunodeficiency virus (HIV)-infection. Little is known about the genital HPV-prevalence in patients with primary immunodeficiencies (PIDs). MethodsWe performed a cross-sectional study of patients with PIDs and took genital swabs from male and female patients, which were analyzed with polymerase chain reaction for the presence of HPV-DNA. Clinical and laboratory data was collected to identify risk factors. Results28 PID patients were included in this study. 10 of 28 (35.7%) had HPV-DNA in their genital swabs. 6 patients had high-risk HPV-types (21.4%). Most patients had asymptomatic HPV-infections, as genital warts were rare (2 of 28 patients) and HPV-associated malignancy was absent. Differences in the HPV-positivity regarding clinical PID-diagnosis, duration of PID, age, sex, immunosuppression, immunoglobulin replacement, or circumcision in males were not present. HPV-positive PID patients had higher numbers of T cells (CD3(+)), of cytotoxic T cells (CD3(+)/CD8(+)), of transitional B cells (CD19(+)/CD38(++)/CD10(+)/IgD(+)), and of plasmablasts (CD19(+)/CD38(+)/CD27(++)/IgD(-)) compared to HPV-negative. ConclusionPID patients exhibit a high rate of genital HPV-infections with a high rate of high-risk HPV-types. Regular screening for symptomatic genital HPV-infection and HPV-associated malignancy in PID patients seems recommendable.	[Gernert, Michael; Froehlich, Matthias; Strunz, Patrick-Pascal; Portegys, Jan; Tony, Hans-Peter; Schmalzing, Marc] Univ Hosp Wurzburg, Dept Med Rheumatol & Clin Immunol 2, Wurzburg, Germany; [Kiesel, Matthias] Univ Hosp Wurzburg, Dept Gynecol & Obstet, Wurzburg, Germany; [Renner, Regina] Friedrich Alexander Univ Erlangen, Inst Sociol, Erlangen, Germany; [Schwaneck, Eva Christina] Asklepios Klin Altona, Rheumatol & Clin Immunol, Hamburg, Germany	University of Wurzburg; University of Wurzburg; University of Erlangen Nuremberg; Asklepios Klinik Altona	Gernert, M (corresponding author), Univ Hosp Wurzburg, Dept Med Rheumatol & Clin Immunol 2, Wurzburg, Germany.	gernert_m1@ukw.de						Al-Herz W, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01231; [Anonymous], 2020, LEITLINIENPROGRAMM O; Arbyn M, 2020, LANCET GLOB HEALTH, V8, pE191, DOI 10.1016/S2214-109X(19)30482-6; Beziat V, 2020, HUM GENET, V139, P919, DOI 10.1007/s00439-020-02183-x; Brown DR, 2005, J INFECT DIS, V191, P182, DOI 10.1086/426867; Bruni L.A.G., 2019, HUMAN PAPILLOMAVIRUS; Bruni L, 2010, J INFECT DIS, V202, P1789, DOI 10.1086/657321; Crosbie EJ, 2013, LANCET, V382, P889, DOI 10.1016/S0140-6736(13)60022-7; De Vuyst H, 2009, EUR J CANCER, V45, P2632, DOI 10.1016/j.ejca.2009.07.019; Forman D, 2012, VACCINE, V30, pF12, DOI 10.1016/j.vaccine.2012.07.055; Gernert M, 2020, ARTHRITIS RES THER, V22, DOI 10.1186/s13075-020-02255-3; Gernert M, 2019, ARTHRITIS RES THER, V21, DOI 10.1186/s13075-019-1889-8; Giuliano AR, 2002, J INFECT DIS, V186, P462, DOI 10.1086/341782; Griesser H., 2013, MUNCHNER NOMENKLATUR, V11, P1042; Harder T, 2018, BMC MED, V16, DOI 10.1186/s12916-018-1098-3; Harper DM, 2004, LANCET, V364, P1757, DOI 10.1016/S0140-6736(04)17398-4; Hebnes JB, 2014, J SEX MED, V11, P2630, DOI 10.1111/jsm.12652; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2012, IARC Monogr Eval Carcinog Risks Hum, V100, P9; Kralickova P, 2019, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03135; Leiding JW, 2012, J ALLERGY CLIN IMMUN, V130, P1030, DOI 10.1016/j.jaci.2012.07.049; Liu G, 2018, AIDS, V32, P795, DOI [10.1097/qad.0000000000001765, 10.1097/QAD.0000000000001765]; Malphettes M, 2009, CLIN INFECT DIS, V49, P1329, DOI 10.1086/606059; Nayar R., 2004, BETHESDA SYSTEM REPO, VThird; Notz Q, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.581338; Pedini V, 2020, ALLERGY ASTHMA CL IM, V16, DOI 10.1186/s13223-020-00451-z; PETRY KU, 1994, INT J CANCER, V57, P836, DOI 10.1002/ijc.2910570612; Robert Koch-Institut, 2012, GESUNDHEITSFRAGEBOGE; Robert Koch-Institut, 2007, MITT STAND IMPFK STI; Robert Koch-Institut:, 2018, AKT KV IMPFS IMPFQ A; Santana IU, 2011, CLIN RHEUMATOL, V30, P665, DOI 10.1007/s10067-010-1606-0; Seidel MG, 2019, J ALLER CL IMM-PRACT, V7, P1763, DOI 10.1016/j.jaip.2019.02.004; Taylor S, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1633-9; Villa LL, 2006, BRIT J CANCER, V95, P1459, DOI 10.1038/sj.bjc.6603469; Wehr C, 2008, BLOOD, V111, P77, DOI 10.1182/blood-2007-06-091744; Weissenborn SJ, 2003, J CLIN MICROBIOL, V41, P2763, DOI 10.1128/JCM.41.6.2763-2767.2003	35	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 16	2021	12								789345	10.3389/fimmu.2021.789345	http://dx.doi.org/10.3389/fimmu.2021.789345			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XH7YU	34868076	gold, Green Published			2022-12-18	WOS:000725646200001
J	Liao, CC; Tsai, CH; Lo, HR; Lin, PR; Lin, CC; Chao, YC				Liao, Chih-Chi; Tsai, Chih-Hsuan; Lo, Huei-Ru; Lin, Pey-Ru; Lin, Chang-Chi; Chao, Yu-Chan			Development of a Scrub Typhus Diagnostic Platform Incorporating Cell-Surface Display Technology (vol 12, 761136, 2021)	FRONTIERS IN IMMUNOLOGY			English	Correction						baculovirus surface display; cell-based ELISA; Orientia tsutsugamushi; scrub typhus; serological diagnosis			[Liao, Chih-Chi; Tsai, Chih-Hsuan; Lo, Huei-Ru; Chao, Yu-Chan] Acad Sinica, Inst Mol Biol, Taipei, Taiwan; [Lin, Pey-Ru; Lin, Chang-Chi] Natl Def Med Ctr, Inst Prevent Med, Taipei, Taiwan; [Chao, Yu-Chan] Natl Chung Hsing Univ, Dept Entomol, Taichung, Taiwan; [Chao, Yu-Chan] Natl Taiwan Univ, Dept Entomol, Coll Bioresources & Agr, Taipei, Taiwan; [Chao, Yu-Chan] Natl Taiwan Univ, Dept Plant Pathol & Microbiol, Coll Bioresources & Agr, Taipei, Taiwan	Academia Sinica - Taiwan; National Defense Medical Center; National Chung Hsing University; National Taiwan University; National Taiwan University	Chao, YC (corresponding author), Acad Sinica, Inst Mol Biol, Taipei, Taiwan.; Lin, CC (corresponding author), Natl Def Med Ctr, Inst Prevent Med, Taipei, Taiwan.; Chao, YC (corresponding author), Natl Chung Hsing Univ, Dept Entomol, Taichung, Taiwan.; Chao, YC (corresponding author), Natl Taiwan Univ, Dept Entomol, Coll Bioresources & Agr, Taipei, Taiwan.; Chao, YC (corresponding author), Natl Taiwan Univ, Dept Plant Pathol & Microbiol, Coll Bioresources & Agr, Taipei, Taiwan.	chalin3@ndmctsgh.edu.tw; mbycchao@imb.sinica.edu.tw						Liao CC, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.761136	1	0	0	3	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 16	2021	12								803807	10.3389/fimmu.2021.803807	http://dx.doi.org/10.3389/fimmu.2021.803807			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XI5JY	34868089	Green Published, gold			2022-12-18	WOS:000726148900001
J	Yang, ZQ; Mitlander, H; Vuorinen, T; Finotto, S				Yang, Zuqin; Mitlaender, Hannah; Vuorinen, Tytti; Finotto, Susetta			Mechanism of Rhinovirus Immunity and Asthma (vol 12, 731846, 2021)	FRONTIERS IN IMMUNOLOGY			English	Correction						asthma; rhinovirus; host defense; immune evasion; interferon type I			[Yang, Zuqin; Mitlaender, Hannah; Finotto, Susetta] Friedrich Alexander Univ FAU Erlangen Numberg, Univ Klinikum Erlangen, Dept Mol Pneumol, Erlangen, Germany; [Vuorinen, Tytti] Univ Turku, Turku Univ Hosp, Inst Biomed, Med Microbiol, Turku, Finland	University of Erlangen Nuremberg; University of Turku	Finotto, S (corresponding author), Friedrich Alexander Univ FAU Erlangen Numberg, Univ Klinikum Erlangen, Dept Mol Pneumol, Erlangen, Germany.	susetta.finotto@uk-erlangen.de						Yang ZQ, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.731846	1	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 16	2021	12								800020	10.3389/fimmu.2021.800020	http://dx.doi.org/10.3389/fimmu.2021.800020			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XI5IR	34868087	Green Published, gold			2022-12-18	WOS:000726145600001
J	Zhong, CQ; Wang, RQ; Hua, MQ; Zhang, C; Han, FJ; Xu, M; Yang, XY; Li, GS; Hu, X; Sun, T; Ji, CY; Ma, DX				Zhong, Chaoqin; Wang, Ruiqing; Hua, Mingqiang; Zhang, Chen; Han, Fengjiao; Xu, Miao; Yang, Xinyu; Li, Guosheng; Hu, Xiang; Sun, Tao; Ji, Chunyan; Ma, Daoxin			NLRP3 Inflammasome Promotes the Progression of Acute Myeloid Leukemia	FRONTIERS IN IMMUNOLOGY			English	Correction						inflammasome; NLRP3; IL-1 beta; acute myeloid leukemia; progression			[Zhong, Chaoqin; Wang, Ruiqing; Hua, Mingqiang; Zhang, Chen; Han, Fengjiao; Xu, Miao; Yang, Xinyu; Li, Guosheng; Hu, Xiang; Sun, Tao; Ji, Chunyan; Ma, Daoxin] Shandong Univ, Dept Hematol, Qilu Hosp, Jinan, Peoples R China; [Zhong, Chaoqin] Shandong Yantai Mt Hosp, Dept Hematol, Yantai, Peoples R China; [Hua, Mingqiang] Shandong Univ, Qilu Hosp, Dept Emergency, Jinan, Peoples R China	Shandong University; Shandong University	Ma, DX (corresponding author), Shandong Univ, Dept Hematol, Qilu Hosp, Jinan, Peoples R China.	daoxinma@sdu.edu.cn							0	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 16	2021	12								808492	10.3389/fimmu.2021.808492	http://dx.doi.org/10.3389/fimmu.2021.808492			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XI5IL	34868093	Green Published, gold			2022-12-18	WOS:000726145000001
J	Ahn, R; Schaenman, J; Qian, ZCY; Pickering, H; Groysberg, V; Rossetti, M; Llamas, M; Hoffmann, A; Gjertson, D; Deng, MR; Bunnapradist, S; Reed, EF				Ahn, Richard; Schaenman, Joanna; Qian, Zachary; Pickering, Harry; Groysberg, Victoria; Rossetti, Maura; Llamas, Megan; Hoffmann, Alexander; Gjertson, David; Deng, Mario; Bunnapradist, Suphamai; Reed, Elaine F.			Acute and Chronic Changes in Gene Expression After CMV DNAemia in Kidney Transplant Recipients	FRONTIERS IN IMMUNOLOGY			English	Article						kidney transplant; RNA-seq; CMV DNAemia; transplant immunology; transcriptomics	T-CELLS; CYTOMEGALOVIRUS-INFECTION; REACTIVITY; UNIVERSAL; REJECTION; IMMUNITY	Cytomegalovirus (CMV) viremia continues to cause significant morbidity and mortality in kidney transplant patients with clinical complications including organ rejection and death. Whole blood gene expression dynamics in CMV viremic patients from onset of DNAemia through convalescence has not been well studied to date in humans. To evaluate how CMV infection impacts whole blood leukocyte gene expression over time, we evaluated a matched cohort of 62 kidney transplant recipients with and without CMV DNAemia using blood samples collected at multiple time points during the 12-month period after transplant. While transcriptomic differences were minimal at baseline between DNAemic and non-DNAemic patients, hundreds of genes were differentially expressed at the long-term timepoint, including genes enriching for pathways important for macrophages, interferon, and IL-8 signaling. Amongst patients with CMV DNAemia, the greatest amount of transcriptomic change occurred between baseline and 1-week post-DNAemia, with increase in pathways for interferon signaling and cytotoxic T cell function. Time-course gene set analysis of these differentially expressed genes revealed that most of the enriched pathways had a significant time-trend. While many pathways that were significantly down- or upregulated at 1 week returned to baseline-like levels, we noted that several pathways important in adaptive and innate cell function remained upregulated at the long-term timepoint after resolution of CMV DNAemia. Differential expression analysis and time-course gene set analysis revealed the dynamics of genes and pathways involved in the immune response to CMV DNAemia in kidney transplant patients. Understanding transcriptional changes caused by CMV DNAemia may identify the mechanism behind patient vulnerability to CMV reactivation and increased risk of rejection in transplant recipients and suggest protective strategies to counter the negative immunologic impact of CMV. These findings provide a framework to identify immune correlates for risk assessment and guiding need for extending antiviral prophylaxis.	[Ahn, Richard; Qian, Zachary; Hoffmann, Alexander] Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA; [Ahn, Richard; Qian, Zachary; Hoffmann, Alexander] Univ Calif Los Angeles, Inst Quantitat & Computat Biosci, Los Angeles, CA 90095 USA; [Schaenman, Joanna; Deng, Mario; Bunnapradist, Suphamai] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA; [Pickering, Harry; Groysberg, Victoria; Rossetti, Maura; Llamas, Megan; Gjertson, David; Reed, Elaine F.] Univ Calif Los Angeles, Dept Pathol & Lab Med, Los Angeles, CA USA; [Gjertson, David] Univ Calif Los Angeles, Dept Biostat, Los Angeles, CA USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Ahn, R (corresponding author), Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA.; Ahn, R (corresponding author), Univ Calif Los Angeles, Inst Quantitat & Computat Biosci, Los Angeles, CA 90095 USA.; Schaenman, J (corresponding author), Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA.				National Institutes of Health [U19 AI128913]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Funding This study was supported by a National Institutes of Health grant U19 AI128913 (PIs: ER and MS). The funding bodies played no role in the collection, analysis, or interpretation of data in this study.	Amir AL, 2010, BLOOD, V115, P3146, DOI 10.1182/blood-2009-07-234906; Andrews S., FASTQC; Bajwa M, 2017, J INFECT DIS, V215, P1212, DOI 10.1093/infdis/jix080; Collins-McMillen D, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10080444; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Sacristan PG, 2013, TRANSPL P, V45, P3620, DOI 10.1016/j.transproceed.2013.11.009; Halloran PF, 2017, AM J TRANSPLANT, V17, P1754, DOI 10.1111/ajt.14200; Hejblum BP, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004310; Jorgenson MR, 2019, TRANSPL INFECT DIS, V21, DOI 10.1111/tid.13080; Kakuta Y, 2012, TRANSPLANTATION, V93, P24, DOI 10.1097/TP.0b013e31823aa585; Kumar D, 2017, AM J TRANSPLANT, V17, P2468, DOI 10.1111/ajt.14347; Kuo HT, 2010, TRANSPLANTATION, V90, P1091, DOI 10.1097/TP.0b013e3181f7c053; L'Huillier AG, 2019, AM J TRANSPLANT, V19, P2495, DOI 10.1111/ajt.15371; Lebedeva A, 2020, AM J MED, V133, P133, DOI 10.1016/j.amjmed.2019.06.021; Li H, 2009, BIOINFORMATICS, V25, P2078, DOI 10.1093/bioinformatics/btp352; Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656; Ljungman P, 2017, CLIN INFECT DIS, V64, P87, DOI 10.1093/cid/ciw668; Marchi E, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00197; Marcinowski L, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002908; Mekker A, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002850; Navarro D, 2019, REV MED VIROL, V29, DOI 10.1002/rmv.2017; Nenna R, 2020, ERJ OPEN RES, V6, DOI 10.1183/23120541.00062-2020; Pantenburg B, 2002, J IMMUNOL, V169, P3686, DOI 10.4049/jimmunol.169.7.3686; Potu H, 2010, CANCER RES, V70, P655, DOI 10.1158/0008-5472.CAN-09-1942; Razonable RR, 2019, CLIN TRANSPLANT, V33, DOI 10.1111/ctr.13512; Richardson AK, 2020, CLIN TRANSL ONCOL, V22, P585, DOI 10.1007/s12094-019-02164-1; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Roman A, 2014, TRANSPLANT REV-ORLAN, V28, P84, DOI 10.1016/j.trre.2014.01.001; Schaenman JM, 2018, HUM IMMUNOL, V79, P659, DOI 10.1016/j.humimm.2018.06.006; Schaenman J, 2021, TRANSPL INFECT DIS, V23, DOI 10.1111/tid.13457; Schreeder DM, 2008, EUR J IMMUNOL, V38, P3159, DOI 10.1002/eji.200838516; Selin LK, 2007, J AM SOC NEPHROL, V18, P2268, DOI 10.1681/ASN.2007030295; Simanek AM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016103; Soderberg-Naucler C, 2016, MECH AGEING DEV, V158, P3, DOI 10.1016/j.mad.2016.06.005; Stern M, 2014, TRANSPLANTATION, V98, P1013, DOI 10.1097/TP.0000000000000160; Team R.C, 2015, R LANG ENV STAT COMP; Wirth TC, 2010, IMMUNITY, V33, P128, DOI 10.1016/j.immuni.2010.06.014; YANG H, 1986, J IMMUNOL, V136, P1186; Yong MK, 2018, CURR OPIN INFECT DIS, V31, P481, DOI [10.1097/QCO.0000000000000502, 10.1097/qco.0000000000000502]	39	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 15	2021	12								750659	10.3389/fimmu.2021.750659	http://dx.doi.org/10.3389/fimmu.2021.750659			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XH7GM	34867983	Green Published, gold			2022-12-18	WOS:000725598500001
J	Dei Zotti, F; Qiu, AN; La Carpia, F; Moriconi, C; Hudson, KE				Dei Zotti, Flavia; Qiu, Annie; La Carpia, Francesca; Moriconi, Chiara; Hudson, Krystalyn E.			A New Murine Model of Primary Autoimmune Hemolytic Anemia (AIHA)	FRONTIERS IN IMMUNOLOGY			English	Article						red blood cell; erythrocyte; autoimmune hemolytic anemia; tolerance; autoimmune disease; primary autoimmune hemolytic anemia; RBC (red-blood-cell); idiopathic autoimmune hemolytic anemia	ANTIGEN LOSS; T-CELLS; ALLOANTIGEN	Loss of humoral tolerance to red blood cells (RBCs) can lead to autoimmune hemolytic anemia (AIHA), a severe, and sometimes fatal disease. Patients with AIHA present with pallor, fatigue, decreased hematocrit, and splenomegaly. While secondary AIHA is associated with lymphoproliferative disorders, infections, and more recently, as an adverse event secondary to cancer immunotherapy, the etiology of primary AIHA is unknown. Several therapeutic strategies are available; however, there are currently no licensed treatments for AIHA and few therapeutics offer treatment-free durable remission. Moreover, supportive care with RBC transfusions can be challenging as most autoantibodies are directed against ubiquitous RBC antigens; thus, virtually all RBC donor units are incompatible. Given the severity of AIHA and the lack of treatment options, understanding the cellular and molecular mechanisms that facilitate the breakdown in tolerance would provide insight into new therapeutics. Herein, we report a new murine model of primary AIHA that reflects the biology observed in patients with primary AIHA. Production of anti-erythrocyte autoantibodies correlated with sex and age, and led to RBC antigen modulation, complement fixation, and anemia, as determined by decreased hematocrit and hemoglobin values and increased reticulocytes in peripheral blood. Moreover, autoantibody-producing animals developed splenomegaly, with altered splenic architecture characterized by expanded white pulp areas and nearly diminished red pulp areas. Additional analysis suggested that compensatory extramedullary erythropoiesis occurred as there were increased frequencies of RBC progenitors detectable in the spleen. No significant correlations between AIHA onset and inflammatory status or microbiome were observed. To our knowledge, this is the first report of a murine model that replicates observations made in humans with idiopathic AIHA. Thus, this is a tractable murine model of AIHA that can serve as a platform to identify key cellular and molecular pathways that are compromised, thereby leading to autoantibody formation, as well as testing new therapeutics and management strategies.	[Dei Zotti, Flavia; Qiu, Annie; La Carpia, Francesca; Moriconi, Chiara; Hudson, Krystalyn E.] Columbia Univ, Irving Med Ctr, Dept Pathol & Cell Biol, New York, NY 10027 USA	Columbia University; NewYork-Presbyterian Hospital	Hudson, KE (corresponding author), Columbia Univ, Irving Med Ctr, Dept Pathol & Cell Biol, New York, NY 10027 USA.	keh2197@cumc.columbia.edu	La Carpia, Francesca/ABH-7087-2020; Moriconi, Chiara/B-7638-2015	Moriconi, Chiara/0000-0001-7942-2166				Alwar Vanamala, 2010, J Lab Physicians, V2, P17, DOI 10.4103/0974-2727.66703; Anguiano-Alvarez VM, 2018, BLOOD RES, V53, P35, DOI 10.5045/br.2018.53.1.35; Barcellini W, 2020, J CLIN MED, V9, DOI 10.3390/jcm9123859; Barcellini W, 2015, TRANSFUS MED HEMOTH, V42, P287, DOI 10.1159/000439002; Barnden MJ, 1998, IMMUNOL CELL BIOL, V76, P34, DOI 10.1046/j.1440-1711.1998.00709.x; Berentsen S, 2015, TRANSFUS MED HEMOTH, V42, P303, DOI 10.1159/000438964; Brodsky RA, 2019, NEW ENGL J MED, V381, P647, DOI 10.1056/NEJMcp1900554; Chadebech P, 2010, BLOOD, V116, P4141, DOI 10.1182/blood-2010-03-276162; Chaudhary R K, 2014, Asian J Transfus Sci, V8, P5, DOI 10.4103/0973-6247.126681; Collins AM, 2016, IMMUNOL CELL BIOL, V94, P949, DOI 10.1038/icb.2016.65; Desmarets M, 2009, BLOOD, V114, P2315, DOI 10.1182/blood-2009-04-214387; FAROLINO DL, 1986, AM J HEMATOL, V21, P415, DOI 10.1002/ajh.2830210410; Fontes JA, 2017, IMMUN INFLAMM DIS, V5, P163, DOI 10.1002/iid3.155; Fukushima Y, 2018, INFLAMM REGEN, V38, DOI 10.1186/s41232-018-0082-9; Garratty G, 1987, Transfus Med Rev, V1, P47, DOI 10.1016/S0887-7963(87)70005-4; Gehrs BC, 2002, AM J HEMATOL, V69, P258, DOI 10.1002/ajh.10062; Glatigny S, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a028977; Go RS, 2017, BLOOD, V129, P2971, DOI 10.1182/blood-2016-11-693689; Goronzy JJ, 2012, CELL MOL LIFE SCI, V69, P1615, DOI 10.1007/s00018-012-0970-0; Gruber DR, 2020, BLOOD ADV, V4, P1526, DOI 10.1182/bloodadvances.2019001299; Hill A, 2018, HEMATOL-AM SOC HEMAT, P382, DOI 10.1182/asheducation-2018.1.382; Honjo K, 2004, TRANSPLANTATION, V77, P452, DOI 10.1097/01.TP.0000112937.12491.42; Howie HL, 2018, CURR OPIN HEMATOL, V25, P473, DOI 10.1097/MOH.0000000000000459; Hudson KE, 2012, HAEMATOL-HEMATOL J, V97, P1836, DOI 10.3324/haematol.2012.065144; Lechner K, 2010, BLOOD, V116, P1831, DOI 10.1182/blood-2010-03-259325; MARSH WL, 1979, AM J HEMATOL, V7, P155, DOI 10.1002/ajh.2830070208; Moras M, 2017, FRONT PHYSIOL, V8, DOI [10.3389/FPHYS.2017.01076, 10.3389/fphys.2017.01076]; Quintero OL, 2012, J AUTOIMMUN, V38, pJ109, DOI 10.1016/j.jaut.2011.10.003; Rao VK, 2011, BLOOD, V118, P5741, DOI 10.1182/blood-2011-07-325217; Richards AL, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01366; Richards AL, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00348; Scatizzi JC, 2012, J IMMUNOL, V188, P3307, DOI 10.4049/jimmunol.1103561; SEYFRIED H, 1972, VOX SANG, V23, P528, DOI 10.1111/j.1423-0410.1972.tb03846.x; Sohawon D, 2012, J MED IMAG RADIAT ON, V56, P538, DOI 10.1111/j.1754-9485.2012.02397.x; Thomas R, 2020, IMMUN AGEING, V17, DOI 10.1186/s12979-020-0173-8; VENGELENTYLER V, 1987, BRIT J HAEMATOL, V65, P231, DOI 10.1111/j.1365-2141.1987.tb02270.x; Vickers MA, 2020, AUTOIMMUNE DISEASES, 6TH EDITION, P897, DOI 10.1016/B978-0-12-812102-3.00047-6; VOS GH, 1971, J IMMUNOL, V106, P1172; Wittenborn TR, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0247501; Wong ASL, 2020, J AUTOIMMUN, V114, DOI 10.1016/j.jaut.2020.102489; Zantek ND, 2012, AM J HEMATOL, V87, P707, DOI 10.1002/ajh.23218; Zimring JC, 2007, BLOOD, V110, P2201, DOI 10.1182/blood-2007-04-083097; Zimring JC, 2009, TRANSFUS MED REV, V23, P189, DOI 10.1016/j.tmrv.2009.03.002; Zimring JC, 2005, BLOOD, V106, P1105, DOI 10.1182/blood-2005-03-1040	44	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 15	2021	12								752330	10.3389/fimmu.2021.752330	http://dx.doi.org/10.3389/fimmu.2021.752330			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XH7EB	34867985	Green Published, gold			2022-12-18	WOS:000725592200001
J	Gaertner, F; Gihring, A; Roth, A; Bischof, J; Xu, PF; Elad, L; Wabitsch, M; Burster, T; Knippschild, U				Gaertner, Fabian; Gihring, Adrian; Roth, Aileen; Bischof, Joachim; Xu, Pengfei; Elad, Leonard; Wabitsch, Martin; Burster, Timo; Knippschild, Uwe			Obesity Prolongs the Inflammatory Response in Mice After Severe Trauma and Attenuates the Splenic Response to the Inflammatory Reflex	FRONTIERS IN IMMUNOLOGY			English	Article						obesity; immune response; severe trauma; inflammatory reflex; monocyte compartment; mass cytometry (CyTOF)	COLONY-STIMULATING FACTOR; DIET-INDUCED OBESITY; MONOCYTE SUBSETS; ADIPOSE-TISSUE; VAGUS NERVE; P-SELECTIN; T-CELLS; IN-VIVO; MACROPHAGES; MOUSE	Thoracic traumas with extra-thoracic injuries result in an immediate, complex host response. The immune response requires tight regulation and can be influenced by additional risk factors such as obesity, which is considered a state of chronic inflammation. Utilizing high-dimensional mass and regular flow cytometry, we define key signatures of obesity-related alterations of the immune system during the response to the trauma. In this context, we report a modification in important components of the splenic response to the inflammatory reflex in obese mice. Furthermore, during the response to trauma, obese mice exhibit a prolonged increase of neutrophils and an early accumulation of inflammation associated CCR2(+)CD62L(+)Ly6C(hi) monocytes in the blood, contributing to a persistent inflammatory phase. Moreover, these mice exhibit differences in migration patterns of monocytes to the traumatized lung, resulting in decreased numbers of regenerative macrophages and an impaired M1/M2 switch in traumatized lungs. The findings presented in this study reveal an attenuation of the inflammatory reflex in obese mice, as well as a disturbance of the monocytic compartment contributing to a prolonged inflammation phase resulting in fewer phenotypically regenerative macrophages in the lung of obese mice.	[Gaertner, Fabian; Gihring, Adrian; Roth, Aileen; Bischof, Joachim; Xu, Pengfei; Elad, Leonard; Knippschild, Uwe] Ulm Univ, Med Ctr, Surg Ctr, Dept Gen & Visceral Surg, Ulm, Germany; [Wabitsch, Martin] Ulm Univ, Med Ctr, Div Pediat Endocrinol & Diabet, Dept Pediat & Adolescent Med, Ulm, Germany; [Burster, Timo] Nazarbayev Univ, Sch Sci & Humanities, Dept Biol, Nur Sultan, Kazakhstan	Ulm University; Ulm University; Nazarbayev University	Knippschild, U (corresponding author), Ulm Univ, Med Ctr, Surg Ctr, Dept Gen & Visceral Surg, Ulm, Germany.	uwe.knippschild@uniklinik-ulm.de		Burster, Timo/0000-0002-9596-6558; Roth, Aileen/0000-0001-9710-9085	Deutsche Forschungsgemeinschaft (DFG) [SFB1149, 251293561]; International PhD Programme of the International Graduate School in Molecular Medicine Ulm [GSC270]; Nazarbayev University FacultyDevelopment Competitive Research Grants Program [280720FD1907]	Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); International PhD Programme of the International Graduate School in Molecular Medicine Ulm; Nazarbayev University FacultyDevelopment Competitive Research Grants Program	MW and UK we r e supported by t h e Deutsche Forschungsgemeinschaft (DFG) as part of the SFB1149 "Danger Response, Disturbance Factors and Regenerative Potential after Acute Trauma" (251293561, project B04). FG, AG, and AR participated in the International PhD Programme of the International Graduate School in Molecular Medicine Ulm (GSC270). TB was funded by the Nazarbayev University FacultyDevelopment Competitive Research Grants Program, reference: 280720FD1907.	Andersson U, 2000, J EXP MED, V192, P565, DOI 10.1084/jem.192.4.565; Atri C, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19061801; Auffray C, 2009, ANNU REV IMMUNOL, V27, P669, DOI 10.1146/annurev.immunol.021908.132557; Avtanski D, 2019, ANIM MODEL EXP MED, V2, P252, DOI 10.1002/ame2.12084; Bagwell CB, 2020, CYTOM PART A, V97, P184, DOI 10.1002/cyto.a.23926; Brown LA, 2015, ACTA PHYSIOL, V215, P46, DOI 10.1111/apha.12537; Cariou B, 2020, DIABETOLOGIA, V63, P1500, DOI 10.1007/s00125-020-05180-x; Chertov O, 1997, J EXP MED, V186, P739, DOI 10.1084/jem.186.5.739; Dai XM, 2002, BLOOD, V99, P111, DOI 10.1182/blood.V99.1.111; Demirhan Recep, 2009, Interact Cardiovasc Thorac Surg, V9, P450, DOI 10.1510/icvts.2009.206599; Drescher HK, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9051106; Duan M, 2016, MUCOSAL IMMUNOL, V9, P550, DOI 10.1038/mi.2015.84; Geissmann F, 2003, IMMUNITY, V19, P71, DOI 10.1016/S1074-7613(03)00174-2; Ghanemi A, 2020, ANIMALS-BASEL, V10, DOI 10.3390/ani10122344; Gibbings SL, 2017, AM J RESP CELL MOL, V57, P66, DOI 10.1165/rcmb.2016-0361OC; Gihring A, 2020, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.00849; Glance LG, 2014, ANN SURG, V259, P576, DOI 10.1097/SLA.0000000000000330; GRIFFIN JD, 1990, J IMMUNOL, V145, P576; Hanna RN, 2011, NAT IMMUNOL, V12, P778, DOI 10.1038/ni.2063; Heijink IH, 2015, AM J RESP CELL MOL, V52, P554, DOI 10.1165/rcmb.2013-0505OC; Hoffmann M, 2012, INJURY, V43, P184, DOI 10.1016/j.injury.2011.05.029; Horckmans M, 2017, EUR HEART J, V38, P187, DOI 10.1093/eurheartj/ehw002; Hulsmans M, 2016, J MOL CELL CARDIOL, V93, P149, DOI 10.1016/j.yjmcc.2015.11.015; Ruiz-Ojeda FJ, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20194888; Jenne CN, 2018, CELL TISSUE RES, V371, P395, DOI 10.1007/s00441-018-2802-5; Kalbitz M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0187270; Karason K, 1999, AM J CARDIOL, V83, P1242, DOI 10.1016/S0002-9149(99)00066-1; Knoferl MW, 2004, SHOCK, V22, P51, DOI 10.1097/01.shk.0000127684.64611.5c; Kushner Robert F, 2002, Semin Gastrointest Dis, V13, P123; Lammermann T, 2013, NATURE, V498, P371, DOI 10.1038/nature12175; Lang P, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-55987-x; Levine JH, 2015, CELL, V162, P184, DOI 10.1016/j.cell.2015.05.047; LEY K, 1995, J EXP MED, V181, P669, DOI 10.1084/jem.181.2.669; Ley K, 2007, NAT REV IMMUNOL, V7, P678, DOI 10.1038/nri2156; Liu R, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01587; Lotfi N, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-58131-2; Mak A, 2019, J IMMUNOTOXICOL, V16, P28, DOI 10.1080/1547691X.2018.1516014; Mausberg AK, 2009, GLIA, V57, P1341, DOI 10.1002/glia.20853; Misharin AV, 2013, AM J RESP CELL MOL, V49, P503, DOI 10.1165/rcmb.2013-0086MA; Misumi I, 2019, CELL REP, V27, P514, DOI 10.1016/j.celrep.2019.03.030; Mortaz E, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02122; Mukherjee R, 2015, SCI REP-UK, V5, DOI 10.1038/srep13886; Nagareddy PR, 2014, CELL METAB, V19, P821, DOI 10.1016/j.cmet.2014.03.029; Nahrendorf M, 2007, J EXP MED, V204, P3037, DOI 10.1084/jem.20070885; Nicolle S, 2012, J MECH BEHAV BIOMED, V9, P130, DOI 10.1016/j.jmbbm.2012.02.005; PASSLICK B, 1989, BLOOD, V74, P2527, DOI 10.1182/blood.V74.7.2527.2527; Pavlov VA, 2012, NAT REV ENDOCRINOL, V8, P743, DOI 10.1038/nrendo.2012.189; Pittman K, 2013, J INNATE IMMUN, V5, P315, DOI 10.1159/000347132; Puri KD, 1997, J IMMUNOL, V158, P405; Richter WO, 1996, INT J OBESITY, V20, P966; Rizzo G, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.130807; Rosas-Ballina M, 2011, SCIENCE, V334, P98, DOI 10.1126/science.1209985; Schyns J, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/5160794; Shi C, 2011, NAT REV IMMUNOL, V11, P762, DOI 10.1038/nri3070; Soehnlein O, 2008, BLOOD, V112, P1461, DOI 10.1182/blood-2008-02-139634; Spada F, 2016, NEW BIOTECHNOL, V33, P514, DOI 10.1016/j.nbt.2015.12.007; Spielmann J, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-76906-5; Springer NL, 2019, AM J PATHOL, V189, P2019, DOI 10.1016/j.ajpath.2019.06.005; Swirski FK, 2009, SCIENCE, V325, P612, DOI 10.1126/science.1175202; Tacke F, 2007, J CLIN INVEST, V117, P185, DOI 10.1172/JCI28549; Tamashiro KLK, 2009, DIABETES, V58, P1116, DOI 10.2337/db08-1129; Tataroglu O, 2018, JCPSP-J COLL PHYSICI, V28, P546, DOI 10.29271/jcpsp.2018.07.546; Tecchio C, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00508; Teh YC, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00834; Tracey KJ, 2002, NATURE, V420, P853, DOI 10.1038/nature01321; Wang C, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/978463; Wang H, 2004, NAT MED, V10, P1216, DOI 10.1038/nm1124; Wang H, 2003, NATURE, V421, P384, DOI 10.1038/nature01339; Wang J, 2016, CELL, V165, P668, DOI 10.1016/j.cell.2016.03.009; Wang XF, 2011, ENDOCRINOLOGY, V152, P836, DOI 10.1210/en.2010-0855; Weber KSC, 1999, ARTERIOSCL THROM VAS, V19, P2085, DOI 10.1161/01.ATV.19.9.2085; Werner JU, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00019; Winfield RD, 2012, SHOCK, V37, P253, DOI 10.1097/SHK.0b013e3182449c0e; Wong KL, 2011, BLOOD, V118, pE15, DOI 10.1182/blood-2010-12-326355; Xu HP, 2008, BLOOD, V112, P1166, DOI 10.1182/blood-2007-06-098327; Xu PF, 2020, RESP RES, V21, DOI 10.1186/s12931-020-01502-0; Xu PF, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00674; Zhao L C, 2001, Dev Immunol, V8, P267, DOI 10.1155/2001/91831; Ziegler D, 2006, EXP CLIN ENDOCR DIAB, V114, P153, DOI 10.1055/s-2006-924083	79	0	0	1	9	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 15	2021	12								745132	10.3389/fimmu.2021.745132	http://dx.doi.org/10.3389/fimmu.2021.745132			19	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XI4WL	34867969	Green Published, gold			2022-12-18	WOS:000726113700001
J	Jiang, JQ; Qin, T; Zhang, L; Liu, Q; Wu, JB; Dai, RX; Zhou, LA; Zhao, Q; Luo, XY; Wang, H; Zhao, XD				Jiang, Jinqiu; Qin, Tao; Zhang, Liang; Liu, Qiao; Wu, Jiabin; Dai, Rongxin; Zhou, Lina; Zhao, Qin; Luo, Xiaoyan; Wang, Hua; Zhao, Xiaodong			IL-21 Rescues the Defect of IL-10-Producing Regulatory B Cells and Improves Allergic Asthma in DOCK8 Deficient Mice	FRONTIERS IN IMMUNOLOGY			English	Article						regulatory B cells; IL-10; DOCK8 deficiency; asthma; IL-21	T-CELLS; ACTIVATION; SUBSET; TRANSCRIPTION; PHENOTYPE; ANTIBODY; IMMUNITY; RECEPTOR	Mutations in human DOCK8 cause a combined immunodeficiency syndrome characterized by allergic diseases such as asthma and food allergy. However, the underlying mechanism is unclear. Regulatory B (Breg) cells that produce IL-10 exert potent immunosuppressive functions in patients with allergic and autoimmune disorders. DOCK8-deficient B cells show diminished responses to TLR9 signaling, suggesting a possible defect in IL-10-producing Breg cells in those with DOCK8 deficiency, which may contribute to allergies. Here, we isolated peripheral blood mononuclear cells from DOCK8-deficient patients and generated a Dock8 KO mouse model to study the effect of DOCK8 deficiency on Breg cells. DOCK8-deficient patients and Dock8 KO mice harbored quantitative and qualitative defects in IL-10-producing Breg cells; these defects were caused by abnormal Dock8(-/-) CD4(+) T cells. We found that recombinant murine (rm)IL-21 restored the function of Bregs both in vitro and in Dock8 KO mice, leading to reduced inflammatory cell infiltration of the lungs in a murine asthma model. Overall, the results provide new insight into the potential design of Breg-based or IL-21-based therapeutic strategies for allergic diseases, including asthma associated with DOCK8 deficiency.	[Jiang, Jinqiu; Luo, Xiaoyan; Wang, Hua] Chongqing Med Univ, Dept Dermatol,Childrens Hosp, Minist Educ,China Int Sci & Technol Cooperat Base, Key Lab Child Dev & Disorders,Natl Clin Res Ctr C, Chongqing, Peoples R China; [Jiang, Jinqiu; Zhang, Liang; Liu, Qiao; Wu, Jiabin; Dai, Rongxin; Zhou, Lina; Zhao, Qin; Zhao, Xiaodong] Chongqing Med Univ, Chongqing Key Lab Child Infect & Immun, Childrens Hosp, Chongqing, Peoples R China; [Qin, Tao] Chongqing Med Univ, Dept Infect Dis, Childrens Hosp, Chongqing, Peoples R China; [Dai, Rongxin; Zhao, Xiaodong] Chongqing Med Univ, Dept Rheumatol & Immunol, Childrens Hosp, Chongqing, Peoples R China	Chongqing Medical University; Chongqing Medical University; Chongqing Medical University; Chongqing Medical University	Zhao, XD (corresponding author), Chongqing Med Univ, Chongqing Key Lab Child Infect & Immun, Childrens Hosp, Chongqing, Peoples R China.; Zhao, XD (corresponding author), Chongqing Med Univ, Dept Rheumatol & Immunol, Childrens Hosp, Chongqing, Peoples R China.	zhaoxd530@aliyun.com						Amu S, 2010, J ALLERGY CLIN IMMUN, V125, P1114, DOI 10.1016/j.jaci.2010.01.018; Aydin SE, 2015, J CLIN IMMUNOL, V35, P189, DOI 10.1007/s10875-014-0126-0; Banko Z, 2017, J IMMUNOL, V198, P1512, DOI 10.4049/jimmunol.1600218; Bankoti R, 2012, J IMMUNOL, V188, P3961, DOI 10.4049/jimmunol.1102880; Blair PA, 2010, IMMUNITY, V32, P129, DOI 10.1016/j.immuni.2009.11.009; Braza F, 2015, ALLERGY, V70, P1421, DOI 10.1111/all.12697; Candando KM, 2014, IMMUNOL REV, V259, P259, DOI 10.1111/imr.12176; Carter NA, 2011, J IMMUNOL, V186, P5569, DOI 10.4049/jimmunol.1100284; Coquet JM, 2015, IMMUNITY, V43, P318, DOI 10.1016/j.immuni.2015.07.015; Gowthaman U, 2019, SCIENCE, V365, P883, DOI 10.1126/science.aaw6433; Habib T, 2003, J ALLERGY CLIN IMMUN, V112, P1033, DOI 10.1016/j.jaci.2003.08.039; Hiromura Y, 2007, J IMMUNOL, V179, P7157, DOI 10.4049/jimmunol.179.10.7157; Iwata Y, 2011, BLOOD, V117, P530, DOI 10.1182/blood-2010-07-294249; Jabara HH, 2012, NAT IMMUNOL, V13, P612, DOI 10.1038/ni.2305; Keles S, 2016, J ALLERGY CLIN IMMUN, V138, P1384, DOI 10.1016/j.jaci.2016.04.023; Krishnaswamy JK, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aam9169; Lampropoulou V, 2008, J IMMUNOL, V180, P4763, DOI 10.4049/jimmunol.180.7.4763; Liu BS, 2014, EUR J IMMUNOL, V44, P2121, DOI 10.1002/eji.201344341; Novy P, 2011, J IMMUNOL, V186, P2729, DOI 10.4049/jimmunol.1003009; Parekh VV, 2003, J IMMUNOL, V170, P5897, DOI 10.4049/jimmunol.170.12.5897; Parrish-Novak J, 2000, NATURE, V408, P57, DOI 10.1038/35040504; Ponsford MJ, 2018, ALLERGY, V73, P2122, DOI 10.1111/all.13578; Qin T, 2016, IMMUNOL RES, V64, P260, DOI 10.1007/s12026-015-8745-y; Randall KL, 2009, NAT IMMUNOL, V10, P1283, DOI 10.1038/ni.1820; Salomon S, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075-017-1244-x; Schneider C, 2020, NAT IMMUNOL, V21, P1528, DOI 10.1038/s41590-020-0795-1; Shen P, 2014, NATURE, V507, P366, DOI 10.1038/nature12979; Singh A, 2008, J IMMUNOL, V180, P7318, DOI 10.4049/jimmunol.180.11.7318; Sun XY, 2018, BLOOD ADV, V2, P401, DOI 10.1182/bloodadvances.2017007880; Suto A, 2002, BLOOD, V100, P4565, DOI 10.1182/blood-2002-04-1115; van de Veen W, 2016, J ALLERGY CLIN IMMUN, V138, P654, DOI 10.1016/j.jaci.2016.07.006; van der Vlugt LEPM, 2014, CLIN EXP ALLERGY, V44, P517, DOI 10.1111/cea.12238; Wu JB, 2018, BIOCHEM BIOPH RES CO, V501, P92, DOI 10.1016/j.bbrc.2018.04.179; Yanaba K, 2008, IMMUNITY, V28, P639, DOI 10.1016/j.immuni.2008.03.017; Yanaba K, 2009, J IMMUNOL, V182, P7459, DOI 10.4049/jimmunol.0900270; Yang ZY, 2020, J EXP MED, V217, DOI 10.1084/jem.20190472; Yoshizaki A, 2012, NATURE, V491, P264, DOI 10.1038/nature11501; Zhang Q, 2016, J CLIN IMMUNOL, V36, P441, DOI 10.1007/s10875-016-0296-z	38	0	0	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 15	2021	12								695596	10.3389/fimmu.2021.695596	http://dx.doi.org/10.3389/fimmu.2021.695596			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XH7GE	34867940	Green Published, Green Submitted, gold			2022-12-18	WOS:000725597700001
J	Kumar, NP; Moideen, K; Nancy, A; Viswanathan, V; Thiruvengadam, K; Sivakumar, S; Hissar, S; Kornfeld, H; Babu, S				Kumar, Nathella Pavan; Moideen, Kadar; Nancy, Arul; Viswanathan, Vijay; Thiruvengadam, Kannan; Sivakumar, Shanmugam; Hissar, Syed; Kornfeld, Hardy; Babu, Subash			Acute Phase Proteins Are Baseline Predictors of Tuberculosis Treatment Failure	FRONTIERS IN IMMUNOLOGY			English	Article						tuberculosis; acute phase proteins; biomarker; inflammation; TB treatment	C-REACTIVE PROTEIN; HIV-INFECTED INDIVIDUALS; PULMONARY TUBERCULOSIS; DIAGNOSTIC-ACCURACY; INFLAMMATION; BIOMARKERS	Systemic inflammation is a characteristic feature of pulmonary tuberculosis (PTB). Whether systemic inflammation is associated with treatment failure in PTB is not known. Participants, who were newly diagnosed, sputum smear and culture positive individuals with drug-sensitive PTB, were treated with standard anti-tuberculosis treatment and classified as having treatment failure or microbiological cure. The plasma levels of acute phase proteins were assessed at baseline (pre-treatment). Baseline levels of C-reactive protein (CRP), alpha-2 macroglobulin (a2M), Haptoglobin and serum amyloid P (SAP) were significantly higher in treatment failure compared to cured individuals. ROC curve analysis demonstrated the utility of these individual markers in discriminating treatment failure from cure. Finally, combined ROC analysis revealed high sensitivity and specificity of 3 marker signatures comprising of CRP, a2M and SAP in distinguishing treatment failure from cured individuals with a sensitivity of 100%, specificity of 100% and area under the curve of 1. Therefore, acute phase proteins are very accurate baseline predictors of PTB treatment failure. If validated in larger cohorts, these markers hold promise for a rapid prognostic testing for adverse treatment outcomes in PTB.	[Kumar, Nathella Pavan; Thiruvengadam, Kannan; Sivakumar, Shanmugam; Hissar, Syed; Babu, Subash] Indian Council Med Res ICMR, Natl Inst Res TB, Chennai, Tamil Nadu, India; [Moideen, Kadar; Nancy, Arul] Natl Inst Hlth, Natl Inst Res TB, Int Ctr Excellence Res, Chennai, Tamil Nadu, India; [Viswanathan, Vijay] Prof M Viswanathan Diabet Res Ctr, Dept Diabetol, Chennai, Tamil Nadu, India; [Kornfeld, Hardy] Univ Massachusetts, Sch Med, Dept Med, Worcester, MA USA; [Babu, Subash] NIAID, Parasit Dis Lab, Natl Inst Hlth, 9000 Rockville Pike, Bethesda, MD 20892 USA	Indian Council of Medical Research (ICMR); ICMR - National Institute for Research in Tuberculosis (NIRT); Indian Council of Medical Research (ICMR); ICMR - National Institute for Research in Tuberculosis (NIRT); University of Massachusetts System; University of Massachusetts Worcester; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Kumar, NP (corresponding author), Indian Council Med Res ICMR, Natl Inst Res TB, Chennai, Tamil Nadu, India.	pavankumarn@nirt.res.in	Thiruvengadam, Kannan/AAQ-8532-2021; Babu, Subash/GXG-4746-2022	Thiruvengadam, Kannan/0000-0002-3758-1094; 	Government of Indias (GOI) Department of Biotechnology (DBT); Indian Council of Medical Research (ICMR); United States National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), Office of AIDS Research (OAR); CRDF Global [USB1-31149-XX-13]; CRDF Global RePORT India Consortium Supplemental Funding [OISE-17-62911-1]	Government of Indias (GOI) Department of Biotechnology (DBT); Indian Council of Medical Research (ICMR)(Indian Council of Medical Research (ICMR)); United States National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), Office of AIDS Research (OAR); CRDF Global; CRDF Global RePORT India Consortium Supplemental Funding	This project has been funded in whole or in part with Federal funds from the Government of Indias (GOI) Department of Biotechnology (DBT), the Indian Council of Medical Research (ICMR), the United States National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), Office of AIDS Research (OAR), and distributed in part by CRDF Global [grant USB1-31149-XX-13]. This work is also funded by CRDF Global RePORT India Consortium Supplemental Funding [grant OISE-17-62911-1].	Andersen CBF, 2017, ANTIOXID REDOX SIGN, V26, P814, DOI 10.1089/ars.2016.6793; Bapat PR, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133928; Bastos HN, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01948; Bedell RA, 2018, TROP MED INT HEALTH, V23, P254, DOI 10.1111/tmi.13025; Bottazzi B, 2016, J HEPATOL, V64, P1416, DOI 10.1016/j.jhep.2016.02.029; Cater JH, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/5410657; Dorhoi A, 2014, SEMIN IMMUNOL, V26, P533, DOI 10.1016/j.smim.2014.10.002; Drain PK, 2014, INT J TUBERC LUNG D, V18, P20, DOI 10.5588/ijtld.13.0519; Furman D, 2019, NAT MED, V25, P1822, DOI 10.1038/s41591-019-0675-0; Goletti D, 2018, EUR RESPIR J, V52, DOI 10.1183/13993003.01089-2018; Jacobs R, 2016, ONCOTARGET, V7, P57581, DOI 10.18632/oncotarget.11420; Kornfeld H, 2016, CHEST, V149, P1501, DOI 10.1016/j.chest.2016.02.675; Kumar NP, 2021, CLIN INFECT DIS, V73, pE3419, DOI 10.1093/cid/ciaa1104; Kumar NP, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.27754; Kumar NP, 2013, CLIN VACCINE IMMUNOL, V20, P704, DOI 10.1128/CVI.00038-13; Lawn SD, 2013, INT J TUBERC LUNG D, V17, P636, DOI 10.5588/ijtld.12.0811; Pai M, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.76; Phalane KG, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/981984; Racanelli AC, 2018, AUTOPHAGY, V14, P221, DOI 10.1080/15548627.2017.1389823; Rockwood N, 2016, EXPERT REV RESP MED, V10, P643, DOI 10.1586/17476348.2016.1166960; Shapiro AE, 2018, AIDS, V32, P1811, DOI 10.1097/QAD.0000000000001902; Sproston NR, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00754; Wallis RS, 2013, LANCET INFECT DIS, V13, P362, DOI 10.1016/S1473-3099(13)70034-3; Wilson D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015248; WONG CT, 1990, TUBERCLE, V71, P193, DOI 10.1016/0041-3879(90)90075-J; Yoon C, 2017, INT J TUBERC LUNG D, V21, P1013, DOI 10.5588/ijtld.17.0078; Yoon C, 2017, LANCET INFECT DIS, V17, P1285, DOI 10.1016/S1473-3099(17)30488-7; Zumla A, 2015, J INTERN MED, V277, P373, DOI 10.1111/joim.12256	28	0	0	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 15	2021	12								731878	10.3389/fimmu.2021.731878	http://dx.doi.org/10.3389/fimmu.2021.731878			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XI4BM	34867953	Green Published, gold, Green Accepted			2022-12-18	WOS:000726059200001
J	Nabi, R; Lewin, AC; Collantes, TM; Chouljenko, VN; Kousoulas, KG				Nabi, Rafiq; Lewin, Andrew C.; Collantes, Therese M.; Chouljenko, Vladimir N.; Kousoulas, Konstantin G.			Intramuscular Vaccination With the HSV-1(VC2) Live-Attenuated Vaccine Strain Confers Protection Against Viral Ocular Immunopathogenesis Associated With gamma delta T Cell Intracorneal Infiltration	FRONTIERS IN IMMUNOLOGY			English	Article						herpes simplex; gamma delta T cells; immunopathogenesis; ocular infection; herpes keratitis	TYPE-1 UL20 PROTEIN; GLYCOPROTEIN K GK; AMINO-TERMINUS; EFFECTOR FUNCTIONS; VIRUS; INFECTION; IMMUNITY; MICE; NEUTROPHILS; EXPRESSION	Herpes simplex virus type-1 (HSV-1) ocular infection is one of the leading causes of infectious blindness in developed countries. The resultant herpetic keratitis (HK) is caused by an exacerbated reaction of the adaptive immune response that persists beyond virus clearance causing substantial damage to the cornea. Intramuscular immunization of mice with the HSV-1(VC2) live-attenuated vaccine strain has been shown to protect mice against lethal ocular challenge. Herein, we show that following ocular challenge, VC2 vaccinated animals control ocular immunopathogenesis in the absence of neutralizing antibodies on ocular surfaces. Ocular protection is associated with enhanced intracorneal infiltration of gamma delta T cells compared to mock-vaccinated animals. The observed gamma delta T cellular infiltration was inversely proportional to the infiltration of neutrophils, the latter associated with exacerbated tissue damage. Inhibition of T cell migration into ocular tissues by the S1P receptors agonist FTY720 produced significant ocular disease in vaccinated mice and marked increase in neutrophil infiltration. These results indicate that ocular challenge of mice immunized with the VC2 vaccine induce a unique ocular mucosal response that leads into the infiltration of gamma delta T cells resulting in the amelioration of infection-associated immunopathogenesis.	[Nabi, Rafiq; Collantes, Therese M.; Chouljenko, Vladimir N.; Kousoulas, Konstantin G.] Louisiana State Univ Sch Vet Med, Dept Pathobiol Sci, Baton Rouge, LA 70803 USA; [Lewin, Andrew C.] Louisiana State Univ Sch Vet Med, Dept Vet Clin Sci, Baton Rouge, LA USA	Louisiana State University School of Veterinary Medicine; Louisiana State University System; Louisiana State University; Louisiana State University School of Veterinary Medicine; Louisiana State University System; Louisiana State University	Kousoulas, KG (corresponding author), Louisiana State Univ Sch Vet Med, Dept Pathobiol Sci, Baton Rouge, LA 70803 USA.	vtgusk@lsu.edu			LSU Division of Biotechnology & Molecular Medicine (BioMMED), School of Veterinary Medicine; Governors Biotechnology Initiative grant from the Louisiana Board of Regents; Cores of the Center for Experimental Infectious Disease Research (CEIDR) - NIH: NIGMS [P30GM110670]; Louisiana Biomedical Research Network (LBRN) - NIH: NIGMS [P20GM103424]	LSU Division of Biotechnology & Molecular Medicine (BioMMED), School of Veterinary Medicine; Governors Biotechnology Initiative grant from the Louisiana Board of Regents; Cores of the Center for Experimental Infectious Disease Research (CEIDR) - NIH: NIGMS; Louisiana Biomedical Research Network (LBRN) - NIH: NIGMS	The work was supported by funds of the LSU Division of Biotechnology & Molecular Medicine (BioMMED), School of Veterinary Medicine, by a Governors Biotechnology Initiative grant from the Louisiana Board of Regents (to KK), and by Cores of the Center for Experimental Infectious Disease Research (CEIDR) and Louisiana Biomedical Research Network (LBRN) supported by NIH: NIGMS P30GM110670 and P20GM103424, respectively.	Abate G, 2005, J INFECT DIS, V192, P1362, DOI 10.1086/444423; Aljurf M, 2002, BLOOD REV, V16, P203, DOI 10.1016/S0268-960X(02)00029-2; Allen SJ, 2014, INVEST OPHTH VIS SCI, V55, P2442, DOI 10.1167/iovs.14-14013; Allen SJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085360; Allen SJ, 2010, VIROLOGY, V399, P11, DOI 10.1016/j.virol.2009.12.011; Anipindi Varun C, 2019, Immunohorizons, V3, P317, DOI 10.4049/immunohorizons.1900040; Awasthi S, 2009, VACCINE, V27, P6845, DOI 10.1016/j.vaccine.2009.09.017; Azher TN, 2017, J IMMUNOL RES, V2017, DOI 10.1155/2017/7261980; Baer A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-29355-0; Bonneville M, 2010, NAT REV IMMUNOL, V10, P467, DOI 10.1038/nri2781; Born WK, 2013, CELL MOL IMMUNOL, V10, P13, DOI 10.1038/cmi.2012.45; Born WK, 2009, ARCH IMMUNOL THER EX, V57, P129, DOI 10.1007/s00005-009-0017-x; Bosurgi L, 2017, SCIENCE, V356, P1072, DOI 10.1126/science.aai8132; Bradley H, 2014, J INFECT DIS, V209, P325, DOI 10.1093/infdis/jit458; Buela KAG, 2015, J IMMUNOL, V194, P379, DOI 10.4049/jimmunol.1402326; Burn C, 2018, J INFECT DIS, V217, P754, DOI 10.1093/infdis/jix628; Carr Daniel J J, 2020, Immunohorizons, V4, P608, DOI 10.4049/immunohorizons.2000060; Cathcart HM, 2011, INVEST OPHTH VIS SCI, V52, P3984, DOI 10.1167/iovs.10-6449; Chien YH, 2014, ANNU REV IMMUNOL, V32, P121, DOI 10.1146/annurev-immunol-032713-120216; Chiuppesi F, 2012, J VIROL, V86, P6563, DOI 10.1128/JVI.00302-12; Chouljenko VN, 2010, J VIROL, V84, P8596, DOI 10.1128/JVI.00298-10; Chouljenko VN, 2009, J VIROL, V83, P12301, DOI 10.1128/JVI.01329-09; Corpuz TM, 2016, J IMMUNOL, V196, P645, DOI 10.4049/jimmunol.1502082; Daheshia M, 1998, EXP EYE RES, V67, P619, DOI 10.1006/exer.1998.0565; Eaton JS, 2017, J OCUL PHARMACOL TH, V33, P718, DOI 10.1089/jop.2017.0108; Fitzpatrick S, 2019, INVEST OPHTH VIS SCI, V60, P3952, DOI 10.1167/iovs.19-27810; Foster TP, 2008, J VIROL, V82, P6310, DOI 10.1128/JVI.00147-08; Foster TP, 2004, J VIROL, V78, P13262, DOI 10.1128/JVI.78.23.13262-13277.2004; Foster TP, 2004, J VIROL, V78, P5347, DOI 10.1128/JVI.78.10.5347-5357.2004; Frank GM, 2012, J IMMUNOL, V188, P1350, DOI 10.4049/jimmunol.1101968; Frencher JT, 2014, J LEUKOCYTE BIOL, V96, P957, DOI 10.1189/jlb.6HI1213-632R; Fukuda Masahiko, 2008, Semin Ophthalmol, V23, P217, DOI 10.1080/08820530802111366; Gerber DJ, 1999, J IMMUNOL, V163, P3076; GOODMAN T, 1989, J EXP MED, V170, P1569, DOI 10.1084/jem.170.5.1569; Gray EE, 2011, J IMMUNOL, V186, P6091, DOI 10.4049/jimmunol.1100427; Hao JL, 2011, J IMMUNOL, V187, P4979, DOI 10.4049/jimmunol.1101389; HAVRAN WL, 1990, NATURE, V344, P68, DOI 10.1038/344068a0; Hayday AC, 2009, IMMUNITY, V31, P184, DOI 10.1016/j.immuni.2009.08.006; Hu K, 2011, IMMUNOL INVEST, V40, P265, DOI 10.3109/08820139.2010.534219; Huang YF, 2015, J IMMUNOL, V195, P5572, DOI 10.4049/jimmunol.1501604; Ito Y, 2009, ARTHRITIS RHEUM-US, V60, P2294, DOI 10.1002/art.24687; ITOHARA S, 1990, NATURE, V343, P754, DOI 10.1038/343754a0; Jackson DG, 2004, APMIS, V112, P526, DOI 10.1111/j.1600-0463.2004.apm11207-0811.x; Jaggi U, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02895; Jambunathan N, 2016, J VIROL, V90, P2230, DOI 10.1128/JVI.02468-15; Kadivar M, 2016, J IMMUNOL, V197, P4584, DOI 10.4049/jimmunol.1601146; Kasubi MJ, 2006, J CLIN MICROBIOL, V44, P2801, DOI 10.1128/JCM.00180-06; Khairallah C, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00105; Koujah L, 2019, CELL MOL LIFE SCI, V76, P405, DOI 10.1007/s00018-018-2938-1; Krishnan S, 2018, P NATL ACAD SCI USA, V115, P10738, DOI 10.1073/pnas.1802320115; Lepisto AJ, 2006, INVEST OPHTH VIS SCI, V47, P3400, DOI 10.1167/iovs.05-0898; Li H, 2006, IMMUNOLOGY, V117, P167, DOI 10.1111/j.1365-2567.2005.02275.x; Li Z, 2007, AM J PATHOL, V171, P838, DOI 10.2353/ajpath.2007.070008; Li ZJ, 2011, FASEB J, V25, P2659, DOI 10.1096/fj.11-184804; LIVERSIDGE J, 1993, AUTOIMMUNITY, V15, P257, DOI 10.3109/08916939309115747; Lobo AM, 2019, OCUL SURF, V17, P40, DOI 10.1016/j.jtos.2018.10.002; Marchitto MC, 2019, P NATL ACAD SCI USA, V116, P10917, DOI 10.1073/pnas.1818256116; Melancon JM, 2007, VIROL J, V4, DOI 10.1186/1743-422X-4-120; Melancon JM, 2004, J VIROL, V78, P7329, DOI 10.1128/JVI.78.14.7329-7343.2004; Molesworth-Kenyon S, 2005, VIROLOGY, V333, P1, DOI 10.1016/j.virol.2005.01.005; Mott KR, 2007, J VIROL, V81, P12962, DOI 10.1128/JVI.01442-07; Musarrat F, 2018, J VIROL, V92, DOI 10.1128/JVI.01842-17; Naidu SK, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0228252; Ngo VL, 2018, P NATL ACAD SCI USA, V115, pE5076, DOI 10.1073/pnas.1718902115; O'Brien RL, 2009, INVEST OPHTH VIS SCI, V50, P3266, DOI 10.1167/iovs.08-2982; Paludan SR, 2011, NAT REV IMMUNOL, V11, P143, DOI 10.1038/nri2937; Ribot JC, 2019, P NATL ACAD SCI USA, V116, P9979, DOI 10.1073/pnas.1814440116; Rowe AM, 2013, PROG RETIN EYE RES, V32, P88, DOI 10.1016/j.preteyeres.2012.08.002; Royer DJ, 2019, MUCOSAL IMMUNOL, V12, P827, DOI 10.1038/s41385-019-0131-y; Royer DJ, 2016, J VIROL, V90, P5514, DOI 10.1128/JVI.00517-16; Saied AA, 2014, CURR EYE RES, V39, P596, DOI 10.3109/02713683.2013.855238; Sciammas R, 1997, J EXP MED, V185, P1969, DOI 10.1084/jem.185.11.1969; Shao LY, 2009, J VIROL, V83, P11959, DOI 10.1128/JVI.00689-09; Shen HB, 2015, EUR J IMMUNOL, V45, P442, DOI 10.1002/eji.201444635; Shen Y, 2002, SCIENCE, V295, P2255, DOI 10.1126/science.1068819; Sheridan BS, 2013, IMMUNITY, V39, P184, DOI 10.1016/j.immuni.2013.06.015; SHIMELD C, 1990, J GEN VIROL, V71, P397, DOI 10.1099/0022-1317-71-2-397; Skelsey ME, 2001, J IMMUNOL, V166, P4327, DOI 10.4049/jimmunol.166.7.4327; Smith JS, 2002, J INFECT DIS, V186, pS3, DOI 10.1086/343739; Sonnenberg GF, 2011, NAT IMMUNOL, V12, P383, DOI 10.1038/ni.2025; Srivastava R, 2018, J IMMUNOL, V201, P2315, DOI 10.4049/jimmunol.1800725; St Leger AJ, 2017, IMMUNITY, V47, P148, DOI 10.1016/j.immuni.2017.06.014; Stanfield BA, 2018, VACCINE, V36, P2842, DOI 10.1016/j.vaccine.2018.03.075; Stanfield BA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109890; Streilein JW, 1997, IMMUNOL TODAY, V18, P443, DOI 10.1016/S0167-5699(97)01114-6; Sumaria N, 2011, J EXP MED, V208, P505, DOI 10.1084/jem.20101824; Suryawanshi A, 2011, J IMMUNOL, V186, P3653, DOI 10.4049/jimmunol.1003239; Sutton CE, 2009, IMMUNITY, V31, P331, DOI 10.1016/j.immuni.2009.08.001; Tagawa T, 2004, J IMMUNOL, V173, P5156, DOI 10.4049/jimmunol.173.8.5156; Thomas J, 1997, J IMMUNOL, V158, P1383; Toma Hassanain S, 2008, Semin Ophthalmol, V23, P249, DOI 10.1080/08820530802111085; Tumpey TM, 1996, J VIROL, V70, P898, DOI 10.1128/JVI.70.2.898-904.1996; Wuest TR, 2010, J EXP MED, V207, P101, DOI 10.1084/jem.20091385; Yun HM, 2014, J VIROL, V88, P7870, DOI 10.1128/JVI.01146-14; Zhao ZY, 2017, FASEB J, V31, P4903, DOI 10.1096/fj.201700533R	95	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 15	2021	12								789454	10.3389/fimmu.2021.789454	http://dx.doi.org/10.3389/fimmu.2021.789454			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XI4UL	34868077	Green Published, gold			2022-12-18	WOS:000726108500001
J	Pieper, AA; Zangl, LM; Speigelman, DV; Feils, AS; Hoefges, A; Jagodinsky, JC; Felder, MA; Tsarovsky, NW; Arthur, IS; Brown, RJ; Birstler, J; Le, T; Carlson, PM; Bates, AM; Hank, JA; Rakhmilevich, AL; Erbe, AK; Sondel, PM; Patel, RB; Morris, ZS				Pieper, Alexander A.; Zangl, Luke M.; Speigelman, Dan V.; Feils, Arika S.; Hoefges, Anna; Jagodinsky, Justin C.; Felder, Mildred A.; Tsarovsky, Noah W.; Arthur, Ian S.; Brown, Ryan J.; Birstler, Jen; Le, Trang; Carlson, Peter M.; Bates, Amber M.; Hank, Jacquelyn A.; Rakhmilevich, Alexander L.; Erbe, Amy K.; Sondel, Paul M.; Patel, Ravi B.; Morris, Zachary S.			Radiation Augments the Local Anti-Tumor Effect of In Situ Vaccine With CpG-Oligodeoxynucleotides and Anti-OX40 in Immunologically Cold Tumor Models	FRONTIERS IN IMMUNOLOGY			English	Article						In situ vaccine; cold tumor models; OX40 agonist; CpG; oligonucleotides; radiation therapy; radioimmunotherapy	ACTIVATED T-CELLS; ENDOTHELIAL-CELLS; OX40 LIGAND; NK CELLS; EXPRESSION; MURINE; COSTIMULATION; MACROPHAGES; COMBINATION; OX40/GP34	IntroductionCombining CpG oligodeoxynucleotides with anti-OX40 agonist antibody (CpG+OX40) is able to generate an effective in situ vaccine in some tumor models, including the A20 lymphoma model. Immunologically "cold" tumors, which are typically less responsive to immunotherapy, are characterized by few tumor infiltrating lymphocytes (TILs), low mutation burden, and limited neoantigen expression. Radiation therapy (RT) can change the tumor microenvironment (TME) of an immunologically "cold" tumor. This study investigated the effect of combining RT with the in situ vaccine CpG+OX40 in immunologically "cold" tumor models. MethodsMice bearing flank tumors (A20 lymphoma, B78 melanoma or 4T1 breast cancer) were treated with combinations of local RT, CpG, and/or OX40, and response to treatment was monitored. Flow cytometry and quantitative polymerase chain reaction (qPCR) experiments were conducted to study differences in the TME, secondary lymphoid organs, and immune activation after treatment. ResultsAn in situ vaccine regimen of CpG+OX40, which was effective in the A20 model, did not significantly improve tumor response or survival in the "cold" B78 and 4T1 models, as tested here. In both models, treatment with RT prior to CpG+OX40 enabled a local response to this in situ vaccine, significantly improving the anti-tumor response and survival compared to RT alone or CpG+OX40 alone. RT increased OX40 expression on tumor infiltrating CD4+ non-regulatory T cells. RT+CpG+OX40 increased the ratio of tumor-infiltrating effector T cells to T regulatory cells and significantly increased CD4+ and CD8+ T cell activation in the tumor draining lymph node (TDLN) and spleen. ConclusionRT significantly improves the local anti-tumor effect of the in situ vaccine CpG+OX40 in immunologically "cold", solid, murine tumor models where RT or CpG+OX40 alone fail to stimulate tumor regression.	[Pieper, Alexander A.; Zangl, Luke M.; Speigelman, Dan V.; Feils, Arika S.; Hoefges, Anna; Jagodinsky, Justin C.; Felder, Mildred A.; Tsarovsky, Noah W.; Arthur, Ian S.; Brown, Ryan J.; Carlson, Peter M.; Bates, Amber M.; Hank, Jacquelyn A.; Rakhmilevich, Alexander L.; Erbe, Amy K.; Sondel, Paul M.; Morris, Zachary S.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Human Oncol, Madison, WI 53705 USA; [Birstler, Jen; Le, Trang] Univ Wisconsin, Sch Med & Publ Hlth, Dept Biostatist & Med Informat, Madison, WI USA; [Sondel, Paul M.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Pediat, Madison, WI USA; [Patel, Ravi B.] Univ Pittsburgh, Hillman Canc Ctr, Dept Radiat Oncol & Bioengn, Pittsburgh, PA USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Morris, ZS (corresponding author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Human Oncol, Madison, WI 53705 USA.	zmorris@humonc.wisc.edu		Tsarovsky, Noah/0000-0001-9036-3515; Pieper, Alex/0000-0001-5288-8214	Midwest Athletes Against Childhood Cancer; Stand Up 2 Cancer; St. Baldrick's Foundation; Crawdaddy Foundation; University of Wisconsin Carbone Cancer Center; public health service grants from National Cancer Institute [TR002373, U54-CA232568, R35-CA197078, 5K08CA241319, 1DP5OD024576, U01-CA233102, P50 DE026787, P01 CA250972]; National Institutes of Health; Department of Health and Human Services; NIH award [TL1 TR002375]; NIH-NCI award [F30CA228315, F30CA250263];  [T32 GM140935]	Midwest Athletes Against Childhood Cancer; Stand Up 2 Cancer; St. Baldrick's Foundation; Crawdaddy Foundation; University of Wisconsin Carbone Cancer Center; public health service grants from National Cancer Institute; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Health and Human Services; NIH award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH-NCI award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); 	This work was supported by Midwest Athletes Against Childhood Cancer; Stand Up 2 Cancer; the St. Baldrick's Foundation; the Crawdaddy Foundation; and the University of Wisconsin Carbone Cancer Center. This research was also supported in part by public health service grants TR002373, U54-CA232568, R35-CA197078, 5K08CA241319, 1DP5OD024576, U01-CA233102, P50 DE026787, P01 CA250972 from the National Cancer Institute; the National Institutes of Health and the Department of Health and Human Services. AP was supported by NIH award TL1 TR002375; PC was supported by the NIH-NCI award F30CA228315 and NIH award TL1 TR002375. JJ was supported by the NIH-NCI award F30CA250263 and NIH award TL1 TR002375. AP, PC, and JJ were funded by T32 GM140935. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Alderson KL, 2013, CANCER IMMUNOL IMMUN, V62, P665, DOI 10.1007/s00262-012-1372-8; Aspeslagh S, 2016, EUR J CANCER, V52, P50, DOI 10.1016/j.ejca.2015.08.021; Baniel CC, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-001262; Bansal-Pakala P, 2004, J IMMUNOL, V172, P4821, DOI 10.4049/jimmunol.172.8.4821; BAUM PR, 1994, EMBO J, V13, P3992, DOI 10.1002/j.1460-2075.1994.tb06715.x; Buhtoiarov IN, 2007, IMMUNOLOGY, V120, P412, DOI 10.1111/j.1365-2567.2006.02517.x; Buhtoiarov IN, 2005, J IMMUNOL, V174, P6013, DOI 10.4049/jimmunol.174.10.6013; Carlson PM, 2021, J IMMUNOTHER CANCER, V9, DOI 10.1136/jitc-2020-002107; Chakraborty M, 2004, CANCER RES, V64, P4328, DOI 10.1158/0008-5472.CAN-04-0073; Couzin-Frankel J, 2013, SCIENCE, V342, P1432, DOI 10.1126/science.342.6165.1432; Demaria S, 2016, TRENDS CANCER, V2, P286, DOI 10.1016/j.trecan.2016.05.002; Deng LF, 2014, IMMUNITY, V41, P843, DOI 10.1016/j.immuni.2014.10.019; Desai P, 2018, J VIROL, V92, DOI 10.1128/JVI.00495-18; Diamond JM, 2018, CANCER IMMUNOL RES, V6, P910, DOI 10.1158/2326-6066.CIR-17-0581; Elpek KG, 2014, CANCER IMMUNOL RES, V2, P655, DOI 10.1158/2326-6066.CIR-13-0209; Gajewski TF, 2015, SEMIN ONCOL, V42, P663, DOI 10.1053/j.seminoncol.2015.05.011; Gentles AJ, 2015, NAT MED, V21, P938, DOI 10.1038/nm.3909; Gulley JL, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djw261; Houot R, 2009, BLOOD, V113, P3546, DOI 10.1182/blood-2008-07-170274; Imura A, 1996, J EXP MED, V183, P2185, DOI 10.1084/jem.183.5.2185; Jagodinsky JC, 2021, THERANOSTICS, V11, P6120, DOI 10.7150/thno.54881; Jagodinsky JC, 2020, SEMIN RADIAT ONCOL, V30, P181, DOI 10.1016/j.semradonc.2019.12.008; Jagodinsky JC, 2020, INT J RADIAT ONCOL, V108, P6, DOI 10.1016/j.ijrobp.2020.04.023; Johnson EE, 2008, CANCER IMMUNOL IMMUN, V57, P1891, DOI 10.1007/s00262-008-0519-0; Karapetyan L, 2020, ONCOTARGETS THER, V13, P10039, DOI 10.2147/OTT.S247050; Kotani A, 2002, IMMUNOL LETT, V84, P1, DOI 10.1016/S0165-2478(02)00082-2; Lane P, 2000, J EXP MED, V191, P201, DOI 10.1084/jem.191.2.201; Linch SN, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00034; Marabelle A, 2017, ANN ONCOL, V28, P33, DOI 10.1093/annonc/mdx683; Marabelle A, 2013, J CLIN INVEST, V123, P2447, DOI 10.1172/JCI64859; Matsumura Y, 1997, ARCH DERMATOL RES, V289, P653, DOI 10.1007/s004030050255; Morris ZS, 2018, CANCER IMMUNOL RES, V6, P825, DOI 10.1158/2326-6066.CIR-17-0353; Morris ZS, 2016, CANCER RES, V76, P3929, DOI 10.1158/0008-5472.CAN-15-2644; Niknam S, 2018, CLIN CANCER RES, V24, P5735, DOI 10.1158/1078-0432.CCR-17-3279; Noubade R, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01014; Patel RB, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abb3631; Patel RB, 2019, ADV MATER, V31, DOI 10.1002/adma.201902626; Patel SA, 2018, IMMUNITY, V48, P417, DOI 10.1016/j.immuni.2018.03.007; Pieper AA, 2021, J IMMUNOTHER CANCER, V9, DOI 10.1136/jitc-2021-002715; Pierce RH, 2015, HUM VACC IMMUNOTHER, V11, P1901, DOI 10.1080/21645515.2015.1049779; Rakhmilevich AL, 2017, J IMMUNOL, V198, P1575, DOI 10.4049/jimmunol.1601255; Reits EA, 2006, J EXP MED, V203, P1259, DOI 10.1084/jem.20052494; Rodriguez-Ruiz ME, 2017, INT J RADIAT ONCOL, V97, P389, DOI 10.1016/j.ijrobp.2016.10.043; Rogers PR, 2001, IMMUNITY, V15, P445, DOI 10.1016/S1074-7613(01)00191-1; Sagiv-Barfi I, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aan4488; Sharabi AB, 2015, CANCER IMMUNOL RES, V3, P345, DOI 10.1158/2326-6066.CIR-14-0196; Sharma P, 2015, SCIENCE, V348, P56, DOI 10.1126/science.aaa8172; Shi YY, 2015, MOL IMMUNOL, V66, P208, DOI 10.1016/j.molimm.2015.03.008; Song AH, 2005, J IMMUNOL, V175, P3534, DOI 10.4049/jimmunol.175.6.3534; Spranger S, 2017, CANCER CELL, V31, P711, DOI 10.1016/j.ccell.2017.04.003; Vanpouille-Box C, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15618; Vilgelm AE, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00333; Vu MD, 2007, BLOOD, V110, P2501, DOI 10.1182/blood-2007-01-070748; Werner LR, 2017, RADIOTHER ONCOL, V124, P418, DOI 10.1016/j.radonc.2017.08.016; Yang RK, 2013, CANCER IMMUNOL IMMUN, V62, P1303, DOI 10.1007/s00262-013-1430-x; Yang RK, 2012, J IMMUNOL, V189, P2656, DOI 10.4049/jimmunol.1200934	56	0	0	6	12	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 15	2021	12								763888	10.3389/fimmu.2021.763888	http://dx.doi.org/10.3389/fimmu.2021.763888			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XI4XW	34868010	gold, Green Published			2022-12-18	WOS:000726117400001
J	Chowdhury, D; Gardner, JC; Satpati, A; Nookala, S; Mukundan, S; Porollo, A; Figueroa, JLA; Vignesh, KS				Chowdhury, Debabrata; Gardner, Jason C.; Satpati, Abhijit; Nookala, Suba; Mukundan, Santhosh; Porollo, Aleksey; Landero Figueroa, Julio A.; Subramanian Vignesh, Kavitha			Metallothionein 3-Zinc Axis Suppresses Caspase-11 Inflammasome Activation and Impairs Antibacterial Immunity	FRONTIERS IN IMMUNOLOGY			English	Article						macrophage; non-canonical inflammasome; zinc; metallothionein; innate immunity; caspase-11 non-canonical inflammasome; MT3	KLEBSIELLA-PNEUMONIAE; ZINC-DEFICIENCY; EXPRESSION; GENE; IL-1-BETA; INDUCTION; INFECTION; PROMOTES; IDENTIFICATION; INTERLEUKIN-1	Non-canonical inflammasome activation by mouse caspase-11 (or human CASPASE-4/5) is crucial for the clearance of certain gram-negative bacterial infections, but can lead to severe inflammatory damage. Factors that promote non-canonical inflammasome activation are well recognized, but less is known about the mechanisms underlying its negative regulation. Herein, we identify that the caspase-11 inflammasome in mouse and human macrophages (M phi) is negatively controlled by the zinc (Zn2+) regulating protein, metallothionein 3 (MT3). Upon challenge with intracellular lipopolysaccharide (iLPS), M phi increased MT3 expression that curtailed the activation of caspase-11 and its downstream targets caspase-1 and interleukin (IL)-1 beta. Mechanistically, MT3 increased intramacrophage Zn2+ to downmodulate the TRIF-IRF3-STAT1 axis that is prerequisite for caspase-11 effector function. In vivo, MT3 suppressed activation of the caspase-11 inflammasome, while caspase-11 and MT3 synergized in impairing antibacterial immunity. The present study identifies an important yin-yang relationship between the non-canonical inflammasome and MT3 in controlling inflammation and immunity to gram-negative bacteria.	[Chowdhury, Debabrata; Subramanian Vignesh, Kavitha] Univ Cincinnati, Coll Med, Div Infect Dis, Cincinnati, OH 45267 USA; [Gardner, Jason C.] Univ Cincinnati, Coll Med, Dept Internal Med, Div Pulm Crit Care & Sleep Med, Cincinnati, OH USA; [Satpati, Abhijit; Nookala, Suba; Mukundan, Santhosh] Univ North Dakota, Sch Med & Hlth Sci, Dept Biomed Sci, Grand Forks, ND USA; [Porollo, Aleksey] Cincinnati Childrens Hosp Med Ctr, Ctr Autoimmune Genom & Etiol, Cincinnati, OH 45229 USA; [Porollo, Aleksey] Cincinnati Childrens Hosp Med Ctr, Div Biomed Informat, Cincinnati, OH 45229 USA; [Porollo, Aleksey] Univ Cincinnati, Dept Pediat, Cincinnati, OH USA; [Landero Figueroa, Julio A.] Univ Cincinnati, Dept Chem, Agilent Technol Metall Ctr Amer, Cincinnati, OH USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University of North Dakota Grand Forks; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Vignesh, KS (corresponding author), Univ Cincinnati, Coll Med, Div Infect Dis, Cincinnati, OH 45267 USA.	Kavitha.Subramanian@uc.edu		Satpati, Abhijit/0000-0003-2674-7973; Gardner, Jason/0000-0002-5924-9201; Landero, Julio/0000-0001-8641-0497; Porollo, Alexey/0000-0002-3202-5099				Aachoui Y, 2013, SCIENCE, V339, P975, DOI 10.1126/science.1230751; Akhter A, 2012, IMMUNITY, V37, P35, DOI 10.1016/j.immuni.2012.05.001; Antonopoulos C, 2015, J BIOL CHEM, V290, P20167, DOI 10.1074/jbc.M115.652321; ARIZONO K, 1995, RES COMMUN MOL PATH, V90, P49; Beck FWJ, 2006, NUTRITION, V22, P1045, DOI 10.1016/j.nut.2006.08.001; Botella H, 2011, CELL HOST MICROBE, V10, P248, DOI 10.1016/j.chom.2011.08.006; Brieger A, 2013, J IMMUNOL, V191, P1808, DOI 10.4049/jimmunol.1301261; Brough D, 2009, EUR J IMMUNOL, V39, P352, DOI 10.1002/eji.200838843; Broz P, 2012, NATURE, V490, P288, DOI 10.1038/nature11419; Case CL, 2013, P NATL ACAD SCI USA, V110, P1851, DOI 10.1073/pnas.1211521110; Casson CN, 2015, P NATL ACAD SCI USA, V112, P6688, DOI 10.1073/pnas.1421699112; Cerqueira DM, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007519; Chatellier S, 2000, INFECT IMMUN, V68, P3523, DOI 10.1128/IAI.68.6.3523-3534.2000; Chen BH, 2013, CELL, V155, P1479, DOI 10.1016/j.cell.2013.12.001; Chen RC, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aav5562; Chowdhury D, 2019, ZINC SIGNALING, 2ND EDITION, P57, DOI 10.1007/978-981-15-0557-7_4; Chowdhury D, 2019, CELL REP, V27, P3873, DOI 10.1016/j.celrep.2019.05.093; Chu LH, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03409-3; Codo AC, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1214-5; DALTON T, 1994, NUCLEIC ACIDS RES, V22, P5016, DOI 10.1093/nar/22.23.5016; Davis SR, 2000, J NUTR, V130, P1085; DOMENICO P, 1985, CAN J MICROBIOL, V31, P472, DOI 10.1139/m85-088; Durfee LA, 2010, SUBCELL BIOCHEM, V54, P228, DOI 10.1007/978-1-4419-6676-6_18; Fettelschoss A, 2011, P NATL ACAD SCI USA, V108, P18055, DOI 10.1073/pnas.1109176108; Finethy R, 2020, EMBO REP, V21, DOI 10.15252/embr.202050830; Foster M, 2012, NUTRIENTS, V4, P676, DOI 10.3390/nu4070676; Gong T, 2018, TRENDS IMMUNOL, V39, P393, DOI 10.1016/j.it.2018.01.009; Guarda G, 2011, IMMUNITY, V34, P213, DOI 10.1016/j.immuni.2011.02.006; Haase H, 2008, J IMMUNOL, V181, P6491, DOI 10.4049/jimmunol.181.9.6491; Haeussler M, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1012-2; Hancz D, 2017, MBIO, V8, DOI 10.1128/mBio.00756-17; Haque M, 2018, INFECT DRUG RESIST, V11, P2321, DOI 10.2147/IDR.S177247; Hara H, 2018, CELL, V175, P1651, DOI 10.1016/j.cell.2018.09.047; Hojyo S, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/6762343; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Kayagaki N, 2011, NATURE, V479, P117, DOI 10.1038/nature10558; Kim B, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00391; Kimura T, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17030336; Knodler LA, 2014, CELL HOST MICROBE, V16, P249, DOI 10.1016/j.chom.2014.07.002; Kobayashi T, 2013, CELL HOST MICROBE, V13, P570, DOI 10.1016/j.chom.2013.04.012; Kovacs SB, 2020, CELL REP, V32, DOI 10.1016/j.celrep.2020.107967; Krause K, 2019, EMBO REP, V20, DOI 10.15252/embr.201948109; Krause K, 2018, AUTOPHAGY, V14, P1928, DOI 10.1080/15548627.2018.1491494; Krezel A, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061237; Krishnan KC, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005732; KURTJONES EA, 1985, P NATL ACAD SCI USA, V82, P1204, DOI 10.1073/pnas.82.4.1204; Lagrange B, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02682-y; LaRock CN, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00518; Lee SJ, 2010, MOL BRAIN, V3, DOI 10.1186/1756-6606-3-30; LEIBBRANDT MEI, 1994, TOXICOL APPL PHARM, V124, P72, DOI 10.1006/taap.1994.1010; Liu X, 2016, NATURE, V535, P153, DOI 10.1038/nature18629; Manda P, 2018, IMMUNITY, V49, P42, DOI 10.1016/j.immuni.2018.06.011; Maret W, 2011, BIOMETALS, V24, P411, DOI 10.1007/s10534-010-9406-1; Maywald M, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18102222; Mueller NJ, 2002, INFECT IMMUN, V70, P2657, DOI 10.1128/IAI.70.5.2657-2664.2002; NCBI Resource Coordinators, 2018, NUCLEIC ACIDS RES, V46, pD8, DOI [10.1093/nar/gkx1095, DOI 10.1093/NAR/GKX1095]; Nookala S, 2018, INFECT IMMUN, V86, DOI 10.1128/IAI.00432-18; Palmiter RD, 1998, P NATL ACAD SCI USA, V95, P8428, DOI 10.1073/pnas.95.15.8428; PALMITER RD, 1992, P NATL ACAD SCI USA, V89, P6333, DOI 10.1073/pnas.89.14.6333; Pletneva LM, 2008, J GEN VIROL, V89, P261, DOI 10.1099/vir.0.83294-0; Prasad AS, 2007, J NUTR, V137, P1345, DOI 10.1093/jn/137.5.1345; Prasad AS, 1997, P ASSOC AM PHYSICIAN, V109, P68; Pyle CJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169531; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Rathinam VAK, 2012, CELL, V150, P606, DOI 10.1016/j.cell.2012.07.007; Reboldi A, 2014, SCIENCE, V345, P679, DOI 10.1126/science.1254790; Santos JC, 2018, EMBO J, V37, DOI 10.15252/embj.201798089; Sayadi A, 2013, INFLAMM RES, V62, P133, DOI 10.1007/s00011-012-0559-y; Shankar AH, 1998, AM J CLIN NUTR, V68, p447S, DOI 10.1093/ajcn/68.2.447S; Shrum Bradly, 2014, BMC Res Notes, V7, P233, DOI 10.1186/1756-0500-7-233; Stocks CJ, 2021, J LEUKOCYTE BIOL, V109, P287, DOI 10.1002/JLB.2HI0420-160R; Stocks CJ, 2019, P NATL ACAD SCI USA, V116, P6341, DOI 10.1073/pnas.1820870116; Summersgill H, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.547; Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI 10.1093/nar/gky1131; Tirumurugaan KG, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12040463; Valderrama JA, 2017, NAT MICROBIOL, V2, P1425, DOI 10.1038/s41564-017-0005-6; Valerius M. Todd, 2002, Mechanisms of Development, V112, P219, DOI 10.1016/S0925-4773(02)00008-4; Vanaja SK, 2016, CELL, V165, P1106, DOI 10.1016/j.cell.2016.04.015; Varela M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100015; Vignesh KS, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18102197; Vignesh KS, 2016, CELL REP, V16, P3232, DOI 10.1016/j.celrep.2016.08.057; Vignesh KS, 2013, IMMUNITY, V39, P697, DOI 10.1016/j.immuni.2013.09.006; von Bulow V, 2005, J IMMUNOL, V175, P4697, DOI 10.4049/jimmunol.175.7.4697; Wang HY, 2013, CELL, V153, P910, DOI 10.1016/j.cell.2013.04.025; Wang J, 2017, INT J MED MICROBIOL, V307, P490, DOI 10.1016/j.ijmm.2017.09.012; Wang K, 2020, CELL, V180, P941, DOI 10.1016/j.cell.2020.02.002; WEI RQ, 1988, BIOL REPROD, V38, P830, DOI 10.1095/biolreprod38.4.830; Wessels I, 2017, NUTRIENTS, V9, DOI 10.3390/nu9121286; Wu AM, 2017, INFECT IMMUN, V85, DOI [10.1128/IAI.00418-17, 10.1128/iai.00418-17]; Yang H, 2014, NAT PROTOC, V9, P1956, DOI 10.1038/nprot.2014.134; Yuan CL, 2017, ADV EXP MED BIOL, V1016, P75, DOI 10.1007/978-3-319-63904-8_4; Zaslona Z, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14945-2	92	0	0	1	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 12	2021	12								755961	10.3389/fimmu.2021.755961	http://dx.doi.org/10.3389/fimmu.2021.755961			24	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XH7IE	34867993	Green Published, gold, Green Submitted			2022-12-18	WOS:000725602900001
J	Garcia-Solis, B; van den Rym, A; Perez-Caraballo, JJ; Al-Ayoubi, A; Alazami, AM; Lorenzo, L; Cubillos-Zapata, C; Lopez-Collazo, E; Perez-Martinez, A; Allende, LM; Markle, J; Fernandez-Arquero, M; Sanchez-Ramon, S; Recio, MJ; Casanova, JL; Mohammed, R; Martinez-Barricarte, R; de Diego, RP				Garcia-Solis, Blanca; van den Rym, Ana; Perez-Caraballo, Jareb J.; Al-Ayoubi, Abdulwahab; Alazami, Anas M.; Lorenzo, Lazaro; Cubillos-Zapata, Carolina; Lopez-Collazo, Eduardo; Perez-Martinez, Antonio; Allende, Luis M.; Markle, Janet; Fernandez-Arquero, Miguel; Sanchez-Ramon, Silvia; Recio, Maria J.; Casanova, Jean-Laurent; Mohammed, Reem; Martinez-Barricarte, Ruben; Perez de Diego, Rebeca			Clinical and Immunological Features of Human BCL10 Deficiency	FRONTIERS IN IMMUNOLOGY			English	Article						primary immunodeficiency; combined immunodeficiency; BCL10; autosomal recessive; mass cytometry; computational immunology; CBM complex; next-generation sequencing	INHERITED CARD9 DEFICIENCY; FUNGAL-INFECTION; MENINGOENCEPHALITIS; MUTATIONS; FAMILY	The CARD-BCL10-MALT1 (CBM) complex is critical for the proper assembly of human immune responses. The clinical and immunological consequences of deficiencies in some of its components such as CARD9, CARD11, and MALT1 have been elucidated in detail. However, the scarcity of BCL10 deficient patients has prevented gaining detailed knowledge about this genetic disease. Only two patients with BCL10 deficiency have been reported to date. Here we provide an in-depth description of an additional patient with autosomal recessive complete BCL10 deficiency caused by a nonsense mutation that leads to a loss of expression (K63X). Using mass cytometry coupled with unsupervised clustering and machine learning computational methods, we obtained a thorough characterization of the consequences of BCL10 deficiency in different populations of leukocytes. We showed that in addition to the near absence of memory B and T cells previously reported, this patient displays a reduction in NK, gamma delta T, Tregs, and T-FH cells. The patient had recurrent respiratory infections since early childhood, and showed a family history of lethal severe infectious diseases. Fortunately, hematopoietic stem-cell transplantation (HSCT) cured her. Overall, this report highlights the importance of early genetic diagnosis for the management of BCL10 deficient patients and HSCT as the recommended treatment to cure this disease.	[Garcia-Solis, Blanca; van den Rym, Ana; Perez de Diego, Rebeca] La Paz Hosp, IdiPAZ Inst Hlth Res, Lab Immunogenet Human Dis, Madrid, Spain; [Garcia-Solis, Blanca; van den Rym, Ana; Cubillos-Zapata, Carolina; Lopez-Collazo, Eduardo; Perez de Diego, Rebeca] La Paz Hosp, IdiPAZ Inst Hlth Res, Innate Immun Grp, Madrid, Spain; [Garcia-Solis, Blanca; van den Rym, Ana; Fernandez-Arquero, Miguel; Sanchez-Ramon, Silvia; Recio, Maria J.; Perez de Diego, Rebeca] Interdept Grp Immunodeficiencies, Madrid, Spain; [Perez-Caraballo, Jareb J.; Markle, Janet; Martinez-Barricarte, Ruben] Vanderbilt Univ, Med Ctr, Div Med Genet, Dept Med,Vanderbilt Genet Inst, Nashville, TN USA; [Perez-Caraballo, Jareb J.; Markle, Janet; Martinez-Barricarte, Ruben] Vanderbilt Univ, Dept Pathol Microbiol & Immunol, Div Mol Pathogenesis,Med Ctr, Vanderbilt Ctr Immunobiol,Vanderbilt Inst Infect, Nashville, TN USA; [Al-Ayoubi, Abdulwahab] King Saud Med City Childrens Hosp, Dept Pediat, Riyadh, Saudi Arabia; [Alazami, Anas M.] King Faisal Specialist Hosp & Res Ctr, Ctr Genom Med, Translat Genom, Riyadh, Saudi Arabia; [Lorenzo, Lazaro] INSERM, Necker Branch, Lab Human Genet Infect Dis, Paris, France; [Cubillos-Zapata, Carolina] CIBEres, Ctr Biomed Res Network, Madrid, Spain; [Perez-Martinez, Antonio] La Paz Univ Hosp, Inst Genet Med & Mol INGEMM IdiPAZ, Translat Res Paediat Oncol, Haematopoiet Stem Cell Transplantat,Cell Therapy, Madrid, Spain; [Perez-Martinez, Antonio] La Paz Univ Hosp, Dept Paediat Haematooncol & Stem Cell Transplanta, Madrid, Spain; [Allende, Luis M.] Univ Complutense Madrid, Res Inst imas12, Hosp 12 Octubre, Dept Immunol, Madrid, Spain; [Fernandez-Arquero, Miguel; Sanchez-Ramon, Silvia] San Carlos Clin Hosp, Clin Immunol Dept, Madrid, Spain; [Recio, Maria J.] Univ Complutense Madrid, Sch Med, Dept Immunol Ophthalmol & ENT, Madrid, Spain; [Casanova, Jean-Laurent] Rockefeller Univ, Rockefeller Branch, St Giles Lab Human Genet Infect Dis, 1230 York Ave, New York, NY 10021 USA; [Casanova, Jean-Laurent] Univ Paris 05, Imagine Inst, Paris, France; [Casanova, Jean-Laurent] Howard Hughes Med Inst, New York, NY USA; [Mohammed, Reem] King Faisal Specialist Hosp & Res Ctr, Div Allergy & Immunol, Dept Pediat, Riyadh, Saudi Arabia; [Mohammed, Reem] Alfaisal Univ, Coll Med, Riyadh, Saudi Arabia	Hospital Universitario La Paz; Hospital Universitario La Paz; Vanderbilt University; Vanderbilt University; King Faisal Specialist Hospital & Research Center; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; CIBER - Centro de Investigacion Biomedica en Red; CIBERES; Hospital Universitario La Paz; Hospital Universitario La Paz; Complutense University of Madrid; Hospital Universitario 12 de Octubre; Complutense University of Madrid; Rockefeller University; UDICE-French Research Universities; Universite Paris Cite; Howard Hughes Medical Institute; King Faisal Specialist Hospital & Research Center; Alfaisal University	de Diego, RP (corresponding author), La Paz Hosp, IdiPAZ Inst Hlth Res, Lab Immunogenet Human Dis, Madrid, Spain.; de Diego, RP (corresponding author), La Paz Hosp, IdiPAZ Inst Hlth Res, Innate Immun Grp, Madrid, Spain.; de Diego, RP (corresponding author), Interdept Grp Immunodeficiencies, Madrid, Spain.	perezdediegor@gmail.com	Zapata, Carolina Cubillos/H-3058-2017; Sanchez-Ramon, Silvia/I-8242-2019; Lopez-Collazo, Eduardo/U-6634-2018	Zapata, Carolina Cubillos/0000-0002-1948-4514; Sanchez-Ramon, Silvia/0000-0001-9585-6167; Markle, Janet/0000-0003-2189-4368; Lopez-Collazo, Eduardo/0000-0003-1957-877X; Perez de Diego, Rebeca/0000-0001-8426-8765; Perez, Jareb/0000-0001-6937-2935				Amu S, 2007, SCAND J IMMUNOL, V66, P77, DOI 10.1111/j.1365-3083.2007.01946.x; Arango-Franco CA, 2018, J CLIN IMMUNOL, V38, P794, DOI 10.1007/s10875-018-0549-0; Cariou B, 2020, DIABETOLOGIA, V63, P1500, DOI 10.1007/s00125-020-05180-x; Celmeli F, 2016, PEDIATR INFECT DIS J, V35, P428, DOI 10.1097/INF.0000000000001028; Cetinkaya PG, 2018, CLIN IMMUNOL, V191, P21, DOI 10.1016/j.clim.2018.01.002; Chen PC, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00260; Corvilain E, 2018, J CLIN IMMUNOL, V38, P656, DOI 10.1007/s10875-018-0539-2; De Bruyne M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02366; de Medeiros AKA, 2016, J CLIN IMMUNOL, V36, P204, DOI 10.1007/s10875-016-0255-8; Diggins KE, 2017, NAT METHODS, V14, P275, DOI [10.1038/NMETH.4149, 10.1038/nmeth.4149]; Drewniak A, 2013, BLOOD, V121, P2385, DOI 10.1182/blood-2012-08-450551; Garcia-Gomez S, 2016, CLIN IMMUNOL, V163, P120, DOI 10.1016/j.clim.2016.01.003; Gavino C, 2018, MYCOSES, V61, P61, DOI 10.1111/myc.12701; Gavino C, 2016, J ALLERGY CLIN IMMUN, V137, P1178, DOI 10.1016/j.jaci.2015.09.016; Gavino C, 2014, CLIN INFECT DIS, V59, P81, DOI 10.1093/cid/ciu215; Glocker EO, 2009, NEW ENGL J MED, V361, P1727, DOI 10.1056/NEJMoa0810719; Gringhuis SI, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001259; Gross O, 2006, NATURE, V442, P651, DOI 10.1038/nature04926; Grumach AS, 2015, J CLIN IMMUNOL, V35, P486, DOI 10.1007/s10875-015-0170-4; Herbst M, 2015, PEDIATR INFECT DIS J, V34, P999, DOI 10.1097/INF.0000000000000736; Jones Nicholas, 2016, BMJ Case Rep, V2016, DOI 10.1136/bcr-2015-214117; Lanternier F, 2015, J ALLERGY CLIN IMMUN, V135, P1558, DOI 10.1016/j.jaci.2014.12.1930; Lanternier F, 2015, J INFECT DIS, V211, P1241, DOI 10.1093/infdis/jiu412; Lanternier F, 2013, CURR OPIN PEDIATR, V25, P736, DOI 10.1097/MOP.0000000000000031; Lanternier F, 2013, NEW ENGL J MED, V369, P1704, DOI 10.1056/NEJMoa1208487; Liu YL, 2004, J BIOL CHEM, V279, P37436, DOI 10.1074/jbc.M400241200; Lu HY, 2019, J ALLERGY CLIN IMMUN, V143, P1661, DOI 10.1016/j.jaci.2019.03.009; Lu HY, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02078; Torres JM, 2014, J CLIN INVEST, V124, P5239, DOI 10.1172/JCI77493; Martin MD, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02692; Notarangelo LD, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abb1662; de Diego RP, 2015, J ALLERGY CLIN IMMUN, V136, P1139, DOI 10.1016/j.jaci.2015.06.031; Quan C, 2019, BRIT J DERMATOL, V180, P1221, DOI 10.1111/bjd.17092; Rieber N, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.89890; Sari S, 2018, J INFECT DIS, V218, P485, DOI 10.1093/infdis/jiy198; Tada R, 2009, IMMUNOL LETT, V123, P144, DOI 10.1016/j.imlet.2009.03.005; Vaezi A, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.02434; Van Den Rym A, 2020, J CLIN IMMUNOL, V40, P388, DOI 10.1007/s10875-020-00760-3; Van Gassen S, 2015, CYTOM PART A, V87A, P636, DOI 10.1002/cyto.a.22625; Wang X, 2019, BRIT J DERMATOL, V180, P213, DOI 10.1111/bjd.17144; Wang XW, 2018, J INVEST DERMATOL, V138, P607, DOI 10.1016/j.jid.2017.10.009; Wang XW, 2014, J ALLERGY CLIN IMMUN, V133, P905, DOI 10.1016/j.jaci.2013.09.033; Wu YCB, 2011, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00081	43	0	1	2	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 12	2021	12								786572	10.3389/fimmu.2021.786572	http://dx.doi.org/10.3389/fimmu.2021.786572			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XL8MM	34868072	gold, Green Published			2022-12-18	WOS:000728395600001
J	Zavala, F; Nombela-Arrieta, C; Ben Nasr, M; Fiorina, P				Zavala, Flora; Nombela-Arrieta, Cesar; Ben Nasr, Moufida; Fiorina, Paolo			Editorial: The Role of Hematopoietic Progenitors in Immune Regulation and Memory	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						hematopoietic progenitors; transplantation; immune memory; hematopoietic niche; stromal cells; trained immunity; autoimmunity; graft versus host disease (GVHD)	STEM-CELL		[Zavala, Flora] Univ Paris, CNRS, UMR8253, INSERM,U1151,Inst Necker Enfants Malades, Paris, France; [Nombela-Arrieta, Cesar] Univ Zurich, Dept Med Oncol & Hematol, Zurich, Switzerland; [Nombela-Arrieta, Cesar] Univ Hosp Zurich, Zurich, Switzerland; [Ben Nasr, Moufida; Fiorina, Paolo] Univ Milan, Int Ctr Type Diabet 1, Pediat Clin Res Ctr Romeo & Enrica Invernizzi, Dept Biomed & Clin Sci, Milan, Italy; [Ben Nasr, Moufida; Fiorina, Paolo] Harvard Med Sch, Boston Childrens Hosp, Nephrol Div, Boston, MA 02115 USA; [Fiorina, Paolo] Terr Healthcare Co Fatebenefratelli Sacco, Div Endocrinol, Milan, Italy	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Zurich; University of Zurich; University Zurich Hospital; University of Milan; Harvard University; Boston Children's Hospital; Harvard Medical School	Zavala, F (corresponding author), Univ Paris, CNRS, UMR8253, INSERM,U1151,Inst Necker Enfants Malades, Paris, France.	flora.zavala@inserm.fr		Zavala, Flora/0000-0002-2338-6802	CNRS; INSERM; Fondation pour la Recherche sur la Sclerose en Plaques (ARSEP); Secular Society (TSS); Swiss National Science Foundation [310030_185171]; Italian Ministry of Health [RF-2016-02362512]	CNRS(Centre National de la Recherche Scientifique (CNRS)); INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Fondation pour la Recherche sur la Sclerose en Plaques (ARSEP); Secular Society (TSS); Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Italian Ministry of Health(Ministry of Health, Italy)	& nbsp;FZ was supported by core funding from CNRS and INSERM and by grants received from Fondation pour la Recherche sur la Sclerose en Plaques (ARSEP) and from The Secular Society (TSS). CN-A is supported by Swiss National Science Foundation (310030_185171). PF was supported by the Italian Ministry of Health grant RF-2016-02362512.	Ben Nasr M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01387; Ben Nasr M, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aam7543; Ben Nasr M, 2016, REGEN MED, V11, P395, DOI 10.2217/rme-2015-0057; Cirovic B, 2020, CELL HOST MICROBE, V28, P322, DOI 10.1016/j.chom.2020.05.014; Cunningham KT, 2021, TRANSPLANTATION, V105, P1666, DOI 10.1097/TP.0000000000003673; D'Addio F, 2014, DIABETES, V63, P3041, DOI 10.2337/db14-0295; Gomariz A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04770-z; Kalafati L, 2020, CELL, V183, P771, DOI 10.1016/j.cell.2020.09.058; Kared H, 2006, IMMUNITY, V25, P823, DOI 10.1016/j.immuni.2006.09.008; Korniotis S, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12134; Massberg S, 2007, CELL, V131, P994, DOI 10.1016/j.cell.2007.09.047; Mitroulis I, 2018, CELL, V172, P147, DOI 10.1016/j.cell.2017.11.034; Montandon R, 2013, P NATL ACAD SCI USA, V110, pE2199, DOI 10.1073/pnas.1222446110; Murphy DM, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.706583; Netea MG, 2020, NAT REV IMMUNOL, V20, P375, DOI 10.1038/s41577-020-0285-6	15	0	0	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 12	2021	12								789139	10.3389/fimmu.2021.789139	http://dx.doi.org/10.3389/fimmu.2021.789139			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XI3WA	34868075	Green Accepted, gold, Green Published			2022-12-18	WOS:000726045000001
J	Calzas, C; Mao, M; Turpaud, M; Viboud, Q; Mettier, J; Figueroa, T; Bessiere, P; Mangin, A; Sedano, L; Herve, PL; Volmer, R; Ducatez, MF; Bourgault, S; Archambault, D; Le Goffic, R; Chevalier, C				Calzas, Cynthia; Mao, Molida; Turpaud, Mathilde; Viboud, Quentin; Mettier, Joelle; Figueroa, Thomas; Bessiere, Pierre; Mangin, Antoine; Sedano, Laura; Herve, Pierre-Louis; Volmer, Romain; Ducatez, Mariette F.; Bourgault, Steve; Archambault, Denis; Le Goffic, Ronan; Chevalier, Christophe			Immunogenicity and Protective Potential of Mucosal Vaccine Formulations Based on Conserved Epitopes of Influenza A Viruses Fused to an Innovative Ring Nanoplatform in Mice and Chickens	FRONTIERS IN IMMUNOLOGY			English	Article						influenza A viruses; highly pathogenic avian influenza virus; mucosal vaccines; adjuvants; nanoparticles; M2e; HA2 subunit vaccines	HETEROSUBTYPIC PROTECTION; T-CELLS; PROTEIN; INFECTION; M2E; ECTODOMAIN; ANTIBODIES; CHALLENGE; COMPLEXES; PARTICLES	Current inactivated vaccines against influenza A viruses (IAV) mainly induce immune responses against highly variable epitopes across strains and are mostly delivered parenterally, limiting the development of an effective mucosal immunity. In this study, we evaluated the potential of intranasal formulations incorporating conserved IAV epitopes, namely the long alpha helix (LAH) of the stalk domain of hemagglutinin and three tandem repeats of the ectodomain of the matrix protein 2 (3M2e), as universal mucosal anti-IAV vaccines in mice and chickens. The IAV epitopes were grafted to nanorings, a novel platform technology for mucosal vaccination formed by the nucleoprotein (N) of the respiratory syncytial virus, in fusion or not with the C-terminal end of the P97 protein (P97c), a recently identified Toll-like receptor 5 agonist. Fusion of LAH to nanorings boosted the generation of LAH-specific systemic and local antibody responses as well as cellular immunity in mice, whereas the carrier effect of nanorings was less pronounced towards 3M2e. Mice vaccinated with chimeric nanorings bearing IAV epitopes in fusion with P97c presented modest LAH- or M2e-specific IgG titers in serum and were unable to generate a mucosal humoral response. In contrast, N-3M2e or N-LAH nanorings admixed with Montanide (TM) gel (MG) triggered strong specific humoral responses, composed of serum type 1/type 2 IgG and mucosal IgG and IgA, as well as cellular responses dominated by type 1/type 17 cytokine profiles. All mice vaccinated with the [N-3M2e + N-LAH + MG] formulation survived an H1N1 challenge and the combination of both N-3M2e and N-LAH nanorings with MG enhanced the clinical and/or virological protective potential of the preparation in comparison to individual nanorings. Chickens vaccinated parenterally or mucosally with N-LAH and N-3M2e nanorings admixed with Montanide (TM) adjuvants developed a specific systemic humoral response, which nonetheless failed to confer protection against heterosubtypic challenge with a highly pathogenic H5N8 strain. Thus, while the combination of N-LAH and N-3M2e nanorings with Montanide (TM) adjuvants shows promise as a universal mucosal anti-IAV vaccine in the mouse model, further experiments have to be conducted to extend its efficacy to poultry.	[Calzas, Cynthia; Mao, Molida; Turpaud, Mathilde; Viboud, Quentin; Mettier, Joelle; Mangin, Antoine; Sedano, Laura; Herve, Pierre-Louis; Le Goffic, Ronan; Chevalier, Christophe] Univ Paris Saclay, Inst Natl Rech Agr Alimentat & Environnement INRA, Mol & Virol Unit VIM, UMR 892, Jouy En Josas, France; [Figueroa, Thomas; Bessiere, Pierre; Volmer, Romain; Ducatez, Mariette F.] Univ Toulouse, Inst Natl Rech Agr Alimentat & Environnement INRA, UMR 1225, Interact Hotes Agents Pathogenes Ecole Natl Vet T, Toulouse, France; [Mangin, Antoine] Cardiff Univ, Dementia Res Inst, Cardiff, Wales; [Herve, Pierre-Louis; Bourgault, Steve] Univ Quebec Montreal, Chem Dept, Montreal, PQ, Canada; [Archambault, Denis] Univ Quebec Montreal, Dept Biol Sci, Montreal, PQ, Canada; [Herve, Pierre-Louis] DBV Technol, Montrouge, France	INRAE; UDICE-French Research Universities; Universite Paris Saclay; INRAE; Universite de Toulouse; Cardiff University; University of Quebec; University of Quebec Montreal; University of Quebec; University of Quebec Montreal	Calzas, C; Chevalier, C (corresponding author), Univ Paris Saclay, Inst Natl Rech Agr Alimentat & Environnement INRA, Mol & Virol Unit VIM, UMR 892, Jouy En Josas, France.	cynthia.calzas@inrae.fr; christophe.chevalier@inrae.fr	Figueroa, Thomas/V-6772-2018; Chevalier, Christophe/C-2575-2009	Figueroa, Thomas/0000-0002-4141-271X; Chevalier, Christophe/0000-0003-3231-9027	Livestock Vaccine Innovation Fund (International Development Research Centre) [108517]; Livestock Vaccine Innovation Fund (Bill & Melinda Gates Foundation) [108517]; Livestock Vaccine Innovation Fund (Global Affairs Canada) [108517]	Livestock Vaccine Innovation Fund (International Development Research Centre); Livestock Vaccine Innovation Fund (Bill & Melinda Gates Foundation); Livestock Vaccine Innovation Fund (Global Affairs Canada)	This work was supported by a grant from the Livestock Vaccine Innovation Fund (International Development Research Centre, Bill & Melinda Gates Foundation, Global Affairs Canada) to ChC and DA (Project ID 108517).	Babapoor Sankhiros, 2011, Influenza Res Treat, V2011, P126794, DOI 10.1155/2011/126794; Blanco-Lobo P, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11020190; Brown DM, 2012, J VIROL, V86, P6792, DOI 10.1128/JVI.07172-11; Calzas C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01605; Calzas C, 2013, INFECT IMMUN, V81, P3106, DOI 10.1128/IAI.00113-13; Castagne N, 2004, J GEN VIROL, V85, P1643, DOI 10.1099/vir.0.79830-0; Cerwenka A, 1999, J EXP MED, V189, P423, DOI 10.1084/jem.189.2.423; Chen SH, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/901817; Dabaghian M, 2014, VET MICROBIOL, V174, P116, DOI 10.1016/j.vetmic.2014.09.009; De Filette M, 2006, VACCINE, V24, P544, DOI 10.1016/j.vaccine.2005.08.061; Deng L, 2017, VIROLOGY, V509, P82, DOI 10.1016/j.virol.2017.06.001; El Bakkouri K, 2011, J IMMUNOL, V186, P1022, DOI 10.4049/jimmunol.0902147; Elaish M, 2015, VACCINE, V33, P4901, DOI 10.1016/j.vaccine.2015.07.049; Elaish M, 2019, VACCINE, V37, P6454, DOI 10.1016/j.vaccine.2019.08.082; Elaish M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171174; Eliasson DG, 2018, MUCOSAL IMMUNOL, V11, P273, DOI 10.1038/mi.2017.14; Ganapathy K, 2005, AVIAN PATHOL, V34, P248, DOI 10.1080/03079450500112344; Gauthier Laurie, 2020, Immunobiology, V225, P151962, DOI 10.1016/j.imbio.2020.151962; Gianfrani C, 2000, HUM IMMUNOL, V61, P438, DOI 10.1016/S0198-8859(00)00105-1; Gong X, 2016, EMERG MICROBES INFEC, V5, DOI 10.1038/emi.2016.51; Gong X, 2016, IMMUNOL LETT, V172, P11, DOI 10.1016/j.imlet.2016.02.006; Hajam IA, 2020, VET RES, V51, DOI 10.1186/s13567-020-00762-4; Hajam IA, 2018, VET RES, V49, DOI 10.1186/s13567-018-0593-z; Hamada H, 2009, J IMMUNOL, V182, P3469, DOI 10.4049/jimmunol.0801814; Herve PL, 2014, J VIROL, V88, P325, DOI 10.1128/JVI.01141-13; Hoft DF, 2017, CLIN VACCINE IMMUNOL, V24, DOI [10.1128/CVI.00414-16, 10.1128/cvi.00414-16]; Jameson J, 1998, J VIROL, V72, P8682, DOI 10.1128/JVI.72.11.8682-8689.1998; Jang YH, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040353; Jansen JM, 2019, J CLIN VIROL, V119, P44, DOI 10.1016/j.jcv.2019.08.009; Kim JH, 2018, VET RES, V49, DOI 10.1186/s13567-018-0509-y; Kolpe A, 2017, EXPERT REV VACCINES, V16, P123, DOI 10.1080/14760584.2017.1240041; Kostolansky F, 2020, ACTA VIROL, V64, P417, DOI 10.4149/av_2020_408; Krammer F, 2019, NAT REV IMMUNOL, V19, P383, DOI 10.1038/s41577-019-0143-6; Krammer F, 2015, NAT REV DRUG DISCOV, V14, P167, DOI 10.1038/nrd4529; Layton SL, 2009, POULTRY SCI, V88, P2244, DOI 10.3382/ps.2009-00251; Le Goffic R, 2010, J IMMUNOL, V185, P4812, DOI 10.4049/jimmunol.0903952; Lee YN, 2014, IMMUNOLOGY, V143, P300, DOI 10.1111/imm.12310; Lee YN, 2014, VACCINE, V32, P4578, DOI 10.1016/j.vaccine.2014.06.040; Li J., 2018, J VIROLOGY ANTIVIRAL, V7, P1, DOI [DOI 10.4172/2324-8955.1000179, 10.4172/2324-8955.1000179]; Mallajosyula VVA, 2013, PROTEINS, V81, P1759, DOI 10.1002/prot.24317; McKinstry KK, 2009, J IMMUNOL, V182, P7353, DOI 10.4049/jimmunol.0900657; Mozdzanowska K, 2007, VIROL J, V4, DOI 10.1186/1743-422X-4-118; Mullarkey CE, 2016, MBIO, V7, DOI 10.1128/mBio.01624-16; Murakami M, 2019, IMMUNITY, V50, P812, DOI 10.1016/j.immuni.2019.03.027; Neirynck S, 1999, NAT MED, V5, P1157, DOI 10.1038/13484; Ni YW, 2017, VACCINE, V35, P7026, DOI 10.1016/j.vaccine.2017.10.051; Pantin-Jackwood MJ, 2009, REV SCI TECH OIE, V28, P113, DOI 10.20506/rst.28.1.1869; Qi M, 2018, SMALL, V14, DOI 10.1002/smll.201703207; Rajao DS, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.00123; Reese Kaleb A, 2013, Vet Med Int, V2013, P316926, DOI 10.1155/2013/316926; Riffault S, 2010, VACCINE, V28, P3722, DOI 10.1016/j.vaccine.2010.03.008; Rogues E, 2013, VACCINE, V31, P2698, DOI 10.1016/j.vaccine.2013.03.068; Roux X, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001766; Sarawar S, 2016, VACCINE, V34, P5090, DOI 10.1016/j.vaccine.2016.08.061; Song BM, 2016, VACCINE, V34, P678, DOI 10.1016/j.vaccine.2015.11.074; Stanekova Z, 2013, ANTIVIR RES, V97, P24, DOI 10.1016/j.antiviral.2012.09.008; Stepanova LA, 2018, J BIOMED SCI, V25, DOI 10.1186/s12929-018-0433-5; Stepanova LA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119520; Swayne D. E., 2016, Animal influenza, P378; Tawar RG, 2009, SCIENCE, V326, P1279, DOI 10.1126/science.1177634; Tomcikova K, 2019, ACTA VIROL, V63, P347, DOI 10.4149/av_2019_408; Tran TL, 2007, J GEN VIROL, V88, P196, DOI 10.1099/vir.0.82282-0; Tsybalova LM, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201429; Wang TT, 2010, P NATL ACAD SCI USA, V107, P18979, DOI 10.1073/pnas.1013387107; Wang T, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12080862; Watkins HC, 2017, VACCINE, V35, P5373, DOI 10.1016/j.vaccine.2017.08.013; WHO, 2018, INFL AV OTH ZOON; Yang WT, 2018, APPL MICROBIOL BIOT, V102, P5077, DOI 10.1007/s00253-018-8924-6; Zens KD, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.85832; Zhang XT, 2011, INTERVIROLOGY, V54, P290, DOI 10.1159/000319440; Zhang Z, 2017, VET MICROBIOL, V203, P143, DOI 10.1016/j.vetmic.2017.03.004; Zheng D, 2016, VACCINE, V34, P6464, DOI 10.1016/j.vaccine.2016.11.026	72	0	0	3	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 11	2021	12								772550	10.3389/fimmu.2021.772550	http://dx.doi.org/10.3389/fimmu.2021.772550			22	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XI3TF	34868036	Green Published, gold, Green Accepted			2022-12-18	WOS:000726037700001
J	Chang, ML; Yeh, CT; Chien, RN; Liaw, YF				Chang, Ming-Ling; Yeh, Chau-Ting; Chien, Rong-Nan; Liaw, Yun-Fan			Overt Acute Hepatitis B Deteriorates in Females: Destructive Immunity With an Exaggerated Interleukin-17 Pathway	FRONTIERS IN IMMUNOLOGY			English	Article						female; AHB; IFN-gamma; IL-4; IL-17	VIRUS INFECTION; ACUTE EXACERBATION; LAMIVUDINE; FULMINANT; THERAPY; AUTOIMMUNITY; REPLICATION; GENOTYPES; FLARES; WOMEN	Background and AimsWe previously showed that overt acute hepatitis B (AHB) was more severe in female patients. Using the same cohort and AHB mouse model, we examined the underlying mechanism. MethodsBaseline biochemistry, virological and cytokine assays, and T helper (Th)1 and Th2 immune markers of 118 consecutive patients were analyzed. The decompensated livers of AHB and chronic hepatitis B (CHB) patients who underwent liver transplantation were analyzed immunohistochemically. B6 mice were hydrodynamically injected with pHBV1.3 plasmids. ResultsDecompensated AHB patients (n=41) were older, more often female, and had higher alanine aminotransferase (ALT), soluble programmed cell death protein 1 (sPD-1) levels, and neutrophil-lymphocyte ratios but lower rates of HBeAg positivity and quantitative HBsAg, interferon (IFN)-gamma-inducible protein 10 (IP-10), IFN-gamma, and interleukin-4 (IL-4) levels than the compensated patients. Female sex (95% CI OR=1.07~54.9), age (1.06~1.40), and ALT levels (1.001~1.004) were associated with hepatic decompensation. Higher sPD-1 but lower IFN-gamma and IL-4 levels were observed in female patients. Compared to CHB, decompensated AHB livers had more IL-17-positive cells but fewer HBsAg-positive cells and lower CD4/CD8 ratios. Higher serum IL-17 levels were noted in the female AHB mice than those in the males. ConclusionsFemales predominated in decompensated AHB, in which downregulated IFN-gamma and IL-4 with augmented hepatic IL-17-positive cell development indicated accelerating destructive immunity to enhance viral clearance. The early surge of serum IL-17 was confirmed in the female AHB mice. Targeting the pathway involving IFN-gamma, IL-4, and IL-17 might prevent liver transplantation or fatality in decompensated AHB.	[Chang, Ming-Ling; Yeh, Chau-Ting; Chien, Rong-Nan; Liaw, Yun-Fan] Chang Gung Mem Hosp, Dept Gastroenterol & Hepatol, Div Hepatol, Liver Res Ctr, Taoyuan, Taiwan; [Chang, Ming-Ling; Yeh, Chau-Ting; Chien, Rong-Nan; Liaw, Yun-Fan] Chang Gung Univ, Coll Med, Dept Med, Taoyuan, Taiwan	Chang Gung Memorial Hospital; Chang Gung University	Chang, ML (corresponding author), Chang Gung Mem Hosp, Dept Gastroenterol & Hepatol, Div Hepatol, Liver Res Ctr, Taoyuan, Taiwan.; Chang, ML (corresponding author), Chang Gung Univ, Coll Med, Dept Med, Taoyuan, Taiwan.	mlchang8210@gmail.com			Chang Gung Medical Research Program [CMRPG3I0412, CMRPG3K0721, CMRPG1K0111, CMRPG1K0112]; National Science Council, Taiwan [MOST 109-2314-B-182-024-, 109-2629-B-182-002-, 110-2629-B-182-001-, 110-2314-B-182-044-]; Prosperous Foundation, Taipei, Taiwan	Chang Gung Medical Research Program; National Science Council, Taiwan(Ministry of Science and Technology, Taiwan); Prosperous Foundation, Taipei, Taiwan	This study was supported by grants from the Chang Gung Medical Research Program (CMRPG3I0412, CMRPG3K0721, CMRPG1K0111, and CMRPG1K0112), the National Science Council, Taiwan (MOST 109-2314-B-182-024-, 109-2629-B-182-002-, 110-2629-B-182-001-, and 110-2314-B-182-044-), and the Prosperous Foundation, Taipei, Taiwan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abe M, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/607073; Antonelli A, 2014, AUTOIMMUN REV, V13, P272, DOI 10.1016/j.autrev.2013.10.010; Baclig MO, 2020, INT J MOL EPIDEMIOL, V11, P26; Bettelli E, 2008, NATURE, V453, P1051, DOI 10.1038/nature07036; Chan HLY, 2011, J HEPATOL, V55, P1121, DOI 10.1016/j.jhep.2011.06.006; Chang ML, 2020, CLIN GASTROENTEROL H, V18, P2064, DOI 10.1016/j.cgh.2020.01.018; Chang ML, 2017, HEPATOLOGY, V66, P995, DOI 10.1002/hep.29196; Chang ML, 2015, CLIN GASTROENTEROL H, V13, P979, DOI 10.1016/j.cgh.2014.10.023; Chang ML, 2014, J HEPATOL, V61, P1407, DOI 10.1016/j.jhep.2014.08.033; Chow SN, 1997, J FORMOS MED ASSOC, V96, P806; Dinesh RK, 2010, AUTOIMMUN REV, V9, P583, DOI 10.1016/j.autrev.2010.04.003; Fabiani S, 2015, CLIN TER, V166, pE188, DOI [10.7417/T.2015.1853, 10.7417/CT.2015.1853]; Fish EN, 2008, NAT REV IMMUNOL, V8, P737, DOI 10.1038/nri2394; Gao YJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137881; Glebe D, 2013, SEMIN LIVER DIS, V33, P103, DOI 10.1055/s-0033-1345717; Ho CF, 2004, J GASTROEN HEPATOL, V19, P602, DOI 10.1111/j.1440-1746.2004.03395.x; Jeng WJ, 2010, CLIN GASTROENTEROL H, V8, P541, DOI 10.1016/j.cgh.2010.02.023; Korn T, 2009, ANNU REV IMMUNOL, V27, P485, DOI 10.1146/annurev.immunol.021908.132710; Kumar M, 2007, HEPATOLOGY, V45, P97, DOI 10.1002/hep.21486; Kwak-Kim J, 2016, AUTOIMMUN REV, V15, P943, DOI 10.1016/j.autrev.2016.07.015; Lafdil F, 2010, CELL MOL IMMUNOL, V7, P250, DOI 10.1038/cmi.2010.5; Lee WC, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003609; Liu CP, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075-015-0859-z; Liu Y, 2010, J CLIN VIROL, V47, P243, DOI 10.1016/j.jcv.2009.12.013; Mangan PR, 2006, NATURE, V441, P231, DOI 10.1038/nature04754; Ozasa A, 2006, HEPATOLOGY, V44, P326, DOI 10.1002/hep.21249; Park JW, 2015, WORLD J GASTROENTERO, V21, P3953, DOI 10.3748/wjg.v21.i13.3953; PHAM BN, 1994, CLIN EXP IMMUNOL, V97, P403; Ponde RAA, 2016, EUR J CLIN MICROBIOL, V35, P29, DOI 10.1007/s10096-015-2522-7; Ratnam D, 2008, HEPATOL INT, V2, pS12, DOI 10.1007/s12072-008-9067-0; Sonneveld MJ, 2013, J HEPATOL, V58, P898, DOI 10.1016/j.jhep.2013.01.029; Stout-Delgado HW, 2009, CELL HOST MICROBE, V6, P446, DOI 10.1016/j.chom.2009.09.011; Su WJ, 2012, J INFECT DIS, V205, P757, DOI 10.1093/infdis/jir852; Tamada Y, 2012, GUT, V61, P765, DOI 10.1136/gutjnl-2011-300832; Tang HW, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159447; Tillmann HL, 2014, INTERVIROLOGY, V57, P181, DOI 10.1159/000360939; Tillmann HL, 2006, J VIRAL HEPATITIS, V13, P256, DOI 10.1111/j.1365-2893.2005.00695.x; Trivedi PJ, 2013, J AUTOIMMUN, V46, P97, DOI 10.1016/j.jaut.2013.06.013; Wang B, 2013, ANTIVIR RES, V97, P285, DOI 10.1016/j.antiviral.2012.12.018; WRIGHT TL, 1993, LANCET, V342, P1340, DOI 10.1016/0140-6736(93)92250-W; Yang PL, 2002, P NATL ACAD SCI USA, V99, P13825, DOI 10.1073/pnas.202398599; Yuen MF, 2005, GUT, V54, P1610, DOI 10.1136/gut.2005.065136; ZAULI D, 1985, J GERONTOL, V40, P415, DOI 10.1093/geronj/40.4.415; Zhang HW, 2008, GUT, V57, P1713, DOI 10.1136/gut.2008.157149; Zhang Y, 2011, GASTROENTEROLOGY, V141, P1897, DOI 10.1053/j.gastro.2011.06.051	45	0	0	2	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 11	2021	12								631976	10.3389/fimmu.2021.631976	http://dx.doi.org/10.3389/fimmu.2021.631976			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XT9OZ	34858385				2022-12-18	WOS:000733909400001
J	Li, PL; Wang, N; Zhang, Y; Wang, CX; Du, LT				Li, Peilong; Wang, Nan; Zhang, Yi; Wang, Chuanxin; Du, Lutao			HLA-G/sHLA-G and HLA-G-Bearing Extracellular Vesicles in Cancers: Potential Role as Biomarkers	FRONTIERS IN IMMUNOLOGY			English	Review						HLA-G; tumor; immune escape; extracellular vesicles; biomarker	LEUKOCYTE-ANTIGEN-G; SQUAMOUS-CELL CARCINOMA; NATURAL-KILLER-CELLS; G GENE POLYMORPHISM; T REGULATORY CELLS; CLASS-I MOLECULES; G EXPRESSION; COLORECTAL-CANCER; POOR-PROGNOSIS; TUMOR-CELLS	As a non-classic major histocompatibility complex (MHC) class I molecule, human leukocyte antigen G (HLA-G) is expressed in fetal-maternal interface and immunoprivileged site only in healthy condition, and in pathological conditions such as cancer, it can be de novo expressed. It is now widely accepted that HLA-G is a key molecule in the process of immune escape of cancer cells, which is ubiquitously expressed in the tumor environment. This raises the possibility that it may play an adverse role in tumor immunity. The expression level of HLA-G has been demonstrated to be highly correlated with clinical parameters in many tumors, and its potential significance in the diagnosis and prognosis of cancer has been postulated. However, because HLA-G itself has up to seven different subtypes, and for some subtypes, detected antibodies are few or absent, it is hard to evaluate the actual expression of HLA-G in tumors. In the present work, we described (a) the structure and three main forms of HLA-G, (b) summarized the mechanism of HLA-G in the immune escape of tumor cells, (c) discussed the potential role of HLA-G as a tumor marker, and reviewed (d) the methods for detecting and quantifying HLA-G.	[Li, Peilong; Wang, Chuanxin; Du, Lutao] Shandong Univ, Hosp 2, Dept Clin Lab, Cheeloo Coll Med, Jinan, Peoples R China; [Li, Peilong; Wang, Chuanxin; Du, Lutao] Shandong Engn & Technol Res Ctr Tumor Marker Dete, Jinan, Peoples R China; [Li, Peilong; Wang, Chuanxin; Du, Lutao] Shandong Prov Clin Med Res Ctr Clin Lab, Jinan, Peoples R China; [Zhang, Yi] Shandong First Med Univ & Shandong Acad Med Sci, Sch Publ Hlth, Tai An, Shandong, Peoples R China; [Wang, Chuanxin] Shandong Univ, Qilu Hosp, Dept Resp & Crit Care Med, Cheeloo Coll Med, Jinan, Peoples R China	Shandong University; Shandong First Medical University & Shandong Academy of Medical Sciences; Shandong University	Wang, CX; Du, LT (corresponding author), Shandong Univ, Hosp 2, Dept Clin Lab, Cheeloo Coll Med, Jinan, Peoples R China.; Wang, CX; Du, LT (corresponding author), Shandong Engn & Technol Res Ctr Tumor Marker Dete, Jinan, Peoples R China.; Wang, CX; Du, LT (corresponding author), Shandong Prov Clin Med Res Ctr Clin Lab, Jinan, Peoples R China.	cxwang@sdu.edu.cn; lutaodu@sdu.edu.cn			National Natural Science Foundation of China [82002228, 82072368]; Key Research and Development Program of Shandong Province [2019GSF108091]; Taishan Scholars Program of Shandong Province	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Key Research and Development Program of Shandong Province; Taishan Scholars Program of Shandong Province	Funding This research was supported by grant from the National Natural Science Foundation of China (82002228 to PL, 82072368 to LD), the Key Research and Development Program of Shandong Province (2019GSF108091 to LD), Taishan Scholars Program of Shandong Province awarded to CXW and LD.	Agnihotri V, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-60811-y; Agnihotri V, 2017, HUM IMMUNOL, V78, P172, DOI 10.1016/j.humimm.2016.12.007; Alegre E, 2013, EUR J IMMUNOL, V43, P1933, DOI 10.1002/eji.201343318; Amiot L, 2015, J HEPATOL, V62, P1430, DOI 10.1016/j.jhep.2015.03.007; Anastassiou G, 2003, INVEST OPHTH VIS SCI, V44, P2016, DOI 10.1167/iovs.02-0810; Andersson E, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1052213; Anna F, 2021, J IMMUNOTHER CANCER, V9, DOI 10.1136/jitc-2020-001998; Rodriguez JA, 2012, PATHOBIOLOGY, V79, P72, DOI 10.1159/000334089; Apps R, 2008, TRENDS IMMUNOL, V29, P313, DOI 10.1016/j.it.2008.02.012; Attia JVD, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21228678; Babay W, 2021, HLA, V98, P357, DOI 10.1111/tan.14374; Babay W, 2018, HUM IMMUNOL, V79, P463, DOI 10.1016/j.humimm.2018.02.012; Bai YX, 2020, J REPROD IMMUNOL, V142, DOI 10.1016/j.jri.2020.103176; Baudhuin J, 2013, P NATL ACAD SCI USA, V110, P17957, DOI 10.1073/pnas.1221535110; Ben Amor A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161210; Ben Yahia H, 2018, MOL IMMUNOL, V99, P82, DOI 10.1016/j.molimm.2018.04.007; Bentata M, 2020, GENES-BASEL, V11, DOI 10.3390/genes11080880; Bertol BC, 2020, INT J CLIN PRACT, V74, DOI 10.1111/ijcp.13585; Blaschitz A, 2005, MOL HUM REPROD, V11, P699, DOI 10.1093/molehr/gah185; Brown R, 2012, BLOOD, V120, P2055, DOI 10.1182/blood-2012-03-416792; Cai MB, 2012, INT J BIOL SCI, V8, P891, DOI 10.7150/ijbs.4383; Cai MY, 2009, CLIN CANCER RES, V15, P4686, DOI 10.1158/1078-0432.CCR-09-0463; Cai ZY, 2019, INT J ONCOL, V54, P1943, DOI 10.3892/ijo.2019.4761; Carosella ED, 2007, SEMIN CANCER BIOL, V17, P411, DOI 10.1016/j.semcancer.2007.06.014; Carosella ED, 2015, ADV IMMUNOL, V127, P33, DOI 10.1016/bs.ai.2015.04.001; Carosella ED, 2003, ADV IMMUNOL, V81, P199, DOI 10.1016/S0065-2776(03)81006-4; Chen HX, 2010, HUM IMMUNOL, V71, P892, DOI 10.1016/j.humimm.2010.06.009; Chen JX, 2013, CLIN EXP MED, V13, P135, DOI 10.1007/s10238-012-0185-6; Chen QY, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.679090; Chen Y, 2012, BIOMARKERS, V17, P9, DOI 10.3109/1354750X.2011.633242; Colombo M, 2014, ANNU REV CELL DEV BI, V30, P255, DOI 10.1146/annurev-cellbio-101512-122326; Cristaldi M, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.01476; Curigliano G, 2013, CLIN CANCER RES, V19, P5564, DOI 10.1158/1078-0432.CCR-12-3697; Dardano A, 2012, J CLIN ENDOCR METAB, V97, P4080, DOI 10.1210/jc.2012-2231; Davidson B, 2005, GYNECOL ONCOL, V96, P42, DOI 10.1016/j.ygyno.2004.09.049; Feitosa NLD, 2014, THYROID, V24, P585, DOI 10.1089/thy.2013.0246; Zermeno-Nava JD, 2018, J OVARIAN RES, V11, DOI 10.1186/s13048-018-0433-9; de Kruijf EM, 2010, J IMMUNOL, V185, P7452, DOI 10.4049/jimmunol.1002629; Delmonico L, 2016, ONCOL LETT, V12, P2145, DOI 10.3892/ol.2016.4828; Dong DD, 2012, HUM IMMUNOL, V73, P998, DOI 10.1016/j.humimm.2012.07.321; Du LT, 2011, CANCER SCI, V102, P1272, DOI 10.1111/j.1349-7006.2011.01951.x; Dunn GP, 2004, ANNU REV IMMUNOL, V22, P329, DOI 10.1146/annurev.immunol.22.012703.104803; EL Andaloussi S, 2013, NAT REV DRUG DISCOV, V12, P348, DOI 10.1038/nrd3978; ELLIS SA, 1986, IMMUNOLOGY, V59, P595; Fainardi E, 2008, MULT SCLER J, V14, P446, DOI 10.1177/1352458507085137; Fainardi E, 2003, J NEUROIMMUNOL, V142, P149, DOI 10.1016/S0165-5728(03)00266-2; Fainardi E, 2011, CELL MOL LIFE SCI, V68, P433, DOI 10.1007/s00018-010-0584-3; Fan X, 2016, J NEUROIMMUNOL, V294, P27, DOI 10.1016/j.jneuroim.2016.03.015; Farjadian Shirin, 2018, Asian Pac J Cancer Prev, V19, P2731; Ferguson R, 2012, INT J CANCER, V131, pE312, DOI 10.1002/ijc.27356; Frumento G, 2000, TISSUE ANTIGENS, V56, P30, DOI 10.1034/j.1399-0039.2000.560104.x; Fu BQ, 2017, IMMUNITY, V47, P1100, DOI [10.15585/mmwr.ss6904a1, 10.1016/j.immuni.2017.11.018]; Fu J, 2020, J INT MED RES, V48, DOI 10.1177/0300060520970758; Furukawa A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20235947; Fuzzi B, 2002, EUR J IMMUNOL, V32, P311, DOI 10.1002/1521-4141(200202)32:2<311::AID-IMMU311>3.3.CO;2-#; Garcia M, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-07113-8; GERAGHTY DE, 1987, P NATL ACAD SCI USA, V84, P9145, DOI 10.1073/pnas.84.24.9145; Goldman-Wohl D, 2001, AM J OBSTET GYNECOL, V185, P476, DOI 10.1067/mob.2001.115994; Goncalves AS, 2015, HUM IMMUNOL, V76, P52, DOI 10.1016/j.humimm.2014.11.002; Gonzalez A, 2012, CRIT REV CL LAB SCI, V49, P63, DOI 10.3109/10408363.2012.677947; Grande MA, 2021, J PERIODONTAL RES, V56, P27, DOI 10.1111/jre.12788; Grange C, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-2025-z; Gregori S, 2010, BLOOD, V116, P935, DOI 10.1182/blood-2009-07-234872; Gros F, 2006, NEOPLASIA, V8, P223, DOI 10.1593/neo.05703; Han L, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0980-8; He X, 2010, ANN SURG ONCOL, V17, P1459, DOI 10.1245/s10434-009-0891-9; HEINRICHS H, 1990, IMMUNOL RES, V9, P265, DOI 10.1007/BF02935526; HoWangYin KY, 2012, CELL MOL LIFE SCI, V69, P4041, DOI 10.1007/s00018-012-1069-3; Ishibashi K, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1169356; Ishigami S, 2006, ANTICANCER RES, V26, P2467; ISHITANI A, 1992, P NATL ACAD SCI USA, V89, P3947, DOI 10.1073/pnas.89.9.3947; Jacobsen DP, 2021, J REPROD IMMUNOL, V143, DOI 10.1016/j.jri.2020.103249; Jeong S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098284; Jung YW, 2009, REPROD SCI, V16, P1103, DOI 10.1177/1933719109342131; Jurisicova A, 1996, P NATL ACAD SCI USA, V93, P161, DOI 10.1073/pnas.93.1.161; Khorrami S, 2016, HUM IMMUNOL, V77, P153, DOI 10.1016/j.humimm.2015.11.005; Kim R, 2007, IMMUNOLOGY, V121, P1, DOI 10.1111/j.1365-2567.2007.02587.x; Kirana C, 2017, INT J CANCER, V140, P2577, DOI 10.1002/ijc.30667; Kleinberg L, 2006, VIRCHOWS ARCH, V449, P31, DOI 10.1007/s00428-005-0144-7; Konig L, 2016, HUM IMMUNOL, V77, P791, DOI 10.1016/j.humimm.2016.01.002; Kowal A, 2015, THORAC CANCER, V6, P613, DOI 10.1111/1759-7714.12232; Kyo S, 1997, CANCER RES, V57, P610; Larsen MH, 2011, MOL HUM REPROD, V17, P727, DOI 10.1093/molehr/gar052; Lazaro-Sanchez AD, 2020, CLIN TRANSL ONCOL, V22, P1166, DOI 10.1007/s12094-019-02244-2; Lee CL, 2015, HUM REPROD, V30, P2263, DOI 10.1093/humrep/dev196; Lehner R, 2001, OBSTET GYNECOL, V97, P965, DOI 10.1016/S0029-7844(01)01131-0; LeMaoult J, 2005, FASEB J, V19, P662, DOI 10.1096/fj.04-1617fje; LeMaoult J, 2015, J HEMATOL ONCOL, V8, DOI 10.1186/s13045-015-0114-8; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Liang S, 2008, P NATL ACAD SCI USA, V105, P8357, DOI 10.1073/pnas.0803341105; Lin A, 2010, J CELL MOL MED, V14, P2318, DOI 10.1111/j.1582-4934.2009.00858.x; Lin AF, 2019, CLIN TRANSL IMMUNOL, V8, DOI 10.1002/cti2.1077; Lin AF, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02164; Lin AF, 2015, MOL MED, V21, P782, DOI 10.2119/molmed.2015.00083; Lin AF, 2012, INT J CANCER, V131, P150, DOI 10.1002/ijc.26375; Lin AF, 2011, INT J CANCER, V129, P1382, DOI 10.1002/ijc.25807; Loustau M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01685; Ludwig AK, 2012, INT J BIOCHEM CELL B, V44, P11, DOI 10.1016/j.biocel.2011.10.005; Mach P, 2010, AM J REPROD IMMUNOL, V63, P387, DOI 10.1111/j.1600-0897.2009.00806.x; Mallet V, 1999, INT IMMUNOL, V11, P889, DOI 10.1093/intimm/11.6.889; MCMASTER MT, 1995, J IMMUNOL, V154, P3771; Mittelbrunn M, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1285; Montilla D, 2016, ARCH BRONCONEUMOL, V52, P420, DOI 10.1016/j.arbres.2016.01.019; Morandi F, 2014, CYTOKINE GROWTH F R, V25, P327, DOI 10.1016/j.cytogfr.2014.04.004; Morel E, 2008, J IMMUNOL, V181, P2368, DOI 10.4049/jimmunol.181.4.2368; Murdaca G, 2018, VIRCHOWS ARCH, V473, P425, DOI 10.1007/s00428-018-2379-0; Naji A, 2012, LEUKEMIA, V26, P1889, DOI 10.1038/leu.2012.62; Nardi FD, 2016, HLA, V88, P77, DOI 10.1111/tan.12844; Negrini S, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00018; NEWMARK CS, 1978, J PERS ASSESS, V42, P366, DOI 10.1207/s15327752jpa4204_6; Noci I, 2005, HUM REPROD, V20, P138, DOI 10.1093/humrep/deh572; Pan YQ, 2016, HUM IMMUNOL, V77, P317, DOI 10.1016/j.humimm.2016.01.009; Park Y, 2012, TISSUE ANTIGENS, V79, P97, DOI 10.1111/j.1399-0039.2011.01814.x; Paul P, 1998, P NATL ACAD SCI USA, V95, P4510, DOI 10.1073/pnas.95.8.4510; Paul P, 2000, HUM IMMUNOL, V61, P1138, DOI 10.1016/S0198-8859(00)00197-X; Peng YJ, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.642902; Persson G, 2020, HUM IMMUNOL, V81, P127, DOI 10.1016/j.humimm.2019.09.006; Polakova K, 2004, HUM IMMUNOL, V65, P157, DOI 10.1016/j.humimm.2003.10.005; Provatopoulou X, 2012, ANTICANCER RES, V32, P1021; Ramos CS, 2014, HUM IMMUNOL, V75, P667, DOI 10.1016/j.humimm.2014.04.005; Rebmann V, 2007, TISSUE ANTIGENS, V69, P143, DOI 10.1111/j.1399-0039.2006.763_5.x; Rebmann V, 2005, HUM IMMUNOL, V66, P853, DOI 10.1016/j.humimm.2005.05.003; Rebmann V, 2010, HUM REPROD, V25, P1691, DOI 10.1093/humrep/deq120; Rebmann V, 2007, HUM IMMUNOL, V68, P251, DOI 10.1016/j.humimm.2006.11.003; Rebmann V, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00173; Rebmann V, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/297073; Riteau B, 2003, HUM IMMUNOL, V64, P1064, DOI 10.1016/j.humimm.2003.08.344; Rizzo R, 2011, CELL MOL LIFE SCI, V68, P341, DOI 10.1007/s00018-010-0578-1; Rodriguez JA, 2017, ONCOL LETT, V14, P4415, DOI 10.3892/ol.2017.6784; da Silva GBRF, 2013, INT J BREAST CANCER, V2013, DOI 10.1155/2013/250435; Rouas-Freiss N, 2005, CANCER RES, V65, P10139, DOI 10.1158/0008-5472.CAN-05-0097; Rutten MJ, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/274584; Schutt P, 2010, HUM IMMUNOL, V71, P489, DOI 10.1016/j.humimm.2010.02.015; Schwich E, 2019, CANCERS, V11, DOI 10.3390/cancers11081106; Schwich E, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-41900-z; Shahraki PK, 2018, IRAN J IMMUNOL, V15, P28, DOI IJIv15i1A3; Shen XJ, 2018, INDIAN J CANCER, V55, P340, DOI 10.4103/ijc.IJC_602_17; Shiroishi M, 2006, J BIOL CHEM, V281, P10439, DOI 10.1074/jbc.M512305200; Simon T, 2020, ONCOGENE, V39, P4477, DOI 10.1038/s41388-020-1308-2; Singer G, 2003, CLIN CANCER RES, V9, P4460; Song XW, 2020, P NATL ACAD SCI USA, V117, P16167, DOI 10.1073/pnas.2001395117; Sun Juan, 2017, Tumour Biol, V39, p1010428317726840, DOI 10.1177/1010428317726840; Swets M, 2018, CLIN IMMUNOL, V194, P80, DOI 10.1016/j.clim.2018.07.005; Swets M, 2016, HUM IMMUNOL, V77, P773, DOI 10.1016/j.humimm.2016.03.001; Tan BB, 2021, EXP MOL PATHOL, V120, DOI 10.1016/j.yexmp.2021.104643; Tawfeek GA, 2018, IMMUNOL INVEST, V47, P315, DOI 10.1080/08820139.2018.1430826; Tilburgs T, 2015, P NATL ACAD SCI USA, V112, P13312, DOI 10.1073/pnas.1517724112; Ullah M, 2019, NEOPLASIA, V21, P331, DOI 10.1016/j.neo.2019.01.001; Urosevic M, 2004, BLOOD, V103, P1796, DOI 10.1182/blood-2003-10-3372; Urosevic M, 2001, AM J PATHOL, V159, P817, DOI 10.1016/S0002-9440(10)61756-7; Vangangelt KMH, 2018, BREAST CANCER RES TR, V168, P601, DOI 10.1007/s10549-017-4617-6; Wan R, 2017, CELL PHYSIOL BIOCHEM, V44, P1828, DOI 10.1159/000485819; Wang Y, 2011, HEPATOB PANCREAT DIS, V10, P158, DOI 10.1016/S1499-3872(11)60025-8; Wang ZQ, 2018, INT J IMMUNOGENET, V45, P266, DOI 10.1111/iji.12390; Wlasiuk P, 2016, POSTEP HIG MED DOSW, V70, P1044; Wu T, 2017, CANCER LETT, V387, P61, DOI 10.1016/j.canlet.2016.01.043; Wuerfel FM, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-72837-3; Xu DP, 2016, HUM IMMUNOL, V77, P800, DOI 10.1016/j.humimm.2016.01.003; Xu HH, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01349; Xu YF, 2015, CURR MOL MED, V15, P360, DOI 10.2174/1566524015666150401102218; Yan WH, 2015, J CELL MOL MED, V19, P778, DOI 10.1111/jcmm.12400; Yanez-Mo M, 2015, J EXTRACELL VESICLES, V4, DOI 10.3402/jev.v4.27066; Yie SM, 2007, LUNG CANCER, V58, P267, DOI 10.1016/j.lungcan.2007.06.011; Yie SM, 2007, ANN SURG ONCOL, V14, P2721, DOI 10.1245/s10434-007-9464-y; Zeestraten ECM, 2014, BRIT J CANCER, V110, P459, DOI 10.1038/bjc.2013.696; Zhang X, 2016, HUM IMMUNOL, V77, P780, DOI 10.1016/j.humimm.2015.12.003; Zhang Y, 2010, J INT MED RES, V38, P949, DOI 10.1177/147323001003800321; Zheng JY, 2014, IMMUNOL LETT, V161, P13, DOI 10.1016/j.imlet.2014.04.007; Zhu CB, 2011, INT J CANCER, V128, P617, DOI 10.1002/ijc.25372	169	0	0	1	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 11	2021	12								791535	10.3389/fimmu.2021.791535	http://dx.doi.org/10.3389/fimmu.2021.791535			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XH7CZ	34868081	gold, Green Published			2022-12-18	WOS:000725589400001
J	Liu, P; Bai, M; Ma, C; Yan, YP; Zhang, GJ; Wu, SD; Li, ZB; Zhao, DD; Ren, KX; Li, HZ; Guo, J				Liu, Pei; Bai, Miao; Ma, Chao; Yan, Yaping; Zhang, Gejuan; Wu, Songdi; Li, Zunbo; Zhao, Daidi; Ren, Kaixi; Li, Hongzeng; Guo, Jun			Case Report: Prominent Brainstem Involvement in Two Patients With Anti-CASPR2 Antibody-Associated Autoimmune Encephalitis	FRONTIERS IN IMMUNOLOGY			English	Article						autoimmune; contactin-associated protein-like 2; encephalitis; brainstem; immunoglobulin G1	CASPR2 ANTIBODIES; SPECTRUM	Anti-contactin-associated protein-like 2 (CASPR2) antibody-associated autoimmune encephalitis is commonly characterized by limbic encephalitis with clinical symptoms of mental and behavior disorders, cognitive impairment, deterioration of memory, and epilepsy. The classical lesions reported are located at the medial temporal lobe or hippocampus, whereas prominent brainstem lesions have not been addressed to date. Herein, we reported two patients mimicking progressive brainstem infarction with severe neurological manifestations. On brain magnetic resonance imaging (MRI), prominent brainstem lesions were noted, although multifocal lesions were also shown in the juxtacortical and subcortical white matters, basal ganglia, hippocampus, and cerebellar hemisphere. Unexpectedly and interestingly, both cases had detectable CASPR2 antibodies in sera, and an exclusive IgG1 subclass was documented in the further analysis. They were treated effectively with aggressive immunosuppressive therapies including corticosteroids, intravenous immunoglobulin G, and rituximab, with the first case achieving a rapid remission and the other undergoing a slow but gradual improvement. To the best of our knowledge, this is the first report on prominent brainstem involvement with definite MRI lesions in anti-CASPR2 antibody-associated autoimmune encephalitis, which helps to expand the clinical spectrum of this rare autoimmune disease and update the lesion patterns in the CNS.	[Liu, Pei; Bai, Miao; Zhao, Daidi; Ren, Kaixi; Li, Hongzeng; Guo, Jun] Air Force Med Univ, Tangdu Hosp, Dept Neurol, Xian, Peoples R China; [Liu, Pei; Wu, Songdi] First Hosp Xian, Dept Neurol, Xian, Peoples R China; [Ma, Chao] Air Force Med Univ, Tangdu Hosp, Dept Cardiol, Xian, Peoples R China; [Yan, Yaping] Shaanxi Normal Univ, Coll Life Sci, Xian, Peoples R China; [Zhang, Gejuan] Xian 3 Hosp, Dept Neurol, Xian, Peoples R China; [Li, Zunbo] Xian Gaoxin Hosp, Dept Neurol, Xian Med Coll, Xian, Peoples R China	Air Force Military Medical University; Air Force Military Medical University; Shaanxi Normal University; Xi'an Medical University	Li, HZ; Guo, J (corresponding author), Air Force Med Univ, Tangdu Hosp, Dept Neurol, Xian, Peoples R China.	llihongzeng@163.com; guojun_81@163.com	wu, songdi/AAD-2395-2022; Guo, Jun/AAC-3573-2021	Guo, Jun/0000-0001-8053-881X; Liu, Pei/0000-0002-1761-8339; Ren, Kaixi/0000-0003-2998-4974				Becker EBE, 2012, J NEUROL NEUROSUR PS, V83, P437, DOI 10.1136/jnnp-2011-301506; Bien CG, 2017, EUR J NEUROL, V24, P175, DOI 10.1111/ene.13180; Binks SNM, 2018, J NEUROL NEUROSUR PS, V89, P526, DOI 10.1136/jnnp-2017-315720; Boyko M, 2020, J NEUROL, V267, P1137, DOI 10.1007/s00415-019-09686-2; Di Giacomo R, 2020, J NEUROL SCI, V413, DOI 10.1016/j.jns.2020.116865; Freund Brin, 2016, J Clin Neuromuscul Dis, V17, P207, DOI 10.1097/CND.0000000000000118; Govert F, 2016, NEUROLOGY, V86, P1353, DOI 10.1212/WNL.0000000000002547; Grau-Rivera O, 2014, JAMA NEUROL, V71, P74, DOI 10.1001/jamaneurol.2013.4857; Joubert B, 2016, JAMA NEUROL, V73, P1115, DOI 10.1001/jamaneurol.2016.1585; Kannoth S, 2018, NEUROL SCI, V39, P455, DOI 10.1007/s10072-017-3222-0; Law LY, 2019, NEUROLOGY, V93, P390, DOI 10.1212/WNL.0000000000008015; Lee CH, 2014, J NEUROL SCI, V341, P36, DOI 10.1016/j.jns.2014.03.043; O'Toole O, 2013, NEUROLOGY, V80, P1133, DOI 10.1212/WNL.0b013e3182886991; Patterson KR, 2018, ANN NEUROL, V83, P40, DOI 10.1002/ana.25120; Qin XX, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.652864; Querol L, 2017, NAT REV NEUROL, V13, P533, DOI 10.1038/nrneurol.2017.84; Rosch RE, 2014, J PERIPHER NERV SYST, V19, P246, DOI 10.1111/jns.12089; Saint-Martin M, 2018, EUR J NEUROSCI, V48, P1906, DOI 10.1111/ejn.14081; Shivaram S, 2021, ANN INDIAN ACAD NEUR, V24, P178, DOI 10.4103/aian.AIAN_574_20; Ueno S, 2014, CASE REP NEUROL, V6, P222, DOI 10.1159/000366408; van Sonderen A, 2016, NEUROLOGY, V87, P521, DOI 10.1212/WNL.0000000000002917; Wang JS, 2021, J NEUROIMMUNOL, V353, DOI 10.1016/j.jneuroim.2021.577515; Warren N, 2019, AUST NZ J PSYCHIAT, V53, P174, DOI 10.1177/0004867418812687; Xing X, 2020, J NEUROIMMUNOL, V348, DOI 10.1016/j.jneuroim.2020.577393	24	0	0	8	14	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 11	2021	12								772763	10.3389/fimmu.2021.772763	http://dx.doi.org/10.3389/fimmu.2021.772763			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XH7MN	34858431	Green Published, gold			2022-12-18	WOS:000725614200001
J	Sullivan, PM; Reed, SJ; Kalia, V; Sarkar, S				Sullivan, Peter M.; Reed, Steven James; Kalia, Vandana; Sarkar, Surojit			Solid Tumor Microenvironment Can Harbor and Support Functional Properties of Memory T Cells	FRONTIERS IN IMMUNOLOGY			English	Article						bystander memory anti-tumor immunity; CAR T therapy; tumor microenvironment; chemokines; CXCR3; antigen	ANTITUMOR IMMUNITY; EFFECTOR; CXCR3; DYSFUNCTION; PD-1; TRAFFICKING; EXHAUSTION; SIGNATURE; MIGRATION	Robust T cell responses are crucial for effective anti-tumor responses and often dictate patient survival. However, in the context of solid tumors, both endogenous T cell responses and current adoptive T cell therapies are impeded by the immunosuppressive tumor microenvironment (TME). A multitude of inhibitory signals, suppressive immune cells, metabolites, hypoxic conditions and limiting nutrients are believed to render the TME non-conducive to sustaining productive T cell responses. In this study we conducted an in-depth phenotypic and functional comparison of tumor-specific T cells and tumor-nonspecific bystander memory T cells within the same TME. Using two distinct TCR transgenic and solid-tumor models, our data demonstrate that despite exposure to the same cell-extrinsic factors of the TME, the tumor-nonspecific bystander CD8 T cells retain the complete panoply of memory markers, and do not share the same exhaustive phenotype as tumor-reactive T cells. Compared to tumor-specific T cells, bystander memory CD8 T cells in the TME also retain functional effector cytokine production capabilities in response to ex vivo cognate antigenic stimulation. Consistent with these results, bystander memory T cells isolated from tumors showed enhanced recall responses to secondary bacterial challenge in a T cell transplant model. Importantly, the tumor-resident bystander memory cells could also efficiently utilize the available resources within the TME to elaborate in situ recall effector functions following intra-tumoral peptide antigen injection. Additionally, CRISPR-Cas9 gene deletion studies showed that CXCR3 was critical for the trafficking of both tumor antigen-specific and bystander memory T cells to solid tumors. Collectively, these findings that T cells can persist and retain their functionality in distinct solid tumor environments in the absence of cognate antigenic stimulation, support the notion that persistent antigenic signaling is the central driver of T cell exhaustion within the TME. These studies bear implications for programming more efficacious TCR- and CAR-T cells with augmented therapeutic efficacy and longevity through regulation of antigen and chemokine receptors.	[Sullivan, Peter M.; Reed, Steven James; Kalia, Vandana; Sarkar, Surojit] Seattle Childrens Res Inst, Ben Towne Ctr Childhood Canc Res, Seattle, WA 98121 USA; [Kalia, Vandana; Sarkar, Surojit] Univ Washington, Dept Pediat, Div Hematol & Oncol, Seattle, WA 98195 USA; [Sarkar, Surojit] Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98195 USA	Seattle Children's Hospital; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Kalia, V; Sarkar, S (corresponding author), Seattle Childrens Res Inst, Ben Towne Ctr Childhood Canc Res, Seattle, WA 98121 USA.; Kalia, V; Sarkar, S (corresponding author), Univ Washington, Dept Pediat, Div Hematol & Oncol, Seattle, WA 98195 USA.; Sarkar, S (corresponding author), Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98195 USA.	sarkarkalia@gmail.com		Sullivan, Peter/0000-0002-5021-060X				Ahn E, 2018, P NATL ACAD SCI USA, V115, P4749, DOI 10.1073/pnas.1718217115; Baumann FM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162674; Chheda ZS, 2016, J IMMUNOL, V197, P2016, DOI 10.4049/jimmunol.1502376; Chow MT, 2019, IMMUNITY, V50, P1498, DOI 10.1016/j.immuni.2019.04.010; Danahy DB, 2020, J IMMUNOL, V204, P1431, DOI 10.4049/jimmunol.1901172; Djenidi F, 2015, J IMMUNOL, V194, P3475, DOI 10.4049/jimmunol.1402711; Duhen T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05072-0; Erkes DA, 2017, J IMMUNOL, V198, P2979, DOI 10.4049/jimmunol.1601064; Fulton AM, 2009, CURR ONCOL REP, V11, P125, DOI 10.1007/s11912-009-0019-1; Groom JR, 2011, EXP CELL RES, V317, P620, DOI 10.1016/j.yexcr.2010.12.017; Gunderson AJ, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15404-8; Hashimoto M, 2018, ANNU REV MED, V69, P301, DOI 10.1146/annurev-med-012017-043208; He R, 2016, NATURE, V537, P412, DOI 10.1038/nature19317; Hu JK, 2011, P NATL ACAD SCI USA, V108, pE118, DOI 10.1073/pnas.1101881108; Hudson WH, 2019, IMMUNITY, V51, P1043, DOI 10.1016/j.immuni.2019.11.002; Im SJ, 2016, NATURE, V537, P417, DOI 10.1038/nature19330; Joyce JA, 2015, SCIENCE, V348, P74, DOI 10.1126/science.aaa6204; Juillerat A, 2019, BMC BIOTECHNOL, V19, DOI 10.1186/s12896-019-0537-3; Kalia V, 2015, IMMUNITY, V42, P1116, DOI 10.1016/j.immuni.2015.05.023; Karin N, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00976; Khan AA, 2013, BLOOD, V121, P4473, DOI 10.1182/blood-2012-06-435412; Kumar A, 2020, ELIFE, V9, DOI 10.7554/eLife.52330; Lanitis E, 2017, ANN ONCOL, V28, P18, DOI 10.1093/annonc/mdx238; Li YL, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01591; Maimela NR, 2019, COMPUT STRUCT BIOTEC, V17, P1, DOI 10.1016/j.csbj.2018.11.004; Martinez-Usatorre A, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00340; Maurice NJ, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12980-2; McLane LM, 2019, ANNU REV IMMUNOL, V37, P457, DOI 10.1146/annurev-immunol-041015-055318; Melero I, 2014, CANCER DISCOV, V4, P522, DOI 10.1158/2159-8290.CD-13-0985; Mestermann K, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aau5907; Mikucki ME, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8458; Miller BC, 2019, NAT IMMUNOL, V20, P326, DOI 10.1038/s41590-019-0312-6; Monjazeb AM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102709; Nakamura K, 2020, CELL MOL IMMUNOL, V17, P1, DOI 10.1038/s41423-019-0306-1; Park S, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20671-6; Peng WY, 2010, CLIN CANCER RES, V16, P5458, DOI 10.1158/1078-0432.CCR-10-0712; Philip M, 2017, NATURE, V545, P452, DOI 10.1038/nature22367; Postow MA, 2015, J CLIN ONCOL, V33, P1974, DOI 10.1200/JCO.2014.59.4358; Raj D, 2019, GUT, V68, P1052, DOI 10.1136/gutjnl-2018-316595; Ribas A, 2018, SCIENCE, V359, P1350, DOI 10.1126/science.aar4060; Richman SA, 2020, MOL THER, V28, P1600, DOI 10.1016/j.ymthe.2020.06.004; Rosato PC, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08534-1; Sarkar S, 2018, J IMMUNOL, V201, P3641, DOI 10.4049/jimmunol.1800906; Scheper W, 2019, NAT MED, V25, P89, DOI 10.1038/s41591-018-0266-5; Schietinger A, 2016, IMMUNITY, V45, P389, DOI 10.1016/j.immuni.2016.07.011; Siddiqui I, 2019, IMMUNITY, V50, P195, DOI 10.1016/j.immuni.2018.12.021; Simoni Y, 2018, NATURE, V557, P575, DOI 10.1038/s41586-018-0130-2; Slaney CY, 2014, CANCER RES, V74, P7168, DOI 10.1158/0008-5472.CAN-14-2458; Spranger S, 2017, CANCER CELL, V31, P711, DOI 10.1016/j.ccell.2017.04.003; Thommen DS, 2018, CANCER CELL, V33, P547, DOI 10.1016/j.ccell.2018.03.012; Weber EW, 2021, SCIENCE, V372, P49, DOI 10.1126/science.aba1786; Weber EW., 2020, TRANSIENT REST INDUC, DOI [10.1101/2020.01.26.920496, DOI 10.1101/2020.01.26.920496]; Wherry EJ, 2007, IMMUNITY, V27, P670, DOI 10.1016/j.immuni.2007.09.006; Wherry EJ, 2011, NAT IMMUNOL, V12, P492, DOI 10.1038/ni.2035; Yeku Oladapo, 2017, Am Soc Clin Oncol Educ Book, V37, P193, DOI 10.14694/EDBK_180328; Yu JW, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0206223; Yuzefpolskiy Y, 2015, CELL MOL IMMUNOL, V12, P400, DOI 10.1038/cmi.2014.48; Zajc CU, 2020, P NATL ACAD SCI USA, V117, P14926, DOI 10.1073/pnas.1911154117; Zhang RY, 2019, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00233; Zhang Z, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00017; Zhong WY, 2020, BMC GENOMICS, V21, DOI 10.1186/s12864-019-6344-3	61	0	0	2	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 11	2021	12								706150	10.3389/fimmu.2021.706150	http://dx.doi.org/10.3389/fimmu.2021.706150			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XH7WA	34867942	Green Published, gold			2022-12-18	WOS:000725638900001
J	Whiteaker, JR; Lundeen, RA; Zhao, L; Schoenherr, RM; Burian, A; Huang, DQ; Voytovich, U; Wang, T; Kennedy, JJ; Ivey, RG; Lin, CW; Murillo, OD; Lorentzen, TD; Thiagarajan, M; Colantonio, S; Caceres, TW; Roberts, RR; Knotts, JG; Reading, JJ; Kaczmarczyk, JA; Richardson, CW; Garcia-Buntley, SS; Bocik, W; Hewitt, SM; Murray, KE; Do, N; Brophy, M; Wilz, SW; Yu, HB; Ajjarapu, S; Boja, E; Hiltke, T; Rodriguez, H; Paulovich, AG				Whiteaker, Jeffrey R.; Lundeen, Rachel A.; Zhao, Lei; Schoenherr, Regine M.; Burian, Aura; Huang, Dongqing; Voytovich, Ulianna; Wang, Tao; Kennedy, Jacob J.; Ivey, Richard G.; Lin, Chenwei; Murillo, Oscar D.; Lorentzen, Travis D.; Thiagarajan, Mathangi; Colantonio, Simona; Caceres, Tessa W.; Roberts, Rhonda R.; Knotts, Joseph G.; Reading, Joshua J.; Kaczmarczyk, Jan A.; Richardson, Christopher W.; Garcia-Buntley, Sandra S.; Bocik, William; Hewitt, Stephen M.; Murray, Karen E.; Do, Nhan; Brophy, Mary; Wilz, Stephen W.; Yu, Hongbo; Ajjarapu, Samuel; Boja, Emily; Hiltke, Tara; Rodriguez, Henry; Paulovich, Amanda G.			Targeted Mass Spectrometry Enables Multiplexed Quantification of Immunomodulatory Proteins in Clinical Biospecimens	FRONTIERS IN IMMUNOLOGY			English	Article						immunotherapy; cancer; correlative biomarkers; mass spectrometry; immuno-MRM	INTEGRATED PROTEOGENOMIC CHARACTERIZATION; PEPTIDE IMMUNOAFFINITY ENRICHMENT; HUMAN COLON; CANCER; ASSAY; PROTEOMICS; IMMUNOTHERAPY; REVEALS; TRANSCRIPTION; THYROGLOBULIN	Immunotherapies are revolutionizing cancer care, producing durable responses and potentially cures in a subset of patients. However, response rates are low for most tumors, grade 3/4 toxicities are not uncommon, and our current understanding of tumor immunobiology is incomplete. While hundreds of immunomodulatory proteins in the tumor microenvironment shape the anti-tumor response, few of them can be reliably quantified. To address this need, we developed a multiplex panel of targeted proteomic assays targeting 52 peptides representing 46 proteins using peptide immunoaffinity enrichment coupled to multiple reaction monitoring-mass spectrometry. We validated the assays in tissue and plasma matrices, where performance figures of merit showed over 3 orders of dynamic range and median inter-day CVs of 5.2% (tissue) and 21% (plasma). A feasibility study in clinical biospecimens showed detection of 48/52 peptides in frozen tissue and 38/52 peptides in plasma. The assays are publicly available as a resource for the research community.	[Whiteaker, Jeffrey R.; Lundeen, Rachel A.; Zhao, Lei; Schoenherr, Regine M.; Burian, Aura; Huang, Dongqing; Voytovich, Ulianna; Wang, Tao; Kennedy, Jacob J.; Ivey, Richard G.; Lin, Chenwei; Murillo, Oscar D.; Lorentzen, Travis D.; Paulovich, Amanda G.] Fred Hutchinson Canc Res Ctr, Clin Res Div, Seattle, WA 98109 USA; [Thiagarajan, Mathangi] Frederick Natl Lab Canc Res, Frederick, MD USA; [Colantonio, Simona; Caceres, Tessa W.; Roberts, Rhonda R.; Knotts, Joseph G.; Reading, Joshua J.; Kaczmarczyk, Jan A.; Richardson, Christopher W.; Garcia-Buntley, Sandra S.; Bocik, William] Canc Res Technol Program, Frederick Natl Lab Canc Res, Antibody Characterizat Lab, Frederick, MD USA; [Hewitt, Stephen M.] Natl Inst Hlth, Natl Canc Inst, Ctr Canc Res, Expt Pathol Lab,Lab Pathol, Bethesda, MD USA; [Murray, Karen E.; Do, Nhan; Brophy, Mary; Ajjarapu, Samuel] Vet Adm VA Boston Healthcare Syst 151MAV, Vet Adm VA Cooperat Studies Program, Jamaica Plain, MA USA; [Do, Nhan; Brophy, Mary; Wilz, Stephen W.] Boston Univ Sch Med, Dept Med, Boston, MA USA; [Wilz, Stephen W.; Yu, Hongbo] Vet Adm VA Boston Healthcare Syst, Pathol & Lab Med Serv Program, Jamaica Plain, MA USA; [Yu, Hongbo] Harvard Med Sch, Dept Pathol, Boston, MA USA; [Ajjarapu, Samuel] Dana Farber Canc Inst, Dept Med, Boston, MA USA; [Boja, Emily; Hiltke, Tara; Rodriguez, Henry] Natl Canc Inst, Off Canc Clin Prote Res, Bethesda, MD USA	Fred Hutchinson Cancer Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Boston University; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Paulovich, AG (corresponding author), Fred Hutchinson Canc Res Ctr, Clin Res Div, Seattle, WA 98109 USA.	apaulovi@fredhutch.org	Lin, Chen/GRR-2799-2022	Murillo, Oscar/0000-0003-1938-3905; ajjarapu, samuel/0000-0002-0066-6086; Lundeen, Rachel/0000-0002-4219-3942	National Cancer Institute (NCI); National Institutes of Health; NCI Beau Biden National Cancer Moonshot [HHSN26100025]; NCI Clinical Proteomics Tumor Analysis Consortium (CPTAC) [U01CA214114]; Applied Proteogenomics Organizational Learning and Outcomes [HHSN261201500003I]; NCI Research Specialist program [R50CA211499]; NCI CPTAC Antibody Characterization Program; Aven Foundation; VA Office of Research and Development, Cooperative Studies Program (CSP)	National Cancer Institute (NCI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI Beau Biden National Cancer Moonshot; NCI Clinical Proteomics Tumor Analysis Consortium (CPTAC); Applied Proteogenomics Organizational Learning and Outcomes; NCI Research Specialist program; NCI CPTAC Antibody Characterization Program; Aven Foundation; VA Office of Research and Development, Cooperative Studies Program (CSP)	This research has been funded in whole or in part with Federal funds from the National Cancer Institute (NCI), National Institutes of Health, under the NCI Beau Biden National Cancer Moonshot (Task Order No. HHSN26100025, Applied Proteogenomics Organizational Learning and Outcomes, under Contract No. HHSN261201500003I), the NCI Clinical Proteomics Tumor Analysis Consortium (CPTAC, grant no. U01CA214114), the NCI Academic Industrial Partnership (grant no. R01CA235575), the NCI Research Specialist program (grant no. R50CA211499), in part by the NCI CPTAC Antibody Characterization Program, and a generous donation from the Aven Foundation. This work was partially supported by the VA Office of Research and Development, Cooperative Studies Program (CSP). The views expressed are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government.	Abdel-Wahab N, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160221; Addona TA, 2009, NAT BIOTECHNOL, V27, P633, DOI 10.1038/nbt.1546; Altan M, 2018, NPJ BREAST CANCER, V4, DOI 10.1038/s41523-018-0095-1; ARCONE R, 1993, EUR J BIOCHEM, V211, P347, DOI 10.1111/j.1432-1033.1993.tb19904.x; Baker M, 2015, NATURE, V521, P274, DOI 10.1038/521274a; Bastid J, 2013, ONCOGENE, V32, P1743, DOI 10.1038/onc.2012.269; Bergom C, 2005, LEUKEMIA LYMPHOMA, V46, P1409, DOI 10.1080/10428190500126091; Betzler AC, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21113949; Bommhardt U, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20143500; Carr SA, 2014, MOL CELL PROTEOMICS, V13, P907, DOI 10.1074/mcp.M113.036095; Cesano A, 2015, J IMMUNOTHER CANCER, V3, DOI 10.1186/s40425-015-0088-7; Cheah MT, 2015, P NATL ACAD SCI USA, V112, P4725, DOI 10.1073/pnas.1424795112; Chen DS, 2013, IMMUNITY, V39, P1, DOI 10.1016/j.immuni.2013.07.012; Chung JY, 2008, PROTEOM CLIN APPL, V2, P1539, DOI 10.1002/prca.200800005; Clark DJ, 2020, CELL, V180, P207, DOI 10.1016/j.cell.2019.12.026; Clark DJ, 2019, CELL, V179, P964, DOI 10.1016/j.cell.2019.10.007; CLSI, 2021, QUANTITATIVE MEASURE; Collins CJ, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00464; Collins CJ, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02756; Dankner M, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1328336; Deutsch EW, 2020, NUCLEIC ACIDS RES, V48, pD1145, DOI 10.1093/nar/gkz984; Do M, 2020, CLIN CHEM, V66, P1339, DOI 10.1093/clinchem/hvaa178; Dostert C, 2019, PHYSIOL REV, V99, P115, DOI 10.1152/physrev.00045.2017; Dou YC, 2020, CELL, V180, P729, DOI 10.1016/j.cell.2020.01.026; Edwards NJ, 2015, J PROTEOME RES, V14, P2707, DOI 10.1021/pr501254j; Fiore LD, 2017, CLIN PHARMACOL THER, V101, P619, DOI 10.1002/cpt.658; Gadalla R, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00415; Gajewski TF, 2006, IMMUNOL REV, V213, P131, DOI 10.1111/j.1600-065X.2006.00442.x; Gillette MA, 2020, CELL, V182, P200, DOI 10.1016/j.cell.2020.06.013; Gillette MA, 2013, NAT METHODS, V10, P28, DOI 10.1038/nmeth.2309; Glatter T, 2012, J PROTEOME RES, V11, P5145, DOI 10.1021/pr300273g; Haura EB, 2005, NAT CLIN PRACT ONCOL, V2, P315, DOI 10.1038/ncponc0195; Hegde PS, 2020, IMMUNITY, V52, P17, DOI 10.1016/j.immuni.2019.12.011; Hembrough T, 2013, J MOL DIAGN, V15, P454, DOI 10.1016/j.jmoldx.2013.03.002; Henle AM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0187323; Hirsch FR, 2017, J THORAC ONCOL, V12, P208, DOI 10.1016/j.jtho.2016.11.2228; Hoofnagle AN, 2016, CLIN CHEM, V62, P48, DOI 10.1373/clinchem.2015.250563; Hornbeck PV, 2012, NUCLEIC ACIDS RES, V40, pD261, DOI 10.1093/nar/gkr1122; Hu YW, 2020, CELL REP, V33, DOI 10.1016/j.celrep.2020.108276; Huang C, 2021, CANCER CELL, V39, P361, DOI 10.1016/j.ccell.2020.12.007; Huang KCY, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-79419-3; Imam R, 2021, BMC CANCER, V21, DOI 10.1186/s12885-021-08045-7; Ippoliti PJ, 2016, ANAL CHEM, V88, P7548, DOI 10.1021/acs.analchem.6b00946; Jiang T, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4073-7; Johnson DB, 2016, NEW ENGL J MED, V375, P1749, DOI 10.1056/NEJMoa1609214; Jones GN, 2018, BRIT J CANCER, V119, P1233, DOI 10.1038/s41416-018-0286-4; Jung S, 2017, J PROTEOME RES, V16, P862, DOI 10.1021/acs.jproteome.6b00828; Kennedy JJ, 2021, CLIN CHEM, V67, P1008, DOI 10.1093/clinchem/hvab047; Kennedy JJ, 2016, J PROTEOME RES, V15, P2717, DOI 10.1021/acs.jproteome.6b00245; Kennedy JJ, 2016, MOL CELL PROTEOMICS, V15, P726, DOI 10.1074/mcp.O115.054940; Kennedy JJ, 2014, NAT METHODS, V11, P149, DOI [10.1038/NMETH.2763, 10.1038/nmeth.2763]; Keren L, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aax5851; Kim Y, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-40527-4; Krug K, 2020, CELL, V183, P1436, DOI 10.1016/j.cell.2020.10.036; Kuhn E, 2012, MOL CELL PROTEOMICS, V11, DOI 10.1074/mcp.M111.013854; Kushnir MM, 2016, CLIN CHEM, V62, P218, DOI 10.1373/clinchem.2015.244012; Kushnir MM, 2013, CLIN CHEM, V59, P982, DOI 10.1373/clinchem.2012.195594; Lajaunias F, 2005, EUR J IMMUNOL, V35, P243, DOI 10.1002/eji.200425273; Lange V, 2008, MOL SYST BIOL, V4, DOI 10.1038/msb.2008.61; Larson RC, 2021, NAT REV CANCER, V21, P145, DOI 10.1038/s41568-020-00323-z; Li Y, 2020, PATHOL ONCOL RES, V26, P1451, DOI 10.1007/s12253-019-00710-4; Li YH, 2017, ONCOTARGET, V8, P4501, DOI 10.18632/oncotarget.13885; Lines JL, 2014, CANCER RES, V74, P1924, DOI 10.1158/0008-5472.CAN-13-1504; Lumsden JM, 2004, J EXP MED, V200, P1111, DOI 10.1084/jem.20041074; Ma ZF, 2016, CLIN CANCER RES, V22, P2969, DOI 10.1158/1078-0432.CCR-15-1655; MacLean B, 2010, BIOINFORMATICS, V26, P966, DOI 10.1093/bioinformatics/btq054; Markosyan N, 2019, J CLIN INVEST, V129, P3594, DOI 10.1172/JCI127755; Mertins P, 2016, NATURE, V534, P55, DOI 10.1038/nature18003; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Munder M, 2006, BLOOD, V108, P1627, DOI 10.1182/blood-2006-11-010389; Netzel BC, 2016, CLIN CHEM, V62, P297, DOI 10.1373/clinchem.2015.245266; Neubert H, 2020, CLIN CHEM, V66, P282, DOI 10.1093/clinchem/hvz022; Nicholls C, 2012, CLIN EXP PHARMACOL P, V39, P674, DOI 10.1111/j.1440-1681.2011.05599.x; Paik S, 2004, NEW ENGL J MED, V351, P2817, DOI 10.1056/NEJMoa041588; Perdigoto AL, 2021, CURR OPIN IMMUNOL, V69, P29, DOI 10.1016/j.coi.2021.02.002; Perez-Riverol Y, 2019, NUCLEIC ACIDS RES, V47, pD442, DOI 10.1093/nar/gky1106; Picotti P, 2013, NAT METHODS, V10, P24, DOI 10.1038/nmeth.2291; Pilard C, 2021, BRIT J CANCER, V125, P927, DOI 10.1038/s41416-021-01413-x; Pino LK, 2020, MASS SPECTROM REV, V39, P229, DOI 10.1002/mas.21540; Raiter A, 2021, ONCOIMMUNOLOGY, V10, DOI 10.1080/2162402X.2021.1929725; Rodriguez H, 2021, CELL, V184, P1661, DOI 10.1016/j.cell.2021.02.055; Samstein RM, 2018, ADV RADIAT ONCOL, V3, P527, DOI 10.1016/j.adro.2018.08.017; Saxena M, 2021, NAT REV CANCER, V21, P360, DOI 10.1038/s41568-021-00346-0; Schoenherr RM, 2020, CLIN CHEM, V66, DOI 10.1093/clinchem/hvaa220; Schoenherr RM, 2019, SCI DATA, V6, DOI 10.1038/s41597-019-0166-7; Schoenherr RM, 2015, MOL CELL PROTEOMICS, V14, P382, DOI 10.1074/mcp.O114.043133; Sharma P, 2021, CANCER DISCOV, V11, P838, DOI 10.1158/2159-8290.CD-20-1680; Sharma V, 2018, MOL CELL PROTEOMICS, V17, P1239, DOI 10.1074/mcp.RA117.000543; Sharpless NE, 2021, CANCER CELL, V39, P889, DOI 10.1016/j.ccell.2021.04.015; Sherry ST, 1999, GENOME RES, V9, P677; Stein R, 2007, CLIN CANCER RES, V13, p5556S, DOI 10.1158/1078-0432.CCR-07-1167; Sullivan RJ, 2022, NAT REV DRUG DISCOV, V21, P495, DOI 10.1038/s41573-021-00259-5; van den Broek I, 2016, CLIN CHEM, V62, P188, DOI 10.1373/clinchem.2015.246702; Vasaikar S, 2019, CELL, V177, P1035, DOI 10.1016/j.cell.2019.03.030; Wang B, 2019, PEERJ, V7, DOI 10.7717/peerj.6903; Wang LB, 2021, CANCER CELL, V39, P509, DOI 10.1016/j.ccell.2021.01.006; Whiteaker Jeffrey R, 2021, Cell Rep Methods, V1, DOI 10.1016/j.crmeth.2021.100015; Whiteaker JR, 2018, DNA REPAIR, V65, P47, DOI 10.1016/j.dnarep.2018.03.003; Whiteaker JR, 2018, RADIAT RES, V189, P505, DOI 10.1667/RR14963.1; Whiteaker JR, 2016, METHODS MOL BIOL, V1410, P223, DOI 10.1007/978-1-4939-3524-6_13; Whiteaker JR, 2014, NAT METHODS, V11, P703, DOI 10.1038/nmeth.3002; Whiteaker JR, 2012, MOL CELL PROTEOMICS, V11, DOI 10.1074/mcp.M111.015347; Whiteaker JR, 2011, CLIN LAB MED, V31, P385, DOI 10.1016/j.cll.2011.07.004; Whiteaker JR, 2010, MOL CELL PROTEOMICS, V9, P184, DOI 10.1074/mcp.M900254-MCP200; Williams R, 2010, PROTEOM CLIN APPL, V4, P618, DOI 10.1002/prca.200900186; Yang MR, 2021, J IMMUNOTHER CANCER, V9, DOI 10.1136/jitc-2020-001136; Zhang B, 2014, NATURE, V513, P382, DOI 10.1038/nature13438; Zhang D, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01066; Zhang H, 2007, MOL CELL PROTEOMICS, V6, P64, DOI 10.1074/mcp.M600160-MCP200; Zhang H, 2016, CELL, V166, P755, DOI 10.1016/j.cell.2016.05.069; Zhao L, 2011, JOVE-J VIS EXP, DOI 10.3791/2812	111	0	0	1	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 11	2021	12								765898	10.3389/fimmu.2021.765898	http://dx.doi.org/10.3389/fimmu.2021.765898			18	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XI5GL	34858420	gold, Green Published			2022-12-18	WOS:000726139800001
J	Yang, WL; Lin, JB; Zhou, J; Zheng, YQ; Jiang, SJ; He, SL; Li, DZ				Yang, Wenling; Lin, Jibin; Zhou, Jin; Zheng, Yuqi; Jiang, Shijiu; He, Shaolin; Li, Dazhu			Innate Lymphoid Cells and Myocardial Infarction	FRONTIERS IN IMMUNOLOGY			English	Review						myocardial infarction; innate lymphoid cells; myocardial ischemia-reperfusion injury; regeneration and repair after myocardial infarction; the acute phase of myocardial infarction	INFLAMMATION; MECHANISMS; PROTECTION; PROMOTES; REPAIR; IL-33	Myocardial infarction results from obstruction of a coronary artery that causes insufficient blood supply to the myocardium and leads to ischemic necrosis. It is one of the most common diseases threatening human health and is characterized by high morbidity and mortality. Atherosclerosis is the pathological basis of myocardial infarction, and its pathogenesis has not been fully elucidated. Innate lymphoid cells (ILCs) are an important part of the human immune system and participate in many processes, including inflammation, metabolism and tissue remodeling, and play an important role in atherosclerosis. However, their specific roles in myocardial infarction are unclear. This review describes the current understanding of the relationship between innate lymphoid cells and myocardial infarction during the acute phase of myocardial infarction, myocardial ischemia-reperfusion injury, and heart repair and regeneration following myocardial infarction. We suggest that this review may provide new potential intervention targets and ideas for treatment and prevention of myocardial infarction.	[Yang, Wenling; Lin, Jibin; Zhou, Jin; Zheng, Yuqi; Jiang, Shijiu; He, Shaolin; Li, Dazhu] Huazhong Univ Sci & Technol, Union Hosp, Dept Cardiol, Tongji Med Coll, Wuhan, Peoples R China	Huazhong University of Science & Technology	He, SL; Li, DZ (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Dept Cardiol, Tongji Med Coll, Wuhan, Peoples R China.	hsl202009@163.com; lidazhuhp@sohu.com			National Key R&D Program of China [2017YFA0208000]; National Natural Science Foundation of China [82070317]	National Key R&D Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	Funding This work was supported by the National Key R&D Program of China (no. 2017YFA0208000 to SH) and the National Natural Science Foundation of China (no. 82070317 to JL).	Annunziato F, 2015, J ALLERGY CLIN IMMUN, V135, P626, DOI 10.1016/j.jaci.2014.11.001; Bekhite MM, 2020, BASIC RES CARDIOL, V115, DOI 10.1007/s00395-020-0796-0; Bracamonte-Baran W, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00634; Cao Q, 2018, J AM SOC NEPHROL, V29, P961, DOI 10.1681/ASN.2017070774; Cardilo-Reis L, 2012, EMBO MOL MED, V4, P1072, DOI 10.1002/emmm.201201374; Chen WY, 2021, THERANOSTICS, V11, P2594, DOI 10.7150/thno.51648; Choi HS, 2020, CELL REP, V30, P2989, DOI 10.1016/j.celrep.2020.02.040; Christia P, 2013, J HISTOCHEM CYTOCHEM, V61, P555, DOI 10.1369/0022155413493912; Deng YF, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00802; Eggenhofer E, 2016, J HEPATOL, V64, P128, DOI 10.1016/j.jhep.2015.08.023; Engelbertsen D, 2015, ARTERIOSCL THROM VAS, V35, P2526, DOI 10.1161/ATVBAHA.115.306048; Franke K, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.570963; Gao XN, 2020, J MOL CELL CARDIOL, V145, P99, DOI 10.1016/j.yjmcc.2020.05.017; Geha M, 2017, J IMMUNOL, V199, P2921, DOI 10.4049/jimmunol.1700655; Gentek R, 2017, ADV EXP MED BIOL, V1003, P251, DOI 10.1007/978-3-319-57613-8_12; Gong XM, 2021, IMMUNOLOGY, V162, P368, DOI 10.1111/imm.13271; Hams E, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00597; Hershey GKK, 2003, J ALLERGY CLIN IMMUN, V111, P677, DOI 10.1067/mai.2003.1333; Heusch G, 2020, NAT REV CARDIOL, V17, P773, DOI 10.1038/s41569-020-0403-y; Heusch G, 2019, BASIC RES CARDIOL, V114, DOI 10.1007/s00395-019-0756-8; Heusch G, 2019, CIRC RES, V124, P26, DOI 10.1161/CIRCRESAHA.118.314331; Hofmann U, 2014, CIRC-HEART FAIL, V7, P822, DOI 10.1161/CIRCHEARTFAILURE.113.001020; Jernberg T, 2015, EUR HEART J, V36, P1163, DOI 10.1093/eurheartj/ehu505; Kang J, 2021, AM J TRANSPLANT, V21, P787, DOI 10.1111/ajt.16163; Kim J, 2019, J ALLERGY CLIN IMMUN, V143, P1769, DOI 10.1016/j.jaci.2018.10.040; Koeppen M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03105-2; Kumric M, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10111514; Ley K, 2007, NAT REV IMMUNOL, V7, P678, DOI 10.1038/nri2156; Li J, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-61903-5; Liao YH, 2012, J AM COLL CARDIOL, V59, P420, DOI 10.1016/j.jacc.2011.10.863; Libby P, 2021, NATURE, V592, P524, DOI 10.1038/s41586-021-03392-8; Libby P, 2019, NAT REV DIS PRIMERS, V5, DOI [10.1038/s41572-019-0116-x, 10.1038/s41572-019-0106-z]; Liberale L, 2021, BASIC RES CARDIOL, V116, DOI 10.1007/s00395-021-00863-x; Meininger I, 2020, TRENDS IMMUNOL, V41, P902, DOI 10.1016/j.it.2020.08.009; Mohammadi MM, 2017, EMBO MOL MED, V9, P265, DOI 10.15252/emmm.201606602; Monticelli LA, 2015, P NATL ACAD SCI USA, V112, P10762, DOI 10.1073/pnas.1509070112; Moran AE, 2014, CIRCULATION, V129, P1493, DOI 10.1161/CIRCULATIONAHA.113.004046; Mouton AJ, 2018, BASIC RES CARDIOL, V113, DOI 10.1007/s00395-018-0686-x; Newland SA, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15781; O'Meara CC, 2015, CIRC RES, V116, P804, DOI 10.1161/CIRCRESAHA.116.304269; Ochel A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20081896; Oliveira JB, 2018, ADV CLIN CHEM, V84, P39, DOI 10.1016/bs.acc.2017.12.002; Pearce L, 2021, BASIC RES CARDIOL, V116, DOI 10.1007/s00395-021-00852-0; Perry HM, 2013, ARTERIOSCL THROM VAS, V33, P2771, DOI 10.1161/ATVBAHA.113.302571; Pluijmert NJ, 2021, FRONT CARDIOVASC MED, V8, DOI 10.3389/fcvm.2021.647785; Quillard T, 2017, CURR OPIN LIPIDOL, V28, P434, DOI 10.1097/MOL.0000000000000440; Ridker PM, 2018, EUR HEART J, V39, P3499, DOI 10.1093/eurheartj/ehy310; Robinette ML, 2015, NAT IMMUNOL, V16, P306, DOI 10.1038/ni.3094; Sacks D, 2018, INT J STROKE, V13, P612, DOI [10.1177/1747493018778713, 10.1016/j.jvir.2017.11.026]; Seki K, 2009, CIRC-HEART FAIL, V2, P684, DOI 10.1161/CIRCHEARTFAILURE.109.873240; Simon T, 2013, EUR HEART J, V34, P570, DOI 10.1093/eurheartj/ehs263; Tang TT, 2018, THERANOSTICS, V8, P4552, DOI 10.7150/thno.24723; Vivier E, 2018, CELL, V174, P1054, DOI 10.1016/j.cell.2018.07.017; Wang S, 2020, CELL RES, V30, P610, DOI 10.1038/s41422-020-0312-y; Wang S, 2017, CELL, V171, P201, DOI 10.1016/j.cell.2017.07.027; Waqas SFH, 2019, METHODS MOL BIOL, V1966, P211, DOI 10.1007/978-1-4939-9195-2_17; Wu C, 2018, SCAND J IMMUNOL, V87, DOI 10.1111/sji.12661; Wynn TA, 2015, NAT REV IMMUNOL, V15, P271, DOI 10.1038/nri3831; Xu JY, 2022, CARDIOVASC RES, V118, P2165, DOI 10.1093/cvr/cvab237; Xu JY, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00062; Yu X, 2021, J AM COLL CARDIOL, V78, P1127, DOI 10.1016/j.jacc.2021.07.018; Zeis P, 2020, IMMUNITY, V53, P775, DOI 10.1016/j.immuni.2020.09.002	62	0	0	13	25	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 11	2021	12								758272	10.3389/fimmu.2021.758272	http://dx.doi.org/10.3389/fimmu.2021.758272			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XH6YY	34867998	Green Published, gold			2022-12-18	WOS:000725578900001
J	Leuzzi, R; Bodini, M; Thomsen, IP; Soldaini, E; Bartolini, E; Muzzi, A; Clemente, B; Galletti, B; Manetti, AGO; Giovani, C; Censini, S; Budroni, S; Spensieri, F; Borgogni, E; Paccani, SR; Margarit, I; Bagnoli, F; Del Giudice, G; Creech, CB				Leuzzi, Rosanna; Bodini, Margherita; Thomsen, Isaac P.; Soldaini, Elisabetta; Bartolini, Erika; Muzzi, Alessandro; Clemente, Bruna; Galletti, Bruno; Manetti, Andrea Guido Oreste; Giovani, Cinzia; Censini, Stefano; Budroni, Sonia; Spensieri, Fabiana; Borgogni, Erica; Paccani, Silvia Rossi; Margarit, Immaculada; Bagnoli, Fabio; Del Giudice, Giuseppe; Creech, Clarence B.			Dissecting the Human Response to Staphylococcus aureus Systemic Infections	FRONTIERS IN IMMUNOLOGY			English	Article						Staphylococcus aureus; invasive; antibody; cytokines; isolates	ANTIBODY	Staphylococcus aureus is a common human commensal and the leading cause of diverse infections. To identify distinctive parameters associated with infection and colonization, we compared the immune and inflammatory responses of patients with a diagnosis of invasive S. aureus disease to healthy donors. We analyzed the inflammatory responses founding a pattern of distinctive cytokines significantly higher in the patients with invasive disease. The measure of antibody levels revealed a wide antibody responsiveness from all subjects to most of the antigens, with significantly higher response for some antigens in the invasive patients compared to control. Moreover, functional antibodies against toxins distinctively associated with the invasive disease. Finally, we examined the genomic variability of isolates, showing no major differences in genetic distribution compared to a panel of representative strains. Overall, our study shows specific signatures of cytokines and functional antibodies in patients with different primary invasive diseases caused by S. aureus. These data provide insight into human responses towards invasive staphylococcal infections and are important for guiding the identification of novel preventive and therapeutic interventions against S. aureus.	[Leuzzi, Rosanna; Bodini, Margherita; Soldaini, Elisabetta; Bartolini, Erika; Muzzi, Alessandro; Clemente, Bruna; Galletti, Bruno; Manetti, Andrea Guido Oreste; Giovani, Cinzia; Censini, Stefano; Budroni, Sonia; Spensieri, Fabiana; Borgogni, Erica; Paccani, Silvia Rossi; Margarit, Immaculada; Bagnoli, Fabio; Del Giudice, Giuseppe] GSK, Siena, Italy; [Thomsen, Isaac P.; Creech, Clarence B.] Vanderbilt Univ, Med Ctr, Vanderbilt Inst Infect Immunol & Infhammat, Nashville, IN USA	GlaxoSmithKline; Vanderbilt University	Leuzzi, R (corresponding author), GSK, Siena, Italy.	rosanna.x.leuzzi@gsk.com		Thomsen, Isaac/0000-0001-9240-0164				Bagnoli F, 2015, P NATL ACAD SCI USA, V112, P3680, DOI 10.1073/pnas.1424924112; Boyle-Vavra S, 2015, MBIO, V6, DOI 10.1128/mBio.02585-14; Brown AF, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005226; Chantratita N, 2017, CLIN MICROBIOL INFEC, V23, DOI 10.1016/j.cmi.2016.08.028; Colque-Navarro P, 2010, CLIN VACCINE IMMUNOL, V17, P1117, DOI 10.1128/CVI.00506-09; Creech CB, 2009, VACCINE, V28, P256, DOI 10.1016/j.vaccine.2009.09.088; den Reijer PM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053391; Dillen CA, 2018, J CLIN INVEST, V128, P1026, DOI 10.1172/JCI96481; Guimaraes AO, 2019, CLIN INFECT DIS, V68, P1502, DOI 10.1093/cid/ciy739; Hawkins J, 2012, CLIN VACCINE IMMUNOL, V19, P1641, DOI 10.1128/CVI.00354-12; Holtfreter S, 2010, INT J MED MICROBIOL, V300, P176, DOI 10.1016/j.ijmm.2009.10.002; Miller LS, 2020, FEMS MICROBIOL REV, V44, P123, DOI 10.1093/femsre/fuz030; Miller LS, 2011, NAT REV IMMUNOL, V11, P505, DOI 10.1038/nri3010; Minejima E, 2016, CRIT CARE MED, V44, P671, DOI 10.1097/CCM.0000000000001465; Mohamed N, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0208356; Rigat F, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00114; Roghmann M, 2005, J HOSP INFECT, V59, P27, DOI 10.1016/j.jhin.2004.07.014; Sakr A, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.02419; Sharma-Kuinkel BK, 2019, CLIN TRANSL IMMUNOL, V8, DOI 10.1002/cti2.1070; SOMPOLINSKY D, 1985, J CLIN MICROBIOL, V22, P828, DOI 10.1128/JCM.22.5.828-834.1985; Thomsen IP, 2014, INFECT IMMUN, V82, P1234, DOI 10.1128/IAI.01558-13; Turner NA, 2019, NAT REV MICROBIOL, V17, P203, DOI 10.1038/s41579-018-0147-4; van Belkum A, 2009, J INFECT DIS, V199, P1820, DOI 10.1086/599119; Verkaik NJ, 2010, EUR J CLIN MICROBIOL, V29, P509, DOI 10.1007/s10096-010-0888-0; Wood JB, 2019, J PEDIAT INF DIS SOC, V8, P128, DOI 10.1093/jpids/piy017; Yu KOA, 2016, J INFECT DIS, V214, P1638, DOI 10.1093/infdis/jiw441	26	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 8	2021	12								749432	10.3389/fimmu.2021.749432	http://dx.doi.org/10.3389/fimmu.2021.749432			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XB1FN	34819932	gold, Green Published			2022-12-18	WOS:000721080600001
J	Chu, BX; Li, YN; Liu, N; Yuan, LX; Chen, SY; Zhu, YH; Wang, JF				Chu, Bing-Xin; Li, Ya-Nan; Liu, Ning-; Yuan, Lan-Xin; Chen, Shi-Yan; Zhu, Yao-Hong; Wang, Jiu-Feng			Salmonella Infantis Delays the Death of Infected Epithelial Cells to Aggravate Bacterial Load by Intermittent Phosphorylation of Akt With SopB	FRONTIERS IN IMMUNOLOGY			English	Article						Salmonella Infantis; Akt; SopB; apoptosis; pyroptosis; inflammation; host-pathogen interactions	ENTERICA SEROVAR INFANTIS; INDUCED APOPTOSIS; EFFECTOR SOPB; DISSEMINATION; PATHOGENICITY; ACTIVATION; AKT/PKB; PATHWAY; BAX	Salmonella Infantis has emerged as a major clinical pathogen causing gastroenteritis worldwide in recent years. As an intracellular pathogen, Salmonella has evolved to manipulate and benefit from the cell death signaling pathway. In this study, we discovered that S. Infantis inhibited apoptosis of infected Caco-2 cells by phosphorylating Akt. Notably, Akt phosphorylation was observed in a discontinuous manner: immediately 0.5 h after the invasion, then before peak cytosolic replication. Single-cell analysis revealed that the second phase was only induced by cytosolic hyper-replicating bacteria at 3-4 hpi. Next, Akt-mediated apoptosis inhibition was found to be initiated by Salmonella SopB. Furthermore, Akt phosphorylation increased mitochondrial localization of Bcl-2 to prevent Bax oligomerization on the mitochondrial membrane, maintaining the mitochondrial network homeostasis to resist apoptosis. In addition, S. Infantis induced pyroptosis, as evidenced by increased caspase-1 (p10) and GSDMS-N levels. In contrast, cells infected with the Delta SopB strain displayed faster but less severe pyroptosis and had less bacterial load. The results indicated that S. Infantis SopB-mediated Akt phosphorylation delayed pyroptosis, but aggravated its severity. The wild-type strain also caused more severe diarrhea and intestinal inflammatory damage than the Delta SopB strain in mice. These findings revealed that S. Infantis delayed the cells' death by intermittent activation of Akt, allowing sufficient time for replication, thereby causing more severe inflammation.	[Chu, Bing-Xin; Li, Ya-Nan; Liu, Ning-; Yuan, Lan-Xin; Chen, Shi-Yan; Zhu, Yao-Hong; Wang, Jiu-Feng] China Agr Univ, Dept Vet Clin Sci, Coll Vet Med, Beijing, Peoples R China	China Agricultural University	Wang, JF (corresponding author), China Agr Univ, Dept Vet Clin Sci, Coll Vet Med, Beijing, Peoples R China.				National Key~R D Program of China [2017YFD0502200]	National Key~R D Program of China	Funding This work was supported by the National Key R&D Program of China (Project No. 2017YFD0502200).	Aviv G, 2019, J INFECT DIS, V220, P1071, DOI 10.1093/infdis/jiz235; Aviv G, 2014, ENVIRON MICROBIOL, V16, P977, DOI 10.1111/1462-2920.12351; Centers for Disease Control and Prevention [CDC], 2013, NAT SALM SURV ANN RE; Chu BX, 2020, VET RES, V51, DOI 10.1186/s13567-020-00823-8; Crowley SM, 2016, CURR TOP MICROBIOL, V397, P43, DOI 10.1007/978-3-319-41171-2_3; Edlich F, 2011, CELL, V145, P104, DOI 10.1016/j.cell.2011.02.034; European Food Safety Authority, 2019, EFSA J, V17, DOI 10.2903/j.efsa.2019.5598; European Food Safety Authority, 2017, EFSA J, V15, pe04694, DOI 10.2903/j.efsa.2017.4694; European Food Safety Authority . European Centre for Disease Prevention and Control, 2017, EFSA J, V15, DOI [10.2903/j.efsa.2017.5077, DOI 10.2903/J.EFSA.2017.5077]; Finn CE, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006354; Garcia-Gil A, 2018, VIRULENCE, V9, P1390, DOI 10.1080/21505594.2018.1509664; Geiser P, 2021, MBIO, V12, DOI 10.1128/mBio.02684-20; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Hakansson A, 2011, NUTRIENTS, V3, P637, DOI 10.3390/nu3060637; Halestrap AP, 2009, J MOL CELL CARDIOL, V46, P821, DOI 10.1016/j.yjmcc.2009.02.021; Haraga A, 2008, NAT REV MICROBIOL, V6, P53, DOI 10.1038/nrmicro1788; Hauser E, 2012, FOODBORNE PATHOG DIS, V9, P352, DOI 10.1089/fpd.2011.1038; Hu GQ, 2017, MOL IMMUNOL, V90, P280, DOI 10.1016/j.molimm.2017.07.011; Huang J, 2011, AUTOPHAGY, V7, P17, DOI 10.4161/auto.7.1.13840; Karch J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130520; Knodler LA, 2005, J BIOL CHEM, V280, P9058, DOI 10.1074/jbc.M412588200; Knodler LA, 2001, MICROBES INFECT, V3, P1321, DOI 10.1016/S1286-4579(01)01493-9; Knodler LA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084681; Knodler LA, 2010, P NATL ACAD SCI USA, V107, P17733, DOI 10.1073/pnas.1006098107; LaRock DL, 2015, NAT REV MICROBIOL, V13, P191, DOI 10.1038/nrmicro3420; Liang JY, 2003, CELL CYCLE, V2, P339, DOI 10.4161/cc.2.4.433; Malik-Kale P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038732; Martinon F, 2007, CELL DEATH DIFFER, V14, P10, DOI 10.1038/sj.cdd.4402038; Miao EA, 2010, NAT IMMUNOL, V11, P1136, DOI 10.1038/ni.1960; Mikhailov V, 2001, J BIOL CHEM, V276, P18361, DOI 10.1074/jbc.M100655200; Ruan HH, 2016, BIOCHEM BIOPH RES CO, V478, P618, DOI 10.1016/j.bbrc.2016.07.116; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Schwan WR, 2000, INFECT IMMUN, V68, P1005, DOI 10.1128/IAI.68.3.1005-1013.2000; Shahada F, 2010, VET MICROBIOL, V140, P136, DOI 10.1016/j.vetmic.2009.07.007; Shi JJ, 2017, TRENDS BIOCHEM SCI, V42, P245, DOI 10.1016/j.tibs.2016.10.004; Song G, 2005, J CELL MOL MED, V9, P59, DOI 10.1111/j.1582-4934.2005.tb00337.x; Takaya A, 2005, CELL MICROBIOL, V7, P79, DOI 10.1111/j.1462-5822.2004.00435.x; Winter SE, 2010, NATURE, V467, P426, DOI 10.1038/nature09415; Wu SY, 2010, CELL MOL IMMUNOL, V7, P271, DOI 10.1038/cmi.2010.17; Yrlid U, 2000, J EXP MED, V191, P613, DOI 10.1084/jem.191.4.613; Yu HB, 2014, MBIO, V5, DOI 10.1128/mBio.00865-14	41	0	0	2	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 5	2021	12								757909	10.3389/fimmu.2021.757909	http://dx.doi.org/10.3389/fimmu.2021.757909			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XA1SQ	34804044	Green Published, gold			2022-12-18	WOS:000720436300001
J	Liang, HY; Song, H; Zhai, RQ; Song, GF; Li, HY; Ding, XF; Kan, QC; Sun, TW				Liang, Huoyan; Song, Heng; Zhai, Ruiqing; Song, Gaofei; Li, Hongyi; Ding, Xianfei; Kan, Quancheng; Sun, Tongwen			Corticosteroids for Treating Sepsis in Adult Patients: A Systematic Review and Meta-Analysis (vol 12, 709155, 2021)	FRONTIERS IN IMMUNOLOGY			English	Correction						corticosteroids; sepsis; mortality; systematic review; meta-analysis			[Liang, Huoyan; Song, Heng; Song, Gaofei; Li, Hongyi; Ding, Xianfei; Sun, Tongwen] Zhengzhou Univ, Henan Engn Res Ctr Crit Care Med, Henan Key Lab Crit Care Med, Zhengzhou Key Lab Sepsis,Affiliated Hosp 1,Gen IC, Zhengzhou, Peoples R China; [Liang, Huoyan; Song, Heng; Song, Gaofei; Li, Hongyi; Sun, Tongwen] Zhengzhou Univ, Acad Med Sci, Zhengzhou, Peoples R China; [Zhai, Ruiqing] Harbin Med Univ, Coll Bioinformat Sci & Technol, Harbin, Peoples R China; [Kan, Quancheng] Zhengzhou Univ, Dept Pharm, Affiliated Hosp 1, Zhengzhou, Peoples R China	Zhengzhou University; Zhengzhou University; Harbin Medical University; Zhengzhou University	Sun, TW (corresponding author), Zhengzhou Univ, Henan Engn Res Ctr Crit Care Med, Henan Key Lab Crit Care Med, Zhengzhou Key Lab Sepsis,Affiliated Hosp 1,Gen IC, Zhengzhou, Peoples R China.; Sun, TW (corresponding author), Zhengzhou Univ, Acad Med Sci, Zhengzhou, Peoples R China.; Kan, QC (corresponding author), Zhengzhou Univ, Dept Pharm, Affiliated Hosp 1, Zhengzhou, Peoples R China.	kanquancheng@126.com; suntongwen@163.com							0	0	0	6	12	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 5	2021	12								771779	10.3389/fimmu.2021.771779	http://dx.doi.org/10.3389/fimmu.2021.771779			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XA6KV	34804063	gold, Green Published			2022-12-18	WOS:000720754000001
J	Lincez, PJ; Shanina, I; Horwitz, MS				Lincez, Pamela J.; Shanina, Iryna; Horwitz, Marc S.			Changes in MDA5 and TLR3 Sensing of the Same Diabetogenic Virus Result in Different Autoimmune Disease Outcomes	FRONTIERS IN IMMUNOLOGY			English	Article						autoimmunity; diabetes; interferon; MDA5; TLR3; coxsackievirus; interferonopathy	PANCREATIC-ISLETS; INTERFERON-ALPHA; TYPE-1; INFECTIONS; PREVENTS; EXPRESSION	Seemingly redundant in function, melanoma differentiation-associated protein 5 (MDA5) and toll-like receptor- 3 (TLR3) both sense RNA viruses and induce type I interferon (IFN-I). Herein, we demonstrate that changes in sensing of the same virus by MDA5 and TLR3 can lead to distinct signatures of IFN-alpha and IFN-ss resulting in different disease outcomes. Specifically, infection with a diabetogenic islet beta cell-tropic strain of coxsackievirus (CB4) results in diabetes protection under reduced MDA5 signaling conditions while reduced TLR3 function retains diabetes susceptibility. Regulating the induction of IFN-I at the site of virus infection creates a local site of interferonopathy leading to loss of T cell regulation and induction of autoimmune diabetes. We have not demonstrated another way to prevent T1D in the NOD mouse, rather we believe this work has provided compounding evidence for a specific control of IFN-I to drive a myriad of responses ranging from virus clearance to onset of autoimmune diabetes.	[Lincez, Pamela J.] Univ British Columbia, Michael Smith Labs, Vancouver, BC, Canada; [Shanina, Iryna; Horwitz, Marc S.] Univ British Columbia, Life Sci Inst, Dept Microbiol & Immunol, Vancouver, BC, Canada	University of British Columbia; University of British Columbia	Horwitz, MS (corresponding author), Univ British Columbia, Life Sci Inst, Dept Microbiol & Immunol, Vancouver, BC, Canada.	mhorwitz@mail.ubc.com			CIHR Funding Source: Medline	CIHR(Canadian Institutes of Health Research (CIHR))		Blum SI, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8070993; Chehadeh W, 2000, J VIROL, V74, P10153, DOI 10.1128/JVI.74.21.10153-10164.2000; de Beeck AO, 2016, NAT REV ENDOCRINOL, V12, P263, DOI 10.1038/nrendo.2016.30; Devendra D, 2005, DIABETES, V54, P2549, DOI 10.2337/diabetes.54.9.2549; Ferreira RC, 2014, DIABETES, V63, P2538, DOI 10.2337/db13-1777; Flodstrom M, 2002, NAT IMMUNOL, V3, P373, DOI 10.1038/ni771; Horwitz MS, 2002, J CLIN INVEST, V109, P79, DOI 10.1172/JCI200211198; Horwitz MS, 1998, NAT MED, V4, P781, DOI 10.1038/nm0798-781; Lincez PJ, 2015, DIABETES, V64, P2184, DOI 10.2337/db14-1223; Lundberg M, 2016, DIABETES, V65, P3104, DOI 10.2337/db16-0616; Marro BS, 2017, P NATL ACAD SCI USA, V114, P3708, DOI 10.1073/pnas.1700878114; McCartney SA, 2011, J CLIN INVEST, V121, P1497, DOI 10.1172/JCI44005; Mostafavi S, 2016, CELL, V164, P564, DOI 10.1016/j.cell.2015.12.032; Mouat IC, 2017, FRONT ENDOCRINOL, V8, DOI 10.3389/fendo.2017.00238; Poma AM, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8071031; Richardson SJ, 2018, CURR OPIN PHARMACOL, V43, P11, DOI 10.1016/j.coph.2018.07.006; Richardson SJ, 2014, DIABETES, V63, P2203, DOI 10.2337/db14-0510; Richer MJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004127; Rodriguez-Calvo T, 2018, CURR DIABETES REP, V18, DOI 10.1007/s11892-018-1084-3; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; SERREZE DV, 1989, J AUTOIMMUN, V2, P759, DOI 10.1016/0896-8411(89)90003-6; Sobel DO, 1998, J AUTOIMMUN, V11, P343, DOI 10.1006/jaut.1998.0203; Swiecki M, 2011, J LEUKOCYTE BIOL, V90, P691, DOI 10.1189/jlb.0311166; Wang JP, 2010, J VIROL, V84, P254, DOI 10.1128/JVI.00631-09	24	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 5	2021	12								751341	10.3389/fimmu.2021.751341	http://dx.doi.org/10.3389/fimmu.2021.751341			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WZ7QY	34804036	Green Published, gold			2022-12-18	WOS:000720159800001
J	Liu, J; Yin, J				Liu, Juan; Yin, Jia			Immunotherapy With Recombinant Alt a 1 Suppresses Allergic Asthma and Influences T Follicular Cells and Regulatory B Cells in Mice	FRONTIERS IN IMMUNOLOGY			English	Article						Alternaria; recombinant Alt a 1; allergen-specific immunotherapy; allergic asthma; T follicular cells; regulatory B cells	ALTERNARIA-ALTERNATA; HELPER; RHINITIS; SENSITIZATION; PHENOTYPE; DIAGNOSIS; RESPONSES; CHILDREN; ICOS	BackgroundAlternaria is a major source of asthma-inducing allergens. Allergen-specific immunotherapy improves the progression of allergic asthma. The current treatment is based on crude Alternaria extracts. Alt a 1 is the predominant allergen in Alternaria. However, the treatment efficacy of recombinant Alt a 1 (rAlt a 1) in an asthmatic animal model and its influence on Tfh and Breg cells are unknown. ObjectiveTo explore the therapeutic treatment effects of rAlt a 1 on the progress of an asthmatic mouse model and its effect on Tfh and Breg cells. MethodsWe synthesized and purified rAlt a 1. Alternaria-sensitized and challenged mice received subcutaneous immunotherapy (SCIT) with four different rAlt a 1 dosages (5, 50, 100, and 150 mu g) or PBS only. Finally, lung and airway inflammation, mouse mast cell protease 1 (MMCP-1), serum immunoglobulin responses, Tfh and Breg cell levels, and the correlation between asthmatic features (inflammation grades and IL-4 and IL-10 levels) and these two cell types were measured after Alternaria rechallenge. ResultsHigh purity and allergenic potency of rAlt a 1 protein were obtained. Following treatment with four different rAlt a 1 dosages, both lung and airway inflammation ameliorated, including lung pathology, serum MMCP-1 levels, inflammatory cell numbers, and cytokine levels in bronchoalveolar lavage fluid (BALF). Additionally, rAlt a 1-SCIT increased the expression of Alternaria-sIgG1, rAlt a 1-sIgG1, rAlt a 1-sIgG2a, and rAlt a 1-sIgG2b in serum. Moreover, the number and percentage of CXCR5(+)PD-1(+)Tfh cells were increased in the PC control, while they decreased in the rAlt a 1-SCIT groups. Meanwhile, the absolute numbers and proportions of Breg cells were evaluated after administration of rAlt a 1. A positive correlation was observed between CXCR5(+)PD-1(+)Tfh cells and inflammation grades (r = 0.50, p = 0.01), as well as a slightly strong positive relationship with IL-4 (r = 0.55, p = 0.005) and IL-10 (r = 0.58, p = 0.003) levels; Breg cells showed an opposite correlation with the grades of inflammation (r = -0.68, p = 0.0003), along with a negative correlation to IL-4 (r = -0.61, p = 0.001) and IL-10 (r = -0.53, p = 0.008) levels. ConclusionsWe verified that treatment with rAlt a 1 can alleviate asthma progression and further have a regulatory effect on Tfh and Breg cells in an Alternaria-induced asthmatic mouse model.	[Liu, Juan; Yin, Jia] Chinese Acad Med Sci, Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Any, Beijing, Peoples R China; [Liu, Juan; Yin, Jia] Peking Union Med Coll Hosp, Dept Allergy, Beijing Key Lab Precis Med Diag & Treatment Aller, Beijing, Peoples R China; [Liu, Juan; Yin, Jia] Petting Union Med Coll Hosp, Dept Allergy, Natl Clin Res Ctr Dermatol & Immunol Dis, Beijing, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Peking Union Medical College Hospital; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College Hospital	Yin, J (corresponding author), Chinese Acad Med Sci, Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Any, Beijing, Peoples R China.; Yin, J (corresponding author), Peking Union Med Coll Hosp, Dept Allergy, Beijing Key Lab Precis Med Diag & Treatment Aller, Beijing, Peoples R China.; Yin, J (corresponding author), Petting Union Med Coll Hosp, Dept Allergy, Natl Clin Res Ctr Dermatol & Immunol Dis, Beijing, Peoples R China.	doctoryinjia@163.com			CAMS Initiative for Innovative Medicine (CAMS-I2M) [2016-I2M-1-003]; Major National Science and Technology Projects for "Significant New Drugs Creation" [2019ZX09301131]	CAMS Initiative for Innovative Medicine (CAMS-I2M); Major National Science and Technology Projects for "Significant New Drugs Creation"	This study was supported by CAMS Initiative for InnovativeMedicine (CAMS-I2M), Grant/Award Number: 2016-I2M-1-003 and Major National Science and Technology Projects for "Significant New Drugs Creation", Grant/Award Number: 2019ZX09301131.	Akdis M, 2014, J ALLERGY CLIN IMMUN, V133, P621, DOI 10.1016/j.jaci.2013.12.1088; Asturias JA, 2005, J ALLERGY CLIN IMMUN, V115, P1210, DOI 10.1016/j.jaci.2005.02.012; Bernardes EV, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.583418; Boonpiyathad T, 2017, ALLERGY, V72, P407, DOI 10.1111/all.12966; Boonpiyathad T, 2019, J ALLERGY CLIN IMMUN, V143, P1077, DOI 10.1016/j.jaci.2018.10.061; Bozek A, 2017, HUM VACC IMMUNOTHER, V13, P2397, DOI [10.1080/21645515.2017.1334745, 10.1080/21645515.2017.1314404]; Caillaud D, 2018, EUR RESPIR REV, V27, DOI 10.1183/16000617.0137-2017; Caraballo L, 2020, WORLD ALLERGY ORGAN, V13, DOI 10.1016/j.waojou.2020.100118; Chruszcz M, 2012, J ALLERGY CLIN IMMUN, V130, P241, DOI 10.1016/j.jaci.2012.03.047; Crotty S, 2019, IMMUNITY, V50, P1132, DOI 10.1016/j.immuni.2019.04.011; Di Bona D, 2019, CURR OPIN ALLERGY CL, V19, P646, DOI 10.1097/ACI.0000000000000582; Dorofeeva Y, 2021, ALLERGY, V76, P131, DOI 10.1111/all.14300; Finkelman FD, 2007, J ALLERGY CLIN IMMUN, V120, P506, DOI 10.1016/j.jaci.2007.07.033; Gao CE, 2020, AM J TRANSL RES, V12, P4434; Gowthaman U, 2020, J LEUKOCYTE BIOL, V107, P409, DOI 10.1002/JLB.3RI1219-425R; Gowthaman U, 2019, SCIENCE, V365, P883, DOI 10.1126/science.aaw6433; Grimbacher B, 2003, NAT IMMUNOL, V4, P261, DOI 10.1038/ni902; Gueguen C, 2019, ALLERGY, V74, P2223, DOI 10.1111/all.13751; Halonen M, 1997, AM J RESP CRIT CARE, V155, P1356, DOI 10.1164/ajrccm.155.4.9105079; Hesse L, 2018, CLIN EXP ALLERGY, V48, P1035, DOI 10.1111/cea.13169; Hesse L, 2018, ALLERGY, V73, P862, DOI 10.1111/all.13382; Tabar AI, 2019, J ALLERGY CLIN IMMUN, V144, P216, DOI 10.1016/j.jaci.2019.02.029; Iwata Y, 2011, BLOOD, V117, P530, DOI 10.1182/blood-2010-07-294249; Jutel M, 2005, J ALLERGY CLIN IMMUN, V116, P608, DOI 10.1016/j.jaci.2005.06.004; Karnekura R, 2015, CLIN IMMUNOL, V158, P204, DOI 10.1016/j.clim.2015.02.016; Kim AS, 2016, J ALLERGY CLIN IMMUN, V138, P1192, DOI 10.1016/j.jaci.2016.03.017; Kobayashi T, 2017, J ALLERGY CLIN IMMUN, V139, P300, DOI 10.1016/j.jaci.2016.04.021; Lee J, 2018, IMMUNE NETW, V18, DOI 10.4110/in.2018.18.e7; Lehmann S, 2017, THER ADV RESPIR DIS, V11, P30, DOI 10.1177/1753465816680786; Li J, 2019, J IMMUNOL, V203, P31, DOI 10.4049/jimmunol.1801182; Liu J, 2021, ALLERGY ASTHMA IMMUN, V13, P106, DOI 10.4168/aair.2021.13.1.106; Mosges R, 2018, ALLERGY, V73, P1254, DOI 10.1111/all.13392; Pauli G, 2008, J ALLERGY CLIN IMMUN, V122, P951, DOI 10.1016/j.jaci.2008.09.017; Pfaar O, 2019, ALLERGY, V74, P3, DOI 10.1111/all.14077; Postigo I, 2011, CLIN EXP ALLERGY, V41, P443, DOI 10.1111/j.1365-2222.2010.03671.x; Prieto Luis, 2010, Allergy Asthma Clin Immunol, V6, P27, DOI 10.1186/1710-1492-6-27; Rosser EC, 2015, IMMUNITY, V42, P607, DOI 10.1016/j.immuni.2015.04.005; Schulten V, 2018, J ALLERGY CLIN IMMUN, V141, P775, DOI 10.1016/j.jaci.2017.04.032; Shamji MH, 2021, J ALLER CL IMM-PRACT, V9, P1769, DOI 10.1016/j.jaip.2021.03.029; Sharif H, 2021, J ALLERGY CLIN IMMUN, V147, P663, DOI 10.1016/j.jaci.2020.10.035; Sharif H, 2019, J ALLERGY CLIN IMMUN, V144, P738, DOI 10.1016/j.jaci.2019.02.023; Siebeneicher S, 2015, ALLERGY, V70, P1559, DOI 10.1111/all.12732; Song WZ, 2019, IMMUNOL REV, V288, P85, DOI 10.1111/imr.12740; Tham R, 2017, J ALLERGY CLIN IMMUN, V139, P1140, DOI 10.1016/j.jaci.2016.06.046; Twaroch TE, 2015, ALLERGY ASTHMA IMMUN, V7, P205, DOI 10.4168/aair.2015.7.3.205; Uwadiae FI, 2019, ALLERGY, V74, P650, DOI 10.1111/all.13602; van de Veen W, 2017, CURR OPIN ALLERGY CL, V17, P447, DOI 10.1097/ACI.0000000000000400; Wang JR, 2017, INT ARCH ALLERGY IMM, V173, P193, DOI 10.1159/000479429; Weber JP, 2015, J EXP MED, V212, P217, DOI 10.1084/jem.20141432; Yao Y, 2019, J ALLERGY CLIN IMMUN, V144, P118, DOI 10.1016/j.jaci.2019.02.008; Yao Y, 2018, J ALLERGY CLIN IMMUN, V142, P321, DOI 10.1016/j.jaci.2018.03.008; Zhang YL, 2020, MEDIAT INFLAMM, V2020, DOI 10.1155/2020/1719467; Zissler UM, 2018, EBIOMEDICINE, V36, P475, DOI 10.1016/j.ebiom.2018.09.016	53	0	0	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 5	2021	12								747730	10.3389/fimmu.2021.747730	http://dx.doi.org/10.3389/fimmu.2021.747730			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XA8CX	34804031	gold, Green Published			2022-12-18	WOS:000720869600001
J	Tang, XW; Zhou, WJ; Huang, DJ; Chen, LL; Zhang, GW				Tang, Xiaowan; Zhou, Weijun; Huang, Danjiang; Chen, Lili; Zhang, Guangwen			Anti-PD-1 Therapy-A Potential Treatment for Myocardial Metastasis From Nasopharyngeal Carcinoma: A Case Report	FRONTIERS IN IMMUNOLOGY			English	Article						nasopharyngeal carcinoma; head and neck tumor; myocardial metastasis; immunotherapy; anti-PD-1 therapy	ANTITUMOR-ACTIVITY	Myocardial metastasis of nasopharyngeal carcinoma (NPC) is rarely reported in the literature. Some autopsy studies found metastases in more than 10% of cases with malignant neoplasm. However, patients are often diagnosed during the postmortem because myocardial metastasis is often asymptomatic, and its Cardiac complications tend to be severe and fatal. Patients with Cardiac metastases are often treated with chemotherapy or surgical intervention, although the prognosis is poor. Immunotherapy with anti-programmed cell death receptor-1 or ligand-1 (PD-1 or PD-L1) inhibitors has recently been reported to be therapeutically significant in multiple cancers, including melanoma, nonsmall cell lung cancer, and NPC, but the treatment of myocardial metastasis of NPC has not been reported. This study described the case of a 50-year-old male patient who presented initially with NPC and received radiotherapy as first-line therapy. For 20 years, he had recurrent Cardiac metastasis of NPC. The pathological examination suggested tPD-L1 expression. Therefore, off-label sintilimab (200 mg every 21 days) was administered. After 10 cycles of treatment, myocardial metastasis shrank and the enlarged mediastinal lymph nodes disappeared. This case report demonstrated that Cardiac metastasis of NPC expressing PD-L1 might have a sustained response to PD-L1 inhibitor-directed therapy.	[Tang, Xiaowan; Chen, Lili; Zhang, Guangwen] Wenzhou Med Affiliated Huangyan Hosp, Peoples Hosp Taizhou 1, Dept Hematol & Oncol, Taizhou, Peoples R China; [Zhou, Weijun] Wenzhou Med Univ, Clin Med Coll 2, Dept Clin Med, Wenzhou, Peoples R China; [Huang, Danjiang] First Peoples Hosp Taizhou, Div Radiol, Wenzhou Med Affiliated Huangyan Hosp, Taizhou, Peoples R China	Wenzhou Medical University	Zhang, GW (corresponding author), Wenzhou Med Affiliated Huangyan Hosp, Peoples Hosp Taizhou 1, Dept Hematol & Oncol, Taizhou, Peoples R China.	guangwenzhang@live.cn						Al-Mamgani A, 2008, INT J CLIN ONCOL, V13, P369, DOI 10.1007/s10147-007-0749-8; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Chen SW, 2011, KAOHSIUNG J MED SCI, V27, P289, DOI 10.1016/j.kjms.2010.08.005; Chen YP, 2021, MOL CANCER, V20, DOI 10.1186/s12943-020-01292-5; Chen YP, 2020, CELL RES, V30, P1024, DOI 10.1038/s41422-020-0374-x; Chen YP, 2019, LANCET, V394, P64, DOI 10.1016/S0140-6736(19)30956-0; Fang WF, 2018, LANCET ONCOL, V19, P1338, DOI 10.1016/S1470-2045(18)30495-9; GALLERSTEIN PE, 1984, J AM COLL CARDIOL, V3, P865, DOI 10.1016/S0735-1097(84)80266-1; Hsu C, 2017, J CLIN ONCOL, V35, P4050, DOI 10.1200/JCO.2017.73.3675; KLATT EC, 1990, CANCER-AM CANCER SOC, V65, P1456, DOI 10.1002/1097-0142(19900315)65:6<1456::AID-CNCR2820650634>3.0.CO;2-5; Larbcharoensub N, 2018, AM J CLIN ONCOL-CANC, V41, P1204, DOI 10.1097/COC.0000000000000449; LI CP, 1994, AM J OTOLARYNG, V15, P307, DOI 10.1016/0196-0709(94)90102-3; Liu XH, 2020, BIOMARK RES, V8, DOI 10.1186/s40364-020-00250-z; Lv JW, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0636-7; Ma BBY, 2018, J CLIN ONCOL, V36, P1412, DOI 10.1200/JCO.2017.77.0388; Nagata S, 2012, INT J ORAL MAX SURG, V41, P1458, DOI 10.1016/j.ijom.2012.07.017; Reynen K, 2004, ANN ONCOL, V15, P375, DOI 10.1093/annonc/mdh086; Shen X, 2018, BMJ-BRIT MED J, V362, DOI 10.1136/bmj.k3529; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Zhang L, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.594558; Zhu Q, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1312240	21	0	0	0	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 5	2021	12								688682	10.3389/fimmu.2021.688682	http://dx.doi.org/10.3389/fimmu.2021.688682			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WZ7XS	34804001	Green Published, gold			2022-12-18	WOS:000720177500001
J	Zheng, ZF; Aihemaiti, Y; Liu, JQ; Afridi, MI; Yang, SM; Zhang, XM; Xu, YF; Chen, CH; Tu, HJ				Zheng, Zhongfan; Aihemaiti, Yilixiati; Liu, Junqiang; Afridi, Muhammad Irfan; Yang, Shengmei; Zhang, Xiumei; Xu, Yongfu; Chen, Chunhong; Tu, Haijun			The bZIP Transcription Factor ZIP-11 Is Required for the Innate Immune Regulation in Caenorhabditis elegans	FRONTIERS IN IMMUNOLOGY			English	Article						innate immunity; bZIP transcription factor; intestine; ATF4; ZIP-11; PMK-1; p38; CEBP-2	SIGNALING PATHWAY; RESPONSE GENES; BILLION YEARS; BINDING; PROTEIN; EXPRESSION; STRESS; DIMERIZATION; INHIBITION; RESISTANCE	Innate immunity is the first line of host defense against pathogen infection in metazoans. However, the molecular mechanisms of the complex immune regulatory network are not fully understood. Based on a transcriptome profiling of the nematode Caenorhabditis elegans, we found that a bZIP transcription factor ZIP-11 was up-regulated upon Pseudomonas aeruginosa PA14 infection. The tissue specific RNAi knock-down and rescue data revealed that ZIP-11 acts in intestine to promote host resistance against P. aeruginosa PA14 infection. We further showed that intestinal ZIP-11 regulates innate immune response through constituting a feedback loop with the conserved PMK-1/p38 mitogen-activated protein signaling pathway. Intriguingly, ZIP-11 interacts with a CCAAT/enhancer-binding protein, CEBP-2, to mediate the transcriptional response to P. aeruginosa PA14 infection independently of PMK-1/p38 pathway. In addition, human homolog ATF4 can functionally substitute for ZIP-11 in innate immune regulation of C. elegans. Our findings indicate that the ZIP-11/ATF4 genetic program activates local innate immune response through conserved PMK-1/p38 and CEBP-2/C/EBP gamma immune signals in C. elegans, raising the possibility that a similar process may occur in other organisms.	[Zheng, Zhongfan; Aihemaiti, Yilixiati; Liu, Junqiang; Afridi, Muhammad Irfan; Yang, Shengmei; Zhang, Xiumei; Xu, Yongfu; Chen, Chunhong; Tu, Haijun] Hunan Univ, Coll Biol, State Key Lab Chemo Biosensing & Chemometr, Changsha, Peoples R China; [Zheng, Zhongfan; Aihemaiti, Yilixiati; Liu, Junqiang; Afridi, Muhammad Irfan; Yang, Shengmei; Zhang, Xiumei; Xu, Yongfu; Chen, Chunhong; Tu, Haijun] Hunan Univ, Shenzhen Res Inst, Shenzhen, Peoples R China	Hunan University; Hunan University	Tu, HJ (corresponding author), Hunan Univ, Coll Biol, State Key Lab Chemo Biosensing & Chemometr, Changsha, Peoples R China.; Tu, HJ (corresponding author), Hunan Univ, Shenzhen Res Inst, Shenzhen, Peoples R China.	haijuntu@hnu.edu.cn	Afridi, Muhammad irfan/GMX-3316-2022	Afridi, Muhammad Irfan/0000-0001-6652-3056; Zheng, Zhongfan/0000-0002-5975-7855	National Key Research and Development Program of China [2021YFA090164]; National Natural Science Foundation of China [31800857]; Key Project of Research and Development Plan of Hunan Province [2020SK2092]; Provincial Natural Science Foundation of Hunan Province [2021JJ30098]; Foundation of Shenzhen Science and Technology Innovation Committee [JCYJ20210324121000001]	National Key Research and Development Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Key Project of Research and Development Plan of Hunan Province; Provincial Natural Science Foundation of Hunan Province(Natural Science Foundation of Hunan Province); Foundation of Shenzhen Science and Technology Innovation Committee	This work was supported by National Key Research and Development Program of China (2021YFA090164 to HT), the National Natural Science Foundation of China (31800857 to CC), Key Project of Research and Development Plan of Hunan Province (2020SK2092 to HT), Provincial Natural Science Foundation of Hunan Province (2021JJ30098 to HT), the Foundation of Shenzhen Science and Technology Innovation Committee (JCYJ20210324121000001).	Aballay A, 2001, P NATL ACAD SCI USA, V98, P2735, DOI 10.1073/pnas.041613098; Alper S, 2007, MOL CELL BIOL, V27, P5544, DOI 10.1128/MCB.02070-06; Ameri K, 2008, INT J BIOCHEM CELL B, V40, P14, DOI 10.1016/j.biocel.2007.01.020; Amoutzias GD, 2007, MOL BIOL EVOL, V24, P827, DOI 10.1093/molbev/msl211; BRENNER S, 1974, GENETICS, V77, P71; Cao XO, 2016, CURR BIOL, V26, P2329, DOI 10.1016/j.cub.2016.06.036; Chen YW, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00774; Dunbar TL, 2012, CELL HOST MICROBE, V11, P375, DOI 10.1016/j.chom.2012.02.008; Engelmann I, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019055; Estes KA, 2010, P NATL ACAD SCI USA, V107, P2153, DOI 10.1073/pnas.0914643107; Garsin DA, 2003, SCIENCE, V300, P1921, DOI 10.1126/science.1080147; Gibson DG, 2011, METHOD ENZYMOL, V498, P349, DOI 10.1016/B978-0-12-385120-8.00015-2; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; Huggins CJ, 2016, MOL CELL BIOL, V36, P693, DOI 10.1128/MCB.00911-15; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; Kilberg MS, 2012, ADV NUTR, V3, P295, DOI 10.3945/an.112.001891; Kim DH, 2002, SCIENCE, V297, P623, DOI 10.1126/science.1073759; Kyriakis JM, 2012, PHYSIOL REV, V92, P689, DOI 10.1152/physrev.00028.2011; Liang J, 2007, DEV BIOL, V305, P714, DOI 10.1016/j.ydbio.2007.02.038; Liberati NT, 2004, P NATL ACAD SCI USA, V101, P6593, DOI 10.1073/pnas.0308625101; McEwan DL, 2016, BMC BIOL, V14, DOI 10.1186/s12915-016-0334-6; Mukherjee D, 2020, IMMUNOL LETT, V228, P24, DOI 10.1016/j.imlet.2020.09.006; O'Neil DA, 1999, J IMMUNOL, V163, P6718; Okkema Peter G, 2005, WormBook, P1; Ooi JY, 2002, EMBO REP, V3, P82, DOI 10.1093/embo-reports/kvf004; Pellegrino MW, 2014, NATURE, V516, P414, DOI 10.1038/nature13818; Reddy KC, 2016, CELL REP, V14, P1581, DOI 10.1016/j.celrep.2016.01.055; Reinke AW, 2013, SCIENCE, V340, P730, DOI 10.1126/science.1233465; Rodriguez-Martinez JA, 2017, ELIFE, V6, DOI 10.7554/elife.19272.001; Rozpedek W, 2016, CURR MOL MED, V16, P533, DOI 10.2174/1566524016666160523143937; Schmeisser S, 2013, MOL METAB, V2, P92, DOI 10.1016/j.molmet.2013.02.002; Schulenburg H, 2004, IMMUNOL REV, V198, P36, DOI 10.1111/j.0105-2896.2004.0125.x; Shapira M, 2006, P NATL ACAD SCI USA, V103, P14086, DOI 10.1073/pnas.0603424103; Shivers RP, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000892; Smith CJ, 2010, DEV BIOL, V345, P18, DOI 10.1016/j.ydbio.2010.05.502; Sun JR, 2011, SCIENCE, V332, P729, DOI 10.1126/science.1203411; Tan MW, 1999, P NATL ACAD SCI USA, V96, P2408, DOI 10.1073/pnas.96.5.2408; Tang HQ, 2016, CELL REP, V17, P2837, DOI 10.1016/j.celrep.2016.11.038; Timmons L, 1998, NATURE, V395, P854, DOI 10.1038/27579; Troemel ER, 2006, PLOS GENET, V2, P1725, DOI 10.1371/journal.pgen.0020183; Tu HJ, 2015, NEURON, V86, P1407, DOI 10.1016/j.neuron.2015.05.013; van der Hoeven R, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002453; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; Viswanathan M, 2005, DEV CELL, V9, P605, DOI 10.1016/j.devcel.2005.09.017; Zhuang JJ, 2011, GENETICS, V188, P235, DOI 10.1534/genetics.111.127209; Zugasti O, 2009, NAT IMMUNOL, V10, P249, DOI 10.1038/ni.1700	46	0	1	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 5	2021	12								744454	10.3389/fimmu.2021.744454	http://dx.doi.org/10.3389/fimmu.2021.744454			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XA8ER	34804026	gold, Green Published			2022-12-18	WOS:000720874300001
J	Chong, AHW; Mitchell, RE; Hemani, G; Smith, GD; Yolken, RH; Richmond, RC; Paternoster, L				Chong, Amanda H. W.; Mitchell, Ruth E.; Hemani, Gibran; Davey Smith, George; Yolken, Robert H.; Richmond, Rebecca C.; Paternoster, Lavinia			Genetic Analyses of Common Infections in the Avon Longitudinal Study of Parents and Children Cohort	FRONTIERS IN IMMUNOLOGY			English	Article						infection; ALSPAC; genetics; antibody; HLA	GENOME-WIDE ASSOCIATION; EPSTEIN-BARR-VIRUS; HELICOBACTER-PYLORI STRAINS; INFLUENZA VACCINE; RISK; PERSISTENCE; ANTIBODIES; LOCI; MEASLES; ENGLAND	The burden of infections on an individual and public health is profound. Many observational studies have shown a link between infections and the pathogenesis of disease; however a greater understanding of the role of host genetics is essential. Children from the longitudinal birth cohort, the Avon Longitudinal Study of Parents and Children, had 14 antibodies measured in plasma at age 7: Alpha-casein protein, beta-casein protein, cytomegalovirus, Epstein-Barr virus, feline herpes virus, Helicobacter pylori, herpes simplex virus 1, influenza virus subtype H1N1, influenza virus subtype H3N2, measles virus, Saccharomyces cerevisiae, Theiler's virus, Toxoplasma gondii, and SAG1 protein domain, a surface antigen of Toxoplasma gondii measured for greater precision. We performed genome-wide association analyses of antibody levels against these 14 infections (N = 357 - 5010) and identified three genome-wide signals (P < 5x10(-8)), two associated with measles virus antibodies and one with Toxoplasma gondii antibodies. In an association analysis focused on the human leukocyte antigen (HLA) region of the genome, we further detected 15 HLA alleles at a two-digit resolution and 23 HLA alleles at a four-digit resolution associated with five antibodies, with eight HLA alleles associated with Epstein-Barr virus antibodies showing strong evidence of replication in UK Biobank. We discuss how our findings from antibody levels complement other studies using self-reported phenotypes in understanding the architecture of host genetics related to infections.	[Chong, Amanda H. W.; Mitchell, Ruth E.; Hemani, Gibran; Davey Smith, George; Richmond, Rebecca C.; Paternoster, Lavinia] Univ Bristol, Bristol Med Sch, MRC Integrat Epidemiol Unit, Populat Hlth Sci, Bristol, Avon, England; [Yolken, Robert H.] Johns Hopkins Univ, Sch Med, Stanley Div Dev Neurovirol, Baltimore, MD USA	University of Bristol; Johns Hopkins University	Chong, AHW (corresponding author), Univ Bristol, Bristol Med Sch, MRC Integrat Epidemiol Unit, Populat Hlth Sci, Bristol, Avon, England.	a.chong@bristol.ac.uk	Davey Smith, George/A-7407-2013	Davey Smith, George/0000-0002-1407-8314; Richmond, Rebecca/0000-0003-0574-5071; Hemani, Gibran/0000-0003-0920-1055				Albrecht CM, 2014, J CARD FAIL, V20, P105, DOI 10.1016/j.cardfail.2013.12.008; Ascherio A, 2001, JAMA-J AM MED ASSOC, V286, P3083, DOI 10.1001/jama.286.24.3083; Astle WJ, 2016, CELL, V167, P1415, DOI 10.1016/j.cell.2016.10.042; Berndt SI, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10933; Berndt SI, 2013, NAT GENET, V45, P868, DOI 10.1038/ng.2652; Boyd A, 2013, INT J EPIDEMIOL, V42, P111, DOI 10.1093/ije/dys064; Chang CC, 2015, GIGASCIENCE, V4, DOI 10.1186/s13742-015-0047-8; Chen D, 2011, HUM MOL GENET, V20, P4714, DOI 10.1093/hmg/ddr383; Chen X, 2018, HUM MOL GENET, V27, P1809, DOI 10.1093/hmg/ddy094; Covid 19 Host Genetics Initiative, 2020, EUR J HUM GENET, V28, P715, DOI 10.1038/s41431-020-0636-6; Creary LE, 2019, MULT SCLER J, V25, P772, DOI 10.1177/1352458518770019; Davidkin I, 2008, J INFECT DIS, V197, P950, DOI 10.1086/528993; Delaneau O, 2012, NAT METHODS, V9, P179, DOI [10.1038/NMETH.1785, 10.1038/nmeth.1785]; Di Bernardo MC, 2008, NAT GENET, V40, P1204, DOI 10.1038/ng.219; Dickerson FB, 2003, ARCH GEN PSYCHIAT, V60, P466, DOI 10.1001/archpsyc.60.5.466; Dine MS, 2004, J INFECT DIS, V189, pS123, DOI 10.1086/380308; Donaldson LJ, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b5213; Emilsson V, 2018, SCIENCE, V361, P769, DOI 10.1126/science.aaq1327; Felldin M, 2014, TRANSPL INT, V27, P197, DOI 10.1111/tri.12237; Flegr J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090203; Fraser A, 2013, INT J EPIDEMIOL, V42, P97, DOI 10.1093/ije/dys066; GOV.UK, 2020, LAB CONF CAS MEASL R; Gunn M, 2000, HEART, V84, P267, DOI 10.1136/heart.84.3.267; Handel AE, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012496; Health UNIo, 2020, MICH IMP SERV; Herrera V, 2009, CLIN MICROBIOL INFEC, V15, P971, DOI 10.1111/j.1469-0691.2009.03031.x; Hsu JP, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-414; Jia XM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064683; Jonsson S, 2017, NAT GENET, V49, P1182, DOI 10.1038/ng.3897; Kachuri Linda, 2020, medRxiv, DOI [10.1186/s13073-020-00790-x, 10.1101/2020.05.01.20088054]; Kanai M, 2018, NAT GENET, V50, P390, DOI 10.1038/s41588-018-0047-6; Kichaev G, 2019, AM J HUM GENET, V104, P65, DOI 10.1016/j.ajhg.2018.11.008; Kuri A, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-09049-x; Lang HLE, 2002, NAT IMMUNOL, V3, P940, DOI 10.1038/ni835; Law PJ, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14175; LeBaron CW, 2007, ARCH PEDIAT ADOL MED, V161, P294, DOI 10.1001/archpedi.161.3.294; Leung SF, 2006, J CLIN ONCOL, V24, P5414, DOI 10.1200/JCO.2006.07.7982; Levin LI, 2010, ANN NEUROL, V67, P824, DOI 10.1002/ana.21978; Li J, 2005, HEREDITY, V95, P221, DOI 10.1038/sj.hdy.6800717; Li ZH, 2005, IMMUNOGENETICS, V56, P781, DOI 10.1007/s00251-004-0723-9; Looker KJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140765; Mayerle J, 2013, JAMA-J AM MED ASSOC, V309, P1912, DOI 10.1001/jama.2013.4350; McMahon G, 2015, HUM MOL GENET, V24, P5930, DOI 10.1093/hmg/ddv293; Mitchell Ruth E, 2018, Wellcome Open Res, V3, P49, DOI 10.12688/wellcomeopenres.14565.1; Morris MC, 2002, J MED VIROL, V67, P522, DOI 10.1002/jmv.10132; Motyer A., 2016, BIORXIV091009, V1, DOI [10.1101/091009, DOI 10.1101/091009]; Nieto FJ, 1996, CIRCULATION, V94, P922, DOI 10.1161/01.CIR.94.5.922; Nyholt DR, 2004, AM J HUM GENET, V74, P765, DOI 10.1086/383251; Pasceri V, 1998, CIRCULATION, V97, P1675, DOI 10.1161/01.CIR.97.17.1675; Perez-Rodriguez M, 2017, HELICOBACTER, V22, DOI 10.1111/hel.12326; Petrie JG, 2015, J INFECT DIS, V212, P1914, DOI 10.1093/infdis/jiv313; Pohl D, 2006, NEUROLOGY, V67, P2063, DOI 10.1212/01.wnl.0000247665.94088.8d; Polk DB, 2010, NAT REV CANCER, V10, P403, DOI 10.1038/nrc2857; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Rowntree LC, 2020, J IMMUNOL, V205, P1524, DOI 10.4049/jimmunol.2000249; Sawcer S, 2011, NATURE, V476, P214, DOI 10.1038/nature10251; Taylor AE, 2018, INT J EPIDEMIOL, V47, P1207, DOI 10.1093/ije/dyy060; Tengvall K, 2019, P NATL ACAD SCI USA, V116, P16955, DOI 10.1073/pnas.1902623116; Thorball CW, 2021, CURR OPIN IMMUNOL, V72, P119, DOI 10.1016/j.coi.2021.03.017; Tian C, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00257-5; v2 UBNL, UK BIOB NEAL LAB V2; Vuckovic D, 2020, CELL, V182, P1214, DOI 10.1016/j.cell.2020.08.008; Vyse AJ, 2009, EPIDEMIOL INFECT, V137, P526, DOI 10.1017/S0950268808001258; Vyse AJ, 2000, SEX TRANSM INFECT, V76, P183, DOI 10.1136/sti.76.3.183; Whincup PH, 1996, HEART, V75, P568, DOI 10.1136/hrt.75.6.568; Winter JR, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-4578-y; Zamani M, 2018, ALIMENT PHARM THER, V47, P868, DOI 10.1111/apt.14561; Zdimerova H, 2021, EUR J IMMUNOL, V51, P64, DOI 10.1002/eji.202048655	68	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 4	2021	12								727457	10.3389/fimmu.2021.727457	http://dx.doi.org/10.3389/fimmu.2021.727457			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XJ1YA	34804013	Green Published, Green Submitted, gold			2022-12-18	WOS:000726591200001
J	Dong, W; Lei, PF; Liu, X; Li, Q; Cheng, XY				Dong, Wen; Lei, Pengfei; Liu, Xin; Li, Qin; Cheng, Xiangyang			Case Report: Complete Response to Nivolumab in a Patient With Programmed Cell Death 1 Ligand 1-Positive and Multiple Gene-Driven Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma	FRONTIERS IN IMMUNOLOGY			English	Article						lung cancer; EML4-ALK; nivolumab; complete remission; PD-L1	ALK; MUTATIONS; OUTCOMES; PATHWAY; CANCER; EGFR	Multiple gene-driven programmed cell death 1 ligand 1 (PD-L1)-expressing non-small-cell lung cancer (NSCLC) is very rare. Previous studies have shown that patients with NSCLC with anaplastic lymphoma kinase (ALK) gene rearrangement rarely benefit from PD-L1 inhibitors. Besides the secondary mutations in ALK gene, other mechanisms might contribute to tumor resistance to ALK tyrosine kinase inhibitors (ALK-TKIs). Herein, we present a case of PD-L1-overexpressing lung adenocarcinoma that harbors both EML4-ALK gene rearrangement and BRAF mutation. In particular, a second molecular analysis after resistance to first- and second-generation ALK-TKIs revealed a high PD-L1 expression and tumor mutation burden. Therefore, treatment with nivolumab monotherapy, an anti-PD-1 inhibitor, was started and the patient achieved complete remission. This case report suggested that PD-1 inhibitors might be an effective treatment option for patients with multiple gene-driven PD-L1-expressing NSCLC harboring ALK gene rearrangement.	[Dong, Wen] Hainan Canc Hosp, Dept Resp Med, Haikou, Hainan, Peoples R China; [Lei, Pengfei] Yueyang Second Peoples Hosp, Dept Cardiothorac Surg, Yueyang, Peoples R China; [Liu, Xin; Li, Qin] Geneplus Beijing Inst, Dept Med Ctr, Beijing, Peoples R China; [Cheng, Xiangyang] Guangzhou Med Univ, Affiliated Hosp 1, Guangzhou Inst Resp Hlth, State Key Lab Resp Dis,Natl Clin Res Ctr Resp Dis, Guangzhou, Peoples R China	Guangzhou Medical University; State Key Laboratory of Respiratory Disease	Cheng, XY (corresponding author), Guangzhou Med Univ, Affiliated Hosp 1, Guangzhou Inst Resp Hlth, State Key Lab Resp Dis,Natl Clin Res Ctr Resp Dis, Guangzhou, Peoples R China.	xuewu1901@sina.com						Awad Mark M, 2014, Clin Adv Hematol Oncol, V12, P429; Calles Antonio, 2020, Am Soc Clin Oncol Educ Book, V40, P372, DOI 10.1200/EDBK_280795; Doebele RC, 2012, CLIN CANCER RES, V18, P1472, DOI 10.1158/1078-0432.CCR-11-2906; Gainor JF, 2016, CLIN CANCER RES, V22, P4585, DOI 10.1158/1078-0432.CCR-15-3101; Jahanzeb M, 2021, CLIN LUNG CANCER, V22, P49, DOI 10.1016/j.cllc.2020.08.003; Jiang XJ, 2019, MOL CANCER, V18, DOI 10.1186/s12943-018-0928-4; Kang J, 2018, THORAC CANCER, V9, P1093, DOI 10.1111/1759-7714.12791; Mazieres J, 2019, ANN ONCOL, V30, P1321, DOI 10.1093/annonc/mdz167; Oya Y, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21072623; Rangachari D, 2017, J THORAC ONCOL, V12, P878, DOI 10.1016/j.jtho.2016.12.026; Schrank Z, 2018, CANCERS, V10, DOI 10.3390/cancers10070224; Shaw AT, 2014, NEW ENGL J MED, V370, P2537, DOI [10.1056/NEJMoa1311107, 10.1056/NEJMc1404894]; Singal G, 2019, JAMA-J AM MED ASSOC, V321, P1391, DOI 10.1001/jama.2019.3241; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6	14	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 4	2021	12								686057	10.3389/fimmu.2021.686057	http://dx.doi.org/10.3389/fimmu.2021.686057			5	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WZ5ZA	34804000	Green Published, gold			2022-12-18	WOS:000720043700001
J	Martin-Romano, P; Adam, J; Scoazec, JY; Gouy, S; Levy, A; Baldini, C; Champiat, S; Soria, JC; Massard, C; Marabelle, A; Deutsch, E; Hollebecque, A				Martin-Romano, Patricia; Adam, Julien; Scoazec, Jean-Yves; Gouy, Sebastien; Levy, Antonin; Baldini, Capucine; Champiat, Stephane; Soria, Jean-Charles; Massard, Christophe; Marabelle, Aurelien; Deutsch, Eric; Hollebecque, Antoine			Case Report: Response to Immunotherapy, Can Radiotherapy Be a Troublemaker?	FRONTIERS IN IMMUNOLOGY			English	Article						immunotherapy; radiation therapy; tumor response; immune microenvironment; anal squamous cell carcinoma	CARCINOMA	Immunotherapy has dramatically changed the treatment landscape for several tumor types. However, the impact of previous radiotherapy (RT) on response to immunotherapy is still unknown. We report the case of a 58-year-old female diagnosed with a squamous anal cell carcinoma previously treated with RT and having a dissociated response to anti-PD1 agent. An extensive analysis of the immune contexture performed on the tissue collected from both previously RT-treated and RT-untreated lesions confirmed differences on immune microenvironment, highlighting the potential impact of radiotherapy on the immune response.	[Martin-Romano, Patricia; Baldini, Capucine; Champiat, Stephane; Soria, Jean-Charles; Massard, Christophe; Marabelle, Aurelien; Hollebecque, Antoine] Gustave Roussy Canc Campus, Early Drug Dev Dept DITEP, Villejuif, France; [Adam, Julien; Scoazec, Jean-Yves] Gustave Roussy Canc Campus, Dept Pathol, Villejuif, France; [Gouy, Sebastien] Gustave Roussy Canc Campus, Dept Surg, Villejuif, France; [Levy, Antonin; Deutsch, Eric] Gustave Roussy Canc Campus, Dept Radiat Oncol, Villejuif, France; [Soria, Jean-Charles; Deutsch, Eric] Gustave Roussy Canc Campus, Inst Natl Stnte Rech Med INSERM, Villejuif, France; [Soria, Jean-Charles; Deutsch, Eric] Univ Paris Saclay, Univ Paris Sud, Le Kremlin Bicetre, France	UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay	Hollebecque, A (corresponding author), Gustave Roussy Canc Campus, Early Drug Dev Dept DITEP, Villejuif, France.	Antoine.hollebecque@gustaveroussy.fr	Levy, Antonin/U-8791-2019	Levy, Antonin/0000-0003-4798-8899				Balermpas P, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1288331; Bigot F, 2017, EUR J CANCER, V84, P212, DOI 10.1016/j.ejca.2017.07.027; Chiang CS, 2012, FRONT ONCOL, V2, P1, DOI 10.3389/fonc.2012.00089; Govindarajan R, 2018, AM J CLIN ONCOL-CANC, V41, P638, DOI 10.1097/COC.0000000000000343; Gunderson LL, 2013, INT J RADIAT ONCOL, V87, P638, DOI 10.1016/j.ijrobp.2013.07.035; Hu WH, 2015, J SURG ONCOL, V112, P421, DOI 10.1002/jso.23998; Islami F, 2017, INT J EPIDEMIOL, V46, P924, DOI 10.1093/ije/dyw276; Kim S, 2018, LANCET ONCOL, V19, P1094, DOI 10.1016/S1470-2045(18)30321-8; Le DT, 2017, SCIENCE, V357, P409, DOI 10.1126/science.aan6733; Morris VK, 2017, LANCET ONCOL, V18, P446, DOI 10.1016/S1470-2045(17)30104-3; Ott PA, 2017, ANN ONCOL, V28, P1036, DOI 10.1093/annonc/mdx029; Shiels MS, 2015, CANCER EPIDEM BIOMAR, V24, P1548, DOI 10.1158/1055-9965.EPI-15-0044; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; Xu JY, 2013, CANCER RES, V73, P2782, DOI 10.1158/0008-5472.CAN-12-3981; Yachida S, 2010, NATURE, V467, P1114, DOI 10.1038/nature09515	15	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 4	2021	12								745146	10.3389/fimmu.2021.745146	http://dx.doi.org/10.3389/fimmu.2021.745146			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WZ6BZ	34804027	gold, Green Published			2022-12-18	WOS:000720051400001
J	Sanchez-Salguero, E; Corona-Cervantes, K; Guzman-Aquino, HA; de la Borbolla-Cruz, MF; Contreras-Vargas, V; Pina-Escobedo, A; Garcia-Mena, J; Santos-Argumedo, L				Sanchez-Salguero, Erick; Corona-Cervantes, Karina; Guzman-Aquino, Hector Armando; de la Borbolla-Cruz, Maria Fernanda; Contreras-Vargas, Victor; Pina-Escobedo, Alberto; Garcia-Mena, Jaime; Santos-Argumedo, Leopoldo			Maternal IgA2 Recognizes Similar Fractions of Colostrum and Fecal Neonatal Microbiota	FRONTIERS IN IMMUNOLOGY			English	Article						IgA2; IgA1; microbiota; maternal transfer; IgA-seq; colostrum	COMMENSAL BACTERIA; GUT; MILK; ANTIBODY; INNATE; INFANTS; BINDING; MUCUS	Microbiota acquired during labor and through the first days of life contributes to the newborn's immune maturation and development. Mother provides probiotics and prebiotics factors through colostrum and maternal milk to shape the first neonatal microbiota. Previous works have reported that immunoglobulin A (IgA) secreted in colostrum is coating a fraction of maternal microbiota. Thus, to better characterize this IgA-microbiota association, we used flow cytometry coupled with 16S rRNA gene sequencing (IgA-Seq) in human colostrum and neonatal feces. We identified IgA bound bacteria (IgA+) and characterized their diversity and composition shared in colostrum fractions and neonatal fecal bacteria. We found that IgA2 is mainly associated with Bifidobacterium, Pseudomonas, Lactobacillus, and Paracoccus, among other genera shared in colostrum and neonatal fecal samples. We found that metabolic pathways related to epithelial adhesion and carbohydrate consumption are enriched within the IgA2+ fecal microbiota. The association of IgA2 with specific bacteria could be explained because these antibodies recognize common antigens expressed on the surface of these bacterial genera. Our data suggest a preferential targeting of commensal bacteria by IgA2, revealing a possible function of maternal IgA2 in the shaping of the fecal microbial composition in the neonate during the first days of life.	[Sanchez-Salguero, Erick; Guzman-Aquino, Hector Armando; de la Borbolla-Cruz, Maria Fernanda; Santos-Argumedo, Leopoldo] Natl Polytech Inst CINVESTAV IPN, Ctr Res & Adv Studies, Dept Mol Biomed, Mexico City, DF, Mexico; [Corona-Cervantes, Karina; Pina-Escobedo, Alberto; Garcia-Mena, Jaime] Natl Polytech Inst CINVESTAV IPN, Ctr Res & Adv Studies, Dept Genet & Mol Biol, Mexico City, DF, Mexico; [Contreras-Vargas, Victor] Inst Secur & Social Serv State Workers ISSSTE, Reg Hosp October 1, Dept Gynecol, Mexico City, DF, Mexico	CINVESTAV - Centro de Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional; CINVESTAV - Centro de Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional	Santos-Argumedo, L (corresponding author), Natl Polytech Inst CINVESTAV IPN, Ctr Res & Adv Studies, Dept Mol Biomed, Mexico City, DF, Mexico.	lesantos@cinvestav.mx	García-Mena, Jaime/B-1625-2008	García-Mena, Jaime/0000-0002-0595-3711; Sanchez Salguero, Erick Saul/0000-0002-4417-2993; Corona-Cervantes, Karina/0000-0003-1370-9601; Pina-Escobedo, Alberto/0000-0002-9917-8065	Consejo Nacional de Ciencia y Tecnologia (CONACYT)	Consejo Nacional de Ciencia y Tecnologia (CONACYT)(Consejo Nacional de Ciencia y Tecnologia (CONACyT))	Funding This research was supported by grants from Consejo Nacional de Ciencia y Tecnologia (CONACYT), Mexico (PDCPN 2015/900) to LS-A, CONACyT 163235 INFR-2011-01 granted to JGM, and SEP-Cinvestav funding (174) to LS-A and JG-M. ES-S (706312) and KC-C (777953), received a scholarship from CONACYT.	Al Nabhani Z, 2019, IMMUNITY, V50, P1276, DOI 10.1016/j.immuni.2019.02.014; Appleton J, 2018, BMC PEDIATR, V18, DOI 10.1186/s12887-017-0977-7; Bergstrom K, 2020, SCIENCE, V370, P467, DOI 10.1126/science.aay7367; Bode S, 2004, J PEDIATR GASTR NUTR, V39, P378, DOI 10.1097/00005176-200410000-00014; Brandtzaeg P, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00222; Bunker JJ, 2015, IMMUNITY, V43, P541, DOI 10.1016/j.immuni.2015.08.007; Cacho NT, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01470; Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303; Corona-Cervantes K, 2020, PEERJ, V8, DOI 10.7717/peerj.9205; Davis NM, 2018, MICROBIOME, V6, DOI 10.1186/s40168-018-0605-2; de Aguero MG, 2016, SCIENCE, V351, P1296, DOI 10.1126/science.aad2571; de Sousa-Pereira P, 2019, ANTIBODIES, V8, DOI 10.3390/antib8040057; Demers-Mathieu V, 2018, NUTRIENTS, V10, DOI 10.3390/nu10050631; Demmelmair H, 2020, CURR DEV NUTR, V4, DOI 10.1093/cdn/nzaa027; Eisenhofer R, 2019, TRENDS MICROBIOL, V27, P105, DOI 10.1016/j.tim.2018.11.003; Fadlallah J, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aan1217; Fehr K, 2020, CELL HOST MICROBE, V28, P285, DOI 10.1016/j.chom.2020.06.009; Fransen F, 2015, IMMUNITY, V43, P527, DOI 10.1016/j.immuni.2015.08.011; Garcia-Mantrana I, 2020, GUT MICROBES, V11, DOI 10.1080/19490976.2020.1730294; Glassing A, 2016, GUT PATHOG, V8, DOI 10.1186/s13099-016-0103-7; Gonzalez R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080299; Gopalakrishna KP, 2020, NUTRIENTS, V12, DOI 10.3390/nu12030823; Harriman GR, 1999, J IMMUNOL, V162, P2521; He QW, 2020, GUT MICROBES, V12, DOI 10.1080/19490976.2020.1794266; Huus KE, 2021, NAT REV IMMUNOL, V21, P514, DOI 10.1038/s41577-021-00506-1; Huus KE, 2020, CELL HOST MICROBE, V27, P909, DOI 10.1016/j.chom.2020.03.012; Johnson JS, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13036-1; Knights D, 2011, NAT METHODS, V8, P761, DOI 10.1038/nmeth.1650; Knoop KA, 2020, P NATL ACAD SCI USA, V117, P7941, DOI 10.1073/pnas.1912022117; Knoop KA, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aao1314; Kohler A, 2021, GUT, V70, P511, DOI 10.1136/gutjnl-2019-319700; Korpela K, 2020, CELL, V183, P324, DOI 10.1016/j.cell.2020.08.047; Kulkarni DH, 2020, MUCOSAL IMMUNOL, V13, P271, DOI 10.1038/s41385-019-0240-7; LADJEVA I, 1989, CLIN EXP IMMUNOL, V78, P85; Laube R, 2021, EXPERT OPIN DRUG SAF, V20, P275, DOI 10.1080/14740338.2021.1873948; Maier C, 2021, APPL MICROBIOL BIOT, V105, P1693, DOI 10.1007/s00253-021-11109-0; Massacand JC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002588; Maya-Lucas O, 2019, ANAEROBE, V55, P11, DOI 10.1016/j.anaerobe.2018.10.009; Moor K, 2017, NATURE, V544, P498, DOI 10.1038/nature22058; Moossavi S, 2019, CELL HOST MICROBE, V25, P324, DOI 10.1016/j.chom.2019.01.011; Mu QH, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2015691118; Okai S, 2017, GUT MICROBES, V8, P486, DOI 10.1080/19490976.2017.1310357; Pabst O, 2020, MUCOSAL IMMUNOL, V13, P12, DOI 10.1038/s41385-019-0227-4; Palm NW, 2014, CELL, V158, P1000, DOI 10.1016/j.cell.2014.08.006; Parkar SG, 2019, MICROORGANISMS, V7, DOI 10.3390/microorganisms7020041; Patel P, 2016, J IMMUNOL, V197, P4201, DOI 10.4049/jimmunol.1600872; Pokhrel B, 2018, BMC PEDIATR, V18, DOI 10.1186/s12887-018-1176-x; Reboldi A, 2016, SCIENCE, V352, DOI 10.1126/science.aaf4822; Rogier EW, 2014, PATHOGENS, V3, P390, DOI 10.3390/pathogens3020390; Salter SJ, 2014, BMC BIOL, V12, DOI 10.1186/s12915-014-0087-z; Sanchez-Salguero Erick, 2019, Matern Health Neonatol Perinatol, V5, P9, DOI 10.1186/s40748-019-0104-x; Sanchez-Salguero ES, 2020, REV INVEST CLIN, V72, P80, DOI [10.24875/RIC.19003230, 10.24875/ric.19003230]; Sedykh S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21186646; Segata N, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-6-r60; Siiman O, 2001, J COLLOID INTERF SCI, V234, P44, DOI 10.1006/jcis.2000.7279; Sterlin D, 2020, J EXP MED, V217, DOI 10.1084/jem.20181635; Stinson LF, 2019, LETT APPL MICROBIOL, V68, P2, DOI 10.1111/lam.13091; Stinson LF, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01124; Suzuki K, 2010, IMMUNOL REV, V237, P180, DOI 10.1111/j.1600-065X.2010.00941.x; Tanaka M, 2017, ALLERGOL INT, V66, P515, DOI 10.1016/j.alit.2017.07.010; Tang Q, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.00151; Urbaniak C, 2014, APPL ENVIRON MICROB, V80, P3007, DOI 10.1128/AEM.00242-14; Urlaub Doris, 2020, Curr Protoc Immunol, V131, pe111, DOI 10.1002/cpim.111; Wan Y, 2020, GUT MICROBES, V11, P1438, DOI 10.1080/19490976.2020.1760711; Weis AM, 2021, CELL HOST MICROBE, V29, P334, DOI 10.1016/j.chom.2021.02.009; Williams JE, 2019, J NUTR, V149, P902, DOI 10.1093/jn/nxy299; Woof JM, 2011, MUCOSAL IMMUNOL, V4, P590, DOI 10.1038/mi.2011.39; Yang M, 2017, FOOD RES INT, V92, P17, DOI 10.1016/j.foodres.2016.11.041; Young SL, 2011, ADV NUTR, V2, P225, DOI 10.3945/an.110.000224	69	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 4	2021	12								712130	10.3389/fimmu.2021.712130	http://dx.doi.org/10.3389/fimmu.2021.712130			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XC9JX	34804008	gold, Green Published			2022-12-18	WOS:000722328200001
J	Perez-Saez, MJ; Uffing, A; Leon, J; Murakami, N; Watanabe, A; Borges, TJ; Sabbisetti, VS; Cureton, P; Kenyon, V; Keating, L; Yee, K; Satiro, CAF; Serena, G; Hildebrandt, F; Riella, CV; Libermann, TA; Wang, MX; Pascual, J; Bonventre, JV; Cravedi, P; Fasano, A; Riella, LV				Perez-Saez, Maria Jose; Uffing, Audrey; Leon, Juliette; Murakami, Naoka; Watanabe, Andreia; Borges, Thiago J.; Sabbisetti, Venkata S.; Cureton, Pamela; Kenyon, Victoria; Keating, Leigh; Yee, Karen; Fernandes Satiro, Carla Aline; Serena, Gloria; Hildebrandt, Friedhelm; Riella, Cristian V.; Libermann, Towia A.; Wang, Minxian; Pascual, Julio; Bonventre, Joseph V.; Cravedi, Paolo; Fasano, Alessio; Riella, Leonardo V.			Immunological Impact of a Gluten-Free Dairy-Free Diet in Children With Kidney Disease: A Feasibility Study (vol 12, 624821, 2021)	FRONTIERS IN IMMUNOLOGY			English	Correction						steroid resistant nephrotic syndrome; inflammation; diet; gluten-free; dairy-free			[Perez-Saez, Maria Jose; Uffing, Audrey; Leon, Juliette; Murakami, Naoka; Borges, Thiago J.; Sabbisetti, Venkata S.; Bonventre, Joseph V.; Riella, Leonardo V.] Harvard Med Sch, Div Renal, Brigham & Womens Hosp, Boston, MA 02115 USA; [Perez-Saez, Maria Jose; Pascual, Julio] Hosp Mar, Serv Nefrol, Barcelona, Spain; [Watanabe, Andreia] Univ Sao Paulo, Dept Pediat, Pediat Nephrol Unit, Inst Crianca,Hosp Clin,Med Sch USP, Sao Paulo, Brazil; [Borges, Thiago J.; Riella, Leonardo V.] Massachusetts Gen Hosp, Dept Surg, Ctr Transplantat Sci, Boston, MA 02114 USA; [Cureton, Pamela; Kenyon, Victoria; Serena, Gloria; Fasano, Alessio] Harvard Med Sch, Ctr Celiac Res & Treatment, Massachusetts Gen Hosp Children, Boston, MA 02115 USA; [Keating, Leigh] Boston Childrens Hosp, Expt Therapeut Intervent Trials Ctr, Boston, MA USA; [Yee, Karen] Brigham & Womens Hosp, Ctr Clin Invest, 75 Francis St, Boston, MA 02115 USA; [Fernandes Satiro, Carla Aline] Univ Sao Paulo, Div Nutr, Inst Crianca, Hosp Clin,Med Sch, Sao Paulo, Brazil; [Hildebrandt, Friedhelm] Harvard Med Sch, Dept Med, Boston Childrens Hosp, Boston, MA 02115 USA; [Riella, Cristian V.] Harvard Med Sch, Div Renal, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA; [Libermann, Towia A.] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Genom Prote Bioinformat & Syst Biol Ctr, Div Interdisciplinary Med & Biotechnol, Boston, MA 02115 USA; [Wang, Minxian] Broad Inst Massachusetts Inst Technol MIT & Harva, Med & Populat Genet Program, Cambridge, MA USA; [Cravedi, Paolo] Icahn Sch Med Mt Sinai, Div Renal, Dept Med, New York, NY 10029 USA; [Riella, Leonardo V.] Harvard Med Sch, Div Nephrol, Massachusetts Gen Hosp, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; Universidade de Sao Paulo; Universidade Federal de Sao Paulo (UNIFESP); Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard University; Brigham & Women's Hospital; Universidade de Sao Paulo; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Icahn School of Medicine at Mount Sinai; Harvard University; Harvard Medical School; Massachusetts General Hospital	Riella, LV (corresponding author), Harvard Med Sch, Div Renal, Brigham & Womens Hosp, Boston, MA 02115 USA.; Riella, LV (corresponding author), Massachusetts Gen Hosp, Dept Surg, Ctr Transplantat Sci, Boston, MA 02114 USA.; Riella, LV (corresponding author), Harvard Med Sch, Div Nephrol, Massachusetts Gen Hosp, Boston, MA 02115 USA.	lriella@mgh.harvard.edu		Perez-Saez, Maria Jose/0000-0002-8601-2699					0	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 2	2021	12								798560	10.3389/fimmu.2021.798560	http://dx.doi.org/10.3389/fimmu.2021.798560			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WZ1NH	34795679	Green Published, gold			2022-12-18	WOS:000719739500001
J	Siracusano, G; Finardi, A; Pastori, C; Martinelli, V; Furlan, R; Lopalco, L				Siracusano, Gabriel; Finardi, Annamaria; Pastori, Claudia; Martinelli, Vittorio; Furlan, Roberto; Lopalco, Lucia			HIV-1 Env Does Not Enable the Development of Protective Broadly Neutralizing Antibodies in an Experimental Autoimmune Encephalomyelitis Mouse Model	FRONTIERS IN IMMUNOLOGY			English	Article						EAE; HIV-1; Env; bNAbs; tolerance	IMMUNODEFICIENCY-VIRUS-INFECTION; SYSTEMIC-LUPUS-ERYTHEMATOSUS; MULTIPLE-SCLEROSIS; B-CELLS; VACCINE; AUTOREACTIVITY; INFLAMMATION; CYTOKINES; RISK	Recent studies showed that immunological tolerance may restrict the development of Env-specific autoreactive broadly neutralizing antibodies. This evidence is consistent with the finding that Env immunization of a systemic lupus erythematosus (SLE) murine model produced antibodies that neutralize tier 2 HIV-1 strains. In this study, we address the possibility of eliciting neutralizing anti-Env antibodies in other autoimmune diseases such as multiple sclerosis (MS). While, as reported for SLE, we showed for the first time that a small number of HIV-1 negative, relapsing remitting MS patients exhibited antibodies with neutralizing properties, our attempts at inducing those antibodies in a EAE mouse model of MS failed. The success in eliciting Env-specific neutralizing antibodies might be related to the specific characteristics of the autoimmune disease, or it might rely in improving the vaccination design. Studies using mouse models are useful to gain insight in how HIV-specific neutralizing antibody responses are regulated in order to develop a protective HIV-1 vaccine.	[Siracusano, Gabriel; Pastori, Claudia; Lopalco, Lucia] Ist Sci San Raffaele, Div Immunol Transplantat & Infect Dis, Immunobiol HIV, Milan, Italy; [Finardi, Annamaria; Furlan, Roberto] Ist Sci San Raffaele, Inst Expt Neurol INSpe, Div Neurosci, Clin Neuroimmunol Unit, Milan, Italy; [Martinelli, Vittorio] Ist Sci San Raffaele, Neurol Dept, Milan, Italy	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	Siracusano, G (corresponding author), Ist Sci San Raffaele, Div Immunol Transplantat & Infect Dis, Immunobiol HIV, Milan, Italy.	siracusano.gabriel@hsr.it			Fondazione Italiana Sclerosi Multipla FISM [2016/R/15]	Fondazione Italiana Sclerosi Multipla FISM(Fondazione Italiana Sclerosi Multipla (FISM))	Funding This work has been supported by Fondazione Italiana Sclerosi Multipla FISM grant 2016/R/15 to RF.	[Anonymous], IDENTIFICATION AUTOA; BARTHEL HR, 1993, SEMIN ARTHRITIS RHEU, V23, P1, DOI 10.1016/S0049-0172(05)80021-6; Bonsignori M, 2014, J CLIN INVEST, V124, P1835, DOI 10.1172/JCI73441; Burton DR, 2005, P NATL ACAD SCI USA, V102, P14943, DOI 10.1073/pnas.0505126102; Cambier JC, 2007, NAT REV IMMUNOL, V7, P633, DOI 10.1038/nri2133; Carugati M, 2013, CLIN RHEUMATOL, V32, P1399, DOI 10.1007/s10067-013-2271-x; Gold J, 2015, J NEUROL NEUROSUR PS, V86, P9, DOI 10.1136/jnnp-2014-307932; Harris A, 2011, P NATL ACAD SCI USA, V108, P11440, DOI 10.1073/pnas.1101414108; Hauser SL, 2006, NEURON, V52, P61, DOI 10.1016/j.neuron.2006.09.011; Haynes Barton F., 2005, Human Antibodies, V14, P59; Haynes BF, 2005, SCIENCE, V308, P1906, DOI 10.1126/science.1111781; Hoot S, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003106; Karampoor S, 2020, INT IMMUNOPHARMACOL, V78, DOI 10.1016/j.intimp.2019.105943; Kaye BR, 1996, CLIN REV ALLERG IMMU, V14, P385; KION TA, 1991, SCIENCE, V253, P1138, DOI 10.1126/science.1909456; Kong LY, 1996, CELL IMMUNOL, V172, P77, DOI 10.1006/cimm.1996.0217; Koudriavtseva T, 2017, J NEUROVIROL, V23, P147, DOI 10.1007/s13365-016-0471-2; KUCHROO VK, 1993, J IMMUNOL, V151, P4371; Liu MF, 2015, J VIROL, V89, P784, DOI 10.1128/JVI.02378-14; LOMBARDI V, 1993, J INFECT DIS, V167, P1267, DOI 10.1093/infdis/167.6.1267; Mascola JR, 2013, IMMUNOL REV, V254, P225, DOI 10.1111/imr.12075; McGuire AT, 2014, J VIROL, V88, P2645, DOI 10.1128/JVI.03228-13; Merrell KT, 2006, IMMUNITY, V25, P953, DOI 10.1016/j.immuni.2006.10.017; Mylonakis E, 2000, ARCH INTERN MED, V160, P2386, DOI 10.1001/archinte.160.15.2386; Palacios R, 2004, INT J STD AIDS, V15, P277, DOI 10.1258/095646204773557857; Palacios R, 2002, LUPUS, V11, P60, DOI 10.1191/0961203302lu141cr; Park H, 2005, NAT IMMUNOL, V6, P1133, DOI 10.1038/ni1261; Pugh-Bernard AE, 2001, J CLIN INVEST, V108, P1061, DOI 10.1172/JCI200112462; Sarkar S, 2019, VACCINE, V37, P2322, DOI 10.1016/j.vaccine.2019.03.044; Schroeder KMS, 2017, J EXP MED, V214, P2283, DOI 10.1084/jem.20161190; Schroeder KMS, 2017, CURR OPIN IMMUNOL, V47, P26, DOI 10.1016/j.coi.2017.06.004; Skarlis C, 2017, IN VIVO, V31, P1041, DOI 10.21873/invivo.11167; Steichen JM, 2019, SCIENCE, V366, P1216, DOI 10.1126/science.aax4380; Verkoczy L, 2011, CURR OPIN IMMUNOL, V23, P383, DOI 10.1016/j.coi.2011.04.003; Vogel F R, 1995, Pharm Biotechnol, V6, P141; Wang Q, 2020, FRONT MED-PRC, V14, P30, DOI 10.1007/s11684-019-0721-9; Wardemann H, 2003, SCIENCE, V301, P1374, DOI 10.1126/science.1086907; West AP, 2014, CELL, V156, P633, DOI 10.1016/j.cell.2014.01.052; Xiao XD, 2009, BIOCHEM BIOPH RES CO, V390, P404, DOI 10.1016/j.bbrc.2009.09.029	39	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 2	2021	12								771359	10.3389/fimmu.2021.771359	http://dx.doi.org/10.3389/fimmu.2021.771359			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WY8MR	34795677	Green Published, gold			2022-12-18	WOS:000719531900001
J	Vymazal, O; Bendickova, K; De Zuani, M; Vlkova, M; Hortova-Kohoutkova, M; Fric, J				Vymazal, Ondrej; Bendickova, Kamila; De Zuani, Marco; Vlkova, Marcela; Hortova-Kohoutkova, Marcela; Fric, Jan			Immunosuppression Affects Neutrophil Functions: Does Calcineurin-NFAT Signaling Matter?	FRONTIERS IN IMMUNOLOGY			English	Review						immunosuppression; calcineurin inbibitors; neutrophil (PMN) function; sepsis; NFAT signaling; pattern recognition receptor (PRR)	LOW-DENSITY GRANULOCYTES; SUPPRESSOR-CELLS; TRANSCRIPTION FACTOR; GENE-EXPRESSION; INNATE IMMUNITY; ACTIVATION; SEPSIS; RECEPTOR; ASPERGILLUS; RESPONSES	Neutrophils are innate immune cells with important roles in antimicrobial defense. However, impaired or dysregulated neutrophil function can result in host tissue damage, loss of homeostasis, hyperinflammation or pathological immunosuppression. A central link between neutrophil activation and immune outcomes is emerging to be the calcineurin-nuclear factor of activated T cells (NFAT) signaling pathway, which is activated by neutrophil detection of a microbial threat via pattern recognition receptors and results in inflammatory cytokine production. This potent pro-inflammatory pathway is also the target of several immunosuppressive drugs used for the treatment of autoimmune disorders, during solid organ and hematopoietic cell transplantations, and as a part of anti-cancer therapy: but what effects these drugs have on neutrophil function, and their broader consequences for immune homeostasis and microbial defense are not yet known. Here, we bring together the emerging literature describing pathology- and drug- induced neutrophil impairment, with particular focus on their effects on calcineurin-NFAT signaling in the innate immune compartment.	[Vymazal, Ondrej; Bendickova, Kamila; De Zuani, Marco; Hortova-Kohoutkova, Marcela; Fric, Jan] St Annes Univ Hosp, Int Clin Res Ctr, Brno, Czech Republic; [Vymazal, Ondrej] Masaryk Univ, Dept Biol, Fac Med, Brno, Czech Republic; [Vlkova, Marcela] Masaryk Univ, Dept Clin Immunol & Allergol, Fac Med, Brno, Czech Republic; [Vlkova, Marcela] St Annes Univ Hosp, Dept Clin Immunol & Allergol, Brno, Czech Republic; [Fric, Jan] Inst Hematol & Blood Transfus, Dept Modern Immunotherapy, Prague, Czech Republic	St Anne's University Hospital Brno (FNUSA-ICRC); Masaryk University Brno; Masaryk University Brno; St Anne's University Hospital Brno (FNUSA-ICRC); Institute of Hematology Prague	Fric, J (corresponding author), St Annes Univ Hosp, Int Clin Res Ctr, Brno, Czech Republic.; Fric, J (corresponding author), Inst Hematol & Blood Transfus, Dept Modern Immunotherapy, Prague, Czech Republic.	jan.fric@fnusa.cz	De Zuani, Marco/F-5782-2019; Hortova-Kohoutkova, Marcela/AAL-9992-2020; Bendickova, Kamila/D-1544-2017; Frič, Jan/P-7444-2018	De Zuani, Marco/0000-0002-1230-2714; Hortova-Kohoutkova, Marcela/0000-0003-1090-1665; Bendickova, Kamila/0000-0001-7767-1003; Frič, Jan/0000-0001-6642-797X; Vlkova, Marcela/0000-0003-2122-7784				Aarts CEM, 2019, BLOOD ADV, V3, P3562, DOI 10.1182/bloodadvances.2019031609; Adrover JM, 2016, TRENDS IMMUNOL, V37, P334, DOI 10.1016/j.it.2016.03.005; Allen E, 2002, ANN RHEUM DIS, V61, P522, DOI 10.1136/ard.61.6.522; Amulic B, 2012, ANNU REV IMMUNOL, V30, P459, DOI 10.1146/annurev-immunol-020711-074942; Aramburu J, 1999, SCIENCE, V285, P2129, DOI 10.1126/science.285.5436.2129; Azzi JR, 2013, J IMMUNOL, V191, P5785, DOI 10.4049/jimmunol.1390055; Bendickova K, 2020, J LEUKOCYTE BIOL, V107, P497, DOI 10.1002/JLB.4VMA0318-138R; Bendickova K, 2017, EMBO MOL MED, V9, P990, DOI 10.15252/emmm.201707698; Blanco-Camarillo C, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.672520; Boomer JS, 2011, JAMA-J AM MED ASSOC, V306, P2594, DOI 10.1001/jama.2011.1829; Brandau S, 2011, J LEUKOCYTE BIOL, V89, P311, DOI 10.1189/jlb.0310162; Bronte V, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12150; Burn GL, 2021, IMMUNITY, V54, P1377, DOI 10.1016/j.immuni.2021.06.006; Busch R, 2016, EUR J IMMUNOL, V46, P634, DOI 10.1002/eji.201545925; Carmona-Rivera C, 2013, SEMIN IMMUNOPATHOL, V35, P455, DOI 10.1007/s00281-013-0375-7; Casanova-Acebes M, 2013, CELL, V153, P1025, DOI 10.1016/j.cell.2013.04.040; Cassetta L, 2019, CANCER IMMUNOL IMMUN, V68, P687, DOI 10.1007/s00262-019-02302-2; Cloke T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048939; Cunha C, 2014, MYCOPATHOLOGIA, V178, P387, DOI 10.1007/s11046-014-9796-7; Danikas DD, 2008, CLIN EXP IMMUNOL, V154, P87, DOI 10.1111/j.1365-2249.2008.03737.x; Darcy CJ, 2014, CRIT CARE, V18, DOI 10.1186/cc14003; De Zuani M, 2021, EUR J IMMUNOL, V51, P1785, DOI 10.1002/eji.202049141; Demaret J, 2015, J LEUKOCYTE BIOL, V98, P1081, DOI 10.1189/jlb.4A0415-168RR; Deng YT, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153567; Deniset JF, 2018, J LEUKOCYTE BIOL, V103, P829, DOI 10.1002/JLB.3RI0917-361R; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; Erdmann Frank, 2011, Biomol Concepts, V2, P65, DOI 10.1515/bmc.2011.011; Esquerdo KF, 2017, CLIN EXP IMMUNOL, V189, P232, DOI 10.1111/cei.12971; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; FORREST MJ, 1991, BIOCHEM PHARMACOL, V42, P1221, DOI 10.1016/0006-2952(91)90257-6; Fric J, 2012, BLOOD, V120, P1380, DOI 10.1182/blood-2012-02-404475; Fu J, 2014, ANN ALLERG ASTHMA IM, V113, P635, DOI 10.1016/j.anai.2014.08.024; Goodridge HS, 2007, J IMMUNOL, V178, P3107, DOI 10.4049/jimmunol.178.5.3107; Grecian R, 2018, BRIT MED BULL, V128, P5, DOI 10.1093/bmb/ldy029; Greenblatt MB, 2010, J EXP MED, V207, P923, DOI 10.1084/jem.20092531; Grommes J, 2011, MOL MED, V17, P293, DOI 10.2119/molmed.2010.00138; Gupta AK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097088; Hardisty GR, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.625922; Hartmann P, 2004, ANN HEMATOL, V83, P212, DOI 10.1007/s00277-003-0802-2; Herbst S, 2015, EMBO MOL MED, V7, P240, DOI 10.15252/emmm.201404556; Herbst S, 2013, DIS MODEL MECH, V6, P643, DOI 10.1242/dmm.010330; HORL WH, 1989, TRANSPLANTATION, V47, P144, DOI 10.1097/00007890-198901000-00032; Hotchkiss RS, 2013, NAT REV IMMUNOL, V13, P862, DOI 10.1038/nri3552; Im SH, 2004, MOL CELLS, V18, P1; Imbert S, 2016, J ALLERGY CLIN IMMUN, V138, P860, DOI 10.1016/j.jaci.2016.02.026; Janols H, 2014, J LEUKOCYTE BIOL, V96, P685, DOI 10.1189/jlb.5HI0214-074R; Jin ML, 2016, INTEGR BIOL-UK, V8, P968, DOI 10.1039/c6ib00097e; KHARAZMI A, 1985, SCAND J IMMUNOL, V21, P585; Kovach MA, 2012, CURR OPIN INFECT DIS, V25, P321, DOI 10.1097/QCO.0b013e3283528c9b; Kovtun A, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/8173983; Kumagai Y, 2020, J SURG RES, V246, P52, DOI 10.1016/j.jss.2019.08.022; La Manna MP, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02761; Lacy Paige, 2006, Allergy Asthma Clin Immunol, V2, P98, DOI 10.1186/1710-1492-2-3-98; Li YJ, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-3701-4; Lood C, 2016, NAT MED, V22, P146, DOI 10.1038/nm.4027; Marongiu L, 2021, SCI SIGNAL, V14, DOI 10.1126/scisignal.aaz2120; Mathias B, 2017, ANN SURG, V265, P827, DOI 10.1097/SLA.0000000000001783; Mayadas TN, 2014, ANNU REV PATHOL-MECH, V9, P181, DOI 10.1146/annurev-pathol-020712-164023; McKenna E, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.602963; Mishalian I, 2017, IMMUNOBIOLOGY, V222, P82, DOI 10.1016/j.imbio.2016.02.001; MORISAKI T, 1992, SURG TODAY, V22, P322, DOI 10.1007/BF00308740; Morrissey SM, 2021, JCI INSIGHT, V6, DOI 10.1172/jci.insight.148435; Moses K, 2016, SEMIN IMMUNOL, V28, P187, DOI 10.1016/j.smim.2016.03.018; Muller MR, 2010, NAT REV IMMUNOL, V10, P645, DOI 10.1038/nri2818; Nathan C, 2006, NAT REV IMMUNOL, V6, P173, DOI 10.1038/nri1785; Nemeth T, 2020, NAT REV DRUG DISCOV, V19, P253, DOI 10.1038/s41573-019-0054-z; Peiseler M, 2019, J CLIN INVEST, V129, P2629, DOI 10.1172/JCI124616; Pillay J, 2012, J CLIN INVEST, V122, P327, DOI 10.1172/JCI57990; Qin JJ, 2014, BBA-REV CANCER, V1846, P297, DOI 10.1016/j.bbcan.2014.07.009; Rieber N, 2015, CELL HOST MICROBE, V17, P507, DOI 10.1016/j.chom.2015.02.007; Rocha BC, 2015, CELL REP, V13, P2829, DOI 10.1016/j.celrep.2015.11.055; Sagiv JY, 2016, METHODS MOL BIOL, V1458, P179, DOI 10.1007/978-1-4939-3801-8_13; Sagiv JY, 2015, CELL REP, V10, P562, DOI 10.1016/j.celrep.2014.12.039; Santus W, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aan2725; Scapini P, 2000, IMMUNOL REV, V177, P195, DOI 10.1034/j.1600-065X.2000.17706.x; Scapini P, 2016, IMMUNOL REV, V273, P48, DOI 10.1111/imr.12448; SCHAFFNER A, 1982, J CLIN INVEST, V69, P617, DOI 10.1172/JCI110489; Schrijver IT, 2019, FRONT IMMUNOL, V10, DOI [10.3389/fimmu.2019.00327, 10.1155/2014/598654]; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; Shen XF, 2017, J CELL MOL MED, V21, P1687, DOI 10.1111/jcmm.13112; Silvestre-Roig C, 2019, TRENDS IMMUNOL, V40, P565, DOI 10.1016/j.it.2019.04.012; Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287; Soehnlein O, 2017, NAT REV IMMUNOL, V17, P248, DOI 10.1038/nri.2017.10; Sonego F, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00155; Summers C, 2010, TRENDS IMMUNOL, V31, P318, DOI 10.1016/j.it.2010.05.006; Tay S, 2020, ARTHRITIS RHEUMATOL, V72, P1587, DOI 10.1002/art.41395; Tourneur E, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003152; Uhel F, 2017, AM J RESP CRIT CARE, V196, P315, DOI 10.1164/rccm.201606-1143OC; Vandewalle A, 2014, CELL COMMUN SIGNAL, V12, DOI 10.1186/1478-811X-12-8; Vega A, 2007, J CELL SCI, V120, P2328, DOI 10.1242/jcs.000331; Veglia F, 2018, NAT IMMUNOL, V19, P108, DOI 10.1038/s41590-017-0022-x; Venet F, 2018, NAT REV NEPHROL, V14, P121, DOI 10.1038/nrneph.2017.165; Vlkova M, 2019, J IMMUNOL, V202, P93, DOI 10.4049/jimmunol.1800102; Wang J, 2018, CELL TISSUE RES, V371, P531, DOI 10.1007/s00441-017-2785-7; Wang X, 2015, MOL CELL BIOL, V35, P598, DOI 10.1128/MCB.01251-14; Yan PK, 2006, J IMMUNOL, V177, P7050, DOI 10.4049/jimmunol.177.10.7050; Zaidi AK, 2006, IMMUNOLOGY, V119, P412, DOI 10.1111/j.1365-2567.2006.02450.x; Zanoni I, 2012, EUR J IMMUNOL, V42, P1924, DOI 10.1002/eji.201242580; Zanoni I, 2009, NATURE, V460, P264, DOI 10.1038/nature08118; Zelante T, 2017, MUCOSAL IMMUNOL, V10, P470, DOI 10.1038/mi.2016.52; Zhang DC, 2015, NATURE, V525, P528, DOI 10.1038/nature15367; Zhang S, 2015, J LEUKOCYTE BIOL, V97, P997, DOI 10.1189/jlb.4CE1214-616R; Zhang SG, 2015, J LEUKOCYTE BIOL, V97, P1003, DOI 10.1189/jlb.3HI0214-123RR; Zhang XQ, 2004, J LEUKOCYTE BIOL, V75, P358, DOI 10.1189/jlb.0903412	104	0	0	3	9	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 2	2021	12								770515	10.3389/fimmu.2021.770515	http://dx.doi.org/10.3389/fimmu.2021.770515			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WZ0OC	34795676	gold, Green Published			2022-12-18	WOS:000719673100001
J	Zhao, SK; Wu, WZ; Jiang, H; Ma, L; Pan, CY; Jin, C; Mo, JG; Wang, LZ; Wang, KP				Zhao, Shankun; Wu, Weizhou; Jiang, Hao; Ma, Lei; Pan, Chengyi; Jin, Chong; Mo, Jinggang; Wang, Liezhi; Wang, Kunpeng			Selective Inhibitor of the c-Met Receptor Tyrosine Kinase in Advanced Hepatocellular Carcinoma: No Beneficial Effect With the Use of Tivantinib?	FRONTIERS IN IMMUNOLOGY			English	Review						tivantinib; MET inhibitor; hepatocellular carcinoma; therapeutic effect; adverse event	ARQ 197; CYTOTOXIC ACTIVITY; ADULT PATIENTS; EMERGING ROLE; LUNG CANCERS; DOUBLE-BLIND; PHASE-II; SORAFENIB; CABOZANTINIB; ERLOTINIB	Advanced hepatocellular carcinoma (HCC) remains a formidable health challenge worldwide, with a 5-year survival rate of 2.4% in patients with distant metastases. The hepatocyte growth factor/cellular-mesenchymal-epithelial transition (HGF/c-Met) signaling pathway represents an encouraging therapeutic target for progressive HCC. Tivantinib, a non-adenosine triphosphate-competitive c-Met inhibitor, showed an attractive therapeutic effect on advanced HCC patients with high MET-expression in phase 2 study but failed to meet its primary endpoint of prolonging the overall survival (OS) in two phase 3 HCC clinical trials. Seven clinical trials have been registered in the "" for investigating the safety and efficacy of tivantinib in treating advanced or unresectable HCC. Eight relevant studies have been published with results. The sample size ranged from 20 to 340 patients. The methods of tivantinib administration and dosage were orally 120/240/360 mg twice daily. MET overexpression was recorded at 34.6% to 100%. Two large sample phase 3 studies (the METIV-HCC study of Australia and European population and the JET-HCC study of the Japanese population) revealed that tivantinib failed to show survival benefits in advanced HCC. Common adverse events with tivantinib treatment include neutropenia, ascites, rash, and anemia, etc. Several factors may contribute to the inconsistency between the phase 2 and phase 3 studies of tivantinib, including the sample size, drug dosing, study design, and the rate of MET-High. In the future, high selective MET inhibitors combined with a biomarker-driven patient selection may provide a potentially viable therapeutic strategy for patients with advanced HCC.	[Zhao, Shankun] Taizhou Univ Hosp, Taizhou Cent Hosp, Dept Urol, Taizhou, Peoples R China; [Wu, Weizhou] Maoming Peoples Hosp, Dept Urol, Maoming, Peoples R China; [Jiang, Hao; Ma, Lei; Pan, Chengyi; Jin, Chong; Mo, Jinggang; Wang, Liezhi; Wang, Kunpeng] Taizhou Univ Hosp, Taizhou Cent Hosp, Dept Gen Surg, Taizhou, Peoples R China	Taizhou University; Taizhou University	Wang, LZ; Wang, KP (corresponding author), Taizhou Univ Hosp, Taizhou Cent Hosp, Dept Gen Surg, Taizhou, Peoples R China.	wanglz6420@tzzxyy.com; wangkp9644@tzzxyy.com	Wang, Kunpeng/HCH-0099-2022	Wang, Kunpeng/0000-0001-5088-2548	Science and Technology Planning Project of Taizhou City, Zhejiang Province [20ywb40]; High-level Hospital Construction Research Project of Maoming People's Hospital; Zhejiang Province Public Welfare Technology Application Research Project [LGF21H160022]; Taizhou Social Development Science and Technology Plan Project [21ywb26, 21ywb29]; Zhejiang Medical and Health Science and Technology Program [2017KY711, 2022RC297]; Natural Science Foundation of Zhejiang Province [Q22H044253]	Science and Technology Planning Project of Taizhou City, Zhejiang Province; High-level Hospital Construction Research Project of Maoming People's Hospital; Zhejiang Province Public Welfare Technology Application Research Project; Taizhou Social Development Science and Technology Plan Project; Zhejiang Medical and Health Science and Technology Program; Natural Science Foundation of Zhejiang Province(Natural Science Foundation of Zhejiang Province)	This work was supported by the grants from Science and Technology Planning Project of Taizhou City, Zhejiang Province (ID: 20ywb40); the High-level Hospital Construction Research Project of Maoming People's Hospital; the Zhejiang Province Public Welfare Technology Application Research Project (No. LGF21H160022), Taizhou Social Development Science and Technology Plan Project (No. 21ywb26 and 21ywb29), Zhejiang Medical and Health Science and Technology Program (No. 2017KY711 and No. 2022RC297) and Natural Science Foundation of Zhejiang Province (No. Q22H044253).	Abou-Alfa GK, 2018, NEW ENGL J MED, V379, P54, DOI 10.1056/NEJMoa1717002; Agwa ES, 2014, CANCER MANAG RES, V6, P397, DOI 10.2147/CMAR.S37345; Asaoka Y, 2020, ONCOLOGY-BASEL, V98, P186, DOI 10.1159/000504806; Au J, 2013, J CLIN TRANSL HEPATO, V1, P75, DOI 10.14218/JCTH.2013.00008; Ayoub NM, 2021, MED ONCOL, V38, DOI 10.1007/s12032-021-01458-1; Basilico C, 2013, CLIN CANCER RES, V19, P2381, DOI 10.1158/1078-0432.CCR-12-3459; Best J, 2017, EXPERT OPIN PHARMACO, V18, P727, DOI 10.1080/14656566.2017.1316376; Bruix J, 2017, LANCET, V389, P56, DOI 10.1016/S0140-6736(16)32453-9; Buttigliero C, 2019, ONCOLOGIST, V24, pE251, DOI 10.1634/theoncologist.2018-0089; Calles A, 2015, MOL ONCOL, V9, P260, DOI 10.1016/j.molonc.2014.08.011; Caremoli ER, 2014, EXPERT OPIN INV DRUG, V23, P1563, DOI 10.1517/13543784.2014.949339; Cecchi F, 2012, EXPERT OPIN THER TAR, V16, P553, DOI 10.1517/14728222.2012.680957; Dang H, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1166-4; Eathiraj S, 2011, J BIOL CHEM, V286, P20666, DOI 10.1074/jbc.M110.213801; El-Khoueiry AB, 2021, CANCER TREAT REV, V98, DOI 10.1016/j.ctrv.2021.102221; Faivre S, 2020, J HEPATOL, V72, P342, DOI 10.1016/j.jhep.2019.09.010; Finn RS, 2020, NEW ENGL J MED, V382, P1894, DOI 10.1056/NEJMoa1915745; Fu JJ, 2021, ONCOGENE, V40, P4625, DOI 10.1038/s41388-021-01863-w; Gao XD, 2019, ONCOTARGETS THER, V12, P1629, DOI 10.2147/OTT.S196713; Gherardi E, 2012, NAT REV CANCER, V12, P89, DOI 10.1038/nrc3205; Gibney GT, 2013, ANN ONCOL, V24, P343, DOI 10.1093/annonc/mds463; Goyal L, 2013, CLIN CANCER RES, V19, P2310, DOI 10.1158/1078-0432.CCR-12-2791; Guo RB, 2020, NAT REV CLIN ONCOL, V17, P569, DOI 10.1038/s41571-020-0377-z; Hu CT, 2017, CANCERS, V9, DOI 10.3390/cancers9060058; Imura Y, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-185; Iscan E, 2017, J CELL COMMUN SIGNAL, V11, P155, DOI 10.1007/s12079-016-0368-0; Jeon HM, 2017, ANN TRANSL MED, V5, DOI 10.21037/atm.2016.12.67; Kang YK, 2014, INVEST NEW DRUG, V32, P355, DOI 10.1007/s10637-013-0057-2; Katayama R, 2013, CANCER RES, V73, P3087, DOI 10.1158/0008-5472.CAN-12-3256; Kim JH, 2017, ONCOTARGET, V8, P73098, DOI 10.18632/oncotarget.20392; Kobayashi K, 2020, BIOL PHARM BULL, V43, P1421, DOI 10.1248/bpb.b19-01100; Kochanny SE, 2020, CANCER-AM CANCER SOC, V126, P2146, DOI 10.1002/cncr.32762; Koeppen H, 2014, CLIN CANCER RES, V20, P4488, DOI 10.1158/1078-0432.CCR-13-1836; Kong LR, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15318-5; Kudo M, 2020, CANCER SCI, V111, P3759, DOI 10.1111/cas.14582; Li H, 2019, GASTROENTEROLOGY, V156, P1849, DOI 10.1053/j.gastro.2019.01.252; Llovet JM, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572-020-00240-3; Llovet JM, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.18, 10.1038/nrdp.2016.19]; Lu S, 2015, ONCOTARGET, V6, P22167, DOI 10.18632/oncotarget.4240; Ma PC, 2003, CANCER METAST REV, V22, P309, DOI 10.1023/A:1023768811842; Moosavi F, 2021, CRIT REV ONCOL HEMAT, V160, DOI 10.1016/j.critrevonc.2021.103234; Munshi N, 2010, MOL CANCER THER, V9, P1544, DOI 10.1158/1535-7163.MCT-09-1173; Noriega-Guerra H, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113300; Okusaka T, 2015, CANCER SCI, V106, P611, DOI 10.1111/cas.12644; Peters S, 2012, NAT REV CLIN ONCOL, V9, P314, DOI 10.1038/nrclinonc.2012.71; Porta C, 2015, EXPERT REV ANTICANC, V15, P615, DOI 10.1586/14737140.2015.1050383; Previdi S, 2012, MOL CANCER THER, V11, P214, DOI 10.1158/1535-7163.MCT-11-0277; Puzanov I, 2015, INVEST NEW DRUG, V33, P159, DOI 10.1007/s10637-014-0167-5; Pyo JS, 2016, PATHOL RES PRACT, V212, P710, DOI 10.1016/j.prp.2016.05.006; Qi XS, 2015, WORLD J GASTROENTERO, V21, P5445, DOI 10.3748/wjg.v21.i18.5445; Rashed WM, 2021, J CANCER RES CLIN, V147, P167, DOI 10.1007/s00432-020-03395-4; Rebouissou S, 2017, CLIN CANCER RES, V23, P4364, DOI 10.1158/1078-0432.CCR-16-3118; Rimassa L, 2019, CLIN COLORECTAL CANC, V18, P125, DOI 10.1016/j.clcc.2019.02.004; Rimassa L, 2018, LANCET ONCOL, V19, P682, DOI 10.1016/S1470-2045(18)30146-3; Rimassa L, 2016, ONCOTARGET, V7, P72622, DOI 10.18632/oncotarget.11621; Rimassa L, 2014, HEPAT ONCOL, V1, P181, DOI [10.2217/hep.14.3, 10.2217/HEP.14.3]; Rimassa L, 2013, FUTURE ONCOL, V9, P153, DOI [10.2217/FON.12.188, 10.2217/fon.12.188]; Santoro A, 2013, BRIT J CANCER, V108, P21, DOI 10.1038/bjc.2012.556; Santoro A, 2013, LANCET ONCOL, V14, P55, DOI 10.1016/S1470-2045(12)70490-4; Scagliotti G, 2015, J CLIN ONCOL, V33, P2667, DOI 10.1200/JCO.2014.60.7317; Scagliotti GV, 2018, J THORAC ONCOL, V13, P849, DOI 10.1016/j.jtho.2017.12.009; Scagliotti GV, 2013, CANCER TREAT REV, V39, P793, DOI 10.1016/j.ctrv.2013.02.001; Schlumberger M, 2017, ANN ONCOL, V28, P2813, DOI 10.1093/annonc/mdx479; Shaw AT, 2013, NEW ENGL J MED, V368, P2385, DOI 10.1056/NEJMoa1214886; Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660; Teufel M, 2019, GASTROENTEROLOGY, V156, P1731, DOI 10.1053/j.gastro.2019.01.261; Trojan J, 2020, DRUGS, V80, P1203, DOI 10.1007/s40265-020-01361-5; Trojan J, 2013, EXPERT OPIN INV DRUG, V22, P141, DOI 10.1517/13543784.2013.741586; Vogel A, 2021, LANCET GASTROENTEROL, V6, P649, DOI 10.1016/S2468-1253(21)00110-2; Wang HY, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00055; Weekes CD, 2018, LANCET ONCOL, V19, P591, DOI 10.1016/S1470-2045(18)30249-3; Wong JSL, 2021, CANCERS, V13, DOI 10.3390/cancers13092002; Woo HY, 2017, EXPERT OPIN PHARMACO, V18, P35, DOI 10.1080/14656566.2016.1261825; Xiang QF, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0238-2; Xu L, 2012, CANCER RES, V72, P3302, DOI 10.1158/0008-5472.CAN-11-3720; Yan SC, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0296-y; Yu JQ, 2021, MED RES REV, V41, P507, DOI 10.1002/med.21738; Zhang YR, 2020, CANCER RES, V80, P30, DOI 10.1158/0008-5472.CAN-19-1389; Zhang YW, 2003, P NATL ACAD SCI USA, V100, P12718, DOI 10.1073/pnas.2135113100; Zhu AX, 2019, LANCET ONCOL, V20, P282, DOI 10.1016/S1470-2045(18)30937-9; Zhu M, 2015, BRIT J CANCER, V112, P429, DOI 10.1038/bjc.2014.649	81	0	0	2	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 2	2021	12								731527	10.3389/fimmu.2021.731527	http://dx.doi.org/10.3389/fimmu.2021.731527			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XE1ZR	34804015	gold, Green Published			2022-12-18	WOS:000723194300001
J	Nurarifah, N; Brahmantyo, HP; Wardhani, SO; Hermanto, DH; Arsana, PM				Nurarifah, Nina; Brahmantyo, Herwindo Pudjo; Wardhani, Shinta Oktya; Hermanto, Djoko Heri; Arsana, Putu Moda			Case Report: Serial Cases: Prolongation of High Immunoglobulin G Level in Repetitive COVID-19 Convalescence Plasma Donor in Saiful Anwar Hospital Malang, Indonesia	FRONTIERS IN IMMUNOLOGY			English	Article						Convalescent plasma; repetitive donor; COVID-19; immunoglobulin G; antibody	PLASMAPHERESIS; COMPLICATIONS; DISEASE	BackgroundConvalescent plasma therapy is expected to be a promising alternative to supportive therapy during the SARS-CoV-2 pandemic outbreak. Altered immune response in repetitive convalescent plasma donors has not been widely studied. This case series was reported to analyze the patterns of immune responses and the factors that might influence them in repetitive convalescent plasma donors and increase awareness of COVID-19 survivors to donate their convalescent plasma. Cases IllustrationThere were five repetitive donors who were eligible as convalescent plasma donor requirements. It was found two donors who showed increment of anti-SARS-CoV-2 IgG level after donation and two others who showed persistent anti-SARS-CoV-2 IgG level more than two months after recovered. DiscussionThere was a difference in immune response in survivors who have the probability of being exposed to same antigens with survivors who did not, where the group of survivors who are at risk of exposure to antigens after recovery could trigger anamnestic immune response that can increase antiSARS-CoV-2 IgG levels. The other factor that influence the prolongation of anti-SARS-CoV-2 IgG levels are the possibility of neutralizing antibodies in plasma upregulation. ConclusionImmunological phenomenon in SARS-CoV-2, both in survivors and convalescent plasma donors, have not been widely observed and studied. From the case series discussed above, it can be concluded that convalescent plasma donation does not yet have strong evidence of decreasing levels of specific antibodies against SARS-CoV-2 and plasmapheresis procedure is safe to be done without reducing the protective effect of donor antibody post-plasma donation.	[Nurarifah, Nina; Brahmantyo, Herwindo Pudjo; Wardhani, Shinta Oktya; Hermanto, Djoko Heri] Dr Saiful Anwar Hosp, Dept Internal Med, Hematol & Med Oncol Div, Malang, Indonesia; [Arsana, Putu Moda] Dr Saiful Anwar Hosp, Dept Internal Med, Endocrine Metabolid & Diabet Div, Malang, Indonesia		Nurarifah, N (corresponding author), Dr Saiful Anwar Hosp, Dept Internal Med, Hematol & Med Oncol Div, Malang, Indonesia.	ninanur@ub.ac.id						Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026; Casadevall A, 2004, NAT REV MICROBIOL, V2, P695, DOI 10.1038/nrmicro974; Casadevall A, 2020, J CLIN INVEST, V130, P1545, DOI 10.1172/JCI138003; Chen YX, 2020, J INFECTION, V81, P420, DOI 10.1016/j.jinf.2020.05.067; CISZEWSKI TS, 1993, TRANSFUSION MED, V3, P59, DOI 10.1111/j.1365-3148.1993.tb00105.x; Gudbjartsson DF, 2020, NEW ENGL J MED, V383, P1724, DOI 10.1056/NEJMoa2026116; Kaiser G., 2020, MICROBIOLOGY; Klein S, 2020, J CLIN INVEST, V130, P6141, DOI 10.1172/JCI142004; Lewis SL, 1997, TRANSFUS SCI, V18, P205; Li G, 2020, J MED VIROL, V92, P424, DOI 10.1002/jmv.25685; Li L, 2020, TRANSFUSION, V60, P1765, DOI 10.1111/trf.15918; Ma H, 2020, CELL MOL IMMUNOL, V17, P773, DOI 10.1038/s41423-020-0474-z; Rojas M, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102554; Salazar E, 2020, AM J PATHOL, V190, P2290, DOI 10.1016/j.ajpath.2020.08.001; Soo YOY, 2004, CLIN MICROBIOL INFEC, V10, P676, DOI 10.1111/j.1469-0691.2004.00956.x; Szczeklik W, 2013, ANAESTH INTENSIVE TH, V45, P7, DOI 10.5603/AIT.2013.0002; van Griensven J, 2016, NEW ENGL J MED, V374, P33, DOI 10.1056/NEJMoa1511812; WASI S, 1991, VOX SANG, V60, P82, DOI 10.1111/j.1423-0410.1991.tb00879.x; Winters JL, 2006, J CLIN APHERESIS, V21, P132, DOI 10.1002/jca.20039	19	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 1	2021	12								633323	10.3389/fimmu.2021.633323	http://dx.doi.org/10.3389/fimmu.2021.633323			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WZ9AS	34790190	gold, Green Published			2022-12-18	WOS:000720253000001
J	Tiburcio, R; Melo, LD; Nunes, S; Barbosa, ALA; de Oliveira, EC; Suarez, M; Borges, VM; Tavares, N; Brodskyn, CI				Tiburcio, Rafael; Melo, Leon Dimitri; Nunes, Sara; Augusto Barbosa, Ana Luisa; de Oliveira, Elaine Carvalho; Suarez, Martha; Borges, Valeria M.; Tavares, Natalia; Brodskyn, Claudia Ida			DC-SIGN Mediates the Interaction Between Neutrophils and Leishmania amazonensis-Infected Dendritic Cells to Promote DC Maturation and Parasite Elimination	FRONTIERS IN IMMUNOLOGY			English	Article						leishmaniasis; polymorphonuclear cells; monocyte-derived dendritic cells; DC-SIGN; DC maturation markers	MACROPHAGES; EXPRESSION	BackgroundLeishmaniasis is a neglected arthropod-borne disease that affects millions of people worldwide. Successful Leishmania infections require the mitigation of immune cell functions leading to parasite survival and proliferation. A large body of evidence highlights the involvement of neutrophils (PMNs) and dendritic cells (DCs) in the establishment of immunological responses against these parasites. However, few studies, contemplate to what extent these cells interact synergistically to constrain Leishmania infection. ObjectiveWe sought to investigate how PMNs and infected DCs interact in an in vitro model of Leishmania amazonensis infection. Material and MethodsBriefly, human PMNs and DCs were purified from the peripheral blood of healthy donors. Next, PMNs were activated with fibronectin and subsequently co-cultured with L. amazonensis-infected DCs. ResultsWe observed that L. amazonensis-infected DC exhibited lower rates of infection when co-cultivated with either resting or activated PMNs. Surprisingly, we found that the release of neutrophil enzymes was not involved in Leishmania killing. Next, we showed that the interaction between PMNs and infected-DCs was intermediated by DC-SIGN, further suggesting that parasite elimination occurs in a contact-dependent manner. Furthermore, we also observed that TNF alpha and ROS production was dependent on DC-SIGN-mediated contact, as well as parasite elimination is dependent on TNF alpha production in the co-culture. Finally, we observed that direct contact between PMNs and DCs are required to restore the expression of DC maturation molecules during L. amazonensis infection. ConclusionOur findings suggest that the engagement of direct contact between PMNs and L. amazonensis-infected DC via DC-SIGN is required for the production of inflammatory mediators with subsequent parasite elimination and DC maturation.	[Tiburcio, Rafael; Melo, Leon Dimitri; Nunes, Sara; Augusto Barbosa, Ana Luisa; de Oliveira, Elaine Carvalho; Suarez, Martha; Borges, Valeria M.; Tavares, Natalia; Brodskyn, Claudia Ida] Fundacao Oswaldo Cruz, Inst Goncalo Moniz, Salvador, BA, Brazil; [Tiburcio, Rafael; Nunes, Sara; de Oliveira, Elaine Carvalho; Suarez, Martha; Borges, Valeria M.; Tavares, Natalia; Brodskyn, Claudia Ida] Univ Fed Bahia, Fac Med Bahia, Salvador, BA, Brazil; [Melo, Leon Dimitri; Brodskyn, Claudia Ida] Inst Natl Ciencia & Tecnol III INCT, Inst Invest Imunol, Sao Paulo, Brazil	Fundacao Oswaldo Cruz; Universidade Federal da Bahia	Brodskyn, CI (corresponding author), Fundacao Oswaldo Cruz, Inst Goncalo Moniz, Salvador, BA, Brazil.; Brodskyn, CI (corresponding author), Univ Fed Bahia, Fac Med Bahia, Salvador, BA, Brazil.; Brodskyn, CI (corresponding author), Inst Natl Ciencia & Tecnol III INCT, Inst Invest Imunol, Sao Paulo, Brazil.	brodskyn@bahia.fiocruz.br	Nunes, Sara/GVS-8426-2022; Borges, Valeria/G-2009-2014	Nunes, Sara/0000-0003-4795-6061; 	National Council of Research (CNPqUniversal) [476926/2011-4, FAPESB APP0108/2016]	National Council of Research (CNPqUniversal)	This work was supported by the National Council of Research (CNPqUniversal) grants 476926/2011-4 for CB and FAPESB APP0108/2016 for VMB. VMB and CB are senior investigators from CNPq. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Afonso L, 2008, J LEUKOCYTE BIOL, V84, P389, DOI 10.1189/jlb.0108018; Allenbach C, 2006, J IMMUNOL, V176, P6656, DOI 10.4049/jimmunol.176.11.6656; Alvar J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035671; Amato VS, 2008, ACTA TROP, V105, P1, DOI 10.1016/j.actatropica.2007.08.003; Nicolas-Avila JA, 2017, IMMUNITY, V46, P15, DOI 10.1016/j.immuni.2016.12.012; Blanco P, 2008, CYTOKINE GROWTH F R, V19, P41, DOI 10.1016/j.cytogfr.2007.10.004; Carneiro PP, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148084; Ceccaldi PE, 2006, J VIROL, V80, P4771, DOI 10.1128/JVI.80.10.4771-4780.2006; Contreras I, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003202; de Oliveira CI, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00145; Desjeux P, 2004, COMP IMMUNOL MICROB, V27, P305, DOI 10.1016/j.cimid.2004.03.004; Favali C, 2007, J LEUKOCYTE BIOL, V82, P1401, DOI 10.1189/jlb.0307187; Figueiredo AB, 2012, EUR J IMMUNOL, V42, P1203, DOI 10.1002/eji.201141926; Gatto M, 2013, REV SOC BRAS MED TRO, V46, P735, DOI 10.1590/0037-8682-0198-2013; Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7; Geijtenbeek TBH, 2009, FUTURE MICROBIOL, V4, P879, DOI 10.2217/FMB.09.51; Holbrook Jonathan, 2019, F1000Res, V8, DOI 10.12688/f1000research.17023.1; Hovius JWR, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.0040031; Ives A, 2011, SCIENCE, V331, P775, DOI 10.1126/science.1199326; Jebbari H, 2002, INFECT IMMUN, V70, P1023, DOI 10.1128/IAI.70.2.1023-1026.2002; Kaye P, 2011, NAT REV MICROBIOL, V9, P604, DOI 10.1038/nrmicro2608; Koppel EA, 2005, IMMUNOBIOLOGY, V210, P203, DOI 10.1016/j.imbio.2005.05.014; Ludwig IS, 2006, CURR OPIN PHARMACOL, V6, P408, DOI 10.1016/j.coph.2006.03.009; Moll H, 2000, ADV EXP MED BIOL, V479, P163; Pinheiro NF, 2006, INFECT IMMUN, V74, P3912, DOI 10.1128/IAI.02103-05; Ribeiro-Gomes FL, 2012, FRONT CELL INFECT MI, V2, DOI 10.3389/fcimb.2012.00059; Roma EH, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1472-y; Rosales C, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00113; Scott P, 2016, NAT REV IMMUNOL, V16, P581, DOI 10.1038/nri.2016.72; Tavares N, 2016, J IMMUNOL, V196, P1865, DOI 10.4049/jimmunol.1502224; Thepaut M, 2021, PLOS PATHOG, V17, DOI 10.1371/journal.ppat.1009576; Thery C, 2001, CURR OPIN IMMUNOL, V13, P45, DOI 10.1016/S0952-7915(00)00180-1; Tiburcio R, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00227; van Gisbergen KPJM, 2005, J EXP MED, V201, P1281, DOI 10.1084/jem.20041276; WHO, 2010, WHO TECH REP SER, V949, P1; Yin XY, 2021, ANNU REV IMMUNOL, V39, P759, DOI 10.1146/annurev-immunol-101819-025146	36	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 1	2021	12								750648	10.3389/fimmu.2021.750648	http://dx.doi.org/10.3389/fimmu.2021.750648			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WZ5HX	34790196	gold, Green Published			2022-12-18	WOS:000719999200001
J	Gao, G; Tian, Q; Han, AP; Yang, RX; Shi, F; Chen, D				Gao, Ge; Tian, Qing; Han, Anpeng; Yang, Rongxia; Shi, Fan; Chen, Dong			Case Report: A Case of Hereditary Gingival Fibromatosis With a High Level of Human beta Defensins in Gingival Epithelium	FRONTIERS IN IMMUNOLOGY			English	Article						non-syndromic hereditary gingival fibromatosis; clinical manifestation; human beta-defensins; case report; oral defense	EXPRESSION; PEPTIDES; INNATE; LL-37	Hereditary gingival fibromatosis [HGF, (MIM 135300)], a rare benign oral condition, has several adverse consequences such as aesthetic changes, malocclusion, speech impediments, and abnormal dentition. However, relatively few studies have addressed the beneficial effects of thick gingival tissues in resisting external stimuli. In this report, we present a unique case of a family affected by HGF that manifests as a 'healthy' gingiva. Human beta-defensins (hBDs) are known to play a pivotal role in the clearance and killing of various microbes, and contribute to maintaining a healthy oral environment, which is currently emerging research area. However, the expression pattern and localisation of hBDs in patients with HGF have not yet been reported. hBD-2 and hBD-3 in the pedigree we collected had relatively elevated expression. High hBD levels in the gingival tissue of patients from the family may be beneficial in protecting oral tissue from external stimuli and promoting periodontal regeneration, but their role and the mechanisms underlying HGF need to be clarified.	[Gao, Ge; Tian, Qing; Han, Anpeng; Yang, Rongxia; Shi, Fan; Chen, Dong] Zhengzhou Univ, Affiliated Hosp 1, Dept Stomatol, Zhengzhou, Peoples R China	Zhengzhou University	Chen, D (corresponding author), Zhengzhou Univ, Affiliated Hosp 1, Dept Stomatol, Zhengzhou, Peoples R China.	chendongfmmu@163.com			The National Natural Science Foundation of China [82170920]; Medical Science and Technology Research Project of Henan Province [22170124]	The National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Medical Science and Technology Research Project of Henan Province	Funding The National Natural Science Foundation of China (82170920); the Medical Science and Technology Research Project of Henan Province (22170124).	Awad F, 2015, ORPHANET J RARE DIS, V10, DOI 10.1186/s13023-015-0295-9; Beer HD, 2000, J INVEST DERM SYMP P, V5, P34, DOI 10.1046/j.1087-0024.2000.00009.x; Chotjumlong P, 2010, J PERIODONTAL RES, V45, P464, DOI 10.1111/j.1600-0765.2009.01259.x; Dale BA, 2005, CURR ISSUES MOL BIOL, V7, P119; Dale BA, 2001, J PERIODONTAL RES, V36, P285, DOI 10.1034/j.1600-0765.2001.360503.x; Finetti M, 2016, ORPHANET J RARE DIS, V11, DOI 10.1186/s13023-016-0542-8; Gawron K, 2016, ORPHANET J RARE DIS, V11, DOI 10.1186/s13023-016-0395-1; Greer A, 2013, PERIODONTOL 2000, V63, P67, DOI 10.1111/prd.12028; Gursoy UK, 2012, J PERIODONTOL, V83, P242, DOI 10.1902/jop.2011.110177; Gursoy Ulvi Kahraman, 2012, J Oral Microbiol, V4, DOI 10.3402/jom.v4i0.15127; Hakkinen L, 2004, AM J PATHOL, V164, P229, DOI 10.1016/S0002-9440(10)63113-6; Hakkinen L, 2007, J DENT RES, V86, P25, DOI 10.1177/154405910708600104; He L, 2012, INT J ORAL SCI, V4, P221, DOI 10.1038/ijos.2012.53; Jin LJ, 2011, PERIODONTOL 2000, V56, P125, DOI 10.1111/j.1600-0757.2010.00364.x; Li LJ, 2020, INT J ORAL SCI, V12, DOI 10.1038/s41368-020-0078-6; McCormick TS, 2010, PERIODONTOL 2000, V54, P195, DOI 10.1111/j.1600-0757.2010.00373.x; Premratanachai P, 2004, ORAL MICROBIOL IMMUN, V19, P111, DOI 10.1111/j.0902-0055.2002.00127.x; Semple F, 2010, EUR J IMMUNOL, V40, P1073, DOI 10.1002/eji.200940041; Shao YM, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-29542-z; Varoga D, 2005, ARTHRITIS RHEUM-US, V52, P1736, DOI 10.1002/art.21090; Wang HY, 2011, PEPTIDES, V32, P888, DOI 10.1016/j.peptides.2011.02.002; Wei A, 2021, ORPHANET J RARE DIS, V16, DOI 10.1186/s13023-021-01689-5; Ye X, 2005, CLIN GENET, V68, P239, DOI 10.1111/j.1399-0004.2005.00488.x	23	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 29	2021	12								763026	10.3389/fimmu.2021.763026	http://dx.doi.org/10.3389/fimmu.2021.763026			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WZ8MI	34795673	gold, Green Published			2022-12-18	WOS:000720215600001
J	Markley, RL; Restori, KH; Katkere, B; Sumner, SE; Nicol, MJ; Tyryshkina, A; Nettleford, SK; Williamson, DR; Place, DE; Dewan, KK; Shay, AE; Carlson, BA; Girirajan, S; Prabhu, KS; Kirimanjeswara, GS				Markley, Rachel L.; Restori, Katherine H.; Katkere, Bhuvana; Sumner, Sarah E.; Nicol, McKayla J.; Tyryshkina, Anastasia; Nettleford, Shaneice K.; Williamson, David R.; Place, David E.; Dewan, Kalyan K.; Shay, Ashley E.; Carlson, Bradley A.; Girirajan, Santhosh; Prabhu, K. Sandeep; Kirimanjeswara, Girish S.			Macrophage Selenoproteins Restrict Intracellular Replication of Francisella tularensis and Are Essential for Host Immunity	FRONTIERS IN IMMUNOLOGY			English	Article						selenium; redox; intracellular bacteria; tularemia; innate immunity	SYSTEMIC INFLAMMATORY RESPONSE; LIVE VACCINE STRAIN; SELENIUM DEFICIENCY; PROTEIN DATABASE; MICRONUTRIENT SUPPLEMENTATION; ALTERNATIVE ACTIVATION; OXIDATIVE STRESS; EPITHELIAL-CELLS; GENE-EXPRESSION; QUALITY-CONTROL	The essential micronutrient Selenium (Se) is co-translationally incorporated as selenocysteine into proteins. Selenoproteins contain one or more selenocysteines and are vital for optimum immunity. Interestingly, many pathogenic bacteria utilize Se for various biological processes suggesting that Se may play a role in bacterial pathogenesis. A previous study had speculated that Francisella tularensis, a facultative intracellular bacterium and the causative agent of tularemia, sequesters Se by upregulating Se-metabolism genes in type II alveolar epithelial cells. Therefore, we investigated the contribution of host vs. pathogen-associated selenoproteins in bacterial disease using F. tularensis as a model organism. We found that F. tularensis was devoid of any Se utilization traits, neither incorporated elemental Se, nor exhibited Se-dependent growth. However, 100% of Se-deficient mice (0.01 ppm Se), which express low levels of selenoproteins, succumbed to F. tularensis-live vaccine strain pulmonary challenge, whereas 50% of mice on Se-supplemented (0.4 ppm Se) and 25% of mice on Se-adequate (0.1 ppm Se) diet succumbed to infection. Median survival time for Se-deficient mice was 8 days post-infection while Se-supplemented and -adequate mice was 11.5 and > 14 days post-infection, respectively. Se-deficient macrophages permitted significantly higher intracellular bacterial replication than Se-supplemented macrophages ex vivo, corroborating in vivo observations. Since Francisella replicates in alveolar macrophages during the acute phase of pneumonic infection, we hypothesized that macrophage-specific host selenoproteins may restrict replication and systemic spread of bacteria. F. tularensis infection led to an increased expression of several macrophage selenoproteins, suggesting their key role in limiting bacterial replication. Upon challenge with F. tularensis, mice lacking selenoproteins in macrophages (TrspM) displayed lower survival and increased bacterial burden in the lung and systemic tissues in comparison to WT littermate controls. Furthermore, macrophages from TrspM mice were unable to restrict bacterial replication ex vivo in comparison to macrophages from littermate controls. We herein describe a novel function of host macrophage-specific selenoproteins in restriction of intracellular bacterial replication. These data suggest that host selenoproteins may be considered as novel targets for modulating immune response to control a bacterial infection.	[Markley, Rachel L.; Sumner, Sarah E.; Nicol, McKayla J.; Nettleford, Shaneice K.] Penn State Univ, Pathobiol Grad Program, University Pk, PA 16802 USA; [Markley, Rachel L.; Restori, Katherine H.; Katkere, Bhuvana; Sumner, Sarah E.; Nicol, McKayla J.; Nettleford, Shaneice K.; Williamson, David R.; Place, David E.; Dewan, Kalyan K.; Shay, Ashley E.; Prabhu, K. Sandeep; Kirimanjeswara, Girish S.] Penn State Univ, Dept Vet & Biomed Sci, University Pk, PA 16802 USA; [Markley, Rachel L.] Cleveland Clin, Lerner Res Inst, Dept Cardiovasc & Metab Sci, Cleveland, OH 44106 USA; [Tyryshkina, Anastasia] Penn State Univ, Huck Inst Life Sci, Neurosci Grad Program, University Pk, PA 16802 USA; [Tyryshkina, Anastasia; Girirajan, Santhosh] Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA; [Place, David E.] St Jude Childrens Res Hosp, Dept Immunol, 332 N Lauderdale St, Memphis, TN 38105 USA; [Dewan, Kalyan K.] Univ Georgia, Dept Infect Dis, Athens, GA 30602 USA; [Shay, Ashley E.] Brigham & Womens Hosp, Dept Anesthesiol Perioperat & Pain Med, Ctr Expt Therapeut & Reperfus Injury, 75 Francis St, Boston, MA 02115 USA; [Shay, Ashley E.] Harvard Med Sch, Boston, MA 02115 USA; [Carlson, Bradley A.] NCI, Off Res Support, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; [Prabhu, K. Sandeep; Kirimanjeswara, Girish S.] Penn State Univ, Ctr Mol Immunol & Infect Dis, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Cleveland Clinic Foundation; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; St Jude Children's Research Hospital; University System of Georgia; University of Georgia; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Kirimanjeswara, GS (corresponding author), Penn State Univ, Dept Vet & Biomed Sci, University Pk, PA 16802 USA.; Kirimanjeswara, GS (corresponding author), Penn State Univ, Ctr Mol Immunol & Infect Dis, University Pk, PA 16802 USA.	gsk125@psu.edu			National Institutes of Health [T32AI074551, T32GM108563, TL1TR002016, T32LM012415, AI123521, AI77917]; USDA-NIFA grant [4771, 0000005];  [GM121907];  [DK077152]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); USDA-NIFA grant; ; 	RLM and DRW were supported by T32AI074551, SES by T32GM108563, MJN by TL1TR002016, and AT by T32LM012415 from the National Institutes of Health. KSP and GSK were supported by USDA-NIFA grant #4771 (Accession number 0000005). In addition, SG was supported by GM121907, KSP was supported by DK077152 and GSK was supported by NIH grants AI123521 and AI77917 from the National Institutes of Health.	Abe T, 2011, NUCLEIC ACIDS RES, V39, pD210, DOI 10.1093/nar/gkq1007; Altimira J, 2000, J COMP PATHOL, V123, P104, DOI 10.1053/jcpa.2000.0399; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Angstwurm MWA, 2007, CRIT CARE MED, V35, P118, DOI 10.1097/01.CCM.0000251124.83436.0E; Angstwurm MWA, 1999, CRIT CARE MED, V27, P1807, DOI 10.1097/00003246-199909000-00017; Aribi M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135515; Armstrong BA, 2017, SURG CLIN N AM, V97, P1339, DOI 10.1016/j.suc.2017.07.003; Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; Asci A, 2015, PEDIATR INT, V57, P1131, DOI 10.1111/ped.12698; AXLEY MJ, 1989, ANNU REV NUTR, V9, P127, DOI 10.1146/annurev.nu.09.070189.001015; Bereswill S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020953; Best A, 2019, TRENDS MICROBIOL, V27, P550, DOI 10.1016/j.tim.2018.12.012; BOCK A, 1991, MOL MICROBIOL, V5, P515, DOI 10.1111/j.1365-2958.1991.tb00722.x; Bradburne CE, 2013, J BIOL CHEM, V288, P10780, DOI 10.1074/jbc.M112.362178; Broad Institute, 2009, PICARD TOOLS BROAD I; Campa A, 2017, NUTR DIET SUPPL, V9, P37, DOI 10.2147/NDS.S123545; Carlson BA, 2009, MOLECULES, V14, P3509, DOI 10.3390/molecules14093509; Celli J, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a010314; CHAMBERL.RE, 1965, APPL MICROBIOL, V13, P232, DOI 10.1128/AEM.13.2.232-235.1965; Chan PP, 2009, NUCLEIC ACIDS RES, V37, pD93, DOI 10.1093/nar/gkn787; Chelkeba L, 2015, ANN INTENSIVE CARE, V5, DOI 10.1186/s13613-015-0071-y; Covarrubias AJ, 2015, SEMIN IMMUNOL, V27, P286, DOI 10.1016/j.smim.2015.08.001; de Moraes ML, 2014, J BRAS PNEUMOL, V40, P269, DOI 10.1590/S1806-37132014000300010; DeLuca DS, 2012, BIOINFORMATICS, V28, P1530, DOI 10.1093/bioinformatics/bts196; Dennis DT, 2001, JAMA-J AM MED ASSOC, V285, P2763, DOI 10.1001/jama.285.21.2763; Diamond AM, 2015, NUTRIENTS, V7, P3938, DOI 10.3390/nu7053938; Dikiy A, 2007, BIOCHEMISTRY-US, V46, P6871, DOI 10.1021/bi602462q; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Edwards JA, 2010, MICROBIOL-SGM, V156, P327, DOI 10.1099/mic.0.031716-0; Ellis J, 2002, CLIN MICROBIOL REV, V15, P631, DOI 10.1128/CMR.15.4.631-646.2002; FERRY JG, 1990, FEMS MICROBIOL LETT, V87, P377, DOI 10.1111/j.1574-6968.1990.tb04940.x; Forceville X, 1998, CRIT CARE MED, V26, P1536, DOI 10.1097/00003246-199809000-00021; FORCHHAMMER K, 1991, J BIOL CHEM, V266, P6318; FORCHHAMMER K, 1989, NATURE, V342, P453, DOI 10.1038/342453a0; FORTIER AH, 1992, INFECT IMMUN, V60, P817, DOI 10.1128/IAI.60.3.817-825.1992; FORTIER AH, 1991, INFECT IMMUN, V59, P2922, DOI 10.1128/IAI.59.9.2922-2928.1991; Frankish A, 2019, NUCLEIC ACIDS RES, V47, pD766, DOI 10.1093/nar/gky955; Gao XJ, 2016, BIOL TRACE ELEM RES, V172, P449, DOI 10.1007/s12011-015-0614-y; Geer LY, 2002, GENOME RES, V12, P1619, DOI 10.1101/gr.278202; Goralski TDP, 2016, ANTIMICROB AGENTS CH, V60, P3276, DOI 10.1128/AAC.03089-15; Groenbaek K, 2006, EUR J GASTROEN HEPAT, V18, P985, DOI 10.1097/01.meg.0000231746.76136.4a; Haft DH, 2008, BIOL DIRECT, V3, DOI 10.1186/1745-6150-3-4; Hall JD, 2007, INFECT IMMUN, V75, P1034, DOI 10.1128/IAI.01254-06; Havelaar AH, 2013, LANCET, V381, P59; Hayes E., 2002, J AM MED ASS, V51, P182; Honn M, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00014; Howard MT, 2013, J BIOL CHEM, V288, P19401, DOI 10.1074/jbc.M113.481051; Kalantari P, 2008, J BIOL CHEM, V283, P33183, DOI 10.1074/jbc.M807403200; Kanehisa M, 2014, NUCLEIC ACIDS RES, V42, pD199, DOI 10.1093/nar/gkt1076; Kassu A, 2006, EUR J CLIN NUTR, V60, P580, DOI 10.1038/sj.ejcn.1602352; Kaushal N, 2014, J IMMUNOL, V193, P3683, DOI 10.4049/jimmunol.1400347; Kawai K, 2014, EPIDEMIOL INFECT, V142, P1505, DOI 10.1017/S0950268813002495; Keim P, 2007, ANN NY ACAD SCI, V1105, P30, DOI 10.1196/annals.1409.011; Khoso PA, 2017, BIOL TRACE ELEM RES, V177, P159, DOI 10.1007/s12011-016-0860-7; Kocan L, 2014, CLIN BIOCHEM, V47, P44, DOI 10.1016/j.clinbiochem.2014.07.004; Korotkov KV, 2002, MOL CELL BIOL, V22, P1402, DOI 10.1128/MCB.22.5.1402-1411.2002; Kryukov GV, 2002, P NATL ACAD SCI USA, V99, P4245, DOI 10.1073/pnas.072603099; Kryukov GV, 2003, SCIENCE, V300, P1439, DOI 10.1126/science.1083516; Labunskyy VM, 2014, PHYSIOL REV, V94, P739, DOI 10.1152/physrev.00039.2013; Law HT, 2011, SCI REP-UK, V1, DOI 10.1038/srep00192; Lee BC, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05230-2; Lee BC, 2013, MOL CELL, V51, P397, DOI 10.1016/j.molcel.2013.06.019; LEINFELDER W, 1988, NATURE, V331, P723, DOI 10.1038/331723a0; Leonhartsberger S, 2002, J MOL MICROB BIOTECH, V4, P269; Liu ZX, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8110532; Loflin J, 2006, J INORG BIOCHEM, V100, P1679, DOI 10.1016/j.jinorgbio.2006.05.018; Mahram Atabak, 2010, 24th ACM International Conference on Supercomputing 2010, P73; Marchler-Bauer A, 2009, NUCLEIC ACIDS RES, V37, pD205, DOI 10.1093/nar/gkn845; McCaffrey RL, 2010, J LEUKOCYTE BIOL, V88, P791, DOI 10.1189/jlb.1209811; Melillo AA, 2009, J BACTERIOL, V191, P6447, DOI 10.1128/JB.00534-09; Murray PJ, 2017, ANNU REV PHYSIOL, V79, P541, DOI 10.1146/annurev-physiol-022516-034339; Muzembo BA, 2019, CLIN NUTR ESPEN, V34, P1, DOI 10.1016/j.clnesp.2019.09.005; Narayan V, 2015, J NUTR BIOCHEM, V26, P138, DOI 10.1016/j.jnutbio.2014.09.009; Nelson SM, 2016, J BIOL CHEM, V291, P2787, DOI 10.1074/jbc.M115.684738; Nelson SM, 2011, J NUTR, V141, P1754, DOI 10.3945/jn.111.141176; Nettleford SK, 2020, FRONT NUTR, V7, DOI 10.3389/fnut.2020.00096; Novoselov SV, 2005, ONCOGENE, V24, P8003, DOI 10.1038/sj.onc.1208940; Oyston PCF, 2004, NAT REV MICROBIOL, V2, P967, DOI 10.1038/nrmicro1045; Parsa KVL, 2008, MOL IMMUNOL, V45, P3428, DOI 10.1016/j.molimm.2008.04.006; Peng T, 2016, ISME J, V10, P2048, DOI 10.1038/ismej.2015.246; Pinske Constanze, 2016, EcoSal Plus, V7, DOI 10.1128/ecosalplus.ESP-0011-2016; Prabhu KS, 2002, BIOCHEM J, V366, P203, DOI 10.1042/BJ20020256; Prauchner CA, 2017, BURNS, V43, P471, DOI 10.1016/j.burns.2016.09.023; Qian FH, 2019, CRIT REV BIOCHEM MOL, V54, P484, DOI 10.1080/10409238.2020.1717430; Rabadi SM, 2016, J BIOL CHEM, V291, P5009, DOI 10.1074/jbc.M115.681478; Rayman MP, 2000, LANCET, V356, P233, DOI 10.1016/S0140-6736(00)02490-9; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Romero H, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-8-r66; Rudolph M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055544; Sakr Y, 2007, BRIT J ANAESTH, V98, P775, DOI 10.1093/bja/aem091; Samaniego S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054124; Schaffer AA, 2001, NUCLEIC ACIDS RES, V29, P2994, DOI 10.1093/nar/29.14.2994; Seyedrezazadeh E, 2008, RESPIROLOGY, V13, P294, DOI 10.1111/j.1440-1843.2007.01200.x; Sheehan HB, 2012, PUBLIC HEALTH NUTR, V15, P538, DOI 10.1017/S1368980011001364; Shirey KA, 2008, J IMMUNOL, V181, P4159, DOI 10.4049/jimmunol.181.6.4159; Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287; Stadtman TC, 1996, ANNU REV BIOCHEM, V65, P83, DOI 10.1146/annurev.bi.65.070196.000503; Stock T, 2009, BBA-GEN SUBJECTS, V1790, P1520, DOI 10.1016/j.bbagen.2009.03.022; STUART BM, 1945, AM J MED SCI, V210, P223, DOI 10.1097/00000441-194508000-00013; Suzuki KT, 2007, BBA-GEN SUBJECTS, V1770, P1053, DOI 10.1016/j.bbagen.2007.03.007; VENDELAND SC, 1995, P NATL ACAD SCI USA, V92, P8749, DOI 10.1073/pnas.92.19.8749; Vunta H, 2007, J BIOL CHEM, V282, P17964, DOI 10.1074/jbc.M703075200; Wang CM, 2009, BMC IMMUNOL, V10, DOI 10.1186/1471-2172-10-55; Wang LG, 2012, BIOINFORMATICS, V28, P2184, DOI 10.1093/bioinformatics/bts356; Whanger PD, 2009, BBA-GEN SUBJECTS, V1790, P1448, DOI 10.1016/j.bbagen.2009.05.010; Yoshizawa S, 2009, BBA-GEN SUBJECTS, V1790, P1404, DOI 10.1016/j.bbagen.2009.03.010; Zhang Y, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-10-r94; Zhang Y, 2010, BIOINFORMATICS, V26, P700, DOI 10.1093/bioinformatics/btp705; Zhang YQ, 2020, NAR GENOM BIOINFORM, V2, DOI 10.1093/nargab/lqaa078; Ziveri J, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00096	110	0	0	4	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 29	2021	12								701341	10.3389/fimmu.2021.701341	http://dx.doi.org/10.3389/fimmu.2021.701341			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WW3NV	34777335	Green Published, gold			2022-12-18	WOS:000717828600001
J	Yuan, E; Matusiak, M; Sirinukunwattana, K; Varma, S; Kidzinski, L; West, R				Yuan, Edwin; Matusiak, Magdalena; Sirinukunwattana, Korsuk; Varma, Sushama; Kidzinski, Lukasz; West, Robert			Self-Organizing Maps for Cellular In Silico Staining and Cell Substate Classification	FRONTIERS IN IMMUNOLOGY			English	Article						self-organization; in silico staining; e-pathology; cell subtype classification; segmentation	GENOME-WIDE EXPRESSION	Cellular composition and structural organization of cells in the tissue determine effective antitumor response and can predict patient outcome and therapy response. Here we present Seg-SOM, a method for dimensionality reduction of cell morphology in H&E-stained tissue images. Seg-SOM resolves cellular tissue heterogeneity and reveals complex tissue architecture. We leverage a self-organizing map (SOM) artificial neural network to group cells based on morphological features like shape and size. Seg-SOM allows for cell segmentation, systematic classification, and in silico cell labeling. We apply the Seg-SOM to a dataset of breast cancer progression images and find that clustering of SOM classes reveals groups of cells corresponding to fibroblasts, epithelial cells, and lymphocytes. We show that labeling the Lymphocyte SOM class on the breast tissue images accurately estimates lymphocytic infiltration. We further demonstrate how to use Seq-SOM in combination with non-negative matrix factorization to statistically describe the interaction of cell subtypes and use the interaction information as highly interpretable features for a histological classifier. Our work provides a framework for use of SOM in human pathology to resolve cellular composition of complex human tissues. We provide a python implementation and an easy-to-use docker deployment, enabling researchers to effortlessly featurize digitalized H&E-stained tissue.</p>	[Yuan, Edwin] Stanford Univ, Dept Appl Phys, Stanford, CA 94305 USA; [Matusiak, Magdalena; Varma, Sushama; West, Robert] Stanford Univ, Dept Pathol, Stanford, CA 94305 USA; [Sirinukunwattana, Korsuk] Univ Oxford, Inst Biomed Engn, Dept Engn Sci, Oxford, England; [Sirinukunwattana, Korsuk] Ground Truth Labs, Oxford, England; [Sirinukunwattana, Korsuk] Univ Oxford, Big Data Inst, Li Ka Shing Ctr Hlth Informat & Discovery, Oxford, England; [Sirinukunwattana, Korsuk] Oxford Univ Natl Hlth Serv NHS Fdn Trust, Natl Inst Hlth Res NIHR, Oxford Biomed Res Ctr, Oxford, England; [Kidzinski, Lukasz] Stanford Univ, Dept Engn, Stanford, CA 94305 USA	Stanford University; Stanford University; University of Oxford; University of Oxford; University of Oxford; Stanford University	Yuan, E (corresponding author), Stanford Univ, Dept Appl Phys, Stanford, CA 94305 USA.; Matusiak, M; West, R (corresponding author), Stanford Univ, Dept Pathol, Stanford, CA 94305 USA.	edy.yuan@gmail.com; mmatusia@stanford.com; rbwest@stanford.edu		West, Robert/0000-0002-8330-8283				Angelo M, 2014, NAT MED, V20, P436, DOI 10.1038/nm.3488; Binnewies M, 2018, NAT MED, V24, P541, DOI 10.1038/s41591-018-0014-x; Christiansen EM, 2018, CELL, V173, P792, DOI 10.1016/j.cell.2018.03.040; Cruz-Roa A, 2014, PROC SPIE, V9041, DOI 10.1117/12.2043872; Denkert C, 2018, LANCET ONCOL, V19, P40, DOI 10.1016/S1470-2045(17)30904-X; Duran JM, 2021, J MED ETHICS, V47, P329, DOI 10.1136/medethics-2020-106820; Ernster VL, 1996, JAMA-J AM MED ASSOC, V275, P913, DOI 10.1001/jama.275.12.913; Ertosun Mehmet Gunhan, 2015, AMIA Annu Symp Proc, V2015, P1899; Fisher ER, 1999, CANCER-AM CANCER SOC, V86, P429, DOI 10.1002/(SICI)1097-0142(19990801)86:3<429::AID-CNCR11>3.0.CO;2-Y; Fridman WH, 2012, NAT REV CANCER, V12, P298, DOI 10.1038/nrc3245; Galon J, 2013, IMMUNITY, V39, P11, DOI 10.1016/j.immuni.2013.07.008; Goltsev Y, 2018, CELL, V174, P968, DOI 10.1016/j.cell.2018.07.010; Hajihashemi MR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045714; Jackson HW, 2020, NATURE, V578, P615, DOI 10.1038/s41586-019-1876-x; Keren L, 2018, CELL, V174, P1373, DOI 10.1016/j.cell.2018.08.039; Kriegel FL, 2018, JOVE-J VIS EXP, DOI 10.3791/58543; Kumar N, 2017, IEEE T MED IMAGING, V36, P1550, DOI 10.1109/TMI.2017.2677499; Litjens G, 2016, SCI REP-UK, V6, DOI 10.1038/srep26286; Lu S, 2019, JAMA ONCOL, V5, P1195, DOI 10.1001/jamaoncol.2019.1549; Macosko EZ, 2015, CELL, V161, P1202, DOI 10.1016/j.cell.2015.05.002; Pages F, 2018, LANCET, V391, P2128, DOI 10.1016/S0140-6736(18)30789-X; Phillips D, 2020, IMMUNE CELL TOPOGRAP, DOI [10.1101/2020.12.06.20244913, DOI 10.1101/2020.12.06.20244913]; Ponmalai R., 2019, LLNLTR791165989807, DOI DOI 10.2172/1566795; R Development Core Team, 2018, R LANG ENV STAT COMP; Rahmat RF, 2018, IOP CONF SER-MAT SCI, V308, DOI 10.1088/1757-899X/308/1/012015; RITTER H, 1989, BIOL CYBERN, V61, P241, DOI 10.1007/BF00203171; Rodriques SG, 2019, SCIENCE, V363, P1463, DOI 10.1126/science.aaw1219; Ronneberger O, 2015, LECT NOTES COMPUT SC, V9351, P234, DOI 10.1007/978-3-319-24574-4_28; Salgado R, 2018, LANCET ONCOL, V19, P3, DOI 10.1016/S1470-2045(17)30905-1; Schurch CM, 2020, CELL, V182, P1341, DOI 10.1016/j.cell.2020.07.005; Sirinukunwattana K, 2020, BLOOD ADV, V4, P3284, DOI 10.1182/bloodadvances.2020002230; Wickham H, 2011, WIRES COMPUT STAT, V3, P180, DOI 10.1002/wics.147; Zhang DC, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00071	33	0	0	2	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 29	2021	12								765923	10.3389/fimmu.2021.765923	http://dx.doi.org/10.3389/fimmu.2021.765923			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WW3TB	34777384	Green Published, gold			2022-12-18	WOS:000717842200001
J	Zhou, JW; Ji, RY; Zhu, R; Zhou, JY; Li, J; Tian, XP; Chen, YX; Zheng, YH				Zhou, Jiawei; Ji, Ruoyu; Zhu, Rui; Zhou, Jingya; Li, Jing; Tian, Xinping; Chen, Yuexin; Zheng, Yuehong			Clinical Features and Risk Factors for Active Tuberculosis in Takayasu Arteritis: A Single-Center Case-Control Study	FRONTIERS IN IMMUNOLOGY			English	Article						Takayasu arteritis; tuberculosis; risk factor (RF); hsCRP; T-SPOT; TB	CLASSIFICATION	Backgrounds Takayasu arteritis (TAK) is a chronic, granulomatous vasculitis correlated with tuberculosis (TB). The two diseases share similar pathological characteristics and clinical manifestations which increase the difficulty to diagnose. Active tuberculosis (ATB) has implications for treatment strategies in TAK patients. Therefore, the investigation of clinical features and potential risk factors of ATB in TAK patients is vital. Methods The study reviewed hospitalized patients diagnosed with TAK in our hospital from 2008, to 2021. TAK patients with ATB were enrolled as the case group. The control group was randomly selected in a 3:1 ratio. The clinical characteristics of TAK patients with and without ATB were compared. Multivariate logistic regression analysis was performed to determine risk factors for ATB in TAK patients. Results We reviewed 1,789 patients and ultimately identified 30 (1.7%) ATB cases. TAK patients with ATB were more prone to develop symptoms including fever (p=0.001), fatigue (p=0.003), cough (p=0.037), expectoration (p < 0.001), weight loss (p=0.003), and night sweating (p < 0.001). Increased level of hypersensitive C reactive protein (hsCRP, p=0.001), decreased level of albumin (p=0.031), and higher positive rate of T-SPOT.TB test (p < 0.001) were observed in the case group. Multivariate logistic regression analysis revealed that hsCRP > 8 mg/L (OR 9.108; 95% CI, 1.096-75.711; p=0.041) and positive T-SPOT.TB result (OR 68.669; 95% CI, 7.291-646.738; p < 0.001) were risk factors for ATB in TAK patients. The proportion of patients undergoing subsequent surgery for Takayasu arteritis was lower in patients with ATB (p < 0.001). Conclusion Our study suggested that the diagnosis of ATB should be considered when TAK patients experienced symptoms including fever, fatigue, weight loss, etc. hsCRP > 8 mg/L and positive T-SPOT.TB result were identified as independent risk factors for ATB in TAK patients.	[Zhou, Jiawei; Chen, Yuexin; Zheng, Yuehong] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Vasc Surg, Beijing, Peoples R China; [Ji, Ruoyu] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Beijing, Peoples R China; [Zhu, Rui; Zhou, Jingya] Chinese Acad Med Sci & Peking Union Med Coll, Dept Med Record, Peking Union Med Coll Hosp, Beijing, Peoples R China; [Li, Jing; Tian, Xinping] Chinese Acad Med Sci & Peking Union Med Coll, Dept Rheumatol, Beijing, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Peking Union Medical College Hospital; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Peking Union Medical College Hospital; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Peking Union Medical College Hospital; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College	Chen, YX; Zheng, YH (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Vasc Surg, Beijing, Peoples R China.	cyuexin2007@163.com; yuehongzheng@yahoo.com			Major Research Program of Natural Science Foundation of China	Major Research Program of Natural Science Foundation of China	This work was supported by grant from the Major Research Program of Natural Science Foundation of China (grant number 51890894), grant from the Natural Science Foundation of China (grant numbers 81770481 and 82070492), and grant from Clinical Disease Diagnosis and Treatment Technology and Translational Research in Capital City (Z201100005520052).	Afsar I, 2018, REV ESP QUIM, V31, P435; Al-Aghbari Khaled, 2010, Heart Views, V11, P117, DOI 10.4103/1995-705X.76804; AREND WP, 1990, ARTHRITIS RHEUM, V33, P1129; Dasari P, 2021, BMJ CASE REP, V14, DOI 10.1136/bcr-2020-238014; Dunlap NE, 2000, AM J RESP CRIT CARE, V161, P1376, DOI 10.1164/ajrccm.161.4.16141; Garay-Baquero DJ, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.137427; Gornik HL, 2008, CIRCULATION, V117, P3039, DOI 10.1161/CIRCULATIONAHA.107.760686; Hata A, 1996, INT J CARDIOL, V54, pS155, DOI 10.1016/S0167-5273(96)02813-6; KERR GS, 1994, ANN INTERN MED, V120, P919, DOI 10.7326/0003-4819-120-11-199406010-00004; Khemiri M, 2016, ANN PEDIAT CARDIOL, V9, P75, DOI 10.4103/0974-2069.171398; Lim AY, 2016, HEART VESSELS, V31, P1277, DOI 10.1007/s00380-015-0731-8; Meyer AJ, 2021, J CLIN MICROBIOL, V59, DOI 10.1128/JCM.02162-20; Olsson O, 2019, OPEN FORUM INFECT DI, V6, DOI 10.1093/ofid/ofz015; Pai M, 2014, CLIN MICROBIOL REV, V27, P3, DOI 10.1128/CMR.00034-13; Pedreira ALS, 2020, CLIN RHEUMATOL, V39, P1019, DOI 10.1007/s10067-019-04818-5; Terao C, 2014, INT J RHEUM DIS, V17, P238, DOI 10.1111/1756-185X.12309; van Timmeren MM, 2014, CURR OPIN RHEUMATOL, V26, P416, DOI 10.1097/BOR.0000000000000068; Vista EGS, 2010, AUTOIMMUN REV, V9, P503, DOI 10.1016/j.autrev.2010.02.010; Wang S, 2018, INT J INFECT DIS, V70, P1, DOI 10.1016/j.ijid.2018.01.007; Watts R, 2009, RHEUMATOLOGY, V48, P1008, DOI 10.1093/rheumatology/kep153; Yang QL, 2020, CLIN CHIM ACTA, V509, P60, DOI 10.1016/j.cca.2020.06.005; Yoon C, 2017, LANCET INFECT DIS, V17, P1285, DOI 10.1016/S1473-3099(17)30488-7; Zhang M, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm.2019.09.110; Zhang Y, 2019, J GERIATR CARDIOL, V16, P648, DOI 10.11909/j.issn.1671-5411.2019.08.003; Zhang ZMY, 2020, ANN VASC SURG, V66, P309, DOI 10.1016/j.avsg.2019.12.007	25	0	0	1	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 29	2021	12								749317	10.3389/fimmu.2021.749317	http://dx.doi.org/10.3389/fimmu.2021.749317			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WW3HK	34777361	Green Published, gold			2022-12-18	WOS:000717811900001
J	Bennstein, SB				Bennstein, Sabrina Bianca			Human Cord Blood ILCs - Unusual Like My Career as a Scientist	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						NK cell; innate lymphoid cells (ILCs); cord blood (CB); women; development	INNATE LYMPHOID-CELLS; LEUKEMIA INHIBITORY FACTOR; IMMUNE-RESPONSE; HUMAN PLACENTA; HETEROGENEITY; EXPRESSION; INJURY		[Bennstein, Sabrina Bianca] Heinrich Heine Univ Dusseldorf, Fac Med, Inst Transplantat Diagnost & Cell Therapeut, Dusseldorf, Germany	Heinrich Heine University Dusseldorf	Bennstein, SB (corresponding author), Heinrich Heine Univ Dusseldorf, Fac Med, Inst Transplantat Diagnost & Cell Therapeut, Dusseldorf, Germany.	Sabrinabianca.bennstein@med.uni-duesseldorf.de	Bennstein, Sabrina B./AFP-6522-2022	Bennstein, Sabrina B./0000-0003-0477-2748	Open-Access-Fonds of the Heinrich-Heine Universitaet.	Open-Access-Fonds of the Heinrich-Heine Universitaet.	Funding Article fee was funded by the Open-Access-Fonds of the Heinrich-Heine Universitaet.	Bennstein SB, 2022, FEBS J, V289, P3967, DOI 10.1111/febs.15866; Bennstein SB, 2021, STEM CELL TRANSL MED, V10, P867, DOI 10.1002/sctm.20-0300; Bennstein SB, 2020, ELIFE, V9, DOI 10.7554/eLife.55232; Bennstein SB, 2019, CYTOM PART A, V95A, P427, DOI 10.1002/cyto.a.23741; Bennstein SB, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01950; Bernink JH, 2013, NAT IMMUNOL, V14, P221, DOI 10.1038/ni.2534; Bjorklund AK, 2016, NAT IMMUNOL, V17, P451, DOI 10.1038/ni.3368; Cella M, 2010, P NATL ACAD SCI USA, V107, P10961, DOI 10.1073/pnas.1005641107; Cella M, 2009, NATURE, V457, P722, DOI 10.1038/nature07537; Cichocki F, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02078; Disteldorf EM, 2015, J AM SOC NEPHROL, V26, P55, DOI 10.1681/ASN.2013101061; Forsberg A, 2014, J ALLERGY CLIN IMMUN, V134, P228, DOI 10.1016/j.jaci.2014.01.027; Freud AG, 2016, CELL REP, V16, P379, DOI 10.1016/j.celrep.2016.05.095; Hazenberg MD, 2019, BLOOD ADV, V3, P3650, DOI 10.1182/bloodadvances.2019000176; Hipp L., 2018, SOCARXIV, DOI [10.31235/osf.io/qsm4x, DOI 10.31235/OSF.IO/QSM4X]; Hipp L, 2020, EUR SOCIOL REV, V36, P250, DOI 10.1093/esr/jcz056; Hoorweg K, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00072; KOJIMA K, 1995, HUM REPROD, V10, P1907, DOI 10.1093/oxfordjournals.humrep.a136205; Krebs CF, 2013, J AM SOC NEPHROL, V24, P1955, DOI 10.1681/ASN.2013020130; Lass A, 2001, FERTIL STERIL, V76, P1091, DOI 10.1016/S0015-0282(01)02878-3; Li S, 2019, J ALLERGY CLIN IMMUN, V143, P2321, DOI 10.1016/j.jaci.2019.01.047; Lim AI, 2019, EUR J IMMUNOL, V49, P11, DOI 10.1002/eji.201747294; Lim AI, 2017, CELL, V168, P1086, DOI 10.1016/j.cell.2017.02.021; Meyer H, 2019, BMC MED EDUC, V19, DOI 10.1186/s12909-018-1443-4; Michel T, 2016, J IMMUNOL, V196, P2923, DOI 10.4049/jimmunol.1502570; Mjosberg JM, 2011, NAT IMMUNOL, V12, P1055, DOI 10.1038/ni.2104; Nagasawa M, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01047; Oliveira-Nascimento L, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00079; Paust HJ, 2016, J AM SOC NEPHROL, V27, P1933, DOI 10.1681/ASN.2015020203; Powell K, 2021, NATURE, V595, P611, DOI 10.1038/d41586-021-01993-x; Roan F, 2016, J IMMUNOL, V196, P2051, DOI 10.4049/jimmunol.1501491; Robbins JR, 2012, INFECT IMMUN, V80, P418, DOI 10.1128/IAI.05899-11; Santos L, 2016, EUR J RES EDUC LEARN, V7, P57, DOI 10.3384/rela.2000-7426.rela9079; Schmidt T, 2015, ARTHRITIS RHEUMATOL, V67, P475, DOI 10.1002/art.38955; Simoni Y, 2017, IMMUNITY, V46, P148, DOI 10.1016/j.immuni.2016.11.005; Spits H, 2013, NAT REV IMMUNOL, V13, P145, DOI 10.1038/nri3365; Turner JE, 2012, J AM SOC NEPHROL, V23, P1486, DOI 10.1681/ASN.2012010040; Turner JE, 2012, AM J PHYSIOL-RENAL, V302, pF1503, DOI 10.1152/ajprenal.00382.2011; Vely F, 2016, NAT IMMUNOL, V17, P1291, DOI 10.1038/ni.3553; Vivier E, 2018, CELL, V174, P1054, DOI 10.1016/j.cell.2018.07.017; Xu W, 2019, IMMUNITY, V50, P1054, DOI 10.1016/j.immuni.2019.02.022; Yokota Y, 1999, NATURE, V397, P702, DOI 10.1038/17812	42	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 28	2021	12								752283	10.3389/fimmu.2021.752283	http://dx.doi.org/10.3389/fimmu.2021.752283			5	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WW3SK	34777362	Green Published, gold			2022-12-18	WOS:000717840500001
J	Dalloul, I; Laffleur, B; Dalloul, Z; Wehbi, B; Jouan, F; Brauge, B; Derouault, P; Moreau, J; Kracker, S; Fischer, A; Durandy, A; Le Noir, S; Cogne, M				Dalloul, Iman; Laffleur, Brice; Dalloul, Zeinab; Wehbi, Batoul; Jouan, Florence; Brauge, Baptiste; Derouault, Paco; Moreau, Jeanne; Kracker, Sven; Fischer, Alain; Durandy, Anne; Le Noir, Sandrine; Cogne, Michel			UnAIDed Class Switching in Activated B-Cells Reveals Intrinsic Features of a Self-Cleaving IgH Locus	FRONTIERS IN IMMUNOLOGY			English	Article						B lymphocyte; class switch DNA recombination (CSR); AICDA; immunoglobulin; class switch	CYTIDINE DEAMINASE AID; RNA-POLYMERASE-II; SOMATIC HYPERMUTATION; RECOMBINATION; DNA; REGION; END; GENOME; RESECTION; DELETION	Activation-induced deaminase (AID) is the major actor of immunoglobulin (Ig) gene diversification in germinal center B-cells. From its first description, it was considered as mandatory for class switch recombination (CSR), and this discovery initiated a long quest for all of the AID-interacting factors controlling its activity. The mechanisms focusing AID-mediated DNA lesions to given target sequences remain incompletely understood with regards the detailed characterization of optimal substrates in which cytidine deamination will lead to double strand breaks (DSBs) and chromosomal cleavage. In an effort to reconsider whether such CSR breaks absolutely require AID, we herein provide evidence, based on deep-sequencing approaches, showing that this dogma is not absolute in both human and mouse B lymphocytes. In activated B-cells from either AID-deficient mice or human AID-deficient patients, we report an intrinsic ability of the IgH locus to undergo "on-target" cleavage and subsequent synapsis of broken regions in conditions able to yield low-level CSR. DNA breaks occur in such conditions within the same repetitive S regions usually targeted by AID, but their repair follows a specific pathway with increased usage of microhomology-mediated repair. These data further demonstrate the role of AID machinery as not initiating de novo chromosomal cleavage but rather catalyzing a process which spontaneously initiates at low levels in an appropriately conformed IgH locus.	[Dalloul, Iman; Dalloul, Zeinab; Wehbi, Batoul; Moreau, Jeanne; Le Noir, Sandrine; Cogne, Michel] Limoges Univ, Unite Mixte Rech UMR 7276, Ctr Natl Rech Sci CNRS, Inst Natl Sante & Rech Med INSERM, Limoges, France; [Laffleur, Brice; Jouan, Florence; Brauge, Baptiste; Cogne, Michel] Rennes1 Univ, Inst Natl Sante & Rech Med INSERM, U 1236, Rennes, France; [Derouault, Paco] CHU Dupuytren, Limoges, France; [Kracker, Sven; Fischer, Alain; Durandy, Anne] Univ Paris, Imagine Inst, Lab Human Lymphohematopoiesis, Unite Mixte Rech UMR 1163,Inst Natl Sante & Rech, Paris, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); CHU Limoges; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Cogne, M (corresponding author), Limoges Univ, Unite Mixte Rech UMR 7276, Ctr Natl Rech Sci CNRS, Inst Natl Sante & Rech Med INSERM, Limoges, France.; Cogne, M (corresponding author), Rennes1 Univ, Inst Natl Sante & Rech Med INSERM, U 1236, Rennes, France.	michel.cogne@inserm.fr	Le Noir, Sandrine/P-5382-2016	Le Noir, Sandrine/0000-0002-2297-4186	Agence Nationale de la Recherche	Agence Nationale de la Recherche(French National Research Agency (ANR))	Funding This work was supported by grants from Agence Nationale de la Recherche (grants ANR-16-CE15-0019-01 and 18-CE18-0022-02) and Fondation ARC (grant PGA1 RF20180207070).	Basu U, 2011, CELL, V144, P353, DOI 10.1016/j.cell.2011.01.001; Begum NA, 2009, P NATL ACAD SCI USA, V106, P2752, DOI 10.1073/pnas.0813252106; Bothmer A, 2011, MOL CELL, V42, P319, DOI 10.1016/j.molcel.2011.03.019; Boyer F, 2017, J IMMUNOL, V198, P4148, DOI 10.4049/jimmunol.1601924; Caval V, 2019, BMC GENOMICS, V20, DOI 10.1186/s12864-019-6216-x; Caval V, 2014, MOL BIOL EVOL, V31, P330, DOI 10.1093/molbev/mst195; Chiarle R, 2011, CELL, V147, P107, DOI 10.1016/j.cell.2011.07.049; COGNE M, 1994, CELL, V77, P737, DOI 10.1016/0092-8674(94)90057-4; Dalloul I, 2019, PLOS GENET, V15, DOI 10.1371/journal.pgen.1007721; Dalloul Z, 2018, J ALLERGY CLIN IMMUN, V142, P1352, DOI 10.1016/j.jaci.2018.06.011; Jeevan-Raj BP, 2011, J EXP MED, V208, P1649, DOI 10.1084/jem.20110118; Kato L, 2012, J IMMUNOL, V188, P3559, DOI 10.4049/jimmunol.1102397; Keijzers G, 2016, CRIT REV BIOCHEM MOL, V51, P440, DOI 10.1080/10409238.2016.1215407; Kenter AL, 2012, SEMIN IMMUNOL, V24, P281, DOI 10.1016/j.smim.2012.06.001; Kim N, 2011, DNA REPAIR, V10, P953, DOI 10.1016/j.dnarep.2011.07.002; Kovalchuk AL, 2007, J EXP MED, V204, P2989, DOI 10.1084/jem.20070882; Laffleur B, 2021, NAT GENET, V53, P230, DOI 10.1038/s41588-020-00772-0; Liu M, 2008, NATURE, V451, P841, DOI 10.1038/nature06547; LORENZ M, 1995, SCIENCE, V267, P1825, DOI 10.1126/science.7892607; Makharashvili N, 2018, ELIFE, V7, DOI 10.7554/eLife.42733; Maul RW, 2010, IMMUNOL RES, V47, P113, DOI 10.1007/s12026-009-8142-5; Maul RW, 2010, ADV IMMUNOL, V105, P159, DOI 10.1016/S0065-2776(10)05006-6; Muramatsu M, 1999, J BIOL CHEM, V274, P18470, DOI 10.1074/jbc.274.26.18470; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; Pasqualucci L, 2008, NAT GENET, V40, P108, DOI 10.1038/ng.2007.35; Pavri R, 2010, CELL, V143, P122, DOI 10.1016/j.cell.2010.09.017; Peron S, 2012, SCIENCE, V336, P931, DOI 10.1126/science.1218692; Pinaud E, 2001, IMMUNITY, V15, P187, DOI 10.1016/S1074-7613(01)00181-9; Qiao Q, 2017, MOL CELL, V67, P361, DOI 10.1016/j.molcel.2017.06.034; Reina-San-Martin B, 2003, J EXP MED, V197, P1767, DOI 10.1084/jem.20030569; Revy P, 2000, CELL, V102, P565, DOI 10.1016/S0092-8674(00)00079-9; Rouaud P, 2014, J EXP MED, V211, P975, DOI 10.1084/jem.20131385; Saintamand A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8084; Sartori AA, 2007, NATURE, V450, P509, DOI 10.1038/nature06337; Staszewski O, 2011, MOL CELL, V41, P232, DOI 10.1016/j.molcel.2011.01.007; Wang LL, 2009, J EXP MED, V206, P1817, DOI 10.1084/jem.20081678; Willmann KL, 2012, J EXP MED, V209, P2099, DOI 10.1084/jem.20112145; Wuerffe R, 2007, IMMUNITY, V27, P711, DOI 10.1016/j.immuni.2007.09.007; Xu ZM, 2010, NAT STRUCT MOL BIOL, V17, P1124, DOI 10.1038/nsmb.1884; Yamane A, 2013, CELL REP, V3, P138, DOI 10.1016/j.celrep.2012.12.006; Yasuhara T, 2018, CELL, V175, P558, DOI 10.1016/j.cell.2018.08.056; Zhang XF, 2019, NATURE, V575, P385, DOI 10.1038/s41586-019-1723-0; Zheng SM, 2015, CELL, V161, P762, DOI 10.1016/j.cell.2015.03.020	43	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 28	2021	12								737427	10.3389/fimmu.2021.737427	http://dx.doi.org/10.3389/fimmu.2021.737427			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WW1SZ	34777346	Green Published, gold			2022-12-18	WOS:000717706800001
J	Juvet, LK; Robertson, AH; Laake, I; Mjaaland, S; Trogstad, L				Juvet, Lene Kristine; Robertson, Anna Hayman; Laake, Ida; Mjaaland, Siri; Trogstad, Lill			Safety of Influenza A H1N1pdm09 Vaccines: An Overview of Systematic Reviews	FRONTIERS IN IMMUNOLOGY			English	Review						H1N1pdm09 vaccination; pandemic vaccines; influenz a vaccines; safety; adverse events	H1N1 INFLUENZA; VACCINATION; NARCOLEPSY; METAANALYSIS; RISK; INFECTION	Background: In 2009, a new influenza A H1N1 virus emerged causing a global pandemic. A range of monovalent influenza A H1N1pdm09 vaccines with or without adjuvants were developed. After the mass vaccination campaigns safety concerns related to H1N1pdm09 vaccines were reported. More than a decade later, reported AEFIs are still under scrutiny. We performed a systematic review aiming to synthesize the evidence on the safety of the H1N1pdm09 vaccines on reported outcomes from existing systematic reviews. Methods: Four electronic databases, PubMed, EMBASE, Epistimonikos and the Cochrane Database of Systematic Reviews were searched for articles on H1N1pdm09 vaccination published from 2009 to January 2021. Systematic reviews assessing short- or long-term adverse events after H1N1pdm09 vaccination were considered for inclusion. Data was extracted from all selected reviews. Outcomes were grouped and results from each included review were presented narratively and in tables. Results: 16 systematic reviews met the inclusion criteria. Reported outcomes were short-term events (3 reviews), fetal/pregnancy outcomes (8 reviews), Guillain-Barre syndrome (GBS) (4 reviews), narcolepsy (2 reviews) demyelinating diseases (1 review based on one study only) and inflammatory bowel disease (IBD) (1 review). Short-term serious adverse events were rare, 3 cases amongst 16725 subjects in 18 randomized controlled trials (0.018%). No deaths were reported. The risks of local events were generally higher for adjuvanted vaccines as compared to unadjuvanted vaccines. Maternal H1N1pdm09 vaccination in any trimester was not associated with an increase in preterm birth, small for gestational age, congenital malformations or fetal death. For GBS, results were conflicting. The main systematic review on narcolepsy found a 5-14-fold increased risk in children, and a 2-7- fold increased risk in adults after vaccination with Pandemrix. The attributable risk of narcolepsy one year after vaccination was 1 case per 18 400 vaccine doses in children/adolescents, and 1 case per 181 000 vaccine doses in adults. Conclusion: Adjuvanted vaccines had more local but not serious adverse events compared to unadjuvanted vaccines. Vaccination with Pandemrix was strongly associated with narcolepsy, particularly in children. No increased risks of pregnancy outcomes were seen after pandemic vaccination. The findings on GBS were inconclusive.	[Juvet, Lene Kristine; Robertson, Anna Hayman; Laake, Ida; Mjaaland, Siri; Trogstad, Lill] Norwegian Inst Publ Hlth, Div Infect Control & Environm Hlth, Oslo, Norway	Norwegian Institute of Public Health (NIPH)	Juvet, LK (corresponding author), Norwegian Inst Publ Hlth, Div Infect Control & Environm Hlth, Oslo, Norway.	LeneKristine.Juvet@fh.no		Juvet, Lene Kristine/0000-0003-3317-8203; Mjaaland, Siri/0000-0002-3870-5861	Norwegian Institute of Public Health	Norwegian Institute of Public Health	Funding The Norwegian Institute of Public Health funded this study.	[Anonymous], 2009, Wkly Epidemiol Rec, V84, P505; [Anonymous], 2009 H1N1 PANDEMIC H; Blomberg B, 2021, NAT MED, V27, P1607, DOI 10.1038/s41591-021-01433-3; Cavaleri M, 2021, LANCET, V397, P355, DOI 10.1016/S0140-6736(21)00085-4; Cuesta JG, 2016, EUROSURVEILLANCE, V21, P25, DOI 10.2807/1560-7917.ES.2016.21.16.30208; de Chambrun GP, 2015, CLIN GASTROENTEROL H, V13, P1405, DOI 10.1016/j.cgh.2015.04.179; Demicheli V, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004876.pub4; Dieleman J, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d3908; Fell DB, 2015, BJOG-INT J OBSTET GY, V122, P17, DOI 10.1111/1471-0528.12977; Foo DYP, 2020, PEDIATRICS, V146, DOI 10.1542/peds.2020-0375; Ghaderi S, 2016, EUR J EPIDEMIOL, V31, P67, DOI 10.1007/s10654-015-0047-0; Giles ML, 2019, HUM VACC IMMUNOTHER, V15, P687, DOI 10.1080/21645515.2018.1540807; Greinacher A, 2021, NEW ENGL J MED, V384, P2092, DOI 10.1056/NEJMoa2104840; Han F, 2013, ANN NEUROL, V73, P560, DOI 10.1002/ana.23799; Han F, 2011, ANN NEUROL, V70, P410, DOI 10.1002/ana.22587; Harder T, 2016, SYST REV-LONDON, V5, DOI 10.1186/s13643-016-0347-9; Hauser MI, 2019, VACCINE, V37, P4246, DOI 10.1016/j.vaccine.2019.06.039; Hunt H, 2018, SYST REV-LONDON, V7, DOI 10.1186/s13643-018-0695-8; Implementation of the International Health Regulations, 2005, WHO 2011 64 WORLD HL; Iuliano AD, 2018, LANCET, V391, P1285, DOI 10.1016/S0140-6736(17)33293-2; Jacob L, 2015, BRAIN BEHAV IMMUN, V47, P44, DOI 10.1016/j.bbi.2014.11.004; Karron RA, 2021, JAMA-J AM MED ASSOC, V325, P2445, DOI 10.1001/jama.2021.7637; Kurz X, 2011, VACCINE, V29, P4378, DOI 10.1016/j.vaccine.2011.04.005; Lansbury LE, 2017, VACCINE, V35, P1996, DOI 10.1016/j.vaccine.2017.02.059; Luo G, 2018, P NATL ACAD SCI USA, V115, pE12323, DOI 10.1073/pnas.1818150116; Magnus P, 2015, VACCINE, V33, P6173, DOI 10.1016/j.vaccine.2015.10.018; Manzoli L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024384; Arias LHM, 2015, VACCINE, V33, P3773, DOI 10.1016/j.vaccine.2015.05.013; McMillan M., 2014, JBI DATABASE SYST RE, V12, P281, DOI [10.11124/jbisrir-2014-126910.11124/issn.2202-4433, DOI 10.11124/JBISRIR-2014-126910.11124/ISSN.2202-4433]; Miller E, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f794; Moher D, 2016, REV ESP NUTR HUM DIE, V20, P148, DOI 10.14306/renhyd.20.2.223; Montplaisir J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108489; Nohynek H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033536; Nunes MC, 2016, AM J PERINAT, V33, P1104, DOI 10.1055/s-0036-1586101; Polyzos KA, 2015, OBSTET GYNECOL, V126, P1075, DOI 10.1097/AOG.0000000000001068; Pormohammad A, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050467; Fadrique RS, 2019, REV ESP QUIM, V32, P288; Sarkanen TO, 2018, SLEEP MED REV, V38, P177, DOI 10.1016/j.smrv.2017.06.006; Schultz NH, 2021, NEW ENGL J MED, V384, P2124, DOI 10.1056/NEJMoa2104882; Seppelt I, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c1279; Shamseer L, 2015, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g7647; Shea BJ, 2017, BMJ-BRIT MED J, V358, DOI 10.1136/bmj.j4008; Stassijns J, 2016, VACCINE, V34, P714, DOI 10.1016/j.vaccine.2015.12.024; Szakacs A, 2013, NEUROLOGY, V80, P1315, DOI 10.1212/WNL.0b013e31828ab26f; Trogstad L, 2017, VACCINE, V35, P1879, DOI 10.1016/j.vaccine.2017.02.053; Vaarala O, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114361; Wachira VK, 2019, TROP MED INT HEALTH, V24, P132, DOI 10.1111/tmi.13181; WHO, 2017, GLOB ADV COM VACC ST; World Health Organization, 2019, CAUSALITY ASSESSMENT; Zhang C, 2018, INT J GYNECOL OBSTET, V141, P141, DOI 10.1002/ijgo.12394; Zorzela L, 2016, BMJ-BRIT MED J, V353, DOI [10.1136/bmj.i2229, 10.1136/bmj.i157]	51	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 28	2021	12								740048	10.3389/fimmu.2021.740048	http://dx.doi.org/10.3389/fimmu.2021.740048			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WW3SM	34777351	Green Published, gold			2022-12-18	WOS:000717840700001
J	Neckermann, P; Boilesen, DR; Willert, T; Pertl, C; Schrodel, S; Thirion, C; Asbach, B; Holst, PJ; Wagner, R				Neckermann, Patrick; Boilesen, Ditte Rahbaek; Willert, Torsten; Pertl, Cordula; Schroedel, Silke; Thirion, Christian; Asbach, Benedikt; Holst, Peter Johannes; Wagner, Ralf			Design and Immunological Validation of Macaca fascicularis Papillomavirus Type 3 Based Vaccine Candidates in Outbred Mice: Basis for Future Testing of a Therapeutic Papillomavirus Vaccine in NHPs	FRONTIERS IN IMMUNOLOGY			English	Article						MfPV3; HPV; therapeutic vaccine; adenoviral vector; immunogen design; DNA vaccine; invariant chain	REPLICATIVE HELICASE E1; T-CELL RESPONSES; CLINICAL-TRIALS; CERVICAL-CANCER; DNA VACCINES; HPV16 E2; ANTIGEN; INFECTION; IMMUNITY; IMMUNOGENICITY	Persistent human papillomavirus (HPV) infections are causative for cervical neoplasia and carcinomas. Despite the availability of prophylactic vaccines, morbidity and mortality induced by HPV are still too high. Thus, an efficient therapy, such as a therapeutic vaccine, is urgently required. Herein, we describe the development and validation of Macaca fascicularis papillomavirus type 3 (MfPV3) antigens delivered via nucleic-acid and adenoviral vectors in outbred mouse models. Ten artificially fused polypeptides comprising early viral regulatory proteins were designed and optionally linked to the T cell adjuvant MHC-II-associated invariant chain. Transfected HEK293 cells and A549 cells transduced with recombinant adenoviruses expressing the same panel of artificial antigens proved proper and comparable expression, respectively. Immunization of outbred CD1 and OF1 mice led to CD8(+) and CD4(+) T cell responses against MfPV3 antigens after DNA- and adenoviral vector delivery. Moreover, in vivo cytotoxicity of vaccine-induced CD8(+) T cells was demonstrated in BALB/c mice by quantifying specific killing of transferred peptide-pulsed syngeneic target cells. The use of the invariant chain as T cell adjuvant enhanced the T cell responses regarding cytotoxicity and in vitro analysis suggested an accelerated turnover of the antigens as causative. Notably, the fusion-polypeptide elicited the same level of T-cell responses as administration of the antigens individually, suggesting no loss of immunogenicity by fusing multiple proteins in one vaccine construct. These data support further development of the vaccine candidates in a follow up efficacy study in persistently infected Macaca fascicularis monkeys to assess their potential to eliminate pre-malignant papillomavirus infections, eventually instructing the design of an analogous therapeutic HPV vaccine.</p>	[Neckermann, Patrick; Asbach, Benedikt; Wagner, Ralf] Univ Regensburg, Inst Med Microbiol & Hyg, Mol Microbiol Virol, Regensburg, Germany; [Boilesen, Ditte Rahbaek; Holst, Peter Johannes] Univ Copenhagen, Panum Inst, Dept Immunol & Microbiol, Ctr Med Parasitol, Copenhagen, Denmark; [Boilesen, Ditte Rahbaek; Holst, Peter Johannes] InProTher APS, Copenhagen, Denmark; [Willert, Torsten; Pertl, Cordula; Schroedel, Silke; Thirion, Christian] SIRION Biotech GmbH, Munich, Germany; [Wagner, Ralf] Univ Hosp Regensburg, Inst Clin Microbiol & Hyg, Regensburg, Germany	University of Regensburg; University of Copenhagen; University of Regensburg	Wagner, R (corresponding author), Univ Regensburg, Inst Med Microbiol & Hyg, Mol Microbiol Virol, Regensburg, Germany.; Holst, PJ (corresponding author), Univ Copenhagen, Panum Inst, Dept Immunol & Microbiol, Ctr Med Parasitol, Copenhagen, Denmark.; Holst, PJ (corresponding author), InProTher APS, Copenhagen, Denmark.; Wagner, R (corresponding author), Univ Hosp Regensburg, Inst Clin Microbiol & Hyg, Regensburg, Germany.	pholst@sund.ku.dk; ralf.wagner@ur.de		Holst, Peter Johannes/0000-0002-1279-304X; Boilesen, Ditte Rahbaek/0000-0003-0675-3655	Eurostars-2 joint programme; European Union [E!12151]; Federal Ministry of Education and Research	Eurostars-2 joint programme; European Union(European Commission); Federal Ministry of Education and Research(Federal Ministry of Education & Research (BMBF))	This project has received funding from the Eurostars-2 joint programme with co-funding from the European Union Horizon 2020 research and innovation programme (E!12151). The project E!12151 was carried out within the framework of the European funding program "Eurostars" and the German partners were funded by the Federal Ministry of Education and Research. The manuscript reflects only the authors' view and the European Commission is not responsible for any use that may be made of the information it contains. The funders had no influence on study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Asbach B, 2019, J VIROL, V93, DOI 10.1128/JVI.01529-18; Barouch DH, 2005, J VIROL, V79, P8828, DOI 10.1128/JVI.79.14.8828-8834.2005; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; Brotherton JML, 2016, CURR OBSTET GYNECOL, V5, P210, DOI 10.1007/s13669-016-0165-z; Brulet JM, 2007, EUR J IMMUNOL, V37, P376, DOI 10.1002/eji.200636233; Capone S, 2014, MOL THER, V22, P1039, DOI 10.1038/mt.2014.15; Chang LH, 2013, J MED VIROL, V85, P646, DOI 10.1002/jmv.23490; Chen ZG, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.02093; Chen ZG, 2009, VIROLOGY, V393, P304, DOI 10.1016/j.virol.2009.07.012; Choi YJ, 2020, CLIN CANCER RES, V26, P1616, DOI 10.1158/1078-0432.CCR-19-1513; COLEMAN N, 1994, AM J CLIN PATHOL, V102, P768, DOI 10.1093/ajcp/102.6.768; de Jong A, 2004, CANCER RES, V64, P5449, DOI 10.1158/0008-5472.CAN-04-0831; Dersh D, 2019, METHODS MOL BIOL, V1988, P109, DOI 10.1007/978-1-4939-9450-2_9; Dillon S, 2007, J GEN VIROL, V88, P803, DOI 10.1099/vir.0.82678-0; EDMONDS C, 1989, J VIROL, V63, P2650, DOI 10.1128/JVI.63.6.2650-2656.1989; Esposito I, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aaz7715; Ewaisha R, 2017, THERANOSTICS, V7, P3814, DOI 10.7150/thno.21098; Fougeroux C, 2019, J IMMUNOL, V202, P2320, DOI 10.4049/jimmunol.1801210; Gan LL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108892; Garza-Morales R, 2019, CANCERS, V11, DOI 10.3390/cancers11010096; Genticel, 2013, PHAS 2 STUD HPV THER; Grujic M, 2009, J GEN VIROL, V90, P414, DOI 10.1099/vir.0.002105-0; Haghshenas M, 2013, INFECT AGENTS CANCER, V8, DOI 10.1186/1750-9378-8-20; Hancock G, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-55014-z; Hibma Merilyn H, 2012, Open Virol J, V6, P241, DOI 10.2174/1874357901206010241; Hildesheim A, 2007, JAMA-J AM MED ASSOC, V298, P743, DOI 10.1001/jama.298.7.743; Ho GYF, 1998, NEW ENGL J MED, V338, P423, DOI 10.1056/NEJM199802123380703; Hobbs Samuel J, 2020, Immunohorizons, V4, P1, DOI 10.4049/immunohorizons.1900070; Holst PJ, 2008, J IMMUNOL, V180, P3339, DOI 10.4049/jimmunol.180.5.3339; Holst PJ, 2011, J IMMUNOL, V186, P3997, DOI 10.4049/jimmunol.1001251; Hung CF, 2008, EXPERT OPIN BIOL TH, V8, P421, DOI [10.1517/14712598.8.4.421, 10.1517/14712598.8.4.421 ]; Joseph S, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00149; Kiener R, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19874-1; Kim JH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018556; Koskimaa HM, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0733-4; Leachman SA, 2002, J VIROL, V76, P7616, DOI 10.1128/JVI.76.15.7616-7624.2002; Lehtinen M, 2012, LANCET ONCOL, V13, P89, DOI 10.1016/S1470-2045(11)70286-8; Liu Y, 1999, J VIROL, V73, P7297, DOI 10.1128/JVI.73.9.7297-7307.1999; Liu ZQ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02460-2; Ma MM, 2018, INFECT AGENTS CANCER, V13, DOI 10.1186/s13027-018-0206-5; Malcles MH, 2002, J VIROL, V76, P11350, DOI 10.1128/JVI.76.22.11350-11358.2002; Mechali F, 2004, J VIROL, V78, P2615, DOI 10.1128/JVI.78.5.2615-2619.2004; Monnier-Benoit S, 2006, GYNECOL ONCOL, V102, P22, DOI 10.1016/j.ygyno.2005.11.039; Nielsen KN, 2014, J IMMUNOL, V193, P1223, DOI 10.4049/jimmunol.1400197; Pantaleo G, 2019, LANCET HIV, V6, pE737, DOI 10.1016/S2352-3018(19)30262-0; Raab David, 2010, Syst Synth Biol, V4, P215, DOI 10.1007/s11693-010-9062-3; Ragonnaud E, 2017, SCAND J IMMUNOL, V85, P182, DOI 10.1111/sji.12522; Ragonnaud E, 2018, VACCINE, V36, P6212, DOI 10.1016/j.vaccine.2018.07.075; Ragonnaud E, 2017, J IMMUNOTHER, V40, P51, DOI 10.1097/CJI.0000000000000153; Ruzsics Z, 2014, METHODS MOL BIOL, V1089, P143, DOI 10.1007/978-1-62703-679-5_11; Sarwar UN, 2015, J INFECT DIS, V211, P549, DOI 10.1093/infdis/jiu511; Schiller JT, 2012, VACCINE, V30, pF123, DOI 10.1016/j.vaccine.2012.04.108; Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660; Turnstone Biologics C, 2018, THIS IS TRIAL MG1 E6; van de Wall S, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1487913; Wieking BG, 2012, CANCER GENE THER, V19, P667, DOI 10.1038/cgt.2012.55; Woo YL, 2010, INT J CANCER, V126, P133, DOI 10.1002/ijc.24804; Wood CE, 2007, J VIROL, V81, P6339, DOI 10.1128/JVI.00233-07; Xue YZ, 2010, CANCER RES, V70, P5316, DOI 10.1158/0008-5472.CAN-09-3789; Yalcin B, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001085	60	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 28	2021	12								761214	10.3389/fimmu.2021.761214	http://dx.doi.org/10.3389/fimmu.2021.761214			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WW2LU	34777375	Green Published, gold			2022-12-18	WOS:000717755700001
J	Swierzko, AS; Jarych, D; Gajek, G; Chojnacka, K; Kobiela, P; Kufelnicka-Babout, M; Michalski, M; Sobczuk, K; Szala-Pozdziej, A; Matsushita, M; Mazela, J; Domzalska-Popadiuk, I; Kilpatrick, DC; Kalinka, J; Sekine, H; Cedzynski, M				Swierzko, Anna S.; Jarych, Dariusz; Gajek, Gabriela; Chojnacka, Karolina; Kobiela, Paulina; Kufelnicka-Babout, Maja; Michalski, Mateusz; Sobczuk, Katarzyna; Szala-Pozdziej, Agnieszka; Matsushita, Misao; Mazela, Jan; Domzalska-Popadiuk, Iwona; Kilpatrick, David C.; Kalinka, Jaroslaw; Sekine, Hideharu; Cedzynski, Maciej			Polymorphisms of the FCN2 Gene 3'UTR Region and Their Clinical Associations in Preterm Newborns	FRONTIERS IN IMMUNOLOGY			English	Article						3'UTR; ficolin-2; FCN2; newborn; prematurity	MANNOSE-BINDING LECTIN; SINGLE NUCLEOTIDE POLYMORPHISMS; L-FICOLIN; RECOGNITION PROTEINS; LARGE COHORT; PATHWAY; COMPLEMENT; INFECTIONS; HAPLOTYPES; ACTIVATION	Ficolin-2 is regarded as an important innate immunity factor endowed with both lectin (carbohydrate recognition) qualities and ability to induce complement activation. The aim of this study was to investigate the association of the FCN2 3'-untranslated region (3'UTR) polymorphisms with ficolin-2 expression and perinatal complications in preterm neonates. The sequencing analysis allowed us to identify six 3'UTR polymorphisms with minor allele frequency (MAF) >1%: rs4521835, rs73664188, rs11103564, rs11103565, rs6537958 and rs6537959. Except for rs4521835, all adhered to Hardy-Weinberg expectations. Moreover, rs6537958 and rs6537959 were shown to be in perfect linkage disequilibrium (LD) with nine other genetic polymorphisms: rs7040372, rs7046516, rs747422, rs7847431, rs6537957, rs6537960, rs6537962, rs11462298 and rs7860507 together stretched on a distance of 1242 bp and very high LD with rs11103565. The 3'UTR region was shown to bind nuclear extract proteins. The polymorphisms at rs4521835 and rs73664188 were found to influence serum ficolin-2 concentration significantly. All polymorphisms identified create (together with exon 8 polymorphism, rs7851696) two haplotype blocks. Among 49 diplotypes (D1-D49) created from rs7851696 (G>T), rs4521835 (T>G), rs73664188 (T>C), rs11103564 (T>C), rs11103565 (G>A) and rs6537959 (T>A), twenty two occurred with frequency >1%. Two diplotypes: D13 (GTTTGT/GGTCGT) and D10 (GTTTGT/GGTCGA), were significantly more frequent among preterm neonates with early onset of infection and pneumonia, compared with newborns with no infectious complications (OR 2.69 and 2.81, respectively; both p<0.05). The minor (C) allele at rs73664188 was associated with an increased risk of very low (<= 1500 g) birthweight (OR=1.95, p=0.042) but was associated with the opposite effect at rs11103564 (OR=0.11, p=0.005).	[Swierzko, Anna S.; Jarych, Dariusz; Gajek, Gabriela; Michalski, Mateusz; Szala-Pozdziej, Agnieszka; Cedzynski, Maciej] Polish Acad Sci, Inst Med Biol, Lab Immunobiol Infect, Lodz, Poland; [Chojnacka, Karolina; Mazela, Jan] Poznan Univ Med Sci, Dept Newborns Infect Dis, Poznan, Poland; [Kobiela, Paulina; Domzalska-Popadiuk, Iwona] Med Univ Gdansk, Dept Neonatol, Gdansk, Poland; [Kufelnicka-Babout, Maja; Sobczuk, Katarzyna; Kalinka, Jaroslaw] Med Univ Lodz, Dept Perinatol, Chair Gynecol & Obstet 1, Lodz, Poland; [Matsushita, Misao] Tokai Univ, Dept Appl Biochem, Hiratsuka, Kanagawa, Japan; [Kilpatrick, David C.] Scottish Natl Blood Transfus Serv, Natl Sci Lab, Edinburgh, Midlothian, Scotland; [Sekine, Hideharu] Fukushima Med Univ, Dept Immunol, Fukushima, Japan	Polish Academy of Sciences; Institute of Medical Biology of the Polish Academy of Sciences; Poznan University of Medical Sciences; Fahrenheit Universities; Medical University Gdansk; Medical University Lodz; Tokai University; Fukushima Medical University	Cedzynski, M (corresponding author), Polish Acad Sci, Inst Med Biol, Lab Immunobiol Infect, Lodz, Poland.	mcedzynski@cbm.pan.pl		Swierzko, Anna/0000-0001-9829-864X; Cedzynski, Maciej/0000-0002-4486-9256; Kufelnicka-Babout, Maja/0000-0002-4404-2726; Kalinka, Jaroslaw/0000-0002-6956-4950	National Science Centre, Poland [2015/17/B/NZ6/04250]	National Science Centre, Poland(National Science Centre, Poland)	Funding This work was funded by National Science Centre, Poland, grant 2015/17/B/NZ6/04250.	Assaf A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034113; Batabyal Subrata, 2014, Biomol Concepts, V5, P21, DOI 10.1515/bmc-2013-0037; Bidula S, 2015, J INFECT DIS, V212, P234, DOI 10.1093/infdis/jiv027; Boyle AP, 2012, GENOME RES, V22, P1790, DOI 10.1101/gr.137323.112; Brazda V, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20225605; Bronkhorst MWGA, 2013, BRIT J SURG, V100, P1818, DOI 10.1002/bjs.9319; Sy BT, 2018, WORLD J GASTROENTERO, V24, P248, DOI 10.3748/wjg.v24.i2.248; Cedzynski M, 2007, CLIN EXP IMMUNOL, V150, P99, DOI 10.1111/j.1365-2249.2007.03471.x; Cedzynski M, 2009, MOL IMMUNOL, V47, P415, DOI 10.1016/j.molimm.2009.08.028; Dabrowska-Zamojcin E, 2018, ARCH IMMUNOL THER EX, V66, P65, DOI 10.1007/s00005-017-0475-5; de Messias-Reason I, 2009, J INFECT DIS, V199, P801, DOI 10.1086/597070; Doi K, 2006, J AM SOC NEPHROL, V17, P823, DOI 10.1681/ASN.2005010094; Endo Y, 1996, GENOMICS, V36, P515, DOI 10.1006/geno.1996.0497; Faik I, 2011, HUM IMMUNOL, V72, P74, DOI 10.1016/j.humimm.2010.10.003; Fukusaki T, 2007, J PERIODONTAL RES, V42, P541, DOI 10.1111/j.1600-0765.2007.00979.x; Gan LB, 2019, EXP BIOL MED, V244, P1438, DOI 10.1177/1535370219880490; Harumiya S, 1996, J BIOCHEM-TOKYO, V120, P745; Hummelshoj T, 2005, HUM MOL GENET, V14, P1651, DOI 10.1093/hmg/ddi173; Jacquet M, 2013, J IMMUNOL, V190, P3721, DOI 10.4049/jimmunol.1202451; Jensen ML, 2007, MOL IMMUNOL, V44, P856, DOI 10.1016/j.molimm.2006.04.002; Kasperkiewicz K, 2017, IMMUNOL CELL BIOL, V95, P666, DOI 10.1038/icb.2017.31; Kilpatrick DC, 2013, HUM IMMUNOL, V74, P867, DOI 10.1016/j.humimm.2013.04.011; Kilpatrick DC, 2009, CLIN RESPIR J, V3, P29, DOI 10.1111/j.1752-699X.2008.00105.x; Krarup A, 2005, INFECT IMMUN, V73, P1052, DOI 10.1128/IAI.73.2.1052-1060.2005; Li D, 2018, DIS MARKERS, V2018, DOI [10.1155/2018/2461815, 10.1155/2018/2461845]; Liu Y, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000015955; Luo FL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073859; Lynch NJ, 2004, J IMMUNOL, V172, P1198, DOI 10.4049/jimmunol.172.2.1198; Ma YG, 2004, J BIOL CHEM, V279, P25307, DOI 10.1074/jbc.M400701200; Ma YJ, 2009, J BIOL CHEM, V284, P28263, DOI 10.1074/jbc.M109.009225; Maqbool SN, 2018, GENE, V679, P44, DOI 10.1016/j.gene.2018.06.102; Metzger ML, 2015, CLIN EXP IMMUNOL, V179, P256, DOI 10.1111/cei.12459; Moszynska A, 2017, OPEN BIOL, V7, DOI 10.1098/rsob.170019; Munthe-Fog L, 2007, SCAND J IMMUNOL, V65, P383, DOI 10.1111/j.1365-3083.2007.01915.x; Giang NT, 2020, INT J INFECT DIS, V95, P253, DOI 10.1016/j.ijid.2020.02.029; Sirisena ND, 2019, BMC RES NOTES, V12, DOI 10.1186/s13104-019-4512-9; Sokolowska A, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-67516-2; Sorensen CA, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01153; Sosoniuk E, 2014, MOL IMMUNOL, V60, P80, DOI 10.1016/j.molimm.2014.03.014; Swierzko AS, 2020, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.03097; Swierzko AS, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02153; Swierzko AS, 2016, INT J MED MICROBIOL, V306, P212, DOI 10.1016/j.ijmm.2016.04.004; Swierzko AS, 2009, MOL IMMUNOL, V46, P551, DOI 10.1016/j.molimm.2008.07.025; Szala A, 2013, CANCER IMMUNOL IMMUN, V62, P1411, DOI 10.1007/s00262-013-1445-3; Szala A, 2013, IMMUNOGENETICS, V65, P439, DOI 10.1007/s00251-013-0696-7; Tak YG, 2015, EPIGENET CHROMATIN, V8, DOI 10.1186/s13072-015-0050-4; Troldborg A, 2017, CLIN EXP IMMUNOL, V188, P138, DOI 10.1111/cei.12909; van Kempen G, 2017, IMMUNOLOGY, V151, P81, DOI 10.1111/imm.12705; Xu N, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000018740; Yan SC, 2019, BMC CANCER, V19, DOI 10.1186/s12885-018-5241-5; Zanetti KA, 2012, CANCER RES, V72, P1467, DOI 10.1158/0008-5472.CAN-11-3073; Zhang J, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000282	52	0	0	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 28	2021	12								741140	10.3389/fimmu.2021.741140	http://dx.doi.org/10.3389/fimmu.2021.741140			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WW1TM	34777352	gold, Green Published			2022-12-18	WOS:000717708100001
J	von Knethen, A; Rodriguez-Barbosa, JI				von Knethen, Andreas; Rodriguez-Barbosa, Jose-Ignacio			Editorial: The Roles of Checkpoint Inhibitors in Inflammatory Diseases	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						sepsis; immune checkpoint inhibition; PD1-PD-L1; inflammation; tolerance			[von Knethen, Andreas] Univ Hosp Frankfurt, Dept Anaesthesiol Intens Care Med & Pain Therapy, Frankfurt, Germany; [Rodriguez-Barbosa, Jose-Ignacio] Univ Leon, Inst Mol Biol Genom & Prote, Sch Biol & Biotechnol, Transplantat,Immunobiol, Leon, Spain	Goethe University Frankfurt; Goethe University Frankfurt Hospital; Universidad de Leon	von Knethen, A (corresponding author), Univ Hosp Frankfurt, Dept Anaesthesiol Intens Care Med & Pain Therapy, Frankfurt, Germany.	andreas.vonknethen@kgu.de		Rodriguez-Barbosa, Jose-Ignacio/0000-0001-7427-5654	Deutsche Forschungsgemeinschaft [KN493/13-1, SFB815 TP3]; Else Kroner-Fresenius Foundation (EKFS); Research Training Group Translational Research Innovation-Pharma (TRIP); State of Hessen; Spanish Ministry of Science and Universities [PID2019-103984RB-I00]; Department of Education of Castilla and Leon Regional Government [LE-006P20]; Spanish Network of Cancer Research [CB16/12/00480]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Else Kroner-Fresenius Foundation (EKFS); Research Training Group Translational Research Innovation-Pharma (TRIP); State of Hessen; Spanish Ministry of Science and Universities(Spanish Government); Department of Education of Castilla and Leon Regional Government; Spanish Network of Cancer Research	Funding This research was supported by grants from the Deutsche Forschungsgemeinschaft (KN493/13-1 and SFB815 TP3). The Else KrOner-Fresenius Foundation (EKFS), the Research Training Group Translational Research Innovation-Pharma (TRIP), and the State of Hessen to the LOEWE Research Centre for Translational Medicine and Pharmacology in part funded the work. This work has been supported by grants of the Spanish Ministry of Science and Universities (Grant # PID2019-103984RB-I00), Department of Education of Castilla and Leon Regional Government (Grant # LE-006P20) to JIRB and it was also partially funded by the Spanish Network of Cancer Research, Ciberonc (Grant # CB16/12/00480).	Bagchi S, 2021, ANNU REV PATHOL-MECH, V16, P223, DOI 10.1146/annurev-pathol-042020-042741; Fallon EA, 2018, J LEUKOCYTE BIOL, V103, P1151, DOI 10.1002/JLB.2MIR0917-377R; Gillis A, 2019, INTENS CARE MED EXP, V7, DOI 10.1186/s40635-019-0260-3; Keir ME, 2008, ANNU REV IMMUNOL, V26, P677, DOI 10.1146/annurev.immunol.26.021607.090331; Liu JH, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.731798; Patil NK, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18112413; Postow MA, 2018, NEW ENGL J MED, V378, P158, DOI [10.1056/NEJMra1703481, 10.1056/NEJMc1801663]; Wakeley ME, 2020, CRIT CARE CLIN, V36, P69, DOI 10.1016/j.ccc.2019.08.006; Wang YT, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00536	9	0	0	2	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 28	2021	12								795495	10.3389/fimmu.2021.795495	http://dx.doi.org/10.3389/fimmu.2021.795495			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WW3SF	34777402	Green Published, gold			2022-12-18	WOS:000717840000001
J	Alfituri, OA; Quintana, JF; MacLeod, A; Garside, P; Benson, RA; Brewer, JM; Mabbott, NA; Morrison, LJ; Capewell, P				Alfituri, Omar A.; Quintana, Juan F.; MacLeod, Annette; Garside, Paul; Benson, Robert A.; Brewer, James M.; Mabbott, Neil A.; Morrison, Liam J.; Capewell, Paul			To the Skin and Beyond: The Immune Response to African Trypanosomes as They Enter and Exit the Vertebrate Host (vol 11, 1250, 2020)	FRONTIERS IN IMMUNOLOGY			English	Correction						African trypanosomiasis; Trypanosoma brucei; skin; transmission; innate immunity; neglected tropical disease			Univ Edinburgh, Royal Dick Sch Vet Studies, Roslin Inst, Edinburgh, Midlothian, Scotland; [Quintana, Juan F.; MacLeod, Annette; Garside, Paul; Benson, Robert A.; Brewer, James M.] Univ Glasgow, Wellcome Ctr Integrat Parasitol, Inst Biodivers Anim Hlth & Comparat Med, Coll Med Vet & Life Sci, Glasgow, Lanark, Scotland; [Capewell, Paul] Univ Glasgow, Coll Med Vet & Life Sci, Inst Biodivers Anim Hlth & Comparat Med, Glasgow, Lanark, Scotland	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Roslin Institute; University of Edinburgh; University of Glasgow; University of Glasgow	Capewell, P (corresponding author), Univ Glasgow, Coll Med Vet & Life Sci, Inst Biodivers Anim Hlth & Comparat Med, Glasgow, Lanark, Scotland.	paul.capewell@glasgow.ac.uk							0	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 27	2021	12								780758	10.3389/fimmu.2021.780758	http://dx.doi.org/10.3389/fimmu.2021.780758			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WW1NM	34777397	Green Published, gold			2022-12-18	WOS:000717692200001
J	Barnes, SA; Trew, I; de Jong, E; Foley, B				Barnes, Samantha A.; Trew, Isabella; de Jong, Emma; Foley, Bree			Making a Killer: Selecting the Optimal Natural Killer Cells for Improved Immunotherapies	FRONTIERS IN IMMUNOLOGY			English	Review						natural killer cells; cancer immunotherapy; donor selection; cell metabolism; phenotype; epigenetics; transcriptomics	IG-LIKE RECEPTOR; MHC CLASS-I; HUMAN CYTOMEGALOVIRUS-INFECTION; CD56(BRIGHT) NK CELLS; INHIBITORY RECEPTORS; LEUKEMIA RELAPSE; HLA-B; METABOLIC CHECKPOINT; DONOR SELECTION; KIR LIGANDS	Over the past 20 years natural killer (NK) cell-based immunotherapies have emerged as a safe and effective treatment option for patients with relapsed or refractory leukemia. Unlike T cell-based therapies, NK cells harbor an innate capacity to eliminate malignant cells without prior sensitization and can be adoptively transferred between individuals without the need for extensive HLA matching. A wide variety of therapeutic NK cell sources are currently being investigated clinically, including allogeneic donor-derived NK cells, stem cell-derived NK cells and NK cell lines. However, it is becoming increasingly clear that not all NK cells are endowed with the same antitumor potential. Despite advances in techniques to enhance NK cell cytotoxicity and persistence, the initial identification and utilization of highly functional NK cells remains essential to ensure the future success of adoptive NK cell therapies. Indeed, little consideration has been given to the identification and selection of donors who harbor NK cells with potent antitumor activity. In this regard, there is currently no standard donor selection criteria for adoptive NK cell therapy. Here, we review our current understanding of the factors which govern NK cell functional fate, and propose a paradigm shift away from traditional phenotypic characterization of NK cell subsets towards a functional profile based on molecular and metabolic characteristics. We also discuss previous selection models for NK cell-based immunotherapies and highlight important considerations for the selection of optimal NK cell donors for future adoptive cell therapies.	[Barnes, Samantha A.; Trew, Isabella; de Jong, Emma; Foley, Bree] Univ Western Australia, Telethon Kids Inst, Nedlands, WA, Australia; [Barnes, Samantha A.; Trew, Isabella] Univ Western Australia, Sch Biomed Sci, Crawley, WA, Australia	Telethon Kids Institute; University of Western Australia; University of Western Australia	Foley, B (corresponding author), Univ Western Australia, Telethon Kids Inst, Nedlands, WA, Australia.	bree.foley@telethonkids.org.au	de Jong, Emma/AHC-9300-2022	de Jong, Emma/0000-0002-2501-6119	Australian Government Research Training Program	Australian Government Research Training Program(Australian Government)	Funding The preparation of this review article received no external funding. This work was supported by the Australian Government Research Training Program Scholarship at The University of Western Australia (scholarship to SB), and the Cancer Council Western Australia and the Western Australia Department of Health (research funding to BF).	Abel AM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01869; Anfossi N, 2006, IMMUNITY, V25, P331, DOI 10.1016/j.immuni.2006.06.013; Angelo LS, 2015, IMMUNOL RES, V62, P341, DOI 10.1007/s12026-015-8664-y; Babor F, 2019, BONE MARROW TRANSPL, V54, P1847, DOI 10.1038/s41409-019-0543-z; Bachanova V, 2014, BLOOD, V123, P3855, DOI 10.1182/blood-2013-10-532531; Barnes S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21228864; Berg M, 2009, CYTOTHERAPY, V11, P341, DOI 10.1080/14653240902807034; Bjorkstrom NK, 2022, NAT REV IMMUNOL, V22, P112, DOI 10.1038/s41577-021-00558-3; Bjorkstrom NK, 2011, J EXP MED, V208, P13, DOI 10.1084/jem.20100762; Boudreau JE, 2018, TRENDS IMMUNOL, V39, P222, DOI 10.1016/j.it.2017.12.001; Boudreau JE, 2017, J CLIN ONCOL, V35, P2268, DOI 10.1200/JCO.2016.70.7059; Brand A, 2016, CELL METAB, V24, P657, DOI 10.1016/j.cmet.2016.08.011; Braud VM, 1998, NATURE, V391, P795, DOI 10.1038/35869; Brillantes M, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.00102; Brodin P, 2009, TRENDS IMMUNOL, V30, P143, DOI 10.1016/j.it.2009.01.006; Bryceson YT, 2006, IMMUNOL REV, V214, P73, DOI 10.1111/j.1600-065X.2006.00457.x; Caligiuri MA, 2008, BLOOD, V112, P461, DOI 10.1182/blood-2007-09-077438; Carr WH, 2005, J IMMUNOL, V175, P5222, DOI 10.4049/jimmunol.175.8.5222; CELLA M, 1994, J EXP MED, V180, P1235, DOI 10.1084/jem.180.4.1235; Chambers AM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02533; Chang CH, 2015, CELL, V162, P1229, DOI 10.1016/j.cell.2015.08.016; Choi C, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287-021-02377-8; Cichocki F, 2016, LEUKEMIA, V30, P456, DOI 10.1038/leu.2015.260; Cichocki F, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.125553; Cichocki F, 2018, J EXP MED, V215, P2379, DOI 10.1084/jem.20172168; Cichocki F, 2017, CANCER RES, V77, P5664, DOI 10.1158/0008-5472.CAN-17-0799; Collins PL, 2019, CELL, V176, P348, DOI 10.1016/j.cell.2018.11.045; Colonna M, 2018, IMMUNITY, V48, P1104, DOI 10.1016/j.immuni.2018.05.013; Cook MA, 2004, BLOOD, V103, P1521, DOI 10.1182/blood-2003-02-0438; Cooley S, 2005, BLOOD, V106, P4370, DOI 10.1182/blood-2005-04-1644; Cooley S, 2019, BIOL BLOOD MARROW TR, V25; Cooley S, 2010, BLOOD, V116, P2411, DOI 10.1182/blood-2010-05-283051; Crinier A, 2021, CELL MOL IMMUNOL, V18, P1290, DOI 10.1038/s41423-020-00574-8; Crinier A, 2018, IMMUNITY, V49, P971, DOI 10.1016/j.immuni.2018.09.009; Cruz-Munoz ME, 2009, NAT IMMUNOL, V10, P297, DOI 10.1038/ni.1693; Dalle JH, 2005, PEDIATR RES, V57, P649, DOI 10.1203/01.PDR.0000156501.55431.20; Della Chiesa M, 2014, J IMMUNOL, V192, P1471, DOI 10.4049/jimmunol.1302053; Dogra P, 2020, CELL, V180, P749, DOI 10.1016/j.cell.2020.01.022; Donnelly RP, 2014, J IMMUNOL, V193, P4477, DOI 10.4049/jimmunol.1401558; Dulphy N, 2008, J IMMUNOL, V181, P2227, DOI 10.4049/jimmunol.181.3.2227; Elliott JM, 2011, TRENDS IMMUNOL, V32, P364, DOI 10.1016/j.it.2011.06.001; Elmaagacli AH, 2016, BLOOD, V128, P456, DOI 10.1182/blood-2016-04-713644; Farag SS, 2006, BIOL BLOOD MARROW TR, V12, P876, DOI 10.1016/j.bbmt.2006.05.007; Foley B, 2020, CLIN TRANSL IMMUNOL, V9, DOI 10.1002/cti2.1151; Foley B, 2012, J IMMUNOL, V189, P5082, DOI 10.4049/jimmunol.1201964; Foley B, 2012, BLOOD, V119, P2665, DOI 10.1182/blood-2011-10-386995; Foley B, 2011, BLOOD, V118, P2784, DOI 10.1182/blood-2011-04-347070; Foley BA, 2008, BLOOD, V112, P435, DOI 10.1182/blood-2008-01-132902; Fujisaki H, 2009, CANCER RES, V69, P4010, DOI 10.1158/0008-5472.CAN-08-3712; Gamliel M, 2018, IMMUNITY, V48, P951, DOI 10.1016/j.immuni.2018.03.030; Gang M, 2020, SEMIN HEMATOL, V57, P185, DOI 10.1053/j.seminhematol.2020.11.003; Gao F, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.02022; Gardiner CM., 2019, IMMUNOMETABOLISM, V1, DOI [10.20900/immunometab20190005, DOI 10.20900/IMMUNOMETAB20190005]; Gaynor LM, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00467; Geller MA, 2020, J CLIN ONCOL, V38; Godal R, 2010, BIOL BLOOD MARROW TR, V16, P612, DOI 10.1016/j.bbmt.2010.01.019; Gonzalez VD, 2009, J IMMUNOL, V183, P6612, DOI 10.4049/jimmunol.0901437; Goodridge JP, 2015, IMMUNOL REV, V267, P197, DOI 10.1111/imr.12325; Guma M, 2004, BLOOD, V104, P3664, DOI 10.1182/blood-2004-05-2058; Gumperz JE, 1997, J IMMUNOL, V158, P5237; Hallner A, 2019, BLOOD, V133, P1479, DOI 10.1182/blood-2018-09-874990; Hammer Q, 2018, NAT IMMUNOL, V19, P453, DOI 10.1038/s41590-018-0082-6; Hanna J, 2006, NAT MED, V12, P1065, DOI 10.1038/nm1452; He YK, 2017, CELL MOL IMMUNOL, V14, P321, DOI 10.1038/cmi.2016.26; Hirayama A, 2009, CANCER RES, V69, P4918, DOI 10.1158/0008-5472.CAN-08-4806; Ho PC, 2015, CELL, V162, P1217, DOI 10.1016/j.cell.2015.08.012; Hsu KC, 2006, BIOL BLOOD MARROW TR, V12, P828, DOI 10.1016/j.bbmt.2006.04.008; Hsu KC, 2002, J IMMUNOL, V169, P5118, DOI 10.4049/jimmunol.169.9.5118; Hsu KC, 2002, IMMUNOL REV, V190, P40, DOI 10.1034/j.1600-065X.2002.19004.x; HU PF, 1995, J ACQ IMMUN DEF SYND, V10, P331; Idso John M, 2020, Oncotarget, V11, P1799, DOI 10.18632/oncotarget.27546; Inagaki J, 2016, BIOL BLOOD MARROW TR, V22, P300, DOI 10.1016/j.bbmt.2015.09.006; Jacobs R, 2001, EUR J IMMUNOL, V31, P3121, DOI 10.1002/1521-4141(2001010)31:10<3121::AID-IMMU3121>3.0.CO;2-4; Joncker NT, 2009, J IMMUNOL, V182, P4572, DOI 10.4049/jimmunol.0803900; Judge SJ, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.00049; Keating SE, 2016, J IMMUNOL, V196, P2552, DOI 10.4049/jimmunol.1501783; Keppel MP, 2015, J IMMUNOL, V194, P1954, DOI 10.4049/jimmunol.1402099; Kim S, 2005, NATURE, V436, P709, DOI 10.1038/nature03847; King A, 2000, EUR J IMMUNOL, V30, P1623, DOI 10.1002/1521-4141(200006)30:6<1623::AID-IMMU1623>3.0.CO;2-M; Lanier LL, 2015, CANCER IMMUNOL RES, V3, P575, DOI 10.1158/2326-6066.CIR-15-0098; Lee J, 2015, IMMUNITY, V42, P431, DOI 10.1016/j.immuni.2015.02.013; Leong JW, 2014, BIOL BLOOD MARROW TR, V20, P463, DOI 10.1016/j.bbmt.2014.01.006; Leung W, 2004, J IMMUNOL, V172, P644, DOI 10.4049/jimmunol.172.1.644; Li K, 2020, GENOM PROTEOM BIOINF, V18, P501, DOI 10.1016/j.gpb.2020.12.003; Li Y, 2017, ONCOTARGET, V8, P41854, DOI 10.18632/oncotarget.16688; Liu LL, 2017, CANCER IMMUNOL RES, V5, P654, DOI 10.1158/2326-6066.CIR-16-0296; Liu LL, 2016, CELL REP, V15, P1088, DOI 10.1016/j.celrep.2016.04.005; Long EO, 2013, ANNU REV IMMUNOL, V31, P227, DOI 10.1146/annurev-immunol-020711-075005; Luetke-Eversloh M, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004441; Luetke-Eversloh M, 2014, EUR J IMMUNOL, V44, P2074, DOI 10.1002/eji.201344072; Luevano M, 2012, HUM IMMUNOL, V73, P248, DOI 10.1016/j.humimm.2011.12.015; Lupo KB, 2019, CANCERS, V11, DOI 10.3390/cancers11060769; Mace EM, 2013, BLOOD, V121, P2669, DOI 10.1182/blood-2012-09-453969; Makanga DR, 2020, CANCERS, V12, DOI 10.3390/cancers12071927; Mancusi A, 2015, BLOOD, V125, P3173, DOI 10.1182/blood-2014-09-599993; Marais A, 2014, NAT IMMUNOL, V15, P749, DOI 10.1038/ni.2936; Merino AM, 2020, J LEUKOCYTE BIOL, V108, P1361, DOI 10.1002/JLB.4MR0620-091R; Miller JS, 2007, BLOOD, V109, P5058, DOI 10.1182/blood-2007-01-065383; Miller JS, 2005, BLOOD, V105, P3051, DOI 10.1182/blood-2004-07-2974; Moesta AK, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00336; Moradi S, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22359-x; Myers JA, 2021, NAT REV CLIN ONCOL, V18, P85, DOI 10.1038/s41571-020-0426-7; Nagumo Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112415; Nakajima H, 1999, EUR J IMMUNOL, V29, P1676, DOI 10.1002/(SICI)1521-4141(199905)29:05<1676::AID-IMMU1676>3.0.CO;2-Y; Nandagopal N, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00187; Nguyen S, 2005, BLOOD, V105, P4135, DOI 10.1182/blood-2004-10-4113; O'Brien KL, 2019, NAT REV IMMUNOL, V19, P282, DOI 10.1038/s41577-019-0139-2; O'Connor GM, 2014, J IMMUNOL, V192, P2875, DOI 10.4049/jimmunol.1303142; Orr MT, 2010, NAT IMMUNOL, V11, P321, DOI 10.1038/ni.1849; Pegram HJ, 2011, IMMUNOL CELL BIOL, V89, P216, DOI 10.1038/icb.2010.78; Pende D, 2009, BLOOD, V113, P3119, DOI 10.1182/blood-2008-06-164103; Perez-Martinez A, 2020, AM J HEMATOL, V95, P28, DOI 10.1002/ajh.25661; Pfeiffer M, 2007, BRIT J HAEMATOL, V138, P97, DOI 10.1111/j.1365-2141.2007.06631.x; Poznanski SM, 2021, CELL METAB, V33, P1205, DOI 10.1016/j.cmet.2021.03.023; Poznanski SM, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01414; Poznanski SM, 2018, CANCER IMMUNOL RES, V6, P1174, DOI 10.1158/2326-6066.CIR-18-0144; Robinson J, 2013, NUCLEIC ACIDS RES, V41, pD1234, DOI 10.1093/nar/gks1140; Romee R, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf2341; Romee R, 2012, BLOOD, V120, P4751, DOI 10.1182/blood-2012-04-419283; ROSENBER.EB, 1972, INT J CANCER, V27, P648, DOI 10.1002/ijc.2910090323; Ruggeri L, 2002, SCIENCE, V295, P2097, DOI 10.1126/science.1068440; Santourlidis S, 2008, J IMMUNOL, V180, P418, DOI 10.4049/jimmunol.180.1.418; Schafer JR, 2019, J ALLERGY CLIN IMMUN, V143, P346, DOI 10.1016/j.jaci.2018.06.047; Schlums H, 2015, IMMUNITY, V42, P443, DOI 10.1016/j.immuni.2015.02.008; Scoville SD, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00360; Shilling HG, 2003, BLOOD, V101, P3730, DOI 10.1182/blood-2002-08-2568; Siewiera J, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10183; Smith SL, 2020, BLOOD ADV, V4, P1388, DOI 10.1182/bloodadvances.2019000699; Solomon SR, 2018, BIOL BLOOD MARROW TR, V24, P789, DOI 10.1016/j.bbmt.2018.01.013; Stewart CA, 2005, P NATL ACAD SCI USA, V102, P13224, DOI 10.1073/pnas.0503594102; Streltsova MA, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0208469; Suck G, 2016, CANCER IMMUNOL IMMUN, V65, P485, DOI 10.1007/s00262-015-1761-x; Surace L, 2021, BLOOD ADV, V5, P26, DOI 10.1182/bloodadvances.2020003458; Takahashi E, 2007, SCAND J IMMUNOL, V65, P126, DOI 10.1111/j.1365-3083.2006.01883.x; Tanaka H, 2003, EUR J HAEMATOL, V71, P29, DOI 10.1034/j.1600-0609.2003.00081.x; Tarek N, 2012, J CLIN INVEST, V122, P3260, DOI 10.1172/JCI62749; Terren I, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02278; Torelli GF, 2014, HAEMATOLOGICA, V99, P1248, DOI 10.3324/haematol.2013.101931; Vago L, 2008, BLOOD, V112, P3488, DOI 10.1182/blood-2007-07-103325; Vaidya SV, 2005, J IMMUNOL, V174, P800, DOI 10.4049/jimmunol.174.2.800; Veillette A, 2002, ANNU REV IMMUNOL, V20, P669, DOI 10.1146/annurev.immunol.20.081501.130710; Veluchamy JP, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00631; Venstrom JM, 2012, NEW ENGL J MED, V367, P805, DOI 10.1056/NEJMoa1200503; Verma S, 1997, EUR J IMMUNOL, V27, P979, DOI 10.1002/eji.1830270426; Viel S, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aad1884; Vogler I, 2011, J INNATE IMMUN, V3, P227, DOI 10.1159/000324112; Voss K, 2021, NAT REV IMMUNOL, V21, P637, DOI 10.1038/s41577-021-00529-8; Wagner JA, 2017, J CLIN INVEST, V127, P4042, DOI 10.1172/JCI90387; Wagner JA, 2017, BIOL BLOOD MARROW TR, V23, P398, DOI 10.1016/j.bbmt.2016.11.018; Wang FJ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07277-9; Wang W, 2017, FUTURE ONCOL, V13, P1043, DOI 10.2217/fon-2017-0039; Wang W, 2016, CANCER IMMUNOL IMMUN, V65, P1047, DOI 10.1007/s00262-016-1864-z; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016; Xia MR, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.672328; Yang C, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11947-7; Yang MX, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12730; Yang MX, 2015, J EXP MED, V212, P253, DOI 10.1084/jem.20141703; Yawata M, 2008, BLOOD, V112, P2369, DOI 10.1182/blood-2008-03-143727; Yu J, 2007, J IMMUNOL, V179, P5977, DOI 10.4049/jimmunol.179.9.5977; Yu JL, 2009, BLOOD, V113, P3875, DOI 10.1182/blood-2008-09-177055; Zaiatz-Bittencourt V, 2018, J IMMUNOL, V200, P3934, DOI 10.4049/jimmunol.1701461; Zhang TX, 2013, J IMMUNOL, V190, P1402, DOI 10.4049/jimmunol.1203034	162	0	0	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 27	2021	12								765705	10.3389/fimmu.2021.765705	http://dx.doi.org/10.3389/fimmu.2021.765705			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WW0DM	34777383	Green Published, gold			2022-12-18	WOS:000717597600001
J	Bulgarelli, J; Piccinini, C; Petracci, E; Pancisi, E; Granato, AM; de Rosa, F; Guidoboni, M; Petrini, M; Ancarani, V; Foschi, G; Romeo, A; Tontini, L; De Giorgi, U; Lolli, C; Gentili, G; Valmorri, L; Rossi, A; Ferroni, F; Casadei, C; Cortesi, P; Crudi, L; Ridolfi, L				Bulgarelli, Jenny; Piccinini, Claudia; Petracci, Elisabetta; Pancisi, Elena; Granato, Anna Maria; de Rosa, Francesco; Guidoboni, Massimo; Petrini, Massimiliano; Ancarani, Valentina; Foschi, Giovanni; Romeo, Antonino; Tontini, Luca; De Giorgi, Ugo; Lolli, Cristian; Gentili, Giorgia; Valmorri, Linda; Rossi, Alice; Ferroni, Fabio; Casadei, Carla; Cortesi, Pietro; Crudi, Laura; Ridolfi, Laura			Radiotherapy and High-Dose Interleukin-2: Clinical and Immunological Results of a Proof of Principle Study in Metastatic Melanoma and Renal Cell Carcinoma	FRONTIERS IN IMMUNOLOGY			English	Article						metastatic melanoma; renal cell carcinoma; radiotherapy; high dose IL-2; IFN-gamma ELISPOT assay; clinical immunomonitoring	LONG-TERM SURVIVAL; RECOMBINANT INTERLEUKIN-2; IMMUNE-RESPONSES; IMMUNOTHERAPY; THERAPY; CANCER; GUIDELINES; EFFICACY; CRITERIA; ELISPOT	High-dose interleukin-2 (HD IL-2) has curative potential in metastatic melanoma (MM) and renal cell carcinoma (RCC). Radiotherapy (RT) kills cancer cells and induces immunomodulatory effects. Prospective trials exploring clinical and immunological properties of combined RT/HD IL-2 are still needed. We designed a phase II, single-arm clinical trial for patients with MM and RCC. The treatment schedule consisted of 3 daily doses of 6-12 Gy of RT to 1-5 non-index metastatic fields, before IL-2 at the first and third treatment cycle. HD IL-2 was administered by continuous infusion for 72 hours and repeated every 3 weeks for up to 4 cycles, thereafter every 4 weeks for a maximum of 2 cycles. The primary endpoint was the immunological efficacy of the combined RT/HD IL-2 treatment (assessed by IFN-gamma ELISPOT). Nineteen out of 22 patients were evaluable for immunological and clinical response. Partial response occurred in 3 (15.7%) patients and stable disease was observed in 7 (36.8%). The disease control rate was 52.6% after a median follow up of 39.2 months. According to Common Terminology Criteria for Adverse Events 4.0 (CTCAE 4.0), the majority of toxicities were grade 1-2. Immunological responses were frequent and detected in 16 (84.2%) patients. Increased levels of IL-8 and IL-10 in melanoma, circulating effector memory CD4+ and intratumoral CD8+ T cells in both tumor types were detected after therapy. Overall the treatment was well tolerated and immunologically active. Immunomonitoring and correlative data on tumor and peripheral blood cell subsets suggest that this combination treatment could be a promising strategy for patients progressing after standard treatments.	[Bulgarelli, Jenny; Piccinini, Claudia; Pancisi, Elena; Granato, Anna Maria; de Rosa, Francesco; Guidoboni, Massimo; Petrini, Massimiliano; Ancarani, Valentina; Foschi, Giovanni; Ridolfi, Laura] IRCCS Ist Romagnolo Studio Tumori IRST Dino Ama, Cell Therapy & Biobank Unit, Immunotherapy, Meldola, Italy; [Petracci, Elisabetta; Gentili, Giorgia; Valmorri, Linda] IRCCS Ist Romagnolo Studio Tumori IRST Dino Ama, Unit Biostat & Clin Trials, Meldola, Italy; [Romeo, Antonino; Tontini, Luca] IRCCS Ist Romagnolo Studio Tumori IRST Dino Ama, Radiotherapy Unit, Meldola, Italy; [De Giorgi, Ugo; Lolli, Cristian] IRCCS Ist Romagnolo Studio Tumori IRST Dino Ama, Dept Med Oncol, Meldola, Italy; [Rossi, Alice; Ferroni, Fabio] IRCCS Ist Romagnolo Studio Tumori IRST Dino Ama, Radiol Unit, Meldola, Italy; [Casadei, Carla] IRCCS Ist Romagnolo Studio Tumori IRST Dino Ama, Anesthesiol Serv, Meldola, Italy; [Cortesi, Pietro] IRCCS Ist Romagnolo Studio Tumori IRST Dino Ama, Cardio Oncol Unit, Meldola, Italy; [Crudi, Laura] IRCCS Ist Romagnolo Studio Tumori IRST Dino Ama, Oncol Pharm Unit, Meldola, Italy		Petracci, E (corresponding author), IRCCS Ist Romagnolo Studio Tumori IRST Dino Ama, Unit Biostat & Clin Trials, Meldola, Italy.	elisabetta.petracci@irst.emr.it	de Rosa, Francesco/AAC-5935-2022; DE ROSA, Francesco Giuseppe/AAC-7275-2022; Bulgarelli, Jenny/AAB-6083-2021; Lolli, Cristian/AAC-4116-2022	de Rosa, Francesco/0000-0003-0511-1298; DE ROSA, Francesco Giuseppe/0000-0001-8338-0130; Bulgarelli, Jenny/0000-0002-6551-0189; Guidoboni, Massimo/0000-0001-7703-790X	Italian Ministry of Health [RF-2009-1547242]	Italian Ministry of Health(Ministry of Health, Italy)	This work was supported by the Italian Ministry of Health (project no. RF-2009-1547242). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aliru ML, 2018, IMMUNOTHERAPY-UK, V10, P299, DOI 10.2217/imt-2017-0082; Alva A, 2016, CANCER IMMUNOL IMMUN, V65, P1533, DOI 10.1007/s00262-016-1910-x; Amato RJ, 2008, CLIN CANCER RES, V14, P7504, DOI 10.1158/1078-0432.CCR-08-0668; Atkins MB, 2000, CANCER J SCI AM, V6, pS11; Bachmann MF, 2007, EMBO REP, V8, P1142, DOI 10.1038/sj.embor.7401099; Buchbinder EI, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0522-3; Bulgarelli J, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02353; Carvalho HD, 2018, CLINICS, V73, DOI 10.6061/clinics/2018/e557s; Cesana GC, 2006, J CLIN ONCOL, V24, P1169, DOI 10.1200/JCO.2005.03.6830; Choueiri TK, 2021, NEW ENGL J MED, V385, P683, DOI 10.1056/NEJMoa2106391; Clark JI, 2021, J INVEST MED, V69, P888, DOI 10.1136/jim-2020-001650; Clark JI, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0387-x; Clark JI, 2017, CLIN GENITOURIN CANC, V15, P31, DOI 10.1016/j.clgc.2016.10.008; Crittenden MR, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25482-w; Curti B, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-000773; De Giorgi U, 2019, BJU INT, V123, P98, DOI 10.1111/bju.14461; Diab A, 2020, CANCER DISCOV, V10, P1158, DOI 10.1158/2159-8290.CD-19-1510; Dutcher JP, 2013, THER ADV UROL, V5, P338, DOI 10.1177/1756287213505672; Dutcher JP, 2011, ONCOLOGY-NY, V25, P427; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Fisher RI, 2000, CANCER J SCI AM, V6, pS55; FYFE G, 1995, J CLIN ONCOL, V13, P688, DOI 10.1200/JCO.1995.13.3.688; Gaucher L, 2021, THER ADV MED ONCOL, V13, DOI 10.1177/1758835921996656; Gutzmer R, 2020, LANCET, V395, P1835, DOI 10.1016/S0140-6736(20)30934-X; Hinrichs CS, 2005, J IMMUNOTHER, V28, P517, DOI 10.1097/01.cji.0000177999.95831.7b; Larkin J, 2019, NEW ENGL J MED, V381, P1535, DOI 10.1056/NEJMoa1910836; Lopes JE, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-000673; Malyguine Anatoli, 2004, J Transl Med, V2, P9, DOI 10.1186/1479-5876-2-9; Masini C, 2022, EUR UROL, V81, P274, DOI 10.1016/j.eururo.2021.09.016; Matek TR, 2008, ANNU REV IMMUNOL, V26, P453, DOI 10.1146/annurev.immunol.26.021607.090357; Mavroukakis S A, 2001, Clin J Oncol Nurs, V5, P207; McDermott D, 2014, CANCER TREAT REV, V40, P1056, DOI 10.1016/j.ctrv.2014.06.012; McDermott DF, 2015, CLIN CANCER RES, V21, P561, DOI 10.1158/1078-0432.CCR-14-1520; Mondini M, 2020, MOL ONCOL, V14, P1529, DOI 10.1002/1878-0261.12658; Motzer RJ, 2019, J NATL COMPR CANC NE, V17, P1279, DOI 10.6004/jnccn.2019.0054; Payne R, 2014, J IMMUNOTHER CANCER, V2, DOI 10.1186/2051-1426-2-13; Quan W, 2004, CANCER BIOTHER RADIO, V19, P350, DOI 10.1089/1084978041424972; Rasmussen S, 2013, IMMUNOPHARM IMMUNOT, V35, P487, DOI 10.3109/08923973.2013.802802; Ricciuti B, 2019, J CLIN ONCOL, V37, P1927, DOI 10.1200/JCO.19.00189; Ridolfi L, 2014, J TRANSL MED, V12, DOI 10.1186/s12967-014-0262-6; Romano E, 2021, CANCERS, V13, DOI 10.3390/cancers13030457; Rosenberg SA, 1998, ANN SURG, V228, P307, DOI 10.1097/00000658-199809000-00004; Schmittel A, 2000, J IMMUNOTHER, V23, P289, DOI 10.1097/00002371-200005000-00001; Schwartzentruber DJ, 2001, J IMMUNOTHER, V24, P287, DOI 10.1097/00002371-200107000-00004; Seymour L, 2017, LANCET ONCOL, V18, pE143, DOI 10.1016/S1470-2045(17)30074-8; Silk AW, 2020, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01483; Simon R, 1989, Oncology (Williston Park), V3, P43; Siota M, 2011, EXPERT REV VACCINES, V10, P299, DOI [10.1586/erv.10.169, 10.1586/ERV.10.169]; Thompson JA, 2012, J IMMUNOTHER, V35, P73, DOI 10.1097/CJI.0b013e31823735d6	49	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 27	2021	12								778459	10.3389/fimmu.2021.778459	http://dx.doi.org/10.3389/fimmu.2021.778459			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WW1JY	34777395	Green Published, gold			2022-12-18	WOS:000717683000001
J	Cui, XT; Wang, QX; Kang, CS				Cui, Xiaoteng; Wang, Qixue; Kang, Chunsheng			Editorial: The State-of-Art in Immuno-Oncology, What to Do With Glioblastoma?	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						glioblastoma; immunotherapy; tumor microenvironment; CAR T cell therapy; multi-target			[Cui, Xiaoteng; Wang, Qixue; Kang, Chunsheng] Tianjin Med Univ, Gen Hosp, Key Lab Post Neuroinjury Neurorepair & Regenerat, Dept Neurosurg,Tianjin Neurol Inst,Lab Neuro Onco, Tianjin, Peoples R China	Tianjin Medical University	Kang, CS (corresponding author), Tianjin Med Univ, Gen Hosp, Key Lab Post Neuroinjury Neurorepair & Regenerat, Dept Neurosurg,Tianjin Neurol Inst,Lab Neuro Onco, Tianjin, Peoples R China.	Kang97061@tmu.edu.cn							0	0	0	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 27	2021	12								788733	10.3389/fimmu.2021.788733	http://dx.doi.org/10.3389/fimmu.2021.788733			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WW1JT	34777399	Green Published, gold			2022-12-18	WOS:000717682500001
J	Laguette, N; Langevin, C; Olagnier, D; Torraca, V; Vanpouille-Box, C; Verrier, ER				Laguette, Nadine; Langevin, Christelle; Olagnier, David; Torraca, Vincenzo; Vanpouille-Box, Claire; Verrier, Eloi R.			Editorial: Nucleic Acid-Associated Inflammation	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						inflammation; nucleic acid sensing; DNA; RNA; type I interferon	IMMUNOGENIC CELL-DEATH; CANCER		[Laguette, Nadine] Univ Montpellier, CNRS, Mol Basis Inflammat Lab, Inst Genet Humaine, Montpellier, France; [Langevin, Christelle] Univ Paris Saclay, INRAE, IERP, UE0907, Jouy En Josas, France; [Olagnier, David] Aarhus Univ, Dept Biomed, Aarhus, Denmark; [Torraca, Vincenzo] London Sch Hyg & Trop Med, Dept Infect Biol, London, England; [Vanpouille-Box, Claire] Weill Cornell Med Coll, Dept Radiat Oncol, New York, NY USA; [Vanpouille-Box, Claire] Sandra & Edward Meyer Canc Ctr, New York, NY USA; [Verrier, Eloi R.] Univ Strasbourg, INSERM, Inst Rech Malad Virales & Hepat, UMR S1110, Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; INRAE; UDICE-French Research Universities; Universite Paris Saclay; Aarhus University; University of London; London School of Hygiene & Tropical Medicine; Cornell University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Laguette, N (corresponding author), Univ Montpellier, CNRS, Mol Basis Inflammat Lab, Inst Genet Humaine, Montpellier, France.; Langevin, C (corresponding author), Univ Paris Saclay, INRAE, IERP, UE0907, Jouy En Josas, France.; Olagnier, D (corresponding author), Aarhus Univ, Dept Biomed, Aarhus, Denmark.; Torraca, V (corresponding author), London Sch Hyg & Trop Med, Dept Infect Biol, London, England.; Vanpouille-Box, C (corresponding author), Weill Cornell Med Coll, Dept Radiat Oncol, New York, NY USA.; Vanpouille-Box, C (corresponding author), Sandra & Edward Meyer Canc Ctr, New York, NY USA.; Verrier, ER (corresponding author), Univ Strasbourg, INSERM, Inst Rech Malad Virales & Hepat, UMR S1110, Strasbourg, France.	nadine.laguette@igh.cnrs.fr; christelle.langevin@inrae.fr; olagnier@biomed.au.dk; vincenzo.torraca@lshtm.ac.uk; clv2002@med.cornell.edu; e.verrier@unistra.fr	Torraca, Vincenzo/O-5425-2016; Laguette, Nadine/A-2764-2019	Torraca, Vincenzo/0000-0001-7340-0249; Olagnier, David/0000-0001-6912-0674; Laguette, Nadine/0000-0001-8072-5607	European Research Council (ERC) [637763, 893772]; LA LIGUE pour la recherche contre le cancer; Agence Nationale de Recherche sur le SIDA et les Hepatites virales [ANRS: ECTZ117448]; EU INFRAIA project VetBioNet (EU H2020 project) [731014]; Lundbeck Foundation [R335-2019-2138]; Kraeftens Bekaempelse [R279-A16218]; Brodrene Hartman Fond; Horslev Fond; fabrikant Einer Willumsens mindelegat; Eva og Henry Fraenkels Mindefond; LSHTM/Wellcome Institutional Strategic Support Fund (ISSF) Fellowship [204928/Z/16/Z]; Dept. of Radiation Oncology at Weill Cornell Medicine (New York, US); WCM Prostate Cancer SPORE Development Research Program Award; ANRS [ECTZ104527]; LabEx HepSYS [ANR-10-LAB-28]; French National Research Agency [ANR-21-CE15-0035-01]	European Research Council (ERC)(European Research Council (ERC)European Commission); LA LIGUE pour la recherche contre le cancer; Agence Nationale de Recherche sur le SIDA et les Hepatites virales(ANRSFrench National Research Agency (ANR)); EU INFRAIA project VetBioNet (EU H2020 project); Lundbeck Foundation(Lundbeckfonden); Kraeftens Bekaempelse; Brodrene Hartman Fond; Horslev Fond; fabrikant Einer Willumsens mindelegat; Eva og Henry Fraenkels Mindefond; LSHTM/Wellcome Institutional Strategic Support Fund (ISSF) Fellowship; Dept. of Radiation Oncology at Weill Cornell Medicine (New York, US); WCM Prostate Cancer SPORE Development Research Program Award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ANRS(ANRSFrench National Research Agency (ANR)); LabEx HepSYS; French National Research Agency(French National Research Agency (ANR))	NL is supported by the European Research Council (ERC-Stg CrIC: 637763, ERC-PoC DIM-CrIC: 893772), "LA LIGUE pour la recherche contre le cancer" and the "Agence Nationale de Recherche sur le SIDA et les He ' patites virales" (ANRS: ECTZ117448). CL is supported by the EU INFRAIA project VetBioNet (EU H2020 project 731014) and received institutional support from INRAE. The INRAE Infectiology of Fishes and Rodents Facility (IERP-UE907, Jouy-en-Josas Research Center, France) belongs to the National Distributed Research Infrastructure for the Control of Animal and Zoonotic Emerging Infectious Diseases through In Vivo Investigation (EMERG'IN DOI: 10.15454/90CK-Y371). DO is supported by the Lundbeck Foundation (R335-2019-2138), a young talented cancer researcher grant from Kraeftens Bekaempelse (R279-A16218), the Brodrene Hartman Fond, the Horslev Fond, the fabrikant Einer Willumsens mindelegat, and the Eva og Henry Fraenkels Mindefond. VT is supported by an LSHTM/Wellcome Institutional Strategic Support Fund (ISSF) Fellowship (204928/Z/16/Z). CV-B is supported by a startup grant from the Dept. of Radiation Oncology atWeill Cornell Medicine (New York, US) and by WCM Prostate Cancer SPORE Development Research Program Award. EV is supported by ANRS (ECTZ104527), LabEx HepSYS (ANR-10-LAB-28), and the French National Research Agency (ANR-21-CE15-0035-01).	Galluzzi L, 2017, NAT REV IMMUNOL, V17, P97, DOI 10.1038/nri.2016.107; Iwasaki A, 2015, NAT IMMUNOL, V16, P343, DOI 10.1038/ni.3123; Kawai T, 2011, IMMUNITY, V34, P637, DOI 10.1016/j.immuni.2011.05.006; Krysko DV, 2012, NAT REV CANCER, V12, P860, DOI 10.1038/nrc3380; Vanpouille-Box C, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15618; Yamazaki T, 2020, NAT IMMUNOL, V21, P1160, DOI 10.1038/s41590-020-0751-0	6	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 27	2021	12								791580	10.3389/fimmu.2021.791580	http://dx.doi.org/10.3389/fimmu.2021.791580			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XB4ZD	34777401	Green Accepted, Green Published, gold			2022-12-18	WOS:000721338300001
J	Akinfenwa, O; Huang, HJ; Linhart, B; Focke-Tejkl, M; Vrtala, S; Poroshina, A; Nikonova, A; Khaitov, M; Campion, NJ; Eckl-Dorna, J; Niederberger-Leppin, V; Kratzer, B; Tauber, PA; Pickl, WF; Kundi, M; Campana, R; Valenta, R				Akinfenwa, Oluwatoyin; Huang, Huey-Jy; Linhart, Birgit; Focke-Tejkl, Margarete; Vrtala, Susanne; Poroshina, Alina; Nikonova, Alexandra; Khaitov, Musa; Campion, Nicholas J.; Eckl-Dorna, Julia; Niederberger-Leppin, Verena; Kratzer, Bernhard; Tauber, Peter Anton; Pickl, Winfried F.; Kundi, Michael; Campana, Raffaela; Valenta, Rudolf			Preventive Administration of Non-Allergenic Bet v 1 Peptides Reduces Allergic Sensitization to Major Birch Pollen Allergen, Bet v 1	FRONTIERS IN IMMUNOLOGY			English	Article						allergy; Bet v 1; T cell epitope-containing peptides; allergen-specific tolerance induction; allergy prophylaxis; prevention; mouse model	T-CELL EPITOPE; IGE REACTIVITY; MURINE MODEL; IMMUNOTHERAPY; INTRANASAL; ANTIBODIES; TOLERANCE; RESPONSES; RISK; SUPPRESSION	IgE-mediated allergy to birch pollen affects more than 100 million patients world-wide. Bet v 1, a 17 kDa protein is the major allergen in birch pollen responsible for allergic rhinoconjunctivitis and asthma in birch pollen allergic patients. Allergen-specific immunotherapy (AIT) based on therapeutic administration of Bet v 1-containing vaccines is an effective treatment for birch pollen allergy but no allergen-specific forms of prevention are available. We developed a mouse model for IgE sensitization to Bet v 1 based on subcutaneous injection of aluminum-hydroxide adsorbed recombinant Bet v 1 and performed a detailed characterization of the specificities of the IgE, IgG and CD4(+) T cell responses in sensitized mice using seven synthetic peptides of 31-42 amino acids length which comprised the Bet v 1 sequence and the epitopes recognized by human CD4(+) T cells. We then demonstrate that preventive systemic administration of a mix of synthetic non-allergenic Bet v 1 peptides to 3-4 week old mice significantly reduced allergic immune responses, including IgE, IgG, IgE-mediated basophil activation, CD4(+) T cell and IL-4 responses to the complete Bet v 1 allergen but not to the unrelated major grass pollen allergen Phl p 5, without inducing Bet v 1-specific allergic sensitization or adaptive immunity. Our results thus demonstrate that early preventive administration of non-allergenic synthetic T cell epitope-containing allergen peptides could be a safe strategy for the prevention of allergen-specific IgE sensitization.	[Akinfenwa, Oluwatoyin; Huang, Huey-Jy; Linhart, Birgit; Focke-Tejkl, Margarete; Vrtala, Susanne; Campana, Raffaela; Valenta, Rudolf] Med Univ Vienna, Ctr Pathophysiol Infectiol & Immunol, Dept Pathophysiol & Allergy Res, Div Immunopathol, Vienna, Austria; [Focke-Tejkl, Margarete; Pickl, Winfried F.; Valenta, Rudolf] Karl Landsteiner Univ Hlth Sci, Krems, Austria; [Poroshina, Alina; Nikonova, Alexandra; Khaitov, Musa; Valenta, Rudolf] Fed Med Biol Agcy FMBA Russia, Natl Res Ctr NRC, Inst Immunol, Moscow, Russia; [Khaitov, Musa] Pirogov Russian Natl Res Med Univ, Immunol Dept, Moscow, Russia; [Campion, Nicholas J.; Eckl-Dorna, Julia; Niederberger-Leppin, Verena] Med Univ Vienna, Dept Otorhinolaryngol, Vienna, Austria; [Kratzer, Bernhard; Tauber, Peter Anton; Pickl, Winfried F.] Med Univ Vienna, Ctr Pathophysiol Infectiol & Immunol, Inst Immunol, Vienna, Austria; [Kundi, Michael] Med Univ Vienna, Ctr Publ Hlth, Inst Hyg & Appl Immunol, Vienna, Austria; [Valenta, Rudolf] Sechenov First Moscow State Med Univ, Dept Clin Immunol & Allergy, Lab Immunopathol, Moscow, Russia	Medical University of Vienna; NRC Institute of Immunology FMBA of Russia; Pirogov Russian National Research Medical University; Medical University of Vienna; Medical University of Vienna; Medical University of Vienna; Sechenov First Moscow State Medical University	Campana, R (corresponding author), Med Univ Vienna, Ctr Pathophysiol Infectiol & Immunol, Dept Pathophysiol & Allergy Res, Div Immunopathol, Vienna, Austria.	raffaela.campana@meduniwien.ac.at	Khaitov, Musa/AAC-1516-2021	Khaitov, Musa/0000-0003-4961-9640; Huang, Huey-Jy/0000-0001-5464-0132; Valenta, Rudolf/0000-0001-5944-3365; Pickl, Winfried F./0000-0003-0430-4952; Eckl-Dorna, Julia/0000-0001-5981-1607; Kratzer, Bernhard/0000-0003-1091-4327	FWF [W1248-B30]; Country of Lower Austria (Danube-ARC); Megagrant of the Government of the Russian Federation [14.W03.31.0024]	FWF(Austrian Science Fund (FWF)); Country of Lower Austria (Danube-ARC); Megagrant of the Government of the Russian Federation	This work was supported by the FWF-funded MCCA PhD-program (W1248-B30), by the Country of Lower Austria (Danube-ARC) and by a Megagrant of the Government of the Russian Federation, grant No 14.W03.31.0024.	Anto JM, 2017, J ALLERGY CLIN IMMUN, V139, P388, DOI 10.1016/j.jaci.2016.12.940; Astori M, 2000, J IMMUNOL, V165, P3497, DOI 10.4049/jimmunol.165.6.3497; Bauer L, 1997, CLIN EXP IMMUNOL, V107, P536, DOI 10.1046/j.1365-2249.1997.d01-953.x; Bouchaud G, 2015, J ALLERGY CLIN IMMUN, V136, P197, DOI 10.1016/j.jaci.2014.12.1938; Boyle RJ, 2016, ALLERGY, V71, P701, DOI 10.1111/all.12848; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; Burton OT, 2014, J ALLERGY CLIN IMMUN, V134, P1310, DOI 10.1016/j.jaci.2014.05.042; Campana R, 2019, J ALLERGY CLIN IMMUN, V143, P1258, DOI 10.1016/j.jaci.2018.11.011; Curin M, 2014, J ALLERGY CLIN IMMUN, V133, P918, DOI 10.1016/j.jaci.2013.10.058; Dorofeeva Y, 2021, ALLERGY, V76, P131, DOI 10.1111/all.14300; Dramburg S, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.02116; Du Toit G, 2015, NEW ENGL J MED, V372, P803, DOI 10.1056/NEJMoa1414850; Elisyutina O, 2021, PEDIAT ALLERG IMM-UK, V32, P251, DOI 10.1111/pai.13354; Elisyutina O, 2019, ALLERGY, V74, P2525, DOI 10.1111/all.13931; Fellrath JM, 2003, J ALLERGY CLIN IMMUN, V111, P854, DOI 10.1067/mai.2003.1337; Focke M, 2004, CLIN EXP ALLERGY, V34, P1525, DOI 10.1111/j.1365-2222.2004.02081.x; GAUR A, 1992, SCIENCE, V258, P1491, DOI 10.1126/science.1279812; Halken S, 2021, PEDIAT ALLERG IMM-UK, V32, P843, DOI 10.1111/pai.13496; Huang HJ, 2019, ALLERGY, V74, P2461, DOI 10.1111/all.13956; Huang X, 2018, ALLERGY, V73, P421, DOI 10.1111/all.13269; Jahn-Schmid B, 2005, J ALLERGY CLIN IMMUN, V116, P213, DOI 10.1016/j.jaci.2005.04.019; Kiewiet MBG, 2015, PEDIAT ALLERG IMM-UK, V26, P206, DOI 10.1111/pai.12354; Kratzer B, 2019, ALLERGY, V74, P246, DOI 10.1111/all.13573; LARCHE M, 1994, INT ARCH ALLERGY IMM, V104, P211, DOI 10.1159/000236667; Linhart B, 2014, CLIN EXP ALLERGY, V44, P278, DOI 10.1111/cea.12216; Matricardi PM, 2014, PEDIAT ALLERG IMM-UK, V25, P15, DOI 10.1111/pai.12200; Mothes N, 2003, CLIN EXP ALLERGY, V33, P1198, DOI 10.1046/j.1365-2222.2003.01699.x; Muller U, 1998, J ALLERGY CLIN IMMUN, V101, P747, DOI 10.1016/S0091-6749(98)70402-6; Narayanan M, 2017, J IMMUNOL, V198, P1685, DOI 10.4049/jimmunol.1501741; OHEHIR RE, 1991, ANNU REV IMMUNOL, V9, P67, DOI 10.1146/annurev.iy.09.040191.000435; Ohsaki A, 2018, J EXP MED, V215, P91, DOI 10.1084/jem.20171163; Pellaton Celine, 2013, Clin Transl Allergy, V3, P17, DOI 10.1186/2045-7022-3-17; Prickett SR, 2015, CLIN EXP ALLERGY, V45, P1015, DOI 10.1111/cea.12554; RIA F, 1990, NATURE, V343, P381, DOI 10.1038/343381a0; Schmidt RM, 2019, PEDIAT ALLERG IMM-UK, V30, P335, DOI 10.1111/pai.13018; Soongrung T, 2020, ALLERGY, V75, P1232, DOI 10.1111/all.14096; Spertini F, 2014, J ALLERGY CLIN IMMUN, V134, P239, DOI 10.1016/j.jaci.2014.04.001; Tulaeva I, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01368; Valenta R, 2018, ADV IMMUNOL, V138, P195, DOI 10.1016/bs.ai.2018.03.002; Valenta R, 2017, IMMUNOL LETT, V189, P19, DOI 10.1016/j.imlet.2017.04.015; VAZ EM, 1971, IMMUNOLOGY, V21, P11; von Garnier C, 2000, EUR J IMMUNOL, V30, P1638, DOI 10.1002/1521-4141(200006)30:6<1638::AID-IMMU1638>3.0.CO;2-R; Von Garnier C, 2002, CLIN EXP ALLERGY, V32, P401, DOI 10.1046/j.1365-2222.2002.01304.x; Vrtala S, 1998, J IMMUNOL, V160, P6137; Vrtala S, 1997, J CLIN INVEST, V99, P1673, DOI 10.1172/JCI119330; Wahn U, 2001, J ALLERGY CLIN IMMUN, V107, P567, DOI 10.1067/mai.2001.112943; WALLNER BP, 1994, ALLERGY, V49, P302, DOI 10.1111/j.1398-9995.1994.tb02272.x; Weijler AM, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.586856; Westman M, 2015, J ALLERGY CLIN IMMUN, V135, P1199, DOI 10.1016/j.jaci.2014.10.042; Wickman M, 2017, EBIOMEDICINE, V26, P91, DOI 10.1016/j.ebiom.2017.11.009; Wiedermann U, 1999, J ALLERGY CLIN IMMUN, V103, P1202, DOI 10.1016/S0091-6749(99)70200-9; Wiedermann U, 2001, INT ARCH ALLERGY IMM, V126, P68, DOI 10.1159/000049496; Wraith DC, 2021, CLIN EXP ALLERGY, V51, P751, DOI 10.1111/cea.13840; Xiong HZ, 2012, J EXP MED, V209, P353, DOI 10.1084/jem.20111941; Zidarn M, 2015, ALLERGY, V70, P547, DOI 10.1111/all.12581	55	0	0	3	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 26	2021	12								744544	10.3389/fimmu.2021.744544	http://dx.doi.org/10.3389/fimmu.2021.744544			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WZ1GD	34795666	gold, Green Published			2022-12-18	WOS:000719720600001
J	Macia, L; Galy, O; Nanan, RKH				Macia, Laurence; Galy, Olivier; Nanan, Ralph Kay Heinrich			Editorial: Modern Lifestyle and Health: How Changes in the Environment Impacts Immune Function and Physiology	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						environment; health; immunity; nutrition; physical activity			[Macia, Laurence; Nanan, Ralph Kay Heinrich] Univ Sydney, Fac Med & Hlth, Darlington, NSW, Australia; [Macia, Laurence; Nanan, Ralph Kay Heinrich] Univ Sydney, Charles Perkins Ctr, Camperdown, NSW, Australia; [Galy, Olivier] Univ New Caledonia, Sch Educ, Noumea, France	University of Sydney; University of Sydney	Macia, L (corresponding author), Univ Sydney, Fac Med & Hlth, Darlington, NSW, Australia.; Macia, L (corresponding author), Univ Sydney, Charles Perkins Ctr, Camperdown, NSW, Australia.		Macia, laurence/D-5983-2016	Macia, laurence/0000-0003-0835-851X	ARC [LP160100627, DP210102943]	ARC(Australian Research Council)	Funding Grant ARC LP160100627 and ARC DP210102943.	Daien CI, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00548; O'Neill LAJ, 2016, NAT REV IMMUNOL, V16, P553, DOI 10.1038/nri.2016.70	2	0	0	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 26	2021	12								762166	10.3389/fimmu.2021.762166	http://dx.doi.org/10.3389/fimmu.2021.762166			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XB5BR	34764963	gold, Green Published			2022-12-18	WOS:000721345100001
J	Yang, YH; Huang, H; Li, TP; Gao, QL; Song, YP; Wang, ZB				Yang, Yonghao; Huang, Hao; Li, Tiepeng; Gao, Quanli; Song, Yongping; Wang, Zibing			Axitinib Reverses Resistance to Anti-Programmed Cell Death-1 Therapy in a Patient With Renal Cell Carcinoma	FRONTIERS IN IMMUNOLOGY			English	Article						anti-angiogenic; PD-1; immunotherapy; low-dose; resistance; axitinib	VASCULAR NORMALIZATION; ACQUIRED-RESISTANCE; CANCER	Owing to broad and notable clinical anti-tumor activity, anti-programmed cell death-1 (PD-1)/anti-programmed cell death-ligand 1 (PD-L1) antibodies have been indicated for almost all types of cancer, and form a part of the current standard of care. However, a large proportion of patients do not respond to anti-PD-1/PD-L1 therapy (primary resistance), and responders often develop progressive disease (acquired resistance). The mechanisms of resistance are complex and largely unknown; therefore, overcoming resistance remains clinically challenging, and data on reversing anti-PD-1 resistance are scarce. Herein, we report the case of a 58-year-old woman with renal cell carcinoma associated with Xp11.2 translocation/transcription factor E3 gene fusion, who had already showed resistance to both anti-PD-1 monotherapy and standard-dose axitinib. However, she finally achieved a partial response with a continuous combination therapy comprising low-dose axitinib and anti-PD-1. We speculate that axitinib played a key role in reversing the primary resistance to anti-PD-1 therapy. Interestingly, we observed that the number of peripheral regulatory T cells increased after the standard-dose axitinib therapy, with accompanied tumor enlargement; however, after the dose was reduced, the number of regulatory T cells decreased gradually, and the tumor regressed. We also reviewed relevant literature, which supported the fact that low-dose axitinib might be more beneficial than standard-dose axitinib in assisting immunotherapy. Given that this is a single-case report, the immunomodulatory effect of axitinib requires further investigation.	[Song, Yongping; Wang, Zibing] Zhengzhou Univ, Dept Immunotherapy, Affiliated Canc Hosp, Zhengzhou, Peoples R China; Henan Canc Hosp, Zhengzhou, Peoples R China	Zhengzhou University; Zhengzhou University	Song, YP; Wang, ZB (corresponding author), Zhengzhou Univ, Dept Immunotherapy, Affiliated Canc Hosp, Zhengzhou, Peoples R China.	songyongping001@126.com; zlyywzb2118@zzu.edu.cn						Amin A, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0420-0; Armah HB, 2010, ARCH PATHOL LAB MED, V134, P124, DOI 10.1043/2008-0391-RSR.1; Buchbinder EI, 2016, AM J CLIN ONCOL-CANC, V39, P98, DOI 10.1097/COC.0000000000000239; Chowdhury S, 2021, CLIN GENITOURIN CANC, V19, P434, DOI 10.1016/j.clgc.2021.04.007; Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730; Gide TN, 2018, CLIN CANCER RES, V24, P1260, DOI 10.1158/1078-0432.CCR-17-2267; Haanen JBAG, 2018, ANN ONCOL, V29, P264, DOI 10.1093/annonc/mdy162; Hirsch L, 2020, DRUGS, V80, P1169, DOI 10.1007/s40265-020-01327-7; Huang YH, 2013, CANCER RES, V73, P2943, DOI 10.1158/0008-5472.CAN-12-4354; Iwai Y, 2002, P NATL ACAD SCI USA, V99, P12293, DOI 10.1073/pnas.192461099; Li Q, 2020, CLIN CANCER RES, V26, P1712, DOI 10.1158/1078-0432.CCR-19-2179; Linehan DC, 2005, IMMUNOL RES, V32, P155, DOI 10.1385/IR:32:1-3:155; Liu D, 2019, AM J CLIN DERMATOL, V20, P41, DOI 10.1007/s40257-018-0389-y; Morelli MB, 2015, ONCOTARGET, V6, P36245, DOI 10.18632/oncotarget.5768; Motzer R, 2021, NEW ENGL J MED, V384, P1289, DOI 10.1056/NEJMoa2035716; Motzer RJ, 2019, NEW ENGL J MED, V380, P1103, DOI 10.1056/NEJMoa1816047; Munari E, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22105123; Rini BI, 2019, LANCET, V393, P2404, DOI 10.1016/S0140-6736(19)30723-8; Rini BI, 2019, NEW ENGL J MED, V380, P1116, DOI 10.1056/NEJMoa1816714; Sharma P, 2017, CELL, V168, P707, DOI 10.1016/j.cell.2017.01.017; Sheng XN, 2019, J CLIN ONCOL, V37, P2987, DOI 10.1200/JCO.19.00210; Shergold AL, 2019, PHARMACOL RES, V145, DOI 10.1016/j.phrs.2019.104258; Shigeta K, 2020, HEPATOLOGY, V71, P1247, DOI 10.1002/hep.30889; Viallard C, 2017, ANGIOGENESIS, V20, P409, DOI 10.1007/s10456-017-9562-9; Weiss SA, 2021, CURR OPIN IMMUNOL, V69, P47, DOI 10.1016/j.coi.2021.02.001; Yuan HQ, 2014, BIOMED PHARMACOTHER, V68, P751, DOI 10.1016/j.biopha.2014.07.002; Zhao S, 2019, CANCER IMMUNOL RES, V7, P630, DOI 10.1158/2326-6066.CIR-17-0640	27	0	1	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 26	2021	12								728750	10.3389/fimmu.2021.728750	http://dx.doi.org/10.3389/fimmu.2021.728750			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XM5XT	34764951	Green Published, gold			2022-12-18	WOS:000728900300001
J	Arbrile, M; Radin, M; Rossi, D; Menegatti, E; Baldovino, S; Sciascia, S; Roccatello, D				Arbrile, Marta; Radin, Massimo; Rossi, Daniela; Menegatti, Elisa; Baldovino, Simone; Sciascia, Savino; Roccatello, Dario			Vedolizumab for the Management of Refractory Behcet's Disease: From a Case Report to New Pieces of Mosaic in a Complex Disease	FRONTIERS IN IMMUNOLOGY			English	Article						vedolizumab; Behcet disease; biological drug; intestinal Behcet; biological therapy	MANIFESTATIONS; THERAPY	Objectives When treating Behcet's disease (BD), anti-tumor necrosis factor (TNF)-alpha agents have become a second-line therapy when conventional immunosuppressive drugs have failed. However, in the case of failure of treatment with anti-TNF alpha drugs, further options are limited. Based on previous reports of the efficacy of vedolizumab (VDZ) in inflammatory bowel diseases, we decided to administer VDZ to treat a patient with intestinal BD. Methods We present the case of a 49-year-old female patient with BD. Her clinical manifestations included erythema nodosum, oro-genital ulcers, positive Pathergy test, positive HLA-B51, and biopsy-proven intestinal BD. The patient was unsuccessfully treated with conventional immunosuppressive and several biological agents. Results Treatment with VDZ was started intravenously at a dose of 300 mg at 0, 2, and 6 weeks and then every 4 weeks. After the second dose of VDZ, the patient reported a marked improvement of intestinal BD and a concomitant amelioration of arthralgia, erythema nodosum lesions and aphthosis. Clinical remission was achieved at 6 months after starting VDZ. Conclusion VDZ might represent a valid option to treat patients with BD who are non-responsive to standard treatments or anti-TNF alpha agents, particularly, those cases with intestinal involvement.	[Sciascia, Savino] S Giovanni Bosco Hosp, Coordinating Ctr Piemonte & Valle dAosta Network, Complex Struct Univ Management SCDU Nephrol & Dia, Ctr Res Immunopathol & Rare Dis,Dept Clin & Biol, Turin, Italy; Univ Turin, Turin, Italy	University of Turin	Sciascia, S (corresponding author), S Giovanni Bosco Hosp, Coordinating Ctr Piemonte & Valle dAosta Network, Complex Struct Univ Management SCDU Nephrol & Dia, Ctr Res Immunopathol & Rare Dis,Dept Clin & Biol, Turin, Italy.	savino.sciascia@unito.it	Baldovino, Simone/D-4627-2009	Baldovino, Simone/0000-0002-4475-4117				Akdeniz N, 2019, CLIN DERMATOL, V37, P227, DOI 10.1016/j.clindermatol.2019.01.001; Akiyama M, 2020, SEMIN ARTHRITIS RHEU, V50, P797, DOI 10.1016/j.semarthrit.2020.05.017; Alpsoy E, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.624795; Atienza-Mateo B., 2021, CLIN EXP RHEUMATOL, V67, P37; Balzola F., 2014, INFLAMMATION BOWEL D, V14, P55, DOI DOI 10.1056/NEJMOA1215739; Bayraktar Y, 2000, J CLIN GASTROENTEROL, V30, P144, DOI 10.1097/00004836-200003000-00006; Caso F, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/107421; Choi HJ, 2015, KOREAN J INTERN MED, V30, P714, DOI 10.3904/kjim.2015.30.5.714; Davatchi F, 2014, J EUR ACAD DERMATOL, V28, P338, DOI 10.1111/jdv.12107; de Menthon M, 2009, ARTHRIT CARE RES, V61, P1287, DOI 10.1002/art.24642; Esatoglu SN, 2019, INTERN EMERG MED, V14, P661, DOI 10.1007/s11739-019-02035-1; Feagan BG, 2013, NEW ENGL J MED, V369, P699, DOI 10.1056/NEJMoa1215734; Fleisher M, 2018, DIGEST DIS SCI, V63, P825, DOI 10.1007/s10620-018-4971-1; Hanzel J, 2021, DRUGS, V81, P333, DOI 10.1007/s40265-020-01460-3; Kim ES, 2007, J KOREAN MED SCI, V22, P918, DOI 10.3346/jkms.2007.22.5.918; Leccese P, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01067; Mitroulis I, 2015, PHARMACOL THERAPEUT, V147, P123, DOI 10.1016/j.pharmthera.2014.11.008; Wyant T, 2016, J CROHNS COLITIS, V10, P1437, DOI 10.1093/ecco-jcc/jjw092	18	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 25	2021	12								769785	10.3389/fimmu.2021.769785	http://dx.doi.org/10.3389/fimmu.2021.769785			5	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WV6XS	34759935	Green Published, gold			2022-12-18	WOS:000717378000001
J	Goldsmith, CD; Donovan, T; Vlahovich, N; Pyne, DB				Goldsmith, Chloe D.; Donovan, Thomasina; Vlahovich, Nicole; Pyne, David B.			Unlocking the Role of Exercise on CD4+T Cell Plasticity	FRONTIERS IN IMMUNOLOGY			English	Article						immune; epigenetics; metabolism; DNA methylation; chromatin remodeling; histone modification; mitochondria	DIFFERENTIATION; HOMOCYSTEINE; MECHANISMS; EXPRESSION; GLUT1; VIEW; TH17	A hallmark of T cell ageing is a loss of effector plasticity. Exercise delays T cell ageing, yet the mechanisms driving the effects of exercise on T cell biology are not well elucidated. T cell plasticity is closely linked with metabolism, and consequently sensitive to metabolic changes induced by exercise. Mitochondrial function is essential for providing the intermediate metabolites necessary to generate and modify epigenetic marks in the nucleus, thus metabolic activity and epigenetic mechanisms are intertwined. In this perspective we propose a role for exercise in CD4+ T cell plasticity, exploring links between exercise, metabolism and epigenetic reprogramming.	[Goldsmith, Chloe D.; Donovan, Thomasina; Pyne, David B.] Univ Canberra, Res Inst Sport & Exercise, Canberra, ACT, Australia; [Donovan, Thomasina] Queensland Univ Technol, Fac Hlth, Australian Ctr Hlth Serv Innovat, Brisbane, Qld, Australia; [Donovan, Thomasina] Queensland Univ Technol, Fac Hlth, Ctr Healthcare Transformat, Sch Publ Hlth & Social Work, Brisbane, Qld, Australia; [Vlahovich, Nicole] Univ Canberra, Fac Hlth, Canberra, ACT, Australia; [Pyne, David B.] Canterbury Christ Church Univ, Fac Sci Engn & Social Sci, Sch Psychol & Life Sci, Canterbury, Kent, England	University of Canberra; Queensland University of Technology (QUT); Queensland University of Technology (QUT); University of Canberra; Canterbury Christ Church University	Goldsmith, CD (corresponding author), Univ Canberra, Res Inst Sport & Exercise, Canberra, ACT, Australia.	Chloe.Goldsmith@canberra.edu.au		Goldsmith, Chloe/0000-0002-1041-4333; Donovan, Thomasina/0000-0002-0127-0091; Pyne, David/0000-0003-1555-5079				Ansel KM, 2003, NAT IMMUNOL, V4, P616, DOI 10.1038/ni0703-616; Asad A, 2020, BMC NEPHROL, V21, DOI 10.1186/s12882-020-02098-9; Aschenbrenner D, 2018, NAT IMMUNOL, V19, P1126, DOI 10.1038/s41590-018-0200-5; Auro K, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5708; Basu S, 2015, J LEUKOCYTE BIOL, V97, P279, DOI 10.1189/jlb.2AB0514-273RR; Caza T, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/521957; Chen ZS, 2018, J CARDIOVASC TRANSL, V11, P230, DOI 10.1007/s12265-018-9794-0; Couto SMF, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/1830934; COYLE EF, 1995, AM J CLIN NUTR, V61, p968S, DOI 10.1093/ajcn/61.4.968S; Dawson H, 2004, MECH AGEING DEV, V125, P107, DOI 10.1016/j.mad.2003.11.013; Dean D, 2000, DIABETES, V49, P1295, DOI 10.2337/diabetes.49.8.1295; Deminice R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151653; Djuretic IM, 2007, NAT IMMUNOL, V8, P145, DOI 10.1038/ni1424; Dong C, 2008, NAT REV IMMUNOL, V8, P337, DOI 10.1038/nri2295; Dorneles GP, 2019, J CELL BIOCHEM, V120, P10726, DOI 10.1002/jcb.28364; Etchegaray JP, 2016, MOL CELL, V62, P695, DOI 10.1016/j.molcel.2016.05.029; Forneris F, 2005, FEBS LETT, V579, P2203, DOI 10.1016/j.febslet.2005.03.015; Gaublomme JT, 2015, CELL, V163, DOI 10.1016/j.cell.2015.11.009; Goldsmith C, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-87457-8; Gonzalez-Becerra K, 2019, LIPIDS HEALTH DIS, V18, DOI 10.1186/s12944-019-1120-6; Harbour SN, 2015, P NATL ACAD SCI USA, V112, P7061, DOI 10.1073/pnas.1415675112; Iwayam Kaito, 2020, Metabol Open, V8, P100067, DOI 10.1016/j.metop.2020.100067; Karmaus PWF, 2019, NATURE, V565, P101, DOI 10.1038/s41586-018-0806-7; Karwacz K, 2017, NAT IMMUNOL, V18, P412, DOI 10.1038/ni.3683; Kostrzewa-Nowak D, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0227993; Laumont CM, 2021, CLIN CANCER RES, V27, P4089, DOI 10.1158/1078-0432.CCR-20-4394; LEHMANN M, 1995, INT J SPORTS MED, V16, P155, DOI 10.1055/s-2007-972984; Lin KY, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18031291; Macintyre AN, 2014, CELL METAB, V20, P61, DOI 10.1016/j.cmet.2014.05.004; Mittelbrunn M, 2021, NAT IMMUNOL, V22, P687, DOI 10.1038/s41590-021-00927-z; Morrish F, 2010, J BIOL CHEM, V285, P36267, DOI 10.1074/jbc.M110.141606; NEWSHOLME EA, 1994, INT J SPORTS MED, V15, pS142, DOI 10.1055/s-2007-1021129; O'Connor CM, 2009, JAMA-J AM MED ASSOC, V301, P1439, DOI 10.1001/jama.2009.454; Oestreich KJ, 2014, NAT IMMUNOL, V15, P957, DOI 10.1038/ni.2985; Peng M, 2016, SCIENCE, V354, P481, DOI 10.1126/science.aaf6284; PENN NW, 1972, BIOCHEM J, V126, P781, DOI 10.1042/bj1260781; Riberio DF, 2018, LIFE SCI, V196, P63, DOI 10.1016/j.lfs.2018.01.003; Roncarolo MG, 2018, IMMUNITY, V49, P1004, DOI 10.1016/j.immuni.2018.12.001; Rothenberg EV, 2010, IMMUNOL REV, V238, P150, DOI 10.1111/j.1600-065X.2010.00964.x; Miyagi MYS, 2018, MOL IMMUNOL, V101, P507, DOI 10.1016/j.molimm.2018.08.014; Miyagi MYS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108543; SAKATA SF, 1993, J BIOL CHEM, V268, P13978; Schubeler D, 2015, NATURE, V517, P321, DOI 10.1038/nature14192; Shi LZ, 2011, J EXP MED, V208, P1367, DOI 10.1084/jem.20110278; Stockinger B, 2017, NAT REV IMMUNOL, V17, P535, DOI 10.1038/nri.2017.50; Wang C, 2015, CELL, V163, DOI 10.1016/j.cell.2015.10.068; Wang H, 2020, J VASC RES, V57, P276, DOI 10.1159/000508077; Wei G, 2009, IMMUNITY, V30, P155, DOI 10.1016/j.immuni.2008.12.009; Zhang JLA, 2012, CELL, V149, P467, DOI 10.1016/j.cell.2012.01.056	49	0	0	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 25	2021	12								729366	10.3389/fimmu.2021.729366	http://dx.doi.org/10.3389/fimmu.2021.729366			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WV5QS	34759918	gold, Green Published			2022-12-18	WOS:000717292200001
J	Pan, P; Atkinson, SN; Taylor, B; Zhu, HJ; Zhou, DA; Flejsierowicz, P; Wang, LS; Morse, M; Liu, C; Gunsolus, IL; Chen, X				Pan, Pan; Atkinson, Samantha N.; Taylor, Brian; Zhu, Haojie; Zhou, Dian; Flejsierowicz, Philip; Wang, Li-Shu; Morse, Matthew; Liu, Chen; Gunsolus, Ian L.; Chen, Xiao			Retinoic Acid Signaling Modulates Recipient Gut Barrier Integrity and Microbiota After Allogeneic Hematopoietic Stem Cell Transplantation in Mice	FRONTIERS IN IMMUNOLOGY			English	Article						retinoic acid; intestinal barrier; gut microbiota; vitamin A; graft-versus-host disease	VERSUS-HOST-DISEASE; VITAMIN-A-DEFICIENCY; GASTROINTESTINAL-TRACT; TIGHT JUNCTIONS; PERMEABILITY; EXPRESSION; INFECTION; SEVERITY; PATHWAY; GVHD	Graft-versus-host disease (GVHD) remains a major complication after allogeneic hematopoietic stem cell transplantation (HSCT). An impaired intestinal epithelial barrier is an important component of GVHD pathogenesis. However, contributing host factors that modulate mucosal barrier integrity during GVHD are poorly defined. We hypothesized that vitamin A and retinoic acid (RA) exert positive impacts on maintaining intestinal barrier function after HSCT, thus preventing or dampening GVHD severity. Unexpectedly, we found that exogenous RA increased intestinal permeability of recipient mice after allogeneic HSCT. Serum bacterial endotoxin levels were significantly higher in GVHD mice fed a vitamin A-high (VAH) diet compared to those fed a vitamin A-normal (VAN) diet, indicating a more compromised intestinal barrier function. Furthermore, VAH mice showed more severe lung GVHD with increased donor T cell infiltration in this tissue and died significantly faster than VAN recipients. 16S rRNA sequencing of fecal samples revealed significant differences in the diversity and composition of gut microbiota between VAN and VAH transplant recipients. Collectively, we show that retinoic acid signaling may negatively impact intestinal barrier function during GVHD. Mild vitamin A supplementation is associated with increased lung GVHD and more profound gut dysbiosis. Micronutrients such as vitamin A could modulate complications of allogeneic HSCT, which may be mediated by shaping gut microbiota.	[Pan, Pan; Taylor, Brian; Zhu, Haojie; Zhou, Dian; Flejsierowicz, Philip; Wang, Li-Shu; Morse, Matthew; Chen, Xiao] Med Coll Wisconsin, Div Hematol & Oncol, Milwaukee, WI 53226 USA; [Pan, Pan; Taylor, Brian; Zhu, Haojie; Zhou, Dian; Flejsierowicz, Philip; Wang, Li-Shu; Morse, Matthew; Chen, Xiao] Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA; [Atkinson, Samantha N.] Med Coll Wisconsin, Ctr Microbiome Res, Milwaukee, WI 53226 USA; [Atkinson, Samantha N.] Med Coll Wisconsin, Dept Microbiol & Immunol, Milwaukee, WI 53226 USA; [Liu, Chen] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA; [Gunsolus, Ian L.] Med Coll Wisconsin, Dept Pathol, Milwaukee, WI 53226 USA	Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin; Yale University; Medical College of Wisconsin	Chen, X (corresponding author), Med Coll Wisconsin, Div Hematol & Oncol, Milwaukee, WI 53226 USA.; Chen, X (corresponding author), Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA.	xchen@mcw.edu			Flow Cytometry Shared Resource at the Medical College of Wisconsin Cancer Center; National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases grant [RO1 AI125334]; Amy Strelzer Manasevit Research Program through The Be The Match Foundation; National Marrow Donor Program	Flow Cytometry Shared Resource at the Medical College of Wisconsin Cancer Center; National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases grant; Amy Strelzer Manasevit Research Program through The Be The Match Foundation; National Marrow Donor Program	The authors thank Dr. William R. Drobyski for critical reading of the manuscript. The authors also thank the staff at the Center for Microbiome Research at the MCW for their expert assistance with microbiota studies. Supported in part by the Flow Cytometry Shared Resource at the Medical College of Wisconsin Cancer Center. This research was supported in part by National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases grant RO1 AI125334 and the Amy Strelzer Manasevit Research Program which is funded through The Be The Match Foundation and the National Marrow Donor Program (both to XC). The authors thank Rachel H. Limpert for generating the schematic summary of the study.	Andermann TM, 2016, CURR HEMATOL MALIG R, V11, P19, DOI 10.1007/s11899-016-0302-9; Aoyama K, 2013, BLOOD, V122, P2125, DOI 10.1182/blood-2012-11-470252; Bailey RL, 2011, J NUTR, V141, P261, DOI 10.3945/jn.110.133025; Bolyen E, 2019, NAT BIOTECHNOL, V37, P852, DOI 10.1038/s41587-019-0209-9; Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303; Carpenter PA, 2017, BLOOD, V129, P2715, DOI 10.1182/blood-2017-03-773226; Castilla-Llorente C, 2014, BONE MARROW TRANSPL, V49, P966, DOI 10.1038/bmt.2014.69; Chen X, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02853; Chen X, 2013, BLOOD, V121, P3970, DOI 10.1182/blood-2012-08-445130; Chen X, 2009, BLOOD, V114, P891, DOI 10.1182/blood-2009-01-197178; Coghill JM, 2011, BLOOD, V117, P3268, DOI 10.1182/blood-2010-12-290403; Cooke KR, 2001, J CLIN INVEST, V107, P1581, DOI 10.1172/JCI12156; Cui W, 2010, BRAZ J MED BIOL RES, V43, P330, DOI [10.1590/S0100-879X2010007500020, 10.1590/S0100-879X2010000400002]; Czech L, 2020, BIOINFORMATICS, V36, P3263, DOI 10.1093/bioinformatics/btaa070; DeFilipp Z, 2018, BLOOD ADV, V2, P745, DOI 10.1182/bloodadvances.2018017731; DePaolo RW, 2011, NATURE, V471, P220, DOI 10.1038/nature09849; Dodge J, 2016, BIOL BLOOD MARROW TR, V22, P2141, DOI 10.1016/j.bbmt.2016.09.001; Eriguchi Y, 2012, BLOOD, V120, P223, DOI 10.1182/blood-2011-12-401166; Ferrara JLM, 2017, J CLIN INVEST, V127, P2441, DOI 10.1172/JCI90592; Frank DN, 2011, INFLAMM BOWEL DIS, V17, P179, DOI 10.1002/ibd.21339; Fukuda S, 2011, NATURE, V469, P543, DOI 10.1038/nature09646; Gerbitz A, 2004, BLOOD, V103, P4365, DOI 10.1182/blood-2003-11-3769; Gjaerde LK, 2020, BONE MARROW TRANSPL, V55, P1457, DOI 10.1038/s41409-019-0760-5; Gunzel D, 2013, PHYSIOL REV, V93, P525, DOI 10.1152/physrev.00019.2012; Harris B, 2016, AM J RESP CRIT CARE, V194, P450, DOI 10.1164/rccm.201507-1491OC; He CM, 2019, FOOD FUNCT, V10, P1235, DOI 10.1039/c8fo01123k; HEINONEN OP, 1994, NEW ENGL J MED, V330, P1029; Hill GR, 2021, ANNU REV IMMUNOL, V39, P19, DOI 10.1146/annurev-immunol-102119-073227; Hill GR, 2000, BLOOD, V95, P2754, DOI 10.1182/blood.V95.9.2754.009k25_2754_2759; Hill GR, 1998, J CLIN INVEST, V102, P115, DOI 10.1172/JCI3132; Jenq RR, 2012, J EXP MED, V209, P902, DOI 10.1084/jem.20112408; Kau AL, 2011, NATURE, V474, P327, DOI 10.1038/nature10213; Koenecke C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038252; Koyama M, 2019, BLOOD, V134, P2139, DOI 10.1182/blood.2019000823; Li YY, 2017, CELL PHYSIOL BIOCHEM, V42, P1390, DOI 10.1159/000479203; Louca S, 2018, BIOINFORMATICS, V34, P1053, DOI 10.1093/bioinformatics/btx701; Lounder DT, 2017, BLOOD, V129, P2801, DOI 10.1182/blood-2017-02-765826; Luettig J, 2015, TISSUE BARRIERS, V3, DOI 10.4161/21688370.2014.977176; Mathewson ND, 2016, NAT IMMUNOL, V17, P505, DOI 10.1038/ni.3400; McCullough FSW, 1999, P NUTR SOC, V58, P289, DOI 10.1017/S0029665199000403; Mohammadpour H, 2018, BIOL BLOOD MARROW TR, V24, P2397, DOI 10.1016/j.bbmt.2018.07.003; Nagalingam NA, 2012, INFLAMM BOWEL DIS, V18, P968, DOI 10.1002/ibd.21866; Nalle SC, 2019, J CLIN INVEST, V129, P902, DOI 10.1172/JCI98554; Nalle SC, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008941; Nik AM, 2013, BIOTECHNIQUES, V55, P42, DOI 10.2144/000114055; Peled JU, 2016, BLOOD, V128, P2395, DOI 10.1182/blood-2016-06-716738; Piper C, 2020, BLOOD, V135, P568, DOI 10.1182/blood.2019001696; Rafei H, 2020, BLOOD, V136, P401, DOI 10.1182/blood.2019000950; Segata N, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-6-r60; Shono Y, 2018, NAT REV CANCER, V18, P283, DOI 10.1038/nrc.2018.10; Shono Y, 2015, INT J HEMATOL, V101, P428, DOI 10.1007/s12185-015-1781-5; Snyder LM, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.559635; Sofi MH, 2021, JCI INSIGHT, V6, DOI 10.1172/jci.insight.136841; Song QX, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21133-3; Stein-Thoeringer CK, 2019, SCIENCE, V366, P1143, DOI 10.1126/science.aax3760; Stephensen CB, 2001, ANNU REV NUTR, V21, P167, DOI 10.1146/annurev.nutr.21.1.167; Suzuki T, 2011, J BIOL CHEM, V286, P31263, DOI 10.1074/jbc.M111.238147; Swimm A, 2018, BLOOD, V132, P2506, DOI 10.1182/blood-2018-03-838193; Taur Y, 2012, CLIN INFECT DIS, V55, P905, DOI 10.1093/cid/cis580; Thangavelu G, 2019, J IMMUNOL, V202, P2795, DOI 10.4049/jimmunol.1800899; Thatcher JE, 2009, EXPERT OPIN DRUG MET, V5, P875, DOI 10.1517/17425250903032681; Tian Y, 2018, J NUTR BIOCHEM, V54, P28, DOI 10.1016/j.jnutbio.2017.10.011; Trumbo P, 2001, J AM DIET ASSOC, V101, P294, DOI 10.1016/S0002-8223(01)00078-5; Vazquez-Baeza Y, 2017, CELL HOST MICROBE, V21, P7, DOI 10.1016/j.chom.2016.12.009; Wang DP, 2013, BIOL BLOOD MARROW TR, V19, P692, DOI 10.1016/j.bbmt.2013.01.008; Wang YY, 2017, J IMMUNOL, V199, P3316, DOI 10.4049/jimmunol.1700152; Wilson AS, 2020, DIGEST DIS SCI, V65, P723, DOI 10.1007/s10620-020-06112-w; Yu HS, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00093; Zeisel MB, 2019, GUT, V68, P547, DOI 10.1136/gutjnl-2018-316906; Zeiser R, 2017, NEW ENGL J MED, V377, P2167, DOI 10.1056/NEJMra1609337; Zhen JW, 2020, AM J TRANSPLANT, V20, P64, DOI 10.1111/ajt.15501; Zheng Jianwei, 2018, J Immunol Res Ther, V3, P124	72	0	0	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 25	2021	12								749002	10.3389/fimmu.2021.749002	http://dx.doi.org/10.3389/fimmu.2021.749002			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WV4ZF	34759928	Green Published, gold			2022-12-18	WOS:000717246000001
J	Pederson, S; Biondi, DM; Allan, B; Cady, R; Schaeffler, B; Baker, B; Latham, J				Pederson, Susan; Biondi, David M.; Allan, Brent; Cady, Roger; Schaeffler, Barbara; Baker, Brian; Latham, John			Clinical Immunogenicity Evaluation of Eptinezumab, a Therapeutic Humanized Monoclonal Antibody Targeting Calcitonin Gene-Related Peptide (CGRP) for the Preventive Treatment of Migraine	FRONTIERS IN IMMUNOLOGY			English	Article						eptinezumab; immunogenicity; anti-drug antibody; monoclonal antibody; migraine; neutralizing antibody; calcitonin gene-related peptide (CGRP)	EPISODIC MIGRAINE	Background Eptinezumab is a humanized monoclonal antibody that selectively binds calcitonin gene-related peptide and is indicated for the preventive treatment of migraine in adults. This analysis characterizes the immunogenic profile of eptinezumab using data from clinical trials of eptinezumab for migraine prevention. Methods Immunogenicity data were collected from five studies that included 2076 patients with episodic or chronic migraine treated with eptinezumab at dose levels ranging from 10 to 1000 mg, administered intravenously for up to 4 doses at 12-week intervals. Anti-drug antibody (ADA) results were available from 2074 of these patients. Four studies were randomized, double-blind, placebo-controlled trials with ADA monitoring for up to 56 weeks; one was a 2-year, open-label, phase 3 safety study with ADA monitoring for 104 weeks. Patients who had a confirmed ADA-positive result at the end-of-study visit were monitored for up to 6 additional months. Development of ADA and neutralizing antibodies (NAbs) were evaluated to explore three key areas of potential impact: pharmacokinetic exposure profile (eptinezumab trough plasma concentrations), efficacy (change in monthly migraine days), and safety (rates of treatment-emergent adverse events). These studies included methods designed to capture the dynamics of a potential humoral immune response to eptinezumab treatment, and descriptive analyses were applied to interpret the relationship of ADA signals to drug exposure, efficacy, and safety. Results Pooled across the five clinical trials, treatment-emergent ADAs and NAbs occurred in 15.8 and 6.2% of eptinezumab-treated patients, respectively. Highly consistent profiles were observed across all studies, with initial onset of detectable ADA observed at the week 8 measurement and maximal ADA frequency and titer observed at week 24, regardless of eptinezumab dose level or number of doses. After 24 weeks, the ADA and NAb titers steadily declined despite additional doses of eptinezumab. Interpretation Collectively, these integrated analyses did not demonstrate any clinically meaningful impact from ADA occurring after treatment with eptinezumab. The ADA profiles were low titer and transient, with the incidence and magnitude of ADA or NAb responses declining after week 24. Development of ADAs and NAbs did not impact the efficacy and safety profiles of eptinezumab.	[Pederson, Susan; Cady, Roger; Schaeffler, Barbara; Baker, Brian] Lundbeck Seattle BioPharmaceut Inc, Bothell, WA 98011 USA; [Biondi, David M.; Allan, Brent; Latham, John] Alder BioPharmaceut Inc, CKA Lundbeck Seattle BioPharmaceut Inc, Bothell, WA USA; [Allan, Brent] Global Safely Docs LLC, Paradise Valley, AZ USA		Cady, R (corresponding author), Lundbeck Seattle BioPharmaceut Inc, Bothell, WA 98011 USA.	ROCD@lundbeck.com			H. Lundbeck A/S (Copenhagen, Denmark)	H. Lundbeck A/S (Copenhagen, Denmark)	This study was funded by H. Lundbeck A/S (Copenhagen, Denmark).	[Anonymous], 2018, BIOANALYTICAL METHOD, V44; [Anonymous], 2021, VYEPTI PACKAGE INSER; Ashina M, 2020, CEPHALALGIA, V40, P241, DOI 10.1177/0333102420905132; Baker B., 2017, NEUROLOGY, V88, P2; Baker B, 2020, PHARMACOL RES PERSPE, V8, DOI 10.1002/prp2.567; Cohen JM, 2021, J HEADACHE PAIN, V22, DOI 10.1186/s10194-020-01211-5; Dodick DW, 2019, CEPHALALGIA, V39, P1075, DOI 10.1177/0333102419858355; Dodick DW, 2014, LANCET NEUROL, V13, P1100, DOI 10.1016/S1474-4422(14)70209-1; EMEA, 2017, 2017 GUID IMM ASS TH; FDA, 2016, GUID IND ASS DEV VAL; [FDA F.a.D. Administration], 2009, GUID IND ASS DEV IMM; FDA, 2014, GUID IND IMM ASS THE; Harding FA, 2010, MABS-AUSTIN, V2, P256, DOI 10.4161/mabs.2.3.11641; Kudrow D, 2021, BMC NEUROL, V21, DOI 10.1186/s12883-021-02123-w; Lipton RB, 2020, NEUROLOGY, V94, pE1365, DOI 10.1212/WNL.0000000000009169; Rosenberg A S, 2003, Dev Biol (Basel), V112, P15; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; Shankar G, 2014, AAPS J, V16, P658, DOI 10.1208/s12248-014-9599-2; Silberstein S, 2020, J HEADACHE PAIN, V21, DOI 10.1186/s10194-020-01186-3; Smith TR, 2021, J HEADACHE PAIN, V22, DOI 10.1186/s10194-021-01227-5; Smith TR, 2020, CLIN THER, V42, P2254, DOI 10.1016/j.clinthera.2020.11.007; Spuntarelli V, 2021, EXPERT OPIN BIOL TH, V21, P999, DOI 10.1080/14712598.2021.1931678; USP, 2012, US PHARM CHAPT 1106; Yan ZY, 2021, J HEADACHE PAIN, V22, DOI 10.1186/s10194-021-01220-y	24	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 25	2021	12								765822	10.3389/fimmu.2021.765822	http://dx.doi.org/10.3389/fimmu.2021.765822			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WV4YP	34759933	gold, Green Published			2022-12-18	WOS:000717244400001
J	Tsunoda, M; Aoki, H; Shimizu, H; Shichino, S; Matsushima, K; Ueha, S				Tsunoda, Mikiya; Aoki, Hiroyasu; Shimizu, Haruka; Shichino, Shigeyuki; Matsushima, Kouji; Ueha, Satoshi			Proportional Tumor Infiltration of T Cells via Circulation Duplicates the T Cell Receptor Repertoire in a Bilateral Tumor Mouse Model	FRONTIERS IN IMMUNOLOGY			English	Article						cancer immunotherapy; immunomonitoring; TCR sequencing; overlap analysis; TCR repertoire	CHECKPOINT; BLOCKADE	Temporal analysis of the T cell receptor (TCR) repertoire has been used to monitor treatment-induced changes in antigen-specific T cells in patients with cancer. However, the lack of experimental models that allow a temporal analysis of the TCR repertoire in the same individual in a homogeneous population limits the understanding of the causal relationship between changes in TCR repertoire and antitumor responses. A bilateral tumor model, where tumor cells were inoculated bilaterally into the backs of mice, could be used for temporal analysis of the TCR repertoire. This study examined the prerequisite for this strategy: the TCR repertoire is conserved between bilateral tumors that grow symmetrically. Bilateral tumors and draining lymph nodes (dLNs) were collected 13 days after tumor inoculation to analyze the TCR repertoire of CD4(+) and CD8(+) T cells. The tumor-infiltrating T-cell clones were highly similar between the bilateral tumors and expanded to a similar extent. In addition, the differences of TCR repertoire between the bilateral tumors were equivalent to Intra-tumoral heterogeneity on one side. On the other hand, the similarity of the TCR repertoire in the bilateral dLNs was markedly lower than that in the tumor, suggesting that tumor-reactive T cell clones induced independently in each dLN are mixed during recirculation and then proportionally infiltrated the bilateral tumors. These findings provide the basis for future analysis of temporal and treatment-induced changes in tumor-reactive T cell clones using this bilateral tumor model.	[Tsunoda, Mikiya; Aoki, Hiroyasu; Shimizu, Haruka; Shichino, Shigeyuki; Matsushima, Kouji; Ueha, Satoshi] Tokyo Univ Sci, Res Inst Biomed Sci, Div Mol Regulat Inflammatory & Immune Dis, Chiba, Japan; [Tsunoda, Mikiya] Tokyo Univ Sci, Fac Pharmaceut Sci, Dept Med & Life Sci, Chiba, Japan; [Aoki, Hiroyasu] Univ Tokyo, Grad Sch Med, Dept Hyg, Tokyo, Japan	Tokyo University of Science; Tokyo University of Science; University of Tokyo	Ueha, S (corresponding author), Tokyo Univ Sci, Res Inst Biomed Sci, Div Mol Regulat Inflammatory & Immune Dis, Chiba, Japan.	ueha@rs.tus.ac.jp		Shichino, Shigeyuki/0000-0002-1683-2448	Japan Society for the Promotion of Science	Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	Funding This work was supported by the Japan Society for the Promotion of Science under Grant Number 20281832 and 17929397, and by the Japan Agency for Medical Research and Development (AMED) under Grant Number JP 21gm6210025. HA was supported by the Tadamitsu Kishimoto Fellowship Program.	Alsaab HO, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00561; Anderson KG, 2014, NAT PROTOC, V9, P209, DOI 10.1038/nprot.2014.005; Aoki H, 2021, CANCER IMMUNOL RES, V9, P624, DOI 10.1158/2326-6066.CIR-20-0989; Aoki H, 2019, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03185; Aversa I, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21072378; Bolotin DA, 2015, NAT METHODS, V12, P380, DOI 10.1038/nmeth.3364; Chen DS, 2013, IMMUNITY, V39, P1, DOI 10.1016/j.immuni.2013.07.012; Chen IX, 2020, P NATL ACAD SCI USA, V117, P23684, DOI 10.1073/pnas.2002806117; Chiffelle J, 2020, CURR OPIN BIOTECH, V65, P284, DOI 10.1016/j.copbio.2020.07.010; DeWitt WS, 2015, J VIROL, V89, P4517, DOI 10.1128/JVI.03474-14; Galluzzi L, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aat7807; Gros A, 2014, J CLIN INVEST, V124, P2246, DOI [10.1172/JC173639, 10.1172/JCI73639]; Gu ZG, 2016, BIOINFORMATICS, V32, P2847, DOI 10.1093/bioinformatics/btw313; Havel JJ, 2019, NAT REV CANCER, V19, P133, DOI 10.1038/s41568-019-0116-x; Kidman J, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.587014; Kim JY, 2019, CANCERS, V11, DOI 10.3390/cancers11111699; Liu X, 2018, CELL BIOL TOXICOL, V34, P441, DOI 10.1007/s10565-018-9426-0; Martin M., 2011, EMBNET J, V17, P10, DOI [10.14806/ej.17.1.200, DOI 10.14806/EJ.17.1.200]; Masucci GV, 2016, J IMMUNOTHER CANCER, V4, DOI 10.1186/s40425-016-0178-1; Pasetto A, 2016, CANCER IMMUNOL RES, V4, P734, DOI 10.1158/2326-6066.CIR-16-0001; Philip H, 2021, ISCIENCE, V24, DOI 10.1016/j.isci.2021.102100; Postow MA, 2018, NEW ENGL J MED, V378, P158, DOI [10.1056/NEJMra1703481, 10.1056/NEJMc1801663]; Ribas A, 2018, SCIENCE, V359, P1350, DOI 10.1126/science.aar4060; Rosati E, 2017, BMC BIOTECHNOL, V17, DOI 10.1186/s12896-017-0379-9; Rudqvist NP, 2018, CANCER IMMUNOL RES, V6, P139, DOI 10.1158/2326-6066.CIR-17-0134; Schmieder R, 2011, BIOINFORMATICS, V27, P863, DOI 10.1093/bioinformatics/btr026; Shitara K, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0677-y; Shugay M, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004503; Topalian SL, 2016, NAT REV CANCER, V16, P275, DOI 10.1038/nrc.2016.36; Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1; Yuzhakova DV, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00512; Zemek RM, 2020, NAT PROTOC, V15, P1628, DOI 10.1038/s41596-020-0299-3	32	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 25	2021	12								744381	10.3389/fimmu.2021.744381	http://dx.doi.org/10.3389/fimmu.2021.744381			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WV5TL	34759926	Green Published, gold			2022-12-18	WOS:000717299300001
J	Wines, BD; Trist, HM; Esparon, S; Impey, RE; Mackay, GA; Andrews, RK; da Costa, TPS; Pietersz, GA; Baker, RI; Hogarth, PM				Wines, Bruce D.; Trist, Halina M.; Esparon, Sandra; Impey, Rachael E.; Mackay, Graham A.; Andrews, Robert K.; da Costa, Tatiana P. Soares; Pietersz, Geoffrey A.; Baker, Ross, I; Hogarth, P. Mark			Fc Binding by Fc gamma RIIa Is Essential for Cellular Activation by the Anti-Fc gamma RIIa mAbs 8.26 and 8.2	FRONTIERS IN IMMUNOLOGY			English	Article						Fc receptor; IgG; Fc?RIIa; effector function; antibody dependent cellular cytotoxicity (ADCC); mAb- monoclonal antibody	HUMAN-IGG; MONOCLONAL-ANTIBODIES; CRYSTAL-STRUCTURE; RECEPTOR IIB; ALPHA-RI; B-CELLS; EFFECTOR; EXPRESSION; MONOCYTES; AFFINITY	Fc gamma R activity underpins the role of antibodies in both protective immunity and auto-immunity and importantly, the therapeutic activity of many monoclonal antibody therapies. Some monoclonal anti-Fc gamma R antibodies activate their receptors, but the properties required for cell activation are not well defined. Here we examined activation of the most widely expressed human Fc gamma R; Fc gamma RIIa, by two non-blocking, mAbs, 8.26 and 8.2. Crosslinking of Fc gamma RIIa by the mAb F(ab')(2) regions alone was insufficient for activation, indicating activation also required receptor engagement by the Fc region. Similarly, when mutant receptors were inactivated in the Fc binding site, so that intact mAb was only able to engage receptors via its two Fab regions, again activation did not occur. Mutation of Fc gamma RIIa in the epitope recognized by the agonist mAbs, completely abrogated the activity of mAb 8.26, but mAb 8.2 activity was only partially inhibited indicating differences in receptor recognition by these mAbs. Fc gamma RIIa inactivated in the Fc binding site was next co-expressed with the Fc gamma RIIa mutated in the epitope recognized by the Fab so that each mAb 8.26 molecule can contribute only three interactions, each with separate receptors, one via the Fc and two via the Fab regions. When the Fab and Fc binding were thus segregated onto different receptor molecules receptor activation by intact mAb did not occur. Thus, receptor activation requires mAb 8.26 Fab and Fc interaction simultaneously with the same receptor molecules. Establishing the molecular nature of Fc gamma R engagement required for cell activation may inform the optimal design of therapeutic mAbs.	[Wines, Bruce D.; Trist, Halina M.; Esparon, Sandra; Pietersz, Geoffrey A.; Hogarth, P. Mark] Burnet Inst, Immune Therapies Lab, Melbourne, Vic, Australia; [Wines, Bruce D.; Hogarth, P. Mark] Monash Univ, Cent Clin Sch, Dept Immunol & Pathol, Melbourne, Vic, Australia; [Wines, Bruce D.; Hogarth, P. Mark] Univ Melbourne, Dept Clin Pathol, Parkville, Vic, Australia; [Impey, Rachael E.; da Costa, Tatiana P. Soares] La Trobe Univ, La Trobe Inst Mol Sci, Dept Biochem & Genet, Melbourne, Vic, Australia; [Mackay, Graham A.] Univ Melbourne, Dept Biochem & Pharmacol, Parkville, Vic, Australia; [Andrews, Robert K.] Australian Natl Univ, John Curtin Sch Med Res, Dept Canc Biol & Therapeut, Canberra, ACT, Australia; [Pietersz, Geoffrey A.] Baker Heart & Diabet Inst, Atherothrombosis & Vasc Biol Lab, Melbourne, Vic, Australia; [Baker, Ross, I] Murdoch Univ, Perth Blood Inst, Perth, WA, Australia; [Baker, Ross, I] Murdoch Univ, Western Australian Ctr Thrombosis & Haemostasis, Murdoch, WA, Australia	Burnet Institute; Monash University; University of Melbourne; La Trobe University; University of Melbourne; Australian National University; John Curtin School of Medical Research; Murdoch University; Murdoch University	Hogarth, PM (corresponding author), Burnet Inst, Immune Therapies Lab, Melbourne, Vic, Australia.; Hogarth, PM (corresponding author), Monash Univ, Cent Clin Sch, Dept Immunol & Pathol, Melbourne, Vic, Australia.; Hogarth, PM (corresponding author), Univ Melbourne, Dept Clin Pathol, Parkville, Vic, Australia.	mark.hogarth@burnet.edu.au	Baker, Ross/AAG-5798-2021	Baker, Ross/0000-0002-2728-6788; Soares da Costa, Tatiana P./0000-0002-6275-7485; Mackay, Graham/0000-0002-9083-1304	Australian NHRMC - Project Grant [GNT1145303]; NHMRC Independent Research Institutes Infrastructure Support Scheme; Victorian State Government Operational Infrastructure grant; Australian Research Council fellowship [DE190100806]	Australian NHRMC - Project Grant; NHMRC Independent Research Institutes Infrastructure Support Scheme(National Health and Medical Research Council (NHMRC) of Australia); Victorian State Government Operational Infrastructure grant; Australian Research Council fellowship(Australian Research Council)	This work was supported by the Australian NHRMC -Project Grant, to PH and BW (GNT1145303). Support to the Burnet Institute comes from the NHMRC Independent Research Institutes Infrastructure Support Scheme and a Victorian State Government Operational Infrastructure grant. TC holds an Australian Research Council fellowship (DE190100806).	Anania JC, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00464; Anania JC, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01809; Bailey EM, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.617767; Bournazos S, 2017, IMMUNOL REV, V275, P285, DOI 10.1111/imr.12482; Bournazos S, 2016, MICROBIOL SPECTR, V4, DOI 10.1128/microbiolspec.MCHD-0045-2016; Brandsma AM, 2016, IMMUNITY, V45, P225, DOI 10.1016/j.immuni.2016.07.006; Bruhns P, 2015, IMMUNOL REV, V268, P25, DOI 10.1111/imr.12350; Chu SY, 2008, MOL IMMUNOL, V45, P3926, DOI 10.1016/j.molimm.2008.06.027; Cloutier N, 2018, P NATL ACAD SCI USA, V115, pE1550, DOI 10.1073/pnas.1720553115; DELISI C, 1981, NATURE, V289, P322, DOI 10.1038/289322a0; Diebolder CA, 2014, SCIENCE, V343, P1260, DOI 10.1126/science.1248943; DiLillo DJ, 2015, CANCER IMMUNOL RES, V3, P704, DOI 10.1158/2326-6066.CIR-15-0120; Gordan S, 2015, IMMUNOL REV, V268, P52, DOI 10.1111/imr.12347; Greinacher A, 2021, NEW ENGL J MED, V384, P2092, DOI 10.1056/NEJMoa2104840; Guilliams M, 2014, NAT REV IMMUNOL, V14, P94, DOI 10.1038/nri3582; HIBBS ML, 1988, P NATL ACAD SCI USA, V85, P2240, DOI 10.1073/pnas.85.7.2240; Hogarth PM, 2012, NAT REV DRUG DISCOV, V11, P311, DOI 10.1038/nrd2909; Hussain K, 2015, BLOOD, V125, P102, DOI 10.1182/blood-2014-08-593061; Huynh A, 2021, NATURE, V596, P565, DOI 10.1038/s41586-021-03744-4; IERINO FL, 1993, J IMMUNOL, V150, P1794; Kaplon H, 2021, MABS-AUSTIN, V13, DOI 10.1080/19420862.2020.1860476; Kerntke C, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00118; KURLANDER RJ, 1983, J IMMUNOL, V131, P140; Lee CS, 2015, BRIT J HAEMATOL, V168, P145, DOI 10.1111/bjh.13071; Lim SH, 2011, BLOOD, V118, P2530, DOI 10.1182/blood-2011-01-330357; Lu JH, 2015, P NATL ACAD SCI USA, V112, P833, DOI 10.1073/pnas.1418812112; Maxwell KF, 1999, NAT STRUCT BIOL, V6, P437; McKenzie SE, 1999, J IMMUNOL, V162, P4311; METZGER H, 1992, J IMMUNOL, V149, P1477; MOLLER NPH, 1979, IMMUNOLOGY, V38, P631; Murin CD, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01635; Nagashima H, 2008, MOL IMMUNOL, V45, P2752, DOI 10.1016/j.molimm.2008.02.003; Nagashima H, 2011, J BIOSCI BIOENG, V111, P391, DOI 10.1016/j.jbiosc.2010.12.007; Nimmerjahn F, 2015, TRENDS IMMUNOL, V36, P325, DOI 10.1016/j.it.2015.04.005; Ortiz DF, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf9418; Patel D, 2010, J IMMUNOL, V184, P6283, DOI 10.4049/jimmunol.0903311; Powell MS, 2006, J IMMUNOL, V176, P7489, DOI 10.4049/jimmunol.176.12.7489; Powell MS, 1999, IMMUNOL LETT, V68, P17, DOI 10.1016/S0165-2478(99)00025-5; Qiao JL, 2015, IMMUNOL REV, V268, P241, DOI 10.1111/imr.12370; Radaev S, 2001, J BIOL CHEM, V276, P16469, DOI 10.1074/jbc.M100350200; Ramsland PA, 2011, J IMMUNOL, V187, P3208, DOI 10.4049/jimmunol.1101467; Roghanian A, 2015, CANCER CELL, V27, P473, DOI 10.1016/j.ccell.2015.03.005; Sondermann P, 2000, NATURE, V406, P267, DOI 10.1038/35018508; TAX WJM, 1984, J IMMUNOL, V133, P1185; Trist HM, 2014, J IMMUNOL, V192, P792, DOI 10.4049/jimmunol.1301554; Wang Q, 2017, MABS-AUSTIN, V9, P393, DOI 10.1080/19420862.2017.1281505; WARMERDAM PAM, 1991, J IMMUNOL, V147, P1338; Wines BD, 2018, J THROMB HAEMOST, V16, P2520, DOI 10.1111/jth.14306; Wines BD, 2004, J BIOL CHEM, V279, P26339, DOI 10.1074/jbc.M403684200; Wines BD, 2006, J BIOL CHEM, V281, P17108, DOI 10.1074/jbc.M601640200; Wines BD, 2017, IMMUNOL CELL BIOL, V95, P272, DOI 10.1038/icb.2016.93; Wines BD, 2016, J IMMUNOL, V197, P1507, DOI 10.4049/jimmunol.1502551; Yang DL, 2017, JOVE-J VIS EXP, DOI 10.3791/55659; Yang JY, 2016, CURR TOP MICROBIOL, V393, P27, DOI 10.1007/82_2015_482	55	0	0	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 25	2021	12								666813	10.3389/fimmu.2021.666813	http://dx.doi.org/10.3389/fimmu.2021.666813			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WV9FB	34759915	Green Published, gold			2022-12-18	WOS:000717533700001
J	Li, X; Zeng, Q; Wang, SY; Li, MY; Chen, XH; Huang, YF; Chen, BF; Zhou, MJ; Lai, YM; Guo, CH; Zhao, SY; Zhang, H; Yang, NS				Li, Xue; Zeng, Qin; Wang, Shuyi; Li, Mengyuan; Chen, Xionghui; Huang, Yuefang; Chen, Binfeng; Zhou, Mianjing; Lai, Yimei; Guo, Chaohuan; Zhao, Siyuan; Zhang, Hui; Yang, Niansheng			CRAC Channel Controls the Differentiation of Pathogenic B Cells in Lupus Nephritis	FRONTIERS IN IMMUNOLOGY			English	Article						lupus nephritis; store-operated Ca2+ entry; Ca2+ release-activated Ca2+ channel; CaMK2; B-cell differentiation	PROTEIN-KINASE-II; OPERATED CA2+ ENTRY; T-CELLS; AMERICAN-COLLEGE; RHEUMATOLOGY/EUROPEAN LEAGUE; CLASSIFICATION CRITERIA; IMMUNE-RESPONSES; CALCIUM; ACTIVATION; ARTHRITIS	Store-operated Ca2+ release-activated Ca2+ (CRAC) channel is the main Ca2+ influx pathway in lymphocytes and is essential for immune response. Lupus nephritis (LN) is an autoimmune disease characterized by the production of autoantibodies due to widespread loss of immune tolerance. In this study, RNA-seq analysis revealed that calcium transmembrane transport and calcium channel activity were enhanced in naive B cells from patients with LN. The increased expression of ORAI1, ORAI2, and STIM2 in naive B cells from patients with LN was confirmed by flow cytometry and Western blot, implying a role of CRAC channel in B-cell dysregulation in LN. For in vitro study, CRAC channel inhibition by YM-58483 or downregulation by ORAI1-specific small-interfering RNA (siRNA) decreased the phosphorylation of Ca2+/calmodulin-dependent protein kinase2 (CaMK2) and suppressed Blimp-1 expression in primary human B cells, resulting in decreased B-cell differentiation and immunoglobulin G (IgG) production. B cells treated with CaMK2-specific siRNA showed defects in plasma cell differentiation and IgG production. For in vivo study, YM-58483 not only ameliorated the progression of LN but also prevented the development of LN. MRL/lpr lupus mice treated with YM-58483 showed lower percentage of plasma cells in the spleen and reduced concentration of anti-double-stranded DNA antibodies in the sera significantly. Importantly, mice treated with YM-58483 showed decreased immune deposition in the glomeruli and alleviated kidney damage, which was further confirmed in NZM2328 lupus mice. Collectively, CRAC channel controlled the differentiation of pathogenic B cells and promoted the progression of LN. This study provides insights into the pathogenic mechanisms of LN and that CRAC channel could serve as a potential therapeutic target for LN.</p>	[Li, Xue; Zeng, Qin; Wang, Shuyi; Li, Mengyuan; Chen, Binfeng; Zhou, Mianjing; Lai, Yimei; Guo, Chaohuan; Zhao, Siyuan; Zhang, Hui; Yang, Niansheng] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Rheumatol, Guangzhou, Peoples R China; [Chen, Xionghui] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Nephrol, Guangzhou, Peoples R China; [Huang, Yuefang] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Pediat, Guangzhou, Peoples R China; [Zhang, Hui] Sun Yat Sen Univ, Affiliated Hosp 1, Inst Precis Med, Guangzhou, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University	Zhang, H; Yang, NS (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 1, Dept Rheumatol, Guangzhou, Peoples R China.; Zhang, H (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 1, Inst Precis Med, Guangzhou, Peoples R China.	zhangh656@mail.sysu.edu.cn; yangnsh@mail.sysu.edu.cn			National Natural Science Foundation of China [81971519, 81671593, 81471598, 81701595, 82071819]; Guangzhou Science and Technology Planning Program [201707010093]; National Key Research and Development Project [2017YFC0907602]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangzhou Science and Technology Planning Program; National Key Research and Development Project	Funding This work is supported by the National Natural Science Foundation of China (81971519, 81671593, 81471598, 81701595, and 82071819), Guangzhou Science and Technology Planning Program (201707010093), and National Key Research and Development Project (2017YFC0907602).	Aletaha D, 2010, ARTHRITIS RHEUM-US, V62, P2569, DOI 10.1002/art.27584; Baba Y, 2016, CURR TOP MICROBIOL, V393, P143, DOI 10.1007/82_2015_477; Bengtsson AA, 2017, J INTERN MED, V281, P52, DOI 10.1111/joim.12529; Berry CT, 2018, CELL CALCIUM, V74, P131, DOI 10.1016/j.ceca.2018.07.003; Faul C, 2008, NAT MED, V14, P931, DOI 10.1038/nm.1857; Ferretti AP, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02113; Feske S, 2007, NAT REV IMMUNOL, V7, P690, DOI 10.1038/nri2152; Feske S, 2010, CLIN IMMUNOL, V135, P169, DOI 10.1016/j.clim.2010.01.011; Franklyn K, 2016, ANN RHEUM DIS, V75, P1615, DOI 10.1136/annrheumdis-2015-207726; Fu R, 2017, ARTHRITIS RHEUMATOL, V69, P1636, DOI 10.1002/art.40155; Furie R, 2020, NEW ENGL J MED, V383, P1117, DOI 10.1056/NEJMoa2001180; Hochberg MC, 1997, ARTHRITIS RHEUM, V40, P1725, DOI 10.1002/art.1780400928; Hofmann K, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00835; Hogan PG, 2010, ANNU REV IMMUNOL, V28, P491, DOI 10.1146/annurev.immunol.021908.132550; Hudmon A, 2002, ANNU REV BIOCHEM, V71, P473, DOI 10.1146/annurev.biochem.71.110601.135410; Jenks SA, 2018, IMMUNITY, V49, P725, DOI 10.1016/j.immuni.2018.08.015; Kim KD, 2014, J IMMUNOL, V192, P110, DOI 10.4049/jimmunol.1302586; Koga T, 2014, J CLIN INVEST, V124, P2234, DOI 10.1172/JCI73411; Kyttaris VC, 2011, ARTHRITIS RHEUM-US, V63, P2058, DOI 10.1002/art.30353; Lacruz RS, 2015, ANN NY ACAD SCI, V1356, P45, DOI 10.1111/nyas.12938; Lech M, 2013, J AM SOC NEPHROL, V24, P1357, DOI 10.1681/ASN.2013010026; Lewis RS, 2007, NATURE, V446, P284, DOI 10.1038/nature05637; Lewis RS, 2001, ANNU REV IMMUNOL, V19, P497, DOI 10.1146/annurev.immunol.19.1.497; Lin MY, 2005, J IMMUNOL, V174, P5583, DOI 10.4049/jimmunol.174.9.5583; Liossis SNC, 1996, J CLIN INVEST, V98, P2549, DOI 10.1172/JCI119073; Liu S, 2017, J IMMUNOL, V199, P1584, DOI 10.4049/jimmunol.1700192; Maeda K, 2018, J CLIN INVEST, V128, P3445, DOI 10.1172/JCI99507; Martins G, 2008, ANNU REV IMMUNOL, V26, P133, DOI 10.1146/annurev.immunol.26.021607.090241; Matsumoto M, 2011, IMMUNITY, V34, P703, DOI 10.1016/j.immuni.2011.03.016; McGargill MA, 2005, J IMMUNOL, V175, P656, DOI 10.4049/jimmunol.175.2.656; Minegishi Y, 1999, SCIENCE, V286, P1954, DOI 10.1126/science.286.5446.1954; Minowa K, 2011, AUTOIMMUNITY, V44, P357, DOI 10.3109/08916934.2010.545846; Morawski PA, 2017, TRENDS IMMUNOL, V38, P373, DOI 10.1016/j.it.2017.02.001; Ohga K, 2008, INT IMMUNOPHARMACOL, V8, P1787, DOI 10.1016/j.intimp.2008.08.016; Parekh AB, 2005, PHYSIOL REV, V85, P757, DOI 10.1152/physrev.00057.2003; Park YJ, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00195; Parodis I, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.00316; Prakriya M, 2015, PHYSIOL REV, V95, P1383, DOI 10.1152/physrev.00020.2014; Prole DL, 2019, CSH PERSPECT BIOL, V11, DOI 10.1101/cshperspect.a035063; Rahman A, 2008, NEW ENGL J MED, V358, P929, DOI 10.1056/NEJMra071297; Rawlings DJ, 1999, CLIN IMMUNOL, V91, P243, DOI 10.1006/clim.1999.4732; Scharer CD, 2019, NAT IMMUNOL, V20, P1071, DOI 10.1038/s41590-019-0419-9; Schuhmann MK, 2010, J IMMUNOL, V184, P1536, DOI 10.4049/jimmunol.0902161; Shaffer AL, 2002, IMMUNITY, V17, P51, DOI 10.1016/S1074-7613(02)00335-7; Shaw Patrick J, 2012, Front Biosci (Elite Ed), V4, P2253; Shiboski CH, 2017, ANN RHEUM DIS, V76, P9, DOI [10.1136/annrheumdis-2016-210571, 10.1002/art.39859]; Suurmond J, 2015, J CLIN INVEST, V125, P2194, DOI 10.1172/JCI78084; Tang HY, 2017, J IMMUNOL, V199, P570, DOI 10.4049/jimmunol.1700109; Vaeth M, 2016, IMMUNITY, V44, P1350, DOI 10.1016/j.immuni.2016.04.013; Wayman GA, 2011, CELL CALCIUM, V50, P1, DOI 10.1016/j.ceca.2011.02.007; Wu BW, 2020, CELL METAB, V32, DOI 10.1016/j.cmet.2020.10.025; Wu CM, 2019, ANN RHEUM DIS, V78, P1090, DOI 10.1136/annrheumdis-2019-215039; Yu P, 2005, IMMUNITY, V22, P451, DOI 10.1016/j.immuni.2005.01.018; Zhang H, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-0911-z; Zhang H, 2015, J AUTOIMMUN, V65, P82, DOI 10.1016/j.jaut.2015.08.010; Zhou MJ, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102424	56	0	0	0	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 22	2021	12								779560	10.3389/fimmu.2021.779560	http://dx.doi.org/10.3389/fimmu.2021.779560			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WU2OL	34745151	Green Published, gold			2022-12-18	WOS:000716389600001
J	Mu, SD; Shi, DY; Ai, LS; Fan, FJ; Peng, F; Sun, CY; Hu, Y				Mu, Shidai; Shi, Deyao; Ai, Lisha; Fan, Fengjuan; Peng, Fei; Sun, Chunyan; Hu, Yu			International Prognostic Index-Based Immune Prognostic Model for Diffuse Large B-Cell Lymphoma	FRONTIERS IN IMMUNOLOGY			English	Article						diffuse large B-cell lymphoma; immune prognostic model; nomogram; immunotherapy; tumor microenvironment	PREDICTION MODELS; EXPRESSION; MUTATIONS; BLOCKADE; PACKAGE; PERFORMANCE; SIGNATURES; CURVES; PD-L1	Background The International Prognostic Index (IPI) is widely used to discriminate the prognosis of patients with diffuse large B-cell lymphoma (DLBCL). However, there is a significant need to identify novel valuable biomarkers in the context of targeted therapy, such as immune checkpoint blockade (ICB). Methods Gene expression data and clinical DLBCL information were obtained from The Cancer Genome Atlas and Gene Expression Omnibus datasets. A total of 371 immune-related genes in DLBCL patients associated with different IPI risk groups were identified by weighted gene co-expression network analysis, and eight genes were selected to construct an IPI-based immune prognostic model (IPI-IPM). Subsequently, we analyzed the somatic mutation and transcription profiles of the IPI-IPM subgroups as well as the potential clinical response to immune checkpoint blockade (ICB) in IPI-IPM subgroups. Results The IPI-IPM was constructed based on the expression of CMBL, TLCD3B, SYNDIG1, ESM1, EPHA3, HUNK, PTX3, and IL12A, where high-risk patients had worse overall survival than low-risk patients, consistent with the results in the independent validation cohorts. The comprehensive results showed that high IPI-IPM risk scores were correlated with immune-related signaling pathways, high KMT2D and CD79B mutation rates, and upregulation of inhibitory immune checkpoints, including PD-L1, BTLA, and SIGLEC7, indicating a greater potential response to ICB therapy. Conclusion The IPI-IPM has independent prognostic significance for DLBCL patients, which provides an immunological perspective to elucidate the mechanisms of tumor progression and sheds light on the development of immunotherapy for DLBCL.	[Mu, Shidai; Ai, Lisha; Fan, Fengjuan; Peng, Fei; Sun, Chunyan; Hu, Yu] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Inst Hematol, Wuhan, Peoples R China; [Shi, Deyao] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Orthopaed, Wuhan, Peoples R China	Huazhong University of Science & Technology; Huazhong University of Science & Technology	Mu, SD; Sun, CY; Hu, Y (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Inst Hematol, Wuhan, Peoples R China.	mushidai9247@126.com; suncy0618@163.com; dr_huyu@126.com		Shi, Deyao/0000-0003-4131-1027	National Natural Science Foundation of China [81974007]; National Key R&D Program of China [2019YFC1316204]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key R&D Program of China	This work was supported by grants from the National Natural Science Foundation of China (No. 81974007 to CS) and the National Key R&D Program of China (Grant No. 2019YFC1316204 to YH).	Aran D, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1349-1; Autio M, 2021, HAEMATOLOGICA, V106, P718, DOI 10.3324/haematol.2019.243626; Bader GD, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-2; Bailey MH, 2018, CELL, V173, P371, DOI [10.1016/j.cell.2018.02.060, 10.1016/j.cell.2018.07.034]; Becht E, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1070-5; Carbon S, 2019, NUCLEIC ACIDS RES, V47, pD330, DOI 10.1093/nar/gky1055; Cardesa-Salzmann TM, 2011, HAEMATOL-HEMATOL J, V96, P996, DOI 10.3324/haematol.2010.037408; Chapuy B, 2018, NAT MED, V24, P679, DOI 10.1038/s41591-018-0016-8; Chen Benjamin J, 2019, Oncotarget, V10, P2030, DOI 10.18632/oncotarget.26771; Chen YW, 2006, BLOOD, V108, P2373, DOI 10.1182/blood-2006-05-022517; Chin CH, 2014, BMC SYST BIOL, V8, DOI 10.1186/1752-0509-8-S4-S11; Ciavarella S, 2018, ANN ONCOL, V29, P2363, DOI 10.1093/annonc/mdy450; Cioroianu AI, 2019, ANAL CELL PATHOL, V2019, DOI 10.1155/2019/8586354; Colaprico A, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/nar/gkv1507; Cui YB, 2021, ESOPHAGUS-TOKYO, V18, P326, DOI 10.1007/s10388-020-00796-9; Doni A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00712; Dubois S, 2019, EBIOMEDICINE, V48, P58, DOI 10.1016/j.ebiom.2019.09.034; Dubois S, 2017, CLIN CANCER RES, V23, P2232, DOI 10.1158/1078-0432.CCR-16-1922; El Hussein S, 2020, MODERN PATHOL, V33, P2422, DOI 10.1038/s41379-020-0616-y; Fabregat A, 2018, NUCLEIC ACIDS RES, V46, pD649, DOI [10.1093/nar/gkx1132, 10.1093/nar/gkz1031]; Friedman J, 2010, J STAT SOFTW, V33, P1, DOI 10.18637/jss.v033.i01; Fu JX, 2020, GENOME MED, V12, DOI 10.1186/s13073-020-0721-z; Godec J, 2016, IMMUNITY, V44, P194, DOI 10.1016/j.immuni.2015.12.006; Groth Detlef, 2013, Methods Mol Biol, V930, P527, DOI 10.1007/978-1-62703-059-5_22; Hanzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-7; Han H, 2018, NUCLEIC ACIDS RES, V46, pD380, DOI 10.1093/nar/gkx1013; Haro M, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00098; Harrell FE, 2015, SPRINGER SER STAT, DOI 10.1007/978-3-319-19425-7; Heagerty PJ, 2000, BIOMETRICS, V56, P337, DOI 10.1111/j.0006-341X.2000.00337.x; Hopken UE, 2019, TRENDS CANCER, V5, P351, DOI 10.1016/j.trecan.2019.05.001; Howe KL, 2021, NUCLEIC ACIDS RES, V49, pD884, DOI 10.1093/nar/gkaa942; Hu JL, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02311-1; Huang SX, 2019, DIAGN PATHOL, V14, DOI 10.1186/s13000-019-0856-7; Kerr KF, 2016, J CLIN ONCOL, V34, P2534, DOI 10.1200/JCO.2015.65.5654; Kim S, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2019.1626653; Kline J, 2020, BLOOD, V135, P523, DOI 10.1182/blood.2019000847; Kotlov N, 2021, CANCER DISCOV, V11, P1468, DOI 10.1158/2159-8290.CD-20-0839; Kraan W, 2013, BLOOD CANCER J, V3, DOI 10.1038/bcj.2013.28; Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-559; Larousserie F, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00563; Leek JT, 2012, BIOINFORMATICS, V28, P882, DOI 10.1093/bioinformatics/bts034; Lenz G, 2008, NEW ENGL J MED, V359, P2313, DOI 10.1056/NEJMoa0802885; Ligges U., 2003, J STAT SOFTWARE, V8, P1, DOI [10.18637/jss.v008.i11, DOI 10.18637/JSS.V008.I11]; London M, 2020, MOL BIOL REP, V47, P5523, DOI 10.1007/s11033-020-05571-8; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Mariathasan S, 2018, NATURE, V554, P544, DOI 10.1038/nature25501; Mayakonda A, 2018, GENOME RES, V28, P1747, DOI 10.1101/gr.239244.118; McCord R, 2019, BLOOD ADV, V3, P531, DOI 10.1182/bloodadvances.2018020602; Mirlekar B, 2021, CANCERS, V13, DOI 10.3390/cancers13020167; Muris JJF, 2004, LEUKEMIA, V18, P589, DOI 10.1038/sj.leu.2403240; Newman AM, 2015, NAT METHODS, V12, P453, DOI [10.1038/NMETH.3337, 10.1038/nmeth.3337]; Ogata H, 1999, NUCLEIC ACIDS RES, V27, P29, DOI 10.1093/nar/27.1.29; Pasqualucci L, 2018, BLOOD, V131, P2307, DOI 10.1182/blood-2017-11-764332; Patil I., 2021, J OPEN SOURCE SOFTW, V6, P3167, DOI 10.21105/joss.03167; Peng F, 2020, J CANCER RES CLIN, V146, P3123, DOI 10.1007/s00432-020-03398-1; Quan LN, 2018, EXP HEMATOL, V60, P47, DOI 10.1016/j.exphem.2018.01.003; Risso D, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-480; Saffie R, 2020, CANCER RES, V80, P2498, DOI 10.1158/0008-5472.CAN-19-2247; Schmitz R, 2018, NEW ENGL J MED, V378, P1396, DOI 10.1056/NEJMoa1801445; Schroder MS, 2011, BIOINFORMATICS, V27, P3206, DOI 10.1093/bioinformatics/btr511; Sha CL, 2019, J CLIN ONCOL, V37, P202, DOI 10.1200/JCO.18.01314; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Singh M, 2020, CELL, V180, P878, DOI 10.1016/j.cell.2020.01.029; Solimando AG, 2020, CANCERS, V12, DOI 10.3390/cancers12071869; Steyerberg EW, 2010, EPIDEMIOLOGY, V21, P128, DOI 10.1097/EDE.0b013e3181c30fb2; Subramanian A, 2017, CELL, V171, P1437, DOI 10.1016/j.cell.2017.10.049; Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI 10.1093/nar/gky1131; Takeuchi T, 2017, CANCER-AM CANCER SOC, V123, P1166, DOI 10.1002/cncr.30404; Tamma R, 2020, J CLIN MED, V9, DOI 10.3390/jcm9082418; Tataranni T, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/8201079; van der Maaten L, 2014, J MACH LEARN RES, V15, P3221; Visco C, 2020, CANCERS, V12, DOI 10.3390/cancers12102913; Wang L, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-01011-z; Wang ZY, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01757; Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1; Wight JC, 2018, BLOOD REV, V32, P400, DOI 10.1016/j.blre.2018.03.005; Wilkerson MD, 2010, BIOINFORMATICS, V26, P1572, DOI 10.1093/bioinformatics/btq170; Xie MX, 2019, INT IMMUNOPHARMACOL, V77, DOI 10.1016/j.intimp.2019.105999; Xu-Monette ZY, 2019, CANCER IMMUNOL RES, V7, P644, DOI 10.1158/2326-6066.CIR-18-0439; Xu-Monette ZY, 2018, BLOOD, V131, P68, DOI 10.1182/blood-2017-07-740993; YAMAOKA K, 1978, J PHARMACOKINET BIOP, V6, P165, DOI 10.1007/BF01117450; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Zeng DQ, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.687975; Zhang B, 2005, STAT APPL GENET MOL, V4, DOI 10.2202/1544-6115.1128; Zhou M, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0580-4	85	0	0	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 22	2021	12								732006	10.3389/fimmu.2021.732006	http://dx.doi.org/10.3389/fimmu.2021.732006			19	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WU5BR	34745101	gold, Green Published			2022-12-18	WOS:000716560500001
J	Zhang, X; Cao, JL; Zhao, SQ; Yang, XT; Dong, J; Tan, YQ; Yu, T; He, YL				Zhang, Xuan; Cao, Jiali; Zhao, Siqi; Yang, Xutong; Dong, Jie; Tan, Yaqi; Yu, Teng; He, Yanling			Nociceptive Sensory Fibers Drive Interleukin-23 Production in a Murine Model of Psoriasis via Calcitonin Gene-Related Peptide	FRONTIERS IN IMMUNOLOGY			English	Article						psoriasis; neuroimmunity; calcitonin gene-related peptide; nociceptive sensory neurons; type17 immune response	IMPROVES ACANTHOSIS; MOUSE MODEL; T-CELLS; SKIN; EXPRESSION; RECEPTOR; INFLAMMATION; NEUROPEPTIDES; PHYSIOLOGY; NEURONS	Neuroimmunity is involved in the pathogenesis of psoriasis, but the mechanism underlying the interaction between the nervous system and the interleukin (IL)-23/IL-17 immune axis is yet unclear. This study reveals the essential role of the sensory neuron-derived calcitonin gene-related peptide (CGRP) in imiquimod (IMQ)-induced expression of IL-23. First, we show that the increased nociceptive behavior was consistent with the development of psoriasiform dermatitis, which requires intact sensory innervation. Systemic ultrapotent Transient receptor potential vanilloid 1 (TRPV1) agonist (resiniferatoxin, RTX) treatment-induced sensory denervation resulted in a significant decrease in IL-23 expression in this model, while the recombinant IL-23 treatment induced IL-17A expression was intact after RTX treatment. In addition, IMQ exposure induced a transient increase in CGRP expression in the dorsal root ganglion. The neuron-derived CGRP expression was completely abolished by sensory denervation, thereby downregulating IL-23 expression, which could be reversed through the introduction of CGRP into the denervated dorsal skin. Our results suggest that nociceptive sensory neurons may drive the production of IL-23, resulting in IL-17A production from gamma delta T cells via the neuropeptide CGRP in the pathology of psoriasis.	[Zhang, Xuan; Cao, Jiali; Zhao, Siqi; Yang, Xutong; Dong, Jie; Tan, Yaqi; Yu, Teng; He, Yanling] Capital Med Univ, Beijing Chao Yang Hosp, Dept Dermatol, Beijing, Peoples R China; [He, Yanling] Branch Beijing Chaoyang Hosp, Natl Clin Res Ctr Skin & Immune Dis, Beijing, Peoples R China	Capital Medical University	He, YL (corresponding author), Capital Med Univ, Beijing Chao Yang Hosp, Dept Dermatol, Beijing, Peoples R China.; He, YL (corresponding author), Branch Beijing Chaoyang Hosp, Natl Clin Res Ctr Skin & Immune Dis, Beijing, Peoples R China.	cydermhe@gmail.com			National Natural Science Foundation of China [81773314]; Beijing Natural Science Foundation [7172082]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Beijing Natural Science Foundation(Beijing Natural Science Foundation)	Funding This research was funded by National Natural Science Foundation of China (81773314), and by Beijing Natural Science Foundation (7172082).	Abraira VE, 2013, NEURON, V79, P618, DOI 10.1016/j.neuron.2013.07.051; Allette YM, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03447-9; Aschenbeck KA, 2018, J AM ACAD DERMATOL, V79, P1156, DOI 10.1016/j.jaad.2018.07.058; Atmaca HT, 2014, NEUROSCIENCE, V269, P184, DOI 10.1016/j.neuroscience.2014.03.049; Barajon I, 2009, J HISTOCHEM CYTOCHEM, V57, P1013, DOI 10.1369/jhc.2009.953539; Boehncke WH, 2015, LANCET, V386, P983, DOI 10.1016/S0140-6736(14)61909-7; Cai YH, 2011, IMMUNITY, V35, P596, DOI 10.1016/j.immuni.2011.08.001; Chang SE, 2007, BRIT J DERMATOL, V156, P1272, DOI 10.1111/j.1365-2133.2007.07935.x; Cohen JA, 2019, CELL, V178, P919, DOI 10.1016/j.cell.2019.06.022; Ding WH, 2016, J IMMUNOL, V196, P2181, DOI 10.4049/jimmunol.1500303; Diogenes A, 2011, J DENT RES, V90, P759, DOI 10.1177/0022034511400225; El-Nour H, 2009, J EUR ACAD DERMATOL, V23, P1240, DOI 10.1111/j.1468-3083.2009.03287.x; Elewski B, 2019, J EUR ACAD DERMATOL, V33, P1465, DOI 10.1111/jdv.15450; Ellison DL, 2017, CRIT CARE NURS CLIN, V29, P397, DOI 10.1016/j.cnc.2017.08.001; HARVIMA IT, 1993, PSYCHOTHER PSYCHOSOM, V60, P168, DOI 10.1159/000288690; Helley MP, 2015, NEUROSCIENCE, V310, P686, DOI 10.1016/j.neuroscience.2015.09.069; Hou QZ, 2011, PAIN, V152, P2036, DOI 10.1016/j.pain.2011.04.033; Hsieh YL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050805; JANCSO G, 1977, NATURE, V270, P741, DOI 10.1038/270741a0; Jiang WY, 1998, INT J DERMATOL, V37, P572, DOI 10.1046/j.1365-4362.1998.00533.x; Kashem SW, 2015, IMMUNITY, V43, P515, DOI 10.1016/j.immuni.2015.08.016; Kemeny A, 2018, J INVEST DERMATOL, V138, P1774, DOI 10.1016/j.jid.2018.02.040; Kou KZ, 2012, ACTA DERM-VENEREOL, V92, P521, DOI 10.2340/00015555-1350; Kubanov AA, 2015, B EXP BIOL MED+, V159, P318, DOI 10.1007/s10517-015-2951-4; Liu T, 2010, NAT NEUROSCI, V13, P1460, DOI 10.1038/nn.2683; Ljosaa TM, 2012, J EUR ACAD DERMATOL, V26, P29, DOI 10.1111/j.1468-3083.2011.04000.x; Martin B, 2009, IMMUNITY, V31, P321, DOI 10.1016/j.immuni.2009.06.020; Maruyama K, 2017, CELL REP, V19, P2730, DOI 10.1016/j.celrep.2017.06.002; Mikami N, 2012, INT IMMUNOL, V24, P681, DOI 10.1093/intimm/dxs075; Ochoa-Cortes F, 2010, AM J PHYSIOL-GASTR L, V299, pG723, DOI 10.1152/ajpgi.00494.2009; Ostrowski SM, 2011, J INVEST DERMATOL, V131, P1530, DOI 10.1038/jid.2011.60; Pinho-Ribeiro FA, 2018, CELL, V173, P1083, DOI 10.1016/j.cell.2018.04.006; Russell FA, 2014, PHYSIOL REV, V94, P1099, DOI 10.1152/physrev.00034.2013; Sakai K, 2017, PAIN, V158, P2196, DOI 10.1097/j.pain.0000000000001025; Sakai K, 2016, PAIN, V157, P2536, DOI 10.1097/j.pain.0000000000000674; Sandor K, 2009, NEUROSCI LETT, V451, P204, DOI 10.1016/j.neulet.2009.01.016; Sato Y, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21186604; Smith CH, 2021, J INVEST DERMATOL, V141, P177, DOI 10.1016/j.jid.2020.02.048; SZOLCSANYI J, 1990, J PHARMACOL EXP THER, V255, P923; van der Fits L, 2009, J IMMUNOL, V182, P5836, DOI 10.4049/jimmunol.0802999; von Mentzer B, 2020, J PHARM PHARMACOL, V72, P1352, DOI 10.1111/jphp.13317; Wang Y, 2020, J LEUKOCYTE BIOL, V108, P267, DOI 10.1002/JLB.3MA0320-363RR; Ward NL, 2012, J INVEST DERMATOL, V132, P1927, DOI 10.1038/jid.2012.60; Zhang X, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01984; Zhang ZJ, 2018, J EXP MED, V215, P3019, DOI 10.1084/jem.20180800; Zhou Y, 2018, J DERMATOL SCI, V92, P264, DOI 10.1016/j.jdermsci.2018.11.009; Zhu TH, 2016, AM J CLIN DERMATOL, V17, P257, DOI 10.1007/s40257-016-0183-7	47	0	0	4	9	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 22	2021	12								743675	10.3389/fimmu.2021.743675	http://dx.doi.org/10.3389/fimmu.2021.743675			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WU3UE	34745116	gold, Green Published			2022-12-18	WOS:000716472800001
J	Zhu, LB; Wu, YN; Lin, CL; Tang, L; Yu, B; Wan, WR; Xuan, JX; Du, YL; Chen, ZR; Liang, W				Zhu, Libing; Wu, Yuning; Lin, Chenglong; Tang, Lin; Yu, Bin; Wan, Wenrong; Xuan, Jingxiu; Du, Yanling; Chen, Zhangran; Liang, Wei			Dynamic Microbial Shifts and Signatures of Long-Term Remission in Allergic Rhinitis After an Herbal Formula Treatment	FRONTIERS IN IMMUNOLOGY			English	Article						Xiao-Qing-Long-Decoction; allergic rhinitis; long-term remission; gut microbiota; 16S rRNA	CHEONG-RYONG-TANG; INTESTINAL MICROBIOTA; MEDICINE; DATABASE; INFANCY; MARKER; IMPACT; DIET	A mixed Chinese herbal formula, Xiao-Qing-Long-Decoction (XQLD), may contribute to sustained remission in allergic rhinitis (AR), but it is unknown which factors determine such long-term effect. Here, we aimed to identify bacterial signatures associated with sustained remission. To this end, samples from AR patients at four different times were analyzed to compare the dynamic bacterial community and structure shifts. Diversity indices Chao1 showed significant difference across different time (p<0.05), and the Kruskal-Wallis test identified that Dialister (OTU_31), Roseburia (OTU_36), Bacteroides (OTU_22), Bacteroides (OTU_2040), and Prevotella_9 (OTU_5) were the significant differential bacterial taxa (p<0.05). These distinctive genera were significantly associated with the change of AR clinical indices and the predicted functional pathways such as PPAR signaling pathway, peroxisome, and citrate cycle (TCA cycle) (p<0.05), indicating that they may be important bacterial signatures involving in the sustained remission in AR (p<0.05). Besides, lower Firmicutes/Bacteroidetes (F/B) ratio at 6 months follow-up may also contribute to the long-term remission of AR. No seriously adverse events and safety concerns were observed in this study. In conclusion, XQLD is a meaningful, long-term efficient and safe medication for AR treatment. The underlying mechanisms of sustained remission in AR after XQLD treatment may be associated with the dynamic alteration of featured gut bacteria taxa.	[Zhu, Libing; Lin, Chenglong] Xiamen Univ, Sch Med, Dept Tradit Chinese Med, Xiamen, Peoples R China; [Zhu, Libing] Xiamen Univ Hosp, Dept Tradit Chinese Med, Xiamen, Peoples R China; [Wu, Yuning; Liang, Wei] Xiamen Univ, Sch Math Sci, Xiamen, Peoples R China; [Tang, Lin; Yu, Bin] Xiamen Hosp Tradit Chinese Med, Dept Otorhinolaryngol, Xiamen, Peoples R China; [Wan, Wenrong] Xiamen Hosp Tradit Chinese Med, Internal Med Dept Tradit Chinese Med, Xiamen, Peoples R China; [Xuan, Jingxiu] Xiamen Univ, Affiliated Hosp 1, Lab Rheumatol & Immunol, Xiamen, Peoples R China; [Du, Yanling] Fujian Univ Tradit Chinese Med, Dept Acupuncture & Tuina, Fuzhou, Peoples R China; [Chen, Zhangran] Xiamen Univ, Inst Microbial Ecol, Sch Med, Xiamen, Peoples R China	Xiamen University; Xiamen University; Xiamen University; Fujian University of Traditional Chinese Medicine; Xiamen University	Zhu, LB (corresponding author), Xiamen Univ, Sch Med, Dept Tradit Chinese Med, Xiamen, Peoples R China.; Zhu, LB (corresponding author), Xiamen Univ Hosp, Dept Tradit Chinese Med, Xiamen, Peoples R China.; Liang, W (corresponding author), Xiamen Univ, Sch Math Sci, Xiamen, Peoples R China.; Chen, ZR (corresponding author), Xiamen Univ, Inst Microbial Ecol, Sch Med, Xiamen, Peoples R China.	zhulb89@xmu.edu.cn; zhangran22105@xmu.edu.cn; wliang@xmu.edu.cn	yu, bin/ABG-6979-2021		Natural Science Foundation of Fujian province [2019J05005]	Natural Science Foundation of Fujian province(Natural Science Foundation of Fujian Province)	Acknowledgments This work was financially supported by the Natural Science Foundation of Fujian province (2019J05005). We appreciate all patients for participating in the research.	Abrahamsson TR, 2014, CLIN EXP ALLERGY, V44, P842, DOI 10.1111/cea.12253; Amagaya S, 2001, PHYTOMEDICINE, V8, P338, DOI 10.1078/0944-7113-00061; Atarashi K, 2013, NATURE, V500, P232, DOI 10.1038/nature12331; Azad MB, 2013, CAN MED ASSOC J, V185, P385, DOI 10.1503/cmaj.121189; Bisgaard H, 2011, J ALLERGY CLIN IMMUN, V128, P646, DOI 10.1016/j.jaci.2011.04.060; Brozek JL, 2017, J ALLERGY CLIN IMMUN, V140, P950, DOI 10.1016/j.jaci.2017.03.050; Byndloss MX, 2017, SCIENCE, V357, P570, DOI 10.1126/science.aam9949; Chang JS, 2013, J ETHNOPHARMACOL, V147, P481, DOI 10.1016/j.jep.2013.03.044; Chen H, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-35; Chiu CY, 2019, WORLD ALLERGY ORGAN, V12, DOI 10.1016/j.waojou.2019.100021; Cole JR, 2014, NUCLEIC ACIDS RES, V42, pD633, DOI 10.1093/nar/gkt1244; Deng N., 2020, CENT S PHARM, V18, P458, DOI [10.7539/j.issn.1672-2981.2020.03.023, DOI 10.7539/J.ISSN.1672-2981.2020.03.023]; DeSantis TZ, 2006, APPL ENVIRON MICROB, V72, P5069, DOI 10.1128/AEM.03006-05; Dziarski R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146162; Edgar RC, 2010, BIOINFORMATICS, V26, P2460, DOI 10.1093/bioinformatics/btq461; Flower A, 2012, EUR J INTEGR MED, V4, pE421, DOI 10.1016/j.eujim.2012.05.004; Fuentes S, 2017, ISME J, V11, P1877, DOI 10.1038/ismej.2017.44; Galazzo G, 2020, GASTROENTEROLOGY, V158, P1584, DOI 10.1053/j.gastro.2020.01.024; He JX, 2007, PHYTOMEDICINE, V14, P452, DOI 10.1016/j.phymed.2006.09.014; Jalali MM, 2019, LARYNGOSCOPE, V129, P1744, DOI 10.1002/lary.27858; Kim MH, 2019, COMPLEMENT THER MED, V45, P50, DOI 10.1016/j.ctim.2019.05.018; Kostic AD, 2012, GENOME RES, V22, P292, DOI 10.1101/gr.126573.111; Langille MGI, 2013, NAT BIOTECHNOL, V31, P814, DOI 10.1038/nbt.2676; Lee JJ, 2019, ALLERGY, V74, P709, DOI 10.1111/all.13608; Li Y, 2000, Zhongguo Zhong Xi Yi Jie He Za Zhi, V20, P40; Liu S, 2019, AM J TRANSL RES, V11, P5812; Magoc T, 2011, BIOINFORMATICS, V27, P2957, DOI 10.1093/bioinformatics/btr507; Meltzer EO, 2011, ANN ALLERG ASTHMA IM, V106, pS12, DOI 10.1016/j.anai.2010.10.014; MINCHIN PR, 1987, VEGETATIO, V69, P89, DOI 10.1007/BF00038690; Mo JH, 2013, EUR ARCH OTO-RHINO-L, V270, P923, DOI 10.1007/s00405-012-2152-y; Nagai T, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/nep151; Nakano E, 2019, EUR J PHARMACOL, V845, P40, DOI 10.1016/j.ejphar.2018.12.036; Oksanen J, 2008, VEGAN COMMUNITY ECOL; Patel S, 2019, NUTR FOOD SCI, V49, P18, DOI [10.1108/NFS-01-2018-0016, 10.1108/nfs-01-2018-0016]; Penders J, 2007, ALLERGY, V62, P1223, DOI 10.1111/j.1398-9995.2007.01462.x; Qian XB, 2020, BMC GENOMICS, V21, DOI 10.1186/s12864-020-6703-0; Qiu M, 2019, MUCOSAL IMMUNOL, V12, P945, DOI 10.1038/s41385-019-0144-6; R Development Core Team, 2018, R LANG ENV STAT COMP; Santangelo R, 2019, FOOD CHEM TOXICOL, V123, P42, DOI 10.1016/j.fct.2018.10.042; Seidman MD, 2015, OTOLARYNG HEAD NECK, V152, pS1, DOI 10.1177/0194599814561600; Tamanai-Shacoori Z, 2017, FUTURE MICROBIOL, V12, P157, DOI 10.2217/fmb-2016-0130; Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1; World Med Assoc, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI 10.1001/jama.2013.281053; [乡世健 Xiang Shijian], 2018, [中国实验方剂学杂志, Chinese Journal of Experimental Traditional Medical Formulae], V24, P95; Zhang MF., 2011, DRUGS CLIN, V26, P05; Zheng HH, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01703; Zhou GF, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/9637479; Zhu LB, 2020, MICROB CELL FACT, V19, DOI 10.1186/s12934-020-01430-0	48	0	0	6	15	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 22	2021	12								774966	10.3389/fimmu.2021.774966	http://dx.doi.org/10.3389/fimmu.2021.774966			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WU3UT	34745150	Green Published, gold			2022-12-18	WOS:000716474300001
J	Balla, Z; Kormanyos, ES; Kui, BL; Balint, ER; Fur, G; Orjan, EM; Ivanyi, B; Vecsei, L; Fueloep, F; Varga, G; Harazin, A; Tubak, V; Deli, MA; Papp, C; Gacser, A; Madacsy, T; Venglovecz, V; Maleth, J; Hegyi, P; Kiss, L; Rakonczay, Z				Balla, Zsolt; Kormanyos, Eszter Sara; Kui, Balazs; Balint, Emese Reka; Fur, Gabriella; Orjan, Erik Mark; Ivanyi, Bela; Vecsei, Laszlo; Fueloep, Ferenc; Varga, Gabriella; Harazin, Andras; Tubak, Vilmos; Deli, Maria A.; Papp, Csaba; Gacser, Attila; Madacsy, Tamara; Venglovecz, Viktoria; Maleth, Jozsef; Hegyi, Peter; Kiss, Lorand; Rakonczay, Zoltan			Kynurenic Acid and Its Analogue SZR-72 Ameliorate the Severity of Experimental Acute Necrotizing Pancreatitis	FRONTIERS IN IMMUNOLOGY			English	Article						acute pancreatitis; kynurenic acid; SZR-72; NMDA receptor-1; NMDA; tryptophan pathway; N-methyl-D-aspartate	HEAT-SHOCK PROTEINS; ACTIVATION; PROTECTION; DISTURBANCES; TRYPSINOGEN; INHIBITION; DISEASES; STRESS; BRAIN; LIVER	The pathophysiology of acute pancreatitis (AP) is not well understood, and the disease does not have specific therapy. Tryptophan metabolite L-kynurenic acid (KYNA) and its synthetic analogue SZR-72 are antagonists of the N-methyl-D-aspartate receptor (NMDAR) and have immune modulatory roles in several inflammatory diseases. Our aims were to investigate the effects of KYNA and SZR-72 on experimental AP and to reveal their possible mode of action. AP was induced by intraperitoneal (i.p.) injection of L-ornithine-HCl (LO) in SPRD rats. Animals were pretreated with 75-300 mg/kg KYNA or SZR-72. Control animals were injected with physiological saline instead of LO, KYNA and/or SZR-72. Laboratory and histological parameters, as well as pancreatic and systemic circulation were measured to evaluate AP severity. Pancreatic heat shock protein-72 and IL-1 beta were measured by western blot and ELISA, respectively. Pancreatic expression of NMDAR1 was investigated by RT-PCR and immunohistochemistry. Viability of isolated pancreatic acinar cells in response to LO, KYNA, SZR-72 and/or NMDA administration was assessed by propidium-iodide assay. The effects of LO and/or SZR-72 on neutrophil granulocyte function was also studied. Almost all investigated laboratory and histological parameters of AP were significantly reduced by administration of 300 mg/kg KYNA or SZR-72, whereas the 150 mg/kg or 75 mg/kg doses were less or not effective, respectively. The decreased pancreatic microcirculation was also improved in the AP groups treated with 300 mg/kg KYNA or SZR-72. Interestingly, pancreatic heat shock protein-72 expression was significantly increased by administration of SZR-72, KYNA and/or LO. mRNA and protein expression of NMDAR1 was detected in pancreatic tissue. LO treatment caused acinar cell toxicity which was reversed by 250 mu M KYNA or SZR-72. Treatment of acini with NMDA (25, 250, 2000 mu M) did not influence the effects of KYNA or SZR-72. Moreover, SZR-72 reduced LO-induced H2O2 production of neutrophil granulocytes. KYNA and SZR-72 have dose-dependent protective effects on LO-induced AP or acinar toxicity which seem to be independent of pancreatic NMDA receptors. Furthermore, SZR-72 treatment suppressed AP-induced activation of neutrophil granulocytes. This study suggests that administration of KYNA and its derivative could be beneficial in AP.	[Balla, Zsolt; Kormanyos, Eszter Sara; Balint, Emese Reka; Fur, Gabriella; Orjan, Erik Mark; Kiss, Lorand; Rakonczay, Zoltan] Univ Szeged, Dept Pathophysiol, Szeged, Hungary; [Kui, Balazs; Madacsy, Tamara; Maleth, Jozsef; Hegyi, Peter] Univ Szeged, Dept Med, Szeged, Hungary; [Ivanyi, Bela] Univ Szeged, Dept Pathol, Szeged, Hungary; [Vecsei, Laszlo] Univ Szeged, Dept Neurol, Interdisciplinary Excellence Ctr, Szeged, Hungary; [Vecsei, Laszlo] Hungarian Acad Sci Univ Szeged, Hungarian Acad Sci Univ Szeged Neurosci Res Grp, Szeged, Hungary; [Fueloep, Ferenc] Univ Szeged, Inst Pharmaceut Chem, Szeged, Hungary; [Fueloep, Ferenc] Hungarian Acad Sci Univ Szeged, Stereochemistry Res Team, Szeged, Hungary; [Varga, Gabriella] Univ Szeged, Inst Surg Res, Szeged, Hungary; [Harazin, Andras; Deli, Maria A.] Biol Res Ctr, Inst Biophys, Szeged, Hungary; [Tubak, Vilmos] Creat Lab Ltd, Szeged, Hungary; [Papp, Csaba; Gacser, Attila] Univ Szeged, Dept Microbiol, Szeged, Hungary; [Papp, Csaba; Gacser, Attila] Univ Szeged, Hungarian Acad Sci Univ Szeged Lendulet Mycobiome, Szeged, Hungary; [Venglovecz, Viktoria] Univ Szeged, Dept Pharmacol & Pharmacotherapy, Szeged, Hungary; [Hegyi, Peter] Hungarian Acad Sci Univ Szeged Translat Gastroent, Szeged, Hungary; [Hegyi, Peter] Univ Pecs, Inst Translat Med, Pecs, Hungary; [Balla, Zsolt] Univ Szeged, Inst Appl Sci, Dept Environm Biol & Educ, Juhasz Gyula Fac Educ, Szeged, Hungary	Szeged University; Szeged University; Szeged University; Szeged University; Szeged University; Szeged University; Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Biological Research Center; Szeged University; Szeged University; Szeged University; University of Pecs; Szeged University	Rakonczay, Z (corresponding author), Univ Szeged, Dept Pathophysiol, Szeged, Hungary.	rakonczay.zoltan@med.u-szeged.hu	Maléth, József/AAK-7131-2021	Maléth, József/0000-0001-5768-3090; Harazin, Andras/0000-0002-0904-5606				Abu-El-Haija M, 2018, PANCREAS, V47, P1185, DOI 10.1097/MPA.0000000000001175; Badzynska B, 2020, N-S ARCH PHARMACOL, V393, P673, DOI 10.1007/s00210-019-01771-7; Banks PA, 2013, GUT, V62, P102, DOI 10.1136/gutjnl-2012-302779; Barreto SG, 2021, GUT, V70, P194, DOI 10.1136/gutjnl-2020-322163; Bhagat L, 2002, GASTROENTEROLOGY, V122, P156, DOI 10.1053/gast.2002.30314; Csati A, 2015, J HEADACHE PAIN, V16, DOI 10.1186/s10194-015-0581-x; Cuthbertson CM, 2006, BRIT J SURG, V93, P518, DOI 10.1002/bjs.5316; Demeter I, 2013, NEUROSCI LETT, V553, P138, DOI 10.1016/j.neulet.2013.08.028; Dobosz M, 2004, WORLD J GASTROENTERO, V10, P2553, DOI 10.3748/wjg.v10.i17.2553; Erces D, 2012, EUR J PHARMACOL, V691, P225, DOI 10.1016/j.ejphar.2012.06.044; Forsmark CE, 2016, NEW ENGL J MED, V375, P1972, DOI 10.1056/NEJMra1505202; FUKUI S, 1991, J NEUROCHEM, V56, P2007, DOI 10.1111/j.1471-4159.1991.tb03460.x; Gukovskaya AS, 2002, GASTROENTEROLOGY, V122, P974, DOI 10.1053/gast.2002.32409; Juhasz L, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.566582; Kassai F, 2015, PHARMACOL REP, V67, P1188, DOI 10.1016/j.pharep.2015.04.015; Kuebler WM, 1996, INT J MICROCIRC, V16, P89, DOI 10.1159/000179155; Kurucz I, 1999, CELL STRESS CHAPERON, V4, P139; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lugo-Huitron R, 2011, NEUROTOXICOL TERATOL, V33, P538, DOI 10.1016/j.ntt.2011.07.002; Lukacs M, 2017, J HEADACHE PAIN, V18, DOI 10.1186/s10194-017-0746-x; Lukacs M, 2016, J HEADACHE PAIN, V17, DOI 10.1186/s10194-016-0654-5; Lunova M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039972; Mandi Y, 2012, J NEURAL TRANSM, V119, P197, DOI 10.1007/s00702-011-0681-y; Mole DJ, 2016, NAT MED, V22, P202, DOI 10.1038/nm.4020; Nahomi RB, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21051795; Pallagi P, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21114005; Pallagi P, 2014, CRIT CARE MED, V42, pE177, DOI 10.1097/CCM.0000000000000101; PANDOL SJ, 1982, J BIOL CHEM, V257, P2024; Peery AF, 2015, GASTROENTEROLOGY, V149, P1731, DOI 10.1053/j.gastro.2015.08.045; Rakonczay Z, 2003, J GASTROEN HEPATOL, V18, P858, DOI 10.1046/j.1440-1746.2003.03076.x; Rakonczay Z, 2003, J CELL PHYSIOL, V195, P383, DOI 10.1002/jcp.10268; Rakonczay Z, 2002, FREE RADICAL BIO MED, V32, P1283, DOI 10.1016/S0891-5849(02)00833-X; Rakonczay Z, 2008, CRIT CARE MED, V36, P2117, DOI 10.1097/CCM.0b013e31817d7f5c; Roberts SE, 2017, PANCREATOLOGY, V17, P155, DOI 10.1016/j.pan.2017.01.005; Rumbus Z, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.01360; Sendler M, 2018, GASTROENTEROLOGY, V154, P704, DOI 10.1053/j.gastro.2017.10.018; Skouras C, 2016, SCI REP-UK, V6, DOI 10.1038/srep33951; Tiszlavicz Z, 2011, N-S ARCH PHARMACOL, V383, P447, DOI 10.1007/s00210-011-0605-2; Tousignant-Laflamme Y, 2005, J PAIN, V6, P341, DOI 10.1016/j.jpain.2005.01.351; Varga G, 2010, NEUROGASTROENT MOTIL, V22, DOI 10.1111/j.1365-2982.2009.01390.x; Vecsei L, 2013, NAT REV DRUG DISCOV, V12, P64, DOI 10.1038/nrd3793; Wagner ACC, 1996, GASTROENTEROLOGY, V111, P1333, DOI 10.1053/gast.1996.v111.pm8898648; Wang QX, 2015, FRONT BIOSCI-LANDMRK, V20, P1116, DOI 10.2741/4363; Winterbourn CC, 2016, ANNU REV BIOCHEM, V85, P765, DOI 10.1146/annurev-biochem-060815-014442; Wirthgen E, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01957; Zhan XB, 2015, J DIGEST DIS, V16, P37, DOI 10.1111/1751-2980.12206; Zhang J, 2020, MOL NUTR FOOD RES, V64, DOI 10.1002/mnfr.201901191	47	0	0	1	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 21	2021	12								702764	10.3389/fimmu.2021.702764	http://dx.doi.org/10.3389/fimmu.2021.702764			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WU5LR	34745090	Green Published, Green Accepted, gold			2022-12-18	WOS:000716587300001
J	Lu, H; Wu, PF; Ma, DL; Zhang, W; Sun, MC				Lu, Hui; Wu, Peng-Fei; Ma, Deng-Lei; Zhang, Wan; Sun, Meichen			Growth Factors and Their Roles in Multiple Sclerosis Risk	FRONTIERS IN IMMUNOLOGY			English	Article						multiple sclerosis; growth factors; fibroblast growth factor 23; Mendelian randomization; genetic epidemiology	MENDELIAN RANDOMIZATION; IGF-I; BIOMARKER; AGE; PROTEINS; ANTIBODY	Background Previous studies have suggested essential roles of growth factors on the risk of Multiple Sclerosis (MS), but it remains undefined whether the effects are causal.</p> Objective We applied Mendelian randomization (MR) approaches to disentangle the causal relationship between genetically predicted circulating levels of growth factors and the risk of MS.</p> Methods Genetic instrumental variables for fibroblast growth factor (FGF) 23, growth differentiation factor 15 (GDF15), insulin growth factor 1 (IGF1), insulin-like growth factor binding proteins 3 (IGFBP3) and vascular endothelial growth factor (VEGF) were obtained from up-to-date genome-wide association studies (GWAS). Summary-level statistics of MS were obtained from the International Multiple Sclerosis Genetics Consortium, incorporating 14,802 subjects with MS and 26,703 healthy controls of European ancestry. Inverse-variance weighted (IVW) MR was used as the primary method and multiple sensitivity analyses were employed in this study.</p> Results Genetically predicted circulating levels of FGF23 were associated with risk of MS. The odds ratio (OR) of IVW was 0.63 (95% confidence interval [CI], 0.49-0.82; p < 0.001) per one standard deviation increase in circulating FGF23 levels. Weighted median estimators also suggested FGF23 associated with lower MS risk (OR = 0.67; 95% CI, 0.51-0.87; p = 0.003). While MR-Egger approach provided no evidence of horizontal pleiotropy (intercept = -0.003, p = 0.95). Results of IVW methods provided no evidence for causal roles of GDF1, IGF1, IGFBP3 and VEGF on MS risks, and additional sensitivity analyses confirmed the robustness of these null findings.</p> Conclusion Our results implied a causal relationship between FGF23 and the risk of MS. Further studies are warranted to confirm FGF23 as a genetically valid target for MS.</p>	[Lu, Hui; Sun, Meichen] Capital Med Univ, Xuanwu Hosp, Dept Neurol, Beijing, Peoples R China; [Wu, Peng-Fei] Cent South Univ, Ctr Med Genet, Sch Life Sci, Changsha, Peoples R China; [Wu, Peng-Fei] Cent South Univ, Hunan Key Lab Med Genet, Sch Life Sci, Changsha, Peoples R China; [Wu, Peng-Fei; Zhang, Wan] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Neurol, Boston, MA 02115 USA; [Ma, Deng-Lei] Capital Med Univ, Xuanwu Hosp, Dept Pharm, Beijing, Peoples R China; [Zhang, Wan] Boston Univ, Dept Biol, 5 Cummington St, Boston, MA 02215 USA	Capital Medical University; Central South University; Central South University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Capital Medical University; Boston University	Lu, H (corresponding author), Capital Med Univ, Xuanwu Hosp, Dept Neurol, Beijing, Peoples R China.	erjihuixin@163.com	Lu, Hui/AAE-4143-2022; Wu, Pengfei/AAT-3602-2021		Beijing Municipal Hospital [PX2021036]	Beijing Municipal Hospital	This work was supported by scientific research and cultivation plan of Beijing Municipal Hospital (grant PX2021036).	Akcali A, 2017, NEUROL RES, V39, P606, DOI 10.1080/01616412.2017.1321711; Aleagha MSE, 2019, J NEUROIMMUNOL, V328, P89, DOI 10.1016/j.jneuroim.2018.12.011; Bowden J, 2016, GENET EPIDEMIOL, V40, P304, DOI 10.1002/gepi.21965; Bowden J, 2015, INT J EPIDEMIOL, V44, P512, DOI 10.1093/ije/dyv080; Burgess S, 2013, GENET EPIDEMIOL, V37, P658, DOI 10.1002/gepi.21758; Chesik D, 2007, INT REV NEUROBIOL, V79, P203, DOI 10.1016/S0074-7742(07)79009-8; Choi SH, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1005874; Davies NM, 2018, BMJ-BRIT MED J, V362, DOI 10.1136/bmj.k601; Ellidag HY, 2016, ANN NEUROSCI, V23, P155, DOI 10.1159/000449181; Emdin CA, 2017, JAMA-J AM MED ASSOC, V318, P1925, DOI 10.1001/jama.2017.17219; Evans DM, 2015, ANNU REV GENOM HUM G, V16, P327, DOI 10.1146/annurev-genom-090314-050016; Fujita Y, 2016, GERIATR GERONTOL INT, V16, P17, DOI 10.1111/ggi.12724; Fujita Y, 2015, MITOCHONDRION, V20, P34, DOI 10.1016/j.mito.2014.10.006; Gill Dipender, 2021, Wellcome Open Res, V6, P16, DOI 10.12688/wellcomeopenres.16544.1; Hemani G, 2018, ELIFE, V7, DOI 10.7554/eLife.34408; Jakimovski D, 2019, NEURODEGENER DIS MAN, V9, P149, DOI 10.2217/nmt-2018-0046; Jiang JY, 2018, FRONT GENET, V9, DOI 10.3389/fgene.2018.00097; Lanzillo R, 2011, EUR J NEUROL, V18, P1402, DOI 10.1111/j.1468-1331.2011.03433.x; Lehtonen JM, 2016, NEUROLOGY, V87, P2290, DOI 10.1212/WNL.0000000000003374; Liu X, 1995, Mult Scler, V1, P2; Lo J, 2021, ARCH PHYS MED REHAB, V102, P115, DOI 10.1016/j.apmr.2020.04.001; Moe SM, 2015, J BONE MINER RES, V30, P539, DOI 10.1002/jbmr.2372; Nageeb RS, 2018, EGYPT J NEUROL PSYCH, V54, DOI 10.1186/s41983-018-0026-y; Nelson MR, 2015, NAT GENET, V47, P856, DOI 10.1038/ng.3314; Nohara S, 2019, J NEUROL SCI, V405, DOI 10.1016/j.jns.2019.116429; Patsopoulos NA, 2019, SCIENCE, V365, P1417, DOI 10.1126/science.aav7188; Perks C, 2008, J MAMMARY GLAND BIOL, V13, P455, DOI 10.1007/s10911-008-9106-4; Proescholdt MA, 1999, J NEUROPATH EXP NEUR, V58, P613, DOI 10.1097/00005072-199906000-00006; Proescholdt MA, 2002, J NEUROPATH EXP NEUR, V61, P914, DOI 10.1093/jnen/61.10.914; Reich DS, 2018, NEW ENGL J MED, V378, P169, DOI 10.1056/NEJMra1401483; Robinson-Cohen C, 2018, J AM SOC NEPHROL, V29, P2583, DOI 10.1681/ASN.2018020192; Shahbazi M, 2017, MULT SCLER RELAT DIS, V13, P33, DOI 10.1016/j.msard.2017.02.002; Shimada T, 2004, J BONE MINER RES, V19, P429, DOI 10.1359/JBMR.0301264; Smith GD, 2003, INT J EPIDEMIOL, V32, P1, DOI 10.1093/ije/dyg070; Stein MS, 2018, MOL MED, V24, DOI 10.1186/s10020-018-0028-3; STEWART CEH, 1993, ENDOCRINOLOGY, V133, P1462, DOI 10.1210/en.133.3.1462; Storm CS, 2020, BRAIN COMMUN, V2, DOI 10.1093/braincomms/fcaa031; Su JJ, 2006, J NEUROL SCI, V243, P21, DOI 10.1016/j.jns.2005.11.006; Teumer A, 2016, AGING CELL, V15, P811, DOI 10.1111/acel.12490; Turner N, 2010, NAT REV CANCER, V10, P116, DOI 10.1038/nrc2780; Vlot MC, 2019, NUTRIENTS, V11, DOI 10.3390/nu11112774; Walton C, 2020, MULT SCLER J, V26, P1816, DOI 10.1177/1352458520970841; Wang Y, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00467; YAO DL, 1995, P NATL ACAD SCI USA, V92, P6190, DOI 10.1073/pnas.92.13.6190; Zanetti D, 2020, CIRC-GENOM PRECIS ME, V13, P671, DOI 10.1161/CIRCGEN.120.002996	45	0	0	3	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 21	2021	12								768682	10.3389/fimmu.2021.768682	http://dx.doi.org/10.3389/fimmu.2021.768682			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WU6DG	34745143	Green Published, gold			2022-12-18	WOS:000716633500001
J	Lopes, ME; dos Santos, LM; Sacks, D; Vieira, LQ; Carneiro, MB				Lopes, Mateus Eustaquio; dos Santos, Liliane Martins; Sacks, David; Vieira, Leda Quercia; Carneiro, Matheus B.			Resistance Against Leishmania major Infection Depends on Microbiota-Guided Macrophage Activation	FRONTIERS IN IMMUNOLOGY			English	Article						Leishmania major; macrophage; monocyte; cell-activation; nitric oxide; microbiota	NITRIC-OXIDE SYNTHASE; ARGINASE-I INDUCTION; MURINE BONE-MARROW; GERM-FREE MICE; CUTANEOUS LEISHMANIASIS; PERITONEAL-MACROPHAGES; AMAZONENSIS INFECTION; INTERFERON-GAMMA; T-CELLS; SKIN	Innate immune cells present a dual role during leishmaniasis: they constitute the first line of host defense but are also the main host cells for the parasite. Response against the infection that results in the control of parasite growth and lesion healing depends on activation of macrophages into a classical activated phenotype. We report an essential role for the microbiota in driving macrophage and monocyte-derived macrophage activation towards a resistance phenotype against Leishmania major infection in mice. Both germ-free and dysbiotic mice showed a higher number of myeloid innate cells in lesions and increased number of infected cells, mainly dermal resident and inflammatory macrophages. Despite developing a Th1 immune response characterized by the same levels of IFN-gamma production as the conventional mice, germ-free mice presented reduced numbers of iNOS(+) macrophages at the peak of infection. Absence or disturbance of host microbiota impaired the capacity of bone marrow-derived macrophage to be activated for Leishmania killing in vitro, even when stimulated by Th1 cytokines. These cells presented reduced expression of inos mRNA, and diminished production of microbicidal molecules, such as ROS, while presenting a permissive activation status, characterized by increased expression of arginase I and il-10 mRNA and higher arginase activity. Colonization of germ-free mice with complete microbiota from conventional mice rescued their ability to control the infection. This study demonstrates the essential role of host microbiota on innate immune response against L. major infection, driving host macrophages to a resistance phenotype.	[Lopes, Mateus Eustaquio; dos Santos, Liliane Martins; Vieira, Leda Quercia; Carneiro, Matheus B.] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Bioquim & Imunol, Lab Gnotobiol & Imunol, Belo Horizonte, MG, Brazil; [Sacks, David] NIAID, Parasit Dis Lab, NIH, Bethesda, MD USA; [Carneiro, Matheus B.] Univ Calgary, Fac Vet Med, Cumming Sch Med & Comparat Biol & Expt Med, Snyder Inst Chron Dis,Dept Microbiol, Calgary, AB, Canada; [Carneiro, Matheus B.] Univ Calgary, Fac Vet Med, Cumming Sch Med & Comparat Biol & Expt Med, Snyder Inst Chron Dis,Dept Immunol, Calgary, AB, Canada; [Carneiro, Matheus B.] Univ Calgary, Fac Vet Med, Cumming Sch Med & Comparat Biol & Expt Med, Snyder Inst Chron Dis,Dept Infect Dis, Calgary, AB, Canada	Universidade Federal de Minas Gerais; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Calgary; University of Calgary; University of Calgary	Vieira, LQ (corresponding author), Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Bioquim & Imunol, Lab Gnotobiol & Imunol, Belo Horizonte, MG, Brazil.	lqvieira@ufmg.br	Eustaquio de Moura Lopes, Mateus/T-3145-2017	Eustaquio de Moura Lopes, Mateus/0000-0001-8730-7336	Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior, Brazil (CAPES)	Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior, Brazil (CAPES)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES))	ML is CNPq fellow. LS is a CAPES fellow. MC is a CNPq fellow. LV is a CNPq fellow. This study was financed in part by Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior, Brazil (CAPES) Finance Code 001, and CNPq grants number 304588/2013-0, 309789/2017-5 and 400729/2014-8, and FAPEMIG grant number CBB APQ-01993-12. This work was funded in part by the intramural research program of the NIAID.	Alvarez-Errico D, 2015, NAT REV IMMUNOL, V15, P7, DOI 10.1038/nri3777; Amaral FA, 2008, P NATL ACAD SCI USA, V105, P2193, DOI 10.1073/pnas.0711891105; ASSREUY J, 1994, EUR J IMMUNOL, V24, P672, DOI 10.1002/eji.1830240328; Atarashi K, 2011, SCIENCE, V331, P337, DOI 10.1126/science.1198469; Balmer ML, 2014, J IMMUNOL, V193, P5273, DOI 10.4049/jimmunol.1400762; Becattini S, 2017, J EXP MED, V214, P1973, DOI 10.1084/jem.20170495; Belkaid Y, 2000, J IMMUNOL, V165, P969, DOI 10.4049/jimmunol.165.2.969; Belkaid Y, 2017, IMMUNITY, V46, P562, DOI 10.1016/j.immuni.2017.04.008; BOGDAN C, 1994, J LEUKOCYTE BIOL, V55, P227, DOI 10.1002/jlb.55.2.227; BOGDAN C, 1991, J EXP MED, V174, P1549, DOI 10.1084/jem.174.6.1549; Bugl S, 2013, BLOOD, V121, P723, DOI 10.1182/blood-2012-05-429589; Burza S., 2018, LANCET, V392, P951; Canesso MCC, 2014, J IMMUNOL, V193, P5171, DOI 10.4049/jimmunol.1400625; Carneiro MB, 2021, CYTOKINE, V147, DOI 10.1016/j.cyto.2020.155309; Carneiro MBH, 2018, J IMMUNOL, V200, P196, DOI 10.4049/jimmunol.1700899; Carneiro MB, 2020, CELL HOST MICROBE, V27, P752, DOI 10.1016/j.chom.2020.03.011; Carneiro MB, 2017, METHODS, V127, P45, DOI 10.1016/j.ymeth.2017.04.012; Carneiro PP, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148084; Charmoy M, 2016, EUR J IMMUNOL, V46, P897, DOI 10.1002/eji.201546015; Chaves MM, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008674; Cisalpino D, 2017, J IMMUNOL, V198, P4096, DOI 10.4049/jimmunol.1600852; Clarke TB, 2010, NAT MED, V16, P228, DOI 10.1038/nm.2087; CORRALIZA IM, 1995, BIOCHEM BIOPH RES CO, V206, P667, DOI 10.1006/bbrc.1995.1094; Costa DL, 2016, J LEUKOCYTE BIOL, V100, P423, DOI 10.1189/jlb.4A0715-288R; de Aguero MG, 2016, SCIENCE, V351, P1296, DOI 10.1126/science.aad2571; de Veer MJ, 2003, EUR J IMMUNOL, V33, P2822, DOI 10.1002/eji.200324128; dos Santos LM, 2011, MED MICROBIOL IMMUN, V200, P29, DOI 10.1007/s00430-010-0170-1; Edwards JP, 2006, J LEUKOCYTE BIOL, V80, P1298, DOI 10.1189/jlb.0406249; Fagundes CT, 2012, J IMMUNOL, V188, P1411, DOI 10.4049/jimmunol.1101682; Ganal SC, 2012, IMMUNITY, V37, P171, DOI 10.1016/j.immuni.2012.05.020; Gimblet C, 2017, CELL HOST MICROBE, V22, P13, DOI 10.1016/j.chom.2017.06.006; Ginhoux F, 2016, NAT IMMUNOL, V17, P34, DOI 10.1038/ni.3324; Goes GR, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004555; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; GREEN SJ, 1990, J IMMUNOL, V145, P4290; Guilliams M, 2018, IMMUNITY, V49, P595, DOI 10.1016/j.immuni.2018.10.005; Carneiro MBH, 2015, J INTERF CYTOK RES, V35, P935, DOI 10.1089/jir.2015.0043; Heyde S, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007374; Hill DA, 2010, MUCOSAL IMMUNOL, V3, P148, DOI 10.1038/mi.2009.132; Holscher C, 2006, J IMMUNOL, V176, P1115, DOI 10.4049/jimmunol.176.2.1115; Holzmuller P, 2006, PARASITOLOGY, V132, pS19, DOI 10.1017/S0031182006000837; Iniesta V, 2005, INFECT IMMUN, V73, P6085, DOI 10.1128/IAI.73.9.6085-6090.2005; Iniesta V, 2002, PARASITE IMMUNOL, V24, P113, DOI 10.1046/j.1365-3024.2002.00444.x; Iwamura C, 2017, BLOOD, V129, P171, DOI 10.1182/blood-2016-06-723742; Jones D, 1998, INFECT IMMUN, V66, P3818, DOI 10.1128/IAI.66.8.3818-3824.1998; Kane MM, 2001, J IMMUNOL, V166, P1141, DOI 10.4049/jimmunol.166.2.1141; Khosravi A, 2014, CELL HOST MICROBE, V15, P374, DOI 10.1016/j.chom.2014.02.006; Kim YG, 2014, CELL HOST MICROBE, V15, P95, DOI 10.1016/j.chom.2013.12.010; Kropf P, 2004, INFECT IMMUN, V72, P1920, DOI 10.1128/IAI.72.4.1920-1928.2004; Kropf P, 2005, FASEB J, V19, P1000, DOI 10.1096/fj.04-3416fje; Kropf P, 2004, J LEUKOCYTE BIOL, V76, P48, DOI 10.1189/jlb.1003484; Laufs H, 2002, INFECT IMMUN, V70, P826, DOI 10.1128/IAI.70.2.826-835.2002; Lee SH, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.aaz4415; Lee SH, 2018, J EXP MED, V215, P357, DOI 10.1084/jem.20171389; Lewis MD, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008456; Li M, 2018, EUR J PHARMACOL, V831, P52, DOI 10.1016/j.ejphar.2018.05.003; LIEW FY, 1990, J IMMUNOL, V144, P4794; Lopes MEM, 2016, PARASITE IMMUNOL, V38, P37, DOI 10.1111/pim.12279; Lykens JE, 2010, J IMMUNOL, V184, P877, DOI 10.4049/jimmunol.0902346; Macfarlane S, 2003, P NUTR SOC, V62, P67, DOI 10.1079/PNS2002207; Mattner J, 2000, EUR J IMMUNOL, V30, P2257, DOI 10.1002/1521-4141(2000)30:8&lt;2257::AID-IMMU2257&gt;3.0.CO;2-U; MODOLELL M, 1995, EUR J IMMUNOL, V25, P1101, DOI 10.1002/eji.1830250436; MORLAND B, 1979, INFECT IMMUN, V26, P1129; MORLAND B, 1984, INFECT IMMUN, V44, P750; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Muraille E, 2003, J IMMUNOL, V170, P4237, DOI 10.4049/jimmunol.170.8.4237; Murray PJ, 2017, ANNU REV PHYSIOL, V79, P541, DOI 10.1146/annurev-physiol-022516-034339; Naik S, 2012, SCIENCE, V337, P1115, DOI 10.1126/science.1225152; NICAISE P, 1995, CYTOKINE, V7, P713, DOI 10.1006/cyto.1995.0084; Nicaise P, 1998, SCAND J IMMUNOL, V48, P585; Olekhnovitch R, 2014, J CLIN INVEST, V124, P1711, DOI 10.1172/JCI72058; Oliveira MR, 2005, PARASITOLOGY, V131, P477, DOI 10.1017/S0031182005008073; Park AY, 2000, J IMMUNOL, V165, P896, DOI 10.4049/jimmunol.165.2.896; Peters NC, 2008, SCIENCE, V321, P970, DOI 10.1126/science.1159194; PLEASANTS JR, 1973, ENDEAVOUR, V32, P112; Polari LP, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00120; Ribeiro-Gomes FL, 2007, J IMMUNOL, V179, P3988, DOI 10.4049/jimmunol.179.6.3988; Ribeiro-Gomes FL, 2014, INFECT IMMUN, V82, P2713, DOI 10.1128/IAI.01600-13; Romano A, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006479; Sacks D, 2002, NAT REV IMMUNOL, V2, P845, DOI 10.1038/nri933; Schamber-Reis BLF, 2013, J BIOL CHEM, V288, P7127, DOI 10.1074/jbc.M112.407684; Schleicher U, 2016, CELL REP, V15, P1062, DOI 10.1016/j.celrep.2016.04.001; Schulthess J, 2019, IMMUNITY, V50, P432, DOI 10.1016/j.immuni.2018.12.018; Scott P, 2016, NAT REV IMMUNOL, V16, P581, DOI 10.1038/nri.2016.72; Seeley JJ, 2017, J LEUKOCYTE BIOL, V101, P107, DOI 10.1189/jlb.3MR0316-118RR; Shakespear MR, 2011, TRENDS IMMUNOL, V32, P335, DOI 10.1016/j.it.2011.04.001; Shi C, 2011, IMMUNITY, V34, P590, DOI 10.1016/j.immuni.2011.02.016; Sousa LMA, 2014, PARASITE IMMUNOL, V36, P13, DOI 10.1111/pim.12078; Souza DG, 2004, J IMMUNOL, V173, P4137, DOI 10.4049/jimmunol.173.6.4137; Spath GF, 2001, EXP PARASITOL, V99, P97, DOI 10.1006/expr.2001.4656; STRASSMANN G, 1994, J EXP MED, V180, P2365, DOI 10.1084/jem.180.6.2365; Tada T, 1996, CELL IMMUNOL, V173, P155, DOI 10.1006/cimm.1996.0261; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; TAUB DD, 1995, J LEUKOCYTE BIOL, V58, P80, DOI 10.1002/jlb.58.1.80; Terrazas C, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14935-3; Thion MS, 2018, CELL, V172, P500, DOI 10.1016/j.cell.2017.11.042; Tolouei S, 2013, SCAND J IMMUNOL, V78, P478, DOI 10.1111/sji.12105; van der Hee B, 2021, TRENDS MICROBIOL, V29, P700, DOI 10.1016/j.tim.2021.02.001; WANG ZE, 1994, J EXP MED, V179, P1367, DOI 10.1084/jem.179.4.1367; Zarrinpar A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05336-9; Zeng MY, 2016, IMMUNITY, V44, P647, DOI 10.1016/j.immuni.2016.02.006; Zhang Xia, 2008, Curr Protoc Immunol, VChapter 14, DOI 10.1002/0471142735.im1401s83	102	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 20	2021	12								730437	10.3389/fimmu.2021.730437	http://dx.doi.org/10.3389/fimmu.2021.730437			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WU5VH	34745100				2022-12-18	WOS:000716612700001
J	Sarkar, S; Spencer, DA; Barnette, P; Pandey, S; Sutton, WF; Basu, M; Burch, RE; Cleveland, JD; Rosenberg, AF; Rangel-Moreno, J; Keefer, MC; Hessell, AJ; Haigwood, NL; Kobie, JJ				Sarkar, Sanghita; Spencer, David A.; Barnette, Philip; Pandey, Shilpi; Sutton, William F.; Basu, Madhubanti; Burch, Reuben E.; Cleveland, John D.; Rosenberg, Alexander F.; Rangel-Moreno, Javier; Keefer, Michael C.; Hessell, Ann J.; Haigwood, Nancy L.; Kobie, James J.			CD4+T Cells Are Dispensable for Induction of Broad Heterologous HIV Neutralizing Antibodies in Rhesus Macaques	FRONTIERS IN IMMUNOLOGY			English	Article						HIV; human immunodeficiency virus; vaccine; antibody; CD4+T cell; B cell; rhesus; neutralizing	BINDING-SITE ANTIBODIES; MEMORY B-CELLS; DOUBLE-BLIND; EFFICACY; VACCINE; RESPONSES; IMMUNITY; DESIGN; ASSAY	Induction of broadly neutralizing antibodies (bNAbs) is a major goal for HIV vaccine development. HIV envelope glycoprotein (Env)-specific bNAbs isolated from HIV-infected individuals exhibit substantial somatic hypermutation and correlate with T follicular helper (Tfh) responses. Using the VC10014 DNA-protein co-immunization vaccine platform consisting of gp160 plasmids and gp140 trimeric proteins derived from an HIV-1 infected subject that developed bNAbs, we determined the characteristics of the Env-specific humoral response in vaccinated rhesus macaques in the context of CD4+ T cell depletion. Unexpectedly, both CD4+ depleted and non-depleted animals developed comparable Tier 1 and 2 heterologous HIV-1 neutralizing plasma antibody titers. There was no deficit in protection from SHIV challenge, no diminution of titers of HIV Env-specific cross-clade binding antibodies, antibody dependent cellular phagocytosis, or antibody-dependent complement deposition in the CD4+ depleted animals. These collective results suggest that in the presence of diminished CD4+ T cell help, HIV neutralizing antibodies were still generated, which may have implications for developing effective HIV vaccine strategies.	[Sarkar, Sanghita; Basu, Madhubanti; Burch, Reuben E.; Kobie, James J.] Univ Alabama Birmingham, Dept Med, Div Infect Dis, Birmingham, AL 35294 USA; [Spencer, David A.; Barnette, Philip; Pandey, Shilpi; Sutton, William F.; Hessell, Ann J.; Haigwood, Nancy L.] Oregon Hlth & Sci Univ, Oregon Natl Primate Res Ctr, Beaverton, OR USA; [Cleveland, John D.] Univ Alabama Birmingham, Sch Publ Hlth, Birmingham, AL 35294 USA; [Rosenberg, Alexander F.] Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA; [Rangel-Moreno, Javier] Univ Rochester, Med Ctr, Dept Med, Div Allergy Immunol & Rheumatol, Rochester, NY 14642 USA; [Keefer, Michael C.] Univ Rochester, Med Ctr, Dept Med, Div Infect Dis, Rochester, NY 14642 USA	University of Alabama System; University of Alabama Birmingham; Oregon Health & Science University; Oregon National Primate Research Center; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Rochester; University of Rochester	Kobie, JJ (corresponding author), Univ Alabama Birmingham, Dept Med, Div Infect Dis, Birmingham, AL 35294 USA.	jjkobie@uabmc.edu		Spencer, David/0000-0002-5789-6202; Hessell, Ann/0000-0001-7471-9366; Haigwood, Nancy/0000-0002-1477-9575	National Institutes of Health (NIH) [5R01AI117787, 5R01DE027245, P51-OD011092, U42-OD023038]; University of Alabama at Birmingham Center for AIDS Research [P30 AI027767];  [P40 OD028116]	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Alabama at Birmingham Center for AIDS Research; 	Funding This research was partially funded by the National Institutes of Health (NIH) (5R01AI117787, 5R01DE027245 to JK; P51-OD011092, U42-OD023038 to NH), and the University of Alabama at Birmingham Center for AIDS Research P30 AI027767.	Ackerman ME, 2011, J IMMUNOL METHODS, V366, P8, DOI 10.1016/j.jim.2010.12.016; Alpert MD, 2012, J VIROL, V86, P12039, DOI 10.1128/JVI.01650-12; BAKER PJ, 1975, TRANSPLANT REV, V26, P3; Balasubramanian P, 2017, VACCINE, V35, P1464, DOI 10.1016/j.vaccine.2016.11.107; Basu M, 2020, CELL REP MED, V1, DOI 10.1016/j.xcrm.2020.100015; Buchbinder SP, 2008, LANCET, V372, P1881, DOI 10.1016/S0140-6736(08)61591-3; Chukwuma VU, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0209437; Defrance T, 2011, CURR OPIN IMMUNOL, V23, P330, DOI 10.1016/j.coi.2011.03.004; Della Valle L, 2014, J IMMUNOL, V193, P1071, DOI 10.4049/jimmunol.1400706; Dey B, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000445; Euler Z, 2010, J INFECT DIS, V201, P1045, DOI 10.1086/651144; Fauci AS, 2014, SCIENCE, V344, P49, DOI 10.1126/science.1250672; Freeman ML, 2014, J VIROL, V88, P7862, DOI 10.1128/JVI.00690-14; Goo L, 2014, NAT MED, V20, P655, DOI 10.1038/nm.3565; Gray ES, 2011, J VIROL, V85, P4828, DOI 10.1128/JVI.00198-11; Gray GE, 2011, LANCET INFECT DIS, V11, P507, DOI 10.1016/S1473-3099(11)70098-6; Haas KM, 2011, J IMMUNOL, V187, P5183, DOI 10.4049/jimmunol.1101990; Hammer SM, 2013, NEW ENGL J MED, V369, P2083, DOI 10.1056/NEJMoa1310566; Haynes BF, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aaz2686; HESS MW, 1963, J IMMUNOL, V91, P425; Hessell AJ, 2016, J IMMUNOL, V196, P3064, DOI 10.4049/jimmunol.1500527; Hollister K, 2014, HUM VACC IMMUNOTHER, V10, P1985, DOI 10.4161/hv.28659; Jardine J, 2013, SCIENCE, V340, P711, DOI 10.1126/science.1234150; Kelleher Anthony D, 2006, Curr HIV/AIDS Rep, V3, P5, DOI 10.1007/s11904-006-0002-5; Kim SH, 1996, ANTICANCER RES, V16, P2821; Kobie JJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035356; Kulp DW, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01549-6; Lynch RM, 2012, J VIROL, V86, P7588, DOI 10.1128/JVI.00734-12; Malherbe DC, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00984; Malherbe DC, 2014, J VIROL, V88, P12949, DOI 10.1128/JVI.01812-14; Malherbe DC, 2011, J VIROL, V85, P5262, DOI 10.1128/JVI.02419-10; Pancera M, 2017, CURR OPIN HIV AIDS, V12, P229, DOI 10.1097/COH.0000000000000360; Phan TG, 2006, J EXP MED, V203, P2419, DOI 10.1084/jem.20061254; Pichichero ME, 2014, VACCINE, V32, P3886, DOI 10.1016/j.vaccine.2014.05.008; Raja A, 2003, J VIROL, V77, P713, DOI 10.1128/JVI.77.1.713-718.2003; Reiss S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186998; Richardson SI, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1006987; Sellhorn G, 2009, VACCINE, V28, P430, DOI 10.1016/j.vaccine.2009.10.028; Spencer DA, 2021, J IMMUNOL, V206, P999, DOI 10.4049/jimmunol.2001082; Srivastava IK, 2003, J VIROL, V77, P2310, DOI 10.1128/JVI.77.4.2310-2320.2003; Taillardet M, 2009, BLOOD, V114, P4432, DOI 10.1182/blood-2009-01-200014; Verbinnen B, 2012, J ALLERGY CLIN IMMUN, V130, P272, DOI 10.1016/j.jaci.2012.04.040; Viant C, 2021, J EXP MED, V218, DOI 10.1084/jem.20202489; Wang YF, 2017, NAT IMMUNOL, V18, P921, DOI 10.1038/ni.3788; Wei XP, 2003, NATURE, V422, P307, DOI 10.1038/nature01470; WHO, 2021, HIV AIDS KEY FACTS 2; Wu XL, 2010, SCIENCE, V329, P856, DOI 10.1126/science.1187659; Zhou TQ, 2007, NATURE, V445, P732, DOI 10.1038/nature05580	49	0	0	2	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 20	2021	12								757811	10.3389/fimmu.2021.757811	http://dx.doi.org/10.3389/fimmu.2021.757811			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WU6GI	34745131				2022-12-18	WOS:000716641500001
J	Di Pauli, F; Morschewsky, P; Berek, K; Auer, M; Bauer, A; Berger, T; Bsteh, G; Rhomberg, P; Schanda, K; Zinganell, A; Deisenhammer, F; Reindl, M; Hegen, H				Di Pauli, Franziska; Morschewsky, Paul; Berek, Klaus; Auer, Michael; Bauer, Angelika; Berger, Thomas; Bsteh, Gabriel; Rhomberg, Paul; Schanda, Kathrin; Zinganell, Anne; Deisenhammer, Florian; Reindl, Markus; Hegen, Harald			Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease and Varicella Zoster Virus Infection-Frequency of an Association	FRONTIERS IN IMMUNOLOGY			English	Article						AQP-4-IgG; MOG-IgG; MOG antibody associated diseases; longitudinally extensive transverse myelitis; varicella zoster virus infection; neuromyelitis optica spectrum disorder	EXTENSIVE TRANSVERSE MYELITIS; OPTICA SPECTRUM DISORDER; NEUROLOGICAL COMPLICATIONS; NEURITIS	To determine whether there is a correlation between myelin oligodendrocyte glycoprotein (MOG) antibody-associated diseases and varicella zoster virus (VZV) infection. We provide a case report and performed a study to determine the frequency of MOG antibodies (MOG-IgG) in neurological VZV infections. Patients admitted to the Medical University of Innsbruck from 2008-2020 with a diagnosis of a neurological manifestation of VZV infection (n=59) were included in this study; patients with neuroborreliosis (n=34) served as control group. MOG-IgG was detected using live cell-based assays. In addition, we performed a literature review focusing on MOG and aquaporin-4 (AQP4) antibodies and their association with VZV infection. Our case presented with VZV-associated longitudinally extensive transverse myelitis and had MOG-IgG at a titer of 1:1280. In the study, we did not detect MOG-IgG in any other patient neither in the VZV group (including 15 with VZV encephalitis/myelitis) nor in the neuroborreliosis group. In the review of the literature, 3 cases with MOG-IgG and additional 9 cases with AQP4 IgG associated disorders in association with a VZV infection were identified. MOG-IgG are rarely detected in patients with VZV infections associated with neurological diseases.</p>	[Di Pauli, Franziska; Morschewsky, Paul; Berek, Klaus; Auer, Michael; Bauer, Angelika; Schanda, Kathrin; Zinganell, Anne; Deisenhammer, Florian; Reindl, Markus; Hegen, Harald] Med Univ Innsbruck, Dept Neurol, Innsbruck, Austria; [Berger, Thomas; Bsteh, Gabriel] Med Univ Vienna, Dept Neurol, Vienna, Austria; [Rhomberg, Paul] Med Univ Innsbruck, Dept Neuroradiol, Innsbruck, Austria	Medical University of Innsbruck; Medical University of Vienna; Medical University of Innsbruck	Reindl, M; Hegen, H (corresponding author), Med Univ Innsbruck, Dept Neurol, Innsbruck, Austria.	markus.reindl@i-med.ac.at; harald.hegen@i-med.ac.at	Berger, Thomas U/HGA-3594-2022; Reindl, Markus/ABE-5880-2020	Bauer, Angelika/0000-0003-2413-3425	Austrian Science Fund [P32699]	Austrian Science Fund(Austrian Science Fund (FWF))	Funding This study was funded by a research grant from the Austrian Science Fund (FWF projects P32699, MR).	Amano H, 2014, BMC NEUROL, V14, DOI 10.1186/s12883-014-0224-x; Arvin A, 2005, NEW ENGL J MED, V352, P2266, DOI 10.1056/NEJMp058091; Auer M, 2016, EUR J NEUROL, V23, P713, DOI 10.1111/ene.12924; Bozzola E, 2012, VACCINE, V30, P5785, DOI 10.1016/j.vaccine.2012.05.057; Di Pauli F, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02753; Dubey D, 2019, JAMA NEUROL, V76, P301, DOI 10.1001/jamaneurol.2018.4053; Eguchi H, 2020, FRONT NEUROL, V11, DOI 10.3389/fneur.2020.585303; Ercolini AM, 2009, CLIN EXP IMMUNOL, V155, P1, DOI 10.1111/j.1365-2249.2008.03834.x; Haanpaa M, 1998, NEUROLOGY, V51, P1405, DOI 10.1212/WNL.51.5.1405; Heerlein K, 2009, J NEUROL SCI, V276, P184, DOI 10.1016/j.jns.2008.08.015; Hegen H, 2020, THER ADV NEUROL DISO, V13, DOI 10.1177/1756286420945135; Hegen H, 2018, CLIN CHEM LAB MED, V56, P1383, DOI 10.1515/cclm-2018-0028; HOGAN EL, 1973, ARCH NEUROL-CHICAGO, V29, P309, DOI 10.1001/archneur.1973.00490290049004; Hung CH, 2012, J NEUROL SCI, V318, P19, DOI 10.1016/j.jns.2012.04.017; Jarius S, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1144-2; Jayarangaiah A, 2014, BMC NEUROL, V14, DOI 10.1186/s12883-014-0200-5; Kennedy PGE, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10110609; Machado C, 2015, J NEUROL SCI, V358, P520, DOI 10.1016/j.jns.2015.09.374; Mariotto S, 2019, NEUROLOGY, V93, pE1867, DOI 10.1212/WNL.0000000000008479; Mathew T, 2017, MULT SCLER RELAT DIS, V18, P93, DOI 10.1016/j.msard.2017.09.022; Mygland A, 2010, EUR J NEUROL, V17, P8, DOI 10.1111/j.1468-1331.2009.02862.x; Nagel MA, 2014, CURR OPIN NEUROL, V27, P356, DOI 10.1097/WCO.0000000000000092; Nakamura M, 2017, MULT SCLER RELAT DIS, V17, P148, DOI 10.1016/j.msard.2017.07.023; Park JS, 2013, J NEUROL SCI, V334, P69, DOI 10.1016/j.jns.2013.07.2510; Reindl M, 2020, NEUROL-NEUROIMMUNOL, V7, DOI 10.1212/NXI.0000000000000674; Shiga Yuji, 2017, Rinsho Shinkeigaku, V57, P579, DOI 10.5692/clinicalneurol.cn-001066; Suda Machiko, 2017, Rinsho Shinkeigaku, V57, P26, DOI 10.5692/clinicalneurol.cn-000820; Turco EC, 2020, MULT SCLER INT, V2020, DOI 10.1155/2020/6151258; Vieira JP, 2017, J CHILD NEUROL, V32, P996, DOI 10.1177/0883073817724927; Viswanathan LG., 2021, CLIN EXP NEUROIMMUNO, V12, P122, DOI [10.1111/cen3.12618, DOI 10.1111/CEN3.12618]; Wang XL, 2018, J NEUROIMMUNOL, V321, P36, DOI 10.1016/j.jneuroim.2018.05.005; Wynford-Thomas R, 2019, J NEUROL, V266, P1280, DOI 10.1007/s00415-018-9122-2	32	0	0	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 19	2021	12								769653	10.3389/fimmu.2021.769653	http://dx.doi.org/10.3389/fimmu.2021.769653			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WT3VK	34737756				2022-12-18	WOS:000715795600001
J	Storm, L; Bruijnesteijn, J; de Groot, NG; Bontrop, RE				Storm, Lisanne; Bruijnesteijn, Jesse; de Groot, Natasja G.; Bontrop, Ronald E.			The Genomic Organization of the LILR Region Remained Largely Conserved Throughout Primate Evolution: Implications for Health And Disease	FRONTIERS IN IMMUNOLOGY			English	Review						leukocyte receptor complex (LRC); leukocyte immunoglobulin-like receptor (LILR); killer immunoglobulin-like receptor (KIR); immunoglobulin Ig-like superfamily (IgSF); non-human primates (NHP); human	IMMUNOGLOBULIN-LIKE RECEPTORS; MHC CLASS-I; NK CELL RECEPTORS; SYSTEMIC-LUPUS-ERYTHEMATOSUS; NATURAL-KILLER-CELLS; CD8(+) T-CELLS; INHIBITORY RECEPTOR; HLA-G; MULTIPLE-SCLEROSIS; DENDRITIC CELLS	The genes of the leukocyte immunoglobulin-like receptor (LILR) family map to the leukocyte receptor complex (LRC) on chromosome 19, and consist of both activating and inhibiting entities. These receptors are often involved in regulating immune responses, and are considered to play a role in health and disease. The human LILR region and evolutionary equivalents in some rodent and bird species have been thoroughly characterized. In non-human primates, the LILR region is annotated, but a thorough comparison between humans and non-human primates has not yet been documented. Therefore, it was decided to undertake a comprehensive comparison of the human and non-human primate LILR region at the genomic level. During primate evolution the organization of the LILR region remained largely conserved. One major exception, however, is provided by the common marmoset, a New World monkey species, which seems to feature a substantial contraction of the number of LILR genes in both the centromeric and the telomeric region. Furthermore, genomic analysis revealed that the killer-cell immunoglobulin-like receptor gene KIR3DX1, which maps in the LILR region, features one copy in humans and great ape species. A second copy, which might have been introduced by a duplication event, was observed in the lesser apes, and in Old and New World monkey species. The highly conserved gene organization allowed us to standardize the LILR gene nomenclature for non-human primate species, and implies that most of the receptors encoded by these genes likely fulfill highly preserved functions.	[Storm, Lisanne; Bruijnesteijn, Jesse; de Groot, Natasja G.; Bontrop, Ronald E.] Biomed Primate Res Ctr, Comparat Genet & Refinement, Rijswijk, Netherlands; [Bontrop, Ronald E.] Univ Utrecht, Theoret Biol & Bioinformat, Utrecht, Netherlands	Utrecht University	Storm, L (corresponding author), Biomed Primate Res Ctr, Comparat Genet & Refinement, Rijswijk, Netherlands.	storm@bprc.nl						Alaoui L, 2018, CELL MOL LIFE SCI, V75, P1871, DOI 10.1007/s00018-017-2712-9; Allen RL, 2001, J IMMUNOL, V167, P5543, DOI 10.4049/jimmunol.167.10.5543; An HY, 2010, J RHEUMATOL, V37, P1596, DOI 10.3899/jrheum.091119; Anderson KJ, 2009, IMMUNOLOGY, V127, P8, DOI 10.1111/j.1365-2567.2009.03097.x; Apps R, 2009, IMMUNOLOGY, V127, P26, DOI 10.1111/j.1365-2567.2008.03019.x; Atwal JK, 2008, SCIENCE, V322, P967, DOI 10.1126/science.1161151; Augusto DG, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00989; Barrow AD, 2008, IMMUNOL REV, V224, P98, DOI 10.1111/j.1600-065X.2008.00653.x; Bashirova AA, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004196; Bashirova AA, 2014, IMMUNOGENETICS, V66, P1, DOI 10.1007/s00251-013-0730-9; Bego MG, 2019, J BIOL CHEM, V294, P10503, DOI 10.1074/jbc.RA119.008481; Belov K, 2007, GENOME RES, V17, P982, DOI 10.1101/gr.6121807; Berg L, 2003, LANCET, V361, P1099, DOI 10.1016/S0140-6736(03)12855-3; Bergstrom CP, 2021, LEUKEMIA RES, V100, DOI 10.1016/j.leukres.2020.106480; Billadeau DD, 2002, J CLIN INVEST, V109, P161, DOI 10.1172/JCI14843; Bleharski JR, 2003, SCIENCE, V301, P1527, DOI 10.1126/science.1087785; Borges L, 2003, BLOOD, V101, P1484, DOI 10.1182/blood-2002-05-1432; Borges L, 1997, J IMMUNOL, V159, P5192; Brown D, 2004, TISSUE ANTIGENS, V64, P215, DOI 10.1111/j.0001-2815.2004.00290.x; Brown DP, 2009, BMC IMMUNOL, V10, DOI 10.1186/1471-2172-10-56; Bruijnesteijn J, 2020, IMMUNOGENETICS, V72, P37, DOI 10.1007/s00251-019-01135-8; Bruijnesteijn J, 2018, J IMMUNOL, V200, P1692, DOI 10.4049/jimmunol.1701480; Burshtyn DN, 2016, J IMMUNOL, V196, P947, DOI 10.4049/jimmunol.1501937; Cai ZY, 2019, INT J ONCOL, V54, P1943, DOI 10.3892/ijo.2019.4761; Canavez F, 2001, J IMMUNOL, V167, P5786, DOI 10.4049/jimmunol.167.10.5786; Cao Q, 2018, NAT CHEM, V10, P1213, DOI 10.1038/s41557-018-0147-z; Cao W, 2010, IMMUNOL REV, V234, P163, DOI 10.1111/j.0105-2896.2009.00867.x; Carvalheiro T, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01793; Cella M, 1997, J EXP MED, V185, P1743, DOI 10.1084/jem.185.10.1743; Chan KR, 2014, P NATL ACAD SCI USA, V111, P2722, DOI 10.1073/pnas.1317454111; Colonna M, 1997, J EXP MED, V186, P1809, DOI 10.1084/jem.186.11.1809; Cosman D, 1997, IMMUNITY, V7, P273, DOI 10.1016/S1074-7613(00)80529-4; CROSS JC, 1994, SCIENCE, V266, P1508, DOI 10.1126/science.7985020; de Groot NG, 2015, IMMUNOL REV, V267, P228, DOI 10.1111/imr.12313; Deng M, 2018, NATURE, V562, P605, DOI 10.1038/s41586-018-0615-z; Dennis G, 2000, P NATL ACAD SCI USA, V97, P13245, DOI 10.1073/pnas.230442897; Du Y, 2015, ANN RHEUM DIS, V74, P2070, DOI 10.1136/annrheumdis-2013-204441; Du Y, 2014, ARTHRITIS RHEUMATOL, V66, P822, DOI 10.1002/art.38308; Freeman GJ, 2000, J EXP MED, V192, P1027, DOI 10.1084/jem.192.7.1027; Fujiyama A, 2002, SCIENCE, V295, P131, DOI 10.1126/science.1065199; Geneious, GEN PRIM 2020 2 4; Glazko GV, 2003, MOL BIOL EVOL, V20, P424, DOI 10.1093/molbev/msg050; Guethlein LA, 2007, IMMUNOGENETICS, V59, P517, DOI 10.1007/s00251-007-0214-x; Guethlein LA, 2015, IMMUNOL REV, V267, P259, DOI 10.1111/imr.12326; Harrison TE, 2020, NATURE, V587, P309, DOI 10.1038/s41586-020-2530-3; Hiby SE, 2008, HUM REPROD, V23, P972, DOI 10.1093/humrep/den011; Hilton HG, 2017, IMMUNOGENETICS, V69, P567, DOI 10.1007/s00251-017-1001-y; Hirayasu K, 2008, AM J HUM GENET, V82, P1075, DOI 10.1016/j.ajhg.2008.03.012; Hirayasu K, 2015, J HUM GENET, V60, P703, DOI 10.1038/jhg.2015.64; Hogan L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034291; Hogan LE, 2016, SCI REP-UK, V6, DOI 10.1038/srep21780; Hsu KC, 2002, IMMUNOL REV, V190, P40, DOI 10.1034/j.1600-065X.2002.19004.x; Huang JH, 2010, J VIROL, V84, P9463, DOI 10.1128/JVI.01009-10; Huard B, 2000, NATURE, V403, P325, DOI 10.1038/35002105; Hudson LE, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00281; Hunt JS, 2005, FASEB J, V19, P681, DOI 10.1096/fj.04-2078rev; Inui M, 2015, INT IMMUNOL, V27, P345, DOI 10.1093/intimm/dxv009; Ishitani A, 2003, J IMMUNOL, V171, P1376, DOI 10.4049/jimmunol.171.3.1376; JAUCH A, 1992, P NATL ACAD SCI USA, V89, P8611, DOI 10.1073/pnas.89.18.8611; Jensen MA, 2013, ANN RHEUM DIS, V72, P596, DOI 10.1136/annrheumdis-2012-202024; Jin JY, 2018, CELL IMMUNOL, V331, P78, DOI 10.1016/j.cellimm.2018.05.011; Jones DC, 2011, J IMMUNOL, V186, P2990, DOI 10.4049/jimmunol.1003078; Ju XS, 2004, GENE, V331, P159, DOI 10.1016/j.gene.2004.02.018; Kabalak G, 2009, ARTHRITIS RHEUM-US, V60, P2923, DOI 10.1002/art.24804; Kim T, 2013, SCIENCE, V341, P1399, DOI 10.1126/science.1242077; Koch S, 2005, GENES IMMUN, V6, P445, DOI 10.1038/sj.gene.6364187; KOVATS S, 1990, SCIENCE, V248, P220, DOI 10.1126/science.2326636; Kumar S, 1998, NATURE, V392, P917, DOI 10.1038/31927; Kuroki K, 2005, HUM MOL GENET, V14, P2469, DOI 10.1093/hmg/ddi247; Lan X, 2021, CLIN EXP IMMUNOL, V203, P286, DOI 10.1111/cei.13529; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Laun K, 2006, PLOS GENET, V2, P707, DOI 10.1371/journal.pgen.0020073; Launay P, 1998, J LEUKOCYTE BIOL, V63, P636, DOI 10.1002/jlb.63.5.636; Lebbink RJ, 2008, J IMMUNOL, V180, P1662, DOI 10.4049/jimmunol.180.3.1662; Lebbink RJ, 2006, J EXP MED, V203, P1419, DOI 10.1084/jem.20052554; Lebbink RJ, 2009, MATRIX BIOL, V28, P202, DOI 10.1016/j.matbio.2009.03.005; Lichterfeld M, 2007, J EXP MED, V204, P2813, DOI 10.1084/jem.20061865; Liu WR, 2000, IMMUNOGENETICS, V51, P659, DOI 10.1007/s002510000183; LJUNGGREN HG, 1990, IMMUNOL TODAY, V11, P237, DOI 10.1016/0167-5699(90)90097-S; Locke DP, 2011, NATURE, V469, P529, DOI 10.1038/nature09687; Lopez-Alvarez MR, 2016, IMMUNOGENETICS, V68, P743, DOI 10.1007/s00251-016-0924-z; Lu HK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033478; Magor KE, 2013, DEV COMP IMMUNOL, V41, P377, DOI 10.1016/j.dci.2013.04.010; Majorczyk E, 2019, INT J IMMUNOGENET, V46, P146, DOI 10.1111/iji.12422; Mamegano K, 2008, GENES IMMUN, V9, P214, DOI 10.1038/gene.2008.5; Manavalan JS, 2003, TRANSPL IMMUNOL, V11, P245, DOI 10.1016/S0966-3274(03)00058-3; Marffy ALL, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00857; Marsh SGE, 2003, IMMUNOGENETICS, V55, P220, DOI 10.1007/s00251-003-0571-z; Martin AM, 2000, IMMUNOGENETICS, V51, P268, DOI 10.1007/s002510050620; Martin AM, 2002, TRENDS IMMUNOL, V23, P81, DOI 10.1016/S1471-4906(01)02155-X; Martin MP, 2003, J IMMUNOL, V171, P2192, DOI 10.4049/jimmunol.171.5.2192; Martinez-Esparza M, 2019, J IMMUNOL RES, V2019, DOI 10.1155/2019/2974753; Meyaard L, 1997, IMMUNITY, V7, P283, DOI 10.1016/S1074-7613(00)80530-0; Meyaard L, 2010, IMMUNOL LETT, V128, P26, DOI 10.1016/j.imlet.2009.09.014; Middleton D, 2002, TRANSPL IMMUNOL, V10, P147, DOI 10.1016/S0966-3274(02)00062-X; Middleton D, 2010, IMMUNOLOGY, V129, P8, DOI 10.1111/j.1365-2567.2009.03208.x; Mitchell A, 2008, EUR J IMMUNOL, V38, P3459, DOI 10.1002/eji.200838415; Mocsai A, 2010, NAT REV IMMUNOL, V10, P387, DOI 10.1038/nri2765; Monsivais-Urenda A, 2007, J AUTOIMMUN, V29, P97, DOI 10.1016/j.jaut.2007.05.003; Muller S, 2003, HUM GENET, V113, P493, DOI 10.1007/s00439-003-0997-2; Nakajima H, 1999, J IMMUNOL, V162, P5; Nikolaidis N, 2005, P NATL ACAD SCI USA, V102, P4057, DOI 10.1073/pnas.0501040102; Nimmerjahn F, 2014, P NATL ACAD SCI USA, V111, P2404, DOI 10.1073/pnas.1324286111; Norman PJ, 2004, IMMUNOGENETICS, V56, P225, DOI 10.1007/s00251-004-0674-1; Norman PJ, 2003, IMMUNOGENETICS, V55, P165, DOI 10.1007/s00251-003-0561-1; Ordonez D, 2009, GENES IMMUN, V10, P579, DOI 10.1038/gene.2009.34; Parham P, 1996, SCIENCE, V272, P67, DOI 10.1126/science.272.5258.67; Parham P, 2013, NAT REV IMMUNOL, V13, P133, DOI 10.1038/nri3370; Parham P, 2012, PHILOS T R SOC B, V367, P800, DOI 10.1098/rstb.2011.0266; Park M, 2017, INNATE IMMUN-LONDON, V23, P381, DOI 10.1177/1753425917699465; Perelman P, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001342; Pessino A, 1998, J EXP MED, V188, P953, DOI 10.1084/jem.188.5.953; Petroff MG, 2002, J REPROD IMMUNOL, V56, P3, DOI 10.1016/S0165-0378(02)00024-4; Ponte M, 1999, P NATL ACAD SCI USA, V96, P5674, DOI 10.1073/pnas.96.10.5674; Rajagopalan S, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00258; Renauer PA, 2015, ARTHRITIS RHEUMATOL, V67, P1361, DOI 10.1002/art.39035; Robinson J, 2018, IMMUNOGENETICS, V70, P571, DOI 10.1007/s00251-018-1064-4; Roe D, 2017, GENES IMMUN, V18, P127, DOI 10.1038/gene.2017.10; Saito F, 2017, NATURE, V552, P101, DOI 10.1038/nature24994; Sambrook JG, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-209; Sanderson ND, 2014, J IMMUNOL, V193, P6016, DOI 10.4049/jimmunol.1401980; Saverino D, 2004, J IMMUNOL, V172, P5629, DOI 10.4049/jimmunol.172.9.5629; Sayers EW, 2019, NUCLEIC ACIDS RES, V47, pD23, DOI [10.1093/nar/gkr1184, 10.1093/nar/gky1069, 10.1093/nar/gks1189]; Scally A, 2012, NATURE, V483, P169, DOI 10.1038/nature10842; Schwartz JC, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02302; Schwartz JC, 2018, IMMUNOGENETICS, V70, P661, DOI 10.1007/s00251-018-1067-1; Sherlock JK, 1996, GENOMICS, V33, P214, DOI 10.1006/geno.1996.0186; Sloane DE, 2004, BLOOD, V104, P2832, DOI 10.1182/blood-2004-01-0268; Slukvin II, 2006, TISSUE ANTIGENS, V67, P331, DOI 10.1111/j.1399-0039.2006.00579.x; Stafford JL, 2007, IMMUNOGENETICS, V59, P77, DOI 10.1007/s00251-006-0169-3; Takai T, 2001, IMMUNOL REV, V181, P215, DOI 10.1034/j.1600-065X.2001.1810118.x; Takeda K, 2017, J BIOCHEM, V162, P73, DOI 10.1093/jb/mvx036; Tedla N, 2011, TISSUE ANTIGENS, V77, P305, DOI 10.1111/j.1399-0039.2011.01633.x; Tedla N, 2003, P NATL ACAD SCI USA, V100, P1174, DOI 10.1073/pnas.0337567100; Tedla N, 2008, J LEUKOCYTE BIOL, V83, P334, DOI 10.1189/jlb.0507314; Torkar M, 1998, EUR J IMMUNOL, V28, P3959, DOI 10.1002/(SICI)1521-4141(199812)28:12<3959::AID-IMMU3959>3.0.CO;2-2; Torkar M, 2000, EUR J IMMUNOL, V30, P3655, DOI 10.1002/1521-4141(200012)30:12<3655::AID-IMMU3655>3.0.CO;2-Y; Trowsdale J, 2001, IMMUNOL REV, V181, P20, DOI 10.1034/j.1600-065X.2001.1810102.x; Vacca P, 2008, INT IMMUNOL, V20, P1395, DOI 10.1093/intimm/dxn105; Valiante NM, 1997, IMMUNOL REV, V155, P155, DOI 10.1111/j.1600-065X.1997.tb00948.x; Veillette A, 2002, ANNU REV IMMUNOL, V20, P669, DOI 10.1146/annurev.immunol.20.081501.130710; Vendelbosch S, 2015, GENES IMMUN, V16, P103, DOI 10.1038/gene.2014.68; Verbrugge A, 2003, INT IMMUNOL, V15, P1349, DOI 10.1093/intimm/dxg134; Verbrugge A, 2006, J LEUKOCYTE BIOL, V79, P828, DOI 10.1189/jlb.0705370; Villa-Alvarez M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02917; Vojvodic S, 2015, BALK J MED GENET, V18, P55, DOI 10.1515/bjmg-2015-0006; Volz A, 2001, IMMUNOL REV, V181, P39, DOI 10.1034/j.1600-065X.2001.1810103.x; Wain HM, 2004, NUCLEIC ACIDS RES, V32, pD255, DOI 10.1093/nar/gkh072; Wallace AE, 2015, J LEUKOCYTE BIOL, V97, P79, DOI 10.1189/jlb.2A0614-282R; Wang H, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00869; Wang XJ, 2014, TUBERCULOSIS, V94, P469, DOI 10.1016/j.tube.2014.03.009; Wende H, 2000, IMMUNOGENETICS, V51, P703, DOI 10.1007/s002510000187; Wiendl H, 2005, BRAIN, V128, P2689, DOI 10.1093/brain/awh609; Willcox BE, 2003, NAT IMMUNOL, V4, P913, DOI 10.1038/ni961; Wilson MJ, 2000, P NATL ACAD SCI USA, V97, P4778, DOI 10.1073/pnas.080588597; Wisniewski A, 2015, TISSUE ANTIGENS, V85, P466, DOI 10.1111/tan.12561; Wisniewski A, 2013, HUM IMMUNOL, V74, P353, DOI 10.1016/j.humimm.2012.12.006; Wroblewski EE, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00177; Xu JF, 2012, NAT GENET, V44, P1231, DOI 10.1038/ng.2424; Xu Z, 2018, J IMMUNOL, V200, P1207, DOI 10.4049/jimmunol.1700553; Yates AD, 2020, NUCLEIC ACIDS RES, V48, pD682, DOI 10.1093/nar/gkz966; Young NT, 2008, BLOOD, V111, P3090, DOI 10.1182/blood-2007-05-089771; Young NT, 2001, J IMMUNOL, V166, P3933, DOI 10.4049/jimmunol.166.6.3933; Young NT, 2001, IMMUNOGENETICS, V53, P270, DOI 10.1007/s002510100332; Zhang FF, 2015, SCI CHINA LIFE SCI, V58, P1216, DOI 10.1007/s11427-015-4925-1; Zhang Y, 2012, MOL MED REP, V5, P910, DOI 10.3892/mmr.2012.744; Zhang ZY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129063; Zheng JK, 2012, NATURE, V485, P656, DOI 10.1038/nature11095	168	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 19	2021	12								716289	10.3389/fimmu.2021.716289	http://dx.doi.org/10.3389/fimmu.2021.716289			19	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WT3KK	34737739	Green Published, gold			2022-12-18	WOS:000715766800001
J	Benedicenti, O; Wang, TH; Morel, E; Secombes, CJ; Soleto, I; Diaz-Rosales, P; Tafalla, C				Benedicenti, Ottavia; Wang, Tiehui; Morel, Esther; Secombes, Christopher J.; Soleto, Irene; Diaz-Rosales, Patricia; Tafalla, Carolina			Type I Interferon Regulates the Survival and Functionality of B Cells in Rainbow Trout (vol 11, 1494, 2020)	FRONTIERS IN IMMUNOLOGY			English	Correction						teleost fish; B cells; interferon (IFN); IgM; phagocytosis			[Benedicenti, Ottavia; Morel, Esther; Soleto, Irene; Diaz-Rosales, Patricia; Tafalla, Carolina] Anim Hlth Res Ctr CISA INIA, Madrid, Spain; [Wang, Tiehui; Secombes, Christopher J.] Univ Aberdeen, Sch Biol Sci, Scottish Fish Immunol Res Ctr, Aberdeen, Scotland	University of Aberdeen	Tafalla, C (corresponding author), Anim Hlth Res Ctr CISA INIA, Madrid, Spain.	tafalla@inia.es	Díaz-Rosales, Patricia/GPG-6820-2022; Diaz-Rosales, Patricia/H-9679-2013; Tafalla, Carolina/J-8074-2014	MOREL, ESTHER/0000-0002-4768-082X; Diaz-Rosales, Patricia/0000-0001-6965-3702; Tafalla, Carolina/0000-0002-0860-2976					0	0	0	3	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 18	2021	12								778085	10.3389/fimmu.2021.778085	http://dx.doi.org/10.3389/fimmu.2021.778085			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WT3FX	34733293	Green Published, gold			2022-12-18	WOS:000715754700001
J	Bjerkan, L; Visweswaran, GRR; Gudjonsson, A; Labbe, GM; Quinkert, D; Pattinson, DJ; Spang, HCL; Draper, SJ; Bogen, B; Braathen, R				Bjerkan, Louise; Visweswaran, Ganesh Ram R.; Gudjonsson, Arnar; Labbe, Genevieve M.; Quinkert, Doris; Pattinson, David J.; Spang, Heidi C. L.; Draper, Simon J.; Bogen, Bjarne; Braathen, Ranveig			APC-Targeted DNA Vaccination Against Reticulocyte-Binding Protein Homolog 5 Induces Plasmodium falciparum-Specific Neutralizing Antibodies and T Cell Responses	FRONTIERS IN IMMUNOLOGY			English	Article						APC-targeting; DNA vaccines; PfRH5; malaria; antibody responses; T cell responses; GIA	VACCINES; INVASION; ANTIGEN; MOLECULES; HEMAGGLUTININ; PROTECTION; INDUCTION; BASIGIN; TITER; RH5	Targeted delivery of antigen to antigen presenting cells (APCs) is an efficient way to induce robust antigen-specific immune responses. Here, we present a novel DNA vaccine that targets the Plasmodium falciparum reticulocyte-binding protein homolog 5 (PfRH5), a leading blood-stage antigen of the human malaria pathogen, to APCs. The vaccine is designed as bivalent homodimers where each chain is composed of an amino-terminal single chain fragment variable (scFv) targeting unit specific for major histocompatibility complex class II (MHCII) expressed on APCs, and a carboxyl-terminal antigenic unit genetically linked by the dimerization unit. This vaccine format, named "Vaccibody", has previously been successfully applied for antigens from other infectious diseases including influenza and HIV, as well as for tumor antigens. Recently, the crystal structure and key functional antibody epitopes for the truncated version of PfRH5 (PfRH5 Delta NL) were characterized, suggesting PfRH5 Delta NL to be a promising candidate for next-generation PfRH5 vaccine design. In this study, we explored the APC-targeting strategy for a PfRH5 Delta NL-containing DNA vaccine. BALB/c mice immunized with the targeted vaccine induced higher PfRH5-specific IgG1 antibody responses than those vaccinated with a non-targeted vaccine or antigen alone. The APC-targeted vaccine also efficiently induced rapid IFN-gamma and IL-4 T cell responses. Furthermore, the vaccine-induced PfRH5-specific IgG showed inhibition of growth of the P. falciparum 3D7 clone parasite in vitro. Finally, sera obtained after vaccination with this targeted vaccine competed for the same epitopes as PfRH5-specific mAbs from vaccinated humans. Robust humoral responses were also induced by a similar P. vivax Duffy-binding protein (PvDBP)-containing targeted DNA vaccine. Our data highlight a novel targeted vaccine platform for the development of vaccines against blood-stage malaria.	[Bjerkan, Louise; Visweswaran, Ganesh Ram R.; Gudjonsson, Arnar; Spang, Heidi C. L.; Bogen, Bjarne; Braathen, Ranveig] Univ Oslo, Inst Clin Med, Oslo, Norway; [Bjerkan, Louise; Visweswaran, Ganesh Ram R.; Gudjonsson, Arnar; Spang, Heidi C. L.; Bogen, Bjarne; Braathen, Ranveig] Oslo Univ Hosp, Oslo, Norway; [Labbe, Genevieve M.; Quinkert, Doris; Pattinson, David J.; Draper, Simon J.] Univ Oxford, Jenner Inst, Oxford, England	University of Oslo; University of Oslo; University of Oxford; Jenner Institute	Braathen, R (corresponding author), Univ Oslo, Inst Clin Med, Oslo, Norway.; Braathen, R (corresponding author), Oslo Univ Hosp, Oslo, Norway.	ranveig.braathen@medisin.uio.no			yy	yy	Funding This work was supported by grants from Research Council of Norway, Globvac grant 234431 (to BB), and Innovation grant 2018 from University of Oslo (to RB). SD is also a Jenner Investigator and a Wellcome Trust Senior Fellow [106917/Z/15/Z]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alam S, 2014, J VIROL, V88, P314, DOI 10.1128/JVI.02077-13; Alanine DGW, 2019, CELL, V178, P216, DOI 10.1016/j.cell.2019.05.025; Andersen TK, 2019, NPJ VACCINES, V4, DOI 10.1038/s41541-019-0101-0; Andersen TK, 2017, J VIROL, V91, DOI 10.1128/JVI.01340-17; Baum J, 2009, INT J PARASITOL, V39, P371, DOI 10.1016/j.ijpara.2008.10.006; Braathen Ranveig, 2018, Immunohorizons, V2, P38, DOI 10.4049/immunohorizons.1700038; Campeotto I, 2017, P NATL ACAD SCI USA, V114, P998, DOI 10.1073/pnas.1616903114; Crosnier C, 2011, NATURE, V480, P534, DOI 10.1038/nature10606; de Cassan SC, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00348; de Cassan SC, 2013, EXPERT REV VACCINES, V12, P365, DOI [10.1586/erv.13.11, 10.1586/ERV.13.11]; Douglas AD, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09894-4; Douglas AD, 2015, CELL HOST MICROBE, V17, P130, DOI 10.1016/j.chom.2014.11.017; Douglas AD, 2014, J IMMUNOL, V192, P245, DOI 10.4049/jimmunol.1302045; Douglas AD, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1615; Draper SJ, 2008, NAT MED, V14, P819, DOI 10.1038/nm.1850; Draper SJ, 2018, CELL HOST MICROBE, V24, P43, DOI 10.1016/j.chom.2018.06.008; Drew DR, 2015, TRENDS PARASITOL, V31, P87, DOI 10.1016/j.pt.2015.02.001; Fredriksen AB, 2006, MOL THER, V13, P776, DOI 10.1016/j.ymthe.2005.10.019; Fredriksen AB, 2007, BLOOD, V110, P1797, DOI 10.1182/blood-2006-06-032938; Grodeland G, 2016, J IMMUNOL, V197, P3575, DOI 10.4049/jimmunol.1600893; Grodeland G, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00367; Grodeland G, 2013, J IMMUNOL, V191, P3221, DOI 10.4049/jimmunol.1300504; Gudjonsson A, 2017, J IMMUNOL, V198, P2785, DOI 10.4049/jimmunol.1601881; Hamid MMA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020547; Hodgson SH, 2014, MOL THER, V22, P2142, DOI 10.1038/mt.2014.157; Jin J, 2018, NPJ VACCINES, V3, DOI 10.1038/s41541-018-0071-7; Li L, 2012, J BIOTECHNOL, V162, P171, DOI 10.1016/j.jbiotec.2012.08.012; Liu MA, 2011, IMMUNOL REV, V239, P62, DOI 10.1111/j.1600-065X.2010.00980.x; Manske M, 2012, NATURE, V487, P375, DOI 10.1038/nature11174; Miura K, 2009, CLIN VACCINE IMMUNOL, V16, P963, DOI 10.1128/CVI.00042-09; Mooij P, 2019, VACCINE, V37, P817, DOI 10.1016/j.vaccine.2018.12.049; Moorthy VS, 2013, LANCET, V382, P1700, DOI 10.1016/S0140-6736(13)62238-2; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; Norderhaug L, 1997, J IMMUNOL METHODS, V204, P77, DOI 10.1016/S0022-1759(97)00034-3; Oynebraten I, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104814; Payne RO, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.96381; Payne RO, 2016, J INFECT DIS, V213, P1743, DOI 10.1093/infdis/jiw039; Ragotte RJ, 2020, TRENDS PARASITOL, V36, P545, DOI 10.1016/j.pt.2020.04.003; SAUL A, 1987, PARASITE IMMUNOL, V9, P1, DOI 10.1111/j.1365-3024.1987.tb00483.x; Singh S, 2006, INFECT IMMUN, V74, P4573, DOI 10.1128/IAI.01679-05; Takala SL, 2009, SCI TRANSL MED, V1, DOI 10.1126/scitranslmed.3000257; Tesfaye DY, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01529; Toellner KM, 1998, J EXP MED, V187, P1193, DOI 10.1084/jem.187.8.1193; Wanaguru M, 2013, P NATL ACAD SCI USA, V110, P20735, DOI 10.1073/pnas.1320771110; Wang JY, 2011, APPL MICROBIOL BIOT, V91, P731, DOI 10.1007/s00253-011-3297-0; Wang RB, 1998, SCIENCE, V282, P476, DOI 10.1126/science.282.5388.476; WHO, 2010, WORLD MALARIA REPORT 2010, P1; Wright KE, 2014, NATURE, V515, P427, DOI 10.1038/nature13715	48	0	0	3	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 18	2021	12								720550	10.3389/fimmu.2021.720550	http://dx.doi.org/10.3389/fimmu.2021.720550			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WT1EX	34733274	Green Published, gold, Green Accepted			2022-12-18	WOS:000715615700001
J	Moller, S; Laskay, T				Moller, Sonja; Laskay, Tamas			Purinergic Enhancement of Anti-Leishmanial Effector Functions of Neutrophil Granulocytes	FRONTIERS IN IMMUNOLOGY			English	Article						Leishmania donovani; ATP; UTP; purinergic; intracellular killing; neutrophils	LEISHMANIA-MAJOR INFECTION; PROGRAMMED CELL-DEATH; ATP; INFLAMMASOME; MOBILIZATION; INHIBITION; MICROBES; INDUCE; ENTRY; KILL	Although macrophages are considered for host cells for the multiplication of Leishmania, recent studies indicate the important role of neutrophil granulocytes as host cells for these intracellular parasites. Neutrophils have been shown to be massively and rapidly recruited to the site of Leishmania infection where they represent the first cells to encounter the parasites. Exposure to ATP and UTP have been shown to enhance anti-Leishmania activity of macrophages and intralesional injection of UTP led to strongly reduced parasite load in vivo. Since the in vivo anti-leishmanial effect of extracellular UTP correlated with enhanced neutrophil recruitment and enhanced ROS production at the site of Leishmania infection we hypothesized that exposure to extracellular nucleotides can directly enhance the killing of Leishmania by neutrophils. Since purinergic signaling is an essential mechanism of neutrophil activation the aim of the present study was to assess whether purinergic exposure results in the activation of anti-leishmanial neutrophil functions and, therefore, represent an essential component of enhanced anti-leishmanial defense in leishmaniasis. We could show that exposure to ATP and UTP led to activation and enhanced CD11b expression of primary human neutrophils in vitro. Leishmania-induced ROS production was strongly enhanced by extracellular ATP and UTP. Importantly, exposure to ATP and UTP resulted in enhanced killing of Leishmania donovani by neutrophils. In addition, ATP strongly enhanced the secretion of IL-8 and IL-1 beta by Leishmania-exposed neutrophils. Our results suggest that signaling via the P2 receptor and phosphorylation of Erk1/2, Akt and p38 are involved in the purinergic enhancement of anti-leishmanial functions of neutrophils.	[Moller, Sonja; Laskay, Tamas] Univ Lubeck, Dept Infect Dis & Microbiol, Lubeck, Germany	University of Lubeck	Laskay, T (corresponding author), Univ Lubeck, Dept Infect Dis & Microbiol, Lubeck, Germany.	Tamas.Laskay@uksh.de						Becker I, 2003, MOL BIOCHEM PARASIT, V130, P65, DOI 10.1016/S0166-6851(03)00160-9; Behnen M, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00184; Carlsen ED, 2015, CLIN EXP IMMUNOL, V182, P109, DOI 10.1111/cei.12674; Cassatella MA, 1999, ADV IMMUNOL, V73, P369, DOI 10.1016/S0065-2776(08)60791-9; Chaves MM, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008674; Chaves MM, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007887; Chaves MM, 2014, J IMMUNOL, V192, P4765, DOI 10.4049/jimmunol.1301058; Chaves SP, 2009, MICROBES INFECT, V11, P842, DOI 10.1016/j.micinf.2009.05.001; Chen Y, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000549; COCKCROFT S, 1989, FEBS LETT, V245, P25, DOI 10.1016/0014-5793(89)80184-X; Coutinho-Silva R, 2012, MICROBES INFECT, V14, P1271, DOI 10.1016/j.micinf.2012.05.009; Degasperi A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087293; Dichmann S, 2000, BLOOD, V95, P973, DOI 10.1182/blood.V95.3.973.003k47_973_978; Erb Laurie, 2012, Wiley Interdiscip Rev Membr Transp Signal, V1, P789; Franchi L, 2012, NAT IMMUNOL, V13, P325, DOI 10.1038/ni.2231; Gasmi L, 1997, IMMUNOLOGY, V90, P154, DOI 10.1046/j.1365-2567.1997.00123.x; Giuliani AL, 2021, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.619458; Guimaraes-Costa AB, 2009, P NATL ACAD SCI USA, V106, P6748, DOI 10.1073/pnas.0900226106; Gurung P, 2015, CELL MICROBIOL, V17, P1286, DOI 10.1111/cmi.12484; Hurrell BP, 2016, TRENDS PARASITOL, V32, P392, DOI 10.1016/j.pt.2016.02.003; Jo EK, 2016, CELL MOL IMMUNOL, V13, P148, DOI 10.1038/cmi.2015.95; Karmakar M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10555; Karsten CM, 2014, METHODS MOL BIOL, V1100, P291, DOI 10.1007/978-1-62703-724-2_23; Kropf P, 2004, INFECT IMMUN, V72, P1920, DOI 10.1128/IAI.72.4.1920-1928.2004; Laskay T, 1997, J IMMUNOL, V158, P1246; Laufs H, 2002, INFECT IMMUN, V70, P826, DOI 10.1128/IAI.70.2.826-835.2002; LEY K, 1991, BLOOD, V77, P2553; Liese J, 2007, EUR J IMMUNOL, V37, P3424, DOI 10.1002/eji.200737182; Lima DS, 2013, NAT MED, V19, P909, DOI 10.1038/nm.3221; Lovaszi M, 2021, BIOCHEM PHARMACOL, V187, DOI 10.1016/j.bcp.2021.114419; Mariathasan S, 2006, NATURE, V440, P228, DOI 10.1038/nature04515; Marques-da-Silva C, 2018, PURINERG SIGNAL, V14, P201, DOI 10.1007/s11302-018-9606-7; Marques-da-Silva C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025356; Marques-da-Silva C, 2011, CELL MICROBIOL, V13, P1410, DOI 10.1111/j.1462-5822.2011.01630.x; Mehta VB, 2001, J BIOL CHEM, V276, P3820, DOI 10.1074/jbc.M006814200; Morciano G, 2017, NAT PROTOC, V12, P1542, DOI 10.1038/nprot.2017.052; Muller K, 2001, MED MICROBIOL IMMUN, V190, P73; Nauseef WM, 2007, IMMUNOL REV, V219, P88, DOI 10.1111/j.1600-065X.2007.00550.x; Neufert C, 2001, J IMMUNOL, V167, P1542, DOI 10.4049/jimmunol.167.3.1542; PAYNE CM, 1994, MICROSC RES TECHNIQ, V28, P327, DOI 10.1002/jemt.1070280408; Peters NC, 2008, SCIENCE, V321, P970, DOI 10.1126/science.1159194; Plagge M, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/2014583; Regli IB, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01558; Rubenich DS, 2021, PURINERG SIGNAL, V17, P371, DOI 10.1007/s11302-021-09786-7; SAVILL JS, 1989, J CLIN INVEST, V83, P865, DOI 10.1172/JCI113970; Schnurr M, 2000, J IMMUNOL, V165, P4704, DOI 10.4049/jimmunol.165.8.4704; Segal AW, 2005, ANNU REV IMMUNOL, V23, P197, DOI 10.1146/annurev.immunol.23.021704.115653; SENGELOV H, 1993, J CLIN INVEST, V92, P1467, DOI 10.1172/JCI116724; Tamassia N, 2018, EUR J CLIN INVEST, V48, DOI 10.1111/eci.12952; Thorstenberg ML, 2020, MEDIAT INFLAMM, V2020, DOI 10.1155/2020/2545682; van Zandbergen G, 2004, J IMMUNOL, V173, P6521, DOI 10.4049/jimmunol.173.11.6521; Vaughan KR, 2007, J IMMUNOL, V179, P8544, DOI 10.4049/jimmunol.179.12.8544; Wang X, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00399; Zimmermann H, 2021, PURINERG SIGNAL, V17, P117, DOI 10.1007/s11302-020-09755-6; Zumerle S, 2019, CELL REP, V27, P1, DOI 10.1016/j.celrep.2019.03.011	55	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 18	2021	12								747049	10.3389/fimmu.2021.747049	http://dx.doi.org/10.3389/fimmu.2021.747049			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WT1UA	34733282				2022-12-18	WOS:000715655000001
J	Ren, JP; Wu, WZ; Zhang, K; Choi, EJ; Wang, PY; Ivanciuc, T; Peniche, A; Qian, YW; Garofalo, RP; Zhou, J; Bao, XY				Ren, Junping; Wu, Wenzhe; Zhang, Ke; Choi, Eun-Jin; Wang, Pingyuan; Ivanciuc, Teodora; Peniche, Alex; Qian, Youwen; Garofalo, Roberto P.; Zhou, Jia; Bao, Xiaoyong			Exchange Protein Directly Activated by cAMP 2 Enhances Respiratory Syncytial Virus-Induced Pulmonary Disease in Mice	FRONTIERS IN IMMUNOLOGY			English	Article						EPAC2; RSV; pulmonary disease; immune response; inflammation	IDENTIFICATION; RESPONSES; CHILDREN; BRONCHIOLITIS; INFECTIONS; INTERFERON; IMMUNITY; SENSOR; CELLS; EPAC1	Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infection in young children. It is also a significant contributor to upper respiratory tract infections, therefore, a major cause for visits to the pediatrician. High morbidity and mortality are associated with high-risk populations including premature infants, the elderly, and the immunocompromised. However, no effective and specific treatment is available. Recently, we discovered that an exchange protein directly activated by cyclic AMP 2 (EPAC2) can serve as a potential therapeutic target for RSV. In both lower and upper epithelial cells, EPAC2 promotes RSV replication and pro-inflammatory cytokine/chemokine induction. However, the overall role of EPAC2 in the pulmonary responses to RSV has not been investigated. Herein, we found that EPAC2-deficient mice (KO) or mice treated with an EPAC2-specific inhibitor showed a significant decrease in body weight loss, airway hyperresponsiveness, and pulmonary inflammation, compared with wild-type (WT) or vehicle-treated mice. Overall, this study demonstrates the critical contribution of the EPAC2-mediated pathway to airway diseases in experimental RSV infection, suggesting the possibility to target EPAC2 as a promising treatment modality for RSV.</p>	[Ren, Junping; Wu, Wenzhe; Zhang, Ke; Choi, Eun-Jin; Ivanciuc, Teodora; Peniche, Alex; Garofalo, Roberto P.; Bao, Xiaoyong] Univ Texas Med Branch, Dept Pediat, Galveston, TX 77555 USA; [Zhang, Ke] Univ Houston Clear Lake, Dept Chem, Clear Lake, TX USA; [Wang, Pingyuan; Zhou, Jia] Univ Texas Med Branch, Dept Pharmacol & Toxicol, Galveston, TX 77555 USA; [Qian, Youwen] Roswell Park Canc Inst, Dept Pathol, Buffalo, NY 14263 USA; [Garofalo, Roberto P.; Bao, Xiaoyong] Univ Texas Med Branch, Inst Translat Sci, Galveston, TX 77555 USA; [Garofalo, Roberto P.; Bao, Xiaoyong] Univ Texas Med Branch, Inst Human Infect & Immun, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Houston System; University of Houston; University of Houston Clear Lake; University of Texas System; University of Texas Medical Branch Galveston; Roswell Park Cancer Institute; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Bao, XY (corresponding author), Univ Texas Med Branch, Dept Pediat, Galveston, TX 77555 USA.; Bao, XY (corresponding author), Univ Texas Med Branch, Inst Translat Sci, Galveston, TX 77555 USA.; Bao, XY (corresponding author), Univ Texas Med Branch, Inst Human Infect & Immun, Galveston, TX 77555 USA.	xibao@utmb.edu	Garofalo, Roberto P./ABL-2322-2022; Garofalo, Roberto P./AAF-7385-2022		NIAID NIH HHS [R01 AI116812, P01 AI062885] Funding Source: Medline; NIA NIH HHS [R21 AG069226] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Al-Romaihi HE, 2020, INT J INFECT DIS, V95, P133, DOI 10.1016/j.ijid.2020.04.008; Azzam R, 2006, AIDS RES HUM RETROV, V22, P619, DOI 10.1089/aid.2006.22.619; Chadha M, 2020, INFLUENZA OTHER RESP, V14, P638, DOI 10.1111/irv.12726; Choi EJ, 2018, J VIROL, V92, DOI 10.1128/JVI.01200-18; Deng JF, 2015, MOL THER, V23, P1622, DOI 10.1038/mt.2015.124; Deng JF, 2015, J GEN VIROL, V96, P2104, DOI 10.1099/vir.0.000178; Drelich A, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10100563; Fujimoto K, 2002, J BIOL CHEM, V277, P50497, DOI 10.1074/jbc.M210146200; GRAHAM BS, 1988, J MED VIROL, V26, P153, DOI 10.1002/jmv.1890260207; Griggs RB, 2019, NEUROBIOL DIS, V127, P76, DOI 10.1016/j.nbd.2019.02.019; Guerrero-Plata A, 2005, J VIROL, V79, P10190, DOI 10.1128/JVI.79.16.10190-10199.2005; Guerrero-Plata A, 2005, J VIROL, V79, P14992, DOI 10.1128/JVI.79.23.14992-14997.2005; Hasegawa K, 2015, J INFECT DIS, V211, P1550, DOI 10.1093/infdis/jiu658; Hosakote YM, 2016, J VIROL, V90, P9618, DOI 10.1128/JVI.01279-16; Hosakote YM, 2011, AM J RESP CRIT CARE, V183, P1550, DOI 10.1164/rccm.201010-1755OC; Clemente MI, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085230; Ivanciuc T, 2016, AM J RESP CELL MOL, V55, P684, DOI 10.1165/rcmb.2015-0385OC; Kirseborn FCM, 2019, MUCOSAL IMMUNOL, V12, P1244, DOI 10.1038/s41385-019-0190-0; Kolli D, 2008, J VIROL, V82, P8560, DOI 10.1128/JVI.00699-08; Kramer R, 2018, VACCINE, V36, P6591, DOI 10.1016/j.vaccine.2018.09.029; Kumar N, 2017, MOL CELL BIOCHEM, V430, P115, DOI 10.1007/s11010-017-2959-3; Liu ZQ, 2017, BIOORG MED CHEM LETT, V27, P5163, DOI 10.1016/j.bmcl.2017.10.056; Metrich M, 2008, CIRC RES, V102, P959, DOI 10.1161/CIRCRESAHA.107.164947; Mizuta K, 2013, RESP RES, V14, DOI 10.1186/1465-9921-14-89; Morgan SJ, 2014, J BIOL CHEM, V289, P23065, DOI 10.1074/jbc.M114.557652; Nair H, 2010, LANCET, V375, P1545, DOI 10.1016/S0140-6736(10)60206-1; Oldenburger A, 2014, FASEB J, V28, P4617, DOI 10.1096/fj.13-248930; Ozaki N, 2000, NAT CELL BIOL, V2, P805, DOI 10.1038/35041046; Piedra FA, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172953; Ren JP, 2013, VIRUS RES, V176, P241, DOI 10.1016/j.virusres.2013.06.014; Ren JP, 2011, J GEN VIROL, V92, P2153, DOI 10.1099/vir.0.032987-0; Resch B, 2017, HUM VACC IMMUNOTHER, V13, P2138, DOI 10.1080/21645515.2017.1337614; Robichaux WG, 2018, PHYSIOL REV, V98, P919, DOI 10.1152/physrev.00025.2017; Shi T, 2017, LANCET, V390, P946, DOI [10.1016/s0140-6736(17)30938-8, 10.1016/S0140-6736(17)30938-8]; Su QN, 2004, NAT CELL BIOL, V6, P941, DOI 10.1038/ncb1169; Swaminathan S, 2012, J IMMUNOL, V188, P6238, DOI 10.4049/jimmunol.1101196; Tao XR, 2014, J VIROL, V88, P3902, DOI 10.1128/JVI.03001-13; Thwaites RS, 2018, AM J RESP CRIT CARE, V198, P1074, DOI 10.1164/rccm.201712-2567OC; Tian B, 2018, J VIROL, V92, DOI 10.1128/JVI.00441-18; Wang QR, 2013, MOL THER, V21, P368, DOI 10.1038/mt.2012.237; Wild CT, 2016, ACS MED CHEM LETT, V7, P460, DOI 10.1021/acsmedchemlett.5b00477; Xu JM, 2021, BIOORGAN MED CHEM, V39, DOI 10.1016/j.bmc.2021.116157; Ye N, 2015, J MED CHEM, V58, P6033, DOI 10.1021/acs.jmedchem.5b00635; Zhang CF, 2019, J MOL CELL BIOL, V11, P395, DOI 10.1093/jmcb/mjy045; Zhang L, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00263; Zhou JH, 2017, J GEN VIROL, V98, P1600, DOI 10.1099/jgv.0.000852	46	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 18	2021	12								757758	10.3389/fimmu.2021.757758	http://dx.doi.org/10.3389/fimmu.2021.757758			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WT2KN	34733289	gold, Green Published			2022-12-18	WOS:000715697900001
J	Guo, AL; Zhao, JF; Gao, L; Huang, HH; Zhang, JY; Zhang, C; Song, JW; Xu, RN; Fan, X; Shi, M; Jiao, YM; Wang, FS				Guo, An-Liang; Zhao, Jin-Fang; Gao, Lin; Huang, Hui-Huang; Zhang, Ji-Yuan; Zhang, Chao; Song, Jin-Wen; Xu, Ruo-Nan; Fan, Xing; Shi, Ming; Jiao, Yan-Mei; Wang, Fu-Sheng			HIV-1-Specific CD11c(+) CD8(+) T Cells Display Low PD-1 Expression and Strong Anti-HIV-1 Activity	FRONTIERS IN IMMUNOLOGY			English	Article						HIV-1; CD11c(+) CD8(+) T cells; immune activation; immune exhaustion; cytotoxicity	IMMUNE ACTIVATION; EXHAUSTION; PERSISTENCE; INDUCTION; RESPONSES	Exhaustion of HIV-1-specific CD8(+) T cells prevents optimal control of HIV-1 infection. Identifying unconventional CD8(+) T cell subsets to effectively control HIV-1 replication is vital. In this study, the role of CD11c(+) CD8(+) T cells during HIV-1 infection was evaluated. The frequencies of CD11c(+) CD8(+) T cells significantly increased and were negatively correlated with viral load in HIV-1-infected treatment-naive patients. HIV-1-specific cells were enriched more in CD11c(+) CD8(+) T cells than in CD11c(-) CD8(+) T cells, which could be induced by HIV-1-derived overlapping peptides, marking an HIV-1-specific CD8(+) T cell population. This subset expressed higher levels of activating markers (CD38 and HLA-DR), cytotoxic markers (granzyme B, perforin, and CD107a), and cytokines (IL-2 and TNF-alpha), with lower levels of PD-1 compared to the CD11c(-) CD8(+) T cell subset. In vitro analysis verified that CD11c(+) CD8(+) T cells displayed a stronger HIV-1-specific killing capacity than the CD11c(-) counterparts. These findings indicate that CD11c(+) CD8(+) T cells have potent immunotherapeutic efficacy in controlling HIV-1 infection.	[Guo, An-Liang] Shandong Univ, Sch Basic Med Sci, Dept Immunol, Cheeloo Coll Med, Jinan, Peoples R China; [Guo, An-Liang; Zhao, Jin-Fang; Gao, Lin; Huang, Hui-Huang; Zhang, Ji-Yuan; Zhang, Chao; Song, Jin-Wen; Xu, Ruo-Nan; Fan, Xing; Shi, Ming; Jiao, Yan-Mei; Wang, Fu-Sheng] Chinese Peoples Liberat Army Gen Hosp, Senior Dept Infect Dis, Natl Clin Res Ctr Infect Dis, Med Ctr 5, Beijing, Peoples R China; [Gao, Lin] Peking Univ, Sch Basic Med Sci, Infect Dis Ctr, Hlth Sci Ctr, Beijing, Peoples R China; [Gao, Lin] Peking Univ, Hlth Sci Ctr, Dept Microbiol, Beijing, Peoples R China	Shandong University; Chinese People's Liberation Army General Hospital; Fifth Medical Center of Chinese PLA General Hospital; Peking University; Peking University	Zhao, JF; Jiao, YM; Wang, FS (corresponding author), Chinese Peoples Liberat Army Gen Hosp, Senior Dept Infect Dis, Natl Clin Res Ctr Infect Dis, Med Ctr 5, Beijing, Peoples R China.	zhaojinfang12@163.com; jiaoyanmei@sina.com; fswang302@163.com		Fan, Xing/0000-0002-0809-9207; Song, Jin-Wen/0000-0002-8582-8012	Innovation Groups of the National Natural Science Foundation of China [81721002]; Peking University Clinical Scientist Program Special [BMU2019LCKXJ013]	Innovation Groups of the National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Peking University Clinical Scientist Program Special	This study was supported by the Innovation Groups of the National Natural Science Foundation of China (grant no. 81721002), Peking University Clinical Scientist Program Special (grant no. BMU2019LCKXJ013).	Betts MR, 2006, BLOOD, V107, P4781, DOI 10.1182/blood-2005-12-4818; Beyer M, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-70; Bozzi G, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aav2045; Collins DR, 2020, NAT REV IMMUNOL, V20, P471, DOI 10.1038/s41577-020-0274-9; Cooney LA, 2013, INFECT IMMUN, V81, P4171, DOI 10.1128/IAI.00871-13; Day CL, 2006, NATURE, V443, P350, DOI 10.1038/nature05115; Fenwick C, 2019, IMMUNOL REV, V292, P149, DOI 10.1111/imr.12823; Fuller MJ, 2003, J IMMUNOL, V170, P477, DOI 10.4049/jimmunol.170.1.477; Gupta PK, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005177; HEUSEL JW, 1994, CELL, V76, P977, DOI 10.1016/0092-8674(94)90376-X; Hoffmann M, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005661; Hsu DC, 2016, DRUGS, V76, P533, DOI 10.1007/s40265-016-0546-7; Jones RB, 2016, J CLIN INVEST, V126, P455, DOI 10.1172/JCI80566; Kim YH, 2005, CELL IMMUNOL, V238, P76, DOI 10.1016/j.cellimm.2006.01.004; Lin YL, 2003, EUR J IMMUNOL, V33, P2736, DOI 10.1002/eji.200324087; MACKEWICZ CE, 1995, P NATL ACAD SCI USA, V92, P2308, DOI 10.1073/pnas.92.6.2308; Martinez GJ, 2015, IMMUNITY, V42, P265, DOI 10.1016/j.immuni.2015.01.006; Migueles SA, 2008, IMMUNITY, V29, P1009, DOI 10.1016/j.immuni.2008.10.010; Ndhlovu ZM, 2015, IMMUNITY, V43, P591, DOI 10.1016/j.immuni.2015.08.012; Nguyen S, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aax4077; Papagno L, 2004, PLOS BIOL, V2, P173, DOI 10.1371/journal.pbio.0020020; Qualai J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154253; Quigley M, 2010, NAT MED, V16, P1147, DOI 10.1038/nm.2232; Rostamzadeh D, 2019, J CELL PHYSIOL, V234, P11986, DOI 10.1002/jcp.27856; Schietinger A, 2014, TRENDS IMMUNOL, V35, P51, DOI 10.1016/j.it.2013.10.001; Seo SK, 2004, NAT MED, V10, P1088, DOI 10.1038/nm1107; Takeda Y, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0416-x; Voskoboinik I, 2006, NAT REV IMMUNOL, V6, P940, DOI 10.1038/nri1983; Wherry EJ, 2003, J VIROL, V77, P4911, DOI 10.1128/JVI.77.8.4911-4927.2003; Xu Y, 2014, BLOOD, V123, P3750, DOI 10.1182/blood-2014-01-552174; Zajac AJ, 1998, J EXP MED, V188, P2205, DOI 10.1084/jem.188.12.2205; Zubkova I, 2014, HEPATOLOGY, V59, P803, DOI 10.1002/hep.26747	32	0	0	5	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 15	2021	12								757457	10.3389/fimmu.2021.757457	http://dx.doi.org/10.3389/fimmu.2021.757457			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6B6RF	34721433	Green Published, gold			2022-12-18	WOS:000881457200001
J	Kalim, KW; Yang, JQ; Modur, V; Nguyen, P; Li, Y; Zheng, Y; Guo, FK				Kalim, Khalid W.; Yang, Jun-Qi; Modur, Vishnu; Nguyen, Phuong; Li, Yuan; Zheng, Yi; Guo, Fukun			Graded RhoA GTPase Expression in Treg Cells Distinguishes Tumor Immunity From Autoimmunity	FRONTIERS IN IMMUNOLOGY			English	Article						RhoA; Treg cells; effector T cells; autoimmunity; tumor immunity	REGULATORY T-CELLS; FAMILY GTPASES; CDC42 GTPASES; TH17; RAC; RECEPTOR; BALANCE; TARGET	RhoA of the Rho GTPase family is prenylated at its C-terminus. Prenylation of RhoA has been shown to control T helper 17 (Th17) cell-mediated colitis. By characterizing T cell-specific RhoA conditional knockout mice, we have recently shown that RhoA is required for Th2 and Th17 cell differentiation and Th2/Th17 cell-mediated allergic airway inflammation. It remains unclear whether RhoA plays a cell-intrinsic role in regulatory T (Treg) cells that suppress effector T cells such as Th2/Th17 cells to maintain immune tolerance and to promote tumor immune evasion. Here we have generated Treg cell-specific RhoA-deficient mice. We found that homozygous RhoA deletion in Treg cells led to early, fatal systemic inflammatory disorders. The autoimmune responses came from an increase in activated CD4(+) and CD8(+) T cells and in effector T cells including Th17, Th1 and Th2 cells. The immune activation was due to impaired Treg cell homeostasis and increased Treg cell plasticity. Interestingly, heterozygous RhoA deletion in Treg cells did not affect Treg cell homeostasis nor cause systemic autoimmunity but induced Treg cell plasticity and an increase in effector T cells. Importantly, heterozygous RhoA deletion significantly inhibited tumor growth, which was associated with tumor-infiltrating Treg cell plasticity and increased tumor-infiltrating effector T cells. Collectively, our findings suggest that graded RhoA expression in Treg cells distinguishes tumor immunity from autoimmunity and that rational targeting of RhoA in Treg cells may trigger anti-tumor T cell immunity without causing autoimmune responses.	[Zheng, Yi; Guo, Fukun] Univ Cincinnati, Coll Med, Div Expt Hematol & Canc Biol, Childrens Hosp,Med Ctr, Cincinnati, OH USA; Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Zheng, Y; Guo, FK (corresponding author), Univ Cincinnati, Coll Med, Div Expt Hematol & Canc Biol, Childrens Hosp,Med Ctr, Cincinnati, OH USA.				National Institutes of Health	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported in part by grants from the National Institutes of Health (R01GM108661 to FG, R56 HL141499 to FG, and R01CA234038 to FG and YZ).	Annunziato F, 2015, J ALLERGY CLIN IMMUN, V135, P626, DOI 10.1016/j.jaci.2014.11.001; Byrne WL, 2011, CANCER RES, V71, P6915, DOI 10.1158/0008-5472.CAN-11-1156; Colamatteo A, 2020, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.03136; Corre I, 2001, J EXP MED, V194, P903, DOI 10.1084/jem.194.7.903; Cortez JT, 2020, NATURE, V582, P416, DOI 10.1038/s41586-020-2246-4; Dang EV, 2011, CELL, V146, P772, DOI 10.1016/j.cell.2011.07.033; del Pozo MA, 1999, EUR J IMMUNOL, V29, P3609; Finn OJ, 2018, J IMMUNOL, V200, P385, DOI 10.4049/jimmunol.1701302; Galandrini R, 1997, IMMUNITY, V7, P163, DOI 10.1016/S1074-7613(00)80519-1; Gomez-Rodriguez J, 2014, J EXP MED, V211, P529, DOI 10.1084/jem.20131459; Guo FK, 2004, MOL CELL BIOL, V24, P1426, DOI 10.1128/MCB.24.3.1426-1438.2004; Heasman SJ, 2010, J CELL BIOL, V190, P553, DOI 10.1083/jcb.201002067; Henning SW, 1997, EMBO J, V16, P2397, DOI 10.1093/emboj/16.9.2397; Kalim KW, 2018, J IMMUNOL, V200, P2313, DOI 10.4049/jimmunol.1601765; Khan U, 2018, INT REV CEL MOL BIO, V341, P125, DOI 10.1016/bs.ircmb.2018.05.008; Komatsu N, 2014, NAT MED, V20, P62, DOI 10.1038/nm.3432; Li S, 2020, NATURE, V587, P121, DOI 10.1038/s41586-020-2850-3; Lin R, 1999, J BIOL CHEM, V274, P23633, DOI 10.1074/jbc.274.33.23633; Lopez-Posadas R, 2019, GASTROENTEROLOGY, V157, P1293, DOI 10.1053/j.gastro.2019.07.007; Melendez J, 2011, J BIOL CHEM, V286, P15132, DOI 10.1074/jbc.C111.229336; Mou F, 2012, J EXP MED, V209, P741, DOI 10.1084/jem.20111692; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Ohkura N, 2013, IMMUNITY, V38, P414, DOI 10.1016/j.immuni.2013.03.002; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Rougerie P, 2013, J IMMUNOL, V190, P748, DOI 10.4049/jimmunol.1201174; Shitara K, 2018, ANN NY ACAD SCI, V1417, P104, DOI 10.1111/nyas.13625; Takahashi R, 2011, J EXP MED, V208, P2055, DOI 10.1084/jem.20110428; Tnimov Z, 2012, J BIOL CHEM, V287, P26549, DOI 10.1074/jbc.M112.371294; Ueno A, 2015, WORLD J GASTROENTERO, V21, P12283, DOI 10.3748/wjg.v21.i43.12283; Vielkind S, 2005, J IMMUNOL, V175, P350, DOI 10.4049/jimmunol.175.1.350; Wan YSY, 2007, NATURE, V445, P766, DOI 10.1038/nature05479; Weil J, 2016, NAT IMMUNOL, V17, P277, DOI 10.1038/ni.3365; Yang JQ, 2019, J LEUKOCYTE BIOL, V106, P1139, DOI 10.1002/JLB.3A0119-025RRR; Yang JQ, 2016, J ALLERGY CLIN IMMUN, V137, P231, DOI 10.1016/j.jaci.2015.05.004; Yang K, 2017, NATURE, V548, P602, DOI 10.1038/nature23665; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	36	0	0	2	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 15	2021	12								726393	10.3389/fimmu.2021.726393	http://dx.doi.org/10.3389/fimmu.2021.726393			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WS0JJ	34721389	gold, Green Published			2022-12-18	WOS:000714876300001
J	McArdle, SEB; Pawelec, G; Pockley, AG; Johansen, P				McArdle, Stephanie E. B.; Pawelec, Graham; Pockley, Alan Graham; Johansen, Pal			Editorial: Frontiers' Research Topic "Cancer Vaccines: Time to Think Differently!"	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						combined immunotherapies; cancer vaccine combination; novel approach; dendritic cells; PD1 and PDL1			[McArdle, Stephanie E. B.; Pockley, Alan Graham] Nottingham Trent Univ, John Van Geest Canc Res Ctr, Nottingham, England; [McArdle, Stephanie E. B.; Pockley, Alan Graham] Nottingham Trent Univ, Ctr Hlth Ageing & Understanding Dis CHAUD, Sch Sci & Technol, Nottingham, England; [Pawelec, Graham] Univ Tubingen, Inst Cell Biol, Dept Immunol, Tubingen, Germany; [Pawelec, Graham] Hlth Sci North Res Inst HSNRI, Canc Solut Program, Sudbury, ON, Canada; [Johansen, Pal] Univ Hosp Zurich, Dept Dermatol, Zurich, Switzerland	Nottingham Trent University; Nottingham Trent University; Eberhard Karls University of Tubingen; University of Zurich; University Zurich Hospital	McArdle, SEB (corresponding author), Nottingham Trent Univ, John Van Geest Canc Res Ctr, Nottingham, England.; McArdle, SEB (corresponding author), Nottingham Trent Univ, Ctr Hlth Ageing & Understanding Dis CHAUD, Sch Sci & Technol, Nottingham, England.	stephanie.mcardle@ntu.ac.uk	Johansen, Pål/A-1403-2013; Pockley, Alan/I-4704-2015	Johansen, Pål/0000-0002-5055-6299; Pockley, Alan/0000-0001-9593-6431					0	0	0	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 15	2021	12								771319	10.3389/fimmu.2021.771319	http://dx.doi.org/10.3389/fimmu.2021.771319			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XI9SF	34721440	Green Accepted, Green Published, gold			2022-12-18	WOS:000726440900001
J	Wang, X; Fan, HX; Wang, YL; Yin, XF; Liu, GY; Gao, C; Li, XF; Liang, B				Wang, Xin; Fan, Hongxuan; Wang, Yongle; Yin, Xufang; Liu, Guangying; Gao, Chong; Li, Xiaofeng; Liang, Bin			Elevated Peripheral T Helper Cells Are Associated With Atrial Fibrillation in Patients With Rheumatoid Arthritis	FRONTIERS IN IMMUNOLOGY			English	Article						T helper cell; atrial fibrillation; rheumatoid arthritis; Th1; Th17; Treg	TH17 CELLS; INFLAMMATION; DISEASE; CONTRIBUTES; PREDICTOR; FREQUENCY; FIBROSIS; RATS	Patients with rheumatoid arthritis (RA) have a significantly high risk of atrial fibrillation (AF). This study aimed to compare the absolute and relative changes in peripheral T cells in patients with RA who were also affected with and without AF. To help make an early diagnosis and prevent the initiation and progression of AF, the changes in the lymphocyte subsets were assessed in RA patients with and without AF. A propensity score matching (PSM) system (1:3) was used to perform a matched case-control study with 40 RA-AF cases and 120 RA controls. Changes in the erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), anti-citrullinated peptide antibody (ACPA), and rheumatoid factor (RF) were examined. The percentage and absolute number of T, B, natural killer (NK), T helper (Th)1, Th2, Th17, and T-regulatory (Treg) cells in the peripheral blood of patients with and without RA-AF were determined using flow cytometry. Univariate and multivariate analyses were performed to determine the association between peripheral lymphocytes and RA-AF. Demographic data, ESR, CRP, ACPA, and the percentage, as well as the absolute value of B, NK, Th2, and Treg cells, showed no significant differences between the propensity score-matched groups of RA and RA-AF. Meanwhile, the absolute number and percentage of Th1 cells, the absolute number of Th17 cells, the ratio of Th1/Treg, Th17/Treg, and RF were significantly higher in patients with RA-AF than those in the control groups (P < 0.05). Univariate and multivariate logistic regression analyses also revealed that the percentage of Th1 cells, the absolute number of Th17 cells, and the ratio of Th1/Treg were associated with a significantly higher risk of AF. This PSM study demonstrated that the incidence of AF was higher in RA patients with Th cell immunological derangements.	[Wang, Xin; Yin, Xufang; Liu, Guangying; Li, Xiaofeng] Shanxi Med Univ, Hosp 2, Dept Rheumatol, Taiyuan, Peoples R China; [Fan, Hongxuan; Liang, Bin] Shanxi Med Univ, Dept Cardiol, Hosp 2, Taiyuan, Peoples R China; [Wang, Yongle] Shanxi Med Univ, Hosp 1, Dept Neurol, Taiyuan, Peoples R China; [Gao, Chong] Harvard Med Sch, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA	Shanxi Medical University; Shanxi Medical University; Shanxi Medical University; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Li, XF (corresponding author), Shanxi Med Univ, Hosp 2, Dept Rheumatol, Taiyuan, Peoples R China.; Liang, B (corresponding author), Shanxi Med Univ, Dept Cardiol, Hosp 2, Taiyuan, Peoples R China.		li, xiaofeng/GXF-9442-2022	Fan, Hongxuan/0000-0002-1234-544X; Wang, Yongle/0000-0002-2337-238X	National Natural Science Foundation of China	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by the National Natural Science Foundation of China (grant number 81970391) and the Excellent Youth Foundation of Shanxi Province (grant number 201901D211504).	Adlan AM, 2014, SEMIN ARTHRITIS RHEU, V44, P283, DOI 10.1016/j.semarthrit.2014.06.003; ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; Bacani AK, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/809514; Camm AJ, 2010, EUROPACE, V12, P1360, DOI [10.1093/eurheartj/ehq278, 10.1093/europace/euq350]; Capuron L, 2014, CURR PHARM DESIGN, V20, P6048, DOI 10.2174/1381612820666140317110217; Carbone F, 2020, CLIN REV ALLERG IMMU, V58, P1, DOI 10.1007/s12016-018-8714-z; Chugh SS, 2014, CIRCULATION, V129, P837, DOI 10.1161/CIRCULATIONAHA.113.005119; Dai H, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.117.007320; DeCoux A, 2014, J MOL CELL CARDIOL, V77, P64, DOI 10.1016/j.yjmcc.2014.09.016; Du X, 2021, HEART, V107, P535, DOI 10.1136/heartjnl-2020-317915; England BR, 2018, BMJ-BRIT MED J, V361, DOI 10.1136/bmj.k1036; Fu XX, 2015, INT J MOL MED, V36, P83, DOI 10.3892/ijmm.2015.2204; Furst DE, 2014, RHEUMATOLOGY, V53, P1560, DOI 10.1093/rheumatology/ket414; Guo YT, 2012, J AM COLL CARDIOL, V60, P2263, DOI 10.1016/j.jacc.2012.04.063; Hak L, 2009, J INTERF CYTOK RES, V29, P327, DOI 10.1089/jir.2008.0082.2906; Hu YF, 2015, NAT REV CARDIOL, V12, P230, DOI 10.1038/nrcardio.2015.2; Huang JQ, 2020, HEART LUNG CIRC, V29, pE168, DOI 10.1016/j.hlc.2019.11.004; James EA, 2014, ARTHRITIS RHEUMATOL, V66, P1712, DOI 10.1002/art.38637; Jarrah AA, 2018, APOPTOSIS, V23, P79, DOI 10.1007/s10495-017-1438-3; Kim SC, 2014, ANN RHEUM DIS, V73, P1091, DOI 10.1136/annrheumdis-2013-203343; Klareskog L, 2009, LANCET, V373, P659, DOI 10.1016/S0140-6736(09)60008-8; Kobayashi Y, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3131; Kondo Y, 2018, ARTHRITIS RHEUMATOL, V70, P653, DOI 10.1002/art.40398; Lazzerini PE, 2017, EUR HEART J, V38, P1717, DOI 10.1093/eurheartj/ehw208; Lee GR, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19030730; Leipe J, 2010, ARTHRITIS RHEUM-US, V62, P2876, DOI 10.1002/art.27622; Lindhardsen J, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e1257; Liu YF, 2012, INT IMMUNOL, V24, P605, DOI 10.1093/intimm/dxs056; Liu YZ, 2018, J MOL CELL CARDIOL, V123, P198, DOI 10.1016/j.yjmcc.2018.09.007; Maradit-Kremers H, 2005, ARTHRITIS RHEUM-US, V52, P402, DOI 10.1002/art.20853; Nikoo MH, 2014, IRAN J IMMUNOL, V11, P246, DOI IJIv11i4A3; Rudolph V, 2010, NAT MED, V16, P470, DOI 10.1038/nm.2124; Shen H, 2009, ARTHRITIS RHEUM-US, V60, P1647, DOI 10.1002/art.24568; Sulzgruber P, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28046-0; Sulzgruber P, 2017, THROMB HAEMOSTASIS, V117, P349, DOI 10.1160/TH16-07-0531; Ungprasert P, 2017, INT J RHEUM DIS, V20, P434, DOI 10.1111/1756-185X.12820; Wiland P, 2004, CLIN RHEUMATOL, V23, P193, DOI 10.1007/s10067-003-0842-y; Wu N, 2016, SCI REP-UK, V6, DOI 10.1038/srep26543; Yadav S, 2018, J ARRYTHM, V34, P281, DOI 10.1002/joa3.12074; Ye J, 2020, MEDIAT INFLAMM, V2020, DOI 10.1155/2020/2369279; Ye J, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00129; Zuo J, 2018, INT IMMUNOPHARMACOL, V56, P78, DOI 10.1016/j.intimp.2018.01.016	42	0	1	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 15	2021	12								744254	10.3389/fimmu.2021.744254	http://dx.doi.org/10.3389/fimmu.2021.744254			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WS0JB	34721413	Green Published, gold			2022-12-18	WOS:000714875500001
J	Anwar, IJ; Jackson, AM; Locke, JE; Kwun, J				Anwar, Imran J.; Jackson, Annette M.; Locke, Jayme E.; Kwun, Jean			Editorial: Sensitization and Desensitization in Organ Transplantation	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						sensitization; desensitization; transplantation; donor specific antibodies; antibody-mediated rejection (AMR)			[Anwar, Imran J.; Jackson, Annette M.; Kwun, Jean] Duke Univ, Med Ctr, Dept Surg, Duke Transplant Ctr, Durham, NC 27710 USA; [Locke, Jayme E.] Univ Alabama Birmingham, Comprehens Transplant Inst, Birmingham, AL USA	Duke University; University of Alabama System; University of Alabama Birmingham	Kwun, J (corresponding author), Duke Univ, Med Ctr, Dept Surg, Duke Transplant Ctr, Durham, NC 27710 USA.	jean.kwun@duke.edu	Kwun, Jean/F-2384-2018; Anwar, Imran/GZM-7933-2022	Kwun, Jean/0000-0002-8563-5472; Anwar, Imran/0000-0002-5075-4148; Locke, Jayme/0000-0002-0220-8716					0	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 14	2021	12								784472	10.3389/fimmu.2021.784472	http://dx.doi.org/10.3389/fimmu.2021.784472			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WU2EQ	34721444	gold, Green Published			2022-12-18	WOS:000716363900001
J	Cai, ZL; Xing, R; Liu, J; Xing, FY				Cai, Zhenlong; Xing, Rui; Liu, Jing; Xing, Feiyue			Commentary: PIRs Mediate Innate Myeloid Cell Memory to Nonself MHC Molecules	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						MHC-1; PIR-A; Ly49; differentiation; specific innate immune memory	LY49 RECEPTORS; INDUCTION		[Cai, Zhenlong; Xing, Feiyue] Jinan Univ, Inst Tissue Transplantat & Immunol, Dept Immunobiol, Minist Educ MOE Key Lab Tumor Mol Biol, Guangzhou, Peoples R China; [Xing, Rui] Tsinghua Univ, Sch Life Sci, Tsinghua Peking Ctr Life Sci, Minist Educ MOE Key Lab Prot Sci, Beijing, Peoples R China; [Liu, Jing] Jinan Univ, Dept Prosthodont, Sch Stomatol, Guangzhou, Peoples R China	Jinan University; Tsinghua University; Jinan University	Xing, FY (corresponding author), Jinan Univ, Inst Tissue Transplantat & Immunol, Dept Immunobiol, Minist Educ MOE Key Lab Tumor Mol Biol, Guangzhou, Peoples R China.; Liu, J (corresponding author), Jinan Univ, Dept Prosthodont, Sch Stomatol, Guangzhou, Peoples R China.	tjliu@jnu.edu.cn; tfyxing@jnu.edu.cn			National Natural Science Foundation of China [81172824]; Guangzhou City Science and Technology Program Synergistic Innovation Major Project [201604020146]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangzhou City Science and Technology Program Synergistic Innovation Major Project	This work was supported by the National Natural Science Foundation of China (grant numbers 81172824), and Guangzhou City Science and Technology Program Synergistic Innovation Major Project (grant number: 201604020146) to FX.	Akkaya M, 2020, NAT REV IMMUNOL, V20, P229, DOI 10.1038/s41577-019-0244-2; Ataide MA, 2020, NAT IMMUNOL, V21, P1397, DOI 10.1038/s41590-020-0786-2; Dai HH, 2020, SCIENCE, V368, P1122, DOI 10.1126/science.aax4040; Flajnik MF, 2018, NAT REV IMMUNOL, V18, P438, DOI 10.1038/s41577-018-0003-9; Nabekura T, 2014, J EXP MED, V211, P2455, DOI 10.1084/jem.20140798; Negi S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02441; Netea MG, 2016, SCIENCE, V352, DOI 10.1126/science.aaf1098; Rahim MMA, 2015, IMMUNOL REV, V267, P137, DOI 10.1111/imr.12318; Theisen DJ, 2018, SCIENCE, V362, P694, DOI 10.1126/science.aat5030; Tough DF, 2020, TRENDS IMMUNOL, V41, P29, DOI 10.1016/j.it.2019.11.008; van den Boorn JG, 2016, IMMUNITY, V44, P1406, DOI 10.1016/j.immuni.2016.05.008; Wight A, 2020, J IMMUNOL, V204, P2867, DOI 10.4049/jimmunol.2000196; Yao YS, 2018, CELL, V175, P1634, DOI 10.1016/j.cell.2018.09.042	13	0	0	2	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 14	2021	12								721344	10.3389/fimmu.2021.721344	http://dx.doi.org/10.3389/fimmu.2021.721344			4	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WR5BL	34804010	gold, Green Published			2022-12-18	WOS:000714514700001
J	Ciano-Petersen, NL; Hamad-Cueto, O; Drissi-Reyes, H; Dona-Diaz, A; Garcia-Martin, G				Ciano-Petersen, Nicolas Lundahl; Hamad-Cueto, Omar; Drissi-Reyes, Hania; Dona-Diaz, Alvaro; Garcia-Martin, Guillermina			Case Report: Autoimmune Psychosis in Chromosome 22q11.2 Deletion Syndrome	FRONTIERS IN IMMUNOLOGY			English	Article						chromosome 22q112 deletion syndrome; psychosis; autoimmune encephalitis; autoimmune psychosis; cognitive impairment	ENCEPHALITIS; DIAGNOSIS	Chromosome 22q11.2 deletion syndrome (22q11DS) is characterized by congenital cardiac abnormalities, hypoplastic thymus, palatal abnormalities, and hypocalcemia, although other clinical features are frequent such as autoimmune and psychiatric disorders. One-third of the patients have psychotic disorders, frequently followed by developmental regression and long-term cognitive disturbances. Despite humoral and cellular immunodeficiency are common in 22q11DS, it is associated with an increased prevalence of autoimmune disorders such as idiopathic thrombocytopenic purpura and juvenile idiopathic arthritis, likely due to immune dysregulations associated with thymic abnormalities, which plays a major role in self-tolerance. We report an unique case of a 14-year-old girl with 22q11DS that presented with subacute psychotic symptoms, intolerance to antipsychotics, CSF pleocytosis, and EEG abnormalities, that was successfully treated with empiric immunotherapy after fulfilling criteria for probable seronegative autoimmune encephalitis and probable autoimmune psychosis. The autoimmune etiology of these clinical features of 22q11DS has never been postulated despite the predisposition of this syndrome to present autoimmune disorders. We suggest the systematic evaluation with serum and CSF neuronal antibodies, MRI, and EEG of patients with 22q11DS that develop subacute psychotic symptoms or rapidly progressive cognitive decline. Early immunomodulatory therapies should be carefully considered if criteria of probable autoimmune psychosis or possible autoimmune encephalitis are fulfilled, as it may prevent long-term disabilities. Further studies are required to assess the autoimmune origin of psychosis and cognitive impairment associated with 22q11DS.</p>	[Ciano-Petersen, Nicolas Lundahl; Garcia-Martin, Guillermina] Inst Invest Biomed Malaga IBIMA, Neuroimmunol & Neuroinflammat Grp, Malaga, Spain; [Ciano-Petersen, Nicolas Lundahl; Garcia-Martin, Guillermina] Hosp Reg Univ Malaga, Serv Neurol, Malaga, Spain; [Ciano-Petersen, Nicolas Lundahl] Univ Malaga, Fac Med, Andalucia Tech, Malaga, Spain; [Ciano-Petersen, Nicolas Lundahl; Garcia-Martin, Guillermina] Red Andaluza Invest Clin & Traslac Neurol Neurore, Malaga, Spain; [Hamad-Cueto, Omar] Hosp Clin Univ Virgen Victoria, Serv Neurol, Malaga, Spain; [Drissi-Reyes, Hania] Hosp El Angel, Serv Urgencias, Malaga, Spain; [Dona-Diaz, Alvaro] Hosp Univ Virgen Victoria, UGC Salud Mental, Malaga, Spain	Universidad de Malaga; Universidad de Malaga; Hospital Virgen de la Victoria; Hospital Virgen de la Victoria	Garcia-Martin, G (corresponding author), Inst Invest Biomed Malaga IBIMA, Neuroimmunol & Neuroinflammat Grp, Malaga, Spain.; Garcia-Martin, G (corresponding author), Hosp Reg Univ Malaga, Serv Neurol, Malaga, Spain.; Garcia-Martin, G (corresponding author), Red Andaluza Invest Clin & Traslac Neurol Neurore, Malaga, Spain.			Garcia Martin, Guillermina/0000-0003-3894-9716				Amaya-Uribe L, 2019, J AUTOIMMUN, V99, P52, DOI 10.1016/j.jaut.2019.01.011; Crowley B, 2018, AM J MED GENET A, V176, P2082, DOI 10.1002/ajmg.a.38597; Gennery AR, 2012, CELL MOL LIFE SCI, V69, P17, DOI 10.1007/s00018-011-0842-z; Graus F, 2016, LANCET NEUROL, V15, P391, DOI 10.1016/S1474-4422(15)00401-9; Hopkins SE, 2018, AM J MED GENET A, V176, P2140, DOI 10.1002/ajmg.a.38614; Klein J, 2000, NEW ENGL J MED, V343, P702, DOI 10.1056/NEJM200009073431006; Lejuste F, 2016, NEUROL-NEUROIMMUNOL, V3, DOI 10.1212/NXI.0000000000000280; McDonald-McGinn DM, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.71; Oskarsdottir S, 2004, ARCH DIS CHILD, V89, P148, DOI 10.1136/adc.2003.026880; Pollak TA, 2020, LANCET PSYCHIAT, V7, P93, DOI 10.1016/S2215-0366(19)30290-1; Qin XZ, 2020, ACTA BIOCH BIOPH SIN, V52, P1181, DOI 10.1093/abbs/gmaa113; Rojas M, 2018, J AUTOIMMUN, V95, P100, DOI 10.1016/j.jaut.2018.10.012; Sullivan KE, 2019, IMMUNOL REV, V287, P186, DOI 10.1111/imr.12701; Tang SX, 2018, AM J MED GENET A, V176, P2192, DOI 10.1002/ajmg.a.38500; Titulaer MJ, 2013, LANCET NEUROL, V12, P157, DOI 10.1016/S1474-4422(12)70310-1; Vogrig A, 2020, THER ADV NEUROL DISO, V13, DOI 10.1177/1756286420932797; Vorstman JAS, 2015, JAMA PSYCHIAT, V72, P377, DOI 10.1001/jamapsychiatry.2014.2671	17	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 14	2021	12								708625	10.3389/fimmu.2021.708625	http://dx.doi.org/10.3389/fimmu.2021.708625			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WQ5BB	34721378	Green Published, gold			2022-12-18	WOS:000713830500001
J	Fung, SY; Lu, HY; Sharma, M; Sharma, AA; Saferali, A; Jia, A; Abraham, L; Klein, T; Gold, MR; Noterangelo, LD; Overall, CM; Turvey, SE				Fung, Shan-Yu; Lu, Henry Y.; Sharma, Mehul; Sharma, Ashish A.; Saferali, Aabida; Jia, Alicia; Abraham, Libin; Klein, Theo; Gold, Michael R.; Noterangelo, Luigi D.; Overall, Christopher M.; Turvey, Stuart E.			MALT1-Dependent Cleavage of HOIL1 Modulates Canonical NF-kappa B Signaling and Inflammatory Responsiveness	FRONTIERS IN IMMUNOLOGY			English	Article						HOIL1 cleavage; LUBAC; MALT1; NF-kappa B; regulation of inflammation	MET1-LINKED UBIQUITIN; PARACASPASE MALT1; IMMUNODEFICIENCY; DEFICIENCY; COMPLEX; AUTOINFLAMMATION; AMYLOPECTINOSIS; REGULATOR; RESPONSES; PROTEASE	Nuclear factor kappa B (NF-kappa B) is a critical transcription factor involved in regulating cell activation, inflammation, and survival. The linear ubiquitin chain assembly complex (LUBAC) which consists of HOIL1, HOIP, and SHARPIN, catalyzes the linear ubiquitination of target proteins-a post-translational modification that is essential for NF-kappa B activation. Human germline pathogenic variants that dysregulate linear ubiquitination and NF-kappa B signaling are associated with immunodeficiency and/or autoinflammation including dermatitis, recurrent fevers, systemic inflammation and enteropathy. We previously identified MALT1 paracaspase as a novel negative regulator of LUBAC by proteolytic cleavage of HOIL1. To directly investigate the impact of HOIL1 cleavage activity on the inflammatory response, we employed a stable transduction system to express and directly compare non-cleavable HOIL1 with wild-type HOIL1 in primary HOIL1-deficient patient skin fibroblasts. We discovered that non-cleavable HOIL1 resulted in enhanced NF-kappa B signaling in response to innate stimuli. Transcriptomics revealed enrichment of inflammation and proinflammatory cytokine-related pathways after stimulation. Multiplexed cytokine assays confirmed a 'hyperinflammatory' phenotype in these cells. This work highlights the physiological importance of MALT1-dependent cleavage and modulation of HOIL1 on NF-kappa B signaling and inflammation, provides a mechanism for the autoinflammation observed in MALT1-deficient patients, and will inform the development of therapeutics that target MALT1 paracaspase and LUBAC function in treating autoinflammatory skin diseases.</p>	[Fung, Shan-Yu; Lu, Henry Y.; Sharma, Mehul; Jia, Alicia; Turvey, Stuart E.] British Columbia Childrens Hosp, Dept Pediat, Vancouver, BC, Canada; [Fung, Shan-Yu; Lu, Henry Y.; Sharma, Mehul; Jia, Alicia; Turvey, Stuart E.] Univ British Columbia, Vancouver, BC, Canada; [Fung, Shan-Yu] Tianjin Med Univ, Prov & Minist Cosponsored Collaborat Innovat Ctr, Sch Basic Med Sci, Key Lab Immune Microenvironm & Dis,Minist Educ, Tianjin, Peoples R China; [Fung, Shan-Yu] Tianjin Med Univ, Dept Immunol, Sch Basic Med Sci, Tianjin, Peoples R China; [Lu, Henry Y.; Sharma, Mehul; Turvey, Stuart E.] Univ British Columbia, Fac Med, Expt Med Program, Vancouver, BC, Canada; [Sharma, Ashish A.] Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA; [Saferali, Aabida] Harvard Med Sch, Brigham & Womens Hosp, Channing Div Network Med, Boston, MA 02115 USA; [Jia, Alicia; Abraham, Libin; Gold, Michael R.; Turvey, Stuart E.] Univ British Columbia, Dept Microbiol & Immunol, Vancouver, BC, Canada; [Klein, Theo] Ducares Triskel BV, Dept Analyt Solut, Utrecht, Netherlands; [Noterangelo, Luigi D.] NIAID, Lab Clin Immunol & Microbiol, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Overall, Christopher M.] Univ British Columbia, Ctr Blood Res, Dept Biochem & Mol Biol, Dept Oral Biol & Med Sci, Vancouver, BC, Canada	BC Childrens Hospital; University of British Columbia; University of British Columbia; Tianjin Medical University; Tianjin Medical University; University of British Columbia; Case Western Reserve University; Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of British Columbia; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of British Columbia	Fung, SY; Turvey, SE (corresponding author), British Columbia Childrens Hosp, Dept Pediat, Vancouver, BC, Canada.; Fung, SY; Turvey, SE (corresponding author), Univ British Columbia, Vancouver, BC, Canada.; Fung, SY (corresponding author), Tianjin Med Univ, Prov & Minist Cosponsored Collaborat Innovat Ctr, Sch Basic Med Sci, Key Lab Immune Microenvironm & Dis,Minist Educ, Tianjin, Peoples R China.; Fung, SY (corresponding author), Tianjin Med Univ, Dept Immunol, Sch Basic Med Sci, Tianjin, Peoples R China.; Turvey, SE (corresponding author), Univ British Columbia, Fac Med, Expt Med Program, Vancouver, BC, Canada.; Turvey, SE (corresponding author), Univ British Columbia, Dept Microbiol & Immunol, Vancouver, BC, Canada.	shanefung@tmu.edu.cn; sturvey@cw.bc.ca	Turvey, Stuart/HGV-1191-2022; Fung, Shan-Yu/E-3477-2014; Lu, Henry/N-4567-2019	Fung, Shan-Yu/0000-0002-4547-8740; Lu, Henry/0000-0002-1645-7748; Turvey, Stuart/0000-0003-1599-1065	Canadian Institutes of Health Research (CIHR); Genome British Columbia [SIP007]; National Natural Science Foundation of China [81971549]; Canadian Allergy, Asthma and Immunology Foundation; BC Children's Hospital Foundation; Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health; CIHR Frederick Banting and Charles Best Canada Graduate Scholarship (CGS-D); Killam Doctoral Scholarship; University of British Columbia Four Year Doctoral Fellowship (4YF); BC Children's Hospital Research Institute Graduate Studentship; CIHR CGS-D; 4YF; CIHR Canada Graduate Scholarship-Master's (CGS-M); CIHR Foundation Grant [FDN148408]; Canada Research Chair in Protease Proteomics and Systems Biology	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Genome British Columbia; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Canadian Allergy, Asthma and Immunology Foundation; BC Children's Hospital Foundation; Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); CIHR Frederick Banting and Charles Best Canada Graduate Scholarship (CGS-D)(Canadian Institutes of Health Research (CIHR)); Killam Doctoral Scholarship; University of British Columbia Four Year Doctoral Fellowship (4YF); BC Children's Hospital Research Institute Graduate Studentship; CIHR CGS-D(Canadian Institutes of Health Research (CIHR)); 4YF; CIHR Canada Graduate Scholarship-Master's (CGS-M)(Canadian Institutes of Health Research (CIHR)); CIHR Foundation Grant(Canadian Institutes of Health Research (CIHR)); Canada Research Chair in Protease Proteomics and Systems Biology	This study was supported by grants from Canadian Institutes of Health Research (CIHR) (ST), Genome British Columbia (SIP007) (ST), National Natural Science Foundation of China (No. 81971549 for SYF), the Canadian Allergy, Asthma and Immunology Foundation, and BC Children's Hospital Foundation. ST holds the Tier 1 Canada Research Chair in Pediatric Precision Health and the Aubrey J. Tingle Professorship in Pediatric Immunology. LN is supported by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health. HL is funded by a CIHR Frederick Banting and Charles Best Canada Graduate Scholarship (CGS-D), Killam Doctoral Scholarship, University of British Columbia Four Year Doctoral Fellowship (4YF), and a BC Children's Hospital Research Institute Graduate Studentship. MS is funded by a CIHR CGS-D and 4YF. AJ is funded by a CIHR Canada Graduate Scholarship-Master's (CGS-M). CO is supported by a CIHR Foundation Grant (FDN148408) and a Canada Research Chair in Protease Proteomics and Systems Biology.	Aksentijevich I, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00399; Boisson B, 2015, J EXP MED, V212, P939, DOI 10.1084/jem.20141130; Boisson Bertrand, 2014, J Exp Med, V211, P1272, DOI 10.1084/jem.2117insight3; Boisson B, 2012, NAT IMMUNOL, V13, P1178, DOI 10.1038/ni.2457; Bonsignore L, 2017, LEUKEMIA, V31, P614, DOI 10.1038/leu.2016.239; Bornancin F, 2015, J IMMUNOL, V194, P3723, DOI 10.4049/jimmunol.1402254; Boston U., 2020, NF KB TARG GEN ONL; Damgaard RB, 2016, CELL, V166, P1215, DOI 10.1016/j.cell.2016.07.019; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Douanne T, 2016, J CELL SCI, V129, P1775, DOI 10.1242/jcs.185025; Elton L, 2016, FEBS J, V283, P403, DOI 10.1111/febs.13597; Fontan L, 2018, J CLIN INVEST, V128, P4397, DOI 10.1172/JCI99436; Fujita H, 2018, CELL REP, V23, P1192, DOI 10.1016/j.celrep.2018.03.112; Fuseya Y, 2020, NAT CELL BIOL, V22, P663, DOI 10.1038/s41556-020-0517-9; Gewies A, 2014, CELL REP, V9, P1292, DOI 10.1016/j.celrep.2014.10.044; Haas TL, 2009, MOL CELL, V36, P831, DOI 10.1016/j.molcel.2009.10.013; Hrdinka M, 2017, MOL CELL, V68, P265, DOI 10.1016/j.molcel.2017.09.001; Hrdinka M, 2016, CELL REP, V14, P2846, DOI 10.1016/j.celrep.2016.02.062; Hu HB, 2016, CELL RES, V26, P457, DOI 10.1038/cr.2016.40; Ikeda F, 2011, NATURE, V471, P637, DOI 10.1038/nature09814; Israel L, 2021, ONCOGENESIS, V10, DOI 10.1038/s41389-021-00321-2; Jaworski M, 2014, EMBO J, V33, P2765, DOI 10.15252/embj.201488987; Kelsall IR, 2019, P NATL ACAD SCI USA, V116, P13293, DOI 10.1073/pnas.1905873116; Keusekotten K, 2013, CELL, V153, P1312, DOI 10.1016/j.cell.2013.05.014; Kirisako T, 2006, EMBO J, V25, P4877, DOI 10.1038/sj.emboj.7601360; Klein T, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9777; Komander D, 2009, EMBO REP, V10, P466, DOI 10.1038/embor.2009.55; Kulpa DA, 2019, J VIROL, V93, DOI 10.1128/JVI.00969-19; Lawrence T, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a001651; Lim SM, 2015, J MED CHEM, V58, P8491, DOI 10.1021/acs.jmedchem.5b01415; Liu T, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2017.23; Lu HY, 2021, CURR OPIN IMMUNOL, V72, P11, DOI 10.1016/j.coi.2021.02.008; Lu HY, 2019, J ALLERGY CLIN IMMUN, V143, P1661, DOI 10.1016/j.jaci.2019.03.009; Lu HY, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02078; Mc Guire C, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-124; McKinnon ML, 2014, J ALLERGY CLIN IMMUN, V133, P1458, DOI 10.1016/j.jaci.2013.10.045; Minina EA, 2020, MOL CELL, V77, P927, DOI 10.1016/j.molcel.2019.12.020; Nabavi M, 2019, J CLIN IMMUNOL, V39, P138, DOI 10.1007/s10875-019-00599-3; Nagel D, 2012, CANCER CELL, V22, P825, DOI 10.1016/j.ccr.2012.11.002; Oda H, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00479; Oeckinghaus A, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a000034; Petrova T, 2021, FEBS J, V288, P5909, DOI 10.1111/febs.15896; Quancard J, 2019, NAT CHEM BIOL, V15, P304, DOI 10.1038/s41589-018-0222-1; Rahighi S, 2009, CELL, V136, P1098, DOI 10.1016/j.cell.2009.03.007; Ruland J, 2019, NAT REV IMMUNOL, V19, P118, DOI 10.1038/s41577-018-0087-2; Sasaki K, 2015, IMMUNOL REV, V266, P175, DOI 10.1111/imr.12308; Sun SC, 2017, NAT REV IMMUNOL, V17, P545, DOI 10.1038/nri.2017.52; Tangye SG, 2020, J CLIN IMMUNOL, V40, P24, DOI 10.1007/s10875-019-00737-x; Taniguchi K, 2018, NAT REV IMMUNOL, V18, P309, DOI 10.1038/nri.2017.142; Taraborrelli L, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06155-8; Tokunaga F, 2009, NAT CELL BIOL, V11, P123, DOI 10.1038/ncb1821; Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016; Nuffel E, 2017, J INVEST DERMATOL, V137, P569, DOI 10.1016/j.jid.2016.09.031; Yamasoba D, 2019, NAT MICROBIOL, V4, P1532, DOI 10.1038/s41564-019-0460-3; Zhang Q, 2017, CELL, V168, P37, DOI 10.1016/j.cell.2016.12.012; Zhou Q, 2016, P NATL ACAD SCI USA, V113, P10127, DOI 10.1073/pnas.1612594113; Zinngrebe J, 2016, J EXP MED, V213, P2671, DOI 10.1084/jem.20160041	57	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 14	2021	12								749794	10.3389/fimmu.2021.749794	http://dx.doi.org/10.3389/fimmu.2021.749794			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WR3UT	34721419	Green Published, gold			2022-12-18	WOS:000714429700001
J	Hansen, L; Zhou, F; Amdam, H; Trieu, MC; Cox, RJ				Hansen, Lena; Zhou, Fan; Amdam, Hakon; Trieu, Mai-Chi; Cox, Rebecca Jane			Repeated Influenza Vaccination Boosts and Maintains H1N1pdm09 Neuraminidase Antibody Titers	FRONTIERS IN IMMUNOLOGY			English	Article						influenza; neuraminidase; neuraminidase inhibition; neuraminidase inhibition (NAI) titer; repeated vaccination; pre-existing immunity; pandemic vaccination	VIRUS NEURAMINIDASE; RESPONSES; VOLUNTEERS; CORRELATE; VACCINES	Antibodies to influenza surface protein neuraminidase (NA) have been found to reduce disease severity and may be an independent correlate of protection. Despite this, current influenza vaccines have no regulatory requirements for the quality or quantity of the NA antigen and are not optimized for induction of NA-specific antibodies. Here we investigate the induction and durability of NA-specific antibody titers after pandemic AS03-adjuvanted monovalent H1N1 vaccination and subsequent annual vaccination in health care workers in a five-year longitudinal study. NA-specific antibodies were measured by endpoint ELISA and functional antibodies measured by enzyme-linked lectin assay (ELLA) and plaque reduction naturalisation assay. We found robust induction of NA inhibition (NAI) titers with a 53% seroconversion rate (>4-fold) after pandemic vaccination in 2009. Furthermore, the endpoint and NAI geometric mean titers persisted above pre-vaccination levels up to five years after vaccination in HCWs that only received the pandemic vaccine, which demonstrates considerable durability. Vaccination with non-adjuvanted trivalent influenza vaccines (TIV) in subsequent influenza seasons 2010/2011 - 2013/2014 further boosted NA-specific antibody responses. We found that each subsequent vaccination increased durable endpoint titers and contributed to maintaining the durability of functional antibody titers. Although the trivalent influenza vaccines boosted NA-specific antibodies, the magnitude of fold-increase at day 21 declined with repeated vaccination, particularly for functional antibody titers. High levels of pre-existing antibodies were associated with lower fold-induction in repeatedly vaccinated HCWs. In summary, our results show that durable NA-specific antibody responses can be induced by an adjuvanted influenza vaccine, which can be maintained and further boosted by TIVs. Although NA-specific antibody responses are boosted by annual influenza vaccines, high pre-existing titers may negatively affect the magnitude of fold-increase in repeatedly vaccinated individuals. Our results support continued development and standardization of the NA antigen to supplement current influenza vaccines and reduce the burden of morbidity and mortality.	[Hansen, Lena; Zhou, Fan; Amdam, Hakon; Trieu, Mai-Chi; Cox, Rebecca Jane] Univ Bergen, Influenza Ctr, Dept Clin Sci, Bergen, Norway; [Cox, Rebecca Jane] Haukeland Hosp, Dept Microbiol, Bergen, Norway	University of Bergen; University of Bergen; Haukeland University Hospital	Hansen, L; Cox, RJ (corresponding author), Univ Bergen, Influenza Ctr, Dept Clin Sci, Bergen, Norway.; Cox, RJ (corresponding author), Haukeland Hosp, Dept Microbiol, Bergen, Norway.	Lena.Hansen@uib.no; Rebecco.Cox@uib.no		Trieu, Mai-Chi/0000-0001-9181-5843	Norwegian Research Council	Norwegian Research Council(Research Council of NorwayEuropean Commission)	Funding LH was supported by Norwegian Research Council grant 271160. This study received intramural funding from the Influenza Centre at the University of Bergen and Haukeland University Hospital. The Influenza Centre is funded by the University of Bergen, Ministry of Health and Care Services, Helse Vest (F-11628), the Trond Mohn Foundation (TMS2020TMT05), the European Union (EU IMI115672 FLUCOP, H2020 874866 INCENTIVE, H2020 101037867 VACCELERATE, EU IMI101007799 Inno4Vac) and Nanomedicines Flunanoair (ERA-NETet EuroNanoMed2, JTC2016), and the Research Council of Norway GLOBVAC program (284930).	Andrews SF, 2015, J VIROL, V89, P3308, DOI 10.1128/JVI.02871-14; Cate TR, 2010, VACCINE, V28, P2076, DOI 10.1016/j.vaccine.2009.12.041; Chen YQ, 2018, CELL, V173, P417, DOI 10.1016/j.cell.2018.03.030; Couch RB, 2012, VACCINE, V31, P190, DOI 10.1016/j.vaccine.2012.10.065; Couzens L, 2014, J VIROL METHODS, V210, P7, DOI 10.1016/j.jviromet.2014.09.003; Ellebedy AH, 2020, P NATL ACAD SCI USA, V117, P17957, DOI 10.1073/pnas.1906613117; Ellebedy AH, 2014, P NATL ACAD SCI USA, V111, P13133, DOI 10.1073/pnas.1414070111; Giurgea LT, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030409; HOBSON D, 1973, LANCET, V2, P155; Iuliano AD, 2018, LANCET, V391, P1285, DOI 10.1016/S0140-6736(17)33293-2; Jacob L, 2015, BRAIN BEHAV IMMUN, V47, P44, DOI 10.1016/j.bbi.2014.11.004; Kilbourne ED, 1995, VACCINE, V13, P1799, DOI 10.1016/0264-410X(95)00127-M; Laguio-Vila MR, 2015, OPEN FORUM INFECT DI, V2, DOI 10.1093/ofid/ofu115; Linderman SL, 2021, CSH PERSPECT MED, V11, DOI 10.1101/cshperspect.a040964; Madhun AS, 2010, VACCINE, V29, P266, DOI 10.1016/j.vaccine.2010.10.038; Margine I, 2013, JOVE-J VIS EXP, DOI 10.3791/51112; Matrosovich M, 2003, J VIROL, V77, P8418, DOI 10.1128/JVI.77.15.8418-8425.2003; Matrosovich M, 2006, VIROL J, V3, DOI 10.1186/1743-422X-3-63; Memoli MJ, 2016, MBIO, V7, DOI 10.1128/mBio.00417-16; Monto AS, 2015, J INFECT DIS, V212, P1191, DOI 10.1093/infdis/jiv195; MURPHY BR, 1972, NEW ENGL J MED, V286, P1329, DOI 10.1056/NEJM197206222862502; PALESE P, 1974, VIROLOGY, V61, P397, DOI 10.1016/0042-6822(74)90276-1; Petrie JG, 2015, J INFECT DIS, V212, P1914, DOI 10.1093/infdis/jiv313; PYHALA R, 1994, VACCINE, V12, P947, DOI 10.1016/0264-410X(94)90039-6; Sanyal M, 2019, J INFECT DIS, V219, P1586, DOI 10.1093/infdis/jiy685; Skarlupka AL, 2021, J VIROL, V95, DOI 10.1128/JVI.00759-21; Stadlbauer D, 2019, SCIENCE, V366, P499, DOI 10.1126/science.aay0678; Wohlbold TJ, 2015, MBIO, V6, DOI 10.1128/mBio.02556-14; Yasuhara A, 2019, NAT MICROBIOL, V4, P1024, DOI 10.1038/s41564-019-0401-1	29	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 14	2021	12								748264	10.3389/fimmu.2021.748264	http://dx.doi.org/10.3389/fimmu.2021.748264			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WS3NB	34721417	gold, Green Published			2022-12-18	WOS:000715090800001
J	Hellesen, A; Aslaksen, S; Breivik, L; Royrvik, EC; Bruserud, O; Edvardsen, K; Brokstad, KA; Susanne, A; Wolff, B; Husebye, ES; Bratland, E				Hellesen, Alexander; Aslaksen, Sigrid; Breivik, Lars; Royrvik, Ellen Christine; Bruserud, Oyvind; Edvardsen, Kine; Brokstad, Karl Albert; Susanne, Anette; Wolff, Boe; Husebye, Eystein Sverre; Bratland, Eirik			21-Hydroxylase-Specific CD8+T Cells in Autoimmune Addison's Disease Are Restricted by HLA-A2 and HLA-C7 Molecules	FRONTIERS IN IMMUNOLOGY			English	Article						CD8+T cells; 21-hydroxylase; autoimmune; Addison's disease; epitopes	T-CELLS; ADRENAL INSUFFICIENCY; NEURAL-NETWORKS; NATURAL-KILLER; GENETIC RISK; AUTOANTIBODIES; ACTIVATION; FREQUENCY; DIAGNOSIS; EPITOPES	ObjectivesCD8+ T cells targeting 21-hydroxylase (21OH) are presumed to play a central role in the destruction of adrenocortical cells in autoimmune Addison's disease (AAD). Earlier reports have suggested two immunodominant CD8+ T cell epitopes within 21OH: LLNATIAEV (21OH(342-350)), restricted by HLA-A2, and EPLARLEL (21OH(431-438)), restricted by HLA-B8. We aimed to characterize polyclonal CD8+ T cell responses to the proposed epitopes in a larger patient cohort with AAD. MethodsRecombinant fluorescent HLA-peptide multimer reagents were used to quantify antigen-specific CD8+ T cells by flow cytometry. Interferon-gamma (IFN gamma) Elispot and biochemical assays were used to functionally investigate the 21OH-specific T cells, and to map the exactly defined epitopes of 21OH. ResultsWe found a significantly higher frequency of HLA-A2 restricted LLNATIAEV-specific cells in patients with AAD than in controls. These cells could also be expanded in vitro in an antigen specific manner and displayed a robust antigen-specific IFN gamma production. In contrast, only negligible frequencies of EPLARLEL-specific T cells were detected in both patients and controls with limited IFN gamma response. However, significant IFN gamma production was observed in response to a longer peptide encompassing EPLARLEL, 21OH(430-447), suggesting alternative dominant epitopes. Accordingly, we discovered that the slightly offset ARLELFVVL (21OH(434-442)) peptide is a novel dominant epitope restricted by HLA-C7 and not by HLA-B8 as initially postulated. ConclusionWe have identified two dominant 21OH epitopes targeted by CD8+ T cells in AAD, restricted by HLA-A2 and HLA-C7, respectively. To our knowledge, this is the first HLA-C7 restricted epitope described for an autoimmune disease.	[Hellesen, Alexander; Aslaksen, Sigrid; Breivik, Lars; Royrvik, Ellen Christine; Bruserud, Oyvind; Edvardsen, Kine; Brokstad, Karl Albert; Susanne, Anette; Wolff, Boe; Husebye, Eystein Sverre; Bratland, Eirik] Univ Bergen, Dept Clin Sci, Bergen, Norway; [Hellesen, Alexander; Aslaksen, Sigrid; Breivik, Lars; Royrvik, Ellen Christine; Bruserud, Oyvind; Wolff, Boe; Husebye, Eystein Sverre; Bratland, Eirik] Univ Bergen, KG Jebsen Ctr Autoimmune Dis, Bergen, Norway; [Breivik, Lars; Wolff, Boe; Husebye, Eystein Sverre] Haukeland Hosp, Dept Med, Bergen, Norway; [Brokstad, Karl Albert] Univ Bergen, Broegelmann Res Lab, Bergen, Norway; [Bratland, Eirik] Haukeland Hosp, Dept Med Genet, Bergen, Norway	University of Bergen; University of Bergen; University of Bergen; Haukeland University Hospital; University of Bergen; University of Bergen; Haukeland University Hospital	Bratland, E (corresponding author), Univ Bergen, Dept Clin Sci, Bergen, Norway.; Bratland, E (corresponding author), Univ Bergen, KG Jebsen Ctr Autoimmune Dis, Bergen, Norway.; Bratland, E (corresponding author), Haukeland Hosp, Dept Med Genet, Bergen, Norway.	eirik.bratland@uib.no		Breivik, Lars/0000-0003-2889-7342				Abreu JRF, 2012, CLIN EXP IMMUNOL, V170, P57, DOI 10.1111/j.1365-2249.2012.04635.x; Agrawal S, 2020, CLIN IMMUNOL, V216, DOI 10.1016/j.clim.2020.108449; Andreatta M, 2016, BIOINFORMATICS, V32, P511, DOI 10.1093/bioinformatics/btv639; Baker PR, 2010, J CLIN ENDOCR METAB, V95, pE263, DOI 10.1210/jc.2010-0508; Bancos I, 2017, EUR J ENDOCRINOL, V176, P471, DOI 10.1530/EJE-16-0969; Betterle C, 2002, ENDOCR REV, V23, P327, DOI 10.1210/er.23.3.327; Blais ME, 2011, IMMUNOLOGY, V133, P1, DOI 10.1111/j.1365-2567.2011.03422.x; Bradley LM, 2005, TRENDS IMMUNOL, V26, P172, DOI 10.1016/j.it.2005.01.004; Bratland E, 2011, MOL CELL ENDOCRINOL, V336, P180, DOI 10.1016/j.mce.2010.12.015; Bratland E, 2009, J CLIN ENDOCR METAB, V94, P5117, DOI 10.1210/jc.2009-1115; Bunce M., 1997, Tissue Antigens, V50, P100, DOI 10.1111/j.1399-0039.1997.tb02847.x; Burrows JM, 2007, EUR J IMMUNOL, V37, P946, DOI 10.1002/eji.200636588; Coco G, 2006, J CLIN ENDOCR METAB, V91, P1637, DOI 10.1210/jc.2005-0860; Curtsinger JM, 2003, J EXP MED, V197, P1141, DOI 10.1084/jem.20021910; Dawoodji A, 2014, J IMMUNOL, V193, P2118, DOI 10.4049/jimmunol.1400056; Debska-Zielkowska J, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10071777; Ehrhart-Bornstein M, 1998, ENDOCR REV, V19, P101, DOI 10.1210/er.19.2.101; Erichsen MM, 2009, J CLIN ENDOCR METAB, V94, P4882, DOI 10.1210/jc.2009-1368; Eriksson D, 2016, J INTERN MED, V280, P595, DOI 10.1111/joim.12569; Eriksson D, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21015-8; Goodson-Gregg FJ, 2020, IMMUNOGENETICS, V72, P205, DOI 10.1007/s00251-020-01161-x; Hoeffel G, 2007, IMMUNITY, V27, P481, DOI 10.1016/j.immuni.2007.07.021; Husebye ES, 2018, NEW ENGL J MED, V378, P1132, DOI 10.1056/NEJMra1713301; Johnston A, 2004, CLIN EXP IMMUNOL, V138, P83, DOI 10.1111/j.1365-2249.2004.00600.x; Kaur G, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15924; Kronenberg D, 2012, DIABETES, V61, P1752, DOI 10.2337/db11-1520; Lalvani A, 1997, J IMMUNOL METHODS, V210, P65, DOI 10.1016/S0022-1759(97)00177-4; Laureti S, 1998, J CLIN ENDOCR METAB, V83, P3507, DOI 10.1210/jc.83.10.3507; Mikhaylova IV, 2007, ENDOCRINOLOGY, V148, P386, DOI 10.1210/en.2006-0726; Miller FW, 2015, GENES IMMUN, V16, P470, DOI 10.1038/gene.2015.28; Monti P, 2007, J IMMUNOL, V179, P5785, DOI 10.4049/jimmunol.179.9.5785; Nielsen M, 2003, PROTEIN SCI, V12, P1007, DOI 10.1110/ps.0239403; Oftedal BE, 2008, CLIN IMMUNOL, V129, P163, DOI 10.1016/j.clim.2008.07.002; Rojas M, 2018, J AUTOIMMUN, V95, P100, DOI 10.1016/j.jaut.2018.10.012; Rottembourg D, 2010, J AUTOIMMUN, V35, P309, DOI 10.1016/j.jaut.2010.07.001; Skinningsrud B, 2011, J CLIN ENDOCR METAB, V96, pE1703, DOI 10.1210/jc.2011-0645; Skowera A, 2015, DIABETES, V64, P916, DOI 10.2337/db14-0332; Thorleifsdottir RH, 2012, J IMMUNOL, V188, P5160, DOI 10.4049/jimmunol.1102834	38	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 14	2021	12								742848	10.3389/fimmu.2021.742848	http://dx.doi.org/10.3389/fimmu.2021.742848			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XI5SV	34721410	gold, Green Published			2022-12-18	WOS:000726172000001
J	Lopez-Trascasa, M; Alonso-Melgar, A; Melgosa-Hijosa, M; Espinosa-Roman, L; Lledin-Barbancho, MD; Garcia-Fernandez, E; de Cordoba, SR; Sanchez-Corral, P				Lopez-Trascasa, Margarita; Alonso-Melgar, Angel; Melgosa-Hijosa, Marta; Espinosa-Roman, Laura; Lledin-Barbancho, Maria Dolores; Garcia-Fernandez, Eugenia; Rodriguez de Cordoba, Santiago; Sanchez-Corral, Pilar			Case Report: Combined Liver-Kidney Transplantation to Correct a Mutation in Complement Factor B in an Atypical Hemolytic Uremic Syndrome Patient	FRONTIERS IN IMMUNOLOGY			English	Article						atypical hemolytic uremic syndrome; complement; factor B; combined liver-kidney transplantation; rare diseases	AHUS; REJECTION; CHILDREN; SURVIVAL; GAIN	Pathogenic gain-of-function variants in complement Factor B were identified as causative of atypical Hemolytic Uremic syndrome (aHUS) in 2007. These mutations generate a reduction on the plasma levels of complement C3. A four-month-old boy was diagnosed with hypocomplementemic aHUS in May 2000, and he suffered seven recurrences during the following three years. He developed a severe hypertension which required 6 anti-hypertensive drugs and presented acrocyanosis and several confusional episodes. Plasma infusion or exchange, and immunosuppressive treatments did not improve the clinical evolution, and the patient developed end-stage renal disease at the age of 3 years. Hypertension and vascular symptoms persisted while he was on peritoneal dialysis or hemodialysis, as well as after bilateral nephrectomy. C3 levels remained low, while C4 levels were normal. In 2005, a heterozygous gain-of-function mutation in Factor B (K323E) was found. A combined liver and kidney transplantation (CLKT) was performed in March 2009, since there was not any therapy for complement inhibition in these patients. Kidney and liver functions normalized in the first two weeks, and the C3/C4 ratio immediately after transplantation, indicating that the C3 activation has been corrected. After remaining stable for 4 years, the patient suffered a B-cell non-Hodgkin lymphoma that was cured by chemotherapy and reduction of immunosuppressive drugs. Signs of liver rejection with cholangitis were observed a few months later, and a second liver graft was done 11 years after the CLKT. One year later, the patient maintains normal kidney and liver functions, also C3 and C4 levels are within the normal range. The 12-year follow-up of the patient reveals that, in spite of severe complications, CLKT was an acceptable therapeutic option for this aHUS patient.</p>	[Lopez-Trascasa, Margarita] Univ Autonoma Madrid, Dept Med, Madrid, Spain; [Lopez-Trascasa, Margarita; Melgosa-Hijosa, Marta; Espinosa-Roman, Laura; Sanchez-Corral, Pilar] La Paz Univ Hosp, Hosp La Paz Inst Hlth Res IdiPAZ, Complement Res Grp, Madrid, Spain; [Alonso-Melgar, Angel; Melgosa-Hijosa, Marta; Espinosa-Roman, Laura] La Paz Univ Hosp, Pediat Nephrol Serv, Madrid, Spain; [Lledin-Barbancho, Maria Dolores] La Paz Univ Hosp, Pediat Hepatol Serv, Madrid, Spain; [Garcia-Fernandez, Eugenia] La Paz Univ Hosp, Pathol Dept, Madrid, Spain; [Rodriguez de Cordoba, Santiago] Ctr Invest Biol CSIC, Dept Mol Biomed, Madrid, Spain; [Rodriguez de Cordoba, Santiago; Sanchez-Corral, Pilar] Ctr Biomed Network Res Rare Dis CIBERER, Madrid, Spain	Autonomous University of Madrid; Hospital Universitario La Paz; Hospital Universitario La Paz; Hospital Universitario La Paz; Hospital Universitario La Paz; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); CIBER - Centro de Investigacion Biomedica en Red; CIBERER	Lopez-Trascasa, M (corresponding author), Univ Autonoma Madrid, Dept Med, Madrid, Spain.; Lopez-Trascasa, M (corresponding author), La Paz Univ Hosp, Hosp La Paz Inst Hlth Res IdiPAZ, Complement Res Grp, Madrid, Spain.	margarita.lopez@uam.es	Sánchez-Corral, Pilar/GLR-0387-2022; Fernández, María Eugenia Garcia/E-8103-2011; Lopez-Trascasa, Margarita/L-2699-2014	Fernández, María Eugenia Garcia/0000-0002-3850-1906; Sanchez-Corral, Pilar/0000-0003-4212-1233; Lopez-Trascasa, Margarita/0000-0001-8594-282X				Melgar AA, 2011, PEDIATR NEPHROL, V26, P1355; Alper C A, 1976, Adv Hum Genet, V7, P141; Bacchetta J, 2015, CURR OPIN ORGAN TRAN, V20, P543, DOI 10.1097/MOT.0000000000000225; CALNE RY, 1970, NATURE, V227, P903, DOI 10.1038/227903a0; Cheong HI, 2004, PEDIATR NEPHROL, V19, P454, DOI 10.1007/s00467-003-1371-2; Cody EM, 2019, PEDIATR CLIN N AM, V66, P235, DOI 10.1016/j.pcl.2018.09.011; Creput C, 2003, AM J TRANSPLANT, V3, P348, DOI 10.1034/j.1600-6143.2003.00050.x; de Castro C, 2020, AM J HEMATOL, V95, P1334, DOI 10.1002/ajh.25960; de Jorge EG, 2007, P NATL ACAD SCI USA, V104, P240, DOI 10.1073/pnas.0603420103; Debray D, 2009, TRANSPL P, V41, P674, DOI 10.1016/j.transproceed.2008.12.020; Del Bello A, 2020, KIDNEY INT REP, V5, P2202, DOI 10.1016/j.ekir.2020.09.018; Everly MJ, 2013, TRANSPLANTATION, V95, P410, DOI 10.1097/TP.0b013e31827d62e3; Hillmen P, 2021, NEW ENGL J MED, V384, P1028, DOI 10.1056/NEJMoa2029073; Hoy SM, 2021, DRUGS, V81, P1423, DOI 10.1007/s40265-021-01560-8; Jalanko H, 2008, AM J TRANSPLANT, V8, P216, DOI 10.1111/j.1600-6143.2007.02029.x; Knechtle SJ, 2009, SEMIN LIVER DIS, V29, P91, DOI 10.1055/s-0029-1192058; Marinozzi MC, 2014, J AM SOC NEPHROL, V25, P2053, DOI 10.1681/ASN.2013070796; Mohan S, 2012, J AM SOC NEPHROL, V23, P2061, DOI 10.1681/ASN.2012070664; Nester CM, 2015, MOL IMMUNOL, V67, P31, DOI 10.1016/j.molimm.2015.03.246; Opelz G, 2002, TRANSPLANTATION, V74, P1390, DOI 10.1097/00007890-200211270-00008; Ranawaka R, 2016, PEDIATR NEPHROL, V31, P1539, DOI 10.1007/s00467-016-3396-3; Remuzzi G, 2005, AM J TRANSPLANT, V5, P1146, DOI 10.1111/j.1600-6143.2005.00783.x; Remuzzi G, 2002, LANCET, V359, P1671, DOI 10.1016/S0140-6736(02)08560-4; Saland JM, 2006, AM J TRANSPLANT, V6, P1948, DOI 10.1111/j.1600-6143.2006.01375.x; Saland J, 2014, PEDIATR NEPHROL, V29, P329, DOI 10.1007/s00467-013-2722-2; Saland JM, 2009, CLIN J AM SOC NEPHRO, V4, P201, DOI 10.2215/CJN.02170508; Saland JM, 2009, J AM SOC NEPHROL, V20, P940, DOI 10.1681/ASN.2008080906; Sanchez-Moreno A, 2021, PEDIATR TRANSPLANT, V25, DOI 10.1111/petr.13903; Taner T, 2016, KIDNEY INT, V89, P909, DOI 10.1016/j.kint.2015.10.016; Urban A, 2018, AUTOIMMUNITY, V51, P18, DOI 10.1080/08916934.2017.1423286; Zhang YZ, 2020, KIDNEY INT, V98, P1265, DOI 10.1016/j.kint.2020.05.028; Zuber J, 2013, TRANSPLANT REV-ORLAN, V27, P117, DOI 10.1016/j.trre.2013.07.003	32	0	0	2	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 14	2021	12								751093	10.3389/fimmu.2021.751093	http://dx.doi.org/10.3389/fimmu.2021.751093			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WQ1NE	34721423	Green Published, gold			2022-12-18	WOS:000713587500001
J	van der Weken, H; Garcia, RS; Sanders, NN; Cox, E; Devriendt, B				Van der Weken, Hans; Sanz Garcia, Raquel; Sanders, Niek N.; Cox, Eric; Devriendt, Bert			Antibody-Mediated Targeting of Antigens to Intestinal Aminopeptidase N Elicits Gut IgA Responses in Pigs	FRONTIERS IN IMMUNOLOGY			English	Article						oral vaccination; aminopeptidase N; epithelial targeting; ETEC; recombinant antibody; mucosal immunity	ORAL IMMUNIZATION; MONOCLONAL-ANTIBODIES; IMMUNE-RESPONSES; DENDRITIC CELLS; F4 FIMBRIAE; RECEPTOR; VACCINE; COLI; GENERATION; INDUCTION	Many pathogens enter the host via the gut, causing disease in animals and humans. A robust intestinal immune response is necessary to protect the host from these gut pathogens. Despite being best suited for eliciting intestinal immunity, oral vaccination remains a challenge due to the gastrointestinal environment, a poor uptake of vaccine antigens by the intestinal epithelium and the tolerogenic environment pervading the gut. To improve uptake, efforts have focused on targeting antigens towards the gut mucosa. An interesting target is aminopeptidase N (APN), a conserved membrane protein present on small intestinal epithelial cells shown to mediate epithelial transcytosis. Here, we aimed to further optimize this oral vaccination strategy in a large animal model. Porcine APN-specific monoclonal antibodies were generated and the most promising candidate in terms of epithelial transcytosis was selected to generate antibody fusion constructs, comprising a murine IgG1 or porcine IgA backbone and a low immunogenic antigen: the F18-fimbriated E. coli tip adhesin FedF. Upon oral delivery of these recombinant antibodies in piglets, both mucosal and systemic immune responses were elicited. The presence of the FedF antigen however appeared to reduce these immune responses. Further analysis showed that F18 fimbriae were able to disrupt the antigen presenting capacity of intestinal antigen presenting cells, implying potential tolerogenic effects of FedF. Altogether, these findings show that targeted delivery of molecules to epithelial aminopeptidase N results in their transcytosis and delivery to the gut immune systems. The results provide a solid foundation for the development of oral subunit vaccines to protect against gut pathogens.</p>	[Van der Weken, Hans; Sanz Garcia, Raquel; Cox, Eric; Devriendt, Bert] Univ Ghent, Fac Vet Med, Lab Immunol, Ghent, Belgium; [Sanders, Niek N.] Univ Ghent, Fac Vet Med, Lab Gene therapy, Ghent, Belgium	Ghent University; Ghent University	Devriendt, B (corresponding author), Univ Ghent, Fac Vet Med, Lab Immunol, Ghent, Belgium.	b.devriendt@ugent.be	Van der Weken, Hans/AAB-8168-2022	Van der Weken, Hans/0000-0002-3104-9355; Cox, Eric/0000-0003-4281-2990; Devriendt, Bert/0000-0002-3222-8769	Ghent University [BOF15/GOA/031]; F.W.O-Vlaanderen	Ghent University(Ghent University); F.W.O-Vlaanderen(FWO)	Funding HV and RS are recipients of a fellowship from the Ghent University (BOF15/GOA/031). BD was supported by a postdoctoral grant of F.W.O-Vlaanderen.	Alvarez B, 2000, TISSUE ANTIGENS, V55, P342, DOI 10.1034/j.1399-0039.2000.550408.x; Auray G, 2016, J IMMUNOL, V197, P4791, DOI 10.4049/jimmunol.1600672; Baert K, 2015, J CONTROL RELEASE, V220, P149, DOI 10.1016/j.jconrel.2015.10.025; BAILEY M, 1992, J IMMUNOL METHODS, V153, P85, DOI 10.1016/0022-1759(92)90309-H; Bakshi S, 2020, J CONTROL RELEASE, V321, P416, DOI 10.1016/j.jconrel.2020.01.033; Bellot P, 2013, VET IMMUNOL IMMUNOP, V152, P101, DOI 10.1016/j.vetimm.2012.09.013; Bimczok D, 2005, EUR J IMMUNOL, V35, P1418, DOI 10.1002/eji.200425726; BROWN WR, 1970, J CLIN INVEST, V49, P1374, DOI 10.1172/JCI106354; Cliquet P, 2001, J AGR FOOD CHEM, V49, P3349, DOI 10.1021/jf001428k; Coddens A, 2009, J BIOL CHEM, V284, P9713, DOI 10.1074/jbc.M807866200; Devriendt B, 2013, EUR J PHARM BIOPHARM, V84, P421, DOI 10.1016/j.ejpb.2012.11.016; Devriendt B, 2012, J CONTROL RELEASE, V160, P431, DOI 10.1016/j.jconrel.2012.02.006; Devriendt B, 2009, VET RES, V40, DOI 10.1051/vetres/2009023; Ekwueme DU, 2002, B WORLD HEALTH ORGAN, V80, P859; Ghosh Mallika, 2012, Bio Protoc, V2, pe305; Grodeland G, 2013, J IMMUNOL, V191, P3221, DOI 10.4049/jimmunol.1300504; Haverson K, 2000, IMMUNOLOGY, V101, P492, DOI 10.1046/j.1365-2567.2000.00128.x; Kang SH, 2018, POLYMERS-BASEL, V10, DOI 10.3390/polym10090948; Kim SH, 2014, EXP MOL MED, V46, DOI 10.1038/emm.2013.165; Lee J, 2012, J IMMUNOL METHODS, V384, P143, DOI 10.1016/j.jim.2012.06.001; Loos M, 2013, VET IMMUNOL IMMUNOP, V152, P82, DOI 10.1016/j.vetimm.2012.09.014; Makala LHC, 1998, VET IMMUNOL IMMUNOP, V61, P67, DOI 10.1016/S0165-2427(97)00125-6; Meijerink E, 1997, MAMM GENOME, V8, P736, DOI 10.1007/s003359900556; Melkebeek V, 2012, MUCOSAL IMMUNOL, V5, P635, DOI 10.1038/mi.2012.37; Mina-Osorio P, 2008, TRENDS MOL MED, V14, P361, DOI 10.1016/j.molmed.2008.06.003; Ohno H, 2010, GUT MICROBES, V1, P407, DOI 10.4161/gmic.1.6.14078; Owen JL, 2013, CURR OPIN CHEM BIOL, V17, P918, DOI 10.1016/j.cbpa.2013.06.013; Pasetti MF, 2011, IMMUNOL REV, V239, P125, DOI 10.1111/j.1600-065X.2010.00970.x; Rath T, 2015, CRIT REV BIOTECHNOL, V35, P235, DOI 10.3109/07388551.2013.834293; Snoeck V, 2008, VET IMMUNOL IMMUNOP, V124, P29, DOI 10.1016/j.vetimm.2006.10.014; Su F, 2016, HUM VACC IMMUNOTHER, V12, P1070, DOI 10.1080/21645515.2015.1114195; Tiels P, 2008, VACCINE, V26, P2154, DOI 10.1016/j.vaccine.2008.01.054; Van den Broeck W, 1999, INFECT IMMUN, V67, P520, DOI 10.1128/IAI.67.2.520-526.1999; Van den Broeck W, 1999, VACCINE, V17, P2020, DOI 10.1016/S0264-410X(98)00406-X; van der Weken H, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010001; Van der Weken H, 2019, MABS-AUSTIN, V11, P559, DOI 10.1080/19420862.2019.1574531; Verdonck F, 2002, VACCINE, V20, P2995, DOI 10.1016/S0264-410X(02)00220-7; Villasenor-Cardoso MI, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/562984; Virdi V, 2019, NAT BIOTECHNOL, V37, P527, DOI 10.1038/s41587-019-0070-x; Wallace AL, 2020, VACCINE, V38, P7490, DOI 10.1016/j.vaccine.2020.09.070; Ye LL, 2011, NAT BIOTECHNOL, V29, P158, DOI 10.1038/nbt.1742	41	0	0	3	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 14	2021	12								753371	10.3389/fimmu.2021.753371	http://dx.doi.org/10.3389/fimmu.2021.753371			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WQ4DC	34721427	Green Published, gold			2022-12-18	WOS:000713767900001
J	Yang, MH; Hu, CC; Wong, CH; Liang, JJ; Ko, HY; He, MH; Lin, YL; Lin, NS; Hsu, YH				Yang, Ming-Hao; Hu, Chung-Chi; Wong, Chi-Hzeng; Liang, Jian-Jong; Ko, Hui-Ying; He, Meng-Hsun; Lin, Yi-Ling; Lin, Na-Sheng; Hsu, Yau-Heiu			Convenient Auto-Processing Vector Based on Bamboo Mosaic Virus for Presentation of Antigens Through Enzymatic Coupling	FRONTIERS IN IMMUNOLOGY			English	Article						Bamboo mosaic virus (BaMV); chimeric virus particle (CVP); nanoparticle; virus-like particle (VLP); antigen presentation platform; Tobacco etch virus protease (TEVp); sortase A; Japanese encephalitis virus (JEV)	STAPHYLOCOCCUS-AUREUS; MEDIATED LIGATION; SURFACE-PROTEINS; CELL-WALL; SORTASE; PARTICLES; PURIFICATION; SUPPRESSOR; COMPLEXES; STRATEGY	We have developed a new binary epitope-presenting CVP platform based on bamboo mosaic virus (BaMV) by using the sortase A (SrtA)-mediated ligation technology. The reconstructed BaMV genome harbors two modifications: 1) a coat protein (CP) with N-terminal extension of the tobacco etch virus (TEV) protease recognition site plus 4 extra glycine (G) residues as the SrtA acceptor; and 2) a TEV protease coding region replacing that of the triple-gene-block proteins. Inoculation of such construct, pKB5G, on Nicotiana benthamiana resulted in the efficient production of filamentous CVPs ready for SrtA-mediated ligation with desired proteins. The second part of the binary platform includes an expression vector for the bacterial production of donor proteins. We demonstrated the applicability of the platform by using the recombinant envelope protein domain III (rEDIII) of Japanese encephalitis virus (JEV) as the antigen. Up to 40% of the BaMV CP subunits in each CVP were loaded with rEDIII proteins in 1 min. The rEDIII-presenting BaMV CVPs (BJLPET5G) could be purified using affinity chromatography. Immunization assays confirmed that BJLPET5G could induce the production of neutralizing antibodies against JEV infections. The binary platform could be adapted as a useful alternative for the development and mass production of vaccine candidates.	[Yang, Ming-Hao; Hu, Chung-Chi; Wong, Chi-Hzeng; Hsu, Yau-Heiu] Natl Chung Hsing Univ, Grad Inst Biotechnol, Taichung, Taiwan; [Hu, Chung-Chi; Hsu, Yau-Heiu] Natl Chung Hsing Univ, Adv Plant Biotechnol Ctr, Taichung, Taiwan; [Liang, Jian-Jong; Ko, Hui-Ying; Lin, Yi-Ling] Acad Sinica, Inst Biomed Sci, Taipei, Taiwan; [He, Meng-Hsun; Lin, Na-Sheng] Acad Sinica, Inst Plant & Microbial Biol, Taipei, Taiwan; [Lin, Yi-Ling] Acad Sinica, Biomed Translat Res Ctr, Taipei, Taiwan	National Chung Hsing University; National Chung Hsing University; Academia Sinica - Taiwan; Academia Sinica - Taiwan; Academia Sinica - Taiwan	Hsu, YH (corresponding author), Natl Chung Hsing Univ, Grad Inst Biotechnol, Taichung, Taiwan.; Hsu, YH (corresponding author), Natl Chung Hsing Univ, Adv Plant Biotechnol Ctr, Taichung, Taiwan.	yhhsu@nchu.edu.tw	Lin, Yi-Ling/N-7128-2018	Lin, Yi-Ling/0000-0002-1838-6410	Ministry of Science and Technology, Taiwan	Ministry of Science and Technology, Taiwan(Ministry of Science and Technology, Taiwan)	Funding This work was supported by grants from the Ministry of Science and Technology, Taiwan (MOST-109-2313-B-005-050 to Y-HH; MOST-108-2320-B-001-030-MY3 to Y-LL), and by the Advanced Plant Biotechnology Center from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education (MOE), Taiwan.	Antos JM, 2016, CURR OPIN STRUC BIOL, V38, P111, DOI 10.1016/j.sbi.2016.05.021; Bachmann MF, 2010, NAT REV IMMUNOL, V10, P787, DOI 10.1038/nri2868; Balke I, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030270; Balke I, 2019, ADV DRUG DELIVER REV, V145, P119, DOI 10.1016/j.addr.2018.08.007; Baumberger N, 2007, CURR BIOL, V17, P1609, DOI 10.1016/j.cub.2007.08.039; Chen I, 2011, P NATL ACAD SCI USA, V108, P11399, DOI 10.1073/pnas.1101046108; Chen LK, 1996, VIROLOGY, V223, P79, DOI 10.1006/viro.1996.0457; Chen TH, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13040572; Chen TH, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.00788; Chen TH, 2012, VIRUS RES, V166, P109, DOI 10.1016/j.virusres.2012.02.021; Chichester JA, 2018, VACCINE, V36, P5865, DOI 10.1016/j.vaccine.2018.08.033; DiMaio F, 2015, NAT STRUCT MOL BIOL, V22, P642, DOI 10.1038/nsmb.3054; Evtushenko EA, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-67023-4; Frankel BA, 2005, BIOCHEMISTRY-US, V44, P11188, DOI 10.1021/bi050141j; Freiburger L, 2015, J BIOMOL NMR, V63, P1, DOI 10.1007/s10858-015-9981-0; Hess GT, 2012, BIOCONJUGATE CHEM, V23, P1478, DOI 10.1021/bc300130z; Hirakawa H, 2015, BIOTECHNOL J, V10, P1487, DOI 10.1002/biot.201500012; Huang YT, 2015, J BIOMED SCI, V22, DOI 10.1186/s12929-015-0181-8; Huang YW, 2017, MOL PLANT MICROBE IN, V30, P631, DOI 10.1094/MPMI-01-17-0012-R; Jobsri J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118096; Kasschau KD, 2003, DEV CELL, V4, P205, DOI 10.1016/S1534-5807(03)00025-X; Kobashigawa Y, 2009, J BIOMOL NMR, V43, P145, DOI 10.1007/s10858-008-9296-5; Kushnir N, 2012, VACCINE, V31, P58, DOI 10.1016/j.vaccine.2012.10.083; Laliberte-Gagne ME, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010033; Laliberte-Gagne ME, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7020049; Langley J, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030393; LIN NS, 1984, J VIROL METHODS, V8, P181, DOI 10.1016/0166-0934(84)90012-0; LIN NS, 1991, PHYTOPATHOLOGY, V81, P1551, DOI 10.1094/Phyto-81-1551; Liu F, 2014, J ORG CHEM, V79, P487, DOI 10.1021/jo4024914; McCluskey AJ, 2007, PROTEIN SCI, V16, P2726, DOI 10.1110/ps.072894407; Morrison PM, 2016, CHEMBIOCHEM, V17, P753, DOI 10.1002/cbic.201500547; Muthamilselvan T, 2016, PLANT BIOTECHNOL J, V14, P231, DOI 10.1111/pbi.12377; Navarre WW, 1999, MICROBIOL MOL BIOL R, V63, P174, DOI 10.1128/MMBR.63.1.174-229.1999; Patterson D, 2017, BIOCONJUGATE CHEM, V28, P2114, DOI 10.1021/acs.bioconjchem.7b00296; Prasanth KR, 2011, J VIROL, V85, P8829, DOI 10.1128/JVI.00556-11; Pritz S, 2007, J ORG CHEM, V72, P3909, DOI 10.1021/jo062331l; Refaei MA, 2011, J BIOMOL NMR, V49, P3, DOI 10.1007/s10858-010-9464-2; Roldao A, 2010, EXPERT REV VACCINES, V9, P1149, DOI [10.1586/erv.10.115, 10.1586/ERV.10.115]; Row RD, 2015, CHEM COMMUN, V51, P12548, DOI 10.1039/c5cc04657b; RYAN MD, 1991, J GEN VIROL, V72, P2727, DOI 10.1099/0022-1317-72-11-2727; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Schoonen L, 2015, BIOCONJUGATE CHEM, V26, P2429, DOI 10.1021/acs.bioconjchem.5b00485; Schwarz B, 2017, ADV VIRUS RES, V97, P1, DOI 10.1016/bs.aivir.2016.09.002; SEIF SA, 1995, VACCINE, V13, P1515, DOI 10.1016/0264-410X(95)00097-K; Shan C, 2017, EBIOMEDICINE, V17, P157, DOI 10.1016/j.ebiom.2017.03.006; Steinhagen M, 2013, BIOORGAN MED CHEM, V21, P3504, DOI 10.1016/j.bmc.2013.03.039; Tang SB, 2016, SCI REP-UK, V6, DOI 10.1038/srep25741; Therien A, 2017, J NANOBIOTECHNOL, V15, DOI 10.1186/s12951-017-0289-y; Ton-That H, 2002, J BIOL CHEM, V277, P7447, DOI 10.1074/jbc.M109945200; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Warden-Rothman R, 2013, ANAL CHEM, V85, P11090, DOI 10.1021/ac402871k; Williamson DJ, 2014, NAT PROTOC, V9, P253, DOI 10.1038/nprot.2014.003; Williamson DJ, 2012, ANGEW CHEM INT EDIT, V51, P9377, DOI 10.1002/anie.201204538; Yamamura Y, 2011, CHEM COMMUN, V47, P4742, DOI 10.1039/c0cc05334a; Yang CF, 2018, EMERG MICROBES INFEC, V7, DOI 10.1038/s41426-018-0191-1; Yang CD, 2007, BMC BIOTECHNOL, V7, DOI 10.1186/1472-6750-7-62; Yusibov V, 2002, VACCINE, V20, P3155, DOI 10.1016/S0264-410X(02)00260-8; Zeltins A, 2018, SUBCELL BIOCHEM, V88, P379, DOI 10.1007/978-981-10-8456-0_16	58	0	0	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 14	2021	12								739837	10.3389/fimmu.2021.739837	http://dx.doi.org/10.3389/fimmu.2021.739837			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WS3MQ	34721406	Green Published, gold			2022-12-18	WOS:000715089700001
J	Yuan, XF; Tang, HM; Wu, RL; Li, XJ; Jiang, HY; Liu, ZG; Zhang, ZD				Yuan, Xiefang; Tang, Hongmei; Wu, Renlan; Li, Xingjie; Jiang, Hongyu; Liu, Zhigang; Zhang, Zongde			Short-Chain Fatty Acids Calibrate RAR alpha Activity Regulating Food Sensitization	FRONTIERS IN IMMUNOLOGY			English	Article						allergy; dendritic cell (DC); microbiota; short-chain fatty acids (SCFAs); type I interferon (IFN-I)	RETINOIC ACID; DENDRITIC CELLS; GUT MICROBIOTA; RECEPTOR-ALPHA; I INTERFERON; EXPRESSION; PROTEIN; INDUCTION; RESPONSES; IMMUNITY	Gut-microbiota dysbiosis links to allergic diseases. The mechanism of the exacerbation of food allergy caused by gut-microbiota dysbiosis remains unknown. Regulation of retinoic acid receptor alpha (RAR alpha) signaling is critical for gut immune homeostasis. Here we clarified that RAR alpha in dendritic cells (DCs) promotes Th2 cell differentiation. Antibiotics treatment stimulates retinoic acid signaling in mucosal DCs. We found microbiota metabolites short-chain fatty acids (SCFAs) maintain IGF-1 levels in serum and mesenteric lymph nodes. The IGF-1/Akt pathway is essential for regulating the transcription of genes targeted by RAR alpha. And RAR alpha in DCs affects type I interferon (IFN-I) responses through regulating transcription of IFN-alpha. Our study identifies SCFAs crosstalk with RAR alpha in dendritic cells as a critical modulator that plays a core role in promoting Th2 cells differentiation at a state of modified/disturbed microbiome.</p>	[Yuan, Xiefang; Tang, Hongmei; Wu, Renlan; Li, Xingjie; Jiang, Hongyu; Zhang, Zongde] Southwest Med Univ, Affiliated Hosp, Inflammat & Allerg Dis Res Unit, Luzhou, Peoples R China; [Li, Xingjie; Jiang, Hongyu; Zhang, Zongde] Southwest Med Univ, Sch Basic Med Sci, Luzhou, Peoples R China; [Liu, Zhigang] Shenzhen Univ, Sch Med, State Key Lab Resp Dis Allergy, Shenzhen, Peoples R China	Southwest Medical University; Southwest Medical University; Shenzhen University; State Key Laboratory of Respiratory Disease	Zhang, ZD (corresponding author), Southwest Med Univ, Affiliated Hosp, Inflammat & Allerg Dis Res Unit, Luzhou, Peoples R China.; Zhang, ZD (corresponding author), Southwest Med Univ, Sch Basic Med Sci, Luzhou, Peoples R China.; Liu, ZG (corresponding author), Shenzhen Univ, Sch Med, State Key Lab Resp Dis Allergy, Shenzhen, Peoples R China.			zhang, zongde/0000-0001-6488-3699	National Natural Science Foundation of China [82001703]; Key Laboratory of Allergy and Immunology, Shenzhen University; Shenzhen Science and Technology Peacock Team Project [KQTD20170331145453160]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Key Laboratory of Allergy and Immunology, Shenzhen University; Shenzhen Science and Technology Peacock Team Project	Funding This work was supported by the National Natural Science Foundation of China (number 82001703); open funding from the Key Laboratory of Allergy and Immunology, Shenzhen University, and the Shenzhen Science and Technology Peacock Team Project (number KQTD20170331145453160).	Benmerzoug S, 2019, CELL REP, V27, P2649, DOI 10.1016/j.celrep.2019.04.110; Bhattacharya N, 2016, IMMUNITY, V45, P641, DOI 10.1016/j.immuni.2016.08.008; Cha HR, 2010, J IMMUNOL, V184, P6799, DOI 10.4049/jimmunol.0902944; Chang PV, 2014, P NATL ACAD SCI USA, V111, P2247, DOI 10.1073/pnas.1322269111; Codella R, 2018, DIGEST LIVER DIS, V50, P331, DOI 10.1016/j.dld.2017.11.016; Connor LM, 2017, J EXP MED, V214, P125, DOI 10.1084/jem.20160470; Delmotte MH, 1999, J BIOL CHEM, V274, P38225, DOI 10.1074/jbc.274.53.38225; Eriksen KW, 2004, J BIOL CHEM, V279, P169, DOI 10.1074/jbc.M310472200; Erkelens MN, 2017, TRENDS IMMUNOL, V38, P168, DOI 10.1016/j.it.2016.12.006; Galvin KC, 2013, CANCER IMMUNOL IMMUN, V62, P1273, DOI 10.1007/s00262-013-1432-8; Hall JA, 2011, IMMUNITY, V34, P435, DOI 10.1016/j.immuni.2011.03.003; Kurche JS, 2012, J IMMUNOL, V188, P585, DOI 10.4049/jimmunol.1102550; La Grutta S, 1996, Minerva Pediatr, V48, P303; Larange A, 2016, ANNU REV IMMUNOL, V34, P369, DOI 10.1146/annurev-immunol-041015-055427; Lee J, 2015, P NATL ACAD SCI USA, V112, P1529, DOI 10.1073/pnas.1417972112; Longhi MP, 2009, J EXP MED, V206, P1589, DOI 10.1084/jem.20090247; Lyu Y, 2018, EXP BIOL MED, V243, P613, DOI 10.1177/1535370218763760; Ma Y, 2013, J CANCER, V4, P36, DOI 10.7150/jca.5046; Mazmanian SK, 2005, CELL, V122, P107, DOI 10.1016/j.cell.2005.05.007; McDonald KG, 2012, AM J PATHOL, V180, P984, DOI 10.1016/j.ajpath.2011.11.009; Montoya M, 2002, BLOOD, V99, P3263, DOI 10.1182/blood.V99.9.3263; Mora JR, 2003, NATURE, V424, P88, DOI 10.1038/nature01726; Mucida D, 2007, SCIENCE, V317, P256, DOI 10.1126/science.1145697; Palm NW, 2012, NATURE, V484, P465, DOI 10.1038/nature11047; Pellefigues C, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01575; Povoleri GAM, 2018, NAT IMMUNOL, V19, P1403, DOI 10.1038/s41590-018-0230-z; Quigley EMM, 2017, CURR NEUROL NEUROSCI, V17, DOI 10.1007/s11910-017-0802-6; ROCHETTEEGLY C, 1995, MOL ENDOCRINOL, V9, P860, DOI 10.1210/me.9.7.860; Roduit C, 2019, ALLERGY, V74, P799, DOI 10.1111/all.13660; Rooks MG, 2016, NAT REV IMMUNOL, V16, P341, DOI 10.1038/nri.2016.42; Sampson TR, 2016, CELL, V167, P1469, DOI 10.1016/j.cell.2016.11.018; Shida K, 2002, CLIN EXP ALLERGY, V32, P563, DOI 10.1046/j.0954-7894.2002.01354.x; Soumelis V, 2002, NAT IMMUNOL, V3, P673, DOI 10.1038/ni805; Srinivas H, 2005, MOL CELL BIOL, V25, P1054, DOI 10.1128/MCB.25.3.1054-1069.2005; Srinivas H, 2006, BIOCHEM J, V395, P653, DOI 10.1042/BJ20051794; Stagg AJ, 2002, EUR J IMMUNOL, V32, P1445, DOI 10.1002/1521-4141(200205)32:5<1445::AID-IMMU1445>3.0.CO;2-E; Stephen-Victor E, 2020, IMMUNITY, V53, P277, DOI 10.1016/j.immuni.2020.07.025; Tisserand J, 2011, J BIOL CHEM, V286, P33369, DOI 10.1074/jbc.M111.225680; Webb LM, 2017, EMBO J, V36, P2404, DOI 10.15252/embj.201695345; Wu RL, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2020.101288; Xiao WH, 1997, J BIOL CHEM, V272, P9742, DOI 10.1074/jbc.272.15.9742; Yan J, 2016, P NATL ACAD SCI USA, V113, pE7554, DOI 10.1073/pnas.1607235113; Zeng R, 2013, MUCOSAL IMMUNOL, V6, P847, DOI 10.1038/mi.2012.123; Zhang ZD, 2016, IMMUNITY, V44, P330, DOI 10.1016/j.immuni.2016.01.004	44	0	0	7	16	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 14	2021	12								737658	10.3389/fimmu.2021.737658	http://dx.doi.org/10.3389/fimmu.2021.737658			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WQ5AA	34721398	Green Published, gold			2022-12-18	WOS:000713827800001
J	Aun, MV; Blanca-Lopez, N; Castells, MC; Giavina-Bianchi, P				Aun, Marcelo Vivolo; Blanca-Lopez, Natalia; Castells, Mariana C.; Giavina-Bianchi, Pedro			Editorial: The Role of Mast Cells in Immediate Hypersensitivity Reactions	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						mast cells; activation; urticaria; hypersensitivity; mastocytosis			[Aun, Marcelo Vivolo] Albert Einstein Coll Med, Fac Israelita Ciencias Saude, Div Host & Def, Sao Paulo, Brazil; [Aun, Marcelo Vivolo; Giavina-Bianchi, Pedro] Univ Sao Paulo, Sch Med, Clin Immunol & Allergy Div, Sao Paulo, Brazil; [Blanca-Lopez, Natalia] Hosp Univ Infanta Leonor, Allergy Serv, Madrid, Spain; [Castells, Mariana C.] Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Div Allergy & Clin Immunol, Boston, MA 02115 USA	Universidade de Sao Paulo; Hospital Universitario Infanta Leonor; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Aun, MV (corresponding author), Albert Einstein Coll Med, Fac Israelita Ciencias Saude, Div Host & Def, Sao Paulo, Brazil.; Aun, MV (corresponding author), Univ Sao Paulo, Sch Med, Clin Immunol & Allergy Div, Sao Paulo, Brazil.	marcelovivoloaun@gmail.com						Ebo DG, 2019, BRIT J ANAESTH, V123, pE38, DOI 10.1016/j.bja.2019.01.031; Krystel-Whittemore M, 2016, FRONT IMMUNOL, V6, P1, DOI 10.3389/fimmu.2015.00620; McNeil BD, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.676354; McNeil BD, 2015, NATURE, V519, P237, DOI 10.1038/nature14022; Zuberbier T, 2018, ALLERGY, V73, P1393, DOI 10.1111/all.13397	5	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 13	2021	12								780829	10.3389/fimmu.2021.780829	http://dx.doi.org/10.3389/fimmu.2021.780829			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WQ2DS	34721442	Green Published, gold			2022-12-18	WOS:000713631200001
J	Baba, SM; Rasool, R; Gull, A; Qureshi, TA; Beigh, AH; Qadri, Q; Shah, ZA				Baba, Shahid M.; Rasool, Roohi; Gull, Ayaz; Qureshi, Taha A.; Beigh, Afaq H.; Qadri, Qurteeba; Shah, Zafar A.			Effectiveness of Sublingual Immunotherapy in the Treatment of HDM-Induced Nasobronchial Allergies: A 3-Year Randomized Case-Control Study From Kashmir	FRONTIERS IN IMMUNOLOGY			English	Article						asthma; allergic rhinitis; sublingual immunotherapy; skin prick test; Kashmir (India); House Dust Mites	HOUSE-DUST MITE; DOUBLE-BLIND; SUBCUTANEOUS IMMUNOTHERAPY; FOLLOW-UP; ASTHMA; CHILDREN; RHINITIS; EFFICACY; PARAMETERS	Allergen immunotherapy (AIT) is the only disease-modifying treatment for allergic disorders that induces immunological tolerance through administration of specific allergens. Studies on AIT for subcutaneous route are in abundance; however, the efficacy of AIT in tablet form through sublingual route has not been well elucidated. The present prospective, parallel-group, controlled study sought to compare the efficacy of sublingual immunotherapy (SLIT) tablets with pharmacotherapy (PT) in 332 house dust mite (HDM)-specific allergic asthma and/or rhinitis patients over a period of 3 years. Patients were followed up for a 6-month run-in period and then randomly stratified as those who would receive SLIT, SLIT in addition to PT (SLIT+PT), and PT alone. AIT was administered in the form of sublingual tablets. Symptom and medication scores were measured every 3 months. In vitro evaluation of serum total and HDM specific immunoglobulin E (HDM sIgE) levels was carried out every 3 months, whereas in vivo skin prick test was performed annually for 3 years. Our study demonstrated sustained clinical improvement, reduction in inhaled corticosteroid (ICS) dose and duration as well as prevention from development of neosensitization to other aero allergens in HDM-allergic asthmatics and/or rhinitis patients treated with 3 years SLIT. Despite a remarkable clinical improvement with AIT, we observed that SLIT did not significantly change the skin reactivity to HDM at 3 years and there was no significant change in the ratio of serum total and HDM sIgE. Given the immune and disease modifying effects of AIT in allergic diseases, the present study supports the notion of its sublingual mode being an effective long-term immunomodulator in HDM-sensitized nasobronchial allergies.	[Baba, Shahid M.; Rasool, Roohi; Gull, Ayaz; Qureshi, Taha A.; Beigh, Afaq H.; Qadri, Qurteeba; Shah, Zafar A.] Sherikashmir Inst Med Sci, Dept Immunol & Mol Med, Srinagar, India	Sher-i-Kashmir Institute of Medical Sciences	Rasool, R (corresponding author), Sherikashmir Inst Med Sci, Dept Immunol & Mol Med, Srinagar, India.	roohi_wani@yahoo.com		Gull, Ayaz/0000-0003-2913-8022	BAC Pharmacy for providing SLIT tablets without interruption for three years.	BAC Pharmacy for providing SLIT tablets without interruption for three years.	Acknowledgments We acknowledge our patients for their participation in the study. We are highly indebted to Dr Paranjothy Kanni and his team from BAC Pharmacy for providing SLIT tablets without interruption for three years.	Akdis CA, 2011, J ALLERGY CLIN IMMUN, V127, P18, DOI 10.1016/j.jaci.2010.11.030; Bahceciler NN, 2001, PEDIATR PULM, V32, P49, DOI 10.1002/ppul.1088; Berthold M., 2014, IMMUNO DIAGNOSTICS J, V1, P4; Bousquet PJ, 2007, ALLERGY, V62, P301, DOI 10.1111/j.1398-9995.2006.01293.x; Brozek JL, 2010, J ALLERGY CLIN IMMUN, V126, P466, DOI 10.1016/j.jaci.2010.06.047; Burks AW, 2013, J ALLERGY CLIN IMMUN, V131, P1288, DOI 10.1016/j.jaci.2013.01.049; Di Rienzo V, 2003, CLIN EXP ALLERGY, V33, P206, DOI 10.1046/j.1365-2222.2003.01587.x; Dong X, 2016, ALLERGY ASTHMA IMMUN, V8, P421, DOI 10.4168/aair.2016.8.5.421; Durham SR, 2012, J ALLERGY CLIN IMMUN, V129, P717, DOI 10.1016/j.jaci.2011.12.973; Eder W, 2006, NEW ENGL J MED, V355, P2226, DOI 10.1056/NEJMra054308; Eifan AO, 2011, CURR OPIN ALLERGY CL, V11, P586, DOI 10.1097/ACI.0b013e32834cb994; European Medicines Agency, 2008, CHMPEWP185042006 EME; Gotzsche PC, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001187.pub3; Jutel M, 2016, ALLERGY ASTHMA IMMUN, V8, P191, DOI 10.4168/aair.2016.8.3.191; Karakoc-Aydiner E, 2015, J INVEST ALLERG CLIN, V25, P334; Lue KH, 2006, PEDIAT ALLERG IMM-UK, V17, P408, DOI 10.1111/j.1399-3038.2006.00443.x; Marcucci F, 2005, PEDIAT ALLERG IMM-UK, V16, P519, DOI 10.1111/j.1399-3038.2005.00301.x; Marogna M, 2004, ALLERGY, V59, P1205, DOI 10.1111/j.1398-9995.2004.00508.x; Marogna M, 2010, J ALLERGY CLIN IMMUN, V126, P969, DOI 10.1016/j.jaci.2010.08.030; Morjaria JB, 2014, CURR ALLERGY ASTHM R, V14, DOI 10.1007/s11882-013-0412-6; Ozdemir C, 2007, PEDIATR ALLERGY IMMU, V18, P508, DOI 10.1111/j.1399-3038.2007.00549.x; PLATTSMILLS TAE, 1989, J ALLERGY CLIN IMMUN, V83, P416, DOI 10.1016/0091-6749(89)90128-0; Radulovic Suzana, 2010, Cochrane Database Syst Rev, pCD002893, DOI 10.1002/14651858.CD002893.pub2; Salo PM, 2011, J ALLERGY CLIN IMMUN, V127, P1226, DOI 10.1016/j.jaci.2010.12.1106; Sheikh A, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001563.pub3; TARI MG, 1990, ALLERGOL IMMUNOPATH, V18, P277; VanRee R, 1997, CLIN EXP ALLERGY, V27, P68, DOI 10.1046/j.1365-2222.1997.d01-416.x; Yukselen A, 2012, INT ARCH ALLERGY IMM, V157, P288, DOI 10.1159/000327566; Zhang WM, 2018, IMMUNOTHERAPY-UK, V10, P579, DOI 10.2217/imt-2017-0138	29	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 13	2021	12								723814	10.3389/fimmu.2021.723814	http://dx.doi.org/10.3389/fimmu.2021.723814			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WP6FA	34721385	Green Published, gold			2022-12-18	WOS:000713223900001
J	Olwenyi, OA; Johnson, SD; Pandey, K; Thurman, M; Acharya, A; Buch, SJ; Fox, HS; Podany, AT; Fletcher, CV; Byrareddy, SN				Olwenyi, Omalla A.; Johnson, Samuel D.; Pandey, Kabita; Thurman, Michellie; Acharya, Arpan; Buch, Shilpa J.; Fox, Howard S.; Podany, Anthony T.; Fletcher, Courtney V.; Byrareddy, Siddappa N.			Diminished Peripheral CD29hi Cytotoxic CD4+T Cells Are Associated With Deleterious Effects During SIV Infection	FRONTIERS IN IMMUNOLOGY			English	Article						CD4+CTLs; SIV; morphine; reservoirs; CD29+CD4+T cells; biomarker	HUMAN-IMMUNODEFICIENCY-VIRUS; CD4(+) T-CELLS; MICROBIAL TRANSLOCATION; IN-VITRO; HIV; ACTIVATION; TRANSMISSION; IMMUNITY; MUCOSAL; AIDS	Cytotoxic CD4+ T cells (CD4+ CTLs) limit HIV pathogenesis, as evidenced in elite controllers (a subset of individuals who suppress the virus without the need for therapy). CD4+ CTLs have also been shown to kill HIV-infected macrophages. However, little is known about their contribution towards HIV persistence, how they are affected following exposure to immune modulators like morphine, and what factors maintain their frequencies and function. Further, the lack of robust markers to identify CD4+ CTLs in various animal models limits understanding of their role in HIV pathogenesis. We utilized various PBMC samples obtained from SIV infected and cART treated rhesus macaques exposed to morphine or saline and subjected to flow cytometry evaluations. Thereafter, we compared and correlated the expression of CD4+ CTL-specific markers to viral load and viral reservoir estimations in total CD4+ T cells. We found that CD29 could be reliably used as a marker to identify CD4+ CTLs in rhesus macaques since CD29hi CD4+ T cells secrete higher cytotoxic and proinflammatory cytokines following PMA/ionomycin or gag stimulation. In addition, this immune cell subset was depleted during untreated SIV infection. Strikingly, we also observed that early initiation of cART reconstitutes depleted CD29hi CD4+ T cells and restores their function. Furthermore, we noted that morphine exposure reduced the secretion of proinflammatory cytokines/cytotoxic molecules in CD29hi CD4+ T cells. Lastly, increased functionality of CD29hi CD4+ T cells as depicted by elevated levels of either IL-21 or granzyme B hi T Bet+ gag specific responses were linked to limiting the size of the replication-competent reservoir during cART treatment. Collectively, our data suggest that CD4+ CTLs are crucial in limiting SIV pathogenesis and persistence.	[Olwenyi, Omalla A.; Johnson, Samuel D.; Pandey, Kabita; Thurman, Michellie; Acharya, Arpan; Buch, Shilpa J.; Byrareddy, Siddappa N.] Univ Nebraska Med Ctr, Dept Pharmacol & Expt Neurosci, Omaha, NE 68198 USA; [Olwenyi, Omalla A.; Johnson, Samuel D.; Pandey, Kabita] Univ Nebraska Med Ctr, Dept Pathol & MicroBiol, Omaha, NE USA; [Fox, Howard S.] Univ Nebraska Med Ctr, Dept Neurol Sci, Omaha, NE USA; [Podany, Anthony T.; Fletcher, Courtney V.] Univ Nebraska Med Ctr, Ctr Drug Discovery, Antiviral Pharmacol Lab, UNMC, Omaha, NE USA; [Byrareddy, Siddappa N.] Univ Nebraska Med Ctr, Dept Genet Cell Biol & Anat, Omaha, NE 68198 USA; [Byrareddy, Siddappa N.] Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; [Byrareddy, Siddappa N.] Karolinska Inst, Dept Lab Med, Div Clin MicroBiol, Stockholm, Sweden	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; Karolinska Institutet	Byrareddy, SN (corresponding author), Univ Nebraska Med Ctr, Dept Pharmacol & Expt Neurosci, Omaha, NE 68198 USA.; Byrareddy, SN (corresponding author), Univ Nebraska Med Ctr, Dept Genet Cell Biol & Anat, Omaha, NE 68198 USA.; Byrareddy, SN (corresponding author), Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA.; Byrareddy, SN (corresponding author), Karolinska Inst, Dept Lab Med, Div Clin MicroBiol, Stockholm, Sweden.	sid.byrareddy@unmc.edu		Johnson, Samuel/0000-0002-9978-6968; Olwenyi, Omalla .A/0000-0002-5497-421X	NIH [ARP-6204, R01DA043164, R01DA041751, R01AI124965];  [P30MH062261]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); 	This study was supported by NIH grants R01DA043164, P30MH062261 to SNB, SJB, and HF, R01DA041751 to SNB and SJB, and R01AI124965 to CF. The funders had no role in designing the study or in the interpretation of the results.	Acharya A, 2021, J VIROL, V95, DOI 10.1128/JVI.01657-20; Ahmad R, 2002, J VIROL, V76, P12448, DOI 10.1128/JVI.76.24.12448-12456.2002; Aid M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00895; Ayasoufi K, 2016, J IMMUNOL, V196, P3180, DOI 10.4049/jimmunol.1501435; Banga R, 2021, CURR OPIN HIV AIDS, V16, P209, DOI 10.1097/COH.0000000000000686; Benmebarek MR, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061283; Beura LK, 2019, J EXP MED, V216, P1214, DOI 10.1084/jem.20181365; Burwitz BJ, 2012, RETROVIROLOGY, V9, DOI 10.1186/1742-4690-9-91; Busman-Sahay K, 2021, CURR OPIN HIV AIDS, V16, P200, DOI 10.1097/COH.0000000000000688; Byrareddy SN, 2014, NAT MED, V20, P1397, DOI 10.1038/nm.3715; Carville A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078793; Caza T, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/521957; Chaillon A, 2020, J CLIN INVEST, V130, P1699, DOI 10.1172/JCI134815; Chang CC, 2013, IMMUNOL REV, V254, P114, DOI 10.1111/imr.12063; Chen BN, 2020, J IMMUNOL, V204, P2722, DOI 10.4049/jimmunol.1900734; Chevalier MF, 2011, J VIROL, V85, P733, DOI 10.1128/JVI.02030-10; Degenhardt L, 2017, LANCET GLOB HEALTH, V5, pE1192, DOI 10.1016/S2214-109X(17)30375-3; Dillon SM, 2016, MUCOSAL IMMUNOL, V9, P24, DOI 10.1038/mi.2015.33; Dillon SM, 2017, AIDS, V31, P510, DOI 10.1097/QAD.0000000000001366; Dillon SM, 2016, AIDS, V30, P2737, DOI 10.1097/QAD.0000000000001289; Doitsh G, 2010, CELL, V143, P789, DOI 10.1016/j.cell.2010.11.001; Dubourg G, 2016, BMJ OPEN GASTROENTER, V3, DOI 10.1136/bmjgast-2016-000080; Dybul M, 2021, LANCET HIV, V8, pe51, DOI 10.1016/S2352-3018(20)30232-0; Estes JD, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001052; Glimcher LH, 2004, NAT REV IMMUNOL, V4, P900, DOI 10.1038/nri1490; Godinho-Santos A, 2020, J INFECT DIS, V221, P122, DOI [10.1093/infdis/ijz431, 10.1093/infdis/jiz431]; Gray JI, 2018, IMMUNOLOGY, V154, P574, DOI 10.1111/imm.12929; Greeneltch KM, 2005, J IMMUNOL, V175, P4999, DOI 10.4049/jimmunol.175.8.4999; GROUX H, 1992, J EXP MED, V175, P331, DOI 10.1084/jem.175.2.331; Handoko R, 2020, J INT AIDS SOC, V23, DOI 10.1002/jia2.25585; Harper J, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-23189-7; Hashimoto K, 2019, P NATL ACAD SCI USA, V116, P24242, DOI 10.1073/pnas.1907883116; Hensley-McBain T, 2016, J VIROL, V90, P4981, DOI 10.1128/JVI.00099-16; Hernandez-Walias F, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-60073-8; Hoefig KP, 2018, J CELL BIOL, V217, P2615, DOI 10.1083/jcb.201708075; Hong HS, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00032; HRDY DB, 1987, REV INFECT DIS, V9, P1109; Iannello A, 2010, CURR HIV RES, V8, P147, DOI 10.2174/157016210790442713; Johnson S, 2015, J VIROL, V89, P7494, DOI 10.1128/JVI.00438-15; Jost S, 2014, J VIROL, V88, P8349, DOI 10.1128/JVI.00924-14; Klatt NR, 2013, TRENDS MICROBIOL, V21, P6, DOI 10.1016/j.tim.2012.09.001; Kuehn BM, 2020, JAMA-J AM MED ASSOC, V323, P1886, DOI 10.1001/jama.2020.7626; Laidlaw BJ, 2016, NAT REV IMMUNOL, V16, P102, DOI 10.1038/nri.2015.10; Macedo AB, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02450; Nicolet BP, 2021, J IMMUNOL, V207, P2966, DOI 10.4049/jimmunol.2100138; Olwenyi OA, 2021, BMC COMPLEMENT MED, V21, DOI 10.1186/s12906-021-03288-0; Olwenyi OA, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9092076; Olwenyi OA, 2016, JAIDS-J ACQ IMM DEF, V72, P15, DOI 10.1097/QAI.0000000000000915; Phetsouphanh C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01844; Porichis F, 2011, CURR OPIN HIV AIDS, V6, P174, DOI 10.1097/COH.0b013e3283454058; Power J, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0202647; Ram DR, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007104; Roederer M, 2011, CYTOM PART A, V79A, P167, DOI 10.1002/cyto.a.21015; Roy S, 2001, SURGERY, V130, P304, DOI 10.1067/msy.2001.116033; Salido J, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02443; Sanchez-Martinez A, 2019, J CLIN VIROL, V119, P17, DOI 10.1016/j.jcv.2019.08.004; Sandler NG, 2012, NAT REV MICROBIOL, V10, P655, DOI 10.1038/nrmicro2848; Schuetz A, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004543; Smith C, 2012, BLOOD, V120, P3237, DOI 10.1182/blood-2012-03-420182; Soghoian DZ, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003165; Swain SL, 2012, NAT REV IMMUNOL, V12, P136, DOI 10.1038/nri3152; Takeuchi A, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00194; Vargas-Inchaustegui DA, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00340; Veazey RS, 2000, J VIROL, V74, P57, DOI 10.1128/JVI.74.1.57-64.2000; Vijayan KKV, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00580; Weiskopf D, 2015, P NATL ACAD SCI USA, V112, pE4256, DOI 10.1073/pnas.1505956112; Wilson EMP, 2013, IMMUNOL REV, V254, P343, DOI 10.1111/imr.12064; Woldemeskel BA, 2020, EBIOMEDICINE, V62, DOI 10.1016/j.ebiom.2020.103118; Woollard SM, 2018, PATHOGENS, V7, DOI 10.3390/pathogens7030070; Yue FY, 2017, J VIROL, V91, DOI 10.1128/JVI.02233-16; Zheng N, 2009, J VIROL, V83, P7668, DOI 10.1128/JVI.00513-09	71	0	0	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 13	2021	12								734871	10.3389/fimmu.2021.734871	http://dx.doi.org/10.3389/fimmu.2021.734871			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WQ0EZ	34721397	Green Published, gold			2022-12-18	WOS:000713497500001
J	Radetz, A; Mladenova, K; Ciolac, D; Gonzalez-Escamilla, G; Fleischer, V; Ellwardt, E; Kraemer, J; Bittner, S; Meuth, SG; Muthuraman, M; Groppa, S				Radetz, Angela; Mladenova, Kalina; Ciolac, Dumitru; Gonzalez-Escamilla, Gabriel; Fleischer, Vinzenz; Ellwardt, Erik; Kraemer, Julia; Bittner, Stefan; Meuth, Sven G.; Muthuraman, Muthuraman; Groppa, Sergiu			Linking Microstructural Integrity and Motor Cortex Excitability in Multiple Sclerosis	FRONTIERS IN IMMUNOLOGY			English	Article						multiple sclerosis; neurite orientation dispersion and density imaging; NODDI; excitability; motor threshold; tract-based spatial statistics	NEURITE ORIENTATION DISPERSION; TRANSCRANIAL MAGNETIC STIMULATION; GRAY-MATTER ATROPHY; DIFFUSION MRI; WHITE; DISABILITY; TRAIL; METAANALYSIS; ASSOCIATION; PERFORMANCE	Motor skills are frequently impaired in multiple sclerosis (MS) patients following grey and white matter damage with cortical excitability abnormalities. We applied advanced diffusion imaging with 3T magnetic resonance tomography for neurite orientation dispersion and density imaging (NODDI), as well as diffusion tensor imaging (DTI) in 50 MS patients and 49 age-matched healthy controls to quantify microstructural integrity of the motor system. To assess excitability, we determined resting motor thresholds using non-invasive transcranial magnetic stimulation. As measures of cognitive-motor performance, we conducted neuropsychological assessments including the Nine-Hole Peg Test, Trail Making Test part A and B (TMT-A and TMT-B) and the Symbol Digit Modalities Test (SDMT). Patients were evaluated clinically including assessments with the Expanded Disability Status Scale. A hierarchical regression model revealed that lower neurite density index (NDI) in primary motor cortex, suggestive for axonal loss in the grey matter, predicted higher motor thresholds, i.e. reduced excitability in MS patients (p = .009, adjusted r(2) = 0.117). Furthermore, lower NDI was indicative of decreased cognitive-motor performance (p = .007, adjusted r(2) = .142 for TMT-A; p = .009, adjusted r(2) = .129 for TMT-B; p = .006, adjusted r(2) = .142 for SDMT). Motor WM tracts of patients were characterized by overlapping clusters of lowered NDI (p <.05, Cohen's d = 0.367) and DTI-based fractional anisotropy (FA) (p <.05, Cohen's d = 0.300), with NDI exclusively detecting a higher amount of abnormally appearing voxels. Further, orientation dispersion index of motor tracts was increased in patients compared to controls, suggesting a decreased fiber coherence (p <.05, Cohen's d = 0.232). This study establishes a link between microstructural characteristics and excitability of neural tissue, as well as cognitive-motor performance in multiple sclerosis. We further demonstrate that the NODDI parameters neurite density index and orientation dispersion index detect a larger amount of abnormally appearing voxels in patients compared to healthy controls, as opposed to the classical DTI parameter FA. Our work outlines the potential for microstructure imaging using advanced biophysical models to forecast excitability alterations in neuroinflammation.	[Radetz, Angela; Mladenova, Kalina; Ciolac, Dumitru; Gonzalez-Escamilla, Gabriel; Fleischer, Vinzenz; Ellwardt, Erik; Bittner, Stefan; Muthuraman, Muthuraman; Groppa, Sergiu] Johannes Gutenberg Univ Mainz, Focus Program Translat Neurosci FTN, Rhine Main Neurosci Network rmn2,Dept Neurol, Neuroimaging & Neurostimulat,Univ Med Ctr, Mainz, Germany; [Ciolac, Dumitru] Nicolae Testemianu State Univ Med & Pharm, Lab Neurobiol & Med Genet, Kishinev, Moldova; [Ciolac, Dumitru] Inst Emergency Med, Dept Neurol, Kishinev, Moldova; [Kraemer, Julia; Meuth, Sven G.] Univ Hosp Munster, Inst Translat Neurol, Dept Neurol, Munster, Germany; [Meuth, Sven G.] Univ Hosp Dusseldorf, Dept Neurol, Dusseldorf, Germany	Johannes Gutenberg University of Mainz; University of Munster; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf Hospital	Groppa, S (corresponding author), Johannes Gutenberg Univ Mainz, Focus Program Translat Neurosci FTN, Rhine Main Neurosci Network rmn2,Dept Neurol, Neuroimaging & Neurostimulat,Univ Med Ctr, Mainz, Germany.		Muthuraman, Muthuraman/ABD-2021-2020; Meuth, Sven G/HHM-8941-2022; Ciolac, Dumitru/AFJ-2909-2022	Muthuraman, Muthuraman/0000-0001-6158-2663; Meuth, Sven G/0000-0003-2571-3501; Ciolac, Dumitru/0000-0003-1243-313X; Bittner, Stefan/0000-0003-2179-3655; Gonzalez Escamilla, Gabriel/0000-0002-7209-1736	German Research Council (DFG) [CRC TR-128]	German Research Council (DFG)(German Research Foundation (DFG))	We thank all participants who took part in the study and Cheryl Ernest for proofreading the manuscript. This study was supported by the German Research Council (DFG, CRC TR-128 to SB, SM, and SG). Parts of this research were conducted using the supercomputer Mogon and advisory services offered by Johannes Gutenberg University Mainz (hpc.uni-mainz.de), which is a member of the AHRP and the Gauss Alliance e.V. We gratefully acknowledge the computing time granted on Mogon.	Archer DB, 2018, CEREB CORTEX, V28, P1685, DOI 10.1093/cercor/bhx066; Bassi MS, 2020, CLIN NEUROPHYSIOL, V131, P566, DOI 10.1016/j.clinph.2019.10.023; Bergsland N, 2018, NEUROIMAGE-CLIN, V17, P444, DOI 10.1016/j.nicl.2017.11.002; Bergsland N, 2015, MULT SCLER J, V21, P1771, DOI 10.1177/1352458515576985; Bhandari A, 2016, CLIN NEUROPHYSIOL, V127, P2834, DOI 10.1016/j.clinph.2016.05.363; Caramia AD, 2004, CLIN NEUROPHYSIOL, V115, P956, DOI 10.1016/j.clinph.2003.11.024; CARAMIA MD, 1991, ELECTROEN CLIN NEURO, V81, P243, DOI 10.1016/0168-5597(91)90009-M; Ceccarelli A, 2007, J NEUROL, V254, P513, DOI 10.1007/s00415-006-0408-4; Cerina M, 2020, J NEUROINFLAMM, V17, DOI 10.1186/s12974-020-01827-z; Crowe SF, 1998, J CLIN PSYCHOL, V54, P585, DOI 10.1002/(SICI)1097-4679(199808)54:5<585::AID-JCLP4>3.0.CO;2-K; Daducci A, 2015, NEUROIMAGE, V105, P32, DOI 10.1016/j.neuroimage.2014.10.026; Deppe M, 2016, HUM BRAIN MAPP, V37, P1866, DOI 10.1002/hbm.23144; Droby A, 2015, NEUROIMAGE-CLIN, V8, P110, DOI 10.1016/j.nicl.2015.03.003; Ellwardt E, 2018, NAT NEUROSCI, V21, P1392, DOI 10.1038/s41593-018-0193-2; Eshaghi A, 2018, ANN NEUROL, V83, P210, DOI 10.1002/ana.25145; Feys P, 2017, MULT SCLER J, V23, P711, DOI 10.1177/1352458517690824; Filippi M, 2012, LANCET NEUROL, V11, P349, DOI 10.1016/S1474-4422(12)70003-0; Fischl B, 2012, NEUROIMAGE, V62, P774, DOI 10.1016/j.neuroimage.2012.01.021; Fisniku LK, 2008, ANN NEUROL, V64, P247, DOI 10.1002/ana.21423; Fleischer V, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-57895-x; Fleischer V, 2019, THER ADV NEUROL DISO, V12, DOI 10.1177/1756286419838673; Fleischer V, 2019, NEUROSCIENCE, V403, P35, DOI 10.1016/j.neuroscience.2017.10.033; Fukutomi H, 2018, NEUROIMAGE, V182, P488, DOI 10.1016/j.neuroimage.2018.02.017; Groppa S, 2012, NEUROIMAGE, V62, P500, DOI 10.1016/j.neuroimage.2012.05.023; Grussu F, 2017, ANN CLIN TRANSL NEUR, V4, P663, DOI 10.1002/acn3.445; Herbsman T, 2009, HUM BRAIN MAPP, V30, P2044, DOI 10.1002/hbm.20649; Hua K, 2008, NEUROIMAGE, V39, P336, DOI 10.1016/j.neuroimage.2007.07.053; Hubers A, 2012, BRAIN STIMUL, V5, P297, DOI 10.1016/j.brs.2011.03.008; Khaleeli Z, 2007, NEUROIMAGE, V37, P253, DOI 10.1016/j.neuroimage.2007.04.056; Kramer J, 2019, PROG NEUROBIOL, V182, DOI 10.1016/j.pneurobio.2019.101663; KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444; Lansley J, 2013, NEUROSCI BIOBEHAV R, V37, P819, DOI 10.1016/j.neubiorev.2013.03.006; Mayka MA, 2006, NEUROIMAGE, V31, P1453, DOI 10.1016/j.neuroimage.2006.02.004; Merluzzi AP, 2016, NEUROBIOL AGING, V43, P79, DOI 10.1016/j.neurobiolaging.2016.03.026; Moccia M, 2017, MULT SCLER J, V23, P1614, DOI 10.1177/1352458517729456; Morgen K, 2006, NEUROIMAGE, V30, P891, DOI 10.1016/j.neuroimage.2005.10.032; Mori S., 2005, MRI ATLAS HUMAN WHIT, V1st; Palacios EM, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aaz6892; Radetz A., 2021, TRANSLATIONAL METHOD, V166; REITAN RM, 1971, PERCEPT MOTOR SKILL, V33, P575, DOI 10.2466/pms.1971.33.2.575; Roosendaal SD, 2009, NEUROIMAGE, V44, P1397, DOI 10.1016/j.neuroimage.2008.10.026; Rovaris M, 2005, NEUROLOGY, V65, P1526, DOI 10.1212/01.wnl.0000184471.83948.e0; Schmidt P, 2012, NEUROIMAGE, V59, P3774, DOI 10.1016/j.neuroimage.2011.11.032; Schmierer K, 2004, ANN NEUROL, V56, P407, DOI 10.1002/ana.20202; Schneider T, 2017, FUNCT NEUROL, V32, P97; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Smith SM, 2009, NEUROIMAGE, V44, P83, DOI 10.1016/j.neuroimage.2008.03.061; Thompson AJ, 2018, LANCET NEUROL, V17, P162, DOI 10.1016/S1474-4422(17)30470-2; Timmers I, 2015, J INHERIT METAB DIS, V38, P295, DOI 10.1007/s10545-014-9780-x; Tournier JD, 2011, MAGN RESON MED, V65, P1532, DOI 10.1002/mrm.22924; Wakana S, 2007, NEUROIMAGE, V36, P630, DOI 10.1016/j.neuroimage.2007.02.049; Wang N, 2019, BRAIN STRUCT FUNCT, V224, P1797, DOI 10.1007/s00429-019-01877-x; WILSON SA, 1993, J NEUROL SCI, V118, P134, DOI 10.1016/0022-510X(93)90102-5; Winkler AM, 2014, NEUROIMAGE, V92, P381, DOI 10.1016/j.neuroimage.2014.01.060; Zakzanis KK, 2005, NEUROPSYCHOLOGIA, V43, P1878, DOI 10.1016/j.neuropsychologia.2005.03.013; Zhang H, 2012, NEUROIMAGE, V61, P1000, DOI 10.1016/j.neuroimage.2012.03.072; Zipser CM, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00393	57	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 12	2021	12								748357	10.3389/fimmu.2021.748357	http://dx.doi.org/10.3389/fimmu.2021.748357			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WP9JY	34712236	Green Submitted, Green Published, gold			2022-12-18	WOS:000713442300001
J	Off, P				Frontiers Production Off			uhrf1 and dnmt1 Loss Induces an Immune Response in Zebrafish Livers Due to Viral Mimicry by Transposable Elements (vol 12, 627926, 2021)	FRONTIERS IN IMMUNOLOGY			English	Correction						uhrf1; dnmt1; transposable element; interferon; TNFa; zebrafish; DNA methylation			[Frontiers Production Off] Frontiers Media SA, Lausanne, Switzerland		Off, P (corresponding author), Frontiers Media SA, Lausanne, Switzerland.								0	0	0	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 11	2021	12								780739	10.3389/fimmu.2021.780739	http://dx.doi.org/10.3389/fimmu.2021.780739			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WP5NR		Green Published, gold			2022-12-18	WOS:000713178700001
J	McGill, MM; Richman, AR; Boyd, JR; Sabikunnahar, B; Lahue, KG; Montgomery, TL; Caldwell, S; Varnum, S; Frietze, S; Krementsov, DN				McGill, Mahalia M.; Richman, Alyssa R.; Boyd, Joseph R.; Sabikunnahar, Bristy; Lahue, Karolyn G.; Montgomery, Theresa L.; Caldwell, Sydney; Varnum, Stella; Frietze, Seth; Krementsov, Dimitry N.			p38 MAP Kinase Signaling in Microglia Plays a Sex-Specific Protective Role in CNS Autoimmunity and Regulates Microglial Transcriptional States	FRONTIERS IN IMMUNOLOGY			English	Article						multiple sclerosis; EAE (experimental autoimmune encephalomyelitis); microglia; sex differences; MAPK; p38 alpha; scRNAseq	ACTIVATED PROTEIN-KINASE; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; MULTIPLE-SCLEROSIS; DIFFERENTIAL ROLES; T-CELLS; MONOCYTES; REVEALS; MACROPHAGES; PHENOTYPES; HEALTH	Multiple sclerosis (MS) is an autoimmune demyelinating disease of the central nervous system, representing the leading cause of non-traumatic neurologic disease in young adults. This disease is three times more common in women, yet more severe in men, but the mechanisms underlying these sex differences remain largely unknown. MS is initiated by autoreactive T helper cells, but CNS-resident and CNS-infiltrating myeloid cells are the key proximal effector cells regulating disease pathology. We have previously shown that genetic ablation of p38 alpha MAP kinase broadly in the myeloid lineage is protective in the autoimmune model of MS, experimental autoimmune encephalomyelitis (EAE), but only in females, and not males. To precisely define the mechanisms responsible, we used multiple genetic approaches and bone marrow chimeras to ablate p38 alpha in microglial cells, peripheral myeloid cells, or both. Deletion of p38 alpha in both cell types recapitulated the previous sex difference, with reduced EAE severity in females. Unexpectedly, deletion of p38 alpha in the periphery was protective in both sexes. In contrast, deletion of p38 alpha in microglia exacerbated EAE in males only, revealing opposing roles of p38 alpha in microglia vs. periphery. Bulk transcriptional profiling revealed that p38 alpha regulated the expression of distinct gene modules in male vs. female microglia. Single-cell transcriptional analysis of WT and p38 alpha-deficient microglia isolated from the inflamed CNS revealed a diversity of complex microglial states, connected by distinct convergent transcriptional trajectories. In males, microglial p38 alpha deficiency resulted in enhanced transition from homeostatic to disease-associated microglial states, with the downregulation of regulatory genes such as Atf3, Rgs1, Socs3, and Btg2, and increased expression of inflammatory genes such as Cd74, Trem2, and MHC class I and II genes. In females, the effect of p38 alpha deficiency was divergent, exhibiting a unique transcriptional profile that included an upregulation of tissue protective genes, and a small subset of inflammatory genes that were also upregulated in males. Taken together, these results reveal a p38 alpha-dependent sex-specific molecular pathway in microglia that is protective in CNS autoimmunity in males, suggesting that autoimmunity in males and females is driven by distinct cellular and molecular pathways, thus suggesting design of future sex-specific therapeutic approaches.	[McGill, Mahalia M.; Richman, Alyssa R.; Boyd, Joseph R.; Sabikunnahar, Bristy; Lahue, Karolyn G.; Montgomery, Theresa L.; Caldwell, Sydney; Varnum, Stella; Frietze, Seth; Krementsov, Dimitry N.] Univ Vermont, Dept Biomed & Hlth Sci, Burlington, VT 05405 USA	University of Vermont	Krementsov, DN (corresponding author), Univ Vermont, Dept Biomed & Hlth Sci, Burlington, VT 05405 USA.	dkrement@uvm.edu			National Multiple Sclerosis Society	National Multiple Sclerosis Society(National Multiple Sclerosis Society)	The research reported here was supported by research grant RR-1602-07780 from the National Multiple Sclerosis Society and a technology development initiative pilot project (under grant U54 GM115516 from the National Institutes of Health for the Northern New England Clinical and Translational Research network) to DK. Research performed at the Flow Cytometry and Cell Sorting Facility at UVM was partially supported by NIGMS P20GM103496.	Abels ER, 2019, CELL REP, V28, P3105, DOI 10.1016/j.celrep.2019.08.036; Absinta M, 2021, NATURE, V597, P709, DOI 10.1038/s41586-021-03892-7; Acosta-Martinez M, 2020, J PHARMACOL EXP THER, V375, P223, DOI 10.1124/jpet.119.264598; Ajami B, 2018, NAT NEUROSCI, V21, P541, DOI 10.1038/s41593-018-0100-x; Araujo LP, 2019, CELL REP, V28, P3120, DOI 10.1016/j.celrep.2019.08.042; Arthur JSC, 2013, NAT REV IMMUNOL, V13, P679, DOI 10.1038/nri3495; Benedek G, 2017, J NEUROIMMUNOL, V305, P59, DOI 10.1016/j.jneuroim.2016.12.018; Benedek G, 2016, J NEUROIMMUNOL, V293, P45, DOI 10.1016/j.jneuroim.2016.02.009; Blankenhorn EP, 2011, ANN NEUROL, V70, P887, DOI 10.1002/ana.22642; Cao JY, 2019, NATURE, V566, P496, DOI 10.1038/s41586-019-0969-x; Chung SH, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.119; Clausen BE, 1999, TRANSGENIC RES, V8, P265, DOI 10.1023/A:1008942828960; Jordao MJC, 2019, SCIENCE, V363, P365, DOI 10.1126/science.aat7554; Cronk JC, 2018, J EXP MED, V215, P1627, DOI 10.1084/jem.20180247; Esaki Y, 2010, P NATL ACAD SCI USA, V107, P12233, DOI 10.1073/pnas.0915112107; Frohman EM, 2006, NEW ENGL J MED, V354, P942, DOI 10.1056/NEJMra052130; Gao H, 2017, CELL REP, V18, P198, DOI 10.1016/j.celrep.2016.11.083; Goldmann T, 2013, NAT NEUROSCI, V16, P1618, DOI 10.1038/nn.3531; Greenstein JI, 2007, DEV NEUROBIOL, V67, P1248, DOI 10.1002/dneu.20387; Haimon Z, 2018, NAT IMMUNOL, V19, P636, DOI 10.1038/s41590-018-0110-6; Hammond TR, 2019, IMMUNITY, V50, P253, DOI 10.1016/j.immuni.2018.11.004; Han JM, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21186824; Hanamsagar R, 2017, GLIA, V65, P1504, DOI 10.1002/glia.23176; Hao Yuhan, 2021, Cell, V184, P3573, DOI 10.1016/j.cell.2021.04.048; Hauser SL, 2013, ANN NEUROL, V74, P317, DOI 10.1002/ana.24009; Heppner FL, 2005, NAT MED, V11, P146, DOI 10.1038/nm1177; Holtman IR, 2017, J CLIN INVEST, V127, P3220, DOI 10.1172/JCI90604; Huang GH, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aaa2147; Huang GH, 2012, NAT IMMUNOL, V13, P152, DOI 10.1038/ni.2207; Ilicic T, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0888-1; Jirmanova L, 2011, BLOOD, V118, P3280, DOI 10.1182/blood-2011-01-333039; Keren-Shaul H, 2017, CELL, V169, P1276, DOI 10.1016/j.cell.2017.05.018; Kim C, 2008, NAT IMMUNOL, V9, P1019, DOI 10.1038/ni.1640; King IL, 2009, BLOOD, V113, P3190, DOI 10.1182/blood-2008-07-168575; Kodama L, 2019, TRENDS MOL MED, V25, P741, DOI 10.1016/j.molmed.2019.05.001; Krementsov DN, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01622; Krementsov DN, 2015, FASEB J, V29, P3446, DOI 10.1096/fj.15-272542; Krementsov DN, 2014, ANN NEUROL, V75, P50, DOI 10.1002/ana.24020; Krementsov DN, 2013, MOL CELL BIOL, V33, P3728, DOI 10.1128/MCB.00688-13; Lemarchand C, 2006, BIOMATERIALS, V27, P108, DOI 10.1016/j.biomaterials.2005.04.041; Li QY, 2019, NEURON, V101, P207, DOI 10.1016/j.neuron.2018.12.006; Lloyd AF, 2019, NAT NEUROSCI, V22, P1046, DOI [10.1038/s41593-019-0418-Z, 10.1038/s41593-019-0418-z]; Masuda T, 2020, CELL REP, V30, P1271, DOI 10.1016/j.celrep.2020.01.010; Masuda T, 2019, NATURE, V566, P388, DOI 10.1038/s41586-019-0924-x; McGill MM, 2020, J NEUROIMMUNOL, V342, DOI 10.1016/j.jneuroim.2020.577209; Mishra MK, 2016, NAT REV NEUROL, V12, P539, DOI 10.1038/nrneurol.2016.110; Mrdjen D, 2018, IMMUNITY, V48, P380, DOI 10.1016/j.immuni.2018.01.011; Nishida K, 2004, MOL CELL BIOL, V24, P10611, DOI 10.1128/MCB.24.24.10611-10620.2004; Noubade R, 2011, BLOOD, V118, P3290, DOI 10.1182/blood-2011-02-336552; Plemel JR, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aay6324; Ramagopalan SV, 2009, CURR OPIN NEUROL, V22, P219, DOI 10.1097/WCO.0b013e32832b5417; Raza A, 2017, J LEUKOCYTE BIOL, V102, P1219, DOI 10.1189/jlb.2AB0116-009RR; Rincon M, 2009, IMMUNOL REV, V228, P212, DOI 10.1111/j.1600-065X.2008.00744.x; Sawcer S, 2011, NATURE, V476, P214, DOI 10.1038/nature10251; Segal B, 2010, SEMIN IMMUNOPATHOL, V32, P71, DOI 10.1007/s00281-009-0186-z; Shemer A, 2015, SEMIN IMMUNOPATHOL, V37, P613, DOI 10.1007/s00281-015-0519-z; Sorge RE, 2015, NAT NEUROSCI, V18, P1081, DOI 10.1038/nn.4053; Sousa C, 2018, EMBO REP, V19, DOI 10.15252/embr.201846171; Spence RD, 2012, FRONT NEUROENDOCRIN, V33, P105, DOI 10.1016/j.yfrne.2011.12.001; Stankiewicz JM, 2014, NEUROBIOL AGING, V35, pS51, DOI 10.1016/j.neurobiolaging.2014.03.039; Steinman L, 2006, ANN NEUROL, V60, P12, DOI 10.1002/ana.20913; Stuart T, 2019, CELL, V177, P1888, DOI 10.1016/j.cell.2019.05.031; Thion MS, 2018, CELL, V172, P500, DOI 10.1016/j.cell.2017.11.042; Villa A, 2018, CELL REP, V23, P3501, DOI 10.1016/j.celrep.2018.05.048; Voet S, 2019, TRENDS MOL MED, V25, P112, DOI 10.1016/j.molmed.2018.11.005; Voskuhl RR, 2018, MULT SCLER J, V24, P22, DOI 10.1177/1352458517737394; Weiner HL, 2009, ANN NEUROL, V65, P239, DOI 10.1002/ana.21640; Wouters E, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01811; Wu WF, 2013, P NATL ACAD SCI USA, V110, P3543, DOI 10.1073/pnas.1300313110; Yamasaki R, 2014, J EXP MED, V211, P1533, DOI 10.1084/jem.20132477; Yona S, 2013, IMMUNITY, V38, P79, DOI 10.1016/j.immuni.2012.12.001; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118	72	0	1	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 11	2021	12								715311	10.3389/fimmu.2021.715311	http://dx.doi.org/10.3389/fimmu.2021.715311			21	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WU6XX	34707603	Green Published, gold			2022-12-18	WOS:000716687200001
J	Zhao, X; Wu, LZ; Ng, EKY; Leow, KWS; Wei, QR; Gascoigne, NRJ; Brzostek, J				Zhao, Xiang; Wu, Liang-Zhe; Ng, Esther K. Y.; Leow, Kerisa W. S.; Wei, Qianru; Gascoigne, Nicholas R. J.; Brzostek, Joanna			Non-Stimulatory pMHC Enhance CD8 T Cell Effector Functions by Recruiting Coreceptor-Bound Lck	FRONTIERS IN IMMUNOLOGY			English	Article						co-agonism; Lck; T cell receptor; non-stimulatory peptide MHC; T cell signaling; T cell effector functions; AKT pathway	MHC CLASS-I; NEGATIVE SELECTION; DENDRITIC CELLS; SELF; ACTIVATION; RESPONSES; RECEPTOR; NAIVE; DIFFERENTIATION; PEPTIDES	Under physiological conditions, CD8(+) T cells need to recognize low numbers of antigenic pMHC class I complexes in the presence of a surplus of non-stimulatory, self pMHC class I on the surface of the APC. Non-stimulatory pMHC have been shown to enhance CD8(+) T cell responses to low amounts of antigenic pMHC, in a phenomenon called co-agonism, but the physiological significance and molecular mechanism of this phenomenon are still poorly understood. Our data show that co-agonist pMHC class I complexes recruit CD8-bound Lck to the immune synapse to modulate CD8(+) T cell signaling pathways, resulting in enhanced CD8(+) T cell effector functions and proliferation, both in vitro and in vivo. Moreover, co-agonism can boost T cell proliferation through an extrinsic mechanism, with co-agonism primed CD8(+) T cells enhancing Akt pathway activation and proliferation in neighboring CD8(+) T cells primed with low amounts of antigen.	[Zhao, Xiang; Wu, Liang-Zhe; Ng, Esther K. Y.; Wei, Qianru; Gascoigne, Nicholas R. J.; Brzostek, Joanna] Natl Univ Singapore, Yong Loo Lin Sch Med, Immunol Translat Res Programme, Singapore, Singapore; [Zhao, Xiang; Wu, Liang-Zhe; Ng, Esther K. Y.; Leow, Kerisa W. S.; Wei, Qianru; Gascoigne, Nicholas R. J.; Brzostek, Joanna] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Microbiol & Immunol, Singapore, Singapore; [Zhao, Xiang] Stanford Univ, Sch Med, Dept Mol & Cellular Physiol, Stanford, CA 94305 USA; [Wei, Qianru] Weill Cornell Med, Dept Med, New York, NY USA; [Brzostek, Joanna] Univ Freiburg, Biol 3, Freiburg, Germany	National University of Singapore; National University of Singapore; Stanford University; Cornell University; University of Freiburg	Gascoigne, NRJ; Brzostek, J (corresponding author), Natl Univ Singapore, Yong Loo Lin Sch Med, Immunol Translat Res Programme, Singapore, Singapore.; Gascoigne, NRJ; Brzostek, J (corresponding author), Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Microbiol & Immunol, Singapore, Singapore.; Brzostek, J (corresponding author), Univ Freiburg, Biol 3, Freiburg, Germany.				Singapore Ministry of Healths National Medical Research Council [CBRG/0064/2014, OFIRG19nov-0066]	Singapore Ministry of Healths National Medical Research Council(National Medical Research Council, Singapore)	This research was supported by the Singapore Ministry of Healths National Medical Research Council under its CBRG/0064/2014 and OFIRG19nov-0066 to NG.	Anikeeva N, 2006, P NATL ACAD SCI USA, V103, P16846, DOI 10.1073/pnas.0607771103; Anikeeva N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041466; Apps R, 2013, SCIENCE, V340, P87, DOI 10.1126/science.1232685; Au-Yeung BB, 2017, J IMMUNOL, V198, P2445, DOI 10.4049/jimmunol.1601453; Bachmann MF, 1999, J EXP MED, V189, P1521, DOI 10.1084/jem.189.10.1521; Brzostek J, 2020, NAT IMMUNOL, V21, P186, DOI 10.1038/s41590-019-0570-3; Butler TC, 2013, P NATL ACAD SCI USA, V110, P11833, DOI 10.1073/pnas.1222467110; Casas J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6624; Cebecauer M, 2005, J BIOL CHEM, V280, P23820, DOI 10.1074/jbc.M500654200; Chudnovskiy A, 2019, CURR OPIN IMMUNOL, V58, P24, DOI 10.1016/j.coi.2019.02.002; Connolly A, 2021, SCI SIGNAL, V14, DOI 10.1126/scisignal.abb5146; Cruz-Guilloty F, 2009, J EXP MED, V206, P51, DOI 10.1084/jem.20081242; Davis Tessa R, 2010, J Vis Exp, DOI 10.3791/2066; DEMOTZ S, 1990, SCIENCE, V249, P1028, DOI 10.1126/science.2118680; Ebert PJR, 2009, NAT IMMUNOL, V10, P1162, DOI 10.1038/ni.1797; Fu G, 2013, NATURE, V504, P441, DOI 10.1038/nature12718; Fulton RB, 2015, NAT IMMUNOL, V16, P107, DOI 10.1038/ni.3043; Gaglia JL, 2001, CELL IMMUNOL, V213, P83, DOI 10.1006/cimm.2001.1867; Gainey MD, 2012, P NATL ACAD SCI USA, V109, pE3260, DOI 10.1073/pnas.1217111109; Gallimore A, 1998, J EXP MED, V187, P1647; Garrido F, 2016, CURR OPIN IMMUNOL, V39, P44, DOI 10.1016/j.coi.2015.12.007; Gascoigne NRJ, 2008, NAT REV IMMUNOL, V8, P895, DOI 10.1038/nri2431; Gascoigne NRJ, 2010, CURR TOP MICROBIOL, V340, P171, DOI 10.1007/978-3-642-03858-7_9; Gerard A, 2013, NAT IMMUNOL, V14, P356, DOI 10.1038/ni.2547; Hamilton KS, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005169; HARDING CV, 1990, NATURE, V346, P574, DOI 10.1038/346574a0; Hoerter JAH, 2013, J EXP MED, V210, P1807, DOI 10.1084/jem.20122528; Horkova V, 2020, CELL REP, V30, P1504, DOI 10.1016/j.celrep.2020.01.008; Juang J, 2010, J EXP MED, V207, P1223, DOI 10.1084/jem.20092170; Kaech SM, 2001, NAT IMMUNOL, V2, P415, DOI 10.1038/87720; Klein L, 2014, NAT REV IMMUNOL, V14, P377, DOI 10.1038/nri3667; Kotsiou E, 2011, ANTIOXID REDOX SIGN, V15, P645, DOI 10.1089/ars.2010.3694; Krogsgaard M, 2005, NATURE, V434, P238, DOI 10.1038/nature03391; LEVIN SD, 1993, J EXP MED, V178, P245, DOI 10.1084/jem.178.1.245; Lo WL, 2009, NAT IMMUNOL, V10, P1155, DOI 10.1038/ni.1796; Mempel TR, 2004, NATURE, V427, P154, DOI 10.1038/nature02238; Nakaya M, 2014, IMMUNITY, V40, P692, DOI 10.1016/j.immuni.2014.04.007; Nika K, 2010, IMMUNITY, V32, P766, DOI 10.1016/j.immuni.2010.05.011; Paster W, 2009, J IMMUNOL, V182, P2160, DOI 10.4049/jimmunol.0802639; Pearce EL, 2003, SCIENCE, V302, P1041, DOI 10.1126/science.1090148; Pope C, 2001, J IMMUNOL, V166, P3402, DOI 10.4049/jimmunol.166.5.3402; Preston GC, 2015, EMBO J, V34, P2008, DOI 10.15252/embj.201490252; Rathmell JC, 2001, J IMMUNOL, V167, P6869, DOI 10.4049/jimmunol.167.12.6869; Reeves E, 2017, IMMUNOLOGY, V150, P16, DOI 10.1111/imm.12675; Sabatos CA, 2008, IMMUNITY, V29, P238, DOI 10.1016/j.immuni.2008.05.017; Schrum Adam G, 2009, Curr Protoc Immunol, VChapter 5, DOI 10.1002/0471142735.im0509s87; Schuren ABC, 2016, CURR OPIN IMMUNOL, V40, P43, DOI 10.1016/j.coi.2016.02.007; Sprent J, 2008, IMMUNOL CELL BIOL, V86, P312, DOI 10.1038/icb.2008.12; Stepanek O, 2014, CELL, V159, P333, DOI 10.1016/j.cell.2014.08.042; van Stipdonk MJB, 2003, NAT IMMUNOL, V4, P361, DOI 10.1038/ni912; van Stipdonk MJB, 2001, NAT IMMUNOL, V2, P423, DOI 10.1038/87730; Voisinne G, 2015, CELL REP, V11, P1208, DOI 10.1016/j.celrep.2015.04.051; Wang RN, 2011, IMMUNITY, V35, P871, DOI 10.1016/j.immuni.2011.09.021; Wei QR, 2020, P NATL ACAD SCI USA, V117, P15809, DOI 10.1073/pnas.1913334117; Wulfing C, 2002, NAT IMMUNOL, V3, P42, DOI 10.1038/ni741; Yachi PP, 2007, J EXP MED, V204, P2747, DOI 10.1084/jem.20062610; Yachi PP, 2005, NAT IMMUNOL, V6, P785, DOI 10.1038/ni1220; Zenke S, 2020, IMMUNITY, V52, P313, DOI 10.1016/j.immuni.2020.01.018; Zhao X, 2019, JOVE-J VIS EXP, DOI 10.3791/59126; Zhao X, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05288-0	60	0	0	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 11	2021	12								721722	10.3389/fimmu.2021.721722	http://dx.doi.org/10.3389/fimmu.2021.721722			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XI5QJ	34707605	gold, Green Published			2022-12-18	WOS:000726165600001
J	Song, JF; Deng, T				Song, Jianfeng; Deng, Tuo			The Adipocyte and Adaptive Immunity (vol 11, 593058, 2020)	FRONTIERS IN IMMUNOLOGY			English	Correction						adipocyte; adaptive immunity; adipokine; T cell; B cell			[Song, Jianfeng; Deng, Tuo] Cent South Univ, Natl Clin Res Ctr Metab Dis, Xiangya Hosp 2, Changsha, Peoples R China; [Song, Jianfeng; Deng, Tuo] Cent South Univ, Dept Metab & Endocrinol, Xiangya Hosp 2, Changsha, Peoples R China; [Song, Jianfeng; Deng, Tuo] Cent South Univ, Key Lab Diabet Immunol, Xiangya Hosp 2, Minist Educ, Changsha, Peoples R China; [Song, Jianfeng; Deng, Tuo] Cent South Univ, Metab Syndrome Res Ctr, Xiangya Hosp 2, Changsha, Peoples R China; [Deng, Tuo] Cent South Univ, Clin Immunol Ctr, Xiangya Hosp 2, Changsha, Peoples R China	Central South University; Central South University; Central South University; Central South University; Central South University	Deng, T (corresponding author), Cent South Univ, Natl Clin Res Ctr Metab Dis, Xiangya Hosp 2, Changsha, Peoples R China.; Deng, T (corresponding author), Cent South Univ, Dept Metab & Endocrinol, Xiangya Hosp 2, Changsha, Peoples R China.; Deng, T (corresponding author), Cent South Univ, Key Lab Diabet Immunol, Xiangya Hosp 2, Minist Educ, Changsha, Peoples R China.; Deng, T (corresponding author), Cent South Univ, Metab Syndrome Res Ctr, Xiangya Hosp 2, Changsha, Peoples R China.; Deng, T (corresponding author), Cent South Univ, Clin Immunol Ctr, Xiangya Hosp 2, Changsha, Peoples R China.	dengtuo@csu.edu.cn	Song, Jianfeng/HGB-1253-2022					Song JF, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.593058	1	0	0	3	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 8	2021	12								784125	10.3389/fimmu.2021.784125	http://dx.doi.org/10.3389/fimmu.2021.784125			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WM6KM	34691088	Green Published, gold			2022-12-18	WOS:000711192300001
J	Brevet, P; Lattard, C; Guillou, C; Rottenberg, P; Fardellone, P; Le-Loet, X; Lequerre, T; Cosette, P; Boyer, O; Freret, M; Vittecoq, O				Brevet, Pauline; Lattard, Claire; Guillou, Clement; Rottenberg, Pascal; Fardellone, Patrice; Le-Loet, Xavier; Lequerre, Thierry; Cosette, Pascal; Boyer, Olivier; Freret, Manuel; Vittecoq, Olivier			Anti-Carbamylated Fibrinogen Antibodies Might Be Associated With a Specific Rheumatoid Phenotype and Include a Subset Recognizing In Vivo Epitopes of Its gamma Chain One of Which Is Not Cross Reactive With Anti-Citrullinated Protein Antibodies	FRONTIERS IN IMMUNOLOGY			English	Article						very early rheumatoid arthritis; anti-carbamylated protein antibodies (anti-CarP); fibrinogen; ACPA; prognosis	EARLY ARTHRITIS; IDENTIFICATION; AUTOANTIBODIES; OPPORTUNITY; WINDOW; TARGET; SERA	To identify the targets recognized by anti-carbamylated protein antibodies (anti-CarP) in patients with early Rheumatoid Arthritis (RA), to study the cross-reactivity between anti-CarP and anti-citrullinated protein antibodies (ACPA) and to evaluate their prognostic value. 331 patients (184 RA and 147 other rheumatisms) from the Very Early Arthritis (VErA) French cohort were analyzed. We performed mass spectrometry analysis of RA sera displaying anti-CarP activity and epitope mapping of the carbamylated fibrinogen gamma chain to identify immunodominant peptides. The specificity of these targets was studied using competition assays with the major antigens recognized by ACPA. The prognostic value of anti-carbamylated fibrinogen IgG antibodies (ACa-Fib IgG) was compared to that of anti-cyclic citrullinated peptide antibodies (anti-CCP) and anti-CarP using an in-house ELISA. Besides the alpha chain, the gamma chain of fibrinogen, particularly one immunodominant epitope that has a specific reactivity, was identified as a circulating carbamylated target in sera. The prevalence of ACa-Fib was 37% at baseline and 10.9% for anti-CCP-negative RA. In anti-CCP-negative patients, ACa-Fib positivity was associated with a more inflammatory and erosive disease at baseline but not with rapid radiological progression, which remains strongly related to anti-CCP antibodies. Fibrinogen seems to be one of the antigens recognized in vivo by the anti-CarP response, particularly 2 epitopes of the gamma chain, one of which is not cross reactive with ACPA. This specificity might be associated with a distinct clinical phenotype since ACa-Fib IgG were shown to be linked to systemic inflammation in very early RA but not to rapid radiological progression.	[Brevet, Pauline; Lattard, Claire; Rottenberg, Pascal; Le-Loet, Xavier; Lequerre, Thierry; Freret, Manuel; Vittecoq, Olivier] Rouen Univ Hosp, Dept Rheumatol, Rouen, France; [Brevet, Pauline; Lattard, Claire; Rottenberg, Pascal; Le-Loet, Xavier; Lequerre, Thierry; Freret, Manuel; Vittecoq, Olivier] CIC CRB1404, Rouen, France; [Brevet, Pauline; Lequerre, Thierry; Boyer, Olivier; Freret, Manuel; Vittecoq, Olivier] Normandie Univ, UNIROUEN, INSERM, U1234, Rouen, France; [Lattard, Claire] Rouen Univ Hosp, Dept Pharmacol, Rouen, France; [Guillou, Clement; Cosette, Pascal] Normandie Univ, UNIROUEN, PISSARO Prote Facil, Rouen, France; [Guillou, Clement; Cosette, Pascal] CNRS, IRIB, PBS UMR6270, Rouen, France; [Fardellone, Patrice] Amiens Univ Hosp, Dept Rheumatol, Amiens, France; [Boyer, Olivier] Rouen Univ Hosp, Dept Immunol, Rouen, France	CHU de Rouen; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Rouen; Centre National de la Recherche Scientifique (CNRS); Picardie Universites; Universite de Picardie Jules Verne (UPJV); CHU Amiens; CHU de Rouen	Vittecoq, O (corresponding author), Rouen Univ Hosp, Dept Rheumatol, Rouen, France.; Vittecoq, O (corresponding author), CIC CRB1404, Rouen, France.; Vittecoq, O (corresponding author), Normandie Univ, UNIROUEN, INSERM, U1234, Rouen, France.	vittecoq.olivier@wanadoo.fr			MSD	MSD	Funding This work was supported by a grant from MSD and Novartis (DREAMER bursary) and financial support from Fondation Arthritis. The funders were not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication.	Ajeganova S, 2017, ANN RHEUM DIS, V76, P112, DOI 10.1136/annrheumdis-2015-208870; Cornillet M, 2014, ANN RHEUM DIS, V73, P1246, DOI 10.1136/annrheumdis-2012-202868; Fautrel B, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar4092; Gaviard C, 2019, J PROTEOME RES, V18, P923, DOI 10.1021/acs.jproteome.8b00556; Jones JD, 2017, ARTHRITIS RHEUMATOL, V69, P1381, DOI 10.1002/art.40098; Juarez M, 2016, ANN RHEUM DIS, V75, P1099, DOI 10.1136/annrheumdis-2014-206785; Kissel T, 2020, ANN RHEUM DIS, V79, P472, DOI 10.1136/annrheumdis-2019-216499; Lac P, 2018, J RHEUMATOL, V45, P302, DOI 10.3899/jrheum.170446; Le Loet X, 2015, JOINT BONE SPINE, V82, P38, DOI 10.1016/j.jbspin.2014.03.008; Lo KC, 2020, ARTHRITIS RHEUMATOL, V72, P242, DOI 10.1002/art.41089; Mahler M, 2003, CLIN IMMUNOL, V107, P65, DOI 10.1016/S1521-6616(03)00037-8; Martinez G, 2016, RHEUMATOL INT, V36, P781, DOI 10.1007/s00296-016-3472-9; Nakabo S, 2017, RHEUMATOLOGY, V56, P1217, DOI 10.1093/rheumatology/kex088; Obry A, 2015, THERANOSTICS, V5, P1214, DOI 10.7150/thno.12403; Reed E, 2016, ARTHRITIS RES THER, V18, DOI 10.1186/s13075-016-1001-6; Sahlstrom P, 2020, ARTHRITIS RHEUMATOL, V72, P1643, DOI 10.1002/art.41385; Scinocca M, 2014, J RHEUMATOL, V41, P270, DOI 10.3899/jrheum.130742; Shi J, 2011, P NATL ACAD SCI USA, V108, P17372, DOI 10.1073/pnas.1114465108; Truchetet ME, 2017, ARTHRITIS RHEUMATOL, V69, P2292, DOI 10.1002/art.40237; van de Stadt LA, 2013, ANN RHEUM DIS, V72, P1920, DOI 10.1136/annrheumdis-2012-202127; van Delft MAM, 2018, RHEUMATOLOGY, V57, P1583, DOI 10.1093/rheumatology/key135; van Nies JAB, 2015, ANN RHEUM DIS, V74, P806, DOI 10.1136/annrheumdis-2014-206047; van Nies JAB, 2014, ANN RHEUM DIS, V73, P861, DOI 10.1136/annrheumdis-2012-203130; Verheul MK, 2021, CLIN EXP RHEUMATOL, V39, P570, DOI 10.55563/clinexprheumatol/0ms5pk; Verheul MK, 2017, J AUTOIMMUN, V80, P77, DOI 10.1016/j.jaut.2017.02.008; Yu HC, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17091510	26	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 7	2021	12								733511	10.3389/fimmu.2021.733511	http://dx.doi.org/10.3389/fimmu.2021.733511			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WK6PH	34691039	gold, Green Published			2022-12-18	WOS:000709846500001
J	Feng, JJ; Fan, SY; Sun, YW; Ren, HT; Guan, HZ; Wang, J				Feng, Jingjing; Fan, Siyuan; Sun, Yinwei; Ren, Haitao; Guan, Hongzhi; Wang, Jing			Comprehensive B-Cell Immune Repertoire Analysis of Anti-NMDAR Encephalitis and Anti-LGI1 Encephalitis	FRONTIERS IN IMMUNOLOGY			English	Article						anti-N-methyl-D-aspartate receptor encephalitis; anti-leucine-rich glioma-inactivated 1 encephalitis; B-cell immune repertoire; common clones; adaptive immune responses	RECEPTOR ENCEPHALITIS; ANTIBODIES; DIAGNOSIS	Anti-N-methyl-D-aspartate receptor encephalitis (anti-NMDARE) and anti-leucine-rich glioma-inactivated 1 encephalitis (anti-LGI1E) are the two most common types of antibody-mediated autoimmune encephalitis. We performed a comprehensive analysis of the B-cell immune repertoire in patients with anti-NMDARE (n = 7) and anti-LGI1E (n = 10) and healthy controls (n = 4). The results revealed the presence of many common clones between patients with these two types of autoimmune encephalitis, which were mostly class-switched. Additionally, many differences were found among the anti-NMDARE, anti-LGI1E, and healthy control groups, including the diversity of the B-cell immune repertoire and gene usage preference. These findings suggest that the same adaptive immune responses occur in patients with anti-NMDARE and anti-LGI1E, which deserves further exploration.	[Feng, Jingjing; Sun, Yinwei; Wang, Jing] Chinese Acad Sci, Inst Psychol, CAS Key Lab Mental Hlth, Beijing, Peoples R China; [Feng, Jingjing; Sun, Yinwei; Wang, Jing] Univ Chinese Acad Sci, Dept Psychol, Beijing, Peoples R China; [Fan, Siyuan; Ren, Haitao; Guan, Hongzhi] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Neurol, Beijing, Peoples R China	Chinese Academy of Sciences; Institute of Psychology, CAS; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Peking Union Medical College Hospital	Wang, J (corresponding author), Chinese Acad Sci, Inst Psychol, CAS Key Lab Mental Hlth, Beijing, Peoples R China.; Wang, J (corresponding author), Univ Chinese Acad Sci, Dept Psychol, Beijing, Peoples R China.; Guan, HZ (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Neurol, Beijing, Peoples R China.	guanhz@263.net; wangjing@psych.ac.cn			CAS Key Laboratory of Mental Health	CAS Key Laboratory of Mental Health	Funding This work was supported by the CAS Key Laboratory of Mental Health, Institute of Psychology, Chinese Academy of Sciences and Peking Union Medical College Hospital Youth Program (Grant No. pumch201911390).	Ahmed R, 2019, CELL, V177, P1583, DOI 10.1016/j.cell.2019.05.007; Armangue T, 2014, ANN NEUROL, V75, P317, DOI 10.1002/ana.24083; Bolotin DA, 2015, NAT METHODS, V12, P380, DOI 10.1038/nmeth.3364; Castillo-Gomez E, 2017, MOL PSYCHIATR, V22, P1776, DOI 10.1038/mp.2016.125; Chao A, 2009, ECOLOGY, V90, P1125, DOI 10.1890/07-2147.1; Cowan GJM, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00395; Dalmau J, 2019, LANCET NEUROL, V18, P1045, DOI 10.1016/S1474-4422(19)30244-3; Dalmau J, 2017, PHYSIOL REV, V97, P839, DOI 10.1152/physrev.00010.2016; Dalmau J, 2016, NEUROLOGY, V87, P2471, DOI 10.1212/WNL.0000000000003414; Emerson RO, 2017, NAT GENET, V49, P659, DOI 10.1038/ng.3822; Feng JJ, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01539; Gleichman AJ, 2012, J NEUROSCI, V32, P11082, DOI 10.1523/JNEUROSCI.0064-12.2012; Graus F, 2016, LANCET NEUROL, V15, P391, DOI 10.1016/S1474-4422(15)00401-9; Gresa-Arribas N, 2014, LANCET NEUROL, V13, P167, DOI 10.1016/S1474-4422(13)70282-5; Gupta NT, 2015, BIOINFORMATICS, V31, P3356, DOI 10.1093/bioinformatics/btv359; Hu SY, 2021, NEUROL SCI, V42, P857, DOI 10.1007/s10072-020-04785-9; Jiang XY, 2020, ACTA NEUROPATHOL COM, V8, DOI 10.1186/s40478-020-00999-2; Kovaltsuk A, 2018, J IMMUNOL, V201, P2502, DOI 10.4049/jimmunol.1800708; Krawczyk K, 2019, MABS-AUSTIN, V11, P1197, DOI 10.1080/19420862.2019.1633884; Lehmann-Horn K, 2020, NEUROL-NEUROIMMUNOL, V7, DOI 10.1212/NXI.0000000000000669; Liu X, 2019, ANN RHEUM DIS, V78, P1070, DOI 10.1136/annrheumdis-2019-215442; Malviya M, 2017, ANN CLIN TRANSL NEUR, V4, P768, DOI 10.1002/acn3.444; Petit-Pedrol M, 2018, BRAIN, V141, P3144, DOI 10.1093/brain/awy253; Ramberger M, 2020, BRAIN, V143, P1731, DOI 10.1093/brain/awaa104; Sayers EW, 2020, NUCLEIC ACIDS RES, V48, pD84, DOI [10.1093/nar/gkz956, 10.1093/nar/gkaa1023]; Sharma R, 2018, ANN CLIN TRANSL NEUR, V5, P935, DOI 10.1002/acn3.592; Shugay M, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004503; Soto C, 2020, CELL REP, V32, DOI 10.1016/j.celrep.2020.107882; Soto C, 2019, NATURE, V566, P398, DOI 10.1038/s41586-019-0934-8; Tachibana N, 2010, INTERNAL MED, V49, P2167, DOI 10.2169/internalmedicine.49.4069; Thomas PG, 2013, P NATL ACAD SCI USA, V110, P1839, DOI 10.1073/pnas.1222149110; Titulaer MJ, 2013, LANCET NEUROL, V12, P157, DOI 10.1016/S1474-4422(12)70310-1; Tuzun E, 2009, ACTA NEUROPATHOL, V118, P737, DOI 10.1007/s00401-009-0582-4; van Sonderen A, 2017, NAT REV NEUROL, V13, P290, DOI 10.1038/nrneurol.2017.43; van Sonderen A, 2016, NEUROLOGY, V87, P1449; Vita R, 2019, NUCLEIC ACIDS RES, V47, pD339, DOI 10.1093/nar/gky1006; Wang LW, 2019, ARTHRITIS RES THER, V21, DOI 10.1186/s13075-019-2069-6; Wenke NK, 2019, ANN NEUROL, V85, P771, DOI 10.1002/ana.25460; Xu XL, 2020, NEUROL-NEUROIMMUNOL, V7, DOI 10.1212/NXI.0000000000000633	39	0	0	1	11	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 7	2021	12								717598	10.3389/fimmu.2021.717598	http://dx.doi.org/10.3389/fimmu.2021.717598			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WK8HG	34691026	Green Published, gold			2022-12-18	WOS:000709961700001
J	Gentile, A; D'Acquisto, F; Leposavic, G				Gentile, Antonietta; D'Acquisto, Fulvio; Leposavic, Gordana			Editorial: The Bidirectional Communication Between Neurons and Immune Cells in the Development of Psychiatric, Neurological and Immune-Mediated Disorders	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						neuroimmune axis; autoimmunity; T cells; microglia and macrophages; animal models			[Gentile, Antonietta] IRCCS San Raffaele Pisana, Synapt Immunopathol Lab, Rome, Italy; [D'Acquisto, Fulvio] Univ Roehampton, Sch Life Sci, London, England; [Leposavic, Gordana] Univ Belgrade, Fac Pharm, Dept Pathobiol, Belgrade, Serbia	IRCCS San Raffaele Pisana; Roehampton University; University of Belgrade	Gentile, A (corresponding author), IRCCS San Raffaele Pisana, Synapt Immunopathol Lab, Rome, Italy.	gntnnt01@uniroma2.it	D'Acquisto, Fulvio/E-7204-2018; Gentile, Antonietta/I-5765-2018	D'Acquisto, Fulvio/0000-0002-4513-1608; Gentile, Antonietta/0000-0003-2456-0769	Italian Ministry of Health [GR-2018-12366154]	Italian Ministry of Health(Ministry of Health, Italy)	& nbsp;AG acknowledges support from the Italian Ministry of Health (GR-2018-12366154).	Bellinger DL, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19041188; Catterall W. A., 2013, ENCY BIOL CHEM, P564, DOI DOI 10.1016/B978-0-12-378630-2.00208-5; Chavan SS, 2017, IMMUNITY, V46, P927, DOI 10.1016/j.immuni.2017.06.008; Gardoni F, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10010077; Rizzo FR, 2018, NEURAL PLAST, V2018, DOI 10.1155/2018/8430123; Salvador AF, 2021, NAT REV IMMUNOL, V21, P526, DOI 10.1038/s41577-021-00508-z	6	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 7	2021	12								781151	10.3389/fimmu.2021.781151	http://dx.doi.org/10.3389/fimmu.2021.781151			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WM3SO	34691086	Green Published, gold			2022-12-18	WOS:000711008700001
J	Peng, ZC; Zhao, CX; Du, XL; Yang, YC; Li, YF; Song, YX; Fang, BC; Zhang, YM; Qin, X; Zhang, YY; Li, XB; Wang, Z; Li, XW; Liu, GW				Peng, Zhicheng; Zhao, Chenxu; Du, Xiliang; Yang, Yuchen; Li, Yunfei; Song, Yuxiang; Fang, Baochen; Zhang, Yuming; Qin, Xia; Zhang, Yuanyuan; Li, Xiaobing; Wang, Zhe; Li, Xinwei; Liu, Guowen			Autophagy Induced by Palmitic Acid Regulates Neutrophil Adhesion Through the Granule-Dependent Degradation of alpha M beta 2 Integrin in Dairy Cows With Fatty Liver	FRONTIERS IN IMMUNOLOGY			English	Article						fatty liver dairy cow; palmitic acid; neutrophil; granule; autophagy; vacuolation; alpha M beta 2 integrin; adhesion	POLYMORPHONUCLEAR LEUKOCYTES; GELATINASE GRANULES; MEDIATED AUTOPHAGY; OXIDIZED PROTEINS; LFA-1; LOCALIZATION; RECOGNITION; DEFICIENCY; EXPRESSION; MOLECULES	beta 2 integrins are critical for neutrophil firm adhesion, trans-endothelial migration, and the recruitment to the inflamed tissue. Autophagy is implicated in cell migration and tumor metastasis through facilitating the turnover of beta 1 integrins; however, whether autophagy is able to control neutrophil migration by promoting the degradation of beta 2 integrins is unexplored. Here, we show that high blood levels of palmitic acid (PA) strongly triggered neutrophil autophagy activation, leading to adhesion deficiency in dairy cows with fatty liver. The three neutrophil granule subtypes, namely, azurophil granules (AGs), specific granules (SGs), and gelatinase granules (GGs), were engulfed by the autophagosomes for degradation, resulting in an increased vacuolation in fatty liver dairy cow neutrophils. Importantly, the adhesion-associated molecules CD11b and CD18 distributed on AGs, SGs, and GGs were degraded with the three granule subtypes by autophagy. Moreover, FGA, Hsc70, and TRIM21 mediated the degradation of cytosolic oxidized-ubiquitinated CD11b and CD18. Collectively, our results demonstrate that high blood PA triggers neutrophil autophagy-dependent vacuolation and granule-dependent adhesion deficiency, decreasing neutrophil mobility, and impairing the innate immune system of dairy cow with fatty liver. This theory extends the category of autophagy in maintaining granule homeostasis and provides a novel strategy to improve the immune of dairy cows with metabolic disease.	[Peng, Zhicheng; Zhao, Chenxu; Du, Xiliang; Yang, Yuchen; Li, Yunfei; Song, Yuxiang; Zhang, Yuming; Qin, Xia; Zhang, Yuanyuan; Li, Xiaobing; Wang, Zhe; Li, Xinwei; Liu, Guowen] Jilin Univ, Coll Vet Med, Key Lab Zoonosis, Minist Educ, Changchun, Jilin, Peoples R China; [Fang, Baochen] Jilin Univ, Coll Food Sci & Engn, Changchun, Jilin, Peoples R China	Jilin University; Jilin University	Liu, GW (corresponding author), Jilin Univ, Coll Vet Med, Key Lab Zoonosis, Minist Educ, Changchun, Jilin, Peoples R China.	liuguowen2008@163.com	Yang, Yuchen/GZK-6062-2022; zhang, yuanyuan/GYA-4428-2022; , Yuxiang/F-1446-2019	, Yuxiang/0000-0002-9392-715X	National Natural Science Foundation of China (Beijing, China) [31672621, 31772810]	National Natural Science Foundation of China (Beijing, China)(National Natural Science Foundation of China (NSFC))	Acknowledgments This work was supported by the National Natural Science Foundation of China (Beijing, China; grant no. 31672621 and 31772810). We thank Dr. Alan Y. Hsu (Harvard medical school) for assistance in writing and editing the manuscript.	Abram CL, 2009, ANNU REV IMMUNOL, V27, P339, DOI 10.1146/annurev.immunol.021908.132554; ANDERSON DC, 1987, ANNU REV MED, V38, P175, DOI 10.1146/annurev.med.38.1.175; Bhattacharya A, 2015, CELL REP, V12, P1731, DOI 10.1016/j.celrep.2015.08.019; Blomgran R, 2007, J LEUKOCYTE BIOL, V81, P1213, DOI 10.1189/jlb.0506359; Bobe G, 2004, J DAIRY SCI, V87, P3105, DOI 10.3168/jds.S0022-0302(04)73446-3; Borregaard N, 1997, ANN NY ACAD SCI, V832, P62, DOI 10.1111/j.1749-6632.1997.tb46237.x; Borregaard N, 2007, TRENDS IMMUNOL, V28, P340, DOI 10.1016/j.it.2007.06.002; Bos JL, 2003, BIOCHEM SOC T, V31, P83, DOI 10.1042/bst0310083; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; Chetty-Raju Nina, 2004, Br J Haematol, V127, P478, DOI 10.1111/j.1365-2141.2004.05192.x; Cowland JB, 2016, IMMUNOL REV, V273, P11, DOI 10.1111/imr.12440; CRAMER E, 1985, BLOOD, V65, P423; Davies KJA, 2001, BIOCHIMIE, V83, P301, DOI 10.1016/S0300-9084(01)01250-0; DIMANCHE MT, 1987, EUR J IMMUNOL, V17, P417, DOI 10.1002/eji.1830170318; Ding WX, 2010, J BIOL CHEM, V285, P27879, DOI 10.1074/jbc.M110.119537; Faurschou M, 2003, MICROBES INFECT, V5, P1317, DOI 10.1016/j.micinf.2003.09.008; GRANGE MJ, 1980, NOUV PRESSE MED, V9, P2553; Jung T, 2007, ARCH BIOCHEM BIOPHYS, V462, P231, DOI 10.1016/j.abb.2007.01.030; KEHRLI ME, 1990, AM J VET RES, V51, P1826; Kirkin V, 2009, MOL CELL, V34, P259, DOI 10.1016/j.molcel.2009.04.026; KJELDSEN L, 1993, BLOOD, V82, P3183; KJELDSEN L, 1994, BLOOD, V83, P1640, DOI 10.1182/blood.V83.6.1640.bloodjournal8361640; LASZLO L, 1991, FEBS LETT, V279, P175, DOI 10.1016/0014-5793(91)80142-P; LeBlanc SJ, 2020, ANIMAL, V14, pS44, DOI 10.1017/S1751731119003227; Lee EK, 1998, AM J VET RES, V59, P37; Lobert VH, 2010, DEV CELL, V19, P148, DOI 10.1016/j.devcel.2010.06.010; Lominadze G, 2005, MOL CELL PROTEOMICS, V4, P1503, DOI 10.1074/mcp.M500143-MCP200; Matsuda N, 2010, J CELL BIOL, V189, P211, DOI 10.1083/jcb.200910140; Mihalache CC, 2011, J IMMUNOL, V186, P6532, DOI 10.4049/jimmunol.1004055; Narendra DP, 2010, AUTOPHAGY, V6, P1090, DOI 10.4161/auto.6.8.13426; OHASHI Y, 1993, HUM MUTAT, V2, P458, DOI 10.1002/humu.1380020606; Papadopoulos C, 2017, CURR BIOL, V27, pR1330, DOI 10.1016/j.cub.2017.11.012; Perretti M, 2000, CELL BIOL INT, V24, P163, DOI 10.1006/cbir.1999.0468; QUIE PG, 1967, J CLIN INVEST, V46, P668, DOI 10.1172/JCI105568; Rains JL, 2011, AM J PHYSIOL-ENDOC M, V301, pE298, DOI 10.1152/ajpendo.00038.2011; Remijsen Q, 2011, CELL RES, V21, P290, DOI 10.1038/cr.2010.150; RIKIHISA Y, 1984, ANAT REC, V208, P319, DOI 10.1002/ar.1092080302; Sharifi MN, 2016, CELL REP, V15, P1660, DOI 10.1016/j.celrep.2016.04.065; Smith CW, 2008, J ALLERGY CLIN IMMUN, V121, pS375, DOI 10.1016/j.jaci.2007.07.030; SPRINGER TA, 1995, ANNU REV PHYSIOL, V57, P827, DOI 10.1146/annurev.ph.57.030195.004143; Subramanian KK, 2007, BLOOD, V109, P4028, DOI 10.1182/blood-2006-10-055319; Kuwabara WMT, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00024; Wang B, 2016, AUTOPHAGY, V12, P1215, DOI 10.1080/15548627.2016.1179401; Wegner CS, 2010, HISTOCHEM CELL BIOL, V133, P41, DOI 10.1007/s00418-009-0643-8; ZIEVE PD, 1966, ARCH INTERN MED, V118, P356, DOI 10.1001/archinte.118.4.356	45	0	0	3	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 7	2021	12								726829	10.3389/fimmu.2021.726829	http://dx.doi.org/10.3389/fimmu.2021.726829			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WK6AF	34691032	gold, Green Published			2022-12-18	WOS:000709806400001
J	Wurm-Kuczera, RI; Buentzel, J; Koenig, JFL; Legler, T; Valk, JJ; Hasenkamp, J; Jung, W; Rademacher, JG; Korsten, P; Wulf, GG				Wurm-Kuczera, Rebecca Isabel; Buentzel, Judith; Koenig, Julia Felicitas Leni; Legler, Tobias; Valk, Jan-Jakob; Hasenkamp, Justin; Jung, Wolfram; Rademacher, Jan-Gerd; Korsten, Peter; Wulf, Gerald Georg			Sarcoidosis Following Hematopoietic Stem Cell Transplantation: Clinical Characteristics and HLA Associations	FRONTIERS IN IMMUNOLOGY			English	Article						sarcoidosis; hematopoietic stem cell transplantation; HLA; allo and autologous transplantation; immunology	IDIOPATHIC PNEUMONIA SYNDROME; SUSCEPTIBILITY; CHEMOTHERAPY; PROGRESSION; MECHANISMS; HLA-DRB1; LYMPHOMA	Purpose Extrinsic factors and genetic predisposition contribute to the etiology of sarcoidosis, converging in a phenotype of altered immune response associated with multisystemic inflammatory granulomatous tissue infiltration. Immunological reconstitution after hematopoietic stem cell transplantation (HSCT) may represent a unique window for the pathogenesis of the disease. We describe the incidence, clinicopathological features, and HLA associations of sarcoidosis after HSCT in a single-center cohort of patients, together with data from previously published cases. Methods We retrospectively analyzed clinical characteristics and HLA haplotypes from allogeneic (allo) or autologous (auto) HSCT patients from January 2001 through May 2021 at the University Medicine Goettingen (UMG), and data from previously published cases. Results A total number of 19 patients was identified. These included 4 patients from our center (3 allo HSCT and 1 auto HSCT) and 15 patients from the literature review. Thirteen patients had received an allo HSCT, and six patients had received an auto HSCT. Sarcoidosis occurred after a median interval of 20 (after allo HSCT) and 7 (after auto HSCT) months, respectively. The predominant HLA allele associated with sarcoidosis was HLA DRB1*03:01. Sarcoidosis involved the respiratory tract in 15 patients (three unknown, one without pulmonary involvement), and it was associated with graft-versus-host disease in 7 of 13 patients receiving allo HSCT. None of the donors or patients had a history of sarcoidosis before transplantation. Disease manifestations resolved with standard glucocorticoid treatment without long-term sequelae. Conclusion Sarcoidosis may occur at low frequency during reconstitution of the immune system after HSCT. HLA allele associations reflect the associations observed in the general population, particularly with DRB1*03:01. Further insights into the interplay between Tcell reconstitution and the development of sarcoidosis could also provide novel approaches to an improved understanding of the pathogenesis in sarcoidosis.	[Wurm-Kuczera, Rebecca Isabel; Buentzel, Judith; Koenig, Julia Felicitas Leni; Hasenkamp, Justin; Jung, Wolfram; Wulf, Gerald Georg] Univ Med Ctr Goettingen, Dept Hematol & Med Oncol, Gottingen, Germany; [Legler, Tobias; Valk, Jan-Jakob] Univ Med Ctr Goettingen, Dept Transfus Med, Gottingen, Germany; [Rademacher, Jan-Gerd; Korsten, Peter] Univ Med Ctr Goettingen, Dept Nephrol & Rheumatol, Gottingen, Germany	University of Gottingen; University of Gottingen; University of Gottingen	Wurm-Kuczera, RI (corresponding author), Univ Med Ctr Goettingen, Dept Hematol & Med Oncol, Gottingen, Germany.; Korsten, P (corresponding author), Univ Med Ctr Goettingen, Dept Nephrol & Rheumatol, Gottingen, Germany.	rebecca.wurm@med.uni-goettingen.de; peter.korsten@med.uni-goettingen.de		Korsten, Peter/0000-0001-6065-5680	Open Access Publication Funds of the Gottingen University	Open Access Publication Funds of the Gottingen University	Funding We acknowledge support by the Open Access Publication Funds of the Gottingen University.	Baughman RP, 2011, AM J RESP CRIT CARE, V183, P573, DOI 10.1164/rccm.201006-0865CI; Bhagat R, 2004, CHEST, V126, P642, DOI 10.1378/chest.126.2.642; Bhalla KS, 2002, AM J RESP CRIT CARE, V166, P1579, DOI 10.1164/rccm.200201-044OC; BREWERTON DA, 1977, CLIN EXP IMMUNOL, V27, P227; BRINCKER H, 1992, ACTA ONCOL, V31, P85, DOI 10.3109/02841869209088273; BRINCKER H, 1986, BRIT J CANCER, V54, P467, DOI 10.1038/bjc.1986.199; BRINCKER H, 1986, CANCER TREAT REV, V13, P147, DOI 10.1016/0305-7372(86)90002-2; Brincker H, 1974, Ugeskr Laeger, V136, P2192; Cacoub P, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0238391; Calender A, 2020, J CLIN MED, V9, DOI 10.3390/jcm9082633; Candore G, 1998, PATHOBIOLOGY, V66, P33, DOI 10.1159/000027992; Co DO, 2004, IMMUNOL LETT, V92, P135, DOI 10.1016/j.imlet.2003.11.023; Conron M, 2001, CLIN EXP ALLERGY, V31, P543, DOI 10.1046/j.1365-2222.2001.01116.x; Costabel U, 2017, KLIN MONATSBL AUGENH, V234, P790, DOI 10.1055/s-0042-105569; EFI, 2019, EUR FED IMM STAND HI, P1; Ferrara JLM, 2006, SEMIN HEMATOL, V43, P3, DOI 10.1053/j.seminhematol.2005.09.001; Fischer A, 2015, CURR OPIN PULM MED, V21, P510, DOI 10.1097/MCP.0000000000000189; Gonzalez-Galarza FF, 2020, NUCLEIC ACIDS RES, V48, pD783, DOI 10.1093/nar/gkz1029; Gooneratne L, 2007, BONE MARROW TRANSPL, V39, P511, DOI 10.1038/sj.bmt.1705606; Graf J, 2018, MULT SCLER J, V24, P1776, DOI 10.1177/1352458518771276; Grunewald J, 2019, NAT REV DIS PRIMERS, V5, DOI 10.1038/s41572-019-0096-x; HEYLL A, 1994, BONE MARROW TRANSPL, V14, P161; Iannuzzi MC, 2007, NEW ENGL J MED, V357, P2153, DOI 10.1056/NEJMra071714; Kornacker M, 2002, ANN HEMATOL, V81, P103, DOI 10.1007/s00277-001-0415-6; Kushima H, 2013, EUR RESPIR J, V41, P1452, DOI 10.1183/09031936.00136112; Lenarsky C, 1995, Curr Opin Hematol, V2, P409; Levin AM, 2015, AM J RESP CELL MOL, V53, P206, DOI 10.1165/rcmb.2014-0227OC; Love B, 2020, MULT SCLER RELAT DIS, V46, DOI 10.1016/j.msard.2020.102526; Manalo Iviensan F, 2016, JAAD Case Rep, V2, P138, DOI 10.1016/j.jdcr.2016.01.008; Marchal A, 2017, REV MED INTERNE, V38, P619, DOI 10.1016/j.revmed.2017.01.001; MERCHANT TE, 1994, LEUKEMIA LYMPHOMA, V13, P339, DOI 10.3109/10428199409056299; Mohty M, 2007, LEUKEMIA, V21, P1387, DOI 10.1038/sj.leu.2404683; Morita R, 2009, BONE MARROW TRANSPL, V43, P507, DOI 10.1038/bmt.2008.340; Muller-Quernheim Joachim, 2012, Presse Med, V41, pe275, DOI 10.1016/j.lpm.2012.03.018; Noor A, 2007, CLIN DERMATOL, V25, P250, DOI 10.1016/j.clindermatol.2007.03.002; Panoskaltsis-Mortari A, 2000, BLOOD, V96, P834, DOI 10.1182/blood.V96.3.834.015k39_834_839; Pfeuffer S, 2018, MULT SCLER J, V24, P1783, DOI 10.1177/1352458518804124; Porrata LF, 2001, MAYO CLIN PROC, V76, P407; Pukiat S, 2011, BONE MARROW TRANSPL, V46, P1032, DOI 10.1038/bmt.2010.235; Rivera NV, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-54612-1; Rossman MD, 2003, AM J HUM GENET, V73, P720, DOI 10.1086/378097; Sato H, 2002, AM J RESP CELL MOL, V27, P406, DOI 10.1165/rcmb.4782; Sato H, 2010, HUM MOL GENET, V19, P4100, DOI 10.1093/hmg/ddq325; Sundar KM, 2001, BONE MARROW TRANSPL, V28, P627, DOI 10.1038/sj.bmt.1703192; Tauro S, 2001, BONE MARROW TRANSPL, V27, P757, DOI 10.1038/sj.bmt.1702874; Teo M, 2013, ACTA ONCOL, V52, P869, DOI 10.3109/0284186X.2012.689854; Valeyre D, 2014, LANCET, V383, P1155, DOI 10.1016/S0140-6736(13)60680-7; Velardi E, 2021, NAT REV IMMUNOL, V21, P277, DOI 10.1038/s41577-020-00457-z; Voorter CEM, 2007, TISSUE ANTIGENS, V70, P18, DOI 10.1111/j.1399-0039.2007.00842.x; Wennerstrom A, 2012, HUM IMMUNOL, V73, P93, DOI 10.1016/j.humimm.2011.10.016; Willis MD, 2018, MULT SCLER J, V24, P1779, DOI 10.1177/1352458518790391; Zhou Y, 2011, HUM IMMUNOL, V72, P571, DOI 10.1016/j.humimm.2011.03.020; Zissel G, 2007, SEMIN RESP CRIT CARE, V28, P3, DOI 10.1055/s-2007-970329	53	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 7	2021	12								746996	10.3389/fimmu.2021.746996	http://dx.doi.org/10.3389/fimmu.2021.746996			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WK8QZ	34691055	gold, Green Published			2022-12-18	WOS:000709987000001
J	Yang, FH; Zhang, YF; Chen, Z; Zhang, L				Yang, Fuhua; Zhang, Yifei; Chen, Zhi; Zhang, Lu			VISTA Blockade Aggravates Bone Loss in Experimental Murine Apical Periodontitis	FRONTIERS IN IMMUNOLOGY			English	Article						immune checkpoint; apical periodontitis; VISTA; bone loss; inflammation	REGULATORY T-CELLS	V-domain Ig suppressor of T cell activation (VISTA) is a novel coinhibitory immune checkpoint molecule that maintains immune homeostasis. The present study explored the role of VISTA in human and murine inflammatory tissues of apical periodontitis (AP). VISTA was upregulated in inflammatory tissues of human AP. In mice, the expression of VISTA gradually increased with the development of mouse experimental apical periodontitis (MAP), the CD3(+) T cells, CD11b(+) myeloid cells, and FOXP3(+) regulatory T cells also gradually accumulated. Moreover, a blockade of VISTA using a mouse in vivo anti-VISTA antibody aggravated periapical bone loss and enhanced the infiltration of immune cells in an experimental mouse periapical periodontitis model. The collective results suggest that VISTA serves as a negative regulator of the development and bone loss of apical periodontitis.	[Yang, Fuhua; Zhang, Yifei; Chen, Zhi; Zhang, Lu] Wuhan Univ, Sch & Hosp Stomatol, Minist Educ KLOBM, State Key Lab Breeding Base Basic Sci Stomatol Hu, Wuhan, Peoples R China; [Yang, Fuhua; Zhang, Yifei; Chen, Zhi; Zhang, Lu] Wuhan Univ, Sch & Hosp Stomatol, Minist Educ KLOBM, Key Lab Oral Biomed, Wuhan, Peoples R China; [Chen, Zhi; Zhang, Lu] Wuhan Univ, Sch & Hosp Stomatol, Dept Endodont, Wuhan, Peoples R China	Wuhan University; Wuhan University; Wuhan University	Zhang, L (corresponding author), Wuhan Univ, Sch & Hosp Stomatol, Minist Educ KLOBM, State Key Lab Breeding Base Basic Sci Stomatol Hu, Wuhan, Peoples R China.; Zhang, L (corresponding author), Wuhan Univ, Sch & Hosp Stomatol, Minist Educ KLOBM, Key Lab Oral Biomed, Wuhan, Peoples R China.; Zhang, L (corresponding author), Wuhan Univ, Sch & Hosp Stomatol, Dept Endodont, Wuhan, Peoples R China.	luzhang2012@whu.edu.cn	Zhang, Yifei/GRO-3001-2022		National Natural Science Foundation of China [81974148, 81771064, 81420108011]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	Funding This work was funded by grants from National Natural Science Foundation of China (81974148, 81771064) to LZ and (81420108011) to ZC.	AlShwaimi E, 2009, J ENDODONT, V35, P1229, DOI 10.1016/j.joen.2009.06.006; Alvarez C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01664; Andrews LP, 2019, NAT IMMUNOL, V20, P1425, DOI 10.1038/s41590-019-0512-0; Araujo-Pires AC, 2015, J BONE MINER RES, V30, P400, DOI 10.1002/jbmr.2376; Baumeister SH, 2016, ANNU REV IMMUNOL, V34, P539, DOI 10.1146/annurev-immunol-032414-112049; Braz-Silva PH, 2019, ACTA ODONTOL SCAND, V77, P173, DOI 10.1080/00016357.2018.1521005; Cadena RH, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01638; Cavalla F, 2021, J DENT RES, V100, P29, DOI 10.1177/0022034520952341; Ceeraz S, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075-017-1474-y; Ceeraz S, 2013, TRENDS IMMUNOL, V34, P556, DOI 10.1016/j.it.2013.07.003; Colic M, 2009, J DENT RES, V88, P997, DOI 10.1177/0022034509347090; Colic M, 2009, MOL IMMUNOL, V47, P101, DOI 10.1016/j.molimm.2009.01.011; Dong M, 2018, CELL PHYSIOL BIOCHEM, V49, P884, DOI 10.1159/000493219; ElTanbouly MA, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.595950; Flies DB, 2014, J CLIN INVEST, V124, P1966, DOI 10.1172/JCI74589; Flies DB, 2011, J IMMUNOL, V187, P1537, DOI 10.4049/jimmunol.1100660; Francisconi CF, 2018, J DENT RES, V97, P917, DOI 10.1177/0022034518759302; Francisconi CF, 2016, J ENDODONT, V42, P120, DOI 10.1016/j.joen.2015.09.022; Garlet GP, 2010, J CLIN PERIODONTOL, V37, P591, DOI 10.1111/j.1600-051X.2010.01586.x; Guo YY, 2021, IMMUNOPHARM IMMUNOT, V43, P380, DOI 10.1080/08923973.2021.1925907; Han X, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aax1159; He X, 2020, CELL RES, V30, P660, DOI [10.19678/j.issn.1000-3428.0058876, 10.1038/s41422-020-0343-4]; Hirai K, 2018, INT J ORAL SCI, V10, DOI 10.1038/s41368-018-0015-0; Johnston RJ, 2019, NATURE, V574, P565, DOI 10.1038/s41586-019-1674-5; Le Mercier I, 2014, CANCER RES, V74, P1933, DOI 10.1158/0008-5472.CAN-13-1506; Li N, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01411-1; Liu HF, 2018, CELL MOL IMMUNOL, V15, P838, DOI 10.1038/cmi.2017.16; Marton IJ, 2000, ORAL MICROBIOL IMMUN, V15, P139, DOI 10.1034/j.1399-302x.2000.150301.x; Naufel AO, 2017, BRAZ ORAL RES, V31, DOI 10.1590/1807-3107bor-2017.vol31.0103; Ohno T, 2017, J INVEST DERMATOL, V137, P1384, DOI 10.1016/j.jid.2016.10.049; Oliveira P, 2016, SCI REP-UK, V6, DOI 10.1038/srep34860; Prodeus A, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.94308; Redlich K, 2012, NAT REV DRUG DISCOV, V11, P234, DOI 10.1038/nrd3669; Sergent PA, 2018, LUPUS, V27, P210, DOI 10.1177/0961203317716322; Sharabi A, 2018, NAT REV DRUG DISCOV, V17, P823, DOI 10.1038/nrd.2018.148; Taira TM, 2019, J DENT RES, V98, P476, DOI 10.1177/0022034518820289; Wang HS, 2016, J DENT RES, V95, P697, DOI 10.1177/0022034516633639; Wang HS, 2018, AM J TRANSL RES, V10, P2677; Wang JH, 2019, IMMUNOLOGY, V156, P74, DOI 10.1111/imm.13001; Wang L, 2014, P NATL ACAD SCI USA, V111, P14846, DOI 10.1073/pnas.1407447111; Wang L, 2011, J EXP MED, V208, P577, DOI 10.1084/jem.20100619; Wang XX, 2019, J CELL PHYSIOL, V234, P22719, DOI 10.1002/jcp.28837; Wykes MN, 2018, NAT REV IMMUNOL, V18, P91, DOI 10.1038/nri.2017.112; Xu WW, 2019, CANCER IMMUNOL RES, V7, P1497, DOI 10.1158/2326-6066.CIR-18-0489; Xu WW, 2018, CELL MOL IMMUNOL, V15, P438, DOI 10.1038/cmi.2017.148; Zhuang Z, 2019, J DENT RES, V98, P200, DOI 10.1177/0022034518805984	46	0	0	4	12	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 7	2021	12								738586	10.3389/fimmu.2021.738586	http://dx.doi.org/10.3389/fimmu.2021.738586			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WK8TG	34691045	gold, Green Published			2022-12-18	WOS:000709992900001
J	Yu, MW; Quail, DF				Yu, M. W.; Quail, D. F.			Immunotherapy for Glioblastoma: Current Progress and Challenges (vol 12, 676301, 2021)	FRONTIERS IN IMMUNOLOGY			English	Correction						glioblastoma; brain cancer; immunotherapy; tumor microenvironment; resistance to therapy													0	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 7	2021	12								782687	10.3389/fimmu.2021.782687	http://dx.doi.org/10.3389/fimmu.2021.782687			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XB8TR		Green Published, gold			2022-12-18	WOS:000721595900001
J	Kostinov, MP; Akhmatova, NK; Magarshak, OO; Vlasenko, AE; Polishchuk, VB; Kostinova, AM; Mashilov, KV				Kostinov, Mikhail Petrovich; Akhmatova, Nelli Kimovna; Magarshak, Olga Olegovna; Vlasenko, Anna Egorovna; Polishchuk, Valentina Borisovna; Kostinova, Aristitsa Mikhailovna; Mashilov, Kirill Vadimovich			Nonspecific Regulation of the Number of Immunocompetent Cells Under the Influence of DT Toxoid in Children With Glomerulonephritis	FRONTIERS IN IMMUNOLOGY			English	Article						glomerulonephritis; vaccination in children; post-vaccination antibodies; T-Lymphocytes; diphtheria and tetanus toxoid	TUMOR-NECROSIS-FACTOR; RENAL INJURY; SEROPROTECTION; DIPHTHERIA; TETANUS	Background Studies aimed at identifying the mechanisms of the immunoregulatory effect of vaccination with diphtheria and tetanus toxoid on the parameters of adaptive immunity in children with kidney pathology are limited. The study aimed to study the effect of revaccination against diphtheria and tetanus on the proliferation and differentiation of immunocompetent cells, the formation of specific antibodies, and the course of the disease in children with glomerulonephritis (GN). Methods The study included 45 children with glomerulonephritis (GN) aged 5 to 15 years, in remission from 6 months up to 4 years. Of these, 25 children were revaccinated with DT toxoid (Diphtheria-Tetanus toxoid with reduced antigenic content) and 20 were in the control group (not vaccinated). The frequency of development of local and systemic reactions and the course of GN were assessed. The subpopulation structure of lymphocytes was studied in dynamics after 1-6-12 months by flow cytometry and IgG levels to diphtheria and tetanus were studied by ELISA. Results In 92% of children with GN, the post-vaccination period was uneventful. 8% showed a rise in temperature up to 37.3 degrees C, without the development of local reactions. During the year, none of the patients had an exacerbation of GN or a concomitant disease. After revaccination with DT toxoid, a significant increase in IgG antibodies against diphtheria and tetanus was revealed, which persisted after 12 months - 7.5 [5.1-10.8] IU/mL (p <0.001) and 7.2 [4.8-10.7] IU/mL (p <0.001), respectively. In the post-vaccination period, a multidirectional change in the concentration of T-lymphocytes was noted: with an initially increased level, their percentage after revaccination with DT toxoid decreases from 83 (81-86) % to 78 (76-80)% after a month (p = 0.04) and up to 75 (69-79)% after 12 months (p<0.001). In the control group, such a decrease was not observed. A similar picture was observed for T-helpers, cytotoxic T-lymphocytes, and in patients with an initially low percentage of cytotoxic T-lymphocytes, on the contrary, its increase was noted (p<0.001), which is comparable with the value of this parameter in the group of children with initially normal value (H = 0.54, p = 0.76). The same patterns were observed in the change in the content of B-cells: one month after revaccination, the relative level of B-cells in patients with an initially lowered value increased (p = 0.02) and remained for 12 months (p<0.001). Conclusion Revaccination with DT toxoid in children with GN not only does not cause undesirable changes in the system of immunocompetent cells but also has an immunomodulatory effect, which contributes to the favorable maintenance of the remission period of the disease.	[Kostinov, Mikhail Petrovich; Polishchuk, Valentina Borisovna; Mashilov, Kirill Vadimovich] II Mechnikov Res Inst Vaccines & Sera, Dept Allergol, Moscow, Russia; [Kostinov, Mikhail Petrovich] Sechenov First Moscow State Med Univ, Dept Epidemiol & Modern Vaccinat Technol, Moscow, Russia; [Akhmatova, Nelli Kimovna; Magarshak, Olga Olegovna] II Mechnikov Res Inst Vaccines & Sera, Dept Immunol, Moscow, Russia; [Vlasenko, Anna Egorovna] Russian Med Acad Continuous Profess Educ, Dept Med Cybernet & Comp Sci, Novokuznetsk State Inst Adv Training Phys, Branch Campus, Novokuznetsk, Russia; [Kostinova, Aristitsa Mikhailovna] NRC Inst Immunol FMBA Russia, Dept Immunol, Moscow, Russia	Russian Academy of Medical Sciences; Research Institute of Vaccines and Sera Mechnikov, RAMS; Sechenov First Moscow State Medical University; Russian Academy of Medical Sciences; Research Institute of Vaccines and Sera Mechnikov, RAMS; NRC Institute of Immunology FMBA of Russia	Mashilov, KV (corresponding author), II Mechnikov Res Inst Vaccines & Sera, Dept Allergol, Moscow, Russia.	k.v.mashilov@gmail.com	Kostinova, Aristitsa/GQO-8886-2022; Kostinov, Mikhail P/J-8296-2018; Polishchuk, Valentina/AAH-4625-2021; Vlasenko, Anna/S-7260-2016	Vlasenko, Anna/0000-0001-6454-4216				Ajay M, 2021, INDIAN PEDIATR, V58, P233, DOI 10.1007/s13312-021-2161-2; Andrade-Oliveira V, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01192; [Anonymous], 2020, GUIDELINES ROUTINE I; Banerjee S, 2016, PEDIATR NEPHROL, V31, P1437, DOI 10.1007/s00467-015-3219-y; Chuchalin AG., 2015, FEDERALNOE RUKOVODST, P1016; Chuchalin AG., 2017, RESPIRATORNAYA MEDIT, P544; Dlin VV., 2017, INFEKTSII MOCHEVOY S, V2-E, P422; Enke BU, 1997, TRANSPLANTATION, V64, P237, DOI 10.1097/00007890-199707270-00010; Ikezumi Y, 2004, J AM SOC NEPHROL, V15, P1775, DOI 10.1097/01.ASN.0000131272.06958.DE; ISHA N, 1989, J IMMUNOL, V142, P3083; Kleinknecth C, 1977, Proc Eur Dial Transplant Assoc, V14, P209; Kostinov M.P., 2009, VACCINATION HEPATITI, P196; Kostinov MP., 1996, VACCINATION CHILDREN, V1st, P432; Kostinov MP., 1997, NEW CLIN DIAGNOSTICS, P110; Kostinov MP, 2013, VACCINATION CHILDREN, V4th, P432; Kraskina NA., 1988, SOVREMENNYE ASPEKTY, P44; Kurts C, 2013, NAT REV IMMUNOL, V13, P738, DOI 10.1038/nri3523; Lopez-Novoa JM, 2010, PHARMACOL THERAPEUT, V128, P61, DOI 10.1016/j.pharmthera.2010.05.006; Mantan M, 2013, PEDIATR NEPHROL, V28, P2125, DOI 10.1007/s00467-013-2538-0; Nikolaenko VN., 1990, THESIS, P179; Nogueira A, 2017, IN VIVO, V31, P1, DOI 10.21873/invivo.11019; Papajan AV., 1997, KLINICHESKAJA NEFROL, P856; Ryu M, 2011, KIDNEY INT, V79, P189, DOI 10.1038/ki.2010.373; Solov'eva IL., 2006, OSOBENNOSTI VAKTSINA, P296; Stefani DV., 1996, KLINICHESKAJA IMMUNO, P384; Tang PCT, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21114018; Timoshanko JR, 2003, J AM SOC NEPHROL, V14, P1785, DOI 10.1097/01.ASN.0000073902.38428.33; Tran CL, 2021, FRONT PEDIATR, V8, DOI 10.3389/fped.2020.619548; Wu CCN, 2004, J BIOL CHEM, V279, P33071, DOI 10.1074/jbc.M311662200	29	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 6	2021	12								715389	10.3389/fimmu.2021.715389	http://dx.doi.org/10.3389/fimmu.2021.715389			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WL0LA	34691025	Green Published, gold			2022-12-18	WOS:000710106700001
J	Le, PT; Ha, N; Tran, NK; Newman, AG; Esselen, KM; Dalrymple, JL; Schmelz, EM; Bhandoola, A; Xue, HH; Singh, PB; Thai, TH				Le, Phuong T.; Ha, Ngoc; Tran, Ngan K.; Newman, Andrew G.; Esselen, Katharine M.; Dalrymple, John L.; Schmelz, Eva M.; Bhandoola, Avinash; Xue, Hai-Hui; Singh, Prim; Thai, To-Ha			Targeting Cbx3/HP1? Induces LEF-1 and IL-21R to Promote Tumor-Infiltrating CD8 T-Cell Persistence	FRONTIERS IN IMMUNOLOGY			English	Article						<p>& nbsp;</p>; <p>Cbx3/HP1 gamma & nbsp;</p>; LEF-1; IL-21 receptor; CD8+T-cell persistence; ovarian cancer; melanoma	HETEROCHROMATIN PROTEIN-1 HP1; GENE-EXPRESSION; BREAST-CANCER; IMMUNOTHERAPY; HP1-GAMMA; DIFFERENTIATION; OVEREXPRESSION; INTERLEUKIN-21; PROLIFERATION; METHYLATION	Immune checkpoint blockade (ICB) relieves CD8(+) T-cell exhaustion in most mutated tumors, and TCF-1 is implicated in converting progenitor exhausted cells to functional effector cells. However, identifying mechanisms that can prevent functional senescence and potentiate CD8(+) T-cell persistence for ICB non-responsive and resistant tumors remains elusive. We demonstrate that targeting Cbx3/HP1 gamma in CD8(+) T cells augments transcription initiation and chromatin remodeling leading to increased transcriptional activity at Lef1 and Il21r. LEF-1 and IL-21R are necessary for Cbx3/HP1 gamma-deficient CD8(+) effector T cells to persist and control ovarian cancer, melanoma, and neuroblastoma in preclinical models. The enhanced persistence of Cbx3/HP1 gamma-deficient CD8(+) T cells facilitates remodeling of the tumor chemokine/receptor landscape ensuring their optimal invasion at the expense of CD4(+) Tregs. Thus, CD8(+) T cells heightened effector function consequent to Cbx3/HP1 gamma deficiency may be distinct from functional reactivation by ICB, implicating Cbx3/HP1 gamma as a viable cancer T-cell-based therapy target for ICB resistant, non-responsive solid tumors.</p>	[Le, Phuong T.; Ha, Ngoc; Tran, Ngan K.; Thai, To-Ha] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02115 USA; [Newman, Andrew G.] Charite Univ Med Berlin, Inst Cell & Neurobiol, Berlin, Germany; [Newman, Andrew G.] Free Univ Berlin, Berlin, Germany; [Newman, Andrew G.] Humboldt Univ, Berlin, Germany; [Newman, Andrew G.] Berlin Inst Hlth, Berlin, Germany; [Esselen, Katharine M.; Dalrymple, John L.] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Div Gynecol Oncol, Boston, MA 02115 USA; [Schmelz, Eva M.] Virginia Tech, Dept Human Nutr Food & Exercise, Blacksburg, VA USA; [Bhandoola, Avinash] NCI, Ctr Canc Res, Bethesda, MD 20892 USA; [Xue, Hai-Hui] Hackensack Univ, Med Ctr, Ctr Discovery & Innovat, Nutley, NJ USA; [Singh, Prim] Nazarbayev Univ, Sch Med, Nur Sultan, Kazakhstan; [Thai, To-Ha] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Canc Res Inst, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Berlin Institute of Health; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Virginia Polytechnic Institute & State University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Hackensack University Medical Center; Nazarbayev University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Thai, TH (corresponding author), Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02115 USA.; Thai, TH (corresponding author), Harvard Med Sch, Beth Israel Deaconess Med Ctr, Canc Res Inst, Boston, MA 02115 USA.	tthai@bidmc.harvard.edu		Newman, Andrew G./0000-0002-0222-9162	NIH [AI099012, CA198263]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Funding This work was supported by NIH grants AI099012, CA198263, Friends for Life Neuroblastoma Research Program and The Mayer Family Fund.	Acharya N, 2020, IMMUNITY, V53, P658, DOI 10.1016/j.immuni.2020.08.005; Allard EL, 2007, EUR J IMMUNOL, V37, P3069, DOI 10.1002/eji.200637017; Alves NL, 2005, J IMMUNOL, V175, P755, DOI 10.4049/jimmunol.175.2.755; Ayoub N, 2008, NATURE, V453, P682, DOI 10.1038/nature06875; Barker BR, 2010, EUR J IMMUNOL, V40, P3085, DOI 10.1002/eji.200939939; Bedognetti D, 2013, BRIT J CANCER, V109, P2412, DOI 10.1038/bjc.2013.557; Berrien-Elliott MM, 2015, CANCER IMMUNOL RES, V3, P116, DOI 10.1158/2326-6066.CIR-14-0159; Carr T, 2015, J EXP MED, V212, P793, DOI 10.1084/jem.20141849; Chen J, 2019, NATURE, V567, P530, DOI 10.1038/s41586-019-0985-x; Chen XG, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165595; Chheda ZS, 2016, J IMMUNOL, V197, P2016, DOI 10.4049/jimmunol.1502376; Cohen CA, 2013, CANCER PREV RES, V6, P1182, DOI 10.1158/1940-6207.CAPR-13-0227; Connolly KA, 2016, ONCOTARGET, V7, P86522, DOI 10.18632/oncotarget.13287; Cruz-Guilloty F, 2009, J EXP MED, V206, P51, DOI 10.1084/jem.20081242; DALTON DK, 1993, SCIENCE, V259, P1739, DOI 10.1126/science.8456300; Davis MR, 2015, CANCER LETT, V358, P107, DOI 10.1016/j.canlet.2014.12.047; Elsaesser H, 2009, SCIENCE, V324, P1569, DOI 10.1126/science.1174182; Facciabene A, 2011, NATURE, V475, P226, DOI 10.1038/nature10169; Frohlich A, 2009, SCIENCE, V324, P1576, DOI 10.1126/science.1172815; Frohlich A, 2007, BLOOD, V109, P2023, DOI 10.1182/blood-2006-05-021600; Gajewski TF, 2011, CURR OPIN IMMUNOL, V23, P286, DOI 10.1016/j.coi.2010.11.013; Goldmit M, 2005, NAT IMMUNOL, V6, P198, DOI 10.1038/ni1154; Hediger F, 2006, CURR OPIN GENET DEV, V16, P143, DOI 10.1016/j.gde.2006.02.013; Im SJ, 2016, NATURE, V537, P417, DOI 10.1038/nature19330; Jeannet G, 2010, P NATL ACAD SCI USA, V107, P9777, DOI 10.1073/pnas.0914127107; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jones DO, 2000, BIOESSAYS, V22, P124, DOI 10.1002/(SICI)1521-1878(200002)22:2&lt;124::AID-BIES4&gt;3.0.CO;2-E; KAGI D, 1994, NATURE, V369, P31, DOI 10.1038/369031a0; Khattar M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085882; Krishna S, 2020, SCIENCE, V370, P1328, DOI 10.1126/science.abb9847; Kroesen M, 2014, INT J CANCER, V134, P1335, DOI 10.1002/ijc.28463; Kurtulus S, 2019, IMMUNITY, V50, P181, DOI 10.1016/j.immuni.2018.11.014; Kwon SH, 2008, MOL CELLS, V26, P217; LaFleur MW, 2019, NAT IMMUNOL, V20, P1335, DOI 10.1038/s41590-019-0480-4; Linnebacher A, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8091104; Liu D, 2021, NAT MED, V27, P985, DOI 10.1038/s41591-021-01331-8; Liu JY, 2015, ONCOTARGET, V6, P24978, DOI 10.18632/oncotarget.4617; Lynn RC, 2019, NATURE, V576, P293, DOI 10.1038/s41586-019-1805-z; Ma GY, 2015, P NATL ACAD SCI USA, V112, P2216, DOI 10.1073/pnas.1419198112; Maekawa Y, 2008, NAT IMMUNOL, V9, P1140, DOI 10.1038/ni.1649; Mao XH, 2001, BLOOD, V97, P324, DOI 10.1182/blood.V97.1.324; Martin SD, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155189; Matulonis UA, 2019, ANN ONCOL, V30, P1080, DOI 10.1093/annonc/mdz135; Mikucki ME, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1116675; Miller BC, 2019, NAT IMMUNOL, V20, P326, DOI 10.1038/s41590-019-0312-6; Minc E, 1999, CHROMOSOMA, V108, P220, DOI 10.1007/s004120050372; Minc E, 2000, CYTOGENET CELL GENET, V90, P279, DOI 10.1159/000056789; Miron M, 2018, J IMMUNOL, V201, P2132, DOI 10.4049/jimmunol.1800716; Mittal D, 2016, CANCER RES, V76, P264, DOI 10.1158/0008-5472.CAN-15-1567; Ha N, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00271; Noguchi N, 2018, INFECT IMMUN, V86, DOI [10.1128/iai.00147-18, 10.1128/IAI.00147-18]; Novy P, 2011, J IMMUNOL, V186, P2729, DOI 10.4049/jimmunol.1003009; Okamura RM, 1998, IMMUNITY, V8, P11, DOI 10.1016/S1074-7613(00)80454-9; Oyama K, 2018, EPIGENET CHROMATIN, V11, DOI 10.1186/s13072-018-0187-z; Pauken KE, 2015, TRENDS IMMUNOL, V36, P265, DOI 10.1016/j.it.2015.02.008; Piacentini L, 2003, J CELL BIOL, V161, P707, DOI 10.1083/jcb.200303012; Pipkin ME, 2010, IMMUNITY, V32, P79, DOI 10.1016/j.immuni.2009.11.012; Ramakrishnan R, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107684; Reya T, 2000, IMMUNITY, V13, P15, DOI 10.1016/S1074-7613(00)00004-2; Roberts PC, 2005, NEOPLASIA, V7, P944, DOI 10.1593/neo.05358; Roby KF, 2000, CARCINOGENESIS, V21, P585, DOI 10.1093/carcin/21.4.585; Sade-Feldman M, 2018, CELL, V175, P998, DOI 10.1016/j.cell.2018.10.038; Saint-Andre V, 2011, NAT STRUCT MOL BIOL, V18, P337, DOI 10.1038/nsmb.1995; Shan Q, 2017, NAT IMMUNOL, V18, P931, DOI 10.1038/ni.3773; Singh PB, 2020, ROY SOC OPEN SCI, V7, DOI 10.1098/rsos.191976; Smallwood A, 2012, GENOME RES, V22, P1426, DOI 10.1101/gr.124818.111; Sun M, 2017, SCI REP-UK, V7, DOI 10.1038/srep42888; Le TP, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01640; Tubo NJ, 2011, AM J PATHOL, V178, P2496, DOI 10.1016/j.ajpath.2011.02.031; Utzschneider DT, 2016, IMMUNITY, V45, P415, DOI 10.1016/j.immuni.2016.07.021; Vakoc CR, 2005, MOL CELL, V19, P381, DOI 10.1016/j.molcel.2005.06.011; Wang LN, 2015, CANCER GENOM PROTEOM, V12, P211; Weber BN, 2011, NATURE, V476, P63, DOI 10.1038/nature10279; Weber EW, 2021, SCIENCE, V372, P49, DOI 10.1126/science.aba1786; Xing SJ, 2016, NAT IMMUNOL, V17, P695, DOI 10.1038/ni.3456; Yao C, 2021, NAT IMMUNOL, V22, P370, DOI 10.1038/s41590-021-00868-7; Yearim A, 2015, CELL REP, V10, P1122, DOI 10.1016/j.celrep.2015.01.038; Yi JS, 2009, SCIENCE, V324, P1572, DOI 10.1126/science.1175194; Zheng XC, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1500673; Zhou XY, 2012, J IMMUNOL, V189, P2722, DOI 10.4049/jimmunol.1201150; Zhou XY, 2010, IMMUNITY, V33, P229, DOI 10.1016/j.immuni.2010.08.002; ZHUMABEKOV T, 1995, J IMMUNOL METHODS, V185, P133, DOI 10.1016/0022-1759(95)00124-S	82	0	0	2	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 6	2021	12								738958	10.3389/fimmu.2021.738958	http://dx.doi.org/10.3389/fimmu.2021.738958			18	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WQ2EM	34721405	Green Published, Green Submitted, gold			2022-12-18	WOS:000713633400001
J	Mollenhauer, M; Bokredenghel, S; Geissen, S; Klinke, A; Morstadt, T; Torun, M; Strauch, S; Schumacher, W; Maass, M; Konradi, J; Peters, VBM; Berghausen, E; Vantler, M; Rosenkranz, S; Mehrkens, D; Braumann, S; Nettersheim, F; Hof, A; Simsekyilmaz, S; Winkels, H; Rudolph, V; Baldus, S; Adam, M; ten Freyhaus, H				Mollenhauer, Martin; Bokredenghel, Senai; Geissen, Simon; Klinke, Anna; Morstadt, Tobias; Torun, Merve; Strauch, Sabrina; Schumacher, Wibke; Maass, Martina; Konradi, Juergen; Peters, Vera B. M.; Berghausen, Eva; Vantler, Marius; Rosenkranz, Stephan; Mehrkens, Dennis; Braumann, Simon; Nettersheim, Felix; Hof, Alexander; Simsekyilmaz, Sakine; Winkels, Holger; Rudolph, Volker; Baldus, Stephan; Adam, Matti; ten Freyhaus, Henrik			Stamp2 Protects From Maladaptive Structural Remodeling and Systolic Dysfunction in Post-Ischemic Hearts by Attenuating Neutrophil Activation	FRONTIERS IN IMMUNOLOGY			English	Article						six-transmembrane protein of prostate 2; Stamp2; Steap4; myocardial infarction; ischemia and reperfusion damage; left ventricular dysfunction; inflammation; polymorphonuclear neutrophils (PMN)	MYOCARDIAL-INFARCTION; INFLAMMATION; MACROPHAGES; ISCHEMIA; OUTCOMES; MOUSE; TIME	The six-transmembrane protein of prostate 2 (Stamp2) acts as an anti-inflammatory protein in macrophages by protecting from overt inflammatory signaling and Stamp2 deficiency accelerates atherosclerosis in mice. Herein, we describe an unexpected role of Stamp2 in polymorphonuclear neutrophils (PMN) and characterize Stamp2's protective effects in myocardial ischemic injury. In a murine model of ischemia and reperfusion (I/R), echocardiography and histological analyses revealed a pronounced impairment of cardiac function in hearts of Stamp2-deficient- (Stamp2(-/-)) mice as compared to wild-type (WT) animals. This difference was driven by aggravated cardiac fibrosis, as augmented fibroblast-to-myofibroblast transdifferentiation was observed which was mediated by activation of the redox-sensitive p38 mitogen-activated protein kinase (p38 MAPK). Furthermore, we observed increased production of reactive oxygen species (ROS) in Stamp2(-/-) hearts after I/R, which is the likely cause for p38 MAPK activation. Although myocardial macrophage numbers were not affected by Stamp2 deficiency after I/R, augmented myocardial infiltration by polymorphonuclear neutrophils (PMN) was observed, which coincided with enhanced myeloperoxidase (MPO) plasma levels. Primary PMN isolated from Stamp2(-/-) animals exhibited a proinflammatory phenotype characterized by enhanced nuclear factor (NF)-kappa B activity and MPO secretion. To prove the critical role of PMN for the observed phenotype after I/R, antibody-mediated PMN depletion was performed in Stamp2(-/-) mice which reduced deterioration of LV function and adverse structural remodeling to WT levels. These data indicate a novel role of Stamp2 as an anti-inflammatory regulator of PMN and fibroblast-to-myofibroblast transdifferentiation in myocardial I/R injury.	[Mollenhauer, Martin; Bokredenghel, Senai; Geissen, Simon; Klinke, Anna; Morstadt, Tobias; Torun, Merve; Strauch, Sabrina; Schumacher, Wibke; Maass, Martina; Konradi, Juergen; Peters, Vera B. M.; Berghausen, Eva; Vantler, Marius; Rosenkranz, Stephan; Mehrkens, Dennis; Braumann, Simon; Nettersheim, Felix; Hof, Alexander; Simsekyilmaz, Sakine; Winkels, Holger; Rudolph, Volker; Baldus, Stephan; Adam, Matti; ten Freyhaus, Henrik] Univ Cologne, Dept Expt Cardiol, Fac Med, Cologne, Germany; [Mollenhauer, Martin; Bokredenghel, Senai; Geissen, Simon; Klinke, Anna; Morstadt, Tobias; Torun, Merve; Strauch, Sabrina; Schumacher, Wibke; Maass, Martina; Konradi, Juergen; Peters, Vera B. M.; Berghausen, Eva; Vantler, Marius; Rosenkranz, Stephan; Mehrkens, Dennis; Braumann, Simon; Nettersheim, Felix; Hof, Alexander; Simsekyilmaz, Sakine; Winkels, Holger; Rudolph, Volker; Baldus, Stephan; Adam, Matti; ten Freyhaus, Henrik] Univ Hosp Cologne, Clin Internal Med 3, Cologne, Germany; [Mollenhauer, Martin; Bokredenghel, Senai; Geissen, Simon; Torun, Merve; Schumacher, Wibke; Peters, Vera B. M.; Berghausen, Eva; Vantler, Marius; Rosenkranz, Stephan; Mehrkens, Dennis; Braumann, Simon; Nettersheim, Felix; Hof, Alexander; Simsekyilmaz, Sakine; Winkels, Holger; Rudolph, Volker; Baldus, Stephan; Adam, Matti; ten Freyhaus, Henrik] Univ Cologne, Ctr Mol Med Cologne CMMC, Cologne, Germany; [Mollenhauer, Martin; Bokredenghel, Senai; Geissen, Simon; Klinke, Anna; Torun, Merve; Schumacher, Wibke; Peters, Vera B. M.; Berghausen, Eva; Vantler, Marius; Rosenkranz, Stephan; Mehrkens, Dennis; Braumann, Simon; Nettersheim, Felix; Hof, Alexander; Winkels, Holger; Baldus, Stephan; Adam, Matti; ten Freyhaus, Henrik] Univ Cologne, Cologne Cardiovasc Res Ctr CCRC, Cologne, Germany; [Klinke, Anna; Rudolph, Volker] Ruhr Univ Bochum, Univ Hosp, Herz & Diabeteszentrum Nordrhein Westfalen, Clin Gen & Intervent Cardiol Angiol, Bad Oeynhausen, Germany	University of Cologne; University of Cologne; University of Cologne; University of Cologne; Ruhr University Bochum	Mollenhauer, M; ten Freyhaus, H (corresponding author), Univ Cologne, Dept Expt Cardiol, Fac Med, Cologne, Germany.; Mollenhauer, M; ten Freyhaus, H (corresponding author), Univ Hosp Cologne, Clin Internal Med 3, Cologne, Germany.; Mollenhauer, M; ten Freyhaus, H (corresponding author), Univ Cologne, Ctr Mol Med Cologne CMMC, Cologne, Germany.; Mollenhauer, M; ten Freyhaus, H (corresponding author), Univ Cologne, Cologne Cardiovasc Res Ctr CCRC, Cologne, Germany.	martin.mollenhauer@uk-koeln.de; henrik.ten-freyhaus@uk-koeln.de	Winkels, Holger/ADQ-0339-2022	Winkels, Holger/0000-0003-1333-2031; Schumacher, Wibke/0000-0003-0277-8070; Mehrkens, Dennis/0000-0002-8578-0290	Deutsche Forschungsgemeinschaft DFG [RU 16783-3, 360043781 - GRK 2407, MO 3438/2-1, 397484323 - TRR259]; Center for Molecular Medicine Cologne [Baldus B-02]; Koln Fortune Program of the University of Cologne [254/2014, 240/2017]; German Foundation of Heart Research [F/45/15, F37/17]	Deutsche Forschungsgemeinschaft DFG(German Research Foundation (DFG)); Center for Molecular Medicine Cologne; Koln Fortune Program of the University of Cologne; German Foundation of Heart Research	This work was funded by the Deutsche Forschungsgemeinschaft DFG (RU 16783-3 and 360043781 - GRK 2407 to VR, 360043781 - GRK 2407 to SB, MO 3438/2-1 to MM and Grant. No. 397484323 - TRR259 to SB, HW and MA) and the Center for Molecular Medicine Cologne funding (Baldus B-02). HF was funded by the Koln Fortune Program of the University of Cologne (254/2014, 240/2017), and by the German Foundation of Heart Research (F/45/15, F37/17).	Ali Muhammad, 2016, JACC Basic Transl Sci, V1, P633, DOI 10.1016/j.jacbts.2016.09.004; Batool M, 2020, BASIC RES CARDIOL, V115, DOI 10.1007/s00395-020-00826-8; Baxter GF, 2002, BASIC RES CARDIOL, V97, P268, DOI 10.1007/s00395-002-0366-7; Bouabdallaoui N, 2020, EUR HEART J, V41, P4092, DOI 10.1093/eurheartj/ehaa659; Carrier L, 2010, CARDIOVASC RES, V85, P330, DOI 10.1093/cvr/cvp247; Castro-Alcaraz S, 2002, J IMMUNOL, V169, P3947, DOI 10.4049/jimmunol.169.7.3947; Davies MJ, 2011, J CLIN BIOCHEM NUTR, V48, P8, DOI 10.3164/jcbn.11-006FR; Dick SA, 2019, NAT IMMUNOL, V20, P29, DOI [10.1038/s41590-018-0272-2, 10.1038/s41590-019-0363-8]; Eltzschig HK, 2011, NAT MED, V17, P1391, DOI 10.1038/nm.2507; ENGLISH D, 1974, J IMMUNOL METHODS, V5, P249, DOI 10.1016/0022-1759(74)90109-4; Han L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078903; Horckmans M, 2017, EUR HEART J, V38, P187, DOI 10.1093/eurheartj/ehw002; Humeres C, 2019, JACC-BASIC TRANSL SC, V4, P449, DOI 10.1016/j.jacbts.2019.02.006; Jin Y, 2015, EMBO MOL MED, V7, P315, DOI 10.15252/emmm.201404181; Kanno S, 2002, J AM SOC ECHOCARDIOG, V15, P601, DOI 10.1067/mje.2002.117560; Lacy Paige, 2006, Allergy Asthma Clin Immunol, V2, P98, DOI 10.1186/1710-1492-2-3-98; Liu T, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2017.23; Luo T, 2019, ANATOL J CARDIOL, V21, P261, DOI 10.14744/AnatolJCardiol.2019.11456; Ma YG, 2016, CARDIOVASC RES, V110, P51, DOI 10.1093/cvr/cvw024; McManus DD, 2011, AM J MED, V124, P40, DOI 10.1016/j.amjmed.2010.07.023; Midwinter RG, 2001, ARCH BIOCHEM BIOPHYS, V394, P13, DOI 10.1006/abbi.2001.2530; Mollenhauer M, 2017, CIRC RES, V121, P56, DOI 10.1161/CIRCRESAHA.117.310870; O'Rourke SA, 2019, FRONT CARDIOVASC MED, V6, DOI 10.3389/fcvm.2019.00101; Odobasic D, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/2349817; Oh YJ, 2018, MOL PHARMACOL, V94, P1401, DOI 10.1124/mol.118.113217; Ohgami RS, 2006, BLOOD, V108, P1388, DOI 10.1182/blood-2006-02-003681; Ponikowski P, 2014, ESC HEART FAIL, V1, P4, DOI 10.1002/ehf2.12005; Prabhu SD, 2016, CIRC RES, V119, P91, DOI 10.1161/CIRCRESAHA.116.303577; Puhl SL, 2019, FRONT CARDIOVASC MED, V6, DOI 10.3389/fcvm.2019.00025; Reed GW, 2017, LANCET, V389, P197, DOI 10.1016/S0140-6736(16)30677-8; Ridker PM, 2017, NEW ENGL J MED, V377, P1119, DOI 10.1056/NEJMoa1707914; Suthahar Navin, 2017, Curr Heart Fail Rep, V14, P235, DOI 10.1007/s11897-017-0343-y; Swirski FK, 2013, SCIENCE, V339, P161, DOI 10.1126/science.1230719; Tardif JC, 2019, NEW ENGL J MED, V381, P2497, DOI 10.1056/NEJMoa1912388; ten Freyhaus H, 2012, CELL METAB, V16, P81, DOI 10.1016/j.cmet.2012.05.009; Travers JG, 2016, CIRC RES, V118, P1021, DOI 10.1161/CIRCRESAHA.115.306565; Turner NA, 2019, J CARDIOVASC DEV DIS, V6, DOI 10.3390/jcdd6030027; Vafadarnejad E, 2020, CIRC RES, V127, pE232, DOI 10.1161/CIRCRESAHA.120.317200; van den Borne SWM, 2010, NAT REV CARDIOL, V7, P30, DOI 10.1038/nrcardio.2009.199; Vettel C, 2017, CIRC RES, V120, P120, DOI 10.1161/CIRCRESAHA.116.310069; Vinten-Johansen J, 2004, CARDIOVASC RES, V61, P481, DOI 10.1016/j.cardiores.2003.10.011; Wang F, 2017, J CELL MOL MED, V21, P3298, DOI 10.1111/jcmm.13233; Wellen KE, 2007, CELL, V129, P537, DOI 10.1016/j.cell.2007.02.049	43	0	0	0	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 6	2021	12								701721	10.3389/fimmu.2021.701721	http://dx.doi.org/10.3389/fimmu.2021.701721			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WJ7DR	34691017	gold, Green Published			2022-12-18	WOS:000709201700001
J	Magalis, BR; Autissier, P; Williams, KC; Chen, XG; Browne, C; Salemi, M				Rife Magalis, Brittany; Autissier, Patrick; Williams, Kenneth C.; Chen, Xinguang; Browne, Cameron; Salemi, Marco			Predator-Prey Dynamics of Intra-Host Simian Immunodeficiency Virus Evolution Within the Untreated Host	FRONTIERS IN IMMUNOLOGY			English	Article						HIV; rhesus macaque; untreated; intra-host; predator-prey; evolution; effective population size; phylodynamic	EFFECTIVE POPULATION-SIZE; CYTOTOXIC T-LYMPHOCYTES; IMMUNE-RESPONSES; RHESUS MACAQUES; GENETIC DIVERSITY; DRUG-RESISTANCE; BLOOD MONOCYTES; CELL RESPONSES; ENV GENE; HIV-1	The dynamic nature of the SIV population during disease progression in the SIV/macaque model of AIDS and the factors responsible for its behavior have not been documented, largely owing to the lack of sufficient spatial and temporal sampling of both viral and host data from SIV-infected animals. In this study, we detail Bayesian coalescent inference of the changing collective intra-host viral effective population size (N-e) from various tissues over the course of infection and its relationship with what we demonstrate is a continuously changing immune cell repertoire within the blood. Although the relative contribution of these factors varied among hosts and time points, the adaptive immune response best explained the overall periodic dynamic behavior of the effective virus population. Data exposing the nature of the relationship between the virus and immune cell populations revealed the plausibility of an eco-evolutionary mathematical model, which was able to mimic the large-scale oscillations in N-e through virus escape from relatively few, early immunodominant responses, followed by slower escape from several subdominant and weakened immune populations. The results of this study suggest that SIV diversity within the untreated host is governed by a predator-prey relationship, wherein differing phases of infection are the result of adaptation in response to varying immune responses. Previous investigations into viral population dynamics using sequence data have focused on single estimates of the effective viral population size (N-e) or point estimates over sparse sampling data to provide insight into the precise impact of immune selection on virus adaptive behavior. Herein, we describe the use of the coalescent phylogenetic frame- work to estimate the relative changes in N-e over time in order to quantify the relationship with empirical data on the dynamic immune composition of the host. This relationship has allowed us to expand on earlier simulations to build a predator-prey model that explains the deterministic behavior of the virus over the course of disease progression. We show that sequential viral adaptation can occur in response to phases of varying immune pressure, providing a broader picture of the viral response throughout the entire course of progression to AIDS.	[Rife Magalis, Brittany; Salemi, Marco] Univ Florida, Dept Pathol Immunol & Lab Med, Gainesville, FL 32610 USA; [Rife Magalis, Brittany; Salemi, Marco] Univ Florida, Emerging Pathogens Inst, Gainesville, FL 32610 USA; [Autissier, Patrick; Williams, Kenneth C.] Boston Coll, Dept Biol, Chestnut Hill, MA 02167 USA; [Chen, Xinguang] Univ Florida, Dept Epidemiol, Gainesville, FL USA; [Browne, Cameron] Univ Louisiana Lafayette, Dept Math, Lafayette, LA 70504 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; Boston College; State University System of Florida; University of Florida; University of Louisiana Lafayette	Salemi, M (corresponding author), Univ Florida, Dept Pathol Immunol & Lab Med, Gainesville, FL 32610 USA.; Salemi, M (corresponding author), Univ Florida, Emerging Pathogens Inst, Gainesville, FL 32610 USA.; Browne, C (corresponding author), Univ Louisiana Lafayette, Dept Math, Lafayette, LA 70504 USA.	cameron.browne@louisiana.edu; salemi@pathology.ufl.edu		Rife Magalis, Brittany/0000-0001-6088-4651	National Institute of Neurological Disease and Stroke at the National Institutes of Health (NIH) [R01 NS063897]; NIH National Institute of Mental Health [F31 MH109398]; National Science Foundation [DMS-1815095]; Stephany W. Holloway University of Florida Chair in AIDS Research	National Institute of Neurological Disease and Stroke at the National Institutes of Health (NIH); NIH National Institute of Mental Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); National Science Foundation(National Science Foundation (NSF)); Stephany W. Holloway University of Florida Chair in AIDS Research	This work was supported in part by the National Institute of Neurological Disease and Stroke at the National Institutes of Health (NIH) [R01 NS063897 to MS], the NIH National Institute of Mental Health [F31 MH109398 to BR], the National Science Foundation [DMS-1815095 to CB], and the Stephany W. Holloway University of Florida Chair in AIDS Research.	Achaz G, 2004, MOL BIOL EVOL, V21, P1902, DOI 10.1093/molbev/msh196; Alizon S, 2013, RETROVIROLOGY, V10, DOI 10.1186/1742-4690-10-49; Asquith B, 2006, PLOS BIOL, V4, P583, DOI 10.1371/journal.pbio.0040090; Bangs SC, 2006, TRENDS IMMUNOL, V27, P518, DOI 10.1016/j.it.2006.09.006; Barker CT, 2020, PLOS COMPUT BIOL, V16, DOI 10.1371/journal.pcbi.1008305; Bates D, 2015, J STAT SOFTW, V67, P1, DOI 10.18637/jss.v067.i01; Betts MR, 2001, J VIROL, V75, P11983, DOI 10.1128/JVI.75.24.11983-11991.2001; Bigot J, 2011, NEUROIMAGE, V55, P1504, DOI 10.1016/j.neuroimage.2011.01.033; Bons E, 2018, IMMUNOL REV, V285, P134, DOI 10.1111/imr.12688; Bouckaert R, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003537; Brown AJL, 1997, P NATL ACAD SCI USA, V94, P1862, DOI 10.1073/pnas.94.5.1862; Browne CJ, 2018, J MATH BIOL, V77, P1833, DOI 10.1007/s00285-018-1224-z; Burdo TH, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000842; Chaillon A, 2020, J CLIN INVEST, V130, P1699, DOI 10.1172/JCI134815; Charlesworth B, 2009, NAT REV GENET, V10, P195, DOI 10.1038/nrg2526; Crowe S, 2003, J LEUKOCYTE BIOL, V74, P635, DOI 10.1189/jlb.0503204; da Silva J, 2012, GENETICS, V190, P1087, DOI 10.1534/genetics.111.136366; De Maio N, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005421; Doitsh G, 2014, NATURE, V505, P509, DOI 10.1038/nature12940; Drummond AJ, 2002, GENETICS, V161, P1307; Drummond AJ, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-214; Drummond AJ, 2006, PLOS BIOL, V4, P699, DOI 10.1371/journal.pbio.0040088; Drummond AJ, 2012, MOL BIOL EVOL, V29, P1969, DOI 10.1093/molbev/mss075; Edwards CTT, 2006, GENETICS, V174, P1441, DOI 10.1534/genetics.105.052019; Eller E, 2004, HUM BIOL, V76, P689, DOI 10.1353/hub.2005.0006; Fang P, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0637-x; Feder AF, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006358; Frost SDW, 2005, P NATL ACAD SCI USA, V102, P18514, DOI 10.1073/pnas.0504658102; Fulcher JA, 2004, J VIROL, V78, P7883, DOI 10.1128/JVI.78.15.7883-7893.2004; Ganusov VV, 2011, J VIROL, V85, P10518, DOI 10.1128/JVI.00655-11; Garcia V, 2018, J R SOC INTERFACE, V15, DOI 10.1098/rsif.2017.0921; Garcia V, 2016, PLOS COMPUT BIOL, V12, DOI 10.1371/journal.pcbi.1004721; Geels MJ, 2003, J VIROL, V77, P12430, DOI 10.1128/JVI.77.23.12430-12440.2003; Gillespie JH, 2000, GENETICS, V155, P909; Goulder P, 1997, IMMUNOL REV, V159, P17, DOI 10.1111/j.1600-065X.1997.tb01004.x; Grant RM, 2002, JAMA-J AM MED ASSOC, V288, P181, DOI 10.1001/jama.288.2.181; Grenfell BT, 2004, SCIENCE, V303, P327, DOI 10.1126/science.1090727; Haas A, 2011, J VIROL, V85, P12102, DOI 10.1128/JVI.05607-11; Haase AT, 1996, SCIENCE, V274, P985, DOI 10.1126/science.274.5289.985; Han JY, 2009, JAIDS-J ACQ IMM DEF, V52, P553, DOI 10.1097/QAI.0b013e3181c1d4fe; Henn MR, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002529; Ho YC, 2013, CELL, V155, P540, DOI 10.1016/j.cell.2013.09.020; Holmes EC, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000505; HUNT RD, 1983, P NATL ACAD SCI-BIOL, V80, P5085, DOI 10.1073/pnas.80.16.5085; Imamichi H, 2011, J INFECT DIS, V204, P309, DOI 10.1093/infdis/jir259; Institute for Laboratory Animal Research, 2011, GUIDE CARE USE LAB A; Kawashima Y, 2009, NATURE, V458, P641, DOI 10.1038/nature07746; Khaitan Alka, 2011, Curr HIV/AIDS Rep, V8, P4, DOI 10.1007/s11904-010-0066-0; Kijak GH, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006510; Kim WK, 2010, J LEUKOCYTE BIOL, V87, P557, DOI 10.1189/jlb.0209082; Lamers SL, 2015, J VIROL, V89, P8484, DOI 10.1128/JVI.01010-15; Lamers SL, 2013, J GEN VIROL, V94, P2469, DOI 10.1099/vir.0.055335-0; Leitner T, 1999, P NATL ACAD SCI USA, V96, P10752, DOI 10.1073/pnas.96.19.10752; Lemey P, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000520; Lin JH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061957; Liu MKP, 2013, J CLIN INVEST, V123, P380, DOI 10.1172/JCI65330; Lotka AJ, 1925, ELEMENTS PHYS BIOL, DOI 10.1038/116461b0; Magalis BR, 2018, VIRUS EVOL, V4, DOI 10.1093/ve/vey018; Magalis BR, 2017, J VIROL, V91, DOI 10.1128/JVI.01162-17; Maldarelli F, 2013, J VIROL, V87, P10313, DOI 10.1128/JVI.01225-12; Mani I, 2002, J VIROL, V76, P10745, DOI 10.1128/JVI.76.21.10745-10755.2002; McMichael AJ, 2010, NAT REV IMMUNOL, V10, P11, DOI 10.1038/nri2674; Milicic A, 2005, J IMMUNOL, V175, P4618, DOI 10.4049/jimmunol.175.7.4618; Minin VN, 2008, PHILOS T R SOC B, V363, P3985, DOI 10.1098/rstb.2008.0176; Minin VN, 2008, MOL BIOL EVOL, V25, P1459, DOI 10.1093/molbev/msn090; Mueller N, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8070200; NOWAK MA, 1991, SCIENCE, V254, P963, DOI 10.1126/science.1683006; Nowak MA, 1996, SCIENCE, V272, P74, DOI 10.1126/science.272.5258.74; Ogg GS, 1999, J VIROL, V73, P797, DOI 10.1128/JVI.73.1.797-800.1999; Palmer S, 2005, J CLIN MICROBIOL, V43, P406, DOI 10.1128/JCM.43.1.406-413.2005; Pybus OG, 2000, GENETICS, V155, P1429; Pybus OG, 2009, NAT REV GENET, V10, P540, DOI 10.1038/nrg2583; Rambaut A, 2008, NATURE, V453, P615, DOI 10.1038/nature06945; Rambaut A, 2016, VIRUS EVOL, V2, DOI 10.1093/ve/vew007; Rehermann B, 2009, J CLIN INVEST, V119, P1745, DOI 10.1172/JCI39133; Rife BD, 2016, J VIROL, V90, P6112, DOI 10.1128/JVI.00137-16; Rouzine IM, 2001, MICROBIOL MOL BIOL R, V65, P151, DOI 10.1128/MMBR.65.1.151-185.2001; Rouzine IM, 1999, P NATL ACAD SCI USA, V96, P10758, DOI 10.1073/pnas.96.19.10758; Salemi M, 2013, INFECT DIS REP, V5, P8, DOI 10.4081/idr.2013.s1.e3; Schmitz JE, 1999, SCIENCE, V283, P857, DOI 10.1126/science.283.5403.857; Seeholzer A, 2014, PHYS REV LETT, V113, DOI 10.1103/PhysRevLett.113.128101; Seo TK, 2002, GENETICS, V160, P1283; Shankarappa R, 1999, J VIROL, V73, P10489, DOI 10.1128/JVI.73.12.10489-10502.1999; Shriner D, 2004, GENETICS, V166, P1155, DOI 10.1534/genetics.166.3.1155; Strickland SL, 2014, J GEN VIROL, V95, P2784, DOI 10.1099/vir.0.070318-0; Strickland SL, 2012, J GEN VIROL, V93, P925, DOI 10.1099/vir.0.039586-0; Strimmer K, 1997, P NATL ACAD SCI USA, V94, P6815, DOI 10.1073/pnas.94.13.6815; Troyer RM, 2005, J VIROL, V79, P9006, DOI 10.1128/JVI.79.14.9006-9018.2005; van Deutekom HWM, 2013, J IMMUNOL, V191, P3277, DOI 10.4049/jimmunol.1300962; Van Valen L, 1973, EVOL THEORY, V1, P1; van Velzen E, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17019-4; VOLTERRA VITO, 1926, MEM R ACCAD NAZ LINCEI CL FIS MAT E NAT, V2, P31; Wang JL, 2003, GENETICS, V163, P429; Wang SP, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004665; Williamson S, 2003, MOL BIOL EVOL, V20, P1318, DOI 10.1093/molbev/msg144; Wilson JDK, 2000, AIDS, V14, P225, DOI 10.1097/00002030-200002180-00003; Xu YN, 2008, J INFECT DIS, V197, P309, DOI 10.1086/524847; Zuniga EI, 2015, ANNU REV VIROL, V2, P573, DOI 10.1146/annurev-virology-100114-055226	98	0	0	2	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 6	2021	12								709962	10.3389/fimmu.2021.709962	http://dx.doi.org/10.3389/fimmu.2021.709962			18	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WJ7CA	34691023	gold, Green Published			2022-12-18	WOS:000709197300001
J	Tewari, A; Prabagar, MGG; Gibbings, SLL; Rawat, K; Jakubzick, CVV				Tewari, Anita; Prabagar, Miglena G. G.; Gibbings, Sophie L. L.; Rawat, Kavita; Jakubzick, Claudia V. V.			LN Monocytes Limit DC-Poly I:C Induced Cytotoxic T Cell Response via IL-10 and Induction of Suppressor CD4 T Cells	FRONTIERS IN IMMUNOLOGY			English	Article						dendritic cells; Ly6C(+) monocytes; antigen-presentation; IL-10; cytotoxic T cells; Poly I; C; suppressor CD4(+) T cells; double-stranded RNA	CONVENTIONAL DENDRITIC CELLS; MONONUCLEAR PHAGOCYTES; MYELOID CELLS; HUMAN LUNG; DIFFERENTIATION; EXPRESSION; REVEALS; MACROPHAGES; CD103(+); SIGNALS	Every immune response has accelerators and brakes. Depending on the pathogen or injury, monocytes can play either role, promoting or resolving immunity. Poly I:C, a potent TLR3 ligand, licenses cross-presenting dendritic cells (DC1) to accelerate a robust cytotoxic T cells response against a foreign antigen. Poly I:C thus has promise as an adjuvant in cancer immunotherapy and viral subunit vaccines. Like DC1s, monocytes are also abundant in the LNs. They may act as either immune accelerators or brakes, depending on the inflammatory mediator they encounter. However, little is known about their contribution to adaptive immunity in the context of antigen and Poly I:C. Using monocyte-deficient and chimeric mice, we demonstrate that LN monocytes indirectly dampen a Poly I:C induced antigen-specific cytotoxic T cell response, exerting a "braking" function. This effect is mediated by IL-10 production and induction of suppressor CD4(+) T cells. In a metastatic melanoma model, we show that a triple-combination prophylactic treatment consisting of anti-IL-10, tumor peptides and Poly I:C works because removing IL-10 counteracts the monocytic brake, resulting in significantly fewer tumors compared to mice treated with tumor peptides and Poly I:C alone. Finally, in human LN tissue, we observed that monocytes (unlike DCs) express high levels of IL-10, suggesting that anti-IL-10 may be an important addition to treatments. Overall, our data demonstrates that LN monocytes regulate the induction of a robust DC1-mediated immune response. Neutralization of either IL-10 or monocytes can augment Poly I:C-based treatments and enhance T cell cytotoxicity.	[Tewari, Anita; Rawat, Kavita; Jakubzick, Claudia V. V.] Geisel Sch Med, Dept Microbiol & Immunol, Hanover, NH 03755 USA; [Prabagar, Miglena G. G.; Gibbings, Sophie L. L.] Natl Jewish Hlth, Dept Pediat, Denver, CO USA	Dartmouth College; National Jewish Health	Jakubzick, CVV (corresponding author), Geisel Sch Med, Dept Microbiol & Immunol, Hanover, NH 03755 USA.	claudia.jakubzick@dartmouth.edu		Tewari, Anita/0000-0001-6331-1701	National Institutes of Health [R01 HL115334, R01 HL135001, R35 HL155458]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	National Institutes of Health supported this work CJ grants: R01 HL115334, R01 HL135001 and R35 HL155458 (CJ).	Atif SM, 2018, AM J RESP CELL MOL, V59, P580, DOI 10.1165/rcmb.2018-0159OC; Bosteels C, 2020, IMMUNITY, V52, P1039, DOI 10.1016/j.immuni.2020.04.005; Cheong C, 2010, CELL, V143, P416, DOI 10.1016/j.cell.2010.09.039; Croxford AL, 2015, IMMUNITY, V43, P502, DOI 10.1016/j.immuni.2015.08.010; Daley JM, 2008, J LEUKOCYTE BIOL, V83, P64, DOI 10.1189/jlb.0407247; Desch AN, 2016, AM J RESP CRIT CARE, V193, P614, DOI 10.1164/rccm.201507-1376OC; Desch AN, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5674; Edelson BT, 2010, J EXP MED, V207, P823, DOI 10.1084/jem.20091627; Gibbings SL, 2018, METHODS MOL BIOL, V1799, P381, DOI 10.1007/978-1-4939-7896-0_28; Gibbings SL, 2017, AM J RESP CELL MOL, V57, P66, DOI 10.1165/rcmb.2016-0361OC; Ginhoux F, 2010, SCIENCE, V330, P841, DOI 10.1126/science.1194637; Guilliams M, 2018, IMMUNITY, V49, P595, DOI 10.1016/j.immuni.2018.10.005; Henson PM., 2009, RECOGNTION REMOVAL A, P341; Hohl TM, 2009, CELL HOST MICROBE, V6, P470, DOI 10.1016/j.chom.2009.10.007; Ingersoll MA, 2010, BLOOD, V115, pE10, DOI 10.1182/blood-2009-07-235028; Jakubzick C, 2008, J IMMUNOL, V180, P3019, DOI 10.4049/jimmunol.180.5.3019; Jakubzick C, 2013, IMMUNITY, V39, P599, DOI 10.1016/j.immuni.2013.08.007; Jakubzick CV, 2017, NAT REV IMMUNOL, V17, P349, DOI 10.1038/nri.2017.28; Kim TS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004204; Ko HJ, 2014, J IMMUNOL, V192, P2202, DOI 10.4049/jimmunol.1302040; Langlet C, 2012, J IMMUNOL, V188, P1751, DOI 10.4049/jimmunol.1102744; Larson SR, 2016, CELL DEATH DIFFER, V23, P997, DOI 10.1038/cdd.2016.24; Leach SM, 2020, CELL REP, V33, DOI 10.1016/j.celrep.2020.108337; Leon B, 2007, IMMUNITY, V26, P519, DOI 10.1016/j.immuni.2007.01.017; Liu K, 2007, NAT IMMUNOL, V8, P578, DOI 10.1038/ni1462; Misharin AV, 2017, J EXP MED, V214, P2387, DOI 10.1084/jem.20162152; Murphy KM, 2013, ADV IMMUNOL, V120, P239, DOI 10.1016/B978-0-12-417028-5.00009-0; Nakano H, 2009, NAT IMMUNOL, V10, P394, DOI 10.1038/ni.1707; Ott PA, 2020, CELL, V183, P347, DOI 10.1016/j.cell.2020.08.053; Ott PA, 2017, NATURE, V547, P217, DOI 10.1038/nature22991; Randolph GJ, 1999, IMMUNITY, V11, P753, DOI 10.1016/S1074-7613(00)80149-1; Ravichandran KS, 2007, NAT REV IMMUNOL, V7, P964, DOI 10.1038/nri2214; Schulz C, 2012, SCIENCE, V336, P86, DOI 10.1126/science.1219179; Scott CL, 2014, IMMUNOL REV, V262, P9, DOI 10.1111/imr.12220; Serbina NV, 2006, NAT IMMUNOL, V7, P311, DOI 10.1038/ni1309; Serbina NV, 2003, IMMUNITY, V19, P59, DOI 10.1016/S1074-7613(03)00171-7; Tussiwand R, 2015, IMMUNITY, V42, P916, DOI 10.1016/j.immuni.2015.04.017; Vieira PL, 2004, J IMMUNOL, V172, P5986, DOI 10.4049/jimmunol.172.10.5986; Wakim LM, 2011, NATURE, V471, P629, DOI 10.1038/nature09863; Yi HF, 2012, J IMMUNOL, V189, P4295, DOI 10.4049/jimmunol.1200086; Yona S, 2013, IMMUNITY, V38, P79, DOI 10.1016/j.immuni.2012.12.001	41	0	0	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 6	2021	12								763379	10.3389/fimmu.2021.763379	http://dx.doi.org/10.3389/fimmu.2021.763379			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WJ7CE	34691085	gold, Green Published			2022-12-18	WOS:000709197700001
J	Alves, JRS; de Araujo, FF; Pires, CV; Teixeira-Carvalho, A; Lima, BAS; Torres, LM; Ntumngia, FB; Adams, JH; Kano, FS; Carvalho, LH				Alves, Jessica R. S.; de Araujo, Fernanda F.; Pires, Camilla V.; Teixeira-Carvalho, Andrea; Lima, Barbara A. S.; Torres, Leticia M.; Ntumngia, Francis B.; Adams, John H.; Kano, Flora S.; Carvalho, Luzia H.			Multiplexed Microsphere-Based Flow Cytometric Assay to Assess Strain Transcending Antibodies to Plasmodium vivax Duffy Binding Protein II Reveals an Efficient Tool to Identify Binding-Inhibitory Antibody Responders	FRONTIERS IN IMMUNOLOGY			English	Article						multiplex assay; inhibitory antibodies; Duffy binding protein; Plasmodium vivax; malaria	MALARIA; DOMAIN; POLYMORPHISMS; PROTECTION; RESPONSES; EPITOPES; IMMUNITY; RECEPTOR; ANTIGEN	Malaria remains a major public health problem worldwide, and Plasmodium vivax is the most widely distributed malaria parasite. Naturally acquired binding inhibitory antibodies (BIAbs) to region II of the Duffy binding protein (DBPII), a P. vivax ligand that is critical for reticulocyte invasion, are associated with a reduced risk of clinical malaria. Owing to methodological issues in evaluating antibodies that inhibit the DBPII-DARC interaction, a limited number of studies have investigated DBPII BIAbs in P. vivax-exposed populations. Based on the assumption that individuals with a consistent BIAb response are characterized by strain-transcending immune responses, we hypothesized that detecting broadly reactive DBPII antibodies would indicate the presence of BIAb response. By taking advantage of an engineered DBPII immunogen targeting conserved DBPII neutralizing epitopes (DEKnull-2), we standardized a multiplex flow cytometry-based serological assay to detect broadly neutralizing IgG antibodies. For this study, a standard in vitro cytoadherence assay with COS-7 cells expressing DBPII was used to test for DBPII BIAb response in long-term P. vivax-exposed Amazonian individuals. Taken together, the results demonstrate that this DBPII-based multiplex assay facilitates identifying DBPII BIAb carriers. Of relevance, the ability of the multiplex assay to identify BIAb responders was highly accurate when the positivity for all antigens was considered. In conclusion, the standardized DBPII-based flow cytometric assay confirmed that DBPII-BIAb activity was associated with the breadth rather than the magnitude of anti-DBPII antibodies. Altogether, our results suggest that multiplex detection of broadly DBPII-reactive antibodies facilitates preliminary screening of BIAb responders.	[Alves, Jessica R. S.; Lima, Barbara A. S.; Torres, Leticia M.; Kano, Flora S.; Carvalho, Luzia H.] Oswaldo Cruz Fdn FIOCRUZ, Rene Rachou Inst, Mol Biol & Malaria Immunol, Belo Horizonte, MG, Brazil; [de Araujo, Fernanda F.; Teixeira-Carvalho, Andrea] Oswaldo Cruz Fdn FIOCRUZ, Rene Rachou Inst, Integrated Res Grp Biomarkers, Belo Horizonte, MG, Brazil; [Pires, Camilla V.; Ntumngia, Francis B.; Adams, John H.] Univ S Florida, Coll Publ Hlth, Ctr Global Hlth & Infect Dis Res, Dept Global Hlth, Tampa, FL 33620 USA	Fundacao Oswaldo Cruz; Fundacao Oswaldo Cruz; State University System of Florida; University of South Florida	Kano, FS; Carvalho, LH (corresponding author), Oswaldo Cruz Fdn FIOCRUZ, Rene Rachou Inst, Mol Biol & Malaria Immunol, Belo Horizonte, MG, Brazil.	flora.kano@fiocruz.br; luzia.carvalho@fiocruz.br	; Adams, John/G-1800-2015	Ntumngia, Francis/0000-0001-9867-3534; Adams, John/0000-0003-3707-7979	National Research Council for Scientific and Technological Development-CNPq [422257/2016-8]; Research Foundation of Minas Gerais-FAPEMIG [APQ-02625-15]; Programa Fiocruz de Fomento a Inovacao: Inova Fiocruz [VPPCB-007-FIO-18-2-33]; NIH Research Project Grant Program [R01AI064478]; CNPq; Coordination for the Improvement of Higher Education Personnel (CAPES) [001]; CAPES	National Research Council for Scientific and Technological Development-CNPq(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Research Foundation of Minas Gerais-FAPEMIG; Programa Fiocruz de Fomento a Inovacao: Inova Fiocruz; NIH Research Project Grant Program(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); CNPq(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Coordination for the Improvement of Higher Education Personnel (CAPES)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); CAPES(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES))	This work was supported by the National Research Council for Scientific and Technological Development-CNPq (422257/2016-8 by LC), the Research Foundation of Minas Gerais-FAPEMIG (APQ-02625-15 by LC), Programa Fiocruz de Fomento a Inovacao: Inova Fiocruz (VPPCB-007-FIO-18-2-33 by FK), and the NIH Research Project Grant Program (R01AI064478 by JA and LC). LC and AT-C are research fellows from CNPq and the Coordination for the Improvement of Higher Education Personnel (CAPES, Finance Code 001). Scholarships were sponsored by CAPES (BASL, JRSA) and CNPq (LC, FA, CP, and LT). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ADAMS JH, 1992, P NATL ACAD SCI USA, V89, P7085, DOI 10.1073/pnas.89.15.7085; Arevalo-Herrera M, 2010, HUM VACCINES, V6, P124, DOI 10.4161/hv.6.1.9931; Armistead JS, 2018, TRENDS PARASITOL, V34, P114, DOI 10.1016/j.pt.2017.10.009; BARNWELL JW, 1995, ANN TROP MED PARASIT, V89, P113, DOI 10.1080/00034983.1995.11812941; Battle KE, 2019, LANCET, V394, P332, DOI 10.1016/S0140-6736(19)31096-7; Carinelli S, 2015, NEW BIOTECHNOL, V32, P521, DOI 10.1016/j.nbt.2015.04.002; Ceravolo IP, 2008, SCAND J IMMUNOL, V67, P270, DOI 10.1111/j.1365-3083.2007.02059.x; Ceravolo IP, 2009, CLIN EXP IMMUNOL, V156, P502, DOI 10.1111/j.1365-2249.2009.03931.x; Ceravolo IP, 2005, AM J TROP MED HYG, V72, P675, DOI 10.4269/ajtmh.2005.72.675; Chan LJ, 2020, CELL MICROBIOL, V22, DOI 10.1111/cmi.13110; Chen E, 2016, P NATL ACAD SCI USA, V113, P6277, DOI 10.1073/pnas.1600488113; Chen E, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003644; Cheng Q, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003413; Chitnis CE, 1996, J EXP MED, V184, P1531, DOI 10.1084/jem.184.4.1531; CHITNIS CE, 1994, J EXP MED, V180, P497, DOI 10.1084/jem.180.2.497; Chootong P, 2014, PARASITOL INT, V63, P858, DOI 10.1016/j.parint.2014.07.014; Chootong P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035769; Cole-Tobian JL, 2009, INFECT IMMUN, V77, P4009, DOI 10.1128/IAI.00158-09; de Cassan SC, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00348; De SL, 2021, EXPERT REV VACCINES, V20, P97, DOI 10.1080/14760584.2021.1880898; de Sousa TN, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022944; FANG XD, 1991, MOL BIOCHEM PARASIT, V44, P125, DOI 10.1016/0166-6851(91)90228-X; Fouda GG, 2006, CLIN VACCINE IMMUNOL, V13, P1307, DOI 10.1128/CVI.00183-06; Gruszczyk J, 2018, SCIENCE, V359, P48, DOI 10.1126/science.aan1078; Harris I, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-254; He WQ, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0006987; Kano FS, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005177; Kano FS, 2012, TROP MED INT HEALTH, V17, P989, DOI 10.1111/j.1365-3156.2012.03016.x; King CL, 2008, P NATL ACAD SCI USA, V105, P8363, DOI 10.1073/pnas.0800371105; Lal G, 2004, CLIN DIAGN LAB IMMUN, V11, P272, DOI 10.1128/CDLI.11.2.272-279.2004; Longley RJ, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005888; Malleret B, 2021, NAT MICROBIOL, V6, P991, DOI 10.1038/s41564-021-00939-3; McKenzie FE, 2002, J PARASITOL, V88, P521, DOI 10.1645/0022-3395(2002)088[0521:PVBSD]2.0.CO;2; Medeiros CMP, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0232786; Michon P, 2000, INFECT IMMUN, V68, P3164, DOI 10.1128/IAI.68.6.3164-3171.2000; Mueller I, 2009, LANCET INFECT DIS, V9, P555, DOI 10.1016/S1473-3099(09)70177-X; Nicolete VC, 2016, J INFECT DIS, V214, P1539, DOI 10.1093/infdis/jiw407; Ntumngia FB, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-13891-2; Ntumngia FB, 2016, MBIO, V7, DOI 10.1128/mBio.01261-16; Ntumngia FB, 2012, INFECT IMMUN, V80, P1203, DOI 10.1128/IAI.05924-11; Ntumngia FB, 2012, CLIN VACCINE IMMUNOL, V19, P30, DOI 10.1128/CVI.05466-11; Ong KIC, 2017, BMJ GLOB HEALTH, V2, DOI 10.1136/bmjgh-2017-000415; Paul AS, 2015, CURR OPIN HEMATOL, V22, P220, DOI 10.1097/MOH.0000000000000135; Pickering JW, 2002, AM J CLIN PATHOL, V117, P589; Pires CV, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0207244; Priest JW, 2018, MALARIA J, V17, DOI 10.1186/s12936-018-2566-0; Rawlinson TA, 2019, NAT MICROBIOL, V4, P1497, DOI 10.1038/s41564-019-0462-1; Sampath S, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003420; Shakri AR, 2012, J IMMUNOASS IMMUNOCH, V33, P403, DOI 10.1080/15321819.2012.659781; Smith RD, 2020, AM J TROP MED HYG, V103, P1871, DOI 10.4269/ajtmh.19-0472; Sousa TN, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-334; Souza-Silva FA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093782; Sullivan KM, 2009, PUBLIC HEALTH REP, V124, P471, DOI 10.1177/003335490912400320; TSUBOI T, 1994, INFECT IMMUN, V62, P5581, DOI 10.1128/IAI.62.12.5581-5586.1994; WHO, 2010, WORLD MALARIA REPORT 2010, P1; Wideman TH, 2013, PAIN, V154, P2262, DOI 10.1016/j.pain.2013.06.005; Xainli J, 2003, INFECT IMMUN, V71, P2508, DOI 10.1128/IAI.71.5.2508-2515.2003	57	0	0	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 5	2021	12								704653	10.3389/fimmu.2021.704653	http://dx.doi.org/10.3389/fimmu.2021.704653			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WK5GS	34675915	Green Published, gold			2022-12-18	WOS:000709754400001
J	Yang, PZ; Ohno, S; Zierhut, M				Yang, Peizeng; Ohno, Shigeaki; Zierhut, Manfred			Editorial: New Insights Into Uveitis: Immunity, Genes, and Microbes	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						uveitis; immunity; genes; microbes; pathogenesis			[Yang, Peizeng] Chongqing Med Univ, Affiliated Hosp 1, Chongqing, Peoples R China; [Ohno, Shigeaki] Hokkaido Univ, Dept Ophthalmol, Fac Med, Sapporo, Hokkaido, Japan; [Ohno, Shigeaki] Hokkaido Univ, Grad Sch Med, Sapporo, Hokkaido, Japan; [Zierhut, Manfred] Univ Tubingen, Ctr Ophthalmol, Tubingen, Germany	Chongqing Medical University; Hokkaido University; Hokkaido University; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital	Yang, PZ (corresponding author), Chongqing Med Univ, Affiliated Hosp 1, Chongqing, Peoples R China.	peizengycmu@126.com			National Natural Science Foundation Key Program [81930023]; Natural Science Foundation Major International (Regional) Joint Research Project [81720108009]; Chongqing Outstanding Scientists Project (2019); Chongqing Key Laboratory of Ophthalmology (CSTC) [2008CA5003]; Chongqing Science & Technology Platform and Base Construction Program [cstc2014pt-sy10002]; Chongqing Chief Medical Scientist Project (2018)	National Natural Science Foundation Key Program; Natural Science Foundation Major International (Regional) Joint Research Project; Chongqing Outstanding Scientists Project (2019); Chongqing Key Laboratory of Ophthalmology (CSTC)(Natural Science Foundation Project of CQ CSTC); Chongqing Science & Technology Platform and Base Construction Program; Chongqing Chief Medical Scientist Project (2018)	National Natural Science Foundation Key Program (81930023), Natural Science Foundation Major International (Regional) Joint Research Project (81720108009), Chongqing Outstanding Scientists Project (2019), Chongqing Key Laboratory of Ophthalmology (CSTC, 2008CA5003), Chongqing Science & Technology Platform and Base Construction Program (cstc2014pt-sy10002) and the Chongqing Chief Medical Scientist Project (2018).		0	0	0	2	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 5	2021	12								765377	10.3389/fimmu.2021.765377	http://dx.doi.org/10.3389/fimmu.2021.765377			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WL9PN	34675943	Green Published, gold			2022-12-18	WOS:000710729700001
J	Deng, LX; Chen, YX; Hu, XF; Zhou, JH; Zhang, Y				Deng, Linxia; Chen, Yaxian; Hu, Xiufen; Zhou, Jianhua; Zhang, Yu			Case Report: Successful Treatment of Refractory Interstitial Lung Disease With Cyclosporine A and Pirfenidone in a Child With SLE	FRONTIERS IN IMMUNOLOGY			English	Article						systemic lupus erythematosus; interstitial lung disease; child; pirfenidone; cyclosporine A (CsA)	OBLITERANS ORGANIZING PNEUMONIA; COMBINATION THERAPY; LUPUS; CYCLOPHOSPHAMIDE; CORTICOSTEROIDS; MANIFESTATION; TRIAL	Interstitial lung disease (ILD) as an initial manifestation of lupus is rare, especially in young children. Here, we report a case of a 3-year-old boy who presented with fever, shortness of breath, and facial erythema. Clinical examination suggested a diagnosis of active systemic lupus erythematosus (SLE) with butterfly rash, anemia, positive antinuclear antibody, positive anti-double-stranded DNA, and hypocomplementemia. On retrospective review of the patient's records, multiple chest computed tomography (CT) images showed non-specific interstitial pneumonia + organizing pneumonia pattern, with no further autoimmune work-up during the visit to a respiratory department. In our opinion, persistent interstitial pneumonia may be a clue to connective tissue disease. The patient received steroid treatment for 1 year, and the radiological and immunological resolution was noted. However, he still suffered from cough and dyspnea. After a 1-year follow-up, he was hospitalized again for SLE relapse. While continuing corticosteroid therapy, the patient was given combination therapy consisting of cyclosporine A (CsA) and monthly-pulse cyclophosphamide for 6 months, and decreased proteinuria was noted. However, the patient's respiratory symptoms and pulmonary radiologic findings did not improve significantly. With continued steroid therapy, the patient was started on a daily regimen of CsA and pirfenidone. Both drugs were sufficiently effective to allow gradual reduction of steroid dosage. After 2 years of treatment, marked improvements in symptoms, pulmonary function and chest CT images were observed. Our experience with this case emphasizes that prompt work-up for connective tissue disease (CTD) should be considered in young children with ILD, and pirfenidone might be a useful add-on therapy with immunosuppressive agents for refractory CTD-ILD in pediatric patients. Nevertheless, further clinical trials including larger numbers of patients need to assess the efficiency and safety of this combination therapy for refractory CTD-ILD.	[Deng, Linxia; Chen, Yaxian; Hu, Xiufen; Zhou, Jianhua; Zhang, Yu] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Pediat, Wuhan, Peoples R China	Huazhong University of Science & Technology	Zhang, Y (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Pediat, Wuhan, Peoples R China.	yuzhang497@163.com			Funding Science and Technology Planning Project of Wuhan [2016060101010041]	Funding Science and Technology Planning Project of Wuhan	Funding Science and Technology Planning Project of Wuhan (NO. 2016060101010041).	Baisya R, 2021, LUPUS, V30, P336, DOI 10.1177/0961203320967439; Enomoto N, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-43782-7; Glassberg MK, 2019, EUR RESPIR J, V54, DOI 10.1183/13993003.00399-2019; Hedrich CM, 2011, CLIN RHEUMATOL, V30, P275, DOI 10.1007/s10067-010-1576-2; Jee AS, 2019, DRUGS, V79, P1511, DOI 10.1007/s40265-019-01178-x; Kameda H, 2005, J RHEUMATOL, V32, P1719; Keane MP, 2000, THORAX, V55, P159, DOI 10.1136/thorax.55.2.159; King TE, 2014, NEW ENGL J MED, V370, P2083, DOI 10.1056/NEJMoa1402582; Kotani T, 2008, J RHEUMATOL, V35, P254; Kumar A, 2013, J Nepal Health Res Counc, V11, P83; Ley B, 2017, AM J RESP CRIT CARE, V196, P756, DOI 10.1164/rccm.201701-0091OC; Ma XY, 2021, CLIN RHEUMATOL, V40, P3185, DOI 10.1007/s10067-021-05794-5; Macias-Barragan J, 2010, FIBROGENESIS TISSUE, V3, DOI 10.1186/1755-1536-3-16; Oku H, 2008, EUR J PHARMACOL, V590, P400, DOI 10.1016/j.ejphar.2008.06.046; Raghu G, 2015, AM J RESP CRIT CARE, V192, pE3, DOI 10.1164/rccm.201506-1063ST; Shimojima Y, 2017, JCR-J CLIN RHEUMATOL, V23, P87, DOI 10.1097/RHU.0000000000000487; Takada H, 2005, PEDIATR PULM, V40, P257, DOI 10.1002/ppul.20224; Tashkin DP, 2006, NEW ENGL J MED, V354, P2655, DOI 10.1056/NEJMoa055120; Tashkin DP, 2016, LANCET RESP MED, V4, P708, DOI 10.1016/S2213-2600(16)30152-7; Volkmann ER, 2020, ACR OPEN RHEUMATOL, V2, P362, DOI 10.1002/acr2.11125; West JB., 2008, PULMONARY PATHOPHYSI; Widemann BC, 2014, PEDIATR BLOOD CANCER, V61, P1598, DOI 10.1002/pbc.25041	22	0	0	1	9	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 4	2021	12								708463	10.3389/fimmu.2021.708463	http://dx.doi.org/10.3389/fimmu.2021.708463			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WV2KA	34671344	Green Published, gold			2022-12-18	WOS:000717065500001
J	Huang, YX; Thornqvist, L; Ohlin, M				Huang, Yixun; Thornqvist, Linnea; Ohlin, Mats			Computational Inference, Validation, and Analysis of 5'UTR-Leader Sequences of Alleles of Immunoglobulin Heavy Chain Variable Genes	FRONTIERS IN IMMUNOLOGY			English	Article						immunoglobulin heavy chain variable domain; leader sequence; immunoglobulin germline gene; adaptive immune receptor repertoire (AIRR); germline gene inference; 5'-untranslated region	REPERTOIRE; DIVERSITY; DATABASE; REGION	Upstream and downstream sequences of immunoglobulin genes may affect the expression of such genes. However, these sequences are rarely studied or characterized in most studies of immunoglobulin repertoires. Inference from large, rearranged immunoglobulin transcriptome data sets offers an opportunity to define the upstream regions (5'-untranslated regions and leader sequences). We have now established a new data pre-processing procedure to eliminate artifacts caused by a 5'-RACE library generation process, reanalyzed a previously studied data set defining human immunoglobulin heavy chain genes, and identified novel upstream regions, as well as previously identified upstream regions that may have been identified in error. Upstream sequences were also identified for a set of previously uncharacterized germline gene alleles. Several novel upstream region variants were validated, for instance by their segregation to a single haplotype in heterozygotic subjects. SNPs representing several sequence variants were identified from population data. Finally, based on the outcomes of the analysis, we define a set of testable hypotheses with respect to the placement of particular alleles in complex IGHV locus haplotypes, and discuss the evolutionary relatedness of particular heavy chain variable genes based on sequences of their upstream regions.</p>	[Huang, Yixun; Thornqvist, Linnea; Ohlin, Mats] Lund Univ, Dept Immunotechnol, Lund, Sweden	Lund University	Ohlin, M (corresponding author), Lund Univ, Dept Immunotechnol, Lund, Sweden.	mats.ohlin@immun.lth.se	Ohlin, Mats/A-7307-2010	Ohlin, Mats/0000-0002-5105-1938	The Swedish Research Council [2018-05973];  [41];  [2019-01042]	The Swedish Research Council(Swedish Research Council); ; 	This study was supported by a grant from The Swedish Research Council [grant number: 2019-01042].	Alamyar Eltaf, 2012, Methods Mol Biol, V882, P569, DOI 10.1007/978-1-61779-842-9_32; Altshuler DM, 2015, NATURE, V526, P68, DOI 10.1038/nature15393; Avnir Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep20842; Benichou J, 2012, IMMUNOLOGY, V135, P183, DOI 10.1111/j.1365-2567.2011.03527.x; Blankenberg D, 2010, BIOINFORMATICS, V26, P1783, DOI 10.1093/bioinformatics/btq281; Boyd SD, 2010, J IMMUNOL, V184, P6986, DOI 10.4049/jimmunol.1000445; Busse CE, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02961; Corcoran MM, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13642; Ford M, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2020.100883; Gadala-Maria D, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00129; Gadala-Maria D, 2015, P NATL ACAD SCI USA, V112, pE862, DOI 10.1073/pnas.1417683112; Gibbs RA, 2007, SCIENCE, V316, P222, DOI 10.1126/science.1139247; Gidoni M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08489-3; Giudicelli W, 2005, NUCLEIC ACIDS RES, V33, pD256, DOI 10.1093/nar/gki010; Huang Y., 2021, COMPUTATIONAL INFERE, DOI [10.1101/2021.06.10.447679, DOI 10.1101/2021.06.10.447679]; Kirik U, 2017, MOL IMMUNOL, V87, P12, DOI 10.1016/j.molimm.2017.03.012; Lefranc MP, 2009, NUCLEIC ACIDS RES, V37, pD1006, DOI 10.1093/nar/gkn838; Leppek K, 2018, NAT REV MOL CELL BIO, V19, P158, DOI 10.1038/nrm.2017.103; Lohse M, 2012, NUCLEIC ACIDS RES, V40, pW622, DOI 10.1093/nar/gks540; Mikocziova I, 2020, NUCLEIC ACIDS RES, V48, P5499, DOI 10.1093/nar/gkaa310; Minoche AE, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-11-r112; Ohlin M, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.603980; Ohlin M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00435; Omer A, 2020, NUCLEIC ACIDS RES, V48, pD1051, DOI 10.1093/nar/gkz872; Parks T, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14946; Ralph DK, 2019, PLOS COMPUT BIOL, V15, DOI 10.1371/journal.pcbi.1007133; Rodriguez OL, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.02136; Saintamand A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00575-0; Sangesland M, 2020, CELL REP, V32, DOI 10.1016/j.celrep.2020.108065; Sheng ZZ, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00537; Simmons MP, 2001, SYST BIOL, V50, P454, DOI 10.1080/106351501300318049; Thornqvist L, 2018, MOL IMMUNOL, V103, P1, DOI 10.1016/j.molimm.2018.08.018; Vander Heiden JA, 2014, BIOINFORMATICS, V30, P1930, DOI 10.1093/bioinformatics/btu138; Wang Y, 2008, IMMUNOL CELL BIOL, V86, P111, DOI 10.1038/sj.icb.7100144; Watson CT, 2017, J IMMUNOL, V198, P3371, DOI 10.4049/jimmunol.1700306; Watson CT, 2013, AM J HUM GENET, V92, P530, DOI 10.1016/j.ajhg.2013.03.004; Wellensiek BP, 2013, PROTEIN SCI, V22, P1392, DOI 10.1002/pro.2325; Xu JL, 2000, IMMUNITY, V13, P37, DOI 10.1016/S1074-7613(00)00006-6; Yaari G, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0243-2; Yates AD, 2020, NUCLEIC ACIDS RES, V48, pD682, DOI 10.1093/nar/gkz966; Zhu Y., 2020, ANTIBODY UPSTREAM SE, DOI [10.1101/2020.09.02.280396, DOI 10.1101/2020.09.02.280396]	41	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 4	2021	12								730105	10.3389/fimmu.2021.730105	http://dx.doi.org/10.3389/fimmu.2021.730105			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WV3AU	34671351	Green Published, gold, Green Submitted			2022-12-18	WOS:000717109800001
J	Song, QL; Javid, A; Zhang, GF; Li, Y				Song, Qingle; Javid, Amaneh; Zhang, Guofang; Li, Yang			Applications of Magnetite Nanoparticles in Cancer Immunotherapies: Present Hallmarks and Future Perspectives	FRONTIERS IN IMMUNOLOGY			English	Review						magnetite nanoparticles; macrophages; cytotoxic T lymphocytes; immune checkpoint blockade; cancer immunotherapy	IRON-OXIDE NANOPARTICLES; IMMUNE CHECKPOINT BLOCKADE; CD47; RITUXIMAB; RESPONSES; CELLS; LIVER	Current immuno-oncotherapeutic protocols that inhibit tumor immune evasion have demonstrated great clinical success. However, the therapeutic response is limited only to a percentage of patients, and the immune-related adverse events can compromise the therapeutic benefits. Therefore, improving cancer immunotherapeutic approaches that pursue high tumor suppression efficiency and low side effects turn out to be a clinical priority. Novel magnetite nanoparticles (MNPs) exhibit great potential for therapeutic and imaging applications by utilizing their properties of superparamagnetism, good biocompatibility, as well as the easy synthesis and modulation/functionalization. In particular, the MNPs can exert magnetic hyperthermia to induce immunogenic cell death of tumor cells for effective antigen release and presentation, and meanwhile polarize tumor-associated macrophages (TAMs) to M1 phenotype for improved tumor killing capability, thus enhancing the anti-tumor immune effects. Furthermore, immune checkpoint antibodies, immune-stimulating agents, or tumor-targeting agents can be decorated on MNPs, thereby improving their selectivity for the tumor or immune cells by the unique magnetic navigation capability of MNPs to promote the tumor killing immune therapeutics with fewer side effects. This mini-review summarizes the recent progress in MNP-based immuno-oncotherapies, including activation of macrophage, promotion of cytotoxic T lymphocyte (CTL) infiltration within tumors and modulation of immune checkpoint blockade, thus further supporting the applications of MNPs in clinical therapeutic protocols.	[Song, Qingle; Javid, Amaneh; Zhang, Guofang; Li, Yang] Chinese Acad Sci, Shenzhen Inst Adv Technol, Lab Immunol & Nanomed, Shenzhen, Peoples R China; [Javid, Amaneh] Sci & Arts Univ, Fac Appl Sci & Engn, Dept Biol Sci, Yazd, Iran	Chinese Academy of Sciences; Shenzhen Institute of Advanced Technology, CAS	Li, Y (corresponding author), Chinese Acad Sci, Shenzhen Inst Adv Technol, Lab Immunol & Nanomed, Shenzhen, Peoples R China.	yang.li@siat.ac.cn	Javed, Ameneh/AAD-8892-2022; Li, Yang/HHN-7327-2022; Li, Yang/ABA-9977-2021	Javed, Ameneh/0000-0002-6445-6176; Li, Yang/0000-0001-7242-4687; Li, Yang/0000-0001-7242-4687	Shenzhen Science and Technology Program	Shenzhen Science and Technology Program	Funding This work was financially supported by the Shenzhen Science and Technology Program (GJHZ20190821155803877), the National Natural Science Foundation of China (32171390 and 31701005), the China Postdoctoral Science Foundation (2020M672898), the SIAT Innovation Program for Excellent Young Researchers (E1G068), and CAS Presidents International Fellowship Initiative (PIFI, 2020VBA0028, 2020VBA0022, 2022VBA0008 and 2021PB0060).	Advani R, 2018, NEW ENGL J MED, V379, P1711, DOI 10.1056/NEJMoa1807315; Alsaab HO, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00561; Bai C, 2018, ADV FUNCT MATER, V28, DOI 10.1002/adfm.201802281; Bourrinet P, 2006, INVEST RADIOL, V41, P313, DOI 10.1097/01.rli.0000197669.80475.dd; Buchbinder E, 2015, J CLIN INVEST, V125, P3377, DOI 10.1172/JCI80012; Bullivant JP, 2013, INT J MOL SCI, V14, P17501, DOI 10.3390/ijms140917501; Byun DJ, 2017, NAT REV ENDOCRINOL, V13, P195, DOI 10.1038/nrendo.2016.205; Cann SAH, 2003, POSTGRAD MED J, V79, P672; Carlson RD, 2020, TOXINS, V12, DOI 10.3390/toxins12040241; Chao MP, 2010, CELL, V142, P699, DOI 10.1016/j.cell.2010.07.044; Chao Y, 2019, NANO LETT, V19, P4287, DOI 10.1021/acs.nanolett.9b00579; Chen DS, 2017, NATURE, V541, P321, DOI 10.1038/nature21349; Chen Q, 2019, NAT NANOTECHNOL, V14, P89, DOI 10.1038/s41565-018-0319-4; Chiang CS, 2018, NAT NANOTECHNOL, V13, P746, DOI 10.1038/s41565-018-0146-7; Cho NH, 2011, NAT NANOTECHNOL, V6, P675, DOI [10.1038/NNANO.2011.149, 10.1038/nnano.2011.149]; Della Camera G, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.692165; Demaria O, 2019, NATURE, V574, P45, DOI 10.1038/s41586-019-1593-5; DeNardo DG, 2019, NAT REV IMMUNOL, V19, P369, DOI 10.1038/s41577-019-0127-6; Deng H, 2018, J CONTROL RELEASE, V290, P28, DOI 10.1016/j.jconrel.2018.09.026; Feng MY, 2019, NAT REV CANCER, V19, P568, DOI 10.1038/s41568-019-0183-z; Ferretti AM, 2021, J COLLOID INTERF SCI, V582, P678, DOI 10.1016/j.jcis.2020.08.026; Fortuin AS, 2018, WIRES NANOMED NANOBI, V10, DOI 10.1002/wnan.1471; Hegde PS, 2020, IMMUNITY, V52, P17, DOI 10.1016/j.immuni.2019.12.011; Hegde PS, 2016, CLIN CANCER RES, V22, P1865, DOI 10.1158/1078-0432.CCR-15-1507; Intlekofer AM, 2013, J LEUKOCYTE BIOL, V94, P25, DOI 10.1189/jlb.1212621; Italiani P, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00514; Jaiswal S, 2009, CELL, V138, P271, DOI 10.1016/j.cell.2009.05.046; Jin J, 2020, J NANOBIOTECHNOL, V18, DOI 10.1186/s12951-020-00629-y; Karbach J, 2012, CLIN CANCER RES, V18, P5449, DOI 10.1158/1078-0432.CCR-12-1116; Kasturi SP, 2011, NATURE, V470, P543, DOI 10.1038/nature09737; Khalil DN, 2016, NAT REV CLIN ONCOL, V13, P273, DOI 10.1038/nrclinonc.2016.25; Krysko DV, 2012, NAT REV CANCER, V12, P860, DOI 10.1038/nrc3380; Lecoultre M, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-001408; Li F, 2019, ACS CENTRAL SCI, V5, P796, DOI 10.1021/acscentsci.9b00060; Li L, 2019, INT J NANOMED, V14, P6721, DOI 10.2147/IJN.S211476; Liu LQ, 2020, SMALL, V16, DOI 10.1002/smll.202003543; Liu WL, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11157-1; Liu XL, 2020, THERANOSTICS, V10, P3793, DOI 10.7150/thno.40805; Liu XL, 2019, ACS NANO, V13, P8811, DOI 10.1021/acsnano.9b01979; Liu YT, 2021, THERANOSTICS, V11, P5365, DOI 10.7150/thno.58390; Lopez-Castro JD, 2011, NANOSCALE, V3, P4597, DOI 10.1039/c1nr10980d; Lu QS, 2020, ONCOTARGETS THER, V13, P9323, DOI 10.2147/OTT.S249822; Majeti R, 2009, CELL, V138, P286, DOI 10.1016/j.cell.2009.05.045; Majidpoor J, 2021, CLIN IMMUNOL, V226, DOI 10.1016/j.clim.2021.108707; Mantovani A, 2018, NEW ENGL J MED, V379, P1777, DOI 10.1056/NEJMe1811699; Matlung HL, 2017, IMMUNOL REV, V276, P145, DOI 10.1111/imr.12527; Naidoo J, 2015, ANN ONCOL, V26, P2375, DOI 10.1093/annonc/mdv383; Najafi M, 2019, J CELL BIOCHEM, V120, P2756, DOI 10.1002/jcb.27646; Nie WD, 2019, ACS NANO, V13, P1469, DOI 10.1021/acsnano.8b07141; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Pathria P, 2019, TRENDS IMMUNOL, V40, P310, DOI 10.1016/j.it.2019.02.003; Pietsch EC, 2017, BLOOD CANCER J, V7, DOI 10.1038/bcj.2017.7; Pouw JJ, 2015, INT J NANOMED, V10, DOI 10.2147/IJN.S76962; Rao L, 2020, ADV MATER, V32, DOI 10.1002/adma.202004853; Reimer P, 2003, EUR RADIOL, V13, P1266, DOI 10.1007/s00330-002-1721-7; Rezaei G, 2017, NANOMEDICINE-UK, V12, P597, DOI 10.2217/nnm-2016-0302; Riley RS, 2019, NAT REV DRUG DISCOV, V18, P175, DOI 10.1038/s41573-018-0006-z; Shao XM, 2021, NAT NANOTECHNOL, V16, P1150, DOI 10.1038/s41565-021-00952-x; Sharma P, 2015, SCIENCE, V348, P56, DOI 10.1126/science.aaa8172; Shin TH, 2015, CHEM SOC REV, V44, P4501, DOI 10.1039/c4cs00345d; Sobhani N, 2021, CANCERS, V13, DOI 10.3390/cancers13061440; Song QL, 2021, ACS APPL MATER INTER, V13, P36824, DOI 10.1021/acsami.1c08201; Steinman RM, 2004, SCIENCE, V305, P197, DOI 10.1126/science.1099688; Sweeney EE, 2018, SMALL, V14, DOI 10.1002/smll.201800678; Trabulo S, 2017, BBA-GEN SUBJECTS, V1861, P1597, DOI 10.1016/j.bbagen.2017.01.035; Trujillo-Alonso V, 2019, NAT NANOTECHNOL, V14, P616, DOI 10.1038/s41565-019-0406-1; Wang SC, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22137010; Wang YXJ, 2017, QUANT IMAG MED SURG, V7, P88, DOI 10.21037/qims.2017.02.09; Wang YXJ, 2015, WORLD J GASTROENTERO, V21, P13400, DOI 10.3748/wjg.v21.i47.13400; Wang Z, 2019, ADV SCI, V6, DOI 10.1002/advs.201901690; Wu XQ, 2021, BIOMED MATER, V16, DOI 10.1088/1748-605X/abd0c4; Xia Q, 2019, ACTA PHARM SIN B, V9, P675, DOI 10.1016/j.apsb.2019.01.011; Yousefi H, 2017, EXPERT REV CLIN IMMU, V13, P1001, DOI 10.1080/1744666X.2017.1366315; Zanganeh S, 2016, NAT NANOTECHNOL, V11, P986, DOI [10.1038/NNANO.2016.168, 10.1038/nnano.2016.168]; Zeng Q, 2017, BIOMATERIALS, V122, P105, DOI 10.1016/j.biomaterials.2017.01.010; Zhang QB, 2017, ACS NANO, V11, P10724, DOI 10.1021/acsnano.7b04955; Zhang YY, 2020, CHEM ENG J, V380, DOI 10.1016/j.cej.2019.122472; Zhang YQ, 2021, WIRES NANOMED NANOBI, V13, DOI 10.1002/wnan.1717; Zhang YQ, 2019, NANOMEDICINE-UK, V14, P2101, DOI 10.2217/nnm-2019-0156; Zhao J, 2020, APPL MATER TODAY, V20, DOI 10.1016/j.apmt.2020.100701; Zhou Y, 2018, CANCER MED-US, V7, P4012, DOI 10.1002/cam4.1670; Zhu Q, 2008, P NATL ACAD SCI USA, V105, P16260, DOI 10.1073/pnas.0805325105	82	0	0	4	19	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 4	2021	12								701485	10.3389/fimmu.2021.701485	http://dx.doi.org/10.3389/fimmu.2021.701485			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WV1XC	34675914	Green Published, gold			2022-12-18	WOS:000717029600001
J	Zhang, D; Qiao, XR; Cui, WJ; Zhang, JT; Pan, Y; Liu, XF; Dong, L				Zhang, Dong; Qiao, Xin-rui; Cui, Wen-Jing; Zhang, Jin-tao; Pan, Yun; Liu, Xiao-fei; Dong, Liang			Syndecan-1 Amplifies Ovalbumin-Induced Airway Remodeling by Strengthening TGF beta 1/Smad3 Action	FRONTIERS IN IMMUNOLOGY			English	Article						syndecan-1; ovalbumin; airway remodeling; TGF beta 1/Smad3 signaling; asthma	EPITHELIAL-MESENCHYMAL TRANSITION; TGF-BETA; INFLAMMATION; FIBROBLAST; EXPRESSION; FIBROSIS	Syndecan-1 (SDC-1) is a transmembrane proteoglycan of heparin sulfate that can regulate various cell signal transduction pathways in the airway epithelial cells and fibroblasts. Airway epithelial cells and human bronchial fibroblasts are crucial in airway remodeling. However, the importance of SDC-1 in the remodeling of asthmatic airways has not been confirmed yet. The present study was the first to uncover SDC-1 overexpression in the airways of humans and mice with chronic asthma. This study also validated that an increase in SDC-1 expression was correlated with TGF beta 1/Smad3-mediated airway remodeling in vivo and in vitro. A small interfering RNA targeting SDC-1 (SDC-1 siRNA) and homo-SDC-1 in pcDNA3.1 (pc-SDC-1) was designed to assess the effects of SDC-1 on TGF beta 1/Smad3-mediated collagen I expression in Beas-2B (airway epithelial cells) and HLF-1 (fibroblasts) cells. Downregulation of the SDC-1 expression by SDC-1 siRNA remarkably attenuated TGF beta 1-induced p-Smad3 levels and collagen I expression in Beas-2B and HLF-1 cells. In addition, SDC-1 overexpression with pc-SDC-1 enhanced TGF beta 1-induced p-Smad3 level and collagen I expression in Beas-2B and HLF-1 cells. Furthermore, the levels of p-Smad3 and collagen I induced by TGF beta 1 were slightly increased after the addition of the recombinant human SDC-1 protein to Beas-2B and HLF-1 cells. These findings in vitro were also confirmed in a mouse model. A short hairpin RNA targeting SDC-1 (SDC-1 shRNA) to interfere with SDC-1 expression considerably reduced the levels of p-Smad3 and remodeling protein (alpha-SMA, collagen I) in the airways induced by ovalbumin (OVA). Similarly, OVA-induced p-Smad3 and remodeling protein levels in airways increased after mice inhalation with the recombinant mouse SDC-1 protein. These results suggested that SDC-1 of airway epithelial cells and fibroblasts plays a key role in the development of airway remodeling in OVA-induced chronic asthma.	[Zhang, Dong; Qiao, Xin-rui; Cui, Wen-Jing; Zhang, Jin-tao; Pan, Yun; Liu, Xiao-fei; Dong, Liang] Shandong Univ, Shandong Qianfoshan Hosp, Cheeloo Coll Med, Dept Resp, Jinan, Peoples R China; [Dong, Liang] Shandong Univ, Shandong Med Univ 1, Affiliated Hosp 1, Shandong Prov Qianfoshan Hosp,Dept Resp,Shandong, Jinan, Peoples R China	Shandong First Medical University & Shandong Academy of Medical Sciences; Shandong University; Shandong First Medical University & Shandong Academy of Medical Sciences; Shandong University	Dong, L (corresponding author), Shandong Univ, Shandong Qianfoshan Hosp, Cheeloo Coll Med, Dept Resp, Jinan, Peoples R China.; Dong, L (corresponding author), Shandong Univ, Shandong Med Univ 1, Affiliated Hosp 1, Shandong Prov Qianfoshan Hosp,Dept Resp,Shandong, Jinan, Peoples R China.	dl5506@126.com	Zhang, Jintao/C-5836-2011	Zhang, Jintao/0000-0002-1029-3404	National Natural Science Foundation of China [81770029]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by the National Natural Science Foundation of China (81770029).	Albadrani GM, 2021, SAUDI J BIOL SCI, V28, P2772, DOI 10.1016/j.sjbs.2021.02.007; Camoretti-Mercado B, 2005, CELL BIOCHEM BIOPHYS, V43, P131, DOI 10.1385/CBB:43:1:131; Casaro M, 2019, METHODS MOL BIOL, V1916, P297, DOI 10.1007/978-1-4939-8994-2_28; Couchman JR, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22084227; Dogne S, 2020, AM J PATHOL, V190, P768, DOI 10.1016/j.ajpath.2019.11.016; Fang LP, 2018, EXP THER MED, V15, P985, DOI 10.3892/etm.2017.5478; Filla MS, 1998, J CELL PHYSIOL, V174, P310, DOI 10.1002/(SICI)1097-4652(199803)174:3<310::AID-JCP5>3.0.CO;2-R; Frey A, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00761; Hammad H, 2021, CELL, V184, P1469, DOI 10.1016/j.cell.2021.02.016; Han L, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11050669; Hayashida K, 2006, J BIOL CHEM, V281, P24365, DOI 10.1074/jbc.M509320200; Hogan KA, 2013, CYTOKINE, V64, P652, DOI 10.1016/j.cyto.2013.09.004; Huang J, 2019, PEDIATR CLIN N AM, V66, P925, DOI 10.1016/j.pcl.2019.06.001; Javadi J, 2021, CANCERS, V13, DOI 10.3390/cancers13040655; Kianian F, 2020, PHARM BIOL, V58, P107, DOI 10.1080/13880209.2019.1710218; Lambrecht BN, 2015, NAT IMMUNOL, V16, P45, DOI 10.1038/ni.3049; Li QL, 2002, CELL, V111, P635, DOI 10.1016/S0092-8674(02)01079-6; Li X, 2021, J ASTHMA ALLERGY, V14, P513, DOI 10.2147/JAA.S307165; Liu P, 2020, RESP RES, V21, DOI 10.1186/s12931-020-1300-y; Meng XL, 2021, EXP THER MED, V21, DOI 10.3892/etm.2021.9642; Mohammadtursun N, 2020, CHIN MED-UK, V15, DOI 10.1186/s13020-020-00373-3; Parimon T, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.129359; Paw M, 2021, BMC MOL CELL BIOL, V22, DOI 10.1186/s12860-021-00356-8; Propp P, 2013, EXPERT REV CLIN IMMU, V9, P1267, DOI 10.1586/1744666X.2013.858601; Schellings MWM, 2010, HYPERTENSION, V55, P249, DOI 10.1161/HYPERTENSIONAHA.109.137885; Shen XY, 2021, CYTOTECHNOLOGY, V73, P179, DOI 10.1007/s10616-021-00455-6; Sugiura Y, 2002, ANN RHEUM DIS, V61, P826, DOI 10.1136/ard.61.9.826; Tkachenko E, 2005, CIRC RES, V96, P488, DOI 10.1161/01.RES.0000159708.71142.c8; Wang N, 2016, RESP RES, V17, DOI 10.1186/s12931-016-0437-1; Wang W, 2020, EVID-BASED COMPL ALT, V2020, DOI 10.1155/2020/5814658; Wang ZG, 2020, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.559470; Xu J, 2005, J IMMUNOL, V174, P5758, DOI 10.4049/jimmunol.174.9.5758; Yang LL, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00165; Yu C, 2021, THERANOSTICS, V11, P2706, DOI 10.7150/thno.48679; Zhang D, 2020, EUR J PHARM SCI, V152, DOI 10.1016/j.ejps.2020.105400; Zhang H, 2020, KAOHSIUNG J MED SCI, V36, P508, DOI 10.1002/kjm2.12197; Zhang Y, 2016, GASTROENT RES PRACT, V2016, DOI 10.1155/2016/6421351; Zou HJ, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.641973	38	0	0	3	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 4	2021	12								744477	10.3389/fimmu.2021.744477	http://dx.doi.org/10.3389/fimmu.2021.744477			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WV3HB	34671356	Green Published, gold			2022-12-18	WOS:000717126200001
J	Zhou, FB; Xu, XD; Cui, XB; Pan, WQ				Zhou, Fangbin; Xu, Xindong; Cui, Xiaobing; Pan, Weiqing			Development and Evaluation of a Fusion Polyprotein Based on HspX and Other Antigen Sequences for the Serodiagnosis of Tuberculosis	FRONTIERS IN IMMUNOLOGY			English	Article						Mycobacterium tuberculosis; active TB; fusion polyprotein; serodiagnosis; sensitivity; specificity	B-CELL EPITOPES; PROTEIN-STRUCTURE; IMMUNE-RESPONSES; I-TASSER; DIAGNOSIS; PEPTIDES; UTILITY; REGIONS; SERVER	Background The lack of suitable diagnostic tools contributes to the high prevalence of tuberculosis (TB) worldwide. Serological tests, based on multiple target antigens, represent an attractive option for diagnosis of this disease due to their rapidity, convenience, and low cost. Methods Measures to reduce non-specific reactions and thereby improve the specificity of serological tests were investigated, including blocking antibodies against common bacteria in serum samples and synthesizing polypeptides covering non-conserved dominant B-cell epitopes of antigens. In addition, a fusion polyprotein containing HspX and eight other antigen sequences was constructed and expressed to increase overall sensitivity of the tests. Results Inclusion of Escherichia coli lysate partially increased the specificity of the serological tests, while synthesis and inclusion of peptides containing non-conserved sequences of TB antigens as well as dominant B-cell epitopes reduced non-specific reactions without a decrease in sensitivity of the tests. A polyprotein fusing HspX and eight other antigen sequences was constructed and displayed 60.2% sensitivity, which was higher than that of HspX and the other individual antigen segments. Moreover, the specificity of the polyprotein was 93.8%, which was not significantly decreased when compared with HspX and the other individual antigen segments. Conclusions The roles of the fusion polyprotein in the humoral immune response against TB infection were demonstrated and provide a potential novel approach for the development of TB diagnostics.	[Zhou, Fangbin; Pan, Weiqing] Naval Med Univ, Dept Trop Dis, Shanghai, Peoples R China; [Zhou, Fangbin] Jinan Univ, Shenzhen Peoples Hosp, Clin Med Coll 2, Clin Med Res Ctr, Shenzhen, Peoples R China; [Zhou, Fangbin; Xu, Xindong; Cui, Xiaobing; Pan, Weiqing] Tongji Univ, Inst Infect Dis & Vaccine Dev, Sch Med, Shanghai, Peoples R China	Naval Medical University; Jinan University; Tongji University	Pan, WQ (corresponding author), Naval Med Univ, Dept Trop Dis, Shanghai, Peoples R China.; Pan, WQ (corresponding author), Tongji Univ, Inst Infect Dis & Vaccine Dev, Sch Med, Shanghai, Peoples R China.	wqpan0912@aliyun.com			Foundation of Shanghai Municipal Commission of Health and Family Planning	Foundation of Shanghai Municipal Commission of Health and Family Planning	Funding This work was supported by Foundation of Shanghai Municipal Commission of Health and Family Planning (GWV-10.2-YQ05), Shenzhen Science Founding (JCYJ20170307095037263), Chinese Postdoctoral Science Foundation (2017M612849) and National S & T Program (2013ZX10003007) in China.	Abebe F, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0190989; Afzal M, 2015, J MICROBIOL METH, V115, P104, DOI 10.1016/j.mimet.2015.06.003; Barik A, 2020, J MOL BIOL, V432, P3379, DOI 10.1016/j.jmb.2019.12.030; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cao J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018477; Chen YQ, 2018, CLIN CHIM ACTA, V487, P369, DOI 10.1016/j.cca.2018.09.008; Feng XY, 2013, J INFECTION, V66, P366, DOI 10.1016/j.jinf.2012.10.029; Furin J, 2019, LANCET, V393, P1642, DOI 10.1016/S0140-6736(19)30308-3; Gandhi NR, 2010, LANCET, V375, P1830, DOI 10.1016/S0140-6736(10)60410-2; Gilpin C., 2011, COMMERCIAL SERODIAGN; Goyal B, 2014, DIAGN MICR INFEC DIS, V78, P391, DOI [10.1016/j.diagmicrobio.2013.12.018, 10.1016/j.diagmicrobio.2013.1]; Hao XH, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm-20-5476; Jiang SHH, 2008, DNA CELL BIOL, V27, P423, DOI 10.1089/dna.2007.0708; Kashyap RS, 2013, CLIN NEUROL NEUROSUR, V115, P678, DOI 10.1016/j.clineuro.2012.07.031; Khalid R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163349; Khurshid S, 2017, BIOLOGICALS, V48, P109, DOI 10.1016/j.biologicals.2017.04.004; Li JL, 2015, INFECT DIS-NOR, V47, P643, DOI 10.3109/23744235.2015.1043941; MacLean E, 2019, NAT MICROBIOL, V4, P748, DOI 10.1038/s41564-019-0380-2; Meier NR, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02476; Meintjes G, 2019, LANCET HIV, V6, pE463, DOI 10.1016/S2352-3018(19)30154-7; Papadopoulos JS, 2007, BIOINFORMATICS, V23, P1073, DOI 10.1093/bioinformatics/btm076; Roy A, 2010, NAT PROTOC, V5, P725, DOI 10.1038/nprot.2010.5; Saha S, 2006, PROTEINS, V65, P40, DOI 10.1002/prot.21078; Wallis RS, 2013, LANCET INFECT DIS, V13, P362, DOI 10.1016/S1473-3099(13)70034-3; Waterhouse A, 2018, NUCLEIC ACIDS RES, V46, pW296, DOI 10.1093/nar/gky427; WHO, 2010, WORLD MALARIA REPORT 2010, P1; Wu L, 2011, J INT MED RES, V39, P514, DOI 10.1177/147323001103900219; Wu ST, 2007, NUCLEIC ACIDS RES, V35, P3375, DOI 10.1093/nar/gkm251; Xu X, 2014, LANCET INFECT DIS, V14, P489, DOI 10.1016/S1473-3099(14)70067-2; Yang JY, 2015, NUCLEIC ACIDS RES, V43, pW174, DOI 10.1093/nar/gkv342; Yang YR, 2015, ANN CLIN LAB SCI, V45, P39; Zhang SL, 2009, TUBERCULOSIS, V89, P278, DOI 10.1016/j.tube.2009.05.005; Zhou FB, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2910-y; Zhou FB, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165291; Zhou FB, 2015, SCI REP-UK, V5, DOI 10.1038/srep15349	35	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 4	2021	12								726920	10.3389/fimmu.2021.726920	http://dx.doi.org/10.3389/fimmu.2021.726920			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WV2JT	34671347	gold, Green Published			2022-12-18	WOS:000717064800001
J	Abos, B; Perez-Fernandez, E; Morel, E; Perdiguero, P; Tafalla, C				Abos, Beatriz; Perez-Fernandez, Elena; Morel, Esther; Perdiguero, Pedro; Tafalla, Carolina			Pro-Inflammatory and B Cell Regulating Capacities of TWEAK in Rainbow Trout (Oncorhynchus mykiss)	FRONTIERS IN IMMUNOLOGY			English	Article						tumor necrosis factor superfamily (TNFSF); TNF-like weak inducer of apoptosis (TWEAK); rainbow trout; head kidney; B cells; inflammation	PROLIFERATIVE KIDNEY-DISEASE; WEAK INDUCER; FUNCTIONAL EXPRESSION; IMMUNE-RESPONSE; SALMO-GAIRDNERI; FN14; TNF; PATHWAY; TISSUE; APOPTOSIS	Tumor necrosis factor (TNF)-like weak inducer of apoptosis or TWEAK is a member of the TNF superfamily involved in the regulation of many biological processes. In mammals, TWEAK has been shown to play a role in some autoimmune or inflammatory conditions, but its immune role is not yet clearly defined. In teleost fish, although a few studies have identified homologues to mammalian TWEAK, their biological effects have never been investigated. In the current study, we have studied the transcriptional regulation of two TWEAK homologues (TWEAK 1 and 2) identified in rainbow trout (Oncorhynchus mykiss) throughout different tissues, in response to parasitic or viral infections, or in head kidney (HK) leukocytes stimulated with different stimuli. Although the transcription of both homologues was modulated when HK leukocytes were exposed to several immune stimuli, only TWEAK 1 was significantly modulated upon pathogenic exposure. Thus, we performed a characterization of the functions exerted by this cytokine in HK leukocytes. Recombinant TWEAK 1 strongly up-regulated the transcription of pro-inflammatory genes and antimicrobial peptides in HK leukocytes, with differential transcriptional effects in IgM(+) B cells, IgM(-) lymphocytes and myeloid cells. TWEAK 1 also increased the survival and promoted the differentiation of B cells in HK leukocyte cultures. Our results demonstrate that in teleost fish, TWEAK 1 is involved in the response to different types of pathogens, through the modulation of antimicrobial and pro-inflammatory genes in different leukocytes subsets. Furthermore, a role for TWEAK as a B cell differentiation factor has also been established in rainbow trout.	[Abos, Beatriz; Perez-Fernandez, Elena; Morel, Esther; Perdiguero, Pedro; Tafalla, Carolina] CSIC, Anim Hlth Res Ctr CISA, Ctr Nacl Inst Invest & Tecnol Agr & Alimentaria I, Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC)	Tafalla, C (corresponding author), CSIC, Anim Hlth Res Ctr CISA, Ctr Nacl Inst Invest & Tecnol Agr & Alimentaria I, Madrid, Spain.	tafalla@inia.es	Perdiguero, Pedro/H-5234-2015; Tafalla, Carolina/J-8074-2014	Perdiguero, Pedro/0000-0002-5471-9550; Tafalla, Carolina/0000-0002-0860-2976; MOREL, ESTHER/0000-0002-4768-082X	European Research Council (ERC) [2016 725061 TEMUBLYM]; Spanish Ministry of Science, Innovation and Universities [AGL2017-85494-C2-1-R]	European Research Council (ERC)(European Research Council (ERC)European Commission); Spanish Ministry of Science, Innovation and Universities(Spanish Government)	This work was supported by the European Research Council (ERC Consolidator Grant 2016 725061 TEMUBLYM) and by the Spanish Ministry of Science, Innovation and Universities (project AGL2017-85494-C2-1-R).	Abos B, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01203; Abos B, 2016, SCI REP-UK, V6, DOI 10.1038/srep30004; Akahori H, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8792; Bailey C, 2017, FISH SHELLFISH IMMUN, V63, P424, DOI 10.1016/j.fsi.2017.02.039; Burkly LC, 2007, CYTOKINE, V40, P1, DOI 10.1016/j.cyto.2007.09.007; Burkly LC, 2011, IMMUNOL REV, V244, P99, DOI 10.1111/j.1600-065X.2011.01054.x; Campbell S, 2006, J IMMUNOL, V176, P1889, DOI 10.4049/jimmunol.176.3.1889; Castro R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111084; Chacon MR, 2006, CYTOKINE, V33, P129, DOI 10.1016/j.cyto.2005.12.005; Chen DY, 2020, MBIO, V11, DOI 10.1128/mBio.03045-19; Cheng H, 2015, J INVEST DERMATOL, V135, P2427, DOI 10.1038/jid.2015.201; Chicheportiche Y, 1997, J BIOL CHEM, V272, P32401, DOI 10.1074/jbc.272.51.32401; Chicheportiche Y, 2000, BIOCHEM BIOPH RES CO, V279, P162, DOI 10.1006/bbrc.2000.3913; Chilmonczyk S, 2002, J FISH DIS, V25, P217, DOI 10.1046/j.1365-2761.2002.00362.x; CLIFTONHADLEY RS, 1987, J FISH DIS, V10, P335, DOI 10.1111/j.1365-2761.1987.tb01081.x; DELUCA D, 1983, EUR J IMMUNOL, V13, P546, DOI 10.1002/eji.1830130706; Desplat-Jego S, 2009, J LEUKOCYTE BIOL, V85, P132, DOI 10.1189/jlb.0608347; Dharmapatni AASSK, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3294; Dohi T, 2009, GASTROENTEROLOGY, V136, P912, DOI 10.1053/j.gastro.2008.11.017; Dostert C, 2019, PHYSIOL REV, V99, P115, DOI 10.1152/physrev.00045.2017; Du MX, 2012, BIOCHEM GENET, V50, P318, DOI 10.1007/s10528-011-9482-0; Feng SLY, 2000, AM J PATHOL, V156, P1253, DOI 10.1016/S0002-9440(10)64996-6; Glenney GW, 2007, J IMMUNOL, V178, P7955, DOI 10.4049/jimmunol.178.12.7955; Granja AG, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02902; Granja AG, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174249; Han ES, 2010, J REPROD IMMUNOL, V84, P16, DOI 10.1016/j.jri.2009.09.009; Ho DH, 2004, CANCER RES, V64, P8968, DOI 10.1158/0008-5472.CAN-04-1879; Kaplan MJ, 2002, J IMMUNOL, V169, P6020, DOI 10.4049/jimmunol.169.10.6020; Kawakita T, 2005, INT J ONCOL, V26, P87; Kawakita T, 2004, BIOCHEM BIOPH RES CO, V318, P726, DOI 10.1016/j.bbrc.2004.04.084; Liu T, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2017.23; Macqueen DJ, 2014, P ROY SOC B-BIOL SCI, V281, DOI 10.1098/rspb.2013.2881; Madrigal-Matute J, 2015, CARDIOVASC RES, V108, P139, DOI 10.1093/cvr/cvv204; Maecker H, 2005, CELL, V123, P931, DOI 10.1016/j.cell.2005.09.022; Marin I, 2020, GENOME BIOL EVOL, V12, P2074, DOI 10.1093/gbe/evaa140; Meighan-Mantha RL, 1999, J BIOL CHEM, V274, P33166, DOI 10.1074/jbc.274.46.33166; Min HK, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-0846-4; Montero J, 2011, J VIROL, V85, P4046, DOI 10.1128/JVI.02519-10; Munoz-Atienza E, 2019, FISH SHELLFISH IMMUN, V86, P25, DOI 10.1016/j.fsi.2018.11.027; Nakayama M, 2003, J IMMUNOL, V170, P341, DOI 10.4049/jimmunol.170.1.341; Nakayama M, 2000, J EXP MED, V192, P1373, DOI 10.1084/jem.192.9.1373; Pandit NP, 2014, GENET MOL RES, V13, P10105, DOI 10.4238/2014.December.4.5; Perdiguero P, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.596975; Qi XF, 2020, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.03066; Ramirez-Gomez F, 2012, J IMMUNOL, V188, P1341, DOI 10.4049/jimmunol.1101938; Sun F, 2018, EXP THER MED, V15, P2611, DOI 10.3892/etm.2018.5711; Tafalla C, 2005, DEV COMP IMMUNOL, V29, P615, DOI 10.1016/j.dci.2004.12.001; Tran NL, 2003, AM J PATHOL, V162, P1313, DOI 10.1016/S0002-9440(10)63927-2; Wajant H, 2013, BRIT J PHARMACOL, V170, P748, DOI 10.1111/bph.12337; Wang HY, 2013, P NATL ACAD SCI USA, V110, P5127, DOI 10.1073/pnas.1221211110; Wen J, 2015, J AUTOIMMUN, V60, P40, DOI 10.1016/j.jaut.2015.03.005; Wiens GD, 2011, DEV COMP IMMUNOL, V35, P1324, DOI 10.1016/j.dci.2011.03.031; Williams SA, 2010, BRIT J HAEMATOL, V150, P373, DOI 10.1111/j.1365-2141.2010.08201.x; Winkles JA, 2008, NAT REV DRUG DISCOV, V7, P411, DOI 10.1038/nrd2488; Wisniacki N, 2013, CLIN THER, V35, P1137, DOI 10.1016/j.clinthera.2013.06.008; Yalcin Kehribar D, 2020, TURK J MED SCI, V50, P1786, DOI 10.3906/sag-2006-96; Zahl IH, 2012, FISH PHYSIOL BIOCHEM, V38, P201, DOI 10.1007/s10695-011-9565-1; Zimmermann M, 2011, J ALLERGY CLIN IMMUN, V127, P200, DOI 10.1016/j.jaci.2010.11.005; Zwollo P, 2005, J IMMUNOL, V174, P6608, DOI 10.4049/jimmunol.174.11.6608	60	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 1	2021	12								748836	10.3389/fimmu.2021.748836	http://dx.doi.org/10.3389/fimmu.2021.748836			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WJ2AG	34659247	gold, Green Published			2022-12-18	WOS:000708849800001
J	Choi, HJ; Tang, CHA; Tian, LL; Wu, YX; Sofi, MH; Ticer, T; Schutt, SD; Hu, CCA; Yu, XZ				Choi, Hee-Jin; Tang, Chih-Hang Anthony; Tian, Linlu; Wu, Yongxia; Sofi, M. Hanief; Ticer, Taylor; Schutt, Steven D.; Hu, Chih-Chi Andrew; Yu, Xue-Zhong			XBP-1s Promotes B Cell Pathogenicity in Chronic GVHD by Restraining the Activity of Regulated IRE-1 alpha-Dependent Decay	FRONTIERS IN IMMUNOLOGY			English	Article						allo-HCT; chronic GVHD; IRE-1 alpha; XBP-1; RIDD; ER stress; UPR	UNFOLDED PROTEIN RESPONSE; VERSUS-HOST-DISEASE; GERMINAL CENTER FORMATION; GENE-EXPRESSION; HELPER-CELLS; ER STRESS; T-CELLS; DIFFERENTIATION; IRE1-ALPHA; ABSENCE	Allogeneic hematopoietic cell transplantation (allo-HCT) is an effective therapeutic procedure to treat hematological malignancies. However, the benefit of allo-HCT is limited by a major complication, chronic graft-versus-host disease (cGVHD). Since transmembrane and secretory proteins are generated and modified in the endoplasmic reticulum (ER), the ER stress response is of great importance to secretory cells including B cells. By using conditional knock-out (KO) of XBP-1, IRE-1 alpha or both specifically on B cells, we demonstrated that the IRE-1 alpha/XBP-1 pathway, one of the major ER stress response mediators, plays a critical role in B cell pathogenicity on the induction of cGVHD in murine models of allo-HCT. Endoribonuclease activity of IRE-1 alpha activates XBP-1 signaling by converting unspliced XBP-1 (XBP-1u) mRNA into spliced XBP-1 (XBP-1s) mRNA but also cleaves other ER-associated mRNAs through regulated IRE-1 alpha-dependent decay (RIDD). Further, ablation of XBP-1s production leads to unleashed activation of RIDD. Therefore, we hypothesized that RIDD plays an important role in B cells during cGVHD development. In this study, we found that the reduced pathogenicity of XBP-1 deficient B cells in cGVHD was reversed by RIDD restriction in IRE-1 alpha kinase domain KO mice. Restraining RIDD activity per se in B cells resulted in an increased severity of cGVHD. Besides, inhibition of RIDD activity compromised B cell differentiation and led to dysregulated expression of MHC II and costimulatory molecules such as CD86, CD40, and ICOSL in B cells. Furthermore, restraining the RIDD activity without affecting XBP-1 splicing increased B cell ability to induce cGVHD after allo-HCT. These results suggest that RIDD is an important mediator for reducing cGVHD pathogenesis through targeting XBP-1s.</p>	[Choi, Hee-Jin; Tian, Linlu; Wu, Yongxia; Sofi, M. Hanief; Ticer, Taylor; Schutt, Steven D.; Yu, Xue-Zhong] Med Univ South Carolina, Microbiol & Immunol, Charleston, SC 29425 USA; [Tang, Chih-Hang Anthony; Hu, Chih-Chi Andrew] Houston Methodist Canc Ctr, Ctr Translat Res Hematol Malignancies, Houston Methodist Res Inst, Houston, TX 77030 USA; [Yu, Xue-Zhong] Med Univ South Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA	Medical University of South Carolina; The Methodist Hospital System; The Methodist Hospital - Houston; Medical University of South Carolina	Yu, XZ (corresponding author), Med Univ South Carolina, Microbiol & Immunol, Charleston, SC 29425 USA.; Hu, CCA (corresponding author), Houston Methodist Canc Ctr, Ctr Translat Res Hematol Malignancies, Houston Methodist Res Inst, Houston, TX 77030 USA.; Yu, XZ (corresponding author), Med Univ South Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA.	cahu@houstonmethodist.org; yux@musc.edu		Schutt, Steven/0000-0002-2069-2556; Hu, Chih-Chi/0000-0001-9024-2932; Tang, Chih-hang/0000-0002-5097-5709	National Institutes of Health, National Institute of Allergy and Infectious Diseases [R01 Al118305]; National Heart, Lung, and Blood Institute [R01 HL140953]; National Cancer Institute [R01 CA163910]; South Carolina Research Center of Economic Excellence; Cell Evaluation & Therapy Shared Resource, Hollings Cancer Center, and Medical University of South Carolina [P30 CA138313]	National Institutes of Health, National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); South Carolina Research Center of Economic Excellence; Cell Evaluation & Therapy Shared Resource, Hollings Cancer Center, and Medical University of South Carolina	This work was supported in part by grants from the National Institutes of Health, National Institute of Allergy and Infectious Diseases (R01 Al118305 to X-ZY), National Heart, Lung, and Blood Institute (R01 HL140953 to X-ZY), and National Cancer Institute (R01 CA163910 to C-CH). This publication was also supported in part by South Carolina Research Center of Economic Excellence and the Cell Evaluation & Therapy Shared Resource, Hollings Cancer Center, and Medical University of South Carolina (P30 CA138313).	Allen JL, 2014, BLOOD, V123, P2108, DOI 10.1182/blood-2013-10-533562; Allen JL, 2012, BLOOD, V120, P2529, DOI 10.1182/blood-2012-06-438911; Anderson BE, 2005, BLOOD, V105, P2227, DOI 10.1182/blood-2004-08-3032; Benhamron S, 2014, EUR J IMMUNOL, V44, P867, DOI 10.1002/eji.201343953; Boes M, 2000, P NATL ACAD SCI USA, V97, P1184, DOI 10.1073/pnas.97.3.1184; Bussone G, 2009, AUTOIMMUN REV, V8, P332, DOI 10.1016/j.autrev.2008.11.004; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; Chen X, 2007, BLOOD, V110, P3804, DOI 10.1182/blood-2007-05-091074; Coghill JM, 2011, BLOOD, V117, P3268, DOI 10.1182/blood-2010-12-290403; Cooke KR, 1996, BLOOD, V88, P3230, DOI 10.1182/blood.V88.8.3230.bloodjournal8883230; Flowers MED, 2015, BLOOD, V125, P606, DOI 10.1182/blood-2014-08-551994; Flynn R, 2014, BLOOD, V123, P3988, DOI 10.1182/blood-2014-03-562231; GIROLOMONI G, 1991, Journal of Dermatology (Tokyo), V18, P314; Hetz C, 2008, P NATL ACAD SCI USA, V105, P757, DOI 10.1073/pnas.0711094105; Hetz C, 2011, PHYSIOL REV, V91, P1219, DOI 10.1152/physrev.00001.2011; Hollien J, 2006, SCIENCE, V313, P104, DOI 10.1126/science.1129631; Hu CCA, 2009, EMBO J, V28, P1624, DOI 10.1038/emboj.2009.117; Iwakoshi NN, 2003, NAT IMMUNOL, V4, P321, DOI 10.1038/ni907; Jaglowski SM, 2018, BLOOD ADV, V2, P2012, DOI 10.1182/bloodadvances.2018013060; Jesus AA, 2008, J CLIN IMMUNOL, V28, pS62, DOI 10.1007/s10875-008-9171-x; Jin H, 2016, BLOOD, V127, P2249, DOI 10.1182/blood-2015-09-668145; Khateb A, 2020, TRENDS CANCER, V6, P960, DOI 10.1016/j.trecan.2020.05.012; Lee AH, 2003, MOL CELL BIOL, V23, P7448, DOI 10.1128/MCB.23.21.7448-7459.2003; McDonald-Hyman C, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa6853; McManigle W, 2019, HUM IMMUNOL, V80, P393, DOI 10.1016/j.humimm.2019.03.003; Miura Y, 2004, BLOOD, V104, P2187, DOI 10.1182/blood-2004-03-1040; Nishimori H, 2012, BLOOD, V119, P285, DOI 10.1182/blood-2011-01-332478; Poe JC, 2017, BLOOD, V130, P2131, DOI 10.1182/blood-2017-05-782466; Reimold AM, 2001, NATURE, V412, P300, DOI 10.1038/35085509; Schutt SD, 2018, BLOOD ADV, V2, P414, DOI 10.1182/bloodadvances.2017009068; Schutt SD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137641; Semple K, 2011, BLOOD, V117, P3096, DOI 10.1182/blood-2010-08-301275; Shao L, 2015, ANN HEMATOL, V94, P1493, DOI 10.1007/s00277-015-2394-z; She K, 2007, BIOL BLOOD MARROW TR, V13, P386, DOI 10.1016/j.bbmt.2006.12.441; Shimabukuro-Vornhagen A, 2009, BLOOD, V114, P4919, DOI 10.1182/blood-2008-10-161638; Shlomchik WD, 2007, NAT REV IMMUNOL, V7, P340, DOI 10.1038/nri2000; So JS, 2018, MOL CELLS, V41, P705, DOI 10.14348/molcells.2018.0241; Srinivasan M, 2012, BLOOD, V119, P1570, DOI 10.1182/blood-2011-07-364414; Tang CHA, 2018, J CELL BIOL, V217, P1739, DOI 10.1083/jcb.201709137; Todd DJ, 2009, J EXP MED, V206, P2151, DOI 10.1084/jem.20090738; Vu F, 2008, J IMMUNOL, V180, P2284, DOI 10.4049/jimmunol.180.4.2284; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Zeiser R, 2017, NEW ENGL J MED, V377, P2167, DOI 10.1056/NEJMra1609337; Zeng HY, 2015, CELL MOL IMMUNOL, V12, P566, DOI 10.1038/cmi.2015.44; Zhang CY, 2006, BLOOD, V107, P2993, DOI 10.1182/blood-2005-09-3623; Zhang KZ, 2011, EMBO J, V30, P1357, DOI 10.1038/emboj.2011.52; Zhang KZ, 2005, J CLIN INVEST, V115, P268, DOI 10.1172/JCI200521848; Zhang MM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01461; Zhou LX, 2007, J INVEST DERMATOL, V127, P281, DOI 10.1038/sj.jid.5700517	49	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 1	2021	12								705484	10.3389/fimmu.2021.705484	http://dx.doi.org/10.3389/fimmu.2021.705484			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WL6DK	34659198	gold, Green Published			2022-12-18	WOS:000710493700001
J	El Haddad, M; Karlmark, K; Donato, XC; Martin, G; Bretelle, F; Lesavre, N; Cocallemen, JF; Martin, M; Picard, C; Roudier, J; Desbriere, R; Lambert, NC				El Haddad, Marina; Karlmark, Karlin; Donato, Xavier-Come; Martin, Gabriel; Bretelle, Florence; Lesavre, Nathalie; Cocallemen, Jean-Francois; Martin, Marielle; Picard, Christophe; Roudier, Jean; Desbriere, Raoul; Lambert, Nathalie C.			Factors Predicting the Presence of Maternal Cells in Cord Blood and Associated Changes in Immune Cell Composition (vol 12, 651399, 2021)	FRONTIERS IN IMMUNOLOGY			English	Correction						cord blood; maternal microchimerism; PAPP-A; HLA compatibility; NK cells; transplantation			[El Haddad, Marina; Karlmark, Karlin; Martin, Gabriel; Martin, Marielle; Roudier, Jean; Lambert, Nathalie C.] Aix Marseille Univ, INSERM UMRs 1097, Arthrit Autoimmunes, Marseille, France; [Donato, Xavier-Come; Desbriere, Raoul] St Joseph Hosp, Dept Obstet & Gynecol, Marseille, France; [Bretelle, Florence; Cocallemen, Jean-Francois] Aix Marseille Univ, AMU, AP HM, Dept Gynaecol & Obstet,Pole Femme Enfant, Marseille, France; [Lesavre, Nathalie] AMU, AP HM, CIC1409, Marseille, France; [Picard, Christophe] Ctr Natl Rech Sci CNRS, UMR7268, ADES, Biol Grp Sanguin, Marseille, France; [Picard, Christophe] Etab Francais Sang EFS, Marseille, France; [Roudier, Jean] Hop St Margurite, AP HM, Serv Rhumatol, Marseille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Ecology & Environment (INEE); Universite Bordeaux-Montaigne; UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	Lambert, NC (corresponding author), Aix Marseille Univ, INSERM UMRs 1097, Arthrit Autoimmunes, Marseille, France.	nathalie.lambert@inserm.fr	Lambert, Nathalie C/P-6816-2016	Lambert, Nathalie C/0000-0001-5817-8686				El Haddad M, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.651399	1	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 1	2021	12								763236	10.3389/fimmu.2021.763236	http://dx.doi.org/10.3389/fimmu.2021.763236			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WL6YL		Green Published, gold			2022-12-18	WOS:000710548700001
J	Postan, M; Rottenberg, ME				Postan, Miriam; Rottenberg, Martin E.			Editorial: Neurotropism of Parasites and the Immune Responses	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						parasites; neurotropism; blood brain barrier; immune responses; fungi		& nbsp;& nbsp;</p>	[Postan, Miriam] Consejo Nacl Invest Cient & Tecn, Consejo Nacl Invest Cient & Tecnol, Buenos Aires, DF, Argentina; [Postan, Miriam] Inst Nacl Parasitol Dr Mario Fatala Chaben, Adm Nacl Labs, Buenos Aires, DF, Argentina; [Postan, Miriam] Inst Salud Dr Carlos G Malbran ANLIS Malbran, Buenos Aires, DF, Argentina; [Rottenberg, Martin E.] Karolinska Inst, Dept Microbiol Tumor & Cell Biol, Stockholm, Sweden	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Karolinska Institutet	Postan, M (corresponding author), Consejo Nacl Invest Cient & Tecn, Consejo Nacl Invest Cient & Tecnol, Buenos Aires, DF, Argentina.; Postan, M (corresponding author), Inst Nacl Parasitol Dr Mario Fatala Chaben, Adm Nacl Labs, Buenos Aires, DF, Argentina.; Postan, M (corresponding author), Inst Salud Dr Carlos G Malbran ANLIS Malbran, Buenos Aires, DF, Argentina.; Rottenberg, ME (corresponding author), Karolinska Inst, Dept Microbiol Tumor & Cell Biol, Stockholm, Sweden.	miriampostan@yahoo.com; martin.rottenberg@ki.se		Rottenberg, Martin/0000-0003-0514-7434	Swedish Foundation for International Cooperation in Research and Higher Education	Swedish Foundation for International Cooperation in Research and Higher Education	Supported by the Swedish Foundation for International Cooperation in Research and Higher Education.	Cesaro S, 2017, EUR J HAEMATOL, V99, P240, DOI 10.1111/ejh.12910; Prodjinotho UF, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0008005; Strickland AB, 2021, CELL MOL LIFE SCI, V78, P3219, DOI 10.1007/s00018-020-03736-z	3	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 1	2021	12								775666	10.3389/fimmu.2021.775666	http://dx.doi.org/10.3389/fimmu.2021.775666			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WL5XQ	34659274	gold, Green Published			2022-12-18	WOS:000710478700001
J	Boning, MAL; Parzmair, GP; Jeron, A; Dusedau, HP; Kershaw, O; Xu, BL; Relja, B; Schluter, D; Dunay, IR; Reinhold, A; Schraven, B; Bruder, D				Boening, Martha A. L.; Parzmair, Gerald P.; Jeron, Andreas; Duesedau, Henning P.; Kershaw, Olivia; Xu, Baolin; Relja, Borna; Schlueter, Dirk; Dunay, Ildiko Rita; Reinhold, Annegret; Schraven, Burkhart; Bruder, Dunja			Enhanced Susceptibility of ADAP-Deficient Mice to Listeria monocytogenes Infection Is Associated With an Altered Phagocyte Phenotype and Function	FRONTIERS IN IMMUNOLOGY			English	Article						ADAP; adaptor protein; Listeria monocytogenes; neutrophils; inflammatory monocytes; phagocytosis; neutrophil extracellular traps	NECROSIS-FACTOR-ALPHA; T-CELL-ACTIVATION; IMMUNE-RESPONSES; STAPHYLOCOCCUS-AUREUS; BACTERIAL-INFECTION; IN-VIVO; NEUTROPHILS; SLP-76; PROTEIN; DEFENSE	The adhesion and degranulation-promoting adaptor protein (ADAP) serves as a multifunctional scaffold and is involved in the formation of immune signaling complexes. To date, only limited data exist regarding the role of ADAP in pathogen-specific immunity during in vivo infection, and its contribution in phagocyte-mediated antibacterial immunity remains elusive. Here, we show that mice lacking ADAP (ADAPko) are highly susceptible to the infection with the intracellular pathogen Listeria monocytogenes (Lm) by showing enhanced immunopathology in infected tissues together with increased morbidity, mortality, and excessive infiltration of neutrophils and monocytes. Despite high phagocyte numbers in the spleen and liver, ADAPko mice only inefficiently controlled pathogen growth, hinting at a functional impairment of infection-primed phagocytes in the ADAP-deficient host. Flow cytometric analysis of hallmark pro-inflammatory mediators and unbiased whole genome transcriptional profiling of neutrophils and inflammatory monocytes uncovered broad molecular alterations in the inflammatory program in both phagocyte subsets following their activation in the ADAP-deficient host. Strikingly, ex vivo phagocytosis assay revealed impaired phagocytic capacity of neutrophils derived from Lm-infected ADAPko mice. Together, our data suggest that an alternative priming of phagocytes in ADAP-deficient mice during Lm infection induces marked alterations in the inflammatory profile of neutrophils and inflammatory monocytes that contribute to enhanced immunopathology while limiting their capacity to eliminate the pathogen and to prevent the fatal outcome of the infection.	[Boening, Martha A. L.; Parzmair, Gerald P.; Jeron, Andreas; Bruder, Dunja] Otto von Guericke Univ, Hlth Campus Immunol Infectiol & Inflammat, Inst Med Mk Robiol, Infect Immunol, Magdeburg, Germany; [Boening, Martha A. L.; Parzmair, Gerald P.; Jeron, Andreas; Bruder, Dunja] Helmholtz Ctr Infect Res, Immune Regulat, Braunschweig, Germany; [Boening, Martha A. L.; Parzmair, Gerald P.; Reinhold, Annegret; Schraven, Burkhart] Otto von Guericke Univ, Hlth Campus Immunol Infectiol & Inflammat, Inst Mol & Clin Immunol, Magdeburg, Germany; [Duesedau, Henning P.; Dunay, Ildiko Rita] Otto von Guericke Univ, Hlth Campus Immunol Infectiol & Inflammat, Inst Inflammat & Neurodegeperat, Magdeburg, Germany; [Kershaw, Olivia] Freie Univ, Inst Vet Pathol, Dept Vet Med, Berlin, Germany; [Xu, Baolin; Relja, Borna] Otto von Guericke Univ, Expt Radiol, Dept Radiol & Nucl Med, Hlth Campus Immunol Infectiol & Inflammat, Magdeburg, Germany; [Schlueter, Dirk] Hannover Med Sch, Inst Med Microbiol & Hosp Epidemiol, Hannover, Germany; [Schlueter, Dirk] Otto von Guericke Univ, Hlth Campus Immunol Infectiol & Inflammat, Inst Med Microbiol & Hosp Hyg, Magdeburg, Germany; [Dunay, Ildiko Rita] Otto von Guericke Univ, Ctr Behav Brain Sci, Magdeburg, Germany; [Parzmair, Gerald P.] Vakzine Projekt Management GmbH, Hannover, Germany	Otto von Guericke University; Helmholtz Association; Helmholtz-Center for Infection Research; Otto von Guericke University; Otto von Guericke University; Free University of Berlin; Otto von Guericke University; Hannover Medical School; Otto von Guericke University; Otto von Guericke University	Bruder, D (corresponding author), Otto von Guericke Univ, Hlth Campus Immunol Infectiol & Inflammat, Inst Med Mk Robiol, Infect Immunol, Magdeburg, Germany.; Bruder, D (corresponding author), Helmholtz Ctr Infect Res, Immune Regulat, Braunschweig, Germany.	dunja.bruder@med.ovgu.de	Relja, Borna/B-6642-2016	Relja, Borna/0000-0002-5625-8823; Kershaw, Olivia/0000-0002-3686-9993; Dusedau, Henning Peter/0000-0002-0805-4084	Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) [97850925-SFB 854]; State of Saxony-Anhalt	Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)(German Research Foundation (DFG)); State of Saxony-Anhalt	This research was funded by theDeutsche Forschungsgemeinschaft (DFG, German Research Foundation)-Project-ID 97850925-SFB 854 (BS B19, DB A23). MB and GP were supported by grants (SI2 and SI3) of the State of Saxony-Anhalt to BS.	ASSOIAN RK, 1983, J BIOL CHEM, V258, P7155; Becker N, 2021, J IMMUNOL RES, V2021, DOI 10.1155/2021/6647753; Bindea G, 2009, BIOINFORMATICS, V25, P1091, DOI 10.1093/bioinformatics/btp101; Block H, 2012, J EXP MED, V209, P407, DOI 10.1084/jem.20111493; Boning MAL, 2020, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.03144; Carr KD, 2011, EUR J IMMUNOL, V41, P2666, DOI 10.1002/eji.201041363; Clemens RA, 2007, J IMMUNOL, V178, P4606, DOI 10.4049/jimmunol.178.7.4606; Coppolino MG, 2001, J CELL SCI, V114, P4307; CZUPRYNSKI CJ, 1988, J IMMUNOL, V140, P962; D'Orazio SEF, 2019, MICROBIOL SPECTR, V7, DOI 10.1128/microbiolspec.GPP3-0065-2019; Dluzniewska J, 2007, EUR J IMMUNOL, V37, P3208, DOI 10.1002/eji.200737094; Dusedau HP, 2019, GLIA, V67, P193, DOI 10.1002/glia.23553; Dunay IR, 2008, IMMUNITY, V29, P306, DOI 10.1016/j.immuni.2008.05.019; EDWARDS SW, 1988, J GEN MICROBIOL, V134, P37; Eisenman J, 2002, CYTOKINE, V20, P121, DOI 10.1006/cyto.2002.1989; El-Benna J, 2008, SEMIN IMMUNOPATHOL, V30, P279, DOI 10.1007/s00281-008-0118-3; Ellis TN, 2004, IMMUNOLOGY, V112, P2, DOI 10.1111/j.1365-2567.2004.01849.x; Eltzschig HK, 2011, NEW ENGL J MED, V364, P656, DOI 10.1056/NEJMra0910283; Figueiredo CA, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00154; Fostel LV, 2006, INT IMMUNOL, V18, P1305, DOI 10.1093/intimm/dxl063; Frentzel S, 2019, EUR J IMMUNOL, V49, P1391, DOI 10.1002/eji.201847961; Geissmann F, 2003, IMMUNITY, V19, P71, DOI 10.1016/S1074-7613(03)00174-2; Gregory SH, 2002, J IMMUNOL, V168, P308, DOI 10.4049/jimmunol.168.1.308; Horejsi V, 2004, NAT REV IMMUNOL, V4, P603, DOI 10.1038/nri1414; Jordan MS, 2003, NAT IMMUNOL, V4, P110, DOI 10.1038/ni0203-110; Kasirer-Friede A, 2004, BLOOD, V103, P3403, DOI 10.1182/blood-2003-10-3664; KLEBANOFF SJ, 1986, J IMMUNOL, V136, P4220; Kurihara T, 1997, J EXP MED, V186, P1757, DOI 10.1084/jem.186.10.1757; Ng LG, 2019, NAT REV IMMUNOL, V19, P255, DOI 10.1038/s41577-019-0141-8; LEIST M, 1994, J IMMUNOL, V153, P1778; Ley K, 2007, NAT REV IMMUNOL, V7, P678, DOI 10.1038/nri2156; MACMICKING JD, 1995, CELL, V81, P641, DOI 10.1016/0092-8674(95)90085-3; Malik A, 2018, IMMUNOL REV, V281, P124, DOI 10.1111/imr.12615; Manfredi AA, 2015, CLIN EXP IMMUNOL, V179, P24, DOI 10.1111/cei.12320; Maugeri N, 2009, BLOOD, V113, P5254, DOI 10.1182/blood-2008-09-180794; Mildner A, 2013, ADV IMMUNOL, V120, P69, DOI 10.1016/B978-0-12-417028-5.00003-X; Musci MA, 1997, J BIOL CHEM, V272, P11674, DOI 10.1074/jbc.272.18.11674; Myung PS, 2001, IMMUNITY, V15, P1011, DOI 10.1016/S1074-7613(01)00253-9; Newbrough Sally A, 2003, Immunity, V19, P761, DOI 10.1016/S1074-7613(03)00305-4; Okunnu Busola M, 2019, Immunohorizons, V3, P573, DOI 10.4049/immunohorizons.1900065; Pamer EG, 2004, NAT REV IMMUNOL, V4, P812, DOI 10.1038/nri1461; Parzmair GP, 2017, J LEUKOCYTE BIOL, V101, P407, DOI 10.1189/jlb.1A0216-090RR; Parzmair GP., 2016, THESIS OTTO VON GUER; Peterson EJ, 2003, IMMUNOL REV, V192, P113, DOI 10.1034/j.1600-065X.2003.00026.x; Peterson EJ, 2001, SCIENCE, V293, P2263, DOI 10.1126/science.1063486; Pham CTN, 2006, NAT REV IMMUNOL, V6, P541, DOI 10.1038/nri1841; Rainard P, 2000, AM J VET RES, V61, P951, DOI 10.2460/ajvr.2000.61.951; Ratthe C, 2004, J LEUKOCYTE BIOL, V76, P162, DOI 10.1189/jlb.0605298; Rosales C, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00113; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; Rudolph J, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02343; Rudolph JM, 2019, MOL CELL BIOL, V39, DOI 10.1128/MCB.00365-18; Segal AW, 2005, ANNU REV IMMUNOL, V23, P197, DOI 10.1146/annurev.immunol.23.021704.115653; Serbina NV, 2012, ADV IMMUNOL, V113, P119, DOI 10.1016/B978-0-12-394590-7.00003-8; Serbina NV, 2003, IMMUNITY, V19, P59, DOI 10.1016/S1074-7613(03)00171-7; Shao X, 2021, BRIEF BIOINFORM, V22, DOI 10.1093/bib/bbaa269; Skarnes WC, 2011, NATURE, V474, P337, DOI 10.1038/nature10163; Sturn A, 2002, BIOINFORMATICS, V18, P207, DOI 10.1093/bioinformatics/18.1.207; Telieps T, 2013, EUR J IMMUNOL, V43, P1499, DOI 10.1002/eji.201242819; Togni M, 2004, MOL IMMUNOL, V41, P615, DOI 10.1016/j.molimm.2004.04.009; Tripal P, 2007, J INTERF CYTOK RES, V27, P44, DOI 10.1089/jir.2007.0086; TRIPP CS, 1993, P NATL ACAD SCI USA, V90, P3725, DOI 10.1073/pnas.90.8.3725; Veale M, 1999, J BIOL CHEM, V274, P28427, DOI 10.1074/jbc.274.40.28427; Vorobjeva N. V., 2020, Moscow University Biological Sciences Bulletin, V75, P173, DOI 10.3103/S0096392520040112; Weber ANR, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01454; Yang Q, 2013, INFECT IMMUN, V81, P1751, DOI 10.1128/IAI.01409-12; Zenewicz LA, 2007, MICROBES INFECT, V9, P1208, DOI 10.1016/j.micinf.2007.05.008; Zhan YF, 1998, BLOOD, V91, P863, DOI 10.1182/blood.V91.3.863.863_863_869	68	0	0	1	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 30	2021	12								724855	10.3389/fimmu.2021.724855	http://dx.doi.org/10.3389/fimmu.2021.724855			20	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WH5ZY	34659211	Green Published, gold			2022-12-18	WOS:000707756600001
J	Fahy, N; Cabeza, VP; Lolli, A; Witte-Bouma, J; Merino, A; Ridwan, Y; Wolvius, EB; Hoogduijn, MJ; Farrell, E; Brama, PAJ				Fahy, Niamh; Cabeza, Virginia Palomares; Lolli, Andrea; Witte-Bouma, Janneke; Merino, Ana; Ridwan, Yanto; Wolvius, Eppo B.; Hoogduijn, Martin J.; Farrell, Eric; Brama, Pieter A. J.			Chondrogenically Primed Human Mesenchymal Stem Cells Persist and Undergo Early Stages of Endochondral Ossification in an Immunocompetent Xenogeneic Model	FRONTIERS IN IMMUNOLOGY			English	Article						mesenchymal stem cells; endochondral ossification; xenogeneic; immunocompetence; adaptive immunity; innate immunity; graft rejection; osteoimmunology	MARROW STROMAL CELLS; HUMAN BONE-MARROW; IN-VITRO; IMMUNE-RESPONSE; ADIPOSE-TISSUE; TRANSPLANTATION; PROLIFERATION; SUPPRESSION; EXPRESSION; INCREASES	Tissue engineering approaches using progenitor cells such as mesenchymal stromal cells (MSCs) represent a promising strategy to regenerate bone. Previous work has demonstrated the potential of chondrogenically primed human MSCs to recapitulate the process of endochondral ossification and form mature bone in vivo, using immunodeficient xenogeneic models. To further the translation of such MSC-based approaches, additional investigation is required to understand the impact of interactions between human MSC constructs and host immune cells upon the success of MSC-mediated bone formation. Although human MSCs are considered hypoimmunogenic, the potential of chondrogenically primed human MSCs to induce immunogenic responses in vivo, as well as the efficacy of MSC-mediated ectopic bone formation in the presence of fully competent immune system, requires further elucidation. Therefore, the aim of this study was to investigate the capacity of chondrogenically primed human MSC constructs to persist and undergo the process of endochondral ossification in an immune competent xenogeneic model. Chondrogenically differentiated human MSC pellets were subcutaneously implanted to wild-type BALB/c mice and retrieved at 2 and 12 weeks post-implantation. The percentages of CD4(+) and CD8(+) T cells, B cells, and classical/non-classical monocyte subsets were not altered in the peripheral blood of mice that received chondrogenic MSC constructs compared to sham-operated controls at 2 weeks post-surgery. However, MSC-implanted mice had significantly higher levels of serum total IgG compared to sham-operated mice at this timepoint. Flow cytometric analysis of retrieved MSC constructs identified the presence of T cells and macrophages at 2 and 12 weeks post-implantation, with low levels of immune cell infiltration to implanted MSC constructs detected by CD45 and CD3 immunohistochemical staining. Despite the presence of immune cells in the tissue, MSC constructs persisted in vivo and were not degraded/resorbed. Furthermore, constructs became mineralised, with longitudinal micro-computed tomography imaging revealing an increase in mineralised tissue volume from 4 weeks post-implantation until the experimental endpoint at 12 weeks. These findings indicate that chondrogenically differentiated human MSC pellets can persist and undergo early stages of endochondral ossification following subcutaneous implantation in an immunocompetent xenogeneic model. This scaffold-free model may be further extrapolated to provide mechanistic insight to osteoimmunological processes regulating bone regeneration and homeostasis.	[Fahy, Niamh; Cabeza, Virginia Palomares; Lolli, Andrea; Witte-Bouma, Janneke; Wolvius, Eppo B.; Farrell, Eric] Erasmus MC, Dept Oral & Maxillofacial Surg, Rotterdam, Netherlands; [Fahy, Niamh] Erasmus MC, Dept Orthopaed & Sports Med, Rotterdam, Netherlands; [Cabeza, Virginia Palomares; Merino, Ana; Hoogduijn, Martin J.] Erasmus MC, Transplantat Inst, Dept Internal Med, Rotterdam, Netherlands; [Cabeza, Virginia Palomares; Brama, Pieter A. J.] Univ Coll Dublin, Sch Vet Med, Dublin, Ireland; [Ridwan, Yanto] Erasmus MC, Dept Genet, Rotterdam, Netherlands; [Ridwan, Yanto] Erasmus MC, Dept Radiol & Nucl Med, Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; University College Dublin; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC	Farrell, E (corresponding author), Erasmus MC, Dept Oral & Maxillofacial Surg, Rotterdam, Netherlands.	e.farrell@erasmusmc.nl			AO Foundation, Switzerland [AOCMF-15-27F]; European Union Horizon 2020 Research and Innovation Program [801159]	AO Foundation, Switzerland; European Union Horizon 2020 Research and Innovation Program	This research was partly supported by the AO Foundation, Switzerland (AOCMF-15-27F). AL is supported by the European Union Horizon 2020 Research and Innovation Program under grant agreement 801159.	Amini Ami R., 2012, Critical Reviews in Biomedical Engineering, V40, P363; Ankrum JA, 2014, NAT BIOTECHNOL, V32, P252, DOI 10.1038/nbt.2816; Arzi B, 2015, ACTA BIOMATER, V23, P72, DOI 10.1016/j.actbio.2015.05.025; BOLANO L, 1991, ORTHOPEDICS, V14, P987; BUDZYNSKI W, 1994, IMMUNOPHARM IMMUNOT, V16, P319, DOI 10.3109/08923979409007097; Cabeza VP, 2019, FRONT BIOENG BIOTECH, V7, DOI 10.3389/fbioe.2019.00142; Chen JC, 2002, MECH AGEING DEV, V123, P145, DOI 10.1016/S0047-6374(01)00347-5; Chen JC, 2002, BLOOD, V99, P561, DOI 10.1182/blood.V99.2.561; Chen X, 2007, STEM CELLS, V25, P364, DOI 10.1634/stemcells.2006-0268; Choi H, 2011, BLOOD, V118, P330, DOI 10.1182/blood-2010-12-327353; Cruz FF, 2015, STEM CELL TRANSL MED, V4, P615, DOI 10.5966/sctm.2014-0268; Cui PC, 2021, ANN OTO RHINOL LARYN, V130, P441, DOI 10.1177/0003489420957357; Du WJ, 2016, STEM CELLS DEV, V25, P1454, DOI 10.1089/scd.2016.0022; El Khassawna T, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00562; Eliopoulos N, 2005, BLOOD, V106, P4057, DOI 10.1182/blood-2005-03-1004; Farrell E, 2011, BMC MUSCULOSKEL DIS, V12, DOI 10.1186/1471-2474-12-31; Farrell E, 2009, TISSUE ENG PART C-ME, V15, P285, DOI 10.1089/ten.tec.2008.0297; Francois M, 2009, BLOOD, V114, P2632, DOI 10.1182/blood-2009-02-207795; Gawlitta D, 2010, TISSUE ENG PART B-RE, V16, P385, DOI [10.1089/ten.teb.2009.0712, 10.1089/ten.TEB.2009.0712]; Huang JI, 2006, J BONE JOINT SURG AM, V88A, P744, DOI 10.2106/JBJS.E.00669; Isakova IA, 2010, EXP HEMATOL, V38, P957, DOI 10.1016/j.exphem.2010.06.011; Kiernan CH, 2018, J TISSUE ENG REGEN M, V12, P1530, DOI 10.1002/term.2682; Kiernan CH, 2020, TISSUE ENG PT A, V26, P490, DOI [10.1089/ten.tea.2019.0177, 10.1089/ten.TEA.2019.0177]; Kiernan CH, 2016, CYTOTHERAPY, V18, P957, DOI 10.1016/j.jcyt.2016.05.002; Knuth CA, 2017, EUR CELLS MATER, V34, P142, DOI 10.22203/eCM.v034a10; Knuth CA, 2018, TISSUE ENG PART C-ME, V24, P313, DOI [10.1089/ten.TEC.2018.0031, 10.1089/ten.tec.2018.0031]; Kovach TK, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/752510; Krasnodembskaya A, 2012, AM J PHYSIOL-LUNG C, V302, pL1003, DOI 10.1152/ajplung.00180.2011; Le Blanc K, 2003, EXP HEMATOL, V31, P890, DOI 10.1016/S0301-472X(03)00110-3; Longoni A, 2018, NPJ REGEN MED, V3, DOI 10.1038/s41536-018-0060-5; Longoni A, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.00651; Luk F, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01042; Miron RJ, 2018, TISSUE ENG PART B-RE, V24, P53, DOI [10.1089/ten.TEB.2017.0242, 10.1089/ten.teb.2017.0242]; Nemeth K, 2009, NAT MED, V15, P42, DOI 10.1038/nm.1905; Niemeyer P, 2008, CYTOTHERAPY, V10, P784, DOI 10.1080/14653240802419302; Pelttari K, 2006, ARTHRITIS RHEUM-US, V54, P3254, DOI 10.1002/art.22136; Pinchuk Lesya M, 2008, Immun Ageing, V5, P1, DOI 10.1186/1742-4933-5-1; Poncelet AJ, 2007, TRANSPLANTATION, V83, P783, DOI 10.1097/01.tp.0000258649.23081.a3; Prockop DJ, 2017, MOL THER, V25, P1748, DOI 10.1016/j.ymthe.2017.06.004; Revell CM, 2009, TISSUE ENG PART B-RE, V15, P1, DOI 10.1089/ten.teb.2008.0189; Ryan AE, 2014, MOL THER, V22, P655, DOI 10.1038/mt.2013.261; Schlundt C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01954; Schlundt C, 2018, BONE, V106, P78, DOI 10.1016/j.bone.2015.10.019; Schu S, 2012, J CELL MOL MED, V16, P2094, DOI 10.1111/j.1582-4934.2011.01509.x; Scotti C, 2013, P NATL ACAD SCI USA, V110, P3997, DOI 10.1073/pnas.1220108110; Scotti C, 2010, P NATL ACAD SCI USA, V107, P7251, DOI 10.1073/pnas.1000302107; SHARP AK, 1984, EUR J IMMUNOL, V14, P102, DOI 10.1002/eji.1830140119; Spaggiari GM, 2008, BLOOD, V111, P1327, DOI 10.1182/blood-2007-02-074997; Stone KR, 1997, TRANSPLANTATION, V63, P640, DOI 10.1097/00007890-199703150-00005; Thompson EM, 2016, TISSUE ENG PT A, V22, P556, DOI [10.1089/ten.tea.2015.0457, 10.1089/ten.TEA.2015.0457]; Toben D, 2011, J BONE MINER RES, V26, P113, DOI 10.1002/jbmr.185; Tse WT, 2003, TRANSPLANTATION, V75, P389, DOI 10.1097/01.TP.0000045055.63901.A9; Walsh MC, 2006, ANNU REV IMMUNOL, V24, P33, DOI 10.1146/annurev.immunol.24.021605.090646; Zhang YP, 2018, STEM CELLS DEV, V27, P1634, DOI 10.1089/scd.2018.0119; Zhao ZG, 2012, IMMUNOL INVEST, V41, P183, DOI 10.3109/08820139.2011.607877	55	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 30	2021	12								715267	10.3389/fimmu.2021.715267	http://dx.doi.org/10.3389/fimmu.2021.715267			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WI5KA	34659205	gold, Green Published			2022-12-18	WOS:000708397700001
J	Guilpain, P; Noel, D; Avouac, J				Guilpain, Philippe; Noel, Daniele; Avouac, Jerome			Editorial: Key Players in Systemic Sclerosis: The Immune System and Beyond	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						systemic sclerosis; pathophysiology; co-stimulation; abatacept; innate immune system; mesenchymal stromal cell; extracellular vesicles; cancer	ABATACEPT		[Guilpain, Philippe] St Eloi Hosp, Local Referral Ctr System & Autoimmune Dis, Dept Internal Med & Multiorgan Dis, Montpellier, France; [Guilpain, Philippe; Noel, Daniele] Univ Montpellier, Fac Med, Montpellier, France; [Guilpain, Philippe; Noel, Daniele] St Eloi Hosp, Inst Regenerat Med & Biotherapy IRMB, INSERM, U1183, Montpellier, France; [Avouac, Jerome] Cochin Hosp, AP HP, Dept Rheumatol, CUP, Paris, France; [Avouac, Jerome] Univ Paris, Univ Paris Descartes, Fac Med, Paris, France; [Avouac, Jerome] Cochin Inst, INSERM U1016, Paris, France; [Avouac, Jerome] Cochin Inst, CNRS UMR8104, Paris, France	Universite de Montpellier; CHU de Montpellier; Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; CHU de Montpellier; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite	Guilpain, P (corresponding author), St Eloi Hosp, Local Referral Ctr System & Autoimmune Dis, Dept Internal Med & Multiorgan Dis, Montpellier, France.; Guilpain, P (corresponding author), Univ Montpellier, Fac Med, Montpellier, France.; Guilpain, P (corresponding author), St Eloi Hosp, Inst Regenerat Med & Biotherapy IRMB, INSERM, U1183, Montpellier, France.	p-guilpain@chu-montpellier.fr	Noel, Daniele/E-5719-2016					Adom D, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aay4799; Allanore Y, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.2; Boleto G, 2018, ARTHRITIS RES THER, V20, DOI 10.1186/s13075-018-1694-9; de Paoli FV, 2014, SCAND J RHEUMATOL, V43, P342, DOI 10.3109/03009742.2013.812238; Elhai M, 2015, JOINT BONE SPINE, V82, P148, DOI 10.1016/j.jbspin.2014.10.010; Elhai M, 2013, ANN RHEUM DIS, V72, P1217, DOI 10.1136/annrheumdis-2012-202657; Khanna D, 2020, ARTHRITIS RHEUMATOL, V72, P125, DOI 10.1002/art.41055; Laurent P, 2021, ANN RHEUM DIS, V80, P1594, DOI 10.1136/annrheumdis-2020-219748; Maumus M, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.00997; Ponsoye M, 2016, ANN RHEUM DIS, V75, P2142, DOI 10.1136/annrheumdis-2015-208213; Rozier P, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22136837; Rozier P, 2021, J AUTOIMMUN, V121, DOI 10.1016/j.jaut.2021.102660	12	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 30	2021	12								770419	10.3389/fimmu.2021.770419	http://dx.doi.org/10.3389/fimmu.2021.770419			4	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WL5JU	34659272	Green Published, gold			2022-12-18	WOS:000710442100001
J	Scheunemann, JF; Reichwald, JJ; Korir, PJ; Kuehlwein, JM; Jenster, LM; Hammerschmidt-Kamper, C; Lewis, MD; Klocke, K; Borsche, M; Schwendt, KE; Soun, C; Thiebes, S; Limmer, A; Engel, DR; Mueller, AK; Hoerauf, A; Hubner, MP; Schumak, B				Scheunemann, Johanna F.; Reichwald, Julia J.; Korir, Patricia Jebett; Kuehlwein, Janina M.; Jenster, Lea-Marie; Hammerschmidt-Kamper, Christiane; Lewis, Matthew D.; Klocke, Katrin; Borsche, Max; Schwendt, Kim E.; Soun, Camille; Thiebes, Stephanie; Limmer, Andreas; Engel, Daniel R.; Mueller, Ann-Kristin; Hoerauf, Achim; Huebner, Marc P.; Schumak, Beatrix			Eosinophils Suppress the Migration of T Cells Into the Brain of Plasmodium berghei-Infected Ifnar1(-/-) Mice and Protect Them From Experimental Cerebral Malaria	FRONTIERS IN IMMUNOLOGY			English	Article						experimental cerebral malaria (ECM); IFNAR1; malaria; CD8 T cells; eosinophils; Plasmodium berghei; NK cells; CCL5	TUMOR-NECROSIS-FACTOR; INTERFERON-GAMMA; I INTERFERON; DISEASE SEVERITY; MURINE MODELS; IFN-GAMMA; NK CELLS; PATHOGENESIS; PARASITE; ALPHA	Cerebral malaria is a potentially lethal disease, which is caused by excessive inflammatory responses to Plasmodium parasites. Here we use a newly developed transgenic Plasmodium berghei ANKA (PbA(Ama1)OVA) parasite that can be used to study parasite-specific T cell responses. Our present study demonstrates that Ifnar1(-/-) mice, which lack type I interferon receptor-dependent signaling, are protected from experimental cerebral malaria (ECM) when infected with this novel parasite. Although CD8(+) T cell responses generated in the spleen are essential for the development of ECM, we measured comparable parasite-specific cytotoxic T cell responses in ECM-protected Ifnar1(-/-) mice and wild type mice suffering from ECM. Importantly, CD8(+) T cells were increased in the spleens of ECM-protected Ifnar1(-/-) mice and the blood-brain-barrier remained intact. This was associated with elevated splenic levels of CCL5, a T cell and eosinophil chemotactic chemokine, which was mainly produced by eosinophils, and an increase in eosinophil numbers. Depletion of eosinophils enhanced CD8(+) T cell infiltration into the brain and increased ECM induction in PbA(Ama1)OVA-infected Ifnar1(-/-) mice. However, eosinophil-depletion did not reduce the CD8(+) T cell population in the spleen or reduce splenic CCL5 concentrations. Our study demonstrates that eosinophils impact CD8(+) T cell migration and proliferation during PbA(Ama1)OVA-infection in Ifnar1(-/-) mice and thereby are contributing to the protection from ECM.</p>	[Scheunemann, Johanna F.; Reichwald, Julia J.; Korir, Patricia Jebett; Kuehlwein, Janina M.; Jenster, Lea-Marie; Klocke, Katrin; Borsche, Max; Schwendt, Kim E.; Hoerauf, Achim; Huebner, Marc P.; Schumak, Beatrix] Univ Hosp Bonn, Inst Med Microbiol Immunol & Parasitol, Bonn, Germany; [Hammerschmidt-Kamper, Christiane; Lewis, Matthew D.; Mueller, Ann-Kristin] Heidelberg Univ Hosp, Ctr Infect Dis, Parasitol Unit, Heidelberg, Germany; [Soun, Camille; Thiebes, Stephanie; Engel, Daniel R.] Univ Hosp Essen, Inst Expt Immunol & Imaging, Essen, Germany; [Limmer, Andreas] Univ Hosp Essen, Clin Anesthesiol & Intens Care, Essen, Germany; [Mueller, Ann-Kristin] German Ctr Infect Res DZIF, Heidelberg, Germany; [Hoerauf, Achim; Huebner, Marc P.] German Ctr Infect Res DZIF, Partner Site Bonn Cologne, Bonn, Germany	University of Bonn; Ruprecht Karls University Heidelberg; University of Duisburg Essen; University of Duisburg Essen; German Center for Infection Research; German Center for Infection Research	Hubner, MP (corresponding author), Univ Hosp Bonn, Inst Med Microbiol Immunol & Parasitol, Bonn, Germany.; Hubner, MP (corresponding author), German Ctr Infect Res DZIF, Partner Site Bonn Cologne, Bonn, Germany.	huebner@uni-bonn.de	Hübner, Marc P/W-9529-2018	Hübner, Marc P/0000-0001-8885-418X; Reichwald, Julia/0000-0002-9255-6780	German Academic Exchange program (DAAD); Jurgen Manchot Stiftung, Dusseldorf, Germany; BONFOR [2012-01-22, 2013-01-29, 2017-5-02, 2018-7-01, 2018-7-02, 2019-7-01, 2019-7-02, 2020-7-03]; DZIF; Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany's Excellence Strategy [EXC2151 -390873048]	German Academic Exchange program (DAAD)(Deutscher Akademischer Austausch Dienst (DAAD)); Jurgen Manchot Stiftung, Dusseldorf, Germany; BONFOR; DZIF; Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany's Excellence Strategy(German Research Foundation (DFG))	PK was supported by a PhD scholarship from the German Academic Exchange program (DAAD). JR and JS were supported by a PhD scholarship from the Jurgen Manchot Stiftung, Dusseldorf, Germany. JK, JR, JS, and BS were supported by BONFOR 2012-01-22, 2013-01-29, 2017-5-02, 2018-7-01, 2018-7-02, 2019-7-01, 2019-7-02, and 2020-7-03. A-KM is a recipient of a DZIF funded Maternity Leave stipend. AH and BS were members of the Bonn Cluster of Excellence ImmunoSensation EXC 1023 and AH and MH are funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany's Excellence Strategy EXC2151 -390873048. AH andMHare members of the German Center for Infection Research (DZIF).	Adu B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029465; Aldinucci D, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/292376; Amani V, 1998, INFECT IMMUN, V66, P4093; Amante FH, 2010, J IMMUNOL, V185, P3632, DOI 10.4049/jimmunol.1000944; Aucan C, 2003, GENES IMMUN, V4, P275, DOI 10.1038/sj.gene.6363962; Ball EA, 2013, J IMMUNOL, V190, P5118, DOI 10.4049/jimmunol.1300114; Belnoue E, 2002, J IMMUNOL, V169, P6369, DOI 10.4049/jimmunol.169.11.6369; Belnoue E, 2003, BLOOD, V101, P4253, DOI 10.1182/blood-2002-05-1493; Belnoue E, 2008, PARASITE IMMUNOL, V30, P544, DOI 10.1111/j.1365-3024.2008.01053.x; Burrack KS, 2019, MALARIA J, V18, DOI 10.1186/s12936-019-2953-1; Cabantous S, 2005, J INFECT DIS, V192, P854, DOI 10.1086/432484; Campanella GSV, 2008, P NATL ACAD SCI USA, V105, P4814, DOI 10.1073/pnas.0801544105; Capuccini B, 2016, SCI REP-UK, V6, DOI 10.1038/srep39258; Carroll RW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013124; Claser C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018720; Curtsinger JM, 2005, J IMMUNOL, V174, P4465, DOI 10.4049/jimmunol.174.8.4465; D'Ombrain MC, 2008, CLIN INFECT DIS, V47, P1380, DOI 10.1086/592971; de Oca MM, 2016, CELL REP, V17, P399, DOI 10.1016/j.celrep.2016.09.015; de Souza JB, 2010, PARASITOLOGY, V137, P755, DOI 10.1017/S0031182009991715; Deroost K, 2016, FEMS MICROBIOL REV, V40, P208, DOI 10.1093/femsre/fuv046; Edwards CL, 2015, CLIN VACCINE IMMUNOL, V22, P477, DOI 10.1128/CVI.00051-15; Edwards CL, 2015, EUR J IMMUNOL, V45, P130, DOI 10.1002/eji.201444824; Franklin BS, 2009, P NATL ACAD SCI USA, V106, P5789, DOI 10.1073/pnas.0809742106; Gazzinelli RT, 2014, NAT REV IMMUNOL, V14, P744, DOI 10.1038/nri3742; Ghazanfari N, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02016; Gimenez F, 2003, CELL MOL LIFE SCI, V60, P1623, DOI 10.1007/s00018-003-2347-x; GRAU GE, 1989, NEW ENGL J MED, V320, P1586, DOI 10.1056/NEJM198906153202404; GRAU GE, 1989, P NATL ACAD SCI USA, V86, P5572, DOI 10.1073/pnas.86.14.5572; Gun SY, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/243713; Hafalla JCR, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003303; Hansen DS, 2007, J IMMUNOL, V178, P5779, DOI 10.4049/jimmunol.178.9.5779; Haque A, 2014, J CLIN INVEST, V124, P2483, DOI 10.1172/JCI70698; Haque A, 2011, EUR J IMMUNOL, V41, P2688, DOI 10.1002/eji.201141539; Haque A, 2011, J IMMUNOL, V186, P6148, DOI 10.4049/jimmunol.1003955; Hermsen C, 1997, PARASITOLOGY, V114, P7, DOI 10.1017/S0031182096008293; Howland SW, 2015, SEMIN IMMUNOPATHOL, V37, P221, DOI 10.1007/s00281-015-0476-6; HUANG KY, 1968, SCIENCE, V162, P123, DOI 10.1126/science.162.3849.123; HWANG SY, 1995, P NATL ACAD SCI USA, V92, P11284, DOI 10.1073/pnas.92.24.11284; Janse CJ, 2006, MOL BIOCHEM PARASIT, V145, P60, DOI 10.1016/j.molbiopara.2005.09.007; Kim CC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048126; King T, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005118; Kohno H, 2014, J IMMUNOL, V192, P3816, DOI 10.4049/jimmunol.1301738; Kurtzhals JAL, 1998, CLIN EXP IMMUNOL, V112, P303; Leao L, 2020, BMC INFECT DIS, V20, DOI 10.1186/s12879-020-05107-2; Lundie RJ, 2008, P NATL ACAD SCI USA, V105, P14509, DOI 10.1073/pnas.0806727105; Maghazachi AA, 2010, CURR TOP MICROBIOL, V341, P37, DOI 10.1007/82_2010_20; Mitchell AJ, 2005, INFECT IMMUN, V73, P5645, DOI 10.1128/IAI.73.9.5645-5653.2005; Miu J, 2008, J IMMUNOL, V180, P1217, DOI 10.4049/jimmunol.180.2.1217; Mooney JP, 2017, TRENDS PARASITOL, V33, P257, DOI 10.1016/j.pt.2016.12.010; Murooka TT, 2008, BLOOD, V111, P4892, DOI 10.1182/blood-2007-11-125039; Nitcheu J, 2003, J IMMUNOL, V170, P2221, DOI 10.4049/jimmunol.170.4.2221; Palomo J, 2013, EUR J IMMUNOL, V43, P2683, DOI 10.1002/eji.201343327; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pombo DJ, 2002, LANCET, V360, P610, DOI 10.1016/S0140-6736(02)09784-2; Ryg-Cornejo V, 2013, IMMUNOBIOLOGY, V218, P263, DOI 10.1016/j.imbio.2012.05.018; Schofield L, 2005, NAT REV IMMUNOL, V5, P722, DOI 10.1038/nri1686; Schumak B, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124080; Sebina I, 2018, IMMUNOLOGY, V155, P176, DOI 10.1111/imm.12971; Sharma S, 2011, IMMUNITY, V35, P194, DOI 10.1016/j.immuni.2011.05.016; Silvie O, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000086; Specht S, 2010, MICROBES INFECT, V12, P635, DOI 10.1016/j.micinf.2010.04.006; Tamura T, 2011, INFECT IMMUN, V79, P3947, DOI 10.1128/IAI.01337-10; Van den Steen PE, 2008, EUR J IMMUNOL, V38, P1082, DOI 10.1002/eji.200737906; Villegas-Mendez A, 2017, INFECT IMMUN, V85, DOI 10.1128/IAI.01035-16; WHO, 2019, WORLD MALARIA REPORT; Wu J, 2014, P NATL ACAD SCI USA, V111, pE511, DOI 10.1073/pnas.1316467111; Yanez DM, 1996, J IMMUNOL, V157, P1620; Yao XY, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005930; Yu X, 2016, IMMUNITY, V45, P1093, DOI 10.1016/j.immuni.2016.10.001; Zander RA, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005945; Zhao H, 2014, CELL HOST MICROBE, V15, P551, DOI 10.1016/j.chom.2014.04.008	71	0	0	4	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 30	2021	12								711876	10.3389/fimmu.2021.711876	http://dx.doi.org/10.3389/fimmu.2021.711876			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WI4ZN	34659202	Green Published, gold			2022-12-18	WOS:000708370300001
J	Wu, H; Qin, JL; Zhao, Q; Lu, L; Li, C				Wu, Hao; Qin, Jiale; Zhao, Qiang; Lu, Lu; Li, Chen			Microdissection of the Bulk Transcriptome at Single-Cell Resolution Reveals Clinical Significance and Myeloid Cells Heterogeneity in Lung Adenocarcinoma	FRONTIERS IN IMMUNOLOGY			English	Article						tumor infiltrating myeloid cells; lung adenocarcinoma; single-cell transcriptome analysis; bulk RNA-seq analysis; deconvolution	DENDRITIC CELLS; TUMOR-ANTIGEN; NEUTROPHILS; EXPRESSION; GENE; INFLAMMASOME; ACTIVATION; CHECKPOINT; SELECTION; IMMUNITY	Background Tumor infiltrating myeloid (TIM) cells constitute a vital element of the tumor microenvironment. The cell-type heterogeneity of TIM has yet to be fully investigated. Methods We used a time saving approach to generate a single-cell reference matrix, allowing quantification of cell-type proportions and cell-type-specific gene abundances in bulk RNA-seq data. Results Two distinct clusters, MSC1 and MSC2 (MSC subtype) were newly identified in lung adenocarcinoma (LUAD) patients, both significantly associated with overall survival and immune blockade therapy responses. Twenty myeloid cell types were detected. Thirteen of these had distinct enrichment patterns between MSC1 and MSC2. LAMP3+ dendritic cells, being a mature and transportable subtype of dendritic cell that may migrate to lymph nodes, were noted as associated with non-responsiveness to immunotargeted therapy. High infiltration level of IFIT3+ neutrophils was strongly related to the response to immune-targeted therapy and was seen to activate CD8+ T cells, partly through inflammasome activation. The infiltration levels of TIMP1+ macrophages and S100A8+ neutrophils were both significantly associated with poor prognosis. TIMP1+ macrophages were noted to recruit S100A8+ neutrophils via the CXCL5-CXCR2 axes and promote LUAD progression. Conclusion Altogether, we performed virtual microdissection of the bulk transcriptome at single-cell resolution and provided a promising TIM infiltration landscape that may shed new light on the development of immune therapy.	[Wu, Hao; Qin, Jiale; Zhao, Qiang; Lu, Lu; Li, Chen] Zhejiang Univ, Dept Ultrasound, Dept Human Genet, Sch Med, Hangzhou, Peoples R China; [Wu, Hao; Qin, Jiale; Zhao, Qiang; Lu, Lu; Li, Chen] Zhejiang Univ, Womens Hosp, Sch Med, Hangzhou, Peoples R China; [Qin, Jiale; Li, Chen] Zhejiang Prov Key Lab Precis Diag & Therapy Major, Hangzhou, Peoples R China; [Li, Chen] Tokyo Med & Dent Univ, M&D Data Sci Ctr, Tokyo, Japan	Zhejiang University; Zhejiang University; Tokyo Medical & Dental University (TMDU)	Li, C (corresponding author), Zhejiang Univ, Dept Ultrasound, Dept Human Genet, Sch Med, Hangzhou, Peoples R China.; Li, C (corresponding author), Zhejiang Univ, Womens Hosp, Sch Med, Hangzhou, Peoples R China.; Li, C (corresponding author), Zhejiang Prov Key Lab Precis Diag & Therapy Major, Hangzhou, Peoples R China.; Li, C (corresponding author), Tokyo Med & Dent Univ, M&D Data Sci Ctr, Tokyo, Japan.	chenli2012@zju.edu.cn			Chinese National Natural Science Foundation [82171939]	Chinese National Natural Science Foundation(National Natural Science Foundation of China (NSFC))	This study was supported by the Chinese National Natural Science Foundation (grant 82171939).	Awad RM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01977; Azizi E, 2018, CELL, V174, P1293, DOI 10.1016/j.cell.2018.05.060; Bao XW, 2021, CANCER IMMUNOL IMMUN, V70, P189, DOI 10.1007/s00262-020-02669-7; Butler A, 2018, NAT BIOTECHNOL, V36, P411, DOI 10.1038/nbt.4096; Chevrier S, 2017, CELL, V169, P736, DOI 10.1016/j.cell.2017.04.016; Coffelt SB, 2016, NAT REV CANCER, V16, P431, DOI 10.1038/nrc.2016.52; Corson TW, 2007, CLIN CANCER RES, V13, P3229, DOI 10.1158/1078-0432.CCR-07-0393; DeNardo DG, 2019, NAT REV IMMUNOL, V19, P369, DOI 10.1038/s41577-019-0127-6; Engblom C, 2016, NAT REV CANCER, V16, P447, DOI 10.1038/nrc.2016.54; Finotello F, 2019, GENOME MED, V11, DOI 10.1186/s13073-019-0638-6; Gao LW, 2018, ONCOTARGETS THER, V11, P7407, DOI 10.2147/OTT.S171705; Gebhardt C, 2015, CLIN CANCER RES, V21, P5453, DOI 10.1158/1078-0432.CCR-15-0676; Ginhoux F, 2016, NAT IMMUNOL, V17, P34, DOI 10.1038/ni.3324; Hu JY, 2020, MOL THER, V28, P1658, DOI 10.1016/j.ymthe.2020.04.023; Huang LL, 2020, CANCER MED-US, V9, P8444, DOI 10.1002/cam4.3466; Jairath NK, 2020, J CLIN MED, V9, DOI 10.3390/jcm9061973; Jiang P, 2018, NAT MED, V24, P1550, DOI 10.1038/s41591-018-0136-1; Kandasamy M, 2011, CELL IMMUNOL, V271, P89, DOI 10.1016/j.cellimm.2011.06.004; Kim N, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16164-1; Lee HO, 2020, NAT GENET, V52, P594, DOI 10.1038/s41588-020-0636-z; Liu WT, 2018, CANCER LETT, V425, P43, DOI 10.1016/j.canlet.2018.03.043; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Maynard A, 2020, CELL, V182, P1232, DOI 10.1016/j.cell.2020.07.017; Meunier E, 2015, NAT IMMUNOL, V16, P476, DOI 10.1038/ni.3119; Miller JC, 2012, NAT IMMUNOL, V13, P888, DOI 10.1038/ni.2370; Newman AM, 2019, NAT BIOTECHNOL, V37, P773, DOI 10.1038/s41587-019-0114-2; Niemira M, 2020, CANCERS, V12, DOI 10.3390/cancers12010037; Oberg HH, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01690; Papadopoulos KP, 2017, CLIN CANCER RES, V23, P5703, DOI 10.1158/1078-0432.CCR-16-3261; Patente TA, 2019, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03176; Qian JB, 2020, CELL RES, V30, P745, DOI 10.1038/s41422-020-0355-0; Ramilowski JA, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8866; Roberts EW, 2016, CANCER CELL, V30, P324, DOI 10.1016/j.ccell.2016.06.003; Sansam CL, 2010, GENE DEV, V24, P183, DOI 10.1101/gad.1860310; Schabath MB, 2016, ONCOGENE, V35, P3209, DOI 10.1038/onc.2015.375; Scrucca L, 2016, R J, V8, P289; Sharma P, 2015, SCIENCE, V348, P56, DOI 10.1126/science.aaa8172; Shenoy AR, 2012, SCIENCE, V336, P481, DOI 10.1126/science.1217141; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Silvestre-Roig C, 2016, BLOOD, V127, P2173, DOI 10.1182/blood-2016-01-688887; Singel KL, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.122311; Steele CW, 2016, CANCER CELL, V29, P832, DOI 10.1016/j.ccell.2016.04.014; Therneau T. M., 2013, MODELING SURVIVAL DA, DOI 10.1007/978-1-4757-3294-8; Tibshirani R, 1997, STAT MED, V16, P385, DOI 10.1002/(SICI)1097-0258(19970228)16:4<385::AID-SIM380>3.0.CO;2-3; Tibshirani R, 2011, J R STAT SOC B, V73, P273, DOI 10.1111/j.1467-9868.2011.00771.x; Van Allen EM, 2015, SCIENCE, V350, P207, DOI 10.1126/science.aad0095; Villani AC, 2017, SCIENCE, V356, DOI 10.1126/science.aah4573; Vonderheide RH, 2020, ANNU REV MED, V71, P47, DOI 10.1146/annurev-med-062518-045435; Wang XR, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08023-x; Xie XM, 2020, NAT IMMUNOL, V21, P1119, DOI 10.1038/s41590-020-0736-z; Yamada M, 2011, CELL MOL IMMUNOL, V8, P305, DOI 10.1038/cmi.2011.8; Yamauchi M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043923; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Yu XJ, 2019, MOL THER-ONCOLYTICS, V14, P288, DOI 10.1016/j.omto.2019.07.004; Zhang CQ, 2020, CANCER LETT, V479, P31, DOI 10.1016/j.canlet.2020.03.016; Zhang L, 2020, CELL, V181, P442, DOI 10.1016/j.cell.2020.03.048; Zhang QM, 2019, CELL, V179, P829, DOI 10.1016/j.cell.2019.10.003; Zhou SL, 2012, HEPATOLOGY, V56, P2242, DOI 10.1002/hep.25907; Zilionis R, 2019, IMMUNITY, V50, P1317, DOI 10.1016/j.immuni.2019.03.009	59	0	0	3	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 30	2021	12								723908	10.3389/fimmu.2021.723908	http://dx.doi.org/10.3389/fimmu.2021.723908			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WI5TP	34659209	Green Published, gold			2022-12-18	WOS:000708422800001
J	Zhou, H; Ma, L; Liu, LY; Yao, XS				Zhou, Hao; Ma, Long; Liu, Longyu; Yao, Xinsheng			TR Locus Annotation and Characteristics of Rhinolophus ferrumequinum	FRONTIERS IN IMMUNOLOGY			English	Article						TR loci; annotation; IMGT; bat; T-cell receptor; immunogenomics	CHAIN DIVERSITY; EVOLUTION; BAT; IMMUNOGLOBULIN; SHEEP; TCR; GENOMES; GENE; RECOMBINATION; ORGANIZATION	T-cell antigen receptors (TRs) in vertebrates can be divided into alpha beta or gamma delta, encoded by TRA/D, TRG, or TRB loci. TRs play a central role in mammal cellular immunity, which occurs by rearrangement of V, D, J, and C genes in the loci. The bat is the only mammal with flying ability and is considered the main host of zoonotic viruses, an important public health concern. However, at present, little is known about the composition of bat TR genes. Based on the whole genome sequence of the greater horseshoe bat (Rhinolophus ferrumequinum) and referring to the TR/IG annotation rules formulated by the international ImMunoGeneTics information system (IMGT), we present a complete annotation of TRA/D, TRG, and TRB loci of R. ferrumequinum. A total of 128 V segments, three D segments, 85 J segments, and 6 C segments were annotated and compared with other known mammalian data. The characteristics of the TR locus and germline genes of R. ferrumequinum are analyzed.	[Zhou, Hao; Ma, Long; Liu, Longyu; Yao, Xinsheng] Zunyi Med Univ, Ctr Immunomol Engn Innovat & Practice Base Grad S, Dept Immunol, Zunyi, Guizhou, Peoples R China	Zunyi Medical University	Ma, L; Yao, XS (corresponding author), Zunyi Med Univ, Ctr Immunomol Engn Innovat & Practice Base Grad S, Dept Immunol, Zunyi, Guizhou, Peoples R China.	immunology01@126.com; 164849671@qq.com			National Natural Science Foundation of China [31860257]; Guizhou Provincial High-level Innovative Talents Project [(2018) 5637]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guizhou Provincial High-level Innovative Talents Project	The National Natural Science Foundation of China (31860257) and Guizhou Provincial High-level Innovative Talents Project [No. (2018) 5637] funded this study.	Ahn M, 2019, NAT MICROBIOL, V4, P789, DOI 10.1038/s41564-019-0371-3; Antonacci R, 2007, VET RES COMMUN, V31, P977, DOI 10.1007/s11259-006-0202-x; Antonacci R, 2020, GENES-BASEL, V11, DOI 10.3390/genes11060624; Baker ML, 2010, IMMUNOGENETICS, V62, P173, DOI 10.1007/s00251-010-0425-4; Banerjee A, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00026; Bratsch S, 2011, DEV COMP IMMUNOL, V35, P421, DOI 10.1016/j.dci.2010.06.004; Burgin CJ, 2018, J MAMMAL, V99, P1, DOI 10.1093/jmammal/gyx147; Butler JE, 2011, DEV COMP IMMUNOL, V35, P273, DOI 10.1016/j.dci.2010.08.011; Connelley TK, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-994; Conrad ML, 2007, VET IMMUNOL IMMUNOP, V115, P346, DOI 10.1016/j.vetimm.2006.10.019; Csorba G., 2003, HORSESHOE BATSS WORL; EARLY P, 1980, CELL, V19, P981, DOI 10.1016/0092-8674(80)90089-6; Giudicelli V, 1999, BIOINFORMATICS, V15, P1047, DOI 10.1093/bioinformatics/15.12.1047; Giudicelli Veronique, 2012, Frontiers in Genetics, V3, P79, DOI 10.3389/fgene.2012.00079; Giudicelli W, 2005, NUCLEIC ACIDS RES, V33, pD256, DOI 10.1093/nar/gki010; Hawkins JA, 2019, P NATL ACAD SCI USA, V116, P11351, DOI 10.1073/pnas.1814995116; Jebb D, 2020, NATURE, V583, P578, DOI 10.1038/s41586-020-2486-3; Krebs JE., 2011, LEWINS GENES, P490; Lane J, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-223; Lei M, 2016, SCI REP-UK, V6, DOI 10.1038/srep27726; Litman GW, 2010, NAT REV IMMUNOL, V10, P543, DOI 10.1038/nri2807; Massari S, 2009, MOL IMMUNOL, V46, P2728, DOI 10.1016/j.molimm.2009.05.008; Massari S, 1998, CHROMOSOME RES, V6, P419, DOI 10.1023/A:1009245830804; Massari S, 2021, GENES-BASEL, V12, DOI 10.3390/genes12040544; MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7; Mehdizadeh R, 2020, MITOCHONDRIAL DNA A, V31, P87, DOI 10.1080/24701394.2020.1741562; Miccoli MC, 2003, J MOL EVOL, V57, P52, DOI 10.1007/s00239-002-2451-9; Miccoli MC, 2001, IMMUNOGENETICS, V53, P416, DOI 10.1007/s002510100340; Murphy K., 2012, JANEWAYS IMMUNOBIOLO, P157; Nei M, 2005, ANNU REV GENET, V39, P121, DOI 10.1146/annurev.genet.39.073003.112240; Nei M, 1997, P NATL ACAD SCI USA, V94, P7799, DOI 10.1073/pnas.94.15.7799; Parra ZE, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-111; Parra ZE, 2007, P NATL ACAD SCI USA, V104, P9776, DOI 10.1073/pnas.0609106104; Parra ZE, 2006, DEV COMP IMMUNOL, V30, P699, DOI 10.1016/j.dci.2005.10.002; Parra ZE, 2012, MOL BIOL EVOL, V29, P3205, DOI 10.1093/molbev/mss128; Parra ZE, 2010, EUR J IMMUNOL, V40, P2319, DOI 10.1002/eji.201040515; Parra ZE, 2009, J IMMUNOL, V182, P154, DOI 10.4049/jimmunol.182.1.154; Pavlovich SS, 2018, CELL, V173, P1098, DOI 10.1016/j.cell.2018.03.070; Pegorier P, 2021, GENES-BASEL, V12, DOI 10.3390/genes12010030; Pegorier P, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00821; Piccinni B, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1790-z; Radtanakatikanon A, 2020, BMC GENOMICS, V21, DOI 10.1186/s12864-019-6431-5; Richards MH, 2000, MOL BIOL EVOL, V17, P146, DOI 10.1093/oxfordjournals.molbev.a026227; Simmons N.B., BAT SPECIES WORLD TA; Simmons NB, 2008, NATURE, V451, P818, DOI 10.1038/nature06549; Su C, 2001, MOL BIOL EVOL, V18, P503, DOI 10.1093/oxfordjournals.molbev.a003829; Teeling EC, 2005, SCIENCE, V307, P580, DOI 10.1126/science.1105113; TJOELKER LW, 1990, P NATL ACAD SCI USA, V87, P7856, DOI 10.1073/pnas.87.20.7856; Vaccarelli G, 2005, GENE, V357, P103, DOI 10.1016/j.gene.2005.05.033; Vaccarelli G, 2012, EUR J IMMUNOL, V42, P3416, DOI 10.1002/eji.201142176; Wang XX, 2011, J IMMUNOL, V187, P5246, DOI 10.4049/jimmunol.1101113; Wynne JW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0052930; Yazawa R, 2008, MOL IMMUNOL, V45, P2150, DOI 10.1016/j.molimm.2007.12.007; Zhou P, 2016, P NATL ACAD SCI USA, V113, P2696, DOI 10.1073/pnas.1518240113	54	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 30	2021	12								741408	10.3389/fimmu.2021.741408	http://dx.doi.org/10.3389/fimmu.2021.741408			18	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WH2GE	34659234	Green Published, gold, Green Submitted			2022-12-18	WOS:000707502400001
J	Zoldan, K; Ehrlich, S; Killmer, S; Wild, K; Smits, M; Russ, M; Globig, AM; Hofmann, M; Thimme, R; Boettler, T				Zoldan, Katharina; Ehrlich, Sabine; Killmer, Saskia; Wild, Katharina; Smits, Maike; Russ, Marissa; Globig, Anna-Maria; Hofmann, Maike; Thimme, Robert; Boettler, Tobias			Th1-Biased Hepatitis C Virus-Specific Follicular T Helper-Like Cells Effectively Support B Cells After Antiviral Therapy	FRONTIERS IN IMMUNOLOGY			English	Article						immunology and infectious diseases; adaptive immunity; cellular immune response; MHC class II; T cell immunity	I INTERFERON; TFH CELLS; CD4(+); INFECTION; RESPONSES; DIFFERENTIATION; INTERLEUKIN-7; EXPRESSION; CXCR5(+); SUSTAIN	Circulating Th1-biased follicular T helper (cTfh1) cells have been associated with antibody responses to viral infection and after vaccination but their B cell helper functionality is less understood. After viral elimination, Tfh1 cells are the dominant subset within circulating Hepatitis C Virus (HCV)-specific CD4 T cells, but their functional capacity is currently unknown. To address this important point, we established a clone-based system to evaluate CD4 T cell functionality in vitro to overcome experimental limitations associated with their low frequencies. Specifically, we analyzed the transcription factor expression, cytokine secretion and B cell help in co-culture assays of HCV- (n = 18) and influenza-specific CD4 T cell clones (n = 5) in comparison to Tfh (n = 26) and Th1 clones (n = 15) with unknown antigen-specificity derived from healthy donors (n = 4) or direct-acting antiviral (DAA)-treated patients (n = 5). The transcription factor expression and cytokine secretion patterns of HCV-specific CD4 T cell clones indicated a Tfh1 phenotype, with expression of T-bet and Bcl6 and production of IFN-gamma and IL-21. Their B helper capacity was superior compared to influenza-specific or Tfh and Th1 clones. Moreover, since Tfh cells are enriched in the IFN-rich milieu of the HCV-infected liver, we investigated the impact of IFN exposure on Tfh phenotype and function. Type I IFN exposure was able to introduce similar phenotypic and functional characteristics in the Tfh cell population within PBMCs or Tfh clones in vitro in line with our finding that Tfh cells are elevated in HCV-infected patients shortly after initiation of IFN-alpha therapy. Collectively, we were able to functionally characterize HCV-specific CD4 T cells in vitro and not only confirmed a Tfh1 phenotype but observed superior Tfh functionality despite their Th1 bias. Furthermore, our results suggest that chronic type I IFN exposure supports the enrichment of highly functional HCV-specific Tfh-like cells during HCV infection. Thus, HCV-specific Tfh-like cells after DAA therapy may be a promising target for future vaccination design aiming to introduce a neutralizing antibody response.	[Zoldan, Katharina; Ehrlich, Sabine; Killmer, Saskia; Wild, Katharina; Smits, Maike; Russ, Marissa; Globig, Anna-Maria; Hofmann, Maike; Thimme, Robert; Boettler, Tobias] Univ Freiburg, Univ Hosp Freiburg, Fac Med, Dept Med 2, Freiburg, Germany; [Wild, Katharina; Russ, Marissa] Univ Freiburg, Fac Chem & Pharm, Freiburg, Germany; [Smits, Maike] Univ Freiburg, Fac Biol, Freiburg, Germany	University of Freiburg; University of Freiburg; University of Freiburg	Boettler, T (corresponding author), Univ Freiburg, Univ Hosp Freiburg, Fac Med, Dept Med 2, Freiburg, Germany.	tobias.boettler@uniklinik-freiburg.de	Boettler, Tobias/E-3331-2012	Boettler, Tobias/0000-0002-1195-055X	Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) [272983813 TP01, 272983813 TP04, 272983813 TP20]; DZIF (German Center for Infection Research)	Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)(German Research Foundation (DFG)); DZIF (German Center for Infection Research)	This work was supported by grants from the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) project 272983813 TP01 to RT, TP04 to TB, TP20 to MH. The project was also supported by the DZIF (German Center for Infection Research).	Adam L, 2018, HEPATOL COMMUN, V2, P1051, DOI 10.1002/hep4.1226; Alfei F, 2019, NATURE, V571, P265, DOI 10.1038/s41586-019-1326-9; Bailey JR, 2019, GASTROENTEROLOGY, V156, P418, DOI 10.1053/j.gastro.2018.08.060; Baiyegunhi O, 2018, J VIROL, V92, DOI 10.1128/JVI.00659-18; Ballesteros-Tato A, 2012, IMMUNITY, V36, P847, DOI 10.1016/j.immuni.2012.02.012; Basho K, 2021, J HEPATOL, V74, P649, DOI 10.1016/j.jhep.2020.10.012; Bentebibel SE, 2016, SCI REP-UK, V6, DOI 10.1038/srep26494; Bentebibel SE, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005191; Boettler T, 2013, J IMMUNOL, V191, P5026, DOI 10.4049/jimmunol.1300013; Bossaller L, 2006, J IMMUNOL, V177, P4927, DOI 10.4049/jimmunol.177.7.4927; Brenna E, 2020, CELL REP, V30, P137, DOI 10.1016/j.celrep.2019.12.016; BRINKMANN V, 1993, J EXP MED, V178, P1655, DOI 10.1084/jem.178.5.1655; Chang KM, 2001, HEPATOLOGY, V33, P267, DOI 10.1053/jhep.2001.21162; Chiodi F, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00451; Choi YS, 2015, NAT IMMUNOL, V16, P980, DOI 10.1038/ni.3226; Cox AL, 2020, CSH PERSPECT MED, V10, DOI 10.1101/cshperspect.a036947; Crawford A, 2014, IMMUNITY, V40, P289, DOI 10.1016/j.immuni.2014.01.005; Crotty S, 2011, ANNU REV IMMUNOL, V29, P621, DOI 10.1146/annurev-immunol-031210-101400; De Giovanni M, 2020, NAT IMMUNOL, V21, P321, DOI 10.1038/s41590-020-0596-6; Frese M, 2001, J GEN VIROL, V82, P723, DOI 10.1099/0022-1317-82-4-723; Grace MJ, 2005, J BIOL CHEM, V280, P6327, DOI 10.1074/jbc.M412134200; Grakoui A, 2003, SCIENCE, V302, P659, DOI 10.1126/science.1088774; Greczmiel U, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01162; Gu ZG, 2016, BIOINFORMATICS, V32, P2847, DOI 10.1093/bioinformatics/btw313; Hale JS, 2013, IMMUNITY, V38, P805, DOI 10.1016/j.immuni.2013.02.020; Heim MH, 2014, J HEPATOL, V61, pS14, DOI 10.1016/j.jhep.2014.06.035; Heit A, 2017, J EXP MED, V214, P2139, DOI 10.1084/jem.20161794; Hensel N, 2021, NAT IMMUNOL, V22, P229, DOI 10.1038/s41590-020-00817-w; Hervas-Stubbs S, 2011, CLIN CANCER RES, V17, P2619, DOI 10.1158/1078-0432.CCR-10-1114; Iyer SS, 2015, J IMMUNOL, V195, P994, DOI 10.4049/jimmunol.1500083; Jacobi FJ, 2019, J HEPATOL, V70, P1103, DOI 10.1016/j.jhep.2019.02.016; Johnston RJ, 2012, J EXP MED, V209, P243, DOI 10.1084/jem.20111174; Khan O, 2019, NATURE, V571, P211, DOI 10.1038/s41586-019-1325-x; Kim CH, 2001, J EXP MED, V193, P1373, DOI 10.1084/jem.193.12.1373; Liang HB, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11754-0; Lim HW, 2007, J IMMUNOL, V179, P7448, DOI 10.4049/jimmunol.179.11.7448; Locci M, 2013, IMMUNITY, V39, P758, DOI 10.1016/j.immuni.2013.08.031; Lohmann V, 1999, SCIENCE, V285, P110, DOI 10.1126/science.285.5424.110; Luxenburger H, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10110645; MATLOUBIAN M, 1994, J VIROL, V68, P8056, DOI 10.1128/JVI.68.12.8056-8063.1994; McLane LM, 2019, ANNU REV IMMUNOL, V37, P457, DOI 10.1146/annurev-immunol-041015-055318; Mihm S, 2004, LAB INVEST, V84, P1148, DOI 10.1038/labinvest.3700135; Morita R, 2011, IMMUNITY, V34, P108, DOI 10.1016/j.immuni.2010.12.012; Nakayamada S, 2014, J IMMUNOL, V192, P2156, DOI 10.4049/jimmunol.1300675; Nguyen TP, 2015, J LEUKOCYTE BIOL, V97, P1139, DOI 10.1189/jlb.4A0714-345RR; Nurieva RI, 2012, J BIOL CHEM, V287, P11234, DOI 10.1074/jbc.M111.324046; Olatunde AC, 2021, TRENDS IMMUNOL, V42, P536, DOI 10.1016/j.it.2021.04.006; Oliviero B, 2011, J HEPATOL, V55, P53, DOI 10.1016/j.jhep.2010.10.016; Osokine I, 2014, P NATL ACAD SCI USA, V111, P7409, DOI 10.1073/pnas.1401662111; Raziorrouh B, 2016, GASTROENTEROLOGY, V150, P696, DOI 10.1053/j.gastro.2015.11.005; Salinas E, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI140590; Schaerli P, 2000, J EXP MED, V192, P1553, DOI 10.1084/jem.192.11.1553; Schmitt N, 2014, NAT IMMUNOL, V15, P856, DOI 10.1038/ni.2947; Seo YB, 2014, J VIROL, V88, P8998, DOI 10.1128/JVI.00534-14; Shao P, 2019, J IMMUNOL, V203, P801, DOI 10.4049/jimmunol.1900581; Shoukry NH, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01480; Smits M, 2020, J CLIN INVEST, V130, P998, DOI 10.1172/JCI129642; Snell LM, 2017, TRENDS IMMUNOL, V38, P542, DOI 10.1016/j.it.2017.05.005; Snell LM, 2016, CELL REP, V16, P3286, DOI 10.1016/j.celrep.2016.08.065; Spaan M, 2015, J HEPATOL, V62, P303, DOI 10.1016/j.jhep.2014.09.024; Swathirajan CR, 2019, PATHOG DIS, V77, DOI 10.1093/femspd/ftz044; Thimme R, 2021, J HEPATOL, V74, P220, DOI 10.1016/j.jhep.2020.09.022; Utzschneider DT, 2016, IMMUNITY, V45, P415, DOI 10.1016/j.immuni.2016.07.021; Vella LA, 2019, J CLIN INVEST, V129, P3185, DOI 10.1172/JCI125628; Velu V, 2016, J IMMUNOL, V197, P1832, DOI 10.4049/jimmunol.1600143; Verma A, 2020, J VIROL, V94, DOI 10.1128/JVI.01737-19; Wang YF, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00169; Wen B, 2019, J VIRAL HEPATITIS, V26, P1002, DOI 10.1111/jvh.13106; Wieland D, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15050; Wu TQ, 2016, SCI IMMUNOL, V1, DOI 10.1126/sciimmunol.aai8593; Wu TQ, 2015, CELL REP, V12, P2099, DOI 10.1016/j.celrep.2015.08.049; Ye CX, 2018, SIGNAL TRANSDUCT TAR, V3, DOI 10.1038/s41392-017-0002-5; Zella D, 2000, J IMMUNOL, V164, P2296, DOI 10.4049/jimmunol.164.5.2296; Zhang J, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-46533-w; Zhang J, 2019, IMMUNOL LETT, V212, P46, DOI 10.1016/j.imlet.2019.06.003; Zhang M, 2016, INT IMMUNOPHARMACOL, V34, P235, DOI 10.1016/j.intimp.2016.03.005; Zhang ZH, 2018, VIRAL IMMUNOL, V31, P417, DOI 10.1089/vim.2018.0010; zur Wiesch JS, 2012, J EXP MED, V209, P61, DOI 10.1084/jem.20100388	78	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 30	2021	12								742061	10.3389/fimmu.2021.742061	http://dx.doi.org/10.3389/fimmu.2021.742061			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WH6GL	34659236	gold, Green Published			2022-12-18	WOS:000707773500001
J	Baranwal, M; Krishnan, S; Oneka, M; Frankel, T; Rao, AR				Baranwal, Mayank; Krishnan, Santhoshi; Oneka, Morgan; Frankel, Timothy; Rao, Arvind			CGAT: Cell Graph ATtention Network for Grading of Pancreatic Disease Histology Images	FRONTIERS IN IMMUNOLOGY			English	Article						PDAC (pancreatic ductal adenocarcinoma); cell-graph; spatial method; pancreas; attention network; chronic pancreatitis; graph convolutional network (GCN)	PRECURSOR LESIONS; CANCER; LYMPHOCYTES	Early detection of Pancreatic Ductal Adenocarcinoma (PDAC), one of the most aggressive malignancies of the pancreas, is crucial to avoid metastatic spread to other body regions. Detection of pancreatic cancer is typically carried out by assessing the distribution and arrangement of tumor and immune cells in histology images. This is further complicated due to morphological similarities with chronic pancreatitis (CP), and the co-occurrence of precursor lesions in the same tissue. Most of the current automated methods for grading pancreatic cancers rely on extensive feature engineering involving accurate identification of cell features or utilising single number spatially informed indices for grading purposes. Moreover, sophisticated methods involving black-box approaches, such as neural networks, do not offer insights into the model's ability to accurately identify the correct disease grade. In this paper, we develop a novel cell-graph based Cell-Graph Attention (CGAT) network for the precise classification of pancreatic cancer and its precursors from multiplexed immunofluorescence histology images into the six different types of pancreatic diseases. The issue of class imbalance is addressed through bootstrapping multiple CGAT-nets, while the self-attention mechanism facilitates visualization of cell-cell features that are likely responsible for the predictive capabilities of the model. It is also shown that the model significantly outperforms the decision tree classifiers built using spatially informed metric, such as the Morisita-Horn (MH) indices.	[Baranwal, Mayank] Tata Consultancy Serv Res, Div Data & Decis Sci, Mumbai, Maharashtra, India; [Baranwal, Mayank] Indian Inst Technol, Dept Syst & Control Engn, Bombay, Maharashtra, India; [Krishnan, Santhoshi; Rao, Arvind] Rice Univ, Dept Elect & Comp Engn, POB 1892, Houston, TX 77251 USA; [Krishnan, Santhoshi; Oneka, Morgan; Rao, Arvind] Univ Michigan, Dept Computat Med & Bioinformat, Ann Arbor, MI 48109 USA; [Frankel, Timothy] Univ Michigan, Dept Surg, Ann Arbor, MI 48109 USA; [Rao, Arvind] Univ Michigan, Dept Biostat, Ann Arbor, MI 48109 USA; [Rao, Arvind] Univ Michigan, Dept Radiat Oncol, Ann Arbor, MI 48109 USA; [Rao, Arvind] Univ Michigan, Dept Biomed Engn, Ann Arbor, MI 48109 USA	Tata Sons; Tata Consultancy Services Limited (TCS); Indian Institute of Technology System (IIT System); Indian Institute of Technology (IIT) - Bombay; Rice University; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Baranwal, M (corresponding author), Tata Consultancy Serv Res, Div Data & Decis Sci, Mumbai, Maharashtra, India.; Baranwal, M (corresponding author), Indian Inst Technol, Dept Syst & Control Engn, Bombay, Maharashtra, India.; Rao, AR (corresponding author), Rice Univ, Dept Elect & Comp Engn, POB 1892, Houston, TX 77251 USA.; Rao, AR (corresponding author), Univ Michigan, Dept Computat Med & Bioinformat, Ann Arbor, MI 48109 USA.; Rao, AR (corresponding author), Univ Michigan, Dept Biostat, Ann Arbor, MI 48109 USA.; Rao, AR (corresponding author), Univ Michigan, Dept Radiat Oncol, Ann Arbor, MI 48109 USA.; Rao, AR (corresponding author), Univ Michigan, Dept Biomed Engn, Ann Arbor, MI 48109 USA.	baranwal.mayank@tcs.com; ukarvind@umich.edu		Oneka, Morgan/0000-0002-9672-0445	CCSG Bioinformatics Shared Resource [5 P30 CA046592]; American Cancer Society [RSG-16-005-01]; NCI [R37CA214955]; University of Michigan (U-M); Precision health Investigator award from U-M Precision Health; Advanced Proteome Informatics of Cancer Training Grant [T32 CA140044]	CCSG Bioinformatics Shared Resource; American Cancer Society(American Cancer Society); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); University of Michigan (U-M)(University of Michigan System); Precision health Investigator award from U-M Precision Health; Advanced Proteome Informatics of Cancer Training Grant	AR, SK and MO were supported by CCSG Bioinformatics Shared Resource 5 P30 CA046592, a gift from Agilent technologies, a Research Scholar Grant from the American Cancer Society (RSG-16-005-01), the NCI Grant R37CA214955, and The University of Michigan (U-M) startup institutional research funds. AR and SK were also partially supported by Precision health Investigator award from U-M Precision Health to AR along with LR and MS. MO was supported by the Advanced Proteome Informatics of Cancer Training Grant (T32 CA140044). None of the funders were involved in the study design, collection, analysis, and interpretation of data, the writing of this article or the decision to submit it for publication.	BALCH CM, 1990, ARCH SURG-CHICAGO, V125, P200; Barua S, 2018, CANCER INFORM, V17, DOI 10.1177/1176935118782880; Basturk O, 2015, AM J SURG PATHOL, V39, P1730, DOI 10.1097/PAS.0000000000000533; Bendall SC, 2011, SCIENCE, V332, P687, DOI 10.1126/science.1198704; Berney DM, 2014, HISTOPATHOLOGY, V64, P405, DOI 10.1111/his.12284; Chen J, 2009, J MACH LEARN RES, V10, P1989; Dakshinamoorthy G, 2019, CANCER RES, V79, DOI 10.1158/1538-7445.AM2019-490; Demir C, 2005, BIOINFORMATICS, V21, P7, DOI 10.1093/bioinformatics/bti1100; Distler M, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/474905; Dries R, 2021, GENOME BIOL, V22, DOI 10.1186/s13059-021-02286-2; Ebert M, 2001, DIGEST DIS, V19, P32, DOI 10.1159/000050651; Ebert MPA, 1998, AM J GASTROENTEROL, V93, P2141; Elsherif SB, 2020, ABDOM RADIOL, V45, P1324, DOI 10.1007/s00261-019-02292-w; Feichtenbeiner A, 2014, CANCER IMMUNOL IMMUN, V63, P111, DOI 10.1007/s00262-013-1491-x; de Arruda PFF, 2013, BMC CLIN PATHOL, V13, DOI 10.1186/1472-6890-13-6; Gavrielides MA, 2014, ANAL CELL PATHOL, V2014, DOI 10.1155/2014/157308; Goggins M, 2011, CLIN CANCER RES, V17, P635, DOI 10.1158/1078-0432.CCR-10-3074; Gordon-Dseagu VL, 2018, INT J EPIDEMIOL, V47, P427, DOI 10.1093/ije/dyx232; Gunduz C, 2004, BIOINFORMATICS, V20, P145, DOI 10.1093/bioinformatics/bth933; Gunduz-Demir C, 2007, MATH BIOSCI, V209, P514, DOI 10.1016/j.mbs.2007.03.005; Howlader N., 2021, SEER CANC STAT REV C; Ketkar N., 2017, DEEP LEARNING PYTHON, V1, P195; Kingma D.P., 2015, 3 INT C LEARN REPR I, P1, DOI DOI 10.1007/S11390-017-1754-7; Lazarus J, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.121932; Magurran AE, 2005, CURR BIOL, V15, pR116, DOI 10.1016/j.cub.2005.02.006; Maley CC, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0638-4; Neishi Masato, 2017, P 4 WORKSH AS TRANSL, P99; Oztan B, 2012, PROC SPIE, V8315, DOI 10.1117/12.911360; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Ramirez R, 2020, FRONT PHYS-LAUSANNE, V8, DOI 10.3389/fphy.2020.00203; Rempala GA, 2013, J MATH BIOL, V67, P1339, DOI 10.1007/s00285-012-0589-7; Sarantis P, 2020, WORLD J GASTRO ONCOL, V12, DOI 10.4251/wjgo.v12.i2.173; Scarselli F, 2009, IEEE T NEURAL NETWOR, V20, P61, DOI 10.1109/TNN.2008.2005605; Vaswani A, 2017, ADV NEUR IN, V30; Wang JW, 2020, I S BIOMED IMAGING, P239, DOI 10.1109/ISBI45749.2020.9098534; Welling M., 2016, ICLR, P1; Wolske KM, 2019, RADIOGRAPHICS, V39, P1965, DOI 10.1148/rg.2019190011; Yan-Ming Zhang, 2013, Machine Learning and Knowledge Discovery in Databases. European Conference (ECML PKDD 2013). Proceedings: LNCS 8189, P660, DOI 10.1007/978-3-642-40991-2_42; Yonezawa S, 2008, GUT LIVER, V2, P137, DOI 10.5009/gnl.2008.2.3.137; Yuan YY, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a026583; Zhou J., 2020, OPEN, V1, DOI [10.1016/j.aiopen.2021.01.001, DOI 10.1016/J.AIOPEN.2021.01.001]; Zhou YN, 2019, IEEE INT CONF COMP V, P388, DOI 10.1109/ICCVW.2019.00050; Zhou YN, 2019, LECT NOTES COMPUT SC, V11492, P682, DOI 10.1007/978-3-030-20351-1_53	43	0	0	4	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 29	2021	12								727610	10.3389/fimmu.2021.727610	http://dx.doi.org/10.3389/fimmu.2021.727610			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WK3KW	34671349	Green Published, gold			2022-12-18	WOS:000709628700001
J	Barcellini, W; Fattizzo, B				Barcellini, Wilma; Fattizzo, Bruno			Immune Phenomena in Myeloid Neoplasms: An "Egg or Chicken" Question	FRONTIERS IN IMMUNOLOGY			English	Review						myelodysplastic syndromes; acute myeloid leukemia; myeloproliferative neoplasms; microbiome; autoimmunity; immunodeficiencies	UNCERTAIN SIGNIFICANCE ICUS/IDUS; CHRONIC MYELOMONOCYTIC LEUKEMIA; PNH-PHENOTYPE CELLS; HEMOLYTIC-ANEMIA; HYPOMEGAKARYOCYTIC THROMBOCYTOPENIA; SOMATIC MUTATIONS; INCREASED NUMBER; AUTOIMMUNE; MANAGEMENT; MICROBIOTA	Immune phenomena are increasingly reported in myeloid neoplasms, and include autoimmune cytopenias/diseases and immunodeficiency, either preceding or complicating acute myeloid leukemia, myelodysplastic syndromes (MDS), chronic myeloproliferative neoplasms, and bone marrow failure (BMF) syndromes. Autoimmunity and immunodeficiency are the two faces of a dysregulated immune tolerance and surveillance and may result, along with contributing environmental and genetic factors, in an increased incidence of both tumors and infections. The latter may fuel both autoimmunity and immune activation, triggering a vicious circle among infections, tumors and autoimmune phenomena. Additionally, alterations of the microbiota and of mesenchymal stem cells (MSCs) pinpoint to the importance of a permissive or hostile microenvironment for tumor growth. Finally, several therapies of myeloid neoplasms are aimed at increasing host immunity against the tumor, but at the price of increased autoimmune phenomena. In this review we will examine the epidemiological association of myeloid neoplasms with autoimmune diseases and immunodeficiencies, and the pivotal role of autoimmunity in the pathogenesis of MDS and BMF syndromes, including the paroxysmal nocturnal hemoglobinuria conundrum. Furthermore, we will briefly examine autoimmune complications following therapy of myeloid neoplasms, as well as the role of MSCs and microbiota in these settings.	[Barcellini, Wilma] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Hematol Unit, Milan, Italy; [Fattizzo, Bruno] Univ Milan, Dept Oncol & Hematooncol, Milan, Italy	IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan	Barcellini, W (corresponding author), Fdn IRCCS Ca Granda Osped Maggiore Policlin, Hematol Unit, Milan, Italy.	Wilma.barcellini@policlinico.mi.it	Fattizzo, Bruno/AAB-6816-2022					Abbas A., 2017, CELL MOL IMMUNOL, V9 ed; Alizadeh M, 2020, CRIT REV ONCOL HEMAT, V153, DOI 10.1016/j.critrevonc.2020.103031; Ames NJ, 2019, ANN HEMATOL, V98, P1351, DOI 10.1007/s00277-019-03599-w; Armando RG, 2019, CLIN GENET, V96, P3, DOI 10.1111/cge.13526; Barcellini W, 2007, HAEMATOL-HEMATOL J, V92, P19, DOI 10.3324/haematol.10546; Barcellini W, 2021, CANCERS, V13, DOI 10.3390/cancers13071532; Barcellini W, 2019, J BLOOD MED, V10, P265, DOI 10.2147/JBM.S190327; Barcellini W, 2017, EXPERT REV HEMATOL, V10, P649, DOI 10.1080/17474086.2017.1339597; Barcellini W, 2017, AM J HEMATOL, V92, pE26, DOI 10.1002/ajh.24618; Bejar R, 2011, NEW ENGL J MED, V364, P2496, DOI 10.1056/NEJMoa1013343; BLALOCK JE, 1985, IMMUNOL TODAY, V6, P115, DOI 10.1016/0167-5699(85)90070-2; Boniel S, 2021, GENES-BASEL, V12, DOI 10.3390/genes12040468; Botia-Sanchez M, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22094846; Caligaris-Cappio F, 1997, HEMATOL CELL THER, V39, pS13, DOI 10.1007/s00282-997-0013-8; Cantoni S, 2019, EUR J INTERN MED, V69, pE3, DOI 10.1016/j.ejim.2019.08.003; Carlsten M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02357; Damianaki A, 2016, EUR J HAEMATOL, V97, P538, DOI 10.1111/ejh.12766; Duan L, 2018, CLIN IMMUNOL, V194, P46, DOI 10.1016/j.clim.2018.06.011; Durrani J, 2020, LEUKEMIA, V34, P957, DOI 10.1038/s41375-019-0601-y; Ekstrand C, 2020, CANCER EPIDEMIOL, V69, DOI 10.1016/j.canep.2020.101806; Elkon K, 2008, NAT CLIN PRACT RHEUM, V4, P491, DOI 10.1038/ncprheum0895; Eskazan AE, 2013, INDIAN J HEMATOL BLO, V29, P173, DOI 10.1007/s12288-012-0173-8; Fattizzo B, 2021, CRIT REV ONCOL HEMAT, V160, DOI 10.1016/j.critrevonc.2021.103289; Fattizzo B, 2021, LEUKEMIA, V35, P3223, DOI 10.1038/s41375-021-01190-9; Fattizzo B, 2021, J CLIN MED, V10, DOI 10.3390/jcm10040870; Fattizzo B, 2021, CANCERS, V13, DOI 10.3390/cancers13010132; Fattizzo B, 2020, J CLIN MED, V9, DOI 10.3390/jcm9123858; Fattizzo B, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21155438; Fattizzo B, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01006; Fattizzo B, 2020, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01435; Fattizzo B, 2018, AM J HEMATOL, V93, pE88, DOI 10.1002/ajh.25020; Fernandez-Francos S, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22073576; Fiorenza S, 2021, BIODRUGS, V35, P281, DOI 10.1007/s40259-021-00477-8; Fozza C, 2018, HEMATOL ONCOL, V36, P15, DOI 10.1002/hon.2423; Fracchiolla NS, 2017, STEM CELLS INT, V2017, DOI 10.1155/2017/6720594; Glenthoj A, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17060944; Grignano E, 2018, ANN HEMATOL, V97, P2015, DOI 10.1007/s00277-018-3472-9; Grignano E, 2016, LEUKEMIA RES, V47, P136, DOI 10.1016/j.leukres.2016.05.013; Haas OA, 2019, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03136; Harris K, 2021, CURR TREAT OPTION ON, V22, DOI 10.1007/s11864-021-00859-8; Hecker JS, 2021, BLOOD, V138, P1727, DOI 10.1182/blood.2020010163; Hochhaus A, 2020, LEUKEMIA, V34, P966, DOI 10.1038/s41375-020-0776-2; Hsieh YC, 2021, LEUKEMIA, V35, P1229, DOI 10.1038/s41375-021-01238-w; Ishimura Masataka, 2019, Rinsho Ketsueki, V60, P702, DOI 10.11406/rinketsu.60.702; Jacobs CF, 2021, BLOOD ADV, V5, P913, DOI 10.1182/bloodadvances.2020003768; Kallen ME, 2019, SEMIN HEMATOL, V56, P69, DOI 10.1053/j.seminhematol.2018.05.016; KHUMBANONDA M, 1969, AM J MED SCI, V258, P89, DOI 10.1097/00000441-196908000-00004; Kichloo A, 2021, WORLD J CLIN ONCOL, V12, P150, DOI 10.5306/wjco.v12.i3.150; Ladikou EE, 2020, CURR ONCOL REP, V22, DOI 10.1007/s11912-020-0885-0; Lanjewar S, 2021, MEDICINE, V100, DOI 10.1097/MD.0000000000025985; Liu CJ, 2020, THROMB RES, V190, P11, DOI 10.1016/j.thromres.2020.03.012; Lundgren S, 2021, LEUKEMIA, V35, P1365, DOI 10.1038/s41375-021-01231-3; Luzzatto Lucio, 2016, F1000Res, V5, DOI 10.12688/f1000research.7288.1; Macor P, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02203; Mekinian A, 2016, RHEUMATOLOGY, V55, P291, DOI 10.1093/rheumatology/kev294; Miller PDE, 2020, BONE MARROW TRANSPL, V55, P441, DOI 10.1038/s41409-019-0680-4; Mufti GJ, 2015, NEW ENGL J MED, V373, P1674, DOI 10.1056/NEJMc1509703; Mustjoki S, 2021, NEW ENGL J MED, V384, P2039, DOI 10.1056/NEJMra2101920; Noureldine HA, 2020, LUPUS, V29, P225, DOI 10.1177/0961203319899986; Picard C, 2018, J CLIN IMMUNOL, V38, P96, DOI 10.1007/s10875-017-0464-9; Raanani P, 2002, ACTA HAEMATOL-BASEL, V107, P133, DOI 10.1159/000057631; Rafferty M, 2018, BRIT J HAEMATOL, V182, P152, DOI 10.1111/bjh.14760; Reda G, 2017, ONCOL LETT, V13, P1307, DOI 10.3892/ol.2016.5549; Richards SJ, 2021, EUR J HAEMATOL, V107, P211, DOI 10.1111/ejh.13640; Saito C, 2016, BRIT J HAEMATOL, V175, P246, DOI 10.1111/bjh.14210; Samuelson DR, 2015, FRONT MICROBIOL, V6, DOI [10.5389/fmicb.2015.01085, 10.3389/fmicb.2015.01085]; Saxena K, 2021, CANCER-AM CANCER SOC, V127, P3761, DOI 10.1002/cncr.33690; Shimizu K, 2020, CANCERS, V12, DOI 10.3390/cancers12040817; Swatler J, 2021, CANCERS, V13, DOI 10.3390/cancers13061203; Tabata R, 2010, INT ARCH ALLERGY IMM, V152, P407, DOI 10.1159/000288294; Taghiloo S, 2021, CRIT REV ONCOL HEMAT, V157, DOI 10.1016/j.critrevonc.2020.103164; Tanaka TN, 2019, BLOOD, V133, P1086, DOI 10.1182/blood-2018-10-844670; Valent P, 2019, PATHOBIOLOGY, V86, P30, DOI 10.1159/000489042; Valent P, 2012, LEUKEMIA RES, V36, P1, DOI 10.1016/j.leukres.2011.08.016; Wang YN, 2021, SCI CHINA LIFE SCI, V64, P766, DOI 10.1007/s11427-020-1788-2; Yoshizato T, 2015, NEW ENGL J MED, V373, P35, DOI 10.1056/NEJMoa1414799; Young NS, 2018, NEW ENGL J MED, V379, P1643, DOI 10.1056/NEJMra1413485; Zaninoni A, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01309; Zaninoni A, 2016, TRANSFUSION, V56, P2037, DOI 10.1111/trf.13652; Zhang XW, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.01550	80	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 29	2021	12								751630	10.3389/fimmu.2021.751630	http://dx.doi.org/10.3389/fimmu.2021.751630			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WV4YT	34659257	gold, Green Published			2022-12-18	WOS:000717244800001
J	D'haeseleer, P; Collette, NM; Lao, V; Segelke, BW; Branda, SS; Franco, M				D'haeseleer, Patrik; Collette, Nicole M.; Lao, Victoria; Segelke, Brent W.; Branda, Steven S.; Franco, Magdalena			Shotgun Immunoproteomic Approach for the Discovery of Linear B-Cell Epitopes in Biothreat Agents Francisella tularensis and Burkholderia pseudomallei	FRONTIERS IN IMMUNOLOGY			English	Article						Francisella; Burkholderia; immunoproteome; B-cell epitope; antigen; peptide vaccine	HUMAN-ANTIBODY RESPONSE; SUBSPECIES TULARENSIS; PROTECTIVE ANTIBODIES; VACCINE; INFECTION; STRAIN; HOST; HEAT; CHALLENGE; PROTEINS	Peptide-based subunit vaccines are coming to the forefront of current vaccine approaches, with safety and cost-effective production among their top advantages. Peptide vaccine formulations consist of multiple synthetic linear epitopes that together trigger desired immune responses that can result in robust immune memory. The advantages of linear compared to conformational epitopes are their simple structure, ease of synthesis, and ability to stimulate immune responses by means that do not require complex 3D conformation. Prediction of linear epitopes through use of computational tools is fast and cost-effective, but typically of low accuracy, necessitating extensive experimentation to verify results. On the other hand, identification of linear epitopes through experimental screening has been an inefficient process that requires thorough characterization of previously identified full- length protein antigens, or laborious techniques involving genetic manipulation of organisms. In this study, we apply a newly developed generalizable screening method that enables efficient identification of B-cell epitopes in the proteomes of pathogenic bacteria. As a test case, we used this method to identify epitopes in the proteome of Francisella tularensis (Ft), a Select Agent with a wellcharacterized immunoproteome. Our screen identified many peptides that map to known antigens, including verified and predicted outer membrane proteins and extracellular proteins, validating the utility of this approach. We then used the method to identify seroreactive peptides in the less characterized immunoproteome of Select Agent Burkholderia pseudomallei (Bp). This screen revealed known Bp antigens as well as proteins that have not been previously identified as antigens. Although B-cell epitope prediction tools Bepipred 2.0 and iBCE-EL classified many of our seroreactive peptides as epitopes, they did not score them significantly higher than the non-reactive tryptic peptides in our study, nor did they assign higher scores to seroreactive peptides from known Ft or Bp antigens, highlighting the need for experimental data instead of relying on computational epitope predictions alone. The present workflow is easily adaptable to detecting peptide targets relevant to the immune systems of other mammalian species, including humans (depending upon the availability of convalescent sera from patients), and could aid in accelerating the discovery of B-cell epitopes and development of vaccines to counter emerging biological threats.	[D'haeseleer, Patrik; Collette, Nicole M.; Lao, Victoria; Segelke, Brent W.; Franco, Magdalena] Lawrence Livermore Natl Lab, Biosci & Biotechnol Div, Livermore, CA 94550 USA; [Branda, Steven S.] Sandia Natl Labs, Mol & Microbiol Dept, Livermore, CA USA	United States Department of Energy (DOE); Lawrence Livermore National Laboratory; United States Department of Energy (DOE); Sandia National Laboratories	D'haeseleer, P (corresponding author), Lawrence Livermore Natl Lab, Biosci & Biotechnol Div, Livermore, CA 94550 USA.	dhaeseleer2@llnl.gov		Collette, Nicole/0000-0002-9068-8712; Segelke, Brent/0000-0003-3358-5028	Lawrence Livermore National Laboratory Directed Research and Development Program (LLNL LDRD) Labwide grant [18-LW-039]; LDRD program at Sandia National Laboratories [218309]; U.S. Department of Energy's National Nuclear Security Administration [DE-NA0003525]; U.S. Department of Energy by Lawrence Livermore National Laboratory [DE-AC52-07NA27344]	Lawrence Livermore National Laboratory Directed Research and Development Program (LLNL LDRD) Labwide grant; LDRD program at Sandia National Laboratories; U.S. Department of Energy's National Nuclear Security Administration(National Nuclear Security Administration); U.S. Department of Energy by Lawrence Livermore National Laboratory(United States Department of Energy (DOE))	This work was supported by Lawrence Livermore National Laboratory Directed Research and Development Program (LLNL LDRD) Labwide grant (18-LW-039) to MF, and by the LDRD program (grant 218309) at Sandia National Laboratories, a multi-mission laboratory managed and operated by National Technology and Engineering Solutions of Sandia, LLC, a wholly owned subsidiary of Honeywell International, Inc., for the U.S. Department of Energy's National Nuclear Security Administration under contract DE-NA0003525. Work at LLNL was performed under the auspices of the U.S. Department of Energy by Lawrence Livermore National Laboratory under Contract DE-AC52-07NA27344. LLNL IM release number LLNL-JRNL-822446. The funders were not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication.	Al-Maleki AR, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127398; Ashkenazy H, 2016, NUCLEIC ACIDS RES, V44, pW344, DOI 10.1093/nar/gkw408; Ashtekar AR, 2008, J LEUKOCYTE BIOL, V84, P1434, DOI 10.1189/jlb.0308215; Ashtekar AR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050460; Bi YK, 2019, VIRAL IMMUNOL, V32, P221, DOI 10.1089/vim.2019.0007; Blakeley-Ruiz JA, 2019, MICROBIOME, V7, DOI 10.1186/s40168-019-0631-8; Burtnick MN, 2011, INFECT IMMUN, V79, P1512, DOI 10.1128/IAI.01218-10; Caron E, 2015, MOL CELL PROTEOMICS, V14, P3105, DOI [10.1074/mcp.O115.052431, 10.1074/mcp.M115.052431]; Clinton SR, 2010, BMC MICROBIOL, V10, DOI 10.1186/1471-2180-10-76; Conlan JW, 2010, VACCINE, V28, P1824, DOI 10.1016/j.vaccine.2009.12.001; Crane DD, 2009, J IMMUNOL, V183, P4593, DOI 10.4049/jimmunol.0901655; Devi YD, 2020, HELIYON, V6, DOI 10.1016/j.heliyon.2020.e05760; DIENST F T Jr, 1963, J La State Med Soc, V115, P114; Dudek NL, 2010, CURR PHARM DESIGN, V16, P3149; Eickhoff CS, 2019, VACCINE, V37, P5371, DOI 10.1016/j.vaccine.2019.07.033; ERICSSON M, 1994, INFECT IMMUN, V62, P178, DOI 10.1128/IAI.62.1.178-183.1994; Felgner PL, 2009, P NATL ACAD SCI USA, V106, P13499, DOI 10.1073/pnas.0812080106; Fiuza TS, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00816; Fulton KM, 2011, INT J MED MICROBIOL, V301, P591, DOI 10.1016/j.ijmm.2011.07.002; Gibney KB, 2019, LANCET INFECT DIS, V19, P800, DOI 10.1016/S1473-3099(19)30303-2; Gonzales SJ, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.594653; Grassl N, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0293-0; Havlasova J, 2005, PROTEOMICS, V5, P2090, DOI 10.1002/pmic.200401123; Henderson B, 2006, INFECT IMMUN, V74, P3693, DOI 10.1128/IAI.01882-05; Hickey TBM, 2009, INFECT IMMUN, V77, P3389, DOI 10.1128/IAI.00143-09; Hogan RJ, 2019, MSPHERE, V4, DOI 10.1128/mSphere.00674-18; Huntley JF, 2007, J BACTERIOL, V189, P561, DOI 10.1128/JB.01505-06; Jaenisch T, 2019, MOL CELL PROTEOMICS, V18, P642, DOI 10.1074/mcp.RA118.000992; Jespersen MC, 2017, NUCLEIC ACIDS RES, V45, pW24, DOI 10.1093/nar/gkx346; Jones SM, 2002, J MED MICROBIOL, V51, P1055, DOI 10.1099/0022-1317-51-12-1055; Khakhum N, 2019, MSPHERE, V4, DOI [10.1128/mSphere.00570-18, 10.1128/msphere.00570-18]; Khan MN, 2009, FEMS IMMUNOL MED MIC, V56, P56, DOI 10.1111/j.1574-695X.2009.00548.x; Kilmury SLN, 2011, FRONT MICROBIOL, V2, DOI 10.3389/fmicb.2010.00143; Kol A, 1999, J CLIN INVEST, V103, P571, DOI 10.1172/JCI5310; Kringelum JV, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002829; Kunert A, 2007, J IMMUNOL, V179, P2979, DOI 10.4049/jimmunol.179.5.2979; Larsen Jens Erik Pontoppidan, 2006, Immunome Res, V2, P2, DOI 10.1186/1745-7580-2-2; Lee BY, 2006, INFECT IMMUN, V74, P4002, DOI 10.1128/IAI.00257-06; Li H, 2017, P NATL ACAD SCI USA, V114, P5023, DOI 10.1073/pnas.1611776114; Li JN, 2006, BIOCHEMISTRY-US, V45, P15168, DOI 10.1021/bi062188q; Li WD, 2014, VACCINES-BASEL, V2, P515, DOI 10.3390/vaccines2030515; Liu T, 2020, BIODATA MIN, V13, DOI 10.1186/s13040-020-00211-0; Long SP, 2020, NPJ BIOFILMS MICROME, V6, DOI 10.1038/s41522-020-0123-4; Lottenberg Richard, 1994, Trends in Microbiology, V2, P20, DOI 10.1016/0966-842X(94)90340-9; Lu ZH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099847; Malonis RJ, 2020, CHEM REV, V120, P3210, DOI 10.1021/acs.chemrev.9b00472; Manavalan B, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01695; Mara-Koosham G, 2011, INFECT IMMUN, V79, P1770, DOI 10.1128/IAI.00605-10; Mullen LM, 2006, TRENDS MICROBIOL, V14, P141, DOI 10.1016/j.tim.2006.01.006; Nakajima R, 2016, J CLIN MICROBIOL, V54, P1755, DOI 10.1128/JCM.02784-15; Ndam NT, 2015, EMERG INFECT DIS, V21, P813, DOI 10.3201/eid2105.141626; Noah CE, 2010, INFECT IMMUN, V78, P1797, DOI 10.1128/IAI.01135-09; Pan XX, 2008, SCIENCE, V320, P1651, DOI 10.1126/science.1158160; Pancholi V, 2003, INT J MED MICROBIOL, V293, P391, DOI 10.1078/1438-4221-00283; Park SKR, 2019, J PROTEOME RES, V18, P616, DOI 10.1021/acs.jproteome.8b00722; Pechous RD, 2009, MICROBIOL MOL BIOL R, V73, P684, DOI 10.1128/MMBR.00028-09; Perez-Riverol Y, 2019, NUCLEIC ACIDS RES, V47, pD442, DOI 10.1093/nar/gky1106; Ponomarenko J, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-514; Propst KL, 2010, INFECT IMMUN, V78, P3136, DOI 10.1128/IAI.01313-09; Purcell AW, 2007, NAT REV DRUG DISCOV, V6, P404, DOI 10.1038/nrd2224; Ray HJ, 2009, CLIN VACCINE IMMUNOL, V16, P444, DOI 10.1128/CVI.00405-08; Ren J, 2014, J BIOINF COMPUT BIOL, V12, DOI 10.1142/S0219720014500231; RHINEHARTJONES TR, 1994, INFECT IMMUN, V62, P3129, DOI 10.1128/IAI.62.8.3129-3137.1994; Safavi A, 2020, VACCINE, V38, P7612, DOI 10.1016/j.vaccine.2020.10.016; Schell MA, 2007, MOL MICROBIOL, V64, P1466, DOI 10.1111/j.1365-2958.2007.05734.x; Shams F, 2014, BIOCHEM SOC T, V42, P1792, DOI 10.1042/BST20140203; Sharma G, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12444-7; Sharma G, 2014, HUM IMMUNOL, V75, P514, DOI 10.1016/j.humimm.2014.03.003; Singh H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062216; Skwarczynski M, 2016, CHEM SCI, V7, P842, DOI 10.1039/c5sc03892h; Sun PP, 2019, CURR TOP MED CHEM, V19, P105, DOI 10.2174/1568026619666181130111827; Sun PP, 2013, COMPUT MATH METHOD M, V2013, DOI 10.1155/2013/943636; Sun T, 2016, ACTA BIOMATER, V30, P62, DOI 10.1016/j.actbio.2015.11.019; Terrier B, 2007, AUTOIMMUN REV, V6, P176, DOI 10.1016/j.autrev.2006.10.004; Twine S, 2012, VACCINE, V30, P3634, DOI 10.1016/j.vaccine.2012.03.036; Valentino MD, 2011, IMMUNOLOGY, V132, P348, DOI 10.1111/j.1365-2567.2010.03387.x; Varga JJ, 2012, VIRULENCE, V3, P510, DOI 10.4161/viru.22056; Vita R, 2019, NUCLEIC ACIDS RES, V47, pD339, DOI 10.1093/nar/gky1006; Wallin RPA, 2002, TRENDS IMMUNOL, V23, P130, DOI 10.1016/S1471-4906(01)02168-8; Wang AP, 2018, INT J BIOL MACROMOL, V118, P1354, DOI 10.1016/j.ijbiomac.2018.06.094; Weiss DS, 2007, P NATL ACAD SCI USA, V104, P6037, DOI 10.1073/pnas.0609675104; Whitlock GC, 2010, PROCEDIA VACCINOL, V2, P73, DOI 10.1016/j.provac.2010.03.013; Yang WJ, 2005, J IMMUNOL METHODS, V304, P15, DOI 10.1016/j.jim.2005.05.009; Yi J, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0006851; Zhang X, 2017, ANAL CHEM, V89, P9407, DOI 10.1021/acs.analchem.7b02224; Zhao DM, 2018, VIROL J, V15, DOI 10.1186/s12985-018-1052-1	86	0	0	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 29	2021	12								716676	10.3389/fimmu.2021.716676	http://dx.doi.org/10.3389/fimmu.2021.716676			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WI5EG	34659206	gold, Green Submitted, Green Published			2022-12-18	WOS:000708382600001
J	Heck, C; Steiner, S; Kaebisch, EM; Frentsch, M; Wittenbecher, F; Scheibenbogen, C; Hanitsch, LG; Nogai, A; le Coutre, P; Bullinger, L; Blau, IW; Na, IK				Heck, Clarissa; Steiner, Sophie; Kaebisch, Eva M.; Frentsch, Marco; Wittenbecher, Friedrich; Scheibenbogen, Carmen; Hanitsch, Leif G.; Nogai, Axel; le Coutre, Philipp; Bullinger, Lars; Blau, Igor-Wolfgang; Na, Il-Kang			CD4+T Cell Dependent B Cell Recovery and Function After Autologous Hematopoietic Stem Cell Transplantation	FRONTIERS IN IMMUNOLOGY			English	Article						B cell defects; autologous hematopoiectic stem cell transplantation; T cell dependent B cell activation; immune reconstitution; multiple myeloma; secondary immunodeficiencies	BONE-MARROW-TRANSPLANTATION; IG-SECRETING CELLS; MULTIPLE-MYELOMA; T-CELL; MARGINAL ZONE; DIFFERENTIATION; BLOOD; RECONSTITUTION; SURVIVAL; LIGAND	IntroductionHigh-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (auto-HSCT) represents a standard treatment regime for multiple myeloma (MM) patients. Common and potentially fatal side effects after auto-HSCT are infections due to a severely compromised immune system with hampered humoral and cellular immunity. This study delineates in depth the quantitative and functional B cell defects and investigates underlying extrinsic or intrinsic drivers. MethodsPeripheral blood of MM patients undergoing high-dose chemotherapy and auto-HSCT (before high-dose chemotherapy and in early reconstitution after HSCT) was studied. Absolute numbers and distribution of B cell subsets were analyzed ex vivo using flow cytometry. Additionally, B cell function was assessed with T cell dependent (TD) and T cell independent (TI) stimulation assays, analyzing proliferation and differentiation of B cells by flow cytometry and numbers of immunoglobulin secreting cells in ELISpots. ResultsQuantitative B cell defects including a shift in the B cell subset distribution occurred after auto-HSCT. Functionally, these patients showed an impaired TD as well as TI B cell immune response. Individual functional responses correlated with quantitative alterations of CD19+, CD4+, memory B cells and marginal zone-like B cells. The TD B cell function could be partially restored upon stimulation with CD40L/IL-21, successfully inducing B cell proliferation and differentiation into plasmablasts and immunoglobulin secreting cells. ConclusionQuantitative and functional B cell defects contribute to the compromised immune defense in MM patients undergoing auto-HSCT. Functional recovery upon TD stimulation and correlation with CD4+ T cell numbers, indicate these as extrinsic drivers of the functional B cell defect. Observed correlations of CD4+, CD19+, memory B and MZ-like B cell numbers with the B cell function suggest that these markers should be tested as potential biomarkers in prospective studies.	[Heck, Clarissa; Kaebisch, Eva M.; Wittenbecher, Friedrich; Nogai, Axel; le Coutre, Philipp; Bullinger, Lars; Blau, Igor-Wolfgang; Na, Il-Kang] Charite Univ Med Berlin, Dept Hematol Oncol & Tumor Immunol, Berlin, Germany; [Heck, Clarissa; Steiner, Sophie; Kaebisch, Eva M.; Wittenbecher, Friedrich; Scheibenbogen, Carmen; Hanitsch, Leif G.; Nogai, Axel; le Coutre, Philipp; Bullinger, Lars; Blau, Igor-Wolfgang; Na, Il-Kang] Free Univ Berlin, Berlin, Germany; [Heck, Clarissa; Steiner, Sophie; Kaebisch, Eva M.; Wittenbecher, Friedrich; Scheibenbogen, Carmen; Hanitsch, Leif G.; Nogai, Axel; le Coutre, Philipp; Bullinger, Lars; Blau, Igor-Wolfgang; Na, Il-Kang] Humboldt Univ, Berlin, Germany; [Heck, Clarissa; Steiner, Sophie; Kaebisch, Eva M.; Wittenbecher, Friedrich; Scheibenbogen, Carmen; Hanitsch, Leif G.; Nogai, Axel; le Coutre, Philipp; Bullinger, Lars; Blau, Igor-Wolfgang; Na, Il-Kang] Berlin Inst Hlth, Berlin, Germany; [Steiner, Sophie; Scheibenbogen, Carmen; Hanitsch, Leif G.] Charite Univ Med Berlin, Inst Med Immunol, Berlin, Germany; [Kaebisch, Eva M.; Wittenbecher, Friedrich; Bullinger, Lars; Na, Il-Kang] Berlin Inst Hlth BIH, Berlin, Germany; [Frentsch, Marco; Scheibenbogen, Carmen; Na, Il-Kang] Charite Univ Med Berlin, Berlin Inst Hlth Ctr Regenerat Therapies, Berlin, Germany; [Bullinger, Lars; Na, Il-Kang] German Canc Consortium DKTK, Berlin, Germany; [Bullinger, Lars] Max Delbruck Ctr Mol Med Helmholtz Assoc, Berlin, Germany; [Na, Il-Kang] Expt & Clin Res Ctr, Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Berlin Institute of Health; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Berlin Institute of Health; Berlin Institute of Health; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; Max Delbruck Center for Molecular Medicine	Heck, C (corresponding author), Free Univ Berlin, Berlin, Germany.; Heck, C (corresponding author), Humboldt Univ, Berlin, Germany.	clarissa.heck@charite.de		Kaebisch, Eva/0000-0001-7752-4126; Scheibenbogen, Carmen/0000-0002-8554-9638; Na, Il-Kang/0000-0001-9902-5424; Steiner, Sophie/0000-0002-2217-7566; Bullinger, Lars/0000-0002-5890-5510; Hanitsch, Leif G./0000-0002-8181-0093	Takeda Pharmaceutical Company I Shire [IIR-DEU-1589]; Octapharma [SAP-Nr. 125051]; Berlin Institute of Health Johanna Quandt Professorship	Takeda Pharmaceutical Company I Shire; Octapharma; Berlin Institute of Health Johanna Quandt Professorship	The project was financed through grants recieved by I-KN from Takeda Pharmaceutical Company I Shire (grant ID number IIR-DEU-1589), Octapharma (grant number: SAP-Nr. 125051) and the Berlin Institute of Health Johanna Quandt Professorship. The funders were not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication. The library of Charite University Medicine Berlin supports the open access publication.	Bemark M, 2012, CLIN EXP IMMUNOL, V167, P15, DOI 10.1111/j.1365-2249.2011.04469.x; Brioli A, 2019, ANN HEMATOL, V98, P713, DOI 10.1007/s00277-019-03621-1; Bryant VL, 2007, J IMMUNOL, V179, P8180, DOI 10.4049/jimmunol.179.12.8180; Cao YR, 2010, J IMMUNOL METHODS, V358, P56, DOI 10.1016/j.jim.2010.03.009; Capolunghi F, 2008, J IMMUNOL, V180, P800, DOI 10.4049/jimmunol.180.2.800; Crotty S, 2004, J IMMUNOL METHODS, V286, P111, DOI 10.1016/j.jim.2003.12.015; Cuss AK, 2006, J IMMUNOL, V176, P1506, DOI 10.4049/jimmunol.176.3.1506; D'Orsogna L, 2009, BIOL BLOOD MARROW TR, V15, P795, DOI 10.1016/j.bbmt.2008.11.024; De Silva NS, 2015, NAT REV IMMUNOL, V15, P137, DOI 10.1038/nri3804; Elgueta R, 2009, IMMUNOL REV, V229, P152, DOI 10.1111/j.1600-065X.2009.00782.x; Engelhard D, 2002, BRIT J HAEMATOL, V117, P444, DOI 10.1046/j.1365-2141.2002.03457.x; Ettinger R, 2005, J IMMUNOL, V175, P7867, DOI 10.4049/jimmunol.175.12.7867; FAUCI AS, 1980, CELL IMMUNOL, V54, P230, DOI 10.1016/0008-8749(80)90204-X; Gernert M, 2019, ARTHRITIS RES THER, V21, DOI 10.1186/s13075-019-1889-8; Goodnow CC, 2010, NAT IMMUNOL, V11, P681, DOI 10.1038/ni.1900; GRATAMA JW, 1984, BLOOD, V63, P1416; Hakim FT, 2005, J CLIN INVEST, V115, P930, DOI 10.1172/JCI22492; Han P, 2004, IMMUNOLOGY, V113, P26, DOI 10.1111/j.1365-2567.2004.01933.x; Jaime-Perez JC, 2020, CLIN TRANSPLANT, V34, DOI 10.1111/ctr.14114; Jantunen E, 2006, EUR J HAEMATOL, V76, P245, DOI 10.1111/j.1600-0609.2005.00605.x; Jimenez-Zepeda VH, 2015, LEUKEMIA LYMPHOMA, V56, P2668, DOI 10.3109/10428194.2014.1003057; Karahan GE, 2014, CLIN EXP IMMUNOL, V177, P333, DOI 10.1111/cei.12305; KEIGHTLEY RG, 1976, J IMMUNOL, V117, P1538; KIESEL S, 1988, BLOOD, V72, P672; King C, 2008, ANNU REV IMMUNOL, V26, P741, DOI 10.1146/annurev.immunol.26.021607.090344; Korholz D, 1996, BONE MARROW TRANSPL, V18, P1123; Kruetzmann S, 2003, J EXP MED, V197, P939, DOI 10.1084/jem.20022020; Kumar SK, 2008, BONE MARROW TRANSPL, V42, P259, DOI 10.1038/bmt.2008.166; Kumar S, 2016, LANCET ONCOL, V17, pE328, DOI 10.1016/S1470-2045(16)30206-6; LANE P, 1993, J EXP MED, V177, P1209, DOI 10.1084/jem.177.4.1209; Lehners N, 2018, CANCER MED-US, V7, P307, DOI 10.1002/cam4.1283; Mackall C, 2009, BONE MARROW TRANSPL, V44, P457, DOI 10.1038/bmt.2009.255; Mackall CL, 2000, BLOOD, V96, P754; Martin F, 2001, IMMUNITY, V14, P617, DOI 10.1016/S1074-7613(01)00129-7; Muir Luke, 2017, Wellcome Open Res, V2, P97, DOI 10.12688/wellcomeopenres.11386.2; Nucci M, 2009, CLIN INFECT DIS, V49, P1211, DOI 10.1086/605664; Palumbo A, 2014, NEW ENGL J MED, V371, P895, DOI 10.1056/NEJMoa1402888; Porrata LF, 2001, BLOOD, V98, P579, DOI 10.1182/blood.V98.3.579; Reich G, 2001, BONE MARROW TRANSPL, V27, P525, DOI 10.1038/sj.bmt.1702822; Rosel AL, 2015, J ALLERGY CLIN IMMUN, V135, P198, DOI 10.1016/j.jaci.2014.06.022; Rueff Jessica, 2014, Biol Blood Marrow Transplant, V20, P896, DOI 10.1016/j.bbmt.2014.03.007; Schutt P, 2006, LEUKEMIA LYMPHOMA, V47, P1570, DOI 10.1080/10428190500472503; SMALL TN, 1990, BLOOD, V76, P1647; Spolski R, 2008, ANNU REV IMMUNOL, V26, P57, DOI 10.1146/annurev.immunol.26.021607.090316; STOREK J, 1993, BONE MARROW TRANSPL, V12, P387; Storek J, 2008, SEMIN IMMUNOPATHOL, V30, P425, DOI 10.1007/s00281-008-0132-5; Talmadge JE, 1997, BONE MARROW TRANSPL, V19, P161, DOI 10.1038/sj.bmt.1700626; Tangye SG, 2003, J IMMUNOL, V170, P261, DOI 10.4049/jimmunol.170.1.261; Teh BW, 2015, BRIT J HAEMATOL, V171, P100, DOI 10.1111/bjh.13532; Victora GD, 2010, CELL, V143, P592, DOI 10.1016/j.cell.2010.10.032; Wehr C, 2008, BLOOD, V111, P77, DOI 10.1182/blood-2007-06-091744; Weill JC, 2009, ANNU REV IMMUNOL, V27, P267, DOI 10.1146/annurev.immunol.021908.132607; Weissenberg SY, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02136; Weller S, 2004, BLOOD, V104, P3647, DOI 10.1182/blood-2004-01-0346; WITHERSPOON RP, 1982, BLOOD, V59, P844	56	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 29	2021	12								736137	10.3389/fimmu.2021.736137	http://dx.doi.org/10.3389/fimmu.2021.736137			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XB8UA	34659226	gold, Green Accepted, Green Published			2022-12-18	WOS:000721596800001
J	Wassmer, SC; Humpel, C; Orian, JM				Wassmer, Samuel C.; Humpel, Christian; Orian, Jacqueline M.			Editorial: Platelets as Players in Neuropathologies: Novel Diagnostic and Therapeutic Targets	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						platelets; neuroinflammatory diseases; neurodegenerative diseases; biomarkers; therapeutic targets	PROTEINS		[Wassmer, Samuel C.] London Sch Hyg & Trop Med, Dept Infect Biol, London, England; [Humpel, Christian] Med Univ Innsbruck, Lab Psychiat & Expt Alzheimers Res, Innsbruck, Austria; [Orian, Jacqueline M.] La Trobe Univ, La Trobe Inst Mol Sci, Dept Biochem & Genet, Melbourne, Vic, Australia	University of London; London School of Hygiene & Tropical Medicine; Medical University of Innsbruck; La Trobe University	Orian, JM (corresponding author), La Trobe Univ, La Trobe Inst Mol Sci, Dept Biochem & Genet, Melbourne, Vic, Australia.	J.Orian@latrobe.edu.au	Wassmer, Samuel/F-8539-2018	Wassmer, Samuel/0000-0002-6753-3376	UK Medical Research Foundation [MR/S009450/1]; US National Institutes of Health [R21AI142472]; La Trobe University Research Focus Area scheme; Multiple Sclerosis Research Australia	UK Medical Research Foundation; US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); La Trobe University Research Focus Area scheme; Multiple Sclerosis Research Australia	SCW was funded by the UK Medical Research Foundation (award number MR/S009450/1) and the US National Institutes of Health (award number R21AI142472). JMO was funded by the La Trobe University Research Focus Area scheme, La Trobe Alumni and Multiple Sclerosis Research Australia.	Camilli M, 2021, EXPERT REV HEMATOL, V14, P537, DOI 10.1080/17474086.2021.1943353; Canobbio I, 2019, RES PRACT THROMB HAE, V3, P564, DOI 10.1002/rth2.12254; Koupenova M, 2018, CIRC RES, V122, P337, DOI 10.1161/CIRCRESAHA.117.310795; Marcus K, 2000, ELECTROPHORESIS, V21, P2622, DOI 10.1002/1522-2683(20000701)21:13<2622::AID-ELPS2622>3.0.CO;2-3; McRedmond JP, 2004, MOL CELL PROTEOMICS, V3, P133, DOI 10.1074/mcp.M300063-MCP200; Menter DG, 2014, CANCER METAST REV, V33, P231, DOI 10.1007/s10555-014-9498-0; Nagalla S, 2011, BLOOD, V117, P5189, DOI 10.1182/blood-2010-09-299719; Neu CT, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21207614; O'Neill EE, 2002, PROTEOMICS, V2, P288, DOI 10.1002/1615-9861(200203)2:3<288::AID-PROT288>3.0.CO;2-0; Roweth HG, 2021, BLOOD, V137, P3174, DOI 10.1182/blood.2019003976; Saenz-Cuesta M, 2014, BIOMARK MED, V8, P653, DOI [10.2217/bmm.14.9, 10.2217/BMM.14.9]; Valiyaveettil M, 2009, J THROMB HAEMOST, V7, P218, DOI 10.1111/j.1538-7836.2009.03422.x; van der Meijden PEJ, 2019, NAT REV CARDIOL, V16, P166, DOI 10.1038/s41569-018-0110-0; Wachowicz B, 2016, ACTA NEUROBIOL EXP, V76, P269, DOI 10.21307/ane-2017-026; Wassmer SC., 2011, DRUG DISCOV TODAY DI, V8, pe15, DOI DOI 10.1016/J.DDMEC.2011.11.004	15	0	0	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 29	2021	12								772352	10.3389/fimmu.2021.772352	http://dx.doi.org/10.3389/fimmu.2021.772352			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WL5MX	34659273	gold, Green Published			2022-12-18	WOS:000710450200001
J	Ye, L; Schnepf, D; Ohnemus, A; Ong, LC; Gad, HH; Hartmann, R; Lycke, N; Staeheli, P				Ye, Liang; Schnepf, Daniel; Ohnemus, Annette; Ong, Li Ching; Gad, Hans Henrik; Hartmann, Rune; Lycke, Nils; Staeheli, Peter			Interferon-lambda Improves the Efficacy of Intranasally or Rectally Administered Influenza Subunit Vaccines by a Thymic Stromal Lymphopoietin-Dependent Mechanism	FRONTIERS IN IMMUNOLOGY			English	Article						interferon-lambda; TSLP pathway; influenza a virus; mucosa; intestinal immunity	IGM(+) B-CELLS; IMMUNE-RESPONSES; MUCOSAL ADJUVANT; DENDRITIC CELLS; TSLP ACTS; IN-VITRO; DIFFERENTIATION; IMMUNIZATION; ANTIBODY	Previous work showed that interferon-lambda (IFN-lambda) can trigger the synthesis of thymic stromal lymphopoietin (TSLP) by specialized epithelial cells in the upper airways of mice, thereby improving the performance of intranasally administered influenza vaccines. Here we demonstrate that protein-only influenza vaccines containing either IFN-lambda or TSLP boosted antigen-specific IgG1 and IgA responses and enhanced the resistance of mice to influenza virus challenge, irrespective of whether the vaccines were applied via the intranasal or the rectal route. TSLP receptor deficiency negatively influenced vaccine-induced antiviral immunity by impairing the migration of dendritic cells from the airways to the draining lymph nodes of immunized mice, thereby restraining follicular helper T cell and germinal center B cell responses. As previously observed during intranasal vaccination, the adjuvant effect of IFN-lambda on a rectally administered influenza vaccine was no longer observed when TSLP receptor-deficient mice were used for immunization, highlighting the central role of the IFN-lambda/TSLP axis for vaccine-induced antiviral immunity in the mucosa.	[Ye, Liang] Shenzhen Univ, Int Canc Ctr, Dept Immunol, Hlth Sci Ctr, Shenzhen, Peoples R China; [Ye, Liang; Schnepf, Daniel; Ohnemus, Annette; Staeheli, Peter] Univ Freiburg, Inst Virol, Med Ctr, Freiburg, Germany; [Ong, Li Ching; Lycke, Nils] Univ Gothenburg, Dept Microbiol & Immunol, Gothenburg, Sweden; [Gad, Hans Henrik; Hartmann, Rune] Aarhus Univ, Dept Mol Biol & Genet, Aarhus, Denmark	Shenzhen University; University of Freiburg; University of Gothenburg; Aarhus University	Ye, L (corresponding author), Shenzhen Univ, Int Canc Ctr, Dept Immunol, Hlth Sci Ctr, Shenzhen, Peoples R China.; Ye, L; Staeheli, P (corresponding author), Univ Freiburg, Inst Virol, Med Ctr, Freiburg, Germany.	liangyeszu@163.com; peter.staeheli@uniklinik-freiburg.de	Ye, Liang/AAC-4651-2022; ye, liang/T-1332-2018	ye, liang/0000-0002-6735-0836; Gad, Hans Henrik/0000-0001-8449-1115; Hartmann, Rune/0000-0003-1159-066X	Deutsche Forschungsgemeinschaft [STA 338/15-1]; Danish Council for Independent Research [11107588]; National Natural Science Foundation of China [32170937]; Shenzhen Science and Technology Program [RCBS20200714114958310, 20200803131335002]; Guangdong medical science and technology research foundation [A2021336]; Guangdong Basic and Applied Basic Research Foundation [2020A1515110410, 2020A1515010917]; SZU Top Ranking Project [86000000210]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Danish Council for Independent Research(Det Frie Forskningsrad (DFF)); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shenzhen Science and Technology Program; Guangdong medical science and technology research foundation; Guangdong Basic and Applied Basic Research Foundation; SZU Top Ranking Project	This work was supported by the Deutsche Forschungsgemeinschaft grant agreement STA 338/15-1 to PS, the Danish Council for Independent Research, Medical Research grant agreement 11107588 to RH and National Natural Science Foundation of China (32170937), Shenzhen Science and Technology Program (RCBS20200714114958310, 20200803131335002), Guangdong medical science and technology research foundation (A2021336), Guangdong Basic and Applied Basic Research Foundation (2020A1515110410, 2020A1515010917), and SZU Top Ranking Project (86000000210) agreement to LY.	Abolhassani M, 2000, INFECT IMMUN, V68, P5657; Chen WH, 2009, TRENDS IMMUNOL, V30, P351, DOI 10.1016/j.it.2009.05.002; Corren J, 2019, NAT IMMUNOL, V20, P1603, DOI 10.1038/s41590-019-0524-9; de Jong JC, 2000, J MED VIROL, V61, P94, DOI 10.1002/(SICI)1096-9071(200005)61:1&lt;94::AID-JMV15&gt;3.0.CO;2-C; Dellgren C, 2009, GENES IMMUN, V10, P125, DOI 10.1038/gene.2008.87; Demehri S, 2016, J CLIN INVEST, V126, P1458, DOI 10.1172/JCI83724; Eliasson DG, 2008, VACCINE, V26, P1243, DOI 10.1016/j.vaccine.2007.12.027; FRIEND SL, 1994, EXP HEMATOL, V22, P321; Gauvreau GM, 2014, NEW ENGL J MED, V370, P2102, DOI 10.1056/NEJMoa1402895; Haber AL, 2017, NATURE, V551, P333, DOI 10.1038/nature24489; He R, 2008, P NATL ACAD SCI USA, V105, P11875, DOI 10.1073/pnas.0801532105; Hellfritzsch M, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11080375; Hemann EA, 2019, NAT IMMUNOL, V20, P1035, DOI 10.1038/s41590-019-0408-z; Joo S, 2017, MUCOSAL IMMUNOL, V10, P901, DOI 10.1038/mi.2016.103; Klinkhammer J, 2018, ELIFE, V7, DOI 10.7554/eLife.33354; Kochs G, 2009, J GEN VIROL, V90, P2990, DOI 10.1099/vir.0.015727-0; Krammer F, 2019, NAT REV IMMUNOL, V19, P383, DOI 10.1038/s41577-019-0143-6; Lazear HM, 2019, IMMUNITY, V50, P907, DOI 10.1016/j.immuni.2019.03.025; Levin SD, 1999, J IMMUNOL, V162, P677; Lo DD, 2018, TRENDS IMMUNOL, V39, P185, DOI 10.1016/j.it.2017.09.002; Marschall P, 2021, J ALLERGY CLIN IMMUN, V147, P1778, DOI 10.1016/j.jaci.2020.10.006; Menzies-Gow A, 2021, NEW ENGL J MED, V384, P1800, DOI 10.1056/NEJMoa2034975; Moreno-Fierros L, 2000, MICROBES INFECT, V2, P885, DOI 10.1016/S1286-4579(00)00398-1; Morrow MP, 2009, BLOOD, V113, P5868, DOI 10.1182/blood-2008-11-190520; Palese P, 2004, NAT MED, V10, pS82, DOI 10.1038/nm1141; Pandey A, 2000, NAT IMMUNOL, V1, P59, DOI 10.1038/76923; Pattarini L, 2017, J EXP MED, V214, P1529, DOI 10.1084/jem.20150402; Shane HL, 2014, J IMMUNOL, V192, P2261, DOI 10.4049/jimmunol.1302085; Talon J, 2000, P NATL ACAD SCI USA, V97, P4309, DOI 10.1073/pnas.070525997; Van Roey GA, 2012, EUR J IMMUNOL, V42, P353, DOI 10.1002/eji.201141787; von Moltke J, 2016, NATURE, V529, P221, DOI 10.1038/nature16161; Wei CJ, 2020, NAT REV DRUG DISCOV, V19, P239, DOI 10.1038/s41573-019-0056-x; Wieland SF, 2019, NAT IMMUNOL, V20, P522, DOI 10.1038/s41590-019-0362-9; Yadava K, 2013, MUCOSAL IMMUNOL, V6, P83, DOI 10.1038/mi.2012.50; Ye L, 2019, J VIROL, V93, DOI [10.1128/JVI.01262-19, 10.1128/JVI.01262-13]; Ye L, 2019, NAT REV IMMUNOL, V19, P614, DOI 10.1038/s41577-019-0182-z; Ye L, 2019, NAT IMMUNOL, V20, P593, DOI 10.1038/s41590-019-0345-x; Zhou BH, 2005, NAT IMMUNOL, V6, P1047, DOI 10.1038/ni1247; Zhou Y, 2017, VIRAL IMMUNOL, V30, P601, DOI 10.1089/vim.2017.0033	39	0	0	1	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 29	2021	12								749325	10.3389/fimmu.2021.749325	http://dx.doi.org/10.3389/fimmu.2021.749325			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WL8XM	34659250	Green Published, gold			2022-12-18	WOS:000710681900001
J	Zhang, K; Zheng, Y; Han, Q; Liu, Y; Wang, WT; Ding, J; Wang, Y; Zhang, B; Jia, JF; Zheng, MW; Zheng, ZH; Zhu, P				Zhang, Kui; Zheng, Yan; Han, Qing; Liu, Ying; Wang, Weitao; Ding, Jin; Wang, Yan; Zhang, Bei; Jia, Junfeng; Zheng, Minwen; Zheng, Zhaohui; Zhu, Ping			The Clinical and MRI Effect of TNF-alpha Inhibitors in Spondyloarthritis Patients With Hip Involvement: A Real-World Observational Clinical Study	FRONTIERS IN IMMUNOLOGY			English	Article						MRI; hip; spondyloarthritis; TNF-alpha; ASDAS-ESR	ANKYLOSING-SPONDYLITIS; PRELIMINARY VALIDATION; RISK-FACTORS; ETANERCEPT; PREVALENCE; SYNOVITIS; ARTHRITIS; CRITERIA; CHINESE	Objectives: Hip involvement is an important cause of disability and poor prognosis in patients with spondyloarthritis (SpA). Tumor necrosis factor (TNF)-a inhibitor treatment has been demonstrated to be effective in SpA patients with hip arthritis; however, quantitative assessment using MRI in long-term follow-up needs further application and observation. Methods: A total of 239 patients were involved in this study. Methotrexate and sulfasalazine were given as basic treatment. In total, 165 patients received TNF-a inhibitors plus basic treatment, and 74 received basic treatment only, as controls. Clinical symptoms were assessed at baseline and at weeks 12, 24, and 52. MRI performances of hip arthritis, including bone marrow edema (BME) and synovitis, were quantitatively assessed using the Hip Inflammation MRI Scoring System (HIMRISS). Results: The clinical values of erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Harris hip score, and Ankylosing Spondylitis Disease Activity Score (ASDAS)-ESR in both groups showed significant clinical remission at week 52 (p < 0.001). However, the change in disease activity levels at week 52 in the control group was significantly worse than in the TNF-a inhibitor group. At week 52, MRI showed a significant remission trend in the TNF-a inhibitor group versus baseline, and total HIMRISS scores were significantly decreased (26.49 +/- 10.37 vs. 20.59 +/- 9.41, p < 0.001); the control group only had slight improvement (p < 0.05). Conclusions: TNF-a inhibitors could significantly improve clinical and MRI manifestations of hip involvement in patients with SpA. Quantitative MRI assessment combined with clinical assessment can be used to accurately evaluate the treatment effect of TNF-a in SpA patients with hip involvement to help guide targeted treatment.	[Zhang, Kui; Zheng, Yan; Han, Qing; Wang, Weitao; Ding, Jin; Wang, Yan; Zhang, Bei; Jia, Junfeng; Zheng, Zhaohui; Zhu, Ping] Fourth Mil Med Univ, Xijing Hosp, Dept Clin Immunol, Xian, Peoples R China; [Zhang, Kui; Zheng, Yan; Han, Qing; Wang, Weitao; Ding, Jin; Wang, Yan; Zhang, Bei; Jia, Junfeng; Zheng, Zhaohui; Zhu, Ping] Natl Translat Sci Ctr Mol Med, Xian, Peoples R China; [Liu, Ying; Zheng, Minwen] Fourth Mil Med Univ, Xijing Hosp, Dept Radiol, Xian, Peoples R China	Air Force Military Medical University; Air Force Military Medical University	Zheng, ZH; Zhu, P (corresponding author), Fourth Mil Med Univ, Xijing Hosp, Dept Clin Immunol, Xian, Peoples R China.; Zheng, ZH; Zhu, P (corresponding author), Natl Translat Sci Ctr Mol Med, Xian, Peoples R China.; Zheng, MW (corresponding author), Fourth Mil Med Univ, Xijing Hosp, Dept Radiol, Xian, Peoples R China.	zhengmw2007@163.com; zhengzh@fmmu.edu.cn; zhuping@fmmu.edu.cn		Ding, Jin/0000-0003-3585-6063	National Basic Research Program of China [2015CB553704]; National Natural Science Foundation of China [81871273]	National Basic Research Program of China(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by the National Basic Research Program of China (No. 2015CB553704) and the National Natural Science Foundation of China (No. 81871273).	AMOR B, 1994, J RHEUMATOL, V21, P1883; Appel H, 2006, ARTHRITIS RHEUM-US, V54, P1805, DOI 10.1002/art.21907; Bethi S, 2013, ARTHRIT CARE RES, V65, P607, DOI 10.1002/acr.21878; Burki V, 2012, CLIN EXP RHEUMATOL, V30, P481; Chen DY, 2016, MOD RHEUMATOL, V26, P933, DOI 10.3109/14397595.2016.1153232; Chen WS, 2009, SCAND J RHEUMATOL, V38, P154, DOI 10.1080/03009740802409504; Garcia-Montoya Leticia, 2018, F1000Res, V7, DOI 10.12688/f1000research.14956.1; Guan MQ, 2013, CLIN RHEUMATOL, V32, P1115, DOI 10.1007/s10067-013-2278-3; Hamdi W, 2012, JOINT BONE SPINE, V79, P94, DOI 10.1016/j.jbspin.2011.05.021; Huang ZG, 2016, BRIT J RADIOL, V89, DOI 10.1259/bjr.20160566; Huang ZG, 2013, EUR J RADIOL, V82, P1487, DOI 10.1016/j.ejrad.2013.03.020; Huang ZX, 2019, CLIN RHEUMATOL, V38, P1595, DOI 10.1007/s10067-019-04466-9; Jones GT, 2020, ANN RHEUM DIS, V79, P914, DOI 10.1136/annrheumdis-2019-216841; Konsta M, 2013, CLIN RHEUMATOL, V32, P1229, DOI 10.1007/s10067-013-2263-x; Krabbe S, 2020, J RHEUMATOL, V47, P50, DOI 10.3899/jrheum.181159; Li JT, 2016, INT J IMMUNOPATH PH, V29, P510, DOI 10.1177/0394632016656013; Lopez-Medina C, 2020, CURR RHEUMATOL REP, V22, DOI 10.1007/s11926-020-00930-7; Mahmoud I, 2020, INT IMMUNOPHARMACOL, V88, DOI 10.1016/j.intimp.2020.106927; Maksymowych WP, 2014, J RHEUMATOL, V41, P370, DOI 10.3899/jrheum.131083; Rudwaleit M, 2009, ANN RHEUM DIS, V68, P777, DOI 10.1136/ard.2009.108233; Ruwaard J, 2018, SCAND J RHEUMATOL, V47, P122, DOI 10.1080/03009742.2017.1330419; Tam LS, 2019, INT J RHEUM DIS, V22, P340, DOI 10.1111/1756-185X.13510; Ungprasert P, 2017, CLIN RHEUMATOL, V36, P1569, DOI 10.1007/s10067-017-3693-7; Vander Cruyssen B, 2013, CURR OPIN RHEUMATOL, V25, P448, DOI 10.1097/BOR.0b013e3283620e04; Vander Cruyssen B, 2010, RHEUMATOLOGY, V49, P73, DOI 10.1093/rheumatology/kep174; VANDERLINDEN S, 1984, ARTHRITIS RHEUM, V27, P361; Ward MM, 2016, ARTHRITIS RHEUMATOL, V68, P282, DOI 10.1002/art.39298; Wink F, 2019, RHEUMATOLOGY, V58, P1040, DOI 10.1093/rheumatology/key382; Zavada J, 2016, ANN RHEUM DIS, V75, P96, DOI 10.1136/annrheumdis-2014-205202; Zheng Y, 2019, INT J RHEUM DIS, V22, P228, DOI 10.1111/1756-185X.13451	30	0	0	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 29	2021	12								740980	10.3389/fimmu.2021.740980	http://dx.doi.org/10.3389/fimmu.2021.740980			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WL1FX	34659233	Green Published, gold			2022-12-18	WOS:000710161000001
J	Di Rosa, F; Cossarizza, A; Hayday, AC				Di Rosa, Francesca; Cossarizza, Andrea; Hayday, Adrian C.			Corrigendum: To Ki or Not to Ki: Re-Evaluating the Use and Potentials of Ki-67 for T Cell Analysis	FRONTIERS IN IMMUNOLOGY			English	Correction						flow cytometry; T cells; cell cycle; Ki-67; DNA dye			[Di Rosa, Francesca] Natl Res Council Italy CNR, Inst Mol Biol & Pathol, Rome, Italy; [Cossarizza, Andrea] Univ Modena & Reggio Emilia, Dept Med & Surg Sci Children & Adults, Modena, Italy; [Cossarizza, Andrea] Natl Inst Cardiovasc Res, Bologna, Italy; [Hayday, Adrian C.] Francis Crick Inst, Immunosurveillance Lab, London, England; [Hayday, Adrian C.] Kings Coll London, Peter Gorer Dept Immunobiol, London, England; [Hayday, Adrian C.] Guys & St Thomas NHS Fdn Trust, Biomed Res Ctr BRC, Natl Inst Hlth Res NIHR, London, England; [Hayday, Adrian C.] Kings Coll London, London, England	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Patologia Molecolari (IBPM-CNR); Universita di Modena e Reggio Emilia; Francis Crick Institute; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Di Rosa, F (corresponding author), Natl Res Council Italy CNR, Inst Mol Biol & Pathol, Rome, Italy.	francesca.dirosa@cnr.it							0	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 28	2021	12								756641	10.3389/fimmu.2021.756641	http://dx.doi.org/10.3389/fimmu.2021.756641			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WF7LP	34650570	gold, Green Published			2022-12-18	WOS:000706483800001
J	Jagannath, C; McBride, JW; Vergne, I				Jagannath, Chinnaswamy; McBride, Jere W.; Vergne, Isabelle			Editorial: The Autophagy Pathway: Bacterial Pathogen Immunity and Evasion	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						autophagy; immunometabolism; Mycobacterium tuberculosis; Staphylococcus aureus; Salmonella typhimurium; Listeria monocytogenes; Anaplasmataceae; host-directed therapies			[Jagannath, Chinnaswamy] Cornell Univ, Weill Cornell Med Coll, Houston Methodist Res Inst, Houston, TX USA; [McBride, Jere W.] Univ Texas Med Branch, Dept Pathol, Galveston, TX 77555 USA; [McBride, Jere W.] Univ Texas Med Branch, Inst Human Infect & Immun, Galveston, TX 77555 USA; [Vergne, Isabelle] Univ Toulouse, UMR CNRS 5089, Inst Pharmacol & Biol Struct, Toulouse, France	Cornell University; The Methodist Hospital System; The Methodist Hospital - Houston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS)	Vergne, I (corresponding author), Univ Toulouse, UMR CNRS 5089, Inst Pharmacol & Biol Struct, Toulouse, France.	isabelle.vergne@ipbs.fr			NIH [RO1 AI-122070, AI123610, AI126144, AI149136]; HMRI, WCM; Fondation pour la Recherche Medicale (Equipes FRM) [DEQ20180339208]; Fondation MSDAvenir (Fight-TB project)	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); HMRI, WCM; Fondation pour la Recherche Medicale (Equipes FRM)(Fondation pour la Recherche Medicale); Fondation MSDAvenir (Fight-TB project)	CJ was supported by NIH RO1 AI-122070 (PI) and seed funds from HMRI, WCM. JM was supported by NIH AI123610, AI126144, and AI149136. IV was supported by Fondation pour la Recherche Me ' dicale (Equipes FRM DEQ20180339208) and the Fondation MSDAvenir (Fight-TB project).	Bah A, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01483; Deretic V, 2013, NAT REV IMMUNOL, V13, P722, DOI 10.1038/nri3532; Kilinc G, 2021, IMMUNOL REV, V301, P62, DOI 10.1111/imr.12951; Levine B, 2011, NATURE, V469, P323, DOI 10.1038/nature09782; Munoz-Sanchez S, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9112372; Silwal P, 2020, SEMIN CELL DEV BIOL, V101, P51, DOI 10.1016/j.semcdb.2019.07.011	6	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 28	2021	12								768935	10.3389/fimmu.2021.768935	http://dx.doi.org/10.3389/fimmu.2021.768935			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WF7BX	34650572	gold, Green Submitted, Green Published			2022-12-18	WOS:000706458100001
J	Ahmed, AR; Aksoy, M				Ahmed, A. Razzaque; Aksoy, Merve			IgM Deficiency in Autoimmune Blistering Mucocutaneous Diseases Following Various Treatments: Long Term Follow-Up and Relevant Observations	FRONTIERS IN IMMUNOLOGY			English	Article						rituximab; post-rituximab; hypogammaglobulinemia; decreased IgM; low IgM; blistering disorder; diseases; immunosuppressive agents; intravenous immunoglobulin	IMMUNOGLOBULIN LEVELS; B-LYMPHOCYTES; B-1 CELLS; RITUXIMAB; ANTIBODIES; HYPOGAMMAGLOBULINEMIA; IMMUNOTHERAPY; SELECTION	IgM deficiency has been reported in patients with many autoimmune diseases treated with Rituximab (RTX). It has not been studied, in detail, in autoimmune mucocutaneous blistering diseases (AIMBD). Our objectives were: (i) Examine the dynamics of IgM levels in patients with and without RTX. (ii) Influence of reduced serum IgM levels on clinical and laboratory parameters. (iii) Explore the possible molecular and cellular basis for reduced serum IgM levels. This retrospective study that was conducted in a single-center from 2000 to 2020. Serial IgM levels were studied in 348 patients with five AIMBD (pemphigus vulgaris, pemphigus foliaceus, bullous pemphigoid, mucous membrane pemphigoid, and ocular cicatricial pemphigoid) and found decreased in 55 patients treated with RTX, IVIG, and conventional immunosuppressive therapy (CIST). Hence the incidence of decreased serum IgM is low. The incidence of decreased IgM in patients treated with RTX was 19.6%, in patients treated with IVIG and CIST, it was 52.8% amongst the 55 patients. IgM levels in the post-RTX group were statistically significantly different from the IVIG group (p<0.018) and CIST group (p<0.001). There were no statistically significant differences between the groups in other clinical and laboratory measures. Decreased serum IgM did not affect depletion or repopulation of CD19+ B cells. Patients in the three groups achieved clinical and serological remission, in spite of decreased IgM levels. Decrease in IgM was isolated, since IgG and IgA were normal throughout the study period. Decreased IgM persisted at the same level, while the patients were in clinical remission, for several years. In spite of persistent decreased IgM levels, the patients did not develop infections, tumors, other autoimmune diseases, or warrant hospitalization. Studies on IgM deficiency in knockout mice provided valuable insights. There is no universally accepted mechanism that defines decreased IgM levels in AIMBD. The data is complex, multifactorial, sometimes contradictory, and not well understood. Nonetheless, data in this study provides novel information that enhances our understanding of the biology of IgM in health and disease.	[Ahmed, A. Razzaque; Aksoy, Merve] Tufts Univ, Sch Med, Ctr Blistering Dis, Dept Dermatol, Boston, MA 02111 USA; [Ahmed, A. Razzaque] Boston Vet Adm Hlth Serv, Dermatol Serv, Boston, MA 02210 USA	Tufts University	Ahmed, AR (corresponding author), Tufts Univ, Sch Med, Ctr Blistering Dis, Dept Dermatol, Boston, MA 02111 USA.; Ahmed, AR (corresponding author), Boston Vet Adm Hlth Serv, Dermatol Serv, Boston, MA 02210 USA.	arahmedmd@msn.com			Dysimmune Diseases Foundation	Dysimmune Diseases Foundation	This study was supported in part, by an unrestricted educational grant from the Dysimmune Diseases Foundation.	Ahmed AR, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01189; Baker N, 2002, J IMMUNOL, V169, P6686, DOI 10.4049/jimmunol.169.12.6686; Basta F, 2020, RHEUMATOL THER, V7, P433, DOI 10.1007/s40744-020-00212-9; Baumgarth N, 2005, SPRINGER SEMIN IMMUN, V26, P347, DOI 10.1007/s00281-004-0182-2; Boes M, 1998, J IMMUNOL, V160, P4776; CASCIOLAROSEN LA, 1994, J EXP MED, V179, P1317, DOI 10.1084/jem.179.4.1317; Chisari CG, 2022, J NEUROL, V269, P159, DOI 10.1007/s00415-020-10362-z; CUNNINGHAMRUNDLES C, 1991, AM J HEMATOL, V37, P69, DOI 10.1002/ajh.2830370202; Das S, 2012, CURR GENOMICS, V13, P95, DOI 10.2174/138920212799860652; De La Torre I, 2012, RHEUMATOLOGY, V51, P833, DOI 10.1093/rheumatology/ker417; Duber S, 2009, BLOOD, V114, P4960, DOI 10.1182/blood-2009-04-218156; Ehrenstein MR, 2010, NAT REV IMMUNOL, V10, P778, DOI 10.1038/nri2849; Ehrenstein MR, 1998, P NATL ACAD SCI USA, V95, P10089, DOI 10.1073/pnas.95.17.10089; Fuentes-Panana EM, 2004, IMMUNOL REV, V197, P26, DOI 10.1111/j.0105-2896.2004.0105.x; Gong Y, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004385.pub2; Hamaguchi Y, 2005, J IMMUNOL, V174, P4389, DOI 10.4049/jimmunol.174.7.4389; Hastings WD, 2006, EUR J IMMUNOL, V36, P1114, DOI 10.1002/eji.200535142; Kallies A, 2004, J EXP MED, V200, P967, DOI 10.1084/jem.20040973; Keven K, 2003, Transpl Infect Dis, V5, P181, DOI 10.1111/j.1399-3062.2003.00035.x; Keystone E, 2007, ARTHRITIS RHEUM-US, V56, P3896, DOI 10.1002/art.23059; Klein J, 2005, P NATL ACAD SCI USA, V102, P169, DOI 10.1073/pnas.0408480102; Kridin K, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102466; MANSIKKA A, 1992, J IMMUNOL, V149, P855; Mouquet H, 2008, J INVEST DERMATOL, V128, P2859, DOI 10.1038/jid.2008.178; Nguyen VK, 2002, IMMUNOGENETICS, V54, P39, DOI 10.1007/s00251-002-0433-0; Notley CA, 2010, J IMMUNOL, V184, P3386, DOI 10.4049/jimmunol.0902640; Ohta Y, 2006, P NATL ACAD SCI USA, V103, P10723, DOI 10.1073/pnas.0601407103; Peng YF, 2005, MOL IMMUNOL, V42, P781, DOI 10.1016/j.molimm.2004.07.045; RANDALL TD, 1992, J BIOL CHEM, V267, P18002; Reddy V, 2017, ARTHRIT CARE RES, V69, P857, DOI 10.1002/acr.22993; Roberts DM, 2015, J AUTOIMMUN, V57, P60, DOI 10.1016/j.jaut.2014.11.009; Ryan GA, 2010, J IMMUNOL, V185, P2800, DOI 10.4049/jimmunol.1000856; Sasaki H, 2018, MOD RHEUMATOL, V28, P913, DOI 10.1080/14397595.2018.1467257; Schmidt E, 2019, LANCET, V394, P882, DOI 10.1016/S0140-6736(19)31778-7; Schmidt E, 2013, LANCET, V381, P320, DOI 10.1016/S0140-6736(12)61140-4; SENALDI G, 1988, ARTHRITIS RHEUM, V31, P1213, DOI 10.1002/art.1780310929; Shah S, 2017, CLIN KIDNEY J, V10, P470, DOI 10.1093/ckj/sfx014; SMOLIN MR, 1988, AM J KIDNEY DIS, V11, P267, DOI 10.1016/S0272-6386(88)80161-6; Stone JH, 2010, NEW ENGL J MED, V363, P221, DOI 10.1056/NEJMoa0909905; Tandan R, 2017, MUSCLE NERVE, V56, P185, DOI 10.1002/mus.25597; Venhoff N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037626; Wong SC, 2002, J BIOL CHEM, V277, P30707, DOI 10.1074/jbc.M202460200; Zhong XM, 2009, ARTHRITIS RHEUM-US, V60, P3734, DOI 10.1002/art.25015; Zisapel Michael, 2019, Harefuah, V158, P595	44	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 27	2021	12								727520	10.3389/fimmu.2021.727520	http://dx.doi.org/10.3389/fimmu.2021.727520			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WE9CP	34646266	gold, Green Published			2022-12-18	WOS:000705915700001
J	Canton, J; Fairn, GD; Jaumouille, V				Canton, Johnathan; Fairn, Gregory D.; Jaumouille, Valentin			Editorial: Phagocytes in Immunity: Linking Material Internalization to Immune Responses and Therapeutic Strategies	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						macrophage; dendritic cell; neutrophil; phagocytosis; efferocytosis; macropinocytosis; immunotherapy; host-pathogen interactions			[Canton, Johnathan] Univ Calgary, Comparat Biol & Expt Med, Calgary, AB, Canada; [Fairn, Gregory D.] Dalhousie Univ, Dept Biol, Halifax, NS, Canada; [Jaumouille, Valentin] Simon Fraser Univ, Mol Biol & Biochem, Burnaby, BC, Canada	University of Calgary; Dalhousie University; Simon Fraser University	Canton, J (corresponding author), Univ Calgary, Comparat Biol & Expt Med, Calgary, AB, Canada.; Fairn, GD (corresponding author), Dalhousie Univ, Dept Biol, Halifax, NS, Canada.; Jaumouille, V (corresponding author), Simon Fraser Univ, Mol Biol & Biochem, Burnaby, BC, Canada.	Johnathan.Canton@ucalgary.ca; gfairn@dal.ca; v_jaumouille@sfu.ca		Jaumouille, Valentin/0000-0001-6656-7833; Canton, Johnathan/0000-0001-8869-8404	Natural Sciences and Engineering Research Council of Canada [NSERC RGPIN2021-03727]	Natural Sciences and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)CGIAR)	VJ acknowledges the support of the Natural Sciences and Engineering Research Council of Canada (NSERC RGPIN2021-03727).		0	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 24	2021	12								772256	10.3389/fimmu.2021.772256	http://dx.doi.org/10.3389/fimmu.2021.772256			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WE9QR	34630442	Green Published, gold			2022-12-18	WOS:000705952700001
J	Kordelas, L; Buttkereit, U; Heinemann, FM; Horn, PA; Giebel, B; Beelen, DW; Reinhardt, HC; Rebmann, V				Kordelas, Lambros; Buttkereit, Ulrike; Heinemann, Falko M.; Horn, Peter A.; Giebel, Bernd; Beelen, Dietrich W.; Reinhardt, H. Christian; Rebmann, Vera			Low Soluble Programmed Cell Death Protein 1 Levels After Allogeneic Stem Cell Transplantation Predict Moderate or Severe Chronic GvHD and Inferior Overall Survival	FRONTIERS IN IMMUNOLOGY			English	Article						allogeneic hematopoietic stem cell transplantation; graft-versus-host disease; PD-1; soluble PD-1; immune checkpoint; inhibitory co-receptor; GvHD biomarker	VERSUS-HOST-DISEASE; PD-1	Programmed cell death protein-1 (PD-1) is an inhibitory co-receptor required for regulating immune responsiveness and maintaining immune homeostasis. As PD-1 can be released as bioactive soluble molecule, we investigated the clinical significance of soluble PD-1 (sPD-1) after allogeneic hematopoietic stem cell transplantation (HSCT) regarding graft-versus-host disease (GvHD), relapse, and overall survival (OS) in a mono-centric cohort of 82 patients. Compared to pre-HSCT and to healthy controls, post-HSCT sPD-1 plasma levels were significantly increased during an observation time of three months. Univariate analysis revealed that low sPD-1 plasma levels at month one, two or three post HSCT were associated with acute GvHD grade III-IV, the onset of moderate/severe chronic GvHD (cGvHD) and inferior OS, DFS, and TRM, respectively. No relationship was detected to relapse rates. sPD-1 plasma levels were significantly increased in ATG-treated patients compared to ATG-untreated patients. Multivariate analysis revealed that a low sPD-1 plasma levels status at one or two month(s) after HSCT is an independent indicator for inferior OS, DFS, or TRM. A low sPD-1 plasma levels status at month three post HSCT is predictive for the onset of moderate/severe cGvHD. Thus, our study pinpoints the soluble inhibitory co-receptor PD-1 as a promising candidate molecule for the prediction of clinical HSCT outcome.</p>	[Kordelas, Lambros; Buttkereit, Ulrike; Beelen, Dietrich W.; Reinhardt, H. Christian] Univ Hosp Essen, Dept Hematol & Stem Cell Transplantat, Essen, Germany; [Heinemann, Falko M.; Horn, Peter A.; Giebel, Bernd; Rebmann, Vera] Univ Hosp Essen, Inst Transfus Med, Essen, Germany	University of Duisburg Essen; University of Duisburg Essen	Kordelas, L (corresponding author), Univ Hosp Essen, Dept Hematol & Stem Cell Transplantat, Essen, Germany.; Rebmann, V (corresponding author), Univ Hosp Essen, Inst Transfus Med, Essen, Germany.	lambros.kordelas@uk-essen.de; vera.rebmann@uk-essen.de			European Union; German federal state North Rhine-Westphalia [EFRE-0800396]	European Union(European Commission); German federal state North Rhine-Westphalia	This study was supported by the European Union and the German federal state North Rhine-Westphalia ("SEVRIT" project, EFRE-0800396).	Filipovich AH, 2005, BIOL BLOOD MARROW TR, V11, P945, DOI 10.1016/j.bbmt.2005.09.004; GLUCKSBERG H, 1974, TRANSPLANTATION, V18, P295, DOI 10.1097/00007890-197410000-00001; Gratwohl A, 2009, CANCER-AM CANCER SOC, V115, P4715, DOI 10.1002/cncr.24531; Hobo W, 2018, BRIT J HAEMATOL, V181, P38, DOI 10.1111/bjh.15078; Ijaz A, 2019, BIOL BLOOD MARROW TR, V25, P94, DOI 10.1016/j.bbmt.2018.08.028; Jain P, 2019, BIOL BLOOD MARROW TR, V25, P216, DOI 10.1016/j.bbmt.2018.09.037; Khan M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.587460; Klobuch S, 2017, ONCOL RES TREAT, V40, P447, DOI 10.1159/000471768; Kuipers H, 2006, EUR J IMMUNOL, V36, P2472, DOI 10.1002/eji.200635978; McDuffee E, 2017, BONE MARROW TRANSPL, V52, P759, DOI 10.1038/bmt.2016.346; Nielsen C, 2005, CELL IMMUNOL, V235, P109, DOI 10.1016/j.cellimm.2005.07.007; Norde WJ, 2011, CANCER RES, V71, P5111, DOI 10.1158/0008-5472.CAN-11-0108; Ortega SG, 2019, SWISS MED WKLY, V149, DOI 10.4414/smw.2019.20150; PRZEPIORKA D, 1995, BONE MARROW TRANSPL, V15, P825; Simonetta F, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01034; Ugurel S, 2020, ANN ONCOL, V31, P144, DOI 10.1016/j.annonc.2019.09.005; Wei SC, 2018, CANCER DISCOV, V8, P1069, DOI 10.1158/2159-8290.CD-18-0367	17	0	0	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 24	2021	12								694843	10.3389/fimmu.2021.694843	http://dx.doi.org/10.3389/fimmu.2021.694843			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WE9DF	34630383	Green Published, gold			2022-12-18	WOS:000705917300001
J	Oladiran, O; Shi, XQ; Fournier, S; Zhang, J				Oladiran, Oladayo; Shi, Xiang Qun; Fournier, Sylvie; Zhang, Ji			CX3CR1 But Not CCR2 Expression Is Required for the Development of Autoimmune Peripheral Neuropathy in Mice (vol 12, 720733, 2021)	FRONTIERS IN IMMUNOLOGY			English	Correction						macrophages; CD8(+) T cells; autoimmune peripheral neuropathy; CX3CR1; CCR2; apoptosis; phagocytosis			[Oladiran, Oladayo; Shi, Xiang Qun; Zhang, Ji] McGill Univ, Alan Edwards Ctr Res Pain, Montreal, PQ, Canada; [Fournier, Sylvie; Zhang, Ji] McGill Univ, Dept Microbiol & Immunol, Montreal, PQ, Canada; [Zhang, Ji] McGill Univ, Dept Neurol & Neurosurg, Montreal, PQ, Canada; [Zhang, Ji] McGill Univ, Fac Dent, Montreal, PQ, Canada	McGill University; McGill University; McGill University; McGill University	Zhang, J (corresponding author), McGill Univ, Alan Edwards Ctr Res Pain, Montreal, PQ, Canada.; Fournier, S; Zhang, J (corresponding author), McGill Univ, Dept Microbiol & Immunol, Montreal, PQ, Canada.; Zhang, J (corresponding author), McGill Univ, Dept Neurol & Neurosurg, Montreal, PQ, Canada.; Zhang, J (corresponding author), McGill Univ, Fac Dent, Montreal, PQ, Canada.	Sylvie.Fournier@mcgill.ca; Ji.Zhang@mcgill.ca						Oladiran O, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.720733	1	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 24	2021	12								765892	10.3389/fimmu.2021.765892	http://dx.doi.org/10.3389/fimmu.2021.765892			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WD7ZE	34630439	Green Published, gold			2022-12-18	WOS:000705154200001
J	Shi, Y; Sezgin, E; Chen, W				Shi, Yan; Sezgin, Erdinc; Chen, Wei			Editorial: The Role of Biomembranes and Biophysics in Immune Cell Signaling	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						cell membrane; lipid domains; membrane biophysics; receptor signaling; T cell receptor			[Shi, Yan] Tsinghua Univ, Beijing Key Lab Immunol Res Chron Dis, Inst Immunol, Sch Med, Beijing, Peoples R China; [Shi, Yan] Univ Calgary, Snyder Inst, Dept Microbiol Immunol & Infect Dis, Calgary, AB, Canada; [Sezgin, Erdinc] Karolinska Inst, Dept Womens & Childrens Hlth, Sci Life Lab, Solna, Sweden; [Chen, Wei] Zhejiang Univ, Affiliated Hosp 2, Dept Cell Biol & Dept Cardiol, Sch Med, Hangzhou, Peoples R China	Tsinghua University; University of Calgary; Karolinska Institutet; Zhejiang University	Shi, Y (corresponding author), Tsinghua Univ, Beijing Key Lab Immunol Res Chron Dis, Inst Immunol, Sch Med, Beijing, Peoples R China.; Shi, Y (corresponding author), Univ Calgary, Snyder Inst, Dept Microbiol Immunol & Infect Dis, Calgary, AB, Canada.; Sezgin, E (corresponding author), Karolinska Inst, Dept Womens & Childrens Hlth, Sci Life Lab, Solna, Sweden.; Chen, W (corresponding author), Zhejiang Univ, Affiliated Hosp 2, Dept Cell Biol & Dept Cardiol, Sch Med, Hangzhou, Peoples R China.	yanshiemail@mail.tsinghua.edu.cn; erdinc.sezgin@ki.se; jackweichen@zju.edu.cn						Cornell CE, 2018, BIOPHYS J, V115, P690, DOI 10.1016/j.bpj.2018.06.027; Dam T, 2021, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.613367; Destainville N, 2018, BIOMOLECULES, V8, DOI 10.3390/biom8040104; Lorent JH, 2020, NAT CHEM BIOL, V16, P644, DOI 10.1038/s41589-020-0529-6; Shimobayashi SF, 2016, EPL-EUROPHYS LETT, V113, DOI 10.1209/0295-5075/113/56005; Stanly TA, 2020, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.568087	6	0	0	0	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 24	2021	12								740373	10.3389/fimmu.2021.740373	http://dx.doi.org/10.3389/fimmu.2021.740373			4	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WD7ZS	34630421	Green Published, gold			2022-12-18	WOS:000705155600001
J	Zou, JT; Jing, HM; Zhang, XL; Liu, YH; Zhao, Z; Duan, LL; Yuan, Y; Chen, ZF; Gou, Q; Xiong, QS; Li, SS; Yang, F; Zeng, H; Zou, QM; Zhang, JY				Zou, Jintao; Jing, Haiming; Zhang, Xiaoli; Liu, Yiheng; Zhao, Zhuo; Duan, Lianli; Yuan, Yue; Chen, Zhifu; Gou, Qiang; Xiong, Qingshan; Li, Sisi; Yang, Feng; Zeng, Hao; Zou, Quanming; Zhang, Jinyong			alpha-Hemolysin-Aided Oligomerization of the Spike Protein RBD Resulted in Improved Immunogenicity and Neutralization Against SARS-CoV-2 Variants	FRONTIERS IN IMMUNOLOGY			English	Article						SARS-CoV-2; COVID-19; subunit vaccine; mHla-RBD; oligomerization	VACCINES; RESIDUES	The increase in confirmed COVID-19 cases and SARS-CoV-2 variants calls for the development of safe and broad cross-protective vaccines. The RBD of the spike protein was considered to be a safe and effective candidate antigen. However, the low immunogenicity limited its application in vaccine development. Herein, we designed and obtained an RBD heptamer (mHla-RBD) based on a carrier protein-aided assembly strategy. The molecular weight of mHla-RBD is up to 450 kDa, approximately 10 times higher than that of the RBD monomer. When formulated with alum adjuvant, mHla-RBD immunization significantly increased the immunogenicity of RBD, as indicated by increased titers of RBD-specific antibodies, neutralizing antibodies, Th2 cellular immune response, and pseudovirus neutralization activity, when compared to RBD monomer. Furthermore, we confirmed that RBD-specific antibodies predominantly target conformational epitopes, which was approximately 200 times that targeting linear epitopes. Finally, a pseudovirus neutralization assay revealed that neutralizing antibodies induced by mHla-RBD against different SARS-CoV-2 variants were comparable to those against the wild-type virus and showed broad-spectrum neutralizing activity toward different SARS-CoV-2 variants. Our results demonstrated that mHla-RBD is a promising candidate antigen for development of SARS-CoV-2 vaccines and the mHla could serve as a universal carrier protein for antigen design.	[Zou, Jintao; Jing, Haiming; Liu, Yiheng; Zhao, Zhuo; Duan, Lianli; Yuan, Yue; Chen, Zhifu; Gou, Qiang; Xiong, Qingshan; Li, Sisi; Yang, Feng; Zeng, Hao; Zou, Quanming; Zhang, Jinyong] Third Mil Med Univ, Dept Microbiol & Biochem Pharm, Coll Pharm, Natl Engn Res Ctr Immunol Prod, Chongqing, Peoples R China; [Zhang, Xiaoli] Third Mil Med Univ, Dept Clin Hematol, Coll Pharm, Chongqing, Peoples R China	Army Medical University; Army Medical University	Zou, QM; Zhang, JY (corresponding author), Third Mil Med Univ, Dept Microbiol & Biochem Pharm, Coll Pharm, Natl Engn Res Ctr Immunol Prod, Chongqing, Peoples R China.	qmzou2007@163.com; zhangjy198217@126.com	Duan, Lianli/GQP-3771-2022	Zhang, Jinyong/0000-0001-9622-5834	National Natural Science Foundation of China [31970138, 32170938]; Chongqing Education Commission [KYYJ202010]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Chongqing Education Commission	This work was supported by grant from the National Natural Science Foundation of China (No. 31970138 and 32170938) and a program form Chongqing Education Commission (No. KYYJ202010).	Conte C, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020309; Dai LP, 2020, CELL, V182, P722, DOI 10.1016/j.cell.2020.06.035; Deng XD, 2021, CELL, V184, P3426, DOI 10.1016/j.cell.2021.04.025; Du YF, 2018, INFECT DRUG RESIST, V11, P1271, DOI 10.2147/IDR.S167779; Fiaschi L, 2016, CLIN VACCINE IMMUNOL, V23, P442, DOI 10.1128/CVI.00091-16; Firacative C, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21039-z; Garcia-Beltran WF, 2021, CELL, V184, P2372, DOI [10.1016/j.cell.2021.03.013, 10.1016/j.cell.2021.04.006]; Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z; Harvey WT, 2021, NAT REV MICROBIOL, V19, P409, DOI 10.1038/s41579-021-00573-0; Hosseini SA, 2021, INT IMMUNOPHARMACOL, V97, DOI 10.1016/j.intimp.2021.107622; Huang WC, 2020, ADV MATER, V32, DOI 10.1002/adma.202005637; Huang Y, 2020, ACTA PHARMACOL SIN, V41, P1141, DOI 10.1038/s41401-020-0485-4; Jangra S, 2021, LANCET MICROBE, V2, pE283, DOI 10.1016/S2666-5247(21)00068-9; Jing HM, 2020, INT J BIOL MACROMOL, V159, P174, DOI 10.1016/j.ijbiomac.2020.05.057; Kim YI, 2021, EMERG MICROBES INFEC, V10, P152, DOI 10.1080/22221751.2021.1872352; Krammer F, 2020, NATURE, V586, P516, DOI 10.1038/s41586-020-2798-3; Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5; Lee WS, 2020, NAT MICROBIOL, V5, P1185, DOI 10.1038/s41564-020-00789-5; Li TT, 2020, EMERG MICROBES INFEC, V9, P2076, DOI 10.1080/22221751.2020.1821583; Liang F, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal2094; Liu YF, 2021, CELL, V184, P3452, DOI 10.1016/j.cell.2021.05.032; Liu ZZ, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00402-5; Liu ZZ, 2020, VIROL SIN, V35, P340, DOI 10.1007/s12250-020-00214-5; Metz SW, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12677-6; Min L, 2021, FRONT MOL BIOSCI, V8, DOI 10.3389/fmolb.2021.671633; Noh JY, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00623-2; Piccoli L, 2020, CELL, V183, P1024, DOI 10.1016/j.cell.2020.09.037; Ren J, 2015, BMC BIOINFORMATICS, V16, DOI 10.1186/1471-2105-16-S18-S12; Sewell HF, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m4838; Shamriz S, 2016, COMPUT BIOL MED, V76, P24, DOI 10.1016/j.compbiomed.2016.06.015; Sinegubova MV, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0242890; Sugawara T, 2015, TOXICON, V108, P226, DOI 10.1016/j.toxicon.2015.09.033; Tai WB, 2020, CELL RES, V30, P932, DOI 10.1038/s41422-020-0387-5; Verghese M, 2021, J CLIN MICROBIOL, V59, DOI 10.1128/JCM.00741-21; Walls Alexandra C, 2020, Cell, V183, P1367, DOI [10.1101/2020.08.11.247395, 10.1016/j.cell.2020.10.043]; Wang WJ, 2021, CELL MOL IMMUNOL, V18, P749, DOI 10.1038/s41423-021-00643-6; Westritschnig K, 2014, HUM VACC IMMUNOTHER, V10, P170, DOI 10.4161/hv.26565; Wetzel S, 2017, BBA-MOL CELL RES, V1864, P2071, DOI 10.1016/j.bbamcr.2017.06.005; Wilke GA, 2010, P NATL ACAD SCI USA, V107, P13473, DOI 10.1073/pnas.1001815107; Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]; Shi Pei-Yong, 2021, Res Sq, DOI [10.1101/2021.01.07.425740, 10.21203/rs.3.rs-143532/v1]; Yang JY, 2020, NATURE, V586, P572, DOI 10.1038/s41586-020-2599-8; Zhang JY, 2015, SCI REP-UK, V5, DOI 10.1038/srep15553; Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017; Zou JT, 2021, PLOS PATHOG, V17, DOI 10.1371/journal.ppat.1009752	45	0	0	3	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 24	2021	12								757691	10.3389/fimmu.2021.757691	http://dx.doi.org/10.3389/fimmu.2021.757691			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WE8SO	34630436	gold, Green Published			2022-12-18	WOS:000705889300001
J	Paes, W; Leonov, G; Partridge, T; Nicastri, A; Ternette, N; Borrow, P				Paes, Wayne; Leonov, German; Partridge, Thomas; Nicastri, Annalisa; Ternette, Nicola; Borrow, Persephone			Elucidation of the Signatures of Proteasome-Catalysed Peptide Splicing (vol 11, 563800, 2020)	FRONTIERS IN IMMUNOLOGY			English	Correction						peptide splicing; proteasome; splicing mechanism; antigen processing; peptide epitopes			[Paes, Wayne; Partridge, Thomas; Borrow, Persephone] Univ Oxford, Nuffield Dept Clin Med, Oxford, England; [Leonov, German] Univ York, York Cross Disciplinary Ctr Syst Anal, York, N Yorkshire, England; [Nicastri, Annalisa; Ternette, Nicola] Univ Oxford, Jenner Inst, Nuffield Dept Clin Med, Oxford, England	University of Oxford; University of York - UK; University of Oxford; Jenner Institute	Paes, W; Borrow, P (corresponding author), Univ Oxford, Nuffield Dept Clin Med, Oxford, England.	wayne.paes@ndm.ox.ac.uk; persephone.borrow@ndm.ox.ac.uk						Paes W, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.563800	1	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 23	2021	12								755002	10.3389/fimmu.2021.755002	http://dx.doi.org/10.3389/fimmu.2021.755002			4	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WC9OJ	34630434	gold, Green Published			2022-12-18	WOS:000704579200001
J	Shibad, V; Bootwala, A; Mao, CC; Bader, H; Vo, H; Landesman-Bollag, E; Guo, C; Rubio, A; Near, R; Gao, WD; Challa, S; Chukka, V; Gao, J; Kelly, A; Landesman, T; VanHelene, T; Zhong, XM				Shibad, Varuna; Bootwala, Ali; Mao, Changchuin; Bader, Hanna; Vo, Hung; Landesman-Bollag, Esther; Guo, Conrad; Rubio, Angel; Near, Richard; Gao, Wenda; Challa, Sreekar; Chukka, Vennela; Gao, Jeffrey; Kelly, Avery; Landesman, Tamar; VanHelene, Tyler; Zhong, Xuemei			L2pB1 Cells Contribute to Tumor Growth Inhibition	FRONTIERS IN IMMUNOLOGY			English	Article						L2pB1 cells; natural IgM; 3D tumor spheroids; melanoma; colon cancer; lipoptosis	B-1 CELLS; B-CELLS; IGM ANTIBODIES; BREAST-CANCER; IMMUNOSURVEILLANCE; PD-L2; MECHANISMS; PROTECT; STRESS; INNATE	Natural IgM (nIgM) antibodies play critical roles in cancer immunosurveillance. However, the role of B-1 B cells, the lymphocytes that produce nIgM, remains to be elucidated. L2pB1 cells, a subpopulation of B-1 B cells, have a unique poly-self-reactive nIgM repertoire and are capable of phagocytosis, potent antigen presentation, and immunomodulation. Using an inducible knock-in and knockout mouse model, we investigated the effect of the loss of L2pB1 cells in a B16F10 melanoma model. Our results show active tumor infiltration of L2pB1 cells in wild type mice, and conversely, depletion of L2pB1 cells results in larger tumor mass and increased angiogenesis. In vitro analysis revealed that L2pB1 cells contribute to the growth inhibition of melanoma cells in both 2D cell culture and 3D tumor spheroids. Similar effects were observed in an MC38 murine colon cancer model. Moreover, our data suggest that one of the ways that L2pB1 cells can induce tumor cell death is via lipoptosis. Lastly, we tested whether L2pB1 cell-derived monoclonal nIgM antibodies can specifically recognize tumor spheroids. Nine of the 28 nIgM-secreting L2pB1 clones demonstrated specific binding to tumor spheroids but did not bind control murine embryonic fibroblasts. Our study provides evidence that L2pB1 cells contribute to cancer immunity through their unique nIgM repertoire, tumor recognition, and lipoptosis. Taken together, because of their ability to recognize common features of tumors that are independent of genetic mutations, L2pB1 cells and their nIgM could be potential candidates for cancer treatment that can overcome tumor heterogeneity-associated drug resistance.</p>	[Shibad, Varuna; Mao, Changchuin; Bader, Hanna; Vo, Hung; Landesman-Bollag, Esther; Guo, Conrad; Near, Richard; Zhong, Xuemei] Boston Univ, Hematol Oncol Sect, Dept Med, Sch Med, Boston, MA 02215 USA; [Shibad, Varuna; Mao, Changchuin; Bader, Hanna; Vo, Hung; Landesman-Bollag, Esther; Guo, Conrad; Rubio, Angel; Near, Richard; Zhong, Xuemei] Boston Med Ctr, Boston, MA 02118 USA; [Bootwala, Ali] Boston Univ, Dept Grad Med Studies, Sch Med, Boston, MA 02215 USA; [Mao, Changchuin; Near, Richard; Gao, Wenda] Antagen Inst Biomed Res, Boston, MA USA; [Rubio, Angel] Boston Univ, Dept Pharmacol, Sch Med, Boston, MA 02215 USA; [Challa, Sreekar; Gao, Jeffrey; VanHelene, Tyler] Sharon High Sch, Sharon, MA USA; [Chukka, Vennela] Lynbrook High Sch, San Jose, CA USA; [Kelly, Avery; Landesman, Tamar] Brookline High Sch, Brookline, MA USA	Boston University; Boston Medical Center; Boston University; Boston University	Zhong, XM (corresponding author), Boston Univ, Hematol Oncol Sect, Dept Med, Sch Med, Boston, MA 02215 USA.; Zhong, XM (corresponding author), Boston Med Ctr, Boston, MA 02118 USA.	xuemei.zhong03@gmail.com			National Cancer Institute [R21 CA205415]; National Institute of Diabetes and Digestive and Kidney Diseases [1R56DK103894-01A1]; National Center for Advancing Translational Sciences, National Institutes of Health, through BU-CTSI [1UL1TR001430]	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); National Center for Advancing Translational Sciences, National Institutes of Health, through BU-CTSI	This study was supported by National Cancer Institute through Grant Number R21 CA205415, by National Institute of Diabetes and Digestive and Kidney Diseases through Grant Number 1R56DK103894-01A1, and by the National Center for Advancing Translational Sciences, National Institutes of Health, through BU-CTSI Grant Number 1UL1TR001430.	Azevedo MC, 2014, IMMUNOBIOLOGY, V219, P357, DOI 10.1016/j.imbio.2013.12.001; Borre PV, 2011, CELL SIGNAL, V23, P1030, DOI 10.1016/j.cellsig.2011.01.018; Brandlein S, 2003, CANCER RES, V63, P7995; Brandlein S, 2007, MOL CANCER THER, V6, P326, DOI 10.1158/1535-7163.MCT-06-0399; BUZZI S, 1973, Cancer Research, V33, P2349; Choi YS, 2012, EUR J IMMUNOL, V42, P120, DOI 10.1002/eji.201141890; Diaz-Zaagoza M, 2015, ONCOL REP, V34, P1106, DOI 10.3892/or.2015.4095; Hansen MH, 2001, P NATL ACAD SCI USA, V98, P12659, DOI 10.1073/pnas.171460798; Haro MA, 2019, CANCER RES, V79, P159, DOI 10.1158/0008-5472.CAN-18-0981; Haro MA, 2016, CANCER IMMUNOL RES, V4, P1027, DOI 10.1158/2326-6066.CIR-16-0184; KEAST D, 1970, LANCET, V2, P710; Kotlan B, 2005, J IMMUNOL, V175, P2278, DOI 10.4049/jimmunol.175.4.2278; Latchman Y, 2001, NAT IMMUNOL, V2, P261, DOI 10.1038/85330; Lee RA, 2015, ANN NY ACAD SCI, V1362, P77, DOI 10.1111/nyas.12865; Lin Ruei-Zhen, 2008, Biotechnology Journal, V3, P1172, DOI 10.1002/biot.200700228; Loi S, 2013, J CLIN ONCOL, V31, P860, DOI 10.1200/JCO.2011.41.0902; McKay JT, 2017, J IMMUNOL, V199, P2020, DOI 10.4049/jimmunol.1700555; Mkrtichyan M, 2012, J IMMUNOL, V189, P2338, DOI 10.4049/jimmunol.1103085; Ollert MW, 1996, P NATL ACAD SCI USA, V93, P4498, DOI 10.1073/pnas.93.9.4498; Panda S, 2015, J IMMUNOL, V194, P13, DOI 10.4049/jimmunol.1400844; Pohle T, 2004, CANCER RES, V64, P3900, DOI 10.1158/0008-5472.CAN-03-3149; Seelige R, 2018, CELL MOL LIFE SCI, V75, P225, DOI 10.1007/s00018-017-2597-7; Silverman GJ, 2011, ARTHRITIS RHEUM-US, V63, P597, DOI 10.1002/art.30140; Sommer CA, 2009, STEM CELLS, V27, P543, DOI 10.1634/stemcells.2008-1075; URBAN JL, 1988, PROG EXP TUMOR RES, V32, P17; Vo H, 2014, IMMUN INFLAMM DIS, V2, P254, DOI 10.1002/iid3.41; Vollmers H. Peter, 2002, Human Antibodies, V11, P131; Vollmers HP, 2009, NEW BIOTECHNOL, V25, P294, DOI 10.1016/j.nbt.2009.03.016; Vollmers HP, 2005, METHOD FIND EXP CLIN, V27, P185, DOI 10.1358/mf.2005.27.3.890876; Weber GF, 2014, J EXP MED, V211, P1243, DOI 10.1084/jem.20131471; Woo JR, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-30; Wu P, 2013, BIOPHYS J, V104, P1605, DOI 10.1016/j.bpj.2013.01.058; Xiao YP, 2014, J EXP MED, V211, P943, DOI 10.1084/jem.20130790; Yan WL, 2017, IMMUNOTHERAPY-UK, V9, P347, DOI 10.2217/imt-2016-0141; Zhong XM, 2007, EUR J IMMUNOL, V37, P2405, DOI 10.1002/eji.200737461; Zhong XM, 2011, MOL IMMUNOL, V48, P1292, DOI 10.1016/j.molimm.2010.12.006; Zhong XM, 2009, ARTHRITIS RHEUM-US, V60, P3734, DOI 10.1002/art.25015	37	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 23	2021	12								722451	10.3389/fimmu.2021.722451	http://dx.doi.org/10.3389/fimmu.2021.722451			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WE9AG	34630396	Green Published, gold			2022-12-18	WOS:000705909500001
J	Gao, WY; Rui, YJ; Li, GQ; Zhai, CY; Su, JM; Liu, H; Zheng, WW; Zheng, BS; Zhang, WY; Yang, YJ; Hua, SC; Yu, XF				Gao, Wenying; Rui, Yajuan; Li, Guangquan; Zhai, Chenyang; Su, Jiaming; Liu, Han; Zheng, Wenwen; Zheng, Baisong; Zhang, Wenyan; Yang, Yongjun; Hua, Shucheng; Yu, Xiaofang			Specific Deubiquitinating Enzymes Promote Host Restriction Factors Against HIV/SIV Viruses	FRONTIERS IN IMMUNOLOGY			English	Article						USP8; deubiquitinating enzymes; antiviral activity; viral proteins; ubiquitin ligase	HIV-1 VIF; CBF-BETA; INFECTION; PROTEIN; SAMHD1; APOBEC3G; INACTIVATION; RELEASE; COMPLEX	Hijacking host ubiquitin pathways is essential for the replication of diverse viruses. However, the role of deubiquitinating enzymes (DUBs) in the interplay between viruses and the host is poorly characterized. Here, we demonstrate that specific DUBs are potent inhibitors of viral proteins from HIVs/simian immunodeficiency viruses (SIVs) that are involved in viral evasion of host restriction factors and viral replication. In particular, we discovered that T cell-functioning ubiquitin-specific protease 8 (USP8) is a potent and specific inhibitor of HIV-1 virion infectivity factor (Vif)-mediated apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3 (APOBEC3)G (A3G) degradation. Ectopic expression of USP8 inhibited Vif-induced A3G degradation and suppressed wild-type HIV-1 infectivity even in the presence of Vif. In addition, specific DUBs repressed Vpr-, Vpu-, and Vpx-triggered host restriction factor degradation. Our study has revealed a previously unrecognized interplay between the host's DUBs and viral replication. Enhancing the antiviral activity of DUBs therefore represents an attractive strategy against HIVs/SIVs.	[Gao, Wenying; Zhai, Chenyang; Zheng, Baisong; Zhang, Wenyan; Yu, Xiaofang] First Hosp Jilin Univ, Inst Virol & AIDS Res, Ctr Pathogen Biol & Infect Dis, Changchun, Peoples R China; [Rui, Yajuan; Su, Jiaming; Zheng, Wenwen; Yu, Xiaofang] Zhejiang Univ, Key Lab Canc Prevent & Intervent, Sch Med, Affiliated Hosp 2,Canc Inst,Minist Educ, Hangzhou, Peoples R China; [Li, Guangquan] Second Hosp Jilin Univ, Jilin Prov Key Lab Mol & Chem Genet, Changchun, Peoples R China; [Liu, Han; Hua, Shucheng] First Hosp Jilin Univ, Dept Resp Med, Changchun, Peoples R China; [Yang, Yongjun] Jilin Univ, Coll Vet Med, Key Lab Zoonosis, Minist Educ, Changchun, Peoples R China	Jilin University; Zhejiang University; Jilin University; Jilin University; Jilin University	Yu, XF (corresponding author), First Hosp Jilin Univ, Inst Virol & AIDS Res, Ctr Pathogen Biol & Infect Dis, Changchun, Peoples R China.; Yu, XF (corresponding author), Zhejiang Univ, Key Lab Canc Prevent & Intervent, Sch Med, Affiliated Hosp 2,Canc Inst,Minist Educ, Hangzhou, Peoples R China.; Hua, SC (corresponding author), First Hosp Jilin Univ, Dept Resp Med, Changchun, Peoples R China.	shuchenghua@126.com; xfyu1@zju.edu.cn	Rui, Yajuan/HGB-4678-2022		National Natural Science Foundation of China [81772169, 31970151, 31900457, 31900133, 82172239, 82102384, 81701988, 81772757]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	Funding This work was supported in part by funding from the National Natural Science Foundation of China (81772169; 31970151; 31900457; 31900133, 82172239, 82102384, 81701988; 81772757), the Chinese Ministry of Science and Technology (2018ZX10731-101-001-014), and the National Natural Science Foundation of Zhejiang Province (LQ21C010001).	Berndsen CE, 2014, NAT STRUCT MOL BIOL, V21, P301, DOI 10.1038/nsmb.2780; Binka M, 2012, J VIROL, V86, P49, DOI 10.1128/JVI.06082-11; Calistri A, 2014, CELLS-BASEL, V3, P386, DOI 10.3390/cells3020386; Clague MJ, 2013, PHYSIOL REV, V93, P1289, DOI 10.1152/physrev.00002.2013; Decorsiere A, 2016, NATURE, V531, P386, DOI 10.1038/nature17170; Dufner A, 2015, NAT IMMUNOL, V16, P950, DOI 10.1038/ni.3230; Fujita M, 2004, MICROBES INFECT, V6, P791, DOI 10.1016/j.micinf.2004.04.011; Greenwood EJD, 2016, ELIFE, V5, DOI 10.7554/eLife.18296; Guo YY, 2014, NATURE, V505, P229, DOI 10.1038/nature12884; Hache G, 2008, CURR BIOL, V18, P819, DOI 10.1016/j.cub.2008.04.073; Harris RS, 2003, CELL, V113, P803, DOI 10.1016/S0092-8674(03)00423-9; Hrecka K, 2011, NATURE, V474, P658, DOI 10.1038/nature10195; Jager S, 2012, NATURE, V481, P371, DOI 10.1038/nature10693; Kuffour EO, 2018, J VIROL, V92, DOI 10.1128/JVI.00592-18; Laguette N, 2011, NATURE, V474, P654, DOI 10.1038/nature10117; Lahouassa H, 2016, P NATL ACAD SCI USA, V113, P5311, DOI 10.1073/pnas.1600485113; Larue RS, 2010, J VIROL, V84, P8193, DOI 10.1128/JVI.00685-10; Liu BD, 2005, J VIROL, V79, P9579, DOI 10.1128/JVI.79.15.9579-9587.2005; Liu XY, 2016, SIGNAL TRANSDUCT TAR, V1, DOI 10.1038/sigtrans.2016.24; Liu Y, 2019, NAT MICROBIOL, V4, P813, DOI 10.1038/s41564-019-0372-2; Lv MY, 2015, SCI REP-UK, V5, DOI 10.1038/srep11736; Malim MH, 2008, CELL HOST MICROBE, V3, P388, DOI 10.1016/j.chom.2008.04.008; Matheson NJ, 2015, CELL HOST MICROBE, V18, P409, DOI 10.1016/j.chom.2015.09.003; Neil SJD, 2008, NATURE, V451, P425, DOI 10.1038/nature06553; Pan T, 2019, ELIFE, V8, DOI 10.7554/eLife.48318; Perez-Caballero D, 2009, CELL, V139, P499, DOI 10.1016/j.cell.2009.08.039; Reincke M, 2015, NAT GENET, V47, P31, DOI 10.1038/ng.3166; Reyes-Turcu FE, 2009, CHEM REV, V109, P1495, DOI 10.1021/cr800470j; Sahtoe DD, 2015, TRENDS BIOCHEM SCI, V40, P456, DOI 10.1016/j.tibs.2015.05.002; Simon V, 2015, NAT IMMUNOL, V16, P546, DOI 10.1038/ni.3156; Sowa ME, 2009, CELL, V138, P389, DOI 10.1016/j.cell.2009.04.042; Su JM, 2019, NAT MICROBIOL, V4, P2552, DOI 10.1038/s41564-019-0585-4; Swatek KN, 2016, CELL RES, V26, P399, DOI 10.1038/cr.2016.39; Wang H, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0095738, 10.1371/journal.pone.0090153]; Wei W, 2014, J VIROL, V88, P745, DOI 10.1128/JVI.02568-13; Wei W, 2014, J VIROL, V88, P583, DOI 10.1128/JVI.02866-13; Wissing S, 2010, MOL ASPECTS MED, V31, P383, DOI 10.1016/j.mam.2010.06.001; Wu HT, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13644; Yan JP, 2019, P NATL ACAD SCI USA, V116, P9568, DOI 10.1073/pnas.1818401116; Yu XH, 2003, SCIENCE, V302, P1056, DOI 10.1126/science.1089591; Zhang JY, 2014, RETROVIROLOGY, V11, DOI 10.1186/s12977-014-0077-9; Zhang WY, 2014, J VIROL, V88, P12528, DOI 10.1128/JVI.02072-14; Zhang WY, 2012, NATURE, V481, P376, DOI 10.1038/nature10718; Zhang WY, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003963; Zhao K, 2015, CELL CYCLE, V14, P838, DOI 10.1080/15384101.2014.1000212; Zhen AJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038771; Zhen AJ, 2010, J VIROL, V84, P1902, DOI 10.1128/JVI.01509-09	47	0	0	5	16	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 22	2021	12								740713	10.3389/fimmu.2021.740713	http://dx.doi.org/10.3389/fimmu.2021.740713			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WC0CA	34630422	gold, Green Published			2022-12-18	WOS:000703930400001
J	Sefik, E; Hori, S; Vasanthakumar, A				Sefik, Esen; Hori, Shohei; Vasanthakumar, Ajithkumar			Editorial: Regulatory T Cell Heterogeneity: Canonical and Non-Canonical Functions	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						regulatory T cells; Foxp3; tissue homeostasis; autoimmunity; gut immunity	DIFFERENTIATION; ACCUMULATION; BATF		[Sefik, Esen] Yale Univ, Sch Med, Immunobiol, New Haven, CT USA; [Hori, Shohei] Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo, Japan; [Vasanthakumar, Ajithkumar] Peter Doherty Inst Infect & Immun, Dept Microbiol & Immunol, Melbourne, Vic, Australia; [Vasanthakumar, Ajithkumar] Olivia Newton John Canc Res Inst, Canc Immunobiol Program, Melbourne, Vic, Australia	Yale University; University of Tokyo; La Trobe University; Olivia Newton-John Cancer Research Institute	Vasanthakumar, A (corresponding author), Peter Doherty Inst Infect & Immun, Dept Microbiol & Immunol, Melbourne, Vic, Australia.; Vasanthakumar, A (corresponding author), Olivia Newton John Canc Res Inst, Canc Immunobiol Program, Melbourne, Vic, Australia.	ajith.vasanthakumar@onjcri.org.au	Hori, Shohei/O-6163-2019	Hori, Shohei/0000-0001-8770-4593				Burzyn D, 2013, NAT IMMUNOL, V14, P1007, DOI 10.1038/ni.2683; Cipolletta D, 2012, NATURE, V486, P549, DOI 10.1038/nature11132; Hayatsu N, 2017, IMMUNITY, V47, P268, DOI 10.1016/j.immuni.2017.07.008; Josefowicz SZ, 2012, ANNU REV IMMUNOL, V30, P531, DOI 10.1146/annurev.immunol.25.022106.141623; Neumann C, 2019, NAT IMMUNOL, V20, P471, DOI 10.1038/s41590-019-0316-2; Sefik E, 2015, SCIENCE, V349, P993, DOI 10.1126/science.aaa9420; Vasanthakumar A, 2020, NATURE, V579, P581, DOI 10.1038/s41586-020-2040-3; Vasanthakumar A, 2015, TRENDS IMMUNOL, V36, P756, DOI 10.1016/j.it.2015.10.002; Vasanthakumar A, 2015, NAT IMMUNOL, V16, P276, DOI 10.1038/ni.3085; Wing JB, 2019, IMMUNITY, V50, P302, DOI 10.1016/j.immuni.2019.01.020	10	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 22	2021	12								722563	10.3389/fimmu.2021.722563	http://dx.doi.org/10.3389/fimmu.2021.722563			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WC4PB	34630397	Green Published, gold			2022-12-18	WOS:000704239600001
J	Bu, J; Huang, SY; Wang, J; Xia, T; Liu, H; You, Y; Wang, ZH; Liu, K				Bu, Jin; Huang, Shiyuan; Wang, Jue; Xia, Tong; Liu, Hui; You, Ya; Wang, Zhaohui; Liu, Kun			The GABA(A) Receptor Influences Pressure Overload-Induced Heart Failure by Modulating Macrophages in Mice (vol 12, 670153, 2021)	FRONTIERS IN IMMUNOLOGY			English	Correction						GABA(A) receptor; amphiregulin; macrophage; monocyte; pressure-overload hypertrophy			[Bu, Jin] Huazhong Univ Sci & Technol, Union Hosp, Dept Pediat, Tongji Med Coll, Wuhan, Peoples R China; [Huang, Shiyuan; Xia, Tong; Liu, Hui; You, Ya; Wang, Zhaohui] Huazhong Univ Sci & Technol, Union Hosp, Dept Geriatr, Tongji Med Coll, Wuhan, Peoples R China; [Wang, Jue] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Hematol, Tongji Med Coll, Wuhan, Peoples R China; [Liu, Kun] Huazhong Univ Sci & Technol, Inst Cardiol, Union Hosp, Tongji Med Coll, Wuhan, Peoples R China	Huazhong University of Science & Technology; Huazhong University of Science & Technology; Huazhong University of Science & Technology; Huazhong University of Science & Technology	Wang, ZH (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Dept Geriatr, Tongji Med Coll, Wuhan, Peoples R China.; Liu, K (corresponding author), Huazhong Univ Sci & Technol, Inst Cardiol, Union Hosp, Tongji Med Coll, Wuhan, Peoples R China.	zhaohuiwang@hust.edu.cn; liukun@hust.edu.cn						Bu J, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.670153	1	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 21	2021	12								753404	10.3389/fimmu.2021.753404	http://dx.doi.org/10.3389/fimmu.2021.753404			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZM3BY	34621280	Green Published, gold			2022-12-18	WOS:000764238300001
J	Hong, C; Lu, HY; Jin, R; Huang, XH; Chen, M; Dai, XQ; Gong, FY; Dong, HL; Wang, HM; Gao, XM				Hong, Chao; Lu, Hongyun; Jin, Rong; Huang, Xiaohong; Chen, Ming; Dai, Xiaoqiu; Gong, Fangyuan; Dong, Hongliang; Wang, Hongmin; Gao, Xiao-Ming			Cytokine Cocktail Promotes Alveolar Macrophage Reconstitution and Functional Maturation in a Murine Model of Haploidentical Bone Marrow Transplantation	FRONTIERS IN IMMUNOLOGY			English	Article						bone marrow transplantation; immune reconstitution; alveolar macrophage; infection; cytokine	PSEUDOMONAS-AERUGINOSA; CELL TRANSPLANTATION; STREPTOCOCCUS-PNEUMONIAE; PULMONARY COMPLICATIONS; LEGIONELLA-PNEUMOPHILA; NATURAL-RESISTANCE; MYELOID-LEUKEMIA; GM-CSF; INFLUENZA; MONOCYTES	Infectious pneumonia is one of the most common complications after bone marrow transplantation (BMT), which is considered to be associated with poor reconstitution and functional maturation of alveolar macrophages (AMs) post-transplantation. Here, we present evidence showing that lack of IL-13-secreting group 2 innate lymphoid cells (ILC2s) in the lungs may underlay poor AM reconstitution in a mouse model of haploidentical BMT (haplo-BMT). Recombinant murine IL-13 was able to potentiate monocyte-derived AM differentiation in vitro. When intranasally administered, a cocktail of granulocyte-macrophage colony-stimulating factor (GM-CSF), IL-13, and CCL2 not only promoted donor monocyte-derived AM reconstitution in haplo-BMT-recipient mice but also enhanced the innate immunity of the recipient animals against pulmonary bacterial infection. These results provide a useful clue for a clinical strategy to prevent pulmonary bacterial infection at the early stage of recipients post-BMT.	[Hong, Chao; Lu, Hongyun; Jin, Rong; Huang, Xiaohong; Chen, Ming; Dai, Xiaoqiu; Gong, Fangyuan; Dong, Hongliang; Wang, Hongmin; Gao, Xiao-Ming] Soochow Univ, Inst Biol & Med Sci, Suzhou, Peoples R China	Soochow University - China	Hong, C; Gao, XM (corresponding author), Soochow Univ, Inst Biol & Med Sci, Suzhou, Peoples R China.	chaohong@suda.edu.cn; xmgao@suda.edu.cn	dong, hongliang/GWZ-6956-2022	Hong, Chao/0000-0002-3678-4068	National Key Research and Development Program of China [2017YFA0104502]; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)	National Key Research and Development Program of China; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)	This work was supported by grant from the National Key Research and Development Program of China (2017YFA0104502) and Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD).	Abdelaziz MH, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02251-w; Aberdein JD, 2013, CLIN EXP IMMUNOL, V174, P193, DOI 10.1111/cei.12170; Aegerter H, 2020, NAT IMMUNOL, V21, P145, DOI 10.1038/s41590-019-0568-x; Afessa B, 2006, SEMIN RESP CRIT CARE, V27, P297, DOI 10.1055/s-2006-945530; Afessa B, 2012, CHEST, V141, P442, DOI 10.1378/chest.10-2889; Aversa F, 1998, NEW ENGL J MED, V339, P1186, DOI 10.1056/NEJM199810223391702; Bansal S, 2018, J IMMUNOL, V200, P1425, DOI 10.4049/jimmunol.1700210; BECKERS MC, 1995, MAMM GENOME, V6, P540, DOI 10.1007/BF00356173; Bhattacharya J, 2016, SEMIN IMMUNOPATHOL, V38, P461, DOI 10.1007/s00281-016-0569-x; Borie R, 2011, EUR RESPIR REV, V20, P98, DOI 10.1183/09059180.00001311; Cohen M, 2018, CELL, V175, P1031, DOI 10.1016/j.cell.2018.09.009; Coomes SM, 2011, IMMUNOL RES, V50, P78, DOI 10.1007/s12026-010-8200-z; de Kleer IM, 2016, IMMUNITY, V45, P1285, DOI 10.1016/j.immuni.2016.10.031; Dockrell DH, 2003, J IMMUNOL, V171, P5380, DOI 10.4049/jimmunol.171.10.5380; Domingo-Gonzalez R, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00126; Domingo-Gonzalez R, 2013, J IMMUNOL, V190, P5809, DOI 10.4049/jimmunol.1203274; Draijer C, 2019, J IMMUNOL, V202, P2700, DOI 10.4049/jimmunol.1801387; Egawa M, 2013, IMMUNITY, V38, P570, DOI 10.1016/j.immuni.2012.11.014; Espinoza JL, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.02317; Fayard A, 2019, BONE MARROW TRANSPL, V54, P1586, DOI 10.1038/s41409-019-0475-7; Galeas-Pena M, 2019, BIOL CHEM, V400, P443, DOI 10.1515/hsz-2018-0304; Ghoneim HE, 2013, J IMMUNOL, V191, P1250, DOI 10.4049/jimmunol.1300014; Gonzalez-Juarrero M, 2005, J LEUKOCYTE BIOL, V77, P914, DOI 10.1189/jlb.1204723; Grant RA, 2021, NATURE, V590, P635, DOI 10.1038/s41586-020-03148-w; Guilliams M, 2017, NAT REV IMMUNOL, V17, P451, DOI 10.1038/nri.2017.42; Guilliams M, 2013, J EXP MED, V210, P1977, DOI 10.1084/jem.20131199; Hartl D, 2018, J INNATE IMMUN, V10, P487, DOI 10.1159/000487057; Hashimoto D, 2013, IMMUNITY, V38, P792, DOI 10.1016/j.immuni.2013.04.004; Hubbard LLN, 2008, EXP LUNG RES, V34, P263, DOI 10.1080/01902140802022518; Hubbard LLN, 2011, AM J RESP CELL MOL, V45, P1050, DOI 10.1165/rcmb.2011-0079OC; Hubbard LLN, 2010, J IMMUNOL, V184, P6299, DOI 10.4049/jimmunol.0902828; Hussell T, 2014, NAT REV IMMUNOL, V14, P81, DOI 10.1038/nri3600; Kanakry CG, 2016, NAT REV CLIN ONCOL, V13, P10, DOI [10.1038/nrclinonc.2015.128, 10.1038/nrclinonc.2015.234]; Knapp S, 2003, AM J RESP CRIT CARE, V167, P171, DOI 10.1164/rccm.200207-698OC; Kooguchi K, 1998, INFECT IMMUN, V66, P3164, DOI 10.1128/IAI.66.7.3164-3169.1998; Kopf M, 2015, NAT IMMUNOL, V16, P36, DOI 10.1038/ni.3052; LeVine AM, 1999, J CLIN INVEST, V103, P563, DOI 10.1172/JCI5212; Marr KA, 2012, HEMATOL-AM SOC HEMAT, P265, DOI 10.1182/asheducation-2012.1.265; Marriott HM, 2007, EXP LUNG RES, V33, P493, DOI 10.1080/01902140701756562; Maus UA, 2003, J IMMUNOL, V170, P3273, DOI 10.4049/jimmunol.170.6.3273; Maus UA, 2006, AM J RESP CELL MOL, V35, P227, DOI 10.1165/rcmb.2005-0241OC; Monticelli LA, 2011, NAT IMMUNOL, V12, P1045, DOI [10.1031/ni.2131, 10.1038/ni.2131]; Mu J, 2018, J ALLERGY CLIN IMMUN, V141, pAB114, DOI 10.1016/j.jaci.2017.12.363; Nio Y, 2012, DIABETOLOGIA, V55, P3350, DOI 10.1007/s00125-012-2710-2; Passweg JR, 2021, BONE MARROW TRANSPL, V56, P1651, DOI 10.1038/s41409-021-01227-8; Pechous RD, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00160; Piccoli L, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8375; Rashidi A, 2019, BLOOD ADV, V3, P1826, DOI 10.1182/bloodadvances.2019000050; Roy RM, 2012, J IMMUNOL, V189, P2545, DOI 10.4049/jimmunol.1200689; Saluzzo S, 2017, CELL REP, V18, P1893, DOI 10.1016/j.celrep.2017.01.071; Schneider C, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004053; Sestili S, 2018, CANCER-AM CANCER SOC, V124, P2142, DOI 10.1002/cncr.31310; Sharma S, 2005, CHEST, V128, P1385, DOI 10.1378/chest.128.3.1385; Sierra-Filardi E, 2014, J IMMUNOL, V192, P3858, DOI 10.4049/jimmunol.1302821; Sodhi A, 2002, J INTERF CYTOK RES, V22, P517, DOI 10.1089/10799900252981990; Soroosh P, 2013, J EXP MED, V210, P775, DOI 10.1084/jem.20121849; Svedberg FR, 2019, NAT IMMUNOL, V20, P571, DOI 10.1038/s41590-019-0352-y; Symons HJ, 2020, BLOOD ADV, V4, P3913, DOI 10.1182/bloodadvances.2020001648; Szydlo R, 1997, J CLIN ONCOL, V15, P1767, DOI 10.1200/JCO.1997.15.5.1767; Todd EM, 2016, BLOOD, V128, P2785, DOI 10.1182/blood-2016-03-705962; Varvel NH, 2016, P NATL ACAD SCI USA, V113, pE5665, DOI 10.1073/pnas.1604263113; Verma AK, 2020, J IMMUNOL, V205, P1601, DOI 10.4049/jimmunol.2000094; Wang JX, 2015, BLOOD, V125, P2771, DOI 10.1182/blood-2014-09-601674; Wang QW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092053; Watanabe S, 2019, J CLIN INVEST, V129, P2619, DOI 10.1172/JCI124615; Westphalen K, 2014, NATURE, V506, P503, DOI 10.1038/nature12902; Whitsett JA, 2015, NAT IMMUNOL, V16, P27, DOI 10.1038/ni.3045; Xu LP, 2017, BONE MARROW TRANSPL, V52, P1512, DOI 10.1038/bmt.2017.59; Yao YS, 2018, CELL, V175, P1634, DOI 10.1016/j.cell.2018.09.042; YOSHIDA SI, 1991, INFECT IMMUN, V59, P428, DOI 10.1128/IAI.59.1.428-432.1991; Yu XY, 2017, IMMUNITY, V47, P903, DOI 10.1016/j.immuni.2017.10.007	71	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 21	2021	12								719727	10.3389/fimmu.2021.719727	http://dx.doi.org/10.3389/fimmu.2021.719727			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WB3RY	34621268	Green Published, gold			2022-12-18	WOS:000703494100001
J	Wang, HW; Zeng, XM; Lin, J				Wang, Huiwen; Zeng, Ximin; Lin, Jun			Ex Vivo Evaluation of Egg Yolk IgY Degradation in Chicken Gastrointestinal Tract	FRONTIERS IN IMMUNOLOGY			English	Article						egg yolk antibody; passive immunization; IgY stability; chicken gizzard; gastrointestinal digestion	PASSIVE-IMMUNIZATION; IMMUNOGLOBULINS; ANTIBODIES; RELEASE; MICROCAPSULES; PURIFICATION; STABILITY; BROILER; PASSAGE	Egg yolk antibody (immunoglobulin Y, IgY), due to its unique features (e.g., cost-effectiveness for mass production), is emerging as a promising passive immune agent and alternative to antibiotics to combat infectious diseases, particularly in livestock. Oral administration of egg yolk IgY is the most common and convenient route that has been extensively investigated for controlling enteric pathogens. However, the in vivo stability of egg yolk IgY in the gastrointestinal (GI) tract, a critical issue for the success of this approach, still has not been clearly elucidated. Our recent study showed instability of orally administered egg yolk IgY in chicken GI tract, as demonstrated by both in vivo and ex vivo evidence. To better understand the magnitude and dynamics of instability of egg yolk IgY in vivo, in this study, we conducted comprehensive ex vivo analyses by spiking hyperimmune egg yolk IgY in fresh GI contents collected from five broilers at each sampling age (2, 4, or 6 weeks). The pH in gizzard slightly increased with age from 2.4 to 3.0, while the pH in the small intestine was around 5.8. ELISA analysis indicated that a short time of treatment (30 or 60 min) of IgY with the gizzard contents from the chickens at 2, 4, and 6 weeks of age greatly reduced specific IgY titer by over 8, 6, and 5 log(2) units, respectively, when compared with saline control. However, small intestine content only had a mild effect on egg yolk IgY, leading to 1 log(2) unit of reduction in IgY titer upon 30 min of treatment. Consistent with these findings, SDS-PAGE and immunoblotting analyses provided direct evidence demonstrating that egg yolk IgY could be drastically degraded to undetectable level in gizzard content upon as short as 5 min of treatment; however, the IgY was only slightly degraded in small intestine content. Immunoblotting also showed that treatment of IgY with HCl (pH 3.0) for 60 min did not affect its integrity at all, further supporting the enzymatic degradation of IgY in gizzard. Collectively, egg yolk IgY could be substantially degraded in chicken gizzard, highly warranting the development of effective approaches, such as encapsulation, for the controlled release and protection of orally administered egg yolk IgY in livestock.</p>	[Wang, Huiwen; Zeng, Ximin; Lin, Jun] Univ Tennessee, Dept Anim Sci, Knoxville, TN 37901 USA	University of Tennessee System; University of Tennessee Knoxville; UT Institute of Agriculture	Lin, J (corresponding author), Univ Tennessee, Dept Anim Sci, Knoxville, TN 37901 USA.	jlin6@utk.edu			United States Department of Agriculture National Institute of Food and Agriculture (NIFA) [2018-67015-28295]	United States Department of Agriculture National Institute of Food and Agriculture (NIFA)	This study was supported by the United States Department of Agriculture National Institute of Food and Agriculture (NIFA) Award No. 2018-67015-28295.	AKITA EM, 1993, J IMMUNOL METHODS, V160, P207, DOI 10.1016/0022-1759(93)90179-B; ASH RW, 1961, J PHYSIOL-LONDON, V156, P93, DOI 10.1113/jphysiol.1961.sp006660; Beasley DE, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134116; BOHAK Z, 1969, J BIOL CHEM, V244, P4638; Diraviyam T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097716; Ducarmon QR, 2019, MICROBIOL MOL BIOL R, V83, DOI 10.1128/MMBR.00007-19; Gu LP, 2021, FOOD HYDROCOLLOID, V112, DOI 10.1016/j.foodhyd.2020.106349; HATTA H, 1993, BIOSCI BIOTECH BIOCH, V57, P1077, DOI 10.1271/bbb.57.1077; Jaradat ZW, 2000, FOOD AGR IMMUNOL, V12, P263, DOI 10.1080/09540100020008137; Kadhim KK, 2011, AFR J BIOTECHNOL, V10, P108; Kovacs-Nolan J, 2005, J IMMUNOL METHODS, V296, P199, DOI 10.1016/j.jim.2004.11.017; Kovacs-Nolan J, 2012, ANNU REV FOOD SCI T, V3, P163, DOI 10.1146/annurev-food-022811-101137; Li XY, 2007, J AGR FOOD CHEM, V55, P2911, DOI 10.1021/jf062900q; McConnell EL, 2008, J PHARM PHARMACOL, V60, P63, DOI 10.1211/jpp.60.1.0008; Merchant HA, 2011, EUR J PHARM SCI, V42, P3, DOI 10.1016/j.ejps.2010.09.019; Pauly Diana, 2011, J Vis Exp, DOI 10.3791/3084; Pereira EPV, 2019, INT IMMUNOPHARMACOL, V73, P293, DOI 10.1016/j.intimp.2019.05.015; SHIMIZU M, 1992, BIOSCI BIOTECH BIOCH, V56, P270, DOI 10.1271/bbb.56.270; SHIRES A, 1987, POULTRY SCI, V66, P289, DOI 10.3382/ps.0660289; Svihus B, 2014, J APPL POULTRY RES, V23, P306, DOI 10.3382/japr.2014-00937; Van Winden SCL, 2002, J VET MED A, V49, P157, DOI 10.1046/j.1439-0442.2002.00429.x; VANDERKLIS JD, 1990, POULTRY SCI, V69, P2185, DOI 10.3382/ps.0692185; Wang HW, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060569; Wang HW, 2019, APPL ENVIRON MICROB, V85, DOI 10.1128/AEM.00358-19; Wu XZ, 2014, RSC ADV, V4, P14603, DOI 10.1039/c3ra46943c; Xu YP, 2011, BIOTECHNOL ADV, V29, P860, DOI 10.1016/j.biotechadv.2011.07.003; Zeng XM, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.629480	27	0	0	1	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 21	2021	12								746831	10.3389/fimmu.2021.746831	http://dx.doi.org/10.3389/fimmu.2021.746831			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WB3NB	34621278	Green Published, gold			2022-12-18	WOS:000703481300001
J	Chernikov, OV; Moon, JS; Chen, A; Hua, KF				Chernikov, Oleg V.; Moon, Jong-Seok; Chen, Ann; Hua, Kuo-Feng			Editorial: NLRP3 Inflammasome: Regulatory Mechanisms, Role in Health and Disease and Therapeutic Potential	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						NLRP3 inflammasome; inflammatory disease; therapeutic approach; drug target; inflammation			[Chernikov, Oleg V.] Russian Acad Sci, GB Elyakov Pacific Inst Bioorgan Chem, Far Eastern Branch, Vladivostok, Russia; [Moon, Jong-Seok] Soonchunhyang Univ, Soonchunhyang Inst Medi Bio Sci SIMS, Dept Integrated Biomed Sci, Cheonan, South Korea; [Chen, Ann] Triserv Gen Hosp, Dept Pathol, Natl Def Med Ctr, Taipei, Taiwan; [Hua, Kuo-Feng] Natl Ilan Univ, Dept Biotechnol & Anim Sci, Ilan, Taiwan; [Hua, Kuo-Feng] China Med Univ, Dept Med Res, China Med Univ Hosp, Taichung, Taiwan	Elyakov Pacific Institute of Bioorganic Chemistry; Russian Academy of Sciences; Soonchunhyang University; National Defense Medical Center; Tri-Service General Hospital; National Ilan University; China Medical University Taiwan; China Medical University Hospital - Taiwan	Hua, KF (corresponding author), Natl Ilan Univ, Dept Biotechnol & Anim Sci, Ilan, Taiwan.; Hua, KF (corresponding author), China Med Univ, Dept Med Res, China Med Univ Hosp, Taichung, Taiwan.	kuofenghua@gmail.com	Chernikov, Oleg/B-9093-2014	Chernikov, Oleg/0000-0002-3076-3637	Ministry of Science and Technology of Taiwan [MOST 110-2628-B-197-001, MOST 108-2923-B-197-001-MY3, MOST 110-2923-B-197-001-MY3]	Ministry of Science and Technology of Taiwan(Ministry of Science and Technology, Taiwan)	This research work is supported by the funding from the Ministry of Science and Technology of Taiwan (MOST 110-2628-B-197-001; MOST 108-2923-B-197-001-MY3; MOST 110-2923-B-197-001-MY3).		0	0	0	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 20	2021	12								765199	10.3389/fimmu.2021.765199	http://dx.doi.org/10.3389/fimmu.2021.765199			4	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WA8FO	34616411	Green Published, gold			2022-12-18	WOS:000703119400001
J	Cuitavi, J; Lorente, JD; Campos-Jurado, Y; Polache, A; Hipolito, L				Cuitavi, Javier; Lorente, Jesus David; Campos-Jurado, Yolanda; Polache, Ana; Hipolito, Lucia			Neuroimmune and Mu-Opioid Receptor Alterations in the Mesocorticolimbic System in a Sex-Dependent Inflammatory Pain-Induced Alcohol Relapse-Like Rat Model	FRONTIERS IN IMMUNOLOGY			English	Article						mu-opioid receptor; alcohol; pain; alcohol deprivation effect; microglia; neuroinflammation	KAPPA-B; ETHANOL; ACTIVATION; TLR4; NEUROINFLAMMATION; DYSFUNCTIONS; CONSUMPTION; PHENOTYPE; BEHAVIOR; DAMAGE	Evidence concerning the role of alcohol-induced neuroinflammation in alcohol intake and relapse has increased in the last few years. It is also proven that mu-opioid receptors (MORs) mediate the reinforcing properties of alcohol and, interestingly, previous research suggests that neuroinflammation and MORs could be related. Our objective is to study neuroinflammatory states and microglial activation, together with adaptations on MOR expression in the mesocorticolimbic system (MCLS) during the abstinence and relapse phases. To do so, we have used a sex-dependent rat model of complete Freund's adjuvant (CFA)-induced alcohol deprivation effect (ADE). Firstly, our results confirm that only CFA-treated female rats, the only experimental group that showed relapse-like behavior, exhibited specific alterations in the expression of phosphorylated NF kappa B, iNOS, and COX2 in the PFC and VTA. More interestingly, the analysis of the IBA1 expression revealed a decrease of the microglial activation in PFC during abstinence and an increase of its expression in the relapse phase, together with an augmentation of this activation in the NAc in both phases that only occur in female CFA-treated rats. Additionally, the expression of IL1 beta also evidenced these dynamic changes through these two phases following similar expression patterns in both areas. Furthermore, the expression of the cytokine IL10 showed a different profile than that of IL1 beta, indicating anti-inflammatory processes occurring only during abstinence in the PFC of CFA-female rats but neither during the reintroduction phase in PFC nor in the NAc. These data indicate a downregulation of microglial activation and pro-inflammatory processes during abstinence in the PFC, whereas an upregulation can be observed in the NAc during abstinence that is maintained during the reintroduction phase only in CFA-female rats. Secondly, our data reveal a correlation between the alterations observed in IL1 beta, IBA1 levels, and MOR levels in the PFC and NAc of CFA-treated female rats. Although premature, our data suggest that neuroinflammatory processes, together with neural adaptations involving MOR, might play an important role in alcohol relapse in female rats, so further investigations are warranted.	[Cuitavi, Javier; Lorente, Jesus David; Campos-Jurado, Yolanda; Polache, Ana; Hipolito, Lucia] Univ Valencia, Dept Pharm & Pharmaceut Technol & Parasitol, Burjassot, Spain	University of Valencia	Hipolito, L (corresponding author), Univ Valencia, Dept Pharm & Pharmaceut Technol & Parasitol, Burjassot, Spain.	lucia.hipolito@uv.es		Cuitavi, Javier/0000-0003-3418-3135; Lorente, Jesus David/0000-0003-4682-290X	Spanish Ministerio de Ciencia e Innovacion [PID2019-109823RB-I00]; Spanish Ministerio de Sanidad, Delegacion del Gobierno para el Plan Nacional sobre Drogas [PNSD2019I038]; Atraccio de Talent PhD Fellowship from the University of Valencia [UV-INV-PREDOC-1327981]	Spanish Ministerio de Ciencia e Innovacion(Ministry of Science and Innovation, Spain (MICINN)Instituto de Salud Carlos IIISpanish Government); Spanish Ministerio de Sanidad, Delegacion del Gobierno para el Plan Nacional sobre Drogas; Atraccio de Talent PhD Fellowship from the University of Valencia	This study has been supported by Spanish Ministerio de Ciencia e Innovacion PID2019-109823RB-I00 (LH) and by Spanish Ministerio de Sanidad, Delegacion del Gobierno para el Plan Nacional sobre Drogas PNSD2019I038 (LH). JC is supported by a Atraccio de Talent PhD Fellowship from the University of Valencia (UV-INV-PREDOC-1327981).	Agustin-Pavon C, 2016, MOL NEURODEGENER, V11, DOI 10.1186/s13024-016-0128-x; Alfonso-Loeches S, 2016, NEUROCHEM RES, V41, P193, DOI 10.1007/s11064-015-1760-5; Alfonso-Loeches S, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00216; Alfonso-Loeches S, 2013, TOXICOLOGY, V311, P27, DOI 10.1016/j.tox.2013.03.001; Azuma Y, 2002, SCAND J IMMUNOL, V56, P260, DOI 10.1046/j.1365-3083.2002.01128.x; Barton EA, 2017, BRAIN SCI, V7, DOI 10.3390/brainsci7100139; Borner C, 2004, MOL PHARMACOL, V66, P1719, DOI 10.1124/mol.104.003806; Bradley T, 2018, CELL, V175, P387, DOI 10.1016/j.cell.2018.08.064; Byrne LS, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-252; Campos-Jurado Y, 2020, PAIN, V161, P2203, DOI 10.1097/j.pain.0000000000001915; Campos-Jurado Y, 2020, PROG NEURO-PSYCHOPH, V100, DOI 10.1016/j.pnpbp.2020.109875; Cantacorps L, 2017, NEUROPHARMACOLOGY, V123, P368, DOI 10.1016/j.neuropharm.2017.05.034; Carnicella S, 2014, ALCOHOL, V48, P243, DOI 10.1016/j.alcohol.2014.01.006; Castro DC, 2014, PHYSIOL BEHAV, V136, P22, DOI 10.1016/j.physbeh.2014.05.022; Cuitavi J, 2021, TRENDS BIOCHEM SCI, V46, P315, DOI 10.1016/j.tibs.2020.10.002; Drobes DJ, 2003, NEUROPSYCHOPHARMACOL, V28, P755, DOI 10.1038/sj.npp.1300101; Dudek KA, 2020, P NATL ACAD SCI USA, V117, P3326, DOI 10.1073/pnas.1914655117; Duncker Swantje C, 2012, PLoS One, V7, pe39841, DOI 10.1371/journal.pone.0039841; Eisenstein TK, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02904; Ezquer F, 2019, ADDICT BIOL, V24, P994, DOI 10.1111/adb.12675; Ezquer F, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22750-7; Fernandez-Lizarbe S, 2008, MOL IMMUNOL, V45, P2007, DOI 10.1016/j.molimm.2007.10.025; Fitzgerald N, 2016, ADDICTION, V111, P1477, DOI 10.1111/add.13438; Gessi S, 2016, FEBS LETT, V590, P2813, DOI 10.1002/1873-3468.12313; Gianoulakis C, 1998, ALCOHOL HEALTH RES W, V22, P202; Gilpin NW, 2008, ALCOHOL RES HEALTH, V31, P185; Groenendyk J, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34891-w; He J, 2008, EXP NEUROL, V210, P349, DOI 10.1016/j.expneurol.2007.11.017; Hipolito L, 2015, J NEUROSCI, V35, P12217, DOI 10.1523/JNEUROSCI.1053-15.2015; Hoogland ICM, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0332-6; Klawonn AM, 2021, IMMUNITY, V54, P225, DOI 10.1016/j.immuni.2020.12.016; Kraus J, 2003, MOL PHARMACOL, V64, P876, DOI 10.1124/mol.64.4.876; Langsdorf EF, 2011, J NEUROIMMUNOL, V236, P57, DOI 10.1016/j.jneuroim.2011.05.009; Lorente JD, 2022, PAIN, V163, pE137, DOI 10.1097/j.pain.0000000000002332; Lupp A, 2011, REGUL PEPTIDES, V167, P9, DOI 10.1016/j.regpep.2010.09.004; Mayfield J, 2013, CURR OPIN NEUROBIOL, V23, P513, DOI 10.1016/j.conb.2013.01.024; Menard C, 2017, NAT NEUROSCI, V20, P1752, DOI 10.1038/s41593-017-0010-3; Merighi S, 2013, BIOCHEM PHARMACOL, V86, P487, DOI 10.1016/j.bcp.2013.05.027; Mitchell JM, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3002902; Montesinos J, 2018, NEUROSCI LETT, V682, P85, DOI 10.1016/j.neulet.2018.05.049; Montesinos J, 2015, BRAIN BEHAV IMMUN, V45, P233, DOI 10.1016/j.bbi.2014.11.015; Niciu MJ, 2013, CNS DRUGS, V27, P777, DOI 10.1007/s40263-013-0096-4; Nutt DJ, 2010, LANCET, V376, P1558, DOI 10.1016/S0140-6736(10)61462-6; Organization WH, 2019, IGI GLOBAL; Palpacuer C, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001924; Parent AJ, 2012, BEHAV BRAIN RES, V229, P160, DOI 10.1016/j.bbr.2012.01.001; Pascual M, 2007, EUR J NEUROSCI, V25, P541, DOI 10.1111/j.1460-9568.2006.05298.x; Pascual M, 2015, NEUROPHARMACOLOGY, V89, P352, DOI 10.1016/j.neuropharm.2014.10.014; Peana AT, 2017, FRONT BEHAV NEUROSCI, V11, DOI 10.3389/fnbeh.2017.00081; Perry CJ, 2013, BEHAV NEUROSCI, V127, P535, DOI 10.1037/a0032981; Richard JM, 2016, NEUROPHARMACOLOGY, V108, P14, DOI 10.1016/j.neuropharm.2016.04.010; Sanchez-Catalan MJ, 2008, ALCOHOL ALCOHOLISM, V43, P401, DOI 10.1093/alcalc/agn012; Shrivastava P, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0844-3; Siemsen BM, 2021, J NEUROSCI RES, V99, P1922, DOI 10.1002/jnr.24683; Tan YL, 2020, MOL PSYCHIATR, V25, P351, DOI 10.1038/s41380-019-0609-8; Tang Y, 2018, AM J TRANSL RES, V10, P4141; World Health Organization World Health Organization. Ageing and Life Course Unit, 2008, WHO GLOB REP FALLP; Yang BY, 2019, ACTA BIOMATER, V88, P392, DOI 10.1016/j.actbio.2019.02.006; Zhang P, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01455; Zhao Y, 2019, EXP THER MED, V17, P230, DOI 10.3892/etm.2018.6949	60	0	0	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 20	2021	12								689453	10.3389/fimmu.2021.689453	http://dx.doi.org/10.3389/fimmu.2021.689453			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WA7CW	34616393	Green Published, gold			2022-12-18	WOS:000703043100001
J	Khan, AA; Alahmari, AA; Almuzaini, Y; Alamri, F; Alsofayan, YM; Aburas, A; Al-Muhsen, S; Van Kerkhove, M; Yezli, S; Ciottone, GR; Assiri, AM; Jokhdar, HA				Khan, Anas A.; Alahmari, Ahmed A.; Almuzaini, Yasir; Alamri, Fahad; Alsofayan, Yousef Mohammad; Aburas, Alhanouf; Al-Muhsen, Saleh; Van Kerkhove, Maria; Yezli, Saber; Ciottone, Gregory R.; Assiri, Abdullah M.; Jokhdar, Hani A.			Potential Cross-Reactive Immunity to COVID-19 Infection in Individuals With Laboratory-Confirmed MERS-CoV Infection: A National Retrospective Cohort Study From Saudi Arabia	FRONTIERS IN IMMUNOLOGY			English	Article						coronavirus disease 2019; Middle East respiratory syndrome coronavirus; Saudi Arabia; cross-immunity; mortality	CLINICAL CHARACTERISTICS; CORONAVIRUS; PATHOGENESIS; PROTECTION; RESPONSES; RECEPTOR; DISEASE; SARS	Background A growing number of experiments have suggested potential cross-reactive immunity between severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and previous human coronaviruses. We conducted the present retrospective cohort study to investigate the relationship between previous Middle East respiratory syndrome-coronavirus (MERS-CoV) infection and the risk of SARS-CoV-2 infection as well as the relationship between previous MERS-CoV and COVID-19-related hospitalization and mortality. Methods Starting in March 2020, we prospectively followed two groups of individuals who tested negative for COVID-19 infection. The first group had a previously confirmed MERS-CoV infection, which was compared to a control group of MERS-negative individuals. The studied cohort was then followed until November 2020 to track evidence of contracting COVID-19 infection. Findings A total of 82 (24%) MERS-positive and 260 (31%) MERS-negative individuals had COVID-19 infection. Patients in the MERS-positive group had a lower risk of COVID-19 infection than those in the MERS-negative group (Risk ratio [RR] 0.696, 95% confidence interval [CI] 0.522-0.929; p =0.014). The risk of COVID-19-related hospitalization in the MERS-positive group was significantly higher (RR 4.036, 95% CI 1.705-9.555; p =0.002). The case fatality rate (CFR) from COVID-19 was 4.9% in the MERS-positive group and 1.2% in the MERS-negative group (p =0.038). The MERS-positive group had a higher risk of death than the MERS-negative group (RR 6.222, 95% CI 1.342-28.839; p =0.019). However, the risk of mortality was similar between the two groups when death was adjusted for age (p =0.068) and age and sex (p =0.057). After controlling for all the independent variables, only healthcare worker occupation and >1 comorbidity were independent predictors of SARS-CoV-2 infection. Interpretation Individuals with previous MERS-CoV infection can exhibit a cross-reactive immune response to SARS-CoV-2 infection. Our study demonstrated that patients with MERS-CoV infection had higher risks of COVID-19-related hospitalization and death than MERS-negative individuals.	[Khan, Anas A.] King Saud Univ, Dept Emergency Med, Coll Med, Riyadh, Saudi Arabia; [Khan, Anas A.; Alahmari, Ahmed A.; Almuzaini, Yasir; Alamri, Fahad; Alsofayan, Yousef Mohammad; Aburas, Alhanouf; Yezli, Saber] Minist Hlth, Global Ctr Mass Gatherings Med, Riyadh, Saudi Arabia; [Al-Muhsen, Saleh] King Saud Univ, King Saud Univ Med City, Coll Med, Immunol Res Lab,Dept Pediat, Riyadh, Saudi Arabia; [Van Kerkhove, Maria] WHO, Hlth Emergencies Programme, Infect Hazards Management, Geneva, Switzerland; [Ciottone, Gregory R.] Harvard Med Sch, Dept Emergency Med, Boston, MA 02115 USA; [Assiri, Abdullah M.; Jokhdar, Hani A.] Minist Hlth, Deputyship Publ Hlth, Riyadh, Saudi Arabia	King Saud University; Ministry of Health - Saudi Arabia; King Saud University; World Health Organization; Harvard University; Harvard Medical School; Ministry of Health - Saudi Arabia	Alahmari, AA (corresponding author), Minist Hlth, Global Ctr Mass Gatherings Med, Riyadh, Saudi Arabia.	ahalalahmari@moh.gov.sa	assiri, abdullah/AAF-5665-2021; Alamri, Fahad/HDM-6584-2022; Assiri, Abdullah M./GQP-2239-2022	assiri, abdullah/0000-0002-5605-2876; Alamri, Fahad/0000-0002-7336-162X; CIOTTONE, MD, GREGORY R/0000-0002-3313-1379; Alsofayan, Yousef M./0000-0001-7028-7930				Al Maani A, 2021, J INFECTION, V82, pE28, DOI 10.1016/j.jinf.2020.11.035; Ali S, 2020, PAK J MED SCI, V36, pS99, DOI 10.12669/pjms.36.COVID19-S4.2790; Alshukairi AN, 2021, EMERG INFECT DIS, V27, P1472, DOI 10.3201/eid2705.204056; [Anonymous], 2020, NEW ENGL J MED, DOI DOI 10.1056/NEJMC2005203; Ansariniya H, 2021, BIOMED RES INT, V2021, DOI 10.1155/2021/8870425; Assiri A, 2013, LANCET INFECT DIS, V13, P752, DOI 10.1016/S1473-3099(13)70204-4; Barnes CO, 2020, NATURE, V588, P682, DOI 10.1038/s41586-020-2852-1; Barry M, 2020, J EPIDEMIOL GLOB HEA, V10, P214, DOI 10.2991/jegh.k.200806.002; Barth RE, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1724; Bastard P, 2020, SCIENCE, V370, P423, DOI 10.1126/science.abd4585; Channappanavar R, 2014, J VIROL, V88, P11034, DOI 10.1128/JVI.01505-14; Channappanavar R, 2014, IMMUNOL RES, V59, P118, DOI 10.1007/s12026-014-8534-z; Chaussabel D, 2010, BMC BIOL, V8, DOI 10.1186/1741-7007-8-84; Chen P, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000020308; Chowdhury MA, 2020, J INFECT PUBLIC HEAL, V13, P1619, DOI 10.1016/j.jiph.2020.07.001; Dan JM, 2021, SCIENCE, V371, P587, DOI 10.1126/science.abf4063; Dean AG, 2013, OPENEPI OPEN SOURCE; Fan YY, 2009, ARCH VIROL, V154, P1093, DOI 10.1007/s00705-009-0409-6; Fehr AR, 2017, ANNU REV MED, V68, P387, DOI 10.1146/annurev-med-051215-031152; Forni G, 2021, CELL DEATH DIFFER, V28, P626, DOI 10.1038/s41418-020-00720-9; Gallais F, 2021, EMERG INFECT DIS, V27, P113, DOI 10.3201/eid2701.203611; Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015; Grifoni A, 2020, CELL HOST MICROBE, V27, P671, DOI 10.1016/j.chom.2020.03.002; Horns F, 2020, CELL REP, V30, P905, DOI 10.1016/j.celrep.2019.12.063; Huang AT, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18450-4; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; Kamepalli M, 2020, U LOUISVILLE J RESP, V4, DOI [10.18297/jri/vol4/iss1/7, DOI 10.18297/JRI/VOL4/ISS1/7]; Kim YS, 2021, CLIN INFECT DIS, V73, pE550, DOI 10.1093/cid/ciaa1345; Lau SKP, 2013, J GEN VIROL, V94, P2679, DOI 10.1099/vir.0.055533-0; Li G, 2020, J MED VIROL, V92, P424, DOI 10.1002/jmv.25685; Li XW, 2020, J PHARM ANAL, V10, P102, DOI 10.1016/j.jpha.2020.03.001; Liang YW, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01022; Liu W, 2006, J INFECT DIS, V193, P792, DOI 10.1086/500469; MOH, 2020, COVID 19 DASHB SAUD; PAHO-WHO, 2020, REH CONS COVID 19 OU, P1; Patel MM, 2020, JAMA-J AM MED ASSOC, V324, P1781, DOI 10.1001/jama.2020.18796; Payne S, 2017, VIRUSES: FROM UNDERSTANDING TO INVESTIGATION, P149, DOI 10.1016/B978-0-12-803109-4.00017-9; Reche PA, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.586984; Rockx B, 2020, SCIENCE, V368, P1012, DOI 10.1126/science.abb7314; Sariol A, 2020, IMMUNITY, V53, P248, DOI 10.1016/j.immuni.2020.07.005; SARS Team and Executive Committee Council of State and Territorial Epidemiologists SARS Investigative Team CDC, 2003, REV US SURV CAS DEF; Sekine T, 2020, CELL, V183, P158, DOI 10.1016/j.cell.2020.08.017; Shah VK, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01949; Situation, 2020, 82 WHO; Sofi Mohd Sharjeel, 2020, Biosaf Health, V2, P217, DOI 10.1016/j.bsheal.2020.11.002; Su S, 2016, TRENDS MICROBIOL, V24, P490, DOI 10.1016/j.tim.2016.03.003; Sui JH, 2004, P NATL ACAD SCI USA, V101, P2536, DOI 10.1073/pnas.0307140101; Sun PF, 2020, J MED VIROL, V92, P548, DOI 10.1002/jmv.25722; Tan MK, 2020, IMMUNOLOGY, V160, P261, DOI 10.1111/imm.13223; Tian SF, 2020, J THORAC ONCOL, V15, P700, DOI 10.1016/j.jtho.2020.02.010; Vabret N, 2020, IMMUNITY, V52, P910, DOI 10.1016/j.immuni.2020.05.002; Verity R, 2020, LANCET INFECT DIS, V20, P669, DOI 10.1016/S1473-3099(20)30243-7; von Elm E, 2007, PREV MED, V45, P247, DOI 10.1016/j.ypmed.2007.08.012; Weisblum Yiska, 2020, bioRxiv, DOI 10.1101/2020.07.21.214759; WHO EMRO, 2019, MERS OUTBR MERS COV; World Health Organization, 2019, ICD 10 VERS; World Med Assoc, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI 10.1001/jama.2013.281053; Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648; Yaqinuddin A, 2020, MED HYPOTHESES, V144, DOI 10.1016/j.mehy.2020.110049; Ying TL, 2016, J INFECT DIS, V213, P877, DOI 10.1093/infdis/jiv381; Zhang Q, 2020, SCIENCE, V370, DOI 10.1126/science.abd4570; Zhang YY, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.02033; Zhao JC, 2010, J VIROL, V84, P9318, DOI 10.1128/JVI.01049-10; Zhao Yu, 2020, American Journal of Respiratory and Critical Care Medicine, V202, P756, DOI 10.1164/rccm.202001-0179LE	65	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 17	2021	12								727989	10.3389/fimmu.2021.727989	http://dx.doi.org/10.3389/fimmu.2021.727989			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WV8CE	34603300	gold, Green Published			2022-12-18	WOS:000717457500001
J	Kwarteng, A; Asiedu, E; Koranteng, KK; Asiedu, SO				Kwarteng, Alexander; Asiedu, Ebenezer; Koranteng, Kelvin Kwaku; Asiedu, Samuel Opoku			Highlighting the Relevance of CD8(+) T Cells in Filarial Infections	FRONTIERS IN IMMUNOLOGY			English	Review						anti-filarial immunity; T cell; CD8(+); filarial co-infections; filarial pathology	WUCHERERIA-BANCROFTI; BRUGIA-MALAYI; ONCHOCERCA-VOLVULUS; LYMPHATIC FILARIASIS; IMMUNE-RESPONSE; MYCOBACTERIUM-TUBERCULOSIS; NEUTROPHIL RECRUITMENT; OCULAR ONCHOCERCIASIS; HELMINTH INFECTION; DENDRITIC CELLS	The T cell immune responses in filarial infections are primarily mediated by CD4(+) T cells and type 2-associated cytokines. Emerging evidence indicates that CD8(+) T cell responses are important for anti-filarial immunity, however, could be suppressed in co-infections. This review summarizes what we know so far about the activities of CD8(+) T cell responses in filarial infections, co-infections, and the associations with the development of filarial pathologies.	[Kwarteng, Alexander; Koranteng, Kelvin Kwaku] Kwame Nkrumah Univ Sci & Technol KNUST, Dept Biochem & Biotechnol, Kumasi, Ghana; [Kwarteng, Alexander; Asiedu, Ebenezer; Asiedu, Samuel Opoku] Kumasi Ctr Collaborat Res Trop Med KCCR, Kumasi, Ghana; [Asiedu, Samuel Opoku] Kwame Nkrumah Univ Sci & Technol KNUST, Dept Theoret & Appl Biol, Kumasi, Ghana	Kwame Nkrumah University Science & Technology; Kumasi Center for Collaborative Research; Kwame Nkrumah University Science & Technology	Kwarteng, A (corresponding author), Kwame Nkrumah Univ Sci & Technol KNUST, Dept Biochem & Biotechnol, Kumasi, Ghana.; Kwarteng, A (corresponding author), Kumasi Ctr Collaborat Res Trop Med KCCR, Kumasi, Ghana.	akwarteng@knust.edu.gh		ASIEDU, EBENEZER/0000-0003-2867-1984				ACTOR JK, 1993, P NATL ACAD SCI USA, V90, P948, DOI 10.1073/pnas.90.3.948; Aliota MT, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0000963; Allen JE, 2001, PARASITE IMMUNOL, V23, P345, DOI 10.1046/j.1365-3024.2001.00394.x; Anand SB, 2011, J HELMINTHOL, V85, P442, DOI 10.1017/S0022149X10000799; Anugraha G, 2015, SCAND J IMMUNOL, V82, P380, DOI 10.1111/sji.12340; Anuradha R, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002762; Anuradha R, 2014, CLIN VACCINE IMMUNOL, V21, P1620, DOI 10.1128/CVI.00598-14; Babayan SA, 2012, PARASITE IMMUNOL, V34, P243, DOI 10.1111/j.1365-3024.2011.01350.x; Babu S, 2014, PARASITE IMMUNOL, V36, P338, DOI 10.1111/pim.12081; Babu S, 2003, J IMMUNOL, V171, P6723, DOI 10.4049/jimmunol.171.12.6723; Babu S, 1999, INFECT IMMUN, V67, P3166, DOI 10.1128/IAI.67.6.3166-3167.1999; Belnoue E, 2002, J IMMUNOL, V169, P6369, DOI 10.4049/jimmunol.169.11.6369; BONE RC, 1992, CHEST, V101, P1481, DOI 10.1378/chest.101.6.1481; Buerfent BC, 2015, IMMUNOLOGY, V145, P150, DOI 10.1111/imm.12435; CHAN CC, 1989, CLIN EXP IMMUNOL, V77, P367; Chatterjee S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094603; Chauhan N, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01520; Chauhan N, 2017, PARASITOL RES, V116, P2821, DOI 10.1007/s00436-017-5593-9; Cho-Ngwa F, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000800; Daehnel K, 2007, PARASITE IMMUNOL, V29, P455, DOI 10.1111/j.1365-3024.2007.00962.x; Dakshinamoorthy G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112982; Dakshinamoorthy G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077394; Dakshinamoorthy G, 2013, VACCINE, V31, P1616, DOI 10.1016/j.vaccine.2012.09.055; Debrah LB, 2019, AM J TROP MED HYG, V101, P84, DOI 10.4269/ajtmh.18-0491; Dennis VA, 1997, PARASITE IMMUNOL, V19, P301, DOI 10.1046/j.1365-3024.1997.d01-212.x; Dietze KK, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005170; Dittrich AM, 2008, J IMMUNOL, V180, P1792, DOI 10.4049/jimmunol.180.3.1792; FOLKARD SG, 1995, PARASITE IMMUNOL, V17, P541, DOI 10.1111/j.1365-3024.1995.tb00885.x; Gangwar M, 2019, VACCINE, V37, P571, DOI 10.1016/j.vaccine.2018.12.015; Gentil K, 2009, INFECT IMMUN, V77, P1606, DOI 10.1128/IAI.00671-08; George PJ, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004375; Ghosh RP, 1999, J PARASITOL, V85, P861, DOI 10.2307/3285822; Gillette-Ferguson I, 2006, INFECT IMMUN, V74, P2442, DOI 10.1128/IAI.74.4.2442-2445.2006; Gillette-Ferguson I, 2007, INFECT IMMUN, V75, P5908, DOI 10.1128/IAI.00991-07; Gopinath R, 2000, J INFECT DIS, V182, P1804, DOI 10.1086/317623; Graham AL, 2005, J INFECT DIS, V191, P410, DOI 10.1086/426871; Gupta J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142548; Hartmann W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068380; Hartmann W, 2011, J IMMUNOL, V186, P2472, DOI 10.4049/jimmunol.0902157; Herricks JR, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005424; Hise AG, 2007, J IMMUNOL, V178, P1068, DOI 10.4049/jimmunol.178.2.1068; Hoerauf A, 2008, MED MICROBIOL IMMUN, V197, P295, DOI 10.1007/s00430-007-0062-1; Hotchkiss RS, 2010, NEW ENGL J MED, V363, P87, DOI 10.1056/NEJMcibr1004371; Hubner MP, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001970; Ichimori K, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003328; Kaech SM, 2012, NAT REV IMMUNOL, V12, P749, DOI 10.1038/nri3307; Kalinkovich A, 1998, CLIN EXP IMMUNOL, V114, P414; Kalyanasundaram R, 2020, TRENDS PARASITOL, V36, P195, DOI 10.1016/j.pt.2019.11.005; Kalyanasundaram R, 2011, RES REP TROP MED, V2, P45, DOI 10.2147/RRTM.S13679; Khatri V, 2018, INT J PARASITOL, V48, P773, DOI 10.1016/j.ijpara.2018.04.002; KING CL, 1992, J CLIN INVEST, V89, P1403, DOI 10.1172/JCI115729; KING CL, 1993, J CLIN INVEST, V92, P1667, DOI 10.1172/JCI116752; Kolbaum J, 2012, EUR J IMMUNOL, V42, P890, DOI 10.1002/eji.201141955; Kroidl I, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007623; Kushwaha S, 2012, MICROBES INFECT, V14, P1330, DOI 10.1016/j.micinf.2012.08.006; Kushwaha V, 2014, VACCINE, V32, P1693, DOI 10.1016/j.vaccine.2014.01.064; Kwarteng A, 2021, INT J PEPT RES THER, V27, P1953, DOI 10.1007/s10989-021-10224-w; Lagatie O, 2018, PARASITE IMMUNOL, V40, DOI 10.1111/pim.12587; LAL RB, 1989, CLIN EXP IMMUNOL, V77, P77; LAL RB, 1990, IMMUNOL LETT, V26, P85, DOI 10.1016/0165-2478(90)90180-X; Lei Y, 2019, PEERJ, V6, DOI 10.7717/peerj.6185; Levy MM, 2003, CRIT CARE MED, V31, P1250, DOI 10.1097/01.CCM.0000050454.01978.3B; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; Maizels RM, 2004, IMMUNOL REV, V201, P89, DOI 10.1111/j.0105-2896.2004.00191.x; Maizels RM, 2003, NAT REV IMMUNOL, V3, P733, DOI 10.1038/nri1183; McKechnie NM, 2002, INVEST OPHTH VIS SCI, V43, P411; Metenou S, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00305; Metenou S, 2012, CURR OPIN HIV AIDS, V7, P231, DOI 10.1097/COH.0b013e3283522c3d; Morris CP, 2013, CLIN MICROBIOL REV, V26, P381, DOI 10.1128/CMR.00002-13; Mouser EEIM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146527; Mueller S.N., 2008, CLIN IMMUNOL; Mukherjee S, 2019, COMMUN BIOL, V2, DOI 10.1038/s42003-019-0392-8; Mukherjee S, 2017, J INFECT DIS, V215, P954, DOI 10.1093/infdis/jix067; Mukhopadhyay S, 2002, J IMMUNOL, V168, P2914, DOI 10.4049/jimmunol.168.6.2914; NELSON FK, 1991, J EXP MED, V173, P659, DOI 10.1084/jem.173.3.659; Nielsen NO, 2007, T ROY SOC TROP MED H, V101, P602, DOI 10.1016/j.trstmh.2007.02.009; Numasaki M, 2004, IMMUNOL LETT, V93, P39, DOI 10.1016/j.imlet.2004.01.014; Nutman TB, 2015, PARASITE IMMUNOL, V37, P304, DOI 10.1111/pim.12194; Nutman TB, 2001, PARASITE IMMUNOL, V23, P389, DOI 10.1046/j.1365-3024.2001.00399.x; O'Garra A, 2013, ANNU REV IMMUNOL, V31, P475, DOI 10.1146/annurev-immunol-032712-095939; Osborne LC, 2014, SCIENCE, V345, P578, DOI 10.1126/science.1256942; Pathak M, 2016, IMMUNOLOGY, V147, P190, DOI 10.1111/imm.12550; Pathak M, 2015, IMMUNOLOGY, V144, P231, DOI 10.1111/imm.12364; Paul R, 2018, PREP BIOCHEM BIOTECH, V48, P823, DOI 10.1080/10826068.2018.1514511; Rajan ATV., 1992, CD8 T LYMPHOCYTES AR; Reimer LJ, 2013, NEW ENGL J MED, V369, P745, DOI 10.1056/NEJMoa1207594; Roger PM, 2009, EUR J CLIN MICROBIOL, V28, P575, DOI 10.1007/s10096-008-0673-5; Salgame P, 2005, CURR OPIN IMMUNOL, V17, P374, DOI 10.1016/j.coi.2005.06.006; Salti SM, 2011, J IMMUNOL, V187, P6301, DOI 10.4049/jimmunol.1100891; Schwandt T, 2012, EMBO J, V31, P201, DOI 10.1038/emboj.2011.380; Shey RA, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-40833-x; Singh PK, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/590281; Specht S, 2004, INFECT IMMUN, V72, P6287, DOI 10.1128/IAI.72.11.6287-6293.2004; Specht S, 2010, MICROBES INFECT, V12, P635, DOI 10.1016/j.micinf.2010.04.006; Steel C, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001527; Stephen-Victor E, 2017, J INFECT DIS, V216, P1281, DOI 10.1093/infdis/jix469; Taylor MJ, 2010, LANCET, V376, P1175, DOI 10.1016/S0140-6736(10)60586-7; Verma SK, 2017, VACCINE, V35, P5201, DOI 10.1016/j.vaccine.2017.07.105; Wammes LJ, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001655; Wynn TA, 2007, J CLIN INVEST, V117, P524, DOI 10.1172/JCI31487; Yamamoto N, 2004, CLIN EXP IMMUNOL, V137, P601, DOI 10.1111/j.1365-2249.2004.02576.x; Zaccone P, 2013, CURR OPIN IMMUNOL, V25, P418, DOI 10.1016/j.coi.2013.02.006	102	0	0	3	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 16	2021	12								714052	10.3389/fimmu.2021.714052	http://dx.doi.org/10.3389/fimmu.2021.714052			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UZ1ZB	34603287	Green Published, gold			2022-12-18	WOS:000702008600001
J	Liu, HH; Yu, ZY; Tang, B; Miao, SC; Qin, CC; Li, Y; Liang, ZY; Shi, YJ; Zhang, Y; Wang, QY; Yan, M; Song, ZY; Ren, HY; Dong, YJ				Liu, Huihui; Yu, Zhengyu; Tang, Bo; Miao, Shengchao; Qin, Chenchen; Li, Yuan; Liang, Zeyin; Shi, Yongjin; Zhang, Yang; Wang, Qingya; Yan, Miao; Song, Zhengyang; Ren, Hanyun; Dong, Yujun			LYG1 Deficiency Attenuates the Severity of Acute Graft-Versus-Host Disease via Skewing Allogeneic T Cells Polarization Towards Treg Cells (vol 12, 647894, 2021)	FRONTIERS IN IMMUNOLOGY			English	Correction						LYG1; aGVHD; allogeneic CD4+T cells; alloreactivity; Th1 cells; Treg cells			[Liu, Huihui; Yu, Zhengyu; Tang, Bo; Miao, Shengchao; Qin, Chenchen; Li, Yuan; Liang, Zeyin; Shi, Yongjin; Zhang, Yang; Wang, Qingya; Yan, Miao; Song, Zhengyang; Ren, Hanyun; Dong, Yujun] Peking Univ First Hosp, Dept Hematol, Beijing, Peoples R China	Peking University	Ren, HY; Dong, YJ (corresponding author), Peking Univ First Hosp, Dept Hematol, Beijing, Peoples R China.	renhy0813@163.com; dongy@hsc.pku.edu.cn						Liu HH, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.647894	1	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 16	2021	12								762728	10.3389/fimmu.2021.762728	http://dx.doi.org/10.3389/fimmu.2021.762728			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZM3BU	34603343	Green Published, gold			2022-12-18	WOS:000764237900001
J	Uetz-Von Allmen, E; Samson, GPB; Purvanov, V; Maeda, T; Legler, DF				Uetz-von Allmen, Edith; Samson, Guerric P. B.; Purvanov, Vladimir; Maeda, Takahiro; Legler, Daniel F.			CAL-1 as Cellular Model System to Study CCR7-Guided Human Dendritic Cell Migration	FRONTIERS IN IMMUNOLOGY			English	Article						human dendritic cell line; cell migration; chemokine receptor CCR7; CCL19; CCL21; chemotaxis; expression of fluorescent reporter proteins; CRISPR; Cas9 mediated CCR7 knockout	PROSTAGLANDIN E-2; SIGNALING PATHWAYS; ANTIGEN; CCL21; PROLIFERATION; EXPRESSION; STATE; LINES	Dendritic cells (DCs) are potent and versatile professional antigen-presenting cells and central for the induction of adaptive immunity. The ability to migrate and transport peripherally acquired antigens to draining lymph nodes for subsequent cognate T cell priming is a key feature of DCs. Consequently, DC-based immunotherapies are used to elicit tumor-antigen specific T cell responses in cancer patients. Understanding chemokine-guided DC migration is critical to explore DCs as cellular vaccines for immunotherapeutic approaches. Currently, research is hampered by the lack of appropriate human cellular model systems to effectively study spatio-temporal signaling and CCR7-driven migration of human DCs. Here, we report that the previously established human neoplastic cell line CAL-1 expresses the human DC surface antigens CD11c and HLA-DR together with co-stimulatory molecules. Importantly, if exposed for three days to GM-CSF, CAL-1 cells induce the endogenous expression of the chemokine receptor CCR7 upon encountering the clinically approved TLR7/8 agonist Resiquimod R848 and readily migrate along chemokine gradients. Further, we demonstrate that CAL-1 cells can be genetically modified to express fluorescent (GFP)-tagged reporter proteins to study and visualize signaling or can be gene-edited using CRISPR/Cas9. Hence, we herein present the human CAL-1 cell line as versatile and valuable cellular model system to effectively study human DC migration and signaling.	[Uetz-von Allmen, Edith; Samson, Guerric P. B.; Purvanov, Vladimir; Legler, Daniel F.] Univ Konstanz, Biotechnol Inst Thurgau BITg, Kreuzlingen, Switzerland; [Samson, Guerric P. B.] Univ Bern, Grad Sch Cellular & Biomed Sci GCB, Bern, Switzerland; [Maeda, Takahiro] Nagasaki Univ, Grad Sch Biomed Sci, Dept Lab Med, Nagasaki, Japan; [Legler, Daniel F.] Univ Bern, Theodor Kocher Inst, Bern, Switzerland; [Legler, Daniel F.] Univ Konstanz, Dept Biol, Constance, Germany	University of Bern; Nagasaki University; University of Bern; University of Konstanz	Legler, DF (corresponding author), Univ Konstanz, Biotechnol Inst Thurgau BITg, Kreuzlingen, Switzerland.; Legler, DF (corresponding author), Univ Bern, Theodor Kocher Inst, Bern, Switzerland.; Legler, DF (corresponding author), Univ Konstanz, Dept Biol, Constance, Germany.	daniel.legler@bitg.ch		Samson, Guerric/0000-0002-4505-6409; Legler, Daniel F./0000-0001-8610-4764	Swiss National Science Foundation	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission)	This study was supported in parts by research funding from the Swiss National Science Foundation (grant number 310030_189144), the Thurgauische Stiftung fur Wissenschaft und Forschung, and the State Secretariat for Education, Research and Innovation to DFL.	Artinger M, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22084158; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Bol KF, 2016, CLIN CANCER RES, V22, P1897, DOI 10.1158/1078-0432.CCR-15-1399; Bryant CE, 2019, SEMIN CELL DEV BIOL, V86, P77, DOI 10.1016/j.semcdb.2018.02.015; Cabeza-Cabrerizo M, 2021, ANNU REV IMMUNOL, V39, P131, DOI 10.1146/annurev-immunol-061020-053707; Carlsen HS, 2005, BLOOD, V106, P444, DOI 10.1182/blood-2004-11-4353; Cuesta-Mateos C, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.662866; Dallari S, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14830; Griffith JW, 2014, ANNU REV IMMUNOL, V32, P659, DOI 10.1146/annurev-immunol-032713-120145; Guermonprez P, 2002, ANNU REV IMMUNOL, V20, P621, DOI 10.1146/annurev.immunol.20.100301.064828; Hammerschmidt SI, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01949; Hauser MA, 2016, J LEUKOCYTE BIOL, V99, P993, DOI 10.1189/jlb.2VMA0915-432RR; Hauser MA, 2016, J LEUKOCYTE BIOL, V99, P869, DOI 10.1189/jlb.2MR0815-380R; Hauser MA, 2016, IMMUNITY, V44, P59, DOI 10.1016/j.immuni.2015.12.010; Helft J, 2015, IMMUNITY, V42, P1197, DOI 10.1016/j.immuni.2015.05.018; Jorgensen AS, 2018, J LEUKOCYTE BIOL, V104, P401, DOI 10.1002/JLB.2VMA0118-008R; Karrich JJ, 2012, BLOOD, V119, P5191, DOI 10.1182/blood-2011-07-370239; Krause P, 2007, J LEUKOCYTE BIOL, V82, P1106, DOI 10.1189/jlb.0905519; Krause P, 2009, BLOOD, V113, P2451, DOI 10.1182/blood-2008-05-157123; Laufer JM, 2019, CELL REP, V29, P995, DOI 10.1016/j.celrep.2019.09.031; Laufer JM, 2019, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03115; Legler Daniel F, 2018, F1000Res, V7, P95, DOI 10.12688/f1000research.13130.1; Legler DF, 2006, J IMMUNOL, V176, P966, DOI 10.4049/jimmunol.176.2.966; Leithner A, 2018, EUR J IMMUNOL, V48, P1074, DOI 10.1002/eji.201747358; Lutz MB, 2016, IMMUNITY, V44, P1, DOI 10.1016/j.immuni.2015.12.013; Lutz MB, 2002, TRENDS IMMUNOL, V23, P445, DOI 10.1016/S1471-4906(02)02281-0; MacDonald KPA, 2002, BLOOD, V100, P4512, DOI 10.1182/blood-2001-11-0097; Maeda T, 2005, INT J HEMATOL, V81, P148, DOI 10.1532/IJH97.04116; Mathas S, 2002, EMBO J, V21, P4104, DOI 10.1093/emboj/cdf389; Matti C, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00720; Mellman I, 2001, CELL, V106, P255, DOI 10.1016/S0092-8674(01)00449-4; Merad M, 2013, ANNU REV IMMUNOL, V31, P563, DOI 10.1146/annurev-immunol-020711-074950; Miura R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154094; Murphy TL, 2016, ANNU REV IMMUNOL, V34, P93, DOI 10.1146/annurev-immunol-032713-120204; Ogilvie P, 2004, J IMMUNOL, V172, P6715, DOI 10.4049/jimmunol.172.11.6715; Palucka K, 2013, IMMUNITY, V39, P38, DOI 10.1016/j.immuni.2013.07.004; Purvanov V, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19123876; Redecke V, 2013, NAT METHODS, V10, P795, DOI [10.1038/NMETH.2510, 10.1038/nmeth.2510]; Saez PJ, 2018, CURR OPIN IMMUNOL, V52, P74, DOI 10.1016/j.coi.2018.04.005; Sallusto F, 1998, EUR J IMMUNOL, V28, P2760, DOI 10.1002/(SICI)1521-4141(199809)28:09<2760::AID-IMMU2760>3.0.CO;2-N; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Sapienza MR, 2019, CANCERS, V11, DOI 10.3390/cancers11050595; Scandella E, 2004, BLOOD, V103, P1595, DOI 10.1182/blood-2003-05-1643; Schaeuble K, 2011, J IMMUNOL, V187, P5645, DOI 10.4049/jimmunol.1101850; Uetz-von Allmen E, 2018, J LEUKOCYTE BIOL, V104, P375, DOI 10.1002/JLB.2VMA1217-492R; Ulvmar MH, 2014, NAT IMMUNOL, V15, P623, DOI 10.1038/ni.2889; van Helden SFG, 2008, IMMUNOL LETT, V117, P191, DOI 10.1016/j.imlet.2008.02.003; Varnai P, 1998, J CELL BIOL, V143, P501, DOI 10.1083/jcb.143.2.501; Weber M, 2013, SCIENCE, V339, P328, DOI 10.1126/science.1228456; Worbs T, 2017, NAT REV IMMUNOL, V17, P30, DOI 10.1038/nri.2016.116	50	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 16	2021	12								702453	10.3389/fimmu.2021.702453	http://dx.doi.org/10.3389/fimmu.2021.702453			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WV6VM	34603281	gold, Green Published			2022-12-18	WOS:000717372200001
J	Wei, J				Wei, Jie			Commentary: Chemokines in Prediabetes and Type 2 Diabetes: A Meta-Analysis	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						letter; chemokines; prediabetes; diabetes; meta			[Wei, Jie] Peoples Hosp Baise, Dept Hematol, Baise, Peoples R China		Wei, J (corresponding author), Peoples Hosp Baise, Dept Hematol, Baise, Peoples R China.	Weijie20212021@126.com			Department of Hematology, People's Hospital of Baise, Baise, China	Department of Hematology, People's Hospital of Baise, Baise, China	Department of Hematology, People's Hospital of Baise, Baise, China.	Pan XF, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.622438; Sindhu S, 2017, J DIABETES METAB DIS, V16, DOI 10.1186/s40200-017-0297-3; Sindhu S, 2016, BMC IMMUNOL, V17, DOI 10.1186/s12865-016-0171-y	3	0	0	4	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 16	2021	12								729702	10.3389/fimmu.2021.729702	http://dx.doi.org/10.3389/fimmu.2021.729702			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UZ3VP	34603304	gold, Green Published			2022-12-18	WOS:000702136500001
J	Duthie, MSS; Goto, Y				Duthie, Malcolm S. S.; Goto, Yasuyuki			Editorial: Emerging Concepts of Innate Immune Responses to Neglected Tropical Diseases	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						innate; infection; skin; spleen; neglected tropical disease (NTD); lymph node			[Duthie, Malcolm S. S.] HDT Bio, Res & Dev, Seattle, WA 98102 USA; [Goto, Yasuyuki] Univ Tokyo, Grad Sch Agr & Life Sci, Dept Anim Resource Sci, Tokyo, Japan	University of Tokyo	Duthie, MSS (corresponding author), HDT Bio, Res & Dev, Seattle, WA 98102 USA.	malcolm.duthie@hdt.bio	Goto, Yasuyuki/E-9028-2011	Goto, Yasuyuki/0000-0002-8654-7888	Global Health Innovative Technology Fund [G2018111]; CRDF Global [62966]; National Institute of Allergy and Infectious Diseases of the National Institutes of Health [R01AI025038, R21AI144641]; Bill and Melinda Gates Foundation [631, 39129]; American Leprosy Missions, Leprosy Research Initiative; Japanese Society for the Promotion of Science [18H02649, 20K21516]; Japan Agency for Medical Research and Development grant for Translational Research Network Program grant Seed A and Japan Agency for Medical Research and Development grant for U.S.Japan Cooperative Medical Sciences Program	Global Health Innovative Technology Fund; CRDF Global; National Institute of Allergy and Infectious Diseases of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation); American Leprosy Missions, Leprosy Research Initiative; Japanese Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Japan Agency for Medical Research and Development grant for Translational Research Network Program grant Seed A and Japan Agency for Medical Research and Development grant for U.S.Japan Cooperative Medical Sciences Program	The authors of this editorial are funded by The Global Health Innovative Technology Fund (G2018111). NTD research conducted by MD has also been funded by grants from CRDF Global (#62966), National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number R01AI025038 and R21AI144641, and the Bill and Melinda Gates Foundation (#631 and #39129), American Leprosy Missions, Leprosy Research Initiative, and de Turing Foundation. NTD research conducted by YG has been supported by Japanese Society for the Promotion of Science grants (#18H02649 and #20K21516), Japan Agency for Medical Research and Development grant for Translational Research Network Program grant Seed A and Japan Agency for Medical Research and Development grant for U.S.Japan Cooperative Medical Sciences Program.	JAMES SL, 1990, CURR TOP MICROBIOL, V155, P21; Mehra V, 1990, Curr Top Microbiol Immunol, V155, P97; Sacks D, 2002, NAT REV IMMUNOL, V2, P845, DOI 10.1038/nri933	3	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 15	2021	12								658553	10.3389/fimmu.2021.658553	http://dx.doi.org/10.3389/fimmu.2021.658553			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UY2RX	34603276	Green Published, gold			2022-12-18	WOS:000701377600001
J	Kato, H; Hayashi, M; Ohashi, W; Yamaguchi, T; Tanaka, S; Kozono, A; Gao, SQ; Katai, A; Niwa, R; Matsuo, T; Ishiyama, K; Ando, T; Ogawa, M; Nakayama, T				Kato, Hidefumi; Hayashi, Megumi; Ohashi, Wataru; Yamaguchi, Takamasa; Tanaka, Satomi; Kozono, Ayumi; Gao, Siqiang; Katai, Akiko; Niwa, Reiko; Matsuo, Tomohito; Ishiyama, Kazuki; Ando, Takanori; Ogawa, Mika; Nakayama, Takayuki			A Retrospective Observational Study of Adverse Reactions Associated With Intravenous Immunoglobulin Infusion	FRONTIERS IN IMMUNOLOGY			English	Article						immunoglobulin; adverse reactions; risk factors; autoimmune diseases; neuromuscular diseases	REPLACEMENT THERAPY; SAFETY; GLOBULIN	Background Although intravenous immunoglobulin (IVIG) therapy is generally safe and well tolerated, adverse reactions (ARs) do occur. The majority of these ARs are mild and transient. Risk factors for ARs associate with IVIG infusions are not well established. This study investigated possible risk factors influencing the occurrence of IVIG-associated ARs. Study Design and Methods This was a retrospective observational analysis of data accumulated over 5 years, including patient demographics, clinical condition, IVIG dosing regimens, number of IVIG infusions, and any ARs. Results ARs were associated with IVIG in 4.9% of patients and 2.5% of infusions. By univariate analyses, ARs correlated with female sex, adult age, high dose IVIG, and autoimmune disease. Multivariate logistic regression identified three statistically significant of risk factors: on a per-patient basis, being female (p=0.0018), having neuromuscular disease (p=0.0002), and receiving higher doses of IVIG per patient body weight (p<0.001), on a per-infusion basis, being female (p < 0.001), being adolescents to middle age (p < 0.001), and having neuromuscular disease (p < 0.001). Conclusion Neuromuscular disease emerged as one of the significant factors for ARs to IVIG.	[Kato, Hidefumi; Hayashi, Megumi; Yamaguchi, Takamasa; Tanaka, Satomi; Kozono, Ayumi; Gao, Siqiang; Katai, Akiko; Niwa, Reiko; Matsuo, Tomohito; Ishiyama, Kazuki; Ando, Takanori; Nakayama, Takayuki] Aichi Med Univ, Dept Transfus Med, Nagakute, Aichi, Japan; [Kato, Hidefumi; Hayashi, Megumi; Yamaguchi, Takamasa; Tanaka, Satomi; Kozono, Ayumi; Gao, Siqiang; Katai, Akiko; Niwa, Reiko; Matsuo, Tomohito; Ishiyama, Kazuki; Ando, Takanori; Nakayama, Takayuki] Aichi Med Univ, Cell Therapy Ctr, Nagakute, Aichi, Japan; [Ohashi, Wataru] Aichi Med Univ Hosp, Clin Res Ctr, Div Biostat, Nagakute, Aichi, Japan; [Ogawa, Mika; Nakayama, Takayuki] Aichi Med Univ, Clin Lab, Nagakute, Aichi, Japan	Aichi Medical University; Aichi Medical University; Aichi Medical University; Aichi Medical University	Kato, H (corresponding author), Aichi Med Univ, Dept Transfus Med, Nagakute, Aichi, Japan.; Kato, H (corresponding author), Aichi Med Univ, Cell Therapy Ctr, Nagakute, Aichi, Japan.	hkato@aichi-med-u.ac.jp						BENCHETRIT E, 1992, NEW ENGL J MED, V326, P270; Berger M, 2008, IMMUNOL ALLERGY CLIN, V28, P413, DOI 10.1016/j.iac.2008.01.008; Bertorini TE, 1996, MUSCLE NERVE, V19, P388, DOI 10.1002/(SICI)1097-4598(199603)19:3<388::AID-MUS20>3.0.CO;2-N; Bichuetti-Silva DC, 2014, INT IMMUNOPHARMACOL, V23, P442, DOI 10.1016/j.intimp.2014.09.015; BRENNAN VM, 1995, J CLIN IMMUNOL, V15, P116, DOI 10.1007/BF01541739; Dashti-Khavidaki S, 2009, J INVEST ALLERG CLIN, V19, P139; Donofrio PD, 2010, ARCH NEUROL-CHICAGO, V67, P1082, DOI 10.1001/archneurol.2010.223; FURUSHO K, 1984, LANCET, V2, P1055; Graf J, 2019, ACTA NEUROL SCAND, V140, P290, DOI 10.1111/ane.13144; Guo Y, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01299; HALL WH, 1990, JAMA-J AM MED ASSOC, V264, P3189; Hoffmann JHO, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01090; ISBT Working Party on Haemovigilance, 2011, PROP STAND DEEF SURV; KOBOSKO J, 1992, CLIN NEPHROL, V37, P216; Lozeron P, 2016, MUSCLE NERVE, V53, P683, DOI 10.1002/mus.24942; Markvardsen LH, 2015, BASIC CLIN PHARMACOL, V117, P409, DOI 10.1111/bcpt.12428; Orbach H, 2005, CLIN REV ALLERG IMMU, V29, P173, DOI 10.1385/CRIAI:29:3:173; Pecoraro A, 2017, INT IMMUNOPHARMACOL, V52, P136, DOI 10.1016/j.intimp.2017.09.005; Qin YH, 2010, BLOOD COAGUL FIBRIN, V21, P713, DOI 10.1097/MBC.0b013e3283401490; Skull S, 1996, ARCH DIS CHILD, V74, P527, DOI 10.1136/adc.74.6.527; Struff WG, 2005, INT J CLIN PHARM TH, V43, P420; Tsurikisawa N, 2017, J RHEUMATOL, V44, P1206, DOI 10.3899/jrheum.161436; Waheed W, 2019, MUSCLE NERVE, V60, P528, DOI 10.1002/mus.26678; Wietek S, 2018, HEMATOLOGY, V23, P242, DOI 10.1080/10245332.2017.1385892	24	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 15	2021	12								740517	10.3389/fimmu.2021.740517	http://dx.doi.org/10.3389/fimmu.2021.740517			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UZ5UC	34603326	Green Published, gold			2022-12-18	WOS:000702269700001
J	Jiang, QH; Wu, T; Zhang, YX; Wang, SH; Wang, LY; Su, WJ; Lin, MZ; Li, XJ				Jiang, Qiuhui; Wu, Ting; Zhang, Yuxian; Wang, Shunhua; Wang, Liying; Su, Weijuan; Lin, Mingzhu; Li, Xuejun			Case Report: A Rare Case of Coexisting of Autoimmune Polyglandular Syndrome Type 3 and Isolated Gonadotropin-Releasing Hormone Deficiency	FRONTIERS IN IMMUNOLOGY			English	Article						autoimmune polyglandular syndrome type 3; secondary amenorrhea; isolated gonadotropin-releasing hormone deficiency; GnRH stimulation test; Graves' disease; type 1 diabetes mellitus	HLA; ASSOCIATION; FAILURE; DISEASE	APS (autoimmune polyglandular syndrome) is defined as the coexistence of at least two kinds of endocrine autoimmune diseases. APS type 3 comprises autoimmune thyroid diseases and other autoimmune diseases but does not involve autoimmune Addison's disease. So far, APS-3 combined with isolated gonadotropin-releasing hormone (GnRH) reduction caused by the suspected autoimmune hypothalamic disease has not been reported. We recently received a 43-year-old woman with a one-year history of Graves' disease (GD) and a four-month history of type 1 diabetes presented with hyperthyroidism and hyperglycemia. After the GnRH stimulation test, she was diagnosed with secondary amenorrhea attributed to suspected autoimmune Hypothalamitis and APS type 3 associated with Graves' disease and Latent Autoimmune Diabetes (LADA). According to this case, the hypothalamus cannot be spared from the general autoimmune process. It is recommended to carry out the GnRH stimulation test when encountering APS patients combined with secondary amenorrhea.	[Jiang, Qiuhui; Wu, Ting] Fujian Med Univ, Sch Clin Med, Fuzhou, Fujian, Peoples R China; [Zhang, Yuxian; Wang, Shunhua; Wang, Liying; Su, Weijuan; Lin, Mingzhu; Li, Xuejun] Xiamen Univ, Xiamen Diabet Inst, Dept Endocrinol & Diabet, Fujian Key Lab Translat Res Diabet,Affiliated Hos, Xiamen, Peoples R China	Fujian Medical University; Xiamen University	Li, XJ (corresponding author), Xiamen Univ, Xiamen Diabet Inst, Dept Endocrinol & Diabet, Fujian Key Lab Translat Res Diabet,Affiliated Hos, Xiamen, Peoples R China.	xmlixuejun@163.com						BARKAN AL, 1985, NEW ENGL J MED, V312, P1535; Betterle Corrado, 2003, Acta Biomed, V74, P9; Boelaert K, 2010, AM J MED, V123, DOI 10.1016/j.amjmed.2009.06.030; Bokhari SA, 2017, SAUDI J MED MED SCI, V5, P71, DOI 10.4103/1658-631X.194251; CHO BY, 1987, TISSUE ANTIGENS, V30, P119; Darby Emily, 2005, Treat Endocrinol, V4, P293, DOI 10.2165/00024677-200504050-00003; Dittmar M, 2003, J CLIN ENDOCR METAB, V88, P2983, DOI 10.1210/jc.2002-021845; EISENBARTH GS, 1979, ANN INTERN MED, V91, P528, DOI 10.7326/0003-4819-91-4-528; Eisenbarth GS, 2004, NEW ENGL J MED, V350, P2068, DOI 10.1056/NEJMra030158; Faubion SS, 2015, CLIMACTERIC, V18, P483, DOI 10.3109/13697137.2015.1020484; FELTKAMP TE, 1974, BMJ-BRIT MED J, V1, P131, DOI 10.1136/bmj.1.5899.131; Fichna M, 2010, ENDOCRINE, V37, P349, DOI 10.1007/s12020-010-9312-x; Frommer L, 2019, J CLIN ENDOCR METAB, V104, P4769, DOI 10.1210/jc.2019-00602; Gow P, 2005, J GASTROEN HEPATOL, V20, P555, DOI 10.1111/j.1440-1746.2005.03605.x; Hansen MP, 2015, WORLD J DIABETES, V6, P67, DOI 10.4239/wjd.v6.i1.67; Horie I, 2012, J CLIN ENDOCR METAB, V97, pE1043, DOI 10.1210/jc.2011-3109; Kahaly GJ, 2012, PRESSE MED, V41, pE663, DOI 10.1016/j.lpm.2012.09.011; MANNS MP, 1991, GASTROENTEROLOGY, V101, P1367, DOI 10.1016/0016-5085(91)90090-8; Patel YA, 2018, CLIN TRANSPLANT, V32, DOI 10.1111/ctr.13388; Rivera CM, 2009, MENOPAUSE, V16, P15, DOI 10.1097/gme.0b013e31818888f7; Sheehan MT, 2009, ENDOCR PRACT, V15, P138, DOI 10.4158/EP.15.2.138; Zhou WB, 2020, J INT MED RES, V48, DOI 10.1177/0300060520961684	22	0	0	1	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 14	2021	12								734685	10.3389/fimmu.2021.734685	http://dx.doi.org/10.3389/fimmu.2021.734685			5	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WD6VL	34594339	gold, Green Published			2022-12-18	WOS:000705076800001
